nct_id,0,1,2,3,4,5,6,7,8,9,valid_sentiments,mode,lf
NCT02157714,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/prasinezumab-failure-parkinsons-phase-2-trial-detailed/', 'title': ""Prasinezumab Failure in Parkinson's Phase 2 Trial Detailed |..."", 'source': ""Parkinson's News Today"", 'date': 'Aug 8, 2022', 'snippet': ""Treatment with prasinezumab, a monoclonal antibody designed to break up \ntoxic alpha-synuclein aggregates, failed to slow the progression of \nParkinson's disease..."", 'thumbnail': 'https://serpapi.com/searches/6721b14bd9c3e647117f1cbd/images/30bc27b2c58cf9de6e381c5f5b2767878ac2e57de04bbd60d11791fcede0a565.png', 'sentiment': 'negative', 'sentiment_prob': 0.7795194983482361}",,,,,,,,,,['negative'],negative,0
NCT03086343,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2008250', 'title': 'Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis', 'source': 'The New England Journal of Medicine', 'date': 'Oct 14, 2020', 'snippet': 'Upadacitinib is an oral selective Janus kinase inhibitor to treat \nrheumatoid arthritis. The efficacy and safety of upadacitinib as compared...', 'thumbnail': 'https://serpapi.com/searches/6721b155adc33bdf8466fd27/images/43cbb0de0312136cddb98b91e28de571c201b1535deb68c5f04ea81c2fdd614c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.876733124256134}",,,,,,,,,,['neutral'],neutral,1
NCT02192424,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-40287-w', 'title': 'Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes', 'source': 'Nature', 'date': 'Jul 27, 2023', 'snippet': 'In early type 2 diabetes, the strategy of “induction” with short-term \nintensive insulin therapy followed by “maintenance” with metformin can...', 'thumbnail': 'https://serpapi.com/searches/6721b1825416d8e6ac1cfa69/images/5ff7ffb3cb20167878647571d036c8103b24ace0f66d617ee07ddac6cdaac77f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8652159571647644}",,,,,,,,,,['neutral'],neutral,1
NCT04886596,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2209604', 'title': 'Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults', 'source': 'The New England Journal of Medicine', 'date': 'Feb 15, 2023', 'snippet': 'Respiratory syncytial virus (RSV) is an important cause of acute \nrespiratory infection, lower respiratory tract disease, clinical...', 'thumbnail': 'https://serpapi.com/searches/6721b18f81bab782f00122a2/images/da5561971d7a5b0ad2832799b633c8c394f3868c8cb3544baddae8da8ee89463.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5248604416847229}","{'position': 2, 'link': 'https://www.drugtopics.com/view/breaking-fda-approves-first-ever-rsv-vaccine', 'title': 'Breaking: FDA Approves First-Ever RSV Vaccine', 'source': 'Drug Topics', 'date': 'May 3, 2023', 'snippet': 'The vaccine is approved for use in adults aged 60 and older to prevent \nlower respiratory tract disease caused by RSV.', 'thumbnail': 'https://serpapi.com/searches/6721b18f81bab782f00122a2/images/da5561971d7a5b0a0b914a0f9b3a1525c5b32e36afc0d6eefc9ba8b3be5ea3ba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6009575724601746}","{'position': 3, 'link': 'https://www.drugtopics.com/view/gsk-s-rsv-vaccine-now-available-in-us-pharmacies-what-you-need-to-know', 'title': 'GSK’s RSV Vaccine Now Available in Some US Pharmacies: What You Need to Know', 'source': 'Drug Topics', 'date': 'Aug 1, 2023', 'snippet': ""The FDA approved GSK's Arexvy on May 3, 2023, making it the first vaccine \nto prevent lower respiratory tract disease caused by RSV in adults aged 60 \nand older."", 'thumbnail': 'https://serpapi.com/searches/6721b18f81bab782f00122a2/images/da5561971d7a5b0a081abe794899ac6a260951750a332921a7f75f174ee72c93.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7245526313781738}","{'position': 4, 'link': 'https://www.drugtopics.com/view/the-value-of-good-neighbor-pharmacy-today-and-tomorrow', 'title': 'The Value of Good Neighbor Pharmacy Today and Tomorrow', 'source': 'Drug Topics', 'date': 'Oct 7, 2020', 'snippet': ""Brian Nightengale, President of GNP, discusses the value of Good Neighbor \nPharmacy's services and solutions in supporting independent..."", 'thumbnail': 'https://serpapi.com/searches/6721b18f81bab782f00122a2/images/da5561971d7a5b0a66f27d0c002a1a71566688c4fd725b94a17f14b6f84bf2ae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5204561948776245}",,,,,,,"['negative', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04199728,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/cob.12676', 'title': 'Glucagon‐like‐peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association - Nguyen - 2024 - Clinical Obesity', 'source': 'Wiley Online Library', 'date': 'May 23, 2024', 'snippet': 'Glucagon-like-peptide 1 receptor agonists (GLP-1RA) have transformed type 2 \ndiabetes (T2D) and obesity management.', 'thumbnail': 'https://serpapi.com/searches/6721b1a47ec4aefa940d1389/images/0c8415dd3b72c692dd48468fdbad020019de4d91a99feafe984a9d5345a9110c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5590799450874329}",,,,,,,,,,['neutral'],neutral,1
NCT00956098,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-022-01119-3', 'title': 'Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)', 'source': 'Nature', 'date': 'Aug 13, 2022', 'snippet': 'In this review, we discussed recent developments in etiology and \nprospective therapeutic targets, as well as pharmacological candidates in \npre/clinical trials...', 'thumbnail': 'https://serpapi.com/searches/6721b1c974f0a452bffe6e81/images/3154712ef40168bb6efa1fcc22d64ab459879cda7d5098e53daac72d68f2bbfe.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9206169247627258}",,,,,,,,,,['neutral'],neutral,1
NCT03844074,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/fda-rejects-intravitreal-formulation-of-bevacizumab-for-wet-amd/', 'title': 'FDA Rejects Intravitreal Formulation of Bevacizumab for Wet AMD', 'source': 'Medical Professionals Reference', 'date': 'Aug 30, 2023', 'snippet': 'The Food and Drug Administration (FDA) has issued a Complete Response \nLetter (CRL) to Outlook Therapeutics regarding the Biologics License \nApplication (BLA)...', 'thumbnail': 'https://serpapi.com/searches/6721b1d0a775f24217d434bd/images/6e68d6abe075243934487d0a371f8a724febdb7d390038f8c3e40aeff361f794.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8640140891075134}",,,,,,,,,,['neutral'],neutral,1
NCT02122913,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1714448', 'title': 'Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children', 'source': 'The New England Journal of Medicine', 'date': 'Feb 21, 2018', 'snippet': 'Fusions involving one of three tropomyosin receptor kinases (TRK) occur in \ndiverse cancers in children and adults. We evaluated the efficacy...', 'thumbnail': 'https://serpapi.com/searches/6721b1e4a54d7ea585de8c48/images/f1a57890d38a78707244ec48d33168d2df3aa8e096563ddf321a43972c0ca760.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.788867712020874}","{'position': 2, 'link': 'https://www.onclive.com/view/dr-subbiah-on-outcomes-with-larotrectinib-in-trk-fusion-positive-solid-tumors', 'title': 'Dr Subbiah on Outcomes With Larotrectinib in TRK Fusion–Positive Solid Tumors', 'source': 'OncLive', 'date': 'Aug 20, 2024', 'snippet': 'Vivek Subbiah, MD, chief, Early-Phase Drug Development, Sarah Cannon \nResearch Institute, discusses key data from the observational VICTORIA...', 'thumbnail': 'https://serpapi.com/searches/6721b1e4a54d7ea585de8c48/images/f1a57890d38a7870bf8955ba0831824928982f3bed9d2241e748c1287b7efc17.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8828447461128235}","{'position': 3, 'link': 'https://www.mdanderson.org/publications/cancer-frontline/targeted-therapy-larotrectinib-shows-marked-responses-in-patient.h00-159381156.html', 'title': 'Larotrectinib shows marked responses with NTRK gene fusions, limited response in non-fusion mutations', 'source': 'MD Anderson Cancer Center', 'date': 'Apr 28, 2020', 'snippet': 'An MD Anderson analysis of three clinical trials shows that the targeted \ntherapy drug larotrectinib resulted in a 79% overall response rate...', 'thumbnail': 'https://serpapi.com/searches/6721b1e4a54d7ea585de8c48/images/f1a57890d38a7870304093ba9d747a9cbb6c924b814053217a14dda21fdad3ee.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8391838669776917}","{'position': 4, 'link': 'https://www.clinicaltrialsarena.com/projects/vitrakvi-larotrectinib-advanced-solid-tumours/', 'title': 'Vitrakvi (larotrectinib) for Advanced Solid Tumours with NTRK Gene Fusion', 'source': 'Clinical Trials Arena', 'date': 'Dec 11, 2018', 'snippet': 'Vitrakvi (larotrectinib) is an oral tyrosine kinase inhibitor for the \ntreatment of advanced solid tumours with NTRK gene fusion.', 'thumbnail': 'https://serpapi.com/searches/6721b1e4a54d7ea585de8c48/images/f1a57890d38a78707577633240854d4eca261f2f8dd4e05781a04241d190e5e3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9096885919570923}","{'position': 5, 'link': 'https://www.cancerhealth.com/blog/fda-approves-companion-diagnostic-test-vitrakvi', 'title': 'FDA Approves Companion Diagnostic Test for Vitrakvi', 'source': 'Cancer Health', 'date': 'Oct 26, 2020', 'snippet': 'On October 23, 2020, the Food and Drug Administration approved the \nnext-generation sequencing (NGS)-based FoundationOne CDx test (Foundation...', 'thumbnail': 'https://serpapi.com/searches/6721b1e4a54d7ea585de8c48/images/f1a57890d38a787043e2d7b280f190ee9b294ea4bad83c263793d71cb47bb1f0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7966646552085876}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01462942,"{'position': 1, 'link': 'https://copdnewstoday.com/news/duaklir-available-copd-patients-us/', 'title': 'Duaklir Now Available to COPD Patients in the U.S.', 'source': 'COPD News Today', 'date': 'Oct 29, 2019', 'snippet': 'Duaklir is now available to patients with chronic obstructive pulmonary \ndisease (COPD) living in the U.S., Circassia Pharmaceuticals...', 'thumbnail': 'https://serpapi.com/searches/6721b1ee8a7c0939084c5c6a/images/03728386d5e4cd12d0739064ee53ec519e57aa668daf7290d19280e62044a556.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7435298562049866}",,,,,,,,,,['neutral'],neutral,1
NCT00120003,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/strokeaha.113.001022', 'title': 'Effects of Candesartan in Acute Stroke on Cognitive Function and Quality of Life:', 'source': 'American Heart Association Journals', 'date': 'May 9, 2013', 'snippet': 'Background and Purpose—High blood pressure is common in the acute phase of \nstroke and is associated with poor outcome.', 'thumbnail': 'https://serpapi.com/searches/6721b1ef8f2bc259e15fa5b3/images/e842102b296d5d013119a0f08766e4fe3d6a69bd51a57374350f48e8a0c3c20a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6420814990997314}",,,,,,,,,,['negative'],negative,0
NCT03602560,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/liver-damage-itch-from-primary-biliary-cholangitis-eased-with-seladelpar/', 'title': 'Seladelpar eases liver damage, itch in primary biliary cholangitis', 'source': 'liverdiseasenews.com', 'date': 'May 22, 2024', 'snippet': ""One year of treatment with Gilead Sciences' seladelpar normalized \nbiomarkers of liver injury and rapidly reduced itch for most people with \nprimary biliary..."", 'thumbnail': 'https://serpapi.com/searches/6721b2182c566df1ca1ef4ba/images/d4e54e170c7ed3ab1ed796f1c379d50f74abc102d033cc670d0e1256644799a9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7402761578559875}","{'position': 2, 'link': 'https://liverdiseasenews.com/news/seladelpar-lowers-levels-il-31-driving-pruritus-pbc-trial/', 'title': 'Seladelpar lowers levels of molecule driving itch with PBC: Phase 3 trial', 'source': 'Liver Disease News', 'date': 'Feb 7, 2024', 'snippet': 'An analysis of Phase 3 trial data found a 52% drop in blood levels of \nIL-31, known to promote itch, in PBC patients treated at high dose.', 'thumbnail': 'https://serpapi.com/searches/6721b2182c566df1ca1ef4ba/images/d4e54e170c7ed3ab74d41e9926347f0381a004d92538d777b9ef5996ff2fd6ab.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7899602055549622}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02624947,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1329426/full', 'title': 'Clinical research on RSV prevention in children and pregnant women: progress and perspectives', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': 'This review provides a comprehensive summary of RSV monoclonal antibody \n(mAb) and vaccine clinical trials registered on ClinicalTrials.gov', 'thumbnail': 'https://serpapi.com/searches/6721b227c024d17e3ab52f67/images/bc4e9b76ee2a7fa7a6ca84854bfd1987b388078abb4807fbc337f9263f0e1617.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8756221532821655}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1908380', 'title': 'Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants', 'source': 'The New England Journal of Medicine', 'date': 'Jul 29, 2020', 'snippet': 'We describe the results of a phase 3 trial evaluating the safety and \nimmunogenicity of RSV F vaccine in pregnant women and vaccine efficacy.', 'thumbnail': 'https://serpapi.com/searches/6721b227c024d17e3ab52f67/images/bc4e9b76ee2a7fa78480896b99bc46dc17ef2c4c7abec4f3742832ff3fad516b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9224299192428589}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03852433,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2213429', 'title': 'A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D', 'source': 'The New England Journal of Medicine', 'date': 'Jun 22, 2023', 'snippet': 'Coinfection with hepatitis D virus (HDV) accelerates the progression of \nliver disease associated with chronic hepatitis B. Bulevirtide inhibits the \nentry of...', 'thumbnail': 'https://serpapi.com/searches/6721b239ba1142b4b1190fcd/images/27389f6b00bc99bd4975146822d5887511a1325be02e4b01fc3b757c85400e3b.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6427436470985413}",,,,,,,,,,['negative'],negative,0
NCT00049829,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa067312', 'title': 'Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis', 'source': 'The New England Journal of Medicine', 'date': 'May 3, 2007', 'snippet': 'A single infusion of intravenous zoledronic acid decreases bone turnover \nand improves bone density at 12 months in postmenopausal women with \nosteoporosis.', 'thumbnail': 'https://serpapi.com/searches/6721b23f4677bf469c242595/images/ea481e20c7b44039c4bb0095c20cd08e873cac561c184cb7d7274be585a40684.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7942545413970947}",,,,,,,,,,['neutral'],neutral,1
NCT02457845,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2024947', 'title': 'Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas', 'source': 'The New England Journal of Medicine', 'date': 'Apr 10, 2021', 'snippet': 'Pediatric brain tumors are highly sensitive to oncolytic virotherapy with \ngenetically engineered herpes simplex virus type 1 (HSV-1) G207.', 'thumbnail': 'https://serpapi.com/searches/6721b24624296a3c4a748beb/images/5c78eb14742d04292ab18b3e000555090dfe082ad1f451fbfb7f1d8a90130d35.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7477931380271912}",,,,,,,,,,['neutral'],neutral,1
NCT03412565,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-023-00805-x', 'title': 'Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS | Blood Cancer Journal', 'source': 'Nature', 'date': 'Mar 7, 2023', 'snippet': 'We report final data from PLEIADES and EQUULEUS, with a median follow-up of \n12.4 and 23.7 months, respectively.', 'thumbnail': 'https://serpapi.com/searches/6721b25e52a04e7b0718215d/images/3426ef1ab2ffc9e7553b57c0d6049518d683e7fc70fd0c8fe4ef6c36fd9d7369.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9076092839241028}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/fda-approves-darzalex-faspro-injection-therapy-for-multiple-myeloma/', 'title': 'FDA Approves Darzalex Faspro as Injection Therapy for Multiple Myeloma', 'source': 'Myeloma Research News', 'date': 'May 5, 2020', 'snippet': ""The U.S. Food and Drug Administration (FDA) approved Janssen's new \nformulation of daratumumab — a subcutaneous or under-the-skin injection..."", 'thumbnail': 'https://serpapi.com/searches/6721b25e52a04e7b0718215d/images/3426ef1ab2ffc9e7fd5d0f68829859a29bbe443f3a2a84b0db55a7118290daf0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6539252400398254}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05567952,"{'position': 1, 'link': 'https://www.cdc.gov/mmwr/volumes/72/wr/mm7251a1.htm', 'title': 'SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals | MMWR', 'source': 'Centers for Disease Control and Prevention (.gov)', 'date': 'Dec 22, 2023', 'snippet': 'CDC reviewed COVID-19 rebound studies among patients who did and did not \nreceive antiviral treatment.', 'thumbnail': 'https://serpapi.com/searches/6721b2789062f826e6c06d4f/images/dde4226fc7f22fe472844a62eba792f208227c41ca5be7c95278aad19354ee12.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8883197903633118}",,,,,,,,,,['neutral'],neutral,1
NCT04778410,"{'position': 1, 'link': 'https://www.onclive.com/view/gilead-discontinues-phase-3-enhance-2-trial-of-magrolimab-plus-azacitidine-in-tp53-mutant-aml', 'title': 'Gilead Discontinues Phase 3 ENHANCE-2 Trial of Magrolimab Plus Azacitidine in TP53-Mutant AML', 'source': 'OncLive', 'date': 'Sep 27, 2023', 'snippet': ""The phase 3 ENHANCE-2 trial examining the frontline combination of \nmagrolimab and azacitidine vs physician's choice of venetoclax with..."", 'thumbnail': 'https://serpapi.com/searches/6721b27b7ef9fa1a056ca893/images/d6e057c5464ce1e2ecb677c9346382bf2ededee9e3ad5c4e7840f8c90b064053.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9308812022209167}",,,,,,,,,,['neutral'],neutral,1
NCT00782067,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1513098', 'title': 'Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis', 'source': 'The New England Journal of Medicine', 'date': 'Jun 30, 2016', 'snippet': 'In this open-label study, midostaurin showed efficacy in patients with \nadvanced systemic mastocytosis, including the highly fatal variant \nmast-cell leukemia.', 'thumbnail': 'https://serpapi.com/searches/6721b28589055e8ea6cb7bce/images/2644e564c08d8b22ec8288f66362de496b328a8816b4ae689e8af47adae6408f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7889068126678467}",,,,,,,,,,['neutral'],neutral,1
NCT00810693,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1209655', 'title': 'Riociguat for the Treatment of Pulmonary Arterial Hypertension', 'source': 'The New England Journal of Medicine', 'date': 'Jul 25, 2013', 'snippet': 'Riociguat, a soluble guanylate cyclase stimulator, has been shown in a \nphase 2 trial to be beneficial in the treatment of pulmonary arterial \nhypertension.', 'thumbnail': 'https://serpapi.com/searches/6721b2aa2da1575f5eaf02f2/images/89db599ddcdad6081b8aa0a9c02b8e0f2a48a92f2f75c070c7de837660151316.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6600370407104492}","{'position': 2, 'link': 'https://sclerodermanews.com/2016/07/29/Adempas-Equally-Beneficial-in-Scleroderma-and-Other-Connective-Tissue-Disease-PAH-patients/', 'title': 'PAH Scleroderma Patients, Others with PAH-CTD Benefit from Adempas', 'source': 'Scleroderma News', 'date': 'Aug 2, 2016', 'snippet': 'Scleroderma patients with pulmonary arterial hypertension (PAH) benefit \nequally well from treatment with Adempas (riociguat) as PAH patients...', 'thumbnail': 'https://serpapi.com/searches/6721b2aa2da1575f5eaf02f2/images/89db599ddcdad6081401e5480016d669b4e23d520b41343cdee2247d507fd59a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7391170859336853}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04927975,"{'position': 1, 'link': 'https://www.medicalnewstoday.com/articles/jak-inhibitors-for-vitiligo', 'title': 'What to know about JAK inhibitor treatments for vitiligo', 'source': 'MedicalNewsToday', 'date': 'Nov 17, 2022', 'snippet': 'Ruxolitinib cream is the first FDA-approved JAK inhibitor for skin \nrepigmentation in people with vitiligo, paving the way for additional oral \nand topical JAK...', 'thumbnail': 'https://serpapi.com/searches/6721b2b50c6668b7c76dbc5c/images/972b6e8ca06d5e785c1ae01eab6212e3ae4f60850a97633013ebbe48e332bf44.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7310158014297485}","{'position': 2, 'link': 'https://www.thepharmaletter.com/biotechnology/phase-ii-rinvoq-trial-hits-main-goal-in-vitiligo', 'title': 'Phase II Rinvoq trial hits main goal in vitiligo', 'source': 'The Pharma Letter', 'date': 'Oct 12, 2023', 'snippet': 'At the European Academy of Dermatology and Venerology (EADV) congress in \nBerlin, AbbVie is presenting positive results from the Phase IIb...', 'thumbnail': 'https://serpapi.com/searches/6721b2b50c6668b7c76dbc5c/images/972b6e8ca06d5e78d5a103c0101db94a45873cf4128feb2f8a3672f6d3cdd375.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5259546637535095}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04204408,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/mim8-better-standard-hemophilia-a-treatments-phase-3-trial/', 'title': 'Mim8 seen as better than standard hem A therapies at bleed control', 'source': 'Hemophilia News Today', 'date': 'May 22, 2024', 'snippet': 'Weekly and monthly treatment with Mim8, an investigational antibody \ntherapy, was seen to be better than on-demand or standard preventive \ntreatments at reducing...', 'thumbnail': 'https://serpapi.com/searches/6721b2b6cb33d011be8457f3/images/0fa4f1ba75b44171d1c504e159101cb1fdf6135335d0ef5afe82471835712811.png', 'sentiment': 'positive', 'sentiment_prob': 0.6799125075340271}",,,,,,,,,,['positive'],positive,1
NCT05252338,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S2405844024030020', 'title': 'The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases', 'source': 'ScienceDirect.com', 'date': 'Mar 15, 2024', 'snippet': 'This review aims to elucidate the advancements in the clinical applications \nof mRNAs for addressing significant health-related challenges such as \ncancer,...', 'thumbnail': 'https://serpapi.com/searches/6721b2c0a5aae9207bffd5d9/images/c01c1600c97f3cf8907bfd5e1721f30bbc02ef932a2c9d1acc9d52a5f20b1672.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8580176830291748}",,,,,,,,,,['neutral'],neutral,1
NCT00652132,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1801109', 'title': 'Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss', 'source': 'The New England Journal of Medicine', 'date': 'Jun 20, 2018', 'snippet': 'Cisplatin chemotherapy and surgery are effective treatments for children \nwith standard-risk hepatoblastoma but may cause considerable and...', 'thumbnail': 'https://serpapi.com/searches/6721b2d818787d3f6f66c9ea/images/2e7d2d5fc3aaa2bcdb97ed23fc5d3df212f169c4db75dfc2576246ac83259823.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6426202654838562}","{'position': 2, 'link': 'https://www.oncologynewscentral.com/article/fda-approves-sodium-thiosulfate-for-prevention-of-platinum-induced-hearing', 'title': 'FDA Approves Sodium Thiosulfate for Prevention of Platinum-Induced Hearing Loss in Kids', 'source': 'www.oncologynewscentral.com', 'date': 'Sep 21, 2022', 'snippet': 'The U.S. Food and Drug Administration approved an unique formulation of \nsodium thiosulfate (Pedmark) for the prevention of platinum-induced...', 'thumbnail': 'https://serpapi.com/searches/6721b2d818787d3f6f66c9ea/images/2e7d2d5fc3aaa2bc5ca3d66c5df15e315ce21744e7834c9f3cd5b2d9b9dea875.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7437710762023926}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05163847,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/flugens-intranasal-flu-vaccine-boosts-flu-shot-efficacy/', 'title': 'FluGen’s intranasal flu vaccine boosts flu shot efficacy', 'source': 'Clinical Trials Arena', 'date': 'Jul 15, 2024', 'snippet': ""A study shows that the co-administration of FluGen's intranasal M2SR and a \nhigh-dose flu shot improves the overall efficacy of flu vaccines in the \nelderly..."", 'thumbnail': 'https://serpapi.com/searches/6721b2e3310300643ce5fbcb/images/5efb290a69d19b8606614c57e1aefde549619dbd587cceceaa43695199e38951.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6190996766090393}",,,,,,,,,,['positive'],positive,1
NCT01376167,"{'position': 1, 'link': 'https://malariajournal.biomedcentral.com/articles/10.1186/s12936-024-04924-z', 'title': 'Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria', 'source': 'Malaria Journal', 'date': 'May 13, 2024', 'snippet': 'A single dose of tafenoquine 300 mg in combination with a 3-day course of \nchloroquine is an important advancement for the radical cure of vivax \nmalaria.', 'thumbnail': 'https://serpapi.com/searches/6721b2ec316650b50a5cc9e0/images/09ece82483e50bb9e6e7c9e186d03569cf4482dbc1fd28e67230bf5b4a109586.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5251345038414001}",,,,,,,,,,['positive'],positive,1
NCT00841191,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-020-19288-6', 'title': 'Immune modulatory effects of oncogenic KRAS in cancer', 'source': 'Nature', 'date': 'Oct 28, 2020', 'snippet': 'We discuss recent reports connecting KRAS mutations with tumour-promoting \ninflammation and immune modulation caused by KRAS that leads to immune \nescape in the...', 'thumbnail': 'https://serpapi.com/searches/6721b2f5fda26de16dd7459d/images/58673e5179b4e93764a95e4644d8dc1eba00b57b5cd9739d391ceae7a7394232.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6028968095779419}",,,,,,,,,,['neutral'],neutral,1
NCT00315757,"{'position': 1, 'link': 'https://www.nature.com/articles/s41418-022-01059-z', 'title': 'Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries', 'source': 'Nature', 'date': 'Oct 4, 2022', 'snippet': 'Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) can \ninduce apoptosis in a wide variety of cancer cells, both in vitro...', 'thumbnail': 'https://serpapi.com/searches/6721b312caddc31ce57667ba/images/4e9b85b643bc3e8d48b341668a3e27a81fa15ed8cf5ded2b649f214e50ce2303.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6938797235488892}",,,,,,,,,,['neutral'],neutral,1
NCT03996369,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00061-2/fulltext', 'title': 'Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies', 'source': 'The Lancet', 'date': 'Mar 2, 2023', 'snippet': 'Etrasimod as induction and maintenance therapy for ulcerative colitis \n(ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies', 'thumbnail': 'https://serpapi.com/searches/6721b31d58e4339464dcd70c/images/e1b78a65141e06bfdf442ca4a3545334ff62c83e542be4d7eb698f23b7edf6e9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7826459407806396}",,,,,,,,,,['neutral'],neutral,1
NCT02482090,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-020-60738-4', 'title': 'CTLA-4 blockade boosts the expansion of tumor-reactive CD8', 'source': 'Nature', 'date': 'Mar 3, 2020', 'snippet': 'Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes \n(TILs) can induce durable complete tumor regression in patients...', 'thumbnail': 'https://serpapi.com/searches/6721b32cee677f6d30533aca/images/1eaeb3d95b78e53391ed6ee37c171c74bd0fe7c25b80ef22ac85240138bf769d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.66169273853302}",,,,,,,,,,['neutral'],neutral,1
NCT02869035,"{'position': 1, 'link': 'https://www.nature.com/articles/s41398-022-02240-1', 'title': 'Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study', 'source': 'Nature', 'date': 'Nov 8, 2022', 'snippet': 'Cognitive disturbances in major depressive disorder (MDD) constitute a \ncritical treatment target and hold promise as an early predictor of \nantidepressant...', 'thumbnail': 'https://serpapi.com/searches/6721b338a5d70237c4700b58/images/2b89c61abac6e1782e83126cb5aa846594f928304308ef377a049a5cf4aa58e2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8646960258483887}",,,,,,,,,,['neutral'],neutral,1
NCT00430365,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1114138', 'title': 'Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma', 'source': 'The New England Journal of Medicine', 'date': 'May 10, 2012', 'snippet': 'High-dose chemotherapy with autologous stem-cell transplantation is a \nstandard treatment for young patients with multiple myeloma.', 'thumbnail': 'https://serpapi.com/searches/6721b3464e9efc40cad56193/images/fdcfec6898eb397201c04ee38fe8d9c823a06f66f6087aac2f2eb881b3b771d9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8278542160987854}",,,,,,,,,,['neutral'],neutral,1
NCT05512949,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/clinical-trial-evaluating-monkeypox-vaccine-begins', 'title': 'Clinical Trial Evaluating Monkeypox Vaccine Begins', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Sep 8, 2022', 'snippet': 'Interested volunteers can visit clinicaltrials.gov and search identifier \nNCT05512949 for more information about the trial, including a list...', 'thumbnail': 'https://serpapi.com/searches/6721b34817b10e7c7bb60bb2/images/527e4e17ccbaf6f13a52c639e5c1d53e825235dab89a9457117698cd20a8345d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9237444400787354}","{'position': 2, 'link': 'https://www.europeanpharmaceuticalreview.com/news/174314/us-begins-monkeypox-vaccine-and-therapeutic-trials/', 'title': 'US begins monkeypox vaccine and therapeutic trials', 'source': 'European Pharmaceutical Review', 'date': 'Sep 12, 2022', 'snippet': 'US National Institutes of Health initiates trials to evaluate antiviral \ntecovirimat (TPOXX) and possibility of delivering Jynneos vaccine \nintradermally.', 'thumbnail': 'https://serpapi.com/searches/6721b34817b10e7c7bb60bb2/images/527e4e17ccbaf6f15e4ac777cd2ca8eb77ce24fdc079a74a26943b869c3a9144.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9237051606178284}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02819518,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2202809', 'title': 'Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jul 20, 2022', 'snippet': 'In an interim analysis of this phase 3 trial, the addition of pembrolizumab \nto chemotherapy resulted in longer progression-free survival...', 'thumbnail': 'https://serpapi.com/searches/6721b350544c49a3ab20630f/images/7c2b43ae9e70674e6bc3e68b4f977013eb0f923dea7f47da282ea12af6cea6cf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7620288729667664}","{'position': 2, 'link': 'https://www.nature.com/articles/s41523-024-00679-7', 'title': 'Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC | npj Breast Cancer', 'source': 'Nature', 'date': '1 month ago', 'snippet': 'In the phase 3 KEYNOTE-355 study (NCT02819518), pembrolizumab plus \nchemotherapy demonstrated statistically significant and clinically...', 'thumbnail': 'https://serpapi.com/searches/6721b350544c49a3ab20630f/images/7c2b43ae9e70674ec8674ba109ac3a46808f42ae534c850acde91faac9137e86.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9065072536468506}","{'position': 3, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.5757', 'title': 'Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355', 'source': 'Wiley Online Library', 'date': 'Mar 14, 2023', 'snippet': 'Overall survival was prolonged with pembrolizumab plus chemotherapy \ncompared with placebo plus chemotherapy among patients with previously...', 'thumbnail': 'https://serpapi.com/searches/6721b350544c49a3ab20630f/images/7c2b43ae9e70674e2872989b79f972ffc2c5fd0d16180130009ba3f8ecc45964.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8783368468284607}","{'position': 4, 'link': 'https://breastcancer-news.com/2020/11/19/fda-approves-keytruda-chemo-combo-for-advanced-tnbc-positive-for-pd-l1/', 'title': 'FDA Approves Keytruda-chemo Combo for Advanced TNBC Positive for PD-L1', 'source': 'Breast Cancer News', 'date': 'Nov 19, 2020', 'snippet': 'The US Food and Drug Administration (FDA) has approved Keytruda \n(pembrolizumab), in combination with chemotherapy, to treat people with \nadvanced triple-...', 'thumbnail': 'https://serpapi.com/searches/6721b350544c49a3ab20630f/images/7c2b43ae9e70674e0d8f088d284881f440ab60585f2654f3ce966e5f740fdfbe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7811800837516785}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT05142722,"{'position': 1, 'link': 'https://www.healio.com/news/cardiology/20221219/pipeline-pulse-a-look-at-tirzepatide-ziltivekimab-and-obicetrapib', 'title': 'Pipeline Pulse: A look at tirzepatide, ziltivekimab and obicetrapib', 'source': 'Healio', 'date': 'Dec 19, 2022', 'snippet': 'The field of cardiology has seen stunning advances in the past several \nyears: HF, dyslipidemia and cardiomyopathy are just three of the...', 'thumbnail': 'https://serpapi.com/searches/6721b36e4300ce5d04a69767/images/74d6f656dad908cf746bafc855a3be8efb28e3e9a8079da73930059d4cea9eb2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8222142457962036}",,,,,,,,,,['positive'],positive,1
NCT00906399,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2021/02/01/biogen-announces-fda-approval-of-plegridy-peginterferon-beta-1a-intramuscular-administration-for-multiple-sclerosis/', 'title': 'FDA Approves Plegridy as Intramuscular Injection for Relapsing MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Feb 2, 2021', 'snippet': 'The US Food and Drug Administration (FDA) has approved an intramuscular \ninjection formulation of Plegridy (peginterferon beta-1a) to treat people \nwith...', 'thumbnail': 'https://serpapi.com/searches/6721b389e30abcd38625fce7/images/369e6dd917186238c0d5c95d5336edee39c35339f1a2516b40f8e8ed51a48278.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8156218528747559}",,,,,,,,,,['neutral'],neutral,1
NCT02782858,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/gnbac1-for-rrms/', 'title': 'Temelimab in MS | Experimental MS Treatments', 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 9, 2022', 'snippet': 'Temelimab is a therapy being evaluated as a potential treatment for MS. \nLearn more about its uses, side effects, and clinical testing.', 'thumbnail': 'https://serpapi.com/searches/6721b3c97ac73169c870ec98/images/674c92c70cbf23ae791467487fd94c4eb14924ac9917403480ce18efadc0ee0a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9337586760520935}",,,,,,,,,,['neutral'],neutral,1
NCT02213263,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/ruxience-biosimilar-rituxan-approved-by-fda-2-anca-vasculitis-subtypes/', 'title': 'FDA Approves Rituxan Biosimilar Ruxience for 2 ANCA Vasculitis Subtypes', 'source': 'ANCA Vasculitis News', 'date': 'Jul 30, 2019', 'snippet': ""The U.S. Food and Drug Administration (FDA) has approved Pfizer's Ruxience \n(rituximab-pvvr), a biosimilar to Rituxan (rituximab),..."", 'thumbnail': 'https://serpapi.com/searches/6721b3d6d11a89f6dc4dfad3/images/16fe07daac8c0bb9e605b0a94597f8f920b2ff7781929c861e419aaafeff552f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7757377624511719}",,,,,,,,,,['neutral'],neutral,1
NCT00390299,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-43076-7', 'title': 'Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial', 'source': 'Nature', 'date': 'Jan 12, 2024', 'snippet': 'Measles virus (MV) vaccine strains have shown significant preclinical \nantitumor activity against glioblastoma (GBM), the most lethal glioma...', 'thumbnail': 'https://serpapi.com/searches/6721b3db9e38e52c96d86bb1/images/3c43ac7db1b41ff924bfb9868d526c53211707cde52284a316acb1198f887980.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7172777652740479}",,,,,,,,,,['neutral'],neutral,1
NCT02494479,"{'position': 1, 'link': 'https://psoriasisnewstoday.com/2017/05/11/cellceutix-has-70-percent-of-patients-it-wants-for-trial-of-psoriasis-therapy-prurisol/', 'title': 'Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target', 'source': 'Psoriasis News Today', 'date': 'May 11, 2017', 'snippet': 'An already started Phase 2b clinical trial of Prurisol as a treatment for \nmoderate-to-severe chronic plaque psoriasis has recruited more than 70 \npercent of the...', 'thumbnail': 'https://serpapi.com/searches/6721b3e5f9f9048808756710/images/cbefdfe81edacc891254279e7f8881443228b46819aacec089db2502a7b7e913.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7885826826095581}",,,,,,,,,,['neutral'],neutral,1
NCT03399370,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1912387', 'title': 'Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol', 'source': 'The New England Journal of Medicine', 'date': 'Mar 18, 2020', 'snippet': 'Previous studies suggest that inclisiran might provide sustained reductions \nin low-density lipoprotein (LDL) cholesterol levels with infrequent dosing.', 'thumbnail': 'https://serpapi.com/searches/6721b3e71397bae53c6bb816/images/c1949dd0ab2c3d4242d47819c8d01e693f98a646b7f0a6af5fd458222f86c48c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8475676774978638}",,,,,,,,,,['neutral'],neutral,1
NCT05074472,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/monoclonal-antibody-granted-orphan-drug-status-for-pancreatic-cancer/', 'title': 'Monoclonal Antibody Granted Orphan Drug Status for Pancreatic Cancer', 'source': 'Medical Professionals Reference', 'date': 'Dec 27, 2022', 'snippet': 'The Food and Drug Administration (FDA) has granted Orphan Drug designation \nto ZB131 for the treatment of pancreatic cancer.', 'thumbnail': 'https://serpapi.com/searches/6721b3ef7ef9fa1a056ca982/images/bdab6e58bafa2139935f2a35bba51a8851b168172f71d1dc08cb2d9b777c7be8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9232718348503113}",,,,,,,,,,['neutral'],neutral,1
NCT01180322,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-019-0395-y', 'title': 'Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine', 'source': 'Nature', 'date': 'Feb 6, 2019', 'snippet': 'The aim of this randomized phase-II study was to evaluate the effect of \nsubstituting cytarabine by azacitidine in intensive induction...', 'thumbnail': 'https://serpapi.com/searches/6721b40d717bffe934197350/images/50a861259f60e73c74634d2c13f8a8e935d30d51462bbf1222932c6681f7db45.png', 'sentiment': 'neutral', 'sentiment_prob': 0.890680193901062}",,,,,,,,,,['neutral'],neutral,1
NCT04362085,"{'position': 1, 'link': 'https://www.bmj.com/content/375/bmj.n2400', 'title': 'Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial', 'source': 'The BMJ', 'date': 'Oct 14, 2021', 'snippet': 'Therapeutic heparin was not significantly associated with a reduction in \nthe primary outcome but the odds of death at 28 days was decreased.', 'thumbnail': 'https://serpapi.com/searches/6721b41cb6a79cce33177d6b/images/591e37c15d8548d37ad7b9950a5f2b21bf154a68f13d313aa1b1e6f9b98deaa8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7524961233139038}",,,,,,,,,,['neutral'],neutral,1
NCT01634139,"{'position': 1, 'link': 'https://lungdiseasenews.com/2017/02/20/asthmatic-children-ages-6-and-older-can-now-use-spiriva-respimat-for-maintenance-therapy/', 'title': 'Asthmatic Kids 6 and Up Can Use Spiriva Respimat as Maintenance Therapy', 'source': 'Lung Disease News', 'date': 'Feb 20, 2017', 'snippet': 'The US Food and Drug Administration (FDA) expanded the approval of \nsteroid-free Spiriva Respimat (tiotropium bromide) for the maintenance \ntreatment of asthma...', 'thumbnail': 'https://serpapi.com/searches/6721b42f9109867ea006e66b/images/a8f188a8c36d3c408cb69a6e3eeed221e5f857cba90218e818041c4f5989e5e3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7848676443099976}",,,,,,,,,,['neutral'],neutral,1
NCT00923312,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.887125/full', 'title': 'mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': 'mRNA therapy is a novel anticancer strategy based on in vitro transcription \n(IVT), which has potential for the treatment of malignant tumors.', 'thumbnail': 'https://serpapi.com/searches/6721b48048b9f7c481f52929/images/8ff6bec5b280e0b77bb44287b603d564c96696156bb08a957854ba0861f0e927.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6790798902511597}","{'position': 2, 'link': 'https://www.sciencedirect.com/science/article/pii/S2405844024030020', 'title': 'The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases', 'source': 'ScienceDirect.com', 'date': 'Mar 15, 2024', 'snippet': 'This review aims to elucidate the advancements in the clinical applications \nof mRNAs for addressing significant health-related challenges such as \ncancer,...', 'thumbnail': 'https://serpapi.com/searches/6721b48048b9f7c481f52929/images/8ff6bec5b280e0b72fa94faf0b051c4a0052ea83717b85b13be0a51d4c380ed5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8580176830291748}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03070119,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2204705', 'title': 'Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS', 'source': 'The New England Journal of Medicine', 'date': 'Sep 21, 2022', 'snippet': 'Tofersen reduced concentrations of SOD1 in CSF and of neurofilament light \nchains in plasma over 28 weeks but did not improve clinical end points and \nwas...', 'thumbnail': 'https://serpapi.com/searches/6721b48c52a04e7ad6d80397/images/c1e33b85e5add2bcc47f21efe599d52ac35800d08ac8466eb2a5ef8023fd4373.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5358057022094727}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2003715', 'title': 'Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS', 'source': 'The New England Journal of Medicine', 'date': 'Jul 8, 2020', 'snippet': 'Tofersen is an antisense oligonucleotide that mediates the degradation of \nsuperoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein \nsynthesis.', 'thumbnail': 'https://serpapi.com/searches/6721b48c52a04e7ad6d80397/images/c1e33b85e5add2bcb50d813ab39627189d8549617201623f674c655aad52bb04.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6357830762863159}","{'position': 3, 'link': 'https://alsnewstoday.com/news/fda-approves-tofersen-now-qalsody-treatment-adults-sod1-als/', 'title': 'FDA approves tofersen, now Qalsody, as treatment for SOD1-ALS |...', 'source': 'ALS News Today', 'date': 'Apr 25, 2023', 'snippet': ""The US Food and Drug Administration (FDA) has granted conditional approval \nto Biogen's tofersen, now named Qalsody, for the treatment of amyotrophic \nlateral..."", 'thumbnail': 'https://serpapi.com/searches/6721b48c52a04e7ad6d80397/images/c1e33b85e5add2bc5bf03d4d75d2cdc7d6fe31d0dc9cedc3aa15c78a23f09662.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7133066058158875}","{'position': 4, 'link': 'https://alsnewstoday.com/news/early-tofersen-treatment-may-slow-sod1-progression-valor-study/', 'title': 'Early Tofersen Treatment May Help to Slow SOD1-ALS Progression |...', 'source': 'ALS News Today', 'date': 'Sep 23, 2022', 'snippet': 'Early treatment with tofersen was found to slow disease progression in \npeople with SOD1-ALS in the VALOR trial and its open-label extension.', 'thumbnail': 'https://serpapi.com/searches/6721b48c52a04e7ad6d80397/images/c1e33b85e5add2bc1d7491e70d57e6205615d81ef8138f5a86cebef7f226e733.png', 'sentiment': 'neutral', 'sentiment_prob': 0.49916312098503113}","{'position': 5, 'link': 'https://alsnewstoday.com/news/als-disease-progression-slowed-real-world-setting-with-qalsody/', 'title': 'Qalsody slows ALS disease progression in real-world settings', 'source': 'ALS News Today', 'date': 'Apr 25, 2024', 'snippet': ""Qalsody also stabilized patients' quality of life and lowered nerve \ndamage-related biomarkers, consistent with data supporting its approval."", 'thumbnail': 'https://serpapi.com/searches/6721b48c52a04e7ad6d80397/images/c1e33b85e5add2bc93067665bc4c0ab686ffc22da2d8e0c86610b4fd2ba129df.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6452931761741638}","{'position': 6, 'link': 'https://alsnewstoday.com/news/fda-expected-decide-tofersen-approval-sod1-als-january/', 'title': 'FDA Expected to Decide on Tofersen Approval for SOD1-ALS in January', 'source': 'ALS News Today', 'date': 'Jul 27, 2022', 'snippet': ""The US Food and Drug Administration (FDA) has agreed to review an \napplication from Biogen for approval of the company's experimental therapy \ntofersen."", 'thumbnail': 'https://serpapi.com/searches/6721b48c52a04e7ad6d80397/images/c1e33b85e5add2bc63c7e3d7417281c189d0bc5f90a01a920afce26a645f32cc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8993838429450989}",,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT00573443,"{'position': 1, 'link': 'https://www.clinicaladvisor.com/features/raising-awareness-of-pseudobulbar-affect-knowing-the-signs-symptoms-and-treatment-for-patients-with-uncontrollable-laughing-or-crying/2/', 'title': 'Raising Awareness of Pseudobulbar Affect: Knowing the Signs, Symptoms, and Treatment for Patients With Uncontrollable Laughing or Crying', 'source': 'Clinical Advisor', 'date': 'Aug 29, 2018', 'snippet': 'These uncontrollable episodes of crying or laughter come with a great deal \nof social anxiety. Patients with PBA have no control over when these \noutbursts will...', 'thumbnail': 'https://serpapi.com/searches/6721b48e4e9efc409f1cb4ef/images/5ffa806e8c34ea9bbc86e8275f2128df573fbf5f13dafdd3fa374d0359db8986.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5087947845458984}",,,,,,,,,,['negative'],negative,0
NCT01552057,"{'position': 1, 'link': 'https://fibromyalgianewstoday.com/2015/08/24/duloxetine-effective-therapy-fibromyalgia-patients-japan/', 'title': 'Duloxetine An Effective Therapy for Fibromyalgia Patients in Japan.', 'source': 'Fibromyalgia News Today', 'date': 'Aug 24, 2015', 'snippet': 'A study recently published in the journal Arthritis Research & Therapy \nrevealed new data from a phase III clinical trial showing that...', 'thumbnail': 'https://serpapi.com/searches/6721b49076585765f5a5caac/images/414f3a0c0f0d8636dde6a3608797c297264f121b64b990f3581a6641d1833ecf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8072672486305237}",,,,,,,,,,['neutral'],neutral,1
NCT03106415,"{'position': 1, 'link': 'https://breastcancer-news.com/2020/02/06/keytruda-mektovi-combo-deemed-safe-in-early-triple-negative-breast-cancer-trial/', 'title': 'Keytruda-Mektovi Combo Deemed Safe in Early Triple Negative Breast Cancer Trial', 'source': 'Breast Cancer News', 'date': 'Feb 6, 2020', 'snippet': 'Phase 1 clinical data testing a new Keytruda-Mektovi combination treatment \nfor advanced breast cancer patients has been shared by Merck.', 'thumbnail': 'https://serpapi.com/searches/6721b4b2e9b6912ba0b616c5/images/4e476a0b9630eda95d6639acaa4e671bc2911fbe3c0792a0a63f2fefb311c69a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8183563947677612}",,,,,,,,,,['neutral'],neutral,1
NCT04442503,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-zurzuvae-an-oral-treatment-for-postpartum-depression/', 'title': 'FDA Approves Zurzuvae, an Oral Treatment for Postpartum Depression', 'source': 'Medical Professionals Reference', 'date': 'Aug 7, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Zurzuvae™ (zuranolone) \nfor the treatment of postpartum depression (PPD) in adults.', 'thumbnail': 'https://serpapi.com/searches/6721b4b474978395dc84c0e4/images/bba6e6750dda0f16f1604d4f38eb439f70da42f62e55a4a0473ef009f1606916.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7844175100326538}","{'position': 2, 'link': 'https://www.empr.com/home/news/oral-postpartum-depression-treatment-zurzuvae-now-available/', 'title': 'Oral Postpartum Depression Treatment Zurzuvae Now Available', 'source': 'Medical Professionals Reference', 'date': 'Dec 14, 2023', 'snippet': 'Zurzuvae (zuranolone) is now available for the treatment of postpartum \ndepression (PPD) in adults. Zuranolone is a neuroactive steroid \ngamma-aminobutyric acid...', 'thumbnail': 'https://serpapi.com/searches/6721b4b474978395dc84c0e4/images/bba6e6750dda0f1633ed673028e4f9151f0f452aa634278b6eefa20ebe9d1be5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.879035234451294}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01343004,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Disposition-of-patients-in-ACTIVExtend-extension-trial-of-the-Abaloparatide-Comparator_fig1_313265181', 'title': 'FIGURE 1. Disposition of patients in ACTIVExtend (extension trial of...', 'source': 'ResearchGate', 'date': 'Mar 15, 2020', 'snippet': 'To assess the efficacy and safety of 18 months of subcutaneous \nabaloparatide (ABL-SC) or placebo (PBO) followed by 6 months of alendronate \n(ALN)', 'thumbnail': 'https://serpapi.com/searches/6721b4bef7adbfc5af9ede19/images/aedc298d9405ec58a2edbe309450d984875d9e6a0ddc11ee3637a5c13cba5ccf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8821626305580139}",,,,,,,,,,['neutral'],neutral,1
NCT01588509,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2016/6217286', 'title': 'Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges', 'source': 'Wiley Online Library', 'date': 'May 26, 2016', 'snippet': 'Sclerostin antibody treatment has demonstrated efficacy and superiority \ncompared to other anabolic treatments for increasing bone formation in both \npreclinical...', 'thumbnail': 'https://serpapi.com/searches/6721b5000a545a31c5325e59/images/927c3ba6555e268547000d0ef6e204a032e4a868a86dd8c7eafd75790e5ab9b0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.635117769241333}",,,,,,,,,,['neutral'],neutral,1
NCT03483103,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00339-4/fulltext', 'title': 'Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study', 'source': 'The Lancet', 'date': 'Jul 12, 2022', 'snippet': 'Patients with relapsed or refractory large B-cell lymphoma after first-line \ntreatment who are not intended for haematopoietic stem-cell...', 'thumbnail': 'https://serpapi.com/searches/6721b516175de6645df63a52/images/398e0b0265fdc6c2d88a081ef98e334ade5ebfbee8d68b1ea3f49feb14910997.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7411497831344604}","{'position': 2, 'link': 'https://www.onclive.com/view/fda-approval-insights-liso-cel-in-second-line-relapsed-refractory-lbcl', 'title': 'FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL', 'source': 'OncLive', 'date': 'Jul 28, 2022', 'snippet': 'Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large \nB-cell lymphoma, pivotal efficacy and safety data from the phase 3...', 'thumbnail': 'https://serpapi.com/searches/6721b516175de6645df63a52/images/398e0b0265fdc6c2d00eaeb47f146b8623f120849ce4d76a3c3d5eb2290555be.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8362480998039246}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00063622,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0907929', 'title': 'Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis', 'source': 'The New England Journal of Medicine', 'date': 'Apr 28, 2010', 'snippet': 'Nonalcoholic steatohepatitis is a common liver disease that can progress to \ncirrhosis. Currently, there is no established treatment for this...', 'thumbnail': 'https://serpapi.com/searches/6721b5202c83d57e0f06b3b3/images/4ce76e98f1b1d33342e35db85608c7f9bb8bc297fc476fc3ef031484a9d33c8b.png', 'sentiment': 'negative', 'sentiment_prob': 0.653390645980835}",,,,,,,,,,['negative'],negative,0
NCT04894240,"{'position': 1, 'link': 'https://alsnewstoday.com/news/fda-pharmaust-discuss-advance-monepantel-als-clinical-trials/', 'title': 'FDA, company to discuss advancing monepantel in ALS clinical trials', 'source': 'ALS News Today', 'date': 'Jan 9, 2024', 'snippet': 'The company intends to file a request to open a Phase 2/3 clinical trial of \nmonepantel in ALS/MND patients by mid-year.', 'thumbnail': 'https://serpapi.com/searches/6721b564f93388203ee90213/images/d6a949ab524d961b12e726ce7b0c51badd2fca343cfc3a29a9350f5bdb50828e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.868453323841095}","{'position': 2, 'link': 'https://alsnewstoday.com/news/benefits-repurposed-monepantel-als-sustained-2-years/', 'title': 'Benefits of repurposed monepantel for ALS sustained for up to 2 years', 'source': 'ALS News Today', 'date': 'Sep 3, 2024', 'snippet': 'Monepantel, a veterinary drug that PharmAust is repurposing for amyotrophic \nlateral sclerosis (ALS), continues to slow disease progression and extend \nsurvival.', 'thumbnail': 'https://serpapi.com/searches/6721b564f93388203ee90213/images/d6a949ab524d961bf57e13329f9ddf2bbeb75e534908ab6d89fc30a14990c83b.png', 'sentiment': 'positive', 'sentiment_prob': 0.6617053151130676}","{'position': 3, 'link': 'https://alsnewstoday.com/news/vet-drug-monepantel-slows-als-mnd-disease-progression-trial/', 'title': 'Vet drug monepantel slows ALS, MND disease progression in trial', 'source': 'ALS News Today', 'date': 'Mar 12, 2024', 'snippet': 'Treatment with monepantel, a drug used in veterinary medicine, slowed ALS \nand MND disease progression by as much as 58% in a Phase 1 trial.', 'thumbnail': 'https://serpapi.com/searches/6721b564f93388203ee90213/images/d6a949ab524d961bf63cdf890f0ea30f33a485505902a3e453a00996a82aadd1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8037352561950684}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT04056026,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332223008302', 'title': 'Gut microbiota interactions with antitumor immunity in colorectal cancer: From understanding to application', 'source': 'ScienceDirect.com', 'date': 'Jun 24, 2023', 'snippet': 'Gut microbiota (GM) shapes antitumor immune responses, affecting cancer \nimmunotherapy, especially ICIs treatment. •. Some beneficial or \ndeleterious...', 'thumbnail': 'https://serpapi.com/searches/6721b573c97e35c26b9edee7/images/d8a63df5e3c76626c6df843ac84b641c8cc5c3aaf341991e58df56036e444dd6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8978184461593628}",,,,,,,,,,['neutral'],neutral,1
NCT00002874,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1607529', 'title': 'Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Feb 2, 2017', 'snippet': 'Salvage radiation therapy is often necessary in men who have undergone \nradical prostatectomy and have evidence of prostate-cancer recurrence...', 'thumbnail': 'https://serpapi.com/searches/6721b575bbc18bbcc5cab3d4/images/d44965ac23ba553a33e7d42599d736e4b2819f0bc3f3029ea07a06e1a616d650.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7846943736076355}","{'position': 2, 'link': 'https://prostatecancernewstoday.com/2020/03/04/decipher-prostate-rp-test-predicts-adt-benefits-after-relapse-in-prostate-cancer-patients/', 'title': 'Genetic Test Seen to Predict Patients Helped by ADT Use After Surgery', 'source': 'Prostate Cancer News Today', 'date': 'Mar 4, 2020', 'snippet': 'A trial analysis found Decipher Prostate RP identified relapsed prostate \ncancer patients who might avoid metastasis by adding ADT to...', 'thumbnail': 'https://serpapi.com/searches/6721b575bbc18bbcc5cab3d4/images/d44965ac23ba553a8798ea971ba5874011d26f829d1bf288f5eb819f5dfaf442.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8665081262588501}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02612155,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-36653-9', 'title': 'Comparing the efficacy in reducing brain injury of different neuroprotective agents following neonatal hypoxia–ischemia in newborn rats: a multi-drug randomized controlled screening trial | Scientific Reports', 'source': 'Nature', 'date': 'Jun 10, 2023', 'snippet': 'We aimed to compare the treatment effects of putative neuroprotective drug \ncandidates following neonatal hypoxic-ischemic (HI) brain injury in an \nestablished P...', 'thumbnail': 'https://serpapi.com/searches/6721b579bb55ff271c7cf6c1/images/8e6242d440b24e34faba55ee3b4daf825a40881e968dc7dd46973f7e7dfdfe7b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8951135873794556}",,,,,,,,,,['neutral'],neutral,1
NCT04470427,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2035389', 'title': 'Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine', 'source': 'The New England Journal of Medicine', 'date': 'Dec 30, 2020', 'snippet': 'Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to \nprotect persons who are at high risk for complications.', 'thumbnail': 'https://serpapi.com/searches/6721b58039e23248aec4e97c/images/4fc3866e99978b500993ed5bd7ac9e7851113fcca54378eba49518b3a7084dd3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.787030816078186}","{'position': 2, 'link': 'https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins', 'title': 'Phase 3 clinical trial of investigational vaccine for COVID-19 begins', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jul 27, 2020', 'snippet': 'A Phase 3 clinical trial designed to evaluate if an investigational vaccine \ncan prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has \nbegun.', 'thumbnail': 'https://serpapi.com/searches/6721b58039e23248aec4e97c/images/4fc3866e99978b502fc32918081796e099e173892a6f3db8893c51211ab82118.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.903743326663971}","{'position': 3, 'link': 'https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine', 'title': 'Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Nov 16, 2020', 'snippet': 'An interim review of trial data suggests that the vaccine is safe and \neffective at preventing symptomatic COVID-19 in adults.', 'thumbnail': 'https://serpapi.com/searches/6721b58039e23248aec4e97c/images/4fc3866e99978b5021ba93c70d6466a5dbbaf7934fe990c00685d2c8430e68e7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.563819408416748}","{'position': 4, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2113017', 'title': 'Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase', 'source': 'The New England Journal of Medicine', 'date': 'Sep 22, 2021', 'snippet': 'At interim analysis in a phase 3, observer-blinded, placebo-controlled \nclinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in...', 'thumbnail': 'https://serpapi.com/searches/6721b58039e23248aec4e97c/images/4fc3866e99978b5009a47a9d4bd4b4b61cc30e8e3cc2da08a221a0ad987e39dc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7600132822990417}","{'position': 5, 'link': 'https://www.researchgate.net/figure/Ongoing-vaccine-development-platforms-for-SARS-CoV-2-live-attenuated-nucleic-acid_fig1_349232724', 'title': 'Fig. 2 Ongoing vaccine development platforms for SARS-CoV-2 (live...', 'source': 'ResearchGate', 'date': 'Oct 21, 2023', 'snippet': 'Ongoing vaccine development platforms for SARS-CoV-2 (live attenuated, \nnucleic acid, viral vector, and protein vaccines. a Candidate vaccines in \nclinical...', 'thumbnail': 'https://serpapi.com/searches/6721b58039e23248aec4e97c/images/4fc3866e99978b509aa5d0b43a9bc618a2a55c86ef7f76fcbd879646db0f7fd8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9133256077766418}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03018730,"{'position': 1, 'link': 'https://fabrydiseasenews.com/news/elfabrio-slows-kidney-decline-adults-bridge-phase-3-trial/', 'title': 'Elfabrio slows kidney decline in adults in BRIDGE Phase 3 trial', 'source': 'Fabry Disease News', 'date': 'Jan 19, 2024', 'snippet': 'A year of treatment with Elfabrio (pegunigalsidase alfa) is well tolerated \nand slows the progression of kidney disease in men and women with Fabry \ndisease.', 'thumbnail': 'https://serpapi.com/searches/6721b589d0c9832b2aa607f1/images/07ff7563b659726712fbde49970537d5a290c64bebf41a1360bf90e4a104bb0e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6687831282615662}","{'position': 2, 'link': 'https://fabrydiseasenews.com/news/protalix-fabry-disease-therapy-pegunigalsidase-alfa-granted-fda-fast-track-designation/', 'title': 'Fabry Disease Therapy Pegunigalsidase Alfa Gets FDA Fast Track Status', 'source': 'Fabry Disease News', 'date': 'Feb 6, 2018', 'snippet': ""The US Food and Drug Administration (FDA) has granted fast track \ndesignation to pegunigalsidase alfa, or PRX-102, Protalix BioTherapeutics' \ntherapy candidate..."", 'thumbnail': 'https://serpapi.com/searches/6721b589d0c9832b2aa607f1/images/07ff7563b65972678bf515846afea9535602abc0488b90b145f12ce0edfa7f1a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8152209520339966}","{'position': 3, 'link': 'https://fabrydiseasenews.com/news/elfabrio-soon-available-fabry-patients-england-low-no-cost/', 'title': 'Elfabrio soon available to Fabry patients in England at low or no cost', 'source': 'Fabry Disease News', 'date': 'Sep 15, 2023', 'snippet': 'Elfabrio was approved in the U.K. as a long-term enzyme replacement therapy \nin adults with Fabry disease in August.', 'thumbnail': 'https://serpapi.com/searches/6721b589d0c9832b2aa607f1/images/07ff7563b65972672aaf24bf4ef1ab7b04d7248720bbb96e0785166d6829b9de.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7245880365371704}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02719327,"{'position': 1, 'link': 'https://www.researchgate.net/publication/339588081_Current_and_Future_Treatments_in_Alzheimer_Disease_An_Update', 'title': '(PDF) Current and Future Treatments in Alzheimer Disease: An Update', 'source': 'ResearchGate', 'date': 'Mar 2, 2020', 'snippet': 'PDF | Disease-modifying treatment strategies for Alzheimer disease (AD) are \nstill under extensive research. Nowadays, only symptomatic treatments exist.', 'thumbnail': 'https://serpapi.com/searches/6721b5f511db454073485a66/images/b4667b0f3f8f61bfa51b309452454b3d4ce985e56309d5b63a607af7836128d8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7160391807556152}",,,,,,,,,,['neutral'],neutral,1
NCT03679884,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00007-2/fulltext', 'title': 'Daridorexant for insomnia disorder', 'source': 'The Lancet', 'date': 'Jan 20, 2022', 'snippet': 'Insomnia disorder is defined by difficulties initiating or maintaining \nsleep, or both, resulting in substantial daytime dysfunction.', 'thumbnail': 'https://serpapi.com/searches/6721b63c8de63cccbee0d41c/images/22902fe6fcd75c7dddcfc13945737cba333e66c972c3d64bd900b5b68dadd6c9.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7720100283622742}",,,,,,,,,,['negative'],negative,0
NCT03869437,"{'position': 1, 'link': 'https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05870-w', 'title': 'Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, ran', 'source': 'BioMed Central', 'date': 'Dec 7, 2021', 'snippet': 'This study will use a multicentre, open-label non-inferiority trial design \ncomparing cefiderocol and standard of care antibiotics.', 'thumbnail': 'https://serpapi.com/searches/6721b693cb33d011be845a6a/images/51c5638c15290716fd71e3de7d82b74cc13eb1cb147a23e497ca951385248cb9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8898130059242249}",,,,,,,,,,['neutral'],neutral,1
NCT02960906,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00128-0/fulltext', 'title': 'Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial', 'source': 'The Lancet', 'date': 'Apr 4, 2022', 'snippet': 'Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as \nfirst-line treatment for metastatic clear-cell renal cell carcinoma \n(BIONIKK)', 'thumbnail': 'https://serpapi.com/searches/6721b6ad6f9f6391e0983006/images/892b02b9ed8348d6198641b24caa864d4e7fd0b5c07709725710befd7a27b1bd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8349693417549133}",,,,,,,,,,['neutral'],neutral,1
NCT03601052,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-33148-5', 'title': 'Topical application of an irreversible small molecule inhibitor of lysyl oxidases ameliorates skin scarring and fibrosis', 'source': 'Nature', 'date': 'Sep 22, 2022', 'snippet': 'Scarring is a lifelong consequence of skin injury, with scar stiffness and \npoor appearance presenting physical and psychological barriers to...', 'thumbnail': 'https://serpapi.com/searches/6721b6b6358539d63868a3cb/images/b6908198b52de1919f2063a00f8e875dd49f402f6bb53063fb04ecb4cfbd2a48.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5087712407112122}",,,,,,,,,,['neutral'],neutral,1
NCT01970371,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMc1807634', 'title': 'Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae', 'source': 'The New England Journal of Medicine', 'date': 'Feb 20, 2019', 'snippet': 'The CARE trial evaluated the efficacy and safety of plazomicin as compared \nwith colistin as part of a combination-therapy regimen for serious CRE \ninfections.', 'thumbnail': 'https://serpapi.com/searches/6721b6ca98876dbcee669cd0/images/97b292b7b6bcce5ecdb6594b8f99eda0588c71aee91438424e001b2541b01ec6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8676716685295105}",,,,,,,,,,['neutral'],neutral,1
NCT02265744,"{'position': 1, 'link': 'https://www.genengnews.com/topics/drug-discovery/bms-licenses-autoimmune-research-program-from-novo-nordisk/', 'title': 'BMS Licenses Autoimmune Research Program from Novo Nordisk', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Mar 24, 2015', 'snippet': ""Deal fits BMS' focus on immunoscience diseases as a core therapeutic area, \nand Novo Nordisk's specialization in diabetes therapies."", 'thumbnail': 'https://serpapi.com/searches/6721b7208de63cccbee0d4b8/images/7a94f8183bc95fbaf44eaa058ec96498a1296588d44df98d87d1deacd65b90b1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8534430861473083}",,,,,,,,,,['neutral'],neutral,1
NCT03667716,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2018/11/02/compugen-bristol-myers-squibb-collaborating-to-test-com701-opdivo-combo-for-ovarian-other-cancers/', 'title': 'For Ovarian, Other Cancers, Phase 1 Trial Testing COM701 with Opdivo', 'source': 'Ovarian Cancer News Today', 'date': 'Nov 2, 2018', 'snippet': 'Compugen has entered into a clinical trial collaboration with Bristol-Myers \nSquibb (BMS) to evaluate the safety and preliminary...', 'thumbnail': 'https://serpapi.com/searches/6721b72fe30abcd3b5d56a32/images/7ba65ffebf4df02401d52342a6248981fe3294d55bb5553e4024c27ed2a12d57.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9168850779533386}",,,,,,,,,,['neutral'],neutral,1
NCT00514696,"{'position': 1, 'link': 'https://www.nature.com/articles/s41573-023-00636-2', 'title': 'Targeting galectin-driven regulatory circuits in cancer and fibrosis', 'source': 'Nature', 'date': 'Feb 9, 2023', 'snippet': 'Galectins are a family of endogenous glycan-binding proteins that have \ncrucial roles in a broad range of physiological and pathological...', 'thumbnail': 'https://serpapi.com/searches/6721b737861b9d0757216488/images/c560ef45e595bef22737cc28412e5e2b696960c49139a63150783cb22326f7ef.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8717686533927917}",,,,,,,,,,['neutral'],neutral,1
NCT02866383,"{'position': 1, 'link': 'https://www.onclive.com/view/nivolumab-ipilimumab-plus-sbrt-shows-antitumor-activity-in-refractory-pancreatic-cancer', 'title': 'Nivolumab/Ipilimumab Plus SBRT Shows Antitumor Activity in Refractory Pancreatic Cancer', 'source': 'OncLive', 'date': 'May 18, 2022', 'snippet': 'Stereotactic body radiation therapy (SBRT) in combination with nivolumab \n(Opdivo) and ipilimumab (Yervoy) demonstrated clinically meaningful...', 'thumbnail': 'https://serpapi.com/searches/6721b75fcc29875e74531b3b/images/4429df9a59dc43a9167bce58d16554820fd5cb8a8c15b70a018bc00b043f2613.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8238801956176758}",,,,,,,,,,['neutral'],neutral,1
NCT04518410,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/four-potential-covid-19-therapeutics-enter-phase-2-3-testing-nih-activ-2-trial', 'title': 'Four potential COVID-19 therapeutics enter Phase 2/3 testing in NIH ACTIV-2 trial', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Feb 12, 2021', 'snippet': 'An adaptive trial designed to test investigational agents in \nnon-hospitalized adult volunteers experiencing mild to moderate COVID-19 \nsymptoms.', 'thumbnail': 'https://serpapi.com/searches/6721b7915c7cb930cf008630/images/366490cac92f2ed72ab70f85a83a9272fa5c98d17678232f5dd2c97a87f18add.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.915380597114563}","{'position': 2, 'link': 'https://www.nature.com/articles/s41564-022-01254-1', 'title': 'Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial', 'source': 'Nature', 'date': 'Oct 26, 2022', 'snippet': 'SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) \ntherapy have been reported. However, it remains unclear whether in...', 'thumbnail': 'https://serpapi.com/searches/6721b7915c7cb930cf008630/images/366490cac92f2ed716c02d1a33c0aee76d85d8d699273377adade91ecfe9d209.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7785572409629822}","{'position': 3, 'link': 'https://www.idse.net/Multimedia/Article/02-23/Commonality-of-COVID-19-Rebound-With-Antiviral-Therapy/69501', 'title': 'Commonality of COVID-19 Rebound With Antiviral Therapy', 'source': 'Infectious Disease Special Edition', 'date': 'Feb 21, 2023', 'snippet': 'Viral and symptom rebound of COVID-19 were not limited to patients taking \nantiviral therapies, such as Paxlovid.', 'thumbnail': 'https://serpapi.com/searches/6721b7915c7cb930cf008630/images/366490cac92f2ed79a73e60f4b62be22a17031b1c9f0e08ebe7f639452768885.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6199172735214233}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02201576,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.651222/full', 'title': 'Therapies for Chronic Allograft Rejection', 'source': 'Frontiers', 'date': 'Feb 16, 2024', 'snippet': 'Remarkable advances have been made in the pathophysiology, diagnosis, and \ntreatment of antibody-mediated rejection (ABMR) over the past decades,...', 'thumbnail': 'https://serpapi.com/searches/6721b7ce7e1d1f5f594acf83/images/db48a38e683f5908fa6b743d36e89e4da31d04df0b6bf77246c143d6fffd4416.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5090750455856323}",,,,,,,,,,['positive'],positive,1
NCT04925934,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/horizon-phase-2-trial-daxdilimab-sle-fails-meet-main-goal/', 'title': 'Horizon: Phase 2 trial of daxdilimab in SLE fails to meet main goal', 'source': 'Lupus News Today', 'date': 'Jul 27, 2023', 'snippet': ""A Phase 2 clinical trial assessing the safety and effectiveness of \ndaxdilimab for systemic lupus erythematosus (SLE) didn't show a \nstatistically significant..."", 'thumbnail': 'https://serpapi.com/searches/6721b7cfd72128f26f324d60/images/8fb114117fe7bfac6f0cbd86fa6fd941ba5120ea764aaf6818ac01d82cae436e.png', 'sentiment': 'negative', 'sentiment_prob': 0.7036017179489136}",,,,,,,,,,['negative'],negative,0
NCT03523351,"{'position': 1, 'link': 'https://www.itnonline.com/content/radiation-therapy-high-risk-asymptomatic-bone-metastases-may-prevent-pain-and-prolong-life', 'title': 'Radiation Therapy for High-risk, Asymptomatic Bone Metastases May Prevent Pain and Prolong Life', 'source': 'Imaging Technology News', 'date': 'Oct 23, 2022', 'snippet': 'Phase II trial suggests radiation could ward off complications of bone \nlesions and extend overall survival for patients with advanced...', 'thumbnail': 'https://serpapi.com/searches/6721b7e6a86921bfc102a567/images/e8598d731bc06cea6861cac90f1448e3e1369e0d46feed2688a18ccdcd817e4d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6383232474327087}","{'position': 2, 'link': 'https://www.cancertherapyadvisor.com/reports/radiotherapy-bone-metastases-asymptomatic-reduces-skeletal-related-events/', 'title': 'Radiotherapy of Asymptomatic Bone Metastases Reduces Skeletal-Related Events', 'source': 'Cancer Therapy Advisor', 'date': 'Nov 3, 2022', 'snippet': 'Adding prophylactic radiotherapy to standard care appears safe and \neffective for treating asymptomatic bone metastases in patients with solid \ntumors.', 'thumbnail': 'https://serpapi.com/searches/6721b7e6a86921bfc102a567/images/e8598d731bc06ceaefc8623c739f48fbc12937572f2e155cc843248d1c5fad22.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6410998106002808}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01617967,"{'position': 1, 'link': 'https://www.cureus.com/articles/261263-rna-interference-therapeutics-for-hereditary-amyloidosis-a-narrative-review-of-clinical-trial-outcomes-and-future-directions', 'title': 'RNA Interference Therapeutics for Hereditary Amyloidosis: A Narrative Review of Clinical Trial Outcomes and Future Directions', 'source': 'Cureus', 'date': 'Jun 23, 2024', 'snippet': 'Hereditary transthyretin amyloidosis (ATTR) is an autosomal dominant, \nlife-threatening genetic disorder caused by a single-nucleotide...', 'thumbnail': 'https://serpapi.com/searches/6721b7f54791c43a82b8a6bd/images/f2d635b823feb69075e61cc59351b64936c2e791e85d891132a69f363390d4e1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8145601153373718}",,,,,,,,,,['neutral'],neutral,1
NCT02134028,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/cea.14389', 'title': 'Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization', 'source': 'Wiley Online Library', 'date': 'Sep 26, 2023', 'snippet': 'Background Fungal sensitization (FS) exacerbates asthma in patients who \nhave elevated type 2 inflammatory response. Dupilumab, a fully human...', 'thumbnail': 'https://serpapi.com/searches/6721b809e50bc0cdb2059332/images/28bb2aec212c5a1dcff065e6cf109834ff80b56df32d2fc4db658ab842983739.png', 'sentiment': 'negative', 'sentiment_prob': 0.5187826752662659}",,,,,,,,,,['negative'],negative,0
NCT03687255,"{'position': 1, 'link': 'https://www.urologytimes.com/view/fda-approves-cefepime-enmetazobactam-for-complicated-uti', 'title': 'FDA approves cefepime/enmetazobactam for complicated UTI', 'source': 'Urology Times', 'date': 'Feb 27, 2024', 'snippet': 'The FDA approval is supported by data from the phase 3 ALLIUM trial, which \ndemonstrated the non-inferiority and superiority of...', 'thumbnail': 'https://serpapi.com/searches/6721b825237938d086ab4abe/images/e2e4dcd6aef5a9662904e60c9751518549a3de1749998050d145cdc831124f96.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5308451652526855}",,,,,,,,,,['neutral'],neutral,1
NCT04872101,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/delgocitinib-cream-improves-chronic-hand-eczema-in-second-phase-3-trial/', 'title': 'Delgocitinib Cream Improves Chronic Hand Eczema in Second Phase 3 Trial', 'source': 'Medical Professionals Reference', 'date': 'Feb 13, 2023', 'snippet': 'Positive results were announced from the DELTA 2 study evaluating \ndelgocitinib cream in patients with moderate to severe chronic hand...', 'thumbnail': 'https://serpapi.com/searches/6721b8d2f3622abe1394ff92/images/4806e2f9e5420c8e0b032b232f5a729463b316a1fcfaea5582f1f833ee88bc8e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5962463021278381}",,,,,,,,,,['neutral'],neutral,1
NCT03418480,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1246682/full', 'title': 'Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities', 'source': 'Frontiers', 'date': 'Feb 6, 2024', 'snippet': 'Since the successful application of messenger RNA (mRNA) vaccines in \npreventing COVID-19, researchers have been striving to develop mRNA \nvaccines for...', 'thumbnail': 'https://serpapi.com/searches/6721b8eca471671c163a1893/images/b00095541cb1887d7de20b959ce4d7ab8ae05833bc909d4f82d7b73594eb0590.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7236034274101257}",,,,,,,,,,['positive'],positive,1
NCT05030311,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/remibrutinib-improves-symptoms-in-patients-with-chronic-spontaneous-urticaria/', 'title': 'Remibrutinib Improves Symptoms in Patients With Chronic Spontaneous Urticaria', 'source': 'Medical Professionals Reference', 'date': 'Aug 9, 2023', 'snippet': 'Treatment with remibrutinib, an investigational Bruton tyrosine kinase \n(BTK) inhibitor, appears to benefit patients with chronic spontaneous \nurticaria (CSU).', 'thumbnail': 'https://serpapi.com/searches/6721b988f9f904883974ea20/images/8940d59fe5301a0e2ae7458577befc0305c60003ef838fd41bb80b5c228bafd3.png', 'sentiment': 'positive', 'sentiment_prob': 0.6247542500495911}",,,,,,,,,,['positive'],positive,1
NCT05520775,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-48780-6', 'title': 'Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population', 'source': 'Nature', 'date': 'May 28, 2024', 'snippet': 'We show that semaglutide compared with other anti-obesity medications is \nassociated with a 50%-56% lower risk for both the incidence and recurrence \nof alcohol...', 'thumbnail': 'https://serpapi.com/searches/6721ba3ae9b6912ba0b61a65/images/2a06a2f54f089733e15cbe163780e2e098bdc25a2032846166d44ded7e943e3d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8500338792800903}",,,,,,,,,,['neutral'],neutral,1
NCT02517489,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2215145', 'title': 'Hydrocortisone in Severe Community-Acquired Pneumonia', 'source': 'The New England Journal of Medicine', 'date': 'Mar 21, 2023', 'snippet': 'In this phase 3, multicenter, double-blind, randomized, controlled trial, \nwe assigned adults who had been admitted to the intensive care unit (ICU) \nfor...', 'thumbnail': 'https://serpapi.com/searches/6721ba4d3ad34d77a222d004/images/25b2ffca900f66c08c6157944cb6cf512e19b8e4a2e571076852e7452cfec655.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.894648551940918}",,,,,,,,,,['neutral'],neutral,1
NCT01263379,"{'position': 1, 'link': 'https://www.manilatimes.net/2024/10/29/tmt-newswire/globenewswire/abeona-therapeutics-completes-pz-cel-biologics-license-application-resubmission-to-us-food-and-drug-administration/1993209', 'title': 'Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration', 'source': 'The Manila Times', 'date': '17 hours ago', 'snippet': 'CLEVELAND, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. \n(Nasdaq: ABEO) today announced that the Company has resubmitted its...', 'thumbnail': 'https://serpapi.com/searches/6721ba5d14c31e91b1a9ca2a/images/d82f897079e6b046a02df14ed22f9bce93841f5c4fd6a26434c7daf663c3a67b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8937640190124512}","{'position': 2, 'link': 'https://epidermolysisbullosanews.com/news/pivotal-eb-101-cell-therapy-trial-rdeb-adds-2nd-site-other-us-coast/', 'title': 'Pivotal EB-101 Cell Therapy Trial Adds 2nd Site on Other US Coast', 'source': 'Epidermolysis Bullosa News', 'date': 'Jul 30, 2021', 'snippet': 'The VIITAL study, testing EB-101 for RDEB at Stanford in California, now \nhas added a second site at UMass Memorial Medical Center.', 'thumbnail': 'https://serpapi.com/searches/6721ba5d14c31e91b1a9ca2a/images/d82f897079e6b04667481d61b63c98d3887a82cde8b81bc70d94e9556132eaf5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9427775144577026}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02635789,"{'position': 1, 'link': 'https://www.empr.com/home/news/hyftor-topical-gel-now-available-for-tsc-associated-facial-angiofibroma/', 'title': 'Hyftor Topical Gel Now Available for TSC-Associated Facial Angiofibroma', 'source': 'Medical Professionals Reference', 'date': 'Aug 30, 2022', 'snippet': 'Hyftor (sirolimus topical gel) is now available for the treatment of facial \nangiofibroma associated with tuberous sclerosis complex (TSC) in patients 6 \nyears...', 'thumbnail': 'https://serpapi.com/searches/6721ba6f7ac73169f85259a6/images/5b592368e0760613c41a918dc45ed0acaed86a0089b332e81c6ede8d7dd60df6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8714544177055359}",,,,,,,,,,['neutral'],neutral,1
NCT02315443,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/SVIN.123.001251', 'title': 'Neurointerventional Advances in 2023', 'source': 'American Heart Association Journals', 'date': 'Feb 16, 2024', 'snippet': 'This past year did not disappoint with major advancements in acute ischemic \nstroke (AIS) and intracranial hemorrhage (ICH) care across...', 'thumbnail': 'https://serpapi.com/searches/6721ba78a5d70237c4700fb6/images/451db7875859d0e92ed280debb8f5d8625ca77174d50c2f8ecbc190c46510a8b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.9299209713935852}",,,,,,,,,,['positive'],positive,1
NCT03934307,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2208391', 'title': 'Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension', 'source': 'The New England Journal of Medicine', 'date': 'Jul 19, 2023', 'snippet': 'Angiotensinogen is the sole precursor of angiotensin peptides and has a key \nrole in the pathogenesis of hypertension.', 'thumbnail': 'https://serpapi.com/searches/6721ba9d51d84d1f0a6ed4e3/images/61c2cfcf12021317c19b30a510f0f76c974213420f1a14797fa989d0a49486c0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8883540034294128}",,,,,,,,,,['neutral'],neutral,1
NCT02122952,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1706198', 'title': 'Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy', 'source': 'The New England Journal of Medicine', 'date': 'Nov 2, 2017', 'snippet': 'Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor \nneuron disease with an onset during infancy that results in failure...', 'thumbnail': 'https://serpapi.com/searches/6721baa698876dbcee669f57/images/b8bccdfd70c084a9398c13fc45deb964d4fea173206e92f506f64dbfdb24e17f.png', 'sentiment': 'negative', 'sentiment_prob': 0.7062687873840332}",,,,,,,,,,['negative'],negative,0
NCT01734928,"{'position': 1, 'link': 'https://www.oncnursingnews.com/view/pvd-confers-a-small-os-benefit-to-patients-with-relapsed-refractory-multiple-myeloma', 'title': 'PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma', 'source': 'Oncology Nursing News', 'date': 'Oct 1, 2023', 'snippet': 'Patients who received pomalidomide, bortezomib, and dexamethasone achieved \na median overall survival of 35.6 months compared with 31.6...', 'thumbnail': 'https://serpapi.com/searches/6721baa99819f38857e0d4f5/images/7874f6e51856b66e3dd716d618ab1ae4c17b9396595efc67469d8bbb9af0e04d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8126075863838196}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/optimismm-trial-shows-benefit-of-pomalyst-combo-for-resistant-mm/', 'title': 'OPTIMISMM Trial Shows Benefit of Pomalyst Combo for Resistant MM', 'source': 'Myeloma Research News', 'date': 'May 31, 2019', 'snippet': 'Pivotal OPTIMISMM trial shows that combining Pomalyst with Velcade and \ndexamethasone can prolong survival of patients with...', 'thumbnail': 'https://serpapi.com/searches/6721baa99819f38857e0d4f5/images/7874f6e51856b66e3d943af1c55ce80abc36143f29ffcc5214897f4f2d172ae6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6882515549659729}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04796896,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2209367', 'title': 'Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age', 'source': 'The New England Journal of Medicine', 'date': 'Oct 19, 2022', 'snippet': 'The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 \ncoronavirus disease 2019 (Covid-19) vaccine in young children are...', 'thumbnail': 'https://serpapi.com/searches/6721bac37f37191077d4c015/images/6da48aefc2480fbd78c48deca5380fd42db1689e23589ca92702ec78b09148c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8973256945610046}",,,,,,,,,,['neutral'],neutral,1
NCT01534403,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/epratuzumab', 'title': 'Epratuzumab', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Systemic Lupus Erythematosus, Pharmacokinetics Study of Epratuzumab in \nSystemic Lupus Erythematosus (SLE), Phase 2, SL0002', 'thumbnail': 'https://serpapi.com/searches/6721baf4f93388203ee905f7/images/f3abd82d09084f422ebd14ec0666a9fd19b1eb6365a4241ca1b411907b57b221.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8819728493690491}",,,,,,,,,,['neutral'],neutral,1
NCT02497001,"{'position': 1, 'link': 'https://copdnewstoday.com/news/copd-trial-breztri-aerosphere-cardiopulmonary-risk-opens/', 'title': 'Phase 3 trial of Breztri in easing cardiopulmonary problems opens', 'source': 'COPD News Today', 'date': 'Mar 18, 2024', 'snippet': 'A Phase 3 clinical trial assessing the potential of triple-combination \nBreztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) to...', 'thumbnail': 'https://serpapi.com/searches/6721bb3aa88278df22a19d32/images/5c4fb1f8415af54692198ed983f6d23eaa3335f6ca23f0cb9a4c90785f802f64.png', 'sentiment': 'neutral', 'sentiment_prob': 0.820160984992981}","{'position': 2, 'link': 'https://copdnewstoday.com/news/copd-maintenance-treatment-breztri-aerosphere-approved-by-fda/', 'title': 'COPD Maintenance Treatment Breztri Aerosphere Approved by FDA', 'source': 'COPD News Today', 'date': 'Jul 28, 2020', 'snippet': ""AstraZeneca's Breztri Aerosphere has been approved by the U.S. Food and \nDrug Administration as a maintenance treatment for COPD."", 'thumbnail': 'https://serpapi.com/searches/6721bb3aa88278df22a19d32/images/5c4fb1f8415af546763eaa59c192c15a9dbdd87483cd21a1caf53a2bf046807d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6785445213317871}","{'position': 3, 'link': 'https://copdnewstoday.com/news/copd-triple-combination-therapy-approved-china-astra-zeneca/', 'title': 'COPD Triple-combination Therapy Approved in China, AstraZeneca Announces', 'source': 'COPD News Today', 'date': 'Jan 3, 2020', 'snippet': ""AstraZeneca's triple-combination therapy has been approved in China for the \nmaintenance treatment of chronic obstructive pulmonary disease..."", 'thumbnail': 'https://serpapi.com/searches/6721bb3aa88278df22a19d32/images/5c4fb1f8415af546eac862fd90d2401202143b0957b45b5ad49d85af407bd8f5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6615996360778809}","{'position': 4, 'link': 'https://copdnewstoday.com/news/european-chmp-gives-positive-opinion-to-copd-therapy-trixeo-aerosphere/', 'title': 'European CHMP Gives Positive Opinion to COPD Therapy Trixeo Aerosphere', 'source': 'COPD News Today', 'date': 'Oct 20, 2020', 'snippet': 'Trixeo Aerosphere has demonstrated strong clinical benefit when compared \nwith dual-combination therapies and this positive recommendation brings us \ncloser to...', 'thumbnail': 'https://serpapi.com/searches/6721bb3aa88278df22a19d32/images/5c4fb1f8415af54659173adcfde9336570494d398a64a01942ed25afebe2fdf9.png', 'sentiment': 'positive', 'sentiment_prob': 0.8232856392860413}",,,,,,,"['neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT00021255,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0910383', 'title': 'Adjuvant Trastuzumab in HER2-Positive Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Oct 6, 2011', 'snippet': 'Trastuzumab improves survival in the adjuvant treatment of HER-positive \nbreast cancer, although combined therapy with anthracycline-based regimens \nhas been...', 'thumbnail': 'https://serpapi.com/searches/6721bb4274f0a452ea2b101b/images/b6c069d0288e17e9b8b20190b632692bcde2b0070cbb459de4cf21583b7da66f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6241481900215149}",,,,,,,,,,['neutral'],neutral,1
NCT04483947,"{'position': 1, 'link': 'https://www.nature.com/articles/s41575-023-00796-x', 'title': 'Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach', 'source': 'Nature', 'date': 'Jun 2, 2023', 'snippet': 'In this Perspective, we discuss why antifibrotic effects observed in NASH \npharmacotherapy trials have been underwhelming and outline potential \napproaches.', 'thumbnail': 'https://serpapi.com/searches/6721bb69667ec57cb39be1be/images/ea7f0e943ff50de71cb4861b4e718643d6afe34a9cf320b97b91b563814ce0bb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8069649934768677}","{'position': 2, 'link': 'https://www.nature.com/articles/s41392-022-01119-3', 'title': 'Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)', 'source': 'Nature', 'date': 'Aug 13, 2022', 'snippet': 'In this review, we discussed recent developments in etiology and \nprospective therapeutic targets, as well as pharmacological candidates in \npre/clinical trials...', 'thumbnail': 'https://serpapi.com/searches/6721bb69667ec57cb39be1be/images/ea7f0e943ff50de7b05404d2a5e77db62d7ba7b66bbf138332061eaf50576ea8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9206169247627258}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05080270,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/06/06/early-promise-treating-ms-seen-with-fibrobiologics-fibroblast-therapy/', 'title': ""Early Promise in Treating MS Seen With FibroBiologic's Fibroblast Therapy"", 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 6, 2022', 'snippet': 'A fibroblast cell therapy developed by FibroBiologics was effective in a \nmouse model of multiple sclerosis and safe in five patients.', 'thumbnail': 'https://serpapi.com/searches/6721bb9cf9f904883974eb58/images/f641d67f4a01c9a2400eca3a34f69bc2c28b8d802b85e96a2690f0023496df56.png', 'sentiment': 'positive', 'sentiment_prob': 0.6921964287757874}",,,,,,,,,,['positive'],positive,1
NCT02580552,"{'position': 1, 'link': 'https://www.nature.com/articles/s12276-023-01050-9', 'title': 'MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies', 'source': 'Nature', 'date': 'Jul 10, 2023', 'snippet': 'As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a \ncrucial role in cancer development. Since the discovery of the...', 'thumbnail': 'https://serpapi.com/searches/6721bbb26ad3c98a6ed69369/images/a3c485ba5dc6b411d1ff481b378ee6b4126fa4861c627c6aa8eca8ede8d43fb9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8747607469558716}",,,,,,,,,,['neutral'],neutral,1
NCT03197935,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-022-00457-3', 'title': 'Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer', 'source': 'Nature', 'date': 'Sep 19, 2022', 'snippet': 'These patient-reported data inform clinical benefit and decision-making for \nadding atezolizumab to neoadjuvant chemotherapy in early-stage TNBC.', 'thumbnail': 'https://serpapi.com/searches/6721bc44ca6f0c61948101f3/images/887d801f34e0fd9377681693f14fb3d79df90c606ecfa49869b19131c0508878.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8834286332130432}",,,,,,,,,,['neutral'],neutral,1
NCT03956355,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2103629', 'title': 'Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Dec 8, 2021', 'snippet': 'Tapinarof cream is a topical aryl hydrocarbon receptor–modulating agent \nunder investigation for the treatment of psoriasis.', 'thumbnail': 'https://serpapi.com/searches/6721bd9849ea55cdb868e635/images/c01e7495a8fa9d3612cf094b681582d85259f706589aaaee69d0b1cb9de3d9ed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8930850028991699}","{'position': 2, 'link': 'https://www.dermatologytimes.com/view/tapinarof-cream-1-is-fda-approved', 'title': 'Tapinarof Cream 1% is FDA Approved', 'source': 'Dermatology Times', 'date': 'May 24, 2022', 'snippet': 'Tapinarof cream 1%, (Vtama; Dermavant Sciences) was approved by the FDA for \ntopical treatment of plaque psoriasis in adults.', 'thumbnail': 'https://serpapi.com/searches/6721bd9849ea55cdb868e635/images/c01e7495a8fa9d3642d0da2eb42df5487f9b70f7d6e0380483723dd2420f58d6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5443679094314575}","{'position': 3, 'link': 'https://www.pharmacypracticenews.com/FDA-Approvals/Article/05-22/FDA-Approves-First-Steroid-Free-Cream-for-Plaque-Psoriasis/67058?ses=ogst', 'title': 'FDA Approves First Steroid-Free Cream for Plaque Psoriasis', 'source': 'Pharmacy Practice News', 'date': 'May 24, 2022', 'snippet': 'With the approval of tapinarof (Vtama, Dermavant) cream, the FDA allowed \nthe marketing of the first steroid-free topical medication for the \ntreatment of adults...', 'thumbnail': 'https://serpapi.com/searches/6721bd9849ea55cdb868e635/images/c01e7495a8fa9d36cb93236c604763ade089de500e3812e9baeaf82ba93488fc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6624809503555298}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT01928576,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-023-02267-1', 'title': 'Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors', 'source': 'Nature', 'date': 'Apr 22, 2023', 'snippet': 'We evaluated whether epigenetic therapy plus IDO1 inhibition and immune \ncheckpoint blockade confers clinical benefit to patients with advanced \nsolid tumors.', 'thumbnail': 'https://serpapi.com/searches/6721bdc27ac73169f8525bea/images/2d8b3bc0f5b55b216b39bef7d0c592baeed9c35535ec9b08fdb4bc53a9ae6b75.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8710958957672119}",,,,,,,,,,['neutral'],neutral,1
NCT00634270,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-0903-x', 'title': 'Translating current basic research into future therapies for neurofibromatosis type 1', 'source': 'Nature', 'date': 'May 22, 2020', 'snippet': 'Neurofibromatosis type 1 (NF1) is a hereditary tumour syndrome that \npredisposes to benign and malignant tumours originating from neural...', 'thumbnail': 'https://serpapi.com/searches/6721be3e993688eab341f3d0/images/43e1efcb9ba5aa049061f5aa7d2cffd708527404179ba39ab5ee2c4c048b8081.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.803081214427948}",,,,,,,,,,['neutral'],neutral,1
NCT03493932,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-024-01226-x', 'title': 'Immunotherapy for glioblastoma: current state, challenges, and future perspectives | Cellular & Molecular Immunology', 'source': 'Nature', 'date': '2 weeks ago', 'snippet': 'Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human \nadults. The standard of care offers minimal clinical benefit,...', 'thumbnail': 'https://serpapi.com/searches/6721be5615c740ab121e3508/images/ffe5a6176753904aceff903155209921eee5fee501454c0779fc7f6f1e6d1046.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7423284649848938}",,,,,,,,,,['negative'],negative,0
NCT00106535,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-020-70942-x', 'title': 'Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis', 'source': 'Nature', 'date': 'Aug 18, 2020', 'snippet': 'The aim of this study was to identify variation in Disease Activity Score \n28 (DAS28) of RA patients in response to Tocilizumab, and to investigate \nboth...', 'thumbnail': 'https://serpapi.com/searches/6721be71717bffe9341979e6/images/e4ca0b8dff55e502bdc307a3c60cf58ee655575a5ef762d32803016a80107f1a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9106734991073608}",,,,,,,,,,['neutral'],neutral,1
NCT04874948,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2022/5099312', 'title': 'Advances in Key Drug Target Identification and New Drug Development for Tuberculosis', 'source': 'Wiley Online Library', 'date': 'Feb 25, 2022', 'snippet': 'In this review, we summarized 45 important drug targets and 15 new drugs \nthat are currently being tested in clinical stages and several prospective \nmolecules.', 'thumbnail': 'https://serpapi.com/searches/6721be74e281ee51ad5bac09/images/61f676097a97963019c2dbb6bcb6938774fdfd13d38aa4cf89ba1d893426b889.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7801258563995361}",,,,,,,,,,['neutral'],neutral,1
NCT03712423,"{'position': 1, 'link': 'https://www.nature.com/articles/d43747-020-00674-4', 'title': 'A clinical-phase cancer biotech with nanomedicine partnering opportunities', 'source': 'Nature', 'date': 'Sep 1, 2020', 'snippet': 'Cristal Therapeutics is improving the treatment options for patients with a \nrange of solid tumors by creating transiently stable nanomedicines.', 'thumbnail': 'https://serpapi.com/searches/6721bec081262aaa2f008621/images/ebe08c868125eb05ea4211db545a09dd48b7391491e37a927005d05d82db916b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6484225392341614}",,,,,,,,,,['positive'],positive,1
NCT02894008,"{'position': 1, 'link': 'https://www.europeanpharmaceuticalreview.com/news/151155/novel-leishmaniasis-vaccine-safely-induces-immune-responses-in-patients/', 'title': 'Novel leishmaniasis vaccine safely induces immune responses in patients', 'source': 'European Pharmaceutical Review', 'date': 'Apr 16, 2021', 'snippet': 'ChAd63-KH, used to treat leishmaniasis rather than prevent in this trial, \nimproved symptoms in patients with dermal leishmaniasis.', 'thumbnail': 'https://serpapi.com/searches/6721becfc821270c41794a3f/images/4128ee0abee92b446c0cfefee98ad0bfa9fa6b395599cef4be1f187764e2d968.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5359059572219849}",,,,,,,,,,['neutral'],neutral,1
NCT00593242,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-020-61311-9', 'title': 'Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety | Scientific Reports', 'source': 'Nature', 'date': 'Mar 12, 2020', 'snippet': 'We conducted a single-arm clinical study to examine the feasibility and \nsafety of intravenous infusion of autologous UCBCs for newborns with HIE.', 'thumbnail': 'https://serpapi.com/searches/6721bed148c429afb9567c7a/images/e451b5484c9b47133c27b2daed4aa5897fc623c2a5e4e9ee71ac9e5c9632af71.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9104992151260376}",,,,,,,,,,['neutral'],neutral,1
NCT03616223,"{'position': 1, 'link': 'https://www.genengnews.com/topics/translational-medicine/astellas-frequency-therapeutics-partner-to-develop-hearing-loss-drug/', 'title': 'Astellas, Frequency Therapeutics Partner to Develop Hearing Loss Drug', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Jul 18, 2019', 'snippet': ""Astellas Pharma will partner with Frequency Therapeutics to develop \nFrequency's lead candidate—the Phase IIa-bound sensorineural hearing..."", 'thumbnail': 'https://serpapi.com/searches/6721bed84a4a1d50e1852ad6/images/78d0bda4120ff4d7050368665402f318639e2b0ca9c47f410a1656d6b8deea3a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9010204672813416}",,,,,,,,,,['neutral'],neutral,1
NCT00832039,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-018-19976-w', 'title': 'Early immune anergy towards recall antigens and mitogens in patients at onset of septic shock', 'source': 'Nature', 'date': 'Jan 29, 2018', 'snippet': 'The pathology of sepsis is typically characterized by an infection and \nexcessive initial inflammation including a cytokine storm,...', 'thumbnail': 'https://serpapi.com/searches/6721bf1fe1d1ad8e5c016171/images/8a3073f5a7ae3358078bf0c6c200431cc6702e1125dbeefa22d6d25b08adf9e8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5468384623527527}",,,,,,,,,,['neutral'],neutral,1
NCT03764488,"{'position': 1, 'link': 'https://alsnewstoday.com/news/fda-expected-decide-tofersen-approval-sod1-als-january/', 'title': 'FDA Expected to Decide on Tofersen Approval for SOD1-ALS in January', 'source': 'ALS News Today', 'date': 'Jul 27, 2022', 'snippet': ""The US Food and Drug Administration (FDA) has agreed to review an \napplication from Biogen for approval of the company's experimental therapy \ntofersen."", 'thumbnail': 'https://serpapi.com/searches/6721bf227b05caf824e9f8ec/images/1f8a20937a9b73de826336f58d93837cf74e3138d0dcd961552473b69a469ad3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8993838429450989}",,,,,,,,,,['neutral'],neutral,1
NCT03777176,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/dasiglucagon-under-priority-review-for-hypoglycemia-in-congenital-hyperinsulinism/', 'title': 'Dasiglucagon Gets Priority Review for Hypoglycemia in Congenital Hyperinsulinism', 'source': 'Medical Professionals Reference', 'date': 'Aug 30, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted for Priority Review the \nNew Drug Application (NDA) for dasiglucagon for the prevention...', 'thumbnail': 'https://serpapi.com/searches/6721bf36a505f73e95b9f123/images/7f8c7bd2022029100051f8808cec05ab649f84cd8a9ead4ea4a29107554e53db.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8679986596107483}",,,,,,,,,,['neutral'],neutral,1
NCT02273739,"{'position': 1, 'link': 'https://blogs.bmj.com/bmj/2019/11/05/unreported-trial-of-the-week-orally-administered-ag-221-in-subjects-with-advanced-solid-tumours-nct02273739/', 'title': 'Unreported clinical trial of the week: Enasidenib for use in advanced solid tumors (NCT02273739)', 'source': 'BMJ Blogs', 'date': 'Nov 5, 2019', 'snippet': 'While Enasidenib is currently only approved in a specific form of leukemia, \nthe IDH-2 mutation it targets also occurs in a variety of solid...', 'thumbnail': 'https://serpapi.com/searches/6721bf3e175de6645df64237/images/5ad31bb586d258852986272e8679e3ac975da94a577dad3b748234c210e75c9d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9006510376930237}",,,,,,,,,,['neutral'],neutral,1
NCT04140123,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-42162-0', 'title': 'ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial', 'source': 'Nature', 'date': 'Oct 12, 2023', 'snippet': 'Non-alcoholic fatty liver disease is a growing health burden with limited \ntreatment options worldwide. Herein we report a randomized,...', 'thumbnail': 'https://serpapi.com/searches/6721bf5cf8b05d603f2559c0/images/0592743749ff108703a93806e8283c00cb0ed149b76579feabac8dfe4a8e0fcd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8327338695526123}",,,,,,,,,,['neutral'],neutral,1
NCT04998201,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2404143', 'title': 'Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia', 'source': 'The New England Journal of Medicine', 'date': 'May 28, 2024', 'snippet': 'Persons with mixed hyperlipidemia are at risk for atherosclerotic \ncardiovascular disease due to an elevated non–high-density lipoprotein...', 'thumbnail': 'https://serpapi.com/searches/6721bf6ba5e50295eeffbad7/images/e9e18597c13304478f2c041317e7e7cd05d3a98768ce4f6f3a71af30b99a0521.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7325981259346008}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.17091', 'title': 'Abstract 17091: ARO-APOC3, an Investigational RNAi Therapeutic, Silences APOC3 and Reduces Atherosclerosis-Associated Lipoproteins in Patients With Mixed Dyslipidemia: MUIR Study Results', 'source': 'American Heart Association Journals', 'date': 'Nov 6, 2023', 'snippet': 'Background: Despite the availability of potent LDL-C-lowering therapies, \npatients with mixed dyslipidemia (MD) remain at high risk of...', 'thumbnail': 'https://serpapi.com/searches/6721bf6ba5e50295eeffbad7/images/e9e18597c1330447094a7861db7cb286993e3db3bc2636907189bf9b1844be16.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8766289353370667}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02276027,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222015724', 'title': 'Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences', 'source': 'ScienceDirect.com', 'date': 'Jan 14, 2023', 'snippet': 'Alpelisib, a selective inhibitor of PI3K, has been demonstrated to be \neffective in combination with endocrine therapy in HR+ PIK3CA-mutated \nadvanced breast...', 'thumbnail': 'https://serpapi.com/searches/6721bf942a48821b6e0a1c94/images/f52c5d14ca9184d0f0818be3c524bd6d5270688f0ef0d2d8af487d5c7a1a7c8e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6108260750770569}",,,,,,,,,,['positive'],positive,1
NCT01765478,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-98255-7', 'title': 'Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection', 'source': 'Nature', 'date': 'Sep 21, 2021', 'snippet': 'The selective Bruton tyrosine kinase (BTK) inhibitor poseltinib has been \nshown to inhibit the BCR signal transduction pathway and cytokine \nproduction in B...', 'thumbnail': 'https://serpapi.com/searches/6721bf9ad403e12400d10bd4/images/ef39507c4dfe624cb034bce12376bdd4f41ae0ed6ef36e6a30924bf2804953dc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8610352277755737}",,,,,,,,,,['neutral'],neutral,1
NCT00063999,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.20.01076', 'title': 'Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Mar 17, 2021', 'snippet': 'GOG0209 was a phase III, randomized, noninferiority, open-label trial. \nInclusion criteria were stage III, stage IV, and recurrent endometrial \ncancers;...', 'thumbnail': 'https://serpapi.com/searches/6721bfdd0197dd056176d680/images/5564374b129abbbf81b50f32ce8f572d043e47341ca9afc306bb708f2a70169b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9077574014663696}","{'position': 2, 'link': 'https://www.onclive.com/view/dr-mirza-on-the-fda-approval-of-dostarlimab-plus-chemotherapy-in-dmmr-msi-h-endometrial-cancer', 'title': 'Dr Mirza on the FDA Approval of Dostarlimab Plus Chemotherapy in dMMR/MSI-H Endometrial Cancer', 'source': 'OncLive', 'date': 'Jul 31, 2023', 'snippet': 'The FDA approved dostarlimab plus carboplatin and paclitaxel followed by \ndostarlimab monotherapy for adult patients with dMMR or MSI-H primary \nadvanced or...', 'thumbnail': 'https://serpapi.com/searches/6721bfdd0197dd056176d680/images/5564374b129abbbf63e4d49b6c751aa36888f3a7a6159740e7c61fbfc2edcebe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8453629016876221}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03683498,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-022-12407-x', 'title': 'Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib', 'source': 'Nature', 'date': 'May 19, 2022', 'snippet': 'The combination of ruxolitinib with Treg showed a higher efficacy as \ncompared to each single treatment alone in our GvHD mouse model in terms of \nGvHD incidence...', 'thumbnail': 'https://serpapi.com/searches/6721c01a1a5b541766454bcb/images/a074f3adae460ece27b807383e5784201d00636f8a616dc78bfaea24e7156cfd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6801929473876953}",,,,,,,,,,['neutral'],neutral,1
NCT03124108,"{'position': 1, 'link': 'https://www.ipsen.com/us/press-releases/ipsen-and-genfit-announce-positive-results-from-phase-iii-elative-trial-of-elafibranor-in-patients-with-primary-biliary-cholangitis-a-rare-cholestatic-liver-disease/', 'title': 'Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease', 'source': 'Ipsen', 'date': 'Jun 30, 2023', 'snippet': 'Trial met primary endpoint with a statistically significant higher \npercentage of patients achieving a clinically meaningful cholestasis...', 'thumbnail': 'https://serpapi.com/searches/6721c02bbe80137f7553e380/images/9b814ba578526b4183fdf69373569144d89a4ad5cb89a079c682db66cebc5c7c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5324159860610962}",,,,,,,,,,['neutral'],neutral,1
NCT03781804,"{'position': 1, 'link': 'https://www.pennmedicine.org/news/news-releases/2024/january/exhalation-system-improves-symptoms-of-chronic-sinus-infections', 'title': ""'Exhalation' System Improves Symptoms of Chronic Sinus Infections"", 'source': 'Penn Medicine', 'date': 'Jan 18, 2024', 'snippet': ""An exhalation delivery system that uses a patient's own breath to carry the \nanti-inflammatory compound fluticasone (EDS-FLU) directly to the sinuses \nreduced..."", 'thumbnail': 'https://serpapi.com/searches/6721c056b5ecbb5708920dfc/images/04c0368bbfc13c79648d9858d11ce16ec6864c6b3b91c1d71585b33b463593ae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8489072918891907}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/drug-device-combo-looks-promising-for-chronic-sinusitis/', 'title': 'Drug-Device Combo Looks Promising for Chronic Sinusitis', 'source': 'Medical Professionals Reference', 'date': 'Mar 7, 2022', 'snippet': 'Positive topline results were announced from a phase 3 trial evaluating the \nintranasal administration of OPN-375 (fluticasone propionate) in patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/6721c056b5ecbb5708920dfc/images/04c0368bbfc13c7917a4ab2cf83c6947e3cbfe38cf03d641af7da6699f74b43a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7450494766235352}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03425539,"{'position': 1, 'link': 'https://fabrydiseasenews.com/news/idorsia-continues-lucerastat-extension-study-long-ter-kidney-heart-benefits/', 'title': 'Lucerastat Extension Trial Will Continue, Focus on Long-term Possibilities', 'source': 'Fabry Disease News', 'date': 'Jan 21, 2022', 'snippet': 'While lucerastat failed in Phase 3 MODIFY trial to ease neuropathic pain, \npossible kidney and cardiac gains merit closer look, Idorsia says.', 'thumbnail': 'https://serpapi.com/searches/6721c0703b3c320a6856e41a/images/9c03df94367c1a89432f8f439edfdb456e59b5b8c7253371e415725cab7705c7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7299506664276123}",,,,,,,,,,['neutral'],neutral,1
NCT01207908,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/increlex-improves-growth-but-not-muscle-function-dmd-boys-early-trial-shows/', 'title': 'In DMD, Increlex Improves Growth, but Not Muscle Function, Study Finds', 'source': 'Muscular Dystrophy News', 'date': 'Mar 12, 2020', 'snippet': 'Treatment for six months with Increlex hormone therapy improved growth but \nnot muscle function in boys with DMD, an early study found.', 'thumbnail': 'https://serpapi.com/searches/6721c09313e5d81f5e772b41/images/268c1266b2bf58a3fa8ed360442a78dc0a3106b49bf09ccc6b6eab9b8c7714a1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7929469347000122}",,,,,,,,,,['neutral'],neutral,1
NCT02569775,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-49902-8', 'title': 'Inflammatory mediators drive neuroinflammation in autism spectrum disorder and cerebral palsy', 'source': 'Nature', 'date': 'Dec 18, 2023', 'snippet': 'In this study, we analyzed the composition of cerebrospinal fluid (CSF) to \nuncover the inflammatory mediators driving the neuro-immune system in ASD \nand CP...', 'thumbnail': 'https://serpapi.com/searches/6721c09da54d7ea54c98e771/images/385dfe9fa0197a21ab45fa733d654015453116e61598189fe41b32e6eaba63b3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7191134691238403}",,,,,,,,,,['neutral'],neutral,1
NCT00771667,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1203572', 'title': ""Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease"", 'source': 'The New England Journal of Medicine', 'date': 'Oct 18, 2012', 'snippet': ""In patients with Crohn's disease, the efficacy of ustekinumab, a human \nmonoclonal antibody against interleukin-12 and interleukin-23,..."", 'thumbnail': 'https://serpapi.com/searches/6721c0a3cc48791ec6d36218/images/3e369c0cd3f587ec9d9c27ddd13ad633339d9d9b9d13e75c08c7719579ceb2c1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8811381459236145}",,,,,,,,,,['neutral'],neutral,1
NCT00893373,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-021-01148-x', 'title': 'Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial', 'source': 'Nature', 'date': '١٨\u200f/٠٢\u200f/٢٠٢١', 'snippet': 'Early results of the randomized placebo-controlled SORAML trial showed \nthat, in patients with newly diagnosed acute myeloid leukaemia (AML),...', 'thumbnail': 'https://serpapi.com/searches/6721c0a4d72128f26f325323/images/3977ffaa311d58b0cf33b38f1b91546eb3e1aadb868b8f1281693cfeca99aad4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.924304723739624}",,,,,,,,,,['neutral'],neutral,1
NCT02955550,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/pnk-007-treatment-after-stem-cell-transplant-leads-to-good-response-rates-in-multiple-myeloma-patients-early-trial-data-show/', 'title': 'Myeloma Patients Respond Well to PNK-007 After Transplant, Data Show', 'source': 'Myeloma Research News', 'date': 'Jan 8, 2020', 'snippet': ""A single infusion of Celularity's PNK-007 — an investigational cell therapy \nderived from placental stem cells — is safe and leads to good..."", 'thumbnail': 'https://serpapi.com/searches/6721c0b7361fd4c8c0465eb8/images/d87c9dc05b02e0e9177d0bfaf9938f9c90f35ddd5293397c31a50152184e083f.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7810468673706055}",,,,,,,,,,['positive'],positive,1
NCT02968004,"{'position': 1, 'link': 'https://www.endocrinologyadvisor.com/reports/somatrogon-4-year-efficacy-safety-pediatric-growth-hormone-deficiency/', 'title': 'Somatrogon Yields 4-Year Efficacy, Safety in Pediatric Growth Hormone Deficiency', 'source': 'Endocrinology Advisor', 'date': 'May 9, 2024', 'snippet': 'Children with pediatric growth hormone deficiency (pGHD) demonstrated \ncatch-up growth and mean height gain after 4 years of somatrogon treatment.', 'thumbnail': 'https://serpapi.com/searches/6721c0bb51d84d1f0a6ed8ea/images/16e83c2d842ebb38a5651c337e8f51630e67cad3757dbb51be497952c8316f64.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6659769415855408}",,,,,,,,,,['neutral'],neutral,1
NCT01634750,"{'position': 1, 'link': 'https://www.nature.com/articles/s41436-021-01259-x', 'title': 'Safety and efficacy of N -acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study', 'source': 'Nature', 'date': 'Jul 13, 2021', 'snippet': 'ManNAc showed long-term safety, biochemical efficacy consistent with the \nintended mechanism of action, and preliminary evidence clinical efficacy in \npatients...', 'thumbnail': 'https://serpapi.com/searches/6721c0d48e13c9f8fd73628a/images/9ca73ceb4e8c6a3757ca030c0cf79e9ed9546f7918599c21eef31b532d61cbcd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6594723463058472}",,,,,,,,,,['neutral'],neutral,1
NCT02096289,"{'position': 1, 'link': 'https://www.nature.com/articles/tpj201676', 'title': 'A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia', 'source': 'Nature', 'date': 'Dec 13, 2016', 'snippet': 'This study was designed to investigate the mode of action of trabectedin in \nmyelomonocytic leukemia cells by applying systems biology...', 'thumbnail': 'https://serpapi.com/searches/6721c0f8d364b4c6b6b0e871/images/b6ce3f4a32b142d90b216e42f34b9f47234f105db4d15c3e88993a92544811cc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9292907118797302}",,,,,,,,,,['neutral'],neutral,1
NCT03926819,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/low-dose-carbon-monoxide-may-protect-neurons-with-parkinsons/', 'title': 'Low-dose carbon monoxide may protect neurons, much like smoking', 'source': ""Parkinson's News Today"", 'date': 'Aug 28, 2024', 'snippet': 'A rat model study found an oral form of carbon monoxide called HBI-002 \n(tested for safety in Phase 1 trial) promoted neuron survival,...', 'thumbnail': 'https://serpapi.com/searches/6721c11ab9458d9fbfbd9ae9/images/66da93253a85c2dac1c29110dd1f96ea098823c9e336e8d452c8dbc3d91402ae.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6187165379524231}",,,,,,,,,,['neutral'],neutral,1
NCT04770935,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/pipeline-moves-hengrui-medicine-triple-negative-breast-cancer/', 'title': 'Pipeline Moves: Hengrui Medicine Phase III breast cancer termination lowers approval prospects', 'source': 'Clinical Trials Arena', 'date': 'May 16, 2023', 'snippet': 'The Clinical Trials Arena team also review assets in the central nervous \nsystem, cardiology, renal, haematological and other oncology...', 'thumbnail': 'https://serpapi.com/searches/6721c12c3c944b513039cd0e/images/b9b643e96af3ec4650d63983fa4e61eb2429b03694fa6f3376853ad0ff800bf2.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6495799422264099}",,,,,,,,,,['negative'],negative,0
NCT02799095,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2020/11/24/alks-4230-keytruda-combo-found-to-halt-disease-progression-reduce-tumor-size-among-ovarian-cancer-patients-in-phase-1-2-trial/', 'title': 'ALKS 4230-Keytruda Combo Found to Reduce Tumor Size, Halt Disease Progression', 'source': 'Ovarian Cancer News Today', 'date': 'Nov 24, 2020', 'snippet': 'An ALKS 4230-Keytruda combo was able to halt disease progression and reduce \ntumor size in women with advanced ovarian cancer,...', 'thumbnail': 'https://serpapi.com/searches/6721c12e5416d8e677207e96/images/5712931b94b39425ed47e4357442e1abcbc34bcd1a7b615289c7a3e79c3c9d6a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7647801637649536}",,,,,,,,,,['neutral'],neutral,1
NCT04346888,"{'position': 1, 'link': 'https://myastheniagravisnews.com/news/mg-therapy-batoclimab-hits-phase-3-trial-main-secondary-goals/', 'title': 'MG therapy batoclimab hits Phase 3 trial main, secondary goals |...', 'source': 'Myasthenia Gravis News', 'date': 'Mar 7, 2023', 'snippet': 'Batoclimab eased the symptoms of generalized myasthenia gravis and their \nimpact on daily function in a Phase 3 clinical trial in China.', 'thumbnail': 'https://serpapi.com/searches/6721c145d997ab91c9b28661/images/48373cfd3ee1d95edc1351e2884355956992835cd8df8317ebf95503960473b2.png', 'sentiment': 'positive', 'sentiment_prob': 0.6334934830665588}","{'position': 2, 'link': 'https://myastheniagravisnews.com/news/gmg-chinese-regulators-agree-consider-approving-batoclimab/', 'title': 'For gMG, Chinese regulators agree to consider approving batoclimab...', 'source': 'Myasthenia Gravis News', 'date': 'Jul 11, 2023', 'snippet': 'Submitted as a biologics license application, the request to review \nbatoclimab is buoyed by positive top-line data from a Phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/6721c145d997ab91c9b28661/images/48373cfd3ee1d95ede623390d8e2802ed9f533156859b69bc15179d9c1b0dd9b.png', 'sentiment': 'positive', 'sentiment_prob': 0.6625019907951355}",,,,,,,,,"['positive', 'positive']",positive,1
NCT04084769,"{'position': 1, 'link': 'https://www.nature.com/articles/s41390-023-02478-5', 'title': 'Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study', 'source': 'Nature', 'date': 'Mar 10, 2023', 'snippet': 'The immunogenicity and safety of a booster dose of tetanus toxoid-conjugate \nquadrivalent meningococcal vaccine (MenACYW-TT),...', 'thumbnail': 'https://serpapi.com/searches/6721c1b66901215767319f13/images/2ab6d5c246efd92966fb0b9feb60d0cb01ce483d5a348617c9012be298cb744a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8912705183029175}",,,,,,,,,,['neutral'],neutral,1
NCT01913340,"{'position': 1, 'link': 'https://www.nature.com/articles/pr201715', 'title': 'High-dose erythropoietin population pharmacokinetics in neonates with hypoxic–ischemic encephalopathy receiving hypothermia', 'source': 'Nature', 'date': 'Jan 18, 2017', 'snippet': 'High-dose erythropoietin (Epo) is a promising neuroprotective treatment in \nneonates with hypoxic–ischemic encephalopathy (HIE) receiving hypothermia.', 'thumbnail': 'https://serpapi.com/searches/6721c1d6caddc31d16315a0f/images/9c06528ee79612acc940a2fe38cacef1597680a905dec64c5fc0cf2ee7cb0238.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5767234563827515}",,,,,,,,,,['neutral'],neutral,1
NCT03183232,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-020-0515-7', 'title': 'Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer', 'source': 'Nature', 'date': 'Sep 16, 2020', 'snippet': 'Vγ9Vδ2 T cells are promising candidates for cellular tumor immunotherapy. \nDue to their HLA-independent mode of action, allogeneic Vγ9Vδ2 T...', 'thumbnail': 'https://serpapi.com/searches/6721c1eb2e33c8f507281b6a/images/41042e290cde505d5fa2cca0b4d2166fcce1b15ad7263c533a5bbbbc5b4e6429.png', 'sentiment': 'positive', 'sentiment_prob': 0.7890372276306152}",,,,,,,,,,['positive'],positive,1
NCT03505099,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01866-4', 'title': 'Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial', 'source': 'Nature', 'date': 'Jun 17, 2022', 'snippet': 'SPR1NT ( NCT03505099 ) was a Phase III, multicenter, single-arm study to \ninvestigate the efficacy and safety of onasemnogene abeparvovec for...', 'thumbnail': 'https://serpapi.com/searches/6721c20d237938d0baf98d04/images/bf1675363e2c64441d5121bdf0575f1fd8fe9a1fc6a6c538e36aec0d5fdde2b2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8673272728919983}","{'position': 2, 'link': 'https://www.empr.com/home/news/onasemnogene-abeparvovec-xioi-zolgensma-age-development-in-spinal-muscular-dystrophy/', 'title': 'Zolgensma Benefits Observed in Presymptomatic SMA Patients', 'source': 'Medical Professionals Reference', 'date': 'Mar 15, 2021', 'snippet': 'Early treatment with onasemnogene abeparvovec-xioi led to age-appropriate \ndevelopment in patients with spinal muscular atrophy.', 'thumbnail': 'https://serpapi.com/searches/6721c20d237938d0baf98d04/images/bf1675363e2c6444526629088c90ab7c4a8725d0c26b95a44f89fc5239bdb8ec.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7931104898452759}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01720446,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1607141', 'title': 'Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Sep 16, 2016', 'snippet': 'The rate of cardiovascular death, nonfatal myocardial infarction, or \nnonfatal stroke was significantly lower among patients receiving \nsemaglutide than among...', 'thumbnail': 'https://serpapi.com/searches/6721c25bfda26de13edfd712/images/5cf641c896a1f8623af0bf94df3008f576855f8fbba0b6deb2ec33ae871e00e8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7180549502372742}","{'position': 2, 'link': 'https://www.endocrinologyadvisor.com/cch/sglt2-inhibitors-glp1-agonists-patients-with-t2dm-and-previous-cvd-high-risk-of-mace/', 'title': 'Reducing Risk of Major Adverse Cardiovascular Events: Role of SGLT2 Inhibitors, GLP-1 Agonists', 'source': 'Endocrinology Advisor', 'date': 'May 17, 2024', 'snippet': 'Patients with type T2DM and previous cardiovascular disease are at high \nrisk of MACE. This article focuses on how SGLT2 inhibitors and GLP-1 \nagonists,...', 'thumbnail': 'https://serpapi.com/searches/6721c25bfda26de13edfd712/images/5cf641c896a1f8626d014a31cd670a4c6896828b965ba60f095f39c2d54f0fc4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8390507698059082}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02049866,"{'position': 1, 'link': 'https://www.nature.com/articles/srep22378', 'title': 'Cyclophilin A (CypA) Plays Dual Roles in Regulation of Bone Anabolism and Resorption', 'source': 'Nature', 'date': 'Mar 2, 2016', 'snippet': 'CypA (Cyclophilin A) is a peptidyl-prolyl isomerase previously shown to be \nrequired for chondrogenic differentiation and endochondral ossification.', 'thumbnail': 'https://serpapi.com/searches/6721c25de8735a1451f2b72b/images/edfb161e4cf3295a6aec5070de48c21e344480a153549dc73b032990d1145794.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8983614444732666}",,,,,,,,,,['neutral'],neutral,1
NCT03761784,"{'position': 1, 'link': 'https://www.dermatologytimes.com/view/twyneo-receives-fda-approval-for-acne', 'title': 'Twyneo Receives FDA Approval for Acne', 'source': 'Dermatology Times', 'date': 'Jul 27, 2021', 'snippet': 'Twyneo, a tretinoin and benzoyl peroxide cream, has been approved by the \nFDA for the treatment of acne vulgaris in patients 9 years and...', 'thumbnail': 'https://serpapi.com/searches/6721c273b28e6b3deb75b7b4/images/f891b367931fd9ebf1976d618c0361644c4cacdcde7be438e4fb016172c1095d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.640620231628418}","{'position': 2, 'link': 'https://www.empr.com/home/news/galderma-announces-launch-of-twyneo-cream-for-acne-vulgaris/', 'title': 'Galderma Announces Launch of Twyneo Cream for Acne Vulgaris', 'source': 'Medical Professionals Reference', 'date': 'Mar 25, 2022', 'snippet': 'Galderma has announced the US launch of Twyneo (tretinoin 0.1% and benzoyl \nperoxide 3%) cream for the topical treatment of acne vulgaris in patients 9 \nyears of...', 'thumbnail': 'https://serpapi.com/searches/6721c273b28e6b3deb75b7b4/images/f891b367931fd9eb2aaa6aba9612a621fc667a87b057453467a12813d24e2edb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8534439206123352}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03899480,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1084109/full', 'title': 'Prospects for NK-based immunotherapy of chronic HBV infection', 'source': 'Frontiers', 'date': 'Feb 21, 2024', 'snippet': 'Effective and long-term treatment is required for controlling chronic \nHepatitis B Virus (HBV) infection. Natural killer (NK) cells are antiviral \ninnate...', 'thumbnail': 'https://serpapi.com/searches/6721c2a4d169156d0d06b3b2/images/92a9a3d62c8139cf2335258eed38943776fd46659ecc6fb16bb9e577614aa321.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8224900364875793}",,,,,,,,,,['neutral'],neutral,1
NCT03635567,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2112435', 'title': 'Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Sep 18, 2021', 'snippet': 'In a double-blind, phase 3 trial, we randomly assigned patients with \npersistent, recurrent, or metastatic cervical cancer in a 1:1 ratio to...', 'thumbnail': 'https://serpapi.com/searches/6721c2ac717bffe934197cd4/images/c3dd33ef9b5ff7fd9a958024e094b460e2b3cf925ca9b6400ca415159de6d6b1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8948957920074463}","{'position': 2, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00052-9/fulltext', 'title': 'Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial', 'source': 'The Lancet', 'date': 'Mar 3, 2023', 'snippet': 'In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody \npembrolizumab to chemotherapy with or without bevacizumab...', 'thumbnail': 'https://serpapi.com/searches/6721c2ac717bffe934197cd4/images/c3dd33ef9b5ff7fd50f305978fbb05b01f06527b40713255c0c3bcc2f7e39792.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8319631814956665}","{'position': 3, 'link': 'https://www.empr.com/home/news/keytruda-approved-as-first-line-treatment-for-persistent-recurrent-or-metastatic-cervical-cancer/', 'title': 'Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer', 'source': 'Medical Professionals Reference', 'date': 'Oct 13, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Keytruda \n(pembrolizumab) in combination with chemotherapy, with or without \nbevacizumab,...', 'thumbnail': 'https://serpapi.com/searches/6721c2ac717bffe934197cd4/images/c3dd33ef9b5ff7fd91ac8a802dae4258ee5c2a4aeee3fa10d1725c5e6a209ead.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8480886220932007}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT01876511,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1500596', 'title': 'PD-1 Blockade in Tumors with Mismatch-Repair Deficiency', 'source': 'The New England Journal of Medicine', 'date': 'May 30, 2015', 'snippet': 'This study showed that mismatch-repair status predicted clinical benefit of \nimmune checkpoint blockade with pembrolizumab.', 'thumbnail': 'https://serpapi.com/searches/6721c2b2f9f904883974f02a/images/41897cdc5b21335573b27ed0b22bd50c10876ecb7ead2cb33cbfb14417411647.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8608921766281128}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-020-17386-z', 'title': 'Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival', 'source': 'Nature', 'date': 'Jul 20, 2020', 'snippet': 'This large study provides deep insights into somatic mutations in CRC, and \ntheir potential relationships with survival and tumor features.', 'thumbnail': 'https://serpapi.com/searches/6721c2b2f9f904883974f02a/images/41897cdc5b21335507e4a32b9166674659a3269b8a7ea0667d100daa21dcf733.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9113010168075562}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03910543,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-30615-x', 'title': 'Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis', 'source': 'Nature', 'date': 'Jun 6, 2022', 'snippet': 'Our results thus show that tofacitinib treatment is associated with \nimproved sarcoidosis symptoms, and predominantly acts by inhibiting type 1 \nimmunity.', 'thumbnail': 'https://serpapi.com/searches/6721c2b475f974f2da18b3bd/images/e39d607948cdbf0603a9ec7e87ddfd32c2851a8df18892ce49ace5eefc70c74f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8527399897575378}",,,,,,,,,,['neutral'],neutral,1
NCT04304534,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061612', 'title': 'A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction | Circulation', 'source': 'American Heart Association Journals', 'date': 'Aug 30, 2022', 'snippet': 'We explored the pharmacodynamics, safety, and efficacy of the oral FXIa \ninhibitor asundexian for secondary prevention after acute myocardial \ninfarction (MI).', 'thumbnail': 'https://serpapi.com/searches/6721c2bc9e38e52c96d87599/images/a27d81a07ab1eb726501b914ceeac9b211eb8ce45e3d0e58a8816bd270d61fea.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8496591448783875}",,,,,,,,,,['neutral'],neutral,1
NCT02962895,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02251-0/abstract?uuid=uuid%3Abf64494f-0e46-4f5c-8218-999221045e2d', 'title': ""Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial"", 'source': 'The Lancet', 'date': 'Nov 30, 2021', 'snippet': ""Sjögren's syndrome is an autoimmune disease characterised by dry eyes and \nmouth, systemic features, and reduced quality of life."", 'thumbnail': 'https://serpapi.com/searches/6721c2bd51d84d1ed7a570af/images/89d893b6f740fa7028f1462b34cd3c2a725f7d03f8fc696cca88356f6ebc073c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7355638146400452}","{'position': 2, 'link': 'https://sjogrenssyndromenews.com/news/ianalumab-vay736-eases-sjogrens-symptoms-over-year-phase-2b-trial/', 'title': 'Ianalumab Safely Lowers Sjögren Activity at High Dose in Clinical Trial', 'source': ""Sjogren's Syndrome News"", 'date': 'Nov 9, 2021', 'snippet': 'The antibody was well-tolerated over 52 weeks in Phase 2b trial, increasing \nsalivary gland production as once-monthly 300 mg injection.', 'thumbnail': 'https://serpapi.com/searches/6721c2bd51d84d1ed7a570af/images/89d893b6f740fa7041d8f7e5d00295e701a1f69a4ba7d70cd2ee8653cc11271f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.4982258677482605}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04964986,"{'position': 1, 'link': 'https://www.hcplive.com/view/apraglutide-reduces-parenteral-support-dependency-in-patients-with-sbs-if-cic', 'title': 'Apraglutide Reduces Parenteral Support Dependency in Patients with SBS-IF, CIC', 'source': 'HCPLive', 'date': 'Oct 19, 2023', 'snippet': 'Final data from STARS Nutrition were presented at United European \nGastroenterology Week 2023, demonstrating a significant reduction in...', 'thumbnail': 'https://serpapi.com/searches/6721c2da2bab902c966219fa/images/371ff0a7838c6d58311418a962f029d2fad4728b753f0dd39546bf03643be4ba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7994058132171631}",,,,,,,,,,['neutral'],neutral,1
NCT05392179,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Deglycosylation-analysis-of-rhodopsin-A-Example-blot-with-rhodopsin-mutation-N15S-P23H_fig3_333184115', 'title': 'Deglycosylation analysis of rhodopsin A. Example blot with rhodopsin...', 'source': 'ResearchGate', 'date': 'Aug 23, 2024', 'snippet': 'Download scientific diagram | Deglycosylation analysis of rhodopsin A. \nExample blot with rhodopsin mutation (N15S, P23H and WT transiently in \nCOS-1 cells),...', 'thumbnail': 'https://serpapi.com/searches/6721c308b57db8b81dcf878b/images/32d0e401f83045d17e220085784fd5bfe253e9843ce82066766bb2e95cb50bed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8983781933784485}",,,,,,,,,,['neutral'],neutral,1
NCT02309580,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-018-32634-5', 'title': 'Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma', 'source': 'Nature', 'date': 'Sep 21, 2018', 'snippet': 'Patients with peripheral T-cell lymphomas generally have poor clinical \noutcomes with conventional chemotherapy.', 'thumbnail': 'https://serpapi.com/searches/6721c33b400bd5bee739a2d1/images/e5197f390786103b96a8f40fb26142fabe12414463f624eefc67e2b7c79e5daf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7779208421707153}",,,,,,,,,,['neutral'],neutral,1
NCT02987543,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1911440', 'title': 'Olaparib for Metastatic Castration-Resistant Prostate Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Apr 28, 2020', 'snippet': 'Multiple loss-of-function alterations in genes that are involved in DNA \nrepair, including homologous recombination repair, are associated...', 'thumbnail': 'https://serpapi.com/searches/6721c35d2da1575f5eaf0ebe/images/89ef21c39b183d024960fa6ecb556302290a2a131112889427ff049d84963b0c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5854230523109436}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2022485', 'title': 'Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Sep 20, 2020', 'snippet': ""Olaparib led to significantly longer imaging-based progression-free \nsurvival than the physician's choice of enzalutamide or abiraterone among \nmen with..."", 'thumbnail': 'https://serpapi.com/searches/6721c35d2da1575f5eaf0ebe/images/89ef21c39b183d0236791017bb5206c3032b536492186e1f3c79ee5fcec4ec18.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7363011240959167}","{'position': 3, 'link': 'https://prostatecancernewstoday.com/2020/12/10/canada-approves-lynparza-metastatic-crpc-specific-mutations/', 'title': 'Canada Approves Lynparza for Metastatic CRPC Patients With Certain Gene Mutations', 'source': 'Prostate Cancer News Today', 'date': 'Dec 10, 2020', 'snippet': 'Canada has approved Lynparza to treat men with metastatic \ncastration-resistant prostate cancer who carry mutations in the in BRCA or \nATM...', 'thumbnail': 'https://serpapi.com/searches/6721c35d2da1575f5eaf0ebe/images/89ef21c39b183d0211e6df73ec7ee8700cd87b4fd0725ea3a037dbcae3fb0ecc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8830963373184204}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT01109095,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1113882/full', 'title': 'The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies', 'source': 'Frontiers', 'date': 'Feb 6, 2024', 'snippet': 'The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy \nin treating hematologic cancers have increased the previously \nunprecedented...', 'thumbnail': 'https://serpapi.com/searches/6721c37dd78a989f43d3e960/images/e67ba41c436526460cc959f3625f99395d0792ea1ba1320756343eb512bf609f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8026973009109497}","{'position': 2, 'link': 'https://www.nature.com/articles/s41698-021-00233-9', 'title': 'GD2 CAR T cells against human glioblastoma', 'source': 'Nature', 'date': 'Oct 27, 2021', 'snippet': 'Glioblastoma is the most malignant primary brain tumor and is still in need \nof effective medical treatment. We isolated patient-derived...', 'thumbnail': 'https://serpapi.com/searches/6721c37dd78a989f43d3e960/images/e67ba41c43652646d424d4f9aaf6dc1b18598fea85860f0ceb972d41f842a242.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7944258451461792}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT05818306,"{'position': 1, 'link': 'https://dravetsyndromenews.com/news/bl-001-therapy-live-gut-microbes-fares-well-healthy-adults/', 'title': 'Therapy based on live gut microbes fares well in healthy adults in trial', 'source': 'Dravet Syndrome News', 'date': 'Aug 22, 2023', 'snippet': 'BL-001, an oral live biotherapeutic for Dravet syndrome, was well-tolerated \nacross multiple-ascending doses in healthy adults, data show.', 'thumbnail': 'https://serpapi.com/searches/6721c3a13103006402ae39f9/images/4a4c8149ca4a909b8f866ea641ee68a9de25c7c9c4196d09873255a2a544772f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5160338878631592}",,,,,,,,,,['neutral'],neutral,1
NCT01450124,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-020-65215-6', 'title': 'Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis', 'source': 'Nature', 'date': 'May 29, 2020', 'snippet': 'Oral treatment with an SFE significantly reduces 5-LO-derived LMs in RR-MS \npatients during an eight-month treatment period.', 'thumbnail': 'https://serpapi.com/searches/6721c3c58b7ba7a75605072f/images/01d9fb01658a599e16776420c607592604df87e8e28b7813daf28202a42b6324.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7867388725280762}",,,,,,,,,,['neutral'],neutral,1
NCT01689519,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1408868', 'title': 'Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 29, 2014', 'snippet': 'This randomized phase 3 study evaluated the combination of the BRAF \ninhibitor vemurafenib and the MEK inhibitor cobimetinib.', 'thumbnail': 'https://serpapi.com/searches/6721c444cf32e0c291d20699/images/ee01076b7cf24cb56a92149e9667213bab72f4fdff70264f8110f89bbb75b2a5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9341273307800293}",,,,,,,,,,['neutral'],neutral,1
NCT03673943,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/61/6/890', 'title': '64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial', 'source': 'Journal of Nuclear Medicine', 'date': 'Jun 1, 2020', 'snippet': '64 Cu-DOTATATE PET/CT is a safe imaging technique that provides \nhigh-quality and accurate images at a dose of 148 MBq (4.0 mCi) for the \ndetection of...', 'thumbnail': 'https://serpapi.com/searches/6721c453b9ab865d2f765adf/images/236a74f67fbda82abe253bf4eddcfd16ca2149e3eed177130d34ff0e511015ba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8963620662689209}",,,,,,,,,,['neutral'],neutral,1
NCT02909751,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-35362-7', 'title': 'Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA', 'source': 'Nature', 'date': 'May 24, 2023', 'snippet': 'Neoadjuvant treatment of breast cancer is applied to an increasing extent, \nbut treatment response varies and side effects pose a challenge.', 'thumbnail': 'https://serpapi.com/searches/6721c47621b01bb4a0504b9e/images/36eee1fc6af0c09f5553ba7b027260a8e7c41ca88281f967f5d7b8cca1d14a46.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8077815771102905}",,,,,,,,,,['neutral'],neutral,1
NCT00444613,"{'position': 1, 'link': 'https://alsnewstoday.com/news/high-dose-b12-slows-functional-decline-early-stage-als-data-show/', 'title': 'High-dose B12 Slows Functional Decline in Early-stage ALS, Data Show', 'source': 'ALS News Today', 'date': 'Jun 17, 2022', 'snippet': 'Ultrahigh-dose methylcobalamin effectively slowed functional decline in \npeople with early-stage ALS, clinical trial data show.', 'thumbnail': 'https://serpapi.com/searches/6721c4f4f922f68abd6e5754/images/141b851e53eb83510f038019cfb3bb65b03cd848ee39e7f5e7be8aa2fda727c7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7989188432693481}","{'position': 2, 'link': 'https://alsnewstoday.com/news/high-dose-vitamin-b12-helpful-early-diagnosis/', 'title': 'ALS Prognosis May Improve with High-Dose Vitamin B12 if Given Early, Study Says', 'source': 'ALS News Today', 'date': 'Jan 17, 2019', 'snippet': 'High doses of vitamin B12 may improve outcomes in patients with amyotrophic \nlateral sclerosis (ALS) who are treated soon after diagnosis,...', 'thumbnail': 'https://serpapi.com/searches/6721c4f4f922f68abd6e5754/images/141b851e53eb83513b743f523aac13e5c38142345cabe8a82e24f6418b81fb83.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7574703097343445}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04077437,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02565-4', 'title': 'MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial', 'source': 'Nature', 'date': 'Sep 14, 2023', 'snippet': 'This multi-site, randomized, double-blind, confirmatory phase 3 study \nevaluated the efficacy and safety of 3...', 'thumbnail': 'https://serpapi.com/searches/6721c508e50bc0cdb2059c53/images/56739149196112e55beecb2522a0432049b3c75e1ffae13f6a4be76c22be59c3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8775330781936646}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/phase-3-trial-evaluating-mdma-assisted-therapy-for-ptsd-meets-endpoints/', 'title': 'Phase 3 Trial Evaluating MDMA-Assisted Therapy for PTSD Meets Endpoints', 'source': 'Medical Professionals Reference', 'date': 'Jan 5, 2023', 'snippet': 'Positive results were announced from a phase 3 study evaluating \nMDMA-assisted psychotherapy in adults with at least moderate PTSD.', 'thumbnail': 'https://serpapi.com/searches/6721c508e50bc0cdb2059c53/images/56739149196112e5c149dc9b24a44ee13eae37ec98e161559556db5dce0117d8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5660721063613892}","{'position': 3, 'link': 'https://psychedelicalpha.com/news/psychedelic-bulletin-103-maps-phase-3-trial-on-schedule-australias-national-science-agency-working-on-psychedelics-death-spiral-financings', 'title': 'Psychedelic Bulletin #103 - MAPS Phase 3 Trial On Schedule; Australia’s National Science Agency Working on Psychedelics; Death Spiral Financings', 'source': 'Psychedelic Alpha', 'date': 'May 22, 2022', 'snippet': ""This week: MAPS' second Phase 3 study of MDMA-AT for PTSD is on schedule; \nAustralia's national science agency is exploring medicinal..."", 'thumbnail': 'https://serpapi.com/searches/6721c508e50bc0cdb2059c53/images/56739149196112e52ff38d586bc60d39c348bf72a38df2bf727fdcd2c2e1010c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9323871731758118}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02715258,"{'position': 1, 'link': 'https://www.empr.com/home/news/brenzavvy-approved-for-adults-with-type-2-diabetes/', 'title': 'Brenzavvy Approved for Adults With Type 2 Diabetes', 'source': 'Medical Professionals Reference', 'date': 'Jan 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Brenzavvy™ \n(bexagliflozin) as an adjunct to diet and exercise to improve glycemic...', 'thumbnail': 'https://serpapi.com/searches/6721c54a76079d9baf77659f/images/a6e980375ee5fcf50dbbcdbb18cca9388d07062c5b5af9c3b04e6b99bbd4a63d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6072625517845154}",,,,,,,,,,['neutral'],neutral,1
NCT04426695,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2108163', 'title': 'REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Sep 29, 2021', 'snippet': 'In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of \nthe monoclonal antibodies casirivimab and imdevimab, reduced the...', 'thumbnail': 'https://serpapi.com/searches/6721c59e2a7727b88578665d/images/3dbcc8705b71bc0e6b6a94af39fec9f3bf8537adf63bf4c2469dc51eae27f517.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8774450421333313}",,,,,,,,,,['neutral'],neutral,1
NCT04820309,"{'position': 1, 'link': 'https://www.nature.com/articles/s41537-022-00320-1', 'title': 'Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia', 'source': 'Nature', 'date': 'Dec 3, 2022', 'snippet': 'KarXT combines xanomeline, an M1/M4 preferring muscarinic agonist with no \ndirect D2 receptor antagonism, with the peripherally restricted...', 'thumbnail': 'https://serpapi.com/searches/6721c5b666d9958464b73c04/images/c36557f9979e9bc54ae8abeff0ffacb4f1f706f2ae0338fbdf2f4477dbb5e869.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8456377983093262}",,,,,,,,,,['neutral'],neutral,1
NCT04466904,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-31328-x', 'title': 'A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes', 'source': 'Nature', 'date': 'Jun 24, 2022', 'snippet': 'IBI362 showed a favourable safety profile and clinically meaningful \nreductions in blood glucose in Chinese patients with T2D.', 'thumbnail': 'https://serpapi.com/searches/6721c5bba5aae9204588c33f/images/0d1e02a8f1f8d2c98851beb6afe3df40c4aacb17dabf42f975e0893005492a59.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7220106720924377}",,,,,,,,,,['neutral'],neutral,1
NCT03439124,"{'position': 1, 'link': 'https://www.contemporarypediatrics.com/view/zevtera-approved-for-community-acquired-bacterial-pneumonia-in-infants-adolescents-teens', 'title': 'Zevtera approved for community-acquired bacterial pneumonia in infants, adolescents, teens', 'source': 'Contemporary Pediatrics', 'date': 'Apr 4, 2024', 'snippet': 'The FDA has approved Zevtera (ceftobiprole medocaril sodium for injection; \nBasilea Pharmaceutica International) in pediatric patients aged 3 months to \nless...', 'thumbnail': 'https://serpapi.com/searches/6721c5da52a04e7b07182eaa/images/4d098e539a2a7b829b459af0a8cdfa9114e48987f04896d04835ffee42b6d04d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7831442356109619}",,,,,,,,,,['neutral'],neutral,1
NCT02519452,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/under-the-skin-form-as-effective-as-intravenous-darzalex-myeloma/', 'title': 'Under-the-skin Formulation as Effective as Intravenous Darzalex for Myeloma Patients, Study Says', 'source': 'Myeloma Research News', 'date': 'Mar 11, 2019', 'snippet': 'An under-the-skin injection of daratumumab is as effective as its \nintravenous formulation at reducing tumor burden in multiple myeloma,...', 'thumbnail': 'https://serpapi.com/searches/6721c5f849ea55cdb868ed43/images/baa6594ebd9f6de3d2a7a015d2b2c89aca7b72ab7cfc03608a8b87e12c3fd3d8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7194610834121704}",,,,,,,,,,['neutral'],neutral,1
NCT02840994,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.34267', 'title': 'Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer', 'source': 'Wiley Online Library', 'date': 'Aug 27, 2022', 'snippet': 'CV301, a poxviral-based vaccine, has been evaluated in a phase 1 clinical \ntrial (NCT02840994) and shown to be safe and immunologically...', 'thumbnail': 'https://serpapi.com/searches/6721c5fd2da1575f8de89413/images/591b707487fe7bb040578c2b8f96c1ed6417b3628971aae53dd7552d9febb5c3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8155730962753296}",,,,,,,,,,['neutral'],neutral,1
NCT02011945,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-021-01238-w', 'title': 'Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape', 'source': 'Nature', 'date': 'Apr 8, 2021', 'snippet': 'This review focuses on immune dysfunction in newly diagnosed CML patients, \nand the role that TKIs and other therapies have in restoring immune \nsurveillance.', 'thumbnail': 'https://serpapi.com/searches/6721c6595809e72491955e68/images/9c66d259838f92595745256731baea796937facac60e546e77fc7133ec798666.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.818343460559845}",,,,,,,,,,['neutral'],neutral,1
NCT03502148,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-31859-3', 'title': 'A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer', 'source': 'Nature', 'date': 'Aug 17, 2022', 'snippet': 'Despite therapeutic advancements, oral cavity squamous cell carcinoma \n(OCSCC) remains a difficult disease to treat.', 'thumbnail': 'https://serpapi.com/searches/6721c69b7e1d1f5f594ada4e/images/de53476125ea940e322bf4b985f1b198caef53a6025b28ac448af9b77725634d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.766242265701294}",,,,,,,,,,['neutral'],neutral,1
NCT04270760,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2211023', 'title': 'Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease', 'source': 'The New England Journal of Medicine', 'date': 'Nov 6, 2022', 'snippet': 'Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular \ndisease. Olpasiran is a small interfering RNA that reduces...', 'thumbnail': 'https://serpapi.com/searches/6721c6af577da59cc43badbd/images/aace41694fa97cb3a07e1417f21b9a961f35718d5f7c5ebbe421ca9b335dfa6d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5568551421165466}",,,,,,,,,,['neutral'],neutral,1
NCT04857138,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2023/2480493', 'title': 'Fibroblast Activation Protein Expression in Sarcomas - Crane - 2023 - Sarcoma', 'source': 'Wiley Online Library', 'date': 'Jun 9, 2023', 'snippet': 'Objectives. Fibroblast activation protein alpha (FAP) is highly expressed \nby cancer-associated fibroblasts in multiple epithelial cancers.', 'thumbnail': 'https://serpapi.com/searches/6721c6f4b4e8d6fcca273037/images/b6dcce36f9b8a4b30dadde416cf7c2a8052b077418747086fb934400d5618d97.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9284780621528625}",,,,,,,,,,['neutral'],neutral,1
NCT00517933,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/ofev-sildenafil-combo-no-added-benefit-ipf-poor-lung-function/', 'title': 'In IPF with Poor Lung Function, Ofev Plus Sildenafil Has No Added Benefit', 'source': 'Pulmonary Fibrosis News', 'date': 'Oct 3, 2018', 'snippet': 'Combining Ofev (nintedanib, marketed by Boehringer Ingelheim) with \nsildenafil does not offer additional clinical benefits when compared to \nOfev treatment alone.', 'thumbnail': 'https://serpapi.com/searches/6721c6f99819f388242beaad/images/382dfbd1f8ea202cecfab13b380aed2f91021e0917d08509a611bb0bd003ea43.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7831881046295166}",,,,,,,,,,['negative'],negative,0
NCT02281318,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/severe-asthma-benefits-from-mepolizumab-regardless-of-background-therapies/', 'title': 'Mepolizumab Effective in Asthma Regardless of Background Controller Therapies', 'source': 'Pulmonology Advisor', 'date': 'Nov 1, 2019', 'snippet': 'Mepolizumab consistently reduced the annual rate of exacerbations in severe \neosinophilic asthma compared with placebo, according to research.', 'thumbnail': 'https://serpapi.com/searches/6721c70171c62b5f892164d3/images/11a2773a827078ebaa3a7b355961cfc9a30cdf1c7527cc910f4ba050e4102681.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5463080406188965}",,,,,,,,,,['positive'],positive,1
NCT02627963,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30735-1/fulltext', 'title': 'Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study', 'source': 'The Lancet', 'date': 'Dec 3, 2019', 'snippet': 'Treatment for renal cell carcinoma has been revolutionised by inhibitors of \nVEGF receptor. Previous studies have suggested that treatment...', 'thumbnail': 'https://serpapi.com/searches/6721c7295f9778874e158f4d/images/69608153ac5670abeb9935773ca637f75ae58804121ad06bfddcbe8c7f253b62.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8977097868919373}",,,,,,,,,,['neutral'],neutral,1
NCT03480763,"{'position': 1, 'link': 'https://www.precisionvaccinations.com/phase-3-studies-pcv-15-%C2%A0launched', 'title': 'Phase 3 Studies on PCV-15 Launched', 'source': 'Precision Vaccinations News', 'date': 'Apr 18, 2018', 'snippet': 'While most people have heard of pneumonia, many are confused who \npneumococcal disease impacts. Each year in the United States, \npneumococcal...', 'thumbnail': 'https://serpapi.com/searches/6721c7499819f388242beaee/images/3f0fa361dee10123d908d1d489c749a933d8918acff6463324a299b2a3bffd2e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.673831045627594}",,,,,,,,,,['neutral'],neutral,1
NCT04342663,"{'position': 1, 'link': 'https://www.infectiousdiseaseadvisor.com/news/fluvoxamine-associated-with-lower-likelihood-of-clinical-deterioration/', 'title': 'Does Fluvoxamine Prevent Clinical Deterioration in Mild COVID-19?', 'source': 'Infectious Disease Advisor', 'date': 'Jan 7, 2021', 'snippet': 'Adults with mild coronavirus disease 2019 (COVID-19) treated with \nfluvoxamine had a lower likelihood of clinical deterioration over 15 days...', 'thumbnail': 'https://serpapi.com/searches/6721c7adf7adbfc5df501cbd/images/8a7a2d22956916940d8e1642d0aad50a8c3db99e16771bff5816d1610f3f47e5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8484810590744019}",,,,,,,,,,['neutral'],neutral,1
NCT05619692,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/dalzanemdor-sage-718-fails-improve-cognition-phase-2-trial/', 'title': 'Dalzanemdor, formerly SAGE-718, fails to aid cognition in Phase 2 trial', 'source': ""Parkinson's News Today"", 'date': 'Apr 24, 2024', 'snippet': ""Dalzanemdor (formerly SAGE-718), a medication for mild cognitive impairment \ndue to Parkinson's, failed to outperform a placebo in a trial."", 'thumbnail': 'https://serpapi.com/searches/6721c7b6993688eae76d0854/images/330d3cae49f9c75a56010d3c62dc97825eadba9cfabc51b85b4004b098af3488.png', 'sentiment': 'negative', 'sentiment_prob': 0.8312615752220154}",,,,,,,,,,['negative'],negative,0
NCT02959658,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/12/14/no-effect-tecfidera-ppms-progression-after-2-years-trial-finds/', 'title': 'Tecfidera Has No Impact on PPMS Progression After 2 Years: Trial Data', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 14, 2022', 'snippet': 'Continuous treatment with Tecfidera for two years did not slow clinical and \nradiological measures of disease progression in PPMS patients.', 'thumbnail': 'https://serpapi.com/searches/6721c7c8667ec57c88a57be4/images/d1ec5a7dbcaa884577b6d3d35501bd29dd5c3660ccc60ca890ff1e97868f60cf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5292136669158936}",,,,,,,,,,['neutral'],neutral,1
NCT03930732,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2303951', 'title': 'Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts', 'source': 'The New England Journal of Medicine', 'date': 'May 21, 2023', 'snippet': 'In some patients with chronic obstructive pulmonary disease (COPD), type 2 \ninflammation may increase exacerbation risk and may be indicated...', 'thumbnail': 'https://serpapi.com/searches/6721c826f3cbfaeee3c36b22/images/a3e536dcd8e195082c2e52b376d003785f9084af31804381170d202948996296.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5304181575775146}","{'position': 2, 'link': 'https://copdnewstoday.com/news/dupixent-eases-flares-aids-lung-function-copd-notus-trial/', 'title': 'Dupixent eases flares, aids lung function with COPD: NOTUS trial', 'source': 'COPD News Today', 'date': 'Jun 17, 2024', 'snippet': 'In a second Phase 3 trial, Dupixent was seen to ease exacerbations and lung \nsymptom severity in people with moderate to severe COPD.', 'thumbnail': 'https://serpapi.com/searches/6721c826f3cbfaeee3c36b22/images/a3e536dcd8e19508c950b18ec82780b96c7266261c0e0f6a99f39cf9547f74e8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7187654376029968}","{'position': 3, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/dupilumab-significantly-reduces-exacerbations-in-copd-trial/', 'title': 'Dupilumab Significantly Reduces Exacerbations in COPD Trial', 'source': 'Medical Professionals Reference', 'date': 'Mar 24, 2023', 'snippet': 'Dupilumab was found to significantly reduce exacerbations in adults with \nuncontrolled chronic obstructive pulmonary disease (COPD) and evidence of \ntype 2...', 'thumbnail': 'https://serpapi.com/searches/6721c826f3cbfaeee3c36b22/images/a3e536dcd8e195087846c7097093d2316506455d7be9a97e3e6573b3a07a0b68.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5708305239677429}","{'position': 4, 'link': 'https://copdnewstoday.com/news/dupixent-now-approved-european-union-treat-uncontrolled-copd/', 'title': 'Dupixent now approved in EU to treat uncontrolled COPD', 'source': 'COPD News Today', 'date': 'Jul 8, 2024', 'snippet': 'Dupixent has been approved in the European Union as a maintenance treatment \nfor adults with uncontrolled COPD and type 2 inflammation.', 'thumbnail': 'https://serpapi.com/searches/6721c826f3cbfaeee3c36b22/images/a3e536dcd8e19508619360be0bb723dde7a64bf2f59d7155f89538f65d69a40e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5909627079963684}","{'position': 5, 'link': 'https://copdnewstoday.com/news/fda-seeks-more-data-dupixent-copd-clinical-trials/', 'title': 'FDA seeks more data on Dupixent COPD clinical trials', 'source': 'COPD News Today', 'date': 'May 6, 2024', 'snippet': 'The US Food and Drug Administration (FDA) has asked for more data from \nclinical trials that tested Dupixent (dupilumab) in people with chronic \nobstructive...', 'thumbnail': 'https://serpapi.com/searches/6721c826f3cbfaeee3c36b22/images/a3e536dcd8e19508945931bbeb1dba58610b7cfc00b43e0ced0a39392112381a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9244242310523987}","{'position': 6, 'link': 'https://copdnewstoday.com/news/decision-dupixent-treat-copd-delayed-fda-until-september/', 'title': 'Decision on Dupixent to treat COPD delayed by FDA until September', 'source': 'COPD News Today', 'date': 'Jun 3, 2024', 'snippet': 'The US Food and Drug Administration (FDA) has delayed by three months its \ndecision about whether to approve Dupixent (dupilumab) as an add-on \ntreatment for...', 'thumbnail': 'https://serpapi.com/searches/6721c826f3cbfaeee3c36b22/images/a3e536dcd8e19508711e516e112257acb49dad287f6cf10e8a802e5b69599e21.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5957253575325012}",,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02769481,"{'position': 1, 'link': 'https://www.empr.com/home/news/brenzavvy-approved-for-adults-with-type-2-diabetes/', 'title': 'Brenzavvy Approved for Adults With Type 2 Diabetes', 'source': 'Medical Professionals Reference', 'date': 'Jan 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Brenzavvy™ \n(bexagliflozin) as an adjunct to diet and exercise to improve glycemic...', 'thumbnail': 'https://serpapi.com/searches/6721c86d4a3fcfceed32100a/images/61600211c9c6418f259900402a03e72eea97ca4d6a948928bb1f96ff6a9684c5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6072625517845154}",,,,,,,,,,['neutral'],neutral,1
NCT01212991,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1405095', 'title': 'Enzalutamide in Metastatic Prostate Cancer before Chemotherapy', 'source': 'The New England Journal of Medicine', 'date': 'Jun 1, 2014', 'snippet': 'Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival \nin men with metastatic castration-resistant prostate cancer', 'thumbnail': 'https://serpapi.com/searches/6721c86f52a04e7ad6d81180/images/ec8490ec686f6a15b1d1d3fc4d475ae7f9ef1179d4c9575920ca653539502a1f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8110305070877075}",,,,,,,,,,['neutral'],neutral,1
NCT02583477,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1025805/full', 'title': 'Neutrophils in pancreatic cancer: Potential therapeutic targets', 'source': 'Frontiers', 'date': 'Jun 29, 2023', 'snippet': 'Pancreatic cancer is a digestive system malignancy and poses a high \nmortality worldwide. Traditionally, neutrophils have been thought to play a \nrole in...', 'thumbnail': 'https://serpapi.com/searches/6721c87303775620cb8ec12f/images/0066e26d0ea4fa5cd9d770aeeec9fe45a638e2d587eb690c84782f30b3d23fab.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5782164931297302}",,,,,,,,,,['neutral'],neutral,1
NCT05369390,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1002/med.22070', 'title': 'Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future', 'source': 'Wiley Online Library', 'date': 'Aug 14, 2024', 'snippet': 'Medicinal Research Reviews is a top-ranked medicinal chemistry journal \nfeaturing critical reviews and opinion articles in medicinal...', 'thumbnail': 'https://serpapi.com/searches/6721c878358539d63868affe/images/4a313e906ac1fe569283c91072819ee85ae70c496a9502494217764f8db9461f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.838219404220581}",,,,,,,,,,['neutral'],neutral,1
NCT03784300,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/pti-125-fails-lower-csf-protein-levels-alzheimers-patients-phase-2-trial/', 'title': 'PTI-125 Fails to Lower Alzheimer’s Protein Levels in Phase 2 Trial', 'source': ""Alzheimer's News Today"", 'date': 'May 18, 2020', 'snippet': ""Cassava Sciences announced PTI-125 failed to significantly lower levels of \nAlzheimer's-relevant markers, a primary trial goal, and data are..."", 'thumbnail': 'https://serpapi.com/searches/6721c8838db3761608d05da3/images/beda2a9615d717cbcf5f7c0b62a733efffded4eca1b337cdaeed74309c3cea74.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6908381581306458}",,,,,,,,,,['negative'],negative,0
NCT02125461,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1709937', 'title': 'Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Sep 8, 2017', 'snippet': 'This phase 3 study compared the anti–programmed death ligand 1 antibody \ndurvalumab as consolidation therapy with placebo in patients with stage III \nNSCLC', 'thumbnail': 'https://serpapi.com/searches/6721c894c05eb50a34938d27/images/f89feef032e3c755ea40a634a50fc64cc3a8cad71c529901e576f335e8ea5e25.png', 'sentiment': 'neutral', 'sentiment_prob': 0.885631799697876}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1809697', 'title': 'Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC', 'source': 'The New England Journal of Medicine', 'date': 'Sep 25, 2018', 'snippet': 'An earlier analysis in this phase 3 trial showed that durvalumab \nsignificantly prolonged progression-free survival, as compared with \nplacebo...', 'thumbnail': 'https://serpapi.com/searches/6721c894c05eb50a34938d27/images/f89feef032e3c7550994624ee9b9026c3e1b0db0198364bedf8ad453d8d13d9e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7740229368209839}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02931539,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/abs/10.1111/tid.14064', 'title': 'Healthcare resource utilization of maribavir versus investigator-assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial', 'source': 'Wiley Online Library', 'date': 'May 8, 2023', 'snippet': 'This exploratory analysis evaluated hospital admissions of patients during \nthe Phase 3 SOLSTICE study. Patients treated with maribavir...', 'thumbnail': 'https://serpapi.com/searches/6721c896a775f2424b77d728/images/34045f649da6038a4e9985acbae58121734c0e5a8c9dd9862da87a28ed04eaa4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9024654626846313}","{'position': 2, 'link': 'https://www.nature.com/articles/s41409-021-01341-7', 'title': 'The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001- O009) | Bone Marrow Transplantation', 'source': 'Nature', 'date': 'Jun 24, 2021', 'snippet': 'The use of PTCY for GVHD prophylaxis resulted in similar outcomes to those \nseen with ATG for patients who underwent an FB2 RIC regimen allo-HCT with a \n10/10...', 'thumbnail': 'https://serpapi.com/searches/6721c896a775f2424b77d728/images/34045f649da6038a03e9c3cbe6a0f57193d1494a1f5af7155bbd12dec4fa16b1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8731558918952942}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02807558,"{'position': 1, 'link': 'https://www.onclive.com/view/enrollment-to-discontinue-for-select-aml-1-trial-of-tamibarotene-triplet-in-newly-diagnosed-rara-aml', 'title': 'Enrollment to Discontinue for SELECT-AML-1 Trial of Tamibarotene Triplet in Newly Diagnosed RARA+ AML', 'source': 'OncLive', 'date': 'Aug 13, 2024', 'snippet': 'Enrollment will discontinue for the SELECT-AML-1 trial of \ntamibarotene/venetoclax/azacitidine in newly diagnosed, RARA-positive \nacute...', 'thumbnail': 'https://serpapi.com/searches/6721c8b8e6862be438ae15f3/images/0a7b47ea93a5af091e9066977a52488521043f4cef57ee27510a87365623c073.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7852614521980286}","{'position': 2, 'link': 'https://www.onclive.com/view/tamibarotene-azacitidine-combination-under-investigation-in-higher-risk-mds', 'title': 'Tamibarotene/Azacitidine Combination Under Investigation in Higher-risk MDS', 'source': 'OncLive', 'date': 'May 3, 2023', 'snippet': 'Ana Alfonso Piérola, MD, PhD, discusses the rationale for targeting \nretinoic acid receptor alpha in patients with higher-risk...', 'thumbnail': 'https://serpapi.com/searches/6721c8b8e6862be438ae15f3/images/0a7b47ea93a5af09b26d79f47e1c0bc5b9d9d93b9e10630795fe5d9acf79514e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9306063055992126}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01694186,"{'position': 1, 'link': 'https://www.nature.com/articles/s41433-021-01608-9', 'title': 'Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis', 'source': 'Nature', 'date': 'Jun 11, 2021', 'snippet': 'Prevention of non-infectious uveitis of the posterior segment (NIU-PS) \nrecurrence using 0.2 μg/day fluocinolone acetonide implant (FAi) was...', 'thumbnail': 'https://serpapi.com/searches/6721c8e1dc969f71fa96d36b/images/28a88a8c095692878088c2ebdf06288b1645e3a671871e27c00de8745be1929c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8141335248947144}",,,,,,,,,,['neutral'],neutral,1
NCT04468009,"{'position': 1, 'link': 'https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06829-7', 'title': 'Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials', 'source': 'BMC Infectious Diseases', 'date': 'Nov 20, 2021', 'snippet': 'Convalescent plasma has been widely used to treat COVID-19 and is under \ninvestigation in numerous randomized clinical trials,...', 'thumbnail': 'https://serpapi.com/searches/6721c8e57f371910a34e3998/images/054017ee40dd241624ee98309d265899f6063ede5c08f929383fb478f21f6984.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9111935496330261}",,,,,,,,,,['neutral'],neutral,1
NCT02898610,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.121.054610', 'title': 'Colchicine in Patients With Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial', 'source': 'American Heart Association Journals', 'date': 'Nov 8, 2021', 'snippet': 'Colchicine in patients with acute coronary syndrome: two-year follow-up of \nthe Australian COPS randomized clinical trial.', 'thumbnail': 'https://serpapi.com/searches/6721c92aa775f24217d44547/images/bb0f3759181bda69a3791289d34176c1fe0fb6661f37d72c6be2534123f06de8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9048358201980591}",,,,,,,,,,['neutral'],neutral,1
NCT01292473,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1215372', 'title': 'Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria', 'source': 'The New England Journal of Medicine', 'date': 'Feb 24, 2013', 'snippet': 'Omalizumab diminished clinical symptoms and signs of chronic idiopathic \nurticaria in patients who had remained symptomatic despite the use of \napproved doses of...', 'thumbnail': 'https://serpapi.com/searches/6721c92bb9ab865cfec09714/images/5180f5fb496f112379ed11a3f01386f883dda099e55cd8352962a2ec2cd39105.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5380107760429382}",,,,,,,,,,['neutral'],neutral,1
NCT03393975,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa2314793', 'title': 'Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura', 'source': 'The New England Journal of Medicine', 'date': 'May 1, 2024', 'snippet': 'During prophylaxis with recombinant ADAMTS13 in patients with congenital \nTTP, ADAMTS13 activity reached approximately 100% of normal levels.', 'thumbnail': 'https://serpapi.com/searches/6721c9520be2f68746bb0c6b/images/26704fdef9e8b8369444def64f55734cf971ddaab9ab877d87bf05437a6d694f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8558619022369385}","{'position': 2, 'link': 'https://www.ajmc.com/view/prophylaxis-with-recombinant-adamts13-demonstrates-superiority-vs-standard-therapy-in-congenital-ttp', 'title': 'Prophylaxis With Recombinant ADAMTS13 Demonstrates Superiority vs Standard Therapy in Congenital TTP', 'source': 'AJMC', 'date': 'Jun 5, 2024', 'snippet': 'The multinational, open-label, controlled, randomized, crossover, phase 3 \nTAK-755 (NCT03393975) trial demonstrated superior efficacy and...', 'thumbnail': 'https://serpapi.com/searches/6721c9520be2f68746bb0c6b/images/26704fdef9e8b8368ff665138e2fe5884cb78a1820d6745cef53dd4c785827c7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7772839665412903}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03679598,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/alvelestat-gets-fast-tracked-for-aatd-associated-lung-disease/', 'title': 'Alvelestat Gets Fast Track Status for AATD-Associated Lung Disease', 'source': 'Medical Professionals Reference', 'date': 'Oct 18, 2022', 'snippet': 'The Food and Drug Administration (FDA) has granted Fast Track designation \nto alvelestat (MPH-966) for the treatment of patients with alpha-1 \nantitrypsin...', 'thumbnail': 'https://serpapi.com/searches/6721c977b9ab865cfec09741/images/a343877b44e753137d6ae1c46fb37f8457a85716fc299f93b129aa60509fae2f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7554808259010315}",,,,,,,,,,['neutral'],neutral,1
NCT00855465,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1209657', 'title': 'Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension', 'source': 'The New England Journal of Medicine', 'date': 'Jul 25, 2013', 'snippet': 'Riociguat, a member of a new class of compounds (soluble guanylate cyclase \nstimulators), has been shown in previous clinical studies to be...', 'thumbnail': 'https://serpapi.com/searches/6721c9f16ad3c98a6ed69eae/images/754398c92a2d7fc4ffccbaa6dbf11a7e0dcbd1ad9a1551e841322c52e35501da.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8995528221130371}",,,,,,,,,,['neutral'],neutral,1
NCT03778931,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.22.00338', 'title': 'Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD', 'source': 'ASCO Publications', 'date': 'Jun 21, 2022', 'snippet': 'PURPOSEPatients with pretreated estrogen receptor (ER)–positive/human \nepidermal growth factor receptor 2 (HER2)–negative advanced breast cancer \nhave poor...', 'thumbnail': 'https://serpapi.com/searches/6721ca1168831ed3890c3212/images/35eea772f8c8fb8d25c39c8eab86cc8edb534c52e82e431ee08f9b76ce5e3a97.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5797135233879089}","{'position': 2, 'link': 'https://www.bcrf.org/blog/sabcs-2021-breast-cancer-clinical-trial-updates/', 'title': 'SABCS 2021: Updates from Breast Cancer Clinical Trials', 'source': 'Breast Cancer Research Foundation', 'date': 'Jan 21, 2022', 'snippet': 'The 2021 San Antonio Breast Cancer Symposium (SABCS) heralded promising \nclinical trial results for breast cancer patients—particularly for...', 'thumbnail': 'https://serpapi.com/searches/6721ca1168831ed3890c3212/images/35eea772f8c8fb8d2a7cc39be086106fd7dc53222603d8dd31faf8fd5bdddf31.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7230058908462524}","{'position': 3, 'link': 'https://www.targetedonc.com/view/elacestrant-provides-treatment-path-forward-in-advanced-breast-cancer', 'title': 'Elacestrant Provides Treatment Path Forward in Advanced Breast Cancer', 'source': 'Targeted Oncology', 'date': 'Mar 11, 2024', 'snippet': 'CASE SUMMARY. A 52-year-old, postmenopausal woman presents with a palpable \nright breast mass with no clinically abnormal axillary lymph...', 'thumbnail': 'https://serpapi.com/searches/6721ca1168831ed3890c3212/images/35eea772f8c8fb8d1b8fb5dd57ab01253d12b81857fbb1aa270987baf3ecc550.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9070744514465332}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT04321031,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/ervogastat-clesacostat-fast-tracked-for-nonalcoholic-steatohepatitis/', 'title': 'Ervogastat/Clesacostat Fast Tracked for Nonalcoholic Steatohepatitis', 'source': 'Medical Professionals Reference', 'date': 'May 26, 2022', 'snippet': 'The Food and Drug Administration (FDA) has granted Fast Track status to the \ncombination of ervogastat and clesacostat for the treatment of...', 'thumbnail': 'https://serpapi.com/searches/6721ca3f6cca5e78b0958aef/images/8f6659a5f56ee2d2c9337443401ef453a9a603204dc3305d9ba2279b0a9d02d4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.884272038936615}",,,,,,,,,,['neutral'],neutral,1
NCT03636269,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1912770', 'title': 'A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus', 'source': 'The New England Journal of Medicine', 'date': 'Nov 8, 2019', 'snippet': 'Difelikefalin is a peripherally restricted and selective agonist of kappa \nopioid receptors that are considered to be important in modulating...', 'thumbnail': 'https://serpapi.com/searches/6721ca411ec32fb261332936/images/135adbb2468c2b462156856122a886bdb317efca42553484e82154b58945bb36.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9061687588691711}","{'position': 2, 'link': 'https://www.empr.com/home/news/korsuva-approved-for-chronic-kidney-disease-associated-pruritus/', 'title': 'Korsuva Approved for Chronic Kidney Disease-Associated Pruritus', 'source': 'Medical Professionals Reference', 'date': 'Aug 24, 2021', 'snippet': 'The Food and Drug Administration has approved Korsuva™ (difelikefalin) \ninjection for the treatment of moderate to severe pruritus associated...', 'thumbnail': 'https://serpapi.com/searches/6721ca411ec32fb261332936/images/135adbb2468c2b4637b6a1127ee0c20c11874e2d29dc95757d0020a0b1ea9579.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.87298184633255}","{'position': 3, 'link': 'https://www.drugtopics.com/view/fda-approves-treatment-for-uremic-pruritis', 'title': 'FDA Approves Treatment for Uremic Pruritis', 'source': 'Drug Topics', 'date': 'Apr 5, 2022', 'snippet': 'The FDA approved difelikefalin (Korsuva) for the treatment of moderate to \nsevere pruritis associated with chronic kidney disease (CKD) in adults \nundergoing...', 'thumbnail': 'https://serpapi.com/searches/6721ca411ec32fb261332936/images/135adbb2468c2b46aacccdf2817b887a3594c0cc9c500224e753f03ebba8d907.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8146046996116638}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00109070,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0304-6', 'title': 'Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer', 'source': 'Nature', 'date': 'Nov 29, 2018', 'snippet': 'Two first-line (1L) bevacizumab trials showed the prognostic value of \nprimary tumour location in metastatic colorectal cancer (mCRC).', 'thumbnail': 'https://serpapi.com/searches/6721ca6d72f7160b7410d3a1/images/db85666d40eef09fb833ef1c8f6760a6b60367a6b5bf466cb1fcaf543334fa3a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7932325005531311}",,,,,,,,,,['neutral'],neutral,1
NCT00078572,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa064320', 'title': 'Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Dec 28, 2006', 'snippet': 'Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor \nreceptor type 2 (HER2, also referred to as HER2/neu) and epidermal...', 'thumbnail': 'https://serpapi.com/searches/6721ca85a5d70237f1dfe29f/images/771d130d2a7a187e17fdde182918f1a77445d92a1fc14022deb187d114cbb3c4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8776703476905823}",,,,,,,,,,['neutral'],neutral,1
NCT00289978,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0909494', 'title': 'A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Jan 20, 2010', 'snippet': 'As compared with placebo, both doses of oral fingolimod improved the \nrelapse rate, the risk of disability progression, and end points on MRI.', 'thumbnail': 'https://serpapi.com/searches/6721ca9c76079d9be2414557/images/eb6ef199f90a80403e77035345d9693d3ddad69c92a08f90f93bb28624fb97a9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7870510220527649}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/12/20/neurofilament-light-chain-studied-ms-prognosis-biomarker/', 'title': 'Neurofilament Light Chain Studied as MS Prognosis Biomarker |...', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 20, 2022', 'snippet': 'A study showed neurofilament light chain tends to be associated with \nmultiple sclerosis progression and is lowered with Gilenya treatment.', 'thumbnail': 'https://serpapi.com/searches/6721ca9c76079d9be2414557/images/eb6ef199f90a80409accbbe081ec479b801724dba3295256c74c7450d10ad299.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8330132365226746}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2019/10/16/extended-treatment-with-fingolimod-for-relapsing-multiple-sclerosis-the-14-year-longterms-study-results/', 'title': 'Long-term Gilenya Treatment Safe and Effective for Relapsing MS Patients, Phase 3 Trial Shows', 'source': 'Multiple Sclerosis News Today', 'date': 'Oct 22, 2019', 'snippet': 'Long-term treatment with Gilenya (fingolimod) in patients with relapsing \nforms of multiple sclerosis (MS) is safe and effective,...', 'thumbnail': 'https://serpapi.com/searches/6721ca9c76079d9be2414557/images/eb6ef199f90a80403f6bb3761932af13eb6993fee07afcd12c17270c6435d5e6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5736227631568909}",,,,,,,,"['neutral', 'neutral', 'positive']",neutral,1
NCT04509167,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/ctm2.1461', 'title': 'Personalised neoantigen‐based therapy in colorectal cancer - Zhu - 2023 - Clinical and Translational Medicine', 'source': 'Wiley Online Library', 'date': 'Nov 3, 2023', 'snippet': 'Abstract Colorectal cancer (CRC) has become one of the most common tumours \nwith high morbidity, mortality and distinctive evolution...', 'thumbnail': 'https://serpapi.com/searches/6721cabe0e6db34182cfe412/images/e48bfe4e52ed4b4581518a017ac42848d5a23641c83ecb8e083877a236d4138d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7398278117179871}",,,,,,,,,,['neutral'],neutral,1
NCT04281472,"{'position': 1, 'link': 'https://www.neurologylive.com/view/fda-approves-efgartigimod-new-treatment-chronic-inflammatory-demyelinating-polyneuropathy', 'title': 'FDA Approves Efgartigimod as New Treatment for Chronic Inflammatory Demyelinating Polyneuropathy', 'source': 'Neurology live', 'date': 'Jun 21, 2024', 'snippet': 'The therapy is the first and only neonatal Fc receptor blocker approved for \nthe treatment of CIDP, and will be available as a once-weekly,...', 'thumbnail': 'https://serpapi.com/searches/6721cae0d997ab920de20d62/images/4c257c381f442a5e592fbe4e36b55d5a635a00ca2479e087516296d74a0d553f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6971869468688965}",,,,,,,,,,['neutral'],neutral,1
NCT02579759,"{'position': 1, 'link': 'https://charcot-marie-toothnews.com/news/patient-enrollment-complete-premier-clinical-trial-pxt3003-cmt1a/', 'title': 'Patient Enrollment Complete for PREMIER Trial of PXT3003 for CMT1A', 'source': 'Charcot-Marie-Tooth News', 'date': 'Jun 3, 2022', 'snippet': ""Enrollment into Pharnext's pivotal Phase 3 PREMIER clinical trial, testing \nthe effectiveness and safety of PXT3003 for people with..."", 'thumbnail': 'https://serpapi.com/searches/6721cb5f39e23248aec4f92b/images/4965ae3d532f65da4e4591835869bdb0f652ab38fd97b1ef2a02af1133f2dec0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8473119139671326}","{'position': 2, 'link': 'https://charcot-marie-toothnews.com/news/pharnext-working-toward-applications-pxt3003-approval/', 'title': 'Pharnext working toward applications for PXT3003 approval', 'source': 'Charcot-Marie-Tooth News', 'date': 'Jan 3, 2024', 'snippet': 'Pharnext is analyzing clinical trial data that could support applications \nto approve PXT3003, a therapy candidate for CMT1A.', 'thumbnail': 'https://serpapi.com/searches/6721cb5f39e23248aec4f92b/images/4965ae3d532f65da2d666798f11f24355b228163335bc67e4da3da54541885fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7428095936775208}","{'position': 3, 'link': 'https://charcot-marie-toothnews.com/news/high-dose-pxt3003-potential-safely-treat-cmt1a-phase-3-trial-data/', 'title': 'PXT3003 at High Dose Shows Potential to Safely Treat CMT1A in Phase 3 Trial', 'source': 'Charcot-Marie-Tooth News', 'date': 'Oct 22, 2021', 'snippet': 'Data from the PLEO-CMT Phase 3 trial of PXT3003 show promising gains and \ngood safety for Charcot–Marie–Tooth type 1A patients, study finds.', 'thumbnail': 'https://serpapi.com/searches/6721cb5f39e23248aec4f92b/images/4965ae3d532f65da3be7c17ea99080e78e5a3912e2c01bf5bf42d71e41771ab2.png', 'sentiment': 'positive', 'sentiment_prob': 0.8206772804260254}","{'position': 4, 'link': 'https://charcot-marie-toothnews.com/news/safety-board-approves-continuation-of-phase-3-trial-of-charcot-marie-tooth-therapy-pxt3003/', 'title': 'Charcot-Marie-Tooth Therapy PXT3003 Obtains Trial Safety Board Sign-off', 'source': 'Charcot-Marie-Tooth News', 'date': 'Sep 8, 2017', 'snippet': 'Read about a safety board recommending the continuation of a Phase 3 \nclinical trial of PXT3003 trial as a treatment for Charcot-Marie-Tooth...', 'thumbnail': 'https://serpapi.com/searches/6721cb5f39e23248aec4f92b/images/4965ae3d532f65dabec1bdc6028daf5cd5691d7526f07db18b31f61b3078451f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9365841746330261}","{'position': 5, 'link': 'https://charcot-marie-toothnews.com/news/pxt3003-delays-disease-onset-rat-model-cmt1a/', 'title': 'Short-term PXT3003 Treatment Delays Disease Onset in Rat Model of CMT1A, Study Shows', 'source': 'Charcot-Marie-Tooth News', 'date': 'Jan 24, 2019', 'snippet': 'Two weeks of treatment with PXT3003 delayed disease onset, corrected motor \ndeficits, and improved dysregulated molecular pathways in a rat...', 'thumbnail': 'https://serpapi.com/searches/6721cb5f39e23248aec4f92b/images/4965ae3d532f65dacd8bf88afe7b33089ca3f36525f6b096c855d93347a749cd.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5911993980407715}","{'position': 6, 'link': 'https://charcot-marie-toothnews.com/experimental-treatments-for-charcot-marie-tooth-disease/', 'title': 'Charcot–Marie–Tooth Disease Experimental Therapies Are in the Works', 'source': 'Charcot-Marie-Tooth News', 'date': 'Sep 13, 2017', 'snippet': 'Several potential CMT therapies are being evaluated in clinical trials. \nPharnext developed PXT3003 to treat people with CMT type 1A, the most \ncommon form of...', 'thumbnail': 'https://serpapi.com/searches/6721cb5f39e23248aec4f92b/images/4965ae3d532f65da4c3c6e01b7571289e3ebcc0e74d7dee3a07226664ad5360d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8754680752754211}",,,,,"['neutral', 'neutral', 'positive', 'neutral', 'negative', 'neutral']",neutral,1
NCT02057692,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/livmarli-sustains-benefit-alagille-patients-over-7-years-trial-data/', 'title': 'Livmarli sustains benefit for Alagille patients over 7 years: Trial data', 'source': 'Liver Disease News', 'date': 'Jun 14, 2024', 'snippet': ""Nearly all children with Alagille syndrome who received Mirum \nPharmaceuticals' Livmarli (maralixibat) for seven years as part of clinical \nstudies continued to..."", 'thumbnail': 'https://serpapi.com/searches/6721cb8189055e8ea6cb8d9f/images/7ba0d46322478ad847acd88c00a6ba2aac06b72209e3e25ffef6477aff2071da.png', 'sentiment': 'positive', 'sentiment_prob': 0.49692490696907043}",,,,,,,,,,['positive'],positive,1
NCT03196284,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/novo-nordisk-pauses-three-clinical-trials-of-concizumab-due-to-safety-concerns/', 'title': 'Safety Concerns Put 3 Hemophilia Trials, Testing Concizumab, on Hold', 'source': 'Hemophilia News Today', 'date': 'Mar 18, 2020', 'snippet': 'Novo Nordisk has paused three clinical trials evaluating concizumab, its \nexperimental treatment candidate for hemophilia A and B, due to safety \nconcerns.', 'thumbnail': 'https://serpapi.com/searches/6721cba248e6680fc6678733/images/9cc362c792692b83c57a53f5311625176673bdd4ebd59de0f615e5e685ffe1d3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5402668714523315}",,,,,,,,,,['neutral'],neutral,1
NCT03834753,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/fda-rejects-intravitreal-formulation-of-bevacizumab-for-wet-amd/', 'title': 'FDA Rejects Intravitreal Formulation of Bevacizumab for Wet AMD', 'source': 'Medical Professionals Reference', 'date': 'Aug 30, 2023', 'snippet': 'The Food and Drug Administration (FDA) has issued a Complete Response \nLetter (CRL) to Outlook Therapeutics regarding the Biologics License \nApplication (BLA)...', 'thumbnail': 'https://serpapi.com/searches/6721cbb8cb33d0118fb63c85/images/de09abc9896cdc43c36c55e59d5438ae85c244e5c7ceaeaab375e738c8d0b181.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8640140891075134}",,,,,,,,,,['neutral'],neutral,1
NCT02878330,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1913556', 'title': 'Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants', 'source': 'The New England Journal of Medicine', 'date': 'Jul 29, 2020', 'snippet': 'Respiratory syncytial virus (RSV) is the most common cause of lower \nrespiratory tract infection in infants, and a need exists for prevention...', 'thumbnail': 'https://serpapi.com/searches/6721cbf2caddc31d1631616c/images/d07f10d281400c51733e894bdc0354fab8a552d1b70ecd371de6f1de1bd8e386.png', 'sentiment': 'negative', 'sentiment_prob': 0.49253952503204346}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-023-40057-8', 'title': 'Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials', 'source': 'Nature', 'date': 'Jul 19, 2023', 'snippet': 'Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial \nvirus (RSV) fusion protein. During the Phase 2b (NCT02878330)...', 'thumbnail': 'https://serpapi.com/searches/6721cbf2caddc31d1631616c/images/d07f10d281400c51172218c81a5fd59a3c58ab08fdb683d218145a0366455f47.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9245671629905701}","{'position': 3, 'link': 'https://www.contemporarypediatrics.com/view/nirsevimab-alip-fda-approved-to-prevent-rsv-in-neonates-infants', 'title': 'Nirsevimab-alip FDA approved to prevent RSV in neonates, infants', 'source': 'Contemporary Pediatrics', 'date': 'Jul 17, 2023', 'snippet': 'The FDA has announced the approval of nirsevimab-alip (Beyfortus; Sanofi \nand AstraZeneca) to prevent respiratory syncytial virus (RSV) lower \nrespiratory tract...', 'thumbnail': 'https://serpapi.com/searches/6721cbf2caddc31d1631616c/images/d07f10d281400c5166acd6b0c0b1c662e7a51cb15500e7d3615dbf84ae4ad3d0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7050540447235107}",,,,,,,,"['negative', 'neutral', 'neutral']",neutral,1
NCT01241292,"{'position': 1, 'link': 'https://www.nature.com/articles/bcj201718', 'title': 'Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis', 'source': 'Nature', 'date': 'Mar 10, 2017', 'snippet': 'A phase 3, international, randomized clinical trial that investigated the \nefficacy and safety of ELd compared with lenalidomide/dexamethasone (Ld) in \npatients...', 'thumbnail': 'https://serpapi.com/searches/6721cbf3db3ac9d20ba67b04/images/e974ffefcc928b6306835354747718bf59e6b6cfe4803cb91330cdfd31387f54.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9092058539390564}",,,,,,,,,,['neutral'],neutral,1
NCT04592484,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-024-06494-z', 'title': 'Roles of exosomes in immunotherapy for solid cancers', 'source': 'Nature', 'date': 'Feb 1, 2024', 'snippet': 'Exosomes are the main type of extracellular vesicles that can deliver \nvarious intracellular molecules to adjacent or distant cells and organs.', 'thumbnail': 'https://serpapi.com/searches/6721cbfc5235f6c6d4e1370b/images/e904accad7ef8cc5eacf79bf31193f6ea8eb7e8f9d80f7c42f6974fffe4e838a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.914504885673523}","{'position': 2, 'link': 'https://www.bioprocessintl.com/chromatography/ligand-based-exosome-affinity-purification-a-scalable-solution-to-extracellular-vesicle-downstream-bottlenecks', 'title': 'Ligand-Based Exosome Affinity Purification: A Scalable Solution to Extracellular Vesicle Downstream Bottlenecks', 'source': 'BioProcess International', 'date': 'Jun 18, 2021', 'snippet': 'Our goal was to demonstrate the suitability of the LEAP platform for \nscalable downstream EV processing of a clinical-grade product.', 'thumbnail': 'https://serpapi.com/searches/6721cbfc5235f6c6d4e1370b/images/e904accad7ef8cc5dd48d6649bf08b4f1bddcbd945c22b0a60b2034451b29bd1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6072063446044922}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01325220,"{'position': 1, 'link': 'https://fragilexnewstoday.com/news/arbaclofen-improved-behavior-half-fragile-x-children-trial/', 'title': 'Arbaclofen Improved Behavior of Almost Half of Children in Phase 3 Trial', 'source': 'Fragile X News Today', 'date': 'Aug 19, 2022', 'snippet': 'The investigational fragile X therapy Arbaclofen improved aspects of \nbehavior in about half of children, ages 5 to 11, in a Phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/6721cbfe24296a3c4a749d3b/images/89f86e34504cbf739c04712ec399b5de05b12f0c7d244904b939da4e5c00062d.png', 'sentiment': 'positive', 'sentiment_prob': 0.5654360055923462}",,,,,,,,,,['positive'],positive,1
NCT02652767,"{'position': 1, 'link': 'https://mitochondrialdiseasenews.com/2017/12/06/gs010-shows-promise-improving-long-term-vision-lhon-gensight-biologics/', 'title': 'GS010 Shows Promise for Improving Long-term Vision in LHON Patients', 'source': 'Mitochondrial Disease News', 'date': 'Dec 6, 2017', 'snippet': ""Learn more about GenSight Biologics' injectable therapy, GS010, which is \nshowing promise in treating patients with Leber Hereditary Optic..."", 'thumbnail': 'https://serpapi.com/searches/6721cc397e1d1f5f594ade31/images/d7e0ad0190e40c682582ae4352870ae636081153706ba888cf7122712dfce394.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6076823472976685}",,,,,,,,,,['positive'],positive,1
NCT04010539,"{'position': 1, 'link': 'https://www.drugtopics.com/view/navigating-women-s-health-utilization-in-a-changing-landscape-amcp-nexus-2024', 'title': ""Navigating Women's Health Utilization in a Changing Landscape | AMCP Nexus 2024"", 'source': 'Drug Topics', 'date': '5 days ago', 'snippet': 'A series of posters presented at AMCP Nexus 2024 focused on 2 key areas: \nthe utilization of medications for preterm birth (PTB) prevention...', 'thumbnail': 'https://serpapi.com/searches/6721cc70e95dbfd3eaa575f6/images/9976821ac111f670bf2485326e61a5b8924ba5d251ed3d7725233817b7dbb2b2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8782874941825867}",,,,,,,,,,['neutral'],neutral,1
NCT04581629,"{'position': 1, 'link': 'https://hypoparathyroidismnews.com/news/encaleret-granted-fda-fast-track-designation-rare-adh1-hypoparathyroidism/', 'title': 'Encaleret for Rare ADH1 Gets FDA Fast Track Designation', 'source': 'Hypoparathyroidism News', 'date': 'Jun 7, 2021', 'snippet': 'The U.S. Food and Drug Administration has granted fast track designation to \nencaleret, an investigational therapy for autosomal dominant...', 'thumbnail': 'https://serpapi.com/searches/6721ccbc642c3145ca26864c/images/684277eac8d6f5d25c6e64df3941541891a3a03ebb1e65e4b9ff2bc0c877a890.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7736688256263733}",,,,,,,,,,['neutral'],neutral,1
NCT02927067,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1714656', 'title': 'Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation', 'source': 'The New England Journal of Medicine', 'date': 'Sep 18, 2019', 'snippet': 'Maribavir at a dose of at least 400 mg twice daily had efficacy similar to \nthat of valganciclovir for clearing CMV viremia among recipients of \nhematopoietic-...', 'thumbnail': 'https://serpapi.com/searches/6721ccd39e5bd52d11a9bebc/images/538fb088a0a213e20957f4d0a0059ead13051e1a2bbbb476eeecc38f0cdafbc8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7918958067893982}",,,,,,,,,,['neutral'],neutral,1
NCT04648033,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-022-02041-9', 'title': 'How the histological structure of some lung cancers shaped almost 70 years of radiobiology', 'source': 'Nature', 'date': 'Nov 7, 2022', 'snippet': 'Pivotal research led by Louis Harold Gray in the 1950s suggested that \noxygen plays a vital role during radiotherapy.', 'thumbnail': 'https://serpapi.com/searches/6721ccdd96a3292c5a242246/images/a5e9b3bc4a78048565514823f860c7a54fbf9968fd0ef942a8f3ca64fdcaddf1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8533828854560852}",,,,,,,,,,['neutral'],neutral,1
NCT05032157,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/remibrutinib-improves-symptoms-in-patients-with-chronic-spontaneous-urticaria/', 'title': 'Remibrutinib Improves Symptoms in Patients With Chronic Spontaneous Urticaria', 'source': 'Medical Professionals Reference', 'date': 'Aug 9, 2023', 'snippet': 'Treatment with remibrutinib, an investigational Bruton tyrosine kinase \n(BTK) inhibitor, appears to benefit patients with chronic spontaneous \nurticaria (CSU).', 'thumbnail': 'https://serpapi.com/searches/6721cce50f2a2cf3975a2db8/images/6ba3beb5b0f62b7157a5949c2eecba0872db952b81d7b9e297f4d4da44fdb114.png', 'sentiment': 'positive', 'sentiment_prob': 0.6247542500495911}",,,,,,,,,,['positive'],positive,1
NCT04659174,"{'position': 1, 'link': 'https://www.nature.com/articles/s41537-022-00320-1', 'title': 'Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia', 'source': 'Nature', 'date': 'Dec 3, 2022', 'snippet': 'KarXT combines xanomeline, an M1/M4 preferring muscarinic agonist with no \ndirect D2 receptor antagonism, with the peripherally restricted...', 'thumbnail': 'https://serpapi.com/searches/6721cd14a3657ab8d46cd736/images/4a1f3e641fde7ef567f3300f4ec574030db843315d62d99fcc7e9a80961585d9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8456377983093262}",,,,,,,,,,['neutral'],neutral,1
NCT02478398,"{'position': 1, 'link': 'https://www.empr.com/home/news/ragwitek-expanded-for-ragweed-pollen-induced-allergic-rhinitis/', 'title': 'Ragwitek Approved for Pediatric Patients With Ragweed Pollen Allergy', 'source': 'Medical Professionals Reference', 'date': 'Apr 19, 2021', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of \nRagwitek (short ragweed pollen allergen extract) to include patients 5 to \n17 years of age.', 'thumbnail': 'https://serpapi.com/searches/6721cd27213c87ebb7b0c530/images/25f51b2eb71fe20e53b48a7d166778fd25f1348eb69c0911ab82d2b8835b1322.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8315685987472534}",,,,,,,,,,['neutral'],neutral,1
NCT01423604,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/mog2.62', 'title': 'Cancer stem cells: Signaling pathways and therapeutic targeting - Talukdar - 2023 - MedComm – Oncology', 'source': 'Wiley Online Library', 'date': 'Dec 28, 2023', 'snippet': 'The activation of several critical signalling pathways cooperatively \nstimulates the cellular and molecular characteristics of cancer stem...', 'thumbnail': 'https://serpapi.com/searches/6721cd28a86921bfc102b545/images/5d67dd038defd109ffa4b03ca40efeb73c07df07ecdca459c6bde08bc8d450dd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9209615588188171}",,,,,,,,,,['neutral'],neutral,1
NCT00045032,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-021-00241-9', 'title': 'The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data', 'source': 'Nature', 'date': 'Mar 22, 2021', 'snippet': 'While many studies have evaluated the relationship between BMI and breast \ncancer outcomes, it is unclear whether this relationship is...', 'thumbnail': 'https://serpapi.com/searches/6721cd3211db4540a6d92b28/images/bb72c3d329dfc3d71d7aab5e3243625e8a12d81b405d69ea1d8089150875865b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7276222705841064}",,,,,,,,,,['neutral'],neutral,1
NCT03729362,"{'position': 1, 'link': 'https://pompediseasenews.com/news/small-changes-walking-ability-meaningful-advanced-lopd/', 'title': 'Small changes in walking ability can be meaningful in advanced LOPD', 'source': 'Pompe Disease News', 'date': 'May 2, 2024', 'snippet': 'For LOPD patients who are already experiencing difficulty walking, even a \nslowing of decline can be a meaningful improvement, a study says.', 'thumbnail': 'https://serpapi.com/searches/6721cd7b5c7cb930cf0095f4/images/f86af157f3933b7ac0a6fffa67d223f3ccac71c12c4bc884d04f26ca0c846e7b.png', 'sentiment': 'positive', 'sentiment_prob': 0.6018885374069214}",,,,,,,,,,['positive'],positive,1
NCT01845987,"{'position': 1, 'link': 'https://www.dermatologyadvisor.com/news/guselkumab-promising-for-treatment-resistant-palmoplantar-pustulosis/', 'title': 'Guselkumab Promising for Treatment-Resistant Palmoplantar Pustulosis', 'source': 'Dermatology Advisor', 'date': 'Mar 14, 2018', 'snippet': 'The aim of the current study was to evaluate the efficacy and safety of \nguselkumab in patients with moderate to severe palmoplantar...', 'thumbnail': 'https://serpapi.com/searches/6721cd8690b57cd5e64c8772/images/b8a2d63c1ee35eba1eee626c888c2b025ddc9c7c0db534b770d6fbfd9333c3ec.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7053316235542297}",,,,,,,,,,['neutral'],neutral,1
NCT00769483,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Study-design-schemes-a-Phase-I-dose-escalation-trial-scheme-b-Phase-II-randomization_fig1_325449512', 'title': 'Fig. 1 Study design schemes. a Phase I dose escalation trial scheme. b...', 'source': 'ResearchGate', 'date': 'Jun 7, 2018', 'snippet': 'A 3 + 3 dose escalation design was used to determine the MK-0646 maximum \ntolerable dose (MTD) in combination with G (gemcitabine) (arm A) or G + E \n(erlotinib)...', 'thumbnail': 'https://serpapi.com/searches/6721cd87ec5410d4be7c779e/images/513569f575e12022f623baa43e7896f302b1ba7d625235956382175447358e44.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9185580015182495}",,,,,,,,,,['neutral'],neutral,1
NCT01039688,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1310476', 'title': 'Tofacitinib versus Methotrexate in Rheumatoid Arthritis', 'source': 'The New England Journal of Medicine', 'date': 'Jun 19, 2014', 'snippet': 'Methotrexate is the most frequently used first-line antirheumatic drug. We \nreport the findings of a phase 3 study of monotherapy with...', 'thumbnail': 'https://serpapi.com/searches/6721ce1a49ea55cdb868f3e7/images/8a45ee432aeebe1184348c1236df77825f6d2cf153076035a9134836789e7444.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8552128076553345}",,,,,,,,,,['neutral'],neutral,1
NCT00383188,"{'position': 1, 'link': 'https://www.nature.com/articles/s41417-023-00622-1', 'title': 'P38 kinase in gastrointestinal cancers', 'source': 'Nature', 'date': 'May 29, 2023', 'snippet': 'Dysregulation of p38 pathways, in particular p38γ, are associated with \ncancer development, metastasis, autophagy and tumor microenvironment.', 'thumbnail': 'https://serpapi.com/searches/6721ce5093bb57f4ee1a318f/images/53abb36e20a5af450f00d0bdb0a7ad40429f742971dc26f79ef1da2390323612.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7579556703567505}",,,,,,,,,,['negative'],negative,0
NCT00027300,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa044397', 'title': 'A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Mar 2, 2006', 'snippet': 'Natalizumab reduced the risk of the sustained progression of disability and \nthe rate of clinical relapse in patients with relapsing multiple sclerosis.', 'thumbnail': 'https://serpapi.com/searches/6721ce9cb9ab865d2f7662e4/images/5fc63b51d4c59a43f115a0fa4a3c93b4e372fad80faec521e004bb4b5af6c7ab.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7991609573364258}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/09/29/study-supports-ms-disability-test-score-outcome-measure-trials/', 'title': 'Study Supports MS Disability Test Score as Outcome Measure in Trials', 'source': 'Multiple Sclerosis News Today', 'date': 'Sep 29, 2022', 'snippet': 'The Overall Disability Response Score, which combines three disability \nscores, may help assess the effectiveness of MS treatments in trials.', 'thumbnail': 'https://serpapi.com/searches/6721ce9cb9ab865d2f7662e4/images/5fc63b51d4c59a437c499e5f93abdb6d307f389f729125628476feab042e05cb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7075560688972473}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04928287,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/pipeline-moves-parkinsons-disease/', 'title': 'Pipeline Moves: advancement prospects jump for Parkinson’s disease stem cell therapy', 'source': 'Clinical Trials Arena', 'date': 'Mar 21, 2023', 'snippet': 'The Clinical Trials Arena team also review assets in asthma, multiple \noncology indications and blood disorder.', 'thumbnail': 'https://serpapi.com/searches/6721cee724296a3c10e59b28/images/a47ffacf3ff47a8f59bd80225df959f8c2adc3c81b91c72fdc024118624a1e70.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7419585585594177}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1139359/full', 'title': 'Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?', 'source': 'Frontiers', 'date': 'Jun 27, 2024', 'snippet': 'Neurological disorders are recognized as major causes of death and \ndisability worldwide. Because of this, they represent one of the largest \npublic health...', 'thumbnail': 'https://serpapi.com/searches/6721cee724296a3c10e59b28/images/a47ffacf3ff47a8f9128ab051d9e46fadc6eaf066c54c9022f1db4084cf7b17b.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5713104009628296}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT03934814,"{'position': 1, 'link': 'https://www.biospectrumasia.com/company-results/48/17177/i-mab-reports-efficacy-of-anti-cd47-monoclonal-ab-on-relapsed-refractory-malignancy.html', 'title': 'I-Mab reports efficacy of Anti-CD47 monoclonal Ab on relapsed/refractory malignancy', 'source': 'BioSpectrum Asia', 'date': 'Nov 25, 2020', 'snippet': 'Initial monotherapy results at Ph 1 clinical trial data demonstrate \ndifferentiated safety and PK profile and efficacy signal of...', 'thumbnail': 'https://serpapi.com/searches/6721d072c117a913ac69f19f/images/69f808d057ce104d3ae8c25ea69662cfbe241c7a33669afac84c34cae5188522.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7492659091949463}",,,,,,,,,,['neutral'],neutral,1
NCT02239120,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1813959', 'title': 'Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source', 'source': 'The New England Journal of Medicine', 'date': 'May 15, 2019', 'snippet': 'Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most \ncryptogenic strokes are considered to be embolic and of undetermined...', 'thumbnail': 'https://serpapi.com/searches/6721d0743c9575674df0d392/images/8406f8558b1276feb5cdede622606039b66728807e0c277cb834ebae2605d845.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7169344425201416}",,,,,,,,,,['neutral'],neutral,1
NCT04449029,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/gsks-hepatitis-b-candidate-bepirovirsen-wins-fda-fast-track-designation/', 'title': ""GSK's hepatitis B candidate bepirovirsen wins FDA fast track designation"", 'source': 'Liver Disease News', 'date': 'Feb 22, 2024', 'snippet': ""The US Food and Drug Administration (FDA) has granted fast track status to \nbepirovirsen, GlaxoSmithKline (GSK)'s candidate treatment for chronic \nhepatitis B (..."", 'thumbnail': 'https://serpapi.com/searches/6721d09b7d533ebd2cab35ab/images/111283b63ea856b34c9b5ebe20f65341bc839c63d4379cf05ae40109cd696119.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5451934933662415}",,,,,,,,,,['neutral'],neutral,1
NCT01895361,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1611770', 'title': 'Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease', 'source': 'The New England Journal of Medicine', 'date': 'Dec 3, 2016', 'snippet': 'The up-regulation of P-selectin in endothelial cells and platelets \ncontributes to the cell–cell interactions that are involved in the...', 'thumbnail': 'https://serpapi.com/searches/6721d09c6273fbfd1bbfe82a/images/6316a775f0436442b487d33a5e2c17123176abb0820ddc63e61595f61563acc0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8581187725067139}","{'position': 2, 'link': 'https://sicklecellanemianews.com/news/adakveo-fails-reduce-scd-crises-latest-phase-3-trial-novartis/', 'title': 'Adakveo Fails to Reduce SCD Crises in Latest Phase 3 Trial | Data...', 'source': 'Sickle Cell Disease News', 'date': 'Jan 31, 2023', 'snippet': 'Treatment with Adakveo (crizanlizumab) did not reduce the yearly occurrence \nof painful vaso-occlusive crises (VOCs) leading to a medical visit.', 'thumbnail': 'https://serpapi.com/searches/6721d09c6273fbfd1bbfe82a/images/6316a775f043644214f74a7b297a4f76c176430469044b0b2297fd2dd8f813c6.png', 'sentiment': 'negative', 'sentiment_prob': 0.8098764419555664}","{'position': 3, 'link': 'https://sicklecellanemianews.com/news/fda-approves-adakveo-novartis-scd-pain-crises-treatment-adults-teens/', 'title': 'FDA Approves Novartis’ Adakveo, 1st Treatment for Pain Crises in Teens and Adults with SCD', 'source': 'Sickle Cell Disease News', 'date': 'Nov 18, 2019', 'snippet': 'Adakveo (crizanlizumab), which works to lower the frequency of painful \nvaso-occlusive crises (VOCs) common in sickle cell disease,...', 'thumbnail': 'https://serpapi.com/searches/6721d09c6273fbfd1bbfe82a/images/6316a775f0436442c75797a8f40dd70ca5df84901ac3ee0acfaad02096cc468b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6581161618232727}",,,,,,,,"['neutral', 'negative', 'neutral']",neutral,1
NCT01963052,"{'position': 1, 'link': 'https://dailynews.ascopubs.org/do/antibody-drug-conjugates-treatment-urothelial-carcinoma', 'title': 'Antibody-Drug Conjugates for Treatment of Urothelial Carcinoma', 'source': 'ASCO Daily News', 'date': 'Dec 3, 2020', 'snippet': 'Antibody-drug conjugates (ADCs) provide a sophisticated pharmacologic \nsystem to deliver cytotoxic drugs to cancer cells.', 'thumbnail': 'https://serpapi.com/searches/6721d0b65bb6a2879cc70c5e/images/5e71cf499ea669ef8f034e7b4b644aaa36b9e0d4fae7090807dda1cc57e5645b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7927020192146301}",,,,,,,,,,['neutral'],neutral,1
NCT03505710,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00064-0/abstract', 'title': 'Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial', 'source': 'The Lancet', 'date': 'Mar 26, 2024', 'snippet': 'DESTINY-Lung01 is a multicentre, open-label, phase 2 study evaluating the \nantitumour activity and safety of trastuzumab deruxtecan, a HER2-directed...', 'thumbnail': 'https://serpapi.com/searches/6721d0f6b9ab865d2f76649f/images/249fc23aa2fab5c315e82f9f1274000f1c75fc38c8711e8a181940827ac0e6e3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.882606565952301}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/fda-grants-accelerated-approval-to-t-dxd-in-advanced-her2-solid-tumors', 'title': 'FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors', 'source': 'Cancer Network', 'date': 'Apr 5, 2024', 'snippet': 'Results from 3 DESTINY trials led to the accelerated approval of \nfam-trastuzumab deruxtecan-nxki for patients with unresectable or...', 'thumbnail': 'https://serpapi.com/searches/6721d0f6b9ab865d2f76649f/images/249fc23aa2fab5c3043a5f4256415b4d53d31ea0ce35d075bff3ca0ef58cd0e5.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5295902490615845}","{'position': 3, 'link': 'https://www.oncnursingnews.com/view/adcs-may-change-the-landscape-of-her2-mutant-nsclc', 'title': 'ADCs May Change the Landscape of HER2-Mutant NSCLC', 'source': 'Oncology Nursing News', 'date': '3 days ago', 'snippet': 'Fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) is being studied in the \nfrontline setting after data showed that the antibody-drug...', 'thumbnail': 'https://serpapi.com/searches/6721d0f6b9ab865d2f76649f/images/249fc23aa2fab5c369d6f9355dff0a0d5406bb653a606394f05591c7c33dbceb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9045876860618591}","{'position': 4, 'link': 'https://www.oncnursingnews.com/view/fda-grants-accelerated-approval-to-fam-trastuzumab-deruxtecan-nxki-in-her2-solid-tumors', 'title': 'FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors', 'source': 'Oncology Nursing News', 'date': 'Apr 5, 2024', 'snippet': 'The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki \n(Enhertu) for patients with unresectable or metastatic HER2-positive...', 'thumbnail': 'https://serpapi.com/searches/6721d0f6b9ab865d2f76649f/images/249fc23aa2fab5c3a9966976c7bd51f977e9dfb95f35388cdb9b9a9c0576b440.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8106153011322021}",,,,,,,"['neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT04719832,"{'position': 1, 'link': 'http://www.msn.com/en-us/health/other/gsk-boasts-win-for-depemokimab-in-asthma-trials/ar-BB1mNpQB?ocid=BingNewsSearch&apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1', 'title': 'GSK boasts win for depemokimab in asthma trials', 'source': 'MSN', 'date': '2 days ago', 'snippet': 'GSK has announced positive data from two Phase III trials of its asthma \ncandidate depemokimab. The pharma giant announced the drug met primary \nendpoints in...', 'thumbnail': 'https://serpapi.com/searches/6721d0fc5bb6a2879cc70cb8/images/d67dc3c970cf8dd58224712ecfb613f3aa40a518cc2962232606a88f34f4f61e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8695101737976074}",,,,,,,,,,['positive'],positive,1
NCT04963270,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/gmg-trial-endpoint-met-not-expected-benefit/', 'title': 'Roche subsidiary upset with Phase III gMG trial despite meeting endpoint', 'source': 'Clinical Trials Arena', 'date': 'Mar 22, 2024', 'snippet': 'Enspryng did show statistical significance in gMG but Chugai \nPharmaceuticals said it did not reach the expected level of clinical \nbenefit.', 'thumbnail': 'https://serpapi.com/searches/6721d10159f9117f369c79c8/images/58620e03f7bf532e4f182345715289cd744a331376f42d14370ad3fe60195f9d.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6063151955604553}","{'position': 2, 'link': 'https://myastheniagravisnews.com/news/enspryng-eases-gmg-symptoms-phase-3-trial-below-expectations/', 'title': 'Enspryng eases gMG symptoms in Phase 3 trial, but falls short of hopes', 'source': 'Myasthenia Gravis News', 'date': 'Mar 26, 2024', 'snippet': 'Enspryng (satralizumab), which Chugai Pharmaceutical is testing for \ngeneralized myasthenia gravis (gMG), showed a significant benefit in easing \ndisease...', 'thumbnail': 'https://serpapi.com/searches/6721d10159f9117f369c79c8/images/58620e03f7bf532ebd84173d02bc51b8a50890619f6d10bd34448b9e62cead28.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7288574576377869}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT01631552,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1814213', 'title': 'Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Feb 20, 2019', 'snippet': 'Standard chemotherapy is associated with low response rates and short \nprogression-free survival among patients with pretreated metastatic...', 'thumbnail': 'https://serpapi.com/searches/6721d1049f8bfc043801958e/images/067a7fbb70cd857b3cd3e4908cc33d900a3b9bc3106fba36f5dd6f6269a61a30.png', 'sentiment': 'negative', 'sentiment_prob': 0.6776492595672607}",,,,,,,,,,['negative'],negative,0
NCT02542254,"{'position': 1, 'link': 'https://copdnewstoday.com/news/verona-pharma-rpl554-copd-named-ensifentrine/', 'title': 'Verona Pharma’s Candidate RPL554 for COPD Will Be Named Ensifentrine', 'source': 'COPD News Today', 'date': 'Jan 15, 2019', 'snippet': ""The World Health Organization approved the name ensifentrine for Verona \nPharma's investigational bronchodilator and anti-inflammatory agent,..."", 'thumbnail': 'https://serpapi.com/searches/6721d10fadc33bdfb7d7aa38/images/713e6a7862a1f30d839315250e6cce6f13af33f7d0bfceec21cdac5e259968ed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8575579524040222}",,,,,,,,,,['neutral'],neutral,1
NCT01272219,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1411892', 'title': 'A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management', 'source': 'The New England Journal of Medicine', 'date': 'Jul 2, 2015', 'snippet': 'Obesity is a chronic disease with serious health consequences, but weight \nloss is difficult to maintain through lifestyle intervention alone...', 'thumbnail': 'https://serpapi.com/searches/6721d13d93bb57f524e12d78/images/be3615bdd3e1c12c131301f0fdd2e3eeff000c2e89c17a1840e41f12c85a5d12.png', 'sentiment': 'negative', 'sentiment_prob': 0.4933868646621704}",,,,,,,,,,['negative'],negative,0
NCT01894815,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1612999', 'title': 'Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression', 'source': 'The New England Journal of Medicine', 'date': 'Jun 29, 2017', 'snippet': 'We compared transcranial direct-current stimulation (tDCS) with a selective \nserotonin-reuptake inhibitor for the treatment of depression.', 'thumbnail': 'https://serpapi.com/searches/6721d14175f974f2da18c07d/images/4cc93ae1f14fa2345555ec0a2ce18e3b03a0aec5c39c7bf89222242dc3dfba34.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8650593757629395}",,,,,,,,,,['neutral'],neutral,1
NCT00719797,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1403108', 'title': 'Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Oct 23, 2014', 'snippet': 'A fluoropyrimidine plus irinotecan or oxaliplatin, combined with \nbevacizumab (a monoclonal antibody against vascular endothelial growth...', 'thumbnail': 'https://serpapi.com/searches/6721d1479872174e09996c24/images/0130bb517e09f12d2549d36732c13d8d9a87dff5bdc9a745d7addae2c4322a2e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8642117381095886}","{'position': 2, 'link': 'https://www.nature.com/articles/s41416-020-01089-9', 'title': 'Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO', 'source': 'Nature', 'date': 'Oct 7, 2020', 'snippet': 'We performed a pooled analysis of treatments after progression to upfront \nFOLFOXIRI/bev in patients enrolled in two randomised Phase 3 studies (TRIBE \nand TRIBE...', 'thumbnail': 'https://serpapi.com/searches/6721d1479872174e09996c24/images/0130bb517e09f12d5127bf8e81af8cbaba645be0c133412224af52e4e82a76da.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9135832190513611}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00059280,"{'position': 1, 'link': 'https://pompediseasenews.com/lumizyme-alglucosidase-alfa-for-the-treatment-of-pompe-disease/', 'title': 'Lumizyme (Alglucosidase Alfa) in Pompe Disease', 'source': 'Pompe Disease News', 'date': 'Jul 15, 2022', 'snippet': 'Lumizyme (alglucosidase alfa) is an enzyme replacement therapy for Pompe \ndisease. Learn about its uses, indications, and side effects.', 'thumbnail': 'https://serpapi.com/searches/6721d153213c87eb83465fc1/images/333ad874b29cf8f821d320376881c29c6d720da2e700672776060555b8ed5c81.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8790404200553894}",,,,,,,,,,['neutral'],neutral,1
NCT02775903,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/news/advancements-in-aml-and-mds-treatment-with-immune-checkpoint-inhibitors/', 'title': 'Immune Checkpoint Inhibitor Combination Therapy Promising for AML, MDS', 'source': 'Hematology Advisor', 'date': 'Dec 14, 2020', 'snippet': 'Immune checkpoint inhibitors show promise in acute myeloid leukemia and \nmyelodysplastic syndromes.', 'thumbnail': 'https://serpapi.com/searches/6721d1a2740bdba705d91e84/images/ae22a0e422e1e0ac4968811bd7d46f0c82ca4eb0fe25ff3ab9c5cf5c34968960.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.714292585849762}",,,,,,,,,,['positive'],positive,1
NCT02923258,"{'position': 1, 'link': 'https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-024-03541-6', 'title': 'Postoperative radiotherapy with docetaxel versus cisplatin for high-risk oral squamous cell carcinoma: a randomized phase II trial with exploratory analysis of ITGB1 as a potential predictive biomarker', 'source': 'BMC Medicine', 'date': 'Jul 29, 2024', 'snippet': 'This randomized trial directly compared Doc-RT with Cis-RT for high-risk \npostoperative OSCC patients, with comparable efficacy and less toxicity.', 'thumbnail': 'https://serpapi.com/searches/6721d1dc2bab902cc6cb3190/images/e90aa975680e1481807ce22cb23d14cb890a1f667eb82d7e364a4749dbe2038b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.898639440536499}",,,,,,,,,,['neutral'],neutral,1
NCT00604214,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa1202290', 'title': 'Drotrecogin Alfa (Activated) in Adults with Septic Shock', 'source': 'The New England Journal of Medicine', 'date': 'Jun 25, 2018', 'snippet': 'In this randomized, double-blind, placebo-controlled, multicenter trial, we \nassigned 1697 patients with infection, systemic inflammation, and shock who \nwere...', 'thumbnail': 'https://serpapi.com/searches/6721d1e28a7c0938d8968202/images/40a8daaf10813e05bd49847d28a6c5453f723600c9d815179365c7c322d771f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8762322068214417}",,,,,,,,,,['neutral'],neutral,1
NCT02017171,"{'position': 1, 'link': 'https://diatribe.org/diabetes-research/perl-study-trial-use-allopurinol-preserve-kidney-function-type-1-diabetes', 'title': 'PERL Study: A Trial on the Use of Allopurinol to Preserve Kidney Function in Type 1 Diabetes', 'source': 'diaTribe', 'date': 'Feb 5, 2015', 'snippet': 'By Leda Espinoza and Alexander Wolf. Twitter summary: Can a drug for gout \nalso help with #t1d kidney function? A new trial on allopurinol...', 'thumbnail': 'https://serpapi.com/searches/6721d223d997ab920de21332/images/4b27bcc3263fbe8016a4a8b9d130665af90672bc30afd207149c549502f5b4fa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8683416843414307}",,,,,,,,,,['neutral'],neutral,1
NCT01931670,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1700089', 'title': 'Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist', 'source': 'The New England Journal of Medicine', 'date': 'May 19, 2017', 'snippet': 'We performed two similar, double-blind, randomized, 6-month phase 3 trials \n(Elaris Endometriosis I and II [EM-I and EM-II]) to evaluate the...', 'thumbnail': 'https://serpapi.com/searches/6721d26f1adaf494051caf95/images/8d0315cfc91855e010ec12dc6a96b49e8462ee70180b29c35e05ce1261c5c3f7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9145580530166626}","{'position': 2, 'link': 'https://endometriosisnews.com/2017/11/06/elagolix-seen-to-lessen-endometriosis-pain-and-spread-in-yearlong-phase-3-studies/', 'title': 'Elagolix Seen to Ease Endometriosis Pain and Spread in Yearlong Phase 3 Studies', 'source': 'endometriosisnews.com', 'date': 'Nov 6, 2017', 'snippet': 'Results of two Phase 3 extension studies showed that one year of treatment \nwith elagolix could reduce pelvic pain, prevent proliferation of...', 'thumbnail': 'https://serpapi.com/searches/6721d26f1adaf494051caf95/images/8d0315cfc91855e017de98128658ee01ecb2041ea1dac5d3f3ac65ed8313906d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7788125872612}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04136756,"{'position': 1, 'link': 'https://www.onclive.com/view/all-eyes-are-on-il-15-in-early-phase-studies', 'title': 'All Eyes Are on IL-15 in Early Phase Studies', 'source': 'OncLive', 'date': 'Mar 29, 2024', 'snippet': 'IL-15, a cytokine of the IL-2 family, is key in the development, \nproliferation, and activation of immune cells such as natural killer (NK) \ncells.', 'thumbnail': 'https://serpapi.com/searches/6721d2807e1d1f5f2dba0d69/images/bd285dcf1cfe2d4af85a7ef15ee573cecda38ef676578a81fe7d91875b4688d3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8828815221786499}",,,,,,,,,,['neutral'],neutral,1
NCT05000372,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-53197-2', 'title': '68Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1/2 clinical trial', 'source': 'Nature', 'date': '3 weeks ago', 'snippet': 'To tackle the clinical challenge of noninvasively assessing immunotherapy \nefficacy in patients, here we used positron emission tomography...', 'thumbnail': 'https://serpapi.com/searches/6721d29d29e6fb3ba7364d13/images/285c1d52c0e1234bb2ce6dca1b73303c8ae7ef224105f2838320abfecacbb68c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8800756335258484}",,,,,,,,,,['neutral'],neutral,1
NCT03345342,"{'position': 1, 'link': 'https://www.empr.com/home/news/invega-hafyera-approved-for-twice-yearly-treatment-of-schizophrenia/', 'title': 'Invega Hafyera Approved for Twice-Yearly Treatment of Schizophrenia', 'source': 'Medical Professionals Reference', 'date': 'Sep 1, 2021', 'snippet': 'The Food and Drug Administration has approved Invega Hafyera™ (paliperidone \npalmitate), an every 6-month injection, for the treatment of...', 'thumbnail': 'https://serpapi.com/searches/6721d2a44300ce5d04a6add3/images/8ac3f9f4ad059bb34a21c60356e9fbd2cc939cca2b76aaa43f8e62c42386dc4c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7487479448318481}",,,,,,,,,,['neutral'],neutral,1
NCT05284617,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/rivus-pharmaceuticals-phase-2a-humain-trial-meets-primary-endpoint-of-weight-loss-and-secondary-endpoints-in-patients-with-obesity-related-heart-failure-302220505.html', 'title': ""Rivus Pharmaceuticals' Phase 2a HuMAIN Trial Meets Primary Endpoint of Weight Loss and Secondary Endpoints in Patients with Obesity-Related Heart Failure"", 'source': 'PR Newswire', 'date': 'Aug 13, 2024', 'snippet': 'HU6, a novel oral, once-daily Controlled Metabolic Accelerator, is a new \nclass of investigational therapies designed to reduce body fat while \npreserving muscle.', 'thumbnail': 'https://serpapi.com/searches/6721d2e890adce9af7485ac4/images/f455ee268f680c6adb7a6ab23c8152efd05972c4f34f42ff36c758d4796235b0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9003722667694092}",,,,,,,,,,['neutral'],neutral,1
NCT02414139,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2002787', 'title': 'Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Sep 2, 2020', 'snippet': 'Capmatinib showed substantial antitumor activity in patients with advanced \nNSCLC with a MET exon 14 skipping mutation, particularly in those not \ntreated...', 'thumbnail': 'https://serpapi.com/searches/6721d2e8e6862be438ae1da4/images/a56847ba0e2f85321101b612c1fdd99bb7a3460ee37ba6b1de9494b73c233080.png', 'sentiment': 'neutral', 'sentiment_prob': 0.759855329990387}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.13790', 'title': 'Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14', 'source': 'Wiley Online Library', 'date': 'Dec 21, 2020', 'snippet': 'Thoracic Cancer is an international oncology journal publishing basic, \ntranslational and applied clinical research in lung, esophageal,...', 'thumbnail': 'https://serpapi.com/searches/6721d2e8e6862be438ae1da4/images/a56847ba0e2f853259880bfa5e7060f41e8d3a723f12cae05952df816a44edca.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5938460230827332}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT03345485,"{'position': 1, 'link': 'https://lymphomanewstoday.com/2019/03/15/phase-1-2-trial-of-tinostamustine-to-treat-blood-cancers-opens-2nd-stage/', 'title': 'Phase 1/2 Trial of Tinostamustine to Treat Blood Cancers Opens 2nd Stage', 'source': 'Lymphoma News Today', 'date': 'Mar 15, 2019', 'snippet': 'An ongoing Phase 1/2 clinical trial of tinostamustine, a multi-action \ntherapy, is enrolling patients with relapsed or refractory blood...', 'thumbnail': 'https://serpapi.com/searches/6721d2ffcf32e0c265e3b757/images/cf2868191fd85dc80405e866650becc1d4a8f6b7ff514b90ebed9ae041c902ba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9252985715866089}",,,,,,,,,,['neutral'],neutral,1
NCT00322153,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/latest-clinical-data-on-namenda-for-alzheimers-disease-confirms-beneficial-effects/', 'title': ""Latest Data on Alzheimer's Drug Namenda Confirms Beneficial Effects"", 'source': ""Alzheimer's News Today"", 'date': 'Apr 24, 2017', 'snippet': ""Results from four recent studies confirmed the beneficial clinical effects \nof Namenda (memantine), an FDA-approved Alzheimer's therapy."", 'thumbnail': 'https://serpapi.com/searches/6721d314a775f2424b77df81/images/3e2675ed0528f321c95ea0dc566530b5f543329c435446abfab685121148d3cf.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8036553859710693}","{'position': 2, 'link': 'https://alzheimersnewstoday.com/news/aanam-memantine-as-add-on-therapy-seen-to-ease-psychosis-other-advanced-alzheimers-symptoms/', 'title': ""#AANAM – Advanced Alzheimer's Symptoms Like Psychosis Eased with..."", 'source': ""Alzheimer's News Today"", 'date': 'May 6, 2019', 'snippet': 'Adding memantine to a cholinesterase inhibitor can significantly ease \ncertain neuropsychiatric symptoms, including psychosis and troubling motor \nor nighttime...', 'thumbnail': 'https://serpapi.com/searches/6721d314a775f2424b77df81/images/3e2675ed0528f321005d3ccb7a5cdc8c8bde617e4522f74a86fef0f71ffda29d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8582038283348083}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT04577352,"{'position': 1, 'link': 'https://friedreichsataxianews.com/friedreichs-ataxia-experimental-treatments/epi-743-vatiquinone/', 'title': ""EPI-743 (Vatiquinone) for Friedreich's Ataxia"", 'source': ""Friedreich's Ataxia News"", 'date': 'Sep 7, 2023', 'snippet': ""EPI-743 (Vatiquinone) is being developed by BioElectron for Friedreich's \nataxia and received FDA orphan drug and fast track designations."", 'thumbnail': 'https://serpapi.com/searches/6721d32021e77b944e41c8bb/images/d9828324d256eb9c963faf5339a280d8dab4ebec12210efc764ee23f2834f604.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8560620546340942}","{'position': 2, 'link': 'https://friedreichsataxianews.com/news/ptc-seek-fda-approval-vatiquinone-friedreichs-ataxia-2024/', 'title': 'PTC to ask for FDA approval of vatiquinone for FA by year’s end', 'source': ""Friedreich's Ataxia News"", 'date': '17 hours ago', 'snippet': ""PTC Therapeutics plans to seek FDA approval for its oral therapy \nvatiquinone for Friedreich's ataxia with a new drug application in..."", 'thumbnail': 'https://serpapi.com/searches/6721d32021e77b944e41c8bb/images/d9828324d256eb9c1c2d501c55a70267f6d85a61416dea9253762f91fbe0963d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8823922872543335}","{'position': 3, 'link': 'https://friedreichsataxianews.com/news/mda-2024-vatiquinone-may-help-extend-fa-patients-ability-walk/', 'title': 'MDA 2024: Vatiquinone may help extend FA patients’ ability to walk', 'source': ""Friedreich's Ataxia News"", 'date': 'Mar 12, 2024', 'snippet': ""Vatiquinone preserved upright stability in an FA trial, which researchers \nsay may predict a delay in the loss of patients' ability to walk."", 'thumbnail': 'https://serpapi.com/searches/6721d32021e77b944e41c8bb/images/d9828324d256eb9cd295f74cb34a3d8ca75d2685c0c71cb025e25f3bf752b9c5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7893941402435303}","{'position': 4, 'link': 'https://friedreichsataxianews.com/news/vatiquinone-slows-fa-progression-after-18-months-trial-data/', 'title': 'Vatiquinone found to slow FA progression by 75% after 1.5 years', 'source': ""Friedreich's Ataxia News"", 'date': 'May 30, 2023', 'snippet': ""The oral therapy vatiquinone was found to slow disease progression in \nFriedreich's ataxia patients by 75% after nearly 18 months in trial."", 'thumbnail': 'https://serpapi.com/searches/6721d32021e77b944e41c8bb/images/d9828324d256eb9cc4eb7f4ebb4f2e8272aa0c3fe6fbcfb8893630bf3c3d96c9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8163461089134216}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03778099,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222008022', 'title': 'Application of nanotechnology to herbal antioxidants as improved phytomedicine: An expanding horizon', 'source': 'ScienceDirect.com', 'date': 'Aug 7, 2022', 'snippet': 'Phytotherapy, based on medicinal plants, have excellent potential in \nmanaging several diseases. A vital part of the healthcare system is herbal \nmedicines,...', 'thumbnail': 'https://serpapi.com/searches/6721d33474978395dc84d75a/images/b19e23be87bf41303193cdde0c8511f3c2a70d6f693a5f5142ddca92e783f43b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.9347379803657532}",,,,,,,,,,['positive'],positive,1
NCT04075318,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-024-03101-8', 'title': 'Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial', 'source': 'Nature', 'date': 'Jun 20, 2024', 'snippet': 'This 44-week, randomized, placebo-controlled, double-blind, single-center \nphase 1 study investigated safety, tolerability and immunogenicity of \nUB-312.', 'thumbnail': 'https://serpapi.com/searches/6721d34b24296a3c4a74a2be/images/242091094c9d79c84a6ffa88a8a613f1e2d9c32d6f9cf441f5c041ea0f9a0496.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8822336196899414}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/parkinsons-vaccine-targets-toxic-protein-phase-1-trial/', 'title': 'Parkinson’s vaccine seen to target toxic alpha-synuclein in Phase 1 trial', 'source': ""Parkinson's News Today"", 'date': 'Mar 11, 2024', 'snippet': 'Treatment with UB-312, a vaccine designed to trigger an immune response \nagainst toxic clumps of the alpha-synuclein protein, reduced these \ndamaging...', 'thumbnail': 'https://serpapi.com/searches/6721d34b24296a3c4a74a2be/images/242091094c9d79c88c565de98404c144dc7e1438483cc301eba3a34667a50538.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7458545565605164}","{'position': 3, 'link': 'https://www.neurologylive.com/view/sls-005-performs-better-without-amx0035-nerivio-gains-commercial-coverage-ub-312-reduces--synuclein', 'title': 'SLS-005 Performs Better Without AMX0035, Nerivio Gains Commercial Coverage, UB-312 Reduces α-Synuclein', 'source': 'Neurology live', 'date': 'Mar 23, 2024', 'snippet': 'Neurology News Network for the week ending March 23, 2024. [WATCH TIME: 3 \nminutes]', 'thumbnail': 'https://serpapi.com/searches/6721d34b24296a3c4a74a2be/images/242091094c9d79c830ef2b516b6b44d5423fe2bdc6aca1934f466809f9e93464.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6642199158668518}","{'position': 4, 'link': 'https://parkinsonsnewstoday.com/news/study-therapeutic-parkinsons-vaccine-safely-inhibits-alpha-synuclein-clumps/', 'title': ""Study: Therapeutic Parkinson's vaccine safely inhibits alpha-synuclein clumps"", 'source': ""Parkinson's News Today"", 'date': 'Jun 27, 2024', 'snippet': 'UB-312, a therapeutic vaccine candidate from Vaxxinity, safely led to \nantibodies being produced that could target toxic clumps of the \nalpha-synuclein protein.', 'thumbnail': 'https://serpapi.com/searches/6721d34b24296a3c4a74a2be/images/242091094c9d79c820804c924184127086b283495b74cbcb475db5157bc4c1ac.png', 'sentiment': 'neutral', 'sentiment_prob': 0.4961884617805481}","{'position': 5, 'link': 'https://parkinsonsnewstoday.com/news/vaccine-trial-early-parkinsons-meets-primary-objectives/', 'title': 'Vaccine trial for early Parkinson’s meets primary objectives |...', 'source': ""Parkinson's News Today"", 'date': 'Jun 26, 2023', 'snippet': ""UB-312 appeared safe and well tolerated, and able to produce an immune \nresponse against toxic alpha-synuclein protein in early Parkinson's."", 'thumbnail': 'https://serpapi.com/searches/6721d34b24296a3c4a74a2be/images/242091094c9d79c86e33b82edfd7a5914572e4bd1abd373f83a5a6dc2e2ea8a1.png', 'sentiment': 'positive', 'sentiment_prob': 0.6929271221160889}","{'position': 6, 'link': 'https://parkinsonsnewstoday.com/news/parkinsons-vaccine-slows-alpha-synuclein-clumping-patients/', 'title': 'Parkinson’s vaccine, UB-312, slows alpha-synuclein clumping in patients', 'source': ""Parkinson's News Today"", 'date': 'Nov 13, 2023', 'snippet': ""Vaxxinity says its vaccine, UB-312, given Parkinson's patients in Phase 1 \ntrial induced alpha-synuclein antibodies to slow protein toxicity."", 'thumbnail': 'https://serpapi.com/searches/6721d34b24296a3c4a74a2be/images/242091094c9d79c8479b08c25dfa79a98fb0c9b645bc7c3691182cfe6d903a49.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8627022504806519}","{'position': 7, 'link': 'https://parkinsonsnewstoday.com/news/parkinsons-vaccine-ub-312-targets-alpha-synuclein-trial/', 'title': 'Parkinson’s vaccine targets toxic alpha-synuclein in Phase 1 trial', 'source': ""Parkinson's News Today"", 'date': 'Jul 19, 2023', 'snippet': 'The immune response triggered by UB-312, an experimental vaccine by \nVaxxinity, effectively targeted alpha-synuclein protein aggregates and \nslowed their toxic...', 'thumbnail': 'https://serpapi.com/searches/6721d34b24296a3c4a74a2be/images/242091094c9d79c89e216c0389a130bc66684dfa408c06acc3e51bca8b57cf7f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6917909979820251}",,,,"['neutral', 'neutral', 'neutral', 'neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT04647890,"{'position': 1, 'link': 'https://sclerodermanews.com/news/certas-ssc-treatmnent-candidate-ft011-generic-name-asengeprast/', 'title': ""Certa's SSc treatment candidate FT011 given generic name asengeprast"", 'source': 'Scleroderma News', 'date': '1 month ago', 'snippet': 'Asengeprast is a first-in-class therapy to block the activity of GPR68, \nwhich is activated with an injury, causing inflammation and...', 'thumbnail': 'https://serpapi.com/searches/6721d3d27ef9fa1a056cc15b/images/049a54451207b0110460ee0feff5fd6dde97c26bffa2e3a38bf339ceebae17af.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8188124895095825}","{'position': 2, 'link': 'https://sclerodermanews.com/news/ft011-showed-promising-effects-disability-lung-function-trial/', 'title': 'FT011 showed promising effects on disability, lung function in trial', 'source': 'Scleroderma News', 'date': 'Nov 21, 2023', 'snippet': 'FT011 led to clinically meaningful improvements in physical disability and \nlung function for some scleroderma patients in a clinical trial.', 'thumbnail': 'https://serpapi.com/searches/6721d3d27ef9fa1a056cc15b/images/049a54451207b011e5f37303c03e71c3c530168b0d2075e8e787a616e2faa972.png', 'sentiment': 'positive', 'sentiment_prob': 0.9240362644195557}","{'position': 3, 'link': 'https://sclerodermanews.com/news/orphan-drug-status-europe-granted-ft011-certa-therapy-ssc/', 'title': 'Certa’s FT011 granted orphan drug status in Europe for SSc', 'source': 'Scleroderma News', 'date': 'Jul 23, 2024', 'snippet': ""The European Medicines Agency granted orphan drug status to FT011, Certa \nTherapeutics' oral treatment candidate for systemic sclerosis..."", 'thumbnail': 'https://serpapi.com/searches/6721d3d27ef9fa1a056cc15b/images/049a54451207b0113712ed16d86d45168506fbf9bdce45e6c82caae8fac6ee03.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9333030581474304}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT01087762,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Cimzia', 'title': 'Certolizumab Pegol (Cimzia®)', 'source': 'UCB', 'date': 'Oct 12, 2018', 'snippet': 'Axial Spondyloarthritis, Certolizumab Pegol in Subjects With Active Axial \nSpondyloarthritis, Phase 3, AKS001 Completed, NCT01087762 · 2009-011719-19 \n· LINK', 'thumbnail': 'https://serpapi.com/searches/6721d425b9458d9fbfbdaa02/images/491b1d3ebc90815720d72792e7d9e624b96f8a39c7cce7bc493dc1e4778822b4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9130622744560242}",,,,,,,,,,['neutral'],neutral,1
NCT02605837,"{'position': 1, 'link': 'https://www.empr.com/home/news/eohilia-an-oral-therapy-for-eosinophilic-esophagitis-gets-fda-approval/', 'title': 'Eohilia, an Oral Therapy for Eosinophilic Esophagitis, Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Feb 12, 2024', 'snippet': 'The approval of Eohilia was based on data from 2 double-blind, \nparallel-group, placebo-controlled 12-week phase 3 trials.', 'thumbnail': 'https://serpapi.com/searches/6721d4924300ce5d3a13efd2/images/124d89f0beba499cba31b31eea0d80a354c9b714c51458fa01753bc423e39199.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6682627201080322}",,,,,,,,,,['neutral'],neutral,1
NCT04019704,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/analyst-comment/zuranolone-mdd-treatment/', 'title': ""Sage Therapeutics/Biogen's Episodic Therapy Zuranolone Could Change MDD Treatment"", 'source': 'Clinical Trials Arena', 'date': 'Jun 24, 2021', 'snippet': 'The pivotal Phase III trial for the new Sage Therapeutics and Biogen \nantidepressant zuranolone has yielded positive results.', 'thumbnail': 'https://serpapi.com/searches/6721d4925416d8e6ac1d14cb/images/29fbae0c14a7e546b5ff14642c59efa0d1a816022a7d344a5198a1cbd5ea45bd.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6174665093421936}",,,,,,,,,,['positive'],positive,1
NCT01032629,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1611925', 'title': 'Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Jun 12, 2017', 'snippet': 'Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces \nglycemia as well as blood pressure, body weight, and albuminuria in...', 'thumbnail': 'https://serpapi.com/searches/6721d4969872174e09996e97/images/da52cf7b6c35b12bb8ba43a83378a997b07d5c77ac3a3657a8ec7e171e8639e9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.848545253276825}",,,,,,,,,,['neutral'],neutral,1
NCT03491215,"{'position': 1, 'link': 'https://www.nature.com/articles/s41409-024-02252-z', 'title': 'Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis | Bone Marrow Transplantation', 'source': 'Nature', 'date': 'Feb 24, 2024', 'snippet': 'Ruxolitinib, a selective JAK 1–2 inhibitor, showed promising results in the \ntreatment of SR-GvHD in adult trial, including patients >12 years old.', 'thumbnail': 'https://serpapi.com/searches/6721d4b9a25104af56cc4726/images/ce4a483918d3e5d25cc40305a642e77cba313428d4a130898fe054535f930246.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6741430759429932}",,,,,,,,,,['neutral'],neutral,1
NCT03633058,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1425038/full', 'title': 'Drug repurposing in Rett and Rett-like syndromes: a promising yet underrated opportunity?', 'source': 'Frontiers', 'date': 'Jul 29, 2024', 'snippet': 'Rett syndrome (RTT) and Rett-like syndromes [i.e., CDKL5 deficiency \ndisorder (CDD) and FOXG1-syndrome] represent rare yet profoundly...', 'thumbnail': 'https://serpapi.com/searches/6721d4fc2bab902cc6cb33d5/images/06106ee2ac9c4c83d8f61e2f336e04f58ac69b0a1c039ad1bc7752cffc50eabe.png', 'sentiment': 'positive', 'sentiment_prob': 0.6214357018470764}","{'position': 2, 'link': 'https://rettsyndromenews.com/news/fda-oks-ketarx-orphan-drug-rett-syndrome-treatment/', 'title': 'FDA OKs Ketarx as orphan drug for Rett syndrome treatment', 'source': 'Rett Syndrome News', 'date': 'Feb 8, 2023', 'snippet': 'Results of a Phase 2 clinical trial to assess the safety and effectiveness \nof oral ketamine for Rett syndrome have yet to be published.', 'thumbnail': 'https://serpapi.com/searches/6721d4fc2bab902cc6cb33d5/images/06106ee2ac9c4c83816297f9b0c6e50ec5e4860a3d07eb32b33773965deea63c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9134847521781921}","{'position': 3, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/oral-ketamine-gets-orphan-drug-status-for-rett-syndrome/', 'title': 'Oral Ketamine Gets Orphan Drug Status for Rett Syndrome', 'source': 'Medical Professionals Reference', 'date': 'Feb 3, 2023', 'snippet': 'The FDA has granted Orphan Drug designation to Ketarx (racemic ketamine) \nfor the treatment of Rett syndrome.', 'thumbnail': 'https://serpapi.com/searches/6721d4fc2bab902cc6cb33d5/images/06106ee2ac9c4c83720cff4c3e8ccf4f3c80ac7c8fda8a4577f70070f01fc47c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9114663600921631}",,,,,,,,"['positive', 'neutral', 'neutral']",neutral,1
NCT02492737,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.27005', 'title': 'Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study', 'source': 'Wiley Online Library', 'date': 'Jun 24, 2023', 'snippet': 'A global, randomized, double-blind, phase 3 study of vorasidenib (AG-881) \nvs placebo in patients with residual/recurrent grade II glioma with an \nisocitrate...', 'thumbnail': 'https://serpapi.com/searches/6721d51df60b6f501487c330/images/9aa2944e069397b1e7acf2e74da4fbaa396b166623ba83f80a50112915bf7780.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8431504964828491}",,,,,,,,,,['neutral'],neutral,1
NCT04479852,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/arrivo-targets-major-depressive-disorder-in-females-after-early-efficacy-data/', 'title': 'Arrivo targets major depressive disorder in females after early efficacy data', 'source': 'Clinical Trials Arena', 'date': '13 hours ago', 'snippet': ""The SIRT6 activator's sex-specific effects shed light on the different \ngenetic profiles of depression between men and women."", 'thumbnail': 'https://serpapi.com/searches/6721d52c51d84d1f0a6ee8e8/images/9923612ac44358a50762e6450075130a92808e06652add60d52af224c2c8bf6d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6750147938728333}",,,,,,,,,,['neutral'],neutral,1
NCT02410733,"{'position': 1, 'link': 'https://www.nature.com/articles/s41587-022-01294-2', 'title': 'The clinical progress of mRNA vaccines and immunotherapies', 'source': 'Nature', 'date': 'May 9, 2022', 'snippet': 'The emergency use authorizations (EUAs) of two mRNA-based severe acute \nrespiratory syndrome coronavirus (SARS-CoV)-2 vaccines approximately...', 'thumbnail': 'https://serpapi.com/searches/6721d5310197dd056176e783/images/286a51ae887355210b8b315ca379d803a4b354fd49c5b41d6135a0c7f93a9f26.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.921474814414978}",,,,,,,,,,['neutral'],neutral,1
NCT05854784,"{'position': 1, 'link': 'https://porphyrianews.com/news/scenesse-may-be-named-orphan-drug-variegate-porphyria-eu/', 'title': 'Scenesse may gain orphan drug status for variegate porphyria in EU', 'source': 'Porphyria News', 'date': 'Jun 26, 2024', 'snippet': 'A European Medicines Agency (EMA) committee has recommended that Scenesse \n(afamelanotide) be designated an orphan drug for the treatment of light \nsensitivity...', 'thumbnail': 'https://serpapi.com/searches/6721d58a0053c753569be4e1/images/a3c2bc728e48db387973dd3a7c0c79e01b30662823f7855b44617ebb6ffa4ea8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9213231801986694}",,,,,,,,,,['neutral'],neutral,1
NCT03843775,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/PO.22.00107', 'title': 'Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors', 'source': 'ASCO Publications', 'date': 'Aug 17, 2022', 'snippet': 'PURPOSENon-V600 mutations comprise approximately 35% of all BRAF mutations \nin cancer. Many of these mutations have been identified as...', 'thumbnail': 'https://serpapi.com/searches/6721d58f069e57ccad40dd2f/images/a9126738a45e916aa920eb5f7df96209681b80eee825abe3e018f45c87a8adfd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.817907989025116}",,,,,,,,,,['neutral'],neutral,1
NCT03347708,"{'position': 1, 'link': 'https://www.cgtlive.com/view/discgenics-discogenic-progenitor-cell-therapy-rebonuputemcel-cleared-phase-3-program-lumbar-degenerative-disc-disease', 'title': 'DiscGenics’ Discogenic Progenitor Cell Therapy Rebonuputemcel Cleared for Phase 3 Program in Lumbar Degenerative Disc Disease', 'source': 'CGTLive®', 'date': 'Jul 26, 2024', 'snippet': ""The clearance is based on the agency's acceptance of clinical trial \nprotocols and a chemistry, manufacturing, and controls clinical..."", 'thumbnail': 'https://serpapi.com/searches/6721d60fb6a79cce33179726/images/665f39756fa38eb2b3612e5797c6401490ca39f2678d0bc21e7b7d2b01d82bc6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9065929055213928}","{'position': 2, 'link': 'https://www.cgtlive.com/view/achieving-regeneration-in-lumbar-degenerative-disc-disease', 'title': 'Achieving Regeneration in Lumbar Degenerative Disc Disease', 'source': 'CGTLive®', 'date': 'Apr 13, 2023', 'snippet': 'Matthew Gornet, MD, spine surgeon from The Orthopedic Center of St. Louis \ndiscussed data seen with IDCT cell therapy.', 'thumbnail': 'https://serpapi.com/searches/6721d60fb6a79cce33179726/images/665f39756fa38eb25e6fab5dfecd341375795765c498801de9ea4b705b76ec39.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9006569385528564}","{'position': 3, 'link': 'https://www.cgtlive.com/view/matthew-gornet-md-developing-alternatives-surgery-lumbar-degenerative-disc-disease', 'title': 'Matthew Gornet, MD, on Developing Alternatives to Surgery in Lumbar Degenerative Disc Disease', 'source': 'CGTLive®', 'date': 'Feb 16, 2023', 'snippet': 'The spine surgeon from The Orthopedic Center of St. Louis discussed unmet \nneeds in the lumbar DDD population.', 'thumbnail': 'https://serpapi.com/searches/6721d60fb6a79cce33179726/images/665f39756fa38eb2de43146e44bff6fd1b5eb65b13fb1a8e4f54e55b9d244fb9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9180173873901367}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02948283,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/ctm2.1442', 'title': 'Untargeted metabolomics identifies metabolic dysregulation of sphingolipids associated with aggressive chronic lymphocytic leukaemia and poor survival', 'source': 'Wiley Online Library', 'date': 'Nov 30, 2023', 'snippet': 'Metabolic dependencies of chronic lymphocytic leukaemia (CLL) cells may \nrepresent new personalized treatment approaches in patients...', 'thumbnail': 'https://serpapi.com/searches/6721d6b1e45f339dd3e6a91d/images/959e305b2e39678cc85391af7f912937a8397b246496baea796821e91d1fda86.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5355123281478882}",,,,,,,,,,['negative'],negative,0
NCT04619628,"{'position': 1, 'link': 'https://www.idsociety.org/news--publications-new/articles/2023/study-shows-covid-19-intranasal-vaccine-candidate-produces-robust-immune-response/', 'title': 'Study Shows COVID-19 Intranasal Vaccine Candidate Produces Robust Immune Response', 'source': 'IDSA', 'date': 'Oct 11, 2023', 'snippet': 'A live-attenuated COVID-19 vaccine candidate that uses a nonpathogenic form \nof the virus and is administered by nose produces a significant immune \nresponse.', 'thumbnail': 'https://serpapi.com/searches/6721d6c7e1d1ad8e8fd4e7d3/images/16e3c5ba5fa76db74917798aa6381c9447bdef52c45a0442ce6f26be65890a03.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8423652648925781}","{'position': 2, 'link': 'https://www.idse.net/Covid-19/Article/10-23/Novel-COVID-19-Vaccine-Candidate-Induces-Humoral-Cellular-Immunity/71756', 'title': 'Novel COVID-19 Vaccine Candidate Induces Humoral, Cellular Immunity', 'source': 'Infectious Disease Special Edition', 'date': 'Oct 11, 2023', 'snippet': 'A novel intranasal, live-attenuated COVID-19 vaccine candidate appears to \ninduce both humoral and cellular immunity in healthy, previously \nunvaccinated adults.', 'thumbnail': 'https://serpapi.com/searches/6721d6c7e1d1ad8e8fd4e7d3/images/16e3c5ba5fa76db736d81457041910d989a506c4ef52d60d092d39af47300149.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8728095293045044}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03375255,"{'position': 1, 'link': 'https://www.thelancet.com/article/S2352-3964(19)30416-5/fulltext', 'title': 'Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases', 'source': 'The Lancet', 'date': 'Dec 13, 2019', 'snippet': 'PPMOs demonstrate effective exon skipping in target muscles and prolonged \nduration of dystrophin restoration after a treatment regime.', 'thumbnail': 'https://serpapi.com/searches/6721d6e9a5e502961aa22480/images/db34dad8fc58f06d85261bde7ab9378eba3bbd9f9241b423cd4c8692cac4007f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8332691192626953}",,,,,,,,,,['neutral'],neutral,1
NCT03430843,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2024/10/04/2958270/0/en/Onco360-Has-Been-Selected-as-The-National-Specialty-Pharmacy-Partner-for-Tevimbra-tislelizumab-jsgr.html', 'title': 'Onco360® Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra® (tislelizumab-jsgr)', 'source': 'GlobeNewswire', 'date': '3 weeks ago', 'snippet': ""LOUISVILLE, Ky., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation's \nleading independent Specialty Pharmacy, has been selected as a..."", 'thumbnail': 'https://serpapi.com/searches/6721d7195bb6a287d7d6e60a/images/4b4f1a316ddc8096f1f36ef68cf5d31ad8e91eddec6af32ad9edb947803fd9bf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6022656559944153}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/fda-approves-second-line-tislelizumab-monotherapy-in-esophageal-cancer', 'title': 'FDA Approves Second-Line Tislelizumab Monotherapy in Esophageal Cancer', 'source': 'Cancer Network', 'date': 'Mar 14, 2024', 'snippet': 'Results from the phase 3 RATIONALE 302 trial led to the approval of \ntislelizumab for patients with unresectable or metastatic esophageal...', 'thumbnail': 'https://serpapi.com/searches/6721d7195bb6a287d7d6e60a/images/4b4f1a316ddc8096b91313bf3227a9fdc4c4659ffb42d833b3a00c4fe73e8302.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7719350457191467}","{'position': 3, 'link': 'https://www.oncnursingnews.com/view/tislelizumab-approved-by-fda-for-unresectable-or-metastatic-pretreated-escc', 'title': 'Tislelizumab Approved by FDA For Unresectable or Metastatic Pretreated ESCC', 'source': 'Oncology Nursing News', 'date': 'Mar 14, 2024', 'snippet': 'Tislelizumab-jsgr (Tevimbra) has been approved for unresectable or \nmetastatic esophageal squamous cell carcinoma (ESCC) among adult patients...', 'thumbnail': 'https://serpapi.com/searches/6721d7195bb6a287d7d6e60a/images/4b4f1a316ddc80960bbe286b978a760d81bd32742f69efd8fd36875267653858.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8805335760116577}","{'position': 4, 'link': 'https://ascopost.com/news/march-2024/fda-approves-tislelizumab-for-previously-treated-patients-with-advanced-esophageal-cancer/', 'title': 'FDA Approves Tislelizumab for Previously Treated Patients With Advanced Esophageal Cancer', 'source': 'The ASCO Post', 'date': 'Mar 15, 2024', 'snippet': 'The US Food and Drug Administration (FDA) approved the humanized \nimmunoglobulin G4 anti–PD-1 monoclonal antibody tislelizumab-jsgr \n(Tevimbra) as monotherapy...', 'thumbnail': 'https://serpapi.com/searches/6721d7195bb6a287d7d6e60a/images/4b4f1a316ddc809605885601f98ef2350192fda50a29ea21cf511e795d07eefc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7800066471099854}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT00002550,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140673609607376/fulltext', 'title': 'Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial', 'source': 'The Lancet', 'date': 'Jul 27, 2009', 'snippet': 'Randomized controlled trial of resection versus radiotherapy after \ninduction chemotherapy in stage IIIA-N2 non-small-cell lung cancer', 'thumbnail': 'https://serpapi.com/searches/6721d72bfc183d1a7918c332/images/c15d806f3d0f7072b48e9ffa3e6db32d0dbbca27c6a752f7baaedfa5fb2055c2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8753236532211304}",,,,,,,,,,['neutral'],neutral,1
NCT00190008,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/efficacy-piracetam-treatment-tardive-dyskinesia-schizophrenic/', 'title': 'Efficacy of Piracetam in the Treatment of Tardive Dyskinesia in Schizophrenic Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study', 'source': 'Psychiatrist.com', 'date': 'Jul 16, 2007', 'snippet': 'The aim of our study was to reexamine the efficacy of piracetam in the \ntreatment of tardive dyskinesia using an oral preparation.', 'thumbnail': 'https://serpapi.com/searches/6721d743b6ed33ccbc254c9f/images/82944c848469bc4e0936b7280d97b53f8c209f6a06746edfbc101477d398eb77.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8918432593345642}",,,,,,,,,,['neutral'],neutral,1
NCT02068339,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-022-01119-3', 'title': 'Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)', 'source': 'Nature', 'date': 'Aug 13, 2022', 'snippet': 'In this review, we discussed recent developments in etiology and \nprospective therapeutic targets, as well as pharmacological candidates in \npre/clinical trials...', 'thumbnail': 'https://serpapi.com/searches/6721d7487ec4aefacc6b9efa/images/850ecf3f99bec1e0253b269e386a2df6cc9810a3f8f0ccf5c445b9d02c004a43.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9206169247627258}",,,,,,,,,,['neutral'],neutral,1
NCT04739865,"{'position': 1, 'link': 'https://www.nature.com/articles/s41386-023-01648-7', 'title': 'Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication', 'source': 'Nature', 'date': 'Jul 13, 2023', 'snippet': 'This phase II, exploratory, international, fixed-dose, open-label study \nexplored the safety, tolerability, and efficacy of a synthetic form of \npsilocybin.', 'thumbnail': 'https://serpapi.com/searches/6721d757cb33d0118fb64621/images/1f71e8430c3c8e2aabb8570a81ed35208967377b1597f1b2f30e32505bd55204.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8705761432647705}",,,,,,,,,,['neutral'],neutral,1
NCT01419639,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-024-00627-5', 'title': 'NF2 : An underestimated player in cancer metabolic reprogramming and tumor immunity', 'source': 'Nature', 'date': 'Jun 15, 2024', 'snippet': 'Neurofibromatosis type 2 (NF2) is a tumor suppressor gene implicated in \nvarious tumors, including mesothelioma, schwannomas, and meningioma.', 'thumbnail': 'https://serpapi.com/searches/6721d7852e33c8f4cecd1aed/images/55f5f80ab089469a0d3941d8534d267e4536d60d4f4ea76b6338c907c01021b9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7420896887779236}",,,,,,,,,,['neutral'],neutral,1
NCT05195528,"{'position': 1, 'link': 'https://www.empr.com/home/news/voquezna-approved-to-relieve-heartburn-with-nonerosive-gerd/', 'title': 'Voquezna Approved to Relieve Heartburn With Nonerosive GERD - MPR', 'source': 'Medical Professionals Reference', 'date': '١٩\u200f/٠٧\u200f/٢٠٢٤', 'snippet': 'The Food and Drug Administration (FDA) has approved Voquezna (vonoprazan), \na potassium-competitive acid blocker, for the relief of heartburn \nassociated with...', 'thumbnail': 'https://serpapi.com/searches/6721d78aadc33bdf84671857/images/368bd50132eecbd59a17148efab742b41f837d2879931c79b6bb9c018d1db4b8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7045413851737976}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/vonoprazan-looks-promising-for-nonerosive-gastroesophageal-reflux-disease/', 'title': 'Vonoprazan Looks Promising for Nonerosive Gastroesophageal Reflux Disease', 'source': 'Medical Professionals Reference', 'date': '٠٩\u200f/٠١\u200f/٢٠٢٣', 'snippet': 'Vonoprazan was associated with a significantly greater percentage of \n24-hour heartburn free days in patients with symptomatic nonerosive \ngastroesophageal...', 'thumbnail': 'https://serpapi.com/searches/6721d78aadc33bdf84671857/images/368bd50132eecbd5d9aaf320174d454110415f914a85042c6be70af8ddb1cc91.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.510735809803009}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT01967758,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1255799/full', 'title': 'Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment', 'source': 'Frontiers', 'date': 'Feb 7, 2024', 'snippet': 'Here, we summarized the current advances in cancer vaccines targeting \nNY-ESO-1 for solid cancer treatment, aiming to provide perspectives for \nfuture research.', 'thumbnail': 'https://serpapi.com/searches/6721d7d9e45f339e0173210c/images/635206891730fc96eb3f9209634b247ae00e9131a3179461f894252a11ae77a2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.875281810760498}",,,,,,,,,,['neutral'],neutral,1
NCT01515007,"{'position': 1, 'link': 'https://bronchiectasisnewstoday.com/2019/11/21/aradigm-ends-effort-linhaliq-europe-approval-for-ncfbe-lung-infections/', 'title': 'Aradigm Ends Effort to Win EU Approval for Linhaliq in Treating NCFBE Chronic Lung Infections', 'source': 'Bronchiectasis News Today', 'date': 'Nov 21, 2019', 'snippet': 'Aradigm withdrew its application for Linhaliq in the European Union to \ntreat flares in non-cystic fibrosis bronchiectasis linked to P.', 'thumbnail': 'https://serpapi.com/searches/6721d7da72f7160b7410df20/images/55592b5747379f800d0da88cf77433b8ab14b43dc6f05f2cbdfcdbee52db7fc3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6251179575920105}","{'position': 2, 'link': 'https://bronchiectasisnewstoday.com/2017/07/28/non-cystic-fibrosis-bronchiectasis-candidate-therpay-nda-submitted-for-linhaliq-for-p-aeruginosa-infection/', 'title': 'Linhaliq’s NDA Submitted to Treat P. Aeruginosa Infection in NCFBE Patients', 'source': 'Bronchiectasis News Today', 'date': 'Jul 28, 2017', 'snippet': 'Aradigm has submitted a new drug application (NDA) to the US Food and Drug \nAdministration (FDA) for Linhaliq (ciprofloxacin) as a treatment for \nnon-cystic...', 'thumbnail': 'https://serpapi.com/searches/6721d7da72f7160b7410df20/images/55592b5747379f80444f02d6df9462b2e3f710c4f38f4f13cc0ee21188991351.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.921363890171051}","{'position': 3, 'link': 'https://bronchiectasisnewstoday.com/2020/12/11/savara-discontinues-development-apulmiq-for-bronchiectasis-ncfb-amid-cost-cutting-measures/', 'title': 'Savara Discontinues Apulmiq Program for NCFB Amid Cost-cutting Measures', 'source': 'Bronchiectasis News Today', 'date': 'Dec 11, 2020', 'snippet': 'Savara Pharmaceuticals has discontinued its clinical program of the inhaled \nantibiotic formulation Apulmiq (ciprofloxacin) for the treatment of \nnon-cystic...', 'thumbnail': 'https://serpapi.com/searches/6721d7da72f7160b7410df20/images/55592b5747379f80408941f785b9474ac5801c79410955afc171daf7c84a6dc0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5745614171028137}","{'position': 4, 'link': 'https://bronchiectasisnewstoday.com/2019/03/14/new-antibiotic-formulation-better-at-controlling-infections-in-bronchiectasis/', 'title': 'New Antibiotic Formulation Better at Controlling Infections in Bronchiectasis', 'source': 'Bronchiectasis News Today', 'date': 'Mar 14, 2019', 'snippet': 'Read about the advantages of a new formulation of antibiotics using \nnanoparticles, called nanoplex, as a delivery vehicle.', 'thumbnail': 'https://serpapi.com/searches/6721d7da72f7160b7410df20/images/55592b5747379f80fba8ea614df4273897c48777f21168343834f1c60c78858e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5055572986602783}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03095274,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-38611-5', 'title': 'Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin', 'source': 'Nature', 'date': 'May 23, 2023', 'snippet': 'Single immune checkpoint blockade in advanced neuroendocrine neoplasms \n(NENs) shows limited efficacy; dual checkpoint blockade may improve...', 'thumbnail': 'https://serpapi.com/searches/6721d80aa5e502961aa225a1/images/677c7f42bb24647780dc4c270537c4d6d3f795350f6e61b69ad88a947bd24a04.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7717600464820862}",,,,,,,,,,['neutral'],neutral,1
NCT04922554,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/orphan-drug-designation-omadacycline-treatment-caused-by-nontuberculous-mycobacteria/', 'title': 'Omadacycline Gets Orphan Drug Status for Nontuberculous Mycobacteria Infections', 'source': 'Medical Professionals Reference', 'date': 'Aug 19, 2021', 'snippet': 'The Food and Drug Administration (FDA) has granted Orphan Drug designation \nto omadacycline for the treatment of infections caused by nontuberculous...', 'thumbnail': 'https://serpapi.com/searches/6721d83bd0c9832b6154c889/images/56d473258a0c1a3ae3f8bb17a2a779ee576d3bd0c76dfa96f3c6ec61ebaeddc4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9041507244110107}",,,,,,,,,,['neutral'],neutral,1
NCT01973543,"{'position': 1, 'link': 'https://www.cureus.com/articles/268812-emerging-gene-therapies-for-alzheimers-and-parkinsons-diseases-an-overview-of-clinical-trials-and-promising-candidates', 'title': 'Emerging Gene Therapies for Alzheimer’s and Parkinson’s Diseases: An Overview of Clinical Trials and Promising Candidates', 'source': 'Cureus', 'date': 'Aug 16, 2024', 'snippet': ""Gene therapy as a disease-modifying therapeutic approach for \nneurodegenerative diseases, such as Alzheimer's disease (AD) and \nParkinson's..."", 'thumbnail': 'https://serpapi.com/searches/6721d875e924567071169a07/images/ff243ea15b14da05ef8b1e4aebe90074199f2230568bee38c6d438519586c62e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9069619178771973}",,,,,,,,,,['neutral'],neutral,1
NCT04387760,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-022-08794-w', 'title': 'Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease | Scientific Reports', 'source': 'Nature', 'date': 'Mar 23, 2022', 'snippet': 'Favipiravir has antiviral activity against influenza, West Nile virus, and \nyellow fever virus and against flaviviruses.', 'thumbnail': 'https://serpapi.com/searches/6721d88cdc969f7233128087/images/95a4d2f6252b94763398dcbd344f95f5f2f6b8e6e5d688c64e6b9fbc9890f6aa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8547126650810242}",,,,,,,,,,['neutral'],neutral,1
NCT02787005,"{'position': 1, 'link': 'https://www.nature.com/articles/s41391-024-00865-5', 'title': 'Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study | Prostate Cancer and Prostatic Diseases', 'source': 'Nature', 'date': 'Aug 12, 2024', 'snippet': 'KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study evaluating \npembrolizumab in patients with metastatic castration-resistant prostate \ncancer (mCRPC).', 'thumbnail': 'https://serpapi.com/searches/6721d8c8ee468296a0062e59/images/ae62b94e7f3ed4af3aed667985df83c814679702e2c853665df717169ef440c9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9012894034385681}",,,,,,,,,,['neutral'],neutral,1
NCT03415854,"{'position': 1, 'link': 'https://dailynews.ascopubs.org/do/pancreatic-tumor-microenvironment-promising-target-complex-challenges', 'title': 'The Pancreatic Tumor Microenvironment Is a Promising Target With Complex Challenges', 'source': 'ASCO Daily News', 'date': 'Jul 10, 2024', 'snippet': 'Key Points: The pancreatic tumor microenvironment (TME) is a promising \ntarget for drug development, with numerous potentially actionable...', 'thumbnail': 'https://serpapi.com/searches/6721d8ca0f1a3356f8cef7d6/images/a6c17003249cc294b68cbae5f4bf7d6d16291e41341f4cb18010741499da9bf3.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7046766877174377}",,,,,,,,,,['positive'],positive,1
NCT01969643,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/novel-therapies-for-metastatic-triple-negative-breast-cancer-spotlight-on-immunotherapy-and-antibody-drug-conjugates', 'title': 'Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates', 'source': 'Cancer Network', 'date': 'May 13, 2021', 'snippet': 'This review article published in the journal ONCOLOGY® looks at the \nsuccessful clinical development of immunotherapies, PARP inhibitors,...', 'thumbnail': 'https://serpapi.com/searches/6721d8f79109867ea0070137/images/307009bcded6aeca2d0aa241f3051259f00c227b8da06a6a6569e9ff7f2fa712.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9157961010932922}",,,,,,,,,,['neutral'],neutral,1
NCT01178073,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1413687', 'title': 'Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension', 'source': 'The New England Journal of Medicine', 'date': 'Aug 27, 2015', 'snippet': 'Initial combination therapy with ambrisentan and tadalafil resulted in a \nsignificantly lower risk of clinical-failure events than the risk with \nambrisentan or...', 'thumbnail': 'https://serpapi.com/searches/6721d8fd06f4f23e4fafc1b2/images/536e2179cbd9e0fad8182b62c4e5fc1839697ee07005211c5d6bac46db426ed6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8586729764938354}",,,,,,,,,,['neutral'],neutral,1
NCT03419858,"{'position': 1, 'link': 'https://www.news-medical.net/news/20241021/Its-official!-Men-and-women-experience-and-manage-pain-differently.aspx', 'title': ""It's official! Men and women experience and manage pain differently"", 'source': 'News-Medical', 'date': '1 week ago', 'snippet': 'New study reveals that men rely on opioid-based systems to relieve pain \nwhile women may use unknown pathways, urging the development of...', 'thumbnail': 'https://serpapi.com/searches/6721d9af7f37191077d4d943/images/f39ba2af5109b91038903c9ad6f7c079ccfc547808ef7e273e9701fe30f7da46.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8547735810279846}",,,,,,,,,,['neutral'],neutral,1
NCT01354132,"{'position': 1, 'link': 'https://www.nature.com/articles/s41398-018-0266-8', 'title': 'N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial | Translational Psychiatry', 'source': 'Nature', 'date': 'Oct 12, 2018', 'snippet': 'In this secondary study, we suggest that NAC add-on treatment may be a safe \nand effective way to protect white matter integrity in early psychosis \npatients.', 'thumbnail': 'https://serpapi.com/searches/6721d9cc48e6680fc6679346/images/f3f36012eccf2b1ee39bc3dd062297917b3b1140af05444751fb2832f3edb82a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5601887702941895}",,,,,,,,,,['positive'],positive,1
NCT03945279,"{'position': 1, 'link': 'https://www.als.org/blog/biogen-shares-latest-updates', 'title': 'Biogen Shares Latest Updates on ALS Clinical Trials', 'source': 'The ALS Association', 'date': 'Dec 29, 2020', 'snippet': 'Biogen spoke of its urgent work in targeting genetic forms of ALS caused by \nmutations in some of the most common ALS-associated genes, such as SOD1 and \nC9orf72.', 'thumbnail': 'https://serpapi.com/searches/6721d9e329e6fb3b7acc8536/images/881db3d1d997030a0f839051de1f0d680fa09bbad04565be57800054d409cecd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8600117564201355}",,,,,,,,,,['neutral'],neutral,1
NCT03980522,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.391', 'title': 'Inflammasome: structure, biological functions, and therapeutic targets - Dai - 2023 - MedComm', 'source': 'Wiley Online Library', 'date': 'Oct 9, 2023', 'snippet': 'Here, we reviewed the activation process and basic structure of \ninflammasomes in both inactive and active states. Biological functions of...', 'thumbnail': 'https://serpapi.com/searches/6721d9f6db3ac9d20ba6878e/images/4ac803904d340c4d8d42d6e4e8377e7984cfcb72a1d6c8363a2faf96e9f78235.png', 'sentiment': 'neutral', 'sentiment_prob': 0.931729257106781}",,,,,,,,,,['neutral'],neutral,1
NCT03439943,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2312323', 'title': 'Trial of Lixisenatide in Early Parkinson’s Disease', 'source': 'The New England Journal of Medicine', 'date': 'Apr 3, 2024', 'snippet': 'Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the \ntreatment of diabetes, has shown neuroprotective properties in a mouse...', 'thumbnail': 'https://serpapi.com/searches/6721da3bb2ebaeb5ae24a09a/images/8340124bf62103207ef69d9f6c874a9b773ab32020532314dc1a8ff939029b64.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8511877059936523}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/trial-results-lixisenatide-slow-parkinsons-progression-early-data-show/', 'title': 'Lixisenatide may slow disease progression, early data show', 'source': ""Parkinson's News Today"", 'date': 'Aug 31, 2023', 'snippet': ""Results from a Phase 2 clinical trial testing lixisenatide, a diabetes \nmedicine, show it may slow motor symptoms progression in Parkinson's."", 'thumbnail': 'https://serpapi.com/searches/6721da3bb2ebaeb5ae24a09a/images/8340124bf6210320f8be0588145d8522688ed1f1eb3d51c1c6d1f824cb7682af.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7267933487892151}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00097188,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/rituximab-for-rrms/', 'title': 'Rituximab in MS | Experimental MS Treatments', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 12, 2022', 'snippet': 'Rituximab is commonly used off-label in multiple sclerosis patients. Learn \nmore about its uses, side effects, and clinical testing.', 'thumbnail': 'https://serpapi.com/searches/6721da405f9778874e159e63/images/ac50672a25af663d6e5476c5ccd3495986ef74287f8c6c40b8c8b9f6f66448ec.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9291795492172241}",,,,,,,,,,['neutral'],neutral,1
NCT03649152,"{'position': 1, 'link': 'https://www.nature.com/articles/s41581-021-00427-1', 'title': 'Therapeutic trials in adult FSGS: lessons learned and the road forward', 'source': 'Nature', 'date': 'May 20, 2021', 'snippet': 'Focal segmental glomerulosclerosis (FSGS) is not a specific disease entity \nbut a lesion that primarily targets the podocyte.', 'thumbnail': 'https://serpapi.com/searches/6721da551f3d4b4be5c99cb0/images/6b8f33023c3cde8a40a68d582ea50d1bcd6cf3d92ad4d99917ae4ff29360f767.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8861932754516602}",,,,,,,,,,['neutral'],neutral,1
NCT02323022,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-023-00948-x', 'title': 'Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study | Blood Cancer Journal', 'source': 'Nature', 'date': 'Nov 27, 2023', 'snippet': 'T(8;21)(q22;q22.1)/RUNX1::RUNX1T1 is found in 5–10% of all AML cases and \nresponds well to conventional chemotherapy [1].', 'thumbnail': 'https://serpapi.com/searches/6721da8d460b156b9c59752c/images/e6b11f21e2721e27b16327781d42e5ba7bf2ee087087bf8607c83e81ff7e463f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9110143184661865}",,,,,,,,,,['neutral'],neutral,1
NCT03705390,"{'position': 1, 'link': 'https://alsnewstoday.com/news/ilb-may-slow-als-progression-small-clinical-trial-data-show/', 'title': 'ILB may slow ALS progression, per data from small clinical trial', 'source': 'ALS News Today', 'date': 'Jul 25, 2024', 'snippet': ""Treatment with a high dose of Tikomed's ILB injection therapy appeared to \nsafely slow ALS progression in a clinical trial with 11 patients."", 'thumbnail': 'https://serpapi.com/searches/6721da92a471671c163a328e/images/85f5034e13d1b9207e87c3d32b24faaa6f80384974df6eb0cd9acea1c0bebc7b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5280773043632507}",,,,,,,,,,['neutral'],neutral,1
NCT05086952,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222002839', 'title': 'Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)', 'source': 'ScienceDirect.com', 'date': 'Apr 2, 2022', 'snippet': 'Vericiguat was first drug approved for the treatment of symptomatic \npatients with chronic HF with reduced ejection fraction (HFrEF) to reduce \nthe occurrence of...', 'thumbnail': 'https://serpapi.com/searches/6721daac0e6db341b26c45a6/images/bd4c8d8e63a33fb650fe279fb7d194e85602181ec062e31edf37565bf6f65563.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6862191557884216}",,,,,,,,,,['neutral'],neutral,1
NCT02965378,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.780650/full', 'title': 'Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer', 'source': 'Frontiers', 'date': 'Mar 25, 2022', 'snippet': 'Fibroblast growth factor receptor (FGFR) inhibitors (FGFRis) are a \npotential therapeutic option for squamous non-small cell lung cancer...', 'thumbnail': 'https://serpapi.com/searches/6721dac0b6ed33cc904cbbee/images/f4b2ee979e2332e22815490df3b2ff9b3052d35db35f145291a5e2170c816a71.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8964763283729553}",,,,,,,,,,['neutral'],neutral,1
NCT04399837,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2111563', 'title': 'Trial of Spesolimab for Generalized Pustular Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Dec 22, 2021', 'snippet': 'Spesolimab, a humanized anti–interleukin-36 receptor monoclonal antibody, \nis being studied for the treatment of GPP flares.', 'thumbnail': 'https://serpapi.com/searches/6721dac403775620cb8ecfb2/images/f94aabe6580f9bb50d74d0b139fb313620ced23bbffd979a14775f11c6e9d456.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9019375443458557}","{'position': 2, 'link': 'https://www.empr.com/home/news/spevigo-gets-expanded-approval-for-generalized-pustular-psoriasis/', 'title': 'Spevigo Gets Expanded Approval for Generalized Pustular Psoriasis', 'source': 'Medical Professionals Reference', 'date': 'Mar 19, 2024', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of Spevigo \n(spesolimab-sbzo) to include the treatment of generalized pustular \npsoriasis (GPP)', 'thumbnail': 'https://serpapi.com/searches/6721dac403775620cb8ecfb2/images/f94aabe6580f9bb529d4395cbddf1abe1ab76d197acaeb89796dfc6ad904c7d1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6945558190345764}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04941781,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/03/29/fda-clears-trial-pipe-307-myelin-restoring-therapy-patients-relapsing-remitting-multiple-sclerosis/', 'title': 'Trial Cleared for PIPE-307, Potential RRMS Myelin Restoration Therapy', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 29, 2022', 'snippet': ""The US Food and Drug Administration (FDA) has cleared a Phase 1b/2a trial \nof PIPE-307, Pipeline Therapeutics' investigational myelin-restoring \ntreatment."", 'thumbnail': 'https://serpapi.com/searches/6721db16059caf1d690c46c7/images/1452c0619f94e7b984ef9afb90a3a16c558549e1552224a1ff1693088ea9a68e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8590291142463684}",,,,,,,,,,['neutral'],neutral,1
NCT02853344,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.20.02365', 'title': 'Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Feb 2, 2021', 'snippet': 'PURPOSEProgrammed death 1 (PD-1) pathway inhibitors have not been \nprospectively evaluated in patients with non–clear cell renal cell...', 'thumbnail': 'https://serpapi.com/searches/6721db2fcb33d0118fb64932/images/2dc632601d56fc23dac85d3780756c9ab023acd8549d4a82974e3edb687fc530.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8765980005264282}",,,,,,,,,,['neutral'],neutral,1
NCT02891811,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/news/thalidomide-lenalidomide-new-multiple-myeloma-treatment-risk/', 'title': 'Thalidomide Vs Lenalidomide for Newly Diagnosed Multiple Myeloma', 'source': 'Hematology Advisor', 'date': 'Jul 8, 2022', 'snippet': 'Recent clinical trial results suggested similar efficacy for thalidomide \n(T), compared with lenalidomide (R), in combination with...', 'thumbnail': 'https://serpapi.com/searches/6721db38e45f339e01732432/images/970b4795ce1fa7829dde3d22d5904667b3aa6acd631d16b1eaec4be3e04763b3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8584061861038208}",,,,,,,,,,['neutral'],neutral,1
NCT02970929,"{'position': 1, 'link': 'https://www.nature.com/articles/s41537-021-00190-z', 'title': 'Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study', 'source': 'Nature', 'date': 'Dec 9, 2021', 'snippet': 'Ulotaront, a trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A \nreceptors agonist, has demonstrated efficacy in the treatment of...', 'thumbnail': 'https://serpapi.com/searches/6721db6e98d8de6762e55a04/images/e6a149342c294da8a34cbafd97d5fdbad2c5968d7ef1ac21de531f77faddb693.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7764618396759033}",,,,,,,,,,['neutral'],neutral,1
NCT03766685,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/bimekizumab-UCB4940', 'title': 'Bimekizumab (Bimzelx®)', 'source': 'UCB', 'date': 'Oct 16, 2018', 'snippet': 'Ankylosing Spondylitis, A Multicenter Study to Evaluate the Efficacy and \nSafety of Different Doses of Bimekizumab in Subjects With Active \nAnkylosing...', 'thumbnail': 'https://serpapi.com/searches/6721db86c7d4a1acec2cd8b0/images/0cb5b90cae34affc6d2713d8f4a5d2a85e3301ea80aad1ce5f5475631dfc98aa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8456552028656006}",,,,,,,,,,['neutral'],neutral,1
NCT02949830,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1807838', 'title': 'Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria', 'source': 'The New England Journal of Medicine', 'date': 'Feb 6, 2019', 'snippet': 'Induction of delta aminolevulinic acid synthase 1 (ALAS1) gene expression \nand accumulation of neurotoxic intermediates result in...', 'thumbnail': 'https://serpapi.com/searches/6721db8ab28e6b3e202841f9/images/5de6b00a0f77e30474e04e2519121bd5f312c2bec1f7e75f1b9292787bfcfa9c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8080363869667053}",,,,,,,,,,['neutral'],neutral,1
NCT04484350,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/SVIN.123.001287', 'title': 'Blood Pressure Management Following Endovascular Stroke Treatment: A Feasibility Trial and Meta‐Analysis of Outcomes', 'source': 'American Heart Association Journals', 'date': 'Feb 26, 2024', 'snippet': 'Although postprocedure blood pressure (BP) correlates with outcome in \npatients undergoing endovascular thrombectomy (EVT), the optimal target is \nunknown.', 'thumbnail': 'https://serpapi.com/searches/6721db9dcb33d0118fb649a2/images/d6d8b59227e7c1029e5faa23a61c66df8ec38012cbedac76febee2b6e547abe2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8891703486442566}",,,,,,,,,,['neutral'],neutral,1
NCT01381094,"{'position': 1, 'link': 'https://ckdnews.com/2017/05/17/akebia-gives-vifor-right-to-provide-its-anemia-therapy-vadadustat-to-dialysis-clinics/', 'title': 'Vifor Pharma to Provide Akebia’s Anemia Therapy Vadadustat to Group of US Dialysis Clinics', 'source': 'CKD News', 'date': 'May 17, 2017', 'snippet': ""Vifor Pharma Group has obtained exclusive rights to sell Akebia \nTherapeutics' kidney-disease-related anti-anemia treatment vadadustat \n(AKB-6548) to Fresenius..."", 'thumbnail': 'https://serpapi.com/searches/6721dbb8fab273f966b90a57/images/b9f03d26df646133ca9f9c9685722d35553a8d1319e63d7902d0054383052bd8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9193611741065979}",,,,,,,,,,['neutral'],neutral,1
NCT00716976,"{'position': 1, 'link': 'https://www.oncologynewscentral.com/article/fda-approves-sodium-thiosulfate-for-prevention-of-platinum-induced-hearing', 'title': 'FDA Approves Sodium Thiosulfate for Prevention of Platinum-Induced Hearing Loss in Kids', 'source': 'oncologynewscentral.com', 'date': 'Sep 21, 2022', 'snippet': 'The U.S. Food and Drug Administration approved an unique formulation of \nsodium thiosulfate (Pedmark) for the prevention of platinum-induced...', 'thumbnail': 'https://serpapi.com/searches/6721dbc998d8de6762e55a62/images/f79ee3c6ee898df0d064edec5441043989273ecfc8caa662436761c0e9302eff.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7437710762023926}",,,,,,,,,,['neutral'],neutral,1
NCT03086278,"{'position': 1, 'link': 'https://www.pnas.org/doi/10.1073/pnas.2306973121', 'title': 'Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy', 'source': 'PNAS', 'date': 'Feb 12, 2024', 'snippet': 'Integrating multimodal neuro- and nanotechnology-enabled precision \nimmunotherapies with extant systemic immunotherapies may finally provide a \nsignificant...', 'thumbnail': 'https://serpapi.com/searches/6721dbd6f963e7b2009fcffe/images/0abd917c740838eb2907d15320e6985d400052ec8f458631fae8a29d2aa80482.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7723827362060547}",,,,,,,,,,['neutral'],neutral,1
NCT01163266,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/randomized-double-blind-placebo-controlled-study-efficacy-safety-vortioxetine-10-20-mg-adults-mdd/', 'title': 'A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults With Major Depressive Disorder', 'source': 'Psychiatrist.com', 'date': 'May 27, 2015', 'snippet': 'Vortioxetine 20 mg significantly reduced MADRS total score at 8 weeks in \nthis study population. Overall, vortioxetine was well tolerated in this \nstudy.', 'thumbnail': 'https://serpapi.com/searches/6721dc02a5d70237c47028c6/images/c2e992aff37d2982c5e00caa3c01803829c1b4b63b3d6fe1e3ed9e7b80cee08e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7644969820976257}",,,,,,,,,,['neutral'],neutral,1
NCT02437136,"{'position': 1, 'link': 'https://lungcancernewstoday.com/2017/06/22/entinostat-keytruda-clinical-trial-nsclc-proceed-next-stage/', 'title': 'Entinostat-Keytruda Clinical Trial in NSCLC Will Proceed to Next Stage', 'source': 'Lung Cancer News Today', 'date': 'Jun 22, 2017', 'snippet': ""A clinical trial exploring entinostat in combination with Merck's Keytruda \n(pembrolizumab) in non-small cell lung cancer (NSCLC) patients..."", 'thumbnail': 'https://serpapi.com/searches/6721dc0b2c566df1ca1f1280/images/9327a6dd9bd769049a26d282df2c4157d27257f2220966f712bc1661e57b5db8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8719929456710815}",,,,,,,,,,['neutral'],neutral,1
NCT04214652,"{'position': 1, 'link': 'https://www.empr.com/home/news/cabtreo-a-triple-combo-topical-gel-for-acne-gets-fda-approval/', 'title': 'Cabtreo, a Triple Combo Topical Gel for Acne, Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Oct 25, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Cabtreo™ (clindamycin \nphosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1%)...', 'thumbnail': 'https://serpapi.com/searches/6721dc0f5a461a4e1aee2b45/images/1f633c84a9efc9f6e5a7d1ac9a371cb82e962802dcc42300603a45c8b11ce7b9.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5522952079772949}",,,,,,,,,,['positive'],positive,1
NCT02034071,"{'position': 1, 'link': 'https://praderwillinews.com/news/dccr-tablets-promote-body-fat-loss-in-prader-willi-syndrome/', 'title': 'DCCR Tablets Reduce Body Fat in PWS Patients, Phase 2 Trial Shows', 'source': 'Prader-Willi Syndrome News', 'date': 'Dec 3, 2018', 'snippet': 'A phase 2 clinical trial showed DCCR tablets can treat excessive eating and \nbehavioral problems of Prader-Willi syndrome patients,...', 'thumbnail': 'https://serpapi.com/searches/6721dc2aacf7f87886b36609/images/ea345e3a92ccacb82a867ef5d3b9ed5cfac65c4268da4d449ff462fb50cc9b7f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7200559973716736}",,,,,,,,,,['neutral'],neutral,1
NCT05035641,"{'position': 1, 'link': 'https://www.manilatimes.net/2024/10/29/tmt-newswire/pr-newswire/kind-presents-positive-results-of-and017-to-treat-anemia-associated-with-chronic-kidney-disease-in-two-phase-ii-and-two-phase-i/1992905', 'title': 'KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I', 'source': 'The Manila Times', 'date': '1 day ago', 'snippet': 'Clinical Trials at American Society of Nephrology (ASN) - Kidney Week 2024. \nSAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Kind Pharmaceutical...', 'thumbnail': 'https://serpapi.com/searches/6721dc4e0053c75325ea867e/images/91ca17ef78620cb3f78063ca9bfcc7d6589d59b76a77ba2b54953a38fcaeb359.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6056104302406311}",,,,,,,,,,['neutral'],neutral,1
NCT02386306,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00456/full', 'title': ""A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease"", 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': ""Neuroinflammation commences decades before Alzheimer's disease (AD) \nclinical onset and represents one of the earliest pathomechanistic \nalterations..."", 'thumbnail': 'https://serpapi.com/searches/6721dc50b7d31dae7a191bea/images/e993e3bee5d4c770acca9e885948b21e8e2edf8b221f011c78ac03c4bed421dc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8680144548416138}",,,,,,,,,,['neutral'],neutral,1
NCT03794544,"{'position': 1, 'link': 'https://ascopost.com/news/september-2023/neocoast-durvalumab-monotherapy-vs-combined-with-other-immunotherapies-for-early-stage-nsclc/', 'title': 'NeoCOAST Durvalumab Monotherapy vs Combined With Other Immunotherapies for Early-Stage NSCLC', 'source': 'The ASCO Post', 'date': 'Sep 21, 2023', 'snippet': 'The anti–PD-L1 monoclonal antibody durvalumab in combination with other \nimmuno-oncology agents may outperform treatment with durvalumab alone in \nthe...', 'thumbnail': 'https://serpapi.com/searches/6721dc7f671f3f3c7492b52d/images/ab003261c0e7ee9e2e491d1658b90a79bddb402e63630e7afd0808eeb3c7ae2a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8585239052772522}",,,,,,,,,,['neutral'],neutral,1
NCT02350673,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1433989/full', 'title': 'IL-2 based cancer immunotherapies: an evolving paradigm', 'source': 'Frontiers', 'date': 'Jul 11, 2024', 'snippet': 'Discovered over 4 decades ago in the supernatants of activated T cells, \ninterleukin-2 (IL-2) is a potent pleiotropic cytokine involved in the \nregulation of...', 'thumbnail': 'https://serpapi.com/searches/6721dc8b8d1473e353fb3594/images/cd840737c2b795787910e622c235ecb68e15041ad61d3022639a3ef9e102682a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8872764706611633}","{'position': 2, 'link': 'https://immuno-oncologynews.com/cergutuzumab-amunaleukin/', 'title': 'Cergutuzumab Amunaleukin', 'source': 'Immuno-Oncology News', 'date': 'Dec 21, 2017', 'snippet': 'Read about cergutuzumab amunaleukin, an immuno-oncology therapy that Roche \nis developing as a potential treatment for advanced solid tumors.', 'thumbnail': 'https://serpapi.com/searches/6721dc8b8d1473e353fb3594/images/cd840737c2b795789958d0d17666416e125e01e3cef0e0dc9f6dcff72ea603cb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9002129435539246}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01309737,"{'position': 1, 'link': 'https://psoriasisnewstoday.com/2017/05/09/xeljanz-reduces-nail-psoriasis-phase-3-trials-plaque-disease/', 'title': 'Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease', 'source': 'Psoriasis News Today', 'date': 'May 9, 2017', 'snippet': 'Learn more about how clinical trials demonstrated that the rheumatoid \narthritis drug Xeljanz (tofacitinib) is effective against nail...', 'thumbnail': 'https://serpapi.com/searches/6721dc9a13e5d81f5e77405a/images/054a913dba220bc49bcb0346c4cb10be8bdf07d3e4dc51f5e0df5df311379829.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6758314371109009}",,,,,,,,,,['neutral'],neutral,1
NCT01737814,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/trial-of-mst-188-in-sickle-cell-disease-fails-to-meet-primary-endpoint/', 'title': 'MST-188 Trial Fails to Achieve Goal as Sickle Cell Disease Therapy', 'source': 'Sickle Cell Disease News', 'date': 'Oct 4, 2016', 'snippet': 'Clinical development of Vepoloxamer (MST-188) likely to be terminated after \nthe drug fails to meet primary endpoints in sickle cell disease...', 'thumbnail': 'https://serpapi.com/searches/6721dcec74978395dc84df7f/images/b97c461e4a7cbdddba597c8f7012e0d16a92debf402a2ce2f53b5b009a19d345.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8003845810890198}",,,,,,,,,,['negative'],negative,0
NCT02586805,"{'position': 1, 'link': 'https://angioedemanews.com/news/takhzyro-safetly-prevents-monthly-hae-attacks-adolescents/', 'title': 'Takhzyro seen to safely prevent monthly HAE attacks in adolescents', 'source': 'Angioedema News', 'date': '1 month ago', 'snippet': 'Study of 21 teenagers treated with Takhzyro in the long-term HELP extension \nstudy found an overall drop of 94.7% in monthly swelling...', 'thumbnail': 'https://serpapi.com/searches/6721dcf454605cf4e9883d30/images/811504abcfb96bbee1b402fe3b641d5c93d4e20ebb208e1408c1e50d361a71cf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7090039849281311}",,,,,,,,,,['neutral'],neutral,1
NCT04974008,"{'position': 1, 'link': 'https://finance.yahoo.com/news/os-therapies-announces-last-patient-120000789.html', 'title': 'OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit', 'source': 'Yahoo Finance', 'date': '4 weeks ago', 'snippet': 'The last patient (Patient #41) enrolled in the AOST-2121 clinical trial \n(NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) has \ncompleted their...', 'thumbnail': 'https://serpapi.com/searches/6721dd287d533ebd2cab3f2a/images/3d74a65f32a68c0e10ac1deb51bbb2137073f3b39f52d1b99a3dcc410e2a28e9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9211674928665161}","{'position': 2, 'link': 'https://finance.yahoo.com/news/os-therapies-announces-last-patient-115300077.html', 'title': 'OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose', 'source': 'Yahoo Finance', 'date': 'Aug 29, 2024', 'snippet': 'The last patient (Patient #41) enrolled in the AOST-2121 clinical trial \n(NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has \nreceived its...', 'thumbnail': 'https://serpapi.com/searches/6721dd287d533ebd2cab3f2a/images/3d74a65f32a68c0ea7b2d84dc0a97673f341d9993ea0897edb405b81aec20645.png', 'sentiment': 'neutral', 'sentiment_prob': 0.91684889793396}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02160782,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/alagille-syndrome-long-term-benefits-livmarli-extend-beyond-itch/', 'title': 'In Alagille syndrome, long-term benefits of Livmarli extend beyond itch', 'source': 'liverdiseasenews.com', 'date': 'Mar 8, 2024', 'snippet': 'Treatment with Livmardi over six years for Alagille syndrome suggest it may \nreplace or delay the need for a liver transplant, a study shows.', 'thumbnail': 'https://serpapi.com/searches/6721dd778a7c0939084c7d33/images/387bfa54c0fa380d06c09d46af3fda374c461109c24b63078919aa90ab759c74.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7927603721618652}",,,,,,,,,,['neutral'],neutral,1
NCT05318937,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/dalzanemdor-sage-718-fails-improve-cognition-phase-2-trial/', 'title': 'Dalzanemdor, formerly SAGE-718, fails to aid cognition in Phase 2 trial', 'source': ""Parkinson's News Today"", 'date': 'Apr 24, 2024', 'snippet': ""Dalzanemdor (formerly SAGE-718), a medication for mild cognitive impairment \ndue to Parkinson's, failed to outperform a placebo in a trial."", 'thumbnail': 'https://serpapi.com/searches/6721ddaad364b4c6e3d6930e/images/be9d83966bfaddadb878fcb0f26dba9536c87f1861155c8ca0dfb65d10a11c1c.png', 'sentiment': 'negative', 'sentiment_prob': 0.8312615752220154}",,,,,,,,,,['negative'],negative,0
NCT00931736,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1714283', 'title': 'Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults', 'source': 'The New England Journal of Medicine', 'date': 'Aug 1, 2018', 'snippet': 'In an open-label trial conducted in nine countries, we randomly assigned \nadults with latent tuberculosis infection to receive treatment with...', 'thumbnail': 'https://serpapi.com/searches/6721ddb56de1e44657d93e7f/images/4c80b33c4c735f755cb1f86a96da42454425c7d00bc35a6eb8a1c548ac8fc4b4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9105907678604126}",,,,,,,,,,['neutral'],neutral,1
NCT01236391,"{'position': 1, 'link': 'https://www.clinicalleader.com/doc/new-fda-guidance-clinical-trial-considerations-to-support-accelerated-approval-of-oncology-therapeutics-0001', 'title': 'New FDA Guidance Clinical Trial Considerations To Support Accelerated Approval Of Oncology Therapeutics', 'source': 'Clinical Leader', 'date': 'Apr 21, 2023', 'snippet': 'On April 6, 2023, AbbVie announced that it was voluntarily withdrawing \nibrutinib, which was granted accelerated approval for two...', 'thumbnail': 'https://serpapi.com/searches/6721de4db4fe87248f8f6be6/images/57771909bd015aab43c77438fd5dfa7941c300cf87b01cc70d620f743d035ecc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8708025217056274}",,,,,,,,,,['neutral'],neutral,1
NCT01568073,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/new-data-support-effectiveness-of-ongentys-for-parkinsons-off-periods/', 'title': 'New Data Support Effectiveness of Ongentys for Parkinson’s ‘Off’ Periods', 'source': ""Parkinson's News Today"", 'date': 'Oct 6, 2020', 'snippet': ""Ongentys (opicapone) can reduce the extent of “off” periods in people with \nParkinson's disease being treated with levodopa, new clinical trial data \nshow."", 'thumbnail': 'https://serpapi.com/searches/6721de8eea57e91078cff57a/images/2a834f2cc0cf484460965dd92398d3c65f165652df6488f26760f310cff3be79.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8502773642539978}",,,,,,,,,,['neutral'],neutral,1
NCT02913313,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2018/11/02/compugen-bristol-myers-squibb-collaborating-to-test-com701-opdivo-combo-for-ovarian-other-cancers/', 'title': 'For Ovarian, Other Cancers, Phase 1 Trial Testing COM701 with Opdivo', 'source': 'Ovarian Cancer News Today', 'date': 'Nov 2, 2018', 'snippet': 'Compugen has entered into a clinical trial collaboration with Bristol-Myers \nSquibb (BMS) to evaluate the safety and preliminary...', 'thumbnail': 'https://serpapi.com/searches/6721dea5cf32e0c291d21c09/images/96bfeb7a2710971d600428daf2ebee0023574d8d9cf249081f4b8bccae20686e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9168850779533386}",,,,,,,,,,['neutral'],neutral,1
NCT01453504,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-021-01442-8', 'title': 'Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis', 'source': 'Nature', 'date': 'Oct 9, 2021', 'snippet': 'We herein confirm the curative potential of current rrHL treatments \nproviding a robust benchmark to evaluate novel therapeutic strategies in \nrrHL.', 'thumbnail': 'https://serpapi.com/searches/6721debae924567041b7e35b/images/07925eaad62d20434fd401581b0ad94a49d6bf6e1f7cf55a50b6746d79e02fbd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8300963044166565}",,,,,,,,,,['neutral'],neutral,1
NCT04340050,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/joim.13185', 'title': 'Journal of Internal Medicine', 'source': 'Wiley Online Library', 'date': 'Oct 9, 2020', 'snippet': 'Clinical predictors of donor antibody titre and correlation with recipient \nantibody response in a COVID-19 convalescent plasma clinical trial', 'thumbnail': 'https://serpapi.com/searches/6721def8e45f339e01732703/images/8a9e7d0d762f6a5fe655c7120dc170f3f81b181e56a762a96f28b00248125f6e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9081891179084778}",,,,,,,,,,['neutral'],neutral,1
NCT04005170,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00060-8/fulltext', 'title': 'Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial', 'source': 'The Lancet', 'date': 'Mar 27, 2023', 'snippet': 'Toripalimab combined with definitive chemoradiotherapy in locally advanced \noesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 \ntrial', 'thumbnail': 'https://serpapi.com/searches/6721df05e924567041b7e399/images/578328e7fdd63452f65722c178100694e01b9c688cd2a24d183171b1bb03da6c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8262819647789001}",,,,,,,,,,['neutral'],neutral,1
NCT01039207,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-0199-6', 'title': 'Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence', 'source': 'Nature', 'date': 'Jul 29, 2020', 'snippet': 'Advanced and recurrent gynecological cancers are associated with poor \nprognosis and lack of effective treatment. The developments of the...', 'thumbnail': 'https://serpapi.com/searches/6721df0bd0d7e3e655d9a8c3/images/51df1b5120ceb1fcd036336501febed40579db850dfe38fa971b0803210ad51e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6648945212364197}",,,,,,,,,,['neutral'],neutral,1
NCT02872103,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/ryzneuta-efbemalenograstim-alfa-evive-fda-biologics-license-application-submission/', 'title': 'Novel Biologic for Chemotherapy-Induced Neutropenia Submitted to FDA', 'source': 'Medical Professionals Reference', 'date': 'Mar 31, 2021', 'snippet': 'The Biologics License Application (BLA) for Ryzneuta™ (efbemalenograstim \nalfa; Evive Biotech) has been submitted to the Food and Drug...', 'thumbnail': 'https://serpapi.com/searches/6721df2cf41044dc44fa9bf7/images/62b9740eed8c78b00e1dbe461a6fa623117fa487cd83fd035e43fac8b2d7938b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9181747436523438}",,,,,,,,,,['neutral'],neutral,1
NCT02494570,"{'position': 1, 'link': 'https://www.onclive.com/view/bui-and-kelly-discuss-the-utility-of-nab-sirolimus-in-advanced-malignant-pecoma', 'title': 'Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa', 'source': 'OncLive', 'date': 'Jul 18, 2024', 'snippet': 'Drs Bui and Kelly discuss key long-term findings from the AMPECT trial \ninvestigating nab-sirolimus in patients with advanced malignant...', 'thumbnail': 'https://serpapi.com/searches/6721df34ee677f6cfefc62d3/images/4b62b490095e8c129f2038ce1faeb0fcf61fc0f5e834740c26a59c7afac41add.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.952530562877655}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20190103005021/en/Aadi-Bioscience-Receives-Breakthrough-Therapy-Designation-for-TARZIFYX%E2%84%A2%C2%A0-ABI-009-in-PEComa-Indication', 'title': 'Aadi Bioscience Receives Breakthrough Therapy Designation for TARZIFYX™ (ABI-009) in PEComa Indication', 'source': 'Business Wire', 'date': 'Jan 3, 2019', 'snippet': 'Aadi Bioscience Receives Breakthrough Therapy Designation for TARZIFYX \n(ABI-009) in PEComa Indication. Registration study completes...', 'thumbnail': 'https://serpapi.com/searches/6721df34ee677f6cfefc62d3/images/4b62b490095e8c12cb7cd6e0466c532dad8969cb0f628cb2a2ca413ea1cbb31e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6182836294174194}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05523297,"{'position': 1, 'link': 'https://www.cmaj.ca/content/195/22/E773', 'title': 'Nonsurgical management of major hemorrhage', 'source': 'CMAJ', 'date': 'Jun 5, 2023', 'snippet': 'Major hemorrhage is a challenging clinical problem that can occur with \ntraumatic injury, postpartum hemorrhage, major surgery and...', 'thumbnail': 'https://serpapi.com/searches/6721df7ec97e35c23b88a2a5/images/b7167889c244c28289d47e4e37b5be16223d6214af0ad15941aeac1aafecbc24.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6239058375358582}",,,,,,,,,,['negative'],negative,0
NCT02485717,"{'position': 1, 'link': 'https://www.empr.com/home/news/natroba-spinosad-topical-suspension-scabies-infestations/', 'title': 'Natroba Topical Suspension Approved for Scabies Treatment', 'source': 'Medical Professionals Reference', 'date': 'Apr 29, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Natroba TM (spinosad) \ntopical suspension for the treatment of scabies infestations in patients 4 \nyears of...', 'thumbnail': 'https://serpapi.com/searches/6721dfbe6901215799fd0cc9/images/eba889911aefc7955b4cd8dfb482660fc014e31e13588f3dd20597759d97617a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8773550987243652}",,,,,,,,,,['neutral'],neutral,1
NCT01642212,"{'position': 1, 'link': 'https://www.empr.com/home/news/eohilia-an-oral-therapy-for-eosinophilic-esophagitis-gets-fda-approval/', 'title': 'Eohilia, an Oral Therapy for Eosinophilic Esophagitis, Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Feb 12, 2024', 'snippet': 'The approval of Eohilia was based on data from 2 double-blind, \nparallel-group, placebo-controlled 12-week phase 3 trials.', 'thumbnail': 'https://serpapi.com/searches/6721e01b163bdf528ce1824a/images/d8be4f3472a7aa5dc91492d75df7ef5ad05666f6f7218c5509b5fa548238923e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6682627201080322}",,,,,,,,,,['neutral'],neutral,1
NCT03121716,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/lary.30971', 'title': 'Immune Checkpoint Inhibitors Serve as the First-Line Treatment for Advanced Head and Neck Cancer', 'source': 'Wiley Online Library', 'date': 'Aug 23, 2023', 'snippet': 'Objectives Immune checkpoint inhibitor (ICI) therapy has demonstrated \nsubstantial benefits for certain patients. We try to evaluate the...', 'thumbnail': 'https://serpapi.com/searches/6721e06d3d629b098cc1c7e0/images/ee24efd1c9d29fdd7adc6e286edc492477c939b8c216a208d6c05885f127eff0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7475776672363281}",,,,,,,,,,['neutral'],neutral,1
NCT03054363,"{'position': 1, 'link': 'https://www.onclive.com/view/tucatinib-letrozole-palbociclib-combination-demonstrates-meaningful-efficacy-in-hr-her2-mbc', 'title': 'Tucatinib/Letrozole/Palbociclib Combination Demonstrates Meaningful Efficacy in HR+/HER2+ mBC', 'source': 'OncLive', 'date': 'Aug 16, 2023', 'snippet': 'Treatment with the all-oral triplet of tucatinib, letrozole, and \npalbociclib yielded clinically meaningful efficacy results and had an...', 'thumbnail': 'https://serpapi.com/searches/6721e06f2c83d57e41df460d/images/435efa31909e863376b945f13e4d60164012265ba85aee553b2c2a9af28e210b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5219252705574036}",,,,,,,,,,['positive'],positive,1
NCT03081689,"{'position': 1, 'link': 'https://ascopubs.org/doi/abs/10.1200/jco.21.02660', 'title': 'Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial) | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'May 16, 2022', 'snippet': 'Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in \nresectable non–small-cell lung cancer (NSCLC) in the NADIM trial.', 'thumbnail': 'https://serpapi.com/searches/6721e108eda5f5f2704c2c34/images/e3379acf23e90f904ecee5a08a3074dcb789b513a3578de04a1f405c321a525e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7534918189048767}",,,,,,,,,,['neutral'],neutral,1
NCT00529984,"{'position': 1, 'link': 'https://www.nature.com/articles/s41417-023-00587-1', 'title': 'Clinical trials of self-replicating RNA-based cancer vaccines', 'source': 'Nature', 'date': 'Feb 10, 2023', 'snippet': 'Therapeutic cancer vaccines, designed to activate immune effectors against \ntumor antigens, utilize a number of different platforms for...', 'thumbnail': 'https://serpapi.com/searches/6721e12ddb3ac9d23d14b124/images/4407d5f80a365a1a4a67c2ff1562f4af47d8b5091e911554fb4fb3769565ac13.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9000220894813538}",,,,,,,,,,['neutral'],neutral,1
NCT02149225,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-51315-8', 'title': 'A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine', 'source': 'Nature', 'date': 'Aug 11, 2024', 'snippet': 'Current treatment outcome of patients with glioblastoma (GBM) remains poor. \nFollowing standard therapy, recurrence is universal with limited...', 'thumbnail': 'https://serpapi.com/searches/6721e139cc48791e95263fc6/images/ddc203382dadf18f87dfb176bc5d24a551a58474f3d799e5207b34695ab3171c.png', 'sentiment': 'negative', 'sentiment_prob': 0.5740231275558472}",,,,,,,,,,['negative'],negative,0
NCT04504279,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/probiotic-skin-therapy-improves-eczema-children-nih-study-suggests', 'title': 'Probiotic skin therapy improves eczema in children, NIH study suggests', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Sep 9, 2020', 'snippet': 'An experimental treatment for eczema that aims to modify the skin \nmicrobiome safely reduced disease severity and increased quality of life \nfor children as...', 'thumbnail': 'https://serpapi.com/searches/6721e1619e5bd52d11a9cf4c/images/12f38e4b488d7b9d7470527c5f8f9e7cb4242ab7d36af64a96bf8437a851ed71.png', 'sentiment': 'positive', 'sentiment_prob': 0.6485627293586731}",,,,,,,,,,['positive'],positive,1
NCT03589469,"{'position': 1, 'link': 'https://www.oncnursingnews.com/view/edema-and-effusion-with-loncastuximab-tesirine-is-manageable-in-patients-with-relapsed-refractory-dlbcl', 'title': 'Edema and Effusion With Loncastuximab Tesirine Is Manageable in Patients With Relapsed/Refractory DLBCL', 'source': 'Oncology Nursing News', 'date': 'May 29, 2022', 'snippet': 'Nurse investigators characterized the onset and management of edema and \neffusion with loncastuximab tesirine in the pivotal LOTIS-2 trial.', 'thumbnail': 'https://serpapi.com/searches/6721e1962a7727b885787b52/images/3757117cd1ccb1b77fc9fbcc458bf015f5548190f959d91e0ad3b624ca6a91fb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9146631360054016}","{'position': 2, 'link': 'https://lymphomanewstoday.com/2019/09/13/adc-therapeutics-freenone-partner-to-identify-dlbcl-patients-likely-to-benefit-adct-402/', 'title': 'Identifying DLBCL Patients Most Likely to Benefit from ADCT-402 Goal of Partnership', 'source': 'Lymphoma News Today', 'date': 'Sep 13, 2019', 'snippet': 'ADCT-402, an antibody-drug conjugate targeting a protein common to blood \ncancers, is in a pivotal Phase 2 trial enrolling people with...', 'thumbnail': 'https://serpapi.com/searches/6721e1962a7727b885787b52/images/3757117cd1ccb1b730526261338e030f99df02364e20723415cd65b0dd7c77cd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6173306107521057}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01991561,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-017-0043-3', 'title': 'Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial', 'source': 'Nature', 'date': 'Jan 23, 2018', 'snippet': 'The hemagglutinination inhibition (HI) response remains the gold standard \nused for the licensure of influenza vaccines.', 'thumbnail': 'https://serpapi.com/searches/6721e19dd78a989f43d4022a/images/d20ddff30e1b9acc701a09ba8ba4eadc780250bdd8a1e92a0c519a0aa762375f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8728938102722168}",,,,,,,,,,['neutral'],neutral,1
NCT05623839,"{'position': 1, 'link': 'https://www.nature.com/articles/s41366-024-01473-y', 'title': 'What is the pipeline for future medications for obesity? - International Journal of Obesity', 'source': 'Nature', 'date': 'Feb 1, 2024', 'snippet': 'In this review, we present the efficacy and safety data for the pipeline of \nobesity pharmacotherapies with a focus on entero-pancreatic hormone-based...', 'thumbnail': 'https://serpapi.com/searches/6721e1b6e1c27656633a5f9c/images/32d80dc0aa5516ee6283ab40de791a6aa9ec03091cf58d2a8b7be05d63d6a9d3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9023082256317139}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/analyst-comment/easd-2024-mazdutide-cardiometabolic-function-overweight-patients/', 'title': 'EASD 2024: Mazdutide improves cardiometabolic function in overweight patients', 'source': 'Clinical Trials Arena', 'date': '1 month ago', 'snippet': 'At EASD 2024, Eli Lilly and Co announced the most recent trial results for \nmazdutide, its dual GLP-1R/ (GCGR) agonist.', 'thumbnail': 'https://serpapi.com/searches/6721e1b6e1c27656633a5f9c/images/32d80dc0aa5516ee7c4700825cbdbb017a4bb4530950ceffdad56c7000f215b1.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8030769228935242}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04089553,"{'position': 1, 'link': 'https://www.onclive.com/view/azd4635-plus-durvalumab-or-oleclumab-has-minimal-clinical-activity-in-mcrpc', 'title': 'AZD4635 Plus Durvalumab or Oleclumab Has Minimal Clinical Activity in mCRPC', 'source': 'OncLive', 'date': 'Sep 26, 2022', 'snippet': 'The addition of AZD4635 to durvalumab or oleclumab did not elicit \nsignificant responses in heavily pretreated patients with metastatic...', 'thumbnail': 'https://serpapi.com/searches/6721e1b96ad3c98a9f93dc22/images/1f3537b1a6c062fd4422bf24f633408b1a08fb74675d282e2647b9a4df06642c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5966070294380188}",,,,,,,,,,['neutral'],neutral,1
NCT05224531,"{'position': 1, 'link': 'https://pulmonaryhypertensionnews.com/news/cereno-pah-investigational-candidate-cs1-granted-compassionate-use/', 'title': ""Cereno's PAH investigational candidate CS1 granted compassionate use"", 'source': 'Pulmonary Hypertension News', 'date': 'Feb 2, 2024', 'snippet': ""The FDA has approved the use of Cereno Scientific's CS1 in an extension of \nthe ongoing Phase 2 trial testing the therapy in people with PAH."", 'thumbnail': 'https://serpapi.com/searches/6721e1d6f3cbfaeee3c380bc/images/a82db1cc5914ee1a7686f0e47f65d6cc498e884629ebe64c5602ae403ee89177.png', 'sentiment': 'neutral', 'sentiment_prob': 0.682741641998291}",,,,,,,,,,['neutral'],neutral,1
NCT03452228,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02222-w', 'title': 'Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial', 'source': 'Nature', 'date': 'Mar 6, 2023', 'snippet': 'This phase 2 trial (NCT03452228) evaluated evinacumab (angiopoietin-like 3 \ninhibitor) in three cohorts of patients with sHTG.', 'thumbnail': 'https://serpapi.com/searches/6721e1e8d910390616b32315/images/f95ec0bd04b62fa6e3a7ec954e69feeacb6823aab712290ee607e01368f7064b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8509107232093811}",,,,,,,,,,['neutral'],neutral,1
NCT02770807,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20240815940181/en/Quince-Therapeutics-Announces-The-Lancet-Neurology-Publication-of-Phase-3-ATTeST-Clinical-Trial-Data-Evaluating-EryDex-for-the-Treatment-of-Ataxia-Telangiectasia-A-T', 'title': 'Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)', 'source': 'Business Wire', 'date': 'Aug 15, 2024', 'snippet': 'The results of this study demonstrate the encouraging efficacy and safety \nprofile of our lead asset, EryDex, for the treatment of patients with AT.', 'thumbnail': 'https://serpapi.com/searches/6721e2520d379f2035abe2c2/images/0ec50457f686f319ce18630085ff2dce1b4452a3243ef0cb307167f16390ff11.png', 'sentiment': 'positive', 'sentiment_prob': 0.5140594244003296}",,,,,,,,,,['positive'],positive,1
NCT02456584,"{'position': 1, 'link': 'https://www.researchgate.net/publication/348670729_Clinical_trial_to_evaluate_pharmacokinetics_and_pharmacodynamics_of_medroxyprogesterone_acetate_after_subcutaneous_administration_of_Depo-Provera', 'title': '(PDF) Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera', 'source': 'ResearchGate', 'date': 'Feb 4, 2021', 'snippet': 'PDF | Objective To evaluate the pharmacokinetics and pharmacodynamics of \nmedroxyprogesterone acetate after a single subcutaneous injection in the.', 'thumbnail': 'https://serpapi.com/searches/6721e253a32436e97b51e473/images/4205906164494f28744294d6d8375c93570586b5da6c52f32448423a28b90929.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9124823212623596}",,,,,,,,,,['neutral'],neutral,1
NCT00296322,"{'position': 1, 'link': 'https://www.nature.com/articles/bjc201386', 'title': 'Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)', 'source': 'Nature', 'date': 'Feb 28, 2013', 'snippet': 'This phase 3 study evaluated the efficacy of new adjuvant chemotherapy \n(MFP), which intensified the mitomycin-C (MMC) plus short-term \ndoxifluridine (Mf) for...', 'thumbnail': 'https://serpapi.com/searches/6721e29dd11a89f6ae7e83e8/images/444670d8015fc2f9fcb1c157cd9394f29ee3f8ec7f6c02b3815e9999e35721b3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8950435519218445}",,,,,,,,,,['neutral'],neutral,1
NCT00543543,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1405044', 'title': 'A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women', 'source': 'The New England Journal of Medicine', 'date': 'Feb 19, 2015', 'snippet': 'The investigational 9-valent viruslike particle vaccine against human \npapillomavirus (HPV) includes the HPV types in the quadrivalent HPV...', 'thumbnail': 'https://serpapi.com/searches/6721e2a31adaf494051cbdc0/images/b44bda8c0fc6a499ca45492e62a79b9271e7eccb43ccb917521e00052037dc5c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8380662202835083}",,,,,,,,,,['neutral'],neutral,1
NCT03226678,"{'position': 1, 'link': 'https://coldagglutininnews.com/news/experimental-cad-therapy-pegcetacoplan-halted-developers/', 'title': 'Experimental CAD therapy pegcetacoplan halted by developers', 'source': 'Cold Agglutinin Disease News', 'date': 'Mar 7, 2024', 'snippet': 'Apellis Pharmaceuticals and Swedish Orphan Biovitrum (Sobi) have stopped \nthe clinical development of the experimental therapy pegcetacoplan for cold \nagglutinin...', 'thumbnail': 'https://serpapi.com/searches/6721e3a0c1c8ddf3d9251fa5/images/bf672af1f9344cb7f0ca0b2b949ee7c545460f16053bf613ab89927cca0ecf97.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5445611476898193}","{'position': 2, 'link': 'https://coldagglutininnews.com/news/cascade-trial-seeks-enroll-57-patients-us-europe-japan/', 'title': 'CASCADE trial seeks to enroll up to 57 patients in US, Europe, Japan', 'source': 'Cold Agglutinin Disease News', 'date': 'Feb 24, 2023', 'snippet': 'Enrollment is underway in a Phase 3 clinical trial testing the \ninvestigational therapy pegcetacoplan in adults with primary cold \nagglutinin disease (CAD).', 'thumbnail': 'https://serpapi.com/searches/6721e3a0c1c8ddf3d9251fa5/images/bf672af1f9344cb7cde61184c261be3fe125945d18827144d66e34361140fe34.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8906036019325256}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT03542838,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2023/09/07/2739412/0/en/Sorrento-Therapeutics-Announces-Positive-Phase-2a-Clinical-Trial-Results-for-Resiniferatoxin-RTX-for-the-Treatment-of-Knee-Pain-in-Moderate-to-Severe-Osteoarthritis-of-the-Knee-OAK.html', 'title': 'Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients', 'source': 'GlobeNewswire', 'date': 'Sep 7, 2023', 'snippet': 'All study objectives were met, demonstrating safety across dose groups and \nconfirming efficacy and durability at the selected doses against...', 'thumbnail': 'https://serpapi.com/searches/6721e3dc20e6eb9381df0055/images/2e64b1ce03ea5a859981b2a63fc9251b6c590cf62458d0de12604dbd1f88df4b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6346057057380676}",,,,,,,,,,['neutral'],neutral,1
NCT03511664,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2107322', 'title': 'Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jun 23, 2021', 'snippet': 'Lutetium-177 ( 177 Lu)–PSMA-617 is a radioligand therapy that delivers \nbeta-particle radiation to PSMA-expressing cells and the surrounding \nmicroenvironment.', 'thumbnail': 'https://serpapi.com/searches/6721e3de9f8bfc043801a47b/images/1c644207db6743f2926f0902a179bac1a73756d6ad67847c31eac1911f2de819.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8383318781852722}","{'position': 2, 'link': 'http://www.urotoday.com/conference-highlights/asco-2021/asco-2021-prostate-cancer/130016-asco-2021-vision.html', 'title': 'ASCO 2021: Phase III Study of Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)', 'source': 'UroToday', 'date': 'Jun 6, 2021', 'snippet': 'ASCO plenary VISION study, VISION Michael Morris, Phase III VISION study \nVISION 177Lu-PSMA-617, VISION targeted radioligand therapy in patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/6721e3de9f8bfc043801a47b/images/1c644207db6743f2f263d2b04e2bf76c08620f13e3f57e0b4cca66cefb65d468.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9214782118797302}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/fda-approves-177lu-psma-617-for-pretreated-psma-metastatic-castration-resistant-prostate-cancer', 'title': 'FDA Approves 177Lu-PSMA-617 for Pretreated PSMA+ Metastatic Castration-Resistant Prostate Cancer', 'source': 'Cancer Network', 'date': 'Mar 23, 2022', 'snippet': 'Based on data from the phase 3 VISION trial, 177Lu-PSMA-617 may now be used \nto treat patients who were previously treated with androgen...', 'thumbnail': 'https://serpapi.com/searches/6721e3de9f8bfc043801a47b/images/1c644207db6743f2d0eac48b140852044f338dfdd236531398fd5889919004a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9058717489242554}","{'position': 4, 'link': 'https://www.targetedonc.com/view/adding-lupsma-to-standard-treatment-extends-os-delays-disease-progression-in-mcrpc', 'title': 'Adding LuPSMA to Standard Treatment Extends OS, Delays Disease Progression in mCRPC', 'source': 'Targeted Oncology', 'date': 'Aug 15, 2021', 'snippet': 'Adding the targeted radioligand LuPSMA to standard of care therapy for \npatients with metastatic castration resistant prostate cancer after...', 'thumbnail': 'https://serpapi.com/searches/6721e3de9f8bfc043801a47b/images/1c644207db6743f23afdc938132dfeb9d7aab3f6169a157dd86dd64d4e20a0cd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6937063932418823}","{'position': 5, 'link': 'https://dailynews.ascopubs.org/do/evaluating-current-role-psma-pet-utility-availability-and-challenges', 'title': 'Evaluating the Current Role of PSMA PET: Utility, Availability, and Challenges', 'source': 'ASCO Daily News', 'date': 'Mar 2, 2022', 'snippet': 'Although the U.S. Food and Drug Administration (FDA) approved a \nprostate-specific membrane antigen (PSMA) imaging agent in 1996...', 'thumbnail': 'https://serpapi.com/searches/6721e3de9f8bfc043801a47b/images/1c644207db6743f24f7385bdb07c36c904338962250bd4f55d710fa33deeff60.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.930873453617096}","{'position': 6, 'link': 'https://www.cancernetwork.com/view/fda-expands-indication-for-illuccix-for-psma-radioligand-selection-in-prostate-cancer', 'title': 'FDA Expands Indication for Illuccix for PSMA Radioligand Selection in Prostate Cancer', 'source': 'Cancer Network', 'date': 'Mar 16, 2023', 'snippet': 'Use of a kit that prepares for gallium Ga 68 gozetotide injection in the \nphase 3 VISION study affirms its ability to identify patients who...', 'thumbnail': 'https://serpapi.com/searches/6721e3de9f8bfc043801a47b/images/1c644207db6743f289b71c2ee45a8ddbe4c22db7c53b55f6d752796d8721ec13.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8985714912414551}",,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02635776,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1812856', 'title': 'AR101 Oral Immunotherapy for Peanut Allergy', 'source': 'The New England Journal of Medicine', 'date': 'Nov 18, 2018', 'snippet': 'AR101 is a new peanut-derived, oral biologic drug that delivers a target \ndaily maintenance dose of 300 mg of peanut protein with a characterized \nprotein...', 'thumbnail': 'https://serpapi.com/searches/6721e42e577da59cf36ce083/images/feddbb2f6d0b5540a872e7286336e36cba4457d6abfa2780746ff90162b7f481.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8246422410011292}",,,,,,,,,,['neutral'],neutral,1
NCT03824080,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-023-02029-1', 'title': 'Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial', 'source': 'Nature', 'date': 'Sep 21, 2023', 'snippet': 'Hypomethylating agents (HMAs) are the standard of care for patients with \nhigher-risk myelodysplastic neoplasms (HR-MDS) and, in combination...', 'thumbnail': 'https://serpapi.com/searches/6721e43b90adce9b27b70ecf/images/c5104f5ee502ce2724a124174e9bc0a89440d995b53cb17d6421ab7b0e8cbce0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7940686345100403}",,,,,,,,,,['neutral'],neutral,1
NCT04875962,"{'position': 1, 'link': 'https://www.nature.com/articles/s41531-023-00552-7', 'title': 'In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease', 'source': 'Nature', 'date': 'Jul 17, 2023', 'snippet': 'Minzasolmin (UCB0599) is an orally bioavailable and brain-penetrant small \nmolecule ASYN misfolding inhibitor in clinical development as a \ndisease-modifying...', 'thumbnail': 'https://serpapi.com/searches/6721e492b9458d9fbfbdb767/images/b658b42c365f55c1974eb90d751a86843baaafeee121ecb47f728a8d15026de6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8114534020423889}",,,,,,,,,,['neutral'],neutral,1
NCT04294667,"{'position': 1, 'link': 'https://investors.biogen.com/news-releases/news-release-details/ucb-and-biogen-announce-positive-topline-results-phase-3-study', 'title': 'UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024', 'source': 'Biogen', 'date': '1 month ago', 'snippet': 'Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical \nimprovement in moderate-to-severe systemic lupus erythematosus;...', 'thumbnail': 'https://serpapi.com/searches/6721e4b78b84c46fd6164220/images/c56b2e21293837bac5984076cf541091e56bf8b6912dd6edd666261faa94f258.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6715901494026184}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/news/ucb-biogen-dapirolizumab-pegol-data-trial/', 'title': 'UCB and Biogen lupus drug succeeds in Phase III, but data yet to be released', 'source': 'Clinical Trials Arena', 'date': '1 month ago', 'snippet': ""UCB and Biogen's drug dapirolizumab pegol has met the primary endpoint of \nimprovement in disease activity in lupus patients."", 'thumbnail': 'https://serpapi.com/searches/6721e4b78b84c46fd6164220/images/c56b2e21293837ba74cb0dc13008b209b8f6ab98bd4b37f5621db0b7b801c1e1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5893003344535828}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT04785612,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2116154', 'title': 'Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study', 'source': 'The New England Journal of Medicine', 'date': 'Jun 22, 2022', 'snippet': 'RSVpreF vaccine was effective against symptomatic RSV infection and viral \nshedding. No evident safety concerns were identified.', 'thumbnail': 'https://serpapi.com/searches/6721e4b9690bb92396ca29d2/images/17d3cfc01286da2e1c82fdbe373267bb6c3d77943ac2718234ec481fe06699b3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7741875052452087}",,,,,,,,,,['neutral'],neutral,1
NCT00333840,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1609324', 'title': 'Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'Mar 9, 2017', 'snippet': 'Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for \npatients with chronic myeloid leukemia (CML).', 'thumbnail': 'https://serpapi.com/searches/6721e4d724296a3c10e5ad70/images/c92474518807fb748645c3afcf192204c993df6e4f4afc41ecead025c42d7b81.png', 'sentiment': 'positive', 'sentiment_prob': 0.6723223924636841}",,,,,,,,,,['positive'],positive,1
NCT03633617,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2205982', 'title': 'Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis', 'source': 'The New England Journal of Medicine', 'date': 'Dec 21, 2022', 'snippet': 'We conducted a three-part, phase 3 trial in which patients 12 years of age \nor older underwent randomization in a 1:1 ratio to receive...', 'thumbnail': 'https://serpapi.com/searches/6721e4f7e8735a1451f2d1eb/images/d6c264e4b791da274f987ea582be99178d576efe3bd6949db4f43fb91f8d0b0b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.871994137763977}",,,,,,,,,,['neutral'],neutral,1
NCT02186873,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2018/01/22/simponi-aria-for-treating-ankylosing-spondylitis-efficient-safe-phase-3-trial-shows/', 'title': 'Ankylosing Spondylitis Therapy Simponi Aria Is Safe, Efficient, Trial Shows', 'source': 'Ankylosing Spondylitis News', 'date': 'Jan 22, 2018', 'snippet': 'Read about the results of a Phase 3 clinical trial showing that intravenous \ninfusion of Simponi Aria significantly improved ankylosing...', 'thumbnail': 'https://serpapi.com/searches/6721e51b17b10e7c5036f801/images/ac9c7d5744a025154dd41427a0eb88a5534f00050442073740a41ee52237e05e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6997513771057129}",,,,,,,,,,['positive'],positive,1
NCT04001517,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-32944-3', 'title': 'Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration', 'source': 'Nature', 'date': 'Sep 21, 2022', 'snippet': 'The endosome-associated GTPase Rab5 is a central player in the molecular \nmechanisms leading to degeneration of basal forebrain cholinergic...', 'thumbnail': 'https://serpapi.com/searches/6721e52d2da98308910ad670/images/a70f16473666115340d4ac49b17f04649d6b169272b8f06559b1ea3d6e48f938.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8358699679374695}",,,,,,,,,,['neutral'],neutral,1
NCT01564784,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1509277', 'title': 'Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'Jun 12, 2016', 'snippet': 'The rate of complete remission was higher with inotuzumab ozogamicin than \nwith standard therapy, and a higher percentage of patients in the \ninotuzumab...', 'thumbnail': 'https://serpapi.com/searches/6721e53af963e7b1d30971b3/images/5a3ec64994b0a327d88106d363311bb9405d246bc2998113bf624bf4c53a22eb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7057051062583923}",,,,,,,,,,['neutral'],neutral,1
NCT04761822,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/nih-begins-study-allergic-reactions-moderna-pfizer-biontech-covid-19-vaccines', 'title': 'NIH begins study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Apr 7, 2021', 'snippet': 'Adults interested in participating in this trial should visit \nClinicalTrials.gov and search under study identifier NCT04761822 for \nstudy...', 'thumbnail': 'https://serpapi.com/searches/6721e55a7ac73169f8527e6b/images/d3eb61f8c9eb2c413ae9c189e31fcd02a1dd193d013aab4aae3ad4db36155a21.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8997783064842224}",,,,,,,,,,['neutral'],neutral,1
NCT02201849,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/vumerity-diroximel-fumarate/', 'title': 'Vumerity (diroximel fumarate) in MS | Uses, side effects, and more...', 'source': 'Multiple Sclerosis News Today', 'date': 'May 3, 2022', 'snippet': 'Vumerity (diroximel fumarate) is an oral treatment for people with \nrelapsing forms of MS. Learn about its uses, indications, and side...', 'thumbnail': 'https://serpapi.com/searches/6721e57abb55ff271c7d1be5/images/d7110ef3d7b42fb848e2704fbfb98325be6368aa6c6517086eba0c89ef7f340a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9147942066192627}",,,,,,,,,,['neutral'],neutral,1
NCT02602509,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-018-31590-4', 'title': 'Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model', 'source': 'Nature', 'date': 'Sep 10, 2018', 'snippet': 'COX-2 inhibition may be of benefit in the treatment of tuberculosis (TB) \nthrough a number of pathways including efflux pump inhibition...', 'thumbnail': 'https://serpapi.com/searches/6721e58de1c27656915c9a93/images/fe36a535187dce2f75b097b951c4729a5f1daae3d614ddaabcf913afbdf67087.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8828105330467224}",,,,,,,,,,['neutral'],neutral,1
NCT02700529,"{'position': 1, 'link': 'https://lungdiseasenews.com/2018/01/19/ubenimex-development-treat-pulmonary-arterial-hypertension-ends/', 'title': 'Ubenimex Development to Treat Pulmonary Arterial Hypertension Ends', 'source': 'Lung Disease News', 'date': 'Jan 19, 2018', 'snippet': ""Eiger BioPharmaceuticals' ubenimex failed to show improvement in pulmonary \nvascular resistance or exercise capacity in the Phase 2 LIBERTY..."", 'thumbnail': 'https://serpapi.com/searches/6721e59b7ef9fa1a316667f1/images/d661cf8618f491fbc5840ee3fb17d4743686f4f30467c194b72d6cadb24101f2.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6212904453277588}",,,,,,,,,,['negative'],negative,0
NCT02395666,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/norgine-bv-submits-marketing-authorisation-application-via-project-orbis-for-eflornithine-difluoromethylornithine-dfmo-in-high-risk-neuroblastoma-302116815.html', 'title': 'Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma', 'source': 'PR Newswire', 'date': 'Apr 15, 2024', 'snippet': 'PRNewswire/ -- Norgine B.V. today announced its first marketing \nauthorisation application submissions on 10 April 2024, seeking approval \nfor...', 'thumbnail': 'https://serpapi.com/searches/6721e5c3358539d6676d5e07/images/e908c2fafd08aefc1f351d44458c026334a5c51c513b1756c7f0fd3258c796cf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9145628213882446}","{'position': 2, 'link': 'https://www.contemporarypediatrics.com/view/fda-approves-eflornithine-for-pediatric-patients-with-high-risk-neuroblastoma', 'title': 'FDA approves eflornithine for pediatric patients with high-risk neuroblastoma', 'source': 'Contemporary Pediatrics', 'date': 'Dec 14, 2023', 'snippet': 'The FDA has approved eflornithine (IWILFIN; US WorldMeds) 192 mg tablets to \nreduce the risk of relapse in adult and pediatric patients with high-risk...', 'thumbnail': 'https://serpapi.com/searches/6721e5c3358539d6676d5e07/images/e908c2fafd08aefc28c893953cf06da5a8f0fff1ec8df3d8453a0bb92ca66895.png', 'sentiment': 'neutral', 'sentiment_prob': 0.815450131893158}","{'position': 3, 'link': 'https://www.cancerhealth.com/blog/fda-approves-iwilfin-highrisk-neuroblastoma', 'title': 'FDA Approves Iwilfin for High-Risk Neuroblastoma', 'source': 'Cancer Health', 'date': 'Dec 18, 2023', 'snippet': 'The Food and Drug Administration approved eflornithine (Iwilfin, USWM, LLC) \nto reduce the risk of relapse in adult and pediatric patients with \nhigh-risk...', 'thumbnail': 'https://serpapi.com/searches/6721e5c3358539d6676d5e07/images/e908c2fafd08aefcf544c78378c6f2e5227256623f8212630a68b90da379350f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8126423358917236}","{'position': 4, 'link': 'https://www.thepharmaletter.com/pharmaceutical/us-worldmeds-nabs-fda-approval-for-eflornithine-in-neuroblastoma', 'title': 'US WorldMeds nabs FDA approval for eflornithine in neuroblastoma', 'source': 'The Pharma Letter', 'date': 'Dec 15, 2023', 'snippet': 'More on this story... FDA vote bodes well for US WorldMeds. Pharmaceutical \n· FDA vote bodes well for US WorldMeds. 5 October 2023.', 'thumbnail': 'https://serpapi.com/searches/6721e5c3358539d6676d5e07/images/e908c2fafd08aefcbfa10f48f56b837521fb2a5cbce5cf7a6d52d68eec0a145b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5894373059272766}","{'position': 5, 'link': 'https://www.empr.com/home/news/iwilfin-an-oral-maintenance-therapy-for-high-risk-neuroblastoma-gets-fda-approval/', 'title': 'Iwilfin, an Oral Maintenance Therapy for High-Risk Neuroblastoma, Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Dec 14, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Iwilfin™ (eflornithine) \nto reduce the risk of relapse in adult and pediatric patients...', 'thumbnail': 'https://serpapi.com/searches/6721e5c3358539d6676d5e07/images/e908c2fafd08aefc3bee780971788ac2e7e92898bcc403f9481f7d80591ef3cf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6843135356903076}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01967173,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1905560', 'title': 'Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 25, 2019', 'snippet': 'Data indicate that patients with inadequately controlled asthma benefit \nmore from addition of a long-acting beta-agonist (LABA) than from \nincreased...', 'thumbnail': 'https://serpapi.com/searches/6721e60913e5d81f5e774890/images/742202b342fd998748127f4d40c455041e8cc123bddcf3f3dc115a2766c45e6e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.560771107673645}",,,,,,,,,,['neutral'],neutral,1
NCT04402060,"{'position': 1, 'link': 'https://www.nature.com/articles/s41577-021-00665-1', 'title': 'The state of complement in COVID-19', 'source': 'Nature', 'date': 'Dec 15, 2021', 'snippet': 'Hyperactivation of the complement and coagulation systems is recognized as \npart of the clinical syndrome of COVID-19.', 'thumbnail': 'https://serpapi.com/searches/6721e68990adce9b27b71078/images/3bf00b819ba8452d41a1f6b593955e0e680942bd195a35514c9beb056d33f7ba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.706369161605835}",,,,,,,,,,['neutral'],neutral,1
NCT04336410,"{'position': 1, 'link': 'https://www.technologynetworks.com/biopharma/blog/13-covid-19-vaccines-are-in-human-clinical-trials-what-are-they-336738', 'title': '13 COVID-19 Vaccines Are in Human Clinical Trials – What Are They?', 'source': 'Technology Networks', 'date': 'Jun 29, 2020', 'snippet': 'The World Health Organization recognizes that, as of June 22, there are \nover 140 vaccines against COVID-19 in various stages of development.', 'thumbnail': 'https://serpapi.com/searches/6721e6901397bae53c6be0ad/images/17f3641db732cac6c128c03b1dd6faf8686f4bc70004e23827791455c502880d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9003502130508423}",,,,,,,,,,['neutral'],neutral,1
NCT01626495,"{'position': 1, 'link': 'https://www.nature.com/articles/s41417-021-00418-1', 'title': 'Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study', 'source': 'Nature', 'date': 'Jan 5, 2022', 'snippet': 'In this review different generations, challenges, and clinical studies \nrelated to chimeric antigen receptor (CAR) T-cells for ALL treatment are \ndiscussed.', 'thumbnail': 'https://serpapi.com/searches/6721e6929109867ed4fff633/images/3b0a5909b15fab98be423f16ebc9a8523d90d915ef041b86e8c6e9557d749b8a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8729193210601807}",,,,,,,,,,['neutral'],neutral,1
NCT02609828,"{'position': 1, 'link': 'https://www.oncologynurseadvisor.com/news/tanezumab-cancerp-ain-no-longer-development/', 'title': 'Tanezumab Can Reduce Cancer Pain but Is No Longer Under Development', 'source': 'Oncology Nurse Advisor', 'date': 'Jul 17, 2023', 'snippet': 'Results of a phase 3 trial suggest that tanezumab can reduce pain in cancer \npatients, but the drug is no longer under development.', 'thumbnail': 'https://serpapi.com/searches/6721e6a32fab6260abe24136/images/90d170105aaef22dc0d17d9f9c1831f2c10772105241a7bc15c99fd8df069f80.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5751845836639404}",,,,,,,,,,['neutral'],neutral,1
NCT02468193,"{'position': 1, 'link': 'https://cushingsdiseasenews.com/news/isturisa-effective-in-treating-cushings-syndrome-other-than-cushings-disease-phase-2-trial-shows/', 'title': 'Isturisa Effective in Treating Cushing’s Syndrome Other Than...', 'source': ""Cushing's Disease News"", 'date': 'Jul 1, 2020', 'snippet': ""Combined with results from previous trials in Cushing's disease, the data \nshows Isturisa is a safe and effective therapy option."", 'thumbnail': 'https://serpapi.com/searches/6721e6acbe80137f75540209/images/3f4a2e7e1a1000241a5d1adfa6197b8eeae1eadd9d5195d117d6a4ece57e6933.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.63901287317276}",,,,,,,,,,['neutral'],neutral,1
NCT03752905,"{'position': 1, 'link': 'https://epidermolysisbullosanews.com/news/phase-2-trial-of-ptr-01-for-rdeb-doses-first-participant/', 'title': 'PTR-01 Protein Replacement Given to 1st RDEB Patient in Phase 2 Trial', 'source': 'Epidermolysis Bullosa News', 'date': 'Oct 28, 2020', 'snippet': 'A Phase 2 clinical trial has dosed its first participant with PTR-01, a \npotential protein replacement drug for recessive dystrophic...', 'thumbnail': 'https://serpapi.com/searches/6721e6b6d9c3e646d94a9d83/images/1ef2c0503ebab7b4e84ab167627bbc89f072c42a57da1f741abf956cba3dd432.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8609854578971863}",,,,,,,,,,['neutral'],neutral,1
NCT04607980,"{'position': 1, 'link': 'https://www.empr.com/home/news/generics-news/interchangeable-biosimilar-wezlana-gets-fda-approval/', 'title': 'Interchangeable Biosimilar Wezlana Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Nov 1, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Wezlana \n(ustekinumab-auub), an interchangeable biosimilar to Stelara (ustekinumab).', 'thumbnail': 'https://serpapi.com/searches/6721e6b7740bdba705d92ee1/images/e86761b106a048a16e1a665143716388a466347b8e606c1b9e125f7157e5c6a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6312623620033264}",,,,,,,,,,['neutral'],neutral,1
NCT04773600,"{'position': 1, 'link': 'https://www.medcentral.com/dermatology/fda-approves-non-steroidal-roflumilast-cream-for-atopic-dermatitis', 'title': 'FDA Approves Non-Steroidal Roflumilast Cream for Atopic Dermatitis', 'source': 'MedCentral', 'date': 'Jul 9, 2024', 'snippet': 'The US Food and Drug Administration (FDA) approved Zoryve (roflumilast \n0.15% cream, Arcutis Biotherapeutics) for adults and children aged 6 years \nand older...', 'thumbnail': 'https://serpapi.com/searches/6721e718d72128f26f3271ce/images/7dcf3534e713a1b869163d8ac6003b3347b5720969a41392ae9d7344f8e4a447.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6863114833831787}","{'position': 2, 'link': 'https://www.contemporarypediatrics.com/view/fda-accepts-snda-for-roflumilast-cream-0-15-to-treat-atopic-dermatitis', 'title': 'FDA accepts sNDA for roflumilast cream 0.15% to treat atopic dermatitis', 'source': 'Contemporary Pediatrics', 'date': 'Nov 29, 2023', 'snippet': 'The FDA has accepted a supplemental New Drug Application (sNDA) for \nroflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in...', 'thumbnail': 'https://serpapi.com/searches/6721e718d72128f26f3271ce/images/7dcf3534e713a1b842b2fa549d082cd06380b694dcf3d68e9b34b66f5a88aa82.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8596817851066589}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05504395,"{'position': 1, 'link': 'https://praderwillinews.com/news/pws-therapy-csti-500-poised-phase-2-clinical-testing/', 'title': 'CSTI-500 poised for Phase 2 clinical testing after positive Phase 1 safety data', 'source': 'Prader-Willi Syndrome News', 'date': 'Jun 1, 2023', 'snippet': 'CSTI-500, an experimental therapy by ConSynance Therapeutics, showed \nfavorable safety and pharmacological profile in a Phase 1 clinical...', 'thumbnail': 'https://serpapi.com/searches/6721e7713c9575674df0e631/images/68962b78ea1b8595c2394c2d5a49e991a9600141e45370a3bbe9a4ed1f178164.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7993170022964478}",,,,,,,,,,['neutral'],neutral,1
NCT03558087,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02568-1', 'title': 'Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial', 'source': 'Nature', 'date': 'Oct 2, 2023', 'snippet': 'We initiated a phase 2 study in which patients with MIBC received four \ncycles of gemcitabine, cisplatin, plus nivolumab followed by clinical \nrestaging.', 'thumbnail': 'https://serpapi.com/searches/6721e7a374f0a452ea2b34af/images/cb4e124f8ea2c09a2bb7c64defb7cf29e8f9a7324b27be420734cccde6c20390.png', 'sentiment': 'neutral', 'sentiment_prob': 0.909838080406189}",,,,,,,,,,['neutral'],neutral,1
NCT00451451,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1206328', 'title': 'Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 20, 2012', 'snippet': 'BG-12 (dimethyl fumarate) is in development as an oral treatment for \nrelapsing–remitting multiple sclerosis, which is commonly treated with...', 'thumbnail': 'https://serpapi.com/searches/6721e8868de63cccedebabb6/images/da1cbca206ad04e4da639b81175a290b228c00fb09913d491291cd235b16a578.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9032967686653137}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/tecfidera-generics-availability-europe/', 'title': 'Generics of Tecfidera not available in Europe until at least 2025', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 22, 2023', 'snippet': 'The European Commission withdraws its marketing authorizations for generic \nversions of Tecfidera (dimethyl fumarate), a RRMS oral therapy.', 'thumbnail': 'https://serpapi.com/searches/6721e8868de63cccedebabb6/images/da1cbca206ad04e4aea69279392c860f4bdc76d21f0236a4c1373cb4921543b1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5986100435256958}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04835519,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-50485-9', 'title': 'C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial', 'source': 'Nature', 'date': 'Jul 22, 2024', 'snippet': 'We conduct an open-label, non-randomized, single-arm, phase I trial of \nC-JUN-overexpressing CAR-T in AML (NCT04835519) with safety and efficacy as \nprimary and...', 'thumbnail': 'https://serpapi.com/searches/6721e8a37a12fd120d0b9590/images/161d517d3ca3881101b3b521c56a2804dbcc641aa8e6d0edf349f57eb27019e3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8961225152015686}",,,,,,,,,,['neutral'],neutral,1
NCT00229944,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa054493', 'title': 'Single-Dose Azithromycin for the Treatment of Cholera in Adults', 'source': 'The New England Journal of Medicine', 'date': 'Jun 8, 2006', 'snippet': 'We conducted a double-blind, randomized trial comparing the equivalence of \nazithromycin and ciprofloxacin (each given in a single 1-g dose...', 'thumbnail': 'https://serpapi.com/searches/6721e8caa5d70237c470335e/images/ab5312c3ab4681bd29923ca7186231d46eac530211d2951f10853c869110c2bc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8981490731239319}",,,,,,,,,,['neutral'],neutral,1
NCT04314934,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/early-alzheimers-anavex-2-73-slows-cognitive-decline-neurodegeneration/', 'title': 'Neurodegeneration and cognitive decline slow with Anavex 2-73', 'source': ""Alzheimer's News Today"", 'date': 'Sep 15, 2023', 'snippet': ""Anavex 2-73 (blarcamesine) significantly slows cognitive and functional \ndecline in people with early Alzheimer's disease, according to a new data \nanalysis."", 'thumbnail': 'https://serpapi.com/searches/6721e8cb460b156b6b84c5d1/images/3ba1bbd9c8e4f2c4abcecf4228e59647500af339768a102cbf9b289c62d416aa.png', 'sentiment': 'negative', 'sentiment_prob': 0.6674517393112183}",,,,,,,,,,['negative'],negative,0
NCT03439657,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0264410X24001944', 'title': 'Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview', 'source': 'ScienceDirect.com', 'date': 'Mar 19, 2024', 'snippet': 'The adjuvanted recombinant zoster vaccine (RZV; Shingrix®, GSK) is a \nsubunit vaccine that has been approved for the prevention of herpes...', 'thumbnail': 'https://serpapi.com/searches/6721e7b7740bdba705d92fa6/images/cc30a536b54dba15d7f0d04066599205894e9b159a56b76655879be93b1df219.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9015368223190308}",,,,,,,,,,['neutral'],neutral,1
NCT01949805,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-023-02008-6', 'title': 'Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment', 'source': 'Nature', 'date': 'Aug 26, 2023', 'snippet': 'Patients with polycythemia vera (PV), an incurable Philadelphia-negative \nmyeloproliferative neoplasm, have shortened survival due to...', 'thumbnail': 'https://serpapi.com/searches/6721e7e77a12fd124142c595/images/4ae038e34f76d30b20e45bdf389f134ce347ebfe094b1dd374c7268b972945ea.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5681083798408508}","{'position': 2, 'link': 'https://www.nature.com/articles/s41408-018-0133-0', 'title': 'Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo', 'source': 'Nature', 'date': 'Oct 4, 2018', 'snippet': 'This study shows that ropeginterferon has a potent targeted activity \nagainst JAK2-mutant cells and is able to drastically reduce the proportion \nof malignant...', 'thumbnail': 'https://serpapi.com/searches/6721e7e77a12fd124142c595/images/4ae038e34f76d30b9c05239ddfd03bf2937e5f1127ce9fdae2aeefa2e5bbfa1d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7643702030181885}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01750918,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Proteomics-data-analysis-confirms-observation-done-at-the-transcriptomic-level-A_fig2_304610135', 'title': 'Figure 4. Proteomics data analysis confirms observation done at the...', 'source': 'ResearchGate', 'date': 'Feb 8, 2018', 'snippet': 'Proteomics data analysis confirms observation done at the transcriptomic \nlevel. A, Analysis of proteomic and phosphoproteomic RPPA data for TCGA \nBRAF mutant...', 'thumbnail': 'https://serpapi.com/searches/6721e8136531cb343cde4aee/images/0b8d39f5b1013c00698050b8ac1dd3f5e555b59b985c5db90fc1c0b95f88a20a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9301082491874695}",,,,,,,,,,['neutral'],neutral,1
NCT03117920,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S2405844024003669', 'title': 'Mechanisms of cancer cell death induction by triptolide: A comprehensive overview', 'source': 'ScienceDirect.com', 'date': 'Jan 30, 2024', 'snippet': 'Triptolide is linked to the induction of death of cancerous cells by \ntriggering cellular apoptosis via inhibiting heat shock protein expression \n(HSP70), and...', 'thumbnail': 'https://serpapi.com/searches/6721e851f41044dc7df5883d/images/d2b63c1fa73c5486618e18b1125eec99f5a39ae2741b4607a94897c24871467c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5419272184371948}",,,,,,,,,,['neutral'],neutral,1
NCT02388919,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.12977', 'title': 'Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303', 'source': 'Wiley Online Library', 'date': 'Jan 21, 2019', 'snippet': 'Thoracic Cancer is an international oncology journal publishing basic, \ntranslational and applied clinical research in lung, esophageal,...', 'thumbnail': 'https://serpapi.com/searches/6721e8642da98308c43cb637/images/98e2743e2769ff15ff0d216dcc4510e6996eddc82e8af223e258c02baf5952c5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7376909852027893}",,,,,,,,,,['neutral'],neutral,1
NCT04567329,"{'position': 1, 'link': 'https://www.empr.com/home/news/miebo-a-prescription-eye-drop-for-dry-eye-disease-now-available/', 'title': 'Miebo, a Prescription Eye Drop for Dry Eye Disease, Now Available', 'source': 'Medical Professionals Reference', 'date': 'Sep 12, 2023', 'snippet': 'Miebo (perfluorohexyloctane ophthalmic solution) is now available for the \ntreatment of the signs and symptoms of dry eye disease.', 'thumbnail': 'https://serpapi.com/searches/6721e9ef08abe4e779954bda/images/8b9c9dd4d7812fc52a82f0267c4e5b84b3fda66992684afc338eae7e570ee396.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8633021116256714}",,,,,,,,,,['neutral'],neutral,1
NCT03941444,"{'position': 1, 'link': 'https://rettsyndromenews.com/news/anavex-2-73-shows-promise-rett-children-but-misses-trial-goal/', 'title': 'Anavex 2-73 shows promise for Rett children but misses trial goal', 'source': 'Rett Syndrome News', 'date': 'Jan 2, 2024', 'snippet': 'Treatment with Anavex 2-73 led to improvements in behavior for Rett \nsyndrome children, but a Phase 2/3 clinical trial failed to meet its...', 'thumbnail': 'https://serpapi.com/searches/6721e9f552a04e7b07184cb3/images/5d94fa4e7dba70866651116da61e872f93e4d636e0c47b0e02a326e0beb55cb5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5686342120170593}","{'position': 2, 'link': 'https://www.nature.com/articles/s41598-021-94079-7', 'title': 'Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy | Scientific Reports', 'source': 'Nature', 'date': 'Aug 25, 2021', 'snippet': 'Fragile X syndrome (FXS), a disorder of synaptic development and function, \nis the most prevalent genetic form of intellectual disability and...', 'thumbnail': 'https://serpapi.com/searches/6721e9f552a04e7b07184cb3/images/5d94fa4e7dba7086b38ab7c1a4895470593f62795c84c11676a2994ca1d657ce.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7516513466835022}","{'position': 3, 'link': 'https://rettsyndromenews.com/news/dosing-complete-anavex-2-73-rett-excellence-safety-trial-girls/', 'title': 'Anavex completes dosing in trial of Anavex 2-73 for Rett |...', 'source': 'Rett Syndrome News', 'date': 'Jun 14, 2023', 'snippet': 'Anavex has completed dosing all 92 girls with Rett syndrome taking part in \na Phase 2/3 clinical trial testing the safety of Anavex 2-73.', 'thumbnail': 'https://serpapi.com/searches/6721e9f552a04e7b07184cb3/images/5d94fa4e7dba7086d6d292edd06010104d7ff9a7f3eaf35ae1bd5f5ba0b16acc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7433744072914124}","{'position': 4, 'link': 'https://www.thepharmaletter.com/pharmaceutical/anavex-therapy-for-rett-syndrome-candidate-shows-promise-but-questions-remain', 'title': ""Anavex' therapy for Rett syndrome candidate shows promise, but questions remain"", 'source': 'The Pharma Letter', 'date': 'Feb 16, 2022', 'snippet': ""Anavex' therapy for Rett syndrome candidate shows promise, but questions \nremain. Pharmaceutical. 16 February 2022. anavex-big."", 'thumbnail': 'https://serpapi.com/searches/6721e9f552a04e7b07184cb3/images/5d94fa4e7dba7086df5ddfd4626e736a52d138f836be7393e00728c1df76e6ea.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8331822752952576}","{'position': 5, 'link': 'https://rettsyndromenews.com/news/phase-2-extension-trial-shows-sustained-benefits-anavex-2-73/', 'title': 'Phase 2 extension trial shows sustained benefits of Anavex 2-73 –...', 'source': 'Rett Syndrome News', 'date': 'Jul 5, 2023', 'snippet': 'The benefits of Anavex 2-73 observed in a Phase 2 clinical trial were \nsustained in an open-label extension phase.', 'thumbnail': 'https://serpapi.com/searches/6721e9f552a04e7b07184cb3/images/5d94fa4e7dba70865f2f9f1031cf91c3d93e6ac31fe97b0fdd5e2fb9b3319538.png', 'sentiment': 'positive', 'sentiment_prob': 0.8122766613960266}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT00364013,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1305275', 'title': 'Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Apr 28, 2018', 'snippet': 'Patients with metastatic colorectal cancer that harbors KRAS mutations in \nexon 2 do not benefit from anti–epidermal growth factor receptor (EGFR) \ntherapy.', 'thumbnail': 'https://serpapi.com/searches/6721eac048e6680fc667a1bd/images/8e1738026d4f2835bec1ac97e3df6270d99f5929192570b7e5f1677227cee038.png', 'sentiment': 'negative', 'sentiment_prob': 0.5422924757003784}",,,,,,,,,,['negative'],negative,0
NCT02549170,"{'position': 1, 'link': 'https://www.empr.com/home/news/hyqvia-reduces-relapse-in-chronic-inflammatory-demyelinating-polyradiculoneuropathy-trial/', 'title': 'Hyqvia Reduces Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Trial', 'source': 'Medical Professionals Reference', 'date': 'Jul 21, 2022', 'snippet': 'Topline data were announced from a phase 3 trial evaluating the efficacy \nand safety of Hyqvia® (immune globulin infusion 10% [human] with...', 'thumbnail': 'https://serpapi.com/searches/6721eac1dda9d9ba7d3b76fa/images/12819658aa301c96eed00a6676c96edc9e5a27670c49892fe1818815896f7f7a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7634502649307251}",,,,,,,,,,['neutral'],neutral,1
NCT03116113,"{'position': 1, 'link': 'https://investors.biogen.com/news-releases/news-release-details/biogen-announces-topline-results-phase-23-gene-therapy-study', 'title': 'Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP', 'source': 'Biogen', 'date': 'May 14, 2021', 'snippet': 'Biogen Inc. (Nasdaq: BIIB) today announced topline results from the Phase \n2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy \nbeing...', 'thumbnail': 'https://serpapi.com/searches/6721ead72a48821b6e0a40e8/images/be86e02987f2e995616c50d1077f6702ca727046531578c6246c16c386ba5a9c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9064289331436157}",,,,,,,,,,['neutral'],neutral,1
NCT06197217,"{'position': 1, 'link': 'https://www.nature.com/articles/s41421-024-00673-0', 'title': 'Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04 | Cell Discovery', 'source': 'Nature', 'date': 'Apr 9, 2024', 'snippet': 'Drug resistance poses a significant challenge in the development of \neffective therapies against SARS-CoV-2. Here, we identified two double...', 'thumbnail': 'https://serpapi.com/searches/6721eadba32436e9acd160b9/images/90dbbf555be6073c4743789c5450f518de629646c43596db25204086746cf387.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5293673276901245}",,,,,,,,,,['negative'],negative,0
NCT02918279,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1916038', 'title': 'A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity', 'source': 'The New England Journal of Medicine', 'date': 'Mar 31, 2020', 'snippet': 'Obesity is a chronic disease with limited treatment options in pediatric \npatients. Liraglutide may be useful for weight management in...', 'thumbnail': 'https://serpapi.com/searches/6721eaf87ec4aefacc6bb0c7/images/6d2c4db10ad37e97231808ea331d47d17682cc02b3f179311ac57b416296cabf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8442195653915405}",,,,,,,,,,['neutral'],neutral,1
NCT04411680,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20210308005639/en/Tanner-Pharma-Group-Expands-Ex-US-Access-Program-to-Provide-LEUKINE%C2%AE-for-Use-in-Patients-with-Respiratory-Illness-Associated-with-COVID-19', 'title': 'Tanner Pharma Group Expands Ex-US Access Program to Provide LEUKINE® for Use in Patients with Respiratory Illness Associated with COVID-19', 'source': 'Business Wire', 'date': 'Mar 8, 2021', 'snippet': 'Tanner Pharma Group Expands Ex-US Access Program to Provide LEUKINE® for \nUse in Patients with Respiratory Illness Associated with COVID-19.', 'thumbnail': 'https://serpapi.com/searches/6721eb2b98fad682bb4fd696/images/44a173005e96c9fb9bc82cf039c2b12d6308ccb2871c92b6457deadd3d5f68de.png', 'sentiment': 'neutral', 'sentiment_prob': 0.802958071231842}",,,,,,,,,,['neutral'],neutral,1
NCT02835742,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa1816216', 'title': 'Inhaled GM-CSF for Pulmonary Alveolar Proteinosis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 5, 2019', 'snippet': 'An open-label, phase 2 study showed some therapeutic efficacy of inhaled \nrecombinant human GM-CSF in patients with severe pulmonary alveolar \nproteinosis.', 'thumbnail': 'https://serpapi.com/searches/6721eb2d9fd3091aa2d90b3e/images/45407ab0f0192d5d9652231d15e6166061b7764ed196938c20f730eaddccdfa4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7692688703536987}",,,,,,,,,,['neutral'],neutral,1
NCT01971242,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/trial-shows-that-diabetes-therapy-byetta-improves-parkinsons-patients-movement/', 'title': 'Diabetes Therapy Byetta Improves Parkinson’s Patients’ Movement, Clinical Trial Shows', 'source': ""Parkinson's News Today"", 'date': 'Aug 8, 2017', 'snippet': ""Read about a Phase 2 clinical trial in Britain showing that the diabetes \ntreatment Byetta improves Parkinson's patients' movement."", 'thumbnail': 'https://serpapi.com/searches/6721e979bcd652e60fd88c10/images/b9304ad2c7cb1ac6be87ba770e771c13b529631632846ff595773d370ba19bc2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5046104788780212}",,,,,,,,,,['neutral'],neutral,1
NCT05232071,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/interim-analysis-fatty-liver-disease-patients-see-benefits-with-lanifibranor/', 'title': 'Interim analysis: Fatty liver disease patients see benefits with lanifibranor', 'source': 'Liver Disease News', 'date': 'Mar 25, 2024', 'snippet': 'Lanifibranor reduced blood sugar levels and eased signs of liver disease in \nMASH patients with diabetes, alone or with Jardiance.', 'thumbnail': 'https://serpapi.com/searches/6721e995b6e4dbcb60713e49/images/b3413d390b9b4b3a2163dbd811c8f94d397d246e556bc94b03da6501f7da5c11.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6301156878471375}",,,,,,,,,,['neutral'],neutral,1
NCT03406962,"{'position': 1, 'link': 'https://adrenoleukodystrophynews.com/2019/09/24/magenta-therapeutics-stem-cell-therapy-mgta-456-fda-regenerative-medicine-advanced-therapy-designation/', 'title': 'MGTA-456 Earns Regenerative Medicine Advanced Therapy Designation', 'source': 'Adrenoleukodystrophy News', 'date': 'Sep 24, 2019', 'snippet': ""The US Food and Drug Administration (FDA) has granted Magenta Therapeutics' \ncell therapy MGTA-456 the Regenerative Medicine Advanced Therapy (RMAT) \ndesignation."", 'thumbnail': 'https://serpapi.com/searches/6721e9ad8d0417be77d4384f/images/7f5c486c98d22f5e2dc403d1ebf1cfd0cc53669f5869e9c4a4b4693bb321e562.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8690577745437622}","{'position': 2, 'link': 'https://adrenoleukodystrophynews.com/2020/03/17/mgta-456-cell-therapy-leads-meaningful-lasting-neurological-benefits-children-cald-trial-data-shows/', 'title': 'MGTA-456 Stem Cell Therapy Leads to Lasting Neurological Benefits in CALD, Data Shows', 'source': 'Adrenoleukodystrophy News', 'date': 'Mar 17, 2020', 'snippet': ""Magenta Therapeutics' stem cell therapy MGTA-456 leads to clinically \nmeaningful and lasting benefits in neurological and cognitive functions."", 'thumbnail': 'https://serpapi.com/searches/6721e9ad8d0417be77d4384f/images/7f5c486c98d22f5e7eba71c029da6e2bebb883dac226b1b09d3153e5e8bee8fb.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5718526244163513}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04129619,"{'position': 1, 'link': 'https://www.drugtopics.com/view/irritable-bowel-syndrome-a-look-at-the-treatment-landscape', 'title': 'Irritable Bowel Syndrome: A Look at the Treatment Landscape', 'source': 'Drug Topics', 'date': 'Jul 5, 2021', 'snippet': 'Treatment typically consists of dietary changes, pharmacotherapy for \nconstipation (IBS-C) and diarrhea (IBS-D), and abdominal pain management.', 'thumbnail': 'https://serpapi.com/searches/6721ea3920e6eb9381df0651/images/80fabca7ec44c72b8954a2fbcfbaaee55e995f627ffe5ad6f57f20d187aed375.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.4977165460586548}",,,,,,,,,,['neutral'],neutral,1
NCT03293498,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMc1803554', 'title': 'Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine', 'source': 'The New England Journal of Medicine', 'date': 'Jun 13, 2018', 'snippet': 'We recently described an adjuvanted recombinant hemagglutinin (HA) \ntrivalent nanoparticle influenza vaccine (tNIV), produced on an Sf9 insect \ncell–recombinant...', 'thumbnail': 'https://serpapi.com/searches/6721ea3b400bd5bee739c146/images/2f906b014f907d8479a5969317554cbf1cdb27547efb97c73bbeea19212c9729.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8668078780174255}",,,,,,,,,,['neutral'],neutral,1
NCT02187744,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0147-1', 'title': 'Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer', 'source': 'Nature', 'date': 'Jul 13, 2018', 'snippet': 'This randomised, double-blind study compared pharmacokinetics, efficacy, \nsafety and immunogenicity of PF-05280014 (potential trastuzumab...', 'thumbnail': 'https://serpapi.com/searches/6721ea5e24079324ada0621e/images/0bc7706b1ad0588e870548b740acf4ba460191b0717c205dd74d16210e804ebb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8882277607917786}",,,,,,,,,,['neutral'],neutral,1
NCT04919473,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/ctm2.1243', 'title': 'The clinical potential of optogenetic interrogation of pathogenesis - Gao - 2023 - Clinical and Translational Medicine', 'source': 'Wiley Online Library', 'date': 'May 2, 2023', 'snippet': 'Opsin-based and opsin-free optogenetics employs light to modulate membrane \nconductance and protein-protein interaction. Clinical trials...', 'thumbnail': 'https://serpapi.com/searches/6721ea688d1473e38aba5627/images/9364dcce7b6d540bd3335bac0210a681e0f3dec9bbb2c72ed073f2580cf58ea8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.814610481262207}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentation-of-key-results-from-phase-2b-restore-trial-of-mco-010-for-the-treatment-of-retinitis-pigmentosa-at-the-arvo-annual-meeting-301809764.html', 'title': 'Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting', 'source': 'PR Newswire', 'date': 'Apr 27, 2023', 'snippet': '100% (18/18) MCO-010 patients experienced a clinically meaningful \nimprovement in vision-guided mobility (MLYMT), near-field object...', 'thumbnail': 'https://serpapi.com/searches/6721ea688d1473e38aba5627/images/9364dcce7b6d540bb783f931cf323379e49ecee3a33bd48f53413785f72845fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5359002351760864}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01319357,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-35589-4', 'title': 'Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis', 'source': 'Nature', 'date': 'Jun 2, 2023', 'snippet': 'This is a cross-sectional analysis of arterial stiffness in 266 patients in \nthe early stage of T2DM who did not have cardiovascular or renal \ncomplications.', 'thumbnail': 'https://serpapi.com/searches/6721ea7af3622abe3e739ce2/images/1113cc09a3e78ab44965f0efd4e2ef0eab7cef3e8cb60748e6e16892beda2053.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9014810919761658}",,,,,,,,,,['neutral'],neutral,1
NCT04880616,"{'position': 1, 'link': 'https://www.bioworld.com/articles/683801-neurocrine-initiates-phase-ii-trial-of-nbi-827104-to-treat-essential-tremor', 'title': 'Neurocrine initiates phase II trial of NBI-827104 to treat essential tremor', 'source': 'BioWorld MedTech', 'date': 'May 20, 2021', 'snippet': 'Neurocrine Biosciences has opened enrollment in a phase II study of \nNBI-827104 for the treatment of essential tremor (ClinicalTrials.gov...', 'thumbnail': 'https://serpapi.com/searches/6721eab371c62b5f51045aa5/images/b5a4e9ecfeed50c3f8ab66a338077995d9bbaf364284f1de51c4e6ffd9f147ae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8823071718215942}",,,,,,,,,,['neutral'],neutral,1
NCT02754076,"{'position': 1, 'link': 'https://sanfilipponews.com/news/allievex-to-continue-biomarins-clinical-program-testing-tralesinidase-alfa-for-sanfilippo-type-b/', 'title': 'Sanfilippo Type B Trials of Tralesinidase Alfa to Continue, Allievex Says', 'source': 'Sanfilippo Syndrome News', 'date': 'Oct 31, 2019', 'snippet': ""Allievex announced that it will continue clinically testing BioMarin \nPharmaceutical's tralesinidase alfa for the treatment of Sanfilippo..."", 'thumbnail': 'https://serpapi.com/searches/6721eb4f7ebde5d9be3a4a3f/images/b57cfb555615eb761393de2a4e8c9cc9fbe9bd1c419a18cd9871b3abd8b4a49b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9404838681221008}",,,,,,,,,,['neutral'],neutral,1
NCT01784757,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/darolutamide-yields-positive-safety-data-in-mcrpc', 'title': 'Darolutamide Yields Positive Safety Data in mCRPC', 'source': 'Cancer Network', 'date': 'Feb 18, 2022', 'snippet': 'Patients with metastatic castration-resistant prostate cancer were observed \nto have a tolerable safety profile when treated with...', 'thumbnail': 'https://serpapi.com/searches/6721eb674791c43abacbd91e/images/c4254b39083895e5edd80ece8b5ba98adbc0de81c9f228590f1993e9e87b453c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.665687620639801}",,,,,,,,,,['neutral'],neutral,1
NCT04655586,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/ATVBAHA.122.318748', 'title': 'Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial', 'source': 'American Heart Association Journals', 'date': 'Jun 29, 2023', 'snippet': 'Thrombo-inflammation is central to COVID-19-associated coagulopathy. TF \n(tissue factor), a driver of disordered coagulation and inflammation...', 'thumbnail': 'https://serpapi.com/searches/6721eb8952a04e7ad6d82eb4/images/37761fb047d7e250e2a49d3584bf256240cc728abb7af8249c8bf34feed76f5e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6286857724189758}",,,,,,,,,,['neutral'],neutral,1
NCT02415881,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-020-19498-y', 'title': 'Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates', 'source': 'Nature', 'date': 'Nov 9, 2020', 'snippet': 'This study demonstrates improved microscopic antibody distribution without \nincreasing uptake (toxicity) in healthy tissue when co-administered with \nthe parent...', 'thumbnail': 'https://serpapi.com/searches/6721ec0dfda26de16dd77391/images/b0b9d59f38e753fc5ee43a4b8acedbbb0a835e121c7283fb1e5a3e86ca0746a8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5531095862388611}",,,,,,,,,,['neutral'],neutral,1
NCT01429415,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/assessing-the-effectiveness-of-nebulized-magnesium-with-albuterol-in-pediatric-refractory-asthma/', 'title': 'Assessing the Effectiveness of Nebulized Magnesium With Albuterol in Pediatric Refractory Asthma', 'source': 'Pulmonology Advisor', 'date': 'Dec 21, 2020', 'snippet': 'The use of nebulized magnesium with albuterol, compared with placebo, does \nnot significantly decrease the hospitalization rate for asthma in the first \n24 hours.', 'thumbnail': 'https://serpapi.com/searches/6721ec5d6ad3c98a9f93e51b/images/8c522e1a1377189c83bac46a8e7b2d4a9630af15228e4323651608db66370c7a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8444584608078003}",,,,,,,,,,['neutral'],neutral,1
NCT00916409,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1441146/full', 'title': 'Case report: Safety of Tumor Treating Fields therapy with an implantable cardiac pacemaker in a patient with glioblastoma', 'source': 'Frontiers', 'date': 'Aug 22, 2024', 'snippet': '1Department of Radiation Oncology, University of Missouri, Columbia, MO, \nUnited States; 2Department of Global Medical Safety, Novocure Inc.,...', 'thumbnail': 'https://serpapi.com/searches/6721ec81f41044dc7df58c39/images/838440fed6e29b9bc520a90d80b59f98b78b5c5318e1ac0de4d286a908a896e9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.91129469871521}",,,,,,,,,,['neutral'],neutral,1
NCT00434811,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/islet-transplantation-restores-blood-sugar-awareness-control-type-1-diabetes', 'title': 'Islet transplantation restores blood sugar awareness and control in type 1 diabetes', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Apr 18, 2016', 'snippet': 'New clinical trial results show that transplantation of pancreatic islets — \ncell clusters that contain insulin-producing cells—prevents severe,...', 'thumbnail': 'https://serpapi.com/searches/6721ec8506f4f23e4fafd1e9/images/e6ee92e026e9f83f1dc94096bed0a71af7d9a272b4ba9e64aef32cbed55fb16d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.572243332862854}",,,,,,,,,,['neutral'],neutral,1
NCT04687072,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/argenx-decides-stop-clinical-development-efgartigimod-aav/', 'title': 'Argenx to stop clinical development of efgartigimod for AAV', 'source': 'ANCA Vasculitis News', 'date': 'May 15, 2024', 'snippet': 'Argenx is not advancing its development plans for efgartigimod in AAV, \nafter considering Phase 3 trial data in two other autoimmune...', 'thumbnail': 'https://serpapi.com/searches/6721ecaba86921bfc102ceb3/images/4dc98da9e2e9b2fdb0fe97ae14d1d93d0c75da3a7ef3aea65078f77fd0064da6.png', 'sentiment': 'negative', 'sentiment_prob': 0.6901589632034302}",,,,,,,,,,['negative'],negative,0
NCT04305405,"{'position': 1, 'link': 'https://www.contemporarypediatrics.com/view/what-the-fda-approval-of-benralizumab-means-for-children-with-severe-asthma', 'title': 'What the FDA approval of benralizumab means for children with severe asthma', 'source': 'Contemporary Pediatrics', 'date': 'Apr 11, 2024', 'snippet': ""The FDA has approved AstraZeneca's benralizumab (Fasenra) as an add-on \nmaintenance therapy for patients aged 6 to 11 years with severe asthma."", 'thumbnail': 'https://serpapi.com/searches/6721ecb363a844c688183f0c/images/99c1e4832ac7c14723bf2bb078b63be3a49d7205d4831bc49fcc91317cd230a5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8715591430664062}","{'position': 2, 'link': 'https://www.drugtopics.com/view/fda-fasenra-approved-as-add-on-maintenance-therapy-for-severe-pediatric-asthma', 'title': 'FDA: Fasenra Approved As Add-On Maintenance Therapy for Severe Pediatric Asthma', 'source': 'Drug Topics', 'date': 'Apr 12, 2024', 'snippet': 'Fasenra was initially approved in 2017 as an add on maintenance therapy in \npatients aged 12 years and older.', 'thumbnail': 'https://serpapi.com/searches/6721ecb363a844c688183f0c/images/99c1e4832ac7c1474c5e346bfb8b87a887d5dbcc4690aa8753f0a86a0814bd6f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8664294481277466}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01599104,"{'position': 1, 'link': 'https://www.nature.com/articles/s41440-021-00819-7', 'title': 'Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study', 'source': 'Nature', 'date': 'Jan 21, 2022', 'snippet': 'This phase III study assessed the efficacy and safety of \nsacubitril/valsartan compared with those of olmesartan in Japanese patients \nwith essential...', 'thumbnail': 'https://serpapi.com/searches/6721ece074f0a452bffe9d46/images/9b99617166962a9e0836c006c31d9d38a422b2016b785d2c065893fefd4c9aec.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8470889329910278}",,,,,,,,,,['neutral'],neutral,1
NCT02287480,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-020-0179-4', 'title': 'Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination | npj Vaccines', 'source': 'Nature', 'date': 'Apr 14, 2020', 'snippet': 'The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after \nimmunization, suggesting the contribution of innate immune responses.', 'thumbnail': 'https://serpapi.com/searches/6721eceed78a989f7c70bdfc/images/4fd1176b69c28900e6b3bff7192f0ff5bcedcb7d27aae24b6d530e21f8a3fbbd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8963407874107361}",,,,,,,,,,['neutral'],neutral,1
NCT04871815,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/n115-nasal-spray-use-pf-patients-improves-lung-function/', 'title': 'N115 Nasal Spray Use in PF Patients Shown to Improve Lung Function', 'source': 'Pulmonary Fibrosis News', 'date': 'Oct 11, 2021', 'snippet': ""Treatment with N115, EmphyCorp's non-steroidal nasal spray, led to \nsignificant lung function improvements in PF patients in a Phase 3 trial."", 'thumbnail': 'https://serpapi.com/searches/6721ed012c566df19c3d7e34/images/d3e5b0a2b07535224e96deec66cb09655aefbc1ad5f87f8e9a0dab4733be7281.png', 'sentiment': 'positive', 'sentiment_prob': 0.7849878668785095}",,,,,,,,,,['positive'],positive,1
NCT04375878,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/ms1819-pert-boosts-fat-absorption-severe-epi/', 'title': 'MS1819 Added to PERT Boosts Fat Absorption in Severe EPI, Trial Shows', 'source': 'Cystic Fibrosis News Today', 'date': 'Aug 19, 2021', 'snippet': 'Combining MS1819 with pancreatic enzyme replacement therapy may help people \nwith CF who have severe exocrine pancreatic insufficiency.', 'thumbnail': 'https://serpapi.com/searches/6721ed0aaab36dd763f68e25/images/d8bbff89304ef50a867fc6c239445572b9ec2685c99dd5bfc636e878b89124a4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7805697321891785}","{'position': 2, 'link': 'https://cysticfibrosisnewstoday.com/news/azurrx-ms1819-plus-pert-fat-absorbtion-severe-epi-interim-trial-data/', 'title': 'MS1819 Plus PERT Aiding Digestion in CF Patients With Severe EPI', 'source': 'Cystic Fibrosis News Today', 'date': 'May 14, 2021', 'snippet': 'Interim Phase 2 data in 18 patients with severe exocrine pancreatic \ninsufficiency found greater fat absorption with daily MS1819 plus PERT.', 'thumbnail': 'https://serpapi.com/searches/6721ed0aaab36dd763f68e25/images/d8bbff89304ef50aa815f82221eabb4a882f90b171beb14db5c3661d973e80df.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7946100234985352}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00023595,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1602001', 'title': 'Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy', 'source': 'The New England Journal of Medicine', 'date': 'Apr 3, 2016', 'snippet': 'Landmark clinical trials have established coronary-artery bypass grafting \n(CABG) as an effective treatment for patients with disabling angina \nsymptoms.', 'thumbnail': 'https://serpapi.com/searches/6721ed3a483e5bd88c7b2718/images/102eecd5e96c6cbe63c5c75e8c64b92cc6a59dde02f147f006a8665466c374cb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8796648383140564}",,,,,,,,,,['neutral'],neutral,1
NCT02581787,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-00436-9', 'title': 'Targeting TGFβ signal transduction for cancer therapy', 'source': 'Nature', 'date': 'Jan 8, 2021', 'snippet': 'Transforming growth factor-β (TGFβ) family members are structurally and \nfunctionally related cytokines that have diverse effects on the...', 'thumbnail': 'https://serpapi.com/searches/6721ed7976079d9baf778715/images/694cee625efdd869575129ac1b36a8b1a1f09dd7da7edf1a2b230bfa134df3a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7691714763641357}",,,,,,,,,,['neutral'],neutral,1
NCT02324257,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-48479-8', 'title': 'CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials', 'source': 'Nature', 'date': 'May 15, 2024', 'snippet': 'Cibisatamab is a bispecific antibody-based construct targeting \ncarcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a \nT-cell engager.', 'thumbnail': 'https://serpapi.com/searches/6721ed8d7ef9fa1a31666e9e/images/86f16e0ce9c19c29ba2fba86866864ca1d36ef50b1ae37d919614602c8cbfa1b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9039309024810791}",,,,,,,,,,['neutral'],neutral,1
NCT00432523,"{'position': 1, 'link': 'https://www.empr.com/home/news/m-m-r-ii-varivax-proquad-vaccines-approved-for-intramuscular-administration/', 'title': 'M-M-R II, Varivax, ProQuad Vaccines Approved for Intramuscular Administration', 'source': 'Medical Professionals Reference', 'date': 'Mar 6, 2023', 'snippet': ""The Food and Drug Administration (FDA) has expanded the approval for \nMerck's MMR II (measles, mumps, and rubella virus vaccine live), Varivax \n(varicella virus..."", 'thumbnail': 'https://serpapi.com/searches/6721edc5a88278deeec7b314/images/3215e96f21c7ac3ff87efad11715d3ce75983d7cda51c62fbe8c444c6c865c2d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8451946973800659}",,,,,,,,,,['neutral'],neutral,1
NCT03583697,"{'position': 1, 'link': 'https://www.nature.com/articles/s41436-021-01287-7', 'title': 'Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study', 'source': 'Nature', 'date': 'Aug 2, 2021', 'snippet': 'Achondroplasia is caused by pathogenic variants in the fibroblast growth \nfactor receptor 3 gene that lead to impaired endochondral...', 'thumbnail': 'https://serpapi.com/searches/6721edc698876dbcc380f6f7/images/2cdbe6fc97aa0871fdfcca81ca560f464bb0a0547a766ddaa514c9043f5c4111.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7574613094329834}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1813446', 'title': 'C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia', 'source': 'The New England Journal of Medicine', 'date': 'Jun 18, 2019', 'snippet': 'Achondroplasia is a genetic disorder that inhibits endochondral \nossification, resulting in disproportionate short stature and clinically...', 'thumbnail': 'https://serpapi.com/searches/6721edc698876dbcc380f6f7/images/2cdbe6fc97aa08714621f05509639c8fdc45b8a28e494a2b746dd7d5a15fea3a.png', 'sentiment': 'negative', 'sentiment_prob': 0.55079585313797}","{'position': 3, 'link': 'https://www.empr.com/home/news/voxzogo-approval-expanded-to-younger-children-with-achondroplasia/', 'title': 'Voxzogo Approval Expanded to Younger Children With Achondroplasia', 'source': 'Medical Professionals Reference', 'date': 'Oct 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of Voxzogo \n(vosoritide) to increase linear growth in children of all ages with \nachondroplasia...', 'thumbnail': 'https://serpapi.com/searches/6721edc698876dbcc380f6f7/images/2cdbe6fc97aa08716c8ca05b589a915bd1664520fdc86e153ef1fe66683b5ea9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6303216814994812}",,,,,,,,"['neutral', 'negative', 'neutral']",neutral,1
NCT03681860,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00501-7/fulltext', 'title': 'Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial', 'source': 'The Lancet', 'date': 'Nov 24, 2023', 'snippet': 'BCG confers reduced, variable protection against pulmonary tuberculosis. A \nmore effective vaccine is needed. We evaluated the safety and...', 'thumbnail': 'https://serpapi.com/searches/6721ede3b691a77af41440cd/images/7acef9e9baadda50a4867a9f088db2b66ff3fa0ef9127269ff7cb236e1dde7f4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8410376310348511}",,,,,,,,,,['neutral'],neutral,1
NCT03938246,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/denifanstat-safely-treat-nash-phase-2b-clinical-trial/', 'title': 'Denifanstat seen to safely treat NASH in Phase 2b clinical trial', 'source': 'Liver Disease News', 'date': 'Feb 5, 2024', 'snippet': 'Denifanstat outperformed a placebo at resolving nonalcoholic \nsteatohepatitis in patients with moderate to severe liver fibrosis \ntreated...', 'thumbnail': 'https://serpapi.com/searches/6721edf14a4a1d50b272fb02/images/fbb286d365e84a376173e3b640353b51b20b85c021b21448c00a8de87e719375.png', 'sentiment': 'positive', 'sentiment_prob': 0.5272930264472961}",,,,,,,,,,['positive'],positive,1
NCT02372253,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-28826-3', 'title': 'Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes', 'source': 'Nature', 'date': 'Mar 3, 2022', 'snippet': 'Currently, no oral medications are available for type 1 diabetes (T1D). \nWhile our recent randomized placebo-controlled T1D trial revealed...', 'thumbnail': 'https://serpapi.com/searches/6721edf4d9c3e646d94aa242/images/a99e5760cdf01debcb0573ee1824738da65dfec384dab92f47a558bc9e66c908.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6621863842010498}",,,,,,,,,,['neutral'],neutral,1
NCT03493269,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1267091/full', 'title': 'The role of inflammation in autoimmune disease: a therapeutic target', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': ""Autoimmune diseases (AIDs) are immune disorders whose incidence and \nprevalence are increasing year by year. AIDs are produced by the immune \nsystem's..."", 'thumbnail': 'https://serpapi.com/searches/6721ee3f5416d8e6ac1d2a86/images/499192012c7c7b27f438fed71d0057c2824f7d0f1da7e36fdd3450e9d4a970da.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.490505188703537}",,,,,,,,,,['negative'],negative,0
NCT03921528,"{'position': 1, 'link': 'https://smanewstoday.com/news/clinical-benefit-apitegromab-sustained-3-years-study/', 'title': 'Clinical benefit of apitegromab sustained for up to 3 years: Study', 'source': 'SMA News Today', 'date': 'Jul 29, 2024', 'snippet': 'Three years of treatment with apitegromab provided clinical benefit to \nchildren and young adults with SMA type 2 or 3, per a study.', 'thumbnail': 'https://serpapi.com/searches/6721ee627ebde5d98affb902/images/1f03d875282e2b8a49992dfc742f0cabc5f2913ff816039353ba287422675978.png', 'sentiment': 'positive', 'sentiment_prob': 0.6395848989486694}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/analyst-comment/scholar-rocks-apitegromab-non-ambulatory-sma/', 'title': 'Scholar Rock’s apitegromab shows promise for non-ambulatory SMA', 'source': 'Clinical Trials Arena', 'date': 'Aug 15, 2024', 'snippet': 'Apitegromab is a monoclonal antibody believed to improve muscle strength by \ninhibiting myostatin activation.', 'thumbnail': 'https://serpapi.com/searches/6721ee627ebde5d98affb902/images/1f03d875282e2b8a072906b566826c67eeb4d2a079105a6859ffd92792a9d548.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7723166942596436}","{'position': 3, 'link': 'https://smanewstoday.com/news/apitegromab-aiding-sma-topaz-patients-phase-3-data-on-way/', 'title': 'Muscle gains with apitegromab still seen in TOPAZ, Phase 3 data on way', 'source': 'SMA News Today', 'date': 'Aug 14, 2024', 'snippet': ""Scholar Rock reports new findings in nonambulatory patients treated for 4 \nyears in Phase 2 TOPAZ trial, SAPPHIRE data due by year's end."", 'thumbnail': 'https://serpapi.com/searches/6721ee627ebde5d98affb902/images/1f03d875282e2b8a1424704da0e550f33cd9dc4cc89a36d7fe41d3d903e99636.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7133463621139526}","{'position': 4, 'link': 'https://smanewstoday.com/news/top-10-sma-stories-2023/', 'title': 'Top 10 SMA stories of 2023', 'source': 'SMA News Today', 'date': 'Jan 3, 2024', 'snippet': 'Here are the Top 10 spinal muscular atrophy news stories brought to our SMA \nNews Today readers in 2023.', 'thumbnail': 'https://serpapi.com/searches/6721ee627ebde5d98affb902/images/1f03d875282e2b8a1e248f88e1a18f19a64d20e1f17022cc82260190f8f1101a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9062528610229492}",,,,,,,"['positive', 'positive', 'neutral', 'neutral']",positive,1
NCT01713946,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/atezolizumab-bevacizumab-demonstrates-comparable-os-to-sunitinib-for-metastatic-rcc', 'title': 'Atezolizumab/Bevacizumab Demonstrates Comparable OS to Sunitinib for Metastatic RCC', 'source': 'Cancer Network', 'date': 'Feb 22, 2022', 'snippet': 'The final analysis of the phase 3 IMmotion151 trial did not reveal a \nsignificant improvement in overall survival with atezolizumab plus...', 'thumbnail': 'https://serpapi.com/searches/6721eea8272a87d7f8c00cc0/images/b73e20fb6e8f8a2932e575d008c2d469db183434044c1720f9bfa50d9349711b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6603785157203674}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/sbrt-controls-metastatic-kidney-cancer-for-as-much-as-2-years-says-expert', 'title': 'SBRT Controls Metastatic Kidney Cancer ‘For As Much as 2 Years’, Says Expert', 'source': 'Cancer Network', 'date': 'Dec 4, 2022', 'snippet': 'Data from recent clinical trials indicate that stereotactic radiation can \nlocally control metastatic kidney cancer and delay systemic therapy for \nclose to 2...', 'thumbnail': 'https://serpapi.com/searches/6721eea8272a87d7f8c00cc0/images/b73e20fb6e8f8a29d9ed762a96423f2a99f278029ec5074fa6f52225dc53d2dd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8868945837020874}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00945490,"{'position': 1, 'link': 'https://bphnews.com/news-posts/2017/06/07/studies-show-enlarged-prostate-therapy-fexapotide-improves-sexual-function/', 'title': 'Enlarged Prostate Therapy Fexapotide Actually Improves Patients’ Sexual Function, Studies Show', 'source': 'BPH News', 'date': 'Jun 7, 2017', 'snippet': 'Fexapotide triflutate improves the sexual functioning of men with an \nenlarged prostate, according to combined results of four Phase 3 clinical \ntrials.', 'thumbnail': 'https://serpapi.com/searches/6721eead2e33c8f507283ed2/images/d9ec322466691148e1509b2072f7ad44eb9ccd4ad7eae4143d1871d7229895b0.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6826880574226379}",,,,,,,,,,['positive'],positive,1
NCT00546351,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Vimpat-lacosamide', 'title': 'Lacosamide (Vimpat®)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Epilepsy, A Study to Evaluate the Efficacy and Safety of Adjunctive Therapy \nWith Lacosamide in Adults With Partial Onset Seizures, Phase 3...', 'thumbnail': 'https://serpapi.com/searches/6721eeccd0253ebcf8559a0b/images/2a85d8b6b2aab2776467a2c8e1667d15b9b14977a7593f0de9a897b547d55e8c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9128645658493042}",,,,,,,,,,['neutral'],neutral,1
NCT04218266,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.049768', 'title': 'Stroke Prevention in Atrial Fibrillation:', 'source': 'American Heart Association Journals', 'date': 'Dec 14, 2020', 'snippet': 'Ischemic strokes related to atrial fibrillation are highly prevalent, \npresenting with severe neurologic syndromes and associated with high...', 'thumbnail': 'https://serpapi.com/searches/6721eef1671f3f3c44ac488d/images/2d2d0cc9a9476cd38d918c407c5c044654c77d5d04c1c09ba4bd81c9c22befae.png', 'sentiment': 'neutral', 'sentiment_prob': 0.4968705475330353}",,,,,,,,,,['neutral'],neutral,1
NCT00134030,"{'position': 1, 'link': 'https://www.onclive.com/view/non-hispanic-black-children-experience-inferior-post-relapse-survival-outcomes-vs-whites-with-nonmetastatic-osteosarcoma', 'title': 'Non-Hispanic Black Children Experience Inferior Post-Relapse Survival Outcomes vs Whites With Nonmetastatic Osteosarcoma', 'source': 'OncLive', 'date': '1 month ago', 'snippet': 'R. Lor Randall, MD, FACS, discusses the relationship between poverty, race, \nethnicity, and survival outcomes in pediatric nonmetastatic...', 'thumbnail': 'https://serpapi.com/searches/6721ef0bfd3b5ab4d17bcd3e/images/512154f05df73aad71372df52f6533dea30ce410f0545627acb099bc85b0e410.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7275171279907227}",,,,,,,,,,['neutral'],neutral,1
NCT01480180,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/esperoct-hemophilia-a-prophylaxis-extended-half-life-therapy/', 'title': 'Esperoct Highly Effective as Prophylaxis for Hemophilia A, Study Suggests', 'source': 'Hemophilia News Today', 'date': 'Jan 29, 2021', 'snippet': 'Severe hemophilia A patients using Esperoct (turoctocog alfa pegol) as a \npreventive treatment do well, with fewer bleeds or breakthrough bleeds, \nlower costs,...', 'thumbnail': 'https://serpapi.com/searches/6721ef29d0d7e3e61e285a57/images/e970b096da82097e8965ea97d89851818e755e833292aa4e364a7b1ae9bc00ba.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5337181091308594}",,,,,,,,,,['positive'],positive,1
NCT04436510,"{'position': 1, 'link': 'https://alsnewstoday.com/news/als-therapy-verdiperstat-fails-healey-trial-efficacy-goals/', 'title': 'ALS Therapy Verdiperstat Fails to Meet Efficacy Goals in HEALEY Trial', 'source': 'ALS News Today', 'date': 'Oct 6, 2022', 'snippet': 'The ALS therapy verdiperstat failed to slow disease progression, improve \nsurvival, or meet other efficacy goals in the HEALEY platform...', 'thumbnail': 'https://serpapi.com/searches/6721ef7c1ec32fb22c825ff7/images/59fcb12340ac3133ba0f6b03e8b2f91cdea5c315db511bc5290774f9eddce66f.png', 'sentiment': 'negative', 'sentiment_prob': 0.7811991572380066}",,,,,,,,,,['negative'],negative,0
NCT02336074,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-42888-3', 'title': 'Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions | Scientific Reports', 'source': 'Nature', 'date': 'Oct 11, 2023', 'snippet': ""'Kick and kill' cure strategies aim to induce HIV protein expression in \nlatently infected cells (kick), and thus trigger their elimination..."", 'thumbnail': 'https://serpapi.com/searches/6721ef9bd9103905e0e02e2b/images/740d5ebaa5d04d9c32d7bb4c7954ee900d815b518985d16b39859e92b858388f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7719951868057251}",,,,,,,,,,['neutral'],neutral,1
NCT01942135,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1810527', 'title': 'Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Oct 20, 2018', 'snippet': 'Palbociclib, in combination with fulvestrant therapy, prolongs \nprogression-free survival among patients with hormone-receptor–positive, \nhuman epidermal growth...', 'thumbnail': 'https://serpapi.com/searches/6721ef9cb4e8d6fcca27518f/images/a7661f5ea4099cb8afdaee62471747fe3331f33ac5044ce0668bc0a0247a4c8e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5874237418174744}","{'position': 2, 'link': 'https://www.nature.com/articles/s41698-022-00297-1', 'title': 'Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib', 'source': 'Nature', 'date': 'Aug 16, 2022', 'snippet': 'While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including \npalbociclib, combined with endocrine therapy (ET), are becoming the...', 'thumbnail': 'https://serpapi.com/searches/6721ef9cb4e8d6fcca27518f/images/a7661f5ea4099cb84e3a81dc54e931d271b2d3021fe5d4c30834f3325a921329.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9147531986236572}","{'position': 3, 'link': 'https://breastcancer-news.com/2018/11/05/faslodex-ibrance-combo-improves-survival-advanced-breast-cancer-patients/', 'title': 'In Breast Cancer, Ibrance-Faslodex Combo Improves Survival, Phase 3 Data Shows', 'source': 'breastcancer-news.com', 'date': 'Nov 5, 2018', 'snippet': ""Adding Pfizer's Ibrance to standard treatment Faslodex significantly \nextended the survival of advanced breast cancer patients in a Phase 3..."", 'thumbnail': 'https://serpapi.com/searches/6721ef9cb4e8d6fcca27518f/images/a7661f5ea4099cb8c82c5ae01f8c863631ab207ff47c28247f76f530c9a89bb7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.631209135055542}","{'position': 4, 'link': 'https://breastcancer-news.com/2018/03/12/ibrance-treatment-success-breast-cancer-blood-test-quick-prediction-study/', 'title': ""Test Could Quickly Predict Breast Cancer Patients' Response to Ibrance"", 'source': 'breastcancer-news.com', 'date': 'Mar 12, 2018', 'snippet': 'A new blood test could predict how a patient will respond to metastatic \nbreast cancer medication Ibrance (palbociclib) months earlier than...', 'thumbnail': 'https://serpapi.com/searches/6721ef9cb4e8d6fcca27518f/images/a7661f5ea4099cb83d68affa06f440857b82837c342d97d76595dc4aee9377c5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9154565930366516}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01108445,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/EDBK_438642', 'title': 'Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances', 'source': 'ASCO Publications', 'date': 'May 22, 2024', 'snippet': 'We detail recent advances in understanding the biology of RCC with variant \nhistology and how such findings have guided novel clinical studies.', 'thumbnail': 'https://serpapi.com/searches/6721ef9de45f339dd3e6beee/images/d562d7dd75da0535f0921692fc71265e5fa15808d79ff4af855bb66984e0705b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7896586060523987}",,,,,,,,,,['neutral'],neutral,1
NCT00087529,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/rituximab-for-rrms/', 'title': 'Rituximab in MS | Experimental MS Treatments', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 12, 2022', 'snippet': 'Rituximab is commonly used off-label in multiple sclerosis patients. Learn \nmore about its uses, side effects, and clinical testing.', 'thumbnail': 'https://serpapi.com/searches/6721efcfe8735a148295865b/images/ba5ae4cb867921e05314a41ef4c92e1e540e41865e548753c78f82ae8a951c6d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9291795492172241}",,,,,,,,,,['neutral'],neutral,1
NCT04976855,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/indivior-announces-dosing-of-first-subject-with-indv-2000-in-a-phase-2-study-assessing-the-safety-and-efficacy-of-indv-2000-in-individuals-with-opioid-use-disorder-302168484.html', 'title': 'Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder', 'source': 'PR Newswire', 'date': 'Jun 10, 2024', 'snippet': 'Double-blind, placebo-controlled study aims to measure safety and efficacy \nof INDV-2000 over 3 months in participants with moderate to...', 'thumbnail': 'https://serpapi.com/searches/6721efd114c31e91e4a4d6c1/images/80b8861580baccb27fed27ee96b1d97b0406ab7f732af8c64443486210fe0815.png', 'sentiment': 'neutral', 'sentiment_prob': 0.903710126876831}",,,,,,,,,,['neutral'],neutral,1
NCT03719586,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1910993', 'title': 'A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics', 'source': 'The New England Journal of Medicine', 'date': 'Nov 27, 2019', 'snippet': 'We conducted a trial of four investigational therapies for EVD in the \nDemocratic Republic of Congo, where an outbreak began in August 2018.', 'thumbnail': 'https://serpapi.com/searches/6721efedf963e7b1d3097a47/images/7d384dc3845c98de0a1941be53c39548faeef1ef4ef26c3f8f354dc9017971ef.png', 'sentiment': 'neutral', 'sentiment_prob': 0.932693600654602}",,,,,,,,,,['neutral'],neutral,1
NCT04676178,"{'position': 1, 'link': 'https://sclerodermanews.com/news/prometheus-launching-phase-2-trial-pra023-treat-ssc-ild/', 'title': 'Phase 2 Trial of PRA023 in SSc-ILD Patients Planned for Next Year', 'source': 'Scleroderma News', 'date': 'Dec 14, 2021', 'snippet': 'Prometheus Biosciences is planning a clinical trial of its investigational \nanti-inflammatory and antifibrotic medication PRA023 in people with \nsystemic...', 'thumbnail': 'https://serpapi.com/searches/6721f0150e6db34182d00447/images/ab0c3be4cd375e57856b86588330eeb6f6430e2d249d972177ea5d9e53749d38.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8826546669006348}",,,,,,,,,,['neutral'],neutral,1
NCT00246753,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-019-0496-4', 'title': 'Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase', 'source': 'Nature', 'date': 'Jun 18, 2019', 'snippet': 'Despite overexpression of the ErbB (EGFR/HER2/ErbB3/ErbB4) family in \ncastration-resistant prostate cancer (CRPC), some inhibitors of this...', 'thumbnail': 'https://serpapi.com/searches/6721f04cd72128f29a8ab060/images/9bd94b2ed431a49aed5a1100410d7540df69678be061a5ed860eed14a03df9b9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6499481797218323}",,,,,,,,,,['neutral'],neutral,1
NCT03227926,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01886-0', 'title': 'Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial', 'source': 'Nature', 'date': 'Aug 1, 2022', 'snippet': 'We report here the results of CHRONOS, an open-label, single-arm phase 2 \nclinical trial exploiting blood-based identification of RAS/BRAF/EGFR \nmutations levels.', 'thumbnail': 'https://serpapi.com/searches/6721f07881262aaa018318bc/images/32d91bb8725856f42271fe08d23700570e96ad10ab8f831a614f05dd9899cba3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9349796772003174}",,,,,,,,,,['neutral'],neutral,1
NCT03439072,"{'position': 1, 'link': 'https://www.empr.com/home/news/ready-to-use-liquid-glucagon-gets-approval-for-severe-hypoglycemia/', 'title': 'Ready-to-Use Liquid Glucagon Gets Approval for Severe Hypoglycemia', 'source': 'Medical Professionals Reference', 'date': 'Sep 11, 2019', 'snippet': 'The Food and Drug Administration (FDA) has approved Gvoke (glucagon; Xeris \nPharmaceuticals) for the treatment of severe hypoglycemia in pediatric and \nadult...', 'thumbnail': 'https://serpapi.com/searches/6721f07f6a5dd3bbff20e5f5/images/58117596eb4bedf4ab785d3f04cdadcbc87708652335e49851d290a63a8565c4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7991900444030762}",,,,,,,,,,['neutral'],neutral,1
NCT01357239,"{'position': 1, 'link': 'https://fragilexnewstoday.com/news/decisional-intervention-may-be-beneficial-for-parents-of-fxs-chidren/', 'title': 'Information, Support May Persuade Parents of FXS Children to Join Trials', 'source': 'Fragile X News Today', 'date': 'Feb 19, 2019', 'snippet': 'Parents of children with fragile X syndrome may benefit from more \ninformation and dedicated support when deciding whether to take part in...', 'thumbnail': 'https://serpapi.com/searches/6721f0943ad34d77a222f9b8/images/fe60f7f62904ca49292d79642fb4eb68e30737e2c318430101716ef123622cca.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8041049838066101}",,,,,,,,,,['neutral'],neutral,1
NCT03068780,"{'position': 1, 'link': 'https://epidermolysisbullosanews.com/news/filsuvez-reduces-wounds-after-15-months-ease-trial/', 'title': 'Filsuvez Significantly Reduces Wounds After 15 Months in Trial', 'source': 'Epidermolysis Bullosa News', 'date': 'Jul 8, 2022', 'snippet': 'People with dystrophic epidermolysis bullosa saw the surface of their \nwounds reduced after Filsuvez treatment for more than a year,...', 'thumbnail': 'https://serpapi.com/searches/6721f0a79062f8271d86192a/images/336bd217ef51d88179bdd7f0397c30e075d4c754f204cfc9369b951fce15264d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7706872820854187}","{'position': 2, 'link': 'https://www.empr.com/home/news/filsuvez-topical-gel-approved-for-junctional-and-dystrophic-epidermolysis-bullosa/', 'title': 'Filsuvez Topical Gel Approved for Junctional and Dystrophic Epidermolysis Bullosa', 'source': 'Medical Professionals Reference', 'date': 'Dec 19, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Filsuvez (birch \ntriterpenes) topical gel for the treatment of partial thickness wounds in \npatients 6 months...', 'thumbnail': 'https://serpapi.com/searches/6721f0a79062f8271d86192a/images/336bd217ef51d881b3f5b1f73cea0b4443f7874cf4e80246c82c15140da0a4de.png', 'sentiment': 'neutral', 'sentiment_prob': 0.841789722442627}","{'position': 3, 'link': 'https://epidermolysisbullosanews.com/news/fda-approves-filsuvez-treat-junctional-dystrophic-eb/', 'title': 'FDA approves Filsuvez to treat dystrophic and junctional EB', 'source': 'Epidermolysis Bullosa News', 'date': 'Dec 20, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has approved Filsuvez (birch \ntriterpenes) to treat skin wounds in patients with dystrophic epidermolysis \nbullosa (DEB...', 'thumbnail': 'https://serpapi.com/searches/6721f0a79062f8271d86192a/images/336bd217ef51d881371ec588014ec4cb2bf63d5995e9b7e72521e657a279f326.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8094314932823181}","{'position': 4, 'link': 'https://epidermolysisbullosanews.com/news/amryt-plans-regulatory-submissions-for-filsuvez-following-positive-phase-3-data/', 'title': 'Positive EB Trial Data Puts Filsuvez on Track for Regulatory Submissions', 'source': 'Epidermolysis Bullosa News', 'date': 'Sep 23, 2020', 'snippet': 'Filsuvez, a topical formulation developed by Amryt Pharma, significantly \nimproved wound closure in people with epidermolysis bullosa in a...', 'thumbnail': 'https://serpapi.com/searches/6721f0a79062f8271d86192a/images/336bd217ef51d881344d64a986db64aa8427d656dbbc0842b2af315cbb2b7bc6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7531502842903137}","{'position': 5, 'link': 'https://epidermolysisbullosanews.com/news/filsuvez-gel-becomes-1st-therapy-approved-eu-eb-wounds/', 'title': 'Filsuvez Gel Becomes 1st Therapy Approved in EU for EB Wounds', 'source': 'Epidermolysis Bullosa News', 'date': 'Jun 24, 2022', 'snippet': 'The European Commission has approved Filsuvez as the first therapy for skin \nwounds caused by epidermolysis bullosa.', 'thumbnail': 'https://serpapi.com/searches/6721f0a79062f8271d86192a/images/336bd217ef51d88141926b77a4da7bcedd5f8f6398952ecbcaa6c590a4b62887.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5485702753067017}",,,,,,"['neutral', 'neutral', 'neutral', 'positive', 'neutral']",neutral,1
NCT00096655,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa050516', 'title': 'Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis', 'source': 'The New England Journal of Medicine', 'date': 'Jul 31, 2017', 'snippet': 'Two randomized, double-blind, placebo-controlled studies — the Active \nUlcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2, respectively) — \nevaluated the...', 'thumbnail': 'https://serpapi.com/searches/6721f0ad316650b53c00d9b2/images/7b222caf14f67be730418870129451ee688f8f4f1a0c33eb60891c53a035feef.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9349810481071472}",,,,,,,,,,['neutral'],neutral,1
NCT03097770,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-021-01345-8', 'title': 'Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial | Leukemia', 'source': 'Nature', 'date': 'Jul 16, 2021', 'snippet': 'Increasing the remission rate and reducing the recurrence rate can improve \nthe clinical efficacy of chimeric antigen receptor (CAR) T cell...', 'thumbnail': 'https://serpapi.com/searches/6721f0e6131502ec3a5f3c92/images/d5d2c0f1f393ba28e1d960e311bdd134ddf518c1104e165fd356fa81449e3848.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8464327454566956}","{'position': 2, 'link': 'https://www.nature.com/articles/s41392-023-01659-2', 'title': 'T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma', 'source': 'Nature', 'date': 'Oct 25, 2023', 'snippet': 'Although chimeric antigen receptor (CAR) T cells have become an important \ntreatment option for patients with relapsed/refractory B-cell...', 'thumbnail': 'https://serpapi.com/searches/6721f0e6131502ec3a5f3c92/images/d5d2c0f1f393ba28237107eb07723474453a0ac492906c62fbddc2fb179b2822.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8680022358894348}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02273973,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30334-1/fulltext', 'title': 'Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial', 'source': 'The Lancet', 'date': 'Aug 8, 2019', 'snippet': 'Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in \npostmenopausal women with oestrogen receptor-positive, HER2-negative, \nearly-stage breast...', 'thumbnail': 'https://serpapi.com/searches/6721f13cfbde0d689940f6a1/images/e38a105238a7330311f0ddf4fdcc14cd8ed7a544921e441912046a14efc1fd97.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8423236608505249}",,,,,,,,,,['neutral'],neutral,1
NCT03575351,"{'position': 1, 'link': 'https://www.onclive.com/view/dr-neelapu-on-clinical-trial-data-with-car-t-cell-therapy-in-lymphoma', 'title': 'Dr Neelapu on Clinical Trial Data With CAR T-Cell Therapy in Lymphoma', 'source': 'OncLive', 'date': 'Jun 11, 2024', 'snippet': 'Sattva S. Neelapu, MD, discusses key clinical trial data that support the \nuse of CAR T-cell therapy in standard practice for patients with...', 'thumbnail': 'https://serpapi.com/searches/6721f20dee468296d3575123/images/870f14f50e45973416d9c11b3b519a8a5e8a87ea946949408e86b819f0593d6d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.746374785900116}","{'position': 2, 'link': 'https://www.cgtlive.com/view/kamdar-liso-cel-continued-efficacy-second-line-lbcl-3-year-follow-up', 'title': ""Manali Kamdar, MD, on Liso-Cel's Continued Efficacy in Second-Line LBCL at 3-Year Follow-up"", 'source': 'CGTLive®', 'date': 'Jun 3, 2024', 'snippet': 'The associate professor of medicine at University of Colorado discussed \nupdated follow-up data from the phase 3 TRANSFORM trial presented at...', 'thumbnail': 'https://serpapi.com/searches/6721f20dee468296d3575123/images/870f14f50e4597345a8a6f1d11081895edb4468cbfffd258420f51f878eda981.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9233295917510986}","{'position': 3, 'link': 'https://www.hematologyadvisor.com/features/lymphoma-tandem-meetings-2023-research-shows-favorable-results-treatment/', 'title': 'Tandem Meetings 2023: Research Shows Favorable Results for Lymphoma Subtypes', 'source': 'Hematology Advisor', 'date': 'Mar 31, 2023', 'snippet': 'Research regarding treatment for marginal zone lymphoma (MZL), large B-cell \nlymphoma (LBCL), and mantle cell lymphoma (MCL) presented at the 2023 \nTandem...', 'thumbnail': 'https://serpapi.com/searches/6721f20dee468296d3575123/images/870f14f50e459734d783c7c0c92fc82af4316789f43eb730c2dca8b33d661a6e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6556333303451538}","{'position': 4, 'link': 'https://www.oncnursingnews.com/view/frontline-pola-r-chp-car-t-second-line-therapy-are-not-cost-effective-choices-for-patients-with-dlbcl', 'title': 'Frontline Pola-R-CHP, CAR-T Second-Line Therapy Are Not Cost-Effective Choices For Patients With DLBCL', 'source': 'Oncology Nursing News', 'date': 'Jan 5, 2023', 'snippet': 'An economic analysis showed that neither polatuzumab vedotin nor \nCD19-directed CAR T-cell therapy are likely to be the most cost-effective...', 'thumbnail': 'https://serpapi.com/searches/6721f20dee468296d3575123/images/870f14f50e459734bb3ad91f5405a61b23f7e21e4665fb3743b42047fd3132e8.png', 'sentiment': 'negative', 'sentiment_prob': 0.6230538487434387}","{'position': 5, 'link': 'https://www.onclive.com/view/liso-cel-shows-improved-efs-pfs-and-durable-responses-in-second-line-lbcl-at-3-years', 'title': 'Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years', 'source': 'OncLive', 'date': 'Jun 27, 2024', 'snippet': 'Lisocabtagene maraleucel (liso-cel; Breyanzi) continued to demonstrate \nimproved disease control and event-free and progression-free survival (PFS) \ncompared...', 'thumbnail': 'https://serpapi.com/searches/6721f20dee468296d3575123/images/870f14f50e4597341d38ad8940071b323e5fda6a66a4e202780c6e4863597982.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.656090497970581}","{'position': 6, 'link': 'https://www.onclive.com/view/fda-approval-insights-liso-cel-in-second-line-relapsed-refractory-lbcl', 'title': 'FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL', 'source': 'OncLive', 'date': 'Jul 28, 2022', 'snippet': 'Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large \nB-cell lymphoma, pivotal efficacy and safety data from the phase 3...', 'thumbnail': 'https://serpapi.com/searches/6721f20dee468296d3575123/images/870f14f50e4597346d4809ef2cc091952277db3d37fe36d3c4652111c707d88f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8362480998039246}",,,,,"['neutral', 'neutral', 'neutral', 'negative', 'positive', 'neutral']",neutral,1
NCT02657343,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-021-00311-y', 'title': 'Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer', 'source': 'Nature', 'date': 'Aug 4, 2021', 'snippet': 'Patients with HER2+ metastatic breast cancer are often treated with a \nmultitude of therapies in the metastatic setting, and additional...', 'thumbnail': 'https://serpapi.com/searches/6721f24472e5c4745ca75a65/images/252b515ba591c7a4932da8546fde12d9621685a19a297b53997db32c000dbae6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8565197587013245}",,,,,,,,,,['neutral'],neutral,1
NCT04519567,"{'position': 1, 'link': 'https://friedreichsataxianews.com/friedreichs-ataxia-experimental-treatments/cti-1601/', 'title': ""CTI-1601 for Friedreich's ataxia"", 'source': ""Friedreich's Ataxia News"", 'date': 'Aug 15, 2017', 'snippet': 'Nomlabofusp, also known as CTI-1601, is a potential FA therapy by Larimar \nTherapeutics designed to increase frataxin levels.', 'thumbnail': 'https://serpapi.com/searches/6721f2c0c5d7695cb84e08ac/images/677d03c0639ba0bf116750372df90c8104a37cfd92604f6d45a0b01eee6dfed3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8881443738937378}","{'position': 2, 'link': 'https://friedreichsataxianews.com/news/first-friedreichs-ataxia-patient-dosed-ole-study-nomlabofusp/', 'title': 'First FA patient dosed in OLE study of nomlabofusp, formerly CTI-1601', 'source': ""Friedreich's Ataxia News"", 'date': 'Mar 19, 2024', 'snippet': 'The first patient has been dosed in a long-term, open-label extension (OLE) \nof a Phase 2 dose escalation study that tested nomlabofusp, formerly \nCTI-1601.', 'thumbnail': 'https://serpapi.com/searches/6721f2c0c5d7695cb84e08ac/images/677d03c0639ba0bfd584ed523e4382d2a1ee14a8dd347a54fc8b10f5e2676454.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8837335109710693}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01227278,"{'position': 1, 'link': 'https://copdnewstoday.com/news/no-reduction-copd-exacerbations-add-on-fasenra-phase-3-trials/', 'title': 'No Reduction in COPD Exacerbations with Fasenra Add-on in Phase 3 Trials', 'source': 'COPD News Today', 'date': 'Jun 11, 2019', 'snippet': 'Add-on treatment with Fasenra (benralizumab) failed to reduce annual \nexacerbations in patients with moderate to very severe COPD,...', 'thumbnail': 'https://serpapi.com/searches/6721f2cbdda9d9ba7d3b7d84/images/cdcda7f5535c5a670c6139b3a5d1426b6f6a83cc238dba29461265f9158c4bb5.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7574577331542969}",,,,,,,,,,['negative'],negative,0
NCT02610283,"{'position': 1, 'link': 'https://www.drugdiscoverytrends.com/quark-pharmaceuticals-reports-positive-phase-2-results-to-evaluate-the-efficacy-and-safety-of-qpi-1002/', 'title': 'Quark Pharmaceuticals Reports Positive Phase 2 Results to Evaluate the Efficacy and Safety of QPI-1002', 'source': 'www.drugdiscoverytrends.com', 'date': 'Jul 28, 2017', 'snippet': 'Quark Pharmaceuticals announced successful completion of a randomized, \ndouble-blinded, placebo-controlled multicenter Phase 2 trial of...', 'thumbnail': 'https://serpapi.com/searches/6721f2e7a32436e9acd167b0/images/25edf0eabe4f06cb488a996a3a29f49220d8a88bf06aa381a414d2abeb23a2c7.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6692343354225159}",,,,,,,,,,['positive'],positive,1
NCT04183335,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02320-9', 'title': 'Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials', 'source': 'Nature', 'date': 'May 4, 2023', 'snippet': 'Prurigo nodularis (PN) is a chronic inflammatory skin disease with \nintensely pruritic nodules. The LIBERTY-PN PRIME and PRIME2 phase 3...', 'thumbnail': 'https://serpapi.com/searches/6721f343c05eb50a3493b07d/images/cea6edddb7ad2beb9a1f5bd40f1e6db960686f354fd2efa5b087a7899e15b161.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7423474192619324}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/significant-improvements-observed-with-dupilumab-in-prurigo-nodularis-trial/', 'title': 'Significant Improvements Observed With Dupilumab in Prurigo Nodularis Trial', 'source': 'Medical Professionals Reference', 'date': 'Jan 19, 2022', 'snippet': 'Patients with prurigo nodularis treated with dupilumab experienced a \nclinically significant reduction in itch, according to new phase 3 data.', 'thumbnail': 'https://serpapi.com/searches/6721f343c05eb50a3493b07d/images/cea6edddb7ad2beb9dfa1688cda8c84d9f06ad38153b92395419f809aa3b48be.png', 'sentiment': 'positive', 'sentiment_prob': 0.6337721347808838}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT00690274,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2012.00072/full', 'title': ""Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse"", 'source': 'Frontiers', 'date': 'Jun 30, 2024', 'snippet': 'Histamine H3 receptor (H3R) antagonists/inverse agonists possess potential \nto treat diverse disease states of the central nervous system (CNS).', 'thumbnail': 'https://serpapi.com/searches/6721f37cfab273f994d8650d/images/4733a86fa039e55260566a557aa1b7218345c0479c092722ec34c045b3fa4ad7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8685241937637329}",,,,,,,,,,['neutral'],neutral,1
NCT00088699,"{'position': 1, 'link': 'https://www.nature.com/articles/s41398-024-02956-2', 'title': 'Functional changes in sleep-related arousal after ketamine administration in individuals with treatment-resistant depression | Translational Psychiatry', 'source': 'Nature', 'date': 'Jun 4, 2024', 'snippet': 'This study sought to evaluate differences in arousal-related sleep metrics \nbetween 36 individuals with treatment-resistant major depression (TRD) and \n25...', 'thumbnail': 'https://serpapi.com/searches/6721f38d3c9575672023d861/images/81a530fb6fa2d900d73bc62c4caef82da974e57fe44b3bce20165926f17f5d8e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9081106185913086}","{'position': 2, 'link': 'https://www.researchgate.net/figure/Effects-of-ketamine-on-mood-Graphs-of-the-marginal-means-derived-from-the-linear-mixed_fig4_323433778', 'title': 'Effects of ketamine on mood. Graphs of the marginal means derived from...', 'source': 'ResearchGate', 'date': 'Dec 27, 2020', 'snippet': 'Download scientific diagram | Effects of ketamine on mood. Graphs of the \nmarginal means derived from the linear mixed models for the \nMontgomery-Åsberg...', 'thumbnail': 'https://serpapi.com/searches/6721f38d3c9575672023d861/images/81a530fb6fa2d90020eea1b59af52c6e5e932943e1824a3fb67e6087ae273aaf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9119168519973755}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02123823,"{'position': 1, 'link': 'https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01382-8', 'title': 'A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer', 'source': 'Breast Cancer Research', 'date': 'Jan 15, 2021', 'snippet': 'This phase Ib/II exploratory trial evaluated xentuzumab plus everolimus and \nexemestane in hormone receptor-positive, locally advanced and/or metastatic \nbreast...', 'thumbnail': 'https://serpapi.com/searches/6721f407d0253ebcf8559da7/images/de09b1904eb2881cb051cc0642824ff6835dda93e17a86ccc02708791d838016.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8782196044921875}",,,,,,,,,,['neutral'],neutral,1
NCT03390296,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-00361-x', 'title': 'Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy', 'source': 'Nature', 'date': 'Dec 18, 2020', 'snippet': 'Here we review the development of novel therapeutics in targeting \napoptosis, receptor tyrosine kinase (RTK) signaling, hedgehog (HH) pathway, \nmitochondrial...', 'thumbnail': 'https://serpapi.com/searches/6721f407ba13f21ac051239f/images/c5e8057f41e376dce779ccb5f136ba760133a2f14b4a69fd7f7a963e7ddfa99d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8912065029144287}",,,,,,,,,,['neutral'],neutral,1
NCT02503657,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/medicinovas-mn-001-ipf-fails-slow-lung-function-decline-trial/', 'title': ""MediciNova's MN-001 for IPF Fails to Slow Lung Function Decline in Trial"", 'source': 'Pulmonary Fibrosis News', 'date': 'Aug 23, 2021', 'snippet': 'Six months of treatment with MN-001 failed to significantly improve lung \nfunction in adults with idiopathic pulmonary fibrosis, data show.', 'thumbnail': 'https://serpapi.com/searches/6721f427cc29875e745349e9/images/7a3d1b25fdd5fbcdad8950ee991973e7b2045315aa2c5acb7ae510d39bbeb74b.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8319323658943176}",,,,,,,,,,['negative'],negative,0
NCT04286750,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332221011471', 'title': 'Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans', 'source': 'ScienceDirect.com', 'date': 'Oct 28, 2021', 'snippet': 'Here, we report the target engagement of ACT-1004-1239 in healthy mice and \nhumans after multiple doses using CXCL11 and CXCL12 as biomarkers.', 'thumbnail': 'https://serpapi.com/searches/6721f430e45f339e017337f0/images/c1238da527b52c07829c8d0d26a114a7e1bc291d0af90df1c455a8f4bf2bc5ad.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7495174407958984}",,,,,,,,,,['neutral'],neutral,1
NCT02743221,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-022-01737-2', 'title': 'First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer', 'source': 'Nature', 'date': 'Apr 19, 2022', 'snippet': 'The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting \nwas evaluated in the TASCO1 trial; here, we present the final overall \nsurvival (OS)...', 'thumbnail': 'https://serpapi.com/searches/6721f452ee677f6cfefc7574/images/ab577a588653f5d6911715bc422a0f74677742f81f020950df32428b1e7a57aa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8699007034301758}",,,,,,,,,,['neutral'],neutral,1
NCT01522820,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1255799/full', 'title': 'Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment', 'source': 'Frontiers', 'date': 'Feb 7, 2024', 'snippet': 'Here, we summarized the current advances in cancer vaccines targeting \nNY-ESO-1 for solid cancer treatment, aiming to provide perspectives for \nfuture research.', 'thumbnail': 'https://serpapi.com/searches/6721f4584d52b8a072853b6e/images/ca52ad25d09cf093b916163c2c4600f3f2bb161fe78283349ebeedb6bff5f41d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.875281810760498}",,,,,,,,,,['neutral'],neutral,1
NCT05261191,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-024-01176-4', 'title': 'Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases', 'source': 'Nature', 'date': 'May 24, 2024', 'snippet': 'By binding to multiple antigens simultaneously, multispecific antibodies \nare expected to substantially improve both the activity and...', 'thumbnail': 'https://serpapi.com/searches/6721f46a49ea55cde45bbb81/images/30f43337d8013f0c50e3aaad03efadd1e3b4a02a294dc8bd877d45522cb2a8f1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7509574294090271}",,,,,,,,,,['neutral'],neutral,1
NCT02928224,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1908075', 'title': 'Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Sep 30, 2019', 'snippet': 'Patients with metastatic colorectal cancer with the BRAF V600E mutation \nhave a poor prognosis, with a median overall survival of 4 to 6...', 'thumbnail': 'https://serpapi.com/searches/6721f4a39109867ea0071961/images/669cb36c7f3370665a023c8eef0370a7ef537eae6b6a16dcc4626c39b9190072.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6425409317016602}","{'position': 2, 'link': 'https://coloncancernewstoday.com/2017/06/01/microsatellite-stable-colorectal-cancer-patients-focus-binimetinib-opdivo-yervoy-trial/', 'title': 'Microsatellite Stable Colorectal Cancer Patients Focus of Binimetinib-Opdivo-Yervoy Trial', 'source': 'Colon Cancer News Today', 'date': 'Jun 1, 2017', 'snippet': 'The MEK inhibitor, binimetinib, will soon be tested in combination with \nOpdivo plus Yervoy in colorectal cancer patients with microsatellite...', 'thumbnail': 'https://serpapi.com/searches/6721f4a39109867ea0071961/images/669cb36c7f337066d1ad0eed2682022e5b4c49cb14197172e803f03adddc1cce.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9217116236686707}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT02252016,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/zepatier-effective-against-hcv-infection-in-sickle-cell-blood-disorders-in-clinical-trial/', 'title': 'Sickle Cell Patients with HCV Infection Treated with Zepatier in Phase 3 Study', 'source': 'Sickle Cell Disease News', 'date': 'Mar 9, 2017', 'snippet': 'Results of a Phase 3 clinical trial in sickle cell and other blood disorder \npatients found Zepatier an effective antiviral agent against HCV...', 'thumbnail': 'https://serpapi.com/searches/6721f4d588bcdefebd9aad46/images/375d5e6c8e991f408ebec79d5e2f73b16843c7d70e94e909de741850d57868fe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8537318706512451}",,,,,,,,,,['neutral'],neutral,1
NCT04435366,"{'position': 1, 'link': 'https://www.genengnews.com/topics/drug-discovery/astellas-to-acquire-iveric-bio-for-5-9b-expanding-eye-disease-pipeline/', 'title': 'Astellas to Acquire Iveric Bio for $5.9B, Expanding Eye Disease Pipeline', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'May 1, 2023', 'snippet': ""Astellas Pharma has agreed to acquire Iveric Bio for approximately $5.9 \nbillion, the companies said today, in a deal designed to expand the buyer's \npipeline of..."", 'thumbnail': 'https://serpapi.com/searches/6721f4dcc76a22ae2333611e/images/2ff36dd471b9d5666a6dbfa6a0c1bbbbc6ed834710d46bbb961ec1a28350ed9f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8609184622764587}",,,,,,,,,,['neutral'],neutral,1
NCT01524289,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/circ.130.suppl_2.9613', 'title': 'Abstract 9613: Randomized Evaluation of Anacetrapib Lipid-Modifying Therapy in Patients With HeteroZygous Familial HypercholesterolEmia (REALIZE Study)', 'source': 'American Heart Association Journals', 'date': 'Nov 25, 2014', 'snippet': 'Introduction: Anacetrapib, a cholesteryl ester transfer protein inhibitor, \nhas been shown to robustly reduce atherogenic lipoproteins...', 'thumbnail': 'https://serpapi.com/searches/6721f4e7b2ebaeb5ae24b6e2/images/8909766d64db820d44a94c72eed94f5cad439a9888e9d5c8301aa9f9f862d165.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8853394389152527}",,,,,,,,,,['neutral'],neutral,1
NCT04402489,"{'position': 1, 'link': 'https://porphyrianews.com/news/mt-7117-eases-sunlight-sensitivity-epp-xlp-patients-phase-2-trial/', 'title': 'MT-7117 found to ease sunlight sensitivity for EPP, XLP patients |...', 'source': 'Porphyria News', 'date': 'Apr 19, 2023', 'snippet': 'The oral therapy MT-7117 was found to ease sunlight sensitivity and improve \nlife quality for porphyria patients in a Phase 2 trial.', 'thumbnail': 'https://serpapi.com/searches/6721f53b69f8eca1f4572dd3/images/7901fa1f41508116d9dc59999af81bf9402ae63bb96fe15801661d918bb2600a.png', 'sentiment': 'positive', 'sentiment_prob': 0.5625188946723938}","{'position': 2, 'link': 'https://porphyrianews.com/phase-3-trial-mt-7117-for-epp-xlp-porphyrias/', 'title': 'MT-7117 Poised for Phase 3 Trial in Two Types of Porphyrias', 'source': 'Porphyria News', 'date': 'May 29, 2020', 'snippet': ""A Phase 3 clinical trial of Mitsubishi Tanabe's investigational therapy \nMT-7117 (dersimelagon) for people with erythropoietic protoporphyria..."", 'thumbnail': 'https://serpapi.com/searches/6721f53b69f8eca1f4572dd3/images/7901fa1f4150811609d12cffbc89610c0d9bace28fddf00271fba67a487e311f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8879155516624451}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT04535986,"{'position': 1, 'link': 'https://copdnewstoday.com/news/benefits-ensifentrine-copd-seen-among-patient-subgroups/', 'title': 'Benefits of ensifentrine for COPD seen among subgroups of patients', 'source': 'COPD News Today', 'date': 'Oct 23, 2023', 'snippet': ""Phase 3 analyses continue to show ensifentrine's benefits, even when \npatients are separated by exacerbation history, background therapy."", 'thumbnail': 'https://serpapi.com/searches/6721f54e88bcdefebd9aada0/images/88f8c7879eb124185e4f2b142e223761532d7360626a24f64ccca995ab6e326f.png', 'sentiment': 'positive', 'sentiment_prob': 0.7557270526885986}","{'position': 2, 'link': 'https://www.drugtopics.com/view/fda-approves-ensifentrine-for-treatment-of-copd', 'title': 'FDA Approves Ensifentrine for Treatment of COPD', 'source': 'Drug Topics', 'date': 'Jun 27, 2024', 'snippet': 'The FDA has approved ensifentrine (Ohtuvayre) for the maintenance treatment \nof chronic obstructive pulmonary disease (COPD) in adult patients.', 'thumbnail': 'https://serpapi.com/searches/6721f54e88bcdefebd9aada0/images/88f8c7879eb12418fad6914dc4f0e0f2656711344904d148038c5122388cc968.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7171338796615601}","{'position': 3, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/nebulized-ensifentrine-significantly-improves-lung-function-copd-symptoms/', 'title': 'Nebulized Ensifentrine Significantly Improves Lung Function, COPD Symptoms', 'source': 'Medical Professionals Reference', 'date': 'Dec 20, 2022', 'snippet': 'Treatment with nebulized ensifentrine resulted in significant improvements \nin lung function and reduced the rate and risk of chronic obstructive \npulmonary...', 'thumbnail': 'https://serpapi.com/searches/6721f54e88bcdefebd9aada0/images/88f8c7879eb1241849101317d2ea671e474739a196b52d114740c8527bd491a8.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6964200139045715}","{'position': 4, 'link': 'https://copdnewstoday.com/news/fda-decision-ensifentrine-expected-june-26-next-year-verona/', 'title': ""FDA's decision on ensifentrine for COPD expected by June 26 next..."", 'source': 'COPD News Today', 'date': 'Sep 18, 2023', 'snippet': ""The U.S. Food and Drug Administration (FDA) has agreed to review Verona \nPharma's application seeking approval of inhaled ensifentrine as a..."", 'thumbnail': 'https://serpapi.com/searches/6721f54e88bcdefebd9aada0/images/88f8c7879eb124187ec230864fb363c4b58e9b8bb6168790820c5f28117d5c48.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9323532581329346}","{'position': 5, 'link': 'https://copdnewstoday.com/news/first-copd-patient-dosed-ensifentrine-enhance-china-trial/', 'title': 'Dosing with ensifentrine begins in ENHANCE China trial | Phase 3...', 'source': 'COPD News Today', 'date': 'Apr 24, 2023', 'snippet': 'Dosing with ensifentrine, a nebulized inhalation therapy, has begun in a \nPhase 3 trial in China in adults with moderate-to-severe COPD.', 'thumbnail': 'https://serpapi.com/searches/6721f54e88bcdefebd9aada0/images/88f8c7879eb12418dd7b3575f4f4040903a5f94e28569c8cd5886448c1d4fe63.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9163825511932373}","{'position': 6, 'link': 'https://copdnewstoday.com/news/inhaled-ensifentrine-improves-lung-function-phase-3-trial-shows/', 'title': 'Inhaled Ensifentrine Improves Lung Function, Phase 3 Trial Shows |...', 'source': 'COPD News Today', 'date': 'Aug 22, 2022', 'snippet': 'Ensifentrine safely and effectively improved lung function and reduced the \nrate and risk of exacerbations in COPD patients in a trial.', 'thumbnail': 'https://serpapi.com/searches/6721f54e88bcdefebd9aada0/images/88f8c7879eb12418c78b1bfa7a8bef69071d989776bb2dc06e53eca4c9a252c8.png', 'sentiment': 'positive', 'sentiment_prob': 0.7553162574768066}","{'position': 7, 'link': 'https://copdnewstoday.com/news/directrx-pharmacy-distributing-copd-therapy-ohtuvayre-us/', 'title': 'DirectRx pharmacy distributing COPD therapy Ohtuvayre in US', 'source': 'COPD News Today', 'date': '1 month ago', 'snippet': 'DirectRx, a specialty pharmacy for people with chronic health disorders, is \nnow part of the exclusive US pharmacy network distributing Ohtuvayre \n(ensifentrine).', 'thumbnail': 'https://serpapi.com/searches/6721f54e88bcdefebd9aada0/images/88f8c7879eb12418cca5e89a56b47a6a428bcf3dae348759ddcc42a6878d0683.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9034528732299805}",,,,"['positive', 'neutral', 'positive', 'neutral', 'neutral', 'positive', 'neutral']",neutral,1
NCT02515838,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/phase-1-trial-test-under-the-skin-injection-sevuparin-scd/', 'title': 'Phase 1 Trial to Test Under-the-Skin Injection of Sevuparin for SCD', 'source': 'Sickle Cell Disease News', 'date': 'Nov 8, 2018', 'snippet': ""The U.S. FDA granted investigational new drug status to Modus Therapeutics' \nlead candidate, sevuparin, for the treatment of sickle cell..."", 'thumbnail': 'https://serpapi.com/searches/6721f6075f9778877f2124d8/images/90631cf744bc5d02d0b35dbd9b0f5f298811f4e2f51bcb9b33b73050be43a23e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8796523809432983}",,,,,,,,,,['neutral'],neutral,1
NCT00949650,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.2012.44.2806', 'title': 'Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Mar 19, 2019', 'snippet': 'PurposeThe LUX-Lung 3 study investigated the efficacy of chemotherapy \ncompared with afatinib, a selective, orally bioavailable ErbB family \nblocker that...', 'thumbnail': 'https://serpapi.com/searches/6721f669ee677f6d30537119/images/d3a4de43486de8dc20736b3b03f85987c9a4d21e598b1da4e2847b266cf87871.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9063786864280701}",,,,,,,,,,['neutral'],neutral,1
NCT02201940,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1512610', 'title': 'Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection', 'source': 'The New England Journal of Medicine', 'date': 'Nov 16, 2015', 'snippet': 'A simple treatment regimen that is effective in a broad range of patients \nwho are chronically infected with the hepatitis C virus (HCV)...', 'thumbnail': 'https://serpapi.com/searches/6721f67a9109867ed40002d2/images/be40677dbf804e199993461eda05716c436e045cc49d160b26bbd17135a3f3d8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8235917091369629}",,,,,,,,,,['neutral'],neutral,1
NCT00150709,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Keppra-levetiracetam', 'title': 'Levetiracetam (Keppra®)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Epilepsy, A Study of Levetiracetam as Monotherapy or Adjunctive Treatment \nof Partial Seizures in Pediatric Epileptic Subjects Ranging From 1...', 'thumbnail': 'https://serpapi.com/searches/6721f6823c944b515f583773/images/d32e44ee6f43434cf0bf14b0265df95b4e28c916cc3eac10ed882145127cd1e8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9234092831611633}",,,,,,,,,,['neutral'],neutral,1
NCT03889639,"{'position': 1, 'link': 'https://www.ajmc.com/view/tolebrutinib-long-term-data-continue-to-show-the-btk-inhibitor-is-safe-clinically-effective-in-ms', 'title': 'Tolebrutinib Long-term Data Continue to Show the BTK Inhibitor Is Safe, Clinically Effective in MS', 'source': 'AJMC', 'date': 'Apr 24, 2023', 'snippet': 'Safety and clinical efficacy data through 120 weeks from a long-term \nextension study of an ongoing phase 2b dose-finding study of...', 'thumbnail': 'https://serpapi.com/searches/6721f583bcd652e60fd895ab/images/2d222d27ca60e226e5925aec4497a8bf061a3b7a500989036466f354e1f1fc38.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7259016633033752}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/tolebrutinib-multiple-sclerosis/', 'title': 'Tolebrutinib in MS | Experimental MS Treatments', 'source': 'Multiple Sclerosis News Today', 'date': 'May 25, 2022', 'snippet': 'Tolebrutinib is an oral antibiotic being evaluated as a potential treatment \nfor MS. Learn more about its uses, side effects, and clinical...', 'thumbnail': 'https://serpapi.com/searches/6721f583bcd652e60fd895ab/images/2d222d27ca60e2265bf296353ab71ab9415a0a4a9b8a7b7a7746e823f9ac3402.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9278059601783752}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/10/16/ectrims-2023-tolebrutinib-prevents-relapses-lesions-3-years/', 'title': 'ECTRIMS 2023: Tolebrutinib found to show benefits for up to 3 years', 'source': 'Multiple Sclerosis News Today', 'date': 'Oct 16, 2023', 'snippet': 'Three years of treatment with tolebrutinib was linked to low relapses rates \nand few new brain lesions among relapsing MS patients,...', 'thumbnail': 'https://serpapi.com/searches/6721f583bcd652e60fd895ab/images/2d222d27ca60e226afeef83364794bb5287556f464c545a9649e655136764630.png', 'sentiment': 'positive', 'sentiment_prob': 0.7722958922386169}",,,,,,,,"['positive', 'neutral', 'positive']",positive,1
NCT03757325,"{'position': 1, 'link': 'https://www.nature.com/articles/s41573-020-0071-y', 'title': 'Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target', 'source': 'Nature', 'date': 'Jul 15, 2020', 'snippet': 'Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a key \nmediator of cell death and inflammation.', 'thumbnail': 'https://serpapi.com/searches/6721f5ae8b84c46faaa3ebad/images/78d801c76955ff9f1fa6cbb2b254d39e46a6a970f1b9a74013fe08d6762460de.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.4965638518333435}",,,,,,,,,,['negative'],negative,0
NCT03748784,"{'position': 1, 'link': 'https://www.cureus.com/articles/110149-ocular-gene-therapy-a-literature-review-with-focus-on-current-clinical-trials', 'title': 'Ocular Gene Therapy: A Literature Review With Focus on Current Clinical Trials', 'source': 'Cureus', 'date': 'Sep 24, 2022', 'snippet': 'Gene therapy has been one of the most researched topics in the last decade. \nIt has now become a revolutionized therapeutic tool of modern...', 'thumbnail': 'https://serpapi.com/searches/6721f5f6cb33d0118fb660a6/images/bebcbd110436bc69cc66cbf2547fbfb74fe3315388f6001544dfe72d1879f0ae.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8775461316108704}",,,,,,,,,,['positive'],positive,1
NCT03036813,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1903212', 'title': 'A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease', 'source': 'The New England Journal of Medicine', 'date': 'Jun 14, 2019', 'snippet': 'In this phase 3 randomized, placebo-controlled trial involving participants \nwith sickle cell disease, voxelotor significantly increased hemoglobin \nlevels and...', 'thumbnail': 'https://serpapi.com/searches/6721f6a264f11dc06ff496f5/images/6a550cccdb4ddb4ded33022936bb76d2faae67d148ca905e6ddbd946a221d515.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9134081602096558}","{'position': 2, 'link': 'https://sicklecellanemianews.com/news/voxelotor-may-reduce-severity-number-leg-ulcers-analysis-trial-results-suggests/', 'title': 'Voxelotor May Reduce Severity and Number of Leg Ulcers, Trial Analysis Suggests', 'source': 'Sickle Cell Disease News', 'date': 'Oct 22, 2019', 'snippet': 'Voxelotor can reduce the severity of existing leg ulcers and the incidence \nof new ones in people with sickle cell disease (SCD), new clinical trial \nresults...', 'thumbnail': 'https://serpapi.com/searches/6721f6a264f11dc06ff496f5/images/6a550cccdb4ddb4da5715b55052c2771694d267e356bba06b4b13047ba1330c7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.828925609588623}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04238793,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/pipeline-moves-novartis-terminate-phase-ii-als-trial-after-benefit-risk-worry/', 'title': 'Pipeline Moves: Novartis terminates Phase II ALS trial after benefit-risk worry', 'source': 'Clinical Trials Arena', 'date': 'Aug 6, 2024', 'snippet': ""On this week's Pipeline Moves, the Clinical Trials Arena team investigates \nassets in the central nervous system, oncology and immunology."", 'thumbnail': 'https://serpapi.com/searches/6721f6a5caddc31d1631838e/images/b1263d98d8309401eedcdd9f45324a016f36c9fce75c281c11b9bcc55df77b5a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7738231420516968}",,,,,,,,,,['neutral'],neutral,1
NCT03461289,"{'position': 1, 'link': 'https://smanewstoday.com/news/canadian-agency-favors-zolgensma-only-for-babies-up-to-6-months-old/', 'title': 'Zolgensma Favored Only for SMA Babies Up to 6 Months Old in Canada', 'source': 'SMA News Today', 'date': 'Oct 6, 2021', 'snippet': 'A Canadian agency found evidence lacking to support gene therapy \nreimbursement in older babies and toddlers with spinal muscular atrophy.', 'thumbnail': 'https://serpapi.com/searches/6721f6e69e5bd52d11a9e220/images/af9da5f7e38277959e02b3b37f1ff32d67f75021bce1834a91a7c25b01d8cc07.png', 'sentiment': 'negative', 'sentiment_prob': 0.6065951585769653}",,,,,,,,,,['negative'],negative,0
NCT03606512,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-020-0200-y', 'title': 'Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice', 'source': 'Nature', 'date': 'Jun 12, 2020', 'snippet': 'An adenoviral vector-based RSV F vaccine candidate (Ad26.RSV.FA2) induces \nTh1-biased protective immune responses, without signs of ERD upon \nsubsequent RSV...', 'thumbnail': 'https://serpapi.com/searches/6721f6fd76079d9be2416a8a/images/958da40a441775d47c9e93827584bb5078b8320f0ead4111df9d570f47ae8950.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8525443077087402}",,,,,,,,,,['neutral'],neutral,1
NCT05621252,"{'position': 1, 'link': 'https://finance.yahoo.com/news/pliant-therapeutics-announces-positive-topline-113000005.html', 'title': 'Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis', 'source': 'Yahoo Finance', 'date': 'May 14, 2024', 'snippet': '12-week treatment with Bexotegrast 160 mg resulted in reduction of total \nlung collagen as measured by PET imaging, compared to an increase on \nplacebo.', 'thumbnail': 'https://serpapi.com/searches/6721f7280c08f2d3680ae1cd/images/0b61191ccc5a955c0090756b741997159528e97d3605db27f3c9145b1a5476e8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6482718586921692}",,,,,,,,,,['neutral'],neutral,1
NCT03228433,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01341-7', 'title': 'Targeting epigenetic regulators to overcome drug resistance in cancers', 'source': 'Nature', 'date': '١٧\u200f/٠٢\u200f/٢٠٢٣', 'snippet': 'Drug resistance is mainly responsible for cancer recurrence and poor \nprognosis. Epigenetic regulation is a heritable change in gene...', 'thumbnail': 'https://serpapi.com/searches/6721f7495ddfba5b08c67525/images/f48cc262febe02175e3ac3db50b410526d5060fcbaad5746d91daf1b8cb0fa53.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6539433002471924}",,,,,,,,,,['negative'],negative,0
NCT03682796,"{'position': 1, 'link': 'https://www.oncozine.com/interim-results-of-phase-i-study-confirms-safety-with-early-signs-of-efficacy-for-trph-222-in-nhl/', 'title': 'Interim Results of Phase I Study Confirms Safety with Early Signs of Efficacy for TRPH-222 in NHL', 'source': ""Onco'Zine"", 'date': 'May 18, 2020', 'snippet': 'TRPH-222, a novel anti-CD22 antibody-drug conjugate (ADC), has significant \nanti-tumor activity in NHL xenografts and reduces B cells in monkeys.', 'thumbnail': 'https://serpapi.com/searches/6721f78221e77b947e9fb10c/images/12c44719db0c42dce31d15d0a46068abed05069db8a88d0196100f5ddf8d50a2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7889788746833801}",,,,,,,,,,['neutral'],neutral,1
NCT02631759,"{'position': 1, 'link': 'https://first10em.com/the-peach-trial-of-seizure-prophylaxis-for-head-bleeds-not-such-a-peach/', 'title': 'The PEACH trial of seizure prophylaxis for head bleeds: Not such a peach', 'source': 'First10EM', 'date': 'Oct 10, 2022', 'snippet': 'Safety and efficacy of prophylactic levetiracetam for prevention of \nepileptic seizures in the acute phase of intracerebral haemorrhage (PEACH)', 'thumbnail': 'https://serpapi.com/searches/6721f78f8f2bc259e15fdba5/images/c714b20ff3b77672821d9c190a4480e441bb373c3a52d5e67fb2d49029567070.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6412749886512756}",,,,,,,,,,['neutral'],neutral,1
NCT04452318,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2109682', 'title': 'Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Aug 4, 2021', 'snippet': 'REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal \nantibodies casirivimab and imdevimab, has been shown to markedly...', 'thumbnail': 'https://serpapi.com/searches/6721f7a1272a87d825ae80ef/images/3499858b27b6742332a764b6f5a6cc155256ce9d37979cac9db923ed9e39ffaa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8475948572158813}",,,,,,,,,,['neutral'],neutral,1
NCT00911495,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/phase-3-trial-recruiting-to-test-rivipansel-for-vaso-occlusive-crisis-in-sickle-cell-disease/', 'title': 'Clinical Trial Seeking Vaso-Occlusive Sickle Cell Patients to Test Rivipansel', 'source': 'Sickle Cell Disease News', 'date': 'May 11, 2017', 'snippet': 'A Phase 3 clinical trial to test the effectiveness and safety of the drug \ncandidate rivipansel (GMI-1070) for the treatment of vaso-occlusive crisis \n(VOC) in...', 'thumbnail': 'https://serpapi.com/searches/6721f7e0f963e7b1d3098179/images/1762751f1282628104c7a268358f9548a1cc1556eb2043d86fdf4a127726b069.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8787412643432617}",,,,,,,,,,['neutral'],neutral,1
NCT04916431,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S2405844024030020', 'title': 'The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases', 'source': 'ScienceDirect.com', 'date': 'Mar 15, 2024', 'snippet': 'This review aims to elucidate the advancements in the clinical applications \nof mRNAs for addressing significant health-related challenges such as \ncancer,...', 'thumbnail': 'https://serpapi.com/searches/6721f80898fad682efca3473/images/efbbb53cb81c8092f6d584bd19081def1c1ec088a65dd49245be3a07580b5ddf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8580176830291748}","{'position': 2, 'link': 'https://www.nature.com/articles/s41435-023-00221-y', 'title': 'IL-2 immunotherapy for targeting regulatory T cells in autoimmunity', 'source': 'Nature', 'date': 'Sep 23, 2023', 'snippet': 'A new and promising focus in drug development are IL-2-based approaches for \nin vivo targeted expansion of T reg or for enhancement of their \nsuppressive...', 'thumbnail': 'https://serpapi.com/searches/6721f80898fad682efca3473/images/efbbb53cb81c8092aed5780a5cd213dad6a8359ea438b3fc3f772c577a4114be.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6119940280914307}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01817530,"{'position': 1, 'link': 'https://endometriosisnews.com/2017/11/06/elagolix-seen-to-lessen-endometriosis-pain-and-spread-in-yearlong-phase-3-studies/', 'title': 'Elagolix Seen to Ease Endometriosis Pain and Spread in Yearlong Phase 3 Studies', 'source': 'endometriosisnews.com', 'date': 'Nov 6, 2017', 'snippet': 'Results of two Phase 3 extension studies showed that one year of treatment \nwith elagolix could reduce pelvic pain, prevent proliferation of...', 'thumbnail': 'https://serpapi.com/searches/6721f8280be2f68716dd1f5f/images/bd06521ab4019504d0a3b9e52dff4125cef329746488a2639967afc5e47c27d6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7788125872612}",,,,,,,,,,['neutral'],neutral,1
NCT03004183,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-022-00486-y', 'title': 'Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors | npj Breast Cancer', 'source': 'Nature', 'date': 'Nov 9, 2022', 'snippet': 'The development of immunotherapy agents has revolutionized the field of \noncology. The only FDA-approved immunotherapeutic approach in breast...', 'thumbnail': 'https://serpapi.com/searches/6721f8562da1575f5eaf3a10/images/8082ff0215287bd30a697b9845f6530e5bc51aac5cb1ffff29f7b1ed4fdc1c17.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5897006392478943}",,,,,,,,,,['neutral'],neutral,1
NCT02967692,"{'position': 1, 'link': 'https://ascopubs.org/doi/abs/10.1200/jco.21.01601', 'title': 'Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma', 'source': 'ASCO Publications', 'date': 'Jan 14, 2022', 'snippet': 'COMBI-i is a phase III trial evaluating spartalizumab, an anti–programmed \ndeath receptor 1 antibody, in combination with dabrafenib and trametinib \n(sparta-...', 'thumbnail': 'https://serpapi.com/searches/6721f858adc33bdf846733d3/images/6b4de0b9b1a1200fc3e69ba464b345a27ed49a125f84ca21c7b54cad047805c6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9034330248832703}",,,,,,,,,,['neutral'],neutral,1
NCT05629962,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/fda-grants-fast-track-status-to-oral-antiviral-bemnifosbuvir-for-covid-19/', 'title': 'FDA Grants Fast Track Status to Oral Antiviral Bemnifosbuvir for COVID-19', 'source': 'Medical Professionals Reference', 'date': 'Apr 25, 2023', 'snippet': 'The Food and Drug Administration (FDA) has granted Fast Track designation \nto bemnifosbuvir, a nucleotide polymerase inhibitor, for the treatment of \nCOVID-19.', 'thumbnail': 'https://serpapi.com/searches/6721f860f60b6f501487e200/images/be9ffe6b52f8cf0a8535d04117506f5b86805ecfd1eba46c93693a788dc110d1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8540853261947632}",,,,,,,,,,['neutral'],neutral,1
NCT03262935,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/reports/trastuzumab-duocarmazine-improves-pfs-her2-advanced-breast-cancer/', 'title': 'Trastuzumab Duocarmazine Improves PFS in HER2+ Advanced Breast Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Oct 23, 2023', 'snippet': 'Results of a phase 3 trial suggest that trastuzumab duocarmazine improves \nprogression-free survival (PFS) over chemotherapy in patients with \npretreated, HER2-...', 'thumbnail': 'https://serpapi.com/searches/6721f87481262aaa2f00b6f0/images/67052d12179adb839ea2bb9f19465b15a2648f01deb0f6b06fdd584edfb1cf58.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5914958715438843}",,,,,,,,,,['neutral'],neutral,1
NCT03215277,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/bimekizumab-UCB4940', 'title': 'Bimekizumab (Bimzelx®)', 'source': 'UCB', 'date': 'Oct 16, 2018', 'snippet': 'Ankylosing Spondylitis, A Multicenter Study to Evaluate the Efficacy and \nSafety of Different Doses of Bimekizumab in Subjects With Active \nAnkylosing...', 'thumbnail': 'https://serpapi.com/searches/6721f919caddc31ce576a0fe/images/4eed49d9bfedf708c5fa77a130362b71435ea96bacf6f5221b1a577bb22f4c37.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8456552028656006}",,,,,,,,,,['neutral'],neutral,1
NCT01847274,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1611310', 'title': 'Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Oct 8, 2016', 'snippet': 'Niraparib is an oral poly(adenosine diphosphate [ADP]–ribose) polymerase \n(PARP) 1/2 inhibitor that has shown clinical activity in patients...', 'thumbnail': 'https://serpapi.com/searches/6721f93f5bb6a287d7d70082/images/390bb411129426192d9002730ebde9f2320ced1aaad4824b97766e77d7738770.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8872370719909668}","{'position': 2, 'link': 'https://ovariancancernewstoday.com/2019/11/01/zejula-maintenance-increases-time-without-symptoms-toxicity-recurrent-ovarian-cancer-patients/', 'title': 'Zejula Maintenance Increases Time Without Symptoms or Toxicity in Recurrent OC Patients, Study Says', 'source': 'Ovarian Cancer News Today', 'date': 'Nov 1, 2019', 'snippet': 'Taking Zejula as maintenance therapy after chemotherapy increases time \nwithout symptoms or toxicities in women with recurrent ovarian cancer...', 'thumbnail': 'https://serpapi.com/searches/6721f93f5bb6a287d7d70082/images/390bb41112942619b40dc01860af67d2a8f254e6bf22363f6b470f1422410d04.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8862812519073486}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02111850,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-022-00486-y', 'title': 'Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors | npj Breast Cancer', 'source': 'Nature', 'date': 'Nov 9, 2022', 'snippet': 'The development of immunotherapy agents has revolutionized the field of \noncology. The only FDA-approved immunotherapeutic approach in breast...', 'thumbnail': 'https://serpapi.com/searches/6721f940861b9d0785b4345a/images/da33155de1f2a93f131a234debcde216aee51fd25a4e9d45b215f226094601f1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5897006392478943}",,,,,,,,,,['neutral'],neutral,1
NCT04607850,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/barinthus-hpv-therapy-meets-primary-endpoint-in-phase-i-ii-trial/', 'title': 'Barinthus’ HPV therapy meets primary endpoint in Phase I/II trial', 'source': 'Clinical Trials Arena', 'date': 'Apr 19, 2024', 'snippet': ""The Phase Ib/II trial evaluated Barinthus' VTP-200 in women with cervical \nlesions due to human papillomavirus (HPV)."", 'thumbnail': 'https://serpapi.com/searches/6721f94574f0a452bffea790/images/1918f92f17aa0d9d2d572836e293fa1c7386f9bd862476c91ebd22c2c4cb0eb0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.858767032623291}",,,,,,,,,,['neutral'],neutral,1
NCT05232175,"{'position': 1, 'link': 'http://m.biospectator.com/view/news_view.php?varAtcId=17887', 'title': '알테오젠, ‘테르가제’ 탑라인 발표..“내년 허가 신청”', 'source': '바이오스펙테이터', 'date': 'Dec 15, 2022', 'snippet': '입력 2022-12-15 10:04 수정 2022-12-15 10:12. 작게 크게. 바이오스펙테이터 김성민 기자. 품목허가용 1상 \n결과 대조군 대비 알러지 발현율 차이없으며,...', 'thumbnail': 'https://serpapi.com/searches/6721f956f3622abe3e73a957/images/f7d07c202c09b3ef9ed923524b60c1c4b91fdc0ec10c16a56ead761c8c10f9c4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8617160320281982}",,,,,,,,,,['neutral'],neutral,1
NCT02363452,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMc1810983', 'title': 'Reverse-Transcriptase Inhibitors in the Aicardi–Goutières Syndrome', 'source': 'The New England Journal of Medicine', 'date': 'Dec 5, 2018', 'snippet': 'The genetic encephalopathy Aicardi–Goutières syndrome is thought to be due \nto misidentification of self-derived nucleic acids and the...', 'thumbnail': 'https://serpapi.com/searches/6721f98cc117a913de2746f3/images/239f31e75fb327710c248d82967db910e6e4e5abe3fb3b199a8a7d13c55b9cc0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5840248465538025}",,,,,,,,,,['neutral'],neutral,1
NCT03166735,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-42398-w', 'title': 'A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis', 'source': 'Nature', 'date': 'Nov 6, 2023', 'snippet': 'Non-alcoholic steatohepatitis (NASH) is a progressive, inflammatory liver \ndisease with no approved pharmacological treatment.', 'thumbnail': 'https://serpapi.com/searches/6721f99fdc969f71fa96fc43/images/71d3ba3ecc6b74291f31d1f3b9a908043f6fec808d889a9c60c0fce12aac08fd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.75046706199646}",,,,,,,,,,['neutral'],neutral,1
NCT04956575,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-39376-7', 'title': 'Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis', 'source': 'Nature', 'date': 'Jun 19, 2023', 'snippet': 'Despite vaccine availability, influenza remains a substantial global public \nhealth concern. Here, we report interim findings on the primary...', 'thumbnail': 'https://serpapi.com/searches/6721f9ad6f9f6391afca334f/images/99b9c2f2d700289d50d356774ba573672caf35e4f417325c02cf6def9bebfc7f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8802207112312317}",,,,,,,,,,['neutral'],neutral,1
NCT02004522,"{'position': 1, 'link': 'https://lymphomanewstoday.com/2019/10/29/copiktra-superior-arzerra-cll-sll-patients-with-2-prior-therapies/', 'title': 'Copiktra Superior to Arzerra for CLL/SLL Patients with Prior Therapies, Data Suggest', 'source': 'Lymphoma News Today', 'date': 'Oct 29, 2019', 'snippet': 'Copiktra doubles response rates and extends the time until disease \nprogression or death in CLL/SLL patients with at least two prior...', 'thumbnail': 'https://serpapi.com/searches/6721f9af56f970a143a4d461/images/eb7736cf2df35e1f6a3dfc288c1c1858eb2ee289bf2c8ae0720bd0129be31d44.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9011181592941284}","{'position': 2, 'link': 'https://lymphomanewstoday.com/2019/11/01/copiktra-possible-treatment-option-advanced-marginal-zone-lymphoma-trial-data-show/', 'title': 'Copiktra May Be Treatment Option for Advanced Marginal Zone Lymphoma, Trial Data Show', 'source': 'Lymphoma News Today', 'date': 'Nov 1, 2019', 'snippet': 'The Phase 2 DYNAMO trial included 18 people with refractory marginal zone \nlymphoma, and found that seven of them responded to Copiktra...', 'thumbnail': 'https://serpapi.com/searches/6721f9af56f970a143a4d461/images/eb7736cf2df35e1ff3daf2098154a4d76f5a68048a25429a9c50218affdef3d2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7104657888412476}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04115293,"{'position': 1, 'link': 'https://myastheniagravisnews.com/news/mda-2024-zilbrysq-benefits-sustained-over-1-year-gmg-study/', 'title': 'MDA 2024: Benefits of Zilbrysq sustained over 1 year in gMG study', 'source': 'Myasthenia Gravis News', 'date': 'Mar 12, 2024', 'snippet': 'Clinical responses to the approved generalized myasthenia gravis (gMG) \ntherapy Zilbrysq (zilucoplan) have now been sustained for more than a...', 'thumbnail': 'https://serpapi.com/searches/6721f9babcd652e5decfc171/images/dbb23267913df3c1905c576e1bfedaa8a3d9c62208154dad6ce4d0870e9c96b8.png', 'sentiment': 'positive', 'sentiment_prob': 0.6832995414733887}","{'position': 2, 'link': 'https://news.unchealthcare.org/2022/05/ucb-presents-efficacy-and-safety-results-for-zilucoplan-and-rozanolixizumab-in-generalized-myasthenia-gravis/', 'title': 'UCB Presents Efficacy, Safety Results for Zilucoplan, Rozanolixizumab for Generalized Myasthenia Gravis', 'source': 'UNC Health', 'date': 'May 10, 2022', 'snippet': 'UCB, a global biopharmaceutical company, announced results from two phase 3 \nstudies evaluating its investigational treatments, zilucoplan.', 'thumbnail': 'https://serpapi.com/searches/6721f9babcd652e5decfc171/images/dbb23267913df3c1e25fdb13bd59762331262e6f7663e63a8c2f83a7c11d9cad.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8845313787460327}","{'position': 3, 'link': 'https://www.empr.com/home/news/zilbrysq-fda-approval-generalized-myasthenia-gravis/', 'title': 'Zilbrysq Gets FDA Approval for Generalized Myasthenia Gravis', 'source': 'Medical Professionals Reference', 'date': 'Oct 18, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Zilbrysq (zilucoplan) \nfor the treatment of generalized myasthenia gravis (gMG) in adult patients.', 'thumbnail': 'https://serpapi.com/searches/6721f9babcd652e5decfc171/images/dbb23267913df3c13b8e780ca127b42070e4c04ec466657f45a87bffe05f866c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6953174471855164}",,,,,,,,"['positive', 'neutral', 'neutral']",neutral,1
NCT03565445,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.958620/full', 'title': 'From protein-protein interactions to immune modulation: Therapeutic prospects of targeting Neuropilin-1 in high-grade glioma', 'source': 'Frontiers', 'date': 'Feb 10, 2024', 'snippet': 'We review the physiology and pathological effects of Neuropilin-1, a \ntransmembrane co-receptor which mediates signal transduction pathways when \nassociated with...', 'thumbnail': 'https://serpapi.com/searches/6721f9d9f60b6f501487e394/images/b998b28e7b62e708c278ec80d5879024b2f8f4d065df38348db22e4b9aabdc19.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9102723002433777}",,,,,,,,,,['neutral'],neutral,1
NCT03153111,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001079', 'title': 'Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association | Circulation', 'source': 'American Heart Association Journals', 'date': 'Jul 11, 2022', 'snippet': 'This science advisory focuses on the need to better understand the \nepidemiology, pathophysiology, and treatment of pulmonary hypertension in \npatients with...', 'thumbnail': 'https://serpapi.com/searches/6721f9f38e13c9f929b44527/images/1163ec01a0bbd01f470d7dc6923393e1acde87f94754acafadb470a90478b20b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8411228060722351}",,,,,,,,,,['neutral'],neutral,1
NCT03625622,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2024/09/30/2955146/0/en/Adaptive-Research-Announces-it-has-Begun-Enrolling-Patients-in-AriBio-s-Phase-3-POLARIS-AD-Clinical-Trial.html', 'title': 'Adaptive Research Announces it has Begun Enrolling Patients in AriBio’s Phase 3 POLARIS-AD Clinical Trial', 'source': 'GlobeNewswire', 'date': '1 month ago', 'snippet': 'SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Adaptive Research, a \nclinical trial site organization whose mission is to democratize...', 'thumbnail': 'https://serpapi.com/searches/6721fa108de63cccedebb9e4/images/996ae48ecbdecbc2489523aeb78021de273f28513f7216602072e7b0eec315a5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.843789279460907}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20211104005378/en/AriBio-Co.-Ltd.-Announces-Topline-Results-from-Phase-2-Study-of-AR1001-in-Mild-to-Moderate-Alzheimer%E2%80%99s-Patients', 'title': 'AriBio Co., Ltd. Announces Topline Results from Phase 2 Study of AR1001 in Mild to Moderate Alzheimer’s Patients', 'source': 'Business Wire', 'date': 'Nov 4, 2021', 'snippet': 'AriBio, a clinical-stage biopharmaceutical company based in South Korea, \nannounced today, the topline results from its phase 2 study of...', 'thumbnail': 'https://serpapi.com/searches/6721fa108de63cccedebb9e4/images/996ae48ecbdecbc2fd9154b0c35bf74743eab901def5a06fb935833de3a6d16a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9163773655891418}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00460096,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/clinical-trial-compares-glassia-prolastin-for-alpha1-antitrypsin-deficiency/', 'title': 'Clinical Trial Compares Glassia, Prolastin for Alpha1-Antitrypsin Deficiency', 'source': 'Pulmonology Advisor', 'date': 'Apr 27, 2022', 'snippet': 'Treatment of AAD with either Glassia or Prolastin appeared equally \neffective in a recent clinical trial of the 2 A1PI.', 'thumbnail': 'https://serpapi.com/searches/6721fa35707fd32d1eac13d5/images/968e27982076c1b00a61e2e1ac52caf91fe04558b228e8b13e9b88aba72d9f2c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8398064970970154}",,,,,,,,,,['neutral'],neutral,1
NCT02231008,"{'position': 1, 'link': 'https://geneticobesitynews.com/2020/08/20/hetlioz-granted-fda-priority-review-for-smith-magenis-syndrome/', 'title': 'FDA Grants Priority Review to Sleep Disorder Therapy Hetlioz for Smith-Magenis Syndrome', 'source': 'geneticobesitynews.com', 'date': 'Aug 20, 2020', 'snippet': ""The US Food and Drug Administration (FDA) has accepted and given priority \nreview to Vanda Pharmaceuticals' request seeking the approval of Hetlioz \n(tasimelteon)"", 'thumbnail': 'https://serpapi.com/searches/6721fa76bd7cf0d6d117fae1/images/729f5ecd6980e3ac0fdeb4514bae34b5621d2848c419880ef3dcdb05336ea9f9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8270958662033081}",,,,,,,,,,['neutral'],neutral,1
NCT02576795,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/roctavian-effective-hemophilia-a-over-7-years-trial-update/', 'title': 'Single dose of Roctavian effective over 7 years, per new trial update', 'source': 'Hemophilia News Today', 'date': 'Feb 7, 2024', 'snippet': 'A single dose of Roctavian (valoctocogene roxaparvovec-rvox) sustainably \nreduced the yearly bleeding rate in adults with severe hemophilia A by up \nto 96%.', 'thumbnail': 'https://serpapi.com/searches/6721fb9ddc969f7233129c9e/images/0b320e46038e1fe503c72b8675380f16df73f43d7fc9e77daed7c962312afd2f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6956309676170349}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1908490', 'title': 'Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A', 'source': 'The New England Journal of Medicine', 'date': 'Jan 1, 2020', 'snippet': 'We report durable efficacy, long-term safety, and clinical and biologic \nresults in 15 adults with severe hemophilia A (factor VIII level, ≤1 IU per \ndeciliter)', 'thumbnail': 'https://serpapi.com/searches/6721fb9ddc969f7233129c9e/images/0b320e46038e1fe5a97af655c9a02eb4f68a9da228cd9c3c58cae6d887d5d94c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6912418007850647}","{'position': 3, 'link': 'https://hemophilianewstoday.com/news/roctavian-zeroes-bleeds-prophylaxis-need-7-years/', 'title': 'Roctavian nearly zeroes out bleeds, prophylaxis need over 7 years', 'source': 'Hemophilia News Today', 'date': 'Aug 20, 2024', 'snippet': 'A single dose of Roctavian nearly zeroed out the number of bleeds and the \nneed for prophylaxis for as long as seven years, per trial data.', 'thumbnail': 'https://serpapi.com/searches/6721fb9ddc969f7233129c9e/images/0b320e46038e1fe5f98375c3ad21aab34760fed93145731525d40514a1d4fc87.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8004980683326721}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02746796,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/home/cancer-topics/gastrointestinal-cancers/nivolumab-prolongs-gastric-cancer-gej-prolongs-survival-treatment-risk/', 'title': 'Nivolumab Prolongs PFS, Not OS in Advanced Gastric/GEJ Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Feb 7, 2022', 'snippet': 'Adding nivolumab to first-line oxaliplatin-based chemotherapy improved \nprogression-free survival in HER2-negative, advanced gastric/GEJ...', 'thumbnail': 'https://serpapi.com/searches/6721fbcfa505f73e63923a53/images/a0378da5f28d05602bbae515c375903f37198f941007c6f56452dccb61a2cc22.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.799066960811615}",,,,,,,,,,['neutral'],neutral,1
NCT00256750,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1506027', 'title': 'Belatacept and Long-Term Outcomes in Kidney Transplantation', 'source': 'The New England Journal of Medicine', 'date': 'Jan 28, 2016', 'snippet': 'In previous analyses of BENEFIT, a phase 3 study, belatacept-based \nimmunosuppression, as compared with cyclosporine-based immunosuppression,...', 'thumbnail': 'https://serpapi.com/searches/6721fbdf5ddfba5b08c6799f/images/7e271d815052706847d4e4ba8119a6a2fd0744d1341577ee1267e459f12821da.png', 'sentiment': 'neutral', 'sentiment_prob': 0.896232008934021}",,,,,,,,,,['neutral'],neutral,1
NCT04563702,"{'position': 1, 'link': 'https://www.europeanpharmaceuticalreview.com/news/130177/first-patient-dosed-in-covid-19-vaccine-tablet-clinical-trial/', 'title': 'First patient dosed in COVID-19 vaccine tablet clinical trial', 'source': 'European Pharmaceutical Review', 'date': 'Oct 14, 2020', 'snippet': 'A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 \nvaccine candidate, has been initiated with the first patient dosed.', 'thumbnail': 'https://serpapi.com/searches/6721fc03cf32e0c265e3d982/images/d8077cad6f8674fd8472bf4ab64e3ebca42fbffcaed7cb97c455b18f617319cb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8912301063537598}","{'position': 2, 'link': 'https://www.genengnews.com/news/vaxart-and-emergent-biosolutions/', 'title': 'Vaxart, Emergent BioSolutions, and Kindred Biosciences – VXA-CoV2-1', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'May 18, 2020', 'snippet': 'Candidate: VXA-CoV2-1. Category: VAX. Type: Oral recombinant vaccine \nadministered by room temperature-stable tablet, and based on...', 'thumbnail': 'https://serpapi.com/searches/6721fc03cf32e0c265e3d982/images/d8077cad6f8674fd8fb732de6ef7acf4c4cbff399e34ceac5a89b3a635466053.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9251697063446045}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01720667,"{'position': 1, 'link': 'https://www.empr.com/home/news/sezaby-approved-to-treat-seizures-in-term-and-preterm-infants/', 'title': 'Sezaby Approved to Treat Seizures in Term and Preterm Infants', 'source': 'Medical Professionals Reference', 'date': 'Nov 21, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Sezaby™ (phenobarbital \nsodium powder for injection) for the treatment of neonatal...', 'thumbnail': 'https://serpapi.com/searches/6721fc5281bab782be64802c/images/e80ab601be883bd0c80b7cbb6f6d881b911d359f74e7ebdd7052cfd1c36b58c7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8150951266288757}",,,,,,,,,,['neutral'],neutral,1
NCT04456673,"{'position': 1, 'link': 'https://copdnewstoday.com/news/dupixent-eases-flares-aids-lung-function-copd-notus-trial/', 'title': 'Dupixent eases flares, aids lung function with COPD: NOTUS trial', 'source': 'COPD News Today', 'date': 'Jun 17, 2024', 'snippet': 'In a second Phase 3 trial, Dupixent was seen to ease exacerbations and lung \nsymptom severity in people with moderate to severe COPD.', 'thumbnail': 'https://serpapi.com/searches/6721fc585809e72491958a84/images/48e54fc7bcfcd5a139d9e2b726bba2a78f8afa95ecca99fec7278c1c7a5b9ef4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7187654376029968}","{'position': 2, 'link': 'https://copdnewstoday.com/news/fda-seeks-more-data-dupixent-copd-clinical-trials/', 'title': 'FDA seeks more data on Dupixent COPD clinical trials', 'source': 'COPD News Today', 'date': 'May 6, 2024', 'snippet': 'The US Food and Drug Administration (FDA) has asked for more data from \nclinical trials that tested Dupixent (dupilumab) in people with chronic \nobstructive...', 'thumbnail': 'https://serpapi.com/searches/6721fc585809e72491958a84/images/48e54fc7bcfcd5a1e7f44aa5c0b6d24ca90b59347c7eaa6eb7554ee281c6717f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9244242310523987}","{'position': 3, 'link': 'https://copdnewstoday.com/news/dupixent-prevents-copd-exacerbations-improves-lung-function-trial/', 'title': 'Dupixent found to prevent COPD exacerbations in Phase 3 trial |...', 'source': 'COPD News Today', 'date': 'Apr 3, 2023', 'snippet': 'Dupixent (dupilumab) — a medication initially approved for exzema — was \nfound to significantly reduce the number of disease exacerbations and to...', 'thumbnail': 'https://serpapi.com/searches/6721fc585809e72491958a84/images/48e54fc7bcfcd5a17bf21571afb98310eb7b7bd135c1ce03742b24bb82d0d9fc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6353323459625244}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT05032859,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/tapinarof-cream-eases-atopic-dermatitis-in-patients-as-young-as-2-years/', 'title': 'Tapinarof Cream Eases Atopic Dermatitis in Patients as Young as 2 Years', 'source': 'Medical Professionals Reference', 'date': 'Mar 15, 2023', 'snippet': 'Tapinarof cream was found to be beneficial for atopic dermatitis patients \nas young as 2 years old, according to findings from the phase 3...', 'thumbnail': 'https://serpapi.com/searches/6721fc8ca9210b1b4b6ba22d/images/ed7f05be4dc411aa8549e250fe45871b7bcdbf7ac8738802b73c3285dbbc9cc1.png', 'sentiment': 'positive', 'sentiment_prob': 0.7262768745422363}","{'position': 2, 'link': 'https://nationaleczema.org/blog/dermavant-101223/', 'title': 'Dermavant Announces New Positive Pruritus Data for VTAMA®(tapinarof) Cream, 1% in Adults and Children as Young as Two Years Old with Atopic Dermatitis at the EADV Congress 2023', 'source': 'National Eczema Association', 'date': 'Oct 16, 2023', 'snippet': 'Dermavant Sciences announced new pruritus data for VTAMA cream from its two \npivotal Phase 3 trials.', 'thumbnail': 'https://serpapi.com/searches/6721fc8ca9210b1b4b6ba22d/images/ed7f05be4dc411aa0278c57e5f2b218d04f8779622b7a34a20c05bfb41158cb7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.677699863910675}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT03867253,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1120911/full', 'title': 'LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': 'Histone lysine-specific demethylase 1 (LSD1/KDM1A) was first identified in \n2004 as an epigenetic enzyme able to demethylate specific lysine residues \nof...', 'thumbnail': 'https://serpapi.com/searches/6721fcc30f2a2cf3975a5646/images/3fdc5d921069f3c60eedc5d4c840e87937564131a05f8f5cd8695de5af2ad111.png', 'sentiment': 'neutral', 'sentiment_prob': 0.916375458240509}",,,,,,,,,,['neutral'],neutral,1
NCT03607487,"{'position': 1, 'link': 'https://www.termedia.pl/Hidradenitis-suppurativa-a-new-therapeutic-approach-for-an-old-disease,7,54608,1,1.html', 'title': 'Hidradenitis suppurativa: a new therapeutic approach for an old disease', 'source': 'Termedia', 'date': 'Aug 12, 2024', 'snippet': 'Hidradenitis suppurativa (HS) is a chronic inflammatory disease \ncharacterised by recurrent painful nodules, abscesses, fistulas and \nscarring...', 'thumbnail': 'https://serpapi.com/searches/6721fcead9c3e646d94aae65/images/c2ee2697aa8a15361c0e43ae8365fb4fcef6d648872d5dd5087dc965c2876ed5.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6704685091972351}",,,,,,,,,,['negative'],negative,0
NCT00273546,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa070956', 'title': 'Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Oct 25, 2007', 'snippet': 'A randomized phase 3 trial of the treatment of squamous-cell carcinoma of \nthe head and neck compared induction chemotherapy with docetaxel plus \ncisplatin and...', 'thumbnail': 'https://serpapi.com/searches/6721fcf511db4540a6d9534f/images/ceca477a9e984e3c3b5aecd70fb5859b1dc01b34641a77ba31c0960216e0f7e3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9047420620918274}",,,,,,,,,,['neutral'],neutral,1
NCT00114530,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1703327', 'title': 'Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma', 'source': 'The New England Journal of Medicine', 'date': 'Jan 3, 2018', 'snippet': 'Despite current therapies, diffuse cutaneous systemic sclerosis \n(scleroderma) often has a devastating outcome. We compared myeloablative...', 'thumbnail': 'https://serpapi.com/searches/6721fd2030dfc13e7b3c087d/images/e8a3ca0a1fcf0d9f8f6814acd65b0f910eb399ae21ac6062b4dbbd1124b1b2ad.png', 'sentiment': 'negative', 'sentiment_prob': 0.7006190419197083}","{'position': 2, 'link': 'https://sclerodermanews.com/news/scleroderma-gene-activity-normalizes-after-stem-cell-transplant-study/', 'title': 'Stem cell transplant normalizes scleroderma gene activity: Study', 'source': 'Scleroderma News', 'date': 'Jul 16, 2024', 'snippet': 'In the SCOT study, 75 adults with severe scleroderma were assigned to an \nautologous stem cell transplant or one year of Cytoxan infusions.', 'thumbnail': 'https://serpapi.com/searches/6721fd2030dfc13e7b3c087d/images/e8a3ca0a1fcf0d9fac9fb4f47333f8169d774e843b9330a0c03d0bb13f8bd8fd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8753800988197327}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT03072147,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2023.1156913/full', 'title': 'Small molecule inhibitors of osteoarthritis: Current development and future perspective', 'source': 'Frontiers', 'date': 'Feb 9, 2024', 'snippet': 'Osteoarthritis (OA) is one of the common degenerative joint diseases in \nclinic. It mainly damages articular cartilage, causing pain, swelling and \nstiffness...', 'thumbnail': 'https://serpapi.com/searches/6721fd31b57db8b84ab78672/images/9d3e6c175ce209a3ac00858afbb007f134980acac1130b6f8d6250649240772d.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6938455104827881}",,,,,,,,,,['negative'],negative,0
NCT01786668,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2019/10/21/xeljanz-reduces-spinal-inflammation-one-third-patients-phase-2-trial/', 'title': 'AS Patients Reduced Spinal Inflammation with Xeljanz, Phase 2 Trial Finds', 'source': 'Ankylosing Spondylitis News', 'date': 'Oct 21, 2019', 'snippet': 'Treatment with Xeljanz (tofacitinib citrate) led to a clinically meaningful \nreduction in spinal and sacroiliac joint inflammation in approximately \none-third of...', 'thumbnail': 'https://serpapi.com/searches/6721fd4563a844c688184c8d/images/c51d9d48d0e3c2bbea296e36f14ae02cce6098fe52d6a866073e80108960fefb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6531134247779846}",,,,,,,,,,['neutral'],neutral,1
NCT01631357,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-00337-x', 'title': 'Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357', 'source': 'Nature', 'date': 'Oct 19, 2020', 'snippet': 'We designed this randomized, multicenter, open-label trial to further \nevaluate the clinical efficacy of CIK cell immunotherapy plus chemotherapy \nin patients...', 'thumbnail': 'https://serpapi.com/searches/6721fd6efab273f966b925d5/images/bc4a2ac5a3a075e03914943452a1938c95769d75f551814053006149bf7e44ba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8522579669952393}",,,,,,,,,,['neutral'],neutral,1
NCT03914326,"{'position': 1, 'link': 'https://www.endocrinologyadvisor.com/news/oral-semaglutide-cuts-mace-risk-in-patients-with-type-2-diabetes/', 'title': 'Oral Semaglutide Cuts MACE Risk in Patients With Type 2 Diabetes', 'source': 'Endocrinology Advisor', 'date': '4 days ago', 'snippet': 'Topline results were announced from a cardiovascular outcomes study \nevaluating oral semaglutide in patients with type 2 diabetes.', 'thumbnail': 'https://serpapi.com/searches/6721fd774a3fcfcebea57c52/images/9724f58436ac1cdb96362d52a5d768ad710d43f52b1d3ff43bef47a0179e8d7b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8928716778755188}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/news/novo-nordisk-plans-label-expansion-for-rybelsus-following-phase-iii-win/', 'title': 'Novo Nordisk plans label expansion for Rybelsus following Phase III win', 'source': 'Clinical Trials Arena', 'date': '1 week ago', 'snippet': 'The oral semaglutide reduced the occurrence of major adverse cardiovascular \nevents (MACE) by 14% in patients with type 2 diabetes.', 'thumbnail': 'https://serpapi.com/searches/6721fd774a3fcfcebea57c52/images/9724f58436ac1cdb1e916e6c2cacdb0ba04fa243b1c741b8112714673474c945.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6132246851921082}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03409198,"{'position': 1, 'link': 'https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02421-w', 'title': 'ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer', 'source': 'Journal of Translational Medicine', 'date': 'Jul 3, 2020', 'snippet': 'Immunotherapy with checkpoint inhibitors (CPI) targeting PD-1 or CTLA-4 has \nemerged as an important treatment modality for several cancer...', 'thumbnail': 'https://serpapi.com/searches/6721fdb3e335ec5c435d35c6/images/c5a043e364ce7c0cf040542c6ea2cfc1b5cadf705b89202c612507eb366c5ad7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8669442534446716}",,,,,,,,,,['neutral'],neutral,1
NCT02022306,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-37359-2', 'title': 'Safe drugs with high potential to block malaria transmission revealed by a spleen-mimetic screening', 'source': 'Nature', 'date': 'Apr 7, 2023', 'snippet': 'Malaria parasites like Plasmodium falciparum multiply in red blood cells \n(RBC), which are cleared from the bloodstream by the spleen when...', 'thumbnail': 'https://serpapi.com/searches/6721fdc6d78a989f43d418a4/images/21d92937ae364d1eefbf7439f8773cc38b035f7f2ddd74cbf08b198940486e71.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7880375981330872}",,,,,,,,,,['neutral'],neutral,1
NCT02316106,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-020-0718-z', 'title': 'Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) | Leukemia', 'source': 'Nature', 'date': 'Feb 5, 2020', 'snippet': 'Current guidelines for smoldering multiple myeloma (SMM) recommend active \nmonitoring until the onset of multiple myeloma (MM) before...', 'thumbnail': 'https://serpapi.com/searches/6721fdfde45f339dd3e6cc38/images/69300aaeea930d83fe6bc603264464e51130863ee9fe64b99b7a849deb58f3e3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9120025038719177}",,,,,,,,,,['neutral'],neutral,1
NCT05027269,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/fda-lifts-clinical-hold-on-aviditys-lead-antibody-conjugate-therapy-trial/', 'title': 'FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial', 'source': 'Clinical Trials Arena', 'date': '4 weeks ago', 'snippet': 'Two years after the FDA placed partial clinical hold, Avidity can resume \nresearch of del-desiran as a treatment for myotonic dystrophy type...', 'thumbnail': 'https://serpapi.com/searches/6721fe3a69f8eca22b505f64/images/a8e62af3fdffac3e372fe0bf15ca312828daaedba733691dcd6832427a7c5c34.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9163219928741455}","{'position': 2, 'link': 'https://musculardystrophynews.com/news/dm1-trial-aoc-1001-improves-measures-muscle-strength/', 'title': 'AOC 1001 improves measures of muscle strength in DM1 trial', 'source': 'Muscular Dystrophy News', 'date': 'Oct 12, 2023', 'snippet': 'People with myotonic dystrophy type 1 (DM1) reported gains in muscle \nstrength following treatment with AOC 1001 in a clinical trial.', 'thumbnail': 'https://serpapi.com/searches/6721fe3a69f8eca22b505f64/images/a8e62af3fdffac3e9758156f992e82ef273fc83c454eb8c60abc8fc7efaf1ff8.png', 'sentiment': 'positive', 'sentiment_prob': 0.566658616065979}","{'position': 3, 'link': 'https://www.prnewswire.com/news-releases/avidity-biosciences-announces-new-positive-aoc-1001-data-demonstrating-improvement-in-multiple-additional-functional-endpoints-and-favorable-long-term-safety-and-tolerability-in-people-with-myotonic-dystrophy-type-1-301949933.html', 'title': 'Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1', 'source': 'PR Newswire', 'date': 'Oct 7, 2023', 'snippet': 'New AOC 1001 data demonstrate improvement in additional functional measures \nincluding hand grip, muscle strength and patient reported outcomes.', 'thumbnail': 'https://serpapi.com/searches/6721fe3a69f8eca22b505f64/images/a8e62af3fdffac3e99661168e86e94ceb775bea18d2590199d2242af21e2d91c.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.661956787109375}","{'position': 4, 'link': 'https://musculardystrophynews.com/news/event-unrelated-dm1-treatment-cause-marina-trial-part-hold/', 'title': ""Rare event, unrelated to DM1 treatment, likely cause of trial's partial hold | Avidity update on MARINA study of AOC 1001"", 'source': 'Muscular Dystrophy News', 'date': 'Apr 4, 2023', 'snippet': 'A rare neurological event likely not related to AOC 1001, the DM1 treatment \nin a Phase 1/2 trial, led to partial study hold,...', 'thumbnail': 'https://serpapi.com/searches/6721fe3a69f8eca22b505f64/images/a8e62af3fdffac3e76dfd53108d40c645e31cb926d11a819029fadcc3fc65413.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5401264429092407}","{'position': 5, 'link': 'https://musculardystrophynews.com/news/fda-grants-breakthrough-designation-dm1-treatment-del-desiran/', 'title': 'Del-desiran for DM1 wins FDA’s breakthrough therapy designation', 'source': 'Muscular Dystrophy News', 'date': 'May 14, 2024', 'snippet': 'Recent data from a clinical trial extension study indicated del-desiran led \nto myotonia severity reductions and muscle strength gains in...', 'thumbnail': 'https://serpapi.com/searches/6721fe3a69f8eca22b505f64/images/a8e62af3fdffac3e2a0d0909d3c0258e4a16fd3553c6c07e8d85fc48571e60d8.png', 'sentiment': 'positive', 'sentiment_prob': 0.5878934264183044}",,,,,,"['neutral', 'positive', 'positive', 'neutral', 'positive']",positive,1
NCT04201093,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/abbvies-8-2bn-parkinsons-disease-drug-shines-in-phase-iii-trial/', 'title': 'AbbVie’s acquired Parkinson’s disease drug shines in Phase III trial', 'source': 'Clinical Trials Arena', 'date': '1 month ago', 'snippet': ""The Phase III TEMPO-1 trial enrolled 529 adults, between the ages of 40 and \n80, diagnosed with Parkinson's for less than three years."", 'thumbnail': 'https://serpapi.com/searches/6721fe60c821270c75820d0f/images/accaac80685c2680a32d862089b854d1e5c5d0be8534da26eced5e97e52f258b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8078458905220032}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/parkinsons-motor-symptoms-improve-tavapadon-phase-3-clinical-trial/', 'title': ""Parkinson's motor symptoms improve with tavapadon in Phase 3 clinical trial"", 'source': ""Parkinson's News Today"", 'date': '1 month ago', 'snippet': ""The TEMPO-1 study tested the efficacy, safety, and tolerability of \ntavapadon to assess changes in the severity of Parkinson's motor..."", 'thumbnail': 'https://serpapi.com/searches/6721fe60c821270c75820d0f/images/accaac80685c268055323f4d7082d6e0e7c4ffced7f9ae57d0ad72505ca67c2a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6867958307266235}","{'position': 3, 'link': 'https://www.clinicaltrialsarena.com/features/trials-to-watch-parkinsons-disease/', 'title': 'Trials to watch: Pipeline Parkinson’s drugs could revolutionise treatment', 'source': 'Clinical Trials Arena', 'date': 'Oct 17, 2023', 'snippet': ""Patients with Parkinson's disease could be given more hope as a number of \npipeline drugs are looking to tackle a variety of unmet needs."", 'thumbnail': 'https://serpapi.com/searches/6721fe60c821270c75820d0f/images/accaac80685c2680560b8637ddc82038f8162ed38c8dbaa484aeaa922a1dff69.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8619078993797302}","{'position': 4, 'link': 'https://parkinsonsnewstoday.com/news/phase-3-trials-tavapadon-parkinsons-motor-symptoms-near-end/', 'title': 'Phase 3 trials of oral tavapadon in easing motor symptoms nearing end', 'source': ""Parkinson's News Today"", 'date': 'Nov 7, 2023', 'snippet': 'An ongoing and global Phase 3 clinical trial program for oral tavapadon, a \nselective dopamine receptor agonist aiming to improve motor function in \npeople with...', 'thumbnail': 'https://serpapi.com/searches/6721fe60c821270c75820d0f/images/accaac80685c268015473c44c0b111db1487d29b1c065016820b70247388db85.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8008778691291809}",,,,,,,"['neutral', 'neutral', 'positive', 'neutral']",neutral,1
NCT04372589,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2105911', 'title': 'Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Aug 4, 2021', 'snippet': 'Thrombosis and inflammation may contribute to the risk of death and \ncomplications among patients with coronavirus disease 2019 (Covid-19).', 'thumbnail': 'https://serpapi.com/searches/6722010818787d3f6f670581/images/cc9d65799bb9376957ffdf80e125b03fee63e35446fcfbc0e5ef753f8af93ee7.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6693536043167114}",,,,,,,,,,['negative'],negative,0
NCT05408572,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Key-stakeholders-and-their-main-responsibilities-in-planning-a-first-in-human-study-CTA_fig1_326637074', 'title': 'Key stakeholders and their main responsibilities in planning a...', 'source': 'ResearchGate', 'date': 'Feb 8, 2024', 'snippet': 'Download scientific diagram | Key stakeholders and their main \nresponsibilities in planning a first‐in‐human study. CTA, clinical trial \napplication; CRO,...', 'thumbnail': 'https://serpapi.com/searches/672200100d379f2003b07ef3/images/7a8ec2374556a415baefaf770869f05857cbc6eec09a2042ca06e309a648e258.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8991522192955017}",,,,,,,,,,['neutral'],neutral,1
NCT01523171,"{'position': 1, 'link': 'https://www.onclive.com/view/next-generation-jak-inhibitors-signal-the-future-of-myelofibrosis-treatment-advances', 'title': 'Next-Generation JAK Inhibitors Signal the Future of Myelofibrosis Treatment Advances', 'source': 'OncLive', 'date': 'Mar 22, 2024', 'snippet': 'Joseph G. Jurcic, MD, discusses the benefits and limitations of several JAK \ninhibitors for patients with myelofibrosis.', 'thumbnail': 'https://serpapi.com/searches/67220012ecf15015f235240e/images/4f54719ab0edec16e30eb29097125c47648412b61b69e25b5ecf55a526f75ff3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8395581245422363}",,,,,,,,,,['neutral'],neutral,1
NCT03168854,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-020-0196-3', 'title': 'Malaria vaccines since 2000: progress, priorities, products', 'source': 'Nature', 'date': 'Jun 9, 2020', 'snippet': 'Malaria vaccine development entered a new era in 2015 when the \npre-erythrocytic Plasmodium falciparum candidate RTS,S was favorably \nreviewed by the European...', 'thumbnail': 'https://serpapi.com/searches/6722002876585765f5a602a7/images/c6d5e6dad16365efe6b282575a4fa290d8ffbf95856d8db659cfbb5db3860736.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8491886258125305}",,,,,,,,,,['neutral'],neutral,1
NCT01367002,"{'position': 1, 'link': 'https://www.nature.com/articles/modpathol2013113', 'title': 'Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice | Modern Pathology', 'source': 'Nature', 'date': 'Jun 14, 2013', 'snippet': 'HER2 overexpression and/or amplification have been reported in endometrial \nserous carcinoma, suggesting that HER2 may be a promising...', 'thumbnail': 'https://serpapi.com/searches/6722002bfab273f994d8704e/images/8d19dfe7fc9c268427c76bb814672fe2a25c4c018cf6d4074e81e3d963e18094.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8552951216697693}",,,,,,,,,,['neutral'],neutral,1
NCT03803475,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/62/5/695', 'title': 'Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center', 'source': 'Journal of Nuclear Medicine', 'date': 'May 10, 2021', 'snippet': 'The purpose of this study was to evaluate differences between patients \nreceiving 18 F-fluciclovine and 68 Ga-prostate-specific membrane antigen ( \n68 Ga-PSMA-11)', 'thumbnail': 'https://serpapi.com/searches/67220036be324f55320f90d5/images/4fbd5ddded8f94588a902c7a41c58c55aeeb3caaf5e09aaca635df1ed93f37f4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9137476086616516}",,,,,,,,,,['neutral'],neutral,1
NCT02986139,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2017/11/27/enbrel-mini-new-autoinjector-system-available-in-us/', 'title': 'New Autoinjector for Prefilled, Single-Dose Enbrel Now Available in the U.S.', 'source': 'Ankylosing Spondylitis News', 'date': 'Nov 27, 2017', 'snippet': 'Read about a new system to administrate Enbrel for all previously approved \nindications, including ankylosing spondylitis, now available in...', 'thumbnail': 'https://serpapi.com/searches/67220045b7d31daeb501e2a1/images/c29f49b39b3fa66da326aa49fabd849b538dd5af02c56c85d81a8cb496e370c4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.777471661567688}",,,,,,,,,,['neutral'],neutral,1
NCT03277248,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2201904', 'title': 'Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Aug 24, 2022', 'snippet': 'Ublituximab resulted in lower annualized relapse rates and fewer brain \nlesions on MRI than teriflunomide over a period of 96 weeks but did not \nresult in a...', 'thumbnail': 'https://serpapi.com/searches/67220054fda26de13ee00871/images/4b85ae2017672402a4ac912fb9c85aa663b85cb35ce4c9d31abed41cf1f8b4dc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8014312386512756}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/09/19/ectrims-2004-ms-relapse-rates-fall-5-years-briumvi/', 'title': 'ECTRIMS 2024: MS relapse rates fall with 5 years on Briumvi', 'source': 'Multiple Sclerosis News Today', 'date': '1 month ago', 'snippet': ""Five years of continuous Briumvi kept MS relapse rates and disability \nprogression low, according to analyses from a trial's extension phase."", 'thumbnail': 'https://serpapi.com/searches/67220054fda26de13ee00871/images/4b85ae20176724028cd014460fa04dfd1ff54547b5c040a510ae8f8c10fc037f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5869046449661255}","{'position': 3, 'link': 'https://www.thepharmaletter.com/biotechnology/bumpy-path-forecast-for-tg-therapeutics-briumvi-in-crowded-ms-market', 'title': 'Bumpy path forecast for TG Therapeutics’ Briumvi in crowded MS market', 'source': 'The Pharma Letter', 'date': 'Jan 13, 2023', 'snippet': ""Bumpy path forecast for TG Therapeutics' Briumvi in crowded MS market. \nBiotechnology. 13 January 2023. tg-therapeutics-large."", 'thumbnail': 'https://serpapi.com/searches/67220054fda26de13ee00871/images/4b85ae2017672402bb57946889cd5717f1f6fc737f78a0e986fa14f8c5a95724.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8876432776451111}","{'position': 4, 'link': 'https://www.empr.com/home/news/briumvi-approved-for-relapsing-forms-of-multiple-sclerosis/', 'title': 'Briumvi Approved for Relapsing Forms of Multiple Sclerosis', 'source': 'Medical Professionals Reference', 'date': 'Dec 29, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Briumvi™ \n(ublituximab-xiiy) for the treatment of relapsing forms of multiple \nsclerosis,...', 'thumbnail': 'https://serpapi.com/searches/67220054fda26de13ee00871/images/4b85ae2017672402161d6e472e7603d25a628ae102e24144664b1f935d753e83.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7864340543746948}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01737697,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1411487', 'title': 'Sodium Zirconium Cyclosilicate in Hyperkalemia', 'source': 'The New England Journal of Medicine', 'date': 'Nov 21, 2014', 'snippet': 'Hyperkalemia (serum potassium level, >5.0 mmol per liter) is associated \nwith increased mortality among patients with heart failure,...', 'thumbnail': 'https://serpapi.com/searches/672200ae0f1a3356cc9c6969/images/d8e857a93fa6c31da55b1b1fcbce4b463705a3ba99b05124ef6fed23468ec133.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5671598315238953}",,,,,,,,,,['neutral'],neutral,1
NCT03454529,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332221006405', 'title': 'The potential use of simvastatin for cancer treatment: A review', 'source': 'ScienceDirect.com', 'date': '١٠\u200f/٠٧\u200f/٢٠٢١', 'snippet': 'In this review, we present an overview of the most important studies \nconducted from 2015 to date on the use of simvastatin in cancer therapy.', 'thumbnail': 'https://serpapi.com/searches/672200b89fd3091a7195fd01/images/26960420ba40b78921353e4c7af9d5ff7e2263be4fee1a743aa6e39c38211099.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7601056694984436}",,,,,,,,,,['neutral'],neutral,1
NCT04505189,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02455-9', 'title': 'Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study', 'source': 'Nature', 'date': 'Jul 24, 2023', 'snippet': 'Anorexia nervosa (AN) is a deadly illness with no proven treatments to \nreverse core symptoms and no medications approved by the US Food and...', 'thumbnail': 'https://serpapi.com/searches/6721fe965f9778877f212ba9/images/8c1ff296cb1bea6cdd42adcfdb9af4021544939f2ee37cf394483c429aa4de7d.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7454364895820618}","{'position': 2, 'link': 'https://pharmaceutical-journal.com/article/feature/untangling-anorexia-psychedelics-offer-hope-for-a-neglected-condition', 'title': 'Untangling anorexia: psychedelics offer hope for a neglected condition', 'source': 'The Pharmaceutical Journal', 'date': 'Mar 2, 2023', 'snippet': 'Anorexia nervosa has the highest mortality rate of any psychiatric disorder \nyet there are no medicines licensed globally to treat it; however, that \nmight be...', 'thumbnail': 'https://serpapi.com/searches/6721fe965f9778877f212ba9/images/8c1ff296cb1bea6c09e739ed69d4c112ea38ce5804d18ea05bcffda1974cdf37.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6351245641708374}",,,,,,,,,"['negative', 'negative']",negative,0
NCT03531060,"{'position': 1, 'link': 'https://www.nature.com/articles/s41531-018-0071-3', 'title': 'Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial', 'source': 'Nature', 'date': 'Dec 6, 2018', 'snippet': 'IRL790 is a novel compound with psychomotor stabilizing properties \nprimarily targeting the dopamine D3 receptor. IRL790 is developed as an...', 'thumbnail': 'https://serpapi.com/searches/6721ff5721e77b947e9fb7bb/images/fb728df8946aae41a7c6279592040676c659eec2f32fa5325009f47b3c3deee9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8828545808792114}",,,,,,,,,,['neutral'],neutral,1
NCT02026271,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-024-01226-x', 'title': 'Immunotherapy for glioblastoma: current state, challenges, and future perspectives | Cellular & Molecular Immunology', 'source': 'Nature', 'date': '2 weeks ago', 'snippet': 'Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human \nadults. The standard of care offers minimal clinical benefit,...', 'thumbnail': 'https://serpapi.com/searches/6721ff6075f974f2da18e649/images/a18d78a54e3d0c28772c01e8a841a62b3eff879c88c604e6a6cf02e92b954f41.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7423284649848938}",,,,,,,,,,['negative'],negative,0
NCT02670551,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0165032724010309', 'title': 'Early improvement with cariprazine as a predictor of antidepressant, anxiolytic, and antimanic response in bipolar I mania and depression: A pooled post hoc analysis of randomized cariprazine trials', 'source': 'ScienceDirect.com', 'date': 'Jun 27, 2024', 'snippet': 'Early symptomatic improvement may predict treatment response in bipolar I \ndisorder. Cariprazine has demonstrated early treatment effects in bipolar \nI...', 'thumbnail': 'https://serpapi.com/searches/6721ff611a5b54176645804d/images/f75c06decfc2f5d234610ebb9aafe7d86216bb5ffef338bb702ee46a79a5cc7b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7281509637832642}",,,,,,,,,,['neutral'],neutral,1
NCT03338816,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1913147', 'title': 'Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria', 'source': 'The New England Journal of Medicine', 'date': 'Jun 10, 2020', 'snippet': 'Up-regulation of hepatic delta-aminolevulinic acid synthase 1 (ALAS1), with \nresultant accumulation of delta-aminolevulinic acid (ALA) and...', 'thumbnail': 'https://serpapi.com/searches/6721ff90e6862be46eca0500/images/051a87936fd6f0924bc57719e77fea5406b4cfd80158e7a06d1f4606c04596e1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8730188012123108}","{'position': 2, 'link': 'https://porphyrianews.com/news/givlaari-porphyria-treatment-long-term-gains-phase-3-trial/', 'title': 'Long-term Givlaari use lowers attack rates, hemin need for AHP patients', 'source': 'Porphyria News', 'date': 'Jul 26, 2023', 'snippet': 'A sustained, up to 3-year drop in attack rates and hemin use with acute \nhepatic porphyria was seen with monthly Givlaari in ENVISION trial.', 'thumbnail': 'https://serpapi.com/searches/6721ff90e6862be46eca0500/images/051a87936fd6f0922b28518e0b98fcc0fc661f0a47cdb2b20993e6d2d8f00a42.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7476909160614014}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01227421,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.01327/full', 'title': 'Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections', 'source': 'Frontiers', 'date': 'Feb 6, 2024', 'snippet': 'This review article focuses on therapies currently under development for \ntreatment of influenza, RSV, and MERS-CoV infections.', 'thumbnail': 'https://serpapi.com/searches/6721ffabc5d7695cb84e1339/images/07a423e15377277c12c72a5a43681689087769a778431013570d13baa7f01db4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9000800848007202}",,,,,,,,,,['neutral'],neutral,1
NCT03976401,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01425-3', 'title': 'Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial', 'source': 'Nature', 'date': 'Jul 8, 2021', 'snippet': 'Preclinical and clinical data suggest that fibroblast growth factor 21 \n(FGF21) is anti-fibrotic, improves metabolic status and has potential...', 'thumbnail': 'https://serpapi.com/searches/6721ffb36aa36434fe42e7ee/images/2aaf7feaa7b06cb53920fc909751e64842de17c4061b2191641c38a30663cde7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.699603259563446}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/efruxifermin-fast-tracked-for-nonalcoholic-steatohepatitis/', 'title': 'Efruxifermin Fast Tracked for Nonalcoholic Steatohepatitis', 'source': 'Medical Professionals Reference', 'date': 'Oct 20, 2021', 'snippet': 'The Food and Drug Administration (FDA) has granted Fast Track designation \nto efruxifermin for the treatment of nonalcoholic steatohepatitis (NASH).', 'thumbnail': 'https://serpapi.com/searches/6721ffb36aa36434fe42e7ee/images/2aaf7feaa7b06cb53472fb5b031b6e9f1fec09fcfc7b4b65ecad553798c7ba6a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8870223760604858}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02345161,"{'position': 1, 'link': 'https://copdnewstoday.com/news/glaxoinnovivas-tripled-copd-inhaler-green-lighted-by-the-european-medicines-agency/', 'title': 'Once-a-day Triple Combo Inhaler for COPD Patients Favored for Approval in EU', 'source': 'COPD News Today', 'date': 'Sep 16, 2017', 'snippet': 'A triple combination inhaler for people with moderate to severe adult \nchronic obstructive pulmonary disease (COPD) was recommended for approval \nand use across...', 'thumbnail': 'https://serpapi.com/searches/6721ffb5272a87d825ae8747/images/f2a78675746de19be9c589abae84f185f0e539dede9f48b8ec5b85ac294ca62a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7231253385543823}",,,,,,,,,,['neutral'],neutral,1
NCT03974178,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00358-4/fulltext', 'title': 'Second stage human African Trypanosomiasis with Trypanosoma brucei rhodesiense treated with fexinidazole', 'source': 'The Lancet', 'date': 'Oct 25, 2023', 'snippet': 'The available treatment for second stage Tb rhodesiense is melarsoprol, \nwhich is toxic with a high frequency of severe, and sometimes fatal, \nadverse drug...', 'thumbnail': 'https://serpapi.com/searches/6721ffc0ba13f21ac0512d76/images/94fa9ef66248c03411162599e41e70f9bcf647ab1ec733a4af4ff825347fbd98.png', 'sentiment': 'neutral', 'sentiment_prob': 0.519517719745636}",,,,,,,,,,['neutral'],neutral,1
NCT05006573,"{'position': 1, 'link': 'https://www.thepharmaletter.com/biotechnology/drug-developers-recent-interest-in-treating-bronchiectasis-holds-potential-to-improve-outcomes', 'title': ""Drug developers' recent interest in treating bronchiectasis holds potential to improve outcomes"", 'source': 'The Pharma Letter', 'date': 'Aug 25, 2022', 'snippet': ""... developers' recent interest in treating bronchiectasis holds potential \nto improve outcomes. Biotechnology. 25 August 2022. \nresearch_biotech_lab_vial_big."", 'thumbnail': 'https://serpapi.com/searches/6721ffc7b6a79cce02302f02/images/2c3abc853ab46d7f37edbf075fa7bcde5a82153611f03a2ce9b6b1343e1660a5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6952041983604431}",,,,,,,,,,['neutral'],neutral,1
NCT04502693,"{'position': 1, 'link': 'https://www.contemporarypediatrics.com/view/fda-accepts-bla-for-meningococcal-abcwy-vaccine-target-action-date-set', 'title': 'FDA accepts BLA for meningococcal ABCWY vaccine, target action date set', 'source': 'Contemporary Pediatrics', 'date': 'Apr 16, 2024', 'snippet': ""The Biologics License Application (BLA) for GSK's 5-in-1 meningococcal \nABCWY (MenABCWY) vaccine candidate has been accepted for review by the FDA."", 'thumbnail': 'https://serpapi.com/searches/6721feb298876dbcee66d73d/images/2212a6f85d8afd067a81677d967de357ec4a14ca59e007b166e35e73f17f6e9e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.854534387588501}",,,,,,,,,,['neutral'],neutral,1
NCT03302234,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2020/11/25/merck-halts-phase-3-keynote-598-trial-yervoy-keytruda-combo-lung-cancer/', 'title': 'Merck Halts Phase 3 Trial on Yervoy-Keytruda Combo in Advanced Lung Cancer', 'source': 'Immuno-Oncology News', 'date': 'Nov 25, 2020', 'snippet': 'Merck is suspending its Phase 3 KEYNOTE-598 trial assessing a \nYervoy/Keytruda combo for advanced non-small cell lung cancer due to a lack \nof...', 'thumbnail': 'https://serpapi.com/searches/6721feb7c5d7695ce97cde18/images/4e26c829dab3050568696d32ec61fba8510cae1bd943ada17f566e6a4eb35e4c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5480629801750183}","{'position': 2, 'link': 'https://immuno-oncologynews.com/2021/02/08/yervoy-keytruda-combo-no-benefit-advanced-lung-cancer-keynote-598-phase-3-trial/', 'title': 'Keytruda-Yervoy Combo of No Benefit to Advanced Lung Cancer Patients', 'source': 'Immuno-Oncology News', 'date': 'Feb 8, 2021', 'snippet': 'Findings of no survival benefits and more toxicity in KEYNOTE-598 trial \nsupport Keytruda alone as first-line therapy for select NSCLC...', 'thumbnail': 'https://serpapi.com/searches/6721feb7c5d7695ce97cde18/images/4e26c829dab3050506ec5cfe9a1adfc62e8942fc65cfbde8298392219ebb8db2.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7513617277145386}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT03298867,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1910434', 'title': 'Teprotumumab for the Treatment of Active Thyroid Eye Disease', 'source': 'The New England Journal of Medicine', 'date': 'Jan 22, 2020', 'snippet': 'Teprotumumab resulted in better outcomes with respect to proptosis, \nClinical Activity Score, diplopia, and quality of life than placebo; \nserious adverse events...', 'thumbnail': 'https://serpapi.com/searches/6721fecb7c1712a3f3a2d8eb/images/579ca8e4d5c2d96ba6f3e9ea23b64abdd7a61cdedd88d6e3f2f8d7f6e4027906.png', 'sentiment': 'neutral', 'sentiment_prob': 0.4944324493408203}","{'position': 2, 'link': 'https://www.nature.com/articles/s41433-021-01539-5', 'title': 'Teprotumumab for thyroid eye disease: early response is not required for benefit', 'source': 'Nature', 'date': 'Jun 28, 2021', 'snippet': 'In recent trials, 50% of patients treated with teprotumumab for thyroid eye \ndisease had significant improvements in proptosis at 6 weeks.', 'thumbnail': 'https://serpapi.com/searches/6721fecb7c1712a3f3a2d8eb/images/579ca8e4d5c2d96b2a680d20ffa6a5ab26827e54b8c9104bb62b66569db2f316.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5698319673538208}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04020380,"{'position': 1, 'link': 'https://sarcoidosisnews.com/news/antibiotic-azithromycin-reduces-cough-in-pulmonary-sarcoidosis-study-concludes/', 'title': 'Antibiotic Azithromycin Curbs Cough in Pulmonary Sarcoidosis, Study Concludes', 'source': 'Sarcoidosis News', 'date': 'Dec 10, 2020', 'snippet': 'Three months of treatment with the common, generic antibiotic azithromycin \nsafely reduced the number of coughs and cough severity, and improved the \nquality of...', 'thumbnail': 'https://serpapi.com/searches/6721feda4677bf466e6a05f2/images/7fb3fdb981ff814cf7a0e1117b4f60f0d5435717172208199eba1216ff72374b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8291922807693481}",,,,,,,,,,['neutral'],neutral,1
NCT04523220,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02794-7', 'title': 'Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial', 'source': 'Nature', 'date': 'Feb 16, 2024', 'snippet': 'Individuals with kidney failure undergoing hemodialysis are at elevated \nrisk for thromboembolic events. Factor (F) XI, which is in the...', 'thumbnail': 'https://serpapi.com/searches/6721fee1f9f904883975238f/images/d6c41accd1a98d98a5711f1e470066829ce616812ce908d6caba7b9c6bd6fdfb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8075672388076782}",,,,,,,,,,['neutral'],neutral,1
NCT01432353,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-019-0178-8', 'title': 'Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma', 'source': 'Nature', 'date': 'Feb 4, 2019', 'snippet': 'FcRH5 is a cell surface marker enriched on malignant plasma cells when \ncompared to other hematologic malignancies and normal tissues.', 'thumbnail': 'https://serpapi.com/searches/6721ff27fda26de13ee00750/images/3fa6d62841e0e15b62c528d095bfc57f2530f375eb58d292de2d4e3114d95a63.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8361889123916626}",,,,,,,,,,['neutral'],neutral,1
NCT02579226,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-023-02185-2', 'title': 'Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours | British Journal of Cancer', 'source': 'Nature', 'date': 'Mar 4, 2023', 'snippet': 'AZD2811 is a potent, selective Aurora kinase B inhibitor. We report the \ndose-escalation phase of a first-in-human study assessing \nnanoparticle-encapsulated AZD...', 'thumbnail': 'https://serpapi.com/searches/6721ff3164f11dc03e973e41/images/81e5315b12dd6e94409ff25fdab671f580ace602204bcc48bb1e4937c8786ccc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8825380206108093}",,,,,,,,,,['neutral'],neutral,1
NCT00004104,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202204335', 'title': 'Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation', 'source': 'Wiley Online Library', 'date': 'Oct 18, 2022', 'snippet': 'In this review, recent advanced nanoformulations targeting specific subset \nof immune cells, such as dendritic cells (DCs), T cells, monocytes, \nmacrophages, and...', 'thumbnail': 'https://serpapi.com/searches/6721ff3bba1142b4b1194bc8/images/d329c98777318ee35b4d407e56246f4e2585c6ea4e9e7717cc86fd3e18fc3bd9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9175722599029541}",,,,,,,,,,['neutral'],neutral,1
NCT02228460,"{'position': 1, 'link': 'https://fabrydiseasenews.com/news/venglustat-lowers-gb3-no-signs-of-disease-progression-trial/', 'title': 'Venglustat Lowers Gb3 With No Signs of Disease Progression in Trial', 'source': 'Fabry Disease News', 'date': 'Dec 2, 2022', 'snippet': 'Venglustat reduced levels of the fatty molecule that accumulates to toxic \nlevels in Fabry disease in a Phase 2 trial, a study shows.', 'thumbnail': 'https://serpapi.com/searches/6721ff41483e5bd88c7b36a2/images/734028871cc457192397c3537015f3efacaf7c916509a28f22e7e618e45001fc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8395367860794067}","{'position': 2, 'link': 'https://fabrydiseasenews.com/experimental-treatments-for-fabry-disease/', 'title': 'Experimental treatments for Fabry disease', 'source': 'Fabry Disease News', 'date': 'May 30, 2024', 'snippet': 'Various potential Fabry disease treatments, like gene therapies and \nsubstrate reduction therapies, are being investigated in clinical...', 'thumbnail': 'https://serpapi.com/searches/6721ff41483e5bd88c7b36a2/images/734028871cc457193ba6602778cd39c57a641a7674d9a14ce823d37c235b3354.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9250966310501099}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03713086,"{'position': 1, 'link': 'https://www.nature.com/articles/s41587-022-01294-2', 'title': 'The clinical progress of mRNA vaccines and immunotherapies', 'source': 'Nature', 'date': 'May 9, 2022', 'snippet': 'The emergency use authorizations (EUAs) of two mRNA-based severe acute \nrespiratory syndrome coronavirus (SARS-CoV)-2 vaccines approximately...', 'thumbnail': 'https://serpapi.com/searches/6722010b74978396090b72f5/images/0da51200210a42d23055fc409ef213dd393c7f29bc194dc409e40cbd06a794bb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.921474814414978}",,,,,,,,,,['neutral'],neutral,1
NCT04811716,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/reports/paroxysmal-hemoglobinuria-png-pozelimab-cemdisiran-combo-effective-treatment/', 'title': 'Pozelimab and Cemdisiran Combination May Be Effective in Paroxysmal Nocturnal Hemoglobinuria', 'source': 'Hematology Advisor', 'date': 'Dec 19, 2022', 'snippet': 'Combining pozelimab and cemdisiran appears to be a promising strategy for \nthe treatment of paroxysmal nocturnal hemoglobinuria (PNH), according to \nresearch.', 'thumbnail': 'https://serpapi.com/searches/672201229872174e099992bf/images/bb85c17d0372feb8155510302f98eb0ee49bd8987aac0a3a812b1cce55d35e42.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5183724164962769}",,,,,,,,,,['positive'],positive,1
NCT03736447,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2212895', 'title': 'Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy', 'source': 'The New England Journal of Medicine', 'date': 'May 10, 2023', 'snippet': 'No approved treatment for peanut allergy exists for children younger than 4 \nyears of age, and the efficacy and safety of epicutaneous...', 'thumbnail': 'https://serpapi.com/searches/6722015b56f970a1704ba8e0/images/f64c4de261874168dbfd879327627f3742544460c241f48e8c97a6a94c63042b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7632521390914917}",,,,,,,,,,['neutral'],neutral,1
NCT03338998,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.119.027134', 'title': 'Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage | Stroke', 'source': 'American Heart Association Journals', 'date': 'Sep 27, 2019', 'snippet': 'Background and Purpose—Perihemorrhagic edema (PHE) is associated with poor \noutcome after intracerebral hemorrhage (ICH).', 'thumbnail': 'https://serpapi.com/searches/6722016bdb3ac9d20ba6a8e4/images/73995db3ffdb33bb7d03e624625f884cb250a3cc8c32fb0268bf60ebf7f78c1d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7439489960670471}",,,,,,,,,,['neutral'],neutral,1
NCT05407064,"{'position': 1, 'link': 'https://www.pharmacytimes.com/view/lsd-d-tartrate-receives-breakthrough-therapy-designation-from-fda-for-generalized-anxiety-disorder', 'title': 'LSD D-Tartrate Receives Breakthrough Therapy Designation From FDA for Generalized Anxiety Disorder', 'source': 'Pharmacy Times', 'date': 'Mar 15, 2024', 'snippet': 'LSD d-tartrate (MM-120) showed rapid improvements in patients with \ngeneralized anxiety disorder by day 2 of the study.', 'thumbnail': 'https://serpapi.com/searches/67220194d72128f29a8abf1f/images/0ecf34bc11938bd3d41ff70741f01b3817606e539f966650c055154268a16576.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6051186919212341}",,,,,,,,,,['positive'],positive,1
NCT03675477,"{'position': 1, 'link': 'https://ibdnewstoday.com/2019/06/24/first-uc-and-cd-patients-dosed-in-phase-2-trials-of-shr0302/', 'title': 'First IBD Patients Dosed in 2 Phase 2 Trials of JAK1 inhibitor SHR0302', 'source': 'ibdnewstoday.com', 'date': 'Jun 24, 2019', 'snippet': ""The first patients have been dosed in two Phase 2 trials assessing the \neffects of SHR0302, Reistone's JAK1 inhibitor for inflammatory bowel..."", 'thumbnail': 'https://serpapi.com/searches/672201bf9e38e52cc8f61f93/images/39a67154ee2042a8e300c535b44acfbb467829cb7af40334be1248f9e811ba97.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9314698576927185}",,,,,,,,,,['neutral'],neutral,1
NCT01424670,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(18)30426-0/abstract', 'title': 'Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial', 'source': 'The Lancet', 'date': 'Jan 7, 2019', 'snippet': 'Efficacy and safety of delamanid in combination with an optimised \nbackground regimen for treatment of multidrug-resistant tuberculosis.', 'thumbnail': 'https://serpapi.com/searches/672202154791c43abacbeb56/images/70270290d85610e65dd226a667e66283d3feda1ce22f26ba592dc65b2f9ff84b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7805803418159485}",,,,,,,,,,['neutral'],neutral,1
NCT05134974,"{'position': 1, 'link': 'https://www.contemporarypediatrics.com/view/fda-approves-phentolamine-ophthalmic-solution-0-75-eye-drops-for-pharmacologically-induced-mydriasis', 'title': 'FDA approves phentolamine ophthalmic solution 0.75% eye drops for pharmacologically-induced mydriasis', 'source': 'Contemporary Pediatrics', 'date': 'Sep 27, 2023', 'snippet': 'Results from the phase 3 MIRA-4 pediatric trial demonstrated a favorable \nsafety and tolerability profile with no reported adverse events.', 'thumbnail': 'https://serpapi.com/searches/67220221acf7f878b6162e2d/images/205f18351f86a4312a8bc1a348f0d381dc5dd3781b642881f760b1351945695e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6098784804344177}","{'position': 2, 'link': 'https://www.empr.com/home/news/ryzumvi-now-available-to-reverse-pharmacologically-induced-mydriasis/', 'title': 'Ryzumvi Now Available to Reverse Pharmacologically-Induced Mydriasis', 'source': 'Medical Professionals Reference', 'date': 'Apr 1, 2024', 'snippet': 'Ryzumvi is a preservative-free eye drop formulation of phentolamine \nmesylate, a nonselective alpha-1 and alpha-2 adrenergic antagonist that...', 'thumbnail': 'https://serpapi.com/searches/67220221acf7f878b6162e2d/images/205f18351f86a43185f32001af71b8a710ebae2ae9ea395a1fb44c89b79609d2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8309853672981262}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04659096,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-46531-1', 'title': 'Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer', 'source': 'Nature', 'date': 'Mar 27, 2024', 'snippet': 'Hyperactivation of YAP/TAZ, the Hippo pathway downstream effectors, is \ncommon in human cancer. The requirement of YAP/TAZ for cancer cell...', 'thumbnail': 'https://serpapi.com/searches/672202347c1712a3f3a2dc41/images/dc9248292d1e1aaff5695491c12de669e5304163dfff802b571cc01e00a5022a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6613737344741821}",,,,,,,,,,['negative'],negative,0
NCT02746744,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/07/15/rituximab-outperforms-tecfidera-preventing-relapses-phase-3-trial/', 'title': 'Rituximab Outperforms Tecfidera at Preventing Relapses in Phase 3 Trial', 'source': 'Multiple Sclerosis News Today', 'date': 'Jul 15, 2022', 'snippet': 'MS patients on rituximab were five times less likely to experience a \nrelapse compared with patients given Tecfidera in a Phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/6722024d20e6eb9381df1ade/images/894bdc9329c0f05d241137014a45fcad8a2f7074df5c7ae92c3200c626d94709.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7178086638450623}",,,,,,,,,,['neutral'],neutral,1
NCT00011076,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2020.00034/full', 'title': 'Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling', 'source': 'Frontiers', 'date': 'Jul 2, 2024', 'snippet': 'Transforming growth factor-β (TGF-β) is a common mediator of cancer \nprogression and fibrosis. Fibrosis can be a significant pathology in \nmultiple organs,...', 'thumbnail': 'https://serpapi.com/searches/672202595ddfba5b347b7a6c/images/62050989f9f5cfb91ec9b77a08a0343b9d8139fd9ce17fd4435cc94dbbcd36dc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6716067790985107}",,,,,,,,,,['neutral'],neutral,1
NCT01010061,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1313984', 'title': 'Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions', 'source': 'The New England Journal of Medicine', 'date': 'Jan 8, 2014', 'snippet': 'The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic \nagents, has been shown to prolong overall survival in physically...', 'thumbnail': 'https://serpapi.com/searches/6722027d14c31e91e4a4e73c/images/9f2e094203a81c0e0bac9e772b1b2f42ac9d46dc1d102376af20ea09eb620e77.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7021942734718323}",,,,,,,,,,['neutral'],neutral,1
NCT04659161,"{'position': 1, 'link': 'https://www.psychiatrictimes.com/view/post-hoc-analysis-explores-risk-benefit-profile-of-karxt', 'title': 'Post Hoc Analysis Explores Risk-Benefit Profile of KarXT', 'source': 'Psychiatric Times', 'date': 'May 31, 2024', 'snippet': 'A poster presented at the 2024 ASCP Annual Meeting discussed the results of \na study on the efficacy and tolerability of the investigational...', 'thumbnail': 'https://serpapi.com/searches/6722028076585765bc440e17/images/36232eae0432bd6aeb9c27d265ed0d81bda4eaf9d471e04d61766f781b016ae7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8977423906326294}","{'position': 2, 'link': 'https://www.psychiatrist.com/jcp/antipsychotic-efficacy-of-karxt-xanomeline-trospium/', 'title': 'Antipsychotic Efficacy of KarXT (Xanomeline−Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study', 'source': 'Psychiatrist.com', 'date': 'May 11, 2022', 'snippet': 'KarXT provided clinically meaningful responder rates on PANSS total score \ncompared with placebo at each response threshold, providing further support \nof the...', 'thumbnail': 'https://serpapi.com/searches/6722028076585765bc440e17/images/36232eae0432bd6a54a6001a5d7e10d9e8a2dfca9ce69e3917a52715df09a5b4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8605852127075195}","{'position': 3, 'link': 'https://www.empr.com/news/cobenfy-approved-for-adult-patients-with-schizophrenia/', 'title': 'Cobenfy Approved for Adult Patients with Schizophrenia', 'source': 'Medical Professionals Reference', 'date': '1 month ago', 'snippet': 'The Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and \ntrospium chloride) for the treatment of adults with schizophrenia.', 'thumbnail': 'https://serpapi.com/searches/6722028076585765bc440e17/images/36232eae0432bd6a657183bf4e1406bfb9263e6ddfac472b5d73a3eafa39f0d0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7815037369728088}","{'position': 4, 'link': 'https://www.psychiatrictimes.com/view/pharmacogenomics-sticking-to-the-evidence-base', 'title': 'Pharmacogenomics: Sticking to the Evidence Base', 'source': 'Psychiatric Times', 'date': 'May 9, 2024', 'snippet': 'John. J. Miller, MD, sat down with us at the 2024 American Psychiatric \nAssociation Annual Meeting to discuss pharmacogenomics, a topic he is very \npassionate...', 'thumbnail': 'https://serpapi.com/searches/6722028076585765bc440e17/images/36232eae0432bd6a115ab9ea7a523e56fea406a04479050d0d1ed56408b5fb28.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7020533680915833}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT05501522,"{'position': 1, 'link': 'https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00317-6/fulltext', 'title': 'Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial - eClinicalMedicine', 'source': 'The Lancet', 'date': 'Sep 7, 2023', 'snippet': 'GBP510 vaccine contains self-assembling, recombinant nanoparticles \ndisplaying SARS-CoV-2 spike receptor-binding domains.', 'thumbnail': 'https://serpapi.com/searches/672203379109867ed4000e79/images/2ca84504421b0e8dd5cf848382a87c544e385ab1de3c35e451b27f4d409191a6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9071503281593323}",,,,,,,,,,['neutral'],neutral,1
NCT04172831,"{'position': 1, 'link': 'https://fibromyalgianewstoday.com/2020/09/08/enrollment-open-in-second-phase-3-trial-of-higher-tnx-102-sl-dose-for-managing-fm/', 'title': 'Enrollment Open in Second Phase 3 Trial of Higher TNX-102 SL Dose for Managing FM', 'source': 'Fibromyalgia News Today', 'date': 'Sep 8, 2020', 'snippet': ""The second Phase 3 clinical trial examining a higher dose of TNX-102 SL \n(sublingual cyclobenzaprine), Tonix Pharmaceuticals' bedtime..."", 'thumbnail': 'https://serpapi.com/searches/67220362a25104af56cc6dea/images/a29526039bb6e19f61a511107e1578e5fdc23d3702e214bd31295438b6c8e50e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9358941316604614}",,,,,,,,,,['neutral'],neutral,1
NCT03782792,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2111563', 'title': 'Trial of Spesolimab for Generalized Pustular Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Dec 22, 2021', 'snippet': 'Spesolimab, a humanized anti–interleukin-36 receptor monoclonal antibody, \nis being studied for the treatment of GPP flares.', 'thumbnail': 'https://serpapi.com/searches/67220367a5aae9204588f7e5/images/b3d16b864ec885ea07bc0329932c4556e2f0a2ff1a6a24ad0d729a5a87045f50.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9019375443458557}",,,,,,,,,,['neutral'],neutral,1
NCT02614794,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1914609', 'title': 'Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Dec 11, 2019', 'snippet': 'Patients with human epidermal growth factor receptor 2 (HER2)–positive \nmetastatic breast cancer who have disease progression after therapy...', 'thumbnail': 'https://serpapi.com/searches/6722038f9109867ea007262b/images/30278cd3cf9b5bfa9a8600b8d817503e968685a3bcc08ac375d8a087cbb0364c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7983696460723877}","{'position': 2, 'link': 'https://news.cuanschutz.edu/cancer-center/tucatinib', 'title': 'Tucatinib “game changing” against stage IV HER2+ breast cancer, especially with brain metastases', 'source': 'University of Colorado Anschutz Medical Campus', 'date': 'Dec 11, 2019', 'snippet': 'Phase III clinical trial results reported today in the New England Journal \nof Medicine and presented concurrently at the San Antonio Breast...', 'thumbnail': 'https://serpapi.com/searches/6722038f9109867ea007262b/images/30278cd3cf9b5bfa479d818ce72b75998571402f9cb3de7f457841801b887b90.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8076128363609314}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/real-world-analysis-of-tucatinib-triplet-yields-positive-safety-profile-in-her2-metastatic-breast-cancer', 'title': 'Real-World Analysis of Tucatinib Triplet Yields Positive Safety Profile in HER2+ Metastatic Breast Cancer', 'source': 'Cancer Network', 'date': 'Dec 8, 2022', 'snippet': 'Results from the real-world analysis of the phase 2 HER2CLIMB trial showed \na good safety profile with the tucatinib triplet regimen in...', 'thumbnail': 'https://serpapi.com/searches/6722038f9109867ea007262b/images/30278cd3cf9b5bfa1131300a192d1122896aab814c359dc1b8b61453f9a1f646.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7039353847503662}","{'position': 4, 'link': 'https://www.ajmc.com/view/t-dxd-sustained-substantial-durable-clinical-activity-in-patients-with-her2-metastatic-breast-cancer', 'title': 'T-DXd Sustained Substantial, Durable Clinical Activity in Patients With HER2+ Metastatic Breast Cancer', 'source': 'AJMC', 'date': '1 month ago', 'snippet': 'According to research presented at the European Society for Medical \nOncology Congress 2024 in Barcelona, Spain, by Nancy Lin, MD,...', 'thumbnail': 'https://serpapi.com/searches/6722038f9109867ea007262b/images/30278cd3cf9b5bfa93ef1f4927e69c96ea487952bf6cdcf2d40e47c7c36490ac.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.899843156337738}","{'position': 5, 'link': 'https://www.targetedonc.com/view/confronting-challenges-and-embracing-progress-in-her2-breast-cancer', 'title': 'Confronting Challenges and Embracing Progress in HER2+ Breast Cancer', 'source': 'Targeted Oncology', 'date': 'Apr 12, 2024', 'snippet': 'Yara Abdou, MD, medical oncologist at the University of North Carolina \n(UNC) in Chapel Hill, looks back on what have been the biggest...', 'thumbnail': 'https://serpapi.com/searches/6722038f9109867ea007262b/images/30278cd3cf9b5bfad5d5a706361bfe03028c66a747fde56ba6743b0fd1808a49.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9009709358215332}","{'position': 6, 'link': 'https://www.bcrf.org/blog/highlights-sabcs-annual-symposium-2019-her2-positive-breast-cancer-updates/', 'title': 'Highlights from SABCS Annual Symposium 2019: HER2-Positive Breast Cancer Updates', 'source': 'Breast Cancer Research Foundation', 'date': 'Jan 15, 2020', 'snippet': 'Reports from clinical trials in HER2-positive breast cancer highlight \npromising new agents for patients with advanced disease.', 'thumbnail': 'https://serpapi.com/searches/6722038f9109867ea007262b/images/30278cd3cf9b5bfac16be89e626d0bb1e4af9814bf791997c5b8d07c7d485e43.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5301448702812195}","{'position': 7, 'link': 'https://breastcancer-news.com/2020/05/14/tukysa-approved-for-metastatic-her2-positive-breast-cancer-treatment-in-switzerland/', 'title': ""Tukysa OK'd in Switzerland for Metastatic HER2-positive Breast Cancer"", 'source': 'Breast Cancer News', 'date': 'May 14, 2020', 'snippet': ""Seattle Genetics' Tukysa, in combination with trastuzumab and Xeloda \n(capecitabine), for treating metastatic HER2-positive breast cancer in..."", 'thumbnail': 'https://serpapi.com/searches/6722038f9109867ea007262b/images/30278cd3cf9b5bfa66ee75d24dea3f14b2205485d96140ea89140a95798ca6ef.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7427335381507874}","{'position': 8, 'link': 'https://www.targetedonc.com/view/activity-with-tucatinib-across-the-blood-brain-barrier-presents-a-vital-option-in-her2-breast', 'title': 'Activity With Tucatinib Across the Blood-Brain Barrier Presents a Vital Option in HER2+ Breast Cancer', 'source': 'Targeted Oncology', 'date': 'May 19, 2020', 'snippet': 'In an interview with Targeted Oncology, Rashmi Murthy, MD, discussed the \nfinal results from the HER2CLIMB study and the future of tucatinib...', 'thumbnail': 'https://serpapi.com/searches/6722038f9109867ea007262b/images/30278cd3cf9b5bfa783826de10752551447b7c69787ceaed6020b1da1fc3c16b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9205821752548218}",,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT03580369,"{'position': 1, 'link': 'https://www.pharmiweb.com/press-release/2024-10-23/global-drug-eruptions-treatment-market-to-reach-usd-71-billion-by-2033-growing-at-a-62-cagr', 'title': 'Global Drug Eruptions Treatment Market to Reach USD 7.1 Billion by 2033, Growing at a 6.2% CAGR', 'source': 'PharmiWeb.com', 'date': '6 days ago', 'snippet': 'Drug Eruptions Treatment MarketThe global drug eruptions treatment market \nis set to experience steady growth over the next decade,...', 'thumbnail': 'https://serpapi.com/searches/672203b571b0e8b89c48c9f9/images/6815d018c3b17219e730bb4529fc420a2fb33a7bf8cffde872159a4c33a36d4d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5003542304039001}",,,,,,,,,,['neutral'],neutral,1
NCT03766581,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-022-08768-y', 'title': 'Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants', 'source': 'Nature', 'date': 'Mar 25, 2022', 'snippet': 'This randomized, double-blind, placebo-controlled, multiple ascending–dose \nstudy evaluated safety, tolerability, pharmacokinetics,...', 'thumbnail': 'https://serpapi.com/searches/6722041b316650b50a5d09e8/images/b8102c7bc6dfd5cd745521d9840219ba6687f66a27786af9a89f679689cd4e3d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8481782674789429}",,,,,,,,,,['neutral'],neutral,1
NCT00137995,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-023-00889-5', 'title': 'Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study | Blood Cancer Journal', 'source': 'Nature', 'date': 'Aug 18, 2023', 'snippet': 'Only one study by Maziarz et al. to date has demonstrated improved patient \nsurvival with tisa-cel using two individual patient data (IPD) from the \nJULIET study...', 'thumbnail': 'https://serpapi.com/searches/6722042dba13f21ac0513148/images/18c6dd8e5623fe03828bc3d9062b8c0f6e81a4785f02e049561c3d97c2f115bc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8898653984069824}",,,,,,,,,,['neutral'],neutral,1
NCT04767373,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/msd-mulls-2025-26-launch-for-rsv-vaccine-after-phase-ii-iii-win/', 'title': 'MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win', 'source': 'Clinical Trials Arena', 'date': '1 week ago', 'snippet': 'A Phase IIb/III trial with infants entering their first respiratory \nsyncytial virus (RSV) season met its primary endpoints.', 'thumbnail': 'https://serpapi.com/searches/6722044af60b6f4fdd4da0f6/images/448db5b452c3c066903c110edb05cebf3ca799be3cab088ad76bb4b17125d4ed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8909560441970825}","{'position': 2, 'link': 'https://www.nature.com/articles/s41541-023-00734-7', 'title': 'The road to approved vaccines for respiratory syncytial virus', 'source': 'Nature', 'date': 'Sep 25, 2023', 'snippet': 'In this review, I will discuss the impact of RSV on human health and how \nstructure-based vaccine design set the stage for numerous RSV \ncountermeasures to...', 'thumbnail': 'https://serpapi.com/searches/6722044af60b6f4fdd4da0f6/images/448db5b452c3c066e52898337ab9245bb928fece4053d3b17fe8206255abbba1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8935171365737915}","{'position': 3, 'link': 'https://www.businesswire.com/news/home/20240723229019/en/Merck-Announces-Topline-Results-from-Phase-2b3-Trial-of-Clesrovimab-MK-1654-an-Investigational-Respiratory-Syncytial-Virus-Preventative-Monoclonal-Antibody-for-Infants', 'title': 'Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants', 'source': 'Business Wire', 'date': 'Jul 23, 2024', 'snippet': 'Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab \n(MK-1654), an Investigational RSV Preventative Monoclonal Antibody for...', 'thumbnail': 'https://serpapi.com/searches/6722044af60b6f4fdd4da0f6/images/448db5b452c3c06600a25af6924b2dbcaafbbeb6c230d43c3b89c1a9e05147cb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9196798801422119}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02344290,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2304146', 'title': 'Pitavastatin to Prevent Cardiovascular Disease in HIV Infection', 'source': 'The New England Journal of Medicine', 'date': 'Jul 23, 2023', 'snippet': 'The risk of cardiovascular disease is increased among persons with human \nimmunodeficiency virus (HIV) infection, so data regarding primary...', 'thumbnail': 'https://serpapi.com/searches/67220470caddc31ce576aaf4/images/0493faeb1e924e7c476134613eda163703e28a2af1b4a101ed5689caf16f6ad2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5175327062606812}",,,,,,,,,,['neutral'],neutral,1
NCT03020160,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/web-based-calculator-helps-finetune-dosage-hemlibra-hemophilia-a-patients/', 'title': 'Hemophilia A Patient Care Facilitated with Hemlibra Dosing Calculator', 'source': 'Hemophilia News Today', 'date': 'May 24, 2019', 'snippet': 'A web-based dosing calculator to help physicians select the correct loading \nand maintenance dose of the treatment Hemlibra according to the body \nmeasurements.', 'thumbnail': 'https://serpapi.com/searches/67220533d0c9832b6154f06d/images/f65fdcbc5d34319309eb0bff46d48ffd53a9d98938339310f41957d57e08cef0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9187051057815552}",,,,,,,,,,['neutral'],neutral,1
NCT02025621,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1616218', 'title': 'Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery', 'source': 'The New England Journal of Medicine', 'date': 'Mar 19, 2017', 'snippet': 'In a multicenter, randomized, placebo-controlled, phase 3 trial, we \nevaluated the efficacy and safety of levosimendan in patients with a...', 'thumbnail': 'https://serpapi.com/searches/672205444e9efc409f1cf450/images/af9af50fca179041a819dc89c14f6fba0473d4fb521c21dfd6ec6b8bafc094d6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8953907489776611}",,,,,,,,,,['neutral'],neutral,1
NCT01728064,"{'position': 1, 'link': 'https://friedreichsataxianews.com/friedreichs-ataxia-experimental-treatments/epi-743-vatiquinone/', 'title': ""EPI-743 (Vatiquinone) for Friedreich's Ataxia"", 'source': ""Friedreich's Ataxia News"", 'date': 'Sep 7, 2023', 'snippet': ""EPI-743 (Vatiquinone) is being developed by BioElectron for Friedreich's \nataxia and received FDA orphan drug and fast track designations."", 'thumbnail': 'https://serpapi.com/searches/6722054d6273fbfd4ebfcd1c/images/14b88fb380f749817079451146d8397034775bc2da8fb063ccf73c9081053b6c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8560620546340942}","{'position': 2, 'link': 'https://friedreichsataxianews.com/news/fa-patients-show-improvements-epi743-phase-trial/', 'title': 'FA Patients Show Improvements with Investigational EPI-743 in Phase 2 Trial', 'source': ""Friedreich's Ataxia News"", 'date': 'Aug 2, 2018', 'snippet': ""Long-term use of EPI-743 (vatiquinone) can improve neurological function \nand prevent progression of Friedreich's ataxia, Phase 2 trial..."", 'thumbnail': 'https://serpapi.com/searches/6722054d6273fbfd4ebfcd1c/images/14b88fb380f74981ec1fbca93ec820bc6113d7839f50e23d9efd808b018a74c4.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7339364886283875}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03164993,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-02126-1', 'title': 'Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial', 'source': 'Nature', 'date': 'Dec 8, 2022', 'snippet': 'The randomized, placebo-controlled ALICE trial (NCT03164993) evaluated the \naddition of atezolizumab (anti-PD-L1) to immune-stimulating chemotherapy in \nmTNBC.', 'thumbnail': 'https://serpapi.com/searches/6722055081bab782be64874e/images/fb5a27343744aa2860bfc4feb3ca15032c2776d5bcf0ee4067182c5c4cd8e608.png', 'sentiment': 'neutral', 'sentiment_prob': 0.905595600605011}",,,,,,,,,,['neutral'],neutral,1
NCT02451696,"{'position': 1, 'link': 'https://www.science.org/doi/10.1126/science.adj2244', 'title': 'Neurosurgery elucidates somatic mutations', 'source': 'Science | AAAS', 'date': 'Dec 21, 2023', 'snippet': 'Somatic variants are genomic alterations present in some cells of the body \nbut not in others. In contrast to inherited germline variants,...', 'thumbnail': 'https://serpapi.com/searches/67220567a3657ab8d46d0591/images/fa823c9cf35a18a98fd99b3d492ae2ab7b0cbe3e9fecfb99e6ecc1d6cb0f497c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8988147974014282}",,,,,,,,,,['neutral'],neutral,1
NCT01673867,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1507643', 'title': 'Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Sep 27, 2015', 'snippet': 'We report the results of a randomized, open-label, international phase 3 \nstudy comparing nivolumab with docetaxel in previously treated patients \nwith advanced...', 'thumbnail': 'https://serpapi.com/searches/6722058b9fd3091aa2d92142/images/aec4ba79dfbb72aedc7a4bf70de82ccb7d101ee3e8def2abdd6b7d7895327601.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9051253795623779}","{'position': 2, 'link': 'https://www.nature.com/articles/s41698-023-00403-x', 'title': 'Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer | npj Precision Oncology', 'source': 'Nature', 'date': 'Jun 1, 2023', 'snippet': 'The tumor immune composition influences prognosis and treatment sensitivity \nin lung cancer. The presence of effective adaptive immune...', 'thumbnail': 'https://serpapi.com/searches/6722058b9fd3091aa2d92142/images/aec4ba79dfbb72aeb95f5cdf12677fe50f269d2ba6b1d10b277c0be08d6b16c9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9170801043510437}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01541215,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1903822', 'title': 'Liraglutide in Children and Adolescents with Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Apr 28, 2019', 'snippet': 'Liraglutide, at a dose of up to 1.8 mg per day (added to metformin, with or \nwithout basal insulin), was efficacious in improving glycemic control over \n52 weeks.', 'thumbnail': 'https://serpapi.com/searches/672205a2fc40bf18ede9935b/images/00254b7c4b99c0765e16d0f5f224eb2a0df5b5258b2d798fe99b227a7dd1f7f5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6073904633522034}",,,,,,,,,,['neutral'],neutral,1
NCT02422615,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.2018.78.9909', 'title': 'Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Jun 3, 2018', 'snippet': 'This phase III study evaluated ribociclib plus fulvestrant in patients with \nhormone receptor–positive/human epidermal growth factor receptor \n2–negative...', 'thumbnail': 'https://serpapi.com/searches/672205b52c566df19c3d92a9/images/70800918f8c20059af7927bdbe91e57de4c04c96f81f3552fff5f867e8aae7f6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9057517647743225}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/ribociclib-plus-fulvestrant-continued-to-improve-os-in-advanced-hr-breast-cancer-regardless-of-setting', 'title': 'Ribociclib Plus Fulvestrant Continued to Improve OS in Advanced, HR+ Breast Cancer, Regardless of Setting', 'source': 'Cancer Network', 'date': 'Jun 5, 2021', 'snippet': 'Ribociclib (Kisqali) plus fulvestrant (Faslodex) maintained significantly \nimproved overall survival (OS) rates after nearly 5 years of...', 'thumbnail': 'https://serpapi.com/searches/672205b52c566df19c3d92a9/images/70800918f8c20059766d44fa6381f86828691ab6770d6f38576c7e7fa246cda0.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5330244302749634}","{'position': 3, 'link': 'https://breastcancer-news.com/2018/07/25/fda-approves-kisqali-for-breast-cancer-in-premenopausal-perimenopausal-women/', 'title': 'FDA Approves Kisqali for Breast Cancer in Pre-, Perimenopausal Women', 'source': 'breastcancer-news.com', 'date': 'Jul 25, 2018', 'snippet': 'Kisqali (ribociclib) now can be used in combination with an aromatase \ninhibitor as first-line therapy for all women with HR-positive, \nHER2-negative advanced or...', 'thumbnail': 'https://serpapi.com/searches/672205b52c566df19c3d92a9/images/70800918f8c20059e5be4ce560d76db196208c8da80c191d36fa3e04b186d332.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8082779049873352}","{'position': 4, 'link': 'https://breastcancer-news.com/2020/06/04/kisqali-prolongs-overall-survival-of-women-with-advanced-breast-cancer-and-internal-organ-metastases/', 'title': 'Kisqali Prolongs Overall Survival in Advanced Breast Cancer Patients with Internal Organ Metastases', 'source': 'Breast Cancer News', 'date': 'Jun 4, 2020', 'snippet': 'Kisqali and endocrine therapy prolongs the survival of women with \nHR-positive, HER2-negative, advanced or metastatic breast cancer anad...', 'thumbnail': 'https://serpapi.com/searches/672205b52c566df19c3d92a9/images/70800918f8c20059ed2e5440ff9b895d94ba2ed9ce9256df3f260dbcb5c2532b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5336280465126038}","{'position': 5, 'link': 'https://breastcancer-news.com/2019/10/16/kisqali-faslodex-combo-prolongs-survival-of-women-with-breast-cancer/', 'title': 'Kisqali-Faslodex Combo Prolongs Survival in Advanced Breast Cancer', 'source': 'breastcancer-news.com', 'date': 'Oct 16, 2019', 'snippet': 'Kisqali-Faslodex combo prolongs survival of women with advanced or \nmetastatic breast cancer, interim analysis of the MONALEESA-3 trial...', 'thumbnail': 'https://serpapi.com/searches/672205b52c566df19c3d92a9/images/70800918f8c2005970b8b038209f5226845164fde0164572554a5aae9a626d3f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5592573285102844}",,,,,,"['neutral', 'positive', 'neutral', 'neutral', 'neutral']",neutral,1
NCT00063713,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-0113-2', 'title': 'Advances in targeted therapy for malignant lymphoma', 'source': 'Nature', 'date': 'Mar 6, 2020', 'snippet': 'The incidence of lymphoma has gradually increased over previous decades, \nand it ranks among the ten most prevalent cancers worldwide.', 'thumbnail': 'https://serpapi.com/searches/672205babe80137f461932ab/images/60ce978491c21d87288646167e81ac2f038995032fb731581b163c336931f9d5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8373763561248779}",,,,,,,,,,['neutral'],neutral,1
NCT00133952,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332221007009', 'title': 'New progress in drugs treatment of diabetic kidney disease', 'source': 'ScienceDirect.com', 'date': 'Jul 20, 2021', 'snippet': 'In this review, we sort out the progress in the treatment of DKD in recent \nyears, the research status of some emerging drugs, and the potential drugs \nfor the...', 'thumbnail': 'https://serpapi.com/searches/672205c9f7adbfc5af9f1fb7/images/0d26985dae31ffb3361ac669e6818e71a3f9ca273dc15600aabfcc7cdd8fec0f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.900636613368988}",,,,,,,,,,['neutral'],neutral,1
NCT02966028,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-020-74592-x', 'title': 'A novel assay to measure calcification propensity: from laboratory to humans', 'source': 'Nature', 'date': 'Oct 16, 2020', 'snippet': 'We examined the pharmacodynamic effects of SNF472, a calcification \ninhibitor, on plasma calcium phosphate crystallization using spectrometric \nmeasurements.', 'thumbnail': 'https://serpapi.com/searches/672205e7f922f68abd6e8b9c/images/979564f5f88b027fe5c6b1658f24e3bf3d7a31bf8a2f587040a10e806e4957f6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9063605666160583}",,,,,,,,,,['neutral'],neutral,1
NCT02990338,"{'position': 1, 'link': 'https://www.onclive.com/view/isatuximab-plus-pomalidomide-and-dexamethasone-shows-meaningful-pfs-benefit-in-multiple-myeloma', 'title': 'Isatuximab Plus Pomalidomide and Dexamethasone Shows Meaningful PFS Benefit in Multiple Myeloma', 'source': 'OncLive', 'date': 'Aug 26, 2022', 'snippet': 'Isatuximab plus pomalidomide and dexamethasone elicited favorable \nprogression-free survival and proved tolerable in pretreated patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/672205ef544c49a3ab20a3a1/images/23d25abe57b552eacb76731a16a31e8a5b8125187d157a28a16b8081b5fc1fff.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7996633052825928}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/sarclisa-extends-survival-rrmm-long-term-phase-3-trial/', 'title': 'Sarclisa Extends Survival in RRMM, Long-term Phase 3 Trial Data Shows', 'source': 'Myeloma Research News', 'date': 'Mar 14, 2022', 'snippet': 'Sarclisa plus Pomalyst and dexamethasone extended survival by 6.9 months in \nrelapsed/refractory multiple myeloma patients, 3-year data show.', 'thumbnail': 'https://serpapi.com/searches/672205ef544c49a3ab20a3a1/images/23d25abe57b552eab52983632ce5cda2b7d83e037db302708fbb5fea532b2244.png', 'sentiment': 'positive', 'sentiment_prob': 0.5437084436416626}","{'position': 3, 'link': 'https://myelomaresearchnews.com/news/fda-approves-sarclisa-combo-to-treat-relapsed-or-refractory-multiple-myeloma/', 'title': 'Sarclisa Combo for Advanced Multiple Myeloma Approved by FDA', 'source': 'Myeloma Research News', 'date': 'Mar 4, 2020', 'snippet': 'The US Food and Drug Administration (FDA) has approved Sarclisa \n(isatuximab-irfc), in combination with Pomalyst (pomalidomide) and \ndexamethasone, to treat...', 'thumbnail': 'https://serpapi.com/searches/672205ef544c49a3ab20a3a1/images/23d25abe57b552ea22940aa5f39e843477815de26f4af675eeef2ba081028f21.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6747493147850037}",,,,,,,,"['positive', 'positive', 'neutral']",positive,1
NCT04056910,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-024-00646-2', 'title': 'Treatment of IDH-mutant glioma in the INDIGO era', 'source': 'Nature', 'date': 'Jul 19, 2024', 'snippet': 'The recently published INDIGO trial, demonstrating the benefit of the \nmutant IDH inhibitor vorasidenib in patients with low-grade IDH-mutant \ngliomas,...', 'thumbnail': 'https://serpapi.com/searches/672205f9e9b6912bceead42b/images/8cd86ca6fca95637e9927ac88cb1aec23b5549637f8f74d885476aeb7907a8c5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7965724468231201}",,,,,,,,,,['neutral'],neutral,1
NCT02123121,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01503-7', 'title': 'The mitophagy pathway and its implications in human diseases | Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': 'Aug 16, 2023', 'snippet': 'Mitophagy serves as a cytoprotective mechanism to remove superfluous or \ndysfunctional mitochondria and maintain mitochondrial fine-tuning numbers \nto balance...', 'thumbnail': 'https://serpapi.com/searches/672205faea57e910a7c0650c/images/b7cdca4620cf80c400f1e3e523dbac0903ab256c71310785329c30ae3324683d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.925862193107605}",,,,,,,,,,['neutral'],neutral,1
NCT05590403,"{'position': 1, 'link': 'https://www.drugdiscoverytrends.com/gsk-rsv-vaccine-approval-arexvy-new-market/', 'title': 'A look at the RSV vaccine landscape as GSK wins FDA approval', 'source': 'Drug Discovery & Development', 'date': 'Oct 30, 2023', 'snippet': 'GSK (NYSE:GSK) is aiming to expand the label for its respiratory syncytial \nvirus (RSV) vaccine Arexvy, which was the first to win FDA approval.', 'thumbnail': 'https://serpapi.com/searches/67220600690121576731d512/images/b8f99b3f08e197ffe7d3b61ab3bcdfcedad1cd21f4cf3548e675b183079e13f5.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7244263291358948}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20240606055012/en/US-FDA-Approves-Expanded-Age-Indication-for-GSK%E2%80%99s-AREXVY-the-First-Respiratory-Syncytial-Virus-RSV-Vaccine-for-Adults-Aged-50-59-at-Increased-Risk', 'title': 'US FDA Approves Expanded Age Indication for GSK’s AREXVY the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk', 'source': 'Business Wire', 'date': 'Jun 7, 2024', 'snippet': 'The US Food and Drug Administration (FDA) has approved AREXVY (Respiratory \nSyncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV \nlower...', 'thumbnail': 'https://serpapi.com/searches/67220600690121576731d512/images/b8f99b3f08e197ffdf9a17cd30dc70087c064e34709cd923e70f89ad000fe9d6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8796454668045044}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT04419506,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2201737', 'title': 'Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis', 'source': 'The New England Journal of Medicine', 'date': 'May 15, 2022', 'snippet': 'In this phase 2, double-blind, placebo-controlled trial, we investigated \nthe efficacy and safety of BI 1015550, an oral preferential inhibitor of \nthe PDE4B...', 'thumbnail': 'https://serpapi.com/searches/672206074a4a1d50e18564aa/images/6e02eb3b6692265de0b489d4ec0acea64797e221fa73ee8bb67c83c8757e19fd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8974422216415405}","{'position': 2, 'link': 'https://www.pulmonologyadvisor.com/news/efficacy-safety-of-ipf-treatment-with-bi-1015550/', 'title': 'Efficacy/Safety of Idiopathic Pulmonary Fibrosis Treatment With BI 1015550', 'source': 'Pulmonology Advisor', 'date': 'Jun 28, 2022', 'snippet': 'BI 1015550, either alone or with background use of an antifibrotic agent, \nprevented a decrease in lung function, according to clinical trial results.', 'thumbnail': 'https://serpapi.com/searches/672206074a4a1d50e18564aa/images/6e02eb3b6692265ded2338de8425755c05653bd8ef13580c4572d526e1f8e16f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.816017210483551}","{'position': 3, 'link': 'https://pulmonaryfibrosisnews.com/news/first-ipf-patient-enrolled-phase-3-trial-testing-bi-1015550/', 'title': 'First Patient Enrolled in Phase 3 Trial Testing BI 1015550', 'source': 'Pulmonary Fibrosis News', 'date': 'Oct 28, 2022', 'snippet': 'Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a \nPhase 3 clinical trial evaluating the efficacy, safety, and tolerability of \nBI 1015550.', 'thumbnail': 'https://serpapi.com/searches/672206074a4a1d50e18564aa/images/6e02eb3b6692265d6c44d134c9229fd79ab51eeac9566241b9545e7a54559275.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8812422156333923}","{'position': 4, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/oral-pde4b-inhibitor-gets-breakthrough-tx-status-for-idiopathic-pulmonary-fibrosis/', 'title': 'Oral PDE4B Inhibitor Gets Breakthrough Tx Status for Idiopathic Pulmonary Fibrosis', 'source': 'Medical Professionals Reference', 'date': 'Feb 24, 2022', 'snippet': 'The Food and Drug Administration (FDA) has granted Breakthrough Therapy \ndesignation to BI 1015550 for the treatment of idiopathic pulmonary \nfibrosis (IPF).', 'thumbnail': 'https://serpapi.com/searches/672206074a4a1d50e18564aa/images/6e02eb3b6692265def93a425fee6d41c105523938c5dbce47ab6450ad3d75508.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8134189248085022}","{'position': 5, 'link': 'https://pulmonaryfibrosisnews.com/news/primary-goal-met-ipf-phase-3-clinical-trial-nerandomilast/', 'title': 'Nerandomilast Phase 3 clinical trial meets its primary goal in IPF', 'source': 'Pulmonary Fibrosis News', 'date': '1 month ago', 'snippet': ""A Phase 3 clinical trial testing Boehringer Ingelheim's oral \ninvestigational treatment nerandomilast in people with idiopathic \npulmonary..."", 'thumbnail': 'https://serpapi.com/searches/672206074a4a1d50e18564aa/images/6e02eb3b6692265d2ecce41508fa5c252aed6167ca1b2efd30ed19ba9d2cc995.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5018900632858276}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT04848688,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00507-8/abstract', 'title': 'Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial', 'source': 'The Lancet', 'date': 'Nov 7, 2023', 'snippet': 'Infection with the soil-transmitted helminth Strongyloides stercoralis \naffects up to 600 million people globally, most of whom live in rural...', 'thumbnail': 'https://serpapi.com/searches/67220619cc48791ec6d39a0f/images/bba9256536cd0d850b9e603ed4c849bfbe50b8313bc15a8d1007db265a4a703a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.722391664981842}",,,,,,,,,,['neutral'],neutral,1
NCT02931214,"{'position': 1, 'link': 'https://breastcancer-news.com/2020/02/07/first-advanced-breast-cancer-patient-dosed-with-gmi-1359-treatment-for-bone-metastasis/', 'title': 'Study of Treatment Aiming to Prevent Advanced Breast Cancer’s Spread to Bone Doses 1st Patient', 'source': 'Breast Cancer News', 'date': 'Feb 7, 2020', 'snippet': 'The first patient with advanced breast cancer has been dosed in a Phase 1b \nclinical trial investigating the ability of its small molecule inhibitor, \nGMI-1359,...', 'thumbnail': 'https://serpapi.com/searches/67220628b4fe87248f8f8ce3/images/20a51c1224e357990ca211786fa19fb08ab907a73f5e8642e460ddddf2ea648e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8458389043807983}",,,,,,,,,,['neutral'],neutral,1
NCT03748186,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2021/02/04/phase-1-trial-starts-testing-ovarian-cancer-patients-with-recommended-stro-002-dose/', 'title': 'Early Trial Starts Testing Recommended STRO-002 Dose for Advanced Cancer', 'source': 'Ovarian Cancer News Today', 'date': 'Feb 4, 2021', 'snippet': 'Sutro Biopharma has dosed the first patient in the dose-expansion group of \nits Phase 1 clinical trial evaluating STRO-002 for advanced...', 'thumbnail': 'https://serpapi.com/searches/6722062e9062f8271d862b71/images/14732bfe9b9d280430a1bb552e9de7533c678d45dd46d2eff2278ac9b15c60c5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9252076745033264}","{'position': 2, 'link': 'https://www.nature.com/articles/s41392-020-0199-6', 'title': 'Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence', 'source': 'Nature', 'date': 'Jul 29, 2020', 'snippet': 'Advanced and recurrent gynecological cancers are associated with poor \nprognosis and lack of effective treatment. The developments of the...', 'thumbnail': 'https://serpapi.com/searches/6722062e9062f8271d862b71/images/14732bfe9b9d2804dbd8a64e375c8879027d3cd80bfda9c39097320b9291e05b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6648945212364197}","{'position': 3, 'link': 'https://ovariancancernewstoday.com/2020/05/06/stro-002-continues-to-show-promising-safety-and-anti-tumor-activity-in-advanced-ovarian-cancer-phase-1-trial-shows/', 'title': 'STRO-002 Continues to Show Promise in Advanced Ovarian Cancer, Early Trial Results Show', 'source': 'Ovarian Cancer News Today', 'date': 'May 6, 2020', 'snippet': 'Read about a Phase 1 trial showing sustained safety and anti-tumor activity \nof STRO-002 in women with advanced ovarian cancer.', 'thumbnail': 'https://serpapi.com/searches/6722062e9062f8271d862b71/images/14732bfe9b9d28045a95f243e4be515d8d6e62fe9eb43449edb5f51c5ad320d5.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6907550692558289}","{'position': 4, 'link': 'https://www.ppf.eu/en/insights/biotech-market/september-2021-review-of-news-from-the-most-innovative-therapeutic-areas-and-the/fda-granted-accelerated-approval-to-tivdak-in-cervical-cancer', 'title': 'FDA granted accelerated approval to Tivdak in cervical cancer', 'source': 'PPF Group', 'date': 'Jun 7, 2022', 'snippet': ""Astellas and Seagen announced that Japan's Ministry of Health, Labour and \nWelfare (MHLW) has approved Padcev (enfortumab vedotin) for radically \nunresectable..."", 'thumbnail': 'https://serpapi.com/searches/6722062e9062f8271d862b71/images/14732bfe9b9d28048c14049789cf07f90e7ccf829ef8eab645db202bc7c568ce.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8190815448760986}",,,,,,,"['neutral', 'neutral', 'positive', 'neutral']",neutral,1
NCT03901339,"{'position': 1, 'link': 'https://www.targetedonc.com/view/batalini-explores-role-of-ugt1a1-in-patients-treated-with-sacituzumab-govitecan-for-hr-mbc', 'title': 'Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC', 'source': 'Targeted Oncology', 'date': 'Apr 22, 2024', 'snippet': 'During a Community Case Forum live event in partnership with The Arizona \nClinical Oncology Society, Felipe Batalini, MD, discussed the...', 'thumbnail': 'https://serpapi.com/searches/67220665aab36dd7965e3bac/images/e07116873fb480630cde02af7d989d4c669c76248aca559f40262e11225987f4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9425888657569885}","{'position': 2, 'link': 'https://www.onclive.com/view/practical-considerations-for-adc-selection-in-hr-her2--mbc', 'title': 'Practical Considerations for ADC Selection in HR+/HER2- mBC', 'source': 'OncLive', 'date': 'Aug 22, 2023', 'snippet': 'Panelists share clinical insight into how to approach treatment selection \namong ADCs in HR+/HER2- metastatic breast cancer both now and in...', 'thumbnail': 'https://serpapi.com/searches/67220665aab36dd7965e3bac/images/e07116873fb4806325fe81c9b74e5bc8723bbd075dd2d77b0b0b1431fa6b985d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9352636337280273}","{'position': 3, 'link': 'https://www.oncnursingnews.com/view/tropics-02-final-os-analysis-shows-superior-outcomes-with-sacituzumab-govitecan-for-hr-her2-breast-cancer', 'title': 'TROPiCS-02 Final OS Analysis Shows Superior Outcomes With Sacituzumab Govitecan For HR+/HER2– Breast Cancer', 'source': 'Oncology Nursing News', 'date': 'Jun 10, 2023', 'snippet': 'The final overall survival (OS) analysis of the phase 3 TROPiCS-02 study \n(NCT03901339) demonstrated better outcomes with sacituzumab...', 'thumbnail': 'https://serpapi.com/searches/67220665aab36dd7965e3bac/images/e07116873fb4806349e20705825620a79a23abf2f105d04de8fb41bc75be2ac6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6686536073684692}","{'position': 4, 'link': 'https://www.empr.com/home/news/trodelvy-approved-for-pretreated-hr-her2-metastatic-breast-cancer/', 'title': 'Trodelvy Approved for Pretreated HR+/HER2- Metastatic Breast Cancer', 'source': 'Medical Professionals Reference', 'date': 'Feb 3, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab \ngovitecan-hziy) for the treatment of adults with unresectable...', 'thumbnail': 'https://serpapi.com/searches/67220665aab36dd7965e3bac/images/e07116873fb480636448d61d2d01c4337aea4482f7c4a9ba30287f63846b7b27.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8821334838867188}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01703754,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1385484/full', 'title': 'Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies', 'source': 'Frontiers', 'date': 'May 14, 2024', 'snippet': 'This review summarizes the current and past intratumoral immunotherapy \nclinical landscape in breast cancer as well as current progress that has \nbeen made in...', 'thumbnail': 'https://serpapi.com/searches/67220693f922f68a8717ac4c/images/f41a37af4eff5c7ff3162ec3b6fdf551207bb1e5354a51929d81f1eaf564367b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.911587119102478}",,,,,,,,,,['neutral'],neutral,1
NCT02207244,"{'position': 1, 'link': 'https://psoriasisnewstoday.com/2017/05/25/janssens-phase-3-trials-on-guselkumab-for-plaque-psoriasis-and-psoriatic-arthritis/', 'title': 'Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis', 'source': 'Psoriasis News Today', 'date': 'May 25, 2017', 'snippet': 'Janssen announced two new Phase 3 clinical trials for psoriasis for its \ninvestigational drug guselkumab. The company intends to explore the...', 'thumbnail': 'https://serpapi.com/searches/672207a9400bd5beae09fa93/images/0e9988d44e1612925651e277b3c8f258dcffcd1e52ea2a905feee04d19118eaf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9209516644477844}","{'position': 2, 'link': 'https://www.indianpharmapost.com/news/janssen-tremfya-excels-as-psoriasis-treatment-outshining-il-17s-says-globaldata-14200', 'title': 'Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData', 'source': 'Indian Pharma Post', 'date': 'May 31, 2023', 'snippet': 'The drug exhibited greater treatment persistence and control of \nmoderate-to-severe PsO symptoms compared to secukinumab and ixekizumab.', 'thumbnail': 'https://serpapi.com/searches/672207a9400bd5beae09fa93/images/0e9988d44e1612923c8fc52c50358883535446d1e2cc9f514f670900fd7e0bc8.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7638751268386841}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03714373,"{'position': 1, 'link': 'https://praderwillinews.com/news/soleno-files-us-approval-dccr-hyperphagia/', 'title': 'Soleno files for US approval of DCCR for hyperphagia', 'source': 'Prader-Willi Syndrome News', 'date': 'Jul 5, 2024', 'snippet': 'Soleno Therapeutics is seeking approval of diazoxide choline \ncontrolled-release (DCCR) tablets in the US for Prader-Willi syndrome (PWS) \npatients, 4 and older,...', 'thumbnail': 'https://serpapi.com/searches/672207accc29875e745358c7/images/433c35969975db74378e848435eb0f271e4fd73e57a6ba247d1eb48e3e27a296.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9158793687820435}","{'position': 2, 'link': 'https://praderwillinews.com/news/children-switch-dccr-placebo-worsening-hyperphagia-trial/', 'title': 'PWS children who switch from DCCR see worsening hyperphagia: Trial', 'source': 'Prader-Willi Syndrome News', 'date': 'Oct 5, 2023', 'snippet': 'PWS patients who switched from daily treatment with DCCR (diazoxide choline \nextended-release tablets) to a placebo experienced worsening excessive \nhunger, or...', 'thumbnail': 'https://serpapi.com/searches/672207accc29875e745358c7/images/433c35969975db743f2b240e1a328b00e734883a5bddf44421b5bace0024d0ab.png', 'sentiment': 'neutral', 'sentiment_prob': 0.565572202205658}","{'position': 3, 'link': 'https://praderwillinews.com/news/new-phase-dccr-trial-could-aid-regulatory-approval-request/', 'title': 'New Phase of DCCR Trial for PWS May Aid Regulatory Approval Request', 'source': 'Prader-Willi Syndrome News', 'date': 'Oct 14, 2022', 'snippet': 'A randomized withdrawal period in the ongoing open-label extension trial of \nDCCR (diazoxide choline extended-release tablets) for people with \nPrader-Willi...', 'thumbnail': 'https://serpapi.com/searches/672207accc29875e745358c7/images/433c35969975db7499e4e474224dcaefd2ac994a05ed97df7e7f79739854292e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9110457897186279}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03500094,"{'position': 1, 'link': 'https://fabrydiseasenews.com/news/galafold-approved-eu-fabry-children-starting-age-12/', 'title': 'Galafold Approved for Children, 12 and Older, With Fabry in Europe', 'source': 'Fabry Disease News', 'date': 'Aug 6, 2021', 'snippet': 'Oral Galafold is approved to treat Fabry disease in children, 12 and older \nwith an “amenable” GLA mutation, across the European Union.', 'thumbnail': 'https://serpapi.com/searches/67220728740bdba705d94b0d/images/3dd5981bfda3a45e46fe332ada34e625816b48b4d1d41bbd163353f9b03de367.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6076036691665649}",,,,,,,,,,['neutral'],neutral,1
NCT01812603,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-021-01259-3', 'title': 'A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma | British Journal of Cancer', 'source': 'Nature', 'date': 'Feb 24, 2021', 'snippet': 'Preclinical data suggest some cannabinoids may exert antitumour effects \nagainst glioblastoma (GBM). Safety and preliminary efficacy of...', 'thumbnail': 'https://serpapi.com/searches/67220729ef60cb84f8178676/images/ba0ca8b4a8d263acc30d3d8f51a874c7b716a0f08143ef29ebf6590d5f55b7ae.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9131330251693726}",,,,,,,,,,['neutral'],neutral,1
NCT02658929,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1817226', 'title': 'Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma', 'source': 'The New England Journal of Medicine', 'date': 'May 1, 2019', 'snippet': 'Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) \nT-cell therapy that targets B-cell maturation antigen (BCMA),...', 'thumbnail': 'https://serpapi.com/searches/6722073ffbde0d68994107b5/images/8d02cdcc5e77bb4ed1979c7055f39c305272670da4808fdb3879ea86b29f0a52.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6933940649032593}",,,,,,,,,,['neutral'],neutral,1
NCT02516813,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-01151-6', 'title': 'A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours', 'source': 'Nature', 'date': 'Nov 24, 2020', 'snippet': 'This open-label, phase 1 trial (NCT02316197) aimed to determine the \nmaximum-tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of...', 'thumbnail': 'https://serpapi.com/searches/672207f54791c43a82b8e61c/images/ee6fc2351051359108551debf600ffcd42a3720500a9a2c788cf508ad414dfad.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9168863892555237}",,,,,,,,,,['neutral'],neutral,1
NCT01901133,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/jcpt.12503', 'title': 'A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects', 'source': 'Wiley Online Library', 'date': 'Mar 1, 2017', 'snippet': 'Enzalutamide, an androgen receptor inhibitor approved for the treatment of \nmetastatic castration-resistant prostate cancer, is eliminated...', 'thumbnail': 'https://serpapi.com/searches/672207febb55ff271c7d39e0/images/bba1c946a5859fd1a4ed3979f576ec3d9ba088eb9f36525075b0e54d793f9cb2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8371971249580383}",,,,,,,,,,['neutral'],neutral,1
NCT05383898,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00110-3/abstract', 'title': '-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial', 'source': 'The Lancet', 'date': 'Jun 10, 2024', 'snippet': 'Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer in \nChina: an open-label, multicentre, single-arm, phase 2 trial', 'thumbnail': 'https://serpapi.com/searches/6722080754605cf4e9886093/images/58a3e8753d8c4c31e19db317551d83d9206093ff54432fab7a3f69475ba784f1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6348698139190674}","{'position': 2, 'link': 'https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(24)00084-1/fulltext', 'title': 'Drug development and evidence for lung cancer targeted therapy in Eastern Asia', 'source': 'The Lancet', 'date': 'Jul 9, 2024', 'snippet': 'The development of targeted drugs in the Eastern Asia region is going \nthrough a flourishing stage. With the continuous advancement of technology \nand medical...', 'thumbnail': 'https://serpapi.com/searches/6722080754605cf4e9886093/images/58a3e8753d8c4c31a0090e49eca60c4cd029d09bf6506407ef5da49733856be2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6210437417030334}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02678780,"{'position': 1, 'link': 'https://www.nature.com/articles/s44276-023-00010-0', 'title': 'Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial', 'source': 'Nature', 'date': 'Aug 2, 2023', 'snippet': 'More accurate predictive biomarkers in patients with gastroenteropancreatic \nneuroendocrine tumours (GEP-NETs) are needed. This study aims to...', 'thumbnail': 'https://serpapi.com/searches/6722082972f7160b741105ed/images/ce63a905c9c158f4c0be03603cb420a11b65d0f7c3124abf26a8819075ca7a9d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8230471611022949}","{'position': 2, 'link': 'https://www.researchgate.net/figure/3D-ROI-within-a-small-neuroendocrine-isthmus-pancreatic-tumor-on-CT-image-on-pancreatic_fig1_331173854', 'title': 'Figure 1. 3D ROI within a small neuroendocrine isthmus pancreatic tumor...', 'source': 'ResearchGate', 'date': 'Feb 24, 2019', 'snippet': 'To evaluate pancreatic neuroendocrine neoplasms (panNENs) grade prediction \nby means of qualitative and quantitative CT evaluation, and 3D CT-texture...', 'thumbnail': 'https://serpapi.com/searches/6722082972f7160b741105ed/images/ce63a905c9c158f407b366cc42d087be6f6b1d2756af06eb6f5e04802f2c9388.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9163271188735962}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03090191,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0264410X23012963', 'title': 'A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age', 'source': 'ScienceDirect.com', 'date': 'Dec 7, 2023', 'snippet': 'Three doses (Months 0,1,6) of toxoid-based C difficile vaccine induced \nrobust neutralizing antibody responses and were well tolerated in healthy \nparticipants...', 'thumbnail': 'https://serpapi.com/searches/67220837c821270c41798356/images/e4c78929f958f3f44886193e6ffbdb2be7db340ed186019c085ee53973d84d10.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7878576517105103}","{'position': 2, 'link': 'https://www.pharmacytimes.com/view/managing-recurrent-c-difficile-infections-past-present-and-future', 'title': 'Managing Recurrent C difficile Infections: Past, Present, and Future', 'source': 'Pharmacy Times', 'date': 'Jan 25, 2024', 'snippet': 'The primary treatments for CDI are vancomycin (Vancocin; ANI \nPharmaceuticals), metronidazole, and fidaxomicin (Dificid; Merck); \ntreatment recurrence may occur...', 'thumbnail': 'https://serpapi.com/searches/67220837c821270c41798356/images/e4c78929f958f3f46980b73222f7b5071ad729a567c226f84f0cde4bb093f708.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8705163598060608}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04391569,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20241017642755/en/Marinus-Pharmaceuticals-Presents-Clinical-Data-From-Pivotal-Phase-3-RAISE-Trial-in-Refractory-Status-Epilepticus-at-the-Neurocritical-Care-Society-2024-Annual-Meeting', 'title': 'Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting', 'source': 'Business Wire', 'date': '2 weeks ago', 'snippet': 'Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company \ndedicated to the development of innovative therapeutics to treat...', 'thumbnail': 'https://serpapi.com/searches/67220840dda9d9ba52efef75/images/34863c85aa5b84525f78b79844468286f7816fe82f17499f267c4954bca81021.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8361420035362244}","{'position': 2, 'link': 'https://www.pharmaceutical-technology.com/news/marinus-fails-to-meet-early-stopping-criteria-for-status-epilepticus-trial/', 'title': 'Marinus fails to meet early stopping criteria for status epilepticus trial', 'source': 'Pharmaceutical Technology', 'date': 'Apr 15, 2024', 'snippet': 'The future development of IV ganaxolone will be determined by results from \nthe Phase III RAISE study, expected in summer 2024.', 'thumbnail': 'https://serpapi.com/searches/67220840dda9d9ba52efef75/images/34863c85aa5b8452d56ed7e254198503ac6df4debefdbca0c753edbd778614d7.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5823642611503601}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT01206608,"{'position': 1, 'link': 'https://retractionwatch.com/2021/04/15/pharma-company-demands-retraction-damages-in-lawsuit-against-journal/', 'title': 'Pharma company demands retraction, damages in lawsuit against journal', 'source': 'Retraction Watch', 'date': 'Apr 15, 2021', 'snippet': 'A drug company that manufactures a painkiller used for surgery patients has \nsued an anesthesiology journal along with its editor and publisher.', 'thumbnail': 'https://serpapi.com/searches/6722085420e6eb9381df1f5e/images/9dc74200c4cbda893dacfd197a7cd7a2cea5b109d6b38d90d219225aa6c2f46b.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7863892912864685}",,,,,,,,,,['negative'],negative,0
NCT03964415,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/lack-of-efficacy-ends-trial-evaluating-janssens-hiv-vaccine-candidate/', 'title': 'Lack of Efficacy Ends Trial Evaluating Janssen’s HIV Vaccine Candidate', 'source': 'Medical Professionals Reference', 'date': 'Jan 18, 2023', 'snippet': 'A phase 3 trial evaluating an investigational HIV vaccine regimen for the \nprevention of HIV-1 infection will be discontinued.', 'thumbnail': 'https://serpapi.com/searches/67220856707fd32ced3b37fa/images/4cccd2dc81017335c7330b88e04f6c2f2f06f72e0225b6f9ddf6a6ae334d7783.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.666358470916748}","{'position': 2, 'link': 'https://www.idse.net/HIV-AIDS--STIs/Article/12-22/Janssen-and-Partners-Discontinue-Mosaico-HIV-Vaccine-Trial-/69229', 'title': 'Mosaico HIV Vaccine Janssen HIV Phase 3 Trial', 'source': 'Infectious Disease Special Edition', 'date': 'Jan 19, 2023', 'snippet': 'The phase 3 Mosaico HIV vaccine clinical trial was discontinued because \nevidence of efficacy was lacking, according to a statement released...', 'thumbnail': 'https://serpapi.com/searches/67220856707fd32ced3b37fa/images/4cccd2dc8101733514cfd18b7e9aae03632b144bef9a805430c8e55b34fd93ec.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5049905180931091}",,,,,,,,,"['negative', 'negative']",negative,0
NCT02290613,"{'position': 1, 'link': 'https://sclerodermanews.com/news/letairis-may-help-prevent-pah-scleroderma-patients-trial-data/', 'title': 'Letairis may help prevent PAH in scleroderma patients: Trial data', 'source': 'Scleroderma News', 'date': 'Jun 25, 2024', 'snippet': 'Treatment with Letairis may help prevent the development of pulmonary \narterial hypertension in systemic sclerosis patients, trial data show.', 'thumbnail': 'https://serpapi.com/searches/6722085aee677f6cfefc85a0/images/d57b57ed89bf9b2e795efec7fdf276d4e24a5297965984335318197a81d8abc7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5316210985183716}",,,,,,,,,,['neutral'],neutral,1
NCT02034110,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02321-8', 'title': 'Dabrafenib plus trametinib in BRAFV600E -mutated rare cancers: the phase 2 ROAR trial', 'source': 'Nature', 'date': 'Apr 14, 2023', 'snippet': 'Here we present final efficacy and safety results of a phase 2 basket trial \nof dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in \neight...', 'thumbnail': 'https://serpapi.com/searches/6722087ec4bcf586aa621835/images/a7814b00ac5091f43b30fd2d0b2bd03bfc8e04d2304e7e4493dfb4a8b3b7986b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8969771862030029}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication', 'title': 'FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E+ Tumor-Agnostic Indication', 'source': 'Cancer Network', 'date': 'Jun 23, 2022', 'snippet': 'Dabrafenib plus trametinib may now be used to treat patients with BRAF \nV600E–positive solid tumors who have no suitable alternative...', 'thumbnail': 'https://serpapi.com/searches/6722087ec4bcf586aa621835/images/a7814b00ac5091f497840de38621091b644b4d811da8653a3dacb2517de2f421.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8445204496383667}","{'position': 3, 'link': 'https://www.onclive.com/view/dabrafenib-trametinib-combo-produces-strong-response-in-braf-v600e-mutated-glioma', 'title': 'Dabrafenib/Trametinib Combo Produces Strong Response in BRAF V600E–Mutated Glioma', 'source': 'OncLive', 'date': 'May 19, 2022', 'snippet': 'Dabrafenib (Tafinlar) plus trametinib (Mekinist) produced clinically \nmeaningful objective responses rates (ORRs) in patients with recurrent...', 'thumbnail': 'https://serpapi.com/searches/6722087ec4bcf586aa621835/images/a7814b00ac5091f4f1f37c9c3b58d35f9b70d783505aaafe2ba32041bb3bddca.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6720641255378723}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02652052,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01923-y', 'title': 'Cellular senescence and senolytics: the path to the clinic', 'source': 'Nature', 'date': 'Aug 11, 2022', 'snippet': 'In this Review, we outline the rationale for senescent cells as a \ntherapeutic target for disorders across the lifespan and discuss the most \npromising...', 'thumbnail': 'https://serpapi.com/searches/6722088548b9f7c4b1c63d1b/images/39d9ebb3dc9be84aca380b55ec4a7533f5fdcbbd1825ba0816f9f026659b51e3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9145572185516357}",,,,,,,,,,['neutral'],neutral,1
NCT01366209,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1402582', 'title': 'A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis', 'source': 'The New England Journal of Medicine', 'date': 'May 18, 2014', 'snippet': 'In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, \nreduced disease progression, as measured by the decline in forced...', 'thumbnail': 'https://serpapi.com/searches/67220920ec5410d487bf9d2a/images/01b1c70ee73d1c63181cf5aa25fba41e30d1783fbc4a56bded25bd6e00b8406c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8116573095321655}","{'position': 2, 'link': 'https://lungdiseasenews.com/2015/08/03/roches-pirfenidone-esbriet-found-offer-therapeutic-benefit-ipf-clinical-practice-setting/', 'title': 'Roche’s Pirfenidone (Esbriet) Found to Offer Therapeutic Benefit For IPF in a Clinical Practice Setting', 'source': 'Lung Disease News', 'date': 'Aug 3, 2015', 'snippet': 'A new study recently published in the journal Advances in Therapy provided \nevidence of the therapeutic benefit of pirfenidone (known by the...', 'thumbnail': 'https://serpapi.com/searches/67220920ec5410d487bf9d2a/images/01b1c70ee73d1c6328bc9cba66477e8d2717bfd5e54d70b410b1f17df2337c44.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5445698499679565}","{'position': 3, 'link': 'https://www.pulmonologyadvisor.com/news/pirfenidone-may-be-effective-for-improving-exercise-capacity-dyspnea-in-idiopathic-pulmonary-fibrosis/', 'title': 'Pirfenidone May Be Effective for Improving Exercise Capacity, Dyspnea in Idiopathic Pulmonary Fibrosis', 'source': 'Pulmonology Advisor', 'date': 'Oct 10, 2018', 'snippet': 'When treated with pirfenidone, patients with idiopathic pulmonary fibrosis \nexperienced significant improvements in 6-minute walking distance...', 'thumbnail': 'https://serpapi.com/searches/67220920ec5410d487bf9d2a/images/01b1c70ee73d1c638b428e6f45192157beb41a89a7d013cd2a46f207e0a70515.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5335983633995056}","{'position': 4, 'link': 'https://pulmonaryfibrosisnews.com/news/australian-ipf-registry-identifies-characteristics-predictors-mortality-among-idiopathic-pulmonary-fibrosis-patients/', 'title': 'Australian IPF Registry Identifies Characteristics, Predictors of...', 'source': 'Pulmonary Fibrosis News', 'date': 'Jun 19, 2017', 'snippet': 'Read about an Australian report that lung function and GAP (gender, age, \nphysiology) stage are key prognostic markers for mortality in IPF.', 'thumbnail': 'https://serpapi.com/searches/67220920ec5410d487bf9d2a/images/01b1c70ee73d1c63a5aa38b006448661c6ba2069dbf78a60c8014e1c821db5e9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8955011367797852}","{'position': 5, 'link': 'https://pulmonaryfibrosisnews.com/news/fda-approves-new-lupin-esbriet-generic-pirfenidone-ipf-2-doses/', 'title': 'FDA approves new Esbriet generic from Lupin for IPF | Treatment is latest to win approval, hit market since 2021', 'source': 'Pulmonary Fibrosis News', 'date': 'Aug 28, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has approved a new generic \nversion of Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF).', 'thumbnail': 'https://serpapi.com/searches/67220920ec5410d487bf9d2a/images/01b1c70ee73d1c63bed92bc0bda48a84538ab5950e8b306edc09b7d2129701b6.png', 'sentiment': 'positive', 'sentiment_prob': 0.7433562874794006}",,,,,,"['neutral', 'neutral', 'positive', 'neutral', 'positive']",neutral,1
NCT02550249,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1255611/full', 'title': 'Immunotherapy: a promising approach for glioma treatment', 'source': 'Frontiers', 'date': 'Feb 8, 2024', 'snippet': 'Gliomas are the most prevalent primary malignant brain tumors worldwide, \nwith glioblastoma (GBM) being the most common and aggressive type.', 'thumbnail': 'https://serpapi.com/searches/67220943ce1e1081fec03664/images/20f2d923e07e5de3215ebed008b44e3c02e3caf5862e448b812b1eadfb5bb339.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6341026425361633}",,,,,,,,,,['neutral'],neutral,1
NCT02519036,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1900907', 'title': 'Targeting Huntingtin Expression in Patients with Huntington’s Disease', 'source': 'The New England Journal of Medicine', 'date': 'May 6, 2019', 'snippet': 'IONIS-HTT Rx (hereafter, HTT Rx ) is an antisense oligonucleotide designed \nto inhibit HTT messenger RNA and thereby reduce concentrations of mutant \nhuntingtin.', 'thumbnail': 'https://serpapi.com/searches/6722095851d84d1f0a6f142e/images/75ff62e6f40989decca0db67d44f90850cbad9add487db023cc67859536ea53c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8518282771110535}","{'position': 2, 'link': 'https://huntingtonsdiseasenews.com/ionis-httrx-rg6042/', 'title': 'Tominersen for Huntington’s disease', 'source': ""Huntington's Disease News"", 'date': 'Jun 6, 2024', 'snippet': 'Last updated June 6, 2024, by Marisa Wexler, MS ✓ Fact-checked by Marta \nFigueiredo, PhD. How tominersen works. Administration. Clinical trials. \nSide effects...', 'thumbnail': 'https://serpapi.com/searches/6722095851d84d1f0a6f142e/images/75ff62e6f40989def2062704789453ea915191ce64e018ea5d85d1d8c51a73bd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9408097863197327}","{'position': 3, 'link': 'https://huntingtonsdiseasenews.com/news/generation-hd1-trial-fails-to-demonstrate-benefits-tominersen/', 'title': 'GENERATION HD1 Trial Fails to Show Benefits of Tominersen', 'source': ""Huntington's Disease News"", 'date': 'May 6, 2021', 'snippet': ""Treatment with tominersen failed to show evidence of clinical benefit in \nadults with Huntington's disease during the Phase 3 trial..."", 'thumbnail': 'https://serpapi.com/searches/6722095851d84d1f0a6f142e/images/75ff62e6f40989ded8b03ef9d0229b2eb9e2b185366ba9ad70474d7f2a0b714a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7655267715454102}","{'position': 4, 'link': 'https://huntingtonsdiseasenews.com/news/rg6042-potential-dmt-in-phase-3-trial-named-orphan-drug-in-japan/', 'title': 'RG6042, Potential DMT in Phase 3 Trial, Named Orphan Drug in Japan', 'source': ""Huntington's Disease News"", 'date': 'Mar 5, 2020', 'snippet': 'Japan named RG6042, designed to target all forms of the disease-causing \nmutant huntingtin protein, an orphan drug – a status also given it...', 'thumbnail': 'https://serpapi.com/searches/6722095851d84d1f0a6f142e/images/75ff62e6f40989de8f0baa0f4d58b03947ced30f5e353fc7b65ad49251941ce7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.882026195526123}",,,,,,,"['neutral', 'neutral', 'negative', 'neutral']",neutral,1
NCT04346654,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/bjh.19074', 'title': 'Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: The iROM study', 'source': 'Wiley Online Library', 'date': 'Sep 21, 2023', 'snippet': 'Thrombopoietin receptor agonists (TPO-RAs) stimulate platelet production, \nwhich might restore immunological tolerance in primary immune \nthrombocytopenia (ITP).', 'thumbnail': 'https://serpapi.com/searches/672209aef59d00190ff65ec4/images/7d8de5d6f0b6d4be47bfbc8db85e4dc543a0660362342250a4ccc04e92d982c3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7507727146148682}",,,,,,,,,,['neutral'],neutral,1
NCT00574132,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1304839', 'title': ""Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease"", 'source': 'The New England Journal of Medicine', 'date': 'Jan 23, 2014', 'snippet': ""Bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, is in \nclinical development for the treatment of Alzheimer's disease."", 'thumbnail': 'https://serpapi.com/searches/672209b8d9c3e646d94ab8de/images/111fc7b79204a072a55759817548523d69095a814d9ec686af843946132aa0db.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8981547355651855}",,,,,,,,,,['neutral'],neutral,1
NCT04904549,"{'position': 1, 'link': 'https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00345-0/fulltext', 'title': 'Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study', 'source': 'The Lancet', 'date': 'Sep 12, 2023', 'snippet': 'Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with \nAS03 adjuvant in adults: a phase 3, multi-country study', 'thumbnail': 'https://serpapi.com/searches/672209bbf6aa530a196e8ebc/images/8a3776e4b941aae38e435192631a3c5f3f8783bcbe382aec9db20c4888614d35.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8498545289039612}",,,,,,,,,,['neutral'],neutral,1
NCT03829436,"{'position': 1, 'link': 'https://mesothelioma.net/bruno-bastos-md/', 'title': 'Dr. Bruno Bastos | Oncologist Mesothelioma Immunotherapy', 'source': 'Mesothelioma.net', 'date': 'Apr 23, 2024', 'snippet': 'Dr. Bruno Bastos is a medical oncologist who practices at the Miami Cancer \nInstitute at Baptist Health in Miami, Florida.', 'thumbnail': 'https://serpapi.com/searches/672209bf6a5dd3bbff20fbf0/images/2b2757b8b9cbb8a50745c7969b3ccd72c936ffd9024e9e48af1831bcdd42a416.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.930178165435791}",,,,,,,,,,['neutral'],neutral,1
NCT01710358,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1608345', 'title': 'Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis', 'source': 'The New England Journal of Medicine', 'date': 'Feb 16, 2017', 'snippet': 'Baricitinib was associated with significant clinical improvements as \ncompared with placebo and adalimumab.', 'thumbnail': 'https://serpapi.com/searches/672209d4213c87eb83468cfe/images/bbc688ac6f628ff35583eb0954cafa9f027c52d12214f464e74396c036180a76.png', 'sentiment': 'positive', 'sentiment_prob': 0.514316201210022}","{'position': 2, 'link': 'https://rheumatoidarthritisnews.com/2017/03/03/olumiant-ra-rheumatoid-arthritis-symptoms-humira-study/', 'title': 'Olumiant Improved RA Symptoms Better Than Humira, Study Finds', 'source': 'rheumatoidarthritisnews.com', 'date': 'Mar 3, 2017', 'snippet': 'Read about how Olumiant improved the clinical outcomes in patients with \nrheumatoid arthritis in comparison to Humira and placebo.', 'thumbnail': 'https://serpapi.com/searches/672209d4213c87eb83468cfe/images/bbc688ac6f628ff396d70469c86ae56b9234ade7b4907b23e53a01c256f129ae.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7494127154350281}",,,,,,,,,"['positive', 'positive']",positive,1
NCT02574455,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2028485', 'title': 'Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Apr 21, 2021', 'snippet': 'Patients with metastatic triple-negative breast cancer have a poor \nprognosis. Sacituzumab govitecan is an antibody–drug conjugate composed...', 'thumbnail': 'https://serpapi.com/searches/672209f0b28e6b3deb75f27e/images/23e4d3d601bc38eb36d96b930e75e7fc3547eca367c7b7f272f64857cdbac65f.png', 'sentiment': 'negative', 'sentiment_prob': 0.5631178617477417}","{'position': 2, 'link': 'https://www.nature.com/articles/s41523-022-00467-1', 'title': 'Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer', 'source': 'Nature', 'date': 'Aug 29, 2022', 'snippet': 'Sacituzumab govitecan (SG) is an anti-Trop-2 antibody-drug conjugate with \nan SN-38 payload. In the ASCENT study, patients with metastatic...', 'thumbnail': 'https://serpapi.com/searches/672209f0b28e6b3deb75f27e/images/23e4d3d601bc38eb201f1ee96f7146215b0723f5b57efb09f4d3065573536430.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8899267315864563}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/phase-3-ascent-trial-in-metastatic-tnbc-meets-primary-end-point-of-pfs', 'title': 'Phase 3 ASCENT Trial in Metastatic TNBC Meets Primary End Point of PFS', 'source': 'Cancer Network', 'date': 'Jul 6, 2020', 'snippet': 'The phase 3 ASCENT trial designed to evaluate sacituzumab govitecan-hziy in \npatients with brain metastasis-negative,...', 'thumbnail': 'https://serpapi.com/searches/672209f0b28e6b3deb75f27e/images/23e4d3d601bc38eb49d1a590a8f17dda1b963fabeee0b14bb021a258820d52b6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9164993762969971}","{'position': 4, 'link': 'https://www.targetedonc.com/view/gupta-explores-sacituzumab-govitecan-in-advanced-breast-cancer-treatment', 'title': 'Gupta Explores Sacituzumab Govitecan in Advanced Breast Cancer Treatment', 'source': 'Targeted Oncology', 'date': '5 days ago', 'snippet': 'Following discussions on ado-trastuzumab emtansine and fam-trastuzumab \nderuxtecan-nxki, Tanya Gupta, MD, discusses sacituzumab govitecan and...', 'thumbnail': 'https://serpapi.com/searches/672209f0b28e6b3deb75f27e/images/23e4d3d601bc38eb0ed4b42cc2917befd673cbc922c998564b16a16964975ca0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9038917422294617}","{'position': 5, 'link': 'https://www.nature.com/articles/s41523-022-00439-5', 'title': 'Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis | npj Breast Cancer', 'source': 'Nature', 'date': 'Jun 9, 2022', 'snippet': 'Sacituzumab govitecan (SG), an antibody-drug conjugate composed of an \nanti-Trop–2 antibody coupled to SN-38 via a hydrolyzable linker, improved \noutcomes over...', 'thumbnail': 'https://serpapi.com/searches/672209f0b28e6b3deb75f27e/images/23e4d3d601bc38ebaa930a8b7087793849507210a94cdc245f27e0b1bcfa752b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8685733675956726}","{'position': 6, 'link': 'https://www.targetedonc.com/view/batalini-explores-role-of-ugt1a1-in-patients-treated-with-sacituzumab-govitecan-for-hr-mbc', 'title': 'Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC', 'source': 'Targeted Oncology', 'date': 'Apr 22, 2024', 'snippet': 'During a Community Case Forum live event in partnership with The Arizona \nClinical Oncology Society, Felipe Batalini, MD, discussed the...', 'thumbnail': 'https://serpapi.com/searches/672209f0b28e6b3deb75f27e/images/23e4d3d601bc38eb1fa8ce30c7b0df474bc17bb9c51af25dc008a56fa6f861ba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9425888657569885}","{'position': 7, 'link': 'https://breastcancer-news.com/2020/04/23/trodelvy-immunomedics-approved-fda-for-heavily-pre-treated-triple-negative-breast-cancer-patients-in-us/', 'title': 'Trodelvy Approved for Heavily Pre-Treated TNBC Patients in US', 'source': 'Breast Cancer News', 'date': 'Apr 23, 2020', 'snippet': ""The US Food and Drug Administration (FDA) has approved Immunomedics' \nantibody-drug conjugate Trodelvy (sacituzumab govitecan) to treat \ntriple-negative breast..."", 'thumbnail': 'https://serpapi.com/searches/672209f0b28e6b3deb75f27e/images/23e4d3d601bc38eb9916f38490796c98303827aac6689d86b9ef1619251b5271.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7552862763404846}","{'position': 8, 'link': 'https://www.empr.com/home/news/trodelvy-sacituzumab-govitecan-hziy-expanded-approval-triple-negative-breast-ca/', 'title': 'FDA Grants Full Approval to Trodelvy for Triple-Negative Breast Cancer', 'source': 'Medical Professionals Reference', 'date': 'Apr 8, 2021', 'snippet': 'The Food and Drug Administration (FDA) has granted full approval to \nTrodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients \nwith unresectable...', 'thumbnail': 'https://serpapi.com/searches/672209f0b28e6b3deb75f27e/images/23e4d3d601bc38eb7a4146846d3144056413491fc93fdff5b48efc7a68a6636d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8838381767272949}",,,"['negative', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT00327678,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1605085', 'title': 'Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'Sep 15, 2016', 'snippet': ""Treatment with rituximab has improved the outcome for patients with \nnon-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic..."", 'thumbnail': 'https://serpapi.com/searches/67220a43f79a017c650dcaa6/images/0906797d8b552264e816520f8ad6b5f0530afe980b5f36b99000519bc1fcd92c.png', 'sentiment': 'positive', 'sentiment_prob': 0.5242841839790344}",,,,,,,,,,['positive'],positive,1
NCT00593697,"{'position': 1, 'link': 'https://www.onclive.com/view/shortened-trastuzumab-administration-does-not-improve-dfs-in-erbb2-breast-cancer', 'title': 'Shortened Trastuzumab Administration Does Not Improve DFS in ERBB2+ Breast Cancer', 'source': 'OncLive', 'date': 'Aug 29, 2024', 'snippet': 'Adjuvant trastuzumab plus concurrent chemotherapy led to inferior DFS \noutcomes when administered for 9 weeks vs 1 year in ERBB2-positive...', 'thumbnail': 'https://serpapi.com/searches/67220a56c05eb50a5fbd7e64/images/2be554b0244216fe07564d071b02c3dd6477eeca292bbda98def13b744fae981.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.786249041557312}",,,,,,,,,,['negative'],negative,0
NCT01749514,"{'position': 1, 'link': 'https://www.nature.com/articles/leu2014325', 'title': 'Myelodysplasia is in the niche: novel concepts and emerging therapies - Leukemia', 'source': 'Nature', 'date': 'Nov 14, 2014', 'snippet': ""In this review, we will discuss the scientific rationale of \n'osteohematology' as an emerging research field in MDS and outline clinical \nimplications."", 'thumbnail': 'https://serpapi.com/searches/67220ad571c62b5f89219c62/images/2913c35622506c97f8ed55e9c250dd442e5d000603457d0cae3ad69a66269085.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9074719548225403}",,,,,,,,,,['neutral'],neutral,1
NCT01863758,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/fda-approves-new-vial-strengths-for-hemophilia-a-therapy-nuwiq/', 'title': 'Hemophilia A Therapy Nuwiq to Come in New Vial Strengths in U.S.', 'source': 'Hemophilia News Today', 'date': 'Aug 28, 2017', 'snippet': ""The US Food and Drug Administration has approved new vial strengths for \nOctopharma's hemophilia A therapy Nuwiq, which means patients will need \nfewer vials per..."", 'thumbnail': 'https://serpapi.com/searches/67220b808d1473e38aba7071/images/0f7893e6374ab6998edcdfb9f940920526bafd10474815574c54610045983caf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8386752605438232}",,,,,,,,,,['neutral'],neutral,1
NCT04498910,"{'position': 1, 'link': 'https://www.mayoclinicproceedings.org/article/S0025-6196(23)00332-4/fulltext', 'title': 'Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside', 'source': 'Mayo Clinic Proceedings', 'date': 'Jan 4, 2024', 'snippet': 'Migraine is a ubiquitous neurologic disorder that afflicts more than 1 \nbillion people worldwide. Recommended therapeutic strategies include...', 'thumbnail': 'https://serpapi.com/searches/67220b88642c3145fd3ad147/images/9ba4fb32e74b9ef928c93db9155849c5bd389d9a587b1767fc263ccb91d4ad6e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7042643427848816}",,,,,,,,,,['neutral'],neutral,1
NCT00642460,"{'position': 1, 'link': 'https://juvenilearthritisnews.com/2019/09/10/tocilizumab-is-safe-and-effective-to-treat-sjia-infants-younger-than-2/', 'title': 'Tocilizumab Safe, Effective to Treat Systemic JIA Infants 2 and Younger', 'source': 'Juvenile Arthritis News', 'date': 'Sep 10, 2019', 'snippet': 'Data from a Phase 1 clinical trial demonstrated that treatment with \ntocilizumab is a safe and effective treatment for sJIA in infants...', 'thumbnail': 'https://serpapi.com/searches/67220c52d9c3e646d94abb55/images/d9cd3009586ef7b9de578eb08f99b69a3ba9959198025f7660431a7ef53ac8dc.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5793243646621704}",,,,,,,,,,['positive'],positive,1
NCT00004978,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0903175', 'title': 'Interleukin-2 Therapy in Patients with HIV Infection', 'source': 'The New England Journal of Medicine', 'date': 'Sep 8, 2017', 'snippet': 'We conducted two trials: the Subcutaneous Recombinant, Human Interleukin-2 \nin HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral \nTherapy...', 'thumbnail': 'https://serpapi.com/searches/67220c67dda9d9ba7d3b91fc/images/e762418aa1a1ab0ba5138d351861c197bac7af42297d0e3bb67c0c0c3653fb6e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9110223054885864}",,,,,,,,,,['neutral'],neutral,1
NCT02076698,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-42380-6', 'title': 'Human thalamic low-frequency oscillations correlate with expected value and outcomes during reinforcement learning', 'source': 'Nature', 'date': 'Oct 17, 2023', 'snippet': 'We found that in both the anterior thalamus (ATN) and dorsomedial thalamus \n(DMTN), low frequency oscillations (LFO, 4-12 Hz) correlated positively \nwith...', 'thumbnail': 'https://serpapi.com/searches/67220cb998d8de6796769164/images/8636d0e15fc3ec1cce7f83210e8bb2c1ccdde2c6bee6ec56c6664fbbc752dae5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8262741565704346}",,,,,,,,,,['neutral'],neutral,1
NCT01958320,"{'position': 1, 'link': 'https://www.nature.com/articles/s41372-019-0347-4', 'title': 'Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320)', 'source': 'Nature', 'date': 'Mar 8, 2019', 'snippet': 'Indomethacin produced the greatest constriction (compared with spontaneous \nconstriction during Conservative management): RR (95% CI) = 3.21 \n(2.05–5.01)),...', 'thumbnail': 'https://serpapi.com/searches/67220d1708abe4e7ae1f8a0b/images/e84faf2670f52ba913b5857c31b67e52d27e1cc734295e4f82dd024d8a0fe902.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8430649042129517}",,,,,,,,,,['neutral'],neutral,1
NCT00937625,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-017-01460-0', 'title': 'Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma', 'source': 'Nature', 'date': 'Nov 23, 2017', 'snippet': 'Adoptive T-cell therapy (ACT) is a highly intensive immunotherapy regime \nthat has yielded remarkable response rates and many durable...', 'thumbnail': 'https://serpapi.com/searches/67220d5b361fd4c8c0469d18/images/e21ad53167bdaaf92c3d9776d406ff98013dbfc1c7d7e8384018d09c21a03389.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5930587649345398}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-017-00786-z', 'title': 'Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model', 'source': 'Nature', 'date': 'Sep 27, 2017', 'snippet': 'we have developed PDXv2.0 — a melanoma PDX model where tumor cells and \ntumor-infiltrating T cells from the same patient are transplanted...', 'thumbnail': 'https://serpapi.com/searches/67220d5b361fd4c8c0469d18/images/e21ad53167bdaaf9fac6ceaf5a3e0b408b6ad985b94fcc2409766a4e50d1c881.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9120576977729797}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02465216,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-36789-2', 'title': 'Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults', 'source': 'Nature', 'date': 'Mar 6, 2023', 'snippet': 'Adjuvant-containing subunit vaccines represent a promising approach for \nprotection against tuberculosis (TB), but current candidates require...', 'thumbnail': 'https://serpapi.com/searches/67220d5dfc40bf18ede99890/images/4800930fe0ae489fec7ab716338ce742501e0d588075e564a3a5f7dfbb7f0f77.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6567094326019287}",,,,,,,,,,['neutral'],neutral,1
NCT03000452,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/fda-halts-imfinzi-combination-trials-after-unexplained-keytruda-related-deaths/', 'title': 'FDA Halts Imfinzi Combination Trials After Unexplained Keytruda-related Deaths', 'source': 'Myeloma Research News', 'date': 'Sep 8, 2017', 'snippet': ""The U.S. Food and Drug Administration (FDA) suspended a Phase 1 clinical \ntrial testing a combination of AstraZeneca's Imfinzi (durvalumab)..."", 'thumbnail': 'https://serpapi.com/searches/67220d86d169156d464f9440/images/7271c2530fab95e91fbee4e024da08655a39b9cbaf302512bc0c6c1e49496b7c.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5682772994041443}",,,,,,,,,,['negative'],negative,0
NCT04056689,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/phase-2b-3-trials-planned-oral-biib122-dnl151-slowing-parkinsons-progression/', 'title': '2 Trials to Test Oral BIIB122/DNL151 in Slowing Parkinson’s Progression', 'source': ""Parkinson's News Today"", 'date': 'Jan 13, 2022', 'snippet': 'Biogen and Denali Therapeutics are planning to launch two late-stage \nclinical trials to further evaluate the potential of their...', 'thumbnail': 'https://serpapi.com/searches/67220dbdee677f6cfefc8a5d/images/0fd0d60d94def3e132340a6612e650f7ad63d998a7a57b5c88c33a2e14585f81.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8970906734466553}",,,,,,,,,,['neutral'],neutral,1
NCT01211262,"{'position': 1, 'link': 'https://immuno-oncologynews.com/imcgp100/', 'title': 'IMCgp100', 'source': 'Immuno-Oncology News', 'date': 'Dec 21, 2017', 'snippet': 'Read about the immune-oncology therapy IMCgp100, which Immunocore is \ndeveloping as a treatment for cancers of the skin and eyes.', 'thumbnail': 'https://serpapi.com/searches/67220e055c7cb930cf00ca9b/images/2e8065064c26eded43ed466646cde49cc66feb778f3fdaf90bb3f75a67af57ec.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8750774264335632}",,,,,,,,,,['neutral'],neutral,1
NCT02899988,"{'position': 1, 'link': 'https://www.dermatologyadvisor.com/news/mirikizumab-safe-efficacious-for-treating-plaque-psoriasis-in-phase-2-study/', 'title': 'Mirikizumab Safe, Efficacious for Treating Plaque Psoriasis in Phase 2 Study', 'source': 'Dermatology Advisor', 'date': 'Mar 21, 2019', 'snippet': 'Phase 2 study results showed that mirikizumab-treated patients had \nsignificantly higher efficacy compared to placebo, with comparable safety...', 'thumbnail': 'https://serpapi.com/searches/67220e0ca54d7ea54c992529/images/a90f7701e5be5963ba340024febed6141ec26a4d53e4d03cf94319ef2c9816fe.png', 'sentiment': 'positive', 'sentiment_prob': 0.635246753692627}",,,,,,,,,,['positive'],positive,1
NCT01747798,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2016/10/10/membrane-fluidity-influences-sensitivity-of-ovarian-cancer-cell-lines-to-auranofin/', 'title': 'Increasing Cell Membrane Fluidity May Enhance Ovarian Cancer Drug', 'source': 'Ovarian Cancer News Today', 'date': 'Oct 10, 2016', 'snippet': 'Cell membrane fluidity may determine ovarian cancer response to the \nanti-rheumatic drug Ridaura (auranofin) currently in trials for epithelial \novarian cancer,...', 'thumbnail': 'https://serpapi.com/searches/67220e325ed3caf6d6de987c/images/9747233e13228880f736e5c6d5e3ad8fba01a1560977ad1bdb02ec31fec4354b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8460758924484253}",,,,,,,,,,['neutral'],neutral,1
NCT06040372,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/rhythm-expands-obesity-portfolio-with-phase-ii-weight-loss-drug-for-100m/', 'title': 'Rhythm expands obesity portfolio with Phase II weight loss drug for $100m', 'source': 'Clinical Trials Arena', 'date': 'Jan 5, 2024', 'snippet': ""Rhythm to acquire global rights for South Korean LG Chem's oral obesity \ndrug LB54640 for $100m in cash and equity."", 'thumbnail': 'https://serpapi.com/searches/67220e36b9ab865cfec0d0de/images/195504f020fe41d3d91cf7b1ec4d58e41c786be6e2ea32e4bef1990a84c574a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8068321943283081}",,,,,,,,,,['neutral'],neutral,1
NCT02996305,"{'position': 1, 'link': 'https://angelmansyndromenews.com/news/final-trial-data-support-ovid-decision-stop-ov101-clinical/', 'title': 'Trial data support Ovid’s decision to stop its OV101 program in 2021', 'source': 'angelmansyndromenews.com', 'date': 'Aug 23, 2023', 'snippet': ""Final trial results have now been published that support Ovid Therapeutics' \ndecision to stop clinical testing of OV101 for Angelman..."", 'thumbnail': 'https://serpapi.com/searches/67220e585f9778874e15c901/images/918ea8bf92853b660e85647c02ff427c3493d63871b3b9e4197e87e98edeacd2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8800973892211914}","{'position': 2, 'link': 'https://angelmansyndromenews.com/news/ovid-to-add-adolescents-to-phase-2-trial-of-its-angelman-syndrome-therapy-ov101/', 'title': ""Ovid's Angelman Therapy Trial Will Be Broadened to Include Adolescents"", 'source': 'Angelman Syndrome News', 'date': 'Dec 12, 2017', 'snippet': ""Read about Ovid's decision to broaden the Phase 2 clinical trial of its \nAngelman syndrome therapy OV101 to include adolescents as well as..."", 'thumbnail': 'https://serpapi.com/searches/67220e585f9778874e15c901/images/918ea8bf92853b66c4732965813712283fbd4d46e5df5b1d1115148f28c630f1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8533443808555603}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03414034,"{'position': 1, 'link': 'https://prostatecancernewstoday.com/2020/02/19/onvansertib-extends-responses-to-zytiga-mcrpc-patients-phase-2-data/', 'title': 'mCRPC Patient Responses to Zytiga Better with Onvansertib, New Trial Data Show', 'source': 'Prostate Cancer News Today', 'date': 'Feb 19, 2020', 'snippet': 'A potential treatment, onvansertib, helped to overcome resistance to Zytiga \nin men with metastatic CRPC and rising PSA levels,...', 'thumbnail': 'https://serpapi.com/searches/67220e607c1712a3f3a2e5c5/images/160ac76f346a964669e554fcbb2b5cfc9fab74019758ade8ee4b37a30a5ffba3.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6121103167533875}",,,,,,,,,,['positive'],positive,1
NCT03822468,"{'position': 1, 'link': 'https://www.onclive.com/view/recent-data-on-adjuvant-therapies-in-hr-her2--breast-cancer', 'title': 'Recent Data on Adjuvant Therapies in HR+/HER2- Breast Cancer', 'source': 'OncLive', 'date': 'Jul 11, 2023', 'snippet': 'Experts on HR+/HER2- breast cancer review data updates on adjuvant \ntherapies from the 2023 ASCO Annual Meeting.', 'thumbnail': 'https://serpapi.com/searches/67220e67cb33d011be84a3c5/images/b21eab510ee231a743c649a5f630d38c617bf4d0e49ee02ed0282340797b0921.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9471691250801086}",,,,,,,,,,['neutral'],neutral,1
NCT03178864,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/STROKEAHA.123.044113', 'title': 'Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis', 'source': 'American Heart Association Journals', 'date': 'Sep 7, 2023', 'snippet': 'A randomized controlled feasibility trial comparing anticoagulation with \nrivaroxaban to standard-of-care in symptomatic cerebral venous thrombosis.', 'thumbnail': 'https://serpapi.com/searches/67220e76237938d086ab92c3/images/a9a238a3cf936d5a7501e3e0043c5e46252fc1395e34567d75fbee135d8fa77c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.879463255405426}",,,,,,,,,,['neutral'],neutral,1
NCT03531957,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-023-00992-4', 'title': 'The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment', 'source': 'Nature', 'date': 'Mar 16, 2023', 'snippet': 'Atopic dermatitis (AD) is the most common inflammatory skin disease, and it \nis considered a complex and heterogeneous condition.', 'thumbnail': 'https://serpapi.com/searches/67220e8e7a12fd124142e61b/images/258249bc2c201b68b66f7a4fa24cb3332dee7413d141d9557b811ab9a96668d5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7401643991470337}",,,,,,,,,,['neutral'],neutral,1
NCT01354691,"{'position': 1, 'link': 'https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-018-0299-8', 'title': 'Advances in developing novel therapeutic strategies for Alzheimer’s disease', 'source': 'Molecular Neurodegeneration', 'date': 'Dec 12, 2018', 'snippet': 'Here, we summarize current strategies and new trends of AD drug \ndevelopment, including pre-clinical and clinical trials that target \ndifferent aspects of...', 'thumbnail': 'https://serpapi.com/searches/67220eb2f79a017c2d030bfb/images/8d2df9eaaa2c2c5a0217b2c9f997ac390d132aa8ba79780ea70423e340b28fbc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8732640743255615}",,,,,,,,,,['neutral'],neutral,1
NCT04983264,"{'position': 1, 'link': 'https://sicklecellanemianews.com/osivelotor-for-sickle-cell-disease/', 'title': 'Osivelotor for sickle cell disease', 'source': 'Sickle Cell Disease News', 'date': 'May 29, 2024', 'snippet': 'Last updated May 29, 2024, by Lindsey Shapiro, PhD ✓ Fact-checked by Joana \nCarvalho, PhD. How osivelotor works. Administration. Clinical trials.', 'thumbnail': 'https://serpapi.com/searches/67220ed5690bb92396ca4cac/images/0a366ccf500b8299324ae66d1a82e9b00ad2d5e10ebcaf9b64e45dace2106a2d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9294475317001343}","{'position': 2, 'link': 'https://sicklecellanemianews.com/news/phase-1-scd-trial-supporting-gbt601-next-gen-therapy-oxbryta/', 'title': 'Phase 1 Trial Supporting GBT601 as Next-gen Therapy to Oxbryta', 'source': 'Sickle Cell Disease News', 'date': 'May 24, 2022', 'snippet': ""Daily doses of GBT601, Global Blood Therapeutics's oral sickle cell disease \ntherapy, were well tolerated and signaled efficacy in 6..."", 'thumbnail': 'https://serpapi.com/searches/67220ed5690bb92396ca4cac/images/0a366ccf500b829920dab618021ef9014895ad1aba6bd3842f7c88dd0d161be5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6596790552139282}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04027439,"{'position': 1, 'link': 'https://copdnewstoday.com/news/veronas-dry-powder-inhaler-ensifentrine-safe-and-effective-for-copd-in-phase-2-trial/', 'title': 'Ensifentrine Dry Powder Inhaler Safe, Effective for COPD in Phase 2 Trial', 'source': 'COPD News Today', 'date': 'Aug 9, 2019', 'snippet': 'Additional results of a Phase 2 trial demonstrate that a dry powder inhaler \nformulation of ensifentrine is safe and effective in moderate to...', 'thumbnail': 'https://serpapi.com/searches/67220ee58d1473e353fb5eba/images/e2547bfb91e9d9d9b6bef33bc8247d110ea4c4f23c9161b4dc85712ec8c63db7.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5965437889099121}",,,,,,,,,,['positive'],positive,1
NCT02566655,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/cpr.12956', 'title': 'Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis', 'source': 'Wiley Online Library', 'date': 'Nov 18, 2020', 'snippet': 'Osteoporosis occurs when the orchestrated balance between bone formation by \nosteoblasts and bone destruction by osteoclasts breaks down,...', 'thumbnail': 'https://serpapi.com/searches/67220f1972e5c4745ca77260/images/2b99c6cc77742e35d9a33e06805f39f45590add09bf15b3b8fdedb7735273ea8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.802518367767334}",,,,,,,,,,['neutral'],neutral,1
NCT05103332,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2024/03/05/2840321/0/en/Roche-and-Alnylam-report-positive-topline-results-from-the-Phase-II-KARDIA-2-study-in-people-with-hypertension-demonstrating-clinically-significant-blood-pressure-reductions-with-z.html', 'title': 'Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care', 'source': 'GlobeNewswire', 'date': 'Mar 5, 2024', 'snippet': 'KARDIA-2 study met its primary endpoint, demonstrating clinically \nsignificant systolic blood pressure reductions in each treatment arm at...', 'thumbnail': 'https://serpapi.com/searches/67220f282da1575f5eaf4c91/images/cf45b252213a718d27ad1e94dbd951755dba9b9a855788c8e3ca5d205c7e5f8e.png', 'sentiment': 'positive', 'sentiment_prob': 0.5929137468338013}",,,,,,,,,,['positive'],positive,1
NCT03132636,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2021/02/12/fda-approves-libtayo-first-immunotherapy-advanced-basal-cell-carcinoma/', 'title': 'FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinoma', 'source': 'Immuno-Oncology News', 'date': 'Feb 12, 2021', 'snippet': 'The U.S. Food and Drug Administration (FDA) has approved Libtayo \n(cemiplimab-rwlc), making it the first immunotherapy for people with...', 'thumbnail': 'https://serpapi.com/searches/67220f3c3c944b515f584aeb/images/2832314aa02e0f175ad0bc6fd99f12566ec7253d30d7b803046a72a1c3212b81.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5599238872528076}",,,,,,,,,,['neutral'],neutral,1
NCT02674152,"{'position': 1, 'link': 'https://www.researchgate.net/publication/384902278_Comprehensive_biomarker_and_modeling_approach_to_support_dose_finding_for_BI_836880_a_VEGFAng-2_inhibitor', 'title': '(PDF) Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor', 'source': 'ResearchGate', 'date': '2 weeks ago', 'snippet': 'PDF | Background BI 836880 is a humanized bispecific nanobody® that binds \nto and blocks vascular endothelial growth factor (VEGF) and...', 'thumbnail': 'https://serpapi.com/searches/67220f6bbd7cf0d69d201d4b/images/77eac7661d7809f53955ba89916054f755fc49b7397ccb565534068282166ca8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.89641934633255}",,,,,,,,,,['neutral'],neutral,1
NCT03005782,"{'position': 1, 'link': 'http://www.msn.com/en-us/health/other/esmo-2024-regeneron-s-melanoma-combo-therapy-benefit-continues-beyond-two-years/ar-AA1qFEHe?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1', 'title': 'ESMO 2024: Regeneron’s melanoma combo therapy benefit continues beyond two years', 'source': 'MSN', 'date': '1 month ago', 'snippet': 'The company presented longer-term data from the Phase I trial (NCT03005782) \nat the European Society for Medical Oncology (ESMO) Annual Meeting from 13 \nto 17...', 'thumbnail': 'https://serpapi.com/searches/67220f8f360f4efda11a981e/images/d1469916ad9bd751e3d0a721d5c452db64d79b49aebb9db2b3fd89c196aa4c88.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6508203148841858}","{'position': 2, 'link': 'https://www.onclive.com/view/fianlimab-cemiplimab-demonstrates-persistent-activity-in-advanced-melanoma-independent-of-lag-3-and-pd-l1-status', 'title': 'Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status', 'source': 'OncLive', 'date': '1 month ago', 'snippet': 'Fianlimab combined with cemiplimab-rwlc (Libtayo) demonstrated persistent \nand significant clinical activity in patients with advanced melanoma, \nirrespective of...', 'thumbnail': 'https://serpapi.com/searches/67220f8f360f4efda11a981e/images/d1469916ad9bd751b624032cab5c485f15b34e887a344dbbefcacae268bffd14.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8469321727752686}","{'position': 3, 'link': 'https://www.onclive.com/view/fianlimab-plus-cemiplimab-yields-early-efficacy-signs-in-pretreated-advanced-ccrcc', 'title': 'Fianlimab Plus Cemiplimab Yields Early Efficacy Signs in Pretreated Advanced ccRCC', 'source': 'OncLive', 'date': 'Jul 12, 2024', 'snippet': 'Treatment with the combination of fianlimab and cemiplimab-rwlc (Libtayo) \nwas well tolerated and led to durable responses in heavily pretreated \npatients.', 'thumbnail': 'https://serpapi.com/searches/67220f8f360f4efda11a981e/images/d1469916ad9bd751b844df1d86402d7d5eb0763e7270e1cc416b9eabf5b18a0f.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5421571135520935}",,,,,,,,"['positive', 'neutral', 'positive']",positive,1
NCT02692716,"{'position': 1, 'link': 'https://www.renalandurologynews.com/news/semaglutide-treatment-cardioprotective-utility-hba1c-levels/', 'title': 'Semaglutide Treatment Exhibits Cardioprotective Utility Across HbA1c Levels', 'source': 'Renal and Urology News', 'date': 'Apr 2, 2024', 'snippet': 'Semaglutide vs placebo reduces major adverse cardiovascular events (MACEs) \nand improves metabolic outcomes regardless of baseline glycated...', 'thumbnail': 'https://serpapi.com/searches/67221027a775f2424b781276/images/744fa45b192caf2b99dc0856a4e10fa027f7c11e558d09a5639a591648ce3ae9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7062504291534424}",,,,,,,,,,['neutral'],neutral,1
NCT03516591,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-021-01265-7', 'title': 'Current challenges and unmet medical needs in myelodysplastic syndromes', 'source': 'Nature', 'date': 'May 28, 2021', 'snippet': 'Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid \nneoplasms that are characterized by ineffective hematopoiesis,...', 'thumbnail': 'https://serpapi.com/searches/6722103bf3cbfaeee3c3a6c0/images/95b1417bcd7d3485eb2b8ff0b37aa3d379bb7e3b27cf9994ddc6279f2ce0f5f0.png', 'sentiment': 'negative', 'sentiment_prob': 0.678302526473999}",,,,,,,,,,['negative'],negative,0
NCT01933802,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/03/10/stem-cell-therapy-msc-np-ease-inflammatory-activity-brain-cells/', 'title': 'Stem cell therapy MSC-NP can ease inflammatory activity in brain cells', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 10, 2023', 'snippet': 'MSC-NP, a form of stem cell therapy in early clinical trials for \nprogressive MS, can reduce the inflammatory activity of microglia, a \nstudy...', 'thumbnail': 'https://serpapi.com/searches/6722107e93584c1ee83b19f0/images/8921ce6adf447f0633ca4646c339465d9de2f933cc1a527335de797357949fa2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7880548238754272}",,,,,,,,,,['neutral'],neutral,1
NCT03085810,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/ocrevus-ocrelizumab-primary-progressive-relapsing-multiple-sclerosis/', 'title': 'Ocrevus (Ocrelizumab) for MS: Uses, Side Effects, and More', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 17, 2022', 'snippet': 'Ocrevus (ocrelizumab) is a disease-modifying therapy for PPMS and relapsing \nMS. Learn more about its uses, indications, and side effects.', 'thumbnail': 'https://serpapi.com/searches/672210d517b10e7c50371c43/images/32bbf26832662d51a3a647556ab368e7d7e389ea291471b15eee4f8cc6f9a951.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9069978594779968}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2020/12/15/fda-approves-shorter-infusion-time-ocrevus-therapy-ms/', 'title': 'FDA Approves Shorter Infusion Time for MS Therapy Ocrevus', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 15, 2020', 'snippet': 'The U.S. Food and Drug Administration approved a shorter infusion time of \nOcrevus (ocrelizumab) for people with relapsing or primary...', 'thumbnail': 'https://serpapi.com/searches/672210d517b10e7c50371c43/images/32bbf26832662d5173daf3982a4391366bc8d81ef98d7f8068206fde7f8e2165.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6980234384536743}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00382889,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa063861', 'title': 'Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma', 'source': 'The New England Journal of Medicine', 'date': 'May 17, 2007', 'snippet': 'Treatment guidelines recommend the regular use of inhaled corticosteroids \nfor patients with mild persistent asthma.', 'thumbnail': 'https://serpapi.com/searches/672210d724296a3c4a74d60d/images/218c54ece62511157a34358e779ade3b7017372b5d53251f1c472ed1b0926d68.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8787112236022949}",,,,,,,,,,['neutral'],neutral,1
NCT03237845,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1811090', 'title': 'Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine', 'source': 'The New England Journal of Medicine', 'date': 'Jul 10, 2019', 'snippet': 'Calcitonin gene–related peptide receptor has been implicated in the \npathogenesis of migraine. Rimegepant is an orally administered,...', 'thumbnail': 'https://serpapi.com/searches/672210f872f7160bb0106df8/images/4f054f695354bcead15fef04b68c11e5808b521ad027981c86ade8c042e42230.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8599758148193359}",,,,,,,,,,['neutral'],neutral,1
NCT04379869,"{'position': 1, 'link': 'https://praderwillinews.com/news/fda-oks-neuren-pharmaceuticals-trial-nnz-2591-pws-children/', 'title': 'FDA Green Lights Phase 2 Trial of NNZ-2591 in Children With PWS |...', 'source': 'Prader-Willi Syndrome News', 'date': 'Jan 27, 2023', 'snippet': 'Neuren Pharmaceuticals will test its therapeutic candidate NNZ-2591 in \nchildren with Prader-Willi syndrome (PWS) in a new Phase 2 clinical trial.', 'thumbnail': 'https://serpapi.com/searches/672211234e9efc40cad5add2/images/b205b6d153b54d9e2f33c05f4735b6f9f3e439ba37b8f557d644b8ea3036469d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8675135374069214}","{'position': 2, 'link': 'https://praderwillinews.com/news/nnz-2591-phase-2-trial-children-with-pws-recruiting-us/', 'title': 'NNZ-2591 Phase 2 trial of children with PWS is recruiting in US |...', 'source': 'Prader-Willi Syndrome News', 'date': 'Jul 6, 2023', 'snippet': 'Neuren Pharmaceuticals has opened the first site for a U.S.-based Phase 2 \nclinical trial of its investigational therapy NNZ-2591 in children...', 'thumbnail': 'https://serpapi.com/searches/672211234e9efc40cad5add2/images/b205b6d153b54d9ebda203eac14cef2c69294147c5242c23282ef90cae1ffe42.png', 'sentiment': 'neutral', 'sentiment_prob': 0.895076334476471}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04669028,"{'position': 1, 'link': 'https://www.globenewswire.com/fr/news-release/2023/06/26/2694368/0/en/index.html', 'title': 'BioVie Presents Data Highlighting Role of Insulin', 'source': 'GlobeNewswire', 'date': 'Jun 26, 2023', 'snippet': 'Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the \nAmerican Diabetes Association Annual Meeting...', 'thumbnail': 'https://serpapi.com/searches/67221159fab273f966b9360f/images/354373fb57db6a5ac5498976d97d2bbb1b477724ddf07edee17f4e1e270c2f04.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.896338701248169}",,,,,,,,,,['neutral'],neutral,1
NCT01426880,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/os-and-efs-improved-with-neoadjuvant-chemotherapy-carboplatin-for-locally-advanced-tnbc', 'title': 'OS and EFS Improved With Neoadjuvant Chemotherapy/Carboplatin for Locally Advanced TNBC', 'source': 'Cancer Network', 'date': 'Dec 10, 2022', 'snippet': 'Patients with operable, locally advanced triple-negative breast cancer \nexperienced notable improvements in survival following treatment with...', 'thumbnail': 'https://serpapi.com/searches/6722116fee468296a0065d0a/images/795f5bdb2ebeca7f2cadb9a7eec26fb6f87a2cbd6cdb2207c8f86ca57a503429.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5052809119224548}",,,,,,,,,,['positive'],positive,1
NCT04209543,"{'position': 1, 'link': 'https://www.endocrinologyadvisor.com/features/2023-menopause-society-annual-meeting-highlights-vasomotor-symptoms-treatment/', 'title': '2023 Menopause Society Annual Meeting Highlights Vasomotor Symptoms Treatment', 'source': 'Endocrinology Advisor', 'date': 'Oct 13, 2023', 'snippet': 'At the North American Menopause Society 2023 Annual Meeting from September \n27 to 30 in Philadelphia, Pennsylvania, many studies focused on...', 'thumbnail': 'https://serpapi.com/searches/672211c7b691a77af4145f00/images/7786a7ce1b983e7298e180218d21ca4226d822c6afbcea2306654e5bbe40d1fa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9407566785812378}",,,,,,,,,,['neutral'],neutral,1
NCT00829166,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1209124', 'title': 'Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Oct 1, 2012', 'snippet': 'Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating \nthe human epidermal growth factor receptor 2 (HER2)–targeted...', 'thumbnail': 'https://serpapi.com/searches/672211d530dfc13e4da29472/images/070f263b51d05c605e7c5a614ab8a71318a11d93cf94f6b4cc5eefa0e42b6d20.png', 'sentiment': 'neutral', 'sentiment_prob': 0.882633626461029}",,,,,,,,,,['neutral'],neutral,1
NCT01213407,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-019-0149-x', 'title': 'Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors', 'source': 'Nature', 'date': 'Jan 16, 2020', 'snippet': 'Glioblastoma is the most prevalent and aggressive brain cancer. With a \nmedian overall survival of ~15–20 months under standard therapy,...', 'thumbnail': 'https://serpapi.com/searches/6722123d81bab782be6491bd/images/6afe82ae92eae88b91472d01c2f42377aa4444748a9176ca56db1a9dd7cffae6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.49266043305397034}",,,,,,,,,,['neutral'],neutral,1
NCT00935623,"{'position': 1, 'link': 'https://www.nature.com/articles/nri2902', 'title': 'Experimental human challenge infections can accelerate clinical malaria vaccine development', 'source': 'Nature', 'date': 'Dec 23, 2010', 'snippet': 'These authors put forward their view that the information obtained from \nexperimental human malaria infections justifies the minimal...', 'thumbnail': 'https://serpapi.com/searches/67221296f963e7b1d30997c6/images/29f5b04927310995f73719d2bdf34e1922b5a0613fc1817b37a40c04f5b55f38.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8248225450515747}",,,,,,,,,,['neutral'],neutral,1
NCT03691623,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2108903', 'title': 'EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge', 'source': 'The New England Journal of Medicine', 'date': 'Feb 16, 2022', 'snippet': 'In a two-part, phase 2a, randomized, double-blind, placebo-controlled \nchallenge trial, we assigned participants who had been inoculated with...', 'thumbnail': 'https://serpapi.com/searches/672212bc4e9efc40cad5af16/images/418180a46e22c478f2f90daeaee027c16956a48ea49b7265907c513d3ff675e2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.899833619594574}",,,,,,,,,,['neutral'],neutral,1
NCT02492711,"{'position': 1, 'link': 'https://breastcancer-news.com/2020/12/21/margenza-approved-fda-pretreated-her2-positive-breast-cancer/', 'title': 'Margenza Approved in US for Pretreated HER2-positive Breast Cancer', 'source': 'Breast Cancer News', 'date': 'Dec 21, 2020', 'snippet': ""The FDA has approved MacroGenics' Margenza, in combination with \nchemotherapy, to treat adults with metastatic HER2-positive breast cancer."", 'thumbnail': 'https://serpapi.com/searches/672212dc30dfc13e7b3c1a93/images/66555a380cbe3711d76ed3c48237eff3c26f2b046b2edb14237e6ba3137c223e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7703570127487183}",,,,,,,,,,['neutral'],neutral,1
NCT04579250,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01660-8', 'title': 'Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial', 'source': 'Nature', 'date': 'Feb 3, 2022', 'snippet': 'Currently, licensed seasonal influenza vaccines display variable vaccine \neffectiveness, and there remains a need for novel vaccine platforms...', 'thumbnail': 'https://serpapi.com/searches/672213a189055e8ea6cbc7e4/images/bb2da977e8746c5bcd932c0d56eedea0335fee8dad34df77ec39ff0f0349b2a2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8805010914802551}","{'position': 2, 'link': 'https://www.nature.com/articles/s41541-024-00959-0', 'title': 'Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine', 'source': 'Nature', 'date': '1 month ago', 'snippet': 'The relative conservation of the influenza hemagglutinin (HA) stem compared \nto that of the immunodominant HA head makes the HA stem an...', 'thumbnail': 'https://serpapi.com/searches/672213a189055e8ea6cbc7e4/images/bb2da977e8746c5b416470e7e13021a1a7ad543c30492723ced224459c2bbbdc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9192789793014526}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04657315,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1139359/full', 'title': 'Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?', 'source': 'Frontiers', 'date': 'Jun 27, 2024', 'snippet': 'Neurological disorders are recognized as major causes of death and \ndisability worldwide. Because of this, they represent one of the largest \npublic health...', 'thumbnail': 'https://serpapi.com/searches/672213bf8f2bc25a1c97fa78/images/16382a4c8c8024c2535e73fb5b7a6929671aa5b7ef5739e67f07c4741196b828.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5713104009628296}",,,,,,,,,,['negative'],negative,0
NCT03160521,"{'position': 1, 'link': 'https://www.nature.com/articles/s41537-020-00127-y', 'title': 'in schizophrenic patients with an acute exacerbation', 'source': 'Nature', 'date': 'Nov 25, 2020', 'snippet': 'Risperidone ISM provided rapid and progressive reduction of symptoms in \npatients with acutely exacerbated schizophrenia without need of oral \nrisperidone...', 'thumbnail': 'https://serpapi.com/searches/6722131bbe1497c4b66ffd86/images/2514dff39f8961a085658e3767311cc83a31e634bd2b748964d074a662e720a2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7882256507873535}",,,,,,,,,,['neutral'],neutral,1
NCT00474630,"{'position': 1, 'link': 'https://www.nature.com/articles/s41366-018-0302-z', 'title': 'Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis', 'source': 'Nature', 'date': 'Jan 21, 2019', 'snippet': 'Anxiety and sleep disorder-related PAEs were more frequent with NB versus \nplacebo but were mostly mild to moderate and generally occurred early.', 'thumbnail': 'https://serpapi.com/searches/6722132f21b01bb4cf0b9fc7/images/9727fde8949cd412671e2123a404523d75fe088f5adf6fc53a29ea4499287260.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6952958106994629}",,,,,,,,,,['neutral'],neutral,1
NCT03070782,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1905239', 'title': 'Lipoprotein(a) Reduction in Persons with Cardiovascular Disease', 'source': 'The New England Journal of Medicine', 'date': 'Jan 1, 2020', 'snippet': 'Lipoprotein(a) levels are genetically determined and, when elevated, are a \nrisk factor for cardiovascular disease and aortic stenosis.', 'thumbnail': 'https://serpapi.com/searches/672213389e38e52c96d8b8df/images/c599d193b9ab02998972a29f070cc29fc64176d44d66bbbe251485157380a3e8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6087671518325806}",,,,,,,,,,['neutral'],neutral,1
NCT03944460,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/pri-002-oral-candidate-alzheimers-disease-safe-phase-1-trial/', 'title': ""PRI-002, Oral Candidate for Alzheimer's, Found Safe in Phase 1 Trial"", 'source': ""Alzheimer's News Today"", 'date': 'May 22, 2019', 'snippet': ""Alzheimer's oral therapy candidate PRI-002 has proven safe for human use in \nan early stage Phase 1 clinical trial, ensuring further testing..."", 'thumbnail': 'https://serpapi.com/searches/67221367f922f68a8717b6c8/images/cb93d25499146e489efbb67109d40e02dba2dfebde98b628fbab44f67985abfa.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6251877546310425}",,,,,,,,,,['positive'],positive,1
NCT02837575,"{'position': 1, 'link': 'https://www.genengnews.com/topics/drug-discovery/vical-halts-development-of-hsv-2-vaccine-after-phase-ii-failure/', 'title': 'Vical Halts Development of HSV-2 Vaccine after Phase II Failure', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Jun 11, 2018', 'snippet': 'The HSV-2 vaccine missed its primary endpoint in the Phase II study of \nannualized lesion recurrence rate.', 'thumbnail': 'https://serpapi.com/searches/672213682a48821b6e0a63b9/images/05bffbe7d2f72be08d37ed35a906e158bd0d61af1a20c37eb69f7de029bcf499.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7711883783340454}",,,,,,,,,,['negative'],negative,0
NCT03350191,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-020-73815-5', 'title': 'Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes', 'source': 'Nature', 'date': 'Oct 7, 2020', 'snippet': 'In this study we investigated the target occupancy of the dual agonist \nSAR425899 at the GLP1R in pancreas and GCGR in liver by Positron Emission \nTomography/...', 'thumbnail': 'https://serpapi.com/searches/6722137dd19f15fb979b5d92/images/b94e2477d1502bc13ce5fd39880a5fec8b24279872ec11b0930f7e6397566ca2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9031040072441101}",,,,,,,,,,['neutral'],neutral,1
NCT02798406,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02347-y', 'title': 'Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial', 'source': 'Nature', 'date': 'May 15, 2023', 'snippet': 'Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and \naugmented with checkpoint inhibition, may be an effective...', 'thumbnail': 'https://serpapi.com/searches/672213e2a54d7ea585ded7ea/images/dcaa21c5d8588b6868ea755167773387e94f0a5b9d60525f24aa4aab6fd1847c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.740546464920044}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.953410/full', 'title': 'Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements', 'source': 'Frontiers', 'date': 'Feb 15, 2024', 'snippet': 'Oncolytic viruses (OVs) have been gaining attention in the pharmaceutical \nindustry as a novel immunotherapeutic and therapeutic adjuvant due to \ntheir...', 'thumbnail': 'https://serpapi.com/searches/672213e2a54d7ea585ded7ea/images/dcaa21c5d8588b682bdf6cb0495265f79f6817a36a06513510d9be42c34c4af2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7581920623779297}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04926701,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/phase-2-trial-etd001-airway-mucus-obstruction-cf-planned/', 'title': 'Phase 2 trial of ETD001, for CF airway mucus obstruction, planned', 'source': 'Cystic Fibrosis News Today', 'date': 'Jun 17, 2024', 'snippet': 'ETD001, an inhaled therapy for mucus clearance, showed safety and efficacy \nat low dose in sheep, and a study in CF patients may soon open.', 'thumbnail': 'https://serpapi.com/searches/672213ff6de1e44657d96b75/images/d9fe3088b707d1e5d8dd75e2d275b708bc0a3d03ec5aca40b42fea5b00454f99.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6532422304153442}",,,,,,,,,,['neutral'],neutral,1
NCT03874897,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01800-8', 'title': 'Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results', 'source': 'Nature', 'date': 'May 9, 2022', 'snippet': 'Despite success in hematologic malignancies, the treatment landscape of \nchimeric antigen receptor (CAR) T cell therapy for solid tumors...', 'thumbnail': 'https://serpapi.com/searches/67221414a5d70237f1e01f51/images/dbbf342000e3abf2aefa352c131c51b3afd27481d5b854afab1e1c35dcfcdaa5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6915398836135864}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/carsgen-announces-enrollment-completion-in-china-gcgej-pivotal-phase-ii-clinical-trial-of-the-first-in-class-claudin18-2-car-t-satri-cel-302225000.html', 'title': 'CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel)', 'source': 'PR Newswire', 'date': 'Aug 19, 2024', 'snippet': 'This study is an open-label, multicenter, randomized clinical trial in \nChina evaluating the efficacy and safety of satri-cel in subjects with \nClaudin18.2-...', 'thumbnail': 'https://serpapi.com/searches/67221414a5d70237f1e01f51/images/dbbf342000e3abf24a68b1d9e5b648ec38cbcb4149461bf3352c8747f788ecde.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8776533603668213}","{'position': 3, 'link': 'https://www.prnewswire.com/news-releases/carsgen-initiates-phase-2-clinical-trial-for-cldn18-2-car-t-cell-product-ct041-in-the-us-301828211.html', 'title': 'CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.', 'source': 'PR Newswire', 'date': 'May 18, 2023', 'snippet': 'PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), \na company focused on innovative CAR T-cell therapies for the...', 'thumbnail': 'https://serpapi.com/searches/67221414a5d70237f1e01f51/images/dbbf342000e3abf2eb38158841eb66219dda082f54b34a408346d4aec4ccb861.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8880912661552429}","{'position': 4, 'link': 'https://www.asiaone.com/business-wires/carsgen-presents-updated-results-satri-cel-nature-medicine-and-2024-asco', 'title': 'CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO, Business Wires News', 'source': 'AsiaOne', 'date': '1 week ago', 'snippet': 'SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings \nLimited (Stock Code: 2171.HK), a company focused on innovative CAR...', 'thumbnail': 'https://serpapi.com/searches/67221414a5d70237f1e01f51/images/dbbf342000e3abf22e4a099ccedb965df5b6bf2be8231892f23e1e5267dad125.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8394809365272522}","{'position': 5, 'link': 'https://www.prnewswire.com/news-releases/two-cases-of-pancreatic-cancer-treatment-with-carsgens-ct041-published-in-journal-of-hematology--oncology-301934471.html', 'title': ""Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncology"", 'source': 'PR Newswire', 'date': 'Sep 21, 2023', 'snippet': 'PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), \na company focused on innovative CAR T-cell therapies for the...', 'thumbnail': 'https://serpapi.com/searches/67221414a5d70237f1e01f51/images/dbbf342000e3abf23e8ff24bda64123151d84457575b42a7fee1942510e8dd17.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9332403540611267}","{'position': 6, 'link': 'https://www.prnewswire.com/news-releases/carsgens-presents-updated-research-results-on-ct041-at-2024-asco-gi-meeting-302038279.html', 'title': ""CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting"", 'source': 'PR Newswire', 'date': 'Jan 19, 2024', 'snippet': 'PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), \na company focused on innovative CAR T-cell therapies for the...', 'thumbnail': 'https://serpapi.com/searches/67221414a5d70237f1e01f51/images/dbbf342000e3abf22d477edfb66bc26fd08b7411e81a04423df056fc33f5b625.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8768885731697083}",,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04903652,"{'position': 1, 'link': 'https://www.onclive.com/view/pyrotinib-plus-metronomic-vinorelbine-is-active-in-her2-advanced-breast-cancer-after-trastuzumab', 'title': 'Pyrotinib Plus Metronomic Vinorelbine Is Active in HER2+ Advanced Breast Cancer After Trastuzumab', 'source': 'OncLive', 'date': '1 month ago', 'snippet': 'Pyrotinib paired with metronomic vinorelbine was safe and displayed \nefficacy in HER2-positive advanced breast cancer after prior...', 'thumbnail': 'https://serpapi.com/searches/672214301adaf494051ce6be/images/7205ddcca07a565a9c6565861be78861e09449b42b45acce17f739175cf826ea.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5048511624336243}",,,,,,,,,,['positive'],positive,1
NCT02348632,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/how-does-solriamfetol-treatment-for-osa-and-narcolepsy-affect-body-weight/', 'title': 'How Does Solriamfetol Treatment for OSA and Narcolepsy Affect Body Weight?', 'source': 'Pulmonology Advisor', 'date': 'Sep 1, 2022', 'snippet': 'Solriamfetol treatment for patients with obstructive sleep apnea (OSA) or \nnarcolepsy is associated with a decrease in body weight in a dose-related \nmanner.', 'thumbnail': 'https://serpapi.com/searches/67221435d997ab91c9b2cbf3/images/16cd26771e5f40633f96b381cd9c430f3bbedd1a13de5cb99de247d7e9c7574f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6752815246582031}",,,,,,,,,,['neutral'],neutral,1
NCT02035605,"{'position': 1, 'link': 'https://hemophilianewstoday.com/fitusiran/', 'title': 'Fitusiran for hemophilia', 'source': 'Hemophilia News Today', 'date': 'Aug 22, 2024', 'snippet': 'Last updated Aug. 22, 2024, by Margarida Maia, PhD ✓ Fact-checked by Inês \nMartins, PhD. How fitusiran works. Administration. Clinical trials. Side \neffects...', 'thumbnail': 'https://serpapi.com/searches/67221452ec5410d4be7cb17d/images/3459770cdea20d657e5b949183dcd5c54e6664fdfd7374a75c229fcfa87f79ae.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9302834868431091}",,,,,,,,,,['neutral'],neutral,1
NCT00084396,"{'position': 1, 'link': 'https://www.nature.com/articles/ncomms12498', 'title': 'Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers', 'source': 'Nature', 'date': 'Aug 9, 2016', 'snippet': 'Resistance to oestrogen-deprivation therapy is common in \noestrogen-receptor-positive (ER+) breast cancer. To better understand the...', 'thumbnail': 'https://serpapi.com/searches/6722145374f0a452ea2b5aa4/images/df9389a4cee83472eb74e0edc860efc0c455c42a8940568fcdf15fb3e77baf8f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.638504683971405}",,,,,,,,,,['neutral'],neutral,1
NCT02375698,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-27029-6', 'title': 'A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients', 'source': 'Nature', 'date': 'Nov 22, 2021', 'snippet': 'We show the first clinical data that H56:IC31 vaccination is safe and \nimmunogenic in tuberculosis patients, supporting further studies of \nH56:IC31 as a host-...', 'thumbnail': 'https://serpapi.com/searches/672214a75ed3caf6a16af5f5/images/d752b913d3d38548eceb8b39c569f657746de368f3e551a35f85dda880685e65.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6584312915802002}",,,,,,,,,,['neutral'],neutral,1
NCT03399604,"{'position': 1, 'link': 'https://pulmonaryhypertensionnews.com/news/open-label-trial-yutrepia-ild-enrolls-first-participant/', 'title': 'Open-label clinical trial of Yutrepia for PH-ILD enrolls 1st participant', 'source': 'Pulmonary Hypertension News', 'date': 'Jan 8, 2024', 'snippet': ""The first patient has entered ASCENT, a clinical study of Liquidia's \nYutrepia, an inhaled dry powder formulation of treprostinil for PH-ILD."", 'thumbnail': 'https://serpapi.com/searches/672214c38d1473e38aba783c/images/6afc786ff67a5b1f840efb20f013a772cf111732e8e49311f83b30b270aa5148.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9160255789756775}","{'position': 2, 'link': 'https://pulmonaryhypertensionnews.com/news/pah-patients-prefer-yutrepia-over-tyvaso-inspire-study/', 'title': 'PAH Patients Prefer Yutrepia Over Tyvaso in INSPIRE Study |...', 'source': 'Pulmonary Hypertension News', 'date': 'Aug 3, 2022', 'snippet': 'Yutrepia, an inhaled form of treprostinil, was preferred for the treatment \nof pulmonary arterial hypertension by patients in the INSPIRE...', 'thumbnail': 'https://serpapi.com/searches/672214c38d1473e38aba783c/images/6afc786ff67a5b1fc9d33a89a3403c41e699a076c43534dc0e20546f426c8b28.png', 'sentiment': 'neutral', 'sentiment_prob': 0.887389063835144}","{'position': 3, 'link': 'https://pulmonaryhypertensionnews.com/news/fda-delays-decision-yutrepia-treat-ph-ild/', 'title': 'FDA delays decision on extending Yutrepia to treat PH-ILD', 'source': 'Pulmonary Hypertension News', 'date': 'Jan 26, 2024', 'snippet': ""The FDA is delaying its decision to extend Yutrepia, Liquidia's inhaled dry \npowder formulation of treprostinil, to treat people with PH-ILD."", 'thumbnail': 'https://serpapi.com/searches/672214c38d1473e38aba783c/images/6afc786ff67a5b1f9c7398dafdb8465da0644ff53d959c9439833d9defc1b053.png', 'sentiment': 'negative', 'sentiment_prob': 0.5138409733772278}","{'position': 4, 'link': 'https://pulmonaryhypertensionnews.com/news/fda-approval-decision-yutrepia-liquida-ph-ild-expected-january/', 'title': 'Approval decision on Yutrepia for PH-ILD expected in January |...', 'source': 'Pulmonary Hypertension News', 'date': 'Sep 27, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has agreed to review an \napplication from Liquidia that seeks to extend the approval of Yutrepia.', 'thumbnail': 'https://serpapi.com/searches/672214c38d1473e38aba783c/images/6afc786ff67a5b1f73052116aa331bdee56ea8caf3933ed3e85aba52bc89dca6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9383014440536499}",,,,,,,"['neutral', 'neutral', 'negative', 'neutral']",neutral,1
NCT05865886,"{'position': 1, 'link': 'https://www.boehringer-ingelheim.com/human-health/lung-diseases/phase-ii-trials-patients-bronchiectasis', 'title': 'Phase II trials for patients with bronchiectasis', 'source': 'Boehringer Ingelheim', 'date': 'Jun 29, 2023', 'snippet': 'Bronchiectasis is a chronically progressive pulmonary disease. Boehringer \nIngelheim investigates a potential new treatment option in two Phase II \ntrials.', 'thumbnail': 'https://serpapi.com/searches/672214efbe324f55320fa276/images/4a49c722fd97a982a220cdb52be1b55d1e44d49a9480bb05115579f10da2413f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9052193760871887}",,,,,,,,,,['neutral'],neutral,1
NCT03196297,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/novo-nordisk-pauses-three-clinical-trials-of-concizumab-due-to-safety-concerns/', 'title': 'Safety Concerns Put 3 Hemophilia Trials, Testing Concizumab, on Hold', 'source': 'Hemophilia News Today', 'date': 'Mar 18, 2020', 'snippet': 'Novo Nordisk has paused three clinical trials evaluating concizumab, its \nexperimental treatment candidate for hemophilia A and B, due to safety \nconcerns.', 'thumbnail': 'https://serpapi.com/searches/672214f411db45407348a9a1/images/741d80a932a04b19d0c9e5b00d024e6b59876954a23f73ad7e22424288cefce0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5402668714523315}",,,,,,,,,,['neutral'],neutral,1
NCT00887224,"{'position': 1, 'link': 'https://www.psychiatrist.com/pcc/efficacy-desvenlafaxine-mgd-versus-placebo-long-term/', 'title': 'Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial', 'source': 'Psychiatrist.com', 'date': 'Aug 27, 2015', 'snippet': 'Patrice Boyer, MD, PhD; Cécile Vialet, MSc; Eunhee Hwang, PhD; and Karen A. \nTourian, MD. Published: August 27, 2015. Efficacy of Desvenlafaxine 50 \nmg/d...', 'thumbnail': 'https://serpapi.com/searches/6722151fc7d4a1acec2d0958/images/0b18424c19d8b5592f3d2cd611a857ed72c46f2ee428dbab93eca8d634dc7845.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9115458130836487}",,,,,,,,,,['neutral'],neutral,1
NCT02664558,"{'position': 1, 'link': 'https://lungdiseasenews.com/2018/01/19/ubenimex-development-treat-pulmonary-arterial-hypertension-ends/', 'title': 'Ubenimex Development to Treat Pulmonary Arterial Hypertension Ends', 'source': 'Lung Disease News', 'date': 'Jan 19, 2018', 'snippet': ""Eiger BioPharmaceuticals' ubenimex failed to show improvement in pulmonary \nvascular resistance or exercise capacity in the Phase 2 LIBERTY..."", 'thumbnail': 'https://serpapi.com/searches/672215a75c7cb9309d9708d1/images/9ecfd1e23a76a534304d2e56f5ebee86d48c37244fe8f9798ff6ac92d68b5f06.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6212904453277588}",,,,,,,,,,['negative'],negative,0
NCT02496897,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/cei.13614', 'title': 'Therapeutic vaccination for treatment of chronic hepatitis B - Cargill - 2021 - Clinical & Experimental Immunology', 'source': 'Wiley Online Library', 'date': 'May 9, 2021', 'snippet': 'In this review we outline the rationale for therapeutic vaccination in \nchronic HBV infection, discuss previous and ongoing trials of novel HBV \ntherapeutic...', 'thumbnail': 'https://serpapi.com/searches/672215c3b7d31daeb501f398/images/549ee5712a92629defe65f197c185f31bb08fdbf9fd47b97fdb8a4ad4e89fb17.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9303779006004333}",,,,,,,,,,['neutral'],neutral,1
NCT02568215,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2031738', 'title': 'Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition', 'source': 'The New England Journal of Medicine', 'date': 'Mar 17, 2021', 'snippet': 'Whether a broadly neutralizing antibody (bnAb) can be used to prevent human \nimmunodeficiency virus type 1 (HIV-1) acquisition is unclear.', 'thumbnail': 'https://serpapi.com/searches/67221620f93388203ee950f8/images/ac588359dd8affc0b764546873ba8daa760a162bb10335179de2469a3f26ed83.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.771469235420227}",,,,,,,,,,['neutral'],neutral,1
NCT04225260,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20241020496709/en/ASDS-2024-New-Phase-III-READY-4-Data-Demonstrate-Long-Term-Safety-and-Efficacy-of-Galderma%E2%80%99s-RelabotulinumtoxinA-Relfydess%E2%84%A2', 'title': 'ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess', 'source': 'Business Wire', 'date': '1 week ago', 'snippet': 'Galderma today announced new phase III data from the READY-4 clinical \ntrial, demonstrating the long-term safety of RelabotulinumtoxinA...', 'thumbnail': 'https://serpapi.com/searches/6722163572f7160bb01071e2/images/c72a2fc1b73b9cba39082d29a159b5fb3db602032e4ecdcefc9c8d8b1f88d7be.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6244627833366394}",,,,,,,,,,['neutral'],neutral,1
NCT03599713,"{'position': 1, 'link': 'https://ascopost.com/issues/may-25-2023/retifanlimab-dlwr-for-metastatic-or-recurrent-locally-advanced-merkel-cell-carcinoma/', 'title': 'Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma', 'source': 'The ASCO Post', 'date': 'May 25, 2023', 'snippet': 'The anti–PD-1 antibody retifanlimab-dlwr was granted accelerated approval \nfor adults with metastatic or recurrent locally advanced Merkel cell \ncarcinoma.', 'thumbnail': 'https://serpapi.com/searches/672216476cca5e787638f925/images/3694aef26584066f1793059996455f3d0f971bea642e66ade88b5a085c7890bd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8447984457015991}",,,,,,,,,,['neutral'],neutral,1
NCT05712538,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/arct-032-inhaled-cf-treatment-showing-safety-phase-1-trial/', 'title': 'ARCT-032, therapy for all with CF, showing safety in Phase 1 trial', 'source': 'Cystic Fibrosis News Today', 'date': 'Jun 12, 2024', 'snippet': 'Early signs of efficacy also were seen in 4 patients given ARCT-032, a \nmessenger RNA therapy allowing healthy CFTR production in lung cells.', 'thumbnail': 'https://serpapi.com/searches/6722168f93bb57f524e16700/images/1819434e1916cdba7e56cb2eff6277081e7b6a07ec87e78d03b398831fe3141b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7940552234649658}","{'position': 2, 'link': 'https://cysticfibrosisnewstoday.com/news/fda-orphan-drug-status-awarded-inhaled-cf-therapy-arct-032/', 'title': 'FDA orphan drug status awarded to inhaled CF therapy ARCT-032', 'source': 'Cystic Fibrosis News Today', 'date': 'Nov 28, 2023', 'snippet': ""The U.S. Food and Drug Administration has granted orphan drug status to \nArcturus' ARCT-032, an inhaled treatment for cystic fibrosis."", 'thumbnail': 'https://serpapi.com/searches/6722168f93bb57f524e16700/images/1819434e1916cdba3674792c6d023e74d5d5bf62fe226021c77575222868a6b4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8929421305656433}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02130557,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-022-01589-y', 'title': 'Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial', 'source': 'Nature', 'date': 'May 28, 2022', 'snippet': 'This analysis from the multicenter, open-label, phase 3 BFORE trial reports \nefficacy and safety of bosutinib in patients with newly...', 'thumbnail': 'https://serpapi.com/searches/672216e5e8735a1451f2facd/images/dbe65edd175871afe3e528992ac87e6285c84bfe58faa4a95684810628042278.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9095726013183594}",,,,,,,,,,['neutral'],neutral,1
NCT02795676,"{'position': 1, 'link': 'https://fabrydiseasenews.com/news/prx-102-shows-safety-efficacy-similar-fabrazyme-top-line-balance-trial/', 'title': 'PRX-102 Shows Safety, Efficacy Similar to Fabrazyme in Phase 3 Trial', 'source': 'Fabry Disease News', 'date': 'Apr 29, 2022', 'snippet': 'Top-line data from Phase 3 BALANCE trial found 2 years of PRX-102 treatment \nsimilar to Fabrazyme in adults with Fabry and kidney disease.', 'thumbnail': 'https://serpapi.com/searches/6722173b11db4540a6d968dd/images/7d48fc2dbcf24afb1005084c0a33ba4aa2b25e99a6e44da8717aaf4cec4f1d05.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7387609481811523}","{'position': 2, 'link': 'https://fabrydiseasenews.com/news/fabry-disease-therapy-prx-102-now-elfabrio-wins-fda-approval/', 'title': 'Fabry disease therapy PRX-102, now Elfabrio, wins FDA approval |...', 'source': 'Fabry Disease News', 'date': 'May 10, 2023', 'snippet': ""PRX-102, now Elfabrio, won the U.S. Food and Drug Administration's approval \nas an intravenous infusion for adults with Fabry disease ."", 'thumbnail': 'https://serpapi.com/searches/6722173b11db4540a6d968dd/images/7d48fc2dbcf24afb7330455ccd4be917ff680e8f5d6302bbf8eee60574226da0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7576220631599426}","{'position': 3, 'link': 'https://fabrydiseasenews.com/news/elfabrio-effective-fabrazyme-kidney-decline-trial/', 'title': 'Elfabrio as effective as Fabrazyme for Fabry with kidney decline: Trial', 'source': 'Fabry Disease News', 'date': 'Dec 15, 2023', 'snippet': 'Elfabrio (pegunigalsidase alfa) is as safe and effective as Fabrazyme \n(agalsidase beta) and can prevent kidney decline in adults with Fabry \ndisease over two...', 'thumbnail': 'https://serpapi.com/searches/6722173b11db4540a6d968dd/images/7d48fc2dbcf24afb6541845dcfb6dcdb3da11883a6fe7aa8f54818689598f887.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5244313478469849}","{'position': 4, 'link': 'https://fabrydiseasenews.com/news/europe-approval-prx-102-plant-based-ert-adults-requested/', 'title': 'PRX-102, Potential Fabry Plant-based ERT, Up for Approval in Europe', 'source': 'Fabry Disease News', 'date': 'Mar 4, 2022', 'snippet': 'Protalix and Chiesi have applied to the European Medicines Agency for \nPRX-102 (pegunigalsidase alfa) to be approved for adults with Fabry.', 'thumbnail': 'https://serpapi.com/searches/6722173b11db4540a6d968dd/images/7d48fc2dbcf24afbe2eafde842332825448bc5a205c9b2ab1dbf92748c92d337.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8462085723876953}","{'position': 5, 'link': 'https://fabrydiseasenews.com/news/elfabrio-soon-available-fabry-patients-england-low-no-cost/', 'title': 'Elfabrio soon available to Fabry patients in England at low or no cost', 'source': 'Fabry Disease News', 'date': 'Sep 15, 2023', 'snippet': 'Elfabrio was approved in the U.K. as a long-term enzyme replacement therapy \nin adults with Fabry disease in August.', 'thumbnail': 'https://serpapi.com/searches/6722173b11db4540a6d968dd/images/7d48fc2dbcf24afb1a694e27b86ff27dd466647adb8ed93b7aad26ceecc48994.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7245880365371704}","{'position': 6, 'link': 'https://fabrydiseasenews.com/news/protalix-fabry-disease-therapy-pegunigalsidase-alfa-granted-fda-fast-track-designation/', 'title': 'Fabry Disease Therapy Pegunigalsidase Alfa Gets FDA Fast Track Status', 'source': 'Fabry Disease News', 'date': 'Feb 6, 2018', 'snippet': ""The US Food and Drug Administration (FDA) has granted fast track \ndesignation to pegunigalsidase alfa, or PRX-102, Protalix BioTherapeutics' \ntherapy candidate..."", 'thumbnail': 'https://serpapi.com/searches/6722173b11db4540a6d968dd/images/7d48fc2dbcf24afb67574235317304e38251581a62cf8e6e1cd56d36737591c8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8152209520339966}",,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03220724,"{'position': 1, 'link': 'https://www.nature.com/articles/s41577-022-00753-w', 'title': 'Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies', 'source': 'Nature', 'date': 'Aug 12, 2022', 'snippet': 'After nearly four decades of research, a safe and effective HIV-1 vaccine \nremains elusive. There are many reasons why the development of a...', 'thumbnail': 'https://serpapi.com/searches/6722174864f11dc03e975087/images/1a32428c5b9715f78057b5cad82b3014957f9ae3af7e58ed6363fd8d03ca47fd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5168700814247131}",,,,,,,,,,['neutral'],neutral,1
NCT03931291,"{'position': 1, 'link': 'https://www.nature.com/articles/s41418-023-01122-3', 'title': 'The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells', 'source': 'Nature', 'date': 'Feb 4, 2023', 'snippet': 'Mutant TP53 proteins are thought to drive the development and sustained \nexpansion of cancers at least in part through the loss of the...', 'thumbnail': 'https://serpapi.com/searches/6722177cf8b05d603f25a1d1/images/160d7695b3828b82ceacb773b16fd2b9eef585bdeb808e174c6496356dcdba3b.png', 'sentiment': 'negative', 'sentiment_prob': 0.6143423318862915}",,,,,,,,,,['negative'],negative,0
NCT02148705,"{'position': 1, 'link': 'https://www.empr.com/home/news/severe-burn-therapy-nexobrid-gets-fda-approval/', 'title': 'Severe Burn Therapy NexoBrid Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Jan 3, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved NexoBrid \n(anacaulase-bcdb) for eschar removal in adults with deep partial thickness \nand/or full thickness...', 'thumbnail': 'https://serpapi.com/searches/6722179d2a48821b6e0a6730/images/0b1fa972f4ca6057bd2710d0e3c0da5687465173ea547990304b337b44571b44.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6989240646362305}","{'position': 2, 'link': 'https://www.empr.com/home/news/nexobrid-now-available-for-treatment-of-severe-thermal-burns/', 'title': 'NexoBrid Now Available for Treatment of Severe Thermal Burns', 'source': 'Medical Professionals Reference', 'date': 'Sep 21, 2023', 'snippet': 'NexoBrid (anacaulase-bcdb) is now available for eschar removal in adults \nwith deep partial thickness and/or full thickness thermal burns.', 'thumbnail': 'https://serpapi.com/searches/6722179d2a48821b6e0a6730/images/0b1fa972f4ca6057dc7ac666377af4608a8b536d1d25c72d5fbb12b6cbfd6266.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8987787961959839}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01654731,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1714519', 'title': 'A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis', 'source': 'The New England Journal of Medicine', 'date': 'Jun 6, 2018', 'snippet': 'Patients with primary biliary cholangitis who have an inadequate response \nto therapy with ursodeoxycholic acid are at high risk for disease...', 'thumbnail': 'https://serpapi.com/searches/672217d9fc183d1a7918f773/images/4713b0ea2948bf8ddf522286b2097a7bbaa176b492fb4852868813aa68574828.png', 'sentiment': 'negative', 'sentiment_prob': 0.6679105162620544}",,,,,,,,,,['negative'],negative,0
NCT04501666,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/galderma-unveils-positive-results-for-prurigo-nodularis-treatment/', 'title': 'Galderma unveils positive results for prurigo nodularis treatment', 'source': 'Clinical Trials Arena', 'date': 'Jul 4, 2023', 'snippet': 'Nemolizumab could soon be used to help alleviate itching arising from \nprurigo nodularis, following the latest Phase III data unveiled by Galderma.', 'thumbnail': 'https://serpapi.com/searches/672217e22c566df19c3da05f/images/8b24e4227fdd1b172661a2fdcbf1800473e2273a18b3d74acbebea18e8f849d4.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7919019460678101}",,,,,,,,,,['positive'],positive,1
NCT02252042,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31999-8/fulltext', 'title': 'Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study', 'source': 'The Lancet', 'date': 'Nov 30, 2018', 'snippet': 'There are few effective treatment options for patients with recurrent or \nmetastatic head-and-neck squamous cell carcinoma.', 'thumbnail': 'https://serpapi.com/searches/672217ea577da59cf36d0ba7/images/444155c177439c4acdbf51964b9661c9c262ec63054d5866d3fe64efb3a6bc8d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5495750308036804}",,,,,,,,,,['neutral'],neutral,1
NCT04615923,"{'position': 1, 'link': 'https://alsnewstoday.com/news/pridopidine-shows-some-potential-in-healey-trial-but-misses-main-goal/', 'title': 'Pridopidine fails primary endpoint but improves speech, early functional decline', 'source': 'ALS News Today', 'date': 'Mar 1, 2023', 'snippet': 'Pridopidine failed to meet its primary endpoint of improved physical \nfunction in HEALEY ALS trial, but improved speech in specific patients.', 'thumbnail': 'https://serpapi.com/searches/672218091397bae56dcc67cc/images/29cb760eb95f811dbdc22d9e7e611efa6b5502fb0ed591fb9bdfc842ea387728.png', 'sentiment': 'negative', 'sentiment_prob': 0.7390066385269165}","{'position': 2, 'link': 'https://alsnewstoday.com/news/phase-3-clinical-trial-pridopidine-als-likely-this-year/', 'title': 'Phase 3 trial of oral pridopidine in treating ALS likely this year', 'source': 'ALS News Today', 'date': 'Jan 29, 2024', 'snippet': 'A Phase 2 HEALEY study tied pridopidine to slower progression and better \nrespiration and speech, particularly with early,...', 'thumbnail': 'https://serpapi.com/searches/672218091397bae56dcc67cc/images/29cb760eb95f811d3be9b080280909b695e2a10e9a4eb56178c586006b56e127.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8719426393508911}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT03520036,"{'position': 1, 'link': 'https://porphyrianews.com/news/mt-7117-eases-sunlight-sensitivity-epp-xlp-patients-phase-2-trial/', 'title': 'MT-7117 found to ease sunlight sensitivity for EPP, XLP patients |...', 'source': 'Porphyria News', 'date': 'Apr 19, 2023', 'snippet': 'The oral therapy MT-7117 was found to ease sunlight sensitivity and improve \nlife quality for porphyria patients in a Phase 2 trial.', 'thumbnail': 'https://serpapi.com/searches/67221853d169156d464f9d1e/images/586acdf8cd5dc178d390d81ce6e87051447273ba93763049cf56793e2715b442.png', 'sentiment': 'positive', 'sentiment_prob': 0.5625188946723938}","{'position': 2, 'link': 'https://porphyrianews.com/phase-3-trial-mt-7117-for-epp-xlp-porphyrias/', 'title': 'MT-7117 Poised for Phase 3 Trial in Two Types of Porphyrias', 'source': 'Porphyria News', 'date': 'May 29, 2020', 'snippet': ""A Phase 3 clinical trial of Mitsubishi Tanabe's investigational therapy \nMT-7117 (dersimelagon) for people with erythropoietic protoporphyria..."", 'thumbnail': 'https://serpapi.com/searches/67221853d169156d464f9d1e/images/586acdf8cd5dc1781b8c7c8a12409f857f2f26319a1eaf43b64a29274c099a6e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8879155516624451}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02546531,"{'position': 1, 'link': 'https://www.researchgate.net/figure/FAK-inhibitors-with-anti-tumor-activity-in-preclinical-studies-and-clinical-trials_tbl1_336934468', 'title': 'FAK inhibitors with anti-tumor activity in preclinical studies and clinical trials.', 'source': 'ResearchGate', 'date': 'Nov 2, 2019', 'snippet': 'Small-cell lung cancer (SCLC) represents 15% of all lung cancers and it is \nclinically the most aggressive type, being characterized by a tendency for \nearly...', 'thumbnail': 'https://serpapi.com/searches/6722189e544c49a379e027bc/images/45a2d53b1346717d950e87cc2687b2593651ab73ec6a306be5840a615c16dbcb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6451858282089233}",,,,,,,,,,['neutral'],neutral,1
NCT04514367,"{'position': 1, 'link': 'https://huntingtonsdiseasenews.com/news/aan2023-huntingtons-therapy-anx005-stabilizes-functional-capacity-trial/', 'title': 'AAN2023: ANX005 stabilizes functional capacity in Phase 2a trial', 'source': ""Huntington's Disease News"", 'date': 'May 9, 2023', 'snippet': ""ANX005 stabilized or improved functional status for early Huntington's \ndisease patients in a Phase 2a trial."", 'thumbnail': 'https://serpapi.com/searches/672218af24296a3c10e5d5d0/images/f111c3b9a19b8daadc091c9ce4d57e7607d5aee1e6c7ebbd1cc4516c0794e880.png', 'sentiment': 'positive', 'sentiment_prob': 0.4970383048057556}",,,,,,,,,,['positive'],positive,1
NCT00197041,"{'position': 1, 'link': 'https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02466-2', 'title': 'Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children', 'source': 'BMC Medicine', 'date': 'Aug 25, 2022', 'snippet': 'RTS,S is the first malaria vaccine recommended for implementation among \nyoung children at risk. However, vaccine efficacy is modest and...', 'thumbnail': 'https://serpapi.com/searches/672218be5a461a4de7e0e00d/images/fec4b9a8ba294dac3c571e3f2063820bfbe174dc28a603235815693d9e587f26.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8192456960678101}",,,,,,,,,,['neutral'],neutral,1
NCT02831231,"{'position': 1, 'link': 'https://www.nature.com/articles/s41537-022-00320-1', 'title': 'Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia', 'source': 'Nature', 'date': 'Dec 3, 2022', 'snippet': 'KarXT combines xanomeline, an M1/M4 preferring muscarinic agonist with no \ndirect D2 receptor antagonism, with the peripherally restricted...', 'thumbnail': 'https://serpapi.com/searches/672218dc93bb57f4ee1a6e1f/images/6e93ed3c286c3260dcb6d121647cbf8c681a5095ee859377269fc95ca6864832.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8456377983093262}",,,,,,,,,,['neutral'],neutral,1
NCT00753545,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0271-y', 'title': 'Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy', 'source': 'Nature', 'date': 'Oct 24, 2018', 'snippet': 'In Study 19, maintenance monotherapy with olaparib significantly prolonged \nprogression-free survival vs placebo in patients with...', 'thumbnail': 'https://serpapi.com/searches/672218ded771bdbb7eb321bd/images/82311aecd7bd68cf6cd26204d419c6d85dc9cc905317dadf1bb54a7ec5f4d591.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8444756269454956}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1105535', 'title': 'Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Mar 27, 2012', 'snippet': 'Olaparib as maintenance treatment significantly improved progression-free \nsurvival among patients with platinum-sensitive, relapsed, high-grade \nserous ovarian...', 'thumbnail': 'https://serpapi.com/searches/672218ded771bdbb7eb321bd/images/82311aecd7bd68cf5b1767d4bfcfc3ebc83421e072eb07e80768a4e3586d23cf.png', 'sentiment': 'positive', 'sentiment_prob': 0.5063502192497253}","{'position': 3, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70228-1/abstract', 'title': 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial', 'source': 'The Lancet', 'date': 'Mar 29, 2015', 'snippet': 'Maintenance monotherapy with the PARP inhibitor olaparib significantly \nprolonged progression-free survival (PFS) versus placebo in patients with \nplatinum-...', 'thumbnail': 'https://serpapi.com/searches/672218ded771bdbb7eb321bd/images/82311aecd7bd68cf183d927a86e15b54ccf00cc0f5966b34694fe733a66c332b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8397908806800842}","{'position': 4, 'link': 'https://www.nature.com/articles/bjc2016348', 'title': 'Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer', 'source': 'Nature', 'date': 'Nov 8, 2016', 'snippet': 'Maintenance treatment with olaparib was well tolerated and had no adverse \nimpact on HRQoL in this study of patients with platinum-sensitive relapsed \nserous...', 'thumbnail': 'https://serpapi.com/searches/672218ded771bdbb7eb321bd/images/82311aecd7bd68cf3413cd0879083f3a4a319c9d68e82171bf472eb5ba1d0abe.png', 'sentiment': 'neutral', 'sentiment_prob': 0.512085497379303}","{'position': 5, 'link': 'https://www.nature.com/articles/s41416-021-01560-1', 'title': 'Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response', 'source': 'Nature', 'date': 'Oct 18, 2021', 'snippet': 'We provide clinical evidence supporting the role of SLFN11 as a DDA therapy \nselection biomarker in SCLC and highlight the need for further clinical...', 'thumbnail': 'https://serpapi.com/searches/672218ded771bdbb7eb321bd/images/82311aecd7bd68cf12f696bafd954eb51d69e3e9dddbf4aace992ab0e5cdb84b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9048330783843994}",,,,,,"['neutral', 'positive', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03347396,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2027760', 'title': 'Sutimlimab in Cold Agglutinin Disease', 'source': 'The New England Journal of Medicine', 'date': 'Apr 7, 2021', 'snippet': 'We conducted a 26-week multicenter, open-label, single-group study to \nassess the efficacy and safety of intravenous sutimlimab in patients with \ncold agglutinin...', 'thumbnail': 'https://serpapi.com/searches/6722190b7ef9fa1a3166915a/images/f25627a3cb49f3e07b678aee027cd252fbb575e5c2dfca472609a2a9eb48b36c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.891872763633728}","{'position': 2, 'link': 'https://coldagglutininnews.com/news/enjaymo-not-cost-effective-current-price-us-analysis/', 'title': 'Enjaymo not cost-effective at current price: US analysis', 'source': 'Cold Agglutinin Disease News', 'date': 'Jun 13, 2024', 'snippet': 'The CAD treatment Enjaymo (sutimlimab) needs to be about 80% cheaper to \nmeet commonly-accepted thresholds for cost-effectiveness, a study...', 'thumbnail': 'https://serpapi.com/searches/6722190b7ef9fa1a3166915a/images/f25627a3cb49f3e08b9485fed8dd23d70e7d5ec5dddf57567b9cfb1987b80a32.png', 'sentiment': 'negative', 'sentiment_prob': 0.5582624673843384}","{'position': 3, 'link': 'https://coldagglutininnews.com/news/patients-enjaymo-immune-response-covid-19-vaccines/', 'title': 'Patients on Enjaymo show immune response to COVID-19 vaccines', 'source': 'Cold Agglutinin Disease News', 'date': 'Mar 14, 2024', 'snippet': 'People with CAD who were on Enjaymo during clinical trials produced \nprotective antibodies in response to COVID-19 vaccination, a study...', 'thumbnail': 'https://serpapi.com/searches/6722190b7ef9fa1a3166915a/images/f25627a3cb49f3e00c09423c38edba40188ff1b7ff46a5da03d8fd64d0bc4428.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8503730893135071}",,,,,,,,"['neutral', 'negative', 'neutral']",neutral,1
NCT05309200,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20220819005390/en/Ocelot-Bio-Receives-FDA-Orphan-Drug-Designation-for-OCE-205-for-the-Treatment-of-Hepatorenal-Syndrome', 'title': 'Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Hepatorenal Syndrome', 'source': 'Business Wire', 'date': 'Aug 22, 2022', 'snippet': 'Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the \ndevelopment of innovative therapeutics to treat complications of...', 'thumbnail': 'https://serpapi.com/searches/67221b097a12fd124142eed5/images/b3dee6fbed81e9e9231e36943b0615a2ee3fceee5abac50258cc11919c5182c4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8745273351669312}",,,,,,,,,,['neutral'],neutral,1
NCT01218659,"{'position': 1, 'link': 'https://www.nature.com/articles/s41436-019-0451-z', 'title': 'Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study | Gen', 'source': 'Nature', 'date': 'Feb 6, 2019', 'snippet': 'Outcomes in patients with Fabry disease receiving migalastat during the \nphase 3 FACETS trial (NCT00925301) were evaluated by phenotype.', 'thumbnail': 'https://serpapi.com/searches/67221b0ccdf15582a043cc3b/images/2cf441f4720aca30f8b55923f8239f27747e549b3f9d8c374f2110175d671215.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9129406213760376}","{'position': 2, 'link': 'https://fabrydiseasenews.com/galafold-migalastat/', 'title': 'Galafold (migalastat) for Fabry disease', 'source': 'Fabry Disease News', 'date': 'Mar 6, 2024', 'snippet': 'Galafold is an approved oral therapy for adults with Fabry disease and \namenable mutations that helps to clear cells of toxic fatty...', 'thumbnail': 'https://serpapi.com/searches/67221b0ccdf15582a043cc3b/images/2cf441f4720aca3013ace41ab8b30a1294592853471a6cc915682f02428cb31d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7855511903762817}","{'position': 3, 'link': 'https://www.nature.com/articles/s41436-020-00968-z', 'title': 'for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease', 'source': 'Nature', 'date': 'Sep 30, 2020', 'snippet': 'To assess the utility of globotriaosylsphingosine (lyso-Gb3) for clinical \nmonitoring of treatment response in patients with Fabry disease...', 'thumbnail': 'https://serpapi.com/searches/67221b0ccdf15582a043cc3b/images/2cf441f4720aca30c24a5ec2369d71414c77f49f8cd7c781d03d0d83707055b7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8680515289306641}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02408913,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-024-00833-z', 'title': 'Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials', 'source': 'Nature', 'date': 'Mar 29, 2024', 'snippet': 'Ebola virus disease (EVD) is a filoviral infection caused by virus species \nof the Ebolavirus genus including Zaire ebolavirus (EBOV) and...', 'thumbnail': 'https://serpapi.com/searches/67221b69460b156b9c59aad2/images/73947c6e57c69d7d02a6e988b6b30685c3ca0bcf78a7912d701c1bfafb087967.png', 'sentiment': 'neutral', 'sentiment_prob': 0.788805365562439}",,,,,,,,,,['neutral'],neutral,1
NCT05104892,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/sanofi-gears-up-for-approval-of-its-btk-inhibitor-meets-phase-iii-endpoint/', 'title': 'Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint', 'source': 'Clinical Trials Arena', 'date': 'Apr 23, 2024', 'snippet': ""Sanofi's rilzabrutinib met the primary endpoint in the Phase III persistent \nor chronic immune thrombocytopenia trial."", 'thumbnail': 'https://serpapi.com/searches/67221b737e1d1f5f594b2279/images/ea1d4432ee5cbc297a3510ead19379a515f969695e5822faf02b6ba4fa7c66e7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6001195311546326}",,,,,,,,,,['neutral'],neutral,1
NCT00075049,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-017-0027-3', 'title': 'Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity', 'source': 'Nature', 'date': 'Sep 8, 2017', 'snippet': 'Combining immunostimulants in adjuvants can improve the quality of the \nimmune response to vaccines. Here, we report a unique mechanism of...', 'thumbnail': 'https://serpapi.com/searches/67221932d78a989f7c70e320/images/f6f6df5badf9138b6aef39140e0dcc13f38a44bfabba2628568b12ac882a81b6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.619517982006073}",,,,,,,,,,['positive'],positive,1
NCT01712438,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/octapharma-hemophilia-a-treatment-nuwiq-showing-further-potential-in-phase-3-study/', 'title': 'Hemophilia A Therapy, Nuwiq, Showing Further Potential in Phase 3 Study', 'source': 'Hemophilia News Today', 'date': 'Apr 21, 2017', 'snippet': ""Nuwiq — Octapharma's human cell line recombinant FVIII — is a U.S. Food and \nDrug Administration (FDA)-approved intravenous therapy for patients..."", 'thumbnail': 'https://serpapi.com/searches/672219411397bae53c6c0dab/images/70c09fd7ca7db423e072b71140db2a32f42583e95052fb146e6835e928a1f588.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.511082649230957}",,,,,,,,,,['neutral'],neutral,1
NCT01344993,"{'position': 1, 'link': 'https://www.nature.com/articles/s41536-019-0081-8', 'title': 'Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells (MA09-hRPE) in macular degeneration', 'source': 'Nature', 'date': 'Aug 27, 2019', 'snippet': 'This review focuses on the first generation of hESC-RPE cell line, named as \n“MA09-hRPE” by Astellas Institute of Regenerative Medicine (AIRM), and \nits...', 'thumbnail': 'https://serpapi.com/searches/672219421fc7c5ec485c8c01/images/f4f883df2c2454c38890e3455ec049fc7107f9ff74303efd199daf2cf61ddc94.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9050300717353821}",,,,,,,,,,['neutral'],neutral,1
NCT04200911,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/cns.14463', 'title': ""mTOR signaling and Alzheimer's disease: What we know and where we are?"", 'source': 'Wiley Online Library', 'date': 'Sep 18, 2023', 'snippet': ""Despite the great body of research done on Alzheimer's disease, the \nunderlying mechanisms have not been vividly investigated."", 'thumbnail': 'https://serpapi.com/searches/6722194c6f9f6391e0987f43/images/8acaacbb0403d5d57f9a6cf6527eced775677a1fc78badd8a596312b8f2f5bb3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6370075345039368}",,,,,,,,,,['neutral'],neutral,1
NCT01282268,"{'position': 1, 'link': 'https://fragilexnewstoday.com/news/arbaclofen-improved-behavior-half-fragile-x-children-trial/', 'title': 'Arbaclofen Improved Behavior of Almost Half of Children in Phase 3 Trial', 'source': 'Fragile X News Today', 'date': 'Aug 19, 2022', 'snippet': 'The investigational fragile X therapy Arbaclofen improved aspects of \nbehavior in about half of children, ages 5 to 11, in a Phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/672219a3d997ab920de24c2c/images/70a52f6441bf094d322954a899e8d8ea7146c6d43b4d375da30fa577839d1103.png', 'sentiment': 'positive', 'sentiment_prob': 0.5654360055923462}",,,,,,,,,,['positive'],positive,1
NCT01989793,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/agm2.12168', 'title': 'Advances in research on pharmacotherapy of sarcopenia - Feike - 2021 - AGING MEDICINE', 'source': 'Wiley Online Library', 'date': 'Aug 9, 2021', 'snippet': 'Sarcopenia is a comprehensive degenerative disease with the progressive \nloss of skeletal muscle mass with age, accompanied by the loss of...', 'thumbnail': 'https://serpapi.com/searches/67221af22fab6260e6d28f26/images/f16c7724502bb84f02c01d15086a5b534d8834534db55ca903a3be0127fdd540.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8888530731201172}",,,,,,,,,,['neutral'],neutral,1
NCT04283461,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2022483', 'title': 'An mRNA Vaccine against SARS-CoV-2 — Preliminary Report', 'source': 'The New England Journal of Medicine', 'date': 'Jul 14, 2020', 'snippet': 'The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all \nparticipants, and no trial-limiting safety concerns were identified.', 'thumbnail': 'https://serpapi.com/searches/67221a325c7cb930cf00d3c6/images/8f9d7dbb5c98ee4b9c4305914703b097c8d66f47e1119149584618ec079742ac.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8116927742958069}","{'position': 2, 'link': 'https://www.nih.gov/news-events/news-releases/nih-clinical-trial-evaluating-moderna-covid-19-variant-vaccine-begins', 'title': 'NIH clinical trial evaluating Moderna COVID-19 variant vaccine begins', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Mar 31, 2021', 'snippet': 'This trial is enrolling adult volunteers in the Atlanta, Cincinnati, \nNashville and Seattle areas. At this time, the research sites...', 'thumbnail': 'https://serpapi.com/searches/67221a325c7cb930cf00d3c6/images/8f9d7dbb5c98ee4b27fcf9e02336d8eb3878dae6eb72456179e0311925cf33f7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9455243349075317}","{'position': 3, 'link': 'https://www.nature.com/articles/s41586-020-2798-3', 'title': 'SARS-CoV-2 vaccines in development', 'source': 'Nature', 'date': 'Sep 23, 2020', 'snippet': 'A phase I trial started in March 2020 and there are currently more than 180 \nvaccines at various stages of development.', 'thumbnail': 'https://serpapi.com/searches/67221a325c7cb930cf00d3c6/images/8f9d7dbb5c98ee4be431d29775b2d541d557864f9e1f84373a54200dc4a5d4f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8990486264228821}","{'position': 4, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2028436', 'title': 'Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults', 'source': 'The New England Journal of Medicine', 'date': 'Sep 29, 2020', 'snippet': 'Testing of vaccine candidates to prevent infection with severe acute \nrespiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population...', 'thumbnail': 'https://serpapi.com/searches/67221a325c7cb930cf00d3c6/images/8f9d7dbb5c98ee4bf303370ee29c4fe6319cb12491bc428d3a460d153cad85d5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8452080488204956}","{'position': 5, 'link': 'https://www.nature.com/articles/s41591-021-01527-y', 'title': 'Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis', 'source': 'Nature', 'date': 'Sep 15, 2021', 'snippet': 'The emergence of SARS-CoV-2 variants of concern (VOCs) and variants of \ninterest (VOIs) with decreased susceptibility to neutralization has...', 'thumbnail': 'https://serpapi.com/searches/67221a325c7cb930cf00d3c6/images/8f9d7dbb5c98ee4be77211bb5f8029235e2e48443c3f61fd72e65ef96bb976b5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8676652908325195}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03754660,"{'position': 1, 'link': 'https://pulmonaryhypertensionnews.com/news/mosliciguat-early-efficacy-results-support-launch-phase-2-study/', 'title': 'Mosliciguat’s early efficacy results support launch of Phase 2 study', 'source': 'Pulmonary Hypertension News', 'date': '1 month ago', 'snippet': 'Mosliciguat, an inhaled once-daily PH medication, can reduce the resistance \nagainst blood flow in lung blood vessels, a Phase 1 trial shows.', 'thumbnail': 'https://serpapi.com/searches/67221aa80f2a2cf3975a6eaf/images/e17174aa3ab3c28214f9fa661e7a70c632c425b6ed4931eb93478f7f777c0b3f.png', 'sentiment': 'positive', 'sentiment_prob': 0.7571675181388855}",,,,,,,,,,['positive'],positive,1
NCT04668274,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/parkinsons-mice-see-coordination-strength-gains-with-resveratrol/', 'title': ""Parkinson's mice see coordination, strength gains with resveratrol..."", 'source': ""Parkinson's News Today"", 'date': 'Feb 28, 2023', 'snippet': ""Jotrol, Jupiter Neuroscience's oral formulation of resveratrol, \nsignificantly improved muscle strength, motor coordination, and behavior in \na mouse model of..."", 'thumbnail': 'https://serpapi.com/searches/67221abc8d0417beb1920ea4/images/9fe131ec49d01a9ddc36af0b29dba527cdad19c4a0c17e06028cb3ba1a6110bc.png', 'sentiment': 'positive', 'sentiment_prob': 0.6498141288757324}",,,,,,,,,,['positive'],positive,1
NCT01176669,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-022-00462-6', 'title': 'Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial', 'source': 'Nature', 'date': 'Sep 20, 2022', 'snippet': 'While therapies such as chemotherapy combined with immunotherapy, \nsacituzumab govitecan, and PARP inhibitors are available for metastatic...', 'thumbnail': 'https://serpapi.com/searches/67221b9858e4339464dd2b50/images/ed2036b44784450298d346a275c7d8271e643c3cc30ff872500aaa72781257fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7451679110527039}",,,,,,,,,,['neutral'],neutral,1
NCT02803749,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/anti-anxiety-buspirone-prevents-development-parkinsons-like-disease-mice/', 'title': ""Parkinson's-like Disease in Mice Eased by Use of Buspirone for Anxiety"", 'source': ""Parkinson's News Today"", 'date': 'Feb 10, 2022', 'snippet': ""Buspirone at higher doses given mice in a Parkinson's model worked to \nprevent inflammation and protect neurons; study in patients was mixed."", 'thumbnail': 'https://serpapi.com/searches/67221b9923a4b546c71668a0/images/2c03c10411cd6ea0619b5174b4273f30576a2b6c86a802202c669f1b21efcb3e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7779766321182251}",,,,,,,,,,['neutral'],neutral,1
NCT01469832,"{'position': 1, 'link': 'https://www.nature.com/articles/s41536-019-0081-8', 'title': 'Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells (MA09-hRPE) in macular degeneration', 'source': 'Nature', 'date': 'Aug 27, 2019', 'snippet': 'This review focuses on the first generation of hESC-RPE cell line, named as \n“MA09-hRPE” by Astellas Institute of Regenerative Medicine (AIRM), and \nits...', 'thumbnail': 'https://serpapi.com/searches/67221b9d7ac73169c8713d01/images/eb113a85f0aa4f9e4805cca4bbad6bdfeb88c432d014bbd20174de2e387081ce.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9050300717353821}",,,,,,,,,,['neutral'],neutral,1
NCT01729598,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2019/9678098', 'title': 'Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells - Soria-Castro - 2019 - Journal of Immunology Research', 'source': 'Wiley Online Library', 'date': 'Mar 14, 2019', 'snippet': 'In this review, we discuss the effects of VPA in the suppression of some \nactivation mechanisms in several immune cells that lead to an \nanti-inflammatory...', 'thumbnail': 'https://serpapi.com/searches/67221b9e3d629b09b8630f85/images/4c46d514a504d56a4294bd2ce3236577d231ac96bc2c76448124fe7a3f33bcbe.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9232328534126282}",,,,,,,,,,['neutral'],neutral,1
NCT03206970,"{'position': 1, 'link': 'https://www.onclive.com/view/indirect-comparison-of-efficacy-of-zanubrutinib-versus-acalabrutinib-in-the-treatment-of-patients-with-relapsed-or-refractory-mantle-cell-lymphoma', 'title': 'Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma', 'source': 'OncLive', 'date': 'Jul 5, 2024', 'snippet': 'The study assessed the comparative efficacy of zanubrutinib vs \nacalabrutinib in patients with R/R MCL, in the absence of head-to-head \nclinical trials.', 'thumbnail': 'https://serpapi.com/searches/67221bc566d99584933556a5/images/3f5eec8366ed93739a4255dfeae6c32ad922aa6929fcf2701b06b1f42a64a8d7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.884205162525177}",,,,,,,,,,['neutral'],neutral,1
NCT03732807,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/pde.15378', 'title': 'Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial', 'source': 'Wiley Online Library', 'date': 'Jul 17, 2023', 'snippet': 'Background/Objectives This subgroup analysis of the ALLEGRO phase 2b/3 \ntrial (NCT03732807) evaluated the efficacy and safety of ritlecitinib...', 'thumbnail': 'https://serpapi.com/searches/67221bcad364b4c6b6b13245/images/ea3488fa2c2881136324e3021cb4c8ded927ad15b29427f402bafd0ac59d93a3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8307723999023438}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17442?af=R', 'title': 'Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis', 'source': 'Wiley Online Library', 'date': '1 month ago', 'snippet': 'This post-hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) \nevaluated the efficacy and safety of ritlecitinib, an oral Janus kinase...', 'thumbnail': 'https://serpapi.com/searches/67221bcad364b4c6b6b13245/images/ea3488fa2c288113e7140ecf3bb49a821281749b7d30aff05d9afa20f7fdb438.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8761537671089172}","{'position': 3, 'link': 'https://www.empr.com/home/news/litfulo-approved-for-severe-alopecia-areata-in-adults-adolescents/', 'title': 'Litfulo Approved for Severe Alopecia Areata in Adults, Adolescents', 'source': 'Medical Professionals Reference', 'date': 'Jun 26, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Litfulo™ (ritlecitinib) \nfor the treatment of severe alopecia areata in adults and...', 'thumbnail': 'https://serpapi.com/searches/67221bcad364b4c6b6b13245/images/ea3488fa2c28811301fee5547833f43d7469bedde0bb4d1659893b39fa8c2db3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6619455218315125}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03744026,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-45818-7', 'title': 'Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial', 'source': 'Nature', 'date': 'Feb 23, 2024', 'snippet': 'Here, the results of a phase 1/2 single-arm trial (NCT03744026) assessing \nthe safety and efficacy of blood-brain barrier (BBB) disruption...', 'thumbnail': 'https://serpapi.com/searches/67221c0ace1e108230a3a1a8/images/475d8fd85d0d3140d0432d568b56b66d1b1befbd4b0ea1563a15129ba38dfb84.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8951340317726135}",,,,,,,,,,['neutral'],neutral,1
NCT00571649,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1111096', 'title': 'Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients', 'source': 'The New England Journal of Medicine', 'date': 'Feb 7, 2013', 'snippet': 'The clinically appropriate duration of thromboprophylaxis in hospitalized \npatients with acute medical illnesses is unknown.', 'thumbnail': 'https://serpapi.com/searches/67221c0d7b05caf7f588fe1b/images/2e56f9a6b0e8552b3a4cef5be60487fffaaa67d6271c6b7a7c3f43b3067708db.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7606247663497925}",,,,,,,,,,['neutral'],neutral,1
NCT04950920,"{'position': 1, 'link': 'https://en.prnasia.com/releases/apac/findings-of-a-phase-iii-clinical-study-of-sanbexin-sublingual-tablets-published-in-jama-437157.shtml', 'title': 'Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA', 'source': 'PR Newswire Asia', 'date': 'Feb 21, 2024', 'snippet': 'NANJING, China, Feb. 21, 2024 /PRNewswire/ -- On February 19, 2024, the \nJournal of American Medical Association•Neurology (JAMA NEUROLOGY,...', 'thumbnail': 'https://serpapi.com/searches/67221c1fd364b4c6b6b132a4/images/d2b752b919e956e52bd5d692d1e8f143bc13fe4e2f156131e429e018742404f1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9447066783905029}",,,,,,,,,,['neutral'],neutral,1
NCT00450372,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/abs/pii/S0960852419310193', 'title': 'Multilevel algorithms and evolutionary hybrid tools for enhanced production of arginine deiminase from Pseudomonas furukawaii RS3', 'source': 'ScienceDirect.com', 'date': 'Feb 23, 2020', 'snippet': 'In the present study a high arginine deiminase (ADI) yielding bacterium was \nisolated from soil samples of Haryana, India and identified as \nPseudomonas...', 'thumbnail': 'https://serpapi.com/searches/67221c2724296a3c4a74dea3/images/9250fbdfdc3e2b9d86f04615a79a039aaf3f4ab2656253c7b2bdae6fcca54da9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8925591111183167}",,,,,,,,,,['neutral'],neutral,1
NCT00704158,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-021-00244-6', 'title': 'Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study | npj Breast Cancer', 'source': 'Nature', 'date': 'May 20, 2021', 'snippet': 'The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, \nglembatumumab vedotin (GV), targeting gpNMB that is overexpressed...', 'thumbnail': 'https://serpapi.com/searches/67221c331b4e34fddd9535e6/images/89a434c09388307a085db59f57de41c0960de88538eedafe80f4664e41e98637.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8773122429847717}",,,,,,,,,,['neutral'],neutral,1
NCT03574363,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.17073', 'title': 'Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study', 'source': 'American Heart Association Journals', 'date': 'May 10, 2021', 'snippet': 'In patients with resistant or poorly controlled hypertension and advanced \nchronic kidney disease, mineralocorticoid receptor antagonists are...', 'thumbnail': 'https://serpapi.com/searches/67221c3924296a3c4a74debd/images/51a615809cea4e1f9a3e532c85e679e3cafbd6e75ecc8f2dd69b2f93fca83d6a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8651843070983887}",,,,,,,,,,['neutral'],neutral,1
NCT03569631,"{'position': 1, 'link': 'https://fragilexnewstoday.com/news/zatolmilast-earns-rare-pediatric-disease-designation-fragile-x/', 'title': 'Zatolmilast earns FDA’s rare pediatric disease designation', 'source': 'Fragile X News Today', 'date': 'Oct 6, 2023', 'snippet': ""The US Food and Drug Administration (FDA) has granted rare pediatric \ndisease (RPD) designation to zatolmilast, Tetra Therapeutics' \ninvestigational oral therapy..."", 'thumbnail': 'https://serpapi.com/searches/67221c4f657c66a83b6685b8/images/29ed462d2c718edee53a6fcd237bb6391e9e4e7890b84c882638079dc63e1bf6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7040296196937561}","{'position': 2, 'link': 'https://fragilexnewstoday.com/news/combination-therapy-gaboxadol-ibudilast-effective-fragile-x-mouse-model/', 'title': 'Combination therapy gaboxadol, ibudilast effective in fragile X mouse model', 'source': 'Fragile X News Today', 'date': 'Mar 1, 2024', 'snippet': 'A combination of ibudilast and gaboxadol was shown to normalize behavior \nand improve memory in a mouse model of fragile X syndrome.', 'thumbnail': 'https://serpapi.com/searches/67221c4f657c66a83b6685b8/images/29ed462d2c718ede44a405cfeb690b6e717e64cd8a4ab116061183a0003582dd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5454389452934265}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03500549,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2029073', 'title': 'Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria', 'source': 'The New England Journal of Medicine', 'date': 'Mar 17, 2021', 'snippet': 'Pegcetacoplan was superior to eculizumab in improving hemoglobin and \nclinical and hematologic outcomes in patients with PNH by providing broad \nhemolysis...', 'thumbnail': 'https://serpapi.com/searches/67221cea03775620cb8f03fd/images/e83f49a66a2095626f1a8ff1f16e1e707101ab12b6a5aaa6a0f0d96f5a43dd80.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6311147212982178}","{'position': 2, 'link': 'https://www.empr.com/home/news/empaveli-approved-for-paroxysmal-nocturnal-hemoglobinuria/', 'title': 'Empaveli Approved for Paroxysmal Nocturnal Hemoglobinuria', 'source': 'Medical Professionals Reference', 'date': 'May 17, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Empaveli™ \n(pegcetacoplan) for the treatment of adults with paroxysmal nocturnal...', 'thumbnail': 'https://serpapi.com/searches/67221cea03775620cb8f03fd/images/e83f49a66a20956223e8817c957825a55721d18234f970a2eb3c2f988b4af2a6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8320205807685852}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03470805,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-022-02108-7', 'title': 'INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12', 'source': 'Nature', 'date': 'Feb 9, 2023', 'snippet': 'Article; Open access; Published: 09 February 2023. Clinical Studies. \nINOVATYON/ ENGOT-ov5 study: Randomized phase III international study \ncomparing...', 'thumbnail': 'https://serpapi.com/searches/67221cfe0664c94c186c6858/images/e44bdbdd6bcf377179c307845b07c978c633c79660e69a91c9e5fcd2638c5d9e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8876173496246338}",,,,,,,,,,['neutral'],neutral,1
NCT02302157,"{'position': 1, 'link': 'https://www.cgtlive.com/view/richard-fessler-opc1-improving-quality-of-life-sci', 'title': 'Richard Fessler, MD, on OPC1 Improving Quality of Life With Spinal Cord Injury', 'source': 'CGTLive®', 'date': 'Aug 18, 2023', 'snippet': 'The professor of neurosurgery at Rush University Medical School discussed \nfollow-up in the phase 1/2 trial of LCTOPC1 and further research...', 'thumbnail': 'https://serpapi.com/searches/67221d414a4a1d50b27323de/images/12df456cde0fa05b3e4915b6547f5305bca446b1e1beb8dbb6412fdfa1ab20b9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8754870891571045}","{'position': 2, 'link': 'https://www.cgtlive.com/view/fessler-progress-cell-therapy-spinal-cord-injury', 'title': 'Richard Fessler, MD, on Progress With Cell Therapy in Spinal Cord Injury', 'source': 'CGTLive®', 'date': 'Aug 3, 2022', 'snippet': ""The professor of neurosurgery at Rush University Medical School discussed \nthe potential of Lineage Cell's LCTOPC1 cell therapy."", 'thumbnail': 'https://serpapi.com/searches/67221d414a4a1d50b27323de/images/12df456cde0fa05b0da099e279a5946137948a06fe2980e2708fd26f575ebd8c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8978031277656555}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03123939,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-023-02042-4', 'title': 'Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia', 'source': 'Nature', 'date': 'Oct 25, 2023', 'snippet': 'In the absence of randomized controlled trials comparing tisagenlecleucel \nvs. standard of care (SOC) in pediatric and young adult patients...', 'thumbnail': 'https://serpapi.com/searches/67221d9ef3cbfaeeb68d4bbf/images/a51427ac497510691324be6d41fee34b979285c2e464eb949520408933271766.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8176721334457397}",,,,,,,,,,['neutral'],neutral,1
NCT00869206,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/zoledronic-acid-every-12-weeks-noninferior-in-bone-metastases-due-to-multiple-myeloma-study-finds/', 'title': 'Treatment of Multiple Myeloma with Bone Metastasis Focus of Study', 'source': 'Myeloma Research News', 'date': 'Jan 23, 2017', 'snippet': 'Patients with bone metastasis due to multiple myeloma, breast or prostate \ncancer, who received zoledronic acid every 12 weeks for two years, did not \nhave...', 'thumbnail': 'https://serpapi.com/searches/67221db4d0253ebcf855bf73/images/80614b7b8841fc0414502dd515b34206bab08df86f0e98acbee94b1476150a14.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7700662612915039}",,,,,,,,,,['neutral'],neutral,1
NCT03363945,"{'position': 1, 'link': 'https://www.cgtlive.com/view/medeor-cell-therapy-mdr-101-allows-patients-taper-immunosuppression-following-kidney-transplant', 'title': 'Medeor’s Cell Therapy MDR-101 Allows Patients to Taper off Immunosuppression Following Kidney Transplant', 'source': 'CGTLive®', 'date': 'Nov 10, 2023', 'snippet': 'Among 20 patients who received MDR-101, 12 have completed participation in \nthe trial and have not taken their immunosuppression therapy for...', 'thumbnail': 'https://serpapi.com/searches/67221dd1bbc18bbcc5cb0920/images/2de7ea5a9d45a8bfd97dcc315942ee1192196d3feb8243611c3dfc6931dd4974.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9105952382087708}","{'position': 2, 'link': 'https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-023-07204-4', 'title': 'Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE', 'source': 'BioMed Central', 'date': 'Mar 11, 2023', 'snippet': 'This extension study will be an important step in evaluating safety issues \npertaining to immune tolerance regimens, long-term effects of which are \nlargely...', 'thumbnail': 'https://serpapi.com/searches/67221dd1bbc18bbcc5cb0920/images/2de7ea5a9d45a8bf0fe6240be225d48c127403361c25b5e2ddf1665a8838f891.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.863823413848877}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03884842,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/resp.14197', 'title': 'Respirology | APSR Respiratory Medicine Journal', 'source': 'Wiley Online Library', 'date': 'Jan 10, 2022', 'snippet': 'Pulmonary functional MRI (PfMRI) using inhaled hyperpolarized, \nradiation-free gases (such as 3He and 129Xe) provides a way to directly...', 'thumbnail': 'https://serpapi.com/searches/67221df85bb6a2879cc74b59/images/f9eda71cf34dab51954f9dd81afb66f5268aefab7e6f48d2cda1de8c2453fe93.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9038953185081482}",,,,,,,,,,['neutral'],neutral,1
NCT01729754,"{'position': 1, 'link': 'https://www.dermatologyadvisor.com/reports/aad-2023-biologic-treatment-for-psoriasis/', 'title': 'AAD 2023 Focus on Psoriasis: Biologics Take Center Stage', 'source': 'Dermatology Advisor', 'date': 'Mar 29, 2023', 'snippet': 'Several research studies on the use of biologics in psoriasis were \npresented, highlighting the efficacy and safety of these agents in patients \nwith the...', 'thumbnail': 'https://serpapi.com/searches/67221e5a6aa36434b415051a/images/87ebc974208f4acdce6e64606e2a6afd0377301b19c94518765944d207d21aad.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7309268116950989}","{'position': 2, 'link': 'https://www.dermatologyadvisor.com/cch/il-23-antagonists-in-the-treatment-of-plaque-psoriasis/', 'title': 'IL-23 Antagonists in the Treatment of Plaque Psoriasis', 'source': 'Dermatology Advisor', 'date': 'May 17, 2024', 'snippet': 'Three selective IL-23 inhibitors are currently approved for the treatment \nof plaque psoriasis: guselkumab, risankizumab, and tildrakizumab.', 'thumbnail': 'https://serpapi.com/searches/67221e5a6aa36434b415051a/images/87ebc974208f4acd81a402525f1dfde2419bd6609d09fb710f41b2a63dd95fdd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.890917956829071}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02316457,"{'position': 1, 'link': 'https://www.nature.com/articles/s41586-023-06063-y', 'title': 'Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer', 'source': 'Nature', 'date': 'May 10, 2023', 'snippet': 'Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients1, yet \nharbours mutation-derived T cell neoantigens that are suitable...', 'thumbnail': 'https://serpapi.com/searches/67221e68d169156d464fa211/images/b59a846cf5290cb29286da8ae4ae2f8e3a738bc9b1e051e45f143649ebd83e84.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7204856276512146}","{'position': 2, 'link': 'https://www.nature.com/articles/s41392-022-01270-x', 'title': 'Neoantigens: promising targets for cancer therapy | Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': 'Jan 6, 2023', 'snippet': 'Recent advances in neoantigen research have accelerated the development and \nregulatory approval of tumor immunotherapies, including cancer...', 'thumbnail': 'https://serpapi.com/searches/67221e68d169156d464fa211/images/b59a846cf5290cb27fae4a0404f99ba2bc210918924853aefb254f87ed96eb27.png', 'sentiment': 'positive', 'sentiment_prob': 0.5982586741447449}",,,,,,,,,"['negative', 'positive']",negative,0
NCT03277105,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/fda-approves-darzalex-faspro-injection-therapy-for-multiple-myeloma/', 'title': 'FDA Approves Darzalex Faspro as Injection Therapy for Multiple Myeloma', 'source': 'Myeloma Research News', 'date': 'May 5, 2020', 'snippet': ""The U.S. Food and Drug Administration (FDA) approved Janssen's new \nformulation of daratumumab — a subcutaneous or under-the-skin injection..."", 'thumbnail': 'https://serpapi.com/searches/67221eb10be2f68746bb5490/images/bff53f29f120cdd7b670dedf63243bfd497b70e00aa5b3212f1321f4db60035e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6539252400398254}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/under-the-skin-form-as-effective-as-intravenous-darzalex-myeloma/', 'title': 'Under-the-skin Formulation as Effective as Intravenous Darzalex for Myeloma Patients, Study Says', 'source': 'Myeloma Research News', 'date': 'Mar 11, 2019', 'snippet': 'An under-the-skin injection of daratumumab is as effective as its \nintravenous formulation at reducing tumor burden in multiple myeloma,...', 'thumbnail': 'https://serpapi.com/searches/67221eb10be2f68746bb5490/images/bff53f29f120cdd719483044e988aff3619d9a75bb4bb7a1650ab609813cb400.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7194610834121704}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03737110,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2027892', 'title': 'Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis', 'source': 'The New England Journal of Medicine', 'date': 'Nov 16, 2020', 'snippet': 'Rilonacept led to rapid resolution of recurrent pericarditis episodes and \nto a significantly lower risk of pericarditis recurrence than placebo.', 'thumbnail': 'https://serpapi.com/searches/67221ede9819f38857e12662/images/ce3cf114779e330ff81f4255d020c86196f12c48287d2d68a1331d621f4acd3a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7393704652786255}",,,,,,,,,,['neutral'],neutral,1
NCT00770874,"{'position': 1, 'link': 'https://cervicalcancernews.com/2017/06/09/phase-3-trial-shows-cervical-cancer-responds-to-combination-of-s-1-and-platinol/', 'title': 'Cervical Cancer Responds to Combination of S-1 and Platinol, Phase 3 Trial Shows', 'source': 'Cervical cancer News', 'date': 'Jun 9, 2017', 'snippet': 'Read about a Phase 3 clinical trial showing that cervical cancer responded \nto a combination of S-1 and Platinol chemotherapy.', 'thumbnail': 'https://serpapi.com/searches/67221ef1cf32e0c291d2512d/images/a4caaf846e2f08d351b07423bded3ccde4b50cb9d9c8ec81145c4a9086adb324.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9084898233413696}",,,,,,,,,,['neutral'],neutral,1
NCT05142774,"{'position': 1, 'link': 'https://www.contemporarypediatrics.com/view/dermavant-submits-snda-tapinarof-cream-treat-ad-2-years-and-up', 'title': 'Dermavant submits sNDA for tapinarof cream, 1% to treat AD in patients 2 years and up', 'source': 'Contemporary Pediatrics', 'date': 'Feb 14, 2024', 'snippet': 'Tapinarof cream, 1% (VTAMA; Dermavant Sciences) to treat atopic dermatitis \n(AD) in adult and children 2 years and older has taken another step forward \nin the...', 'thumbnail': 'https://serpapi.com/searches/67221f063b3c320a68572d50/images/e6f726cbbc1bb31c75a3da0675b9d4d50f6aad0476f08415b28b2304fb158d54.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6871433258056641}",,,,,,,,,,['neutral'],neutral,1
NCT04864834,"{'position': 1, 'link': 'https://www.europeanpharmaceuticalreview.com/news/185771/sandoz-to-file-for-approval-of-aflibercept-biosimilar/', 'title': 'Sandoz to file for approval of aflibercept biosimilar', 'source': 'European Pharmaceutical Review', 'date': 'Aug 16, 2023', 'snippet': 'Sandoz intends to seek regulatory approval for its aflibercept biosimilar \nin the US and EU, following positive results for a Phase III...', 'thumbnail': 'https://serpapi.com/searches/67221f7af8b05d603f25a808/images/1aa51cfa061df9816308033fe7cf3f8d8823c545280fe0a05086918b861a4619.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6097245812416077}",,,,,,,,,,['neutral'],neutral,1
NCT02278250,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-023-02436-2', 'title': 'A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours | British Journal of Cancer', 'source': 'Nature', 'date': 'Jan 29, 2024', 'snippet': 'Gartisertib is an oral inhibitor of ataxia telangiectasia and Rad3-related \nprotein (ATR), a key kinase of the DNA damage response.', 'thumbnail': 'https://serpapi.com/searches/67221f7cbb55ff271c7d4d9f/images/3423c7a90b022519173c2afa4723d9295221ddc5a7782d2c7a90371c262c1931.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9014711976051331}","{'position': 2, 'link': 'https://medicalxpress.com/news/2024-01-atr-inhibition-gartisertib-patient-derived.html', 'title': 'ATR inhibition using gartisertib in patient-derived glioblastoma cell lines', 'source': 'Medical Xpress', 'date': 'Jan 17, 2024', 'snippet': 'A new research paper titled ""ATR inhibition using gartisertib enhances cell \ndeath and synergises with temozolomide and radiation in...', 'thumbnail': 'https://serpapi.com/searches/67221f7cbb55ff271c7d4d9f/images/3423c7a90b022519fc8906c939d14d7bb0c37c9c6cd5c779ee14d718fc1d5b3b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9163128733634949}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01741194,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/accera-blames-alzheimers-disease-clinical-trial-failure-on-low-drug-uptake/', 'title': ""Alzheimer's Trial for AC-1204 Fails; Accera Blames Results on Low Uptake"", 'source': ""Alzheimer's News Today"", 'date': 'Mar 3, 2017', 'snippet': ""Yet another Alzheimer's disease clinical trial (NCT01741194) has ended in \ndisappointment. Accera, noting that its Phase 3 trial of AC-1204..."", 'thumbnail': 'https://serpapi.com/searches/67221f7fb5ecbb5708925a2a/images/8b49d27476da5f7a373a388ac26ee03ba6ff892e3b3b16885d110b6af0d1454c.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7464489340782166}",,,,,,,,,,['negative'],negative,0
NCT04901416,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/coeptis-therapeutics-completes-exclusive-license-for-allogeneic-immuno-oncology-platform-and-clinical-stage-assets-from-deverra-therapeutics-301903022.html', 'title': 'Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics', 'source': 'PR Newswire', 'date': 'Aug 17, 2023', 'snippet': 'Coeptis acquires exclusive rights to two Investigational New Drug (IND) \napplications and two assets in the Phase 1 clinical trial stage.', 'thumbnail': 'https://serpapi.com/searches/67221f857b05caf7f58900d4/images/f9f2d841334fae7e1059429ebf06c728bbfe8435eff920a2e59826f39c16b6de.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8665703535079956}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/coeptis-therapeutics-provides-safety-and-dosing-update-from-phase-1-trials-investigating-dvx201-in-relapsedrefractory-aml-or-high-risk-mds-and-hospitalized-covid-19-infection-301927462.html', 'title': 'Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection', 'source': 'PR Newswire', 'date': 'Sep 14, 2023', 'snippet': 'DVX201, a first-ever allogeneic, cord-blood derived, natural killer (NK) \ncell therapy, has been administered to 16 patients with no dose limiting \ntoxicities.', 'thumbnail': 'https://serpapi.com/searches/67221f857b05caf7f58900d4/images/f9f2d841334fae7ec0e85395f09d1dde1f1bc6a80792564e2dfb9a4eb3d52191.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8037376999855042}","{'position': 3, 'link': 'https://www.prnewswire.com/news-releases/coeptis-therapeutics-signs-agreement-to-acquire-allogeneic-immuno-oncology-nk-platform-in-phase-1-clinical-trials-from-deverra-therapeutics-301799765.html', 'title': 'Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics', 'source': 'PR Newswire', 'date': 'Apr 18, 2023', 'snippet': 'Proposed transaction would provide Coeptis with two clinical stage assets \nleveraging NK cell therapies in relapsed or refractory acute myeloid \nleukemia (AML)', 'thumbnail': 'https://serpapi.com/searches/67221f857b05caf7f58900d4/images/f9f2d841334fae7ec3a5acf713af2576acdea610b4c8aa24bf1e971c1b0de4b3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8679749965667725}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT05538572,"{'position': 1, 'link': 'https://dailynews.ascopubs.org/do/considering-adjuvant-cdk4-6-inhibitors-monarche-and-natalee-clinical-practice', 'title': 'Considering Adjuvant CDK4/6 Inhibitors?: monarchE and NATALEE in Clinical Practice', 'source': 'ASCO Daily News', 'date': 'Aug 17, 2023', 'snippet': 'Key Points: The NATALEE and monarchE studies looked at adjuvant CDK4/6 \ninhibitors ribociclib and abemaciclib, respectively, as options for...', 'thumbnail': 'https://serpapi.com/searches/6722205b707fd32ced3b4b00/images/bdc113de90469aaafcc5f9b30483a66f39cbc0500381dd2efc48f5849c4f3183.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9415512681007385}",,,,,,,,,,['neutral'],neutral,1
NCT04305470,"{'position': 1, 'link': 'https://www.globenewswire.com/en/news-release/2021/01/12/2157307/0/en/NX-Development-Corp-NXDC-Receives-FDA-Orphan-Drug-Designation-for-Gleolan-aminolevulinic-acid-HCl-in-Meningioma.html', 'title': 'NX Development Corp. (NXDC) Receives FDA Orphan-Drug', 'source': 'GlobeNewswire', 'date': 'Jan 12, 2021', 'snippet': 'Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. \n(NXDC), a life sciences company wholly owned by photonamic GmbH & Co.', 'thumbnail': 'https://serpapi.com/searches/67222065fbde0d6899411c25/images/34e68d14d5612ac58a8a30fad048e273ef2bb857d905527e5951ead3f869070a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7542619705200195}",,,,,,,,,,['neutral'],neutral,1
NCT04984993,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-clears-otc-topical-gel-for-treatment-of-erectile-dysfunction/', 'title': 'FDA Clears OTC Topical Gel for Treatment of Erectile Dysfunction', 'source': 'Medical Professionals Reference', 'date': 'Jun 14, 2023', 'snippet': 'The Food and Drug Administration (FDA) has granted marketing authorization \nto Futura Medical for the over-the-counter (OTC) sale of MED3000, a \ntopical...', 'thumbnail': 'https://serpapi.com/searches/672220730053c753569c215c/images/b00112eeb4023762fde328c02f8dcd414babf7e87615225347ab78804287cfbf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.912825882434845}",,,,,,,,,,['neutral'],neutral,1
NCT03124433,"{'position': 1, 'link': 'https://www.nature.com/articles/s41391-022-00496-8', 'title': 'NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer', 'source': 'Nature', 'date': 'Jan 28, 2022', 'snippet': 'Treatment efficacy of androgen deprivation therapy with radical \nprostatectomy for intermediate- to high-risk prostate cancer is less...', 'thumbnail': 'https://serpapi.com/searches/67222095b4b72dc1309f1921/images/1e5e5ed1b2f99cf0f773a1e3e2aeda05a3cf7cfa9bea8dd28f0ecb20a67b0cf2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8785178661346436}",,,,,,,,,,['neutral'],neutral,1
NCT02527200,"{'position': 1, 'link': 'https://praderwillinews.com/news/liraglutide-controls-hunger-pws-youth-no-impact-weight-trial/', 'title': 'Liraglutide Controls Hunger in PWS Youth; No Impact on Weight: Trial', 'source': 'Prader-Willi Syndrome News', 'date': 'Dec 9, 2022', 'snippet': 'Liraglutide, an appetite-suppressing medication, had no effect on weight \nloss, despite being given with an exercise and diet program.', 'thumbnail': 'https://serpapi.com/searches/672220ddd0c9832b61550788/images/ef4d3a0a088bcaa3aa6649a5e76f7be88c731ef067ace1ec9488e39d24c65578.png', 'sentiment': 'negative', 'sentiment_prob': 0.543334424495697}",,,,,,,,,,['negative'],negative,0
NCT02097810,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.20.03025', 'title': 'Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer', 'source': 'ASCO Publications', 'date': 'Mar 1, 2021', 'snippet': 'Entrectinib continued to demonstrate a high level of clinical benefit for \npatients with ROS1 fusion–positive NSCLC, including patients with CNS \nmetastases.', 'thumbnail': 'https://serpapi.com/searches/672220f4361fd4c8c046acd6/images/9a99f83e4e80ba6f30ac28b5a5ba302f82d40d7b51f3b65e7d41d7431e9428fe.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6408447623252869}","{'position': 2, 'link': 'https://news.cuanschutz.edu/cancer-center/entrectinib-effective-against-ros1-ntrk', 'title': 'Lancet Oncology: Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases', 'source': 'University of Colorado Anschutz Medical Campus', 'date': 'Dec 13, 2019', 'snippet': 'Pooled analysis of three phase 1 and 2 clinical trials published online \nahead of print in the journal Lancet Oncology show that the drug...', 'thumbnail': 'https://serpapi.com/searches/672220f4361fd4c8c046acd6/images/9a99f83e4e80ba6f978c29215ad648d07dfa941b3180531703a7f49d710de3e4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5145595073699951}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT04973228,"{'position': 1, 'link': 'https://www.empr.com/home/news/zoryve-topical-foam-approved-for-seborrheic-dermatitis/', 'title': 'Zoryve Topical Foam Approved for Seborrheic Dermatitis', 'source': 'Medical Professionals Reference', 'date': 'Dec 18, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Zoryve (roflumilast) \ntopical foam, 0.3% for the treatment of seborrheic dermatitis in adult and \npediatric...', 'thumbnail': 'https://serpapi.com/searches/6722211bf60b6f4fdd4db818/images/85d48bd6ff28a4798e4666807ba00770658f18339b7c8a04c6ec4d5e4e109931.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8059292435646057}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/roflumilast-foam-looks-promising-in-seborrheic-dermatitis-trial/', 'title': 'Roflumilast Foam Looks Promising in Seborrheic Dermatitis Trial', 'source': 'Medical Professionals Reference', 'date': 'Jun 6, 2022', 'snippet': 'A phase 3 trial evaluating the efficacy and safety of roflumilast foam for \nthe treatment of patients with moderate to severe seborrheic dermatitis.', 'thumbnail': 'https://serpapi.com/searches/6722211bf60b6f4fdd4db818/images/85d48bd6ff28a479badd361633eb64f87f739d997ce0fb3d0235418a8ceaa8cc.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6775094866752625}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT01189214,"{'position': 1, 'link': 'https://www.nature.com/articles/srep09708', 'title': 'Low-dose add-on memantine treatment may improve cognitive performance and self-reported health conditions in opioid-dependent patients undergoing methadone-maintenance-therapy', 'source': 'Nature', 'date': 'May 19, 2015', 'snippet': 'An important interaction between opioid and dopamine systems has been \nindicated and using opioids may negatively affect cognitive...', 'thumbnail': 'https://serpapi.com/searches/6722214717b10e7c7bb66506/images/10fd2da80629dbf65111a62e6d0a321a1d6c83aa93c6a79aaeb3abb6eda1533f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6647046208381653}",,,,,,,,,,['neutral'],neutral,1
NCT03792308,"{'position': 1, 'link': 'https://www.nature.com/articles/s41429-020-0291-8', 'title': 'Antibiotics in the clinical pipeline in October 2019 - The Journal of Antibiotics', 'source': 'Nature', 'date': 'Mar 10, 2020', 'snippet': 'The development of new and effective antibacterial drugs to treat \nmulti-drug resistant (MDR) bacteria, especially Gram-negative (G−ve)...', 'thumbnail': 'https://serpapi.com/searches/67222150dc969f71fa971cb0/images/c1caeced61bffce8d6b4e6fe40dce1b9e3eddfa047dfb97f94c68b10f6288761.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7636564373970032}",,,,,,,,,,['neutral'],neutral,1
NCT02588833,"{'position': 1, 'link': 'https://www.ajmc.com/view/pegcetacoplan-may-reduce-fatigue-in-pnh-accompanied-by-anemia', 'title': 'Pegcetacoplan May Reduce Fatigue in PNH Accompanied by Anemia', 'source': 'AJMC', 'date': 'Aug 28, 2024', 'snippet': 'Findings from a post hoc analysis of 3 clinical trials support the \nswitching to or initiation of pegcetacoplan to manage fatigue for patients \nwith paroxysmal...', 'thumbnail': 'https://serpapi.com/searches/67222181b28e6b3e2028785a/images/56a0f16c792af251539736c9b7bd68150c13a5a5cb7427f8b0b9f82bc5c68e84.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8557630777359009}",,,,,,,,,,['neutral'],neutral,1
NCT01375699,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.627229/full', 'title': 'New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil', 'source': 'Frontiers', 'date': 'Feb 26, 2021', 'snippet': 'The use of already-approved drugs to treat new or alternative diseases has \nproved to be beneficial in medicine, because it reduces both drug...', 'thumbnail': 'https://serpapi.com/searches/6722219a48e6680f9823ba13/images/1a2d3e2a027ce71d71d6e0fd8aad8e15098daf2e27353fa589401658f4b1a456.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6271712779998779}",,,,,,,,,,['neutral'],neutral,1
NCT05076032,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/oxolifes-infertility-pill-increased-ivf-success-by-over-10-in-phase-ii-trial/', 'title': 'Oxolife’s infertility pill increased IVF success by over 10% in Phase II trial', 'source': 'Clinical Trials Arena', 'date': 'Jul 8, 2024', 'snippet': ""The Phase II results showed that the company's infertility pill improved \npregnancy and live birth rates by 10.6% and 6.9%, respectively."", 'thumbnail': 'https://serpapi.com/searches/6722220ae30abcd386265351/images/7df2c773a624dfd68db9e6f2b92e53317ead6408e41ee70a00090511ddc4f69f.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7687418460845947}",,,,,,,,,,['positive'],positive,1
NCT02653391,"{'position': 1, 'link': 'https://mitochondrialdiseasenews.com/2016/03/14/eye-drop-treatment-fuchs-mitochondria-related-disease-starts-phase-2-testing/', 'title': 'Eye Drop Treatment for Fuchs, a Mitochondria-related Disease, Starts Phase 2 Testing', 'source': 'Mitochondrial Disease News', 'date': 'Mar 14, 2016', 'snippet': ""Read about Stealth BioTherapeutics' start of a Phase 2 clinical trial of \nelamipretide eye drop formulation to treat Fuchs' corneal..."", 'thumbnail': 'https://serpapi.com/searches/672222336273fbfd4ebfe3d4/images/f03820ea3698c91aa536d3d31cd0d7a525574308f56fbfc5751cdc053c1887d3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9226963520050049}",,,,,,,,,,['neutral'],neutral,1
NCT00641537,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/04/11/mavenclad-benefits-ms-sustained-up-15-years-after-last-treatment/', 'title': 'Mavenclad benefits for MS sustained up to 15 years after last treatment', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 11, 2023', 'snippet': 'The benefits of Mavenclad (cladribine) were sustained for up to 15 years \nafter its last treatment course in people with relapsing MS.', 'thumbnail': 'https://serpapi.com/searches/6722225069f8eca1f45752c3/images/da3a91f3178030f3348e8e136261417e51f5a43b38f4f6574507e0cbfa4daabb.png', 'sentiment': 'positive', 'sentiment_prob': 0.6188135743141174}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/2018/07/31/fda-accepts-resubmitted-nda-cladribine-tablets-treatment-relapsing-ms/', 'title': 'FDA to Review EMD Serono’s New Request for Approval of Cladribine for Treating Relapsing MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Jul 31, 2018', 'snippet': ""The FDA accepted for review EMD Serono's resubmitted New Drug Application \n(NDA) for cladribine tablets as a treatment for patients with..."", 'thumbnail': 'https://serpapi.com/searches/6722225069f8eca1f45752c3/images/da3a91f3178030f3c5da8a4c67c3a9bb4daf29226067f38d382c834fc56ceb97.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8431360125541687}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2016/09/19/ectrims-2016-merck-presents-new-data-on-long-term-benefits-cladribine-tablets-in-relapsing-multiple-sclerosis/', 'title': '#ECTRIMS2016 - RMS Therapy, Cladribine, Shows Long-Term Benefit in Studies', 'source': 'Multiple Sclerosis News Today', 'date': 'Sep 19, 2016', 'snippet': 'Merck recently presented new efficacy data from its three Phase 3 clinical \ntrials, showing that a relatively short course of treatment with...', 'thumbnail': 'https://serpapi.com/searches/6722225069f8eca1f45752c3/images/da3a91f3178030f3c5a6cd3d1b5144bf39f7a135d058e609c33d882b1c2722a6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8320334553718567}",,,,,,,,"['positive', 'neutral', 'positive']",positive,1
NCT02203032,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1501646', 'title': 'A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Jul 9, 2015', 'snippet': 'Little is known about the effect of specific anti–interleukin-23 therapy, \nas compared with established anti–tumor necrosis factor therapies,...', 'thumbnail': 'https://serpapi.com/searches/6722225a0f2a2cf3975a75fa/images/5811004c075760bd31221140dbb9b5fffe1a878c9d1236ef10b2396a101cc202.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7835938930511475}","{'position': 2, 'link': 'https://psoriasisnewstoday.com/2017/05/25/janssens-phase-3-trials-on-guselkumab-for-plaque-psoriasis-and-psoriatic-arthritis/', 'title': 'Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis', 'source': 'Psoriasis News Today', 'date': 'May 25, 2017', 'snippet': 'Janssen announced two new Phase 3 clinical trials for psoriasis for its \ninvestigational drug guselkumab. The company intends to explore the...', 'thumbnail': 'https://serpapi.com/searches/6722225a0f2a2cf3975a75fa/images/5811004c075760bd6e2f3b661f5e4a0789e4704a78b783e1d8501039d753480a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9209516644477844}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02542696,"{'position': 1, 'link': 'https://www.pharmaceutical-technology.com/analyst-comment/ean-2024-sublingual-apomorphine/', 'title': 'EAN 2024: sublingual apomorphine better tolerated by dopamine agonist users', 'source': 'Pharmaceutical Technology', 'date': 'Jul 5, 2024', 'snippet': 'SL-APO is marketed by Bial in France, Germany, Spain and the UK for the \non-demand treatment of leveodopa wear-off.', 'thumbnail': 'https://serpapi.com/searches/672222762da1575f8de8e077/images/0b0a143a8ccb7c0cbd8ac43483c48794ac3b72b1cb9e1501c170aaffa766d354.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5052707195281982}",,,,,,,,,,['neutral'],neutral,1
NCT02120807,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-33719-6', 'title': 'Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas', 'source': 'Nature', 'date': 'Oct 15, 2022', 'snippet': 'We previously identified a chemotherapy-induced paracrine inflammatory loop \nthat paradoxically mitigates the anti-tumor effect of...', 'thumbnail': 'https://serpapi.com/searches/672222784d52b8a0a028bac8/images/21ffa320a34a81daacdb574df21b71af35f0bd7aa5f1db620b1af14c1a7d0692.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8641873598098755}",,,,,,,,,,['neutral'],neutral,1
NCT02118012,"{'position': 1, 'link': 'https://www.nih.gov/news-events/nih-research-matters/allergy-drug-treats-hepatitis-c-mice', 'title': 'Allergy Drug Treats Hepatitis C in Mice', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Apr 20, 2015', 'snippet': 'A common over-the-counter allergy drug lowered hepatitis C virus levels in \ninfected mice. The drug is currently being tested in patients...', 'thumbnail': 'https://serpapi.com/searches/672222a098876dbcee66f373/images/b2429133dd7ba3ae2b54c7caeabbe73b9058d426e0dbc7832c68046a1e602042.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7960674166679382}",,,,,,,,,,['neutral'],neutral,1
NCT01930188,"{'position': 1, 'link': 'https://www.medwirenews.com/showcase/a-quick-guide-to-the-sustain-trials/', 'title': 'A quick guide to the SUSTAIN trials', 'source': 'medwirenews.com', 'date': 'Apr 7, 2017', 'snippet': 'Here is our guide to the 15 trials launched to date, which are complete, \nand which have so far been published in a peer-reviewed journal.', 'thumbnail': 'https://serpapi.com/searches/672222c615c740ab121e858e/images/f00c4aa9067b23a477c9a39df68f8baf5688c799325d88c3c045a502e252d02d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.865156352519989}",,,,,,,,,,['neutral'],neutral,1
NCT01584648,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1904059', 'title': 'Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma', 'source': 'The New England Journal of Medicine', 'date': 'Jun 4, 2019', 'snippet': 'Patients who have unresectable or metastatic melanoma with a BRAF V600E or \nV600K mutation have prolonged progression-free survival and...', 'thumbnail': 'https://serpapi.com/searches/6722233756f970a143a4f6bd/images/d5457361556dab96162f31b1eb7dc1e739968d51aec9024c645d06133f9b11ce.png', 'sentiment': 'neutral', 'sentiment_prob': 0.615032434463501}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1406037', 'title': 'Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 29, 2014', 'snippet': 'In this phase 3 trial, we randomly assigned 423 previously untreated \npatients who had unresectable stage IIIC or stage IV melanoma with a...', 'thumbnail': 'https://serpapi.com/searches/6722233756f970a143a4f6bd/images/d5457361556dab963373cf553636b0b290d4a521802c2387c3d8b0b977234c7c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9368438720703125}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00525616,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-019-40203-7', 'title': 'B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid', 'source': 'Nature', 'date': 'Mar 5, 2019', 'snippet': 'Bullous Pemphigoid is the most common auto-immune bullous skin disease. It \nis characterized by the production of auto-antibodies directed...', 'thumbnail': 'https://serpapi.com/searches/67222351bb64ac22bd85ba37/images/6b024cb0364fbdab37ef7c2840b5da0b687fca5b3843970194902a4be5ff8e25.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6479204297065735}",,,,,,,,,,['negative'],negative,0
NCT01284322,"{'position': 1, 'link': 'https://www.science.org/doi/10.1126/scitranslmed.aao0475', 'title': 'Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials', 'source': 'Science | AAAS', 'date': 'Jan 3, 2018', 'snippet': 'Tissues stiffen during aging and during the pathological progression of \ncancer, fibrosis, and cardiovascular disease.', 'thumbnail': 'https://serpapi.com/searches/672223647ebde5d9be3a773f/images/1b983a54cdfcfda9e24137c3d71f92b4964638b0ed1f83ea9a6f2518a54e60fe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8034569025039673}",,,,,,,,,,['neutral'],neutral,1
NCT05205746,"{'position': 1, 'link': 'https://www.mountsinai.org/about/newsroom/2023/castlevax-inc-receives-barda-project-nextgen-award-valued-at-up-to-three-hundred-thirty-eight-million-to-advance-intranasal-ndvbased-covid-booster-vaccine-into-phase-twob-clinical-efficacy-testing', 'title': 'CastleVax Inc. Receives BARDA Project NextGen Award Valued at up to $338 Million to Advance Intranasal NDV-based COVID-19 Booster Vaccine into Phase 2b Clinical Efficacy Testing', 'source': 'Mount Sinai', 'date': 'Oct 17, 2023', 'snippet': 'CastleVax, a clinical stage vaccine platform company, has received a \nProject NexGen award valued at up to $338 million from the Biomedical...', 'thumbnail': 'https://serpapi.com/searches/6722239793584c1f1a579027/images/54524a8694b228342cc2ac79dead7ed3931155375bf3bab41f57faa9d06dc29a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7130514979362488}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20240730713002/en/CastleVax-Inc.-Receives-34-Million-from-BARDA-to-Continue-Advancing-Intranasal-NDV-based-COVID-19-Vaccine-into-Phase-2b-Clinical-Efficacy-Testing', 'title': 'CastleVax Inc. Receives $34 Million from BARDA to Continue Advancing Intranasal NDV-based COVID-19 Vaccine into Phase 2b Clinical Efficacy Testing', 'source': 'Business Wire', 'date': 'Jul 30, 2024', 'snippet': 'CastleVax, a clinical stage mucosal vaccine platform company, has received \nan additional Project NextGen award valued at approximately $34...', 'thumbnail': 'https://serpapi.com/searches/6722239793584c1f1a579027/images/54524a8694b22834b9a248d53f187e8f71a1431375da2e30148ed67bb12431bc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6780118346214294}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03875729,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/type-1-diabetes-progression-trials-to-watch-2023/', 'title': 'Delaying type 1 diabetes progression: major trial readouts to watch in 2023', 'source': 'Clinical Trials Arena', 'date': 'Feb 17, 2023', 'snippet': 'Four clinical trials aim to slow or delay type 1 diabetes progression, but \neach targets different patients and assesses different endpoints.', 'thumbnail': 'https://serpapi.com/searches/6722239c8cf8ae72e23bc622/images/857fdf9a1a3bb3f16d09d4a22e3b084538e1b122407cad5ab7cd0b98cd116ccb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6979893445968628}",,,,,,,,,,['neutral'],neutral,1
NCT01138657,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1509852', 'title': 'Adalimumab in Patients with Active Noninfectious Uveitis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 8, 2016', 'snippet': 'We conducted a trial to assess the efficacy and safety of adalimumab as a \nglucocorticoid-sparing agent for the treatment of noninfectious uveitis.', 'thumbnail': 'https://serpapi.com/searches/672223a371c62b5f5104892e/images/2fd003115a6bcac779a88c07d15886f76099f99b768ca3cc8fc36ead296f2fdc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.856410026550293}",,,,,,,,,,['neutral'],neutral,1
NCT02447666,"{'position': 1, 'link': 'https://ascopost.com/issues/august-25-2022/azacitidine-for-newly-diagnosed-juvenile-myelomonocytic-leukemia/', 'title': 'Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia', 'source': 'The ASCO Post', 'date': 'Aug 25, 2022', 'snippet': 'Azacitidine for injection was approved by the US Food and Drug \nAdministration for pediatric patients with newly diagnosed juvenile \nmyelomonocytic leukemia.', 'thumbnail': 'https://serpapi.com/searches/672223e67c1712a3f3a2f73f/images/f2b8dab66c5bc6d2af2c4f679b48baf38a808152da29e265e285d8f1696d7b18.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7814248204231262}",,,,,,,,,,['neutral'],neutral,1
NCT03622580,"{'position': 1, 'link': 'https://www.globenewswire.com/de/news-release/2024/07/17/2914761/0/en/Roche-s-Vabysmo-showed-extended-durability-continued-efficacy-and-a-consistent-safety-profile-in-long-term-diabetic-macular-edema-DME-study.html', 'title': 'Roche’s Vabysmo showed extended durability, continued', 'source': 'GlobeNewswire', 'date': 'Jul 17, 2024', 'snippet': 'More than 90% of patients had absence of DME after four years in a \npre-specified exploratory endpointPeople treated with Vabysmo sustained...', 'thumbnail': 'https://serpapi.com/searches/67222433be80137f46194b19/images/42d0d1b462380ed9294d98fce2f223d22212600f7a8c029ce66fab5a6691e33f.png', 'sentiment': 'positive', 'sentiment_prob': 0.5305542945861816}","{'position': 2, 'link': 'https://www.globenewswire.com/de/news-release/2023/04/25/2654401/0/en/New-Vabysmo-data-suggest-greater-retinal-drying-versus-aflibercept-in-nAMD-and-DME.html', 'title': 'New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME', 'source': 'GlobeNewswire', 'date': 'Apr 25, 2023', 'snippet': ""Post-hoc analyses from four phase III studies indicate Vabysmo dried \nretinal fluid faster with fewer injections in neovascular or 'wet'..."", 'thumbnail': 'https://serpapi.com/searches/67222433be80137f46194b19/images/42d0d1b462380ed939d6b9faca53b3f42e623509180bc0f139aa3e452b35635e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8941206932067871}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT04213807,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.049768', 'title': 'Stroke Prevention in Atrial Fibrillation:', 'source': 'American Heart Association Journals', 'date': 'Dec 14, 2020', 'snippet': 'Ischemic strokes related to atrial fibrillation are highly prevalent, \npresenting with severe neurologic syndromes and associated with high...', 'thumbnail': 'https://serpapi.com/searches/67222442f59d0018ddb8b909/images/fa629c3615968079d91b142e0b668a1c8be896b38775cf633d48883d2688e723.png', 'sentiment': 'neutral', 'sentiment_prob': 0.4968705475330353}","{'position': 2, 'link': 'https://www.genengnews.com/topics/drug-discovery/bleeding-edge-anthos-pursues-a-monthly-anticoagulant/', 'title': 'Bleeding Edge: Anthos Pursues a Monthly Anticoagulant', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Aug 4, 2021', 'snippet': 'Blackstone/Novartis-launched startup publishes positive Phase II data for \nits blood clot inhibiting antibody, abelacimab.', 'thumbnail': 'https://serpapi.com/searches/67222442f59d0018ddb8b909/images/fa629c36159680793bf730b42206dbeec7a31827df52144f035963b6d19662aa.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.56215900182724}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03031782,"{'position': 1, 'link': 'https://www.empr.com/home/news/cosentyx-approved-for-enthesitis-related-arthritis-juvenile-psoriatic-arthritis/', 'title': 'Cosentyx Approved for Enthesitis-Related Arthritis, Juvenile Psoriatic Arthritis', 'source': 'Medical Professionals Reference', 'date': 'Dec 27, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) \nfor the treatment of active enthesitis-related arthritis (ERA) in patients \n4 years...', 'thumbnail': 'https://serpapi.com/searches/67222523b7d31daeb5020035/images/319bf5a54f5c3a71d98432a252dd4e638545065a219cab529f30232c9506d1ab.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7559860944747925}",,,,,,,,,,['neutral'],neutral,1
NCT02981329,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/type-2-diabetes-drug-metformin-may-be-used-to-treat-sickle-cell-anemia-study-says/', 'title': 'Sickle Cell Anemia Patients May Benefit from Diabetes Drug Metformin, Study Suggests', 'source': 'Sickle Cell Disease News', 'date': 'Jan 12, 2017', 'snippet': 'A study by researchers in Texas suggests that metformin, a common drug for \ntype 2 diabetes, could be used to treat sickle cell anemia.', 'thumbnail': 'https://serpapi.com/searches/672225260053c753569c25e2/images/4c78fb644d9472d8920912477752907f65baa84b0b6ddae1a71120e0ab2c904d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8132133483886719}",,,,,,,,,,['neutral'],neutral,1
NCT00388726,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/eribulin-yields-similar-benefit-to-standard-chemotherapeutics-for-her2-low-and-her2-0-metastatic-breast-cancer', 'title': 'Eribulin Yields Similar Benefit to Standard Chemotherapeutics for HER2-low and HER2-0 Metastatic Breast Cancer', 'source': 'Cancer Network', 'date': 'Dec 8, 2022', 'snippet': 'Treatment with eribulin mesylate (Halaven) resulted in a trend towards \nimproved overall survival (OS) in a population of patients diagnosed...', 'thumbnail': 'https://serpapi.com/searches/6722252c213c87ebb7b10fe7/images/a9e7dd1f959379fbdd5c28ef694effe75f61266fef7bf5587bc613a6cf6fbee5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8202352523803711}",,,,,,,,,,['neutral'],neutral,1
NCT03832621,"{'position': 1, 'link': 'https://www.onclive.com/view/temozolomide-plus-nivolumab-shows-efficacy-in-previously-treated-es-sclc', 'title': 'Temozolomide Plus Nivolumab Shows Efficacy in Previously Treated ES-SCLC', 'source': 'OncLive', 'date': 'Aug 8, 2022', 'snippet': 'Temozolomide in combination with nivolumab induced a promising overall \nresponse rates in patients who previously received chemotherapy for...', 'thumbnail': 'https://serpapi.com/searches/6722249fc4bcf586aa622f3b/images/031ce5dcc08fb4f220974c0ce1c1a20d8a53f302a1adbf23446a8c5ee389c9b6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7707393765449524}",,,,,,,,,,['positive'],positive,1
NCT03439670,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/features-duchenne-muscular-dystrophy-trials-to-watch/', 'title': 'Duchenne muscular dystrophy: major trials and events to watch in 2023', 'source': 'Clinical Trials Arena', 'date': 'Mar 16, 2023', 'snippet': 'A possible gene therapy approval and major trials readouts set the stage \nfor a busy year of drug development in Duchenne muscular dystrophy.', 'thumbnail': 'https://serpapi.com/searches/672226e7ecf15015f235432e/images/bf307ce294e87df5e66d6b298594f2cb72ab0fa53725f3c1ada5d2dbed83bf09.png', 'sentiment': 'neutral', 'sentiment_prob': 0.78264981508255}","{'position': 2, 'link': 'https://musculardystrophynews.com/news/vamorolone-shows-sustained-efficacy-safety-48-weeks-vision-dmd-trial/', 'title': 'In DMD Trial, Vamorolone Shows Efficacy and Safety Over 48 Weeks', 'source': 'Muscular Dystrophy News', 'date': 'Dec 2, 2021', 'snippet': ""Across the VISION-DMD trial, vamorolone's use led to muscle function gains \nwith fewer side effects than prednisone, including in behavior."", 'thumbnail': 'https://serpapi.com/searches/672226e7ecf15015f235432e/images/bf307ce294e87df5f19838e54e0b106cc0a8aa735d9ed580a20f1e0699d7c82d.png', 'sentiment': 'positive', 'sentiment_prob': 0.8401336669921875}","{'position': 3, 'link': 'https://musculardystrophynews.com/news/agamree-approved-european-union-treatment-dmd-boys-4-older/', 'title': 'Agamree approved in Europe to treat DMD boys ages 4 and older', 'source': 'Muscular Dystrophy News', 'date': 'Dec 19, 2023', 'snippet': 'The European Commission has approved Agamree (vamorolone), a dissociative \ncorticosteroid — a treatment expected to have fewer side effects than...', 'thumbnail': 'https://serpapi.com/searches/672226e7ecf15015f235432e/images/bf307ce294e87df598db2ceb68d7f0258e8bd273c682e166125709c792fce163.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5237804055213928}","{'position': 4, 'link': 'https://musculardystrophynews.com/news/vamorolone-improves-muscle-function-in-dmd-boys-phase-2a-data/', 'title': 'Vamorolone Improves Muscle Function in DMD Boys, Phase 2a Trial Data Show', 'source': 'Muscular Dystrophy News', 'date': 'Sep 4, 2019', 'snippet': 'Read about the findings of an extension study from a Phase 2a trial showing \nthat vamorolone improves muscle function in boys with DMD.', 'thumbnail': 'https://serpapi.com/searches/672226e7ecf15015f235432e/images/bf307ce294e87df5cfda7a804e3b0f579fe6352496f15824ac358784379d35ff.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5145846605300903}",,,,,,,"['neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT03345836,"{'position': 1, 'link': 'https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-moderately-severely-active-crohns-disease', 'title': 'FDA approves first oral treatment for moderately to severely active Crohn’s disease', 'source': 'U.S. Food and Drug Administration (.gov)', 'date': 'May 18, 2023', 'snippet': ""FDA has approved Rinvoq (upadacitinib) for adults with moderately to \nseverely active Crohn's disease who have had an inadequate response or..."", 'thumbnail': 'https://serpapi.com/searches/6722270474f0a452ea2b6a90/images/ffc719f14c89b4a4feaab12181e6b6b13d450b420219cc5840f1e53eb00866e8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8076032996177673}","{'position': 2, 'link': 'https://www.empr.com/home/news/rinvoq-approved-for-moderately-to-severely-active-crohn-disease/', 'title': 'Rinvoq Approved for Moderately to Severely Active Crohn Disease', 'source': 'Medical Professionals Reference', 'date': 'May 19, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib) \nfor the treatment of adults with moderately to severely active Crohn \ndisease.', 'thumbnail': 'https://serpapi.com/searches/6722270474f0a452ea2b6a90/images/ffc719f14c89b4a4c8aeef2d2a18a02139bfe63db02ce6ace274df7986429543.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8569288849830627}","{'position': 3, 'link': 'https://www.europeanpharmaceuticalreview.com/news/179158/mhra-approves-first-oral-advanced-therapy-for-crohns-disease/', 'title': 'MHRA approves first oral advanced therapy for Crohn’s disease', 'source': 'European Pharmaceutical Review', 'date': 'Feb 2, 2023', 'snippet': ""The MHRA has approved the first marketing authorisation globally for the \nuse of RINVOQ (upadacitinib) in Crohn's disease."", 'thumbnail': 'https://serpapi.com/searches/6722270474f0a452ea2b6a90/images/ffc719f14c89b4a46ceb0961ae0c0f15e29a36da51b1cf71aa69e7438503b016.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7778432965278625}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02564042,"{'position': 1, 'link': 'https://www.genengnews.com/topics/drug-discovery/gsk-sells-psoriasis-dermatitis-candidate-tapinarof-to-dermavant/', 'title': 'GSK Sells Psoriasis/Dermatitis Candidate Tapinarof to Dermavant', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Jul 12, 2018', 'snippet': 'Dermavant agreed to pay up to £250M ($330M) for mostly-global rights to the \ntherapeutic aryl hydrocarbon receptor modulating agent (TAMA),...', 'thumbnail': 'https://serpapi.com/searches/6722273251d84d1ed7a5c2b1/images/833ce623087812d32e3bdd9c1c7cc45bf5c810d130690a14d577d19629e189de.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9153958559036255}",,,,,,,,,,['neutral'],neutral,1
NCT01829711,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-018-0210-1', 'title': 'Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia', 'source': 'Nature', 'date': 'Jul 20, 2018', 'snippet': 'This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, \na recombinant CD22-targeting immunotoxin, in hairy cell leukemia...', 'thumbnail': 'https://serpapi.com/searches/67222767fc183d1a7919038a/images/8b53aafc3d80d5ab05f6cc2dc3e840cb0ecbdbdc67aef63a3c207951060a1f9e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7538529634475708}",,,,,,,,,,['neutral'],neutral,1
NCT04975256,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.21.02752', 'title': 'First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS', 'source': 'ASCO Publications', 'date': 'Feb 15, 2022', 'snippet': 'Adagrasib 600 mg twice a day was well tolerated and exhibited antitumor \nactivity in patients with advanced solid tumors harboring the KRAS G12C \nmutation.', 'thumbnail': 'https://serpapi.com/searches/6722278272e5c4748b855263/images/a3a7c081cd722bd6f96fe1809085355593293a533b43395ce500190dac49324b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7405776977539062}",,,,,,,,,,['neutral'],neutral,1
NCT02432846,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2021/03/03/ilixadencel-sutent-combo-meaningful-survival-newly-diagnosed-metastatic-kidney-cancer-phase-2-trial-shows/', 'title': 'Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patients', 'source': 'Immuno-Oncology News', 'date': 'Mar 3, 2021', 'snippet': 'Updated Phase 2 trilal data found clinically meaningful overall survival in \nmetastatic renal cell carinoma patients treated with ilixadencel...', 'thumbnail': 'https://serpapi.com/searches/672227916aa36434fe430824/images/8f2198978a68f11ad255812c02a3a55fff56dc5acf581d03856bf686e3076ae9.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.549407958984375}",,,,,,,,,,['positive'],positive,1
NCT01092182,"{'position': 1, 'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.20.00303', 'title': 'Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma', 'source': 'ASCO Publications', 'date': 'May 26, 2020', 'snippet': 'PURPOSEBurkitt lymphoma is an aggressive B-cell lymphoma curable with \ndose-intensive chemotherapy derived from pediatric leukemia regimens.', 'thumbnail': 'https://serpapi.com/searches/6722257f68831ed3b6935a36/images/d5527541319a84610ff5f201c99fe372c015a8229a0f8998c867f1dff337b738.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8118109107017517}",,,,,,,,,,['neutral'],neutral,1
NCT04429503,"{'position': 1, 'link': 'https://www.empr.com/home/news/eylea-hd-approved-for-wet-amd-diabetic-macular-edema-diabetic-retinopathy/', 'title': 'Eylea HD Approved for Wet AMD, Diabetic Macular Edema, Diabetic Retinopathy', 'source': 'Medical Professionals Reference', 'date': 'Aug 21, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Eylea HD (aflibercept) \nfor the treatment of patients with wet age-related macular degeneration \n(wAMD),...', 'thumbnail': 'https://serpapi.com/searches/6722259474f0a452bffecce6/images/65709439b639461490f3f88b9130e33eee5897d15c419e9d0757a53f05493aeb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.869649350643158}",,,,,,,,,,['neutral'],neutral,1
NCT04446377,"{'position': 1, 'link': 'https://www.nature.com/articles/s42003-022-03766-2', 'title': 'PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19', 'source': 'Nature', 'date': 'Aug 12, 2022', 'snippet': 'Here we show that, while Apilimod and other PIKfyve inhibitors have potent \nantiviral activity in various cell lines against multiple human \ncoronaviruses,', 'thumbnail': 'https://serpapi.com/searches/672225aa7ebde5d9be3a78ef/images/c51c21f8c0be4852f4c14f6a8093aa2f0f29a177abd33bba5a388aadb00226ee.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6733592748641968}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20200727005096/en/AI-Therapeutics-Announces-Start-of-Phase-II-Trial-of-LAM-002A-apilimod-dimesylate-for-Treatment-of-COVID-19-Patients', 'title': 'AI Therapeutics Announces Start of Phase II Trial of LAM-002A (apilimod dimesylate) for Treatment of COVID-19 Patients', 'source': 'Business Wire', 'date': 'Jul 27, 2020', 'snippet': 'AI Therapeutics is starting a Phase II clinical trial for the treatment of \nnewly diagnosed COVID-19 patients in collaboration with Yale...', 'thumbnail': 'https://serpapi.com/searches/672225aa7ebde5d9be3a78ef/images/c51c21f8c0be485261c3612cc0edef8bb27da0c2f92f4c9cd1fad6a89cf749c1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9199429154396057}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01355445,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/vincristine-irinotecan-plus-temozolomide-shows-improved-efficacy-in-relapsed-refractory-rhabdomyosarcoma', 'title': 'Vincristine/Irinotecan Plus Temozolomide Shows Improved Efficacy in Relapsed/Refractory Rhabdomyosarcoma', 'source': 'Cancer Network', 'date': 'Oct 14, 2021', 'snippet': 'The addition of temozolomide to vincristine and irinotecan appears to be a \nnew standard of care for adult and pediatric patients with...', 'thumbnail': 'https://serpapi.com/searches/672225ad740bdba705d9656b/images/c98732be0ca0ce838e1ade6b10f2c7a04db5f0f77be7be9cff357f09f6b1f326.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6265175938606262}",,,,,,,,,,['positive'],positive,1
NCT02014844,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2018.00459/full', 'title': 'Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy', 'source': 'Frontiers', 'date': 'Feb 6, 2024', 'snippet': 'Despite advances in surgery, radiotherapy, and chemotherapy, glioblastoma \n(GBM) remains a malignancy with poor prognosis. The molecular profile of \nGBM is...', 'thumbnail': 'https://serpapi.com/searches/672225cb175de6645df693d2/images/6a374b9f5d5ec559061f5b93c39ba12b9f162114df2186c97f3e85f17ac5bd40.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5509600639343262}",,,,,,,,,,['negative'],negative,0
NCT00003667,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/abs/10.1002/cti2.1095', 'title': 'Clinical & Translational Immunology | ASI Journal', 'source': 'Wiley Online Library', 'date': 'Nov 29, 2019', 'snippet': 'The discovery of defined peptidoglycan metabolites that activate host \nimmunity and their specific receptors has revealed fundamental insights \ninto host–microbe...', 'thumbnail': 'https://serpapi.com/searches/672225ec90adce9b27b74448/images/5b30d4cedabd07fbe433f4847a0f25d5334b6e4dcdaf0c20bec0cf3198a396c5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7340048551559448}",,,,,,,,,,['neutral'],neutral,1
NCT02174978,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/tropical-diseases/articles/10.3389/fitd.2022.988665/full', 'title': 'Malaria vaccine approaches leveraging technologies optimized in the COVID-19 era', 'source': 'Frontiers', 'date': 'Apr 24, 2024', 'snippet': 'Africa bears the greatest burden of malaria with more than 200 million \nclinical cases and more than 600000 deaths in 2020 alone. While \nmalaria-associated de...', 'thumbnail': 'https://serpapi.com/searches/67222605b9ab865cfec0e45a/images/ab1347ee42e3a259058d838ef174102618266964ccafa266d94fe0a1e093a268.png', 'sentiment': 'negative', 'sentiment_prob': 0.7410832643508911}",,,,,,,,,,['negative'],negative,0
NCT01950689,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/reports/nimorazole-head-and-neck-cancers-tumor-hypoxia-provides-no-benefit/', 'title': 'Nimorazole Provides No Benefit in Head and Neck Cancers With Tumor Hypoxia', 'source': 'Cancer Therapy Advisor', 'date': 'Jun 14, 2023', 'snippet': 'Adding nimorazole to radiotherapy does not improve outcomes in patients \nwith locally advanced head and neck cancer who have tumor hypoxia.', 'thumbnail': 'https://serpapi.com/searches/6722263c131502ec3a5f6a9c/images/5738b8f37d6d7b47c62a68ea72cd1ffa63ce913a52aa2d681c39acbc1f1fa424.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8600849509239197}",,,,,,,,,,['negative'],negative,0
NCT00937872,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-55923-8', 'title': 'Emerging roles of SIRT1 activator, SRT2104, in disease treatment', 'source': 'Nature', 'date': 'Mar 6, 2024', 'snippet': 'Silent information regulator 1 (SIRT1) is a NAD+-dependent class III \ndeacetylase that plays important roles in the pathogenesis of numerous...', 'thumbnail': 'https://serpapi.com/searches/672226407c1712a3f3a2f90e/images/e7142d601419a7db5adfd5f34de1306670d55c5163078fe3754c24b71c5496cb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8164551258087158}",,,,,,,,,,['neutral'],neutral,1
NCT00734682,"{'position': 1, 'link': 'https://www.azonano.com/news.aspx?newsID=39127', 'title': 'How Nanomedicines can Shape the Future of Glioblastoma Therapy', 'source': 'AZoNano', 'date': 'May 16, 2022', 'snippet': 'Authors summarized glioma stem cell-based therapies and their mechanism of \naction against glioblastoma, drawing attention to nanomedicine...', 'thumbnail': 'https://serpapi.com/searches/672226a3993688eab342471b/images/4b7a46000500300681bc7fd09db87ce8e0b641976b574452228153bf86e5098f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9088749885559082}",,,,,,,,,,['neutral'],neutral,1
NCT05260437,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-02061-1', 'title': 'The landscape of mRNA nanomedicine', 'source': 'Nature', 'date': 'Nov 10, 2022', 'snippet': 'In this Review, we present the latest advances and innovations in the \ngrowing field of mRNA nanomedicine, in the context of ongoing clinical \ntranslation and...', 'thumbnail': 'https://serpapi.com/searches/672226a8c024d17e3ab589b7/images/d47ef21533f803e8b3bc38f36bf18c2f3db99f86214cc54055c79e46b887bdba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6047077775001526}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-023-36110-1', 'title': 'Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models', 'source': 'Nature', 'date': 'Feb 13, 2023', 'snippet': 'Combining optimized spike (S) protein-encoding mRNA vaccines to target \nmultiple SARS-CoV-2 variants could improve control of the COVID-19...', 'thumbnail': 'https://serpapi.com/searches/672226a8c024d17e3ab589b7/images/d47ef21533f803e80d60a64bc52fcb0d28c7fe39d82acd9b575cfcf930b0d50c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8680277466773987}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03507699,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-024-02217-7', 'title': 'Targeting the innate immune system in pediatric and adult AML - Leukemia', 'source': 'Nature', 'date': 'Mar 8, 2024', 'snippet': 'While the introduction of T cell-based immunotherapies has improved \noutcomes in many cancer types, the development of immunotherapies for...', 'thumbnail': 'https://serpapi.com/searches/672226ba6cca5e78b095d8a5/images/14f9d71e22c66002e1c7b01c0ace0dbe9b510601369c740d7a72bb8626448092.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8018168807029724}",,,,,,,,,,['neutral'],neutral,1
NCT00627640,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/equifina-xadago-in-us-eu-approved-south-korea-as-levodopa-add-on-therapy/', 'title': ""Equfina Approved in South Korea as Levodopa Add-on for Parkinson's"", 'source': ""Parkinson's News Today"", 'date': 'Jun 29, 2020', 'snippet': ""Equfina (safinamide) has been approved in South Korea as an add-on therapy \nto levodopa for Parkinson's disease patients who experience “off” episodes."", 'thumbnail': 'https://serpapi.com/searches/672227c9aab36dd7965e572f/images/3871ab0f407621e8822e255935dc7275607b54dc80141b41ffdc31045d9e7f33.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8036103248596191}",,,,,,,,,,['neutral'],neutral,1
NCT04593940,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/immune-modulator-drugs-improved-survival-people-hospitalized-covid-19', 'title': 'Immune modulator drugs improved survival for people hospitalized with COVID-19', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jun 2, 2022', 'snippet': 'A large randomized, placebo-controlled clinical trial led by the National \nInstitutes of Health shows that treating adults hospitalized with COVID-19 \nwith...', 'thumbnail': 'https://serpapi.com/searches/6722283729e6fb3ba7368fa6/images/cba0f7f99016625bbf4acbbbb93092818c843d3275e0a3ee33723e67c518067e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5261252522468567}",,,,,,,,,,['neutral'],neutral,1
NCT00672542,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332220301888', 'title': 'RNA-based pharmacotherapy for tumors: From bench to clinic and back', 'source': 'ScienceDirect.com', 'date': 'Feb 14, 2020', 'snippet': 'RNA therapy is a treatment that regulates cell proteins and cures diseases \nby affecting the metabolism of mRNAs in cells.', 'thumbnail': 'https://serpapi.com/searches/67222855577da59cf36d1a1e/images/b882c67cf6a2a0e5d265c6a21c63d068e674cba20b887d3b0a3d96c9872f2323.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7626101970672607}",,,,,,,,,,['neutral'],neutral,1
NCT02409459,"{'position': 1, 'link': 'https://fibromyalgianewstoday.com/2017/11/22/fibromyalgia-symptoms-improve-injectafer-iron-replacement-therapy-phase-2-study/', 'title': 'Fibromyalgia Symptoms Better After Injectafer Iron Replacement Therapy', 'source': 'Fibromyalgia News Today', 'date': 'Nov 22, 2017', 'snippet': 'Read about a trial showing that Injectafer treatment can improve the \nsymptoms of fibromyalgia in patients with iron deficiency.', 'thumbnail': 'https://serpapi.com/searches/672228bc131502ec05c76586/images/594da76e79260bcf8b742aeae77a4ff30d55123c2ae60b19731324814f644e98.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5954317450523376}",,,,,,,,,,['positive'],positive,1
NCT04695847,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1252652/full', 'title': 'A narrative review of antibody–drug conjugates in EGFR -mutated non-small cell lung cancer', 'source': 'Frontiers', 'date': 'Dec 11, 2023', 'snippet': 'In the past 15 years, non-small cell lung cancer (NSCLC) treatment has \nchanged with the discovery of mutations and the development of new targeted \ntherapies...', 'thumbnail': 'https://serpapi.com/searches/67222a02ecf150161f81d2fc/images/eb790cecda4d0a5a6b2f2247d1ea5953fd618354e6f2c868ea13149fbfacd61d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7807655930519104}",,,,,,,,,,['neutral'],neutral,1
NCT04527354,"{'position': 1, 'link': 'https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03660-9', 'title': 'Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial', 'source': 'Journal of Translational Medicine', 'date': 'Nov 3, 2022', 'snippet': '4 weeks oral administration of 50 mg Treamid was associated with clinically \nsignificant improvement in the post-COVID patients, evident by an increase \nin FVC...', 'thumbnail': 'https://serpapi.com/searches/67222a0da3657ab8a2fdc971/images/4365c4ab24e5dfd2b8d23ce7f229eda24ce0dc48f59098b9aa94566530a10aaa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7464807033538818}",,,,,,,,,,['neutral'],neutral,1
NCT01588548,"{'position': 1, 'link': 'https://www.nature.com/articles/s41388-020-1202-y', 'title': 'Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer', 'source': 'Nature', 'date': 'Feb 10, 2020', 'snippet': 'The proviral integration of Moloney virus (PIM) family of protein kinases \nare overexpressed in many haematological and solid tumours.', 'thumbnail': 'https://serpapi.com/searches/6722291288bcdefebd9ad870/images/631b8a0410aa4c2a24449825e25e974f006d6776aa6bfba3f83cd57a8e1794b8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8570730686187744}",,,,,,,,,,['neutral'],neutral,1
NCT00206115,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/efficacy-tolerability-once-daily-extended-release/', 'title': 'Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study', 'source': 'Psychiatrist.com', 'date': 'Jun 15, 2007', 'snippet': 'René S. Kahn, MD, PhD; S. Charles Schulz, MD; Veselin D. Palazov, MD; Efren \nB. Reyes, MD; Martin Brecher, MD, DMSc, MBA; Ola Svensson, MD,...', 'thumbnail': 'https://serpapi.com/searches/6722292a0be2f68746bb5e84/images/2b8efddcd1d6e9ac180721ee7494aeeb5314f77cc8fcd7328bccfdf6f6900b09.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8995078802108765}",,,,,,,,,,['neutral'],neutral,1
NCT02930655,"{'position': 1, 'link': 'https://fabrydiseasenews.com/experimental-treatments-for-fabry-disease/', 'title': 'Experimental treatments for Fabry disease', 'source': 'Fabry Disease News', 'date': 'May 30, 2024', 'snippet': 'Various potential Fabry disease treatments, like gene therapies and \nsubstrate reduction therapies, are being investigated in clinical...', 'thumbnail': 'https://serpapi.com/searches/6722293075f974f2a8bdfaaa/images/ca1c9aec16f702af8a9983f6bf288e66d392dc315a118fd6c8afb42912305ae1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9250966310501099}",,,,,,,,,,['neutral'],neutral,1
NCT02660034,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-023-02349-0', 'title': 'Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial | British Journal of Cancer', 'source': 'Nature', 'date': 'Jul 20, 2023', 'snippet': 'The aim of this study was to investigate the antitumour activity, safety, \nand tolerability of pamiparib plus tislelizumab in patients with...', 'thumbnail': 'https://serpapi.com/searches/672229408e13c9f929b46b8c/images/ae9b4190851b0b9347ba0f16880e46703128c32580e3d256b61ecd098c232d44.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9109912514686584}",,,,,,,,,,['neutral'],neutral,1
NCT03281096,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-00213-8', 'title': 'Overcoming cancer therapeutic bottleneck by drug repurposing | Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': 'Jul 2, 2020', 'snippet': 'Ever present hurdles for the discovery of new drugs for cancer therapy have \nnecessitated the development of the alternative strategy of drug...', 'thumbnail': 'https://serpapi.com/searches/6722295368831ed3890c7d8e/images/169aec4e0b7120107ca42e080a809534ec531cb92cbdbdded21f5a24d67dcbe0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6857283115386963}",,,,,,,,,,['neutral'],neutral,1
NCT03037424,"{'position': 1, 'link': 'https://www.specialtypharmacycontinuum.com/FDA-News/Article/08-24/FDA-Approves-Fibryga-for-Acquired-Fibrinogen-Deficiency/74497', 'title': 'FDA Approves Fibryga for Acquired Fibrinogen Deficiency', 'source': 'Specialty Pharmacy Continuum', 'date': 'Aug 6, 2024', 'snippet': 'The FDA expanded the approval for fibrinogen (human) lyophilized powder for \nreconstitution (Fibryga, Octapharma) to include fibrinogen replacement in \nbleeding...', 'thumbnail': 'https://serpapi.com/searches/67222956175de6645df6970a/images/fea6ac08151dbaec80e99e218d6e376b2aa12e971b4e39d7cfe95c7cd274eee5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.793091356754303}",,,,,,,,,,['neutral'],neutral,1
NCT02075255,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1703501', 'title': 'Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma', 'source': 'The New England Journal of Medicine', 'date': 'May 22, 2017', 'snippet': 'Benralizumab showed significant, clinically relevant benefits, as compared \nwith placebo, on oral glucocorticoid use and exacerbation rates.', 'thumbnail': 'https://serpapi.com/searches/672229662da1575f5eaf618d/images/67a7318670d4727f1f5a15bc37637766513ee2ef3dbe002f513e673bd275b2ea.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6633275151252747}",,,,,,,,,,['neutral'],neutral,1
NCT00952289,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1110557', 'title': 'A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis', 'source': 'The New England Journal of Medicine', 'date': 'Mar 1, 2012', 'snippet': 'Ruxolitinib, as compared with placebo, provided significant clinical \nbenefits in patients with myelofibrosis by reducing spleen size, \nameliorating debilitating...', 'thumbnail': 'https://serpapi.com/searches/6722296c7d533ebd2cab7d6c/images/c2119892e0856f83fef2dd80e58add091c3b6bd5ba7eb926fd14fb330a1bdeb3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5456220507621765}","{'position': 2, 'link': 'https://www.onclive.com/view/ruxolitinib-improves-spleen-volume-tss-in-myelofibrosis-irrespective-of-baseline-anemia-transfusion-status', 'title': 'Ruxolitinib Improves Spleen Volume, TSS in Myelofibrosis Irrespective of Anemia, Transfusion Status', 'source': 'OncLive', 'date': 'Jun 10, 2023', 'snippet': 'Ruxolitinib was found to improve spleen volume and tumor symptom score in \npatients with myelofibrosis, irrespective of their anemia and...', 'thumbnail': 'https://serpapi.com/searches/6722296c7d533ebd2cab7d6c/images/c2119892e0856f839d6eb70a4cab6b2e25bfbdec627682c007efe6b809cc1075.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5063223838806152}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04185246,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-54432-y', 'title': 'Power-Doppler-based NH002 microbubble sonoporation with chemotherapy relieves hypoxia and enhances the efficacy of chemotherapy and immunotherapy for pancreatic tumors', 'source': 'Nature', 'date': 'Jun 3, 2024', 'snippet': 'Pancreatic ductal adenocarcinoma (PDAC) poses challenges due to late-stage \ndiagnosis and limited treatment response, often attributed to the...', 'thumbnail': 'https://serpapi.com/searches/6722297093bb57f4ee1a7d7f/images/7c1f12a08e6a8b55517a529f85111bd331aa05027ff48807ec9725949342f2ca.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6457999348640442}",,,,,,,,,,['neutral'],neutral,1
NCT01419665,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/granulomatosis-with-polyangiitis-and-microscopic-polyangiitis-patients-can-use-mabthera-biosimilar-rixathon-following-ec-approval/', 'title': 'EC Approves MabThera Biosimilar Rixathon for 2 AAV Disorders', 'source': 'ANCA Vasculitis News', 'date': 'Jul 14, 2017', 'snippet': ""The EC has approved the use and marketing of Sandoz's Mabthera biosimilar \ndrug Rixathon for the treatment of blood cancers and immunological..."", 'thumbnail': 'https://serpapi.com/searches/67222a40ef60cb84f817a41e/images/ee6f8718fcad080888d656239a50ddf8293d5b3db16a1e23b58d7f3293741112.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8589828014373779}",,,,,,,,,,['neutral'],neutral,1
NCT04971395,"{'position': 1, 'link': 'https://sarcoidosisnews.com/news/sarcoidosis-therapy-xtmab-16-stops-granuloma-formation-cell-model/', 'title': 'Sarcoidosis Therapy XTMAB-16 Stops Granuloma Formation in Cell Model', 'source': 'Sarcoidosis News', 'date': 'Jun 24, 2022', 'snippet': 'The effects of XTMAB-16, an investigational TNF-alpha inhibitor for \nsarcoidosis, at reducing granulomas were comparable to prednisone.', 'thumbnail': 'https://serpapi.com/searches/67222b121fc7c5ec78ae2caa/images/3af41ee3b0896e9137db7626bf5dc63e7c1d972471658b3ffff376d3e18d800d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7950399518013}",,,,,,,,,,['neutral'],neutral,1
NCT02607891,"{'position': 1, 'link': 'https://dravetsyndromenews.com/news/epidiolex-may-interact-with-diacomit-seems-ok-with-depacon-small-trial-finds/', 'title': 'Epidiolex May Interact With Diacomit But With Depacon Seems OK, Small Trial Finds', 'source': 'Dravet Syndrome News', 'date': 'Jul 21, 2020', 'snippet': 'A trial in people on anti-epileptic medications found use of the \ncannabidiol Epidiolex slightly raised blood concentrations of Diacomit;...', 'thumbnail': 'https://serpapi.com/searches/67222b77f8b05d601069fac7/images/13dbd05aa0c16a258fe20b28d83550683dace9950b86a1af3d81b107ae8fd828.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8843804001808167}",,,,,,,,,,['neutral'],neutral,1
NCT04731324,"{'position': 1, 'link': 'https://alsnewstoday.com/news/zydus-phase-2-trial-anti-inflammatory-therapy-zyil1/', 'title': 'Zydus launches Phase 2 trial of anti-inflammatory therapy ZYIL1', 'source': 'ALS News Today', 'date': 'Oct 26, 2023', 'snippet': 'Zydus Lifesciences has launched a Phase 2 clinical trial to evaluate the \nsafety and effectiveness of its experimental anti-inflammatory therapy \nZYIL1 in people...', 'thumbnail': 'https://serpapi.com/searches/67222b982fab6260abe27963/images/e1a11b419b5891bfe66562c7eb40a4b4d9ef1b35d53bfdc4b61aa32ff0a87d88.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8816696405410767}","{'position': 2, 'link': 'https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/zydus-begins-phase-ii-trial-of-zyil1-nlrp3-inhibitor-in-patients-with-als/104689856', 'title': 'Zydus begins Phase II trial of ZYIL1, NLRP3 inhibitor in patients with ALS', 'source': 'ET HealthWorld', 'date': 'Oct 25, 2023', 'snippet': ""Zydus Life Sciences is to initiate the Phase II clinical study of NLRP3 \ninhibitor 'ZYIL1' in patients with amyotrophic lateral sclerosis (ALS)."", 'thumbnail': 'https://serpapi.com/searches/67222b982fab6260abe27963/images/e1a11b419b5891bfec08d58602d6482d61be8a780f0e149d048b13bb03dae61b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8477136492729187}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02489344,"{'position': 1, 'link': 'https://fabrydiseasenews.com/news/venglustat-lowers-gb3-no-signs-of-disease-progression-trial/', 'title': 'Venglustat Lowers Gb3 With No Signs of Disease Progression in Trial', 'source': 'Fabry Disease News', 'date': 'Dec 2, 2022', 'snippet': 'Venglustat reduced levels of the fatty molecule that accumulates to toxic \nlevels in Fabry disease in a Phase 2 trial, a study shows.', 'thumbnail': 'https://serpapi.com/searches/67222ba159f9117f369cc316/images/3a10ae7d8375b5164b39588974cc164ca072b97730c5b47c78e7cff53e68f30c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8395367860794067}",,,,,,,,,,['neutral'],neutral,1
NCT04105543,"{'position': 1, 'link': 'https://www.researchgate.net/figure/A-novel-diapeutic-platform-is-based-on-phospholipid-ether-analogs-Cellectar-Biosciences_fig6_266624067', 'title': 'Figure 1. A novel diapeutic platform is based on phospholipid ether...', 'source': 'ResearchGate', 'date': 'Feb 8, 2018', 'snippet': 'Download scientific diagram | A novel diapeutic platform is based on \nphospholipid ether analogs. Cellectar Biosciences has developed a \nphospholipid ether...', 'thumbnail': 'https://serpapi.com/searches/67222ba7be1497c4b67012bf/images/9a14e2ce210b9217bb433db92519e94cdb33e506d79920774c27fd9b2ad912c5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8868414759635925}",,,,,,,,,,['neutral'],neutral,1
NCT03837756,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02547-6', 'title': 'Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial', 'source': 'Nature', 'date': 'Sep 11, 2023', 'snippet': 'Inducing antiretroviral therapy (ART)-free virological control is a \ncritical step toward a human immunodeficiency virus type 1 (HIV-1) cure.', 'thumbnail': 'https://serpapi.com/searches/67222c4d707fd32ced3b555b/images/31ba03a88939cd574f56380ea5e596298ed5cf6fbe4ff86e4a559cd5b90c7626.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8635776042938232}",,,,,,,,,,['neutral'],neutral,1
NCT01822080,"{'position': 1, 'link': 'https://endometriosisnews.com/2017/11/01/endometriosis-pain-study-china-finds-visanne-effective/', 'title': 'Visanne Seen as Effective at Reducing Endometriosis Pain in China Study', 'source': 'Endometriosis News Today', 'date': 'Nov 1, 2017', 'snippet': 'Results of a Phase 3 trial in China showed the safety and effectiveness of \nVisanne (dienogest) at preventing pelvic pain associated with...', 'thumbnail': 'https://serpapi.com/searches/67222c7e5ddfba5b08c6a189/images/f4d0b7a247037f5bd37796392f156a75d8976ba97e9ec82847a93d4139f3b17d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6414404511451721}",,,,,,,,,,['neutral'],neutral,1
NCT05517603,"{'position': 1, 'link': 'https://smanewstoday.com/news/spinal-bulbar-muscular-atrophy-trial-aj201-enrolled-results-due-this-year/', 'title': 'Spinal and bulbar muscular atrophy trial of AJ201 enrolled, results due this year', 'source': 'SMA News Today', 'date': 'Jan 5, 2024', 'snippet': 'A Phase 1b/2a clinical trial testing the experimental therapy AJ201 in \npeople with spinal and bulbar muscular atrophy (SBMA) has finished \nenrolling patients.', 'thumbnail': 'https://serpapi.com/searches/67222c83ba13f21ac0515283/images/d993453ebfc86c8ada91337211f64f5963f8207735de940bb626b146c02ec538.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9117767810821533}",,,,,,,,,,['neutral'],neutral,1
NCT02039674,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2020/11/13/keytruda-chemo-combo-improves-survival-outcomes-in-advanced-lung-cancer-patients-trial-shows/', 'title': 'Keytruda-Chemo Combo Improves Survival Outcomes in Advanced Lung Cancer', 'source': 'Immuno-Oncology News', 'date': 'Nov 13, 2020', 'snippet': 'Keytruda combined with chemotherapy prolonged survival and lowered the risk \nof disease progression and death in patients with NSCLC, a trial...', 'thumbnail': 'https://serpapi.com/searches/67222cdf76079d9baf77bb01/images/374b6afbb0d8acd37839b86f2b7c48941bb6347c5a0b163bbceac7fd6a72e783.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5165478587150574}",,,,,,,,,,['positive'],positive,1
NCT01405963,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1402895', 'title': 'Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses', 'source': 'The New England Journal of Medicine', 'date': 'May 20, 2014', 'snippet': 'Treatment with AMG 157 reduced allergen-induced bronchoconstriction and \nindexes of airway inflammation before and after allergen challenge.', 'thumbnail': 'https://serpapi.com/searches/67222ce0bb64ac22eedffc95/images/9d81cf9ef627d4872d6e0c8a6eee3d49b7390d97e0312e054348e392d929fbcd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.827753484249115}",,,,,,,,,,['neutral'],neutral,1
NCT01991873,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/maintenance-therapy-panitumumab-plus-5-fu-leucovorin-improves-survival-in-ras-wild-type-metastatic-crc', 'title': 'Maintenance Therapy Panitumumab Plus 5-FU/Leucovorin Improves Survival in RAS Wild-Type Metastatic CRC', 'source': 'Cancer Network', 'date': 'Jun 8, 2021', 'snippet': 'Adding panitumumab to 5-FU and leucovorin significantly improved PFS \ncompared with 5-FU/leucovorin alone as a maintenance therapy for patients \nwith RAS wild-...', 'thumbnail': 'https://serpapi.com/searches/67222d1221b01bb4a050a266/images/87af466e1ddcef42f8ef55aeb5e55dce5f8dbfd3d213b97e64d44ced54d49def.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7188137173652649}",,,,,,,,,,['neutral'],neutral,1
NCT01332968,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1614598', 'title': 'Obinutuzumab for the First-Line Treatment of Follicular Lymphoma', 'source': 'The New England Journal of Medicine', 'date': 'Oct 5, 2017', 'snippet': 'Rituximab-based immunochemotherapy has improved outcomes in patients with \nfollicular lymphoma. Obinutuzumab is a glycoengineered type II...', 'thumbnail': 'https://serpapi.com/searches/67222d2548e6680f9823c41c/images/aabc464b4634607d00ae2687148ef569e67cae7e84749535b2ccf526f70a3d9c.png', 'sentiment': 'positive', 'sentiment_prob': 0.7159891724586487}",,,,,,,,,,['positive'],positive,1
NCT03025542,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/bjd.20827', 'title': 'Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study* - Oliver - 2022 - British Journal of Dermatology', 'source': 'Wiley Online Library', 'date': 'Oct 23, 2021', 'snippet': 'Funding sources This study was funded by UCB Pharma. Support for \nthird-party writing assistance for this article, provided by Joe Dixon,...', 'thumbnail': 'https://serpapi.com/searches/67222d6b7b05caf824ea5639/images/af6ba3cb52b3d98dfcea5ebb76cc01cd33c5cbb00c33a816824e6b1d0835fff6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8969607949256897}",,,,,,,,,,['neutral'],neutral,1
NCT02630316,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/teton-ppf-study-nebulized-tyvaso-enrolls-first-patient/', 'title': 'First patient enrolled in TETON PPF study of nebulized Tyvaso', 'source': 'Pulmonary Fibrosis News', 'date': 'Nov 10, 2023', 'snippet': 'The first patient has been enrolled in a Phase 3 clinical trial of \nnebulized Tyvaso (treprostinil) inhalation solution for treating...', 'thumbnail': 'https://serpapi.com/searches/67222dd0fda26de13ee02d59/images/b413c38327b7004c071706c6db15ee913535db021e0c9186220c3e9b71b883f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8311435580253601}",,,,,,,,,,['neutral'],neutral,1
NCT03710707,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/potential-parkinsons-therapy-dnl201-safely-targets-enzyme-studies/', 'title': ""Potential Parkinson's Therapy DNL201 Safely Targets Enzyme: Studies"", 'source': ""Parkinson's News Today"", 'date': 'Jun 23, 2022', 'snippet': ""DNL201, an investigational therapy for Parkinson's, was tolerated in \nhealthy volunteers and patients, and engaged with the LRRK2 protein."", 'thumbnail': 'https://serpapi.com/searches/67222ddc6531cb343cde830f/images/807261c4b541cdead1d63576e1f688683ab0b675da4629ca51aa0864c1c56a49.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5823979377746582}",,,,,,,,,,['neutral'],neutral,1
NCT01649375,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1505066', 'title': 'Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis', 'source': 'The New England Journal of Medicine', 'date': 'Dec 24, 2015', 'snippet': 'In two double-blind trials, we randomly assigned patients to receive \nsecukinumab or placebo. In MEASURE 1, a total of 371 patients received...', 'thumbnail': 'https://serpapi.com/searches/67222de77ac73169c8714bbf/images/caaf87d8387cce3c69e96a0d2b4a8bde97a6d4a7fef5b774f7a777f2c55deb47.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8936644792556763}","{'position': 2, 'link': 'https://ankylosingspondylitisnews.com/2022/10/06/real-world-database-study-cosentyx-side-effects/', 'title': 'Real-world Database Study Used to Identify Cosentyx Side Effects |...', 'source': 'Ankylosing Spondylitis News', 'date': 'Oct 6, 2022', 'snippet': 'Diarrhea, cold-like symptoms, itchy skin, and rash are the most common \nreal-world side effects associated with Cosentyx, an approved treatment for \nankylosing...', 'thumbnail': 'https://serpapi.com/searches/67222de77ac73169c8714bbf/images/caaf87d8387cce3ce2081207f5720f964675643e1a1b951001e4cab7d7a190a7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5941896438598633}","{'position': 3, 'link': 'https://ankylosingspondylitisnews.com/2018/06/25/as-therapy-cosentyx-added-public-drug-programs-across-canada/', 'title': 'AS Therapy Cosentyx Added to Public Drug Programs Across Canada', 'source': 'Ankylosing Spondylitis News', 'date': 'Jun 25, 2018', 'snippet': 'Ontario and other regions of Canada will now reimburse Cosentyx \n(secukinumab) under public drug programs for adults with ankylosing...', 'thumbnail': 'https://serpapi.com/searches/67222de77ac73169c8714bbf/images/caaf87d8387cce3c10fb336d224b0d39340303b77b69daff87ef0063a03c92f6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8980309963226318}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03744676,"{'position': 1, 'link': 'https://www.onclive.com/view/dr-maris-on-key-results-from-the-outreach-trial-of-liso-cel-in-dlbcl', 'title': 'Dr. Maris on Key Results From the OUTREACH Trial of Liso-cel in DLBCL', 'source': 'OncLive', 'date': 'Feb 1, 2023', 'snippet': 'Michael Maris, MD, discusses key efficacy and safety data from the phase 2 \nOUTREACH trial in diffuse large B-cell lymphoma.', 'thumbnail': 'https://serpapi.com/searches/67222e0a14c31e91e4a50a28/images/fa8ec28f883ca95a2e3f300d86f4471bb45e258e5fe8528a5b34b7f6782ef74c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8466346263885498}",,,,,,,,,,['neutral'],neutral,1
NCT03928847,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.794997/full', 'title': 'Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis', 'source': 'Frontiers', 'date': 'Feb 6, 2024', 'snippet': 'Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease \ncharacterized by an abnormal reepithelialisation, an excessive tissue \nremodelling...', 'thumbnail': 'https://serpapi.com/searches/67222e14e1c27656915cd5f7/images/e89749495fe5ea6a4ae9f053caa5249e994adff2bc1f5dcfcb38e621711f7546.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6219959855079651}",,,,,,,,,,['negative'],negative,0
NCT03928743,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/bimekizumab-UCB4940', 'title': 'Bimekizumab (Bimzelx®)', 'source': 'UCB', 'date': 'Oct 16, 2018', 'snippet': 'Ankylosing Spondylitis, A Multicenter Study to Evaluate the Efficacy and \nSafety of Different Doses of Bimekizumab in Subjects With Active \nAnkylosing...', 'thumbnail': 'https://serpapi.com/searches/67222e4313e5d81f5e77847d/images/9882cad5960942cfa4e588883ed48b2e3c7bde8401b17e1e43599aefa060f0e6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8456552028656006}","{'position': 2, 'link': 'https://www.expresspharma.in/eu-approval-boosts-bimzelxs-profile-as-innovative-interleukin-17-inhibitor-therapy-globaldata/', 'title': 'EU approval boosts Bimzelx’s profile as innovative interleukin-17 inhibitor therapy: GlobalData', 'source': 'Express Pharma', 'date': 'Jun 23, 2023', 'snippet': 'Bimzelx is set to become a blockbuster for the treatment of these \ndebilitating, chronic conditions, with a global sales forecast of $2.4 \nbillion by 2029.', 'thumbnail': 'https://serpapi.com/searches/67222e4313e5d81f5e77847d/images/9882cad5960942cfa1b8f99923e935dede3ad31b5de36a58bca470948d26b840.png', 'sentiment': 'positive', 'sentiment_prob': 0.8411182165145874}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT00488618,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0165032724010309', 'title': 'Early improvement with cariprazine as a predictor of antidepressant, anxiolytic, and antimanic response in bipolar I mania and depression: A pooled post hoc analysis of randomized cariprazine trials', 'source': 'ScienceDirect.com', 'date': 'Jun 27, 2024', 'snippet': 'Early symptomatic improvement may predict treatment response in bipolar I \ndisorder. Cariprazine has demonstrated early treatment effects in bipolar \nI...', 'thumbnail': 'https://serpapi.com/searches/67222e5d20e6eb934c149301/images/cf2b6ddb2384db58b0ec4e5e746d36a44e7a7deeff1a8cf96284e014d5c34f99.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7281509637832642}",,,,,,,,,,['neutral'],neutral,1
NCT04652479,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-new-data-supporting-broader-potential-of-avexitide-in-patients-with-post-bariatric-hypoglycemia-and-hyperinsulinemic-hypoglycemia-after-gastrointestinal-surgeries-301566413.html', 'title': 'Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries', 'source': 'PR Newswire', 'date': 'Jun 13, 2022', 'snippet': 'PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a \ncommercial-stage biopharmaceutical company focused on the development of...', 'thumbnail': 'https://serpapi.com/searches/67222e73c4bcf586aa6237b2/images/b47bb4ecfe008032259d13a50c7fbce5983f154fffccdbd255d0701e2c7ac0c8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.867247998714447}",,,,,,,,,,['neutral'],neutral,1
NCT02589782,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2117166', 'title': 'A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis', 'source': 'The New England Journal of Medicine', 'date': 'Dec 21, 2022', 'snippet': 'In patients with rifampin-resistant tuberculosis, all-oral treatment \nregimens that are more effective, shorter, and have a more acceptable...', 'thumbnail': 'https://serpapi.com/searches/67222e985235f6c6a16c074e/images/6fd9b39131d5ef0bd9e2be1afdd1982797d74a370eb2b6f75eed6ba373772b16.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8543369174003601}",,,,,,,,,,['neutral'],neutral,1
NCT01014429,"{'position': 1, 'link': 'https://coloncancernewstoday.com/2017/05/30/colon-cancer-therapy-pcm-075-proves-safe-in-phase-1-clinical-trial/', 'title': 'PCM-075 Proves Safe as Treatment for Colon, Other Cancer Types, Phase 1 Trial Shows', 'source': 'Colon Cancer News Today', 'date': 'May 30, 2017', 'snippet': ""Read about Trovagene's PCM-075, a therapy for several blood and solid tumor \ntherapies, proving safe in a Phase 1 clinical trial."", 'thumbnail': 'https://serpapi.com/searches/67222ecca3657ab8a2fdcd10/images/6e34aa190fd88f19c16eccfaff653812327227b0704a6ca7b434f1ec5dfa9d44.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.49582603573799133}",,,,,,,,,,['neutral'],neutral,1
NCT00813709,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/2017/03/23/early-rebif-treatment-prolongs-progression-clinically-definite-ms-multiple-sclerosis/', 'title': 'Progression to Clinically Definite MS Delayed with Early Rebif Treatment', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 23, 2017', 'snippet': 'Read about a study that finds early treatment with Rebif can prolong the \nprogression to a clinically definite multiple sclerosis diagnosis.', 'thumbnail': 'https://serpapi.com/searches/67222f28d1119547a74d3828/images/b58f209b5b0f04f43e2c41191a0d8b59ce8a118d19a89ecaef173ef84c88a61f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8990524411201477}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/12/14/tracking-brain-changes-early-predict-odds-progression/', 'title': 'Tracking brain changes in early MS can predict odds of progression', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 29, 2023', 'snippet': 'Certain brain changes on MRI in the first years of treatment for early MS \ncan predict the odds of a definite MS diagnosis, a study finds.', 'thumbnail': 'https://serpapi.com/searches/67222f28d1119547a74d3828/images/b58f209b5b0f04f429f6482df6d5e5b6f5ba63ec98ecb975121304c58cdc91e2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9105907678604126}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02164513,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1713901', 'title': 'Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD', 'source': 'The New England Journal of Medicine', 'date': 'Apr 18, 2018', 'snippet': 'The benefits of triple therapy for chronic obstructive pulmonary disease \n(COPD) with an inhaled glucocorticoid, a long-acting muscarinic...', 'thumbnail': 'https://serpapi.com/searches/67222f2c8de63cccedebe485/images/4ebfac22afc938ebff5d3250f235eca22e18f65270e338697e6cb6a96b2e55a1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8423652052879333}","{'position': 2, 'link': 'https://copdnewstoday.com/news/fda-approves-triple-combo-known-as-trelegy-ellipta-as-a-maintenance-therapy-for-copd/', 'title': 'COPD Triple Combo Maintenance Therapy, Trelegy Ellipta, Obtains FDA Approval', 'source': 'COPD News Today', 'date': 'Sep 20, 2017', 'snippet': 'The U.S. Food and Drug Administration has approved a triple combination \ntreatment developed by GlaxoSmithKline as a maintenance therapy for...', 'thumbnail': 'https://serpapi.com/searches/67222f2c8de63cccedebe485/images/4ebfac22afc938eb9837b9663b0e0b4e67c6bfeec41718b9369f86d373e1f176.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7620609402656555}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03698513,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-67182-8', 'title': 'Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants', 'source': 'Nature', 'date': 'Jul 18, 2024', 'snippet': 'Milvexian, an oral activated Factor XI (FXIa) inhibitor, is in clinical \nstudies where it may be combined with antiplatelet agents,...', 'thumbnail': 'https://serpapi.com/searches/67222f2e8b84c46faaa41ae1/images/bdde6a6136796c6aa22cdfadac1673474d9ee95c6ecff7425d9dd97dbce6f5ac.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8128746747970581}",,,,,,,,,,['neutral'],neutral,1
NCT02488759,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00088-3/fulltext', 'title': 'Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial', 'source': 'The Lancet', 'date': 'Apr 9, 2024', 'snippet': 'In preliminary findings from the recurrent or metastatic cervical cancer \ncohort of CheckMate 358, nivolumab showed durable anti-tumour...', 'thumbnail': 'https://serpapi.com/searches/67222f3dcdf15582712e597b/images/c537fe067d0f577e8beecbf6ebdf5c8ce9218ffe34bcd93c5a9c8dcce4cc7230.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9017629027366638}","{'position': 2, 'link': 'https://cervicalcancernews.com/2017/06/07/opdivo-nivolumab-shows-promise-as-monotherapy-in-early-clinical-trial-results-in-advanced-cervical-cancer-patients/', 'title': 'Advanced Cervical Cancer Patients Responding to Opdivo in Clinical Trial', 'source': 'Cervical cancer News', 'date': 'Jun 7, 2017', 'snippet': 'Preliminary data from the ongoing CheckMate-358 Phase 1/2 trial shows that \nOpdivo monotherapy was effective in 26.3% of advanced cervical...', 'thumbnail': 'https://serpapi.com/searches/67222f3dcdf15582712e597b/images/c537fe067d0f577e2b18a33fb834bd28830e236a2e8c2c15d03926e5d5e53dc0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9081020355224609}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01161082,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1105803', 'title': 'Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol', 'source': 'The New England Journal of Medicine', 'date': 'Mar 22, 2012', 'snippet': 'Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine \nproteases, binds to low-density lipoprotein (LDL) receptors, leading to...', 'thumbnail': 'https://serpapi.com/searches/67222f578e13c9f8fd73bf81/images/6d2a454f0b8391d4da418c346263461881128c49e10b66fc59809355255b3a65.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8045197129249573}",,,,,,,,,,['neutral'],neutral,1
NCT03220217,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/63/3/376', 'title': 'Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors', 'source': 'Journal of Nuclear Medicine', 'date': 'Mar 1, 2022', 'snippet': 'Abstract. 68Ga-satoreotide trizoxetan is a novel somatostatin receptor \nantagonist associated with high sensitivity and reproducibility in...', 'thumbnail': 'https://serpapi.com/searches/67222f895bb6a2879cc75a0b/images/d5f59235ae58d271e4d1db3c867029814fa0d932c08533e975d79d921f718dd7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.895088255405426}",,,,,,,,,,['neutral'],neutral,1
NCT01989676,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0147-1', 'title': 'Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer', 'source': 'Nature', 'date': 'Jul 13, 2018', 'snippet': 'This randomised, double-blind study compared pharmacokinetics, efficacy, \nsafety and immunogenicity of PF-05280014 (potential trastuzumab...', 'thumbnail': 'https://serpapi.com/searches/67222f98bd7cf0d6d118264e/images/f152b32f078b62ff5d35c7c50497ad4cea1f155941ed2ab793f79bf055bf3e1c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8882277607917786}",,,,,,,,,,['neutral'],neutral,1
NCT04681170,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/lomitapide-reduces-ldl-c-in-children-with-homozygous-familial-hypercholesterolemia/', 'title': 'Lomitapide Reduces LDL-C in Children With Homozygous Familial Hypercholesterolemia', 'source': 'Medical Professionals Reference', 'date': 'Jan 6, 2023', 'snippet': 'Lomitapide was associated with statistically significant reductions in \nlow-density lipoprotein cholesterol (LDL-C) in children with homozygous \nfamilial...', 'thumbnail': 'https://serpapi.com/searches/67222fe8361fd4c8f6049893/images/2c00c335cac0a95ad64c7db16421735e8474fc7cedd5d050423e7305433c9b6e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.611164927482605}",,,,,,,,,,['neutral'],neutral,1
NCT01594333,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1809798', 'title': 'Low-Dose Methotrexate for the Prevention of Atherosclerotic Events', 'source': 'The New England Journal of Medicine', 'date': 'Nov 10, 2018', 'snippet': 'Inflammation is causally related to atherothrombosis. Treatment with \ncanakinumab, a monoclonal antibody that inhibits inflammation by...', 'thumbnail': 'https://serpapi.com/searches/67223009b4fe87245f4865b1/images/0c6164443a86551dd7398fc415efa7c929921ec8dafe4b2b35b3891ae2edaa32.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5578489899635315}","{'position': 2, 'link': 'https://www.rheumatologyadvisor.com/news/low-dose-methotrexate-associated-with-increased-risk-for-certain-adverse-events/', 'title': 'Low-Dose Methotrexate Associated With Increased Risk for Certain Adverse Events', 'source': 'Rheumatology Advisor', 'date': 'Mar 23, 2020', 'snippet': 'Researchers investigated rates, risk, and risk differences of adverse \nevents in patients receiving low-dose methotrexate compared with...', 'thumbnail': 'https://serpapi.com/searches/67223009b4fe87245f4865b1/images/0c6164443a86551da61db3ac869fa6532080d230fcc896cf8a485bec7684c68a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8042680025100708}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03620474,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.730176/full', 'title': 'Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy', 'source': 'Frontiers', 'date': 'Jun 27, 2024', 'snippet': 'In this review, we classify and summarize the relevant targets and drugs \nunder research and development for the treatment of liver fibrosis at home \nand abroad.', 'thumbnail': 'https://serpapi.com/searches/67223033dc969f71fa9728b5/images/8dd0371f2ebd29d6bd95d7848c7f5ad0554b5f5eebadf617940ac931c2c77a53.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9247708916664124}",,,,,,,,,,['neutral'],neutral,1
NCT01266460,"{'position': 1, 'link': 'https://cervicalcancernews.com/2016/10/26/advaxis-experimental-vaccine-increases-cervical-cancer-survival-rate-50-percent/', 'title': 'Advaxis’ Experimental Vaccine Increases Cervical Cancer 1-Year Survival Rates by 50% in Clinical Trial', 'source': 'Cervical cancer News', 'date': 'Oct 26, 2016', 'snippet': ""Patients with persistent or recurrent metastatic carcinoma of the cervix \n(PRmCC) may strongly benefit from treatment with Advaxis' experimental \nvaccine..."", 'thumbnail': 'https://serpapi.com/searches/67223043a32436e97b522410/images/043659263b598ffd0c75c247ff4653dcae0a1535cfdf5ff6aa0255dbdd1884c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7993733286857605}","{'position': 2, 'link': 'https://cervicalcancernews.com/2016/11/09/advaxis-begins-phase-3-study-axal-advanced-cervical-cancer/', 'title': 'Advaxis Begins Phase 3 Study of AXAL for Advanced Cervical Cancer', 'source': 'Cervical cancer News', 'date': 'Nov 9, 2016', 'snippet': 'Advaxis has begun its Phase 3 clinical trial evaluating axalimogene \nfilolisbac, or AXAL, in women with high-risk, locally advanced cervical...', 'thumbnail': 'https://serpapi.com/searches/67223043a32436e97b522410/images/043659263b598ffd60394a4feb7bff1702cb54f1562b630713cbc188912a062a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9055874943733215}","{'position': 3, 'link': 'https://cervicalcancernews.com/2017/03/17/clinical-trial-shows-vaccine-significantly-increases-cervical-cancer-survival-rate/', 'title': 'Cervical Cancer Vaccine Significantly Increases Survival, Trial Shows', 'source': 'Cervical cancer News', 'date': 'Mar 17, 2017', 'snippet': ""Read about clinical trial results showing that Advaxis' axalimogene \nfilolisbac vaccine significantly increased cervical cancer survival..."", 'thumbnail': 'https://serpapi.com/searches/67223043a32436e97b522410/images/043659263b598ffdd9f83091d45416b34d0fdf1ab82b6e497802ae7f02853122.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.85700923204422}","{'position': 4, 'link': 'https://cervicalcancernews.com/2017/02/27/advaxis-data-on-metastatic-cervical-cancer-vaccine-to-be-presented-at-sgo-meeting/', 'title': 'Advaxis’ Trial Data on Metastatic Cervical Cancer Vaccine to Be Presented at SGO Meeting', 'source': 'Cervical cancer News', 'date': 'Feb 27, 2017', 'snippet': 'Advaxis will present data from its Phase 2 clinical trial evaluating a new \nvaccine therapy, axalimogene filolisbac, for the treatment of metastatic \ncervical...', 'thumbnail': 'https://serpapi.com/searches/67223043a32436e97b522410/images/043659263b598ffd53d226eaa021d477a33f1d83f1a0ebc0922a01e59aaad7a9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8757531046867371}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04136184,"{'position': 1, 'link': 'https://fapnewstoday.com/news/eplontersens-efficacy-fap-supported-full-phase-3-trial-results/', 'title': 'Full eplontersen Phase 3 trial results support efficacy in FAP', 'source': 'FAP News Today', 'date': 'Oct 2, 2023', 'snippet': 'More than a year of eplontersen reduces blood levels of the protein that \naccumulates to toxic levels in familial amyloid polyneuropathy...', 'thumbnail': 'https://serpapi.com/searches/6722306898876dbcee66ff1a/images/37ee8c36f4e0aba24eb8dc1da138b68f5aa683906cf44a14b4dc92b3654a0220.png', 'sentiment': 'positive', 'sentiment_prob': 0.6226806640625}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/eplontersen-phase-3-results-published-in-jama-show-consistent-and-sustained-benefit-301942033.html', 'title': 'Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit', 'source': 'PR Newswire', 'date': 'Sep 28, 2023', 'snippet': 'Publication of NEURO-TTRansform study in patients with hereditary \ntransthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed...', 'thumbnail': 'https://serpapi.com/searches/6722306898876dbcee66ff1a/images/37ee8c36f4e0aba2058f8c41c2c9c4e2a0eb1d96855a2ec044e559008e0b945c.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6229185461997986}","{'position': 3, 'link': 'https://fapnewstoday.com/news/wainua-fap-treatment-slows-progression-key-patient-groups/', 'title': 'Wainua slows FAP progression in key patient groups: Phase 3 trial', 'source': 'FAP News Today', 'date': 'Jun 3, 2024', 'snippet': ""Recent analyses of Phase 3 NEURO-TTRansform trial data support Wainua's \nbenefits, with gains seen across patients by sex and age at onset."", 'thumbnail': 'https://serpapi.com/searches/6722306898876dbcee66ff1a/images/37ee8c36f4e0aba2c47551d33c2e69ae7bbddea188c17ef63a6045e5c2e7ff72.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5215402245521545}","{'position': 4, 'link': 'https://fapnewstoday.com/news/eplontersen-may-stabilize-slow-heart-damage-fap-patients-study/', 'title': 'Eplontersen may stabilize, slow heart damage in FAP patients', 'source': 'FAP News Today', 'date': 'Dec 18, 2023', 'snippet': ""A little more than a year of treatment with eplontersen was found to \nstabilize or even improve the heart's structure and function in people with \nfamilial..."", 'thumbnail': 'https://serpapi.com/searches/6722306898876dbcee66ff1a/images/37ee8c36f4e0aba271b0ce03dbd07b867c5f7fdbb78c65dc16f7ab01b2660fd4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7362790703773499}",,,,,,,"['positive', 'positive', 'neutral', 'neutral']",positive,1
NCT02261714,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-0752-7', 'title': 'TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial', 'source': 'Nature', 'date': 'Feb 17, 2020', 'snippet': 'TG01 is the first cancer immunotherapy targeting KRAS oncogenic mutations. \nThis study assessed the safety and efficacy of TG01/GM-CSF in...', 'thumbnail': 'https://serpapi.com/searches/67223078861b9d075721c8f6/images/65366c04ca22d03eaf511a905a070490839a35e18f36ee056d45d6363eb17b69.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9147586226463318}",,,,,,,,,,['neutral'],neutral,1
NCT02344628,"{'position': 1, 'link': 'https://www.infectiousdiseaseadvisor.com/news/standard-dose-vs-low-dose-azithromycin-for-treatment-of-yaws/', 'title': 'Standard-Dose vs Low-Dose Azithromycin for Treatment of Yaws', 'source': 'Infectious Disease Advisor', 'date': 'Mar 20, 2018', 'snippet': 'Low-dose azithromycin did not meet the prespecified noninferiority margin \ncompared with standard-dose azithromycin in achieving clinical and...', 'thumbnail': 'https://serpapi.com/searches/6722308d861b9d0785b46183/images/fff3b59a030d51c45a3e26b4d3c55afa0f4ba85904f1aaf419eb795e9fb589e6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5120266079902649}",,,,,,,,,,['neutral'],neutral,1
NCT03144583,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-023-01966-1', 'title': 'Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome', 'source': 'Nature', 'date': 'Jul 14, 2023', 'snippet': 'Chimeric antigen receptor (CAR) T cells provide new perspectives for \ntreatment of hematological malignancies.', 'thumbnail': 'https://serpapi.com/searches/672230932c83d57e0f071805/images/09338af02ed6ea8a9024821d94556e2cfac4a43533c94a334fe3180c58028512.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7708558440208435}",,,,,,,,,,['neutral'],neutral,1
NCT04191577,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/cerevance-adds-47m-funding-will-start-cvn424-phase-3-trial/', 'title': 'Cerevance adds $47M in funding, will start CVN424 Phase 3 trial', 'source': ""Parkinson's News Today"", 'date': 'Apr 30, 2024', 'snippet': ""Cerevance is planning to launch a Phase 3 clinical trial to test its oral \nmolecule CVN424, designed to treat people with early-stage Parkinson's \ndisease."", 'thumbnail': 'https://serpapi.com/searches/672230c3a25104af56cc92ba/images/8c9cd8837a805be65272de7476333c6aa1ec8abba0a8b5a7e3fe36c88b4e7591.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6493569612503052}",,,,,,,,,,['neutral'],neutral,1
NCT03720470,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2019380', 'title': 'Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis', 'source': 'The New England Journal of Medicine', 'date': 'Mar 24, 2021', 'snippet': 'In this trial, abrocitinib at a dose of either 200 mg or 100 mg once daily \nresulted in significantly greater reductions in signs and symptoms of \nmoderate-to-...', 'thumbnail': 'https://serpapi.com/searches/672230cedc969f71fa972920/images/1a924cd4954c65f2dbc72901f78e47606f601e8ffaedfd851c944d69f9bf381e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7691386938095093}",,,,,,,,,,['neutral'],neutral,1
NCT03822208,"{'position': 1, 'link': 'https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00536-9/fulltext', 'title': 'Inhibitory Siglec-sialic acid interactions in balancing immunological activation and tolerance during viral infections', 'source': 'The Lancet', 'date': 'Nov 10, 2022', 'snippet': 'Siglecs are a family of emerging glyco-immune checkpoints. Inhibiting them \ncan enhance the functions of several types of immune cells,...', 'thumbnail': 'https://serpapi.com/searches/672230d38b84c46fd616808f/images/de1eb75f263b3aaf738befb99fa813c7af25cffc78c58090ca17cef825af8a42.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8865010738372803}",,,,,,,,,,['neutral'],neutral,1
NCT01689207,"{'position': 1, 'link': 'https://www.nature.com/articles/ja201386', 'title': 'Antibiotics in the clinical pipeline in 2013', 'source': 'Nature', 'date': 'Sep 4, 2013', 'snippet': 'The continued emergence of multi-drug-resistant bacteria is a major public \nhealth concern. The identification and development of new...', 'thumbnail': 'https://serpapi.com/searches/67223104f7adbfc5df50721e/images/2ddf1e170fdc9fcba4df7a34d58bcdd940153f55ff86f15b54f3d299cc6e18f7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5702385902404785}",,,,,,,,,,['neutral'],neutral,1
NCT03329690,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-024-02992-x', 'title': 'Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial', 'source': 'Nature', 'date': 'May 14, 2024', 'snippet': 'Trastuzumab deruxtecan (T-DXd) showed statistically significant clinical \nimprovement in patients with human epidermal growth factor receptor \n2-positive (HER2 +...', 'thumbnail': 'https://serpapi.com/searches/67223150a775f24217d49cb3/images/94d46d9002e805fd82d29ad1349692cd7fe4dbdff20aa000d1cf83abd1c3e838.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7972193956375122}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2022.847835/full', 'title': 'Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers', 'source': 'Frontiers', 'date': 'Jun 25, 2024', 'snippet': 'Antibody-drug conjugates (ADCs) represent a new and promising class of \nanticancer therapeutics that combine the cancer specificity of antibodies \nwith...', 'thumbnail': 'https://serpapi.com/searches/67223150a775f24217d49cb3/images/94d46d9002e805fd9135408e27e29618bb129c5da88baf3723389cc9553b951e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7782331705093384}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03333057,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20181023005947/en/Novaliq-Announces-Positive-Topline-Results-for-Its-SEECASE-Phase-2-Trial-of-NOV03-for-the-Treatment-of-Patients-with-Dry-Eye-Disease', 'title': 'Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease', 'source': 'Business Wire', 'date': 'Oct 24, 2018', 'snippet': 'NOV03 (100% perfluorohexyloctane) is a preservative-free ophthalmic \nsolution and the first drug developed to treat evaporative DED associated \nwith meibomian...', 'thumbnail': 'https://serpapi.com/searches/672231b5b7d31daeb5020928/images/bfd41d19bf61d457e41500031a75e06c4185e650ccc6e622f6a1bfc4bb6fea23.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5880693793296814}",,,,,,,,,,['positive'],positive,1
NCT00882102,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25854', 'title': 'American Journal of Hematology | Blood Research Journal', 'source': 'Wiley Online Library', 'date': 'Apr 30, 2020', 'snippet': 'A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed \nand relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.', 'thumbnail': 'https://serpapi.com/searches/672231c6e30abcd386266027/images/46269aac781263cb84c9d2f48843b417e011c7d916e21dc44ed4c83d72384c5f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9031131267547607}",,,,,,,,,,['neutral'],neutral,1
NCT04139798,"{'position': 1, 'link': 'https://www.empr.com/home/news/miebo-approved-to-treat-signs-and-symptoms-of-dry-eye-disease/', 'title': 'Miebo Approved to Treat Signs and Symptoms of Dry Eye Disease', 'source': 'Medical Professionals Reference', 'date': 'May 18, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Miebo™ \n(perfluorohexyloctane ophthalmic solution) for the treatment of the signs \nand...', 'thumbnail': 'https://serpapi.com/searches/6722321266d9958464b79485/images/95451deb0a11ace04d037c7d4039f2e7ded0029cdf41584cf146caf294cdd2fc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8509652018547058}",,,,,,,,,,['neutral'],neutral,1
NCT01551758,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1608033', 'title': 'Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice', 'source': 'The New England Journal of Medicine', 'date': 'Sep 4, 2016', 'snippet': 'Evidence for the management of chronic obstructive pulmonary disease (COPD) \ncomes from closely monitored efficacy trials involving groups of...', 'thumbnail': 'https://serpapi.com/searches/672232d88b7ba7a724a7f131/images/fd9e76ddbc7e2a1eed5323fbb8183694ccc50ef76d53b5fe79281e7eaac8b5e7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8639252781867981}",,,,,,,,,,['neutral'],neutral,1
NCT03790839,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-36946-7', 'title': 'A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity', 'source': 'Nature', 'date': 'Mar 14, 2023', 'snippet': 'This is a phase 1, open-label, single-sequence, multiple-dose, \nsingle-center trial conducted in the US (NCT03790839), to evaluate the \nclinical pharmacokinetics...', 'thumbnail': 'https://serpapi.com/searches/67223386e10f0a8ec4c285cf/images/5b6136ceecd13587173229067adc2361d80d482b1e41018b542c28ef7b5d8bd7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9017764925956726}",,,,,,,,,,['neutral'],neutral,1
NCT03799718,"{'position': 1, 'link': 'https://www.prnewswire.com/il/news-releases/brainstorm-cell-therapeutics-reaches-alignment-with-fda-on-cmc-aspects-of-phase-3b-nurown-clinical-trial-302183061.html', 'title': 'BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial', 'source': 'PR Newswire', 'date': 'Jun 26, 2024', 'snippet': 'PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading \ndeveloper of adult stem cell therapeutics for neurodegenerative...', 'thumbnail': 'https://serpapi.com/searches/672233f8b57db8b81dcfe21f/images/3482470dbcaf50a94d3cb67a6fa49ee3fcaf651a322cce3f036be1e47cac6ae1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9033440947532654}","{'position': 2, 'link': 'https://www.streetinsider.com/Basic+Content/BrainStorm+to+Announce+Third+Quarter+2023+Financial+Results+and+Provide+a+Corporate+Update/22369647.html', 'title': 'BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update', 'source': 'StreetInsider', 'date': 'Nov 7, 2023', 'snippet': '7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a \nleading developer of cellular therapies for neurodegenerative...', 'thumbnail': 'https://serpapi.com/searches/672233f8b57db8b81dcfe21f/images/3482470dbcaf50a971c2c64c4f347d9971ead68b532e25b3756034ac1e07aa5a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7812823057174683}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02415439,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/vamorolone-improves-muscle-function-in-dmd-boys-phase-2a-data/', 'title': 'Vamorolone Improves Muscle Function in DMD Boys, Phase 2a Trial Data Show', 'source': 'Muscular Dystrophy News', 'date': 'Sep 4, 2019', 'snippet': 'Read about the findings of an extension study from a Phase 2a trial showing \nthat vamorolone improves muscle function in boys with DMD.', 'thumbnail': 'https://serpapi.com/searches/672234724a4a1d50b27337a9/images/679612d23e33bef74a34673afed4c8eecf8cc00c770ad4d2f35887c504abc970.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5145846605300903}",,,,,,,,,,['neutral'],neutral,1
NCT00174655,"{'position': 1, 'link': 'https://www.marktechpost.com/2024/04/04/twin-gpt-a-large-language-model-based-digital-twin-creation-approach-for-clinical-trials/', 'title': 'TWIN-GPT: A Large Language Model-based Digital Twin Creation Approach for Clinical Trials', 'source': 'MarkTechPost', 'date': 'Apr 4, 2024', 'snippet': 'Clinical trials play a crucial role in medical advancements by rigorously \nevaluating the safety and efficacy of new treatments.', 'thumbnail': 'https://serpapi.com/searches/67223591667ec57c88a5d884/images/4f4dd5f14b1589165719dd9e1e9ca01268e6ebdb0a7da567f1d529688fe34259.png', 'sentiment': 'neutral', 'sentiment_prob': 0.547235906124115}",,,,,,,,,,['neutral'],neutral,1
NCT02344407,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1614067', 'title': 'Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia', 'source': 'The New England Journal of Medicine', 'date': 'Oct 12, 2017', 'snippet': 'The safety and efficacy of vaccines to prevent Ebola virus disease (EVD) \nwere unknown when the incidence of EVD was peaking in Liberia.', 'thumbnail': 'https://serpapi.com/searches/672235a60c6668b794e92705/images/e8a46b5b3aa79ccb489bc0a371624266b780840d3c34adb8f5bf14f7a79dcca2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7979072332382202}",,,,,,,,,,['neutral'],neutral,1
NCT02026583,"{'position': 1, 'link': 'https://www.dovepress.com/regulating-cholesterol-in-tumorigenesis-a-novel-paradigm-for-tumor-nan-peer-reviewed-fulltext-article-IJN', 'title': 'Regulating Cholesterol in Tumorigenesis: A Novel Paradigm for Tumor Nanotherapeutics', 'source': 'Dove Medical Press', 'date': 'Feb 1, 2024', 'snippet': 'This review provides an overview of cholesterol-integrated membrane lipid \nnanotherapeutics for cancer therapy through cholesterol regulation.', 'thumbnail': 'https://serpapi.com/searches/67223632a88278deeec7ece6/images/b0747c4bfdfdd2257a042b9eaac786f58103b3991f805ab657e1b3733cce22f6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9186954498291016}",,,,,,,,,,['neutral'],neutral,1
NCT04990037,"{'position': 1, 'link': 'https://finance.yahoo.com/news/cantargia-strong-phase-2-clinical-052000499.html', 'title': 'Cantargia’s Strong Phase 2 Clinical Data in Pancreatic Cancer with Nadunolimab Published in Clinical Cancer Research', 'source': 'Yahoo Finance', 'date': '3 weeks ago', 'snippet': 'LUND, SWEDEN / ACCESSWIRE / October 10, 2024 / Cantargia (STO:CANTA) \nCantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the...', 'thumbnail': 'https://serpapi.com/searches/672236dfce1a75e004e26de8/images/5265659460cbc0a6147981e651525eb202c7dbf14648a0163aad4664430e1a69.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8587148189544678}","{'position': 2, 'link': 'https://www.notimerica.com/comunicados/noticia-comunicado-cantargia-presents-new-data-at-sitc-2022-supporting-nadunolimabs-promising-antitumor-clinical-efficacy-20221107141601.html', 'title': ""Cantargia presents new data at SITC 2022 supporting nadunolimab's promising antitumor clinical efficacy"", 'source': 'Notimérica', 'date': 'Nov 7, 2022', 'snippet': 'Data shows nadunolimab dual mechanism potently reduces levels of \ntumor-promoting molecules. LUND, Sweden, Nov.', 'thumbnail': 'https://serpapi.com/searches/672236dfce1a75e004e26de8/images/5265659460cbc0a632f647e33bf9044d73a237f5b9c980785dc917fe99f82e10.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8620907068252563}","{'position': 3, 'link': 'https://www.notimerica.com/comunicados/noticia-comunicado-cantargia-presents-new-robust-data-at-asco-2022-confirming-promising-effects-of-nadunolimab-in-treatment-of-pancreatic-20220527003000.html', 'title': 'Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic c', 'source': 'Notimérica', 'date': 'May 26, 2022', 'snippet': '(NASDAQ Stockholm: CANTA) today reported extended interim results in \nfirst-line pancreatic cancer (PDAC)...', 'thumbnail': 'https://serpapi.com/searches/672236dfce1a75e004e26de8/images/5265659460cbc0a63521f894e8e18f6f22e730b85951bbbc59def529f4d37600.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7977784276008606}","{'position': 4, 'link': 'https://www.notimerica.com/comunicados/noticia-comunicado-cantargia-presents-clinical-interim-results-at-asco-2022-highlighting-the-potential-of-nadunolimab-in-combination-with-20220526233306.html', 'title': 'Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with c', 'source': 'Notimérica', 'date': 'May 26, 2022', 'snippet': '(NASDAQ Stockholm: CANTA) today reported new results from the phase Ib \nclinical trial CIRIFOUR in 15 solid...', 'thumbnail': 'https://serpapi.com/searches/672236dfce1a75e004e26de8/images/5265659460cbc0a61c5b99fe5b5afb2d49e24836d10f54efd509858264bd61f1.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7152458429336548}","{'position': 5, 'link': 'https://www.notimerica.com/comunicados/noticia-comunicado-cantargia-asco-2022-presentation-strengthens-positive-phase-iia-interim-results-for-nadunolimab-in-nsclc-20220527002150.html', 'title': 'Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC', 'source': 'Notimérica', 'date': 'May 26, 2022', 'snippet': 'today reported updated interim results for non-small cell lung cancer \n(NSCLC) patients treated with...', 'thumbnail': 'https://serpapi.com/searches/672236dfce1a75e004e26de8/images/5265659460cbc0a6b1fb15ec8f72c86258132524cae386e3268e24ab6c131775.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5094895958900452}",,,,,,"['neutral', 'positive', 'positive', 'positive', 'positive']",positive,1
NCT03325556,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2034634', 'title': 'Trial of Pimavanserin in Dementia-Related Psychosis', 'source': 'The New England Journal of Medicine', 'date': 'Jul 21, 2021', 'snippet': 'Patients with dementia-related psychosis who had a response to pimavanserin \nhad a lower risk of relapse with continuation of the drug than with \ndiscontinuation.', 'thumbnail': 'https://serpapi.com/searches/672236ed8d1473e38aba931c/images/4f10701a6aa958dd950ff37121a4c89f7ffc32939dcd4be46b2a2ec797d4d260.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8467076420783997}","{'position': 2, 'link': 'https://alzheimersnewstoday.com/news/bid-nuplazid-treat-alzheimers-psychosis-rejected-fda/', 'title': ""Bid for Nuplazid to Treat Alzheimer's Psychosis Rejected by FDA"", 'source': ""Alzheimer's News Today"", 'date': 'Aug 8, 2022', 'snippet': ""The U.S. Food and Drug Administration has affirmed its decision rejecting \nNuplazid as a treatment for Alzheimer's disease-related psychosis."", 'thumbnail': 'https://serpapi.com/searches/672236ed8d1473e38aba931c/images/4f10701a6aa958dd5651601cf04a5b0c96192ca75ea84eb995c82a7574617ed8.png', 'sentiment': 'negative', 'sentiment_prob': 0.6054498553276062}","{'position': 3, 'link': 'https://parkinsonsnewstoday.com/news/nuplazid-parkinsons-drug-psychosis-effective-dementia/', 'title': ""Nuplazid, Parkinson's drug for psychosis, effective with dementia"", 'source': ""Parkinson's News Today"", 'date': 'Dec 19, 2023', 'snippet': ""The Phase 3 HARMONY trial found Nuplazidoutperformed a placebo at managing \npsychosis in Parkinson's disease dementia patients."", 'thumbnail': 'https://serpapi.com/searches/672236ed8d1473e38aba931c/images/4f10701a6aa958ddb25a878ff62d267d0a7e35519e6fa27ebeb26d6b5dbe606e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5408130288124084}","{'position': 4, 'link': 'https://alzheimersnewstoday.com/news/nuplazid-significantly-delays-relapses-dementia-related-psychosis-alzheimers-harmony-trial/', 'title': 'Nuplazid Significantly Delays Relapses in Dementia-related Psychosis, Phase 3 Study Shows', 'source': ""Alzheimer's News Today"", 'date': 'Oct 11, 2019', 'snippet': ""Treatment with Nuplazid significantly delays time to a psychosis relapse in \ndementia-related disorders such as Alzheimer's, a Phase 3 trial..."", 'thumbnail': 'https://serpapi.com/searches/672236ed8d1473e38aba931c/images/4f10701a6aa958dd62d8e0aa935d02e61e17ceac54f829186a278b4ba689d3f3.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5234055519104004}",,,,,,,"['neutral', 'negative', 'neutral', 'negative']",neutral,1
NCT02503332,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-34139-2', 'title': 'Clinical validation for automated geographic atrophy monitoring on OCT under complement inhibitory treatment', 'source': 'Nature', 'date': 'Apr 29, 2023', 'snippet': 'The main purpose of this study was the clinical validation of an artificial \nintelligence (AI)-based algorithm to segment a topographic 2D GA area on a \n3D...', 'thumbnail': 'https://serpapi.com/searches/6722379688bcdefebd9ae39f/images/0b19fad7925fae49faaab0af016c94123ce642f1c84782c7ec8d2ae5a9719923.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9083051681518555}",,,,,,,,,,['neutral'],neutral,1
NCT02040194,"{'position': 1, 'link': 'https://www.genengnews.com/news/auris-medicals-tinnitus-candidate-keyzilen-fails-second-phase-iii-trial/', 'title': 'Auris Medical’s Tinnitus Candidate Keyzilen Fails Second Phase III Trial', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Mar 14, 2018', 'snippet': 'Auris Medical has acknowledged the second Phase III failure in 19 months \nfor its tinnitus candidate Keyzilen (AM-101), promising a future update on \nits plans.', 'thumbnail': 'https://serpapi.com/searches/672237e0d169156d0d07122f/images/dc52e59ecfd7f87a738890403fbc30c62810876a78d0837a6e71f66a0cc01173.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5285354852676392}",,,,,,,,,,['neutral'],neutral,1
NCT04657016,"{'position': 1, 'link': 'https://www.empr.com/home/news/significant-weight-loss-observed-with-tirzepatide-in-two-phase-3-studies/', 'title': 'Significant Weight Loss Observed With Tirzepatide in Two Phase 3 Studies', 'source': 'Medical Professionals Reference', 'date': 'Jul 27, 2023', 'snippet': 'Treatment with tirzepatide led to significant weight loss in adults with \nobesity or overweight with weight-related comorbidities (excluding type 2 \ndiabetes)', 'thumbnail': 'https://serpapi.com/searches/67223806a88278df22a20276/images/d5989b8aacded2bb601ca48d78cc8b93150737d01658d0e24510fd4765544e33.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7856768369674683}",,,,,,,,,,['neutral'],neutral,1
NCT02166021,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/03/07/ms-stem-cell-therapy-ng-01-shows-neuroprotective-effects-trial/', 'title': 'NG-01 Stem Cell Therapy for MS Shows Neuroprotective Effects in Trial', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 7, 2022', 'snippet': ""The new data support NG-01's neuroprotective effects and shed light on the \nunderlying mechanisms of its clinical benefits in this patient population."", 'thumbnail': 'https://serpapi.com/searches/67223823c5d7695ce97d0e4c/images/638cf3dc67dedb2000787e13b3dd493598a4f79457c01c4e12bc75df120cb724.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6918380260467529}",,,,,,,,,,['neutral'],neutral,1
NCT03100942,"{'position': 1, 'link': 'https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-023-07087-5', 'title': 'A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients', 'source': 'BioMed Central', 'date': 'Feb 15, 2023', 'snippet': ""Primary Sjogren's syndrome (pSS) is a systemic autoimmune disease involving \nmultiple organ systems. The Janus kinase/signal transduction and..."", 'thumbnail': 'https://serpapi.com/searches/67223883d11a89f6ae7eca2b/images/11c106513d52223cbaa0fe828280a980f213684fa897d1ba070476d16a2e8fa7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8893328309059143}",,,,,,,,,,['neutral'],neutral,1
NCT01102426,"{'position': 1, 'link': 'https://www.researchgate.net/figure/The-marine-organism-Aplidium-albicans-reused-with-permission-from-PharmaMar-R-Spain_fig4_329338056', 'title': 'Fig. 4. The marine organism Aplidium albicans (reused with permission...', 'source': 'ResearchGate', 'date': 'Dec 2, 2018', 'snippet': 'Intrinsic or acquired drug resistance, adverse drug reactions and tumor \nheterogeneity between and within cancer patients limit the efficacy of \nclinical...', 'thumbnail': 'https://serpapi.com/searches/67223a9854605cf4e9888ab5/images/6ee1d3dccd9a8182dd2dd11bc08cffe052da8b907ed0a6ddcc65da4c2b4b7287.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6151346564292908}",,,,,,,,,,['negative'],negative,0
NCT00575055,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1304839', 'title': ""Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease"", 'source': 'The New England Journal of Medicine', 'date': 'Jan 23, 2014', 'snippet': ""Bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, is in \nclinical development for the treatment of Alzheimer's disease."", 'thumbnail': 'https://serpapi.com/searches/67223b1c7d533ebcf913a8d6/images/ed02d71d2bd11e5c4b156f80360a6df78922332668a486a7db504cc31eae6803.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8981547355651855}",,,,,,,,,,['neutral'],neutral,1
NCT03136185,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20201119005341/en/Imago-BioSciences-Raises-80-Million-in-Series-C-Financing', 'title': 'Imago BioSciences Raises $80 Million in Series C Financing', 'source': 'Business Wire', 'date': 'Nov 19, 2020', 'snippet': 'Imago BioSciences, Inc. (Imago), a clinical-stage biopharmaceutical company \ndeveloping innovative treatments for myeloproliferative neoplasms, today \nannounced...', 'thumbnail': 'https://serpapi.com/searches/6722388af59d0018ddb8c975/images/d2b027c81b2e5fa3892f0772a7c7f3a0e01f7e9a878a33bbe50c1cac8c3bbe6d.png', 'sentiment': 'positive', 'sentiment_prob': 0.6281275153160095}",,,,,,,,,,['positive'],positive,1
NCT02459886,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/biogen-announcement-discontinue-cinpanemab-parkinsons/', 'title': ""Biogen Discontinues Development of Cinpanemab for Parkinson's"", 'source': ""Parkinson's News Today"", 'date': 'Feb 4, 2021', 'snippet': 'Due to negative clinical trial findings, Biogen has discontinued the \ndevelopment of cinpanemab (BIIB054), an investigational medication...', 'thumbnail': 'https://serpapi.com/searches/6722388ca775f24217d4a1cd/images/d0a35cab265426cb4a97a3bec742cf19129cefae134896dd688c1120b59ae56a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5776012539863586}",,,,,,,,,,['negative'],negative,0
NCT04480957,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-022-00590-x', 'title': 'A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine', 'source': 'Nature', 'date': 'Dec 13, 2022', 'snippet': 'A first-in-human clinical trial of the safety, tolerability and \nimmunogenicity of ARCT-021, a self-transcribing and replicating mRNA (STARR \nTM ) vaccine...', 'thumbnail': 'https://serpapi.com/searches/672238a975f974f2a8be07dd/images/2edb267d607b9cdd678fe6daa86cfba8dfb412e18916874eecd5b17d4a947bcd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.887642502784729}",,,,,,,,,,['neutral'],neutral,1
NCT03406507,"{'position': 1, 'link': 'https://www.empr.com/home/news/ultomiris-approved-for-pediatric-patients-with-paroxysmal-nocturnal-hemoglobinuria/', 'title': 'Ultomiris Approved for Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria', 'source': 'Medical Professionals Reference', 'date': 'Jun 8, 2021', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of \nUltomiris (ravulizumab-cwvz) to include patients 1 month of age and older \nwith paroxysmal...', 'thumbnail': 'https://serpapi.com/searches/672238b5400bd5bee73a0274/images/3a21c1518f356812494b658894298cd0f7b6d34ecad949cb8e96e2fe87690fee.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8257713913917542}",,,,,,,,,,['neutral'],neutral,1
NCT05067335,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/EVENITY-Romosozumab', 'title': 'Romosozumab (EVENITY®)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Osteoporosis, A study to learn how romosozumab worked in women with \nosteoporosis who had gone through menopause, Phase 3, 20070337', 'thumbnail': 'https://serpapi.com/searches/672238e62bab902c96627caa/images/1fe2ee72f86d53da4608ceb1569de5598aa736f0b2ed808bb52f7637e2b0b702.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8978717923164368}",,,,,,,,,,['neutral'],neutral,1
NCT04072315,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/63/supplement_2/2236', 'title': 'Phase 2 drug target engagement study of PLN-74809 in patients with idiopathic pulmonary fibrosis using a novel αvβ6 cystine knot PET imaging tracer', 'source': 'Journal of Nuclear Medicine', 'date': 'Aug 1, 2022', 'snippet': 'Mirwais Wardak, Scott Turner, Joshua Mooney, Gaia Rizzo, Karen Morris, \nsusan Jacobs, Heying Duan, Eric Lefebvre, Gregory Cosgrove,...', 'thumbnail': 'https://serpapi.com/searches/6722393e9e5bd52d11aa1ac3/images/ef98056d1ca10585297527f08ae71501c4880a0f3f9b073a7f9589b4c4c2b8fe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8908429145812988}",,,,,,,,,,['neutral'],neutral,1
NCT01265849,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20231204232873/en/UK%E2%80%99S-National-Institute-for-Health-and-Care-Excellence-NICE-Selects-CEL-SCI%E2%80%99s-Multikine-as-Potential-New-Standard-of-Care-for-Head-Neck-Cancer', 'title': 'UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer', 'source': 'Business Wire', 'date': 'Dec 4, 2023', 'snippet': 'NICE has selected Multikine (Leukocyte Interleukin, Injection) to be \nevaluated as the potential new standard of care for squamous cell carcinoma \nof the head...', 'thumbnail': 'https://serpapi.com/searches/6722399d8e13c9f8fd73c88f/images/7b449671712395345c005b5b0424200954a663a0f0e9c4726940225eec9a59cb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9246986508369446}","{'position': 2, 'link': 'https://cervicalcancernews.com/2016/11/23/fda-partial-clinical-hold-clinical-trial-multikine/', 'title': 'FDA Asked to Lift Partial Clinical Hold on Multikine Clinical Trial', 'source': 'Cervical cancer News', 'date': 'Nov 23, 2016', 'snippet': ""CEL-SCI's Phase 3 clinical trial assessing its investigational drug \nMultikine in patients with squamous cell carcinoma of the head and neck \n(SCCHN) recently..."", 'thumbnail': 'https://serpapi.com/searches/6722399d8e13c9f8fd73c88f/images/7b449671712395344b2b629575ee8174c68b4f77af86a3055199ceaa4f4e6306.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8735347390174866}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02912104,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S2589537024003237', 'title': 'Safety and efficacy of allogenic human amniotic epithelial cells transplantation via ovarian artery in patients with premature ovarian failure: a single-arm, phase 1 clinical trial', 'source': 'ScienceDirect.com', 'date': 'Jul 31, 2024', 'snippet': 'Premature ovarian failure (POF) is a prevalent and severe condition that \nimpairs female health but there is currently no effective treatment \navailable to...', 'thumbnail': 'https://serpapi.com/searches/672239e2a9210b1b7b08908c/images/1a95536cae4e459586c0aa4c912578f63699c266d6cb09f50a62ccd1f7fdc41c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5064108371734619}",,,,,,,,,,['neutral'],neutral,1
NCT00650091,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1113354', 'title': 'Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis', 'source': 'The New England Journal of Medicine', 'date': 'May 20, 2012', 'snippet': 'A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has \nbeen widely used as a treatment for idiopathic pulmonary fibrosis.', 'thumbnail': 'https://serpapi.com/searches/67223b4efc40bf18bd76cce2/images/5b07fc0bc9691a2625d0dfdb8ad215ba01473cce26a6422705742bfcf977a959.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8677869439125061}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.794997/full', 'title': 'Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis', 'source': 'Frontiers', 'date': 'Feb 6, 2024', 'snippet': 'Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease \ncharacterized by an abnormal reepithelialisation, an excessive tissue \nremodelling...', 'thumbnail': 'https://serpapi.com/searches/67223b4efc40bf18bd76cce2/images/5b07fc0bc9691a260da91b865bf58fed127551dddfb4e4127f8ef51ce98e3d86.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6219959855079651}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT02370498,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/news/gastric-cancer-data-suggest-clinical-efficacy-molecular-determinant-risk/', 'title': 'Study Identifies Molecular Determinants of Gastric/Gastroesophageal Junction Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Aug 10, 2021', 'snippet': 'Data suggest that tissue tumor mutational burden is a significant and \nindependent predictor of clinical efficacy.', 'thumbnail': 'https://serpapi.com/searches/67223b6cb2ebaeb57e2b385e/images/596ff65385086511cfbf9812f5aa065ad050ea11f66e8487b82d6e3a51ee35c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7947157025337219}",,,,,,,,,,['neutral'],neutral,1
NCT04184622,"{'position': 1, 'link': 'https://investor.lilly.com/news-releases/news-release-details/tirzepatide-reduced-risk-developing-type-2-diabetes-94-adults', 'title': 'Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight', 'source': 'Eli Lilly and Company', 'date': 'Aug 20, 2024', 'snippet': '176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the \nlongest completed trial of tirzepatide to date.', 'thumbnail': 'https://serpapi.com/searches/67223b83e30abcd3862667f0/images/d33a14507c1ac8bb7acba22ccab5f8a84ba69d88bd98029e8f88f79d25b41161.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5982460975646973}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/news/zepbound-eli-lilly-diabetes-prevention/', 'title': 'Lilly’s blockbuster Zepbound prevents type 2 diabetes in obese patients', 'source': 'Clinical Trials Arena', 'date': 'Aug 20, 2024', 'snippet': ""Eli Lilly's blockbuster drug Zepbound (tirzepatide) has been effective in \npreventing the development of type 2 diabetes (T2D) in patients who are \noverweight or..."", 'thumbnail': 'https://serpapi.com/searches/67223b83e30abcd3862667f0/images/d33a14507c1ac8bba410bab5509bd2279b7b771724cdea28833566a70c2a4432.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5146840214729309}","{'position': 3, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine', 'title': ""Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight"", 'source': 'Eli Lilly and Company', 'date': 'May 13, 2022', 'snippet': ""Detailed results from Lilly 's first phase 3 trial in obesity or overweight \npresented at the American Diabetes Association's ® 82nd..."", 'thumbnail': 'https://serpapi.com/searches/67223b83e30abcd3862667f0/images/d33a14507c1ac8bb9cdbdc65ba2eec8c3e4f4a06b4f9208407beb2a05e38145d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7818043828010559}","{'position': 4, 'link': 'https://www.endocrinologyadvisor.com/news/tirzepatide-reduces-10-year-atherosclerosis-risk-among-patients-with-obesity/', 'title': 'Tirzepatide Reduces 10-Year Atherosclerosis Risk Among Patients With Obesity', 'source': 'Endocrinology Advisor', 'date': 'Nov 30, 2023', 'snippet': 'Tirzepatide treatment is associated with a significant reduction in 10-year \nrisk for atherosclerosis among individuals with obesity or overweight and \nwithout...', 'thumbnail': 'https://serpapi.com/searches/67223b83e30abcd3862667f0/images/d33a14507c1ac8bb8e363093ef813f94085a7cac14446b6cfda8be6dc2cae4e3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7338991761207581}","{'position': 5, 'link': 'https://www.empr.com/home/news/zepbound-approved-for-chronic-weight-management/', 'title': 'Zepbound Approved for Chronic Weight Management', 'source': 'Medical Professionals Reference', 'date': 'Nov 8, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Zepbound™ (tirzepatide) \nas an adjunct to a reduced-calorie diet and increased physical...', 'thumbnail': 'https://serpapi.com/searches/67223b83e30abcd3862667f0/images/d33a14507c1ac8bbb9972ccf12a470cdf63377b843e89d2f72035e74b12b4655.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6654108166694641}","{'position': 6, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or', 'title': ""Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1"", 'source': 'Eli Lilly and Company', 'date': 'Apr 28, 2022', 'snippet': 'Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week \nphase 3 study. 63% of participants taking tirzepatide 15 mg...', 'thumbnail': 'https://serpapi.com/searches/67223b83e30abcd3862667f0/images/d33a14507c1ac8bb34a25447add72a600ff5d5c5b7fd42c723dbffc266c41d27.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7193176746368408}",,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03761056,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01731-4', 'title': 'Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial', 'source': 'Nature', 'date': 'Mar 21, 2022', 'snippet': 'We conclude that axi-cel is highly effective as part of first-line therapy \nfor high-risk LBCL, with a manageable safety profile.', 'thumbnail': 'https://serpapi.com/searches/67223b8d7ca6b36e4282f45b/images/72ece01b16a1182203240861ae35c567024e15c4aaa614902e774dadf3213989.png', 'sentiment': 'positive', 'sentiment_prob': 0.62087082862854}",,,,,,,,,,['positive'],positive,1
NCT03467113,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Fenfluramine%20%20%28Fintepla%29', 'title': 'Fenfluramine (Fintepla)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Dravet Syndrome, A Study to Evaluate Safety, Tolerability, and \nPharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to \nLess...', 'thumbnail': 'https://serpapi.com/searches/67223bd048c429afb956e2e9/images/598efd6ca4e31c9e47e52e07db5064ee5d8d5f82f8f4064179a9d63e6180619b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8484590649604797}",,,,,,,,,,['neutral'],neutral,1
NCT00423410,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-020-71246-w', 'title': 'Dose–response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin', 'source': 'Nature', 'date': 'Sep 2, 2020', 'snippet': 'In a multisite phase 1 clinical study of crolibulin (NCT00423410), we \nmeasured treatment-induced changes in tumor perfusion and water diffusivity \n(ADC)', 'thumbnail': 'https://serpapi.com/searches/67223c0f6de1e4461d91474c/images/3ac37f60ab47498c8f6db1ac8b88787121846c941ee9ce859ee3337f582dcc8d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9077230095863342}",,,,,,,,,,['neutral'],neutral,1
NCT04712500,"{'position': 1, 'link': 'https://www.manilatimes.net/2024/10/29/tmt-newswire/pr-newswire/kind-presents-positive-results-of-and017-to-treat-anemia-associated-with-chronic-kidney-disease-in-two-phase-ii-and-two-phase-i/1992905', 'title': 'KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I', 'source': 'The Manila Times', 'date': '1 day ago', 'snippet': 'Clinical Trials at American Society of Nephrology (ASN) - Kidney Week 2024. \nSAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Kind Pharmaceutical...', 'thumbnail': 'https://serpapi.com/searches/67223c221f3d4b4c18f5c08a/images/74514df067118fe582e2ae4c4ab890b236231156948057be6c4f47602c1c46ba.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6056104302406311}",,,,,,,,,,['neutral'],neutral,1
NCT00234832,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1003114', 'title': 'Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects', 'source': 'The New England Journal of Medicine', 'date': 'Sep 2, 2010', 'snippet': 'The Sibutramine Cardiovascular Outcomes (SCOUT) trial evaluated the \nlong-term effects of sibutramine treatment combined with diet and exercise \non the rates of...', 'thumbnail': 'https://serpapi.com/searches/67223d9ed0253ebcf855dc61/images/a7bfdd1f9067afdb144d2bbbbc320dfe26845c0611049e2904cc86a97ea54740.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9058936834335327}",,,,,,,,,,['neutral'],neutral,1
NCT01430416,"{'position': 1, 'link': 'https://www.nature.com/articles/s41417-022-00457-2', 'title': 'Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling', 'source': 'Nature', 'date': 'Mar 29, 2022', 'snippet': 'In this study, we examined the signaling and functional effects of two PKC \ninhibitors (AEB071 and IDE196) in a panel of UM cell models.', 'thumbnail': 'https://serpapi.com/searches/67223e36e45f339e0173778c/images/af28dee7fff0a8c499331eef60405c2a570100fb8950352e447d4030d1109991.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8511186838150024}",,,,,,,,,,['neutral'],neutral,1
NCT03823287,"{'position': 1, 'link': 'https://www.globenewswire.com/de/news-release/2023/04/25/2654401/0/en/New-Vabysmo-data-suggest-greater-retinal-drying-versus-aflibercept-in-nAMD-and-DME.html', 'title': 'New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME', 'source': 'GlobeNewswire', 'date': 'Apr 25, 2023', 'snippet': ""Post-hoc analyses from four phase III studies indicate Vabysmo dried \nretinal fluid faster with fewer injections in neovascular or 'wet'..."", 'thumbnail': 'https://serpapi.com/searches/67223e49d78a989f43d44cd7/images/e85ccf5749f39218d7a93e3a857e0c64175c6b94a605e5ffc7ae7e78af1b6881.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8941206932067871}",,,,,,,,,,['neutral'],neutral,1
NCT02885610,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.539797/full', 'title': 'A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target', 'source': 'Frontiers', 'date': 'Feb 6, 2024', 'snippet': 'This review summarizes the biological agents that are in the preclinical \nand clinical trial study of SLE.', 'thumbnail': 'https://serpapi.com/searches/67223e5bcf32e0c291d26c05/images/c8785598eb81e4d3175d91b4184877c28596d5027139e8287c59c1d9a81abd8c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9278648495674133}",,,,,,,,,,['neutral'],neutral,1
NCT03571620,"{'position': 1, 'link': 'http://www.biospectator.com/view/news_print.php?varAtcId=7298', 'title': ""Qurient, presented the P2a results for atopic dermatitis candidate 'Q301' at the AAD 2019"", 'source': '바이오스펙테이터', 'date': 'Mar 15, 2019', 'snippet': '바이오스펙테이터 Sungmin Kim 기자. At the largest dermatology conference in the \nUnited States, Qurient delivered oral and poster...', 'thumbnail': 'https://serpapi.com/searches/67223caaecf150161f81e2a9/images/e85dc127d07af42893f87d368aae4f19b5c9de7f39561b65ac11c9487e86c656.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8518079519271851}",,,,,,,,,,['neutral'],neutral,1
NCT01825785,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2016/6217286', 'title': 'Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges', 'source': 'Wiley Online Library', 'date': 'May 26, 2016', 'snippet': 'Sclerostin antibody treatment has demonstrated efficacy and superiority \ncompared to other anabolic treatments for increasing bone formation in both \npreclinical...', 'thumbnail': 'https://serpapi.com/searches/67223cc03c944b51303a302e/images/a17730b98943fcb7c753167619c210049d36c616590941c65774ce9d08f2e940.png', 'sentiment': 'neutral', 'sentiment_prob': 0.635117769241333}",,,,,,,,,,['neutral'],neutral,1
NCT01737398,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1716793', 'title': 'Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis', 'source': 'The New England Journal of Medicine', 'date': 'Jul 4, 2018', 'snippet': 'Hereditary transthyretin amyloidosis is caused by pathogenic \nsingle-nucleotide variants in the gene encoding transthyretin (TTR) that \ninduce...', 'thumbnail': 'https://serpapi.com/searches/67223cc8c5d7695ce97d135a/images/dd801045b8c73fa042b084b46cf2367cafc81d21410bf78eabe4cb431540ab4a.png', 'sentiment': 'negative', 'sentiment_prob': 0.6270034313201904}","{'position': 2, 'link': 'https://fapnewstoday.com/news/real-world-study-shows-long-term-benefits-fap-with-tegsedi-treatment/', 'title': 'Long-term benefits of Tegsedi for FAP seen in real-world study', 'source': 'FAP News Today', 'date': 'May 13, 2024', 'snippet': 'Tegsedi (inotersen) safely and effectively slowed the progression of \npolyneuropathy, or damage to multiple nerves, when taken for up to about \nsix years for 10...', 'thumbnail': 'https://serpapi.com/searches/67223cc8c5d7695ce97d135a/images/dd801045b8c73fa0e540e41054a36087bc12befcc35a92382e1dbd25a60649bb.png', 'sentiment': 'positive', 'sentiment_prob': 0.5440833568572998}","{'position': 3, 'link': 'https://fapnewstoday.com/news/results-fully-enrolled-fap-neuro-ttransform-trial-eplontersen-expected-mid-2022/', 'title': 'Results From Fully Enrolled NEURO-TTRansform Trial Due Mid-2022', 'source': 'FAP News Today', 'date': 'Aug 2, 2021', 'snippet': ""Patient enrollment is complete for the NEURO-TTRansform trial testing \nIonis' eplontersen in adults with FAP, with results due in mid-2022."", 'thumbnail': 'https://serpapi.com/searches/67223cc8c5d7695ce97d135a/images/dd801045b8c73fa0e933ef19809cec947be0187ccc8823172a88e35ea1749fa2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8340455889701843}",,,,,,,,"['negative', 'positive', 'neutral']",negative,0
NCT04097314,"{'position': 1, 'link': 'https://www.researchgate.net/publication/376715534_Precision_Pharmacotherapy_With_Zibotentan_in_Microvascular_Angina_a_randomized_placebo-controlled_cross-over_trial', 'title': '(PDF) Precision Pharmacotherapy With Zibotentan in Microvascular Angina: a randomized, placebo-controlled, cross-over trial.', 'source': 'ResearchGate', 'date': 'Dec 21, 2023', 'snippet': 'The trial compared zibotentan, an oral endothelin A receptor selective \nantagonist, with placebo in 118 patients with microvascular angina.', 'thumbnail': 'https://serpapi.com/searches/67223d18a775f2424b78397a/images/2aed15c2b2a5e9220db98279c4caa930290584f5ac1caee64a67963177cea959.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8792782425880432}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1156456/full', 'title': 'Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA)', 'source': 'Frontiers', 'date': 'Jun 16, 2023', 'snippet': ""In today's era of individualized precision medicine drug repurposing \nrepresents a promising approach to offer patients fast access to novel \ntreatments."", 'thumbnail': 'https://serpapi.com/searches/67223d18a775f2424b78397a/images/2aed15c2b2a5e9227bf3e5163852dc239e1edaf24d7d871e4618d72f48ec397b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5737496614456177}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03560531,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-023-00523-4', 'title': 'An emerging generation of endocrine therapies in breast cancer: a clinical perspective | npj Breast Cancer', 'source': 'Nature', 'date': 'Apr 5, 2023', 'snippet': 'Anti-estrogen therapy is a key component of the treatment of both early and \nadvanced-stage hormone receptor (HR)-positive breast cancer.', 'thumbnail': 'https://serpapi.com/searches/67223d220d379f2003b0af95/images/f0e60483985415318cc47717d7771f597c3e1f92451c31b022f6b7af4f4aee41.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8845224976539612}",,,,,,,,,,['neutral'],neutral,1
NCT03928821,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01815-1', 'title': 'Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial', 'source': 'Nature', 'date': 'May 12, 2022', 'snippet': 'HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) \nhas shown viral escape, indicating that at least a triple bNAb...', 'thumbnail': 'https://serpapi.com/searches/67223ee07e1d1f5f2dba6646/images/0111f55d09da3d36e2aef61ab09d5b432dbfa44bf6aede0274b90d64aa22a58a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8841989636421204}",,,,,,,,,,['neutral'],neutral,1
NCT00636168,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1611299', 'title': 'Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy', 'source': 'The New England Journal of Medicine', 'date': 'Oct 8, 2016', 'snippet': 'On the basis of data from a phase 2 trial that compared the checkpoint \ninhibitor ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram...', 'thumbnail': 'https://serpapi.com/searches/67223f21d9c3e646d94ae442/images/dace67e9ace08bab8166c7beb720e031d4d541f36f8f4de2ae67cc4f18cd5f8f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8651557564735413}",,,,,,,,,,['neutral'],neutral,1
NCT03639194,"{'position': 1, 'link': 'https://dailynews.ascopubs.org/do/adc-novel-sez6-target-well-tolerated-preliminary-efficacy-small-cell-lung-cancer-phase', 'title': 'ADC With Novel SEZ6 Target Well-Tolerated With Preliminary Efficacy in Small Cell Lung Cancer Phase 1 Trial', 'source': 'ASCO Daily News', 'date': 'Jun 5, 2023', 'snippet': 'ABBV-011, an antibody-drug conjugate (ADC) targeting seizure-related \nhomolog protein (SEZ6), was well-tolerated and demonstrated antitumor \nactivity.', 'thumbnail': 'https://serpapi.com/searches/67223f29d11a89f6ae7ecfad/images/36a7e94f3f7ff20f8fcdf9e56acf1aeebfb5f4526c6582c5bde86f1e92a07e6a.png', 'sentiment': 'positive', 'sentiment_prob': 0.521563708782196}",,,,,,,,,,['positive'],positive,1
NCT00123916,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1507574', 'title': 'Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy', 'source': 'The New England Journal of Medicine', 'date': 'Sep 1, 2015', 'snippet': ""The role of trypanocidal therapy in patients with established Chagas' \ncardiomyopathy is unproven.We conducted a prospective, multicenter,..."", 'thumbnail': 'https://serpapi.com/searches/6722408b7ebde5d9be3a9049/images/ab289c72c63151320bb0b8bdbc00c13476e5618b35543194cccb5eaef300fb3a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6657135486602783}",,,,,,,,,,['neutral'],neutral,1
NCT03769090,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2203163', 'title': 'Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma', 'source': 'The New England Journal of Medicine', 'date': 'May 15, 2022', 'snippet': 'The use of a fixed-dose combination of albuterol and budesonide, as \ncompared with albuterol alone, as rescue medication might reduce the risk \nof severe asthma...', 'thumbnail': 'https://serpapi.com/searches/672240a558e43394362230d7/images/8273b6c82a06d7ed7b46b59e098c8a55e0e3f86b661aa07b6650aa85a999f8a4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8807826042175293}",,,,,,,,,,['neutral'],neutral,1
NCT02722278,"{'position': 1, 'link': 'https://www.empr.com/home/news/new-oral-tx-approved-for-males-with-certain-types-of-hypogonadism/', 'title': 'New Oral Tx Approved for Males With Certain Types of Hypogonadism - MPR', 'source': 'Medical Professionals Reference', 'date': 'Mar 28, 2019', 'snippet': 'The Food and Drug Administration (FDA) has approved Jatenzo (testosterone \nundecanoate; Clarus Therapeutics) capsules for testosterone...', 'thumbnail': 'https://serpapi.com/searches/672240a6069e57ccad4130cc/images/2e078a5469dcd790186da2ca352d443f173e140d6a3b17792ca7416d1778db5b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8623235821723938}",,,,,,,,,,['neutral'],neutral,1
NCT02683213,"{'position': 1, 'link': 'https://www.researchgate.net/publication/339582818_Update_on_the_EFFECTS_study_of_fluoxetine_for_stroke_recovery_A_randomised_controlled_trial_in_Sweden', 'title': '(PDF) Update on the EFFECTS study of fluoxetine for stroke recovery: A randomised controlled trial in Sweden', 'source': 'ResearchGate', 'date': 'Aug 12, 2020', 'snippet': 'PDF | Studies have suggested that fluoxetine might improve neurological \nrecovery after stroke, but the results remain inconclusive. The EFFECTS.', 'thumbnail': 'https://serpapi.com/searches/6722410edb3ac9d20ba6dbcf/images/0329f6333540fe5acf06a31ab4aef53ad062661074eb18d79a449bc28e328a2d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9180974960327148}",,,,,,,,,,['neutral'],neutral,1
NCT02410772,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2033400', 'title': 'Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis', 'source': 'The New England Journal of Medicine', 'date': 'May 5, 2021', 'snippet': 'In an open-label, phase 3, randomized, controlled trial involving persons \nwith newly diagnosed pulmonary tuberculosis from 13 countries,...', 'thumbnail': 'https://serpapi.com/searches/67224139efad21cb4a6af16c/images/c98bb78fe7b788a28d0e93839c06d5ed456c1b15fac19d67f5e6d6e7dc0c9ba3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9226011633872986}",,,,,,,,,,['neutral'],neutral,1
NCT03819647,"{'position': 1, 'link': 'https://www.nature.com/articles/s41581-022-00661-1', 'title': 'Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope', 'source': 'Nature', 'date': 'Jan 5, 2023', 'snippet': 'Primary hyperoxaluria (PH) is an inherited disorder that results from the \noverproduction of endogenous oxalate, leading to recurrent kidney...', 'thumbnail': 'https://serpapi.com/searches/672241a149ea55cdb86953f6/images/1b9f62983ac2c19511cb59aea0c1968003b4cb1dcfa88f5e366f751c3814cf4c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8578411340713501}",,,,,,,,,,['neutral'],neutral,1
NCT03717272,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02381-w', 'title': 'receptor for cannabis use disorder: phase 1 and phase 2a randomized trials', 'source': 'Nature', 'date': 'Jun 8, 2023', 'snippet': 'AEF0117, the first of a new pharmacological class, is a signaling-specific \ninhibitor of the cannabinoid receptor 1 (CB 1 -SSi).', 'thumbnail': 'https://serpapi.com/searches/672241d55ddfba5b347bae83/images/9f55e64768606847dd159f98334eb531b0d6b74f5a854ac2e6f22805b69608e6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9198508858680725}",,,,,,,,,,['neutral'],neutral,1
NCT02297945,"{'position': 1, 'link': 'https://cushingsdiseasenews.com/news/metopirone-safely-normalized-significantly-lowered-urine-cortisol-levels-cushings-patients-clinical-trial/', 'title': ""Metopirone Fares Well in Phase 3/4 Clinical Trial of Cushing's Patients"", 'source': ""Cushing's Disease News"", 'date': 'Sep 18, 2020', 'snippet': ""Metopirone (metyrapone) safely normalized, or at least lowered by half, the \nlevels of cortisol found in the urine of patients with endogenous \nCushing's..."", 'thumbnail': 'https://serpapi.com/searches/67224200fc183d1a4363f5f0/images/d73293d9a098525da8da72db9eade73fa90c400e9dde743935ff7184fe12217b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5527316331863403}",,,,,,,,,,['neutral'],neutral,1
NCT00526149,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-94259-5', 'title': 'High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma', 'source': 'Nature', 'date': 'Jul 20, 2021', 'snippet': 'We demonstrated that combining navitoclax with irradiation resulted in \nsynergistic in vitro antitumor effects in HNSCC cell lines.', 'thumbnail': 'https://serpapi.com/searches/6722420acc48791e952690ea/images/1e52debcbcdcbfc027a6bc2e9bb43e3e9148fa8e67aaf4720127434f9e4754ba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8691082000732422}",,,,,,,,,,['neutral'],neutral,1
NCT02151526,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/first-sickle-cell-disease-patient-successfully-treated-with-gene-therapy/', 'title': ""Sickle Cell Patient Becomes World's First to be Successfully Treated WIth Gene Therapy"", 'source': 'Sickle Cell Disease News', 'date': 'Mar 7, 2017', 'snippet': ""A 13-year-old boy with sickle cell disease has become the world's first \npatient to be successfully treated with gene therapy."", 'thumbnail': 'https://serpapi.com/searches/672242a11b4e34fdab3d7d56/images/dcf14c07bf6715869f8e95c98aad0725ca388fd9bc28216177c3326fe297b791.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6654171347618103}",,,,,,,,,,['neutral'],neutral,1
NCT02326194,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60553-0/abstract', 'title': 'Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial', 'source': 'The Lancet', 'date': 'Mar 24, 2015', 'snippet': 'Up to now, all tested Ebola virus vaccines have been based on the virus \nstrain from the Zaire outbreak in 1976. We aimed to assess the...', 'thumbnail': 'https://serpapi.com/searches/6722436fee468296d35793ad/images/66a7029f973c49861c343a4fea44c4b617a42debb36e596538efa21e0fe3bf8f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8658244609832764}",,,,,,,,,,['neutral'],neutral,1
NCT01485926,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-023-00572-9', 'title': 'Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer | npj Breast Cancer', 'source': 'Nature', 'date': 'Sep 27, 2023', 'snippet': 'HER2-positive (HER2+) breast cancer accounts for 20–25% of all breast \ncancers. Predictive biomarkers of neoadjuvant therapy response are...', 'thumbnail': 'https://serpapi.com/searches/6722438cbd7cf0d69d204616/images/193f84881eaeb7084264c025658faaf42845f28ea6bc85b40c6e1813c6259510.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7186137437820435}","{'position': 2, 'link': 'https://www.nature.com/articles/s41416-023-02375-y', 'title': 'Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy | British Journal of Cancer', 'source': 'Nature', 'date': 'Jul 28, 2023', 'snippet': 'The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared \nchemotherapy in combination with trastuzumab, lapatinib or both...', 'thumbnail': 'https://serpapi.com/searches/6722438cbd7cf0d69d204616/images/193f84881eaeb70838fe09f65c255872371394fec6e6670b980551983bdad9fa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8899237513542175}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01358175,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1505066', 'title': 'Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis', 'source': 'The New England Journal of Medicine', 'date': 'Dec 24, 2015', 'snippet': 'In two double-blind trials, we randomly assigned patients to receive \nsecukinumab or placebo. In MEASURE 1, a total of 371 patients received...', 'thumbnail': 'https://serpapi.com/searches/672245d4e92456707116f58a/images/02cee8506acfe07639cac40dbeb7c82dd332a79d33329c56e6c4e8096a80134f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8936644792556763}","{'position': 2, 'link': 'https://ankylosingspondylitisnews.com/2022/10/06/real-world-database-study-cosentyx-side-effects/', 'title': 'Real-world Database Study Used to Identify Cosentyx Side Effects |...', 'source': 'Ankylosing Spondylitis News', 'date': 'Oct 6, 2022', 'snippet': 'Diarrhea, cold-like symptoms, itchy skin, and rash are the most common \nreal-world side effects associated with Cosentyx, an approved treatment for \nankylosing...', 'thumbnail': 'https://serpapi.com/searches/672245d4e92456707116f58a/images/02cee8506acfe07651bff6e0b904559b333935ab18a8f9fd6299890219d2099f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5941896438598633}","{'position': 3, 'link': 'https://ankylosingspondylitisnews.com/2018/06/25/as-therapy-cosentyx-added-public-drug-programs-across-canada/', 'title': 'AS Therapy Cosentyx Added to Public Drug Programs Across Canada', 'source': 'Ankylosing Spondylitis News', 'date': 'Jun 25, 2018', 'snippet': 'Ontario and other regions of Canada will now reimburse Cosentyx \n(secukinumab) under public drug programs for adults with ankylosing...', 'thumbnail': 'https://serpapi.com/searches/672245d4e92456707116f58a/images/02cee8506acfe07657bd8c357c06c314d0f99af43a0476730a84f1517a0161db.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8980309963226318}","{'position': 4, 'link': 'https://ankylosingspondylitisnews.com/2017/11/08/novartis-cosentyx-shows-no-radiographic-progression-in-patients-with-ankylosing-spondylitis/', 'title': 'Little Ankylosing Spondylitis Progression When Using Cosentyx, Data Says', 'source': 'Ankylosing Spondylitis News', 'date': 'Nov 8, 2017', 'snippet': 'Novartis recently reported that long-term radiographic data from a clinical \ntrial showed that treatment of ankylosing spondylitis (AS) with...', 'thumbnail': 'https://serpapi.com/searches/672245d4e92456707116f58a/images/02cee8506acfe0761f447130209b6e917a8db858832d7f794dbce4ef88b0f923.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.890432596206665}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT05955586,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2024/08/05/2924591/0/en/Spero-Therapeutics-Announces-Second-Quarter-2024-Operating-Results-and-Provides-a-Business-Update.html', 'title': 'Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update', 'source': 'GlobeNewswire', 'date': 'Aug 5, 2024', 'snippet': 'Enrollment concluded in the Phase 2a proof-of-concept clinical trial \nevaluating SPR720 in nontuberculous mycobacterial pulmonary disease...', 'thumbnail': 'https://serpapi.com/searches/672245dc5809e7249195c6e8/images/e79fdffd32c2e25321264bb0f776b6c3677c02cc46badb5b8fd20ef21774d442.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9027279019355774}",,,,,,,,,,['neutral'],neutral,1
NCT02446912,"{'position': 1, 'link': 'https://www.empr.com/home/news/saphnelo-approved-for-systemic-lupus-erythematosus/', 'title': 'Saphnelo Approved for Systemic Lupus Erythematosus', 'source': 'Medical Professionals Reference', 'date': 'Aug 2, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Saphnelo \n(anifrolumab-fnia) for the treatment of adults with moderate to severe \nsystemic lupus...', 'thumbnail': 'https://serpapi.com/searches/672245faf8b05d603f25c8dd/images/4cc7b5ed49f54cd57bbec1c76b3ae3a9029b14d3ea1bfdd93f74e06fec5c4afb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.850493848323822}",,,,,,,,,,['neutral'],neutral,1
NCT00002840,"{'position': 1, 'link': 'https://www.targetedonc.com/view/long-term-survival-possible-with-vincristine-plus-radiotherapy-in-anaplastic-oligodendroglial-tumors', 'title': 'Long-Term Survival Possible With Vincristine Plus Radiotherapy in Anaplastic Oligodendroglial Tumors', 'source': 'Targeted Oncology', 'date': 'Jun 30, 2022', 'snippet': 'Findings from 2 studies suggest that long-term survival is possible in a \nsignificant proportion of patients with a 1p/19q co-deleted...', 'thumbnail': 'https://serpapi.com/searches/6722460fb691a77af4148d58/images/3a57e236a6a661f29ef13ab0ecbdf52405a4fdf573d78280dcfd2f6f4c70cfc9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6290527582168579}",,,,,,,,,,['neutral'],neutral,1
NCT04563026,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/durect-corporation-announces-topline-results-from-phase-2b-ahfirm-trial-of-larsucosterol-in-alcohol-associated-hepatitis-with-promising-effect-on-mortality-301980628.html', 'title': 'DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality', 'source': 'PR Newswire', 'date': 'Nov 7, 2023', 'snippet': 'Compelling efficacy signal in favor of larsucosterol in the key secondary \nendpoint of mortality at 90 days. Clinically relevant reduction in...', 'thumbnail': 'https://serpapi.com/searches/6722461fcc48791e95269501/images/f3494c4c1f6834a814877174266c2b7946395c298855265255e0f5fa55b86f40.png', 'sentiment': 'positive', 'sentiment_prob': 0.5870905518531799}","{'position': 2, 'link': 'https://liverdiseasenews.com/news/fda-breakthrough-designation-granted-larsucosterol-hepatitis/', 'title': 'FDA breakthrough designation granted to larsucosterol for AH', 'source': 'liverdiseasenews.com', 'date': 'May 23, 2024', 'snippet': ""The US Food and Drug Administration (FDA) has granted breakthrough therapy \ndesignation to larsucosterol, Durect's investigational therapy for people \nwith..."", 'thumbnail': 'https://serpapi.com/searches/6722461fcc48791e95269501/images/f3494c4c1f6834a8412e34aa8f8aad460874378748dc394699c48932209a22a8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5488607883453369}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT03760146,"{'position': 1, 'link': 'https://www.koreabiomed.com/news/articleView.html?idxno=13140', 'title': 'Pfizer scores European approval for 20-valent pneumococcal vaccine', 'source': 'KBR', 'date': 'Feb 16, 2022', 'snippet': 'Pfizer, which dominated the global pneumococcal vaccine market with \n13-valent Prevnar 13, said it won approval for a 20-valent vaccine in \nEurope.', 'thumbnail': 'https://serpapi.com/searches/672246221397bae56dcc8ea1/images/b00cf21a3bfd37fbf5f3ba32328fe43e187c212eba172cb9cd32393815eab101.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5019819736480713}",,,,,,,,,,['positive'],positive,1
NCT04949841,"{'position': 1, 'link': 'https://finance.yahoo.com/news/leo-pharma-announces-publication-chronic-060000540.html', 'title': 'LEO Pharma Announces Publication of Chronic Hand Eczema Phase 3 Data in The Lancet', 'source': 'Yahoo Finance', 'date': 'Jul 19, 2024', 'snippet': 'The findings of the DELTA 1 and DELTA 2 phase 3 clinical trials for \ndelgocitinib cream have been published in The Lancet.', 'thumbnail': 'https://serpapi.com/searches/672246232da1575f5eaf78b1/images/bc004840436f61a30a54d6f4bed5285c754669532d6e00cf822dff2d1a09f115.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8991910219192505}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20231030388942/en/LEO-Pharma-Announces-Positive-Outcome-of-DELTA-3-Open-Label-Extension-Trial-of-Delgocitinib-Cream-in-the-Treatment-of-Adults-With-Moderate-to-Severe-Chronic-Hand-Eczema-CHE', 'title': 'LEO Pharma Announces Positive Outcome of DELTA 3 Open-Label Extension Trial of Delgocitinib Cream in the Treatment of Adults With Moderate to Severe Chronic Hand Eczema (CHE)', 'source': 'Business Wire', 'date': 'Oct 30, 2023', 'snippet': 'DELTA 3 is a phase 3, single-arm, open-label extension trial of \ndelgocitinib cream, an investigational topical pan-Janus kinase \n(JAK)-inhibitor.', 'thumbnail': 'https://serpapi.com/searches/672246232da1575f5eaf78b1/images/bc004840436f61a3b18a85921a44dedf2a3b64c5e1175526599d78038d96b150.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6695564985275269}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04620733,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa2312100', 'title': 'A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis', 'source': 'The New England Journal of Medicine', 'date': 'Feb 21, 2024', 'snippet': 'In this phase 3, 12-month, double-blind, placebo-controlled trial, we \nrandomly assigned (in a 2:1 ratio) patients who had had an inadequate...', 'thumbnail': 'https://serpapi.com/searches/6722462c237938d086abc237/images/3f08cb563a3cace9569a83b0233e4a0131b8a715cc3e664455c6a994334908a5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8429213166236877}","{'position': 2, 'link': 'https://liverdiseasenews.com/news/liver-damage-itch-from-primary-biliary-cholangitis-eased-with-seladelpar/', 'title': 'Seladelpar eases liver damage, itch in primary biliary cholangitis', 'source': 'liverdiseasenews.com', 'date': 'May 22, 2024', 'snippet': ""One year of treatment with Gilead Sciences' seladelpar normalized \nbiomarkers of liver injury and rapidly reduced itch for most people with \nprimary biliary..."", 'thumbnail': 'https://serpapi.com/searches/6722462c237938d086abc237/images/3f08cb563a3cace91526849e1f949d0156fba45d54095c08b3a6704cd61342bb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7402761578559875}","{'position': 3, 'link': 'https://www.empr.com/news/livdelzi-granted-accelerated-approval-for-primary-biliary-cholangitis/', 'title': 'Livdelzi Granted Accelerated Approval for Primary Biliary Cholangitis', 'source': 'Medical Professionals Reference', 'date': 'Aug 15, 2024', 'snippet': 'The Food and Drug Administration (FDA) has granted accelerated approval to \nLivdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC)', 'thumbnail': 'https://serpapi.com/searches/6722462c237938d086abc237/images/3f08cb563a3cace924f1e44f66e627d4b02af9768b27d9d0068246ad45c41aed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8262484669685364}","{'position': 4, 'link': 'https://liverdiseasenews.com/news/seladelpar-reduces-disease-activity-itch-pbc-patients-trial/', 'title': 'Seladelpar found to reduce disease activity, itch in PBC patients in trial', 'source': 'Liver Disease News', 'date': 'Mar 6, 2024', 'snippet': 'Daily treatment with seladelpar was found to normalize liver enzymes and \nreduce itch in primary biliary cholangitis patients, per trial...', 'thumbnail': 'https://serpapi.com/searches/6722462c237938d086abc237/images/3f08cb563a3cace92cfb514c866cf6abc64f87ef3fef9e7aa21015acf1c5b27a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7049957513809204}","{'position': 5, 'link': 'https://liverdiseasenews.com/news/orsini-pantherx-pharmacies-will-dispense-livdelzi-pbc-us/', 'title': 'Orsini, Pantherx pharmacies will dispense Livdelzi for PBC in US', 'source': 'Liver Disease News', 'date': 'Aug 21, 2024', 'snippet': 'Livdelzi, which won FDA approval last week to treat primary biliary \ncholangitis, will be distributed in the U.S. by Orsini and Pantherx...', 'thumbnail': 'https://serpapi.com/searches/6722462c237938d086abc237/images/3f08cb563a3cace97467b1c01400645ac8e1dfc6ff0c3925f45fd71a6be1f444.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8587095141410828}","{'position': 6, 'link': 'https://liverdiseasenews.com/news/fda-approves-gileads-seladelpar-now-livdelzi-treat-pbc-adults/', 'title': 'FDA approves seladelpar, now Livdelzi, to treat adults with PBC', 'source': 'Liver Disease News', 'date': 'Aug 14, 2024', 'snippet': ""The US Food and Drug Administration (FDA) has granted accelerated approval \nto Gilead Sciences' oral candidate seladelpar as a second-line therapy for \nadults..."", 'thumbnail': 'https://serpapi.com/searches/6722462c237938d086abc237/images/3f08cb563a3cace985c4cedcf9aa52300d0056a1f7d72d974c54a1b75d5b873a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7787725925445557}","{'position': 7, 'link': 'https://liverdiseasenews.com/news/application-investigational-pbc-treatment-seladelpar-get-fda-review/', 'title': 'Application for investigational PBC treatment seladelpar to get FDA review', 'source': 'Liver Disease News', 'date': 'Feb 14, 2024', 'snippet': ""The US Food and Drug Administration (FDA) will review CymaBay Therapeutics' \napplication for seladelpar, an oral investigational treatment for adults \nwith..."", 'thumbnail': 'https://serpapi.com/searches/6722462c237938d086abc237/images/3f08cb563a3cace912de27dd85b5090528900c423ff94aa2b74cb3c0c0c50244.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9271091818809509}",,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02285062,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-50830-y', 'title': 'Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation', 'source': 'Nature', 'date': 'Aug 8, 2024', 'snippet': 'This high-risk cluster is enriched for activated B-cell cell-of-origin, low \nimmune infiltration, high MYC expression, and copy number aberrations.', 'thumbnail': 'https://serpapi.com/searches/6722464aecf15015f2355f2f/images/f70264fd2bd01a457126e5ab3caee975a21bdeb4e69fa28c0a4b4e49c31b64cf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8239750862121582}",,,,,,,,,,['neutral'],neutral,1
NCT04174170,"{'position': 1, 'link': 'https://www.psychiatrictimes.com/view/brexpiprazole-sertraline-combination-for-ptsd-submitted-for-snda-review', 'title': 'Brexpiprazole + Sertraline Combination for PTSD Submitted for sNDA Review', 'source': 'Psychiatric Times', 'date': 'Apr 11, 2024', 'snippet': 'Based on data from several phase 3 and phase 2 clinical trials, Otsuka \nPharmaceutical Co., Ltd. and H. Lundbeck A/S submitted a supplemental...', 'thumbnail': 'https://serpapi.com/searches/672246c3657c66a83b66a8f8/images/4f59873023bf03c108592943440fd5704fb0400602a7ea6896083bf5a1e4b99a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.916138231754303}",,,,,,,,,,['neutral'],neutral,1
NCT03747224,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/circ.142.suppl_3.15751', 'title': 'Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia', 'source': 'American Heart Association Journals', 'date': 'Nov 12, 2020', 'snippet': 'Background: Angiopoietin-like protein 3 (ANGPTL3) regulates triglyceride \n(TG) and lipoprotein (LP) metabolism by inhibiting liver and...', 'thumbnail': 'https://serpapi.com/searches/672243bc316650b50a5d3d89/images/f1b63bb3d334d36b36eaddccffaec4d52f1befbcb9442b888e24fcf17f91eaff.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8859959840774536}",,,,,,,,,,['neutral'],neutral,1
NCT03761849,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMc2300400', 'title': 'Tominersen in Adults with Manifest Huntington’s Disease', 'source': 'The New England Journal of Medicine', 'date': 'Dec 6, 2023', 'snippet': ""A trial of tominersen, designed to slow Huntington's disease progression by \nlowering levels of huntingtin protein, was stopped prematurely,..."", 'thumbnail': 'https://serpapi.com/searches/6722445f740bdba6cefd8b16/images/bd4b353115a8d0f146c8450a409d7ac1d3930cb81ff3deddea3133c28a37188c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5398553609848022}","{'position': 2, 'link': 'https://huntingtonsdiseasenews.com/news/generation-hd1-trial-fails-to-demonstrate-benefits-tominersen/', 'title': 'GENERATION HD1 Trial Fails to Show Benefits of Tominersen', 'source': ""Huntington's Disease News"", 'date': 'May 6, 2021', 'snippet': ""Treatment with tominersen failed to show evidence of clinical benefit in \nadults with Huntington's disease during the Phase 3 trial..."", 'thumbnail': 'https://serpapi.com/searches/6722445f740bdba6cefd8b16/images/bd4b353115a8d0f1068648fd00558750d38347e5f541b21c387940b0094694fc.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7655267715454102}","{'position': 3, 'link': 'https://www.nature.com/articles/s41593-022-01207-1', 'title': 'An RNA-targeting CRISPR–Cas13d system alleviates disease-related phenotypes in Huntington’s disease models', 'source': 'Nature', 'date': 'Dec 12, 2022', 'snippet': ""Huntington's disease (HD) is a fatal, dominantly inherited \nneurodegenerative disorder caused by CAG trinucleotide expansion in exon 1 \nof the..."", 'thumbnail': 'https://serpapi.com/searches/6722445f740bdba6cefd8b16/images/bd4b353115a8d0f14d68dd59cee4ae5a931fe596384a8168cdce7b0725fa7ccd.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5353351831436157}","{'position': 4, 'link': 'https://huntingtonsdiseasenews.com/news/roche-planning-phase-2-tominersen-trial-generation-hd1-post-hoc-analysis/', 'title': 'New Trial of Tominersen Possible in Younger, Milder Disease Patients', 'source': ""Huntington's Disease News"", 'date': 'Jan 25, 2022', 'snippet': 'A post-hoc analysis of GENERATION HD1 data may support a Phase 2 trial of \ntominersen in younger patients with milder disease, Roche says.', 'thumbnail': 'https://serpapi.com/searches/6722445f740bdba6cefd8b16/images/bd4b353115a8d0f1fbe48754c8fa0eb5c6890200a27bd96ee27b549e27393a75.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8569520711898804}","{'position': 5, 'link': 'https://huntingtonsdiseasenews.com/news/hdsa-2024-huntingtons-disease-clinical-trials-enrolling-us/', 'title': 'HDSA 2024: Huntington’s disease clinical trials enrolling in US', 'source': ""Huntington's Disease News"", 'date': 'Jun 7, 2024', 'snippet': ""Clinical trials testing either tominersen or dalzanemdor are enrolling \nHuntington's patients in the U.S., developers said at HDSA 2024."", 'thumbnail': 'https://serpapi.com/searches/6722445f740bdba6cefd8b16/images/bd4b353115a8d0f16bb4cc26ca921d8714819f74a7b36e694774a214865d373f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9507646560668945}","{'position': 6, 'link': 'https://huntingtonsdiseasenews.com/news/rg6042-potential-dmt-in-phase-3-trial-named-orphan-drug-in-japan/', 'title': 'RG6042, Potential DMT in Phase 3 Trial, Named Orphan Drug in Japan', 'source': ""Huntington's Disease News"", 'date': 'Mar 5, 2020', 'snippet': 'Japan named RG6042, designed to target all forms of the disease-causing \nmutant huntingtin protein, an orphan drug – a status also given it...', 'thumbnail': 'https://serpapi.com/searches/6722445f740bdba6cefd8b16/images/bd4b353115a8d0f12924ce79bde932ccad50d4671aace892c5bc56917064c793.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.882026195526123}","{'position': 7, 'link': 'https://huntingtonsdiseasenews.com/columns/what-is-cap-score-how-do-i-calculate-it/', 'title': 'What is a CAP score, and how do I calculate it?', 'source': ""Huntington's Disease News"", 'date': 'Mar 15, 2023', 'snippet': ""A CAP score is often used to determine eligibility in Huntington's disease \nclinical trials, explains columnist B.J. Viau. Here's a primer."", 'thumbnail': 'https://serpapi.com/searches/6722445f740bdba6cefd8b16/images/bd4b353115a8d0f1b4834ec71ea0d857eacd5618d8d9dbbfe149c28b088dec9d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9442566633224487}",,,,"['neutral', 'negative', 'negative', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01975701,"{'position': 1, 'link': 'https://www.targetedonc.com/view/present-and-future-precision-medications-signal-promise-for-adults-with-glioma', 'title': 'Present and Future Precision Medications Signal Promise for Adults With Glioma', 'source': 'Targeted Oncology', 'date': 'Feb 4, 2023', 'snippet': 'In an interview with Targeted Oncology, Patrick Wen, MD, discussed \nprecision medicine for adult gliomas, including present and future \ntreatment options.', 'thumbnail': 'https://serpapi.com/searches/672244b67ca6b36e741825b4/images/735ff6a12d4c3a6f2a1877ebbb80ce1b6dec8f1f921c1e418c2550796d87d1b7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.856313169002533}",,,,,,,,,,['neutral'],neutral,1
NCT01915498,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-019-0472-2', 'title': 'Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia', 'source': 'Nature', 'date': 'Apr 9, 2019', 'snippet': 'Older adults with acute myeloid leukemia (AML) who are not fit for standard \nchemotherapy historically have poor outcomes.', 'thumbnail': 'https://serpapi.com/searches/6722453b76079d9baf77d0de/images/7177c9c171c99cec2ca43e4f68d8481a9b0ed74401f79f98dd3853aecd7b0d0f.png', 'sentiment': 'negative', 'sentiment_prob': 0.7587125897407532}",,,,,,,,,,['negative'],negative,0
NCT04186819,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/early/2024/06/13/jnumed.123.267306', 'title': 'Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies', 'source': 'Journal of Nuclear Medicine', 'date': 'Jun 13, 2024', 'snippet': 'Phillip H. Kuo, Giuseppe Esposito, Gary A. Ulaner, Don Yoo, Katherine \nZukotynski, Gregory C. Ravizzini, Ross Penny, Matthew P. Miller,...', 'thumbnail': 'https://serpapi.com/searches/672246f43c9575674df13b60/images/bc4e744662aacaeff64a908f7ce43399f71ec2267f4e73e09e091ac883ae1498.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9256315231323242}","{'position': 2, 'link': 'https://www.itnonline.com/content/blue-earth-diagnostics-highlights-upcoming-presentation-additional-results-investigational', 'title': 'Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study', 'source': 'Imaging Technology News', 'date': 'Feb 9, 2023', 'snippet': 'Results of the Investigational Phase 3 LIGHTHOUSE Study of 18F-rhPSMA-7.3 \nin newly diagnosed prostate cancer to be presented at 2023 ASCO...', 'thumbnail': 'https://serpapi.com/searches/672246f43c9575674df13b60/images/bc4e744662aacaef200fcdbd53be37bc4dc5c10c1e406a1d699ff2b0837cfd10.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9308755993843079}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02064166,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/intranasal-insulin-improve-verbal-fluency-motor-function-parkinsons-multiple-system-atrophy/', 'title': 'Treatment with Intranasal Insulin May Improve Verbal Fluency and Motor Function, Early Study Shows', 'source': ""Parkinson's News Today"", 'date': 'May 2, 2019', 'snippet': ""Treatment with intranasal insulin — which is atomized into a spray and \ninhaled through the nose — may ease Parkinson's disease-related cognitive..."", 'thumbnail': 'https://serpapi.com/searches/672247c7a505f73e63927d8e/images/32d2ad3424c53fc9ecefaf4988477f9a72614cf5614ed3f5fbdf884ceb940c94.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5133353471755981}",,,,,,,,,,['positive'],positive,1
NCT02874742,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-024-01088-6', 'title': 'Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN | Blood Cancer Journal', 'source': 'Nature', 'date': 'Jul 8, 2024', 'snippet': 'The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab \nplus lenalidomide/bortezomib/dexamethasone (D-RVd) in...', 'thumbnail': 'https://serpapi.com/searches/67224817c0028ebdd77d3bde/images/d91e1fa696afe9c9814258ac2ccbaf20d519ce566f37bd1b56bbfb44218c28ca.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9279817342758179}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/adding-daratumumab-to-rvd-improves-mrd-negativity-pfs-in-newly-diagnosed-myeloma', 'title': 'Adding Daratumumab to RVd Improves MRD Negativity, PFS in Newly Diagnosed Myeloma', 'source': 'Cancer Network', 'date': 'Jun 5, 2022', 'snippet': 'Daratumumab, lenalidomide, bortezomib and dexamethasone (RVd) outperformed \nRVd alone when it came to minimal residual disease and progression-free \nsurvival.', 'thumbnail': 'https://serpapi.com/searches/67224817c0028ebdd77d3bde/images/d91e1fa696afe9c9599798736264edb6b1ce4f93076ef9b49fa6400be93c1eb1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7527785301208496}","{'position': 3, 'link': 'https://www.oncnursingnews.com/view/daratumumab-quadruplet-therapy-yields-promising-hrqol-scores-newly-diagnosed-multiple-myeloma-griffin', 'title': 'Daratumumab-Quadruplet Therapy Yields Promising HRQOL Scores in Transplant Eligible, Newly Diagnosed, Multiple Myeloma', 'source': 'Oncology Nursing News', 'date': 'Dec 11, 2022', 'snippet': 'Adding daratumumab to bortezomib, lenalidomide, and dexamethasone showed \nmeaningful improvements in patient-reported outcomes in the phase 2...', 'thumbnail': 'https://serpapi.com/searches/67224817c0028ebdd77d3bde/images/d91e1fa696afe9c9dcf069d0e4e41e271437920436cf7921a75958a45954d04a.png', 'sentiment': 'positive', 'sentiment_prob': 0.5846643447875977}","{'position': 4, 'link': 'https://www.nature.com/articles/s41408-022-00653-1', 'title': 'Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN | Blood Cancer Journal', 'source': 'Nature', 'date': 'Apr 13, 2022', 'snippet': 'We report a post hoc subgroup analysis of the GRIFFIN study examining the \nefficacy and safety of D-RVd in Black patients after all patients completed \n≥12...', 'thumbnail': 'https://serpapi.com/searches/67224817c0028ebdd77d3bde/images/d91e1fa696afe9c931050d7c88973f1e5648c27aff8ccfb75888560ec40568f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8947310447692871}","{'position': 5, 'link': 'https://myelomaresearchnews.com/news/adding-darzalex-to-a-velcade-revlimid-combo-boosts-cancer-disappearance-in-newly-diagnosed-multiple-myeloma-phase-2-trial-shows/', 'title': 'Adding Darzalex to a Velcade-Revlimid Combo Boosts Cancer...', 'source': 'Myeloma Research News', 'date': 'Jul 24, 2019', 'snippet': 'Read about Phase 2 results showing the benefits of adding Darzalex to \ntreatment with Velcade and Revlimid in patients with multiple myeloma.', 'thumbnail': 'https://serpapi.com/searches/67224817c0028ebdd77d3bde/images/d91e1fa696afe9c9fe4fd1a6bedef29467153cb1532bab0f676c15ab3a02826e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5408183336257935}",,,,,,"['neutral', 'neutral', 'positive', 'neutral', 'positive']",neutral,1
NCT04570657,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/pipeline-moves-parkinsons-disease/', 'title': 'Pipeline Moves: advancement prospects jump for Parkinson’s disease stem cell therapy', 'source': 'Clinical Trials Arena', 'date': 'Mar 21, 2023', 'snippet': 'The Clinical Trials Arena team also review assets in asthma, multiple \noncology indications and blood disorder.', 'thumbnail': 'https://serpapi.com/searches/67224a8b163bdf528ce1d8a9/images/69f12dca28903d1ac0524cb949cd26192c681ee1d5f67fb87a68f05e7ed1cc6c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7419585585594177}",,,,,,,,,,['neutral'],neutral,1
NCT05387733,"{'position': 1, 'link': 'https://www.biospace.com/press-releases/caliway-announces-the-initiation-of-subject-recruitment-in-cbl-514-phase-2b-study-for-dercums-disease', 'title': ""Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease"", 'source': 'BioSpace', 'date': 'Sep 3, 2024', 'snippet': ""The study will enroll approximately 30 Dercum's disease subjects with four \nto ten painful lipomas and randomize them 1:1 into two groups to receive \nCBL-514..."", 'thumbnail': 'https://serpapi.com/searches/672248261f3d4b4c18f5cb7f/images/c7e3cb8273c4af132b0b2be34baa5c40e6cdd94e3dd1f7c37c691497e6017ac2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9136601686477661}",,,,,,,,,,['neutral'],neutral,1
NCT04172441,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/dasiglucagon-under-priority-review-for-hypoglycemia-in-congenital-hyperinsulinism/', 'title': 'Dasiglucagon Gets Priority Review for Hypoglycemia in Congenital Hyperinsulinism', 'source': 'Medical Professionals Reference', 'date': 'Aug 30, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted for Priority Review the \nNew Drug Application (NDA) for dasiglucagon for the prevention...', 'thumbnail': 'https://serpapi.com/searches/672248270d379f2035ac3712/images/80b9e7d9222e258060e9549bc946d4297d8881e90b2dd5a72f63c28d485dcc68.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8679986596107483}","{'position': 2, 'link': 'https://www.globenewswire.com/news-release/2022/05/19/2446817/0/en/Zealand-Pharma-Announces-Positive-Results-from-Phase-3-Trial-of-Dasiglucagon-in-Pediatric-Patients-with-Congenital-Hyperinsulinism-CHI.html', 'title': 'Zealand Pharma Announces Positive Results from Phase 3', 'source': 'GlobeNewswire', 'date': 'May 19, 2022', 'snippet': 'Positive top-line results from its second Phase 3 clinical trial of \ndasiglucagon in pediatric patients with congenital hyperinsulinism (CHI).', 'thumbnail': 'https://serpapi.com/searches/672248270d379f2035ac3712/images/80b9e7d9222e258065b773730a1c58a58f668f188c0e4dd0f71f9ab9c30e4508.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6932388544082642}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04618211,"{'position': 1, 'link': 'https://angioedemanews.com/news/pharvaris-gearing-up-launch-phase-3-trial-phvs416-hae-2024/', 'title': 'Pharvaris aims to launch Phase 3 trial of PHVS416 for HAE in 2024', 'source': 'Angioedema News', 'date': 'Nov 6, 2023', 'snippet': 'Pharvaris is now gearing up startup activities with clinical site \ninvestigators and staff to launch a Phase 3 trial next year of PHVS416.', 'thumbnail': 'https://serpapi.com/searches/67224987272a87d825aec64b/images/c0d225561e5ad69abc069bdaeb90a36cf84e263eb556ab96fcf8d7122d1cce53.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6231164336204529}","{'position': 2, 'link': 'https://angioedemanews.com/news/pharvaris-starts-phase-3-trial-deucrictibant-on-demand-therapy/', 'title': 'Pharvaris starts Phase 3 trial of deucrictibant as on-demand therapy', 'source': 'Angioedema News', 'date': 'Mar 21, 2024', 'snippet': 'Pharvaris has started a Phase 3 clinical trial called RAPIDe-3 to test an \nimmediate-release capsule formulation of deucrictibant as an on-demand \ntreatment to...', 'thumbnail': 'https://serpapi.com/searches/67224987272a87d825aec64b/images/c0d225561e5ad69a2880c2e372232f6b7ad20a1e404ec2f5dfabedc87da4d71b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9026741981506348}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03635047,"{'position': 1, 'link': 'https://www.researchgate.net/publication/339588081_Current_and_Future_Treatments_in_Alzheimer_Disease_An_Update', 'title': '(PDF) Current and Future Treatments in Alzheimer Disease: An Update', 'source': 'ResearchGate', 'date': '1 week ago', 'snippet': 'PDF | Disease-modifying treatment strategies for Alzheimer disease (AD) are \nstill under extensive research.', 'thumbnail': 'https://serpapi.com/searches/67224a364677bf469c24a63d/images/6395e69577dc3c7a253576552e5b4964d1b391124624495d89816cbc13620bb5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9267868399620056}",,,,,,,,,,['neutral'],neutral,1
NCT04501679,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2301333', 'title': 'Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis', 'source': 'The New England Journal of Medicine', 'date': 'Oct 25, 2023', 'snippet': 'Prurigo nodularis is a chronic, debilitating, and severely pruritic \nneuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor...', 'thumbnail': 'https://serpapi.com/searches/67224a465809e724c2f6783d/images/2ed39f667d153329f98f68d22d1f0c390880ad0b94e8a8fd62677bf4829f7b07.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5598675608634949}",,,,,,,,,,['negative'],negative,0
NCT02512068,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/jdi.13126', 'title': 'Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study', 'source': 'Wiley Online Library', 'date': 'Aug 7, 2019', 'snippet': 'Journal of Diabetes Investigation is a clinical and experimental diabetes \nresearch journal publishing basic science, clinical practice,...', 'thumbnail': 'https://serpapi.com/searches/67224bf96ad3c98a9f9436eb/images/be7a7674c389bf23f2bd246cd33baf31cccd27d624f3f25c95054c1135d92a8c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8972136974334717}",,,,,,,,,,['neutral'],neutral,1
NCT01755598,"{'position': 1, 'link': 'https://www.gsk.com/en-gb/media/press-releases/gsk-candidate-vaccine-demonstrates-sustained-level-of-protection-against-active-pulmonary-tuberculosis/', 'title': 'GSK candidate vaccine demonstrates sustained level of protection against active pulmonary tuberculosis', 'source': 'GSK', 'date': 'Oct 29, 2019', 'snippet': 'Analysis of phase IIb study published in the New England Journal of \nMedicine, presented at the 50th Union World Conference on Lung Health.', 'thumbnail': 'https://serpapi.com/searches/67224cccc76a22ae2333ae14/images/8f9069c333695fc31a48af1f68b6d520df5148d8dd42e2a1f1b03cfa6b4d33e0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6271110773086548}",,,,,,,,,,['neutral'],neutral,1
NCT04227106,"{'position': 1, 'link': 'https://www.manilatimes.net/2024/10/29/tmt-newswire/globenewswire/abeona-therapeutics-completes-pz-cel-biologics-license-application-resubmission-to-us-food-and-drug-administration/1993209', 'title': 'Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration', 'source': 'The Manila Times', 'date': '1 day ago', 'snippet': 'CLEVELAND, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. \n(Nasdaq: ABEO) today announced that the Company has resubmitted its...', 'thumbnail': 'https://serpapi.com/searches/67224d4f8e13c9f929b48ab0/images/b0c485a5820ede28803c4c6bde45e5861b79404dcf614a0880f855dbdb0f57b8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8937640190124512}","{'position': 2, 'link': 'https://epidermolysisbullosanews.com/news/review-fda-pz-cel-treating-rdeb-progressing-schedule/', 'title': 'Review by FDA of pz-cel for treating RDEB progressing on schedule', 'source': 'Epidermolysis Bullosa News', 'date': 'Feb 2, 2024', 'snippet': 'Abeona Therapeutics said a mid-cycle meeting with the U.S. Food and Drug \nAdministration was held about its RDEB gene-corrected cell therapy.', 'thumbnail': 'https://serpapi.com/searches/67224d4f8e13c9f929b48ab0/images/b0c485a5820ede289de9ba8d43fe1495873973083573ecd3207595781fb1a4a0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9089530110359192}","{'position': 3, 'link': 'https://epidermolysisbullosanews.com/news/fda-decision-expected-may-pz-cel-cell-therapy-rdeb-was-eb-101/', 'title': 'FDA approval decision expected in May on RDEB cell therapy pz-cel', 'source': 'Epidermolysis Bullosa News', 'date': 'Dec 1, 2023', 'snippet': 'The U.S. Food and Drug Administration (FDA) has granted priority review to \nan application seeking approval of pz-cel (prademagene...', 'thumbnail': 'https://serpapi.com/searches/67224d4f8e13c9f929b48ab0/images/b0c485a5820ede28706519d4f3acb9f8bf2c5909eaa9c380246338661ffcd5a3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8910080194473267}","{'position': 4, 'link': 'https://epidermolysisbullosanews.com/news/abeona-seeks-fda-approval-eb-101-cell-therapy-rdeb-orphan-drug/', 'title': 'Abeona seeks FDA approval for EB-101 cell therapy for RDEB', 'source': 'Epidermolysis Bullosa News', 'date': 'Sep 29, 2023', 'snippet': 'Abeona Therapeutics is seeking US Food and Drug Administration (FDA) \napproval for EB-101, an investigational cell therapy for recessive \ndystrophic...', 'thumbnail': 'https://serpapi.com/searches/67224d4f8e13c9f929b48ab0/images/b0c485a5820ede28716fd6be21ae4e6dff0a421ccdfb1d3e0340594bfeca80e0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8894243836402893}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04302103,"{'position': 1, 'link': 'https://myastheniagravisnews.com/news/telitacicept-reduces-gmg-severity-phase-2-study/', 'title': 'Telitacicept reduces gMG severity in Phase 2 study', 'source': 'Myasthenia Gravis News', 'date': 'May 28, 2024', 'snippet': 'Treatment with telitacicept for almost six months lessened disease activity \nin gMG adults positive for anti-AChR antibodies, per a study.', 'thumbnail': 'https://serpapi.com/searches/67224d8e213c87ebb7b13514/images/81cfbd8c86eb79cc74a1bb38ff31f5b41eda7b9017527a43e9b77758fb91dc69.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7434861660003662}","{'position': 2, 'link': 'https://myastheniagravisnews.com/news/1st-us-patient-enrolled-phase-3-trial-gmg-therapy-telitacicept/', 'title': '1st US patient enrolled in Phase 3 trial of gMG therapy telitacicept', 'source': 'Myasthenia Gravis News', 'date': 'Aug 7, 2024', 'snippet': 'Remegen enrolled the first U.S. patient in a Phase 3 trial testing the \nsafety and efficacy of telitacicept for generalized myasthenia...', 'thumbnail': 'https://serpapi.com/searches/67224d8e213c87ebb7b13514/images/81cfbd8c86eb79ccb90cec275b7e67963d248733923661bc54f86621c10b8124.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9223296046257019}","{'position': 3, 'link': 'https://myastheniagravisnews.com/news/telitacicept-shows-signs-efficacy-phase-2-trial-mg-adults/', 'title': 'Telitacicept Shows Signs of Efficacy, Safety in Phase 2 Trial in MG Adults', 'source': 'Myasthenia Gravis News', 'date': 'Nov 3, 2022', 'snippet': 'Nearly six months of treatment with telitacicept (RC18), an \nanti-inflammatory developed by RemeGen, safely lessened disease severity in \nadults with myasthenia...', 'thumbnail': 'https://serpapi.com/searches/67224d8e213c87ebb7b13514/images/81cfbd8c86eb79cce392c743bfa2a3570a7ed1e249c4f3a7e4cca75e6ad4a226.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5126982927322388}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00112658,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1011923', 'title': 'FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer', 'source': 'The New England Journal of Medicine', 'date': 'May 12, 2011', 'snippet': 'Data are lacking on the efficacy and safety of a combination chemotherapy \nregimen consisting of oxaliplatin, irinotecan, fluorouracil,...', 'thumbnail': 'https://serpapi.com/searches/67224da993584c1f1a57b6c8/images/8172c25c325a561fccaea2c18056d49939972bf547e6e8343a09c8ad80ff8e70.png', 'sentiment': 'negative', 'sentiment_prob': 0.5360261797904968}",,,,,,,,,,['negative'],negative,0
NCT01678898,"{'position': 1, 'link': 'https://fabrydiseasenews.com/news/protalix-and-chiesi-get-fda-ok-to-seek-accelerated-approval-of-prx-102-for-fabry-disease/', 'title': 'FDA OKs Plan for Accelerated Approval of Fabry Therapy PRX-102', 'source': 'Fabry Disease News', 'date': 'Nov 27, 2019', 'snippet': 'Investigational Fabry therapy PRX-102 is closer to gainng accelerated \napproval after a successful pre-biologics license application meeting...', 'thumbnail': 'https://serpapi.com/searches/67224e0896a3292c5a248cdc/images/06bff0c0302becd0f4ce99c9c7298abeb5f2565c93270df640f9def7e835f8a3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5469818711280823}",,,,,,,,,,['neutral'],neutral,1
NCT02509494,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-022-00564-z', 'title': 'Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola | npj Vaccines', 'source': 'Nature', 'date': 'Nov 30, 2022', 'snippet': 'Without clinical efficacy data, vaccine protective effect may be \nextrapolated from animals to humans using an immunologic marker that...', 'thumbnail': 'https://serpapi.com/searches/67224e7e93584c1f1a57b762/images/b87ba15e688022f5b3cb8f41125f2efb589e22ea00649c6c40aaeedc0a7156ba.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8734168410301208}",,,,,,,,,,['neutral'],neutral,1
NCT04944901,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-30909-0', 'title': 'Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder', 'source': 'Nature', 'date': 'Mar 30, 2023', 'snippet': 'This first-in-human placebo-controlled, double-blind, crossover study \ninvestigated the safety (primary objective) and efficacy of oral SB-121.', 'thumbnail': 'https://serpapi.com/searches/67224e902bab902cc6cb9d7e/images/891b9b5bbb8aabbf4dd78703fd1b2e1817d46a56adaa653ec3571866b6e29faf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.917510449886322}",,,,,,,,,,['neutral'],neutral,1
NCT00639639,"{'position': 1, 'link': 'https://www.nature.com/articles/s41420-023-01782-7', 'title': 'Dendritic cell therapy for neurospoagioma: Immunomodulation mediated by tumor vaccine | Cell Death Discovery', 'source': 'Nature', 'date': 'Jan 6, 2024', 'snippet': 'In this review, we summarize the immunomodulatory effects and related \nmechanisms of DC vaccines in neurospoagioma as well as the progress of \nclinical trials.', 'thumbnail': 'https://serpapi.com/searches/67224ebab9458d9ff0f375e6/images/6415281016ddf2ee6a0777a229eeaa93dc9d236f0ec559d9612d0d694ef96207.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9114742875099182}",,,,,,,,,,['neutral'],neutral,1
NCT03556345,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2022.847835/full', 'title': 'Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers', 'source': 'Frontiers', 'date': 'Jun 25, 2024', 'snippet': 'Antibody-drug conjugates (ADCs) represent a new and promising class of \nanticancer therapeutics that combine the cancer specificity of antibodies \nwith...', 'thumbnail': 'https://serpapi.com/searches/67225071316650b50a5d4b67/images/0c7fae72f79fdd01c5beabe1976b5979a231f822ed50834820eb97ec311c266b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7782331705093384}",,,,,,,,,,['neutral'],neutral,1
NCT04523571,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01330-9', 'title': 'Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study', 'source': 'Nature', 'date': 'Apr 22, 2021', 'snippet': 'An effective vaccine is needed to end the severe acute respiratory syndrome \ncoronavirus 2 (SARS-CoV-2) pandemic.', 'thumbnail': 'https://serpapi.com/searches/67225074b57db8b84ab7d146/images/536b0fedc06522f7b806d6164f0078c1712422cfb1c92b86c68e8120f2b0d5aa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7470804452896118}",,,,,,,,,,['neutral'],neutral,1
NCT02586987,"{'position': 1, 'link': 'https://www.nature.com/articles/bjc2017271', 'title': 'SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting', 'source': 'Nature', 'date': 'Aug 24, 2017', 'snippet': 'We investigated selumetinib (AZD6244, ARRY-142886), an oral, potent, and \nhighly selective, allosteric MEK1/2 inhibitor, plus platinum-doublet \nchemotherapy.', 'thumbnail': 'https://serpapi.com/searches/672251476cca5e78b095ff40/images/5d715dbaf7230f2e436f66d597ea8fa4901fa95a59bdf44352238775243b1c84.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8633266091346741}",,,,,,,,,,['neutral'],neutral,1
NCT01526135,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1809775', 'title': 'FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Dec 19, 2018', 'snippet': 'Among patients with metastatic pancreatic cancer, combination chemotherapy \nwith fluorouracil, leucovorin, irinotecan, and oxaliplatin...', 'thumbnail': 'https://serpapi.com/searches/67225158e1c27656915cf583/images/b0dfe77c386ba155c67ec4326d68658f77d95f838a9220ca9f6b06bffbdba831.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8954422473907471}","{'position': 2, 'link': 'https://www.cancertherapyadvisor.com/news/folfirinox-or-gemcitabine-as-adjuvant-therapy-for-pancreatic-cancer/', 'title': 'FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Jan 3, 2019', 'snippet': 'Study results suggest a new combination regimen could become the standard \nof care for some patients.', 'thumbnail': 'https://serpapi.com/searches/67225158e1c27656915cf583/images/b0dfe77c386ba15522edc606cfd58173912226e32c4eab002240fabf976c68c4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8897259831428528}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04143802,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S1550413122003126', 'title': 'LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept', 'source': 'ScienceDirect.com', 'date': 'Sep 6, 2022', 'snippet': 'LY3437943 is a novel triple agonist peptide at the glucagon receptor \n(GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and \nglucagon-like...', 'thumbnail': 'https://serpapi.com/searches/6722519248c429afe8ebf048/images/bc63ece6fe03bb65feb1c26bd7a433181c4587e10401dd36bb1b71b8f211df22.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7908094525337219}",,,,,,,,,,['neutral'],neutral,1
NCT04372186,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2030340', 'title': 'Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia', 'source': 'The New England Journal of Medicine', 'date': 'Dec 17, 2020', 'snippet': 'Coronavirus disease 2019 (Covid-19) pneumonia is often associated with \nhyperinflammation. Despite the disproportionate incidence of Covid-19...', 'thumbnail': 'https://serpapi.com/searches/6722524adc969f723312e599/images/ef406edc862f93217d83bbf6170abec691928334289a158a9458abc7c10f2967.png', 'sentiment': 'negative', 'sentiment_prob': 0.6772830486297607}",,,,,,,,,,['negative'],negative,0
NCT00048542,"{'position': 1, 'link': 'https://juvenilearthritisnews.com/2020/08/21/humira-shows-long-term-efficacy-safety-in-polyarticular-jia-phase-3-trial/', 'title': 'Humira Shows Long-term Efficacy and Safety in Polyarticular JIA, Phase 3 Trial Reports', 'source': 'Juvenile Arthritis News', 'date': 'Aug 21, 2020', 'snippet': 'Clinical remission was seen in 37% of polyarticular JIA patients given \nHumira for years, and low disease activity in others; 36% finished...', 'thumbnail': 'https://serpapi.com/searches/672253c6d78a989f7c711623/images/6aa724970cd7533aaa277fb5d7613e377c01e99fa27f6f037543fc79d2ad14f5.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6278648972511292}",,,,,,,,,,['positive'],positive,1
NCT03855137,"{'position': 1, 'link': 'https://www.empr.com/home/news/qulipta-approval-expanded-to-include-preventive-treatment-of-chronic-migraine/', 'title': 'Qulipta Approval Expanded to Include Preventive Treatment of Chronic Migraine', 'source': 'Medical Professionals Reference', 'date': 'Apr 18, 2023', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of Qulipta \n(atogepant) to include the preventive treatment of chronic migraine in \nadults.', 'thumbnail': 'https://serpapi.com/searches/6722549007c7becf1fc1ee69/images/b44029309da65ab920d08a0515cc95231033f1aa1b11c144f84397101fa58061.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8299829959869385}",,,,,,,,,,['neutral'],neutral,1
NCT05006521,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20240904367252/en/Kinaset-Therapeutics-to-Share-Outcomes-from-the-Phase-1-Clinical-Evaluation-of-Frevecitinib-KN-002-an-Inhaled-Pan-JAK-Inhibitor-in-Patients-with-Moderate-to-Severe-Asthma-and-COPD-via-Oral-Presentations-and-Poster-at-ERS-Congress', 'title': 'Kinaset Therapeutics to Share Outcomes from the Phase 1 Clinical Evaluation of Frevecitinib (KN-002), an Inhaled Pan JAK Inhibitor, in Patients with Moderate to Severe Asthma and COPD via Oral Presentations and Poster at ERS Congress', 'source': 'Business Wire', 'date': 'Sep 4, 2024', 'snippet': 'Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing \ninhaled therapeutics to treat serious respiratory diseases,...', 'thumbnail': 'https://serpapi.com/searches/672254c0708e2e561f26ef93/images/2a6e5663445d3024cdb70d114657c3cf67c713b1f972be832356632dcbda531f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9161072373390198}",,,,,,,,,,['neutral'],neutral,1
NCT02465606,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2206714', 'title': 'Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis', 'source': 'The New England Journal of Medicine', 'date': 'Mar 15, 2023', 'snippet': 'We conducted two identically designed, 52-week, randomized, double-blind, \nplacebo-controlled, phase 3 trials; both trials included a 16-week...', 'thumbnail': 'https://serpapi.com/searches/672254fbd9103905e0e08501/images/36e6007087b82511c1151c1abc2316748a1e2d0d25e7dc0de001e3a277123d6a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8677979707717896}",,,,,,,,,,['neutral'],neutral,1
NCT04128579,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/itolizumab-reduces-urine-protein-levels-phase-1b-clinical-trial/', 'title': 'Itolizumab reduces urine protein levels in Phase 1B clinical trial', 'source': 'Lupus News Today', 'date': 'Apr 8, 2024', 'snippet': 'Treatment with the investigational injection therapy itolizumab \nsignificantly reduced urine protein levels, a marker of kidney dysfunction, \nin people with...', 'thumbnail': 'https://serpapi.com/searches/672255c06f9f6391e098b918/images/ac84764f574f6ecca2edade78e9642bd1a6bc7dc7c203099512c3621dc92e34a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6059826612472534}",,,,,,,,,,['neutral'],neutral,1
NCT01545271,"{'position': 1, 'link': 'https://www.nature.com/articles/pr201549', 'title': 'Adding 5 h delayed xenon to delayed hypothermia treatment improves long-term function in neonatal rats surviving to adulthood', 'source': 'Nature', 'date': 'Mar 11, 2015', 'snippet': 'We previously reported that combining immediate hypothermia with immediate \nor 2 h delayed inhalation of an inert gas, xenon, gave additive...', 'thumbnail': 'https://serpapi.com/searches/6722561b0a545a31f1b8b484/images/c4db627589c5554bea991a2de92b2c8392ada1676a79d51921556f0b6511e30b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7068072557449341}",,,,,,,,,,['neutral'],neutral,1
NCT04117711,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/fda-requests-clinical-outcomes-data-for-galactosemia-treatment/', 'title': 'FDA Requests Clinical Outcomes Data for Galactosemia Treatment', 'source': 'Medical Professionals Reference', 'date': 'Jan 5, 2022', 'snippet': 'Applied Therapeutics announced that it would hold on submitting the New \nDrug Application for AT-007 for the treatment of galactosemia.', 'thumbnail': 'https://serpapi.com/searches/6722569148b9f7c481f5af47/images/335f12a72a8a00ce07ecc317e1b8e5293d55cc0b688371207e2f4b92a139b276.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9303452968597412}",,,,,,,,,,['neutral'],neutral,1
NCT02576717,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/06/30/long-term-data-zeposia-help-cognitive-function-patients/', 'title': 'Long-term Zeposia May Help Cognitive Function in Patients, Data Show', 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 30, 2022', 'snippet': 'Long-term treatment with Zeposia stabilizes or even improves cognitive \nfunction in most adults with relapsing forms of MS, data show.', 'thumbnail': 'https://serpapi.com/searches/6722574666d9958464b7b6ec/images/c8156e7dc525701ce58fda5ca3b601098e10940117c783799779e392a0b3db46.png', 'sentiment': 'positive', 'sentiment_prob': 0.6353581547737122}",,,,,,,,,,['positive'],positive,1
NCT02935790,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-33889-3', 'title': 'HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma | Scientific Reports', 'source': 'Nature', 'date': 'Aug 1, 2023', 'snippet': 'This study identifies HDAC1 and HDAC6 as important and drug-targetable \nenzymes that are necessary for growth and invasiveness in IDH1 mutant \ngliomas.', 'thumbnail': 'https://serpapi.com/searches/672257a4207c885b7cac5e27/images/b23d23e4d31b8b051cde54ead46e5c9adb450efe5807f9757296583179ef5522.png', 'sentiment': 'positive', 'sentiment_prob': 0.7654210925102234}",,,,,,,,,,['positive'],positive,1
NCT00136084,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-024-00643-5', 'title': 'Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials | npj Precision Oncology', 'source': 'Nature', 'date': 'Aug 1, 2024', 'snippet': 'In this study, we leveraged machine-learning tools by evaluating expression \nof genes of pharmacological relevance to standard-AML...', 'thumbnail': 'https://serpapi.com/searches/672258451397bae53c6c4913/images/9eb2fb1a36464fc07c901108a20e5c95bd81ac2afe1923be71aaf387893084f1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.894627571105957}",,,,,,,,,,['neutral'],neutral,1
NCT01766817,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/ipf-lung-function-decline-may-slow-with-lpa1-antagonist-bms-986278/', 'title': 'IPF lung function decline may slow with LPA1 antagonist BMS-986278...', 'source': 'Pulmonary Fibrosis News', 'date': 'May 26, 2023', 'snippet': 'BMS-986278 did better than a placebo at slowing lung function decline for \nup to 26 weeks in people with idiopathic pulmonary fibrosis.', 'thumbnail': 'https://serpapi.com/searches/6722586aa471671c163a9db0/images/7aa4eba30459a8bc116b0df4e4b2ad29efbed00178db41fd204a9cd0139d7b3b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6781575083732605}",,,,,,,,,,['neutral'],neutral,1
NCT00545688,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-45591-7', 'title': 'Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial', 'source': 'Nature', 'date': 'Mar 9, 2024', 'snippet': 'The randomized, multicenter, double-blind, placebo-controlled, phase III \nPEONY trial (NCT02586025) demonstrated significantly improved total...', 'thumbnail': 'https://serpapi.com/searches/672258f7d19f15fbc622d4b9/images/b2a98d34975f42adc02d461b4ea6ed659b360d83bdf4a730376621bfb9b6a5b8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8156763315200806}",,,,,,,,,,['neutral'],neutral,1
NCT04252287,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01703-8', 'title': 'The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial', 'source': 'Nature', 'date': 'Feb 28, 2022', 'snippet': 'In the CHIEF-HF trial (NCT04252287), 476 participants with HF, regardless \nof EF or diabetes status, were randomized to 100 mg of canagliflozin or \nplacebo.', 'thumbnail': 'https://serpapi.com/searches/672258f9ecf15015f2357216/images/4070c5aa7f1866b61c8c1ec711eae4fc40f7e6210a7ba58e4dcaf44633850b40.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8635004162788391}",,,,,,,,,,['neutral'],neutral,1
NCT00834704,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-62470-9', 'title': 'Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials', 'source': 'Nature', 'date': 'May 21, 2024', 'snippet': 'Pre-clinical and clinical studies have shown that PEGPH20 depletes \nintratumoral hyaluronic acid (HA), which is linked to high interstitial...', 'thumbnail': 'https://serpapi.com/searches/6722593a6ad3c98a6ed71d4c/images/054886bbee314c40e56b6f4c37bc304e193a9e6fbbc3208ccacdd92909168952.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8239365816116333}",,,,,,,,,,['neutral'],neutral,1
NCT02135419,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2201048', 'title': 'Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jun 15, 2022', 'snippet': 'The incidence of anal cancer is substantially higher among persons living \nwith the human immunodeficiency virus (HIV) than in the general...', 'thumbnail': 'https://serpapi.com/searches/6722593ec0028ebd8f5b8d89/images/1143f046335dbf0e47b27b1e1d750ef32989b116972912b5c8af9c87c8c124d7.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6387670040130615}",,,,,,,,,,['negative'],negative,0
NCT02431468,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/bryostatin-neurotrope-improves-cognition-advanced-alzheimers/', 'title': ""Bryostatin by Neurotrope Improved Cognition in Advanced Alzheimer's"", 'source': ""Alzheimer's News Today"", 'date': 'Mar 21, 2018', 'snippet': ""Learn more about how Bryostatin, an investigational therapy by Neurotrope, \nwas associated with improved cognition in advanced Alzheimer's..."", 'thumbnail': 'https://serpapi.com/searches/67225a074a3fcfceed32877a/images/da550101955a89c373cab9825e6c1b04e9402eadd6707acf59e5abee9e0f4e05.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5256300568580627}",,,,,,,,,,['positive'],positive,1
NCT02648282,"{'position': 1, 'link': 'https://www.science.org/doi/10.1126/sciadv.adk1827', 'title': 'Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells', 'source': 'Science | AAAS', 'date': 'Feb 7, 2024', 'snippet': 'Radiotherapy is hypothesized to have an immune-modulating effect on the \ntumor microenvironment (TME) of pancreatic ductal adenocarcinoma...', 'thumbnail': 'https://serpapi.com/searches/67225a26358539d638692cf7/images/74c26d1b1e4fb03d57345ebbfba2eb4c2d75119613896d80ab28a4b9af5ad9e3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8607778549194336}",,,,,,,,,,['neutral'],neutral,1
NCT01112527,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-018-37437-2', 'title': 'Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy | Scientific Reports', 'source': 'Nature', 'date': 'Jan 15, 2019', 'snippet': 'In this study, we established a matched pair of glioblastoma stem-like cell \n(GSC) cultures from patient glioblastoma samples before and after epidermal \ngrowth...', 'thumbnail': 'https://serpapi.com/searches/67225a7aba13f21ac0517dc4/images/1c8f6f89acc9adffd39dcd70dcfd31d781772b419014a331291790ebd3c21c7c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8742778897285461}",,,,,,,,,,['neutral'],neutral,1
NCT00127530,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/01/17/acorda-taking-over-global-sales-ampyra-fampyra-ms/', 'title': 'Acorda taking over global sales of Ampyra and Fampyra for MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Jan 17, 2024', 'snippet': 'An agreement with Acorda is ending that had Biogen handle sales of Fampyra, \nas the MS walking aid treatment is known outside the US.', 'thumbnail': 'https://serpapi.com/searches/67225e1f72e5c43d84fcf717/images/05ad9221ef3e7ad612bfeda62d50a23ce7de4f4acc583af8f0ce31f7d12b7368.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9308282136917114}",,,,,,,,,,['neutral'],neutral,1
NCT02503839,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-27029-6', 'title': 'A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients', 'source': 'Nature', 'date': 'Nov 22, 2021', 'snippet': 'We show the first clinical data that H56:IC31 vaccination is safe and \nimmunogenic in tuberculosis patients, supporting further studies of \nH56:IC31 as a host-...', 'thumbnail': 'https://serpapi.com/searches/67225e64213c87b91cffb67b/images/8e118b88c1a4b348fbf6d0b56c2887bd3e77cf4798ef3b00d657706e681fbc1f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6584312915802002}",,,,,,,,,,['neutral'],neutral,1
NCT04014075,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00215-2/fulltext', 'title': 'Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyse', 'source': 'The Lancet', 'date': 'Jun 14, 2023', 'snippet': 'We report primary and updated analyses of the single-arm, phase 2 \nDESTINY-Gastric02 trial, which aimed to examine trastuzumab deruxtecan in \npatients living in...', 'thumbnail': 'https://serpapi.com/searches/67225e78d9c3e6fb8aae1f0a/images/8be07ce3af40b8469a2fda4ff98534888b75104a1f95cecc9e55f6d5974850c5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.878913938999176}",,,,,,,,,,['neutral'],neutral,1
NCT03867123,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-023-02356-1', 'title': 'A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma | British Journal of Cancer', 'source': 'Nature', 'date': 'Jul 24, 2023', 'snippet': 'The first-in-class brain-penetrating synthetic hydroxylated lipid \nidroxioleic acid (2-OHOA; sodium 2-hydroxyoleate), activates \nsphingomyelin...', 'thumbnail': 'https://serpapi.com/searches/67225e7fc97e356b10d663a1/images/20d78c0a27fc6d6df1ab6c0ba13e06dc7117cd5903bd58337c5ade54eed09ce7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8801302909851074}",,,,,,,,,,['neutral'],neutral,1
NCT03988608,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-45607-0', 'title': 'Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia', 'source': 'Nature', 'date': 'Nov 2, 2023', 'snippet': 'This is the first prospective study to show that eltrombopag is efficacious \nand has a favorable safety profile in a Chinese patient population with r/r \nSAA.', 'thumbnail': 'https://serpapi.com/searches/67225f0e9936889d40bd01be/images/359a7805e48b91469082f712531719e4f8fc7476c6fdb261e52d3715fdf885ad.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5287815928459167}",,,,,,,,,,['neutral'],neutral,1
NCT01212952,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/optimismm-trial-shows-benefit-of-pomalyst-combo-for-resistant-mm/', 'title': 'OPTIMISMM Trial Shows Benefit of Pomalyst Combo for Resistant MM', 'source': 'Myeloma Research News', 'date': 'May 31, 2019', 'snippet': 'Pivotal OPTIMISMM trial shows that combining Pomalyst with Velcade and \ndexamethasone can prolong survival of patients with...', 'thumbnail': 'https://serpapi.com/searches/67225c2c642c3145fd3b1bd5/images/0f750b2e65cf5147a8016ac82bb7517ecca935e6a0abe139996496c965d0b666.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6882515549659729}",,,,,,,,,,['positive'],positive,1
NCT05782179,"{'position': 1, 'link': 'https://pf-media.co.uk/news/minervax-begins-phase-1-clinical-study-of-novel-gbs-vaccine/', 'title': 'MinervaX begins phase 1 clinical study of novel GBS vaccine', 'source': 'Pf Media', 'date': 'Apr 17, 2023', 'snippet': 'MinervaX has announced the first phase 1 clinical study in older adults of \nits novel vaccine for Group B Streptococcus.', 'thumbnail': 'https://serpapi.com/searches/67225fe07ca6b31d9b999726/images/6dadcfd6e0e1b953db3e5226ed44a2b4599023ef6a5d5cf471a316cf13d590a8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8728817105293274}",,,,,,,,,,['neutral'],neutral,1
NCT01885078,"{'position': 1, 'link': 'https://rheumatoidarthritisnews.com/baricitinib-olumiant-for-rheumatoid-arthritis/', 'title': 'Baricitinib (Olumiant) for Rheumatoid Arthritis', 'source': 'Rheumatoid Arthritis News', 'date': 'Apr 24, 2017', 'snippet': 'Read about Baricitinib (Olumiant), which inhibits the inflammation \nassociated with rheumatoid arthritis, easing the joint pain that stems from \nthe disease.', 'thumbnail': 'https://serpapi.com/searches/67225fec7ac731301bf5e382/images/8209b323ac00ad1f011e11cc4e51e55836b6a4237800f48d63a0b5a24305d024.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7946578860282898}",,,,,,,,,,['neutral'],neutral,1
NCT02067910,"{'position': 1, 'link': 'https://sjogrenssyndromenews.com/news/orencia-fails-to-reduce-disease-activity-in-patients-with-early-active-primary-sjogrens-syndrome-trial-shows/', 'title': 'In Early Active pSS, Orencia Fails to Reduce Disease Activity, Trial Shows', 'source': ""Sjogren's Syndrome News"", 'date': 'Dec 5, 2019', 'snippet': ""Orencia (abatacept), an immunotherapy used in rheumatic diseases, failed to \nreduce disease activity in patients with early active primary Sjögren's \nsyndrome..."", 'thumbnail': 'https://serpapi.com/searches/67226044be324f0a65575bcd/images/0d1089c7371f6674b2d4182cb89d7359816b27489e7f689f74966edd4381599d.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6500769853591919}",,,,,,,,,,['negative'],negative,0
NCT03036124,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1911303', 'title': 'Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction', 'source': 'The New England Journal of Medicine', 'date': 'Sep 19, 2019', 'snippet': 'In patients with type 2 diabetes, inhibitors of sodium–glucose \ncotransporter 2 (SGLT2) reduce the risk of a first hospitalization for \nheart failure,...', 'thumbnail': 'https://serpapi.com/searches/6722609dc4bcf53569db5d02/images/97355a20fe5b27f505d46bde8821742497cd7c617c89217e960620983e36cd0b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7701650261878967}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044133', 'title': 'Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age | Circulation', 'source': 'American Heart Association Journals', 'date': 'Nov 17, 2019', 'snippet': 'Background:The DAPA-HF trial (Dapagliflozin and Prevention of \nAdverse-Outcomes in Heart Failure) showed that dapagliflozin added to \nother...', 'thumbnail': 'https://serpapi.com/searches/6722609dc4bcf53569db5d02/images/97355a20fe5b27f5db7ff1c250092ee8939f70fc889f9e02007c11645429c8a1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9021070599555969}","{'position': 3, 'link': 'https://www.thecardiologyadvisor.com/news/dapagliflozin-baseline-hyponatremia-clinical-outcomes-patients-with-hfref/', 'title': 'Dapagliflozin, Baseline Hyponatremia, and Clinical Outcomes for Patients With HFrEF', 'source': 'The Cardiology Advisor', 'date': 'May 18, 2022', 'snippet': 'Researchers have found that baseline serum sodium concentration has \nprognostic value and does not affect dapagliflozin therapy in patients...', 'thumbnail': 'https://serpapi.com/searches/6722609dc4bcf53569db5d02/images/97355a20fe5b27f5b5ef2dc920bb3b55d933038902ec2f6e7b213810e428ce8f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9023642539978027}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03336216,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20200218005144/en/Five-Prime-Therapeutics-Provides-Update-on-Phase-2-Trial-of-Cabiralizumab-Combined-with-Opdivo%C2%AE-in-Pancreatic-Cancer', 'title': 'Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo', 'source': 'Business Wire', 'date': 'Feb 18, 2020', 'snippet': 'SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. \n(NASDAQ: FPRX), a clinical-stage biotechnology company focused...', 'thumbnail': 'https://serpapi.com/searches/672260c2361fd48e0c18cf6f/images/985c49bc23a5595e30adc83234f88819f6ba0a5d93d5b1abe48ed21b33e90596.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8890454769134521}",,,,,,,,,,['neutral'],neutral,1
NCT02501096,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.19.02627', 'title': 'Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer', 'source': 'ASCO Publications', 'date': 'Mar 13, 2020', 'snippet': 'PURPOSEPatients with advanced endometrial carcinoma have limited treatment \noptions. We report final primary efficacy analysis results for a...', 'thumbnail': 'https://serpapi.com/searches/6722617dbcd6529d7b4dc287/images/dfbbf581d1624fcdeae3b9796b699a1ade277a01d75d0258280e2a3927533ab7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6532766222953796}",,,,,,,,,,['neutral'],neutral,1
NCT01904604,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/skin-patch-treat-peanut-allergy-shows-benefit-children', 'title': 'Skin patch to treat peanut allergy shows benefit in children', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Oct 26, 2016', 'snippet': 'NIH-funded study suggests patch is safe, convenient mode of treatment.', 'thumbnail': 'https://serpapi.com/searches/672261fe3c944b0711a23d79/images/f2f97987d7da4337078fd6b20948550a08ccd859aa75effc6115c587e4d4de5b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8203513026237488}",,,,,,,,,,['positive'],positive,1
NCT00776984,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1208606', 'title': 'Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy', 'source': 'The New England Journal of Medicine', 'date': 'Sep 3, 2012', 'snippet': 'In two replicate, randomized, controlled trials involving 912 patients with \nasthma who were receiving inhaled glucocorticoids and LABAs,...', 'thumbnail': 'https://serpapi.com/searches/672262385bb6a23fb5db78d9/images/dd05a42e681564cbe5b8866c90b9970ca6b99deac4f49f4c92d0373c0ccaf30a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5179815888404846}",,,,,,,,,,['neutral'],neutral,1
NCT03738397,"{'position': 1, 'link': 'https://www.dermatologytimes.com/view/upadacitinib-superior-to-dupilumab-in-atopic-dermatitis', 'title': 'Upadacitinib Superior to Dupilumab in Atopic Dermatitis', 'source': 'Dermatology Times', 'date': 'Aug 5, 2021', 'snippet': 'AbbVie announced that JAMA Dermatology has published 24-week results from \nthe phase 3b Heads Up (NCT03738397) study, evaluating the safety...', 'thumbnail': 'https://serpapi.com/searches/672262c774f0a40f8f69227c/images/fd19f5cac8b125a18cff2b1da9c3de372bbbc302d081d7249279b5f09ed8f3db.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8350872993469238}",,,,,,,,,,['neutral'],neutral,1
NCT01722487,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1509388', 'title': 'Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'Dec 6, 2015', 'snippet': 'Chronic lymphocytic leukemia (CLL) primarily affects older persons who \noften have coexisting conditions in addition to disease-related...', 'thumbnail': 'https://serpapi.com/searches/672262d45f97783800f29298/images/2edffffe9c84c26ade95a49a9fd9cd05c1bcf88c4d0e4e40f3ec91f7ee2cd5fc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5221536755561829}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/survival-benefit-at-7-years-reported-with-first-line-ibrutinib-for-chronic-lymphocytic-leukemia', 'title': 'Survival Benefit at 7 Years Reported With First-Line Ibrutinib for Chronic Lymphocytic Leukemia', 'source': 'Cancer Network', 'date': 'Jun 5, 2021', 'snippet': 'Median progression-free and overall survival in patients with CLL/SLL \nreceiving ibrutinib in the frontline still not reached at 7-year...', 'thumbnail': 'https://serpapi.com/searches/672262d45f97783800f29298/images/2edffffe9c84c26a46cb95999312d6ddc2ceee0d87ac2e301d4665cf8890f469.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8391682505607605}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02603432,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2002788', 'title': 'Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 18, 2020', 'snippet': 'Platinum-based chemotherapy is standard-of-care first-line treatment for \nadvanced urothelial carcinoma. However, progression-free survival...', 'thumbnail': 'https://serpapi.com/searches/6722642e69f8ec4c8370fa7a/images/b18f46a50458346cbaf5534e6bf62296942e2b64f5a6b8d6262ab9f166aec41f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8636462092399597}","{'position': 2, 'link': 'https://www.merckgroup.com/en/news/bavencio-asco-gu-18-02-2022.html', 'title': 'Bavencio - ASCO GU | Merck', 'source': 'Merck KGaA', 'date': 'Feb 18, 2022', 'snippet': 'Merck announced the results of an exploratory analysis from the Phase III \nJAVELIN Bladder 100 trial with 19 additional months of follow-up...', 'thumbnail': 'https://serpapi.com/searches/6722642e69f8ec4c8370fa7a/images/b18f46a50458346ce1e44b60dd32655f71a1b43084ae058d75035f8974fdf8ed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9185054898262024}","{'position': 3, 'link': 'https://immuno-oncologynews.com/2020/07/02/advanced-bladder-cancer-maintenance-therapy-bavencio-approved-by-fda/', 'title': 'FDA Approves Bavencio Maintenance Therapy for Advanced Bladder Cancer', 'source': 'Immuno-Oncology News', 'date': 'Jul 2, 2020', 'snippet': 'The US Food and Drug Administration (FDA) has approved Bavencio (avelumab) \nas a first-line maintenance therapy for people with advanced urothelial \ncarcinoma.', 'thumbnail': 'https://serpapi.com/searches/6722642e69f8ec4c8370fa7a/images/b18f46a50458346c7e29ed3dfda6c03eb67798b10b7a60c09c3cbb305f03d528.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6843408942222595}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00024102,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0810266', 'title': 'Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'May 14, 2009', 'snippet': 'Older women with breast cancer are underrepresented in clinical trials, and \ndata on the effects of adjuvant chemotherapy in such patients...', 'thumbnail': 'https://serpapi.com/searches/67226596f79a012cbdaaa102/images/7852de504fc320e283e74f9f54a1ad37f59ca907f73b2186cc6017c2845d8bff.png', 'sentiment': 'negative', 'sentiment_prob': 0.5890551805496216}",,,,,,,,,,['negative'],negative,0
NCT05600036,"{'position': 1, 'link': 'https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00406-1/fulltext', 'title': 'Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors', 'source': 'The Lancet', 'date': 'Oct 18, 2023', 'snippet': 'Deucravacitinib, a first-in-class allosteric TYK2 inhibitor, represents a \nremarkable advancement in the field.', 'thumbnail': 'https://serpapi.com/searches/672266a26a5dd3743d5ce049/images/f15b44a9d82555cfc36fbbf31d414715c63da6fe8b27826fdcdc99c3fb68815e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6672559976577759}",,,,,,,,,,['positive'],positive,1
NCT02423863,"{'position': 1, 'link': 'https://www.nature.com/articles/s41571-021-00507-y', 'title': 'Intratumoural administration and tumour tissue targeting of cancer immunotherapies', 'source': 'Nature', 'date': 'May 18, 2021', 'snippet': 'Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells \nare revolutionizing oncology and haematology practice.', 'thumbnail': 'https://serpapi.com/searches/672266a6ce1e10268110c145/images/a3b35cdda3655b99315f6e67dfbb90f131616c0eab8ff695312e743114f6eca1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.730464518070221}",,,,,,,,,,['neutral'],neutral,1
NCT02449239,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.6768', 'title': 'Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer', 'source': 'Wiley Online Library', 'date': 'Dec 1, 2023', 'snippet': 'There are limited therapeutic options for BCG-unresponsive patients with \nnon-muscle-invasive bladder cancer. The development of long-term...', 'thumbnail': 'https://serpapi.com/searches/672266b348c42962df24918a/images/56263c0b92a53a60d55052bc35d0719ea0c874039de70c9c037f635297b9615d.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6403945088386536}","{'position': 2, 'link': 'https://www.onclive.com/view/sesen-bio-pauses-clinical-development-for-vicineum-in-bcg-unresponsive-nmibc', 'title': 'Sesen Bio Pauses Clinical Development for Vicineum in BCG-Unresponsive NMIBC', 'source': 'OncLive', 'date': 'Jul 18, 2022', 'snippet': 'The clinical development of Vicineum for use as a potential therapeutic \noption in patients with high-risk,...', 'thumbnail': 'https://serpapi.com/searches/672266b348c42962df24918a/images/56263c0b92a53a60265260f25c644b24855a4d358bfbcb3c241c361c5cbd94e9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9031475782394409}","{'position': 3, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/sesen-bio-puts-development-of-bladder-cancer-drug-vicineum-on-pause/', 'title': 'Sesen Bio Puts Development of Bladder Cancer Drug Vicineum on Pause', 'source': 'Medical Professionals Reference', 'date': 'Jul 18, 2022', 'snippet': 'Sesen Bio has decided to pause development of Vicineum (oportuzumab \nmonatox-qqrs) for bacillus Calmette-Guérin-unresponsive NMIBC.', 'thumbnail': 'https://serpapi.com/searches/672266b348c42962df24918a/images/56263c0b92a53a6047ca117d71ddc272d6c8c9f7ed7f53804a1577f0086a99ec.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5333302617073059}",,,,,,,,"['negative', 'neutral', 'negative']",negative,0
NCT02953782,"{'position': 1, 'link': 'https://www.nature.com/articles/s41573-022-00520-5', 'title': 'Macrophages as tools and targets in cancer therapy', 'source': 'Nature', 'date': 'Aug 16, 2022', 'snippet': 'Macrophages can mediate phagocytosis of cancer cells and cytotoxic tumour \nkilling, and engage in effective bidirectional interactions with components \nof the...', 'thumbnail': 'https://serpapi.com/searches/6722673b17a2e2f6d195722b/images/ff18e086776506a0375e50abccb2f619f4b81e5793a142a6ca3ef43ed006c23f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8500427007675171}",,,,,,,,,,['neutral'],neutral,1
NCT03523117,"{'position': 1, 'link': 'https://www.nature.com/articles/s41390-023-02644-9', 'title': 'Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia', 'source': 'Nature', 'date': 'May 19, 2023', 'snippet': 'This Phase 2, non-randomized, multicenter study characterized the safety \nprofile and determined appropriate dosing of ferric carboxymaltose (FCM) in \nchildren...', 'thumbnail': 'https://serpapi.com/searches/672267c9acf7f8291ac4bd68/images/dffbb12ea7c27e3323beeabfefc904bc16e19e42c689f2fa22c3ef6cf9c15d6c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8832054734230042}",,,,,,,,,,['neutral'],neutral,1
NCT03635983,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-024-00641-7', 'title': 'Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab | npj Precision Oncology', 'source': 'Nature', 'date': 'Jul 19, 2024', 'snippet': 'In PIVOT IO 001 (NCT03635983), the combination of the investigational \ninterleukin-2 agonist bempegaldesleukin (BEMPEG) with nivolumab (NIVO)...', 'thumbnail': 'https://serpapi.com/searches/672268c512345731e8181c96/images/8a4f53328ba23e3f2045b57913b8ebe153dd8ae9ab2cbcae89b7bb7153b30f54.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8947779536247253}",,,,,,,,,,['neutral'],neutral,1
NCT01740427,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1607303', 'title': 'Palbociclib and Letrozole in Advanced Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Nov 17, 2016', 'snippet': 'A phase 2 study showed that progression-free survival was longer with \npalbociclib plus letrozole than with letrozole alone in the initial...', 'thumbnail': 'https://serpapi.com/searches/6722694052a04e2ed020973f/images/37a0143b66a6a965f34dd676e8df3fd73e94328525acd9da4506009c6257725c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8232983350753784}","{'position': 2, 'link': 'https://www.nature.com/articles/s41698-022-00297-1', 'title': 'Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib', 'source': 'Nature', 'date': 'Aug 16, 2022', 'snippet': 'While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including \npalbociclib, combined with endocrine therapy (ET), are becoming the...', 'thumbnail': 'https://serpapi.com/searches/6722694052a04e2ed020973f/images/37a0143b66a6a96543636b65316c67a708664f7eeaa9a95f788f6fcfd175de51.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9147531986236572}","{'position': 3, 'link': 'https://www.onclive.com/view/dr-ramaswamy-on-the-real-world-data-implications-of-palbociclib-in-hr-positive-breast-cancer', 'title': 'Dr. Ramaswamy on the Real-World Data Implications of Palbociclib in HR-Positive Breast Cancer', 'source': 'OncLive', 'date': 'Aug 24, 2023', 'snippet': 'Bhuvaneswari Ramaswamy, MD, assistant professor, The Ohio State University \n(OSU) Medical Center, breast medical oncologist,...', 'thumbnail': 'https://serpapi.com/searches/6722694052a04e2ed020973f/images/37a0143b66a6a96517bb59a8117217ca49cc466b7d6f0f6c80b794fb5bf4c55b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.921372652053833}","{'position': 4, 'link': 'https://breastcancer-news.com/2018/11/05/faslodex-ibrance-combo-improves-survival-advanced-breast-cancer-patients/', 'title': 'In Breast Cancer, Ibrance-Faslodex Combo Improves Survival, Phase 3 Data Shows', 'source': 'breastcancer-news.com', 'date': 'Nov 5, 2018', 'snippet': ""Adding Pfizer's Ibrance to standard treatment Faslodex significantly \nextended the survival of advanced breast cancer patients in a Phase 3..."", 'thumbnail': 'https://serpapi.com/searches/6722694052a04e2ed020973f/images/37a0143b66a6a9659a690d79ab605faeb422965d860dcd7928df7012f8b66b62.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.631209135055542}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02617667,"{'position': 1, 'link': 'https://www.medscape.com/viewarticle/993024', 'title': 'FDA Approves Second Waterless Solution for Dry Eye Disease', 'source': 'Medscape', 'date': 'Jun 9, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has approved the first waterless \ncyclosporine-based solution for treating the signs and symptoms of dry eye \ndisease.', 'thumbnail': 'https://serpapi.com/searches/672269e848c97d6230042a38/images/e504f3d467c47f17e1553e75fab047ff94b2b60ece4cc21be77a14087220c612.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7421690225601196}","{'position': 2, 'link': 'https://www.empr.com/home/news/water-free-dry-eye-disease-therapy-vevye-gets-fda-approval/', 'title': 'Water-Free Dry Eye Disease Therapy Vevye Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Jun 8, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Vevye™ (cyclosporine \nophthalmic solution) 0.1% for the treatment of the signs and...', 'thumbnail': 'https://serpapi.com/searches/672269e848c97d6230042a38/images/e504f3d467c47f1737be3652ba6ee21013be5c41673b6a5d1187188776f9ceeb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6431905627250671}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03355209,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Fenfluramine%20%20%28Fintepla%29', 'title': 'Fenfluramine (Fintepla)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Dravet Syndrome, A Study to Evaluate Safety, Tolerability, and \nPharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to \nLess...', 'thumbnail': 'https://serpapi.com/searches/67226b522e33c8a63deb5d50/images/ed0ecf9cfe921c1b37f0a1eb2c5e65fbd1c512bac7e3e99a64be2ede48835421.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8484590649604797}",,,,,,,,,,['neutral'],neutral,1
NCT03259789,"{'position': 1, 'link': 'https://www.empr.com/home/news/brenzavvy-approved-for-adults-with-type-2-diabetes/', 'title': 'Brenzavvy Approved for Adults With Type 2 Diabetes', 'source': 'Medical Professionals Reference', 'date': 'Jan 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Brenzavvy™ \n(bexagliflozin) as an adjunct to diet and exercise to improve glycemic...', 'thumbnail': 'https://serpapi.com/searches/67226bdebb64accebe968500/images/82d87b4e41d4b1e4f0e8e90a2d031cb4e31fa8181b92a3257f9f66920f0ebe14.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6072625517845154}",,,,,,,,,,['neutral'],neutral,1
NCT03192202,"{'position': 1, 'link': 'https://dailynews.ascopubs.org/do/bispecific-agents-live-up-their-potential-treatment-lymphoma', 'title': 'Will Bispecific Agents Live Up to Their Potential in the Treatment of Lymphoma?', 'source': 'ASCO Daily News', 'date': 'Nov 2, 2022', 'snippet': 'The treatment of lymphomas has evolved rapidly over the past 3 decades, \nprogressing from conventional cytotoxic agents to the incorporation...', 'thumbnail': 'https://serpapi.com/searches/67226c04fbde0d1890fe72ae/images/3d30ae5e97f3e511b8d3d3da62c62d7896b9a1dd039936f693ef2548f5a05992.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7519627213478088}",,,,,,,,,,['neutral'],neutral,1
NCT04491006,"{'position': 1, 'link': 'https://finance.yahoo.com/news/athira-stock-topples-alzheimer-drug-153331413.html', 'title': 'Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial', 'source': 'Yahoo Finance', 'date': 'Sep 4, 2024', 'snippet': ""Athira Pharma has released topline data from the Phase II/III LIFT-AD trial \nof its lead Alzheimer's disease therapy, fosgonimeton."", 'thumbnail': 'https://serpapi.com/searches/67226d4959f9112fb149819a/images/d2576b43563f33d9558e9d586da133041c5456541b48d306fb7fe867777add84.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5180739760398865}",,,,,,,,,,['negative'],negative,0
NCT01072799,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1002/rmv.2498', 'title': 'Virus‐like particles as powerful vaccination strategy against human viruses', 'source': 'Wiley Online Library', 'date': 'Dec 20, 2023', 'snippet': 'Nowadays, viruses are not only seen as causative agents of viral infectious \ndiseases but also as valuable research materials for various...', 'thumbnail': 'https://serpapi.com/searches/67226d64a2e99c352b088dc7/images/ea72dc9e393a94fd9ec8a0c7331864d2c88fb6d2669c3d672a14f1b0c639706b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8243274092674255}",,,,,,,,,,['neutral'],neutral,1
NCT02968719,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/corium-reports-positive-results-in-pilot-bioequivalence-study-of-aripex-donepezil-skin-patch-for-alzheimers/', 'title': ""Alzheimer's Patients Taking Aricept as a Skin Patch in Phase 1 Trial"", 'source': ""Alzheimer's News Today"", 'date': 'Mar 27, 2017', 'snippet': ""Transdermal (through the skin) delivery of Aricept (donepezil \nhydrochloride) may be as effective as the drug's oral form, according to \nresults of a pilot..."", 'thumbnail': 'https://serpapi.com/searches/67226d725ed3cab1a3ea523e/images/a79f57c2ad9ea53804424c87eda4442dd4e42298682168a6c7041c1e1e6ec984.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7539610862731934}",,,,,,,,,,['neutral'],neutral,1
NCT03204500,"{'position': 1, 'link': 'https://alsnewstoday.com/news/lithium-valproic-acid-combo-may-slow-als-progression-trial/', 'title': 'Bipolar Disorder Therapy May Slow ALS Progression, Pilot Trial Reports', 'source': 'ALS News Today', 'date': 'Sep 12, 2022', 'snippet': 'A small pilot trial in ALS patients found VPA-Li, oral combination of \nlithium and valproic acid, showed potential to slow functional...', 'thumbnail': 'https://serpapi.com/searches/67226d7c72e5c43d37ced1d2/images/9db5ece8ec2f5967fee023516b9c6aaeda491fc2441f2d5500b12ba251e63bd6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.543114960193634}",,,,,,,,,,['neutral'],neutral,1
NCT04534842,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-26524-0', 'title': 'Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering', 'source': 'Nature', 'date': 'Oct 28, 2021', 'snippet': 'In phenylketonuria (PKU) patients, a genetic defect in the enzyme \nphenylalanine hydroxylase (PAH) leads to elevated systemic phenylalanine...', 'thumbnail': 'https://serpapi.com/searches/67226d84460b151ec53607a3/images/19c669b1bd126c7b8c0b00d227340adf0e974b4ad0e43c0aecaec2914e34b241.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7500093579292297}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/labafenogene-marselecobac-fast-tracked-for-pku-treatment/', 'title': 'Labafenogene Marselecobac Fast Tracked for PKU Treatment', 'source': 'Medical Professionals Reference', 'date': 'Jul 12, 2023', 'snippet': ""The Food and Drug Administration (FDA) has granted Fast Track designation \nto Synlogic's labafenogene marselecobac for the treatment of..."", 'thumbnail': 'https://serpapi.com/searches/67226d84460b151ec53607a3/images/19c669b1bd126c7be9e671dcea06d4ec5b28c5b404fd7ea97a52a638f2b232c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8758198618888855}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03162055,"{'position': 1, 'link': 'https://copdnewstoday.com/news/aeristo-copd-trial-shows-bevespi-aerosphere-similar-to-anoro-elipta/', 'title': 'Bevespi Aerosphere Shows Similar Effectiveness as Anoro Elipta for...', 'source': 'COPD News Today', 'date': 'Aug 24, 2018', 'snippet': ""Read the latest AERISTO clinical trial data on AstraZeneca's Bevespi \nAerosphere for the treatment of COPD as compared to GSK's Anoro Elipta."", 'thumbnail': 'https://serpapi.com/searches/67226d909fd309c7d4cc2693/images/b6da4b705379c3e3607f6bda4f6ed43652d2dbaae9c39d0e67d18ab921fe2f81.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.858304500579834}",,,,,,,,,,['neutral'],neutral,1
NCT03566238,"{'position': 1, 'link': 'https://www.thelancet.com/journals/langas/article/PIIS2468-1253(22)00093-0/fulltext', 'title': 'Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial', 'source': 'The Lancet', 'date': 'Jun 30, 2022', 'snippet': 'Progressive familial intrahepatic cholestasis (PFIC) is a group of \ninherited paediatric liver diseases resulting from mutations in genes...', 'thumbnail': 'https://serpapi.com/searches/67226db256f9705a7399251b/images/5d33a1ddab0a035276ba82e5180555efff7604f8c017b7ff6a6244851749ef04.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8294240236282349}",,,,,,,,,,['neutral'],neutral,1
NCT00406016,"{'position': 1, 'link': 'https://www.nature.com/articles/s41413-022-00199-9', 'title': 'Progression in translational research on spinal cord injury based on microenvironment imbalance', 'source': 'Nature', 'date': 'Apr 8, 2022', 'snippet': 'This review summarizes the latest research progress on two aspects of SCI \npathology: intraneuronal microenvironment imbalance and regenerative \nmicroenvironment...', 'thumbnail': 'https://serpapi.com/searches/67226db97f3719c39a62de7c/images/be873b623d55685f0afaa3df62a67fe6e8e0e2eb1b4d66d726fe7dc4af16da51.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9022295475006104}",,,,,,,,,,['neutral'],neutral,1
NCT01523587,"{'position': 1, 'link': 'https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00220-0/fulltext', 'title': 'Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial', 'source': 'The Lancet', 'date': 'Jun 17, 2021', 'snippet': 'LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib \nand erlotinib as second-line treatment of patients with advanced squamous \ncell...', 'thumbnail': 'https://serpapi.com/searches/67226e948db376c3934f4181/images/0177f462cc2ec047e8bcf4996fc9fef17504c8a2725f9ee69d73041cd2cbd228.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9027174115180969}",,,,,,,,,,['neutral'],neutral,1
NCT03734016,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2211582', 'title': 'Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'Dec 13, 2022', 'snippet': ""In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's \ntyrosine kinase (BTK) inhibitor, was compared with zanubrutinib,..."", 'thumbnail': 'https://serpapi.com/searches/67226ecff3622a724e9b822d/images/5e61a5d66bfb3647124c79e90183bf22f344547e32a0ea6da85bd430e8ee42f0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8463090062141418}","{'position': 2, 'link': 'https://ascopost.com/issues/february-25-2023/zanubrutinib-for-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma/', 'title': 'Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma', 'source': 'The ASCO Post', 'date': 'Feb 25, 2023', 'snippet': 'On January 19, 2023, the kinase inhibitor zanubrutinib was approved for \ntreatment of chronic lymphocytic leukemia (CLL) or small lymphocytic \nlymphoma (SLL).', 'thumbnail': 'https://serpapi.com/searches/67226ecff3622a724e9b822d/images/5e61a5d66bfb3647073060da8c13a13e8eeb49d34ab108f3403bbf684ba61242.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8339903950691223}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02814097,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036259', 'title': 'Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction', 'source': 'American Heart Association Journals', 'date': 'Mar 11, 2019', 'snippet': 'Mitochondrial abnormalities can significantly contribute to impaired oxygen \nutilization and the resulting exercise intolerance in HFpEF.', 'thumbnail': 'https://serpapi.com/searches/67226f01d169151c1d617258/images/c493416014e133a16cdaaddb8c5fbe2d0ea69903a41f9ee8217d47f17398c3ca.png', 'sentiment': 'negative', 'sentiment_prob': 0.7354979515075684}",,,,,,,,,,['negative'],negative,0
NCT00088452,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0902014', 'title': 'Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy', 'source': 'The New England Journal of Medicine', 'date': 'Mar 4, 2010', 'snippet': 'In a double-blind, randomized, controlled clinical trial, we compared the \nefficacy, tolerability, and neuropsychological effects of...', 'thumbnail': 'https://serpapi.com/searches/67226fbaee46823f19e92ddb/images/b6d1e2309295a42625981ad9be3a66eec5d25bcb80be12c754cb93b669cf8978.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8668129444122314}",,,,,,,,,,['neutral'],neutral,1
NCT03053635,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/php.13726', 'title': 'Photodynamic Therapy for Bladder Cancers, A Focused Review† - Rahman - 2023 - Photochemistry and Photobiology', 'source': 'Wiley Online Library', 'date': 'Sep 22, 2022', 'snippet': 'Bladder cancer is the first cancer for which PDT was clinically approved in \n1993. Unfortunately, it was unsuccessful due to side effects...', 'thumbnail': 'https://serpapi.com/searches/67226ff88d147392a7c2f125/images/d862b3ea53f132d16e483f169aaf04368d0d6ab93a11e096d582e14d0e10ebe3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5593463778495789}",,,,,,,,,,['neutral'],neutral,1
NCT03050879,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-42712-6', 'title': 'Indocyanine green fluorescence imaging-guided versus conventional laparoscopic lymphadenectomy for gastric cancer: long-term outcomes of a phase 3 randomised clinical trial', 'source': 'Nature', 'date': 'Nov 16, 2023', 'snippet': 'Indocyanine green (ICG) fluorescence imaging-guided lymphadenectomy has \nbeen demonstrated to be effective in increasing the number of lymph...', 'thumbnail': 'https://serpapi.com/searches/67227074a86921c0f30b9d38/images/809f79110503ed0e82646f7ad0226324a1a1ae3e4b2deb2f606866a97640071a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9205148816108704}",,,,,,,,,,['neutral'],neutral,1
NCT05149313,"{'position': 1, 'link': 'https://www.contemporarypediatrics.com/view/bla-resubmitted-for-lebrikizumab-to-treat-ad-patients-12-years-and-up', 'title': 'BLA resubmitted for lebrikizumab to treat AD patients 12 years and up', 'source': 'Contemporary Pediatrics', 'date': 'Apr 30, 2024', 'snippet': 'Eli Lilly and Company has resubmitted a Biologic License Application (BLA) \nfor the treatment of moderate-to-severe atopic dermatitis (AD) in adults \nand...', 'thumbnail': 'https://serpapi.com/searches/6722707a6273fbad5367f8d1/images/7209fb4cb41e103a8cc63c74859b7929330b22424109c3e929cf2a4d956e9994.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8648383021354675}",,,,,,,,,,['neutral'],neutral,1
NCT03214250,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01829-9', 'title': 'Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial', 'source': 'Nature', 'date': 'Jun 3, 2022', 'snippet': 'Chemotherapy combined with immunotherapy has improved the treatment of \ncertain solid tumors, but effective regimens remain elusive for...', 'thumbnail': 'https://serpapi.com/searches/672270837c1712784f806358/images/4b0fbe1f40dcbcba51607794a46f43fae21be432eb1c1e55089602bc0a842a23.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8624395728111267}",,,,,,,,,,['neutral'],neutral,1
NCT03307148,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-020-18636-w', 'title': 'Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer', 'source': 'Nature', 'date': 'Sep 24, 2020', 'snippet': 'Pre-clinical models have shown that targeting pancreatic stellate cells \nwith all-trans-retinoic-acid (ATRA) reprograms pancreatic stroma to...', 'thumbnail': 'https://serpapi.com/searches/672271854791c4eceb2e3f6c/images/7aed216d781837bb52f950be30f54e7fa0da07659aa6251a8601069d41f072bb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9115622639656067}","{'position': 2, 'link': 'https://www.nature.com/articles/s41698-021-00192-1', 'title': 'Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma | npj Precision Oncology', 'source': 'Nature', 'date': 'Jun 29, 2021', 'snippet': 'PTX3 is a putative stromally-derived biomarker for PDAC which warrants \nfurther testing in prospective, larger, multi-center cohorts and within \nclinical trials.', 'thumbnail': 'https://serpapi.com/searches/672271854791c4eceb2e3f6c/images/7aed216d781837bb6aa50c0e7bb15aa9d5cbe761cdd88295316b036382f793bf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9184646606445312}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02094053,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/dmcn.15517', 'title': 'State‐of‐the‐art therapy for Down syndrome - Lorenzon - 2023 - Developmental Medicine & Child Neurology', 'source': 'Wiley Online Library', 'date': 'Jan 24, 2023', 'snippet': 'This review covers five key areas: (1) What has happened in the last 10 \nyears? (2) From symptomatic to disease-modifying therapy:...', 'thumbnail': 'https://serpapi.com/searches/672271daf6aa53bdaefae4b1/images/aae44a77737dd1e1bf0daa96d11346714cbf23752304ffd0a828a1aea83c5b7b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9450766444206238}",,,,,,,,,,['neutral'],neutral,1
NCT00204516,"{'position': 1, 'link': 'https://www.nature.com/articles/s41587-022-01294-2', 'title': 'The clinical progress of mRNA vaccines and immunotherapies', 'source': 'Nature', 'date': 'May 9, 2022', 'snippet': 'The emergency use authorizations (EUAs) of two mRNA-based severe acute \nrespiratory syndrome coronavirus (SARS-CoV)-2 vaccines approximately...', 'thumbnail': 'https://serpapi.com/searches/67227240a882788f7cdd1988/images/d3466bca219e1e6346d0b0b741dcbb11f97e22eb9b07d581d092184a08baf632.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.921474814414978}",,,,,,,,,,['neutral'],neutral,1
NCT04200248,"{'position': 1, 'link': 'https://www.nature.com/articles/s41433-023-02848-7', 'title': 'Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients | Eye', 'source': 'Nature', 'date': 'Nov 30, 2023', 'snippet': 'Intravitreal injections of anti-vascular endothelial growth factor (VEGF) \nagents are the first-line treatment for exudative age-related...', 'thumbnail': 'https://serpapi.com/searches/67227281a2510461cc6c57f8/images/d312448570e6742ee5000c6a4231b917d6ca10e170e633abfcc531de19955055.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8916304111480713}",,,,,,,,,,['neutral'],neutral,1
NCT03288324,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.655100/full', 'title': ""What's New in the Treatment of Systemic Lupus Erythematosus"", 'source': 'Frontiers', 'date': 'Mar 5, 2021', 'snippet': 'The aim of this review is to summarize data on SLE treatment that have \nemerged over the last 3 years. We will put emphasis on studies evaluating \npotential...', 'thumbnail': 'https://serpapi.com/searches/67227312b5ecbb099a1b2dd2/images/434d3895567fc63e0baff2a8d817cbd94aee78fa9d9288cd8e7a1ba94f448c56.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9232494831085205}",,,,,,,,,,['neutral'],neutral,1
NCT03461211,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1910434', 'title': 'Teprotumumab for the Treatment of Active Thyroid Eye Disease', 'source': 'The New England Journal of Medicine', 'date': 'Jan 22, 2020', 'snippet': 'Teprotumumab resulted in better outcomes with respect to proptosis, \nClinical Activity Score, diplopia, and quality of life than placebo; \nserious adverse events...', 'thumbnail': 'https://serpapi.com/searches/67227330fc40bfd05b717980/images/b87e8384e6138f478577e7b2f9e833afae945e2d1069ca0768f37898cff7c27f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.4944324493408203}",,,,,,,,,,['neutral'],neutral,1
NCT00466583,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1082057/full', 'title': 'The hypoxia-inducible factor-1α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting', 'source': 'Frontiers', 'date': 'Feb 8, 2023', 'snippet': 'Hypoxia-inducible factor-1α (HIF-1α) is a crucial mediator of intra-tumoral \nheterogeneity, tumor progression, and unresponsiveness to...', 'thumbnail': 'https://serpapi.com/searches/672274268f2bc20cba223b79/images/0e733e721127813ff6d4a8f81b2b06d8e028cae959ce9e561f2dd188cdc69bae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.679175615310669}",,,,,,,,,,['neutral'],neutral,1
NCT01848639,"{'position': 1, 'link': 'https://www.springermedizin.de/mineralocorticoid-receptor-overactivation-targeting-systemic-imp/26555368', 'title': 'Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists', 'source': 'springermedizin.de', 'date': 'Dec 22, 2023', 'snippet': 'The overactivation of the mineralocorticoid receptor (MR) promotes \npathophysiological processes related to multiple physiological systems, \nincluding.', 'thumbnail': 'https://serpapi.com/searches/67227439b6a79c89e80b7eca/images/c83ffed3da4c3484dad03d415de255f1cf3333a8a9ef7716ac6ca79cca77dd56.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7335309982299805}",,,,,,,,,,['neutral'],neutral,1
NCT02411253,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-34162-3', 'title': 'Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes', 'source': 'Nature', 'date': 'Nov 28, 2022', 'snippet': 'Despite early clinical successes, the mechanisms of action of low-dose \ninterleukin-2 (LD-IL-2) immunotherapy remain only partly understood.', 'thumbnail': 'https://serpapi.com/searches/67227457fc40bfd05b717a7e/images/f0c61b6a774b0481c9c41acde0825014bb570297124b093d9a7b73d511eb4066.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.66771000623703}",,,,,,,,,,['neutral'],neutral,1
NCT01073865,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/nccn-guidelines-support-goserelin-for-ovarian-suppression-in-breast-cancer', 'title': 'NCCN Guidelines Support Goserelin for Ovarian Suppression in Breast Cancer', 'source': 'Cancer Network', 'date': 'Feb 17, 2024', 'snippet': 'The National Comprehensive Cancer Network has issued a category 2A \nrecommendation for the use of goserelin for ovarian function suppression...', 'thumbnail': 'https://serpapi.com/searches/672274d32bab90dba326aad1/images/c0bc80c49e32cf7a3ba2b712d19d94fe7a52467091ae431963e701249f0a7718.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9110586643218994}",,,,,,,,,,['neutral'],neutral,1
NCT03090100,"{'position': 1, 'link': 'https://psoriasisnewstoday.com/2017/05/25/janssens-phase-3-trials-on-guselkumab-for-plaque-psoriasis-and-psoriatic-arthritis/', 'title': 'Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis', 'source': 'Psoriasis News Today', 'date': 'May 25, 2017', 'snippet': 'Janssen announced two new Phase 3 clinical trials for psoriasis for its \ninvestigational drug guselkumab. The company intends to explore the...', 'thumbnail': 'https://serpapi.com/searches/6722754adc969f1f112023a4/images/575361c5a3dd0ee91148d670251f13b1cb805194ff243b0ee5a90e3f376b5f52.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9209516644477844}",,,,,,,,,,['neutral'],neutral,1
NCT00731263,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Graph-of-effect-of-gastric-pH-on-the-cumulative-appearance-of-AZD8055-in-jejunal-and_fig3_221870360', 'title': 'Fig. 3. Graph of effect of gastric pH on the cumulative appearance of...', 'source': 'ResearchGate', 'date': 'Mar 9, 2018', 'snippet': 'Download scientific diagram | Graph of effect of gastric pH on the \ncumulative appearance of AZD8055 in jejunal and ileal fi ltrates versus \ntime after dosing...', 'thumbnail': 'https://serpapi.com/searches/6722759711db450186c6e55b/images/ce5acc81792df7dc74aa06aaa679c227fef33ea92624329ef6a561dbb91c76b4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9149064421653748}",,,,,,,,,,['neutral'],neutral,1
NCT05925114,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/alnylam-win-amvuttra-attr-amyloidosis/', 'title': 'Pipeline Moves: Alnylam’s Amvuttra approval prospects up after Phase III win', 'source': 'Clinical Trials Arena', 'date': 'Jul 8, 2024', 'snippet': 'The Clinical Trials Arena team also investigates candidates in metabolic \ndisorders, oncology and central nervous system.', 'thumbnail': 'https://serpapi.com/searches/672275a2642c31fec49cd484/images/506f80fb4777ff8a06ffc75778567eabec9565dff5d3bb2619c39bcbffb55e80.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5443851947784424}",,,,,,,,,,['positive'],positive,1
NCT02864147,"{'position': 1, 'link': 'https://medicine.yale.edu/profile/masoud-azodi/', 'title': 'Masoud Azodi, MD', 'source': 'Yale School of Medicine', 'date': 'Nov 14, 2022', 'snippet': 'Dr. Azodi is board certified in both Ob/Gyn and in Gynecologic Oncology. He \ntreats all gynecologic cancers and pre-cancers using numerous therapies.', 'thumbnail': 'https://serpapi.com/searches/67227616fbde0d1847a33cfa/images/504e7a3b7762a437e262b7eb16f647e241cb149726e7c22353ba967bfe25c6a8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.626664936542511}","{'position': 2, 'link': 'https://medicine.yale.edu/profile/mitchell-clark/', 'title': 'Mitchell Clark, MD, MPH', 'source': 'Yale School of Medicine', 'date': 'Nov 14, 2022', 'snippet': 'Dr. Clark holds the rank of assistant professor of Obstetrics and \nGynecology in the Division of Gynecologic Oncology at Yale University \nSchool of Medicine.', 'thumbnail': 'https://serpapi.com/searches/67227616fbde0d1847a33cfa/images/504e7a3b7762a43735f94ce1a95215de6207849a6dc7ad3992dda296637cf950.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8801649808883667}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02852655,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-24293-4', 'title': 'Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1', 'source': 'Nature', 'date': 'Jun 29, 2021', 'snippet': 'The response of patients with recurrent glioblastoma multiforme to \nneoadjuvant immune checkpoint blockade has been challenging to interpret...', 'thumbnail': 'https://serpapi.com/searches/67227622e95dbf88bcceeaae/images/4c518f2558cc3b0bae97e5cadfa43e678e32dfc9ad961ca9792408dec5ee1fd4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.763203501701355}",,,,,,,,,,['neutral'],neutral,1
NCT04819854,"{'position': 1, 'link': 'https://copdnewstoday.com/news/fda-oks-phase-2-clinical-trial-ep395-copd-patients/', 'title': 'FDA OKs Phase 2 Clinical Trial of EP395 for COPD Patients', 'source': 'COPD News Today', 'date': 'Nov 28, 2022', 'snippet': 'The US Food and Drug Administration (FDA) has authorized EpiEndo \nPharmaceuticals to conduct a Phase 2a clinical trial of its antibiotic \ntreatment EP395 in...', 'thumbnail': 'https://serpapi.com/searches/67227676361fd48e5031fcf4/images/6c8b739e780d5cf38a54628a628e2994e24fc31a4942d8cd035d28064b8b70b1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8805156350135803}","{'position': 2, 'link': 'https://copdnewstoday.com/news/phase-1-study-copd-therapy-completed-phase-2-set-this-year/', 'title': 'Phase 1 Study of EP395 Completed; Phase 2 Trial Planned for This Year', 'source': 'COPD News Today', 'date': 'May 19, 2022', 'snippet': ""A first-in-human clinical trial testing the safety of EP395, EpiEndo \nPharmaceuticals' experimental COPD therapy, is now finished."", 'thumbnail': 'https://serpapi.com/searches/67227676361fd48e5031fcf4/images/6c8b739e780d5cf36a5790c1316e3def7206c4947ac5ecbefa22fcb6fb2140bb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8569240570068359}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02847637,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1803550', 'title': 'Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors', 'source': 'The New England Journal of Medicine', 'date': 'Aug 29, 2018', 'snippet': 'Emicizumab prophylaxis administered subcutaneously once weekly or every 2 \nweeks led to a significantly lower bleeding rate than no prophylaxis among \npersons...', 'thumbnail': 'https://serpapi.com/searches/672276f25ed3cab1ee1bad54/images/9d14c8a7629df52de1383bd2d2bf059c5aabdc5760af6695b65d476735b33ae1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7872651219367981}","{'position': 2, 'link': 'https://hemophilianewstoday.com/news/in-trial-hemlibra-improves-joint-health-younger-hem-a-patients-hemophilia-a-treatment/', 'title': 'In Trial, Hemlibra Improves Joint Health for Younger Hem A Patients', 'source': 'Hemophilia News Today', 'date': 'Aug 19, 2022', 'snippet': 'Treatment with Hemlibra (emicizumab) improved joint health for people with \nhemophilia A in the HAVEN 3 clinical trial, a study finds.', 'thumbnail': 'https://serpapi.com/searches/672276f25ed3cab1ee1bad54/images/9d14c8a7629df52dc110ed176f0223fa3820717a25fdbaabed5ffc23b2b33ad6.png', 'sentiment': 'positive', 'sentiment_prob': 0.7654368877410889}","{'position': 3, 'link': 'https://hemophilianewstoday.com/news/web-based-calculator-helps-finetune-dosage-hemlibra-hemophilia-a-patients/', 'title': 'Hemophilia A Patient Care Facilitated with Hemlibra Dosing Calculator', 'source': 'Hemophilia News Today', 'date': 'May 24, 2019', 'snippet': 'A web-based dosing calculator to help physicians select the correct loading \nand maintenance dose of the treatment Hemlibra according to the body \nmeasurements.', 'thumbnail': 'https://serpapi.com/searches/672276f25ed3cab1ee1bad54/images/9d14c8a7629df52d22602768f030a2ef7949d834f6aafd0de2de1b29982f97af.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9187051057815552}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT03450915,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.852904/full', 'title': 'Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine', 'source': 'Frontiers', 'date': 'Apr 6, 2022', 'snippet': 'OVX836 is a recombinant protein-based vaccine targeting the highly \nconserved influenza nucleoprotein (NP), which aims to confer a \nbroad-spectrum protection...', 'thumbnail': 'https://serpapi.com/searches/672277049e5bd5d95e2ead8e/images/b623000f16e3a8459ede6189da57b93da30db9fdd7f460e9870bea58f75b9bf2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.899326741695404}",,,,,,,,,,['neutral'],neutral,1
NCT03088878,"{'position': 1, 'link': 'https://lymphomanewstoday.com/2020/05/04/cirmtuzumab-imbruvica-encouraging-response-rates-mantle-cell-lymphoma-ongoing-cirll-trial/', 'title': ""In MCL, Cirmtuzumab Combo Yields 'Encouraging' Responses, Data Show"", 'source': 'Lymphoma News Today', 'date': 'May 4, 2020', 'snippet': 'A combination of cirmtuzumab plus Imbruvica leads to ""highly encouraging"" \nresponse rates among patients with mantle cell lymphoma,...', 'thumbnail': 'https://serpapi.com/searches/6722772a98fad63805a8aefd/images/06c97b7dffe5db4b3c297b76a54d511cb39add31f4dfe3ceca62e862b1774b04.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.839240312576294}",,,,,,,,,,['positive'],positive,1
NCT03554317,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-44514-2', 'title': 'Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial', 'source': 'Nature', 'date': 'Jan 2, 2024', 'snippet': 'Cyclic high-dose testosterone administration, known as bipolar androgen \ntherapy (BAT), is a treatment strategy for patients with metastatic \ncastration-...', 'thumbnail': 'https://serpapi.com/searches/672277828b7ba755dfb947f8/images/09517d44960ad20a0804b0aa00aac4fd9c539da95472097af008bdbe87960b12.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7530305981636047}",,,,,,,,,,['neutral'],neutral,1
NCT02274558,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/valbenazine-for-tardive-dyskinesia-results-from-the-kinect-study/', 'title': 'Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study', 'source': 'Psychiatrist.com', 'date': 'Dec 18, 2018', 'snippet': 'Participants treated with valbenazine (40 or 80 mg/d) had statistically \nsignificant and clinically relevant improvements in TD severity both \noverall and in...', 'thumbnail': 'https://serpapi.com/searches/6722793fb9ab860ead166912/images/94712774ade8a24f02efc8041201553e82984b74ea826e252263c4918ab44891.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8357340097427368}",,,,,,,,,,['neutral'],neutral,1
NCT05364554,"{'position': 1, 'link': 'https://www.ajmc.com/view/jnj-2113-shows-promising-response-rates-compared-with-competitor-oral-therapies-for-psoriasis', 'title': 'JNJ-2113 Shows Promising Response Rates Compared With Competitor Oral Therapies for Psoriasis', 'source': 'AJMC', 'date': 'Mar 19, 2024', 'snippet': 'In the phase 2b FRONTIER 2 clinical trial (NCT05364554), JNJ-2113—the first \nand only investigational targeted oral peptide designed to block...', 'thumbnail': 'https://serpapi.com/searches/67227940a2e99c34e3f31465/images/664cd4571c011ffba424c2ad2ce0549909495549f6050d2d6400d852aac518c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6388537883758545}",,,,,,,,,,['neutral'],neutral,1
NCT01147653,"{'position': 1, 'link': 'https://cerebralpalsynewstoday.com/2017/11/06/cerebral-palsy-children-motor-skills-improved-umbilical-cord-blood-cell-infusion/', 'title': ""CF Children's Motor Function Improves with Umbilical Cord Cell Infusion"", 'source': 'Cerebral Palsy News Today', 'date': 'Nov 6, 2017', 'snippet': 'Read about a trial showing that infusion of cells collected from autologous \ncord blood improved motor skills of young children with cerebral...', 'thumbnail': 'https://serpapi.com/searches/6722797798d8de1821ee2939/images/5f7ef64858eca981c2c6f2cb30b38db001a0209d28351930c17da7a642395592.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5686376094818115}",,,,,,,,,,['positive'],positive,1
NCT03434041,"{'position': 1, 'link': 'https://www.koreabiomed.com/news/articleView.html?idxno=23305', 'title': 'Spravato faces crisis after back-to-back clinical trial failures in Japan and China', 'source': 'KBR', 'date': 'Feb 6, 2024', 'snippet': ""Janssen's antidepressant Spravato (esketamine) has failed to demonstrate \nefficacy in clinical trials in China following Japan, raising questions \nabout its..."", 'thumbnail': 'https://serpapi.com/searches/672279cbb7d31d5d44bdfea0/images/c9e6f3d34447a1ba96dbba6e42513779daa59e547b7618efc321764d07979809.png', 'sentiment': 'negative', 'sentiment_prob': 0.8149158954620361}",,,,,,,,,,['negative'],negative,0
NCT02294851,"{'position': 1, 'link': 'https://www.nature.com/articles/s43587-023-00523-w', 'title': 'TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease', 'source': 'Nature', 'date': 'Nov 27, 2023', 'snippet': 'a randomized, double-blind, placebo-controlled, parallel-group and \nmultiple-dose long-term trial of gosuranemab—a monoclonal antibody to N-...', 'thumbnail': 'https://serpapi.com/searches/67227a1417b10e3121971984/images/a6410cafe304493e7808a655dc8f76388ce6591ef5a1f0ca89ba77885fa64886.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.783279299736023}",,,,,,,,,,['neutral'],neutral,1
NCT01697267,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/rituximab-treatment-better-than-azathioprine-aav-remission-study/', 'title': 'Rituximab treatment seen to lower relapse risk in AAV patients in trial', 'source': 'ANCA Vasculitis News', 'date': 'Apr 3, 2023', 'snippet': 'Rituximab worked better than azathioprine treatment at maintaining \nremission in relapsing AAV patients in a Phase 3 trial, full data show.', 'thumbnail': 'https://serpapi.com/searches/67227a197e1d1f17db4097dc/images/b437004b9845cc032db1c7ebc28c6c2d79f93fe7d51445fc9b3754f072a9f55b.png', 'sentiment': 'positive', 'sentiment_prob': 0.6379266381263733}",,,,,,,,,,['positive'],positive,1
NCT05256017,"{'position': 1, 'link': 'https://www.nature.com/articles/s41579-022-00777-y', 'title': 'Anti-trypanosomatid drug discovery: progress and challenges', 'source': 'Nature', 'date': 'Aug 22, 2022', 'snippet': 'Leishmaniasis (visceral and cutaneous), Chagas disease and human African \ntrypanosomiasis cause substantial death and morbidity,...', 'thumbnail': 'https://serpapi.com/searches/67227a39f7adbf910b6b993b/images/ed6715433b0824bdea3c616249d02e9cf6514956afd5d55efcc7251ffff837e0.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7218205332756042}",,,,,,,,,,['negative'],negative,0
NCT02999984,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2027675', 'title': 'Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency', 'source': 'The New England Journal of Medicine', 'date': 'May 11, 2021', 'snippet': 'Severe combined immunodeficiency due to adenosine deaminase (ADA) \ndeficiency (ADA-SCID) is a rare and life-threatening primary...', 'thumbnail': 'https://serpapi.com/searches/67227b3293584c270e7b08a2/images/efbf84d72a6773f355e13af8f6d56a8091ecabeb7a67062585fec3b9279a15b3.png', 'sentiment': 'negative', 'sentiment_prob': 0.6079689860343933}",,,,,,,,,,['negative'],negative,0
NCT01675076,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/full/10.1161/CIRCEP.119.007545', 'title': 'Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma:', 'source': 'American Heart Association Journals', 'date': 'Oct 15, 2019', 'snippet': 'Concomitant antiplatelet use in anticoagulated patients undergoing device \nsurgery is associated with a 2-fold increase in the risk of clinically \nsignificant...', 'thumbnail': 'https://serpapi.com/searches/67227b4b5c7cb9ea52f7c947/images/76f26187150b7bbe5544f74980a5fe4cac9b7ea1a51e612166761fb6fdd78335.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5843335390090942}",,,,,,,,,,['neutral'],neutral,1
NCT05021484,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2400763', 'title': 'A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection', 'source': 'The New England Journal of Medicine', 'date': 'May 25, 2024', 'snippet': 'We conducted a phase 2, randomized, double-blind, placebo-controlled trial \nto evaluate the safety, side-effect profile, and preliminary efficacy of \nfelzartamab', 'thumbnail': 'https://serpapi.com/searches/67227bb381bab7385d2609ad/images/f3950e0841dd035a3883b8829bcdfc4d71ee6370ea5be672503fc14fd25f8003.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.86485356092453}",,,,,,,,,,['neutral'],neutral,1
NCT00223691,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.14483', 'title': 'Predictors of the Pressor Response to the Norepinephrine Transporter Inhibitor, Atomoxetine, in Neurogenic Orthostatic Hypotension', 'source': 'American Heart Association Journals', 'date': 'Jun 28, 2021', 'snippet': 'The norepinephrine transporter inhibitor, atomoxetine, improved standing \nblood pressure and lightheadedness in patients with neurogenic orthostatic \nhypotension...', 'thumbnail': 'https://serpapi.com/searches/67227c792da1570475f1da6c/images/40d60d453a8214d12b0bad2f7789f9b843600c68b96cf7c21e15dec73c8dd5fd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8129895329475403}",,,,,,,,,,['neutral'],neutral,1
NCT05545111,"{'position': 1, 'link': 'https://www.genengnews.com/topics/drug-discovery/stockwatch-neurocrine-tumbles-as-schizophrenia-data-disappoints/', 'title': 'StockWatch: Neurocrine Tumbles as Schizophrenia Data Disappoints', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Aug 29, 2024', 'snippet': ""According to results trumpeted by Neurocine from the Phase II \nNBI-1117568-SCZ2028 trial (NCT05545111), a once daily, 20 mg dose of '568..."", 'thumbnail': 'https://serpapi.com/searches/67227cb364f11d789995ce38/images/b131307cc928cd8251b790ae82268237739093b8729a01acce8750cfcea48594.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5235870480537415}",,,,,,,,,,['negative'],negative,0
NCT04285827,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/csl889-designated-orphan-drug-europe-and-us-treating-sickle-cell-disease/', 'title': 'CSL889 Designated as Orphan Drug in Europe and US for Treating...', 'source': 'Sickle Cell Disease News', 'date': 'Nov 5, 2020', 'snippet': 'The European Commission and the FDA have granted orphan drug status to \nCSL889, an investigational therapy for sickle cell disease.', 'thumbnail': 'https://serpapi.com/searches/67227e318f2bc20cba22437f/images/64f800cf334507955e57e79edf9c559337b9ac7fb75eeb59a80a2a2a19635f7d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9184723496437073}",,,,,,,,,,['neutral'],neutral,1
NCT02461719,"{'position': 1, 'link': 'https://sjogrenssyndromenews.com/news/cyporin-n-supports-faster-relief-sjogrens-dry-eye-symptoms/', 'title': 'New Cyclosporin A Formulation Treats Sjögren’s Dry Eye Symptoms Faster, Trial Shows', 'source': ""Sjogren's Syndrome News"", 'date': 'Apr 30, 2019', 'snippet': ""Cyporin N, Taejoon's new cyclosporin A formulation, provides faster relief \nof chronic dry eye than Restasis in Sjögren's syndrome, a Phase 3..."", 'thumbnail': 'https://serpapi.com/searches/67227f9fa86921c0f30baa75/images/e533eabac68f46a491bc19591d7e81dfb8e4659b5d1e3b2f3519aaa7e524cc81.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6618289351463318}",,,,,,,,,,['neutral'],neutral,1
NCT05890118,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/rani-reports-positive-data-for-non-injectable-stelara-biosimilar/', 'title': 'Rani reports positive data for non-injectable Stelara biosimilar', 'source': 'Clinical Trials Arena', 'date': 'Feb 6, 2024', 'snippet': 'US-based Rani Therapeutics has announced positive topline data from the \nPhase I clinical study (NCT05890118) of RT-111, an ustekinumab biosimilar \nin...', 'thumbnail': 'https://serpapi.com/searches/67227fb6f59d00c5c47b4a28/images/715c4425511a0b0a32318a8c4af2124b006ef40240388c6dd14171e5cc69e2ac.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5926501154899597}",,,,,,,,,,['neutral'],neutral,1
NCT00094653,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1003466', 'title': 'Improved Survival with Ipilimumab in Patients with Metastatic Melanoma', 'source': 'The New England Journal of Medicine', 'date': 'Jun 5, 2010', 'snippet': 'An improvement in overall survival among patients with metastatic melanoma \nhas been an elusive goal. In this phase 3 study,...', 'thumbnail': 'https://serpapi.com/searches/67227fdeee677f260a21dee7/images/8409448396154598046dfe80efe6ade5aaa40eb76c90312bfb46faa8331bd323.png', 'sentiment': 'positive', 'sentiment_prob': 0.5156893134117126}",,,,,,,,,,['positive'],positive,1
NCT02278718,"{'position': 1, 'link': 'https://www.contemporarypediatrics.com/view/fda-accepts-sbla-for-nexobrid-to-remove-eschar-in-pediatric-thermal-burn-patients', 'title': 'FDA accepts sBLA for NexoBrid to remove eschar in pediatric thermal burn patients', 'source': 'Contemporary Pediatrics', 'date': 'Jan 10, 2024', 'snippet': 'NexoBrid, a topical biologic drug that enzymatically removes nonviable burn \ntissue, is 1 step closer to being FDA-approved for a pediatric indication.', 'thumbnail': 'https://serpapi.com/searches/67227ffd0197ddc6e9722918/images/5ce385f0c98e641165ec3478d38442212caa016c40307b3f6ca7e4de9ed49da8.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6434242725372314}",,,,,,,,,,['positive'],positive,1
NCT02675998,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/fda-to-review-resubmitted-tenapanor-nda-for-hyperphosphatemia-in-ckd/', 'title': 'FDA to Review Resubmitted Tenapanor NDA for Hyperphosphatemia in CKD', 'source': 'Medical Professionals Reference', 'date': 'May 17, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted for review the \nresubmitted New Drug Application (NDA) for tenapanor (Xphozah®) for the...', 'thumbnail': 'https://serpapi.com/searches/67228014f963e765fe784224/images/0a5356555af13d041512e8596d0cbdc4fe805013afb2bb3019b2ab7844f1a605.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9136853218078613}",,,,,,,,,,['neutral'],neutral,1
NCT00489489,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/2018/11/20/fda-approves-generic-of-aubagio-tablets-to-treat-relapsing-ms-glenmark-pharma-announces/', 'title': 'FDA Approves Generic Version of Aubagio to Treat Relapsing MS, Glenmark Pharma Says', 'source': 'Multiple Sclerosis News Today', 'date': 'Nov 20, 2018', 'snippet': 'The US Food and Drug Administration (FDA) has approved a generic version of \nAubagio (teriflunomide) tablets at the 7 mg and 14 mg doses marketed by \nSanofi.', 'thumbnail': 'https://serpapi.com/searches/6722815f14c31e44d922d2bf/images/9a609a3f51ab3ef0fe97a3f5fbc6c4c17b2ac06e58228fcca4fc3c2d92100ad0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7734127044677734}",,,,,,,,,,['neutral'],neutral,1
NCT04478708,"{'position': 1, 'link': 'https://www.nature.com/articles/s42255-023-00966-w', 'title': 'A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings', 'source': 'Nature', 'date': 'Feb 5, 2024', 'snippet': 'Obesity is a major public health crisis. Multi-specific peptides have \nemerged as promising therapeutic strategies for clinical weight loss.', 'thumbnail': 'https://serpapi.com/searches/672281982a772766c55728a8/images/932097234c49ecdf68490fff497957d6be41cc539c09092f7dd58b8ba970ebe5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5846526026725769}","{'position': 2, 'link': 'https://www.insideprecisionmedicine.com/topics/precision-medicine/amgens-weight-loss-candidate-shines-in-phase-i-study/', 'title': 'Amgen’s Weight Loss Candidate Shines in Phase I Study', 'source': 'Inside Precision Medicine', 'date': 'Feb 6, 2024', 'snippet': ""Amgen's weight-loss drug MariTide produces similar effects but is \nlonger-lasting than current market leaders in an early trial."", 'thumbnail': 'https://serpapi.com/searches/672281982a772766c55728a8/images/932097234c49ecdf9a802d3fa0506f9f45473f299c85addaa0b60da3f772b128.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5440323352813721}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03643965,"{'position': 1, 'link': 'https://www.empr.com/home/news/tarpeyo-approved-to-reduce-proteinuria-in-primary-iga-nephropathy/', 'title': 'Tarpeyo Approved to Reduce Proteinuria in Primary IgA Nephropathy', 'source': 'Medical Professionals Reference', 'date': 'Dec 17, 2021', 'snippet': 'The Food and Drug Administration (FDA) has granted accelerated approval to \nTarpeyo™ (budesonide) to reduce proteinuria in adults with...', 'thumbnail': 'https://serpapi.com/searches/672281d6ee677f25be4e1d82/images/bdfbb9340917379e8be39d6455431e2ae8b17c7addfb215c1626b716bb60e90a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7529929280281067}","{'position': 2, 'link': 'https://www.empr.com/home/news/tarpeyo-gets-priority-review-for-full-approval-in-lga-nephropathy/', 'title': 'Tarpeyo Gets Priority Review for Full Approval in lgA Nephropathy', 'source': 'Medical Professionals Reference', 'date': 'Aug 18, 2023', 'snippet': 'The Food and Drug Administration (FDA) has granted Priority Review for the \nsupplemental New Drug Application for Tarpeyo (budesonide) seeking full \napproval.', 'thumbnail': 'https://serpapi.com/searches/672281d6ee677f25be4e1d82/images/bdfbb9340917379ea9fadffc44429600431ab5b94d079500d91d0a539ebca666.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8492562770843506}","{'position': 3, 'link': 'https://www.empr.com/home/news/tarpeyo-proteinuria-immunoglobulina-nephropathy-available/', 'title': 'Tarpeyo Now Available to Reduce Proteinuria in Primary IgA Nephropathy', 'source': 'Medical Professionals Reference', 'date': 'Jan 28, 2022', 'snippet': 'Tarpeyo (budesonide) is now available to reduce proteinuria in adults with \nprimary immunoglobulin A nephropathy at risk of rapid disease...', 'thumbnail': 'https://serpapi.com/searches/672281d6ee677f25be4e1d82/images/bdfbb9340917379ecc21598862f5fa7f7fb265093042d07607374b46cca183a2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8431398868560791}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03664232,"{'position': 1, 'link': 'https://www.nature.com/articles/s41386-020-00888-1', 'title': 'The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study', 'source': 'Nature', 'date': 'Oct 18, 2020', 'snippet': 'JNJ-42165279 appears to elicit an anxiolytic effect in subjects with SAD \nalthough trough concentrations with 25 mg once daily appeared to be \ninsufficient to...', 'thumbnail': 'https://serpapi.com/searches/672282bc2e33c8a68aaebb6c/images/46ccead9f596b120d3f8c9a1cddf4b859e2ab9aff6fc2d07e669f0850449fc52.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7222075462341309}",,,,,,,,,,['neutral'],neutral,1
NCT01396239,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/exondys-51-can-slow-respiratory-decline-in-duchenne-dmd-patients/', 'title': 'Exondys 51 Can Slow Respiratory Decline in DMD Patients, Study Shows', 'source': 'Muscular Dystrophy News', 'date': 'Jan 2, 2018', 'snippet': 'An analysis of clinical trial data shows that Exondys 51 can effectively \nslow respiratory function decline in patients with Duchenne...', 'thumbnail': 'https://serpapi.com/searches/672282f439e232ed224d11d9/images/cc4a77d93af2a28e1268b309085366404a7328402396a7d3f89c7375574a04f0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8547712564468384}",,,,,,,,,,['neutral'],neutral,1
NCT02257918,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1706988', 'title': 'Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea', 'source': 'The New England Journal of Medicine', 'date': 'Nov 7, 2018', 'snippet': 'Zoliflodacin is a new antibiotic that inhibits DNA biosynthesis. In this \nmulticenter, phase 2 trial, zoliflodacin was evaluated for the treatment \nof...', 'thumbnail': 'https://serpapi.com/searches/6722832474f0a40f4043466c/images/965035affdfc61d85273c26e3fb7199dccf13be2878894956e0b5d12c9f25573.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8380105495452881}",,,,,,,,,,['neutral'],neutral,1
NCT03277261,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2201904', 'title': 'Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Aug 24, 2022', 'snippet': 'Ublituximab resulted in lower annualized relapse rates and fewer brain \nlesions on MRI than teriflunomide over a period of 96 weeks but did not \nresult in a...', 'thumbnail': 'https://serpapi.com/searches/672283d4a3657a6c2f22be26/images/0c5af9726a6816f8ed7b1cddef09b7661fdf9fde1b6bea74cea4eb31a5f24a7e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8014312386512756}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/09/19/ectrims-2004-ms-relapse-rates-fall-5-years-briumvi/', 'title': 'ECTRIMS 2024: MS relapse rates fall with 5 years on Briumvi', 'source': 'Multiple Sclerosis News Today', 'date': '1 month ago', 'snippet': ""Five years of continuous Briumvi kept MS relapse rates and disability \nprogression low, according to analyses from a trial's extension phase."", 'thumbnail': 'https://serpapi.com/searches/672283d4a3657a6c2f22be26/images/0c5af9726a6816f89163c7abed21985ffb0c19c71fa0186fa315ff6850eba273.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5869046449661255}","{'position': 3, 'link': 'https://www.thepharmaletter.com/biotechnology/bumpy-path-forecast-for-tg-therapeutics-briumvi-in-crowded-ms-market', 'title': 'Bumpy path forecast for TG Therapeutics’ Briumvi in crowded MS market', 'source': 'The Pharma Letter', 'date': 'Jan 13, 2023', 'snippet': ""Bumpy path forecast for TG Therapeutics' Briumvi in crowded MS market. \nBiotechnology. 13 January 2023. tg-therapeutics-large."", 'thumbnail': 'https://serpapi.com/searches/672283d4a3657a6c2f22be26/images/0c5af9726a6816f8fa6587b76ad1c2b05b3d4cc27f8f284718ae637e90a024c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8876432776451111}","{'position': 4, 'link': 'https://www.empr.com/home/news/briumvi-approved-for-relapsing-forms-of-multiple-sclerosis/', 'title': 'Briumvi Approved for Relapsing Forms of Multiple Sclerosis', 'source': 'Medical Professionals Reference', 'date': 'Dec 29, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Briumvi™ \n(ublituximab-xiiy) for the treatment of relapsing forms of multiple \nsclerosis,...', 'thumbnail': 'https://serpapi.com/searches/672283d4a3657a6c2f22be26/images/0c5af9726a6816f872a463cd1451d7604d181450a6f676cb9f386f1d4d83f291.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7864340543746948}","{'position': 5, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/12/12/briumvi-ublituximab-approved-relapsing-ms-us/', 'title': 'Ublituximab, Now Briumvi, Approved in US for Relapsing Forms of MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 28, 2022', 'snippet': ""The US Food and Drug Administration has approved TG Therapeutics' \nB-cell-depleting therapy ublituximab under the brand name Briumvi for the \ntreatment of adults..."", 'thumbnail': 'https://serpapi.com/searches/672283d4a3657a6c2f22be26/images/0c5af9726a6816f88b59bde445e8c10be481694a97854a4e4c2b6762ad4b80e2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8163254857063293}","{'position': 6, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/03/08/briumvi-infusion-treatment-ms-granted-3-more-patents/', 'title': 'Briumvi, an infusion treatment for MS, granted 3 more patents', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 8, 2024', 'snippet': ""TG Therapeutics has secured three additional U.S. patents covering Briumvi, \nan anti-CD20 antibody that's an infusion treatment for MS."", 'thumbnail': 'https://serpapi.com/searches/672283d4a3657a6c2f22be26/images/0c5af9726a6816f82b63624e30058f555cefc8eb14c26cbad5c8ebecbda274b8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7473829388618469}","{'position': 7, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/02/29/briumvi-relapsing-ms-therapy-now-available-european-patients/', 'title': 'Briumvi for relapsing MS forms now available for patients in Europe', 'source': 'Multiple Sclerosis News Today', 'date': 'Feb 29, 2024', 'snippet': 'Briumvi (ublituximab-xiiy), an approved treatment for relapsing forms of \nmultiple sclerosis (MS), is now available to patients in Europe.', 'thumbnail': 'https://serpapi.com/searches/672283d4a3657a6c2f22be26/images/0c5af9726a6816f820d63ce74b24a865ac187579c2cab835f91e6a912dead6d8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6790398359298706}","{'position': 8, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/relapsing-ms-therapy-briumvi-commercially-available-us/', 'title': 'Relapsing MS Therapy Briumvi Now Commercially Available in US –...', 'source': 'Multiple Sclerosis News Today', 'date': 'Jan 27, 2023', 'snippet': ""TG Therapeutics' Briumvi (ublituximab-xiiy), a CD20 inhibitor recently \napproved for adults with relapsing forms of multiple sclerosis (MS), is now \ncommercially..."", 'thumbnail': 'https://serpapi.com/searches/672283d4a3657a6c2f22be26/images/0c5af9726a6816f85a32536b94d07198dc3c5c54e6755f6caa3fdfa3d15943f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7444673180580139}","{'position': 9, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/briumvi-approved-europe-active-relapsing-forms-ms/', 'title': 'Briumvi approved in Europe for active, relapsing forms of MS –...', 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 2, 2023', 'snippet': 'The European Commission has approved Briumvi (ublituximab) for the \ntreatment of adults with relapsing forms of multiple sclerosis (MS) who \nhave active disease.', 'thumbnail': 'https://serpapi.com/searches/672283d4a3657a6c2f22be26/images/0c5af9726a6816f88da7509a441abcb829db27c663c97758ab8d0f5b8b1c379d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6688001751899719}",,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04519658,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2213169', 'title': 'Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension', 'source': 'The New England Journal of Medicine', 'date': 'Nov 7, 2022', 'snippet': 'Aldosterone synthase controls the synthesis of aldosterone and has been a \npharmacologic target for the treatment of hypertension for several...', 'thumbnail': 'https://serpapi.com/searches/672285079f8bfcb9eede2247/images/9009d9a35c1b802b2edf5f9a1aa6b0f7a779ab62c5303720edeedf877813ac90.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8641997575759888}",,,,,,,,,,['neutral'],neutral,1
NCT04599881,"{'position': 1, 'link': 'https://epidermolysisbullosanews.com/news/rdeb-phase-2-trial-shows-ptr-01-promotes-wound-healing-eases-pain/', 'title': 'PTR-01 Promotes Wound Healing, Eases Pain in Phase 2 RDEB Trial', 'source': 'Epidermolysis Bullosa News', 'date': 'May 27, 2022', 'snippet': ""Treatment with the experimental protein replacement therapy, PTR-01, \nresulted in RDEB patients' mean total pain scores decreasing by 36%."", 'thumbnail': 'https://serpapi.com/searches/6722852059f9112fb1499875/images/3eaeed74c06fee916eac17dbfc53e494091bb1596d4a3f8cb3d26ad5e0701013.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6647908091545105}","{'position': 2, 'link': 'https://epidermolysisbullosanews.com/news/phase-2-trial-of-ptr-01-for-rdeb-doses-first-participant/', 'title': 'PTR-01 Protein Replacement Given to 1st RDEB Patient in Phase 2 Trial', 'source': 'Epidermolysis Bullosa News', 'date': 'Oct 28, 2020', 'snippet': 'A Phase 2 clinical trial has dosed its first participant with PTR-01, a \npotential protein replacement drug for recessive dystrophic...', 'thumbnail': 'https://serpapi.com/searches/6722852059f9112fb1499875/images/3eaeed74c06fee9199b145829216ccd00eba9e5d55bb2fc804d2e486fe3fd82a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8609854578971863}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02165397,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1802917', 'title': 'Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia', 'source': 'The New England Journal of Medicine', 'date': 'Jun 1, 2018', 'snippet': ""Single-agent ibrutinib has shown substantial activity in patients with \nrelapsed Waldenström's macroglobulinemia, a rare form of B-cell..."", 'thumbnail': 'https://serpapi.com/searches/672285342b5fa7dc9a89f69e/images/c38b02f06c0b67acd13a64318de0e60ac3f84ea7eba5a81cfc201f3c3f715203.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8184304237365723}",,,,,,,,,,['neutral'],neutral,1
NCT04510194,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2201662', 'title': 'Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Aug 17, 2022', 'snippet': 'Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an \nimportant component of the comprehensive response to the severe...', 'thumbnail': 'https://serpapi.com/searches/672285c7d403e1d51e6f9918/images/0b5319cb839180a8ce96017b32b12081afd1ccff011b1da27d0a3157f2431ee2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8001853823661804}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/news/metformin-long-covid-study/', 'title': 'Metformin could reduce long Covid rates, large study finds', 'source': 'Clinical Trials Arena', 'date': 'Jun 9, 2023', 'snippet': 'The anti-diabetic drug metformin, when taken at the time of Covid-19 \ninfection, could reduce the rate of long Covid-19, a new study found.', 'thumbnail': 'https://serpapi.com/searches/672285c7d403e1d51e6f9918/images/0b5319cb839180a84735823fde3fbe4bdc669b4bd6e8d5ace6ae1380b7ff9c2e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7970713973045349}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01529424,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa1400283', 'title': 'Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia', 'source': 'The New England Journal of Medicine', 'date': 'Jul 1, 2018', 'snippet': 'We conducted a randomized, double-blind, placebo-controlled, dose-ranging, \nphase 2 study to evaluate ISIS 304801 in untreated patients with fasting...', 'thumbnail': 'https://serpapi.com/searches/672285ecb28e6bea4b5ac7ec/images/c8f7f3b72cd78c079a7252fb00a64f09a490701b8aa5e3a63834990b05c4ee0f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8942911028862}",,,,,,,,,,['neutral'],neutral,1
NCT04091646,"{'position': 1, 'link': 'https://www.empr.com/home/news/zoryve-topical-foam-approved-for-seborrheic-dermatitis/', 'title': 'Zoryve Topical Foam Approved for Seborrheic Dermatitis', 'source': 'Medical Professionals Reference', 'date': 'Dec 18, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Zoryve (roflumilast) \ntopical foam, 0.3% for the treatment of seborrheic dermatitis in adult and \npediatric...', 'thumbnail': 'https://serpapi.com/searches/6722863398876d773369ac44/images/1ad8f1ec1850d62265cf4efc6394a2525124802aea33d39cea8fc2826ced91fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8059292435646057}",,,,,,,,,,['neutral'],neutral,1
NCT00844649,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1304369', 'title': 'Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine', 'source': 'The New England Journal of Medicine', 'date': 'Dec 8, 2016', 'snippet': 'In a phase 1–2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus \ngemcitabine, substantial clinical activity was noted in patients with \nadvanced...', 'thumbnail': 'https://serpapi.com/searches/672286dc90b57c80eeffd352/images/cbdc98e31344fcefefe23073f9df456bf378eafea5e3d50ffbeb74f50869d748.png', 'sentiment': 'positive', 'sentiment_prob': 0.6090841889381409}","{'position': 2, 'link': 'https://www.cancertherapyadvisor.com/features/vitamin-d-pancreatic-cancer-link-treatment-risk/', 'title': 'Vitamin D and Pancreatic Cancer: is There a Link?', 'source': 'Cancer Therapy Advisor', 'date': 'Feb 11, 2021', 'snippet': 'In recent years, plasma 25-hydroxyvitamin-D (vitamin D) levels have been \nimplicated in the pathogenesis of pancreatic cancer.', 'thumbnail': 'https://serpapi.com/searches/672286dc90b57c80eeffd352/images/cbdc98e31344fcef44589f86c533ecc7ba2a52b752908485589b448e46d48185.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6798728108406067}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT04476030,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/zuranolone-vs-placebo-in-mdd/', 'title': 'Zuranolone in Major Depressive Disorder: Results From MOUNTAIN—A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial', 'source': 'Psychiatrist.com', 'date': 'Feb 20, 2023', 'snippet': 'This phase 3 RCT found significant improvement in depressive symptoms with \nzuranolone beginning at day 3 of treatment.', 'thumbnail': 'https://serpapi.com/searches/67228767069e577c45983a7a/images/2d664236304e80fd56c0352d2c9b41e1f1885eab21a36bbc8f1ee9f7d38bdfb0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7433127164840698}","{'position': 2, 'link': 'https://www.psychiatrist.com/jcp/safety-efficacy-initial-and-repeat-zuranolone-for-major-depressive-disorder/', 'title': 'Long-Term Safety and Efficacy of Zuranolone in MDD', 'source': 'Psychiatrist.com', 'date': 'Dec 27, 2023', 'snippet': 'Most patients with MDD achieved response after 14 days of zuranolone \ntreatment. For patients who responded to their first treatment,...', 'thumbnail': 'https://serpapi.com/searches/67228767069e577c45983a7a/images/2d664236304e80fd076b02af13dedb5fabf6c09c4751d11ffac565fbbd86f16d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5939822196960449}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01785602,"{'position': 1, 'link': 'https://www.researchgate.net/figure/An-overview-of-the-pathogenesis-of-atopic-dermatitis-on-the-skin-Emerging-drugs-and_fig1_334806931', 'title': 'Fig. 1 An overview of the pathogenesis of atopic dermatitis on the...', 'source': 'ResearchGate', 'date': 'Feb 20, 2020', 'snippet': 'Atopic dermatitis (AD) is a chronic, inflammatory skin disease \ncharacterized by pruritus, inflammatory erythematous skin lesions, and \nskin-barrier defect.', 'thumbnail': 'https://serpapi.com/searches/672287710be2f63ada29c0af/images/feb1c50773f1049bca1f599f44d0bc82c9eef4e06f279ea0a69267bbb98c801c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6052362322807312}",,,,,,,,,,['neutral'],neutral,1
NCT00337103,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/eribulin-yields-similar-benefit-to-standard-chemotherapeutics-for-her2-low-and-her2-0-metastatic-breast-cancer', 'title': 'Eribulin Yields Similar Benefit to Standard Chemotherapeutics for HER2-low and HER2-0 Metastatic Breast Cancer', 'source': 'Cancer Network', 'date': 'Dec 8, 2022', 'snippet': 'Treatment with eribulin mesylate (Halaven) resulted in a trend towards \nimproved overall survival (OS) in a population of patients diagnosed...', 'thumbnail': 'https://serpapi.com/searches/6722888454163d58f7188d5d/images/0a166711b4dd808b344809c24e93e9b384714fe97a3eefe66cf2c9c78ec72d43.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8202352523803711}",,,,,,,,,,['neutral'],neutral,1
NCT01898364,"{'position': 1, 'link': 'https://pompediseasenews.com/news/sanofis-next-generation-ert-halts-progression-of-pompe-disease-in-patients-interim-trial-data-show/', 'title': 'Sanofi’s Next-generation ERT Halts Progression of Pompe Disease in Patients, Interim Trial Data Show', 'source': 'Pompe Disease News', 'date': 'Feb 13, 2020', 'snippet': ""Sanofi Genzyme's avalglucosidase alfa safely halts disease progression in \npeople with Pompe disease, according to interim data from two..."", 'thumbnail': 'https://serpapi.com/searches/672288a864f11d789995d8fd/images/380729bf14ca18da17bd81c715898c30fa71fa328be314b1bf610a9296439612.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8510002493858337}",,,,,,,,,,['neutral'],neutral,1
NCT02389842,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-29425-y', 'title': 'Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models', 'source': 'Nature', 'date': 'Feb 15, 2023', 'snippet': 'Our results revealed that mTOR inhibition is more effective than PI3K \ninhibition in overcoming resistance, irrespective of PIK3CA mutation status.', 'thumbnail': 'https://serpapi.com/searches/67228901ee46823f19e9451a/images/e5599305bafc16b1ae995adc42ef04927ca095b58b01e3fa709adde19b866ca4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6151317358016968}",,,,,,,,,,['neutral'],neutral,1
NCT03921411,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Nemolizumab-serum-pharmacokinetic-parame-ters-estimated-with-popPK-analysis-adolescent_tbl2_358199212', 'title': 'Nemolizumab serum pharmacokinetic parame- ters estimated with popPK analysis (adolescent PK popu- lation, N = 18)', 'source': 'ResearchGate', 'date': 'Feb 2, 2022', 'snippet': 'This study evaluated the pharmacokinetics (PK) and safety of nemolizumab in \nadolescents with moderate to severe AD as well as the relationship between \nnemol', 'thumbnail': 'https://serpapi.com/searches/6722891cd364b47823e12155/images/98f7f47be83121fbd258a092c6ddad037a94a8e7458990074f388c09d374a90c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8758065104484558}",,,,,,,,,,['neutral'],neutral,1
NCT00259740,"{'position': 1, 'link': 'https://myelomaresearchnews.com/xgeva-denosumab/', 'title': 'XGEVA (Denosumab)', 'source': 'Myeloma Research News', 'date': 'Feb 9, 2018', 'snippet': 'Xgeva (denosumab) was approved by the US Food and Drug Administration (FDA) \nto treat bone problems (skeletal-related events) in multiple myeloma (MM) \npatients.', 'thumbnail': 'https://serpapi.com/searches/672289c57ca6b31d9b99bbb4/images/e13658cc84e13b13c43b2c5c33d323673285d54587cd75e1025cbaf66f64d7c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7067121267318726}",,,,,,,,,,['neutral'],neutral,1
NCT01879319,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1500858', 'title': 'Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events', 'source': 'The New England Journal of Medicine', 'date': 'Mar 15, 2015', 'snippet': 'Evolocumab, a monoclonal antibody that inhibits proprotein convertase \nsubtilisin–kexin type 9 (PCSK9), significantly reduced low-density...', 'thumbnail': 'https://serpapi.com/searches/67228a6216779391e19a23c6/images/ca32998ec34335723d17d1308ff628f80f35cd3de98133fb3877212ebe99a282.png', 'sentiment': 'neutral', 'sentiment_prob': 0.796350359916687}",,,,,,,,,,['neutral'],neutral,1
NCT03098797,"{'position': 1, 'link': 'https://www.yahoo.com/finance/news/fda-adcom-votes-favour-stealth-173237365.html', 'title': 'FDA AdCom votes in favour of Stealth’s Barth syndrome drug', 'source': 'Yahoo', 'date': '3 weeks ago', 'snippet': ""The Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in support \nof Stealth's elamipretide for the ultra-rare disorder."", 'thumbnail': 'https://serpapi.com/searches/67228a6624296aed45f1105f/images/538fd29451342ecba9a3215580a6d2208be71591680692c216427bc0014014d4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7460616230964661}","{'position': 2, 'link': 'https://mitochondrialdiseasenews.com/2017/07/26/trial-elamipretide-treatment-barth-syndrome-started/', 'title': 'Potential Barth Syndrome Therapy, Elamipretide, to Be Tested in Clinical Trial', 'source': 'Mitochondrial Disease News', 'date': 'Jul 26, 2017', 'snippet': 'A Phase 2/3 clinical trial of elamipretide, a potential treatment for a \nrare mitochondrial disease known as Barth syndrome, is now enrolling \npatients.', 'thumbnail': 'https://serpapi.com/searches/67228a6624296aed45f1105f/images/538fd29451342ecbf8e5444eb88dcbd43ad3c931612a1c56680135ba3d9fbcae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9102270603179932}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05493995,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-024-01857-6', 'title': 'First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial | Signal Transduction and Targete', 'source': 'Nature', 'date': 'Jun 7, 2024', 'snippet': 'Metastatic pancreatic cancer (mPC) has a dismal prognosis. Herein, we \nconducted a prospective, multicentre, single-arm, phase II trial...', 'thumbnail': 'https://serpapi.com/searches/67228af93c944b0711a261c4/images/8fb99c4d8bc72e1060a039101a2b072eb47b4ad5fbbf3b0139154ff2b9b05d24.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5156915187835693}",,,,,,,,,,['neutral'],neutral,1
NCT00158600,"{'position': 1, 'link': 'https://pompediseasenews.com/lumizyme-alglucosidase-alfa-for-the-treatment-of-pompe-disease/', 'title': 'Lumizyme (Alglucosidase Alfa) in Pompe Disease', 'source': 'Pompe Disease News', 'date': 'Jul 15, 2022', 'snippet': 'Lumizyme (alglucosidase alfa) is an enzyme replacement therapy for Pompe \ndisease. Learn about its uses, indications, and side effects.', 'thumbnail': 'https://serpapi.com/searches/67228ba0671f3fe9cb229d8c/images/b65cdf54e08878770b193d4d71c91a715012e4b48b53948d7e5b85ef76b35b29.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8790404200553894}",,,,,,,,,,['neutral'],neutral,1
NCT02172950,"{'position': 1, 'link': 'https://hemophilianewstoday.com/afstyla-for-hemophilia-a/', 'title': 'Afstyla (lonoctocog alfa) for hemophilia', 'source': 'Hemophilia News Today', 'date': 'Nov 15, 2023', 'snippet': 'Afstyla is an injectable factor replacement therapy used to prevent and \ntreat bleeding episodes in hemophilia A patients.', 'thumbnail': 'https://serpapi.com/searches/67228ed12e33c8a68aaec5b7/images/6364eb787bb242b944a5e88ed02d18d1a76a430dae2099b6f611225a5837230f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8757435083389282}",,,,,,,,,,['neutral'],neutral,1
NCT02510794,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20170619005283/en/Vital-Art-and-Science-Announces-License-Agreement-with-Genentech-for-Its-mVT%C2%AE-Service', 'title': 'Vital Art and Science Announces License Agreement with Genentech for Its mVT® Service', 'source': 'Business Wire', 'date': 'Jun 19, 2017', 'snippet': 'Vital Art and Science, LLC today announced that it has signed a license \nagreement with Genentech, a member of the Roche Group, for the use of Vital \nArt and...', 'thumbnail': 'https://serpapi.com/searches/67228f0ff60b6f07ae86a45e/images/da30b8ea1d5e89c66ffd23ab39a58d85795a3c0e0bf768e57fb99c3bafb3c770.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8740266561508179}",,,,,,,,,,['neutral'],neutral,1
NCT02626364,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2023.1325214/full', 'title': 'Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment', 'source': 'Frontiers', 'date': 'Jun 25, 2024', 'snippet': 'Glioblastoma multiforme (GBM) is a highly aggressive malignant primary \ntumor in the central nervous system. Despite extensive efforts in \nradiotherapy,...', 'thumbnail': 'https://serpapi.com/searches/67228f7ebe80133871043e7e/images/1f978b6735e2ffed48b67f2e875c34943b1faf6dbfff1d66f47ee2cdff591b3c.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5473702549934387}",,,,,,,,,,['negative'],negative,0
NCT00004031,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1301077', 'title': ""Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma"", 'source': 'The New England Journal of Medicine', 'date': 'Oct 31, 2013', 'snippet': 'Early autologous stem-cell transplantation improved progression-free \nsurvival among patients with high-intermediate-risk or high-risk disease.', 'thumbnail': 'https://serpapi.com/searches/67228c2eb4b72d6f8cf4b4ff/images/926d9cea5e55be0517a1d5a45ed25198d29e9bba6c8343dfaddd129410a70044.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7844066619873047}",,,,,,,,,,['neutral'],neutral,1
NCT00329628,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0800374', 'title': 'Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty', 'source': 'The New England Journal of Medicine', 'date': 'Jun 26, 2008', 'snippet': 'This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral \ndirect inhibitor of factor Xa, with those of enoxaparin for...', 'thumbnail': 'https://serpapi.com/searches/67228c6de50bc07d7714ea31/images/b3d64155f55c07e7fa1fbc00b05d8b05953b088b7457f220450942b6cab88053.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8526756763458252}",,,,,,,,,,['neutral'],neutral,1
NCT04360434,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2303765', 'title': 'Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid', 'source': 'The New England Journal of Medicine', 'date': 'May 20, 2023', 'snippet': 'NI006 is a recombinant human anti-ATTR antibody that was developed for the \nremoval of ATTR by phagocytic immune cells.', 'thumbnail': 'https://serpapi.com/searches/67228c75be324f0a655783b2/images/9514ec35aedfcb3cf65f07318df4c0b1dc6b687dcb8e76469ea3aa9539f7bedd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9107809662818909}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1073503/full', 'title': 'Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy', 'source': 'Frontiers', 'date': 'Dec 19, 2022', 'snippet': 'Cardiac amyloidosis is a rare, debilitating, and usually fatal disease \nincreasingly recognized in clinical practice despite patients...', 'thumbnail': 'https://serpapi.com/searches/67228c75be324f0a655783b2/images/9514ec35aedfcb3c4bd6495b01ec8a0f0d27c8f6f8387a89b37b209f44246734.png', 'sentiment': 'negative', 'sentiment_prob': 0.6490713953971863}","{'position': 3, 'link': 'https://www.clinicaltrialsarena.com/features/pipeline-moves-phase-iii-oncology-trial-failure/', 'title': 'Pipeline Moves: Prospects drop after Phase III ovarian cancer trial failure', 'source': 'Clinical Trials Arena', 'date': 'Nov 13, 2023', 'snippet': 'The Clinical Trials Arena team also review assets in oncology, infectious \ndiseases and cardiology.', 'thumbnail': 'https://serpapi.com/searches/67228c75be324f0a655783b2/images/9514ec35aedfcb3c0a1abcb8d35bc76d65ab2d959afe4d77e449a69df4bcfcff.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6975389719009399}",,,,,,,,"['neutral', 'negative', 'negative']",negative,0
NCT00799617,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1506119', 'title': 'Effects of Testosterone Treatment in Older Men', 'source': 'The New England Journal of Medicine', 'date': 'Feb 18, 2016', 'snippet': 'Serum testosterone concentrations decrease as men age, but benefits of \nraising testosterone levels in older men have not been established.', 'thumbnail': 'https://serpapi.com/searches/67228ccdcc29870e922ba64b/images/fed7a43315cc1e0b8cf8db6d2e94ae3fde2f4037fee6bc87b22e3ae549e63835.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5868699550628662}",,,,,,,,,,['neutral'],neutral,1
NCT00411619,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1001671', 'title': 'Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Nov 4, 2010', 'snippet': 'Neurosurgical resection is the standard treatment for subependymal \ngiant-cell astrocytomas in patients with the tuberous sclerosis complex.', 'thumbnail': 'https://serpapi.com/searches/67228d07e6862ba379585640/images/8e9a9b659fd3b33912ace28b85f973f8f3c98cbcca333d1cb0ad9e3983a2b679.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.880478024482727}",,,,,,,,,,['neutral'],neutral,1
NCT03728504,"{'position': 1, 'link': 'https://nationaleczema.org/blog/asana-42221/', 'title': 'Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Oral SYK/JAK Inhibitor Gusacitinib at AAD VMX Late-Breaking Session', 'source': 'National Eczema Association', 'date': 'Apr 22, 2021', 'snippet': 'The results of this trial are very impressive and provide evidence that \ngusacitinib may be an effective once-daily, oral treatment option for CHE \npatients.', 'thumbnail': 'https://serpapi.com/searches/67228d6ef93388d03dc82e1e/images/5ddd239ea00c2db64b1814c5f66447e088a6e31175b46bc1e166c34463d2416e.png', 'sentiment': 'positive', 'sentiment_prob': 0.6924538612365723}",,,,,,,,,,['positive'],positive,1
NCT02760472,"{'position': 1, 'link': 'https://www.nature.com/articles/s41390-022-02134-4', 'title': 'Postnatal serum IGF-1 levels associate with brain volumes at term in extremely preterm infants', 'source': 'Nature', 'date': 'Jun 9, 2022', 'snippet': 'Growth factors important for normal brain development are low in preterm \ninfants. This study investigated the link between growth factors...', 'thumbnail': 'https://serpapi.com/searches/6722924252a04e2f12614cf8/images/bf78def8e216645beb4a7f20db25f13244cf72c635749d43efa156e40300d7a5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7522196173667908}",,,,,,,,,,['neutral'],neutral,1
NCT02108652,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/news/fda-grants-atezolizumab-accelerated-approval-for-bladder-cancer/', 'title': 'FDA Grants Atezolizumab Accelerated Approval for Bladder Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Apr 18, 2017', 'snippet': 'The US Food and Drug Administration (FDA) has granted the PD-L1-targeting \nmonoclonal antibody atezolizumab (Tecentriq) accelerated approval for \nfirst-line...', 'thumbnail': 'https://serpapi.com/searches/672293300c08f282b39198c0/images/1cdce7b7855a6fc9568148ccea17f8eb0292c262ff30cae98c0465947f4b486b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8297524452209473}",,,,,,,,,,['neutral'],neutral,1
NCT03115112,"{'position': 1, 'link': 'https://www.empr.com/home/news/brenzavvy-approved-for-adults-with-type-2-diabetes/', 'title': 'Brenzavvy Approved for Adults With Type 2 Diabetes', 'source': 'Medical Professionals Reference', 'date': 'Jan 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Brenzavvy™ \n(bexagliflozin) as an adjunct to diet and exercise to improve glycemic...', 'thumbnail': 'https://serpapi.com/searches/6722949e9e5bd5d95e2ec68d/images/f0d0f200f625b349596006cd1740756c3fac544c0c68229b1d3744efa034fbac.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6072625517845154}",,,,,,,,,,['neutral'],neutral,1
NCT04514796,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2022/08/18/fda-approves-higher-concentration-hadlima-humira-biosimilar/', 'title': 'FDA Approves Higher Concentration of Hadlima, a Humira Biosimilar...', 'source': 'Ankylosing Spondylitis News', 'date': 'Aug 18, 2022', 'snippet': ""The US Food and Drug Administration (FDA) has approved a new, more highly \nconcentrated formulation of Hadlima (adalimumab-bwwd), a biosimilar to \nAbbVie's..."", 'thumbnail': 'https://serpapi.com/searches/672296bad169151c1d6194bd/images/6f5afd5db7b04a40dc30a473862d4db719fc61ee58e8ac664178911a289c52a2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5983152985572815}",,,,,,,,,,['neutral'],neutral,1
NCT00934544,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1110556', 'title': 'JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis', 'source': 'The New England Journal of Medicine', 'date': 'Mar 1, 2012', 'snippet': 'Treatment options for myelofibrosis are limited. We evaluated the efficacy \nand safety of ruxolitinib, a potent and selective Janus kinase...', 'thumbnail': 'https://serpapi.com/searches/672298b3ba13f2d17b1d2e7d/images/d6104c947726d4d553331f4fadda46e3aa31619dd7a01a331d10aba2a788a848.png', 'sentiment': 'neutral', 'sentiment_prob': 0.806252121925354}","{'position': 2, 'link': 'https://www.onclive.com/view/ruxolitinib-improves-spleen-volume-tss-in-myelofibrosis-irrespective-of-baseline-anemia-transfusion-status', 'title': 'Ruxolitinib Improves Spleen Volume, TSS in Myelofibrosis Irrespective of Anemia, Transfusion Status', 'source': 'OncLive', 'date': 'Jun 10, 2023', 'snippet': 'Ruxolitinib was found to improve spleen volume and tumor symptom score in \npatients with myelofibrosis, irrespective of their anemia and...', 'thumbnail': 'https://serpapi.com/searches/672298b3ba13f2d17b1d2e7d/images/d6104c947726d4d5de85cc509d2eda4b9e908509f2ec22d804b60de71fd29743.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5063223838806152}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02165111,"{'position': 1, 'link': 'https://raynaudsnews.com/2017/04/26/botulinum-toxin-has-variable-effectiveness-in-scleroderma-associated-raynauds-phenomenon/', 'title': 'Botulinum Toxin Has Variable Effectiveness in Patients with Scleroderma-associated Raynaud’s', 'source': 'Raynaud News', 'date': 'Apr 26, 2017', 'snippet': ""Botulinum Toxin Type A (Btx-A) treatment for Raynaud's phenomenon (RP) may \nnot be effective for all patients diagnosed with scleroderma, according \nto..."", 'thumbnail': 'https://serpapi.com/searches/672298ea5bb6a23fb5dba960/images/b3d5ad2dc1f7f8e52250a4a91561b81e1f4c144da5f3834dfd061ae7458fe6ec.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5942825078964233}",,,,,,,,,,['neutral'],neutral,1
NCT00819013,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/abs/pii/S014181302400062X', 'title': 'Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice', 'source': 'ScienceDirect.com', 'date': 'Jan 7, 2024', 'snippet': 'The prokaryotically expressed multiepitope nanovaccine elicits long-lasting \nmucosal immunity, broad humoral immunity, and robust cellular immunity \nwithout any...', 'thumbnail': 'https://serpapi.com/searches/67229905671f3fe9cb22a9ec/images/bc5a4723af82af28cba9ae63c6e6e33d13be4cde76d85228501dfda1042ca830.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6536120176315308}",,,,,,,,,,['neutral'],neutral,1
NCT03558139,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2020/02/14/checkpoint-inhibitor-combination-well-tolerated-effective-in-ovarian-cancer-patients-phase-1b-trial-shows/', 'title': 'OC Patients Show Positive Responses to Magrolimab-Bavencio in Trial', 'source': 'Ovarian Cancer News Today', 'date': 'Feb 14, 2020', 'snippet': 'A mix of the checkpoint inhibitors magrolimab and Bavencio was \nwell-tolerated and showed anti-tumor activity in ovarian cancer patients,...', 'thumbnail': 'https://serpapi.com/searches/67229948ca6f0c0e9b69e073/images/e5f76687eee7a6fc68957e178ba732329e1cd81a7018d284f788e68f84cf4cb9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6095201373100281}",,,,,,,,,,['neutral'],neutral,1
NCT04799353,"{'position': 1, 'link': 'https://www.aidsmap.com/news/oct-2023/pd-1-inhibitor-budigalimab-may-delay-viral-rebound', 'title': 'PD-1 inhibitor budigalimab may delay viral rebound', 'source': 'Aidsmap', 'date': 'Oct 26, 2023', 'snippet': 'Budigalimab, a monoclonal antibody that blocks the PD-1 receptor on immune \ncells, was associated with delayed HIV rebound or sustained low viral load.', 'thumbnail': 'https://serpapi.com/searches/67229973c05eb5bb709fe814/images/e62fa39278c91ad339033987fc4c4831597c9ef4b5e9a270933f3161ec88603a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7458714246749878}",,,,,,,,,,['negative'],negative,0
NCT02180217,"{'position': 1, 'link': 'https://cushingsdiseasenews.com/news/isturisa-effective-in-treating-cushings-syndrome-other-than-cushings-disease-phase-2-trial-shows/', 'title': 'Isturisa Effective in Treating Cushing’s Syndrome Other Than...', 'source': ""Cushing's Disease News"", 'date': 'Jul 1, 2020', 'snippet': ""Combined with results from previous trials in Cushing's disease, the data \nshows Isturisa is a safe and effective therapy option."", 'thumbnail': 'https://serpapi.com/searches/67229983c117a9c51223c34d/images/3c52504554445838a9cf7e5ebb06acafebbef25650ac721f1f704f5efdc7ad73.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.63901287317276}","{'position': 2, 'link': 'https://cushingsdiseasenews.com/news/japan-oks-isturisa-for-endogenous-cushings/', 'title': 'Isturisa Approved in Japan for Endogenous Cushing’s Syndrome', 'source': ""Cushing's Disease News"", 'date': 'Mar 26, 2021', 'snippet': ""The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved \nIsturisa (osilodrostat) for endogenous Cushing's syndrome."", 'thumbnail': 'https://serpapi.com/searches/67229983c117a9c51223c34d/images/3c525045544458388f853d508d9263e210a1d65e80a5b3c8cb8b89a4e41f491b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8995946049690247}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05821153,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/coya-301-encouraging-results-8-patients-no-cogitive-decline/', 'title': 'COYA 301 therapy shows ‘encouraging results’ for Alzheimer’s', 'source': ""Alzheimer's News Today"", 'date': 'May 19, 2023', 'snippet': '""Encouraging results"" were reported in eight Alzheimer\'s patients with \ndementia who were treated with the experimental therapy COYA 301.', 'thumbnail': 'https://serpapi.com/searches/672299f8f60b6f07ae86adf1/images/b65ae4f460c615d7192edea7e2e37dcc0d085e6c8045ceb63055768a31f2b9bc.png', 'sentiment': 'positive', 'sentiment_prob': 0.5928337574005127}",,,,,,,,,,['positive'],positive,1
NCT00688740,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0910320', 'title': 'Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Dec 2, 2010', 'snippet': 'A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior \nto a regimen of fluorouracil, doxorubicin, and cyclophosphamide...', 'thumbnail': 'https://serpapi.com/searches/67229b1789055e436d6c6dd4/images/2d18485817b4fe247f2fdf3de050fa86187c47f0f7526cd6cb6197cde595e104.png', 'sentiment': 'neutral', 'sentiment_prob': 0.786040723323822}",,,,,,,,,,['neutral'],neutral,1
NCT01927419,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1414428', 'title': 'Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma', 'source': 'The New England Journal of Medicine', 'date': 'Dec 8, 2015', 'snippet': 'In this double-blind study involving 142 patients with metastatic melanoma \nwho had not previously received treatment, we randomly assigned patients in \na 2:1...', 'thumbnail': 'https://serpapi.com/searches/67229b4d690bb9df0c32badc/images/0f6f92448a8e71457e520f2c7d1159bfcee78f569de312b98b5eec10ba1fffd6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9109342694282532}",,,,,,,,,,['neutral'],neutral,1
NCT03295786,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/herantis-closer-nasal-spray-formulation-cdnf-potential-parkinsons-dmt/', 'title': 'CDNF, Potential DMT for Parkinson’s, May Work as Nasal Spray', 'source': ""Parkinson's News Today"", 'date': 'Sep 14, 2021', 'snippet': ""Herantis' cerebral dopamine neurotrophic factor, a potential \ndisease-modifying therapy, works as tiny nanoparticles for alternative..."", 'thumbnail': 'https://serpapi.com/searches/67229c190e6db3f1485a2847/images/9e5be450b78b72f0a81b2384efc72fe487cc4e585f7c8a2adfadb5aef3482723.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8680492043495178}",,,,,,,,,,['neutral'],neutral,1
NCT04845620,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/roflumilast-cream-effective-in-pediatric-atopic-dermatitis-trial/', 'title': 'Roflumilast Cream Effective in Pediatric Atopic Dermatitis Trial', 'source': 'Medical Professionals Reference', 'date': 'Sep 19, 2023', 'snippet': 'A phase 3 trial evaluating rolfumilast cream 0.05% in children with mild to \nmoderate atopic dermatitis met its primary and all secondary...', 'thumbnail': 'https://serpapi.com/searches/67229c80b691a72d63999ccf/images/40f0b9a05af6d5ecb2301ec0abaf2bd7cae19caa211b9c9f561f20271f453723.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7180405855178833}",,,,,,,,,,['neutral'],neutral,1
NCT01904136,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-021-01349-4', 'title': 'Decrease post-transplant relapse using donor-derived expanded NK-cells - Leukemia', 'source': 'Nature', 'date': 'Jul 26, 2021', 'snippet': 'In this phase I/II clinical trial, we investigated the safety and efficacy \nof high doses of mb-IL21 ex vivo expanded donor-derived NK cells to \ndecrease relapse.', 'thumbnail': 'https://serpapi.com/searches/6722a62cacf7f8296777baee/images/cbf70b9feb38b29db98e00df82c57465ed5abd19802a65865b848356287a2225.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8814918398857117}",,,,,,,,,,['neutral'],neutral,1
NCT00720941,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1303989', 'title': 'Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma', 'source': 'The New England Journal of Medicine', 'date': 'Aug 22, 2013', 'snippet': 'Pazopanib and sunitinib provided a progression-free survival benefit, as \ncompared with placebo or interferon, in previous phase 3 studies...', 'thumbnail': 'https://serpapi.com/searches/6722a64e8b7ba755dfb96f35/images/22f19eee7c4c05bbc40b934f96f9c800b4703cb4d8647386041abc8d4336984a.png', 'sentiment': 'positive', 'sentiment_prob': 0.5386547446250916}",,,,,,,,,,['positive'],positive,1
NCT00878293,"{'position': 1, 'link': 'https://www.medcentral.com/meds/opioids/cebranopadol-opioid-alternative', 'title': 'Cebranopadol (GRT-6005) as an Opioid Alternative', 'source': 'MedCentral', 'date': 'May 22, 2020', 'snippet': 'This investigational drug may be helpful in relieving pain associated with \nosteoarthritis, cancer, the lumbar region, diabetic neuropathy, and surgery.', 'thumbnail': 'https://serpapi.com/searches/6722a66b7ef9facbe756ee44/images/e13756c21023989a877b45e9e2d7175b9f81f7fd7668f247b49a7c68781029a9.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6515068411827087}",,,,,,,,,,['positive'],positive,1
NCT03036150,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2024816', 'title': 'Dapagliflozin in Patients with Chronic Kidney Disease', 'source': 'The New England Journal of Medicine', 'date': 'Sep 24, 2020', 'snippet': 'Patients with chronic kidney disease have a high risk of adverse kidney and \ncardiovascular outcomes. The effect of dapagliflozin in patients...', 'thumbnail': 'https://serpapi.com/searches/67229c87e1c27611dea98cad/images/5420b29fdd247467eac1241ce159d3b2f147866fb2f97cc03b25057de72fd0cf.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5958799719810486}","{'position': 2, 'link': 'https://www.empr.com/home/news/farxiga-approved-for-patients-with-ckd-at-risk-of-progression/', 'title': 'Farxiga Approved for Patients With CKD at Risk of Progression - MPR', 'source': 'Medical Professionals Reference', 'date': 'May 3, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) \nto reduce the risk of sustained estimated glomerular filtration rate (eGFR) \ndecline.', 'thumbnail': 'https://serpapi.com/searches/67229c87e1c27611dea98cad/images/5420b29fdd2474675bca0a0a905b38e0b578b2f8b8cdb6c40978816275c9c8eb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8881173729896545}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT02792218,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1917246', 'title': 'Ofatumumab versus Teriflunomide in Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Aug 5, 2020', 'snippet': 'Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively \ndepletes B cells. Teriflunomide, an oral inhibitor of pyrimidine...', 'thumbnail': 'https://serpapi.com/searches/67229cfc2379388066543347/images/0c72577149ad4ae174884c048d73b035195c9f7ab01b39bfadf32f70e95407d0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8694962859153748}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/07/26/kesimpta-better-aubagio-ethnically-diverse-groups-study/', 'title': 'Kesimpta better than Aubagio for ethnically diverse groups: Study', 'source': 'Multiple Sclerosis News Today', 'date': 'Jul 26, 2024', 'snippet': 'Kesimpta was more effective than Aubagio among people with RRMS from \nethnically diverse groups, an analysis of clinical trial data shows.', 'thumbnail': 'https://serpapi.com/searches/67229cfc2379388066543347/images/0c72577149ad4ae1f846fe860632b2e5ce17970b4873c4e67e7fa5b9a0b1313e.png', 'sentiment': 'positive', 'sentiment_prob': 0.6640809178352356}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/06/27/ms-patients-kesimpta-4-years-saw-no-disease-activity-trials/', 'title': 'MS Patients on Kesimpta for 4 Years Saw No Disease Activity in Trials', 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 28, 2022', 'snippet': 'ALITHIOS trial participants who started on Kesimpta were about four times \nmore likely to have no MS symptoms than those starting on Aubagio.', 'thumbnail': 'https://serpapi.com/searches/67229cfc2379388066543347/images/0c72577149ad4ae1f107124a4d2a0f1ab7f953bb765cd976bb2e1f2c44968761.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6928902268409729}","{'position': 4, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2020/08/21/fda-approves-kesimpta-b-cell-targeting-therapy-relapsing-ms/', 'title': 'FDA Approves Kesimpta, B-cell Targeting Therapy for Relapsing MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Aug 21, 2020', 'snippet': 'Kesimpta (ofatumumab) was seen as superior to Aubagio in trials at lowering \nrelapses and slowing disease progression, with comparable...', 'thumbnail': 'https://serpapi.com/searches/67229cfc2379388066543347/images/0c72577149ad4ae125cf8dbc00323c9d694fcb4e6aaac07fd0d1ec1077c5c6cb.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5676406025886536}","{'position': 5, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2020/09/08/novartis-data-at-actrims-ectrims-highlight-the-strength-of-leading-multiple-sclerosis-ms-portfolio-with-life-changing-therapies-for-people-across-the-ms-spectrum/', 'title': '#MSVirtual2020 – Novartis to Present Latest Data on Kesimpta, Mayzent and Gilenya', 'source': 'Multiple Sclerosis News Today', 'date': 'Sep 11, 2020', 'snippet': 'Novartis will present latest study findings on its approved therapies for \nrelapsing MS at the MSVirtual2020 meeting running Sept. 11 to 13..', 'thumbnail': 'https://serpapi.com/searches/67229cfc2379388066543347/images/0c72577149ad4ae10b8ae153cc2fd92e8346dd88a0bbbd19625286ac0b606220.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.857699453830719}",,,,,,"['neutral', 'positive', 'neutral', 'positive', 'neutral']",neutral,1
NCT00044486,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa061094', 'title': 'Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia', 'source': 'The New England Journal of Medicine', 'date': 'Jan 25, 2007', 'snippet': 'In this randomized, multicenter study involving evaluators who were unaware \nof treatment assignments, we compared the efficacy and safety of...', 'thumbnail': 'https://serpapi.com/searches/67229d84c5d7690e8575d217/images/b943dd8104ede2deb5e4c470a5a3f4823df98593f1e21506e36345f01d51639d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8904995322227478}",,,,,,,,,,['neutral'],neutral,1
NCT01370018,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2019.00278/full', 'title': 'T Cells Requires Alpha-1 Antitrypsin as Observed by Treatment in HIV-1 Infected and Uninfected Controls', 'source': 'Frontiers', 'date': 'Nov 20, 2019', 'snippet': 'Immune cells are, by default, migratory cells that traverse tissue for the \npurpose of carrying out recognition and recruitment in pathologic...', 'thumbnail': 'https://serpapi.com/searches/67229e60a86921c14170c57c/images/31ba58cc38a8e7c8edef9b3e359a72832e978a99a2759e9b884f0e77066fdceb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.918792724609375}",,,,,,,,,,['neutral'],neutral,1
NCT01795859,"{'position': 1, 'link': 'https://huntingtonsdiseasenews.com/news/fda-approves-new-dosages-austedo-xr-huntingtons-chorea/', 'title': ""FDA approves new dosages of Austedo XR for Huntington's chorea"", 'source': ""Huntington's Disease News"", 'date': 'May 30, 2024', 'snippet': 'The US Food and Drug Administration (FDA) has authorized new dosage \nstrengths of Austedo XR (deutetrabenazine) extended-release tablets for \nmanaging chorea.', 'thumbnail': 'https://serpapi.com/searches/67229e6e17a2e2f6d195a3b1/images/cac4f09863eaf1cff6a22e3e1aa637d99cd1a8a16c637fccdf3b76e864fdb4b4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7764703035354614}","{'position': 2, 'link': 'https://huntingtonsdiseasenews.com/news/china-approves-austedo-for-huntingtons-related-chorea/', 'title': 'China Approves Austedo for Huntington’s-related Chorea', 'source': ""Huntington's Disease News"", 'date': 'May 26, 2020', 'snippet': ""Teva Pharmaceuticals' Austedo (deutetrabenazine tablets) has been approved \nby China's National Medical Products Administration (NMPA) for..."", 'thumbnail': 'https://serpapi.com/searches/67229e6e17a2e2f6d195a3b1/images/cac4f09863eaf1cf9f1b764167c1c61f716288f0e53a341f5b621575961ea65c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8606238961219788}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02705625,"{'position': 1, 'link': 'https://www.nature.com/articles/s12276-021-00710-y', 'title': 'Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions', 'source': 'Nature', 'date': 'Nov 30, 2021', 'snippet': 'This review describes the current developmental status of DMOADs and the \ncorresponding results from preclinical and clinical trials', 'thumbnail': 'https://serpapi.com/searches/67229ef0922cce60a478dd2d/images/750df968b6c70cb24a20eec1ab79381135db2124955f6bb887a0ce18f688ae62.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9270862340927124}",,,,,,,,,,['neutral'],neutral,1
NCT01004029,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-withdraws-approval-of-makena-for-preventing-preterm-birth/', 'title': 'FDA Withdraws Approval of Makena for Preventing Preterm Birth', 'source': 'Medical Professionals Reference', 'date': 'Apr 6, 2023', 'snippet': 'The Food and Drug Administration has made a final decision to withdraw the \napproval of Makena (hydroxyprogesterone caproate) and its generic \nequivalents.', 'thumbnail': 'https://serpapi.com/searches/6722a241e1c2761191a8338d/images/f57b8b1425cf9d4ee4538f63d3e6734aa996d57a3ba2701febbbf6a0416a152f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.831075131893158}",,,,,,,,,,['neutral'],neutral,1
NCT03083691,"{'position': 1, 'link': 'https://www.nature.com/articles/s41586-024-07177-7', 'title': 'Evolutionary trajectories of small cell lung cancer under therapy', 'source': 'Nature', 'date': 'Mar 13, 2024', 'snippet': 'We uncover key processes of the genomic evolution of SCLC under therapy, \nidentify the common ancestor as the source of clonal diversity at relapse.', 'thumbnail': 'https://serpapi.com/searches/67229f2c749783416cf3a76e/images/598912582797d70d056fa835ee6dc0035aedd2ef86ae9ac0bd0c5365fab3f869.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9211716055870056}",,,,,,,,,,['neutral'],neutral,1
NCT02853305,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/metastatic-urothelial-carcinoma-overview-of-treatment-options', 'title': 'Metastatic Urothelial Carcinoma: Overview of Treatment Options', 'source': 'Cancer Network', 'date': 'Oct 13, 2022', 'snippet': ""Transcript: Petros Grivas, MD, PhD: Tian, we're discussing the metastatic \ndisease setting. So much is changing. Can you give us an overview..."", 'thumbnail': 'https://serpapi.com/searches/67229fbfe10f0a459b6664c9/images/9a90fa43bd6214d24ffa020f97bc386e0c869cdd105e112886ec129547599862.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9048632383346558}",,,,,,,,,,['neutral'],neutral,1
NCT00634049,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-31788-1', 'title': 'Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies', 'source': 'Nature', 'date': 'Apr 25, 2023', 'snippet': 'Isavuconazole is a triazole with broad-spectrum antifungal activity. In \nthis post-hoc analysis of two prospective clinical trials (VITAL and...', 'thumbnail': 'https://serpapi.com/searches/6722a055f7adbf90c7a7007e/images/2ff9dd127638c8ae2747d6fc6f5217112b56f858b1789501f025417a138b9a8b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8639057874679565}",,,,,,,,,,['neutral'],neutral,1
NCT02438215,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/rxr-agonist-irx4204-shows-potential-safely-treat-parkinsons/', 'title': 'RXR agonist, IRX4204, safely eases motor symptoms in Phase 1 trial', 'source': ""Parkinson's News Today"", 'date': 'Jul 15, 2024', 'snippet': ""IRX4204 showed safety in 15 early Parkinson's patients in Phase 1 trial, \nwith better motor scores seen in 13 at two weeks of daily..."", 'thumbnail': 'https://serpapi.com/searches/6722a09c175de61448579a67/images/a72936d0217791ffbe2cd89c86c0cf657411e774a0b8b35de91917d062b7b7a0.png', 'sentiment': 'positive', 'sentiment_prob': 0.6982822418212891}",,,,,,,,,,['positive'],positive,1
NCT01392326,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1412679', 'title': 'Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis', 'source': 'The New England Journal of Medicine', 'date': 'Oct 1, 2015', 'snippet': 'In a phase 2 study, the inhibition of the interleukin-17A receptor improved \nsigns and symptoms of psoriatic arthritis. We sought to evaluate...', 'thumbnail': 'https://serpapi.com/searches/6722a0c6d72128a2208afc3c/images/133418af0d1d7325559f97491a5c38c32a42b80d4e764012bbcbd715bc0e901b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8859652876853943}",,,,,,,,,,['neutral'],neutral,1
NCT03053115,"{'position': 1, 'link': 'https://www.endocrinologyadvisor.com/news/levothyroxine-plus-liothyronine-improves-biometric-outcomes-not-quality-of-life/', 'title': 'Levothyroxine Plus Liothyronine Improves Biometric Outcomes, Not Quality of Life', 'source': 'Endocrinology Advisor', 'date': 'Jan 11, 2024', 'snippet': 'Levothyroxine plus liothyronine combination therapy was linked to improved \nthyroid levels but unchanged quality of life among hypothyroidism...', 'thumbnail': 'https://serpapi.com/searches/6722a1ede50bc07d7714fc7f/images/8f1ddf3bdc1841dac58d23cf09c93490de4ef1e242a09099f554f9cb2139fdb0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7069607973098755}",,,,,,,,,,['neutral'],neutral,1
NCT02760485,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-0113-2', 'title': 'Advances in targeted therapy for malignant lymphoma', 'source': 'Nature', 'date': 'Mar 6, 2020', 'snippet': 'The incidence of lymphoma has gradually increased over previous decades, \nand it ranks among the ten most prevalent cancers worldwide.', 'thumbnail': 'https://serpapi.com/searches/6722a2eda3657a6c2f22d831/images/73174bc83ee9076d62251d180d3e4f136475830d253040194356133c168e0370.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8373763561248779}",,,,,,,,,,['neutral'],neutral,1
NCT04661514,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02455-9', 'title': 'Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study', 'source': 'Nature', 'date': 'Jul 24, 2023', 'snippet': 'Anorexia nervosa (AN) is a deadly illness with no proven treatments to \nreverse core symptoms and no medications approved by the US Food and...', 'thumbnail': 'https://serpapi.com/searches/6722a2f8ec541086449a5542/images/37cb101fbeb1e3ac183ad39e083244c61f32d23c98746b0528c3b7eb372b7d17.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7454364895820618}",,,,,,,,,,['negative'],negative,0
NCT02708680,"{'position': 1, 'link': 'https://www.nature.com/articles/s41388-024-03054-9', 'title': 'A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance | Oncogene', 'source': 'Nature', 'date': 'May 8, 2024', 'snippet': 'Epigenetic regulation established during development to maintain patterns \nof transcriptional expression and silencing for metabolism and...', 'thumbnail': 'https://serpapi.com/searches/6722a349be149776eaba696a/images/37c1425d245b5b7ae2f3a3d6cc70a5494e9c7ffa8ab1fa5dbd46a533d2304802.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9292553067207336}",,,,,,,,,,['neutral'],neutral,1
NCT03548584,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20240731398299/en/Otsuka-and-Lundbeck-Present-New-REXULTI%C2%AE-brexpiprazole-Post-Hoc-Efficacy-Data-Analyses-for-Agitation-Associated-with-Dementia-Due-to-Alzheimer%E2%80%99s-Disease-at-Alzheimer%E2%80%99s-Association-International-Conference-AAIC-2024', 'title': 'Otsuka and Lundbeck Present New REXULTI® (brexpiprazole) Post Hoc Efficacy Data Analyses for Agitation Associated with Dementia Due to Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2024', 'source': 'Business Wire', 'date': 'Jul 31, 2024', 'snippet': ""New analysis from an extension trial confirmed the efficacy of REXULTI in \ntreating patients with agitation associated with dementia due to \nAlzheimer's disease."", 'thumbnail': 'https://serpapi.com/searches/6722a3f30d379fd08d192e59/images/9ce94f4dc2e9031cfdb9e61bafc3aba508b512d10efa09573e6bd763c49c6756.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.821667492389679}",,,,,,,,,,['neutral'],neutral,1
NCT02603809,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.14504', 'title': 'Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension', 'source': 'American Heart Association Journals', 'date': 'Feb 17, 2020', 'snippet': 'This study examined the dose-response characteristics of aprocitentan, a \ndual endothelin A/endothelin B receptor antagonist, in patients with \nessential...', 'thumbnail': 'https://serpapi.com/searches/6722a4275ed3cab1a3ea832f/images/2b6dc8a47a1193d75c80ff108e855f60f55a696b80978618e9e1e1e53a4baf4d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9017771482467651}",,,,,,,,,,['neutral'],neutral,1
NCT02399085,"{'position': 1, 'link': 'https://ascopost.com/issues/august-25-2020/tafasitamab-cxix-in-the-treatment-of-diffuse-large-b-cell-lymphoma/', 'title': 'Tafasitamab-cxix in the Treatment of Diffuse Large B-Cell Lymphoma', 'source': 'The ASCO Post', 'date': 'Aug 25, 2020', 'snippet': 'In the Clinic provides overviews of novel oncology agents, addressing \nindications, mechanisms of action, administration recommendations,...', 'thumbnail': 'https://serpapi.com/searches/6722a43ab2ebae61ac670c7b/images/1190d524d7288305eef00c08bd68ae5ac08388d3f5aa8beaa27c431cf23b0efc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9126263856887817}","{'position': 2, 'link': 'https://lymphomanewstoday.com/2020/01/14/morphosys-requests-fda-approval-tafasitamab-relapsed-refractory-dlbcl/', 'title': 'MorphoSys Requests FDA Approval of Tafasitamab for Relapsed or Refractory DLBCL', 'source': 'Lymphoma News Today', 'date': 'Jan 14, 2020', 'snippet': 'MorphoSys is asking the US Food and Drug Administration (FDA) to approve \nits CD19 antibody tafasitamab, in combination with Revlimid (lenalidomide), \nto treat...', 'thumbnail': 'https://serpapi.com/searches/6722a43ab2ebae61ac670c7b/images/1190d524d728830517c3305ba92f304ece9e879ada1e5523a7e99316cf9a0430.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9081448912620544}","{'position': 3, 'link': 'https://lymphomanewstoday.com/2020/03/10/tafasitamab-plus-revlimid-granted-fda-priority-review-for-relapsed-or-refractory-dlbcl/', 'title': 'DLBCL Therapy Combo Tafasitamab-Revlimid Gets FDA Priority Review', 'source': 'Lymphoma News Today', 'date': 'Mar 10, 2020', 'snippet': ""The US Food and Drug Administration (FDA) has granted priority review to \nMorphoSys' application seeking approval of its CD19 antibody tafasitamab, \nin..."", 'thumbnail': 'https://serpapi.com/searches/6722a43ab2ebae61ac670c7b/images/1190d524d7288305cb0922f748adc2d13944054f63aef14fb793e2c1f14a010c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.848609447479248}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT05054530,"{'position': 1, 'link': 'https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext', 'title': 'Pharmacotherapy of obesity: an update on the available medications and drugs under investigation', 'source': 'The Lancet', 'date': 'Mar 20, 2023', 'snippet': 'Obesity is an epidemic and a public health threat. Medical weight \nmanagement remains one of the options for the treatment of excess weight...', 'thumbnail': 'https://serpapi.com/searches/6722a4a621e77b5006cf94bf/images/e8c0d47d0a065f682b927eb8bd218d951d990f932b52f969d6decd1a1e65645d.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6295787692070007}",,,,,,,,,,['negative'],negative,0
NCT00082641,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332223004730', 'title': 'Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy', 'source': 'ScienceDirect.com', 'date': 'Apr 12, 2023', 'snippet': 'In this review, we summarize the immunomodulatory effects and related \nmechanisms of DC vaccine in breast cancer as well as the progress of \nclinical trials.', 'thumbnail': 'https://serpapi.com/searches/6722a722240793cdd0158e22/images/a7ad2746621117917e76a3664aca56eff399da800888d11fca57c7ab22865a24.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9265865087509155}",,,,,,,,,,['neutral'],neutral,1
NCT02891226,"{'position': 1, 'link': 'https://www.appliedclinicaltrialsonline.com/view/fda-reaches-agreement-on-endpoints-for-approval-of-budiodarone-for-the-management-of-atrial-fibrillation', 'title': 'FDA Reaches Agreement on Endpoints for Approval of Budiodarone for the Management of Atrial Fibrillation', 'source': 'Applied Clinical Trials', 'date': 'Feb 26, 2024', 'snippet': 'Biopharma company XYRA and FDA have concluded a series of Phase II meetings \non managing key studies for potential atrial fibrillation...', 'thumbnail': 'https://serpapi.com/searches/6722a7799e5bd5d9a6fbf4f2/images/7b1ca9a77db2c5dacb9dd7aced3eeb4c0f31deb4de1cea20f75a0e3076a0a6d4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.85378497838974}",,,,,,,,,,['neutral'],neutral,1
NCT03014089,"{'position': 1, 'link': 'https://www.nature.com/articles/s41587-022-01294-2', 'title': 'The clinical progress of mRNA vaccines and immunotherapies', 'source': 'Nature', 'date': 'May 9, 2022', 'snippet': 'The emergency use authorizations (EUAs) of two mRNA-based severe acute \nrespiratory syndrome coronavirus (SARS-CoV)-2 vaccines approximately...', 'thumbnail': 'https://serpapi.com/searches/6722a77a2c566da2e23fa3a5/images/f16e0834da269bdd9168c627ce746a3a037ecd6bd1dda4050fb8a1d6a16f557d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.921474814414978}","{'position': 2, 'link': 'https://www.nature.com/articles/s41541-023-00656-4', 'title': 'An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection | npj Vaccines', 'source': 'Nature', 'date': 'Apr 20, 2023', 'snippet': 'mRNA-1893 generated comparable neutralizing antibody titers to mRNA-1325 at \n1/20th of the dose and provided complete protection from ZIKV challenge in \nnon-...', 'thumbnail': 'https://serpapi.com/searches/6722a77a2c566da2e23fa3a5/images/f16e0834da269bdd22c08886db0abc341d34df70923553a9db52ef270fc7343f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7196072936058044}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04103450,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/vibegron-effective-in-men-with-overactive-bladder-receiving-bph-treatment/', 'title': 'Vibegron Effective in Men With Overactive Bladder Receiving BPH Treatment', 'source': 'Medical Professionals Reference', 'date': 'Sep 11, 2023', 'snippet': 'A phase 3 study evaluating vibegron in men with OAB symptoms receiving \npharmacological therapy for BPH met its coprimary and all secondary...', 'thumbnail': 'https://serpapi.com/searches/6722a8447ebde58fad24c624/images/48c657537f67816e4005c577cc510c05ab8553e12d239c3605bf2e3f1dc33200.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7995201945304871}",,,,,,,,,,['neutral'],neutral,1
NCT02316197,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-01151-6', 'title': 'A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours', 'source': 'Nature', 'date': 'Nov 24, 2020', 'snippet': 'This open-label, phase 1 trial (NCT02316197) aimed to determine the \nmaximum-tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of...', 'thumbnail': 'https://serpapi.com/searches/6722a86018787d0b95978bfb/images/79d1d98009d069aab095dc22b982027dab38127df71295e4f483dea8a604337d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9168863892555237}",,,,,,,,,,['neutral'],neutral,1
NCT00346164,"{'position': 1, 'link': 'https://www.onclive.com/view/investigating-risk-based-treatment-strategies-for-pediatric-non-rhabdomyosarcoma-soft-tissue-sarcoma', 'title': 'Investigating Risk-Based Treatment Strategies for Pediatric Non-Rhabdomyosarcoma Soft-Tissue Sarcoma', 'source': 'OncLive', 'date': 'Jul 7, 2024', 'snippet': 'A phase 3 trial (NCT00346164; ARST 0332) is investigating risk-based \ntreatment strategies for patients under the age of 30 with \nnon-rhabdomyosarcoma soft...', 'thumbnail': 'https://serpapi.com/searches/6722a8992da15704c0e272a3/images/5f8daa6526046a3e9a842c77944ec2836027a449d4b060e60c8f1a281f255bef.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9119342565536499}",,,,,,,,,,['neutral'],neutral,1
NCT01313676,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/inhaled-corticosteroids-do-not-increase-risk-for-pneumonia-in-copd/', 'title': 'Inhaled Corticosteroids Do Not Increase Risk for Pneumonia in COPD', 'source': 'Pulmonology Advisor', 'date': 'Oct 20, 2017', 'snippet': 'In contrast to previous study findings, inhaled corticosteroids do not \nappear to increase risk for pneumonia in patients with COPD with...', 'thumbnail': 'https://serpapi.com/searches/6722a8bf48c42962df24cb42/images/1995024893841a3ace77d0a3692172a9b4b6b027febcc294ed964aaaf4ef1867.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7664764523506165}",,,,,,,,,,['neutral'],neutral,1
NCT00000102,"{'position': 1, 'link': 'https://towardsdatascience.com/clinical-trial-outcome-prediction-a4c6d279fd42', 'title': 'Clinical Trial Outcome Prediction', 'source': 'Towards Data Science', 'date': 'Oct 19, 2023', 'snippet': 'I recently came across this article: HINT: Hierarchical interaction network \nfor clinical-trial-outcome predictions from Fu et al.', 'thumbnail': 'https://serpapi.com/searches/6722a8e2740bdb65847033f6/images/268feab5cb3b67e88429fc5dd022f375d6e25dd51a0861d117f21367c3eb6b0e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9227460026741028}",,,,,,,,,,['neutral'],neutral,1
NCT02460198,"{'position': 1, 'link': 'https://ascopubs.org/doi/abs/10.1200/jco.19.02107', 'title': 'Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Nov 14, 2019', 'snippet': 'KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab \nin previously treated, metastatic, microsatellite instability–high/mismatch \nrepair–...', 'thumbnail': 'https://serpapi.com/searches/6722a9297a12fdc533090235/images/f83134b9bf937ed054e774bef81b78bab2c87cdaa73265142aadcdea2592ac3a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8730010986328125}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/fda-gives-full-approval-to-pembrolizumab-in-dmmr-msi-h-solid-tumors', 'title': 'FDA Gives Full Approval to Pembrolizumab in dMMR/MSI-H Solid Tumors', 'source': 'Cancer Network', 'date': 'Mar 29, 2023', 'snippet': 'Based on results from the phase 2 KEYNOTE-158, KEYNOTE-164, and KEYNOTE-051 \ntrials, the FDA has given full approval to pembrolizumab for...', 'thumbnail': 'https://serpapi.com/searches/6722a9297a12fdc533090235/images/f83134b9bf937ed0e6b2bdafe501aa54bafbc2bb0138aa46bdda92f5000ca834.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7076309323310852}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01313624,"{'position': 1, 'link': 'https://bronchiectasisnewstoday.com/2020/05/18/cayston-effective-for-some-bronchiectasis-symptoms-but-not-all-study/', 'title': 'Antibiotic Cayston Effective for Some Bronchiectasis Symptoms but Not All, Study Says', 'source': 'Bronchiectasis News Today', 'date': 'May 18, 2020', 'snippet': 'Treatment with the inhaled antibiotic Cayston (aztreonam lysine) reduced \ncough and sputum production, but was not effective against breathlessness \nand wheezing...', 'thumbnail': 'https://serpapi.com/searches/6722a96959f9112ff993c96a/images/ae50f44f68ecc8b08bbe1e5a0415484f6caf32fa1eda962294d05fa3abc83b83.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5014094710350037}",,,,,,,,,,['negative'],negative,0
NCT00748644,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/blocking-b-and-t-cells-interaction-contributes-to-rituxan-efficacy-in-aav-study-says/', 'title': ""Rituxan's Efficacy Linked to It Blocking How B-cells Interact with Certain T-cells, Study Says"", 'source': 'ANCA Vasculitis News', 'date': 'Nov 20, 2018', 'snippet': 'Blocking the interaction between immune B-cells and CD8-positive T-cells \nmay be what makes Rituxan (rituximab) an effective treatment for \nANCA-associated...', 'thumbnail': 'https://serpapi.com/searches/6722aa05f9f9043541f13966/images/1c31dbab4ef2e646dd0bbdbdfa07e322ca7df101422149d9ee25cb1b0f761eb0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8923890590667725}",,,,,,,,,,['neutral'],neutral,1
NCT04380142,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/fda-issues-second-abbv-951-rejection-parkinsons-motor-fluctuations/', 'title': 'FDA issues second rejection of ABBV-951 for motor fluctuations', 'source': ""Parkinson's News Today"", 'date': 'Jun 26, 2024', 'snippet': ""The U.S. Food and Drug Administration (FDA) has rejected for the second \ntime AbbVie's application of ABBV-951 (foscarbidopa/foslevodopa) for..."", 'thumbnail': 'https://serpapi.com/searches/6722ab8a2e33c8a63deb95c6/images/51b31c620f152adc9896c467c1fecc16a1d7a26966e219114bc83f83287a29ab.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6129431128501892}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/approval-parkinsons-therapy-abbv-951-delayed-request/', 'title': ""Approval of Parkinson's therapy ABBV-951 delayed by FDA request |..."", 'source': ""Parkinson's News Today"", 'date': 'Mar 23, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has requested more information \nabout the specialized pump used to administer ABBV-951 \n(foslevodopa/foscarbidopa).', 'thumbnail': 'https://serpapi.com/searches/6722ab8a2e33c8a63deb95c6/images/51b31c620f152adc9e5b02171f46d01d8652ba9a9b9c362795c8c10359e7fabe.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7294243574142456}","{'position': 3, 'link': 'https://parkinsonsnewstoday.com/news/fda-approves-abbvie-therapy-now-vyalev-advanced-parkinsons/', 'title': 'AbbVie levodopa therapy approved as Vyalev for advanced Parkinson’s', 'source': ""Parkinson's News Today"", 'date': '2 weeks ago', 'snippet': 'The U.S. Food and Drug Administration (FDA) has approved foslevodopa and \nfoscarbidopa, a levodopa therapy given as a 24-hour under-the-skin...', 'thumbnail': 'https://serpapi.com/searches/6722ab8a2e33c8a63deb95c6/images/51b31c620f152adc480037febd8e70357307d767ec713981091e08a9ec6b57b5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.694657564163208}","{'position': 4, 'link': 'https://parkinsonsnewstoday.com/news/abbvie-produodopa-advanced-parkinsons-eu/', 'title': 'AbbVie launches Produodopa for advanced Parkinson’s in EU', 'source': ""Parkinson's News Today"", 'date': 'Jan 12, 2024', 'snippet': ""AbbVie has launched Produodopa, its continuous carbidopa/levodopa infusion \ntherapy, for advanced Parkinson's patients in the European Union."", 'thumbnail': 'https://serpapi.com/searches/6722ab8a2e33c8a63deb95c6/images/51b31c620f152adce7abd2d497b302a0e25c1abcd58ef26c2dc451d743ac337e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8016548752784729}","{'position': 5, 'link': 'https://parkinsonsnewstoday.com/news/abbv-951-increases-on-time-versus-oral-levodopa-phase-3-trial/', 'title': ""Parkinson's Patients Show Longer 'On' Time With ABBV-951"", 'source': ""Parkinson's News Today"", 'date': 'Nov 5, 2021', 'snippet': 'On time was significantly longer in advanced patients on ABBV-951 \n(continuous levodopa/carbidopa infusion) than oral therapy in Phase 3...', 'thumbnail': 'https://serpapi.com/searches/6722ab8a2e33c8a63deb95c6/images/51b31c620f152adcbba77711587873007d59151dc8fb5f6d58a116b22358a2d7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8844574093818665}","{'position': 6, 'link': 'https://parkinsonsnewstoday.com/news/vyalev-severe-parkinsons-motor-symptoms-available-canada/', 'title': ""Vyalev, for severe Parkinson's motor symptoms, arrives in Canada"", 'source': ""Parkinson's News Today"", 'date': 'Feb 12, 2024', 'snippet': 'The continuous, infusion pump therapy is for advanced disease and severe \nfluctuations no longer controlled by oral levodopa/carbidopa.', 'thumbnail': 'https://serpapi.com/searches/6722ab8a2e33c8a63deb95c6/images/51b31c620f152adc817b673a7c906ed958121aea15cf2291bb3647f091d8d461.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8271430730819702}","{'position': 7, 'link': 'https://parkinsonsnewstoday.com/news/abbv-951-now-available-low-no-cost-england-certain-patients/', 'title': 'ABBV-951 now available at low, no cost in England to certain patients', 'source': ""Parkinson's News Today"", 'date': 'Oct 30, 2023', 'snippet': ""ABBV-951 (foslevodopa/foscarbidopa) — Abbvie's continuous infusion \nformulation of levodopa/carbidopa that's administered under the skin..."", 'thumbnail': 'https://serpapi.com/searches/6722ab8a2e33c8a63deb95c6/images/51b31c620f152adc887a4e31fcdd323c9d512a1a1b57f6b36dce33577e15ee21.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7059088349342346}",,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT00699972,"{'position': 1, 'link': 'https://dravetsyndromenews.com/news/fda-approves-fycompa-focal-seizures-children-ages-4-older/', 'title': 'FDA Approves Fycompa to Treat Focal Seizures in Children 4 and Older', 'source': 'Dravet Syndrome News', 'date': 'Oct 4, 2018', 'snippet': 'The U.S. Food and Drug Administration approved Fycompa (perampanel) – alone \nor as an add-on therapy – for focal seizures in children ages 4...', 'thumbnail': 'https://serpapi.com/searches/6722ab9de30abc8601a270a1/images/35dc87ed6f60e7159f5e00fc3599ba6e1993c744f69cb60c9b3f2c57a261d339.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7756399512290955}","{'position': 2, 'link': 'https://dravetsyndromenews.com/news/fycompa-effectively-reduces-seizure-rate-refractrory-epilepsy-dravet-syndrome/', 'title': 'Add-on Fycompa Effectively Reduces Seizure Rate in Real-world Study', 'source': 'Dravet Syndrome News', 'date': 'Jul 12, 2018', 'snippet': 'Add-on therapy with Fycompa (perampanel) is safe and effective in \npreventing seizures in adolescents with treatment-resistant refractory \nepilepsy.', 'thumbnail': 'https://serpapi.com/searches/6722ab9de30abc8601a270a1/images/35dc87ed6f60e71558642bc7c633d200fd36fa9ba08925c59118613557d6d117.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6034088730812073}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04354259,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-34709-4', 'title': 'Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity', 'source': 'Nature', 'date': 'Nov 16, 2022', 'snippet': 'Interferons induced early after SARS-CoV-2 infection are crucial for \nshaping immunity and preventing severe COVID-19.', 'thumbnail': 'https://serpapi.com/searches/6722abbd90b57c813ae9a87e/images/afa71b2f74fcce0a0c72bddd134663bf79b8eb364e04ca536374ab5073b196fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7410551309585571}",,,,,,,,,,['neutral'],neutral,1
NCT03396211,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2024/09/12/2945136/0/en/Elevar-Therapeutics-Reports-Advances-in-HCC-and-Other-Oncology-Clinical-Programs-for-Rivoceranib-Plus-Camrelizumab-at-the-European-Society-for-Medical-Oncology-Congress-2024.html', 'title': 'Elevar Therapeutics Reports Advances in HCC and Other', 'source': 'GlobeNewswire', 'date': '1 month ago', 'snippet': 'The results to be presented at ESMO continue to support the safety and \nefficacy of rivoceranib in combination with camrelizumab as a first-line \nsystemic...', 'thumbnail': 'https://serpapi.com/searches/6722abbfe10f0a459b666f1f/images/4f56505bd5759c50d99daa2baadfdfeb00ba804506aa81d555ade47f6c83cfc5.png', 'sentiment': 'positive', 'sentiment_prob': 0.6583443880081177}",,,,,,,,,,['positive'],positive,1
NCT04656418,"{'position': 1, 'link': 'https://angioedemanews.com/news/fda-ema-agree-consider-garadacimab-treating-hae/', 'title': 'FDA, EMA agree to consider garadacimab for treating HAE', 'source': 'Angioedema News', 'date': 'Dec 18, 2023', 'snippet': ""CSL Behring's garadacimab applications are based mostly on the VANGUARD \nstudy, where it was tested against a placebo in 64 people with HAE."", 'thumbnail': 'https://serpapi.com/searches/6722abef48c42962df24ce2f/images/32473c253a9cc802037165acb676ab31275ddeccb492a6e962a2fc258a62ac7d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9014557003974915}",,,,,,,,,,['neutral'],neutral,1
NCT01385826,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/news/adalimumab-effective-in-jia-associated-uveitis-unresponsive-to-methotrexate/', 'title': 'Adalimumab Effective in JIA-Associated Uveitis Unresponsive to Methotrexate', 'source': 'Rheumatology Advisor', 'date': 'Jan 29, 2018', 'snippet': 'Results from a study published in the Annals of the Rheumatic Diseases \nsupport the use of adalimumab in patients with early-onset idiopathic...', 'thumbnail': 'https://serpapi.com/searches/6722abf73ad34d329f4f31e4/images/3f809db143e64a9fb3e65ac8a9fdd4a65ba853b8c7ceef05d324f16484379da8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8062268495559692}",,,,,,,,,,['neutral'],neutral,1
NCT01042535,"{'position': 1, 'link': 'https://www.precisionvaccinations.com/breast-cancer-vaccines-men-are-clinical-trials', 'title': 'Is There a Breast Cancer Vaccine for Men?', 'source': 'Precision Vaccinations News', 'date': 'Oct 20, 2017', 'snippet': 'Breast cancer vaccines for men are in clinical trials.', 'thumbnail': 'https://serpapi.com/searches/6722ac521ec32f6a1a1c4632/images/d3b088ea747c0d8437733bbab49cf3bd66a55f6b0a4f5a5f1e49fdcb7da47550.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9014884829521179}",,,,,,,,,,['neutral'],neutral,1
NCT04765436,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-35662-y', 'title': 'Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B', 'source': 'Nature', 'date': 'May 26, 2023', 'snippet': 'Access to vaccines against SARS-CoV-2 virus was limited in poor countries \nduring the COVID-19 pandemic. Therefore, a low-cost mRNA vaccine,...', 'thumbnail': 'https://serpapi.com/searches/6722ac90dda9d967302869de/images/8a6867c33b0a1c3d031465be46038cd159d755b195de01d6c0ecab2e1ce136cc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6920947432518005}",,,,,,,,,,['neutral'],neutral,1
NCT00725985,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/2018/07/31/fda-accepts-resubmitted-nda-cladribine-tablets-treatment-relapsing-ms/', 'title': 'FDA to Review EMD Serono’s New Request for Approval of Cladribine for Treating Relapsing MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Jul 31, 2018', 'snippet': ""The FDA accepted for review EMD Serono's resubmitted New Drug Application \n(NDA) for cladribine tablets as a treatment for patients with..."", 'thumbnail': 'https://serpapi.com/searches/6722ace7707fd3dba6dc11e9/images/46fab06d9c0f8dc2c51d5faa6d4f07636232ec38356e054f10a47002fb65bc39.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8431360125541687}",,,,,,,,,,['neutral'],neutral,1
NCT05601778,"{'position': 1, 'link': 'https://www.pharmaceutical-technology.com/news/chiesi-partners-with-haisco-to-commercialise-bronchiectasis-drug/', 'title': 'Chiesi partners with Haisco to commercialise bronchiectasis drug', 'source': 'Pharmaceutical Technology', 'date': 'Nov 20, 2023', 'snippet': 'Chiesi Group and Haisco Pharmaceutical have entered a licence agreement to \njointly develop HSK31858 to treat respiratory diseases such as \nbronchiectasis.', 'thumbnail': 'https://serpapi.com/searches/6722ad291f3d4bf2c8b51e75/images/483c6d921449b732bb25035d9683a200413c6396086882835c219c9fb267c82e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8996458053588867}",,,,,,,,,,['neutral'],neutral,1
NCT02460224,"{'position': 1, 'link': 'https://immuno-oncologynews.com/imp701/', 'title': 'IMP701', 'source': 'Immuno-Oncology News', 'date': 'Dec 21, 2017', 'snippet': 'IMP701 is an immuno-oncology therapy for patients with advanced solid \ntumors. Prima BioMed developed the immune checkpoint inhibitor, but has \nlicensed it to...', 'thumbnail': 'https://serpapi.com/searches/6722ad638d04176e811e0de5/images/8bdf47d1c325b2f453e4394152fac500692691e1f666a0afda04bb2a1a4f872c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9127680659294128}",,,,,,,,,,['neutral'],neutral,1
NCT01960348,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1716153', 'title': 'Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis', 'source': 'The New England Journal of Medicine', 'date': 'Jul 4, 2018', 'snippet': 'In this phase 3 trial, we randomly assigned patients with hereditary \ntransthyretin amyloidosis with polyneuropathy, in a 2:1 ratio,...', 'thumbnail': 'https://serpapi.com/searches/6722ad9deda5f59f0966d289/images/9db1ad694511e2d54c42be5a6c2ac69595ee11bc3c51b8f481bb518d36944573.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9006444811820984}","{'position': 2, 'link': 'https://fapnewstoday.com/news/aan-2023-onpattro-amvuttra-lower-nerve-damage-marker-fap/', 'title': 'AAN 2023: Onpattro, Amvuttra reduce levels of nerve damage marker', 'source': 'FAP News Today', 'date': 'Apr 27, 2023', 'snippet': 'Onpattro or Amvuttra lower NfL levels, which may be useful in assessing \ndisease severity in familial amyloid polyneuropathy, study suggests.', 'thumbnail': 'https://serpapi.com/searches/6722ad9deda5f59f0966d289/images/9db1ad694511e2d52235cdbdd57de5f44d693150f2a5479d4133e671cab5cebc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8044478297233582}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00904683,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1312889', 'title': ""Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease"", 'source': 'The New England Journal of Medicine', 'date': 'Jan 23, 2014', 'snippet': 'Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to \nimprove cognition or functional ability.', 'thumbnail': 'https://serpapi.com/searches/6722adac8f2bc20d0bf5c15e/images/1bec4710ff1a6c522e934da466e9718507a54dcafb3a2cc508cdd9d71dded092.png', 'sentiment': 'negative', 'sentiment_prob': 0.6797337532043457}",,,,,,,,,,['negative'],negative,0
NCT02573233,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(18)30275-3/fulltext', 'title': 'Anti-interleukin 13 for asthma: stick or twist?', 'source': 'The Lancet', 'date': 'Aug 2, 2018', 'snippet': 'The results of the STRATOS trials. 1. Panettieri, Jr, RA ∙ Sjöbring, U ∙ \nPéterffy, A ∙ et al. Tralokinumab for severe, uncontrolled asthma...', 'thumbnail': 'https://serpapi.com/searches/6722aecbb691a72daec1467d/images/9eb136a47b5a331d735d0984b385fc8316ae6f0bbfcda7d49244537dbdd07705.png', 'sentiment': 'neutral', 'sentiment_prob': 0.893603503704071}",,,,,,,,,,['neutral'],neutral,1
NCT05154240,"{'position': 1, 'link': 'https://www.nature.com/articles/s41587-024-02143-0', 'title': 'A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models', 'source': 'Nature', 'date': 'Mar 8, 2024', 'snippet': 'Idiopathic pulmonary fibrosis (IPF) is an aggressive interstitial lung \ndisease with a high mortality rate. Putative drug targets in IPF have...', 'thumbnail': 'https://serpapi.com/searches/6722aedf657c665394947aec/images/12f5c957379cb7735487ae4336485803c2b3379ee1f7a75daa985112a79def7b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5609192252159119}","{'position': 2, 'link': 'https://pulmonaryfibrosisnews.com/news/dosing-begins-ism001-055-oral-iph-therapy-phase-1-trial/', 'title': 'Dosing of ISM001-055, Oral IPF Therapy, Begins in Phase 1 Trial', 'source': 'Pulmonary Fibrosis News', 'date': 'Mar 7, 2022', 'snippet': 'Dosing has begun in healthy volunteers in a Phase 1 clinical trial of \nISM001-055, a small molecule potential treatment of idiopathic pulmonary \nfibrosis (IPF).', 'thumbnail': 'https://serpapi.com/searches/6722aedf657c665394947aec/images/12f5c957379cb773a034fc3ce80a4e132cc0c55673a4a5563b1f9182eb2e478b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9026865363121033}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03188965,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.103', 'title': 'Targeting DNA repair pathway in cancer: Mechanisms and clinical application - Wang - 2021 - MedComm', 'source': 'Wiley Online Library', 'date': 'Dec 7, 2021', 'snippet': 'Over the last decades, the growing understanding on DNA damage response \n(DDR) pathways has broadened the therapeutic landscape in oncology.', 'thumbnail': 'https://serpapi.com/searches/6722af12e30abc8601a2746b/images/4d3c61c8663caeca270b1a44a741a978049e518ce908bdba53ca912ddccfdbfe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.791668713092804}",,,,,,,,,,['neutral'],neutral,1
NCT04065789,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-022-00779-2', 'title': 'The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review', 'source': 'Nature', 'date': 'Jan 5, 2023', 'snippet': 'Most studies demonstrated a consistent benefit of MM interventions among \nthe frail and non-frail populations, however in general, frail patients had \nworse...', 'thumbnail': 'https://serpapi.com/searches/6722afa1d11195ffb1d038f8/images/f43a27ce2e570f0d3212fbec99a30566d98f4c4e52bd7922fe2036ce90267c5d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8518561124801636}",,,,,,,,,,['neutral'],neutral,1
NCT02633397,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/riociguat-could-help-scd-patients-with-risk-factors-study/', 'title': 'Riociguat could help SCD patients with risk factors: Study', 'source': 'Sickle Cell Disease News', 'date': 'Apr 16, 2024', 'snippet': 'PH treatment riociguat safely lowered blood pressure in people with sickle \ncell disease, early findings from a clinical trial showed.', 'thumbnail': 'https://serpapi.com/searches/6722afc17ac731301bf62a50/images/bed796f39e371bb5f6e01092519712ca5bf5eb20d410d4b213dbff8aa0da4c28.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.570620596408844}",,,,,,,,,,['positive'],positive,1
NCT04904913,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-44067-4', 'title': 'A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity', 'source': 'Nature', 'date': 'Dec 14, 2023', 'snippet': 'Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon \nreceptor dual agonist. We evaluated the efficacy and safety of...', 'thumbnail': 'https://serpapi.com/searches/6722b023a86921c14170d7b7/images/7b0e9dba16151d176c4c4d706fc7b4a5f686180169cfb7938767b1dd7b1241ef.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8939656615257263}","{'position': 2, 'link': 'https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext', 'title': 'Pharmacotherapy of obesity: an update on the available medications and drugs under investigation', 'source': 'The Lancet', 'date': 'Mar 20, 2023', 'snippet': 'Obesity is an epidemic and a public health threat. Medical weight \nmanagement remains one of the options for the treatment of excess weight...', 'thumbnail': 'https://serpapi.com/searches/6722b023a86921c14170d7b7/images/7b0e9dba16151d17406b26a1b6bf1856e231aea73b19f8486258312773bf890a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6295787692070007}","{'position': 3, 'link': 'https://www.biospace.com/innovent-dosed-first-participant-in-phase-3-clinical-study-glory-2-of-mazdutide-ibi362-higher-dose-9-mg-in-chinese-adults-with-obesity', 'title': 'Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity', 'source': 'BioSpace', 'date': 'Jan 1, 2024', 'snippet': 'The first participant has been successfully dosed in a Phase 3 clinical \ntrial of higher dose 9 mg mazdutide, a glucagon-like peptide 1 receptor and \nglucagon...', 'thumbnail': 'https://serpapi.com/searches/6722b023a86921c14170d7b7/images/7b0e9dba16151d17b5939df71d32f34b13347b9805d507eabd38d0e8c32d0cb3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7575648427009583}","{'position': 4, 'link': 'https://www.prnewswire.com/apac/news-releases/innovent-announces-publication-of-mazdutide-ibi362-phase-2-full-results-in-chinese-patients-with-overweight-or-obesity-in-nature-communications-302017400.html', 'title': 'Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications', 'source': 'PR Newswire', 'date': 'Dec 18, 2023', 'snippet': 'The results of this Phase 2 study showed favorable safety, rapid and robust \nweight loss efficacy, multiple cardiovascular and metabolic benefits of \nmazdutide...', 'thumbnail': 'https://serpapi.com/searches/6722b023a86921c14170d7b7/images/7b0e9dba16151d17beb3c1aa095008c6573ed6d6c26cf52830baf55fd38ed4ae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5445898771286011}","{'position': 5, 'link': 'https://www.globenewswire.com/news-release/2021/08/20/2283935/0/en/Obesity-Pipeline-Insights-into-Key-Pharma-Companies-Clinical-Trials-Drug-Pipeline-R-D-and-Emerging-Obesity-Pipeline-Trends.html', 'title': 'Obesity Pipeline: Insights into Key Pharma Companies,', 'source': 'GlobeNewswire', 'date': 'Aug 19, 2021', 'snippet': 'Los Angeles, USA, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Obesity Pipeline: \nInsights into Key Pharma Companies, Clinical Trials, Drug Pipeline,...', 'thumbnail': 'https://serpapi.com/searches/6722b023a86921c14170d7b7/images/7b0e9dba16151d1717345eb3b115c6e01010899ac70dccd4efbe93aa42bb0b09.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9020337462425232}","{'position': 6, 'link': 'https://www.alliedmarketresearch.com/anti-obesity-drugs-market', 'title': 'Anti-Obesity Drugs Market Statistics, Segments | Forecast - 2023', 'source': 'Allied Market Research', 'date': 'Sep 13, 2017', 'snippet': 'Anti-Obesity Drugs Market Research, 2032. The anti-obesity drugs market \nsize was valued at $1,605.36 million in 2022 and is estimated to reach \n$4,439.34...', 'thumbnail': 'https://serpapi.com/searches/6722b023a86921c14170d7b7/images/7b0e9dba16151d1751f9e896c58d85269e822e0d858a3eae4ff5f6f91269ffe4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.879167914390564}",,,,,"['neutral', 'negative', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT00546793,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1038/icb.2017.6', 'title': 'Immunology & Cell Biology | ASI Journal', 'source': 'Wiley Online Library', 'date': 'Feb 21, 2017', 'snippet': 'The April 2017 issue of Immunology & Cell Biology contains a Special \nFeature on Cancer Immunotherapy. This series of reviews highlights some...', 'thumbnail': 'https://serpapi.com/searches/6722b0cc90adce4a729e5781/images/cf59fe0eafa2b0e0074ddd6ccc8ad5adab6077ae1a09fbe2336385b7102ee732.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.942265510559082}",,,,,,,,,,['neutral'],neutral,1
NCT01516879,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1316222', 'title': 'A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia', 'source': 'The New England Journal of Medicine', 'date': 'Mar 29, 2014', 'snippet': 'Evolocumab, a monoclonal antibody that inhibits proprotein convertase \nsubtilisin/kexin type 9 (PCSK9), significantly reduced low-density...', 'thumbnail': 'https://serpapi.com/searches/6722b19798876d773369d1b9/images/467ca517731e1f034910e96be04c7fd8b6e99e71ed2ebaf514194296fc84917b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8380778431892395}",,,,,,,,,,['neutral'],neutral,1
NCT01606241,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-020-18962-z', 'title': 'Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients', 'source': 'Nature', 'date': 'Oct 14, 2020', 'snippet': 'In ovarian cancer (OC), IL-17-producing T cells (Th17s) predict improved \nsurvival, whereas regulatory T cells predict poorer survival.', 'thumbnail': 'https://serpapi.com/searches/6722b1dbd0c983e63245d0c9/images/8cf510c9bd4c68b4847c1f7a2d2bb1949096579a392ec8e78386ba22f72bfb9c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6748889684677124}",,,,,,,,,,['neutral'],neutral,1
NCT03354429,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1916870', 'title': 'Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA', 'source': 'The New England Journal of Medicine', 'date': 'Jul 15, 2020', 'snippet': 'Trials have evaluated the use of clopidogrel and aspirin to prevent stroke \nafter an ischemic stroke or transient ischemic attack (TIA).', 'thumbnail': 'https://serpapi.com/searches/6722b1f05ddfba0914de1d52/images/a2551d9cd58d001fb7a8284b0b7df43f3f4b2b84ddbbadd87e65c57e223aef42.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8524799942970276}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.032239', 'title': 'Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin', 'source': 'American Heart Association Journals', 'date': 'Nov 16, 2020', 'snippet': 'Background and Purpose:Among patients with a transient ischemic attack or \nminor ischemic strokes, those with ipsilateral atherosclerotic...', 'thumbnail': 'https://serpapi.com/searches/6722b1f05ddfba0914de1d52/images/a2551d9cd58d001fdcaa93cedd2abf4e4086871055172361e34cc050c636a898.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8694614171981812}","{'position': 3, 'link': 'https://www.neurologylive.com/view/ticagrelor-fda-approved-for-recurrent-stroke-prevention', 'title': 'Ticagrelor Approved for Recurrent Stroke Prevention', 'source': 'Neurology live', 'date': 'Nov 6, 2020', 'snippet': 'The decision was based on findings from the phase 3 THALES trial, which \nshowed aspirin plus ticagrelor significantly reduced stroke and...', 'thumbnail': 'https://serpapi.com/searches/6722b1f05ddfba0914de1d52/images/a2551d9cd58d001f032895661f0c453047dccdead4b3fb4656e1181211548cd8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5632188320159912}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02241135,"{'position': 1, 'link': 'https://www.nature.com/articles/s41587-022-01294-2', 'title': 'The clinical progress of mRNA vaccines and immunotherapies', 'source': 'Nature', 'date': 'May 9, 2022', 'snippet': 'The emergency use authorizations (EUAs) of two mRNA-based severe acute \nrespiratory syndrome coronavirus (SARS-CoV)-2 vaccines approximately...', 'thumbnail': 'https://serpapi.com/searches/6722b22135853984af1106d0/images/2eed3adc99587474016241cbc62598155e3a36d1231338dfa4e5c8795554b383.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.921474814414978}",,,,,,,,,,['neutral'],neutral,1
NCT03912233,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/vertex-phase-3-trials-vx121-vx561-tezacaftor-triple-combination-cf-therapy/', 'title': 'Vertex Planning Phase 3 Trials in New Triple Combo Therapy for CF', 'source': 'Cystic Fibrosis News Today', 'date': 'Jul 30, 2021', 'snippet': 'Vertex Pharmaceuticals is initiating two Phase 3 clinical trials into the \nsafety and efficacy of a potentially new, next-generation triple...', 'thumbnail': 'https://serpapi.com/searches/6722b258c97e356b10d6ae77/images/3d2868697807fa071838d08ba18512336ce838f7183f99445b4f6c5e99a70cdf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8972020149230957}",,,,,,,,,,['neutral'],neutral,1
NCT04969276,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/home/general-medicine/quadrivalent-influenza-vaccine-qiv-hd-mrna-covid-19-vaccine-safe-phase-2-clinical-trial/', 'title': 'Coadministration of QIV-HD Influenza Vaccine, mRNA-1273 COVID-19 Vaccine Is Safe', 'source': 'Cancer Therapy Advisor', 'date': 'Mar 16, 2022', 'snippet': 'Phase 2 results indicate no safety concerns or immune interference for \nadults who receive concomitant QIV-HD and mRNA-1273 vaccination.', 'thumbnail': 'https://serpapi.com/searches/6722b4b2efad219305049743/images/e9da91275c21551fe82f8feb55e1621158a679e2dc5bbbe59d952018f5816be3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6734781861305237}",,,,,,,,,,['neutral'],neutral,1
NCT06129409,"{'position': 1, 'link': 'https://www.nature.com/articles/s12276-024-01261-8', 'title': 'NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders', 'source': 'Nature', 'date': 'Jul 1, 2024', 'snippet': 'Proinflammatory cytokines and chemokines play a crucial role in regulating \nthe inflammatory response, which is essential for the proper...', 'thumbnail': 'https://serpapi.com/searches/6722b5db4a4a1d0f4b82749f/images/236af27967fe85c26ac067afed759032496a20931ca30489bdaf38c2ce2f76e5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8756292462348938}",,,,,,,,,,['neutral'],neutral,1
NCT00887198,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1209096', 'title': 'Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy', 'source': 'The New England Journal of Medicine', 'date': 'Dec 10, 2012', 'snippet': 'The study was unblinded after a planned interim analysis that was performed \nafter 43% of the expected deaths had occurred.', 'thumbnail': 'https://serpapi.com/searches/6722b66193bb57b0a3dfcb56/images/e1c2105576be5a924f8490f55d02f26961c556090be8f80bc204cb76a75e4638.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.514735758304596}","{'position': 2, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71205-7/fulltext', 'title': 'Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 stud', 'source': 'The Lancet', 'date': 'Jan 15, 2015', 'snippet': 'Abiraterone acetate plus prednisone versus placebo plus prednisone in \nchemotherapy-naive men with metastatic castration-resistant prostate cancer', 'thumbnail': 'https://serpapi.com/searches/6722b66193bb57b0a3dfcb56/images/e1c2105576be5a9212f52dcf35347696bbefe65134ae0688f57e6f9be86403a0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8303014636039734}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01664923,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.2015.64.9285', 'title': 'Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial', 'source': 'ASCO Publications', 'date': 'Mar 22, 2019', 'snippet': 'PurposeEnzalutamide, a potent oral androgen receptor inhibitor, improves \nsurvival in men with metastatic castration-resistant prostate cancer (CRPC) \nbefore...', 'thumbnail': 'https://serpapi.com/searches/6722b680e281ee0144ea51dc/images/c3769bda3def856f56987ca58098a6be1707a0a72f74181e0a056b08ab6fdf8c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6053585410118103}",,,,,,,,,,['neutral'],neutral,1
NCT04629443,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-024-06810-7', 'title': 'Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia | Cell Death & Disease', 'source': 'Nature', 'date': 'Jun 12, 2024', 'snippet': 'We review the emerging mechanisms of intrinsic and acquired venetoclax \nresistance in AML and highlight recent efforts to identify novel strategies \nto overcome...', 'thumbnail': 'https://serpapi.com/searches/6722b7bbc05eb5bbb96986ea/images/c879124a76ef66f6103d5a01c88f3eee6c84a1f8fce50ef3c2de75b0ea8cb322.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7743048667907715}","{'position': 2, 'link': 'https://www.nature.com/articles/s43856-023-00380-z', 'title': 'Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients | Communications Medicine', 'source': 'Nature', 'date': 'Oct 25, 2023', 'snippet': 'ABBV-467 is a new drug that blocks the action of MCL-1 (an MCL-1 inhibitor) \nand could promote apoptosis. In animal models, ABBV-467 led to cancer cell \ndeath...', 'thumbnail': 'https://serpapi.com/searches/6722b7bbc05eb5bbb96986ea/images/c879124a76ef66f676cc5534aa8299b9b6338fea3a4e0887c9c5f9faa792d53a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.680879533290863}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02343458,"{'position': 1, 'link': 'https://copdnewstoday.com/news/bevespi-aerosphere-demonstrates-statistically-significant-improvement-in-lung-function-in-patients-with-copd/', 'title': 'Bevespi Aerosphere Progressing Toward OK for COPD in Europe, Asia', 'source': 'COPD News Today', 'date': 'Oct 5, 2017', 'snippet': ""Learn more about positive results on AstraZeneca's Bevespi Aerosphere \nPINNACLE 4 clinical trial in patients with moderate to very severe..."", 'thumbnail': 'https://serpapi.com/searches/6722b7f2db3ac9838cb84a26/images/e2dbc907124692eb4a314a32f3c267de106cb0d35028073ee9095fe0edca8f68.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6521616578102112}","{'position': 2, 'link': 'https://copdnewstoday.com/news/aeristo-copd-trial-shows-bevespi-aerosphere-similar-to-anoro-elipta/', 'title': 'Bevespi Aerosphere Shows Similar Effectiveness as Anoro Elipta for...', 'source': 'COPD News Today', 'date': 'Aug 24, 2018', 'snippet': ""Read the latest AERISTO clinical trial data on AstraZeneca's Bevespi \nAerosphere for the treatment of COPD as compared to GSK's Anoro Elipta."", 'thumbnail': 'https://serpapi.com/searches/6722b7f2db3ac9838cb84a26/images/e2dbc907124692eb681c1d46200a6887cba0594d7c5397ad9168e78f065daf43.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.858304500579834}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT04177108,"{'position': 1, 'link': 'https://www.targetedonc.com/view/investigators-tailor-tnbc-therapy-using-genomic-alterations', 'title': 'Investigators Tailor TNBC Therapy Using Genomic Alterations', 'source': 'Targeted Oncology', 'date': 'Oct 21, 2020', 'snippet': 'In a presentation at the 2020 Lynn Sage Breast Cancer Symposium, Virginia \nG. Kaklamani, MD, DSc, reviewed the current genomic tools in the...', 'thumbnail': 'https://serpapi.com/searches/6722b7fc93bb57b04c3db2bc/images/d5b46cae95fb40d45cfb8d270bd260a53ef21389165a5578fe49c15ead262082.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9546643495559692}",,,,,,,,,,['neutral'],neutral,1
NCT03987919,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2107519', 'title': 'Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Jun 25, 2021', 'snippet': 'Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and \nglucagon-like peptide-1 (GLP-1) receptor agonist that is under development \nfor the...', 'thumbnail': 'https://serpapi.com/searches/6722b80b76079d5720a0b842/images/9bdfdf32bd826a8d01f37054c70480273b941cf93d0216217ded97f58f3647f9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9040133357048035}","{'position': 2, 'link': 'https://www.renalandurologynews.com/news/tirzepatide-vs-semaglutide-lower-metabolic-syndrome-prevalence/', 'title': 'Tirzepatide vs Semaglutide Linked to Lower Metabolic Syndrome Prevalence', 'source': 'Renal and Urology News', 'date': 'Apr 12, 2024', 'snippet': 'Use of tirzepatide, compared with placebo, semaglutide, and insulin \ndegludec and glargine, is associated with a lower prevalence of metabolic \nsyndrome among...', 'thumbnail': 'https://serpapi.com/searches/6722b80b76079d5720a0b842/images/9bdfdf32bd826a8d91272658ea1fd97d3f5171d743e9433e58afc1582136d8ba.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8086218237876892}","{'position': 3, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-surpass-2-results-published-new-england-journal-medicine', 'title': ""Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes"", 'source': 'Eli Lilly and Company', 'date': 'Jun 25, 2021', 'snippet': ""Lilly's SURPASS-2 results published in The New England Journal of Medicine \nshow tirzepatide achieved superior A1C and body weight reductions..."", 'thumbnail': 'https://serpapi.com/searches/6722b80b76079d5720a0b842/images/9bdfdf32bd826a8d8ea2cf3d0d03729cb11585e2f2f6ab7bffab7e166eb2a5a3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7059458494186401}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03545191,"{'position': 1, 'link': 'https://www.empr.com/home/news/quviviq-approved-for-the-treatment-of-insomnia/', 'title': 'Quviviq Approved for the Treatment of Insomnia', 'source': 'Medical Professionals Reference', 'date': 'Jan 10, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Quviviq™ (daridorexant) \nfor the treatment of adults with insomnia characterized by...', 'thumbnail': 'https://serpapi.com/searches/6722b8365809e7d53c92d8d2/images/51a53d5c31c23e0e38ad108647e9e1633a85f527a84d69ab35190ece21bcaba8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7724179029464722}",,,,,,,,,,['neutral'],neutral,1
NCT00853658,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1514859', 'title': 'Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure', 'source': 'The New England Journal of Medicine', 'date': 'Apr 4, 2016', 'snippet': 'Among patients with chronic heart failure, angiotensin-converting–enzyme \n(ACE) inhibitors reduce mortality and hospitalization, but the role...', 'thumbnail': 'https://serpapi.com/searches/6722b932bb64accf02315f81/images/14ebb6e59eadad2cf25a95f27904d206581971491546277045689438d008cce4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6626197099685669}",,,,,,,,,,['neutral'],neutral,1
NCT02332980,"{'position': 1, 'link': 'https://www.onclive.com/view/pembrolizumab-plus-b-cell-receptor-inhibitors-generates-response-in-richter-transformation-of-cll-sll', 'title': 'Pembrolizumab Plus B-Cell Receptor Inhibitors Generates Responses in Richter Transformation of CLL/SLL', 'source': 'OncLive', 'date': 'Jul 22, 2024', 'snippet': 'The addition of a B-cell receptor (BCR) inhibitor to pembrolizumab \n(Keytruda) led to responses in patients with Richter transformation of \nchronic lymphocytic...', 'thumbnail': 'https://serpapi.com/searches/6722b9dde10f0a45ebd65498/images/c90e695b213cc8223465226115c708f482414e76b7399bd9c2ea8ef619225176.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8919400572776794}","{'position': 2, 'link': 'https://www.nature.com/articles/s41408-021-00477-5', 'title': 'Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome', 'source': 'Nature', 'date': 'May 10, 2021', 'snippet': 'Richter syndrome (RS) refers to transformation of chronic lymphocytic \nleukemia (CLL) to an aggressive lymphoma, most commonly diffuse large \nB-cell lymphoma.', 'thumbnail': 'https://serpapi.com/searches/6722b9dde10f0a45ebd65498/images/c90e695b213cc822c9542aaca1c20f388893a04069e52649fefc1ecb1085601f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7535958290100098}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04932941,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00229-6/fulltext', 'title': 'Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: a multicentre, randomised double-blind, placebo-controlled phase 2a trial', 'source': 'The Lancet', 'date': 'Dec 6, 2023', 'snippet': 'We assessed here the efficacy and safety of MP1032, a host-directed \nanti-viral/anti-inflammatory drug in hospitalised patients with moderate to \nsevere COVID-19.', 'thumbnail': 'https://serpapi.com/searches/6722b9f820e6eb462887bfda/images/51d6261f7bcf95527963d1b19b6323813e775ad95bbc7fbfadd401c2f2fe3898.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8371482491493225}",,,,,,,,,,['neutral'],neutral,1
NCT02220725,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1510991', 'title': 'Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity', 'source': 'The New England Journal of Medicine', 'date': 'Nov 11, 2015', 'snippet': 'Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban \nin older healthy participants within minutes after administration and for \nthe...', 'thumbnail': 'https://serpapi.com/searches/6722bae4717bff91dacafe61/images/ddfb9853a4466a1ce4f8efc4dc5d316eb38aa937e6268b4de4535b3f0bd75cad.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9071860909461975}",,,,,,,,,,['neutral'],neutral,1
NCT03308565,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-46259-y', 'title': 'Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial', 'source': 'Nature', 'date': 'Apr 1, 2024', 'snippet': 'Intrathecal delivery of autologous culture-expanded adipose tissue-derived \nmesenchymal stem cells (AD-MSC) could be utilized to treat traumatic spinal \ncord...', 'thumbnail': 'https://serpapi.com/searches/6722bc04d771bd6b2e5e1b06/images/2c46d57890091caeb1111f7721918021dc617ff142120345820d3f128e2cdbb4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8826764822006226}",,,,,,,,,,['neutral'],neutral,1
NCT02578901,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/news/thrombocytopenia-tranexamic-acid-prophylaxis-improve-bleeding-risk-treatment/', 'title': 'Tranexamic Acid Prophylaxis Does Not Improve Bleeding Risk for Thrombocytopenia in Hematologic Malignancies', 'source': 'Hematology Advisor', 'date': 'Oct 4, 2022', 'snippet': 'Recent clinical trial results suggest that in patients receiving certain \ntreatments for hematologic malignancy who are at risk of...', 'thumbnail': 'https://serpapi.com/searches/6722bcbf0664c9fe85c66a52/images/0428b1147910dec4b744c994294d6fdb8102c83556c01a49fed8fca37860b584.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.695556104183197}",,,,,,,,,,['negative'],negative,0
NCT03030105,"{'position': 1, 'link': 'https://fragilexnewstoday.com/news/fda-grants-bpn14770-orphan-drug-status-fragile-x-syndrome/', 'title': 'Potential Fragile X Therapy BPN14770 Receives FDA Orphan Drug Status', 'source': 'Fragile X News Today', 'date': 'Apr 12, 2018', 'snippet': 'Investigational therapy BPN14770 has been granted orphan drug status by the \nU.S. Food and Drug Administration for the treatment of fragile X...', 'thumbnail': 'https://serpapi.com/searches/6722c1e2e1c27611dea9b2eb/images/3ca4f7a4078183f7e36032dff80b113c93a44664b2b890a9a51b1a1edca3faaa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8758559226989746}",,,,,,,,,,['neutral'],neutral,1
NCT02106832,"{'position': 1, 'link': 'https://bronchiectasisnewstoday.com/2017/07/18/ciprofloxacin-dpi-bayer-treating-non-cystic-fibrosis-bronchiectasis/', 'title': 'Bayer’s Ciprofloxacin DPI Shows Promise in Treating Non-cystic Fibrosis Bronchiectasis', 'source': 'Bronchiectasis News Today', 'date': 'Jul 18, 2017', 'snippet': 'Bayer is conducting two Phase 3 clinical trials evaluating ciprofloxacin \nDry Powder for Inhalation (ciprofloxacin DPI) as a treatment for...', 'thumbnail': 'https://serpapi.com/searches/6722bd8958e433496eb8fec9/images/a90c5bef79b49dea8953aa8e7c4a5151de1df1ff07edafcd6e0b769e32a50031.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7611814737319946}","{'position': 2, 'link': 'https://bronchiectasisnewstoday.com/2017/11/17/fda-panel-opposed-ciprofloxacin-dry-powder-for-inhalation-cipro-dpi-to-treat-non-cf-bronchiectasis/', 'title': 'FDA Panel Opposes Use of Cipro DPI to Treat Non-CF Bronchiectasis', 'source': 'Bronchiectasis News Today', 'date': 'Nov 17, 2017', 'snippet': 'A US Food and Drug Administration (FDA) advisory panel voted not to \nrecommend ciprofloxacin dry powder for inhalation (Cipro DPI), being \ndeveloped by Bayer, to...', 'thumbnail': 'https://serpapi.com/searches/6722bd8958e433496eb8fec9/images/a90c5bef79b49dea05bed0af2adda4f27f207e7cd21f1e1cee176394405c6c52.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5384337902069092}","{'position': 3, 'link': 'https://bronchiectasisnewstoday.com/2018/01/04/top-10-bronchiectasis-stories-2017/', 'title': 'Top 10 Bronchiectasis Stories of 2017', 'source': 'Bronchiectasis News Today', 'date': 'Jan 4, 2018', 'snippet': ""Here are Bronchiectasis News Today's Top 10 most-read stories of 2017 with \nsummaries of why they were interesting to bronchiectasis patients..."", 'thumbnail': 'https://serpapi.com/searches/6722bd8958e433496eb8fec9/images/a90c5bef79b49dea365e2ec560f1de5c2458c87d5e494a128336f2f1f468a09d.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5398268699645996}",,,,,,,,"['neutral', 'neutral', 'positive']",neutral,1
NCT04688164,"{'position': 1, 'link': 'https://www.psychiatrist.com/pcc/subanalysis-of-subjective-cognitive-measures-from-a-phase-2-double-blind-randomized-trial-of-rel-1017-in-patients-with-major-depressive-disorder/', 'title': 'Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder', 'source': 'Psychiatrist.com', 'date': 'Feb 14, 2023', 'snippet': 'REL-1017 improved subjective measures of cognitive impairment, in addition \nto improving total MADRS and SDQ scores.', 'thumbnail': 'https://serpapi.com/searches/6722bdc6861b9dc3860ce5b6/images/e845fd17280e9149d68f9f7251cc6c3eb9cedb301e31829adf32ce433ecb6d18.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8551734685897827}",,,,,,,,,,['neutral'],neutral,1
NCT03282149,"{'position': 1, 'link': 'https://finance.yahoo.com/news/xalud-therapeutics-presents-clinical-data-120000385.html', 'title': 'Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis at the 2023 Osteoarthritis Research Society International World Congress', 'source': 'Yahoo Finance', 'date': 'Mar 20, 2023', 'snippet': 'Results demonstrate that XT-150 can facilitate improved knee function \nduring walking gait, which persists to 180 days following a single...', 'thumbnail': 'https://serpapi.com/searches/6722c0e1acf7f8291ac51292/images/d26bf4d7b0dc0dd5699aa1cc8994b5c389ad1b0885a728a615eb5db2ff2dbc95.png', 'sentiment': 'positive', 'sentiment_prob': 0.5747060775756836}",,,,,,,,,,['positive'],positive,1
NCT01634152,"{'position': 1, 'link': 'https://lungdiseasenews.com/2017/02/20/asthmatic-children-ages-6-and-older-can-now-use-spiriva-respimat-for-maintenance-therapy/', 'title': 'Asthmatic Kids 6 and Up Can Use Spiriva Respimat as Maintenance Therapy', 'source': 'Lung Disease News', 'date': 'Feb 20, 2017', 'snippet': 'The US Food and Drug Administration (FDA) expanded the approval of \nsteroid-free Spiriva Respimat (tiotropium bromide) for the maintenance \ntreatment of asthma...', 'thumbnail': 'https://serpapi.com/searches/6722c2f5c1c8dda1bab11d99/images/61ead68d6b6435eb40bdbd1fe35899533b84c5574f611efc265da78fffcfd160.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7848676443099976}",,,,,,,,,,['neutral'],neutral,1
NCT02697630,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-25332-w', 'title': 'The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma', 'source': 'Nature', 'date': 'Aug 27, 2021', 'snippet': 'Preclinical studies have suggested that epigenetic therapy could enhance \nimmunogenicity of cancer cells. We report the results of the PEMDAC...', 'thumbnail': 'https://serpapi.com/searches/6722c397b6a79c8a3025c944/images/a9aede969d04e16e8eea68e878e9d249f646208b8c4a1630feeb20d63376084b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8703714609146118}",,,,,,,,,,['neutral'],neutral,1
NCT02690207,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1603800', 'title': 'Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older', 'source': 'The New England Journal of Medicine', 'date': 'Sep 15, 2016', 'snippet': 'A trial involving adults 50 years of age or older (ZOE-50) showed that the \nherpes zoster subunit vaccine (HZ/su) containing recombinant...', 'thumbnail': 'https://serpapi.com/searches/6722c3b00d379fd0d7080d6d/images/c33441e6ddc2c0a116c91b8c24a1d4e8d8b50955d441b6c35a76404146b43d48.png', 'sentiment': 'neutral', 'sentiment_prob': 0.90052330493927}",,,,,,,,,,['neutral'],neutral,1
NCT02997202,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1902688', 'title': 'Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML', 'source': 'The New England Journal of Medicine', 'date': 'Oct 30, 2019', 'snippet': 'Patients with relapsed or refractory acute myeloid leukemia (AML) with \nmutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently...', 'thumbnail': 'https://serpapi.com/searches/6722c3c2667ec536558eb418/images/46ee387ee27982206495ce8f562638c64f1093b9e7e2766897455d3b2a97b7dd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7907082438468933}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/astellas-and-bmt-ctn-announce-topline-results-from-phase-3-morpho-trial-of-gilteritinib-301767481.html', 'title': 'Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib', 'source': 'PR Newswire', 'date': 'Mar 9, 2023', 'snippet': 'PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji \nYasukawa, Ph.D., ""Astellas"") and the Blood and Marrow Transplant...', 'thumbnail': 'https://serpapi.com/searches/6722c3c2667ec536558eb418/images/46ee387ee27982200246621738305a56255cd0867948e808120df236551f50e6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9033066630363464}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01636141,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332221002274', 'title': 'Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease', 'source': 'ScienceDirect.com', 'date': 'Mar 3, 2021', 'snippet': 'The incidence and prevalence of inflammatory bowel disease (IBD) are \nincreasing worldwide. Current approved medication for IBD treatment in the \nclinic...', 'thumbnail': 'https://serpapi.com/searches/6722c4329fd309c821525934/images/0f1cb2ca06269091fee7ae9579dd65aa76ef415198c1655a308744d37c7a2012.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7565747499465942}",,,,,,,,,,['neutral'],neutral,1
NCT03730662,"{'position': 1, 'link': 'https://www.renalandurologynews.com/news/tirzepatide-vs-semaglutide-lower-metabolic-syndrome-prevalence/', 'title': 'Tirzepatide vs Semaglutide Linked to Lower Metabolic Syndrome Prevalence', 'source': 'Renal and Urology News', 'date': 'Apr 12, 2024', 'snippet': 'Use of tirzepatide, compared with placebo, semaglutide, and insulin \ndegludec and glargine, is associated with a lower prevalence of metabolic \nsyndrome among...', 'thumbnail': 'https://serpapi.com/searches/6722c4557ef9facbe7571346/images/e3f25578fc9f04e627a67934c3ead45fe9b2789298e9e1951668e02f8846c26c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8086218237876892}",,,,,,,,,,['neutral'],neutral,1
NCT02978690,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMc1811317', 'title': 'Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Mar 6, 2019', 'snippet': 'Seven patients with pustular psoriasis, three with mutations in IL36RN, \nwere treated with a monoclonal antibody against interleukin-36...', 'thumbnail': 'https://serpapi.com/searches/6722c47da5e5024406b7e2e2/images/dc0f0951ff096067b7d1515cd0b3df9757dac1939ad23bb8decc1bf1429e4f4e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8942992091178894}",,,,,,,,,,['neutral'],neutral,1
NCT04497987,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/clinical-trials-monoclonal-antibodies-prevent-covid-19-now-enrolling', 'title': 'Clinical trials of monoclonal antibodies to prevent COVID-19 now enrolling', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Aug 10, 2020', 'snippet': 'Two Phase 3, randomized, placebo-controlled, double-blind clinical trials \ntesting whether experimental monoclonal antibodies (mAbs) can prevent \ninfection by...', 'thumbnail': 'https://serpapi.com/searches/6722c4b0b9458d4a5076f40a/images/ac7ca5b92f525b290fc06f494e53dfd7359f506f1ff33c1483885e078626aef2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9068235754966736}","{'position': 2, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-neutralizing-antibody-bamlanivimab-ly-cov555-prevented', 'title': ""Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents"", 'source': 'Eli Lilly and Company', 'date': 'Jan 21, 2021', 'snippet': ""Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 \nat nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent \nfor..."", 'thumbnail': 'https://serpapi.com/searches/6722c4b0b9458d4a5076f40a/images/ac7ca5b92f525b29bc08d801cba6e48eaee5cd5f0fa0430d861df11dd80430b8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8190174698829651}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03004534,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-022-01849-9', 'title': 'Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer | British Journal of Cancer', 'source': 'Nature', 'date': 'May 26, 2022', 'snippet': 'Radiation therapy (RT) and hormone receptor (HR) inhibition are used for \nthe treatment of HR-positive breast cancers; however,...', 'thumbnail': 'https://serpapi.com/searches/6722c4cdf79a012c6dca9c73/images/00378939135fd1d30aa07abb8bcb67c2ea5d4d75764727d316d24f768378134d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9168511033058167}",,,,,,,,,,['neutral'],neutral,1
NCT03722329,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/jha2.632', 'title': 'A phase III, randomised, double‐blind, multi‐national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria - Jang - 2023 - eJHaem', 'source': 'Wiley Online Library', 'date': 'Dec 20, 2022', 'snippet': 'This randomised, double-blind, multi-national cross-over Phase III study in \nPNH patients aimed to demonstrate the equivalence of the proposed \neculizumab...', 'thumbnail': 'https://serpapi.com/searches/6722c4f7a25104618241d4d5/images/048879306fbc9d2e5af8f963ca0277f09feb1a111e81de1ddcfdb87c4e37bee4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8888051509857178}",,,,,,,,,,['neutral'],neutral,1
NCT01155778,"{'position': 1, 'link': 'https://sanfilipponews.com/news/polish-researchers-review-treatment-advances-for-sanfilippo-disease/', 'title': 'Sanfilippo Disease Treatment Advances Reviewed by Polish Researchers', 'source': 'Sanfilippo Syndrome News', 'date': 'Mar 15, 2018', 'snippet': 'Researchers at University of Gdańsk, Poland, reviewed the latest \npreclinical and clinical advances in this field.', 'thumbnail': 'https://serpapi.com/searches/6722c506069e577bfa32d33b/images/fd64d89fd39f73007d457635eb875f385f5afdf357bf35f9ca6dd9860c4462cd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9271643757820129}",,,,,,,,,,['neutral'],neutral,1
NCT00992186,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.5674', 'title': 'Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study', 'source': 'Wiley Online Library', 'date': 'Feb 22, 2023', 'snippet': 'Cancer Medicine is an open access, broad-scope oncology journal covering \nclinical cancer research, cancer biology, cancer prevention,...', 'thumbnail': 'https://serpapi.com/searches/6722c52a037756ce45680ebd/images/5c0f07f67c9eab8e097df41f887800f12a9096ecc7820afd95942c5508e99899.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.884207010269165}",,,,,,,,,,['neutral'],neutral,1
NCT00298038,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa0907893', 'title': 'Rifaximin Treatment in Hepatic Encephalopathy', 'source': 'The New England Journal of Medicine', 'date': 'Jun 25, 2018', 'snippet': 'Hepatic encephalopathy is a chronically debilitating complication of \nhepatic cirrhosis. The efficacy of rifaximin, a minimally absorbed \nantibiotic,...', 'thumbnail': 'https://serpapi.com/searches/6722c54a35853984f88bad64/images/5f4f4da05d57b02deb2febf413f116c63219e0d42331eb5fcb7537ce75d24d2e.png', 'sentiment': 'negative', 'sentiment_prob': 0.5058525800704956}",,,,,,,,,,['negative'],negative,0
NCT05842967,"{'position': 1, 'link': 'https://www.gastroendonews.com/PRN/Article/10-24/Pfizer-RSV-Vaccine-Indication/75243', 'title': 'Pfizer RSV Vaccine Indication', 'source': 'Gastroenterology & Endoscopy News', 'date': '6 days ago', 'snippet': ""The FDA granted a new indication for Pfizer's respiratory syncytial virus \nprefusion F (RSVpreF) vaccine (Abrysvo) to prevent lower..."", 'thumbnail': 'https://serpapi.com/searches/6722c572272a878897ddf53d/images/159337a95da7d985cb1eb3f3f2c7d3bb625028ace53532d7ad2903cde5e4784a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8785856366157532}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20240812622927/en/Pfizer-Announces-Top-Line-Results-of-ABRYSVO%C2%AE-for-RSV-in-Immunocompromised-Adults', 'title': 'Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults', 'source': 'Business Wire', 'date': 'Aug 12, 2024', 'snippet': 'Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and \nimmunogenicity results from substudy B of the ongoing pivotal Phase 3...', 'thumbnail': 'https://serpapi.com/searches/6722c572272a878897ddf53d/images/159337a95da7d985dc828a16581db4a971dab1fb315053e19f114ee7b7685739.png', 'sentiment': 'positive', 'sentiment_prob': 0.5051237940788269}","{'position': 3, 'link': 'https://www.businesswire.com/news/home/20240409770386/en/Pfizer-Announces-Positive-Top-Line-Results-from-Phase-3-Study-of-ABRYSVO%C2%AE-in-Adults-Aged-18-to-59-at-Increased-Risk-for-RSV-Disease', 'title': 'Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO', 'source': 'Business Wire', 'date': 'Apr 9, 2024', 'snippet': 'Pfizer Inc. (NYSE: PFE) today announced positive top-line immunogenicity \nand safety data from the ongoing pivotal Phase 3 clinical trial...', 'thumbnail': 'https://serpapi.com/searches/6722c572272a878897ddf53d/images/159337a95da7d9857b445896d789f5f8ffbe75d5963907974b178a6019849654.png', 'sentiment': 'positive', 'sentiment_prob': 0.6759746074676514}","{'position': 4, 'link': 'https://www.precisionvaccinations.com/2024/04/09/rsv-vaccine-people-18-59-years-posts-positive-phase-3-results', 'title': 'RSV Vaccine for People 18 to 59 Years Posts Positive Phase 3 Results', 'source': 'Precision Vaccinations News', 'date': 'Apr 9, 2024', 'snippet': 'Pfizer Inc. today reported encouraging top-line data regarding the safety \nand immunogenicity of its ABRYSVO® vaccine from an ongoing Phase 3...', 'thumbnail': 'https://serpapi.com/searches/6722c572272a878897ddf53d/images/159337a95da7d985b4e8127ad6f0796a8438b03c15b97cc109e4dded8cf81730.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6904248595237732}","{'position': 5, 'link': 'https://www.drugtopics.com/view/fda-approves-abrysvo-for-adults-18-59-at-increased-risk-for-rsv', 'title': 'FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV', 'source': 'Drug Topics', 'date': '1 week ago', 'snippet': ""Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has been \napproved by the FDA for the prevention RSV-associated of lower..."", 'thumbnail': 'https://serpapi.com/searches/6722c572272a878897ddf53d/images/159337a95da7d985d31d568ffd4ab111c3295bdfa763d0c0ba165741ebd39a04.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.857796311378479}","{'position': 6, 'link': 'https://www.businesswire.com/news/home/20241018199265/en/U.S.-FDA-Approves-Pfizer%E2%80%99s-RSV-Vaccine-ABRYSVO%C2%AE-for-Adults-Aged-18-to-59-at-Increased-Risk-for-Disease', 'title': 'U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease', 'source': 'Business Wire', 'date': '1 week ago', 'snippet': 'Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug \nAdministration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus...', 'thumbnail': 'https://serpapi.com/searches/6722c572272a878897ddf53d/images/159337a95da7d985714151323775cd9f0b4d635dab6ef8ba7076ab782cd415f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8342057466506958}",,,,,"['neutral', 'positive', 'positive', 'positive', 'neutral', 'neutral']",neutral,1
NCT00014911,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa061267', 'title': 'International Trial of the Edmonton Protocol for Islet Transplantation', 'source': 'The New England Journal of Medicine', 'date': 'Jan 29, 2017', 'snippet': 'Islet transplantation offers the potential to improve glycemic control in a \nsubgroup of patients with type 1 diabetes mellitus who are disabled by...', 'thumbnail': 'https://serpapi.com/searches/6722c57b163bdffdff21f419/images/04862eb7d370d13f1684e754ea958478ab07aa8c2b7924337f264f741a5bd980.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6982526183128357}",,,,,,,,,,['neutral'],neutral,1
NCT01583218,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1601747', 'title': 'Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients', 'source': 'The New England Journal of Medicine', 'date': 'May 27, 2016', 'snippet': 'We undertook a randomized trial of betrixaban, an oral, direct factor Xa \ninhibitor, for extended thromboprophylaxis in acutely ill medical patients.', 'thumbnail': 'https://serpapi.com/searches/6722c584e1c2761191a85e3c/images/d338b5a7c4f74f76dc123ca85bdc340a4424c5ba3c9b388f6be8baca0abd4a3d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.826765239238739}",,,,,,,,,,['neutral'],neutral,1
NCT04607005,"{'position': 1, 'link': 'https://www.gsk.com/en-gb/media/press-releases/gsk-s-regulatory-submission-accepted-for-review-by-japanese-regulator-for-use-of-nucala-mepolizumab/', 'title': 'GSK’s regulatory submission accepted for review by Japanese regulator for use of Nucala (mepolizumab) in adults with chronic rhinosinusitis with nasal polyps', 'source': 'GSK', 'date': 'Sep 1, 2023', 'snippet': 'The Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted for \nreview a supplementary new drug application (sJNDA) for Nucala \n(mepolizumab).', 'thumbnail': 'https://serpapi.com/searches/6722c58aee46823f19e982a7/images/09968276f5422dc66206c36775d7dc972f44b37e63b30f2316ae0ef5c2eb9774.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8980457782745361}",,,,,,,,,,['neutral'],neutral,1
NCT03149640,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2310307', 'title': 'Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia', 'source': 'The New England Journal of Medicine', 'date': 'Oct 25, 2023', 'snippet': 'Whether preventive inhaled antibiotics may reduce the incidence of \nventilator-associated pneumonia is unclear.In this investigator-initiated, \nmulticenter,...', 'thumbnail': 'https://serpapi.com/searches/6722c607b28e6beaadfedb5b/images/14b3c0b91110c5890e696e767855c6381d7683a36858ffa917d1f174981f9bcc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8450440764427185}",,,,,,,,,,['neutral'],neutral,1
NCT02227459,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.730176/full', 'title': 'Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy', 'source': 'Frontiers', 'date': 'Jun 27, 2024', 'snippet': 'In this review, we classify and summarize the relevant targets and drugs \nunder research and development for the treatment of liver fibrosis at home \nand abroad.', 'thumbnail': 'https://serpapi.com/searches/6722c6b0d403e1d4d10559cd/images/77b56487e44b956b2b8b58161a7d2d55aea61b39199f5961297bce65fea2c952.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9247708916664124}",,,,,,,,,,['neutral'],neutral,1
NCT04922593,"{'position': 1, 'link': 'https://www.europeanpharmaceuticalreview.com/news/176830/promising-schizophrenia-drug-faces-tough-competition/', 'title': 'Promising schizophrenia drug faces tough competition', 'source': 'European Pharmaceutical Review', 'date': 'Nov 25, 2022', 'snippet': 'LY03010, which could reduce the risk of patient relapse is at risk of being \nhidden in a crowded long-acting injectable market.', 'thumbnail': 'https://serpapi.com/searches/6722c7f2c1c8dda202219ac2/images/c0a5e6a601a84257cce2e14f5fb6bb660b9b86ceae3b93ea8c2c9f8abed401d9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5549529194831848}","{'position': 2, 'link': 'https://www.psychiatrictimes.com/view/fda-approves-erzofri-for-the-treatment-of-schizophrenia-and-schizoaffective-disorder', 'title': 'FDA Approves Erzofri for the Treatment of Schizophrenia and Schizoaffective Disorder', 'source': 'Psychiatric Times', 'date': 'Jul 30, 2024', 'snippet': 'The US Food and Drug Administration has approved Erzofri, a paliperidone \npalmitate extended-release injectable suspension for the treatment...', 'thumbnail': 'https://serpapi.com/searches/6722c7f2c1c8dda202219ac2/images/c0a5e6a601a842573febf140fda201cb9df246af8bc0f8a6fd81082d6c500295.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7432510852813721}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04311034,"{'position': 1, 'link': 'https://www.oncozine.com/remegen-initiates-clinical-trial-for-distamab-vedotin-a-novel-anti-her2-antibody-drug-conjugate/', 'title': 'RemeGen Initiates Clinical Trial for Distamab vedotin, a Novel anti-HER2 Antibody-drug Conjugate', 'source': ""Onco'Zine"", 'date': 'May 1, 2020', 'snippet': 'Earlier this week, the U.S. Food and Drug Administration (FDA) has cleared \nan Investigational New Drug (IND) application allowing...', 'thumbnail': 'https://serpapi.com/searches/6722c83a6a5dd373ed507c3f/images/05334d9d729d9f9edea2816f0f2f10a18e39c11500b72b4f35d9d210c43f13f4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8768057227134705}",,,,,,,,,,['neutral'],neutral,1
NCT02924688,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/spirometry-measurements-obtained-at-home-vs-clinic-evaluated/', 'title': 'Spirometry Measurements Obtained at Home vs Clinic Evaluated', 'source': 'Pulmonology Advisor', 'date': 'May 17, 2021', 'snippet': 'Researchers obtained home and clinic spirometry data from a phase 3A study \nin adults with uncontrolled asthma despite pharmacologic therapy.', 'thumbnail': 'https://serpapi.com/searches/6722c72b163bdffe4770b504/images/1cd4eb1ffee695ee4d6d931174eca34b4eb073d10c8f8176036a5a9dd06699a2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9275723099708557}",,,,,,,,,,['neutral'],neutral,1
NCT03398148,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/risankizumab-improves-ulcerative-colitis-symptoms-in-phase-3-induction-study/', 'title': 'Risankizumab Improves Ulcerative Colitis Symptoms in Phase 3 Induction Study', 'source': 'Medical Professionals Reference', 'date': 'Mar 24, 2023', 'snippet': 'Treatment with risankizumab resulted in clinical remission and an \nimprovement in symptoms, according to findings from the phase 3 INSPIRE \ninduction study.', 'thumbnail': 'https://serpapi.com/searches/6722c72f5ed3cab1ee1bf9d4/images/62a212b9e1a3112d9af153a70ca5777488893b3d2219c0fc314e36d98063e12c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6772766709327698}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/clinical-remission-observed-with-risankizumab-in-ulcerative-colitis-maintenance-study/', 'title': 'Clinical Remission Observed With Risankizumab in Ulcerative Colitis Maintenance Study', 'source': 'Medical Professionals Reference', 'date': 'Jun 15, 2023', 'snippet': 'Treatment with risankizumab led to a significant proportion of adults with \nmoderately to severely active ulcerative colitis achieving clinical \nremission.', 'thumbnail': 'https://serpapi.com/searches/6722c72f5ed3cab1ee1bf9d4/images/62a212b9e1a3112d9a1629fc1cef2833f390d824089b67d6327a692ffb1a1bc6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.874496340751648}","{'position': 3, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/risankizumab-under-review-for-moderately-to-severely-active-ulcerative-colitis/', 'title': 'Risankizumab Under Review for Moderately to Severely Active Ulcerative Colitis', 'source': 'Medical Professionals Reference', 'date': 'Aug 28, 2023', 'snippet': 'AbbVie has submitted a regulatory application to the Food and Drug \nAdministration (FDA) seeking approval of risankizumab for the treatment of \nadults with...', 'thumbnail': 'https://serpapi.com/searches/6722c72f5ed3cab1ee1bf9d4/images/62a212b9e1a3112d0d54bb48bdf3bd9403bf932922e96130b85298f4da3b3cf6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8749272227287292}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00375258,"{'position': 1, 'link': 'http://first10em.com/the-crash-2-trial/', 'title': 'The CRASH-2 trial (a review)', 'source': 'First10EM', 'date': 'Feb 17, 2020', 'snippet': 'A randomised controlled trial and economic evaluation of the effects of \ntranexamic acid on death, vascular occlusive events and transfusion \nrequirement in...', 'thumbnail': 'https://serpapi.com/searches/6722c8ccca6f0c0e9b6a0fa7/images/5484302d362865619e334c8833ad3cac3c09a0ba3e25a39980a07d6fb1ab7a8a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8708266019821167}",,,,,,,,,,['neutral'],neutral,1
NCT02953678,"{'position': 1, 'link': 'https://www.nature.com/articles/s41409-019-0562-9', 'title': 'The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Oral Session', 'source': 'Nature', 'date': 'Jul 3, 2019', 'snippet': 'The time of starting of immunosuppression drugs after haplo in combination \nwith PT-Cy influences the results of unmanipulated haploidentical \ntransplant.', 'thumbnail': 'https://serpapi.com/searches/6722c8d606f4f2e9ae16594a/images/cd5b092bd2241066b981c056d7a60f90d0b5e02ec300885d70bb27f601466802.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9350588917732239}",,,,,,,,,,['neutral'],neutral,1
NCT04064905,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-023-00656-4', 'title': 'An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection | npj Vaccines', 'source': 'Nature', 'date': 'Apr 20, 2023', 'snippet': 'mRNA-1893 generated comparable neutralizing antibody titers to mRNA-1325 at \n1/20th of the dose and provided complete protection from ZIKV challenge in \nnon-...', 'thumbnail': 'https://serpapi.com/searches/6722c8ddb6ed337ce072c298/images/32604785819d8476fce8417a7d46d0255c3aa1fa6fc4d6ff8251f8d2fa32110d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7196072936058044}",,,,,,,,,,['neutral'],neutral,1
NCT01207440,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1306494', 'title': 'A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias', 'source': 'The New England Journal of Medicine', 'date': 'Apr 24, 2018', 'snippet': 'We conducted a phase 2 trial of ponatinib in patients with chronic myeloid \nleukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic \nleukemia (Ph-...', 'thumbnail': 'https://serpapi.com/searches/6722c8e89062f8d53b311a8c/images/528e99fd57836572a07d85a969d8d708cb3aad4627e4987d1086474cc67dd97d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9004957675933838}",,,,,,,,,,['neutral'],neutral,1
NCT02007512,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-023-00544-z', 'title': 'Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer | npj Breast Cancer', 'source': 'Nature', 'date': 'May 20, 2023', 'snippet': 'This clinical trial combined fulvestrant with the anti-androgen \nenzalutamide in women with metastatic ER+/HER2− breast cancer (BC).', 'thumbnail': 'https://serpapi.com/searches/6722c8f31fc7c5993698dfb8/images/e01a8ab47fccf0efe4ed3bb367ec2cc0a2dcf9fa1233d5a40e0bec10399cafda.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8781253099441528}",,,,,,,,,,['neutral'],neutral,1
NCT05035095,"{'position': 1, 'link': 'https://www.ajmc.com/view/experts-highlight-how-glp-1s-have-revolutionized-management-of-t2d-and-obesity', 'title': 'Experts Highlight How GLP-1s Have Revolutionized Management of T2D and Obesity', 'source': 'AJMC', 'date': 'Jun 13, 2024', 'snippet': 'The number of Americans with type 2 diabetes and/or obesity is rising, and \nthe entry of therapies such as glucagon-like peptide-1 (GLP-1)...', 'thumbnail': 'https://serpapi.com/searches/6722c9ec6f9f633c74d9ed5a/images/5b9ebae72e606c95ee97184959c276e94dca612c22ee1a965e87257f7a5ac35f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7236489057540894}","{'position': 2, 'link': 'https://www.endocrinologyadvisor.com/reports/semaglutide-improves-prediabetic-glycemic-control/', 'title': 'Semaglutide Improves Prediabetic Glycemic Control', 'source': 'Endocrinology Advisor', 'date': 'Oct 20, 2023', 'snippet': 'Once-daily oral semaglutide 50 mg improved glycemic control among \nindividuals with prediabetes, according to study findings presented at \nObesityWeek® 2023.', 'thumbnail': 'https://serpapi.com/searches/6722c9ec6f9f633c74d9ed5a/images/5b9ebae72e606c95520d1a8792a7b9093b2fc5928517a5dbd574f97612d21107.png', 'sentiment': 'positive', 'sentiment_prob': 0.557879626750946}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04722484,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222002839', 'title': 'Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)', 'source': 'ScienceDirect.com', 'date': 'Apr 2, 2022', 'snippet': 'Vericiguat was first drug approved for the treatment of symptomatic \npatients with chronic HF with reduced ejection fraction (HFrEF) to reduce \nthe occurrence of...', 'thumbnail': 'https://serpapi.com/searches/6722ca40a775f2f8ec0e22b0/images/451fd558a9b11c3967b3d0d6a8ad72973425fd55c8bc4b92190dc23c7b7b964c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6862191557884216}",,,,,,,,,,['neutral'],neutral,1
NCT03132467,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1256360/full', 'title': 'Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer', 'source': 'Frontiers', 'date': 'Oct 4, 2023', 'snippet': 'Breast cancer is characterized by a high incidence rate and its treatment \nchallenges, particularly in certain subtypes. Consequently, there is an \nurgent...', 'thumbnail': 'https://serpapi.com/searches/6722ca49ecf150c72970d49b/images/1576bcc26f7b1b15e3a7adf2985068255fc592bf158d034f16dbfeaabc30da9c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8037545680999756}",,,,,,,,,,['neutral'],neutral,1
NCT04724837,"{'position': 1, 'link': 'https://www.renalandurologynews.com/reports/zibotentan-dapagliflozin-combo-further-reduces-albuminuria-in-ckd/', 'title': 'Zibotentan, Dapagliflozin Combo Further Reduces Albuminuria in CKD', 'source': 'Renal and Urology News', 'date': 'Nov 8, 2023', 'snippet': 'ZENITH-CKD is the first randomized trial comparing combined SGLT2 and \nendothelin A inhibition in patients with chronic kidney disease.', 'thumbnail': 'https://serpapi.com/searches/6722ca9d20e6eb462887d44b/images/5a715863f6eebbf4edf1ceb06ab1a8b807decab8c46205bab9e8517166f0e3ec.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8572437167167664}",,,,,,,,,,['neutral'],neutral,1
NCT01045421,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Kinase-substrate-enrichment-analysis-a-Predicted-upstream-kinases-enriched-across-five_fig5_339042892', 'title': 'Figure 5. Kinase-substrate enrichment analysis. (a) Predicted upstream...', 'source': 'ResearchGate', 'date': 'Feb 6, 2020', 'snippet': 'Download scientific diagram | Kinase-substrate enrichment analysis. (a) \nPredicted upstream kinases enriched across five cancer types.', 'thumbnail': 'https://serpapi.com/searches/6722cbbd5bb6a2400c71c882/images/3c13098865e1b4281a7d54bb465693f43245554167316505c32ec753c240dab1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9439812302589417}",,,,,,,,,,['neutral'],neutral,1
NCT01207388,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/fda-gives-full-approval-to-blinatumomab-in-mrd-positive-b-cell-all', 'title': 'FDA Gives Full Approval to Blinatumomab in MRD-Positive B-Cell ALL', 'source': 'Cancer Network', 'date': 'Jun 21, 2023', 'snippet': 'Blinatumomab has been granted full approval by the FDA for patients with \nB-cell acute lymphoblastic leukemia and minimal residual disease of...', 'thumbnail': 'https://serpapi.com/searches/6722cbccd78a985a6b5acf36/images/7c95c2ac1490abfba5796159bbb1058d5689c7948ac8cdc4ffb9825d7fda5dd5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5017969608306885}",,,,,,,,,,['neutral'],neutral,1
NCT03446001,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/alzheimers-tau-targeting-therapy-slows-cognition-functional-drops-trial/', 'title': 'Tau-targeting Treatment Slows Cognitive, Functional Declines: Trial', 'source': ""Alzheimer's News Today"", 'date': 'Jun 6, 2022', 'snippet': ""Alzheimer's patients given the tau-targeting therapy HMTM in the clinical \ntrial LUCIDITY showed substantially slower declines than expected."", 'thumbnail': 'https://serpapi.com/searches/6722cc1ff6aa53bdf3522017/images/0fbccb5422e183ed9cf4f071765b1b5e0216f119122b021b650b859f69abca5d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5801092386245728}",,,,,,,,,,['neutral'],neutral,1
NCT03433183,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-021-00145-8', 'title': 'Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor', 'source': 'Nature', 'date': 'Feb 12, 2021', 'snippet': 'The prognosis of recurrent malignant peripheral nerve sheath tumors (MPNST) \nis dismal, with surgical resection being the only definitive...', 'thumbnail': 'https://serpapi.com/searches/6722cc6821b01b712dab21cf/images/f986b08782acb252d605ecde211ffa4890ca9a2183eb7211c6c0b76f967c6e97.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7937101125717163}",,,,,,,,,,['negative'],negative,0
NCT00731549,"{'position': 1, 'link': 'https://www.nature.com/articles/npjschz201539', 'title': 'Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study', 'source': 'Nature', 'date': 'Nov 4, 2015', 'snippet': 'This study assessed the long-term safety, tolerability, and maintenance of \nthe therapeutic effect of aripiprazole once-monthly 400 mg (AOM 400) in \npatients...', 'thumbnail': 'https://serpapi.com/searches/6722cd2fa86921c0f30bf7d6/images/001a90fcae3c486c26a82f24156e389f9223327da6622fc03700682ec960afda.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8929340243339539}",,,,,,,,,,['neutral'],neutral,1
NCT01975246,"{'position': 1, 'link': 'https://www.nature.com/articles/hr2016124', 'title': 'Effect of hydrochlorothiazide in addition to telmisartan/amlodipine combination for treating hypertensive patients uncontrolled with telmisartan/amlodipine: a randomized, double-blind study', 'source': 'Nature', 'date': 'Oct 20, 2016', 'snippet': 'The efficacy and safety of telmisartan 80 mg/amlodipine 5 mg plus \nhydrochlorothiazide 12.5 mg (T80/A5/H12.5) was examined for its ability \nto...', 'thumbnail': 'https://serpapi.com/searches/6722cd3a2da15704c0e29bb9/images/1b79b63d51ffae9ca438d0f662edd7fab350cec2c4cad3759ffff0f61afc5f3b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7973392605781555}",,,,,,,,,,['neutral'],neutral,1
NCT00304070,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/news/adrenocortical-cancer-excellent-outcomes-room-improvement-treatment/', 'title': '‘Excellent’ Outcomes and Room for Improvement in Pediatric Adrenocortical Carcinoma', 'source': 'Cancer Therapy Advisor', 'date': 'Aug 13, 2021', 'snippet': 'Disease stage is significantly associated with outcomes in pediatric \npatients with adrenocortical carcinoma, a study suggests.', 'thumbnail': 'https://serpapi.com/searches/6722cdfb2c566da2e23fcd5c/images/cf780e2056ba580bb624b84ba1ce58ca3a5c1c3571c8b0acfd0903d31b579aff.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.566736102104187}",,,,,,,,,,['neutral'],neutral,1
NCT03009019,"{'position': 1, 'link': 'https://www.neurologyadvisor.com/news/celecoxib-effective-migraine-pain-relief-symptoms-aura-status-ahs-2022/', 'title': 'Celecoxib Effective for Migraine Pain Relief, Symptoms Regardless of Aura Status', 'source': 'Neurology Advisor', 'date': 'Jun 15, 2022', 'snippet': 'Oral celecoxib is more effective than placebo for the treatment of acute \nmigraine with or without aura, according to a pooled analysis of data from \n2 clinical...', 'thumbnail': 'https://serpapi.com/searches/6722ce888de63c891833e165/images/1bd348287a5ef4f2fcbd571e58bc47c6949b76e7aa7b588d703446f6c9364894.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6028152108192444}","{'position': 2, 'link': 'https://www.clinicalpainadvisor.com/news/treating-acute-migraine-symptoms-with-the-nsaid-celecoxib/', 'title': 'Celecoxib Effectively Relieves Episodic Migraine-Related Symptoms', 'source': 'Clinical Pain Advisor', 'date': 'Nov 16, 2021', 'snippet': 'Celecoxib, a cyclooxygenase-2 selective nonsteroidal anti-inflammatory \ndrug, was found to be more effective than placebo at reducing acute \nmigraine pain.', 'thumbnail': 'https://serpapi.com/searches/6722ce888de63c891833e165/images/1bd348287a5ef4f2780c9abec92761b15bc6897685f1610358ba618816a129bb.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6282522082328796}","{'position': 3, 'link': 'https://www.empr.com/home/news/elyxyb-now-available-for-acute-migraine-treatment/', 'title': 'Elyxyb Now Available for Acute Migraine Treatment', 'source': 'Medical Professionals Reference', 'date': 'Feb 24, 2022', 'snippet': 'Elyxyb (celecoxib oral solution) is now available for the acute treatment \nof migraine with or without aura in adults.', 'thumbnail': 'https://serpapi.com/searches/6722ce888de63c891833e165/images/1bd348287a5ef4f28b641b9ef7a569b124c7ef0e6b22871dcefdf90dc03bd2d5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.773752748966217}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT02421094,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-022-01119-3', 'title': 'Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)', 'source': 'Nature', 'date': 'Aug 13, 2022', 'snippet': 'In this review, we discussed recent developments in etiology and \nprospective therapeutic targets, as well as pharmacological candidates in \npre/clinical trials...', 'thumbnail': 'https://serpapi.com/searches/6722cf1281bab7385d266088/images/01e4a5e87fd78b4e3b97ee20cf2aac671e2b19f1585bb0a46376018016a44912.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9206169247627258}",,,,,,,,,,['neutral'],neutral,1
NCT02090764,"{'position': 1, 'link': 'https://www.infectiousdiseaseadvisor.com/home/topics/skin-infections/topical-antibacterial-agent-effective-for-treatment-of-impetigo/', 'title': 'Topical Antibacterial Agent Effective for Treatment of Impetigo', 'source': 'Infectious Disease Advisor', 'date': 'Dec 3, 2018', 'snippet': 'Topical ozenoxacin 1% cream is a rapid and effective treatment for patients \nwith impetigo. The agent demonstrates consistent clinical and bacteriologic \neffects.', 'thumbnail': 'https://serpapi.com/searches/6722cf25bd7cf087401d4383/images/2dc7c8777e39eac5b81f4457aa14460b9f83c402cdc7750a47df2584947ab30f.png', 'sentiment': 'positive', 'sentiment_prob': 0.7753939628601074}",,,,,,,,,,['positive'],positive,1
NCT01037790,"{'position': 1, 'link': 'https://www.onclive.com/view/dr-karasic-on-palbociclib-in-esophageal-and-gastric-cancer', 'title': 'Dr. Karasic on Palbociclib in Esophageal and Gastric Cancer', 'source': 'OncLive', 'date': 'Jan 29, 2018', 'snippet': 'Thomas Karasic, MD, investigator at Penn Medicine, discusses the rationale \nbehind the phase II trial (NCT01037790) of palbociclib (Ibrance)...', 'thumbnail': 'https://serpapi.com/searches/6722cf439e5bd5d9a6fc200a/images/4a42f5272c63d865b8a45e493cf822ba3d82973a0ebffc76e702d1d490fed8bc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9411104917526245}",,,,,,,,,,['neutral'],neutral,1
NCT03244228,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/heptares-administers-alzheimers-therapy-htl0016878-to-first-phase-1-trial-participant/', 'title': ""Alzheimer's Therapy HTL0016878 Is Being Administered to First Participant in Phase 1 Trial"", 'source': ""Alzheimer's News Today"", 'date': 'Sep 5, 2017', 'snippet': ""The first participant in a Phase 1 clinical trial of HTL0016878 as a \ntreatment for cognitive impairment in Alzheimer's disease is receiving the \ntherapy."", 'thumbnail': 'https://serpapi.com/searches/6722cf4facf7f8296777e777/images/5be6cfa19be8c6b44b1180cf85f1f3e54c27aae8758951ad38a2727954057c33.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8841114044189453}",,,,,,,,,,['neutral'],neutral,1
NCT02594371,"{'position': 1, 'link': 'https://breastcancer-news.com/2020/09/03/fda-reviewing-oral-paclitaxel-combo-as-metastatic-breast-cancer-treatment/', 'title': 'FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer Treatment', 'source': 'Breast Cancer News', 'date': 'Sep 3, 2020', 'snippet': 'The new drug application from Athenex for oral Paclitaxel has been granted \npriority review. A decision is expected in 2021.', 'thumbnail': 'https://serpapi.com/searches/6722cf7954163d58f718d36f/images/e882d59bc8ad69b89b89d0579178b052463e1a01033ae04907d1c3a984e86ca3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8881188035011292}",,,,,,,,,,['neutral'],neutral,1
NCT02902029,"{'position': 1, 'link': 'https://www.onclive.com/view/early-switch-therapy-to-atezolizumab-after-vemurafenib-cobimetinib-run-in-improves-os-in-braf-v600-positive-melanoma', 'title': 'Early Switch Therapy to Atezolizumab After Vemurafenib/Cobimetinib Run-in Improves OS in BRAF V600–Positive Melanoma', 'source': 'OncLive', 'date': '1 month ago', 'snippet': 'Early switch therapy to atezolizumab after run-in with vemurafenib plus \ncobimetinib led to improved 4- and 5-month OS rates in BRAF V600–positive \nmelanoma.', 'thumbnail': 'https://serpapi.com/searches/6722cfd4bb55ffdd70c730e6/images/089f0dc49bd3e0c66b8e2b67cd0d09ee4c8c3be590a4f18112182000a1fffde8.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.509925127029419}",,,,,,,,,,['positive'],positive,1
NCT03306264,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00338-1/abstract', 'title': 'Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study', 'source': 'The Lancet', 'date': 'Feb 13, 2024', 'snippet': 'The DNA methyltransferase inhibitors azacitidine and decitabine for \nindividuals with myelodysplastic syndromes or chronic myelomonocytic \nleukaemia are...', 'thumbnail': 'https://serpapi.com/searches/6722d008717bff9194f9f6f0/images/6c890e53293bf624db20aad5664b3898ef87f204ea685cb3c650a0a972da7af6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8850045800209045}","{'position': 2, 'link': 'https://www.onclive.com/view/oral-decitabine-and-cedazuridine-wins-eu-approval-for-newly-diagnosed-aml', 'title': 'Oral Decitabine and Cedazuridine Wins EU Approval for Newly Diagnosed AML', 'source': 'OncLive', 'date': 'Sep 19, 2023', 'snippet': 'The European Commission has approved oral decitabine and cedazuridine for \nthe treatment of adult patients with newly diagnosed acute myeloid...', 'thumbnail': 'https://serpapi.com/searches/6722d008717bff9194f9f6f0/images/6c890e53293bf62484cb28ac76aacd1ea7d315a014326095f89402dddbde27c7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8428905010223389}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/ema-accepts-marketing-authorization-application-for-decitabine-and-cedazuridine-in-adult-aml', 'title': 'EMA Accepts Marketing Authorization Application for Decitabine and Cedazuridine in Adult AML', 'source': 'Cancer Network', 'date': 'Aug 24, 2022', 'snippet': 'Adult patients with acute myeloid leukemia who are not eligible for \ntreatment with standard induction chemotherapy may benefit from...', 'thumbnail': 'https://serpapi.com/searches/6722d008717bff9194f9f6f0/images/6c890e53293bf624744eaebac96fd4e731ca0190ae204ff10eaf6af96e4f8084.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9203475713729858}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04754802,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/news-vistagen-phase-iii-social-anxiety-disorder/', 'title': 'VistaGen shakes up Phase III social anxiety disorder program', 'source': 'Clinical Trials Arena', 'date': 'Mar 31, 2023', 'snippet': 'VistaGen will halt on ongoing Phase III trial of its fast-acting nasal \nspray to pursue a new Phase III approach in social anxiety disorder.', 'thumbnail': 'https://serpapi.com/searches/6722d07231665066b0013e8f/images/8bf09af2a34a579696071e8a3be7b2cb4a9b1481111ccb76c1d6f3a633176d38.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5160417556762695}",,,,,,,,,,['neutral'],neutral,1
NCT03559192,"{'position': 1, 'link': 'https://www.nature.com/articles/s41386-024-01862-x', 'title': 'Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study', 'source': 'Nature', 'date': 'Apr 22, 2024', 'snippet': 'This was a double-blind, randomized, phase 2 study of adults (18–64 years) \nwith DSM−5 diagnosis of major depressive disorder (MDD),...', 'thumbnail': 'https://serpapi.com/searches/6722d0ba29e6fbf3605b13b7/images/0cfc281aab9131fc67148bf58da8d5bc12e7689ea42ac399c173083e937d4dfa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8731998205184937}",,,,,,,,,,['neutral'],neutral,1
NCT01387763,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/reports/myeloproliferative-neoplasm-mpn-hydroxyurea-outcomes-treatment-risk/', 'title': 'No Significant Differences in Outcomes Seen Between Hydroxyurea and IFNα in Patients With MPNs', 'source': 'Hematology Advisor', 'date': 'Dec 12, 2023', 'snippet': 'The final analysis of the DALIAH trial (ClinicalTrials.gov Identifier: \nNCT01387763), which was presented at the ASH Annual Meeting 2023,...', 'thumbnail': 'https://serpapi.com/searches/6722d0c87b05caaa903b5e85/images/b6ed9452bdcf1b312f5221a8bab47e47265956b333f74377153cd246ce8ec354.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8983315825462341}",,,,,,,,,,['neutral'],neutral,1
NCT05158023,"{'position': 1, 'link': 'https://nationaleczema.org/blog/aslan-12122/', 'title': 'ASLAN Pharmaceuticals initiates Phase 2b study of ASLAN004 (eblasakimab) in moderate-to-severe atopic dermatitis', 'source': 'National Eczema Association', 'date': 'Feb 10, 2022', 'snippet': 'The randomized, double-blind, placebo-controlled, dose-ranging clinical \nstudy will evaluate the efficacy and safety of eblasakimab in adult \npatients with...', 'thumbnail': 'https://serpapi.com/searches/6722d0ffe30abc8601a29b1b/images/f42035aab07052c0a8af5a6e6b7bf18394fcf72152151cb3d9673f47db0e8e3b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8525307774543762}",,,,,,,,,,['neutral'],neutral,1
NCT02265705,"{'position': 1, 'link': 'https://rheumatoidarthritisnews.com/baricitinib-olumiant-for-rheumatoid-arthritis/', 'title': 'Baricitinib (Olumiant) for Rheumatoid Arthritis', 'source': 'Rheumatoid Arthritis News', 'date': 'Apr 24, 2017', 'snippet': 'Read about Baricitinib (Olumiant), which inhibits the inflammation \nassociated with rheumatoid arthritis, easing the joint pain that stems from \nthe disease.', 'thumbnail': 'https://serpapi.com/searches/6722d1334677bf0ea03abea1/images/acf114c5e4dd1729c8e2f4f098ec85a833387c00e31cbf3e7104c40298db017a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7946578860282898}",,,,,,,,,,['neutral'],neutral,1
NCT01791153,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1613849', 'title': 'Trial of Tocilizumab in Giant-Cell Arteritis', 'source': 'The New England Journal of Medicine', 'date': 'Jul 27, 2017', 'snippet': 'Giant-cell arteritis commonly relapses when glucocorticoids are tapered, \nand the prolonged use of glucocorticoids is associated with side...', 'thumbnail': 'https://serpapi.com/searches/6722d149d72128a1d3459d82/images/d54102965f7791e7c23ed27a6d9950880addf75d79e053c810ffdaf323fee7ef.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6366521716117859}",,,,,,,,,,['neutral'],neutral,1
NCT03536728,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-023-02525-2', 'title': 'Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial | British Journal of Cancer', 'source': 'Nature', 'date': 'Jan 10, 2024', 'snippet': 'MYC genes regulate ornithine decarboxylase (Odc) to increase intratumoral \npolyamines. We conducted a Phase I trial [NCT02030964] to...', 'thumbnail': 'https://serpapi.com/searches/6722d3191f3d4bf318db2e4c/images/84d52b915665ddba9ed3aae3e442c4a8b4f2476557441a4f27f11e75192d0edd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8940494656562805}",,,,,,,,,,['neutral'],neutral,1
NCT01144338,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1612917', 'title': 'Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Sep 14, 2017', 'snippet': 'The cardiovascular effects of adding once-weekly treatment with exenatide \nto usual care in patients with type 2 diabetes are unknown.', 'thumbnail': 'https://serpapi.com/searches/6722d4285ed3cab1ee1c0573/images/65c65e56915ff0ad35b692a511eed46e2a09a8c6edb7e1545201fd17fed403ea.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7171388268470764}",,,,,,,,,,['neutral'],neutral,1
NCT04242446,"{'position': 1, 'link': 'https://www.ajmc.com/view/bimekizumab-elicits-clinically-meaningful-responses-in-moderate-to-severe-hidradenitis-suppurativa', 'title': 'Bimekizumab Elicits Clinically Meaningful Responses in Moderate to Severe Hidradenitis Suppurativa', 'source': 'AJMC', 'date': 'May 24, 2024', 'snippet': 'In newly published findings from the pivotal phase 3 BE HEARD I \n(NCT04242446) and BE HEARD II (NCT04242498) trials, bimekizumab was well...', 'thumbnail': 'https://serpapi.com/searches/6722d4449062f8d4f3792369/images/606181fd0c5c2de2525faed887fb07d61ee73303de8267bfeaebbd27492f3cb3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6742416024208069}",,,,,,,,,,['neutral'],neutral,1
NCT04115488,"{'position': 1, 'link': 'https://www.empr.com/home/news/generics-news/fda-approves-biosimilar-tyruko-for-multiple-sclerosis-crohn-disease/', 'title': 'FDA Approves Biosimilar Tyruko for Multiple Sclerosis, Crohn Disease', 'source': 'Medical Professionals Reference', 'date': 'Aug 25, 2023', 'snippet': 'The Food and Drug Administration has approved Tyruko (natalizumab-sztn), a \nbiosimilar to Tysabri (natalizumab).', 'thumbnail': 'https://serpapi.com/searches/6722d48bf9f90434f5ac6fb6/images/abbc521a6ad69595257f79badc348a79717b17999226cde86fa90513ff366e32.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6632517576217651}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/02/03/biosimilar-pb006-comparable-safety-efficacy-tysabri-phase-3/', 'title': 'Biosimilar Comparable in Safety, Efficacy to Tysabri in Phase 3 Trial', 'source': 'Multiple Sclerosis News Today', 'date': 'Feb 3, 2023', 'snippet': 'PB006, a biosimilar to Tysabri, showed similar safety and efficacy as the \noriginal medication in people with RRMS in a Phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/6722d48bf9f90434f5ac6fb6/images/abbc521a6ad695959ac146dd87be94876a2f220a2111d9dcbad966e1691a7914.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5543018579483032}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/07/19/natalizumab-tysabri-biosimilar-ms-approval-review-europe/', 'title': 'Natalizumab, Tysabri Biosimilar, Up for Approval in Europe |...', 'source': 'Multiple Sclerosis News Today', 'date': 'Jul 19, 2022', 'snippet': ""The European Medicines Agency will consider for approval Polpharma \nBiologics' natalizumab, an MS antibody therapy similar to Tysabri."", 'thumbnail': 'https://serpapi.com/searches/6722d48bf9f90434f5ac6fb6/images/abbc521a6ad69595bc5b573acc3a1bf37bde2b66abaaf19305adbe2fb1c4e318.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9038274884223938}","{'position': 4, 'link': 'https://multiplesclerosisnewstoday.com/tyruko-first-tysabri-biosimilar-approved-europe-rmms/', 'title': 'Tyruko, first Tysabri biosimilar, approved in Europe for RMMS –...', 'source': 'Multiple Sclerosis News Today', 'date': 'Sep 28, 2023', 'snippet': 'The European Commission has approved Tyruko, the first biosimilar of \nTysabri, for the treatment of adults with highly active RRMS.', 'thumbnail': 'https://serpapi.com/searches/6722d48bf9f90434f5ac6fb6/images/abbc521a6ad69595fe926d21aacbd6a971def092d973048a01ebf18cb841dcfb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6000606417655945}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT00405756,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1112704', 'title': 'Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma', 'source': 'The New England Journal of Medicine', 'date': 'May 10, 2012', 'snippet': 'Lenalidomide has tumoricidal and immunomodulatory activity against multiple \nmyeloma. This double-blind, multicenter, randomized study...', 'thumbnail': 'https://serpapi.com/searches/6722d49c76079d5760ef546d/images/dea5ff2b02c5f46926d23c1e38b9831a85c4074c1d44265e270bf08718efa2ab.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9088589549064636}",,,,,,,,,,['neutral'],neutral,1
NCT00109499,"{'position': 1, 'link': 'https://www.cureus.com/articles/110149-ocular-gene-therapy-a-literature-review-with-focus-on-current-clinical-trials', 'title': 'Ocular Gene Therapy: A Literature Review With Focus on Current Clinical Trials', 'source': 'Cureus', 'date': 'Sep 24, 2022', 'snippet': 'Gene therapy has been one of the most researched topics in the last decade. \nIt has now become a revolutionized therapeutic tool of modern...', 'thumbnail': 'https://serpapi.com/searches/6722d5fb2fab620db4097b0f/images/1b48f780a923ff4befdb81b057fd3a13489ce4b21ba9b9f8f46279132a4b2ab6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8775461316108704}",,,,,,,,,,['positive'],positive,1
NCT03851146,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-23331-5', 'title': 'CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy', 'source': 'Nature', 'date': 'May 28, 2021', 'snippet': 'Here we show that targeting A 2A R with a clinically relevant CRISPR/Cas9 \nstrategy significantly enhances their in vivo efficacy, leading to improved \nsurvival...', 'thumbnail': 'https://serpapi.com/searches/6722d65e0a545a3021a89822/images/d905aafdd4ff06690f71b83f3ace0c9736893287c4c870ca3c5047e13096653f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5505958795547485}",,,,,,,,,,['neutral'],neutral,1
NCT02387996,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/nivolumab-ipilimumab-boosts-improves-responses-in-bladder-cancer-non-responders', 'title': 'Nivolumab/Ipilimumab Boosts Improves Responses in Bladder Cancer Non-Responders', 'source': 'Cancer Network', 'date': 'Apr 28, 2023', 'snippet': 'Data from the phase 2 TITAN-TCC trial suggest that early non-responders \nwith metastatic urothelial carcinoma with PD-L1–positive tumors...', 'thumbnail': 'https://serpapi.com/searches/6722d69eee46823f19e99300/images/9f92583875f9fcf1cd880133cb4f74cc4039fec00a1599ec239bf6caa7173c2c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7841391563415527}",,,,,,,,,,['neutral'],neutral,1
NCT04079803,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/pti-125-fails-lower-csf-protein-levels-alzheimers-patients-phase-2-trial/', 'title': 'PTI-125 Fails to Lower Alzheimer’s Protein Levels in Phase 2 Trial', 'source': ""Alzheimer's News Today"", 'date': 'May 18, 2020', 'snippet': ""Cassava Sciences announced PTI-125 failed to significantly lower levels of \nAlzheimer's-relevant markers, a primary trial goal, and data are..."", 'thumbnail': 'https://serpapi.com/searches/6722d7498a7c09ea79016cf0/images/df29584baa8b93f1b3c98c10ae56790d8cea4743d913a6926a1b82e291122715.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6908381581306458}",,,,,,,,,,['negative'],negative,0
NCT02941926,"{'position': 1, 'link': 'https://breastcancer-news.com/2018/07/25/fda-approves-kisqali-for-breast-cancer-in-premenopausal-perimenopausal-women/', 'title': 'FDA Approves Kisqali for Breast Cancer in Pre-, Perimenopausal Women', 'source': 'breastcancer-news.com', 'date': 'Jul 25, 2018', 'snippet': 'Kisqali (ribociclib) now can be used in combination with an aromatase \ninhibitor as first-line therapy for all women with HR-positive, \nHER2-negative advanced or...', 'thumbnail': 'https://serpapi.com/searches/6722d79021e77b4fba2e1560/images/c82092e678fd61f7c260bcc53bfa6aae0251d866d283345170f768111fcfb7e8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8082779049873352}",,,,,,,,,,['neutral'],neutral,1
NCT02776813,"{'position': 1, 'link': 'https://lymphomahub.com/medical-information/fda-safety-concerns-halt-actr087-b-cell-non-hodgkin-lymphoma-clinical-trial', 'title': 'FDA safety concerns halt ACTR087 B cell non-Hodgkin lymphoma clinical trial', 'source': 'Lymphoma Hub', 'date': 'Jul 5, 2019', 'snippet': 'The U.S. Food and Drug Administration has decided to place on hold clinical \ntrial ATTCK-20-2 investigating an experimental T-cell therapy...', 'thumbnail': 'https://serpapi.com/searches/6722d7aacf32e0735598dc05/images/50a24013534257995cd490e5f1f1ab512af1c520fccd88524160421096bfe0f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.509852409362793}",,,,,,,,,,['neutral'],neutral,1
NCT00844545,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1208981', 'title': 'Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome', 'source': 'The New England Journal of Medicine', 'date': 'Apr 15, 2018', 'snippet': 'Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic \ndisease of complement-mediated thrombotic microangiopathy.', 'thumbnail': 'https://serpapi.com/searches/6722d95b690bb9df0c32f8f5/images/dbb74919b7b3b2fe457ef5ad27060f0515d17cd4ed600b55fcd28049a8aba13f.png', 'sentiment': 'negative', 'sentiment_prob': 0.5254178047180176}",,,,,,,,,,['negative'],negative,0
NCT00273364,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/autologous-stem-cell-transplant-safe-effective-rrms-study/', 'title': 'Stem cell therapy found safe, effective in RRMS study', 'source': 'Multiple Sclerosis News Today', 'date': 'Sep 29, 2023', 'snippet': 'About three quarters of relapsing MS patients did not show signs of disease \nactivity five years after an autologous stem cell transplant.', 'thumbnail': 'https://serpapi.com/searches/6722d96496a329d9498ff292/images/3153d3ff322a4f7a24335ff0dc2f45ec01afe2912a2a2c30ae322d69befb9c92.png', 'sentiment': 'positive', 'sentiment_prob': 0.5159249305725098}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/03/22/autologous-hematopoietic-stem-cell-transplant-multiple-sclerosis-ahsct/', 'title': 'Stem Cell Transplant Gaining Ground as MS Therapy Option', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 22, 2022', 'snippet': 'Autologous hematopoietic stem cell transplant, despite risks, may be a \nviable treatment option for some MS patients when other options fail.', 'thumbnail': 'https://serpapi.com/searches/6722d96496a329d9498ff292/images/3153d3ff322a4f7a2f121eea99f03e424b27f25298b49b110dd7ced77c74e2af.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5916305780410767}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT01092195,"{'position': 1, 'link': 'https://www.nhlbi.nih.gov/news/2020/hpv-vaccine-safely-evokes-immune-response-hpv-women-who-have-had-stem-cell-transplant', 'title': 'HPV vaccine safely evokes immune response to HPV in women who have had a stem cell transplant', 'source': 'nhlbi, nih (.gov)', 'date': 'Mar 4, 2020', 'snippet': 'Multi-institute NIH study suggests that the HPV vaccine could protect women \nagainst new HPV infections after stem cell transplantation.', 'thumbnail': 'https://serpapi.com/searches/6722d9a7d364b477d7d0173e/images/6210aff57801fd7f4258ecdbd51d3c0b8b6fe95b98bde894d7f49b5c7adab8f2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.49816372990608215}",,,,,,,,,,['positive'],positive,1
NCT02554773,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/fda-lifts-clinical-hold-fitusiran-hemophilia-therapy/', 'title': 'FDA Lifts Clinical Hold on Fitusiran, an Investigational...', 'source': 'Hemophilia News Today', 'date': 'Dec 20, 2017', 'snippet': 'The U.S. Food and Drug Administration (FDA) has lifted the hold on clinical \nstudies with fitusiran, an investigational therapy for...', 'thumbnail': 'https://serpapi.com/searches/6722d9a8f3622a724e9bebd6/images/0004fe532cfeee0906fd6c5b7e95d7e5f9e8d17d87dc93e6424a834e87f0622c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.914143443107605}",,,,,,,,,,['neutral'],neutral,1
NCT01765244,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332223004006', 'title': 'Successful restoration of corneal surface integrity with a tissue-engineered allogeneic implant in severe keratitis patients', 'source': 'ScienceDirect.com', 'date': 'Mar 28, 2023', 'snippet': 'Our findings suggest that the surgical application of this allogeneic \nanterior human corneal substitute is feasible and safe, showing partial \nefficacy.', 'thumbnail': 'https://serpapi.com/searches/6722d9bae335ec07aa0c5ce8/images/72ab58adb5be61fe99a57341af827f0ccca87bb69fa14d148819b8490b92ce1b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7509590983390808}",,,,,,,,,,['positive'],positive,1
NCT00094458,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0904492', 'title': ""Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease"", 'source': 'The New England Journal of Medicine', 'date': 'Jul 20, 2017', 'snippet': 'In this randomized, double-blind trial, we evaluated the efficacy of \ninfliximab monotherapy, azathioprine monotherapy, and the two drugs \ncombined in 508...', 'thumbnail': 'https://serpapi.com/searches/6722d9cc6aa364e94d034246/images/f9f60fe7672cdf31a3e2097b4aa359a00a42a5ea6a4dbc0186d012dbdd7d5b98.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9141035676002502}",,,,,,,,,,['neutral'],neutral,1
NCT02570672,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.718942/full', 'title': 'A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': '1Department of Medical Education, Weill Cornell Medicine-Qatar, Al-Rayyan, \nQatar; 2Inflammation Research Network and Snyder Institute for Chronic \nDiseases,...', 'thumbnail': 'https://serpapi.com/searches/6722da0d9062f8d4f3792a90/images/4acc26bcbcd954ecbd54a2453a91682411303784d135c31407ee6662b93573ae.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8297540545463562}",,,,,,,,,,['neutral'],neutral,1
NCT03761810,"{'position': 1, 'link': 'https://www.dermatologytimes.com/view/twyneo-receives-fda-approval-for-acne', 'title': 'Twyneo Receives FDA Approval for Acne', 'source': 'Dermatology Times', 'date': 'Jul 27, 2021', 'snippet': 'Twyneo, a tretinoin and benzoyl peroxide cream, has been approved by the \nFDA for the treatment of acne vulgaris in patients 9 years and...', 'thumbnail': 'https://serpapi.com/searches/6722d7efe9b691ed2477641d/images/ff14ecb8b35d78d26ccb48128a33854fc621535b38b2d6472e4312d2c3abf890.png', 'sentiment': 'neutral', 'sentiment_prob': 0.640620231628418}","{'position': 2, 'link': 'https://www.empr.com/home/news/galderma-announces-launch-of-twyneo-cream-for-acne-vulgaris/', 'title': 'Galderma Announces Launch of Twyneo Cream for Acne Vulgaris', 'source': 'Medical Professionals Reference', 'date': 'Mar 25, 2022', 'snippet': 'Galderma has announced the US launch of Twyneo (tretinoin 0.1% and benzoyl \nperoxide 3%) cream for the topical treatment of acne vulgaris in patients 9 \nyears of...', 'thumbnail': 'https://serpapi.com/searches/6722d7efe9b691ed2477641d/images/ff14ecb8b35d78d2f2a80d631eaf0839757658d6cef3bcb8a4e6d4932628d51c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8534439206123352}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04805983,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/parkinsons-clinical-trial-testing-alx-001-dmt-starting-soon/', 'title': 'Parkinson’s clinical trial of ALX-001 DMT to start by month’s end', 'source': ""Parkinson's News Today"", 'date': 'Mar 7, 2024', 'snippet': 'Allyx Therapeutics said it will begin a clinical trial by the end of the \nmonth to test its lead candidate ALX-001, a disease-modifying therapy for...', 'thumbnail': 'https://serpapi.com/searches/6722d830167793922c3be51a/images/cc914b556cde9d3db807289d5e3867a26391b4395c1127825e409cccd647b703.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9142948985099792}",,,,,,,,,,['neutral'],neutral,1
NCT04509674,"{'position': 1, 'link': 'https://www.newswise.com/articles/sglt2-inhibitor-empagliflozin-is-shown-to-be-safe-and-effective-for-treating-patients-who-have-suffered-a-heart-attack', 'title': 'SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe | Newswise', 'source': 'Newswise', 'date': 'Sep 1, 2024', 'snippet': 'The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and \ncan therefore be given safely and effectively to patients when they...', 'thumbnail': 'https://serpapi.com/searches/6722d8c8c76a3a6c4ef8dc65/images/7b181b30418474b7a31438e273c216e5ee35758b71816d3c3d630da01a755845.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6182878613471985}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2314051', 'title': 'Empagliflozin after Acute Myocardial Infarction', 'source': 'The New England Journal of Medicine', 'date': 'Apr 6, 2024', 'snippet': 'Empagliflozin improves cardiovascular outcomes in patients with heart \nfailure, patients with type 2 diabetes who are at high cardiovascular...', 'thumbnail': 'https://serpapi.com/searches/6722d8c8c76a3a6c4ef8dc65/images/7b181b30418474b706f836a95193b8addf0310ce5e68f10b194d8740885d9e5f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5914516448974609}","{'position': 3, 'link': 'https://www.news-medical.net/news/20240901/New-study-confirms-safety-of-SGLT2-inhibitors-after-acute-myocardial-infarction.aspx', 'title': 'New study confirms safety of SGLT2 inhibitors after acute myocardial infarction', 'source': 'News-Medical', 'date': 'Sep 1, 2024', 'snippet': 'The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and \ncan therefore be given safely and effectively to patients when they are \nhospitalized...', 'thumbnail': 'https://serpapi.com/searches/6722d8c8c76a3a6c4ef8dc65/images/7b181b30418474b768402c228992a980124409be4274c0291495820a68e6bfb4.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5745395421981812}",,,,,,,,"['positive', 'neutral', 'positive']",positive,1
NCT04725175,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/03/14/ms-myelin-restoring-therapy-pipe-307-safe-healthy-adults-clinical-trial/', 'title': 'PIPE-307, MS Therapy to Restore Myelin, Found Safe in Healthy Adults', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 14, 2022', 'snippet': 'A Phase 1 clinical trial in 70 healthy adults found safety and tolerability \nat varying doses of PIPE-307; new study in patients possible.', 'thumbnail': 'https://serpapi.com/searches/6722d8cd21e77b4fba2e1688/images/36d5538ac4a5e6b1a48d54238132a3efa0a334acd6c4ad2f92bae6232639fb7a.png', 'sentiment': 'positive', 'sentiment_prob': 0.6085591316223145}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/03/29/fda-clears-trial-pipe-307-myelin-restoring-therapy-patients-relapsing-remitting-multiple-sclerosis/', 'title': 'Trial Cleared for PIPE-307, Potential RRMS Myelin Restoration Therapy', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 29, 2022', 'snippet': ""The US Food and Drug Administration (FDA) has cleared a Phase 1b/2a trial \nof PIPE-307, Pipeline Therapeutics' investigational myelin-restoring \ntreatment."", 'thumbnail': 'https://serpapi.com/searches/6722d8cd21e77b4fba2e1688/images/36d5538ac4a5e6b1264fdd6b805066b11d7c7f7cea25f0f6eb6351e9565d5ba1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8590291142463684}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT03053466,"{'position': 1, 'link': 'https://immuno-oncologynews.com/cbt-501-genolimzumab/', 'title': 'Immuno-oncology Therapy CBT-501 Sics Immune Cells on Cancer', 'source': 'Immuno-Oncology News', 'date': 'Dec 20, 2017', 'snippet': ""Read about CBT Pharmaceutical's immuno-oncology therapy CBT-501, which \nworks by teaching immune cells to go after solid tumors."", 'thumbnail': 'https://serpapi.com/searches/6722d90e5ed3cab1ee1c0b2a/images/1a8a9bacaf67fae0d9950eb517c3e77d72c4fe3e16f5597bb937728e111f2324.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8868026733398438}",,,,,,,,,,['neutral'],neutral,1
NCT02828020,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1813049', 'title': 'Ubrogepant for the Treatment of Migraine', 'source': 'The New England Journal of Medicine', 'date': 'Dec 4, 2019', 'snippet': 'Ubrogepant is an oral, small-molecule calcitonin gene–related peptide \nreceptor antagonist for acute migraine treatment.', 'thumbnail': 'https://serpapi.com/searches/6722daf413e5d8d03563fd97/images/ee3724f6a182a3f2e544cdb3c14404e4715a111f048124c52bfa9ebba38a42f5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8721967935562134}",,,,,,,,,,['neutral'],neutral,1
NCT00510068,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1009290', 'title': 'Everolimus for Advanced Pancreatic Neuroendocrine Tumors', 'source': 'The New England Journal of Medicine', 'date': 'Apr 30, 2018', 'snippet': 'Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has \nshown antitumor activity in patients with advanced pancreatic \nneuroendocrine...', 'thumbnail': 'https://serpapi.com/searches/6722db2689055e43b766b55b/images/8a8693e4a3533b00a11ab742d29d949857ea52475dd00516b3c2c28c4eff6bb3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8966723084449768}",,,,,,,,,,['neutral'],neutral,1
NCT01844505,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1709684', 'title': 'Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 11, 2017', 'snippet': 'Nivolumab combined with ipilimumab resulted in longer progression-free \nsurvival and a higher objective response rate than ipilimumab alone in a \nphase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/6722db2d2fab620d6b1e388b/images/f914252b7a637ee82c3d0c904516f04b6278c59edd3ad8a4df833fc819c203b2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5171077251434326}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1910836', 'title': 'Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma', 'source': 'The New England Journal of Medicine', 'date': 'Oct 11, 2019', 'snippet': 'Nivolumab plus ipilimumab or nivolumab alone resulted in longer \nprogression-free and overall survival than ipilimumab alone in a trial...', 'thumbnail': 'https://serpapi.com/searches/6722db2d2fab620d6b1e388b/images/f914252b7a637ee8349e3028d435414e10f62570a431be64476ecebe6a23663f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8075810074806213}","{'position': 3, 'link': 'https://melanomanewstoday.com/2017/04/06/opdivo-yervoy-combo-improved-survival-advanced-melanoma-phase-3-trial/', 'title': 'Opdivo, Yervoy Combo Improved Survival in Advanced Melanoma Phase 3 Trial', 'source': 'Melanoma News Today', 'date': 'Apr 6, 2017', 'snippet': 'Opdivo (nivolumab) in combination with Yervoy (ipilimumab), as well as \nOpdivo alone, outperformed Yervoy monotherapy in terms of overall survival \nin a Phase 3...', 'thumbnail': 'https://serpapi.com/searches/6722db2d2fab620d6b1e388b/images/f914252b7a637ee8b81671a6011009df1fda2eef00ffbe1de0c57b16669b8a8a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5838354229927063}","{'position': 4, 'link': 'https://melanomanewstoday.com/2016/10/20/keytruda-pembrolizumab-plus-yervoy-ipilimumab-seen-as-safe-effective-for-advanced-melanoma-in-study/', 'title': 'Advanced Melanomas Seen to Respond to Keytruda-Yervoy Combo in Study', 'source': 'Melanoma News Today', 'date': 'Oct 20, 2016', 'snippet': 'Data from a Phase 1/2 study found a Keytruda-Yervoy combination to have \npotent anti-tumor activity and acceptable toxicity in advanced...', 'thumbnail': 'https://serpapi.com/searches/6722db2d2fab620d6b1e388b/images/f914252b7a637ee8775772e20b00989a962495fbaf907f762bee5fd3623a09d0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.84476637840271}",,,,,,,"['neutral', 'neutral', 'positive', 'neutral']",neutral,1
NCT04173065,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/vk2809-treatment-reduces-nash-related-liver-fat-fibrosis-phase-2b-trial/', 'title': 'In NASH, VK2809 treatment reduces liver fat, fibrosis: Phase 2b trial', 'source': 'Liver Disease News', 'date': 'Jun 10, 2024', 'snippet': 'VK2809 outperformed a placebo at reducing liver fat content and fibrosis in \nNASH patients after up to a year of treatment.', 'thumbnail': 'https://serpapi.com/searches/6722db7796a329d9498ff49e/images/99673de35188292a313c4cde5673ec54f40f0e467d7ece36558941d44abc32e3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5632349252700806}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20230516005532/en/Ligand%E2%80%99s-Partner-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2b-VOYAGE-Study-of-VK2809-in-Patients-with-Biopsy-Confirmed-Non-Alcoholic-Steatohepatitis-NASH', 'title': 'Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)', 'source': 'Business Wire', 'date': 'May 16, 2023', 'snippet': 'Ligand is entitled to receive a $10 million milestone payment upon \ninitiation of a Phase 3 clinical trial as well as royalties of 3.5% to...', 'thumbnail': 'https://serpapi.com/searches/6722db7796a329d9498ff49e/images/99673de35188292a6feaabe292f1bcfbdd2d6266bf57ebf2d273ff1798670592.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5859358310699463}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02549040,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222012574', 'title': 'State-of-the-art cerium nanoparticles as promising agents against human viral infections', 'source': 'ScienceDirect.com', 'date': 'Oct 15, 2022', 'snippet': 'Cerium nanoparticles have unique chemical and physical properties that make \nthem particularly promising for viral infections.', 'thumbnail': 'https://serpapi.com/searches/6722db869872170750981911/images/192aff09fccd82a8b392349251fd8257738c6ff57e7a53d061ea18dbc82b5c0f.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8233255743980408}",,,,,,,,,,['positive'],positive,1
NCT02970019,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/phase-2-trial-is-recruiting-people-with-early-parkinsons-to-test-k0706/', 'title': 'Phase 2 Clinical Trial Recruiting People with Early Parkinson’s to Explore Experimental K0706', 'source': ""Parkinson's News Today"", 'date': 'Sep 12, 2019', 'snippet': ""SPARC is conducting a Phase 2 clinical study to evaluate the safety and \neffectiveness of its oral therapy K0706 for early Parkinson's..."", 'thumbnail': 'https://serpapi.com/searches/6722dc1ac76a3a6c930170e1/images/347101c13091b548389682e0552a8be501bff6ef74bc9d3dd7881a70999a86a1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9327069520950317}",,,,,,,,,,['neutral'],neutral,1
NCT04394689,"{'position': 1, 'link': 'https://www.bioworld.com/articles/700687-patent-update-georgia-tech-develops-wax-microneedle-drug-delivery-patches', 'title': 'Patent update: Georgia Tech develops wax microneedle drug delivery patches', 'source': 'BioWorld MedTech', 'date': 'Sep 5, 2023', 'snippet': 'Researchers at the Georgia Institute of Technology (Georgia Tech) in \nAtlanta have developed melting microneedle patches comprising a drug \ndissolved or...', 'thumbnail': 'https://serpapi.com/searches/6722dc25b57db86eba98fb06/images/8a65a422ddcbe5a1f5f042eff55a6ca5e7c5ca71312d3d703b110b8cad4c9492.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9256421327590942}",,,,,,,,,,['neutral'],neutral,1
NCT02614066,"{'position': 1, 'link': 'https://www.onclive.com/view/dr-bezerra-on-the-real-world-efficacy-of-brexu-cel-in-b-all', 'title': 'Dr Bezerra on the Real-World Efficacy of Brexu-Cel in B-ALL', 'source': 'OncLive', 'date': 'Jan 11, 2024', 'snippet': 'Evandro D. Bezerra, MD, discusses real-world outcomes associated with \nbrexucabtagene autoleucel in relapsed/refractory B-cell acute...', 'thumbnail': 'https://serpapi.com/searches/6722dc28fc40bfd05b71e136/images/b007e7350917b1326909260bb149a8e0149ac28dc76e3216da40ebc5bfd6e7f5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9344419836997986}",,,,,,,,,,['neutral'],neutral,1
NCT05414422,"{'position': 1, 'link': 'https://psychedelicalpha.com/news/atais-pcn-101-candidate-fails-to-meet-primary-endpoint-in-heavily-anticipated-phase-2a-trial', 'title': 'atai’s PCN-101 Candidate Fails to Meet Primary Endpoint in Heavily-Anticipated Phase 2a Trial', 'source': 'Psychedelic Alpha', 'date': 'Jan 6, 2023', 'snippet': 'Today, atai Life Sciences published a heavily anticipated press release \ndiscussing the high-level outcomes of its Phase 2a study of PCN-101...', 'thumbnail': 'https://serpapi.com/searches/6722dc6c7b05caaa903b6ac4/images/0caba1bde06a9849d4859aee2c42c1319813f463ec5712748334b43f27bde790.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5357847213745117}",,,,,,,,,,['neutral'],neutral,1
NCT02918318,"{'position': 1, 'link': 'https://www.koreabiomed.com/news/articleView.html?idxno=23305', 'title': 'Spravato faces crisis after back-to-back clinical trial failures in Japan and China', 'source': 'KBR', 'date': 'Feb 6, 2024', 'snippet': ""Janssen's antidepressant Spravato (esketamine) has failed to demonstrate \nefficacy in clinical trials in China following Japan, raising questions \nabout its..."", 'thumbnail': 'https://serpapi.com/searches/6722dc8c7e1d1f1827f6ab2c/images/169e930685a4c158452116153fa892818171f76ea8a1fae3f1fdd96bd65b6f13.png', 'sentiment': 'negative', 'sentiment_prob': 0.8149158954620361}",,,,,,,,,,['negative'],negative,0
NCT04432831,"{'position': 1, 'link': 'https://www.stocktitan.net/news/RHHBY/roche-s-vabysmo-improved-vision-in-underrepresented-populations-with-y3hygys486ou.html', 'title': 'Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study', 'source': 'Stock Titan', 'date': '2 weeks ago', 'snippet': 'Roche announced positive one-year results from the ELEVATUM study, \nevaluating Vabysmo® (faricimab) for diabetic macular edema (DME) in...', 'thumbnail': 'https://serpapi.com/searches/6722dc92a54d7e5ab852471a/images/339f67b270150f6c49588edb657a9a2f20c57663ff7ccb7fbe15e6bfb994f179.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7804692983627319}","{'position': 2, 'link': 'https://www.globenewswire.com/news-release/2024/07/30/2920702/0/en/European-Commission-approves-Roche-s-Vabysmo-for-treatment-of-retinal-vein-occlusion-RVO.html', 'title': 'European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)', 'source': 'GlobeNewswire', 'date': 'Jul 30, 2024', 'snippet': 'Approval is based on data from two Phase III studies in branch and central \nretinal vein occlusion (RVO) showing early and sustained vision...', 'thumbnail': 'https://serpapi.com/searches/6722dc92a54d7e5ab852471a/images/339f67b270150f6cb094c64f404d452b56065f65ed2344eb32a6c10e826dc2d0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6009171605110168}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT00887328,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1813046', 'title': 'Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke', 'source': 'The New England Journal of Medicine', 'date': 'May 8, 2019', 'snippet': 'The time to initiate intravenous thrombolysis for acute ischemic stroke is \ngenerally limited to within 4.5 hours after the onset of symptoms.', 'thumbnail': 'https://serpapi.com/searches/6722dcd672e5c43d37cf3d95/images/92e20b1abc4d6d2ddba593316438e680369b72dccbc173fdf00eeefb4fc887cd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8518437743186951}",,,,,,,,,,['neutral'],neutral,1
NCT04000594,"{'position': 1, 'link': 'https://huntingtonsdiseasenews.com/news/generation-hd1-trial-fails-to-demonstrate-benefits-tominersen/', 'title': 'GENERATION HD1 Trial Fails to Show Benefits of Tominersen', 'source': ""Huntington's Disease News"", 'date': 'May 6, 2021', 'snippet': ""Treatment with tominersen failed to show evidence of clinical benefit in \nadults with Huntington's disease during the Phase 3 trial..."", 'thumbnail': 'https://serpapi.com/searches/6722dd1098fad63805a90f3f/images/a63e7f6b7e4cab068c9af1874379de31b7c8c5f0206fd21a87ceb50f8b2cad4c.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7655267715454102}",,,,,,,,,,['negative'],negative,0
NCT01227655,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/analyst-comment/ean-2024-opicapone-efficacy-real-world-clinical-practice/', 'title': 'EAN 2024: Opicapone demonstrates efficacy in real-world clinical practice', 'source': 'Clinical Trials Arena', 'date': 'Jul 5, 2024', 'snippet': 'At EAN, Dr Maria-Rosario Luquin presented the results of the 12-month, \nobservational, retrospective OPTIMO study.', 'thumbnail': 'https://serpapi.com/searches/6722dd619872170750981ad9/images/4e0f530c5824ecd1e30d2e6fe60d14c5752488420cd6bfcf201c859a277a538a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5519387125968933}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/new-data-support-effectiveness-of-ongentys-for-parkinsons-off-periods/', 'title': 'New Data Support Effectiveness of Ongentys for Parkinson’s ‘Off’ Periods', 'source': ""Parkinson's News Today"", 'date': 'Oct 6, 2020', 'snippet': ""Ongentys (opicapone) can reduce the extent of “off” periods in people with \nParkinson's disease being treated with levodopa, new clinical trial data \nshow."", 'thumbnail': 'https://serpapi.com/searches/6722dd619872170750981ad9/images/4e0f530c5824ecd1ab715a12ab925a9eaf8354e177730001794b83a37ec405bf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8502773642539978}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT01072266,"{'position': 1, 'link': 'https://www.nature.com/articles/srep11749', 'title': 'INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models', 'source': 'Nature', 'date': 'Jul 3, 2015', 'snippet': 'The objective of this study was to determine the efficacy of a novel, \nhighly potent, orally-bioavailable c-MET inhibitor, INC280, in blocking \ncell phenotypes...', 'thumbnail': 'https://serpapi.com/searches/6722ddcec0028e6e4e04f9a3/images/2d5adff31dc77be5c043977e23e36c8d52fe11d804cdd6d78a095bc37d52ee45.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8308812379837036}",,,,,,,,,,['neutral'],neutral,1
NCT01636622,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-022-00341-0', 'title': 'BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study | npj Precision Oncology', 'source': 'Nature', 'date': 'Feb 18, 2023', 'snippet': 'We performed a pooled analysis of four phase one studies evaluating the \nsafety and efficacy of vemurafenib monotherapy and vemurafenib combined \nwith targeted...', 'thumbnail': 'https://serpapi.com/searches/6722de43a32436a16214aab2/images/21ee6dace00080128be9cc62912362013d6da5a6044fcdc80b75d81059317f99.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9065907597541809}",,,,,,,,,,['neutral'],neutral,1
NCT04018755,"{'position': 1, 'link': 'https://sanfilipponews.com/news/individualized-trials-sanfilippo-anti-inflammatory-therapies-sought/', 'title': 'Individualized trials of Sanfilippo anti-inflammatory therapies sought', 'source': 'Sanfilippo Syndrome News', 'date': 'Jul 6, 2023', 'snippet': 'Researchers are calling for individualized clinical trials that would test \nthe effects of anti-inflammatory therapies for Sanfilippo syndrome and \nrelated...', 'thumbnail': 'https://serpapi.com/searches/6722de66749783416cf3e947/images/b17f50999a62ec7bc4d4e88b1d2f5951d7c3f5037186927e8ec4757a3bc34ebe.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9001984596252441}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/abs/10.1111/jnc.15891', 'title': 'Biomarkers for predicting disease course in Sanfilippo syndrome: An urgent unmet need in childhood-onset dementia', 'source': 'Wiley Online Library', 'date': 'Jun 26, 2023', 'snippet': 'In this review, we discuss the development of biomarker assays for \nSanfilippo based on the neuropathological pathways known to change leading \ninto symptom...', 'thumbnail': 'https://serpapi.com/searches/6722de66749783416cf3e947/images/b17f50999a62ec7bdbe70ccec1ec23926f845b2d0a8805a3f8dd90106e37ef1d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8570588827133179}","{'position': 3, 'link': 'https://sanfilipponews.com/news/anakinra-approved-kineret-for-inflammatory-disorders-in-phase-2-3-trial-for-sanfilippo/', 'title': 'Anakinra, Approved as Anti-inflammatory, in Phase 2/3 Trial for...', 'source': 'Sanfilippo Syndrome News', 'date': 'Jun 25, 2020', 'snippet': 'An ongoing clinical trial is investigating an approved anti-inflammatory \ncompound anakinra, sold under the brand name Kineret, as a potential \ntreatment for...', 'thumbnail': 'https://serpapi.com/searches/6722de66749783416cf3e947/images/b17f50999a62ec7b9d6dcc7b719dfe56f55b4c3661dd579c96f465591282b1f8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8642048835754395}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02472795,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/cenerimod-shows-promise-sle-phase-2b-study-phase-3-begins/', 'title': 'Cenerimod Shows Promise for SLE in Phase 2b Study; Phase 3 Begins...', 'source': 'Lupus News Today', 'date': 'Dec 19, 2022', 'snippet': 'Treatment with cenerimod showed promising trends toward reducing disease \nactivity in systemic lupus erythematosus (SLE), especially in people with \nmore severe...', 'thumbnail': 'https://serpapi.com/searches/6722df05d78a985ac5d5a0be/images/2827d11b3e855ef3c2a04db21d66ca18f633e36e4f175f2c51e8189bbca85d95.png', 'sentiment': 'positive', 'sentiment_prob': 0.7075773477554321}",,,,,,,,,,['positive'],positive,1
NCT02267655,"{'position': 1, 'link': 'https://copdnewstoday.com/news/pulmonary-hypertension-associated-with-chronic-obstructive-pulmonary-disease-investigational-therapy-inopulse-shows-positive-results-bellerophon-says/', 'title': 'PH-COPD Investigational Therapy INOpulse Shows Positive Phase 2 Results, Bellerophon Says', 'source': 'COPD News Today', 'date': 'Sep 12, 2017', 'snippet': 'INOpulse as a therapy for pulmonary hypertension associated with chronic \nobstructive pulmonary disease (PH-COPD) showed promising results in a Phase \n2 clinical...', 'thumbnail': 'https://serpapi.com/searches/6722df1088bcdeacaef27e57/images/649a1cda862d08576a0f86cc4e3905b0f3c9bb3decc099e03e5b40cb515892a5.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5401460528373718}",,,,,,,,,,['positive'],positive,1
NCT05603754,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01330-w', 'title': 'Osteoarthritis: pathogenic signaling pathways and therapeutic targets', 'source': 'Nature', 'date': 'Feb 3, 2023', 'snippet': 'Osteoarthritis (OA) is a chronic degenerative joint disorder that leads to \ndisability and affects more than 500 million population worldwide...', 'thumbnail': 'https://serpapi.com/searches/6722df2fee46823ed9bdd89e/images/74b64f9d8801b26554ec345b43e76128a9681ed2f92a285e2eaaf5c4b5453089.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7383952736854553}",,,,,,,,,,['negative'],negative,0
NCT05558410,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2209870', 'title': 'Selective Inhibition of NaV1.8 with VX-548 for Acute Pain', 'source': 'The New England Journal of Medicine', 'date': 'Aug 2, 2023', 'snippet': 'The NaV1.8 voltage-gated sodium channel, expressed in peripheral \nnociceptive neurons, plays a role in transmitting nociceptive signals.', 'thumbnail': 'https://serpapi.com/searches/6722df41b4e8d6ba085f4a84/images/4e886f38544a67a6febecf07ad71698344192a6f53a798c228d572879bcb81e7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8272075057029724}",,,,,,,,,,['neutral'],neutral,1
NCT01170897,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-62470-9', 'title': 'Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials', 'source': 'Nature', 'date': 'May 21, 2024', 'snippet': 'Pre-clinical and clinical studies have shown that PEGPH20 depletes \nintratumoral hyaluronic acid (HA), which is linked to high interstitial...', 'thumbnail': 'https://serpapi.com/searches/6722df4f59f9112fb149f3f5/images/d29e71f900c627dba4a0fecb0a6d89d35421b943e8c0a1ae66731ec830803953.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8239365816116333}",,,,,,,,,,['neutral'],neutral,1
NCT01568866,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30578-8/fulltext', 'title': 'Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial', 'source': 'The Lancet', 'date': 'Aug 23, 2017', 'snippet': 'The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome \ninhibitors in patients with relapsed or refractory multiple...', 'thumbnail': 'https://serpapi.com/searches/6722df76cf32e0739b20642e/images/646ceb3b67fe1432b4fce22a2c46ed1e6d17ff765766bfcfbe0df2a44df3d487.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9209470152854919}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/kyprolis-improved-survival-confirmed-latest-results/', 'title': 'Long-term Data Confirm Kyprolis Survival Benefit in Relapsed...', 'source': 'Myeloma Research News', 'date': 'Sep 6, 2017', 'snippet': 'New long-term data from the ENDEAVOR trial shows that Kyprolis plus \ndexamethasone extends the median survival by 9 months over Velcade in...', 'thumbnail': 'https://serpapi.com/searches/6722df76cf32e0739b20642e/images/646ceb3b67fe143280d50ea85b4ccc8e35747653259ab267303c181e9e8b0117.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5090252161026001}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02540993,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2025845', 'title': 'Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Oct 23, 2020', 'snippet': 'Finerenone, a nonsteroidal, selective mineralocorticoid receptor \nantagonist, reduced albuminuria in short-term trials involving patients \nwith chronic kidney...', 'thumbnail': 'https://serpapi.com/searches/6722df948b84c41a795d32f2/images/3e085d2cae9e87839eada3a55350dfaedbb4958574d3c013a4912e0c56d6b162.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8269692063331604}","{'position': 2, 'link': 'https://www.nature.com/articles/s41598-024-51938-3', 'title': 'A comparative study of clinical trial and real-world data in patients with diabetic kidney disease', 'source': 'Nature', 'date': 'Jan 19, 2024', 'snippet': 'A growing body of research is focusing on real-world data (RWD) to \nsupplement or replace randomized controlled trials (RCTs).', 'thumbnail': 'https://serpapi.com/searches/6722df948b84c41a795d32f2/images/3e085d2cae9e8783d125dd84910d83fc731f4fe562b0aa2d508eeb3da23dd0df.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9166094660758972}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04197479,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02603-1', 'title': 'Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial', 'source': 'Nature', 'date': 'Oct 16, 2023', 'snippet': 'Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no \napproved treatment. MAESTRO-NAFLD-1 was a 52-week randomized,...', 'thumbnail': 'https://serpapi.com/searches/6722dfb5059cafd210267ffa/images/6f8a01af386ad7322b64bbbee61e0780b96a0caf3ac5915b986302481c001c41.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5281579494476318}","{'position': 2, 'link': 'https://www.hepmag.com/article/resmetirom-improves-nash-liver-fibrosis-phase-iii-trial', 'title': 'Resmetirom Improves NASH and Liver Fibrosis in Phase III Trial', 'source': 'www.hepmag.com', 'date': 'Jun 23, 2023', 'snippet': 'The findings could potentially lead to the first FDA approval of a \ntreatment for fatty liver disease.', 'thumbnail': 'https://serpapi.com/searches/6722dfb5059cafd210267ffa/images/6f8a01af386ad732f0145beeb03c2a802f76116ab4b2ee972f87872cc7e90035.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6385818123817444}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02654132,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1805762', 'title': 'Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma', 'source': 'The New England Journal of Medicine', 'date': 'Nov 7, 2018', 'snippet': 'The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and \ndexamethasone has been shown to be effective in patients with relapsed or \nrefractory...', 'thumbnail': 'https://serpapi.com/searches/6722e0660664c9fe85c69022/images/1926f0ff383e62b7db9e7dec921b54b11af34dc4241b3b095b1bd7b80293b098.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7223803997039795}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/fda-approves-empliciti-combination-relapsed-refractory-multiple-myeloma/', 'title': 'FDA Approves Empliciti Combination for Relapsed or Refractory Multiple Myeloma', 'source': 'Myeloma Research News', 'date': 'Nov 12, 2018', 'snippet': ""The U.S. Food and Drug Administration has approved Bristol-Myers Squibb's \nEmpliciti (elotuzumab), in combination with Pomalyst..."", 'thumbnail': 'https://serpapi.com/searches/6722e0660664c9fe85c69022/images/1926f0ff383e62b70600c702fa8b66d182e5d3d9d9a29a60867ca3bbf634b612.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7444874048233032}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00414128,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/fatigue-persists-at-high-levels-in-some-aav-patients-despite-treatment-study-shows/', 'title': 'In Some AAV Patients, Fatigue Seen to Persist at High Levels Despite Treatment', 'source': 'ANCA Vasculitis News', 'date': 'Jul 11, 2019', 'snippet': 'A small subgroup can continue to have high fatigue levels, according to a \nstudy in 150 newly diagnosed patients who took part in clinical trials.', 'thumbnail': 'https://serpapi.com/searches/6722e08abe80133871049248/images/7d2e1163da4b5d6518f95f05297640cc1c9e81106899012faeb2dc2e8a54bb65.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6142919659614563}",,,,,,,,,,['neutral'],neutral,1
NCT03285178,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/cyclerion-suspends-development-of-olinciguat-for-sickle-cell-disease/', 'title': 'Cyclerion Suspends Development of Olinciguat for Sickle Cell Disease', 'source': 'Sickle Cell Disease News', 'date': 'Oct 20, 2020', 'snippet': ""Cyclerion Therapeutics' decisions about olinciguat was based top-line \nresults of the Phase 2 clinical trial STRONG-SCD (NCT03285178)."", 'thumbnail': 'https://serpapi.com/searches/6722e0a475f974affaee69b6/images/7715a7656ae9d8698f039a62a73a921aaf4958057338a71f69e9ef645a30c9c7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.53346186876297}",,,,,,,,,,['neutral'],neutral,1
NCT03624127,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.16740', 'title': 'Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double‐blind, placebo‐controlled, global phase 3 trial - Imafuku - 2023 - The Journal of Der', 'source': 'Wiley Online Library', 'date': 'Mar 7, 2023', 'snippet': 'Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 (TYK2) \ninhibitor that demonstrated superior efficacy versus placebo and apremilast \nin a...', 'thumbnail': 'https://serpapi.com/searches/6722e0c8c0028e6e9896d3e0/images/f85a4a03d9e79cd4d4437f6eee2aed97d461c927365fd4c9e42d205694050bf8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8855554461479187}","{'position': 2, 'link': 'https://www.thepharmaletter.com/biotechnology/2-9-billion-in-sales-forecast-for-bms-sotyktu-by-2029', 'title': '$2.9 billion in sales forecast for BMS’ Sotyktu by 2029', 'source': 'The Pharma Letter', 'date': 'May 11, 2023', 'snippet': ""$2.9 billion in sales forecast for BMS' Sotyktu by 2029. Biotechnology. 11 \nMay 2023. bristol_myers_squibb_shutterstock_large."", 'thumbnail': 'https://serpapi.com/searches/6722e0c8c0028e6e9896d3e0/images/f85a4a03d9e79cd403eb03602d49f55454a75de03670e117498703dc472d040b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7873889207839966}","{'position': 3, 'link': 'https://www.empr.com/home/news/fda-approves-sotyktu-for-moderate-to-severe-plaque-psoriasis/', 'title': 'FDA Approves Sotyktu for Moderate to Severe Plaque Psoriasis', 'source': 'Medical Professionals Reference', 'date': 'Sep 12, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Sotyktu™ \n(deucravacitinib) for the treatment of adults with moderate to severe \nplaque...', 'thumbnail': 'https://serpapi.com/searches/6722e0c8c0028e6e9896d3e0/images/f85a4a03d9e79cd49211eb76522881f6544bde73318abcc2117857fa74681451.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7778393626213074}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02748837,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-022-16564-x', 'title': 'Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial', 'source': 'Nature', 'date': 'Jul 19, 2022', 'snippet': 'Currently, ERY974, a humanized IgG4 bispecific T cell-redirecting antibody \nrecognizing glypican-3 and CD3, is in phase I clinical trials.', 'thumbnail': 'https://serpapi.com/searches/6722e0ef1397baa002ea04a4/images/7fc891f2e9aef903fd6248d05040069df274a203763002d0a15e2fd3ca6458c0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9179657697677612}","{'position': 2, 'link': 'https://www.nature.com/articles/nrd.2017.237', 'title': 'Bispecific antibody directs T cells to solid tumours', 'source': 'Nature', 'date': 'Nov 17, 2017', 'snippet': 'A new paper from Chugai Pharmaceutical uses a bispecific antibody, ERY974, \nto direct T cells to non-immunogenic tumours using expression of glypican 3 \n(GPC3)...', 'thumbnail': 'https://serpapi.com/searches/6722e0ef1397baa002ea04a4/images/7fc891f2e9aef903352c6860394b76300c2bd0c721cbf23aa34cee6d1baae5fe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.891222357749939}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04798586,"{'position': 1, 'link': 'https://www.oncnursingnews.com/view/elranatamab-induces-responses-in-patients-with-relapsed-refractory-multiple-myeloma-following-bcma-directed-therapy', 'title': 'Elranatamab Induces Responses in Patients With Relapsed/Refractory Multiple Myeloma Following BCMA-Directed Therapy', 'source': 'Oncology Nursing News', 'date': 'Jun 15, 2023', 'snippet': 'A pooled analyses of the phase 1 MagnetisMM-1 (NCT03269136), phase 1 \nMagnetisMM-2 (NCT04798586), phase 2 MagnetisMM-3 (NCT04649359),...', 'thumbnail': 'https://serpapi.com/searches/6722e0f4e335ec0759a45c49/images/272cbe2353d0d1c55da85a412a232cffc9bb29e91b0e8edabbf3d12e51374691.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9129993319511414}",,,,,,,,,,['neutral'],neutral,1
NCT02048488,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-019-0503-9', 'title': 'A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas', 'source': 'Nature', 'date': 'Jun 20, 2019', 'snippet': 'Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers \nin non-small-cell lung cancer (NSCLC). TSR-011 is a dual ALK and...', 'thumbnail': 'https://serpapi.com/searches/6722e1078e13c9aa82df7831/images/68c39e289a132ceb009108602496fc6c9e172707b5ace7f8d7e91caaf688c106.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8019287586212158}",,,,,,,,,,['neutral'],neutral,1
NCT02574923,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-49902-8', 'title': 'Inflammatory mediators drive neuroinflammation in autism spectrum disorder and cerebral palsy', 'source': 'Nature', 'date': 'Dec 18, 2023', 'snippet': 'In this study, we analyzed the composition of cerebrospinal fluid (CSF) to \nuncover the inflammatory mediators driving the neuro-immune system in ASD \nand CP...', 'thumbnail': 'https://serpapi.com/searches/6722e12548b9f773a3a650af/images/bb300bce3647adfe16f1de1092b84b48970c03ba15bb645756c26bb0198e06fd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7191134691238403}",,,,,,,,,,['neutral'],neutral,1
NCT04394351,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/dupilumab-demonstrates-benefit-in-pediatric-eosinophilic-esophagitis-trial/', 'title': 'Dupilumab Demonstrates Benefit in Pediatric Eosinophilic Esophagitis Trial', 'source': 'Medical Professionals Reference', 'date': 'Jul 14, 2022', 'snippet': 'A phase 3 study evaluating dupilumab in patients 1 to 11 years of age with \neosinophilic esophagitis demonstrated histological remission.', 'thumbnail': 'https://serpapi.com/searches/6722e13a0664c9fe85c69123/images/d7152ec12e37fe3473591c7a182c2805b1c8da5bfcae438978f7f434f3ba1181.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.653374969959259}",,,,,,,,,,['neutral'],neutral,1
NCT03864614,"{'position': 1, 'link': 'https://www.nature.com/articles/s41386-023-01751-9', 'title': 'Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study', 'source': 'Nature', 'date': 'Oct 24, 2023', 'snippet': 'These results demonstrate that zuranolone+ADT provided more rapid \nimprovement in depressive symptoms compared with placebo+ADT in patients \nwith MDD.', 'thumbnail': 'https://serpapi.com/searches/6722e14723a4b50ac51e40c7/images/51ab92105393e1434f28102b26f7db78673f54bbc496c05383acece0f63e098a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5984835028648376}","{'position': 2, 'link': 'https://www.psychiatrist.com/jcp/zuranolone-vs-placebo-in-mdd/', 'title': 'Zuranolone in Major Depressive Disorder: Results From MOUNTAIN—A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial', 'source': 'Psychiatrist.com', 'date': 'Feb 20, 2023', 'snippet': 'This phase 3 RCT found significant improvement in depressive symptoms with \nzuranolone beginning at day 3 of treatment.', 'thumbnail': 'https://serpapi.com/searches/6722e14723a4b50ac51e40c7/images/51ab92105393e1435cbddf1fafbe614004a1a81907b4a55f69c74b1a658542fa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7433127164840698}","{'position': 3, 'link': 'https://www.psychiatrist.com/jcp/safety-efficacy-initial-and-repeat-zuranolone-for-major-depressive-disorder/', 'title': 'Long-Term Safety and Efficacy of Zuranolone in MDD', 'source': 'Psychiatrist.com', 'date': 'Dec 27, 2023', 'snippet': 'Most patients with MDD achieved response after 14 days of zuranolone \ntreatment. For patients who responded to their first treatment,...', 'thumbnail': 'https://serpapi.com/searches/6722e14723a4b50ac51e40c7/images/51ab92105393e143d69bea676a03fb46112c5b9cfcad2517cd9f99dfa10c4d96.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5939822196960449}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT01312961,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1304048', 'title': 'Dupilumab in Persistent Asthma with Elevated Eosinophil Levels', 'source': 'The New England Journal of Medicine', 'date': 'May 21, 2013', 'snippet': 'The objective of this study was to assess the efficacy and safety of \ndupilumab in adults with persistent, moderate-to-severe asthma and elevated \neosinophil...', 'thumbnail': 'https://serpapi.com/searches/6722e148ca6f0c0e9b6a270c/images/eb57dc6ceb9d91422ce10a8ae3da4ba1b8aa1423cefc0339e7ceda4cce93398e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8558856248855591}",,,,,,,,,,['neutral'],neutral,1
NCT02970968,"{'position': 1, 'link': 'https://www.renalandurologynews.com/news/fda-denies-approval-of-tradipitant-for-gastroparesis/', 'title': 'FDA Denies Approval of Tradipitant for Gastroparesis', 'source': 'Renal and Urology News', 'date': '1 month ago', 'snippet': 'The Food and Drug Administration (FDA) has issued a Complete Response \nLetter (CRL) to Vanda Pharmaceuticals regarding the New Drug Application \n(NDA) for...', 'thumbnail': 'https://serpapi.com/searches/6722e14e272a878897de1056/images/d43b34c2b7e27ade2afc01291d6e0e7eaef0f46cab6404374c5a47d9688304ac.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5645280480384827}","{'position': 2, 'link': 'https://ehlersdanlosnews.com/news/eds-mutations-evident-gastroparesis-patients/', 'title': 'EDS and Its Mutations Unusually Evident in People With Gastroparesis', 'source': 'Ehlers-Danlos News', 'date': 'Sep 26, 2022', 'snippet': 'Ehlers-Danlos syndrome and its known mutations were found to occur more \noften than expected in people enrolled in two gastroparesis trials.', 'thumbnail': 'https://serpapi.com/searches/6722e14e272a878897de1056/images/d43b34c2b7e27ade8faf3997abe67338dae9e7cb0129d4d36e7158f2fbc55799.png', 'sentiment': 'negative', 'sentiment_prob': 0.5144873261451721}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT03470545,"{'position': 1, 'link': 'https://www.empr.com/home/news/camzyos-approved-for-obstructive-hypertrophic-cardiomyopathy/', 'title': 'Camzyos Approved for Obstructive Hypertrophic Cardiomyopathy', 'source': 'Medical Professionals Reference', 'date': 'Apr 29, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Camzyos™ (mavacamten) \nfor the treatment of adults with symptomatic New York Heart...', 'thumbnail': 'https://serpapi.com/searches/6722e16b7c1712784f80ce64/images/081b4e353225663b9d02fb99ad008bcbcd856281ef93c5e302458f094ffb0c0a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8542414307594299}",,,,,,,,,,['neutral'],neutral,1
NCT02485899,"{'position': 1, 'link': 'https://battendiseasenews.com/news/brineura-cerliponase-alfa-approved-in-europe-to-treat-cln2-type-of-batten-disease/', 'title': 'Batten Disease Therapy, Brineura, Approved in Europe', 'source': 'Batten Disease News', 'date': 'Jun 2, 2017', 'snippet': 'Read about Brineura (cerliponase alfa), by BioMarin, being approved in \nEurope to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease.', 'thumbnail': 'https://serpapi.com/searches/6722e170361fd48e0c194881/images/6284d02fd81d693f3659aa4d9943cb919eef39fd522786fc5b660ba09920b980.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8003149032592773}",,,,,,,,,,['neutral'],neutral,1
NCT04000165,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/agios-launches-phase-2-3-trial-rise-up-mitapivat/', 'title': 'Agios Launches Phase 2/3 Trial, RISE UP, of Mitapivat for SCD', 'source': 'Sickle Cell Disease News', 'date': 'Jan 4, 2022', 'snippet': 'Agios began the trial to test its investigational therapy mitapivat \n(AG-348) in people with sickle cell disease. It is not yet recruiting.', 'thumbnail': 'https://serpapi.com/searches/6722e176d78a985a6b5ae0f7/images/01ff39197298bb9999e99ce59488d4078347b15f0ff59536cd351238117ad455.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9094328880310059}",,,,,,,,,,['neutral'],neutral,1
NCT02643420,"{'position': 1, 'link': 'https://www.empr.com/home/news/rolvedon-approved-for-chemotherapy-induced-neutropenia/', 'title': 'Rolvedon Approved for Chemotherapy-Induced Neutropenia - MPR', 'source': 'Medical Professionals Reference', 'date': 'Sep 12, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Rolvedon™ \n(eflapegrastim-xnst) to decrease the incidence of infection, as manifested \nby...', 'thumbnail': 'https://serpapi.com/searches/6722e185b691a72daec180a3/images/1cbd7b54fc5f33693b5f9b54981358fc158886e3d22411a3f539e0273f6e14f4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8527393937110901}",,,,,,,,,,['neutral'],neutral,1
NCT02426359,"{'position': 1, 'link': 'http://www.biospectator.com/view/news_print.php?varAtcId=7298', 'title': ""Qurient, presented the P2a results for atopic dermatitis candidate 'Q301' at the AAD 2019"", 'source': '바이오스펙테이터', 'date': 'Mar 15, 2019', 'snippet': 'Qurient presented the P2a trial results for Q301, a topical treatment for \natopic dermatitis currently under Phase 2b, on the international stage.', 'thumbnail': 'https://serpapi.com/searches/6722e1a32fab620d6b1e3e9d/images/cfc387201ea0fe52b0c77cfb89549d18bd4f4b4b513d0895bb591cca147315cc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9321069121360779}",,,,,,,,,,['neutral'],neutral,1
NCT03406780,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/dmd-three-years-cap-1002-still-showing-stabilized-arm-heart-function/', 'title': 'In DMD, three years of CAP-1002 still showing stabilized arm, heart function', 'source': 'Muscular Dystrophy News', 'date': 'Jun 6, 2024', 'snippet': 'Topline data from the Phase 3 HOPE-3 trial, which is testing CAP-1002 in \nDMD patients with impaired muscle function, is expected this year.', 'thumbnail': 'https://serpapi.com/searches/6722e1ae8db376c3e953fd26/images/ea7ef43a783fb9c7f3b38d9a8bdc502d3f23b1ae6c5037f36378181f6cc11c48.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8677300810813904}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/news/capricor-therapeutics-long-term-data-positive/', 'title': 'Capricor’s cell therapy shows three year benefit in DMD patients', 'source': 'Clinical Trials Arena', 'date': 'Jul 1, 2024', 'snippet': 'Capricor Therapeutics has announced its deramiocel cell therapy continues \nto be safe and effective after three years for Duchenne muscular dystrophy \n(DMD).', 'thumbnail': 'https://serpapi.com/searches/6722e1ae8db376c3e953fd26/images/ea7ef43a783fb9c7b6eee7bb5ee95bb9cab2764867761d24fe19b796bc9bad81.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8001108765602112}","{'position': 3, 'link': 'https://www.cgtlive.com/view/duchenne-muscular-dystrophy-cell-therapy-cap-1002-demonstrates-improvements-lvef', 'title': 'Duchenne Muscular Dystrophy Cell Therapy CAP-1002 Demonstrates Improvements in LVEF', 'source': 'CGTLive®', 'date': 'Jul 6, 2023', 'snippet': ""In terms of safety, Capricor Therapeutics' CAP-1002 was reported to be \nwell-tolerated."", 'thumbnail': 'https://serpapi.com/searches/6722e1ae8db376c3e953fd26/images/ea7ef43a783fb9c7e6869a8767b8f83e7a5285ab56fadadbc9c6a5b91143363b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7191162109375}",,,,,,,,"['neutral', 'positive', 'positive']",positive,1
NCT03872453,"{'position': 1, 'link': 'https://www.empr.com/home/news/zavzpret-nasal-spray-approved-for-acute-treatment-of-migraine/', 'title': 'Zavzpret Nasal Spray Approved for Acute Treatment of Migraine', 'source': 'Medical Professionals Reference', 'date': 'Mar 10, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Zavzpret™ (zavegepant) \nnasal spray, a calcitonin gene-related peptide (CGRP) receptor...', 'thumbnail': 'https://serpapi.com/searches/6722e1d0a9210bcfd56b54fa/images/1dbac2e012798c312eb394a70eaf5ec1e8a84d8e2a9d79e0159912c2bc6b5ab1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6946619749069214}","{'position': 2, 'link': 'https://www.empr.com/home/news/zavzpret-nasal-spray-now-available-for-acute-treatment-of-migraine/', 'title': 'Zavzpret Nasal Spray Now Available for Acute Treatment of Migraine', 'source': 'Medical Professionals Reference', 'date': 'Jul 6, 2023', 'snippet': 'Zavzpret (zavegepant) nasal spray is now available for the acute treatment \nof migraine with or without aura in adults.', 'thumbnail': 'https://serpapi.com/searches/6722e1d0a9210bcfd56b54fa/images/1dbac2e012798c313c426b6d8a8f4ee2fcec06b57a00879d825a2f12014f335c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8405698537826538}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00630812,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/inhaled-mannitol-mucociliary-clearance/', 'title': 'Bronchitol (Mannitol)', 'source': 'Cystic Fibrosis News Today', 'date': 'Mar 22, 2021', 'snippet': 'Bronchitol (mannitol), by Pharmaxis, is a dry powder inhalation treatment \nfor cystic fibrosis, approved in the U.S., EU,...', 'thumbnail': 'https://serpapi.com/searches/6722e2015ed3cab1a3eac4c3/images/c934317d6a94a65bd4b702fcb1e2417b23ff873a26487dc479024440838986aa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9064784049987793}",,,,,,,,,,['neutral'],neutral,1
NCT03556358,"{'position': 1, 'link': 'https://www.oncozine.com/samsung-bioepis-and-merck-launch-trastuzumab-biosimilar-in-the-united-states/', 'title': 'Samsung Bioepis and Merck Launch Trastuzumab Biosimilar in the United States.', 'source': ""Onco'Zine"", 'date': 'Apr 15, 2020', 'snippet': 'Samsung Bioepis, a joint venture of Samsung Biologics and Biogen, and Merck \n& Co (MSD) have lauched a trastuzumab biosimilar...', 'thumbnail': 'https://serpapi.com/searches/6722e21bb6a79c89e80be94d/images/31dbe1f123b5e00775fe966473cf0164c06a3ecd4254dbea308189753772b483.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7702255845069885}",,,,,,,,,,['neutral'],neutral,1
NCT03941093,"{'position': 1, 'link': 'https://www.onclive.com/view/pamrevlumab-fails-to-provide-os-benefit-in-pancreatic-cancer', 'title': 'Pamrevlumab Fails to Provide OS Benefit in Pancreatic Cancer', 'source': 'OncLive', 'date': 'Jul 31, 2024', 'snippet': 'Two late-stage trials investigating the efficacy and safety of pamrevlumab \nin pancreatic cancer failed to meet their primary end points of...', 'thumbnail': 'https://serpapi.com/searches/6722e2131adaf44caa61d51f/images/51dff4a4deb667503ea256df7bbc2a00da7c791fa5c860c2739a7748c559f267.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7233176231384277}",,,,,,,,,,['negative'],negative,0
NCT01026142,"{'position': 1, 'link': 'https://www.researchgate.net/figure/APHINITY-is-a-prospective-phase-III-study-evaluating-the-role-of-trastuzumab-plus_fig2_230714315', 'title': 'Figure 2. APHINITY is a prospective phase III study evaluating the role...', 'source': 'ResearchGate', 'date': 'Feb 11, 2018', 'snippet': 'Download scientific diagram | APHINITY is a prospective phase III study \nevaluating the role of trastuzumab plus pertuzumab combination versus \ntrastuzumab...', 'thumbnail': 'https://serpapi.com/searches/6722e2cd861b9dc3d5d8c9e5/images/8de0c3bdef9323424edfffb42218712985bed303bd340f2e136fa2b8db93f6cf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9367532730102539}",,,,,,,,,,['neutral'],neutral,1
NCT05020249,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/bimekizumab-UCB4940', 'title': 'Bimekizumab (Bimzelx®)', 'source': 'UCB', 'date': 'Oct 16, 2018', 'snippet': 'Ankylosing Spondylitis, A Multicenter Study to Evaluate the Efficacy and \nSafety of Different Doses of Bimekizumab in Subjects With Active \nAnkylosing...', 'thumbnail': 'https://serpapi.com/searches/6722e31ce30abc864c264649/images/eab8bd70dc1267d52ee1cf72ff89e5b57679bf378fdb6d3745291318b5c4266a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8456552028656006}",,,,,,,,,,['neutral'],neutral,1
NCT01938443,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-019-0452-3', 'title': 'A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours', 'source': 'Nature', 'date': 'Apr 17, 2019', 'snippet': 'Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater \nanticancer effect than FAK monotherapy. This dose-finding phase...', 'thumbnail': 'https://serpapi.com/searches/6722e36498d8de1868aaa9c1/images/5117133d8d159f633a0b2bf84883929920261da4003dc2b9492a4f65775a5dbb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8846467733383179}",,,,,,,,,,['neutral'],neutral,1
NCT00441337,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332218364102', 'title': 'PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer', 'source': 'ScienceDirect.com', 'date': 'Dec 3, 2018', 'snippet': 'We present a comprehensive knowledge of immune therapy through PD-1/PD-L1 \nblockade that argues how efficient the process is, in colon cancer \ncarcinoma.', 'thumbnail': 'https://serpapi.com/searches/6722e371fc40bfd05b71e72b/images/da6a7dc48cc373e20e69863324a651f292cb6363dfda6fcd464b384df75bdb9f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5837924480438232}",,,,,,,,,,['neutral'],neutral,1
NCT04553068,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/vaginal-ph-modulator-misses-primary-endpoint-in-sti-clinical-trial/', 'title': 'Vaginal pH Modulator Misses Primary Endpoint in STI Clinical Trial', 'source': 'Medical Professionals Reference', 'date': 'Oct 12, 2022', 'snippet': 'Topline results were announced from a phase 3 trial evaluating EVO100 for \nthe prevention of urogenital Chlamydia trachomatis (CT) and Neisseria \ngonorrhoeae (GC...', 'thumbnail': 'https://serpapi.com/searches/6722e37b8e13c9aa82df7a54/images/affb3a5afd5500b11258bf9ad48eca39ba1191e474f9201aefc886fe682b870d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.85575932264328}",,,,,,,,,,['neutral'],neutral,1
NCT02550652,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/gazyva-lupus-nephritis-treatment-boosts-standard-care/', 'title': 'Gazyva, lupus nephritis treatment, boosts standard care in Phase 2 trial', 'source': 'Lupus News Today', 'date': 'Nov 27, 2023', 'snippet': 'Adding Gazyva (obinutuzumab) to standard-of-care therapy for two years \nreduced the risk of treatment failure, diminished kidney function or death \nby 60% in...', 'thumbnail': 'https://serpapi.com/searches/6722e39c7d533e6b3c105406/images/0aae74cac3066f00cedf95ed126cd98c36be5f47fc5a6d29d70211a41c443f82.png', 'sentiment': 'positive', 'sentiment_prob': 0.5715087652206421}",,,,,,,,,,['positive'],positive,1
NCT01969838,"{'position': 1, 'link': 'https://www.pharmacytimes.com/view/lead-investigator-provides-insight-into-fda-approval-of-momelotinib-for-myelofibrosis', 'title': 'Lead Investigator Provides Insight Into FDA Approval of Momelotinib for Myelofibrosis', 'source': 'Pharmacy Times', 'date': 'Sep 29, 2023', 'snippet': 'The FDA recently approved momelotinib to treat myelofibrosis in patients \nwith anemia based on data from the MOMENTUM and SIMPLIFY-1 trials.', 'thumbnail': 'https://serpapi.com/searches/6722e3d4acf7f8291ac533bd/images/934e093614527ab0e18ff5827f3d6035359b6de0c7ddc7f367727fdb715a404c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8080514073371887}","{'position': 2, 'link': 'https://www.hematologyadvisor.com/cch/ojjaara-for-intermediate-or-high-risk-myelofibrosis/', 'title': 'Ojjaara for Intermediate or High-Risk Myelofibrosis', 'source': 'Hematology Advisor', 'date': 'Sep 18, 2023', 'snippet': 'In September 2023, the US Food and Drug Administration (FDA) approved \nOjjaara (momelotinib; GlaxoSmithKline), a kinase inhibitor,...', 'thumbnail': 'https://serpapi.com/searches/6722e3d4acf7f8291ac533bd/images/934e093614527ab06f7d201555cdc98c4825778b81c2fb0db4508789281d69c7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8874692916870117}","{'position': 3, 'link': 'https://www.targetedonc.com/view/momelotinib-improves-anemia-in-jak-inhibitor-naive-myelofibrosis', 'title': 'Momelotinib Improves Anemia in JAK Inhibitor-Naive Myelofibrosis', 'source': 'Targeted Oncology', 'date': 'May 9, 2024', 'snippet': 'Compared with ruxolitinib, momelotinib improved mild, moderate, and severe \nanemia in patients with myelofibrosis who were naive to JAK...', 'thumbnail': 'https://serpapi.com/searches/6722e3d4acf7f8291ac533bd/images/934e093614527ab00a82780ccaefabd08022c42176982a71357dce5cb34938b8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7391460537910461}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04782388,"{'position': 1, 'link': 'https://www.researchgate.net/publication/378467857_Pharmacokinetics_of_Staccato_alprazolam_in_healthy_adult_participants_in_two_phase_1_studies_An_open-label_smoker_study_and_a_randomized_placebo-controlled_ethnobridging_study', 'title': '(PDF) Pharmacokinetics of Staccato alprazolam in healthy adult participants in two phase 1 studies: An open‐label smoker study and a randomized, placebo‐controlled ethnobridging study', 'source': 'ResearchGate', 'date': 'Jun 26, 2024', 'snippet': 'PDF | Objective Staccato® alprazolam is a single‐use, drug–device \ncombination delivering alprazolam to the deep lung that is being \nevaluated...', 'thumbnail': 'https://serpapi.com/searches/6722e40f39e232ed6dec16b3/images/60858720fa8a9816a56f35234801599c489f1fd63564c9312431fb62dcb63439.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8950238227844238}",,,,,,,,,,['neutral'],neutral,1
NCT00537368,"{'position': 1, 'link': 'https://www.nature.com/articles/s42003-020-01441-y', 'title': 'Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy', 'source': 'Nature', 'date': 'Nov 27, 2020', 'snippet': 'Immunotherapies targeting the PD-1/PD-L1 axis are now a mainstay in the \nclinical management of multiple cancer types, however,...', 'thumbnail': 'https://serpapi.com/searches/6722e4585bb6a2400c71ddf9/images/fc730225a2db4334a0af2080ef9a2dfed477ae8d0191f57277a849fbe2ad5a78.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.832412600517273}",,,,,,,,,,['neutral'],neutral,1
NCT04751136,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/dmcn.15517', 'title': 'State‐of‐the‐art therapy for Down syndrome - Lorenzon - 2023 - Developmental Medicine & Child Neurology', 'source': 'Wiley Online Library', 'date': 'Jan 24, 2023', 'snippet': 'This review covers five key areas: (1) What has happened in the last 10 \nyears? (2) From symptomatic to disease-modifying therapy:...', 'thumbnail': 'https://serpapi.com/searches/6722e45dba11426bb27b36f4/images/7e8883b0f95e4f123ed2d26f45cbf688237ff19fda3e2eae04c34ef43c50bd3c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9450766444206238}",,,,,,,,,,['neutral'],neutral,1
NCT03781167,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/vyalev-severe-parkinsons-motor-symptoms-available-canada/', 'title': ""Vyalev, for severe Parkinson's motor symptoms, arrives in Canada"", 'source': ""Parkinson's News Today"", 'date': 'Feb 12, 2024', 'snippet': 'The continuous, infusion pump therapy is for advanced disease and severe \nfluctuations no longer controlled by oral levodopa/carbidopa.', 'thumbnail': 'https://serpapi.com/searches/6722e48e6a5dd373ed509849/images/0f83474cef5d4edf20c172323779c0addf8ec8c80d8cac960d7e43e700b4a19d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8271430730819702}",,,,,,,,,,['neutral'],neutral,1
NCT02301624,"{'position': 1, 'link': 'https://myastheniagravisnews.com/news/generalized-mg-symptoms-may-worsen-severely-after-discontinuing-soliris-treatment-case-study-reports/', 'title': 'MG Symptoms Worsen Severely After Stopping Soliris, Case Study Finds', 'source': 'Myasthenia Gravis News', 'date': 'Oct 23, 2020', 'snippet': 'A Japanese man with generalized myasthenia gravis (gMG) experienced a \nsevere worsening of symptoms after stopping Soliris treatment,...', 'thumbnail': 'https://serpapi.com/searches/6722e49948b9f773a3a65498/images/897f5dad8878a6b87bf1b536db177d73795f4a904d92f2fd246e5ec69b1b20e9.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6118899583816528}",,,,,,,,,,['negative'],negative,0
NCT00450814,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-020-0828-7', 'title': 'Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma', 'source': 'Nature', 'date': 'Apr 23, 2020', 'snippet': 'Oncolytic virus therapy leads to immunogenic death of virus-infected tumor \ncells and this has been shown in preclinical models to enhance...', 'thumbnail': 'https://serpapi.com/searches/6722e5d848c42962967b42f2/images/6cefe4818eeb3150c56788e095fec51ab51dd464c2e586baa78c60ff45786ebd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6280909180641174}",,,,,,,,,,['neutral'],neutral,1
NCT04945772,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-positive-topline-results-from-phase-2b-restore-trial-of-mco-010-for-the-treatment-of-retinitis-pigmentosa-301785351.html', 'title': 'Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa', 'source': 'PR Newswire', 'date': 'Mar 30, 2023', 'snippet': 'Results showed vision function improvements after treatment with MCO-010 \nconsistent with previous studies as well as a favorable safety profile.', 'thumbnail': 'https://serpapi.com/searches/6722e5de667ec536558ed5af/images/775b2e30d75ef75632774459070c954759360452bfa7c06ced4b7c755e6be39f.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8123757243156433}","{'position': 2, 'link': 'https://www.cgtlive.com/view/advanced-retinitis-pigmentosa-optogenetic-therapy-demonstrates-vision-function-improvements', 'title': 'Advanced Retinitis Pigmentosa Optogenetic Therapy Demonstrates Vision Function Improvements', 'source': 'CGTLive®', 'date': 'Apr 29, 2023', 'snippet': 'MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) \noptogenetic therapy intended to treat patients advanced retinitis \npigmentosa (RP)...', 'thumbnail': 'https://serpapi.com/searches/6722e5de667ec536558ed5af/images/775b2e30d75ef7560856bbcf2df67f6239fc082d069c4a2584aabfb241d443cf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8376827836036682}","{'position': 3, 'link': 'https://www.clinicaltrialsarena.com/news/nanoscopes-gene-therapy-nabs-phase-ii-win-in-retinitis-pigmentosa/', 'title': 'Nanoscope’s gene therapy nabs Phase II win in retinitis pigmentosa', 'source': 'Clinical Trials Arena', 'date': 'Mar 30, 2023', 'snippet': 'MCO-010 met its primary endpoint in a small, sham-controlled Phase IIb \ntrial targeting retinitis pigmentosa.', 'thumbnail': 'https://serpapi.com/searches/6722e5de667ec536558ed5af/images/775b2e30d75ef756e973e71733a72fcb7bb197e909aeb073884e4913fd6b4a64.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6853397488594055}","{'position': 4, 'link': 'https://www.pharmaceutical-technology.com/analyst-comment/aao-2024-nanoscope-therapeutics-vision-rp-patients/', 'title': 'AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients', 'source': 'Pharmaceutical Technology', 'date': '1 week ago', 'snippet': ""This trial investigated the potential of Nanoscope Therapeutics' MCO-010 to \nrestore vision in patients with retinitis pigmentosa (RP)."", 'thumbnail': 'https://serpapi.com/searches/6722e5de667ec536558ed5af/images/775b2e30d75ef756e17236cc548848b4984611ff762826c8262875439557c3b7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6891240477561951}","{'position': 5, 'link': 'https://www.morningstar.com/news/pr-newswire/20241021da36166/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration', 'title': 'Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration', 'source': 'Morningstar', 'date': '1 week ago', 'snippet': 'PR Newswire. DALLAS, Oct. 21, 2024. DALLAS, Oct. 21, 2024 /PRNewswire/ -- \nNanoscope Therapeutics Inc., a late-stage clinical biotechnology...', 'thumbnail': 'https://serpapi.com/searches/6722e5de667ec536558ed5af/images/775b2e30d75ef756f7e4ebd60fe6aa4461f575c457bd21ec92b7b2158e7453aa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9169276356697083}","{'position': 6, 'link': 'https://www.cgtlive.com/view/ramos-platt-looking-forward-gene-therapy-growth', 'title': 'Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth', 'source': 'CGTLive®', 'date': 'Jul 9, 2024', 'snippet': 'The clinical professor of neurology and pediatrics at Keck School of \nMedicine of USC also discussed current strategies with gene therapy...', 'thumbnail': 'https://serpapi.com/searches/6722e5de667ec536558ed5af/images/775b2e30d75ef75620e7cdb0b34e102ad8740876881209da3d373448188eb9fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6632293462753296}","{'position': 7, 'link': 'https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentation-of-key-results-from-phase-2b-restore-trial-of-mco-010-for-the-treatment-of-retinitis-pigmentosa-at-the-arvo-annual-meeting-301809764.html', 'title': 'Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting', 'source': 'PR Newswire', 'date': 'Apr 27, 2023', 'snippet': '100% (18/18) MCO-010 patients experienced a clinically meaningful \nimprovement in vision-guided mobility (MLYMT), near-field object...', 'thumbnail': 'https://serpapi.com/searches/6722e5de667ec536558ed5af/images/775b2e30d75ef7560fc140e7416cc745e2bcf57874e8989c4f9d2b3a214ee9f0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5359002351760864}","{'position': 8, 'link': 'https://www.modernretina.com/view/asrs-2019-street-team-netan-choudhry-md-frcsc-dabo', 'title': 'ASRS 2019 Street Team: Netan Choudhry, MD, FRCSC, DABO', 'source': 'Modern Retina', 'date': 'Jul 27, 2019', 'snippet': 'Netan Choudhry, MD, FRCSC, DABO, shares the take-home message from the \npresentation he delivered at the 2019 meeting of the American Society of \nRetina...', 'thumbnail': 'https://serpapi.com/searches/6722e5de667ec536558ed5af/images/775b2e30d75ef756bc66663a9da00d363afbb6bcb359e039d08119aa68bc2f12.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9289470911026001}","{'position': 9, 'link': 'https://www.cgtlive.com/view/abca4-retinopathy-gene-therapy-demonstrates-efficacy-in-preclinical-study', 'title': 'ABCA4 Retinopathy Gene Therapy Demonstrates Efficacy in Preclinical Study', 'source': 'CGTLive®', 'date': 'Mar 17, 2023', 'snippet': ""Intergalactic Therapeutics' IG-002, an investigational nonviral gene \ntherapy intended to treat retinopathies associated with mutations in the \nABCA4 gene,"", 'thumbnail': 'https://serpapi.com/searches/6722e5de667ec536558ed5af/images/775b2e30d75ef7566cff1c025101a4ee77dac563835e76c2a033150260d3b75b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8845294117927551}","{'position': 10, 'link': 'https://www.prnewswire.com/news-releases/nanoscope-therapeutics-receives-fast-track-designation-by-the-fda-for-mco-010-for-the-treatment-of-stargardt-disease-301733054.html', 'title': 'Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt Disease', 'source': 'PR Newswire', 'date': 'Jan 30, 2023', 'snippet': 'PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology \ncompany developing gene therapies for retinal degenerative...', 'thumbnail': 'https://serpapi.com/searches/6722e5de667ec536558ed5af/images/775b2e30d75ef75608a95f9ec322d3a3145299b63190ca86847bcf48711d6c82.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.840072512626648}","['positive', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02762812,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2018/03/19/infliximab-biosimilar-for-ankylosing-spondylitis-approved-in-russia/', 'title': 'Ankylosing Spondylitis Therapy Infliximab Biosimilar Approved in Russia', 'source': 'Ankylosing Spondylitis News', 'date': 'Mar 19, 2018', 'snippet': ""Russian regulators have approved the Russian company BIOCAD's infliximab \nbiosimilar as a treatment for rheumatoid arthritis and ankylosing \nspondylitis."", 'thumbnail': 'https://serpapi.com/searches/6722e5da1adaf44caa61d9a8/images/d7e84d5994ec8e940589e9a9e7d38660fffa06b324ee0d4f8d0fcbd254258423.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7923818826675415}",,,,,,,,,,['neutral'],neutral,1
NCT02876679,"{'position': 1, 'link': 'https://www.nature.com/articles/s41409-021-01341-7', 'title': 'The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001- O009) | Bone Marrow Transplantation', 'source': 'Nature', 'date': 'Jun 24, 2021', 'snippet': 'The use of PTCY for GVHD prophylaxis resulted in similar outcomes to those \nseen with ATG for patients who underwent an FB2 RIC regimen allo-HCT with a \n10/10...', 'thumbnail': 'https://serpapi.com/searches/6722e5f3cb33d0c31b4b19fe/images/c386ad28b1efd177c29daba39c16f6b18662f4c27d5a684a2ce1893d43229cd2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8731558918952942}",,,,,,,,,,['neutral'],neutral,1
NCT03347422,"{'position': 1, 'link': 'https://coldagglutininnews.com/news/long-term-enjaymo-treatment-yields-sustained-benefits-trial-data/', 'title': 'Long-term Enjaymo treatment yields sustained benefits: Trial data', 'source': 'Cold Agglutinin Disease News', 'date': 'Jul 25, 2024', 'snippet': 'Long-term treatment with Enjaymo continued to lead to clinical benefits for \nadult CAD patients in a Phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/6722e6260be2f63ada2a1cb3/images/6be90f46c66d38db8d5715071073e0b66a4976d9548ee7034408486503641aaf.png', 'sentiment': 'positive', 'sentiment_prob': 0.9203765988349915}","{'position': 2, 'link': 'https://coldagglutininnews.com/news/patients-enjaymo-immune-response-covid-19-vaccines/', 'title': 'Patients on Enjaymo show immune response to COVID-19 vaccines', 'source': 'Cold Agglutinin Disease News', 'date': 'Mar 14, 2024', 'snippet': 'People with CAD who were on Enjaymo during clinical trials produced \nprotective antibodies in response to COVID-19 vaccination, a study...', 'thumbnail': 'https://serpapi.com/searches/6722e6260be2f63ada2a1cb3/images/6be90f46c66d38db4e30d0a4ef7516c679bad03e683d3821ac7ad8a4dcfe8c21.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8503730893135071}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT03672175,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/zuranolone-vs-placebo-in-mdd/', 'title': 'Zuranolone in Major Depressive Disorder: Results From MOUNTAIN—A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial', 'source': 'Psychiatrist.com', 'date': 'Feb 20, 2023', 'snippet': 'This phase 3 RCT found significant improvement in depressive symptoms with \nzuranolone beginning at day 3 of treatment.', 'thumbnail': 'https://serpapi.com/searches/6722e63a48b9f773a3a656ae/images/b6ca9e6fa85b27b01d95f2593d83400df0bafd30d41867ebb1698f61fc64f256.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7433127164840698}",,,,,,,,,,['neutral'],neutral,1
NCT00065442,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1001294', 'title': 'Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jul 29, 2010', 'snippet': 'In this double-blind, placebo-controlled, multicenter phase 3 trial, we \nrandomly assigned 512 patients in a 2:1 ratio to receive either...', 'thumbnail': 'https://serpapi.com/searches/6722e6536273fbad0a9d29b0/images/804cfa7fcc4df796df360d99efaff6c30c129c85e25cbf5bbf94080ceb70a8d3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.884008526802063}",,,,,,,,,,['neutral'],neutral,1
NCT02394795,"{'position': 1, 'link': 'https://www.ncc.go.jp/en/information/press_release/0419/index.html', 'title': 'World-first confirmation of standard treatment for RAS wild-type colorectal cancer－Paper published in JAMA－', 'source': '国立がん研究センター', 'date': 'Apr 19, 2023', 'snippet': 'April 19, 2023. National Cancer Center Yokohama City University In \nJapanese. Highlights. A prospective clinical trial demonstrated the \nstatistically...', 'thumbnail': 'https://serpapi.com/searches/6722e6698de63c891833f99d/images/c581b2ad0f49ca8316245df75d5b3d1499deaad8cf7d05988702c767174cc27a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.903398871421814}","{'position': 2, 'link': 'https://www.cancerhealth.com/article/vectibix-combination-therapy-improves-survival-people-metastatic-colorectal-cancer', 'title': 'Vectibix Combination Therapy Improves Survival for People With Metastatic Colorectal Cancer', 'source': 'Cancer Health', 'date': 'Jul 28, 2022', 'snippet': 'People with left-sided tumors treated with Vectibix plus standard \nchemotherapy had an 18% lower risk of death.', 'thumbnail': 'https://serpapi.com/searches/6722e6698de63c891833f99d/images/c581b2ad0f49ca831ee73ecdcbb71d8999e2bc9e797c3d463e7003903a77ed2a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5767766237258911}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00326287,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/basilea-seeks-approval-of-intravenous-antibiotic-ceftobiprole/', 'title': 'Basilea Seeks Approval of Intravenous Antibiotic Ceftobiprole', 'source': 'Medical Professionals Reference', 'date': 'Aug 4, 2023', 'snippet': 'The New Drug Application (NDA) for ceftobiprole medocaril (ceftobiprole) \nhas been submitted for review to the Food and Drug Administration...', 'thumbnail': 'https://serpapi.com/searches/6722e66fa5e5024406b80459/images/7e03e0e197f5eb28d65d9f1c41be1208f35b78587b68c1963c2a88cdbc340ff2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8470795154571533}",,,,,,,,,,['neutral'],neutral,1
NCT05069623,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-46223-8', 'title': 'A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses', 'source': 'Nature', 'date': 'Nov 2, 2023', 'snippet': 'Throughout the COVID-19 pandemic, several variants of concern (VoC) of the \nsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have...', 'thumbnail': 'https://serpapi.com/searches/6722e4e0f59d00c60f7e5a57/images/b572a79e9e737f9221a36596e3f4b5b7327f27b11ed6ce0137a6d07228815b11.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8024792671203613}",,,,,,,,,,['neutral'],neutral,1
NCT04704869,"{'position': 1, 'link': 'https://first10em.com/cryostat-2/', 'title': 'CRYOSTAT-2: Empiric cryoprecipitate in traumatic massive hemorrhage', 'source': 'First10EM', 'date': 'Oct 16, 2023', 'snippet': 'A critical appraisal of the CRYOSTAT-2 study, looking at empiric \ncryoprecipitate in trauma patients with massive hemorrhage.', 'thumbnail': 'https://serpapi.com/searches/6722e4e24a4a1d0f98dc7087/images/17697474c7f19ad468ae52edd2bc372fe997791040db287250c5f255b4294bc2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.783839225769043}",,,,,,,,,,['neutral'],neutral,1
NCT01072175,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1210093', 'title': 'Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations', 'source': 'The New England Journal of Medicine', 'date': 'Sep 29, 2012', 'snippet': 'We conducted a phase 1 and 2 study to investigate the combination of the \nBRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with \nmetastatic...', 'thumbnail': 'https://serpapi.com/searches/6722e4eafda26d9833ac4dee/images/0231d2bf8152e869bd16c53e70333212038583c8f143f68201dc0ff90f43bac5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9338291883468628}",,,,,,,,,,['neutral'],neutral,1
NCT04307173,"{'position': 1, 'link': 'http://biospectator.com/view/news_view.php?varAtcId=11820', 'title': 'KoBioLabs’ Different Approach to Develop ‘Microbiome-based Drugs’', 'source': '바이오스펙테이터', 'date': 'Nov 18, 2020', 'snippet': ""KoBioLabs Inc. strives for the development of microbiome new drugs based on \n'Single strain of microorganisms or effective substance originated from \nthem'."", 'thumbnail': 'https://serpapi.com/searches/6722e4ee1397baa002ea08eb/images/af6b5add9fc77358e3ead784a75e7c8329292e8d3bff78b88d9d27732a346313.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7078294157981873}",,,,,,,,,,['neutral'],neutral,1
NCT06005402,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/cessation-trial-success-monoclonal-antibody-opioid-abuse/', 'title': 'Cessation to launch Phase IIa monoclonal antibody trial in opioid abuse', 'source': 'Clinical Trials Arena', 'date': 'Jun 20, 2024', 'snippet': 'In the Phase Ia trial, CSX-1004 was well tolerated with no serious adverse \nevents. Cessation is looking to initiate a Phase IIa trial.', 'thumbnail': 'https://serpapi.com/searches/6722e53d2da983cc9f603186/images/357eb2677f88c448cf3770b0d2c760a0f1bc1e825d7314b1244fc0214ab876fc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7092806100845337}",,,,,,,,,,['neutral'],neutral,1
NCT02979366,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-023-02430-8', 'title': 'Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma', 'source': 'Nature', 'date': 'Sep 19, 2023', 'snippet': 'Combination of NK cell-based immunotherapy with BH3-mimetics may further \nincrease killing of chemoresistant neuroblastoma, outlining a new treatment \nstrategy...', 'thumbnail': 'https://serpapi.com/searches/6722e5455235f67e9e040673/images/52ad03f73ac5341f1868b03cf8867bd64b5a8857b5065c6e2d036894de7c8c48.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8269267678260803}",,,,,,,,,,['neutral'],neutral,1
NCT03952806,"{'position': 1, 'link': 'https://alsnewstoday.com/news/als-therapy-verdiperstat-fails-healey-trial-efficacy-goals/', 'title': 'ALS Therapy Verdiperstat Fails to Meet Efficacy Goals in HEALEY Trial', 'source': 'ALS News Today', 'date': 'Oct 6, 2022', 'snippet': 'The ALS therapy verdiperstat failed to slow disease progression, improve \nsurvival, or meet other efficacy goals in the HEALEY platform...', 'thumbnail': 'https://serpapi.com/searches/6722e7098de63c88d27b720f/images/175823a4c4b8c606f49c4c3c0d3e9413c3b8a612c1c260e70f720ad67dba511e.png', 'sentiment': 'negative', 'sentiment_prob': 0.7811991572380066}",,,,,,,,,,['negative'],negative,0
NCT01807949,"{'position': 1, 'link': 'https://lungdiseasenews.com/2018/01/12/european-union-oks-orkambi-children-cf/', 'title': 'European Union OKs Orkambi Use for Children 6-11 Years Old With CF', 'source': 'Lung Disease News', 'date': 'Jan 12, 2018', 'snippet': 'EU grants extension of marketing authorization for Orkambi to include \nchildren aged 6 to 11 who have CF and two copies of the F508del...', 'thumbnail': 'https://serpapi.com/searches/6722e709e281ee018cee075e/images/726ef2eca94161520ef408ac810cd3665a9290eec936a4259601ba91971cca9a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7960894703865051}",,,,,,,,,,['neutral'],neutral,1
NCT02514772,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/granulomatosis-with-polyangiitis-and-microscopic-polyangiitis-patients-can-use-mabthera-biosimilar-rixathon-following-ec-approval/', 'title': 'EC Approves MabThera Biosimilar Rixathon for 2 AAV Disorders', 'source': 'ANCA Vasculitis News', 'date': 'Jul 14, 2017', 'snippet': ""The EC has approved the use and marketing of Sandoz's Mabthera biosimilar \ndrug Rixathon for the treatment of blood cancers and immunological..."", 'thumbnail': 'https://serpapi.com/searches/6722e7140e6db3f0ffff3c60/images/df35ad6012b44ad9b8fe933e97a30604126e1b0ccc81db6eaa03db9112c22761.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8589828014373779}",,,,,,,,,,['neutral'],neutral,1
NCT01365455,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1314258', 'title': 'Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials', 'source': 'The New England Journal of Medicine', 'date': 'Jul 9, 2014', 'snippet': 'In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response \nand Safety of Two Fixed Secukinumab Regimens in Psoriasis) and...', 'thumbnail': 'https://serpapi.com/searches/6722e74e69f8ec4c837178f1/images/15c55eee413b63816a67c7a2ee7c44d11b7226e6d5fbcf261b01a32205fc13ae.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9034740328788757}",,,,,,,,,,['neutral'],neutral,1
NCT04462536,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/STROKEAHA.122.042200', 'title': 'Infarcts in a New Territory: Insights From the ESCAPE-NA1 Trial | Stroke', 'source': 'American Heart Association Journals', 'date': 'Apr 21, 2023', 'snippet': 'Data are from ESCAPE-NA1 trial (Safety and Efficacy of Nerinetide [NA-1] in \nSubjects Undergoing Endovascular Thrombectomy for Stroke),...', 'thumbnail': 'https://serpapi.com/searches/6722e77a0664c9fe85c697ae/images/f54df08e472c0298f955c36805fca2a1bcfb68ab3d7df26bd6d75e78a00cced8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9402480125427246}",,,,,,,,,,['neutral'],neutral,1
NCT04720534,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2210645', 'title': 'Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk', 'source': 'The New England Journal of Medicine', 'date': 'Nov 5, 2022', 'snippet': 'Pemafibrate, a selective peroxisome proliferator–activated receptor α \nmodulator, reduces triglyceride levels and improves other lipid levels.', 'thumbnail': 'https://serpapi.com/searches/6722e799fc183dcdb20afe66/images/52f6ca4f31d89b456de48341382376bd6b42b78872e69614b8e4867c6fe15c8e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8284250497817993}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20221107006012/en/Arrowhead-Presents-New-Phase-2-Data-at-AHA-2022-on-Cardiometabolic-Pipeline', 'title': 'Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline', 'source': 'Business Wire', 'date': 'Nov 7, 2022', 'snippet': 'Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the \npresentation of new clinical data on its pipeline of investigational...', 'thumbnail': 'https://serpapi.com/searches/6722e799fc183dcdb20afe66/images/52f6ca4f31d89b45cfe5150235637c575a3dd8f8b92cda5fe7f7ff2bd7273630.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8771486878395081}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02544217,"{'position': 1, 'link': 'https://mitochondrialdiseasenews.com/2017/10/18/kh176-mitochondrial-disease-clinical-trial-healthy-men-tolerated/', 'title': 'KH176 Well-Tolerated in Healthy Men, Study Shows', 'source': 'Mitochondrial Disease News', 'date': 'Oct 18, 2017', 'snippet': 'Researchers report that KH176, under development for the treatment of \nmitochondrial disease, is well-tolerated when administered to healthy men.', 'thumbnail': 'https://serpapi.com/searches/6722e7ae9936889cf983a909/images/170020e3cd5ca71150c2177004075046774d673ca3bde5dca988949b5c258556.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7947092056274414}",,,,,,,,,,['positive'],positive,1
NCT04466891,"{'position': 1, 'link': 'https://www.onclive.com/view/zanidatamab-shows-durable-responses-with-longer-follow-up-in-pretreated-her2-biliary-tract-cancer', 'title': 'Zanidatamab Shows Durable Responses With Longer Follow-up in Pretreated HER2+ Biliary Tract Cancer', 'source': 'OncLive', 'date': 'Jun 2, 2024', 'snippet': 'Zanidatamab continued to show clinical benefit in previously treated \npatients with advanced, unresectable, or metastatic HER2-amplified...', 'thumbnail': 'https://serpapi.com/searches/6722e7d072f716bbac1760d2/images/e25bc28a7ccfb16b683ab7a675c2e1ef07f405e1d4c44823d68a612e32cded31.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5846796035766602}",,,,,,,,,,['neutral'],neutral,1
NCT00097591,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0706482', 'title': 'Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes', 'source': 'The New England Journal of Medicine', 'date': 'Feb 1, 2017', 'snippet': 'Prasugrel therapy was associated with significantly reduced rates of \nischemic events, including stent thrombosis, but with an increased risk of \nmajor bleeding,...', 'thumbnail': 'https://serpapi.com/searches/6722e83aa505f7f6768d38f4/images/b3464fa6a6c87187b7159fa2db6f919710501a910e8346c4526e3b1b5a3c78ee.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8359673619270325}",,,,,,,,,,['neutral'],neutral,1
NCT04142749,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-022-01119-3', 'title': 'Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)', 'source': 'Nature', 'date': 'Aug 13, 2022', 'snippet': 'Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become \nthe leading cause of liver disease worldwide.', 'thumbnail': 'https://serpapi.com/searches/6722e8d1d9c3e6fbd0fc12cd/images/988b694b2564fa9aa705508a8a1a887de903d66cc61e358c0c626f1a41f424ba.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6808437705039978}",,,,,,,,,,['neutral'],neutral,1
NCT04647383,"{'position': 1, 'link': 'https://www.empr.com/home/news/dayvigo-labeling-updated-with-data-on-use-in-patients-with-osa-copd/', 'title': 'Dayvigo Labeling Updated With Data on Use in Patients With OSA, COPD', 'source': 'Medical Professionals Reference', 'date': 'Apr 25, 2023', 'snippet': 'The prescribing information for Dayvigo (lemborexant) has been updated to \ninclude clinical trial data related to the use of the insomnia medication.', 'thumbnail': 'https://serpapi.com/searches/6722e9040664c9fe85c699a4/images/d78a65df1535fda414a66bf4c553ed5323238cd2f22c5bcb26591fd92f2a4109.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9325548410415649}",,,,,,,,,,['neutral'],neutral,1
NCT00925301,"{'position': 1, 'link': 'https://www.nature.com/articles/s41436-019-0451-z', 'title': 'Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study | Gen', 'source': 'Nature', 'date': 'Feb 6, 2019', 'snippet': 'Outcomes in patients with Fabry disease receiving migalastat during the \nphase 3 FACETS trial (NCT00925301) were evaluated by phenotype.', 'thumbnail': 'https://serpapi.com/searches/6722e92a2bab90dba32722e1/images/8292e8a91d2816131dae3b5654e227119d727fffa1ccb11fa4fb7501e8fd0e9e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9129406213760376}","{'position': 2, 'link': 'https://fabrydiseasenews.com/galafold-migalastat/', 'title': 'Galafold (migalastat) for Fabry disease', 'source': 'Fabry Disease News', 'date': 'Mar 6, 2024', 'snippet': 'Galafold is an approved oral therapy for adults with Fabry disease and \namenable mutations that helps to clear cells of toxic fatty...', 'thumbnail': 'https://serpapi.com/searches/6722e92a2bab90dba32722e1/images/8292e8a91d281613ea7faa30955fe23d930f8f57e11215a4fc348facccdac123.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7855511903762817}","{'position': 3, 'link': 'https://www.nature.com/articles/s41436-020-00968-z', 'title': 'for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease', 'source': 'Nature', 'date': 'Sep 30, 2020', 'snippet': 'Although used as a pharmacodynamic biomarker in research and clinical \nstudies, plasma lyso-Gb 3 may not be a suitable biomarker for monitoring \ntreatment...', 'thumbnail': 'https://serpapi.com/searches/6722e92a2bab90dba32722e1/images/8292e8a91d281613df2f7f9e841ebb71f0bddd1ff76bbb48a064e164123391e3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5827186703681946}","{'position': 4, 'link': 'https://fabrydiseasenews.com/news/fabry-disease-amenable-mutations-therapy-candidate-migalastat-amicus-therapeutics-files-fda-new-drug-application/', 'title': ""Fabry Disease Therapy Migalastat's Approval Under FDA Review"", 'source': 'Fabry Disease News', 'date': 'Jan 25, 2018', 'snippet': 'Read how Amicus Therapeutics has submitted a new drug application to the \nFDA for oral migalastat in Fabry disease in patients with amenable...', 'thumbnail': 'https://serpapi.com/searches/6722e92a2bab90dba32722e1/images/8292e8a91d2816133c306657705f0276db95f4c8ce1cf907ed21f98df2a8316f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8668466210365295}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01709864,"{'position': 1, 'link': 'https://copdnewstoday.com/news/new-copd-treament-option-seebri-neohaler-now-available-to-us-patients/', 'title': 'New COPD Treament Option, Seebri Neohaler, Now Available to U.S. Patients', 'source': 'COPD News Today', 'date': 'Oct 23, 2017', 'snippet': 'Seebri Neohaler, a long-term maintenance therapy for airflow obstruction in \npatients with chronic obstructive pulmonary disease (COPD), is now \navailable at US...', 'thumbnail': 'https://serpapi.com/searches/6722e9bf93584c2752099357/images/438e3dd0e0139869d344e84dccdc9b1a2750933f93ab010b34665b5adb61c23b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8668889403343201}",,,,,,,,,,['neutral'],neutral,1
NCT01027364,"{'position': 1, 'link': 'https://hemophilianewstoday.com/alprolix-hemophilia-b-therapy/', 'title': 'Alprolix (eftrenonacog alfa) for hemophilia', 'source': 'Hemophilia News Today', 'date': 'Sep 28, 2023', 'snippet': 'Alprolix is the first approved therapy to prevent and control bleeds in \nadults and children with hemophilia B.', 'thumbnail': 'https://serpapi.com/searches/6722e9c97b05caaa46af10e3/images/3cc9dbbaa235de3f40f073f7095fd93571e2499be288e94f9db279313b59d85c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6439523100852966}",,,,,,,,,,['neutral'],neutral,1
NCT04086602,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332221002274', 'title': 'Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease', 'source': 'ScienceDirect.com', 'date': 'Mar 3, 2021', 'snippet': 'The incidence and prevalence of inflammatory bowel disease (IBD) are \nincreasing worldwide. Current approved medication for IBD treatment in the \nclinic...', 'thumbnail': 'https://serpapi.com/searches/6722ea3a400bd56961857c7d/images/9b9cbdd259c5363b0dfbfd99a62ba9ddf9c6571af68b9c0b777d506b1d2f5c96.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7565747499465942}","{'position': 2, 'link': 'https://www.nature.com/articles/s12276-024-01261-8', 'title': 'NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders', 'source': 'Nature', 'date': 'Jul 1, 2024', 'snippet': 'Proinflammatory cytokines and chemokines play a crucial role in regulating \nthe inflammatory response, which is essential for the proper...', 'thumbnail': 'https://serpapi.com/searches/6722ea3a400bd56961857c7d/images/9b9cbdd259c5363b141041b9b070d366ff88822870489902761c337b69eda4de.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8756292462348938}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03547245,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-024-00811-5', 'title': 'Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming | npj Vaccines', 'source': 'Nature', 'date': 'Mar 11, 2024', 'snippet': 'Vaccine priming immunogens that activate germline precursors for broadly \nneutralizing antibodies (bnAbs) have promise for development of...', 'thumbnail': 'https://serpapi.com/searches/6722ea63e45f334e584ee8aa/images/f7575fddcbd8b4d967999f31c94ef2aa5f3dbcbe9c7238bde078686faf3ad2b0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.898286759853363}",,,,,,,,,,['neutral'],neutral,1
NCT03434028,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2212663', 'title': 'Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension', 'source': 'The New England Journal of Medicine', 'date': 'Jan 21, 2023', 'snippet': 'The restrictive fluid strategy that was used in this trial did not result \nin significantly lower (or higher) mortality before discharge home by day \n90 than the...', 'thumbnail': 'https://serpapi.com/searches/6722ea7afc40bfd05b71ef93/images/e7e6fc1a3ae39492ea98326ff0c4798183b2b64240e7cdc3e9becb3cde705a5c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5839207768440247}","{'position': 2, 'link': 'https://www.nhlbi.nih.gov/news/2022/nhlbi-petal-network-ends-phase-3-sepsis-trial-early', 'title': 'NHLBI PETAL Network ends phase 3 sepsis trial early', 'source': 'nhlbi, nih (.gov)', 'date': 'Feb 9, 2022', 'snippet': 'Enrollment in a National Institutes of Health-supported trial with 1566 \npatients being treated for sepsis at 51 U.S. medical centers ended...', 'thumbnail': 'https://serpapi.com/searches/6722ea7afc40bfd05b71ef93/images/e7e6fc1a3ae394922911eca5dd3b13467dbbd363c178a0c9712a789efd1cbe3c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8735569715499878}","{'position': 3, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa2212663', 'title': 'Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension', 'source': 'The New England Journal of Medicine', 'date': 'Jan 21, 2023', 'snippet': 'In an unblinded superiority trial conducted at 60 U.S. centers, we randomly \nassigned patients to either a restrictive fluid strategy...', 'thumbnail': 'https://serpapi.com/searches/6722ea7afc40bfd05b71ef93/images/e7e6fc1a3ae3949290592e5b71853696429fc258e7133fbb553e2d387546f9bb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8000256419181824}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02061293,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-52967-8', 'title': 'Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study | Scientific Reports', 'source': 'Nature', 'date': 'Feb 7, 2024', 'snippet': 'This pilot study investigated psilocybin-induced changes in neural \nreactivity to alcohol and emotional cues in patients with alcohol use \ndisorder (AUD).', 'thumbnail': 'https://serpapi.com/searches/6722ea8b1397baa002ea0f73/images/74273c282bc784c45a97089c9cc8cdb11343720150e1648b7c3d7f5107815cab.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8987141847610474}",,,,,,,,,,['neutral'],neutral,1
NCT04052425,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2118828', 'title': 'Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo', 'source': 'The New England Journal of Medicine', 'date': 'Oct 19, 2022', 'snippet': 'Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A \ncream formulation of ruxolitinib (an inhibitor of Janus kinase 1...', 'thumbnail': 'https://serpapi.com/searches/6722eaa281bab738a9d5aebc/images/a2b12e1b1b6ddc77f492c49d854225649641d96cd7190ee7736ee64efe868231.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6550623774528503}","{'position': 2, 'link': 'https://www.ajmc.com/view/fda-approves-ruxolitinib-cream-as-first-repigmentation-therapy-for-vitiligo', 'title': 'FDA Approves Ruxolitinib Cream as First Repigmentation Therapy for Vitiligo', 'source': 'AJMC', 'date': 'Jul 19, 2022', 'snippet': 'Ruxolitinib (Opzelura) cream is the first and only FDA-approved treatment \nfor repigmentation in patients with vitiligo.', 'thumbnail': 'https://serpapi.com/searches/6722eaa281bab738a9d5aebc/images/a2b12e1b1b6ddc77973c417d16cad0888f32efa99a5c7a3b0e9d54d315ee1bd2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.49729543924331665}","{'position': 3, 'link': 'https://www.businesswire.com/news/home/20230705273477/en/MHRA-Grants-Marketing-Authorisation-for-Opzelura%C2%AE-ruxolitinib-Cream-for-the-Treatment-of-Non-Segmental-Vitiligo-with-Facial-Involvement-in-Adults-and-Adolescents', 'title': '(ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents', 'source': 'Business Wire', 'date': 'Jul 5, 2023', 'snippet': 'Opzelura® is the first approved treatment in the United Kingdom (UK) to \naddress repigmentation in non-segmental vitiligo...', 'thumbnail': 'https://serpapi.com/searches/6722eaa281bab738a9d5aebc/images/a2b12e1b1b6ddc7728a52cd9380016f078ec2f2c6398fbbce953f1d4228d1672.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8357210159301758}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT04651153,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/ucb-novartis-partner-develop-oral-treatments-in-clinical-phase-2-trialparkinsons-disease/', 'title': 'UCB and Novartis Join to Advance Oral Therapy Now in Phase 2 Trial', 'source': ""Parkinson's News Today"", 'date': 'Dec 6, 2021', 'snippet': 'UCB and Novartis will jointly develop UCB0599, an oral treatment designed \nto block alpha-synuclein misfolding now in enrolling global trial.', 'thumbnail': 'https://serpapi.com/searches/6722eabc1315029c728916ef/images/8f9a32a6a4ecebd4560d7ea76b526da77337ff2889ce767389ab19ce2990f755.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6784752607345581}",,,,,,,,,,['neutral'],neutral,1
NCT00141323,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0808692', 'title': 'Lasofoxifene in Postmenopausal Women with Osteoporosis', 'source': 'The New England Journal of Medicine', 'date': 'Feb 25, 2010', 'snippet': 'The effects of lasofoxifene on the risk of fractures, breast cancer, and \ncardiovascular disease are uncertain.In this randomized trial,...', 'thumbnail': 'https://serpapi.com/searches/6722eaea7a12fdc533094836/images/19f134475a00ca31cf76c025ae1a1121885c2e41e215edcb4c1923f49508f68a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7203640937805176}",,,,,,,,,,['neutral'],neutral,1
NCT01651143,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/news/lpa1-receptor-antagonist-sar100842-safe-well-tolerated-in-systemic-sclerosis/', 'title': 'LPA1 Receptor Antagonist SAR100842 Safe, Well Tolerated in Systemic Sclerosis', 'source': 'Rheumatology Advisor', 'date': 'May 30, 2018', 'snippet': 'An investigational drug known as SAR100842, which inhibits lysophosphatidic \nacid (LPA), was safe, moderately effective, and well tolerated in patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/6722eb0e20e6eb4673fa9f3f/images/6031830bca05fe0402c3da948a17989df31753da03515d1cc2919dfcb853e548.png', 'sentiment': 'positive', 'sentiment_prob': 0.6546438932418823}",,,,,,,,,,['positive'],positive,1
NCT04406623,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2020/10/20/shattuck-opens-phase-1-trial-sl-172154-in-treating-advanced-ovarian-cancer/', 'title': 'Phase 1 Trial of SL-172154 in Treating Advanced Ovarian Cancer Opens', 'source': 'Ovarian Cancer News Today', 'date': 'Oct 20, 2020', 'snippet': 'Shattuck Labs has opened a Phase 1 clinical trial to investigate its lead \ncandidate, SL-172154, in treating people with advanced ovarian...', 'thumbnail': 'https://serpapi.com/searches/6722eb11ba11426bb27b3f1e/images/e90bd05fdc0891ec8d633aca0fb1167cfc453fa64a555eac1b06b5bc687af089.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9088085293769836}",,,,,,,,,,['neutral'],neutral,1
NCT03049735,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2008283', 'title': 'Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy', 'source': 'The New England Journal of Medicine', 'date': 'Feb 17, 2021', 'snippet': 'Uterine fibroids are a common cause of heavy menstrual bleeding and pain. \nTreatment with the combination of relugolix (an oral...', 'thumbnail': 'https://serpapi.com/searches/6722ec1ae10f0a45ebd687fb/images/25ea382ec901532ae6cb9d8046e90980edbd48f2636b4769816de44f693b0f7e.png', 'sentiment': 'negative', 'sentiment_prob': 0.5476033687591553}","{'position': 2, 'link': 'https://www.empr.com/home/news/myfembree-approved-relugolix-estradiol-norethindrone-acetate-uterine-leiomyomas/', 'title': 'Myfembree Approved for Heavy Menstrual Bleeding With Uterine Fibroids', 'source': 'Medical Professionals Reference', 'date': 'May 27, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Myfembree (relugolix, \nestradiol, and norethindrone acetate) for the management of heavy menstrual \nbleeding.', 'thumbnail': 'https://serpapi.com/searches/6722ec1ae10f0a45ebd687fb/images/25ea382ec901532ae9e31fd67f2d05ff3670918e5c74d09e5e739ef25d676f2b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7920190691947937}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT02469896,"{'position': 1, 'link': 'https://alsnewstoday.com/news/arthritis-therapy-actemra-eases-signs-inflammation-als-phase-2-trial/', 'title': 'Arthritis Treatment Eases Signs of Inflammation in ALS Patients in Trial', 'source': 'ALS News Today', 'date': 'Aug 5, 2021', 'snippet': 'Actemra (tocilizumab), an approved treatment for rheumatoid arthritis, was \nfound to be safe and well-tolerated, and to reduce a key marker of \ninflammation in...', 'thumbnail': 'https://serpapi.com/searches/6722ecb7f59d00c60f7e629f/images/a94902088820ac354370705d41ed9573bcce6b1ff2875e069f7e7c428fadafd6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6534419655799866}",,,,,,,,,,['neutral'],neutral,1
NCT04908215,"{'position': 1, 'link': 'https://epidermolysisbullosanews.com/news/enrollment-done-phase-2-trial-cannabinol-cream-inm-755/', 'title': 'Enrollment done for Phase 2 trial of cannabinol cream INM-755 for...', 'source': 'Epidermolysis Bullosa News', 'date': 'Mar 31, 2023', 'snippet': 'InMed Pharmaceuticals has completed enrollment for a Phase 2 trial testing \nINM-755, an investigational cannabinol cream, for people with epidermolysis \nbullosa...', 'thumbnail': 'https://serpapi.com/searches/6722ed026a5dd3743d5d6797/images/5bb4628ffb7d3be36a2d05d671e6056bb9d92959473e9e85b94a89cd49d7ffd2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8687229752540588}",,,,,,,,,,['neutral'],neutral,1
NCT03722472,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-36789-2', 'title': 'Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults', 'source': 'Nature', 'date': 'Mar 6, 2023', 'snippet': 'Adjuvant-containing subunit vaccines represent a promising approach for \nprotection against tuberculosis (TB), but current candidates require...', 'thumbnail': 'https://serpapi.com/searches/6722ed0913e5d8cff1152dd7/images/5349bf79592f132b117fd5a0f9c2a72611ba5998687414c9c933d467f8c2ec23.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6567094326019287}",,,,,,,,,,['neutral'],neutral,1
NCT02677896,"{'position': 1, 'link': 'https://ascopubs.org/doi/abs/10.1200/jco.19.00799', 'title': 'ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Jul 22, 2019', 'snippet': 'ARCHES (ClinicalTrials.gov identifier: NCT02677896) is a multinational, \ndouble-blind, phase III trial, wherein 1,150 men with mHSPC were...', 'thumbnail': 'https://serpapi.com/searches/6722ed1b5a461af941f022cf/images/0a35416bbe9664305cfde792bafc2bccb4cdb0cd10693753fa3668f96a778ce6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9199913144111633}","{'position': 2, 'link': 'https://www.nature.com/articles/s41391-021-00447-9', 'title': 'Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials', 'source': 'Nature', 'date': 'Sep 13, 2021', 'snippet': 'Fatigue is a multifactorial symptom commonly reported by patients with \nprostate cancer as a result of disease and treatment. This study...', 'thumbnail': 'https://serpapi.com/searches/6722ed1b5a461af941f022cf/images/0a35416bbe9664305d622ee3605000e31ed1eb646eae4dee347c5490af3d614c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7892088890075684}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/enzalutamide-plus-adt-yields-lasting-survival-benefit-in-metastatic-hormone-sensitive-prostate-cancer-prior-therapy', 'title': 'Enzalutamide Plus ADT Yields Lasting Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer ± Prior Therapy', 'source': 'Cancer Network', 'date': 'May 21, 2022', 'snippet': 'Findings from the phase 3 ARCHES trial highlighted a long-lasting survival \nimprovement for patients with metastatic hormone-sensitive...', 'thumbnail': 'https://serpapi.com/searches/6722ed1b5a461af941f022cf/images/0a35416bbe96643019d7a5ce2c38d66a0d609d8e299f934bdf78d39605ba4fa5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5410369634628296}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00533949,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-02910-y', 'title': 'Quantum deep reinforcement learning for clinical decision support in oncology: application to adaptive radiotherapy', 'source': 'Nature', 'date': 'Dec 7, 2021', 'snippet': ""Subtle differences in a patient's genetics and physiology may alter \nradiotherapy (RT) treatment responses, motivating the need for a more..."", 'thumbnail': 'https://serpapi.com/searches/6722ed1a7ebde58f676ef6dc/images/b10e25f6fc462f33665466a6ff53171e312b225a54b88b13cc76cebe98237725.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8670821785926819}",,,,,,,,,,['neutral'],neutral,1
NCT05274802,"{'position': 1, 'link': 'https://www.nature.com/articles/s41429-023-00629-8', 'title': 'Antibiotics in the clinical pipeline as of December 2022 - The Journal of Antibiotics', 'source': 'Nature', 'date': 'Jun 8, 2023', 'snippet': 'The need for new antibacterial drugs to treat the increasing global \nprevalence of drug-resistant bacterial infections has clearly attracted...', 'thumbnail': 'https://serpapi.com/searches/6722edb9740bdb6530455e14/images/342f99db0925ad853f78b6cf66c455f185f0a4cf2c0e3dd4a9f20c36346fb0f7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8837066888809204}",,,,,,,,,,['neutral'],neutral,1
NCT02998450,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/potential-sickle-cell-disease-therapy-safe-imara-phase-1-trial-shows/', 'title': 'Phase 1 Trial Shows Imara’s Potential Therapy Safe for Treatment of Sickle Cell Disease', 'source': 'Sickle Cell Disease News', 'date': 'Sep 28, 2017', 'snippet': ""A Phase 1 clinical trial of Imara's new investigational drug, IMR-687, \nshowed that it was safe and well-tolerated in healthy volunteers."", 'thumbnail': 'https://serpapi.com/searches/6722ee3dd771bd6b2e5e4db3/images/e208d2f0bb35f40ba3293f81aa06816064f943d503c1e2710713028a19bfb744.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8105300068855286}","{'position': 2, 'link': 'https://sicklecellanemianews.com/news/cydan-raises-34-million-to-accelerate-new-treatments-for-rare-genetic-diseases/', 'title': 'Sickle Cell Potential Therapy to Benefit from $34M in Cydan Research Funding', 'source': 'Sickle Cell Disease News', 'date': 'Oct 24, 2017', 'snippet': ""Read about Cydan's $34 million financing round to help advance drug \ncandidates like IMR-687 to treat rare genetic diseases such as sickle..."", 'thumbnail': 'https://serpapi.com/searches/6722ee3dd771bd6b2e5e4db3/images/e208d2f0bb35f40be664e4de9bc7a3c4639785cfa7e61c5514e146744f11b993.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5925441384315491}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT00809965,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1112277', 'title': 'Rivaroxaban in Patients with a Recent Acute Coronary Syndrome', 'source': 'The New England Journal of Medicine', 'date': 'Apr 30, 2018', 'snippet': 'Acute coronary syndromes arise from coronary atherosclerosis with \nsuperimposed thrombosis. Since factor Xa plays a central role in \nthrombosis,...', 'thumbnail': 'https://serpapi.com/searches/6722ee8f24296aed45f173df/images/6ae901166944bbafe273efecf372dd022429066d65a1d8fbc72abfb0317a00a4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5768699645996094}",,,,,,,,,,['neutral'],neutral,1
NCT02725567,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/kalydeco-approved-eu-cf-children-young-1-month/', 'title': 'Kalydeco approved in EU for CF children as young as 1 month', 'source': 'Cystic Fibrosis News Today', 'date': 'Apr 29, 2024', 'snippet': 'The European Commission has approved Kalydeco (ivacaftor) for CF infants as \nyoung as a month with at least one CFTR gating mutation.', 'thumbnail': 'https://serpapi.com/searches/6722eec529e6fbf3605b31a1/images/cbc22cd2f87676629ef629bc3f8de1627bffe466ae372e63825fc18f78621ef7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8572079539299011}","{'position': 2, 'link': 'https://www.pulmonologyadvisor.com/news/ivacaftor-may-be-effective-for-infants-with-cystic-fibrosis-and-gating-mutation/', 'title': 'Ivacaftor May Be Effective for Infants With Cystic Fibrosis and Gating Mutation', 'source': 'Pulmonology Advisor', 'date': 'Nov 2, 2020', 'snippet': 'Researchers conducted a clinical trial in 25 infants with a confirmed \ndiagnosis of CF and a CFTR gating mutation on 1 or more allele.', 'thumbnail': 'https://serpapi.com/searches/6722eec529e6fbf3605b31a1/images/cbc22cd2f8767662a5a816d96a597e21c3fc4fb91dba2637afba764c63882644.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8510521054267883}","{'position': 3, 'link': 'https://lungdiseasenews.com/2017/12/12/cf-phase-3-arrival-study-shows-kalydeco-ivacaftor-effective-safe-treating-infants-toddlers-1-2/', 'title': 'Kalydeco Seen As Safe in Treating CF in Young Children, Ages 1 to 2, Study Data Show', 'source': 'Lung Disease News', 'date': 'Dec 12, 2017', 'snippet': 'Preliminary data from a Phase 3 trial show that Kalydeco is safe, \nwell-tolerated, and effective in treating CF patients ages 1 to 2,...', 'thumbnail': 'https://serpapi.com/searches/6722eec529e6fbf3605b31a1/images/cbc22cd2f87676623b3461efa267df1fe3a9bed1ae224e78bbd9e73812dec205.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.513891875743866}","{'position': 4, 'link': 'https://www.empr.com/home/news/kalydeco-approved-for-cystic-fibrosis-in-children-as-young-as-1-month-old/', 'title': 'Kalydeco Approved for Cystic Fibrosis in Children as Young as 1 Month Old', 'source': 'Medical Professionals Reference', 'date': 'May 4, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) \nfor use in children with cystic fibrosis (CF) ages 1 month to less than 4 \nmonths old.', 'thumbnail': 'https://serpapi.com/searches/6722eec529e6fbf3605b31a1/images/cbc22cd2f87676628afca53d193b8fd436f679b124df49a55ffff1bd76b1878f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8542404770851135}",,,,,,,"['neutral', 'neutral', 'positive', 'neutral']",neutral,1
NCT02091375,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1611618', 'title': 'Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome', 'source': 'The New England Journal of Medicine', 'date': 'May 25, 2017', 'snippet': 'We conducted a randomized, double-blind, placebo-controlled trial of \ncannabidiol to treat drug-resistant epilepsy in the Dravet syndrome.', 'thumbnail': 'https://serpapi.com/searches/6722ef32ba13f2d132aa5325/images/29e2c18de143e4e5a7989615ad71a9e789753398e6a538421b625c7ad652567f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8767561912536621}","{'position': 2, 'link': 'https://dravetsyndromenews.com/news/cannabis-derived-epidiolex-cleared-for-clinical-trials-in-japan-to-treat-dravet-lennox-gastaut-syndromes/', 'title': 'Epidiolex Cleared for Dravet, Lennox-Gastaut Trials in Japan', 'source': 'Dravet Syndrome News', 'date': 'Mar 28, 2019', 'snippet': 'Japan has approved the cannabis compound Epidiolex for clinical trials in \nepileptic patients with Dravet and Lennox-Gastaut syndromes.', 'thumbnail': 'https://serpapi.com/searches/6722ef32ba13f2d132aa5325/images/29e2c18de143e4e5d5c836f7029ff332c530490276c04a27061ed655a2ee0f07.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8571611046791077}","{'position': 3, 'link': 'https://dravetsyndromenews.com/news/dravet-treatment-candidates-dravet-syndrome-hopeful-review/', 'title': 'New Dravet Treatment Candidates Give Reasons for Hope, Review Says', 'source': 'Dravet Syndrome News', 'date': 'Apr 10, 2018', 'snippet': 'Current first-line therapies for Dravet syndrome have limited \neffectiveness, but treatment candidates now undergoing clinical testing \nshow significant promise.', 'thumbnail': 'https://serpapi.com/searches/6722ef32ba13f2d132aa5325/images/29e2c18de143e4e5ce06bcd19d9e59d678f703d116f0381a337624cf967cb505.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6929994821548462}",,,,,,,,"['neutral', 'neutral', 'positive']",neutral,1
NCT04524351,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/annovis-bio-wins-phase-3-trial-approval-parkinsons-therapy-buntanetap/', 'title': ""Annovis Bio Wins Phase 3 Trial Approval for Parkinson's Therapy..."", 'source': ""Parkinson's News Today"", 'date': 'Jul 12, 2022', 'snippet': ""The U.S. Food and Drug Administration has approved Annovis Bio for a Phase \n3 clinical trial of buntanetap for early-stage Parkinson's."", 'thumbnail': 'https://serpapi.com/searches/6722ef6b64f11d7899964040/images/9e5beae07c1884f6d1a9faebfa5eedddcf0f70d6750a9697e39c4a4d5fd46fcc.png', 'sentiment': 'positive', 'sentiment_prob': 0.5276041030883789}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/buntanet-shown-halt-cognitive-decline-early-parkinsons-trial/', 'title': 'Buntanetap found to halt cognitive decline in early Parkinson’s trial', 'source': ""Parkinson's News Today"", 'date': 'Jul 8, 2024', 'snippet': ""In a trial, once-daily buntanetap halted cognitive decline in early-stage \nParkinson's and improved cognition in patients with mild dementia."", 'thumbnail': 'https://serpapi.com/searches/6722ef6b64f11d7899964040/images/9e5beae07c1884f611d4e7aea41df681993621483956d07ee38d9abd33a96b97.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6456438899040222}","{'position': 3, 'link': 'https://parkinsonsnewstoday.com/news/annovis-plans-phase-3-trials-buntanetap-early-late-stage-parkinsons/', 'title': 'Planned Phase 3 Trials of Oral Buntanetap to Span Disease Stages', 'source': ""Parkinson's News Today"", 'date': 'Jan 27, 2022', 'snippet': ""The U.S. Food and Drug Administration (FDA) has given positive feedback to \nAnnovis Bio's plans to start two Phase 3 clinical trials of..."", 'thumbnail': 'https://serpapi.com/searches/6722ef6b64f11d7899964040/images/9e5beae07c1884f61887e08e150ebaf6562acf7e607825ea909ec7323c56d484.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7023013830184937}",,,,,,,,"['positive', 'neutral', 'neutral']",neutral,1
NCT03138512,"{'position': 1, 'link': 'https://www.targetedonc.com/view/adjuvant-nivolumab-falls-short-of-disease-free-survival-endpoint-in-locally-advanced-high-risk-rcc', 'title': 'Adjuvant Nivolumab Falls Short of Disease-Free Survival End Point in Locally Advanced High-Risk RCC', 'source': 'Targeted Oncology', 'date': 'Jan 27, 2024', 'snippet': 'In the phase 3 CheckMate 914 trial, the use of nivolumab did not meet the \nprimary endpoint of disease-free survival when compared to a...', 'thumbnail': 'https://serpapi.com/searches/6722efc3861b9dc3860d175b/images/250efc03b892aa2cb5729961f95efc36db9f84e448b9d05f027c9a3f9ba7516a.png', 'sentiment': 'negative', 'sentiment_prob': 0.6068782210350037}",,,,,,,,,,['negative'],negative,0
NCT04596878,"{'position': 1, 'link': 'https://pf-media.co.uk/news/minervax-begins-phase-1-clinical-study-of-novel-gbs-vaccine/', 'title': 'MinervaX begins phase 1 clinical study of novel GBS vaccine', 'source': 'Pf Media', 'date': 'Apr 17, 2023', 'snippet': 'MinervaX has announced the first phase 1 clinical study in older adults of \nits novel vaccine for Group B Streptococcus.', 'thumbnail': 'https://serpapi.com/searches/6722eff5b6ed337ce072e99b/images/61ab751dcddf4f0509d8a2c81bed64ff78700a790d5b818661f7aa752c53a010.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8728817105293274}",,,,,,,,,,['neutral'],neutral,1
NCT03003676,"{'position': 1, 'link': 'https://melanomanewstoday.com/2017/05/18/first-patient-enrolled-in-oncos-102-keytruda-combo-trial-advanced-melanoma/', 'title': 'First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma', 'source': 'Melanoma News Today', 'date': 'May 18, 2017', 'snippet': ""The first patient has been enrolled in Targovax's pilot clinical trial for \nadvanced or unresectable melanoma patients whose cancer..."", 'thumbnail': 'https://serpapi.com/searches/6722f00aba13f2d17b1d89c1/images/e2e4e4e72b7f850f7385256c9ba70ef4e13aaff9bca2549eb9127f406b314b9c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9091613292694092}",,,,,,,,,,['neutral'],neutral,1
NCT01589185,"{'position': 1, 'link': 'https://pneumoniaresearchnews.com/2017/06/06/salvecin-based-combo-therapy-outperforms-antibiotics-alone-against-pneumonia/', 'title': 'Pneumonia Combo Therapy with Salvecin Outperforms Antibiotics Alone, Trial Shows', 'source': 'Pneumonia Research News', 'date': 'Jun 6, 2017', 'snippet': 'Read about a Phase 2a clinical trial showing that a combination of Salvecin \nand antibiotics outperformed antibiotics alone as a pneumonia...', 'thumbnail': 'https://serpapi.com/searches/6722f083b9458d4a50771fb0/images/154cab5bb3debbe2b9e00e28bdd2ae424d06a78a5c360bc7e5b275c9014bf144.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8695399761199951}",,,,,,,,,,['neutral'],neutral,1
NCT03217136,"{'position': 1, 'link': 'https://www.empr.com/home/news/zerbaxa-approved-for-complicated-pediatric-intra-abdominal-urinary-tract-infections/', 'title': 'Zerbaxa Approved for Complicated Pediatric Intra-abdominal, Urinary Tract Infections', 'source': 'Medical Professionals Reference', 'date': 'Apr 26, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved the supplemental New \nDrug Applications (sNDAs) for Zerbaxa (ceftolozane and tazobactam) to \ninclude...', 'thumbnail': 'https://serpapi.com/searches/6722f0973c944b0711a2c853/images/499b62f0e33a2440434aaa909517e35891ba3e9dc7eca1f3aa45974137d3082b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8938506841659546}",,,,,,,,,,['neutral'],neutral,1
NCT00324311,"{'position': 1, 'link': 'https://www.empr.com/home/news/severe-burn-therapy-nexobrid-gets-fda-approval/', 'title': 'Severe Burn Therapy NexoBrid Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Jan 3, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved NexoBrid \n(anacaulase-bcdb) for eschar removal in adults with deep partial thickness \nand/or full thickness...', 'thumbnail': 'https://serpapi.com/searches/6722f09e81262a594b8d1c7d/images/1b320fe45a273d42df69f1c1829156b4f93784aa197b766a0ee25b68110b89bf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6989240646362305}","{'position': 2, 'link': 'https://www.empr.com/home/news/nexobrid-now-available-for-treatment-of-severe-thermal-burns/', 'title': 'NexoBrid Now Available for Treatment of Severe Thermal Burns', 'source': 'Medical Professionals Reference', 'date': 'Sep 21, 2023', 'snippet': 'NexoBrid (anacaulase-bcdb) is now available for eschar removal in adults \nwith deep partial thickness and/or full thickness thermal burns.', 'thumbnail': 'https://serpapi.com/searches/6722f09e81262a594b8d1c7d/images/1b320fe45a273d425c39c15a4652df5fe95de85dc1ffd0f830514475bb0e17d3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8987787961959839}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02706847,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31116-4/abstract', 'title': 'Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial', 'source': 'The Lancet', 'date': 'Jun 13, 2018', 'snippet': 'Safety and efficacy of upadacitinib in patients with active rheumatoid \narthritis refractory to biologic disease-modifying anti-rheumatic...', 'thumbnail': 'https://serpapi.com/searches/6722f0d5ba13f2d132aa553a/images/d59b8b438d2bcb79d528b894ff029fe25b29960808b4ead7a263e0b27b556bac.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8150492906570435}",,,,,,,,,,['neutral'],neutral,1
NCT02443298,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2030880', 'title': 'Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial', 'source': 'The New England Journal of Medicine', 'date': 'Oct 27, 2021', 'snippet': 'Interleukin-23 has been implicated in airway inflammation that is mediated \nby type 2 and type 17 cytokines. Whether targeting interleukin-23...', 'thumbnail': 'https://serpapi.com/searches/6722f0db9fd309c7d4ccaaba/images/1d804c6adc9f09b668db81a9ba8a285812acb369a6b55c3569237d0f134a3238.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6266525387763977}",,,,,,,,,,['neutral'],neutral,1
NCT05660109,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20241015961357/en/Topas-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2a-Trial-Evaluating-TPM502-in-Patients-with-Celiac-Disease', 'title': 'Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease', 'source': 'Business Wire', 'date': '2 weeks ago', 'snippet': 'TPM502 demonstrated a good safety profile in celiac disease patients; The \ndata indicates proof of concept that TPM502 induced targeted,...', 'thumbnail': 'https://serpapi.com/searches/6722f1372fab620db40993b2/images/f00f7608417477a250290c4d3effaa58747eed21c047e7e61444b31910f7d332.png', 'sentiment': 'positive', 'sentiment_prob': 0.7479203939437866}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20230525005412/en/Topas-Therapeutics-Initiates-Phase-2a-Clinical-Trial-for-TPM502-in-Celiac-Disease-Appoints-Chief-Business-Officer-and-Chief-Operating-Officer', 'title': 'Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease; Appoints Chief Business Officer and Chief Operating Officer', 'source': 'Business Wire', 'date': 'May 25, 2023', 'snippet': 'Topas Therapeutics, a clinical stage biotech company developing novel \nantigen-specific immune tolerance therapies to treat autoimmune...', 'thumbnail': 'https://serpapi.com/searches/6722f1372fab620db40993b2/images/f00f7608417477a250ea4f7728d0506505a7b8beeb053d644769d9d61de625a5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8499126434326172}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT03367533,"{'position': 1, 'link': 'https://www.nature.com/articles/s41380-021-01121-1', 'title': 'Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor', 'source': 'Nature', 'date': 'May 7, 2021', 'snippet': 'The discovery of robust antidepressant actions exerted by the \nN-methyl-D-aspartate receptor (NMDAR) antagonist (R,S)-ketamine has been \na...', 'thumbnail': 'https://serpapi.com/searches/6722f1c115c7405910f6573c/images/59e8689da258fc2d995c1ac0257785b5d64b9bbbf8fe86d198892d8ecb428330.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8802525401115417}",,,,,,,,,,['neutral'],neutral,1
NCT02744339,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIR.0000000000001079', 'title': 'Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association', 'source': 'American Heart Association Journals', 'date': 'Jul 11, 2022', 'snippet': 'This science advisory focuses on the need to better understand the \nepidemiology, pathophysiology, and treatment of pulmonary hypertension in \npatients with...', 'thumbnail': 'https://serpapi.com/searches/6722f1eed169151c1d61f1b2/images/952df31dcb32a9f1ba0405215787fb283d5ab55b1eff9ab9119eac396b8b0d3f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8376390933990479}",,,,,,,,,,['neutral'],neutral,1
NCT05351047,"{'position': 1, 'link': 'https://www.insideprecisionmedicine.com/topics/precision-medicine/phase-i-win-for-kidney-disease-drug-in-subtype-common-to-people-of-african-descent/', 'title': 'Phase I Win for Kidney Disease Drug in Subtype Common to People of African Descent', 'source': 'Inside Precision Medicine', 'date': 'May 30, 2024', 'snippet': 'What could be the first precision medicine for APOL1-mediated kidney \ndisease (AKMD) has successfully completed a Phase I trial.', 'thumbnail': 'https://serpapi.com/searches/6722f1f04300ce10a7ea87b5/images/81f8179a8b7269cc2b880ce084c34daa9e89ff1badb9d14da9c4aa830943741d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5857201814651489}",,,,,,,,,,['neutral'],neutral,1
NCT03732638,"{'position': 1, 'link': 'https://www.empr.com/home/news/nurtec-odt-approval-expanded-to-include-migraine-prevention/', 'title': 'Nurtec ODT Approval Expanded to Include Migraine Prevention', 'source': 'Medical Professionals Reference', 'date': 'Jun 1, 2021', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of Nurtec \nODT (rimegepant) to include preventive treatment of episodic migraine in \nadults.', 'thumbnail': 'https://serpapi.com/searches/6722f21676079d5720a0f448/images/909ff22102672eafd6ccb11148214ffa328bb1532bbbb04ea38a90a426911342.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7403613924980164}",,,,,,,,,,['neutral'],neutral,1
NCT01625559,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-020-02955-3', 'title': 'Stem/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials | Cell Death & Disease', 'source': 'Nature', 'date': 'Sep 23, 2020', 'snippet': 'Retinal degeneration (RD) is one of the dominant causes of irreversible \nvision impairment and blindness worldwide.', 'thumbnail': 'https://serpapi.com/searches/6722f2380f2a2ca367b4c3c8/images/4f314025bdc318afaea99018acbc3bfa7b8b7321c73b98dbfd363689fd648ec5.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.540476381778717}",,,,,,,,,,['negative'],negative,0
NCT02091141,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30904-5/fulltext', 'title': 'Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study', 'source': 'The Lancet', 'date': 'Mar 8, 2019', 'snippet': 'Therapies targeting HER2 have improved clinical outcomes in HER2-positive \nbreast and gastric cancers, and are emerging as potential...', 'thumbnail': 'https://serpapi.com/searches/6722f24d987217070576c145/images/62035555b98f04c49213ae174062600d4925561255815f3df7a55070c006131b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7397531270980835}",,,,,,,,,,['neutral'],neutral,1
NCT03457649,"{'position': 1, 'link': 'https://myastheniagravisnews.com/news/argx-113-mysasthenia-gravis-shows-promise-reducing-autoantibodies-clinical-trial/', 'title': ""In MG, Argenx's ARGX-113 Appears Safe, Effective in Reducing Autoantibodiess"", 'source': 'Myasthenia Gravis News', 'date': 'Jul 27, 2018', 'snippet': ""A Phase 1 study of argenx's efgartigimod (ARGX-113) shows promise in \nreducing IgG autoantibodies in immune related diseases,..."", 'thumbnail': 'https://serpapi.com/searches/6722f25b7ca6b31d5be30507/images/c81cf4ea55ac9955029719ab08f3c5d20909f6e3da9b925f4e04e27b81cd219d.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5817119479179382}",,,,,,,,,,['positive'],positive,1
NCT04165837,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/fb-101-well-tolerated-phase-1-parkinsons-clinical-trial/', 'title': ""FB-101 Well-tolerated in Phase 1 Parkinson's Clinical Trial |..."", 'source': ""Parkinson's News Today"", 'date': 'Oct 20, 2022', 'snippet': ""FB-101 is an experimental oral medicine that 1ST Biotherapeutics is testing \nin a Phase 1 Parkinson's disease clinical trial."", 'thumbnail': 'https://serpapi.com/searches/6722f26d75f974affaee7ca1/images/707937c93d33683d0edd67f6b3fa250d4991918251aa1b0fb64cbb7a3bcaaa94.png', 'sentiment': 'positive', 'sentiment_prob': 0.6935677528381348}",,,,,,,,,,['positive'],positive,1
NCT04983589,"{'position': 1, 'link': 'https://www.empr.com/home/news/vuity-approval-expanded-to-allow-for-second-dose-of-presbyopia-treatment/', 'title': 'Vuity Approval Expanded to Allow for Second Dose of Presbyopia Treatment', 'source': 'Medical Professionals Reference', 'date': 'Mar 30, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved the supplemental New \nDrug Application (sNDA) for Vuity (pilocarpine hydrochloride...', 'thumbnail': 'https://serpapi.com/searches/6722f2a4ba13f2d17b1d8bd3/images/7f09df38fcac535543cd413b54f72326bad3bd2fa5b4e4de4e929b0af0029ce4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8455018997192383}",,,,,,,,,,['neutral'],neutral,1
NCT03693781,"{'position': 1, 'link': 'https://alsnewstoday.com/news/als-mnd-2023-gout-med-colchicine-als-progression/', 'title': 'ALS/MND 2023: Gout med colchicine did not slow ALS progression', 'source': 'ALS News Today', 'date': 'Dec 8, 2023', 'snippet': 'The gout medication colchicine failed to significantly slow ALS progression \nin a small clinical trial conducted in Europe.', 'thumbnail': 'https://serpapi.com/searches/6722f2c616779391e19a8918/images/0abf2a848997d5f1f0e5572e45df1cb245618585b9c6455647836b5c9f778f93.png', 'sentiment': 'negative', 'sentiment_prob': 0.7509196400642395}",,,,,,,,,,['negative'],negative,0
NCT00325195,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/news/remission-criteria-validated-new-criteria-defined-for-complete-response-in-chronic-refractory-gout/', 'title': 'Remission Criteria Validated, New Criteria Defined for Complete Response in Chronic Refractory Gout', 'source': 'Rheumatology Advisor', 'date': 'Dec 17, 2019', 'snippet': 'The objective of this study was to generate evidence-based criteria for \ngout remission and develop new criteria for complete response using data \nfrom...', 'thumbnail': 'https://serpapi.com/searches/6722f2dccc29870e922c0aea/images/449a1f08cccc74d6448faa962942a9c51f6a57080118c681305050dee97de059.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8911468982696533}",,,,,,,,,,['neutral'],neutral,1
NCT04166383,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S075333222300224X', 'title': 'The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade', 'source': 'ScienceDirect.com', 'date': 'Feb 24, 2023', 'snippet': 'Immunotherapy has revolutionized treatment of cancer during the last \ndecades. Oncolytic virotherapy has also emerged as a strategy to fight \nagainst cancer...', 'thumbnail': 'https://serpapi.com/searches/6722f2e4b691a72d6399f5c1/images/aa9b0a77b7048baa02d3554023667e302fc9cb84b511db318e0febe76ffc5767.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6491599082946777}",,,,,,,,,,['positive'],positive,1
NCT01539512,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1315226', 'title': 'Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'Jan 22, 2014', 'snippet': 'Patients with relapsed chronic lymphocytic leukemia (CLL) who have \nclinically significant coexisting medical conditions are less able to...', 'thumbnail': 'https://serpapi.com/searches/6722f316175de61401c71e2b/images/6bc542f90fe349f877aec1090412b9dc8f77b33e4b0cfe5d7aef152339977f96.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6612946391105652}",,,,,,,,,,['neutral'],neutral,1
NCT01594450,"{'position': 1, 'link': 'https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-131', 'title': 'Use of biological mesh versus standard wound care in infected incisional ventral hernias, the SIMBIOSE study: a study protocol for a randomized multicenter controlled trial', 'source': 'BioMed Central', 'date': 'May 7, 2013', 'snippet': 'In infected incisional ventral hernias (IVHs), the use of a synthetic \nnon-absorbable mesh is not recommended and biological meshes hold...', 'thumbnail': 'https://serpapi.com/searches/6722f386b6a79c89e80bfb98/images/5b1517b4937ed8592ff3c450226402731477b6bc77128a1eb6c6d11445b2b725.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7720320820808411}",,,,,,,,,,['neutral'],neutral,1
NCT00943722,"{'position': 1, 'link': 'https://publications.aap.org/pediatrics/article/152/4/e2022060993/193886/Ten-Year-Follow-up-of-9-Valent-Human', 'title': 'Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety', 'source': 'AAP', 'date': 'Sep 5, 2023', 'snippet': 'The 9-valent human papillomavirus (9vHPV) vaccine Phase III immunogenicity \nstudy in 9- to 15-year-old boys and girls was extended to assess \nimmunogenicity and...', 'thumbnail': 'https://serpapi.com/searches/6722f3a6fcd69e83509dbd29/images/6215f85a5bbd3536f2f16db24aed83b2acecd2125f221034e11e66450bc12ca6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8899199366569519}",,,,,,,,,,['neutral'],neutral,1
NCT03347344,"{'position': 1, 'link': 'https://www.neurologyadvisor.com/news/spinocerebellar-ataxia-type-2-treatment-riluzole-efficacious/', 'title': 'Spinocerebellar Ataxia Type 2 Treatment: Is Riluzole Effective?', 'source': 'Neurology Advisor', 'date': 'Feb 8, 2022', 'snippet': 'A randomized trial found that riluzole did not improve clinical or \nradiological outcomes among patients with spinocerebellar ataxia type 2 \n(SCA2).', 'thumbnail': 'https://serpapi.com/searches/6722f4098d147392a7c36e73/images/067682706a5162072fcafb8e4d3ba2d24b4f73969ed10dd76d4811b7ce73354a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5791459679603577}",,,,,,,,,,['negative'],negative,0
NCT05364021,"{'position': 1, 'link': 'https://dravetsyndromenews.com/news/study-shows-benefits-bexicaserin-dravet-syndrome-epilepsy-types/', 'title': 'Bexicaserin benefits seen for Dravet syndrome, other epilepsy types', 'source': 'Dravet Syndrome News', 'date': '1 month ago', 'snippet': 'Bexicaserin maker Longboard Pharmaceuticals is on track to initiate its \nglobal Phase 3 program for the Dravet syndrome therapy this year.', 'thumbnail': 'https://serpapi.com/searches/6722f41da54d7e5b1f72f4e0/images/6030e970123a4ede114e95c074036ed0ffd68d5b5082618431511720918f171c.png', 'sentiment': 'positive', 'sentiment_prob': 0.5893202424049377}","{'position': 2, 'link': 'https://dravetsyndromenews.com/news/seizure-treatment-bexicaserin-fda-breakthrough-therapy-not/', 'title': 'Seizure treatment bexicaserin gets FDA breakthrough therapy nod', 'source': 'Dravet Syndrome News', 'date': 'Jul 9, 2024', 'snippet': ""The US Food and Drug Administration (FDA) has granted breakthrough therapy \ndesignation to Longboard Pharmaceuticals' bexicaserin to treat seizures."", 'thumbnail': 'https://serpapi.com/searches/6722f41da54d7e5b1f72f4e0/images/6030e970123a4ede1ac251b094bcbcbf6946a2723b3dee8257aced8bdb32176e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5533022284507751}","{'position': 3, 'link': 'https://dravetsyndromenews.com/news/pacific-study-lp352-dravet-other-epilepsies-hits-enrollment-goal/', 'title': 'PACIFIC study of LP352 for epilepsies hits enrollment target', 'source': 'Dravet Syndrome News', 'date': 'Sep 5, 2023', 'snippet': 'Longboard Pharmaceuticals has finished enrolling patients in PACIFIC, its \nPhase 1b/2a clinical study of LP352, an investigational oral...', 'thumbnail': 'https://serpapi.com/searches/6722f41da54d7e5b1f72f4e0/images/6030e970123a4ede1cfc4fd9b0e527bd32a9151ac285ef2a0df1b9dbefcb98f6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8198975324630737}",,,,,,,,"['positive', 'neutral', 'neutral']",neutral,1
NCT03285477,"{'position': 1, 'link': 'https://www.dermatologytimes.com/view/tirbanibulin-safe-effective-for-ak-on-face-scalp', 'title': 'Tirbanibulin Safe, Effective for AK on Face, Scalp', 'source': 'Dermatology Times', 'date': 'Feb 11, 2021', 'snippet': 'Two recent, identical phase 3 studies showed tirbanibulin 1% ointment \napplied once daily for 5 days (Klisyri; Almirall) achieved...', 'thumbnail': 'https://serpapi.com/searches/6722f41621e77b5006cfe703/images/a68e6f2cfde08ec38086d3f3f9f537cb1062765b5b79d213b2863416830b91a4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5473994612693787}",,,,,,,,,,['neutral'],neutral,1
NCT04955626,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2200674', 'title': 'Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine', 'source': 'The New England Journal of Medicine', 'date': 'Mar 23, 2022', 'snippet': 'Active immunization with the BNT162b2 vaccine (Pfizer–BioNTech) has been a \ncritical mitigation tool against severe acute respiratory...', 'thumbnail': 'https://serpapi.com/searches/6722f428d19f15b5303801cf/images/043cb8bba67bc7fa603ce50a6bed2fc23e4c891a7833357ce601b264ff099ced.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8373353481292725}","{'position': 2, 'link': 'https://www.abc10.com/article/news/local/sacramento/uc-davis-health-partners-with-pfizer-to-offer-two-new-booster-trials/103-aba8779b-423d-4129-b60b-59e11050f41b', 'title': 'UC Davis Health partners with Pfizer to offer two new COVID-19 booster trials', 'source': 'ABC10', 'date': 'Mar 8, 2022', 'snippet': 'UC Davis Health and Pfizer are partnering to offer two new clinical trials \nin Sacramento for the COVID-19 booster vaccine.', 'thumbnail': 'https://serpapi.com/searches/6722f428d19f15b5303801cf/images/043cb8bba67bc7fabe9f990909a7a89dcb1136e142706a54ac803c6bf4c68682.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8946214914321899}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00422058,"{'position': 1, 'link': 'https://www.nature.com/articles/ijo2013149', 'title': 'Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults', 'source': 'Nature', 'date': 'Aug 14, 2013', 'snippet': 'Liraglutide 3.0 mg, with diet and exercise, produced substantial weight \nloss over 1 year that was sustained over 2 years in obese...', 'thumbnail': 'https://serpapi.com/searches/6722f432ea57e9bfc89a63f3/images/4ad534718eeae55716ceb8173ee35602937d73e60059c40a12e8bf644bef3651.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8196178078651428}",,,,,,,,,,['neutral'],neutral,1
NCT03508947,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/wave-life-sciences-discontinues-suvodirsen-development-for-dmd/', 'title': 'Wave Life Sciences Discontinues Development of Suvodirsen for DMD', 'source': 'Muscular Dystrophy News', 'date': 'Dec 17, 2019', 'snippet': 'Following its failure to increase dystrophin levels of patients in an \nearly-stage clinical trial, Wave Life Sciences has discontinued...', 'thumbnail': 'https://serpapi.com/searches/6722f438d78a985ac5d5b624/images/784bc15c6e8bfac939b424021903bb6569aee1c3510b4bfa9aef4d227020b4a1.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7621912956237793}",,,,,,,,,,['negative'],negative,0
NCT02006121,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/fda-needs-more-info-spn-830-before-making-approval-decision-device/', 'title': 'FDA says it needs more info on SPN-830 before decision on device', 'source': ""Parkinson's News Today"", 'date': 'Apr 8, 2024', 'snippet': 'The US Food and Drug Administration (FDA) said it needs more information \nbefore deciding whether to approve the apomorphine infusion pump SPN-830 \nfor the...', 'thumbnail': 'https://serpapi.com/searches/6722f4380197ddc6e9729c65/images/c81fc69d06b756587be644acb5b0d4734a76a6fe6a227f29819a4140c95078eb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9497389197349548}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/fda-sets-2024-decision-date-apomorphine-pump-spn-830-parkinsons/', 'title': 'FDA sets date in 2024 for decision on SPN-830 apomorphine pump', 'source': ""Parkinson's News Today"", 'date': 'Nov 3, 2023', 'snippet': ""The U.S. Food and Drug Administration (FDA) has accepted Supernus \nPharmaceuticals' new application seeking approval of its apomorphine..."", 'thumbnail': 'https://serpapi.com/searches/6722f4380197ddc6e9729c65/images/c81fc69d06b75658ba1e791c93075d2cb1ee1cdb6052841deb0713ffddbe8a0b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8884477615356445}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02386839,"{'position': 1, 'link': 'https://www.nature.com/articles/s41390-018-0228-0', 'title': 'Preventing bronchopulmonary dysplasia: new tools for an old challenge', 'source': 'Nature', 'date': 'Nov 21, 2018', 'snippet': 'Bronchopulmonary dysplasia (BPD) is the most prevalent chronic lung disease \nin infants and presents as a consequence of preterm birth.', 'thumbnail': 'https://serpapi.com/searches/6722f43c2bab90dbe8e60296/images/61b4790f14f2ad06a452ac34cc7d8becdefb8c3e8fd16d8d5bc80fe95d9da77f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6512972116470337}",,,,,,,,,,['neutral'],neutral,1
NCT02437318,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1813904', 'title': 'Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'May 15, 2019', 'snippet': 'PIK3CA mutations occur in approximately 40% of patients with hormone \nreceptor (HR)–positive, human epidermal growth factor receptor 2...', 'thumbnail': 'https://serpapi.com/searches/6722f46b671f3fe9cb2306da/images/68a4a81ed82235def73bc8e57d5e402d89784b24bb62dd2dd91ed68ee05441c3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6224144101142883}","{'position': 2, 'link': 'https://breastcancer-news.com/2020/08/24/eu-approves-piqray-faslodex-combo-hr-positive-her2-negative-breast-cancer-pik3ca-mutation/', 'title': 'EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation', 'source': 'Breast Cancer News', 'date': 'Aug 24, 2020', 'snippet': 'The EU has approved Piqray with Faslodex as a treatment for HR+/HER2- \nadvanced or metastatic breast cancer that harbors a PIK3CA mutation.', 'thumbnail': 'https://serpapi.com/searches/6722f46b671f3fe9cb2306da/images/68a4a81ed82235deca621edc8bd65669b252721032a99025280f2908cbd9bb54.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8750541806221008}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02598557,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/news/breast-cancer-exemestane-given-3-times-week-is-noninferior-daily-dosing/', 'title': 'Exemestane Given 3 Times a Week Is Noninferior to Daily Dosing in Breast Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Apr 4, 2023', 'snippet': 'A 3-times-weekly dose of exemestane appears noninferior to standard daily \ndosing in estrogen receptor-positive breast cancer patients, according to \nresearch.', 'thumbnail': 'https://serpapi.com/searches/6722f4b2bcd6529d39ba6535/images/6c01e0f93d816c5ff991c2129d3e9e03e9ec0dc2ecfdd4e4797d9c7af315254b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5581798553466797}",,,,,,,,,,['neutral'],neutral,1
NCT02450552,"{'position': 1, 'link': 'https://www.als.org/blog/motor-neuron-excitability-reduced-people-als-following-ezogabine-treatment', 'title': 'Motor Neuron Excitability is Reduced in People with ALS Following Ezogabine Treatment', 'source': 'The ALS Association', 'date': 'Dec 24, 2020', 'snippet': 'Dr. Brian Wainger from the Massachusetts General Hospital (MGH) presented \ninitial top-level results from a recently completed phase II clinical trial \nof...', 'thumbnail': 'https://serpapi.com/searches/6722f4d9fc183dcd64140629/images/cdc891ecc00c1acbf18a396cb5e82b78906bd46ba791d98bdb1e82c375d17ac0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7142907977104187}",,,,,,,,,,['neutral'],neutral,1
NCT01776424,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046048', 'title': 'The COMPASS Trial:', 'source': 'American Heart Association Journals', 'date': 'May 21, 2020', 'snippet': 'Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 \nmg reduced the risk of cardiovascular events as compared with ASA \nmonotherapy in...', 'thumbnail': 'https://serpapi.com/searches/6722f4eee9245621f556e18d/images/6c330b78031be42b448a7355328d52b53ded8afed1e69ddb944e01e8275db9f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8436346054077148}",,,,,,,,,,['neutral'],neutral,1
NCT03201913,"{'position': 1, 'link': 'https://breastcancer-news.com/2020/09/17/ttc-352-safe-hormone-therapy-resistant-patients-phase-1-clinical-trial/', 'title': 'TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds', 'source': 'Breast Cancer News', 'date': 'Sep 17, 2020', 'snippet': 'The investigative oral therapy was found tolerable and safe at high dose, \nand may be alternative to chemo for select ER-positive patients.', 'thumbnail': 'https://serpapi.com/searches/6722f4efe8735ac10d484227/images/2bedb35f35208dbedc70ac556ca3ec7158279846ea2bce7a148b7509e96ce474.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.586205244064331}",,,,,,,,,,['positive'],positive,1
NCT03065010,"{'position': 1, 'link': 'https://www.nature.com/articles/s41388-022-02347-1', 'title': 'Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer', 'source': 'Nature', 'date': 'May 14, 2022', 'snippet': 'Transcriptional deregulation has emerged as a hallmark of several cancer \ntypes. In metastatic castration-resistant prostate cancer,...', 'thumbnail': 'https://serpapi.com/searches/6722f54a81262a594b8d21a2/images/a8c69fda1ec041758af73961d6db2e2c9a580660daccfca48be53afaf69672b4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.586356520652771}",,,,,,,,,,['neutral'],neutral,1
NCT02267603,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1603702', 'title': 'PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma', 'source': 'The New England Journal of Medicine', 'date': 'Mar 11, 2017', 'snippet': 'In this study, first-line therapy with pembrolizumab in patients with \nadvanced Merkel-cell carcinoma was associated with an objective response \nrate of 56%.', 'thumbnail': 'https://serpapi.com/searches/6722f57e59f9112fb14a0a95/images/934e6c6ae82a1b13428fe5d180a2c77005de75aedae5962abd012044a455fdf0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.861939549446106}","{'position': 2, 'link': 'https://immuno-oncologynews.com/2019/02/22/keytruda-better-than-chemotherapy-untreated-advanced-merkel-cell/', 'title': 'Study: Keytruda Better Than Chemotherapy for Untreated Merkel Cell', 'source': 'Immuno-Oncology News', 'date': 'Feb 22, 2019', 'snippet': 'Patients with an aggressive kind of skin cancer called Merkel cell \ncarcinoma appear to have better responses and live longer when given the \nPD-1 inhibitor...', 'thumbnail': 'https://serpapi.com/searches/6722f57e59f9112fb14a0a95/images/934e6c6ae82a1b138db736a6d8802612e105d6d9a0f82fa7de3fa998e69c3f58.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5485749244689941}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03507790,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/ct1812-slows-cognitive-decline-proof-concept-alzheimers-trial/', 'title': 'CT1812 slows cognitive decline in proof-of-concept clinical trial', 'source': ""Alzheimer's News Today"", 'date': 'Aug 22, 2024', 'snippet': ""CT1812 was shown to slow the decline of cognitive function in adults with \nAlzheimer's disease in a proof-of-concept clinical trial."", 'thumbnail': 'https://serpapi.com/searches/6722f5c19819f339e37905e6/images/85f9911ffccb61dc1986c291e2add39afa15e9aa687ac17c91b6e68985e36f59.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7613821625709534}","{'position': 2, 'link': 'https://www.neurologylive.com/view/neurovoices-anthony-caggiano-therapeutic-progress-alzheimer-agent-ct1812', 'title': 'NeuroVoices: Anthony Caggiano, MD, PhD, on Therapeutic Progress of Alzheimer Agent CT1812', 'source': 'Neurology live', 'date': 'Aug 21, 2024', 'snippet': 'The chief medical officer and head of Research & Development at Cognition \nTherapeutics discussed data from the phase 2 proof-of-concept...', 'thumbnail': 'https://serpapi.com/searches/6722f5c19819f339e37905e6/images/85f9911ffccb61dc123eeaec0b18e0816e2ef9b5bcaa105b7ec61f3a5ef4a608.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9362901449203491}","{'position': 3, 'link': 'https://www.morningstar.com/news/globe-newswire/9263884/cognition-therapeutics-announces-results-of-pre-specified-analysis-of-shine-study-data-presented-at-ctad', 'title': 'Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD', 'source': 'Morningstar', 'date': '1 day ago', 'snippet': 'Results show CT1812 dramatically slowed cognitive decline in patients with \nlower levels of plasma p-tau217, an important biomarker of...', 'thumbnail': 'https://serpapi.com/searches/6722f5c19819f339e37905e6/images/85f9911ffccb61dcdf45b94745b430f5c34d69434dd7db406d983703705a5054.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8459738492965698}","{'position': 4, 'link': 'https://finance.yahoo.com/news/cognition-therapeutics-proof-concept-phase-110000080.html', 'title': 'Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients', 'source': 'Yahoo Finance', 'date': 'Jul 29, 2024', 'snippet': 'The SHINE trial showed that after 182 days of treatment, CT1812 \ndemonstrated evidence of clinical improvements on cognition coupled with a \nfavorable safety and...', 'thumbnail': 'https://serpapi.com/searches/6722f5c19819f339e37905e6/images/85f9911ffccb61dcf977bfb6d07c0172448ad6caed0c4b05fb1376d5cf3aac65.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5829297304153442}","{'position': 5, 'link': 'https://www.genengnews.com/topics/drug-discovery/as-biopharma-giants-reshape-the-field-cognition-therapeutics-sees-a-place-for-its-alzheimers-drug/', 'title': 'As Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a Place for Its Alzheimer’s Drug', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Oct 23, 2023', 'snippet': ""Cognition Therapeutics' CT1812 is a once-daily, oral, brain penetrant \nsmall-molecule antagonist of the sigma-2 receptor (S2R) that has completed \none Phase II..."", 'thumbnail': 'https://serpapi.com/searches/6722f5c19819f339e37905e6/images/85f9911ffccb61dceb88639302fe3a8bf5aa8b7f0c51663dd3e2e1ef9ae5d81b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8050349354743958}","{'position': 6, 'link': 'https://alzheimersnewstoday.com/ct1812/', 'title': 'Elayta (CT1812)', 'source': ""Alzheimer's News Today"", 'date': 'Apr 7, 2018', 'snippet': ""CT1812 is an oral medication being developed by Cognition Therapeutics, now \nin clinical testing, to possibly treat mild-to-moderate Alzheimer's disease \nby..."", 'thumbnail': 'https://serpapi.com/searches/6722f5c19819f339e37905e6/images/85f9911ffccb61dc1eb62a57e71905b90dd953e63db1677e78bf968210f450e6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8871570825576782}",,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03804996,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/hon.3164_434', 'title': 'First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients with B-Cell Lymphoma', 'source': 'Wiley Online Library', 'date': 'Jun 9, 2023', 'snippet': 'TG-1801 is a CD19/CD47 bispecific antibody designed to selectively block \nCD47 on CD19+ cells, while retaining a functional IgG1 Fc domain.', 'thumbnail': 'https://serpapi.com/searches/6722f5e654163d58a7b240aa/images/742ad47e0dd68e900a5b8e43034103d4fcef01d2f813983261a98ca33cabc0fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8992688059806824}",,,,,,,,,,['neutral'],neutral,1
NCT01371305,"{'position': 1, 'link': 'https://www.science.org/doi/10.1126/scitranslmed.aao0475', 'title': 'Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials', 'source': 'Science | AAAS', 'date': 'Jan 3, 2018', 'snippet': 'Tissues stiffen during aging and during the pathological progression of \ncancer, fibrosis, and cardiovascular disease.', 'thumbnail': 'https://serpapi.com/searches/6722f5f1e8735ac0c37c7fc4/images/a441ca2300929f1b9ecc36eba69a13f92cf0c804bef2f4a3ba5df3d28786b2a4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8034569025039673}",,,,,,,,,,['neutral'],neutral,1
NCT01241552,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1602615', 'title': 'Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection', 'source': 'The New England Journal of Medicine', 'date': 'Jan 26, 2017', 'snippet': 'Clostridium difficile is the most common cause of infectious diarrhea in \nhospitalized patients. Recurrences are common after antibiotic...', 'thumbnail': 'https://serpapi.com/searches/6722f5f464f11d7899964714/images/613b9272534a2ee048819a2f7b5c03c69f5ca9a697e4b93c2844298beb090344.png', 'sentiment': 'negative', 'sentiment_prob': 0.6945229172706604}",,,,,,,,,,['negative'],negative,0
NCT04146363,"{'position': 1, 'link': 'https://www.empr.com/news/ebglyss-approved-for-moderate-to-severe-atopic-dermatitis/', 'title': 'Ebglyss Approved for Moderate to Severe Atopic Dermatitis', 'source': 'Medical Professionals Reference', 'date': '1 month ago', 'snippet': 'The Food and Drug Administration (FDA) has approved Ebglyss™ \n(lebrikizumab-lbkz) for the treatment of adult and pediatric patients aged \n12...', 'thumbnail': 'https://serpapi.com/searches/6722f623a47167cbfaf0f5a0/images/64183e5bc8362918b6a340c8d3c10674744cc65627123f4c97e4d3a6d9eeda20.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8664060831069946}","{'position': 2, 'link': 'https://www.dermatologyadvisor.com/cch/moderate-to-severe-atopic-dermatitis-clinician-insights-2022-american-academy-of-dermatology-annual-meeting/', 'title': 'Moderate to Severe Atopic Dermatitis: Treatment Insights From the 2022 American Academy of Dermatology Annual Meeting', 'source': 'Dermatology Advisor', 'date': 'May 17, 2024', 'snippet': 'Brett King, MD, PhD, FAAD, an associate professor of dermatology at Yale \nSchool of Medicine in New Haven, Connecticut, shares his perspective on \nrecent...', 'thumbnail': 'https://serpapi.com/searches/6722f623a47167cbfaf0f5a0/images/64183e5bc8362918d89db91e1baf96c05a3c5cd43f0cc6c62b11f9bd3eb6bd14.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.937115490436554}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04989816,"{'position': 1, 'link': 'https://www.onclive.com/view/t-dxd-wins-conditional-approval-in-china-for-pretreated-her2-gastric-gej-cancer', 'title': 'T-DXd Wins Conditional Approval in China for Pretreated HER2+ Gastric/GEJ Cancer', 'source': 'OncLive', 'date': 'Aug 13, 2024', 'snippet': ""Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) has been granted \nconditional approval by China's National Medical Products Administration..."", 'thumbnail': 'https://serpapi.com/searches/6722f648fc40bfd007d1d7e5/images/f14c1f15138b8b36cde7c0661e7da3a74ac092e5815a9afef6a6cf343eefa6c6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8588294386863708}",,,,,,,,,,['neutral'],neutral,1
NCT02201901,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1512614', 'title': 'Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis', 'source': 'The New England Journal of Medicine', 'date': 'Nov 16, 2015', 'snippet': 'As the population that is infected with the hepatitis C virus (HCV) ages, \nthe number of patients with decompensated cirrhosis is expected to...', 'thumbnail': 'https://serpapi.com/searches/6722f68cb9ab860ead16e22f/images/448c30f29c04b49de0ecea079eab62ba0f5f312f2d4f57ec0933d6120e729961.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8350131511688232}",,,,,,,,,,['neutral'],neutral,1
NCT03456882,"{'position': 1, 'link': 'https://alsnewstoday.com/news/short-course-treatment-rns60-extends-survival-als-patients/', 'title': 'Short course of treatment with RNS60 extends survival in ALS', 'source': 'ALS News Today', 'date': '1 month ago', 'snippet': 'A short course of treatment with RNS60, as an add-on to riluzole, extended \nthe survival of ALS patients by about six months, a study found.', 'thumbnail': 'https://serpapi.com/searches/6722f7e2922cce60593a1a59/images/389029b77de31f0707109caa5721cb2219ded18425917fd2b5ed004d6c3acfce.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8640610575675964}",,,,,,,,,,['neutral'],neutral,1
NCT03937479,"{'position': 1, 'link': 'https://copdnewstoday.com/news/nebulized-ensifentrine-add-on-therapy-copd-verona-pharma/', 'title': 'Nebulized Ensifentrine Shows Promise as Add-on Therapy', 'source': 'COPD News Today', 'date': 'Apr 29, 2021', 'snippet': 'Verona Pharma announced results of a trial about the use of nebulized \nensifentrine added to tiotropium for treating chronic obstructive...', 'thumbnail': 'https://serpapi.com/searches/6722f82588bcdeacfd8f0c97/images/c17602ee6aba3cf6d5e5ff5faa66667d131c2c933b32b7a1f4422c3431753132.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.562683641910553}","{'position': 2, 'link': 'https://www.pulmonologyadvisor.com/news/first-in-class-dual-pde-inhibitor-plus-tiotropium-may-improve-lung-function-in-copd/', 'title': 'First-in-Class Dual PDE Inhibitor Plus Tiotropium May Improve Lung Function in COPD', 'source': 'Pulmonology Advisor', 'date': 'Aug 10, 2020', 'snippet': 'Nebulized ensifentrine, when added to tiotropium, produced clinically \nmeaningful and significant improvements in lung function and quality of \nlife in patients...', 'thumbnail': 'https://serpapi.com/searches/6722f82588bcdeacfd8f0c97/images/c17602ee6aba3cf68afba898ba669d359333585e1cc43974cbe538e88d8ef970.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7554508447647095}","{'position': 3, 'link': 'https://copdnewstoday.com/news/verona-starts-phase-2b-trial-to-test-nebulized-ensifentrine-as-add-on-therapy/', 'title': 'Verona Starts Phase 2b Trial to Test Nebulized Ensifentrine as Add-on Therapy', 'source': 'COPD News Today', 'date': 'May 28, 2019', 'snippet': 'Verona Pharma starts Phase 2b study testing nebulized ensifentrine as an \nadd-on therapy to a bronchodilator in patients with moderate to...', 'thumbnail': 'https://serpapi.com/searches/6722f82588bcdeacfd8f0c97/images/c17602ee6aba3cf6e54577a6a07a8ed71ca1258f558f0d26d03196c08702026d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9140104651451111}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT04940624,"{'position': 1, 'link': 'https://dravetsyndromenews.com/news/soticlestat-trial-narrowly-misses-main-goal-findings-promising/', 'title': 'Soticlestat trial narrowly misses main goal, but findings promising', 'source': 'Dravet Syndrome News', 'date': 'Jun 18, 2024', 'snippet': 'A Phase 3 clinical trial testing soticlestat in people with Dravet syndrome \nshowed that patients given soticlestat tended to have fewer seizures than \nthose...', 'thumbnail': 'https://serpapi.com/searches/6722f6ba8d1473925355a079/images/7b58af3bebe15eeea9feec2fe6c5425810561c11d4c497691c74b206ee1d8d6d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7790983319282532}","{'position': 2, 'link': 'https://dravetsyndromenews.com/news/skyline-study-dravet-syndrome-treatment-enrolling-patients-ages-2-21/', 'title': 'Skyline Study to Test Soticlestat Safety, Efficacy in Patients Ages 2–21', 'source': 'Dravet Syndrome News', 'date': 'May 24, 2022', 'snippet': 'A Phase 3 clinical trial is recruiting Dravet syndrome patients between the \nages of 2 and 21 to assess the effectiveness, safety, and tolerability of \nthe...', 'thumbnail': 'https://serpapi.com/searches/6722f6ba8d1473925355a079/images/7b58af3bebe15eee29d414bef88139fde799cec23cfdfa86f5cc07a29c4de02a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9025710225105286}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02409290,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/features/fda-alert-pulmonology-drug-approvals-recalls-device-updates/', 'title': 'FDA Alert: Pulmonology Drug Approvals and Recalls, Medical Device Updates', 'source': 'Pulmonology Advisor', 'date': '1 month ago', 'snippet': 'The US Food and Drug Administration (FDA) approved an adult respiratory \nsyncytial virus (RSV) vaccine and a pneumococcal 21-valent conjugate \nvaccine.', 'thumbnail': 'https://serpapi.com/searches/6722f78068831e828e5d3371/images/6377c29361f68c0ae4144e4b95f45e4a0c34ee94dce2f10fc96cf86bb3dcd980.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8262734413146973}",,,,,,,,,,['neutral'],neutral,1
NCT00425607,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/full/10.1161/circulationaha.116.022188', 'title': 'Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome', 'source': 'American Heart Association Journals', 'date': 'Jul 8, 2016', 'snippet': 'A previous single-arm clinical trial demonstrated that the protein \nfarnesyltransferase inhibitor lonafarnib ameliorates some aspects of \ncardiovascular and bone...', 'thumbnail': 'https://serpapi.com/searches/6722f7a069f8ec4c3c807ec1/images/58b32ea8bc9725adcc5b1638276e0347f1ea423acae2e1990ad0db8f8f86017f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9124721884727478}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/abs/10.1161/circulationaha.113.008285', 'title': 'Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome | Circulation', 'source': 'American Heart Association Journals', 'date': 'May 2, 2014', 'snippet': 'This study provides a robust untreated disease survival profile that can be \nused for comparisons now and in the future to assess changes in survival \nwith...', 'thumbnail': 'https://serpapi.com/searches/6722f7a069f8ec4c3c807ec1/images/58b32ea8bc9725ad5f6bc58bf32cdf75010edededf90bc155ec8a1c2e8e72ad4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8798786401748657}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02811263,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2119660', 'title': 'Trial of Erythropoietin for Hypoxic–Ischemic Encephalopathy in Newborns', 'source': 'The New England Journal of Medicine', 'date': 'Jul 13, 2022', 'snippet': 'Neonatal hypoxic–ischemic encephalopathy is an important cause of death as \nwell as long-term disability in survivors.', 'thumbnail': 'https://serpapi.com/searches/6722f7a9cc4879ca15c166bc/images/c6eeb9f6b8d4e6a754a60afd148bb9aef2e36bf67c86e2a4651ab22d466f58cf.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6995729804039001}","{'position': 2, 'link': 'https://pubs.rsna.org/doi/abs/10.1148/ryai.240076', 'title': 'Artificial Intelligence Outcome Prediction in Neonates with Encephalopathy (AI-OPiNE)', 'source': 'Radiological Society of North America | RSNA', 'date': 'Jul 10, 2024', 'snippet': 'A deep learning algorithm effectively identified patients who experienced \ndeath or neurodevelopmental impairment at 2 years using multisequence MRI \nand...', 'thumbnail': 'https://serpapi.com/searches/6722f7a9cc4879ca15c166bc/images/c6eeb9f6b8d4e6a7727c942d75aa2bc9199956e8611185f5e2eba5082ea84f26.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8899710178375244}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT01660451,"{'position': 1, 'link': 'https://www.onclive.com/view/bayer-withdraws-us-indication-for-copanlisib-in-relapsed-follicular-lymphoma', 'title': 'Bayer Withdraws US Indication for Copanlisib in Relapsed Follicular Lymphoma', 'source': 'OncLive', 'date': 'Nov 13, 2023', 'snippet': 'Bayer has announced the intention to voluntarily withdraw the new drug \napplication for copanlisib in adult patients with relapsed follicular...', 'thumbnail': 'https://serpapi.com/searches/6722f84a2a4882d38f3830c1/images/50ddb8151698556c1106eeb8fa634dc51f897dba2662c333334d77c83d444163.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8012410402297974}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/bayer-receives-fda-approval-for-aliqopa-copanlisib-60-mg-vial-for-injection-in-adults-with-relapsed-follicular-lymphoma-after-two-prior-systemic-therapies-300520109.html', 'title': 'Bayer Receives FDA Approval for Aliqopa™ (copanlisib) 60 mg vial for Injection in Adults with Relapsed Follicular Lymphoma after Two Prior Systemic Therapies', 'source': 'PR Newswire', 'date': 'Sep 14, 2017', 'snippet': 'Continued approval for this indication may be contingent upon verification \nand description of clinical benefit in a confirmatory trial(1).', 'thumbnail': 'https://serpapi.com/searches/6722f84a2a4882d38f3830c1/images/50ddb8151698556cca72b8becd62558b86211d9fadcd0d8ceac42ee7f1d2545a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8838237524032593}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04405076,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2022483', 'title': 'An mRNA Vaccine against SARS-CoV-2 — Preliminary Report', 'source': 'The New England Journal of Medicine', 'date': 'Jul 14, 2020', 'snippet': 'The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all \nparticipants, and no trial-limiting safety concerns were identified.', 'thumbnail': 'https://serpapi.com/searches/6722f981749783416cf4037f/images/c2c3c5400fb589bed26f8006b0a30ea1ddd800f00cfb101869bfcc3f980d3cde.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8116927742958069}","{'position': 2, 'link': 'https://www.nature.com/articles/s41591-021-01527-y', 'title': 'Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis', 'source': 'Nature', 'date': 'Sep 15, 2021', 'snippet': 'The emergence of SARS-CoV-2 variants of concern (VOCs) and variants of \ninterest (VOIs) with decreased susceptibility to neutralization has...', 'thumbnail': 'https://serpapi.com/searches/6722f981749783416cf4037f/images/c2c3c5400fb589be64c6e151198d80f023eb94b688f7b6bf2c0b94fa7a304599.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8676652908325195}","{'position': 3, 'link': 'https://www.nature.com/articles/s41591-022-01739-w', 'title': 'Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial', 'source': 'Nature', 'date': 'Mar 3, 2022', 'snippet': 'Rising breakthrough infections of severe acute respiratory syndrome \ncoronavirus 2 (SARS-CoV-2) in previously immunized individuals have...', 'thumbnail': 'https://serpapi.com/searches/6722f981749783416cf4037f/images/c2c3c5400fb589be27a8757bed51dc513e62f157d66545c6835a75ced92c061a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7612559795379639}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02918357,"{'position': 1, 'link': 'https://www.urotoday.com/video-lectures/imaging-prostate-cancer/video/1960-68ga-psma-11-joins-fda-approved-tools-for-management-of-prostate-cancer-thomas-hope.html', 'title': '68Ga-PSMA-11 Joins FDA-Approved Tools for Management of Prostate Cancer - Thomas Hope', 'source': 'UroToday', 'date': 'Dec 7, 2020', 'snippet': '68 Ga-PSMA-11, the first drug for PET imaging of prostate-specific membrane \nantigen (PSMA)–positive lesions in men with prostate cancer (PC), was FDA \napproved...', 'thumbnail': 'https://serpapi.com/searches/6722f9a0d9c3e6fbd0fc2251/images/289c94af9fc5f13f0c8dd0a4c025dd3b3e317d3849474b313a11f453bbb511c9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7859143018722534}",,,,,,,,,,['neutral'],neutral,1
NCT02409342,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1917346', 'title': 'Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC', 'source': 'The New England Journal of Medicine', 'date': 'Sep 30, 2020', 'snippet': 'Atezolizumab treatment resulted in significantly longer overall survival \nthan platinum-based chemotherapy among patients with NSCLC with high PD-L1 \nexpression.', 'thumbnail': 'https://serpapi.com/searches/6722f9b7b2ebae6228943e05/images/3301baee804db6e56f95e701b8034ee517e1b5f1bc8cc91e37a3ecf0810998f8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7920814156532288}",,,,,,,,,,['neutral'],neutral,1
NCT02318329,"{'position': 1, 'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.19.01834', 'title': 'Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma', 'source': 'ASCO Publications', 'date': 'Mar 13, 2020', 'snippet': 'PURPOSETo evaluate the safety, pharmacokinetics, and preliminary activity \nof bemarituzumab in patients with FGFR2b-overexpressing gastric...', 'thumbnail': 'https://serpapi.com/searches/6722f9b5a32436a16214c69c/images/7901d8a007e83a48bdc49bb7649c91d24b43829f46bf6e75293d91b36dd0dd29.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8843021988868713}",,,,,,,,,,['neutral'],neutral,1
NCT04436497,"{'position': 1, 'link': 'https://alsnewstoday.com/news/ucb-stops-zilucoplan-arm-early-healey-trial-als-lack-of-efficacy/', 'title': 'Zilucoplan Arm in HEALEY Trial for ALS Stopped Early for Lack of Benefit', 'source': 'ALS News Today', 'date': 'Mar 7, 2022', 'snippet': ""The Phase 2/3 clinical trial testing UCB's investigational therapy \nzilucoplan for amyotrophic lateral sclerosis (ALS) — one of the arms of..."", 'thumbnail': 'https://serpapi.com/searches/6722f9fa240793cdd015e136/images/393ca474590a1b4751da2c64fb6afd48867666111d9f3f91c7c36db70cfeb3ff.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.616557776927948}","{'position': 2, 'link': 'https://alsnewstoday.com/news/als-therapy-verdiperstat-fails-healey-trial-efficacy-goals/', 'title': 'ALS Therapy Verdiperstat Fails to Meet Efficacy Goals in HEALEY Trial', 'source': 'ALS News Today', 'date': 'Oct 6, 2022', 'snippet': 'The ALS therapy verdiperstat failed to slow disease progression, improve \nsurvival, or meet other efficacy goals in the HEALEY platform...', 'thumbnail': 'https://serpapi.com/searches/6722f9fa240793cdd015e136/images/393ca474590a1b473860e9efc283d720e386c42c2cdb3b4964260e4d46d29bf1.png', 'sentiment': 'negative', 'sentiment_prob': 0.7811991572380066}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT01807923,"{'position': 1, 'link': 'https://lungdiseasenews.com/2018/01/12/european-union-oks-orkambi-children-cf/', 'title': 'European Union OKs Orkambi Use for Children 6-11 Years Old With CF', 'source': 'Lung Disease News', 'date': 'Jan 12, 2018', 'snippet': 'EU grants extension of marketing authorization for Orkambi to include \nchildren aged 6 to 11 who have CF and two copies of the F508del...', 'thumbnail': 'https://serpapi.com/searches/6722fa19d771bd6b2e5e596d/images/31b853aceafdf51dbbfaf40207a8e0abcaf3012a1daa2ecfa15cf7837df994d6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7960894703865051}",,,,,,,,,,['neutral'],neutral,1
NCT04751539,"{'position': 1, 'link': 'https://www.abc4.com/business/press-releases/cision/20241028CN42084/kind-presents-positive-results-of-and017-to-treat-anemia-associated-with-chronic-kidney-disease-in-two-phase-ii-and-two-phase-i', 'title': 'KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I', 'source': 'ABC4 Utah', 'date': '2 days ago', 'snippet': 'Clinical Trials at American Society of Nephrology (ASN) – Kidney Week 2024. \nSAN FRANCISCO, Oct. 28, 2024 /PRNewswire/ -- Kind Pharmaceutical...', 'thumbnail': 'https://serpapi.com/searches/6722f87d717bff91dacb3ae2/images/c2c8d2e4e9bd4d530a87957ec4ec61f7cc7915b8ca2787b6f3cdb5bd574bcb20.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.606677770614624}",,,,,,,,,,['neutral'],neutral,1
NCT04411628,"{'position': 1, 'link': 'https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03345-3', 'title': 'Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab', 'source': 'Journal of Translational Medicine', 'date': 'Mar 18, 2022', 'snippet': 'This safety-focused study aims to monitor and characterize the immune \nresponse to SARS-CoV-2 infection via analysis of peripheral blood and \nnasopharyngeal swab...', 'thumbnail': 'https://serpapi.com/searches/6722f89dc05eb5bbb969cb31/images/c2ea3c2cf7aae872c0bd02e09ed0631e122fada7fc14e2938011037c35bf3037.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8966588973999023}",,,,,,,,,,['neutral'],neutral,1
NCT02819856,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/spi-1005-may-help-prevent-ear-damage-due-antibiotics-use-cf/', 'title': 'SPI-1005 may help prevent ear damage due to antibiotics use in CF', 'source': 'Cystic Fibrosis News Today', 'date': 'Jan 31, 2024', 'snippet': 'In a Phase 2 trial, treatment with SPI-1005 appeared to decrease the risk \nof ear damage linked to antibiotics use among adults with CF .', 'thumbnail': 'https://serpapi.com/searches/6722f9160053c7013aadad32/images/1c5322cc8a44fbe99d05eacf6facf7776df1c48d2512f17f597a1cbe9a2df3f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7376077771186829}",,,,,,,,,,['neutral'],neutral,1
NCT02780167,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Time-to-achieve-PP-NRS3-and-PP-NRS4-response-Values-represent-median-95-CI-NE-not_fig2_352783895', 'title': 'Figure 4. Time to achieve PP-NRS3 and PP-NRS4 response. Values...', 'source': 'ResearchGate', 'date': 'Jun 25, 2023', 'snippet': 'Time to achieving a PP-NRS3 response was 9, 13, and 59 days after \ninitiating abrocitinib 200 mg, abrocitinib 100 mg, and placebo, \nrespectively.', 'thumbnail': 'https://serpapi.com/searches/6722f922be149776eabac309/images/c19f1fefe4a3096fd0a89880b84628a6db564affff5d32c6e3e7b263f4f9a695.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9172170758247375}",,,,,,,,,,['neutral'],neutral,1
NCT02186509,"{'position': 1, 'link': 'https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00317-1/fulltext', 'title': 'Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms', 'source': 'The Lancet', 'date': 'Aug 9, 2023', 'snippet': 'Pharmacological synergisms are an attractive anticancer strategy. However, \nwith more than 5000 approved-drugs and compounds in clinical...', 'thumbnail': 'https://serpapi.com/searches/6722f930b9ab860ead16e47e/images/43bc572ced46b58430c721f7fc2bef946d202b69ff7008363ac7efd32a8bc629.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7012706398963928}",,,,,,,,,,['neutral'],neutral,1
NCT05358821,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/dalzanemdor-sage-718-fails-improve-cognition-phase-2-trial/', 'title': 'Dalzanemdor, formerly SAGE-718, fails to aid cognition in Phase 2 trial', 'source': ""Parkinson's News Today"", 'date': 'Apr 24, 2024', 'snippet': ""Dalzanemdor (formerly SAGE-718), a medication for mild cognitive impairment \ndue to Parkinson's, failed to outperform a placebo in a trial."", 'thumbnail': 'https://serpapi.com/searches/6722f944a25104618242088a/images/0ff6a78ffe5e47d57570376ae79353778ec19c16247e9a7a54f6d604a00e0cc7.png', 'sentiment': 'negative', 'sentiment_prob': 0.8312615752220154}","{'position': 2, 'link': 'https://huntingtonsdiseasenews.com/news/phase-2-trial-dalzanemdor-safe-huntingtons-affects-cognition/', 'title': 'Phase 2 trial shows dalzanemdor’s safety, disease’s cognitive impact', 'source': ""Huntington's Disease News"", 'date': 'Jun 18, 2024', 'snippet': ""Oral dalzanemdor (SAGE-718) was well-tolerated by Huntington's patients in \nthe SURVEYOR trial, which also showed disease's cognitive toll."", 'thumbnail': 'https://serpapi.com/searches/6722f944a25104618242088a/images/0ff6a78ffe5e47d5606539f25b4d66342a87d91bd4f49630a317208e43459921.png', 'sentiment': 'positive', 'sentiment_prob': 0.552502453327179}","{'position': 3, 'link': 'https://huntingtonsdiseasenews.com/news/fda-names-sage-718-orphan-drug-huntingtons-disease/', 'title': 'FDA names SAGE-718 orphan drug for Huntington’s disease', 'source': ""Huntington's Disease News"", 'date': 'Oct 31, 2023', 'snippet': ""The US Food and Drug Administration (FDA) has granted orphan drug status to \nSAGE-718, Sage Therapeutics' experimental oral therapy for Huntington's \ndisease."", 'thumbnail': 'https://serpapi.com/searches/6722f944a25104618242088a/images/0ff6a78ffe5e47d5b1a729867faaf73039e2bc57e336c48f38c9e7f0a1311a99.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8941439390182495}",,,,,,,,"['negative', 'positive', 'neutral']",negative,0
NCT03738150,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/iid3.1079', 'title': 'Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension', 'source': 'Wiley Online Library', 'date': 'Nov 9, 2023', 'snippet': 'Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating lung \ndisease characterized by irreversible scarring of the lungs.', 'thumbnail': 'https://serpapi.com/searches/6722f94f1ec32f69d6332f44/images/48478db6f5db71c79c86b2edda8ede3ac0b8f8ace049304d4011f94f78c49201.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7054986357688904}",,,,,,,,,,['neutral'],neutral,1
NCT02504645,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/lupuzor-shows-promising-results-in-phase-3-study-in-lupus-patients/', 'title': 'SLE Therapy Lupuzor Fails Phase 3 Goal of Increased Response Rate', 'source': 'Lupus News Today', 'date': 'Apr 23, 2018', 'snippet': 'Lupuzor (rigerimod) combined with standard therapy failed to achieving a \nstatistically significant response in lupus patients but showed a...', 'thumbnail': 'https://serpapi.com/searches/6722f95411db450134b52a9c/images/9fce92c09966d6ef370ce70d97912209386cde99286ece4dac7325e999414b36.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7614134550094604}",,,,,,,,,,['negative'],negative,0
NCT05548270,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/scopolamine-nasal-gel-prevents-motion-induced-nausea-vomiting/', 'title': 'Scopolamine Nasal Gel Prevents Motion-Induced Nausea, Vomiting', 'source': 'Medical Professionals Reference', 'date': 'Jun 6, 2023', 'snippet': 'Intranasal scopolamine (DPI-386) was found to effectively prevent nausea \nand vomiting induced by motion, according to results from a phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/6722f9728a7c09eac70146c9/images/e30e8706652a9a8923ace907f9c3a591d0f05950d9fc62c74a0437d2bcac38c7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6838697791099548}",,,,,,,,,,['neutral'],neutral,1
NCT04165850,"{'position': 1, 'link': 'https://alsnewstoday.com/news/primec-safe-lowers-als-disease-biomarkers-phase-2-clinical-study/', 'title': 'PrimeC Safe, Lowers ALS Disease Biomarkers in Phase 2 Clinical Study', 'source': 'ALS News Today', 'date': 'Sep 20, 2022', 'snippet': 'PrimeC, an experimental combination treatment for ALS, lowered disease \nbiomarkers in a Phase 2 clinical trial and was well tolerated.', 'thumbnail': 'https://serpapi.com/searches/6722f97bb691a72d6399fb8a/images/ab876361d100adff565ac6d1d5040c3d2f5813379558b6245637ff93f6fdc6f0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5605102777481079}","{'position': 2, 'link': 'https://alsnewstoday.com/news/fda-oks-neurosenses-cmc-primec-ahead-phase-3-trial/', 'title': ""FDA OKs Neurosense's CMC for PrimeC ahead of Phase 3 trial"", 'source': 'ALS News Today', 'date': 'Nov 16, 2023', 'snippet': 'The U.S. Food and Drug Administration (FDA) has signed off on the \nchemistry, manufacturing, and controls (CMC) clinical development plan \nfor...', 'thumbnail': 'https://serpapi.com/searches/6722f97bb691a72d6399fb8a/images/ab876361d100adff382d9fdafbb3d6c6976d2a27dc5b06a2741c2dc065e29a7d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8224320411682129}","{'position': 3, 'link': 'https://alsnewstoday.com/news/primec-boosts-survival-als-patient-derived-motor-neurons/', 'title': 'PrimeC boosts survival of motor neurons derived from ALS patients...', 'source': 'ALS News Today', 'date': 'Oct 11, 2023', 'snippet': ""PrimeC, NeuroSense Therapeutics' investigational, fixed-dose combination \ntherapy for amyotrophic lateral sclerosis (ALS), significantly boosted the \nsurvival of..."", 'thumbnail': 'https://serpapi.com/searches/6722f97bb691a72d6399fb8a/images/ab876361d100adff72af829d6f23ba0bd873166422f975d15ef8b1c29ee50484.png', 'sentiment': 'positive', 'sentiment_prob': 0.6819302439689636}","{'position': 4, 'link': 'https://alsnewstoday.com/news/primec-potential-als-therapy-earns-patents-in-europe-japan-israel/', 'title': 'PrimeC, potential ALS therapy, earns patents in Europe, Japan, Israel', 'source': 'ALS News Today', 'date': 'Oct 2, 2023', 'snippet': 'NeuroSense received patents covering the use of PrimeC in Europe, Japan, \nand Israel; topline data from the Phase 2 trial are expected soon.', 'thumbnail': 'https://serpapi.com/searches/6722f97bb691a72d6399fb8a/images/ab876361d100adffe575327cc820d1038b326e55e164cc6353acb95a918c0488.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6243241429328918}","{'position': 5, 'link': 'https://alsnewstoday.com/news/als-combination-therapy-primec-receives-fdas-orphan-drug-designation-enters-clinical-trials/', 'title': ""ALS Combo Therapy PrimeC Granted FDA's Orphan Drug Status"", 'source': 'ALS News Today', 'date': 'Feb 12, 2020', 'snippet': 'PrimeC, a combination treatment by NeuroSense Therapeutics to slow down or \nhalt the progression of ALS, has received orphan drug status from...', 'thumbnail': 'https://serpapi.com/searches/6722f97bb691a72d6399fb8a/images/ab876361d100adff2378bb02cce2b23c81bc86b8f9f79570ed9ef04cc930477f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8949474096298218}",,,,,,"['neutral', 'neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT03433482,"{'position': 1, 'link': 'https://www.empr.com/home/news/single-vial-presentation-of-meningococcal-vaccine-menveo-gets-fda-approval/', 'title': 'Single-Vial Presentation of Meningococcal Vaccine Menveo Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Oct 17, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved a new ready-to-use \nsingle dose vial presentation of Menveo (meningococcal [Groups A, C, Y, \nW-135]...', 'thumbnail': 'https://serpapi.com/searches/6722fa5c1f3d4bf318db5586/images/0c1aef7e6175be52335f49b3cc1d9a37fc466d7d2039776521a350a151952ade.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.648646891117096}",,,,,,,,,,['neutral'],neutral,1
NCT02912468,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/alr.22780', 'title': 'Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps', 'source': 'Wiley Online Library', 'date': 'Feb 21, 2021', 'snippet': 'Additional Supporting Information may be found in the online version of \nthis article. Funding sources for the study: Sanofi (Cambridge,...', 'thumbnail': 'https://serpapi.com/searches/6722fb08fd3b5a6447517944/images/62a0ad683b2128fa7f4462759d505de02975c86e021d50ca57469cdd80407dfb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8970773816108704}",,,,,,,,,,['neutral'],neutral,1
NCT00122681,"{'position': 1, 'link': 'https://www.infectiousdiseaseadvisor.com/news/bivalent-quadrivalent-human-papillomavirus-vaccine-immunogenicity/', 'title': 'Immunogenicity, Cross-Protective Efficacy of Bivalent vs Quadrivalent HPV Vaccine', 'source': 'Infectious Disease Advisor', 'date': 'Jun 30, 2021', 'snippet': 'Immunogenicity of HPV vaccines are correlated to their cross-protective \nefficacy, with significant differences in induced antibody...', 'thumbnail': 'https://serpapi.com/searches/6722fb624e9efcf6a8efa805/images/b0269bbb0df3e1a4787e7328381dc2d5ce6dbfcbb9441f21e7240f208bc486c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8467316627502441}",,,,,,,,,,['neutral'],neutral,1
NCT04885218,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIR.0000000000001200', 'title': 'Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association’s Scientific Sessions 2023 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2023', 'source': 'American Heart Association Journals', 'date': 'Dec 18, 2023', 'snippet': 'Late-Breaking Science: Obesity - Novel Therapeutics and Implications for \nPopulation Health 22962: Semaglutide and Cardiovascular Outcomes in \nPatients With...', 'thumbnail': 'https://serpapi.com/searches/6722fb93e10f0a459b66c3d9/images/91accd788a601d243e112590b8061dec6b620ce8305e457e6937ca8e38a2b83f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9537796974182129}",,,,,,,,,,['neutral'],neutral,1
NCT04881760,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2301972', 'title': 'Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial', 'source': 'The New England Journal of Medicine', 'date': 'Jun 26, 2023', 'snippet': 'Retatrutide (LY3437943) is an agonist of the glucose-dependent \ninsulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.', 'thumbnail': 'https://serpapi.com/searches/6722fbc971c62b0afdbdde1d/images/f5d975c7344af9f1210027ec06440f98c94c90f5b6f4fb54897c87e3fec53f75.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8586753606796265}","{'position': 2, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal', 'title': ""Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight"", 'source': 'Eli Lilly and Company', 'date': 'Jun 26, 2023', 'snippet': 'The investigational molecule achieved up to 17.5% mean weight reduction at \n24 weeks in adults with obesity and overweight.', 'thumbnail': 'https://serpapi.com/searches/6722fbc971c62b0afdbdde1d/images/f5d975c7344af9f13f1deb885f9883871e2d6c12091073b6ac9a7ed38e8ab01a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8676040172576904}","{'position': 3, 'link': 'https://www.clinicaltrialsarena.com/analyst-comment/esc-2024-retatrutide-lipid-cardiovascular-risk-profile-phase-ii/', 'title': 'ESC 2024: Retatrutide improves lipid and cardiovascular risk profile in Phase II trial', 'source': 'Clinical Trials Arena', 'date': 'Aug 30, 2024', 'snippet': 'At ESC Congress 2024, Eli Lilly and Co announced the most recent trial \nresults for retatrutide related to cardiovascular risk factors.', 'thumbnail': 'https://serpapi.com/searches/6722fbc971c62b0afdbdde1d/images/f5d975c7344af9f1c3f1354173b4a813d5c5ce1e58f1c1cf5b3dcebfa70d6b3a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5915625691413879}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02896192,"{'position': 1, 'link': 'https://geneticobesitynews.com/2020/07/23/setmelanotide-prevents-obesity-mouse-model-pomc-deficiency-study/', 'title': 'Obesity From POMC Deficiency Prevented by Setmelanotide, Study Says', 'source': 'geneticobesitynews.com', 'date': 'Jul 23, 2020', 'snippet': 'Continuous setmelanotide treatment in mice with a form of POMC deficiency \nprevented the development of obesity, a study reports.', 'thumbnail': 'https://serpapi.com/searches/6722fbe2f9f9043541f18ccf/images/66b82b3f346364b8a29faa9befe882bda45ca105ed7d0ab1378900a10f1c3733.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8007467985153198}",,,,,,,,,,['neutral'],neutral,1
NCT01997229,"{'position': 1, 'link': 'https://myastheniagravisnews.com/news/soliris-response-gmg-longer-3-months-regain-ole-trial-analysis/', 'title': 'Response to Soliris May Take Longer Than 3 Months for Some With gMG', 'source': 'Myasthenia Gravis News', 'date': 'Jun 8, 2021', 'snippet': 'Trial data found that up to 17% of people with generalized myasthenia \ngravis took longer than 12 weeks to show response to Soliris.', 'thumbnail': 'https://serpapi.com/searches/6722fbe517b10e3121979c00/images/7d4a66bcca9169c8dc1aeea4c4ff96599c51a32ccc6d5f17ed6a16525def94dc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5196812152862549}","{'position': 2, 'link': 'https://myastheniagravisnews.com/news/generalized-mg-symptoms-may-worsen-severely-after-discontinuing-soliris-treatment-case-study-reports/', 'title': 'MG Symptoms Worsen Severely After Stopping Soliris, Case Study Finds', 'source': 'Myasthenia Gravis News', 'date': 'Oct 23, 2020', 'snippet': 'A Japanese man with generalized myasthenia gravis (gMG) experienced a \nsevere worsening of symptoms after stopping Soliris treatment,...', 'thumbnail': 'https://serpapi.com/searches/6722fbe517b10e3121979c00/images/7d4a66bcca9169c8f75f44806f81f75a636a3dd011492b54573a8521894a4084.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6118899583816528}","{'position': 3, 'link': 'https://myastheniagravisnews.com/news/myasthenia-gravis-therapy-soliris-may-see-significant-cost-increase/', 'title': 'Forecast for Myasthenia Gravis Drug Soliris Is for Significant Cost Hike', 'source': 'Myasthenia Gravis News', 'date': 'May 8, 2018', 'snippet': 'According to a new study, the expanded use of Soliris for myasthenia gravis \ncould lead to a significant increase in the wholesale cost for...', 'thumbnail': 'https://serpapi.com/searches/6722fbe517b10e3121979c00/images/7d4a66bcca9169c834565bed1821af17749a7986c4ae7fd79626d173045d3452.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8907734751701355}",,,,,,,,"['neutral', 'negative', 'neutral']",neutral,1
NCT03785678,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa2310392', 'title': 'Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection', 'source': 'The New England Journal of Medicine', 'date': 'Feb 21, 2024', 'snippet': 'We conducted a multicenter, double-blind, randomized, placebo-controlled \ntrial involving patients with ischemic stroke to compare tenecteplase (0.25 \nmg per...', 'thumbnail': 'https://serpapi.com/searches/6722fc06adc33b93e06ea68c/images/4f6191ed57053d6fecd5524daca9ee8251042e43d9b6929ca8b59700b425f43d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.908034086227417}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/full/10.1161/SVIN.121.000276', 'title': '2022 Brief Practice Update on Intravenous Thrombolysis Before Thrombectomy in Patients With Large Vessel Occlusion Acute Ischemic Stroke: A Statement from Society of Vascular and Interventional Neurology Guidelines and Practice Standards (GAPS) Co', 'source': 'American Heart Association Journals', 'date': 'Jun 3, 2022', 'snippet': 'BackgroundThe Society of Vascular & Interventional Neurology Guidelines and \nPractice Standards committee established the “Brief Practice...', 'thumbnail': 'https://serpapi.com/searches/6722fc06adc33b93e06ea68c/images/4f6191ed57053d6f114f1eb9a55da175225e37d1af3002a896ccb9be6cc77738.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9203912615776062}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00340834,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0909494', 'title': 'A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Mar 4, 2018', 'snippet': 'Oral fingolimod, a sphingosine-1-phosphate–receptor modulator that prevents \nthe egress of lymphocytes from lymph nodes, significantly improved relapse \nrates...', 'thumbnail': 'https://serpapi.com/searches/6722fc64cc4879ca15c16abd/images/6aaefe43ed6b51e50eaae18a2eb4df38a217e8a96aa70e6ca5738c009ae623a6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8717503547668457}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/02/06/real-world-data-can-help-compare-efficacy-ms-treatments-study/', 'title': 'Real-world data can be used to compare efficacy of MS treatments', 'source': 'Multiple Sclerosis News Today', 'date': 'Feb 6, 2024', 'snippet': 'Real-world data collected from a registry can be used to reliably compare \nthe effectiveness of different multiple sclerosis (MS) treatments.', 'thumbnail': 'https://serpapi.com/searches/6722fc64cc4879ca15c16abd/images/6aaefe43ed6b51e53a36e9e4085bab71823568cb06d84d738b56ab62f2ea9c5d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8964168429374695}","{'position': 3, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0907839', 'title': 'Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Jan 20, 2010', 'snippet': 'Fingolimod (FTY720), a sphingosine-1-phosphate–receptor modulator that \nprevents lymphocyte egress from lymph nodes, showed clinical efficacy...', 'thumbnail': 'https://serpapi.com/searches/6722fc64cc4879ca15c16abd/images/6aaefe43ed6b51e5db5f10c04b942aad99e97dfd4bbb7f152fd3d44a2fedbb03.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8348361253738403}","{'position': 4, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2019/04/15/aan2019-efficacy-and-safety-of-fingolimod-05-mg-and-025-mg-versus-glatiramer-acetate-20-mg-in-patients-with-relapsing-remitting-multiple-sclerosis-assess-study-group/', 'title': '#AANAM - Fewer Relapses in RRMS Patients with Gilenya Than Copaxone, Phase 3 Trial Shows', 'source': 'Multiple Sclerosis News Today', 'date': 'May 16, 2019', 'snippet': 'A Phase 3b trial, by Novartis and other researchers, found MS patients on \nGilenya at 0.5 mg had fewer relapses and lesser disease activity...', 'thumbnail': 'https://serpapi.com/searches/6722fc64cc4879ca15c16abd/images/6aaefe43ed6b51e5d2ac4987c7ec77f8902478ba67ed6826eed0708e03b22910.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.795064389705658}","{'position': 5, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/12/20/neurofilament-light-chain-studied-ms-prognosis-biomarker/', 'title': 'Neurofilament Light Chain Studied as MS Prognosis Biomarker |...', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 20, 2022', 'snippet': 'A study showed neurofilament light chain tends to be associated with \nmultiple sclerosis progression and is lowered with Gilenya treatment.', 'thumbnail': 'https://serpapi.com/searches/6722fc64cc4879ca15c16abd/images/6aaefe43ed6b51e59e09f5895b6bdd97e75763a6401b173fa862e1a44f7ecc1b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8330132365226746}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04435431,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/phase-3-trial-mesdopeta-parkinsons-dyskinesia-planned/', 'title': 'Irlab moving on Phase 3 trial of mesdopetam to treat dyskinesia', 'source': ""Parkinson's News Today"", 'date': 'Mar 26, 2024', 'snippet': 'Following meeting with FDA, Irlab Therapeutics is preparing to start a \nPhase 3 clinical trial of mesdopetam in patients with daily off...', 'thumbnail': 'https://serpapi.com/searches/6722fc7afab273ad2fda4a42/images/78ce89e37f027c21d54c0c46148ecb3283c73a72e77571b39c9b6b904373ef66.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8904695510864258}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/phase-2b-parkinsons-trial-mesdopetam-misses-main-goal/', 'title': 'Phase 2b Trial of Mesdopetam Misses Main Goal', 'source': ""Parkinson's News Today"", 'date': 'Jan 19, 2023', 'snippet': 'A Phase 2b clinical trial testing the investigational oral therapy \nmesdopetam, which aims to reduce levodopa-induced dyskinesia (involuntary \nmovements) in...', 'thumbnail': 'https://serpapi.com/searches/6722fc7afab273ad2fda4a42/images/78ce89e37f027c21f78f927a473c1fd324f7f0666aa8d423c186f066715be8b7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5435033440589905}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03739996,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01815-1', 'title': 'Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial', 'source': 'Nature', 'date': 'May 12, 2022', 'snippet': 'HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) \nhas shown viral escape, indicating that at least a triple bNAb...', 'thumbnail': 'https://serpapi.com/searches/6722fc98adc33b93947e2b12/images/4dd272e99605ccfbecde4d371415e153d88cbba25d88d4dd1c75443fafaeefc0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8841989636421204}",,,,,,,,,,['neutral'],neutral,1
NCT03832946,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/galactic-1-trial-inhaled-ipf-therapy-reaches-enrollment-target/', 'title': ""GALACTIC-1 Trial of Galecto's Inhaled IPF Therapy Hits Enrollment Target"", 'source': 'Pulmonary Fibrosis News', 'date': '٠٣\u200f/٠٥\u200f/٢٠٢٢', 'snippet': 'Galecto has reached its enrollment target for its Phase 2b clinical trial, \nGALACTIC-1, testing GB0139 as a once-daily inhaled therapy for...', 'thumbnail': 'https://serpapi.com/searches/6722fced175de61401c726df/images/683b46b5d1a2f9d4094abb086135499bf32000f5ab1e150e9a55355b54fb1720.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5557882189750671}",,,,,,,,,,['neutral'],neutral,1
NCT04233814,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/inhaled-ipf-therapy-lti-03-well-tolerated-healthy-volunteers-trial/', 'title': 'Inhaled IPF Therapy LTI-03 Well-tolerated in Healthy Volunteers in Trial', 'source': 'Pulmonary Fibrosis News', 'date': 'Mar 23, 2022', 'snippet': ""Lung Therapeutics' LTI-03 candidate for idiopathic pulmonary fibrosis was \nsafe and well-tolerated in healthy people in a Phase 1a trial."", 'thumbnail': 'https://serpapi.com/searches/6722fd19a775f2f9324b7e7f/images/4e7b9bbb1049d8c22f682c15fafdc42c56cd1fc2b83b90ede1b1a98713de5175.png', 'sentiment': 'neutral', 'sentiment_prob': 0.623710572719574}",,,,,,,,,,['neutral'],neutral,1
NCT03471871,"{'position': 1, 'link': 'https://www.empr.com/home/news/dayvigo-labeling-updated-with-data-on-use-in-patients-with-osa-copd/', 'title': 'Dayvigo Labeling Updated With Data on Use in Patients With OSA, COPD', 'source': 'Medical Professionals Reference', 'date': 'Apr 25, 2023', 'snippet': 'The prescribing information for Dayvigo (lemborexant) has been updated to \ninclude clinical trial data related to the use of the insomnia medication.', 'thumbnail': 'https://serpapi.com/searches/6722fd7e8b84c41ade1dd79a/images/a9e0c9988ed6e4ff4583d4dde020c1552493bdfd05e6e1d752a4aca8071ea688.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9325548410415649}",,,,,,,,,,['neutral'],neutral,1
NCT05687903,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20240531655762/en/Takeda%E2%80%99s-TAK-861-Phase-2b-Late-Breaking-Data-Presentations-at-SLEEP-2024-Demonstrate-Clinically-Meaningful-Impact-of-Oral-Orexin-Agonist-in-Narcolepsy-Type-1-Compared-to-Placebo', 'title': 'Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo', 'source': 'Business Wire', 'date': 'Jun 3, 2024', 'snippet': 'Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its \nPhase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as...', 'thumbnail': 'https://serpapi.com/searches/6722fd8b7f3719c39a636c5a/images/82db10643763e0565c286b79d87eb317d1aec52cc11debe611eeb7d45f3119cd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7174250483512878}",,,,,,,,,,['neutral'],neutral,1
NCT03096457,"{'position': 1, 'link': 'https://www.infectiousdiseaseadvisor.com/news/topical-15-paromomycin-aquaphilic-effective-for-new-world-leishmaniasis/', 'title': 'Topical 15% Paromomycin-Aquaphilic Effective For New World Leishmaniasis', 'source': 'Infectious Disease Advisor', 'date': 'Dec 4, 2018', 'snippet': 'Treatment for cutaneous leishmaniasis caused by Leishmania braziliensis, \nusing 15% paromomycin-Aquaphilic, was superior to a negative vehicle \ncontrol.', 'thumbnail': 'https://serpapi.com/searches/6722fde5dda9d9673028be48/images/e650d98fdcf3bfc221dbf50796225d76f62358d082f261e0e116eb1779aae654.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6814292669296265}",,,,,,,,,,['neutral'],neutral,1
NCT03136484,"{'position': 1, 'link': 'https://www.medwirenews.com/showcase/a-quick-guide-to-the-sustain-trials/', 'title': 'A quick guide to the SUSTAIN trials', 'source': 'medwirenews.com', 'date': 'Apr 7, 2017', 'snippet': 'Here is our guide to the 15 trials launched to date, which are complete, \nand which have so far been published in a peer-reviewed journal.', 'thumbnail': 'https://serpapi.com/searches/6722fe3da5aae9d2bd030cd8/images/af01dfeb73cc3bfe0e2cdbffbca11836bdc5bde4349b710e543512d966f84b90.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.865156352519989}",,,,,,,,,,['neutral'],neutral,1
NCT03298672,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/fosgonimeton-shows-safety-phase-1-study-phase-3-trial-enrolling-us/', 'title': 'Fosgonimeton Shows Safety in Early Trial, Phase 3 Study Enrolling in US', 'source': ""Alzheimer's News Today"", 'date': 'Feb 28, 2022', 'snippet': ""Fosgonimeton, an experimental therapy Athira Pharma is developing to treat \nAlzheimer's disease, was well-tolerated overall in a Phase 1 clinical trial."", 'thumbnail': 'https://serpapi.com/searches/6722fe4607c7be84e55fc004/images/dbb87506f336120ff7429c4363d84f038d450393d108f10ec211e14938f51a0b.png', 'sentiment': 'positive', 'sentiment_prob': 0.7711381912231445}",,,,,,,,,,['positive'],positive,1
NCT02669121,"{'position': 1, 'link': 'https://www.pharmaceutical-technology.com/news/hillevax-slashes-workforce-by-40-after-norovirus-vaccine-trial-failure/', 'title': 'HilleVax slashes workforce by 40% after norovirus vaccine trial failure', 'source': 'Pharmaceutical Technology', 'date': 'Aug 1, 2024', 'snippet': ""HilleVax's norovirus vaccine HIL-214 failed to meet key endpoints in its \nPhase IIb trial in infants prompting the company to let go of 41..."", 'thumbnail': 'https://serpapi.com/searches/6722fe5508abe49569de87d6/images/7f5e89132441f981c0af359c3f9feb607c02e53ac1334e4a171917b215885e0b.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8878931999206543}",,,,,,,,,,['negative'],negative,0
NCT01620528,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1700089', 'title': 'Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist', 'source': 'The New England Journal of Medicine', 'date': 'Nov 10, 2017', 'snippet': 'We performed two similar, double-blind, randomized, 6-month phase 3 trials \n(Elaris Endometriosis I and II [EM-I and EM-II]) to evaluate the effects of \ntwo...', 'thumbnail': 'https://serpapi.com/searches/6722fe5cd771bd6b2e5e5d46/images/58f7012fa8a92fa6fb5b7c3f5e34b7601456ece304bccd0e3c91125cd75f62ac.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9132484197616577}",,,,,,,,,,['neutral'],neutral,1
NCT01496365,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2023/4893436', 'title': 'The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids', 'source': 'Wiley Online Library', 'date': 'Apr 28, 2023', 'snippet': ""Background. Neuropathic pain is a complex sort of pain that is detrimental \nto individuals' health, both physically and mentally,..."", 'thumbnail': 'https://serpapi.com/searches/6722fe7223a4b50b0bc0046e/images/996d1fc41ef3be33e33d554c3b59b28099403d717ca36a1df31f543de4d3cc90.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5292758941650391}",,,,,,,,,,['neutral'],neutral,1
NCT03109756,"{'position': 1, 'link': 'https://angelmansyndromenews.com/news/ovid-to-add-adolescents-to-phase-2-trial-of-its-angelman-syndrome-therapy-ov101/', 'title': ""Ovid's Angelman Therapy Trial Will Be Broadened to Include Adolescents"", 'source': 'Angelman Syndrome News', 'date': 'Dec 12, 2017', 'snippet': ""Read about Ovid's decision to broaden the Phase 2 clinical trial of its \nAngelman syndrome therapy OV101 to include adolescents as well as..."", 'thumbnail': 'https://serpapi.com/searches/6722fe827ac731301bf67953/images/04dc5500f1d51630ca63e1525df96859579d9bc949c06cda48e9989a59a7ba2d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8533443808555603}",,,,,,,,,,['neutral'],neutral,1
NCT04442490,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/safety-efficacy-initial-and-repeat-zuranolone-for-major-depressive-disorder/', 'title': 'Long-Term Safety and Efficacy of Zuranolone in MDD', 'source': 'Psychiatrist.com', 'date': 'Dec 27, 2023', 'snippet': 'Most patients with MDD achieved response after 14 days of zuranolone \ntreatment. For patients who responded to their first treatment,...', 'thumbnail': 'https://serpapi.com/searches/6722feb171b0e875fe4d5e8b/images/1eeb5da733dcbd6abd88c0276333952f9dcd5105a0834f7736e42f95d21cae48.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5939822196960449}","{'position': 2, 'link': 'https://www.nature.com/articles/s41386-023-01751-9', 'title': 'Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study', 'source': 'Nature', 'date': 'Oct 24, 2023', 'snippet': 'These results demonstrate that zuranolone+ADT provided more rapid \nimprovement in depressive symptoms compared with placebo+ADT in patients \nwith MDD.', 'thumbnail': 'https://serpapi.com/searches/6722feb171b0e875fe4d5e8b/images/1eeb5da733dcbd6aa6300e2c7e87d1d7c09d5791edd135f2d856d0a8d707d4f0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5984835028648376}","{'position': 3, 'link': 'https://finance.yahoo.com/news/sage-therapeutics-biogen-episodic-therapy-051219447.html', 'title': 'Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment', 'source': 'Yahoo Finance', 'date': 'Jul 22, 2024', 'snippet': 'The pivotal Phase III trial for the new Sage Therapeutics and Biogen \nantidepressant zuranolone has yielded positive results.', 'thumbnail': 'https://serpapi.com/searches/6722feb171b0e875fe4d5e8b/images/1eeb5da733dcbd6a3e7bd014ef6b41a897e9dde7f6f5d23df40e7bb8598e9929.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5952813029289246}",,,,,,,,"['neutral', 'neutral', 'positive']",neutral,1
NCT03861793,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2020/11/24/alks-4230-keytruda-combo-found-to-halt-disease-progression-reduce-tumor-size-among-ovarian-cancer-patients-in-phase-1-2-trial/', 'title': 'ALKS 4230-Keytruda Combo Found to Reduce Tumor Size, Halt Disease Progression', 'source': 'Ovarian Cancer News Today', 'date': 'Nov 24, 2020', 'snippet': 'An ALKS 4230-Keytruda combo was able to halt disease progression and reduce \ntumor size in women with advanced ovarian cancer,...', 'thumbnail': 'https://serpapi.com/searches/6722fef818787d0b9597e56f/images/fb44b969b66857d3698a83862bf795b520f42451eada2b04d8a0fc05ee5c0c70.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7647801637649536}",,,,,,,,,,['neutral'],neutral,1
NCT02877927,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30275-0/abstract', 'title': 'Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial', 'source': 'The Lancet', 'date': 'Aug 29, 2019', 'snippet': 'We aimed to compare the efficacy and safety of once-daily oral \nomadacycline, an aminomethylcycline antibiotic, versus twice-daily oral \nlinezolid for treatment...', 'thumbnail': 'https://serpapi.com/searches/6722ff0f2c566da299be7086/images/be84cc07086a42f4b48016cd49ef878241b34dc54cca0ebfecc3405d00fdf7df.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8593938946723938}",,,,,,,,,,['neutral'],neutral,1
NCT00478205,"{'position': 1, 'link': 'https://www.nature.com/articles/s41746-021-00452-1', 'title': 'Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer’s disease', 'source': 'Nature', 'date': 'May 14, 2021', 'snippet': 'In this study, we explored the feasibility of using real-world data (RWD) \nfrom a large clinical research network to simulate real-world...', 'thumbnail': 'https://serpapi.com/searches/67230053e50bc07d77155e9d/images/7fcfb94e3de4b2392467b11b41d1a52f1c469dfb378a241083ef849a85687dba.png', 'sentiment': 'neutral', 'sentiment_prob': 0.887079119682312}",,,,,,,,,,['neutral'],neutral,1
NCT02464228,"{'position': 1, 'link': 'https://lymphomanewstoday.com/2020/03/05/tipifarnib-granted-fda-fast-track-designation-for-t-cell-lymphomas/', 'title': 'Tipifarnib Granted FDA Fast Track Designation for T-cell Lymphomas', 'source': 'Lymphoma News Today', 'date': 'Mar 5, 2020', 'snippet': 'Tipifarnib was given fast track status by the US Food and Drug \nAdministration (FDA) for the treatment of adult patients with different \nsubtypes of peripheral T...', 'thumbnail': 'https://serpapi.com/searches/67230069f8b05d136843dc51/images/8932433ba06b3c65c14d101f63ec3c47417ab59d04baacf5d319d41db0cec159.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7629967331886292}",,,,,,,,,,['neutral'],neutral,1
NCT03548987,"{'position': 1, 'link': 'https://www.specialtypharmacycontinuum.com/Online-First/Article/09-23/Cardiovascular-Benefit-Could-Pave-the-Way-for-Wider-Use-of-Wegovy/71579', 'title': 'Cardiovascular Benefit Could Pave the Way for Wider Use of Wegovy', 'source': 'Specialty Pharmacy Continuum', 'date': 'Sep 25, 2023', 'snippet': 'By Myles Starr The recent announcement of phase 3 clinical trial results \ndemonstrating that semaglutide 2.4 mg (Wegovy, Novo Nordisk)...', 'thumbnail': 'https://serpapi.com/searches/67230094f79a012c6dcad41a/images/c5853a4b3ced80f80ec72374354bcdb84817f465eb536fb80346855b43df9bd1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5210405588150024}",,,,,,,,,,['neutral'],neutral,1
NCT03579628,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-01028-8', 'title': 'A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours', 'source': 'Nature', 'date': 'Aug 25, 2020', 'snippet': 'AsiDNA, a first-in-class oligonucleotide-mimicking double-stranded DNA \nbreaks, acts as a decoy agonist to DNA damage response in tumour...', 'thumbnail': 'https://serpapi.com/searches/672300c7e95dbf8877425161/images/6e40ecc88ed4efaea19d4baccfe440b91b1f5a50dfaff056c7f41ce917b46bcb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.894868016242981}",,,,,,,,,,['neutral'],neutral,1
NCT03535194,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/bjd.21743', 'title': 'Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)', 'source': 'Wiley Online Library', 'date': 'Jul 6, 2022', 'snippet': 'The primary efficacy endpoints were met, with significantly greater \nimprovements in clinical response observed with mirikizumab than with...', 'thumbnail': 'https://serpapi.com/searches/6722ff34a505f7f6768d4ddc/images/860ec86cc706882911da066f910626a4106b794cca0ee04a1d417370226eff47.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6558184623718262}",,,,,,,,,,['positive'],positive,1
NCT01369329,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1602773', 'title': 'Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease', 'source': 'The New England Journal of Medicine', 'date': 'Nov 17, 2016', 'snippet': 'Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and \ninterleukin-23, was evaluated as an intravenous induction therapy in two...', 'thumbnail': 'https://serpapi.com/searches/6722ff5d8db376c3934fc90d/images/307b8ed5a897cdba09706c1a000b0dae31a04eb982e34ad12f0b27f50c065a72.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9213168025016785}",,,,,,,,,,['neutral'],neutral,1
NCT01242488,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Olokizumzab', 'title': 'Olokizumab', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': ""Crohn's Disease, A Phase II Study to Assess the Efficacy and Safety of \nOlokizumab in Patients With Crohn's Disease, Phase 2, CD0001"", 'thumbnail': 'https://serpapi.com/searches/6722ff6ca54d7e5ab8526985/images/1869d733b50c4e73834c3aa639a45d0d7aa7d0cf628c1a8d6704710809275939.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8582401275634766}",,,,,,,,,,['neutral'],neutral,1
NCT03283670,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/nitrous-oxide-reduced-suicidal-ideation-in-treatment-resistant-major-depression/', 'title': 'Nitrous Oxide Reduced Suicidal Ideation in Treatment-Resistant Major Depression in Exploratory Analysis', 'source': 'Psychiatrist.com', 'date': 'Aug 16, 2023', 'snippet': 'This post hoc analysis of 3 crossover trials demonstrated that N 2 O, as \ncompared to placebo, reduced SI in a TRMD sample.', 'thumbnail': 'https://serpapi.com/searches/6722ffc575f974affaee885f/images/faaa0a7306b9e87be26ca01eb451bcbb5d9811f9c19d96d9783cacf94d29d14c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8201837539672852}",,,,,,,,,,['neutral'],neutral,1
NCT05385783,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/cybin-starts-final-cohort-dosing-in-psychedelic-mdd-treatment-trial/', 'title': 'Cybin starts final cohort dosing in psychedelic MDD treatment trial', 'source': 'Clinical Trials Arena', 'date': 'Aug 2, 2023', 'snippet': 'Cybin is closer to demonstrating results across all six cohorts from its \nPhase II trial investigating CYB003 in MDD.', 'thumbnail': 'https://serpapi.com/searches/6722ffec3c957520b177f0f8/images/ced8252ccb47bc540d57558ba57f43c0046a29dff376c148590fce958bba6cdf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.597998857498169}","{'position': 2, 'link': 'https://www.drugdiscoverytrends.com/the-future-of-mdd-treatment-a-comparative-table-highlighting-the-emergence-of-fast-acting-therapies/', 'title': 'MDD treatment landscape snapshot, including fast-acting options', 'source': 'www.drugdiscoverytrends.com', 'date': 'Nov 9, 2023', 'snippet': 'The treatment landscape for major depressive disorder (MDD) continues to \ndiversify, and in the coming years, psychedelic options may be available.', 'thumbnail': 'https://serpapi.com/searches/6722ffec3c957520b177f0f8/images/ced8252ccb47bc5466adc9cc0a1433364dfd9ba3c76f3f7bf25b4b48fe1f25ea.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7957701086997986}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02119468,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/relapsed-multiple-myeloma-patients-refractory-revlimid-benefit-ninlaro-pomalyst-dexamethasone-combo-trial-suggests/', 'title': 'Myeloma Patients Refractory to Revlimid May Benefit from Ninlaro, Pomalyst, Dexamethasone Combo', 'source': 'Myeloma Research News', 'date': 'Mar 19, 2018', 'snippet': 'Read about the results of a Phase 1/2 clinical trial showing that a triple \ncombo with Ninlaro, Pomalyst, and dexamethasone may help relapsed...', 'thumbnail': 'https://serpapi.com/searches/6722fffdd72128a2208b5b24/images/f251a879a7b3c49603ff490246b9de8c995505f03a14bf6b35692b792069b526.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7254173159599304}",,,,,,,,,,['neutral'],neutral,1
NCT02471144,"{'position': 1, 'link': 'https://www.empr.com/home/news/cosentyx-approved-for-pediatric-plaque-psoriasis/', 'title': 'Cosentyx Approved for Pediatric Plaque Psoriasis', 'source': 'Medical Professionals Reference', 'date': 'Jun 2, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) \nfor the treatment of moderate to severe plaque psoriasis in patients 6 \nyears of age...', 'thumbnail': 'https://serpapi.com/searches/6723013793584c270e7b8d3a/images/4d8fc567a53f476463c2ce68fe8415195c68687c5a22ac7e018f99fb7ef33a86.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8089482188224792}",,,,,,,,,,['neutral'],neutral,1
NCT01252719,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1310422', 'title': 'Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections', 'source': 'The New England Journal of Medicine', 'date': 'Jun 5, 2014', 'snippet': 'Oritavancin is a lipoglycopeptide with bactericidal activity against \ngram-positive bacteria. Its concentration-dependent activity and...', 'thumbnail': 'https://serpapi.com/searches/6723015dd771bd6b2e5e6048/images/f5dfeec4d7ee0160483d228a899e521b63da14827fad135e1f776d2cf4336bd4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6456476449966431}",,,,,,,,,,['neutral'],neutral,1
NCT01968980,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1614062', 'title': 'Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab', 'source': 'The New England Journal of Medicine', 'date': 'Mar 17, 2017', 'snippet': 'Bococizumab, a humanized monoclonal antibody targeting proprotein \nconvertase subtilisin–kexin type 9 (PCSK9), reduces levels of low-density \nlipoprotein (LDL)...', 'thumbnail': 'https://serpapi.com/searches/67230185667ec5369e74040a/images/2241c71954287b085a9470c6b8d70559ebe551a3c6c4f557686d4d48afa2d340.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.855465292930603}",,,,,,,,,,['neutral'],neutral,1
NCT03181503,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1908316', 'title': 'Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis', 'source': 'The New England Journal of Medicine', 'date': 'Feb 19, 2020', 'snippet': 'Prurigo nodularis is a chronic pruritic skin disease with multiple nodular \nskin lesions. Nemolizumab is a monoclonal antibody targeting the...', 'thumbnail': 'https://serpapi.com/searches/672301a62fab620db409a074/images/b7de354e230310ebc78cf8d682e19bf807e7746d9dc82e78192667cf5cadee88.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5970710515975952}",,,,,,,,,,['neutral'],neutral,1
NCT02707861,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1711460', 'title': 'Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1', 'source': 'The New England Journal of Medicine', 'date': 'Aug 15, 2018', 'snippet': 'Ibalizumab, a humanized IgG4 monoclonal antibody, blocks the entry of human \nimmunodeficiency virus type 1 (HIV-1) by noncompetitive binding...', 'thumbnail': 'https://serpapi.com/searches/672301b12e33c8a68aaf340d/images/d15e682a23aa2d1e9f3c8e9e526640a9cac14161bb26849d9626766b37f4646b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8326910734176636}",,,,,,,,,,['neutral'],neutral,1
NCT02984995,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/jha2.616', 'title': 'Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome', 'source': 'Wiley Online Library', 'date': 'Nov 21, 2022', 'snippet': 'This study analyzes the efficacies of various FLT3i (types 1 and 2) tested \nin clinical trials in treating R/R AML and high-risk myelodysplastic \nsyndromes (HR-...', 'thumbnail': 'https://serpapi.com/searches/672301e78b84c41ade1ddb52/images/3ea014a3fe2118cda56e10e9f52d24110c29a910d0dab3f0d14a4ac6fe0f8f1d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8564883470535278}",,,,,,,,,,['neutral'],neutral,1
NCT01458106,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/eloctate-alprolix-effective-preventing-surgical-hemophilia-study/', 'title': 'Study: Eloctate, Alprolix Effective at Preventing Surgical Bleeds', 'source': 'Hemophilia News Today', 'date': 'Aug 5, 2022', 'snippet': 'Replacement therapies Eloctate and Alprolix are safe and effective at \npreventing bleeds during surgery in people with hemophilia A and B.', 'thumbnail': 'https://serpapi.com/searches/672301ee069e577bfa330bdf/images/3cfb494a77851099a08ac6fcf52ef6961fdd6599ce9706d1b26e6e069d6b9cee.png', 'sentiment': 'positive', 'sentiment_prob': 0.5989962220191956}",,,,,,,,,,['positive'],positive,1
NCT01458951,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1606910', 'title': 'Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis', 'source': 'The New England Journal of Medicine', 'date': 'May 4, 2017', 'snippet': 'Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to \nhave potential efficacy as induction therapy for ulcerative...', 'thumbnail': 'https://serpapi.com/searches/67230201e335ec07aa0c8393/images/04dd18a2a65ac51dead87796832446f313ab26a8279a9f98d7de81df7f8dcee6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8574879169464111}",,,,,,,,,,['neutral'],neutral,1
NCT00003653,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1201546', 'title': 'Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy', 'source': 'The New England Journal of Medicine', 'date': 'Sep 6, 2012', 'snippet': 'Intermittent androgen deprivation for prostate-specific antigen (PSA) \nelevation after radiotherapy may improve quality of life and delay hormone \nresistance.', 'thumbnail': 'https://serpapi.com/searches/6723021bd771bd6ae74f90ad/images/67e48a51b6bc69534617d88ede94b403c691dcf1892101095e50c1029b188865.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5439366698265076}",,,,,,,,,,['neutral'],neutral,1
NCT05477160,"{'position': 1, 'link': 'https://angioedemanews.com/news/fda-oks-clinical-trials-hae-treatment-star-0215-healthy-volunteers/', 'title': 'FDA OKs 1st-in-Human Clinical Trials of STAR-0215 HAE Treatment', 'source': 'Angioedema News', 'date': 'Aug 1, 2022', 'snippet': 'The US Food and Drug Administration (FDA) has cleared Astria Therapeutics \nto move STAR-0215, its experimental treatment for preventing swelling \nattacks in...', 'thumbnail': 'https://serpapi.com/searches/6723022ebb55ffdd70c765f4/images/442c135c5e5c4d03bc2c447a5b3618ad2f106043ea1a525fe2dabbc01a845698.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8257156014442444}",,,,,,,,,,['neutral'],neutral,1
NCT00938275,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-55923-8', 'title': 'Emerging roles of SIRT1 activator, SRT2104, in disease treatment', 'source': 'Nature', 'date': 'Mar 6, 2024', 'snippet': 'Silent information regulator 1 (SIRT1) is a NAD+-dependent class III \ndeacetylase that plays important roles in the pathogenesis of numerous...', 'thumbnail': 'https://serpapi.com/searches/67230237544c49553073b9bd/images/fa5f6db99f3cfcf5a3f37d438c7a00b98a8c19a2763a4b49819b6974a121faa6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8164551258087158}",,,,,,,,,,['neutral'],neutral,1
NCT02460276,"{'position': 1, 'link': 'https://www.onclive.com/view/ibrutinib-plus-lenalidomide-and-rituximab-demonstrates-activity-in-r-r-mcl', 'title': 'Ibrutinib Plus Lenalidomide and Rituximab Demonstrates Activity in R/R MCL', 'source': 'OncLive', 'date': 'Aug 7, 2024', 'snippet': 'The combination of ibrutinib, lenalidomide, and rituximab elicited a high \nresponse rate in patients with relapsed/refractory mantle cell...', 'thumbnail': 'https://serpapi.com/searches/672302995c7cb9ea52f850c4/images/a27606c5448337b39ff88f533fb963c18eb631aa928889ccc96898f074b97b22.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8419263958930969}",,,,,,,,,,['neutral'],neutral,1
NCT02238626,"{'position': 1, 'link': 'https://alsnewstoday.com/news/ibudilast-most-effective-in-people-with-short-history-of-als-analysis-suggests/', 'title': 'Ibudilast Most Effective in People with Short History of ALS, Analysis Suggests', 'source': 'ALS News Today', 'date': 'Dec 13, 2019', 'snippet': 'The experimental therapeutic ibudilast may be most effective for treating \nALS in people who have a shorter history of the disease,...', 'thumbnail': 'https://serpapi.com/searches/672302b3f93388d03dc8a384/images/cb07980c988cc1c46698c66d03b2d2f07a4a21b331c523c10c60520e6a69d98f.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6239985823631287}","{'position': 2, 'link': 'https://alsnewstoday.com/news/ibudilast-mn-166-named-orphan-drug-for-amyotrophic-lateral-sclerosis-by-fda/', 'title': 'Ibudilast, Possible ALS Treatment, Named Orphan Drug by FDA', 'source': 'ALS News Today', 'date': 'Oct 18, 2016', 'snippet': ""Read about the FDA granting orphan drug designation to MediciNova's \nIbudilast (MN-166) as a potential treatment for amyotrophic lateral..."", 'thumbnail': 'https://serpapi.com/searches/672302b3f93388d03dc8a384/images/cb07980c988cc1c40d50ec4b631a25cf1881b9d20b1f59e22b8fdd0805918395.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8990402817726135}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT03840148,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/cefepime-taniborbactam-gets-priority-review-for-complicated-uti/', 'title': 'Cefepime-Taniborbactam Gets Priority Review for Complicated UTI - MPR', 'source': 'Medical Professionals Reference', 'date': 'Aug 15, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted for Priority Review the \nNew Drug Application (NDA) for cefepime-taniborbactam for the treatment of \nadults...', 'thumbnail': 'https://serpapi.com/searches/672302b5eda5f59f5496de98/images/7772a68f51a8f956bdf71d0b720efc2e34415f15746e5faa6723d87420501479.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9070265889167786}",,,,,,,,,,['neutral'],neutral,1
NCT01300208,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30448-3/fulltext', 'title': 'Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial', 'source': 'The Lancet', 'date': 'Mar 16, 2021', 'snippet': 'Current tuberculosis treatments leave patients with clinically significant \nlung injury and increased all-cause mortality post-cure.', 'thumbnail': 'https://serpapi.com/searches/672302b8c76a2266cd4d47b4/images/7dae0200bd2bc1ee7cb0f86d25bcafa381fa9f37ee03c4253e56a98b28e6d3be.png', 'sentiment': 'negative', 'sentiment_prob': 0.586892306804657}",,,,,,,,,,['negative'],negative,0
NCT04022473,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2020/05/04/fda-approves-bafiertam-banner-life-science-tecfidera-bioequivalent-relapsing-ms/', 'title': 'FDA Approves Bafiertam, Tecfidera Bioequivalent, for Relapsing MS', 'source': 'Multiple Sclerosis News Today', 'date': 'May 5, 2020', 'snippet': ""The US Food and Drug Administration (FDA) has given final approval to \nBanner Life Sciences' Bafiertam (monomethyl fumarate), a bioequivalent \nalternative to..."", 'thumbnail': 'https://serpapi.com/searches/672302fd81262a58f42c155a/images/039d296a082973ca823d84201c9f799a61c3a140d0abda4d61d4902609d3e85f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8079429864883423}",,,,,,,,,,['neutral'],neutral,1
NCT03568136,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-42595-z', 'title': 'Inhibition of IL-17 ameliorates keratinocyte-borne cytokine responses in an in vitro model for house-dust-mite triggered atopic dermatitis', 'source': 'Nature', 'date': 'Oct 3, 2023', 'snippet': 'This study aimed to investigate the potential of allergen-induced, \nimmune-cell derived IL-17 on the induction of inflammatory processes in \nkeratinocytes.', 'thumbnail': 'https://serpapi.com/searches/6723031b66d9954175f0df8d/images/16f7e6573faaba6663910202cafc70be16b0e1f28ceab88d4e8c7e8a2a92292a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8545948266983032}",,,,,,,,,,['neutral'],neutral,1
NCT04029116,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-brexafemme-for-recurrent-vulvovaginal-candidiasis/', 'title': 'FDA Approves Brexafemme for Recurrent Vulvovaginal Candidiasis', 'source': 'Medical Professionals Reference', 'date': 'Dec 1, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Brexafemme \n(ibrexafungerp) for the reduction in the incidence of recurrent \nvulvovaginal candidiasis (RVVC).', 'thumbnail': 'https://serpapi.com/searches/6723033723793880add40517/images/f9ceea736377e61c03347cfae7982f27bb881919800d0efc16c1e8325e33022c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7310283184051514}",,,,,,,,,,['neutral'],neutral,1
NCT00005007,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/hematuria-may-predict-renal-relapse-in-anca-patients/', 'title': 'In AAV Patients, Persistent Blood in Urine Seen to Indicate Kidney Relapse in Study', 'source': 'ANCA Vasculitis News', 'date': 'Feb 6, 2018', 'snippet': 'A study, looking at two clinical trials, suggests that urinalysis showing \npersistent blood in the urine (hematuria) can help identify...', 'thumbnail': 'https://serpapi.com/searches/6723039bb5ecbb095a174535/images/d80928584523f66d3dd269d5e3797a43f189cfd60e862be1a3695e6c08f42770.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9162073135375977}",,,,,,,,,,['neutral'],neutral,1
NCT01170663,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70420-6/abstract', 'title': 'Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial', 'source': 'The Lancet', 'date': 'Sep 17, 2014', 'snippet': 'We assessed whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, \nin combination with paclitaxel would increase overall survival in \npatients...', 'thumbnail': 'https://serpapi.com/searches/672303a4fbde0d1847a3c65f/images/3d57042afe4fb498f70d04cf51af9b208467ff0430ca3ab9de18577c8c1c85ad.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8744474649429321}",,,,,,,,,,['neutral'],neutral,1
NCT01849497,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/circulationaha.116.025233', 'title': 'Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies', 'source': 'American Heart Association Journals', 'date': 'Mar 1, 2017', 'snippet': 'Background:Evolocumab, a fully human monoclonal antibody to PCSK9 \n(proprotein convertase subtilisin/kexin type 9), markedly reduces...', 'thumbnail': 'https://serpapi.com/searches/672303a4e30abc8601a2cb07/images/3cb16dde566065c4af95e5a6a35f8afdcd2ffff5b0350322fac88804ada3913d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8608872890472412}",,,,,,,,,,['neutral'],neutral,1
NCT02133573,"{'position': 1, 'link': 'https://www.endocrinologyadvisor.com/news/vaginal-progesterone-during-pregnancy/', 'title': 'Vaginal Progesterone During Pregnancy Could Benefit Neurodevelopment in CHD', 'source': 'Endocrinology Advisor', 'date': 'Jun 18, 2024', 'snippet': 'Vaginal progesterone during pregnancy showed some neurodevelopmental \nbenefits among female infants with congenital heart defects.', 'thumbnail': 'https://serpapi.com/searches/672303dc4e9efcf6a8efae8d/images/e5ba7b6130bcc212052ad80e94f586f48536e14c5dc0149dce28783b9b3d8f9e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8359719514846802}",,,,,,,,,,['neutral'],neutral,1
NCT04915729,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/full/10.1161/SVIN.124.001363', 'title': 'Tenecteplase Versus Alteplase in Acute Ischemic Stroke in Chinese Patients: Protocol for the ORIGINAL Study', 'source': 'American Heart Association Journals', 'date': 'May 7, 2024', 'snippet': 'BackgroundTenecteplase, a bioengineered variant of alteplase, is a new \nalternative thrombolytic agent. The ORIGINAL study aims to evaluate...', 'thumbnail': 'https://serpapi.com/searches/672303de483e5b863e715ede/images/b426d54b1a6d13a064b22bbcaf260e09d5b150c2b75125407990d3257a46d785.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9223576188087463}",,,,,,,,,,['neutral'],neutral,1
NCT03219268,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02593-0', 'title': 'The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial', 'source': 'Nature', 'date': 'Oct 19, 2023', 'snippet': 'Tebotelimab, a bispecific PD-1×LAG-3 DART molecule that blocks both PD-1 \nand LAG-3, was investigated for clinical safety and activity in a...', 'thumbnail': 'https://serpapi.com/searches/672303e2f3622a724e9c146c/images/277f94a83f3764ee2cf6cecd5865fd1d31860fbcddc22820366fa19d4b83d1b5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9052724838256836}",,,,,,,,,,['neutral'],neutral,1
NCT01826201,"{'position': 1, 'link': 'https://lymphomanewstoday.com/2019/08/30/trial-of-cutaneous-t-cell-lymphoma-therapy-wp1220-fully-enrolled/', 'title': 'Trial of Cutaneous T-cell Lymphoma Therapy WP1220 Fully Enrolled', 'source': 'Lymphoma News Today', 'date': 'Aug 30, 2019', 'snippet': 'Read about the completed enrollment in a clinical trial of WP1220, a \ntopical treatment candidate for patients with cutaneous T-cell...', 'thumbnail': 'https://serpapi.com/searches/6723040a15c74058c296703c/images/2bdfca8836019330cd37f5bb32635b53483deaad6896aad11cbde7736b66dade.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9216471910476685}",,,,,,,,,,['neutral'],neutral,1
NCT05715528,"{'position': 1, 'link': 'https://www.mountsinai.org/clinical-trials/study-of-obeldesivir-in-nonhospitalized-participants-with-covid-19', 'title': 'Study of Obeldesivir in Nonhospitalized Participants With COVID-19', 'source': 'Mount Sinai', 'date': 'Jul 21, 2023', 'snippet': 'The goal of this clinical study is to test if obeldesivir (formerly \nGS-5245) is safe and effective for the treatment of coronavirus disease \n2019 (COVID-19)', 'thumbnail': 'https://serpapi.com/searches/672304dd15c7405910f66883/images/96b39b058265ad4b8df2b4760a454e9ccbf7a73f03b0e5ce9a8ac040e56da32e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8410796523094177}","{'position': 2, 'link': 'https://journals.asm.org/doi/10.1128/cmr.00119-23', 'title': 'COVID-19 therapeutics', 'source': 'ASM Journals', 'date': 'May 22, 2024', 'snippet': 'In this article, we review the antiviral activity, mechanism of action, \npharmacokinetics, and safety of COVID-19 antiviral therapies.', 'thumbnail': 'https://serpapi.com/searches/672304dd15c7405910f66883/images/96b39b058265ad4bd2908fe557bb42996952fb0294ec1e76198795e1fac61296.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9253212213516235}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00849134,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332223003967', 'title': 'In silico and pharmacological study of N,S-acetal juglone derivatives as inhibitors of the P2X7 receptor-promoted in vitro and in vivo inflammatory response', 'source': 'ScienceDirect.com', 'date': 'Mar 31, 2023', 'snippet': 'P2X7 receptor (P2X7R) is an ATP-gated ion channel involved in several \ninflammatory diseases and neuropathic pain. •. P2X7R activation triggers \nseveral...', 'thumbnail': 'https://serpapi.com/searches/672304f163a8447394d092df/images/7e5576961cca819373d5715d8a7bf6ceb2621dc59c287dc7fb54b6fab530fef6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8596197366714478}",,,,,,,,,,['neutral'],neutral,1
NCT04586153,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01323-9', 'title': 'Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial', 'source': 'Nature', 'date': 'Jan 30, 2023', 'snippet': 'Meplazumab, a humanized CD147 antibody, has shown favourable safety and \nefficacy in our previous clinical studies. In DEFLECT (NCT04586153)...', 'thumbnail': 'https://serpapi.com/searches/672304ec7f3719c320ef4d6f/images/e648e26c7a42b96de09fe1302a749fee071b866a43030cd76ea6d1fffee58b57.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5692375302314758}",,,,,,,,,,['neutral'],neutral,1
NCT01702129,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01536-y', 'title': 'Nanomedicine in cancer therapy - Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': 'Aug 7, 2023', 'snippet': 'This Review outlines current and prospective strategies in the design of \ntumor tissue-, cell-, and organelle-targeted cancer nanomedicines.', 'thumbnail': 'https://serpapi.com/searches/67230515dda9d966e6c60674/images/345e56d83158c97983d87e923bad33b189793368a7f5046c945219d038b1928b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9363467693328857}",,,,,,,,,,['neutral'],neutral,1
NCT02054130,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1704064', 'title': 'Tezepelumab in Adults with Uncontrolled Asthma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 7, 2017', 'snippet': 'In some patients with moderate-to-severe asthma, particularly those with \nnoneosinophilic inflammation, the disease remains uncontrolled.', 'thumbnail': 'https://serpapi.com/searches/6723055229e6fbf3a9ca447c/images/4c18499a8b46d6adbbf2f472bb2c704514916b6990f61374995f913a306a32e0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7404904365539551}","{'position': 2, 'link': 'https://www.empr.com/home/news/tezspire-approved-as-add-on-maintenance-treatment-for-severe-asthma/', 'title': 'Tezspire Approved as Add-On Maintenance Treatment for Severe Asthma', 'source': 'Medical Professionals Reference', 'date': 'Dec 20, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Tezspire™ \n(tezepelumab-ekko) for the add-on maintenance treatment of patients 12 \nyears...', 'thumbnail': 'https://serpapi.com/searches/6723055229e6fbf3a9ca447c/images/4c18499a8b46d6add03e66ecf08860785eeeb83ed39da288360bdc4d4b9053fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8576986193656921}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02366143,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-51316-7', 'title': 'Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy', 'source': 'Nature', 'date': 'Aug 10, 2024', 'snippet': 'Various ctDNA features predict outcomes in 1 L NSCLC post \nchemoimmunotherapy, with nadir of ctDNA tumor load as a key predictor of \nPFS and OS.', 'thumbnail': 'https://serpapi.com/searches/672305540f1a33107cb1b909/images/a8fdc68e49d9c1e4fc71dc95eff5064ca1efd131fbd050184e97f1d5910a1873.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8839113712310791}",,,,,,,,,,['neutral'],neutral,1
NCT02165826,"{'position': 1, 'link': 'https://copdnewstoday.com/news/copd-therapy-daliresp-dosage-approved-by-fda-for-severe-cases/', 'title': 'COPD Therapy Daliresp Dosage Approved by FDA for Severe Cases', 'source': 'COPD News Today', 'date': 'Jan 29, 2018', 'snippet': ""Read about the FDA's approval of the 250 mcg dose of Daliresp as a \nfist-line therapy in patients with severe COPD."", 'thumbnail': 'https://serpapi.com/searches/67230576d771bd6ae74f94d7/images/e348386212a23ae26c4819144383c380c8c30e7cc808966a90482dd76ed68386.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8375487923622131}",,,,,,,,,,['neutral'],neutral,1
NCT03340064,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Keppra-levetiracetam', 'title': 'Levetiracetam (Keppra®)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Epilepsy, A Study of Levetiracetam as Monotherapy or Adjunctive Treatment \nof Partial Seizures in Pediatric Epileptic Subjects Ranging From 1...', 'thumbnail': 'https://serpapi.com/searches/672305b7360f4ea99e345667/images/eaa8ac7a5d5cf9eba98ea674c231e79b72c6ddfbf83d3335c1b31c8c2056f55f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9234092831611633}",,,,,,,,,,['neutral'],neutral,1
NCT01527136,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-023-00364-1', 'title': 'Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer', 'source': 'Nature', 'date': 'Mar 8, 2023', 'snippet': 'Toll-like receptors (TLRs), which serve as a bridge between innate and \nadaptive immunity, may be viable treatment targets.', 'thumbnail': 'https://serpapi.com/searches/672305bbc05eb5bb70a054d9/images/d6072cf5bad274b5c87df8b3de79f6c4d5c5b5529593b55b3394d5a45701a287.png', 'sentiment': 'neutral', 'sentiment_prob': 0.743283212184906}",,,,,,,,,,['neutral'],neutral,1
NCT00074581,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMp1107275', 'title': 'Pediatric HIV — A Neglected Disease?', 'source': 'The New England Journal of Medicine', 'date': 'Jan 25, 2017', 'snippet': 'The results of the HIV Prevention Trials Network 052 (ClinicalTrials.gov \nnumber, NCT00074581) study were released this past May, 30 years after the \nfirst...', 'thumbnail': 'https://serpapi.com/searches/672305e4a5e50243b325ae4b/images/51af563af5b8a0f96a8f70e192b5f3d5ae8ee31c2e00a6049482e196ac3a03b8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8415622711181641}",,,,,,,,,,['neutral'],neutral,1
NCT01694849,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-022-01119-3', 'title': 'Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)', 'source': 'Nature', 'date': 'Aug 13, 2022', 'snippet': 'In this review, we discussed recent developments in etiology and \nprospective therapeutic targets, as well as pharmacological candidates in \npre/clinical trials...', 'thumbnail': 'https://serpapi.com/searches/6723060554163d58a7b24fa2/images/e7482b9edee247e1abaa39df6d0050e95842906091761f44ae63d06ab58a0415.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9206169247627258}",,,,,,,,,,['neutral'],neutral,1
NCT00990054,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.01672/full', 'title': 'Targeting CXCR4 in AML and ALL', 'source': 'Frontiers', 'date': 'Jun 30, 2023', 'snippet': 'The interaction of acute myeloid leukemia (AML) and acute lymphoblastic \nleukemia (ALL) blasts with the bone marrow microenvironment regulates \nself-renewal,...', 'thumbnail': 'https://serpapi.com/searches/6723065148c97d623004c04b/images/fa03a4c17b534edcb12cc18583c1913a2bfae2fdc1eee05fd4e18f79144f3869.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8959121108055115}",,,,,,,,,,['neutral'],neutral,1
NCT02542384,"{'position': 1, 'link': 'https://www.nature.com/articles/nrd.2017.161', 'title': 'The evolving intellectual property landscape for pruritus therapies', 'source': 'Nature', 'date': 'Sep 8, 2017', 'snippet': 'Pruritus, or itching, is the unpleasant sensation that causes a desire to \nscratch. Chronic pruritus can be a debilitating manifestation of...', 'thumbnail': 'https://serpapi.com/searches/672306b815c7405910f66aa5/images/84e12545c2bb23610e604521f6ec44d076a3ca7b1221cdd4de5fd38c3e6e9e17.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7680660486221313}",,,,,,,,,,['negative'],negative,0
NCT03221257,"{'position': 1, 'link': 'https://sclerodermanews.com/news/phase-2-trial-of-cellcept-plus-esbriet-for-ssc-ild-enrolling-in-us/', 'title': 'Phase 2 Trial of CellCept Plus Esbriet for SSc-ILD Enrolling in US', 'source': 'Scleroderma News', 'date': 'Aug 31, 2020', 'snippet': 'The Scleroderma Lung Study III (SLSIII), a Phase 2 clinical trial of oral \nCellCept (mycophenolate mofetil) alone or in combination with...', 'thumbnail': 'https://serpapi.com/searches/672306c47b05caaa46af2d34/images/8f9cc5487d86b1c5c2a29d3bd7f0dacfd99734bad93dad63e0f9988a51ae2dd1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.907543420791626}",,,,,,,,,,['neutral'],neutral,1
NCT02656498,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-89797-x', 'title': 'Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer’s disease', 'source': 'Nature', 'date': 'May 14, 2021', 'snippet': ""Imaging biomarkers support the diagnosis of Alzheimer's disease (AD). We \naimed to determine whether combining automated brain volumetry on..."", 'thumbnail': 'https://serpapi.com/searches/67230735ee46823ed9be00d4/images/0d9f5be1e9b6a5740628bcdba19ab34aabb1bea3a27ce72d776470146f5c83b3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9096342325210571}",,,,,,,,,,['neutral'],neutral,1
NCT02876835,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2113380', 'title': 'Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis', 'source': 'The New England Journal of Medicine', 'date': 'Nov 5, 2021', 'snippet': 'Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase \ninhibitor. In patients with chronic kidney disease (CKD) who are not...', 'thumbnail': 'https://serpapi.com/searches/6723073d71b0e875fe4d67d8/images/f829126ba1837eb193766e321c6557c57cbf306c894bbf66e46800c1f48f00fe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5780116319656372}",,,,,,,,,,['neutral'],neutral,1
NCT04753606,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01936-7', 'title': 'Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial', 'source': 'Nature', 'date': 'Aug 11, 2022', 'snippet': 'Global guidelines for the management of high-cardiovascular-risk patients \ninclude aggressive goals for low-density lipoprotein cholesterol...', 'thumbnail': 'https://serpapi.com/searches/672307b6fab273ad73e134ec/images/37d8aaf6ecb022422b2e33114a94f3b80428f262c35aa849f9250964e654ae0b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8734360337257385}",,,,,,,,,,['neutral'],neutral,1
NCT03533257,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/amx0035-improves-core-alzheimers-related-biomarkers-study/', 'title': 'Oral AMX0035 found to improve core Alzheimer’s-related biomarkers', 'source': ""Alzheimer's News Today"", 'date': 'Aug 29, 2024', 'snippet': ""Amylyx Pharmaceuticals' oral therapy candidate AMX0035 improves levels of \nseveral biomarkers associated with Alzheimer's, per a new..."", 'thumbnail': 'https://serpapi.com/searches/672307cf2c566da2e24005a4/images/86a77f6b5f44c98795a6fab2de6508ac182dcf1175d1f0a0344e0befa1380b5b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5265592336654663}",,,,,,,,,,['neutral'],neutral,1
NCT04060199,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/ns-pharma-shares-preliminary-results-of-viltolarsen-ns-065--ncnp-01-phase-3-clinical-trial-racer53-study-302155379.html', 'title': 'NS Pharma Shares Preliminary Results of Viltolarsen (NS-065 / NCNP-01) Phase 3 Clinical Trial (RACER53 Study)', 'source': 'PR Newswire', 'date': 'May 27, 2024', 'snippet': 'It has received preliminary analysis results from the global Phase 3 \nclinical trial (RACER53 study, NCT04060199) of NS-065/NCNP-01 (generic \nname: viltolarsen).', 'thumbnail': 'https://serpapi.com/searches/672307ece9b691ecd065ad02/images/08bfec3beab092ceffd5c000668479333c4c4cfb5e754db4747b84eb8ff07144.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8659732937812805}",,,,,,,,,,['neutral'],neutral,1
NCT00074737,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01589-z', 'title': 'Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials', 'source': 'Nature', 'date': 'Sep 6, 2023', 'snippet': 'In this review, we focus on the recent development of drug discovery \ntargeting “undruggable” proteins and their application in clinic.', 'thumbnail': 'https://serpapi.com/searches/67230867400bd56961859a10/images/72a9acda4ffcbab4bac3539b0a6e60373820573652df20d30cdc1248bae324f2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8479585647583008}",,,,,,,,,,['neutral'],neutral,1
NCT04247542,"{'position': 1, 'link': 'https://fox4kc.com/business/press-releases/cision/20240926NY15860/acurx-announces-additional-ibezapolstat-ph2b-results-in-cdi-as-well-as-anthrax-b-anthracis-susceptibility-to-acx-375-analogues', 'title': 'Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues', 'source': 'FOX4KC.com', 'date': '1 month ago', 'snippet': ""New analyses extend data on beneficial effects of ibezapolstat on the gut \nmicrobiome; Confirmed ibezapolstat's favorable pharmacokinetics..."", 'thumbnail': 'https://serpapi.com/searches/672308a4ec541086449ac2b7/images/126ca864b5d845f822568426821654879ba9e4e55cb5d8008bf0cd935a07daaf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6499823331832886}",,,,,,,,,,['neutral'],neutral,1
NCT01722331,"{'position': 1, 'link': 'https://www.dermatologyadvisor.com/cch/il-23-antagonists-in-the-treatment-of-plaque-psoriasis/', 'title': 'IL-23 Antagonists in the Treatment of Plaque Psoriasis', 'source': 'Dermatology Advisor', 'date': 'May 17, 2024', 'snippet': 'Three selective IL-23 inhibitors are currently approved for the treatment \nof plaque psoriasis: guselkumab, risankizumab, and tildrakizumab.', 'thumbnail': 'https://serpapi.com/searches/672308bacf32e07355990aa6/images/1b94f8b2f978e2528a212b19653eb88d326258f7ac3bd3604c8401de2958871d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.890917956829071}",,,,,,,,,,['neutral'],neutral,1
NCT05632211,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2023/12/04/in-early-trial-avt05-shows-similar-pharmacological-profile-to-simponi/', 'title': 'In early trial, AVT05 shows similar pharmacological profile to Simponi', 'source': 'Ankylosing Spondylitis News', 'date': 'Dec 4, 2023', 'snippet': ""AVT05, Alvotech's biosimilar candidate to treat ankylosing spondylitis, \nshowed a similar pharmacological profile to Simponi (golimumab)."", 'thumbnail': 'https://serpapi.com/searches/672308eb5f97783800f33060/images/604cbc87fbb27f426cf1ed9fa558595e43fec10bc245a920408fb98ef7880d9f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8694635629653931}",,,,,,,,,,['neutral'],neutral,1
NCT04377711,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/ciclesonide-metered-dose-inhaler-alvesco-symptomatic-covid-19-trial/', 'title': 'Mixed Results for Ciclesonide Metered-Dose Inhaler in COVID-19 Study', 'source': 'Medical Professionals Reference', 'date': 'Apr 15, 2021', 'snippet': 'Topline results were announced from a phase 3 study evaluating the efficacy \nand safety of ciclesonide metered-dose inhaler (Alvesco; Covis \nPharmaceuticals)', 'thumbnail': 'https://serpapi.com/searches/67230a2f1a5b54c4951a8c69/images/0cbcc6a778231793543537febca43aac29528d200e060085d0f888d0e777c5d2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8548741340637207}",,,,,,,,,,['neutral'],neutral,1
NCT02981303,"{'position': 1, 'link': 'https://melanomanewstoday.com/2017/06/01/biothera-to-present-initial-trial-results-combo-therapy-melanoma-breast-cancer/', 'title': 'Initial Trial Results in Advanced Melanoma to Be Presented by Biothera', 'source': 'Melanoma News Today', 'date': 'Jun 1, 2017', 'snippet': 'Biothera Pharmaceuticals will present the detailed study design of the \nIMPRIME-1 clinical trial at the upcoming 2017 ASCO Annual Meeting...', 'thumbnail': 'https://serpapi.com/searches/67230a30c82127bb8ea5bf81/images/8fb858dc8924246c3d9af3326d2f0777056b1f1ece3c9c2076169f6685ce9b0e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9139280915260315}",,,,,,,,,,['neutral'],neutral,1
NCT02689284,"{'position': 1, 'link': 'https://www.onclive.com/view/fda-grants-margetuximab-orphan-drug-status-for-gastric-cancer', 'title': 'FDA Grants Margetuximab Orphan Drug Status for Gastric Cancer', 'source': 'OncLive', 'date': 'Jun 5, 2020', 'snippet': 'The FDA has granted margetuximab an Orphan Drug designation for the \ntreatment of patients with gastric and gastroesophageal junction cancer.', 'thumbnail': 'https://serpapi.com/searches/67230a38d0253e8b77108e2c/images/2bb9d735fa1183ad2f66b8ab74a19e1e6fdf7fc5f36cc17f89bee0f2b16e9024.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8816794753074646}",,,,,,,,,,['neutral'],neutral,1
NCT00594568,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1210951', 'title': ""A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease"", 'source': 'The New England Journal of Medicine', 'date': 'Jul 25, 2013', 'snippet': ""Alzheimer's disease is characterized by the presence of cortical \namyloid-beta (Aβ) protein plaques, which result from the sequential \naction..."", 'thumbnail': 'https://serpapi.com/searches/67230a4d23a4b50ac51e6a20/images/d5f351c2cfd987cdfb307fbde2ac18abdbafafc68e26460443f4c0119d26e7f7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8145344257354736}",,,,,,,,,,['neutral'],neutral,1
NCT03891524,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2113194', 'title': 'Milvexian for the Prevention of Venous Thromboembolism', 'source': 'The New England Journal of Medicine', 'date': 'Nov 15, 2021', 'snippet': 'Factor XIa inhibitors for the prevention and treatment of venous and \narterial thromboembolism may be more effective and result in less...', 'thumbnail': 'https://serpapi.com/searches/67230a8375f974afac11385c/images/b536ae0e83e2eaf5c06f29c6829360238c5dd015617cd59b62964e974402b598.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7155522108078003}",,,,,,,,,,['neutral'],neutral,1
NCT00943826,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1308345', 'title': 'Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma', 'source': 'The New England Journal of Medicine', 'date': 'Feb 20, 2014', 'snippet': 'In this phase 3 study, we evaluated the effect of the addition of \nbevacizumab to radiotherapy–temozolomide for the treatment of newly \ndiagnosed glioblastoma.', 'thumbnail': 'https://serpapi.com/searches/67230aa9efad21930504ef84/images/b7b3b76407e72bc2f3ccaa3aad28df232280daf156a08807e9331c0d19763930.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9009138345718384}",,,,,,,,,,['neutral'],neutral,1
NCT03579459,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0264410X23012963', 'title': 'A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age', 'source': 'ScienceDirect.com', 'date': 'Dec 7, 2023', 'snippet': 'Three doses (Months 0,1,6) of toxoid-based C difficile vaccine induced \nrobust neutralizing antibody responses and were well tolerated in healthy \nparticipants...', 'thumbnail': 'https://serpapi.com/searches/67230ac3483e5b863e7166b6/images/24c2ac4a1951bdbaf9a1be692643de011390a7d769ee95c810f649b9fe19afc4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7878576517105103}",,,,,,,,,,['neutral'],neutral,1
NCT02926768,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01589-z', 'title': 'Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials', 'source': 'Nature', 'date': 'Sep 6, 2023', 'snippet': 'In this review, we focus on the recent development of drug discovery \ntargeting “undruggable” proteins and their application in clinic.', 'thumbnail': 'https://serpapi.com/searches/67230b624677bf0e20da2509/images/b31af61af41a899a71685ed505045974f98f6929ef0573420a45efae60071dba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8479585647583008}",,,,,,,,,,['neutral'],neutral,1
NCT03321513,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/type-step-therapy-effective-strategy-diabetic-eye-disease', 'title': 'A type of ‘step therapy’ is an effective strategy for diabetic eye disease', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jul 14, 2022', 'snippet': 'NIH-funded clinical trial finds that starting with a cheaper drug and \nswitching to a more expensive drug as needed leads to good vision...', 'thumbnail': 'https://serpapi.com/searches/67230b6831030010587ad5c6/images/42ffb5949db0a7adee553d91ed5378fe3871c39349551f26d55a8337b2bebdae.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6853460073471069}",,,,,,,,,,['positive'],positive,1
NCT00112931,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/reports/ash-2022-follicular-lymphoma-trials-show-promising-results/', 'title': 'ASH 2022: Trials Show Promising Results in Follicular Lymphoma', 'source': 'Cancer Therapy Advisor', 'date': 'Dec 20, 2022', 'snippet': 'Results from 4 trials presented at the 2022 ASH Annual Meeting may help \ninform the treatment of newly diagnosed and relapsed/refractory follicular \nlymphoma (FL...', 'thumbnail': 'https://serpapi.com/searches/67230b70f963e765fe78c987/images/8ed157d06a53eb12f5d73387624570af23dfad4d93e4d84a6d219dbd0ba75cc7.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7179461121559143}",,,,,,,,,,['positive'],positive,1
NCT04744363,"{'position': 1, 'link': 'https://www.pharmacytimes.com/view/fda-approves-ustekinumab-biosimilar-to-stelara-for-treatment-of-plaque-psoriasis', 'title': 'FDA Approves Ustekinumab Biosimilar to Stelara for Treatment of Plaque Psoriasis', 'source': 'Pharmacy Times', 'date': 'Apr 17, 2024', 'snippet': 'Ustekinumab (Stelara; Janssen Immunology) is a human monoclonal antibody \nthat treats immune-mediated diseases such as psoriasis and...', 'thumbnail': 'https://serpapi.com/searches/67230ba0400bd56961859d57/images/9928ea78c70d193b8f014436f995e97f5c30beebb636e5e5eaed0da3f119ee56.png', 'sentiment': 'neutral', 'sentiment_prob': 0.846770167350769}",,,,,,,,,,['neutral'],neutral,1
NCT01363388,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/chemocentryx-on-track-present-topline-data-advocate-trial-avacopan/', 'title': ""AAV: ADVOCATE Trial's Topline Data Expected to be Presented This Year"", 'source': 'ANCA Vasculitis News', 'date': 'May 14, 2019', 'snippet': 'ChemoCentryx remains on track to report topline results later this year \nfrom its ongoing Phase 3 clinical trial assessing the safety and...', 'thumbnail': 'https://serpapi.com/searches/67230be36531cbe579007554/images/0478e52860f851d0e47cdb818462c106efe1fe18d50414bdcd78a390ccb037d5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8710752725601196}","{'position': 2, 'link': 'https://ancavasculitisnews.com/news/rituxan-soliris-combo-may-replace-glucocorticoids-aav-treatment/', 'title': 'For AAV, Rituxan-Soliris Combo May Replace Glucocorticoids, Study Says', 'source': 'ANCA Vasculitis News', 'date': 'May 30, 2019', 'snippet': 'A combination of Rituxan and Soliris may be used to replace glucocorticoids \nfor the treatment of patients with severe AAV, a case report...', 'thumbnail': 'https://serpapi.com/searches/67230be36531cbe579007554/images/0478e52860f851d02c70f090a6987ce8372236465fc911654cb4558a782b2463.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9202865362167358}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03664518,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.27141', 'title': 'Efficacy and safety of eltrombopag in the treatment of immune thrombocytopenia patients with hepatitis B virus infection: A prospective, multicenter, single arm, phase II trial', 'source': 'Wiley Online Library', 'date': 'Oct 26, 2023', 'snippet': 'Hepatitis B virus (HBV) infection is the most common chronic viral \ninfection worldwide. Epidemiological data showed that the hepatitis virus...', 'thumbnail': 'https://serpapi.com/searches/67230d50069e577bfa331901/images/33e4f31b28d213d763660e80e9b3b740dab10c1bd437f07ece17e19c1f4ef2ce.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7033538818359375}",,,,,,,,,,['neutral'],neutral,1
NCT04056065,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/circ.142.suppl_4.278', 'title': 'Abstract 278: A Novel Resuscitative Agent, Centhaquine (Lyfaquin®), has the Potential to Treat Acute Kidney Injury Following Hemorrhagic Shock', 'source': 'American Heart Association Journals', 'date': 'Nov 9, 2020', 'snippet': 'Introduction: Centhaquine (CQ) is being developed as a first-in-class \nresuscitative agent to treat hemorrhagic shock.', 'thumbnail': 'https://serpapi.com/searches/67230c68d11a89a60d58fcfc/images/f4de02842a658031e775b82b6ea6dfc5178c02d73742e894d58ef49aaadc8840.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8361145257949829}",,,,,,,,,,['neutral'],neutral,1
NCT03558152,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332223000616', 'title': 'Role of Interleukin-22 in ulcerative colitis', 'source': 'ScienceDirect.com', 'date': 'Jan 23, 2023', 'snippet': 'IL-22 plays a crucial role in UC, which is closely related to AhR, STAT3, \nCARD9, MSC, Treg, RA and intestinal flora. •. In clinical practice, IL-22 \nand its...', 'thumbnail': 'https://serpapi.com/searches/67230c6ca775f2f8ec0e64d4/images/10a326e80f49d9e6c7e8bdd73fabbed0cc4a678bb7964e058110be49ce574dd7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.879794716835022}",,,,,,,,,,['neutral'],neutral,1
NCT05083260,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/parkinsons-trial-anti-inflammatory-ne3107-may-open-summer/', 'title': 'Phase 2 trial of NE3107, an anti-inflammatory, may open in summer', 'source': ""Parkinson's News Today"", 'date': 'Mar 18, 2024', 'snippet': 'BioVie is planning to launch in late summer a Phase 2b clinical trial of \nNE3107, its investigational anti-inflammatory small molecule, as an initial \nand stand-...', 'thumbnail': 'https://serpapi.com/searches/67230cbfcf32e07355990feb/images/a278315a2f09288a129106ead6aeca25eab9c00651d000a7cf49db502776db8a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.790367066860199}","{'position': 2, 'link': 'https://www.globenewswire.com/News-Release/2022/12/05/2567854/0/En/BioVie-Announces-Positive-Results-for-NE3107-in-Parkinson-s-and-Alzheimer-s-Phase-2-Trials.html', 'title': 'BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials', 'source': 'GlobeNewswire', 'date': 'Dec 5, 2022', 'snippet': ""NE3107-treated patients experienced greater motor control in Parkinson's \ntrial Patients treated with the combination of NE3107 and levodopa..."", 'thumbnail': 'https://serpapi.com/searches/67230cbfcf32e07355990feb/images/a278315a2f09288aec592acb8b2a3b6d7e92676b624fdc51ae97cbc3491ff130.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5283809304237366}","{'position': 3, 'link': 'https://parkinsonsnewstoday.com/news/parkinsons-adding-ne3107-levodopa-aids-motor-nonmotor-benefits/', 'title': 'NE3107 added to levodopa enhances motor, non-motor benefits', 'source': ""Parkinson's News Today"", 'date': 'Mar 4, 2024', 'snippet': ""Adding NE3107 to carbidopa/levodopa therapy eases motor and non-motor \nsymptoms in people with Parkinson's disease, a Phase 2a trial shows."", 'thumbnail': 'https://serpapi.com/searches/67230cbfcf32e07355990feb/images/a278315a2f09288a1ebcd2590b81f711fa6af39acba1d17595e2d1cfe7f47216.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7265336513519287}","{'position': 4, 'link': 'https://parkinsonsnewstoday.com/news/add-on-ne3107-now-bezisterim-eases-parkinsons-symptoms/', 'title': 'Add-on NE3107, now bezisterim, eases Parkinson’s symptoms', 'source': ""Parkinson's News Today"", 'date': 'May 29, 2024', 'snippet': ""NE3107, now bezisterim, eases Parkinson's motor and nonmotor symptoms when \nused along with other therapies, study data showed."", 'thumbnail': 'https://serpapi.com/searches/67230cbfcf32e07355990feb/images/a278315a2f09288a735558571bb4d7e6c227c56413fbf575db5ed19869a0234c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.748104453086853}",,,,,,,"['neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT04234204,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/astellas-announces-topline-12-week-results-from-phase-3-study-of-fezolinetant-for-the-nonhormonal-treatment-of-vasomotor-symptoms-in-women-in-asia-301502322.html', 'title': 'Astellas Announces Topline 12-week Results from Phase 3 Study of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Women in Asia', 'source': 'PR Newswire', 'date': 'Mar 14, 2022', 'snippet': ""Astellas' MOONLIGHT 1TM clinical trial evaluating investigational \nfezolinetant 30 mg administered once daily."", 'thumbnail': 'https://serpapi.com/searches/67230cc1d78a985ac5d5ce53/images/0f22063710c0aedc4b518e0d1e1f982556201a478d7a4e8ee9a0c1ea3b83c131.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9121507406234741}",,,,,,,,,,['neutral'],neutral,1
NCT02743897,"{'position': 1, 'link': 'https://hepatitisnewstoday.com/2017/05/02/doctors-transplant-kidneys-with-hepatitis-c-and-then-cure-the-infection/', 'title': 'Doctors Transplant Kidneys with Hepatitis C, Then Cure Recipients’ Infection', 'source': 'Hepatitis News Today', 'date': 'May 2, 2017', 'snippet': 'Ten clinical trial participants were cured of hepatitis C after receiving a \nkidney transplant from deceased donors who were infected with the virus.', 'thumbnail': 'https://serpapi.com/searches/67230ccd71b0e875b539cfce/images/6ebd8d506156a29c264bca444156fe64409f3377d18e2ba782e61d22b19e4314.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8083324432373047}",,,,,,,,,,['neutral'],neutral,1
NCT04250337,"{'position': 1, 'link': 'https://www.empr.com/news/ebglyss-approved-for-moderate-to-severe-atopic-dermatitis/', 'title': 'Ebglyss Approved for Moderate to Severe Atopic Dermatitis', 'source': 'Medical Professionals Reference', 'date': '1 month ago', 'snippet': 'The Food and Drug Administration (FDA) has approved Ebglyss™ \n(lebrikizumab-lbkz) for the treatment of adult and pediatric patients aged \n12...', 'thumbnail': 'https://serpapi.com/searches/67230cd8a32436a1abacbe63/images/15db818c448439c59b06bbfdb60d031eb8fe0006d863b498ddf0e70b62f1fe6d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8664060831069946}",,,,,,,,,,['neutral'],neutral,1
NCT00521053,"{'position': 1, 'link': 'https://finance.yahoo.com/news/provectus-biopharmaceuticals-announces-presentation-meta-120000734.html', 'title': 'Provectus Biopharmaceuticals Announces Presentation of Meta-Analysis Results of Single-Agent PV-10® in Stage III Cutaneous Melanoma at Society for Melanoma Research (SMR) 2021', 'source': 'Yahoo Finance', 'date': 'Nov 1, 2021', 'snippet': '184 patients: 44.9 months median overall survival774 PV-10-injected lesions \n(121 patients): 56% complete response KNOXVILLE, TN, Nov.', 'thumbnail': 'https://serpapi.com/searches/67230ceed19f15b530381b36/images/096ecfab1122bc5cd10eb8dee4a1d9e94921526492e8cacc77be2bc997dff997.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9119287133216858}",,,,,,,,,,['neutral'],neutral,1
NCT04306146,"{'position': 1, 'link': 'https://www.nature.com/articles/s41386-023-01614-3', 'title': 'Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry | Neuropsychopharmacology', 'source': 'Nature', 'date': 'Jun 27, 2023', 'snippet': 'NMDA receptor modulators have long been considered as potential treatments \nfor psychiatric disorders including depression and schizophrenia, \nneurodevelopmental...', 'thumbnail': 'https://serpapi.com/searches/67230d00f79a012cbdab47ce/images/50dfdb7875c32b2c53c2db3745e64cb732550e3722dce6619a670df2f9af6498.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7463937401771545}",,,,,,,,,,['neutral'],neutral,1
NCT03375294,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/does-nitrous-oxide-help-veterans-with-ptsd/', 'title': 'Does Nitrous Oxide Help Veterans With Posttraumatic Stress Disorder? A Case Series', 'source': 'Psychiatrist.com', 'date': 'Jun 30, 2020', 'snippet': 'This case series investigates the potential for nitrous oxide to rapidly \nreduce symptoms of posttraumatic stress disorder. Did it help the 3...', 'thumbnail': 'https://serpapi.com/searches/67230d11e95dbf8877425eef/images/2ca76daf3ffd45580e5332a42d989fcb35c328cbd2a6679d13f096a93a5bb66c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7989832162857056}",,,,,,,,,,['neutral'],neutral,1
NCT03485911,"{'position': 1, 'link': 'https://angioedemanews.com/news/trial-data-long-term-orladeyo-hae-patients-safe-effective/', 'title': 'Long-term Orladeyo safe, effective in HAE patients: Trial data', 'source': 'Angioedema News', 'date': 'Dec 21, 2023', 'snippet': 'Long-term prophylaxis, or preventive treatment, with Orladeyo \n(berotralstat) is well tolerated, and results in sustained reductions in \nswelling attacks and...', 'thumbnail': 'https://serpapi.com/searches/67230d28b4fe87d275d34e82/images/bfe31008c14e5ddb84f5e2e7ab8335ce02cc5abf9c908fcaa144aba069ccc1e1.png', 'sentiment': 'positive', 'sentiment_prob': 0.5627046823501587}","{'position': 2, 'link': 'https://angioedemanews.com/news/orladeyo-set-to-launch-by-years-end-if-approved-biocryst-says/', 'title': ""HAE Drug Orladeyo to Launch by Year's End if Approved, BioCryst Says"", 'source': 'Angioedema News', 'date': 'Aug 19, 2020', 'snippet': ""BioCryst Pharmaceuticals will launch Orladeyo (berotralstat) by year's end \nif this oral drug for hereditary angioedema is approved,..."", 'thumbnail': 'https://serpapi.com/searches/67230d28b4fe87d275d34e82/images/bfe31008c14e5ddb4a439b054c62d1072178ed3fb65c356e0f33cdde8a24c09a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.840570867061615}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT04523129,"{'position': 1, 'link': 'https://www.medscape.com/viewarticle/993024', 'title': 'FDA Approves Second Waterless Solution for Dry Eye Disease', 'source': 'Medscape', 'date': 'Jun 9, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has approved the first waterless \ncyclosporine-based solution for treating the signs and symptoms of dry eye \ndisease.', 'thumbnail': 'https://serpapi.com/searches/67230d5a7ebde58f676f15f4/images/49f2635955ee55ae1cfc47560b498a8dd8c60744d3b3b3973f590f5d3009e9a8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7421690225601196}","{'position': 2, 'link': 'https://www.empr.com/home/news/water-free-dry-eye-disease-therapy-vevye-gets-fda-approval/', 'title': 'Water-Free Dry Eye Disease Therapy Vevye Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Jun 8, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Vevye™ (cyclosporine \nophthalmic solution) 0.1% for the treatment of the signs and...', 'thumbnail': 'https://serpapi.com/searches/67230d5a7ebde58f676f15f4/images/49f2635955ee55ae20c5c556fe3d519f4a23b019c673adda1e9e718019de0e51.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6431905627250671}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02534844,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/experimental-treatment-niemann-pick-disease-type-c1-appears-safe-effective', 'title': 'Experimental treatment for Niemann-Pick disease type C1 appears safe, effective', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Aug 11, 2017', 'snippet': 'NIH-led clinical trial suggests that drug slows progression of rare \nneurological disease.', 'thumbnail': 'https://serpapi.com/searches/67230d658f2bc20cba22ce6d/images/0cb8c2d1f1e5ba000cd0ad607d67dd56dd2c6f077794e7df60c3ef95644d76e9.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.561607837677002}","{'position': 2, 'link': 'https://www.europeanpharmaceuticalreview.com/news/65610/experimental-treatment-niemann-pick/', 'title': 'Experimental treatment for Niemann-Pick disease appears safe', 'source': 'European Pharmaceutical Review', 'date': 'Aug 14, 2017', 'snippet': 'An experimental drug has appeared to slow the progression of Niemann-Pick \ndisease type C1 (NPC1), the drug, 2-hydroxypropyl-beta-cyclodextrin \n(VTS-270), is...', 'thumbnail': 'https://serpapi.com/searches/67230d658f2bc20cba22ce6d/images/0cb8c2d1f1e5ba00434b9b55e234d334c06363494937c9758e209022df3e7a3a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7627475261688232}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02650895,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S1550413122003047', 'title': 'CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder', 'source': 'ScienceDirect.com', 'date': 'Aug 2, 2022', 'snippet': 'We report that the CD24-Siglec-E axis, but not other Siglecs, is a key \nsuppressor of obesity-related metabolic dysfunction.', 'thumbnail': 'https://serpapi.com/searches/67230d9768831e823dc94227/images/f24d290357d293d1a0081ecbf03f663e63993bd9be88d3296fc22008cd45f3a7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.873424768447876}",,,,,,,,,,['neutral'],neutral,1
NCT02570997,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/ct1812/', 'title': 'Elayta (CT1812)', 'source': ""Alzheimer's News Today"", 'date': 'Apr 7, 2018', 'snippet': ""CT1812 is an oral medication being developed by Cognition Therapeutics, now \nin clinical testing, to possibly treat mild-to-moderate Alzheimer's disease \nby..."", 'thumbnail': 'https://serpapi.com/searches/67230de8acf7f8291ac55e17/images/3e201025f406e8c99bfc7e1a3451f6d3405bdb6fa698ff92d9b20fc5613c5965.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8871570825576782}",,,,,,,,,,['neutral'],neutral,1
NCT04430855,"{'position': 1, 'link': 'https://www.termedia.pl/Hidradenitis-suppurativa-a-new-therapeutic-approach-for-an-old-disease,7,54608,1,1.html', 'title': 'Hidradenitis suppurativa: a new therapeutic approach for an old disease', 'source': 'Termedia', 'date': 'Aug 12, 2024', 'snippet': 'Hidradenitis suppurativa (HS) is a chronic inflammatory disease \ncharacterised by recurrent painful nodules, abscesses, fistulas and \nscarring...', 'thumbnail': 'https://serpapi.com/searches/67230ded8b7ba7562cbd4f2e/images/f3e83ae9691bd6b62bc54c038570b43bb40fe5251103435093cab529b8e6608e.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6704685091972351}",,,,,,,,,,['negative'],negative,0
NCT02543827,"{'position': 1, 'link': 'https://www.renalandurologynews.com/news/mv140-bacterial-vaccine-may-prevent-recurrent-urinary-tract-infections-utis/', 'title': 'MV140 Vaccine May Prevent Recurrent Urinary Tract Infections', 'source': 'Renal and Urology News', 'date': 'Mar 2, 2022', 'snippet': 'MV140, a sublingual vaccine of whole-cell inactivated bacteria, may prevent \nurinary tract infections (UTIs) in women with recurrent UTIs, according to \nnew...', 'thumbnail': 'https://serpapi.com/searches/67230dee2da983cce1208602/images/d5ca1e16f628b96f9a505aff6151d87fa33e6278392b5332ba6c2da3d63ff62f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8997668027877808}",,,,,,,,,,['neutral'],neutral,1
NCT02721589,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-022-01213-6', 'title': 'Phase I study of camrelizumab in patients with advanced solid tumors', 'source': 'Nature', 'date': 'Feb 1, 2023', 'snippet': 'Dear Editor,. Camrelizumab (SHR-1210) is a humanized monoclonal antibody \n(mAb) that binds to programmed cell death protein 1 (PD-1).', 'thumbnail': 'https://serpapi.com/searches/67230e659819f3396e1cec01/images/c258920e670871cb052f944d4a6cffc0663d36406da0497e0c30c1815d757cbd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8546786904335022}",,,,,,,,,,['neutral'],neutral,1
NCT03829241,"{'position': 1, 'link': 'https://www.bioworld.com/articles/670274-first-patient-enrolled-in-phase-iii-study-of-troriluzole-in-generalized-anxiety-disorder', 'title': 'First patient enrolled in phase III study of troriluzole in generalized anxiety disorder', 'source': 'BioWorld MedTech', 'date': 'Feb 21, 2019', 'snippet': 'Biohaven Pharmaceutical announced that it has enrolled its first patient in \na phase III clinical trial assessing the efficacy and safety of...', 'thumbnail': 'https://serpapi.com/searches/67230e9049ea558318e554a7/images/73ee5437a5326f36e4d0535c2dda21a2489810117816ddfd173331553527ab5a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8288338780403137}",,,,,,,,,,['neutral'],neutral,1
NCT02950051,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2213093', 'title': 'First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'May 10, 2023', 'snippet': 'Randomized trials of venetoclax plus anti-CD20 antibodies as first-line \ntreatment in fit patients (i.e., those with a low burden of...', 'thumbnail': 'https://serpapi.com/searches/67230e96be1497773c62e4cf/images/9eeec4d3a9f422c988b5eccce0de25f94582ff88b6e15368c33a408056ab5329.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8882309794425964}","{'position': 2, 'link': 'https://www.onclive.com/view/fixed-duration-venetoclax-based-combos-maintain-benefit-in-frontline-cll', 'title': 'Fixed-Duration Venetoclax-Based Combos Maintain Benefit in Frontline CLL', 'source': 'OncLive', 'date': 'Jul 17, 2024', 'snippet': 'Additional follow-up from the phase 3 GAIA/CLL13 trial (NCT02950051) \ndemonstrated that fixed-duration treatment with venetoclax (Venclexta)...', 'thumbnail': 'https://serpapi.com/searches/67230e96be1497773c62e4cf/images/9eeec4d3a9f422c9319f43029ba14cd89b8ad34ceaa2b9bb36ca3ec0c9bcb4b2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8059571981430054}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00004041,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2021.621831/full', 'title': 'Current Approaches for Glioma Gene Therapy and Virotherapy', 'source': 'Frontiers', 'date': 'Jun 27, 2024', 'snippet': 'Glioblastoma (GBM) is the most common and aggressive primary brain tumor in \nthe adult population and it carries a dismal prognosis. Inefficient drug...', 'thumbnail': 'https://serpapi.com/searches/67230e9ac024d129ff76bac7/images/b07a8e06b6fd94adbc550e6a8e16f8a2ece80b7d22c7633e5dfb6fb05a42c7e7.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7528362274169922}",,,,,,,,,,['negative'],negative,0
NCT01101438,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-021-00275-z', 'title': 'Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial', 'source': 'Nature', 'date': 'Jun 8, 2021', 'snippet': 'Metformin may exert anticancer effects through indirect (mediated by \nmetabolic changes) or direct mechanisms. The goal was to examine...', 'thumbnail': 'https://serpapi.com/searches/67230eca21b01b712dab6492/images/c69758c14acdca6488d8763012de87e67381f6dd2e70d98c9168f0f5fcd63410.png', 'sentiment': 'neutral', 'sentiment_prob': 0.91813063621521}",,,,,,,,,,['neutral'],neutral,1
NCT00118209,"{'position': 1, 'link': 'https://www.cureus.com/abstracts/1204-the-theoretical-role-for-radiotherapy-in-patients-with-diffuse-large-b-cell-lymphoma-a-secondary-analysis-of-a-prospective-randomized-controlled-trial', 'title': 'The Theoretical Role for Radiotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Secondary Analysis of a Prospective Randomized Controlled Trial', 'source': 'Cureus', 'date': 'Feb 13, 2024', 'snippet': 'In this secondary analysis of a phase III randomized trial of chemotherapy \nalone for DLBCL, initial bulk was not shown to be significantly associated \nwith PFS...', 'thumbnail': 'https://serpapi.com/searches/67230f7b749783416cf416f2/images/6ab07846301800d26eb8af9888819cbaca510b59565ef508db25194b432f988c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9078344106674194}",,,,,,,,,,['neutral'],neutral,1
NCT02737748,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.557758/full', 'title': 'Holistic Approach of Swiss Fetal Progenitor Cell Banking: Optimizing Safe and Sustainable Substrates for Regenerative Medicine and Biotechnology', 'source': 'Frontiers', 'date': 'Jun 27, 2024', 'snippet': 'A renewed model of single organ donation bioprocessing is proposed, \nachieving sustained standards and potential production of billions of \naffordable and...', 'thumbnail': 'https://serpapi.com/searches/67230f8d671f3fe97e4138a8/images/cdc528ef23949f0739a6795edef9ec353385673a34ab9f61e8549910be22222b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7384865880012512}",,,,,,,,,,['neutral'],neutral,1
NCT00240331,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0810177', 'title': 'Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis', 'source': 'The New England Journal of Medicine', 'date': 'Apr 30, 2018', 'snippet': 'We conducted an international, multicenter, randomized, double-blind, \nprospective trial involving 2776 patients, 50 to 80 years of age, who were \nundergoing...', 'thumbnail': 'https://serpapi.com/searches/67230f8def60cb338d94c8ab/images/426ec2a684de04e3fcdb61efa4df1bc5946b46dd8cce5bc35010c1c1ffd96435.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8750075101852417}",,,,,,,,,,['neutral'],neutral,1
NCT04740905,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2024/07/30/2920702/0/en/European-Commission-approves-Roche-s-Vabysmo-for-treatment-of-retinal-vein-occlusion-RVO.html', 'title': 'European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)', 'source': 'GlobeNewswire', 'date': 'Jul 30, 2024', 'snippet': 'Approval is based on data from two Phase III studies in branch and central \nretinal vein occlusion (RVO) showing early and sustained vision...', 'thumbnail': 'https://serpapi.com/searches/67230edec7d4a15f9713c5d9/images/0f704900f53993e39f98ee774d831a8ee43541fa72f4699cc6fa50172e9ec23d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6009171605110168}",,,,,,,,,,['neutral'],neutral,1
NCT03021499,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/lupkynis-approved-japan-treat-lupus-nephritis/', 'title': 'Lupkynis approved in Japan to treat lupus nephritis', 'source': 'Lupus News Today', 'date': '4 weeks ago', 'snippet': 'Lupkynis (voclosporin) is now approved in Japan to treat lupus nephritis, a \ncomplication of lupus marked by kidney damage and inflammation.', 'thumbnail': 'https://serpapi.com/searches/67230ee40d379fd08d19993c/images/9aaaa852a9d992b0e4217915a4956133bab7054e189fce334282ad3717d6e991.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6324307918548584}","{'position': 2, 'link': 'https://lupusnewstoday.com/news/otsuka-seeks-approval-japan-lupkynis-voclosporin-lupus-nephritis/', 'title': 'Otsuka seeks approval in Japan of Lupkynis for lupus nephritis', 'source': 'Lupus News Today', 'date': 'Nov 16, 2023', 'snippet': 'Otsuka Pharmaceutical is seeking approval in Japan to manufacture and \nmarket Lupkynis (voclosporin) for the treatment of lupus nephritis.', 'thumbnail': 'https://serpapi.com/searches/67230ee40d379fd08d19993c/images/9aaaa852a9d992b04abae5f445428f975d6cd7ef70015cc06b28f4812ae277f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8836975693702698}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05186818,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa2401424', 'title': 'Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy', 'source': 'The New England Journal of Medicine', 'date': 'May 13, 2024', 'snippet': 'Aficamten is an oral selective cardiac myosin inhibitor that reduces left \nventricular outflow tract gradients by mitigating cardiac \nhypercontractility.', 'thumbnail': 'https://serpapi.com/searches/67230eec0f2a2ca3ad67ea5e/images/9d175d7cbb422ba8c4086ebe9738f1a44c356e9b74ef8b41b2290d169036e6a6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8317034840583801}","{'position': 2, 'link': 'https://consultqd.clevelandclinic.org/advances-in-hypertrophic-cardiomyopathy-therapy-valor-hcm-may-be-just-the-beginning', 'title': 'Advances in Hypertrophic Cardiomyopathy Therapy: VALOR-HCM May Be Just the Beginning', 'source': 'Cleveland Clinic', 'date': 'Jan 27, 2023', 'snippet': 'An abundance of promising studies are on the horizon. \n22-HVI-3509429_obstructive-hypertrophic-cardiomyopathy_650x450. When \nCleveland Clinic...', 'thumbnail': 'https://serpapi.com/searches/67230eec0f2a2ca3ad67ea5e/images/9d175d7cbb422ba88e8ba016fb55fc2cbfddd2e9fe450f6c84b2d9bfca9d31fe.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8903656005859375}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02012491,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1715726', 'title': 'Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss', 'source': 'The New England Journal of Medicine', 'date': 'Jun 6, 2018', 'snippet': 'Medical management of early pregnancy loss is an alternative to uterine \naspiration, but standard medical treatment with misoprostol commonly...', 'thumbnail': 'https://serpapi.com/searches/67230f02e281ee018cee3229/images/95a2f9dbe9fe6023c3fd0e1a009f1ac87f7b5d72a335d47f79f38f53e8b04abd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6485427021980286}",,,,,,,,,,['neutral'],neutral,1
NCT04738123,"{'position': 1, 'link': 'https://www.psychiatryadvisor.com/news/karxt-efficacy-safety-acute-psychosis-schizophrenia/', 'title': 'KarXT Demonstrates Efficacy, Safety for Acute Psychosis in Schizophrenia', 'source': 'Psychiatry Advisor', 'date': 'May 10, 2024', 'snippet': 'Xanomeline-trospium chloride (KarXT) was efficacious and well-tolerated \namong individuals with schizophrenia experiencing acute psychosis, \naccording to phase 3...', 'thumbnail': 'https://serpapi.com/searches/67230f0e4677bf0e20da28e5/images/bea66a2131ba78ed8273400e92656ec9bd1123a70ee0452d0c2c20f8f6df265d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5799948573112488}","{'position': 2, 'link': 'https://www.empr.com/news/cobenfy-approved-for-adult-patients-with-schizophrenia/', 'title': 'Cobenfy Approved for Adult Patients with Schizophrenia', 'source': 'Medical Professionals Reference', 'date': '1 month ago', 'snippet': 'The Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and \ntrospium chloride) for the treatment of adults with schizophrenia.', 'thumbnail': 'https://serpapi.com/searches/67230f0e4677bf0e20da28e5/images/bea66a2131ba78ed28fc9f13c573701252d44c93941777e7276150ffb5a7d21b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7815037369728088}","{'position': 3, 'link': 'https://www.psychiatrist.com/jcp/antipsychotic-efficacy-of-karxt-xanomeline-trospium/', 'title': 'Antipsychotic Efficacy of KarXT (Xanomeline−Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study', 'source': 'Psychiatrist.com', 'date': 'May 11, 2022', 'snippet': 'KarXT provided clinically meaningful responder rates on PANSS total score \ncompared with placebo at each response threshold, providing further support \nof the...', 'thumbnail': 'https://serpapi.com/searches/67230f0e4677bf0e20da28e5/images/bea66a2131ba78ed4e5bde2db5a4ce20c94fc62c1de3bef0249b91e5a776faff.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8605852127075195}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02454634,"{'position': 1, 'link': 'https://www.nature.com/articles/s41586-021-03363-z', 'title': 'A vaccine targeting mutant IDH1 in newly diagnosed glioma', 'source': 'Nature', 'date': 'Mar 24, 2021', 'snippet': 'Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct \nsubtype of diffuse glioma1–3. The most common IDH1 mutation in...', 'thumbnail': 'https://serpapi.com/searches/67230f6b0f1a33107cb1c4df/images/c1d536ababd97c1164cf73e792f983398cafbf23ba48f17ed9c6c8a8fc7d9b49.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8800758719444275}",,,,,,,,,,['neutral'],neutral,1
NCT04436744,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00268-1/fulltext', 'title': 'Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study', 'source': 'The Lancet', 'date': 'Nov 1, 2023', 'snippet': 'The development of more potent selective oestrogen receptor antagonists and \ndegraders (SERDs) that can be orally administered could help to...', 'thumbnail': 'https://serpapi.com/searches/67230fb058e433496eb9514e/images/b249f61a2b348ad6e0ce373fa34e4749aed0855a5fccdd76479c7452d83f4de0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8613340258598328}",,,,,,,,,,['neutral'],neutral,1
NCT03276572,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/reports/225ac-j591-yields-responses-in-difficult-to-treat-metastatic-prostate-cancer/', 'title': '225Ac-J591 Yields Responses in Difficult-to-Treat Metastatic Prostate Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Dec 2, 2023', 'snippet': 'The radiopharmaceutical 225Ac-J591 produced responses in patients with \nmetastatic prostate cancer in a phase 1 study.', 'thumbnail': 'https://serpapi.com/searches/67230fba16779391e19aa8c2/images/9ca3fae3d60dc79991c0deb1074a6330befdad3b0568f7d055c42a7e91e6ee89.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.566058874130249}",,,,,,,,,,['neutral'],neutral,1
NCT04751682,"{'position': 1, 'link': 'https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00025-1/fulltext', 'title': 'Intranasal COVID-19 vaccines: From bench to bed - eBioMedicine', 'source': 'The Lancet', 'date': 'Jan 24, 2022', 'snippet': 'Intranasal (IN) vaccination method has been demonstrated to be potent in \ninducing both mucosal and systemic immune responses.', 'thumbnail': 'https://serpapi.com/searches/67230fbd81bab738a9d5d3c3/images/b165a205af28f3dc02cf4b43d5f1d2673c3c8a9563706099efba1036ebc513b5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7254720330238342}",,,,,,,,,,['neutral'],neutral,1
NCT01830855,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1614474', 'title': 'A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults', 'source': 'The New England Journal of Medicine', 'date': 'Dec 14, 2017', 'snippet': 'MenB-FHbp is a licensed meningococcal B vaccine targeting factor H–binding \nprotein. Two phase 3 studies assessed the safety of the vaccine...', 'thumbnail': 'https://serpapi.com/searches/67230fd6e6862ba37958da22/images/4cce7afd12191fb0a4632cf8832b2f721bea04cac89770d5fb1c395799ff7f68.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8811836242675781}",,,,,,,,,,['neutral'],neutral,1
NCT00638690,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1014618', 'title': 'Abiraterone and Increased Survival in Metastatic Prostate Cancer', 'source': 'The New England Journal of Medicine', 'date': 'May 26, 2011', 'snippet': 'We evaluated whether abiraterone acetate, an inhibitor of androgen \nbiosynthesis, prolongs overall survival among patients with metastatic \ncastration-resistant...', 'thumbnail': 'https://serpapi.com/searches/67230fef7ac731301bf68a26/images/e62f22b06b41aec62ec2fa667d4f844be9a79da7aea30666b8f69b58e43d0433.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8556347489356995}","{'position': 2, 'link': 'https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-021-01460-1', 'title': 'Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study', 'source': 'BMC Medical Research Methodology', 'date': 'Nov 27, 2021', 'snippet': 'Estimates of future survival can be a key evidence source when deciding if \na medical treatment should be funded. Current practice is to use...', 'thumbnail': 'https://serpapi.com/searches/67230fef7ac731301bf68a26/images/e62f22b06b41aec6aebd21ea9d931f5665aa72d3361ebdb1cb55622020c4ceaf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9093783497810364}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03872791,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-45160-y', 'title': 'The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial', 'source': 'Nature', 'date': 'Feb 3, 2024', 'snippet': 'This multicenter, phase II study (NCT03872791) aims to evaluate the \nefficacy and safety of the anti-PD-L1/CTLA-4 bispecific antibody KN046...', 'thumbnail': 'https://serpapi.com/searches/67230fffc117a9c5638bae4e/images/fcbb8c170d6b48ac111446ca888b23d265544ab465f232b66995bc49002de810.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8952354788780212}",,,,,,,,,,['neutral'],neutral,1
NCT01864746,"{'position': 1, 'link': 'https://www.onclive.com/view/adjuvant-cdk4-6-inhibitors-demonstrate-success-in-early-stage-hr-breast-cancer-development', 'title': 'Adjuvant CDK4/6 Inhibitors Demonstrate Success in Early-Stage HR+ Breast Cancer Development', 'source': 'OncLive', 'date': 'Mar 4, 2022', 'snippet': 'CDK4/6 inhibitors in the metastatic setting have demonstrated clinical \nbenefit in the hormone receptor–positive breast cancer population,...', 'thumbnail': 'https://serpapi.com/searches/67231031b57db86eba993299/images/952b1f0fe77e090fb7dc3e6a02a9ce5fec49ee96947b78db06223188747bd666.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7529317736625671}",,,,,,,,,,['neutral'],neutral,1
NCT00877903,"{'position': 1, 'link': 'https://www.science.org/doi/10.1126/sciadv.aba6884', 'title': 'Shattering barriers toward clinically meaningful MSC therapies', 'source': 'Science | AAAS', 'date': 'Jul 22, 2020', 'snippet': 'More than 1050 clinical trials are registered at FDA.gov that explore \nmultipotent mesenchymal stromal cells (MSCs) for nearly every clinical...', 'thumbnail': 'https://serpapi.com/searches/67231073a2e99c352b092c9e/images/644a2d1af410b196da7c0c738856a862203bffdae880c058808d6519d4569470.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7360979318618774}",,,,,,,,,,['neutral'],neutral,1
NCT01618136,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-0916-5', 'title': 'First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor', 'source': 'Nature', 'date': 'Jun 11, 2020', 'snippet': 'This phase 1 study examined the safety, maximum-tolerated dose (MTD) and \nantitumour activity of E7449, a novel PARP 1/2 and tankyrase 1/2 inhibitor.', 'thumbnail': 'https://serpapi.com/searches/672312190f2a2ca367b4e116/images/03866fb5a411893a900edd0616e742be4b9471ca93c250afb9415c937941c233.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8785817623138428}",,,,,,,,,,['neutral'],neutral,1
NCT02348216,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1707447', 'title': 'Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma', 'source': 'The New England Journal of Medicine', 'date': 'Dec 10, 2017', 'snippet': 'In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous \nanti-CD19 chimeric antigen receptor (CAR) T-cell therapy,...', 'thumbnail': 'https://serpapi.com/searches/672311311f3d4bf2c8b58811/images/5c5c798be4998f313d2c072297708a03d9a26e143ff3bdbedf8f07d199fe1054.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8957856297492981}","{'position': 2, 'link': 'https://www.onclive.com/view/real-world-use-of-car-t-cell-therapy-in-relapsed-refractory-dlbcl', 'title': 'Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL', 'source': 'OncLive', 'date': 'Jul 10, 2023', 'snippet': 'Following their discussion on axicabtagene ciloleucel and lisocabtagene \nmaraleucel, panelists reflect on the real-world use of CAR T-cell...', 'thumbnail': 'https://serpapi.com/searches/672311311f3d4bf2c8b58811/images/5c5c798be4998f312a30b63fada84062a2779560db49039a68f5776daf229866.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9351696968078613}","{'position': 3, 'link': 'https://lymphomanewstoday.com/2017/10/19/fda-approves-yescarta-first-car-t-cell-therapy-for-lymphoma/', 'title': 'FDA Approves Yescarta, First CAR T-cell Therapy for Lymphoma', 'source': 'Lymphoma News Today', 'date': 'Oct 19, 2017', 'snippet': ""The U.S. Food and Drug Administration (FDA) approved Kite Pharma's Yescarta \n(axicabtagene ciloleucel) for the treatment of relapsed or..."", 'thumbnail': 'https://serpapi.com/searches/672311311f3d4bf2c8b58811/images/5c5c798be4998f315fe41efdb8d55ef5f8de52a655cdac6e416b89f1c68cdb4e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6092697381973267}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02600130,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/lomecel-b-cell-therapy-shows-promising-effects-alzheimers-trial/', 'title': 'Cell therapy Lomecel-B shows promising effects in Phase 2a trial', 'source': ""Alzheimer's News Today"", 'date': 'Dec 22, 2023', 'snippet': ""Treatment with Lomecel-B in early Alzheimer's patients led to improvements \nin cognitive tests relative to a placebo in a clinical trial."", 'thumbnail': 'https://serpapi.com/searches/67231160fbde0d1890ff18c8/images/99c7cead1369a63589024d2f0f13d0bbbc4ab700aaaea3928869fce7b21c25de.png', 'sentiment': 'positive', 'sentiment_prob': 0.8894076943397522}","{'position': 2, 'link': 'https://alzheimersnewstoday.com/news/phase-2a-trial-initiated-lomecel-b-mild-alzheimers-disease/', 'title': 'Phase 2a Trial Initiated for Lomecel-B in Mild Alzheimer’s Disease', 'source': ""Alzheimer's News Today"", 'date': 'Jan 18, 2022', 'snippet': 'Longeveron is initiating a Phase 2a clinical trial for its Lomecel-B \ntreatment — an investigational, bone marrow-derived, medicinal signaling...', 'thumbnail': 'https://serpapi.com/searches/67231160fbde0d1890ff18c8/images/99c7cead1369a635799fec59348814510a5cd9561f0b8f5f2c685d2114375f26.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9124618768692017}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT00098397,"{'position': 1, 'link': 'https://www.nature.com/articles/s41388-024-03054-9', 'title': 'A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance | Oncogene', 'source': 'Nature', 'date': 'May 8, 2024', 'snippet': 'Epigenetic regulation established during development to maintain patterns \nof transcriptional expression and silencing for metabolism and...', 'thumbnail': 'https://serpapi.com/searches/6723122c0d379fd08d199c60/images/d644a99fbad5194303befde404f96b25501849cebdc720cddbcd972de6838bfa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9292553067207336}",,,,,,,,,,['neutral'],neutral,1
NCT05234554,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/reproxalap-ophthalmic-solution-reduces-ocular-itching-in-allergic-conjunctivitis-trial/', 'title': 'Reproxalap Ophthalmic Solution Reduces Ocular Itching in Allergic Conjunctivitis Trial - MPR', 'source': 'Medical Professionals Reference', 'date': 'Jun 15, 2023', 'snippet': 'Treatment with reproxalap 0.25% ophthalmic solution led to statistically \nsignificant improvements in patients with allergic conjunctivitis.', 'thumbnail': 'https://serpapi.com/searches/6723125aeda5f59f5496ee52/images/ef9cc0f53c89e8d42f23b4a81cf40a1d8463b4805473f8ccbc7659b212a88085.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.4931565225124359}",,,,,,,,,,['neutral'],neutral,1
NCT01283009,"{'position': 1, 'link': 'http://first10em.com/steroids-for-community-acquired-pneumonia-the-evidence/', 'title': 'Steroids for community acquired pneumonia – the evidence', 'source': 'First10EM', 'date': 'Jan 26, 2021', 'snippet': ""More people aren't prescribing steroids for pneumonia. They all conclude \nfairly strongly that there is a benefit – and not just any benefit, but a \nmortality..."", 'thumbnail': 'https://serpapi.com/searches/6723125dc7d4a15f9713c8a5/images/139b34aa36248f6036ee3e460b4cf6f07d4fcf20341940147810eddead930c12.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7739244103431702}",,,,,,,,,,['neutral'],neutral,1
NCT02491983,"{'position': 1, 'link': 'https://www.onclive.com/view/real-world-data-on-cdk4-6-inhibitors-in-hr-her2--metastatic-breast-cancer-and-ongoing-trials', 'title': 'Real-World Data on CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer and Ongoing Trials', 'source': 'OncLive', 'date': 'Jul 25, 2023', 'snippet': 'Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 \ninhibitors and share excitement about first-line trials that have...', 'thumbnail': 'https://serpapi.com/searches/6723126ef7adbf910b6c30cf/images/0c4251ef092f9c0870564422a1a09dc6bc104441fe8996102289dc17ba2f836e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8841817378997803}",,,,,,,,,,['neutral'],neutral,1
NCT01264432,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/INMD.20220013', 'title': 'Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatment', 'source': 'Wiley Online Library', 'date': 'Mar 30, 2023', 'snippet': 'In this paper, we discuss the mechanism of PARPis, the clinical application \nof PARPis as monotherapy and the possible induced resistance mechanism.', 'thumbnail': 'https://serpapi.com/searches/6723125e6aa364e94d0379e8/images/5b0f92e9d1fa75b7b53319cad1f366682c7ef19808f3585ba9b61cac7f0c47a2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8849785327911377}",,,,,,,,,,['neutral'],neutral,1
NCT03274219,"{'position': 1, 'link': 'https://www.nature.com/articles/s41417-024-00750-2', 'title': 'CAR T therapies in multiple myeloma: unleashing the future - Cancer Gene Therapy', 'source': 'Nature', 'date': 'Mar 4, 2024', 'snippet': 'A cutting-edge therapeutic approach called CAR T-cell therapy has emerged \nas a game-changer in treating multiple myeloma (MM).', 'thumbnail': 'https://serpapi.com/searches/6723128417a2e2f68afaccbd/images/336455461484566ca3e2ff7c9d2c36b71f9d36c4dd519ff87bf00b6a5cc0d016.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6385563015937805}",,,,,,,,,,['positive'],positive,1
NCT02608736,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-95845-3', 'title': 'Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid', 'source': 'Nature', 'date': 'Aug 12, 2021', 'snippet': 'Evaluate the biological action of valproic acid in the acetylation of \nhistones and in the methylation of tumor suppressor genes via oral...', 'thumbnail': 'https://serpapi.com/searches/6723132e7e1d1f17db41315a/images/ecd9a0258d419d98946f9311e6af9bea607208c24666004f309f5faa0449f7d9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8334558606147766}",,,,,,,,,,['neutral'],neutral,1
NCT03229538,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2212667', 'title': 'Methylprednisolone for Heart Surgery in Infants — A Randomized, Controlled Trial', 'source': 'The New England Journal of Medicine', 'date': 'Nov 6, 2022', 'snippet': 'Although perioperative prophylactic glucocorticoids have been used for \ndecades, whether they improve outcomes in infants after heart surgery...', 'thumbnail': 'https://serpapi.com/searches/67231351a5d7020ce116a2ae/images/be497bbfe45bff163b32ef2e1c82a771742f72e50482e0a482fcc5f290551ec0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8854561448097229}",,,,,,,,,,['neutral'],neutral,1
NCT00814307,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1109071', 'title': 'Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis', 'source': 'The New England Journal of Medicine', 'date': 'Aug 9, 2012', 'snippet': 'Tofacitinib (CP-690550) is a novel oral Janus kinase inhibitor that is \nbeing investigated as a targeted immunomodulator and...', 'thumbnail': 'https://serpapi.com/searches/6723140e15c74058c29680df/images/28932a8b1ce589bc58a5f56ba36f7bba9923c819ab0082680577d1a0804ccb6d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9134076237678528}",,,,,,,,,,['neutral'],neutral,1
NCT04583969,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/nih-study-aims-identify-promising-covid-19-treatments-larger-clinical-trials', 'title': 'NIH study aims to identify promising COVID-19 treatments for larger clinical trials', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Oct 13, 2020', 'snippet': 'The ACTIV-5 Big Effects Trial will enroll adult volunteers hospitalized \nwith COVID-19.', 'thumbnail': 'https://serpapi.com/searches/6723153dbcd6529d7b4e6bd3/images/4818b38eb8bc396c2ce82ac13f1bd46246fdc46172a680d8f15fb8fe54c42a25.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8178715705871582}",,,,,,,,,,['neutral'],neutral,1
NCT00056836,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa054481', 'title': 'Ranibizumab for Neovascular Age-Related Macular Degeneration', 'source': 'The New England Journal of Medicine', 'date': 'Oct 5, 2006', 'snippet': 'In this multicenter, 2-year, double-blind, sham-controlled study, we \nrandomly assigned patients with age-related macular degeneration with...', 'thumbnail': 'https://serpapi.com/searches/6723154231665067268ca7df/images/7c470b77e149eb0401105c398071a8e531f0e9115805b6704b9b6e9360a2e05c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9084883332252502}",,,,,,,,,,['neutral'],neutral,1
NCT03197870,"{'position': 1, 'link': 'https://www.genengnews.com/news/aerpio-shares-plummet-after-lead-candidate-fails-phase-iib-diabetic-retinopathy-trial/', 'title': 'Aerpio Shares Plummet after Lead Candidate Fails Phase IIb Diabetic Retinopathy Trial', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Mar 18, 2019', 'snippet': 'Aerpio Pharmaceuticals acknowledged the failure of its lead pipeline \ncandidate in a Phase IIb trial in patients with moderate to severe \nnon-proliferative...', 'thumbnail': 'https://serpapi.com/searches/67231591efad2193710cbb43/images/56bd0254e8675e02f56288cd1a42b1895406adac9fb3581226a231353e943a2f.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8294599652290344}",,,,,,,,,,['negative'],negative,0
NCT04650399,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00641-4/fulltext', 'title': 'Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial', 'source': 'The Lancet', 'date': 'Jun 12, 2023', 'snippet': 'VLA1553 is a live-attenuated vaccine candidate for active immunisation and \nprevention of disease caused by chikungunya virus.', 'thumbnail': 'https://serpapi.com/searches/672315a5fc183dcdb20b298a/images/6113295576c3de4a53804996e65732c6cf65baa8db80fa3d7fc5e669163375f1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7965168356895447}","{'position': 2, 'link': 'https://valneva.com/press-release/valneva-reports-positive-pivotal-phase-3-immunogenicity-data-in-adolescents-for-its-single-shot-chikungunya-vaccine-candidate/', 'title': 'Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate', 'source': 'Valneva', 'date': 'Nov 13, 2023', 'snippet': 'Valneva reported positive pivotal immunogenicity data for its single-dose \nchikungunya virus (CHIKV) vaccine candidate VLA1553.', 'thumbnail': 'https://serpapi.com/searches/672315a5fc183dcdb20b298a/images/6113295576c3de4a1c53f3c89096ac155c4c11720378c471a241c42765e798c7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7725892066955566}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01431274,"{'position': 1, 'link': 'https://www.dovepress.com/long-term-safety-of-tiotropiumolodaterol-respimatreg-in-patients-with--peer-reviewed-fulltext-article-COPD', 'title': 'Long-term safety of tiotropium/olodaterol RespimatReg in patients with | COPD', 'source': 'Dove Medical Press', 'date': 'Jun 1, 2018', 'snippet': 'Craig LaForce,1 Eric Derom,2 Ulrich Bothner,3 Isabel M Kloer,3 Matthias \nTrampisch,4 Roland Buhl5 1NC Clinical Research, Raleigh, NC, USA;...', 'thumbnail': 'https://serpapi.com/searches/672315d69e38e5ea8105a588/images/a249ff51401fc0fa03beca6af39ad41a30c8e2481f7f81a3117eeb3309145fbb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8798441886901855}",,,,,,,,,,['neutral'],neutral,1
NCT01888874,"{'position': 1, 'link': 'https://rheumatoidarthritisnews.com/2017/06/07/ra-patients-improve-with-filgotinib-methotrexate-combination-study-suggests/', 'title': 'Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests', 'source': 'Rheumatoid Arthritis News', 'date': 'Jun 7, 2017', 'snippet': 'Active RA patients whose response to methotrexate (MTX) therapy was \ninsufficient showed improvement when MTX was combined with filgotinib,...', 'thumbnail': 'https://serpapi.com/searches/672314700053c7013aadc7c2/images/b9bc293e52453c29260cafdf4cf6362e9520a2f49ffd187f60f6dfe8609fb82d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5993414521217346}",,,,,,,,,,['neutral'],neutral,1
NCT05653856,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/early/2024/07/18/jnumed.123.267126', 'title': '61Cu-PSMA–Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging', 'source': 'Journal of Nuclear Medicine', 'date': 'Jul 18, 2024', 'snippet': 'Tais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, Sandra Zanger, \nRaghuvir H. Gaonkar, Lisa McDougall, Francesco De Rose,...', 'thumbnail': 'https://serpapi.com/searches/67231484a882788f7cddb568/images/4819b152a82617bd4603750e4f7bc9e3d36006d0d9b3b364500f79f10c68c60f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.94233238697052}",,,,,,,,,,['neutral'],neutral,1
NCT00061594,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa062655', 'title': 'Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration', 'source': 'The New England Journal of Medicine', 'date': 'Oct 5, 2006', 'snippet': 'During the first year of this 2-year, multicenter, double-blind study, we \nrandomly assigned patients in a 1:1:1 ratio to receive monthly...', 'thumbnail': 'https://serpapi.com/searches/6723148cfcd69e8306c91d72/images/4f036387153424e38222d88909aa7b37d61d40032655d40a4d631bd07c8c74f1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9034882187843323}",,,,,,,,,,['neutral'],neutral,1
NCT03197766,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1813446', 'title': 'C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia', 'source': 'The New England Journal of Medicine', 'date': 'Jun 18, 2019', 'snippet': 'Achondroplasia is a genetic disorder that inhibits endochondral \nossification, resulting in disproportionate short stature and clinically \nsignificant medical...', 'thumbnail': 'https://serpapi.com/searches/67231494240793cd7e65ac7c/images/7cef2d09141bee2ddac030061e3b17dcfab4a4b074e0be001499a2fb4d1d653c.png', 'sentiment': 'negative', 'sentiment_prob': 0.5959500074386597}","{'position': 2, 'link': 'https://www.empr.com/home/news/voxzogo-gets-fda-approval-for-achondroplasia/', 'title': 'Voxzogo Gets FDA Approval for Achondroplasia', 'source': 'Medical Professionals Reference', 'date': 'Nov 19, 2021', 'snippet': 'The Food and Drug Administration (FDA) has granted accelerated approval to \nVoxzogo (vosoritide) injection, a C-type natriuretic peptide...', 'thumbnail': 'https://serpapi.com/searches/67231494240793cd7e65ac7c/images/7cef2d09141bee2dc69d21a265e28fbc1547a7ccd87c1c38d76109c7e4326903.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5544262528419495}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT01546038,"{'position': 1, 'link': 'https://www.researchgate.net/figure/History-of-AML-therapies-Timeline-of-approved-clinical-therapies-in-the-United-States_fig1_347673267', 'title': 'Fig. 1 History of AML therapies. Timeline of approved clinical...', 'source': 'ResearchGate', 'date': 'May 8, 2022', 'snippet': 'For many years, treatment options for AML remained stagnant, with the \nstandard 7+3 regimen of cytarabine and daunorubicin and SCT being the only \noption for...', 'thumbnail': 'https://serpapi.com/searches/672314a339e232ed6dec4a01/images/660d615952f0ae6e30fea235a5b11ce2d8ea2ca9b0b49e9348d63b501934f972.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5696207880973816}",,,,,,,,,,['neutral'],neutral,1
NCT03227471,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/cf-patients-with-mental-health-issues-benefit-from-lower-kaftrio-dose/', 'title': 'CF patients with mental health issues benefit from lower Kaftrio dose', 'source': 'Cystic Fibrosis News Today', 'date': 'May 23, 2023', 'snippet': 'Reducing the dose of Kaftrio should be weighed for cystic fibrosis patients \nwho report cognitive, psychological side effects, a study shows.', 'thumbnail': 'https://serpapi.com/searches/6723150da86921c0f30c3eef/images/f4ea918baf9eaf66805897d83375f031b7c9fb41ff12fb591295ce6c820408f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8073989152908325}",,,,,,,,,,['neutral'],neutral,1
NCT03334253,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/low-dose-atropine-eyedrops-no-better-placebo-slowing-myopia-progression', 'title': 'Low-dose atropine eyedrops no better than placebo for slowing myopia progression', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jul 13, 2023', 'snippet': 'NIH-funded trial underscores need for more research to head off high myopia.', 'thumbnail': 'https://serpapi.com/searches/6723151e90adce4a729ebdc4/images/55393f3c33d9778d6374840caab50e80e81faeed09145d6573e05a855759117e.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7677732110023499}",,,,,,,,,,['negative'],negative,0
NCT02689505,"{'position': 1, 'link': 'https://www.researchgate.net/publication/384902278_Comprehensive_biomarker_and_modeling_approach_to_support_dose_finding_for_BI_836880_a_VEGFAng-2_inhibitor', 'title': '(PDF) Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor', 'source': 'ResearchGate', 'date': '2 weeks ago', 'snippet': 'PDF | Background BI 836880 is a humanized bispecific nanobody® that binds \nto and blocks vascular endothelial growth factor (VEGF) and...', 'thumbnail': 'https://serpapi.com/searches/672315f0ef60cb338d94cfa3/images/f0c3129b72328330b7ab9173415a7c2b7ade4761ff722565670be82d7df8e434.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.89641934633255}",,,,,,,,,,['neutral'],neutral,1
NCT02297698,"{'position': 1, 'link': 'https://www.thepharmaletter.com/pharmaceutical/galena-tanks-as-it-pulls-the-plug-on-neuvax-trial', 'title': 'Galena tanks as it pulls the plug on NeuVax trial', 'source': 'The Pharma Letter', 'date': 'Jun 29, 2016', 'snippet': 'More on this story... Midatech to acquire Zuplenz from Galena Biopharma. \nPharmaceutical · Midatech to acquire Zuplenz from Galena Biopharma.', 'thumbnail': 'https://serpapi.com/searches/672315f5708e2e045142103a/images/7f1cc5c8e7ea88972ff88e21f1ba3a40ff62b0d89ee219190b1051d270bcb3bc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7706093788146973}",,,,,,,,,,['neutral'],neutral,1
NCT00932893,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1214886', 'title': 'Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jun 1, 2013', 'snippet': 'In single-group studies, chromosomal rearrangements of the anaplastic \nlymphoma kinase gene (ALK) have been associated with marked clinical...', 'thumbnail': 'https://serpapi.com/searches/6723160ef410449024f45a2d/images/eec97444a11dc39a5912a3bb5fb453fd4d1e433f0273d7ae2b8297e1ef3b39af.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8160057067871094}",,,,,,,,,,['neutral'],neutral,1
NCT04251910,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/on-demand-bxcl501-seen-ease-alzheimers-agitation-phase-3-trial/', 'title': ""BXCL501 seen to ease Alzheimer's agitation in Phase 3 trial |..."", 'source': ""Alzheimer's News Today"", 'date': 'Jun 30, 2023', 'snippet': ""On-demand treatment with BXCL501 was found to significantly ease episodes \nof agitation for Alzheimer's patients in a Phase 3 clinical trial."", 'thumbnail': 'https://serpapi.com/searches/6723162f8b84c41a795d67cc/images/c295280e81d96bb5493dbed8aace6554cc10699dc18328a2772604ef505ea3e3.png', 'sentiment': 'positive', 'sentiment_prob': 0.5488898754119873}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/dexmedetomidine-acute-treatment-agitation-associated-dementia-breakthrough-therapy/', 'title': 'Dexmedetomidine Oral Film Gets Breakthrough Tx Status for Acute Agitation With Dementia', 'source': 'Medical Professionals Reference', 'date': 'Mar 15, 2021', 'snippet': 'The Food and Drug Administration (FDA) has granted Breakthrough Therapy \ndesignation to BXCL501 (dexmedetomidine; BioXcel Therapeutics) for the \nacute treatment...', 'thumbnail': 'https://serpapi.com/searches/6723162f8b84c41a795d67cc/images/c295280e81d96bb5c77381c2d26048301c199273a9ccd40606e122eda4bce2c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6966283321380615}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT00073528,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-82318-w', 'title': 'Clinical data mining reveals analgesic effects of lapatinib in cancer patients', 'source': 'Nature', 'date': 'Feb 11, 2021', 'snippet': 'Microsomal prostaglandin E2 synthase 1 (mPGES-1) is recognized as a \npromising target for a next generation of anti-inflammatory drugs that...', 'thumbnail': 'https://serpapi.com/searches/67231666e45f334e584f169f/images/329c59e4f9a83aac9a8098d882055cba10e04bf54c32ccc9c45813d4203d580a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7619749307632446}",,,,,,,,,,['neutral'],neutral,1
NCT04818346,"{'position': 1, 'link': 'https://www.dermatologytimes.com/view/incyte-announces-positive-52-week-data-at-eadv-of-povorcitinib-for-extensive-nonsegmental-vitiligo', 'title': 'Incyte Announces Positive 52-Week Data at EADV of Povorcitinib for Extensive Nonsegmental Vitiligo', 'source': 'Dermatology Times', 'date': 'Oct 12, 2023', 'snippet': 'Incyte recently announced positive 52-week data from a phase 2b clinical \ntrial evaluating the safety and efficacy of povorcitinib...', 'thumbnail': 'https://serpapi.com/searches/6723167efab273ad2fda63f6/images/81c6d658ee10ac2d0278079b1991ac8816070e82a44c91e999eadd3ba734167b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5580693483352661}",,,,,,,,,,['neutral'],neutral,1
NCT02194426,"{'position': 1, 'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.20.00596', 'title': 'First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors', 'source': 'ASCO Publications', 'date': 'Dec 10, 2020', 'snippet': 'PURPOSEA first-in-human study was performed with MP0250, a DARPin drug \ncandidate. MP0250 specifically inhibits both vascular endothelial...', 'thumbnail': 'https://serpapi.com/searches/67231693adc33b93e06ec020/images/d6211da28c0599f457348fb35db6819e8a058ca5b1c18f7103a1a3c659182c9a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9029291272163391}",,,,,,,,,,['neutral'],neutral,1
NCT01740297,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-019-0530-6', 'title': 'Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma', 'source': 'Nature', 'date': 'Jul 29, 2019', 'snippet': 'We explored response patterns from a phase 2 study evaluating patients with \nunresectable stage IIIB–IVM1c malignant melanoma who received T-VEC plus \nipilimumab...', 'thumbnail': 'https://serpapi.com/searches/672316b417a2e2f68afad022/images/cd16ace245bb2725dcf98aa2ee405ecffae20c0a7ba9deb44abde437789b6b46.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8980348110198975}",,,,,,,,,,['neutral'],neutral,1
NCT03790709,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/early-alzheimers-anavex-2-73-slows-cognitive-decline-neurodegeneration/', 'title': 'Neurodegeneration and cognitive decline slow with Anavex 2-73', 'source': ""Alzheimer's News Today"", 'date': 'Sep 15, 2023', 'snippet': ""Anavex is preparing meetings with regulatory authorities in the U.S., \nEurope, and Asia-Pacific to discuss Anavex 2-73's potential approval."", 'thumbnail': 'https://serpapi.com/searches/672316cec1c8dda1bab16cdc/images/34c457f18dbd072b960828fbcb3969bfe059e915d33280daac80544d148d7b4e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8807852864265442}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/news/anavex-seek-ema-approval-shaky-results/', 'title': 'Anavex seek EMA approval despite shaky pivotal Alzheimer’s trial data', 'source': 'Clinical Trials Arena', 'date': 'Jul 29, 2024', 'snippet': ""The clinical benefit of blarcamesine was observed, but only one co-primary \nendpoint was met in the Alzheimer's disease trial."", 'thumbnail': 'https://serpapi.com/searches/672316cec1c8dda1bab16cdc/images/34c457f18dbd072b617b29db84858078c3bf7380cd2facc712310b8cf02a2d5a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7897889018058777}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00036439,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa050516', 'title': 'Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis', 'source': 'The New England Journal of Medicine', 'date': 'Jul 31, 2017', 'snippet': 'Two randomized, double-blind, placebo-controlled studies — the Active \nUlcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2, respectively) — \nevaluated the...', 'thumbnail': 'https://serpapi.com/searches/672317119fd309c82152a443/images/bef9416cf6c79ba8e4d7c785d3e37b27077a65ba2906498f36f6b8a0ce4f2276.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9349810481071472}",,,,,,,,,,['neutral'],neutral,1
NCT02393859,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-022-01770-3', 'title': 'Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL', 'source': 'Nature', 'date': 'Dec 8, 2022', 'snippet': 'For children with high-risk, first-relapse B-cell precursor acute \nlymphoblastic leukemia (B-ALL), allogeneic hematopoietic stem cell...', 'thumbnail': 'https://serpapi.com/searches/67231721b57db86eba9938dd/images/ece58ee0ffee17fc39048ef747486e5773a78fcfeb6726cb1c9df66ac83582f4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7785382270812988}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/fda-gives-full-approval-to-blinatumomab-in-mrd-positive-b-cell-all', 'title': 'FDA Gives Full Approval to Blinatumomab in MRD-Positive B-Cell ALL', 'source': 'Cancer Network', 'date': 'Jun 21, 2023', 'snippet': 'Blinatumomab has been granted full approval by the FDA for patients with \nB-cell acute lymphoblastic leukemia and minimal residual disease of...', 'thumbnail': 'https://serpapi.com/searches/67231721b57db86eba9938dd/images/ece58ee0ffee17fc3eac902eb48d85f19c40023b4b853a06bf451c3ab02c8fad.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5017969608306885}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05157841,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/exparel-application-under-review-for-sciatic-and-femoral-nerve-blocks/', 'title': 'Exparel Application Under Review for Sciatic and Femoral Nerve Blocks', 'source': 'Medical Professionals Reference', 'date': 'Mar 31, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted the supplemental New \nDrug Application (sNDA) for Exparel (bupivacaine liposome injectable \nsuspension)', 'thumbnail': 'https://serpapi.com/searches/672317ca4a4a1d0f98dca306/images/88dd6ec26fed4b4810325a44803bcc3f0055cf1443bfa80a8fcd002c7e896ccc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9170256853103638}",,,,,,,,,,['neutral'],neutral,1
NCT02113878,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-020-73249-z', 'title': 'The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells', 'source': 'Nature', 'date': 'Oct 1, 2020', 'snippet': 'Radiotherapy has a central role in the treatment of head and neck squamous \ncell carcinoma (HNSCC). Activation of the PI3K/AKT/mTOR pathway...', 'thumbnail': 'https://serpapi.com/searches/672317e3dc969f1f1120c1ce/images/c655d8d5408e77858add1448600543efe0ce2c52cbb173b8803e742d9b19917b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9116150736808777}",,,,,,,,,,['neutral'],neutral,1
NCT04424316,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2216480', 'title': 'Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants', 'source': 'The New England Journal of Medicine', 'date': 'Apr 5, 2023', 'snippet': 'Whether vaccination during pregnancy could reduce the burden of respiratory \nsyncytial virus (RSV)–associated lower respiratory tract illness...', 'thumbnail': 'https://serpapi.com/searches/6723173ebe801338c03decbe/images/9b6859b670eba33842bf0f8ec0027468cc82d72c709fe28f630d4c8c9a2faaf2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8381577730178833}","{'position': 2, 'link': 'https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2022/story/a-step-closer-in-the-fight-against-respiratory-syncytial-virus/', 'title': 'Pfizer progresses novel vaccine candidate for respiratory syncytial virus (RSV) called PF-06928316 or RSVpreF', 'source': 'Pfizer', 'date': 'Jan 3, 2024', 'snippet': 'Respiratory syncytial virus (RSV) is a contagious, common and pervasive \ncause of acute respiratory illness among older adults and young children.1 \nIn the...', 'thumbnail': 'https://serpapi.com/searches/6723173ebe801338c03decbe/images/9b6859b670eba3380ec014eae04f2921b17cde9e5088c27202189b6ee0132cf4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7410576343536377}","{'position': 3, 'link': 'https://www.businesswire.com/news/home/20230821069057/en/U.S.-FDA-Approves-ABRYSVO%E2%84%A2-Pfizer%E2%80%99s-Vaccine-for-the-Prevention-of-Respiratory-Syncytial-Virus-RSV-in-Infants-Through-Active-Immunization-of-Pregnant-Individuals-32-36-Weeks-of-Gestational-Age', 'title': 'U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age', 'source': 'Business Wire', 'date': 'Aug 21, 2023', 'snippet': ""... FDA's decision is based on data from the pivotal Phase 3 clinical trial \nin more than 7,000 pregnant individuals, and including their..."", 'thumbnail': 'https://serpapi.com/searches/6723173ebe801338c03decbe/images/9b6859b670eba33814fef5c682b56e89ad4301574a1d8c2084fdc72bfe2ad1b2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8601066470146179}","{'position': 4, 'link': 'https://www.drugtopics.com/view/fda-approves-abrysvo-for-adults-18-59-at-increased-risk-for-rsv', 'title': 'FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV', 'source': 'Drug Topics', 'date': '1 week ago', 'snippet': ""Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has been \napproved by the FDA for the prevention RSV-associated of lower..."", 'thumbnail': 'https://serpapi.com/searches/6723173ebe801338c03decbe/images/9b6859b670eba33824c7cb5dcdc24926c6857287e7b78fef5b06b3b0a901a9ad.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.857796311378479}","{'position': 5, 'link': 'https://www.prnewswire.com/apac/news-releases/pfizer-receives-authorization-from-health-authority-for-the-first-dual-indication-vaccine-approved-in-hong-kong-302139477.html', 'title': 'Pfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong', 'source': 'PR Newswire', 'date': 'May 8, 2024', 'snippet': 'A Vaccine to Fight Against Respiratory Syncytial Virus (RSV) in Older \nAdults Aged 60 and Above and Infants (Through Maternal Immunization)...', 'thumbnail': 'https://serpapi.com/searches/6723173ebe801338c03decbe/images/9b6859b670eba3382b442383cb6dc915935948b41b233eedd40494325ed6f5d7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8212655782699585}","{'position': 6, 'link': 'https://www.expresspharma.in/us-fda-approves-abrysvo-pfizers-maternal-rsv-vaccine-for-infants/', 'title': 'US FDA approves ABRYSVO, Pfizer’s maternal RSV vaccine for infants', 'source': 'Express Pharma', 'date': 'Aug 22, 2023', 'snippet': ""The US Food and Drug Administration (FDA) has approved ABRYSVO (Respiratory \nSyncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) \nvaccine."", 'thumbnail': 'https://serpapi.com/searches/6723173ebe801338c03decbe/images/9b6859b670eba338d4fff9f08256f1f187c4fcf860c5f017c642e8b20e97b358.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7450793981552124}","{'position': 7, 'link': 'https://www.drugtopics.com/view/acip-votes-to-lower-recommended-age-of-pneumococcal-vaccination', 'title': 'ACIP Votes to Lower Recommended Age of Pneumococcal Vaccination', 'source': 'Drug Topics', 'date': '6 days ago', 'snippet': 'The CDC Advisory Committee on Immunization Practices (ACIP) has voted to \nlower recommended age for pneumococcal vaccination from 65 years to...', 'thumbnail': 'https://serpapi.com/searches/6723173ebe801338c03decbe/images/9b6859b670eba338ca1c6af95a4935cf63052fc5410728082fe8294897caedef.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9366915822029114}","{'position': 8, 'link': 'https://www.drugtopics.com/view/novel-antifungal-treatment-approved-for-vaginal-candidiasis', 'title': 'Novel Antifungal Treatment Approved for Vaginal Candidiasis', 'source': 'Drug Topics', 'date': 'Jul 14, 2021', 'snippet': 'On June 2,2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by \nthe FDA for vulvovaginal candidiasis (VVC) in adult women and...', 'thumbnail': 'https://serpapi.com/searches/6723173ebe801338c03decbe/images/9b6859b670eba338c824db9a21cf1ca51229aee54c44fd02cdfc71e1ead19636.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8588642477989197}",,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03574753,"{'position': 1, 'link': 'https://fnih.org/our-programs/master-protocol-for-treatment-of-non-small-cell-lung-cancer-lung-map/', 'title': 'Master Protocol For Treatment Of Non-Small Cell Lung Cancer (Lung-MAP)', 'source': 'FNIH', 'date': 'Jun 1, 2023', 'snippet': 'A groundbreaking multi-center clinical trial that uses a multi-sub-study, \ntargeted screening approach to match patients, based on their unique tumor \nprofiles.', 'thumbnail': 'https://serpapi.com/searches/67231742fbde0d1847a3d935/images/121c36c7a9821398e4c73eb25cdef15aa6fbbe3bbe12b33ffa43f7200897e61b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.732329785823822}",,,,,,,,,,['neutral'],neutral,1
NCT03037385,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01931-y', 'title': 'Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial', 'source': 'Nature', 'date': 'Aug 12, 2022', 'snippet': 'Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, \nselective inhibitor of RET receptor tyrosine kinase.', 'thumbnail': 'https://serpapi.com/searches/67231748e281ee0144eab124/images/fb1bb0e98a09b2b6e81f334d0c00739c67f45a175666566bded6fbdf896e899a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7561172842979431}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/fda-grants-regular-approval-to-pralsetinib-in-advanced-nsclc', 'title': 'FDA Grants Regular Approval to Pralsetinib in Advanced NSCLC', 'source': 'Cancer Network', 'date': 'Aug 9, 2023', 'snippet': 'Patients with metastatic RET fusion-positive non–small cell lung cancer may \nnow be treated with pralsetinib, which has been granted regular...', 'thumbnail': 'https://serpapi.com/searches/67231748e281ee0144eab124/images/fb1bb0e98a09b2b6e093249c1159a5d67835c2e837b8d21e55d3a09d2870d0d4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8916344046592712}","{'position': 3, 'link': 'https://ascopost.com/news/august-2023/fda-approves-pralsetinib-for-ret-fusion-positive-nsclc/', 'title': 'FDA Approves Pralsetinib for RET Fusion–Positive NSCLC', 'source': 'The ASCO Post', 'date': 'Aug 11, 2023', 'snippet': 'The US Food and Drug Administration (FDA) granted regular approval to \npralsetinib (Gavreto) for adults with metastatic RET fusion–positive \nnon–small cell lung...', 'thumbnail': 'https://serpapi.com/searches/67231748e281ee0144eab124/images/fb1bb0e98a09b2b6cc886e47f66bd3c9f7ddbb2cb0c770ecf24d19d3b4b0b1df.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6970062851905823}","{'position': 4, 'link': 'https://www.nature.com/articles/s41467-022-30908-1', 'title': 'Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer', 'source': 'Nature', 'date': 'Jun 17, 2022', 'snippet': 'The study provides evidence in favour of pralsetinib as a first-line \ntreatment for RET fusion-positive aNSCLC.', 'thumbnail': 'https://serpapi.com/searches/67231748e281ee0144eab124/images/fb1bb0e98a09b2b6cea64d94d84dded52d62c871987761d441e1e5b3df2e152e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7061426043510437}","{'position': 5, 'link': 'https://www.empr.com/home/news/gavreto-granted-full-approval-for-ret-fusion-positive-nsclc/', 'title': 'Gavreto Granted Full Approval for RET Fusion-Positive NSCLC - MPR', 'source': 'Medical Professionals Reference', 'date': 'Aug 10, 2023', 'snippet': 'The Food and Drug Administration (FDA) has granted full approval to Gavreto \n(pralsetinib) for the treatment of adult patients with metastatic \nrearranged during...', 'thumbnail': 'https://serpapi.com/searches/67231748e281ee0144eab124/images/fb1bb0e98a09b2b639a62cf25c86c605e9bd2b711d08836c74c41e40a89b61af.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7846548557281494}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01458717,"{'position': 1, 'link': 'https://dailynews.ascopubs.org/do/contemporary-approaches-resectable-pancreatic-ductal-adenocarcinoma-reflexive-nuanced', 'title': 'Contemporary Approaches to Resectable Pancreatic Ductal Adenocarcinoma: Reflexive or Nuanced Utilization of Neoadjuvant Approaches?', 'source': 'ASCO Daily News', 'date': 'Apr 19, 2023', 'snippet': 'some groups advocate that an alternative approach—namely neoadjuvant \ntherapy (NAT) in all cases—is necessary to improve survival...', 'thumbnail': 'https://serpapi.com/searches/67231768b691a72d639a18dd/images/59818896186cfc06d5722712fb2052ee5aaa83765a42a3fcc9a879774af73ef0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.895675778388977}",,,,,,,,,,['neutral'],neutral,1
NCT02469155,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/lumateperone-treatment-schizophrenia-number-needed-treat-number-needed-harm-likelihood-helped-harmed/', 'title': 'Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed', 'source': 'Psychiatrist.com', 'date': 'Mar 6, 2023', 'snippet': 'The benefit-risk assessment of lumateperone was favorable as measured by \nnumber-needed-to-treat and number-needed-to-harm analyses.', 'thumbnail': 'https://serpapi.com/searches/6723177d4791c4eca64d6bf9/images/ba747c52340847cf39dcb2ae1c4cb0a88e45b5c55bc3263cd473f17bbf02f0ac.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7699416875839233}",,,,,,,,,,['neutral'],neutral,1
NCT03930615,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-extended-prevymis-regimen-for-hsct-patients-at-risk-for-late-cmv/', 'title': 'FDA Approves Extended Prevymis Regimen for HSCT Patients at Risk for Late CMV', 'source': 'Medical Professionals Reference', 'date': 'Aug 9, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved the extended use of \nPrevymis (letermovir) from 100 to 200 days post-transplant for the \nprophylaxis of...', 'thumbnail': 'https://serpapi.com/searches/67231791069e577c4598c840/images/2c1198f8289b359d6c034c51e4c2b12ce46a6d31b4652586e6dea464043e0a23.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8427796363830566}",,,,,,,,,,['neutral'],neutral,1
NCT04091360,"{'position': 1, 'link': 'https://copdnewstoday.com/news/copd-treatment-pmdi-ensifentrine-improves-lung-function/', 'title': 'Treatment With pMDI Ensifentrine Found to Improve Lung Function', 'source': 'COPD News Today', 'date': 'Oct 18, 2021', 'snippet': 'Seven days of treatment with ensifentrine, given using a pressurized \nmetered-dose inhaler — called a pMDI — resulted in marked lung function...', 'thumbnail': 'https://serpapi.com/searches/6723179e75f974affaee9f77/images/ca1c9466ae750b2b6695eaab3a0bb8b67e9fb8f4dace76fd9f17daf25afd23e9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5474724769592285}","{'position': 2, 'link': 'https://copdnewstoday.com/news/ensifentrine-pressurized-dose-inhaler-formulation-showing-efficacy-copd-phase-2-trial/', 'title': 'Ensifentrine, in Pressurized Dose Inhaler, Showing Efficacy in...', 'source': 'COPD News Today', 'date': 'Apr 2, 2020', 'snippet': 'A single dose of a pressurized metered-dose inhaler formulation of \nensifentrine (RPL544) significantly improved lung function, compared to a \nplacebo.', 'thumbnail': 'https://serpapi.com/searches/6723179e75f974affaee9f77/images/ca1c9466ae750b2b1c5439af1098a76fa57d11662419a118834ca89384c3b040.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6491924524307251}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT01671150,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-022-16364-3', 'title': 'Interleukin-8 and depressive responses to an inflammatory challenge: secondary analysis of a randomized controlled trial', 'source': 'Nature', 'date': 'Jul 24, 2022', 'snippet': 'Emerging evidence suggests that interleukin (IL)-8 has a protective role in \nthe context of depression. Higher levels of IL-8 are associated...', 'thumbnail': 'https://serpapi.com/searches/6723179f690bb9df0c333405/images/65cbd8586e76e1bd3b07c0b387ecd9645f3d50571da01df9a98afefd8ed61841.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8534020781517029}",,,,,,,,,,['neutral'],neutral,1
NCT03077659,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.647110/full', 'title': 'Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020', 'source': 'Frontiers', 'date': 'Jun 30, 2023', 'snippet': 'The overall aging of the world population has contributed to the continuous \nupward trend in the incidence of prostate cancer (PC). Trials on PC therapy \nhave...', 'thumbnail': 'https://serpapi.com/searches/6723182f069e577bfa33228a/images/281f09b16baef784e2d86f9512abbda05595e22e0c59c0848f98eac1b57aa5dd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5001696944236755}",,,,,,,,,,['neutral'],neutral,1
NCT02065063,"{'position': 1, 'link': 'https://www.oncologynurseadvisor.com/news/triple-therapy-shows-promise-in-treatment-resistant-subtype-of-lung-cancer/', 'title': 'Triple Therapy Shows Promise in Treatment Resistant Subtype of Lung Cancer', 'source': 'Oncology Nurse Advisor', 'date': 'Jan 13, 2016', 'snippet': 'Lung cancers with KRAS-related gene mutations might benefit from a triple \ntherapy regimen of 2 experimental drugs plus radiation therapy.', 'thumbnail': 'https://serpapi.com/searches/6723183bb57db86f007ad600/images/9d35e773e2bb165c45b7123a4b4b9440899a05ea3c6336054e82de3654b6ce7b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7427494525909424}",,,,,,,,,,['neutral'],neutral,1
NCT01843530,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2016/3930923', 'title': 'The Use of Plasma-Derived Complement C1-Esterase Inhibitor Concentrate (Berinert®) in the Treatment of Angiotensin Converting Enzyme-Inhibitor Related Angioedema', 'source': 'Wiley Online Library', 'date': 'Mar 31, 2016', 'snippet': 'We here present a case of severe angiotensin converting enzyme-inhibitor \nrelated angioedema (ACEi-AE) of the hypopharynx that completely resolved \nrapidly.', 'thumbnail': 'https://serpapi.com/searches/672319c8fab273ad73e14751/images/a13d72b24521c7e4cb064242724976190bf4f35462d80f9f54ead4854233b06a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8316097259521484}",,,,,,,,,,['neutral'],neutral,1
NCT02464605,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-27945-7', 'title': 'Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia', 'source': 'Nature', 'date': 'Jan 12, 2022', 'snippet': 'Biologic drugs have transformed the standard of care for many diseases. \nHowever, many biologics induce the formation of anti-drug antibodies...', 'thumbnail': 'https://serpapi.com/searches/6723193af3cbfaa09d7b197e/images/10e3587584f58a51cbb1bbde8ec7fd7e5c78eeb8ecf6cc2d1647127b0fb0eb61.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6858675479888916}",,,,,,,,,,['neutral'],neutral,1
NCT03606876,"{'position': 1, 'link': 'https://www.empr.com/home/news/generics-news/tofidence-tocilizumab-biosimilar-approved/', 'title': 'FDA Approves Tofidence, the First Biosimilar to Tocilizumab', 'source': 'Medical Professionals Reference', 'date': 'Oct 2, 2023', 'snippet': 'The Food and Drug Administration has approved Tofidence (tocilizumab-bavi), \nthe first biosimilar to Actemra (tocilizumab).', 'thumbnail': 'https://serpapi.com/searches/6723196aee46823ed9be12f4/images/4f18fc2711f2f81974f0c8ab8f151a948abe256ccf53bb329235828e86fd49c4.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5141994953155518}",,,,,,,,,,['positive'],positive,1
NCT01927159,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-36789-2', 'title': 'Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults', 'source': 'Nature', 'date': 'Mar 6, 2023', 'snippet': 'Adjuvant-containing subunit vaccines represent a promising approach for \nprotection against tuberculosis (TB), but current candidates require...', 'thumbnail': 'https://serpapi.com/searches/67231969c024d12a48a69cfb/images/538f5d41bdc9dc75ebef0558fe7f0583a14cf65433fccd2a1c99429a63fc1187.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6567094326019287}",,,,,,,,,,['neutral'],neutral,1
NCT02728752,"{'position': 1, 'link': 'https://www.specialtypharmacycontinuum.com/FDA-News/Article/07-21/FDA-Grants-New-Indication-for-Octagam-10-for-Adult-Dermatomyositis/64132', 'title': 'FDA Grants New Indication for Octagam 10% for Adult Dermatomyositis', 'source': 'Specialty Pharmacy Continuum', 'date': 'Apr 25, 2024', 'snippet': 'The FDA granted a new indication to Immune Globulin Intravenous (Human) \n(Octagam 10%, Octapharma USA), for the treatment of adult dermatomyositis.', 'thumbnail': 'https://serpapi.com/searches/672319740be2f63ada2a4ea3/images/7bdf924c9fe6c8f23bc6cc837d109b0da74e4be0d27f256de0853529d5f3de25.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7153904438018799}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20210720005999/en/FDA-Approves-Octapharma%E2%80%99s-Octagam%C2%AE-10-for-Adult-Dermatomyositis', 'title': 'FDA Approves Octapharma’s Octagam® 10% for Adult Dermatomyositis', 'source': 'Business Wire', 'date': 'Jul 20, 2021', 'snippet': 'PARAMUS, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) \nhas granted approval to Octapharma USA for Octagam® 10% [Immune...', 'thumbnail': 'https://serpapi.com/searches/672319740be2f63ada2a4ea3/images/7bdf924c9fe6c8f2067d0cd4de90c29c7bd7c55cf0572dea6af81fe0511a2c7b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8596963286399841}","{'position': 3, 'link': 'https://www.businesswire.com/news/home/20210830005059/en/FDA-Orphan-Drug-Approval-Octapharma%E2%80%99s-Octagam%C2%AE-10-Receives-7-Years-of-Market-Exclusivity-for-Adult-Dermatomyositis', 'title': '10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis', 'source': 'Business Wire', 'date': 'Aug 30, 2021', 'snippet': 'Octapharma USA announced the FDA has awarded seven years of marketing \nexclusivity for Octagam® 10%, the only IVIg indicated for adult...', 'thumbnail': 'https://serpapi.com/searches/672319740be2f63ada2a4ea3/images/7bdf924c9fe6c8f24b4d3806d6f990e1422e8624d1738a95b512712b4426f217.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.564315915107727}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04120116,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1002/pat.6193?af=R', 'title': 'Advances in injectable hydrogel: Design, functional regulation, and biomedical applications', 'source': 'Wiley Online Library', 'date': 'Oct 2, 2023', 'snippet': 'Recently, injectable hydrogels have been considered smart materials and \nhave been widely researched for their use as scaffolds.', 'thumbnail': 'https://serpapi.com/searches/6723198a3c944b0711a2effb/images/0843c57872eb5fb87cc918028dd3df6bdc85b8af11db9d71714982816fd6c07e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5245862603187561}",,,,,,,,,,['positive'],positive,1
NCT05304611,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/experimental-nih-malaria-monoclonal-antibody-protective-malian-children', 'title': 'Experimental NIH malaria monoclonal antibody protective in Malian children', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Apr 26, 2024', 'snippet': 'Mid-stage trial shows treatment prevents infection, disease.', 'thumbnail': 'https://serpapi.com/searches/67231991b4fe87d275d35925/images/dc387c04aa31da3fc0c0f1a536c44c828af4d613c8635c7f6bc0966a17b4af2a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8246906995773315}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2312775', 'title': 'Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria', 'source': 'The New England Journal of Medicine', 'date': 'Apr 26, 2024', 'snippet': 'Subcutaneous administration of the monoclonal antibody L9LS protected \nadults against controlled Plasmodium falciparum infection in a phase 1...', 'thumbnail': 'https://serpapi.com/searches/67231991b4fe87d275d35925/images/dc387c04aa31da3f78c32ce057f046e04b931508469396aca3a733422c0ffff5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8696849346160889}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01667536,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/58/9/1408', 'title': 'Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection', 'source': 'Journal of Nuclear Medicine', 'date': 'Sep 1, 2017', 'snippet': '99m Tc-trofolastat SPECT/CT detects PCa with high sensitivity in patients \nwith intermediate- and high-risk PCa compared with histology.', 'thumbnail': 'https://serpapi.com/searches/6723199993584c270e7ba4a3/images/4572fe181e012eceb52b6d9479c756648e17fc8b84642a7bd5466aaff053ab23.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8805703520774841}",,,,,,,,,,['neutral'],neutral,1
NCT04984356,"{'position': 1, 'link': 'https://www.cgtlive.com/view/news-cell-therapy-rare-cancer-day-2024', 'title': 'News in Cell and Gene Therapy for Rare Cancer Day 2024', 'source': 'CGTLive®', 'date': '1 month ago', 'snippet': ""In observance of Rare Cancer Day, held annually on September 30, catch up \non the past few months' news related to gene and cell therapies in..."", 'thumbnail': 'https://serpapi.com/searches/672318c15c7cb9ea52f8677b/images/891781de514dd81d64164fb0656fd6983c40a53c5c60b2eabdc84f94890720c4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8710896372795105}",,,,,,,,,,['neutral'],neutral,1
NCT02378480,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1800170', 'title': 'Omadacycline for Acute Bacterial Skin and Skin-Structure Infections', 'source': 'The New England Journal of Medicine', 'date': 'Feb 6, 2019', 'snippet': 'Omadacycline was noninferior to linezolid for the treatment of acute \nbacterial skin and skin-structure infections and had a similar safety \nprofile.', 'thumbnail': 'https://serpapi.com/searches/672318cc642c31fec49d7aa3/images/7ff4d8bc4774be61ba7f9d45aba1c933aaf94641faac6bd75b4fb074a764c9b6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8277717232704163}",,,,,,,,,,['neutral'],neutral,1
NCT05277350,"{'position': 1, 'link': 'https://www.nature.com/articles/s41587-023-01759-y', 'title': 'Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice', 'source': 'Nature', 'date': 'May 4, 2023', 'snippet': 'Antibiotic treatments have detrimental effects on the microbiome and lead \nto antibiotic resistance. To develop a phage therapy against a...', 'thumbnail': 'https://serpapi.com/searches/672318d6213c87b971b47242/images/db765d9898739e17fce5b70f8b82d3967aeabc41bec949ae290ec35c532b76ed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5392537117004395}",,,,,,,,,,['neutral'],neutral,1
NCT04469621,"{'position': 1, 'link': 'https://www.genengnews.com/news/sanofi-and-denali-therapeutics-sar443122-dnl758/', 'title': 'Sanofi and Denali Therapeutics – SAR443122 (DNL758)', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Sep 8, 2020', 'snippet': 'Small molecule inhibitor of RIPK1 that does not cross the blood-brain \nbarrier, and is in development for patients with peripheral inflammatory \ndiseases.', 'thumbnail': 'https://serpapi.com/searches/672318f0ef60cb338d94d255/images/a8721252d31508df6ac0768d6f61171f3dfa10187ae2d4bdc95a2a119bc3bea3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.816842794418335}",,,,,,,,,,['neutral'],neutral,1
NCT02982941,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Trials-including-patients-with-desmoplastic-small-round-cell-tumor_tbl1_340814307', 'title': 'Trials including patients with desmoplastic small round cell tumor.', 'source': 'ResearchGate', 'date': 'May 2, 2020', 'snippet': 'Desmoplastic small round cell tumor (DSRCT) is a devastating disease which \nmost commonly affects adolescents, with a male predominance.', 'thumbnail': 'https://serpapi.com/searches/672319017f3719c39a63881f/images/5b4be3aebf3bcfcf68a2d95714808b209d5bd5539544842ff61259f72e7715bc.png', 'sentiment': 'negative', 'sentiment_prob': 0.8475664854049683}",,,,,,,,,,['negative'],negative,0
NCT00883129,"{'position': 1, 'link': 'https://sclerodermanews.com/news/study-confirms-mmf-is-effective-treatment-for-scleroderma-related-lung-disease/', 'title': 'Scleroderma-related Lung Disease Study Confirms MMF Is Effective Therapy', 'source': 'Scleroderma News', 'date': 'Sep 14, 2017', 'snippet': 'Read about a study confirming that mycophenolate mofetil is an effective \ntreatment for people with scleroderma-related lung disease.', 'thumbnail': 'https://serpapi.com/searches/67231906b691a72daec1b893/images/5386e494a12633c8686dddf8c1fca4a6296f9f8d2e8d10e35fff19347f95ade8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5428546667098999}",,,,,,,,,,['neutral'],neutral,1
NCT02802345,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1811737', 'title': 'Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 15, 2018', 'snippet': 'Nintedanib is an approved treatment for idiopathic pulmonary fibrosis \n(IPF). A subgroup analysis of a previously published trial suggested...', 'thumbnail': 'https://serpapi.com/searches/672319ead11a89a65f48af4a/images/aaf97825665861be782eb1ecb21854c6ad57cf2004b05e4d7faa55c2dd20785f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8332849740982056}",,,,,,,,,,['neutral'],neutral,1
NCT03057951,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2107038', 'title': 'Empagliflozin in Heart Failure with a Preserved Ejection Fraction', 'source': 'The New England Journal of Medicine', 'date': 'Aug 27, 2021', 'snippet': 'In this double-blind trial, we randomly assigned 5988 patients with class \nII–IV heart failure and an ejection fraction of more than 40% to receive...', 'thumbnail': 'https://serpapi.com/searches/672319f390adce4aba20bc34/images/fa5a87c827aa39f92a21bc985fe4a3cacce59707ebc5f6c7aabe33c32aac1318.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.727074146270752}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057812', 'title': 'Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial | Circulation', 'source': 'American Heart Association Journals', 'date': 'Nov 15, 2021', 'snippet': 'Background:Patients with heart failure with preserved ejection fraction \nhave significant impairment in health-related quality of life.', 'thumbnail': 'https://serpapi.com/searches/672319f390adce4aba20bc34/images/fa5a87c827aa39f925b052083547ac2744373319a44f9d0923eb340db5b82d8c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8105812668800354}","{'position': 3, 'link': 'https://www.researchgate.net/figure/The-trial-design-and-key-outcome-measures-from-the-DELIVER-study-Figure-adapted-from_fig2_343918465', 'title': 'Fig. 2 The trial design and key outcome measures from the DELIVER...', 'source': 'ResearchGate', 'date': 'Nov 23, 2020', 'snippet': 'DELIVER trial is a phase III international, multicentre, parallel-group, \nrandomised, Table 2 and the study design is presented in Fig.', 'thumbnail': 'https://serpapi.com/searches/672319f390adce4aba20bc34/images/fa5a87c827aa39f9c8b783f064d571cbd4bad0bdcac355a9cae6c6c94f5e361c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9150642156600952}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04927221,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S1550413122000948', 'title': 'Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial', 'source': 'ScienceDirect.com', 'date': 'May 3, 2022', 'snippet': 'We report the discovery of DC371739, an indole-containing \ntetrahydroisoquinoline compound with promising lipid-lowering effects, both \nin vitro and in vivo, and...', 'thumbnail': 'https://serpapi.com/searches/67231a02b2ebae6228945e63/images/44c5c4a4756925bc261722fce3a731f379ab82e9f939c1051d9cf554e271c57e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5752447843551636}",,,,,,,,,,['positive'],positive,1
NCT04667377,"{'position': 1, 'link': 'https://www.patientcareonline.com/view/survodutide-novel-gcgr-glp-1ra-shows-promise-in-obesity-mash-treatment', 'title': 'Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment', 'source': 'Patient Care Online', 'date': '1 month ago', 'snippet': 'New data presented at the 60th Annual Meeting of the European Association \nfor the Study of Diabetes (EASD) 2024 showed survodutide...', 'thumbnail': 'https://serpapi.com/searches/67231a18dc969f1f5a2fdd0a/images/6755ec5efb0529727c71b34884a6bb604daad29ec2922c4bcd78393e7ddcb3cc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6515651941299438}",,,,,,,,,,['neutral'],neutral,1
NCT03104699,"{'position': 1, 'link': 'https://cervicalcancernews.com/2017/04/24/clinical-trial-agenus-new-therapy-cervical-cancer-solid-tumors/', 'title': 'Agenus Begins Clinical Trial Testing New Therapy for Cervical Cancer, Solid Tumors', 'source': 'Cervical cancer News', 'date': 'Apr 24, 2017', 'snippet': ""The first patient has been dosed in the Phase 1/2 trial testing AGEN2034, \nAgenus' new PD-1 inhibitor, in patients with advanced solid tumors and \ncervical..."", 'thumbnail': 'https://serpapi.com/searches/67231a322e33c8a63dec0975/images/e63c53d3e8d110848fd0a7b737fdd9368ef0bc12d921570574f841ca42b183b4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9088606834411621}",,,,,,,,,,['neutral'],neutral,1
NCT02686658,"{'position': 1, 'link': 'https://www.nature.com/articles/s41433-023-02497-w', 'title': 'Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial', 'source': 'Nature', 'date': 'Mar 24, 2023', 'snippet': 'Over this 18-month study, ACP 2 mg and 4 mg showed continued reductions in \nthe progression of GA growth compared to sham and continued to be generally \nwell...', 'thumbnail': 'https://serpapi.com/searches/67231a7b749783416cf42082/images/50822c1ec399bde71487da36e37b7cb9d46ec77ae555d09e8b14b4d8bbd8eca1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8611340522766113}","{'position': 2, 'link': 'https://www.genengnews.com/topics/drug-discovery/astellas-to-acquire-iveric-bio-for-5-9b-expanding-eye-disease-pipeline/', 'title': 'Astellas to Acquire Iveric Bio for $5.9B, Expanding Eye Disease Pipeline', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'May 1, 2023', 'snippet': ""Astellas Pharma has agreed to acquire Iveric Bio for approximately $5.9 \nbillion, the companies said today, in a deal designed to expand the buyer's \npipeline of..."", 'thumbnail': 'https://serpapi.com/searches/67231a7b749783416cf42082/images/50822c1ec399bde7d8c6ef7c7fa9c0a8bb75d7d5ccd37cde329ec60d33ff314e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8609184622764587}","{'position': 3, 'link': 'https://www.empr.com/home/news/izervay-approved-for-geographic-atrophy-secondary-to-amd/', 'title': 'Izervay Approved for Geographic Atrophy Secondary to AMD', 'source': 'Medical Professionals Reference', 'date': 'Aug 7, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Izervay™ (avacincaptad \npegol intravitreal solution) for the treatment of geographic...', 'thumbnail': 'https://serpapi.com/searches/67231a7b749783416cf42082/images/50822c1ec399bde77e43fa5d3c9756a19700a59ee330d63d1862f081e23d3476.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7763739824295044}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00632866,"{'position': 1, 'link': 'https://sjogrenssyndromenews.com/news/sjogrens-symptoms-not-affected-by-seasonal-changes-study-finds/', 'title': 'Sjögren’s Symptoms Not Affected by Seasonal Changes, Study Finds', 'source': ""Sjogren's Syndrome News"", 'date': 'Apr 8, 2020', 'snippet': ""Seasonal changes do not appear to influence the main symptoms of primary \nSjögren's syndrome — pain, fatigue, and dryness — according to a..."", 'thumbnail': 'https://serpapi.com/searches/67231a9ea86921c141714a6e/images/c73f645a2df627bbf7b98faa09c5f5d028747b513075a77cdf6abf3e567fef41.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8096309900283813}","{'position': 2, 'link': 'https://sjogrenssyndromenews.com/news/sjogrens-can-be-classified-in-four-subgroups-depending-on-symptoms-study-suggests/', 'title': 'Sjögren’s Patients Fall into 4 Distinct Groups Depending on Symptoms, Study Suggests', 'source': ""Sjogren's Syndrome News"", 'date': 'Jan 2, 2020', 'snippet': ""People with Sjögren's syndrome may be classified into four groups based on \nsymptoms, each possibly with a distinct disease biology and..."", 'thumbnail': 'https://serpapi.com/searches/67231a9ea86921c141714a6e/images/c73f645a2df627bb9c631ce908e9f9f006b0bc82484415fa94817ca5a40a0ab1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6786310076713562}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02485704,"{'position': 1, 'link': 'https://www.empr.com/home/news/natroba-spinosad-topical-suspension-scabies-infestations/', 'title': 'Natroba Topical Suspension Approved for Scabies Treatment', 'source': 'Medical Professionals Reference', 'date': 'Apr 29, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Natroba TM (spinosad) \ntopical suspension for the treatment of scabies infestations in patients 4 \nyears of...', 'thumbnail': 'https://serpapi.com/searches/67231aaee281ee018cee3d21/images/75d119db06fdb8119aa3fcb6bb167088f5abb538f4d1dc13bf85b11a4fde6cb9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8773550987243652}",,,,,,,,,,['neutral'],neutral,1
NCT01011868,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/jcpt.13521', 'title': 'Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta-analysis based on randomized controlled trials', 'source': 'Wiley Online Library', 'date': 'Sep 20, 2021', 'snippet': 'As an oral hypoglycaemic drug that significantly reduces cardiovascular \nrisk, empagliflozin is often used in patients with type 2 diabetes...', 'thumbnail': 'https://serpapi.com/searches/67231ab772f716bb6101ca49/images/362394ba0cc8b5f700d352bace8ebb679c6a338b0e72df3649d96f06e0f1723e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.867742657661438}",,,,,,,,,,['neutral'],neutral,1
NCT02332499,"{'position': 1, 'link': 'https://www.nature.com/articles/aps2017199', 'title': 'Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species', 'source': 'Nature', 'date': 'Apr 5, 2018', 'snippet': 'Anlotinib is a new oral tyrosine kinase inhibitor; this study was designed \nto characterize its pharmacokinetics and disposition.', 'thumbnail': 'https://serpapi.com/searches/67231abbd364b47823e1b023/images/eecbace0949d509e36517aee4f98ce74f1b4175a86eda90a123afdeb89f556aa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9290844798088074}",,,,,,,,,,['neutral'],neutral,1
NCT02631070,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1908892', 'title': 'Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes', 'source': 'The New England Journal of Medicine', 'date': 'Jan 8, 2020', 'snippet': 'Patients with anemia and lower-risk myelodysplastic syndromes in whom \nerythropoiesis-stimulating agent therapy is not effective generally...', 'thumbnail': 'https://serpapi.com/searches/67231b01b28e6bea4b5b55e2/images/3d4e0b2a8bc5392373ba4e228f2c03c817557f99d717eb9b580c1593002401d5.png', 'sentiment': 'negative', 'sentiment_prob': 0.5493323802947998}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/luspatercept-aamt-yields-improved-rbc-ti-and-hemoglobin-increase-vs-epoetin-alfa-in-mds', 'title': 'Luspatercept-aamt Yields Improved RBC-TI and Hemoglobin Increase Vs Epoetin Alfa in MDS', 'source': 'Cancer Network', 'date': 'Nov 1, 2022', 'snippet': 'Topline results from the phase 3 COMMAND trial (NCT03682536) indicated that \nthe use of luspatercept-aamt (Reblozyl) for treating adult...', 'thumbnail': 'https://serpapi.com/searches/67231b01b28e6bea4b5b55e2/images/3d4e0b2a8bc5392347fbeba456b253fcfc0d4c9527beb62f3d5b0f66d7f7d49c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5078725218772888}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT03178032,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa2202028', 'title': 'Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma', 'source': 'The New England Journal of Medicine', 'date': 'Jun 29, 2022', 'snippet': 'We conducted a single-center, dose-escalation study of DNX-2401, an \noncolytic adenovirus that selectively replicates in tumor cells, in \npatients with newly...', 'thumbnail': 'https://serpapi.com/searches/67231b3075f974afac1148b5/images/37061444b86f1c96d5a7638c4170e2374d0be079574a0320bd47d2a816be13ca.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7948493361473083}",,,,,,,,,,['neutral'],neutral,1
NCT03387137,"{'position': 1, 'link': 'https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/article-1-challenges-developing-vaccine-respiratory-syncytial-virus.html', 'title': 'Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada, CCDR 46(4)', 'source': 'Canada.ca', 'date': 'Apr 2, 2020', 'snippet': 'A vaccine for respiratory syncytial virus (RSV) has been actively sought \nfor over 60 years due to the health impacts of RSV disease in infants.', 'thumbnail': 'https://serpapi.com/searches/67231b3df6aa53bdf3526bf6/images/e2ba98a550bab50e51de90f01b4c3540e76f67d564da39416582c714d680702c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.867176353931427}",,,,,,,,,,['neutral'],neutral,1
NCT04280705,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2007764', 'title': 'Remdesivir for the Treatment of Covid-19 — Final Report', 'source': 'The New England Journal of Medicine', 'date': 'May 22, 2020', 'snippet': 'Our data show that remdesivir was superior to placebo in shortening the \ntime to recovery in adults who were hospitalized with Covid-19 and had \nevidence of...', 'thumbnail': 'https://serpapi.com/searches/67231b41a54d7e5ab852835d/images/cd3a8dfe27833d94db850a57ad7e44bf29c7fa7777c6d7281cdad9cbdbdc6dc8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6877774000167847}","{'position': 2, 'link': 'https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins', 'title': 'NIH clinical trial of remdesivir to treat COVID-19 begins', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Feb 25, 2020', 'snippet': 'A randomized, controlled clinical trial to evaluate the safety and efficacy \nof the investigational antiviral remdesivir in hospitalized adults \ndiagnosed with...', 'thumbnail': 'https://serpapi.com/searches/67231b41a54d7e5ab852835d/images/cd3a8dfe27833d946bb45728710d742941e9d70259941d1dfdb3da4f6704b627.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.887718915939331}","{'position': 3, 'link': 'https://www.nih.gov/news-events/news-releases/nih-clinical-trial-hydroxychloroquine-potential-therapy-covid-19-begins', 'title': 'NIH clinical trial of hydroxychloroquine, a potential therapy for COVID-19, begins', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Apr 9, 2020', 'snippet': 'A clinical trial to evaluate the safety and effectiveness of \nhydroxychloroquine for the treatment of adults hospitalized with \ncoronavirus disease 2019 (COVID-...', 'thumbnail': 'https://serpapi.com/searches/67231b41a54d7e5ab852835d/images/cd3a8dfe27833d94ca6154f029005179cf12330452889ffe6c3836e1f0b74ead.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9046974182128906}","{'position': 4, 'link': 'https://www.infectiousdiseaseadvisor.com/news/10-day-course-of-remdesivir-shorten-time-to-recovery-in-coronavirus-patients/', 'title': 'Remdesivir Superior to Placebo in Hospitalized Patients With COVID-19', 'source': 'Infectious Disease Advisor', 'date': 'Nov 25, 2020', 'snippet': 'A 10-day course of remdesivir was superior to placebo in shortening the \ntime to recovery in hospitalized patients with coronavirus disease 2019 \n(COVID-19).', 'thumbnail': 'https://serpapi.com/searches/67231b41a54d7e5ab852835d/images/cd3a8dfe27833d9463188772cdc105138dd1420ce7206068bcf4253e284b63f7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7959307432174683}","{'position': 5, 'link': 'https://leadstories.com/hoax-alert/2020/05/fact-check-hydrochloroquine-not-a-vaccine-being-held-back-and-studies-are-underway-for-drugs-that-will-not-be-immediately-injected-into-people.html', 'title': 'Fact Check: Hydroxychloroquine is NOT A Drug Being Held Back, And Studies ARE Underway For Vaccines That Will NOT Be Immediately Injected in People.', 'source': 'leadstories.com', 'date': 'May 2, 2020', 'snippet': 'Is it true that ""thousands of doctors"" say hydroxychloroquine ""cures"" \nCOVID-19 patients,"" but the cure won\'t be valid until a...', 'thumbnail': 'https://serpapi.com/searches/67231b41a54d7e5ab852835d/images/cd3a8dfe27833d94e055d80893b79d83a44d08f4dabd80c6934989778c1f49f9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7088871598243713}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04165824,"{'position': 1, 'link': 'https://alsnewstoday.com/news/radicava-prolongs-survival-als-patients-study-japan/', 'title': 'Radicava Prolongs Survival in ALS Patients, Study from Japan Indicates', 'source': 'ALS News Today', 'date': 'Aug 18, 2021', 'snippet': 'Long-term treatment with Radicava (edaravone) is generally safe and nearly \ndoubles survival time in adults with amyotrophic lateral...', 'thumbnail': 'https://serpapi.com/searches/67231b524a4a1d0f98dca5c5/images/02f7b708068587fc74152dae9b03c970df509c712bb5d9746ae3c501bc3c5486.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5691385865211487}",,,,,,,,,,['positive'],positive,1
NCT05223868,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/investigational-targeted-oral-peptide-jnj-2113-demonstrated-positive-results-in-moderate-to-severe-plaque-psoriasis-in-phase-2b-study-published-in-new-england-journal-of-medicine-302056740.html', 'title': 'Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine', 'source': 'PR Newswire', 'date': 'Feb 7, 2024', 'snippet': 'Data from FRONTIER 1, a Phase 2b clinical trial, show JNJ-2113, the first \nand only targeted oral peptide that selectively blocks the IL-23...', 'thumbnail': 'https://serpapi.com/searches/67231b8f21e77b4fba2e5546/images/372b071306862a803e4b6ed84840261f6fa561337864750ae6796ddbfaa67f38.png', 'sentiment': 'neutral', 'sentiment_prob': 0.65118408203125}",,,,,,,,,,['neutral'],neutral,1
NCT03611582,"{'position': 1, 'link': 'https://www.nature.com/articles/s41366-020-00733-x', 'title': 'Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data', 'source': 'Nature', 'date': 'Jan 18, 2021', 'snippet': 'This article reviews how intercurrent events during weight management \ntrials can influence placebo-adjusted treatment effects.', 'thumbnail': 'https://serpapi.com/searches/67231bb0c4bcf53569dc15b4/images/1416fb43534628ed47dedea58cc523d807d67dbe9aece6f75d31259aee87d4fd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8437772989273071}",,,,,,,,,,['neutral'],neutral,1
NCT03387852,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2024257', 'title': 'Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma', 'source': 'The New England Journal of Medicine', 'date': 'Oct 27, 2021', 'snippet': 'Itepekimab treatment improved asthma control and quality of life, as \ncompared with placebo, and led to a greater reduction in the mean blood \neosinophil count.', 'thumbnail': 'https://serpapi.com/searches/67231bb5a505f7f6768d69b3/images/8cc50a63ee7645d5f9c31c749e95a51650a1339cda05d1b670c2e9f14fd3a381.png', 'sentiment': 'positive', 'sentiment_prob': 0.632533609867096}",,,,,,,,,,['positive'],positive,1
NCT02716675,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2031738', 'title': 'Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition', 'source': 'The New England Journal of Medicine', 'date': 'Mar 17, 2021', 'snippet': 'Whether a broadly neutralizing antibody (bnAb) can be used to prevent human \nimmunodeficiency virus type 1 (HIV-1) acquisition is unclear.', 'thumbnail': 'https://serpapi.com/searches/67231bc268831e828e5d538a/images/776af3c1ce2d9ecc10b7ae60dd2f75c9cb99a5330c9264a3f8c9cab4de27fcbe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.771469235420227}",,,,,,,,,,['neutral'],neutral,1
NCT01606579,"{'position': 1, 'link': 'https://www.nature.com/articles/s12276-020-0380-6', 'title': 'Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex', 'source': 'Nature', 'date': 'Feb 10, 2020', 'snippet': 'Wnt/β-catenin signaling is implicated in many physiological processes, \nincluding development, tissue homeostasis, and tissue regeneration.', 'thumbnail': 'https://serpapi.com/searches/67231bcf1b4e34a513c6f937/images/023c6d565789197bc5e3cb8a147c1ba7c8d04247c39a064be1027f8bd42c0899.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8630236387252808}",,,,,,,,,,['neutral'],neutral,1
NCT03448939,"{'position': 1, 'link': 'https://www.empr.com/home/news/epsolay-cream-now-available-for-rosacea/', 'title': 'Epsolay Cream Now Available for Rosacea', 'source': 'Medical Professionals Reference', 'date': 'Jun 3, 2022', 'snippet': 'Epsolay® (benzoyl peroxide) cream is now available for the treatment of \ninflammatory lesions of rosacea in adults.', 'thumbnail': 'https://serpapi.com/searches/67231c670c66687b6cb6d518/images/f2dab4359c9adbb9454d9d5c83946b8496a2e673906970087a3c16f8944a94d2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7307189106941223}",,,,,,,,,,['neutral'],neutral,1
NCT03511391,"{'position': 1, 'link': 'https://www.oncologynurseadvisor.com/news/cancer-sbrt-radiotherapy-monotherapy-survival-benefit-treatment-risk/', 'title': 'No Survival Benefit From Adding SBRT to ICI Monotherapy in Advanced Solid Tumors', 'source': 'Oncology Nurse Advisor', 'date': 'Jul 21, 2023', 'snippet': 'Adding subablative stereotactic body radiotherapy (SBRT) of a limited \nnumber of metastatic lesions to immune checkpoint inhibitor (ICI) \nmonotherapy is safe,...', 'thumbnail': 'https://serpapi.com/searches/67231c739062f8d4f3796ab1/images/9edb7d0480db3f06152619284cb5ca9a0656e2b0a5b784553dc1076811dd0468.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5246069431304932}",,,,,,,,,,['neutral'],neutral,1
NCT03760003,"{'position': 1, 'link': 'https://ibdnewstoday.com/2020/12/21/abivax-completes-enrollment-for-phase-2b-trial-testing-abx464-for-moderate-to-severe-ulcerative-colitis-uc/', 'title': 'Abivax Completes Enrollment in ABX464 Trial for Ulcerative Colitis', 'source': 'IBD News Today', 'date': 'Dec 21, 2020', 'snippet': 'Abivax completed patient enrollment ahead of schedule for a trial testing \nABX464 for people with moderate to severe ulcerative colitis.', 'thumbnail': 'https://serpapi.com/searches/67231c767ebde58fad253a62/images/5e5582cdc1b6a48abb1eedc31b0d54ae20ec8138af06f4ef9987f615cabac644.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8923408389091492}",,,,,,,,,,['neutral'],neutral,1
NCT02303990,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0281-9', 'title': 'A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours', 'source': 'Nature', 'date': 'Oct 15, 2018', 'snippet': 'We conducted a phase I trial evaluating pembrolizumab+hypofractionated \nradiotherapy (HFRT) for patients with metastatic cancers.', 'thumbnail': 'https://serpapi.com/searches/67231c9d11db450134b54cc1/images/f07f4fc7220c6de29f30d3aab3421735d8c9bf305f2112fb4dcc170f898ccf15.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9073079228401184}",,,,,,,,,,['neutral'],neutral,1
NCT01903993,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00587-0/fulltext', 'title': 'Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial', 'source': 'The Lancet', 'date': 'Mar 9, 2016', 'snippet': 'Outcomes are poor for patients with previously treated, advanced or \nmetastatic non-small-cell lung cancer (NSCLC). The anti-programmed death...', 'thumbnail': 'https://serpapi.com/searches/67231ca9efad2193710cc197/images/389582f1cff1e55360e8c424f122867d60789bc902d33841cd40e2be9df261d2.png', 'sentiment': 'negative', 'sentiment_prob': 0.6142983436584473}","{'position': 2, 'link': 'https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05509-9', 'title': 'Integrating knowledge graphs into machine learning models for survival prediction and biomarker discovery in patients with non–small-cell lung cancer', 'source': 'Journal of Translational Medicine', 'date': 'Aug 5, 2024', 'snippet': 'Accurate survival prediction for Non-Small Cell Lung Cancer (NSCLC) \npatients remains a significant challenge for the scientific and clinical...', 'thumbnail': 'https://serpapi.com/searches/67231ca9efad2193710cc197/images/389582f1cff1e5530118766f2c3db7c0b61afa48b54b5731a0807017d0364d9f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7933346629142761}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT02943785,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2111016', 'title': 'Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR', 'source': 'The New England Journal of Medicine', 'date': 'Aug 28, 2021', 'snippet': 'The role of direct oral anticoagulants as compared with vitamin K \nantagonists for atrial fibrillation after successful transcatheter...', 'thumbnail': 'https://serpapi.com/searches/67231cbc23a4b50b0bc021f5/images/b2d57f173e2268af472debd206a91ee959632919480f2a4a7c3c7cb91b84a55c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9063099026679993}",,,,,,,,,,['neutral'],neutral,1
NCT02301039,"{'position': 1, 'link': 'https://www.targetedonc.com/view/sarcoma-awareness-month-impact-of-molecular-testing-and-individualized-treatments', 'title': 'Sarcoma Awareness Month: Impact of Molecular Testing and Individualized Treatments', 'source': 'Targeted Oncology', 'date': 'Jul 19, 2023', 'snippet': 'For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, \ndiscussed the importance of understanding the genomics of sarcomas...', 'thumbnail': 'https://serpapi.com/searches/67231d0f2c566da299be8d81/images/5acfce28e2637339f4f413694acd22e820cb3d1b7f954a9652b6c7f82899a9c6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8926946520805359}",,,,,,,,,,['neutral'],neutral,1
NCT00675584,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1104647', 'title': 'Daily or Intermittent Budesonide in Preschool Children with Recurrent Wheezing', 'source': 'The New England Journal of Medicine', 'date': 'May 3, 2018', 'snippet': 'Daily inhaled glucocorticoids are recommended for young children at risk \nfor asthma exacerbations, as indicated by a positive value on the modified \nasthma...', 'thumbnail': 'https://serpapi.com/searches/67231d17c117a9c5122441cc/images/0443c2d8a224f595491f6ccae6a2cdb432d779aa5da291facc410fbc773fec5d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8345343470573425}",,,,,,,,,,['neutral'],neutral,1
NCT00422981,"{'position': 1, 'link': 'https://www.nature.com/articles/s41398-024-03118-0', 'title': 'Davunetide sex-dependently boosts memory in prodromal Alzheimer’s disease | Translational Psychiatry', 'source': 'Nature', 'date': '1 month ago', 'snippet': 'The tauopathy inhibitor, davunetide shows sex-dependent efficacy in women \nsuffering from progressive supranuclear palsy.', 'thumbnail': 'https://serpapi.com/searches/67231d1b11db450134b54d3d/images/05bbd4a7382e3950db19481fdbee9016e4d55718730b66b5cbc94fbf883af64b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7483072280883789}",,,,,,,,,,['neutral'],neutral,1
NCT04355767,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2103784', 'title': 'Early Convalescent Plasma for High-Risk Outpatients with Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Aug 18, 2021', 'snippet': 'Early administration of convalescent plasma obtained from blood donors who \nhave recovered from coronavirus disease 2019 (Covid-19) may...', 'thumbnail': 'https://serpapi.com/searches/67231d1bef60cb33d411cd02/images/c3b7f9720593f7a8fc182a457d232fbe179c24006eb4bc6227c1d03651b17fca.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.863638162612915}",,,,,,,,,,['neutral'],neutral,1
NCT01633970,"{'position': 1, 'link': 'https://www.nature.com/articles/ncomms12624', 'title': 'Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma', 'source': 'Nature', 'date': 'Aug 30, 2016', 'snippet': 'This study investigates how VEGF blockade with bevacizumab could potentiate \nPD-L1 checkpoint inhibition with atezolizumab in mRCC.', 'thumbnail': 'https://serpapi.com/searches/67231d6ea3657a6c2f235359/images/d387aefdff2919582b1efd900776430c6c8898c4e05e1f27cb2978c1128b50f2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8066033720970154}",,,,,,,,,,['neutral'],neutral,1
NCT03995706,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-50558-9', 'title': 'Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial', 'source': 'Nature', 'date': 'Aug 7, 2024', 'snippet': 'Sacituzumab Govitecan (SG) is an antibody-drug conjugate that has \ndemonstrated efficacy in patients with TROP-2 expressing epithelial...', 'thumbnail': 'https://serpapi.com/searches/67231d8171c62b0ab62332e0/images/04a958011c1ab8e37e6fc822102549c80d1bf9619961589ce4fd0f5bb5b5b499.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8924646377563477}","{'position': 2, 'link': 'https://www.oncozine.com/esmo-2020-encouraging-early-stage-clinical-results-with-sacituzumab-govitecan-in-brain-cancer/', 'title': 'ESMO 2020: Encouraging Early-Stage Clinical Results with Sacituzumab Govitecan in Brain Cancer', 'source': ""Onco'Zine"", 'date': 'Sep 18, 2020', 'snippet': 'A clinical trial (NCT03995706) studying the extent by which sacituzumab \ngovitecan (Trodelvy™; Immunomedics) is able to get into the brain...', 'thumbnail': 'https://serpapi.com/searches/67231d8171c62b0ab62332e0/images/04a958011c1ab8e3243ba7e86c7ab68b2c8a4c261cdffae957bb33caa5cca150.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8611966371536255}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05040438,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/jgh.16584?af=R', 'title': 'Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma', 'source': 'Wiley Online Library', 'date': 'May 27, 2024', 'snippet': 'The Journal of Gastroenterology and Hepatology publishes digestive and \nliver disease research in the fields of gastroenterology,...', 'thumbnail': 'https://serpapi.com/searches/67232022987217beec27b28f/images/f3b44c75e4eaa39a77888e67345f20f5733f6ba84ad88797798d906c6fa6468b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8760159015655518}",,,,,,,,,,['neutral'],neutral,1
NCT04018027,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/analyst-comment/pipeline-agents-pruritus-dermatitis/', 'title': 'Pipeline agents to improve the management of pruritus in atopic dermatitis', 'source': 'Clinical Trials Arena', 'date': 'Oct 26, 2022', 'snippet': 'Pruritus is currently managed using a range of topical and systemic \ntreatments such as topical corticosteroids (TCS), immunomodulators, and \nbiologics.', 'thumbnail': 'https://serpapi.com/searches/672323f2bb55ffa22779c770/images/ef64ccd8fd441b13a44a97eb2096acdfd3fe97ae488d687541483e0af44307d2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.83791184425354}",,,,,,,,,,['neutral'],neutral,1
NCT04147858,"{'position': 1, 'link': 'https://fibromyalgianewstoday.com/2020/09/29/aptinyx-reopens-enrollment-for-phase-2-nyx-2925-trial-for-fibromyalgia/', 'title': 'Aptinyx Reopens Enrollment in Phase 2 Study of NYX-2925 for Chronic Pain', 'source': 'Fibromyalgia News Today', 'date': 'Sep 29, 2020', 'snippet': 'A Phase 2 clinical trial testing NYX-2925 for chronic pain has resumed \nenrollment of adults with fibromyalgia, according to Aptinyx.', 'thumbnail': 'https://serpapi.com/searches/6723249a2a772726ba49792c/images/4be06fa6147b2befd5107c06c87b25a0cd01e6da7a3fdf58c3a84ee55a263c87.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9278391599655151}",,,,,,,,,,['neutral'],neutral,1
NCT03792490,"{'position': 1, 'link': 'https://alsnewstoday.com/news/study-early-stage-als-fasudil-safe-preserves-motor-neurons/', 'title': 'Fasudil safe, preserves motor neurons in early-stage ALS: Study', 'source': 'ALS News Today', 'date': 'Jun 27, 2024', 'snippet': 'Treatment with fasudil (RT1968), which Raya Therapeutic is testing for \namyotrophic lateral sclerosis (ALS), was safe and outperformed a placebo at \npreserving...', 'thumbnail': 'https://serpapi.com/searches/672325bf64f11d36b5af1459/images/767c79ff518ae9d3ae70b42ad18fac3bdea130ddada4565e36c17a1a65781d98.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5164152383804321}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2024.1308577/full', 'title': 'Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD)', 'source': 'Frontiers', 'date': 'Feb 14, 2024', 'snippet': ""The Rho-kinase (ROCK) inhibitor Fasudil has shown symptomatic and \ndisease-modifying effects in Parkinson's disease (PD) models in vitro and \nin vivo."", 'thumbnail': 'https://serpapi.com/searches/672325bf64f11d36b5af1459/images/767c79ff518ae9d30d79895fa9a0a8f73b31074ecb5f496f0e507e7532e5cd26.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8606524467468262}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02285998,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1608862', 'title': 'Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older', 'source': 'The New England Journal of Medicine', 'date': 'Jun 22, 2017', 'snippet': 'Improved influenza vaccines are needed to control seasonal epidemics. This \ntrial compared the protective efficacy in older adults of a...', 'thumbnail': 'https://serpapi.com/searches/67239f4a3d629bbc1df0d679/images/74e2d41bb85c406f1c446deb6e8206af280603e6c371035c0a764eb9a89b5ddf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8649623394012451}",,,,,,,,,,['neutral'],neutral,1
NCT01810705,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.807266/full', 'title': 'Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells', 'source': 'Frontiers', 'date': 'Jun 27, 2023', 'snippet': 'Despite intensive chemotherapy regimens, up to 60% of adults with acute \nmyeloid leukaemia (AML) will relapse and eventually succumb to their \ndisease.', 'thumbnail': 'https://serpapi.com/searches/6723a1130f1a33123715b955/images/7187e325b7727d878e31ef7cc8780a6497f9977a1c7365542d1b696dca0e2a70.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6279506683349609}",,,,,,,,,,['neutral'],neutral,1
NCT01985126,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/characteristics-myeloma-disease-may-impact-exposure-darzalex-study-reports/', 'title': 'Type of Multiple Myeloma May Affect Responses to Darzalex, Study Finds', 'source': 'Myeloma Research News', 'date': 'Oct 20, 2017', 'snippet': 'A new study reports that the specific type of multiple myeloma (MM) may \naffect how long the drug Darzalex (daratumumab) remains in circulation.', 'thumbnail': 'https://serpapi.com/searches/6723a137adc33b91195e3858/images/8bbf8332ec543451729f479f0fdd7b9965533a11902036d8822344eed95833d3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8073411583900452}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/myeloma-study-finds-pomalyst-more-cost-effective-than-kyprolis-or-darzalex/', 'title': 'Myeloma Study Finds Pomalyst More Cost-Effective Than Two Rivals', 'source': 'Myeloma Research News', 'date': 'Oct 30, 2017', 'snippet': 'Read about a study reporting that a combination of Pomalyst and \ndexamethasone is a more cost-effective therapy for myeloma than Kyprolis \nor...', 'thumbnail': 'https://serpapi.com/searches/6723a137adc33b91195e3858/images/8bbf8332ec5434510a5b8af2b6adcfcbbb695f495222693d138c05f9292d78c8.png', 'sentiment': 'positive', 'sentiment_prob': 0.5470622777938843}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02516553,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-022-01815-5', 'title': 'Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic', 'source': 'Nature', 'date': 'Apr 20, 2022', 'snippet': 'BET inhibitors have been tested in several clinical trials where, despite \nencouraging preclinical results, substantial clinical benefit in...', 'thumbnail': 'https://serpapi.com/searches/6723a37498721711d1e0bc32/images/9bbce920f65f669f0eee1635424e79a95f0b8710f5824a20419e961c10fc64b6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6351170539855957}","{'position': 2, 'link': 'https://www.nature.com/articles/s41388-018-0150-2', 'title': 'The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML', 'source': 'Nature', 'date': 'Mar 1, 2018', 'snippet': 'This work presents a novel potent and selective BET inhibitor (BI 894999), \nwhich has recently entered clinical trials (NCT02516553).', 'thumbnail': 'https://serpapi.com/searches/6723a37498721711d1e0bc32/images/9bbce920f65f669fe080b33279772c20d84b945ce43fdd1c3e712b5402697964.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8765249848365784}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03192345,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-00436-9', 'title': 'Targeting TGFβ signal transduction for cancer therapy', 'source': 'Nature', 'date': 'Jan 8, 2021', 'snippet': 'Transforming growth factor-β (TGFβ) family members are structurally and \nfunctionally related cytokines that have diverse effects on the...', 'thumbnail': 'https://serpapi.com/searches/6723a3bbcf32e074c2cdad37/images/d22ef5da1c85d369a437f621d8e11be0d328f170917f20a8aaafdf2a39fb9f01.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7691714763641357}",,,,,,,,,,['neutral'],neutral,1
NCT03328494,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0081-2', 'title': 'Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division', 'source': 'Nature', 'date': 'May 8, 2018', 'snippet': 'Our study shows that the synergy between taxanes and Mps1 inhibitors \ndepends on increased errors in cell division, allowing further optimisation \nof this...', 'thumbnail': 'https://serpapi.com/searches/6723a3961b4e34a58fb8193c/images/c6477718b0eec777e70e10c10414c3f011c1895c40e1b6a74d91b25547c4aebf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7922691106796265}",,,,,,,,,,['neutral'],neutral,1
NCT00105300,"{'position': 1, 'link': 'https://ibdnewstoday.com/ibd-treatment/humira-adalimumab/', 'title': 'Range of Bowel Diseases Can Be Treated with Humira', 'source': 'ibdnewstoday.com', 'date': 'Aug 31, 2017', 'snippet': 'Humira (adalimumab) is a biological therapy that the US Food and Drug \nAdministration approved for treating inflammatory bowel disease, or IBD.', 'thumbnail': 'https://serpapi.com/searches/6723a41f1397ba9ff37f4fed/images/c2cbed506a6ac5b3d4732296d65946da43c7856898c74ecc4cd35d2673ae9126.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9108577370643616}",,,,,,,,,,['neutral'],neutral,1
NCT01345006,"{'position': 1, 'link': 'https://www.nature.com/articles/s41536-019-0081-8', 'title': 'Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells (MA09-hRPE) in macular degeneration', 'source': 'Nature', 'date': 'Aug 27, 2019', 'snippet': 'This review focuses on the first generation of hESC-RPE cell line, named as \n“MA09-hRPE” by Astellas Institute of Regenerative Medicine (AIRM), and \nits...', 'thumbnail': 'https://serpapi.com/searches/6723a6802b5fa7f3c396d07e/images/d68c47bb5ed00b9f8a70b0dc585526bb1b80f25fbf941211baf2f02a1538422c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9050300717353821}",,,,,,,,,,['neutral'],neutral,1
NCT04625725,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2116620', 'title': 'Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Apr 20, 2022', 'snippet': 'The monoclonal-antibody combination AZD7442 is composed of tixagevimab and \ncilgavimab, two neutralizing antibodies against severe acute...', 'thumbnail': 'https://serpapi.com/searches/6723acdef41044934315b4fa/images/79eec1284dc1c4ee64a135b06858be0b99f8d43211d6a17e48e55b90c8802845.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8653955459594727}",,,,,,,,,,['neutral'],neutral,1
NCT04575259,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/long-term-anavex-2-73-reduced-parkinsons-dementia-symptoms/', 'title': 'Long-term Anavex 2-73 reduced dementia, motor symptoms', 'source': ""Parkinson's News Today"", 'date': 'Mar 31, 2023', 'snippet': ""One year of Anavex 2-73 treatment safely led to symptom reduction in 20 \npeople with Parkinson's dementia in a Phase 2 trial extension study."", 'thumbnail': 'https://serpapi.com/searches/6723aceb93584c7cb4f95580/images/28919380434d05dc078704347957b1498b9d2cd48c054bdbefba89a05612c800.png', 'sentiment': 'positive', 'sentiment_prob': 0.5137033462524414}",,,,,,,,,,['positive'],positive,1
NCT03088813,"{'position': 1, 'link': 'https://www.targetedonc.com/view/liposomal-irinotecan-shows-comparable-efficacy-with-topotecan-in-relapsed-sclc', 'title': 'Liposomal Irinotecan Shows Comparable Efficacy With Topotecan in Relapsed SCLC', 'source': 'Targeted Oncology', 'date': 'Jun 18, 2024', 'snippet': 'While the primary end point of overall survival was not met in the phase 3 \nRESILIENT study, the overall response rate was 44.1% vs 21.6%...', 'thumbnail': 'https://serpapi.com/searches/6723b57e037756cd95594d51/images/c8b80e2e19a9579b9b442ed65133b928b52ed00ca55c50a010aa5d40a0fe6c9f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7184060215950012}",,,,,,,,,,['neutral'],neutral,1
NCT03721510,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01815-1', 'title': 'Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial', 'source': 'Nature', 'date': 'May 12, 2022', 'snippet': 'HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) \nhas shown viral escape, indicating that at least a triple bNAb...', 'thumbnail': 'https://serpapi.com/searches/6723b585717bff8eb9c86b5b/images/84f4393a0b6b3292f455de508edaa12e56f3582840d4c75bf811882d35bfa8ac.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8841989636421204}",,,,,,,,,,['neutral'],neutral,1
NCT00034645,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa061098', 'title': 'Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease', 'source': 'The New England Journal of Medicine', 'date': 'Jan 25, 2007', 'snippet': 'In an international, randomized, double-blind trial, we compared oral \nposaconazole with oral fluconazole for prophylaxis against invasive...', 'thumbnail': 'https://serpapi.com/searches/6723b6c10053c76850fb0d4c/images/815633cf30d762401704c31126a4333c3afd946afb7dbc427957f9084a6a11e3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8868744969367981}",,,,,,,,,,['neutral'],neutral,1
NCT01986010,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-021-00342-3', 'title': 'A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial', 'source': 'Nature', 'date': 'Jun 2, 2021', 'snippet': 'A conditionally replication-defective human cytomegalovirus (HCMV) vaccine, \nV160, was shown to be safe and immunogenic in a two-part, double-blind, \nrandomized,...', 'thumbnail': 'https://serpapi.com/searches/6723b6e8e95dbfe0bbe48d92/images/e17b65496add6c7cb97fe7b34b80712ecaa9e5baf0edab046ee188a7b2a36aea.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7006304860115051}",,,,,,,,,,['neutral'],neutral,1
NCT04231968,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-45241-y', 'title': 'Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor', 'source': 'Nature', 'date': 'Feb 8, 2024', 'snippet': 'Respiratory syncytial virus (RSV) is a common cause of acute lower \nrespiratory tract infection in infants, older adults and the...', 'thumbnail': 'https://serpapi.com/searches/6723afe54a3fcf8116858f78/images/4b338b68b8d481d75189caf5ce8cae606fb5207d3b74a7bc54d717a7e36a4b38.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5343520641326904}",,,,,,,,,,['negative'],negative,0
NCT03391232,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2019/06/18/colorectal-cancer-vaccine-candidate-induces-potent-immune-responses-interim-trial-results-show/', 'title': 'Colon Cancer Vaccine PolyPEPI1018 Shows Promising Mid-Trial Results', 'source': 'Immuno-Oncology News', 'date': 'Jun 18, 2019', 'snippet': 'PolyPEPI1018 with standard maintenance therapy induced promising immune \nresponses in metastatic colorectal cancer patients, interim trial...', 'thumbnail': 'https://serpapi.com/searches/6723b18576585714a50a23d0/images/ce147ee739558e3f6751171022fcf6f1592dd55db557fcc699a385e253497057.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6676478385925293}",,,,,,,,,,['positive'],positive,1
NCT01910220,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-019-46428-w', 'title': 'Changes in DXA-derived lean mass and MRI-derived cross-sectional area of the thigh are modestly associated', 'source': 'Nature', 'date': 'Jul 11, 2019', 'snippet': 'The purpose of this study was to determine the accuracy of DXA at detecting \nchanges in lean mass, using MRI-derived MV as a reference standard.', 'thumbnail': 'https://serpapi.com/searches/6723b1b9a775f2fae9822aef/images/5b9ed27a7179d3ac047577782668edb6703a7990df2c578b9f41a2ce5774737d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8964696526527405}",,,,,,,,,,['neutral'],neutral,1
NCT00467779,"{'position': 1, 'link': 'https://www.nature.com/articles/bjc201710', 'title': 'A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor', 'source': 'Nature', 'date': 'Feb 2, 2017', 'snippet': 'Binimetinib (MEK162; ARRY-438162) is a potent and selective oral MEK 1/2 \ninhibitor. This phase 1 study determined the maximum tolerated dose...', 'thumbnail': 'https://serpapi.com/searches/6723b4194677bf11ee639839/images/f45c7b11f3500fcbd2e44bc9bed2935cf0a845afe56faa04e0405a56e784eb86.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8930802345275879}",,,,,,,,,,['neutral'],neutral,1
NCT02410213,"{'position': 1, 'link': 'https://www.nature.com/articles/s41390-023-02644-9', 'title': 'Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia', 'source': 'Nature', 'date': 'May 19, 2023', 'snippet': 'This Phase 2, non-randomized, multicenter study characterized the safety \nprofile and determined appropriate dosing of ferric carboxymaltose (FCM) in \nchildren...', 'thumbnail': 'https://serpapi.com/searches/6723b4c00be2f64e8dcbb533/images/2758287e84ace32897c683c64304bdf90cc9d98d7485c037706b0a183f70425e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8832054734230042}",,,,,,,,,,['neutral'],neutral,1
NCT03564132,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0378874122001362', 'title': ""Effects of Yi-Gan-san on the psychiatric behavior of children and adolescents with Tourette's Syndrome: A randomized, double-blind, controlled preliminary study"", 'source': 'ScienceDirect.com', 'date': 'May 23, 2022', 'snippet': 'A double-blind, randomized, controlled preliminary study was conducted. A \ntotal of 38 patients with TS were assigned to the control group...', 'thumbnail': 'https://serpapi.com/searches/6723b5087f3719caf9b46c2d/images/d5b1f691716f0f966a49b3f17dfb753667a47e1ea3640afe62852493e43a5e09.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8454774022102356}",,,,,,,,,,['neutral'],neutral,1
NCT02528214,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1804093', 'title': 'Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma', 'source': 'The New England Journal of Medicine', 'date': 'May 21, 2018', 'snippet': 'Dupilumab treatment has been shown to reduce the rate of exacerbations and \nimprove lung function in patients with uncontrolled moderate-to-severe \nasthma.', 'thumbnail': 'https://serpapi.com/searches/6723b5dafda26da806ff0b7c/images/d498be2707b87a41ca8f6e745e7c345db96e1ffd1150d01f591a553133a9e085.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6738165020942688}",,,,,,,,,,['neutral'],neutral,1
NCT02493361,"{'position': 1, 'link': 'https://melanomanewstoday.com/2017/05/16/immunopulse-il-12-keytruda-combo-therapy-phase-2-trial/', 'title': 'ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial', 'source': 'Melanoma News Today', 'date': 'May 16, 2017', 'snippet': 'Learn more about the Phase 2 trial to be conducted by OncoSec in \ncollaboration with Merck, testing the efficacy of ImmunoPulse IL-12,...', 'thumbnail': 'https://serpapi.com/searches/6723b6042a488234547b502c/images/4d8a5287fbaf9fe35d39c792b1ad760eab1a62d9d67a8f9cf8ac6889da0d54a8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9118946194648743}",,,,,,,,,,['neutral'],neutral,1
NCT02614612,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.18300', 'title': 'A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease', 'source': 'Wiley Online Library', 'date': 'Jun 11, 2022', 'snippet': 'An official journal of the British Society for Haematology, the British \nJournal of Haematology offers high visibility for clinical,...', 'thumbnail': 'https://serpapi.com/searches/6723b60a81bab78d989153b2/images/2e927927eee1b0f6428f0995de0df59b0374311b45ba12587e298fbb985ede15.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8829355239868164}",,,,,,,,,,['neutral'],neutral,1
NCT02697734,"{'position': 1, 'link': 'https://cushingsdiseasenews.com/news/isturisa-found-safe-effective-cushings-long-term-trial-extension/', 'title': 'Isturisa found to be safe, effective in long-term trial extension', 'source': ""Cushing's Disease News"", 'date': 'Aug 25, 2023', 'snippet': 'Long-term treatment with Isturisa (osilodrostat) led to a sustained \nnormalization in cortisol levels, symptom relief, and improved quality of \nlife for people...', 'thumbnail': 'https://serpapi.com/searches/6723b67c0a545ab58bdb9bf1/images/5fa166bc06cbf07d4115e0979c7473ffa78763aec48a7f08d45a86e787317db6.png', 'sentiment': 'positive', 'sentiment_prob': 0.8726891875267029}",,,,,,,,,,['positive'],positive,1
NCT05184127,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/mabi.202300102', 'title': 'Current Status and Trends in Nucleic Acids for Cancer Therapy: A Focus on Polysaccharide-Based Nanomedicines', 'source': 'Wiley Online Library', 'date': 'May 22, 2023', 'snippet': 'This review will analyze the status of the ongoing clinical trials for \ncancer therapy, including vaccination and immunotherapy approaches, \nexploiting polymeric...', 'thumbnail': 'https://serpapi.com/searches/6723b6aa69f8ec9d9f4def1d/images/0bb0abf0515b258334e2d11a2f5e1199adf4ec77e52a3d4e0d81cd7e317335ab.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9422082304954529}",,,,,,,,,,['neutral'],neutral,1
NCT02578940,"{'position': 1, 'link': 'https://www.itnonline.com/content/majority-recurrent-prostate-cancer-patients-treatment-plan-changed-following-fluciclovine', 'title': ""Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT"", 'source': 'Imaging Technology News', 'date': 'Oct 4, 2017', 'snippet': 'Results presented at 2017 ASTRO Annual Meeting evaluate clinical utility of \nfluciclovine (18F) PET/CT imaging in men with recurrent prostate...', 'thumbnail': 'https://serpapi.com/searches/6723b6f564f11dda37af0411/images/de228a505701079f8cfa6cbcb183521e05be1bcf36a176164684ac57a71b7258.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8590338230133057}","{'position': 2, 'link': 'https://www.itnonline.com/content/falcon-trial-fluciclovine-petct-imaging-stops-recruitment-after-successful-interim-analysis', 'title': 'FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment After Successful Interim Analysis', 'source': 'Imaging Technology News', 'date': 'May 15, 2017', 'snippet': 'Study evaluates clinical utility of fluciclovine (18F) PET/CT imaging in \nmen with recurrent prostate cancer following prior treatment.', 'thumbnail': 'https://serpapi.com/searches/6723b6f564f11dda37af0411/images/de228a505701079fe4d171643ba2310830664d1fb3dfaabf5f451e6e37f25e66.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8319514393806458}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04292314,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/news/thalassemia-omega3-fish-oil-manuka-honey-soc-improved-oxidative-stress/', 'title': 'Adding Omega-3 Fish Oil and Manuka Honey to SOC Improved Oxidative Stress in Beta Thalassemia', 'source': 'Hematology Advisor', 'date': 'Aug 9, 2023', 'snippet': 'The addition of omega-3 fish oil and a Manuka honey lozenge to the standard \nof care treatment for beta thalassemia improved oxidative stress markers.', 'thumbnail': 'https://serpapi.com/searches/6723b770f8b05d6f6b3863cc/images/9500233d167a656620fff6c6334148f1b05cb3ce8fa98d093616c2d602a9505f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8556686043739319}",,,,,,,,,,['neutral'],neutral,1
NCT03674177,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1329426/full', 'title': 'Clinical research on RSV prevention in children and pregnant women: progress and perspectives', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': 'This review provides a comprehensive summary of RSV monoclonal antibody \n(mAb) and vaccine clinical trials registered on ClinicalTrials.gov', 'thumbnail': 'https://serpapi.com/searches/6723b7cc2a7727c0d914d6e9/images/6b0c8115f5daaa43acf9ef648143572cd678a2bb90141c4a1dbfdea3f5ca1c72.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8756221532821655}",,,,,,,,,,['neutral'],neutral,1
NCT03418090,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-xenoview-for-evaluating-lung-ventilation/', 'title': 'FDA Approves Xenoview for Evaluating Lung Ventilation', 'source': 'Medical Professionals Reference', 'date': 'Dec 29, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Xenoview™ (xenon Xe 129 \nhyperpolarized), a hyperpolarized contrast agent indicated for...', 'thumbnail': 'https://serpapi.com/searches/6723b829b9458db2487eced5/images/d3decdb20c23eeb903c4e760c43e8f3f7d65330f2e10ea9c608777e36916b128.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7300285696983337}",,,,,,,,,,['neutral'],neutral,1
NCT00852423,"{'position': 1, 'link': 'https://www.researchgate.net/publication/383703770_Population_pharmacokinetics_of_amodiaquine_and_piperaquine_in_African_pregnant_women_with_uncomplicated_Plasmodium_falciparum_infections', 'title': '(PDF) Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections', 'source': 'ResearchGate', 'date': 'Sep 4, 2024', 'snippet': 'This study aimed to evaluate the PK properties of amodiaquine and its \nactive metabolite, desethylamodiaquine, and piperaquine in women in their \nsecond and...', 'thumbnail': 'https://serpapi.com/searches/6723b99f5ed3ca2003f02bd7/images/e29f6c9f3f6baf94b70e94a7dae0d1015e39c99ce5a286770fe26c755c3db879.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.908347487449646}",,,,,,,,,,['neutral'],neutral,1
NCT01058707,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-01041-x', 'title': 'Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer', 'source': 'Nature', 'date': 'Sep 11, 2020', 'snippet': 'This Phase 1 dose-escalation/expansion study assessed safety/tolerability \nof sapanisertib, an oral, highly selective inhibitor of mTORC1/mTORC2, in \nadvanced...', 'thumbnail': 'https://serpapi.com/searches/6723b9ab6f9f639bd2671a64/images/cca7723c1dc9048e76c70d2255320132a567cd4cb87ae6357e3b690402183c3d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8821236491203308}",,,,,,,,,,['neutral'],neutral,1
NCT03544125,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-021-00232-w', 'title': 'Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies', 'source': 'Nature', 'date': 'Oct 19, 2021', 'snippet': 'In a pilot study, we evaluated the feasibility of real-time deep analysis \nof serial tumor samples from triple negative breast cancer patients.', 'thumbnail': 'https://serpapi.com/searches/6723b9ae657c66ad86b29c20/images/2a8b5b94d0e2180ec57071fa4446e84935bda88d880e26120d45b20a43d8e652.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8951044082641602}",,,,,,,,,,['neutral'],neutral,1
NCT01593696,"{'position': 1, 'link': 'https://www.onclive.com/view/tisa-cel-reinfusion-shows-potential-as-hsct-bridging-therapy-in-pediatric-b-all', 'title': 'Tisa-cel Reinfusion Shows Potential as HSCT Bridging Therapy in Pediatric B-ALL', 'source': 'OncLive', 'date': 'Feb 19, 2023', 'snippet': 'Second infusion with tisagenlecleucel after prior tisagenlecleucel infusion \nproduced short durations of minimal residual disease-negative...', 'thumbnail': 'https://serpapi.com/searches/6723b9c8be80139b2f173fcf/images/ec3d31d258f58991d5dcae278c65acb2911967ae0e44cde279bff703b3ec4834.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7540166974067688}",,,,,,,,,,['neutral'],neutral,1
NCT03986138,"{'position': 1, 'link': 'https://www.empr.com/home/news/gadopiclenol-a-new-macrocyclic-gadolinium-based-contrast-agent-gets-fda-approval/', 'title': 'Gadopiclenol, a New Macrocyclic Gadolinium-Based Contrast Agent, Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Sep 22, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved 2 new macrocyclic \ngadolinium-based contrast agents (GBCAs), Elucirem™ (gadopiclenol) and...', 'thumbnail': 'https://serpapi.com/searches/6723b9d2fc183d2d1bec010b/images/c0593d9565db63ae5d34ab12f901968b7c1697205929bc010befe2c8feef1951.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5789949893951416}",,,,,,,,,,['positive'],positive,1
NCT04401579,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2031994', 'title': 'Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Dec 11, 2020', 'snippet': 'Baricitinib plus remdesivir was superior to remdesivir alone in reducing \nrecovery time and accelerating improvement in clinical status among \npatients with...', 'thumbnail': 'https://serpapi.com/searches/6723b889b6ed33ddf7931879/images/1204dd23a4d473fc16b49e8af6492fccf9286e4d2068fa90bbc28a60cc96fead.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6585750579833984}","{'position': 2, 'link': 'https://www.conservativewoman.co.uk/remdesivir-papers-allege-controversial-drug-used-to-treat-service-members-led-to-601-deaths/', 'title': 'Lethal drug given to US service personnel – and hundreds died', 'source': 'The Conservative Woman', 'date': '2 weeks ago', 'snippet': 'A MILITARY whistleblower has released a series of documents revealing 601 \ndeaths of service personnel and a high rate of serious adverse...', 'thumbnail': 'https://serpapi.com/searches/6723b889b6ed33ddf7931879/images/1204dd23a4d473fc8822d82c945be05cf1af85bf654b90569122ded00a244d5d.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8413755893707275}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT03677934,"{'position': 1, 'link': 'https://www.optometrytimes.com/view/what-s-hot-and-not-in-retinal-news', 'title': 'What’s hot (and not) in retinal news', 'source': 'Optometry Times', 'date': 'May 12, 2022', 'snippet': 'A look at the latest developments in retinal disease, including clinical \ntrials and advanced therapies.', 'thumbnail': 'https://serpapi.com/searches/6723b88b98721769691ba202/images/7867b719df09571c74b0305fd746de531faa8ec4efe2ffc53d4d9d142f6d9472.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8849452137947083}",,,,,,,,,,['neutral'],neutral,1
NCT05579691,"{'position': 1, 'link': 'https://friedreichsataxianews.com/news/fda-lifts-partial-clinical-hold-nomlabofusp-friedreichs-ataxia/', 'title': 'Partial clinical hold on nomlabofusp for Friedreich’s ataxia lifted', 'source': ""Friedreich's Ataxia News"", 'date': 'May 28, 2024', 'snippet': ""The US Food and Drug Administration (FDA) has removed the partial hold on \nthe clinical development of nomlabofusp, an experimental treatment for \nFriedreich's..."", 'thumbnail': 'https://serpapi.com/searches/6723b9906aa3644f4ad2ecab/images/3710c96b313c16688a1036f9774d8d8e061745a7def4e116530abb53f6b4de8f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9237340092658997}","{'position': 2, 'link': 'https://friedreichsataxianews.com/news/cti-1601-high-dose-safely-raises-frataxin-fa-clinical-trial/', 'title': 'CTI-1601 at high dose safely raises frataxin levels in FA clinical trial', 'source': ""Friedreich's Ataxia News"", 'date': 'Feb 21, 2024', 'snippet': 'Daily treatment with CTI-1601, now nomlabofusp, at 50 mg dose was safe, \nwith higher frataxin levels in cells of patients in Phase 2 trial.', 'thumbnail': 'https://serpapi.com/searches/6723b9906aa3644f4ad2ecab/images/3710c96b313c16689f60c0df0fd1041e79657360d685a29a9e6c7bf18c9da3f6.png', 'sentiment': 'positive', 'sentiment_prob': 0.5327481031417847}","{'position': 3, 'link': 'https://friedreichsataxianews.com/news/higher-dose-fa-treatment-cti-1601-ole-study-win-fda-clearance/', 'title': 'Higher dose of FA treatment CTI-1601, OLE study win FDA clearance...', 'source': ""Friedreich's Ataxia News"", 'date': 'Aug 1, 2023', 'snippet': ""The US Food and Drug Administration (FDA) has greenlighted a request by \nLarimar Therapeutics to test a 50 mg dose of CTI-1601 on people with \nFriedreich's..."", 'thumbnail': 'https://serpapi.com/searches/6723b9906aa3644f4ad2ecab/images/3710c96b313c1668fc18e21285d99f4535495f9141476699daa8831386527068.png', 'sentiment': 'neutral', 'sentiment_prob': 0.627572774887085}","{'position': 4, 'link': 'https://friedreichsataxianews.com/news/first-friedreichs-ataxia-patient-dosed-ole-study-nomlabofusp/', 'title': 'First FA patient dosed in OLE study of nomlabofusp, formerly CTI-1601', 'source': ""Friedreich's Ataxia News"", 'date': 'Mar 19, 2024', 'snippet': 'The first patient has been dosed in a long-term, open-label extension (OLE) \nof a Phase 2 dose escalation study that tested nomlabofusp, formerly \nCTI-1601.', 'thumbnail': 'https://serpapi.com/searches/6723b9906aa3644f4ad2ecab/images/3710c96b313c166838ba9a9130c1c9f05e95250d3bcce17512ff52710d19ddc8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8837335109710693}","{'position': 5, 'link': 'https://friedreichsataxianews.com/friedreichs-ataxia-experimental-treatments/cti-1601/', 'title': ""CTI-1601 for Friedreich's ataxia"", 'source': ""Friedreich's Ataxia News"", 'date': 'Aug 15, 2017', 'snippet': 'Nomlabofusp, also known as CTI-1601, is a potential FA therapy by Larimar \nTherapeutics designed to increase frataxin levels.', 'thumbnail': 'https://serpapi.com/searches/6723b9906aa3644f4ad2ecab/images/3710c96b313c16681146737074ee0d82772038cd333f733f64735f38d6cb7e55.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8881443738937378}",,,,,,"['neutral', 'positive', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01941537,"{'position': 1, 'link': 'https://www.dermatologyadvisor.com/news/severe-atopic-dermatitis-may-benefit-from-fezakinumab/', 'title': 'Severe Atopic Dermatitis May Benefit From Fezakinumab', 'source': 'Dermatology Advisor', 'date': 'Feb 16, 2018', 'snippet': 'Adults with moderate to severe atopic dermatitis (AD) have demonstrated \nsustained clinical improvement and drug tolerability when treated with the \nanti–...', 'thumbnail': 'https://serpapi.com/searches/6723b8aa98d8de716e457b45/images/4ce5466aac21503ee673c26ea1434a379379b6ca8be5d553fe0b311e417b02d4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7847092151641846}",,,,,,,,,,['neutral'],neutral,1
NCT04129528,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/clinical-diabetes-and-healthcare/articles/10.3389/fcdhc.2023.1244613/full', 'title': 'Investigating the value of glucodensity analysis of continuous glucose monitoring data in type 1 diabetes: an exploratory analysis', 'source': 'Frontiers', 'date': 'Sep 11, 2023', 'snippet': 'IntroductionContinuous glucose monitoring (CGM) devices capture \nlongitudinal data on interstitial glucose levels and are increasingly \nused...', 'thumbnail': 'https://serpapi.com/searches/6723b8b375f9740b5b7a09b5/images/b080c98e915c2fe2874d5678c1b62832eb15ef692b26dc1b3da97d69c141d18c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9110513925552368}",,,,,,,,,,['neutral'],neutral,1
NCT04392830,"{'position': 1, 'link': 'https://smanewstoday.com/news/avenue-acquires-license-rights-aj201-sbma-certain-countries/', 'title': 'Avenue acquires rights to AJ201 for SBMA in certain countries |...', 'source': 'SMA News Today', 'date': 'Mar 6, 2023', 'snippet': ""A new deal gives Avenue Therapeutics exclusive rights to AnnJi's AJ201 for \nspinal and bulbar muscular atrophy (SBMA) in certain countries."", 'thumbnail': 'https://serpapi.com/searches/6723b8fcbb64ac4559af247f/images/26aed8aaed95511d153b83878e76d9fcf27c2872e88ed469879cc6f099047982.png', 'sentiment': 'neutral', 'sentiment_prob': 0.940361738204956}",,,,,,,,,,['neutral'],neutral,1
NCT02985190,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-36193-w', 'title': 'Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation', 'source': 'Nature', 'date': 'Feb 3, 2023', 'snippet': 'Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders, \nrepresenting high risk of progression to acute myeloid leukaemia,...', 'thumbnail': 'https://serpapi.com/searches/6723b92e717bffe55912f9fb/images/6b8ce168718f9d51e61af9cdf64f108d87b2857438437fac8bb5d72e6f231091.png', 'sentiment': 'negative', 'sentiment_prob': 0.6979492902755737}",,,,,,,,,,['negative'],negative,0
NCT02819635,"{'position': 1, 'link': 'https://ibdnewstoday.com/2020/12/21/rinvoq-found-safe-effective-for-ulcerative-colitis-ongoing-phase-3-trial/', 'title': 'Rinvoq Found Safe, Effective for Ulcerative Colitis in Ongoing Phase 3 Trial', 'source': 'IBD News Today', 'date': 'Dec 21, 2020', 'snippet': 'Rinvoq (upadacitinib), an anti-inflammatory, was found to be safe and \neffective in treating moderate-to-severe ulcerative colitis in adults.', 'thumbnail': 'https://serpapi.com/searches/6723b9382fab626b124a568e/images/fdb244eca877b1f32bdaf1544223d8b1e3d82dd27048c42a8657d061afe4739a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5544900298118591}","{'position': 2, 'link': 'https://www.empr.com/home/news/rinvoq-approved-for-moderately-to-severely-active-ulcerative-colitis/', 'title': 'Rinvoq Approved for Moderately to Severely Active Ulcerative Colitis - MPR', 'source': 'Medical Professionals Reference', 'date': 'Mar 17, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib) \nfor the treatment of adults with moderately to severely active ulcerative \ncolitis.', 'thumbnail': 'https://serpapi.com/searches/6723b9382fab626b124a568e/images/fdb244eca877b1f3d428f46d7495614ee52bdb25d29659545b23a15ef3a3fdf5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8225958347320557}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01159288,"{'position': 1, 'link': 'https://www.nature.com/articles/s44222-022-00008-2', 'title': 'Technological challenges of biomembrane-coated top-down cancer nanotherapy', 'source': 'Nature', 'date': 'Jan 31, 2023', 'snippet': 'Top-down drug delivery strategies, including exosomes and cell \nmembrane-coated particles, can improve safety and efficacy owing to the \ninnate biointerfacial...', 'thumbnail': 'https://serpapi.com/searches/6723ba845416d8fd44a55d3e/images/3e7cc3b7a4a7512443d6286962d2ccb9281c19e8e038260452d727f0b6323097.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.48859986662864685}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/10.1002/ctm2.1448', 'title': 'Haematopoietic cell-derived exosomes in cancer development and therapeutics: From basic science to clinical practice', 'source': 'Wiley Online Library', 'date': 'Oct 13, 2023', 'snippet': 'The tumour microenvironment (TME) is a specialised niche involving \nintercellular communication among cancer cells and various host cells.', 'thumbnail': 'https://serpapi.com/searches/6723ba845416d8fd44a55d3e/images/3e7cc3b7a4a7512416d44792689d7df15c9adf8d0813f0b79004822eccc82490.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9238121509552002}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03186989,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02326-3', 'title': 'in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial', 'source': 'Nature', 'date': 'Apr 24, 2023', 'snippet': 'We sought to inhibit MAPT expression with a tau-targeting antisense \noligonucleotide (MAPT Rx ) and reduce tau levels in patients with mild AD.', 'thumbnail': 'https://serpapi.com/searches/6723ba8a059caf650f19bc72/images/369b284e08088b4229f951eff0513dea045141caacacc67c6eca08925395dfa4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8654584288597107}","{'position': 2, 'link': 'https://alzheimersnewstoday.com/news/biib080-shows-alzheimers-related-tau-protein-reduction-study/', 'title': ""BIIB080 shows Alzheimer's-related tau protein reduction in study |..."", 'source': ""Alzheimer's News Today"", 'date': 'Mar 31, 2023', 'snippet': ""New PET data from the Phase 1b extension study showed tau aggregation was \nreduced across all tested Alzheimer's patients brain regions."", 'thumbnail': 'https://serpapi.com/searches/6723ba8a059caf650f19bc72/images/369b284e08088b42512abe078dd3dabf72c89844b7e3cf59c3daceeb9a6e9adf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7541296482086182}","{'position': 3, 'link': 'https://www.researchgate.net/figure/Percent-free-from-Alzheimers-dementia-Kaplan-Meier-curves-were-generated-from_fig1_338994482', 'title': 'Percent free from Alzheimer’s dementia Kaplan–Meier curves were...', 'source': 'ResearchGate', 'date': 'Nov 18, 2020', 'snippet': ""Download scientific diagram | Percent free from Alzheimer's dementia \nKaplan–Meier curves were generated from Alzheimer's dementia cases and \ncognitively..."", 'thumbnail': 'https://serpapi.com/searches/6723ba8a059caf650f19bc72/images/369b284e08088b42f8a331a24339fe7e5d3ed84d5a87e7a1aa65b630e67366a2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8985739350318909}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00331955,"{'position': 1, 'link': 'https://www.nature.com/articles/6605293', 'title': 'Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker', 'source': 'Nature', 'date': 'Sep 8, 2009', 'snippet': 'Histone deacetylase inhibitors (HDACi) can sensitise cancer cells to \ntopoisomerase inhibitors by increasing their access and binding to DNA.', 'thumbnail': 'https://serpapi.com/searches/6723ba949fd30930f1a86922/images/dc77ba92e9d1b613798e28edb5be5a787359e8ad900edc9e516ba687bcf767d2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8336589932441711}",,,,,,,,,,['neutral'],neutral,1
NCT03478891,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/investigational-monoclonal-antibody-treat-ebola-safe-adults', 'title': 'Investigational monoclonal antibody to treat Ebola is safe in adults', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jan 25, 2019', 'snippet': 'The investigational Ebola treatment mAb114 is safe, well-tolerated, and \neasy to administer, according to findings from an early-stage clinical \ntrial published...', 'thumbnail': 'https://serpapi.com/searches/6723baf17ef9fa2958e90dd9/images/49db16959d81e73f87a1dcba932c4b157cdeffddee8939ad384d0fbae0a19948.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6047368049621582}",,,,,,,,,,['positive'],positive,1
NCT02136914,"{'position': 1, 'link': 'https://www.nature.com/articles/s41531-022-00291-1', 'title': 'Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease', 'source': 'Nature', 'date': 'Mar 18, 2022', 'snippet': 'An amantadine delayed release/extended release (DR/ER) formulation (Gocovri \n® ) indicated for dyskinesia received additional FDA approval as an adjunct \nto...', 'thumbnail': 'https://serpapi.com/searches/6723baf9d16915e4d3acbd51/images/8e7accc706b56382bfd30b46a4d75e71d0dffcc6791ef4e42fcf013a9edf7d08.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6950205564498901}",,,,,,,,,,['neutral'],neutral,1
NCT02562755,"{'position': 1, 'link': 'https://www.genengnews.com/news/pexa-vec-nexavar-combination-fails-phase-iii-trial-in-liver-cancer/', 'title': 'Pexa-Vec/Nexavar Combination Fails Phase III Trial in Liver Cancer', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Aug 2, 2019', 'snippet': 'SillaJen and collaboration partner Transgene today separately acknowledged \nthe failure of their lead product Pexa-Vec (pexastimogene...', 'thumbnail': 'https://serpapi.com/searches/6723bb0251d84d25a324abe8/images/9f87ac300026344c5a6f96d4219991e23d15193b3fb5504f43ee7bf5296cbf5e.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7049565315246582}",,,,,,,,,,['negative'],negative,0
NCT02536404,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00061-2/fulltext', 'title': 'Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies', 'source': 'The Lancet', 'date': 'Mar 2, 2023', 'snippet': 'Etrasimod as induction and maintenance therapy for ulcerative colitis \n(ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies', 'thumbnail': 'https://serpapi.com/searches/6723bb06caddc353d22fa5a3/images/770190240893f28ec33812a4303ea0a60351ab1ea0768e810c29b198f877f233.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7826459407806396}",,,,,,,,,,['neutral'],neutral,1
NCT04551950,"{'position': 1, 'link': 'https://www.aacr.org/blog/2024/03/27/editors-picks-march-2024-synergys-impact-on-resistance-new-early-detection-tools-and-more/', 'title': 'Editors’ Picks, March 2024: Synergy’s Impact on Resistance, New Early Detection Tools, and More', 'source': 'American Association for Cancer Research', 'date': 'Mar 27, 2024', 'snippet': 'Studies of antibiotic combinations show that synergistic drug interactions \ncan accelerate the emergence of resistance.', 'thumbnail': 'https://serpapi.com/searches/6723bb4b18787d7fa1f0d295/images/23c05343ed949f3a5f79122c58dad3336893a7910e491d6385f1a78e4d74339f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8679391145706177}",,,,,,,,,,['neutral'],neutral,1
NCT02371369,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30764-0/fulltext', 'title': 'Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial', 'source': 'The Lancet', 'date': 'Jun 19, 2019', 'snippet': 'Tenosynovial giant cell tumour (TGCT), a rare, locally aggressive neoplasm, \noverexpresses colony-stimulating factor 1 (CSF1).', 'thumbnail': 'https://serpapi.com/searches/6723bb5517a2e2709600a414/images/7d3f193906622a767f5cf7794b86933b63f4e49cb6002891f0d184c82c209d25.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8731662631034851}",,,,,,,,,,['neutral'],neutral,1
NCT02997358,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa2403394', 'title': 'Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 4, 2024', 'snippet': 'We conducted a phase 3 trial involving patients with metastatic or \nunresectable leiomyosarcoma who had not received chemotherapy previously.', 'thumbnail': 'https://serpapi.com/searches/6723bb7d358539e84cebd4c9/images/46b1a26111fb3c1ae2637ce04f03849953ff15f3eb6420a17173c61ba611e1c1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9007108211517334}",,,,,,,,,,['neutral'],neutral,1
NCT02955823,"{'position': 1, 'link': 'https://lymphomahub.com/medical-information/chemo-free-combination-of-lenalidomide-rituximab-in-elderlyfrail-patients-with-mcl-and-dlbcl', 'title': 'Chemo-free combination of lenalidomide + rituximab in elderly/frail patients with MCL and DLBCL', 'source': 'Lymphoma Hub', 'date': 'Jan 24, 2022', 'snippet': 'The Lymphoma & CLL Hub is an independent medical education platform, \nsponsored by Beigene and Roche, and supported through educational...', 'thumbnail': 'https://serpapi.com/searches/6723bb80b7d31db0b3f97e88/images/0958f5f2f1667aa4e784c56a5508b1b8b06c9ed91f403279fc31a433a60769f5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8440457582473755}",,,,,,,,,,['neutral'],neutral,1
NCT03184467,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/gv1001-shows-promise-moderate-severe-alzheimers-phase-2-trial-data/', 'title': ""GV1001 Shows Promise in Moderate to Severe Alzheimer's, Study Says"", 'source': ""Alzheimer's News Today"", 'date': 'Apr 12, 2021', 'snippet': ""Treatment with GV1001 provided benefits for adults with moderate to severe \nAlzheimer's, who take Aricept for dementia, Phase 2 trial show."", 'thumbnail': 'https://serpapi.com/searches/6723bbaac024d1935d72ca6d/images/56272523e784133f4e2702f7a851dec6fdfdc7c8617d40b439acba2f3ed1a4ea.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5016673803329468}",,,,,,,,,,['positive'],positive,1
NCT03079167,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2119660', 'title': 'Trial of Erythropoietin for Hypoxic–Ischemic Encephalopathy in Newborns', 'source': 'The New England Journal of Medicine', 'date': 'Jul 13, 2022', 'snippet': 'Neonatal hypoxic–ischemic encephalopathy is an important cause of death as \nwell as long-term disability in survivors.', 'thumbnail': 'https://serpapi.com/searches/6723bbb490adceb1fd425edc/images/426ce5ebcb260c3ff36290775f3844eae9285eb930e1a44d99cfd69580ccaa6f.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6995729804039001}","{'position': 2, 'link': 'https://www.nature.com/articles/s41390-022-02295-2', 'title': 'Neuroprotective therapies in the NICU in term infants: present and future', 'source': 'Nature', 'date': 'Oct 4, 2022', 'snippet': 'Outcomes of neonatal encephalopathy (NE) have improved since the widespread \nimplementation of therapeutic hypothermia (TH) in high-resource...', 'thumbnail': 'https://serpapi.com/searches/6723bbb490adceb1fd425edc/images/426ce5ebcb260c3f41872b463a42702ea54893a922671d2a23b3bb69df536623.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5098544359207153}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT02870634,"{'position': 1, 'link': 'https://alsnewstoday.com/news/new-study-uncovers-mechanism-cuatsm-als-therapy-now-trials/', 'title': 'New Study Uncovers Mechanism of CuATSM, ALS Therapy Now in Trials...', 'source': 'ALS News Today', 'date': 'Nov 2, 2022', 'snippet': ""CuATSM, a potential amyotrophic lateral sclerosis (ALS) therapy that's now \nin clinical trials, may work by altering how certain cells in the brain \ngenerate..."", 'thumbnail': 'https://serpapi.com/searches/6723bbbabe324f73dd70cc39/images/228774c88c95b6c363888d926bab2f1e07a36883792ffb43be337fc44fdb0755.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8705291748046875}",,,,,,,,,,['neutral'],neutral,1
NCT03829722,"{'position': 1, 'link': 'https://healthcare-in-europe.com/en/news/radiation-therapy-oropharynx-cancer-fdg-pet.html', 'title': 'De-escalating radiation therapy for oropharynx cancer with FDG-PET', 'source': 'healthcare-in-europe.com', 'date': 'Nov 29, 2022', 'snippet': 'Using fluorodeoxyglucose positron emission tomography (FDG-PET) imaging may \ngive insights into possible dose reductions in ongoing radiation...', 'thumbnail': 'https://serpapi.com/searches/6723bbbda5aae9317e5b898b/images/4d1e1332f4a9185b5015568a35ddeb9558563d3f0d2dc49664ee25f3cc394243.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9167354702949524}",,,,,,,,,,['neutral'],neutral,1
NCT04564833,"{'position': 1, 'link': 'https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00541-2/fulltext', 'title': 'Effects of RBT-1 on preconditioning response biomarkers in patients undergoing coronary artery bypass graft or heart valve surgery: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial', 'source': 'The Lancet', 'date': 'Jan 8, 2024', 'snippet': 'RBT-1 is a combination drug of stannic protoporfin (SnPP) and iron sucrose \n(FeS) that elicits a preconditioning response through activation of \nantioxidant,...', 'thumbnail': 'https://serpapi.com/searches/6723bbd15ddfba6b641faa86/images/88dedac8bce83c7ed09c39a6f75c512782c9d06c4a33311e73e81845ce12e376.png', 'sentiment': 'neutral', 'sentiment_prob': 0.865233302116394}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/renibus-announces-first-patient-enrolled-in-protect-phase-3-study-of-rbt-1-to-reduce-post-operative-complications-after-cardiothoracic-surgery-301967256.html', 'title': 'Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complications After Cardiothoracic Surgery', 'source': 'PR Newswire', 'date': 'Oct 25, 2023', 'snippet': 'PRNewswire/ -- Renibus Therapeutics® (""Renibus""), a clinical-stage \nbiopharmaceutical company focusing on the prevention and treatment of...', 'thumbnail': 'https://serpapi.com/searches/6723bbd15ddfba6b641faa86/images/88dedac8bce83c7e099e13b8348ce1db0b9659fd16c2a57c3f9bb82cc0d46b77.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8609927892684937}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04202679,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/significant-improvements-observed-with-dupilumab-in-prurigo-nodularis-trial/', 'title': 'Significant Improvements Observed With Dupilumab in Prurigo Nodularis Trial', 'source': 'Medical Professionals Reference', 'date': 'Jan 19, 2022', 'snippet': 'Patients with prurigo nodularis treated with dupilumab experienced a \nclinically significant reduction in itch, according to new phase 3 data.', 'thumbnail': 'https://serpapi.com/searches/6723bbd71397ba0102a6af7d/images/22a7ef5d5522bc95e384e0d792d10592a4ad44d4e587d8902b7a4b7e6d8b0476.png', 'sentiment': 'positive', 'sentiment_prob': 0.6337721347808838}",,,,,,,,,,['positive'],positive,1
NCT03729219,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30571-7/fulltext', 'title': 'Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial', 'source': 'The Lancet', 'date': 'Nov 19, 2019', 'snippet': 'Enterotoxigenic Escherichia coli causes diarrhoea, leading to substantial \nmortality and morbidity in children, but no specific vaccine...', 'thumbnail': 'https://serpapi.com/searches/6723bbdbb28e6b49d942248a/images/83fae9147f81b3d16dceb832bbd360dea7bd54dc685171efd511d955c5c98c36.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8389658331871033}",,,,,,,,,,['neutral'],neutral,1
NCT03910244,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa2312749', 'title': 'Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia', 'source': 'The New England Journal of Medicine', 'date': '1 month ago', 'snippet': 'We conducted a randomized, placebo-controlled trial to evaluate the safety \nand efficacy of pomalidomide for the treatment of HHT.', 'thumbnail': 'https://serpapi.com/searches/6723bbdf3ad34d91d84c6166/images/19b5b593a5b3cefb49e7ff06f244140afd18d8c47236fbdbead6417893e2e6f4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8589326739311218}",,,,,,,,,,['neutral'],neutral,1
NCT01441635,"{'position': 1, 'link': 'https://endometriosisnews.com/2017/04/17/endometriosis-therapy-elagolix-reduces-menstrual-bleeding-women-uterine-fibroids/', 'title': 'Endometriosis Therapy Elagolix Also Reduces Menstrual Bleeding in Women with Uterine Fibroids, Says AbbVie', 'source': 'endometriosisnews.com', 'date': 'Apr 17, 2017', 'snippet': ""AbbVie's investigational drug elagolix (ABT-620) decreased heavy menstrual \nbleeding and improved quality of life in women with uterine fibroids."", 'thumbnail': 'https://serpapi.com/searches/6723bbeaf7adbffe3f0d7cce/images/2c30e50e8812cbe888ad9804e66262e4a1d2276d552129da0dfd968444be97aa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5828814506530762}",,,,,,,,,,['neutral'],neutral,1
NCT02660944,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/most-benefit-rslv-132-seen-patients-more-active-sle-trial/', 'title': 'Most benefit of RSLV-132 seen in patients with more active SLE', 'source': 'Lupus News Today', 'date': 'Feb 19, 2024', 'snippet': 'RSLV-132 failed to lessen damage caused by skin lesions in SLE in a trial, \nbut tended to ease symptoms in patients with more active disease.', 'thumbnail': 'https://serpapi.com/searches/6723bc80c76a22c3c0f84968/images/5fe1b636950dbfce1e51c5007adeda4f99f3bfb3c58d0d28c11c578d148b9cdf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5446957945823669}",,,,,,,,,,['neutral'],neutral,1
NCT01165177,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1501184', 'title': 'Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults', 'source': 'The New England Journal of Medicine', 'date': 'Apr 28, 2015', 'snippet': 'In previous phase 1–2 clinical trials involving older adults, a subunit \nvaccine containing varicella–zoster virus glycoprotein E and the...', 'thumbnail': 'https://serpapi.com/searches/6723bca98b7ba7b61e2cc441/images/04dd0487b1835f53696e0aa4e5bd2b2a00a00397c34c71c95b97dffb06acbb80.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9057449102401733}","{'position': 2, 'link': 'https://www.infectiousdiseaseadvisor.com/news/vaccine-lessens-incidence-of-herpes-zoster-complications-in-immuncompetent-older-adults/', 'title': 'Vaccine Lessens Incidence of Herpes Zoster Complications in Immuncompetent Older Adults', 'source': 'Infectious Disease Advisor', 'date': 'Apr 6, 2018', 'snippet': 'Researchers reviewed clinical trial data to evaluate the efficacy of herpes \nzoster subunit vaccine in preventing complications,...', 'thumbnail': 'https://serpapi.com/searches/6723bca98b7ba7b61e2cc441/images/04dd0487b1835f534a56c5bc6aad09683c341e7bdbaf029c8eabd9f5a18e8f3e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8871312737464905}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03277313,"{'position': 1, 'link': 'https://www.contemporarypediatrics.com/view/fda-approves-expansion-of-primary-immunodeficiency-medicine-for-treatment-in-children', 'title': 'FDA approves expansion of primary immunodeficiency medicine for treatment in children', 'source': 'Contemporary Pediatrics', 'date': 'Apr 14, 2023', 'snippet': 'The FDA recently approved Hyqvia, expanding its use to treat pediatric \npatients with primary immunodeficiency (PI) aged 2 to 16 years.', 'thumbnail': 'https://serpapi.com/searches/6723bcab8d1473ed5bed2dd8/images/42e5b18a33970733966e432007a56fd1bfe2016e051f39b44b53dbf752c00959.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.524799108505249}","{'position': 2, 'link': 'https://www.empr.com/home/news/hygvia-approval-expanded-to-include-children-with-primary-immunodeficiency/', 'title': 'HyQvia Approval Expanded to Include Children With Primary Immunodeficiency', 'source': 'Medical Professionals Reference', 'date': 'Apr 11, 2023', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of HyQvia \n(immune globulin [IG] infusion 10% [human] with recombinant human \nhyaluronidase)', 'thumbnail': 'https://serpapi.com/searches/6723bcab8d1473ed5bed2dd8/images/42e5b18a33970733b0799a8a35006d7fb1d6539d3d2bc49c6c307f98cee197fd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7432705760002136}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01810939,"{'position': 1, 'link': 'https://ckdnews.com/2016/11/07/data-veltassa-treatment-high-blood-potassium-ckd-patients-set-kidney-week-2016/', 'title': 'Data on Veltassa, Treatment for High Blood Potassium in CKD Patients, Set for Kidney Week 2016', 'source': 'ckdnews.com', 'date': 'Nov 7, 2016', 'snippet': 'Relypsa will report new and updated analyses from several trials evaluating \nVeltassa (patiromer for oral suspension) in treating hyperkalemia.', 'thumbnail': 'https://serpapi.com/searches/6723bcbd1a5b5420bf6887b9/images/8c4d554266d0bef7d2dd216b4ac4083442658e3f571727203324485c937cf4bb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9409993886947632}",,,,,,,,,,['neutral'],neutral,1
NCT00220233,"{'position': 1, 'link': 'https://www.nature.com/articles/hr201426', 'title': 'Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone', 'source': 'Nature', 'date': 'Jun 19, 2014', 'snippet': 'The olmesartan/amlodipine combination effectively reduces BP over 24 h, \nincluding the morning hours, in a dose-related manner.', 'thumbnail': 'https://serpapi.com/searches/6723bc114677bf6b4cf32d1f/images/3a668cec2c257f169931faa40969c96ddf4794da9f6b5e3cc1be5d55b39653b4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6604747772216797}",,,,,,,,,,['neutral'],neutral,1
NCT01080391,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1411321', 'title': 'Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma', 'source': 'The New England Journal of Medicine', 'date': 'Dec 6, 2014', 'snippet': 'The combination of the proteasome inhibitor carfilzomib with lenalidomide \nand dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed \nmultiple...', 'thumbnail': 'https://serpapi.com/searches/6723bc15d9c3e65ff681f4c4/images/42cabbb68a838447e5aedc2e5937c9c6f0d7ac1de5804a9ac60cbd71d7e0f461.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7921257019042969}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/kyprolis-improved-survival-confirmed-latest-results/', 'title': 'Long-term Data Confirm Kyprolis Survival Benefit in Relapsed...', 'source': 'Myeloma Research News', 'date': 'Sep 6, 2017', 'snippet': 'New long-term data from the ENDEAVOR trial shows that Kyprolis plus \ndexamethasone extends the median survival by 9 months over Velcade in...', 'thumbnail': 'https://serpapi.com/searches/6723bc15d9c3e65ff681f4c4/images/42cabbb68a838447b4201805bfcc3208fc942b7af9dea2559641d416dd01c2d0.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5090252161026001}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT01489059,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0328-y', 'title': 'Cytokines in clinical cancer immunotherapy', 'source': 'Nature', 'date': 'Nov 9, 2018', 'snippet': 'In this review, we provide an overview of the novel trends in the cytokine \nimmunotherapy field that are yielding therapeutic agents for clinical \ntrials.', 'thumbnail': 'https://serpapi.com/searches/6723bc3fd78a98c21a5e1951/images/52678c2625aee4ed1c8f59f28ab828424a9a35effbed163d9f7c75c93fb75e7d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7964982390403748}",,,,,,,,,,['neutral'],neutral,1
NCT03359980,"{'position': 1, 'link': 'https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00288-2/fulltext', 'title': 'Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial', 'source': 'The Lancet', 'date': 'Jul 26, 2023', 'snippet': 'Failure of gastrointestinal acute graft-versus-host disease (GI-aGvHD) to \nrespond to steroid therapy is associated with limited further...', 'thumbnail': 'https://serpapi.com/searches/6723bc45e6862b091b6e944d/images/329b4ce82d97a313f7d8d1d7d26212de71ac81dc3c822b778247f795005b2bd3.png', 'sentiment': 'negative', 'sentiment_prob': 0.5754161477088928}",,,,,,,,,,['negative'],negative,0
NCT02131636,"{'position': 1, 'link': 'https://www.dermatologyadvisor.com/news/topical-oxymetazoline-effective-for-reducing-rosacea-associated-erythema/', 'title': 'Topical Oxymetazoline Effective for Reducing Rosacea-Associated Erythema', 'source': 'Dermatology Advisor', 'date': 'Mar 2, 2018', 'snippet': 'In REVEAL 1 and REVEAL 2, participants were randomly assigned to treatment \nwith oxymetazoline or vehicle once daily for 29 days and were...', 'thumbnail': 'https://serpapi.com/searches/6723bc4cacf7f88b430d5fe4/images/9155c5b454a7f915417fcd78014bff3cddfc0fcb239e279893cd05b8a27a1a6b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7858423590660095}",,,,,,,,,,['neutral'],neutral,1
NCT02666664,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1803917', 'title': 'Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol', 'source': 'The New England Journal of Medicine', 'date': 'Mar 13, 2019', 'snippet': 'In this 52-week trial, bempedoic acid added to maximally tolerated statin \ntherapy did not lead to a higher incidence of overall adverse events than \nplacebo.', 'thumbnail': 'https://serpapi.com/searches/6723bc5b71b0e8d30badc758/images/160058833313ce2f9b6f09c06abe79524eabac13a4ef52f27cd7525905566a07.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7770769596099854}",,,,,,,,,,['neutral'],neutral,1
NCT00551928,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1402888', 'title': 'Autologous Transplantation and Maintenance Therapy in Multiple Myeloma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 4, 2014', 'snippet': 'This open-label, randomized, phase 3 study compared melphalan at a dose of \n200 mg per square meter of body-surface area plus autologous...', 'thumbnail': 'https://serpapi.com/searches/6723bc67e9b6914d2fbe69e0/images/522cee8e121a6e04983a73b9baabc6a7757696c95ee9f4057024542c49115484.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9010096788406372}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/study-reports-that-myeloma-patients-who-receive-maintenance-therapy-revlimid-live-longer/', 'title': 'Myeloma Patients Who Receive the Maintenance Therapy Revlimid Live Longer, Study Shows', 'source': 'Myeloma Research News', 'date': 'Aug 16, 2017', 'snippet': 'Read about a study reporting that myeloma patients who take Revlimid after \na stem cell transplant live significantly longer than those who...', 'thumbnail': 'https://serpapi.com/searches/6723bc67e9b6914d2fbe69e0/images/522cee8e121a6e04a219b873c19db95442a899e554a393d832884008a88ae5a5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6481115818023682}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01721057,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/news/targeted-jak-inhibition-effective-ra-treatment-in-csdmard-inadequate-responders/', 'title': 'Targeted JAK Inhibition Effective RA Treatment in csDMARD-Inadequate Responders', 'source': 'Rheumatology Advisor', 'date': 'Oct 12, 2016', 'snippet': 'Summary and Clinical Applicability In patients with moderate to severely \nactive RA who had failed prior treatment with or have interollance...', 'thumbnail': 'https://serpapi.com/searches/6723bc73f41044ef14218192/images/a81e326fb4c7bb4dd8d73d8299350e5e6636c70b604fa8d8ccb7b9553873ff94.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7526852488517761}",,,,,,,,,,['neutral'],neutral,1
NCT00477815,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Median-dose-in-mCi-of-90-Y-Zevalin-to-achieve-Gy-target-to_tbl2_319472701', 'title': 'Median dose in mCi of 90 Y Zevalin to achieve Gy target to', 'source': 'ResearchGate', 'date': 'Mar 2, 2020', 'snippet': 'This phase 1 study (clinical trial NCT00477815) was conducted to determine \nthe maximum tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan \n(90Y-Zevalin)...', 'thumbnail': 'https://serpapi.com/searches/6723bdad9872176e6669bb33/images/782d814062a86c14708a93a9a783e7f55d58bd0d399ddb38a6e820b9431e973d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8649235367774963}",,,,,,,,,,['neutral'],neutral,1
NCT03512756,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/patients-with-metastatic-pancreatic-cancer-who-reported-higher-daily-step-counts-had-greater-qol-on-sm-88', 'title': 'Patients With Metastatic Pancreatic Cancer Who Reported Higher Daily Step Counts Had Greater QoL on SM-88', 'source': 'Cancer Network', 'date': 'Jan 18, 2021', 'snippet': 'A preliminary exploratory analysis from part 2 of the phase 2/3 \nTYME-88-Panc trial (NCT03512756) of SM-88 (racemetyrosine) in patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/6723bdd29e38e54024ff1b39/images/098913c5c580a6c41330c48c998af4e853a9667418c7c71c56104fc5d089fa43.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9106556177139282}",,,,,,,,,,['neutral'],neutral,1
NCT02774187,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-00264-x', 'title': 'Targeted therapy for hepatocellular carcinoma - Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': 'Aug 11, 2020', 'snippet': 'The last 3 years have seen the emergence of promising targeted therapies \nfor the treatment of hepatocellular carcinoma (HCC).', 'thumbnail': 'https://serpapi.com/searches/6723bdeab9458db70e907e5f/images/192077fe220a3ae0fe5f44f2269ae7162dbd4dd1e015605a0b6cec716bbc1b84.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6826193332672119}",,,,,,,,,,['neutral'],neutral,1
NCT03052127,"{'position': 1, 'link': 'https://melanomanewstoday.com/2017/04/04/phase-1-eye-melanoma-trial-evaluates-less-invasive-treatment-approach/', 'title': 'Phase 1 Eye Melanoma Trial Evaluates Less-invasive Treatment Approach', 'source': 'Melanoma News Today', 'date': 'Apr 4, 2017', 'snippet': 'The trial (NCT03052127), which is being conducted at Wills Eye Hospital in \nPhiladelphia, will test the light-activated drug AU-001 in small to medium \nprimary...', 'thumbnail': 'https://serpapi.com/searches/6723bd62f79a019b57ddaf25/images/bf2fcfcdac1ad6cc104d7042f1af50178cf960d2e1db986d751d090968ac87a7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9085409045219421}",,,,,,,,,,['neutral'],neutral,1
NCT02293863,"{'position': 1, 'link': 'https://www.nature.com/articles/d41587-019-00013-8', 'title': 'Drug makers chase anti-flu pill', 'source': 'Nature', 'date': 'May 12, 2019', 'snippet': 'Drug makers are targeting flu virus vulnerabilities to develop antivirals \nthat not only stop infections in their tracks, but also temper emergence of \ndrug...', 'thumbnail': 'https://serpapi.com/searches/6723bd7bfcd69ee1d5dd4ef0/images/e87f6baf91a71ac1e4d10f3445f8c7805accc2e4ed60d7211c90ff2fd80a37c9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7620350122451782}",,,,,,,,,,['neutral'],neutral,1
NCT03238963,"{'position': 1, 'link': 'https://www.nature.com/articles/s41433-024-03017-0', 'title': 'ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathy | Eye', 'source': 'Nature', 'date': 'May 28, 2024', 'snippet': 'To evaluate the safety and efficacy of BI 1467335 in patients with \nnon-proliferative diabetic retinopathy (NPDR). ROBIN is a Phase IIa,...', 'thumbnail': 'https://serpapi.com/searches/6723bdfe52a04e946bb2950c/images/e861d9bf174740a428a6769f7ac2580c657515f5f0edd25257df1a7f86acf928.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8770884275436401}",,,,,,,,,,['neutral'],neutral,1
NCT01629758,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0328-y', 'title': 'Cytokines in clinical cancer immunotherapy', 'source': 'Nature', 'date': 'Nov 9, 2018', 'snippet': 'In this review, we provide an overview of the novel trends in the cytokine \nimmunotherapy field that are yielding therapeutic agents for clinical \ntrials.', 'thumbnail': 'https://serpapi.com/searches/6723be1754163dba153e41b9/images/ab87ca260f64d4ddab1e2cf482867dfe10d300c3e12bbe44245680c2d5e32af3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7964982390403748}",,,,,,,,,,['neutral'],neutral,1
NCT01812616,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-021-01259-3', 'title': 'A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma | British Journal of Cancer', 'source': 'Nature', 'date': 'Feb 24, 2021', 'snippet': 'Preclinical data suggest some cannabinoids may exert antitumour effects \nagainst glioblastoma (GBM). Safety and preliminary efficacy of...', 'thumbnail': 'https://serpapi.com/searches/6723be2917b10e8d8c7765de/images/0925fd098e31048b175508d5a4600d0047d04285c7971693a504b23d67c14757.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9131330251693726}",,,,,,,,,,['neutral'],neutral,1
NCT06097273,"{'position': 1, 'link': 'https://www.genengnews.com/topics/drug-discovery/stockwatch-analysts-mixed-on-moderna-despite-750m-financing-vaccine-updates/', 'title': 'StockWatch: Analysts Mixed on Moderna Despite $750M Financing, Vaccine Updates', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Apr 1, 2024', 'snippet': 'Analysts remain decidedly mixed in their assessment of Moderna despite a \nflurry of financing and clinical updates at its recent Vaccine Day.', 'thumbnail': 'https://serpapi.com/searches/6723be5e15c740d14127ec0b/images/b04a0176f946f1b3884efdecc2c9941cd3a0d8934205c4d159a4b8f70dbe0198.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.608450710773468}",,,,,,,,,,['neutral'],neutral,1
NCT03985293,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20230625157557/en/Pfizer-Provides-Update-on-GLP-1-RA-Clinical-Development-Program-for-Adults-with-Obesity-and-Type-2-Diabetes-Mellitus', 'title': 'Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus', 'source': 'Business Wire', 'date': 'Jun 26, 2023', 'snippet': 'Pfizer Inc. (NYSE: PFE) today announced its decision to continue to \nprogress one oral late-stage glucagon-like peptide-1 receptor agonist...', 'thumbnail': 'https://serpapi.com/searches/6723be82f922f69a88ec5daa/images/62ffb0cbf831a756732f0c5eb72dd8b79716d15a022cf09dac041ff5e507db25.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9171797037124634}",,,,,,,,,,['neutral'],neutral,1
NCT02453256,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30318-0/abstract', 'title': 'Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial', 'source': 'The Lancet', 'date': 'Aug 28, 2020', 'snippet': 'A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in \nsystemic sclerosis. We assessed skin fibrosis and systemic...', 'thumbnail': 'https://serpapi.com/searches/6723be8be8735a1b3a72487d/images/25a82e5e23b98bf182f22c997ef6c037d9863fbf449c747a2185ec56a0d1ba1d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7601886987686157}","{'position': 2, 'link': 'https://www.empr.com/home/news/actemra-tocilizumab-injection-pulmonary-function-systemic-sclerosis-interstitial-lung-disease/', 'title': 'Actemra Gains New Indication for Systemic Sclerosis-Associated Interstitial Lung Disease', 'source': 'Medical Professionals Reference', 'date': 'Mar 5, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Actemra (tocilizumab; \nGenentech) subcutaneous injection for slowing the rate of decline in \npulmonary...', 'thumbnail': 'https://serpapi.com/searches/6723be8be8735a1b3a72487d/images/25a82e5e23b98bf18d320586e3a6717a143e91fa8b839546f270d8a2a8bec775.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7725078463554382}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00292045,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-022-01876-6', 'title': 'Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity | British Journal of Cancer', 'source': 'Nature', 'date': 'Jul 28, 2022', 'snippet': 'Over the past decade, tremendous progress has taken place in tumour \nimmunotherapy, relying on the fast development of combination therapy...', 'thumbnail': 'https://serpapi.com/searches/6723bec77ebde5eeab29f23c/images/2de0e2dcfd40d577928f9d240e34ae277b1f47fed6194554549046320cd7107f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7099482417106628}",,,,,,,,,,['neutral'],neutral,1
NCT01721148,"{'position': 1, 'link': 'https://breastcancer-news.com/2017/02/08/new-drug-shown-to-effectively-block-breast-cancer-bone-degradation/', 'title': 'Breast Cancer Patients with Bone Degradation May Benefit from Drug in Clinical Testing', 'source': 'breastcancer-news.com', 'date': 'Feb 8, 2017', 'snippet': 'A new oral drug in a first-in-human clinical trial has shown promise in \ninhibiting the bone degradation caused by breast cancer cells.', 'thumbnail': 'https://serpapi.com/searches/6723bf06dda9d9c73b31bfd1/images/da9870d9ea6ad915a848a285e9ccb1af06208193a32dc6fb2a9e7c8b5c442605.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6646877527236938}",,,,,,,,,,['neutral'],neutral,1
NCT05876767,"{'position': 1, 'link': 'https://www.nature.com/articles/s41435-023-00221-y', 'title': 'IL-2 immunotherapy for targeting regulatory T cells in autoimmunity', 'source': 'Nature', 'date': 'Sep 23, 2023', 'snippet': 'A new and promising focus in drug development are IL-2-based approaches for \nin vivo targeted expansion of T reg or for enhancement of their \nsuppressive...', 'thumbnail': 'https://serpapi.com/searches/6723bf12e335ec621cd245ff/images/16dcf4b1db34ff3deb9b6bb074109925a5c723f5f19cd2702855903454663198.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6119940280914307}",,,,,,,,,,['neutral'],neutral,1
NCT04101721,"{'position': 1, 'link': 'https://www.empr.com/home/news/eylea-approved-for-preterm-infants-with-retinopathy-of-prematurity/', 'title': 'Eylea Approved for Preterm Infants With Retinopathy of Prematurity', 'source': 'Medical Professionals Reference', 'date': 'Feb 9, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Eylea (aflibercept) for \nthe treatment of preterm infants with retinopathy of prematurity (ROP).', 'thumbnail': 'https://serpapi.com/searches/6723bf296531cb46dc2de16b/images/d7a5f5d0420ccf410d69e501cc0c7813b8c7825726af08bee1476a9099158a2f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8532078266143799}",,,,,,,,,,['neutral'],neutral,1
NCT01395641,"{'position': 1, 'link': 'https://www.cgtlive.com/view/upstaza-approved-aadc-deficiency-uk', 'title': 'Upstaza Approved for AADC Deficiency in UK', 'source': 'CGTLive®', 'date': 'Nov 21, 2022', 'snippet': 'Upstaza (eladocagene exuparvovec), a recombinant adeno-associated virus \nserotype 2 (AAV2)-based gene therapy intended to treat aromatic L–amino \nacid...', 'thumbnail': 'https://serpapi.com/searches/6723bf5571b0e8d34ac50de2/images/5c8bbeee6cf16c505aba741514eb1e8d35bc5a9a3eef4b0fd5b90ec14d951e5b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8430208563804626}","{'position': 2, 'link': 'https://aadcnews.com/news/upstaza-boosts-patient-survival-quality-life-prediction-model/', 'title': 'Upstaza boosts patient survival, quality of life in prediction...', 'source': 'AADC News', 'date': 'Oct 11, 2023', 'snippet': 'Treatment with Upstaza (eladocagene exuparvovec) is estimated to prolong \nsurvival and lead to life quality gains for aromatic l-amino acid \ndecarboxylase (AADC)...', 'thumbnail': 'https://serpapi.com/searches/6723bf5571b0e8d34ac50de2/images/5c8bbeee6cf16c504ab71881962cde804522c3736ddec58b15eee917814536a0.png', 'sentiment': 'positive', 'sentiment_prob': 0.8483631610870361}","{'position': 3, 'link': 'https://www.cgtlive.com/view/hwu-questions-remaining-aadc-deficiency', 'title': 'Paul Wuh-Liang Hwu, MD, PhD, on Questions Remaining With AADC Deficiency', 'source': 'CGTLive®', 'date': 'Jul 22, 2022', 'snippet': 'CGTLive spoke with study investigator Paul Wuh-Liang Hwu, MD, PhD, \nprofessor, National Taiwan University Hospital, about Upstaza as well as \nhis work in Pompe...', 'thumbnail': 'https://serpapi.com/searches/6723bf5571b0e8d34ac50de2/images/5c8bbeee6cf16c50a5a21572373a1e430125019ca06db907bad6450c358703a3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9344761371612549}","{'position': 4, 'link': 'https://aadcnews.com/news/review-highlights-gene-therapies-that-greatly-improve-potential-for-cure-ptc-aadc/', 'title': 'Review Highlights Advances in Gene Therapies With Potential for Cure', 'source': 'AADC News', 'date': 'Mar 4, 2021', 'snippet': 'The science behind viral gene therapy — which may hold a potential cure in \na single treatment for genetic diseases such as aromatic l-amino...', 'thumbnail': 'https://serpapi.com/searches/6723bf5571b0e8d34ac50de2/images/5c8bbeee6cf16c50cd331b6c2bc82f504fe3563a378806a4245491a567fdb5b6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6926557421684265}","{'position': 5, 'link': 'https://aadcnews.com/news/upstaza-gene-therapy-aadc-deficiency-approved-uk/', 'title': 'Upstaza, Gene Therapy for AADC Deficiency, Approved in UK', 'source': 'AADC News', 'date': 'Nov 23, 2022', 'snippet': 'The gene therapy Upstaza (eladocagene exuparvovec) has been approved in the \nUK to treat adults and children, 18 months and older, with aromatic l-amino \nacid...', 'thumbnail': 'https://serpapi.com/searches/6723bf5571b0e8d34ac50de2/images/5c8bbeee6cf16c50daffa4731ea4901bd8fb26f6068101e16d70229502cf47b5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.784906268119812}",,,,,,"['neutral', 'positive', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01483599,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1501646', 'title': 'A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Jul 9, 2015', 'snippet': 'Little is known about the effect of specific anti–interleukin-23 therapy, \nas compared with established anti–tumor necrosis factor therapies,...', 'thumbnail': 'https://serpapi.com/searches/6723bfba6a5dd3df11063160/images/88859825ee0d647cd9940f87fcf46b68832548419e053641eba746e19c4d22d0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7835938930511475}",,,,,,,,,,['neutral'],neutral,1
NCT04525131,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-021-03836-z', 'title': 'Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex', 'source': 'Nature', 'date': 'May 31, 2021', 'snippet': 'Ciclopirox (CPX) is an FDA-approved topical antifungal agent that has \ndemonstrated preclinical anticancer activity in a number of solid and \nhematologic...', 'thumbnail': 'https://serpapi.com/searches/6723bfbbecf15028b3d55008/images/f0a7942f2d11284c1bb21e56e33ed4d13337748392f6f38773070a1e718ad85e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7911655902862549}",,,,,,,,,,['neutral'],neutral,1
NCT04076462,"{'position': 1, 'link': 'https://www.endocrinologyadvisor.com/news/manufacturing-issue-delays-decision-on-acromegaly-therapy/', 'title': 'Manufacturing Issue Delays Decision on Acromegaly Therapy', 'source': 'Endocrinology Advisor', 'date': '6 days ago', 'snippet': 'The Food and Drug Administration (FDA) has issued a Complete Response \nLetter (CRL) to Camurus regarding the New Drug Application (NDA) for...', 'thumbnail': 'https://serpapi.com/searches/6723c006f3cbfa08dbfc74fd/images/7ce4df4a318c6fab8ca62848f9992aa24823d7da584b287d4a6ba2d520477fab.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8548938035964966}",,,,,,,,,,['neutral'],neutral,1
NCT02496741,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00335/full', 'title': 'Re-purposing Chloroquine for Glioblastoma: Potential Merits and Confounding Variables', 'source': 'Frontiers', 'date': 'Aug 27, 2018', 'snippet': 'There is a growing evidence that antimalarial chloroquine could be \nre-purposed for cancer treatment. A dozen of clinical trials have been...', 'thumbnail': 'https://serpapi.com/searches/6723c0de81bab791da7f1998/images/a077b767b49bcb9a73bdafdebcf7bbf2a000298d17480ecf498833a52c2de082.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9061118960380554}",,,,,,,,,,['neutral'],neutral,1
NCT02160145,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1710030', 'title': 'Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease', 'source': 'The New England Journal of Medicine', 'date': 'Nov 4, 2017', 'snippet': 'In a previous trial involving patients with early autosomal dominant \npolycystic kidney disease (ADPKD; estimated creatinine clearance,...', 'thumbnail': 'https://serpapi.com/searches/6723c0e98b7ba7b65972bf52/images/384d068f9f93c4a31dfd099de1e321f0dfe1f5e651076e44a45ed5a4a85f51fd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8663855195045471}",,,,,,,,,,['neutral'],neutral,1
NCT05249621,"{'position': 1, 'link': 'https://pompediseasenews.com/news/pompe-disease-treatment-mze001-shows-promise-phase-1-trial/', 'title': 'Pompe disease treatment MZE001 shows promise in Phase 1 trial |...', 'source': 'Pompe Disease News', 'date': 'Mar 9, 2023', 'snippet': 'The experimental Pompe disease treatment MZE001 was well tolerated and \nreduced glycogen levels in healthy volunteers in a Phase 1 trial.', 'thumbnail': 'https://serpapi.com/searches/6723c0f30d379f3731cbd6b5/images/94b1b0eada3952fee4a22d657eccd7c88de191c1ddc44ac311462e5f5dabb3c6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8214936852455139}",,,,,,,,,,['positive'],positive,1
NCT03678259,"{'position': 1, 'link': 'https://fapnewstoday.com/news/imaging-agent-at-01-can-detect-amyloid-deposits-in-heart-of-asymptomatic-amyloidosis-patients-study/', 'title': 'AT-01 Can Detect Amyloid Deposits in Heart in Asymptomatic Patients', 'source': 'FAP News Today', 'date': 'May 24, 2021', 'snippet': ""A Phase 1/2 trial showed that Attralus' imaging agent AT-01 is able to \ndetect amyloid deposits even in patients without heart symptoms."", 'thumbnail': 'https://serpapi.com/searches/6723c1087f371927460f9504/images/68b3279f3507a17f7b3238facf4f957f7d0dc8dc87d38e18fbec95bdc5438c9d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.812371551990509}",,,,,,,,,,['neutral'],neutral,1
NCT04328961,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-43185-9', 'title': 'Simultaneous LC–MS/MS method for the quantitation of Azithromycin, Hydroxychloroquine and its metabolites in SARS-CoV-2(−/ +) populations using dried blood spots', 'source': 'Nature', 'date': 'Sep 30, 2023', 'snippet': 'In this study, we developed and validated the first sensitive and selective \nsimultaneous LC–MS/MS method to accurately quantitate the concentration of \nHCQ, HCQ...', 'thumbnail': 'https://serpapi.com/searches/6723c10a17b10e8d8c7767e4/images/7714df5f2e717adcdc6d4390e3e0c035cac339b113c3adb623798f180e5d0a0d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8897202610969543}",,,,,,,,,,['neutral'],neutral,1
NCT02678689,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.785841/full', 'title': 'Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials', 'source': 'Frontiers', 'date': 'Feb 7, 2022', 'snippet': 'Conducting clinical trials in rare diseases is challenging. In trials that \naim to use natural history control cohorts for evaluation of...', 'thumbnail': 'https://serpapi.com/searches/6723c030be8013a020dc9325/images/c02049ff8d03b099db1d4fabad1760dfc0390303c211437e68dbab5b1a807230.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8298519253730774}","{'position': 2, 'link': 'https://battendiseasenews.com/news/brineura-approved-as-batten-treatment-in-europe-us-as-clinical-trials-continue/', 'title': 'Brineura Approved as Batten Treatment in Both Europe and US as Clinical Studies Continue', 'source': 'Batten Disease News', 'date': 'Jun 2, 2017', 'snippet': 'Brineura, by BioMarin, is now approved to treat CLN2 type Batten disease in \nEurope and the U.S., as clinical trials continue to gather data.', 'thumbnail': 'https://serpapi.com/searches/6723c030be8013a020dc9325/images/c02049ff8d03b099602a34e3fad976ea10de6c5aaf98da0e87ed98a195bba057.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.595138430595398}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02302066,"{'position': 1, 'link': 'https://www.infectiousdiseaseadvisor.com/features/second-dose-of-tetravalent-dengue-vaccine-candidate-shows-enhanced-immunogenicity/', 'title': 'Second Dose of Tetravalent Dengue Vaccine Candidate Shows Enhanced Immunogenicity', 'source': 'Infectious Disease Advisor', 'date': 'Aug 18, 2017', 'snippet': 'A tetravalent dengue vaccine candidate (TDV) was found to be safe and \nimmunogenic in an ongoing phase 2 trial.', 'thumbnail': 'https://serpapi.com/searches/6723c08bd19f1513f5c5216f/images/b008219db6169ec9ba3e21add8a3b9da06ad2bfa1b6b394f2b0bac6a835232c1.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5370800495147705}",,,,,,,,,,['positive'],positive,1
NCT04727138,"{'position': 1, 'link': 'https://www.genengnews.com/topics/artificial-intelligence/bms-collaboration-paying-off-for-exscientia/', 'title': 'BMS Collaboration Paying Off for Exscientia', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Feb 7, 2023', 'snippet': 'Exscientia, the Oxford-based pioneer in artificial intelligence (AI)-based \ndrug development, has advanced the first of three candidates...', 'thumbnail': 'https://serpapi.com/searches/6723c08df6aa5324950753f5/images/aedd92eee461725dbbb84bea82351b0fda7cd5143935ffbc0cb062fbcd00ec70.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7788528800010681}",,,,,,,,,,['positive'],positive,1
NCT02213003,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Illustration-of-the-Sernova-Cell-Pouch-A-Plugs-in-situ-within-the-Cell-Pouch-B_fig1_309010262', 'title': 'Figure 1. Illustration of the Sernova Cell Pouch™. A, Plugs in situ...', 'source': 'ResearchGate', 'date': 'Feb 17, 2018', 'snippet': 'Despite advances in clinical islet transplanta-tion, intraportal islet \ndelivery is limited by en-graftment, neovascularization, immune protection \nand...', 'thumbnail': 'https://serpapi.com/searches/6723c0a06de1e45934c48bd3/images/d1516387d8aa42369e467f274e006c4dd0d03622c8e50884d7756ab75580b1c5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8343610763549805}",,,,,,,,,,['neutral'],neutral,1
NCT02029573,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Diagnostic-prognostic-and-predictive-biomarkers-in-glioblastoma_tbl1_379918538', 'title': 'Diagnostic, prognostic and predictive biomarkers in glioblastoma.', 'source': 'ResearchGate', 'date': 'May 2, 2024', 'snippet': 'Glioblastoma, the most aggressive and common malignant primary brain \ntumour, is characterized by infiltrative growth, abundant \nvascularization,...', 'thumbnail': 'https://serpapi.com/searches/6723c127e8735a1afc6b6dc6/images/96863508730eff3ae80bcf51db9f9dbcf59bf802856dc07fd1c564858498c3fe.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6789846420288086}",,,,,,,,,,['neutral'],neutral,1
NCT03538314,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2020/10/23/cancer-vaccine-uv1-keytruda-combo-shows-safety-early-effective-advanced-melanoma-phase-1-trial/', 'title': 'Cancer Vaccine UV1 Plus Keytruda Shows Safety, Early Efficacy in Advanced Melanoma Trial', 'source': 'Immuno-Oncology News', 'date': 'Oct 23, 2020', 'snippet': 'Top-line data from Phase 1 trial in adults with untreated metastatic \nmelanoma found UV1-Keytruda combo safe, and many without disease...', 'thumbnail': 'https://serpapi.com/searches/6723c14f910986a69be95ad6/images/3f5ea788a2a28b00bbc50f7693e3bbd50a382413515678578d0680451ddec6a7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.625566303730011}",,,,,,,,,,['neutral'],neutral,1
NCT01366534,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-021-00372-x', 'title': 'Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection', 'source': 'Nature', 'date': 'Aug 30, 2021', 'snippet': 'RTS,S/AS01 is an advanced pre-erythrocytic malaria vaccine candidate with \ndemonstrated vaccine efficacy up to 86.7% in controlled human...', 'thumbnail': 'https://serpapi.com/searches/6723c152163bdf5e17e1871f/images/24cf2f2f79a247978d4997f0f05dd8595a92a0293de55df5671a295be56a120a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8443019986152649}",,,,,,,,,,['neutral'],neutral,1
NCT02597933,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1903076', 'title': 'Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease', 'source': 'The New England Journal of Medicine', 'date': 'May 20, 2019', 'snippet': 'Nintedanib, a tyrosine kinase inhibitor, has been shown to have \nantifibrotic and antiinflammatory effects in preclinical models of systemic \nsclerosis and ILD.', 'thumbnail': 'https://serpapi.com/searches/6723c16b7d533e3e728c03c7/images/1594c533d1ee43352e4acb871e6438cb0bd2e55d42c1ed293c92115050bb52af.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6077403426170349}",,,,,,,,,,['neutral'],neutral,1
NCT03788967,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/fda-needs-more-data-on-tebipenem-hbr-for-complicated-uti/', 'title': 'FDA Needs More Data on Tebipenem HBr for Complicated UTI - MPR', 'source': 'Medical Professionals Reference', 'date': 'Jun 28, 2022', 'snippet': 'The FDA has issued a Complete Response Letter regarding the New Drug \nApplication for tebipenem HBr for complicated urinary tract infections.', 'thumbnail': 'https://serpapi.com/searches/6723c196be1497d86725f5bf/images/c533e0ed21558bc9c514958e82c13927b34fcfb1b0631ceed05c5b98e7546d7a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9202463030815125}","{'position': 2, 'link': 'https://www.contagionlive.com/view/oral-carbapenems-promise-peril-and-pushbacks', 'title': 'Oral Carbapenems: Promise, Peril, and Pushbacks', 'source': 'Contagion Live', 'date': 'Jul 27, 2022', 'snippet': 'Tebipenem and sulopenem are carbapenems with oral formulations that have \nbeen studied in phase 3 trials.', 'thumbnail': 'https://serpapi.com/searches/6723c196be1497d86725f5bf/images/c533e0ed21558bc9fa371cd854c7af6dfaddd58b3115c4c236b21a78c54e19a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9414225816726685}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02069145,"{'position': 1, 'link': 'https://www.nature.com/articles/s12276-020-0380-6', 'title': 'Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex', 'source': 'Nature', 'date': 'Feb 10, 2020', 'snippet': 'Wnt/β-catenin signaling is implicated in many physiological processes, \nincluding development, tissue homeostasis, and tissue regeneration.', 'thumbnail': 'https://serpapi.com/searches/6723c1987ac7318caebc08cb/images/86f4c029d46b8eba9a4083ab605a8b27fa3fe90989c13825278b18e353e0a734.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8630236387252808}",,,,,,,,,,['neutral'],neutral,1
NCT04320615,"{'position': 1, 'link': 'https://juvenilearthritisnews.com/2020/03/27/phase-3-clinical-trial-tests-actemra-for-covid-19-pneumonia/', 'title': 'Phase 3 Clinical Trial Tests Actemra for COVID-19 Pneumonia', 'source': 'Juvenile Arthritis News', 'date': 'Mar 27, 2020', 'snippet': ""A Phase 3 trial will test Genentech's approved JIA treatment Actemra in \npatients with pneumonia caused by COVID-19 infection."", 'thumbnail': 'https://serpapi.com/searches/6723c2512bab90365063a58c/images/a1e66cb6be54d1fee7a73284b87ef45f3bdf2e68e5e9ce7775e87ed2bf8b670e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9040188789367676}",,,,,,,,,,['neutral'],neutral,1
NCT01959529,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1615692', 'title': 'Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Apr 23, 2018', 'snippet': 'Degludec is an ultralong-acting, once-daily basal insulin that is approved \nfor use in adults, adolescents, and children with diabetes.', 'thumbnail': 'https://serpapi.com/searches/6723c253069e57e9813ca64a/images/22e75d31ca9f38b2cc48251aa6ee5880be794383b89723bbb04a30ef1dbbdaa8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8787471055984497}",,,,,,,,,,['neutral'],neutral,1
NCT03039673,"{'position': 1, 'link': 'https://alsnewstoday.com/news/als-disease-progression-slowed-with-low-dose-aldesleukin-trial/', 'title': 'Low-dose Aldesleukin Slows ALS Progression, Extends Survival: Trial', 'source': 'ALS News Today', 'date': 'Dec 16, 2022', 'snippet': 'A low dose of aldesleukin, an immunotherapy approved for certain cancers, \nslowed disease progression and significantly improved survival in people \nwith...', 'thumbnail': 'https://serpapi.com/searches/6723c206bcd652fc3b3dbda4/images/b90af191c5c5d0f3052763fb10d67b4c2430d76e6608ca60eb4c1ce6f8d03642.png', 'sentiment': 'positive', 'sentiment_prob': 0.5697094202041626}",,,,,,,,,,['positive'],positive,1
NCT02412878,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-020-0300-y', 'title': 'Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis', 'source': 'Nature', 'date': 'Mar 9, 2020', 'snippet': 'The phase 3 A.R.R.O.W. study demonstrated that treatment with once-weekly \ncarfilzomib (70 mg/m2) and dexamethasone (once-weekly Kd70 mg/m2)...', 'thumbnail': 'https://serpapi.com/searches/6723c214c97e35cb6520d828/images/ef9174eaee7c795b7a2b5bbeeaa08e133a8e526aef66cd34ca1dbb422b0ee117.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8960174918174744}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/once-weekly-kyprolis-effective-untreated-multiple-myeloma-patients/', 'title': 'Once-weekly Kyprolis Safe, Effective for Untreated Multiple Myeloma Patients, Study Finds', 'source': 'Myeloma Research News', 'date': 'Mar 6, 2019', 'snippet': 'Treatment with Kyprolis (carfilzomib) once a week is as safe and effective \nas the twice-weekly regimen used for the initial treatment of multiple \nmyeloma...', 'thumbnail': 'https://serpapi.com/searches/6723c214c97e35cb6520d828/images/ef9174eaee7c795b2948585c621baab2b6b6a101628dbb97634eb977518d023e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5886017084121704}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00213135,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0902533', 'title': 'A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Jan 20, 2010', 'snippet': 'Treatment with cladribine tablets significantly reduced relapse rates, the \nrisk of disability progression, and MRI measures of disease activity at 96 \nweeks.', 'thumbnail': 'https://serpapi.com/searches/6723c220b4fe873094b79b93/images/6c49c3f6586e3eddacf460f6a5c868998677bb468e6411504a0aedf6fe61d574.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7651755213737488}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/04/11/mavenclad-benefits-ms-sustained-up-15-years-after-last-treatment/', 'title': 'Mavenclad benefits for MS sustained up to 15 years after last treatment', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 11, 2023', 'snippet': 'The benefits of Mavenclad (cladribine) were sustained for up to 15 years \nafter its last treatment course in people with relapsing MS.', 'thumbnail': 'https://serpapi.com/searches/6723c220b4fe873094b79b93/images/6c49c3f6586e3edd8036cdb26538a39def1547ce10a438dc9cfc459a1d876333.png', 'sentiment': 'positive', 'sentiment_prob': 0.6188135743141174}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/2018/07/31/fda-accepts-resubmitted-nda-cladribine-tablets-treatment-relapsing-ms/', 'title': 'FDA to Review EMD Serono’s New Request for Approval of Cladribine for Treating Relapsing MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Jul 31, 2018', 'snippet': ""The FDA accepted for review EMD Serono's resubmitted New Drug Application \n(NDA) for cladribine tablets as a treatment for patients with..."", 'thumbnail': 'https://serpapi.com/searches/6723c220b4fe873094b79b93/images/6c49c3f6586e3eddf87a19463d37e47066c313d3b9af8accc89784ce00eb4611.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8431360125541687}","{'position': 4, 'link': 'https://multiplesclerosisnewstoday.com/mavenclad-cladribine/', 'title': 'Mavenclad (Cladribine) in MS | Uses, Side Effects, and More', 'source': 'Multiple Sclerosis News Today', 'date': 'May 2, 2022', 'snippet': 'Mavenclad (cladribine) is a disease-modifying therapy for RRMS and active \nSPMS. Learn more about its uses, indications, and side effects.', 'thumbnail': 'https://serpapi.com/searches/6723c220b4fe873094b79b93/images/6c49c3f6586e3edd715624930d26ed744bddaef948ce21b40615da1f441bb785.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9230253100395203}",,,,,,,"['neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT03728634,"{'position': 1, 'link': 'https://fapnewstoday.com/news/results-fully-enrolled-fap-neuro-ttransform-trial-eplontersen-expected-mid-2022/', 'title': 'Results From Fully Enrolled NEURO-TTRansform Trial Due Mid-2022', 'source': 'FAP News Today', 'date': 'Aug 2, 2021', 'snippet': ""Patient enrollment is complete for the NEURO-TTRansform trial testing \nIonis' eplontersen in adults with FAP, with results due in mid-2022."", 'thumbnail': 'https://serpapi.com/searches/6723c221fc40bf3211c18dee/images/01ec5679f5c9cd9ef7b5f6449db15389176d309c888b3679c30c4c70fb1c5e94.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8340455889701843}",,,,,,,,,,['neutral'],neutral,1
NCT04964557,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/ionis-provides-update-on-development-program-evaluating-pcsk9-antisense-medicine-for-the-treatment-of-hypercholesterolemia-301631819.html', 'title': 'Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia', 'source': 'PR Newswire', 'date': 'Sep 23, 2022', 'snippet': 'PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced \nthat topline results from the Phase 2b SOLANO study in patients...', 'thumbnail': 'https://serpapi.com/searches/6723c22aa54d7ebee9d523b0/images/a9a2011b89ae420f15a620510e26cd07c0ca7dc368068e16f6295b6ed10f6fa5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9042848348617554}",,,,,,,,,,['neutral'],neutral,1
NCT04992260,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-50802-2', 'title': 'Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial', 'source': 'Nature', 'date': 'Aug 6, 2024', 'snippet': 'Safe and effective vaccines against COVID-19 for children and adolescents \nare needed. This international multicenter, randomized,...', 'thumbnail': 'https://serpapi.com/searches/6723c24508abe4f8a8c7fb1c/images/20acc24a5c174b51a1d5653bfae55acd63efadb8bd09fac8e5c6b4ce849aa70f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6900764107704163}",,,,,,,,,,['neutral'],neutral,1
NCT01979536,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1203471/full', 'title': 'Brentuximab vedotin use in pediatric anaplastic large cell lymphoma', 'source': 'Frontiers', 'date': 'May 18, 2023', 'snippet': '1University of Michigan, Division of Pediatric Hematology-Oncology, Ann \nArbor, MI, United States; 2Eastern Virginia Medical School,...', 'thumbnail': 'https://serpapi.com/searches/6723c24ad364b4d1b56f896d/images/2dd6c17fce5cb5568cdba5b9405b3b984c2f726eee71ebf220f27c663d5ead48.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9270607233047485}",,,,,,,,,,['neutral'],neutral,1
NCT04192214,"{'position': 1, 'link': 'https://www.esanum.de/today/posts/bc-007-und-long-covid-lizenz-zur-heilung-noch-ausstehend', 'title': 'BC 007 und Long Covid: Lizenz zur Heilung noch ausstehend', 'source': 'esanum', 'date': 'Oct 11, 2021', 'snippet': 'Ein Berliner Start-up mit dem Namen ""Berlin Cures"" hat bereits vor einigen \nJahren ein Medikament entwickelt, das sich zur Behandlung von...', 'thumbnail': 'https://serpapi.com/searches/6723c24f460b157f97ff9d4f/images/06255a7aee2a1fd5ab0fff9c05d601594383c8eb88886498f244257c983a5f3a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8751393556594849}",,,,,,,,,,['neutral'],neutral,1
NCT01794507,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/relapsed-refractory-multiple-myeloma-clinical-trial-venetoclax-bortezomib-dexamethasone-combo-promising-effectiveness-safety/', 'title': 'Myeloma Trial of Venclexta, Velcade, Dexamethasone Combo Shows Promising Results', 'source': 'Myeloma Research News', 'date': 'Oct 13, 2017', 'snippet': 'Adding Venclexta (venetoclax) to Velcade (bortezomib) and dexamethasone has \nshown promising effectiveness and an acceptable safety profile in multiple \nmyeloma...', 'thumbnail': 'https://serpapi.com/searches/6723c34d3ad34d921e89426c/images/358ea7f939474aa730d170e1a77124ba987acc70dda748a6d53d14b72af2b42a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5157041549682617}",,,,,,,,,,['neutral'],neutral,1
NCT05119686,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/features/fda-roundup-emerging-drug-treatments-for-gout/', 'title': 'FDA Roundup: Pipeline Drugs for Gout', 'source': 'Rheumatology Advisor', 'date': 'Feb 9, 2024', 'snippet': 'There have been promising recent advancements in gout treatment, \nparticularly with innovative developments entering phase 3 clinical trials.', 'thumbnail': 'https://serpapi.com/searches/6723c36d0e6db34d71d352d3/images/943181bb5874bb9bff1f94d6c77b698623418ca604bd6cdf7e9ff994c45b8ae7.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.9072781205177307}",,,,,,,,,,['positive'],positive,1
NCT03363893,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-40061-y', 'title': 'Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib', 'source': 'Nature', 'date': 'Jul 24, 2023', 'snippet': 'Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, \nopen-label Phase I study to evaluate safety and tolerability of...', 'thumbnail': 'https://serpapi.com/searches/6723c36eecf1502902239bcd/images/a06ed8de327a5b6e0411317ffe694388694570dbca02fee48ae1e80f4a4ab54f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9001786112785339}",,,,,,,,,,['neutral'],neutral,1
NCT05506176,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2301425', 'title': 'Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Jan 17, 2024', 'snippet': 'Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has \nbeen found to have in vitro activity against severe acute...', 'thumbnail': 'https://serpapi.com/searches/6723c379ce1a75fb4bff085f/images/6db75ed55eb219faf61ec5fec8b1d370bb2386ead7f1472093a6b09095b9e7ef.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8903830051422119}",,,,,,,,,,['neutral'],neutral,1
NCT03329092,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/aztreonam-avibactam-effective-against-serious-bacterial-infections-in-phase-3-trials/', 'title': 'Aztreonam-Avibactam Effective Against Serious Bacterial Infections in Phase 3 Trials', 'source': 'Medical Professionals Reference', 'date': 'Jun 1, 2023', 'snippet': 'The investigational antibiotic combination aztreonam-avibactam was found to \nbe effective for treating serious bacterial infections caused by \nGram-negative...', 'thumbnail': 'https://serpapi.com/searches/6723c387f60b6f6962214bc9/images/12109e6a1536f89df101dcb7383fb0f4dbf342068f2e5ed8114ef0b95276d6c4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7394492626190186}",,,,,,,,,,['neutral'],neutral,1
NCT02651584,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/news/brixadi-now-available-for-weekly-or-monthly-administration-to-treat-opioid-use-disorder/', 'title': 'Brixadi Now Available for Weekly or Monthly Administration to Treat Opioid Use Disorder', 'source': 'Hematology Advisor', 'date': 'Sep 11, 2023', 'snippet': 'Brixadi® (buprenorphine) extended-release subcutaneous injection is now \navailable for the treatment of moderate to severe opioid use...', 'thumbnail': 'https://serpapi.com/searches/6723c2cc39e23253ca9ded0c/images/545456683568279abce809b84b30c70aab867b7670092a7900488c18134d4cc5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9039714336395264}",,,,,,,,,,['neutral'],neutral,1
NCT03948763,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01579-1', 'title': 'mRNA vaccines in disease prevention and treatment | Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': 'Sep 20, 2023', 'snippet': 'mRNA vaccines have emerged as highly effective strategies in the \nprophylaxis and treatment of diseases, thanks largely although not totally \nto their...', 'thumbnail': 'https://serpapi.com/searches/6723c31881bab791929efb8b/images/9879cf2fa0b9071143e4e4798dce31c267e10265066b2ac7a5ec85923a7447a9.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6464226245880127}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202305769', 'title': 'Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid‐Based Nanoparticles', 'source': 'Wiley Online Library', 'date': 'Dec 6, 2023', 'snippet': 'The implementation of advanced preclinical models such as tumor organoids, \nincorporating immune system cells and tumor extracellular matrix,...', 'thumbnail': 'https://serpapi.com/searches/6723c31881bab791929efb8b/images/9879cf2fa0b90711fcdd76e36dabfb3c581b0b04742835fea764ca8e3dbc79a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9186938405036926}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02564978,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/inflammation-reducing-drug-shows-no-benefit-dry-age-related-macular-degeneration-nih-trial', 'title': 'Inflammation-reducing drug shows no benefit for dry age-related macular degeneration in NIH trial', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Mar 20, 2024', 'snippet': 'The drug minocycline, an antibiotic that also decreases inflammation, \nfailed to slow vision loss or expansion of geographic atrophy in people \nwith dry age-...', 'thumbnail': 'https://serpapi.com/searches/6723c3eca88278e9fc574269/images/f150f504b273f55e66625a4fd571158837f83d55e787a63a3f74cbfd09543eef.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7418887615203857}",,,,,,,,,,['negative'],negative,0
NCT01730950,"{'position': 1, 'link': 'https://www.onclive.com/view/bevacizumab-plus-reirradiation-improves-pfs-in-glioblastoma-multiforme', 'title': 'Bevacizumab Plus Reirradiation Improves PFS in Glioblastoma Multiforme', 'source': 'OncLive', 'date': 'Oct 24, 2022', 'snippet': 'Bevacizumab along with reirradiation extended progression-free survival \ncompared with bevacizumab alone for patients with recurrent glioblastoma \nmultiforme.', 'thumbnail': 'https://serpapi.com/searches/6723c4038de63cf49777a864/images/ef9f7df27832b42372fa22554d6c06286c1cc022fe247bdb5b4f2892a36ca70a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6825342774391174}",,,,,,,,,,['positive'],positive,1
NCT01154140,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1408440', 'title': 'First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Dec 4, 2014', 'snippet': 'We conducted an open-label, phase 3 trial comparing crizotinib with \nchemotherapy in 343 patients with advanced ALK-positive nonsquamous...', 'thumbnail': 'https://serpapi.com/searches/6723c40fa25104bf530ff4aa/images/2f8f8dc177cc4b94c600b05d791e67dcf38b6c29257144091bf6e3cef2b162fd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9059361219406128}",,,,,,,,,,['neutral'],neutral,1
NCT05111249,"{'position': 1, 'link': 'https://huntingtonsdiseasenews.com/news/branaplam-dosing-huntingtons-trial-paused-side-effects/', 'title': 'Dosing Paused in Phase 2 Branaplam Trial Due to Possible Side Effects', 'source': ""Huntington's Disease News"", 'date': 'Aug 30, 2022', 'snippet': ""Due to possible side effects, dosing is being paused in the Phase 2 \nVIBRANT-HD clinical trial of oral branaplam (LMI070) in adults with \nHuntington's disease."", 'thumbnail': 'https://serpapi.com/searches/6723c41cc97e35cb6520d918/images/d7dc2d378e0ab3aa1a2d3b45901439d9fc6b7211154d764b55d72a07d7d98e2b.png', 'sentiment': 'negative', 'sentiment_prob': 0.508709728717804}",,,,,,,,,,['negative'],negative,0
NCT02040506,"{'position': 1, 'link': 'https://www.oncozine.com/magenta-therapeutics-voluntarily-stops-phase-1-2-study-of-adc-mgta-117-due-to-serious-adverse-event/', 'title': 'Magenta Therapeutics Voluntarily Stops Phase 1/2 Study of ADC MGTA-117 Due to Serious Adverse Event', 'source': ""Onco'Zine"", 'date': 'Feb 11, 2023', 'snippet': 'Clinical-stage biotech Magenta Therapeutics confirmed that latest \nparticipant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing \nMGTA-117 Phase 1/2...', 'thumbnail': 'https://serpapi.com/searches/6723c4694e9efc5a64221da6/images/b638d94d7322015dff5cfa5900819671abfadde189a6a8df32261f5662d3c22b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7435821294784546}",,,,,,,,,,['neutral'],neutral,1
NCT02395601,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-02181-7', 'title': 'EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine', 'source': 'Nature', 'date': 'Nov 23, 2021', 'snippet': 'Small intestinal neuroendocrine tumors (SI-NETs) are slow-growing tumors \nthat seem genetically quite stable without highly recurrent...', 'thumbnail': 'https://serpapi.com/searches/6723c4c3ce1a75fb4bff093d/images/93c73793905dc25b8ad3e038c321c1595fea05c4c21c3acdb0e65e6720c65f8b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8022369146347046}",,,,,,,,,,['neutral'],neutral,1
NCT01148459,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30161-X/abstract', 'title': 'Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial', 'source': 'The Lancet', 'date': 'Jul 6, 2016', 'snippet': 'Malaria remains a major global public health concern, especially in \nsub-Saharan Africa. The RTS,S/AS01 malaria candidate vaccine was...', 'thumbnail': 'https://serpapi.com/searches/6723c4c6c024d1935d72cfb8/images/007010cb5136254227563c489cf40a8910c30897ba01b8ce3493db8539941d1e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5545780658721924}",,,,,,,,,,['neutral'],neutral,1
NCT01865487,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-018-0075-3', 'title': 'Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making', 'source': 'Nature', 'date': 'Sep 17, 2018', 'snippet': 'Unlike drug dose optimisation, mathematical modelling has not been applied \nto vaccine dose finding.', 'thumbnail': 'https://serpapi.com/searches/6723c4e2d111956b5d3ac7b2/images/3820e2259cfee66219505e18f85b832507fabcf597048dd677dff20e618f4bc1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8495684862136841}",,,,,,,,,,['neutral'],neutral,1
NCT04050085,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-023-00364-1', 'title': 'Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer', 'source': 'Nature', 'date': 'Mar 8, 2023', 'snippet': 'In this review, we describe the TLR agonists that are being evaluated \nclinically as new therapies for solid tumors.', 'thumbnail': 'https://serpapi.com/searches/6723c4e6ca6f0c674d72a919/images/3b60f77a72cd38592ee8143e3f552cfb839e35a92899a18e70c70dc8de65cf72.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9042466282844543}",,,,,,,,,,['neutral'],neutral,1
NCT00921947,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/abs/pii/S014181302400062X', 'title': 'Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice', 'source': 'ScienceDirect.com', 'date': 'Jan 7, 2024', 'snippet': 'The prokaryotically expressed multiepitope nanovaccine elicits long-lasting \nmucosal immunity, broad humoral immunity, and robust cellular immunity \nwithout any...', 'thumbnail': 'https://serpapi.com/searches/6723c4f8213c87b600cd7ce8/images/33f10b0df2ba6a2be03eee8bed10097ac04bb3bc936268d8502fb73438d47e12.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6536120176315308}",,,,,,,,,,['neutral'],neutral,1
NCT01483144,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1916063', 'title': 'Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 9, 2020', 'snippet': 'The efficacy and safety of combination therapy with eflornithine and \nsulindac, as compared with either drug alone, in delaying disease...', 'thumbnail': 'https://serpapi.com/searches/6723c54d2da98353886f0da6/images/921079b0bc211c37d621021fa8b1f7527c3a73ec9905b77dc6b8ae27b3acaf05.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8110136985778809}",,,,,,,,,,['neutral'],neutral,1
NCT04241315,"{'position': 1, 'link': 'https://www.pennmedicine.org/news/news-releases/2022/december/fda-approves-glowing-tumor-imaging-drug-for-lung-cancer-surgery', 'title': 'FDA Approves “Glowing Tumor” Imaging Drug for Lung Cancer Surgery', 'source': 'Penn Medicine', 'date': 'Dec 16, 2022', 'snippet': 'Glowing tumor” targeted imaging agent approved for use in lung cancer \nsurgery after clinical testing led by Penn Medicine.', 'thumbnail': 'https://serpapi.com/searches/6723c58352a04e946bb29984/images/b39b425afac25a057532b9d0b13607a7746332cffaeb25073529ebe87621e874.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7413339018821716}",,,,,,,,,,['neutral'],neutral,1
NCT00864032,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.3103', 'title': 'BRAF mutation and its inhibitors in sarcoma treatment - Liu - 2020 - Cancer Medicine', 'source': 'Wiley Online Library', 'date': 'May 31, 2020', 'snippet': 'Cancer Medicine is an open access, broad-scope oncology journal covering \nclinical cancer research, cancer biology, cancer prevention,...', 'thumbnail': 'https://serpapi.com/searches/6723c586a54d7ebea390b707/images/c7813b8507d029096837c779090a367e7172145bfdb7c1806200b8a84dc918e3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9235926866531372}",,,,,,,,,,['neutral'],neutral,1
NCT01396499,"{'position': 1, 'link': 'https://www.jci.org/articles/view/78090/figure/2', 'title': 'MicroRNA regulation of lymphocyte tolerance and autoimmunity', 'source': 'JCI - Welcome', 'date': 'Jun 1, 2015', 'snippet': 'PI3K inhibitors are currently in clinical trials for acute and advanced \nleukemia (ClinicalTrials.gov identifiers NCT01756118 and...', 'thumbnail': 'https://serpapi.com/searches/6723c59ef7adbffdff08182c/images/be8540f67c684813fcd924f86361cfe51b2f2480ed953cfaa442ed8e9ed2e6a5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9191775918006897}",,,,,,,,,,['neutral'],neutral,1
NCT02178358,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1188277/full', 'title': 'Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma', 'source': 'Frontiers', 'date': '٠٨\u200f/٠٢\u200f/٢٠٢٤', 'snippet': 'This review aims to provide insights into the hepatic immune \nmicroenvironment in HCC and summarize the mechanisms of action and clinical \nusage of...', 'thumbnail': 'https://serpapi.com/searches/6723c5a6b4b72de072b1efd0/images/05873397379eb97ece0544fca093b923022ed8d421436214d3da6a7140b732d9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8974184393882751}",,,,,,,,,,['neutral'],neutral,1
NCT00511238,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/myeloma-study-finds-pomalyst-more-cost-effective-than-kyprolis-or-darzalex/', 'title': 'Myeloma Study Finds Pomalyst More Cost-Effective Than Two Rivals', 'source': 'Myeloma Research News', 'date': 'Oct 30, 2017', 'snippet': 'Read about a study reporting that a combination of Pomalyst and \ndexamethasone is a more cost-effective therapy for myeloma than Kyprolis \nor...', 'thumbnail': 'https://serpapi.com/searches/6723c5b0d364b4d16b1c5df7/images/d5261506c7d82f535408254ebc88aed70c705384a1ceea563be848edba7bd474.png', 'sentiment': 'positive', 'sentiment_prob': 0.5470622777938843}",,,,,,,,,,['positive'],positive,1
NCT05352815,"{'position': 1, 'link': 'https://www.researchgate.net/publication/380177828_Once-weekly_insulins_a_promising_approach_to_reduce_the_treatment_burden_in_people_with_diabetes', 'title': '(PDF) Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes', 'source': 'ResearchGate', 'date': 'Aug 30, 2024', 'snippet': 'PDF | Despite the availability of new classes of glucose-lowering drugs \nthat improve glycaemic levels and minimise long-term complications,...', 'thumbnail': 'https://serpapi.com/searches/6723c65bc76a3acd090f8664/images/33ce6b930e2e8c53c3631c10bc4d92aea4a497886d21ea554f747c7666394e9b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5478062033653259}",,,,,,,,,,['neutral'],neutral,1
NCT00987389,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/lower-glucocorticoids-dosage-regimen-may-lower-risk-death-study/', 'title': 'Lower Dosage of Glucocorticoids May Decrease Risk of Death, Study Suggests', 'source': 'ANCA Vasculitis News', 'date': 'Mar 30, 2022', 'snippet': 'A reduced-dose regimen may lower the risk of death and serious infections, \nwhile not increasing the risk of kidney failure, in people with \nANCA-associated...', 'thumbnail': 'https://serpapi.com/searches/6723c5ad5a461a60b367dcd5/images/bb4c66ba6a4731d9b8740d8b9ade7bac39690bf38e420cc9427f2fbeeda97f02.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8226317763328552}",,,,,,,,,,['neutral'],neutral,1
NCT05154578,"{'position': 1, 'link': 'https://pf-media.co.uk/news/minervax-begins-phase-1-clinical-study-of-novel-gbs-vaccine/', 'title': 'MinervaX begins phase 1 clinical study of novel GBS vaccine', 'source': 'Pf Media', 'date': 'Apr 17, 2023', 'snippet': 'MinervaX has announced the first phase 1 clinical study in older adults of \nits novel vaccine for Group B Streptococcus.', 'thumbnail': 'https://serpapi.com/searches/6723c5da310300720f02786a/images/b8e1f01681792a61650b4cc32b5a86f825edf75c347db99a534aacf716036726.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8728817105293274}",,,,,,,,,,['neutral'],neutral,1
NCT03831971,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/nih-test-experimental-drug-curb-opioid-cravings', 'title': 'NIH to test experimental drug to curb opioid cravings', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Mar 21, 2019', 'snippet': 'A clinical trial of an experimental drug designed to treat cravings \nassociated with opioid use disorder (OUD) has begun in the National \nInstitutes of Health...', 'thumbnail': 'https://serpapi.com/searches/6723c5ee59f91190a5e1e9f2/images/a5932992eae753f3b33c147654ec6bfd0bb0fdaa5b1cba311da17967514df655.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8840211033821106}",,,,,,,,,,['neutral'],neutral,1
NCT03745716,"{'position': 1, 'link': 'https://aml-hub.com/medical-information/efficacy-and-safety-of-eprenetapopt-apr-246-combined-with-azacitidine-in-patients-with-tp53-mutant-mds-and-oligoblastic-aml', 'title': 'Efficacy and safety of eprenetapopt (APR-246) combined with azacitidine in patients with TP53-mutant MDS and oligoblastic AML', 'source': 'aml-hub.com', 'date': 'Jan 5, 2022', 'snippet': 'Eprenetapopt (APR-246), a p53 reactivator, has recently demonstrated \npromising efficacy and safety in two phase II trials (NCT03072043 and \nNCT03588078) when...', 'thumbnail': 'https://serpapi.com/searches/6723c5eefcd69ee1d5dd53a6/images/2fb0b0fa13580cd03700c8003d144b93d59bd7ee078da1a72b316d109f33b26b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.742760956287384}","{'position': 2, 'link': 'https://www.ajmc.com/view/phase-3-trials-in-high-risk-mds-highlight-future-directions', 'title': 'Phase 3 Trials in High-Risk MDS Highlight Future Directions', 'source': 'AJMC', 'date': 'Dec 8, 2022', 'snippet': 'A recent review emphasizes a need for novel therapies, summarizes current \nphase 3 clinical trials, and suggests several considerations for...', 'thumbnail': 'https://serpapi.com/searches/6723c5eefcd69ee1d5dd53a6/images/2fb0b0fa13580cd0f1d02f7d3caa96d5d3e12f820a9d8d6d12084de44eb06e62.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8933826088905334}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02105636,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1602252', 'title': 'Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck', 'source': 'The New England Journal of Medicine', 'date': 'Oct 9, 2016', 'snippet': 'Treatment with nivolumab resulted in longer overall survival than treatment \nwith standard, single-agent therapy.', 'thumbnail': 'https://serpapi.com/searches/6723c61f6ad3c99a920eb1f1/images/c9a25a9f0baa6c116b7561ac98ea690fa42eba317eddf144a59d78be6f1f95a9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6905208230018616}",,,,,,,,,,['neutral'],neutral,1
NCT03230838,"{'position': 1, 'link': 'https://www.empr.com/home/news/zerbaxa-approved-for-complicated-pediatric-intra-abdominal-urinary-tract-infections/', 'title': 'Zerbaxa Approved for Complicated Pediatric Intra-abdominal, Urinary Tract Infections', 'source': 'Medical Professionals Reference', 'date': 'Apr 26, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved the supplemental New \nDrug Applications (sNDAs) for Zerbaxa (ceftolozane and tazobactam) to \ninclude...', 'thumbnail': 'https://serpapi.com/searches/6723c644749783a6b49d4986/images/b24ff181e9e0fd3e11af037319d023d89f1cb3c0274f3bbbaf114097d01f6d10.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8938506841659546}",,,,,,,,,,['neutral'],neutral,1
NCT03858634,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-023-00992-4', 'title': 'The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment', 'source': 'Nature', 'date': 'Mar 16, 2023', 'snippet': 'Atopic dermatitis (AD) is the most common inflammatory skin disease, and it \nis considered a complex and heterogeneous condition.', 'thumbnail': 'https://serpapi.com/searches/6723c6fb58e433ac9f7c0e2e/images/2e293d4939fd2c8371d6af6ee894e7697eeb9efd679f5140e44d086e99a3ad61.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7401643991470337}",,,,,,,,,,['neutral'],neutral,1
NCT01225731,"{'position': 1, 'link': 'https://www.dermatologyadvisor.com/cch/il-23-antagonists-in-the-treatment-of-plaque-psoriasis/', 'title': 'IL-23 Antagonists in the Treatment of Plaque Psoriasis', 'source': 'Dermatology Advisor', 'date': 'May 17, 2024', 'snippet': 'Three selective IL-23 inhibitors are currently approved for the treatment \nof plaque psoriasis: guselkumab, risankizumab, and tildrakizumab.', 'thumbnail': 'https://serpapi.com/searches/6723c70ed364b4d16b1c5ecb/images/0dc444f390426e6e3f5dc24b79573d54ebbb83ee9ec0ab7ba23c17e8a07e8d49.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.890917956829071}",,,,,,,,,,['neutral'],neutral,1
NCT02552212,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/news/certolizumab-pegol-demonstrates-positive-results-in-phase-3-trial-for-nonradiographic-axial-spondyloarthritis/', 'title': 'Certolizumab Pegol Demonstrates Positive Results in Phase 3 Trial for Nonradiographic Axial Spondyloarthritis', 'source': 'Rheumatology Advisor', 'date': 'May 17, 2018', 'snippet': 'Results from a phase 3 placebo-controlled study show that CIMZIA® \n(certolizumab pegol) improves the signs and symptoms of nonradiographic \naxial...', 'thumbnail': 'https://serpapi.com/searches/6723c7133c863d7bb83135e8/images/a671e933e56cfe05b7d802be2b8d6abad115c84e32d2b8b5e40dba295b92bd35.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.520475447177887}",,,,,,,,,,['positive'],positive,1
NCT03725722,"{'position': 1, 'link': 'https://www.empr.com/home/news/delgocitinib-cream-leo-pharma-chronic-hand-eczema/', 'title': 'Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema', 'source': 'Medical Professionals Reference', 'date': 'Aug 5, 2020', 'snippet': 'The Food and Drug Administration (FDA) has granted Fast Track designation \nto delgocitinib cream (Leo Pharma) for the treatment of adults with \nmoderate to...', 'thumbnail': 'https://serpapi.com/searches/6723c7120d379f3731cbda0d/images/20bf9e08df625886fcedb0ee3fc3f5fae3597559d4552864192759cbfffd4b06.png', 'sentiment': 'neutral', 'sentiment_prob': 0.786065936088562}",,,,,,,,,,['neutral'],neutral,1
NCT03823404,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/fda-places-full-hold-clinical-testing-cortexyme-cor388-alzheimers/', 'title': 'FDA Puts Full Hold on Clinical Testing of Cortexyme’s COR388', 'source': ""Alzheimer's News Today"", 'date': 'Feb 7, 2022', 'snippet': ""The U.S. Food and Drug Administration placed a full clinical hold on \nCOR388, an oral therapy from Cortexyme for Alzheimer's disease."", 'thumbnail': 'https://serpapi.com/searches/6723c71a48c97dd4ce243693/images/df045440e007bd7683775d6f35b2587d063d9adc08643f41c338c05a45f78e08.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8587650060653687}","{'position': 2, 'link': 'https://alzheimersnewstoday.com/news/cortexyme-gain-trial-atuzaginstat-potential-benefit-alzheimers-patients-severe-gum-disease/', 'title': 'Atuzaginstat Shows Potential in GAIN Trial Patients With Severe Gum Disease', 'source': ""Alzheimer's News Today"", 'date': 'Nov 2, 2021', 'snippet': 'Treatment with atuzaginstat (COR388) appeared to slow their cognitive \ndecline, according to results from the Phase 2/3 GAIN clinical trial.', 'thumbnail': 'https://serpapi.com/searches/6723c71a48c97dd4ce243693/images/df045440e007bd7641bb8f47c7774d312892cb800111e48dfb0f200e96d75d30.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8065990805625916}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03824392,"{'position': 1, 'link': 'https://sarcoidosisnews.com/news/benefits-seen-efzofitimod-pulmonary-sarcoidosis-treatment-trial/', 'title': '1st in class aTyr treatment shows promise in pulmonary sarcoidosis...', 'source': 'Sarcoidosis News', 'date': 'Jun 14, 2023', 'snippet': 'Efzofitimod has shown promise as a pulmonary sarcoidosis treatment in a \nclinical trial, with more exposure linked to better lung function.', 'thumbnail': 'https://serpapi.com/searches/6723c74c5bb6a2a99227b1dd/images/5a8fdf0134badae28a4ab3b2b6f74aa316d20e9cf3a457899c5b6f8b7eae4915.png', 'sentiment': 'positive', 'sentiment_prob': 0.8347368836402893}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/novel-immunomodulator-gets-orphan-drug-status-for-sarcoidosis/', 'title': 'Novel Immunomodulator Gets Orphan Drug Status for Sarcoidosis', 'source': 'Medical Professionals Reference', 'date': 'Jan 6, 2022', 'snippet': 'The Food and Drug Administration (FDA) has granted Orphan Drug designation \nto ATYR1923 for the treatment of sarcoidosis.', 'thumbnail': 'https://serpapi.com/searches/6723c74c5bb6a2a99227b1dd/images/5a8fdf0134badae247cdf78aab85321d4bdcc6d7da54bf3f5d4cb62486ca55a6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8696157336235046}","{'position': 3, 'link': 'https://sarcoidosisnews.com/news/experimental-pulmonary-sarcoidosis-treatment-efzofitimod-fast-track/', 'title': 'Experimental Pulmonary Sarcoidosis Treatment Efzofitimod on Fast Track', 'source': 'Sarcoidosis News', 'date': 'Aug 12, 2022', 'snippet': ""Efzofitimod, an experimental treatment for pulmonary sarcoidosis that's set \nto begin Phase 3 clinical testing later this year, has been granted fast \ntrack..."", 'thumbnail': 'https://serpapi.com/searches/6723c74c5bb6a2a99227b1dd/images/5a8fdf0134badae26c89ad77302316c26bf5085df9cec31307788d3998f1cde6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8707942962646484}",,,,,,,,"['positive', 'neutral', 'neutral']",neutral,1
NCT02260505,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/6-year-imatinib-maintenance-therapy-reduces-recurrence-risk-in-gist', 'title': 'Six-Year Imatinib Maintenance Therapy Reduces Recurrence Risk in GIST', 'source': 'Cancer Network', 'date': 'May 9, 2024', 'snippet': 'Investigators found that imatinib maintenance therapy for 6 years reduced \nthe risk of recurrence in patients with gastrointestinal stromal...', 'thumbnail': 'https://serpapi.com/searches/6723c751213c87b600cd7e16/images/f8a1128d2286f93df8abc5f2d10920802fc5c8921e9b62e04ba17563b604ebf1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8645538687705994}",,,,,,,,,,['neutral'],neutral,1
NCT00287729,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/pirfenidone-may-be-effective-for-improving-exercise-capacity-dyspnea-in-idiopathic-pulmonary-fibrosis/', 'title': 'Pirfenidone May Be Effective for Improving Exercise Capacity, Dyspnea in Idiopathic Pulmonary Fibrosis', 'source': 'Pulmonology Advisor', 'date': 'Oct 10, 2018', 'snippet': 'When treated with pirfenidone, patients with idiopathic pulmonary fibrosis \nexperienced significant improvements in 6-minute walking distance...', 'thumbnail': 'https://serpapi.com/searches/6723c758be8013a061929cbd/images/489f3f01c5ce0177f9a5af7c82c7e100393a8d54e09a75a82a127a42d047f3fe.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5335983633995056}",,,,,,,,,,['positive'],positive,1
NCT06006871,"{'position': 1, 'link': 'https://www.researchgate.net/figure/IDEAL-Games-framework-22-adapted-to-create-a-general-guide-for-game-based-attention_fig1_362409691', 'title': 'Figure 1. IDEAL-Games framework [22] adapted to create a general guide...', 'source': 'ResearchGate', 'date': 'May 5, 2023', 'snippet': 'Video game–based therapeutic interventions have demonstrated some \neffectiveness in decreasing the symptoms of attention deficit hyperactivity \ndisorder...', 'thumbnail': 'https://serpapi.com/searches/6723c766ec5410e2f56ef64b/images/54942d71fd92605410b4e794efee4a2a8d4cc5636db5cf7541a1e0d312512c9c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8364045023918152}",,,,,,,,,,['neutral'],neutral,1
NCT00097032,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/cognitive-functioning-acute-sedative-effects-risperidone/', 'title': 'Cognitive Functioning and Acute Sedative Effects of Risperidone and Quetiapine in Patients With Stable Bipolar I Disorder: A Randomized, Double-Blind, Crossover Study', 'source': 'Psychiatrist.com', 'date': 'Aug 15, 2007', 'snippet': 'The results indicate that initiation of quetiapine treatment was associated \nwith more immediate adverse cognitive effects and increased somnolence \nthan...', 'thumbnail': 'https://serpapi.com/searches/6723c79d24079331fb3a7195/images/38d8d3eb2816b406d40cb4c2b11e8539f344d668bc18c2c5479e44a246b81a32.png', 'sentiment': 'neutral', 'sentiment_prob': 0.814086377620697}",,,,,,,,,,['neutral'],neutral,1
NCT03548220,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/mitapivat-safely-increases-hemoglobin-levels-in-patients-early-data-phase-1-trial/', 'title': 'SCD Trial Shows Mitapivat Safely Boosts Hemoglobin Levels in Patients', 'source': 'Sickle Cell Disease News', 'date': 'Jun 25, 2020', 'snippet': 'Early Phase 1 trial results show mitapivat safely increases hemoglobin \nlevels and lowers red blood cell damage in adults with sickle cell...', 'thumbnail': 'https://serpapi.com/searches/6723c7bb63a844cecdffced1/images/eb194d649512c70d2cd098e64fdf41ebdffd1448fd5f55a5f9965e3d53665b46.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5431870222091675}",,,,,,,,,,['neutral'],neutral,1
NCT02728843,"{'position': 1, 'link': 'https://www.nature.com/articles/s41531-022-00345-4', 'title': 'Empirical evidence for biometal dysregulation in Parkinson’s disease from a systematic review and Bradford Hill analysis', 'source': 'Nature', 'date': 'Jun 27, 2022', 'snippet': ""The available evidence supports an etiological role for iron and copper \ndysregulation in Parkinson's disease, substantiating current clinical \ntrials."", 'thumbnail': 'https://serpapi.com/searches/6723c7cbcaddc3538c85522d/images/d964a67ac740af89894bae9427c3dd039a92e87acfe146f4c55e3cc3a2b6ea10.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8967313766479492}",,,,,,,,,,['neutral'],neutral,1
NCT03703102,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/amgen-and-kyowa-kirin-present-positive-late-breaking-data-from-phase-2-study-of-amg-451khk4083-in-adult-patients-with-moderate-to-severe-atopic-dermatitis-at-eadv-congress-301391185.html', 'title': 'Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress', 'source': 'PR Newswire', 'date': 'Oct 2, 2021', 'snippet': 'AMG 451/KHK4083 is a potential first-in-class anti-OX40 fully human \nmonoclonal antibody in development for the treatment of moderate-to-severe \natopic...', 'thumbnail': 'https://serpapi.com/searches/6723c7dcb28e6b4a1f154121/images/bfcd0ee47ed62d082aee7d4208982c2ae3149d0720cd70a32e1f00e526a0ec54.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7533566951751709}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/amgen-to-showcase-new-data-from-inflammation-portfolio-at-eadv-virtual-congress-2021-301375267.html', 'title': 'Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021', 'source': 'PR Newswire', 'date': 'Sep 13, 2021', 'snippet': '32 Week Data From the Phase 3 ADVANCE Trial Investigating the Safety and \nEfficacy of Otezla to Improve Mild-to-Moderate Plaque Psoriasis...', 'thumbnail': 'https://serpapi.com/searches/6723c7dcb28e6b4a1f154121/images/bfcd0ee47ed62d08b7bf634a16965770d78844b55670721d21efa571b8b9ad23.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8882607221603394}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00118274,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-46877-6', 'title': 'Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial', 'source': 'Nature', 'date': 'Mar 22, 2024', 'snippet': 'The critical roles of CD4+ T cells have been understudied for cancer \nvaccines. Here we report long-term clinical outcomes of a randomized...', 'thumbnail': 'https://serpapi.com/searches/6723c7e0d771bdcb8c631f05/images/3f5ce838ffb7b191d0ebbf4f1982a4f05b8cc474189bef69aa323652adf79bcc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9029699563980103}",,,,,,,,,,['neutral'],neutral,1
NCT01531361,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-022-00341-0', 'title': 'BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study | npj Precision Oncology', 'source': 'Nature', 'date': 'Feb 18, 2023', 'snippet': 'We performed a pooled analysis of four phase one studies evaluating the \nsafety and efficacy of vemurafenib monotherapy and vemurafenib combined \nwith targeted...', 'thumbnail': 'https://serpapi.com/searches/6723c83ab6a79cfdeda5b3ed/images/324164902ca70f6f4ca57f5297ff5539e3e7fe00d48be9394b22bae591402fc6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9065907597541809}",,,,,,,,,,['neutral'],neutral,1
NCT01471444,"{'position': 1, 'link': 'https://www.nature.com/articles/s41409-022-01705-7', 'title': 'A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation', 'source': 'Nature', 'date': 'May 24, 2022', 'snippet': 'Pretransplant conditioning with Fludarabine (Flu)-Busulfan (Bu) is safe, \nbut clofarabine (Clo) has improved antileukemic activity.', 'thumbnail': 'https://serpapi.com/searches/6723c88a657c66b440e30352/images/2339f6a2fcb444d89f7f18eb8812032a76158588ce87a3625b785f14465f498a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.774931013584137}",,,,,,,,,,['neutral'],neutral,1
NCT03186781,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01660-8', 'title': 'Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial', 'source': 'Nature', 'date': 'Feb 3, 2022', 'snippet': 'Currently, licensed seasonal influenza vaccines display variable vaccine \neffectiveness, and there remains a need for novel vaccine platforms...', 'thumbnail': 'https://serpapi.com/searches/6723c89298fad6961dd80955/images/c7a8b0a64bc71050358ee8fef439b73ec86819b311399ac8a9ffda7138a47230.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8805010914802551}",,,,,,,,,,['neutral'],neutral,1
NCT03382405,"{'position': 1, 'link': 'https://journals.asm.org/doi/10.1128/jvi.01603-23', 'title': 'Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults', 'source': 'ASM Journals', 'date': 'Mar 25, 2024', 'snippet': 'mRNA-1647 is an investigational mRNA-based vaccine against cytomegalovirus \n(CMV) that contains sequences encoding the CMV proteins glycoprotein B and \npentamer.', 'thumbnail': 'https://serpapi.com/searches/6723c92148c429c80104c11e/images/f287a8a77578335b94e6f780c844d858444c3f00c0b630411d68f7fc283bd14f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9078482985496521}",,,,,,,,,,['neutral'],neutral,1
NCT01910012,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-017-10542-4', 'title': 'A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients', 'source': 'Nature', 'date': 'Sep 12, 2017', 'snippet': 'Exogenous arginine is required for growth in some argininosuccinate \nsynthetase (ASS)-deficient cancers. Arginine deiminase (ADI) inhibits...', 'thumbnail': 'https://serpapi.com/searches/6723c940708e2e6934b543b7/images/00d84f7cd576268d220a364a81d95efefc2904a51b1b13fecdeb3821be381cc9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8377330303192139}",,,,,,,,,,['neutral'],neutral,1
NCT01159028,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332220301888', 'title': 'RNA-based pharmacotherapy for tumors: From bench to clinic and back', 'source': 'ScienceDirect.com', 'date': 'Feb 14, 2020', 'snippet': 'RNA therapy is a treatment that regulates cell proteins and cures diseases \nby affecting the metabolism of mRNAs in cells.', 'thumbnail': 'https://serpapi.com/searches/6723c8a80f1a336e05f57ab7/images/8d23c03105862d0b51381c35cea17ef430638d7efb60ffdaaaf0fa5d2e4566e3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7626101970672607}",,,,,,,,,,['neutral'],neutral,1
NCT00787059,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/joim.13308', 'title': 'Gene therapy for ischaemic heart disease and heart failure - Korpela - 2021 - Journal of Internal Medicine', 'source': 'Wiley Online Library', 'date': 'May 25, 2021', 'snippet': 'Gene therapy has been expected to become a novel treatment method since the \nstructure of DNA was discovered in 1953.', 'thumbnail': 'https://serpapi.com/searches/6723c8afa5e502a8e8204c0e/images/9aff288308d711348f2d332617f960ab08a2d639ea180cf4a95e4b5ba2dab81b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7769891619682312}",,,,,,,,,,['neutral'],neutral,1
NCT02861534,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1915928', 'title': 'Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction', 'source': 'The New England Journal of Medicine', 'date': 'Mar 28, 2020', 'snippet': 'The effect of vericiguat, a novel oral soluble guanylate cyclase \nstimulator, in patients with heart failure and reduced ejection fraction \nwho had recently...', 'thumbnail': 'https://serpapi.com/searches/6723c8bdd364b4d1b56f8c17/images/b1ff0fcdc5cf4dc96553d44282629f05d1db6bbee0a8ca28bdc755ee74196d70.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8445867896080017}",,,,,,,,,,['neutral'],neutral,1
NCT05596734,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2024.1412478/full', 'title': 'Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines', 'source': 'Frontiers', 'date': 'Jun 29, 2024', 'snippet': 'This review delves into the major advancements in the field of combined \nvaccine research, underscoring the strategic use of various platforms.', 'thumbnail': 'https://serpapi.com/searches/6723c8e9861b9d38e4f1e35d/images/1df0ac5edd14a931aaa2a319db32ce3801f29c843c8c5e571dc4e2baa9fb65fa.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5735475420951843}",,,,,,,,,,['positive'],positive,1
NCT05397119,"{'position': 1, 'link': 'https://pubs.acs.org/doi/10.1021/acsnano.3c10797', 'title': 'Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges', 'source': 'ACS Publications', 'date': 'Aug 26, 2024', 'snippet': 'Multiple vaccine platforms have been employed to develop the nasal \nSARS-CoV-2 vaccines in preclinical studies, and the dominating pipelines...', 'thumbnail': 'https://serpapi.com/searches/6723c8ec8d0417cf92184f09/images/b3cce3728694140faa7d7a65ca924eb111f4ed0699dc3561d356cd231115ab75.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8946354389190674}",,,,,,,,,,['neutral'],neutral,1
NCT00781742,"{'position': 1, 'link': 'https://www.psychiatrictimes.com/view/ketamine-induced-optimism-new-hope-development-rapid-acting-antidepressants', 'title': 'Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants', 'source': 'Psychiatric Times', 'date': 'Jul 13, 2012', 'snippet': 'There is rapidly escalating interest in drugs that target the glutamatergic \nneurotransmitter system, especially NMDA receptor modulators.', 'thumbnail': 'https://serpapi.com/searches/6723c8f44a4a1daf8986358b/images/9157f2d8b536fe5a756d7fb53865b1ed790969c0de1ea6286f867d698c1779c7.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.798674464225769}",,,,,,,,,,['positive'],positive,1
NCT04208958,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01522-4', 'title': 'Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends', 'source': 'Nature', 'date': 'Aug 28, 2023', 'snippet': 'Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, \nand PD-L1, novel targeting LAG-3 drugs have also been approved...', 'thumbnail': 'https://serpapi.com/searches/6723c8f7163bdf5e17e18aaa/images/ff3741126700dd2e758b5850e97bfca4609e3a878bc05879d30f0616ae8fae48.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9091306924819946}",,,,,,,,,,['neutral'],neutral,1
NCT05033886,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/astellas-fezolinetant-reduces-frequency-and-severity-of-vms-associated-with-menopause-in-women-considered-unsuitable-for-hormone-therapy-302001281.html', 'title': ""Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy"", 'source': 'PR Newswire', 'date': 'Nov 29, 2023', 'snippet': 'Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated \nfezolinetant 45 mg achieved statistically significant reductions in the...', 'thumbnail': 'https://serpapi.com/searches/6723c8f71f3d4b4cf1a9fd7b/images/1d1dc7d957c59c2974e4f74112ba88058922b605d26481840a98d21fefae53c5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7966688275337219}",,,,,,,,,,['neutral'],neutral,1
NCT00000389,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-34938-7', 'title': 'The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing', 'source': 'Nature', 'date': 'Jul 26, 2023', 'snippet': ""In medical trials, 'blinding' ensures the equal distribution of expectancy \neffects between treatment arms in theory; however, blinding often..."", 'thumbnail': 'https://serpapi.com/searches/6723c8f9059caf650f19c45b/images/705bbfbc027f4abddf4b31419d1e83000aef3f55a4a8779b518f605dc66e4c37.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9171350598335266}",,,,,,,,,,['neutral'],neutral,1
NCT03915470,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/destiny-pharma-research-treating-mrsa-infections-cf-xf-73/', 'title': 'Destiny Pharma Will Research Treating MRSA Infections in CF With XF-73', 'source': 'Cystic Fibrosis News Today', 'date': 'Jul 14, 2022', 'snippet': 'Destiny Pharma received a Cystic Fibrosis Foundation award to research \ntreating MRSA infections with the investigational compound XF-73.', 'thumbnail': 'https://serpapi.com/searches/6723c959358539e88f8212e6/images/de5c6c21e79e5734c1b29fa4d6cb05d2276d25229acfb51e31497562ed19ee2b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.854690432548523}",,,,,,,,,,['neutral'],neutral,1
NCT03959488,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2110275', 'title': 'Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants', 'source': 'The New England Journal of Medicine', 'date': 'Mar 2, 2022', 'snippet': 'Respiratory syncytial virus (RSV) is a major cause of lower respiratory \ntract infection and hospitalization in infants.', 'thumbnail': 'https://serpapi.com/searches/6723c96fb9458db70e908458/images/4b61eee0033ffc943ae0bf853f4607de43fbfdd3de9219347ae07516881fc049.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6536106467247009}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMc2112186', 'title': 'Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity', 'source': 'The New England Journal of Medicine', 'date': 'Mar 2, 2022', 'snippet': 'Nirsevimab is a monoclonal antibody targeting respiratory syncytial virus. \nIn this trial, the safety of nirsevimab was assessed in infants...', 'thumbnail': 'https://serpapi.com/searches/6723c96fb9458db70e908458/images/4b61eee0033ffc943bed07d247d63ebc535bf35e68b2cce07ca448245bf8f430.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8949854373931885}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT01817166,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/09/20/ectrims-2024-high-dose-vitamin-d-delay-progression-ms/', 'title': 'ECTRIMS 2024: High-dose vitamin D can help delay progression to MS', 'source': 'Multiple Sclerosis News Today', 'date': '1 month ago', 'snippet': 'High-dose cholecalciferol (vitamin D) is safe and can nearly double the \ntime it takes for clinically isolated syndrome to progress to MS.', 'thumbnail': 'https://serpapi.com/searches/6723c9713c944b6c22938b4b/images/61e96f9ec50e4d9f1d4394860f0ef8c099fa7c6ce97f5cded849f4437a0052dd.png', 'sentiment': 'positive', 'sentiment_prob': 0.8597730398178101}",,,,,,,,,,['positive'],positive,1
NCT02737501,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1810171', 'title': 'Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Sep 25, 2018', 'snippet': 'Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, \nhas robust efficacy in patients with ALK-positive non–small-cell...', 'thumbnail': 'https://serpapi.com/searches/6723c980aab36de635619ceb/images/0898b36e57dc3a51c24b041599ee23e8d40aedb22a1860fb0c33124fbd372041.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7678595781326294}","{'position': 2, 'link': 'https://www.targetedonc.com/view/differences-in-tkis-may-sway-choice-of-first-line-therapy-in-alk-nsclc', 'title': 'Differences in TKIs May Sway Choice of First-Line Therapy in ALK+ NSCLC', 'source': 'Targeted Oncology', 'date': 'May 21, 2024', 'snippet': 'Both brigatinib and [alectinib], and even lorlatinib, are superior to \ncrizotinib and they are all acceptable frontline options, with subtle \ndifferences between...', 'thumbnail': 'https://serpapi.com/searches/6723c980aab36de635619ceb/images/0898b36e57dc3a51c36702ab4b1e3a7d3b42f79f7bd7411f9f595ecd296cf218.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7617494463920593}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04773587,"{'position': 1, 'link': 'https://www.medcentral.com/dermatology/fda-approves-non-steroidal-roflumilast-cream-for-atopic-dermatitis', 'title': 'FDA Approves Non-Steroidal Roflumilast Cream for Atopic Dermatitis', 'source': 'MedCentral', 'date': 'Jul 9, 2024', 'snippet': 'The US Food and Drug Administration (FDA) approved Zoryve (roflumilast \n0.15% cream, Arcutis Biotherapeutics) for adults and children aged 6 years \nand older...', 'thumbnail': 'https://serpapi.com/searches/6723c99266d995af2816bdb1/images/4338d020608cc8effd027e72dbb7e8ca0e6131cb97a9d46360b9074ad6ce586a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6863114833831787}","{'position': 2, 'link': 'https://www.contemporarypediatrics.com/view/fda-accepts-snda-for-roflumilast-cream-0-15-to-treat-atopic-dermatitis', 'title': 'FDA accepts sNDA for roflumilast cream 0.15% to treat atopic dermatitis', 'source': 'Contemporary Pediatrics', 'date': 'Nov 29, 2023', 'snippet': 'The FDA has accepted a supplemental New Drug Application (sNDA) for \nroflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in...', 'thumbnail': 'https://serpapi.com/searches/6723c99266d995af2816bdb1/images/4338d020608cc8ef9a5522fa21bc9c4f906f97cbe414012f3d8f9d8f2e62bd40.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8596817851066589}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00837239,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1274336/full', 'title': 'An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives', 'source': 'Frontiers', 'date': 'Feb 7, 2024', 'snippet': 'Bufalin is one of the bufadienolides in toad venom that has been \nextensively studied for its potential in refractory and drug-resistant \ncancer treatments in...', 'thumbnail': 'https://serpapi.com/searches/6723c9a7d997ab18f561115f/images/02e9f92f313b678b6f39f5e767c8b0d68bf6986b4131ccea964b470f16664a5e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9103862047195435}","{'position': 2, 'link': 'https://www.science.org/doi/10.1126/sciadv.ade5393', 'title': 'Na, K-ATPase α1 cooperates with its endogenous ligand to reprogram immune microenvironment of lung carcinoma and promotes immune escape', 'source': 'Science | AAAS', 'date': 'Feb 10, 2023', 'snippet': 'The Na, K-ATPase α1/EO signaling facilitates immune escape in lung cancer, \nand manipulation of this signaling shows great promise in improving \nimmunotherapy...', 'thumbnail': 'https://serpapi.com/searches/6723c9a7d997ab18f561115f/images/02e9f92f313b678b320c2bfd1c7fe45f87b2d6187aec7012fe55854ada0f19cb.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5957642197608948}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04446312,"{'position': 1, 'link': 'https://www.empr.com/home/news/suflave-a-low-volume-colonoscopy-preparation-gets-fda-approval/', 'title': 'Suflave, a Low-Volume, Colonoscopy Preparation, Gets FDA Approval - MPR', 'source': 'Medical Professionals Reference', 'date': 'Jun 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Suflave™ (polyethylene \nglycol 3350, sodium sulfate, potassium chloride,...', 'thumbnail': 'https://serpapi.com/searches/6723c9b51a5b542101c4093f/images/97c7c5f40e7b1229e58ca6e4c202229358e55a2111ce99fa6e95717211e2a00c.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5583792328834534}",,,,,,,,,,['positive'],positive,1
NCT04771273,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/severe-fatty-liver-disease-lowered-with-survodutide-adults-phase-2-trial/', 'title': 'Severe fatty liver disease lowered with survodutide in adults in Phase 2 trial', 'source': 'Liver Disease News', 'date': 'Mar 4, 2024', 'snippet': 'Weekly survodutide injections lowered the severity of a fatty liver disease \ncalled metabolic-associated steatohepatitis and liver scarring.', 'thumbnail': 'https://serpapi.com/searches/6723c9b69e38e54024ff21c0/images/9d5d6cdb52d42927f3e8c1523203dc7ab136e55bacb99e7876ab1533b457f32c.png', 'sentiment': 'negative', 'sentiment_prob': 0.6533967852592468}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2401755', 'title': 'A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis', 'source': 'The New England Journal of Medicine', 'date': 'Jun 7, 2024', 'snippet': 'Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) \nreceptor may be more effective than GLP-1 receptor agonism alone for...', 'thumbnail': 'https://serpapi.com/searches/6723c9b69e38e54024ff21c0/images/9d5d6cdb52d429279c18f49daebf60a3df67c528bc2160b9d55a5a7ebadf526d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8140966296195984}","{'position': 3, 'link': 'https://www.globenewswire.com/en/news-release/2024/02/26/2834806/0/en/Survodutide-Phase-II-trial-shows-83-of-adults-treated-achieved-groundbreaking-results-in-liver-disease-due-to-MASH-with-significant-improvements-in-fibrosis.html', 'title': 'Survodutide Phase II trial shows 83% of adults treated', 'source': 'GlobeNewswire', 'date': 'Feb 26, 2024', 'snippet': 'Survodutide has potential to become best-in-class treatment for metabolic \ndysfunction-associated steatohepatitis (MASH)*, after meeting its...', 'thumbnail': 'https://serpapi.com/searches/6723c9b69e38e54024ff21c0/images/9d5d6cdb52d429272e15dc6c42ab370cc7fe22ae78460cad0b4d52528af30126.png', 'sentiment': 'positive', 'sentiment_prob': 0.8356006741523743}","{'position': 4, 'link': 'https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00147-9/fulltext', 'title': 'European association for the study of the liver (EASL) congress 2024', 'source': 'The Lancet', 'date': 'Jun 18, 2024', 'snippet': ""The European Association for the Study of the Liver (EASL) congress, \nEurope's largest event in hepatology, took place in Milan, Italy from 5 to \n8 June 2024 in..."", 'thumbnail': 'https://serpapi.com/searches/6723c9b69e38e54024ff21c0/images/9d5d6cdb52d42927256c0c2c0d00026aa317da33d625b7eeb0f811ce5e225418.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9003056883811951}","{'position': 5, 'link': 'https://www.globenewswire.com/news-release/2022/09/21/2520159/0/en/Zealand-Pharma-Announces-Oral-Presentation-of-Phase-2-Data-for-BI-456906-at-the-58th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes-EASD.html', 'title': 'Zealand Pharma Announces Oral Presentation of Phase 2 Data', 'source': 'GlobeNewswire', 'date': 'Sep 21, 2022', 'snippet': 'Treatment with BI 456906 resulted in dose-dependent HbA1c reductions, up to \na maximum of -1.88% at Week 16 in people with type 2 diabetes (T2D).', 'thumbnail': 'https://serpapi.com/searches/6723c9b69e38e54024ff21c0/images/9d5d6cdb52d42927067c0ae0256c375e97546cd3d05e663076e2e9ed7bf4e6d3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7375938296318054}",,,,,,"['negative', 'neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT02215616,"{'position': 1, 'link': 'https://huntingtonsdiseasenews.com/news/aanam-laquinimod-reduces-brain-atrophy-in-early-hd-legato-hd-trial/', 'title': '#AANAM - Laquinimod Reduces Brain Atrophy in Early HD, Study Shows', 'source': ""Huntington's Disease News"", 'date': 'May 14, 2019', 'snippet': ""Laquinimod reduced brain atrophy but does not improve motor function in \nearly Huntington's disease, results from the Phase 2 LEGATO-HD trial..."", 'thumbnail': 'https://serpapi.com/searches/6723c9b81397ba009d171ac0/images/bf987dae4c25f267e6fe746ecfd996b4c10ed81876b9670fe15bd7325d78fb85.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8253983855247498}",,,,,,,,,,['neutral'],neutral,1
NCT04676724,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2210027', 'title': 'Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection', 'source': 'The New England Journal of Medicine', 'date': 'Nov 8, 2022', 'snippet': 'In this phase 2b trial, bepirovirsen at a dose of 300 mg per week for 24 \nweeks resulted in sustained HBsAg and HBV DNA loss in 9 to 10% of \nparticipants with...', 'thumbnail': 'https://serpapi.com/searches/6723c9cde9245683a8b966f9/images/b4825f7ae24421b38bf030e7bc91bff74c8a659aa6264c079a8191da896c8c13.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5814180374145508}",,,,,,,,,,['neutral'],neutral,1
NCT02611830,"{'position': 1, 'link': 'https://ibdnewstoday.com/2020/03/04/panel-recommends-european-approval-of-entyvio-at-home-injection/', 'title': ""At-Home Entyvio Injection for Crohn's Recommended for Europe Approval"", 'source': 'IBD News Today', 'date': 'Mar 4, 2020', 'snippet': ""A European Medicines Agency panel recommended approval of an at-home \ninjection of Entyvio, which is used to treat Crohn's and ulcerative..."", 'thumbnail': 'https://serpapi.com/searches/6723c9e121e77bb0b56ea3e6/images/1e34fe6717113a57b4285917d1438152870f87abb97514720bab4c198b99592f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8984673619270325}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/fda-to-review-sc-formulation-of-vedolizumab-for-ulcerative-colitis/', 'title': 'FDA to Review SC Formulation of Vedolizumab for Ulcerative Colitis', 'source': 'Medical Professionals Reference', 'date': 'Apr 27, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted for review the \nresubmitted Biologics License Application (BLA) for the investigational \nsubcutaneous (SC)...', 'thumbnail': 'https://serpapi.com/searches/6723c9e121e77bb0b56ea3e6/images/1e34fe6717113a5778add1a2b4769aefda81f74d7d8031a7e58487485a52c7ec.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9246930480003357}","{'position': 3, 'link': 'https://ibdnewstoday.com/2019/04/05/ema-advances-under-the-skin-injection-entyvio-crohns-colitis/', 'title': 'EMA Advances Under-the-skin Injection of Entyvio for Crohn’s and Ulcerative Colitis', 'source': 'ibdnewstoday.com', 'date': 'Apr 5, 2019', 'snippet': 'EMA has accepted the Marketing Authorization Line Extension Application for \na new subcutaneous (under-the-skin) form of Entyvio.', 'thumbnail': 'https://serpapi.com/searches/6723c9e121e77bb0b56ea3e6/images/1e34fe6717113a5738f20b6985cbcdddfde539610bec54e56b6d2640c1639702.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.925054132938385}","{'position': 4, 'link': 'https://www.empr.com/home/news/entyvio-for-subcutanous-administration-approved-for-ulcerative-colitis/', 'title': 'Entyvio for Subcutanous Administration Approved for Ulcerative Colitis', 'source': 'Medical Professionals Reference', 'date': 'Sep 28, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved the subcutaneous (SC) \nadministration of Entyvio (vedolizumab) for maintenance treatment of adults \nwith...', 'thumbnail': 'https://serpapi.com/searches/6723c9e121e77bb0b56ea3e6/images/1e34fe6717113a571a10dc6879cb1c121febda3a0453922300021d5bebe82de6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8984530568122864}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01239134,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2018/08/10/collaboration-tests-trx518-bavencio-combo-clinical-trial-solid-tumors/', 'title': 'Collaboration Tests TRX518-Bavencio Combo in Clinical Trial of Solid Tumors', 'source': 'Ovarian Cancer News Today', 'date': 'Aug 10, 2018', 'snippet': 'Collaboration agreement between Leap Therapeutics with Merck KGaA and \nPfizer will support new Phase 1/2 trial testing TRX518 in combination...', 'thumbnail': 'https://serpapi.com/searches/6723ca5a0f2a2cff3865e63e/images/b8f09dcd0ed66f521978c5f5a4c4ff3ba0a293bc1042d98e7dd61865c559a115.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8667848110198975}",,,,,,,,,,['neutral'],neutral,1
NCT02620046,"{'position': 1, 'link': 'https://ibdnewstoday.com/2020/03/04/panel-recommends-european-approval-of-entyvio-at-home-injection/', 'title': ""At-Home Entyvio Injection for Crohn's Recommended for Europe Approval"", 'source': 'IBD News Today', 'date': 'Mar 4, 2020', 'snippet': ""A European Medicines Agency panel recommended approval of an at-home \ninjection of Entyvio, which is used to treat Crohn's and ulcerative..."", 'thumbnail': 'https://serpapi.com/searches/6723ca5ed721280175b4cb2a/images/a54a6d717cda7d8d460c44f16e023917c27341540d8f2cd7fa9453e11d08c7c4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8984673619270325}",,,,,,,,,,['neutral'],neutral,1
NCT05485987,"{'position': 1, 'link': 'https://friedreichsataxianews.com/friedreichs-ataxia-experimental-treatments/epi-743-vatiquinone/', 'title': ""EPI-743 (Vatiquinone) for Friedreich's Ataxia"", 'source': ""Friedreich's Ataxia News"", 'date': 'Sep 7, 2023', 'snippet': ""EPI-743 (Vatiquinone) is being developed by BioElectron for Friedreich's \nataxia and received FDA orphan drug and fast track designations."", 'thumbnail': 'https://serpapi.com/searches/6723ca6575f974110b4e6f7d/images/737ebe335e6c96d663391c90057c8fec11feb60bd2d91c6cff1238169e9fd1d8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8560620546340942}",,,,,,,,,,['neutral'],neutral,1
NCT02840279,"{'position': 1, 'link': 'https://fragilexnewstoday.com/news/fda-grants-bpn14770-orphan-drug-status-fragile-x-syndrome/', 'title': 'Potential Fragile X Therapy BPN14770 Receives FDA Orphan Drug Status', 'source': 'Fragile X News Today', 'date': 'Apr 12, 2018', 'snippet': 'Investigational therapy BPN14770 has been granted orphan drug status by the \nU.S. Food and Drug Administration for the treatment of fragile X...', 'thumbnail': 'https://serpapi.com/searches/6723ca7fd997ab19584a7f62/images/b34484f800abecc95cff34196eb841ce9d974000472639fdfd61696eefa0329b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8758559226989746}",,,,,,,,,,['neutral'],neutral,1
NCT05186051,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/fda-oks-phase-2-clinical-trial-oral-zyil1-parkinsons/', 'title': 'FDA OKs Phase 2 clinical trial of oral ZYIL1 in Parkinson’s patients', 'source': ""Parkinson's News Today"", 'date': 'Dec 20, 2023', 'snippet': ""The Parkinson's clinical trial will test the safety and tolerability of \nZYIL1, an inhibitor of the NLRP3 protein tied to brain inflammation."", 'thumbnail': 'https://serpapi.com/searches/6723ca9efd3b5abd335a5063/images/3c0e9c10142e6c0fd0366a7e061a092aa1bd2e11bd3b70b44b357f2f6c738d52.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8039805889129639}","{'position': 2, 'link': 'https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/zydus-begins-phase-ii-trial-of-zyil1-nlrp3-inhibitor-in-patients-with-als/104689856', 'title': 'Zydus begins Phase II trial of ZYIL1, NLRP3 inhibitor in patients with ALS', 'source': 'ET HealthWorld', 'date': 'Oct 25, 2023', 'snippet': ""Zydus Life Sciences is to initiate the Phase II clinical study of NLRP3 \ninhibitor 'ZYIL1' in patients with amyotrophic lateral sclerosis (ALS)."", 'thumbnail': 'https://serpapi.com/searches/6723ca9efd3b5abd335a5063/images/3c0e9c10142e6c0fd0bdfa2f8b657ef1f911fa3fa288ed90103c51fa00718893.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8477136492729187}","{'position': 3, 'link': 'https://www.expresspharma.in/zydus-begins-phase-ii-trial-of-zyil1-nlrp3-inhibitor-in-patients-with-als/', 'title': 'Zydus begins Phase II trial of ZYIL1, NLRP3 inhibitor in patients with ALS', 'source': 'Express Pharma', 'date': 'Oct 25, 2023', 'snippet': ""Zydus Life Sciences has received permission from CDSCO, India, to initiate \nthe Phase II clinical study of NLRP3 inhibitor 'ZYIL1' in patients with \namyotrophic..."", 'thumbnail': 'https://serpapi.com/searches/6723ca9efd3b5abd335a5063/images/3c0e9c10142e6c0fc31c3a287448aa93acbce6fab8bb634b3713b293cb25edee.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8100893497467041}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03690206,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2022/09/30/2525830/0/en/Zealand-Pharma-Announces-Positive-Results-from-Phase-3-Trial-of-Glepaglutide-in-Patients-with-Short-Bowel-Syndrome-EASE-1.html', 'title': 'Zealand Pharma Announces Positive Results from Phase 3', 'source': 'GlobeNewswire', 'date': 'Sep 30, 2022', 'snippet': 'Glepaglutide significantly reduced the volume of parenteral support \nrequired compared to placebo when administered to patients with SBS and \nintestinal failure.', 'thumbnail': 'https://serpapi.com/searches/6723ca9e9f8bfc1ce8111fa1/images/a314c625ed1e924ca395076f442807be7a84d3d1389767d7dfca740c3b649bab.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6700024008750916}",,,,,,,,,,['neutral'],neutral,1
NCT03218917,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2021713', 'title': 'Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 7, 2020', 'snippet': 'In this 24-week trial, reduction of neutrophil serine protease activity \nwith brensocatib in patients with bronchiectasis was associated with \nimprovements in...', 'thumbnail': 'https://serpapi.com/searches/6723c9ff56f970c1fd841d58/images/5932a854787a5fe83216a121ff976a87ced44a6e98478db48a46f102f7095756.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8518407940864563}","{'position': 2, 'link': 'https://bronchiectasisnewstoday.com/2020/04/27/brensocatib-potential-bronchiectasis-therapy-being-tested-against-covid-19-in-uk-trial/', 'title': 'Brensocatib, Potential Bronchiectasis Therapy, To Enter COVID-19 Trial', 'source': 'Bronchiectasis News Today', 'date': 'Apr 27, 2020', 'snippet': ""Insmed's oral potential therapy, which blocks a protein crucial to immune \ncells called neutrophils, will be tested on hospitalized COVID-19..."", 'thumbnail': 'https://serpapi.com/searches/6723c9ff56f970c1fd841d58/images/5932a854787a5fe88cc067902e55eb04b70abfb82092cb444a9db44f0113cc1b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8686081767082214}","{'position': 3, 'link': 'https://bronchiectasisnewstoday.com/2020/06/15/brensocatib-granted-fda-breakthrough-therapy-status-for-non-cystic-fibrosis-bronchiectasis/', 'title': 'Non-CF Bronchiectasis Drug Brensocatib Gets FDA Breakthrough Status', 'source': 'Bronchiectasis News Today', 'date': 'Jun 15, 2020', 'snippet': ""The U.S. Food and Drug Administration has granted breakthrough therapy \nstatus to Insmed's brensocatib to treat non-cystic fibrosis..."", 'thumbnail': 'https://serpapi.com/searches/6723c9ff56f970c1fd841d58/images/5932a854787a5fe8011caabd591fc4bd60a84aab823a59fe496325e14b780522.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6882180571556091}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT01374425,"{'position': 1, 'link': 'https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00004-4/fulltext', 'title': 'Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials', 'source': 'The Lancet', 'date': 'Feb 4, 2023', 'snippet': 'Antiangiogenic drug (AAD)-triggered oxygen and nutrient depletion through \nsuppression of angiogenesis switches glucose-dependent to...', 'thumbnail': 'https://serpapi.com/searches/6723ca03be324f741d448ca1/images/40040d61387fc6fea9836c921ef85a85687627d1d43381758a82ea6253635bd8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.836558997631073}",,,,,,,,,,['neutral'],neutral,1
NCT04740814,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Cimzia', 'title': 'Certolizumab Pegol (Cimzia®)', 'source': 'UCB', 'date': 'Oct 12, 2018', 'snippet': 'Axial Spondyloarthritis, Certolizumab Pegol in Subjects With Active Axial \nSpondyloarthritis, Phase 3, AKS001 Completed, NCT01087762 · 2009-011719-19 \n· LINK', 'thumbnail': 'https://serpapi.com/searches/6723ca2808abe4f8a8c7fec7/images/a25925d8aeb6229ff3965f829d057e3e224c86eef560c3df057455788e0cffce.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9130622744560242}",,,,,,,,,,['neutral'],neutral,1
NCT04736628,"{'position': 1, 'link': 'https://www.renalandurologynews.com/news/avenciguat-reduces-albuminuria-in-ckd/', 'title': 'Avenciguat Reduces Albuminuria in CKD', 'source': 'Renal and Urology News', 'date': 'Jun 17, 2024', 'snippet': 'Investigators report pooled results of phase 2b trials investigating \navenciguat and albuminuria in patients with chronic kidney disease...', 'thumbnail': 'https://serpapi.com/searches/6723ca31a32436063d414319/images/c6b368ec3c761ec0add62b7ba0a72c1b42077b191e7b08d3c3a69fbb2e30b810.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9056670665740967}",,,,,,,,,,['neutral'],neutral,1
NCT02840474,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.697683/full', 'title': 'Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application', 'source': 'Frontiers', 'date': 'Feb 8, 2024', 'snippet': 'In this review, we summarize the recent development of bNAbs and its \napplication in HIV-1 acquisition prevention as well as discuss the \ninnovative approaches...', 'thumbnail': 'https://serpapi.com/searches/6723ca3b0f2a2cff3865e62f/images/87c69ac1af1e5d9f702438cc000198239f53a7e55c6875ca8e37da88423a54b8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8679898381233215}",,,,,,,,,,['neutral'],neutral,1
NCT03272347,"{'position': 1, 'link': 'https://life4me.plus/pt/news/implant-mk-8591-5421/', 'title': 'MK-8591 implant has been shown to be highly effective at low dosages', 'source': 'Life4me+', 'date': 'Aug 13, 2019', 'snippet': 'MK-8591 developed by Merck showed high antiviral activity against HIV-1 \nwith a single dose of 0.5 mg.', 'thumbnail': 'https://serpapi.com/searches/6723ca3cfab27313f4a09819/images/22096f7b1aadd2edb2a114cfac3684896fc2f06c7b542010327271be1768d2d2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8965582847595215}",,,,,,,,,,['positive'],positive,1
NCT00971165,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/circ.138.suppl_1.14342', 'title': 'Abstract 14342: Effectiveness of Chlorthalidone With Amiloride versus Losartan in Patients With Diabetes Mellitus and Stage I Hypertension: Results of a Randomized, Double-Blind, Clinical Trial', 'source': 'American Heart Association Journals', 'date': 'Nov 5, 2018', 'snippet': 'Treatment of hypertension based on a combination of chlorthalidone and \namiloride is more effective than losartan to lower BP in patients with \ndiabetes and...', 'thumbnail': 'https://serpapi.com/searches/6723cabd56f970c1fd841d96/images/46c279ec33cb3961f354d7ab524e3aea51453447e17d691b094aa2c8ff759d78.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7573176026344299}",,,,,,,,,,['neutral'],neutral,1
NCT04446299,"{'position': 1, 'link': 'https://www.empr.com/home/news/suflave-a-low-volume-colonoscopy-preparation-gets-fda-approval/', 'title': 'Suflave, a Low-Volume, Colonoscopy Preparation, Gets FDA Approval - MPR', 'source': 'Medical Professionals Reference', 'date': 'Jun 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Suflave™ (polyethylene \nglycol 3350, sodium sulfate, potassium chloride,...', 'thumbnail': 'https://serpapi.com/searches/6723cac96cca5ed2960d2b0d/images/f1556e37529369a38eb4753d2d7a59bbc5e3e87525c23d816e2ac135d09eda4f.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5583792328834534}",,,,,,,,,,['positive'],positive,1
NCT05384119,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/news/tti-101-in-hr-positive-her2-negative-breast-cancer/', 'title': 'Clinical Trial: TTI-101 in HR-Positive, HER2-Negative Breast Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Nov 2, 2023', 'snippet': 'Researchers are conducting a phase 1b/2 study of TTI-101 plus palbociclib \nand an aromatase inhibitor or fulvestrant in HR+, HER2- breast...', 'thumbnail': 'https://serpapi.com/searches/6723cae1bcd652fbf0f89d00/images/1bc8f60b31d248fdbac6bf674bb682a63ab311673751acfdf1488a5f80cad8c1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9230514764785767}",,,,,,,,,,['neutral'],neutral,1
NCT03051659,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-25769-z', 'title': 'Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer', 'source': 'Nature', 'date': 'Sep 21, 2021', 'snippet': 'We present final overall survival (OS) results (n = 88) from a randomized \nphase 2 trial of eribulin ± pembrolizumab for patients with metastatic HR+ \nbreast...', 'thumbnail': 'https://serpapi.com/searches/6723caf7690121692ff1390d/images/42efd0d7845f6603b71abed921b1326cb18245262cb33ff56475ba4d66a04ffd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8877944350242615}",,,,,,,,,,['neutral'],neutral,1
NCT03066778,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2021/03/05/keytruda-use-us-stopped-advanced-small-cell-lung-cancer/', 'title': 'Keytruda Will No Longer Treat Advanced Small Cell Lung Cancers in US', 'source': 'Immuno-Oncology News', 'date': 'Mar 5, 2021', 'snippet': 'Keytruda failed in confirmatory trial to significantly extent survival, and \nwill no longer be available in U.S. for metastatic SCLC patients...', 'thumbnail': 'https://serpapi.com/searches/6723caf9c117a9277757bf09/images/8df69ce1468c0c4970f8cc4efcb4c33f0f0cc0fd3ecfcf51f0723193fd48a513.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8349505662918091}",,,,,,,,,,['negative'],negative,0
NCT00554606,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332221002274', 'title': 'Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease', 'source': 'ScienceDirect.com', 'date': 'Mar 3, 2021', 'snippet': 'The incidence and prevalence of inflammatory bowel disease (IBD) are \nincreasing worldwide. Current approved medication for IBD treatment in the \nclinic...', 'thumbnail': 'https://serpapi.com/searches/6723cb09fab27313b26fb094/images/358acf9e777df31121ca9da7a570d284e0230b8aa356fdcfc1fa3e7ec2642d62.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7565747499465942}",,,,,,,,,,['neutral'],neutral,1
NCT04153929,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2022/09/21/2520159/0/en/Zealand-Pharma-Announces-Oral-Presentation-of-Phase-2-Data-for-BI-456906-at-the-58th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes-EASD.html', 'title': 'Zealand Pharma Announces Oral Presentation of Phase 2 Data', 'source': 'GlobeNewswire', 'date': 'Sep 21, 2022', 'snippet': 'Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of \nPhase 2 Data for BI 456906 at the 58th Annual Meeting of the...', 'thumbnail': 'https://serpapi.com/searches/6723cb0bd721280175b4cb59/images/6116193844a2984028897a57b2aa6fc572962a59b6cf7f5531c1a7f70f920017.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9457303881645203}",,,,,,,,,,['neutral'],neutral,1
NCT02215967,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.01243/full', 'title': 'CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions', 'source': 'Frontiers', 'date': 'Jun 27, 2023', 'snippet': 'CAR T-cell therapy has changed the treatment landscape of B-cell \nmalignancies, providing a potentially curative option for patients who are \nrefractory to...', 'thumbnail': 'https://serpapi.com/searches/6723cb0e207c88686f8a1e17/images/23905793e027047f45905aeaa4668f7c05a59d9b7224c6c3127dbacc62f3dd36.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5597637295722961}",,,,,,,,,,['neutral'],neutral,1
NCT01220492,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-022-01119-3', 'title': 'Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)', 'source': 'Nature', 'date': 'Aug 13, 2022', 'snippet': 'In this review, we discussed recent developments in etiology and \nprospective therapeutic targets, as well as pharmacological candidates in \npre/clinical trials...', 'thumbnail': 'https://serpapi.com/searches/6723cb30fd3b5abd335a5096/images/df33c19193181cfb7169a8c632bf12b115d31054dc778be0645fa05004b05190.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9206169247627258}",,,,,,,,,,['neutral'],neutral,1
NCT02307513,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1816594', 'title': 'Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome', 'source': 'The New England Journal of Medicine', 'date': 'Nov 13, 2019', 'snippet': 'In a phase 2 trial, apremilast was effective in reducing the number of oral \nulcers, the pain associated with oral ulcers, and overall disease activity.', 'thumbnail': 'https://serpapi.com/searches/6723cb32d403e13e40130115/images/f114b1a83b7d1a5f78db4d24d5a3dd63b82edc2afc525f5b7603a2cbf0fe3bd3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7539490461349487}",,,,,,,,,,['neutral'],neutral,1
NCT02594124,"{'position': 1, 'link': 'https://investors.biogen.com/news-releases/news-release-details/new-spinrazar-nusinersen-data-reinforce-sustained-efficacy-and', 'title': 'New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients', 'source': 'Biogen', 'date': 'May 18, 2020', 'snippet': 'New data show that continuous treatment with SPINRAZA for up to six and a \nhalf years improved or stabilized motor function and disease activity in a \nbroad...', 'thumbnail': 'https://serpapi.com/searches/6723cb382c566d0ec8034aae/images/278cd00c384301526e87697b1c748786fcba010c072177a6d2e178f7f2cfa645.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5165205001831055}","{'position': 2, 'link': 'https://smanewstoday.com/news/anesthesia-spinraza-administration-safe-effective-children-type-2-sma-study/', 'title': 'For SMA Type 2 Children, Anesthesia Safe for Spinraza Injection, Study Says', 'source': 'SMA News Today', 'date': 'Oct 17, 2018', 'snippet': 'Standard general anesthesia for the administration of Spinraza (nusinersen) \nis safe and effective in children with type 2 SMA,...', 'thumbnail': 'https://serpapi.com/searches/6723cb382c566d0ec8034aae/images/278cd00c384301524e91baa427decd74c955c09186971ea10c87275e0443b3ae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.668415367603302}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04350177,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/risvodetinib-slow-progression-parkinsons-clinical-trial/', 'title': 'Risvodetinib shows potential to slow disease progression in clinical trial', 'source': ""Parkinson's News Today"", 'date': 'Mar 11, 2024', 'snippet': 'Researchers and patients in ongoing Phase 2 study of this oral therapy are \nreporting stability in impressions of disease status, severity.', 'thumbnail': 'https://serpapi.com/searches/6723cb3d08abe4f8a8c7ff1c/images/4501760687721318a1d05447a7a50bca0bf7488b3aec819cd0ca1ff8a6627177.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7606872320175171}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/no-serious-side-effects-found-inhibikase-ikt-148009-200-mg-dose/', 'title': 'Inhibikase takes steps ahead of study of IkT-148009 for...', 'source': ""Parkinson's News Today"", 'date': 'May 3, 2023', 'snippet': ""A once-daily 200 mg dose of IkT-148009, Inhibikase Therapeutics' \ninvestigational therapy for Parkinson's disease, reached steady levels in \nthe body after four..."", 'thumbnail': 'https://serpapi.com/searches/6723cb3d08abe4f8a8c7ff1c/images/45017606877213180a14f8ac780db521abeb8e1b5250e618ffed7d6ccde26885.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7618847489356995}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00346918,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0907419', 'title': 'Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease', 'source': 'The New England Journal of Medicine', 'date': 'Jun 26, 2010', 'snippet': 'In this 18-month, open-label, randomized, controlled trial, we sought to \ndetermine whether sirolimus halts the growth in kidney volume among \npatients with...', 'thumbnail': 'https://serpapi.com/searches/6723cb47cf32e0cd92f923b3/images/eb1d5d7d27fc840166c99cb797ff57a432b9fcf063131405356de3bb01de9b00.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9128749966621399}",,,,,,,,,,['neutral'],neutral,1
NCT00316914,"{'position': 1, 'link': 'https://charcot-marie-toothnews.com/news/chemo-induced-nerve-damage-less-likely-cmt-patients-with-uncommon-gene-variants/', 'title': 'Chemo-induced Nerve Damage Less Likely in Certain CMT Patients, Study Finds', 'source': 'Charcot-Marie-Tooth News', 'date': 'Jul 17, 2020', 'snippet': 'A study reports that oxaliplatin, a chemo agent, does not increase the risk \nof neuropathy in patients carrying uncommon variants in...', 'thumbnail': 'https://serpapi.com/searches/6723cb4bf41044ef14218938/images/a37cf1e19832c2245b7c5f31ea10717e69f20cb18d86413d9cb62d510b025cc0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8533989787101746}",,,,,,,,,,['neutral'],neutral,1
NCT03844386,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2024/2147912', 'title': 'The Question of HIV Vaccine: Why Is a Solution Not Yet Available? - Libera - 2024 - Journal of Immunology Research', 'source': 'Wiley Online Library', 'date': 'Apr 8, 2024', 'snippet': 'Ever since its discovery, human immunodeficiency virus type 1 (HIV-1) \ninfection has remained a significant public health concern.', 'thumbnail': 'https://serpapi.com/searches/6723cb60c05eb51be919d944/images/54162ff205ac858befd3af8fbd9c1a1ae9a54bd859064772b26aca33925afe14.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5477708578109741}",,,,,,,,,,['neutral'],neutral,1
NCT03812263,"{'position': 1, 'link': 'https://www.cgtlive.com/view/fda-crl-rocket-lad-i-gene-therapy-kresladi', 'title': 'FDA Issues CRL for Rocket’s LAD-I Gene Therapy', 'source': 'CGTLive®', 'date': 'Jun 28, 2024', 'snippet': ""The FDA has issued a complete response letter (CRL) to Rocket \nPharmaceuticals' marnetegragene autotemcel(RP-L201), to be marketed under \nthe name Kresladi."", 'thumbnail': 'https://serpapi.com/searches/6723cb6c3b3c3212f7fbc2b7/images/c121746706d19af045f9d9fd8e932196992acef6a52eaaa33155c6caf7218afc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9389774799346924}","{'position': 2, 'link': 'https://www.cgtlive.com/view/gene-therapy-yields-100-1-year-survival-in-lad-1', 'title': 'Gene Therapy Yields 100% 1-Year Survival in LAD-1', 'source': 'CGTLive®', 'date': 'Feb 17, 2023', 'snippet': 'The gene therapy RP-L201 (Rocket Pharma) was well-tolerated and yielded \ngenotypic and phenotypic corrections in children with leukocyte adhesion \ndeficiency-1 (...', 'thumbnail': 'https://serpapi.com/searches/6723cb6c3b3c3212f7fbc2b7/images/c121746706d19af0e5a3c87c9375322b4f39e8842bfcd2dd011b05db0f20f662.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6991526484489441}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04557800,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/phase-2b-3-trials-planned-oral-biib122-dnl151-slowing-parkinsons-progression/', 'title': '2 Trials to Test Oral BIIB122/DNL151 in Slowing Parkinson’s Progression', 'source': ""Parkinson's News Today"", 'date': 'Jan 13, 2022', 'snippet': 'Biogen and Denali Therapeutics are planning to launch two late-stage \nclinical trials to further evaluate the potential of their...', 'thumbnail': 'https://serpapi.com/searches/6723cb835235f6e4c97c72da/images/c75d3edc0f415bed05a93f8072af5b02206ffb78c260d7eab099194cb4008153.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8970906734466553}",,,,,,,,,,['neutral'],neutral,1
NCT02597127,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1615758', 'title': 'Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol', 'source': 'The New England Journal of Medicine', 'date': 'Mar 17, 2017', 'snippet': 'In a previous study, a single injection of inclisiran, a chemically \nsynthesized small interfering RNA designed to target PCSK9 messenger RNA...', 'thumbnail': 'https://serpapi.com/searches/6723cb87e281ee6ac1857d6c/images/95a87b98814a0e323d6a25586a64953fe4da496afcfa6dc40b9fa9b45908c0d1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8285010457038879}",,,,,,,,,,['neutral'],neutral,1
NCT02719574,"{'position': 1, 'link': 'https://ascopost.com/issues/january-25-2023/olutasidenib-for-relapsed-or-refractory-acute-myeloid-leukemia-with-a-susceptible-idh1-mutation/', 'title': 'Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia With a Susceptible IDH1 Mutation', 'source': 'The ASCO Post', 'date': 'Jan 25, 2023', 'snippet': 'On December 1, 2022, the IDH1 inhibitor olutasidenib was approved for the \ntreatment of adults with relapsed or refractory acute myeloid...', 'thumbnail': 'https://serpapi.com/searches/6723cb86fab27313b26fb0bf/images/56a6825ad17595b42ab507d837b6b9a3e2e8b3e67cccd69672bab1062436de30.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8930202722549438}",,,,,,,,,,['neutral'],neutral,1
NCT03020771,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S2405844021022647', 'title': 'Development of a protective inactivated vaccine against Crimean–Congo hemorrhagic fever infection', 'source': 'ScienceDirect.com', 'date': 'Oct 13, 2021', 'snippet': 'In this study, we showed that cell-culture-purified and \nformalin-inactivated vaccine candidates induced strong and robust immunity \nin vaccinated mice dose-...', 'thumbnail': 'https://serpapi.com/searches/6723cbaa07c7bee603a27463/images/24fb63b58c39a474297551e272659153683bf0ae1802fa9dfad62bd33daeacc3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6813912987709045}",,,,,,,,,,['neutral'],neutral,1
NCT05713318,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-40933-3', 'title': 'An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants', 'source': 'Nature', 'date': 'Aug 25, 2023', 'snippet': 'Many of the currently available COVID-19 vaccines and therapeutics are not \neffective against newly emerged SARS-CoV-2 variants.', 'thumbnail': 'https://serpapi.com/searches/6723cbcea5d702aba6fc5e6f/images/01fc61c8a857c5a3f9bb12dd36e3a38e32a04dd1b6fd99f42e9d7b9c32836d7b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5404082536697388}",,,,,,,,,,['neutral'],neutral,1
NCT02954458,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/jpn3.12276', 'title': 'Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure', 'source': 'Wiley Online Library', 'date': 'Jun 14, 2024', 'snippet': 'Objectives Patients with short bowel syndrome-associated intestinal failure \n(SBS-IF) require long-term parenteral nutrition and/or...', 'thumbnail': 'https://serpapi.com/searches/6723cbd87ac7318c72f6d616/images/8a77d8205ffeb69c427071fccd3c8928981adf72ef3ac9c87b53f3f4212cbbda.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8563302755355835}",,,,,,,,,,['neutral'],neutral,1
NCT05259722,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20240123989016/en/LEO-Pharma-Announces-Positive-Phase-3-Head-to-head-Data-Results-from-DELTA-FORCE-Trial-Comparing-Delgocitinib-Cream-With-Alitretinoin-Capsules-in-Adults-With-Severe-Chronic-Hand-Eczema-CHE', 'title': 'LEO Pharma Announces Positive Phase 3 Head-to-head Data Results from DELTA FORCE Trial Comparing Delgocitinib Cream With Alitretinoin Capsules in Adults With Severe Chronic Hand Eczema (CHE)', 'source': 'Business Wire', 'date': 'Jan 24, 2024', 'snippet': 'DELTA FORCE is a head-to-head trial in adult participants with severe \nchronic hand eczema (CHE) comparing a potential new topical treatment with \na systemic...', 'thumbnail': 'https://serpapi.com/searches/6723cbd8a505f751d8746db1/images/ab49346ecfc96c4419d338c6edee9f1e922e263b669979a8e09043ac3bd133d2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7723872661590576}",,,,,,,,,,['neutral'],neutral,1
NCT03790072,"{'position': 1, 'link': 'https://www.cgtlive.com/view/allogeneic-cell-therapy-shows-early-efficacy-in-acute-myeloid-leukemia', 'title': 'Allogeneic Cell Therapy Shows Early Efficacy in Acute Myeloid Leukemia', 'source': 'CGTLive®', 'date': 'Apr 6, 2023', 'snippet': 'Although the TCB-202-001 trial ended prematurely due to the COVID-19 \npandemic, promising results warrant a phase 2 trial.', 'thumbnail': 'https://serpapi.com/searches/6723cc0513150201ded951af/images/44dec42d80ea09e241dc21ed85e03baaca480373f3fe5ced740256ccc8932f50.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6259142756462097}",,,,,,,,,,['positive'],positive,1
NCT01134263,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60128-1/fulltext', 'title': 'Dengue vaccine prospects: a step forward', 'source': 'The Lancet', 'date': 'Jan 29, 2011', 'snippet': 'The worldwide expansion of dengue fever is a growing health problem. \nCrucial issues surround this global expansion and some of them present...', 'thumbnail': 'https://serpapi.com/searches/6723cc78a5e502a8e8204d11/images/d14a44eb5fb8d6c37e8e182557ad467b3866807e8f39554c6c0aafc30964ea96.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6025897264480591}",,,,,,,,,,['neutral'],neutral,1
NCT01358578,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1314258', 'title': 'Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials', 'source': 'The New England Journal of Medicine', 'date': 'Jul 9, 2014', 'snippet': 'In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response \nand Safety of Two Fixed Secukinumab Regimens in Psoriasis) and...', 'thumbnail': 'https://serpapi.com/searches/6723cca1d111956b5d3acab5/images/0a7ed8cce97a3b9248b793c5916e88afdf1a641b80fe19811f53b7b01671d91d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9034740328788757}",,,,,,,,,,['neutral'],neutral,1
NCT03968978,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-tezspire-for-self-administration-with-new-prefilled-pen/', 'title': 'FDA Approves Tezspire for Self-Administration With New Prefilled Pen', 'source': 'Medical Professionals Reference', 'date': 'Feb 2, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved a new prefilled, \nsingle-use pen for Tezspire™ (tezepelumab-ekko) for the add-on...', 'thumbnail': 'https://serpapi.com/searches/6723ccb7a471672a2b12973b/images/68fddd178fd2e5c605fe93983fa65803bfb02d270b8e352b435d826549f872db.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6245538592338562}",,,,,,,,,,['neutral'],neutral,1
NCT01473524,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/fda-delays-approval-ocaliva-primary-biliary-cholangitis/', 'title': 'Full approval on Ocaliva for primary biliary cholangitis delayed', 'source': 'Liver Disease News', 'date': '1 week ago', 'snippet': ""The delay follows a committee vote that Ocaliva's clinical benefit isn't \nshown by data and it doesn't have a favorable benefit-risk profile."", 'thumbnail': 'https://serpapi.com/searches/6723ccc85416d8fd44a56657/images/c18307987a61ec8089ddc5933c1a2940da64884c16cdbbe33befc7883842d7a4.png', 'sentiment': 'negative', 'sentiment_prob': 0.7211492657661438}","{'position': 2, 'link': 'https://liverdiseasenews.com/news/full-approval-pbc-therapy-ocaliva-rejected-fda-committee-10-1-vote/', 'title': 'Full approval of PBC therapy Ocaliva rejected by FDA committee in 10-1 vote', 'source': 'Liver Disease News', 'date': '1 month ago', 'snippet': ""A US Food and Drug Administration (FDA) advisory committee voted 10-1 that \nOcaliva (obeticholic acid) doesn't have a benefit-risk profile that would \nsupport..."", 'thumbnail': 'https://serpapi.com/searches/6723ccc85416d8fd44a56657/images/c18307987a61ec80654b418fe549ee418e5ea5f1ec67cecaa9f08e4cc406c905.png', 'sentiment': 'negative', 'sentiment_prob': 0.746898889541626}","{'position': 3, 'link': 'https://liverdiseasenews.com/news/ocaliva-shown-reduce-markers-liver-damage-scarring-pbc-trial/', 'title': 'Ocaliva shown to reduce markers of liver damage, scarring in PBC trial', 'source': 'Liver Disease News', 'date': 'May 29, 2024', 'snippet': 'Ocaliva (obeticholic acid) — an oral therapy with conditional approval in \nboth the U.S. and Europe — reduced levels of additional markers of...', 'thumbnail': 'https://serpapi.com/searches/6723ccc85416d8fd44a56657/images/c18307987a61ec800c59cbc5d1b56dd00a82c87b8aab71fd6a6f69f5bbf9c9d3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7353088855743408}","{'position': 4, 'link': 'https://liverdiseasenews.com/news/fda-decide-of-full-approval-ocaliva-treatment-pbc/', 'title': 'FDA to decide on full approval for Ocaliva in treating adults with PBC', 'source': 'Liver Disease News', 'date': 'Mar 20, 2024', 'snippet': 'The US Food and Drug Administration (FDA) agreed to review an application \nseeking full and formal approval of Ocaliva (obeticholic acid) as a \ntreatment for...', 'thumbnail': 'https://serpapi.com/searches/6723ccc85416d8fd44a56657/images/c18307987a61ec8071054e22c88c7ac022d299d11203fb006bc7614fee34b668.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9330844283103943}",,,,,,,"['negative', 'negative', 'neutral', 'neutral']",negative,0
NCT03580356,"{'position': 1, 'link': 'https://www.pharmiweb.com/press-release/2024-10-23/global-drug-eruptions-treatment-market-to-reach-usd-71-billion-by-2033-growing-at-a-62-cagr', 'title': 'Global Drug Eruptions Treatment Market to Reach USD 7.1 Billion by 2033, Growing at a 6.2% CAGR', 'source': 'PharmiWeb.com', 'date': '1 week ago', 'snippet': 'Drug Eruptions Treatment MarketThe global drug eruptions treatment market \nis set to experience steady growth over the next decade,...', 'thumbnail': 'https://serpapi.com/searches/6723cccdd771bdcbe3abe574/images/90e70827c17ca891a32fe8823849fa864761f4c9670e7fdb7853ad2c1d6d43d8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5003542304039001}",,,,,,,,,,['neutral'],neutral,1
NCT01590771,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.12456', 'title': 'Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin', 'source': 'Wiley Online Library', 'date': 'Aug 8, 2016', 'snippet': 'Mean HbA1c over time for sitagliptin 100 mg (n = 231–248) and placebo (n = \n213–249) in the entire study cohort. Data are the mean ± SE.', 'thumbnail': 'https://serpapi.com/searches/6723ccf15c7cb9c8be013a62/images/f2a23f4ee41c88d54048f461734c5cc3decf20647fad6646ba014cb3e752ace3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8350858688354492}",,,,,,,,,,['neutral'],neutral,1
NCT03515837,"{'position': 1, 'link': 'https://www.ajmc.com/view/asco-2023-solid-tumors', 'title': 'ASCO 2023: Solid Tumors', 'source': 'AJMC', 'date': 'Jul 31, 2023', 'snippet': 'Coverage of clinical trial results presented across a range of solid tumor \ncancers, including breast, ovarian, colorectal, and non-small cell lung \ncancer.', 'thumbnail': 'https://serpapi.com/searches/6723cd3913e5d82f479b41a1/images/5f1e63d16847b00bbbb31bd33fc4be7fa565c560bdec8e576b4cfa5314e6ff15.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8581488728523254}","{'position': 2, 'link': 'https://www.ajmc.com/view/searching-for-new-solutions-in-treating-egfr-mutant-nsclc', 'title': 'Searching for New Solutions in Treating EGFR-Mutant NSCLC', 'source': 'AJMC', 'date': 'Jun 27, 2023', 'snippet': 'Abstracts were presented in a session on metastatic lung cancer on the \nfinal day of the 2023 American Society of Clinical Oncology Annual...', 'thumbnail': 'https://serpapi.com/searches/6723cd3913e5d82f479b41a1/images/5f1e63d16847b00bb2a3174c7d87aababa3e89e26b9e2761b5f5a16b78980782.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9306378960609436}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03488524,"{'position': 1, 'link': 'https://alsnewstoday.com/news/als-therapies-amx-0035-radicava-ors-may-add-benefit-cost-effective/', 'title': 'AMX0035, Radicava ORS Costs Could Cloud Therapies’ Benefits: ICER', 'source': 'ALS News Today', 'date': 'Aug 9, 2022', 'snippet': 'Note: This story was updated Aug. 10, 2022, to clarify the U.S. Food and \nDrug Administration advisory committee voted there is no...', 'thumbnail': 'https://serpapi.com/searches/6723cf8698fad6961dd80b61/images/0ec772192398fd106ba205ee84b23d828c539a5a4eaf8f71459a3a4eb4101597.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8640235066413879}",,,,,,,,,,['neutral'],neutral,1
NCT05462756,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/with-once-a-week-dosing-insulin-efsitora-alfa-delivers-a1c-reduction-and-safety-profile-consistent-with-daily-insulin-302147034.html', 'title': 'With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin', 'source': 'PR Newswire', 'date': 'May 16, 2024', 'snippet': 'PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive \ntopline results from the QWINT-2 and QWINT-4 phase 3 clinical...', 'thumbnail': 'https://serpapi.com/searches/6723cf8729e6fb4ffa08bef6/images/d8a498c495e9dc78575a2da7add15a825e25b7f175d2ccb712b0dcc835557e3a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5389407873153687}","{'position': 2, 'link': 'https://www.pharmacytimes.com/view/once-weekly-efsitora-shows-non-inferiority-in-a1c-reductions-compared-to-daily-basal-insulin', 'title': 'Once Weekly Efsitora Shows Non-Inferiority in A1c Reductions Compared With Daily Basal Insulin', 'source': 'Pharmacy Times', 'date': 'May 31, 2024', 'snippet': 'Topline results of QWINT-2 and QWINT-4 met the primary end point of change \nin hemoglobin A1c compared to degludec and glargine, respectively...', 'thumbnail': 'https://serpapi.com/searches/6723cf8729e6fb4ffa08bef6/images/d8a498c495e9dc783d8d9d61c20c94bc772b5c9fbccaa9e2fe35a53e3665bccc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8300167918205261}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04611802,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/phase-3-trial-novavax-investigational-covid-19-vaccine-opens', 'title': 'Phase 3 trial of Novavax investigational COVID-19 vaccine opens', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Dec 28, 2020', 'snippet': 'NIH- and BARDA-funded trial will enroll up to 30000 volunteers.', 'thumbnail': 'https://serpapi.com/searches/6723cf8c6aa36453b527f312/images/a63b35fc714fc8bed38a19043a50fa8a50e17afa04272004b85ed54b18060f7d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8932388424873352}","{'position': 2, 'link': 'https://www.europeanpharmaceuticalreview.com/news/166746/novavaxs-covid-19-vaccine-highly-effective-in-preventing-disease/', 'title': 'Novavax’s COVID-19 vaccine highly effective in preventing disease', 'source': 'European Pharmaceutical Review', 'date': 'Dec 17, 2021', 'snippet': ""New Phase III trial data suggests Novavax's investigational COVID-19 \nvaccine is 90 percent effective at preventing COVID-19 illness."", 'thumbnail': 'https://serpapi.com/searches/6723cf8c6aa36453b527f312/images/a63b35fc714fc8be46730c80746fcbbc77d6cca7b59b769ea3bd56a649122918.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7524675726890564}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02734862,"{'position': 1, 'link': 'https://www.empr.com/home/news/rezzayo-now-available-for-candidemia-invasive-candidiasis-treatment/', 'title': 'Rezzayo Now Available for Candidemia, Invasive Candidiasis Treatment', 'source': 'Medical Professionals Reference', 'date': 'Jul 31, 2023', 'snippet': 'Rezzayo™ (rezafungin for injection) is now available for the treatment of \ncandidemia and invasive candidiasis in adults with limited or no...', 'thumbnail': 'https://serpapi.com/searches/6723cf950be2f6aacef1816e/images/0a4b423f28f4b04ceaabfce632448d59cfcd02831170bc8d1851b3e1856088d5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9036893248558044}",,,,,,,,,,['neutral'],neutral,1
NCT02971007,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.759408/full', 'title': 'Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis', 'source': 'Frontiers', 'date': 'Jun 26, 2024', 'snippet': 'Candida species are the leading cause of invasive fungal infections \nworldwide and are associated with acute mortality rates of ~50%.', 'thumbnail': 'https://serpapi.com/searches/6723cfa5e9245683a8b968c7/images/26942c043ff670be2d222843100b73fbfdf3d222681a6c865ec1a35ebebdd962.png', 'sentiment': 'negative', 'sentiment_prob': 0.8415127396583557}",,,,,,,,,,['negative'],negative,0
NCT03022799,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/fascinate-therapeutics-km-819-fda-approval-phase-2-trial-parkinsons/', 'title': 'FDA Approval Sought to Begin Phase 2 Trial of KM-819', 'source': ""Parkinson's News Today"", 'date': 'Nov 4, 2021', 'snippet': ""Fascinate Therapeutics submitted an investigational new drug application to \nbegin the trial evaluating KM-819 as a Parkinson's therapy."", 'thumbnail': 'https://serpapi.com/searches/6723d019b6a79cfdeda5b635/images/a01c307e8d9a7748ff18d5e7e8254613adf68a7ab7a8b9d82b75d10f04e036be.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8712620139122009}",,,,,,,,,,['neutral'],neutral,1
NCT01650701,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1805104', 'title': 'Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma', 'source': 'The New England Journal of Medicine', 'date': '٠٥\u200f/٠٩\u200f/٢٠١٨', 'snippet': 'Rituximab plus chemotherapy has been shown to be effective in patients with \nadvanced-stage, previously untreated follicular lymphoma;...', 'thumbnail': 'https://serpapi.com/searches/6723d01dbb64ac4f0fdce775/images/eaf9d4f66f6a9db90ba3c229a3d194d9cc5bca1ab6a1428439d48f02b28055a1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5880722999572754}","{'position': 2, 'link': 'https://www.oncnursingnews.com/view/lenalidomide-rituximab-represents-an-acceptable-chemo-free-regimen-for-advanced-follicular-lymphoma', 'title': 'Lenalidomide/Rituximab Represents an Acceptable Chemo-Free Regimen for Advanced Follicular Lymphoma', 'source': 'Oncology Nursing News', 'date': '٣٠\u200f/٠٩\u200f/٢٠٢٢', 'snippet': 'Six-year follow-up data showed an overall survival rate of 89% among \npatients with follicular lymphoma who received either lenalidomide plus...', 'thumbnail': 'https://serpapi.com/searches/6723d01dbb64ac4f0fdce775/images/eaf9d4f66f6a9db93a0f00f23183023be85caac0a8f377ba54d5ed285bfe8ab7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6342554688453674}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05573698,"{'position': 1, 'link': 'https://friedreichsataxianews.com/news/phase-1-friedreichs-ataxia-treatment-program-dt-216-track/', 'title': 'Phase 1 DT-216 Program for FA on Track; Initial Data Expected Soon', 'source': ""Friedreich's Ataxia News"", 'date': 'Nov 8, 2022', 'snippet': ""The Phase 1 clinical program of DT-216, Design Therapeutics' experimental \ntherapy for Friedreich's ataxia (FA), remains on track, with initial data \nexpected by..."", 'thumbnail': 'https://serpapi.com/searches/6723d030c76a3acd5b80d084/images/f59f145f605a3c6f8d00f9ddc811b0b15a7d0c5e8d0dc58b9fb2262156a1a260.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8831232786178589}",,,,,,,,,,['neutral'],neutral,1
NCT00065468,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa066838', 'title': 'Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma', 'source': 'The New England Journal of Medicine', 'date': 'May 1, 2018', 'snippet': 'In this multicenter, phase 3 trial, we randomly assigned 626 patients with \npreviously untreated, poor-prognosis metastatic renal-cell carcinoma to \nreceive...', 'thumbnail': 'https://serpapi.com/searches/6723d03274f0a46c18e52727/images/e33decbbd076dc7d82f3de9ae7948db512eb6bc7b3bed6932a138ad6f15778a3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8770727515220642}",,,,,,,,,,['neutral'],neutral,1
NCT02740335,"{'position': 1, 'link': 'https://www.pharmacytimes.com/view/fda-approves-complex-for-urgent-reversal-of-excess-bleeding-in-surgery', 'title': 'FDA Approves Complex for Urgent Reversal of Excess Bleeding in Surgery', 'source': 'Pharmacy Times', 'date': 'Jul 26, 2023', 'snippet': 'Prothrombin complex concentrate human-Ians can quickly improve blood \ncoagulation in patients who are at risk of excess bleeding but need...', 'thumbnail': 'https://serpapi.com/searches/6723d03de281ee6aff8fcf70/images/384c7e5c7e14b83538e5b4776ceedc8f206b0c0531a07759005f952d689d8bb2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6276233196258545}","{'position': 2, 'link': 'https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/new-drug-development-approvals-regulatory-news/octapharma-usa%C2%A0today-announced-that-balfaxar-has-received-fd/', 'title': 'Octapharma USA today announced that Balfaxar has received FDA approval', 'source': 'European Pharmaceutical Manufacturer', 'date': 'Jul 27, 2023', 'snippet': 'Balfaxar (prothrombin complex concentrate, human-lans; marketed in Europe \nand Canada as octaplex) has received US Food and Drug Administration (FDA) \napproval.', 'thumbnail': 'https://serpapi.com/searches/6723d03de281ee6aff8fcf70/images/384c7e5c7e14b835b179cbdc74d2e231f2cafeda1dff3d66d03b73f0d703ae43.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6028887629508972}","{'position': 3, 'link': 'https://www.thepharmaletter.com/biotechnology/fda-green-light-for-octapharma-s-balfaxar', 'title': ""FDA green light for Octapharma's Balfaxar"", 'source': 'The Pharma Letter', 'date': 'Jul 26, 2023', 'snippet': 'More on this story... Swiss firm spreads tentacles with US rare disease \napproval · Biotechnology · Swiss firm spreads tentacles with US rare...', 'thumbnail': 'https://serpapi.com/searches/6723d03de281ee6aff8fcf70/images/384c7e5c7e14b83548afd8bfcd8eca572114bc7360b24a7411259945a83816de.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9057815670967102}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04419467,"{'position': 1, 'link': 'https://www.nature.com/articles/s41420-023-01304-5', 'title': 'Simultaneous blockade of VEGF-B and IL-17A ameliorated diabetic kidney disease by reducing ectopic lipid deposition and alleviating inflammation response | Cell Death Discovery', 'source': 'Nature', 'date': 'Jan 16, 2023', 'snippet': 'The pathogenesis of diabetic kidney disease (DKD) is complicated. Current \nclinical treatments fail to achieve satisfactory efficacy in the...', 'thumbnail': 'https://serpapi.com/searches/6723d049fcd69ee1d5dd5740/images/d1c88ec6c328f3bd8f711d15fb85295d2c7a5f8fdf84145631361530b5f1a4ee.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.517368495464325}",,,,,,,,,,['negative'],negative,0
NCT05642546,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/fda-clears-phase-2-trial-antibody-therapy-ruxoprubart-aav/', 'title': 'FDA clears Phase 2 trial of antibody therapy ruxoprubart in AAV', 'source': 'ANCA Vasculitis News', 'date': 'Jun 24, 2024', 'snippet': 'The US Food and Drug Administration (FDA) has given NovelMed the green \nlight to initiate a Phase 2 clinical trial to test its investigational \nantibody-based...', 'thumbnail': 'https://serpapi.com/searches/6723d04e7b05ca0e36f00a7e/images/d9f81c54e17ae5cf19bd2ba05b9636073da9cae91efd4f7a0225a9aa11937507.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7502970099449158}",,,,,,,,,,['neutral'],neutral,1
NCT03882970,"{'position': 1, 'link': 'https://www.renalandurologynews.com/news/tirzepatide-vs-semaglutide-lower-metabolic-syndrome-prevalence/', 'title': 'Tirzepatide vs Semaglutide Linked to Lower Metabolic Syndrome Prevalence', 'source': 'Renal and Urology News', 'date': 'Apr 12, 2024', 'snippet': 'Use of tirzepatide, compared with placebo, semaglutide, and insulin \ndegludec and glargine, is associated with a lower prevalence of metabolic \nsyndrome among...', 'thumbnail': 'https://serpapi.com/searches/6723d05b88bcde1b95c7c7c1/images/40b3520352c2c696925b14dc867c6224588ace432322cdc1b4655108b4a00f20.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8086218237876892}",,,,,,,,,,['neutral'],neutral,1
NCT02289950,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/morphotek-and-eurofarma-laboratorios-sa-sign-exclusive-licensing-agreement-for-farletuzumab-in-latin-america-300337215.html', 'title': 'Morphotek and Eurofarma Laboratórios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America', 'source': 'PR Newswire', 'date': 'Oct 3, 2016', 'snippet': 'PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced \ntoday that it signed an exclusive licensing agreement with Eurofarma...', 'thumbnail': 'https://serpapi.com/searches/6723d05b5809e735b9893e87/images/79752ef603ec51c8083cfc880de6ba62eaad6d9acfc00d67ddb1c2c6c062a0a2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9180112481117249}",,,,,,,,,,['neutral'],neutral,1
NCT04123561,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332223016177', 'title': 'Harnessing the multifunctionality of lipid-based drug delivery systems for the local treatment of osteoarthritis', 'source': 'ScienceDirect.com', 'date': 'Nov 7, 2023', 'snippet': 'This review emphasizes recent advancements in lipid-based drug delivery \nsystems (DDSs) for intra-articular administration of OA therapeutics.', 'thumbnail': 'https://serpapi.com/searches/6723cfa79f8bfc1ce81120da/images/4791edeaaa67385508e96f2a2fb8056daf61675d2222628acf61ab2307c6a730.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.650626003742218}",,,,,,,,,,['neutral'],neutral,1
NCT03019419,"{'position': 1, 'link': 'https://alsnewstoday.com/news/study-evaluating-perampanel-als-stopped-adverse-events/', 'title': 'Study Evaluating Perampanel in ALS Stopped Due to Adverse Events', 'source': 'ALS News Today', 'date': 'Nov 9, 2021', 'snippet': 'A small open-label study evaluating the epilepsy medication perampanel in \nadults with amyotrophic lateral sclerosis (ALS) was halted due to adverse \nevents that...', 'thumbnail': 'https://serpapi.com/searches/6723cfea51d84d25a324b51a/images/fe990e2914cd6d4a85e418fb0706b572eca0b3d09546ee10aa3e35577cefd097.png', 'sentiment': 'negative', 'sentiment_prob': 0.5237719416618347}",,,,,,,,,,['negative'],negative,0
NCT02256917,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/fda-approves-new-vial-strengths-for-hemophilia-a-therapy-nuwiq/', 'title': 'Hemophilia A Therapy Nuwiq to Come in New Vial Strengths in U.S.', 'source': 'Hemophilia News Today', 'date': 'Aug 28, 2017', 'snippet': ""The US Food and Drug Administration has approved new vial strengths for \nOctopharma's hemophilia A therapy Nuwiq, which means patients will need \nfewer vials per..."", 'thumbnail': 'https://serpapi.com/searches/6723cffcc82127187f68d3db/images/800e297b534a0b92bb28686d370472b4f38429f41c90a9431d84ef276bb3942a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8386752605438232}",,,,,,,,,,['neutral'],neutral,1
NCT05054621,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-33146-7', 'title': 'A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19', 'source': 'Nature', 'date': 'Sep 17, 2022', 'snippet': 'Heterologous prime-boost COVID-19 vaccine strategy may facilitate mass \nCOVID-19 immunization. We reported early immunogenicity and safety...', 'thumbnail': 'https://serpapi.com/searches/6723d063d111956b07a12e7c/images/526e8275acf053841a09bed1b67c3ea91c26471549c7e70b30e0e71696c7c242.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8337039947509766}",,,,,,,,,,['neutral'],neutral,1
NCT04994483,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/topline-results-phase-3-studies-simufilam-alzheimers-due-this-year/', 'title': 'Topline results from Phase 3 trial of simufilam due this year', 'source': ""Alzheimer's News Today"", 'date': 'Feb 8, 2024', 'snippet': ""Two Phase 3 clinical trials are testing the effectiveness of simufilam, an \nexperimental oral therapy that's designed to improve cognition in people \nwith..."", 'thumbnail': 'https://serpapi.com/searches/6723d09fdb3ac9f357ce4602/images/dfc826cc872839a4db402e1ff9227951228bb7cf0640f6b3584499246f10bc4c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5712019801139832}","{'position': 2, 'link': 'https://alzheimersnewstoday.com/news/simufilam-found-safe-review-ongoing-alzheimers-drug-trials/', 'title': 'Simufilam found safe in review of ongoing Alzheimer’s clinical trials', 'source': ""Alzheimer's News Today"", 'date': '1 month ago', 'snippet': 'an independent safety monitoring board has recommended the continuation — \nwithout modifications — of two ongoing Phase 3 clinical trials testing...', 'thumbnail': 'https://serpapi.com/searches/6723d09fdb3ac9f357ce4602/images/dfc826cc872839a43c3a8df11b23eb249879dbb8eed286bf82bfab5bf30ad969.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6725298762321472}","{'position': 3, 'link': 'https://alzheimersnewstoday.com/news/simufilam-aid-cognition-alzheimers-patients-phase-2-study/', 'title': 'Simufilam aids cognition in 47% of Alzheimer’s patients in Phase 2 study', 'source': ""Alzheimer's News Today"", 'date': 'Mar 14, 2023', 'snippet': ""Cognitive benefits were reported in nearly half of the Alzheimer's disease \npatients given simufilam for one year in a clinical trial."", 'thumbnail': 'https://serpapi.com/searches/6723d09fdb3ac9f357ce4602/images/dfc826cc872839a4407e5a5294e09315a639fa4932025b5f6e8788c66056eed4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5083126425743103}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03209973,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01600-7', 'title': 'Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma', 'source': 'Nature', 'date': 'Sep 20, 2023', 'snippet': 'Anti-programmed cell death-1 (anti-PD-1) therapies have shown a favorable \nefficacy and good tolerance for relapsed or refractory (r/r) classical \nHodgkin...', 'thumbnail': 'https://serpapi.com/searches/6723d0bf237938e78b848cf0/images/fd9d55a0884c5a58f845abe70e0e7474ed4476b4866edadfc3594ca231f7c090.png', 'sentiment': 'neutral', 'sentiment_prob': 0.668369472026825}",,,,,,,,,,['neutral'],neutral,1
NCT02949011,"{'position': 1, 'link': 'https://newsroom.uvahealth.com/2018/09/07/single-dose-drug-can-shorten-flu-symptoms-by-about-one-day-studies-suggest/', 'title': 'Single-Dose Drug Can Shorten Flu Symptoms By About a Day, Studies Suggest', 'source': 'UVA Health Newsroom', 'date': 'Sep 7, 2018', 'snippet': 'A single dose of a new influenza drug can significantly shorten the \nduration of the illness in teens and adults, according to a study...', 'thumbnail': 'https://serpapi.com/searches/6723d0c0d78a98c1c8871b32/images/7477fa5904c09083b15df98eedcec3e1dcffc4dfba4988a8cafe64627e80759e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7333375215530396}",,,,,,,,,,['neutral'],neutral,1
NCT02184195,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1903387', 'title': 'Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jun 2, 2019', 'snippet': 'Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup \nof those with metastatic pancreatic cancer. The poly(adenosine \ndiphosphate–ribose)...', 'thumbnail': 'https://serpapi.com/searches/6723d0dae1c27684e5a6509c/images/0c4abf085cb0cd5d5b0a599a5638a28a6d4e4d75cb74437b70f1772c90881b61.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7973864674568176}",,,,,,,,,,['neutral'],neutral,1
NCT00004125,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0707056', 'title': 'Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Apr 17, 2008', 'snippet': 'Weekly paclitaxel after standard adjuvant chemotherapy with doxorubicin and \ncyclophosphamide improves disease-free and overall survival in women with \nbreast...', 'thumbnail': 'https://serpapi.com/searches/6723d0dd49ea55e48af25255/images/44b08bc6175c48abad8e01379d046bf496f25ca386d8c800fcb071ec683c3d3a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.584206223487854}",,,,,,,,,,['neutral'],neutral,1
NCT02392559,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2019910', 'title': 'Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia', 'source': 'The New England Journal of Medicine', 'date': 'Aug 29, 2020', 'snippet': 'In this trial involving pediatric patients with familial \nhypercholesterolemia, evolocumab reduced the LDL cholesterol level and \nother lipid variables.', 'thumbnail': 'https://serpapi.com/searches/6723d0e729e6fb4ffa08bf5a/images/0ee6478a78446f2b6b018a8a5d6fab5b8c7ef516f777758c229ef090d495ffc2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.830830991268158}","{'position': 2, 'link': 'https://www.empr.com/home/news/repatha-approved-for-younger-patients-with-hefh-and-hofh/', 'title': 'Repatha Approved for Younger Patients with HeFH and HoFH', 'source': 'Medical Professionals Reference', 'date': 'Sep 27, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Repatha (evolocumab) \ninjection as an adjunct to diet and other low-density lipoprotein \ncholesterol (LDL-C)-...', 'thumbnail': 'https://serpapi.com/searches/6723d0e729e6fb4ffa08bf5a/images/0ee6478a78446f2bd5d6b16a7cd5e6217fec0aec6ba393f1f375c8caae6d5041.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7352215647697449}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04465955,"{'position': 1, 'link': 'https://www.genengnews.com/gen-edge/stockwatch-failed-trial-sinks-ngm-bio-will-merck-opt-into-eye-disorder-drug/', 'title': 'StockWatch: Failed Trial Sinks NGM Bio; Will Merck Opt Into Eye Disorder Drug?', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Oct 20, 2022', 'snippet': 'NGM Biopharmaceuticals (NGM) shares plunge after the company acknowledges \nthat its eye disorder candidate NGM621 failed a Phase II trial.', 'thumbnail': 'https://serpapi.com/searches/6723d1022c566d0f0ff61b5d/images/47283f7bf858131d66c4a7711ed02a763ccdbbcd663981f1ad90761c0f5207da.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7887478470802307}",,,,,,,,,,['negative'],negative,0
NCT02008227,"{'position': 1, 'link': 'https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05509-9', 'title': 'Integrating knowledge graphs into machine learning models for survival prediction and biomarker discovery in patients with non–small-cell lung cancer', 'source': 'Journal of Translational Medicine', 'date': 'Aug 5, 2024', 'snippet': 'Accurate survival prediction for Non-Small Cell Lung Cancer (NSCLC) \npatients remains a significant challenge for the scientific and clinical...', 'thumbnail': 'https://serpapi.com/searches/6723d104ee677f95bc3ebf1e/images/d32b9a274d7b0ad74208dbe606b1a2dbf76465a125fa25fbafd7743cb523cfa8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7933346629142761}","{'position': 2, 'link': 'https://www.nature.com/articles/s41698-023-00443-3', 'title': 'Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy', 'source': 'Nature', 'date': 'Sep 11, 2023', 'snippet': 'Programmed cell death ligand 1 (PD-L1) expression remains the most widely \nused biomarker for predicting response to immune checkpoint...', 'thumbnail': 'https://serpapi.com/searches/6723d104ee677f95bc3ebf1e/images/d32b9a274d7b0ad71dc9ceefad5677081415b1dfb29d6b92ea5a1574126d261d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9057897925376892}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02187991,"{'position': 1, 'link': 'https://oncolo.jp/news/210518y01', 'title': 'エストロゲン受容体陽性HER2陰性/トリプルネガティブ転移性乳がん対するパクリタキセル＋アリゼルチブ併用療法、パクリタキセル単剤療法に比べて無増悪生存期間を改善', 'source': 'がん情報サイト「オンコロ」', 'date': 'May 18, 2021', 'snippet': 'この記事の3つのポイント・エストロゲン受容体陽性HER2陰性/トリプルネガティブ転移性乳がん患者が対象の第2相試験・パクリタキセル＋Alisertib（...', 'thumbnail': 'https://serpapi.com/searches/6723d10a577da532b1007ad1/images/372ef4755688a07a0c30b4fa5cf4adb91ee038e8e0353fe529f35938a39a9f76.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8210965991020203}",,,,,,,,,,['neutral'],neutral,1
NCT02942277,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-023-00712-z', 'title': 'A human antibody epitope map of the malaria vaccine antigen Pfs25 - npj Vaccines', 'source': 'Nature', 'date': 'Aug 4, 2023', 'snippet': 'Pfs25 is a leading antigen for a malaria transmission-blocking vaccine and \nshows moderate transmission-blocking activity and induction of rapidly \ndecreasing...', 'thumbnail': 'https://serpapi.com/searches/6723d14014c31eac29edf535/images/94c58f35a349cd72e80879f79e7b0d8003e5aed495c1812ea913f495c720cc7d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9248698353767395}","{'position': 2, 'link': 'https://www.nature.com/articles/s41541-024-00929-6', 'title': 'Antibody gene features associated with binding and functional activity in malaria vaccine-derived human mAbs', 'source': 'Nature', 'date': 'Aug 10, 2024', 'snippet': 'Here, we characterize the impact of two adjuvants, Alhydrogel® and AS01, on \nantibody clonotype diversity, binding and function, post malaria \nvaccination.', 'thumbnail': 'https://serpapi.com/searches/6723d14014c31eac29edf535/images/94c58f35a349cd72defeb4e901190edd4012c3d35183cec806b02d13db901b60.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9158818125724792}","{'position': 3, 'link': 'https://www.nature.com/articles/s42003-020-01123-9', 'title': 'Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins', 'source': 'Nature', 'date': 'Jul 24, 2020', 'snippet': 'Proteins Pfs230 and Pfs48/45 are Plasmodium falciparum \ntransmission-blocking (TB) vaccine candidates that form a membrane-bound \nprotein complex on gametes.', 'thumbnail': 'https://serpapi.com/searches/6723d14014c31eac29edf535/images/94c58f35a349cd721124b3f99b8ef4f4a5373403a7d5ee4045b0404e3dc6b388.png', 'sentiment': 'neutral', 'sentiment_prob': 0.805415689945221}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02057900,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.601560/full', 'title': 'Cell Therapy With Human ESC-Derived Cardiac Cells: Clinical Perspectives', 'source': 'Frontiers', 'date': 'Oct 26, 2020', 'snippet': 'In the ongoing quest for the “ideal” cell type for heart repair, \npluripotent stem cells (PSC) derived from either embryonic or \nreprogrammed...', 'thumbnail': 'https://serpapi.com/searches/6723d13e6ad3c99ad220c2ca/images/021b26e807c5f242f4c85729821ae96bfcdb123335a7cf992e2828e9df567c11.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8939337134361267}",,,,,,,,,,['neutral'],neutral,1
NCT03713593,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2020/09/04/fda-rejects-keytruda-lenvima-combo-as-first-line-treatment-for-liver-cancer/', 'title': 'FDA Rejects Keytruda-Lenvima Combo as First-line Treatment for Liver Cancer', 'source': 'Immuno-Oncology News', 'date': 'Sep 4, 2020', 'snippet': 'The U.S. Food and Drug Administration (FDA) has issued a complete response \nletter stating that it will not approve the combination of...', 'thumbnail': 'https://serpapi.com/searches/6723d1556aa36453b527f3b6/images/566d8216587f478f4fda83e4d63fc002e735446cc7de8f2a3371d34f472811e3.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6010357737541199}",,,,,,,,,,['negative'],negative,0
NCT02424799,"{'position': 1, 'link': 'https://www.nature.com/articles/s41577-023-00877-7', 'title': 'Protein kinases: drug targets for immunological disorders', 'source': 'Nature', 'date': 'May 15, 2023', 'snippet': 'Protein kinases play a major role in cellular activation processes, \nincluding signal transduction by diverse immunoreceptors.', 'thumbnail': 'https://serpapi.com/searches/6723d1f49fd30930f1a87383/images/3a085f967b65b3483866c48e918053ee38a8e3d3f4940e8c71458d055d2818cf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8678420186042786}",,,,,,,,,,['neutral'],neutral,1
NCT01469039,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/therapeutic-durability-of-aripiprazole-lauroxil/', 'title': 'Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia', 'source': 'Psychiatrist.com', 'date': 'Sep 19, 2017', 'snippet': 'Injectable antipsychotics can help address the problem of nonadherence, \nwhich can lead to relapse. This study looks at the efficacy of the...', 'thumbnail': 'https://serpapi.com/searches/6723d1fae1d1ad99be01b6f0/images/d2646718a8c76ed2f919dac0705c93124549cf364b2c6bef500e4590b002820c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7088669538497925}",,,,,,,,,,['neutral'],neutral,1
NCT04268303,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/sublingual-dexmedetomidine-for-agitation-schizophrenia/', 'title': 'Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial', 'source': 'Psychiatrist.com', 'date': 'Oct 3, 2022', 'snippet': 'This RCT determined whether a single dose of sublingual dexmedetomidine \nreduced acute agitation associated with schizophrenia or...', 'thumbnail': 'https://serpapi.com/searches/6723d189b7d31db0fc7f7d7b/images/a770f11e410eb79b2095ca25506eb2ac34be294e17bf403d4e40887f642ed046.png', 'sentiment': 'neutral', 'sentiment_prob': 0.90085369348526}",,,,,,,,,,['neutral'],neutral,1
NCT02858908,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/amo-pharma-myotonic-dystrophy-therapy-improves-cognition-and-function/', 'title': 'AMO Pharma’s Myotonic Dystrophy Therapy Improves Cognition and Function, Phase 2 Trial Shows', 'source': 'Muscular Dystrophy News', 'date': 'Mar 21, 2018', 'snippet': ""AMO Pharma's myotonic dystrophy treatment improved patients' cognition, \nfatigue and ability to perform daily tasks, a Phase 2 clinical trial showed."", 'thumbnail': 'https://serpapi.com/searches/6723d1967e1d1f86725827fd/images/f550b9fac77c188c16f6a9ad23de0dc8cc257e3bd563a57dbb5d9e2cab2ca19a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7412872910499573}",,,,,,,,,,['positive'],positive,1
NCT05139810,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2402478', 'title': 'Efficacy and Safety of Donidalorsen for Hereditary Angioedema', 'source': 'The New England Journal of Medicine', 'date': 'May 31, 2024', 'snippet': 'Donidalorsen treatment reduced the hereditary angioedema attack rate, a \nfinding that supports potential prophylactic use for hereditary angioedema.', 'thumbnail': 'https://serpapi.com/searches/6723d1a198fad6961dd80bf4/images/351efbcfdc83a17afd356d9c510e6ee9565ad1cff5bb3d92bb36ba563728f391.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7784955501556396}","{'position': 2, 'link': 'https://angioedemanews.com/news/phase-3-trial-results-hae-therapy-donidalorsen-due-2024/', 'title': 'Phase 3 trial results of HAE therapy donidalorsen due in 2024 |...', 'source': 'Angioedema News', 'date': 'Jun 5, 2023', 'snippet': 'Results from the placebo-controlled study, dubbed OASIS-HAE (NCT05139810), \nare expected in the first half of 2024.', 'thumbnail': 'https://serpapi.com/searches/6723d1a198fad6961dd80bf4/images/351efbcfdc83a17a882627374d4eb550dc0ddc8f41bea1c75c3f6077491d92e9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9253244996070862}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02670538,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0165032724010309', 'title': 'Early improvement with cariprazine as a predictor of antidepressant, anxiolytic, and antimanic response in bipolar I mania and depression: A pooled post hoc analysis of randomized cariprazine trials', 'source': 'ScienceDirect.com', 'date': 'Jun 27, 2024', 'snippet': 'Early symptomatic improvement may predict treatment response in bipolar I \ndisorder. Cariprazine has demonstrated early treatment effects in bipolar \nI...', 'thumbnail': 'https://serpapi.com/searches/6723d1bb922ccec6df09d394/images/9799ce315a80aee38972fbec74ec82ff473538dd84ae1d8f900b5327eaf03787.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7281509637832642}",,,,,,,,,,['neutral'],neutral,1
NCT01965353,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-021-00407-5', 'title': 'Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma', 'source': 'Nature', 'date': 'Feb 5, 2021', 'snippet': 'Panobinostat is among the most potent HDACis in clinical development and \nthe only HDACi approved for the treatment of RRMM, in combination with \nbortezomib and...', 'thumbnail': 'https://serpapi.com/searches/6723d1c314c31eac29edf553/images/81687c2f5db2f53c07d3e98cb202e994a2909e50fd31494465ef81a36e6ab9db.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6467630863189697}",,,,,,,,,,['neutral'],neutral,1
NCT04245709,"{'position': 1, 'link': 'https://alsnewstoday.com/news/asthma-medicine-slows-als-disease-progression-small-trial/', 'title': 'Asthma medicine slows ALS disease progression in small trial', 'source': 'ALS News Today', 'date': 'Jul 25, 2023', 'snippet': 'Among the 11 ALS patients who completed the 24-week study, clenbuterol was \nassociated with lung function gains and increased strength.', 'thumbnail': 'https://serpapi.com/searches/6723d1df9872176ea7feee56/images/34b78a03ff6d8d05933039072ce7e9d39fccfa9045d2df2d5f1dc1e8b6d80697.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8271586298942566}",,,,,,,,,,['neutral'],neutral,1
NCT04045405,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-020-14349-2', 'title': 'Preclinical development of a miR-132 inhibitor for heart failure treatment', 'source': 'Nature', 'date': 'Jan 31, 2020', 'snippet': 'We propose that miR-132 may serve as a therapeutic target in HF therapy. \nHere we report mode of action details of a locked nucleic acid based \nantisense...', 'thumbnail': 'https://serpapi.com/searches/6723d1f00f1a336e4473aa4d/images/218c5b73e9c5fc2147cd2ea2933cc21f13f61e03606abaa166f7a020ead78728.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7852481603622437}",,,,,,,,,,['neutral'],neutral,1
NCT02315703,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/experimental-hiv-vaccine-regimen-well-tolerated-elicits-immune-responses', 'title': 'Experimental HIV vaccine regimen is well-tolerated, elicits immune responses', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jul 24, 2017', 'snippet': 'Results from an early-stage clinical trial called APPROACH show that an \ninvestigational HIV vaccine regimen was well-tolerated and generated immune \nresponses...', 'thumbnail': 'https://serpapi.com/searches/6723d22a749783a716793b21/images/be339a895b4c93f81532064e2927f376a25a858858dddc551641e11a86998a5a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5365678668022156}",,,,,,,,,,['positive'],positive,1
NCT01968187,"{'position': 1, 'link': 'https://praderwillinews.com/news/fda-wants-additional-trial-pws-nasal-spray-lv-101-confirm-efficacy/', 'title': 'FDA Wants Additional Trial of PWS Nasal Spray LV-101 to Confirm Efficacy', 'source': 'Prader-Willi Syndrome News', 'date': 'Jan 20, 2022', 'snippet': 'The US Food and Drug Administration (FDA) has told Levo Therapeutics that \nan additional clinical trial will be necessary to confirm the efficacy of \nLV-101.', 'thumbnail': 'https://serpapi.com/searches/6723d239f59d009e292086df/images/bfb4178a4f29758df4879c02a3db26e06294b10a7582731291c5aaecbb6b19b5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8743943572044373}","{'position': 2, 'link': 'https://praderwillinews.com/news/acadia-trial-testing-carbetocin-nasal-spray-hyperphagia-pws/', 'title': 'New Acadia trial testing carbetocin nasal spray to treat insatiable hunger in PWS', 'source': 'Prader-Willi Syndrome News', 'date': 'Dec 7, 2023', 'snippet': 'Acadia Pharmaceuticals has launched a Phase 3 clinical trial testing the \nsafety and efficacy of ACP-101, an experimental carbetocin nasal spray, for \nthe...', 'thumbnail': 'https://serpapi.com/searches/6723d239f59d009e292086df/images/bfb4178a4f29758d834480d64d2e4d0bd16e01d656d1717484285739f1df97fa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8832798004150391}","{'position': 3, 'link': 'https://praderwillinews.com/news/phase-2-trial-shows-lv-101-reduces-symptoms-pws-children/', 'title': 'Potential PWS Therapy LV-101 Reduces Symptoms in Children, Trial Finds', 'source': 'Prader-Willi Syndrome News', 'date': 'Jun 25, 2018', 'snippet': ""Results from a Phase 2 clinical trial show that Levo Therapeutics' lead \ntherapy candidate, LV-101 (intranasal carbetocin), can effectively reduce \nsymptoms of..."", 'thumbnail': 'https://serpapi.com/searches/6723d239f59d009e292086df/images/bfb4178a4f29758d6dfdd6963ee38b4073e892584d27d7d6f9a1cf025639e5bd.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5229090452194214}",,,,,,,,"['neutral', 'neutral', 'positive']",neutral,1
NCT04269031,"{'position': 1, 'link': 'https://www.insideprecisionmedicine.com/topics/precision-medicine/phase-i-win-for-kidney-disease-drug-in-subtype-common-to-people-of-african-descent/', 'title': 'Phase I Win for Kidney Disease Drug in Subtype Common to People of African Descent', 'source': 'Inside Precision Medicine', 'date': 'May 30, 2024', 'snippet': 'What could be the first precision medicine for APOL1-mediated kidney \ndisease (AKMD) has successfully completed a Phase I trial.', 'thumbnail': 'https://serpapi.com/searches/6723d250a505f7518bfa9ce9/images/a3d0c513733dfa983af04d0d6fd25c7f31845fe5714fe6cdb99a30150c57fbe3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5857201814651489}",,,,,,,,,,['neutral'],neutral,1
NCT03332212,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332223014841', 'title': 'Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications', 'source': 'ScienceDirect.com', 'date': 'Oct 19, 2023', 'snippet': 'In this review, we discuss the protective effects of EMPA in \nchemotherapy-induced cardiotoxicity from molecular, immunological, and \nneuroimmunological aspects.', 'thumbnail': 'https://serpapi.com/searches/6723d2614a3fcfdcc671a152/images/a4bf1024cfac29d0fadb911e30b070cb2a492c59e9d9d93e23f79b23017f842e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8832970261573792}",,,,,,,,,,['neutral'],neutral,1
NCT04707313,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/pfizers-weight-loss-drug-hits-primary-endpoint-in-phase-iib-trial/', 'title': 'Pfizer’s weight loss drug hits primary endpoint in Phase IIb trial', 'source': 'Clinical Trials Arena', 'date': 'Dec 1, 2023', 'snippet': ""Pfizer's entry into the obesity drug market has seen successful progression \nas it joins the multi-billion dollar weight loss market."", 'thumbnail': 'https://serpapi.com/searches/6723d2612e33c808cd2ff169/images/8ff30a0769759761204892e3068ce829553ac1c3028777b00ad99cf10f01a471.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8142448663711548}","{'position': 2, 'link': 'https://www.biopharmadive.com/news/biotech-10-clinical-trials-watch-2023-second-half/653845/', 'title': '10 clinical trials to watch in the second half of 2023', 'source': 'BioPharma Dive', 'date': 'Jun 28, 2023', 'snippet': 'A Duchenne gene therapy faces a crucial test, while highly anticipated \nstudy results lay ahead in lung cancer, obesity and heart disease.', 'thumbnail': 'https://serpapi.com/searches/6723d2612e33c808cd2ff169/images/8ff30a07697597611916f65bd8a00be2de4a348f2c77aa84217df61699e2b1a1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.790732741355896}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02054897,"{'position': 1, 'link': 'https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-ozempic', 'title': 'Drug Trial Snapshot: Ozempic', 'source': 'U.S. Food and Drug Administration (.gov)', 'date': 'Aug 20, 2020', 'snippet': 'HOW TO USE THIS SNAPSHOT The information provided in Snapshots highlights \nwho participated in the clinical trials that supported the FDA...', 'thumbnail': 'https://serpapi.com/searches/6723d299f9338828b180e1f1/images/ab2b889246677da18d276b48d113423638151e4f62b6c671824c74076cffdcd5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9079004526138306}","{'position': 2, 'link': 'https://www.medwirenews.com/showcase/a-quick-guide-to-the-sustain-trials/', 'title': 'A quick guide to the SUSTAIN trials', 'source': 'medwirenews.com', 'date': 'Apr 7, 2017', 'snippet': 'Here is our guide to the 15 trials launched to date, which are complete, \nand which have so far been published in a peer-reviewed journal.', 'thumbnail': 'https://serpapi.com/searches/6723d299f9338828b180e1f1/images/ab2b889246677da10aec7d1bb770e9166a5830f2f5869fc53e5cca4dfa918746.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.865156352519989}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03954834,"{'position': 1, 'link': 'https://www.renalandurologynews.com/news/tirzepatide-vs-semaglutide-lower-metabolic-syndrome-prevalence/', 'title': 'Tirzepatide vs Semaglutide Linked to Lower Metabolic Syndrome Prevalence', 'source': 'Renal and Urology News', 'date': 'Apr 12, 2024', 'snippet': 'Use of tirzepatide, compared with placebo, semaglutide, and insulin \ndegludec and glargine, is associated with a lower prevalence of metabolic \nsyndrome among...', 'thumbnail': 'https://serpapi.com/searches/6723d2a50f1a336e4473aa72/images/33981df3de5e18d71de977b3a74ebb1d7a37663c4ae13e54608daa74de28db0a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8086218237876892}","{'position': 2, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-surpass-1-results-published-lancet-show-tirzepatides', 'title': ""Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes"", 'source': 'Eli Lilly and Company', 'date': 'Jun 26, 2021', 'snippet': ""Data presented at ADA's 81st Scientific Sessions® show the highest dose of \ntirzepatide (15 mg) reduced A1C by 2.07 percent and weight by 9.5 kg (20.9 \nlb., 11.0..."", 'thumbnail': 'https://serpapi.com/searches/6723d2a50f1a336e4473aa72/images/33981df3de5e18d7743afe728373eceab6ee230cab62fffd4bf27adeb9bd4b4b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5547938942909241}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04759768,"{'position': 1, 'link': 'https://www.empr.com/home/news/opvee-nasal-spray-approved-for-treatment-of-opioid-overdose/', 'title': 'Opvee Nasal Spray Approved for Treatment of Opioid Overdose', 'source': 'Medical Professionals Reference', 'date': 'May 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Opvee (nalmefene) nasal \nspray for the emergency treatment of known or suspected overdose induced by \nnatural...', 'thumbnail': 'https://serpapi.com/searches/6723d2a97a12fd36d112a05f/images/74536ea478aaddb7fd87f258d33e0a09ea6ce391729e0286307bef1012729d32.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8920722007751465}",,,,,,,,,,['neutral'],neutral,1
NCT03058289,"{'position': 1, 'link': 'https://www.onclive.com/view/int230-6-alone-with-ipilimumab-induces-positive-os-results-in-metastatic-sarcomas', 'title': 'INT230-6 Alone, With Ipilimumab Induces Positive OS Results in Metastatic Sarcomas', 'source': 'OncLive', 'date': 'Dec 30, 2022', 'snippet': 'INT230-6 demonstrated direct tumor killing in soft tissue sarcoma and \nelicits an anti-cancer immune response within the injected tumor both...', 'thumbnail': 'https://serpapi.com/searches/6723d2b729e6fb4ffa08bfb9/images/7ed99248b557312cd0f69f1230d9e87e13136f5415057b4da09d2ea28f70f2a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8363605737686157}",,,,,,,,,,['neutral'],neutral,1
NCT01877668,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1615975', 'title': 'Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis', 'source': 'The New England Journal of Medicine', 'date': 'Oct 19, 2017', 'snippet': 'Tofacitinib is an oral Janus kinase inhibitor that is under investigation \nfor the treatment of psoriatic arthritis. We evaluated tofacitinib...', 'thumbnail': 'https://serpapi.com/searches/6723d2c2bcd652fc3b3dc3ac/images/8082cef55897aedb870f11929684c659dff770dfbe925207c0ce51e0b34dc17f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9073402285575867}","{'position': 2, 'link': 'https://psoriasisnewstoday.com/2016/12/08/pfizer-phase-3-opal-trials-show-xeljanz-benefits-psoriatic-arthritis-patients/', 'title': 'Phase 3 Trials of Xeljanz in Psoriatic Arthritis Show Benefit', 'source': 'Psoriasis News Today', 'date': 'Dec 8, 2016', 'snippet': 'Pfizer presented positive results from its Phase 3 OPAL clinical program \nevaluating the effectiveness and safety of Xeljanz (tofacitinib...', 'thumbnail': 'https://serpapi.com/searches/6723d2c2bcd652fc3b3dc3ac/images/8082cef55897aedb8647e67349e80bb2fc2bc8cdf68711c927c1edfdb8d1ba07.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6341595649719238}","{'position': 3, 'link': 'https://psoriasisnewstoday.com/2017/05/04/psoriatic-arthritis-therapy-xeljanz-reviewed-fda-following-approval-pfizer-snda/', 'title': 'FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients', 'source': 'Psoriasis News Today', 'date': 'May 4, 2017', 'snippet': ""The U.S. Food and Drug Administration (FDA) will review Pfizer's medication \nXeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults..."", 'thumbnail': 'https://serpapi.com/searches/6723d2c2bcd652fc3b3dc3ac/images/8082cef55897aedb98953d312596045a74d368858905a3082ffa3ff3b40f3aba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9127993583679199}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT04582201,"{'position': 1, 'link': 'https://www.oncozine.com/first-pateint-dosed-with-allogeneic-off-the-shelf-invariant-natural-killer-t-cell-therapy/', 'title': 'First Pateint Dosed with Allogeneic, off-the-shelf, Invariant Natural Killer T-cell Therapy', 'source': ""Onco'Zine"", 'date': 'Mar 3, 2022', 'snippet': 'A first patient has been dosed with a novel, allogeneic, off-the-shelf, \ninvariant natural killer T (iNKT) cell therapy to treat cancer and other \nimmune-...', 'thumbnail': 'https://serpapi.com/searches/6723d3062c566d0ec8034c98/images/d5be052205c76c4fd15a9dfb02ebcd5be6ef109c3c1cfbecd122c20fb065db8c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8653754591941833}",,,,,,,,,,['neutral'],neutral,1
NCT02993406,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2215024', 'title': 'Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients', 'source': 'The New England Journal of Medicine', 'date': 'Mar 4, 2023', 'snippet': 'Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density \nlipoprotein (LDL) cholesterol levels and is associated with a low...', 'thumbnail': 'https://serpapi.com/searches/6723d3103d629b1615675019/images/8cfecd6c042329d821aaf5724894596f1e21f6967584a37c2d108fd748d704c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8117720484733582}","{'position': 2, 'link': 'https://www.managedhealthcareexecutive.com/view/key-data-analysis-from-clear-outcomes-trial', 'title': 'Key Data Analysis from CLEAR Outcomes Trial', 'source': 'Managed Healthcare Executive', 'date': 'Jun 7, 2023', 'snippet': 'Leslie Cho, M.D., FACC, FESC, FSCAI: Maybe we can now jump toward the \noutcome of the trial [CLEAR Outcomes, NCT02993406].', 'thumbnail': 'https://serpapi.com/searches/6723d3103d629b1615675019/images/8cfecd6c042329d855cf15a85424e0b2593978ea4a5f501107c72dba2263261a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7394821643829346}","{'position': 3, 'link': 'https://www.drugtopics.com/view/fda-approves-updated-ldl-c-lowering-indication-for-esperion-s-nexletol-nexlizet-tablets', 'title': 'FDA Approves Updated LDL-C Lowering Indication for Esperion’s Nexletol, Nexlizet Tablets', 'source': 'Drug Topics', 'date': 'Dec 18, 2023', 'snippet': 'The federal agency also removed the maximally tolerated qualifier for \nstatin use and the prior cardiovascular morbidity and mortality...', 'thumbnail': 'https://serpapi.com/searches/6723d3103d629b1615675019/images/8cfecd6c042329d8cec590f2200a91042ac9cd78885f68d72736e5d33779239a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7774533629417419}","{'position': 4, 'link': 'https://www.empr.com/home/news/fda-approval-broadens-eligibility-for-treatment-with-nexletol-nexlizet/', 'title': 'FDA Approval Broadens Eligibility for Treatment With Nexletol, Nexlizet', 'source': 'Medical Professionals Reference', 'date': 'Mar 25, 2024', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of Nexletol\n® (bempedoic acid 180mg tablets) and Nexlizet® (bempedoic acid...', 'thumbnail': 'https://serpapi.com/searches/6723d3103d629b1615675019/images/8cfecd6c042329d83de9a29c3e48c41ecb7a4eb9786739ae7c1638895af74233.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5737812519073486}",,,,,,,"['neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT04478227,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.13991', 'title': 'Research progress on the hematopoietic microenvironment in aplastic anemia', 'source': 'Wiley Online Library', 'date': 'May 19, 2023', 'snippet': 'European Journal of Haematology is an international haematology journal for \nbasic & clinical research, covering all diseases of the blood,...', 'thumbnail': 'https://serpapi.com/searches/6723d31474f0a46c50e7562b/images/56c3545c46c5f2c5a7d66ec790da6b37fe9b4dcd76c307e51279183bc2e93c42.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8685745596885681}",,,,,,,,,,['neutral'],neutral,1
NCT03008070,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2036205', 'title': 'A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH', 'source': 'The New England Journal of Medicine', 'date': 'Oct 20, 2021', 'snippet': 'Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical \nneed. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated...', 'thumbnail': 'https://serpapi.com/searches/6723d32cc76a22c378943260/images/c329527252539f9cb425e9c65d48288ab525ec1563c302009cb41076b3507a88.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8593646287918091}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-024-47919-9', 'title': 'The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis', 'source': 'Nature', 'date': 'May 10, 2024', 'snippet': 'Lanifibranor, a pan-PPAR agonist, improves liver histology in patients with \nmetabolic dysfunction-associated steatohepatitis (MASH), who have poor...', 'thumbnail': 'https://serpapi.com/searches/6723d32cc76a22c378943260/images/c329527252539f9cb41226edd5b2d361c3bc3fa591b659ed2369513afca45d66.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5004666447639465}","{'position': 3, 'link': 'https://liverdiseasenews.com/news/lanifibranor-may-promote-liver-gains-seen-phase-3-mash-trial/', 'title': 'Lanifibranor may be reason for liver gains seen in Phase 3 MASH trial', 'source': 'Liver Disease News', 'date': '1 month ago', 'snippet': 'An early analysis of MASH patients in the NATiV3 study found signs of \nbetter liver health, but data cover lanifibranor and placebo groups.', 'thumbnail': 'https://serpapi.com/searches/6723d32cc76a22c378943260/images/c329527252539f9c5ad342455d36a06aa84ef169f15619f5a73b5c05c9647b57.png', 'sentiment': 'neutral', 'sentiment_prob': 0.738456666469574}","{'position': 4, 'link': 'https://liverdiseasenews.com/news/nash-experimental-therapy-iva337-shows-good-safety-profile-monkey-trial-reports-inventiva/', 'title': 'NASH Experimental Therapy IVA337 Shows Good Safety Profile in Monkey Trial, Reports Inventive', 'source': 'liverdiseasenews.com', 'date': 'May 17, 2017', 'snippet': ""Inventiva's drug candidate IVA337, currently in Phase 2 studies for both \nnon-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc),..."", 'thumbnail': 'https://serpapi.com/searches/6723d32cc76a22c378943260/images/c329527252539f9c453b1158200828ae2d171b273b4bc3a93ae4164cd217527c.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6033857464790344}",,,,,,,"['neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT00440193,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1007903', 'title': 'Oral Rivaroxaban for Symptomatic Venous Thromboembolism', 'source': 'The New England Journal of Medicine', 'date': 'Oct 12, 2017', 'snippet': 'We conducted an open-label, randomized, event-driven, noninferiority study \nthat compared oral rivaroxaban alone (15 mg twice daily for 3 weeks,...', 'thumbnail': 'https://serpapi.com/searches/6723d330c0028ed39d6aa68e/images/accc2a2fc693d1e98341c4661df741cf6e89cc4c68eb7517500654462cb3165c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8873749375343323}",,,,,,,,,,['neutral'],neutral,1
NCT03372161,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/dexamethasone-injectable-gel-fast-tracked-for-lumbosacral-radicular-pain/', 'title': 'Dexamethasone Injectable Gel Fast Tracked for Lumbosacral Radicular Pain', 'source': 'Medical Professionals Reference', 'date': 'Dec 10, 2021', 'snippet': 'The Food and Drug Administration (FDA) has granted Fast Track designation \nto SP-102 (injectable dexamethasone sodium phosphate viscous gel) for the \ntreatment...', 'thumbnail': 'https://serpapi.com/searches/6723d34dfc40bf31d03988df/images/67b106d236d9e110d49e56f361e12f8da95c28fee68f75b561cc76c0f6d405d6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9042247533798218}",,,,,,,,,,['neutral'],neutral,1
NCT03683719,"{'position': 1, 'link': 'https://www.empr.com/home/news/delgocitinib-cream-leo-pharma-chronic-hand-eczema/', 'title': 'Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema', 'source': 'Medical Professionals Reference', 'date': 'Aug 5, 2020', 'snippet': 'The Food and Drug Administration (FDA) has granted Fast Track designation \nto delgocitinib cream (Leo Pharma) for the treatment of adults with \nmoderate to...', 'thumbnail': 'https://serpapi.com/searches/6723d36730dfc1525c009246/images/e73dc6bc1995cda6c7de07f4eb58f9b21e4f4d7a1fcec576f3eff9ef9b59cecc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.786065936088562}",,,,,,,,,,['neutral'],neutral,1
NCT02269423,"{'position': 1, 'link': 'https://www.nature.com/articles/srep27944', 'title': 'Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine | Scientific Reports', 'source': 'Nature', 'date': 'Jun 21, 2016', 'snippet': 'We analyzed human cellular immune responses induced by a single dose of the \nrVSV-ZEBOV vaccine candidate, which showed significant protective efficacy \nin...', 'thumbnail': 'https://serpapi.com/searches/6723d37393584cf63bb0256c/images/8bdf4290f0005eba6f4a50e601c139b815d72c7fa9744b1a6499e65c97afa850.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8583385348320007}",,,,,,,,,,['neutral'],neutral,1
NCT01865747,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1510016', 'title': 'Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 25, 2015', 'snippet': 'Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that \ntargets vascular endothelial growth factor receptor (VEGFR) as well...', 'thumbnail': 'https://serpapi.com/searches/6723d37b3c863d7b6c1233a2/images/4a899f632badef3ba42034cb86cf8c7f6f955635067ea5672cee1992f6016778.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9222884178161621}","{'position': 2, 'link': 'https://www.nature.com/articles/s41416-018-0061-6', 'title': 'Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma', 'source': 'Nature', 'date': 'Mar 26, 2018', 'snippet': 'In the phase 3 METEOR trial (NCT01865747), cabozantinib significantly \nimproved progression-free survival, overall survival, and objective...', 'thumbnail': 'https://serpapi.com/searches/6723d37b3c863d7b6c1233a2/images/4a899f632badef3b99e060f73fdd3680c613535e9cdded6e151f22d7f3a05f7c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7984726428985596}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/post-immunotherapy-cabozantinib-safe-feasible-for-metastatic-rcc-after-treatment-failure', 'title': 'Post-Immunotherapy Cabozantinib Safe, Feasible for Metastatic RCC After Treatment Failure', 'source': 'Cancer Network', 'date': 'Feb 19, 2022', 'snippet': 'New findings indicate that treatment with cabozantinib following failure of \nimmunotherapy proved to be safe and feasible in metastatic renal cell \ncarcinoma.', 'thumbnail': 'https://serpapi.com/searches/6723d37b3c863d7b6c1233a2/images/4a899f632badef3b72b17a05b87a89bb3693cb1ee946d0205097311dd65afca7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5715137720108032}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04906421,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/denifanstat-safely-treat-nash-phase-2b-clinical-trial/', 'title': 'Denifanstat seen to safely treat NASH in Phase 2b clinical trial', 'source': 'Liver Disease News', 'date': 'Feb 5, 2024', 'snippet': 'Denifanstat outperformed a placebo at resolving nonalcoholic \nsteatohepatitis in patients with moderate to severe liver fibrosis \ntreated...', 'thumbnail': 'https://serpapi.com/searches/6723d3af7658576d4a18396c/images/5e7dea6037aeb26572884c2664af4848db3e08375d35be60d8e0e716d0c03b55.png', 'sentiment': 'positive', 'sentiment_prob': 0.5272930264472961}",,,,,,,,,,['positive'],positive,1
NCT04558918,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa2308695', 'title': 'Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria', 'source': 'The New England Journal of Medicine', 'date': 'Mar 13, 2024', 'snippet': 'Iptacopan, a first-in-class oral factor B inhibitor, has been shown to \nimprove hemoglobin levels in these patients.', 'thumbnail': 'https://serpapi.com/searches/6723d3d3ecf150290223a10e/images/195a42c31ba71b5f9309c8855c2604ec0d8d3fbb3ee232310cff8210e74e7067.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8150742650032043}","{'position': 2, 'link': 'https://www.empr.com/home/news/fabhalta-approved-for-paroxysmal-nocturnal-hemoglobinuria/', 'title': 'Fabhalta Approved for Paroxysmal Nocturnal Hemoglobinuria - MPR', 'source': 'Medical Professionals Reference', 'date': 'Dec 6, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Fabhalta (iptacopan) \nfor the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).', 'thumbnail': 'https://serpapi.com/searches/6723d3d3ecf150290223a10e/images/195a42c31ba71b5fc9d8116d7cda197361a36505a703567bae05748b4db6ed6c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7750747203826904}","{'position': 3, 'link': 'https://www.hematologyadvisor.com/reports/anemia-pnh-oral-iptacopan-monotherapy-long-term-benefits-treatment/', 'title': 'Oral Iptacopan Monotherapy May Provide Long-Term Benefits in Anti-C5-Treated Patients With PNH and Persistent Anemia', 'source': 'Hematology Advisor', 'date': 'Dec 11, 2023', 'snippet': 'Long-term data from the phase III APPLY-PNH trial (ClinicalTrials.gov \nIdentifier: NCT04558918) presented at the ASH Annual Meeting 2023...', 'thumbnail': 'https://serpapi.com/searches/6723d3d3ecf150290223a10e/images/195a42c31ba71b5f0078dd41d4ccfdcfa483f0a0dacfea1656bba76ebd4a191b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5908665657043457}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00660179,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1213917', 'title': 'Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension', 'source': 'The New England Journal of Medicine', 'date': 'Aug 29, 2013', 'snippet': 'Current therapies for pulmonary arterial hypertension have been adopted on \nthe basis of short-term trials with exercise capacity as the...', 'thumbnail': 'https://serpapi.com/searches/6723d40af41044ef5e28dc8c/images/57d312f8144667e15b9bd5e965355b6f97544aa5a9a1bff82240aec9ba99a7ae.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9136669039726257}",,,,,,,,,,['neutral'],neutral,1
NCT01787383,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/jdv.13211', 'title': 'Journal of the European Academy of Dermatology and Venereology', 'source': 'Wiley Online Library', 'date': 'Aug 24, 2015', 'snippet': 'Background Actinic keratoses (AKs) are precursors to invasive squamous cell \ncarcinoma and can progress if untreated.', 'thumbnail': 'https://serpapi.com/searches/6723d40fa5e502a89cf9850c/images/41728dd53a9bdac628d20b52943749f2c28cbd9f61d2d84579d52280e61f8639.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9365453720092773}",,,,,,,,,,['neutral'],neutral,1
NCT01634217,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1075813/full', 'title': 'The emerging role of regulatory cell-based therapy in autoimmune disease', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': '1Student Research Committee, Kermanshah University of Medical Sciences, \nKermanshah, Iran; 2Universal Scientific Education and Research Network \n(USERN)...', 'thumbnail': 'https://serpapi.com/searches/6723d4395416d8fd8231f174/images/e1d0cfcddb9dcdd4d0ac7e975158046bc55996fda8ed6e966a0d35b540a4d5c6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9207028150558472}",,,,,,,,,,['neutral'],neutral,1
NCT01438489,"{'position': 1, 'link': 'https://www.empr.com/home/news/saphnelo-approved-for-systemic-lupus-erythematosus/', 'title': 'Saphnelo Approved for Systemic Lupus Erythematosus', 'source': 'Medical Professionals Reference', 'date': 'Aug 2, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Saphnelo \n(anifrolumab-fnia) for the treatment of adults with moderate to severe \nsystemic lupus...', 'thumbnail': 'https://serpapi.com/searches/6723d42dd997ab18f5611413/images/218163593d1506062cbf76d947bd684586fa06a68d528b0503937e24a3b8d2f7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.850493848323822}",,,,,,,,,,['neutral'],neutral,1
NCT04296890,"{'position': 1, 'link': 'https://www.ajmc.com/view/review-reinforces-safety-efficacy-of-mirvetuximab-soravtansine-in-recurrent-fr--positive-ovarian-cancer', 'title': 'Review Reinforces Safety, Efficacy of Mirvetuximab Soravtansine in Recurrent FRα-Positive Ovarian Cancer', 'source': 'AJMC', 'date': 'Feb 14, 2024', 'snippet': 'A review and meta-analysis found mirvetuximab soravtansine to have \nencouraging efficacy and a tolerable safety profile in patients with...', 'thumbnail': 'https://serpapi.com/searches/6723d440efad215bb81d42a9/images/792a3b1d44b0ebd212837f9cb70184671831494bfcc5c64282163124f6db9439.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.662169873714447}","{'position': 2, 'link': 'https://www.immunogen.com/patients-and-caregivers/', 'title': 'Patients and Caregivers |ImmunoGen ADC Technology-focused Cancer Treatments', 'source': 'ImmunoGen', 'date': 'May 14, 2018', 'snippet': 'Patients and caregivers are often blind-sided by cancer diagnoses and \nconfused by our complicated treatment plan using ADC Technology. Learn more \nhere.', 'thumbnail': 'https://serpapi.com/searches/6723d440efad215bb81d42a9/images/792a3b1d44b0ebd2309ac1132c727ddcc0e8175acee2a75490e612acfcdebde4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5577406287193298}","{'position': 3, 'link': 'https://www.cancerhealth.com/article/fda-approves-new-treatment-option-ovarian-cancer', 'title': 'FDA Approves New Treatment Option for Ovarian Cancer', 'source': 'Cancer Health', 'date': 'Nov 17, 2022', 'snippet': 'Elahere, a new antibody-drug conjugate, shrank tumors in about a third of \ntreatment-experienced patients.', 'thumbnail': 'https://serpapi.com/searches/6723d440efad215bb81d42a9/images/792a3b1d44b0ebd209c6dd6c4336e3d37a4731e3f1c7941d7a89f5034b48ca3e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7404248118400574}","{'position': 4, 'link': 'https://www.empr.com/home/news/elahere-granted-accelerated-approval-for-platinum-resistant-ovarian-cancer/', 'title': 'Elahere Granted Accelerated Approval for Platinum-Resistant Ovarian Cancer - MPR', 'source': 'Medical Professionals Reference', 'date': 'Nov 15, 2022', 'snippet': 'The Food and Drug Administration (FDA) has granted accelerated approval to \nElahere (mirvetuximab soravtansine-gynx) for the treatment of adult \npatients with...', 'thumbnail': 'https://serpapi.com/searches/6723d440efad215bb81d42a9/images/792a3b1d44b0ebd28d1fad53d67607e17fafe80e8df0295a672014bf5e3a9fd7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8012616038322449}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT00259376,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa054686', 'title': 'Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter', 'source': 'The New England Journal of Medicine', 'date': 'Sep 6, 2007', 'snippet': 'In two identical multicenter, double-blind, randomized trials, one \nconducted in Europe (ClinicalTrials.gov number, NCT00259428) and one...', 'thumbnail': 'https://serpapi.com/searches/6723d46e98fad695d7644c36/images/a6de4685bc60e27e58a92c1614f9c2f08190e9f61e961b76434ca32be7444995.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8912765979766846}",,,,,,,,,,['neutral'],neutral,1
NCT04916470,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02526-x', 'title': 'Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial', 'source': 'Nature', 'date': 'Aug 27, 2023', 'snippet': 'In the STEP-HFpEF trial, semaglutide improved symptoms, physical \nlimitations and exercise function and reduced body weight in patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/6723d48ed0c98349f3f117ce/images/5fd2add37440235e37d13ba86b7ee13cbb13edc2ea384cb62e4ccae2e744e09e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7419707179069519}","{'position': 2, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa2313917', 'title': 'Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Apr 7, 2024', 'snippet': 'Obesity and type 2 diabetes are prevalent in patients with heart failure \nwith preserved ejection fraction and are characterized by a high symptom \nburden.', 'thumbnail': 'https://serpapi.com/searches/6723d48ed0c98349f3f117ce/images/5fd2add37440235eed76db90bd0402f1ae793a0ba455130ddb42c4d23b57ae56.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6510336995124817}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT04141670,"{'position': 1, 'link': 'https://www.bioworld.com/articles/675357-arm-210-studied-in-new-clinical-trial-for-ryanodine-receptor-type-1-related-myopathies', 'title': 'ARM-210 studied in new clinical trial for ryanodine receptor type 1-related myopathies', 'source': 'BioWorld MedTech', 'date': 'Dec 18, 2019', 'snippet': 'ARMGO Pharma has announced the initiation of a clinical trial of ARM-210 \n(S-48168) for the treatment for patients with ryanodine receptor...', 'thumbnail': 'https://serpapi.com/searches/6723d489f60b6f6962215197/images/f52d9f103f610ad9c7cbf9dee20d63dc177a439ac0e5e62a7e566838743f3f0a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8976263999938965}",,,,,,,,,,['neutral'],neutral,1
NCT02105948,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1708208', 'title': 'Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease', 'source': 'The New England Journal of Medicine', 'date': 'Sep 12, 2017', 'snippet': 'We performed two phase 3, randomized, placebo-controlled, double-blind, \nparallel-group trials comparing mepolizumab (100 mg in METREX,...', 'thumbnail': 'https://serpapi.com/searches/6723d49ca2e99c954cff3b19/images/74ccc71da01a9b5490c7a73938aceeb3a7870759884f9224a353f3f2cad3f055.png', 'sentiment': 'neutral', 'sentiment_prob': 0.860298752784729}","{'position': 2, 'link': 'https://copdnewstoday.com/news/mepolizumab-antibody-copd-lessens-exacerbations-improves-quality-of-life/', 'title': 'Mepolizumab Lessens Exacerbations, Improves Quality of Life', 'source': 'COPD News Today', 'date': 'Aug 9, 2021', 'snippet': 'mepolizumab, an antibody designed to lower the levels of eosinophils — \nimmune cells linked with worse chronic obstructive pulmonary disease (...', 'thumbnail': 'https://serpapi.com/searches/6723d49ca2e99c954cff3b19/images/74ccc71da01a9b54e131fbfb667a5c61336e71d903df66c58b16ddc7779b8e6d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6641448736190796}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03654274,"{'position': 1, 'link': 'https://www.empr.com/home/news/myfembree-approved-for-management-of-endometriosis-pain/', 'title': 'Myfembree Approved for Management of Endometriosis Pain', 'source': 'Medical Professionals Reference', 'date': 'Aug 8, 2022', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of \nMyfembree® (relugolix, estradiol, and norethindrone acetate) to include...', 'thumbnail': 'https://serpapi.com/searches/6723d4b1a5aae9313a6ba7b5/images/e232f363f3462745ac2593f366ee5e417ab02de724ff11614d1165393f02cc2f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7937327027320862}",,,,,,,,,,['neutral'],neutral,1
NCT04752059,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01935-8', 'title': 'Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial', 'source': 'Nature', 'date': 'Aug 8, 2022', 'snippet': 'Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial \nactivity in human epidermal growth factor receptor 2 (HER2)-positive \nmetastatic...', 'thumbnail': 'https://serpapi.com/searches/6723d4c3c5d76966143b1592/images/ee6f9f80a3fa3a0d682f871596cac279c18ad51dfd0ec43de0ff94bfa86d7b9a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8184293508529663}","{'position': 2, 'link': 'https://www.onclive.com/view/dr-bartsch-on-the-tuxedo-1-trial-of-t-dxd-in-her2-breast-cancer-with-brain-metastases', 'title': 'Dr Bartsch on the TUXEDO-1 Trial of T-DXd in HER2+ Breast Cancer With Brain Metastases', 'source': 'OncLive', 'date': 'Jan 4, 2024', 'snippet': 'Rupert Bartsch, MD, associate professor, Department of Medicine, Division \nof Oncology, Medical University of Vienna, discusses findings from...', 'thumbnail': 'https://serpapi.com/searches/6723d4c3c5d76966143b1592/images/ee6f9f80a3fa3a0dc03c8268dfe71c54d7224c57549d592f90a7bcf91552fbf0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9377330541610718}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03321136,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.711255/full', 'title': 'Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin', 'source': 'Frontiers', 'date': 'Jul 12, 2021', 'snippet': 'The psychedelic lysergic acid diethylamide (LSD) has experienced a revival \nin research, including clinical trials that evaluate LSD-assisted...', 'thumbnail': 'https://serpapi.com/searches/6723d4ee74f0a46c18e52853/images/d73bb0feeb4f77b151087d0eb812674c9d9038962ff58279c3fa6bfd9126fc5d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8811450004577637}",,,,,,,,,,['neutral'],neutral,1
NCT04387461,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20230501005139/en/CG-Oncology-Announces-New-Phase-2-Data-with-Cretostimogene-Grenadenorepvec-CG0070-in-Combination-with-KEYTRUDA%C2%AE-pembrolizumab-in-BCG-Unresponsive-NMIBC', 'title': 'CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC', 'source': 'Business Wire', 'date': 'May 1, 2023', 'snippet': ""An ongoing Phase 2 clinical trial of cretostimogene grenadenorepvec \n(CG0070) in combination with Merck's anti-PD-1 therapy KEYTRUDA® \n(pembrolizumab)."", 'thumbnail': 'https://serpapi.com/searches/6723d5087b05ca0df8c8eda9/images/89421387e385b533ea906087d0a435628535cfa1532481b3cf09c8aa977f4c1e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9056834578514099}","{'position': 2, 'link': 'https://www.cgtlive.com/view/cg0070-genetically-modified-immunotherapy-non-muscle-invasive-bladder-cancer', 'title': 'CG0070: A Genetically Modified Immunotherapy for Non-Muscle Invasive Bladder Cancer', 'source': 'CGTLive®', 'date': 'Jul 30, 2021', 'snippet': ""The first patient in CG Oncology's phase 2 study of CG0070 was dosed in \nDecember 2020."", 'thumbnail': 'https://serpapi.com/searches/6723d5087b05ca0df8c8eda9/images/89421387e385b5334f4b926d70dd28e651a47f429eb224b1988c0f72d0bc2664.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9119356870651245}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02104245,"{'position': 1, 'link': 'https://bronchiectasisnewstoday.com/2019/11/21/aradigm-ends-effort-linhaliq-europe-approval-for-ncfbe-lung-infections/', 'title': 'Aradigm Ends Effort to Win EU Approval for Linhaliq in Treating NCFBE Chronic Lung Infections', 'source': 'Bronchiectasis News Today', 'date': 'Nov 21, 2019', 'snippet': 'Aradigm withdrew its application for Linhaliq in the European Union to \ntreat flares in non-cystic fibrosis bronchiectasis linked to P.', 'thumbnail': 'https://serpapi.com/searches/6723d50c48c429c80104c466/images/d11681bda91ea64386a74a154cc20424e774a02fa0e81afe2206366dded684b0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6251179575920105}","{'position': 2, 'link': 'https://bronchiectasisnewstoday.com/2017/07/28/non-cystic-fibrosis-bronchiectasis-candidate-therpay-nda-submitted-for-linhaliq-for-p-aeruginosa-infection/', 'title': 'Linhaliq’s NDA Submitted to Treat P. Aeruginosa Infection in NCFBE Patients', 'source': 'Bronchiectasis News Today', 'date': 'Jul 28, 2017', 'snippet': 'Aradigm has submitted a new drug application (NDA) to the US Food and Drug \nAdministration (FDA) for Linhaliq (ciprofloxacin) as a treatment for \nnon-cystic...', 'thumbnail': 'https://serpapi.com/searches/6723d50c48c429c80104c466/images/d11681bda91ea643e80d2b619a051ac35a660e875a560e329d8dc2c03acbf6f0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.921363890171051}","{'position': 3, 'link': 'https://bronchiectasisnewstoday.com/2017/09/26/fda-accepts-aradigms-nda-for-linhaliq-to-treat-non-cystic-fibrosis-bronchiectasis/', 'title': ""Aradigm's NDA for Linhaliq for non-CF Bronchiectasis Accepted by FDA"", 'source': 'Bronchiectasis News Today', 'date': 'Sep 26, 2017', 'snippet': 'A new drug application (NDA) submitted by Aradigm for Linhaliq (inhaled \nciprofloxacin) was recently accepted for filing with priority review...', 'thumbnail': 'https://serpapi.com/searches/6723d50c48c429c80104c466/images/d11681bda91ea64313c6bb19d64b6434584dc1676c70ffb8e8fb5576484a4775.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7861056923866272}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03150862,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-021-01632-2', 'title': 'Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours', 'source': 'Nature', 'date': 'Nov 18, 2021', 'snippet': 'Pamiparib, a PARP1/2 inhibitor, demonstrated antitumor activity in \npreclinical models. This Phase 1A/1B dose-escalation/dose-expansion study...', 'thumbnail': 'https://serpapi.com/searches/6723d5115235f6e4905ed5ac/images/d7931de8c5b7549ce17e06d56f3218f767950d7ab0d5923ac15089f2d7cca262.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8837805390357971}",,,,,,,,,,['neutral'],neutral,1
NCT05297578,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/pneumococcal-24-valent-conjugate-vaccine-gets-fast-track-designation/', 'title': 'Pneumococcal 24-Valent Conjugate Vaccine Gets Fast Track Designation', 'source': 'Medical Professionals Reference', 'date': 'Aug 4, 2022', 'snippet': 'The Food and Drug Administration (FDA) has granted Fast Track designation \nto VAX-24 for the prevention of invasive pneumococcal disease in adults 18 \nyears of...', 'thumbnail': 'https://serpapi.com/searches/6723d517b6e4dbfe4c292d08/images/ce456507ce012e9284a5df35d2881579362d632e95baf0092adfea5a3f0ce653.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9023721218109131}",,,,,,,,,,['neutral'],neutral,1
NCT02115373,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-021-01334-9', 'title': 'Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression', 'source': 'Nature', 'date': 'Apr 6, 2021', 'snippet': 'This Phase 1b/2 study evaluated tepotinib, a highly selective MET \ninhibitor, in US/European patients with sorafenib pretreated advanced \nhepatocellular...', 'thumbnail': 'https://serpapi.com/searches/6723d5194791c44bbf92909a/images/5d67ec3eff9c1614db8e65b9ee297fa938fd840bbdd68a9f7c3cb04f9785c89d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8844035267829895}",,,,,,,,,,['neutral'],neutral,1
NCT01980628,"{'position': 1, 'link': 'https://www.clinicalleader.com/doc/new-fda-guidance-clinical-trial-considerations-to-support-accelerated-approval-of-oncology-therapeutics-0001', 'title': 'New FDA Guidance Clinical Trial Considerations To Support Accelerated Approval Of Oncology Therapeutics', 'source': 'Clinical Leader', 'date': 'Apr 21, 2023', 'snippet': 'On April 6, 2023, AbbVie announced that it was voluntarily withdrawing \nibrutinib, which was granted accelerated approval for two...', 'thumbnail': 'https://serpapi.com/searches/6723d53bcdf1558f138a344b/images/63f2c7d3fe747eb69a23e1cd4053a585b75fc5f054965da42d3b89cd4e05cef5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8708025217056274}","{'position': 2, 'link': 'https://www.oncnursingnews.com/view/ibrutinib-is-no-longer-available-for-mantle-cell-lymphoma-or-marginal-zone-lymphoma-in-the-united-states', 'title': 'Ibrutinib is No Longer Available for Mantle Cell Lymphoma or Marginal Zone Lymphoma in the United States', 'source': 'Oncology Nursing News', 'date': 'Apr 14, 2023', 'snippet': 'AbbVie has withdrawn the indications for previously pretreated patients \nwith mantle cell lymphoma and marginal zone lymphoma.', 'thumbnail': 'https://serpapi.com/searches/6723d53bcdf1558f138a344b/images/63f2c7d3fe747eb6cde6aec40e597054af2df1176fc7f6a1e4a5a72ff7abf499.png', 'sentiment': 'negative', 'sentiment_prob': 0.6539507508277893}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT00375674,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1611406', 'title': 'Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy', 'source': 'The New England Journal of Medicine', 'date': 'Oct 10, 2016', 'snippet': 'Sunitinib, a vascular endothelial growth factor pathway inhibitor, is an \neffective treatment for metastatic renal-cell carcinoma.', 'thumbnail': 'https://serpapi.com/searches/6723d54e7ca6b38082a7f5da/images/50a4dfc9ea9e9770f64c6b7394f8ff0a384cfba97a84e9f7167ff9dce616dcc5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8611674308776855}",,,,,,,,,,['neutral'],neutral,1
NCT03970252,"{'position': 1, 'link': 'https://www.targetedonc.com/view/adding-nivolumab-to-neoadjuvant-chemotherapy-spurs-more-evaluation-in-pancreatic-cancer', 'title': 'Adding Nivolumab to Neoadjuvant Chemotherapy Spurs More Evaluation in Pancreatic Cancer', 'source': 'Targeted Oncology', 'date': 'Jun 18, 2024', 'snippet': 'Modified FOLFIRINOX with nivolumab in the neoadjuvant setting was \nassociated with favorable rates of R0 resection in patients with...', 'thumbnail': 'https://serpapi.com/searches/6723d733dda9d9c73b31c8c7/images/8af1f9a4f3313ce41d2380f828c1d5e52ac4e59eefe25956d2ad889641bd5d03.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8890814781188965}",,,,,,,,,,['neutral'],neutral,1
NCT04972188,"{'position': 1, 'link': 'https://alsnewstoday.com/news/zydus-phase-2-trial-anti-inflammatory-therapy-zyil1/', 'title': 'Zydus launches Phase 2 trial of anti-inflammatory therapy ZYIL1', 'source': 'ALS News Today', 'date': 'Oct 26, 2023', 'snippet': 'Zydus Lifesciences has launched a Phase 2 clinical trial to evaluate the \nsafety and effectiveness of its experimental anti-inflammatory therapy \nZYIL1 in people...', 'thumbnail': 'https://serpapi.com/searches/6723d741861b9d38e4f1e6fc/images/9293230fcde1ef67def5b3a056f3c142d675594624b8a38d5a04641774c8b6c9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8816696405410767}","{'position': 2, 'link': 'https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/zydus-begins-phase-ii-trial-of-zyil1-nlrp3-inhibitor-in-patients-with-als/104689856', 'title': 'Zydus begins Phase II trial of ZYIL1, NLRP3 inhibitor in patients with ALS', 'source': 'ET HealthWorld', 'date': 'Oct 25, 2023', 'snippet': ""Zydus Life Sciences is to initiate the Phase II clinical study of NLRP3 \ninhibitor 'ZYIL1' in patients with amyotrophic lateral sclerosis (ALS)."", 'thumbnail': 'https://serpapi.com/searches/6723d741861b9d38e4f1e6fc/images/9293230fcde1ef67510d66e6574492f648e9d62aeef3d4f8e4a4975f02505e1e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8477136492729187}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00554502,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1415463', 'title': 'Intensive Supportive Care plus Immunosuppression in IgA Nephropathy', 'source': 'The New England Journal of Medicine', 'date': 'Dec 3, 2015', 'snippet': 'The outcomes of immunosuppressive therapy, when added to supportive care, \nin patients with IgA nephropathy are uncertain.', 'thumbnail': 'https://serpapi.com/searches/6723d74190b57cda8ec59182/images/b62e5dfa2b7360d480f7131d61b8365fe3db720eb62ff95e08c1b372410bbbf2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.606076180934906}",,,,,,,,,,['neutral'],neutral,1
NCT05606913,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/easd-2024-innovent-shows-off-mazdutides-efficacy-in-diabetes-and-obesity/', 'title': 'EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity', 'source': 'Clinical Trials Arena', 'date': '1 month ago', 'snippet': ""The data from two Phase III trials demonstrated GLP-1/glucagon agonist's \nefficacy in reducing blood glucose and weight."", 'thumbnail': 'https://serpapi.com/searches/6723d75139e23253ca9df388/images/fae2385cfec4ee7059d645c9a3b7466ef1035050467084b7be8a945d28317f87.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7004231810569763}","{'position': 2, 'link': 'https://www.manilatimes.net/2024/09/12/tmt-newswire/pr-newswire/head-to-head-superiority-over-dulaglutide-innovents-phase-3-clinical-trial-dreams-2-of-mazdutide-in-chinese-patients-with-type-2-diabetes-were-orally-presented-at-easd-2024/1970914', 'title': ""Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024"", 'source': 'The Manila Times', 'date': '1 month ago', 'snippet': 'SAN FRANCISCO and SUZHOU, China, Sept. 12, 2024 /PRNewswire/ -- Innovent \nBiologics, Inc. (Innovent) (HKEX: 01801), a world-class...', 'thumbnail': 'https://serpapi.com/searches/6723d75139e23253ca9df388/images/fae2385cfec4ee70d6e942ecb5f4c13bc13f3c6d25f1830f714b9539f66ed8f1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7202430963516235}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02770378,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-024-02608-8', 'title': 'Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro', 'source': 'Nature', 'date': 'Feb 23, 2024', 'snippet': 'Glioblastoma represents a brain tumor with a notoriously poor prognosis. \nFirst-line therapy may include adjunctive Tumor Treating Fields...', 'thumbnail': 'https://serpapi.com/searches/6723d756fc183d321a411178/images/c37f870e663f334374ac1d9d350b830752071a5d57c53feea5ebca97f0271d58.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5039960145950317}",,,,,,,,,,['negative'],negative,0
NCT02489448,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-021-00219-7', 'title': 'Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer', 'source': 'Nature', 'date': 'Feb 8, 2021', 'snippet': 'The goal of this Phase I/II trial is to assess the safety and efficacy of \nadministering durvalumab concurrent with weekly nab-paclitaxel and \ndose-dense...', 'thumbnail': 'https://serpapi.com/searches/6723d56d23a4b58469dab82e/images/2b8d0ac2c74ec86dbba9bd8b448716c633baefa613f7bb35adc96bbd23234a21.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8751313090324402}",,,,,,,,,,['neutral'],neutral,1
NCT00205465,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-021-04240-3', 'title': 'A long way to go: caspase inhibitors in clinical use', 'source': 'Nature', 'date': 'Oct 15, 2021', 'snippet': 'Caspases are an evolutionary conserved family of cysteine-dependent \nproteases that are involved in many vital cellular processes including...', 'thumbnail': 'https://serpapi.com/searches/6723d5712b5fa75457cfec6c/images/9d94480568179dac0f29c5be783d75ee35b8ee7da3914fd2092af5eab55a0481.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8237717151641846}",,,,,,,,,,['neutral'],neutral,1
NCT04001803,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1909512', 'title': 'Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection', 'source': 'The New England Journal of Medicine', 'date': 'Mar 4, 2020', 'snippet': 'Long-acting injectable regimens may simplify therapy for patients with \nhuman immunodeficiency virus type 1 (HIV-1) infection.We conducted a phase \n3,...', 'thumbnail': 'https://serpapi.com/searches/6723d57b2a7727c51fde5564/images/82e94ca81ce0cab70238da7e32bc2b4de032239b3bd9465400451350eb5790d3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8906351923942566}",,,,,,,,,,['neutral'],neutral,1
NCT01449461,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/long-term-efficacy-continues-with-brigatinib-in-alk-nsclc-after-crizotinib', 'title': 'Long-Term Efficacy Continues With Brigatinib in ALK+ NSCLC After Crizotinib', 'source': 'Cancer Network', 'date': 'Jun 10, 2021', 'snippet': 'Long-term efficacy and safety results from the phase 1/2 (NCT01449461) and \nphase 2 ALTA (NCT02094573) trials reported at the 2021 American...', 'thumbnail': 'https://serpapi.com/searches/6723d5857ebde5eeab29fb09/images/61c9ba1d9254b12badfd9e5c6a7d67e98122838e5fa1049225981ea5b556612c.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6142606735229492}",,,,,,,,,,['positive'],positive,1
NCT02035553,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/bid-nuplazid-treat-alzheimers-psychosis-rejected-fda/', 'title': ""Bid for Nuplazid to Treat Alzheimer's Psychosis Rejected by FDA"", 'source': ""Alzheimer's News Today"", 'date': 'Aug 8, 2022', 'snippet': ""The U.S. Food and Drug Administration has affirmed its decision rejecting \nNuplazid as a treatment for Alzheimer's disease-related psychosis."", 'thumbnail': 'https://serpapi.com/searches/6723d6fe30dfc1525c009357/images/8e02d1ff37d05cf6032d542ede0bfed3fac2da900adbdf27b115f91f7f33152b.png', 'sentiment': 'negative', 'sentiment_prob': 0.6054498553276062}",,,,,,,,,,['negative'],negative,0
NCT03267316,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/fda-grants-orphan-drug-designation-to-nt-i7-in-advanced-pancreatic-cancer', 'title': 'FDA Grants Orphan Drug Designation to NT-I7 in Advanced Pancreatic Cancer', 'source': 'Cancer Network', 'date': 'Feb 5, 2024', 'snippet': 'Treatment with NT-I7 may boost the immune system and enhance antitumor \nactivity in patients with pancreatic cancer and other solid tumors.', 'thumbnail': 'https://serpapi.com/searches/6723d6d9e10f0aab3a6244d9/images/22a1972b0aea68f3582a4b9f4f15471aac6582f4afc2799ce16797105c5f3928.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6071109771728516}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/shubham-pant-md-on-the-future-of-treatment-of-pancreatic-cancer-with-targeted-therapies', 'title': 'Shubham Pant, MD, on the Future of Treatment of Pancreatic Cancer With Targeted Therapies', 'source': 'Cancer Network', 'date': 'Jun 18, 2022', 'snippet': 'In an interview with CancerNetwork® during the 2022 American Society of \nClinical Oncology (ASCO) Annual Meeting, Shubham Pant, MD,...', 'thumbnail': 'https://serpapi.com/searches/6723d6d9e10f0aab3a6244d9/images/22a1972b0aea68f3ad7133c9dee887129d752cbf77dc50a2bffc2b09470aa594.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9141588807106018}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/atezolizumab-plus-bevacizumab-induces-promising-clinical-responses-in-neuroendocrine-tumors', 'title': 'Atezolizumab Plus Bevacizumab Induces Promising Clinical Responses in Neuroendocrine Tumors', 'source': 'Cancer Network', 'date': 'Jul 19, 2022', 'snippet': 'The use of atezolizumab (Tecentriq) and bevacizumab (Avastin) yielded \npromising clinical responses and progression-free survival (PFS) in...', 'thumbnail': 'https://serpapi.com/searches/6723d6d9e10f0aab3a6244d9/images/22a1972b0aea68f35df365f995f311ab7c0c25fc56f43653c75a22a8417c2dc9.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5143183469772339}","{'position': 4, 'link': 'https://www.cancernetwork.com/view/eileen-m-oreilly-md-challenges-treating-patients-pancreatic-cancer', 'title': 'Eileen M. O’Reilly, MD, on the Challenges of Treating Patients with Pancreatic Cancer', 'source': 'Cancer Network', 'date': 'Jan 27, 2020', 'snippet': 'The medical oncologist from Memorial Sloan Kettering Cancer Center \ndiscussed challenges in treating patients with pancreatic center,...', 'thumbnail': 'https://serpapi.com/searches/6723d6d9e10f0aab3a6244d9/images/22a1972b0aea68f38900f73a3fb0d1341d9f0030d40382b2740b17c48751ce1b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9265167713165283}","{'position': 5, 'link': 'https://www.cancernetwork.com/view/frontline-nalirifox-approved-by-fda-in-metastatic-pdac', 'title': 'Frontline NALIRIFOX Approved by FDA in Metastatic PDAC', 'source': 'Cancer Network', 'date': 'Feb 13, 2024', 'snippet': 'Patients with metastatic pancreatic ductal adenocarcinoma may now receive \nirinotecan liposome in combination with 5-fluorouracil/leucovorin...', 'thumbnail': 'https://serpapi.com/searches/6723d6d9e10f0aab3a6244d9/images/22a1972b0aea68f3c546f32cd67221b1ad8b1573a7dd2cc12c91d8bc9353d9b8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8191787004470825}","{'position': 6, 'link': 'https://www.cancernetwork.com/view/individuals-with-pathogenic-atm-variant-have-an-increased-lifetime-risk-of-developing-pancreatic-cancer', 'title': 'Individuals With Pathogenic ATM Variant Have an Increased Lifetime Risk of Developing Pancreatic Cancer', 'source': 'Cancer Network', 'date': 'Oct 5, 2021', 'snippet': 'Research of family registries found that individuals with a germline \npathogenic ATM variant gene had greater lifetime risk of developing...', 'thumbnail': 'https://serpapi.com/searches/6723d6d9e10f0aab3a6244d9/images/22a1972b0aea68f35a42baf669b4f50fdfa8397163189f0440cd5aed036742bc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6251764297485352}","{'position': 7, 'link': 'https://www.cancernetwork.com/view/weight-loss-surgery-may-decrease-risk-of-developing-pancreatic-cancer-in-obese-diabetic-patients', 'title': 'Weight Loss Surgery May Decrease Risk of Developing Pancreatic Cancer in Obese, Diabetic Patients', 'source': 'Cancer Network', 'date': 'Nov 1, 2020', 'snippet': 'This 20-year analysis suggested that weight loss surgery significantly \ndecreases the risk of developing pancreatic cancer in individuals who are \nobese with...', 'thumbnail': 'https://serpapi.com/searches/6723d6d9e10f0aab3a6244d9/images/22a1972b0aea68f321219f4813f848872e5160988f85ff134805c6fd65b7b0d3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7835648655891418}","{'position': 8, 'link': 'https://www.notimerica.com/comunicados/noticia-comunicado-cantargia-presents-new-robust-data-at-asco-2022-confirming-promising-effects-of-nadunolimab-in-treatment-of-pancreatic-20220527003000.html', 'title': 'Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic c', 'source': 'Notimérica', 'date': 'May 26, 2022', 'snippet': '(NASDAQ Stockholm: CANTA) today reported extended interim results in \nfirst-line pancreatic cancer (PDAC)...', 'thumbnail': 'https://serpapi.com/searches/6723d6d9e10f0aab3a6244d9/images/22a1972b0aea68f3898509639828c2db8b1cde81ad971ac29e4bd7f60bc95729.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7977784276008606}",,,"['positive', 'neutral', 'positive', 'neutral', 'neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT04039113,"{'position': 1, 'link': 'https://copdnewstoday.com/news/adults-with-moderate-severe-copd-saw-fewer-exacerabations-with-tezepelumab/', 'title': 'Adults with moderate, severe COPD saw fewer exacerbations with tezepelumab', 'source': 'COPD News Today', 'date': 'May 20, 2024', 'snippet': 'Tezepelumab, which is approved for severe asthma, tended to reduce the \nfrequency of exacerbations in adults with moderate to very severe chronic \nobstructive...', 'thumbnail': 'https://serpapi.com/searches/6723d6e37ef9fa291b901e92/images/d059737f48be67728eb2908787b89ebaa3b3494a5e9188bcb2be28a6f36e866b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7825015187263489}","{'position': 2, 'link': 'https://copdnewstoday.com/news/tezepelumab-fdas-breakthrough-designation-eosinophilic-copd/', 'title': 'Tezepelumab wins breakthrough designation for eosinophilic COPD', 'source': 'COPD News Today', 'date': 'Aug 12, 2024', 'snippet': 'The US Food and Drug Administration (FDA) has granted breakthrough \ndesignation to tezepelumab, an approved therapy for severe asthma, as an \nadd-on maintenance...', 'thumbnail': 'https://serpapi.com/searches/6723d6e37ef9fa291b901e92/images/d059737f48be67724725bb04ff706c5c9c9b78de4115df83b65d54b997a795aa.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5824113488197327}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04538625,"{'position': 1, 'link': 'https://www.onclive.com/view/crofelemer-misses-diarrhea-end-point-in-patients-with-solid-tumors-receiving-targeted-therapy', 'title': 'Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy', 'source': 'OncLive', 'date': 'Jul 23, 2024', 'snippet': 'Prophylaxis with crofelemer (Mytesi) did not lead to a statistically \nsignificant improvement in the incidence of diarrhea vs placebo in...', 'thumbnail': 'https://serpapi.com/searches/6723d6f263a844cf0f6aea28/images/bdb8b23c6339ee053db59031a8bcb3cae230d7129c6d3fe594f0b4fb26f65423.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5886012315750122}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/news/jaguar-diarrhoea-drug-breast-cancer-benefit/', 'title': 'Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup', 'source': 'Clinical Trials Arena', 'date': '1 month ago', 'snippet': 'The drug, which is approved to treat diarrhoea in HIV/AIDS patients, failed \nto meet the primary endpoint in a Phase III solid tumour trial.', 'thumbnail': 'https://serpapi.com/searches/6723d6f263a844cf0f6aea28/images/bdb8b23c6339ee05f61300bc93b24d89f80ce54ee582d54d0310f046f4b8e23b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6101589202880859}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT02292537,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1710504', 'title': 'Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy', 'source': 'The New England Journal of Medicine', 'date': 'Feb 14, 2018', 'snippet': 'We conducted a multicenter, double-blind, sham-controlled, phase 3 trial of \nnusinersen in 126 children with SMA who had symptom onset after 6 months of \nage.', 'thumbnail': 'https://serpapi.com/searches/6723d5ae20e6ebb17b22b689/images/c2d894389c9157bb1e3d95b9f805de732cac332e040ff38cd1dc4168536eeeb4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8977910876274109}","{'position': 2, 'link': 'https://smanewstoday.com/news/anesthesia-spinraza-administration-safe-effective-children-type-2-sma-study/', 'title': 'For SMA Type 2 Children, Anesthesia Safe for Spinraza Injection, Study Says', 'source': 'SMA News Today', 'date': 'Oct 17, 2018', 'snippet': 'Standard general anesthesia for the administration of Spinraza (nusinersen) \nis safe and effective in children with type 2 SMA,...', 'thumbnail': 'https://serpapi.com/searches/6723d5ae20e6ebb17b22b689/images/c2d894389c9157bbc1bbc6f61c4188d5732d75986c999c2a0936461730b1cfb5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.668415367603302}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02931838,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1806382', 'title': 'Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 11, 2018', 'snippet': 'Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine \nsignaling, are implicated in the pathophysiology of psoriasis.', 'thumbnail': 'https://serpapi.com/searches/6723d5b881262ab5dba9937c/images/104fef32e1b0501f077f46eb59959c549b717535f760f557f93e0617cb2828e8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5730414986610413}",,,,,,,,,,['neutral'],neutral,1
NCT00000620,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1001286', 'title': 'Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus', 'source': 'The New England Journal of Medicine', 'date': 'Mar 14, 2010', 'snippet': 'There is no evidence from randomized trials to support a strategy of \nlowering systolic blood pressure below 135 to 140 mm Hg in persons with \ntype 2 diabetes...', 'thumbnail': 'https://serpapi.com/searches/6723d5c013e5d82f479b43fc/images/e45487a315d963f6d8f9a54bf65bf739040084965a07447cb42cedd1b9b04ee6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5974773168563843}",,,,,,,,,,['neutral'],neutral,1
NCT01555242,"{'position': 1, 'link': 'https://www.nature.com/articles/bjc2017474', 'title': 'Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer', 'source': 'Nature', 'date': 'Jan 30, 2018', 'snippet': 'Docetaxel used for first-line treatment of advanced prostate cancer (PCa) \nis only marginally effective. We previously showed, using the...', 'thumbnail': 'https://serpapi.com/searches/6723d5bf29e6fb4ffa08c091/images/e331ec7c8199e03f48a150b142d191893bdb0239eb0699807956a7ce26f2834a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6811469793319702}",,,,,,,,,,['neutral'],neutral,1
NCT04232280,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S2405844024030020', 'title': 'The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases', 'source': 'ScienceDirect.com', 'date': 'Mar 15, 2024', 'snippet': 'This review aims to elucidate the advancements in the clinical applications \nof mRNAs for addressing significant health-related challenges such as \ncancer,...', 'thumbnail': 'https://serpapi.com/searches/6723d5c7fbde0d8873b38dd6/images/c3db3c89525003ebc89b47c2e8eea18febed6c8c80041ba74daa73fd7feb129b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8580176830291748}",,,,,,,,,,['neutral'],neutral,1
NCT01502800,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0278-4', 'title': 'Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis', 'source': 'Nature', 'date': 'Oct 15, 2018', 'snippet': 'NAD(P)H:quinone oxidoreductase 1 (NQO1) is a two-electron oxidoreductase \nexpressed in multiple tumour types. ARQ 761 is a β-lapachone...', 'thumbnail': 'https://serpapi.com/searches/6723d657069e57e9bd9f8dd9/images/514e40b6ee10f65d66cf9045fdc25d5b9aa4776313c0aeb8d29b50ef5ca9c5e3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8053973317146301}",,,,,,,,,,['neutral'],neutral,1
NCT03417687,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-xenoview-for-evaluating-lung-ventilation/', 'title': 'FDA Approves Xenoview for Evaluating Lung Ventilation', 'source': 'Medical Professionals Reference', 'date': 'Dec 29, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Xenoview™ (xenon Xe 129 \nhyperpolarized), a hyperpolarized contrast agent indicated for...', 'thumbnail': 'https://serpapi.com/searches/6723d664cf32e0cd50e32f2f/images/2e40a5456d2c128948da93eaa3071e54082b7670e3c7ad146e160277eb0ec7ad.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7300285696983337}",,,,,,,,,,['neutral'],neutral,1
NCT02347098,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/full/10.1161/CIRCINTERVENTIONS.119.008933', 'title': 'Plaque Regression and Endothelial Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER)', 'source': 'American Heart Association Journals', 'date': 'Aug 14, 2020', 'snippet': 'Background:Low-density lipoproteins (LDLs) are removed by extracorporeal \nfiltration during LDL apheresis. It is mainly used in familial...', 'thumbnail': 'https://serpapi.com/searches/6723d6707c1712ec9a29f3ee/images/9cd397c5696edb5a460876184479063523e76e2f36b1452d2017b174918ea5f3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8262351751327515}",,,,,,,,,,['neutral'],neutral,1
NCT02948569,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/denifanstat-safely-treat-nash-phase-2b-clinical-trial/', 'title': 'Denifanstat seen to safely treat NASH in Phase 2b clinical trial', 'source': 'Liver Disease News', 'date': 'Feb 5, 2024', 'snippet': 'Denifanstat outperformed a placebo at resolving nonalcoholic \nsteatohepatitis in patients with moderate to severe liver fibrosis \ntreated...', 'thumbnail': 'https://serpapi.com/searches/6723d684b57db8ce1fd87bd0/images/38b2eebc4ac1336efbd29004633023957427054e242d88da3d2d5ee56ef92b16.png', 'sentiment': 'positive', 'sentiment_prob': 0.5272930264472961}",,,,,,,,,,['positive'],positive,1
NCT04674189,"{'position': 1, 'link': 'https://www.joghr.org/article/21369-covid-19-vaccine-therapeutic-trials-review-published-results-and-registered-protocols', 'title': 'COVID-19 vaccine therapeutic trials review: published results and registered protocols', 'source': 'Journal of Global Health Reports', 'date': 'Jan 27, 2022', 'snippet': ""This review summarizes COVID-19 vaccines clinical trials in phase III and \nIV and all published clinical trials' results."", 'thumbnail': 'https://serpapi.com/searches/6723d694a5aae9317e5b944f/images/e9cafdac18dfe840cea01a717188409a27c8b553e82566fa208a139edb76c9e7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9377875328063965}",,,,,,,,,,['neutral'],neutral,1
NCT04228445,"{'position': 1, 'link': 'https://www.empr.com/home/news/bludigo-approved-as-diagnostic-dye-for-cystoscopic-assessment-of-ureters/', 'title': 'Bludigo Approved as Diagnostic Dye for Cystoscopic Assessment of Ureters', 'source': 'Medical Professionals Reference', 'date': 'Jul 13, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Bludigo™ \n(indigotindisulfonate sodium, USP) as a diagnostic dye indicated for use as \na...', 'thumbnail': 'https://serpapi.com/searches/6723d6999fd30930a618be67/images/ea659dca43e40548e2f0371c0a87d7c25889b3aa28e6301aad5cfcdb6335d008.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.890252947807312}",,,,,,,,,,['neutral'],neutral,1
NCT04507841,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-024-01970-6', 'title': 'Advancing clinical-basic-clinical research: exploring novel immunotargets for ovarian cancer', 'source': 'Nature', 'date': '1 month ago', 'snippet': 'In a recent paper published in Cell, Luo and colleagues performed a \nmulti-omics analysis of a prospective phase II clinical trial and...', 'thumbnail': 'https://serpapi.com/searches/6723d6169819f39c78e2d53d/images/7d402c2cc48c9f217f7244c1d44a78e46abe239c29f5ac270daa4e9918feedad.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8881241679191589}",,,,,,,,,,['neutral'],neutral,1
NCT03846453,"{'position': 1, 'link': 'http://biospectator.com/view/news_view.php?varAtcId=7342', 'title': 'HanAll starts Phase 3 clinical trial of HL036, a new drug for dry eye, in the U.S.', 'source': '바이오스펙테이터', 'date': 'Mar 25, 2019', 'snippet': ""HanAll BioPharma announced on February 10th, 2019 that it started in Phase \n3 clinical trial the first administration of 'HL036', a new..."", 'thumbnail': 'https://serpapi.com/searches/6723d6175a461a60b367e143/images/623399a82c5045189ab11ef46e149f15c8aee75bb383e98ebf35a44661519a7b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.891913115978241}",,,,,,,,,,['neutral'],neutral,1
NCT01447719,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMp1208061', 'title': 'Brain Amyloid Imaging — FDA Approval of Florbetapir F18 Injection', 'source': 'The New England Journal of Medicine', 'date': 'Sep 6, 2012', 'snippet': ""The FDA has approved a new radiopharmaceutical agent to assist in detecting \ncauses of cognitive impairment other than Alzheimer's disease."", 'thumbnail': 'https://serpapi.com/searches/6723d6406de1e45934c4936f/images/679091b773e4219e391cb59840f24f8f61cdfd7a56633d471c2264cee0823ef2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8487148284912109}",,,,,,,,,,['neutral'],neutral,1
NCT05351671,"{'position': 1, 'link': 'https://copdnewstoday.com/news/fda-clears-phase-2-trial-testing-rls-0071-copd-exacerbations/', 'title': 'FDA clears Phase 2 trial of RLS-0071 for COPD exacerbations', 'source': 'COPD News Today', 'date': 'Nov 6, 2023', 'snippet': ""The US Food and Drug Administration (FDA) has approved ReAlta Life \nSciences' request to launch a Phase 2 clinical trial testing its \nexperimental anti-..."", 'thumbnail': 'https://serpapi.com/searches/6723d64b56f970c23ad1b038/images/f9cf795b7b54f865db5d0dd8d4c871229b50aabe4b1159cab0221ecb931a30c4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.849418044090271}",,,,,,,,,,['neutral'],neutral,1
NCT03507166,"{'position': 1, 'link': 'https://www.oncozine.com/disitamab-vedotin-conditionally-approved-by-chinese-regulator-for-treatment-of-gastric-cancer/', 'title': 'Disitamab Vedotin Conditionally Approved by Chinese Regulator for treatment of Gastric Cancer', 'source': ""Onco'Zine"", 'date': 'Jun 15, 2021', 'snippet': 'Disitamab vedotin (爱地希®/Aidixi®; Previously known as RC48), an \nantibody-drug conjugate being developed by Yantai (China-) based Remegen...', 'thumbnail': 'https://serpapi.com/searches/6723d771910986a69be96211/images/f62840756c8327f0241193c4098e8c4e768836c3cf44f6f76a044234bbc0e15f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.89381343126297}",,,,,,,,,,['neutral'],neutral,1
NCT02484092,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/gene-therapy-reduces-bleeding-men-with-hemophilia-b/', 'title': 'Gene Therapy Reduces Bleeding in Men With Hemophilia B |...', 'source': 'Hemophilia News Today', 'date': 'Jan 18, 2023', 'snippet': 'Experimental gene therapy fidanacogene elaparvovec treatment led to lower \nrates of bleeding for participants in a Phase 3 clinical trial.', 'thumbnail': 'https://serpapi.com/searches/6723d772175de673526ae68b/images/b7c41ffb84e228034b958e60a64e55d951341e6e5407359d7bd53b728987cf53.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5573880076408386}","{'position': 2, 'link': 'https://hemophilianewstoday.com/news/hemophilia-b-gene-therapy-beqvez-offers-new-choice-pfizer-official/', 'title': 'Hemophilia B gene therapy Beqvez offers new choice: Pfizer official', 'source': 'Hemophilia News Today', 'date': 'May 17, 2024', 'snippet': 'A Pfizer executive says company is preparing to launch gene therapy Beqvez, \noffering hemophilia B patients a new treatment option.', 'thumbnail': 'https://serpapi.com/searches/6723d772175de673526ae68b/images/b7c41ffb84e22803248cfc5105c9d9987315afa96d79e78696adf573d0f1af9b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7357036471366882}","{'position': 3, 'link': 'https://hemophilianewstoday.com/news/study-shows-spk-9001-boosts-clotting-factor-and-cuts-bleeding-in-hemophiliacs/', 'title': 'Hemophilia Therapy Boosts Clotting Factor, Cuts Bleeding Episodes', 'source': 'Hemophilia News Today', 'date': 'Apr 7, 2017', 'snippet': 'Read about clinical trial results showing that SPK-9001 boosted a clotting \nfactor and reduced bleeding episodes in hemophiliacs.', 'thumbnail': 'https://serpapi.com/searches/6723d772175de673526ae68b/images/b7c41ffb84e2280319d769ec505b8ae8073798ca185b535c151527167aab5e1d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5944496989250183}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03423186,"{'position': 1, 'link': 'https://sanfilipponews.com/news/sobi003-safe-reduces-heparan-sulfate-levels-in-1st-trial-humans-experimental-treatment/', 'title': 'SOBI003 Safe, Reduces Heparan Sulfate Levels in 1st Trial in Humans', 'source': 'Sanfilippo Syndrome News', 'date': 'Aug 18, 2022', 'snippet': 'SOBI003, a now-discontinued experimental treatment for Sanfilippo syndrome \ntype A, was generally well-tolerated in a clinical trial.', 'thumbnail': 'https://serpapi.com/searches/6723d772910986a69be96212/images/ba3fc45cee08ddb7d0802106a1235d7a23b8f467f04bd2429117cb0ea94aac7a.png', 'sentiment': 'positive', 'sentiment_prob': 0.7193895578384399}",,,,,,,,,,['positive'],positive,1
NCT02941328,"{'position': 1, 'link': 'https://smanewstoday.com/news/top-10-sma-stories-2023/', 'title': 'Top 10 SMA stories of 2023', 'source': 'SMA News Today', 'date': 'Jan 3, 2024', 'snippet': 'Here are the Top 10 spinal muscular atrophy news stories brought to our SMA \nNews Today readers in 2023.', 'thumbnail': 'https://serpapi.com/searches/6723d78bce1e107b7720327e/images/1262457feea2a7efaa82445e9cb4d5dfc766c478d0aa83839dddb6c53cff9fb9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9062528610229492}","{'position': 2, 'link': 'https://smanewstoday.com/news/pyridostigmine-may-be-add-on-treatment-fatigue-sma-trial-shows/', 'title': 'Muscle Strengthener Found to Ease Patient Fatigue in Small Study', 'source': 'SMA News Today', 'date': 'Jan 18, 2023', 'snippet': 'Treatment with pyridostigmine led to reductions in patient-reported fatigue \namong h SMA patients with types 2-4 in a small clinical trial.', 'thumbnail': 'https://serpapi.com/searches/6723d78bce1e107b7720327e/images/1262457feea2a7efc9281d657438767bdad5a0a2039d231344524bd35367f80a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.587851345539093}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01857115,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/once-weekly-kyprolis-effective-untreated-multiple-myeloma-patients/', 'title': 'Once-weekly Kyprolis Safe, Effective for Untreated Multiple Myeloma Patients, Study Finds', 'source': 'Myeloma Research News', 'date': 'Mar 6, 2019', 'snippet': 'Treatment with Kyprolis (carfilzomib) once a week is as safe and effective \nas the twice-weekly regimen used for the initial treatment of multiple \nmyeloma...', 'thumbnail': 'https://serpapi.com/searches/6723d7a90053c76d043be7ce/images/fe3694714c112ff965248224f45ba2fc1f11b86105ec588a4ad583324087f5f1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5886017084121704}",,,,,,,,,,['neutral'],neutral,1
NCT05279131,"{'position': 1, 'link': 'https://www.empr.com/home/news/klisyri-approved-to-treat-actinic-keratosis-over-larger-surface-areas/', 'title': 'Klisyri Approved to Treat Actinic Keratosis Over Larger Surface Areas', 'source': 'Medical Professionals Reference', 'date': 'Jun 10, 2024', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of Klisyri \n(tirbanibulin) to include the treatment of actinic keratosis on areas of \nthe face...', 'thumbnail': 'https://serpapi.com/searches/6723d7db11db456d905d7916/images/925ba557ff222beee66b8230ad80f0ecf8c5dbe9df3f2bec9e52e81a953792ac.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.804269015789032}",,,,,,,,,,['neutral'],neutral,1
NCT01369342,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1602773', 'title': 'Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease', 'source': 'The New England Journal of Medicine', 'date': 'Nov 17, 2016', 'snippet': 'Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and \ninterleukin-23, was evaluated as an intravenous induction therapy in two...', 'thumbnail': 'https://serpapi.com/searches/6723d7f4d771bdcb8c6323a0/images/ca1eca76e881c143b029f85811dcceeff1fc4db638e667e010db20992056aacb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9213168025016785}",,,,,,,,,,['neutral'],neutral,1
NCT03280056,"{'position': 1, 'link': 'https://themalaysianreserve.com/2024/10/30/brainstorm-cell-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement/', 'title': 'BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement', 'source': 'The Malaysian Reserve', 'date': '21 hours ago', 'snippet': 'NEW YORK, Oct. 30, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. \n(NASDAQ: BCLI), a leading developer of cellular therapies for...', 'thumbnail': 'https://serpapi.com/searches/6723d7f90be2f6aacef183d7/images/181d0bbe50437b78886df7a0614483cfb14e5f2045aa70ecf7f0ede553b7ee71.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.747658371925354}","{'position': 2, 'link': 'https://alsnewstoday.com/news/als-patient-samples-nurown-phase-3-trial-aid-research/', 'title': 'Samples From ALS Patients in Phase 3 NurOwn Trial Open to Researchers', 'source': 'ALS News Today', 'date': 'Jan 16, 2023', 'snippet': 'Biological samples from amyotrophic lateral sclerosis (ALS) patients who \ntook part in the Phase 3 clinical trial of NurOwn, a cell-based therapy, \nare being...', 'thumbnail': 'https://serpapi.com/searches/6723d7f90be2f6aacef183d7/images/181d0bbe50437b783d80a2f8ba2aed2aa9278d9d8f06b6ecf74e7a46b3bed371.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9174297451972961}","{'position': 3, 'link': 'https://www.cgtlive.com/view/stacy-lindborg-phd-upcoming-fda-advisory-committee-meeting-nurown-als', 'title': 'Stacy Lindborg, PhD, on the Upcoming FDA Advisory Committee Meeting for NurOwn in ALS', 'source': 'CGTLive®', 'date': 'Mar 27, 2023', 'snippet': 'The co-CEO of BrainStorm Cell Therapeutics spoke on the supporting data for \nthe investigational ALS cell therapy that will be discussed at...', 'thumbnail': 'https://serpapi.com/searches/6723d7f90be2f6aacef183d7/images/181d0bbe50437b7894b29d10832f3878d9f8fb47784e03b5e5a1ec9e3921968b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9066799879074097}","{'position': 4, 'link': 'https://www.streetinsider.com/Basic+Content/BrainStorm+Cell+Therapeutics+Reaches+Alignment+with+FDA+on+CMC+Aspects+of+Phase+3b+NurOwn%C2%AE+Clinical+Trial/23398728.html', 'title': 'BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial', 'source': 'StreetInsider', 'date': 'Jun 26, 2024', 'snippet': 'NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. \n(NASDAQ: BCLI), a leading developer of adult stem cell...', 'thumbnail': 'https://serpapi.com/searches/6723d7f90be2f6aacef183d7/images/181d0bbe50437b78be4a23e22ef6ad4666052bbca25de2b5d3d710e4d36fdb57.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8863623738288879}","{'position': 5, 'link': 'https://alsnewstoday.com/news/long-term-nurown-use-shows-survival-benefit-als-analysis/', 'title': 'Long-term use of NurOwn shows survival benefit in ALS: New data', 'source': 'ALS News Today', 'date': '6 hours ago', 'snippet': 'Long-term treatment with the cell therapy NurOwn was found to significantly \nextend survival for ALS patients compared with controls.', 'thumbnail': 'https://serpapi.com/searches/6723d7f90be2f6aacef183d7/images/181d0bbe50437b78b443d53994f6757de1cfcf1ad3f583e58f8af8253eeb15a9.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7653230428695679}","{'position': 6, 'link': 'https://www.cgtlive.com/view/stacy-lindborg-phd-addressing-unmet-needs-als-cell-therapy', 'title': 'Stacy Lindborg, PhD, on Addressing Unmet Needs in ALS With Cell Therapy', 'source': 'CGTLive®', 'date': 'Apr 3, 2023', 'snippet': 'The co-CEO of BrainStorm Cell Therapeutics spoke about the current \nstandards of care in ALS and the potential of NurOwn to address unmet...', 'thumbnail': 'https://serpapi.com/searches/6723d7f90be2f6aacef183d7/images/181d0bbe50437b789e4e2feabfe408208997f955c77261dab3660094f62edc73.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9022493958473206}","{'position': 7, 'link': 'https://alsnewstoday.com/news/brainstorm-drops-application-nurown-als-regroup/', 'title': 'BrainStorm drops application for NurOwn for ALS, plans to regroup', 'source': 'ALS News Today', 'date': 'Oct 20, 2023', 'snippet': 'BrainStorm is withdrawing its application requesting FDA approval of NurOwn \nfor the treatment of amyotrophic lateral sclerosis (ALS).', 'thumbnail': 'https://serpapi.com/searches/6723d7f90be2f6aacef183d7/images/181d0bbe50437b787d217473368db36d0e821f787dc1d565271b4eb1cb6b0ce3.png', 'sentiment': 'negative', 'sentiment_prob': 0.5969218015670776}","{'position': 8, 'link': 'https://alsnewstoday.com/news/nurown-trial-slower-als-progression-tied-lower-nfl-levels/', 'title': 'Slower ALS progression evident with lower NfL levels: NurOwn trial', 'source': 'ALS News Today', 'date': 'Jul 12, 2023', 'snippet': 'NurOwn, an experimental treatment, significantly lowered neurofilament \nlight chain (NfL) levels in the spinal fluid, a marker of nerve damage, and \nthis seems...', 'thumbnail': 'https://serpapi.com/searches/6723d7f90be2f6aacef183d7/images/181d0bbe50437b7887c9c673f67fa775ad0f884c60b4853b7cdf7e928e2429a2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5257608294487}","{'position': 9, 'link': 'https://alsnewstoday.com/news/fda-final-approval-decision-brainstorms-nurown-als-due-december/', 'title': 'FDA final approval decision on NurOwn for ALS due by year’s end |...', 'source': 'ALS News Today', 'date': 'Jun 8, 2023', 'snippet': 'A final decision by the US Food and Drug Administration (FDA) on whether or \nnot to approve NurOwn for amyotrophic lateral sclerosis (ALS) is now \nexpected no...', 'thumbnail': 'https://serpapi.com/searches/6723d7f90be2f6aacef183d7/images/181d0bbe50437b78c42ccddfb16f2ac712e2ff0c068fb8e9def2f71c876991fd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8978535532951355}","{'position': 10, 'link': 'https://alsnewstoday.com/news/certain-spinal-fluid-biomarkers-als-predict-responses-nurown/', 'title': 'Certain spinal fluid biomarkers in ALS may predict responses to NurOwn', 'source': 'ALS News Today', 'date': 'Apr 23, 2024', 'snippet': 'Treatment with NurOwn may bring about changes in biomarkers of inflammation \nand neurodegeneration that predict clinical outcomes.', 'thumbnail': 'https://serpapi.com/searches/6723d7f90be2f6aacef183d7/images/181d0bbe50437b78d4d3bc0d697a04e21a1ba3b7f854e29da8fca42c8e2e36de.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8579881191253662}","['neutral', 'neutral', 'neutral', 'neutral', 'positive', 'neutral', 'negative', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02072070,"{'position': 1, 'link': 'https://www.nature.com/articles/s41536-018-0055-2', 'title': 'Trends in clinical trials for articular cartilage repair by cell therapy', 'source': 'Nature', 'date': 'Oct 11, 2018', 'snippet': 'In this study, we examined the clinical research trends related to cell \ntherapy products in the cartilage repair field based on data obtained from \nthe...', 'thumbnail': 'https://serpapi.com/searches/6723d80b6f9f63a05efdfada/images/540d6187a68b9118093f7fe0dde6ad327ca5c8cf8005cc062279d78e2ef17ddf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9175892472267151}",,,,,,,,,,['neutral'],neutral,1
NCT00391872,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0904327', 'title': 'Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes', 'source': 'The New England Journal of Medicine', 'date': 'Apr 10, 2018', 'snippet': 'Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine \ndiphosphate receptor P2Y12 that has a more rapid onset and more \npronounced...', 'thumbnail': 'https://serpapi.com/searches/6723d873b4e8d61b8b89d922/images/916e58a56785d5c4d05e3d49c9623f97acc03ada2ebb6ad5807b959750993341.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.870658814907074}",,,,,,,,,,['neutral'],neutral,1
NCT00612170,"{'position': 1, 'link': 'https://fibromyalgianewstoday.com/2020/01/17/axsome-therapeutics-licenses-pfizers-potential-fibromyalgia-treatment-esreboxetine/', 'title': 'Axsome Therapeutics Licenses Pfizer’s Potential Fibromyalgia Treatment Esreboxetine in US', 'source': 'Fibromyalgia News Today', 'date': 'Jan 17, 2020', 'snippet': 'Following an agreement with Pfizer, Axsome Therapeutics now has exclusive \nrights to develop and commercialize AXS-14 (esreboxetine) — a drug...', 'thumbnail': 'https://serpapi.com/searches/6723d898fbde0d882067e606/images/27f4f0031ce970a627d2df8a4bf6fef8ce26a353e99958ea6a6e67244487cad6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8637092709541321}",,,,,,,,,,['neutral'],neutral,1
NCT03077685,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20231010850022/en/Interim-Results-from-a-NanOlogy-Phase-2-Clinical-Trial-of-its-Intratumoral-Investigational-Drug-in-the-Treatment-of-Locally-Advanced-Pancreatic-Cancer', 'title': 'Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer', 'source': 'Business Wire', 'date': 'Oct 10, 2023', 'snippet': 'Research article published in Pancreas Journal reports initial safety and \nclinical outcome data from a Phase 2a clinical trial of IT...', 'thumbnail': 'https://serpapi.com/searches/6723d8b20664c95f19993fa2/images/9e5b44ca04a40558a7c0bb65945f8e7c5e418538923ffc526161a2bc6d89633d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9105743765830994}",,,,,,,,,,['neutral'],neutral,1
NCT04786444,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00641-4/fulltext', 'title': 'Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial', 'source': 'The Lancet', 'date': 'Jun 12, 2023', 'snippet': 'VLA1553 is a live-attenuated vaccine candidate for active immunisation and \nprevention of disease caused by chikungunya virus.', 'thumbnail': 'https://serpapi.com/searches/6723d8c4163bdf5e17e18ecf/images/a7ee50642c8469e5101ddfbe8325b60f2086f25848618ab7fcc5d267eadeaf33.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7965168356895447}",,,,,,,,,,['neutral'],neutral,1
NCT02228369,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.19.00457', 'title': 'Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study', 'source': 'ASCO Publications', 'date': 'Dec 6, 2019', 'snippet': 'PURPOSEIn this phase I study (BLOOM), osimertinib, a third-generation \nepidermal growth factor receptor (EGFR) tyrosine kinase inhibitor...', 'thumbnail': 'https://serpapi.com/searches/6723d8c77ca6b38082a7f69a/images/46848478050de8ffdb306a9cbc10c058b25a16bda5884853a895f043562035f5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8860406875610352}","{'position': 2, 'link': 'https://lungcancernewstoday.com/2017/06/15/phase-3-trial-shows-70-percent-of-brain-cancer-originating-in-lungs-responds-to-tagrisso/', 'title': '70% of Patients with Brain Cancer Originating in the Lungs Responded to Tagrisso, Trial Shows', 'source': 'Lung Cancer News Today', 'date': 'Jun 15, 2017', 'snippet': 'Read about a Phase 3 clinical trial showing that 70 percent of patients \nwith brain cancer that originated in the lungs responded to...', 'thumbnail': 'https://serpapi.com/searches/6723d8c77ca6b38082a7f69a/images/46848478050de8ffe9ff442cf9f8743ba78d00825c2c1c521f070c6875dc45bc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9100687503814697}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02020889,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1702079', 'title': 'Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis', 'source': 'The New England Journal of Medicine', 'date': 'May 18, 2017', 'snippet': 'Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood \neosinophil counts and may have value in the treatment of eosinophilic \ngranulomatosis with...', 'thumbnail': 'https://serpapi.com/searches/6723d9297c1712ec9a29f48f/images/d4351ccd7f9550e59e42a631c421b573dfcaba8d894f2535d1adf16716672111.png', 'sentiment': 'neutral', 'sentiment_prob': 0.807154655456543}","{'position': 2, 'link': 'https://ancavasculitisnews.com/news/long-term-nucala-safely-eases-egpa-symptoms-real-world-study/', 'title': 'Long-term Nucala safely eases EGPA symptoms: Real-word study', 'source': 'ANCA Vasculitis News', 'date': 'Jan 31, 2024', 'snippet': 'Treatment with Nucala for EGPA for three or more years is safe, and can \nreduce symptoms and the risk of relapse, a real-world study shows.', 'thumbnail': 'https://serpapi.com/searches/6723d9297c1712ec9a29f48f/images/d4351ccd7f9550e5f9227c54651598ad851632bf0267f77727f9e038b0b4fdc0.png', 'sentiment': 'positive', 'sentiment_prob': 0.5656896829605103}","{'position': 3, 'link': 'https://ancavasculitisnews.com/news/nucala-corticosteroids-can-help-boost-remission-rates-egpa-patients-small-study/', 'title': 'Nucala with Corticosteroids Can Boost EGPA Remission Rate, Study Says', 'source': 'ANCA Vasculitis News', 'date': 'Apr 28, 2021', 'snippet': 'Nucala is effective and safe with corticosteroids for the treatment of \neosinophilic granulomatosis with polyangiitis, a study says.', 'thumbnail': 'https://serpapi.com/searches/6723d9297c1712ec9a29f48f/images/d4351ccd7f9550e526337c8b220749bba84905c02260bae5cfbe762dc3cfb0a6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7394481301307678}",,,,,,,,"['neutral', 'positive', 'positive']",positive,1
NCT00938912,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Vimpat-lacosamide', 'title': 'Lacosamide (Vimpat®)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Epilepsy, A Study to Evaluate the Efficacy and Safety of Adjunctive Therapy \nWith Lacosamide in Adults With Partial Onset Seizures, Phase 3...', 'thumbnail': 'https://serpapi.com/searches/6723d939707fd33e0a051dcc/images/5899963e45e9c379ba8f2967e54e0908095cdca0b5574791361ccaf36d40022b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9128645658493042}",,,,,,,,,,['neutral'],neutral,1
NCT02187003,"{'position': 1, 'link': 'https://www.genengnews.com/topics/drug-discovery/pfizer-glycomimetics-phase-iii-drug-fails-phase-iii-trial-for-sickle-cell-complication/', 'title': 'Pfizer, GlycoMimetics Phase III Drug Fails Phase III Trial for Sickle Cell Complication', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Aug 5, 2019', 'snippet': 'Pfizer has acknowledged that the synthetic glycomimetic it licensed from \nGlycoMimetics in 2011 has failed a Phase III trial in patients with sickle \ncell...', 'thumbnail': 'https://serpapi.com/searches/6723d93e2a48823c590d204b/images/0255b15e33c995961a0ac48f38c7d082e17fb991a3733344e377db2a0bbf0b96.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7833572030067444}","{'position': 2, 'link': 'https://sicklecellanemianews.com/news/pfizer-executive-outlines-vision-for-treating-sickle-cell-disease-other-rare-diseases/', 'title': 'Pfizer Executive Outlines Vision for Treating SCD, Other Rare Diseases', 'source': 'Sickle Cell Disease News', 'date': 'Apr 4, 2019', 'snippet': 'Learn more about efforts by Pfizer to treat a variety of rare disorders \nsuch as sickle cell disease, ALS, Duchenne muscular dystrophy and...', 'thumbnail': 'https://serpapi.com/searches/6723d93e2a48823c590d204b/images/0255b15e33c9959688abbfbc47c94a0398e1a4d818cabcfcb4f99b17f8b0d61e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8279264569282532}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT01349660,"{'position': 1, 'link': 'https://www.nature.com/articles/srep20189', 'title': 'BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma', 'source': 'Nature', 'date': 'Feb 5, 2016', 'snippet': 'BKM-120 is a CNS-penetrant pan-class I phosphatidyl-inositol-3 kinase \n(PI3K) inhibitor in clinical trials for solid tumors, including \nglioblastoma.', 'thumbnail': 'https://serpapi.com/searches/6723d9448b84c4faa569fc61/images/75175fe68ef5071a0763c139143de63a2fb176132c57e949e677d585374d3a79.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8177277445793152}",,,,,,,,,,['neutral'],neutral,1
NCT04546724,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00641-4/fulltext', 'title': 'Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial', 'source': 'The Lancet', 'date': 'Jun 12, 2023', 'snippet': 'VLA1553 is a live-attenuated vaccine candidate for active immunisation and \nprevention of disease caused by chikungunya virus.', 'thumbnail': 'https://serpapi.com/searches/6723da20c821271837d7b109/images/564ca8cc39920bf0594915b9d7ab578c5b1fc98b558bf90ea53747d5234078d6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7965168356895447}","{'position': 2, 'link': 'https://www.pharmacytimes.com/view/vla1553-chikungunya-virus-vaccine-shows-antibody-persistence-up-to-2-years-following-administration', 'title': 'VLA1553 Chikungunya Virus Vaccine Shows Antibody Persistence Up to 2 Years Following Administration', 'source': 'Pharmacy Times', 'date': '1 month ago', 'snippet': 'The investigators of the phase 3b trial (NCT04838444) will continue to \nfollow up with patients for up to 10 years.', 'thumbnail': 'https://serpapi.com/searches/6723da20c821271837d7b109/images/564ca8cc39920bf0df418ed607971b4304525e59a0525e5de5a2b021e479e18f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8918190598487854}","{'position': 3, 'link': 'https://www.europeanpharmaceuticalreview.com/news/159755/chikungunya-vaccine-effective-in-98-5-percent-of-participants/', 'title': 'Chikungunya vaccine effective in 98.5 percent of participants', 'source': 'European Pharmaceutical Review', 'date': 'Aug 6, 2021', 'snippet': ""Valneva's single-shot chikungunya vaccine induced neutralising antibody \ntiters in 98.5 percent of participants in a Phase III study."", 'thumbnail': 'https://serpapi.com/searches/6723da20c821271837d7b109/images/564ca8cc39920bf074e0e56ee947cfeaac18ac8b17b4d25d6a736b67b7c5eced.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5637613534927368}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02872259,"{'position': 1, 'link': 'https://melanomanewstoday.com/2017/05/25/advanced-melanoma-targeted-in-clinical-trial-for-axl-kinase-inhibitor-bgb324-as-treatment/', 'title': 'Advanced Melanoma Trial Tests Efficacy of AXL kinase inhibitor BGB324', 'source': 'Melanoma News Today', 'date': 'May 25, 2017', 'snippet': 'A new clinical trial is underway assessing the addition of the \nfirst-in-class AXL kinase inhibitor, BGB324, to standard of care \ntreatment...', 'thumbnail': 'https://serpapi.com/searches/6723da27a9210b29e2f64d8b/images/828be226eaf0e4395e568dca3bbf7cb3c589415b2a0b98f7c2d3954612dca02f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9204961061477661}",,,,,,,,,,['neutral'],neutral,1
NCT00152490,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa067594', 'title': ""Certolizumab Pegol for the Treatment of Crohn's Disease"", 'source': 'The New England Journal of Medicine', 'date': 'May 4, 2018', 'snippet': 'Certolizumab pegol is a pegylated humanized Fab′ fragment that binds tumor \nnecrosis factor α.In a randomized, double-blind, placebo-controlled \ntrial,...', 'thumbnail': 'https://serpapi.com/searches/6723da36d111956b5d3acdff/images/9724a26d590e26198d4a11f195cbab6a5fe25989d4c9c4854c595fd11da202df.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9034447073936462}","{'position': 2, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Cimzia', 'title': 'Certolizumab Pegol (Cimzia®)', 'source': 'UCB', 'date': 'Oct 12, 2018', 'snippet': 'Axial Spondyloarthritis, Certolizumab Pegol in Subjects With Active Axial \nSpondyloarthritis, Phase 3, AKS001 Completed, NCT01087762 · 2009-011719-19 \n· LINK', 'thumbnail': 'https://serpapi.com/searches/6723da36d111956b5d3acdff/images/9724a26d590e2619bc339349e7cf597c187301c93c39c262910e862449770575.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9130622744560242}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04900454,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/coeptis-therapeutics-signs-agreement-to-acquire-allogeneic-immuno-oncology-nk-platform-in-phase-1-clinical-trials-from-deverra-therapeutics-301799765.html', 'title': 'Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics', 'source': 'PR Newswire', 'date': 'Apr 18, 2023', 'snippet': 'Proposed transaction would provide Coeptis with two clinical stage assets \nleveraging NK cell therapies in relapsed or refractory acute myeloid \nleukemia (AML)', 'thumbnail': 'https://serpapi.com/searches/6723d8db59f91190a5e1ef5c/images/b9eeaa12e70ec6625b5dccb67a47b0e967f2b2fe8bdd010c24a2fe54c971d2f7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8679749965667725}",,,,,,,,,,['neutral'],neutral,1
NCT01484496,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/benlysta-formulation-approved-for-sle-patients/', 'title': 'New Benlysta Self-Injectable Formulation Granted FDA Approval', 'source': 'Lupus News Today', 'date': 'Jul 22, 2017', 'snippet': 'Systemic Lupus Erythematosus (SLE) patients taking Benlysta as part of \ntheir treatment regimen can now self-administer the drug at home.', 'thumbnail': 'https://serpapi.com/searches/6723d8f2efad215bb81d43d7/images/48f03bd4886413a126f0c91b70dff64860b3eaecaec6d49ce92e356bfe96c8de.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8993012309074402}",,,,,,,,,,['neutral'],neutral,1
NCT00259428,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa054686', 'title': 'Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter', 'source': 'The New England Journal of Medicine', 'date': 'Sep 6, 2007', 'snippet': 'In two identical multicenter, double-blind, randomized trials, one \nconducted in Europe (ClinicalTrials.gov number, NCT00259428) and one...', 'thumbnail': 'https://serpapi.com/searches/6723d9194791c44b726c1c62/images/5dfb6bdd13a6753dab378ffbdeaf802286dd46b10980e2a57e573f11019e007d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8912765979766846}",,,,,,,,,,['neutral'],neutral,1
NCT04621058,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.836738/full', 'title': 'The Role of Vitamin D in COVID-19 and the Impact of Pandemic Restrictions on Vitamin D Blood Content', 'source': 'Frontiers', 'date': 'Feb 21, 2022', 'snippet': 'Vitamin D is a hormone regulating the immune system and playing a pivotal \nrole in responses to microbial infections.', 'thumbnail': 'https://serpapi.com/searches/6723d92724296a565c6e15bd/images/815c86872eaf47730f4dfe5f4bcad6583a81651f58b1fd1667578b03b157e619.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7742504477500916}",,,,,,,,,,['neutral'],neutral,1
NCT02609386,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20181107005688/en/Brooklyn-ImmunoTherapeutics-Acquires-IRX-Therapeutics', 'title': 'Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics', 'source': 'Business Wire', 'date': 'Nov 7, 2018', 'snippet': ""IRX Therapeutics announces that the company's assets have been acquired by \nthe newly formed Brooklyn ImmunoTherapeutics."", 'thumbnail': 'https://serpapi.com/searches/6723d92848b9f7cd4969105b/images/9f831c6c9baf19dbc829e45a4a0220c39fe76f3e06d4df88bf344fe9a329ac69.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9218343496322632}",,,,,,,,,,['neutral'],neutral,1
NCT04304053,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2021801', 'title': 'A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Nov 24, 2020', 'snippet': 'Current strategies for preventing severe acute respiratory syndrome \ncoronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic...', 'thumbnail': 'https://serpapi.com/searches/6723d951dda9d9c73b31c948/images/44ad67f5f8b2b1f000c94b2ee2fe69c792eaabd5885ef0ccb65cd25ed17b89f7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5501527190208435}",,,,,,,,,,['neutral'],neutral,1
NCT02564523,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-022-00564-z', 'title': 'Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola | npj Vaccines', 'source': 'Nature', 'date': 'Nov 30, 2022', 'snippet': 'Without clinical efficacy data, vaccine protective effect may be \nextrapolated from animals to humans using an immunologic marker that...', 'thumbnail': 'https://serpapi.com/searches/6723d9e2460b157f97ffa4f5/images/ec147af1127043c639185f4575fd58aa4fccb7d01025cfc0fe6192f521393dad.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8734168410301208}",,,,,,,,,,['neutral'],neutral,1
NCT03046953,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/EDBK_200549', 'title': 'Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma', 'source': 'ASCO Publications', 'date': 'Mar 24, 2019', 'snippet': 'Nivolumab and pembrolizumab are the first two US Food and Drug \nAdministration (FDA)–approved monoclonal antibodies targeting PD-1.', 'thumbnail': 'https://serpapi.com/searches/6723d9e8460b157fe0902897/images/5bc33e488645afaffe8441da505471f8cdde0c6ea6bccac49ac06c85f23ccbd5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8910646438598633}",,,,,,,,,,['neutral'],neutral,1
NCT03692312,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/amo-02-aids-muscle-heart-health-mouse-model-dmd/', 'title': 'Oral AMO-02 aids muscle, heart health in mouse model of DMD |...', 'source': 'Muscular Dystrophy News', 'date': 'Sep 26, 2023', 'snippet': 'AMO-02, an experimental oral therapy tested in CDM1 children in a clinical \ntrial, showed promise in a Duchenne MD mouse model.', 'thumbnail': 'https://serpapi.com/searches/6723da0717a2e2703ff743a6/images/450026c21baaee867ba188d434720174185178a1dad7cda101dc748dbbba4382.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7822775840759277}",,,,,,,,,,['neutral'],neutral,1
NCT03355365,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/04/25/aan-2023-stem-cell-therapy-aids-walking-progressive-ms/', 'title': 'AAN 2023: MSC-NP aids walking in advanced progressive MS patients', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 25, 2023', 'snippet': 'Primary and secondary progressive MS patients with EDSS scores of 6-6.5 \nshowed walking ability gains after MSC-NP treatment in Phase 2...', 'thumbnail': 'https://serpapi.com/searches/6723da0717b10e8d8c777066/images/0078dcfebd805361b1a03b64ce335195e8b5f345eb389ec13a0f1b4407df22ba.png', 'sentiment': 'neutral', 'sentiment_prob': 0.593652606010437}","{'position': 2, 'link': 'https://www.neurologylive.com/view/intrathecal-mesenchymal-stem-cells-potential-treatment-progressive-multiple-sclerosis-saud-sadiq', 'title': 'Intrathecal Mesenchymal Stem Cells as a Potential Treatment for Progressive Multiple Sclerosis: Saud A. Sadiq, MD, FAAN', 'source': 'Neurology live', 'date': 'May 8, 2023', 'snippet': 'The director and chief research scientist at Tisch MS Research Center of \nNew York talked about a phase 2 data study on stem cell treatment...', 'thumbnail': 'https://serpapi.com/searches/6723da0717b10e8d8c777066/images/0078dcfebd8053615330b55b91f1a8743414f60e24ad3a5870178267a48fe6e5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.92734295129776}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02142738,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1606774', 'title': 'Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Oct 9, 2016', 'snippet': 'In this open-label, phase 3 trial, we randomly assigned 305 patients who \nhad previously untreated advanced NSCLC with PD-L1 expression on at...', 'thumbnail': 'https://serpapi.com/searches/6723da0b7ac7318c72f6d958/images/83941f527f73ed05b303e979d1216bd4cce5478c6e971abe5c102f28977f80d2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9094976782798767}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/new-5-year-keynote-024-data-show-pembrolizumab-continues-to-prolong-os-in-nsclc', 'title': 'New 5-Year KEYNOTE-024 Data Show Pembrolizumab Continues to Prolong OS in NSCLC', 'source': 'Cancer Network', 'date': 'May 11, 2021', 'snippet': 'New 5-year data from the closely watched KEYNOTE-024 trial (NCT02142738) \nshow pembrolizumab (Keytruda) roughly doubles 5-year overall survival (OS) \nrates.', 'thumbnail': 'https://serpapi.com/searches/6723da0b7ac7318c72f6d958/images/83941f527f73ed05a8f2f9de3a886efa2949d397c293a386b8e779365e138ab1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8887069225311279}","{'position': 3, 'link': 'https://immuno-oncologynews.com/2017/09/27/first-line-lung-cancer-treatment-keytruda-approved-in-canada/', 'title': 'Keytruda Approved as First-Line Lung Cancer Treatment in Canada', 'source': 'Immuno-Oncology News', 'date': 'Sep 27, 2017', 'snippet': ""Canadian patients with metastatic non-small cell lung cancer (NSCLC) can \nnow receive Merck's Keytruda (pembrolizumab) as their first..."", 'thumbnail': 'https://serpapi.com/searches/6723da0b7ac7318c72f6d958/images/83941f527f73ed052b1cd52a9686bc56935b98acb4d7c7c59f1b98094fc60a78.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.750982940196991}","{'position': 4, 'link': 'https://lungcancernewstoday.com/2017/06/13/update-shows-lung-cancer-therapy-keytruda-outperforms-standard-chemo/', 'title': 'Lung Cancer Therapy Keytruda Outperforms Standard Chemo, Update Shows', 'source': 'Lung Cancer News Today', 'date': 'Jun 13, 2017', 'snippet': 'Read about an update of a Phase 3 clinical trial showing that Keytruda \noutperforms standard chemo as a treatment for non-small cell lung...', 'thumbnail': 'https://serpapi.com/searches/6723da0b7ac7318c72f6d958/images/83941f527f73ed05affbd45d4580e0b21e9a979fa9ad2438ae57c250a0f56937.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8445651531219482}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT00004067,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa052122', 'title': 'Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Oct 20, 2005', 'snippet': 'We present the combined results of two trials that compared adjuvant \nchemotherapy with or without concurrent trastuzumab in women with...', 'thumbnail': 'https://serpapi.com/searches/6723da0cf963e7cdccd22b0a/images/040e5fc8681d6245bde28fde8d5787a6fca92921a3a77d2e3af096f17dc8b437.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9143195152282715}",,,,,,,,,,['neutral'],neutral,1
NCT03043313,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/reports/tucatinib-trastuzumab-her2-metastatic-crc/', 'title': 'Tucatinib Plus Trastuzumab Shows ""Clinically Meaningful"" Activity in HER2+ Metastatic CRC', 'source': 'Cancer Therapy Advisor', 'date': 'Jun 18, 2024', 'snippet': 'Treatment with tucatinib and trastuzumab can produce durable responses in \nadults with previously treated, HER2-positive, RAS-wildtype, unresectable \nor...', 'thumbnail': 'https://serpapi.com/searches/6723d965e1d1ad99be01b879/images/83388c52a3093f73095aaaec97595b0734f42f8d77623f04dcdf535c52df2a4d.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6085677742958069}",,,,,,,,,,['positive'],positive,1
NCT01292603,"{'position': 1, 'link': 'https://www.nature.com/articles/bjc2013371', 'title': 'Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase', 'source': 'Nature', 'date': 'Sep 3, 2013', 'snippet': 'Rituximab and trastuzumab were the first therapeutic monoclonal antibodies \n(mAbs) approved in oncology. Both antibodies are delivered by the...', 'thumbnail': 'https://serpapi.com/searches/6723d9722c83d5927f338d85/images/9f7dd113710194d79e6a7c647a4b6dfbc4da626be22b5572907e838d90b46044.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.807932436466217}",,,,,,,,,,['neutral'],neutral,1
NCT02274155,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-21383-1', 'title': 'Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells', 'source': 'Nature', 'date': '١٦\u200f/٠٢\u200f/٢٠٢١', 'snippet': 'Despite the success of checkpoint blockade in some cancer patients, there \nis an unmet need to improve outcomes.', 'thumbnail': 'https://serpapi.com/searches/6723d9a45f97789cdc77acab/images/0ed67b8c91fa31eae8661318cae98f847565a0b33018169ec3b648ccead1e6dd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.645016610622406}",,,,,,,,,,['neutral'],neutral,1
NCT02329327,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057844', 'title': 'Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors', 'source': 'American Heart Association Journals', 'date': 'Feb 20, 2023', 'snippet': 'Background:Andexanet alfa is a modified recombinant inactive factor Xa \n(FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa,...', 'thumbnail': 'https://serpapi.com/searches/6723da4d690bb94a0aba7cd8/images/edf4ddad4ec5ed6d2aaa7c68b5f10b499adba4ed8c9c0ad07e5f1c6e2deabb93.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8420325517654419}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1814051', 'title': 'Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors', 'source': 'The New England Journal of Medicine', 'date': 'Feb 7, 2019', 'snippet': 'Treatment with andexanet markedly reduced anti–factor Xa activity, and 82% \nof patients had excellent or good hemostatic efficacy at 12 hours.', 'thumbnail': 'https://serpapi.com/searches/6723da4d690bb94a0aba7cd8/images/edf4ddad4ec5ed6d98fc4505351bff43ad850e1c9d78c8652d5cc555333dc2dc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7344655394554138}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04039503,"{'position': 1, 'link': 'https://www.renalandurologynews.com/news/tirzepatide-vs-semaglutide-lower-metabolic-syndrome-prevalence/', 'title': 'Tirzepatide vs Semaglutide Linked to Lower Metabolic Syndrome Prevalence', 'source': 'Renal and Urology News', 'date': 'Apr 12, 2024', 'snippet': 'Use of tirzepatide, compared with placebo, semaglutide, and insulin \ndegludec and glargine, is associated with a lower prevalence of metabolic \nsyndrome among...', 'thumbnail': 'https://serpapi.com/searches/6723da54b691a7869c2a6f25/images/3882fcdbde42402b1469cdff0979ec19706e6d211a4bbd42539051b48e4b9a85.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8086218237876892}",,,,,,,,,,['neutral'],neutral,1
NCT02928523,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-23376-6', 'title': 'Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients', 'source': 'Nature', 'date': 'May 25, 2021', 'snippet': 'AFMT appears to be safe and may be effective for gut microbiota restoration \nin AML patients receiving intensive chemotherapy and antibiotics.', 'thumbnail': 'https://serpapi.com/searches/6723da82c76a3acd090f8c24/images/059be7c84d84e63fb7459bae997f00821cac5d48df6e858bb773b138347a605c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5216175317764282}",,,,,,,,,,['neutral'],neutral,1
NCT05041062,"{'position': 1, 'link': 'https://www.mesotheliomaguide.com/mesothelioma/peritoneal/treatment/immunotherapy/', 'title': 'Peritoneal Mesothelioma Immunotherapy', 'source': 'Mesothelioma Guide', 'date': 'Apr 14, 2023', 'snippet': 'Peritoneal mesothelioma immunotherapy is a treatment option for the rare \nand aggressive cancer known as peritoneal mesothelioma.', 'thumbnail': 'https://serpapi.com/searches/6723da8fb9458db70e90885b/images/c561b4efac6af7ecc94dcf1d8a8f875a03fd4579795000b5f3b268a2e1b084ca.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8685808777809143}",,,,,,,,,,['neutral'],neutral,1
NCT01375842,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-24112-w', 'title': 'Molecular determinants of response to PD-L1 blockade across tumor types', 'source': 'Nature', 'date': 'Jun 25, 2021', 'snippet': 'Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable \nclinical responses in subsets of cancer patients across multiple...', 'thumbnail': 'https://serpapi.com/searches/6723daa3c05eb51c2f511fcb/images/fea7f98157de9931c2f9493e3694a3433c05bfbc130a6616be90d5c95fa40ee5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8604558110237122}",,,,,,,,,,['neutral'],neutral,1
NCT02601313,"{'position': 1, 'link': 'https://www.onclive.com/view/brexu-cel-delivers-prolonged-os-benefit-in-relapsed-refractory-mcl', 'title': 'Brexu-Cel Delivers Prolonged OS Benefit in Relapsed/Refractory MCL', 'source': 'OncLive', 'date': 'Feb 28, 2024', 'snippet': 'Andre H. Goy, MD, discusses how the ZUMA-18 trial data support the benefit \nof earlier-line use of brexucabtagene autoleucel in mantle cell...', 'thumbnail': 'https://serpapi.com/searches/6723dabb08abe4f8e76af46d/images/c1295e64d1cb7847cdd8e75ba5e68aeefbe192e3aa183db2b47385acc5e8998d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.581397533416748}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1914347', 'title': 'KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma', 'source': 'The New England Journal of Medicine', 'date': 'Apr 1, 2020', 'snippet': 'KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may \nhave benefit in patients with relapsed or refractory mantle-cell lymphoma.', 'thumbnail': 'https://serpapi.com/searches/6723dabb08abe4f8e76af46d/images/c1295e64d1cb78474e5da3305af7e91cf8ad91257acd3b78373b32b51d959b4a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8843450546264648}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02682927,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Fenfluramine%20%20%28Fintepla%29', 'title': 'Fenfluramine (Fintepla)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Dravet Syndrome, A Study to Evaluate Safety, Tolerability, and \nPharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to \nLess...', 'thumbnail': 'https://serpapi.com/searches/6723dabdd16915e4d3acc90e/images/051c791fed0f8e09ca5b5258708b9b90e13090f4e9ae1ed3d88bc399568e8579.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8484590649604797}","{'position': 2, 'link': 'https://dravetsyndromenews.com/news/finteplas-potential-dual-mechanism-of-action-may-explain-effectiveness-at-reducing-seizures-in-dravet-syndrome/', 'title': 'Fintepla Fares Well in Study of Seizure Reduction in Dravet Syndrome', 'source': 'Dravet Syndrome News', 'date': 'Apr 14, 2020', 'snippet': 'The potential dual mechanism of action of Fintepla may explain its strong \nand durable effectiveness at reducing seizures in patients with...', 'thumbnail': 'https://serpapi.com/searches/6723dabdd16915e4d3acc90e/images/051c791fed0f8e097abbb396409486dc859c5d2cd1597a2eb451a3128ca5f546.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5350711345672607}","{'position': 3, 'link': 'https://dravetsyndromenews.com/news/zx008-receives-fda-breakthrough-therapy-designation-dravet-syndrome/', 'title': 'Investigative Antiepileptic ZX008 Receives FDA’s Breakthrough Therapy Tag', 'source': 'Dravet Syndrome News', 'date': 'Feb 22, 2018', 'snippet': 'The US Food and Drug Administration has granted breakthrough therapy \ndesignation to ZX008 to treat seizures associated with Dravet syndrome.', 'thumbnail': 'https://serpapi.com/searches/6723dabdd16915e4d3acc90e/images/051c791fed0f8e098564cbfe4c7077c823787725355fbd99af10541b69db07bf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7138826251029968}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04181723,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02398-1', 'title': 'Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study', 'source': 'Nature', 'date': 'Jun 8, 2023', 'snippet': 'Rett syndrome is a rare, genetic neurodevelopmental disorder. Trofinetide \nis a synthetic analog of glycine–proline–glutamate, the N-terminal...', 'thumbnail': 'https://serpapi.com/searches/6723db26a471672a2b129a83/images/b14f070225ab78f80614de36e8cb59541f854a719fab9ff5926b52618416da6d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8433476686477661}","{'position': 2, 'link': 'https://rettsyndromenews.com/news/daybue-first-rett-syndrome-treatment-approved-canada/', 'title': 'Daybue becomes first Rett syndrome therapy to win approval in Canada', 'source': 'Rett Syndrome News', 'date': '1 week ago', 'snippet': 'Health Canada favored the daily solution therapy for patients age 2 and \nolder, based on trial findings of behavioral and communication...', 'thumbnail': 'https://serpapi.com/searches/6723db26a471672a2b129a83/images/b14f070225ab78f87cebcce9633a4acd252e3e6b294b4a59c8e7de738ab7e742.png', 'sentiment': 'positive', 'sentiment_prob': 0.5950222611427307}","{'position': 3, 'link': 'https://rettsyndromenews.com/news/long-term-daybue-led-continual-improvements-patients-data/', 'title': 'Long-term Daybue led to continual improvements in patients: Studies', 'source': 'Rett Syndrome News', 'date': 'Jul 24, 2024', 'snippet': 'Long-term treatment with Daybue (trofinetide) led to continual improvements \nin symptoms in people with Rett syndrome in extension studies,...', 'thumbnail': 'https://serpapi.com/searches/6723db26a471672a2b129a83/images/b14f070225ab78f8baf6050e0577db31c3e52e89ab3a998a41b76760f0c3e35c.png', 'sentiment': 'positive', 'sentiment_prob': 0.6373507380485535}","{'position': 4, 'link': 'https://www.empr.com/home/news/fda-greenlights-daybue-for-treatment-of-rett-syndrome/', 'title': 'FDA Greenlights Daybue for Treatment of Rett Syndrome', 'source': 'Medical Professionals Reference', 'date': 'Mar 13, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Daybue™ (trofinetide) \nfor the treatment of Rett syndrome in adults and pediatric...', 'thumbnail': 'https://serpapi.com/searches/6723db26a471672a2b129a83/images/b14f070225ab78f812fedd48db3f8c4ea87b016a9e8f7be4150030e44c3ae387.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8059519529342651}","{'position': 5, 'link': 'https://rettsyndromenews.com/news/fda-decision-due-march-2023-trofinetide-1st-rett-treatment/', 'title': 'FDA Decision Due March 2023 on Trofinetide as 1st-ever Rett Treatment', 'source': 'Rett Syndrome News', 'date': 'Sep 14, 2022', 'snippet': 'The U.S. Food and Drug Administration has set an action date of March 12, \n2023 to decide whether to approve trofinetide for Rett syndrome.', 'thumbnail': 'https://serpapi.com/searches/6723db26a471672a2b129a83/images/b14f070225ab78f8b3860a09c8486ca51d765b3168bb41c2efba75b541636a35.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9425840973854065}","{'position': 6, 'link': 'https://rettsyndromenews.com/news/aan-2023-daybue-easing-rett-girls-ages-2-4-daffodil-trial/', 'title': 'AAN 2023: Daybue easing Rett symptoms in girls, ages 2-4, in DAFFODIL trial', 'source': 'Rett Syndrome News', 'date': 'May 3, 2023', 'snippet': ""Daybue (trofinetide), approved in US to treat Rett, is safely helping with \nyoung patients' neurobehavioral symptoms in a Phase 2/3 trial."", 'thumbnail': 'https://serpapi.com/searches/6723db26a471672a2b129a83/images/b14f070225ab78f81b78557c64b86dedd959091d5d1f8c16acd964ad31e2a7b4.png', 'sentiment': 'positive', 'sentiment_prob': 0.6152435541152954}","{'position': 7, 'link': 'https://rettsyndromenews.com/news/acadia-opening-phase-2-3-trial-of-trofinetide-in-young-girls-2-5/', 'title': 'Acadia Opening Phase 2/3 Trial of Trofinetide in Young Girls, 2-5', 'source': 'Rett Syndrome News', 'date': 'Sep 3, 2021', 'snippet': 'Acadia Pharmaceuticals is launching an open-label clinical trial of its \noral investigational medication trofinetide in toddlers and young girls \nwith Rett...', 'thumbnail': 'https://serpapi.com/searches/6723db26a471672a2b129a83/images/b14f070225ab78f84999511cf58ad70014546d3f29131c47633e0904fd431e9c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8887419104576111}","{'position': 8, 'link': 'https://rettsyndromenews.com/news/fda-approves-trofinetide-now-daybue-first-rett-treatment-us/', 'title': 'FDA approves trofinetide, now Daybue, as 1st treatment for Rett |...', 'source': 'Rett Syndrome News', 'date': 'Mar 13, 2023', 'snippet': ""Acadia Pharmaceuticals' trofinetide has become the first treatment to be \napproved by the US Food and Drug Administration (FDA) for Rett syndrome."", 'thumbnail': 'https://serpapi.com/searches/6723db26a471672a2b129a83/images/b14f070225ab78f883b5eed29596cbe56478f05ac4b5919d90c5edd9f1a54947.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5799347758293152}","{'position': 9, 'link': 'https://rettsyndromenews.com/news/fda-grants-rare-pediatric-disease-designation-to-trofinetide-for-rett-syndrome/', 'title': 'FDA Grants Rare Pediatric Disease Designation to Trofinetide for Rett Syndrome', 'source': 'Rett Syndrome News', 'date': 'Mar 6, 2020', 'snippet': 'The US Food and Drug Administration (FDA) granted rare pediatric disease \ndesignation to trofinetide, a potential oral therapy for people with Rett \nsyndrome.', 'thumbnail': 'https://serpapi.com/searches/6723db26a471672a2b129a83/images/b14f070225ab78f8cc5cbe5cc4cdbe29fc52ff156df6b4147c2a841e9aa7135f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8714703321456909}",,"['neutral', 'positive', 'positive', 'neutral', 'neutral', 'positive', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03292809,"{'position': 1, 'link': 'https://www.medscape.com/viewarticle/993024', 'title': 'FDA Approves Second Waterless Solution for Dry Eye Disease', 'source': 'Medscape', 'date': 'Jun 9, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has approved the first waterless \ncyclosporine-based solution for treating the signs and symptoms of dry eye \ndisease.', 'thumbnail': 'https://serpapi.com/searches/6723db3421b01bd6478a83e5/images/2b5866bd4a12d242356d648532b8267c26462afe1fe4f8f7a3f16d96666cd101.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7421690225601196}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20181017005727/en/Novaliq-Announces-Positive-Topline-Results-for-Its-CyclASol%C2%AE-Phase-2B3-Essence-Trial-in-Patients-with-Dry-Eye-Disease', 'title': 'Novaliq Announces Positive Topline Results for Its CyclASol', 'source': 'Business Wire', 'date': 'Oct 18, 2018', 'snippet': 'Novaliq, a specialty pharmaceutical company for the development and \ncommercialization of first- and best-in-class ocular therapeutics based...', 'thumbnail': 'https://serpapi.com/searches/6723db3421b01bd6478a83e5/images/2b5866bd4a12d242ba671535508982f91e2595c44670b6ad18471b18560c2d70.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7384086847305298}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT05417126,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-positive-top-line-results-from-randomized-controlled-trial-of-mco-010-for-retinitis-pigmentosa-302098510.html', 'title': 'Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa', 'source': 'PR Newswire', 'date': 'Mar 26, 2024', 'snippet': 'The Phase 1/2a study of MCO-010 in advanced RP patients demonstrated \nfavorable safety and dose-dependent improvement in visual acuity.', 'thumbnail': 'https://serpapi.com/searches/6723db490377562eb44f33df/images/8fdf047e1f0fbe9ee842dc0689ddb8dc3001391d7d0ebd1f5f18a32c4d58c03e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5982081890106201}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-first-patient-dosed-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease-301591857.html', 'title': 'Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease', 'source': 'PR Newswire', 'date': 'Jul 25, 2022', 'snippet': 'The first patient has been dosed in a Phase 2 trial of its \nMulti-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic \nmonotherapy for Stargardt...', 'thumbnail': 'https://serpapi.com/searches/6723db490377562eb44f33df/images/8fdf047e1f0fbe9e4d687bdb9a1ee18d0f20a82e68d25b9f3b4dde0bda1f8cee.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.907120406627655}","{'position': 3, 'link': 'https://www.cgtlive.com/view/ramos-platt-looking-forward-gene-therapy-growth', 'title': 'Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth', 'source': 'CGTLive®', 'date': 'Jul 9, 2024', 'snippet': 'The clinical professor of neurology and pediatrics at Keck School of \nMedicine of USC also discussed current strategies with gene therapy...', 'thumbnail': 'https://serpapi.com/searches/6723db490377562eb44f33df/images/8fdf047e1f0fbe9e8134b4a5a3a8e9755fe9808698e4131885556e5bf8c3e679.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6632293462753296}","{'position': 4, 'link': 'https://www.cgtlive.com/view/abca4-retinopathy-gene-therapy-demonstrates-efficacy-in-preclinical-study', 'title': 'ABCA4 Retinopathy Gene Therapy Demonstrates Efficacy in Preclinical Study', 'source': 'CGTLive®', 'date': 'Mar 17, 2023', 'snippet': ""Intergalactic Therapeutics' IG-002, an investigational nonviral gene \ntherapy intended to treat retinopathies associated with mutations in the \nABCA4 gene,"", 'thumbnail': 'https://serpapi.com/searches/6723db490377562eb44f33df/images/8fdf047e1f0fbe9edd5c9f4f89517000e7952215450438e042173bf7d250fbed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8845294117927551}","{'position': 5, 'link': 'https://www.prnewswire.com/news-releases/nanoscope-therapeutics-unveils-clinical-trial-results-for-mco-010-in-treating-stargardt-disease-301896754.html', 'title': 'Nanoscope Therapeutics Unveils Clinical Trial Results for MCO-010 in Treating Stargardt Disease', 'source': 'PR Newswire', 'date': 'Aug 9, 2023', 'snippet': 'PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology \ncompany focused on gene therapies for retinal degenerative...', 'thumbnail': 'https://serpapi.com/searches/6723db490377562eb44f33df/images/8fdf047e1f0fbe9e146b97a51003fd65208795f21c8ac0677d1377cd14c069ed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9110512137413025}","{'position': 6, 'link': 'https://www.prnewswire.com/news-releases/nanoscope-therapeutics-receives-fast-track-designation-by-the-fda-for-mco-010-for-the-treatment-of-stargardt-disease-301733054.html', 'title': 'Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt Disease', 'source': 'PR Newswire', 'date': 'Jan 30, 2023', 'snippet': 'PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology \ncompany developing gene therapies for retinal degenerative...', 'thumbnail': 'https://serpapi.com/searches/6723db490377562eb44f33df/images/8fdf047e1f0fbe9e495cc6854c1c330b65234488e80effce332a6f6b1d88a039.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.840072512626648}",,,,,"['positive', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03518086,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2207940', 'title': 'Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis', 'source': 'The New England Journal of Medicine', 'date': 'Jun 28, 2023', 'snippet': 'Mirikizumab, a p19-directed antibody against interleukin-23, showed \nefficacy in the treatment of ulcerative colitis in a phase 2 trial.', 'thumbnail': 'https://serpapi.com/searches/6723db4cc76a22c37894343d/images/5ad2dee40b3e277d067045adb09256d0c6aec68f86ff9a2fe616ec49d0c22926.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.750523030757904}","{'position': 2, 'link': 'https://www.empr.com/home/news/omvoh-a-novel-treatment-for-ulcerative-colitis-receives-fda-approval/', 'title': 'Omvoh, a Novel Treatment for Ulcerative Colitis, Receives FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Oct 27, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Omvoh™ \n(mirikizumab-mrkz) for the treatment of moderately to severely active \nulcerative...', 'thumbnail': 'https://serpapi.com/searches/6723db4cc76a22c37894343d/images/5ad2dee40b3e277ddda9d07770597a9c0163248ec6a0ae594dd2b486610a793d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.653825581073761}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03136653,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.20.00596', 'title': 'First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors', 'source': 'ASCO Publications', 'date': 'Dec 10, 2020', 'snippet': 'PURPOSEA first-in-human study was performed with MP0250, a DARPin drug \ncandidate. MP0250 specifically inhibits both vascular endothelial...', 'thumbnail': 'https://serpapi.com/searches/6723db5806f4f25c8742cf37/images/15bc15cd8445f2e60bd4b5b66fc551d38b6a892e04d5e59fa0e77a756fab9d4d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9029291272163391}",,,,,,,,,,['neutral'],neutral,1
NCT02347761,"{'position': 1, 'link': 'https://copdnewstoday.com/news/analyses-phase-3-trials-sun-101-eflow-safe-effective-copd/', 'title': 'Analyses of Phase 3 Trials Show SUN-101/eFlow Safe, Effective for COPD', 'source': 'COPD News Today', 'date': 'Nov 2, 2017', 'snippet': 'Pooled data from three Phase 3 clinical trials shows that the investigative \nSUN-101/eFlow product is well-tolerated and improves lung...', 'thumbnail': 'https://serpapi.com/searches/6723db63a54d7ebee9d52b85/images/c92cdc4787651d913ce84592720cffc06f77c64dbaebaea858ae07b4268c7683.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6960063576698303}","{'position': 2, 'link': 'https://copdnewstoday.com/news/new-drug-application-sunovion-copd-therapy-accepted-fda/', 'title': 'New Drug Application for Sunovion’s COPD Therapy Accepted by FDA', 'source': 'COPD News Today', 'date': 'Oct 20, 2016', 'snippet': ""The FDA recently accepted a New Drug Application (NDA) for Sunovion's \ninvestigational treatment SUN-101 (glycopyrrolate) administered by the \neFlow nebulizer."", 'thumbnail': 'https://serpapi.com/searches/6723db63a54d7ebee9d52b85/images/c92cdc4787651d911671d05362a2571f1d64cede18829f3955e28402fa3a22a3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7852656841278076}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT00625209,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1705716', 'title': 'Hydrocortisone plus Fludrocortisone for Adults with Septic Shock', 'source': 'The New England Journal of Medicine', 'date': 'Feb 28, 2018', 'snippet': 'In this trial involving patients with septic shock, 90-day all-cause \nmortality was lower among those who received hydrocortisone plus \nfludrocortisone than...', 'thumbnail': 'https://serpapi.com/searches/6723dbaa069e57e9bd9f8ef3/images/6db33ce45775456506723801ec47ac1dc4d46618ce1a7fb874f55cfe05e27628.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8493665456771851}",,,,,,,,,,['neutral'],neutral,1
NCT02015481,"{'position': 1, 'link': 'https://www.nature.com/articles/ncomms14848', 'title': 'PABPN1 gene therapy for oculopharyngeal muscular dystrophy', 'source': 'Nature', 'date': 'Mar 31, 2017', 'snippet': 'Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant, \nlate-onset muscle disorder characterized by ptosis,...', 'thumbnail': 'https://serpapi.com/searches/6723dbaa21e77bb06b9d4887/images/0294aab36c6da9f1c47d485eb52036c5017db0d3b123ac87a4b29d0906f67f47.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.519301176071167}",,,,,,,,,,['negative'],negative,0
NCT03449446,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-024-03172-7', 'title': 'AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases', 'source': 'Nature', 'date': 'Aug 7, 2024', 'snippet': 'AIM-MASH may assist pathologists in histologic review of MASH clinical \ntrials, reducing inter-rater variability on trial outcomes.', 'thumbnail': 'https://serpapi.com/searches/6723dbc8272a87e7668461a7/images/4ba9ca3906cfe68085d8398b881ea82025903695b6419504b4c96be3e6bc8759.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7298288345336914}","{'position': 2, 'link': 'https://www.nature.com/articles/s41392-022-01119-3', 'title': 'Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)', 'source': 'Nature', 'date': 'Aug 13, 2022', 'snippet': 'In this review, we discussed recent developments in etiology and \nprospective therapeutic targets, as well as pharmacological candidates in \npre/clinical trials...', 'thumbnail': 'https://serpapi.com/searches/6723dbc8272a87e7668461a7/images/4ba9ca3906cfe680caa9f58356ac26aa337bedbb82922648cc3bfc433140983f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9206169247627258}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02980341,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/patritumab-deruxtecan-yields-positive-response-rates-in-her3-expressing-metastatic-breast-cancer', 'title': 'Patritumab Deruxtecan Yields Positive Response Rates in HER3-Expressing Metastatic Breast Cancer', 'source': 'Cancer Network', 'date': 'Jun 5, 2022', 'snippet': 'Results from the phase 1/2 U31402-J101 trial (NCT02980341) showed positive \nresponses in patients with metastatic HER3-expressing or...', 'thumbnail': 'https://serpapi.com/searches/6723dbc966d995af2816c216/images/3e936af79e7952126243a8b772f30afb240a80145de46835a9c0ec0950e53ec0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.710087239742279}","{'position': 2, 'link': 'https://www.targetedonc.com/view/patritumab-deruxtecan-elicits-clinical-activity-in-some-patients-with-lung-and-breast-cancer', 'title': 'Patritumab Deruxtecan Elicits Clinical Activity in Some Patients With Lung and Breast Cancer', 'source': 'Targeted Oncology', 'date': 'Mar 20, 2023', 'snippet': 'Updated data from phase 1 and phase 1/2 trials (NCT03260491; NCT02980341) \nevaluating patritumab deruxtecan have shown encouraging activity...', 'thumbnail': 'https://serpapi.com/searches/6723dbc966d995af2816c216/images/3e936af79e795212ad51139ce284e456e459aa6317c2eef6b28f544b654efd28.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.879045307636261}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05398796,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-mrna-nipah-virus-vaccine', 'title': 'NIH launches clinical trial of mRNA Nipah virus vaccine', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jul 11, 2022', 'snippet': 'The experimental mRNA-1215 Nipah virus vaccine will be tested in a \ndose-escalation clinical trial to evaluate its safety, tolerability, and \nability to generate...', 'thumbnail': 'https://serpapi.com/searches/6723dbced16915e4d3acc95e/images/90b544438a8c54938f7b84ba179422f9ec94131d88c94500a2ffea8cf4a8aff9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9209970831871033}","{'position': 2, 'link': 'https://www.jci.org/articles/view/164946', 'title': 'Recombinant vesicular stomatitis virus–vectored vaccine induces long-lasting immunity against Nipah virus disease', 'source': 'JCI - Welcome', 'date': 'Nov 29, 2022', 'snippet': 'The emergence of the novel henipavirus, Langya virus, received global \nattention after the virus sickened over three dozen people in China.', 'thumbnail': 'https://serpapi.com/searches/6723dbced16915e4d3acc95e/images/90b544438a8c5493fb7c4e81ca09b7b860ab3a75e608bbe90bc842bee95bcf2b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7746442556381226}","{'position': 3, 'link': 'https://www.europeanpharmaceuticalreview.com/news/173100/nipah-virus-vaccine-enters-phase-i-trial/', 'title': 'Nipah virus vaccine enters Phase I trial', 'source': 'European Pharmaceutical Review', 'date': 'Jul 13, 2022', 'snippet': 'The investigational mRNA-1215 vaccine developed to prevent Nipah virus – a \nbat-borne disease of pandemic potential, will be evaluated for safety, \ntolerability...', 'thumbnail': 'https://serpapi.com/searches/6723dbced16915e4d3acc95e/images/90b544438a8c54931555943df8739c8981fa78462d21779b7757ad0b5f81402f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8358054161071777}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00516373,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0900212', 'title': 'Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers', 'source': 'The New England Journal of Medicine', 'date': 'Jun 24, 2009', 'snippet': 'Olaparib has few of the adverse effects of conventional chemotherapy, \ninhibits PARP, and has antitumor activity in cancer associated with the \nBRCA1 or BRCA2...', 'thumbnail': 'https://serpapi.com/searches/6723dbd8c76a22c3c0f854e6/images/1b1ce13fccbd901dd85c317cdf9a22fcb9ec1085dd2ef26eebf988a85dd58246.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7652683854103088}",,,,,,,,,,['neutral'],neutral,1
NCT00000611,"{'position': 1, 'link': 'https://www.endocrinologyadvisor.com/news/calcium-vitamin-d-supplement-use-cancer-mortality/', 'title': 'Calcium and Vitamin D Supplement Use Decreases Cancer Mortality', 'source': 'Endocrinology Advisor', 'date': 'Apr 18, 2024', 'snippet': 'Calcium and vitamin D supplementation is associated with decreased overall \ncancer mortality but increased cardiovascular disease (CVD)...', 'thumbnail': 'https://serpapi.com/searches/6723dbd96f9f63a00dd9b71f/images/27dc6f8952795b01c5a7bf592f5940264f01110b016dd4e635dada683cac7601.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8061755895614624}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa055218', 'title': 'Calcium plus Vitamin D Supplementation and the Risk of Fractures', 'source': 'The New England Journal of Medicine', 'date': 'Feb 16, 2006', 'snippet': ""We recruited 36,282 postmenopausal women, 50 to 79 years of age, who were \nalready enrolled in a Women's Health Initiative (WHI) clinical..."", 'thumbnail': 'https://serpapi.com/searches/6723dbd96f9f63a00dd9b71f/images/27dc6f8952795b0100fb95fe9c764202ae1928f51deb4e20828f107a49a3f46e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9269220232963562}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02567799,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20241030659386/en/Humanetics-Advances-Development-of-Novel-Radiation-Protection-Drug-With-New-Study-Results', 'title': 'Humanetics Advances Development of Novel Radiation Protection Drug With New Study Results', 'source': 'Business Wire', 'date': '1 day ago', 'snippet': 'Humanetics Corporation (Humanetics) announced the publication of two \nnoteworthy manuscripts detailing the development of BIO 300 as a...', 'thumbnail': 'https://serpapi.com/searches/6723dbdbf963e7ce0fc7db47/images/3de9a2b71df1250907de42467c2a4c5459296851d9ecf01e7eac556af105a08e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8621382117271423}",,,,,,,,,,['neutral'],neutral,1
NCT03230318,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0334-0', 'title': 'Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma', 'source': 'Nature', 'date': 'Nov 13, 2018', 'snippet': 'Next-generation sequencing has identified actionable genetic aberrations in \nintrahepatic cholangiocarcinomas (iCCA), including the...', 'thumbnail': 'https://serpapi.com/searches/6723dbf07ac7318c72f6d9df/images/392e314e7efcc16c5fdb09f341c1e00250676af388947411e6faaf12e63323e2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8415749669075012}",,,,,,,,,,['neutral'],neutral,1
NCT03380871,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-020-66902-0', 'title': 'Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer', 'source': 'Nature', 'date': 'Jun 17, 2020', 'snippet': 'We used multiplexed, targeted mass spectrometry (MS) to quantify \nimmunotherapy target proteins PD-1, PD-L1, PD-L2, IDO1, LAG3, TIM3, ICOSLG, \nVISTA, GITR, and...', 'thumbnail': 'https://serpapi.com/searches/6723dbfcefad215b69491571/images/d509ac1d752c2092eba4aec184ba8508011eac7d687734cf2af0adf7b5d80bc6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9140447974205017}",,,,,,,,,,['neutral'],neutral,1
NCT01106014,"{'position': 1, 'link': 'https://pulmonaryhypertensionnews.com/news/fda-tentaitvely-approves-generic-selexipag-pah-treatment/', 'title': 'FDA tentatively approves generic selexipag as PAH treatment', 'source': 'Pulmonary Hypertension News', 'date': 'Jul 15, 2024', 'snippet': ""The US Food & Drug Administration (FDA) has tentatively approved Alembic \nPharmaceuticals' generic formulation of injectable selexipag as a treatment \nfor..."", 'thumbnail': 'https://serpapi.com/searches/6723dc1f88bcde1b95c7ca80/images/72c912d51c7c8374806900049ee2532fa927af990bd7aeb76b16e08c1e812885.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9098172783851624}",,,,,,,,,,['neutral'],neutral,1
NCT03300050,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-022-00583-w', 'title': 'Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination', 'source': 'Nature', 'date': 'Dec 10, 2022', 'snippet': 'A phase 1 clinical trial to test the immunogenicity of a chimeric group 1 \nHA (cHA) universal influenza virus vaccine targeting the conserved...', 'thumbnail': 'https://serpapi.com/searches/6723dc1f21b01bd60031052b/images/e082ee5e68ebc0b5d30dc9e869f4aa78ddf5181f8f240377842cd861c968d15a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9300333857536316}",,,,,,,,,,['neutral'],neutral,1
NCT03610334,"{'position': 1, 'link': 'https://alsnewstoday.com/news/boosting-cell-stress-response-may-be-promising-approach-treating-als-phase-2-trial-suggests/', 'title': 'Boosting Cell Stress Response May Be Promising Therapy Approach', 'source': 'ALS News Today', 'date': 'May 6, 2021', 'snippet': 'Boosting the unfolded protein response, a cellular stress-response \nmechanism, may slow disease progression in early ALS patients,...', 'thumbnail': 'https://serpapi.com/searches/6723dc882bab90360de140ac/images/d1e1643ee2afd25bdd6c8befc3204dfdde235f728f31d07b50df53575b9419f4.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7019141912460327}",,,,,,,,,,['positive'],positive,1
NCT02268552,"{'position': 1, 'link': 'https://smanewstoday.com/news/novartis-stopping-development-branaplam-sma-oral-therapy/', 'title': 'Novartis Stopping Work on Branaplam as Oral SMA Therapy', 'source': 'SMA News Today', 'date': 'Jul 26, 2021', 'snippet': 'Novartis is stopping the clinical development of branaplam (LMI070), its \nexperimental oral treatment for spinal muscular atrophy (SMA) being \nevaluated in a...', 'thumbnail': 'https://serpapi.com/searches/6723dcb008abe4f8e76af4f3/images/498563dcb9ff7e97b71bee437e51f8df938da4b410d5921a8e1a9f8133043026.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6980227828025818}",,,,,,,,,,['negative'],negative,0
NCT04529538,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32541-1/fulltext', 'title': 'Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials', 'source': 'The Lancet', 'date': 'Dec 9, 2020', 'snippet': 'Two novel type 2 oral poliovirus vaccine (OPV2) candidates, novel OPV2-c1 \nand novel OPV2-c2, designed to be more genetically stable than the...', 'thumbnail': 'https://serpapi.com/searches/6723dcb899368806a2d1a819/images/8b152ac0220a59e18bce1d25c5d72063540f21298967b223575f1a524b9434bb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8806279897689819}",,,,,,,,,,['neutral'],neutral,1
NCT04877990,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222015633', 'title': 'Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies', 'source': 'ScienceDirect.com', 'date': 'Dec 31, 2022', 'snippet': 'Emerging biologics and small molecule drugs are navigating the clinical \nlandscape of inflammatory bowel disease (IBD).', 'thumbnail': 'https://serpapi.com/searches/6723dcbeb57db8cde2a46fb1/images/05de8d0b89a6c8c6ededd8cc11731f44dcced85cadf9694ba1630267e1e97049.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.830076277256012}",,,,,,,,,,['neutral'],neutral,1
NCT03587805,"{'position': 1, 'link': 'https://www.dermatologytimes.com/view/final-ecztend-study-results-confirm-long-term-safety-and-efficacy-of-tralokinumab-for-moderate-to-severe-atopic-dermatitis', 'title': 'Final ECZTEND Study Results Confirm Long-Term Safety and Efficacy of Tralokinumab for Moderate-to-Severe Atopic Dermatitis', 'source': 'Dermatology Times', 'date': '5 days ago', 'snippet': 'LEO Pharma announced final results of the phase 3 ECZTEND study \n(NCT03587805) at the Fall Clinical Dermatology Conference .1 The data,...', 'thumbnail': 'https://serpapi.com/searches/6723dcc6b691a7869c2a6feb/images/41730331e68a96bff35f441f20488fd62e398b02fa72311b104424a38158f9dc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.859636127948761}",,,,,,,,,,['neutral'],neutral,1
NCT04878055,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1002/eji.202250010', 'title': 'Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis', 'source': 'Wiley Online Library', 'date': 'Oct 14, 2022', 'snippet': 'Neutrophils play a role in the immunopathology SARS-CoV-2 infection by \ntriggering the formation of NETs, producing cytokines including...', 'thumbnail': 'https://serpapi.com/searches/6723dc2e5bb6a2a9d05e94d0/images/2f9a1ea8da2ef9551cd17a95b9231a5e907a383885bc9dfd8ae04e7742a516f5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6651533842086792}",,,,,,,,,,['neutral'],neutral,1
NCT05582629,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00577-7/fulltext', 'title': 'Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study', 'source': 'The Lancet', 'date': 'Nov 22, 2023', 'snippet': 'Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in \nChina: a multicentre, double-blind, phase 3, randomised controlled study', 'thumbnail': 'https://serpapi.com/searches/6723dc3929e6fb4fb01112db/images/0670cb435e8e8fb868a4b700ea0721d0dfcf73d4a3a58cff071808804a0ec077.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8359487056732178}",,,,,,,,,,['neutral'],neutral,1
NCT05105035,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2022/09/28/2524718/33448/en/Idera-Pharmaceuticals-Acquires-Aceragen.html', 'title': 'Idera Pharmaceuticals Acquires Aceragen', 'source': 'GlobeNewswire', 'date': 'Sep 28, 2022', 'snippet': 'Acquisition includes late-stage rare disease portfolio with anticipated \n2023 clinical milestones and first potential product approval as early as \nlate 2024.', 'thumbnail': 'https://serpapi.com/searches/6723dc6bfc40bf31d0398afa/images/13af37850bb6f51d120e408e99ab3005253ee7d12d6c601df7a375972868dd8b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8883594870567322}",,,,,,,,,,['neutral'],neutral,1
NCT02694328,"{'position': 1, 'link': 'https://www.empr.com/home/news/lybalvi-approved-for-schizophrenia-bipolar-i-disorder/', 'title': 'Lybalvi Approved for Schizophrenia, Bipolar I Disorder', 'source': 'Medical Professionals Reference', 'date': 'Jun 2, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Lybalvi™ (olanzapine \nand samidorphan) for the treatment of schizophrenia,...', 'thumbnail': 'https://serpapi.com/searches/6723dc7a2b5fa7541e6e4df6/images/2cacb057793e35bca8b56bfae319d462b5cd0c1cfac897dba492842d3e4c4df8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8041929006576538}",,,,,,,,,,['neutral'],neutral,1
NCT02005471,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1713976', 'title': 'Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'Mar 21, 2018', 'snippet': 'Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically \noverexpressed and that is central to the survival of chronic...', 'thumbnail': 'https://serpapi.com/searches/6723dce306f4f25c8742cf96/images/ed0f910ef84ebde3a2f71240052ca2c82fb578ef3b36dfb7f79887de7470e88f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8034161925315857}",,,,,,,,,,['neutral'],neutral,1
NCT02538536,"{'position': 1, 'link': 'https://lungdiseasenews.com/2017/10/26/ipf-therapy-ofev-shows-long-term-effectiveness-regardless-of-baseline-lung-function-early-analysis/', 'title': 'Early Analysis of Ofev in INPULSIS-ON Trial Shows Long-Term Effectiveness in Treating IPF', 'source': 'Lung Disease News', 'date': 'Oct 26, 2017', 'snippet': 'Read about how Ofev (nintedanib) was shown to slow down IPF progression \nregardless of baseline lung function in the Phase 3 INPULSIS...', 'thumbnail': 'https://serpapi.com/searches/6723dcea0377562eb44f3432/images/da7248cb7119cd18a0deef712f7a422c987ea35edfc6608484473efefe99d9d6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6172102093696594}","{'position': 2, 'link': 'https://lungdiseasenews.com/2018/02/21/pbi-4050-pulmonary-fibrosis-targets-new-antifibrotic-pathway/', 'title': 'PF Therapy PBI-4050 Targets New Antifibrotic Pathway, Study Shows', 'source': 'Lung Disease News', 'date': 'Feb 21, 2018', 'snippet': ""PBI-4050, Prometics' lead therapy candidate, targets a new antifibrotic \npathway by regulating two receptors that play an opposite role in..."", 'thumbnail': 'https://serpapi.com/searches/6723dcea0377562eb44f3432/images/da7248cb7119cd1892a39a3efe8b3c83ca94f174af2ca799e5caa9d7114e37ad.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9064428210258484}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05415462,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-39376-7', 'title': 'Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis', 'source': 'Nature', 'date': 'Jun 19, 2023', 'snippet': 'Despite vaccine availability, influenza remains a substantial global public \nhealth concern. Here, we report interim findings on the primary...', 'thumbnail': 'https://serpapi.com/searches/6723dd4eef60cb9afd658a6d/images/451ac8fb865d96cafd252b415ecf45c37f1504fe4258d76b4fdbe114e2672503.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8802207112312317}",,,,,,,,,,['neutral'],neutral,1
NCT03607838,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/intradiscal-injection-of-condoliase-looks-promising-for-lumbar-herniation/', 'title': 'Intradiscal Injection of Condoliase Looks Promising for Lumbar Herniation', 'source': 'Medical Professionals Reference', 'date': 'May 26, 2023', 'snippet': 'Topline results were announced from a phase 3 trial evaluating SI-6603 \n(condoliase), an investigational treatment for lumbar disc...', 'thumbnail': 'https://serpapi.com/searches/6723dd59861b9d3920a7a60f/images/18fa1cb2a498f531396a582be696e48a3173b160a9ec10545e69bbd467eb0074.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.697502076625824}","{'position': 2, 'link': 'https://www.biospace.com/press-releases/ferring-presents-efficacy-and-safety-data-from-two-phase-3-studies-for-investigational-treatment-si-6603-condoliase-in-lumbar-disc-herniation-at-nass-2024', 'title': 'Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at NASS 2024', 'source': 'BioSpace', 'date': '1 month ago', 'snippet': 'SI-6603 (generic name: condoliase), an investigational product being \nstudied for the treatment of radicular leg pain associated with lumbar disc \nherniation (...', 'thumbnail': 'https://serpapi.com/searches/6723dd59861b9d3920a7a60f/images/18fa1cb2a498f531fd9b9543f10377121f69d8e5f6c80e28a5139a60e4f9e53c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9054080247879028}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT01641250,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/mog2.62', 'title': 'Cancer stem cells: Signaling pathways and therapeutic targeting - Talukdar - 2023 - MedComm – Oncology', 'source': 'Wiley Online Library', 'date': 'Dec 28, 2023', 'snippet': 'The activation of several critical signalling pathways cooperatively \nstimulates the cellular and molecular characteristics of cancer stem...', 'thumbnail': 'https://serpapi.com/searches/6723dd6bea57e93143a44636/images/20b12530a40cd9631a57c26e18dc71e2e4b9ead2fc86518b3555c666d27b226e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9209615588188171}",,,,,,,,,,['neutral'],neutral,1
NCT02291029,"{'position': 1, 'link': 'https://sjogrenssyndromenews.com/news/antibody-therapy-iscalimab-shows-promising-results-in-primary-sjogrens-pilot-trial/', 'title': ""Primary Sjögren's Patients May Benefit From Iscalimab, Pilot Trial Shows"", 'source': ""Sjogren's Syndrome News"", 'date': 'Feb 27, 2020', 'snippet': 'Iscalimab, an investigational antibody therapy from Novartis, showed \npromise for safety and preliminary efficacy for lessening disease activity \nin people with...', 'thumbnail': 'https://serpapi.com/searches/6723ddcd5a461a60b367e2c6/images/4c71566c8dde80e0d63b46284d9f471da8ae6af0f9c596931bf74306c82beb69.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.539388120174408}",,,,,,,,,,['positive'],positive,1
NCT02655952,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-021-00701-5', 'title': 'Wnt/β-catenin signaling in cancers and targeted therapies', 'source': 'Nature', 'date': 'Aug 30, 2021', 'snippet': 'In this study, we systematically reviewed the most updated knowledge of \nWnt/β-catenin signaling in cancers and relatively targeted therapies.', 'thumbnail': 'https://serpapi.com/searches/6723ddd41fc7c5f7684d276a/images/008a0ed8a9d34c5a19d9921208bc6d70474deada9bdc9a194bfce42d8513ad5c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9130144715309143}",,,,,,,,,,['neutral'],neutral,1
NCT01194219,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Efficacy-and-Safety-Trial-Evaluating-the-Effects-of-Apremilast-in-Psoriasis-1-study_fig5_278414160', 'title': 'Efficacy and Safety Trial Evaluating the Effects of Apremilast in...', 'source': 'ResearchGate', 'date': 'Feb 7, 2018', 'snippet': 'ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for \nmoderate to severe plaque psoriasis.', 'thumbnail': 'https://serpapi.com/searches/6723dddccaddc353d22fb212/images/922fee90ebca6cda5497f5b03f1e68c6c96ce231db208396516499238cec10d8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8844858407974243}",,,,,,,,,,['neutral'],neutral,1
NCT01998841,"{'position': 1, 'link': 'https://www.nia.nih.gov/news/nia-statement-crenezumab-trial-results-anti-amyloid-drug-did-not-demonstrate-statistically', 'title': 'NIA statement on crenezumab trial results: Anti-amyloid drug did not demonstrate a statistically significant clinical benefit in people with inherited form of Alzheimer’s disease', 'source': 'National Institute on Aging (.gov)', 'date': 'Jun 16, 2022', 'snippet': 'Preliminary results from an NIH-funded clinical trial appear to show that \nan investigational anti-amyloid drug, crenezumab, did not...', 'thumbnail': 'https://serpapi.com/searches/6723e1950f2a2cff75e55802/images/f1afd30f51df6ecd55f2774e2c282e89520db118af2434efd99b47904e7e89e8.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5876600742340088}",,,,,,,,,,['negative'],negative,0
NCT03524170,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-019-0133-7', 'title': 'If we build it they will come: targeting the immune response to breast cancer', 'source': 'Nature', 'date': 'Oct 29, 2019', 'snippet': 'Historically, breast cancer tumors have been considered immunologically \nquiescent, with the majority of tumors demonstrating low lymphocyte...', 'thumbnail': 'https://serpapi.com/searches/6723e1a317b10e8d8c777228/images/911992f750464a94864a840f5e5102fe6cfe1f51369f1f3c193ff6abbd96fce1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7764731049537659}",,,,,,,,,,['neutral'],neutral,1
NCT03819153,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/flow-trial-semaglutide-reduces-risk-of-kidney-disease-progression/', 'title': 'FLOW Trial: Semaglutide Reduces Risk of Kidney Disease Progression', 'source': 'Medical Professionals Reference', 'date': 'Mar 5, 2024', 'snippet': 'The randomized, double-blind, parallel-group, placebo-controlled FLOW trial \ncompared the effects of semaglutide 1mg, a GLP-1 receptor...', 'thumbnail': 'https://serpapi.com/searches/6723df6ef7adbffe3f0d89fa/images/057e2ea37812ebd9941766659503a08b3f1c781cc4e4359849a6a283a87df3d7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7354961037635803}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2403347', 'title': 'Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'May 24, 2024', 'snippet': 'Semaglutide reduced the risk of clinically important kidney outcomes and \ndeath from cardiovascular causes in patients with type 2 diabetes and \nchronic kidney...', 'thumbnail': 'https://serpapi.com/searches/6723df6ef7adbffe3f0d89fa/images/057e2ea37812ebd9144fd582946d15c3a1718447f6f9f3acdae554aa4d9d397f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.747295618057251}","{'position': 3, 'link': 'https://www.nature.com/articles/s41591-024-03133-0', 'title': 'Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial', 'source': 'Nature', 'date': 'Jun 24, 2024', 'snippet': 'People with type 2 diabetes and chronic kidney disease have a high risk for \nkidney failure and cardiovascular (CV) complications.', 'thumbnail': 'https://serpapi.com/searches/6723df6ef7adbffe3f0d89fa/images/057e2ea37812ebd9ce3fee4614eafd992edd8c88f30031453e52076bb40283d2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7017889022827148}","{'position': 4, 'link': 'https://www.pharmacypracticenews.com/Clinical/Article/10-24/Pharm-Capsules/75038', 'title': 'Pharm Capsules', 'source': 'Pharmacy Practice News', 'date': '4 weeks ago', 'snippet': 'The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide helps \nprevent the progression of chronic kidney disease in patients with type 2 \ndiabetes.', 'thumbnail': 'https://serpapi.com/searches/6723df6ef7adbffe3f0d89fa/images/057e2ea37812ebd9b752ba63bb2b03b1076e512c7a74d746c18f1a87d1d6ce57.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7873850464820862}","{'position': 5, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/semaglutide-kidney-outcomes-trial-ends-early/', 'title': 'Semaglutide Kidney Outcomes Trial Ends Early; Findings Appear Positive - MPR', 'source': 'Medical Professionals Reference', 'date': 'Oct 11, 2023', 'snippet': 'Novo Nordisk has stopped its phase 3 FLOW trial evaluating semaglutide on \nthe progression of renal impairment in adults with type 2 diabetes...', 'thumbnail': 'https://serpapi.com/searches/6723df6ef7adbffe3f0d89fa/images/057e2ea37812ebd95aac1e9b36355106cab4a68f30803cb355d07ad0ef293606.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8685750365257263}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01229007,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/voncento-found-safe-and-effective-for-ages-up-to-12/', 'title': 'Voncento Safe, Effective in Young Children With Hemophilia A, Trial Finds', 'source': 'Hemophilia News Today', 'date': 'Jul 14, 2021', 'snippet': 'Voncento as on-demand and preventive treatment safely controlled bleeds in \nchildren up to age 12 with severe hemophilia A in Phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/6723e15b9e38e53fdf8ca017/images/3ab6a25a1fe95d43420b6d50dc4c6731e74cf6c519e2a3f14a765ec6fd3641a3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6696758270263672}",,,,,,,,,,['neutral'],neutral,1
NCT04081350,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/all.16271', 'title': 'Recent patents in allergy and immunology: The interleukin-2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases', 'source': 'Wiley Online Library', 'date': 'Aug 17, 2024', 'snippet': 'Regulatory T cells (Tregs) hold a pivotal role in orchestrating immune \nhomeostasis through their ability to modulate the activity of T...', 'thumbnail': 'https://serpapi.com/searches/6723e15de281ee6ac18582af/images/951bbc3bd6abcd4b9e1a76d701f5046597f2853b5d7d97de22842bf35335934e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7278765439987183}",,,,,,,,,,['neutral'],neutral,1
NCT00646607,"{'position': 1, 'link': 'https://coloncancernewstoday.com/2017/06/06/certain-colon-cancer-patients-may-require-shorter-chemotherapy-course/', 'title': 'Certain Colon Cancer Patients May Need a Shorter Chemotherapy Course, International Study Finds', 'source': 'Colon Cancer News Today', 'date': 'Jun 6, 2017', 'snippet': 'Chemotherapy following surgery could be reduced from six to three months in \ncertain colon cancer patients, according to an analysis of over...', 'thumbnail': 'https://serpapi.com/searches/6723e15e49ea55e4487da6f3/images/0b5fdd1c66d03a0a2708597ca46b9ad2cc64ec7258273d0a34bce97dffa59c31.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.738676130771637}",,,,,,,,,,['neutral'],neutral,1
NCT04546425,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20240306876116/en/European-Commission-Approves-Pfizer%E2%80%99s-PREVENAR-20%C2%AE-to-Help-Protect-Infants-and-Children-Against-Pneumococcal-Disease', 'title': 'to Help Protect Infants and Children Against Pneumococcal Disease', 'source': 'Business Wire', 'date': 'Mar 13, 2024', 'snippet': ""The European Commission (EC) has granted marketing authorization for the \ncompany's 20-valent pneumococcal conjugate vaccine, marketed in the \nEuropean Union..."", 'thumbnail': 'https://serpapi.com/searches/6723e175e95dbfe4d9d2a3c1/images/c43e532f6ba23b1116fd4cff5d766a21aa6e1ad1a206168a7546b26ffa2d2289.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8275774717330933}","{'position': 2, 'link': 'https://www.indianpharmapost.com/drug-approval/european-commission-approves-pfizers-prevenar-20-to-help-protect-infants-and-children-against-pneumococcal-disease-15390', 'title': 'European Commission approves Pfizer’s Prevenar 20 to help protect infants and children against pneumococcal disease', 'source': 'Indian Pharma Post', 'date': 'Mar 13, 2024', 'snippet': 'PREVENAR offers the broadest serotype coverage of any pediatric \npneumococcal conjugate vaccine to help protect infants and children from \nthe 20 serotypes.', 'thumbnail': 'https://serpapi.com/searches/6723e175e95dbfe4d9d2a3c1/images/c43e532f6ba23b110b7e894141a456b377e596ad15d444de332261360ec0383e.png', 'sentiment': 'positive', 'sentiment_prob': 0.5063306093215942}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02090101,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-021-00670-9', 'title': 'Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer', 'source': 'Nature', 'date': 'Oct 7, 2021', 'snippet': 'MDSCs are a heterogenic population of immature myeloid cells with \nimmunosuppressive effects, which undergo massive expansion during tumor \nprogression.', 'thumbnail': 'https://serpapi.com/searches/6723e1780197dd29898efa09/images/53005ec62477c3a468f60c4cb58cf7ac0e25510e20a0119a909ee21b3ccd31ae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5490086674690247}",,,,,,,,,,['neutral'],neutral,1
NCT02367781,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30167-6/fulltext', 'title': 'Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3', 'source': 'The Lancet', 'date': 'May 20, 2019', 'snippet': 'Atezolizumab (a monoclonal antibody against PD-L1), which restores \nanticancer immunity, improved overall survival in patients with...', 'thumbnail': 'https://serpapi.com/searches/6723dedf81bab791929f03e6/images/4e4d3879b8d03f63bdfa03fdbd3d8277e1f735b729b8b6e97a384a099497ad1f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7582529783248901}",,,,,,,,,,['neutral'],neutral,1
NCT02631577,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-021-00539-8', 'title': 'Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial', 'source': 'Nature', 'date': 'Aug 20, 2021', 'snippet': 'We evaluated the triplet regimen obinutuzumab-atezolizumab-lenalidomide \n(G-atezo-len) for patients with relapsed/refractory (R/R) follicular...', 'thumbnail': 'https://serpapi.com/searches/6723dee73b3c3212f7fbc776/images/e91a479ae53f7af1473e7110e7c16aed2ecad0095bf201b396c38a37a6131b1b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8935147523880005}",,,,,,,,,,['neutral'],neutral,1
NCT03367403,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2100708', 'title': 'Donanemab in Early Alzheimer’s Disease', 'source': 'The New England Journal of Medicine', 'date': 'Mar 13, 2021', 'snippet': ""We conducted a phase 2 trial of donanemab in patients with early \nsymptomatic Alzheimer's disease who had tau and amyloid deposition on \npositron-emission..."", 'thumbnail': 'https://serpapi.com/searches/6723df1024079331fb3a774c/images/bb491c223e26dc09bf72b779711415389f48a1a340b2363f094fe738e00e2e90.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9071123600006104}","{'position': 2, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-receives-us-fdas-breakthrough-therapy', 'title': ""Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease"", 'source': 'Eli Lilly and Company', 'date': 'Jun 24, 2021', 'snippet': 'A randomized, placebo-controlled, double-blind, multi-center Phase 2 study \nto assess the safety, tolerability and efficacy of donanemab in patients \nwith early...', 'thumbnail': 'https://serpapi.com/searches/6723df1024079331fb3a774c/images/bb491c223e26dc09ec47994533a4b51e2d584306f0011eedf1ab4fe14d2df5b1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7800639271736145}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02196857,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25198', 'title': 'Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3 -ITD Mutated Acute Myeloid Leukemia', 'source': 'Wiley Online Library', 'date': 'Jul 20, 2018', 'snippet': 'Based on our previous study of the combination of sorafenib with \n5-azacytidine (AZA) in relapsed/refractory patients with FLT3 mutated acute \nmyeloid leukemia (...', 'thumbnail': 'https://serpapi.com/searches/6723de0ecaddc3538c8557db/images/c75e1187d6c625c4a55bc51b326494d07f80bb94e3230296c5dac6faa23c48c5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.834568440914154}",,,,,,,,,,['neutral'],neutral,1
NCT02473289,"{'position': 1, 'link': 'https://www.nature.com/articles/s41380-019-0471-8', 'title': 'Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders', 'source': 'Nature', 'date': 'Aug 19, 2019', 'snippet': 'Novel immune-therapeutics can produce antidepressant effects in depressed \npatients with primary inflammatory disorders that are not entirely \nexplained by...', 'thumbnail': 'https://serpapi.com/searches/6723de9fe335ec626eede356/images/79638e652744782899caae3329df303ac114153f291d0a0f34e2f5f4a17466d6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8209405541419983}",,,,,,,,,,['neutral'],neutral,1
NCT03625505,"{'position': 1, 'link': 'https://ascopubs.org/doi/abs/10.1200/jco.22.00602', 'title': 'Venetoclax Plus Gilteritinib for FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia', 'source': 'ASCO Publications', 'date': 'Sep 3, 2022', 'snippet': 'PURPOSEThe FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is \nstandard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute \nmyeloid...', 'thumbnail': 'https://serpapi.com/searches/6723ded2ee4682999580c66e/images/cef8962fe8bd1bfeefbd988db36a91407fdd6ff3646c480955dd33a487a17196.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8481619954109192}",,,,,,,,,,['neutral'],neutral,1
NCT03269136,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02528-9', 'title': 'Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results', 'source': 'Nature', 'date': 'Aug 15, 2023', 'snippet': 'Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific \nantibody. In the ongoing phase 2 MagnetisMM-3 trial,...', 'thumbnail': 'https://serpapi.com/searches/6723de17717bffe990a03cad/images/bbc6cf1bb66bd969fa40b97042a2f760bb6d2b0021416cb21a9b985ccf40b6e7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9085099101066589}",,,,,,,,,,['neutral'],neutral,1
NCT02141672,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/features/belimumab-or-voclosporin-for-lupus-nephritis-debated-by-michelle-petri-brad-rovin-at-acr-2021/', 'title': 'ACR 2021 Debate: Enhancing Standard Lupus Nephritis Therapy With Belimumab or Voclosporin', 'source': 'Rheumatology Advisor', 'date': 'Nov 12, 2021', 'snippet': 'Lupus nephritis (LN) is known to affect approximately 40% of patients with \nsystemic lupus erythematous (SLE),1 with kidney disease being one...', 'thumbnail': 'https://serpapi.com/searches/6723de18ef60cb9afd658a9f/images/0276fd5a5d988b69290a26ed156ecfa28ee91c34c8b9564725d4dcf9ee8be2d3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7611857056617737}",,,,,,,,,,['neutral'],neutral,1
NCT03525600,"{'position': 1, 'link': 'https://www.ophthalmologytimes.com/view/asrs-live-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-geographic-atrophy', 'title': 'ASRS Live: A novel glyco-mimetic nanoparticle for the treatment of geographic atrophy', 'source': 'Ophthalmology Times', 'date': 'Aug 2, 2023', 'snippet': 'Tarek Hassan, MD, spoke with our team about a novel glyco-mimetic \nnanoparticle for the treatment of geographic atrophy at the 2023 ASRS...', 'thumbnail': 'https://serpapi.com/searches/6723de36f3622a497245938a/images/11f769b942d01fa6b38d67bec186cbebc56dc51148f71707b50412acfae0afdb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9001842141151428}","{'position': 2, 'link': 'https://www.empr.com/home/news/syfovre-approved-for-geographic-atrophy-secondary-to-amd/', 'title': 'Syfovre Approved for Geographic Atrophy Secondary to AMD', 'source': 'Medical Professionals Reference', 'date': 'Feb 21, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Syfovre™ (pegcetacoplan \ninjection, for intravitreal use) for the treatment of geographic...', 'thumbnail': 'https://serpapi.com/searches/6723de36f3622a497245938a/images/11f769b942d01fa6863253a08b4e081c4a155ebd9633c3ffa3cc10fa54840ac6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8288508653640747}","{'position': 3, 'link': 'https://www.ophthalmologytimes.com/view/asrs-2023-pegcetacoplan-vs-avacincaptad-pegol-in-patients-with-geographic-atrophy', 'title': 'ASRS 2023: Pegcetacoplan vs avacincaptad pegol in patients with geographic atrophy', 'source': 'Ophthalmology Times', 'date': 'Aug 4, 2023', 'snippet': 'Paul Hahn, MD, PhD, spoke with our team about comparing the relative \nefficacy of pegcetacoplan versus avacincaptad pegol in patients with...', 'thumbnail': 'https://serpapi.com/searches/6723de36f3622a497245938a/images/11f769b942d01fa695fff27ffe6f0f2fe3e1d5b624f3da45b203ee1d46c1bed9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9235212802886963}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02139267,"{'position': 1, 'link': 'https://cervicalcancernews.com/2016/11/18/genexine-merck-collaborate-clinical-trial-therapy-combo-hpv-induced-cervical-cancer/', 'title': 'Clinical Trial in HPV-induced Cervical Cancer to Evaluate Drug Combo', 'source': 'Cervical cancer News', 'date': 'Nov 18, 2016', 'snippet': 'Read about how Genexine and Merck are collaborating in a clinical trial to \nevaluate a therapy combination for patients with HPV-induced...', 'thumbnail': 'https://serpapi.com/searches/6723de506cca5ed2960d3006/images/7aa2c2adb6f599565310b817555aa58d619eb4a5d3928a2ad4e2701742d9dc1a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9329053163528442}",,,,,,,,,,['neutral'],neutral,1
NCT01007552,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-00324-2', 'title': 'Overview of current targeted therapy in gallbladder cancer', 'source': 'Nature', 'date': 'Oct 7, 2020', 'snippet': 'Gallbladder cancer (GBC) is rare, but is the most malignant type of biliary \ntract tumor. Unfortunately, only a small population of cancer...', 'thumbnail': 'https://serpapi.com/searches/6723de67f59d009e78054575/images/0ef7f351577aca28708ade8a229adf09dfabb9ca0c86104990b19c1f449f40c8.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7814876437187195}",,,,,,,,,,['negative'],negative,0
NCT00802347,"{'position': 1, 'link': 'https://www.drugdiscoverytrends.com/quark-pharmaceuticals-reports-positive-phase-2-results-to-evaluate-the-efficacy-and-safety-of-qpi-1002/', 'title': 'Quark Pharmaceuticals Reports Positive Phase 2 Results to Evaluate the Efficacy and Safety of QPI-1002', 'source': 'drugdiscoverytrends.com', 'date': 'Jul 28, 2017', 'snippet': 'Quark Pharmaceuticals announced successful completion of a randomized, \ndouble-blinded, placebo-controlled multicenter Phase 2 trial of...', 'thumbnail': 'https://serpapi.com/searches/6723de68e10f0aab7ad452df/images/32007432b77fe922847a8e27947d4feeb85365796070cfe203a8bfccc52d9989.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6692343354225159}",,,,,,,,,,['positive'],positive,1
NCT00876486,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S2405844024041975', 'title': 'Efficacy tumor therapeutic applications of stimuli-responsive block copolymer-based nano-assemblies', 'source': 'ScienceDirect.com', 'date': 'Apr 15, 2024', 'snippet': 'These nano-assemblies serve as carriers for anti-tumor bioactive, enhancing \ndrug stability and prolonging their circulation time in vivo.', 'thumbnail': 'https://serpapi.com/searches/6723de866cca5ed2960d3014/images/f438afdd057dc5886b19a60dd6e9e35b7584d9b505cc75a5b37c311565872742.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7241175770759583}",,,,,,,,,,['neutral'],neutral,1
NCT01362140,"{'position': 1, 'link': 'https://www.nature.com/articles/leu2017192', 'title': 'A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes', 'source': 'Nature', 'date': 'Jun 19, 2017', 'snippet': 'The use of darbepoetin alfa to treat anemia in patients with lower-risk \nmyelodysplastic syndromes (MDS) was evaluated in a phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/6723df7ed0c98349f3f119f5/images/786d652e25934d736816eb56eefd2575962017493e6ded92d36591a21b8d0db8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9045476913452148}",,,,,,,,,,['neutral'],neutral,1
NCT02926222,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30675-2/fulltext', 'title': 'Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial', 'source': 'The Lancet', 'date': 'Dec 3, 2018', 'snippet': 'Regorafenib compared with lomustine in patients with relapsed glioblastoma \n(REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial', 'thumbnail': 'https://serpapi.com/searches/6723df8617b10e8d8c7771bd/images/49f0d21c2166dd7d54c67f730cb3b2c38cd29a5be43c9684a54f9cc52f417a0b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8436331748962402}",,,,,,,,,,['neutral'],neutral,1
NCT04003974,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/enrollment-complete-in-phase-3-trial-of-losmapimod-for-fshd/', 'title': 'Enrollment complete in Phase 3 trial of losmapimod for FSHD –...', 'source': 'Muscular Dystrophy News', 'date': 'Sep 14, 2023', 'snippet': 'Fulcrum Therapeutics has completed patient enrollment for its Phase 3 \nclinical trial evaluating losmapimod as a potential treatment for people \nwith...', 'thumbnail': 'https://serpapi.com/searches/6723df87e335ec621cd25020/images/a867d5890b9be392aaea35c89a9362cc15b0224e700f40bcc316d2d10dad3168.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8541843295097351}","{'position': 2, 'link': 'https://musculardystrophynews.com/news/lessons-final-losmapimod-trial-data-help-future-fshd-studies/', 'title': 'Lessons from final losmapimod trial data help inform future studies', 'source': 'Muscular Dystrophy News', 'date': 'May 16, 2024', 'snippet': 'Lessons found in the final published data from a Phase 2 trial of \nlosmapimod helped inform its further clinical development for FSHD.', 'thumbnail': 'https://serpapi.com/searches/6723df87e335ec621cd25020/images/a867d5890b9be39218acd2b4a06cd0fac3c75985317509b63dc148ff69ec190b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7732641100883484}","{'position': 3, 'link': 'https://musculardystrophynews.com/news/fshd-outcomes-fail-improve-losmapimod-phase-3-clinical-trial/', 'title': 'FSHD outcomes fail to improve with losmapimod in Phase 3 clinical trial', 'source': 'Muscular Dystrophy News', 'date': '1 month ago', 'snippet': ""Patients in the REACH trial given losmapimod did see gains over 48 weeks, \nbut the placebo group didn't show a functional status decline."", 'thumbnail': 'https://serpapi.com/searches/6723df87e335ec621cd25020/images/a867d5890b9be392b18e8a07dafa24061398107206e6686f9eb73e70fe4c926a.png', 'sentiment': 'negative', 'sentiment_prob': 0.6226062178611755}","{'position': 4, 'link': 'https://musculardystrophynews.com/news/study-upper-limb-function-fshd-improved-stabilized-with-losmapimod/', 'title': 'Losmapimod improved, stabilized FSHD upper limb function: Study', 'source': 'Muscular Dystrophy News', 'date': 'Jul 11, 2024', 'snippet': 'One year of twice daily losmapimod improved or stabilized upper limb \nfunction in adults with facioscapulohumeral muscular dystrophy (FSHD).', 'thumbnail': 'https://serpapi.com/searches/6723df87e335ec621cd25020/images/a867d5890b9be392bdf1838b67fe29c4e01a8b4ca463df8097829886ec632f81.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8635152578353882}","{'position': 5, 'link': 'https://musculardystrophynews.com/news/fda-puts-investigational-fshd-therapy-losmapimod-on-fast-track/', 'title': 'FDA Puts Investigational FSHD Therapy Losmapimod on Fast Track', 'source': 'Muscular Dystrophy News', 'date': 'May 13, 2021', 'snippet': 'The US Food and Drug Administration (FDA) has granted fast track \ndesignation to losmapimod, a potential treatment for facioscapulohumeral \nmuscular dystrophy (...', 'thumbnail': 'https://serpapi.com/searches/6723df87e335ec621cd25020/images/a867d5890b9be3923ef3377353919dc75789c2ba6152c77b2f6559dda72c67a7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8209603428840637}","{'position': 6, 'link': 'https://musculardystrophynews.com/news/fulcrum-plans-phase-3-trial-losmapimod-potential-1st-oral-therapy-fshd/', 'title': 'Fulcrum Plans to Launch Phase 3 Trial of Oral Losmapimod for FSHD', 'source': 'Muscular Dystrophy News', 'date': 'Mar 8, 2022', 'snippet': 'Fulcrum Therapeutics plans to start a Phase 3 trial of losmapimod, a \npotential oral drug for facioscapulohumeral muscular dystrophy,...', 'thumbnail': 'https://serpapi.com/searches/6723df87e335ec621cd25020/images/a867d5890b9be3929de6f80838d7609ed4ba5fd056b0acfddcc134958e09400a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8962217569351196}",,,,,"['neutral', 'neutral', 'negative', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04549870,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00058-3/fulltext', 'title': 'Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)', 'source': 'The Lancet', 'date': 'Apr 21, 2023', 'snippet': 'Roflumilast is a targeted inhibitor of phosphodiesterase (PDE)-4 and has \nbeen approved for treatment of severe chronic obstructive pulmonary disease \nfor more...', 'thumbnail': 'https://serpapi.com/searches/6723dfae98fad6961dd80f43/images/82d1ce5b69f192b136da60617751912f7f341b9f6e96026a3a0e76e3e6652bd3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8678744435310364}",,,,,,,,,,['neutral'],neutral,1
NCT02028884,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1901747', 'title': 'Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder', 'source': 'The New England Journal of Medicine', 'date': 'Nov 27, 2019', 'snippet': 'Satralizumab added to immunosuppressant treatment led to a lower risk of \nrelapse than placebo but did not differ from placebo in its effect on pain \nor fatigue.', 'thumbnail': 'https://serpapi.com/searches/6723e1351397ba009d17200e/images/cb74515c1f4ac66fa5a02e645cad7249c62ee4d11532688c9f63c8a8572ef216.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8175929188728333}",,,,,,,,,,['neutral'],neutral,1
NCT04513366,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/features/fda-roundup-emerging-drug-treatments-for-gout/', 'title': 'FDA Roundup: Pipeline Drugs for Gout', 'source': 'Rheumatology Advisor', 'date': 'Feb 9, 2024', 'snippet': 'There have been promising recent advancements in gout treatment, \nparticularly with innovative developments entering phase 3 clinical trials.', 'thumbnail': 'https://serpapi.com/searches/6723e13b9872176ea7fef1bb/images/8efbfb4c7bbf510b20b46d756089150dc122cd9e480caffc3e340c45b7f2dd8c.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.9072781205177307}",,,,,,,,,,['positive'],positive,1
NCT02053493,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1510774', 'title': 'Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction', 'source': 'The New England Journal of Medicine', 'date': 'Oct 24, 2016', 'snippet': 'Nitrates are commonly prescribed to enhance activity tolerance in patients \nwith heart failure and a preserved ejection fraction. We compared the \neffect of...', 'thumbnail': 'https://serpapi.com/searches/6723e13ed771bdcb8c632589/images/bf4b188cee1e15bdb9c6738d9e2c22880f86c7737096241535669acc8d7eda16.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8532211780548096}",,,,,,,,,,['neutral'],neutral,1
NCT02931929,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/61/12/1749', 'title': 'MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of', 'source': 'Journal of Nuclear Medicine', 'date': 'Dec 1, 2020', 'snippet': 'This phase I/IIa study provides safety data for 68 Ga-NeoBOMB1, a promising \nradiopharmaceutical for targeting GRPR-expressing tumors.', 'thumbnail': 'https://serpapi.com/searches/6723e145f9f90497df3e4ad1/images/e5b9f3a8e62a665d5fd3658dd0dfefaef600cdee44815fb778062e8bc7b0d9be.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7982731461524963}",,,,,,,,,,['neutral'],neutral,1
NCT03626012,"{'position': 1, 'link': 'https://www.als.org/blog/biogen-shares-latest-updates', 'title': 'Biogen Shares Latest Updates on ALS Clinical Trials', 'source': 'The ALS Association', 'date': 'Dec 29, 2020', 'snippet': 'Biogen spoke of its urgent work in targeting genetic forms of ALS caused by \nmutations in some of the most common ALS-associated genes, such as SOD1 and \nC9orf72.', 'thumbnail': 'https://serpapi.com/searches/6723e00de95dbfe4d9d2a37f/images/26c1016dce1f65a72548d8659973de2b06a136cf80e471e07c47d7cbd33b899a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8600117564201355}","{'position': 2, 'link': 'https://alsnewstoday.com/news/biogen-ionis-discontinuing-biib078-development-c9orf72-associated-als/', 'title': 'Biogen, Ionis Stopping BIIB078 Development Due to Lack of Benefit', 'source': 'ALS News Today', 'date': 'Apr 11, 2022', 'snippet': 'Biogen and Ionis are discontinuing the clinical development of BIIB078 for \nALS based on data from a Phase 1 trial showing no benefit.', 'thumbnail': 'https://serpapi.com/searches/6723e00de95dbfe4d9d2a37f/images/26c1016dce1f65a71ee7c89b3357a565451d9df08c1c5fff5f2500e4e81aba65.png', 'sentiment': 'negative', 'sentiment_prob': 0.8082938194274902}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT03783377,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/abs/10.1161/circ.144.suppl_1.10357', 'title': 'Abstract 10357: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia', 'source': 'American Heart Association Journals', 'date': 'Nov 8, 2021', 'snippet': 'Background: Familial chylomicronemia syndrome (FCS) is an ultrarare \ncondition caused by biallelic pathogenic DNA variants in...', 'thumbnail': 'https://serpapi.com/searches/6723e02b07c7bee5ae616889/images/93fc30545c2c92b4d4f30a381172f9cb9e69ee11e8f15c3e08a0e2454a19fc99.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8986329436302185}",,,,,,,,,,['neutral'],neutral,1
NCT01251367,"{'position': 1, 'link': 'https://cerebralpalsynewstoday.com/2017/06/19/fda-expands-dysport-approval-for-treatment-of-lower-limb-spasticity-in-adults/', 'title': 'FDA Expands Dysport Approval for Treatment of Lower Limb Spasticity in Adults', 'source': 'Cerebral Palsy News Today', 'date': 'Jun 19, 2017', 'snippet': 'The US Food and Drug Administration (FDA) has expanded approval of Dysport \n(abobotulinumtoxinA) for the treatment of lower limb spasticity in adults.', 'thumbnail': 'https://serpapi.com/searches/6723e0318e13c9143cc5b384/images/4d0a7c700ac99c52c57bf9314f2545de7c8b0151bdf5375a012d08c718d30473.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7941434383392334}",,,,,,,,,,['neutral'],neutral,1
NCT04440163,"{'position': 1, 'link': 'https://www.biopharma-reporter.com/Article/2022/09/15/Pfizer-Phase-3-results-for-pentavalent-meningococcal-vaccine', 'title': 'Pfizer: Phase 3 results for pentavalent meningococcal vaccine', 'source': 'biopharma-reporter.com', 'date': 'Sep 15, 2022', 'snippet': 'Pfizer will submit a Biologics License Application (BLA) for its \ninvestigational pentavalent meningococcal vaccine (MenABCWY) to the US \nFood...', 'thumbnail': 'https://serpapi.com/searches/6723e12330dfc1521a48b561/images/db414187439cef6d9eb592d9f2f4486dc65cbc40514735932d77729f2735720e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9041036367416382}",,,,,,,,,,['neutral'],neutral,1
NCT00075764,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1811714', 'title': 'Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Mar 27, 2019', 'snippet': 'The addition of fulvestrant to anastrozole was associated with increased \nlong-term survival as compared with anastrozole alone.', 'thumbnail': 'https://serpapi.com/searches/6723e056d9c3e6603367c235/images/e2e4db6c9529c56b71e4d1bd38ac9b639189f0f5526518144f6b38929f2c3094.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8019725680351257}",,,,,,,,,,['neutral'],neutral,1
NCT03870945,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/pipeline-moves-novartis-terminate-phase-ii-als-trial-after-benefit-risk-worry/', 'title': 'Pipeline Moves: Novartis terminates Phase II ALS trial after benefit-risk worry', 'source': 'Clinical Trials Arena', 'date': 'Aug 6, 2024', 'snippet': ""On this week's Pipeline Moves, the Clinical Trials Arena team investigates \nassets in the central nervous system, oncology and immunology."", 'thumbnail': 'https://serpapi.com/searches/6723e0606aa364537522b8b2/images/6496e9c4ffef084ea0f8ca1980971fcecbf7e2abe03396816b3d8b537d1286cb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7738231420516968}","{'position': 2, 'link': 'https://www.prescouter.com/2022/06/car-t-cell-therapy/', 'title': 'CAR T-cell therapy: Targeting cancer cell antigens with genetically altered T cells', 'source': 'PreScouter', 'date': 'Jun 16, 2022', 'snippet': ""CAR T-cell therapy is a promising new immunotherapy that weaponizes a \npatient's own T cells to fight blood cancers like leukemia & lymphoma."", 'thumbnail': 'https://serpapi.com/searches/6723e0606aa364537522b8b2/images/6496e9c4ffef084e3ccd2a5ae6f5115f5a32eb7c325eb713e13068e40c29d849.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7965629696846008}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03375086,"{'position': 1, 'link': 'https://www.drugtargetreview.com/article/151965/out-of-the-lab-and-into-patients-targeting-ape1-ref-1/', 'title': 'Out of the lab and into patients: targeting APE1/Ref-1', 'source': 'Drug Target Review', 'date': 'Aug 8, 2024', 'snippet': 'Dr Mark R. Kelley elucidates what makes APE1/Ref-1 a promising target for \ncancer therapy.', 'thumbnail': 'https://serpapi.com/searches/6723e0d3c024d1935d72d733/images/6079bb99e8849d5bd1b18449bbf6c5d84d32e708bbdcf6d0ca91c7f657a6bdb3.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5830124616622925}",,,,,,,,,,['positive'],positive,1
NCT01922258,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/schizophrenia-medication-brexpiprazole-lowered-agitation-in-alzheimers-patients-in-phase-3-study/', 'title': ""Alzheimer's Agitation Seen to Ease with Schizophrenia Drug, Brexpiprazole, in Clinical Trial"", 'source': ""Alzheimer's News Today"", 'date': 'May 5, 2017', 'snippet': ""Read about how the schizophrenia medication brexpiprazole seemed to reduce \nsymptoms of agitation in Alzheimer's disease patients."", 'thumbnail': 'https://serpapi.com/searches/6723e0de15c740d14127f744/images/07eb924935c019d7f21c132f0556544e80d9d29a40d83bccec0b470dd850aee5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8714643716812134}",,,,,,,,,,['neutral'],neutral,1
NCT02365818,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.953410/full', 'title': 'Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements', 'source': 'Frontiers', 'date': 'Feb 15, 2024', 'snippet': 'Oncolytic viruses (OVs) have been gaining attention in the pharmaceutical \nindustry as a novel immunotherapeutic and therapeutic adjuvant due to \ntheir...', 'thumbnail': 'https://serpapi.com/searches/6723e0e0c97e35cb6520e08f/images/29fcccf9a1a01fe4f8f2bd6403a7073ce0d150a3eaf34d75fe501c9983a55c81.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7581920623779297}",,,,,,,,,,['neutral'],neutral,1
NCT04571060,"{'position': 1, 'link': 'https://www.empr.com/home/news/zavzpret-nasal-spray-now-available-for-acute-treatment-of-migraine/', 'title': 'Zavzpret Nasal Spray Now Available for Acute Treatment of Migraine', 'source': 'Medical Professionals Reference', 'date': 'Jul 6, 2023', 'snippet': 'Zavzpret (zavegepant) nasal spray is now available for the acute treatment \nof migraine with or without aura in adults.', 'thumbnail': 'https://serpapi.com/searches/6723e0dd63a844cf0f6aec1d/images/60333bcdae733f019925f31c7679ff553b34b48ebd832e72b7ef9acf148f2c59.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8405698537826538}","{'position': 2, 'link': 'https://www.empr.com/home/news/zavzpret-nasal-spray-approved-for-acute-treatment-of-migraine/', 'title': 'Zavzpret Nasal Spray Approved for Acute Treatment of Migraine', 'source': 'Medical Professionals Reference', 'date': 'Mar 10, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Zavzpret™ (zavegepant) \nnasal spray, a calcitonin gene-related peptide (CGRP) receptor...', 'thumbnail': 'https://serpapi.com/searches/6723e0dd63a844cf0f6aec1d/images/60333bcdae733f01b75ecff69fddd9fd0396f5647b670911b74140527bc375b9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6946619749069214}","{'position': 3, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/significant-pain-relief-observed-with-intranasal-zavegepant-in-migraine-trial/', 'title': 'Significant Pain Relief Observed With Intranasal Zavegepant in Migraine Trial', 'source': 'Medical Professionals Reference', 'date': 'Dec 6, 2021', 'snippet': 'Topline results were announced from a phase 3 trial evaluating intranasal \nzavegepant for the acute treatment of migraines in adults.', 'thumbnail': 'https://serpapi.com/searches/6723e0dd63a844cf0f6aec1d/images/60333bcdae733f0181d3bd4bd9c85a5d1a6cf1ec8242a7508f954dbb2c710dd8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7664857506752014}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT01998971,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-023-00805-x', 'title': 'Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS | Blood Cancer Journal', 'source': 'Nature', 'date': 'Mar 7, 2023', 'snippet': 'We report final data from PLEIADES and EQUULEUS, with a median follow-up of \n12.4 and 23.7 months, respectively.', 'thumbnail': 'https://serpapi.com/searches/6723e0efa88278ea4c0d0526/images/dbcfa68a19d2d76cdd13e36a779704b9621747d9f12dcdb5514ab39c9e0a373c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9076092839241028}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/fda-approves-combo-therapy-that-includes-darzalex-as-multiple-myeloma-treatment/', 'title': 'Multiple Myeloma Combo Therapy That Includes Darzalex Wins FDA Approval', 'source': 'Myeloma Research News', 'date': 'Jun 21, 2017', 'snippet': 'The U.S. Federal Drug Administration approves a combination therapy that \nincludes Darzalex for treating multiple myeloma patients.', 'thumbnail': 'https://serpapi.com/searches/6723e0efa88278ea4c0d0526/images/dbcfa68a19d2d76c2293179f095a9345be7403385106adef2a0ef9153b76d393.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5960658192634583}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT01919801,"{'position': 1, 'link': 'https://angioedemanews.com/news/patients-in-germany-treat-attacks-with-firazyr-earlier-with-better-results-study-finds/', 'title': 'Patients in Germany Treat Acute Attacks with Firazyr Earlier Than Those Elsewhere with Better Results, Study Finds', 'source': 'Angioedema News', 'date': 'Sep 13, 2018', 'snippet': 'A study finds German patients treat their acute attacks with Firazyr \nearlier that patients in 11 other countries, possibly due to good...', 'thumbnail': 'https://serpapi.com/searches/6723e10572f71617291ab5d6/images/2f7558133464b3ae7fbe39fdd3ffc96b8333ccb3789b6405c99bb0895b98bcd2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5521395802497864}",,,,,,,,,,['positive'],positive,1
NCT02255422,"{'position': 1, 'link': 'https://mitochondrialdiseasenews.com/2015/08/26/mitochondria-many-disorders-compose-mitochondrial-disease/', 'title': 'Mitochondria and the Many Disorders That Compose ""Mitochondrial...', 'source': 'Mitochondrial Disease News', 'date': 'Aug 26, 2015', 'snippet': 'Mitochondria (singular mitochondrion) are tiny subunits present inside \nevery cell of the human body except red blood cells, from the skin to...', 'thumbnail': 'https://serpapi.com/searches/6723e108b4b72de02896341d/images/7057ae3bbf0748985d3337d5799dbad7a13346c183b44b5ed525e90f566f761f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.889778733253479}",,,,,,,,,,['neutral'],neutral,1
NCT02713178,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/exparel-application-under-review-for-sciatic-and-femoral-nerve-blocks/', 'title': 'Exparel Application Under Review for Sciatic and Femoral Nerve Blocks', 'source': 'Medical Professionals Reference', 'date': 'Mar 31, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted the supplemental New \nDrug Application (sNDA) for Exparel (bupivacaine liposome injectable \nsuspension)', 'thumbnail': 'https://serpapi.com/searches/6723e1100f1a336e05f58119/images/63fb008bee710a4d7a255681fcbcbbdaa0b8a6483aebae7f83b66bb5c01da3fa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9170256853103638}",,,,,,,,,,['neutral'],neutral,1
NCT03928210,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01725-9', 'title': 'New insights into the correlations between circulating tumor cells and target organ metastasis', 'source': 'Nature', 'date': 'Dec 21, 2023', 'snippet': 'Numerous studies demonstrated that CTCs exhibited huge clinical value \nincluding predicting distant metastasis, assessing prognosis and monitoring \ntreatment...', 'thumbnail': 'https://serpapi.com/searches/6723e1aef3cbfa091e5a6abc/images/aa2f46c5bd8879446f3f838777c281a68954591d576090969c928e67b920837d.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5702199339866638}",,,,,,,,,,['positive'],positive,1
NCT01346787,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/once-weekly-kyprolis-effective-untreated-multiple-myeloma-patients/', 'title': 'Once-weekly Kyprolis Safe, Effective for Untreated Multiple Myeloma Patients, Study Finds', 'source': 'Myeloma Research News', 'date': 'Mar 6, 2019', 'snippet': 'Treatment with Kyprolis (carfilzomib) once a week is as safe and effective \nas the twice-weekly regimen used for the initial treatment of multiple \nmyeloma...', 'thumbnail': 'https://serpapi.com/searches/6723e1b2a32436068562daab/images/5e42584e1711a99c9db91b88002fd1ededb878b4af2d9de89e262879661cb0ad.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5886017084121704}",,,,,,,,,,['neutral'],neutral,1
NCT04414345,"{'position': 1, 'link': 'https://alsnewstoday.com/news/long-term-survival-benefit-seen-cnm-au8-healey-als-analyses-trial/', 'title': 'Long-term ALS survival benefit with CNM-Au8 seen in trial analyses...', 'source': 'ALS News Today', 'date': 'Sep 28, 2023', 'snippet': 'New HEALEY ALS trial analyses showed a significant long-term survival \nbenefit for ALS patients treated with CNM-Au8 for up to 2.5 years.', 'thumbnail': 'https://serpapi.com/searches/6723e1b72a48823c174de8a4/images/92104293b7e2214e474d921d55c025be4b89ed789c869289d570658831775383.png', 'sentiment': 'positive', 'sentiment_prob': 0.6370849609375}","{'position': 2, 'link': 'https://alsnewstoday.com/news/cnm-au8-expanded-access-program-will-enroll-more-als-patients/', 'title': 'Clene expanding CNM-Au8 expanded access program in US', 'source': 'ALS News Today', 'date': 'Jun 3, 2024', 'snippet': 'Clene has expanded by 80% the number of ALS patients to be enrolled in a \nsoon-to-launch expanded access program (EAP) for CNM-Au8.', 'thumbnail': 'https://serpapi.com/searches/6723e1b72a48823c174de8a4/images/92104293b7e2214e749cf0f2e258477b1c6fda99bb490c55bfef47fab1126905.png', 'sentiment': 'positive', 'sentiment_prob': 0.7117204666137695}","{'position': 3, 'link': 'https://alsnewstoday.com/news/cnm-au8-delayed-clinical-worsening-als-patients-healey-trial/', 'title': 'CNM-Au8 found to delay clinical worsening in ALS HEALEY trial |...', 'source': 'ALS News Today', 'date': 'Mar 10, 2023', 'snippet': ""Treatment with Clene's CNM-Au8 significantly delayed clinical worsening in \nALS patients participating in an arm of the HEALEY platform..."", 'thumbnail': 'https://serpapi.com/searches/6723e1b72a48823c174de8a4/images/92104293b7e2214ec6a1d38f0f637a28262894ca6251a6b676d106542e932ddf.png', 'sentiment': 'negative', 'sentiment_prob': 0.5408130288124084}",,,,,,,,"['positive', 'positive', 'negative']",positive,1
NCT02644460,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1248753/full', 'title': 'Ewing sarcoma from molecular biology to the clinic', 'source': 'Frontiers', 'date': 'Jun 25, 2024', 'snippet': 'In Europe, with an incidence of 7.5 cases per million, Ewing sarcoma (ES) \nis the second most common primary malignant bone tumor in children,...', 'thumbnail': 'https://serpapi.com/searches/6723e1c13d629b1615675369/images/7400813e35313a175bc10e64a9df558e266724511ec4fcd5d918470c45d3edda.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6943160891532898}",,,,,,,,,,['neutral'],neutral,1
NCT03127514,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1916945', 'title': 'Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 2, 2020', 'snippet': 'Sodium phenylbutyrate–taurursodiol resulted in slower functional decline \nthan placebo as measured by the ALSFRS-R score over a period of 24 weeks.', 'thumbnail': 'https://serpapi.com/searches/6723e1cd9062f835cfd4679a/images/d53bb38d36904bda8065808ffb531ca07ebb3ae2e68fc8224021d8ad7e1a0cdd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.63248211145401}","{'position': 2, 'link': 'https://alsnewstoday.com/amx0035/', 'title': 'What is Relyvrio for ALS?', 'source': 'ALS News Today', 'date': 'Apr 11, 2024', 'snippet': 'Relyvrio was an oral treatment approved in the U.S. and Canada for adults \nwith amyotrophic lateral sclerosis that has now been discontinued.', 'thumbnail': 'https://serpapi.com/searches/6723e1cd9062f835cfd4679a/images/d53bb38d36904bda7303b884dbb0a5d0030f54935d323dbd1c07b9c37b5bc529.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5614924430847168}","{'position': 3, 'link': 'https://www.pharmaceutical-technology.com/news/amylyx-axes-als-drug-from-market-after-phase-iii-failure/', 'title': 'Amylyx axes ALS drug from market after Phase III failure', 'source': 'Pharmaceutical Technology', 'date': 'Apr 5, 2024', 'snippet': 'Last month, Amylyx announced that the Phase III confirmatory trial of ALS \ndrug Relyvrio failed to meet its primary and secondary endpoints.', 'thumbnail': 'https://serpapi.com/searches/6723e1cd9062f835cfd4679a/images/d53bb38d36904bda54e6db562187dc98b5b23b656718727060935d9eed6fb36a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8077023029327393}","{'position': 4, 'link': 'https://www.clinicaltrialsarena.com/news/amylyx-decision-als-endpoints/', 'title': 'Looming Amylyx drug approval decision renews debate over ALS endpoints', 'source': 'Clinical Trials Arena', 'date': 'Sep 15, 2022', 'snippet': ""With the FDA's decision on Amylyx's AMX-0035 fast approaching, we dive into \ntensions over ALS endpoints and major drug trials to watch."", 'thumbnail': 'https://serpapi.com/searches/6723e1cd9062f835cfd4679a/images/d53bb38d36904bda4eaf098acceef1bd7e52fa8c0a1c8400860455cd7fe07a28.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.896506130695343}","{'position': 5, 'link': 'https://alsnewstoday.com/news/phoenix-trial-approved-als-therapy-relyvrio-amx0035-enrolled/', 'title': 'Enrollment complete in new trial of approved ALS therapy Relyvrio', 'source': 'ALS News Today', 'date': 'Feb 6, 2023', 'snippet': ""A Phase 3 clinical trial confirming the safety and efficacy of Amylyx's \napproved ALS therapy Relyvrio, formerly AMX0035, is fully enrolled."", 'thumbnail': 'https://serpapi.com/searches/6723e1cd9062f835cfd4679a/images/d53bb38d36904bda72145bd219c89b70c490806397071a98316dd91fff6b9780.png', 'sentiment': 'positive', 'sentiment_prob': 0.5213114023208618}","{'position': 6, 'link': 'https://alsnewstoday.com/news/amx0035-survival-als-patients-centaur-clinical-trial-analysis-amylyx/', 'title': 'AMX0035 Extended Survival in ALS Patients By More Than 10 Months', 'source': 'ALS News Today', 'date': 'May 6, 2022', 'snippet': 'AMX0035 significantly extended median survival by more than 10 months in \nthe Phase 2 CENTAUR clinical trial, a new analysis indicates.', 'thumbnail': 'https://serpapi.com/searches/6723e1cd9062f835cfd4679a/images/d53bb38d36904bda5c1fae98a4a9be91970942d1c3b67bf9d504495b8bb6c00d.png', 'sentiment': 'positive', 'sentiment_prob': 0.7468807697296143}","{'position': 7, 'link': 'https://alsnewstoday.com/news/centaur-data-relyvrio-lowers-als-inflammatory-biomarkers/', 'title': 'Relyvrio reduces inflammatory biomarkers in ALS: CENTAUR data', 'source': 'ALS News Today', 'date': 'Dec 18, 2023', 'snippet': 'Treatment with Relyvrio significantly reduced levels of neuroinflammatory \nbiomarkers in the bloodstream of ALS patients after three months.', 'thumbnail': 'https://serpapi.com/searches/6723e1cd9062f835cfd4679a/images/d53bb38d36904bda8d2988df105a8ea9e33ace82f793afe7183b6bc3ffac5c15.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5478339195251465}","{'position': 8, 'link': 'https://alsnewstoday.com/news/als-therapies-amx-0035-radicava-ors-may-add-benefit-cost-effective/', 'title': 'AMX0035, Radicava ORS Costs Could Cloud Therapies’ Benefits: ICER', 'source': 'ALS News Today', 'date': 'Aug 9, 2022', 'snippet': 'Note: This story was updated Aug. 10, 2022, to clarify the U.S. Food and \nDrug Administration advisory committee voted there is no...', 'thumbnail': 'https://serpapi.com/searches/6723e1cd9062f835cfd4679a/images/d53bb38d36904bda567318592d828b27af0566be9af439d173a79b6010e44aca.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8640235066413879}","{'position': 9, 'link': 'https://alsnewstoday.com/news/amx0035-oral-als-therapy-called-albrioza-approved-canada/', 'title': 'AMX0035, Oral ALS Therapy Now Known as Albrioza, Approved in Canada', 'source': 'ALS News Today', 'date': 'Jun 13, 2022', 'snippet': 'Albrioza, formerly AMX0035, was conditionally approved by Health Canada \nprovided safety and efficacy shown in ongoing Phase 3 PHOENIX trial.', 'thumbnail': 'https://serpapi.com/searches/6723e1cd9062f835cfd4679a/images/d53bb38d36904bda3851cedec66eebac672cd88797fbbedd6230873ce82ae929.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7737936973571777}",,"['neutral', 'neutral', 'negative', 'neutral', 'positive', 'positive', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03907969,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.998388/full', 'title': 'Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation', 'source': 'Frontiers', 'date': 'Jun 29, 2023', 'snippet': 'DNA damage response inhibitors are widely used anti-cancer agents that have \npotent activity against tumor cells with deficiencies in various DNA \ndamage...', 'thumbnail': 'https://serpapi.com/searches/6723e1d1a2e99c954cff3ddb/images/3a4f9a463332c947d202669a1b3455e4eac0a83e76ebc7621211d78892b8720e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7443199753761292}",,,,,,,,,,['neutral'],neutral,1
NCT02094573,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/long-term-efficacy-continues-with-brigatinib-in-alk-nsclc-after-crizotinib', 'title': 'Long-Term Efficacy Continues With Brigatinib in ALK+ NSCLC After Crizotinib', 'source': 'Cancer Network', 'date': 'Jun 10, 2021', 'snippet': 'Long-term efficacy and safety results from the phase 1/2 (NCT01449461) and \nphase 2 ALTA (NCT02094573) trials reported at the 2021 American...', 'thumbnail': 'https://serpapi.com/searches/6723e1d5db3ac9f357ce498a/images/2a2ed3f334ccf2f0437c7a928544810808571e1f74bb6871375c0239782c3c7d.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6142606735229492}",,,,,,,,,,['positive'],positive,1
NCT01356498,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/news/remission-criteria-validated-new-criteria-defined-for-complete-response-in-chronic-refractory-gout/', 'title': 'Remission Criteria Validated, New Criteria Defined for Complete Response in Chronic Refractory Gout', 'source': 'Rheumatology Advisor', 'date': 'Dec 17, 2019', 'snippet': 'The objective of this study was to generate evidence-based criteria for \ngout remission and develop new criteria for complete response using data \nfrom...', 'thumbnail': 'https://serpapi.com/searches/6723e204544c49af4a618775/images/448b118e3014063167f5cb93f8a47a29265211c1779297ac1a12a3dbff7d4a96.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8911468982696533}",,,,,,,,,,['neutral'],neutral,1
NCT02361112,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01322-w', 'title': 'Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer', 'source': 'Nature', 'date': 'Mar 19, 2023', 'snippet': 'Pyrotinib combined with capecitabine (P + C) achieved clinically and \nstatistically significant improvement in the PFS and a trend of benefits in \nthe OS.', 'thumbnail': 'https://serpapi.com/searches/6723e20ad910391563813d41/images/206e3b84ef0a58c56d50cc0153ce9e8c35218c1dda9a42aee55561b6bf93b6ef.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8146460056304932}",,,,,,,,,,['positive'],positive,1
NCT00128661,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-022-00431-x', 'title': 'HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial', 'source': 'Nature', 'date': 'Mar 29, 2022', 'snippet': 'The HPV vaccine has shown sustained efficacy and consistent stabilization \nof antibody levels, even after a single dose.', 'thumbnail': 'https://serpapi.com/searches/6723e227b2ebaec13d1f0e4b/images/e9bdc0e3831e6bcbd81df12cbe2c53cd8210e8ad1d9045e66f526586ce7774d7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.785798966884613}",,,,,,,,,,['neutral'],neutral,1
NCT03852251,"{'position': 1, 'link': 'https://www.nature.com/articles/s41388-024-03066-5', 'title': 'Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4 - Oncogene', 'source': 'Nature', 'date': 'May 28, 2024', 'snippet': 'The combination of programmed cell death protein 1 (PD-1) and cytotoxic T \nlymphocyte antigen 4 (CTLA-4) antibodies has potential for...', 'thumbnail': 'https://serpapi.com/searches/6723e22d24296a561cf2cc0f/images/644cc10cf284d9942783711483835b83ca97c9bf71a8d05c6bc1dff189abaf15.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9039801955223083}",,,,,,,,,,['neutral'],neutral,1
NCT03608397,"{'position': 1, 'link': 'https://www.empr.com/home/news/daxxify-approved-for-cervical-dystonia-treatment/', 'title': 'Daxxify Approved for Cervical Dystonia Treatment', 'source': 'Medical Professionals Reference', 'date': 'Aug 14, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Daxxify \n(daxibotulinumtoxinA-lanm) for the treatment of cervical dystonia in adults.', 'thumbnail': 'https://serpapi.com/searches/6723e2444e9efc5aa2bbe85b/images/f9b4c7578b35b70812868838bdcdbd200f7ec51e80b8986da16fa8e2d2e395ff.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7787346243858337}",,,,,,,,,,['neutral'],neutral,1
NCT01865617,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.886546/full', 'title': 'Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation', 'source': 'Frontiers', 'date': 'May 23, 2022', 'snippet': 'Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable \nsuccess in long-term remission of cancers and other autoimmune...', 'thumbnail': 'https://serpapi.com/searches/6723e245d771bdcb8c6325cc/images/ba9d3f1f500b158e2e68efda18a2425de5013448bb6d9d189893f8f8d93301cb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6530438661575317}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-024-52503-2', 'title': 'Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion', 'source': 'Nature', 'date': '1 month ago', 'snippet': 'Chimeric antigen receptor-modified T cell (CAR-T) immunotherapy has \nrevolutionised blood cancer treatment. Parsing the genetic underpinnings...', 'thumbnail': 'https://serpapi.com/searches/6723e245d771bdcb8c6325cc/images/ba9d3f1f500b158e818422480422b5b3be329298f6b6181902c9b9af904c5d8a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9020484089851379}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04102189,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2208601', 'title': 'Once-Weekly Semaglutide in Adolescents with Obesity', 'source': 'The New England Journal of Medicine', 'date': 'Nov 2, 2022', 'snippet': 'A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like \npeptide-1 receptor agonist, is used to treat obesity in adults, but \nassessment of...', 'thumbnail': 'https://serpapi.com/searches/6723e27007c7bee603a27985/images/2a4bb363887500be69610dea786bb3b7f35a3e747d649f7a3e2e3a9a55e701ff.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8316576480865479}",,,,,,,,,,['neutral'],neutral,1
NCT01716312,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/news/omalizumab-safe-well-tolerated-in-mild-to-moderate-systemic-lupus-erythematosus/', 'title': 'Omalizumab Safe, Well-Tolerated in Mild to Moderate Systemic Lupus Erythematosus', 'source': 'Rheumatology Advisor', 'date': 'Feb 4, 2019', 'snippet': 'Omalizumab, an immunoglobulin E (IgE)-binding monoclonal antibody that \nlimits type I interferon production, was safe and well-tolerated compared \nwith placebo.', 'thumbnail': 'https://serpapi.com/searches/6723e277a9210b29e2f64f3b/images/b59aeba077c84da5b3df637f3a98193413f9d93c7ddcdb58f3d6c1b28b10361b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5995998978614807}",,,,,,,,,,['neutral'],neutral,1
NCT02403531,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-24288-1', 'title': 'Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial', 'source': 'Nature', 'date': 'Jun 29, 2021', 'snippet': 'This randomized phase II trial aims to compare the efficacy and safety of \ninduction chemotherapy followed by definitive chemoradiotherapy (CRT) \nversus CRT alone', 'thumbnail': 'https://serpapi.com/searches/6723e288bbc18bcd514ff212/images/da7d1f5355fb41da8651946d37bd1f9a4345366d3aed6f971c2e740e832e7f5d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8786394596099854}",,,,,,,,,,['neutral'],neutral,1
NCT02374060,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/therapy-applied-directly-inside-eye-best-treating-uveitic-macular-edema', 'title': 'Therapy applied directly inside the eye best for treating uveitic macular edema', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Sep 27, 2018', 'snippet': 'NIH-funded clinical trial compares treatments for complication of \ninflammatory eye disease.', 'thumbnail': 'https://serpapi.com/searches/6723e297f79a019b1b54b926/images/f997bfdda7f1de0aa187af2e61973fcbd7770b4657e3c1673514cf01e42727c6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8161140084266663}",,,,,,,,,,['neutral'],neutral,1
NCT04003142,"{'position': 1, 'link': 'https://www.empr.com/cch/veozah-for-the-treatment-of-vasomotor-symptoms-due-to-menopause/', 'title': 'Veozah for the Treatment of Vasomotor Symptoms Due to Menopause', 'source': 'Medical Professionals Reference', 'date': '1 jun 2023', 'snippet': 'Veozah (fezolinetant; Astellas Pharma US, Inc) became the first medication \nwithin its class to be approved by the US Food and Drug Administration (FDA)', 'thumbnail': 'https://serpapi.com/searches/6723e2a8316650c2f97c9544/images/00637858a2398c39dbc6be691d18fe081722d1b3b61eb17326511d8c6a291552.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7362357974052429}","{'position': 2, 'link': 'https://www.empr.com/home/news/veozah-approved-for-moderate-to-severe-vasomotor-symptoms-due-to-menopause/', 'title': 'Veozah Approved for Moderate to Severe Vasomotor Symptoms Due to Menopause', 'source': 'Medical Professionals Reference', 'date': '15 may 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Veozah™ (fezolinetant) \nfor the treatment of moderate to severe vasomotor symptoms due to...', 'thumbnail': 'https://serpapi.com/searches/6723e2a8316650c2f97c9544/images/00637858a2398c39f20a79f5660a3849fa1ecab16318087d4849177f43f88835.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7814399600028992}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02636582,"{'position': 1, 'link': 'https://breastcancer-news.com/2019/08/19/phase-2-trial-of-sellas-neuvax-vaccine-her2-positive-dcis-breast-cancer-fully-enrolled/', 'title': 'Phase 2 Trial of NeuVax Vaccine for HER2-positive DCIS Fully Enrolled, Sellas Announces', 'source': 'breastcancer-news.com', 'date': 'Aug 19, 2019', 'snippet': ""Early data from the Phase 2 trial evaluating NeuVax in 13 women with early \nstage HER2-positive ductal carcinoma in situ is likely by year's..."", 'thumbnail': 'https://serpapi.com/searches/6723e2b1a5aae9313a6baa93/images/54bffc226ff7c917c595e143f8132cfeac1f8c36e45e98bcafb89827e2c3b853.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9314606785774231}",,,,,,,,,,['neutral'],neutral,1
NCT00436046,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(10)70157-2/abstract', 'title': 'Needle-free influenza vaccination', 'source': 'The Lancet', 'date': 'Nov 1, 2010', 'snippet': 'Vaccination is the cornerstone of influenza control in epidemic and \npandemic situations. Influenza vaccines are typically given by...', 'thumbnail': 'https://serpapi.com/searches/6723e3df2b5fa7541e6e4fa5/images/3f7912b7d679ddbbe7e8ea2a4935edbf4e20d2f4136b0c9a1695133739a20909.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7493371963500977}",,,,,,,,,,['neutral'],neutral,1
NCT02083068,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-29226-3', 'title': 'Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine', 'source': 'Nature', 'date': 'Mar 25, 2022', 'snippet': 'A randomized, double-blind, controlled vaccine clinical trial was conducted \nto assess, as the primary outcome, the safety and protective...', 'thumbnail': 'https://serpapi.com/searches/6723e3e3c821271837d7b2f3/images/f525cf8f440924670c3da4e58ce814897c0d4e121f46e3efd13deacb6b563cb6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9074186086654663}",,,,,,,,,,['neutral'],neutral,1
NCT01328379,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/2018/09/25/dalfampridine-extended-release-tablets-generic-form-of-ampyra-available-in-us/', 'title': 'Oral Medicine for MS Walking Problems, Generic of Ampyra, Now Available in US', 'source': 'Multiple Sclerosis News Today', 'date': 'Sep 25, 2018', 'snippet': ""Read about Mylan's U.S. launch of dalfampridine ER tablets, the authorized \ngeneric version of Ampyra, for MS patients with walking..."", 'thumbnail': 'https://serpapi.com/searches/6723e2d59e5bd54156a5ebcd/images/046a8f700d0817a4d509cd3a1581fa380e893130392360b8485929b08ab3e954.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8621646761894226}",,,,,,,,,,['neutral'],neutral,1
NCT03919526,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-023-00813-x', 'title': 'CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study', 'source': 'Nature', 'date': 'Mar 24, 2023', 'snippet': 'Dear Editor,. Measurable residual disease (MRD) is now considered as one of \nthe most important prognostic factors for B cell acute...', 'thumbnail': 'https://serpapi.com/searches/6723e2f9fd3b5abd7063d59b/images/1f5960eb7a604d835b106c215c5d032324215b11253871f1aa080deb1ad3d2de.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9013963341712952}",,,,,,,,,,['neutral'],neutral,1
NCT02756611,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00070-6/fulltext', 'title': 'Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial', 'source': 'The Lancet', 'date': 'Mar 8, 2024', 'snippet': 'Most patients with chronic lymphocytic leukaemia progress after treatment \nor retreatment with targeted therapy or chemoimmunotherapy and...', 'thumbnail': 'https://serpapi.com/searches/6723e2febd7cf0e79f8de23d/images/c0d8b50faec975b64719ae931fa9a88df9c64c386585596ace6884a7a1c0b6b1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8870301842689514}",,,,,,,,,,['neutral'],neutral,1
NCT03987711,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061647', 'title': 'Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and End-Stage Renal Disease: Lessons Learned', 'source': 'American Heart Association Journals', 'date': 'Dec 5, 2022', 'snippet': 'Observational studies suggest that warfarin is associated with net harm in \npatients with AF on dialysis, 3 but the data are of low quality.', 'thumbnail': 'https://serpapi.com/searches/6723e329483e5be72afbceea/images/1f01b0fadd699d5f3e3e3ad074a6cac362451a02513f3495c7cf8631f783cb64.png', 'sentiment': 'negative', 'sentiment_prob': 0.6714184880256653}",,,,,,,,,,['negative'],negative,0
NCT04512001,"{'position': 1, 'link': 'https://www.empr.com/home/news/generics-news/fda-approves-tocilizumab-biosimilar-for-iv-and-subcutaneous-administration/', 'title': 'FDA Approves Tocilizumab Biosimilar for IV and Subcutaneous Administration', 'source': 'Medical Professionals Reference', 'date': 'Mar 7, 2024', 'snippet': 'The Food and Drug Administration (FDA) has approved Tyenne \n(tocilizumab-aazg), the first biosimilar to Actemra (tocilizumab) for both \nintravenous (IV) and...', 'thumbnail': 'https://serpapi.com/searches/6723e33d2a48823c590d2298/images/429263368bf2900e26d618cac9787da2fa45daf0cd4419d673fad6da27028a42.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6924965381622314}","{'position': 2, 'link': 'https://www.empr.com/home/news/generics-news/subcutaneous-formulation-of-biosimilar-tyenne-now-available/', 'title': 'Subcutaneous Formulation of Biosimilar Tyenne Now Available', 'source': 'Medical Professionals Reference', 'date': 'Jul 2, 2024', 'snippet': 'Tyenne (tocilizumab-aazg), a biosimilar to Actemra, is now available in a \nsubcutaneous formulation in addition to the IV presentation.', 'thumbnail': 'https://serpapi.com/searches/6723e33d2a48823c590d2298/images/429263368bf2900e43ca006042beaed604cf7d9eed21c7ab660db595f03eb680.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9088817834854126}","{'position': 3, 'link': 'https://www.empr.com/home/news/intravenous-formulation-of-biosimilar-tyenne-now-available/', 'title': 'Intravenous Formulation of Biosimilar Tyenne Now Available', 'source': 'Medical Professionals Reference', 'date': 'Apr 15, 2024', 'snippet': 'Tyenne (tocilizumab-aazg) is now available as a biosimilar to Actemra® \n(tocilizumab) in an intravenous (IV) formulation.', 'thumbnail': 'https://serpapi.com/searches/6723e33d2a48823c590d2298/images/429263368bf2900ecb1a4c6e5369c77f33c21bcd16eade7505645b156ada3365.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8585377931594849}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03028142,"{'position': 1, 'link': 'https://copdnewstoday.com/news/two-trials-demonstrate-rpl554-potential-as-add-on-therapy-for-copd/', 'title': 'Trials Demonstrate RPL554 Has Potential as Add-on Therapy for COPD', 'source': 'COPD News Today', 'date': 'Sep 7, 2018', 'snippet': ""The addition of Verona Pharma's investigational agent RPL554 to standard \nshort- and long-acting bronchodilators offers greater clinical..."", 'thumbnail': 'https://serpapi.com/searches/6723e342993688064fac03d0/images/e69c222211a67adc0c19ba253f60033ca32c21dc7796e82faf91d2ec79b7662a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5002123117446899}","{'position': 2, 'link': 'https://copdnewstoday.com/news/verona-pharma-rpl554-copd-named-ensifentrine/', 'title': 'Verona Pharma’s Candidate RPL554 for COPD Will Be Named Ensifentrine', 'source': 'COPD News Today', 'date': 'Jan 15, 2019', 'snippet': ""The World Health Organization approved the name ensifentrine for Verona \nPharma's investigational bronchodilator and anti-inflammatory agent,..."", 'thumbnail': 'https://serpapi.com/searches/6723e342993688064fac03d0/images/e69c222211a67adc8a757c745f1b62768a560158f7bb480c6e2b8bd7bcfcdb0a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8575579524040222}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03697161,"{'position': 1, 'link': 'https://fragilexnewstoday.com/news/combination-therapy-gaboxadol-ibudilast-effective-fragile-x-mouse-model/', 'title': 'Combination therapy gaboxadol, ibudilast effective in fragile X mouse model', 'source': 'Fragile X News Today', 'date': 'Mar 1, 2024', 'snippet': 'A combination of ibudilast and gaboxadol was shown to normalize behavior \nand improve memory in a mouse model of fragile X syndrome.', 'thumbnail': 'https://serpapi.com/searches/6723e34898d8de76ab11bb78/images/8d0e875974c34d8ad617f16f5b2864d8c9705bb2caac3bcf867dc17a67240118.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5454389452934265}","{'position': 2, 'link': 'https://fragilexnewstoday.com/news/gaboxadol-combo-therapy-fragile-x-worth-pursuing-healx-says/', 'title': 'Gaboxadol in Combo Therapy for Fragile X Worth Pursuing: Healx', 'source': 'Fragile X News Today', 'date': 'Feb 25, 2022', 'snippet': 'Healx entered into an agreement with Ovid to continue work on gaboxadol as \npart of a potential combination treatment for fragile X syndrome.', 'thumbnail': 'https://serpapi.com/searches/6723e34898d8de76ab11bb78/images/8d0e875974c34d8ae388e69c102fd69275575d69dcd1bcc2c63f03c69d08f316.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7769938111305237}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05821387,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/05/15/lucid-ms-clinical-trial-doses-1st-group-healthy-volunteers/', 'title': 'Lucid-21-302 MS clinical trial doses 1st group of healthy...', 'source': 'Multiple Sclerosis News Today', 'date': 'May 15, 2023', 'snippet': 'FSD Pharma has completed dosing in the first group of healthy volunteers \nenrolled in its Phase 1 clinical trial testing Lucid-21-302, an oral \nmedication...', 'thumbnail': 'https://serpapi.com/searches/6723e35df79a019b1b54b954/images/efefe2c0e92a131cf96937c4ff6eba43551d09dd5a4f0f95eeaf188c56e1096c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6708123087882996}",,,,,,,,,,['neutral'],neutral,1
NCT02584283,"{'position': 1, 'link': 'https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-023-07402-0', 'title': 'End-ischemic hypothermic oxygenated perfusion for extended criteria donors in liver transplantation: a multicenter, randomized controlled trial—HOPExt', 'source': 'BioMed Central', 'date': 'Jun 6, 2023', 'snippet': 'Given the scarce donor supply, an increasing number of so-called marginal \nor extended criteria donor (ECD) organs are used for liver...', 'thumbnail': 'https://serpapi.com/searches/6723e3652b5fa75457cfef02/images/71a03d2f9c12e8612e2da72b213138d72130a1f1ea8113068ae0066706f94d98.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8399129509925842}",,,,,,,,,,['neutral'],neutral,1
NCT03397121,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1913805', 'title': 'Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia', 'source': 'The New England Journal of Medicine', 'date': 'Mar 18, 2020', 'snippet': 'Familial hypercholesterolemia is characterized by an elevated level of \nlow-density lipoprotein (LDL) cholesterol and an increased risk of...', 'thumbnail': 'https://serpapi.com/searches/6723e3aa8db3762fbcd4bf7d/images/35f837e3e450633280bc3bb41fbfb089b354d02387b35c6920b30fa00b6e100c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6064899563789368}",,,,,,,,,,['neutral'],neutral,1
NCT03553940,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/experimental-nasal-influenza-vaccine-tested-kids-teens', 'title': 'Experimental nasal influenza vaccine tested in kids, teens', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Sep 17, 2018', 'snippet': 'An early-stage clinical trial testing the safety and immune-stimulating \nability of an experimental nasal influenza vaccine in healthy 9- to \n17-year-old...', 'thumbnail': 'https://serpapi.com/searches/6723e3e752a04e94a93f192f/images/0892867ef3170a6dd7622257470670946b73b7fbede4c8ad53f020f7a2c6f7e4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8606119155883789}",,,,,,,,,,['neutral'],neutral,1
NCT03976349,"{'position': 1, 'link': 'https://www.nature.com/articles/s41531-024-00660-y', 'title': 'G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage', 'source': 'Nature', 'date': 'Mar 1, 2024', 'snippet': ""Pathogenic mutations in LRRK2 cause Parkinson's disease (PD). The G2019S \nvariant is the most common, which results in abnormally high kinase..."", 'thumbnail': 'https://serpapi.com/searches/6723e60eb9ab86664a9fd180/images/2e9c49b6fdf52818722f830436cd6fe0290542da3ce603ca9751595c17e46e66.png', 'sentiment': 'negative', 'sentiment_prob': 0.8432062864303589}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00807/full', 'title': 'Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics', 'source': 'Frontiers', 'date': 'Aug 6, 2020', 'snippet': ""Genetic studies have identified variants in the LRRK2 gene as important \ncomponents of Parkinson's disease (PD) pathobiology."", 'thumbnail': 'https://serpapi.com/searches/6723e60eb9ab86664a9fd180/images/2e9c49b6fdf52818ee1907d32c3358f3abde99acdde6cace1096eadb6f0bf38e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9109451770782471}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT01782963,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-023-00912-9', 'title': 'In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management | Blood Cancer Journal', 'source': 'Nature', 'date': 'Sep 19, 2023', 'snippet': 'Long-term proteasome inhibitor (PI) treatment can improve multiple myeloma \n(MM) outcomes, but this can be difficult to achieve in clinical...', 'thumbnail': 'https://serpapi.com/searches/6723e6486531cb46dc2ded50/images/cba6245d88569365f0cbc43dcf296cc9bd4849fe3e56edb045657296f0258a31.png', 'sentiment': 'neutral', 'sentiment_prob': 0.862856924533844}",,,,,,,,,,['neutral'],neutral,1
NCT04977479,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/nih-launches-trial-study-allergic-reactions-covid-19-mrna-vaccine', 'title': 'NIH launches trial to study allergic reactions to COVID-19 mRNA vaccine', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Mar 9, 2022', 'snippet': 'Researchers from the National Institute of Allergy and Infectious Diseases \n(NIAID) are conducting a clinical trial designed to help...', 'thumbnail': 'https://serpapi.com/searches/6723e400671f3f492b26ed15/images/1d1545461ffb1d4d0e46870a0c63f9040c4df0f5da1a7ed613bf9d5629201346.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8957304358482361}",,,,,,,,,,['neutral'],neutral,1
NCT02252211,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-022-04984-6', 'title': 'Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1', 'source': 'Nature', 'date': 'Jun 6, 2022', 'snippet': 'The cell signaling factors EGFR, EphA2, and Ephexin1 are associated with \nlung and colorectal cancer and play an important role in tumorigenesis.', 'thumbnail': 'https://serpapi.com/searches/6723e41c93584cf63bb0290e/images/9065ccd4b32e25b13ca8fb7ab5ee245b516b7714a34557117635a3fcb4f8a69f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8681862950325012}",,,,,,,,,,['neutral'],neutral,1
NCT03995888,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/62/12/1719', 'title': 'Detection Efficacy of 18F‐rhPSMA‐7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment', 'source': 'Journal of Nuclear Medicine', 'date': 'Dec 1, 2021', 'snippet': '18 F-rhPSMA-7.3 PET offered high detection efficacy in patients with \nbiochemical recurrence after radical prostatectomy and before potential \nsalvage therapy.', 'thumbnail': 'https://serpapi.com/searches/6723e5ea3b3c321342fab432/images/0d4c3d204ead60e463dcb338341f7443dddc26a7f349b96eeaccf34bf9056b21.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7946215271949768}",,,,,,,,,,['neutral'],neutral,1
NCT04184063,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2021.720220/full', 'title': 'Novel Therapies for Parkinsonian Syndromes–Recent Progress and Future Perspectives', 'source': 'Frontiers', 'date': 'Jun 26, 2024', 'snippet': ""1Students' Scientific Association of the Department of Neurology, Medical \nUniversity of Warsaw, Warsaw, Poland; 2Department of Neurology, Medical \nUniversity..."", 'thumbnail': 'https://serpapi.com/searches/6723e5f8c1c8ddff1711d2ff/images/9cca4754d112e6a0da5a5819421e047010b14c88b842314ac4dfdcf41e7e6fee.png', 'sentiment': 'neutral', 'sentiment_prob': 0.93094402551651}",,,,,,,,,,['neutral'],neutral,1
NCT02564055,"{'position': 1, 'link': 'https://www.genengnews.com/topics/drug-discovery/gsk-sells-psoriasis-dermatitis-candidate-tapinarof-to-dermavant/', 'title': 'GSK Sells Psoriasis/Dermatitis Candidate Tapinarof to Dermavant', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Jul 12, 2018', 'snippet': 'Dermavant agreed to pay up to £250M ($330M) for mostly-global rights to the \ntherapeutic aryl hydrocarbon receptor modulating agent (TAMA),...', 'thumbnail': 'https://serpapi.com/searches/6723e474e10f0aab7ad45432/images/0badadd883f590af3d1462f7773a1d448763915caf99bc7accdeedfe83410997.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9153958559036255}",,,,,,,,,,['neutral'],neutral,1
NCT02047734,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/02/14/zeposia-not-affect-heart-heath-long-term-use-trials/', 'title': 'Zeposia’s long-term use doesn’t affect heart health, Phase 3 trials show', 'source': 'Multiple Sclerosis News Today', 'date': 'Feb 14, 2023', 'snippet': 'Relapsing MS patients treated with oral Zeposia for up to 2 years in Phase \n3 trials show no clinically significant changes in heart health.', 'thumbnail': 'https://serpapi.com/searches/6723e47e4677bf6b0eccad01/images/03c208b86dab04190e454c9d5a965bf40f5122f58b0a577b8b4de3620febcfad.png', 'sentiment': 'neutral', 'sentiment_prob': 0.705949604511261}",,,,,,,,,,['neutral'],neutral,1
NCT01070407,"{'position': 1, 'link': 'https://www.nature.com/articles/nrd3687', 'title': 'Steps towards an HCV vaccine', 'source': 'Nature', 'date': 'Feb 17, 2012', 'snippet': 'Results from a clinical study (ClinicalTrials.gov identifier: NCT01070407) \nof an investigational adenovirus-based vaccine against hepatitis...', 'thumbnail': 'https://serpapi.com/searches/6723e4d4caddc3538c855966/images/ae70670cc3a79dc3185fdd6551113247f54276bb5719c3048bcda2cd6a3b16e8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9137281179428101}",,,,,,,,,,['neutral'],neutral,1
NCT02224157,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1715275', 'title': 'As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma', 'source': 'The New England Journal of Medicine', 'date': 'May 16, 2018', 'snippet': 'Patients with mild asthma often rely on inhaled short-acting β2-agonists \nfor symptom relief and have poor adherence to maintenance therapy.', 'thumbnail': 'https://serpapi.com/searches/6723e507ef60cb9afd658c2f/images/e0cdf4a054ab460082b9bc2cf9f9a6278898c95f4151e4f5062ac22a47d97512.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5013684034347534}",,,,,,,,,,['neutral'],neutral,1
NCT03122652,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/aan-2023-aubagio-lowered-risk-ms-symptoms-emerging-ris/', 'title': 'AAN 2023: Aubagio reduced risk of developing MS symptoms in RIS trial', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 27, 2023', 'snippet': 'Treatment with Aubagio significantly reduces the risk that adults with RIS \nwill develop symptoms of MS, trial data show.', 'thumbnail': 'https://serpapi.com/searches/6723e67393bb5714313051f4/images/51d91be44177713980564b06dcc34c043793f59bc17dc46bee2a1f28c1da78f2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8027360439300537}",,,,,,,,,,['neutral'],neutral,1
NCT03249376,"{'position': 1, 'link': 'https://www.empr.com/home/news/caplyta-approved-for-bipolar-depression-in-adults/', 'title': 'Caplyta Approved for Bipolar Depression in Adults', 'source': 'Medical Professionals Reference', 'date': 'Dec 20, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Caplyta (lumateperone) \nfor the treatment of depressive episodes associated with bipolar I or II \ndisorder in...', 'thumbnail': 'https://serpapi.com/searches/6723e686f6aa5324447d9508/images/f3a877065f06f1d6ad4041ed3c1c44fab0c52fcfbb21b8a865477afa4caa1267.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7934946417808533}",,,,,,,,,,['neutral'],neutral,1
NCT02081378,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-024-02278-8', 'title': 'Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results', 'source': 'Nature', 'date': 'May 16, 2024', 'snippet': ""These results show asciminib's effectiveness, including in almost 50% of \nponatinib pretreated patients, and confirm its risk-benefit profile."", 'thumbnail': 'https://serpapi.com/searches/6723e6b0993688064fac049b/images/27e2e4718579870e81cc4ea26f2ecce83fb562d1ebdad88019bfa7c233ca056a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6183647513389587}",,,,,,,,,,['neutral'],neutral,1
NCT00931632,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/inhaled-nitric-oxide-and-survival-in-preterm-infants-without-bronchopulmonary-dysplasia/', 'title': 'Inhaled Nitric Oxide and Survival in Preterm Infants Without Bronchopulmonary Dysplasia', 'source': 'Pulmonology Advisor', 'date': 'Oct 18, 2017', 'snippet': 'The use of inhaled nitric oxide in premature infants without \nbronchopulmonary dysplasia (BPD) appears to be safe, but it does not \nimprove survival rates.', 'thumbnail': 'https://serpapi.com/searches/6723e6c58de63cf49777b1e3/images/ae7b2e7e8f04a01dc6588c0294160f664cf9ae927aa8da3bc4777b7fb196aec0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7672607898712158}",,,,,,,,,,['neutral'],neutral,1
NCT04121221,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/03/11/fda-declines-us-approval-ga-depot-relapsing-ms-treatment/', 'title': 'FDA declines to approve GA Depot as treatment for relapsing MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 11, 2024', 'snippet': 'The U.S. Food and Drug Administration (FDA) has decided not to approve an \napplication seeking clearance of GA Depot — a long-acting formulation...', 'thumbnail': 'https://serpapi.com/searches/6723e6cfdc969f85ff181446/images/c093819cf27482011a412654b48b99c0dd9db49e4bfb4ae65d665097ac43e813.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5317093729972839}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/long-acting-glatiramer-acetate-depot-under-review-for-relapsing-ms/', 'title': 'Long-Acting Glatiramer Acetate Depot Under Review for Relapsing MS', 'source': 'Medical Professionals Reference', 'date': 'Aug 7, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted for review the New Drug \nApplication for glatiramer acetate (GA) Depot 40mg for the treatment of \nrelapsing...', 'thumbnail': 'https://serpapi.com/searches/6723e6cfdc969f85ff181446/images/c093819cf2748201bb0c4646deac16e972ddc82a9d61f46cfe46649dce339af5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8663263916969299}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/fda-decision-ga-depot-relapsing-ms-expected-march-2024/', 'title': 'FDA decision on GA Depot for relapsing MS expected March 2024 –...', 'source': 'Multiple Sclerosis News Today', 'date': 'Aug 8, 2023', 'snippet': ""The U.S. Food and Drug Administration (FDA) has agreed to review Viatris \nand Mapi Pharma's application seeking approval of GA Depot for the..."", 'thumbnail': 'https://serpapi.com/searches/6723e6cfdc969f85ff181446/images/c093819cf2748201557b20a5c2d2998dd44849305d2dff315bc6f5edd869bef3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9419379234313965}","{'position': 4, 'link': 'https://multiplesclerosisnewstoday.com/ga-depot/', 'title': 'GA Depot in MS | Experimental MS Treatments', 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 18, 2022', 'snippet': 'GA Depot is a form of glatiramer acetate being evaluated as a potential MS \ntreatment. Learn about uses, side effects, and clinical testing.', 'thumbnail': 'https://serpapi.com/searches/6723e6cfdc969f85ff181446/images/c093819cf27482016343345f8f494ed78fa9af79528bfb843ddaffb0c94e8995.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9161229729652405}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT05007951,"{'position': 1, 'link': 'https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00317-6/fulltext', 'title': 'Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial - eClinicalMedicine', 'source': 'The Lancet', 'date': 'Sep 7, 2023', 'snippet': 'GBP510 vaccine contains self-assembling, recombinant nanoparticles \ndisplaying SARS-CoV-2 spike receptor-binding domains.', 'thumbnail': 'https://serpapi.com/searches/6723e6dfbe324f73dd70da8b/images/df3e74f84c4eea3e9babf762043c53123ff63ebb7f37506d7ebe6a89d1527d77.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9071503281593323}",,,,,,,,,,['neutral'],neutral,1
NCT01538381,"{'position': 1, 'link': 'https://www.nature.com/articles/cddis2013548', 'title': 'Clinical update on cancer: molecular oncology of head and neck cancer', 'source': 'Nature', 'date': 'Jan 23, 2014', 'snippet': 'Head and neck cancers encompass a heterogeneous group of tumours that, in \ngeneral, are biologically aggressive in nature.', 'thumbnail': 'https://serpapi.com/searches/6723e6e671c62b695e0d0029/images/0cd5b9e1b6b361d34b3d8255e75116a9501ba321b765370fef4c6352cd5cbe1e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6260771155357361}",,,,,,,,,,['neutral'],neutral,1
NCT05681715,"{'position': 1, 'link': 'https://myastheniagravisnews.com/rozanolixizumab-ucb7665/', 'title': 'Rystiggo (rozanolixizumab-noli) for myasthenia gravis', 'source': 'Myasthenia Gravis News', 'date': 'Jan 25, 2024', 'snippet': 'Rystiggo (rozanolixizumab-noli) is an injection therapy approved for adults \nwith generalized myasthenia gravis (gMG) who have antibodies against the...', 'thumbnail': 'https://serpapi.com/searches/6723e7015f97789cdc77af8d/images/1f70d30e97dd2924603e5643c7c637347a9a679ef1c16a86695190b667cd4f02.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8568547368049622}",,,,,,,,,,['neutral'],neutral,1
NCT03099304,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/jdv.20236', 'title': 'Journal of the European Academy of Dermatology and Venereology', 'source': 'Wiley Online Library', 'date': 'Jul 16, 2024', 'snippet': 'Ruxolitinib cream produced clinically meaningful repigmentation of all body \nareas, including hands and feet.', 'thumbnail': 'https://serpapi.com/searches/6723e71e0664c95f199942e6/images/42c909639e2fb24a391b652e1d0e0094b82c02f4936a380bd7df9468342b6515.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6719179153442383}",,,,,,,,,,['neutral'],neutral,1
NCT02810418,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Direct-synergism-causes-increased-apoptosis-in-multiple-models-A-T3M4-cells-were_fig3_311759559', 'title': 'Figure 3: Direct synergism causes increased apoptosis in multiple...', 'source': 'ResearchGate', 'date': 'Sep 19, 2018', 'snippet': 'The RG7787 RIT targets the cancer antigen mesothelin to deliver a \nrecombinantly-engineered, reduced immunogenicity variant of Pseudomonas \nexotoxin A (PE) to...', 'thumbnail': 'https://serpapi.com/searches/6723e9507a12fd36806190c6/images/96da842c5ee42c8b6ea00bbe1de1d609a4818c226117d24e0fe04d40cacf5f4e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7711139917373657}",,,,,,,,,,['neutral'],neutral,1
NCT00647348,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/09/24/ectrims-2024-simvastatin-fails-slow-disability-progression-spms/', 'title': 'ECTRIMS 2024: Simvastatin fails to slow disability progression in SPMS', 'source': 'Multiple Sclerosis News Today', 'date': '1 month ago', 'snippet': 'Confirmed six-month disability progression rates over 4 years were similar \nin patients given the oral statin or a placebo in Phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/6723e98ce45f33ae4e644522/images/8d2c636aad025b7552c8c4a4f0e5e7acbcbbf79c53e28763486c61a25a4cf7f8.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7357134819030762}",,,,,,,,,,['negative'],negative,0
NCT02961257,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/cabazitaxel-at-lowered-dose-increased-frequency-reduces-neutropenic-complications-in-older-patients-with-mcrpc', 'title': 'Cabazitaxel at Lowered Dose, Increased Frequency Reduces Neutropenic Complications in Older Patients With mCRPC', 'source': 'Cancer Network', 'date': 'Oct 25, 2022', 'snippet': 'Results of the randomized phase 3 CABASTY trial (NCT02961257), which were \nrecently presented at the 2022 European Society for Medical...', 'thumbnail': 'https://serpapi.com/searches/6723e74f0f1a336e05f582a0/images/67984c641d43640c9e718e38e3c121d32cc6b3fbed84fe8e3c2420437676ce31.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8543075323104858}",,,,,,,,,,['neutral'],neutral,1
NCT02507219,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-022-04875-y', 'title': 'Neuronally-enriched exosomal microRNA-27b mediates acute effects of ibuprofen on reward-related brain activity in healthy adults: a randomized, placebo-controlled, double-blind trial', 'source': 'Nature', 'date': '١٧\u200f/٠١\u200f/٢٠٢٢', 'snippet': 'This double-blind, randomized, within-subjects design evaluated whether \nacute administration of an anti-inflammatory drug modulates...', 'thumbnail': 'https://serpapi.com/searches/6723e773db3ac9f318304d31/images/b981b56a37a2844fba57fe07e94ad15076fc178f2484411929bd210253e1565a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.836776614189148}",,,,,,,,,,['neutral'],neutral,1
NCT02741323,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/nih-clinical-trial-track-outcomes-kidney-transplantation-hiv-positive-donors-hiv-positive-recipients', 'title': 'NIH clinical trial to track outcomes of kidney transplantation from HIV-positive donors to HIV-positive recipients', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'May 7, 2018', 'snippet': 'The first large-scale clinical trial to study kidney transplantations \nbetween people with HIV has begun at clinical centers across the United \nStates.', 'thumbnail': 'https://serpapi.com/searches/6723e8eafd3b5abd335a573d/images/1f64e7b096d8c53bd11c97fb9989f354fd673e0995118871e0c7d597caa1160e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9262402653694153}","{'position': 2, 'link': 'https://news.emory.edu/stories/2016/09/pearson_hiv_positive_kidney_transplant_drug_trial/index.html', 'title': 'Emory will study use of FDA-approved drug in HIV positive patients receiving kidney transplants', 'source': 'Emory University', 'date': 'Sep 1, 2016', 'snippet': 'Thomas Pearson, MD, is the principal investigator of an Emory clinical \ntrial testing a FDA-approved drug in HIV positive patients receiving a \nkidney transplant.', 'thumbnail': 'https://serpapi.com/searches/6723e8eafd3b5abd335a573d/images/1f64e7b096d8c53bbf9cce90cf3bb6b604512e0be7ed572bfbc55c74e41222ed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9237295389175415}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02030860,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2022.1020888/full', 'title': 'Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components', 'source': 'Frontiers', 'date': 'Oct 9, 2022', 'snippet': 'In our review, we shed light on how crosstalk of complex environmental \ncomponents modulates PDAC drug resistance, and we summarize related \nclinical trials.', 'thumbnail': 'https://serpapi.com/searches/6723e8eaf60b6f691fb48d0e/images/d17afde4a79ee652a2028702914d5f1bd029747e137a1c670e82d2d39cd0f0a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8721804618835449}",,,,,,,,,,['neutral'],neutral,1
NCT05658107,"{'position': 1, 'link': 'https://www.pharmalive.com/boehringer-ingelheim-2023-facing-down-uncertainty/', 'title': 'Boehringer Ingelheim 2023: Facing down uncertainty', 'source': 'PharmaLive', 'date': 'Oct 10, 2023', 'snippet': 'In 2022, Boehringer Ingelheim spent €5.05 billion ($5.32 billion) on \nresearch and development, an increase of 22.3 percent more than in 2021.', 'thumbnail': 'https://serpapi.com/searches/6723e9018d1473eda1c663f2/images/8fe726dcf7e89cf41fa58fdaf9559f919b412e66677deef1b355360189de38d0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8379125595092773}",,,,,,,,,,['neutral'],neutral,1
NCT02322775,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(17)30190-X/abstract', 'title': 'Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial', 'source': 'The Lancet', 'date': 'May 22, 2017', 'snippet': 'Benralizumab is a humanised, anti-interleukin 5 receptor α monoclonal \nantibody that directly and rapidly depletes eosinophils, reduces asthma \nexacerbations,...', 'thumbnail': 'https://serpapi.com/searches/6723e917e1c27684e5a655ad/images/293b580063bd251ae1fd00b2e9ede06b8268a10d62ec86f6084406b6958de6f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8085067868232727}",,,,,,,,,,['neutral'],neutral,1
NCT03758924,"{'position': 1, 'link': 'https://rettsyndromenews.com/news/anavex-2-73-shows-promise-rett-children-but-misses-trial-goal/', 'title': 'Anavex 2-73 shows promise for Rett children but misses trial goal', 'source': 'Rett Syndrome News', 'date': 'Jan 2, 2024', 'snippet': 'Treatment with Anavex 2-73 led to improvements in behavior for Rett \nsyndrome children, but a Phase 2/3 clinical trial failed to meet its...', 'thumbnail': 'https://serpapi.com/searches/6723e9194a4a1dafcdcf2e50/images/dd7d89e203c8bdf70cb0576c84a2b99edc196f6dbf5d46eab259e7dd87056f3b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5686342120170593}","{'position': 2, 'link': 'https://rettsyndromenews.com/news/trial-results-anavex-2-73-rett-syndrome-very-promising/', 'title': 'Latest Trial Results of Anavex 2-73 ‘Very Promising’', 'source': 'Rett Syndrome News', 'date': 'Jun 23, 2021', 'snippet': 'Clinical improvements with Anavex 2-73, by Anavex Life Sciences, correlated \nwith activation of the SIGMAR1 gene in a Phase 2 clinical trial.', 'thumbnail': 'https://serpapi.com/searches/6723e9194a4a1dafcdcf2e50/images/dd7d89e203c8bdf75f4800e02515e3d18bc4d2596151810f26b8b2f2e45ccc66.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8713425993919373}","{'position': 3, 'link': 'https://www.nature.com/articles/s41598-021-94079-7', 'title': 'Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy | Scientific Reports', 'source': 'Nature', 'date': 'Aug 25, 2021', 'snippet': 'Fragile X syndrome (FXS), a disorder of synaptic development and function, \nis the most prevalent genetic form of intellectual disability and...', 'thumbnail': 'https://serpapi.com/searches/6723e9194a4a1dafcdcf2e50/images/dd7d89e203c8bdf7a14f56639574d5740da1f516ec9a81e4a1d6122c9e4c5fec.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7516513466835022}","{'position': 4, 'link': 'https://rettsyndromenews.com/news/phase-2-extension-trial-shows-sustained-benefits-anavex-2-73/', 'title': 'Phase 2 extension trial shows sustained benefits of Anavex 2-73 –...', 'source': 'Rett Syndrome News', 'date': 'Jul 5, 2023', 'snippet': 'The benefits of Anavex 2-73 observed in a Phase 2 clinical trial were \nsustained in an open-label extension phase.', 'thumbnail': 'https://serpapi.com/searches/6723e9194a4a1dafcdcf2e50/images/dd7d89e203c8bdf78c12b18445279b4965c7515ebfa05577cca8cf4f994a9bbd.png', 'sentiment': 'positive', 'sentiment_prob': 0.8122766613960266}",,,,,,,"['neutral', 'positive', 'neutral', 'positive']",neutral,1
NCT04166773,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2401943', 'title': 'Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis', 'source': 'The New England Journal of Medicine', 'date': 'Jun 8, 2024', 'snippet': 'Treatment with tirzepatide for 52 weeks was more effective than placebo \nwith respect to resolution of MASH without worsening of fibrosis.', 'thumbnail': 'https://serpapi.com/searches/6723e9199e5bd54156a5ed31/images/bad94597ce305927bf4033579593a6c09f56fb4b6386d8a66bbe7176439ea669.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6512543559074402}","{'position': 2, 'link': 'https://liverdiseasenews.com/news/tirzepatide-weight-treats-fatty-liver-disease-phase-2-trial/', 'title': 'Tirzepatide for weight loss treats fatty liver disease in Phase 2 trial', 'source': 'Liver Disease News', 'date': 'Feb 12, 2024', 'snippet': 'Weekly injections of tirzepatide, an approved obesity and diabetes \ntreatment, showed promise in people with nonalcoholic steatohepatitis \n(NASH).', 'thumbnail': 'https://serpapi.com/searches/6723e9199e5bd54156a5ed31/images/bad94597ce305927e72d0fe4b88111bd42cecd201332c616c910969d87e68134.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6470713019371033}","{'position': 3, 'link': 'https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00074-2/fulltext', 'title': 'Tirzepatide adds hepatoprotection to its armoury', 'source': 'The Lancet', 'date': 'Apr 22, 2022', 'snippet': 'In The Lancet Diabetes & Endocrinology, Amalia Gastaldelli and colleagues. \n1. Gastaldelli, A ∙ Cusi, K ∙ Fernández Landó, L ∙ et al.', 'thumbnail': 'https://serpapi.com/searches/6723e9199e5bd54156a5ed31/images/bad94597ce3059271dca105d26ef0d26093dccb3b0ff7179610524c21ce71d45.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6948352456092834}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02573259,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20240530243565/en/Onc.AI-to-Present-Collaboration-Results-Demonstrating-Immunotherapy-Response-Prediction-Using-a-Radiomic-Signature-in-Late-Stage-Lung-Cancer', 'title': 'Onc.AI to Present Collaboration Results Demonstrating Immunotherapy Response Prediction Using a Radiomic Signature in Late-Stage Lung Cancer', 'source': 'Business Wire', 'date': 'May 30, 2024', 'snippet': 'Onc.AI, a digital health company developing a novel oncology clinical \nmanagement solution, today announced that new data will be presented...', 'thumbnail': 'https://serpapi.com/searches/6723e7869872176ea7fef34a/images/31512b1edddd9a873ce6e870787d896751d15cca7ccfaf7c914d8d9acd333d08.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8213077187538147}",,,,,,,,,,['neutral'],neutral,1
NCT02223052,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-019-50099-y', 'title': 'Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples', 'source': 'Nature', 'date': 'Sep 16, 2019', 'snippet': 'Our objectives were to determine whether clinic-pathological markers and \nimmune-related gene signatures in breast cancer exhibit any change...', 'thumbnail': 'https://serpapi.com/searches/6723e89ab9458db6b3587b0c/images/e7e3b0717f4906e184627fedf3ab082a740e2b7870f9339c7a597e62c2866e89.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9364905953407288}",,,,,,,,,,['neutral'],neutral,1
NCT04565756,"{'position': 1, 'link': 'https://www.news-medical.net/news/20240305/Exonate-first-in-class-eye-drop-Phase-IbIIa-trial-data-demonstrate-safety-and-biological-activity-in-treatment-of-diabetic-retinopathy-and-diabetic-macular-oedema.aspx', 'title': 'Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema', 'source': 'News-Medical', 'date': 'Mar 5, 2024', 'snippet': 'EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and \nsignals of biological response as monotherapy for these...', 'thumbnail': 'https://serpapi.com/searches/6723e8bb1b4e34015b421f08/images/1b7b8064432ce33e5512415dc6ed55afb274b11c89d5eeb949d44c565e35d4a8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6337299942970276}","{'position': 2, 'link': 'https://medicaldialogues.in/ophthalmology/news/new-eye-drops-found-safe-and-effective-in-diabetic-retinopathy-and-diabetic-macular-edema-in-new-trial-125824', 'title': 'New eye drops found safe and effective in diabetic retinopathy and diabetic macular edema in New trial', 'source': 'Medical Dialogues', 'date': 'Mar 14, 2024', 'snippet': 'New eye drop treatment has been found to be safe and tolerable with 100% \nparticipants completing the study for diabetic retinopathy and...', 'thumbnail': 'https://serpapi.com/searches/6723e8bb1b4e34015b421f08/images/1b7b8064432ce33ee51361123377e5038acd650e337179b6107facbc0d566b9b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8344739675521851}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02962908,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/abs/pii/S014181302400062X', 'title': 'Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice', 'source': 'ScienceDirect.com', 'date': 'Jan 7, 2024', 'snippet': 'The prokaryotically expressed multiepitope nanovaccine elicits long-lasting \nmucosal immunity, broad humoral immunity, and robust cellular immunity \nwithout any...', 'thumbnail': 'https://serpapi.com/searches/6723e8c524296a561cf2cdab/images/4c28dc6464c6cdcf03e587e59bb8746e56b251f2cd3757593c9f6f125f7cba6b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6536120176315308}",,,,,,,,,,['neutral'],neutral,1
NCT05172050,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-022-04961-z', 'title': 'Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants', 'source': 'Nature', 'date': 'May 25, 2022', 'snippet': 'We identified the drug raloxifene, a known Selective Estrogen Receptor \nModulator (SERM), as a new potential agent to treat mild-to-moderate \nCOVID-19 patients.', 'thumbnail': 'https://serpapi.com/searches/6723e7b2fda26d0643902730/images/faa12e2be434fb118ffd14a4fce0e6b651fed45c60115f290efc1604622ddb01.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8710779547691345}",,,,,,,,,,['neutral'],neutral,1
NCT02256436,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1613683', 'title': 'Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma', 'source': 'The New England Journal of Medicine', 'date': 'Feb 17, 2017', 'snippet': 'In this open-label, international, phase 3 trial, we randomly assigned 542 \npatients with advanced urothelial cancer that recurred or...', 'thumbnail': 'https://serpapi.com/searches/6723e7ba2b5fa7541e6e5082/images/155da3d5a683bcf88540367d90c76d1b00540107487f8e744c44231489521842.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8931952714920044}",,,,,,,,,,['neutral'],neutral,1
NCT04580407,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/obizur-effective-acquired-hemophilia-a-treatment-study/', 'title': 'Obizur effective as acquired hemophilia A treatment: Study', 'source': 'Hemophilia News Today', 'date': '1 month ago', 'snippet': 'Obizur was effective and safe in treating severe bleeding episodes in \nJapanese patients with acquired hemophilia A, per a study.', 'thumbnail': 'https://serpapi.com/searches/6723e80fe30abce600f7676e/images/9c640409ccb3d78cae946bb0a5bef66e1ca6de2d213ea3c353508f4531427d91.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5109249949455261}",,,,,,,,,,['neutral'],neutral,1
NCT01894958,"{'position': 1, 'link': 'https://fragilexnewstoday.com/news/decisional-intervention-may-be-beneficial-for-parents-of-fxs-chidren/', 'title': 'Information, Support May Persuade Parents of FXS Children to Join Trials', 'source': 'Fragile X News Today', 'date': 'Feb 19, 2019', 'snippet': 'Parents of children with intellectual disability, in particular those \naffected by fragile X syndrome, may benefit from more information and \ndedicated support.', 'thumbnail': 'https://serpapi.com/searches/6723e8330c08f2dbea83031d/images/90e7e8c2f18376ac68f8f854f00c4a34d0f48b652a74e5ec2d1953e5c792115b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6160650849342346}",,,,,,,,,,['neutral'],neutral,1
NCT02782741,"{'position': 1, 'link': 'https://pompediseasenews.com/news/nexviadyme-next-generation-ert-now-available-uk-nhs/', 'title': 'Nexviadyme, next-generation ERT for Pompe, is now available in UK...', 'source': 'Pompe Disease News', 'date': 'Feb 9, 2023', 'snippet': ""Nexviadyme (avalglucosidase alfa), a next-generation enzyme replacement \ntherapy for Pompe disease, will be available through the U.K.'s NHS."", 'thumbnail': 'https://serpapi.com/searches/6723e9a05416d8fd44a56d32/images/1adb8b48e5f033108fc6981ff5548fb9d665754b13d0cf7ce9139988207a9f85.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7312231659889221}","{'position': 2, 'link': 'https://pompediseasenews.com/news/fda-approves-nexviazyme-next-generation-enzyme-replacement-therapy-late-onset-pompe-disease/', 'title': 'Next-generation ERT Nexviazyme Approved by FDA for Late-onset Pompe', 'source': 'Pompe Disease News', 'date': 'Aug 9, 2021', 'snippet': 'The US Food and Drug Administration (FDA) has approved Nexviazyme \n(avalglucosidase alfa), a next-generation enzyme replacement therapy for \nlate-onset Pompe...', 'thumbnail': 'https://serpapi.com/searches/6723e9a05416d8fd44a56d32/images/1adb8b48e5f033106ff60ff0a8d01d87649b3a58f7ecf81a15d13b7754e6266a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.798860490322113}","{'position': 3, 'link': 'https://pompediseasenews.com/news/eu-approval-urged-new-pompe-ert-avalglucosidase-alfa/', 'title': 'EU Approval Urged for New Sanofi ERT Avalglucosidase Alfa', 'source': 'Pompe Disease News', 'date': 'Jul 27, 2021', 'snippet': 'A European Medicines Agency committee recommended that avalglucosidase alfa \nbe approved as an enzyme replacement therapy for Pompe disease.', 'thumbnail': 'https://serpapi.com/searches/6723e9a05416d8fd44a56d32/images/1adb8b48e5f033104882d1c811c240de5b24cfe374a88aa8814d3bdb4cf581c5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8937884569168091}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03951623,"{'position': 1, 'link': 'https://www.onclive.com/view/nmpa-accepts-and-grants-priority-review-to-nda-for-sovleplenib-in-primary-immune-thrombocytopenia', 'title': 'NMPA Accepts and Grants Priority Review to NDA for Sovleplenib in Primary Immune Thrombocytopenia', 'source': 'OncLive', 'date': 'Jan 11, 2024', 'snippet': 'The China National Medical Products Administration has accepted the NDA \nseeking approval of sovleplenib in patients with primary immune...', 'thumbnail': 'https://serpapi.com/searches/6723eb02c024d1931bae8118/images/7d4d7dd5d02be36c2874f2755a6c47f7fde25a588d9b0cceb424fe04c95e84c8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8363224864006042}",,,,,,,,,,['neutral'],neutral,1
NCT01810393,"{'position': 1, 'link': 'https://www.onclive.com/view/subcutaneous-trastuzumab-proves-safe-and-tolerable-in-her2-metastatic-breast-cancer', 'title': 'Subcutaneous Trastuzumab Proves Safe and Tolerable in HER2+ Metastatic Breast Cancer', 'source': 'OncLive', 'date': 'Aug 28, 2023', 'snippet': 'The safety profile of subcutaneous trastuzumab (Herceptin) was consistent \nwith the known profile of intravenous administration of the agent and there \nwere no...', 'thumbnail': 'https://serpapi.com/searches/6723eb04c821271837d7b487/images/08de0b266d16ff872a5324897164fca5a2ac523a4795d1b3e6551e007ffa508c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5896600484848022}",,,,,,,,,,['neutral'],neutral,1
NCT05059301,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-023-00729-4', 'title': 'Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models', 'source': 'Nature', 'date': 'Sep 29, 2023', 'snippet': 'Respiratory syncytial virus (RSV) causes a high disease burden in older \nadults. An effective vaccine for this RSV-primed population may need...', 'thumbnail': 'https://serpapi.com/searches/6723eb081fc7c5f7684d2a45/images/e55329cc307046245f5c0637914c9a3c9b9331240a58f1e062b5a2f95eb45b4b.png', 'sentiment': 'negative', 'sentiment_prob': 0.6014541983604431}",,,,,,,,,,['negative'],negative,0
NCT03971474,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.22.00912', 'title': 'Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Jun 4, 2022', 'snippet': 'PURPOSEResistance to immune checkpoint inhibition (ICI) in advanced \nnon–small-cell lung cancer (NSCLC) represents a major unmet need.', 'thumbnail': 'https://serpapi.com/searches/6723eb200c08f2dbea8303c7/images/64473c1e2eee80120604e661ac0427d3312607a47e36cf45801ebbaa0370c5cb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8705222010612488}",,,,,,,,,,['neutral'],neutral,1
NCT02899195,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01541-0', 'title': 'Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial', 'source': 'Nature', 'date': 'Nov 8, 2021', 'snippet': 'Mesothelioma is a rare and fatal cancer with limited therapeutic options \nuntil the recent approval of combination immune checkpoint blockade...', 'thumbnail': 'https://serpapi.com/searches/6723eb22d910391563813f67/images/2985465df2a4132f286b7cafc40f82c220bd6ee5c076bdbd4b65321bd4551970.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7101077437400818}",,,,,,,,,,['neutral'],neutral,1
NCT05662332,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/in-a-first-of-its-kind-fixed-dose-study-once-weekly-insulin-efsitora-alfa-leads-to-a1c-reduction-similar-to-daily-insulin-302238497.html', 'title': 'In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin', 'source': 'PR Newswire', 'date': 'Sep 5, 2024', 'snippet': 'PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive \ntopline results from the QWINT-1 and QWINT-3 phase 3 clinical...', 'thumbnail': 'https://serpapi.com/searches/6723e9f41a5b542101c410fc/images/a6693ae3d43e288d7a6e5e593d68d9b6f6c6dbfdeb562ad3b96bf55d1329fdd1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8551015853881836}","{'position': 2, 'link': 'https://www.endocrinologyadvisor.com/news/insulin-efsitora-alfa/', 'title': 'Insulin Efsitora Alfa Demonstrates Non-Inferior Glycemic Control in T2D', 'source': 'Endocrinology Advisor', 'date': '1 month ago', 'snippet': 'Treatment with once-weekly insulin efsitora alfa, compared with daily basal \ninsulins, effects non-inferior glycemic control and a similar safety \nprofile.', 'thumbnail': 'https://serpapi.com/searches/6723e9f41a5b542101c410fc/images/a6693ae3d43e288d790a1076a0f1ce8d1daa3785c23a9f916e6178df54097322.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8644056916236877}","{'position': 3, 'link': 'https://www.endocrinologyadvisor.com/news/qwint-trials-once-weekly-insulin-efsitora-noninferior-to-daily-basal-insulin-in-t2d/', 'title': 'QWINT Trials: Once-Weekly Insulin Efsitora Noninferior to Daily Basal Insulin in T2D', 'source': 'Endocrinology Advisor', 'date': '1 month ago', 'snippet': 'Topline data were announced from 2 studies in the QWINT phase 3 clinical \ndevelopment program investigating insulin efsitora alfa,...', 'thumbnail': 'https://serpapi.com/searches/6723e9f41a5b542101c410fc/images/a6693ae3d43e288d4ab5d8928e52cd1e519891a29353bd34d3f5664379fb91ce.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9359068274497986}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT05081167,"{'position': 1, 'link': 'https://www.psychiatrist.com/pcc/subanalysis-of-subjective-cognitive-measures-from-a-phase-2-double-blind-randomized-trial-of-rel-1017-in-patients-with-major-depressive-disorder/', 'title': 'Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder', 'source': 'Psychiatrist.com', 'date': 'Feb 14, 2023', 'snippet': 'In a Phase 2a clinical trial, REL-1017 improved subjective measures of \ncognitive impairment, in addition to improving total MADRS and SDQ scores.', 'thumbnail': 'https://serpapi.com/searches/6723ea38fc40bf31d0398dac/images/bf60e2a8cc24f1e339a29ecf1929f5f110e631c9188882bef014573fd8fac44e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.776265025138855}",,,,,,,,,,['neutral'],neutral,1
NCT00972179,"{'position': 1, 'link': 'https://www.dermatologyadvisor.com/news/two-phase-1-studies-evaluate-safety-of-tezepelumab-for-atopic-dermatitis/', 'title': 'Two Phase 1 Studies Evaluate Safety of Tezepelumab for Atopic Dermatitis', 'source': 'Dermatology Advisor', 'date': 'Mar 22, 2019', 'snippet': 'Two phase 1 studies assessed the safety, tolerability, and pharmacokinetics \nof tezepelumab with evidence of efficacy in asthma and potential...', 'thumbnail': 'https://serpapi.com/searches/6723ea41c82127187f68d9d7/images/9d037f00a876e142c73ec899b330f112ed2f4411b219831c859487c388dd41f7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8194459676742554}",,,,,,,,,,['neutral'],neutral,1
NCT04728360,"{'position': 1, 'link': 'https://www.biospace.com/bio-thera-solutions-announces-positive-results-from-phase-3-study-of-bat2206-a-proposed-biosimilar-referencing-stelara', 'title': 'Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara', 'source': 'BioSpace', 'date': 'Nov 29, 2023', 'snippet': 'Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company \ndeveloping a pipeline of biosimilars and innovative assets,...', 'thumbnail': 'https://serpapi.com/searches/6723ea6facf7f88b430d6f81/images/85b76f9261ca59bfd6de2525845cbc0d10e4cbee5079a606538c16165005aed7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5072025060653687}",,,,,,,,,,['neutral'],neutral,1
NCT01837251,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2020/07/30/liposomal-doxorubicin-based-regimen-improves-outcomes-in-platinum-sensitive-recurrent-ovarian-cancer/', 'title': 'In Platinum-sensitive OC, Liposomal Doxorubicin Found to Extend Survival', 'source': 'Ovarian Cancer News Today', 'date': 'Jul 30, 2020', 'snippet': 'A combination of bevacizumab, carboplatin, and liposomal doxorubicin may \nimprove the outcomes of platinum-sensitive ovarian cancer patients,...', 'thumbnail': 'https://serpapi.com/searches/6723eac00f2a2cff3865edce/images/a8cf070273cf414a1bac74aedfe1ac0e780d4d0905b3a745668ef69dcde83766.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5243479609489441}",,,,,,,,,,['neutral'],neutral,1
NCT01764477,"{'position': 1, 'link': 'https://www.nature.com/articles/s12276-020-0380-6', 'title': 'Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex', 'source': 'Nature', 'date': 'Feb 10, 2020', 'snippet': 'Wnt/β-catenin signaling is implicated in many physiological processes, \nincluding development, tissue homeostasis, and tissue regeneration.', 'thumbnail': 'https://serpapi.com/searches/6723eb3013e5d82f044c80c9/images/099852b03ca1d269eb31685e9bd5035a8ff6d59da6d27f3622369817f7f06f1c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8630236387252808}",,,,,,,,,,['neutral'],neutral,1
NCT02676947,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2020/1926908', 'title': 'Successful Treatment of Pulmonary Arterial Hypertension in Systemic Sclerosis with Anticentriole Antibody', 'source': 'Wiley Online Library', 'date': 'Feb 26, 2020', 'snippet': 'Systemic sclerosis (SSc) is characterized by skin sclerosis and multiple \norgan damages which may cause mortality and is usually accompanied...', 'thumbnail': 'https://serpapi.com/searches/6723eb3263a844cecdffd725/images/36505c50a74ecf163dba8aacb4904c3b0c2ff5a472a4cc5c8308fec3d220ac5a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5149408578872681}",,,,,,,,,,['neutral'],neutral,1
NCT05668754,"{'position': 1, 'link': 'https://www.stocktitan.net/news/ZVRA/zevra-therapeutics-to-present-top-line-data-from-the-phase-2-rm8qea7dn9fn.html', 'title': 'Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024', 'source': 'Stock Titan', 'date': '1 month ago', 'snippet': ""Zevra's KP1077 shows promise for idiopathic hypersomnia in Phase 2 trial. \nLearn about the clinically meaningful benefits and future Phase 3..."", 'thumbnail': 'https://serpapi.com/searches/6723eb36b9458db6b3587b85/images/904c74c0764eaaaa78388e7f87592fd706de2bb786232a736f0525509ec753d7.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6451144218444824}","{'position': 2, 'link': 'https://finance.yahoo.com/news/zevra-therapeutics-present-top-line-113000013.html', 'title': 'Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024', 'source': 'Yahoo Finance', 'date': '1 month ago', 'snippet': 'The Phase 2 clinical trial (NCT05668754) was a double-blind, \nplacebo-controlled, randomized-withdrawal, dose-optimizing, multi-center \nstudy.', 'thumbnail': 'https://serpapi.com/searches/6723eb36b9458db6b3587b85/images/904c74c0764eaaaa943d1b784a54e4c1af55e5de07c61bb20b4a491158bb5be4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8803951144218445}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT03818607,"{'position': 1, 'link': 'https://ahusnews.com/news/fda-approves-bkemv-biosimilar-soliris-ahus-treatment/', 'title': 'FDA approves Bkemv, biosimilar of Soliris, as aHUS treatment', 'source': 'aHUS News', 'date': 'Jun 5, 2024', 'snippet': 'The US Food and Drug Administration (FDA) has approved Bkemv \n(eculizumab-aeeb), the first interchangeable biosimilar to Soliris \n(eculizumab), to treat people...', 'thumbnail': 'https://serpapi.com/searches/6723eb3d7ef9fa2958e91daf/images/2fbaeefaa1b7375e82bc7a02781913d3d26e51ff7805f8a5d3e99afa143304cc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7452104091644287}",,,,,,,,,,['neutral'],neutral,1
NCT00574288,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/characteristics-myeloma-disease-may-impact-exposure-darzalex-study-reports/', 'title': 'Type of Multiple Myeloma May Affect Responses to Darzalex, Study Finds', 'source': 'Myeloma Research News', 'date': 'Oct 20, 2017', 'snippet': 'A new study reports that the specific type of multiple myeloma (MM) may \naffect how long the drug Darzalex (daratumumab) remains in circulation.', 'thumbnail': 'https://serpapi.com/searches/6723eb562e33c8091375f2c8/images/7ccc8a302396d57752c55cd9ba5fe19a1ccdf8e5964bb054a1fb94e522e4b9f5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8073411583900452}",,,,,,,,,,['neutral'],neutral,1
NCT02881177,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-99957-8', 'title': 'Oxytocin increases physiological linkage during group therapy for methamphetamine use disorder: a randomized clinical trial', 'source': 'Nature', 'date': 'Oct 25, 2021', 'snippet': 'Patients and psychotherapists often exhibit behavioral, psychological, and \nphysiological similarity. Here, we test whether oxytocin—a...', 'thumbnail': 'https://serpapi.com/searches/6723ec63708e2e68f4830db4/images/708812dc56981c470c873a93a4f9ba518f64785eda3c8cea67b96ddca7442bc4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6083284616470337}",,,,,,,,,,['neutral'],neutral,1
NCT05397041,"{'position': 1, 'link': 'https://dravetsyndromenews.com/news/dosing-begins-phase-1-trial-dravet-therapy-bmb-101/', 'title': 'Dosing Begins In Phase 1 Trial of Bright Minds’ BMB-101 for Dravet', 'source': 'Dravet Syndrome News', 'date': 'Sep 6, 2022', 'snippet': 'BMB-101 is an orally available serotonergic medication, a class that \nmodulate pathways associated with the signaling chemical serotonin.', 'thumbnail': 'https://serpapi.com/searches/6723ec68b6ed33e205757a63/images/f94749bdf013d9fb4908079f94cc4c8eba29f5508405e53e1b4ed7ca96cc20f6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.872501790523529}","{'position': 2, 'link': 'https://dravetsyndromenews.com/news/serotonin-agonist-bmb-101-safe-well-tolerated-healthy-adults/', 'title': 'Serotonin agonist BMB-101 found safe, well-tolerated in healthy adults', 'source': 'Dravet Syndrome News', 'date': 'Aug 8, 2023', 'snippet': 'BMB-101, an oral serotonin agonist being developed by Bright Minds \nBiosciences for the treatment of Dravet syndrome and other forms of \nepilepsy, was found to...', 'thumbnail': 'https://serpapi.com/searches/6723ec68b6ed33e205757a63/images/f94749bdf013d9fbd7dc57531efb7c694ba21eb38c7db53e75e683e1173c60b4.png', 'sentiment': 'positive', 'sentiment_prob': 0.707444965839386}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT01147250,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1509225', 'title': 'Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome', 'source': 'The New England Journal of Medicine', 'date': 'Dec 3, 2015', 'snippet': 'Lixisenatide, a once-daily GLP-1–receptor agonist, is effective in reducing \nthe glycated hemoglobin level in patients with type 2 diabetes.', 'thumbnail': 'https://serpapi.com/searches/6723ec7ff9338828f2fba762/images/2e91becad5f42f85e03046467a05c9b02d22a4310dab2efb0d371d098a7bfa09.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7547563314437866}",,,,,,,,,,['neutral'],neutral,1
NCT00643201,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1302507', 'title': 'Oral Apixaban for the Treatment of Acute Venous Thromboembolism', 'source': 'The New England Journal of Medicine', 'date': 'Oct 13, 2017', 'snippet': 'In this randomized, double-blind study, we compared apixaban (at a dose of \n10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) \nwith...', 'thumbnail': 'https://serpapi.com/searches/6723ec914791c44bbf929587/images/581c12a58a5c91ae34600a3dc3907b5a1fd83c654958e6f9df08a3df8e7a7b2d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9214367270469666}",,,,,,,,,,['neutral'],neutral,1
NCT00377637,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1014460', 'title': 'Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis', 'source': 'The New England Journal of Medicine', 'date': 'Nov 17, 2011', 'snippet': 'We carried out a 36-month, randomized, double-blind, double-dummy, phase 3 \nstudy comparing oral mycophenolate mofetil (2 g per day) and oral...', 'thumbnail': 'https://serpapi.com/searches/6723ec96b9ab866692fd863a/images/ad61954f57d97180f0ef1b721c1697e338c555b63c2bdbbb4a4db3875b213971.png', 'sentiment': 'neutral', 'sentiment_prob': 0.874181866645813}",,,,,,,,,,['neutral'],neutral,1
NCT03748706,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/pti-125-fails-lower-csf-protein-levels-alzheimers-patients-phase-2-trial/', 'title': 'PTI-125 Fails to Lower Alzheimer’s Protein Levels in Phase 2 Trial', 'source': ""Alzheimer's News Today"", 'date': 'May 18, 2020', 'snippet': ""Cassava Sciences announced PTI-125 failed to significantly lower levels of \nAlzheimer's-relevant markers, a primary trial goal, and data are..."", 'thumbnail': 'https://serpapi.com/searches/6723ec945809e735fa49a04a/images/279084ab4bf2150dfc7bfd4c37cb9cec6cb30e850b8f2fcf1418012ca99d9db2.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6908381581306458}",,,,,,,,,,['negative'],negative,0
NCT02870972,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1716995', 'title': 'Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema', 'source': 'The New England Journal of Medicine', 'date': 'Jul 25, 2018', 'snippet': 'Hereditary angioedema is a life-threatening illness caused by mutations in \nthe gene encoding C1 inhibitor (also called C1 esterase...', 'thumbnail': 'https://serpapi.com/searches/6723ec9e360f4e0d8d27819d/images/759fe7ded13549ca4f6a59344bbc658d2c13d4aad59eeeb7f7c010da500f5333.png', 'sentiment': 'negative', 'sentiment_prob': 0.511378824710846}",,,,,,,,,,['negative'],negative,0
NCT01596140,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-022-00341-0', 'title': 'BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study | npj Precision Oncology', 'source': 'Nature', 'date': 'Feb 18, 2023', 'snippet': 'We performed a pooled analysis of four phase one studies evaluating the \nsafety and efficacy of vemurafenib monotherapy and vemurafenib combined \nwith targeted...', 'thumbnail': 'https://serpapi.com/searches/6723ec9fc024d1935d72d9c8/images/e32e8f23b37e52272032042f269c20bece3039a83aca83ba9450ee9bed26dc6d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9065907597541809}",,,,,,,,,,['neutral'],neutral,1
NCT01030861,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1902226', 'title': 'An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Jun 9, 2019', 'snippet': 'We conducted a phase 2, randomized, placebo-controlled, double-blind trial \nof teplizumab (an Fc receptor–nonbinding anti-CD3 monoclonal antibody) \ninvolving...', 'thumbnail': 'https://serpapi.com/searches/6723eb80b6a79cfdeda5bc19/images/e9b54e4f9508c9bded9758438422fe818d8745362cb6ff80114b859cb2da4810.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8965128660202026}","{'position': 2, 'link': 'https://www.empr.com/home/news/tzield-approved-to-delay-onset-of-stage-3-type-1-diabetes/', 'title': 'Tzield Approved to Delay Onset of Stage 3 Type 1 Diabetes', 'source': 'Medical Professionals Reference', 'date': 'Nov 18, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved the Biologics License \nApplication (BLA) for Tzield (teplizumab-mzwv) to delay the onset of stage \n3 type 1...', 'thumbnail': 'https://serpapi.com/searches/6723eb80b6a79cfdeda5bc19/images/e9b54e4f9508c9bd9ba1da523deb23d245eca11dd61ff59c56a896a64c62de37.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9044457077980042}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02733042,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/fda-halts-imfinzi-combination-trials-after-unexplained-keytruda-related-deaths/', 'title': 'FDA Halts Imfinzi Combination Trials After Unexplained Keytruda-related Deaths', 'source': 'Myeloma Research News', 'date': 'Sep 8, 2017', 'snippet': ""The U.S. Food and Drug Administration (FDA) suspended a Phase 1 clinical \ntrial testing a combination of AstraZeneca's Imfinzi (durvalumab)..."", 'thumbnail': 'https://serpapi.com/searches/6723eb831234579518e2985e/images/fe06c6d032804674677ae2249df2216e305b0e754768aae7d748bc2bcb56b916.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5682772994041443}",,,,,,,,,,['negative'],negative,0
NCT02551094,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1912388', 'title': 'Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction', 'source': 'The New England Journal of Medicine', 'date': 'Nov 16, 2019', 'snippet': 'Experimental and clinical evidence supports the role of inflammation in \natherosclerosis and its complications. Colchicine is an orally...', 'thumbnail': 'https://serpapi.com/searches/6723eb8668831ef2f63f5666/images/da361e3ecd530af35aa6e27009dbbb356d2581af8d3f1c795cd99a1da9fd1a9b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.80702805519104}",,,,,,,,,,['neutral'],neutral,1
NCT05573568,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20221104005328/en/Biomind-Labs-Announces-Positive-Initial-Results-From-Its-Phase-II-Trial-on-Its-BMND01-Candidate-for-Treatment-Resistant-Depression', 'title': 'Biomind Labs Announces Positive Initial Results From Its Phase II Trial on Its BMND01 Candidate for Treatment Resistant Depression', 'source': 'Business Wire', 'date': 'Nov 4, 2022', 'snippet': 'Biomind Labs is developing novel pharmaceutical formulations of the main \npsychedelic molecules DMT, 5-MeO-DMT and mescaline for treating a wide \nrange of...', 'thumbnail': 'https://serpapi.com/searches/6723eb8cc7d4a1b45b719eec/images/33eb91861e69af637729e310065e4c9acdd3f0eee49a36bc2267f1245d0bd77e.png', 'sentiment': 'positive', 'sentiment_prob': 0.5965028405189514}",,,,,,,,,,['positive'],positive,1
NCT02892149,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2025956', 'title': 'Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis', 'source': 'The New England Journal of Medicine', 'date': 'Apr 28, 2021', 'snippet': 'We conducted two randomized, open-label, noninferiority phase 3 trials to \nevaluate the safety and efficacy of vadadustat, as compared with...', 'thumbnail': 'https://serpapi.com/searches/6723ebacd0d7e3f792a15e6c/images/244d797c72379de53ce2f3791273006daf2d908518bab0ec3f8ac5a572a15639.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8818969130516052}",,,,,,,,,,['neutral'],neutral,1
NCT04542499,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/abbvies-8-2bn-parkinsons-disease-drug-shines-in-phase-iii-trial/', 'title': 'AbbVie’s acquired Parkinson’s disease drug shines in Phase III trial', 'source': 'Clinical Trials Arena', 'date': '1 month ago', 'snippet': ""The Phase III TEMPO-1 trial enrolled 529 adults, between the ages of 40 and \n80, diagnosed with Parkinson's for less than three years."", 'thumbnail': 'https://serpapi.com/searches/6723ebbd2da98353c6208f14/images/e49c281f663549c404a2a4f4ea0ad75f38204d225c114a7e8e0d6f5d62fe9ae4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8078458905220032}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/parkinsons-motor-symptoms-improve-tavapadon-phase-3-clinical-trial/', 'title': ""Parkinson's motor symptoms improve with tavapadon in Phase 3 clinical trial"", 'source': ""Parkinson's News Today"", 'date': '1 month ago', 'snippet': ""The TEMPO-1 study tested the efficacy, safety, and tolerability of \ntavapadon to assess changes in the severity of Parkinson's motor..."", 'thumbnail': 'https://serpapi.com/searches/6723ebbd2da98353c6208f14/images/e49c281f663549c4f95785e14dfcc05f86ee6345565464c16f374afa30bbe916.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6867958307266235}","{'position': 3, 'link': 'https://parkinsonsnewstoday.com/news/phase-3-trials-tavapadon-parkinsons-motor-symptoms-near-end/', 'title': 'Phase 3 trials of oral tavapadon in easing motor symptoms nearing end', 'source': ""Parkinson's News Today"", 'date': 'Nov 7, 2023', 'snippet': 'An ongoing and global Phase 3 clinical trial program for oral tavapadon, a \nselective dopamine receptor agonist aiming to improve motor function in \npeople with...', 'thumbnail': 'https://serpapi.com/searches/6723ebbd2da98353c6208f14/images/e49c281f663549c473733b0c221fe9b0fae1acb194b4c0511e88e2738984a3ed.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8008778691291809}","{'position': 4, 'link': 'https://www.clinicaltrialsarena.com/features/trials-to-watch-parkinsons-disease/', 'title': 'Trials to watch: Pipeline Parkinson’s drugs could revolutionise treatment', 'source': 'Clinical Trials Arena', 'date': 'Oct 17, 2023', 'snippet': ""Patients with Parkinson's disease could be given more hope as a number of \npipeline drugs are looking to tackle a variety of unmet needs."", 'thumbnail': 'https://serpapi.com/searches/6723ebbd2da98353c6208f14/images/e49c281f663549c41407b19f4472569cb05d9e7f2159b733a6269bfd38207758.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8619078993797302}","{'position': 5, 'link': 'https://parkinsonsnewstoday.com/news/add-on-tavapadon-eases-symptoms-late-parkinsons-data-show/', 'title': 'Add-on tavapadon eases symptoms in late Parkinson’s, data show', 'source': ""Parkinson's News Today"", 'date': 'Apr 26, 2024', 'snippet': ""Six months of tavapadon as an add-on to levodopa significantly eased \ndyskinesia in late-stage Parkinson's, per top-line data from a study."", 'thumbnail': 'https://serpapi.com/searches/6723ebbd2da98353c6208f14/images/e49c281f663549c4d9ebbce5221fa376c604e52ad9dc1ac320a5d74ab00c226d.png', 'sentiment': 'positive', 'sentiment_prob': 0.5423953533172607}",,,,,,"['neutral', 'neutral', 'neutral', 'positive', 'positive']",neutral,1
NCT02531438,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1800201', 'title': 'Omadacycline for Community-Acquired Bacterial Pneumonia', 'source': 'The New England Journal of Medicine', 'date': 'Feb 6, 2019', 'snippet': 'Omadacycline, a new once-daily aminomethylcycline antibiotic agent that can \nbe administered intravenously or orally, reaches high...', 'thumbnail': 'https://serpapi.com/searches/6723ebd34e9efc5aa2bbea8b/images/77e8a649ea65cde5247a02ff4149b7ce6f8a21bb8e3b06ef975c4e937f902a6d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.873505175113678}","{'position': 2, 'link': 'https://pneumoniaresearchnews.com/2017/06/08/paratek-says-omadacycline-shows-punch-against-drug-resistant-pneumonia/', 'title': 'Omadacycline Shows Punch Against Drug-Resistant Bacteria, Studies Indicate', 'source': 'Pneumonia Research News', 'date': 'Jun 8, 2017', 'snippet': 'Read about studies indicating that the antibiotic omadacycline has shown \npunch against drug-resistant respiratory bacteria that cause...', 'thumbnail': 'https://serpapi.com/searches/6723ebd34e9efc5aa2bbea8b/images/77e8a649ea65cde5d35655b62bc676148d79158b6178d78aab3ae4ff7e9c4116.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8464609980583191}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03284424,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2020/06/26/fda-approves-keytruda-treatment-advanced-squamous-cell-skin-cancer/', 'title': 'FDA Approves Keytruda for Advanced Squamous Cell Skin Cancer', 'source': 'Immuno-Oncology News', 'date': 'Jun 26, 2020', 'snippet': 'The US Food and Drug Administration (FDA) has approved Keytruda \n(pembrolizumab) as a treatment for people with recurrent or metastatic \ncutaneous squamous cell...', 'thumbnail': 'https://serpapi.com/searches/6723ebf193bb5713f02df4a8/images/4f449ea20fb15f88004f08430e04fcbb5e18aa00b2b7a1c3f5091d04591ad2ef.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7842790484428406}",,,,,,,,,,['neutral'],neutral,1
NCT04209634,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-greenlights-veopoz-the-first-treatment-for-chaple-disease/', 'title': 'FDA Greenlights Veopoz, the First Treatment for CHAPLE Disease', 'source': 'Medical Professionals Reference', 'date': 'Aug 21, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Veopoz™ \n(pozelimab-bbfg) for the treatment of adult and pediatric patients 1 year \nof age...', 'thumbnail': 'https://serpapi.com/searches/6723ec16d78a98c21a5e27f0/images/097adef8310ff1aae38ee1f6602128b48469d21c96a37b4e611a08fe3c03d6b7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.609762966632843}",,,,,,,,,,['neutral'],neutral,1
NCT02408549,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Vimpat-lacosamide', 'title': 'Lacosamide (Vimpat®)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Epilepsy, A Study to Evaluate the Efficacy and Safety of Adjunctive Therapy \nWith Lacosamide in Adults With Partial Onset Seizures, Phase 3...', 'thumbnail': 'https://serpapi.com/searches/6723ec2c708e2e68f4830da5/images/2663d44999db29cc837c223b833c49a0d70f2ccec87e1457bdd4847057bc4922.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9128645658493042}",,,,,,,,,,['neutral'],neutral,1
NCT04493541,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/phase-2-trial-oral-afimetoran-for-sle-now-underway-formerly-bms-986256/', 'title': 'Phase 2 Trial of Oral Afimetoran for SLE Now Underway |...', 'source': 'Lupus News Today', 'date': 'Aug 29, 2022', 'snippet': 'A Phase 1 trial assessing the safety of afimetoran (BMS-986256) in up to 24 \nadults with active cutaneous lupus erythematosus is also...', 'thumbnail': 'https://serpapi.com/searches/6723ec399819f39cba455e2f/images/5d457abe726028a1c9e4844da454340f4bd9390d38eccd30deab4f4723927e41.png', 'sentiment': 'neutral', 'sentiment_prob': 0.906686007976532}",,,,,,,,,,['neutral'],neutral,1
NCT02719691,"{'position': 1, 'link': 'https://www.onclive.com/view/the-role-of-mtor-aurora-a-kinase-combination-therapy-requires-further-elucidation-in-solid-tumors', 'title': 'The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors', 'source': 'OncLive', 'date': 'Jul 5, 2024', 'snippet': 'S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib \nand Aurora A kinase inhibitor alisertib in patients with solid...', 'thumbnail': 'https://serpapi.com/searches/6723ec3edda9d9c73b31cd63/images/3034977a59a3271faf3eee02096138f0b9b6502cee9562123e524f2515b2475a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9422652721405029}",,,,,,,,,,['neutral'],neutral,1
NCT01622933,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-42881-4', 'title': 'Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients', 'source': 'Nature', 'date': 'Nov 8, 2023', 'snippet': 'Efficacy of cancer vaccines remains low and mechanistic understanding of \nantigen presenting cell function in cancer may improve vaccine...', 'thumbnail': 'https://serpapi.com/searches/6723ecb11fc7c5f7684d2ab7/images/0deb6129d4373c997a93231826fb0ac78955ac3aceb4a45d239d72a3dbd42a70.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7334927320480347}",,,,,,,,,,['neutral'],neutral,1
NCT02644278,"{'position': 1, 'link': 'https://www.nature.com/articles/s41388-020-1250-3', 'title': 'Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizer', 'source': 'Nature', 'date': 'Mar 10, 2020', 'snippet': 'This review discusses the clinical criteria for radiation resistance in \npatients with head and neck cancer and summarizes how cancer cells evade \nradiation-...', 'thumbnail': 'https://serpapi.com/searches/6723eccc1fc7c5f7684d2ac0/images/41bfa3066de47fd678f84a35828618ab03194e61b124915ffa27d6ca64387786.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6196272969245911}","{'position': 2, 'link': 'https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00762', 'title': 'BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies', 'source': 'ACS Publications', 'date': 'Aug 24, 2021', 'snippet': 'In in vitro studies, BAY-8400 showed synergistic activity of DNA-PK \ninhibition with DNA damage-inducing targeted alpha therapy.', 'thumbnail': 'https://serpapi.com/searches/6723eccc1fc7c5f7684d2ac0/images/41bfa3066de47fd6d905c29a07d6792ff7016c642a7f54d2f1f32d482eb9cd66.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7920029163360596}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02954887,"{'position': 1, 'link': 'https://dravetsyndromenews.com/news/epidiolex-being-tested-in-dravet-seen-in-phase-3-trial-in-lgs-patients-to-lessen-drop-seizures/', 'title': 'Epidiolex, Being Tested in Dravet Patients, Seen in Phase 3 Trial to Lessen Drop Seizures in LGS', 'source': 'Dravet Syndrome News', 'date': 'Feb 15, 2018', 'snippet': 'Epidiolex by GW Pharmaceuticals, a cannabis-based therapy under testing in \nDravet patients, showed benefit in a Phase 3 trial in...', 'thumbnail': 'https://serpapi.com/searches/6723eccf1adaf4a8dc0ea8c6/images/22e61d54a4c580d66212b50a234f619b05a670bd6a98165dd3ea8ccb5e39ac1e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.660070538520813}",,,,,,,,,,['neutral'],neutral,1
NCT04599972,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-qlosi-for-presbyopia-in-adults/', 'title': 'FDA Approves Qlosi for the Treatment of Presbyopia in Adults', 'source': 'Medical Professionals Reference', 'date': 'Oct 19, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Qlosi™ (pilocarpine \nhydrochloride ophthalmic solution) 0.4% for the treatment of...', 'thumbnail': 'https://serpapi.com/searches/6723ecfc75f974110b4e77a3/images/a8bc3d2d496111838b9cb50169f4cecc9abff94087b9e670b6f2952fa7b56523.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6376069784164429}",,,,,,,,,,['neutral'],neutral,1
NCT04058158,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/jha2.632', 'title': 'A phase III, randomised, double‐blind, multi‐national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria - Jang - 2023 - eJHaem', 'source': 'Wiley Online Library', 'date': 'Dec 20, 2022', 'snippet': 'This randomised, double-blind, multi-national cross-over Phase III study in \nPNH patients aimed to demonstrate the equivalence of the proposed \neculizumab...', 'thumbnail': 'https://serpapi.com/searches/6723ed11ecf15028b3d55d5a/images/0a0363b7ac5a5d4095c0cbc718c88a68ecef990e7ceca3684f0bceab11b98166.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8888051509857178}","{'position': 2, 'link': 'https://www.pharmalive.com/fda-approves-samsung-bioepis-epysqli-as-a-biosimilar-to-soliris/', 'title': 'FDA approves Samsung Bioepis’ EPYSQLI as a biosimilar to Soliris', 'source': 'PharmaLive', 'date': 'Jul 22, 2024', 'snippet': 'The US Food and Drug Administration (FDA) has approved the Biologics \nLicense Application (BLA) for EPYSQLI (eculizumab-aagh) as a biosimilar to \nSoliris.', 'thumbnail': 'https://serpapi.com/searches/6723ed11ecf15028b3d55d5a/images/0a0363b7ac5a5d40a2ea59b67628245100468e5237b46c7937eeddb5fab18117.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7531968355178833}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00056368,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa066906', 'title': 'Anidulafungin versus Fluconazole for Invasive Candidiasis', 'source': 'The New England Journal of Medicine', 'date': 'May 4, 2018', 'snippet': 'We compared anidulafungin with fluconazole in a randomized, double-blind, \nnoninferiority trial of treatment for invasive candidiasis.', 'thumbnail': 'https://serpapi.com/searches/6723ed24671f3f496c1121b3/images/33698884f1945ee410c2b740c9fba2df6c0de684b39b92e64e614c7a9b9671ae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9005207419395447}",,,,,,,,,,['neutral'],neutral,1
NCT02228850,"{'position': 1, 'link': 'https://raynaudsnews.com/2017/04/10/apricus-to-advance-raynauds-treatment-rayva-phase-2b-trial/', 'title': 'Apricus Advancing RayVa to Phase 2b Trial for Raynaud’s Treatment', 'source': 'Raynaud News', 'date': 'Apr 10, 2017', 'snippet': ""Read about how Apricus Biosciences plans to initiate a Phase 2b trial \nevaluating its RayVa (alprostadil) ointment to treat Raynaud's..."", 'thumbnail': 'https://serpapi.com/searches/6723ed2721b01bd6003108ee/images/af03ced92e4c9ef0179854531322de0f5af763d6db82fc2cee8c195f19230aa4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9262201189994812}",,,,,,,,,,['neutral'],neutral,1
NCT01663402,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1801174', 'title': 'Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome', 'source': 'The New England Journal of Medicine', 'date': 'Nov 7, 2018', 'snippet': 'We sought to determine whether alirocumab, a human monoclonal antibody to \nproprotein convertase subtilisin–kexin type 9 (PCSK9), would improve \ncardiovascular...', 'thumbnail': 'https://serpapi.com/searches/6723ed31e9b6914d2fbe79ce/images/aaaa23a9b9553d933b7fdad7a255f8cff6e2fab9897c4567a789779e370e56a8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9103638529777527}",,,,,,,,,,['neutral'],neutral,1
NCT00593450,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1102673', 'title': 'Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration', 'source': 'The New England Journal of Medicine', 'date': 'Apr 28, 2011', 'snippet': 'Clinical trials have established the efficacy of ranibizumab for the \ntreatment of neovascular age-related macular degeneration (AMD).', 'thumbnail': 'https://serpapi.com/searches/6723ed41a5aae9313a6bad13/images/7dc62b06bba232ceb1a0834508c2383f6b924e92a5ed5e025c7e99de13ea17c4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6410437822341919}",,,,,,,,,,['neutral'],neutral,1
NCT04057573,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20230705273477/en/MHRA-Grants-Marketing-Authorisation-for-Opzelura%C2%AE-ruxolitinib-Cream-for-the-Treatment-of-Non-Segmental-Vitiligo-with-Facial-Involvement-in-Adults-and-Adolescents', 'title': '(ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents', 'source': 'Business Wire', 'date': 'Jul 5, 2023', 'snippet': 'Opzelura® is the first approved treatment in the United Kingdom (UK) to \naddress repigmentation in non-segmental vitiligo...', 'thumbnail': 'https://serpapi.com/searches/6723ed620377562eb44f37c6/images/9776fc7825c007843cb2aa7051d02f9a8584ab05583e5ba52eaee8b3e798af65.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8357210159301758}",,,,,,,,,,['neutral'],neutral,1
NCT02676869,"{'position': 1, 'link': 'https://melanomanewstoday.com/2017/04/25/imp321-keytruda-combo-trial-last-patient-cohort/', 'title': 'IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group', 'source': 'Melanoma News Today', 'date': 'Apr 25, 2017', 'snippet': ""Read about the approval for the third cohort of a Phase 1 melanoma trial \nassessing the combination of Prima Biomed's IMP321 and Keytruda."", 'thumbnail': 'https://serpapi.com/searches/6723ed874791c44b726c20ff/images/968a6b5bff41a4942f3f5393b2b3ab7d285bbf2209ba4b10b7a39c55158ed7f9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8649411201477051}",,,,,,,,,,['neutral'],neutral,1
NCT04003389,"{'position': 1, 'link': 'https://www.empr.com/home/news/veozah-approved-for-moderate-to-severe-vasomotor-symptoms-due-to-menopause/', 'title': 'Veozah Approved for Moderate to Severe Vasomotor Symptoms Due to Menopause', 'source': 'Medical Professionals Reference', 'date': 'May 15, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Veozah™ (fezolinetant) \nfor the treatment of moderate to severe vasomotor symptoms due to...', 'thumbnail': 'https://serpapi.com/searches/6723ed897ca6b38026f051fe/images/8359209662b3cdc60e1566c40d8ddd364bace2e5c97aec2ee01e43007893ca36.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7814399600028992}",,,,,,,,,,['neutral'],neutral,1
NCT05133323,"{'position': 1, 'link': 'https://www.patientcareonline.com/view/lundbeck-moves-pacap-targeting-antibody-into-multinational-phase-2b-clinical-trial', 'title': 'Lundbeck Moves PACAP-Targeting Antibody into Multinational Phase 2b Clinical Trial', 'source': 'Patient Care Online', 'date': 'Mar 18, 2024', 'snippet': 'PROCEED will assess the efficacy and safety of the PACAP antagonist as a \nmigraine preventive in individuals who have failed to get relief...', 'thumbnail': 'https://serpapi.com/searches/6723eda62a7727c51fde5ab8/images/4d61f1269333c7a51168974579b9651d1cb93dd98f7438fcb2f79361f7cf39a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8799661993980408}","{'position': 2, 'link': 'https://www.mayoclinicproceedings.org/article/S0025-6196(23)00332-4/fulltext', 'title': 'Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside', 'source': 'Mayo Clinic Proceedings', 'date': 'Jan 4, 2024', 'snippet': 'Migraine is a ubiquitous neurologic disorder that afflicts more than 1 \nbillion people worldwide. Recommended therapeutic strategies include...', 'thumbnail': 'https://serpapi.com/searches/6723eda62a7727c51fde5ab8/images/4d61f1269333c7a552736b1302b0667a9dec9bce09464b3afd3eb3cc09fc3140.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7042643427848816}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04233424,"{'position': 1, 'link': 'https://www.manilatimes.net/2024/10/21/tmt-newswire/globenewswire/polypid-announces-publication-in-international-journal-of-surgery-highlighting-results-of-phase-3-shield-i-trial-of-d-plex-in-prevention-of-surgical-site-infections-in-abdominal-colorectal-surgery/1988141', 'title': 'PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery', 'source': 'The Manila Times', 'date': '1 week ago', 'snippet': 'SHIELD I Study is One of the Largest Phase 3 Trials in the Prevention of \nSSIs in Colorectal Resection Conducted in Over a Decade.', 'thumbnail': 'https://serpapi.com/searches/6723edc807c7bee5ae616b8d/images/39ce0603430a1cb77085381df24abd93fe0666622cb479ee0e7bfb310ff9e8a6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.880541980266571}",,,,,,,,,,['neutral'],neutral,1
NCT02200614,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1815671', 'title': 'Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Feb 14, 2019', 'snippet': 'We conducted a randomized, double-blind, placebo-controlled, phase 3 trial \ninvolving men with nonmetastatic, castration-resistant prostate...', 'thumbnail': 'https://serpapi.com/searches/6723edcd690121692ff140ee/images/4e15e243bf7e66bab9228a9695f8f3ae24a3767773c7391447b2c3c64c468ef8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8830628395080566}","{'position': 2, 'link': 'https://www.onclive.com/view/adt-plus-darolutamide-is-associated-with-lower-rates-of-psa-progression-in-nmcrpc', 'title': 'ADT Plus Darolutamide Is Associated With Lower Rates of PSA Progression in nmCRPC', 'source': 'OncLive', 'date': 'Aug 29, 2024', 'snippet': 'Alicia Morgans, MD, MPH, discusses the use of ADT in combination with \ndarolutamide or placebo in nonmetastatic castration-resistant prostate...', 'thumbnail': 'https://serpapi.com/searches/6723edcd690121692ff140ee/images/4e15e243bf7e66baa8dd1014b502ce7c64bf71104b865efb3e40c914a3c1daca.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.908994734287262}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03179631,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/european-committee-not-favor-renewing-translarna-approval/', 'title': 'European committee not in favor of renewing Translarna’s approval', 'source': 'Muscular Dystrophy News', 'date': 'Feb 1, 2024', 'snippet': 'A European committee, known as the CHMP, has maintained its recommendation \nnot to renew the conditional approval of Translarna for DMD.', 'thumbnail': 'https://serpapi.com/searches/6723edd4bcd652fc3b3dc9fa/images/2cc0b1b3a49744ce9247ef7b74c25519e001d8c023c6fa20bacf0f0266e35b99.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6303384900093079}","{'position': 2, 'link': 'https://musculardystrophynews.com/news/exon-skipping-dominates-duchenne-gene-therapy-horizon/', 'title': 'Exon Skipping Dominates DMD Treatment, But What’s on Horizon?', 'source': 'Muscular Dystrophy News', 'date': 'Feb 25, 2021', 'snippet': 'Amondys 45 is the fourth exon-skipping therapy available in the U.S. for \neligible patients, and two gene therapies are in testing.', 'thumbnail': 'https://serpapi.com/searches/6723edd4bcd652fc3b3dc9fa/images/2cc0b1b3a49744ce5c605396ac58c0b879cbb30ee8f763e91f5fae20c7712991.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9107903838157654}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03248531,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/bimekizumab-UCB4940', 'title': 'Bimekizumab (Bimzelx®)', 'source': 'UCB', 'date': 'Oct 16, 2018', 'snippet': 'Ankylosing Spondylitis, A Multicenter Study to Evaluate the Efficacy and \nSafety of Different Doses of Bimekizumab in Subjects With Active \nAnkylosing...', 'thumbnail': 'https://serpapi.com/searches/6723edd7db3ac9f357ce4c2f/images/a0a69ddde1295212e230eaedc525e1b9ee111fdd0aae7e38ee151479769a5d66.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8456552028656006}",,,,,,,,,,['neutral'],neutral,1
NCT04318704,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/new-trial-np-120-chronic-cough-planned-ipf-delayed/', 'title': 'New Trial for NP-120 in Chronic Cough Planned, IPF Study Delayed', 'source': 'Pulmonary Fibrosis News', 'date': 'Jan 10, 2023', 'snippet': 'Algernon is planning a Phase 2b clinical trial of NP-120 (ifenprodil) in \ntreating chronic cough, but postponing its testing in IPF patients.', 'thumbnail': 'https://serpapi.com/searches/6723ee02a88278e9fc574d1d/images/68f1caa809c3d835ae22fdd05571031a33b9b9f92795610a897d887d0b7e796c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7561503052711487}",,,,,,,,,,['neutral'],neutral,1
NCT03440814,"{'position': 1, 'link': 'https://praderwillinews.com/news/children-switch-dccr-placebo-worsening-hyperphagia-trial/', 'title': 'PWS children who switch from DCCR see worsening hyperphagia: Trial', 'source': 'Prader-Willi Syndrome News', 'date': 'Oct 5, 2023', 'snippet': 'PWS patients who switched from daily treatment with DCCR (diazoxide choline \nextended-release tablets) to a placebo experienced worsening excessive \nhunger, or...', 'thumbnail': 'https://serpapi.com/searches/6723ee1cfab27313b26fb84b/images/cc4eecc221972a3159308a9003ac8f9c1ae86ce75437378450dc63d1af755f36.png', 'sentiment': 'neutral', 'sentiment_prob': 0.565572202205658}","{'position': 2, 'link': 'https://praderwillinews.com/news/dccr-efficacy-hyperphagia-destiny-pws-interview-soleno-jennifer-miller/', 'title': 'DCCR Shows ‘Life-changing’ Potential in Troubled Trial, Doctor Says in Interview', 'source': 'Prader-Willi Syndrome News', 'date': 'Jun 1, 2021', 'snippet': 'A DESTINY PWS investigator says diazoxide choline controlled release \ntablets show potential to ease both Prader-Willi hunger and behaviors.', 'thumbnail': 'https://serpapi.com/searches/6723ee1cfab27313b26fb84b/images/cc4eecc221972a3109be6b685f5add75e34a824898fb9404eb389d5d4ee6e4c9.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5544370412826538}","{'position': 3, 'link': 'https://praderwillinews.com/news/new-phase-dccr-trial-could-aid-regulatory-approval-request/', 'title': 'New Phase of DCCR Trial for PWS May Aid Regulatory Approval Request', 'source': 'Prader-Willi Syndrome News', 'date': 'Oct 14, 2022', 'snippet': 'A randomized withdrawal period in the ongoing open-label extension trial of \nDCCR (diazoxide choline extended-release tablets) for people with \nPrader-Willi...', 'thumbnail': 'https://serpapi.com/searches/6723ee1cfab27313b26fb84b/images/cc4eecc221972a31dd272a743a651dbc365a6334ba22f74325710b54fc316110.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9110457897186279}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT04435665,"{'position': 1, 'link': 'https://www.science.org/doi/10.1126/sciadv.adk4946', 'title': 'Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1', 'source': 'Science | AAAS', 'date': 'May 1, 2024', 'snippet': 'This phase 2a trial investigated the efficacy of NFX-179 Topical Gel, a \nmetabolically labile MEK inhibitor, in the treatment of cutaneous \nneurofibromas (cNFs)...', 'thumbnail': 'https://serpapi.com/searches/6723ee5981262ab5dba9992b/images/2058f93217ad322d11e6d1368cdbb41f256f32033f46840dfdba05dc2c479fee.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8717843294143677}",,,,,,,,,,['neutral'],neutral,1
NCT05101109,"{'position': 1, 'link': 'http://m.biospectator.com/view/news_view.php?varAtcId=15561', 'title': '‘Turning point’ of ABL, T cell engager is “the reason to be confident”', 'source': '바이오스펙테이터', 'date': 'Feb 18, 2022', 'snippet': ""ABL Bio is confident in the 'best-in-class' of the 4-1BB bispecific \nantibody, and is setting up a strategy for positioning each project in a \ncompetitive..."", 'thumbnail': 'https://serpapi.com/searches/6723eea7272a87e7a64f8d4e/images/2dcf8fe8a52868ea538abca6383da7fc47dbd45b71d40ffdec8ead6d382089ce.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8598195314407349}",,,,,,,,,,['positive'],positive,1
NCT03453619,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/apellis-to-stop-developing-apl-2-for-lupus-nephritis-after-phase-2-trial/', 'title': 'Apellis to Stop Developing APL-2 for Lupus Nephritis After Phase 2 Trial', 'source': 'Lupus News Today', 'date': 'Oct 21, 2019', 'snippet': 'Apellis Pharmaceuticals has decided to stop the development of APL-2 for \nlupus nephritis after the completion of an ongoing Phase 2 clinical...', 'thumbnail': 'https://serpapi.com/searches/6723eeddf60b6f691fb48eae/images/e4607cfd47389c132cbe59a9281c88376dc60b3570a04806eadddfc410c19019.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5071778297424316}",,,,,,,,,,['neutral'],neutral,1
NCT01657162,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Disposition-of-patients-in-ACTIVExtend-extension-trial-of-the-Abaloparatide-Comparator_fig1_313265181', 'title': 'FIGURE 1. Disposition of patients in ACTIVExtend (extension trial of...', 'source': 'ResearchGate', 'date': 'Mar 15, 2020', 'snippet': 'To assess the efficacy and safety of 18 months of subcutaneous \nabaloparatide (ABL-SC) or placebo (PBO) followed by 6 months of alendronate \n(ALN)', 'thumbnail': 'https://serpapi.com/searches/6723ef2fb2ebaec178350856/images/725c90dc74d48b1ef0cebfb2af4855f8f9c62af0c15561294acf680f22732eaa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8821626305580139}",,,,,,,,,,['neutral'],neutral,1
NCT00004074,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.01544/full', 'title': 'Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy', 'source': 'Frontiers', 'date': 'Feb 10, 2024', 'snippet': '1Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; 2Department \nof Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain...', 'thumbnail': 'https://serpapi.com/searches/6723ef346a5dd3df5310b4aa/images/2948bd2e9e8d4265b3e18d675ec041535b262b52d062e816433590e3dd35f782.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9315255880355835}",,,,,,,,,,['neutral'],neutral,1
NCT02926937,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1238399/full', 'title': 'Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': 'BackgroundsThe safety of different sodium-glucose transporter 2 (SGLT-2) \ninhibitors remains uncertain due to the lack of head-to-head comparisons.', 'thumbnail': 'https://serpapi.com/searches/6723efbc72e5c4a7a613aba7/images/309e9006afe655f15cb465c57ed13e462eef246040c1093e6cafb239c5f8a739.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8960149884223938}",,,,,,,,,,['neutral'],neutral,1
NCT02006732,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20150817005379/en/New-data-show-Spiolto-Respimat-provides-meaningful-quality-of-life-improvements-in-COPD', 'title': 'New data show Spiolto Respimat provides meaningful quality of life improvements in COPD', 'source': 'Business Wire', 'date': 'Aug 17, 2015', 'snippet': 'Boehringer Ingelheim OTEMTO® trials show Spiolto® Respimat® provides \nclinically meaningful >4 point reduction in SGRQ score compared to...', 'thumbnail': 'https://serpapi.com/searches/6723efcdc0028ed39d6aad05/images/19618e78c6081c11d39167f73fee3b435280cca49367266735dc9aa59c1d0c8b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6147310137748718}",,,,,,,,,,['positive'],positive,1
NCT02001506,"{'position': 1, 'link': 'https://bydrug.pharmcube.com/news/detail/4f606be3faf2d4b6c8b2b867b501d95d', 'title': '【SABCS2015】AC4-D4对比FEC3-D3新辅助序贯化疗用于淋巴结阳性乳腺癌的随机Ⅲ期试验（Neo-Shorter）', 'source': 'ByDrug', 'date': 'Apr 16, 2024', 'snippet': '[P1-14-15] A randomized phase III trial of neoadjuvant sequential \nchemotherapy with 4 cycles of adriamycin plus cyclophosphamide followed by \n4 cycles of...', 'thumbnail': 'https://serpapi.com/searches/6723eff3a5e502a89cf98b13/images/79556814c0e3951ef9ffe94dcec9e9442174106f9bed2382f06d9f309556414e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9291498064994812}",,,,,,,,,,['neutral'],neutral,1
NCT00699998,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1205512', 'title': 'Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization', 'source': 'The New England Journal of Medicine', 'date': 'Aug 27, 2012', 'snippet': 'In this double-blind, randomized trial, in a primary analysis involving \n7243 patients under the age of 75 years receiving aspirin,...', 'thumbnail': 'https://serpapi.com/searches/6723f02c71b0e8d30badd7ba/images/1fd522ca82b7ea185c8692a6dfde9ac2537edba7a7c137f74f3698b151405ec1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.879413902759552}",,,,,,,,,,['neutral'],neutral,1
NCT02586155,"{'position': 1, 'link': 'https://ckdnews.com/2017/05/19/apabetalone-approved-for-phase-2-trial-on-end-stage-ckd-patients/', 'title': 'FDA Approves Design of Phase 2a Trial of Apabetalone for Kidney Disease Patients on Dialysis', 'source': 'CKD News', 'date': 'May 19, 2017', 'snippet': 'Find more about the new Phase 2 trial for chronic kidney disease undergoing \ndialysis conducted by Resverlogix to test is candidate drug...', 'thumbnail': 'https://serpapi.com/searches/6723f0615c7cb9c8be0142a3/images/61291308a29f8d6df537fd8b5cbfde0ca668f57fd6cfafb4c92bd13c85fc8622.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.850470244884491}",,,,,,,,,,['neutral'],neutral,1
NCT00002569,"{'position': 1, 'link': 'https://www.targetedonc.com/view/long-term-survival-possible-with-vincristine-plus-radiotherapy-in-anaplastic-oligodendroglial-tumors', 'title': 'Long-Term Survival Possible With Vincristine Plus Radiotherapy in Anaplastic Oligodendroglial Tumors', 'source': 'Targeted Oncology', 'date': 'Jun 30, 2022', 'snippet': 'Findings from 2 studies suggest that long-term survival is possible in a \nsignificant proportion of patients with a 1p/19q co-deleted...', 'thumbnail': 'https://serpapi.com/searches/6723f0657ebde5eeab2a0134/images/8eb596f0d3f4c5ba937d8c0fb6bf1bff9ba0db66ce119acb6d18bffe32b03523.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6290527582168579}",,,,,,,,,,['neutral'],neutral,1
NCT05117060,"{'position': 1, 'link': 'https://nationaleczema.org/blog/leo-121421/', 'title': 'LEO Pharma Initiates a Phase 2b Dose-Ranging Clinical Trial With an Oral H4R Antagonist in Adult Patients With Moderate-to-Severe Atopic Dermatitis (AD)', 'source': 'National Eczema Association', 'date': 'Jan 3, 2022', 'snippet': 'December 14, 2021 03:55 AM Eastern Standard Time. BALLERUP, \nDenmark–(BUSINESS WIRE)–LEO Pharma A/S, a global leader in medical \ndermatology,...', 'thumbnail': 'https://serpapi.com/searches/6723f07c7c1712ec9a29f99b/images/3bb2a481e2e8035bb91d2be12ed6b4e57c0c9b8842b7db7c8c2ec1ee39f5367c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9154162406921387}",,,,,,,,,,['neutral'],neutral,1
NCT04142125,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/STROKEAHA.123.043632', 'title': 'Randomized Secondary Prevention Trials in Participants With Symptomatic Intracranial Atherosclerotic Stenosis', 'source': 'American Heart Association Journals', 'date': 'Jan 22, 2024', 'snippet': 'This review focuses on randomized secondary prevention trials involving \nantithrombotic therapy, endovascular treatment, open surgical therapy, and \nremote...', 'thumbnail': 'https://serpapi.com/searches/6723f0987ebde5ee6bbf4531/images/260f3ae3d5666eb1e22c15e80c8142e65ab20c3f245904d9ba4ecbee30454e84.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9185848832130432}",,,,,,,,,,['neutral'],neutral,1
NCT02546921,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-39679-9', 'title': 'Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial', 'source': 'Nature', 'date': 'Jul 25, 2023', 'snippet': 'All antibodies approved for cancer therapy are monoclonal IgGs but the \nbiology of IgE, supported by comparative preclinical data, offers the...', 'thumbnail': 'https://serpapi.com/searches/6723f0a64677bf6b0eccaffd/images/80f8926597ca744b73ca3af1cc704a33635c99c819aa16af71cdd5d497c11ab6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8681574463844299}",,,,,,,,,,['neutral'],neutral,1
NCT02224703,"{'position': 1, 'link': 'https://dravetsyndromenews.com/news/cannabis-derived-epidiolex-cleared-for-clinical-trials-in-japan-to-treat-dravet-lennox-gastaut-syndromes/', 'title': 'Epidiolex Cleared for Dravet, Lennox-Gastaut Trials in Japan', 'source': 'Dravet Syndrome News', 'date': 'Mar 28, 2019', 'snippet': 'Japan has approved the cannabis compound Epidiolex for clinical trials in \nepileptic patients with Dravet and Lennox-Gastaut syndromes.', 'thumbnail': 'https://serpapi.com/searches/6723f0af059caf6568e06720/images/1be9f3a70a9348a7f0568fad00d5b3205402f7604299d196c2eeb978fd62e95f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8571611046791077}",,,,,,,,,,['neutral'],neutral,1
NCT02616874,"{'position': 1, 'link': 'https://www.nature.com/articles/s41421-024-00658-z', 'title': 'Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study | Cell Discovery', 'source': 'Nature', 'date': 'May 14, 2024', 'snippet': 'Our study supported the potential of M10 CAR-T cells as a novel, safe, and \neffective therapeutic option for the functional cure of HIV-1/AIDS.', 'thumbnail': 'https://serpapi.com/searches/6723f0bc657c66b440e30d42/images/4fe82b898d0f9fba2150cf08616ca4b17eb842d3cc5bf01183c0094a75bb6bf9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.512550950050354}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00418/full', 'title': 'In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial', 'source': 'Frontiers', 'date': 'Mar 19, 2020', 'snippet': 'Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor \napproved for the treatment of cutaneous T-cell lymphoma. in vitro and...', 'thumbnail': 'https://serpapi.com/searches/6723f0bc657c66b440e30d42/images/4fe82b898d0f9fba5b068931df562795edc2cc7e0b0644cabd80122d2ebe6c0d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8966920375823975}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00434148,"{'position': 1, 'link': 'https://cushingsdiseasenews.com/news/signifor-safe-effective-long-term-option-treat-cushings-disease/', 'title': 'Signifor May be Safe, Effective Option to Treat Cushing’s Long-term, Study Indicates', 'source': ""Cushing's Disease News"", 'date': 'Jul 21, 2017', 'snippet': 'Read about a clinical trial investigating the long-term safety and \neffectiveness of Signifor (pasireotide) treatment in patients with...', 'thumbnail': 'https://serpapi.com/searches/6723f100a9210b29e2f65296/images/d8ba64c5785f3981806fa05f3c062fdee5292ad3a4cf291b585b9090078e5dc1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.668583869934082}","{'position': 2, 'link': 'https://cushingsdiseasenews.com/news/cushings-patients-pituitary-tumor-shrinks-with-signifor-review/', 'title': ""Cushing's Patients' Pituitary Tumor Shrinks With Signifor: Review..."", 'source': ""Cushing's Disease News"", 'date': 'Aug 5, 2022', 'snippet': ""Signifor (pasireotide) sizably shrinks benign pituitary tumors in more than \n40% of Cushing's disease patients, according to a review study."", 'thumbnail': 'https://serpapi.com/searches/6723f100a9210b29e2f65296/images/d8ba64c5785f39816431a10f2d50be148e3aac73d9854e6bb832a051ccbace71.png', 'sentiment': 'neutral', 'sentiment_prob': 0.807914137840271}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03248427,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-024-00625-7', 'title': 'Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy | npj Breast Cancer', 'source': 'Nature', 'date': 'Mar 6, 2024', 'snippet': 'In this study, we performed genomic analyses of cell cycle and tumor \nmicroenvironment changes during and after ribociclib and letrozole or \nchemotherapy in the...', 'thumbnail': 'https://serpapi.com/searches/6723f10590adceb1fd426f64/images/6e56465692de528f56a6f0a9c5c057e6e25f8cbc31eb303967acadc31087ecbe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8755719661712646}",,,,,,,,,,['neutral'],neutral,1
NCT05285540,"{'position': 1, 'link': 'https://friedreichsataxianews.com/news/phase-1-friedreichs-ataxia-treatment-program-dt-216-track/', 'title': 'Phase 1 DT-216 Program for FA on Track; Initial Data Expected Soon', 'source': ""Friedreich's Ataxia News"", 'date': 'Nov 8, 2022', 'snippet': ""The Phase 1 clinical program of DT-216, Design Therapeutics' experimental \ntherapy for Friedreich's ataxia (FA), remains on track, with initial data \nexpected by..."", 'thumbnail': 'https://serpapi.com/searches/6723f12d207c88686f8a26ea/images/a636e559b87f6a2ecaa90c638c844ae90f2de971ee81f0b63abfa991edb4997d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8831232786178589}","{'position': 2, 'link': 'https://www.genengnews.com/topics/omics/stockwatch-illumina-results-leave-investors-analysts-anxious/', 'title': 'StockWatch: Illumina Results Leave Investors, Analysts Anxious', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Aug 17, 2023', 'snippet': ""Illumina's Q2 revenue rose nearly 1% from $1.162 billion to $1.172 billion, \nahead of company guidance and analyst estimates."", 'thumbnail': 'https://serpapi.com/searches/6723f12d207c88686f8a26ea/images/a636e559b87f6a2e624e14c49d54b8730161d2529b80357edb6b67fd7ca75e87.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6198692321777344}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT04932434,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/top-10-parkinsons-news-stories-bionews-published-2023/', 'title': 'Top 10 Parkinson’s stories of 2023', 'source': ""Parkinson's News Today"", 'date': 'Jan 2, 2024', 'snippet': ""Here are the 10 most widely read stories published in 2023 by Parkinson's \nNews Today, which reports on disease discoveries and developments."", 'thumbnail': 'https://serpapi.com/searches/6723f14faab36de63561a60e/images/ffffc5183f49259b21be7a54482a059a4b600fb01aef50e4e0adb083714c69fa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7124320864677429}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/psychedelic-psilocybin-clinical-trial-parkinsons-nears-end/', 'title': ""Psychedelic Psilocybin Clinical Trial in Parkinson's Nears End –..."", 'source': ""Parkinson's News Today"", 'date': 'Jan 12, 2023', 'snippet': ""A clinical trial testing low doses of psilocybin on inflammatory activity \nin Parkinson's patients will be complete by the end of February."", 'thumbnail': 'https://serpapi.com/searches/6723f14faab36de63561a60e/images/ffffc5183f49259b7d8eeee7753bd9b64feaa898b6b12730363dadd97bd9d7c6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8835334777832031}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03759366,"{'position': 1, 'link': 'https://myastheniagravisnews.com/soliris-eculizumab-for-myasthenia-gravis/', 'title': 'Soliris (eculizumab) for myasthenia gravis', 'source': 'Myasthenia Gravis News', 'date': 'Nov 25, 2017', 'snippet': 'Soliris (eculizumab) is an infusion therapy approved for the treatment of \nadults with generalized myasthenia gravis.', 'thumbnail': 'https://serpapi.com/searches/6723f1f0e9b6914d2fbe7ade/images/f773944fe7c1f2cc30d8b893ecc9ac448d13860f3846b03e8e33221228727776.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8798476457595825}",,,,,,,,,,['neutral'],neutral,1
NCT01307631,"{'position': 1, 'link': 'https://www.nature.com/articles/bjc2013183', 'title': 'Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO', 'source': 'Nature', 'date': 'Apr 23, 2013', 'snippet': 'Patients with recurrent/metastatic endometrial cancer that progresses after \nchemotherapy have limited treatment options and poor outcomes.', 'thumbnail': 'https://serpapi.com/searches/6723f1f59062f835cfd46baf/images/8a7368efa74d800432876a88b0bd66af2a1c5b326c939e974a1ec4089ac6b533.png', 'sentiment': 'negative', 'sentiment_prob': 0.741053581237793}",,,,,,,,,,['negative'],negative,0
NCT04786847,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/prostact-select-study-of-tlx591-interim-readout-positive-results-confirm-safety-and-tolerability-301961317.html', 'title': 'ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability', 'source': 'PR Newswire', 'date': 'Oct 18, 2023', 'snippet': 'PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) \ntoday announces positive preliminary results from the Phase I...', 'thumbnail': 'https://serpapi.com/searches/6723f1f671c62b69a6f2ec6e/images/25049aadb7b0397a6ff3ca936c7195ede28fc0d4b450b71711ecca4924b6819d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5408878922462463}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/first-patient-dosed-in-phase-iii-prostact-global-study-of-antibody-based-prostate-cancer-therapy-candidate-tlx591-301985365.html', 'title': 'First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591', 'source': 'PR Newswire', 'date': 'Nov 12, 2023', 'snippet': 'PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) \ntoday announces that the first patient has been dosed in the...', 'thumbnail': 'https://serpapi.com/searches/6723f1f671c62b69a6f2ec6e/images/25049aadb7b0397ac2620fca76c76972a4f6c2dc2789942a76dcc557f93908bc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9382062554359436}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01339871,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-020-58366-z', 'title': 'Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies', 'source': 'Nature', 'date': 'Feb 20, 2020', 'snippet': 'We performed two phase I trials of the histone deacetylase inhibitor \nvorinostat combined with either the vascular endothelial growth factor...', 'thumbnail': 'https://serpapi.com/searches/6723f1ff5f97789cdc77b1ff/images/0456994f4a1f3281bb9792e0fd693c88d43d148c39c63e5c6d3e50c2fbd6392a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9028980135917664}",,,,,,,,,,['neutral'],neutral,1
NCT03073486,"{'position': 1, 'link': 'https://www.genengnews.com/a-lists/unlucky-13-top-clinical-trial-failures-of-2018/', 'title': 'Unlucky 13: Top Clinical Trial Failures of 2018', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Feb 11, 2019', 'snippet': 'Reasons for clinical trial failures are biological considerations, \ninadequate study design, improper dose selection,non-optimal assessment...', 'thumbnail': 'https://serpapi.com/searches/6723f21be45f33d6a07af983/images/149bf1b7c6dfd50ff2a677cc76507a7b2aed85930063dd2908234f72d345daae.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8755886554718018}",,,,,,,,,,['negative'],negative,0
NCT01597908,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1412690', 'title': 'Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib', 'source': 'The New England Journal of Medicine', 'date': 'Nov 16, 2014', 'snippet': 'The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as \nmonotherapies in patients with previously untreated metastatic...', 'thumbnail': 'https://serpapi.com/searches/6723f2282bab90365063b331/images/6d499a3dde8a004019f125cd1f98315093e904e39ba1b1b4943ffc6c1fd0f5ff.png', 'sentiment': 'positive', 'sentiment_prob': 0.5727618932723999}",,,,,,,,,,['positive'],positive,1
NCT05172934,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.027', 'title': 'Abstract 027: Adjunctive Intra‐Arterial Tenecteplase Following Mechanical Thrombectomy. (ALLY) Pilot Trial', 'source': 'American Heart Association Journals', 'date': 'Nov 10, 2023', 'snippet': 'This study evaluated the safety and efficacy of intraarterial Tenecteplase \n(IA TNK) as an adjunctive therapy to mechanical thrombectomy in patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/6723f23858e433cfdc869519/images/94a4e92e0294dbffa82c54625d6bd1ed4d5622ae550dd9e93a7f7a445b19cd7c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8906093835830688}",,,,,,,,,,['neutral'],neutral,1
NCT02185417,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2212270', 'title': 'Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events', 'source': 'The New England Journal of Medicine', 'date': 'Dec 14, 2022', 'snippet': 'Whether chlorthalidone is superior to hydrochlorothiazide for preventing \nmajor adverse cardiovascular events in patients with hypertension is \nunclear.', 'thumbnail': 'https://serpapi.com/searches/6723f18ac76a3acd090f919e/images/7fa4e6e2814219817275dc6f335913aa90957e922f78b7369d34eb43af3c9dcf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8023682832717896}",,,,,,,,,,['neutral'],neutral,1
NCT04214860,"{'position': 1, 'link': 'https://www.nature.com/articles/s41418-023-01122-3', 'title': 'The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells', 'source': 'Nature', 'date': 'Feb 4, 2023', 'snippet': 'Mutant TP53 proteins are thought to drive the development and sustained \nexpansion of cancers at least in part through the loss of the...', 'thumbnail': 'https://serpapi.com/searches/6723f190d91039151cfaaf0a/images/3d263429da4e2742de50c52af2940b6cadfb1d6d16107b4179a33d9470e9f830.png', 'sentiment': 'negative', 'sentiment_prob': 0.6143423318862915}",,,,,,,,,,['negative'],negative,0
NCT02545049,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2110956', 'title': 'Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Aug 28, 2021', 'snippet': 'Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, \nhas favorable effects on cardiorenal outcomes in patients with \npredominantly stage...', 'thumbnail': 'https://serpapi.com/searches/6723f1997ca6b38026f05303/images/ae385cf0e9d82a6efcdf76f32d7483da4c7c5a179d830a0aef54579c3c70a546.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8563430309295654}","{'position': 2, 'link': 'https://www.thecardiologyadvisor.com/news/finerenone-cardiovascular-events-chronic-kidney-disease-ckd-type-2-diabetes-t2d/', 'title': 'Edoxaban Non-Inferior to Vitamin K Antagonists in Atrial Fibrillation Post-TAVR', 'source': 'The Cardiology Advisor', 'date': 'Dec 28, 2021', 'snippet': 'Patients with type 2 diabetes and chronic kidney disease who received \nfinerenone had a lower heart failure hospitalization rate,...', 'thumbnail': 'https://serpapi.com/searches/6723f1997ca6b38026f05303/images/ae385cf0e9d82a6ea5a36306b4c3ede28f07cae88c73a4bb07e010c87ad309f2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8240056037902832}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04004611,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/lilly-discloses-first-in-class-interim-phase-2-data-in-pediatric-patients-and-new-analysis-from-phase-3-program-in-adult-patients-for-mirikizumab-in-ulcerative-colitis-301818874.html', 'title': 'Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis', 'source': 'PR Newswire', 'date': 'May 9, 2023', 'snippet': 'PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new \ninvestigational data for mirikizumab in patients with moderately to...', 'thumbnail': 'https://serpapi.com/searches/6723f19d690bb94a0aba81d6/images/a42fcc0d207e1d8dc8ea11993efe3a4caf8bc425b7c537683020089cddc7bda9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.903488039970398}",,,,,,,,,,['neutral'],neutral,1
NCT03319459,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.566401/full', 'title': 'Next-Generation Immunotherapies to Improve Anticancer Immunity', 'source': 'Frontiers', 'date': 'Feb 12, 2024', 'snippet': ""Cancer immunotherapy harnesses the patient's own immune system to fight \nagainst cancer, distinguishing immunotherapy from conventional cancer \ntherapies."", 'thumbnail': 'https://serpapi.com/searches/6723f1a539e23253ca9df918/images/592e8faf96aada0271ccecf0753bf717438134bf91309b4170b9824a34b7b91a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.741769552230835}",,,,,,,,,,['neutral'],neutral,1
NCT05158335,"{'position': 1, 'link': 'https://hypoparathyroidismnews.com/news/dosing-starts-phase-2-trial-mbx-2109-pth-replacement-therapy/', 'title': 'Dosing starts in clinical trial of MBX 2109, PTH replacement therapy', 'source': 'Hypoparathyroidism News', 'date': '3 weeks ago', 'snippet': 'Dosing is underway in a Phase 2 clinical trial of MBX 2109, an \ninvestigational hormone replacement therapy for people with...', 'thumbnail': 'https://serpapi.com/searches/6723f1c89e5bd5411c0a6dcb/images/c40231f6d192e7f1b1e250aab563bb136025aba6011227a16d809822b46ebf29.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9303702712059021}","{'position': 2, 'link': 'https://hypoparathyroidismnews.com/news/test-hypoparathyroidism-therapy-mbx-2109-advances/', 'title': 'Trial Testing MBX 2109 in Healthy Volunteers Advances to Part 2', 'source': 'Hypoparathyroidism News', 'date': 'Oct 10, 2022', 'snippet': ""A Phase 1 clinical trial evaluating the safety and pharmacological \nproperties of MBX 2109 — MBX Biosciences' investigational hormone \nreplacement..."", 'thumbnail': 'https://serpapi.com/searches/6723f1c89e5bd5411c0a6dcb/images/c40231f6d192e7f126aadee931c1b25ca30fbcfc7d1ceb4041dc1e4d7e3096c7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.914821445941925}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02363855,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/darolutamide-yields-positive-safety-data-in-mcrpc', 'title': 'Darolutamide Yields Positive Safety Data in mCRPC', 'source': 'Cancer Network', 'date': 'Feb 18, 2022', 'snippet': 'Patients with metastatic castration-resistant prostate cancer were observed \nto have a tolerable safety profile when treated with...', 'thumbnail': 'https://serpapi.com/searches/6723f2425bb6a2a9d05e9986/images/d0b79c8c13bfa29701ae4b41a1ce7e4e40409f748c62aa46b828a2ab239516f6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.665687620639801}",,,,,,,,,,['neutral'],neutral,1
NCT02602119,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-30265-z', 'title': 'Targeted detection of cancer at the cellular level during biopsy by near-infrared confocal laser endomicroscopy', 'source': 'Nature', 'date': 'May 17, 2022', 'snippet': 'Suspicious nodules detected by radiography are often investigated by \nbiopsy, but the diagnostic yield of biopsies of small nodules is poor.', 'thumbnail': 'https://serpapi.com/searches/6723f24b17b10eb84e16b634/images/dfcc126537b6fb008a0cfb3c43799e1e90b26b7ad61baa82164990e55805e009.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6216023564338684}",,,,,,,,,,['neutral'],neutral,1
NCT02676986,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-022-01849-9', 'title': 'Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer | British Journal of Cancer', 'source': 'Nature', 'date': 'May 26, 2022', 'snippet': 'Radiation therapy (RT) and hormone receptor (HR) inhibition are used for \nthe treatment of HR-positive breast cancers; however,...', 'thumbnail': 'https://serpapi.com/searches/6723f25181bab7b92fca11b7/images/b59be5951b2a73ec731203f3603459e18a1518c13842f60715d1f4757ffb3518.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9168511033058167}",,,,,,,,,,['neutral'],neutral,1
NCT00918983,"{'position': 1, 'link': 'https://bphnews.com/news-posts/2017/06/07/studies-show-enlarged-prostate-therapy-fexapotide-improves-sexual-function/', 'title': 'Enlarged Prostate Therapy Fexapotide Actually Improves Patients’ Sexual Function, Studies Show', 'source': 'BPH News', 'date': 'Jun 7, 2017', 'snippet': 'Fexapotide triflutate improves the sexual functioning of men with an \nenlarged prostate, according to combined results of four Phase 3 clinical \ntrials.', 'thumbnail': 'https://serpapi.com/searches/6723f25a3b3c32388571a899/images/77af5d809809fed0c00dd6a3bcb1195e47d7a1f5ee94b554d57eb44cee76e57a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6826880574226379}",,,,,,,,,,['positive'],positive,1
NCT00974311,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1207506', 'title': 'Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy', 'source': 'The New England Journal of Medicine', 'date': 'Aug 15, 2012', 'snippet': 'In our phase 3, double-blind, placebo-controlled trial, we stratified 1199 \nmen with castration-resistant prostate cancer after chemotherapy...', 'thumbnail': 'https://serpapi.com/searches/6723f275aab36d0ca8ac0c3d/images/0531194e44e51d9c497f33eb4fe95c88cb816f4cc91a544e946c93d35efee574.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6584006547927856}",,,,,,,,,,['neutral'],neutral,1
NCT04004208,"{'position': 1, 'link': 'https://www.empr.com/home/news/eylea-approved-for-preterm-infants-with-retinopathy-of-prematurity/', 'title': 'Eylea Approved for Preterm Infants With Retinopathy of Prematurity', 'source': 'Medical Professionals Reference', 'date': 'Feb 9, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Eylea (aflibercept) for \nthe treatment of preterm infants with retinopathy of prematurity (ROP).', 'thumbnail': 'https://serpapi.com/searches/6723f2784677bf90f1c1a308/images/10fc36e966b742e8ee7edf504689538d53521c3e11bae103835726fba0a4501e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8532078266143799}",,,,,,,,,,['neutral'],neutral,1
NCT01588132,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-91165-8', 'title': 'In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα', 'source': 'Nature', 'date': 'Jun 3, 2021', 'snippet': 'The interaction of platelet GPIbα with von Willebrand factor (VWF) is \nessential to initiate platelet adhesion and thrombosis,...', 'thumbnail': 'https://serpapi.com/searches/6723f282544c49d507809eef/images/8b4c601291c8d0dccce32be2c7b2e548c0c33206a83701ff6d17bd2b55ce90ea.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9050597548484802}",,,,,,,,,,['neutral'],neutral,1
NCT03342404,"{'position': 1, 'link': 'https://www.onclive.com/view/eu-approves-luspatercept-for-anemia-in-patients-with-non-transfusion-dependent-beta-thalassemia', 'title': 'EU Approves Luspatercept for Anemia in Patients with Non–Transfusion-Dependent Beta Thalassemia', 'source': 'OncLive', 'date': 'Mar 7, 2023', 'snippet': 'The European Commission has granted a full marketing authorization to \nluspatercept-aamt (Reblozyl) for use in adult patients with anemia \nassociated with non–...', 'thumbnail': 'https://serpapi.com/searches/6723f2a3bcd65222bfec8b64/images/52324d3b642ad5b2e5a99d8bb4585d2bc1424dd0e9b85148c591a42635d13b5b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8462667465209961}",,,,,,,,,,['neutral'],neutral,1
NCT02658968,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-019-0677-4', 'title': 'Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest', 'source': 'Nature', 'date': 'Dec 13, 2019', 'snippet': 'Some patients with B-cell non-Hodkin lymphoma Lymphoma (NHL) become \nrefractory to rituximab (anti-CD20 antibody) therapy associated with...', 'thumbnail': 'https://serpapi.com/searches/6723f2cfc024d1be854f2256/images/d7ef6b2bc3b0024d2d6818c5cbd8483d10ea5d55ebb3385ccb5472d2ffe748d5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7524910569190979}",,,,,,,,,,['neutral'],neutral,1
NCT02657889,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-020-15315-8', 'title': 'Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer', 'source': 'Nature', 'date': 'Mar 19, 2020', 'snippet': 'Combined PARP and immune checkpoint inhibition has yielded encouraging \nresults in ovarian cancer, but predictive biomarkers are lacking.', 'thumbnail': 'https://serpapi.com/searches/6723f2dec0028efea8a60b55/images/b256625247414e9734381e0b32b06877bfd4cd56f2e0001edc86f63b51c3d77c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7548379898071289}",,,,,,,,,,['neutral'],neutral,1
NCT04620213,"{'position': 1, 'link': 'https://www.empr.com/home/news/ryzumvi-now-available-to-reverse-pharmacologically-induced-mydriasis/', 'title': 'Ryzumvi Now Available to Reverse Pharmacologically-Induced Mydriasis', 'source': 'Medical Professionals Reference', 'date': 'Apr 1, 2024', 'snippet': 'Ryzumvi is a preservative-free eye drop formulation of phentolamine \nmesylate, a nonselective alpha-1 and alpha-2 adrenergic antagonist that...', 'thumbnail': 'https://serpapi.com/searches/6723f30098d8de9a4cff9ab9/images/db02fcc4f5a06a5ca74a22d1b7cf992d51974710a801e5c6dd86cb4e0d619a78.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8309853672981262}",,,,,,,,,,['neutral'],neutral,1
NCT02621931,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1709038', 'title': 'Fremanezumab for the Preventive Treatment of Chronic Migraine', 'source': 'The New England Journal of Medicine', 'date': 'Nov 30, 2017', 'snippet': 'Fremanezumab as a preventive treatment for chronic migraine resulted in a \nlower frequency of headache than placebo in this 12-week trial.', 'thumbnail': 'https://serpapi.com/searches/6723f3012c83d5b81af4bd21/images/4058d5e5ee78736f45fa83733c98bb4dc2c9c5f18fa498cf922fc75789fb24ae.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8298872113227844}",,,,,,,,,,['neutral'],neutral,1
NCT05116891,"{'position': 1, 'link': 'https://www.notimerica.com/comunicados/noticia-comunicado-cantargia-presents-new-data-at-sitc-2022-supporting-nadunolimabs-promising-antitumor-clinical-efficacy-20221107141601.html', 'title': ""Cantargia presents new data at SITC 2022 supporting nadunolimab's promising antitumor clinical efficacy"", 'source': 'Notimérica', 'date': 'Nov 7, 2022', 'snippet': 'Data shows nadunolimab dual mechanism potently reduces levels of \ntumor-promoting molecules. LUND, Sweden, Nov.', 'thumbnail': 'https://serpapi.com/searches/6723f303f963e7f4ae6a7e46/images/99074ebc9056637adb7e09eef92d1c02dc61e584e92609e9390d6399abdb24b2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8620907068252563}","{'position': 2, 'link': 'https://www.notimerica.com/comunicados/noticia-comunicado-cantargia-asco-2022-presentation-strengthens-positive-phase-iia-interim-results-for-nadunolimab-in-nsclc-20220527002150.html', 'title': 'Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC', 'source': 'Notimérica', 'date': 'May 26, 2022', 'snippet': 'today reported updated interim results for non-small cell lung cancer \n(NSCLC) patients treated with...', 'thumbnail': 'https://serpapi.com/searches/6723f303f963e7f4ae6a7e46/images/99074ebc9056637a257cadb1c1bde98f4cbc545eed6d94d47deb00fce7742583.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5094895958900452}","{'position': 3, 'link': 'https://www.notimerica.com/comunicados/noticia-comunicado-cantargia-presents-clinical-interim-results-at-asco-2022-highlighting-the-potential-of-nadunolimab-in-combination-with-20220526233306.html', 'title': 'Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with c', 'source': 'Notimérica', 'date': 'May 26, 2022', 'snippet': '(NASDAQ Stockholm: CANTA) today reported new results from the phase Ib \nclinical trial CIRIFOUR in 15 solid...', 'thumbnail': 'https://serpapi.com/searches/6723f303f963e7f4ae6a7e46/images/99074ebc9056637a57296e8c8ad29fdb711095a632841b6ea92e192f49fcb387.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7152458429336548}","{'position': 4, 'link': 'https://www.notimerica.com/comunicados/noticia-comunicado-cantargia-presents-new-robust-data-at-asco-2022-confirming-promising-effects-of-nadunolimab-in-treatment-of-pancreatic-20220527003000.html', 'title': 'Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic c', 'source': 'Notimérica', 'date': 'May 26, 2022', 'snippet': '(NASDAQ Stockholm: CANTA) today reported extended interim results in \nfirst-line pancreatic cancer (PDAC)...', 'thumbnail': 'https://serpapi.com/searches/6723f303f963e7f4ae6a7e46/images/99074ebc9056637a17bb522f23f9f207dc2e7a2a9fbde8eef2193ef2f19131ad.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7977784276008606}",,,,,,,"['positive', 'positive', 'positive', 'positive']",positive,1
NCT00496769,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1107039', 'title': 'Apixaban versus Warfarin in Patients with Atrial Fibrillation', 'source': 'The New England Journal of Medicine', 'date': 'Aug 30, 2011', 'snippet': 'In patients with atrial fibrillation, apixaban was superior to warfarin in \npreventing stroke or systemic embolism, caused less bleeding, and resulted \nin lower...', 'thumbnail': 'https://serpapi.com/searches/6723f321717bff0ef140c6a6/images/b2cb1033c7930921f7c223be7a1b163585b5bb84f9b94461dce7170d3341685b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8256852626800537}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1007432', 'title': 'Apixaban in Patients with Atrial Fibrillation', 'source': 'The New England Journal of Medicine', 'date': 'Feb 10, 2011', 'snippet': 'In patients with atrial fibrillation for whom vitamin K antagonist therapy \nwas unsuitable, apixaban reduced the risk of stroke or systemic embolism.', 'thumbnail': 'https://serpapi.com/searches/6723f321717bff0ef140c6a6/images/b2cb1033c79309218a3ac97fe46b3959869348c10fe6290a06653a5a84fec188.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5466678738594055}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03842969,"{'position': 1, 'link': 'https://huntingtonsdiseasenews.com/news/generation-hd1-trial-fails-to-demonstrate-benefits-tominersen/', 'title': 'GENERATION HD1 Trial Fails to Show Benefits of Tominersen', 'source': ""Huntington's Disease News"", 'date': 'May 6, 2021', 'snippet': ""Treatment with tominersen failed to show evidence of clinical benefit in \nadults with Huntington's disease during the Phase 3 trial..."", 'thumbnail': 'https://serpapi.com/searches/6723f3508b7ba7dbdcee4b59/images/4f9464099dbdccf098a0e6e02a3ce03aeb61f188cecadeadc0f8e1beaa4ca4a6.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7655267715454102}",,,,,,,,,,['negative'],negative,0
NCT03385928,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/STROKEAHA.123.043209', 'title': 'Exploring Hematoma Expansion Shift With Recombinant Factor VIIa: A Pooled Analysis of 4 Randomized Controlled Trials', 'source': 'American Heart Association Journals', 'date': 'Oct 8, 2023', 'snippet': 'rFVIIa (recombinant factor VIIa) is a hemostatic agent that reduces \nhematoma expansion in patients presenting with acute intracerebral \nhemorrhage (ICH).', 'thumbnail': 'https://serpapi.com/searches/6723f35afda26d2cf83e91cd/images/89458d3e676be59df6a7f74ab7226cc16f3bf748dd7adab96a7a4cb3ff935000.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9016638398170471}",,,,,,,,,,['neutral'],neutral,1
NCT00740948,"{'position': 1, 'link': 'https://sjogrenssyndromenews.com/news/sjogrens-symptoms-not-affected-by-seasonal-changes-study-finds/', 'title': 'Sjögren’s Symptoms Not Affected by Seasonal Changes, Study Finds', 'source': ""Sjogren's Syndrome News"", 'date': 'Apr 8, 2020', 'snippet': ""Seasonal changes do not appear to influence the main symptoms of primary \nSjögren's syndrome — pain, fatigue, and dryness — according to a..."", 'thumbnail': 'https://serpapi.com/searches/6723f35d7c171214635fbcf4/images/68d21d2264e629aac9eee75e8f4a12b38e2369669374c679a39536b183c85c64.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8096309900283813}",,,,,,,,,,['neutral'],neutral,1
NCT03363854,"{'position': 1, 'link': 'https://www.dermatologytimes.com/view/when-to-progress-to-systemic-therapy', 'title': 'When to Progress to Systemic Therapy', 'source': 'Dermatology Times', 'date': 'Aug 11, 2022', 'snippet': 'This is an exciting time for offering safe and effective novel therapies to \npatients with moderate-to-severe AD who are inadequately controlled with \ntopical...', 'thumbnail': 'https://serpapi.com/searches/6723f376fcd69e0952237682/images/9d0c6da25047cebc0c44be493801177fb322f0d23ecdea50be20bf4ea2c08fd4.png', 'sentiment': 'positive', 'sentiment_prob': 0.7247567772865295}",,,,,,,,,,['positive'],positive,1
NCT05802173,"{'position': 1, 'link': 'https://www.pharmnews.com/news/articleView.html?idxno=239267', 'title': 'Technoderma Medicines Phase 2 Clinical Trial of TDM-105795 Demonstrates Hair Growth in Androgenetic Alopecia', 'source': '팜뉴스', 'date': 'Feb 5, 2024', 'snippet': 'CHENGDU, China, Feb. 5, 2024 /PRNewswire/ -- Technoderma Medicines, Inc. \n(""the Company""), a clinical stage biopharmaceutical company,...', 'thumbnail': 'https://serpapi.com/searches/6723f3bd11db459557e82f74/images/d1df6834fc71d1789ae2cbd5db807d3dbbdc6ab138b85780bd0e98a59db51934.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9008333683013916}",,,,,,,,,,['neutral'],neutral,1
NCT03924427,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.16740', 'title': 'Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double‐blind, placebo‐controlled, global phase 3 trial - Imafuku - 2023 - The Journal of Der', 'source': 'Wiley Online Library', 'date': 'Mar 7, 2023', 'snippet': 'Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 (TYK2) \ninhibitor that demonstrated superior efficacy versus placebo and apremilast \nin a...', 'thumbnail': 'https://serpapi.com/searches/6723f3c4e30abc0f5d3da21b/images/78b9a2a3d6b693251a3f1b296d8b9fd0e4784173afb1afb9bedced38c675b700.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8855554461479187}",,,,,,,,,,['neutral'],neutral,1
NCT05011851,"{'position': 1, 'link': 'https://angelmansyndromenews.com/news/angelman-syndrome-clinical-trial-nnz-2591-opens-australia/', 'title': 'Phase 2 Trial of NNZ-2591 for Angelman Opens in Australia', 'source': 'angelmansyndromenews.com', 'date': 'Jul 13, 2022', 'snippet': 'Up to 20 children with Angelman are being enrolled in the Phase 2 clinical \ntrial of oral NNZ-2591; all will be treated for 13 weeks.', 'thumbnail': 'https://serpapi.com/searches/6723f3c7a54d7ee64ebd05ee/images/06892f197fb4bfbe8f73f211ae2bcc19fb917fd42fd9920a80ef9f38722ebbba.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9281002283096313}","{'position': 2, 'link': 'https://angelmansyndromenews.com/news/phase-2-trial-nnz-2591-cleared-start-us-fda-australia-ethics-committee/', 'title': 'Phase 2 Trial of Neuren’s NNZ-2591 Cleared to Start in US, Australia', 'source': 'angelmansyndromenews.com', 'date': 'Mar 30, 2022', 'snippet': 'Neuren has received the green light from regulators in the U.S. and \nAustralia to conduct its Phase 2 trial of NNZ-2591 for Angelman...', 'thumbnail': 'https://serpapi.com/searches/6723f3c7a54d7ee64ebd05ee/images/06892f197fb4bfbe570413862fcf660574c6bf09acdde0bd1758a687057dc50b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8420169949531555}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04280328,"{'position': 1, 'link': 'https://www.science.org/doi/10.1126/sciadv.ade5111', 'title': 'Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development', 'source': 'Science | AAAS', 'date': 'May 5, 2023', 'snippet': 'Hypoxia-induced adenosine creates an immunosuppressive tumor \nmicroenvironment (TME) and dampens the efficacy of immune checkpoint \ninhibitors...', 'thumbnail': 'https://serpapi.com/searches/6723f3faf7adbf2bb8d4fe24/images/feec0339687b1611493ae6d2a0a85225d22ef7760cfaa179dfe03ed8be115a69.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.808730959892273}",,,,,,,,,,['negative'],negative,0
NCT02199197,"{'position': 1, 'link': 'https://theoncologist.onlinelibrary.wiley.com/doi/10.1002/onco.13949', 'title': 'Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results', 'source': 'The Oncologist', 'date': 'Aug 22, 2021', 'snippet': 'Lessons Learned Long-term safety of radium-223 with enzalutamide was \nconfirmed in this clinical trial. PSA-PFS2 was prolonged with the...', 'thumbnail': 'https://serpapi.com/searches/6723f42b76585795dffb18f3/images/7db0850cfd3d35e9ad32963e023bf87019c1568bac26b78948896036d4720419.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8476401567459106}",,,,,,,,,,['neutral'],neutral,1
NCT02416453,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-022-00564-z', 'title': 'Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola | npj Vaccines', 'source': 'Nature', 'date': 'Nov 30, 2022', 'snippet': 'Without clinical efficacy data, vaccine protective effect may be \nextrapolated from animals to humans using an immunologic marker that...', 'thumbnail': 'https://serpapi.com/searches/6723f431059caf911a6bd567/images/957d7d769de9f46eb67ac5db20ad63b70c12cf3686adb0823cf021c3ffc8b6eb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8734168410301208}",,,,,,,,,,['neutral'],neutral,1
NCT01180036,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1814427', 'title': 'Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy', 'source': 'The New England Journal of Medicine', 'date': 'Jul 3, 2019', 'snippet': 'Rituximab was noninferior to cyclosporine in inducing complete or partial \nremission of proteinuria at 12 months and was superior in maintaining \nproteinuria...', 'thumbnail': 'https://serpapi.com/searches/6723f563577da558bd156352/images/f4020a96b72d8e1963c6ae667a694bbc8d79acae4dd9d70a96e6de53dd3e3105.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8242969512939453}",,,,,,,,,,['neutral'],neutral,1
NCT03472040,"{'position': 1, 'link': 'https://angioedemanews.com/news/orladeyo-set-to-launch-by-years-end-if-approved-biocryst-says/', 'title': ""HAE Drug Orladeyo to Launch by Year's End if Approved, BioCryst Says"", 'source': 'Angioedema News', 'date': 'Aug 19, 2020', 'snippet': ""BioCryst Pharmaceuticals will launch Orladeyo (berotralstat) by year's end \nif this oral drug for hereditary angioedema is approved,..."", 'thumbnail': 'https://serpapi.com/searches/6723f59af79a01c19a37e29e/images/7a0a9bdf3eaeae913632f2ef107615c27ab81f409409dcb1a3f8e4bf718abda7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.840570867061615}","{'position': 2, 'link': 'https://angioedemanews.com/news/argentina-approves-orladeyo-prevent-hae-attacks/', 'title': 'Argentina approves oral Orladeyo to prevent HAE attacks', 'source': 'Angioedema News', 'date': 'Dec 7, 2023', 'snippet': ""Argentina's regulatory body has approved Orladeyo to prevent swelling \nattacks in adults and adolescents, ages 12 and older, with HAE."", 'thumbnail': 'https://serpapi.com/searches/6723f59af79a01c19a37e29e/images/7a0a9bdf3eaeae9186561844e9d4055f8759ace30256017cfb54271c94a1ce82.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8729593753814697}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04737876,"{'position': 1, 'link': 'https://ibdnewstoday.com/2021/02/08/biomxs-ibd-phage-therapy-bx002-shows-promise-first-in-human-clinical-trial/', 'title': ""BiomX's IBD Phage Therapy BX002 Shows Promise in First-in-human Trial"", 'source': 'IBD News Today', 'date': 'Feb 8, 2021', 'snippet': 'BX002, an oral phage therapy BiomX is developing for inflammatory bowel \ndisease (IBD), showed a good safety profile, as well as the ability to \neffectively...', 'thumbnail': 'https://serpapi.com/searches/6723f4ec69012193a5fecbd2/images/e2e1f06e8961c0ae72b928ff505f2a25b87af5d270eb7328760c4f347b464254.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6927630305290222}",,,,,,,,,,['positive'],positive,1
NCT00781391,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1310907', 'title': 'Edoxaban versus Warfarin in Patients with Atrial Fibrillation', 'source': 'The New England Journal of Medicine', 'date': 'Nov 19, 2013', 'snippet': 'We conducted a randomized, double-blind, double-dummy trial comparing two \nonce-daily regimens of edoxaban with warfarin in 21,105 patients...', 'thumbnail': 'https://serpapi.com/searches/6723f4f9d771bdf6b3351c2e/images/fee46ccd9eba223f404a82dc65abc33692d0a671c9bd3943e3c600376a46e5d9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9197425246238708}",,,,,,,,,,['neutral'],neutral,1
NCT03815825,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/ionis-partner-licenses-rare-kidney-disease-treatment-and-will-advance-into-phase-3-clinical-study-301583315.html', 'title': 'Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study', 'source': 'PR Newswire', 'date': 'Jul 11, 2022', 'snippet': 'PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced \nthat its long-standing partner, Roche, will license and advance...', 'thumbnail': 'https://serpapi.com/searches/6723f5439062f85c40db746d/images/6be8dd3e0f68c8711d67161a5fad28e3f0a90f9ff32fc8ac88accaf1600fa074.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.672743022441864}",,,,,,,,,,['neutral'],neutral,1
NCT01474512,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1512711', 'title': 'Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Jun 8, 2016', 'snippet': 'Ixekizumab, a monoclonal antibody against interleukin-17A, was superior to \nplacebo and etanercept in the treatment of moderate-to-severe psoriasis.', 'thumbnail': 'https://serpapi.com/searches/6723f54581262ade5a9c4e9a/images/ad6be2d26caeea1e04fd3a74e46cc5bb98d061d6ced3292d9cd5521e963ced12.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7625470161437988}","{'position': 2, 'link': 'https://psoriasisnewstoday.com/2017/02/14/study-shows-retreatment-of-psoriasis-with-taltz-after-interruption-of-therapy-is-effective/', 'title': 'Retreatment of Psoriasis with Taltz after Interruption in Therapy Is Effective, Study Suggests', 'source': 'Psoriasis News Today', 'date': 'Feb 14, 2017', 'snippet': 'Retreatment with Taltz (ixekizumab), after the end of initial treatment led \nto a relapse, restored response in most psoriasis patients, according to a \nstudy.', 'thumbnail': 'https://serpapi.com/searches/6723f54581262ade5a9c4e9a/images/ad6be2d26caeea1e398137c97d598f3520e2348ca32f96782b1c3183da15a7fd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6104496717453003}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04476017,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/dalzanemdor-sage-718-fails-improve-cognition-phase-2-trial/', 'title': 'Dalzanemdor, formerly SAGE-718, fails to aid cognition in Phase 2 trial', 'source': ""Parkinson's News Today"", 'date': 'Apr 24, 2024', 'snippet': ""Dalzanemdor (formerly SAGE-718), a medication for mild cognitive impairment \ndue to Parkinson's, failed to outperform a placebo in a trial."", 'thumbnail': 'https://serpapi.com/searches/6723f467fda26d2cf83e91fe/images/c9978c0864ffbbcee219ce1c11f9dc293b83a239ee3e52d88e94d6261c651b02.png', 'sentiment': 'negative', 'sentiment_prob': 0.8312615752220154}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/sage-718-showing-potential-aid-cognition-phase-2-paradigm-trial/', 'title': 'SAGE-718 Showing Potential to Aid Patients’ Thinking, Memory in Trial', 'source': ""Parkinson's News Today"", 'date': 'Mar 18, 2022', 'snippet': ""Early results from the Phase 2 clinical trial of oral SAGE-718 showed the \ninvestigative therapy's use was associated with cognitive gains in people \nwith mild..."", 'thumbnail': 'https://serpapi.com/searches/6723f467fda26d2cf83e91fe/images/c9978c0864ffbbceabd996a0070eac5de57da57fba41d4d4dc07ee004f20102d.png', 'sentiment': 'positive', 'sentiment_prob': 0.5563304424285889}",,,,,,,,,"['negative', 'positive']",negative,0
NCT02851797,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00036-X/fulltext', 'title': 'Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial', 'source': 'The Lancet', 'date': 'Apr 18, 2024', 'snippet': 'Duchenne muscular dystrophy, the most common childhood muscular dystrophy, \nis caused by dystrophin deficiency. Preclinical and phase 2 study...', 'thumbnail': 'https://serpapi.com/searches/6723f49ac5d7698b697f62e7/images/35d00584df105161bbf7d633c156859913f959b36effb4b30305b96ee5767dc4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8534465432167053}","{'position': 2, 'link': 'https://musculardystrophynews.com/news/givinostat-slowed-motor-function-loss-dmd-boys-trial-shows/', 'title': 'Givinostat slows motor function loss in boys with DMD in trial: Results', 'source': 'Muscular Dystrophy News', 'date': 'Mar 21, 2024', 'snippet': 'Treatment with Givinostat was found to significantly slow motor function \nloss in boys with Duchenne muscular dystrophy in a clinical trial.', 'thumbnail': 'https://serpapi.com/searches/6723f49ac5d7698b697f62e7/images/35d00584df1051614e1e9b03465273329475f1398bd468bd78f86b016ac8d7c6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7054391503334045}","{'position': 3, 'link': 'https://www.drugtopics.com/view/nda-for-givinostat-to-treat-duchenne-muscular-dystrophy-accepted-by-fda', 'title': 'NDA for Givinostat to Treat Duchenne Muscular Dystrophy Accepted by FDA', 'source': 'Drug Topics', 'date': 'Jun 30, 2023', 'snippet': 'The FDA has accepted the New Drug Application (NDA) for givinostat \n(ITF2357; Italfarmaco Group), a proprietary histone deacetylase (HDAC) \ninhibitor to treat...', 'thumbnail': 'https://serpapi.com/searches/6723f49ac5d7698b697f62e7/images/35d00584df1051619a30ec6564d5dff4b6f1e204a5de10ce6a0417d5e25dbdae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7797130942344666}","{'position': 4, 'link': 'https://www.empr.com/home/news/duvyzat-a-nonsteroidal-treatment-for-duchenne-muscular-dystrophy-gets-fda-approval/', 'title': 'Duvyzat, a Nonsteroidal Treatment for Duchenne Muscular Dystrophy, Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Mar 22, 2024', 'snippet': 'The approval was based on data from the randomized, double-blind, \nplacebo-controlled phase 3 EPIDYS study.', 'thumbnail': 'https://serpapi.com/searches/6723f49ac5d7698b697f62e7/images/35d00584df105161e104424df1e40ebd91957dc069ce18ca290695576cd5e087.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6453707814216614}","{'position': 5, 'link': 'https://www.nature.com/articles/d41573-023-00151-4', 'title': 'Upcoming market catalysts in Q4 2023', 'source': 'Nature', 'date': 'Sep 8, 2023', 'snippet': 'Upcoming catalysts for the fourth quarter of 2023 include approval \ndecisions by the US FDA on givinostat for Duchenne muscular dystrophy \n(DMD), aprocitentan...', 'thumbnail': 'https://serpapi.com/searches/6723f49ac5d7698b697f62e7/images/35d00584df105161f0752056356a8c6dfd377be2a6ef1fb9983c760bbc204d28.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5077378153800964}","{'position': 6, 'link': 'https://www.biospace.com/itf-therapeutics-llc-announces-u-s-commercial-availability-of-duvyzat-givinostat-for-treatment-of-patients-with-duchenne-muscular-dystrophy', 'title': 'ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy', 'source': 'BioSpace', 'date': 'Jul 25, 2024', 'snippet': 'First nonsteroidal treatment approved for patients six years of age and \nolder with DMD regardless of genetic mutation now available in the US.', 'thumbnail': 'https://serpapi.com/searches/6723f49ac5d7698b697f62e7/images/35d00584df105161ff24f1bd68cde5b8460e618a058c5eddb9be53fc63da1cfa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.674735963344574}","{'position': 7, 'link': 'https://musculardystrophynews.com/news/duvyzat-now-available-dmd-patients-6-older-us/', 'title': 'Duvyzat now available to DMD patients 6 and older in US', 'source': 'Muscular Dystrophy News', 'date': 'Jul 30, 2024', 'snippet': 'Duvyzat (givinostat), a newly approved treatment for Duchenne muscular \ndystrophy (DMD), is now available in the US.', 'thumbnail': 'https://serpapi.com/searches/6723f49ac5d7698b697f62e7/images/35d00584df105161833372b05a6e30ad9c4d61174e166e4ea0bd3e99bbb72aba.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5288257598876953}","{'position': 8, 'link': 'https://www.contractpharma.com/contents/view_breaking-news/2024-03-22/italfarmaco-spas-duvyzat-approved-by-fda/', 'title': 'Italfarmaco S.p.A.’s Duvyzat Approved By FDA', 'source': 'Contract Pharma', 'date': 'Mar 22, 2024', 'snippet': 'Orally administered treatment for Duchenne muscular dystrophy approved in \npatients 6 years and older.', 'thumbnail': 'https://serpapi.com/searches/6723f49ac5d7698b697f62e7/images/35d00584df105161298b4978f2051a916dc1c6e1f77cde7a360a3c95cda3e170.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7186108827590942}","{'position': 9, 'link': 'https://musculardystrophynews.com/news/rollout-expected-us-3rd-quarter-approved-dmd-therapy-duvyzat/', 'title': 'Rollout expected by fall in US for new DMD therapy Duvyzat', 'source': 'Muscular Dystrophy News', 'date': 'Apr 2, 2024', 'snippet': ""Italfarmaco's newly approved Duchenne muscular dystrophy (DMD) therapy, in \nthe U.S — expects the oral medication to be available to eligible..."", 'thumbnail': 'https://serpapi.com/searches/6723f49ac5d7698b697f62e7/images/35d00584df1051614a8b42adda234fd9f9db24bed15e1f179d2ea3d7cf2bae1c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8522807955741882}",,"['neutral', 'neutral', 'neutral', 'neutral', 'positive', 'neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT04118855,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/urology/articles/10.3389/fruro.2022.864778/full', 'title': 'Neoadjuvant Systemic Therapy in Localized and Locally Advanced Renal Cell Carcinoma', 'source': 'Frontiers', 'date': 'Apr 24, 2024', 'snippet': 'While the majority of renal cell carcinoma (RCC) cases present at an early \nstage, a significant number of patients are diagnosed with either locally...', 'thumbnail': 'https://serpapi.com/searches/6723f4bf7f3719505b760612/images/0fcccebfe7e5973bc87d78ed8efb645c3861106cabe37d9306fcdcadbdf633c3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8618273138999939}",,,,,,,,,,['neutral'],neutral,1
NCT02664181,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1122352/full', 'title': 'Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer', 'source': 'Frontiers', 'date': 'Feb 8, 2024', 'snippet': 'The morbidity and mortality of lung cancer are increasing, seriously \nthreatening human health and life. Non-small cell lung cancer (NSCLC) has \nan insidious...', 'thumbnail': 'https://serpapi.com/searches/6723f4d4efad2183fae89338/images/038e818be8cc580f7f85e929ebde9d46f67e57171f6c4d790a364806184650ab.png', 'sentiment': 'negative', 'sentiment_prob': 0.6864020824432373}",,,,,,,,,,['negative'],negative,0
NCT00471497,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-020-01111-2', 'title': 'Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis', 'source': 'Nature', 'date': 'Jan 7, 2021', 'snippet': 'In the ENESTnd study, with ≥10 years follow-up in patients with newly \ndiagnosed chronic myeloid leukemia (CML) in chronic phase,...', 'thumbnail': 'https://serpapi.com/searches/6723f5b754605c243c1bb941/images/86555888f480f6b3b5589756bdf6595c48a27dba987615133e748eeb139d8cd3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8985676765441895}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0912614', 'title': 'Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'Jan 26, 2017', 'snippet': 'Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to \nimatinib in patients with newly diagnosed chronic-phase Philadelphia \nchromosome–...', 'thumbnail': 'https://serpapi.com/searches/6723f5b754605c243c1bb941/images/86555888f480f6b3c6c3f8771b5eef0755b5f1eb5c3942266d3350e21a0c0c50.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8109325170516968}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03410992,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-bimzelx-for-plaque-psoriasis/', 'title': 'FDA Approves Bimzelx for Moderate to Severe Plaque Psoriasis', 'source': 'Medical Professionals Reference', 'date': 'Oct 18, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Bimzelx \n(bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis \nin adults.', 'thumbnail': 'https://serpapi.com/searches/6723f5bedb3ac91c61a1f5a2/images/5447b7517d385d6808951bc671677b21c5ce91e7bf2cf82d001dae076c231a1c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7481014132499695}",,,,,,,,,,['neutral'],neutral,1
NCT05113862,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01557-7', 'title': 'Vaccine adjuvants: mechanisms and platforms - Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': '١٩\u200f/٠٧\u200f/٢٠٢٣', 'snippet': 'Adjuvants are defined as various components that enhance the immunogenicity \nof vaccines when administered in conjunction with vaccine antigens.', 'thumbnail': 'https://serpapi.com/searches/6723f5d2b691a7acb28e8e16/images/2913b499c27b8f183b07ddff972f6f30504b64582f2c9b83f338fe11c20f1e89.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9136331677436829}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/ddr.21969', 'title': 'The potential of developing a protective peptide‐based vaccines against SARS‐CoV‐2', 'source': 'Wiley Online Library', 'date': '٢٥\u200f/٠٦\u200f/٢٠٢٢', 'snippet': 'Peptide-based vaccines hold great promise in countering COVID-19 as they \nmay overcome most of the shortcomings of RNA/DNA and protein vaccines.', 'thumbnail': 'https://serpapi.com/searches/6723f5d2b691a7acb28e8e16/images/2913b499c27b8f18f7413e8193f2942ac147ab1ba020f750e921d3c71ae51482.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.824072003364563}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT00783718,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1215734', 'title': 'Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis', 'source': 'The New England Journal of Medicine', 'date': 'Aug 22, 2013', 'snippet': 'We conducted two integrated randomized, double-blind, placebo-controlled \ntrials of vedolizumab in patients with active disease.', 'thumbnail': 'https://serpapi.com/searches/6723f5e506f4f28543e6b8ad/images/116b9ed7297dec5c1632bc2991d026448a706ca5dba67db4d2eb93be1a923895.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8720484972000122}",,,,,,,,,,['neutral'],neutral,1
NCT01179217,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1715971', 'title': 'A Phase 3 Trial of l-Glutamine in Sickle Cell Disease | NEJM', 'source': 'The New England Journal of Medicine', 'date': 'Jul 18, 2018', 'snippet': 'Oxidative stress contributes to the complex pathophysiology of sickle cell \ndisease. Oral therapy with pharmaceutical-grade l-glutamine (USAN...', 'thumbnail': 'https://serpapi.com/searches/6723f5fa5ddfba8fdaa1f67e/images/3b90aa2aceafa49b7e455575ba44063d9b8c645abbe9a874c115e0a504a81a08.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7132492661476135}","{'position': 2, 'link': 'https://sicklecellanemianews.com/news/emmaus-seeks-approval-oral-endari-medication-scd-kuwait/', 'title': 'Emmaus Seeks Approval of Oral Medication Endari in Kuwait', 'source': 'Sickle Cell Disease News', 'date': 'Jul 20, 2021', 'snippet': 'Emmaus Life Sciences has submitted an application seeking the approval of \nEndari as a treatment for sickle cell disease in Kuwait.', 'thumbnail': 'https://serpapi.com/searches/6723f5fa5ddfba8fdaa1f67e/images/3b90aa2aceafa49b9e8126dc8aa5b87d845d0f4afb37ca224a7c362034bcc252.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.921515703201294}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01006980,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1103782', 'title': 'Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation', 'source': 'The New England Journal of Medicine', 'date': 'Aug 2, 2014', 'snippet': 'Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib \n(PLX4032) have shown response rates of more than 50% in patients with \nmetastatic...', 'thumbnail': 'https://serpapi.com/searches/6723f5feeda5f52faf00ead7/images/673a74dc58b71259c482630f91cf506be2ad2ae7d45e0f4767d16e290b212ed7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5213320851325989}",,,,,,,,,,['neutral'],neutral,1
NCT02852551,"{'position': 1, 'link': 'https://lungdiseasenews.com/2017/08/28/pharmaakea-completes-phase-1-clinical-trial-of-pulmonary-fibrosis-therapy-pat-1251/', 'title': ""Pulmonary Fibrosis Therapy PAT-1251's Phase 1 Clinical Trial Is Over"", 'source': 'Lung Disease News', 'date': 'Aug 28, 2017', 'snippet': 'Read about PharmaAkea completing a Phase 1 clinical trial indicating that \nits PAT-1251 therapy binds with an enzyme linked to pulmonary...', 'thumbnail': 'https://serpapi.com/searches/6723f600c024d1be4923cc1e/images/45a6acd3fcad479b75dba4af6a70b620dd5f54234760742cc028e5e8b7d5d820.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8932006359100342}",,,,,,,,,,['neutral'],neutral,1
NCT00811889,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1105351', 'title': 'Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Jun 24, 2011', 'snippet': 'Chronic kidney disease (CKD) associated with type 2 diabetes is the leading \ncause of kidney failure, with both inflammation and oxidative...', 'thumbnail': 'https://serpapi.com/searches/6723f6262c566d38f2509662/images/6875fdd9c432581ab51c5b7e91da4aead8fd10f73a1767eefbb99bfb19464c71.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6634526252746582}",,,,,,,,,,['negative'],negative,0
NCT01743651,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/arbaclofen-er-tablets-similar-potency-spasticity-baclofen/', 'title': 'Arbaclofen ER Tablets Show Similar Potency for Spasticity as Baclofen', 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 28, 2019', 'snippet': 'Read about how arbaclofen extended-release tablets can reduce spasticity in \npatients with MS similarly to the standard baclofen treatment.', 'thumbnail': 'https://serpapi.com/searches/6723f66fdda9d9effefd2cf1/images/9c0981ac99c62e3ac2fecf101ed992d6d881756a3d660317fb47891b9bc0c4ff.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7216485738754272}",,,,,,,,,,['neutral'],neutral,1
NCT02684058,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02321-8', 'title': 'Dabrafenib plus trametinib in BRAFV600E -mutated rare cancers: the phase 2 ROAR trial', 'source': 'Nature', 'date': 'Apr 14, 2023', 'snippet': 'Here we present final efficacy and safety results of a phase 2 basket trial \nof dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in \neight...', 'thumbnail': 'https://serpapi.com/searches/6723f674be324f9cf1aca366/images/e319749236215c96937db7bd6f44afbf2b94a54915a5723960cf05372c1ae868.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8969771862030029}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2303815', 'title': 'Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations', 'source': 'The New England Journal of Medicine', 'date': 'Sep 20, 2023', 'snippet': 'Detection of the BRAF V600E mutation in pediatric low-grade glioma has been \nassociated with a lower response to standard chemotherapy.', 'thumbnail': 'https://serpapi.com/searches/6723f674be324f9cf1aca366/images/e319749236215c965adbcf746026cdf03d3a5cc376ccd18757cff0caf28f04e2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5143287777900696}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation', 'title': 'FDA Approves Dabrafenib Plus Trametinib in Low-Grade Glioma With BRAF V600E Mutation', 'source': 'Cancer Network', 'date': 'Mar 17, 2023', 'snippet': 'Results from the phase 2 CDRB436G2201 trial lead to the approval of \ndabrafenib plus trametinib in patients with low-grade glioma and a BRAF...', 'thumbnail': 'https://serpapi.com/searches/6723f674be324f9cf1aca366/images/e319749236215c9693f823591419f861d09c32a3e1e391da44bd03ff37014a49.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7758387327194214}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03056339,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02785-8', 'title': 'Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19', 'source': 'Nature', 'date': 'Jan 18, 2024', 'snippet': 'We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) \ncells expressing anti-CD19 chimeric antigen receptor and interleukin-15 \n(CAR19/IL-15)...', 'thumbnail': 'https://serpapi.com/searches/6723f695e335ec8a493129fa/images/e40530aee34749f3d864f929b74ef84da37f0dfb637e3f10466560810e2d1422.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8290050029754639}","{'position': 2, 'link': 'https://lymphomanewstoday.com/2020/02/25/car-nk-cells-demonstrate-high-response-rate-safety-lymphoma-leukemia-early-trial/', 'title': 'NHL, CLL Respond to Anti-CD19 CAR NK Cell Therapy, Early Data Show', 'source': 'Lymphoma News Today', 'date': 'Feb 25, 2020', 'snippet': ""CAR NK cells targeting CD19 show a high response rate and safety in \nnon-Hodgkin's lymphoma and chronic lymphocytic leukemia, early trial..."", 'thumbnail': 'https://serpapi.com/searches/6723f695e335ec8a493129fa/images/e40530aee34749f3d1c4359a979a19e7ed06f7bf161ff2bd977e7f235f43729e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6805907487869263}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03259074,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2018/01/10/phase-3-trial-in-ankylosing-spondylitis-compares-cosentyx-to-adalimumab-biosimilar/', 'title': 'Novartis Initiates Phase 3 Trial in AS Comparing Cosentyx to Adalimumab Biosimilar', 'source': 'Ankylosing Spondylitis News', 'date': 'Jan 10, 2018', 'snippet': 'Novartis recently initiated a Phase 3 clinical trial comparing its \nFDA-approved therapy Cosentyx (secukinumab) with GP2017 — an adalimumab...', 'thumbnail': 'https://serpapi.com/searches/6723f797e50bc005c852d2cf/images/cb25c26f190dc35628bc76b7778a48d95e56e25de1810de432661a43fe62f5eb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9141103625297546}",,,,,,,,,,['neutral'],neutral,1
NCT04105010,"{'position': 1, 'link': 'https://www.onclive.com/view/golidocitinib-nda-under-nmpa-review-for-relapsed-refractory-ptcl', 'title': 'Golidocitinib NDA Under NMPA Review for Relapsed/Refractory PTCL', 'source': 'OncLive', 'date': 'Sep 14, 2023', 'snippet': ""The Center for Drug Evaluation of China's National Medical Products \nAdministration has accepted the new drug application seeking the approval \nof golidocitinib."", 'thumbnail': 'https://serpapi.com/searches/6723f7a4d771bdf678dc5166/images/0677b2284a34c9fe4505e2e3bb13e00eee55b6d3d601fd4c74634d6cb476c7d4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9207753539085388}","{'position': 2, 'link': 'https://lymphomahub.com/medical-information/phase-i-data-of-golidocitinib-rr-peripheral-t-cell-lymphoma-jackpot8-trial', 'title': 'Phase I data of golidocitinib for R/R peripheral T-cell lymphoma: JACKPOT8 trial', 'source': 'Lymphoma Hub', 'date': 'Aug 8, 2022', 'snippet': 'The study met its primary endpoint, elucidating the adverse events \nassociated with golidocitinib in patients with R/R PTCL.', 'thumbnail': 'https://serpapi.com/searches/6723f7a4d771bdf678dc5166/images/0677b2284a34c9fe5aa5826a51518b6d90e9501e6ce61a14c1a808605656689e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7840216755867004}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02700685,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S1756464622003164', 'title': 'Clinical Investigation of French Maritime Pine Bark Extract on Attention-Deficit Hyperactivity Disorder as compared to Methylphenidate and Placebo: Part 1: Efficacy in a Randomised Trial', 'source': 'ScienceDirect.com', 'date': 'Sep 14, 2022', 'snippet': 'PBE is a valuable treatment option in paediatric ADHD especially for those \nnot willing to take standard medication or experiencing side effects.', 'thumbnail': 'https://serpapi.com/searches/6723f7c7d910393e41a1ada7/images/1c4e5c0c6e597d9984782d43b06aa9d050f52be4ca81e8472d1d2b2410e9213f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6286596655845642}",,,,,,,,,,['neutral'],neutral,1
NCT01450761,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01522-4', 'title': 'Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends', 'source': 'Nature', 'date': 'Aug 28, 2023', 'snippet': 'Immune checkpoint blockade (ICB) drugs have been initially approved as \nearly as 2011 for the treatment of unresectable advanced melanoma after \nclassical...', 'thumbnail': 'https://serpapi.com/searches/6723f7d70f1a3393cf1ee9f4/images/319790ffd2cb8dcae8680166a1065ee310e3c4fb23e23bc694b3eeb5845c986e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8954232335090637}",,,,,,,,,,['neutral'],neutral,1
NCT04147234,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1485546/full', 'title': 'Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects', 'source': 'Frontiers', 'date': '1 month ago', 'snippet': 'The STING (Stimulator of Interferon Genes) pathway is pivotal in activating \ninnate immunity, making it a promising target for cancer...', 'thumbnail': 'https://serpapi.com/searches/6723f86d0a545ae252f68063/images/b8487bb1494ab30e691eaec8f6055a71fc4cb495ca389f365a0c72933f34ecc5.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6190875768661499}",,,,,,,,,,['positive'],positive,1
NCT02656069,"{'position': 1, 'link': 'https://www.empr.com/home/news/ready-to-use-liquid-glucagon-gets-approval-for-severe-hypoglycemia/', 'title': 'Ready-to-Use Liquid Glucagon Gets Approval for Severe Hypoglycemia', 'source': 'Medical Professionals Reference', 'date': 'Sep 11, 2019', 'snippet': 'The Food and Drug Administration (FDA) has approved Gvoke (glucagon; Xeris \nPharmaceuticals) for the treatment of severe hypoglycemia in pediatric and \nadult...', 'thumbnail': 'https://serpapi.com/searches/6723f877123457bbede2cf0e/images/45d7789ff9746d71ffc646a6e216f64e6f985827d8c3c18ce6ddc10f95a00b64.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7991900444030762}",,,,,,,,,,['neutral'],neutral,1
NCT01974440,"{'position': 1, 'link': 'https://ascopost.com/news/april-2023/update-on-withdrawal-of-ibrutinib-accelerated-approvals-for-mcl-and-mzl-in-the-united-states/', 'title': 'Update on Withdrawal of Ibrutinib Accelerated Approvals for MCL and MZL in the United States', 'source': 'The ASCO Post', 'date': 'Apr 12, 2023', 'snippet': 'AbbVie announced that it intends to voluntarily withdraw, in the United \nStates, accelerated ibrutinib (Imbruvica) approvals for patients with \nmantle cell...', 'thumbnail': 'https://serpapi.com/searches/6723f6b603775653ac4aa78c/images/bcefa027bc9f9948481c1e3a27546d39bf48ed0cf610a25ae1e5330c21d3be4c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9219139218330383}","{'position': 2, 'link': 'https://www.clinicalleader.com/doc/new-fda-guidance-clinical-trial-considerations-to-support-accelerated-approval-of-oncology-therapeutics-0001', 'title': 'New FDA Guidance Clinical Trial Considerations To Support Accelerated Approval Of Oncology Therapeutics', 'source': 'Clinical Leader', 'date': 'Apr 21, 2023', 'snippet': 'On April 6, 2023, AbbVie announced that it was voluntarily withdrawing \nibrutinib, which was granted accelerated approval for two...', 'thumbnail': 'https://serpapi.com/searches/6723f6b603775653ac4aa78c/images/bcefa027bc9f994812730fed0a84a663e6c6e37cb34d78642578c64436714fe7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8708025217056274}","{'position': 3, 'link': 'https://www.cancertherapyadvisor.com/news/imbruvica-no-longer-approved-to-treat-mcl-mzl/', 'title': 'Imbruvica No Longer Approved to Treat MCL, MZL in the US', 'source': 'Cancer Therapy Advisor', 'date': 'Apr 12, 2023', 'snippet': 'Janssen and AbbVie are withdrawing the accelerated approvals of Imbruvica \n(ibrutinib) for mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL)', 'thumbnail': 'https://serpapi.com/searches/6723f6b603775653ac4aa78c/images/bcefa027bc9f9948d1d35565e18d0dce7257fe236450a5166ef0bb56495461c0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.501125693321228}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT05036512,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/phase-1-scd-trial-supporting-gbt601-next-gen-therapy-oxbryta/', 'title': 'Phase 1 Trial Supporting GBT601 as Next-gen Therapy to Oxbryta', 'source': 'Sickle Cell Disease News', 'date': 'May 24, 2022', 'snippet': ""Daily doses of GBT601, Global Blood Therapeutics's oral sickle cell disease \ntherapy, were well tolerated and signaled efficacy in 6..."", 'thumbnail': 'https://serpapi.com/searches/6723f6be910986cb31d68eee/images/4a0d0ed6d4792bad8ba436278ad191a48dd5d8afadd7738874509b38a121d749.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6596790552139282}",,,,,,,,,,['neutral'],neutral,1
NCT03496207,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/sotatercept-may-have-long-term-benefit-in-pulmonary-arterial-hypertension/', 'title': 'Sotatercept May Have Long Term Benefit in Pulmonary Arterial Hypertension', 'source': 'Pulmonology Advisor', 'date': 'Oct 3, 2022', 'snippet': 'Long-term sotatercept use may allow patients with PAH to maintain \nsignificantly reduced pulmonary vascular resistance.', 'thumbnail': 'https://serpapi.com/searches/6723f6cd861b9d63abef856a/images/248f9e1bdd18e9cd3211f76c79a1a00aa406c707529239c749146445b1f4aaee.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6029508709907532}",,,,,,,,,,['positive'],positive,1
NCT04510987,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062353', 'title': 'Pharmacology and Clinical Development of Factor XI Inhibitors | Circulation', 'source': 'American Heart Association Journals', 'date': 'Mar 13, 2023', 'snippet': 'This article reviews the rationale, pharmacology, results of medium or \nsmall phase 2 studies, and future perspectives of drugs inhibiting FXI.', 'thumbnail': 'https://serpapi.com/searches/6723f6e1c5d7698b996f414d/images/8d805aec9677b7e5d5576fee3e4ad60efb4d6bb83b10a01c5109e82410882a4e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9230654835700989}",,,,,,,,,,['neutral'],neutral,1
NCT04445831,"{'position': 1, 'link': 'https://finance.yahoo.com/news/ac-immune-wins-fda-fast-165352311.html', 'title': 'AC Immune wins FDA fast track for Alzheimer’s vaccine', 'source': 'Yahoo Finance', 'date': 'Jul 25, 2024', 'snippet': ""AC Immune's phosphorylated Tau (pTau)-targeting vaccine has secured a fast \ntrack designation from the US Food and Drug Administration (FDA) to treat \nAlzheimer'..."", 'thumbnail': 'https://serpapi.com/searches/6723f6ededa5f52fe2b30fd7/images/92d3ba82314df855c356f04bf32513d46e89360e410bce8dd41ab09198441dab.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5348968505859375}",,,,,,,,,,['positive'],positive,1
NCT00403767,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1009638', 'title': 'Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation', 'source': 'The New England Journal of Medicine', 'date': 'Aug 10, 2011', 'snippet': 'In a double-blind trial, we randomly assigned 14,264 patients with \nnonvalvular atrial fibrillation who were at increased risk for stroke to...', 'thumbnail': 'https://serpapi.com/searches/6723f70eadc33b152f2c5d6a/images/9b641d553ca3745834846a0c43a8d37ba19acc865fed2a15bdac853fe476afd7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8792414665222168}",,,,,,,,,,['neutral'],neutral,1
NCT03815695,"{'position': 1, 'link': 'https://sicklecellanemianews.com/ft-4202/', 'title': 'Etavopivat for sickle cell disease', 'source': 'Sickle Cell Disease News', 'date': 'Jun 29, 2024', 'snippet': 'Last updated June 29, 2024, by Margarida Maia, PhD ✓ Fact-checked by Joana \nCarvalho, PhD. How etavopivat works. Administration. Clinical trials.', 'thumbnail': 'https://serpapi.com/searches/6723f713d16915231ac92f68/images/22410aacf09994fb8697054f070c6a1f8c94dbeee588182a222c3af5a7679d2d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9281692504882812}",,,,,,,,,,['neutral'],neutral,1
NCT02333799,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1901814', 'title': 'Treatment of Highly Drug-Resistant Pulmonary Tuberculosis', 'source': 'The New England Journal of Medicine', 'date': 'Mar 4, 2020', 'snippet': 'we investigated treatment with three oral drugs — bedaquiline, pretomanid, \nand linezolid — that have bactericidal activity against tuberculosis...', 'thumbnail': 'https://serpapi.com/searches/6723f71cd78a98ea9b0125a5/images/55892d0d415ba9e473f73cc7b84af8305403df13483dba93c3843bb8bc1af8a3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8777911067008972}",,,,,,,,,,['neutral'],neutral,1
NCT03804268,"{'position': 1, 'link': 'https://www.optometrytimes.com/view/what-to-know-about-new-topical-presbyopia-correcting-drops', 'title': 'What to know about new topical presbyopia-correcting drops', 'source': 'Optometry Times', 'date': 'Sep 22, 2022', 'snippet': 'With the recent approval of the first topical presbyopia-correcting drops, \nand several other products making their way through FDA clinical...', 'thumbnail': 'https://serpapi.com/searches/6723f71e7ec4ae37dedeb175/images/eed2fbe838e173cda29cb8d3ad5644c09c7b341bfccd5b422aac5afdac434950.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8269004821777344}",,,,,,,,,,['neutral'],neutral,1
NCT02343172,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.2017.74.9598', 'title': 'Clinical and Molecular Spectrum of Liposarcoma | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Dec 8, 2017', 'snippet': 'The classification of liposarcomas into four principal subtypes reflects \nthe distinct clinical behavior, treatment sensitivity, and underlying \nbiology...', 'thumbnail': 'https://serpapi.com/searches/6723f72f1fc7c51ed0ec1b95/images/87afd0f506fa41cfee825f9e98eb0f7117ec192f58e26c9351b8bc148b18d6b3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.912874698638916}",,,,,,,,,,['neutral'],neutral,1
NCT01131676,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1504720', 'title': 'Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Oct 31, 2016', 'snippet': 'Patients with type 2 diabetes at high risk for cardiovascular events who \nreceived empagliflozin, as compared with placebo, had a lower rate of the \nprimary...', 'thumbnail': 'https://serpapi.com/searches/6723f74018787da4074e81b2/images/5fef1bd1cea9c580e670b7f6000f42a1f5a7d3915c5d9e1b044a6df10b01613c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6489055752754211}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.037778', 'title': 'Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial | Circulation', 'source': 'American Heart Association Journals', 'date': 'Dec 6, 2018', 'snippet': 'Background:In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] \nCardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients)...', 'thumbnail': 'https://serpapi.com/searches/6723f74018787da4074e81b2/images/5fef1bd1cea9c58037c2fe6d5dcd7098878cb6cd70c1cb343ce5616b9a448a8b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.907488226890564}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00322452,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0909530', 'title': 'Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR', 'source': 'The New England Journal of Medicine', 'date': 'Jun 24, 2010', 'snippet': 'Non–small-cell lung cancer with sensitive mutations of the epidermal growth \nfactor receptor (EGFR) is highly responsive to EGFR tyrosine...', 'thumbnail': 'https://serpapi.com/searches/6723f74098d8de9a7e2548c4/images/a0e65893af89cdcaa01c0192abb92fd740f533519da82b95b1c18c4d91e4e463.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8041620850563049}",,,,,,,,,,['neutral'],neutral,1
NCT03217591,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1272073/full', 'title': 'Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases', 'source': 'Frontiers', 'date': 'Feb 13, 2024', 'snippet': ""1Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan \nProvincial People's Hospital, School of Medicine, University of Electronic \nScience..."", 'thumbnail': 'https://serpapi.com/searches/6723f746e30abc0f9798368a/images/cb12b3375e8fec8dd4e7098f29482734065b77c7cf26119c89aa611dfc714a65.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8857882022857666}",,,,,,,,,,['neutral'],neutral,1
NCT04176991,"{'position': 1, 'link': 'https://friedreichsataxianews.com/news/dosing-complete-in-phase-1-trial-of-cti-1601-synthetic-frataxin-for-fa/', 'title': 'Dosing Complete in Phase 1 Trial of CTI-1601, Synthetic Frataxin for FA', 'source': ""Friedreich's Ataxia News"", 'date': 'Dec 10, 2020', 'snippet': 'Larimar Therapeutics completed dosing for the single-ascending dose portion \nof a Phase 1 clinical trial of CTI-1601, in the treatment of...', 'thumbnail': 'https://serpapi.com/searches/6723f748749783cf6fad587f/images/14fc97b13c547aa5178ccdd48630ffcbfd3b95c54cbaa9c6cf7371b6fdfb534d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8179010152816772}","{'position': 2, 'link': 'https://friedreichsataxianews.com/news/first-friedreichs-ataxia-patient-dosed-ole-study-nomlabofusp/', 'title': 'First FA patient dosed in OLE study of nomlabofusp, formerly CTI-1601', 'source': ""Friedreich's Ataxia News"", 'date': 'Mar 19, 2024', 'snippet': 'The first patient has been dosed in a long-term, open-label extension (OLE) \nof a Phase 2 dose escalation study that tested nomlabofusp, formerly \nCTI-1601.', 'thumbnail': 'https://serpapi.com/searches/6723f748749783cf6fad587f/images/14fc97b13c547aa5cd3df3b920f1749905b25c3302a2cac95f19bdb4a244a84b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8837335109710693}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02696785,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2024/04/29/taltz-eased-ankylosing-spondylitis-pain-regardless-inflammation-reduction/', 'title': 'Ankylosing spondylitis pain eased with Taltz even if inflammation isn’t', 'source': 'Ankylosing Spondylitis News', 'date': 'Apr 29, 2024', 'snippet': 'The Phase 3 COAST-V clinical trial tested Taltz against either a placebo or \nadalimumab, sold as Humira or biosimilars, in 341 adults with...', 'thumbnail': 'https://serpapi.com/searches/6723f76aeda5f52fe2b31007/images/86e1633442b75d0f984673515351a39874b82cb911d8ac942ec34ca90e831449.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7398726344108582}",,,,,,,,,,['neutral'],neutral,1
NCT01763931,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1082057/full', 'title': 'The hypoxia-inducible factor-1α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting', 'source': 'Frontiers', 'date': 'Feb 8, 2023', 'snippet': 'Hypoxia-inducible factor-1α (HIF-1α) is a crucial mediator of intra-tumoral \nheterogeneity, tumor progression, and unresponsiveness to...', 'thumbnail': 'https://serpapi.com/searches/6723f773f79a01c19a37e32e/images/055ab054e532bad8618cf14c8ce5d494c858b99918df5cb6ba162c528f6f97ad.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.679175615310669}",,,,,,,,,,['neutral'],neutral,1
NCT00483652,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/01/17/acorda-taking-over-global-sales-ampyra-fampyra-ms/', 'title': 'Acorda taking over global sales of Ampyra and Fampyra for MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Jan 17, 2024', 'snippet': 'An agreement with Acorda is ending that had Biogen handle sales of Fampyra, \nas the MS walking aid treatment is known outside the US.', 'thumbnail': 'https://serpapi.com/searches/6723f77fbb64ac868bab9c64/images/0fe5c17ad3e9c5683bc6e43c6a42537849c027999eae7ea8fa6fd4d0895644e9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9308282136917114}",,,,,,,,,,['neutral'],neutral,1
NCT03482050,"{'position': 1, 'link': 'https://alsnewstoday.com/news/pluri-enters-deal-manufacture-kadimastem-astrorx-als/', 'title': 'Pluri enters deal to manufacture Kadimastem’s AstroRx for ALS', 'source': 'ALS News Today', 'date': 'Jul 22, 2024', 'snippet': 'Kadimastem has partnered with Pluri to produce its experimental cell-based \ntherapy AstroRx for a Phase 2a clinical trial in ALS in the U.S..', 'thumbnail': 'https://serpapi.com/searches/6723f790a47167508784557e/images/addd39d10420ba4d6362c6aeb8efb226d5f3fc5413e1710e93c2060657d7cd2c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.933204710483551}","{'position': 2, 'link': 'https://www.cgtlive.com/view/kadimastem-itolerance-immunosuppression-free-diabetes-cell-therapy-itol-102-trials', 'title': 'Kadimastem and iTolerance Work to Bring Immunosuppression-Free Diabetes Cell Therapy to Trials', 'source': 'CGTLive®', 'date': 'Jan 13, 2024', 'snippet': ""Kadimasem's lead clinical candidate, AstroRx, was recently cleared for \ntrials in the US for people with ALS."", 'thumbnail': 'https://serpapi.com/searches/6723f790a47167508784557e/images/addd39d10420ba4d7ab373233fd8d079c29c1942de6c49cf7523a8b3f718cff7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6663820743560791}","{'position': 3, 'link': 'https://alsnewstoday.com/news/astrorx-safe-slows-als-progression-phase-1-2-clinical-trial/', 'title': 'AstroRx safe and slows ALS progression in Phase 1/2 clinical trial...', 'source': 'ALS News Today', 'date': 'Feb 24, 2023', 'snippet': ""A single intrathecal injection of Kadimastem's AstroRx was safe and \nsignificantly slowed ALS progression in a Phase 1/2 study."", 'thumbnail': 'https://serpapi.com/searches/6723f790a47167508784557e/images/addd39d10420ba4db21a9e2d22fcccf42984e041d71eacdc6ce5093555d7db0d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5787036418914795}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02643303,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1256360/full', 'title': 'Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer', 'source': 'Frontiers', 'date': 'Oct 4, 2023', 'snippet': 'Breast cancer is characterized by a high incidence rate and its treatment \nchallenges, particularly in certain subtypes. Consequently, there is an \nurgent...', 'thumbnail': 'https://serpapi.com/searches/6723f794a3657a0b50ff84ec/images/93432cbef129a6aa486f16f5fe87305c70daff8a609889e5362aa6cbe9ecaedb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8037545680999756}",,,,,,,,,,['neutral'],neutral,1
NCT03972215,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-25952-2', 'title': 'Berberine is an insulin secretagogue targeting the KCNH6 potassium channel', 'source': 'Nature', 'date': 'Sep 23, 2021', 'snippet': 'In this study, we identify BBR as a glucose-dependent insulin secretagogue \nfor treating diabetes without causing hypoglycemia that targets KCNH6 \nchannels.', 'thumbnail': 'https://serpapi.com/searches/6723f81bb6e4db2835632609/images/cb8af4e5c52f9e0d3500ecd3f9fdb88a09c295768618d77e13f20bc8f41ecca4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9191226363182068}",,,,,,,,,,['neutral'],neutral,1
NCT05576662,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(23)00154-2/fulltext', 'title': 'Post-COVID cognitive dysfunction: current status and research recommendations for high risk population', 'source': 'The Lancet', 'date': 'Jul 5, 2023', 'snippet': 'Post-COVID cognitive dysfunction (PCCD) is a condition in which patients \nwith a history of severe acute respiratory syndrome coronavirus 2...', 'thumbnail': 'https://serpapi.com/searches/6723f82d6ad3c9c2f7a69c19/images/7ef011f789a4b2d7473a61b6afc3d258269da8df3595c06a2ddf7c204c3599f9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5858355760574341}",,,,,,,,,,['neutral'],neutral,1
NCT01642004,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1504627', 'title': 'Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'May 31, 2015', 'snippet': 'Overall survival, response rate, and progression-free survival were \nsignificantly better with nivolumab than with docetaxel, regardless of \nPD-L1 expression...', 'thumbnail': 'https://serpapi.com/searches/6723f82d6f9f63c8a936f993/images/d8f2afe54d95f5c218409c2dfa8be11fe9b480611beb36dc1403f991b50ea142.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6158267855644226}","{'position': 2, 'link': 'https://immuno-oncologynews.com/2017/09/11/advanced-lung-cancer-long-term-survival-rates-improved-by-opdivo-data-show/', 'title': 'Advanced Lung Cancer Long-Term Survival Rates Improved with Opdivo, Data Show', 'source': 'Immuno-Oncology News', 'date': 'Sep 11, 2017', 'snippet': 'Opdivo (nivolumab) outperformed the cancer drug Taxotere (docetaxel) in \nclinical trials of advanced and earlier treated lung cancer, with survival \nrates about...', 'thumbnail': 'https://serpapi.com/searches/6723f82d6f9f63c8a936f993/images/d8f2afe54d95f5c2f625923ebb0639371b602cfc228b14c8139e31c53ade67fe.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5211159586906433}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04085601,"{'position': 1, 'link': 'https://docwirenews.com/post/pegcetacoplan-associated-with-substantial-cost-savings-for-patients-with-paroxysmal-nocturnal-hemoglobinuria', 'title': 'Pegcetacoplan Associated With Substantial Cost Savings for Patients With Paroxysmal Nocturnal Hemoglobinuria', 'source': 'Docwire News', 'date': 'Sep 15, 2023', 'snippet': 'Results of a recent study in the Journal of Comparative Effectiveness \nResearch suggest that pegcetacoplan is a cost-effective alternative...', 'thumbnail': 'https://serpapi.com/searches/6723f8367e1d1fae374b52b0/images/f952a8f33bcf9f46624dbd3e8483d881b5d8b171432c9a41afe39facf38029e2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8797586560249329}","{'position': 2, 'link': 'https://www.europeanpharmaceuticalreview.com/news/155252/pegcetacoplan-safe-and-effective-in-paroxysmal-nocturnal-haemoglobinuria-trial/', 'title': 'Pegcetacoplan safe and effective in paroxysmal nocturnal haemoglobinuria trial', 'source': 'European Pharmaceutical Review', 'date': 'May 26, 2021', 'snippet': 'In a trial pegcetacoplan resulted in 86 percent of paroxysmal nocturnal \nhaemoglobinuria (PNH) patients achieving haemoglobin stabilisation.', 'thumbnail': 'https://serpapi.com/searches/6723f8367e1d1fae374b52b0/images/f952a8f33bcf9f46b0757fb40ef27da49ef31990dd18743acb376f6180f2e96e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.694446861743927}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02926066,"{'position': 1, 'link': 'https://www.cgtlive.com/view/upstaza-approved-aadc-deficiency-uk', 'title': 'Upstaza Approved for AADC Deficiency in UK', 'source': 'CGTLive®', 'date': 'Nov 21, 2022', 'snippet': 'Upstaza (eladocagene exuparvovec), a recombinant adeno-associated virus \nserotype 2 (AAV2)-based gene therapy intended to treat aromatic L–amino \nacid...', 'thumbnail': 'https://serpapi.com/searches/6723f838b28e6b6e596dd7fa/images/6100cfe5bc6d2cf8f436d424b95de7974b98366c1e3111df5fd35696c2144680.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8430208563804626}","{'position': 2, 'link': 'https://aadcnews.com/news/upstaza-gene-therapy-aadc-deficiency-approved-uk/', 'title': 'Upstaza, Gene Therapy for AADC Deficiency, Approved in UK', 'source': 'AADC News', 'date': 'Nov 23, 2022', 'snippet': 'The gene therapy Upstaza (eladocagene exuparvovec) has been approved in the \nUK to treat adults and children, 18 months and older, with aromatic l-amino \nacid...', 'thumbnail': 'https://serpapi.com/searches/6723f838b28e6b6e596dd7fa/images/6100cfe5bc6d2cf8e8844be08486ddd3cc9cec19787ad0db5bd506484890d141.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.784906268119812}","{'position': 3, 'link': 'https://www.cgtlive.com/view/hwu-questions-remaining-aadc-deficiency', 'title': 'Paul Wuh-Liang Hwu, MD, PhD, on Questions Remaining With AADC Deficiency', 'source': 'CGTLive®', 'date': 'Jul 22, 2022', 'snippet': 'CGTLive spoke with study investigator Paul Wuh-Liang Hwu, MD, PhD, \nprofessor, National Taiwan University Hospital, about Upstaza as well as \nhis work in Pompe...', 'thumbnail': 'https://serpapi.com/searches/6723f838b28e6b6e596dd7fa/images/6100cfe5bc6d2cf8b3ea48da96895671925fa24375f7ceaad443e430db1d73ee.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9344761371612549}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02220894,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext', 'title': 'Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial', 'source': 'The Lancet', 'date': 'Apr 4, 2019', 'snippet': 'First-line pembrolizumab monotherapy improves overall and progression-free \nsurvival in patients with untreated metastatic non-small-cell...', 'thumbnail': 'https://serpapi.com/searches/6723f83b3c863da05c1811ca/images/a07fd9ccb40acfd17ed9e117c37de67a04f253da4a4cd9c0dc1af7db8e5b89a9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8304150104522705}",,,,,,,,,,['neutral'],neutral,1
NCT04542057,"{'position': 1, 'link': 'https://copdnewstoday.com/news/inhaled-ensifentrine-improves-lung-function-phase-3-trial-shows/', 'title': 'Inhaled Ensifentrine Improves Lung Function, Phase 3 Trial Shows |...', 'source': 'COPD News Today', 'date': 'Aug 22, 2022', 'snippet': 'Ensifentrine safely and effectively improved lung function and reduced the \nrate and risk of exacerbations in COPD patients in a trial.', 'thumbnail': 'https://serpapi.com/searches/6723f84e74f0a4921704ea9e/images/96aeab566eed0a283563c5c507f739f492530552d5c9bbb2a8148442d0a37f55.png', 'sentiment': 'positive', 'sentiment_prob': 0.7553162574768066}","{'position': 2, 'link': 'https://www.drugtopics.com/view/fda-approves-ensifentrine-for-treatment-of-copd', 'title': 'FDA Approves Ensifentrine for Treatment of COPD', 'source': 'Drug Topics', 'date': 'Jun 27, 2024', 'snippet': 'The FDA has approved ensifentrine (Ohtuvayre) for the maintenance treatment \nof chronic obstructive pulmonary disease (COPD) in adult patients.', 'thumbnail': 'https://serpapi.com/searches/6723f84e74f0a4921704ea9e/images/96aeab566eed0a28a64eae68f8ecd0ebd40ff3ee439681d7426e9a684de1141b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7171338796615601}","{'position': 3, 'link': 'https://copdnewstoday.com/news/enhance-1-trial-testing-ensifentrine-copd-completes-enrollment/', 'title': 'Enrollment Complete – Tops 800 – in ENHANCE-1 Trial of Ensifentrine', 'source': 'COPD News Today', 'date': 'Jun 16, 2022', 'snippet': ""Enrollment is now complete in ENHANCE-1, a Phase 3 clinical trial testing \nVerona Pharma's experimental inhalation therapy ensifentrine in more than \n800 people."", 'thumbnail': 'https://serpapi.com/searches/6723f84e74f0a4921704ea9e/images/96aeab566eed0a2818218a018cab8f702ef867cbc68015e604bbc066db9a316e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8384408950805664}",,,,,,,,"['positive', 'neutral', 'neutral']",neutral,1
NCT03536884,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2102383', 'title': 'Bimekizumab versus Secukinumab in Plaque Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Apr 23, 2021', 'snippet': 'Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both \ninterleukin-17A and interleukin-17F. The efficacy and safety of...', 'thumbnail': 'https://serpapi.com/searches/6723f84e7d533e68053dcb81/images/a81d4fd6a9e3186716d375b7d1f341601a4265a35cac770d8a76bb726f05772c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8939939141273499}",,,,,,,,,,['neutral'],neutral,1
NCT02279160,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/long-term-safety-and-tolerability-of-ralinepag-in-pah/', 'title': 'Long-Term Safety, Tolerability of Ralinepag in Pulmonary Arterial Hypertension', 'source': 'Pulmonology Advisor', 'date': 'May 31, 2022', 'snippet': 'An open-label extension study of the long-term safety of ralinepag for PAH \nfound a positive risk-benefit ratio similar to that of the parent...', 'thumbnail': 'https://serpapi.com/searches/6723f8620053c79278d24911/images/f8d2400354eec98a48dec93bd14601e108241e99edc4d55c0c22d2b789b18cbc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8393498659133911}",,,,,,,,,,['neutral'],neutral,1
NCT04508621,"{'position': 1, 'link': 'https://fibromyalgianewstoday.com/2020/09/08/enrollment-open-in-second-phase-3-trial-of-higher-tnx-102-sl-dose-for-managing-fm/', 'title': 'Enrollment Open in Second Phase 3 Trial of Higher TNX-102 SL Dose for Managing FM', 'source': 'Fibromyalgia News Today', 'date': 'Sep 8, 2020', 'snippet': ""The second Phase 3 clinical trial examining a higher dose of TNX-102 SL \n(sublingual cyclobenzaprine), Tonix Pharmaceuticals' bedtime..."", 'thumbnail': 'https://serpapi.com/searches/6723f8643c944b934c0ea887/images/f25750ad05bcba56b073a70acee5c8c6f1e1f2526beaff3f7ad12cbb48c0798a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9358941316604614}",,,,,,,,,,['neutral'],neutral,1
NCT03411161,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-66244-1', 'title': 'A whole-genome CRISPR screen identifies the spindle accessory checkpoint as a locus of nab-paclitaxel resistance in a pancreatic cancer cell line', 'source': 'Nature', 'date': 'Jul 10, 2024', 'snippet': 'A genome-wide CRISPR interference and knockout screen in the PANC-1 cell \nline with the drug nab-paclitaxel has identified a group of spindle \nassembly...', 'thumbnail': 'https://serpapi.com/searches/6723f8ce29e6fb794b244596/images/87b717f17b63d8bd364298e8933ca8d5c46ff57325c8812ec6cafcccfba70d7a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.834575355052948}",,,,,,,,,,['neutral'],neutral,1
NCT01006265,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/08/30/long-term-ponvory-treatment-safe-effective-rrms-trial-data/', 'title': 'Long-term Ponvory Treatment Safe, Effective in RRMS, Trial Data Show', 'source': 'Multiple Sclerosis News Today', 'date': 'Aug 30, 2022', 'snippet': 'Long-term treatment with Ponvory was found to reduce the rate of relapses \nand prevent brain volume loss in relapsing-remitting MS patients.', 'thumbnail': 'https://serpapi.com/searches/6723f8ddfd3b5ae60890cbe8/images/56774a592d50f7103c602d762cc97475e35baa153c33819d1177acbfaddcaf9c.png', 'sentiment': 'positive', 'sentiment_prob': 0.6364147067070007}",,,,,,,,,,['positive'],positive,1
NCT01668849,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-27893-2', 'title': 'Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2', 'source': 'Nature', 'date': 'Jan 20, 2022', 'snippet': 'The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused \nthe pandemic of the coronavirus induced disease 2019 (COVID-19)...', 'thumbnail': 'https://serpapi.com/searches/6723f8eafc40bf5af06cdd46/images/730d53f9dd83ee82057ef990d07462fc160ab8baf3526857005582afacc1f914.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6649355888366699}",,,,,,,,,,['negative'],negative,0
NCT02574598,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.6453', 'title': 'The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis', 'source': 'Wiley Online Library', 'date': 'Aug 16, 2023', 'snippet': 'Cancer Medicine is an open access, broad-scope oncology journal covering \nclinical cancer research, cancer biology, cancer prevention,...', 'thumbnail': 'https://serpapi.com/searches/6723f8fbcc487953868270a7/images/1b0498b7b5e551d045efd01da8371fdb6e7b29d999c5b2b3756aa64ea2841390.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8414208889007568}",,,,,,,,,,['neutral'],neutral,1
NCT01639339,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2001180', 'title': 'Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 16, 2020', 'snippet': 'In this trial involving patients with active lupus nephritis, more patients \nwho received belimumab plus standard therapy had a primary efficacy renal \nresponse.', 'thumbnail': 'https://serpapi.com/searches/6723f923213c87df1ae4a86d/images/c71fc39cbf4501704dfa5b2e9ac5797ec5ccc81003933358610d2c3770513a83.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8875280618667603}",,,,,,,,,,['neutral'],neutral,1
NCT01838551,"{'position': 1, 'link': 'https://www.endocrinologyadvisor.com/news/phase-3-sonics-trial-investigates-levoketoconazole-for-cushing-syndrome/', 'title': 'Levoketoconazole Effectively Treats Endogenous Cushing Syndrome in Phase 3 Trial', 'source': 'Endocrinology Advisor', 'date': 'Oct 2, 2019', 'snippet': 'According to results of the phase 3 SONICS trial, levoketoconazole is a \nsafe and effective treatment option for patients with Cushing...', 'thumbnail': 'https://serpapi.com/searches/6723f9323d629b3e007c6607/images/4e2c9617c31fa424b8a866eeb8ba54fb87f9bf9192a2c749bc73a076a131d180.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5104603171348572}","{'position': 2, 'link': 'https://cushingsdiseasenews.com/news/recorlev-approved-adults-endogenous-cushings-syndrome/', 'title': 'FDA Approves Recorlev for Adults With Endogenous Cushing’s', 'source': ""Cushing's Disease News"", 'date': 'Jan 5, 2022', 'snippet': ""The U.S. Food and Drug Administration (FDA) has approved Recorlev \n(levoketoconazole), and it's expected to be available early this year."", 'thumbnail': 'https://serpapi.com/searches/6723f9323d629b3e007c6607/images/4e2c9617c31fa424e3b9445dce47236e8cab478dda3780263c8c9ab8e1e19746.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5631511211395264}","{'position': 3, 'link': 'https://cushingsdiseasenews.com/news/approved-therapy-recorlev-granted-orphan-drug-exclusivity-fda/', 'title': 'Approved Therapy Recorlev Now Wins FDA Orphan-drug Exclusivity', 'source': ""Cushing's Disease News"", 'date': 'Feb 1, 2023', 'snippet': ""The FDA has granted Xeris Pharmaceuticals orphan-drug exclusivity for \nRecorlev, its approved treatment for endogenous Cushing's syndrome."", 'thumbnail': 'https://serpapi.com/searches/6723f9323d629b3e007c6607/images/4e2c9617c31fa424a4b319194511eb4d39f43565860465811b872af40bf8cf5f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5163628458976746}",,,,,,,,"['positive', 'neutral', 'neutral']",neutral,1
NCT03289455,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01497-1', 'title': 'CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial', 'source': 'Nature', 'date': 'Oct 12, 2021', 'snippet': 'Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown \nremarkable activity in B cell acute lymphoblastic leukemia (B-ALL).', 'thumbnail': 'https://serpapi.com/searches/6723f936f6aa534e9217e4ed/images/283c66684c722f6af40751f95efbd333ca1b8558302fc77ce7fc73fb05e0b885.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9159050583839417}",,,,,,,,,,['neutral'],neutral,1
NCT01524978,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-022-00341-0', 'title': 'BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study | npj Precision Oncology', 'source': 'Nature', 'date': 'Feb 18, 2023', 'snippet': 'We performed a pooled analysis of four phase one studies evaluating the \nsafety and efficacy of vemurafenib monotherapy and vemurafenib combined \nwith targeted...', 'thumbnail': 'https://serpapi.com/searches/6723f9567ac731b61c940734/images/7475048598d1cb8f44fad53f5e53d9b2a920fa975e62aee045dc6e3a5d7bd428.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9065907597541809}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1502309', 'title': 'Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations', 'source': 'The New England Journal of Medicine', 'date': 'Aug 20, 2015', 'snippet': 'We undertook a histology-independent phase 2 “basket” study of vemurafenib \nin BRAF V600 mutation–positive nonmelanoma cancers.', 'thumbnail': 'https://serpapi.com/searches/6723f9567ac731b61c940734/images/7475048598d1cb8f73c0341ef207cb1772cfac1d0e9ac9ba2febc7c88ee16d22.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9230263233184814}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03178487,"{'position': 1, 'link': 'https://www.empr.com/home/news/rinvoq-approved-for-active-ankylosing-spondylitis/', 'title': 'Rinvoq Approved for Active Ankylosing Spondylitis', 'source': 'Medical Professionals Reference', 'date': 'May 2, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib) \nfor the treatment of adults with active ankylosing spondylitis (AS).', 'thumbnail': 'https://serpapi.com/searches/6723f9570e6db3745b1e2a9e/images/9c20dbe67bfdff2ed57336fdc11d75bf5ac700e5f7763095fcf7e979c49915d7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7677649855613708}",,,,,,,,,,['neutral'],neutral,1
NCT04332276,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/study-review-highlights-limits-levodopa-effectiveness/', 'title': 'Study review highlights limits of levodopa effectiveness', 'source': ""Parkinson's News Today"", 'date': '1 month ago', 'snippet': 'Levodopa becomes less effective with age and disease progression, per a \nstudy from Inbrain, which is developing a new form of the treatment.', 'thumbnail': 'https://serpapi.com/searches/6723f9660c666800a3357139/images/5accb66396e6e202af249a6256b6a329ad40be5c07fc03a6a104c14e2c78fca1.png', 'sentiment': 'negative', 'sentiment_prob': 0.622397780418396}",,,,,,,,,,['negative'],negative,0
NCT01239797,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1505654', 'title': 'Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma', 'source': 'The New England Journal of Medicine', 'date': 'Jun 2, 2015', 'snippet': 'In this phase 3 study, we randomly assigned patients to receive either \nelotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or...', 'thumbnail': 'https://serpapi.com/searches/6723f99f8db3765529660de2/images/e220a1dcc5cb6e48155f31e432f35ecf1ab8e714da45db2af97f8ae53f0fed73.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9350350499153137}","{'position': 2, 'link': 'https://www.nature.com/articles/s41408-020-00357-4', 'title': 'Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study', 'source': 'Nature', 'date': 'Sep 4, 2020', 'snippet': 'Prolonging overall survival (OS) remains an unmet need in relapsed or \nrefractory multiple myeloma (RRMM). In ELOQUENT-2 (NCT01239797),...', 'thumbnail': 'https://serpapi.com/searches/6723f99f8db3765529660de2/images/e220a1dcc5cb6e489e63cbb9ffe26e6b7a165c8e03c5f185a46fcd45beacc232.png', 'sentiment': 'neutral', 'sentiment_prob': 0.806358814239502}","{'position': 3, 'link': 'https://www.nature.com/articles/bcj201718', 'title': 'Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis', 'source': 'Nature', 'date': 'Mar 10, 2017', 'snippet': 'A phase 3, international, randomized clinical trial that investigated the \nefficacy and safety of ELd compared with lenalidomide/dexamethasone (Ld) in \npatients...', 'thumbnail': 'https://serpapi.com/searches/6723f99f8db3765529660de2/images/e220a1dcc5cb6e48ff2059e61d32b4b531bd6deb4bca2a88b8c108e952b3a532.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9092058539390564}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT01095497,"{'position': 1, 'link': 'https://angioedemanews.com/cinryze/', 'title': 'Cinryze (human C1 esterase inhibitor) for hereditary angioedema', 'source': 'Angioedema News', 'date': 'Jan 9, 2024', 'snippet': 'Cinryze, marketed by Shire, is an approved injectable medicine to prevent \nsevere swelling attacks in people with hereditary angioedema...', 'thumbnail': 'https://serpapi.com/searches/6723f9a252a04ebbcc463b3a/images/55044db00070d18dc0d9ed630e0508e1b49937ca3c679e1418f8f5dbd4dc4a9b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8004082441329956}",,,,,,,,,,['neutral'],neutral,1
NCT01979952,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/ipf-patients-live-longer-on-nintedanib-pooled-data-from-six-trials-show/', 'title': 'IPF Patients Live Longer on Ofev Compared with Placebo, Analysis Shows', 'source': 'Pulmonary Fibrosis News', 'date': 'Apr 16, 2019', 'snippet': 'Treatment with Ofev (nintedanib) can significantly extend the survival of \npatients with idiopathic pulmonary fibrosis (IPF), an analysis of pooled \ndata from...', 'thumbnail': 'https://serpapi.com/searches/6723f9c8213c87df4d44ab93/images/eec62ea8cf06b1de5906744c8456a634be4f3fa27f030868d3164578cf32006f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.544462263584137}",,,,,,,,,,['neutral'],neutral,1
NCT02623699,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2204705', 'title': 'Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS', 'source': 'The New England Journal of Medicine', 'date': 'Sep 21, 2022', 'snippet': 'Tofersen reduced concentrations of SOD1 in CSF and of neurofilament light \nchains in plasma over 28 weeks but did not improve clinical end points and \nwas...', 'thumbnail': 'https://serpapi.com/searches/6723f9de4677bf90f1c1a4e6/images/0958658b8385b190f0e92739110ea961f5943abf999dabad2f47f465cc15d180.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5358057022094727}","{'position': 2, 'link': 'https://investors.biogen.com/news-releases/news-release-details/biogen-announces-topline-results-tofersen-phase-3-study-and-its', 'title': 'Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS', 'source': 'Biogen', 'date': 'Oct 17, 2021', 'snippet': 'In the Phase 3 VALOR study, the primary endpoint as measured by the Revised \nAmyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R)...', 'thumbnail': 'https://serpapi.com/searches/6723f9de4677bf90f1c1a4e6/images/0958658b8385b190b666f1a7778b0ef42a29712444b4194318c7d91f23ab5edb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7961919903755188}","{'position': 3, 'link': 'https://www.nih.gov/news-events/news-releases/next-generation-als-drug-silences-inherited-form-disease-animal-models', 'title': 'Next-generation ALS drug silences inherited form of the disease in animal models', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jul 25, 2018', 'snippet': 'NIH-funded preclinical study suggests drug may be ready for early stage \nclinical trials.', 'thumbnail': 'https://serpapi.com/searches/6723f9de4677bf90f1c1a4e6/images/0958658b8385b19004a873b6ca0dbc29c5a1be82919c304e8db7df1d1db57434.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9003764986991882}","{'position': 4, 'link': 'https://alsnewstoday.com/news/fda-approves-tofersen-now-qalsody-treatment-adults-sod1-als/', 'title': 'FDA approves tofersen, now Qalsody, as treatment for SOD1-ALS |...', 'source': 'ALS News Today', 'date': 'Apr 25, 2023', 'snippet': ""The US Food and Drug Administration (FDA) has granted conditional approval \nto Biogen's tofersen, now named Qalsody, for the treatment of amyotrophic \nlateral..."", 'thumbnail': 'https://serpapi.com/searches/6723f9de4677bf90f1c1a4e6/images/0958658b8385b1906ce44b6124b935656da0f469efb877ce0ee308921964ddf6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7133066058158875}","{'position': 5, 'link': 'https://alsnewstoday.com/news/phase-3-tofersen-trial-fails-slow-sod1-als-trends-hopeful-valor-trial/', 'title': 'Tofersen Fails to Slow SOD1-ALS in VALOR Trial, But Hopeful Trends Seen', 'source': 'ALS News Today', 'date': 'Oct 20, 2021', 'snippet': 'Top-line results of Phase 3 VALOR trial show tofersen failed to \nsignificantly slow disease progression in ALS patients with SOD1 mutations.', 'thumbnail': 'https://serpapi.com/searches/6723f9de4677bf90f1c1a4e6/images/0958658b8385b1906a0b2870503937ad8bc2d1d8c7212f46728bc5c767572cfe.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5634244084358215}","{'position': 6, 'link': 'https://alsnewstoday.com/news/tofersen-to-treat-sod1-als-under-review-for-european-union/', 'title': 'Tofersen to Treat SOD1 ALS Under Review for European Union | EMA Joins FDA in Considering Approval', 'source': 'ALS News Today', 'date': 'Dec 6, 2022', 'snippet': ""The EMA will review Biogen's application for tofersen's approval in \ntreating ALS caused by SOD1 gene mutations; FDA decision due in April."", 'thumbnail': 'https://serpapi.com/searches/6723f9de4677bf90f1c1a4e6/images/0958658b8385b190167993f0790501a61d11b641635d9c95478d17c271967721.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9256871938705444}","{'position': 7, 'link': 'https://alsnewstoday.com/news/committee-favors-eu-approval-qalsody-1st-treatment-sod1-als/', 'title': 'Committee favors EU approval of Qalsody for adults with SOD1-ALS', 'source': 'ALS News Today', 'date': 'Feb 28, 2024', 'snippet': ""An advisory committee of the European Medicines Agency (EMA) has \nrecommended that Biogen's Qalsody (tofersen) be approved in the European \nUnion under..."", 'thumbnail': 'https://serpapi.com/searches/6723f9de4677bf90f1c1a4e6/images/0958658b8385b19034222a5c1459b03c71b502259ed2dcd91bb44fa19c46f77f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8269476294517517}","{'position': 8, 'link': 'https://alsnewstoday.com/news/qalsody-biogen-approved-european-union-treat-sod1-als/', 'title': ""Biogen's Qalsody approved in European Union to treat SOD1-ALS"", 'source': 'ALS News Today', 'date': 'May 31, 2024', 'snippet': 'The European Commission has approved Qalsody to treat ALS patients in the \nEU whose disease is associated with mutations in the SOD1 gene.', 'thumbnail': 'https://serpapi.com/searches/6723f9de4677bf90f1c1a4e6/images/0958658b8385b19097068ef9d2183b7f65c2866a27dedff959a1ea384add98d1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8798172473907471}","{'position': 9, 'link': 'https://alsnewstoday.com/news/panel-favors-tofersen-biomarker-data-mixed-on-efficacy-sod1-als/', 'title': 'Panel favors tofersen biomarker, is mixed on efficacy in SOD1-ALS...', 'source': 'ALS News Today', 'date': 'Mar 24, 2023', 'snippet': 'A FDA committee agrees that changes in NfL levels are reasonably likely to \npredict effectiveness from tofersen in people with SOD1-ALS.', 'thumbnail': 'https://serpapi.com/searches/6723f9de4677bf90f1c1a4e6/images/0958658b8385b19047b3ea68792ba07e42c12e857762cdfd48cde69c7fff8824.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8805062770843506}",,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT05192265,"{'position': 1, 'link': 'https://www.koreabiomed.com/news/articleView.html?idxno=13058', 'title': 'Shinpoong completes malaria trial of Pyramax in Nigeria', 'source': 'KBR', 'date': 'Feb 3, 2022', 'snippet': 'Shinpoong Pharmaceutical has completed an overseas clinical trial of \nantimalarial treatment Pyramax (ingredient: artesunate/pyronaridine), \ndrawing attention to...', 'thumbnail': 'https://serpapi.com/searches/6723f9ed49ea5508f96ddcfb/images/adb5bd79b4283d5585cf30286c3fc2b9cec89b9c313938e0885a95038ac71425.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8780995607376099}",,,,,,,,,,['neutral'],neutral,1
NCT04966871,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-022-00510-z', 'title': 'A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection', 'source': 'Nature', 'date': 'Aug 23, 2022', 'snippet': 'Immunization with radiation-attenuated Plasmodium falciparum (Pf) \nsporozoites (SPZ) in PfSPZ Vaccine, has provided better vaccine efficacy...', 'thumbnail': 'https://serpapi.com/searches/6723f9f6e92456ab794d3b00/images/6a31272cbdfbf05bbbbbfa374c4ad2ae3d6d5b1dad85fe8321c1da755c49fc0c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6426528692245483}",,,,,,,,,,['neutral'],neutral,1
NCT04187144,"{'position': 1, 'link': 'https://www.infectiousdiseaseadvisor.com/reports/patient-characteristics-in-uncomplicated-uti-due-to-esbl-positive-uropathogens/', 'title': 'Patient Characteristics in Uncomplicated UTI Differ by Presence of ESBL Uropathogens', 'source': 'Infectious Disease Advisor', 'date': '1 week ago', 'snippet': 'Baseline characteristics such as race and ethnicity, symptom severity, age, \nand recurrent urinary tract infection (UTI) history differ...', 'thumbnail': 'https://serpapi.com/searches/6723f9f94a4a1df3ffaf01a9/images/2e6cefc4f730cb4e8c1ecfa27c8e332d1d6becb876e2fec95fe1c0db7b7b22f6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7364347577095032}",,,,,,,,,,['neutral'],neutral,1
NCT02688985,"{'position': 1, 'link': 'https://www.pnas.org/doi/10.1073/pnas.2207291120', 'title': 'Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity', 'source': 'PNAS', 'date': 'Jan 12, 2023', 'snippet': 'A small proportion of multiple sclerosis (MS) patients develop new disease \nactivity soon after starting anti-CD20 therapy.', 'thumbnail': 'https://serpapi.com/searches/6723fa04c05eb54577d23448/images/5b4478fb9c40eb7aa79ba77650d2f789db48586882dfcb97a259a226d293e6bb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6783986687660217}",,,,,,,,,,['neutral'],neutral,1
NCT03199053,"{'position': 1, 'link': 'https://www.ajmc.com/view/fda-approves-dapagliflozin-for-children-with-type-2-diabetes', 'title': 'FDA Approves Dapagliflozin for Children With Type 2 Diabetes', 'source': 'AJMC', 'date': 'Jun 13, 2024', 'snippet': 'Children aged 10 years and older with type 2 diabetes can now improve their \nglycemic control with a drug previously only approved for...', 'thumbnail': 'https://serpapi.com/searches/6723fa1793bb5739c43e81a8/images/d7213f4b9d9573850bf4541b95f47975a6b44d5f5211862c9d491d76ae862dae.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5265743732452393}","{'position': 2, 'link': 'https://www.contemporarypediatrics.com/view/fda-approves-dapagliflozin-to-improve-glycemic-control-in-pediatric-t2d-patients', 'title': 'FDA approves dapagliflozin to improve glycemic control in pediatric T2D patients', 'source': 'Contemporary Pediatrics', 'date': 'Jun 12, 2024', 'snippet': 'The decision is based on statistical significance achieved in the T2NOW \ntrial, which demonstrated reduction of A1C.', 'thumbnail': 'https://serpapi.com/searches/6723fa1793bb5739c43e81a8/images/d7213f4b9d95738549f3df1e2d51c75cd251fda7fff8aca0cfc22e9cb8191d98.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5605904459953308}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02481323,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/2-common-heart-disease-treatments-may-work-to-slow-or-prevent-vascular-dementia-uk-study-finds/', 'title': ""Vascular Dementia Tied to Alzheimer's Treated with Heart Disease Medications in UK Study"", 'source': ""Alzheimer's News Today"", 'date': 'Apr 3, 2019', 'snippet': 'Two prescription treatments for heart disease and angina — cilostazol and \nisosorbide mononitrate — show a potential to prevent or reduce...', 'thumbnail': 'https://serpapi.com/searches/6723fa2a5809e75d46aed5eb/images/903d40e17bd5661033d9ab99d166f2bda21aa712c79ce19a00482643de9c66fd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.850676417350769}",,,,,,,,,,['neutral'],neutral,1
NCT03706209,"{'position': 1, 'link': 'https://copdnewstoday.com/news/mp1032-may-protect-lungs-from-oxidative-stress-inhibit-biomarker-3-nitrotyrosine-preclinical-study/', 'title': 'MP1032 May Protect Lungs From Oxidative Stress, COPD Model Suggests', 'source': 'COPD News Today', 'date': 'Apr 16, 2020', 'snippet': 'The research suggests that MP1032 may protect the lungs from oxidative \nstress, preventing the damage to air sacs that characterizes the condition.', 'thumbnail': 'https://serpapi.com/searches/6723fa746cca5eff8197124f/images/1586f6794c9a3be9c6f6304ff6797a66ac463fe01778d960379e64efa0b9de4a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7829424142837524}",,,,,,,,,,['neutral'],neutral,1
NCT04347031,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-020-02842-x', 'title': 'On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2', 'source': 'Nature', 'date': 'Aug 19, 2020', 'snippet': 'The current epidemic of coronavirus disease-19 (COVID-19) caused by severe \nacute respiratory syndrome coronavirus-2 (SARS-CoV-2) calls for...', 'thumbnail': 'https://serpapi.com/searches/6723fa7ece1e10a3d76f11aa/images/ee7aba0d4495fa8e1a1a8b7a886a4dcabd6da26263d27694297037ae31fbb997.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7110959887504578}",,,,,,,,,,['negative'],negative,0
NCT00221442,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/zonisamide-treatment-binge-eating-disorder-obesity/', 'title': 'Zonisamide in the Treatment of Binge Eating Disorder With Obesity: A Randomized Controlled Trial', 'source': 'Psychiatrist.com', 'date': 'Oct 21, 2023', 'snippet': 'Susan L. McElroy, M.D.; Renu Kotwal, M.D.; Anna I. Guerdjikova, Ph.D.; \nJeffrey A. Welge, Ph.D.; Erik B. Nelson, M.D.; Kathleen A. Lake, M.S.W.;...', 'thumbnail': 'https://serpapi.com/searches/6723fa94bd7cf00e347d2a65/images/138f79603b8dcab533775eacdc7cdb016337b5b531b54832e7c01144b62eb8cc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8905035853385925}",,,,,,,,,,['neutral'],neutral,1
NCT02883062,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-022-00500-3', 'title': 'A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013 | npj Breast Cancer', 'source': 'Nature', 'date': 'Dec 30, 2022', 'snippet': 'This trial evaluated neoadjuvant carboplatin and paclitaxel with or without \natezolizumab in patients with clinical stages II-III TNBC.', 'thumbnail': 'https://serpapi.com/searches/6723fab5b5ecbb92470e4e98/images/e1c78c4f7263853488f8501e3b94a96a096e288168de2abb26bae2cb5ddf88a1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9144248366355896}",,,,,,,,,,['neutral'],neutral,1
NCT01838655,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/nitisinone-increases-melanin-people-albinism', 'title': 'Nitisinone increases melanin in people with albinism', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Feb 20, 2019', 'snippet': 'A small pilot clinical study at the National Eye Institute (NEI) suggests \nthat the drug nitisinone increases melanin production in some people with...', 'thumbnail': 'https://serpapi.com/searches/6723fab8ba114203b64bab2e/images/4cb6956ef575ae5106598ecacf2f0f2e79fc7d44a5e89efefb825808f834c446.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8951959013938904}",,,,,,,,,,['neutral'],neutral,1
NCT05352516,"{'position': 1, 'link': 'https://www.onclive.com/view/ema-validates-filings-for-denosumab-biosimilar-candidate-hlx14-for-osteoporosis', 'title': 'EMA Validates Filings for Denosumab Biosimilar Candidate HLX14 for Osteoporosis', 'source': 'OncLive', 'date': 'May 24, 2024', 'snippet': 'The European Medicines Agency has validated the marketing authorization \napplications (MAAs) for HLX14, an investigational denosumab...', 'thumbnail': 'https://serpapi.com/searches/6723fac3483e5b0d0915ed8c/images/5c48bfa2ecf015297f7fd80cefc90fe728fd13a517a77314c387d7690de7df9b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9015045762062073}",,,,,,,,,,['neutral'],neutral,1
NCT02913443,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01341-7', 'title': 'Targeting epigenetic regulators to overcome drug resistance in cancers', 'source': 'Nature', 'date': 'Feb 17, 2023', 'snippet': 'Drug resistance is mainly responsible for cancer recurrence and poor \nprognosis. Epigenetic regulation is a heritable change in gene...', 'thumbnail': 'https://serpapi.com/searches/6723fae4ea57e9589361b28e/images/116795376c6967159b25014d11cc8011f7f51ff8d91cec0c792daffb3873b865.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6539433002471924}",,,,,,,,,,['negative'],negative,0
NCT03516773,"{'position': 1, 'link': 'https://hypoparathyroidismnews.com/news/entera-bio-improving-its-eb612-add-on-therapy-for-hypoparathyroidism-publishes-earlier-phase-2a-study/', 'title': 'Entera Bio Improving Its EB612 Add-on Therapy, Publishes Earlier Study', 'source': 'Hypoparathyroidism News', 'date': 'Mar 3, 2021', 'snippet': 'Entera Bio is developing a better formulation of EB612, its add-on therapy \nfor maintaining normal blood calcium levels in people with \nhypoparathyroidism.', 'thumbnail': 'https://serpapi.com/searches/6723faebbbc18bf1889e44cb/images/468d773b1fba27629a2df5cdc11b300ce0a6a729a0bbc3d46a8f17d05ae610c9.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7531988620758057}",,,,,,,,,,['positive'],positive,1
NCT04811040,"{'position': 1, 'link': 'https://www.aidsmap.com/news/feb-2023/lenacapavir-plus-broadly-neutralising-antibodies-may-offer-twice-yearly-treatment', 'title': 'Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option', 'source': 'Aidsmap', 'date': 'Feb 28, 2023', 'snippet': 'Lenacapavir (Sunlenca), a new antiretroviral that can be taken every six \nmonths, might be combined with a pair of broadly neutralising antibodies to \nconstruct...', 'thumbnail': 'https://serpapi.com/searches/6723fb2fd0253e3d8bb50f1a/images/73ef236154ab4a6cbaa6564737cfb30e8283814f2d2578ad8a2d8f79283cb5b3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8706300854682922}",,,,,,,,,,['neutral'],neutral,1
NCT03718286,"{'position': 1, 'link': 'https://www.dicardiology.com/article/dramatic-cholesterol-reduction-pcsk9-inhibitor-achieved-epic-stemi-trial', 'title': 'Dramatic Cholesterol Reduction from PCSK9 Inhibitor Achieved in EPIC-STEMI Trial', 'source': 'Diagnostic and Interventional Cardiology', 'date': 'Oct 17, 2022', 'snippet': 'Significant findings from the highly-anticipated EPIC-STEMI study were \npresented by Shamir R. Mehta, MD, MSc, FACC, during a late-breaking...', 'thumbnail': 'https://serpapi.com/searches/6723fb8211db4595229e6e02/images/6c84322f12d6a00a7748ca9f3a70c02a0a6199f78d358f399e2054603c735660.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.758817195892334}",,,,,,,,,,['positive'],positive,1
NCT02765802,"{'position': 1, 'link': 'https://lungdiseasenews.com/2018/01/19/ubenimex-development-treat-pulmonary-arterial-hypertension-ends/', 'title': 'Ubenimex Development to Treat Pulmonary Arterial Hypertension Ends', 'source': 'Lung Disease News', 'date': 'Jan 19, 2018', 'snippet': ""Eiger BioPharmaceuticals' ubenimex failed to show improvement in pulmonary \nvascular resistance or exercise capacity in the Phase 2 LIBERTY..."", 'thumbnail': 'https://serpapi.com/searches/6723fb8f23a4b5ab475845e3/images/0ee8f6d21762f4f838fa72c82e144379bbc6639712d8f242275ae4c6d0b80455.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6212904453277588}","{'position': 2, 'link': 'https://hepatitisnewstoday.com/2016/10/20/eiger-announces-first-patient-dosed-in-phase-2-study-of-pegylated-interferon-lambda-in-hepatitis-d-virus-hdv-infection/', 'title': 'First Patient in Phase 2 Trial Receives Lambda as Therapy for Hepatitis D Virus Infection', 'source': 'Hepatitis News Today', 'date': 'Oct 20, 2016', 'snippet': 'A Phase 2 clinical trial evaluating Lambda (pegylated interferon lambda 1a) \nmonotherapy for the treatment of chronic hepatitis delta virus (HDV) \ninfection.', 'thumbnail': 'https://serpapi.com/searches/6723fb8f23a4b5ab475845e3/images/0ee8f6d21762f4f852d464482830fcc6e5496699005c80c4a50c546297e71a87.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8928371071815491}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT01371747,"{'position': 1, 'link': 'https://ckdnews.com/2016/11/07/data-veltassa-treatment-high-blood-potassium-ckd-patients-set-kidney-week-2016/', 'title': 'Data on Veltassa, Treatment for High Blood Potassium in CKD Patients, Set for Kidney Week 2016', 'source': 'ckdnews.com', 'date': 'Nov 7, 2016', 'snippet': 'Relypsa will report new and updated analyses from several trials evaluating \nVeltassa (patiromer for oral suspension) in treating hyperkalemia.', 'thumbnail': 'https://serpapi.com/searches/6723fb9ebe1497ff0398eae2/images/a231afaa777135607d4919bc7be35717f4f32232c4202353028ff2f2fd5aca0a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9409993886947632}",,,,,,,,,,['neutral'],neutral,1
NCT05361031,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/jns.12543', 'title': 'Journal of the Peripheral Nervous System | PNS Neuroscience Journal', 'source': 'Wiley Online Library', 'date': 'Mar 25, 2023', 'snippet': 'Charcot–Marie–Tooth (CMT) neuropathies are a group of genetically and \nphenotypically heterogeneous disorders that predominantly affect the...', 'thumbnail': 'https://serpapi.com/searches/6723fbb84a4a1df3ccc6b098/images/502435a8ad68af7ff6bc7097486a1d8df621823155f96a9fc1cb1df0dbb22017.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8251110911369324}",,,,,,,,,,['neutral'],neutral,1
NCT02977156,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1324744/full', 'title': 'Oncolytic vaccinia virus and cancer immunotherapy', 'source': 'Frontiers', 'date': 'Feb 10, 2024', 'snippet': 'Oncolytic virotherapy (OVT) is a promising form of cancer treatment that \nuses genetically engineered viruses to replicate within cancer cells and \ntrigger anti-...', 'thumbnail': 'https://serpapi.com/searches/6723fbb95416d82ede485be7/images/c8fabd35ca4c41be9f8ceab93ebe10a05c9aa19da31d43c12b6febe3982961bf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8326082229614258}","{'position': 2, 'link': 'https://www.nature.com/articles/s41571-021-00507-y', 'title': 'Intratumoural administration and tumour tissue targeting of cancer immunotherapies', 'source': 'Nature', 'date': 'May 18, 2021', 'snippet': 'Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells \nare revolutionizing oncology and haematology practice.', 'thumbnail': 'https://serpapi.com/searches/6723fbb95416d82ede485be7/images/c8fabd35ca4c41be2c4a85a5f159586b39f8be1d8b2afe3736439cc0dc50daa8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.730464518070221}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02193633,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-0199-6', 'title': 'Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence', 'source': 'Nature', 'date': 'Jul 29, 2020', 'snippet': 'Advanced and recurrent gynecological cancers are associated with poor \nprognosis and lack of effective treatment. The developments of the...', 'thumbnail': 'https://serpapi.com/searches/6723fbc6ce1e10a3d76f11fe/images/9bc3c6f7724678546ab14c2de0ea4bb03153f30ed6fe79e21b8924d5f841162e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6648945212364197}",,,,,,,,,,['neutral'],neutral,1
NCT02907567,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/ct1812/', 'title': 'Elayta (CT1812)', 'source': ""Alzheimer's News Today"", 'date': 'Apr 7, 2018', 'snippet': ""CT1812 is an oral medication being developed by Cognition Therapeutics, now \nin clinical testing, to possibly treat mild-to-moderate Alzheimer's disease \nby..."", 'thumbnail': 'https://serpapi.com/searches/6723fbd656f97029dc7a0ddf/images/ede46ce1ee0e2089dd5403ae03b2fb6e76d188e5673b11180163019f001820d2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8871570825576782}",,,,,,,,,,['neutral'],neutral,1
NCT02610361,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.19.02654', 'title': 'Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors', 'source': 'ASCO Publications', 'date': 'Mar 17, 2020', 'snippet': 'Lifirafenib is a novel inhibitor of key RAF family kinases and EGFR, with \nan acceptable risk-benefit profile and antitumor activity in patients with \nB-RAF V600...', 'thumbnail': 'https://serpapi.com/searches/6723fbe207c7be0ecb87fe7f/images/207b0594ad9f7b4a1df0a09122e4931fa026e85c0f2b05710aad427feb7159e1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8226337432861328}",,,,,,,,,,['neutral'],neutral,1
NCT00640328,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/ofatumumab-for-multiple-sclerosis/', 'title': 'Kesimpta (ofatumumab) for MS: Uses, side effects, and more', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 15, 2022', 'snippet': 'Kesimpta (ofatumumab) is a disease-modifying therapy used for relapsing \nforms of MS. Learn more about its uses, indications, and side...', 'thumbnail': 'https://serpapi.com/searches/6723fbefa54d7ee64ebd082b/images/90472f6fe2b003fc34620ba5b09b50315502aeaa362dba4e46c417e60d8ad62d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9349552392959595}",,,,,,,,,,['neutral'],neutral,1
NCT04816643,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2116298', 'title': 'Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age', 'source': 'The New England Journal of Medicine', 'date': 'Nov 9, 2021', 'snippet': 'A phase 1, dose-finding study and an ongoing phase 2–3 randomized trial are \nbeing conducted to investigate the safety, immunogenicity,...', 'thumbnail': 'https://serpapi.com/searches/6723fc370197dd4da32e5f24/images/14fada644b32253ff2d82d4381e43956d6b13b6e70e12baec3515fd83e3496c0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9000569581985474}",,,,,,,,,,['neutral'],neutral,1
NCT01528618,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/news/nasopharyngeal-cancer-gemcitabine-cisplatin-improves-survival-risk/', 'title': 'Gemcitabine Plus Cisplatin Improves Overall Survival in Advanced Nasopharyngeal Carcinoma', 'source': 'Cancer Therapy Advisor', 'date': 'Aug 20, 2021', 'snippet': 'Gemcitabine plus cisplatin significantly improved overall survival (OS) \nwhen compared with fluorouracil plus cisplatin in treatment-naïve patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/6723fd52f59d00c57d401c41/images/2b88b97f25e14819cfed60ac27d654ee3e52697a74cba6f85baf2564560692d0.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7264753580093384}",,,,,,,,,,['positive'],positive,1
NCT02149199,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1715274', 'title': 'Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma', 'source': 'The New England Journal of Medicine', 'date': '16 May 2018', 'snippet': 'In patients with mild asthma, as-needed use of an inhaled glucocorticoid \nplus a fast-acting β2-agonist may be an alternative to conventional...', 'thumbnail': 'https://serpapi.com/searches/6723fd611677932211856f81/images/29875c24c360ebdac9a87a07700ae7a8e5691a4eed22aa1165c78efb02caf690.png', 'sentiment': 'neutral', 'sentiment_prob': 0.877912700176239}",,,,,,,,,,['neutral'],neutral,1
NCT05289037,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/nih-begins-clinical-trial-evaluating-second-covid-19-booster-shots-adults', 'title': 'NIH begins clinical trial evaluating second COVID-19 booster shots in adults', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Mar 31, 2022', 'snippet': 'Adults interested in joining this study should visit clinicaltrials.gov and \nsearch identifier NCT05289037 for a list of sites and contacts.', 'thumbnail': 'https://serpapi.com/searches/6723fd6abd7cf00dff1d56d5/images/36b469637751018aa2f30724bfb76677c78bb458dee828573c85b32a49f07d3c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8881411552429199}","{'position': 2, 'link': 'https://www.nature.com/articles/s41591-023-02503-4', 'title': 'Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial', 'source': 'Nature', 'date': 'Aug 28, 2023', 'snippet': 'Our study shows that updated vaccines targeting Beta or Omicron BA.1 \nprovide broadly crossprotective neutralizing antibody responses against \ndiverse SARS-CoV-2...', 'thumbnail': 'https://serpapi.com/searches/6723fd6abd7cf00dff1d56d5/images/36b469637751018ae77b3bcbbc6d26877d3f16db05b677e72867f614b4f776bc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8610926866531372}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00287716,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/pirfenidone-may-be-effective-for-improving-exercise-capacity-dyspnea-in-idiopathic-pulmonary-fibrosis/', 'title': 'Pirfenidone May Be Effective for Improving Exercise Capacity, Dyspnea in Idiopathic Pulmonary Fibrosis', 'source': 'Pulmonology Advisor', 'date': 'Oct 10, 2018', 'snippet': 'When treated with pirfenidone, patients with idiopathic pulmonary fibrosis \nexperienced significant improvements in 6-minute walking distance...', 'thumbnail': 'https://serpapi.com/searches/6723fc69c7d4a1e0188e874a/images/a9c4b25403ea574ebd92c41a5145ec00eb9d7b9d98a56920bb30d12d488191c5.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5335983633995056}",,,,,,,,,,['positive'],positive,1
NCT00129090,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-024-02231-9', 'title': 'Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial | Leukemia', 'source': 'Nature', 'date': 'Mar 27, 2024', 'snippet': 'The R-MegaCHOEP trial investigated the use of high-dose chemotherapy and \nrituximab with subsequent autologous stem cell transplantations compared \nto...', 'thumbnail': 'https://serpapi.com/searches/6723fc6c63a844f7ee9886bb/images/4a7dd47d86c049d026f75f2182ee4f8cbfb033601d15b2921b0e6408c869c074.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8797037601470947}",,,,,,,,,,['neutral'],neutral,1
NCT05420961,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/analyst-comment/capvaxive-protection-pneumococcal-disease/', 'title': 'Capvaxive will enhance protection against pneumococcal disease in older adults', 'source': 'Clinical Trials Arena', 'date': 'Jun 26, 2024', 'snippet': ""The FDA has approved MSD's Capvaxive for the prevention of invasive \npneumococcal disease (IPD) and pneumococcal pneumonia in adults aged 18..."", 'thumbnail': 'https://serpapi.com/searches/6723fc701397ba2adff5771f/images/679fb11da105ce3359474d6a338253dc7c99870426e9dde01e72e0b302fbc105.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5787367224693298}","{'position': 2, 'link': 'https://www.empr.com/home/news/fda-approves-21-valent-pneumococcal-conjugate-vaccine-capvaxive/', 'title': 'FDA Approves 21-Valent Pneumococcal Conjugate Vaccine Capvaxive', 'source': 'Medical Professionals Reference', 'date': 'Jun 18, 2024', 'snippet': 'The Food and Drug Administration (FDA) has approved Capvaxive™ (V116; \npneumococcal 21-valent conjugate vaccine) for:.', 'thumbnail': 'https://serpapi.com/searches/6723fc701397ba2adff5771f/images/679fb11da105ce3361f9eb69a92c01352fbf9b3a76846e045844015cdf41f292.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7008212804794312}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04626921,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/01/09/cnm-au8-leads-clinical-gains-rrms-patients-extension-study/', 'title': 'CNM-Au8 leads to clinical gains for RRMS patients in extension study', 'source': 'Multiple Sclerosis News Today', 'date': 'Jan 9, 2024', 'snippet': 'Daily treatment with CNM-Au8 led to visual and cognitive improvements \nsustained for up to about three years in relapsing MS patients,...', 'thumbnail': 'https://serpapi.com/searches/6723fc7872e5c4d03834f6f6/images/7ce5640c17776ba4c21bb2f435bf37b70fe9e03043c42312063fc257453ac70a.png', 'sentiment': 'positive', 'sentiment_prob': 0.8537219762802124}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/04/18/aan-2024-ms-study-long-term-cnm-au8-shows-myelin-nerve-cell-gains/', 'title': 'AAN 2024: In MS study, long-term CNM-Au8 shows myelin, nerve cell gains', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 18, 2024', 'snippet': 'After a year, patients given CNM-Au8 had improvements in vision and data \nsuggested the therapy improved the health of brain nerve fibers.', 'thumbnail': 'https://serpapi.com/searches/6723fc7872e5c4d03834f6f6/images/7ce5640c17776ba4111fe0e28f2557c8116ff28a874bcf1d814d53e1e25acee7.png', 'sentiment': 'positive', 'sentiment_prob': 0.6827456951141357}",,,,,,,,,"['positive', 'positive']",positive,1
NCT01468233,"{'position': 1, 'link': 'https://www.dermatologyadvisor.com/news/adalimumab-reduces-skin-pain-in-hidradenitis-suppurativa/', 'title': 'Adalimumab Reduces Skin Pain in Hidradenitis Suppurativa', 'source': 'Dermatology Advisor', 'date': 'Jun 22, 2018', 'snippet': 'Outcomes were examined in 2 randomized, double-blind, placebo-controlled, \nparallel-group clinical trials: PIONEER I (ClinicalTrials.gov...', 'thumbnail': 'https://serpapi.com/searches/6723fc84be1497ff0398eb1c/images/3bd1ec65a22f53e9be90074057ce823d190bf5c79e2658b4536e88e4ca15836c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.767997682094574}",,,,,,,,,,['neutral'],neutral,1
NCT01304524,"{'position': 1, 'link': 'https://cervicalcancernews.com/2017/02/15/inovio-and-apollobio-to-collaborate-on-development-and-commercialization-of-hpv-pre-cancer-immunotherapy-vgx-3100-in-greater-china/', 'title': 'HPV Vaccine for China, Taiwan to be Jointly Developed by Inovio, ApolloBio', 'source': 'Cervical cancer News', 'date': 'Feb 15, 2017', 'snippet': ""ApolloBio now has the exclusive right to develop and commercialize Inovio' \nsDNA immunotherapy product, VGX-3100, in China and Taiwan."", 'thumbnail': 'https://serpapi.com/searches/6723fcb1c97e35f1e2a60cbc/images/43e3294c6b3a2207270b109c2fbec930d45df9bf2b382873465d0c63d04187eb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8801657557487488}","{'position': 2, 'link': 'https://cervicalcancernews.com/2017/04/26/inovio-starts-phase-2-trial-of-vgx-3100-vaccine-for-pre-cancerous-vulvar-lesions/', 'title': 'Inovio Starts Phase 2 Trial of VGX-3100 Vaccine for Pre-cancerous Vulvar Lesions', 'source': 'Cervical cancer News', 'date': 'Apr 26, 2017', 'snippet': ""Inovio's Phase 2 trial assessing the effectiveness of VGX-3100 in patients \nwith pre-cancerous lesions of the vulva, or vulvar intraepithelial \nneoplasia (VIN),..."", 'thumbnail': 'https://serpapi.com/searches/6723fcb1c97e35f1e2a60cbc/images/43e3294c6b3a22074375cd489b43f06112e1b5b3488bf4f1d25a072a690122fd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8871462941169739}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03850444,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2019/10/09/keytruda-approved-china-first-line-lung-cancer-treatment/', 'title': 'Keytruda Approved in China as First-Line Lung Cancer Treatment', 'source': 'Immuno-Oncology News', 'date': 'Oct 9, 2019', 'snippet': 'The Chinese National Medical Products Administration (NMPA) has approved \nKeytruda (pembrolizumab) as a first-line treatment for locally advanced or \nmetastatic...', 'thumbnail': 'https://serpapi.com/searches/6723fcb258e433d00fab0f22/images/6e033b3972c061a38181a2dc2b7a85472813e60b819075cc0208152310744201.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8392622470855713}",,,,,,,,,,['neutral'],neutral,1
NCT05084911,"{'position': 1, 'link': 'https://www.researchgate.net/publication/382334364_PBPK-led_assessment_of_antimalarial_drugs_as_candidates_for_Covid-19_Simulating_concentrations_at_the_site_of_action_to_inform_repurposing_strategies', 'title': 'for Covid- 19: Simulating concentrations at the site of action', 'source': 'ResearchGate', 'date': 'Jul 26, 2024', 'snippet': 'PDF | The urgent need for safe, efficacious, and accessible drug treatments \nto treat coronavirus disease 2019 (COVID‐19) prompted a global...', 'thumbnail': 'https://serpapi.com/searches/6723fd29cc48795386827179/images/870e4c8258b2b1d8aa32ab19feabd9e3f366231011e8088fa107f653748419b6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8669917583465576}",,,,,,,,,,['neutral'],neutral,1
NCT04476043,"{'position': 1, 'link': 'https://www.termedia.pl/Hidradenitis-suppurativa-a-new-therapeutic-approach-for-an-old-disease,7,54608,1,1.html', 'title': 'Hidradenitis suppurativa: a new therapeutic approach for an old disease', 'source': 'Termedia', 'date': 'Aug 12, 2024', 'snippet': 'Hidradenitis suppurativa (HS) is a chronic inflammatory disease \ncharacterised by recurrent painful nodules, abscesses, fistulas and \nscarring...', 'thumbnail': 'https://serpapi.com/searches/6723fd382b5fa77e1b8859f2/images/ae7f86628ea705746d356cfd6a27a3c4f7eb4b41eaaf8bac798d944fcd7512da.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6704685091972351}",,,,,,,,,,['negative'],negative,0
NCT05355805,"{'position': 1, 'link': 'https://www.termedia.pl/Hidradenitis-suppurativa-a-new-therapeutic-approach-for-an-old-disease,7,54608,1,1.html', 'title': 'Hidradenitis suppurativa: a new therapeutic approach for an old disease', 'source': 'Termedia', 'date': 'Aug 12, 2024', 'snippet': 'Hidradenitis suppurativa (HS) is a chronic inflammatory disease \ncharacterised by recurrent painful nodules, abscesses, fistulas and \nscarring...', 'thumbnail': 'https://serpapi.com/searches/6723fcdd8e13c941ba96a2a5/images/5bd1228a48fffd045a9b0b77e80405364e460fe1f2134acd41431a5038c64402.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6704685091972351}",,,,,,,,,,['negative'],negative,0
NCT01776840,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2201817', 'title': 'Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma', 'source': 'The New England Journal of Medicine', 'date': 'Jun 3, 2022', 'snippet': ""Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit \nwhen administered in combination with bendamustine and rituximab and \nfollowed by..."", 'thumbnail': 'https://serpapi.com/searches/6723fce5361fd42d611f4508/images/86afae91f82bbf2e60c74c4259a847ec5c135fd0eb7a4a7e0a3d8f0041d05a33.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.75749671459198}","{'position': 2, 'link': 'https://www.onclive.com/view/shine-study-ibrutinib-bendamustine-rituximab-in-elderly-patients-with-mcl', 'title': 'SHINE Study: Ibrutinib Plus Bendamustine and Rituximab in Elderly Patients With MCL', 'source': 'OncLive', 'date': 'Jan 31, 2023', 'snippet': 'Transcript: Alexey V. Danilov, MD, PhD: We just discussed the TRIANGLE \nstudy [NCT02858258], which enrolled younger patients with mantle cell...', 'thumbnail': 'https://serpapi.com/searches/6723fce5361fd42d611f4508/images/86afae91f82bbf2e0e2ecfc1afec3e502012d281646de8694d3d1f5b8652aef2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8881753087043762}","{'position': 3, 'link': 'https://www.clinicalleader.com/doc/new-fda-guidance-clinical-trial-considerations-to-support-accelerated-approval-of-oncology-therapeutics-0001', 'title': 'New FDA Guidance Clinical Trial Considerations To Support Accelerated Approval Of Oncology Therapeutics', 'source': 'Clinical Leader', 'date': 'Apr 21, 2023', 'snippet': 'On April 6, 2023, AbbVie announced that it was voluntarily withdrawing \nibrutinib, which was granted accelerated approval for two...', 'thumbnail': 'https://serpapi.com/searches/6723fce5361fd42d611f4508/images/86afae91f82bbf2e7fc51bcfa6d508fad048c4d977023f7e5bbb8dc1f93f97fd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8708025217056274}","{'position': 4, 'link': 'https://ascopost.com/news/april-2023/update-on-withdrawal-of-ibrutinib-accelerated-approvals-for-mcl-and-mzl-in-the-united-states/', 'title': 'Update on Withdrawal of Ibrutinib Accelerated Approvals for MCL and MZL in the United States', 'source': 'The ASCO Post', 'date': 'Apr 12, 2023', 'snippet': 'AbbVie announced that it intends to voluntarily withdraw, in the United \nStates, accelerated ibrutinib (Imbruvica) approvals for patients with \nmantle cell...', 'thumbnail': 'https://serpapi.com/searches/6723fce5361fd42d611f4508/images/86afae91f82bbf2e8e7692eac69f6b3f26f84dc0eb8718371a02ce5c562a99c7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9219139218330383}","{'position': 5, 'link': 'https://www.cancertherapyadvisor.com/news/imbruvica-no-longer-approved-to-treat-mcl-mzl/', 'title': 'Imbruvica No Longer Approved to Treat MCL, MZL in the US', 'source': 'Cancer Therapy Advisor', 'date': 'Apr 12, 2023', 'snippet': 'Janssen and AbbVie are withdrawing the accelerated approvals of Imbruvica \n(ibrutinib) for mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL)', 'thumbnail': 'https://serpapi.com/searches/6723fce5361fd42d611f4508/images/86afae91f82bbf2ee1ba7335a483e5d56fb66cdef29b4823df95ff209dc408a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.501125693321228}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02419287,"{'position': 1, 'link': 'https://www.science.org/doi/10.1126/scitranslmed.abo3826', 'title': 'Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma', 'source': 'Science | AAAS', 'date': 'Jun 28, 2023', 'snippet': 'Blockade of PI3Kγ or CCR7 signaling together with ALK TKI treatment reduces \nprimary resistance and the survival of persister lymphoma cells in ALCL.', 'thumbnail': 'https://serpapi.com/searches/6723fcf46aa3647845dbdebc/images/d91c8bd0b3d3178bc8b9503ce531f357bc3261ae386dc16f4af05c63aabf10db.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7612215280532837}",,,,,,,,,,['neutral'],neutral,1
NCT02734160,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0246-z', 'title': 'Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer', 'source': 'Nature', 'date': 'Oct 15, 2018', 'snippet': 'Galunisertib is the first-in-class, first-in-human, oral small-molecule \ntype I transforming growth factor-beta receptor (ALK5)...', 'thumbnail': 'https://serpapi.com/searches/6723fcf67ac731b61c940814/images/2650686842ad26b996d501dbffd59b341d76cc173530397c53e243b8198d4cef.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8163897395133972}",,,,,,,,,,['neutral'],neutral,1
NCT02825940,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(22)00232-2/fulltext', 'title': 'Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study', 'source': 'The Lancet', 'date': 'Oct 10, 2022', 'snippet': 'KL-A167 is a fully humanized monoclonal antibody targeting programmed cell \ndeath-ligand 1. This phase 2 study aimed to evaluate the efficacy...', 'thumbnail': 'https://serpapi.com/searches/6723fcf854605c248370e78e/images/35d3b0725001ffaef7217f909c2337dca9cab20dcdf88b6e59caf951756dbd21.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9025993943214417}",,,,,,,,,,['neutral'],neutral,1
NCT04076943,"{'position': 1, 'link': 'https://www.onclive.com/view/chinese-phase-3-trial-of-roxadustat-in-non-myeloid-malignancies-meets-primary-end-point', 'title': 'Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point', 'source': 'OncLive', 'date': 'May 18, 2023', 'snippet': 'Roxadustat proved to be noninferior to recombinant erythropoietin alfa with \nregard to change in hemoglobin level from baseline to an average...', 'thumbnail': 'https://serpapi.com/searches/6723fd177d533e68053dccdb/images/f11e777649455d2ca83de5fda4a886a5f27209e713f0a418da348d21260e7fa6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8067212104797363}",,,,,,,,,,['neutral'],neutral,1
NCT02472145,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-020-0773-5', 'title': 'Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study', 'source': 'Nature', 'date': 'Mar 16, 2020', 'snippet': 'Talacotuzumab, a humanized anti-CD123 monoclonal antibody, was evaluated in \ncombination with decitabine in elderly patients with acute myeloid leukemia \n(AML)...', 'thumbnail': 'https://serpapi.com/searches/6723fd1ed910393e41a1aeea/images/ad934a64aab9da3c12189490bc14c149f6a3dd014c78955cdf25927200f9b61d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.857531726360321}",,,,,,,,,,['neutral'],neutral,1
NCT03393520,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/avp-786-fails-ease-alzheimers-related-agitation-phase-3-trial/', 'title': 'AVP-786 fails to ease Alzheimer’s-related agitation in Phase 3 trial', 'source': ""Alzheimer's News Today"", 'date': 'Feb 29, 2024', 'snippet': ""A Phase 3 clinical trial of AVP-786 failed to meet its main goal of easing \nagitation in adults with dementia due to Alzheimer's disease."", 'thumbnail': 'https://serpapi.com/searches/6723fd97213c87df4d44ac84/images/65ed674586a620c84ef2537bfdd0a19dcd1552513cb6cca4776dcf3f9c02d0fe.png', 'sentiment': 'negative', 'sentiment_prob': 0.8483138084411621}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20240522034559/en/Otsuka-to-Terminate-Development-of-AVP-786', 'title': 'Otsuka to Terminate Development of AVP-786', 'source': 'Business Wire', 'date': 'May 22, 2024', 'snippet': 'Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announce \ntermination of development of the novel compound AVP-786.', 'thumbnail': 'https://serpapi.com/searches/6723fd97213c87df4d44ac84/images/65ed674586a620c81fceb611c4469460cf02eaf387ce41cbf706c0f4e04bda60.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7247691750526428}","{'position': 3, 'link': 'https://www.neurologylive.com/view/nd0612-receives-complete-letter-response-otsuka-terminates-avp-786-tsha-102-performs-phase-1-2-reveal-studies', 'title': 'ND0612 Receives Complete Letter Response, Otsuka Terminates AVP-786, TSHA-102 Performs in Phase 1/2 REVEAL Studies', 'source': 'Neurology live', 'date': 'Jun 23, 2024', 'snippet': 'Neurology News Network. for the week ending June 22, 2024. [WATCH TIME: 4 \nminutes]', 'thumbnail': 'https://serpapi.com/searches/6723fd97213c87df4d44ac84/images/65ed674586a620c8f09bb0e9f8ed9a42269599c1eadd078221dd5bae111e4965.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9419007897377014}","{'position': 4, 'link': 'https://alzheimersnewstoday.com/news/otsuka-stops-development-avp-786-agitation-alzheimers/', 'title': 'Otsuka stops developing AVP-786 therapy for Alzheimer’s agitation', 'source': ""Alzheimer's News Today"", 'date': 'May 23, 2024', 'snippet': ""Otsuka is stopping the development of AVP-786, its experimental therapy to \ntreat agitation in people with Alzheimer's disease."", 'thumbnail': 'https://serpapi.com/searches/6723fd97213c87df4d44ac84/images/65ed674586a620c8961cd60e6994df9ac462d546f121db90087410ceaa0e4c57.png', 'sentiment': 'negative', 'sentiment_prob': 0.7110889554023743}",,,,,,,"['negative', 'neutral', 'neutral', 'negative']",negative,0
NCT01854034,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-019-0038-9', 'title': 'Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer | Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': 'Mar 8, 2019', 'snippet': 'Inframe insertions of three or more base pairs in exon 20 of the epidermal \ngrowth factor receptor (EGFR) gene were among the first EGFR...', 'thumbnail': 'https://serpapi.com/searches/6723fda151d84d4f569b65a3/images/d3e8d992a3232d0eb86cdbc9c03f3ac7473254d3230367578947a5605c16b6d5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8813299536705017}",,,,,,,,,,['neutral'],neutral,1
NCT00600249,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-021-00334-5', 'title': 'Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies', 'source': 'Nature', 'date': 'Sep 17, 2021', 'snippet': 'Our results indicate that high expression of cell cycle genes, combined \nwith cold immunological phenotype, may predict strong TNBC resistance to \nNAT and rapid...', 'thumbnail': 'https://serpapi.com/searches/6723fdaad9c3e68834f91862/images/b755d43add6d4199d85a6c855c2de3deae9b05b1033a336ac4cec7496cd16101.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8336379528045654}",,,,,,,,,,['neutral'],neutral,1
NCT03263429,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/61/supplement_1/630', 'title': 'PET imaging of glutamine metabolism in a clinical trial of metastatic colorectal cancer', 'source': 'Journal of Nuclear Medicine', 'date': 'May 1, 2020', 'snippet': 'Allison Cohen, Adria Payne, Gary Smith, Jennifer Whisenant, Todd Peterson, \nKristen Ciombor, Dana Cardin, Cathy Eng, Laura Goff, Satya Das,...', 'thumbnail': 'https://serpapi.com/searches/6723fdc0a505f777dd204287/images/116330fb6a70ec93236f60df07f6c7219cdfcfb1e0bb23c434aab395fcc63de8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9362392425537109}",,,,,,,,,,['neutral'],neutral,1
NCT03298087,"{'position': 1, 'link': 'https://www.urologytimes.com/view/dr-nickols-on-phase-2-solar-trial-of-multimodal-therapy-in-prostate-cancer', 'title': 'Dr. Nickols on phase 2 SOLAR trial of multimodal therapy in prostate cancer', 'source': 'Urology Times', 'date': '1 month ago', 'snippet': 'In this video, Nicholas G. Nickols, MD, PhD, highlights the background and \ninitial findings from the phase 2 SOLAR trial (NCT03298087).', 'thumbnail': 'https://serpapi.com/searches/6723fde6922cceedec28834c/images/89bfb8b05af48ef4837db41a76beea2cde381307ab8a94c58cad3aafda3ed383.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9172107577323914}",,,,,,,,,,['neutral'],neutral,1
NCT02783482,"{'position': 1, 'link': 'https://www.biospace.com/gc-biopharma-announces-us-fda-approval-for-alyglo-immune-globulin-intravenous-human-stwk-10-percent-liquid-for-adults-with-primary-humoral-immunodeficiency-pi', 'title': 'GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)', 'source': 'BioSpace', 'date': 'Dec 17, 2023', 'snippet': 'The US Food and Drug Administration has approved ALYGLO 10% Liquid, \nformerly referred to as “GC5107,” for the treatment of adult patients aged \n17 years and...', 'thumbnail': 'https://serpapi.com/searches/6723fdfbea57e958c5952254/images/b5c9a4eb7f0774495ff9e25f81357028298a551bb51e0ac94a25c7a201897b11.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8150995969772339}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/investigational-ivig-product-under-review-for-primary-immunodeficiency/', 'title': 'Investigational IVIG Product Under Review for Primary Immunodeficiency', 'source': 'Medical Professionals Reference', 'date': 'Jul 31, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted the resubmitted \nBiologics License Application (BLA) for GC5107B (immune globulin \nintravenous [human])', 'thumbnail': 'https://serpapi.com/searches/6723fdfbea57e958c5952254/images/b5c9a4eb7f077449b27c3e562fe5ed7f11557a3fc467dff02852b94e1567f000.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.911652147769928}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00028990,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa072113', 'title': 'Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Mar 27, 2016', 'snippet': 'In an open-label, randomized, phase 3 trial, we compared the efficacy and \nsafety of paclitaxel with that of paclitaxel plus bevacizumab, a \nmonoclonal...', 'thumbnail': 'https://serpapi.com/searches/6723fe2ef410441876f4f6ba/images/076044cc4a6e0e07a1be658447148d6c160d0f387a0a9e5a0b2e4639419eae7b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8797870874404907}",,,,,,,,,,['neutral'],neutral,1
NCT03777059,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2035908', 'title': 'Atogepant for the Preventive Treatment of Migraine', 'source': 'The New England Journal of Medicine', 'date': 'Aug 24, 2021', 'snippet': 'Oral atogepant once daily was effective in reducing the number of migraine \ndays and headache days over a period of 12 weeks. Adverse events included...', 'thumbnail': 'https://serpapi.com/searches/6723fe3471c62b8d36d24d58/images/3761f74dc5cfc8c5a11c9e6fd6be8f0c6fac14f8f42953ffdd5071c3b86f9d40.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7206376194953918}",,,,,,,,,,['neutral'],neutral,1
NCT01397461,"{'position': 1, 'link': 'https://www.infectiousdiseaseadvisor.com/home/topics/skin-infections/topical-antibacterial-agent-effective-for-treatment-of-impetigo/', 'title': 'Topical Antibacterial Agent Effective for Treatment of Impetigo', 'source': 'Infectious Disease Advisor', 'date': 'Dec 3, 2018', 'snippet': 'Topical ozenoxacin 1% cream is a rapid and effective treatment for patients \nwith impetigo. The agent demonstrates consistent clinical and bacteriologic \neffects.', 'thumbnail': 'https://serpapi.com/searches/6723fe460664c983dca14474/images/3cbdc4b145921ea9cec1337d4aecf9577b638f0b2c6a228666898a34d11a21cd.png', 'sentiment': 'positive', 'sentiment_prob': 0.7753939628601074}",,,,,,,,,,['positive'],positive,1
NCT01110486,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0020-2', 'title': 'Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial', 'source': 'Nature', 'date': 'Mar 19, 2018', 'snippet': 'Ilorasertib (ABT-348) inhibits Aurora and VEGF receptor (VEGFR) kinases. \nPatients with advanced solid tumours participated in a phase 1 \ndose-escalation trial.', 'thumbnail': 'https://serpapi.com/searches/6723fe508cf8aebaab22c641/images/916a27025804ba00342d9472676cff814a44c3daa172680e1045371ee2143d92.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9103592038154602}",,,,,,,,,,['neutral'],neutral,1
NCT05247489,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2118828', 'title': 'Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo', 'source': 'The New England Journal of Medicine', 'date': 'Oct 19, 2022', 'snippet': 'Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A \ncream formulation of ruxolitinib (an inhibitor of Janus kinase 1...', 'thumbnail': 'https://serpapi.com/searches/6723fe6917b10eb87f490a11/images/a8e2ce6910b1b97a687a50c8adefbb26dbdd2d719219958bcc25d65e69545738.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6550623774528503}",,,,,,,,,,['neutral'],neutral,1
NCT05310422,"{'position': 1, 'link': 'https://www.cgtlive.com/view/sylentis-sirna-therapy-fails-to-improve-symptoms-dry-eye-disease-sjogren', 'title': 'Sylentis’ siRNA Therapy Fails to Improve Symptoms of Dry Eye Disease Due to Sjögren’s Syndrome', 'source': 'CGTLive®', 'date': 'Feb 13, 2024', 'snippet': ""Sylentis' phase 3 clinical trial (NCT04819269) of tivanisiran RNA therapy \nhas failed the primary endpoint of improving dry eye symptoms associated \nwith Sjögren..."", 'thumbnail': 'https://serpapi.com/searches/6723fe7b9936882cb5f0ccd2/images/a65f169b6229d0002a2ec0f1edaca4dc8a07ee43723daf5e26453e13dc220263.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8161905407905579}",,,,,,,,,,['negative'],negative,0
NCT05005845,"{'position': 1, 'link': 'https://www.science.org/doi/10.1126/sciadv.adk4946', 'title': 'Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1', 'source': 'Science | AAAS', 'date': 'May 1, 2024', 'snippet': 'This phase 2a trial investigated the efficacy of NFX-179 Topical Gel, a \nmetabolically labile MEK inhibitor, in the treatment of cutaneous \nneurofibromas (cNFs)...', 'thumbnail': 'https://serpapi.com/searches/6723fea2d771bdf6b3351eb4/images/5e50ffe4c5a0e68b891b3e37143598f30146fb867fd34eb9cc430b26eb615953.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8717843294143677}",,,,,,,,,,['neutral'],neutral,1
NCT04722003,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0264410X23000865', 'title': 'Vaccine value profile for Neisseria gonorrhoeae', 'source': 'ScienceDirect.com', 'date': 'Jul 25, 2024', 'snippet': 'This vaccine value profile (VVP) provides a high level, holistic assessment \nof the current data to inform the potential public health, economic and \nsocietal...', 'thumbnail': 'https://serpapi.com/searches/6723feaed0253e3d8bb51033/images/28a3f363ded8cb2956fb33587245303c5083959d0ff30fbe01fea2e0e23a8bd5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8531647324562073}",,,,,,,,,,['neutral'],neutral,1
NCT00856492,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-023-00535-0', 'title': 'Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial | npj Breast Cancer', 'source': 'Nature', 'date': 'May 13, 2023', 'snippet': 'We assessed the predictive value of an image analysis-based \ntumor-infiltrating lymphocytes (TILs) score for pathologic complete \nresponse (pCR) and event-free...', 'thumbnail': 'https://serpapi.com/searches/6723feb254163de3afe419a5/images/457a83cf4ba856622e3ee5729e8bfc520f32afc90550c6467c46ed3ee9262807.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8688086271286011}",,,,,,,,,,['neutral'],neutral,1
NCT02445794,"{'position': 1, 'link': 'https://friedreichsataxianews.com/news/retrotope-gives-fda-the-design-of-a-pivotal-trial-for-its-friedreichs-ataxia-therapy/', 'title': ""Friedreich's Ataxia Therapy Maker Retrotope Submits Pivotal-Trial Design to FDA"", 'source': ""Friedreich's Ataxia News"", 'date': 'Apr 19, 2018', 'snippet': ""Read about Retrotope submitting the design of a pivotal clinical trial for \nits Friedreich's ataxia therapy RT001 to the U.S. Food and Drug..."", 'thumbnail': 'https://serpapi.com/searches/6723feb77a12fd60490b6cab/images/d365ba4631026cba3cec423bc50b9b8769fb81caba62fd75dea75c564930939f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8871482014656067}",,,,,,,,,,['neutral'],neutral,1
NCT03529175,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-023-02170-9', 'title': 'Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma', 'source': 'Nature', 'date': 'Feb 22, 2023', 'snippet': 'Readily measurable patient variables can aid the prediction of outcomes \nfrom combination chemotherapy used to treat metastatic PDAC.', 'thumbnail': 'https://serpapi.com/searches/6723febd72f7163db9b6fd20/images/a1ff6ea3375d898a2ebb919238581a7ef806e49f7cea850f385fc18415504e52.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8889390826225281}",,,,,,,,,,['neutral'],neutral,1
NCT04539262,"{'position': 1, 'link': 'https://www.nature.com/articles/s41564-023-01356-4', 'title': 'Therapeutics for COVID-19', 'source': 'Nature', 'date': 'May 4, 2023', 'snippet': 'Vaccines and monoclonal antibody treatments to prevent severe coronavirus \ndisease 2019 (COVID-19) illness were available within a year of the \npandemic being...', 'thumbnail': 'https://serpapi.com/searches/6723fec0bcd65222896571e3/images/f3ecaa2ee672d813e2de1d633078f5516967bff06ca652a7001a5adf10006584.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7230387330055237}",,,,,,,,,,['neutral'],neutral,1
NCT06105528,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2024/10/30/2971622/0/en/ProMIS-Neurosciences-Presents-Positive-Data-from-PMN310-Phase1a-Clinical-Trial-at-the-17th-Clinical-Trials-on-Alzheimer-s-Disease-Conference.html', 'title': 'ProMIS Neurosciences Presents Positive Data from PMN310', 'source': 'GlobeNewswire', 'date': '1 day ago', 'snippet': 'Results indicated PMN310 was generally well-tolerated and monthly dosing \ncan provide CSF levels adequate for target engagement Initiation of...', 'thumbnail': 'https://serpapi.com/searches/6723fec9f60b6f8f33efe041/images/86a088210923e6946ec1c7715f06a0112603cdd9582892b89be78c5875796fd7.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8455473780632019}","{'position': 2, 'link': 'https://www.globenewswire.com/news-release/2024/04/01/2855463/0/en/ProMIS-Neurosciences-Announces-Full-Year-2023-Financial-Results-and-Recent-Highlights.html', 'title': 'ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights', 'source': 'GlobeNewswire', 'date': 'Apr 1, 2024', 'snippet': ""Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a \ntreatment for Alzheimer's disease on track for mid-2024..."", 'thumbnail': 'https://serpapi.com/searches/6723fec9f60b6f8f33efe041/images/86a088210923e694f7c2bcd5defcefd5c419f3f79d1f7c2b1970855205cc36b7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8202195167541504}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT04380701,"{'position': 1, 'link': 'https://www.nature.com/articles/s41586-020-2814-7', 'title': 'COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses', 'source': 'Nature', 'date': 'Sep 30, 2020', 'snippet': 'Here we present antibody and T cell responses after vaccination with \nBNT162b1 from a second, non-randomized open-label phase I/II trial in \nhealthy adults.', 'thumbnail': 'https://serpapi.com/searches/6723fedac05eb54546b6878e/images/1fe91fc51711fc830c24b739a1bdf6f77aa2e55e9e48249e2c018c310115e614.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9030770063400269}","{'position': 2, 'link': 'https://www.nature.com/articles/s41586-021-03653-6', 'title': 'BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans', 'source': 'Nature', 'date': 'May 27, 2021', 'snippet': 'BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that \nencodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its...', 'thumbnail': 'https://serpapi.com/searches/6723fedac05eb54546b6878e/images/1fe91fc51711fc839a3d36eebc51a3d671c51bf71a5000d85c2ee5b1607776dd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8637851476669312}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05412004,"{'position': 1, 'link': 'https://www.appliedclinicaltrialsonline.com/view/tirzepatide-shows-significant-reduction-in-severity-of-obstructive-sleep-apnea-in-patients-with-obesity', 'title': 'Tirzepatide Shows Significant Reduction in Severity of Obstructive Sleep Apnea in Patients with Obesity', 'source': 'Applied Clinical Trials', 'date': 'Apr 17, 2024', 'snippet': ""Findings from the Phase III SURMOUNT-OSA (NCT05412004) clinical trial \ndemonstrated the efficacy of Eli Lilly's tirzepatide in lowering the..."", 'thumbnail': 'https://serpapi.com/searches/6723fee624296a895db7aa07/images/3b2407b4d46c491b51360c828df2019569dcb9415e17179f051c767d4d5c96f3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5443980693817139}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/tirzepatide-reduced-sleep-apnea-severity-by-up-to-nearly-two-thirds-in-adults-with-obstructive-sleep-apnea-osa-and-obesity-302118929.html', 'title': 'Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity', 'source': 'PR Newswire', 'date': 'Apr 17, 2024', 'snippet': 'PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive \ntopline results of the SURMOUNT-OSA phase 3 clinical trials that...', 'thumbnail': 'https://serpapi.com/searches/6723fee624296a895db7aa07/images/3b2407b4d46c491b8f86e204ac04d3b9eaec6c18a2453599cbf63ecd577ffe29.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.62837815284729}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03093259,"{'position': 1, 'link': 'https://ibdnewstoday.com/2020/12/21/abivax-completes-enrollment-for-phase-2b-trial-testing-abx464-for-moderate-to-severe-ulcerative-colitis-uc/', 'title': 'Abivax Completes Enrollment in ABX464 Trial for Ulcerative Colitis', 'source': 'IBD News Today', 'date': 'Dec 21, 2020', 'snippet': 'Abivax completed patient enrollment ahead of schedule for a trial testing \nABX464 for people with moderate to severe ulcerative colitis.', 'thumbnail': 'https://serpapi.com/searches/6723feebe45f33d6d26908ab/images/f0882c5801bd173aad133d6126445d8409f9eda07310c9e64f8c4ad295b8a142.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8923408389091492}",,,,,,,,,,['neutral'],neutral,1
NCT02579252,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/aadvac1-alzheimers-vaccine-lessens-signs-neurodegeneration-phase-2-adamant-trial/', 'title': 'Vaccine Seen to Lessen Signs of Neurodegeneration in Phase 2 Trial', 'source': ""Alzheimer's News Today"", 'date': 'Jul 22, 2021', 'snippet': ""AADvac1, an investigational vaccine targeting abnormal tau protein, a \nhallmark of Alzheimer's disease, was found to be safe and effectively \nreduced the signs..."", 'thumbnail': 'https://serpapi.com/searches/6723feedb6ed3307b69fdd31/images/7907bdc54503d2078b0c415bad7b9661a0bc326d5d62f396fe0d409091b3c2a8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8057160377502441}",,,,,,,,,,['neutral'],neutral,1
NCT04961541,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2024.1412478/full', 'title': 'Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines', 'source': 'Frontiers', 'date': 'Jun 29, 2024', 'snippet': 'This review delves into the major advancements in the field of combined \nvaccine research, underscoring the strategic use of various platforms.', 'thumbnail': 'https://serpapi.com/searches/6723ff0fe30abc0f979838b3/images/652ef65adb50cbfb89f7006d6b25fd4d3f9d351e866a47e770473efc678e9a9a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5735475420951843}",,,,,,,,,,['positive'],positive,1
NCT03548935,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2032183', 'title': 'Once-Weekly Semaglutide in Adults with Overweight or Obesity', 'source': 'The New England Journal of Medicine', 'date': 'Feb 10, 2021', 'snippet': 'In this double-blind trial, we enrolled 1961 adults with a body-mass index \n(the weight in kilograms divided by the square of the height in...', 'thumbnail': 'https://serpapi.com/searches/6723ff49d11195906dd6ecbd/images/b1663899130cf0b46634e3a30d6dcb1df65542731182e2b147187334cc8a2f27.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8971408605575562}","{'position': 2, 'link': 'https://www.specialtypharmacycontinuum.com/Online-First/Article/09-23/Cardiovascular-Benefit-Could-Pave-the-Way-for-Wider-Use-of-Wegovy/71579', 'title': 'Cardiovascular Benefit Could Pave the Way for Wider Use of Wegovy', 'source': 'Specialty Pharmacy Continuum', 'date': 'Sep 25, 2023', 'snippet': 'By Myles Starr The recent announcement of phase 3 clinical trial results \ndemonstrating that semaglutide 2.4 mg (Wegovy, Novo Nordisk)...', 'thumbnail': 'https://serpapi.com/searches/6723ff49d11195906dd6ecbd/images/b1663899130cf0b4e5296cbb556e30bb5026c62298d26f309acd6aef73c0f605.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5210405588150024}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02952534,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/journal-efficacy-of-parp-inhibitors-as-maintenance-therapy-for-metastatic-castration-resistant-prostate-cancer-a-meta-analysis-of-randomized-controlled-trials', 'title': 'Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials', 'source': 'Cancer Network', 'date': 'Nov 18, 2021', 'snippet': 'The aim of this meta-analysis is to analyze the efficacy of these drugs in \nthe treatment of mCRPC in terms of progression-free survival...', 'thumbnail': 'https://serpapi.com/searches/6723ff6f66d995de0393b7e9/images/c933074e0237e455541bbbe0caed9b8d12955efe7aabf1e1b9d021ef2830ff9b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8892879486083984}",,,,,,,,,,['neutral'],neutral,1
NCT03084237,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/trastuzumab-strf-gets-fda-approval-in-overexpressing-breast-and-gastric-cancers', 'title': 'Trastuzumab-strf Gets FDA Approval in Overexpressing Breast and Gastric Cancers', 'source': 'Cancer Network', 'date': 'Apr 29, 2024', 'snippet': 'Trastuzumab-strf (HLX02; Hercessi) a monoclonal antibody biosimilar, has \nbeen approved as adjuvant therapy for patients with...', 'thumbnail': 'https://serpapi.com/searches/6723ff90c117a94b594c00a0/images/11260211169277dc6c2169b85001935c78e145ee79fe91c971c614ece6167fd1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7989016771316528}",,,,,,,,,,['neutral'],neutral,1
NCT01178294,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/hae.12627', 'title': 'Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A', 'source': 'Wiley Online Library', 'date': 'Jan 27, 2015', 'snippet': 'Acquired haemophilia A (AHA) is a rare bleeding disorder caused by \nautoantibodies against human factor VIII (hFVIII). OBI-1 is an...', 'thumbnail': 'https://serpapi.com/searches/6723ff9617a2e29b0ee5df5c/images/08c2a6ebe70f092b068f0d4e1d5c2d37d30938dbfd1cdb6e533645744e4b1ec3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6210319995880127}",,,,,,,,,,['neutral'],neutral,1
NCT03669588,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-52539-w', 'title': 'Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov', 'source': 'Nature', 'date': 'Jan 24, 2024', 'snippet': 'Novel biologics in MG therapy research is on the rise. This research aimed \nto investigate the characteristics of registered trials on novel...', 'thumbnail': 'https://serpapi.com/searches/6723ff9ae335ec8a13a6800e/images/169f469717dec7767d9f64879e2b1c761796d2197513bc93f57e471acb1c4e6c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9105547070503235}","{'position': 2, 'link': 'https://myastheniagravisnews.com/news/vyvgart-now-approved-in-canada-for-adults-with-achr-related-gmg/', 'title': 'Vyvgart now approved in Canada for adults with AChR-related gMG |...', 'source': 'Myasthenia Gravis News', 'date': 'Sep 28, 2023', 'snippet': 'Health Canada has approved Vyvgart (efgartigimod alfa-fcab) to treat adults \nwith generalized myasthenia gravis (gMG) who are positive for antibodies \ntargeting...', 'thumbnail': 'https://serpapi.com/searches/6723ff9ae335ec8a13a6800e/images/169f469717dec77611b064d427d919d0c71b6e308a6f8b8747a085dc5f51db7a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7124826312065125}","{'position': 3, 'link': 'https://myastheniagravisnews.com/news/vyvgart-efgartigimod-approved-myasthenia-gravis-gmg-israel/', 'title': 'Vyvgart for efgartigimod infusion now approved in Israel for gMG |...', 'source': 'Myasthenia Gravis News', 'date': 'May 11, 2023', 'snippet': 'Vyvgart, the intravenous formulation of efgartigimod alfa-fcab, is now \napproved in Israel for treating generalized myasthenia gravis (gMG).', 'thumbnail': 'https://serpapi.com/searches/6723ff9ae335ec8a13a6800e/images/169f469717dec776ee665cf5ad94edf7ae2a390cc12aab2031b52c7dff05fcc3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7930164933204651}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03384940,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-38032-4', 'title': 'Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer', 'source': 'Nature', 'date': 'Jun 7, 2023', 'snippet': 'DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial \nassessing the efficacy and safety of trastuzumab deruxtecan (T-DXd)...', 'thumbnail': 'https://serpapi.com/searches/6723ffa6e30abc0f5d3da4eb/images/3ffc57d856b4cb9dc60b70ab37aa17f233d19d67a4da381d6ef636a76522d6c5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8918474912643433}",,,,,,,,,,['neutral'],neutral,1
NCT01564537,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1516282', 'title': 'Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma', 'source': 'The New England Journal of Medicine', 'date': 'Apr 28, 2016', 'snippet': 'Ixazomib is an oral proteasome inhibitor that is currently being studied \nfor the treatment of multiple myeloma.In this double-blind,...', 'thumbnail': 'https://serpapi.com/searches/6724005a6a5dd30cc97d9592/images/01be5b20678f6e950f795999120a8e8a994e4ba919351ddb9ba01b167b1abb35.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9209146499633789}","{'position': 2, 'link': 'https://www.oncnursingnews.com/view/ixazomib-lenalidomide-dexamethasone-shows-consistent-outcomes-in-3-real-world-analyses-of-use-for-patients-with-r-r-multiple-myeloma', 'title': 'Ixazomib/Lenalidomide/Dexamethasone Shows Consistent Outcomes in 3 Real-World Analyses of Use for Patients with R/R Multiple Myeloma', 'source': 'Oncology Nursing News', 'date': 'Jul 21, 2022', 'snippet': 'A combined analysis of 3 real-world studies assessing the use of \nixazomib/lenalidomide/dexamethasone (IRd) in patients with relapsed or...', 'thumbnail': 'https://serpapi.com/searches/6724005a6a5dd30cc97d9592/images/01be5b20678f6e954f2a110c22d5ed686acda80ada557d6522883d4a9a442667.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8197699785232544}","{'position': 3, 'link': 'https://ascopubs.org/doi/abs/10.1200/jco.21.00972', 'title': 'Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Jun 12, 2021', 'snippet': 'The double-blind, placebo-controlled, phase III TOURMALINE-MM1 study \ndemonstrated a statistically significant improvement in progression-free \nsurvival with...', 'thumbnail': 'https://serpapi.com/searches/6724005a6a5dd30cc97d9592/images/01be5b20678f6e95092bc3f876cf2db27675b6e1f0c099584436f57be205d0e5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8305513262748718}","{'position': 4, 'link': 'https://myelomaresearchnews.com/news/relapsed-multiple-myeloma-patients-refractory-revlimid-benefit-ninlaro-pomalyst-dexamethasone-combo-trial-suggests/', 'title': 'Myeloma Patients Refractory to Revlimid May Benefit from Ninlaro, Pomalyst, Dexamethasone Combo', 'source': 'Myeloma Research News', 'date': 'Mar 19, 2018', 'snippet': 'Read about the results of a Phase 1/2 clinical trial showing that a triple \ncombo with Ninlaro, Pomalyst, and dexamethasone may help relapsed...', 'thumbnail': 'https://serpapi.com/searches/6724005a6a5dd30cc97d9592/images/01be5b20678f6e951f25c809651c290ba9b6c41dd134cc9395352301755963e3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7254173159599304}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03096795,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-36642-y', 'title': 'Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction', 'source': 'Nature', 'date': 'Jun 17, 2023', 'snippet': 'Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive \ninflammatory responses following tissue damage or infection and is a...', 'thumbnail': 'https://serpapi.com/searches/6724006074f0a491e21875ae/images/0d97a0f3b56fd471f5035e079867f0c39fd1ba098ee4928d5428a55ee732d157.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8236860036849976}",,,,,,,,,,['neutral'],neutral,1
NCT00109707,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa055104', 'title': 'Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL', 'source': 'The New England Journal of Medicine', 'date': 'Jun 15, 2006', 'snippet': 'Resistance to imatinib mesylate can occur in chronic myelogenous leukemia \n(CML). Preclinical in vitro studies have shown that nilotinib...', 'thumbnail': 'https://serpapi.com/searches/6724006efab27339ce5500ce/images/32f008aadb4eed92f033af0423b3e824b4f2313dbe1ed7f6609798e3a9a63053.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8856596946716309}",,,,,,,,,,['neutral'],neutral,1
NCT02194595,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-33867-9', 'title': 'The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial', 'source': 'Nature', 'date': 'Oct 16, 2022', 'snippet': 'Combining a glucagon-like peptide-1 receptor agonist (GLP1-RA) with basal \ninsulin is an emerging option when initiating injectable therapy...', 'thumbnail': 'https://serpapi.com/searches/6723ffb47a12fd60490b6cdd/images/222c6de5fdb92d20e4aa53f63a66115796d7ab23363bc94e58362b70037ef660.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9047425985336304}",,,,,,,,,,['neutral'],neutral,1
NCT02941822,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/parkinsons-clinical-trial-test-cough-medicine-ambroxol/', 'title': ""Parkinson's Clinical Trial Will Test Cough Medicine Ambroxol |..."", 'source': ""Parkinson's News Today"", 'date': 'Jan 13, 2023', 'snippet': ""The world-first Phase 3 clinical trial testing the ability of ambroxol, a \nmedicine used for decades to treat lung conditions, to slow Parkinson's \ndisease..."", 'thumbnail': 'https://serpapi.com/searches/6723ffbab2ebaee6e82f3ac1/images/586e8bbaa65ad7f7bb1fc825c083fe44507e63c3ead1e2b99e8a279de468b3ee.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8358374834060669}",,,,,,,,,,['neutral'],neutral,1
NCT01314716,"{'position': 1, 'link': 'https://bronchiectasisnewstoday.com/2020/05/18/cayston-effective-for-some-bronchiectasis-symptoms-but-not-all-study/', 'title': 'Antibiotic Cayston Effective for Some Bronchiectasis Symptoms but Not All, Study Says', 'source': 'Bronchiectasis News Today', 'date': 'May 18, 2020', 'snippet': 'Treatment with the inhaled antibiotic Cayston (aztreonam lysine) reduced \ncough and sputum production, but was not effective against breathlessness \nand wheezing...', 'thumbnail': 'https://serpapi.com/searches/6723ffca5416d82ea7280309/images/aecd728ee7919a5fa77a7827299308ff45d3e4edc27b645464ce5a4e3839272f.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5014094710350037}",,,,,,,,,,['negative'],negative,0
NCT02423915,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1075813/full', 'title': 'The emerging role of regulatory cell-based therapy in autoimmune disease', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': '1Student Research Committee, Kermanshah University of Medical Sciences, \nKermanshah, Iran; 2Universal Scientific Education and Research Network \n(USERN)...', 'thumbnail': 'https://serpapi.com/searches/6723ffd1be1497ff0398ebe9/images/b623dc74d68667b740bc3a3b94e2f97e5e6e3f941de6ead7272b596cbbca264b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9207028150558472}",,,,,,,,,,['neutral'],neutral,1
NCT01565655,"{'position': 1, 'link': 'https://www.cureus.com/articles/195961-fda-approved-janus-kinase-signal-transducer-and-activator-of-transcription-jak-stat-inhibitors-for-managing-rheumatoid-arthritis-a-narrative-review-of-the-literature', 'title': 'FDA-Approved Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) Inhibitors for Managing Rheumatoid Arthritis: A Narrative Review of the Literature', 'source': 'Cureus', 'date': 'May 9, 2024', 'snippet': 'Rheumatoid arthritis (RA) is a complex autoimmune disease causing chronic \njoint inflammation and, in more serious cases, organ involvement.', 'thumbnail': 'https://serpapi.com/searches/6723ffd7f79a01c1cc6c3f83/images/ad07aff05f9ed3f3d294595285bc299fd4680662a0e14e598c90b157eb51e29e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8903322219848633}",,,,,,,,,,['neutral'],neutral,1
NCT02008890,"{'position': 1, 'link': 'https://www.dermatologyadvisor.com/news/examining-the-potential-benefits-of-secukinumab-in-palmoplantar-pustular-psoriasis-treatment/', 'title': 'Examining the Potential Benefits of Secukinumab in Palmoplantar Pustular Psoriasis Treatment', 'source': 'Dermatology Advisor', 'date': 'Mar 14, 2019', 'snippet': 'Secukinumab 300 mg showed promise in treating patients with palmoplantar \npustular psoriasis (PPP), according to clinical trial results.', 'thumbnail': 'https://serpapi.com/searches/6723ffe2c76a3af3eaa51515/images/9a482b2b841ff6d8b29f8f6131ab43326fd746838ecd5563dfb537121c6148ab.png', 'sentiment': 'positive', 'sentiment_prob': 0.7529481649398804}",,,,,,,,,,['positive'],positive,1
NCT01938638,"{'position': 1, 'link': 'https://www.nature.com/articles/s41388-022-02347-1', 'title': 'Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer', 'source': 'Nature', 'date': 'May 14, 2022', 'snippet': 'Transcriptional deregulation has emerged as a hallmark of several cancer \ntypes. In metastatic castration-resistant prostate cancer,...', 'thumbnail': 'https://serpapi.com/searches/6723ffebef60cbc523a381e1/images/1c0ce10a90312063137e4dff52f306b2b700bb3e61eda8239fd1d6bc460e09f4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.586356520652771}",,,,,,,,,,['neutral'],neutral,1
NCT00446680,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/inhaled-mannitol-mucociliary-clearance/', 'title': 'Bronchitol (Mannitol)', 'source': 'Cystic Fibrosis News Today', 'date': 'Mar 22, 2021', 'snippet': 'Bronchitol (mannitol), by Pharmaxis, is a dry powder inhalation treatment \nfor cystic fibrosis, approved in the U.S., EU,...', 'thumbnail': 'https://serpapi.com/searches/6723fffa667ec5ccf1485131/images/383999f1069c7671b537e3c19d9d8c4e5e4676b3c4fb2a8372129b496d9e9ebb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9064784049987793}",,,,,,,,,,['neutral'],neutral,1
NCT04819269,"{'position': 1, 'link': 'https://www.cgtlive.com/view/sylentis-sirna-therapy-fails-to-improve-symptoms-dry-eye-disease-sjogren', 'title': 'Sylentis’ siRNA Therapy Fails to Improve Symptoms of Dry Eye Disease Due to Sjögren’s Syndrome', 'source': 'CGTLive®', 'date': 'Feb 13, 2024', 'snippet': ""Sylentis' phase 3 clinical trial (NCT04819269) of tivanisiran RNA therapy \nhas failed the primary endpoint of improving dry eye symptoms associated \nwith Sjögren..."", 'thumbnail': 'https://serpapi.com/searches/672400056ad3c9c2f7a69e3c/images/cce37bbe55c778b604848b1bd58557b7cd4aaf3beb5ae97c004138a2dfed1d7a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8161905407905579}",,,,,,,,,,['negative'],negative,0
NCT03983980,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2103629', 'title': 'Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis', 'source': 'The New England Journal of Medicine', 'date': '٠٨\u200f/١٢\u200f/٢٠٢١', 'snippet': 'Tapinarof cream is a topical aryl hydrocarbon receptor–modulating agent \nunder investigation for the treatment of psoriasis.', 'thumbnail': 'https://serpapi.com/searches/6724001d7a12fd60490b6cf8/images/c3d80f2ad17438c83db62d3c249bc77a4449b5631da81dbcd43f721f723d1f70.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8930850028991699}","{'position': 2, 'link': 'https://www.dermatologytimes.com/view/tapinarof-cream-1-is-fda-approved', 'title': 'Tapinarof Cream 1% is FDA Approved', 'source': 'Dermatology Times', 'date': '٢٤\u200f/٠٥\u200f/٢٠٢٢', 'snippet': 'Tapinarof cream 1%, (Vtama; Dermavant Sciences) was approved by the FDA for \ntopical treatment of plaque psoriasis in adults.', 'thumbnail': 'https://serpapi.com/searches/6724001d7a12fd60490b6cf8/images/c3d80f2ad17438c814ef188e2714d16bde9ce736758c550d1f6c6160fbc248af.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5443679094314575}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02207634,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1500858', 'title': 'Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events', 'source': 'The New England Journal of Medicine', 'date': 'Mar 15, 2015', 'snippet': 'Evolocumab, a monoclonal antibody that inhibits proprotein convertase \nsubtilisin–kexin type 9 (PCSK9), significantly reduced low-density...', 'thumbnail': 'https://serpapi.com/searches/67240022207c888e32841de6/images/b25b5743d4addd52b5e17db0bdd7932434b4b0995f98b5ba45dd36d3dc5b144f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.796350359916687}",,,,,,,,,,['neutral'],neutral,1
NCT01870778,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1801291', 'title': 'Effects of Serelaxin in Patients with Acute Heart Failure', 'source': 'The New England Journal of Medicine', 'date': 'Aug 21, 2019', 'snippet': 'Previous studies have suggested that treatment with serelaxin may result in \nrelief of symptoms and in better outcomes in patients with acute heart \nfailure.', 'thumbnail': 'https://serpapi.com/searches/67240023ee4682bcbcfc41c1/images/69c4dfd9d5e98cc52a6706a8da5d1918afc74562eff76e767b1cac994ed60ee9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7693448662757874}",,,,,,,,,,['neutral'],neutral,1
NCT04992065,"{'position': 1, 'link': 'https://www.endocrinologyadvisor.com/news/pcsk9-inhibitor-nnc0385-0434-lowers-ldl-cholesterol/', 'title': 'PCSK9 Inhibitor NNC0385-0434 Lowers LDL Cholesterol', 'source': 'Endocrinology Advisor', 'date': 'Feb 27, 2024', 'snippet': 'The PCSK9 inhibitor NNC0385-0434 demonstrates excellent efficacy in \nreducing low-density lipoprotein (LDL) cholesterol levels over 12 weeks \namong patients with...', 'thumbnail': 'https://serpapi.com/searches/6724002cc024d1be854f25a3/images/0a75bbd966873435d09806759dae43936142e2fdd32ef0a224917b0f7c610229.png', 'sentiment': 'positive', 'sentiment_prob': 0.5411518216133118}",,,,,,,,,,['positive'],positive,1
NCT02321540,"{'position': 1, 'link': 'https://www.nature.com/articles/s41388-017-0079-x', 'title': 'Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner', 'source': 'Nature', 'date': 'Feb 5, 2018', 'snippet': 'Alterations in ERBB family members have been associated with many tumor \nmalignancies. EGFR and ERBB2 have been extensively explored in...', 'thumbnail': 'https://serpapi.com/searches/6724003bb7d31dd6bebdb803/images/156aa2650dcb708a75e84d97300032267a1d756d046ac139da31eb3bc7831cd2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5141918659210205}",,,,,,,,,,['neutral'],neutral,1
NCT03248882,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-67843-8', 'title': 'SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH)', 'source': 'Nature', 'date': 'Jul 24, 2024', 'snippet': 'Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis \n(NASH) are major metabolic diseases with increasing global...', 'thumbnail': 'https://serpapi.com/searches/672400845ed3ca4f6318ed0b/images/6c05e7d7377daec7a483b1e462e446cccebd8a163b386af25158b575553b995d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.856010913848877}",,,,,,,,,,['neutral'],neutral,1
NCT03846427,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/features/lymphoma-tandem-meetings-2023-research-shows-favorable-results-treatment/', 'title': 'Tandem Meetings 2023: Research Shows Favorable Results for Lymphoma Subtypes', 'source': 'Hematology Advisor', 'date': 'Mar 31, 2023', 'snippet': 'Research regarding treatment for marginal zone lymphoma (MZL), large B-cell \nlymphoma (LBCL), and mantle cell lymphoma (MCL) presented at the 2023 \nTandem...', 'thumbnail': 'https://serpapi.com/searches/6724008a7e1d1fae6f2e3364/images/029d16f704568387de5945b4ab1e1bfce73fcdcf81beb86e31b3183b36f0c170.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6556333303451538}",,,,,,,,,,['neutral'],neutral,1
NCT01578239,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1607427', 'title': 'Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors', 'source': 'The New England Journal of Medicine', 'date': 'Jan 12, 2017', 'snippet': 'Patients with advanced midgut neuroendocrine tumors who have had disease \nprogression during first-line somatostatin analogue therapy have...', 'thumbnail': 'https://serpapi.com/searches/6724008d1adaf4d0201be8f7/images/ae6a361baaf2f99e97bea695b0a75eddf1acb39b25cc0e8eea3b38706727a43e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8830488920211792}","{'position': 2, 'link': 'https://ascopost.com/news/april-2024/fda-approves-lu-177-dotatate-for-pediatric-patients-with-gep-nets/', 'title': 'FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs', 'source': 'The ASCO Post', 'date': 'Apr 24, 2024', 'snippet': 'The US Food and Drug Administration (FDA) approved lutetium Lu-177 dotatate \n(Lutathera) for pediatric patients aged 12 years and older with \nsomatostatin...', 'thumbnail': 'https://serpapi.com/searches/6724008d1adaf4d0201be8f7/images/ae6a361baaf2f99ea8a0dd6a6ca34186504405caacbf91fecc58c6d7007cacb4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.750058650970459}","{'position': 3, 'link': 'https://www.oncnursingnews.com/view/fda-approves-first-radioactive-drug-for-children-with-sstr-positive-gep-nets', 'title': 'FDA Approves First Radioactive Drug for Children With SSTR-Positive GEP-NETs', 'source': 'Oncology Nursing News', 'date': 'Apr 23, 2024', 'snippet': 'Lutetium Lu 177 dotatate was approved by the FDA for children aged 12 years \nand older with somatostatin receptor-positive...', 'thumbnail': 'https://serpapi.com/searches/6724008d1adaf4d0201be8f7/images/ae6a361baaf2f99ea67785512d62f3fd1921c9283f94fb21ed7b46d7bf4c5f23.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5331282615661621}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00090233,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa052664', 'title': 'Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine', 'source': 'The New England Journal of Medicine', 'date': 'Mar 8, 2017', 'snippet': 'Rotavirus is a leading cause of childhood gastroenteritis and death \nworldwide.We studied healthy infants approximately 6 to 12 weeks old who \nwere randomly...', 'thumbnail': 'https://serpapi.com/searches/672400b3d364b4f6c8975546/images/a9615b32531b80f50a3e57b2d30cfefabb777275959a021c69aeaa794761c43d.png', 'sentiment': 'negative', 'sentiment_prob': 0.5254733562469482}",,,,,,,,,,['negative'],negative,0
NCT05108623,"{'position': 1, 'link': 'https://www.oncozine.com/first-pateint-dosed-with-allogeneic-off-the-shelf-invariant-natural-killer-t-cell-therapy/', 'title': 'First Pateint Dosed with Allogeneic, off-the-shelf, Invariant Natural Killer T-cell Therapy', 'source': ""Onco'Zine"", 'date': 'Mar 3, 2022', 'snippet': 'A first patient has been dosed with a novel, allogeneic, off-the-shelf, \ninvariant natural killer T (iNKT) cell therapy to treat cancer and other \nimmune-...', 'thumbnail': 'https://serpapi.com/searches/672400bcfbde0db7f6a33b42/images/dfec19083d9de9ec70a3bffab7ed0a4c9276d75d5490716ef6074277e4ca6098.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8653754591941833}",,,,,,,,,,['neutral'],neutral,1
NCT02139540,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/nitrous-oxide-reduced-suicidal-ideation-in-treatment-resistant-major-depression/', 'title': 'Nitrous Oxide Reduced Suicidal Ideation in Treatment-Resistant Major Depression in Exploratory Analysis', 'source': 'Psychiatrist.com', 'date': 'Aug 16, 2023', 'snippet': 'This post hoc analysis of 3 crossover trials demonstrated that N 2 O, as \ncompared to placebo, reduced SI in a TRMD sample.', 'thumbnail': 'https://serpapi.com/searches/672400d2a882781053035d34/images/3cb40dd2ef77324f9ff93b60e4f1a66b27f5b82d7b22a8b630ce841e020f25fc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8201837539672852}",,,,,,,,,,['neutral'],neutral,1
NCT04530643,"{'position': 1, 'link': 'https://www.bioworld.com/articles/689573-hy-209-a-gpcr19-agonist-inhibiting-nlrp3-inflammasome-activation-as-a-potential-therapeutic-for-atopic-dermatitis', 'title': 'HY-209: a GPCR19 agonist inhibiting NLRP3 inflammasome activation as a potential therapeutic for atopic dermatitis', 'source': 'BioWorld MedTech', 'date': 'Sep 13, 2022', 'snippet': 'Researchers from Shaperon Inc. presented positive preclinical data for \ntheir clinical-stage candidate, sodium taurodeoxycholate (HY-209),...', 'thumbnail': 'https://serpapi.com/searches/672400db63a844f82690ee80/images/e5a54c8662113b5844b5c309c917ea61b8ece058c03eedea107913ca2383fcaa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8575100898742676}",,,,,,,,,,['neutral'],neutral,1
NCT05282797,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20231006392162/en/Anebulo-Pharmaceuticals-Announces-New-CEO', 'title': 'Anebulo Pharmaceuticals Announces New CEO', 'source': 'Business Wire', 'date': 'Oct 6, 2023', 'snippet': 'AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: \nANEB) (""Anebulo""), a clinical-stage biopharmaceutical company...', 'thumbnail': 'https://serpapi.com/searches/672400e9e45f33d6a07afdad/images/03403a9209961d572c51ca4198202c738b0864ec0d0ac68578da317fb7305535.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7890937328338623}",,,,,,,,,,['neutral'],neutral,1
NCT05357989,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/phase-3-trial-buntanetap-for-early-stage-parkinsons-end/', 'title': 'Phase 3 trial of buntanetap for early-stage Parkinson’s nears end', 'source': ""Parkinson's News Today"", 'date': 'Dec 7, 2023', 'snippet': ""Annovis Bio has announced the last patient completed the final visit in its \nPhase 3 clinical trial testing buntanetap for people with early-stage \nParkinson's..."", 'thumbnail': 'https://serpapi.com/searches/67240101fcd69e09522379db/images/27cd1f5e2b63614f3b0ca7c689b6b930ce9f86a27896837806053009ada22a04.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8905943632125854}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/news/annovis-stock-swells-after-phase-iii-parkinsons-subgroup-success/', 'title': 'Annovis stock swells after Phase III Parkinson’s subgroup success', 'source': 'Clinical Trials Arena', 'date': 'Jul 3, 2024', 'snippet': ""Buntanetap showed a statistical improvement in several disease-related \nscores in certain Parkinson's patients who had been diagnosed for..."", 'thumbnail': 'https://serpapi.com/searches/67240101fcd69e09522379db/images/27cd1f5e2b63614f3b1e4d5c32a90db726290c5dc38270ef1d8d4342352a18be.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5898541808128357}","{'position': 3, 'link': 'https://www.apdaparkinson.org/article/new-parkinsons-treatment-in-clinical-trials-2023/', 'title': 'New Parkinson’s Treatments in the Clinical Trial Pipeline for 2024', 'source': 'American Parkinson Disease Association', 'date': 'Sep 26, 2023', 'snippet': ""Extensive research is underway to develop new medications for Parkinson's \ndisease (PD), with several promising candidates at different..."", 'thumbnail': 'https://serpapi.com/searches/67240101fcd69e09522379db/images/27cd1f5e2b63614f63a67b2add40472877ca589759aba81f3b224bc40fa1d13e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5578852891921997}","{'position': 4, 'link': 'https://www.clinicaltrialsarena.com/features/trials-to-watch-parkinsons-disease/', 'title': 'Trials to watch: Pipeline Parkinson’s drugs could revolutionise treatment', 'source': 'Clinical Trials Arena', 'date': 'Oct 17, 2023', 'snippet': ""Patients with Parkinson's disease could be given more hope as a number of \npipeline drugs are looking to tackle a variety of unmet needs."", 'thumbnail': 'https://serpapi.com/searches/67240101fcd69e09522379db/images/27cd1f5e2b63614f6157cf27fae467e4ecf60bc69521bd4538db5e57a08acce7.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8619078993797302}","{'position': 5, 'link': 'https://parkinsonsnewstoday.com/news/delay-early-efficacy-data-buntanetap-trial-now-expected-june/', 'title': 'Early efficacy data from buntanetap trial delayed, now expected in June', 'source': ""Parkinson's News Today"", 'date': 'May 13, 2024', 'snippet': ""Topline efficacy data from a Phase 3 clinical trial of buntanetap for \nearly-stage Parkinson's are now expected in June after analysis..."", 'thumbnail': 'https://serpapi.com/searches/67240101fcd69e09522379db/images/27cd1f5e2b63614f6fe9b8d2eaf30600a22b640949e382dabd0acf53be5b818d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.822671115398407}","{'position': 6, 'link': 'https://parkinsonsnewstoday.com/news/analysis-phase-3-trial-parkinsons-therapy-buntanetap-due/', 'title': ""Analysis of Phase 3 Trial of Parkinson's Therapy Buntanetap Due |..."", 'source': ""Parkinson's News Today"", 'date': 'Jan 26, 2023', 'snippet': ""Annovis Bio anticipates an interim data analysis from a Phase 3 trial of \nits therapeutic candidate buntanetap in people with early-stage Parkinson's \ndisease..."", 'thumbnail': 'https://serpapi.com/searches/67240101fcd69e09522379db/images/27cd1f5e2b63614f260a91ce2f3d5b0178019f94bcd0422e4fe7ae9dee6aecd8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9205260872840881}","{'position': 7, 'link': 'https://parkinsonsnewstoday.com/news/buntanet-shown-halt-cognitive-decline-early-parkinsons-trial/', 'title': 'Buntanetap found to halt cognitive decline in early Parkinson’s trial', 'source': ""Parkinson's News Today"", 'date': 'Jul 8, 2024', 'snippet': ""In a trial, once-daily buntanetap halted cognitive decline in early-stage \nParkinson's and improved cognition in patients with mild dementia."", 'thumbnail': 'https://serpapi.com/searches/67240101fcd69e09522379db/images/27cd1f5e2b63614f497ab62a2e042c185bbed9be02ca38909da8ef12c99a8f84.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6456438899040222}","{'position': 8, 'link': 'https://parkinsonsnewstoday.com/news/positive-safety-review-buntanetap-parkinsons-clinical-trial/', 'title': 'Buntanetap Phase 3 study to move forward after positive safety review', 'source': ""Parkinson's News Today"", 'date': 'Jun 23, 2023', 'snippet': ""Following a positive safety review, Annovis Bio's Phase 3 clinical trial of \noral buntanetap for early-stage Parkinson's can move forward."", 'thumbnail': 'https://serpapi.com/searches/67240101fcd69e09522379db/images/27cd1f5e2b63614f29736887315820bd85df42e74a760b05d7e2974d0a54bad8.png', 'sentiment': 'positive', 'sentiment_prob': 0.7051039338111877}","{'position': 9, 'link': 'https://parkinsonsnewstoday.com/news/buntanetaps-efficacy-parkinsons-trial-supports-phase-3-study/', 'title': 'Buntanetap Shows Efficacy, Supports Soon-to-open Phase 3 Study', 'source': ""Parkinson's News Today"", 'date': 'Aug 3, 2022', 'snippet': ""Buntanetap, Annovis Bio's investigational oral treatment for \nneurodegenerative diseases, was safe and showed effectiveness in people \nwith..."", 'thumbnail': 'https://serpapi.com/searches/67240101fcd69e09522379db/images/27cd1f5e2b63614f3912a128723c9472ce143265ae48cb449f3f7466c309858d.png', 'sentiment': 'positive', 'sentiment_prob': 0.8342639803886414}",,"['neutral', 'positive', 'positive', 'positive', 'neutral', 'neutral', 'neutral', 'positive', 'positive']",positive,1
NCT03538951,"{'position': 1, 'link': 'https://www.onclive.com/view/vda-1102-demonstrates-favorable-activity-in-mycosis-fungoides', 'title': 'VDA-1102 Demonstrates Favorable Activity in Mycosis Fungoides', 'source': 'OncLive', 'date': 'Jan 29, 2024', 'snippet': 'VDA-1102 led to an objective response rate of 56% in patients with mycosis \nfungoides, according to findings from an interim analysis of a...', 'thumbnail': 'https://serpapi.com/searches/6724010bc05eb54546b6881f/images/07ebd69271e5397e8e8e500218081bd0b66766a3c6604b8309d26fe9864d8a72.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.539094865322113}",,,,,,,,,,['positive'],positive,1
NCT01103323,"{'position': 1, 'link': 'https://www.targetedonc.com/view/regorafenib-continues-to-benefit-patients-with-advanced-crc', 'title': 'Regorafenib Continues to Benefit Patients With Advanced CRC', 'source': 'Targeted Oncology', 'date': 'Mar 26, 2024', 'snippet': 'Daniel H. Ahn, DO, medical director of the clinical cancer research office, \noncologist, and associate professor at the Mayo Clinic in...', 'thumbnail': 'https://serpapi.com/searches/67240110d0c9837151d482a5/images/d42c7add30db7a0cce78559fef160762bfbc7b209f24021cf4b9168ac897b888.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5602507591247559}",,,,,,,,,,['neutral'],neutral,1
NCT03384420,"{'position': 1, 'link': 'https://www.nature.com/articles/s41536-021-00167-7', 'title': 'cells from healthy donors and patients with mitochondrial DNA disorders confers functional benefit', 'source': 'Nature', 'date': 'Sep 24, 2021', 'snippet': 'Mitochondria are cellular organelles critical for numerous cellular \nprocesses and harboring their own circular mitochondrial DNA (mtDNA).', 'thumbnail': 'https://serpapi.com/searches/6724012da775f278c7cc5f7f/images/c421ba5d8f52dee48dda29cc642c644f707a957e2e0b11829e40c9503bde6c92.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6002292037010193}",,,,,,,,,,['neutral'],neutral,1
NCT02949362,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/jpn3.12276', 'title': 'Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure', 'source': 'Wiley Online Library', 'date': 'Jun 14, 2024', 'snippet': 'We report the long-term safety, efficacy, and predictors of response in \npediatric patients with SBS-IF receiving teduglutide over 96 weeks.', 'thumbnail': 'https://serpapi.com/searches/6724014e0197dd4dd75e82ce/images/7aa649a430397efa6a86aa44f1ba7e9d8e81c6f9b49f947b4e0d81b7a806a991.png', 'sentiment': 'neutral', 'sentiment_prob': 0.662468433380127}",,,,,,,,,,['neutral'],neutral,1
NCT03139604,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.18300', 'title': 'A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease', 'source': 'Wiley Online Library', 'date': 'Jun 11, 2022', 'snippet': 'An official journal of the British Society for Haematology, the British \nJournal of Haematology offers high visibility for clinical,...', 'thumbnail': 'https://serpapi.com/searches/67240152fc183d5db397cb9c/images/e4ba1325b34a1716ff705fdf4801ed5fa911ad759e732a8cf57e49a826556a0a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8829355239868164}",,,,,,,,,,['neutral'],neutral,1
NCT04568434,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/ionis-announces-positive-olezarsen-topline-results-from-phase-3-study-in-people-with-familial-chylomicronemia-syndrome-301938328.html', 'title': 'Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome', 'source': 'PR Newswire', 'date': 'Sep 26, 2023', 'snippet': 'Olezarsen met the primary endpoint with a statistically significant \nreduction in triglyceride levels versus placebo First study to show an...', 'thumbnail': 'https://serpapi.com/searches/67240175861b9d637bfa3695/images/b7b6e9030c53f1ef286ad1adc71237b7c8bebf05715a77355aacea80ff0126f5.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5509459972381592}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/olezarsen-cuts-triglyceride-levels-in-patients-with-familial-chylomicronemia-syndrome/', 'title': 'Olezarsen Cuts Triglyceride Levels in Patients With Familial Chylomicronemia Syndrome', 'source': 'Medical Professionals Reference', 'date': 'Sep 26, 2023', 'snippet': 'Treatment with olezarsen significantly reduced triglyceride levels in \npatients with familial chylomicronemia syndrome (FCS), according to phase 3 \ntrial results.', 'thumbnail': 'https://serpapi.com/searches/67240175861b9d637bfa3695/images/b7b6e9030c53f1efc2d38f35d68e30bd121e1f1f1e214281b2d0eac6fa1b0541.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8422852754592896}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT03505723,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2201171', 'title': 'Tranexamic Acid in Patients Undergoing Noncardiac Surgery', 'source': 'The New England Journal of Medicine', 'date': 'Apr 2, 2022', 'snippet': 'Perioperative bleeding is common in patients undergoing noncardiac surgery. \nTranexamic acid is an antifibrinolytic drug that may safely...', 'thumbnail': 'https://serpapi.com/searches/6724017b1677932211857094/images/72aad37cdf6ad4830253b50c89db487962a6ebbcf98bfaf9d86532e7535ba598.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7663593888282776}",,,,,,,,,,['neutral'],neutral,1
NCT03815916,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/phase-2-trial-supports-larger-study-cnm-au8-parkinsons/', 'title': 'Phase 2 trial findings support larger study of CNM-Au8 for Parkinson’s', 'source': ""Parkinson's News Today"", 'date': 'Feb 19, 2024', 'snippet': ""Treatment with CNM-Au8, an investigational gold nanocrystal suspension \ntherapy, boosted energy production in the brains of people with Parkinson's \ndisease and..."", 'thumbnail': 'https://serpapi.com/searches/6724017f98721799073fefe4/images/4ba0231e34725232716bc098eb7b42316d235c42722b32ebe4cde91b4aa3c389.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6706705689430237}",,,,,,,,,,['neutral'],neutral,1
NCT04759131,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/fda-approves-updated-altuviiio-label-full-xtend-kids-data/', 'title': 'FDA approves updated Altuviiio label with full XTEND-Kids data', 'source': 'Hemophilia News Today', 'date': '١٥\u200f/٠٥\u200f/٢٠٢٤', 'snippet': 'The US Food and Drug Administration (FDA) has approved an update to the \nprescribing information for Altuviiio (efanesoctocog alfa), a long-lasting \nfactor VIII...', 'thumbnail': 'https://serpapi.com/searches/6724018d9062f85c40db7784/images/5a81247f7a62540b4407702878486b38fcb823ba0aaade122643327e07fbebed.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7442442774772644}","{'position': 2, 'link': 'https://www.contemporarypediatrics.com/view/fda-approves-altuviiio-updated-label-for-bleed-protection-in-children-with-hemophilia-a', 'title': 'FDA approves ALTUVIIIO updated label for bleed protection in children with hemophilia', 'source': 'Contemporary Pediatrics', 'date': '١٣\u200f/٠٥\u200f/٢٠٢٤', 'snippet': 'The extended label approval is based on full evidence from the XTEND-Kids \nstudy.', 'thumbnail': 'https://serpapi.com/searches/6724018d9062f85c40db7784/images/5a81247f7a62540b62d7a3ba3ae11ee40ac2fef0a8503b697cebd749d28ccf09.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8187620043754578}","{'position': 3, 'link': 'https://www.hematologyadvisor.com/news/hemophilia-efanesoctocog-alfa-prevent-inhibitor-development-treatment-risk/', 'title': 'Efanesoctocog Alfa Appears to Prevent Inhibitor Development, Reduce Bleeding in Children With Severe Hemophilia A', 'source': 'Hematology Advisor', 'date': '١٧\u200f/٠٧\u200f/٢٠٢٣', 'snippet': 'The phase 3 XTEND-Kids study met its primary endpoint, with no inhibitor \ndevelopment seen with treatment in children with severe hemophilia...', 'thumbnail': 'https://serpapi.com/searches/6724018d9062f85c40db7784/images/5a81247f7a62540bf79ce1f742df542351a517458a66237fe88a5e6d2bc78661.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8442665338516235}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04775953,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00104-2/fulltext', 'title': 'European society of clinical microbiology and infectious diseases (ESCMID) global 2024', 'source': 'The Lancet', 'date': 'May 20, 2024', 'snippet': 'The 34th Congress of the European Society of Clinical Microbiology and \nInfectious Diseases (ESCMID Global) took place in Barcelona under its new \nbrand name.', 'thumbnail': 'https://serpapi.com/searches/672404210c08f201ce46d9dc/images/d5c2da71310326a82cf48b7885a75236c442b4609aa8d8102cbf9e65c7bc358b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9165834784507751}",,,,,,,,,,['neutral'],neutral,1
NCT02345863,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-022-01629-7', 'title': 'Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial', 'source': 'Nature', 'date': 'Jun 25, 2022', 'snippet': 'The prospective, open-label, multicenter phase II trial CLL2-BIG \n(registered at www.clinicaltrials.gov as # NCT02345863) was the first of...', 'thumbnail': 'https://serpapi.com/searches/672404283ad34db688948d23/images/17c628c3db8d9810b75b8ef5b1e11cf08663d702ab6c5de49d4a99d9f5d4a03e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8752250075340271}",,,,,,,,,,['neutral'],neutral,1
NCT03339661,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Characteristics-of-patients-with-cytomegalovirus-CMV-infection-and-compar-isons_tbl1_11850856', 'title': 'Characteristics of patients with cytomegalovirus (CMV) infection and...', 'source': 'ResearchGate', 'date': 'Sep 8, 2018', 'snippet': 'γδ T cells undergo massive expansion in the peripheral blood of renal \ntransplant recipients who are infected with cytomegalovirus (CMV).', 'thumbnail': 'https://serpapi.com/searches/672404346aa364780f49ce38/images/b584755660f5511b996e2b39c59eba779a9c0d870c7e6790f94e27007df6fa75.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5117400884628296}",,,,,,,,,,['neutral'],neutral,1
NCT05584657,"{'position': 1, 'link': 'https://www.drugtopics.com/view/fda-approves-sulopenem-etzadroxil-and-probenecid-for-uncomplicated-urinary-tract-infections', 'title': 'FDA Approves Sulopenem Etzadroxil and Probenecid for Uncomplicated UTIs', 'source': 'Drug Topics', 'date': '6 days ago', 'snippet': 'The FDA has approved just the second treatment for uncomplicated urinary \ntract infections (UTIs) in the last 2 decades.', 'thumbnail': 'https://serpapi.com/searches/67240436d0c9837151d48334/images/accd70f36f4fbd57a00767001fe549ab9a3b4b80161297a527f9ae135b364aeb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6426243782043457}","{'position': 2, 'link': 'https://www.urologytimes.com/view/oral-sulopenem-shows-superiority-to-amoxicillin-clavulanate-for-uutis', 'title': 'Oral sulopenem shows superiority to amoxicillin/clavulanate for uUTIs', 'source': 'Urology Times', 'date': 'Jan 31, 2024', 'snippet': 'The phase 3 REASSURE trial (NCT05584657) achieved noninferiority for its \nprimary end point of overall response and demonstrated statistical...', 'thumbnail': 'https://serpapi.com/searches/67240436d0c9837151d48334/images/accd70f36f4fbd57e6a93ca44e43de2b3b88c53ebb0c4df391ddc7ebdceb0736.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5682632923126221}","{'position': 3, 'link': 'https://www.contagionlive.com/view/fda-approves-oral-sulopenem-orlynvah-for-uncomplicated-urinary-tract-infections', 'title': 'FDA Approves Oral Sulopenem (Orlynvah) for Uncomplicated Urinary Tract Infections', 'source': 'Contagion Live', 'date': '2 days ago', 'snippet': 'Iterum Therapeutics receives approval for Orlynvah as the first oral penem \nfor treating uncomplicated urinary tract infections in adult...', 'thumbnail': 'https://serpapi.com/searches/67240436d0c9837151d48334/images/accd70f36f4fbd57a16d2991217bc34b2178f1338683fa294bc2c0684f2dfd1b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8403930068016052}","{'position': 4, 'link': 'https://www.urologytimes.com/view/live-updates-from-fda-advisory-committee-meeting-on-oral-sulopenem-for-uuti', 'title': 'FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI', 'source': 'Urology Times', 'date': '1 month ago', 'snippet': ""Follow Urology Times' coverage of the full-day FDA advisory committee \nmeeting regarding Iterum Therapeutics' new drug application for oral..."", 'thumbnail': 'https://serpapi.com/searches/67240436d0c9837151d48334/images/accd70f36f4fbd5728bf4c5286182454a38bb01e5572506739bdc8946e2b65ce.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9455567598342896}","{'position': 5, 'link': 'https://www.drugtopics.com/view/small-doses-october-21-to-october-25', 'title': 'Small Doses: October 21 to October 25', 'source': 'Drug Topics', 'date': '5 days ago', 'snippet': ""The FDA has approved Iterum Therapeutics' sulopenem etzadroxil and \nprobenecid (Orlynvah) for the treatment of uUTIs in adult women who have..."", 'thumbnail': 'https://serpapi.com/searches/67240436d0c9837151d48334/images/accd70f36f4fbd579f3734d95e2877447169408a2e5a752db5917c4ecacd8dc8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.84382164478302}","{'position': 6, 'link': 'https://www.drugtopics.com/view/breaking-fda-approves-moderna-s-mrna-rsv-vaccine-mresvia', 'title': 'Breaking: FDA Approves Moderna’s mRNA RSV Vaccine, mRESVIA', 'source': 'Drug Topics', 'date': 'May 31, 2024', 'snippet': 'mRESVIA is the first mRNA vaccine approved for a disease other than \nCOVID-19.', 'thumbnail': 'https://serpapi.com/searches/67240436d0c9837151d48334/images/accd70f36f4fbd5719a0b3350ad6a81a73a4839461d70c8b1dfd4839276f556d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6358482241630554}","{'position': 7, 'link': 'https://www.drugtopics.com/view/fda-roundup-agency-highlights-from-june-2024', 'title': 'FDA Roundup: Agency Highlights From June 2024', 'source': 'Drug Topics', 'date': 'Jun 28, 2024', 'snippet': 'The FDA approved ensifentrine (Ohtuvayre) for the maintenance treatment of \nchronic obstructive pulmonary disease (COPD) in adult patients,...', 'thumbnail': 'https://serpapi.com/searches/67240436d0c9837151d48334/images/accd70f36f4fbd575ba2477048bbfd2d9bfc300b99ab86969b153921e8695b7d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8896152973175049}","{'position': 8, 'link': 'https://www.drugtopics.com/view/majority-of-infants-in-icu-for-rsv-have-no-underlying-health-conditions', 'title': 'Majority of Infants in ICU for RSV Have No Underlying Health Conditions', 'source': 'Drug Topics', 'date': 'Aug 21, 2023', 'snippet': 'A recent study found that Infants younger than 3 months, those born \nprematurely, and those who were publicly insured were at a higher risk...', 'thumbnail': 'https://serpapi.com/searches/67240436d0c9837151d48334/images/accd70f36f4fbd57d0d660e889fd91837e3ef16e28d87ee44d9ec620e6716f6e.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5712602734565735}","{'position': 9, 'link': 'https://www.drugtopics.com/view/miebo-first-prescription-eye-drop-to-treat-tear-evaporation-in-dry-eye-disease-now-available', 'title': 'Miebo, First Prescription Eye Drop to Treat Tear Evaporation in Dry Eye Disease, Now Available', 'source': 'Drug Topics', 'date': 'Sep 15, 2023', 'snippet': 'The perfluorohexyloctane ophthalmic solution from Bausch + Lomb was \napproved by the FDA in May and will have a whole acquisition cost of...', 'thumbnail': 'https://serpapi.com/searches/67240436d0c9837151d48334/images/accd70f36f4fbd5769f117d9063adb566ea046d2a251ca904c262a91ce7ffb69.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8044151663780212}","{'position': 10, 'link': 'https://www.drugtopics.com/view/rsv-poses-more-danger-to-older-adults-than-covid-19-flu', 'title': 'RSV Poses More Danger to Older Adults Than COVID-19, Flu', 'source': 'Drug Topics', 'date': 'Oct 11, 2023', 'snippet': 'A new study found that more patients hospitalized with RSV needed standard \nflow oxygen, HFNC, NIV, and ICU admission than the patients with...', 'thumbnail': 'https://serpapi.com/searches/67240436d0c9837151d48334/images/accd70f36f4fbd57510aacd24ab38748fe31656c140db58f03d124cc82657de0.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5299963355064392}","['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'negative', 'neutral', 'negative']",neutral,1
NCT01791595,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-0727-8', 'title': 'A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965 | British Journal of Cancer', 'source': 'Nature', 'date': 'Feb 20, 2020', 'snippet': 'A 47-year-old man with metastatic melanoma presented with refractory \nhyperlactaemic acidosis following the first dose of the...', 'thumbnail': 'https://serpapi.com/searches/672403e0fd3b5ae5d2b98a7c/images/d05734b348a4ad07cdec90d7d5b055436420abd9713dd00c9c37d0bc81567919.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6695555448532104}",,,,,,,,,,['neutral'],neutral,1
NCT01274182,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/granulomatosis-with-polyangiitis-and-microscopic-polyangiitis-patients-can-use-mabthera-biosimilar-rixathon-following-ec-approval/', 'title': 'EC Approves MabThera Biosimilar Rixathon for 2 AAV Disorders', 'source': 'ANCA Vasculitis News', 'date': 'Jul 14, 2017', 'snippet': ""The EC has approved the use and marketing of Sandoz's Mabthera biosimilar \ndrug Rixathon for the treatment of blood cancers and immunological..."", 'thumbnail': 'https://serpapi.com/searches/672403e093584c2b3cbbfa07/images/f5794a3bd80a9affc2737edc8e62225770abc2d0ef7b7734d850ed308995d1ae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8589828014373779}",,,,,,,,,,['neutral'],neutral,1
NCT02292758,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.756214/full', 'title': 'Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials', 'source': 'Frontiers', 'date': 'Jun 27, 2023', 'snippet': 'This study aimed to provide the complete efficacy and safety profiles and \nranking of systemic therapies for the treatment of unresectable advanced \nor...', 'thumbnail': 'https://serpapi.com/searches/672403e67c171214322e972d/images/13d0e7ba078c501f4e840e36b6a9610e4e9dc7a246fb69b8a0c8db09a7d68807.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8807002902030945}",,,,,,,,,,['neutral'],neutral,1
NCT02514239,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/early-efficacy-data-shows-amg-420-potential-for-relapse-refractory-myeloma/', 'title': 'AMG 420 Immunotherapy Shows Promise in Relapsed or Refractory Multiple Myeloma', 'source': 'Myeloma Research News', 'date': 'Dec 10, 2018', 'snippet': ""The first in-human clinical study of Amgen's immunotherapy AMG 420 \ndemonstrated its potential to treat patients with relapsed or refractory..."", 'thumbnail': 'https://serpapi.com/searches/6724041614c31ed5c411c870/images/d0fda3cb48dc1f63746458e9c5d933f33cf5f55561c02986a3737c0f7ee48914.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5650992393493652}",,,,,,,,,,['positive'],positive,1
NCT04921969,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/atopic-dermatitis-improvement-observed-with-ruxolitinib-cream-in-pediatric-trial/', 'title': 'Atopic Dermatitis Improvement Observed With Ruxolitinib Cream in Pediatric Trial', 'source': 'Medical Professionals Reference', 'date': 'Jul 12, 2023', 'snippet': 'Positive topline results were announced from a phase 3 trial evaluating the \nefficacy and safety of ruxolitinib cream in pediatric patients with \natopic...', 'thumbnail': 'https://serpapi.com/searches/672401a96531cb6eb855f93b/images/4dd75f0900b4ecca7a01c363b821b35ca92958450c4200e55a776af70bf2f1e8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6511391997337341}",,,,,,,,,,['neutral'],neutral,1
NCT02456740,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1705848', 'title': 'A Controlled Trial of Erenumab for Episodic Migraine', 'source': 'The New England Journal of Medicine', 'date': 'Jan 5, 2018', 'snippet': 'We tested erenumab, a fully human monoclonal antibody that inhibits the \ncalcitonin gene–related peptide receptor, for the prevention of episodic \nmigraine.', 'thumbnail': 'https://serpapi.com/searches/672401aab5ecbb920dded6ed/images/e978cbe18b3c240ce488e83e857d6d1a9cbe9f7163537c7af10f60be2ef84599.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8950312733650208}",,,,,,,,,,['neutral'],neutral,1
NCT01669252,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-021-00282-0', 'title': 'The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers', 'source': 'Nature', 'date': 'Jun 7, 2021', 'snippet': 'The biology of breast cancer response to neoadjuvant therapy is \nunderrepresented in the literature and provides a window-of-opportunity \nto...', 'thumbnail': 'https://serpapi.com/searches/672401adf93388521a29a789/images/7b7a34cdd4d7fd4205fb565bbb4058226ec434e1e288d597e15ca29528fd2adc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8353123664855957}",,,,,,,,,,['neutral'],neutral,1
NCT03359785,"{'position': 1, 'link': 'https://www.nature.com/articles/s41386-023-01560-0', 'title': 'The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial', 'source': 'Nature', 'date': 'Mar 16, 2023', 'snippet': 'Several attempts have been made to enhance N-methyl-D-aspartate (NMDA) \nreceptor function in schizophrenia, but they have yielded mixed...', 'thumbnail': 'https://serpapi.com/searches/672401ae7ebde514439a825b/images/f0bb3b1005b6be20afd1a43e91fbe022616720e56de0b70df2e04b13fd36343b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8239313364028931}",,,,,,,,,,['neutral'],neutral,1
NCT03203005,"{'position': 1, 'link': 'https://www.biomedcentral.com/collections/MMHD', 'title': 'Molecular Mimicry in Human Diseases', 'source': 'BioMed Central', 'date': 'Apr 12, 2024', 'snippet': 'Guest Editors: Luigi Buonaguro, MD, National Cancer Institute Pascale, \nItaly Jamie Rossjohn, PhD, Monash Biomedicine Discovery Institute, \nAustralia...', 'thumbnail': 'https://serpapi.com/searches/672401ca7ec4ae3813c71f54/images/ce0c9e167a214d9fe3884808d9f063b345d25eaf3d44e85ac37177253077ea25.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9315586090087891}",,,,,,,,,,['neutral'],neutral,1
NCT03960580,"{'position': 1, 'link': 'https://www.pennmedicine.org/news/news-releases/2024/january/exhalation-system-improves-symptoms-of-chronic-sinus-infections', 'title': ""'Exhalation' System Improves Symptoms of Chronic Sinus Infections"", 'source': 'Penn Medicine', 'date': 'Jan 18, 2024', 'snippet': ""An exhalation delivery system that uses a patient's own breath to carry the \nanti-inflammatory compound fluticasone (EDS-FLU) directly to the sinuses \nreduced..."", 'thumbnail': 'https://serpapi.com/searches/672401e80664c984116fd9df/images/6d2e88b11747b7d67ad4a8c9475b52f5739e30bb298379179d8f858b5528b6be.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8489072918891907}",,,,,,,,,,['neutral'],neutral,1
NCT05616221,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/ap-pa02-safely-treat-pseudomonas-aeruginosa-infection/', 'title': 'Phage cocktail, AP-PA02, may safely treat Pseudomonas aeruginosa...', 'source': 'Cystic Fibrosis News Today', 'date': 'Mar 7, 2023', 'snippet': 'The phage therapy was well tolerated and eased Pseudomonas aeruginosa \nairway load in treated trial patients, Phase 2b CF study proposed.', 'thumbnail': 'https://serpapi.com/searches/672401f18e13c94185f183b7/images/504f77fbd38e83144fe86d88e3ee55c2f4d55652d3b318a3f09aaebddfdb12d3.png', 'sentiment': 'positive', 'sentiment_prob': 0.8077670931816101}",,,,,,,,,,['positive'],positive,1
NCT02311673,"{'position': 1, 'link': 'https://praderwillinews.com/news/prader-willi-syndrome-investigational-therapy-rm-853-acquired-rhythm-pharmaceuticals/', 'title': 'Rhythm Pharmaceuticals Acquires Rights to Develop Investigational Therapy RM-853', 'source': 'Prader-Willi Syndrome News', 'date': 'Apr 9, 2018', 'snippet': 'Rhythm Pharmaceuticals has acquired the rights to develop and commercialize \nRM-853, an investigational therapy currently in preclinical research for \nPrader-...', 'thumbnail': 'https://serpapi.com/searches/6724020f2da15795533ddac8/images/5255d25d08cf3fe696bee9dde62afdb85be2657a5a18707523092ea8b318e605.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.906080961227417}",,,,,,,,,,['neutral'],neutral,1
NCT04785144,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/nih-clinical-trial-evaluating-moderna-covid-19-variant-vaccine-begins', 'title': 'NIH clinical trial evaluating Moderna COVID-19 variant vaccine begins', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Mar 31, 2021', 'snippet': 'This trial is enrolling adult volunteers in the Atlanta, Cincinnati, \nNashville and Seattle areas. At this time, the research sites...', 'thumbnail': 'https://serpapi.com/searches/67240216e45f33d6d2690976/images/6609609ef79ebbca82e5f2e717a67a49ef2af5b727aa108025aadb15da54e7e8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9455243349075317}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-022-29219-2', 'title': 'Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates', 'source': 'Nature', 'date': 'Mar 31, 2022', 'snippet': 'The emergence of severe acute respiratory syndrome coronavirus 2 \n(SARS-CoV-2) variants that partly evade neutralizing antibodies raises...', 'thumbnail': 'https://serpapi.com/searches/67240216e45f33d6d2690976/images/6609609ef79ebbca74a5faf8754f2e49b4b3e83004073dc6e43f9540a494d958.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5325437784194946}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05295875,"{'position': 1, 'link': 'https://www.pharmaceutical-technology.com/news/ada-2024-altimmunes-glp-1-drug-shows-weight-loss-potential/', 'title': 'ADA 2024: Altimmune’s GLP-1 drug shows weight loss potential', 'source': 'Pharmaceutical Technology', 'date': 'Jun 24, 2024', 'snippet': 'As the obesity drug development space gains traction, Altimmune shared \npositive data from a Phase II trial for pemvidutide.', 'thumbnail': 'https://serpapi.com/searches/672402186de1e482835ae27b/images/49ade9080485b795e0443facb433a09f78b698386a415c38551948a697fe6e2e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7039597034454346}",,,,,,,,,,['positive'],positive,1
NCT01304927,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-22734-8', 'title': 'RANKL regulates male reproductive function', 'source': 'Nature', 'date': 'Apr 23, 2021', 'snippet': 'This translational study suggests that RANKL is a regulator of male \nreproductive function, however, predictive biomarkers for treatment-outcome \nrequires...', 'thumbnail': 'https://serpapi.com/searches/67240230ec54100b3215bcbd/images/2580b0c07a9101d55f267c990ebaa6bf05417cee7b9e9dbadf733123850260f6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9219090342521667}",,,,,,,,,,['neutral'],neutral,1
NCT03670953,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/amneals-extended-release-carbidopa-levodopa-to-get-review/', 'title': 'Amneal’s Extended-release Carbidopa/Levodopa to Get Review |...', 'source': ""Parkinson's News Today"", 'date': 'Nov 14, 2022', 'snippet': ""The U.S. Food and Drug Administration (FDA) will review Amneal \nPharmaceuticals' application for IPX203, its extended-release..."", 'thumbnail': 'https://serpapi.com/searches/672403cef60b6f8ef9bda30e/images/3dd07681f4efffba33346ed0c38104c18278c17033101f1dae29c0d90c6bd04e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9473481774330139}","{'position': 2, 'link': 'https://www.neurologylive.com/view/rise-parkinson-disease-study-ipx-203-alberto-espay', 'title': 'The RISE-PD Study of IPX-203: Alberto J. Espay, MD, MSc', 'source': 'Neurology live', 'date': 'Oct 12, 2021', 'snippet': ""The research chair for Parkinson's Disease and Movement Disorders at \nUniversity of Cincinnati Health discussed the therapy's results in a..."", 'thumbnail': 'https://serpapi.com/searches/672403cef60b6f8ef9bda30e/images/3dd07681f4efffba4f3d95316c1d53fdba1fe486944775c241f7b7401e320563.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.953052818775177}","{'position': 3, 'link': 'https://parkinsonsnewstoday.com/news/application-parkinsons-therapy-ipx203-resubmitted-fda/', 'title': ""Application for Parkinson's therapy IPX203 resubmitted to FDA"", 'source': ""Parkinson's News Today"", 'date': 'Feb 12, 2024', 'snippet': ""Amneal Pharmaceuticals' IPX203 formulation for Parkinson's disease is \ndesigned to maintain steady bodily levels of carbidopa and levodopa."", 'thumbnail': 'https://serpapi.com/searches/672403cef60b6f8ef9bda30e/images/3dd07681f4efffba8eb634723faba8382d6d1346dfd934258f6fe152ab85540d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9042649269104004}","{'position': 4, 'link': 'https://parkinsonsnewstoday.com/news/aan-2022-ipx-203-extended-release-gives-more-good-on-time-dose-parkinsons-trial/', 'title': ""#AAN2022 - IPX-203 Reduced Parkinsons' 'Off Time' 1.5+ Hours in Trial"", 'source': ""Parkinson's News Today"", 'date': 'Mar 28, 2022', 'snippet': 'IPX-203, an extended-release version of CD/LD therapy, performed better \nthan immediate-release medicine, according to clinical trial data.', 'thumbnail': 'https://serpapi.com/searches/672403cef60b6f8ef9bda30e/images/3dd07681f4efffba1f44ae8186697514c5ba2fbfe23d513de74bc7832f0e752a.png', 'sentiment': 'positive', 'sentiment_prob': 0.5773031115531921}",,,,,,,"['neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT03035591,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-01077-z', 'title': 'First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours', 'source': 'Nature', 'date': 'Sep 29, 2020', 'snippet': 'Bromodomain and extra-terminal domain (BET) proteins are reported to be \nepigenetic anti-cancer drug targets. This first-in-human study...', 'thumbnail': 'https://serpapi.com/searches/6724024516779322118570c2/images/c8f2458204dd087d0b58d2737707c7a30d5f810fbb26e723826dba803d106007.png', 'sentiment': 'neutral', 'sentiment_prob': 0.90174800157547}",,,,,,,,,,['neutral'],neutral,1
NCT02294058,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/06/30/long-term-data-zeposia-help-cognitive-function-patients/', 'title': 'Long-term Zeposia May Help Cognitive Function in Patients, Data Show', 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 30, 2022', 'snippet': 'Long-term treatment with Zeposia stabilizes or even improves cognitive \nfunction in most adults with relapsing forms of MS, data show.', 'thumbnail': 'https://serpapi.com/searches/6724024d48b9f7f46b77579d/images/15d2aa0de0664ce9d2d1ba338d7894a609816199ac07bdba4e657f96beef27c2.png', 'sentiment': 'positive', 'sentiment_prob': 0.6353581547737122}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/02/14/zeposia-not-affect-heart-heath-long-term-use-trials/', 'title': 'Zeposia’s long-term use doesn’t affect heart health, Phase 3 trials show', 'source': 'Multiple Sclerosis News Today', 'date': 'Feb 14, 2023', 'snippet': 'Relapsing MS patients treated with oral Zeposia for up to 2 years in Phase \n3 trials show no clinically significant changes in heart health.', 'thumbnail': 'https://serpapi.com/searches/6724024d48b9f7f46b77579d/images/15d2aa0de0664ce942181746d03fe4f6f04d4b1a8ce88a55588391c911a6d990.png', 'sentiment': 'neutral', 'sentiment_prob': 0.705949604511261}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT00289211,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0805538', 'title': 'Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema', 'source': 'The New England Journal of Medicine', 'date': 'Aug 5, 2010', 'snippet': 'We report the results of two randomized trials of nanofiltered C1 inhibitor \nconcentrate for the management of hereditary angioedema.', 'thumbnail': 'https://serpapi.com/searches/67240254316650e9680477db/images/a8fcf14e32675d743a7e647671110d0f317d6f8a6911a320ccfe979cbe0ea585.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9361838698387146}","{'position': 2, 'link': 'https://angioedemanews.com/cinryze/', 'title': 'Cinryze (human C1 esterase inhibitor) for hereditary angioedema', 'source': 'Angioedema News', 'date': 'Jan 9, 2024', 'snippet': 'Cinryze, marketed by Shire, is an approved injectable medicine to prevent \nsevere swelling attacks in people with hereditary angioedema...', 'thumbnail': 'https://serpapi.com/searches/67240254316650e9680477db/images/a8fcf14e32675d74db1ab0affb3d534a4c90dc0eaa116bf41ff2eebe279b6a21.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8004082441329956}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02191826,"{'position': 1, 'link': 'https://fapnewstoday.com/news/new-molecule-potentially-potent-fap-treatment/', 'title': 'New molecule seen as potentially potent FAP treatment', 'source': 'FAP News Today', 'date': 'Oct 30, 2023', 'snippet': 'Scientists in Spain developed PITB, a second-generation TTR stabilizer that \nwas more potent and effective than tolcapone in lab studies.', 'thumbnail': 'https://serpapi.com/searches/67240260be8013c71954fb24/images/3d7160dccd5aede226f37cab3a6744ca385069b7a743d5bf67f086a56049c1a5.png', 'sentiment': 'positive', 'sentiment_prob': 0.7142612338066101}","{'position': 2, 'link': 'https://www.nature.com/articles/ncomms10787', 'title': 'Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity', 'source': 'Nature', 'date': 'Feb 23, 2016', 'snippet': 'Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal \nsystemic amyloidoses. TTR tetramer dissociation precedes...', 'thumbnail': 'https://serpapi.com/searches/67240260be8013c71954fb24/images/3d7160dccd5aede2ad1fbc5a99dff98f85d64d414aa46aeb75b7bb6ab7b60312.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6535580158233643}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02752113,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-35589-4', 'title': 'Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis', 'source': 'Nature', 'date': 'Jun 2, 2023', 'snippet': 'This is a cross-sectional analysis of arterial stiffness in 266 patients in \nthe early stage of T2DM who did not have cardiovascular or renal \ncomplications.', 'thumbnail': 'https://serpapi.com/searches/6724027ec7d4a1e0188e88c2/images/eeb6ad58be55f091eefc38eabec0374ba8ac3c979cda4e5bbea5143fbcb3d06d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9014810919761658}",,,,,,,,,,['neutral'],neutral,1
NCT00402831,"{'position': 1, 'link': 'https://www.empr.com/home/news/m-m-r-ii-varivax-proquad-vaccines-approved-for-intramuscular-administration/', 'title': 'M-M-R II, Varivax, ProQuad Vaccines Approved for Intramuscular Administration', 'source': 'Medical Professionals Reference', 'date': 'Mar 6, 2023', 'snippet': ""The Food and Drug Administration (FDA) has expanded the approval for \nMerck's MMR II (measles, mumps, and rubella virus vaccine live), Varivax \n(varicella virus..."", 'thumbnail': 'https://serpapi.com/searches/672402df2c83d5b81af4c11f/images/b813f186228b9d7517f4828ff586363b1751f440fd3fead8f82e9ba9a0fed19d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8451946973800659}",,,,,,,,,,['neutral'],neutral,1
NCT03010527,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/bimekizumab-UCB4940', 'title': 'Bimekizumab (Bimzelx®)', 'source': 'UCB', 'date': 'Oct 16, 2018', 'snippet': 'Ankylosing Spondylitis, A Multicenter Study to Evaluate the Efficacy and \nSafety of Different Doses of Bimekizumab in Subjects With Active \nAnkylosing...', 'thumbnail': 'https://serpapi.com/searches/6724029376079d039968ff9d/images/44098e76aa3c26570c8f047801882c70e92a92b34bdcc1e9bc12bf89a3ea8f0a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8456552028656006}",,,,,,,,,,['neutral'],neutral,1
NCT02138916,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1905248', 'title': 'Benralizumab for the Prevention of COPD Exacerbations', 'source': 'The New England Journal of Medicine', 'date': 'May 20, 2019', 'snippet': 'In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a \nratio of approximately 2:1 on the basis of eosinophil count [≥220 per \ncubic...', 'thumbnail': 'https://serpapi.com/searches/67240298316650e93040c5be/images/6707c2d5928c1d4358d2ff6ff653d909b01bd8ff69a759a2936f949615b5d767.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8859856724739075}","{'position': 2, 'link': 'https://lungdiseasenews.com/2018/01/16/severe-eosinophilic-asthma-therapy-fasenra-benralizumab-astrazeneca-receives-eu-approval/', 'title': 'Fasenra Approved in EU for Treatment of Severe Eosinophilic Asthma', 'source': 'Lung Disease News', 'date': 'Jan 16, 2018', 'snippet': 'Read about the approval of Fasenra (benralizumab) in the EU for the \ntreatment of severe eosinophilic asthma. The U.S. FDA approved Fasenra...', 'thumbnail': 'https://serpapi.com/searches/67240298316650e93040c5be/images/6707c2d5928c1d439ad26619ec24fb54d0d20a60e23c2a9b58c81cab202f4c25.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.831265389919281}","{'position': 3, 'link': 'https://copdnewstoday.com/news/no-reduction-copd-exacerbations-add-on-fasenra-phase-3-trials/', 'title': 'No Reduction in COPD Exacerbations with Fasenra Add-on in Phase 3 Trials', 'source': 'COPD News Today', 'date': 'Jun 11, 2019', 'snippet': 'Add-on treatment with Fasenra (benralizumab) failed to reduce annual \nexacerbations in patients with moderate to very severe COPD,...', 'thumbnail': 'https://serpapi.com/searches/67240298316650e93040c5be/images/6707c2d5928c1d438a10895f35277e2210b7733d7b373a5022067ec8794c4984.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7574577331542969}",,,,,,,,"['neutral', 'neutral', 'negative']",neutral,1
NCT02969382,"{'position': 1, 'link': 'https://www.nature.com/articles/s41537-021-00190-z', 'title': 'Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study', 'source': 'Nature', 'date': 'Dec 9, 2021', 'snippet': 'Ulotaront, a trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A \nreceptors agonist, has demonstrated efficacy in the treatment of...', 'thumbnail': 'https://serpapi.com/searches/672402a1bb55ff6f6c744400/images/a8d78613aaabab4f6164f90cab29d097c2ede73760055f4b3ca2fe351847d1c3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7764618396759033}",,,,,,,,,,['neutral'],neutral,1
NCT03597295,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2021/01/25/retifanlimab-under-fda-priority-review-for-advanced-anal-canal-cancer/', 'title': 'Retifanlimab Under FDA Priority Review for Advanced Anal Canal Cancer', 'source': 'Immuno-Oncology News', 'date': 'Jan 25, 2021', 'snippet': 'Retifanlimab is under FDA review for treating adults with advanced squamous \ncell carcinoma of the anal canal, who progressed after initial...', 'thumbnail': 'https://serpapi.com/searches/672402b62b5fa77e1b885b41/images/2d117e81697dfc00a8e80da10c457fca5e2e73a5379492a95639eebfc0c2e017.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8957542777061462}",,,,,,,,,,['neutral'],neutral,1
NCT02965001,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/63/8/1169', 'title': 'Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with 18F-FDG PET/CT: A Single-Center Prospective Study', 'source': 'Journal of Nuclear Medicine', 'date': 'Aug 1, 2022', 'snippet': 'Abstract. The aim of this phase II clinical trial (NCT02965001) was to \nevaluate the prognostic value of urokinase-type plasminogen activator...', 'thumbnail': 'https://serpapi.com/searches/672402bfd403e1663f070f6a/images/fbea3c88dbf06e753926d4bc048c2ed9e9b52d8c38d8d061c77e5c102136e5a8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8865150809288025}",,,,,,,,,,['neutral'],neutral,1
NCT00441207,"{'position': 1, 'link': 'https://www.researchgate.net/publication/355780963_High-dose_intravenous_vitamin_C_a_promising_multi-targeting_agent_in_the_treatment_of_cancer', 'title': '(PDF) High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer', 'source': 'ResearchGate', 'date': 'Nov 4, 2021', 'snippet': 'Mounting evidence indicates that vitamin C has the potential to be a potent \nanti-cancer agent when administered intravenously and in high doses \n(high-dose IVC).', 'thumbnail': 'https://serpapi.com/searches/672402c56de1e482835ae296/images/7f92810abdb5eb139656c28e84830c0aa9b54d46f5ae0db04a45ef1cce170920.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7034693956375122}",,,,,,,,,,['positive'],positive,1
NCT01764841,"{'position': 1, 'link': 'https://bronchiectasisnewstoday.com/2017/07/18/ciprofloxacin-dpi-bayer-treating-non-cystic-fibrosis-bronchiectasis/', 'title': 'Bayer’s Ciprofloxacin DPI Shows Promise in Treating Non-cystic Fibrosis Bronchiectasis', 'source': 'Bronchiectasis News Today', 'date': 'Jul 18, 2017', 'snippet': 'Bayer is conducting two Phase 3 clinical trials evaluating ciprofloxacin \nDry Powder for Inhalation (ciprofloxacin DPI) as a treatment for...', 'thumbnail': 'https://serpapi.com/searches/672402c78a7c0972a22e3525/images/b91c10e1bd445f0cc2023b8abd5863bd17607f075db39c16b5d816ac721a0090.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7611814737319946}","{'position': 2, 'link': 'https://bronchiectasisnewstoday.com/2017/11/17/fda-panel-opposed-ciprofloxacin-dry-powder-for-inhalation-cipro-dpi-to-treat-non-cf-bronchiectasis/', 'title': 'FDA Panel Opposes Use of Cipro DPI to Treat Non-CF Bronchiectasis', 'source': 'Bronchiectasis News Today', 'date': 'Nov 17, 2017', 'snippet': 'A US Food and Drug Administration (FDA) advisory panel voted not to \nrecommend ciprofloxacin dry powder for inhalation (Cipro DPI), being \ndeveloped by Bayer, to...', 'thumbnail': 'https://serpapi.com/searches/672402c78a7c0972a22e3525/images/b91c10e1bd445f0c1835a7e9c01816840176d738d0680e03428778e8f7f49cd8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5384337902069092}","{'position': 3, 'link': 'https://bronchiectasisnewstoday.com/2018/01/04/top-10-bronchiectasis-stories-2017/', 'title': 'Top 10 Bronchiectasis Stories of 2017', 'source': 'Bronchiectasis News Today', 'date': 'Jan 4, 2018', 'snippet': ""Here are Bronchiectasis News Today's Top 10 most-read stories of 2017 with \nsummaries of why they were interesting to bronchiectasis patients..."", 'thumbnail': 'https://serpapi.com/searches/672402c78a7c0972a22e3525/images/b91c10e1bd445f0c852361e8b986483bf4eb78911ba197dd4d7fb618f2c5a068.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5398268699645996}",,,,,,,,"['neutral', 'neutral', 'positive']",neutral,1
NCT04874350,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/lpcn-1148-phase-2-study-meets-primary-endpoint-in-patients-with-cirrhosis-301886930.html', 'title': 'LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis', 'source': 'PR Newswire', 'date': 'Jul 27, 2023', 'snippet': 'This Phase 2 proof of concept study is an ongoing randomized \nplacebo-controlled study in sarcopenic male patients with cirrhosis on the \nliver transplant...', 'thumbnail': 'https://serpapi.com/searches/6724032f4a4a1df3ffaf03e2/images/aff36becaef0228807fb0165398d66314c7dd70ea2a22bd854ac05553f649dea.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9118776917457581}",,,,,,,,,,['neutral'],neutral,1
NCT02128958,"{'position': 1, 'link': 'https://www.onclive.com/view/state-of-science-summit-gastrointestinal-cancer---chaired-by-tanios-bekaii-saab-md-and-darshil-shah-md-mph', 'title': 'State of Science Summit: Gastrointestinal Cancer - Chaired by: Tanios Bekaii-Saab, MD and Darshil Shah, MD, MPH', 'source': 'OncLive', 'date': '1 month ago', 'snippet': 'State of Science Summit: Gastrointestinal Cancer - Chaired by: Tanios \nBekaii-Saab, MD and Darshil Shah, MD, MPH.', 'thumbnail': 'https://serpapi.com/searches/67240348b2ebaee6e82f3ba2/images/8df87159b5d6879539fcc9fc823652a318c40716dc06f4390d10d1e346bfc182.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8446627259254456}","{'position': 2, 'link': 'https://www.onclive.com/view/dr-sapisochin-on-neoadjuvant-treatment-for-hcc', 'title': 'Dr. Sapisochin on Neoadjuvant Treatment for HCC', 'source': 'OncLive', 'date': 'Sep 20, 2018', 'snippet': 'Gonzalo Sapisochin, MD, assistant professor of surgery, University of \nToronto, discusses neoadjuvant treatment for patients with hepatocellular \ncarcinoma (HCC).', 'thumbnail': 'https://serpapi.com/searches/67240348b2ebaee6e82f3ba2/images/8df87159b5d68795ba431e2524ba186951f6a53e3840383946200ac436747427.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9181070327758789}","{'position': 3, 'link': 'https://www.onclive.com/view/dr-hidalgo-medina-on-treatment-considerations-in-pancreatic-cancer', 'title': 'Dr. Hidalgo Medina on Treatment Considerations in Pancreatic Cancer', 'source': 'OncLive', 'date': 'Dec 4, 2019', 'snippet': 'Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical \nOncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital,...', 'thumbnail': 'https://serpapi.com/searches/67240348b2ebaee6e82f3ba2/images/8df87159b5d68795f48dd6bb1186b0c5bba37adef6ca46c5155cab9ed9cee8c2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.934554398059845}","{'position': 4, 'link': 'https://www.onclive.com/view/dr-oneil-on-neuroendocrine-tumors', 'title': ""Dr. O'Neil on Neuroendocrine Tumors"", 'source': 'OncLive', 'date': 'May 21, 2018', 'snippet': ""Bert O'Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, \nprofessor of medicine, and director of the Phase I and..."", 'thumbnail': 'https://serpapi.com/searches/67240348b2ebaee6e82f3ba2/images/8df87159b5d687956682399807616ebae8441115871a9eba7111b712ade142a1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9435071349143982}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04685265,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.852003/full', 'title': ""Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies"", 'source': 'Frontiers', 'date': 'Feb 13, 2024', 'snippet': 'Here, we review recent pre-clinical and clinical work that offers promising \ntreatment strategies to sequester, degrade, or silence asyn expression.', 'thumbnail': 'https://serpapi.com/searches/67240349f3cbfa2f8b13c134/images/d35ca066d46bbee5858c641b6959118708de976f392b1ad9e3572297e84fc480.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8726274967193604}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-022-32797-w', 'title': 'The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils', 'source': 'Nature', 'date': 'Sep 14, 2022', 'snippet': 'Aggregation of amyloidogenic proteins is a characteristic of multiple \nneurodegenerative diseases. Atomic resolution of small molecule...', 'thumbnail': 'https://serpapi.com/searches/67240349f3cbfa2f8b13c134/images/d35ca066d46bbee570fd00430ae8368ce84c17b5ce37ef7636ad43f3f86bd251.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8575400710105896}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03105128,"{'position': 1, 'link': 'https://ibdnewstoday.com/2021/01/18/risankizumab-induces-clinical-endoscopic-remission-after-12-weeks-in-crohns-disease-clinical-trials/', 'title': ""Crohn's Remission Shown After 12 Weeks in Risankizumab Clinical Trial"", 'source': 'ibdnewstoday.com', 'date': 'Jan 18, 2021', 'snippet': ""Treatment with risankizumab for 12 weeks induced both clinical and \nendoscopic remission in people with Crohn's disease, trial data show."", 'thumbnail': 'https://serpapi.com/searches/6724034b7d533e6839e29268/images/1260b470d06b690eba5ba639de63c36a8315197b600bc99ddab164dfac6da297.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.879081130027771}",,,,,,,,,,['neutral'],neutral,1
NCT02040298,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00027-9/fulltext?rss=yes', 'title': 'Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges', 'source': 'The Lancet', 'date': 'Feb 15, 2024', 'snippet': 'Several immunomodulatory approaches that have modest but clinically \nmeaningful effects have been approved for the management of progressive \nmultiple sclerosis.', 'thumbnail': 'https://serpapi.com/searches/672403559fd3095e762f8e10/images/c29c1e3afc75c5cb1e4b52bb341bb75cb2a0de101468a51be2dc99a97a082d95.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8122972249984741}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/tavist-clemastinetavist-clemastine/', 'title': 'Tavist (Clemastine) for RRMS', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 13, 2017', 'snippet': 'Tavist (clemastine) is an over-the-counter antihistamine that is being \ndeveloped as a potential treatment for relapsing remitting multiple \nsclerosis (RRMS).', 'thumbnail': 'https://serpapi.com/searches/672403559fd3095e762f8e10/images/c29c1e3afc75c5cb6b0765f8c7ba3b0fec7279f8ac31d75ae4f5952f04966fd5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8968601822853088}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04089579,"{'position': 1, 'link': 'https://www.vice.com/en/article/duke-stem-cells-autism-cryocell/', 'title': 'Duke Has Quietly Discontinued a Costly, Unproven Autism Treatment', 'source': 'VICE', 'date': 'Apr 17, 2023', 'snippet': 'For several years, parents of autistic children have paid between $10,000 \nand $15,000 to have their children undergo unproven stem cell and...', 'thumbnail': 'https://serpapi.com/searches/6724036274f0a4921704ed49/images/532ef8ac461d5908c2b870e62c69ee83e0ba7cfc3d0fd9f2982f03530d440d68.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5620641708374023}",,,,,,,,,,['neutral'],neutral,1
NCT03831295,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-023-00364-1', 'title': 'Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer', 'source': 'Nature', 'date': 'Mar 8, 2023', 'snippet': 'In this review, we describe the TLR agonists that are being evaluated \nclinically as new therapies for solid tumors.', 'thumbnail': 'https://serpapi.com/searches/6724036b9872179945fc35ac/images/205a9ac660bd7e76ffa07be419454e7b162d9cfd73e07cc2b1cf3a027d914222.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9042466282844543}",,,,,,,,,,['neutral'],neutral,1
NCT03422510,"{'position': 1, 'link': 'https://www.nature.com/articles/s41581-021-00427-1', 'title': 'Therapeutic trials in adult FSGS: lessons learned and the road forward', 'source': 'Nature', 'date': 'May 20, 2021', 'snippet': 'Focal segmental glomerulosclerosis (FSGS) is not a specific disease entity \nbut a lesion that primarily targets the podocyte.', 'thumbnail': 'https://serpapi.com/searches/6724037f1fc7c51f052f05c5/images/5a40d8a56331359ed162f6b4d449996e306f60f1bb67cf76e575b43f0aa7fe99.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8861932754516602}",,,,,,,,,,['neutral'],neutral,1
NCT04369586,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01323-9', 'title': 'Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial', 'source': 'Nature', 'date': 'Jan 30, 2023', 'snippet': 'Meplazumab, a humanized CD147 antibody, has shown favourable safety and \nefficacy in our previous clinical studies. In DEFLECT (NCT04586153)...', 'thumbnail': 'https://serpapi.com/searches/672403a5708e2e993b0dd95e/images/97d45dfba701ff28b0eae2c442bf0c6351fd556c753b99796fd8d6562931b47a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5692375302314758}",,,,,,,,,,['neutral'],neutral,1
NCT02606682,"{'position': 1, 'link': 'https://www.apdaparkinson.org/article/future-parkinsons-disease-treatments/', 'title': 'The Future of Parkinson’s Disease Treatments', 'source': 'American Parkinson Disease Association', 'date': 'Aug 25, 2020', 'snippet': 'There are many new and exciting potential therapies that are under \ninvestigation and we will continue to update you as results of these trials \nare available.', 'thumbnail': 'https://serpapi.com/searches/672403b4f9f904be4fe0a50a/images/763fdf5e92e755a3ce90d18ef6c37c675703119d777e6f1d4b4e114f2775d3ac.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7533977031707764}",,,,,,,,,,['positive'],positive,1
NCT04561258,"{'position': 1, 'link': 'https://www.europeanpharmaceuticalreview.com/news/155658/first-patient-treated-with-potentially-curative-hiv-cell-and-gene-therapy/', 'title': 'First patient treated with potentially curative HIV cell and gene therapy', 'source': 'European Pharmaceutical Review', 'date': 'Jun 1, 2021', 'snippet': 'The first-in-human study will evaluate the safety and efficacy AGT103-T, a \ncell and gene therapy product for HIV, in up to six participants.', 'thumbnail': 'https://serpapi.com/searches/672403c2d364b4f6fa6df322/images/4d874fa47c16accf1c4c670cca27e9f3b1dda3ece05d882350ca1224f03d22f7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8429476022720337}","{'position': 2, 'link': 'https://www.cgtlive.com/view/conant-more-research-needed-hiv-therapies', 'title': 'Marcus Conant, MD, on More Research Needed With HIV Therapies', 'source': 'CGTLive®', 'date': 'Jun 4, 2024', 'snippet': 'The Chief Medical Officer of Addimmune discussed the unmet need with HIV \nand research the company is conducting.', 'thumbnail': 'https://serpapi.com/searches/672403c2d364b4f6fa6df322/images/4d874fa47c16accf1410a4018a02000786358e809b21e663187f6c451c190d19.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9322260618209839}","{'position': 3, 'link': 'https://www.prnewswire.com/news-releases/agt-announces-progress-with-hiv-cure-program-phase-1-clinical-trial-301300466.html', 'title': 'AGT Announces Progress with HIV Cure Program, Phase 1 Clinical Trial', 'source': 'PR Newswire', 'date': 'May 27, 2021', 'snippet': 'PRNewswire/ -- American Gene Technologies (AGT), a clinical-stage \nbiotechnology company, announced treatment of the first participant in \nits...', 'thumbnail': 'https://serpapi.com/searches/672403c2d364b4f6fa6df322/images/4d874fa47c16accfc3114bcfc29f299bb2c022afe893a83aee70fa5215e74bd0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7963420748710632}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT01592370,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2023.1244494/full', 'title': 'Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trial', 'source': 'Frontiers', 'date': 'Sep 12, 2023', 'snippet': 'PurposeThe phase I/II trial CheckMate 039 (NCT01592370) evaluated the \nsafety, tolerability, and efficacy of nivolumab-daratumumab (ND) in...', 'thumbnail': 'https://serpapi.com/searches/672403c158e433cfdc86995c/images/2ea290601f982697039cd6ff5162882c1df9c5691961b3217eedf82c5abb21f8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9009431004524231}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/safety-concerns-prompt-fda-to-put-a-hold-on-opdivo-combination-trials-for-myeloma/', 'title': '3 Myeloma Trials of Opdivo Put on Hold Due to Safety Concerns Over Other Therapies', 'source': 'Myeloma Research News', 'date': 'Sep 8, 2017', 'snippet': 'The US Food and Drug Administration has ordered Bristol-Myers Squibb to put \na hold on three clinical trials evaluating Opdivo (nivolumab) in \ncombination with...', 'thumbnail': 'https://serpapi.com/searches/672403c158e433cfdc86995c/images/2ea290601f982697af35f930eb56b23458154036ffc0b641531f42c7ce6c0a35.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7855069041252136}","{'position': 3, 'link': 'https://www.nature.com/articles/s41598-023-50262-6', 'title': 'Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab', 'source': 'Nature', 'date': 'Jan 7, 2024', 'snippet': 'Lirilumab, the most clinically advanced NK cell checkpoint inhibitor, \ntargets inhibitory killer immunoglobulin-like receptors (KIRs), however it \nhas yet to...', 'thumbnail': 'https://serpapi.com/searches/672403c158e433cfdc86995c/images/2ea290601f982697620876972e98c1bc4460926e6ad977638fad2323afe4dbe0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.884059488773346}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02824003,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01333-7', 'title': 'Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study', 'source': 'Nature', 'date': 'Mar 2, 2023', 'snippet': 'Epigenetics regulates gene expression and has been confirmed to play a \ncritical role in a variety of metabolic diseases, such as diabetes,...', 'thumbnail': 'https://serpapi.com/searches/672404815bb6a2d585eda4f5/images/17003a54fb9eb404104c31ffa7226cbe094f11fcc537fa4630a27244deaba15b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.921919047832489}",,,,,,,,,,['neutral'],neutral,1
NCT03354273,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-99212-0', 'title': 'Development and preclinical evaluation of novel fluorinated ammonium salts for PET myocardial perfusion imaging', 'source': 'Nature', 'date': 'Oct 4, 2021', 'snippet': 'The current study aimed to increase the clinical applicability of PET-MPI \nby designing and synthesizing fluorinated ammonium salt derivatives.', 'thumbnail': 'https://serpapi.com/searches/67240487f922f6c63082ec99/images/8e0202b8ea802854d96029bb35901dc8ec3459bbe2ab4eadc78365ac58357768.png', 'sentiment': 'neutral', 'sentiment_prob': 0.871613621711731}",,,,,,,,,,['neutral'],neutral,1
NCT00809562,"{'position': 1, 'link': 'https://www.psychiatrictimes.com/view/ketamine-induced-optimism-new-hope-development-rapid-acting-antidepressants', 'title': 'Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants', 'source': 'Psychiatric Times', 'date': 'Jul 13, 2012', 'snippet': 'There is rapidly escalating interest in drugs that target the glutamatergic \nneurotransmitter system, especially NMDA receptor modulators.', 'thumbnail': 'https://serpapi.com/searches/67240495d997ab53a5e9a57d/images/5f49d7a12e3882f1791e8cb10847ad2ba9cfef1bf9f7fb36584ddb22412aecd0.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.798674464225769}",,,,,,,,,,['positive'],positive,1
NCT01665144,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2020/09/08/novartis-data-at-actrims-ectrims-highlight-the-strength-of-leading-multiple-sclerosis-ms-portfolio-with-life-changing-therapies-for-people-across-the-ms-spectrum/', 'title': '#MSVirtual2020 – Novartis to Present Latest Data on Kesimpta, Mayzent and Gilenya', 'source': 'Multiple Sclerosis News Today', 'date': 'Sep 11, 2020', 'snippet': 'Novartis will present latest study findings on its approved therapies for \nrelapsing MS at the MSVirtual2020 meeting running Sept. 11 to 13..', 'thumbnail': 'https://serpapi.com/searches/6724049d5416d82ede485ded/images/67212637e34fcbf4c19f52d51859e235281c123f3976f7b10306c82e642db304.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.857699453830719}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2020/03/06/health-canada-approves-novartis-mayzent-siponimod-to-treat-spms/', 'title': 'SPMS Treatment Mayzent Approved by Health Canada, Novartis Says', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 6, 2020', 'snippet': ""Health Canada has approved Novartis's Mayzent (siponimod) for adults with \nactive secondary progressive multiple sclerosis to delay..."", 'thumbnail': 'https://serpapi.com/searches/6724049d5416d82ede485ded/images/67212637e34fcbf41e9369d9ae4979d82d03c1e6350a70e83dcfb6c7aebbd2ea.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6169264912605286}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2017/02/15/new-treatment-may-hold-promise-for-progressive-form-of-multiple-sclerosis-study-suggests/', 'title': 'SPMS Anti-Inflammatory Agent Gilenya Counters Effect of Astrocytes', 'source': 'Multiple Sclerosis News Today', 'date': 'Feb 15, 2017', 'snippet': 'Gilenya (fingolimod) a multiple sclerosis (MS) drug developed to target the \nimmune system and control inflammation, can also reduce the negative action \nof...', 'thumbnail': 'https://serpapi.com/searches/6724049d5416d82ede485ded/images/67212637e34fcbf43bd7f275909e62ca13ba0149eecafd25c6ded77dee1f1c4a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8465134501457214}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00006343,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1609324', 'title': 'Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'Mar 9, 2017', 'snippet': 'Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for \npatients with chronic myeloid leukemia (CML).', 'thumbnail': 'https://serpapi.com/searches/672404b61a5b544a7349191f/images/10b319e36f4a15c0e5e57e18565665a382303dafd3006ad7c96c937cfbe76e87.png', 'sentiment': 'positive', 'sentiment_prob': 0.6723223924636841}",,,,,,,,,,['positive'],positive,1
NCT03004833,"{'position': 1, 'link': 'https://dailynews.ascopubs.org/do/nivahl-trial-nivolumab-and-avd-show-favorable-long-term-safety-and-efficacy-early-stage', 'title': 'NIVAHL Trial: Nivolumab and AVD Show Favorable Long-Term Safety and Efficacy in Early-Stage Unfavorable Classical Hodgkin Lymphoma', 'source': 'ASCO Daily News', 'date': 'Dec 21, 2022', 'snippet': 'A first-line treatment regimen of nivolumab plus doxorubicin, vinblastine, \nand dacarbazine (AVD) was associated with consistent favorable...', 'thumbnail': 'https://serpapi.com/searches/672404dd1315022822549534/images/50daa4dca09e29628d0a18b9c5627ed6b32a9b2feb142251fa5aa861e5c00b1e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6480887532234192}",,,,,,,,,,['neutral'],neutral,1
NCT00799903,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1315878', 'title': 'Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease', 'source': 'The New England Journal of Medicine', 'date': 'Mar 30, 2014', 'snippet': 'Elevated lipoprotein-associated phospholipase A2 activity promotes the \ndevelopment of vulnerable atherosclerotic plaques, and elevated...', 'thumbnail': 'https://serpapi.com/searches/672404dfce1e10a40aec60ee/images/24b61b6c5d8cdb89df7a25b15d2f39aba0d2c864bf25960acac908bea59cc88d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7910451292991638}",,,,,,,,,,['neutral'],neutral,1
NCT02535689,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-23361-z', 'title': 'Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus', 'source': 'Nature', 'date': 'Jun 7, 2021', 'snippet': ""The tofacitinib is found to be safe in SLE meeting study's primary \nendpoint. We also show that tofacitinib improves cardiometabolic and \nimmunologic parameters."", 'thumbnail': 'https://serpapi.com/searches/672404e0cb33d0457864580d/images/844e9cafacd69a994a4782de7b56156b5bf4c0f12438c7159494157b3d8b2710.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6576781868934631}",,,,,,,,,,['positive'],positive,1
NCT02323412,"{'position': 1, 'link': 'https://www.bmj.com/content/367/bmj.l5654', 'title': 'Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes (the AIM study): double blind, randomised, placebo controlled, multicentre trial', 'source': 'The BMJ', 'date': 'Oct 16, 2019', 'snippet': '... placebo controlled, multicentre trial. BMJ 2019; 367 doi: \nhttps://doi.org/10.1136/bmj.l5654 (Published 16 October 2019) Cite this as: \nBMJ 2019;367:l5654.', 'thumbnail': 'https://serpapi.com/searches/672404fc6cca5eff81971515/images/c0c78698d47bea707a8f9bad16129a65bc86209b6342eda46b3d5bedfd256870.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8757321238517761}",,,,,,,,,,['neutral'],neutral,1
NCT01740557,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1018962/full', 'title': 'Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': '1Department of Immunology, School of Medicine, Iran University of Medical \nSciences, Tehran, Iran; 2Immunology Research Center, Institute of \nImmunology and...', 'thumbnail': 'https://serpapi.com/searches/67240501123457bbbd4c2516/images/dd2b73ed15a16e99c56312af44ed67edf75a2194d146e9feb314824139b49e5b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7887113094329834}",,,,,,,,,,['neutral'],neutral,1
NCT01563263,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-023-00672-4', 'title': 'Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa | npj Vaccines', 'source': 'Nature', 'date': 'May 25, 2023', 'snippet': 'Pseudomonas aeruginosa (PA) is a leading cause of hospital-acquired and \nventilator-associated pneumonia. The multidrug-resistance (MDR) rate...', 'thumbnail': 'https://serpapi.com/searches/67240521059caf91502b3f5c/images/030e314329f4e15d32e78c370b006db5da486f6e34684e957b18e71f37ed99c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7648937106132507}",,,,,,,,,,['neutral'],neutral,1
NCT00117676,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0802878', 'title': 'Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B', 'source': 'The New England Journal of Medicine', 'date': 'Dec 4, 2008', 'snippet': 'Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent \ninhibitor of human immunodeficiency virus type 1 reverse...', 'thumbnail': 'https://serpapi.com/searches/67240523a5aae957db4375b1/images/43310ec6f3d15ef402057d0eb3ea2e4fd93e924ab1eec4aaec1662c3b737d399.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8598584532737732}",,,,,,,,,,['neutral'],neutral,1
NCT02354131,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2020/06/11/zejula-bevacizumab-combo-delays-progression-in-relapsed-ovarian-cancer-trial-finds/', 'title': 'Zejula-Bevacizumab Combo Delays Progression in Relapsed Ovarian Cancer, Trial Finds', 'source': 'Ovarian Cancer News Today', 'date': 'Jun 11, 2020', 'snippet': 'Adding bevacizumab to Zejula significantly extended time without disease \nprogression in platinum-sensitive relapsed cancer patients in a...', 'thumbnail': 'https://serpapi.com/searches/67240525c76a22ec71b6285f/images/cb5b81f27d987be06db2633775c8eab34c266772cbf5d5d1df3e987439aff778.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8594561219215393}",,,,,,,,,,['neutral'],neutral,1
NCT05180708,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/investigational-topical-rapamycin-misses-in-pachyonychia-congenita-trial/', 'title': 'Investigational Topical Rapamycin Misses in Pachyonychia Congenita Trial', 'source': 'Medical Professionals Reference', 'date': 'Jul 20, 2023', 'snippet': 'The phase 3 VAPAUS study evaluated QTORIN™ 3.9% rapamycin anhydrous gel for \nthe treatment of adults with pachyonychia congenita.', 'thumbnail': 'https://serpapi.com/searches/67240535400bd5fee9261208/images/a82546bab7b643404ad147ebcb8754f5387ad577f9b01f111282f381e84e1467.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8269616365432739}",,,,,,,,,,['neutral'],neutral,1
NCT02138162,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/jcpt.12503', 'title': 'A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects', 'source': 'Wiley Online Library', 'date': 'Mar 1, 2017', 'snippet': 'Enzalutamide, an androgen receptor inhibitor approved for the treatment of \nmetastatic castration-resistant prostate cancer, is eliminated...', 'thumbnail': 'https://serpapi.com/searches/672405427ebde514439a8312/images/9f87039a8ea2702154bb5e5f2f8d5e32957abf86cdd1c5afaa53e3354c45c42c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8371971249580383}",,,,,,,,,,['neutral'],neutral,1
NCT01314001,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-98883-z', 'title': 'Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans', 'source': 'Nature', 'date': 'Oct 1, 2021', 'snippet': 'We conducted sex-stratified genome-wide association studies of the NMR in \nEuropean American (EA) and African American (AA) smokers.', 'thumbnail': 'https://serpapi.com/searches/6724054cc024d1be854f26d0/images/a20abf019ca305fb571af000bbee2ca3408ca2ea4b417a6fe29d18ce455debc7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9292051792144775}",,,,,,,,,,['neutral'],neutral,1
NCT03574597,"{'position': 1, 'link': 'https://www.pharmacypracticenews.com/Clinical/Article/11-23/Cardiovascular-Benefit-Could-Pave-The-Way-for-Wider-Use-of-Wegovy/71923', 'title': 'Cardiovascular Benefit Could Pave The Way for Wider Use of Wegovy', 'source': 'Pharmacy Practice News', 'date': 'Nov 23, 2023', 'snippet': 'Phase 3 clinical trial results demonstrating that semaglutide 2.4 mg \nreduces the incidence of major cardiovascular events may enable the drug to \nbe...', 'thumbnail': 'https://serpapi.com/searches/67240559b4e8d6482d623285/images/215b3d4a34c84d4dc8bc0ce6062e15fce8188e1a3181e939095e819664e23803.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6485494375228882}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/features/obesity-trial-surge-puts-the-focus-back-on-decentralisation/', 'title': 'Obesity trial surge puts the focus back on decentralisation', 'source': 'Clinical Trials Arena', 'date': '3 weeks ago', 'snippet': 'As obesity clinical trials evolve, there is a growing emphasis on how \ndecentralisation and new technologies can play a role.', 'thumbnail': 'https://serpapi.com/searches/67240559b4e8d6482d623285/images/215b3d4a34c84d4d1454c878cc78484353b4a80e925684d57721728ee94dca47.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6600452065467834}","{'position': 3, 'link': 'https://www.drugtopics.com/view/aha-semaglutide-significantly-reduces-mace-in-adults-with-overweight-or-obesity-cvd', 'title': 'AHA: Semaglutide Significantly Reduces MACE in Adults With Overweight or Obesity, CVD', 'source': 'Drug Topics', 'date': 'Nov 14, 2023', 'snippet': 'Data demonstrated a 20% risk reduction for major adverse cardiovascular \nevents in adults with overweight or obesity and established cardiovascular \ndisease.', 'thumbnail': 'https://serpapi.com/searches/67240559b4e8d6482d623285/images/215b3d4a34c84d4daecddca1291079882bca8550ffe896d55c16b35796f92038.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7996431589126587}","{'position': 4, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/semaglutide-2-4mg-cuts-mace-risk-in-obese-overweight-patients/', 'title': 'Semaglutide 2.4mg Cuts MACE Risk in Obese, Overweight Patients', 'source': 'Medical Professionals Reference', 'date': 'Aug 8, 2023', 'snippet': 'Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events \nby 20% in adults with overweight or obesity in the SELECT trial.', 'thumbnail': 'https://serpapi.com/searches/67240559b4e8d6482d623285/images/215b3d4a34c84d4d98fe5c1d886d2bf373249f72c10f237e3216deb791a64ed8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7005930542945862}",,,,,,,"['positive', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02698735,"{'position': 1, 'link': 'https://epidermolysisbullosanews.com/news/antibiotic-gentamicin-may-show-promise-certain-epidermolysis-bullosa-patients/', 'title': 'Some Epidermolysis Bullosa Patients May Benefit from Use of Gentamicin', 'source': 'Epidermolysis Bullosa News', 'date': 'Aug 24, 2017', 'snippet': 'Short-term application of the antibiotic gentamicin, either topical or \nintradermal, reversed the effect of nonsense mutations in a small group of \npatients.', 'thumbnail': 'https://serpapi.com/searches/6724056e123457bbede2d22b/images/4492e6b8bf31efd5079ca1b500c5a44f1e670f2db2601d46b5ffc94193b0384c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.720325231552124}","{'position': 2, 'link': 'https://epidermolysisbullosanews.com/news/gentamicin-may-improve-outcome-80-percent-herlitz-jeb-patients/', 'title': 'In Herlitz JEB, Gentamicin May Improve Outcome in 80% of Patients', 'source': 'Epidermolysis Bullosa News', 'date': 'Jul 30, 2018', 'snippet': 'Read about a study showing that the antibiotic gentamicin may be beneficial \nfor about 80% of patients with Herlitz JEB who have LAMB3...', 'thumbnail': 'https://serpapi.com/searches/6724056e123457bbede2d22b/images/4492e6b8bf31efd5fd9551d65294b32a6503115f02917caaa9c1134bed343a6b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8839682936668396}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02775435,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1810865', 'title': 'Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Sep 25, 2018', 'snippet': 'Standard first-line therapy for metastatic, squamous non–small-cell lung \ncancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for...', 'thumbnail': 'https://serpapi.com/searches/6724057b7ebde51475550db8/images/4a5472c92830fe89e96be74e3819fa77129ec5b335956250de055a2971c6bd76.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8316283226013184}",,,,,,,,,,['neutral'],neutral,1
NCT00749450,"{'position': 1, 'link': 'https://coloncancernewstoday.com/2017/06/06/certain-colon-cancer-patients-may-require-shorter-chemotherapy-course/', 'title': 'Certain Colon Cancer Patients May Need a Shorter Chemotherapy Course, International Study Finds', 'source': 'Colon Cancer News Today', 'date': 'Jun 6, 2017', 'snippet': 'Chemotherapy following surgery could be reduced from six to three months in \ncertain colon cancer patients, according to an analysis of over...', 'thumbnail': 'https://serpapi.com/searches/67240581f7adbf2bb8d502a8/images/e9bb4f178d2308fe37c1e2dadb2989a69b9f15a7553866a4dde6f8d7e71a4ccb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.738676130771637}",,,,,,,,,,['neutral'],neutral,1
NCT04722562,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222002839', 'title': 'Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)', 'source': 'ScienceDirect.com', 'date': 'Apr 2, 2022', 'snippet': 'Vericiguat was first drug approved for the treatment of symptomatic \npatients with chronic HF with reduced ejection fraction (HFrEF) to reduce \nthe occurrence of...', 'thumbnail': 'https://serpapi.com/searches/67240594a775f278f90829ab/images/f2d6766c3b7f2a8dd629077a40038e7d758814846f0f8c94afeb11d8f154ab20.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6862191557884216}",,,,,,,,,,['neutral'],neutral,1
NCT06173570,"{'position': 1, 'link': 'https://www.dicardiology.com/content/oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-top-statin-phase-i-trial', 'title': 'Oral PCSK9 Inhibitor Demonstrated Significant LDL-C Reduction on Top of Statin in Phase I Trial Presented at EAS Congress', 'source': 'Diagnostic and Interventional Cardiology', 'date': 'May 29, 2024', 'snippet': 'Data was presented by AstraZeneca, at the European Atherosclerosis Society \n(EAS) Congress in France,on AZD0780, an oral PCSK9 inhibitor...', 'thumbnail': 'https://serpapi.com/searches/672405a05a461a844d4dcb4d/images/142e5885d368aa2c946ee53d251a1d56356d412290d192890ef06dfb3ac2dc8a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8306660056114197}",,,,,,,,,,['neutral'],neutral,1
NCT04528641,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-022-00531-8', 'title': 'Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results', 'source': 'Nature', 'date': 'Sep 24, 2022', 'snippet': 'Despite the successful deployment of efficacious vaccines and therapeutics, \nthe development of novel vaccines for SARS-CoV-2 remains a major...', 'thumbnail': 'https://serpapi.com/searches/6724082f2da98377dae11e2b/images/1a780122ffc0c6f6bc3be0d8d03ba93bee2047e7c2045bdfcc4fe7c02d1eaa89.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6663995385169983}",,,,,,,,,,['neutral'],neutral,1
NCT05050149,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/investigational-topical-rapamycin-misses-in-pachyonychia-congenita-trial/', 'title': 'Investigational Topical Rapamycin Misses in Pachyonychia Congenita Trial', 'source': 'Medical Professionals Reference', 'date': 'Jul 20, 2023', 'snippet': 'The phase 3 VAPAUS study evaluated QTORIN™ 3.9% rapamycin anhydrous gel for \nthe treatment of adults with pachyonychia congenita.', 'thumbnail': 'https://serpapi.com/searches/6724082defad2183fae89871/images/2614cae6ee376cfbe2025538a8d7758d2779b6cc1a994352acff3b140091a853.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8269616365432739}",,,,,,,,,,['neutral'],neutral,1
NCT00567190,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20240910563143/en/REVEAL-GENOMICS%C2%AE-Announces-Positive-Top-line-Results-for-HER2DX%C2%AE-in-CLEOPATRA-Phase-III-Trial', 'title': 'REVEAL GENOMICS® Announces Positive Top-line Results for HER2DX® in CLEOPATRA Phase III Trial', 'source': 'Business Wire', 'date': '1 month ago', 'snippet': 'HER2DX® was evaluated in tumor samples from 214 patients with advanced \nHER2+ breast cancer treated with docetaxel, trastuzumab,...', 'thumbnail': 'https://serpapi.com/searches/672408320be2f6d0b30ac8ed/images/9afbcca7d45a0f05de1b8d5edb1a35486f98953c4af2e7744c3d8e7057e82ff8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5440479516983032}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1413513', 'title': 'Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Mar 30, 2018', 'snippet': 'Progression-free survival was significantly improved after first-line \ntherapy with pertuzumab, trastuzumab, and docetaxel, as compared with \nplacebo,...', 'thumbnail': 'https://serpapi.com/searches/672408320be2f6d0b30ac8ed/images/9afbcca7d45a0f05dade91eb4da017d52d7e54f9d2783053f9211632ce3b5ca3.png', 'sentiment': 'positive', 'sentiment_prob': 0.5908378958702087}","{'position': 3, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70130-X/fulltext', 'title': 'Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study', 'source': 'The Lancet', 'date': 'Apr 18, 2013', 'snippet': 'CLEOPATRA is a phase 3 study to compare the efficacy and safety of \npertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and \ndocetaxel in patients...', 'thumbnail': 'https://serpapi.com/searches/672408320be2f6d0b30ac8ed/images/9afbcca7d45a0f05ec86e35cca90e7212f7e43d030c55e395e41e70dd512ced4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8298313021659851}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT01631214,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1708322', 'title': 'Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 11, 2017', 'snippet': 'Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, \nincreases bone formation, and decreases bone resorption.', 'thumbnail': 'https://serpapi.com/searches/6724083e2c566d38f2509b2c/images/4aa953a8994b9838015d87666cd20048e4313eada34709254fa7a50fdb3158fd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8531666398048401}",,,,,,,,,,['neutral'],neutral,1
NCT03181633,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.01157/full', 'title': 'Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': '1Department of Clinical Medicine and Surgery, Federico II University of \nNaples, Naples, Italy; 2Severe Aplastic Anemia Working Party of the \nEuropean Group...', 'thumbnail': 'https://serpapi.com/searches/67240841d0253e3d8bb512a8/images/fd89841dc056e52062085be14995ecdc69e3d640625a51d924a7675331c0bb2b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7861200571060181}",,,,,,,,,,['neutral'],neutral,1
NCT03069703,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/higher-dose-pneumonia-vaccine-boosts-immunity-aav-rituximab/', 'title': 'Higher Dose Pneumonia Vaccine Boosts Immunity for AAV Patients |...', 'source': 'ANCA Vasculitis News', 'date': 'Nov 14, 2022', 'snippet': 'AAV patients in trial given a pneumonia vaccination at higher dose showed \nstronger immune responses to bacteria than those on standard...', 'thumbnail': 'https://serpapi.com/searches/672405bad771bdf678dc54e6/images/03a1d6f91d712dc539afe59bd4c691dcaada84f9eb5123c2031d42fd68f1ed77.png', 'sentiment': 'positive', 'sentiment_prob': 0.5563899874687195}",,,,,,,,,,['positive'],positive,1
NCT05051579,"{'position': 1, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-results-published-new-england-journal-medicine', 'title': ""Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight"", 'source': 'Eli Lilly and Company', 'date': 'Jun 23, 2023', 'snippet': 'Orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved \nup to 14.7% mean weight reduction at 36 weeks in adults with obesity or \noverweight.', 'thumbnail': 'https://serpapi.com/searches/672405d0707fd367742aa251/images/748143c7fea99b48c1771120f55084cb1a57d4e463b42b1b5247c542b0128245.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8391620516777039}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2302392', 'title': 'Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity', 'source': 'The New England Journal of Medicine', 'date': 'Jun 23, 2023', 'snippet': 'Obesity is a major risk factor for many leading causes of illness and death \nworldwide. Data are needed regarding the efficacy and safety of the \nnonpeptide...', 'thumbnail': 'https://serpapi.com/searches/672405d0707fd367742aa251/images/748143c7fea99b4861faeebb5a1efda9b1f4b1be3380e125b46e88a935900019.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5316299200057983}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT02935907,"{'position': 1, 'link': 'https://www.nature.com/articles/s41420-021-00465-5', 'title': 'MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models', 'source': 'Nature', 'date': 'May 3, 2021', 'snippet': 'Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous \nclonal disease associated with unmet medical needs.', 'thumbnail': 'https://serpapi.com/searches/672405da7ebde514439a8333/images/2aae4af91dbb83c6b44037d00a166e50782a607cc3b98c96617ef57846a1cfd6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8203384876251221}",,,,,,,,,,['neutral'],neutral,1
NCT00049517,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-022-00736-z', 'title': 'Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999', 'source': 'Nature', 'date': 'Sep 23, 2022', 'snippet': ""Integrative analysis identifies an older female-linked AML patient group \nwith better risk in ECOG-ACRIN Cancer Research Group's clinical trial."", 'thumbnail': 'https://serpapi.com/searches/672405e4b4fe875869b7a03e/images/5d3db9dd3ead90c37576305ffe911fc018d61fdf8db9dd3a25daabe72f15f180.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9069530367851257}","{'position': 2, 'link': 'https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-021-01239-4', 'title': 'Group testing can improve the cost-efficiency of prospective-retrospective biomarker studies', 'source': 'BMC Medical Research Methodology', 'date': 'Mar 19, 2021', 'snippet': 'Cancer treatment is increasingly dependent on biomarkers for \nprognostication and treatment selection. Potential biomarkers are \nfrequently...', 'thumbnail': 'https://serpapi.com/searches/672405e4b4fe875869b7a03e/images/5d3db9dd3ead90c34e2a17c17773ec723194cdc457331ddc73f630923d330f34.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8181770443916321}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03564119,"{'position': 1, 'link': 'https://www.empr.com/home/news/epsolay-cream-now-available-for-rosacea/', 'title': 'Epsolay Cream Now Available for Rosacea', 'source': 'Medical Professionals Reference', 'date': 'Jun 3, 2022', 'snippet': 'Epsolay® (benzoyl peroxide) cream is now available for the treatment of \ninflammatory lesions of rosacea in adults.', 'thumbnail': 'https://serpapi.com/searches/672406006531cb6e7f95080e/images/28ed79b7394459b8bcf00cd98fd7c0da01c9764888bffdba8082e3d47280ac92.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7307189106941223}",,,,,,,,,,['neutral'],neutral,1
NCT01639300,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/gnbac1-for-rrms/', 'title': 'Temelimab in MS | Experimental MS Treatments', 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 9, 2022', 'snippet': 'Temelimab is a therapy being evaluated as a potential treatment for MS. \nLearn more about its uses, side effects, and clinical testing.', 'thumbnail': 'https://serpapi.com/searches/67240605e50bc005c852d69d/images/39faf292d8dc4010d897ea7da8424b0e3c7dd2a8c7efe1b99722727f882b735d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9337586760520935}",,,,,,,,,,['neutral'],neutral,1
NCT02977195,"{'position': 1, 'link': 'https://www.nature.com/articles/s41586-023-06367-z', 'title': 'Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer', 'source': 'Nature', 'date': 'Aug 2, 2023', 'snippet': 'Netrin-1 blockade, using an anti-netrin-1 antibody (NP137), is effective in \nreduction of tumour progression in an EC mouse model.', 'thumbnail': 'https://serpapi.com/searches/672406786de1e482835ae368/images/858eed2621115a92202b40369702f43f346e794438d759d41ac3e8c7609a9d7b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7568995952606201}",,,,,,,,,,['neutral'],neutral,1
NCT02500121,"{'position': 1, 'link': 'http://www.urotoday.com/conference-highlights/asco-2019-annual-meeting/asco-2019-bladder-cancer/113070-asco-2019-pembrolizumab-versus-placebo-after-first-line-chemotherapy-in-patients-with-metastatic-urothelial-cancer-hcrn-gu14-182.html', 'title': 'ASCO 2019: Pembrolizumab Versus Placebo After First-Line Chemotherapy In Patients With Metastatic Urothelial Cancer: HCRN GU14-182', 'source': 'UroToday', 'date': 'Jun 5, 2019', 'snippet': 'ASCO maintenance pembrolizumab versus placebo after first-line chemotherapy \nin patients with metastatic urothelial cancer, HCRN GU14-182 trial for \npatients...', 'thumbnail': 'https://serpapi.com/searches/6724068581bab7b8fdf0d1e2/images/d35c23e4916537f7364d9e6a6c2c57f99a6f57dcb661c3eaecea15b9395f5ac5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9102288484573364}",,,,,,,,,,['neutral'],neutral,1
NCT04078386,"{'position': 1, 'link': 'https://sjogrenssyndromenews.com/news/telitacicept-shows-promise-phase-2-study-primary-sjogrens/', 'title': 'Telitacicept Shows Promise in Primary Sjögren’s in Phase 2 Study', 'source': ""Sjogren's Syndrome News"", 'date': 'Feb 8, 2022', 'snippet': ""RemeGen's Telitacicept significantly eased disease activity in a Phase 2 \nclinical trial involving patients with primary Sjögren's syndrome."", 'thumbnail': 'https://serpapi.com/searches/67240688ce1a752227e9c563/images/da0340b893c9404e39ddb2c4783534f2b36febc74ef99a6bfa12a02681f9a2e4.png', 'sentiment': 'positive', 'sentiment_prob': 0.5237519145011902}",,,,,,,,,,['positive'],positive,1
NCT02597946,"{'position': 1, 'link': 'https://dailynews.ascopubs.org/do/getting-into-groove-targeting-her2-mutations-non-x2013-small-cell-lung-cancer-treatment', 'title': 'Getting Into the Groove: Targeting HER2 Mutations for Non–Small Cell Lung Cancer Treatment', 'source': 'ASCO Daily News', 'date': '٠٨\u200f/٠٩\u200f/٢٠٢٢', 'snippet': 'Research on the molecular background of lung cancer has yielded insights \ninto various signaling pathways that are driving lung tumorigenesis...', 'thumbnail': 'https://serpapi.com/searches/6724068ddc969faceef7c165/images/d09ca98ea0f78f8102a7911285194a8b36117b7065d4848210e7c298bf019b84.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9010814428329468}",,,,,,,,,,['neutral'],neutral,1
NCT01170065,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/ipf-patients-live-longer-on-nintedanib-pooled-data-from-six-trials-show/', 'title': 'IPF Patients Live Longer on Ofev Compared with Placebo, Analysis Shows', 'source': 'Pulmonary Fibrosis News', 'date': 'Apr 16, 2019', 'snippet': 'Treatment with Ofev (nintedanib) can significantly extend the survival of \npatients with idiopathic pulmonary fibrosis (IPF), an analysis of pooled \ndata from...', 'thumbnail': 'https://serpapi.com/searches/67240697b6ed330785cbaf4d/images/f06db2ef4668d8e3ff50e01ffd84d0ae3b8de80f433da6e64ddabf4da89d73d9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.544462263584137}",,,,,,,,,,['neutral'],neutral,1
NCT04287985,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2305635', 'title': 'A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy', 'source': 'The New England Journal of Medicine', 'date': 'Nov 2, 2023', 'snippet': 'A proliferation-inducing ligand (APRIL) is implicated in the pathogenesis \nof IgA nephropathy. Sibeprenlimab is a humanized IgG2 monoclonal antibody \nthat...', 'thumbnail': 'https://serpapi.com/searches/672406993ad34db6ba164cf5/images/05412e5c9189389f8c8743b3f3804787348bc15a727e96428dc4366c45fa9343.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8776761889457703}","{'position': 2, 'link': 'https://www.renalandurologynews.com/news/sibeprenlimab-shows-promise-for-iga-nephropathy/', 'title': 'Sibeprenlimab Shows Promise for IgA Nephropathy', 'source': 'Renal and Urology News', 'date': 'Jan 25, 2024', 'snippet': 'Sibeprenlimab significantly reduces proteinuria in patients with high-risk \nIgA nephropathy (IgAN), according to trial results published in...', 'thumbnail': 'https://serpapi.com/searches/672406993ad34db6ba164cf5/images/05412e5c9189389f6f7b94e922ccf6edbcd3894a7ae6dbf44fc2205d7c6bdb43.png', 'sentiment': 'positive', 'sentiment_prob': 0.6506113409996033}","{'position': 3, 'link': 'https://www.businesswire.com/news/home/20240216785648/en/Sibeprenlimab-Receives-U.S.-FDA-Breakthrough-Therapy-Designation-for-the-Treatment-of-Immunoglobulin-A-Nephropathy', 'title': 'Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy', 'source': 'Business Wire', 'date': 'Feb 16, 2024', 'snippet': 'Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC); Otsuka \nPharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc.,...', 'thumbnail': 'https://serpapi.com/searches/672406993ad34db6ba164cf5/images/05412e5c9189389f3b9d34eff09fb5d11ca091af874b8e6c66e86d31f7745672.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8188655972480774}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT03101839,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-021-00780-4', 'title': 'KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': 'Nov 15, 2021', 'snippet': 'KRAS has been deemed a challenging therapeutic target, even “undruggable”, \nafter drug-targeting efforts over the past four decades.', 'thumbnail': 'https://serpapi.com/searches/6724062aba114203b64bae6f/images/498a9408e6a6fbcc6ccdcb2a4a472313a6acb68e16e3e3153c67e85d28439a93.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.552814781665802}",,,,,,,,,,['negative'],negative,0
NCT03639714,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01937-6', 'title': 'Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results', 'source': 'Nature', 'date': 'Aug 15, 2022', 'snippet': 'Checkpoint inhibitor (CPI) therapies provide limited benefit to patients \nwith tumors of low immune reactivity. T cell-inducing vaccines hold...', 'thumbnail': 'https://serpapi.com/searches/67240633a324362e5bcaefc0/images/624ff23b283e591aae225198a0ebca6abdfdf98582adb7a1e2565db55cd8f746.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.547188937664032}",,,,,,,,,,['negative'],negative,0
NCT03183219,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-020-0515-7', 'title': 'Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer', 'source': 'Nature', 'date': 'Sep 16, 2020', 'snippet': 'Vγ9Vδ2 T cells are promising candidates for cellular tumor immunotherapy. \nDue to their HLA-independent mode of action, allogeneic Vγ9Vδ2 T...', 'thumbnail': 'https://serpapi.com/searches/6724065b6f9f63c8a936fd07/images/87d078fb731f3684080043c76a0eaeccb9a50c8cfa2906a6a5d2606eefd9c370.png', 'sentiment': 'positive', 'sentiment_prob': 0.7890372276306152}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.780145/full', 'title': 'Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials', 'source': 'Frontiers', 'date': 'Feb 8, 2024', 'snippet': 'Novel strategies to create an “off the shelf” allogeneic product that would \ncircumvent these limitations are an extensive area of research.', 'thumbnail': 'https://serpapi.com/searches/6724065b6f9f63c8a936fd07/images/87d078fb731f3684ce12b3f1aec37870e157c6e4dcc9110859fed0d37b4718f4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6790682077407837}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02195479,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1714678', 'title': 'Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma', 'source': 'The New England Journal of Medicine', 'date': 'Apr 30, 2018', 'snippet': 'The combination of bortezomib, melphalan, and prednisone is a standard \ntreatment for patients with newly diagnosed multiple myeloma who are \nineligible for...', 'thumbnail': 'https://serpapi.com/searches/6724065b90adceda3c8284ab/images/df351efe7de6b5dd566f81c7a01420eb5a1b13e0401a0c947086cfa54bdd1c37.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8853434324264526}",,,,,,,,,,['neutral'],neutral,1
NCT04370548,"{'position': 1, 'link': 'https://www.contemporaryobgyn.net/view/fda-approves-clindamycin-phosphate-gel-for-treatment-of-bacterial-vaginosis', 'title': 'FDA approves clindamycin phosphate gel for treatment of bacterial vaginosis', 'source': 'Contemporary OB/GYN', 'date': 'Dec 8, 2021', 'snippet': 'The US Food and Drug Administration (FDA) has approved the New Drug \nApplication (NDA) clindamycin phosphate vaginal gel, 2% (Xaciato; Daré \nBioscience),...', 'thumbnail': 'https://serpapi.com/searches/6724066a1a5b544aac27069c/images/ad2d4c09ceb301d5416e8b9081d50fe3b62d056fc746ca6caa9aec61adfbe69e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8243190050125122}",,,,,,,,,,['neutral'],neutral,1
NCT00409682,"{'position': 1, 'link': 'https://ibdnewstoday.com/ibd-treatment/humira-adalimumab/', 'title': 'Range of Bowel Diseases Can Be Treated with Humira', 'source': 'ibdnewstoday.com', 'date': 'Aug 31, 2017', 'snippet': 'Humira (adalimumab) is a biological therapy that the US Food and Drug \nAdministration approved for treating inflammatory bowel disease, or IBD.', 'thumbnail': 'https://serpapi.com/searches/6724066ca775f278f90829f7/images/3f6c7365de3e132de965ae09554ab8308b082dd8330ec3b70395cae3f6246d5a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9108577370643616}",,,,,,,,,,['neutral'],neutral,1
NCT05308472,"{'position': 1, 'link': 'https://porphyrianews.com/news/adults-with-epp-spend-more-time-sun-with-bitopertin-phase-2-trial/', 'title': 'Adults with EPP spend more time in the sun with bitopertin: Phase 2 trial', 'source': 'Porphyria News', 'date': 'Dec 13, 2023', 'snippet': 'Treatment with the oral therapy bitopertin substantially increased sunlight \ntolerance for adults with erythropoietic protoporphyria (EPP) in a Phase 2 \nclinical...', 'thumbnail': 'https://serpapi.com/searches/6724066d163bdf81353cfecc/images/d18aa7980af96a6988e9cb3f661d2fdb12a4eff07c33595a292ba993a643e95d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6675302386283875}","{'position': 2, 'link': 'https://www.sciencedirect.com/science/article/abs/pii/S1550413124000846?via%3Dihub', 'title': 'A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis', 'source': 'ScienceDirect.com', 'date': 'Apr 2, 2024', 'snippet': 'We found that bitopertin, a clinical-stage glycine uptake inhibitor, \nsuppresses osteoclast differentiation and ameliorates ovariectomy-induced \nbone loss by...', 'thumbnail': 'https://serpapi.com/searches/6724066d163bdf81353cfecc/images/d18aa7980af96a69de44f1917e4cc11edb3bac6629c8fb901c1025aa268aad9e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.876714825630188}","{'position': 3, 'link': 'https://porphyrianews.com/news/bitopertin-reduces-toxic-metabolite-ppix-phase-2-aurora-trial/', 'title': 'Bitopertin reduces toxic metabolite PPIX in Phase 2 AURORA trial', 'source': 'Porphyria News', 'date': 'Apr 3, 2024', 'snippet': 'The Phase 2 AURORA clinical trial has met its main goal, demonstrating that \ntreatment with the experimental oral medication bitopertin...', 'thumbnail': 'https://serpapi.com/searches/6724066d163bdf81353cfecc/images/d18aa7980af96a69abe2c7547a9159fe20a5f6e0c535bc328110f848182db1dc.png', 'sentiment': 'positive', 'sentiment_prob': 0.7151975035667419}","{'position': 4, 'link': 'https://porphyrianews.com/news/bitopertin-boosts-sunlight-tolerance-life-quality-epp-trial/', 'title': 'Bitopertin seen to boost sunlight tolerance, life quality in patients', 'source': 'Porphyria News', 'date': 'Jun 14, 2023', 'snippet': 'Bitopertin increased sunlight tolerance and life quality for erythropoietic \nprotoporphyria (EPP) patients in a clinical trial, results show.', 'thumbnail': 'https://serpapi.com/searches/6724066d163bdf81353cfecc/images/d18aa7980af96a69665597ec00e35914d729787c16561f0c2384475ae9336f39.png', 'sentiment': 'positive', 'sentiment_prob': 0.7560920119285583}","{'position': 5, 'link': 'https://porphyrianews.com/news/beacon-aurora-trials-of-bitopertin-complete-enrollment/', 'title': 'BEACON, AURORA trials of bitopertin complete enrollment', 'source': 'Porphyria News', 'date': 'Nov 15, 2023', 'snippet': 'The BEACON and AURORA Phase 2 clinical trials testing the investigational \noral therapy bitopertin in people with erythropoietic porphyrias...', 'thumbnail': 'https://serpapi.com/searches/6724066d163bdf81353cfecc/images/d18aa7980af96a69ce25351b584cb31ad901386d0761aa642fad247d5a27b0bf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8817107081413269}",,,,,,"['neutral', 'neutral', 'positive', 'positive', 'neutral']",neutral,1
NCT03918629,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0264410X23012963', 'title': 'A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age', 'source': 'ScienceDirect.com', 'date': 'Dec 7, 2023', 'snippet': 'Three doses (Months 0,1,6) of toxoid-based C difficile vaccine induced \nrobust neutralizing antibody responses and were well tolerated in healthy \nparticipants...', 'thumbnail': 'https://serpapi.com/searches/6724066d069e5712506e0bae/images/dca7a3132e90146495ece7727330450c875f8c2cac7194990459232764f1bce2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7878576517105103}",,,,,,,,,,['neutral'],neutral,1
NCT02048865,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1814468', 'title': 'Apixaban to Prevent Venous Thromboembolism in Patients with Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Dec 4, 2018', 'snippet': 'Patients with active cancer have an increased risk of venous \nthromboembolism, which results in substantial morbidity, mortality,...', 'thumbnail': 'https://serpapi.com/searches/67240783069e5712506e0be1/images/8dbb50845d32e3fe36500ea84b67d141df4dcf3ee3c931c235ef4ce3ac31ad65.png', 'sentiment': 'negative', 'sentiment_prob': 0.6136891841888428}",,,,,,,,,,['negative'],negative,0
NCT03969888,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/addition-3-cftr-modulators-sionas-efforts-cf-franchise/', 'title': ""Addition of 3 CFTR modulators aids Sionna's efforts to expand CF 'franchise '"", 'source': 'Cystic Fibrosis News Today', 'date': 'Jul 17, 2024', 'snippet': 'Sionna has won the rights to three AbbVie clinical-stage compounds to \nexpand its pipeline of small molecules for restoring CFTR function.', 'thumbnail': 'https://serpapi.com/searches/672407e84791c478ee375b87/images/56c36c1b2dacada7c190334e4dbd3de90fa11b65075a4d07b2f629e4215f2f64.png', 'sentiment': 'positive', 'sentiment_prob': 0.615005373954773}",,,,,,,,,,['positive'],positive,1
NCT02387307,"{'position': 1, 'link': 'https://immuno-oncologynews.com/rsifn-co/', 'title': 'rSIFN-co', 'source': 'Immuno-Oncology News', 'date': 'Dec 20, 2017', 'snippet': ""Read about rSIFN-co, an immuno-oncology therapy that Singapore's Sichuan \nHuiyang designed to fight a number of kinds of cancer."", 'thumbnail': 'https://serpapi.com/searches/672407e9ce1a752227e9c5c1/images/e8d6fdbf7cf84f17a8cd208249b8f4dc25c8f310b24d3cb3b29632cd06f1bdce.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8684569597244263}",,,,,,,,,,['neutral'],neutral,1
NCT02659943,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.886546/full', 'title': 'Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation', 'source': 'Frontiers', 'date': 'May 23, 2022', 'snippet': 'Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable \nsuccess in long-term remission of cancers and other autoimmune...', 'thumbnail': 'https://serpapi.com/searches/672407f6bcd65222bfec9063/images/ee2fd838907c92fa2ef8a8200d0621b60c4d783b44d2610fb40bd5bd3eab31b6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6530438661575317}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/01/23/fda-grants-fast-track-status-kyv-101-progressive-forms-ms/', 'title': 'FDA grants fast track status to KYV-101 for progressive forms of MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Jan 23, 2024', 'snippet': ""The US Food and Drug Administration (FDA) has granted fast track status to \nKYV-101, Kyverna Therapeutics' cell-based therapy candidate for people \nwith..."", 'thumbnail': 'https://serpapi.com/searches/672407f6bcd65222bfec9063/images/ee2fd838907c92fa01cea5bb6cbab47b667013715c57ef869acf0a67d65865c4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7148295044898987}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04315298,"{'position': 1, 'link': 'https://juvenilearthritisnews.com/2020/03/27/phase-3-clinical-trial-tests-actemra-for-covid-19-pneumonia/', 'title': 'Phase 3 Clinical Trial Tests Actemra for COVID-19 Pneumonia', 'source': 'Juvenile Arthritis News', 'date': 'Mar 27, 2020', 'snippet': ""A Phase 3 trial will test Genentech's approved JIA treatment Actemra in \npatients with pneumonia caused by COVID-19 infection."", 'thumbnail': 'https://serpapi.com/searches/672407f9b28e6b6e24e1df44/images/f748ffc20fffa9d05c4f20a96775809f31b5b371d0c57141d594a245da195f4c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9040188789367676}",,,,,,,,,,['neutral'],neutral,1
NCT02477644,"{'position': 1, 'link': 'https://www.targetedonc.com/view/recent-long-term-data-on-parp-inhibitors-in-ovarian-cancer', 'title': 'Recent Long-Term Data on PARP Inhibitors in Ovarian Cancer', 'source': 'Targeted Oncology', 'date': 'Jun 16, 2023', 'snippet': 'Case: A 55-Year-Old Woman with BRCA-Mutated Ovarian Cancer. A 55-year-old \npresents to her PCP for heartburn and abdominal pain that started...', 'thumbnail': 'https://serpapi.com/searches/672406b648b9f7f4a84c72ac/images/6578c6e7c134720da622400024c443f050f3abcfbdae73ed96c5d9015adcd322.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6634000539779663}",,,,,,,,,,['neutral'],neutral,1
NCT03300947,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-39812-0', 'title': 'Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey', 'source': 'Nature', 'date': 'Aug 17, 2023', 'snippet': 'A renewed interest in the use of psychedelics for treating obsessive \ncompulsive disorder (OCD) has emerged in the last 20 years.', 'thumbnail': 'https://serpapi.com/searches/672406ba13e5d85abd9d796a/images/57bfc13080b9b71562cf99e3754415e822d8acc1c41c27312005ee520a666478.png', 'sentiment': 'positive', 'sentiment_prob': 0.597964346408844}",,,,,,,,,,['positive'],positive,1
NCT04681833,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext', 'title': 'Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape', 'source': 'The Lancet', 'date': 'Aug 8, 2022', 'snippet': 'A study to evaluate the safety and efficacy of mRNA-1345 vaccine targeting \nrespiratory syncytial virus (RSV) in adults ≥60 years of age.', 'thumbnail': 'https://serpapi.com/searches/672406df54163de37cb7c2e2/images/c2bc12b26d7d146e8a8415d8639765b99418e3e01eabb047d95ddaa675470dbd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8734835982322693}",,,,,,,,,,['neutral'],neutral,1
NCT04663737,"{'position': 1, 'link': 'https://www.nature.com/articles/s12276-023-01062-5', 'title': 'SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways', 'source': 'Nature', 'date': 'Aug 1, 2023', 'snippet': 'Solute carrier family 39 member 10 (SLC39A10) belongs to a subfamily of \nzinc transporters and plays a key role in B-cell development.', 'thumbnail': 'https://serpapi.com/searches/672406e18d0417f53161710d/images/497bc56597d897271bd670f2c0f50dcd0644899aeaf646201b8e00eec0a26e9d.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5658173561096191}",,,,,,,,,,['negative'],negative,0
NCT05074498,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/signs-alzheimers-reversed-eased-after-3-months-tb006/', 'title': '3 months of TB006 eased, reversed signs of Alzheimer’s disease: Trial', 'source': ""Alzheimer's News Today"", 'date': 'Apr 21, 2023', 'snippet': ""Nearly half the Alzheimer's disease patients treated with TrueBinding's \ninvestigational therapy TB006 showed cognitive improvement signs."", 'thumbnail': 'https://serpapi.com/searches/672406f75ed3ca4f9d3c285d/images/573716688d805d03171db61d0bd54288790b088f41ad7e17eecd5acf3eabb5cb.png', 'sentiment': 'positive', 'sentiment_prob': 0.5443678498268127}",,,,,,,,,,['positive'],positive,1
NCT03754309,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-023-00992-4', 'title': 'The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment', 'source': 'Nature', 'date': 'Mar 16, 2023', 'snippet': 'Atopic dermatitis (AD) is the most common inflammatory skin disease, and it \nis considered a complex and heterogeneous condition.', 'thumbnail': 'https://serpapi.com/searches/6724072b9936882cb5f0cf37/images/0f779b3d48893ee19e441e8f9e11ae7a5175540d96559a8e155a690acc273e51.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7401643991470337}",,,,,,,,,,['neutral'],neutral,1
NCT05355402,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2402309', 'title': 'Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk', 'source': 'The New England Journal of Medicine', 'date': 'Apr 7, 2024', 'snippet': 'Reducing the levels of triglycerides and triglyceride-rich lipoproteins \nremains an unmet clinical need. Olezarsen is an antisense...', 'thumbnail': 'https://serpapi.com/searches/6724072f3ad34db6ba164d1d/images/f092e5bf3e01c4fb5cc17904ffaccbbba84a0995c2b2e3d01043c24391a80793.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5698548555374146}",,,,,,,,,,['negative'],negative,0
NCT04368728,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2110345', 'title': 'Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months', 'source': 'The New England Journal of Medicine', 'date': 'Sep 15, 2021', 'snippet': 'BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA \nvaccine encoding a prefusion-stabilized, membrane-anchored severe acute...', 'thumbnail': 'https://serpapi.com/searches/67240735657c66db78be63b0/images/3cb5adb4f7be2f46c5f8c793eb43ba5ca13760935ea15779f863dfa9cd9712fd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8851207494735718}","{'position': 2, 'link': 'https://www.nature.com/articles/s41586-020-2798-3', 'title': 'SARS-CoV-2 vaccines in development', 'source': 'Nature', 'date': 'Sep 23, 2020', 'snippet': 'A phase I trial started in March 2020 and there are currently more than 180 \nvaccines at various stages of development.', 'thumbnail': 'https://serpapi.com/searches/67240735657c66db78be63b0/images/3cb5adb4f7be2f4635d861936d2744747db88598e760b3fd1cda2f760a310d63.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8990486264228821}","{'position': 3, 'link': 'https://www.thelancet.com/article/S0140-6736(20)32137-1/fulltext', 'title': 'SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates', 'source': 'The Lancet', 'date': 'Dec 29, 2020', 'snippet': 'In this Review, we discuss what is currently known about human humoral and \ncellular immune responses to severe acute respiratory syndrome coronavirus 2', 'thumbnail': 'https://serpapi.com/searches/67240735657c66db78be63b0/images/3cb5adb4f7be2f462bff94946e5f9db1dba15e05d506cba1c89add9a2a257d22.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.890227735042572}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04469465,"{'position': 1, 'link': 'https://www.astrazeneca.com/media-centre/press-releases/2023/danicopan-as-add-on-to-ultomiris-or-soliris-improved-haemoglobin-levels-and-maintained-disease-control-in-patients.html', 'title': 'Danicopan as add-on to Ultomiris or Soliris improved haemoglobin levels and maintained disease control in patients with PNH experiencing signs or symptoms of clinically significant extravascular haemolysis', 'source': 'AstraZeneca', 'date': 'Jun 9, 2023', 'snippet': 'The ALPHA trial demonstrated that adding danicopan to standard of care with \neculizumab or ravulizumab significantly improved fatigue and anaemia and \nreduced...', 'thumbnail': 'https://serpapi.com/searches/6724073e0053c7922c4d7ffd/images/b660ec4f1a4877cb570b33890b36bc91bacd0c01966c3637fbfcd41f5a8798e6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7747477889060974}",,,,,,,,,,['neutral'],neutral,1
NCT01450488,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/03/04/masitinib-slows-disability-progression-ppms-non-active-spms-abo7002-trial/', 'title': 'Masitinib Slows Disability Progression in PPMS, Non-active SPMS', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 4, 2022', 'snippet': 'Masitinib significantly slows disability progression in adults with PPMS \nand non-active SPMS, according to final data from the AB07002...', 'thumbnail': 'https://serpapi.com/searches/6724074215c74000bab4fb3d/images/c9888771d3661411641cefca9727ed1a0894654d0cc3fe7ad09cf19a71d21f66.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8049895167350769}",,,,,,,,,,['neutral'],neutral,1
NCT04480463,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-65815-6', 'title': 'Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration', 'source': 'Nature', 'date': 'Jun 26, 2024', 'snippet': 'SCD411 has equivalent efficacy compared with reference aflibercept in \npatients with neovascular age-related macular degeneration and has a \ncomparable safety...', 'thumbnail': 'https://serpapi.com/searches/672407448de63c1a678fffa9/images/4eda15e2a01e811f22a6d4f3300917dd23ee1d4ea9cdeda32f92fac9ebbedc88.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6794275641441345}",,,,,,,,,,['neutral'],neutral,1
NCT05925647,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332223017687', 'title': 'Boosting the therapeutic potential of cell secretome against osteoarthritis: Comparison of cytokine-based priming strategies', 'source': 'ScienceDirect.com', 'date': 'Dec 2, 2023', 'snippet': 'The secretome, or conditioned medium (CM), from Mesenchymal Stem/stromal \nCells (MSCs) has recently emerged as a promising cell-free therapeutic \nagainst...', 'thumbnail': 'https://serpapi.com/searches/67240766a505f777dd204502/images/d99625aa67cab4a3e32a32bddb9fc01547c74320391d82920fc799f7f5fb46c3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7115183472633362}",,,,,,,,,,['neutral'],neutral,1
NCT02022982,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-019-08380-1', 'title': 'SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer', 'source': 'Nature', 'date': 'Feb 4, 2019', 'snippet': 'Tumor suppressor SMARCA4 (BRG1), a key SWI/SNF chromatin remodeling gene, \nis frequently inactivated in cancers and is not directly druggable...', 'thumbnail': 'https://serpapi.com/searches/6724078e9e38e5657f9eba4e/images/aadea264c5170a19c06190ed21b163db1ebf7382062e88dc7c432011058db8bc.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7650928497314453}",,,,,,,,,,['negative'],negative,0
NCT01964352,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20150817005379/en/New-data-show-Spiolto-Respimat-provides-meaningful-quality-of-life-improvements-in-COPD', 'title': 'New data show Spiolto Respimat provides meaningful quality of life improvements in COPD', 'source': 'Business Wire', 'date': 'Aug 17, 2015', 'snippet': 'Boehringer Ingelheim OTEMTO® trials show Spiolto® Respimat® provides \nclinically meaningful >4 point reduction in SGRQ score compared to...', 'thumbnail': 'https://serpapi.com/searches/6724079996a329686adfb9f4/images/9576ba83f168b48f5bf4f5d8cedbfbafb3df30a485ba2b17cf35b9a7ad2844d2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6147310137748718}",,,,,,,,,,['positive'],positive,1
NCT03354598,"{'position': 1, 'link': 'https://www.drugtopics.com/view/fda-approves-sulopenem-etzadroxil-and-probenecid-for-uncomplicated-urinary-tract-infections', 'title': 'FDA Approves Sulopenem Etzadroxil and Probenecid for Uncomplicated UTIs', 'source': 'Drug Topics', 'date': '6 days ago', 'snippet': 'The FDA has approved just the second treatment for uncomplicated urinary \ntract infections (UTIs) in the last 2 decades.', 'thumbnail': 'https://serpapi.com/searches/672407c435853912625195f5/images/6879bbc0ffa6d0951a17d9222d0f2045c02a8c1015e372b8a42b9017f8b5d4e3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6426243782043457}","{'position': 2, 'link': 'https://www.drugtopics.com/view/breaking-fda-approves-moderna-s-mrna-rsv-vaccine-mresvia', 'title': 'Breaking: FDA Approves Moderna’s mRNA RSV Vaccine, mRESVIA', 'source': 'Drug Topics', 'date': 'May 31, 2024', 'snippet': 'The FDA has approved mRESVIA (mRNA-1345) an mRNA respiratory syncytial \nvirus (RSV) vaccine for adults aged 60 years and older to protect against \nlower...', 'thumbnail': 'https://serpapi.com/searches/672407c435853912625195f5/images/6879bbc0ffa6d0953a3e3b107901f67f123ac6c82e5ab966ba79284e2e1814d9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7456569671630859}","{'position': 3, 'link': 'https://www.drugtopics.com/view/small-doses-october-21-to-october-25', 'title': 'Small Doses: October 21 to October 25', 'source': 'Drug Topics', 'date': '5 days ago', 'snippet': ""The FDA has approved Iterum Therapeutics' sulopenem etzadroxil and \nprobenecid (Orlynvah) for the treatment of uUTIs in adult women who have..."", 'thumbnail': 'https://serpapi.com/searches/672407c435853912625195f5/images/6879bbc0ffa6d0953ca5a7f0b30a38e3b91f777eb0749d666dc7bdb3d027d160.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.84382164478302}","{'position': 4, 'link': 'https://www.drugtopics.com/view/discussing-the-fda-panel-s-rejection-of-mdma-assisted-therapy-for-ptsd', 'title': 'Discussing the FDA Panel’s Rejection of MDMA-Assisted Therapy for PTSD', 'source': 'Drug Topics', 'date': 'Jun 10, 2024', 'snippet': 'The Psychopharmacologic Drugs Advisory Committee voted against the use of \nmidomafetamine (MDMA)-assisted therapy to treat post-traumatic stress \ndisorder (PTSD).', 'thumbnail': 'https://serpapi.com/searches/672407c435853912625195f5/images/6879bbc0ffa6d095b2443624f01a846956f58a7036a65fc4b13d3272689d67cc.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5458381175994873}","{'position': 5, 'link': 'https://www.drugtopics.com/view/fda-approves-ensifentrine-for-treatment-of-copd', 'title': 'FDA Approves Ensifentrine for Treatment of COPD', 'source': 'Drug Topics', 'date': 'Jun 27, 2024', 'snippet': 'The FDA has approved ensifentrine (Ohtuvayre) for the maintenance treatment \nof chronic obstructive pulmonary disease (COPD) in adult patients.', 'thumbnail': 'https://serpapi.com/searches/672407c435853912625195f5/images/6879bbc0ffa6d0957fef52a7b461229e01207014e0d6324017a06b5811e65804.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7171338796615601}","{'position': 6, 'link': 'https://www.drugtopics.com/view/fda-roundup-agency-highlights-from-june-2024', 'title': 'FDA Roundup: Agency Highlights From June 2024', 'source': 'Drug Topics', 'date': 'Jun 28, 2024', 'snippet': 'The FDA approved ensifentrine (Ohtuvayre) for the maintenance treatment of \nchronic obstructive pulmonary disease (COPD) in adult patients,...', 'thumbnail': 'https://serpapi.com/searches/672407c435853912625195f5/images/6879bbc0ffa6d0951a3883925f22fca93904eb339bc6b85f94583b7ae5286a0a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8896152973175049}","{'position': 7, 'link': 'https://www.drugtopics.com/view/majority-of-infants-in-icu-for-rsv-have-no-underlying-health-conditions', 'title': 'Majority of Infants in ICU for RSV Have No Underlying Health Conditions', 'source': 'Drug Topics', 'date': 'Aug 21, 2023', 'snippet': 'A recent study found that Infants younger than 3 months, those born \nprematurely, and those who were publicly insured were at a higher risk...', 'thumbnail': 'https://serpapi.com/searches/672407c435853912625195f5/images/6879bbc0ffa6d095a02d10c2eea53ffdabe0c029f45658ef85ca1e0f607d740f.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5712602734565735}","{'position': 8, 'link': 'https://www.drugtopics.com/view/miebo-first-prescription-eye-drop-to-treat-tear-evaporation-in-dry-eye-disease-now-available', 'title': 'Miebo, First Prescription Eye Drop to Treat Tear Evaporation in Dry Eye Disease, Now Available', 'source': 'Drug Topics', 'date': 'Sep 15, 2023', 'snippet': 'The perfluorohexyloctane ophthalmic solution from Bausch + Lomb was \napproved by the FDA in May and will have a whole acquisition cost of...', 'thumbnail': 'https://serpapi.com/searches/672407c435853912625195f5/images/6879bbc0ffa6d095c0e31a7dc6e5d2f0d1799a23c6bf47b1a705911c0af32db7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8044151663780212}","{'position': 9, 'link': 'https://www.drugtopics.com/view/rsv-poses-more-danger-to-older-adults-than-covid-19-flu', 'title': 'RSV Poses More Danger to Older Adults Than COVID-19, Flu', 'source': 'Drug Topics', 'date': 'Oct 11, 2023', 'snippet': 'A new study found that more patients hospitalized with RSV needed standard \nflow oxygen, HFNC, NIV, and ICU admission than the patients with...', 'thumbnail': 'https://serpapi.com/searches/672407c435853912625195f5/images/6879bbc0ffa6d095bf7e07b821437a874bac23082dab901eec2ca6ee011e61e4.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5299963355064392}","{'position': 10, 'link': 'https://www.drugtopics.com/view/shingles-on-the-face-complications-and-treatment', 'title': 'Shingles On the Face: Complications and Treatment', 'source': 'Drug Topics', 'date': 'Aug 3, 2021', 'snippet': 'The patient is at risk for potentially serious complications like facial \npain, numbness, tingling, or paralysis; damage to the eyes, and hair loss.', 'thumbnail': 'https://serpapi.com/searches/672407c435853912625195f5/images/6879bbc0ffa6d095b9f8eef5dcec717935c5b63a7b32745668e34e1c4caa9900.png', 'sentiment': 'negative', 'sentiment_prob': 0.7037845849990845}","['neutral', 'neutral', 'neutral', 'negative', 'neutral', 'neutral', 'negative', 'neutral', 'negative', 'negative']",neutral,1
NCT04536688,"{'position': 1, 'link': 'https://www.biospace.com/regulus-therapeutics-announces-top-line-data-from-the-first-cohort-of-phase-1b-clinical-trial-of-rgls4326-for-the-treatment-of-patients-with-autosomal-dominant-polycystic-kidney-disease-adpkd', 'title': 'Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)', 'source': 'BioSpace', 'date': 'May 3, 2021', 'snippet': 'Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company \nfocused on the discovery and development of innovative medicines targeting \nmicroRNAs.', 'thumbnail': 'https://serpapi.com/searches/672407d7fda26d2cf83e96ad/images/8b5680b6e72a67ec32fac50096907f86500c22f941007b9338a5a1a410e8ece6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8504105806350708}",,,,,,,,,,['neutral'],neutral,1
NCT03828617,"{'position': 1, 'link': 'https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2021/story/new-data-to-support-vaccination-adherence/', 'title': 'Top-line study results support potential for co-administration of PREVNAR 20™ and seasonal flu vaccine in single appointment in line with CDC guidance', 'source': 'Pfizer', 'date': 'Mar 19, 2022', 'snippet': 'Top-line results from a phase 3 clinical trial we conducted demonstrated \nthat PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) and a \nseasonal...', 'thumbnail': 'https://serpapi.com/searches/672407e03c9575b4e24eabef/images/15767e15b19c3dcd1b137ab0f8442d380dfc726c6fed998b4f6d203abef96302.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6269888281822205}","{'position': 2, 'link': 'https://www.koreabiomed.com/news/articleView.html?idxno=13140', 'title': 'Pfizer scores European approval for 20-valent pneumococcal vaccine', 'source': 'KBR', 'date': 'Feb 16, 2022', 'snippet': 'Pfizer, which dominated the global pneumococcal vaccine market with \n13-valent Prevnar 13, said it won approval for a 20-valent vaccine in \nEurope.', 'thumbnail': 'https://serpapi.com/searches/672407e03c9575b4e24eabef/images/15767e15b19c3dcd13bbc1a60b938426dc16930bd63950e51cb16291834e4e38.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5019819736480713}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03538041,"{'position': 1, 'link': 'https://coldagglutininnews.com/news/parsaclisib-safe-effective-cad-patients-phase-2-clinical-trial/', 'title': 'Parsaclisib safe, effective for some CAD patients in Phase 2 trial', 'source': 'Cold Agglutinin Disease News', 'date': '1 week ago', 'snippet': ""About half of the cold agglutinin disease patients in a small Phase 2 trial \nresponded to Incyte's experimental oral therapy parsaclisib."", 'thumbnail': 'https://serpapi.com/searches/6724088f17a2e29b4744d695/images/7e3b9a899e84d5cda3bf3e51925eda9770687e0f99c39573176a6f4b50c63f52.png', 'sentiment': 'positive', 'sentiment_prob': 0.6235363483428955}",,,,,,,,,,['positive'],positive,1
NCT02926898,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Fenfluramine%20%20%28Fintepla%29', 'title': 'Fenfluramine (Fintepla)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Dravet Syndrome, A Study to Evaluate Safety, Tolerability, and \nPharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to \nLess...', 'thumbnail': 'https://serpapi.com/searches/6724089fa471674ff9681b39/images/298952dda638e237c1db359dc114fd1e44d515567fd95d86751a291b7eb33179.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8484590649604797}","{'position': 2, 'link': 'https://dravetsyndromenews.com/news/finteplas-potential-dual-mechanism-of-action-may-explain-effectiveness-at-reducing-seizures-in-dravet-syndrome/', 'title': 'Fintepla Fares Well in Study of Seizure Reduction in Dravet Syndrome', 'source': 'Dravet Syndrome News', 'date': 'Apr 14, 2020', 'snippet': 'The potential dual mechanism of action of Fintepla may explain its strong \nand durable effectiveness at reducing seizures in patients with...', 'thumbnail': 'https://serpapi.com/searches/6724089fa471674ff9681b39/images/298952dda638e237856e0c0717db666ff0fd9772a8a3b9d0b3a2f0264c2f7d8c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5350711345672607}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01394939,"{'position': 1, 'link': 'https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01630-z', 'title': 'Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis', 'source': 'Virology Journal', 'date': 'Jul 31, 2021', 'snippet': 'Oncolytic viruses (OVs) have shown prospects in advanced and metastatic \ncancer, and many clinical trials have been carried out.', 'thumbnail': 'https://serpapi.com/searches/672408a1861b9d63abef89ff/images/4c8bc1493a2312e592fd6322d8fa8eb8a75ab75d69b15e1da4acb4ebfb0b873c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8832862377166748}",,,,,,,,,,['neutral'],neutral,1
NCT06141889,"{'position': 1, 'link': 'https://www.genengnews.com/topics/drug-discovery/with-170m-bioage-joins-lilly-in-oral-muscle-preserving-obesity-treatment/', 'title': 'With $170M, BioAge Joins Lilly in Oral, Muscle Preserving Obesity Treatment', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Feb 15, 2024', 'snippet': 'BioAge Labs has completed an oversubscribed $170 million Series D \nfinancing, the proceeds of which will support Phase II trials of a \ntherapy...', 'thumbnail': 'https://serpapi.com/searches/672408b424296a895db7ac56/images/488e081705331bb5e6bca6b4b69d06006582e3051a0bd0997eafb1d60f35b078.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6264560222625732}",,,,,,,,,,['neutral'],neutral,1
NCT02144714,"{'position': 1, 'link': 'https://juvenilearthritisnews.com/2018/10/19/imraldi-humira-biosimilar-now-available-eu-ja-other-conditions/', 'title': 'Imraldi, BioSimilar to Humira, Now Available in Europe to Treat JIA, Other Conditions', 'source': 'Juvenile Arthritis News', 'date': 'Oct 19, 2018', 'snippet': 'Imraldi, an adalimumab biosimilar to Humira, will now be available in the \nEuropean Union for the treatment of juvenile arthritis and other...', 'thumbnail': 'https://serpapi.com/searches/672408cdd1691523570522ff/images/52c1235ee7549ffb1dae31b409e975c154e1274a0fc877335371849721e88d52.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8594298958778381}",,,,,,,,,,['neutral'],neutral,1
NCT03361748,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2024850', 'title': 'Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma', 'source': 'The New England Journal of Medicine', 'date': 'Feb 24, 2021', 'snippet': 'Idecabtagene vicleucel (ide-cel, also called bb2121) showed promising \nefficacy in a phase 1 study involving patients with relapsed or refractory \nmyeloma.', 'thumbnail': 'https://serpapi.com/searches/672409252a7727e9d2444000/images/0894aa7d84f6fd179976ac601d5b297157b184a40284cc09bda2f260379f51ce.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7197477221488953}","{'position': 2, 'link': 'https://www.nature.com/articles/s41408-021-00507-2', 'title': 'KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma', 'source': 'Nature', 'date': 'Jun 18, 2021', 'snippet': 'This study demonstrated that ide-cel significantly improved responses and \nsurvival compared with currently available therapies in triple-class \nexposed RRMM.', 'thumbnail': 'https://serpapi.com/searches/672409252a7727e9d2444000/images/0894aa7d84f6fd176179b316cbd74e655da2f24c0fb546a6b9e107bfcc832a29.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6598561406135559}","{'position': 3, 'link': 'https://www.ajmc.com/view/ash-abstracts-reveal-disparate-car-t-cell-therapy-access-and-outcomes-in-mm-dlbcl', 'title': 'ASH Abstracts Reveal Disparate CAR T-Cell Therapy Access and Outcomes in MM, DLBCL', 'source': 'AJMC', 'date': 'Jan 7, 2023', 'snippet': 'Access to and outcomes of chimeric antigen receptor (CAR) T-cell therapies \nmay differ by characteristics such as race, ethnicity, gender,...', 'thumbnail': 'https://serpapi.com/searches/672409252a7727e9d2444000/images/0894aa7d84f6fd1706e2fd6f264c4fbfa653584b12cfb7ffff03b9ff713e0de4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.696790874004364}","{'position': 4, 'link': 'https://www.ajmc.com/view/ash-2022-car-t-cell-therapy', 'title': 'ASH 2022: CAR T-Cell Therapy', 'source': 'AJMC', 'date': 'Feb 5, 2023', 'snippet': 'Investigators detailed patient and financial outcomes associated with \nchimeric antigen receptor (CAR) T-cell therapies vs standard of care (SOC) \nfor treatment...', 'thumbnail': 'https://serpapi.com/searches/672409252a7727e9d2444000/images/0894aa7d84f6fd174490878e4603bdfa82184f38ade7fef422014d373ff788fa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9080037474632263}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT05082051,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/cdx-7108-shows-promise-epi-common-symptom-phase-1-trial/', 'title': 'CDX-7108 shows promise for EPI, common CF symptom, in Phase 1...', 'source': 'Cystic Fibrosis News Today', 'date': 'Feb 27, 2023', 'snippet': 'CDX-7108, an experimental treatment for exocrine pancreatic insufficiency, \nmay safely boost fat absorption in CF, according to trial data.', 'thumbnail': 'https://serpapi.com/searches/6724092cce1e10a40aec6225/images/1f7178e7a0404e862aab07d471a54c466cb40879f09045ccfd861fc3072837b8.png', 'sentiment': 'positive', 'sentiment_prob': 0.7909238338470459}",,,,,,,,,,['positive'],positive,1
NCT04196491,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02496-0', 'title': 'Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial', 'source': 'Nature', 'date': 'Aug 17, 2023', 'snippet': 'Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen \n(BCMA)-directed chimeric antigen receptor T cell therapy.', 'thumbnail': 'https://serpapi.com/searches/6724093621b01bfe86d64afb/images/d1ff65a19f8cdfdc03d09babc77b4b8129bf6ab05f8200b2e7924a08335b8325.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9099538326263428}",,,,,,,,,,['neutral'],neutral,1
NCT01283516,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1311107', 'title': 'Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jan 25, 2017', 'snippet': 'Non–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase \ngene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib,...', 'thumbnail': 'https://serpapi.com/searches/672409908b7ba7dc1574cdac/images/1822ee99e267911f8a86a5561cf7a7485e4e60c5744422cc6488c323a2cd2f63.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6633459329605103}",,,,,,,,,,['neutral'],neutral,1
NCT02631044,"{'position': 1, 'link': 'https://www.onclive.com/view/subgroup-analysis-makes-the-case-for-earlier-liso-cel-administration-in-r-r-mcl', 'title': 'Subgroup Analysis Makes the Case for Earlier Liso-Cel Administration in R/R MCL', 'source': 'OncLive', 'date': 'Aug 13, 2024', 'snippet': 'Manali Kamdar, MD, discusses responses with liso-cel according to prior \nlines of therapy and BTK inhibitor exposure in mantle cell lymphoma.', 'thumbnail': 'https://serpapi.com/searches/672409ddfcd69e091e955ab4/images/4d13f06767571e1f44a0dd89a5178545ee2112229307a3c3d0c6eb9c1ca8c014.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9156875610351562}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/liso-cel-may-show-benefit-in-earlier-therapy-lines-for-lymphoma-subgroups', 'title': 'Liso-cel May Show Benefit in Earlier Therapy Lines for Lymphoma Subgroups', 'source': 'Cancer Network', 'date': 'Jun 14, 2024', 'snippet': 'Investigators must continue to explore the space for lisocabtagene \nmaraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.', 'thumbnail': 'https://serpapi.com/searches/672409ddfcd69e091e955ab4/images/4d13f06767571e1fccec4e224cd9c14e163b22baf5c1a4b4c1826c37eb0454d7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7087181210517883}","{'position': 3, 'link': 'https://www.cgtlive.com/view/wang-liso-cel-approval-mantle-cell-lymphoma', 'title': ""Michael Wang, MD, on Liso-Cel's Approval in Mantle Cell Lymphoma"", 'source': 'CGTLive®', 'date': 'Jun 6, 2024', 'snippet': 'The professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer \nCenter discussed the advantages the newly approved CAR-T has for...', 'thumbnail': 'https://serpapi.com/searches/672409ddfcd69e091e955ab4/images/4d13f06767571e1f76cb0f752d656cd854c2c3c65346847f1d33b7ca458436e5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7924081087112427}","{'position': 4, 'link': 'https://www.onclive.com/view/liso-cel-elicits-clinically-meaningful-activity-in-heavily-pretreated-relapsed-refractory-mcl', 'title': 'Liso-Cel Elicits Clinically Meaningful Activity in Heavily Pretreated, Relapsed/Refractory MCL', 'source': 'OncLive', 'date': 'Jun 20, 2024', 'snippet': 'Liso-cel demonstrated clinically meaningful activity regardless of the \nnumber of previous lines of systemic therapy or response to prior BTK...', 'thumbnail': 'https://serpapi.com/searches/672409ddfcd69e091e955ab4/images/4d13f06767571e1fb35868f228b8f85d6a48936c0172d35ab3a21f9e20e54924.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8159653544425964}","{'position': 5, 'link': 'https://immuno-oncologynews.com/2021/02/10/car-t-cell-therapy-breyanzi-approved-large-b-cell-lymphomas/', 'title': 'CAR T-cell Therapy Breyanzi Approved for Large B-cell Lymphomas', 'source': 'Immuno-Oncology News', 'date': 'Feb 10, 2021', 'snippet': 'The US Food and Drug Administration (FDA) has approved the CAR T-cell \ntherapy Breyanzi (lisocabtagene maraleucel) for treating adults with \nrelapsed or...', 'thumbnail': 'https://serpapi.com/searches/672409ddfcd69e091e955ab4/images/4d13f06767571e1f48a78ccc552c139bcd15309bccc5f6b0c8c52ab1ef1ef40c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8064560890197754}","{'position': 6, 'link': 'https://lymphomanewstoday.com/2020/01/07/potential-lymphoma-therapy-liso-cel-submitted-for-fda-approval/', 'title': 'Bristol-Myers Seeks FDA Approval of CAR T-cell Therapy Liso-Cel for Aggressive Large B-cell Lymphomas', 'source': 'Lymphoma News Today', 'date': 'Jan 7, 2020', 'snippet': 'Bristol-Myers Squibb has asked the US Food and Drug Administration (FDA) to \napprove its investigational CAR T-cell therapy lisocabtagene maraleucel \n(liso-cel)...', 'thumbnail': 'https://serpapi.com/searches/672409ddfcd69e091e955ab4/images/4d13f06767571e1f5d3e16cffed8c74406d16fc63aee5d36f3bb732a6427bc12.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9084925651550293}","{'position': 7, 'link': 'https://www.onclive.com/view/lisocabtagene-maraleucel-in-r-r-mcl-primary-analysis-results-from-the-mcl-cohort-of-the-single-arm-multicenter-seamless-design-transcend-nhl-001-study', 'title': 'Lisocabtagene Maraleucel in R/R MCL: Primary Analysis Results from the MCL Cohort of the Single-Arm, Multicenter, Seamless Design TRANSCEND NHL 001 Study', 'source': 'OncLive', 'date': 'Dec 5, 2023', 'snippet': 'Alexey Danilov, MD, PhD, reviews data from the TRANSCEND NHL 001 study \ninvestigating lisocabtagene maraleucel in patients with...', 'thumbnail': 'https://serpapi.com/searches/672409ddfcd69e091e955ab4/images/4d13f06767571e1f6dbd9389aee088011de0d6a06893b7134bbe919bdc511156.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9374514222145081}","{'position': 8, 'link': 'https://www.onclive.com/view/patient-prioritization-is-the-foundation-for-a-successful-neurologic-oncology-career-with-d-ross-camidge-md-phd-and-douglas-ney-md', 'title': 'Patient Prioritization Is the Foundation for a Successful Neurologic Oncology Career: With D. Ross Camidge, MD, PhD; and Douglas Ney, MD', 'source': 'OncLive', 'date': '1 week ago', 'snippet': ""Drs Camidge and Ney discuss Dr Ney's journey to becoming a neurologic \noncologist and his experience as a physician with Tourette syndrome."", 'thumbnail': 'https://serpapi.com/searches/672409ddfcd69e091e955ab4/images/4d13f06767571e1f51dd0b3f38292fe27e5d3c24e33c4a9811d96751996d8ef9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6013492345809937}",,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04338958,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-023-01979-w', 'title': 'The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial', 'source': 'Nature', 'date': 'Jul 28, 2023', 'snippet': 'Dysregulated hyperinflammatory response is key in the pathogenesis in \npatients with severe COVID-19 leading to acute respiratory distress...', 'thumbnail': 'https://serpapi.com/searches/67240941ea57e958c5952500/images/0c5fd13459f28bb99920cde4c2870b9c165283c49ca4c8fb77262351639e933b.png', 'sentiment': 'negative', 'sentiment_prob': 0.5567591786384583}",,,,,,,,,,['negative'],negative,0
NCT03235752,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222015633', 'title': 'Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies', 'source': 'ScienceDirect.com', 'date': 'Dec 31, 2022', 'snippet': 'Emerging biologics and small molecule drugs are navigating the clinical \nlandscape of inflammatory bowel disease (IBD).', 'thumbnail': 'https://serpapi.com/searches/672409420f1a3393cf1eee8e/images/5af755cd99e29fb6a8b237907525b6a66776d3020356f4fcec45dd04fe2a7d6d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.830076277256012}",,,,,,,,,,['neutral'],neutral,1
NCT04165122,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/reproductive-health/articles/10.3389/frph.2023.1337479/full', 'title': 'Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy', 'source': 'Frontiers', 'date': 'Jun 25, 2024', 'snippet': 'Monoclonal antibodies (mAbs) are currently being produced for a number of \nclinical applications including contraception and the prevention of \nsexually...', 'thumbnail': 'https://serpapi.com/searches/6724094aca6f0c8fd81b8e79/images/23986391bf72d7f856ba4a56204e5ba6cab4e55e57c3e0dd475b88149b7df0f3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8703041672706604}",,,,,,,,,,['neutral'],neutral,1
NCT04205643,"{'position': 1, 'link': 'https://www.empr.com/home/news/zymfentra-approved-as-the-first-subcutaneous-infliximab-for-inflammatory-bowel-disease/', 'title': 'Zymfentra, a Subcutaneous Formulation of Infliximab, Approved for IBD', 'source': 'Medical Professionals Reference', 'date': 'Oct 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Zymfentra \n(infliximab-dyyb) for the maintenance treatment of adults with moderately \nto severely active...', 'thumbnail': 'https://serpapi.com/searches/6724094f7d533e6839e29418/images/c089cad9239e036e7e59638ec1019c4fec5f2d372ab4c9af10afb14f8e158dd1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.762981116771698}",,,,,,,,,,['neutral'],neutral,1
NCT00730639,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1200690', 'title': 'Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jun 2, 2012', 'snippet': 'Anti–PD-1 antibody produced objective responses in approximately one in \nfour to one in five patients with non–small-cell lung cancer, melanoma, or \nrenal-cell...', 'thumbnail': 'https://serpapi.com/searches/67240962922cceee225ab673/images/0d89bd79f9644a3c98f43db2f254bad38f17e68499b8bbc4ea98769de47ecc4c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8709130883216858}","{'position': 2, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332218364102', 'title': 'PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer', 'source': 'ScienceDirect.com', 'date': 'Dec 3, 2018', 'snippet': 'We present a comprehensive knowledge of immune therapy through PD-1/PD-L1 \nblockade that argues how efficient the process is, in colon cancer \ncarcinoma.', 'thumbnail': 'https://serpapi.com/searches/67240962922cceee225ab673/images/0d89bd79f9644a3c4b7ba5ecc933776a0254907c5ac0a1009a4fc6b985baec34.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5837924480438232}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01891864,"{'position': 1, 'link': 'https://juvenilearthritisnews.com/2017/08/29/biosimilar-erelzi-approved-in-canada-for-juvenile-arthritis-other-chronic-inflammatory-diseases/', 'title': 'Juvenile Arthritis Drug Erelzi, a Biosimilar of Enbrel, Is Approved in Canada', 'source': 'Juvenile Arthritis News', 'date': 'Aug 29, 2017', 'snippet': 'Erelzi, a biosimilar of Enbrel, has been approved in Canada for the \ntreatment of juvenile arthritis and other chronic inflammatory diseases.', 'thumbnail': 'https://serpapi.com/searches/67240963316650e93040c75c/images/eb3654b45ca1e22ee448edb1f7e196b7ec38bff90290c07c87d6957b8797c912.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6023288369178772}",,,,,,,,,,['neutral'],neutral,1
NCT03137173,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/ceftobiprole-antibiotic-fda-review-infections/', 'title': 'IV Antibiotic Ceftobiprole Under Review for Serious Bacterial Infections', 'source': 'Medical Professionals Reference', 'date': 'Oct 2, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted the New Drug \nApplication for ceftobiprole, an investigational, broad spectrum \ncephalosporin antibiotic for...', 'thumbnail': 'https://serpapi.com/searches/6724096ed16915231ac93424/images/d4e2326bad66ba77aaaec05d4bca7d08361ec19a216bd2683417442f1037471e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.898817777633667}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/basilea-seeks-approval-of-intravenous-antibiotic-ceftobiprole/', 'title': 'Basilea Seeks Approval of Intravenous Antibiotic Ceftobiprole', 'source': 'Medical Professionals Reference', 'date': 'Aug 4, 2023', 'snippet': 'The New Drug Application (NDA) for ceftobiprole medocaril (ceftobiprole) \nhas been submitted for review to the Food and Drug Administration...', 'thumbnail': 'https://serpapi.com/searches/6724096ed16915231ac93424/images/d4e2326bad66ba773d156fa7cc72fd871e4a98201ad53009ae5f5425207c63c3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8470795154571533}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04676516,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-37706-9', 'title': 'Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer', 'source': 'Nature', 'date': 'Jul 3, 2023', 'snippet': 'Protein arginine methyltransferase 5 (PRMT5) catalyzes mono-methylation and \nsymmetric di-methylation on arginine residues and has emerged as...', 'thumbnail': 'https://serpapi.com/searches/6724097693584c2b3cbbfb82/images/556140fe68baecfee20f21c58227aea71d8e7e29c9ce1d43c191edfa1668a8a4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.892833948135376}",,,,,,,,,,['neutral'],neutral,1
NCT00288080,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.18.02158', 'title': 'Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial', 'source': 'ASCO Publications', 'date': 'Mar 12, 2019', 'snippet': 'PURPOSERadiotherapy (RT) plus long-term androgen suppression (AS) are a \nstandard treatment option for patients with high-risk localized...', 'thumbnail': 'https://serpapi.com/searches/67240982dc969faceef7c216/images/246ff694216108ecbaacdd38749df9f326c5d3c82589e15fb28ed21740eb21b9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9201226234436035}",,,,,,,,,,['neutral'],neutral,1
NCT02292238,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/45m-grant-funds-trial-benfotiamine-vitamin-b1-precursor-cognitive-decline/', 'title': '$45M Grant Funds Trial of Vitamin B1 Precursor for Cognitive Decline', 'source': ""Alzheimer's News Today"", 'date': 'Jul 14, 2022', 'snippet': ""A clinical trial was given a $45-million NIH grant to test benfotiamine, a \nprecursor of thiamine, for slowing Alzheimer's cognitive decline."", 'thumbnail': 'https://serpapi.com/searches/67240989544c49d54eeae096/images/a210ca5c27755fa1832609735876d161e480a28355368fd2a2b9752eb7d238a1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8107326626777649}",,,,,,,,,,['neutral'],neutral,1
NCT04844450,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20230215005235/en/Arrowhead-Pharmaceuticals-Gains-Full-Rights-to-NASH-Candidate-ARO-PNPLA3-with-Promising-Phase-1-Results', 'title': 'Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results', 'source': 'Business Wire', 'date': 'Feb 15, 2023', 'snippet': 'Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has \ngained rights to ARO-PNPLA3, formerly called JNJ-75220795,...', 'thumbnail': 'https://serpapi.com/searches/672409de81262ade2810abbc/images/4c589304a73e86e93977af81995f8e5dbd654f92e6f1f64a44126683ec33e10c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7633824348449707}",,,,,,,,,,['neutral'],neutral,1
NCT00927836,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/strokeaha.113.001531', 'title': 'Granulocyte Colony–Stimulating Factor in Patients With Acute Ischemic Stroke:', 'source': 'American Heart Association Journals', 'date': 'Aug 20, 2013', 'snippet': 'Background and Purpose—Granulocyte colony–stimulating factor (G-CSF; AX200; \nFilgrastim) is a stroke drug candidate with excellent...', 'thumbnail': 'https://serpapi.com/searches/672409e064f11d07486b2679/images/2e36a35034773208f43e4353f80ede6e0a04edb718df2ba6ea38b535ff54a412.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7083484530448914}",,,,,,,,,,['neutral'],neutral,1
NCT04660643,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/tirzepatide-demonstrated-significant-and-superior-weight-loss-compared-to-placebo-in-two-pivotal-studies-301887287.html', 'title': 'Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies', 'source': 'PR Newswire', 'date': 'Jul 27, 2023', 'snippet': 'PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results of two \nphase 3 tirzepatide studies in adults with obesity or overweight...', 'thumbnail': 'https://serpapi.com/searches/672409e4f8b05d9ece9f13dd/images/11259507ec07782cc8fa3e79edac4bfe8fb715341855e44b0239ea3a12e9f49c.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6481562852859497}",,,,,,,,,,['positive'],positive,1
NCT04819776,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/iloperidone-benefits-patients-with-bipolar-i-disorder-in-phase-3-trial/', 'title': 'Iloperidone Benefits Patients With Bipolar I Disorder in Phase 3 Trial', 'source': 'Medical Professionals Reference', 'date': 'Dec 19, 2022', 'snippet': 'Iloperidone was associated with significant improvement in adults with \nbipolar I disorder, according to results from a phase 3 study.', 'thumbnail': 'https://serpapi.com/searches/672409ed0664c984116fdc2e/images/d059bf0f52e2e8ffe0c43384b9264cae29a41577a5de51529078b8ec7b92fa77.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7241905331611633}",,,,,,,,,,['positive'],positive,1
NCT01101035,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1710895', 'title': 'Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout', 'source': 'The New England Journal of Medicine', 'date': 'Mar 12, 2018', 'snippet': 'Cardiovascular risk is increased in patients with gout. We compared \ncardiovascular outcomes associated with febuxostat, a nonpurine xanthine...', 'thumbnail': 'https://serpapi.com/searches/672409fe81bab7b92fca17d0/images/3aba9bc48dd99b15567b72986afa24faa7d994d1c7537201e1999ccc4460f70e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6810529828071594}",,,,,,,,,,['neutral'],neutral,1
NCT04725877,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-024-00818-y', 'title': 'Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV—workshop report | npj Vaccines', 'source': 'Nature', 'date': 'Feb 21, 2024', 'snippet': 'The goal of this workshop was to review data on leading vaccine candidates \nand to discuss the best strategies for combining these approaches to \noptimize...', 'thumbnail': 'https://serpapi.com/searches/67240a0db4fe875869b7a179/images/d940fc65a24191b40e506796ab97cb68a0eef600a8c757730295144583d872ef.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7899861931800842}",,,,,,,,,,['neutral'],neutral,1
NCT02760277,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/mda2021-long-term-vamorolone-disease-progression-dmd-boys-phase-2-trial/', 'title': '#MDA2021 – Long-term Vamorolone Slowed Disease Progression in DMD Boys', 'source': 'Muscular Dystrophy News', 'date': 'Mar 24, 2021', 'snippet': 'Long-term treatment with vamorolone safely delays motor function decline in \nboys with Duchenne muscular dystrophy, according to final trial...', 'thumbnail': 'https://serpapi.com/searches/67240a103c9575b4b1b6bf59/images/76372088000d7553d201e246d58637ab5817f8b164601b6a6d518b7bfc937e18.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8507468104362488}",,,,,,,,,,['neutral'],neutral,1
NCT04246489,"{'position': 1, 'link': 'https://www.onclive.com/view/bintrafusp-alfa-induces-responses-in-post-platinum-metastatic-cervical-cancer', 'title': 'Bintrafusp Alfa Induces Responses in Post-Platinum Metastatic Cervical Cancer', 'source': 'OncLive', 'date': 'Jul 25, 2024', 'snippet': 'Bintrafusp alfa showcased clinical activity in patients with recurrent or \nmetastatic cervical cancer with disease progression during or...', 'thumbnail': 'https://serpapi.com/searches/67240a1bc05eb54577d2384c/images/51225fcc3a4579dc3f53b216ad82fdc8a9850bc5119cf7d0e41891a45a777821.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9027925729751587}",,,,,,,,,,['neutral'],neutral,1
NCT03631706,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-021-00868-x', 'title': 'Emerging new therapeutic antibody derivatives for cancer treatment | Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': 'Feb 7, 2022', 'snippet': 'In this review, we summarize antibodies of various molecular types, \nantibody applications in cancer therapy, and details of clinical study \nadvances.', 'thumbnail': 'https://serpapi.com/searches/67240a1ff922f6c63082ee00/images/a40273889b31936216bc0216a1f8868a6b7965165b802474ec1d6222f48a6f78.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8890555500984192}",,,,,,,,,,['neutral'],neutral,1
NCT00326898,"{'position': 1, 'link': 'https://www.onclive.com/view/kim-1-demonstrates-potential-utility-as-a-biomarker-with-worse-dfs-outcomes-in-kim-1-high-rcc', 'title': 'KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC', 'source': 'OncLive', 'date': 'Jul 21, 2024', 'snippet': 'A third prospective trial has shown that higher KIM-1 levels at baseline \nresult in worse disease-free survival (DFS) outcomes for patients with \nresected high-...', 'thumbnail': 'https://serpapi.com/searches/67240a35f9f904be4fe0a67b/images/678807e2f73649ceaeb02adc0e6a15e7f538e78c2e113020356e3bf7daab1180.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6850661039352417}",,,,,,,,,,['negative'],negative,0
NCT02926950,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1238399/full', 'title': 'Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': 'BackgroundsThe safety of different sodium-glucose transporter 2 (SGLT-2) \ninhibitors remains uncertain due to the lack of head-to-head comparisons.', 'thumbnail': 'https://serpapi.com/searches/67240a48ecf150501c764808/images/58002a8ec4fe44c6ae7b3632614885987ce3f0abd2f3e67ddca3b20092203b2f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8960149884223938}",,,,,,,,,,['neutral'],neutral,1
NCT03028441,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/niaid-sponsored-trial-experimental-chikungunya-vaccine-begins', 'title': 'NIAID-Sponsored Trial of Experimental Chikungunya Vaccine Begins', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jun 5, 2017', 'snippet': 'A clinical trial of an experimental vaccine to prevent infection with \nchikungunya virus is now enrolling healthy adult volunteers at three sites \nin the United...', 'thumbnail': 'https://serpapi.com/searches/67240a57b6a79c9a7bf4c1ef/images/736c69a0937e5004b2f3df4c303c2de8509edac4f20cb2b95fcfda22e1b37a7e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9215162992477417}",,,,,,,,,,['neutral'],neutral,1
NCT04317040,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20201123005593/en/Merck-to-Acquire-OncoImmune', 'title': 'Merck to Acquire OncoImmune', 'source': 'Business Wire', 'date': 'Nov 23, 2020', 'snippet': 'Merck will accelerate development of CD24Fc, a candidate for the treatment \nof patients with severe and critical COVID-19...', 'thumbnail': 'https://serpapi.com/searches/67240a5f48e668587c2366e4/images/1701f3bdc693cdf7503cbe65e73fd99a7a966f1f7e366b833f2232f085f5f930.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6530737280845642}",,,,,,,,,,['neutral'],neutral,1
NCT01733186,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-023-01020-1', 'title': 'Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success', 'source': 'Nature', 'date': 'Apr 25, 2023', 'snippet': 'We evaluated 15 randomized controlled clinical trials (RCTs) and 11 \nnonrandomized RCTs using culture-expanded MSCs in the treatment of knee OA, \nand we found...', 'thumbnail': 'https://serpapi.com/searches/67240a6b2da15795533ddc95/images/7d4c7a6dae122b92f9cf31ebe3a2c73bedfb8f6e7b1427718bf6ba6c3c9d08e5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8233572840690613}",,,,,,,,,,['neutral'],neutral,1
NCT04927065,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02517-y', 'title': 'Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results', 'source': 'Nature', 'date': 'Aug 31, 2023', 'snippet': 'This ongoing, open-label, phase 2/3 trial compared the safety and \nimmunogenicity of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222...', 'thumbnail': 'https://serpapi.com/searches/67240a988cf8aebaab22c965/images/5bfad3f4179328820014f9b0e3e4e69ee051807803df3f0d8144f25cdb26eba6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8937976956367493}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2208343', 'title': 'A Bivalent Omicron-Containing Booster Vaccine against Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Sep 16, 2022', 'snippet': 'The safety and immunogenicity of the bivalent omicron-containing \nmRNA-1273.214 booster vaccine are not known.In this ongoing, phase 2–3...', 'thumbnail': 'https://serpapi.com/searches/67240a988cf8aebaab22c965/images/5bfad3f417932882285e1f2c3ae37743ace9ffe2cacd17a59755816fb0a3f6ef.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8018212914466858}","{'position': 3, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMc2119912', 'title': 'SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination', 'source': 'The New England Journal of Medicine', 'date': 'Jan 26, 2022', 'snippet': 'Neutralization of the omicron variant was assessed in serum samples \nobtained from persons who had received an mRNA-1273 booster.', 'thumbnail': 'https://serpapi.com/searches/67240a988cf8aebaab22c965/images/5bfad3f4179328821e846cb1318fe8dc52edd026cfec248edfc0c3642bc1a801.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7621810436248779}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT01204749,"{'position': 1, 'link': 'https://www.nature.com/articles/bjc2012541', 'title': 'Targeted anti-vascular therapies for ovarian cancer: current evidence', 'source': 'Nature', 'date': 'Feb 5, 2013', 'snippet': 'This review attempts to discuss progress to date in tackling a more general \ntarget applicable to ovary cancer—angiogenesis...', 'thumbnail': 'https://serpapi.com/searches/67240ab40e6db374244f6e96/images/ad29760b360d4b0b52724d826ec78c1d95d5c8ccc46e629854f2033d15a81b7e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9021773934364319}",,,,,,,,,,['neutral'],neutral,1
NCT05301517,"{'position': 1, 'link': 'https://www.onclive.com/view/chinese-phase-3-trial-of-roxadustat-in-non-myeloid-malignancies-meets-primary-end-point', 'title': 'Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point', 'source': 'OncLive', 'date': 'May 18, 2023', 'snippet': 'Roxadustat proved to be noninferior to recombinant erythropoietin alfa with \nregard to change in hemoglobin level from baseline to an average...', 'thumbnail': 'https://serpapi.com/searches/67240b22069e571284ade305/images/e07bda9fa900c63b9fccc90a7ecf443c48a4945f488550308d8d1422a827a913.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8067212104797363}",,,,,,,,,,['neutral'],neutral,1
NCT02719977,"{'position': 1, 'link': 'https://www.nature.com/articles/s41588-023-01602-9', 'title': 'The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells', 'source': 'Nature', 'date': 'Nov 30, 2023', 'snippet': 'Although CX-5461 exhibits synthetic lethality in BRCA1-/BRCA2-deficient \ncells, it also causes extensive, nonselective, collateral mutagenesis in \nall three cell...', 'thumbnail': 'https://serpapi.com/searches/67240b25acf7f8b0d80cf6da/images/704c69d7a8407c95dd46ee66c54d6e947171d81dc7e4c42ac87546bedf3ff2dd.png', 'sentiment': 'negative', 'sentiment_prob': 0.7724517583847046}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-022-31199-2', 'title': 'Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies', 'source': 'Nature', 'date': 'Jun 24, 2022', 'snippet': 'CX-5461 is a G-quadruplex stabilizer that exhibits synthetic lethality in \nhomologous recombination-deficient models.', 'thumbnail': 'https://serpapi.com/searches/67240b25acf7f8b0d80cf6da/images/704c69d7a8407c95b4e7ba2a18eaf25df9b68f0ffa0ac19cce2a2e4493dbacf8.png', 'sentiment': 'negative', 'sentiment_prob': 0.6291135549545288}","{'position': 3, 'link': 'https://ovariancancernewstoday.com/2020/07/21/small-inhibitor-may-boost-effectiveness-of-parp-inhibitors-in-some-ovarian-cancers-mouse-study-finds/', 'title': 'Small Inhibitor May Boost Effectiveness of PARP Inhibitors in Some Ovarian Cancers, Mouse Study Finds', 'source': 'Ovarian Cancer News Today', 'date': 'Jul 21, 2020', 'snippet': 'A small inhibitor that prevents cells from making ribosomes may improve \nPARP inhibitor efficacy across ovarian cancers with mutations in DNA...', 'thumbnail': 'https://serpapi.com/searches/67240b25acf7f8b0d80cf6da/images/704c69d7a8407c9502624899283edea49fa3e83da97c3ec7133d176e9717da96.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.614351749420166}",,,,,,,,"['negative', 'negative', 'neutral']",negative,0
NCT00233324,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1208506', 'title': 'Neurodevelopmental Outcomes in the Early CPAP and Pulse Oximetry Trial', 'source': 'The New England Journal of Medicine', 'date': 'Dec 27, 2012', 'snippet': 'Previous results from our trial of early treatment with continuous positive \nairway pressure (CPAP) versus early surfactant treatment in...', 'thumbnail': 'https://serpapi.com/searches/67240b2a8a7c0972a22e3706/images/194fd90c445de0c1faca65c15a9f6671a0b69cadf24dbd1c9a05aa496bc90606.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9130668640136719}",,,,,,,,,,['neutral'],neutral,1
NCT03611751,"{'position': 1, 'link': 'https://www.thepharmaletter.com/biotechnology/2-9-billion-in-sales-forecast-for-bms-sotyktu-by-2029', 'title': '$2.9 billion in sales forecast for BMS’ Sotyktu by 2029', 'source': 'The Pharma Letter', 'date': 'May 11, 2023', 'snippet': ""$2.9 billion in sales forecast for BMS' Sotyktu by 2029. Biotechnology. 11 \nMay 2023. bristol_myers_squibb_shutterstock_large."", 'thumbnail': 'https://serpapi.com/searches/67240ade167793224537b7fb/images/adbfb6a36999c2329132239a2d3c3cac3571b5dfa3634a69b3164687c8a2738d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7873889207839966}","{'position': 2, 'link': 'https://www.empr.com/home/news/fda-approves-sotyktu-for-moderate-to-severe-plaque-psoriasis/', 'title': 'FDA Approves Sotyktu for Moderate to Severe Plaque Psoriasis', 'source': 'Medical Professionals Reference', 'date': 'Sep 12, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Sotyktu™ \n(deucravacitinib) for the treatment of adults with moderate to severe \nplaque...', 'thumbnail': 'https://serpapi.com/searches/67240ade167793224537b7fb/images/adbfb6a36999c23206b152fa72c5a6d2a1b8032258dd5656fdaa960e1e606a7c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7778393626213074}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02570308,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20180521006120/en/Immunocore-to-Present-New-Data-from-IMCgp100-102-Trial-in-Metastatic-Uveal-Melanoma-at-2018-ASCO-Annual-Meeting', 'title': 'Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting', 'source': 'Business Wire', 'date': 'May 22, 2018', 'snippet': 'OXFORD, United Kingdom & CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Immunocore \nLimited, a leading T cell receptor (TCR) company focused on...', 'thumbnail': 'https://serpapi.com/searches/67240af5acf7f8b0d80cf6cc/images/0916090242846d6644e608a5a4a5bec1ea30b57eb8e9328ef53d8c00b9b697b3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9128562211990356}",,,,,,,,,,['neutral'],neutral,1
NCT02588105,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0286-4', 'title': 'pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry', 'source': 'Nature', 'date': 'Nov 2, 2018', 'snippet': 'AZD0156 and AZD6738 are potent and selective inhibitors of \nataxia-telangiectasia-kinase (ATM) and ataxia-telangiectasia-mutated and...', 'thumbnail': 'https://serpapi.com/searches/67240b095bb6a2d5bbfd1709/images/3211434848e21f5150e49d90b3749d0bb6c387d6712de2758c71bdb54d521e59.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8375502228736877}","{'position': 2, 'link': 'https://news.cuanschutz.edu/cancer-center/irinotecan-breaks-cancer-cell-dna', 'title': 'Irinotecan breaks cancer cell DNA – AZD0156 keeps the body from repairing it', 'source': 'University of Colorado Anschutz Medical Campus', 'date': 'Apr 3, 2019', 'snippet': 'The chemotherapy drug irinotecan creates DNA damage leading to cell death \nand is used to treat colorectal cancer, among other cancer types.', 'thumbnail': 'https://serpapi.com/searches/67240b095bb6a2d5bbfd1709/images/3211434848e21f510f8c5541f8b6206e4a9b39ebc17db083d2eba3369de8dd4b.png', 'sentiment': 'negative', 'sentiment_prob': 0.8050485253334045}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT02714218,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.18.01998', 'title': 'Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Feb 27, 2019', 'snippet': 'This study showed that nivolumab 1 mg/kg plus ipilimumab 3 mg/kg led to \nhigher rates of objective response and greater aggregate clinical activity.', 'thumbnail': 'https://serpapi.com/searches/67240b386273fb2911088887/images/bfa45e81f0c684a0001cf00e46464e0db5065920287bdbddaa1841cccd91c41a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9069010615348816}",,,,,,,,,,['neutral'],neutral,1
NCT02976129,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-019-50545-x', 'title': 'Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients', 'source': 'Nature', 'date': 'Oct 1, 2019', 'snippet': 'V565 is an engineered TNFα-neutralising single domain antibody formulated \ninto enteric coated mini-tablets to enable release in the intestine after \noral...', 'thumbnail': 'https://serpapi.com/searches/67240b42a5aae957db43771c/images/c55bb2722445eb0e41c231656fdf8f6c5f9e42d30e5e5077e5771dbe0010fdd1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8417642712593079}",,,,,,,,,,['neutral'],neutral,1
NCT02308969,"{'position': 1, 'link': 'https://www.nature.com/articles/tp201754', 'title': 'Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects', 'source': 'Nature', 'date': 'Apr 4, 2017', 'snippet': 'Lysergic acid diethylamide (LSD) induces profound changes in various mental \ndomains, including perception, self-awareness and emotions.', 'thumbnail': 'https://serpapi.com/searches/67240b48c76a22eca4180c0d/images/9d082ccbf40cc6928f8b1d6fcc0b023fd110def8e0c7171ddbdc1985916ab325.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8194146156311035}",,,,,,,,,,['neutral'],neutral,1
NCT02042989,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-020-58366-z', 'title': 'Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies', 'source': 'Nature', 'date': 'Feb 20, 2020', 'snippet': 'We performed two phase I trials of the histone deacetylase inhibitor \nvorinostat combined with either the vascular endothelial growth factor...', 'thumbnail': 'https://serpapi.com/searches/67240b58e95dbf1012f1512a/images/e2bf59158cebd7b84f6025c9cba882c201dea749fced236d8aefbe4c2b1d8b58.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9028980135917664}",,,,,,,,,,['neutral'],neutral,1
NCT05308953,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/nervgen-completes-dosing-group-ms-candidate-nvg-291/', 'title': 'NervGen Completes Dosing Another Group With MS Candidate NVG-291', 'source': 'Multiple Sclerosis News Today', 'date': 'Nov 18, 2022', 'snippet': ""A Phase 1 trial testing NVG-291, NervGen Pharma's candidate for MS, has \ncompleted dosing in the final group of healthy postmenopausal women."", 'thumbnail': 'https://serpapi.com/searches/67240b675a461a844d4dccba/images/b9ec3d34cd92b8a68c5197f72bd9c017724665ebed0bee0c5a313506d63958d0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9050969481468201}",,,,,,,,,,['neutral'],neutral,1
NCT01437397,"{'position': 1, 'link': 'https://copdnewstoday.com/news/duaklir-available-copd-patients-us/', 'title': 'Duaklir Now Available to COPD Patients in the U.S.', 'source': 'COPD News Today', 'date': 'Oct 29, 2019', 'snippet': 'Duaklir is now available to patients with chronic obstructive pulmonary \ndisease (COPD) living in the U.S., Circassia Pharmaceuticals...', 'thumbnail': 'https://serpapi.com/searches/67240b6a6a5dd30cfdf5f9d3/images/8c1b6cbb5da6776ddc9894ce64b84cae6cf2e2810060b7716f20d636099069af.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7435298562049866}",,,,,,,,,,['neutral'],neutral,1
NCT03665285,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-022-13997-2', 'title': 'Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma', 'source': 'Nature', 'date': 'Jun 21, 2022', 'snippet': 'Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) might be \ninvolved in the activation of important pathways related to tumor...', 'thumbnail': 'https://serpapi.com/searches/67240b73a324362e226c5cb7/images/eb5c4eb1a6b559f9c60e95125d04d4c810b1963fa2f6a7afd50c2a6fa532de3e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8968281149864197}",,,,,,,,,,['neutral'],neutral,1
NCT03588130,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/mediwound-reinforces-wound-therapy-escharex-data-ahead-of-phase-iii-trial/', 'title': 'MediWound reinforces wound therapy EscharEx data ahead of Phase III trial', 'source': 'Clinical Trials Arena', 'date': 'Jul 30, 2024', 'snippet': 'MediWound has published Phase II trial data showing that its wound \ndebridement therapy, EscharEx, is superior at treating venous leg ulcers \nthan other non-...', 'thumbnail': 'https://serpapi.com/searches/67240b8f7ca6b3ab4347d760/images/f0de7046fe5e75e842db3e8006253bd43d76dc8d37c753b46b081b06b4740037.png', 'sentiment': 'positive', 'sentiment_prob': 0.7243747711181641}",,,,,,,,,,['positive'],positive,1
NCT03399786,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2004215', 'title': 'Evinacumab for Homozygous Familial Hypercholesterolemia', 'source': 'The New England Journal of Medicine', 'date': 'Aug 19, 2020', 'snippet': 'Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential \nbenefit in patients with homozygous familial hypercholesterolemia.', 'thumbnail': 'https://serpapi.com/searches/67240baeb6a79c9a7bf4c23b/images/9ff15079438ed670df7d53240fa46cd3d942ad1452ed977472eebf22de9cd39e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7179078459739685}",,,,,,,,,,['neutral'],neutral,1
NCT00634712,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0805450', 'title': 'Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction', 'source': 'The New England Journal of Medicine', 'date': 'May 1, 2018', 'snippet': 'Approximately 50% of patients with heart failure have a left ventricular \nejection fraction of at least 45%, but no therapies have been shown to \nimprove the...', 'thumbnail': 'https://serpapi.com/searches/67240bbf98d8de9a4cffa089/images/43bb73587daadab440417f01ba4be41bfb556396b2110b48fb5fa9e21b190897.png', 'sentiment': 'negative', 'sentiment_prob': 0.6149664521217346}",,,,,,,,,,['negative'],negative,0
NCT01935973,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-0199-6', 'title': 'Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence', 'source': 'Nature', 'date': 'Jul 29, 2020', 'snippet': 'Advanced and recurrent gynecological cancers are associated with poor \nprognosis and lack of effective treatment. The developments of the...', 'thumbnail': 'https://serpapi.com/searches/67240bc893584c2b705856e6/images/4b21a89701e72e1f57d4cd5870f36b217e780307db089b4b5ec2dfc1f3679e15.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6648945212364197}",,,,,,,,,,['neutral'],neutral,1
NCT02474290,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01614-1', 'title': 'Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study', 'source': 'Nature', 'date': 'Sep 14, 2023', 'snippet': 'Sorafenib therapy improves overall survival (OS) in patients with FLT3 \ninternal tandem duplication (ITD) acute myeloid leukemia (AML)...', 'thumbnail': 'https://serpapi.com/searches/67240bcafcd69e0952237cad/images/fe98535e38d7d1abe1939fd4682372142a8589081dd5750c251735c4ced3c7b1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.673363983631134}",,,,,,,,,,['neutral'],neutral,1
NCT04242498,"{'position': 1, 'link': 'https://www.ajmc.com/view/bimekizumab-elicits-clinically-meaningful-responses-in-moderate-to-severe-hidradenitis-suppurativa', 'title': 'Bimekizumab Elicits Clinically Meaningful Responses in Moderate to Severe Hidradenitis Suppurativa', 'source': 'AJMC', 'date': 'May 24, 2024', 'snippet': 'In newly published findings from the pivotal phase 3 BE HEARD I \n(NCT04242446) and BE HEARD II (NCT04242498) trials, bimekizumab was well...', 'thumbnail': 'https://serpapi.com/searches/67240be6400bd5fea40fd58f/images/d17c06d7aa86505bbf371933d2565d41faebf11dc1cfecfcc6a62f86fe2a73b6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6742416024208069}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/phase-3-data-analysis-presented-at-eadv-2023-showed-bimekizumab-achieved-high-thresholds-of-clinical-response-in-hidradenitis-suppurativa-301955218.html', 'title': 'Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa', 'source': 'PR Newswire', 'date': 'Oct 12, 2023', 'snippet': 'Bimekizumab treatment resulted in clinically meaningful improvements in \nHiSCR50 and the more stringent endpoints HiSCR75,...', 'thumbnail': 'https://serpapi.com/searches/67240be6400bd5fea40fd58f/images/d17c06d7aa86505be13c7a8c453101694f6c575530a4019345d671ed6b3cabd0.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6450156569480896}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03697109,"{'position': 1, 'link': 'https://cushingsdiseasenews.com/news/significant-benefits-seen-relacorilant-trial-cushings-patients/', 'title': 'Relacorilant shows significant benefits in Cushing’s patients in trial', 'source': ""Cushing's Disease News"", 'date': 'Apr 24, 2024', 'snippet': ""Relacorilant treatment is being seen to reduce high blood pressure and \nblood sugar levels in Cushing's syndrome patients in a Phase 3 trial."", 'thumbnail': 'https://serpapi.com/searches/67240bf7c05eb54546b68afa/images/18dbca316189c286beed5c6c09cf5802c07af0f18927b8d318239cf8ba3290ec.png', 'sentiment': 'positive', 'sentiment_prob': 0.8991308212280273}","{'position': 2, 'link': 'https://cushingsdiseasenews.com/news/enrollment-complete-relacorilant-phase-3-gradient-trial/', 'title': 'Enrollment complete in relacorilant Phase 3 GRADIENT trial', 'source': ""Cushing's Disease News"", 'date': 'Apr 3, 2024', 'snippet': ""The GRADIENT trial testing relacorilant in Cushing's caused by adrenal \nadenomas or adrenal hyperplasia has finished enrolling participants."", 'thumbnail': 'https://serpapi.com/searches/67240bf7c05eb54546b68afa/images/18dbca316189c28633269c4462b8cea31e151d515659dab9fe7a03b465bc3b35.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8997235894203186}","{'position': 3, 'link': 'https://cushingsdiseasenews.com/news/grace-phase-3-trial-relacorilant-nears-complete-enrollment/', 'title': 'GRACE Phase 3 trial of relacorilant nears complete enrollment', 'source': ""Cushing's Disease News"", 'date': 'Mar 3, 2023', 'snippet': ""Enrollment is nearly complete for the GRACE Phase 3 trial testing \nrelacorilant in people with Cushing's syndrome due to any underlying..."", 'thumbnail': 'https://serpapi.com/searches/67240bf7c05eb54546b68afa/images/18dbca316189c28664b71311ed37fd7b8cdce74dd2363319df928e50b6fb43d4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7574314475059509}","{'position': 4, 'link': 'https://cushingsdiseasenews.com/news/corcept-attributes-revenue-boost-better-recognition/', 'title': 'Corcept attributes its revenue boost to better recognition of Cushing’s', 'source': ""Cushing's Disease News"", 'date': 'Nov 3, 2023', 'snippet': ""Corcept Therapeutics is expected to earn nearly $500 million this year, due \nto the increased awareness about Cushing's,..."", 'thumbnail': 'https://serpapi.com/searches/67240bf7c05eb54546b68afa/images/18dbca316189c28687bd763f8fb812eb4338110b48d2565c9a9adf4571f35e66.png', 'sentiment': 'positive', 'sentiment_prob': 0.8713839650154114}","{'position': 5, 'link': 'https://cushingsdiseasenews.com/news/trial-data-cushings-treatments-relacorilant-korlym-due-next-year/', 'title': ""Trial data for Cushing's treatments relacorilant, Korlym due next year"", 'source': ""Cushing's Disease News"", 'date': 'Aug 4, 2023', 'snippet': ""The Phase 3 GRACE trial testing relacorilant in people with Cushing's \nsyndrome has completed enrollment and data from it is expected next year."", 'thumbnail': 'https://serpapi.com/searches/67240bf7c05eb54546b68afa/images/18dbca316189c28629c3ba35e68fd62db5d3d45442f7b6ed5486febcd6a248d6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9183561205863953}",,,,,,"['positive', 'neutral', 'neutral', 'positive', 'neutral']",neutral,1
NCT04831281,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/fosgonimeton-trial-parkinsons-dementia-have-fewer-participants/', 'title': 'Fosgonimeton trial in Parkinson’s dementia to have fewer participants', 'source': ""Parkinson's News Today"", 'date': 'Mar 29, 2023', 'snippet': ""Athira Pharma is completing its Phase 2 clinical trial of the experimental \ntherapy fosgonimeton in people with Parkinson's disease dementia or \ndementia with..."", 'thumbnail': 'https://serpapi.com/searches/67240c34a5d702d2fbdaac4f/images/d32b218adce7211b37e703dd2357fd9969bf6a261f02d0dd71cbee585925b684.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8284434676170349}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/fosgonimeton-shows-potential-dementia-treatment-athira/', 'title': 'Fosgonimeton shows potential as dementia treatment, Athira says', 'source': ""Parkinson's News Today"", 'date': 'Mar 13, 2024', 'snippet': ""Data presented at a neurological diseases conference support fosgonimeton's \npotential to treat dementia in Parkinson's and Alzheimer's."", 'thumbnail': 'https://serpapi.com/searches/67240c34a5d702d2fbdaac4f/images/d32b218adce7211b03416e9a11df6a7151405ab0e348931944a446ef99b50f8f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5620019435882568}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05006885,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/pemvidutide-lowers-liver-fat-masld-patients-clinical-trial/', 'title': 'Pemvidutide seen to lower liver fat in MASLD patients in Phase 1 trial', 'source': 'Liver Disease News', 'date': 'Aug 5, 2024', 'snippet': 'Pemvidutide lowered liver fat, inflammation, and body weight for overweight \nor obese adults with mild fatty liver disease in a Phase 1...', 'thumbnail': 'https://serpapi.com/searches/67240c3952a04ebc004722ba/images/61f61a097328bcfe1f7185f2228585c8ede4a539424f12454a52ce20dfe5ef20.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7375694513320923}",,,,,,,,,,['neutral'],neutral,1
NCT04638491,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-54223-5', 'title': 'A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer', 'source': 'Nature', 'date': 'Feb 13, 2024', 'snippet': 'This single-arm, multi-center clinical trial aimed to evaluate the safety, \ntolerability, DLT, recommended dose (RD), preliminary efficacy,...', 'thumbnail': 'https://serpapi.com/searches/67240c4290b57c018e6f3afd/images/480bed35aeaa1e83cc51e42880c7cdc8a1ddae2eb44c2a5899cbc4edd5dc4980.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7706957459449768}",,,,,,,,,,['neutral'],neutral,1
NCT05325775,"{'position': 1, 'link': 'https://pharmaceutical-journal.com/article/feature/managing-menopause-treating-hot-flushes-without-hormones', 'title': 'Managing menopause: treating hot flushes without hormones', 'source': 'The Pharmaceutical Journal', 'date': 'Nov 17, 2022', 'snippet': ""A new class of drugs is in clinical trials — neurokinin 3 receptor (NK3R) \nantagonists, which act on the brain's thermoregulatory centres to..."", 'thumbnail': 'https://serpapi.com/searches/67240c4290b57c018e6f3afe/images/86d5c656b44521a484b45507e5fbc5b3a02028a0c00734b7dca935c2429b4e33.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8747931718826294}",,,,,,,,,,['neutral'],neutral,1
NCT05338099,"{'position': 1, 'link': 'https://www.cgtlive.com/view/genetic-medicine-in-dmd-end-points-assessment-and-approvals', 'title': 'Genetic Medicine in DMD: End Points, Assessment, and Approvals', 'source': 'CGTLive®', 'date': 'Jun 16, 2023', 'snippet': 'CGTLive takes a look at challenges that have beset the first gene therapy \ncoming close to market for treating Duchenne muscular dystrophy in 2023.', 'thumbnail': 'https://serpapi.com/searches/67240c49cc48795386827569/images/489edfe535dbcea160b78c48879228a8ba965caf44e94b494e4b4ed7b7d3883a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9204220771789551}",,,,,,,,,,['neutral'],neutral,1
NCT01548404,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1314768', 'title': 'Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis', 'source': 'The New England Journal of Medicine', 'date': 'Jul 10, 2014', 'snippet': 'We performed randomized, double-blind, placebo-controlled trials involving \nadults who had moderate-to-severe atopic dermatitis despite treatment with \ntopical...', 'thumbnail': 'https://serpapi.com/searches/67240c4e98876dfdc6bb4a5c/images/b6793db9c20180b421869caf3f00b51e3ee188edd6d98ae7c9fffe5c3a5fe84f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8305745720863342}",,,,,,,,,,['neutral'],neutral,1
NCT00063206,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/randomized-double-blind-placebo-controlled-trial-desvenlafaxine/', 'title': 'A Randomized, Double-Blind, Placebo-Controlled Trial of Desvenlafaxine Succinate in Adult Outpatients With Major Depressive Disorder', 'source': 'Psychiatrist.com', 'date': 'Oct 21, 2023', 'snippet': 'This study evaluated the efficacy and tolerability of desvenlafaxine \nsuccinate (desvenlafaxine) in the treatment of major depressive disorder \n(MDD).', 'thumbnail': 'https://serpapi.com/searches/67240c60dda9d9effefd3292/images/840ac977cc8cbaa8415e603957199f692e7d089a47b2b4659a7bb8d1712965da.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8758249878883362}",,,,,,,,,,['neutral'],neutral,1
NCT05413161,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20240725869572/en/Kashiv-BioSciences-Announces-Completion-of-Enrollment-for-Phase-III-Clinical-Trial-of-ADL018-a-Biosimilar-Candidate-to-XOLAIR%C2%AE-omalizumab', 'title': 'Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR® (omalizumab)', 'source': 'Business Wire', 'date': 'Jul 25, 2024', 'snippet': 'Kashiv BioSciences, LLC today announced the completion of patient \nenrollment for its Phase III clinical trial of ADL018, a biosimilar \ncandidate to XOLAIR®.', 'thumbnail': 'https://serpapi.com/searches/67240c61361fd42d611f48cc/images/c588e59b68879d237980125042688cc005bcedfb624c500d3ab989d26acc45b1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8760218024253845}",,,,,,,,,,['neutral'],neutral,1
NCT03107793,"{'position': 1, 'link': 'https://ibdnewstoday.com/2020/02/24/stelara-leads-to-high-clinical-response-remission-in-severely-active-crohns-phase-3-study-shows/', 'title': ""Crohn's Patients Respond to Stelara, Results From Phase 3 Trial Show"", 'source': 'IBD News Today', 'date': 'Feb 24, 2020', 'snippet': ""Stelara treatment for severely active Crohn's disease resulted in high \nclinical response and clinical remission rates, according to 16-week..."", 'thumbnail': 'https://serpapi.com/searches/67240c653d629b3e007c6b00/images/da271521a09ea0e4ba083af30929bece8e12caa20447463df8e9e12b4a67c29a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7287803292274475}",,,,,,,,,,['neutral'],neutral,1
NCT03257267,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2112187', 'title': 'Survival with Cemiplimab in Recurrent Cervical Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Feb 9, 2022', 'snippet': 'Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, \nthe fully human programmed cell death 1 (PD-1)–blocking antibody...', 'thumbnail': 'https://serpapi.com/searches/67240cf3db3ac91c252ac325/images/bd5e32001c6706b6c7ac9c7007d8ba02e5f9bdb98d104334120d0d9c29f0a426.png', 'sentiment': 'negative', 'sentiment_prob': 0.8167092204093933}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/cemiplimab-as-second-line-monotherapy-confers-long-term-survival-benefit-in-recurrent-metastatic-cervical-cancer', 'title': 'Cemiplimab as Second-Line Monotherapy Confers Long-Term Survival Benefit in Recurrent/Metastatic Cervical Cancer', 'source': 'Cancer Network', 'date': 'Sep 10, 2022', 'snippet': 'Findings from long-term follow-up of the EMPOWER-Cervical 1 study \ndemonstrated that cemiplimab improved survival vs chemotherapy and...', 'thumbnail': 'https://serpapi.com/searches/67240cf3db3ac91c252ac325/images/bd5e32001c6706b6078d72fee7ea5e20523da106924e46daa080823fe669ea25.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7015032768249512}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT02469090,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/kynmobi-discontinued-us-canada-limited-use-sunovion/', 'title': 'Kynmobi to be discontinued in US and Canada due to limited use |...', 'source': ""Parkinson's News Today"", 'date': 'Jun 12, 2023', 'snippet': ""Kynmobi (apomorphine hydrochloride), an under-the-tongue therapy approved \nto help manage off episodes in Parkinson's disease, is being discontinued \nin the US..."", 'thumbnail': 'https://serpapi.com/searches/67240cfb4a4a1df3ffaf0675/images/6bd6fafa111b4d1e96b116188548c36f791c07514e4594dd2e3a5c4965851aca.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5540068745613098}",,,,,,,,,,['negative'],negative,0
NCT04279314,"{'position': 1, 'link': 'https://rettsyndromenews.com/news/long-term-daybue-led-continual-improvements-patients-data/', 'title': 'Long-term Daybue led to continual improvements in patients: Studies', 'source': 'Rett Syndrome News', 'date': 'Jul 24, 2024', 'snippet': 'Long-term treatment with Daybue (trofinetide) led to continual improvements \nin symptoms in people with Rett syndrome in extension studies,...', 'thumbnail': 'https://serpapi.com/searches/67240cf7bd7cf00dff1d5a9d/images/9789e79d4503fdad16d55d53ac06fabc3d27f7c09162e3fe4a30b0b3dfe2a4e2.png', 'sentiment': 'positive', 'sentiment_prob': 0.6373507380485535}",,,,,,,,,,['positive'],positive,1
NCT02729298,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.811247/full', 'title': 'The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges', 'source': 'Frontiers', 'date': 'Jun 28, 2023', 'snippet': 'AXL, along with MER and TYRO3, is a receptor tyrosine kinase from the TAM \nfamily. Although AXL itself is not thought to be a potent oncogenic \ndriver,...', 'thumbnail': 'https://serpapi.com/searches/67240d1b76585795dffb1f14/images/4d97b0f353f7688a5235ac7d5e980f36a538cd613ef8a3d228033d4e9c358ed6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9306911826133728}",,,,,,,,,,['neutral'],neutral,1
NCT04090684,"{'position': 1, 'link': 'https://alsnewstoday.com/news/als-combination-therapy-primec-receives-fdas-orphan-drug-designation-enters-clinical-trials/', 'title': ""ALS Combo Therapy PrimeC Granted FDA's Orphan Drug Status"", 'source': 'ALS News Today', 'date': 'Feb 12, 2020', 'snippet': 'PrimeC, a combination treatment by NeuroSense Therapeutics to slow down or \nhalt the progression of ALS, has received orphan drug status from...', 'thumbnail': 'https://serpapi.com/searches/67240c852c83d5b81af4c39e/images/08a8fd8bcec5ec0bdd8ccc833c6e2d5dddd59f7245eb71983b35a9ff8813f8fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8949474096298218}",,,,,,,,,,['neutral'],neutral,1
NCT02401347,"{'position': 1, 'link': 'https://www.nature.com/articles/s43018-022-00439-1', 'title': 'A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes', 'source': 'Nature', 'date': 'Oct 17, 2022', 'snippet': 'Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 \n(gBRCA1/2)-mutant advanced breast cancer, but its activity beyond...', 'thumbnail': 'https://serpapi.com/searches/67240c92310300962cf1b322/images/b1effafb884a5c42d1da1f9bf21b9a416dfdef2abb63c5d08805e1872b768425.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8995737433433533}",,,,,,,,,,['neutral'],neutral,1
NCT04030026,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/trevi-therapeutics-to-present-final-data-from-phase-2-trial-of-oral-nalbuphine-extended-release-for-chronic-cough-in-ipf-at-bts-winter-meeting-301660829.html', 'title': ""Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting"", 'source': 'PR Newswire', 'date': 'Oct 27, 2022', 'snippet': 'PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage \nbiopharmaceutical company developing an investigational therapy...', 'thumbnail': 'https://serpapi.com/searches/67240c93ce1e10a40aec62f0/images/0b96ed3fc020bc3ad6938aefc83abcfcf28778ce18f69024f1db0cec1ab1946e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9143315553665161}",,,,,,,,,,['neutral'],neutral,1
NCT01640067,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-019-1582-5', 'title': 'Transplantation of clinical-grade human neural stem cells reduces neuroinflammation, prolongs survival and delays disease progression in the SOD1 rats | Cell Death & Disease', 'source': 'Nature', 'date': 'Apr 25, 2019', 'snippet': 'Stem cells are emerging as a therapeutic option for incurable diseases, \nsuch as Amyotrophic Lateral Sclerosis (ALS).', 'thumbnail': 'https://serpapi.com/searches/67240c94f6aa534e9217e9a8/images/580c29a86b18194fd52a488bf4cd98c6281ee9b966197e2cc9fa8b80ded25284.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8031284213066101}",,,,,,,,,,['neutral'],neutral,1
NCT02030834,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1708566', 'title': 'Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas', 'source': 'The New England Journal of Medicine', 'date': 'Dec 10, 2017', 'snippet': 'Patients with diffuse large B-cell lymphoma or follicular lymphoma that is \nrefractory to or that relapses after immunochemotherapy and...', 'thumbnail': 'https://serpapi.com/searches/67240ca3cc2987a5b0417827/images/2d0b06589e42b9a14b87cf0b9d40a0061c9dd584178f65a848172f1a0574aa73.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8451695442199707}",,,,,,,,,,['neutral'],neutral,1
NCT02358031,"{'position': 1, 'link': 'https://www.onclive.com/view/dr-weiss-on-outcomes-with-versamune-hpv-plus-pembrolizumab-in-hpv16-hnscc', 'title': 'Dr Weiss on Outcomes With Versamune HPV Plus Pembrolizumab in HPV16+ HNSCC', 'source': 'OncLive', 'date': '2 weeks ago', 'snippet': 'Jared Weiss, MD, discusses outcomes with first-line Versamune HPV plus \npembrolizumab in HPV16–positive recurrent or metastatic HNSCC.', 'thumbnail': 'https://serpapi.com/searches/67240cb9272a8712a14a4efb/images/8fa4a7bdd884cf8e7093900ee39b7e82ff4631f4a6d43019c4043a32f195cf76.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9437682032585144}",,,,,,,,,,['neutral'],neutral,1
NCT03922308,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/news/ittp-thrombotic-purpura-recombitant-adamtd13-clinical-promise-treatment-risk/', 'title': 'Recombinant ADAMTS13 Shows Clinical Promise in iTTP', 'source': 'Hematology Advisor', 'date': 'Jul 6, 2023', 'snippet': 'Recombinant ADAMTS13 (rADAMTS13) appears to confer clinical benefit to \npatients with immune-mediated thrombotic thrombocytopenic purpura (iTTP), \naccording to...', 'thumbnail': 'https://serpapi.com/searches/67240cc15ddfba8fdaa1fc0d/images/769c77fd47bb54b641221461c743bc7672210c4b385302c5bbe663f72e01fa17.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7599084377288818}",,,,,,,,,,['positive'],positive,1
NCT01087788,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Cimzia', 'title': 'Certolizumab Pegol (Cimzia®)', 'source': 'UCB', 'date': 'Oct 12, 2018', 'snippet': 'Axial Spondyloarthritis, Certolizumab Pegol in Subjects With Active Axial \nSpondyloarthritis, Phase 3, AKS001 Completed, NCT01087762 · 2009-011719-19 \n· LINK', 'thumbnail': 'https://serpapi.com/searches/67240cce89055ecfb6d6151f/images/760d1398e5e5f6ef433147c6daec977936165d6990b8266b2a1c35af27272c43.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9130622744560242}",,,,,,,,,,['neutral'],neutral,1
NCT01162967,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1313122', 'title': ""Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease"", 'source': 'The New England Journal of Medicine', 'date': 'May 4, 2018', 'snippet': 'We performed a prospective, randomized clinical trial to assess the \nefficacy and safety of posaconazole as compared with the efficacy and \nsafety of...', 'thumbnail': 'https://serpapi.com/searches/67240d30b4b72d05f511ffb8/images/d4fe81c206f85e6fe4b1508fc3c2210c4c5bcfbb48174754df6d5c69cf4784e8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8674216866493225}",,,,,,,,,,['neutral'],neutral,1
NCT03926117,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/ziltivekimab-reduced-inflammatory-biomarkers-associated-with-atherosclerosis-in-people-with-chronic-kidney-disease-in-phase-2-trial-301292574.html', 'title': 'Ziltivekimab reduced inflammatory biomarkers associated with atherosclerosis in people with chronic kidney disease in phase 2 trial', 'source': 'PR Newswire', 'date': 'May 17, 2021', 'snippet': 'PRNewswire/ -- Novo Nordisk today presented results from RESCUE, a phase 2 \nrandomised, double-blind, placebo controlled clinical trial...', 'thumbnail': 'https://serpapi.com/searches/67240d4771b0e8fab8e07044/images/3a4f27e3ce2b62165027b8d2fd2b5e19c8b58a2510b9ca3ad7b04c6cbb0a0463.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8959338665008545}","{'position': 2, 'link': 'https://www.renalandurologynews.com/news/ziltivekimab-improves-anemia-parameters-in-chronic-kidney-disease-ckd/', 'title': 'Ziltivekimab Improves Anemia Parameters in Patients With CKD', 'source': 'Renal and Urology News', 'date': 'Feb 13, 2024', 'snippet': 'Ziltivekimab, a novel anti-IL-6 ligand antibody, improves \ninflammation-related anemia in patients with chronic kidney disease (CKD), \nnew study findings suggest.', 'thumbnail': 'https://serpapi.com/searches/67240d4771b0e8fab8e07044/images/3a4f27e3ce2b621653194c116f64609fffd04d77ce7144e56884b3e622077e9f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7796452045440674}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02298179,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0264410X20313712', 'title': 'The respiratory syncytial virus fusion protein-specific B cell receptor repertoire reshaped by post-fusion subunit vaccination', 'source': 'ScienceDirect.com', 'date': 'Nov 25, 2020', 'snippet': 'Respiratory syncytial virus (RSV) is the major cause of acute lower \nrespiratory illness in children of less than 5 years of age which...', 'thumbnail': 'https://serpapi.com/searches/67240d5471b0e8fa83649468/images/607ebfc9da9e947c88800119bcb1c3105886b885345262d92cddc68f05b2701a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6357153654098511}","{'position': 2, 'link': 'https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/article-1-challenges-developing-vaccine-respiratory-syncytial-virus.html', 'title': 'Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada, CCDR 46(4)', 'source': 'Canada.ca', 'date': 'Apr 2, 2020', 'snippet': 'A vaccine for respiratory syncytial virus (RSV) has been actively sought \nfor over 60 years due to the health impacts of RSV disease in infants.', 'thumbnail': 'https://serpapi.com/searches/67240d5471b0e8fa83649468/images/607ebfc9da9e947c844e9c78b91a65990242e064c8d1ce52e56c548c7bc953c6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.867176353931427}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT01829295,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/two-commonly-used-uveitis-drugs-perform-similarly-nih-funded-clinical-trial', 'title': 'Two commonly used uveitis drugs perform similarly in NIH-funded clinical trial', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Sep 10, 2019', 'snippet': 'Methotrexate and the more expensive mycophenolate mofetil performed \nsimilarly in a head-to-head clinical trial that compared the two drugs for \ntreating...', 'thumbnail': 'https://serpapi.com/searches/67240d605a461a841bce4836/images/63dcaeabda5748dcae111f02680e8640e856281f036a5184d675595b37cb50cf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8104745149612427}",,,,,,,,,,['neutral'],neutral,1
NCT02639260,"{'position': 1, 'link': 'https://www.researchgate.net/figure/ManNAc-phase-1-clinical-trial-inclusion-exclusion-criteria_tbl2_334008130', 'title': 'ManNAc phase 1 clinical trial inclusion/exclusion criteria', 'source': 'ResearchGate', 'date': 'Nov 11, 2019', 'snippet': 'Download scientific diagram | ManNAc phase 1 clinical trial \ninclusion/exclusion criteria from publication: Rationale and Design for a \nPhase 1 Study of...', 'thumbnail': 'https://serpapi.com/searches/67240d668e13c941ba96a6c0/images/16cbec9789fce828394cdbff3786789e54f8ce2a144b35827d39c2fd88823a74.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9265741109848022}",,,,,,,,,,['neutral'],neutral,1
NCT01349842,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-01227-3', 'title': 'Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial', 'source': 'Nature', 'date': 'Jan 21, 2021', 'snippet': 'CirCe01 trial aimed to assess the clinical utility of circulating tumour \ncell (CTC)-based monitoring in metastatic breast cancer (MBC) patients \nbeyond the...', 'thumbnail': 'https://serpapi.com/searches/67240d7b3c863da05c1816f6/images/89148d59a99dce0c0bad74b044acfc4af45f3c7efd0572f87fdc57ef4ffc6240.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9005095958709717}",,,,,,,,,,['neutral'],neutral,1
NCT00526474,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1200933', 'title': 'Vorapaxar in the Secondary Prevention of Atherothrombotic Events', 'source': 'The New England Journal of Medicine', 'date': 'Mar 24, 2012', 'snippet': 'We randomly assigned 26,449 patients who had a history of myocardial \ninfarction, ischemic stroke, or peripheral arterial disease to receive...', 'thumbnail': 'https://serpapi.com/searches/67240dacf7adbf2bb8d504da/images/dd3b7c204d62576b4b1e93a7e2580b1fff4752029ee73215b1a917a2a04d0683.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8535400032997131}",,,,,,,,,,['neutral'],neutral,1
NCT03456804,"{'position': 1, 'link': 'https://dailynews.ascopubs.org/do/novel-therapies-prostate-cancer', 'title': 'Novel Therapies for Prostate Cancer', 'source': 'ASCO Daily News', 'date': 'Mar 27, 2019', 'snippet': 'Article Highlights: An increased understanding of potential therapeutic \ntargets have led to a surge in clinical trials testing novel...', 'thumbnail': 'https://serpapi.com/searches/67240dc31ec32ff94367b561/images/ec4c81e269c2ba04d1146a4d056f70d3b9f1daab0e86533124c5f5553ad1a151.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7590967416763306}",,,,,,,,,,['neutral'],neutral,1
NCT03742037,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/cenerimod-shows-promise-sle-phase-2b-study-phase-3-begins/', 'title': 'Cenerimod Shows Promise for SLE in Phase 2b Study; Phase 3 Begins...', 'source': 'Lupus News Today', 'date': 'Dec 19, 2022', 'snippet': 'Treatment with cenerimod showed promising trends toward reducing disease \nactivity in systemic lupus erythematosus (SLE), especially in people with \nmore severe...', 'thumbnail': 'https://serpapi.com/searches/67240dcc81bab7b8fdf0d3a2/images/2ff37593b11c62b19ce4dd3479ee9dd6f3683b478480214f6f13b7f444e4d21f.png', 'sentiment': 'positive', 'sentiment_prob': 0.7075773477554321}","{'position': 2, 'link': 'https://sjogrenssyndromenews.com/news/oral-cenerimod-reduced-gland-inflammation-sjogrens-mouse-models/', 'title': 'In Sjögren’s Mouse Models, Oral Cenerimod Reduced Gland Inflammation', 'source': ""Sjogren's Syndrome News"", 'date': 'Jan 11, 2022', 'snippet': ""Cenerimod prevented immune cells from entering the salivary glands and \nreduced gland inflammation in two Sjögren's syndrome mouse models."", 'thumbnail': 'https://serpapi.com/searches/67240dcc81bab7b8fdf0d3a2/images/2ff37593b11c62b12a9c54c6b86ad4dccb636de623b5ae722fa049bc50598fc1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8783015608787537}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT03400800,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1912387', 'title': 'Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol', 'source': 'The New England Journal of Medicine', 'date': 'Mar 18, 2020', 'snippet': 'Previous studies suggest that inclisiran might provide sustained reductions \nin low-density lipoprotein (LDL) cholesterol levels with infrequent dosing.', 'thumbnail': 'https://serpapi.com/searches/67240e02690bb9743c555255/images/bb2d76ac8e7578b1fe61a6aad4bc7b35c05f79a317307443759150d53c8968c2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8475676774978638}","{'position': 2, 'link': 'https://www.empr.com/home/news/leqvio-approved-as-twice-yearly-injection-to-lower-ldl-c-in-high-risk-patients/', 'title': 'Leqvio Approved as Twice-Yearly Injection to Lower LDL-C in High-Risk Patients', 'source': 'Medical Professionals Reference', 'date': 'Dec 27, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Leqvio® (inclisiran) as \nan adjunct to diet and maximally tolerated statin therapy.', 'thumbnail': 'https://serpapi.com/searches/67240e02690bb9743c555255/images/bb2d76ac8e7578b1f84f342735693980ff594b025ee556f6a09a1b500747fd6e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5743811726570129}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01527513,"{'position': 1, 'link': 'https://epilepsynewstoday.com/2017/06/30/phase-2-trial-shows-zebinix-or-aptiom-does-not-impair-cognition-in-children-with-epilepsy/', 'title': 'Zebinix/Aptiom Does Not Reduce Cognition in Epileptic Children, Phase 2 Clinical Trial Indicates', 'source': 'Epilepsy News Today', 'date': 'Jun 30, 2017', 'snippet': 'The epilepsy therapy known as Zebinix in Europe and Aptiom in the United \nStates does not impair cognition in children, a Phase 2 clinical trial \nindicates.', 'thumbnail': 'https://serpapi.com/searches/67240e078b7ba7dc1574ceb2/images/9d5819cfcb0c753b14269460453b8b36fb5e4d1499b524826f2f06df45f1af87.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8400121927261353}",,,,,,,,,,['neutral'],neutral,1
NCT04358731,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2013615', 'title': 'Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers', 'source': 'The New England Journal of Medicine', 'date': 'Jun 2, 2021', 'snippet': 'We conducted a phase 2, observer-blinded, randomized, controlled trial \ninvolving Malian children 12 to 16 months of age.', 'thumbnail': 'https://serpapi.com/searches/67240e1bbb55ff6f9d2231da/images/9a695c7ce93ce60cc11c7a46b5429edfa7b59f66416e8d55d42943279a0727d4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9085061550140381}",,,,,,,,,,['neutral'],neutral,1
NCT04157751,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01659-1', 'title': 'The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial', 'source': 'Nature', 'date': 'Feb 28, 2022', 'snippet': 'The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk \nof cardiovascular death or heart failure hospitalization in...', 'thumbnail': 'https://serpapi.com/searches/67240e24db3ac91c252ac372/images/06514122031c80bad69fd3adaeca4b419d37f5c6a14b242b30b8ed28efe0179f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8560826182365417}",,,,,,,,,,['neutral'],neutral,1
NCT03708718,"{'position': 1, 'link': 'https://www.nature.com/articles/s41584-022-00765-9', 'title': 'Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need', 'source': 'Nature', 'date': 'Mar 15, 2022', 'snippet': ""The rapidly progressive painful, itchy skin tightening that characterizes \ndcSSc is the symptom that has the greatest effect on patients' quality of \nlife."", 'thumbnail': 'https://serpapi.com/searches/67240e3f96a329686adfbb8f/images/0ad5b467fa69e9b2307e4bf4cf68823d4a74e6830bebd0212ae8ec2c2a367106.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.81516033411026}",,,,,,,,,,['negative'],negative,0
NCT01343043,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-32491-x', 'title': 'Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma', 'source': 'Nature', 'date': 'Sep 8, 2022', 'snippet': 'This post-hoc analysis identifies associations of response to lete-cel with \nlymphodepleting chemotherapy regimen (LDR), product attributes, cell \nexpansion,...', 'thumbnail': 'https://serpapi.com/searches/67240e437a12fd607b5970cf/images/e5017fb4e6bc8e86e05d8b528c3395751a886d4d84e4dae6dc02bc7929542b16.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9031964540481567}",,,,,,,,,,['neutral'],neutral,1
NCT05107115,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/sanofi-gears-up-for-approval-of-its-btk-inhibitor-meets-phase-iii-endpoint/', 'title': 'Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint', 'source': 'Clinical Trials Arena', 'date': 'Apr 23, 2024', 'snippet': ""Sanofi's rilzabrutinib met the primary endpoint in the Phase III persistent \nor chronic immune thrombocytopenia trial."", 'thumbnail': 'https://serpapi.com/searches/67240e4c6531cb6e7f950a0f/images/ba03d915b107bbaf42b845cdcba9ddc5f5c87fb97344a13af34fc92ba664b61c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6001195311546326}",,,,,,,,,,['neutral'],neutral,1
NCT03895801,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.888816/full', 'title': 'Complement Inhibition in ANCA-Associated Vasculitis', 'source': 'Frontiers', 'date': 'Jul 7, 2022', 'snippet': 'Activation of alternative complement pathway plays an important role in the \npathogenesis of AAV. Avacopan (C5a receptor inhibitor) was demonstrated to \nhave at...', 'thumbnail': 'https://serpapi.com/searches/67240e4dc821274057f71743/images/cc8f7dc369d5e9d0c169bd2e08b6c7765476103c32152ade7ebd27edfa475606.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7718417048454285}",,,,,,,,,,['neutral'],neutral,1
NCT02792231,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1917246', 'title': 'Ofatumumab versus Teriflunomide in Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Aug 5, 2020', 'snippet': 'Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively \ndepletes B cells. Teriflunomide, an oral inhibitor of pyrimidine...', 'thumbnail': 'https://serpapi.com/searches/67240e60d771bdf678dc5744/images/a772ff9c88cff77bf8ce62e09564b4f0487596032eefb7acf90ed9171c23605d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8694962859153748}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/06/27/ms-patients-kesimpta-4-years-saw-no-disease-activity-trials/', 'title': 'MS Patients on Kesimpta for 4 Years Saw No Disease Activity in Trials', 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 28, 2022', 'snippet': 'ALITHIOS trial participants who started on Kesimpta were about four times \nmore likely to have no MS symptoms than those starting on Aubagio.', 'thumbnail': 'https://serpapi.com/searches/67240e60d771bdf678dc5744/images/a772ff9c88cff77bf11ac9193500902b128801ae53d022a575de59081412cdbf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6928902268409729}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/07/06/fewer-ms-relapses-brain-lesions-seen-up-5-years-with-kesimpta/', 'title': 'Fewer MS relapses, brain lesions seen for up to 5 years with Kesimpta', 'source': 'Multiple Sclerosis News Today', 'date': 'Jul 6, 2023', 'snippet': 'In people with relapsing MS, treatment with Kesimpta resulted in reductions \nin relapse rates and brain lesions, and increases in NEDA-3.', 'thumbnail': 'https://serpapi.com/searches/67240e60d771bdf678dc5744/images/a772ff9c88cff77b704afbb1c0eb06a69ebf4f223f9f7e95c73fec2da1aa0e38.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8175560235977173}","{'position': 4, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2020/09/08/novartis-data-at-actrims-ectrims-highlight-the-strength-of-leading-multiple-sclerosis-ms-portfolio-with-life-changing-therapies-for-people-across-the-ms-spectrum/', 'title': '#MSVirtual2020 – Novartis to Present Latest Data on Kesimpta, Mayzent and Gilenya', 'source': 'Multiple Sclerosis News Today', 'date': 'Sep 11, 2020', 'snippet': 'Novartis will present latest study findings on its approved therapies for \nrelapsing MS at the MSVirtual2020 meeting running Sept. 11 to 13..', 'thumbnail': 'https://serpapi.com/searches/67240e60d771bdf678dc5744/images/a772ff9c88cff77bc2aec63cdee2b7ce475d1b310e942198e9a696c00cc9c9de.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.857699453830719}","{'position': 5, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/10/25/iv-ofatumumab-reduces-relapses-but-not-better-than-kesimpta/', 'title': 'IV Ofatumumab Reduces Relapses in MS, But Not Better Than Kesimpta', 'source': 'Multiple Sclerosis News Today', 'date': 'Oct 25, 2022', 'snippet': 'An into-the-vein formulation of ofatumumab reduced relapse rates for MS \npatients, but not by as much as the approved under-the-skin...', 'thumbnail': 'https://serpapi.com/searches/67240e60d771bdf678dc5744/images/a772ff9c88cff77b047d91ae9f67ade6d262fd78270fcf80d148331d51ca4ce9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5159135460853577}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT00105443,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0708857', 'title': 'Sorafenib in Advanced Hepatocellular Carcinoma', 'source': 'The New England Journal of Medicine', 'date': 'Apr 28, 2018', 'snippet': 'No effective systemic therapy exists for patients with advanced \nhepatocellular carcinoma. A preliminary study suggested that sorafenib, an \noral multikinase...', 'thumbnail': 'https://serpapi.com/searches/67240e6496a32968339e6251/images/0ce2af43f79dd96563bf06407eb2e19a51e2143ad9106354f164d4d7ff945f69.png', 'sentiment': 'negative', 'sentiment_prob': 0.8031277060508728}",,,,,,,,,,['negative'],negative,0
NCT02721069,"{'position': 1, 'link': 'https://dravetsyndromenews.com/news/fda-approves-valtoco-to-treat-seizure-clusters-in-epilepsy-patients-6-and-older/', 'title': 'FDA Approves Valtoco Nasal Spray to Treat Seizure Clusters in Epilepsy Patients, 6 and Older', 'source': 'Dravet Syndrome News', 'date': 'Jan 28, 2020', 'snippet': 'The United States Food and Drug Administration (FDA) has approved Valtoco \n(diazepam nasal spray) as a rescue treatment for acute, repetitive seizures \n(seizure...', 'thumbnail': 'https://serpapi.com/searches/67240e7e3c9575b4e24ead82/images/3455b0060bee105bd2e6fa9f0366eea0b81c7699b499c4085546d7f1c7d0bcd9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8092251420021057}",,,,,,,,,,['neutral'],neutral,1
NCT01715285,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1704174', 'title': 'Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jun 4, 2017', 'snippet': 'Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus \nprednisone is indicated for metastatic castration-resistant prostate cancer.', 'thumbnail': 'https://serpapi.com/searches/67240e8d9936882cebcb8112/images/e910dc00e8cc12e94eee3093be7276d409beaecc326acd242ba1d41590035bb2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5481367707252502}","{'position': 2, 'link': 'https://ascopubs.org/doi/10.1200/JCO.19.00799', 'title': 'ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Jul 22, 2019', 'snippet': 'ARCHES (ClinicalTrials.gov identifier: NCT02677896) is a multinational, \ndouble-blind, phase III trial, wherein 1,150 men with mHSPC were...', 'thumbnail': 'https://serpapi.com/searches/67240e8d9936882cebcb8112/images/e910dc00e8cc12e95e410a459b655aab7b8961a4d6010e7cab2bf15c91783aba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9199913144111633}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01764633,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1500858', 'title': 'Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events', 'source': 'The New England Journal of Medicine', 'date': 'Mar 15, 2015', 'snippet': 'Evolocumab, a monoclonal antibody that inhibits proprotein convertase \nsubtilisin–kexin type 9 (PCSK9), significantly reduced low-density...', 'thumbnail': 'https://serpapi.com/searches/67240e96e281ee90d3f2acd5/images/58fd87c8eedce350b686500358558ab910333a030a524bad17b6189493357d95.png', 'sentiment': 'neutral', 'sentiment_prob': 0.796350359916687}",,,,,,,,,,['neutral'],neutral,1
NCT04797650,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/ctp-543-alopecia-areata-thrive-aa2-trial-results/', 'title': 'Study Investigating Oral JAK Inhibitor for Alopecia Areata Meets Endpoint', 'source': 'Medical Professionals Reference', 'date': 'Aug 1, 2022', 'snippet': 'Positive topline results were announced from a second phase 3 trial \nevaluating CTP-543 in adults with moderate to severe alopecia areata.', 'thumbnail': 'https://serpapi.com/searches/67240eae0053c7922c4d81d7/images/a8c346acb16f4d094762c096c56078151328442f220b38e8f6aee635c57b507c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8479276895523071}",,,,,,,,,,['neutral'],neutral,1
NCT03920293,"{'position': 1, 'link': 'https://myastheniagravisnews.com/news/health-canada-approves-ultomiris-achr-positive-gmg/', 'title': 'Health Canada Approves Ultomiris for AChR-positive gMG', 'source': 'Myasthenia Gravis News', 'date': 'Jan 19, 2023', 'snippet': 'Canada has approved Ultomiris for adults with generalized myasthenia gravis \nwho are positive for antibodies against the acetylcholine...', 'thumbnail': 'https://serpapi.com/searches/67240eb2163bdf817b30ef07/images/0b9fa6266e4428b4d23eef25f144017cc5a52f6b09715c5b2dd0ae643c4c736d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5866038203239441}",,,,,,,,,,['neutral'],neutral,1
NCT03112174,"{'position': 1, 'link': 'https://dailynews.ascopubs.org/do/sympatico-results-support-concurrent-ibrutinib-and-venetoclax-tp53--mutated-mantle-cell', 'title': 'SYMPATICO Results Support Concurrent Ibrutinib and Venetoclax in TP53-Mutated Mantle Cell Lymphoma', 'source': 'ASCO Daily News', 'date': 'Jun 1, 2024', 'snippet': 'Results from the phase 3 SYMPATICO study conducted in patients with MCL \nreveal encouraging efficacy outcomes with concurrent ibrutinib and \nvenetoclax.', 'thumbnail': 'https://serpapi.com/searches/67240eb92407935cc5390db8/images/5cf54f410be74b6c673fd6adaa2b637e80e8dc134750e74b9411c582377cc032.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6122835278511047}",,,,,,,,,,['neutral'],neutral,1
NCT04102579,"{'position': 1, 'link': 'https://huntingtonsdiseasenews.com/news/ingrezza-effects-chorea-stronger-over-time-trial-analysis/', 'title': 'Ingrezza’s effects on chorea become stronger over time: Trial analysis', 'source': ""Huntington's Disease News"", 'date': 'Jun 11, 2024', 'snippet': ""Ingrezza's effects on Huntington's-associated chorea appear stronger over \ntime, according to an analysis of the Phase 3 KINECT-HD trial."", 'thumbnail': 'https://serpapi.com/searches/67240ec31397ba2adff57b8e/images/21af894216da2367dbb70e123b5ccaac9dc59ca87fd8124166f67fd6ab3aa2a5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6118873953819275}","{'position': 2, 'link': 'https://www.empr.com/home/news/ingrezza-gains-approval-for-huntington-disease-chorea/', 'title': 'Ingrezza Gains Approval for Huntington Disease Chorea', 'source': 'Medical Professionals Reference', 'date': 'Aug 21, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) \nfor the treatment of adults with chorea associated with Huntington disease.', 'thumbnail': 'https://serpapi.com/searches/67240ec31397ba2adff57b8e/images/21af894216da23670939ed4264a4c0ebdf09429f02b9e887f40a2ba9b4130b03.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7544659376144409}","{'position': 3, 'link': 'https://huntingtonsdiseasenews.com/news/fda-approves-ingrezza-sprinkle-treat-huntingtons-chorea-adults/', 'title': 'FDA approves Ingrezza Sprinkle to treat chorea in Huntington’s', 'source': ""Huntington's Disease News"", 'date': 'May 1, 2024', 'snippet': ""The U.S. Food and Drug Administration (FDA) has approved Neurocrine \nBiosciences' oral granules formulation of Ingrezza (valbenazine) — called..."", 'thumbnail': 'https://serpapi.com/searches/67240ec31397ba2adff57b8e/images/21af894216da2367a3f0497036b627180b2916862204480b8c3afcc27c8c1d71.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8127304315567017}","{'position': 4, 'link': 'https://huntingtonsdiseasenews.com/news/chorea-severity-remains-reduced-1-year-ingrezza-trial/', 'title': 'Chorea severity remains reduced after about 1 year on Ingrezza: Trial', 'source': ""Huntington's Disease News"", 'date': 'Nov 14, 2023', 'snippet': ""Nearly a year of Ingrezza treatment led to significant reductions in \nuncontrolled movements known as chorea in a Huntington's Phase 3 trial."", 'thumbnail': 'https://serpapi.com/searches/67240ec31397ba2adff57b8e/images/21af894216da2367a212575e8e5a32d4f275c9fd4cdc75a118e43f0703c695e4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7346864938735962}","{'position': 5, 'link': 'https://huntingtonsdiseasenews.com/news/granulated-ingrezza-huntingtons-chorea-get-fda-review/', 'title': 'FDA to review application for granulated form of Ingrezza', 'source': ""Huntington's Disease News"", 'date': 'Sep 19, 2023', 'snippet': ""The US Food and Drug Administration (FDA) will review Neurocrine \nBiosciences' application of a new oral granule formulation of Ingrezza \n(valbenazine) for..."", 'thumbnail': 'https://serpapi.com/searches/67240ec31397ba2adff57b8e/images/21af894216da2367e285849069f2fe11b90e3e0f44c9cfccd449838f717a94e4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9428393840789795}","{'position': 6, 'link': 'https://huntingtonsdiseasenews.com/news/potential-chorea-treatment-valbenazine-under-review-us/', 'title': 'Potential Chorea Treatment Valbenazine Under Review in US |...', 'source': ""Huntington's Disease News"", 'date': 'Jan 3, 2023', 'snippet': ""The U.S. Food and Drug Administration is reviewing an application that \nseeks the approval of valbenazine for Huntington's-associated chorea."", 'thumbnail': 'https://serpapi.com/searches/67240ec31397ba2adff57b8e/images/21af894216da2367b3f995a9473b1fac37361cc7af46d4e4f0842d29a7c83df4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9441635608673096}","{'position': 7, 'link': 'https://huntingtonsdiseasenews.com/news/kinect-hd2-study-oral-valbenazine-chorea-enrolling/', 'title': ""Huntington's Patients Sought for KINECT-HD2 Study of Oral Valbenazine"", 'source': ""Huntington's Disease News"", 'date': 'Dec 7, 2021', 'snippet': ""The Huntington Study Group seeks 30 patients to join KINECT-HD2, a U.S. and \nCanada study of valbenazine capsules for chorea in Huntington's."", 'thumbnail': 'https://serpapi.com/searches/67240ec31397ba2adff57b8e/images/21af894216da2367ebaca8959a714c584e6adff53da44eba6ea72bf8bbdd8efa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9417083263397217}",,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03905330,"{'position': 1, 'link': 'https://www.empr.com/home/news/livmarli-approved-for-cholestatic-pruritus-in-progressive-familial-intrahepatic-cholestasis/', 'title': 'Livmarli Approved for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis', 'source': 'Medical Professionals Reference', 'date': 'Mar 14, 2024', 'snippet': 'The Food and Drug Administration (FDA) has approved Livmarli (maralixibat) \nfor the treatment of cholestatic pruritus in patients 5 years of age and \nolder with...', 'thumbnail': 'https://serpapi.com/searches/67240ec471b0e8fa836494b8/images/296e858e3c5bbeb06a0ebe932483b434acbd9a3e081bceeb24eb6bc130daadeb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8471744656562805}","{'position': 2, 'link': 'https://liverdiseasenews.com/news/dramatic-responses-seen-livmarli-pfic-trial-mirum-exec-says/', 'title': 'Livmarli led to ‘dramatic responses’ in PFIC trial, Mirum exec says', 'source': 'Liver Disease News', 'date': 'Mar 26, 2024', 'snippet': 'In an interview, Mirum CEO Chris Peetz called patient responses ""dramatic"" \nfor now-approved therapy Livmarli in the broadest-ever PFIC...', 'thumbnail': 'https://serpapi.com/searches/67240ec471b0e8fa836494b8/images/296e858e3c5bbeb042a854304e9c4e6b77b039dbea51b38834e7121137d5cdd5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7903364300727844}","{'position': 3, 'link': 'https://liverdiseasenews.com/news/mirums-livmarli-approved-us-pfic-patients-ages-5-older/', 'title': ""Mirum's Livmarli approved in US for PFIC patients ages 5 and older"", 'source': 'Liver Disease News', 'date': 'Mar 13, 2024', 'snippet': ""The US Food and Drug Administration (FDA) has approved Mirum \nPharmaceuticals' Livmarli (maralixibat) to reduce pruritus, or itching, in \nadults and children, 5..."", 'thumbnail': 'https://serpapi.com/searches/67240ec471b0e8fa836494b8/images/296e858e3c5bbeb04e6533d292dce7500d38621ba8a054e002467c01900bcf59.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6755688786506653}","{'position': 4, 'link': 'https://liverdiseasenews.com/news/livmarli-now-approved-eu-treat-pfic-adults-children/', 'title': 'Livmarli now approved in EU to treat adults, children with PFIC', 'source': 'Liver Disease News', 'date': 'Jul 9, 2024', 'snippet': ""Mirum's oral therapy Livmarli is now approved in the European Union for \nadults and children ages 3 months and older with PFIC."", 'thumbnail': 'https://serpapi.com/searches/67240ec471b0e8fa836494b8/images/296e858e3c5bbeb0d8ca524e9078614af334a108ea67cc387436005f78a95234.png', 'sentiment': 'positive', 'sentiment_prob': 0.6278282403945923}",,,,,,,"['neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT02935712,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-019-08852-4', 'title': 'Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes', 'source': 'Nature', 'date': 'Feb 20, 2019', 'snippet': 'Chemically modified mRNA is an efficient, biocompatible modality for \ntherapeutic protein expression. We report a first-time-in-human study...', 'thumbnail': 'https://serpapi.com/searches/67240ed4069e571284ade401/images/0626027473c58e1f225087ee596ea333710da8d8dccf57ebe8498c74b98ad4f6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7369531393051147}","{'position': 2, 'link': 'https://www.sciencedirect.com/science/article/pii/S2405844024030020', 'title': 'The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases', 'source': 'ScienceDirect.com', 'date': 'Mar 15, 2024', 'snippet': 'This review aims to elucidate the advancements in the clinical applications \nof mRNAs for addressing significant health-related challenges such as \ncancer,...', 'thumbnail': 'https://serpapi.com/searches/67240ed4069e571284ade401/images/0626027473c58e1f9564bb444408ffc9846cb0e9eb4496a7a7f1419abbf898d8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8580176830291748}","{'position': 3, 'link': 'https://www.nature.com/articles/s41573-021-00355-6', 'title': 'VEGFA mRNA for regenerative treatment of heart failure', 'source': 'Nature', 'date': 'Dec 6, 2021', 'snippet': ""The first potential 'secreted protein' mRNA drug — designed to deliver \nvascular endothelial growth factor A (VEGF-A) to induce regenerative..."", 'thumbnail': 'https://serpapi.com/searches/67240ed4069e571284ade401/images/0626027473c58e1f3e3454b3747c8229833fc82afb2a0d8127ce3313c1130f4c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8303226828575134}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02962167,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.953410/full', 'title': 'Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements', 'source': 'Frontiers', 'date': 'Feb 15, 2024', 'snippet': 'Oncolytic viruses (OVs) have been gaining attention in the pharmaceutical \nindustry as a novel immunotherapeutic and therapeutic adjuvant due to \ntheir...', 'thumbnail': 'https://serpapi.com/searches/67240ee0ee677fc047a90932/images/5427a21a6ef66ac06c25efebc7e76cdca2c54c0fb24bfa9ac5791772b15b536c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7581920623779297}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/mef2.61', 'title': 'Oncolytic viral therapy as promising immunotherapy against glioma - Hu - 2023 - MedComm – Future Medicine', 'source': 'Wiley Online Library', 'date': 'Oct 16, 2023', 'snippet': 'Multiple preclinical experiments and clinical trials have shown that \noncolytic viruses (OVs) exhibit good antitumor activity in treating...', 'thumbnail': 'https://serpapi.com/searches/67240ee0ee677fc047a90932/images/5427a21a6ef66ac05f7108013a711720a75ef7284b8641965bb0757a2510961d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5113049745559692}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01537926,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.119.313569', 'title': 'Novel Therapies for Prevention and Early Treatment of Cardiomyopathies:', 'source': 'American Heart Association Journals', 'date': 'May 23, 2019', 'snippet': 'Heritable cardiomyopathies are a class of heart diseases caused by \nvariations in a number of genetic loci. Genetic variants on one allele...', 'thumbnail': 'https://serpapi.com/searches/67240ee3d169152357052468/images/b26c94d891d16eacc4d112874e68df934ac3e56e86b7189a31be522ce3c0968d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6038366556167603}",,,,,,,,,,['neutral'],neutral,1
NCT04631016,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-36642-y', 'title': 'Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction', 'source': 'Nature', 'date': 'Jun 17, 2023', 'snippet': 'Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive \ninflammatory responses following tissue damage or infection and is a...', 'thumbnail': 'https://serpapi.com/searches/67240ef83ad34db6ba164f0d/images/e643e8e6a23448d455b25231fe5187d5888c4a8597eee13393149e36a640813a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8236860036849976}",,,,,,,,,,['neutral'],neutral,1
NCT02913482,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2009965', 'title': 'Risdiplam in Type 1 Spinal Muscular Atrophy', 'source': 'The New England Journal of Medicine', 'date': 'Feb 24, 2021', 'snippet': 'In infants with type 1 spinal muscular atrophy, treatment with oral \nrisdiplam led to an increased expression of functional SMN protein in the \nblood.', 'thumbnail': 'https://serpapi.com/searches/67240f260197dd4dd75e85de/images/36bca74b50ae808a3de0be00d64720797cef31492408629f25853315425b1b3e.png', 'sentiment': 'negative', 'sentiment_prob': 0.5097610950469971}","{'position': 2, 'link': 'https://smanewstoday.com/news/british-columbia-funds-evrysdi-canadian-province-sma-patients/', 'title': 'Evrysdi for SMA Patients in British Columbia Being Offered at No Cost', 'source': 'SMA News Today', 'date': 'Feb 21, 2022', 'snippet': 'The provincial government of British Columbia will cover the cost of \nEvrysdi (risdiplam), the oral spinal muscular atrophy (SMA) therapy \napproved by Health...', 'thumbnail': 'https://serpapi.com/searches/67240f260197dd4dd75e85de/images/36bca74b50ae808ac4a0b2a620092558945127b966709c08885d3a1ab927c79f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9134345054626465}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT02435849,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa1709866', 'title': 'Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'May 2, 2018', 'snippet': 'In a single-center phase 1–2a study, the anti-CD19 chimeric antigen \nreceptor (CAR) T-cell therapy tisagenlecleucel produced high rates of \ncomplete remission...', 'thumbnail': 'https://serpapi.com/searches/67240f44a3657a0b1b93349a/images/376bd3c636d57558885b411cee1292f6a893db10b831279f75fd21e836f3ce6e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8682266473770142}",,,,,,,,,,['neutral'],neutral,1
NCT01253629,"{'position': 1, 'link': 'https://fragilexnewstoday.com/news/decisional-intervention-may-be-beneficial-for-parents-of-fxs-chidren/', 'title': 'Information, Support May Persuade Parents of FXS Children to Join Trials', 'source': 'Fragile X News Today', 'date': 'Feb 19, 2019', 'snippet': 'Parents of children with intellectual disability, in particular those \naffected by fragile X syndrome, may benefit from more information and \ndedicated support.', 'thumbnail': 'https://serpapi.com/searches/67240f43671f3f6cb4ef6937/images/c356a640c4ad8b7a51ea8b83e5d7a580497becbfaf879a8f0ff74febb122b2d7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6160650849342346}",,,,,,,,,,['neutral'],neutral,1
NCT03493854,"{'position': 1, 'link': 'https://www.targetedonc.com/view/pharmacokinetics-of-subcutaneous-her2-therapy-noninferior-in-bc', 'title': 'Pharmacokinetics of Subcutaneous HER2 Therapy Noninferior in BC', 'source': 'Targeted Oncology', 'date': 'Feb 29, 2024', 'snippet': 'Rebecca A. Shatsky, MD, discusses the outcomes of the phase 3 FeDeriCa \nstudy of subcutaneous trastuzumab and pertuzumab in patients with...', 'thumbnail': 'https://serpapi.com/searches/67240f47f933885255e2a916/images/ef0c2bb4f847fbca9a4d6e64087685ea476b2a92948f6ba54c99c746a395711a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9377185702323914}",,,,,,,,,,['neutral'],neutral,1
NCT02578680,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.22.01989', 'title': 'Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Feb 21, 2023', 'snippet': 'Clinical trials frequently include multiple end points that mature at \ndifferent times. The initial report, typically on the based on the...', 'thumbnail': 'https://serpapi.com/searches/67240f49be1497febb69e31c/images/69fa963e7d62a308b9341e1c04f2efa2dd4a35a06de2129658bb6df91b97b5e1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9086083769798279}",,,,,,,,,,['neutral'],neutral,1
NCT00328653,"{'position': 1, 'link': 'https://www.empr.com/home/news/verkazia-approved-for-vernal-keratoconjunctivitis/', 'title': 'Verkazia Approved for Vernal Keratoconjunctivitis', 'source': 'Medical Professionals Reference', 'date': 'Jun 24, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Verkazia™ (cyclosporine \nophthalmic emulsion) 0.1% for the treatment of vernal...', 'thumbnail': 'https://serpapi.com/searches/67240f4cf79a01c1cc6c4326/images/a8e20ae82a3fed7ff67dcf0d0bdaec685da2f9db0c0e4d4c285c37580a183da2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.849105179309845}",,,,,,,,,,['neutral'],neutral,1
NCT03225651,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-49902-8', 'title': 'Inflammatory mediators drive neuroinflammation in autism spectrum disorder and cerebral palsy', 'source': 'Nature', 'date': 'Dec 18, 2023', 'snippet': 'Inflammation conditions are associated with autism spectrum disorder (ASD) \nand cerebral palsy (CP), primarily observed in the peripheral...', 'thumbnail': 'https://serpapi.com/searches/67240f4ef7adbf2b84005e1c/images/813c123c77574b898b8dfb8f4d6380bd0dbfacef529cd296798343757b60a2e8.png', 'sentiment': 'negative', 'sentiment_prob': 0.7171703577041626}",,,,,,,,,,['negative'],negative,0
NCT01303172,"{'position': 1, 'link': 'https://www.nature.com/articles/bjc2016271', 'title': 'Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer', 'source': 'Nature', 'date': 'Sep 6, 2016', 'snippet': 'Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, \nphase II, first-line, proof of concept study (NCT01303172),...', 'thumbnail': 'https://serpapi.com/searches/67240f57b4b72d05f5120035/images/cae5d65a2fc2a1089a139f78cce867d933d438503a2e1fedde5609711fe2ada7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8937485814094543}",,,,,,,,,,['neutral'],neutral,1
NCT02062060,"{'position': 1, 'link': 'https://www.empr.com/home/news/xeglyze-abametapir-head-lice-treatment-approved/', 'title': 'Head Lice Treatment Xeglyze Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Jul 29, 2020', 'snippet': ""The Food and Drug Administration (FDA) has approved Xeglyze™ (abametapir; \nDr. Reddy's Laboratories) for the treatment of head lice..."", 'thumbnail': 'https://serpapi.com/searches/67240fc998876dfdc6bb4b43/images/4004f09e3131124d1016e4a00e0e6d8bd9d9a3069873c40349e7ac690644849d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7157039046287537}",,,,,,,,,,['neutral'],neutral,1
NCT05438602,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2309002', 'title': 'Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Jul 17, 2024', 'snippet': 'Clinical trials of treatments for coronavirus disease 2019 (Covid-19) have \nnot shown a significant benefit of postexposure prophylaxis.', 'thumbnail': 'https://serpapi.com/searches/67240f9c5c7cb9f0907716d8/images/a79be84c4a5721f7343a5d20ec1996a512f2690515524418742eeef297b699ce.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5386345982551575}","{'position': 2, 'link': 'https://pharmaceutical-journal.com/article/ld/webinar-covid-19-antivirals-where-are-we-now', 'title': 'Webinar: COVID-19 antivirals — where are we now?', 'source': 'The Pharmaceutical Journal', 'date': 'Sep 25, 2023', 'snippet': 'A panel of experts discuss the use of antivirals for the treatment of \nCOVID-19, with consideration for the current landscape and future variants.', 'thumbnail': 'https://serpapi.com/searches/67240f9c5c7cb9f0907716d8/images/a79be84c4a5721f7bded451cd37bf44fdc415335d3140e77d149c48adadd723c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9275721311569214}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01862926,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00359-9/fulltext', 'title': 'Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial', 'source': 'The Lancet', 'date': 'Nov 11, 2022', 'snippet': 'Rituximab is often used as rescue therapy in interstitial lung disease \n(ILD) associated with connective tissue disease (CTD),...', 'thumbnail': 'https://serpapi.com/searches/67240fa514c31ed5ff5a4893/images/d42b26e5f95eeab7227dceffc54bde8b1e089519f3406a79054de3545443b857.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9003040194511414}",,,,,,,,,,['neutral'],neutral,1
NCT02564900,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1914510', 'title': 'Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Dec 11, 2019', 'snippet': 'Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of \nan anti-HER2 (human epidermal growth factor receptor 2) antibody, a \ncleavable...', 'thumbnail': 'https://serpapi.com/searches/67240fab08abe42058644364/images/22b746555f0a1e6c2ea9b920b2d1c399a69e293711c3f9a7fa29f0ba04f44edf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8794534802436829}","{'position': 2, 'link': 'https://www.nature.com/articles/s41598-024-61957-9', 'title': 'HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer', 'source': 'Nature', 'date': 'May 27, 2024', 'snippet': 'Many targeted cancer therapies rely on biomarkers assessed by scoring of \nimmunohistochemically (IHC)-stained tissue, which is subjective,...', 'thumbnail': 'https://serpapi.com/searches/67240fab08abe42058644364/images/22b746555f0a1e6c01e90e410efefc7d228a38e0f2431bcaf627c048906760c8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8105503916740417}","{'position': 3, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19%2930097-X/fulltext', 'title': 'Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study', 'source': 'The Lancet', 'date': 'Apr 29, 2019', 'snippet': 'Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug \nconjugate with a humanised anti-HER2 antibody,...', 'thumbnail': 'https://serpapi.com/searches/67240fab08abe42058644364/images/22b746555f0a1e6caba2414df2e90318d47779b060b5dadebe6832e34207abd9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8882864713668823}","{'position': 4, 'link': 'https://www.researchgate.net/publication/376779456_HER2_quantitative_continuous_scoring_for_accurate_patient_selection_in_HER2-negative_trastuzumab_deruxtecan-treated_breast_cancer', 'title': '(PDF) HER2 quantitative continuous scoring for accurate patient selection in HER2-negative trastuzumab deruxtecan–treated breast cancer', 'source': 'ResearchGate', 'date': 'Dec 8, 2023', 'snippet': 'PDF | Many targeted cancer therapies rely on biomarkers assessed by scoring \nof immunohistochemically (IHC)-stained tissue,...', 'thumbnail': 'https://serpapi.com/searches/67240fab08abe42058644364/images/22b746555f0a1e6c8c13c5204199bc155a19534118c0615c1b4e6abc9bc28f3b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8549423217773438}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04124965,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Rozanolixizumab-UCB7665', 'title': 'Rozanolixizumab (Rystiggo®)', 'source': 'UCB', 'date': 'Aug 30, 2024', 'snippet': 'Autoimmune Encephalitis, A Study to Test the Efficacy, Safety, and \nPharmacokinetics of Rozanolixizumab in Adult Study Participants With...', 'thumbnail': 'https://serpapi.com/searches/67240fbaa88278108589f26c/images/469d1f1d65fa4e8d87fb79faab049dbdc34303ce00dbe8510197831edd5d65a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8345304131507874}","{'position': 2, 'link': 'https://myastheniagravisnews.com/rozanolixizumab-ucb7665/', 'title': 'Rystiggo (rozanolixizumab-noli) for myasthenia gravis', 'source': 'Myasthenia Gravis News', 'date': 'Jan 25, 2024', 'snippet': 'Rystiggo (rozanolixizumab-noli) is an injection therapy approved for adults \nwith generalized myasthenia gravis (gMG) who have antibodies against the...', 'thumbnail': 'https://serpapi.com/searches/67240fbaa88278108589f26c/images/469d1f1d65fa4e8d43b5ea1ec64e995d6a2912853599110d7a48989df462a5a7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8568547368049622}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01472198,"{'position': 1, 'link': 'https://www.science.org/doi/10.1126/scitranslmed.aao0475', 'title': 'Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials', 'source': 'Science | AAAS', 'date': 'Jan 3, 2018', 'snippet': 'Tissues stiffen during aging and during the pathological progression of \ncancer, fibrosis, and cardiovascular disease.', 'thumbnail': 'https://serpapi.com/searches/67240fe59f8bfc44aaac882e/images/a421162c58a07382c338d352c7c05ce03206f25ea26df2a0d90a72ba255da649.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8034569025039673}",,,,,,,,,,['neutral'],neutral,1
NCT05141305,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/full/10.1161/SVIN.123.001110', 'title': 'A Systematic Review of the Efficacy and Safety of Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Time to Pass the Torch', 'source': 'American Heart Association Journals', 'date': 'Apr 26, 2024', 'snippet': 'Alteplase, a biosynthetic form of human tissue‐type plasminogen activator, \nis Food and Drug Administration‐approved for the treatment of...', 'thumbnail': 'https://serpapi.com/searches/67241001460b15a5b5a4b7f1/images/a259ae7735156aa4aa585c7000eaccf10e117b9b0a1a68a86051aa976f4f8ad7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9013330936431885}",,,,,,,,,,['neutral'],neutral,1
NCT01384734,"{'position': 1, 'link': 'https://life4me.plus/en/news/fostemsavir-5423/', 'title': 'On CROI were presented the latest data of the effectiveness and safety of fostemsavir', 'source': 'Life4me+', 'date': 'Aug 12, 2019', 'snippet': 'In Seattle were released the latest information about studies of \nfostemsavir - a drug for the treatment of HIV infection of a fundamentally \nnew type.', 'thumbnail': 'https://serpapi.com/searches/672410018db376555d9e59c8/images/3617882acf256bb49073606bfd994e6780fd4fd90ef0c1c45a0b8fae1520c791.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8979955315589905}",,,,,,,,,,['neutral'],neutral,1
NCT02057341,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCGEN.122.003730', 'title': 'Efficacy and Safety of ARRY-371797 in LMNA -Related Dilated Cardiomyopathy: A Phase 2 Study', 'source': 'American Heart Association Journals', 'date': 'Dec 14, 2022', 'snippet': 'Background:Lamin A/C gene (LMNA)-related dilated cardiomyopathy is a \nserious and life-threatening condition with a high unmet medical need.', 'thumbnail': 'https://serpapi.com/searches/672410288b84c422b06ed859/images/5cbb9e4a30e88055f6524e6923f168572b798e5d570ef878a7295a6cced91f91.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7965096831321716}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.00761/full', 'title': 'The Broad Spectrum of LMNA Cardiac Diseases: From Molecular Mechanisms to Clinical Phenotype', 'source': 'Frontiers', 'date': 'Jul 3, 2020', 'snippet': '1Humanitas Clinical and Research Center – IRCCS, Rozzano, Italy; 2Institute \nof Genetic and Biomedical Research (IRGB) – UOS of Milan,...', 'thumbnail': 'https://serpapi.com/searches/672410288b84c422b06ed859/images/5cbb9e4a30e88055c128c6fab487ece1d09c32ae0dde5c6010c92dff7d1e416f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9251209497451782}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02974855,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/marstacimab-lowers-bleed-rates-hemophilia-patients-no-inhibitors/', 'title': 'Marstacimab seen to lower bleed rates in hemophilia in Phase 3 trial', 'source': 'Hemophilia News Today', 'date': '٣١\u200f/٠٥\u200f/٢٠٢٣', 'snippet': ""In a Phase 3 clinical trial, Pfizer's marstacimab was found to lower bleed \nrates for both hemophilia A and B patients without inhibitors."", 'thumbnail': 'https://serpapi.com/searches/672410294791c4792972095f/images/e169e39effb17a7a1b03e3fec80b1d798ea8ff88112cbbd7f8ccc647ebdc9136.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6721058487892151}","{'position': 2, 'link': 'https://hemophilianewstoday.com/news/hemophilia-patients-treated-with-marstacimab-see-fewer-bleeds-study/', 'title': 'Hemophilia Patients Treated With Marstacimab See Fewer Bleeds: Study', 'source': 'Hemophilia News Today', 'date': '٢٣\u200f/٠٩\u200f/٢٠٢٢', 'snippet': 'The positive results with the experimental antibody marstacimab held up for \nboth hemophilia A and B patients, even those with an inhibitor.', 'thumbnail': 'https://serpapi.com/searches/672410294791c4792972095f/images/e169e39effb17a7a24de2fde45d0c1a7fac78c377acf0cffa9c1c3ca75a7f291.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6740753054618835}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00102739,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa073275', 'title': 'Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura', 'source': 'The New England Journal of Medicine', 'date': 'Mar 13, 2017', 'snippet': 'This study was designed to assess whether eltrombopag could safely increase \nplatelet counts in adults with relapsed or refractory chronic ITP.', 'thumbnail': 'https://serpapi.com/searches/67241031a324362e226c5de4/images/27a75636bea1b0b9a7c096bccff6bb1fe538a7e5374d9d8c25221ce38ddaa480.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8934575915336609}","{'position': 2, 'link': 'https://www.hematologyadvisor.com/home/topics/anemia/alvaiz-approved-for-itp-thrombocytopenia-with-hep-c-and-severe-aplastic-anemia/', 'title': 'Alvaiz Approved for ITP, Thrombocytopenia With Hep C, and Severe Aplastic Anemia', 'source': 'Hematology Advisor', 'date': 'Dec 5, 2023', 'snippet': 'The Food and Drug Administration has approved Alvaiz (eltrombopag tablets), \na thrombopoietin receptor agonist.', 'thumbnail': 'https://serpapi.com/searches/67241031a324362e226c5de4/images/27a75636bea1b0b9d8a34d4b9db53e5018a9f29aa275789b00f6aab57a0e1c4c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7984627485275269}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00428948,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1205511', 'title': 'Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease', 'source': 'The New England Journal of Medicine', 'date': 'Nov 3, 2012', 'snippet': 'In this phase 3, multicenter, double-blind, placebo-controlled, 3-year \ntrial, we randomly assigned 1445 patients, 18 to 50 years of age,...', 'thumbnail': 'https://serpapi.com/searches/6724103a9e5bd566565c442b/images/835e7ffae9fbee07334ced9e2385328dc44be7447e957742ee92f5f25e7df701.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8659112453460693}","{'position': 2, 'link': 'https://www.researchgate.net/figure/New-treatment-proposals-for-chronic-kidney-diseases_tbl2_374836838', 'title': 'New treatment proposals for chronic kidney diseases.', 'source': 'ResearchGate', 'date': 'Nov 24, 2023', 'snippet': 'Chronic kidney disease (CKD) is characterized by renal parenchymal damage \nleading to a reduction in the glomerular filtration rate.', 'thumbnail': 'https://serpapi.com/searches/6724103a9e5bd566565c442b/images/835e7ffae9fbee0791301004fd06268b6e2544ca0c3ad9ec827b58b81d1df311.png', 'sentiment': 'negative', 'sentiment_prob': 0.6147511005401611}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT01142726,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/news/baseline-mri-inflammation-may-predict-treatment-response-in-rheumatoid-arthritis/', 'title': 'Baseline MRI Inflammation May Predict Treatment Response in Early Rheumatoid Arthritis', 'source': 'Rheumatology Advisor', 'date': 'Oct 23, 2019', 'snippet': 'Patients with early RA and a high level of MRI inflammation at baseline \nwere more likely to achieve clinical remission with abatacept plus MTX \ncompared with...', 'thumbnail': 'https://serpapi.com/searches/6724104ba5e502cdefc57101/images/53510f0803000bfdb81c63eb341514162f85a42a2769e1dd22c9e57c0ee754fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8113713264465332}",,,,,,,,,,['neutral'],neutral,1
NCT02395250,"{'position': 1, 'link': 'https://www.frontiersin.org/articles/10.3389/fimmu.2022.963031/full', 'title': 'Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report', 'source': 'Frontiers', 'date': 'Jul 29, 2022', 'snippet': 'The clinical efficacy of current therapies for Hepatocellular carcinoma \n(HCC) are unsatisfactory. In recent years, chimeric antigen receptor...', 'thumbnail': 'https://serpapi.com/searches/6724104df8b05d9e91665a0d/images/85f520fb17d7727648af155199074b250b0cec2e21d2fb3318463685fc7a76a5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6280092597007751}",,,,,,,,,,['neutral'],neutral,1
NCT02736266,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.18.01148', 'title': 'Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Oct 20, 2018', 'snippet': 'In the PURE-01 study, patients had a predominant urothelial carcinoma \nhistology and clinical (c)T≤3bN0 stage tumor.', 'thumbnail': 'https://serpapi.com/searches/672410583c944b931648f33e/images/406fceefa75d995e85779e83bec91b3ca8cbcd4e7cdce98c4006b5deceaf1e48.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8714836835861206}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-023-37568-9', 'title': 'Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer', 'source': 'Nature', 'date': 'Apr 27, 2023', 'snippet': 'Our study identifies signatures associated with response to CPI that can be \nused to molecularly stratify patients and suggests therapeutic alternatives.', 'thumbnail': 'https://serpapi.com/searches/672410583c944b931648f33e/images/406fceefa75d995e2f4e4081af60b6515463c87097fe4cb95f5e4a9a62d3c216.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8693649172782898}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02320812,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-020-02955-3', 'title': 'Stem/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials | Cell Death & Disease', 'source': 'Nature', 'date': 'Sep 23, 2020', 'snippet': 'We provide a comprehensive overview on the progression of clinical trials \nfor RD treatment using four types of stem/progenitor cell-based \ntransplantation.', 'thumbnail': 'https://serpapi.com/searches/6724105f39e2327bf63a6edf/images/976cde1b450f8f0a45df4465d6b3cc8d20d5f2ad617111ac3f773a164d4ac431.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9178408980369568}",,,,,,,,,,['neutral'],neutral,1
NCT01546818,"{'position': 1, 'link': 'https://pharmafile.com/news/hiv-vaccine-candidate-successfully-optimised-for-industrial-production/', 'title': 'HIV vaccine candidate successfully optimised for industrial production', 'source': 'Pharmafile', 'date': '1 day ago', 'snippet': 'Natalia Elliot | October 30, 2024 | News story | Research and Development | \nHIV, HIV/AIDS, Naobios, Sumagen, Vaccine, agreement.', 'thumbnail': 'https://serpapi.com/searches/6724106b167793224537b949/images/ad8ad597b60297f5271b5cb15bdac969d998f99c1e4d6a431874de538b4db62a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6182410717010498}",,,,,,,,,,['positive'],positive,1
NCT02933697,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062779', 'title': 'A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study | Circulation', 'source': 'American Heart Association Journals', 'date': 'Nov 6, 2022', 'snippet': 'Background:Non–vitamin K oral anticoagulants have become the standard \ntherapy for preventing stroke and ischemic thromboembolism in most...', 'thumbnail': 'https://serpapi.com/searches/67241074a9210b5559bfdc13/images/471003ae5327eadb6a421b549d69428547113d48039aa66bb54bdd5095f2655e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9289031028747559}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061647', 'title': 'Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and End-Stage Renal Disease: Lessons Learned', 'source': 'American Heart Association Journals', 'date': 'Dec 5, 2022', 'snippet': 'Observational studies suggest that warfarin is associated with net harm in \npatients with AF on dialysis, 3 but the data are of low quality.', 'thumbnail': 'https://serpapi.com/searches/67241074a9210b5559bfdc13/images/471003ae5327eadbbe846d54e50befd5a1b85a53b0c3034ad9624aba17f626b3.png', 'sentiment': 'negative', 'sentiment_prob': 0.6714184880256653}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT05333289,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-39376-7', 'title': 'Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis', 'source': 'Nature', 'date': 'Jun 19, 2023', 'snippet': 'Despite vaccine availability, influenza remains a substantial global public \nhealth concern. Here, we report interim findings on the primary...', 'thumbnail': 'https://serpapi.com/searches/6724107eec54100b6f92697c/images/f9a6f0d53259978b39ebd6c2d6cd9316321bda1c255558ef8e3f19a0ba5a46ec.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8802207112312317}",,,,,,,,,,['neutral'],neutral,1
NCT01743768,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1411776', 'title': 'Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme', 'source': 'The New England Journal of Medicine', 'date': 'May 17, 2015', 'snippet': 'The most prevalent phenotype of asthma is characterized by \neosinophil-dominated inflammation that is driven by a type 2 helper T cell \n(Th2).', 'thumbnail': 'https://serpapi.com/searches/67241082ca6f0c90182439cd/images/fabec85ac2aef8165bb81fe3cec2867e70fb75917e23db6c1135fefc45f6e706.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5749281644821167}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/adma.202300374', 'title': 'Therapeutic DNAzymes: From Structure Design to Clinical Applications - Yan - 2023 - Advanced Materials', 'source': 'Wiley Online Library', 'date': 'Feb 4, 2023', 'snippet': 'During the tortuous development period, the research direction of \ntherapeutic deoxyribozymes changes from verification of therapeutic...', 'thumbnail': 'https://serpapi.com/searches/67241082ca6f0c90182439cd/images/fabec85ac2aef81699b524cdc4a616d6cc966ad6daf694a9bbcdb4cb08d8de81.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8990408778190613}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01901432,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-020-0735-y', 'title': 'Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study', 'source': 'Nature', 'date': 'Feb 11, 2020', 'snippet': 'Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (cMPN) \ncharacterized by stem cell-derived clonal myeloproliferation...', 'thumbnail': 'https://serpapi.com/searches/6724109e7b05ca37a09e4a1a/images/23f9c506787b4a53ecf460eabf66a5c093dba3eb59ff71888885329b6861e716.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8484344482421875}",,,,,,,,,,['neutral'],neutral,1
NCT01761266,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2020/11/06/tecentriq-avastin-combo-approved-europe-to-treat-advanced-or-inoperable-liver-cancer/', 'title': 'Tecentriq-Avastin Combo Approved in Europe for Advanced or Inoperable Liver Cancer', 'source': 'Immuno-Oncology News', 'date': 'Nov 6, 2020', 'snippet': 'Tecentriq plus Avastin was found to be superior to standard care as a \nfirst-line treatment of adults with advanced or inoperable...', 'thumbnail': 'https://serpapi.com/searches/672410a25ddfba8fdaa1fcf6/images/c1109c06f82b40996153efc92fe382c33d6ff0a640c2308c375969fa10f77ebf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5336371064186096}",,,,,,,,,,['neutral'],neutral,1
NCT02655822,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1172931/full', 'title': 'The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy', 'source': 'Frontiers', 'date': 'Feb 9, 2024', 'snippet': 'Immunotherapy has revolutionized cancer treatment and revitalized efforts \nto harness the power of the immune system to combat a variety of cancer \ntypes more...', 'thumbnail': 'https://serpapi.com/searches/672410a4ecf1504fe14bb99c/images/0db71081554c4669a020fdfeb950b421c5213b0134a395ad7586a39015bf106b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5026456117630005}",,,,,,,,,,['neutral'],neutral,1
NCT03945188,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00061-2/fulltext', 'title': 'Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies', 'source': 'The Lancet', 'date': 'Mar 2, 2023', 'snippet': 'Etrasimod as induction and maintenance therapy for ulcerative colitis \n(ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies', 'thumbnail': 'https://serpapi.com/searches/672410ba2fab6292b8d52dde/images/731fdba1ea8363b56207092852a6434bd7b283d27a0b0ba52cf65d0ebcf565b2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7826459407806396}","{'position': 2, 'link': 'https://www.genengnews.com/topics/drug-discovery/pfizer-to-acquire-arena-for-6-7b-expanding-immuno-inflammatory-pipeline/', 'title': 'Pfizer to Acquire Arena for $6.7B, Expanding Immuno-Inflammatory Pipeline', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Dec 13, 2021', 'snippet': ""Pfizer has agreed to acquire Arena Pharmaceuticals for approximately $6.7 \nbillion, the companies said today, in a deal designed to expand the buyer's \nimmuno-..."", 'thumbnail': 'https://serpapi.com/searches/672410ba2fab6292b8d52dde/images/731fdba1ea8363b5f988b644e8faf2d6654272fedd1ccac97edd8b49c6ee9360.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8256548047065735}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01259050,"{'position': 1, 'link': 'https://www.cbsnews.com/detroit/news/adeona-reports-positive-study-results-for-zinc-treatment-of-als/', 'title': 'Adeona Reports Positive Study Results For Zinc Treatment Of ALS', 'source': 'CBS News', 'date': 'Nov 30, 2011', 'snippet': 'ANN ARBOR -- Adeona Pharmaceuticals (NYSE Amex: AEN) Wednesday said that \nits clinical collaborator for amyotrophic lateral sclerosis (ALS),...', 'thumbnail': 'https://serpapi.com/searches/672410cbf9f904be0f4593a5/images/0a3e83ab9162d21b2688464235df2f2d01b62b5db02f5f6f6bc19dd1018d7a12.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5707696676254272}",,,,,,,,,,['neutral'],neutral,1
NCT04155645,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/abs/10.1161/circ.144.suppl_1.9747', 'title': 'Abstract 9747: Safety, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD8233, Targeting PCSK9, in Patients with Dyslipidemia', 'source': 'American Heart Association Journals', 'date': 'Nov 8, 2021', 'snippet': 'Introduction: Inhibition of proprotein convertase subtilisin/kexin type 9 \n(PCSK9) reduces cardiovascular risk by lowering low-density...', 'thumbnail': 'https://serpapi.com/searches/672410dbe45f33d6d2690d01/images/a890bc4c1a9486bf20884cb9f50a17132f17dee38befb5b27af0a04f11f5f818.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8961273431777954}",,,,,,,,,,['neutral'],neutral,1
NCT02623322,"{'position': 1, 'link': 'https://www.nature.com/articles/d41587-019-00013-8', 'title': 'Drug makers chase anti-flu pill', 'source': 'Nature', 'date': 'May 12, 2019', 'snippet': 'Drug makers are targeting flu virus vulnerabilities to develop antivirals \nthat not only stop infections in their tracks, but also temper emergence of \ndrug...', 'thumbnail': 'https://serpapi.com/searches/672410efb57db8f4c1c62dab/images/b3281d41d9f5af7a42d7b1ac47e86e3703bfb74ebd616246813845c9d2eaba1d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7620350122451782}",,,,,,,,,,['neutral'],neutral,1
NCT03343626,"{'position': 1, 'link': 'https://www.nature.com/articles/s41579-018-0039-7', 'title': 'Zika virus vaccines', 'source': 'Nature', 'date': 'Jun 19, 2018', 'snippet': 'In this Progress article, we discuss recent preclinical studies and lessons \nlearned from first-in-human clinical trials with ZIKV vaccines.', 'thumbnail': 'https://serpapi.com/searches/67241102b28e6b6e596dddef/images/5ba23ed7d8aae9568f623b611acded9f4599d93f1c44b8b40bfb7bb7877b55c3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9234530925750732}",,,,,,,,,,['neutral'],neutral,1
NCT04084951,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-023-00641-x', 'title': 'Microfluidic cell squeeze-based vaccine comes into clinical investigation', 'source': 'Nature', 'date': 'May 4, 2023', 'snippet': 'Cancer immunotherapy has been widely applied to fight various cancers as \none of the most successful anticancer therapeutic approaches in...', 'thumbnail': 'https://serpapi.com/searches/672411238b7ba7dbdcee52ab/images/2da2e67f6701e135ddaeb342c20f1352de8293b2d158cec82ed766933d58daae.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5192486047744751}",,,,,,,,,,['positive'],positive,1
NCT01566695,"{'position': 1, 'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.20.02619', 'title': 'Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Mar 25, 2021', 'snippet': 'Treatment options are limited for patients with lower-risk myelodysplastic \nsyndromes (LR-MDS). This phase III, placebo-controlled trial...', 'thumbnail': 'https://serpapi.com/searches/672411250f1a3394018c9e6e/images/8149385868d4827f7df6218fcddc9a8eb4abae2ec2f6fff9c0a7df708e5c4b71.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7065016031265259}",,,,,,,,,,['neutral'],neutral,1
NCT05375838,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2024.1412478/full', 'title': 'Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines', 'source': 'Frontiers', 'date': 'Jun 29, 2024', 'snippet': 'This review delves into the major advancements in the field of combined \nvaccine research, underscoring the strategic use of various platforms.', 'thumbnail': 'https://serpapi.com/searches/67241139d1691523570524dc/images/d2e49ac7e8c39252729200517ff34d045ea3f823251c9fbe13af04def6b785d2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5735475420951843}",,,,,,,,,,['positive'],positive,1
NCT03418688,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/all-patients-gain-trial-show-signs-gum-disease-bacteria-porphyromonas-gingivalis/', 'title': 'All Patients in GAIN Trial Show Signs of Gum Disease Bacteria', 'source': ""Alzheimer's News Today"", 'date': 'Aug 30, 2021', 'snippet': ""Every participant in the Phase 2/3 GAIN clinical trial, which is testing \nCortexyme's experimental medication COR388 (atuzaginstat) in people..."", 'thumbnail': 'https://serpapi.com/searches/6724114f1f3d4b758d225a36/images/771df91804708d00714f836549879dc6d7c7a9920c2acae44dc3f11a86234c5a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7752336263656616}",,,,,,,,,,['neutral'],neutral,1
NCT01920711,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1908655', 'title': 'Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction', 'source': 'The New England Journal of Medicine', 'date': 'Sep 1, 2019', 'snippet': 'The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a \nreduced risk of hospitalization for heart failure or death from \ncardiovascular...', 'thumbnail': 'https://serpapi.com/searches/672411692a7727e9d24441c4/images/cb7484a2f2056406c2ced4e3c6e1fdd0bc48b1147e65465bc9d3711c53dbf254.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6263095140457153}",,,,,,,,,,['neutral'],neutral,1
NCT01247324,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1601277', 'title': 'Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Dec 21, 2016', 'snippet': 'In two identical phase 3 trials, we randomly assigned 821 and 835 patients \nwith relapsing multiple sclerosis to receive intravenous...', 'thumbnail': 'https://serpapi.com/searches/6724116bcc487953868276a6/images/672047ae58d60d02bff1208903f859d517174c4e3bdd3fd268e669f9d70dbea2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9104704856872559}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/03/14/ocrevus-blood-levels-confirmed-disability-progression/', 'title': 'Higher blood levels of Ocrevus lower confirmed disability progression risk', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 14, 2023', 'snippet': 'Higher blood levels of Ocrevus associate with a significantly lower risk of \nconfirmed disability progression during treatment,...', 'thumbnail': 'https://serpapi.com/searches/6724116bcc487953868276a6/images/672047ae58d60d0235a2aea612378ab1fc4f077cfceac47d15c1b88299821667.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7976104617118835}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04821479,"{'position': 1, 'link': 'https://alsnewstoday.com/news/mesenchymal-stem-cell-therapy-safe-potential-slow-als-progression-trial/', 'title': 'ALS Stem Cell Therapy Safe, Shows Potential to Slow Progression in Trial', 'source': 'ALS News Today', 'date': 'Dec 3, 2021', 'snippet': 'A small trial found repeat injections of mesenchymal stem cells safe, with \na potential to significantly slow the rate of ALS progression.', 'thumbnail': 'https://serpapi.com/searches/6724117681bab7b8fdf0d45f/images/e1728962f5126d78447c1b6b0d50d77d3b99c3bd3c268258c6152b2543fbf634.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6009451150894165}",,,,,,,,,,['neutral'],neutral,1
NCT00949949,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-00324-2', 'title': 'Overview of current targeted therapy in gallbladder cancer', 'source': 'Nature', 'date': 'Oct 7, 2020', 'snippet': 'Gallbladder cancer (GBC) is rare, but is the most malignant type of biliary \ntract tumor. Unfortunately, only a small population of cancer...', 'thumbnail': 'https://serpapi.com/searches/6724117be30abc0f5d3da90b/images/9a37ec817b1bb5567a0ebb656600b50c924b1b4d33adee06157542c0ec64c56e.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7814876437187195}",,,,,,,,,,['negative'],negative,0
NCT02611817,"{'position': 1, 'link': 'https://www.empr.com/home/news/entyvio-for-subcutaneous-use-approved-for-maintenance-in-crohn-disease/', 'title': 'Entyvio for Subcutaneous Use Approved for Maintenance in Crohn Disease', 'source': 'Medical Professionals Reference', 'date': 'Apr 19, 2024', 'snippet': 'The Food and Drug Administration (FDA) has approved the subcutaneous (SC) \nadministration of Entyvio (vedolizumab) for maintenance therapy in adults.', 'thumbnail': 'https://serpapi.com/searches/6724117fce1a752257c17e81/images/a464dd904abec412e20ce3b085a5945f0fd016c3cabcc7ae067190908ef2dd18.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8533787131309509}","{'position': 2, 'link': 'https://ibdnewstoday.com/2020/02/26/new-entyvio-formulation-given-injection-at-home-leads-crohns-remission-after-one-year-phase-3-trial-results-takeda-announces/', 'title': ""New Entyvio Formulation – Given as Injection at Home – Leads to Crohn's Remission After One Year, Takeda Announces"", 'source': 'IBD News Today', 'date': 'Feb 26, 2020', 'snippet': ""Entyvio maintenance therapy – given as a self-injection at home – led to \nCrohn's disease remission after one year in a Phase 3 study,..."", 'thumbnail': 'https://serpapi.com/searches/6724117fce1a752257c17e81/images/a464dd904abec4124735bf513700663d908ed2312c9744c62423592409907907.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9027442932128906}","{'position': 3, 'link': 'https://ibdnewstoday.com/2020/03/04/panel-recommends-european-approval-of-entyvio-at-home-injection/', 'title': ""At-Home Entyvio Injection for Crohn's Recommended for Europe Approval"", 'source': 'IBD News Today', 'date': 'Mar 4, 2020', 'snippet': ""A European Medicines Agency panel recommended approval of an at-home \ninjection of Entyvio, which is used to treat Crohn's and ulcerative..."", 'thumbnail': 'https://serpapi.com/searches/6724117fce1a752257c17e81/images/a464dd904abec412968dc37e9b06a5dd8770affc040a029cde06a71f48a32e8c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8984673619270325}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02276222,"{'position': 1, 'link': 'https://copdnewstoday.com/news/analyses-phase-3-trials-sun-101-eflow-safe-effective-copd/', 'title': 'Analyses of Phase 3 Trials Show SUN-101/eFlow Safe, Effective for COPD', 'source': 'COPD News Today', 'date': 'Nov 2, 2017', 'snippet': 'Pooled data from three Phase 3 clinical trials shows that the investigative \nSUN-101/eFlow product is well-tolerated and improves lung...', 'thumbnail': 'https://serpapi.com/searches/672411811397ba2adff57c25/images/a178281535f3e944b9b4a3deb05ba52644819667ff95775c62fff69f085b83ef.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6960063576698303}","{'position': 2, 'link': 'https://www.researchgate.net/figure/Study-Schematic-for-the-GOLDEN-3-and-GOLDEN-4-studies-a_fig1_318552432', 'title': 'Fig. 1. Study Schematic for the GOLDEN 3 and GOLDEN 4 studies. a', 'source': 'ResearchGate', 'date': 'Mar 3, 2020', 'snippet': 'SUN-101 is a combination of glycopyrrolate delivered through an innovative, \nelectronic nebulizer, intended for the treatment of patients with COPD.', 'thumbnail': 'https://serpapi.com/searches/672411811397ba2adff57c25/images/a178281535f3e944ca11de918b00980983f7b62893415803c992b778622a2254.png', 'sentiment': 'neutral', 'sentiment_prob': 0.907075822353363}","{'position': 3, 'link': 'https://copdnewstoday.com/news/new-drug-application-sunovion-copd-therapy-accepted-fda/', 'title': 'New Drug Application for Sunovion’s COPD Therapy Accepted by FDA', 'source': 'COPD News Today', 'date': 'Oct 20, 2016', 'snippet': ""Read about the FDA acceptance of a New Drug Application for Sunovion's COPD \ntreatment SUN-101 delivered with the eFlow nebulizer."", 'thumbnail': 'https://serpapi.com/searches/672411811397ba2adff57c25/images/a178281535f3e9445da0733d1405d7fd53631abd8301e18626ccb2c31ca5ef75.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7361782193183899}",,,,,,,,"['positive', 'neutral', 'neutral']",neutral,1
NCT04799249,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/g1-therapeutics-discontiue-tnbc-trial-flop/', 'title': 'G1 Therapeutics discontinue COSELA in TNBC following Phase III flop', 'source': 'Clinical Trials Arena', 'date': 'Jun 25, 2024', 'snippet': 'The Preserve-2 trial did not meet the primary endpoint of overall survival, \nwith G1 Therapeutics stating it will focus efforts on SCLC.', 'thumbnail': 'https://serpapi.com/searches/67241187d9c3e68834f91d2e/images/3623c95b65b88db7b718f23e8fcd83942bfb609f874ae88bbbedf1cec3e1fcc1.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7938660383224487}",,,,,,,,,,['negative'],negative,0
NCT01266486,"{'position': 1, 'link': 'https://www.researchgate.net/publication/337858993_Transcriptomic_analysis_of_human_primary_breast_cancer_identifies_fatty_acid_oxidation_as_a_target_for_metformin', 'title': '(PDF) Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin', 'source': 'ResearchGate', 'date': 'Jan 15, 2020', 'snippet': 'PDF | Epidemiological studies suggest that metformin may reduce the \nincidence of cancer in patients with diabetes and multiple late phase \nclinical.', 'thumbnail': 'https://serpapi.com/searches/6724118a96a32968339e6306/images/36bc91641efbbf89424e4786bcc157de2bab94685bf2beb5b5427f2fed711d55.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8698205947875977}",,,,,,,,,,['neutral'],neutral,1
NCT02445248,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1804980', 'title': 'Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma', 'source': 'The New England Journal of Medicine', 'date': 'Dec 1, 2018', 'snippet': 'The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets \nand eliminates CD19-expressing B cells and showed efficacy against B-cell \nlymphomas.', 'thumbnail': 'https://serpapi.com/searches/6724119235853912a0cb0993/images/3a683ae888bf257d2776fd9d8d76a95e04b1156a8e9395dccc344448046c1168.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8563516139984131}","{'position': 2, 'link': 'https://www.uchicagomedicine.org/forefront/immunotherapy-articles/2018/november/car-t-cell-update-phase-2-clinical-trial', 'title': 'CAR T-cell update: therapy improves outcomes for patients with B-cell lymphoma', 'source': 'UChicago Medicine', 'date': 'Nov 30, 2018', 'snippet': 'An international phase-2 trial of a CAR T-cell therapy found that 52 \npercent of patients responded favorably.', 'thumbnail': 'https://serpapi.com/searches/6724119235853912a0cb0993/images/3a683ae888bf257d448c1a11066029b7b705a1eea37074ccddc8a226beb7afea.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.820311427116394}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04003155,"{'position': 1, 'link': 'https://www.empr.com/cch/veozah-for-the-treatment-of-vasomotor-symptoms-due-to-menopause/', 'title': 'Veozah for the Treatment of Vasomotor Symptoms Due to Menopause', 'source': 'Medical Professionals Reference', 'date': 'Jun 1, 2023', 'snippet': 'Veozah (fezolinetant; Astellas Pharma US, Inc) became the first medication \nwithin its class to be approved by the US Food and Drug Administration (FDA)', 'thumbnail': 'https://serpapi.com/searches/6724119469f8ecce36647418/images/78052b22ac7b8c69b4513feb9782dcde0fe1baa0e8d5c306854e519a1053067a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7362357974052429}","{'position': 2, 'link': 'https://www.empr.com/home/news/veozah-approved-for-moderate-to-severe-vasomotor-symptoms-due-to-menopause/', 'title': 'Veozah Approved for Moderate to Severe Vasomotor Symptoms Due to Menopause', 'source': 'Medical Professionals Reference', 'date': 'May 15, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Veozah™ (fezolinetant) \nfor the treatment of moderate to severe vasomotor symptoms due to...', 'thumbnail': 'https://serpapi.com/searches/6724119469f8ecce36647418/images/78052b22ac7b8c69bb9e1dd6890ac9027ae398ffec1c8170925711dc467d319f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7814399600028992}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00880620,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/parkinsons-disease-treatments-motor-symptoms-rytary/', 'title': 'Rytary (carbidopa and levodopa) for Parkinson’s disease', 'source': ""Parkinson's News Today"", 'date': 'May 8, 2023', 'snippet': ""Rytary is an approved extended-release formulation of carbidopa and \nlevodopa that can help ease disease symptoms in people with Parkinson's."", 'thumbnail': 'https://serpapi.com/searches/6724119fb4fe875869b7a359/images/2346314bc968beab908937df3d552c277bb62ebbc1dd546087d93391d11c605e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6894364356994629}",,,,,,,,,,['neutral'],neutral,1
NCT05232461,"{'position': 1, 'link': 'https://www.prnewswire.com/il/news-releases/neurosense-therapeutics-commences-enrollment-and-dosing-in-its-pharmacokinetic-study-of-primec-for-als-301522680.html', 'title': 'NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS', 'source': 'PR Newswire', 'date': 'Apr 11, 2022', 'snippet': 'It has enrolled and dosed the first healthy volunteer in its \npharmacokinetic (PK) study (NCT05232461) of its lead combination drug \ncandidate PrimeC.', 'thumbnail': 'https://serpapi.com/searches/672411a821b01bfe86d64cef/images/05cf84cd7181ad91b2a00a35ca8306f2e18ecbaf1b2c516d509a54f8d089a441.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8010069727897644}",,,,,,,,,,['neutral'],neutral,1
NCT03496662,"{'position': 1, 'link': 'https://www.nature.com/articles/s43018-022-00349-2', 'title': 'Translational advances in pancreatic ductal adenocarcinoma therapy', 'source': 'Nature', 'date': 'Mar 29, 2022', 'snippet': 'Here, we review recent advances in targeted therapy and immunotherapy for \ntreating subtypes of PDAC with diverse molecular alterations.', 'thumbnail': 'https://serpapi.com/searches/672411b8c0028efedf6861d2/images/e5b2a2513fc003ad627576afc8cf2c9bae5f49694a62b64f1f58d71d40c99678.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8488385677337646}",,,,,,,,,,['neutral'],neutral,1
NCT01363401,"{'position': 1, 'link': 'https://alsnewstoday.com/news/corestem-shares-protocol-long-term-neuronata-r-phase-3-als-trial/', 'title': 'Corestem Shares Protocol for Long-term NeuroNata-R Phase 3 ALS Trial', 'source': 'ALS News Today', 'date': 'Jul 7, 2022', 'snippet': 'Corestem is still enrolling participants in its Phase 3 clinical trial of \nNeuroNata-R (lenzumestrocel), a stem cell therapy that is...', 'thumbnail': 'https://serpapi.com/searches/6724120de45f33d6d2690d4c/images/c2f0d5899f457c14728a8ad6adb46a32bb142ce68635294df4d9c2f080a5650b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9255658388137817}",,,,,,,,,,['neutral'],neutral,1
NCT05363293,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/alzamend-neuro-sets-trial-dosage-al001-lithium-therapy/', 'title': 'Alzamend Neuro sets trial dosage for AL001 lithium therapy', 'source': ""Alzheimer's News Today"", 'date': '1 week ago', 'snippet': ""Alzamend Neuro has determined the dosage of AL001, its lithium therapy for \nAlzheimer's disease, that will be used in future clinical trials."", 'thumbnail': 'https://serpapi.com/searches/6724121afc40bf5b24977fb7/images/2cdedad8d2fbe7f059935fde2949e5a97369ccf763aaa934f5c159f501410ee6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9257797598838806}","{'position': 2, 'link': 'https://alzheimersnewstoday.com/news/phase-2-trial-dosing-starts-experimental-dementia-therapy-al001/', 'title': 'Phase 2 Trial Dosing Starts for Experimental Dementia Treatment AL001', 'source': ""Alzheimer's News Today"", 'date': 'May 18, 2022', 'snippet': 'Alzamend Neuro has dosed the first patient in the multiple ascending dose \nportion of its Phase 2a clinical trial of AL001, an investigational oral \ntherapy for...', 'thumbnail': 'https://serpapi.com/searches/6724121afc40bf5b24977fb7/images/2cdedad8d2fbe7f01da677195ba62f23c36846e2894f4846844590b7d9fe2319.png', 'sentiment': 'neutral', 'sentiment_prob': 0.909375786781311}","{'position': 3, 'link': 'https://alzheimersnewstoday.com/news/trial-results-expected-june-lithium-formulation-alzheimers/', 'title': 'Phase 2 trial of lithium formulation for Alzheimer’s now complete', 'source': ""Alzheimer's News Today"", 'date': 'Mar 24, 2023', 'snippet': 'Alzamend Neuro has completed the clinical portion of a Phase 2 trial \ntesting AL001, an investigational formulation of lithium that the company \nis developing to...', 'thumbnail': 'https://serpapi.com/searches/6724121afc40bf5b24977fb7/images/2cdedad8d2fbe7f0cd29bf4a2013edacb2e2875ca4216973658021d3c9463fc5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8931167721748352}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02435680,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Dose-Cohort-Assignment-QW-weekly-Q2W-every-2weeks_fig1_349542499', 'title': 'Dose Cohort Assignment. QW: weekly; Q2W: every 2 weeks', 'source': 'ResearchGate', 'date': 'Jun 13, 2021', 'snippet': 'This phase 1 study determined the safety, tolerability, \npharmacokinetics-pharmacodynamics, immunogenicity, and efficacy of the \nanti–CSF-1R antibody LY3.', 'thumbnail': 'https://serpapi.com/searches/67241229f3622a70cad26f36/images/67f22c68ceb8d6bc628b0751a17c39deecc9d64ab5eeb05dae64fcd6829450af.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8917114734649658}",,,,,,,,,,['neutral'],neutral,1
NCT03434379,"{'position': 1, 'link': 'https://www.targetedonc.com/view/atezolizumab-bevacizumab-shows-survival-and-qol-benefit-in-hcc', 'title': 'Atezolizumab/Bevacizumab Shows Survival and QOL Benefit in HCC', 'source': 'Targeted Oncology', 'date': 'May 1, 2024', 'snippet': 'Stacey Stein, MD, discusses the background and outcomes of the IMbrave150 \ntrial of atezolizumab plus bevacizumab in patients with advanced...', 'thumbnail': 'https://serpapi.com/searches/6724122e5c7cb9f090771767/images/bc7fae9ff80c2cf679bda11313bc9cc65cf9bf2c0641cbfb0af7faefb6fd1f78.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8851877450942993}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1915745', 'title': 'Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma', 'source': 'The New England Journal of Medicine', 'date': 'May 13, 2020', 'snippet': 'The combination of atezolizumab and bevacizumab showed encouraging \nantitumor activity and safety in a phase 1b trial involving patients with...', 'thumbnail': 'https://serpapi.com/searches/6724122e5c7cb9f090771767/images/bc7fae9ff80c2cf6715871eb5a1fb6a998caa6e0667b16e91ba494b057e99a34.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7301519513130188}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01713361,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1405760', 'title': 'Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis', 'source': 'The New England Journal of Medicine', 'date': 'Dec 7, 2014', 'snippet': 'Experimental data indicate that reducing factor XI levels attenuates \nthrombosis without causing bleeding, but the role of factor XI in the...', 'thumbnail': 'https://serpapi.com/searches/6724123dc76a3af3b9d83f24/images/4e41f06a6fe9b75fb87c51a661ade3090e6eb821e75e97da734d02412a981d98.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8540341854095459}",,,,,,,,,,['neutral'],neutral,1
NCT00312000,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61086-1/abstract', 'title': 'Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial', 'source': 'The Lancet', 'date': 'Jul 14, 2007', 'snippet': 'Combination treatment does not significantly improve overall survival \ncompared with the sequential use of cytotoxic drugs in advanced colorectal \ncancer.', 'thumbnail': 'https://serpapi.com/searches/67241245caddc398a0e802ea/images/d74f23b12a88a10e6c50028ab93f4f4f1cf916e267a1ff05cb7086b57dfc254a.png', 'sentiment': 'negative', 'sentiment_prob': 0.7410749793052673}",,,,,,,,,,['negative'],negative,0
NCT04586985,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/ftx-6058-raised-fetal-hemoglobin-sickle-cell-patient-trial-hold/', 'title': 'FTX-6058 shown to raise fetal hemoglobin in SCD patient in trial', 'source': 'Sickle Cell Disease News', 'date': 'May 16, 2023', 'snippet': 'Treatment with FTX-6058 raised fetal hemoglobin levels to 24.9% in a sickle \ncell patient prior to a clinical hold placed on the trial.', 'thumbnail': 'https://serpapi.com/searches/6724124bcb33d04578645b7f/images/b57a90365a91fb4d90bf9b4ffff7aca8171490e0213335276a075b2e20661d8f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7876183986663818}","{'position': 2, 'link': 'https://sicklecellanemianews.com/news/oral-ftx-6058-shows-promise-raising-fetal-hemoglobin-healthy-adults/', 'title': 'FTX-6058 Shows Promise in Boosting Fetal Hemoglobin in Healthy Adults', 'source': 'Sickle Cell Disease News', 'date': 'Sep 7, 2021', 'snippet': 'FTX-6058 was found to be effective at raising the levels of fetal \nhemoglobin in healthy adults participating in a Phase 1 trial.', 'thumbnail': 'https://serpapi.com/searches/6724124bcb33d04578645b7f/images/b57a90365a91fb4dfe3f71347905ca4c6874dbc392bd6ee8d329fd042facdb28.png', 'sentiment': 'positive', 'sentiment_prob': 0.8372976779937744}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03902080,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/vibegron-effective-in-men-with-overactive-bladder-receiving-bph-treatment/', 'title': 'Vibegron Effective in Men With Overactive Bladder Receiving BPH Treatment', 'source': 'Medical Professionals Reference', 'date': 'Sep 11, 2023', 'snippet': 'A phase 3 study evaluating vibegron in men with OAB symptoms receiving \npharmacological therapy for BPH met its coprimary and all secondary...', 'thumbnail': 'https://serpapi.com/searches/67241326e50bc005c852d9fe/images/3c626a151c4f2ec378d763c37298cbc66cdd54dd01e4bab8a6d47ea39b7a88a1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7995201945304871}",,,,,,,,,,['neutral'],neutral,1
NCT03529877,"{'position': 1, 'link': 'https://epidermolysisbullosanews.com/news/rdeb-wound-closure-promoted-with-skin-derived-stem-cells/', 'title': 'Skin-derived stem cells promoted wound closure in RDEB: Study', 'source': 'Epidermolysis Bullosa News', 'date': 'Apr 21, 2023', 'snippet': 'Skin-derived stem cells enhanced wound closure in people with recessive \ndystrophic epidermolysis bullosa (RDEB), according to clinical trial data.', 'thumbnail': 'https://serpapi.com/searches/6724125488bcde40dd0324e1/images/33c6f0590b6aa8bdacdb541596ad0ffdc7aa3112ca2e5a0e2e99d213ef9be444.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6645285487174988}","{'position': 2, 'link': 'https://epidermolysisbullosanews.com/news/skin-stem-cell-therapy-prevent-new-wounds-rdeb-study/', 'title': 'Skin stem cell therapy helps prevent new wounds in RDEB: Study –...', 'source': 'Epidermolysis Bullosa News', 'date': 'Jul 7, 2023', 'snippet': 'People with recessive dystrophic epidermolysis bullosa (RDEB) developed \nfewer new wounds after treatment with skin-derived stem cells.', 'thumbnail': 'https://serpapi.com/searches/6724125488bcde40dd0324e1/images/33c6f0590b6aa8bdc983671c89f5c816f7168112466da4db36bf801320cd07eb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7420727014541626}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02773849,"{'position': 1, 'link': 'https://www.urologytimes.com/view/nadofaragene-firadenovec-sustains-efficacy-in-nmibc-at-5-year-follow-up', 'title': 'Nadofaragene firadenovec sustains efficacy in NMIBC at 5-year follow-up', 'source': 'Urology Times', 'date': 'May 5, 2024', 'snippet': 'The gene therapy nadofaragene firadenovec-vncg (Adstiladrin) continued to \ndemonstrate durable clinical activity in patients with high-risk, \nBCG-unresponsive...', 'thumbnail': 'https://serpapi.com/searches/672412d0ec54100b3215c0f7/images/51b13b6a496f1df27cc89e3362645ee01a8dabb0ed4a40afa76953e7c5654480.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5285101532936096}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.6768', 'title': 'Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer', 'source': 'Wiley Online Library', 'date': 'Dec 1, 2023', 'snippet': 'There are limited therapeutic options for BCG-unresponsive patients with \nnon-muscle-invasive bladder cancer. The development of long-term...', 'thumbnail': 'https://serpapi.com/searches/672412d0ec54100b3215c0f7/images/51b13b6a496f1df28e4ecbfe3cd63200d36d9f6e25b6fa89b7b7b1a76dd5c0b0.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6403945088386536}","{'position': 3, 'link': 'https://www.targetedonc.com/view/immunotherapy-meets-the-frontline-in-bladder-cancer-leaving-gaps-in-later-lines', 'title': 'Immunotherapy Meets the Frontline in Bladder Cancer, Leaving Gaps in Later Lines', 'source': 'Targeted Oncology', 'date': 'Jun 24, 2024', 'snippet': 'Recent data, trials, approvals, and presentations during the 2024 American \nUrological Association Annual Meeting paint a positive treatment...', 'thumbnail': 'https://serpapi.com/searches/672412d0ec54100b3215c0f7/images/51b13b6a496f1df25c21fd0da18e14101b94cf8202f4e1257c6bf602370c5977.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6940205097198486}",,,,,,,,"['neutral', 'negative', 'neutral']",neutral,1
NCT02975206,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-023-00992-4', 'title': 'The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment', 'source': 'Nature', 'date': 'Mar 16, 2023', 'snippet': 'Atopic dermatitis (AD) is the most common inflammatory skin disease, and it \nis considered a complex and heterogeneous condition.', 'thumbnail': 'https://serpapi.com/searches/672412dc577da5588d9471da/images/0d9c1ea360fd7ca7b71bf5e3071ac83e72f6eb5de93ae52e6099f3a56014e195.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7401643991470337}",,,,,,,,,,['neutral'],neutral,1
NCT03096314,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1911124', 'title': 'Early High-Dose Vitamin D3 for Critically Ill, Vitamin D–Deficient Patients', 'source': 'The New England Journal of Medicine', 'date': 'Dec 11, 2019', 'snippet': 'We conducted a randomized, double-blind, placebo-controlled, phase 3 trial \nof early vitamin D 3 supplementation in critically ill, vitamin D–deficient \npatients...', 'thumbnail': 'https://serpapi.com/searches/672412f2bb64ac868baba277/images/a4311811c055a54306305fd2e50b620be08e454465a1d5fff30b67165bba12af.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8818767070770264}",,,,,,,,,,['neutral'],neutral,1
NCT01997333,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-021-00244-6', 'title': 'Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study | npj Breast Cancer', 'source': 'Nature', 'date': 'May 20, 2021', 'snippet': 'The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, \nglembatumumab vedotin (GV), targeting gpNMB that is overexpressed...', 'thumbnail': 'https://serpapi.com/searches/672412f3059caf91502b42b8/images/3e5e36b47510530b3c8c2cee43fa3a9a7d3b3dacbf46ee08471cfffcc2a9f7ee.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8773122429847717}",,,,,,,,,,['neutral'],neutral,1
NCT00976352,"{'position': 1, 'link': 'https://pompediseasenews.com/raav1-cmv-hgaa/', 'title': 'rAAV1-CMV-hGAA for Pompe disease', 'source': 'Pompe Disease News', 'date': 'Jun 13, 2023', 'snippet': 'Learn more about rAAV1-CMV-hGAA, a type of gene therapy for Pompe disease \nthat was developed by researchers at the University of Florida.', 'thumbnail': 'https://serpapi.com/searches/672412f817a2e29b0ee5e3df/images/30e6eb752b0fa9bf1c8e3257b3453b5ae96f64be1c79e5f1111fdd926c07cfbd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.94797283411026}",,,,,,,,,,['neutral'],neutral,1
NCT03448419,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.054669', 'title': 'Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials', 'source': 'American Heart Association Journals', 'date': 'Aug 16, 2021', 'snippet': 'Sodium-glucose cotransporter-2 inhibitors elicit an initial decline in \nestimated glomerular filtration rate (eGFR).', 'thumbnail': 'https://serpapi.com/searches/672412fabcd65222bfec92c5/images/8187f1b32b6a19ef8c069515ed4d4380d7f76846d912d8da5655577b769b7ef7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7206818461418152}","{'position': 2, 'link': 'https://investor.lilly.com/news-releases/news-release-details/boehringer-ingelheim-and-lilly-expand-heart-failure-program', 'title': 'Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials', 'source': 'Eli Lilly and Company', 'date': 'Apr 6, 2018', 'snippet': 'EMPERIAL clinical trials will evaluate the effect of Jardiance \n(empagliflozin) on exercise ability and heart failure symptoms in people \nwith chronic heart...', 'thumbnail': 'https://serpapi.com/searches/672412fabcd65222bfec92c5/images/8187f1b32b6a19ef7206920225b56592aa8f82808e63dad686b3a185d62f6967.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8594703674316406}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02954354,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1716197', 'title': 'Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents', 'source': 'The New England Journal of Medicine', 'date': 'Sep 5, 2018', 'snippet': 'We conducted two randomized, double-blind, controlled trials involving \notherwise healthy outpatients with acute uncomplicated influenza.', 'thumbnail': 'https://serpapi.com/searches/672412fa167793224537b9f9/images/06eeab0b5959988fb82241f9935b7b71e38507f64b8ef9d03ffa6912ac7a20fe.png', 'sentiment': 'neutral', 'sentiment_prob': 0.897260308265686}",,,,,,,,,,['neutral'],neutral,1
NCT03989102,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-022-00510-z', 'title': 'A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection', 'source': 'Nature', 'date': 'Aug 23, 2022', 'snippet': 'Immunization with radiation-attenuated Plasmodium falciparum (Pf) \nsporozoites (SPZ) in PfSPZ Vaccine, has provided better vaccine efficacy...', 'thumbnail': 'https://serpapi.com/searches/6724126768831e1cdffbda7c/images/a806b6fbec30c301978e214592c0e7f8121ae4f9ae24fda6df32af042a1eb75e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6426528692245483}",,,,,,,,,,['neutral'],neutral,1
NCT01850238,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/aadvac1-alzheimers-vaccine-lessens-signs-neurodegeneration-phase-2-adamant-trial/', 'title': 'Vaccine Seen to Lessen Signs of Neurodegeneration in Phase 2 Trial', 'source': ""Alzheimer's News Today"", 'date': 'Jul 22, 2021', 'snippet': ""AADvac1, an investigational vaccine targeting abnormal tau protein, a \nhallmark of Alzheimer's disease, was found to be safe and effectively \nreduced the signs..."", 'thumbnail': 'https://serpapi.com/searches/6724126a2bab905d1d426e77/images/f094f6dfd128534b7cb08babae3fd275b57d49e480aecaf2fcfa3ab1b938eed2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8057160377502441}",,,,,,,,,,['neutral'],neutral,1
NCT03118765,"{'position': 1, 'link': 'https://copdnewstoday.com/gsp-304-tiotropium-bromide/', 'title': 'COPD Therapy Candidate GSP 304 Widens Airways to the Lungs', 'source': 'COPD News Today', 'date': 'May 21, 2018', 'snippet': 'Read about GSP 304, a COPD therapy that Glenmark Pharmaceuticals is \ndeveloping. The mist-delivered treatment widens airway passages to the \nlungs.', 'thumbnail': 'https://serpapi.com/searches/6724126ca505f777dd2047c0/images/898d8a4214f7975014a1621a3460a22cb36e5a90434a7f67d814587a86844b83.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9299271702766418}",,,,,,,,,,['neutral'],neutral,1
NCT02623426,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/intraocular-corticosteroids-best-treating-complications-chronic-inflammatory-eye-condition', 'title': 'Intraocular corticosteroids best for treating complications of chronic inflammatory eye condition', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jun 13, 2023', 'snippet': 'Repeat treatment with corticosteroid injections improved vision in people \nwith persistent or recurrent uveitis-related macular edema better than two \nother...', 'thumbnail': 'https://serpapi.com/searches/67241278cc4879535044e67b/images/5509c71851d9a2216c01f64a3bc403b88ad62010d6ef360193c0baa697a85ad2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5174453258514404}",,,,,,,,,,['positive'],positive,1
NCT01468207,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1504370', 'title': 'Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa', 'source': 'The New England Journal of Medicine', 'date': 'Aug 4, 2016', 'snippet': 'Treatment with adalimumab (40 mg weekly), as compared with placebo, \nresulted in significantly higher clinical response rates in both trials at \n12 weeks.', 'thumbnail': 'https://serpapi.com/searches/6724127df3cbfa2fbc7c75f0/images/a61f6e82b0bbf06aad020c4af7cec2ebca216cccfab69fac74225b272b43b0e6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8673570156097412}","{'position': 2, 'link': 'https://www.dermatologyadvisor.com/news/adalimumab-reduces-skin-pain-in-hidradenitis-suppurativa/', 'title': 'Adalimumab Reduces Skin Pain in Hidradenitis Suppurativa', 'source': 'Dermatology Advisor', 'date': 'Jun 22, 2018', 'snippet': 'Outcomes were examined in 2 randomized, double-blind, placebo-controlled, \nparallel-group clinical trials: PIONEER I (ClinicalTrials.gov...', 'thumbnail': 'https://serpapi.com/searches/6724127df3cbfa2fbc7c75f0/images/a61f6e82b0bbf06aa7bda045521d76cd553183441993409ab32431ff94ba9e83.png', 'sentiment': 'neutral', 'sentiment_prob': 0.767997682094574}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03841110,"{'position': 1, 'link': 'https://health.ucsd.edu/news/press-releases/2019-04-01-uc-san-diego-health-treats-cancer-patient-with-stem-cell-derived-natural-killer-cells/', 'title': 'UC San Diego Health Treats 1st Cancer Patient with Stem-Cell Derived Natural Killer Cells', 'source': 'UC San Diego Health', 'date': 'Apr 1, 2019', 'snippet': 'Ruff became the first patient in the world to be treated for cancer with a \nhuman-induced pluripotent stem cell (iPSC)-derived cell therapy called \nFT500.', 'thumbnail': 'https://serpapi.com/searches/672412962379380c131b48cf/images/1fae65866d287361e6b369d38536d88eb53b8587cb929813eb4d60e795798a22.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8793442249298096}",,,,,,,,,,['neutral'],neutral,1
NCT02054806,"{'position': 1, 'link': 'https://cervicalcancernews.com/2017/05/26/early-analysis-of-keytruda-in-advanced-cervical-cancer-showing-promise-in-phase-2-trial/', 'title': 'Keytruda Shows Promise in People with Advanced Disease, Early Phase 2 Trial Results Show', 'source': 'Cervical cancer News', 'date': 'May 26, 2017', 'snippet': 'Read about how Keytruda seems to benefit women with advanced cervical \nsquamous cell cancer in a preliminary analysis of clinical trial data.', 'thumbnail': 'https://serpapi.com/searches/672412a569f8ecce3664745d/images/b7e4841c167a1aed147665b3a96d84ba6af350221fae3ae4b6d6110a1d11ea1e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.774665355682373}",,,,,,,,,,['positive'],positive,1
NCT00291642,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Xyzal-levocetirizine', 'title': 'Levocetirizine (Xyzal®)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Allergic Rhinitis, Efficacy and Safety of Levocetirizine 8 Weeks Prior and \nAfter the Onset of the Grass Pollen Season in Subjects With SAR...', 'thumbnail': 'https://serpapi.com/searches/672412a7b7d31dd6bebdbc27/images/79fae632296aca5f2674afa69342843811e1d9c91b15ddad3e5a5ca3fc1f0718.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8934985995292664}",,,,,,,,,,['neutral'],neutral,1
NCT02807636,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30230-0/fulltext', 'title': 'Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial', 'source': 'The Lancet', 'date': 'May 16, 2020', 'snippet': 'Atezolizumab can induce sustained responses in metastatic urothelial \ncarcinoma. We report the results of IMvigor130, a phase 3 trial that...', 'thumbnail': 'https://serpapi.com/searches/6724132ab9ab868c6579b2c1/images/a887f6372947b6a77a75d7d732f7c7191c5a9a1e598f27a9cc2c5a28dfb0f873.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8183580040931702}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/atezolizumab-no-longer-available-in-us-for-a-certain-type-of-bladder-cancer', 'title': 'Atezolizumab No Longer Available in US for a Certain Type of Bladder Cancer', 'source': 'Cancer Network', 'date': 'Nov 29, 2022', 'snippet': 'The U.S. indication for atezolizumab (Tecentriq) to treat patients with \npreviously untreated locally advanced or metastatic urothelial...', 'thumbnail': 'https://serpapi.com/searches/6724132ab9ab868c6579b2c1/images/a887f6372947b6a7846fb606612d9b579fb163ca696f99a9b619ebab3217d127.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5652068853378296}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02348918,"{'position': 1, 'link': 'https://www.nature.com/articles/s41433-021-01766-w', 'title': 'An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma', 'source': 'Nature', 'date': 'Jan 1, 2022', 'snippet': 'In the real-world setting, there is suboptimal compliance with treatments \nthat require frequent administration and assessment visits.', 'thumbnail': 'https://serpapi.com/searches/672416f9d0d7e31d070b7527/images/a53f59fee87ab97d4fe5d0f2b30d944a2f7c464a73bf37747ca73718bd6f1c1d.png', 'sentiment': 'negative', 'sentiment_prob': 0.590781033039093}",,,,,,,,,,['negative'],negative,0
NCT03412747,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2102388', 'title': 'Bimekizumab versus Adalimumab in Plaque Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Apr 23, 2021', 'snippet': 'In this 56-week trial, bimekizumab was noninferior and superior to \nadalimumab through 16 weeks in reducing symptoms and signs of plaque \npsoriasis.', 'thumbnail': 'https://serpapi.com/searches/67241721f6aa534e9217ec63/images/2af04b53012d6a56188b6f97b24fad8cd6fab8024a5e42d10d5d7e5f0fbf0ac6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7030984163284302}",,,,,,,,,,['neutral'],neutral,1
NCT00863655,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1109653', 'title': 'Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Dec 7, 2011', 'snippet': 'Resistance to endocrine therapy in breast cancer is associated with \nactivation of the mammalian target of rapamycin (mTOR) intracellular...', 'thumbnail': 'https://serpapi.com/searches/67241759fc40bf5af06ce428/images/6e6205ef96d8b70895bbe634695c9bab62b4983cf444abf8acab4a9dd2e06699.png', 'sentiment': 'negative', 'sentiment_prob': 0.5681521892547607}",,,,,,,,,,['negative'],negative,0
NCT00833833,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/myeloma-study-finds-pomalyst-more-cost-effective-than-kyprolis-or-darzalex/', 'title': 'Myeloma Study Finds Pomalyst More Cost-Effective Than Two Rivals', 'source': 'Myeloma Research News', 'date': 'Oct 30, 2017', 'snippet': 'Read about a study reporting that a combination of Pomalyst and \ndexamethasone is a more cost-effective therapy for myeloma than Kyprolis \nor...', 'thumbnail': 'https://serpapi.com/searches/672417608b84c422b06eda1e/images/d552f8207c4e0c49d8defc21ee5301bc5a856b558f7bf9e948c1d12f8736565b.png', 'sentiment': 'positive', 'sentiment_prob': 0.5470622777938843}",,,,,,,,,,['positive'],positive,1
NCT01882985,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332221010106', 'title': 'A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer', 'source': 'ScienceDirect.com', 'date': 'Sep 28, 2021', 'snippet': 'Prostate cancer expresses IGF1 receptors that contribute to treatment \nresistance via suppression of apoptosis. •. Prostate cancer models \ndemonstrated that...', 'thumbnail': 'https://serpapi.com/searches/6724134c6531cb6eb855fd92/images/88660b3603491f909e2c1bd01d91aaed1bc9cff2562a3a5a72e96bed5bf121f2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6526914834976196}",,,,,,,,,,['neutral'],neutral,1
NCT02246595,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.811504/full', 'title': 'Complement Mediated Endothelial Damage in Thrombotic Microangiopathies', 'source': 'Frontiers', 'date': 'Jun 28, 2024', 'snippet': 'The relationship between complement dysregulation and endothelial damage as \nthe main causes of TMA will be reviewed here.', 'thumbnail': 'https://serpapi.com/searches/6724135bf7adbf2b84005f0e/images/7e6cd25d644cdffa642d53eb041629e9fcfd2095967c4115949df4711ec95ba0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6897194385528564}",,,,,,,,,,['neutral'],neutral,1
NCT02230566,"{'position': 1, 'link': 'https://www.nature.com/articles/gim201710', 'title': 'Quantitative clinical characteristics of 53 patients with MPS VII: a cross-sectional analysis', 'source': 'Nature', 'date': 'Apr 6, 2017', 'snippet': 'The main purpose of the study was to provide quantitative data regarding \nsurvival and diagnostic delay. Mucopolysaccharidosis (MPS) type VII...', 'thumbnail': 'https://serpapi.com/searches/6724135d4d52b8d43dc2789f/images/5b08399c828383f92af51aee56a8f46283bccafadbe4d5bfdcfb43784a58e24c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9253908395767212}",,,,,,,,,,['neutral'],neutral,1
NCT02347657,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1709846', 'title': 'Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del', 'source': 'The New England Journal of Medicine', 'date': 'Nov 3, 2017', 'snippet': 'In this phase 3, randomized, double-blind, multicenter, placebo-controlled, \nparallel-group trial, we evaluated combination therapy with...', 'thumbnail': 'https://serpapi.com/searches/6724136ece1a752227e9c8ba/images/7d270941c681dd49e33ea9a022c7d150ff84507bdeb0c219dd2fe96e643b6458.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8578660488128662}",,,,,,,,,,['neutral'],neutral,1
NCT01507831,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1501031', 'title': 'Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events', 'source': 'The New England Journal of Medicine', 'date': 'Nov 29, 2016', 'snippet': 'Over a period of 78 weeks, alirocumab, when added to statin therapy at the \nmaximum tolerated dose, significantly reduced LDL cholesterol levels.', 'thumbnail': 'https://serpapi.com/searches/6724136d4a3fcf0651641bf3/images/6d992d0f313b447f120213f199afa3114c606d7c8f002207a45602f1f64c2381.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6424835324287415}",,,,,,,,,,['neutral'],neutral,1
NCT02826486,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-00267-8', 'title': 'Targeting chemokines/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma', 'source': 'Nature', 'date': 'Aug 11, 2020', 'snippet': 'In recent study published on Nature Medicine, Bockorny et al. performed a \nsingle-arm phase IIa trial (COMBAT study, NCT02826486) to evaluate...', 'thumbnail': 'https://serpapi.com/searches/672414465f9778ca2b75c534/images/4b1ac69a8a9af64256613eff23fdab657053392cdbd61baf0ea8d06faea2b713.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5100520849227905}",,,,,,,,,,['neutral'],neutral,1
NCT03056989,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/columns/cystic-fibrosis-epithelium-sodium-channel-spx-101-spyryx/', 'title': 'Cystic Fibrosis and the Epithelium Sodium Channel: Could SPX-101 Fix It?', 'source': 'Cystic Fibrosis News Today', 'date': 'Mar 26, 2018', 'snippet': ""Columnist Reid D'Amico shares background on an investigational CF therapy \ncalled SPX-101, developed by Spyryx Biosciences, which has shown..."", 'thumbnail': 'https://serpapi.com/searches/6724145dcc4879538682775f/images/f4f78f99ebdc7e8137f2fe24da4dee0bf329f843f1bac1c9704b079198a76264.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8881894946098328}",,,,,,,,,,['neutral'],neutral,1
NCT04735432,"{'position': 1, 'link': 'https://www.neurologylive.com/view/understanding-adapt-sc-results-subcutaneous-efgartigimod-tuan-vu', 'title': 'Understanding the ADAPT-SC Results of Subcutaneous Efgartigimod: Tuan Vu, MD', 'source': 'Neurology live', 'date': 'Nov 2, 2023', 'snippet': 'An overview of the open-label findings from ADAPT-SC, a phase 3 study \nassessing subcutaneous efgartigimod in patients with myasthenia gravis.', 'thumbnail': 'https://serpapi.com/searches/6724138d0197dd4da32e64a7/images/5274a4647b124b1a033fb06115968bcaea274cbdfbf63a6a33865415deb65a72.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9305896759033203}","{'position': 2, 'link': 'https://www.empr.com/home/news/sc-injectable-vyvgart-hytrulo-gets-fda-nod-for-generalized-myasthenia-gravis/', 'title': 'SC Injectable Vyvgart Hytrulo Gets FDA Nod for Generalized Myasthenia Gravis', 'source': 'Medical Professionals Reference', 'date': 'Jun 21, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Vyvgart Hytrulo \n(efgartigimod alfa and hyaluronidase-qvfc) for the treatment of generalized \nmyasthenia...', 'thumbnail': 'https://serpapi.com/searches/6724138d0197dd4da32e64a7/images/5274a4647b124b1a954c3a2f47f31ba08688510d0694469fc744e801f4f6ef27.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8111444115638733}","{'position': 3, 'link': 'https://myastheniagravisnews.com/news/mda-2024-vyvgart-hytrulo-eases-generalized-myasthenia-gravis-symptoms/', 'title': 'MDA 2024: Vyvgart Hytrulo eases disease severity, boosts life quality', 'source': 'Myasthenia Gravis News', 'date': 'Mar 7, 2024', 'snippet': ""Across a Phase 3 extension study's multiple treatment cycles, Vyvgart \nHytrulo reduced myasthenia gravis severity and improved quality of..."", 'thumbnail': 'https://serpapi.com/searches/6724138d0197dd4da32e64a7/images/5274a4647b124b1ae09962fc572824f25de4ef32a3cd49a605ee0e05b7d12abf.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6409837603569031}","{'position': 4, 'link': 'https://myastheniagravisnews.com/news/fda-approves-subcutaneous-efgartigimod-vyvgart-hytrulo-gmg/', 'title': 'FDA approves under-the-skin Vyvgart Hytrulo as treatment for gMG |...', 'source': 'Myasthenia Gravis News', 'date': 'Jun 21, 2023', 'snippet': 'Note: This story was updated June 28, 2023, to correct the time frame of \nthe ADAPT-SC+ clinical trial, in which patients will be treated for...', 'thumbnail': 'https://serpapi.com/searches/6724138d0197dd4da32e64a7/images/5274a4647b124b1ae210bbe630dd6532231a077669b0d563126d2f5b93c8cc37.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9257835149765015}","{'position': 5, 'link': 'https://myastheniagravisnews.com/news/under-skin-vyvgart-injection-approved-europe-achr-positive-gmg/', 'title': 'Under-the-skin Vyvgart approved in Europe for AChR-positive gMG', 'source': 'Myasthenia Gravis News', 'date': 'Nov 17, 2023', 'snippet': 'A new under-the-skin injectable formulation of Vyvgart (efgartigimod alfa) \nhas been approved by the European Commission for adults with generalized \nmyasthenia...', 'thumbnail': 'https://serpapi.com/searches/6724138d0197dd4da32e64a7/images/5274a4647b124b1a37fb4aba6c71c1f533cb5bd27064614131dc730c0c6f11d4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7352441549301147}",,,,,,"['neutral', 'neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT02684006,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1816047', 'title': 'Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma', 'source': 'The New England Journal of Medicine', 'date': 'Feb 16, 2019', 'snippet': 'In a single-group, phase 1b trial, avelumab plus axitinib resulted in \nobjective responses in patients with advanced renal-cell carcinoma.', 'thumbnail': 'https://serpapi.com/searches/672413b2f8b05d9e91665aeb/images/64530f482d7df12249ebbbb57804cc3c4df4b129200656c32906f3619a17e273.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8833085298538208}",,,,,,,,,,['neutral'],neutral,1
NCT00351468,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/home/topics/anemia/alvaiz-approved-for-itp-thrombocytopenia-with-hep-c-and-severe-aplastic-anemia/', 'title': 'Alvaiz Approved for ITP, Thrombocytopenia With Hep C, and Severe Aplastic Anemia', 'source': 'Hematology Advisor', 'date': 'Dec 5, 2023', 'snippet': 'The Food and Drug Administration has approved Alvaiz (eltrombopag tablets), \na thrombopoietin receptor agonist.', 'thumbnail': 'https://serpapi.com/searches/672413e817b10eb84e16bed3/images/798e35d097c59fea87b4157ee1b283e0eaf72171a8e918ef66e89ad6174ba462.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7984627485275269}",,,,,,,,,,['neutral'],neutral,1
NCT05333406,"{'position': 1, 'link': 'https://charcot-marie-toothnews.com/news/stem-cell-therapy-en001-eases-cmt1a-symptoms-small-trial/', 'title': 'Stem cell therapy safely eases CMT1A symptoms in small trial', 'source': 'Charcot-Marie-Tooth News', 'date': 'Jul 3, 2024', 'snippet': 'EN001, a stem cell therapy being developed by Encell, safely eased symptoms \nof CMT1A in a Phase 1 clinical trial involving nine patients.', 'thumbnail': 'https://serpapi.com/searches/672413eea86921b78b34a999/images/6c7afc2c210d42906a9f25e72362c414330414a0560496c29af6905a373f43b5.png', 'sentiment': 'positive', 'sentiment_prob': 0.579399049282074}",,,,,,,,,,['positive'],positive,1
NCT02586025,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-45591-7', 'title': 'Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial', 'source': 'Nature', 'date': 'Mar 9, 2024', 'snippet': 'The randomized, multicenter, double-blind, placebo-controlled, phase III \nPEONY trial (NCT02586025) demonstrated significantly improved total...', 'thumbnail': 'https://serpapi.com/searches/67241409d1119590a4975da7/images/4864fe00ebd34965ac6d2b953a511bf7f3332fa53f228ec23ff07cbf5dcf6695.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8156763315200806}","{'position': 2, 'link': 'https://www.onclive.com/view/neoadjuvant-adjuvant-pertuzumab-trastuzumab-regimen-continues-to-have-clinical-benefit-in-early-or-locally-advanced-her2-breast-cancer', 'title': 'Neoadjuvant, Adjuvant Pertuzumab/Trastuzumab Regimen Continues to Have Clinical Benefit in Early or Locally Advanced HER2+ Breast Cancer', 'source': 'OncLive', 'date': 'Dec 30, 2022', 'snippet': 'Neoadjuvant and adjuvant pertuzumab plus trastuzumab with docetaxel \ncontinued to show improvements in event-free survival, disease-free...', 'thumbnail': 'https://serpapi.com/searches/67241409d1119590a4975da7/images/4864fe00ebd34965bf297351336f63f7ebea7070788e51d914b8d5380c279620.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.525199294090271}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT00757042,"{'position': 1, 'link': 'https://www.dermatologyadvisor.com/news/two-phase-1-studies-evaluate-safety-of-tezepelumab-for-atopic-dermatitis/', 'title': 'Two Phase 1 Studies Evaluate Safety of Tezepelumab for Atopic Dermatitis', 'source': 'Dermatology Advisor', 'date': 'Mar 22, 2019', 'snippet': 'Two phase 1 studies assessed the safety, tolerability, and pharmacokinetics \nof tezepelumab with evidence of efficacy in asthma and potential...', 'thumbnail': 'https://serpapi.com/searches/672416830d379f62864f8520/images/2ac871a9902d85d66526072cc19e0681982a039334b123145d526cbf812fb144.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8194459676742554}",,,,,,,,,,['neutral'],neutral,1
NCT02312245,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-87470-x', 'title': 'Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting', 'source': 'Nature', 'date': 'Apr 13, 2021', 'snippet': 'Repeated measures studies are frequently performed in patient-derived \nxenograft (PDX) models to evaluate drug activity or compare...', 'thumbnail': 'https://serpapi.com/searches/6724168890b57c015b728636/images/2d55c41a872d13c2dc36e25f843d880a796168eb0308598e6b0475cf7320ada5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8915107250213623}",,,,,,,,,,['neutral'],neutral,1
NCT01751126,"{'position': 1, 'link': 'https://www.empr.com/home/news/verkazia-approved-for-vernal-keratoconjunctivitis/', 'title': 'Verkazia Approved for Vernal Keratoconjunctivitis', 'source': 'Medical Professionals Reference', 'date': 'Jun 24, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Verkazia™ (cyclosporine \nophthalmic emulsion) 0.1% for the treatment of vernal...', 'thumbnail': 'https://serpapi.com/searches/672416c072f7163db9b7030f/images/c4533000b7245407438ba60fcbca790839b0dcd983a8332f47c79b5fe69ce099.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.849105179309845}",,,,,,,,,,['neutral'],neutral,1
NCT05938920,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/clinical-studies-ipf-treatment-candidate-advancing-china-us/', 'title': 'Clinical studies of oral IPF treatment INS018_055 advancing in US, China', 'source': 'Pulmonary Fibrosis News', 'date': 'Jul 12, 2024', 'snippet': 'A Phase 2a clinical trial testing the safety of treatment candidate \nINS018_055 among idiopathic pulmonary fibrosis (IPF) patients in the US is \nstill seeking...', 'thumbnail': 'https://serpapi.com/searches/672416d221e77bd9839ca8dd/images/2098aad2b1b0b84a005f793594c8a53aedd6c2fa63a52eeedf70b064dae0a4f6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9229093194007874}","{'position': 2, 'link': 'https://www.eurekalert.org/news-releases/1058384', 'title': 'Insilico Medicine reports positive Phase IIa results for ISM001-055, a novel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) designed using generative AI', 'source': 'EurekAlert!', 'date': '1 month ago', 'snippet': 'Insilico Medicine reports positive Phase IIa results for ISM001-055, a \nnovel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) \ndesigned...', 'thumbnail': 'https://serpapi.com/searches/672416d221e77bd9839ca8dd/images/2098aad2b1b0b84a3a2516c758af9c97bf8616a9962843eefc2d35fc5637a20f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6900705099105835}","{'position': 3, 'link': 'https://www.nature.com/articles/s41587-024-02143-0', 'title': 'A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models', 'source': 'Nature', 'date': 'Mar 8, 2024', 'snippet': 'Idiopathic pulmonary fibrosis (IPF) is an aggressive interstitial lung \ndisease with a high mortality rate. Putative drug targets in IPF have...', 'thumbnail': 'https://serpapi.com/searches/672416d221e77bd9839ca8dd/images/2098aad2b1b0b84a3db8fc0042b7fcd637c95c2f7d863686c28fc34743910451.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5609192252159119}","{'position': 4, 'link': 'https://pharmatimes.com/news/insilico-medicine-reports-positive-results-for-idiopathic-pulmonary-fibrosis-therapy/', 'title': 'Insilico Medicine reports positive results for idiopathic pulmonary fibrosis therapy', 'source': 'PharmaTimes', 'date': '1 month ago', 'snippet': 'Insilico Medicine, a clinical-stage generative AI-driven drug discovery \ncompany, has announced positive preliminary results from its Phase 2a \nclinical trial of...', 'thumbnail': 'https://serpapi.com/searches/672416d221e77bd9839ca8dd/images/2098aad2b1b0b84aea316f02e392eb62f1da51183d98deee89f273a9c6ebe00a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6266455054283142}","{'position': 5, 'link': 'https://www.eurekalert.org/news-releases/1048870', 'title': 'Insilico Medicine completes patient enrollment in its Phase IIa Study in China investigating INS018_055 for Idiopathic Pulmonary Fibrosis (IPF)', 'source': 'EurekAlert!', 'date': 'Jun 20, 2024', 'snippet': 'The randomized, double-blind, placebo-controlled study is being conducted \nacross 29 clinical centers in China and has completed enrollment...', 'thumbnail': 'https://serpapi.com/searches/672416d221e77bd9839ca8dd/images/2098aad2b1b0b84a3f2389aa742ba09d4dc2b467e64ac92223a5433662fb9813.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8771718144416809}","{'position': 6, 'link': 'https://www.unite.ai/ai-driven-drug-discovery-achieves-milestone-with-insilico-medicines-phase-iia-success-in-treating-pulmonary-fibrosis/', 'title': 'AI-Driven Drug Discovery Achieves Milestone with Insilico Medicine’s Phase IIa Success in Treating Pulmonary Fibrosis', 'source': 'Unite.AI', 'date': '1 month ago', 'snippet': ""Insilico Medicine's Generative AI-designed Drug ISM001-055 Shows Promising \nResults in Phase IIa Clinical Trials."", 'thumbnail': 'https://serpapi.com/searches/672416d221e77bd9839ca8dd/images/2098aad2b1b0b84ae4bb3b07ade871bd359838f244d84132ebad12e9ad9dd6ac.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8786435127258301}",,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT00760149,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00191-X/fulltext', 'title': 'Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials', 'source': 'The Lancet', 'date': 'Oct 10, 2023', 'snippet': 'Respiratory tract microbiota has been described as the gatekeeper for \nrespiratory health. We aimed to assess the impact of standard-of-care...', 'thumbnail': 'https://serpapi.com/searches/672416d42c83d5b853e6b908/images/d067471a2841385e022e37dfe16c3af29d761d1d445089eb9a778f3e7c0e1ed5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9092090129852295}",,,,,,,,,,['neutral'],neutral,1
NCT03180437,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-020-0515-7', 'title': 'Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer', 'source': 'Nature', 'date': 'Sep 16, 2020', 'snippet': 'Vγ9Vδ2 T cells are promising candidates for cellular tumor immunotherapy. \nDue to their HLA-independent mode of action, allogeneic Vγ9Vδ2 T...', 'thumbnail': 'https://serpapi.com/searches/672416d611db4595229e7504/images/737737db5e084f45c17f34710914b206b2c7309e14c0d05adb1f4bceef2d2acd.png', 'sentiment': 'positive', 'sentiment_prob': 0.7890372276306152}","{'position': 2, 'link': 'https://www.nature.com/articles/s41392-020-00260-1', 'title': 'Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients', 'source': 'Nature', 'date': 'Oct 23, 2020', 'snippet': 'Immunotherapy has limited efficacy against locally advanced pancreatic \ncancer (LAPC) due to the presence of an immunosuppressive...', 'thumbnail': 'https://serpapi.com/searches/672416d611db4595229e7504/images/737737db5e084f45e24b523dbd6f0aa5cc34caf5410e20e7b96cc78b495e4e17.png', 'sentiment': 'neutral', 'sentiment_prob': 0.4920717477798462}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02546440,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1264842/full', 'title': 'Novel potential pharmacological applications of dimethyl fumarate—an overview and update', 'source': 'Frontiers', 'date': 'Feb 7, 2024', 'snippet': 'Dimethyl fumarate (DMF) is an FDA-approved drug for the treatment of \npsoriasis and multiple sclerosis. DMF is known to stabilize the \ntranscription factor...', 'thumbnail': 'https://serpapi.com/searches/67241474cc4879535044e6fb/images/3f00ba4b7993a5c58a1d2ac1b4034c76dbc01dd8079fdb4a948f4c6272637dd7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6468765139579773}",,,,,,,,,,['neutral'],neutral,1
NCT00985725,"{'position': 1, 'link': 'https://www.nature.com/articles/npp2013334', 'title': 'Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder', 'source': 'Nature', 'date': 'Dec 6, 2013', 'snippet': 'In this trial, LDX augmentation significantly improved executive \ndysfunction and depressive symptoms in participants with mild MDD.', 'thumbnail': 'https://serpapi.com/searches/6724154c460b15a5b5a4b933/images/c4ea4eb8b42ffaa7eff2ec0665ab609eb4c5fa4036618cb851ac3e811401e7e8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7135171294212341}",,,,,,,,,,['neutral'],neutral,1
NCT01487863,"{'position': 1, 'link': 'http://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/61648-asco-2013-poster-a-randomized-phase-ii-trial-of-sipuleucel-t-with-concurrent-or-sequential-abiraterone-acetate-plus-prednisone-in-metastatic-castrate-resistant-prostate-cancer-mcrpc.html', 'title': 'ASCO 2013 - Poster: A randomized, phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate plus prednisone in metastatic castrate-resistant prostate cancer (mCRPC)', 'source': 'UroToday', 'date': 'Jun 10, 2013', 'snippet': 'CHICAGO, IL USA (UroToday.com) - Presented by Small EJ,1 Lance RS,2 Redfern \nCH,3 Millard FE,4 Gardner TA,5 Karsh LI,6 Dawson N,7 McCoy C,8...', 'thumbnail': 'https://serpapi.com/searches/6724154f8cf8aebae1372273/images/16598361c6c8b27a21bbd675ee1c92ddb6a2cad99e5ea1484a45a6bedc721f39.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9061769843101501}",,,,,,,,,,['neutral'],neutral,1
NCT02851407,"{'position': 1, 'link': 'https://www.nature.com/articles/s41409-023-02007-2', 'title': 'Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: a never-ending story and no easy answer', 'source': 'Nature', 'date': 'May 25, 2023', 'snippet': 'The Harmony Trial (NCT02851407), a prospective randomized trial conducted \namong adults and children, reported that defibrotide was not...', 'thumbnail': 'https://serpapi.com/searches/67241550f79a01c1cc6c448e/images/4b4b3af7d984f889877c83cccbeebdb7142c6da49aa4a530b2964b04c5c43825.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5698968768119812}","{'position': 2, 'link': 'https://www.nature.com/articles/s41409-019-0474-8', 'title': 'Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)', 'source': 'Nature', 'date': 'Feb 25, 2019', 'snippet': 'Veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome \n(SOS), is a potentially life-threatening complication of...', 'thumbnail': 'https://serpapi.com/searches/67241550f79a01c1cc6c448e/images/4b4b3af7d984f8898f2ab47935c741affa91c582d2aaa49dd734ff8dbbf184fa.png', 'sentiment': 'negative', 'sentiment_prob': 0.5912196636199951}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT01596335,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-017-18387-7', 'title': 'Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial', 'source': 'Nature', 'date': 'Jan 31, 2018', 'snippet': 'We compared the efficacy and safety of infliximab with intravenous \nimmunoglobulin (IVIG), a standard therapy, in a phase 3 trial...', 'thumbnail': 'https://serpapi.com/searches/6724155069012193a5fed36d/images/711599a13e9821aaafd8df2123e1cd2da69f4f6a5237438045cb1c0cda036d6a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8821622729301453}",,,,,,,,,,['neutral'],neutral,1
NCT01119833,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/phase-3-trial-recruiting-to-test-rivipansel-for-vaso-occlusive-crisis-in-sickle-cell-disease/', 'title': 'Clinical Trial Seeking Vaso-Occlusive Sickle Cell Patients to Test Rivipansel', 'source': 'Sickle Cell Disease News', 'date': 'May 11, 2017', 'snippet': 'A Phase 3 clinical trial to test the effectiveness and safety of the drug \ncandidate rivipansel (GMI-1070) for the treatment of vaso-occlusive crisis \n(VOC) in...', 'thumbnail': 'https://serpapi.com/searches/6724155e642c3189bcbd539a/images/99ac5a983febbbecab4ae38249c75821f9b4d938e9574a2a78bc6330a5b6b5ae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8787412643432617}",,,,,,,,,,['neutral'],neutral,1
NCT04094142,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-47198-4', 'title': 'Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial', 'source': 'Nature', 'date': 'Mar 30, 2024', 'snippet': 'The authors report a single-arm phase II clinical trial of combination of \nacalabrutinib, lenalidomide and rituximab (R2A) in patients with aggressive \nrelapsed/...', 'thumbnail': 'https://serpapi.com/searches/6724155ed9c3e6887205ef06/images/6107c3b1253085177757ce6bf78c5c8ef69bc5f40b0b36ab70f3d2a0d8f510a4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.903610348701477}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/hon.3164_326', 'title': 'Combination of acalabrutinib with rituximab and lenalidomide in relapsed/refractory B cell non-Hodgkin lymphoma', 'source': 'Wiley Online Library', 'date': 'Jun 9, 2023', 'snippet': 'Previous studies have shown that combination of acalabrutinib with \nrituximab and lenalidomide has a synergistic effect in killing NHL cells.', 'thumbnail': 'https://serpapi.com/searches/6724155ed9c3e6887205ef06/images/6107c3b125308517e5329a1fc4deb06ec9c1e1e2e1d1d445c9480b371e426357.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6753286123275757}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00420212,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/tecfidera-generics-availability-europe/', 'title': 'Generics of Tecfidera not available in Europe until at least 2025', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 22, 2023', 'snippet': 'The European Commission withdraws its marketing authorizations for generic \nversions of Tecfidera (dimethyl fumarate), a RRMS oral therapy.', 'thumbnail': 'https://serpapi.com/searches/6724157cefad2183fae89b8a/images/4c4bb47576d6b81729729bbd37fa70e41c1b9db96bbf33a9f60e99bb70f6b498.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5986100435256958}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/tecfidera-dimethyl-fumarate-multiple-sclerosis/', 'title': 'Tecfidera (dimethyl fumarate) for MS | Uses, side effects, and more', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 22, 2022', 'snippet': 'Tecfidera (dimethyl fumarate) is an oral treatment for relapsing forms of \nMS. Learn more about its uses, indications, and side effects.', 'thumbnail': 'https://serpapi.com/searches/6724157cefad2183fae89b8a/images/4c4bb47576d6b81757343b4cae65af78db5c68b0f61cb5ae245b0813b09abf6b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8988696932792664}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00274352,"{'position': 1, 'link': 'https://sarcoidosisnews.com/news/adalimumab-humira-can-improve-verrucous-sarcoidosis-case-report/', 'title': 'Benefits of Adalimumab (Humira) in Verrucous Sarcoidosis Cited in Case Report', 'source': 'Sarcoidosis News', 'date': 'Nov 6, 2018', 'snippet': 'Adalimumab can help treat verrucous sarcoidosis — a rare type of skin \nsarcoidosis — associated with human papillomavirus (HPV), according to...', 'thumbnail': 'https://serpapi.com/searches/6724159c20e6ebd6b690e170/images/09f5ae249a0a2fcab2087b60d0bdb58ea37c241f0d0e8e5cc3fcddf52d64911d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6959171891212463}",,,,,,,,,,['neutral'],neutral,1
NCT04737187,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2214963', 'title': 'Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer', 'source': 'The New England Journal of Medicine', 'date': 'May 3, 2023', 'snippet': 'In a previous phase 3 trial, treatment with trifluridine–tipiracil \n(FTD–TPI) prolonged overall survival among patients with metastatic...', 'thumbnail': 'https://serpapi.com/searches/672414c97e1d1fae374b59b8/images/fe16294867b8f512571121e492b496313e0cf6ac234111a102dc2f643499b1f9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8692559599876404}","{'position': 2, 'link': 'https://dailynews.ascopubs.org/do/trifluridine-tipiracil-plus-bevacizumab-provides-benefit-refractory-metastatic', 'title': 'Trifluridine/Tipiracil Plus Bevacizumab Provides Benefit in Refractory Metastatic Colorectal Cancer', 'source': 'ASCO Daily News', 'date': 'Jan 21, 2023', 'snippet': 'In the global phase 3 SUNLIGHT study, adding bevacizumab to \ntrifluridine/tipiracil in the treatment of refractory metastatic \ncolorectal...', 'thumbnail': 'https://serpapi.com/searches/672414c97e1d1fae374b59b8/images/fe16294867b8f5122fdec964b30d634aa2164d0028145762c936a69b321b86d3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.785142183303833}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/trifluridine-tipiracil-receives-fda-approval-in-metastatic-crc', 'title': 'Trifluridine/Tipiracil Receives FDA Approval in Metastatic CRC', 'source': 'Cancer Network', 'date': 'Aug 2, 2023', 'snippet': 'Results from the phase 3 SUNLIGHT trial support the approval of \ntrifluridine/tipiracil plus bevacizumab in patients with previously \ntreated,...', 'thumbnail': 'https://serpapi.com/searches/672414c97e1d1fae374b59b8/images/fe16294867b8f512793248ff8cc9482f4f88690c9b35e9a72f23abb5ab15aa79.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7108086347579956}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02682693,"{'position': 1, 'link': 'https://www.onclive.com/view/addition-of-denosumab-to-neoadjuvant-chemo-does-not-lead-to-significant-idfs-differences-in-early-breast-cancer', 'title': 'Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer', 'source': 'OncLive', 'date': 'May 17, 2024', 'snippet': 'Adding denosumab to neoadjuvant nab-paclitaxel did not improve 5-year \ninvasive disease-free survival rates in patients with early-stage...', 'thumbnail': 'https://serpapi.com/searches/672414fad0d7e31d070b74b9/images/6e95e5c45472d09580a2dcf36b320055a53285015f06e78b747113f7d32b5769.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.621461808681488}",,,,,,,,,,['negative'],negative,0
NCT03228836,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-021-00768-0', 'title': 'Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)', 'source': 'Nature', 'date': 'Oct 27, 2021', 'snippet': 'This study (ORIENT-4) aimed to assess the efficacy and safety of \nsintilimab, a humanized anti-PD-1 antibody, in patients with...', 'thumbnail': 'https://serpapi.com/searches/672415165416d82ea72807f5/images/4ac2701d25a52895ada5e5358bf03a8d386aff8ae6537d353b4e61207711a0d8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.880325436592102}",,,,,,,,,,['neutral'],neutral,1
NCT04908462,"{'position': 1, 'link': 'https://fabrydiseasenews.com/news/first-clinical-site-china-opens-phase-2-trial-al01211/', 'title': 'First clinical site in China opens for Phase 2 trial of AL01211 –...', 'source': 'Fabry Disease News', 'date': 'Aug 18, 2023', 'snippet': 'AceLink Therapeutics opened its first clinical site in China for a Phase 2 \nclinical trial testing AL01211 as a treatment for Fabry disease.', 'thumbnail': 'https://serpapi.com/searches/672415e090b57c018e6f3d1b/images/906abbdfba61e2d15f72c0a9c3162e41d41487cb393f305857ea137a5ff4d71d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8989226818084717}",,,,,,,,,,['neutral'],neutral,1
NCT02460094,"{'position': 1, 'link': 'https://www.nature.com/articles/s43587-023-00523-w', 'title': 'TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease', 'source': 'Nature', 'date': 'Nov 27, 2023', 'snippet': 'a randomized, double-blind, placebo-controlled, parallel-group and \nmultiple-dose long-term trial of gosuranemab—a monoclonal antibody to N-...', 'thumbnail': 'https://serpapi.com/searches/672415eb9819f3ccdf1052ef/images/90cfd5dd59c5c3b177449123652aa1d0c884657be0a76adb72c3a7a16aad4fdb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.783279299736023}",,,,,,,,,,['neutral'],neutral,1
NCT01338610,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2015/704946', 'title': 'A Comprehensive Review on Dry Eye Disease: Diagnosis, Medical Management, Recent Developments, and Future Challenges - Phadatare - 2015 - Advances in Pharmaceutics', 'source': 'Wiley Online Library', 'date': 'Jan 28, 2015', 'snippet': 'Dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS) is a common \ndisorder of the tear film caused by decreased tear production or...', 'thumbnail': 'https://serpapi.com/searches/67241606361fd42d611f4ad4/images/6017bf8f05cf4d151da37fcf1021c39532585903e9d3f9e20c0ca156da2f5452.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8953704237937927}",,,,,,,,,,['neutral'],neutral,1
NCT05061693,"{'position': 1, 'link': 'https://www.dermatologytimes.com/view/late-breaking-data-povorcitinib-significantly-improves-itch-and-lesions-in-prurigo-nodularis', 'title': 'Late-Breaking Data: Povorcitinib Significantly Improves Itch and Lesions in Prurigo Nodularis', 'source': 'Dermatology Times', 'date': 'Mar 12, 2024', 'snippet': 'Shawn Kwatra, MD, shares positive updates on phase 2 oral povorcitinib for \nprurigo nodularis at AAD 2024.', 'thumbnail': 'https://serpapi.com/searches/67241627d0253e3d8bb515c8/images/1b378282af625911749256cf7e33ef4db9dd8569807d388218b01dbbd1b47c85.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6833504438400269}",,,,,,,,,,['positive'],positive,1
NCT03248492,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1914510', 'title': 'Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': '١١\u200f/١٢\u200f/٢٠١٩', 'snippet': 'Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of \nan anti-HER2 (human epidermal growth factor receptor 2) antibody,...', 'thumbnail': 'https://serpapi.com/searches/6724162dbe324f9cf1acab43/images/e1f84ce66f2c4834c324c1526eea531f3d27dfb23677bd8c2adec271af1cc481.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8805821537971497}","{'position': 2, 'link': 'https://www.bcrf.org/blog/highlights-sabcs-annual-symposium-2019-her2-positive-breast-cancer-updates/', 'title': 'Highlights from SABCS Annual Symposium 2019: HER2-Positive Breast Cancer Updates', 'source': 'Breast Cancer Research Foundation', 'date': '١٥\u200f/٠١\u200f/٢٠٢٠', 'snippet': 'Reports from clinical trials in HER2-positive breast cancer highlight \npromising new agents for patients with advanced disease.', 'thumbnail': 'https://serpapi.com/searches/6724162dbe324f9cf1acab43/images/e1f84ce66f2c48341597245a4cc0bd6ea60ea6fce1dd62f8de7b9f3bc5354047.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5301448702812195}","{'position': 3, 'link': 'https://breastcancer-news.com/2021/01/25/enhertu-conditionally-approved-in-european-union-eu-for-inoperable-advanced-her2-positive-breast-cancer/', 'title': 'Enhertu Approved in EU for Inoperable, Advanced Breast Cancer', 'source': 'Breast Cancer News', 'date': '٢٥\u200f/٠١\u200f/٢٠٢١', 'snippet': 'The European Commission has conditionally approved Enhertu (trastuzumab \nderuxtecan) for adults in the EU with inoperable or metastatic \nHER2-positive breast...', 'thumbnail': 'https://serpapi.com/searches/6724162dbe324f9cf1acab43/images/e1f84ce66f2c48348876f0a488cd4770851e6b6e0a4c7d6ffbf0efff58a2347a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7442876100540161}","{'position': 4, 'link': 'https://breastcancer-news.com/2020/04/30/enhertu-approved-in-japan-to-treat-her2-positive-inoperable-or-metastatic-breast-cancer/', 'title': 'Enhertu Approved for HER2-Positive Inoperable or Metastatic Cancer in Japan', 'source': 'Breast Cancer News', 'date': '٣٠\u200f/٠٤\u200f/٢٠٢٠', 'snippet': ""Enhertu, an antibody-drug conjugate, was approved in Japan to treat adults \nwith inoperable or metastatic breast cancer that's resistant to..."", 'thumbnail': 'https://serpapi.com/searches/6724162dbe324f9cf1acab43/images/e1f84ce66f2c483473a39ed3eeedd31d50dc6df4cac1cc63a7d6c02a950f3248.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.808199942111969}",,,,,,,"['neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT00729664,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1200694', 'title': 'Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jun 2, 2012', 'snippet': 'Antibody-mediated blockade of PD-L1 induced durable tumor regression \n(objective response rate of 6 to 17%) and prolonged stabilization of \ndisease.', 'thumbnail': 'https://serpapi.com/searches/67241641b7d31dd6bebdbd10/images/3e4825d465decd1b34913677087b024038ecf5f026083ce583e29bb413c8fdf9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8075860738754272}",,,,,,,,,,['neutral'],neutral,1
NCT02442765,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/avp-786-fails-ease-alzheimers-related-agitation-phase-3-trial/', 'title': 'AVP-786 fails to ease Alzheimer’s-related agitation in Phase 3 trial', 'source': ""Alzheimer's News Today"", 'date': 'Feb 29, 2024', 'snippet': ""A Phase 3 clinical trial of AVP-786 failed to meet its main goal of easing \nagitation in adults with dementia due to Alzheimer's disease."", 'thumbnail': 'https://serpapi.com/searches/672416455a461a841bce4a49/images/91822a38a61756316a0c6a225a052a0aa6a7ed938d8ca25a6f9d6a3528aadde5.png', 'sentiment': 'negative', 'sentiment_prob': 0.8483138084411621}",,,,,,,,,,['negative'],negative,0
NCT03611946,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/nih-begins-clinical-trial-live-attenuated-zika-vaccine', 'title': 'NIH begins clinical trial of live, attenuated Zika vaccine', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Aug 16, 2018', 'snippet': 'Vaccinations have begun in a first-in-human trial of an experimental live, \nattenuated Zika virus vaccine developed by scientists at the...', 'thumbnail': 'https://serpapi.com/searches/67241657bb55ff6f6c7448a0/images/0250c23472eb70bdba009b8abd3b38db406a5735024ca2f0671586a1e5b4b57a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9299003481864929}",,,,,,,,,,['neutral'],neutral,1
NCT05028582,"{'position': 1, 'link': 'https://www.pharmacytimes.com/view/fda-accepts-snda-of-roflumilast-foam-for-scalp-and-body-psoriasis', 'title': 'FDA Accepts sNDA of Roflumilast Foam for Scalp and Body Psoriasis', 'source': 'Pharmacy Times', 'date': '1 month ago', 'snippet': 'The FDA assigned a Prescription Drug User Fee Act action date of May 22, \n2025.', 'thumbnail': 'https://serpapi.com/searches/6724166a7b05ca376cd59059/images/11aa4b30f5fe9fe15c22bbcca1fb638d3663a7bc3e6cd30eafc425fadcdebd2a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9067659378051758}",,,,,,,,,,['neutral'],neutral,1
NCT03006926,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2020/09/04/fda-rejects-keytruda-lenvima-combo-as-first-line-treatment-for-liver-cancer/', 'title': 'FDA Rejects Keytruda-Lenvima Combo as First-line Treatment for Liver Cancer', 'source': 'Immuno-Oncology News', 'date': 'Sep 4, 2020', 'snippet': 'The U.S. Food and Drug Administration (FDA) has issued a complete response \nletter stating that it will not approve the combination of...', 'thumbnail': 'https://serpapi.com/searches/672416782a7727e9d2444312/images/742113a7ab73c34cfa9866dcf7b0ad89fb6f8fea11705e2f1b464ae67993b64e.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6010357737541199}",,,,,,,,,,['negative'],negative,0
NCT03931681,"{'position': 1, 'link': 'https://news.cuanschutz.edu/cancer-center/onkure-and-cu-cancer-center-announce-first-patient-enrolled-in-clinical-trial-of-oki-179', 'title': 'OnKure and CU Cancer Center announce first patient enrolled in clinical trial of OKI-179, a potent and selective HDAC inhibitor', 'source': 'University of Colorado Anschutz Medical Campus', 'date': 'Jun 17, 2019', 'snippet': 'OnKure, Inc. and the University of Colorado Cancer Center announced \nenrollment of the first patient in a first-in-human phase 1 clinical trial.', 'thumbnail': 'https://serpapi.com/searches/6724167cbd7cf00e347d3124/images/11755ccddec38544219b6b671124055cb02b09c666a21d578362f2f62a5b68bd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.934752345085144}",,,,,,,,,,['neutral'],neutral,1
NCT01757184,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1501365', 'title': 'A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency', 'source': 'The New England Journal of Medicine', 'date': 'Sep 10, 2015', 'snippet': 'Sebelipase alfa therapy resulted in a reduction in multiple disease-related \nhepatic and lipid abnormalities in children and adults with lysosomal acid \nlipase...', 'thumbnail': 'https://serpapi.com/searches/6724179f2da15795533ddf3c/images/65c68207089ea1d4c9bb12d8e15d7e63120cd8057f498ed653d726befb44e4ef.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8553785681724548}",,,,,,,,,,['neutral'],neutral,1
NCT02211209,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1715944', 'title': 'Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome', 'source': 'The New England Journal of Medicine', 'date': 'Aug 7, 2019', 'snippet': 'Familial chylomicronemia syndrome is a rare genetic disorder that is caused \nby loss of lipoprotein lipase activity and characterized by...', 'thumbnail': 'https://serpapi.com/searches/672417afd997ab53a5e9aa0b/images/cb98e0da1cb6cae4392f5c1d7241ffbd78ad5cef6883e9699671b1b0b7a2248d.png', 'sentiment': 'negative', 'sentiment_prob': 0.6402949094772339}",,,,,,,,,,['negative'],negative,0
NCT03953235,"{'position': 1, 'link': 'https://www.globenewswire.com/en/news-release/2024/04/15/2862633/0/en/Nature-Medicine-Publishes-Interim-Results-from-Gritstone-bio-s-Phase-1-2-Study-of-Off-the-Shelf-Neoantigen-Vaccine-Platform-SLATE.html', 'title': 'Nature Medicine Publishes Interim Results from Gritstone', 'source': 'GlobeNewswire', 'date': 'Apr 15, 2024', 'snippet': ""Paper details vaccine design optimization process of Gritstone's \n“off-the-shelf” or shared neoantigen vaccine platform, SLATE."", 'thumbnail': 'https://serpapi.com/searches/672417c3ee4682bcbcfc474a/images/50a7ea1a101bce8197f4ed733401bc1c8d8656dc04ccaebc9ccc21cfb874be66.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9221785068511963}",,,,,,,,,,['neutral'],neutral,1
NCT02277743,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1610020', 'title': 'Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis', 'source': 'The New England Journal of Medicine', 'date': 'Oct 1, 2016', 'snippet': 'In two randomized, placebo-controlled, phase 3 trials of identical design \n(SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe...', 'thumbnail': 'https://serpapi.com/searches/672417f64791c47929720b04/images/25c230bead31c862548675d72c27e3fd661da4532b2f2741a29a0703bcde16bb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8945711851119995}","{'position': 2, 'link': 'https://www.researchgate.net/publication/377449873_Efficacy_Comparison_of_Targeted_Systemic_Monotherapies_Including_Lebrikizumab_for_Moderate-to-Severe_Atopic_Dermatitis_a_Network_Meta-Analysis', 'title': 'Moderate to- Severe Atopic Dermatitis: a Network Meta Analysis', 'source': 'ResearchGate', 'date': 'Jan 19, 2024', 'snippet': 'PDF | Background: Atopic dermatitis (AD) is a chronic inflammatory skin \ndisease affecting 2–7% of adults globally, with 30% experiencing.', 'thumbnail': 'https://serpapi.com/searches/672417f64791c47929720b04/images/25c230bead31c8628c3394e6344bbc9b4985e196b3db34c4f435b5354a41d579.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5824444890022278}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00672191,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-022-01007-w', 'title': 'mRNA-based therapeutics: powerful and versatile tools to combat diseases | Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': 'May 21, 2022', 'snippet': 'The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat \na wide range of incurable diseases. Recent rapid advances in...', 'thumbnail': 'https://serpapi.com/searches/672417fbdc969fad1f5ae655/images/6f5ef6ae6c30f43ebc72cf5ce58854c63014adc1d812db4b0db524b585547b39.png', 'sentiment': 'positive', 'sentiment_prob': 0.7752447724342346}",,,,,,,,,,['positive'],positive,1
NCT02644668,"{'position': 1, 'link': 'https://smanewstoday.com/ck-2127107-ck-107/', 'title': 'Reldesemtiv for SMA', 'source': 'SMA News Today', 'date': 'Aug 16, 2024', 'snippet': 'Reldesemtiv (formerly CK-2127107) was being developed by Cytokinetics to \ntreat spinal muscular atrophy and ALS.', 'thumbnail': 'https://serpapi.com/searches/67241814f9f904be0f459556/images/e24d6322f11e68e83410237d06377c9d806717570ba955d0cda9300a94eda401.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9099122881889343}",,,,,,,,,,['neutral'],neutral,1
NCT05271552,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/on-demand-bxcl501-seen-ease-alzheimers-agitation-phase-3-trial/', 'title': ""BXCL501 seen to ease Alzheimer's agitation in Phase 3 trial |..."", 'source': ""Alzheimer's News Today"", 'date': 'Jun 30, 2023', 'snippet': ""On-demand treatment with BXCL501 was found to significantly ease episodes \nof agitation for Alzheimer's patients in a Phase 3 clinical trial."", 'thumbnail': 'https://serpapi.com/searches/67241816f8b05d9e91665be5/images/90f1fa62ebba5dea07f603471be23d688707c7522400eb95fe60af045d65c2b8.png', 'sentiment': 'positive', 'sentiment_prob': 0.5488898754119873}",,,,,,,,,,['positive'],positive,1
NCT04073602,"{'position': 1, 'link': 'https://www.onclive.com/view/disitamab-vedotin-shows-efficacy-in-her2-negative-metastatic-urothelial-carcinoma', 'title': 'Disitamab Vedotin Shows Efficacy in HER2-Negative Metastatic Urothelial Carcinoma', 'source': 'OncLive', 'date': 'Jun 30, 2022', 'snippet': 'Disitamab vedotin (RC48-ADC) demonstrated promising efficacy with a \ntolerable safety profile in patients with HER2-negative metastatic \nurothelial carcinoma.', 'thumbnail': 'https://serpapi.com/searches/67241824e92456ab794d42cf/images/f672edf9049ee52c712ca9847d3a3c1f642f0747732eef24a59cbfb9ce4f710f.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6696291565895081}",,,,,,,,,,['positive'],positive,1
NCT03347279,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2034975', 'title': 'Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma', 'source': 'The New England Journal of Medicine', 'date': 'May 12, 2021', 'snippet': 'We conducted a phase 3, multicenter, randomized, double-blind, \nplacebo-controlled trial. Patients (12 to 80 years of age) were randomly...', 'thumbnail': 'https://serpapi.com/searches/67241868d364b4f6c8975ad2/images/0dc1473abb6c3984b05a030a5b56a2992c7f6f038b469d31127a9c33252615e0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8530923128128052}",,,,,,,,,,['neutral'],neutral,1
NCT04770220,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/alz-801-sustains-cognition-2-year-early-alzheimers-trial-data/', 'title': 'ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s...', 'source': ""Alzheimer's News Today"", 'date': 'Sep 22, 2023', 'snippet': ""Two years of oral ALZ-801 sustained cognition and lower levels of \ndisease-related biomarkers in early Alzheimer's patients with APOE4..."", 'thumbnail': 'https://serpapi.com/searches/6724187f5ddfba8fdaa1fefb/images/b2e281e64f04fcce6921af0423ddca72829625a5471fa90fb65fd001dd7a39a3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6040478348731995}",,,,,,,,,,['neutral'],neutral,1
NCT03803007,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/abs/10.1161/SVIN.03.suppl_2.006', 'title': 'Abstract 006: Glenzocimab Is Associated With Less Haemorrhagic Transformation Using Artificial Intelligence Imaging In Mechanical Thrombectomy Patients', 'source': 'American Heart Association Journals', 'date': 'Nov 10, 2023', 'snippet': 'IntroductionLesion volume measurement provides an objective and \nquantitative assessment of stroke severity and it is often used as a...', 'thumbnail': 'https://serpapi.com/searches/672418813ad34db6889491c3/images/bf1b37174f51dd2520590d046966d6e8f5530f5874d3b77ad4c52ed86bd688b5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9045994877815247}",,,,,,,,,,['neutral'],neutral,1
NCT01556776,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/news/lenalidomide-chronic-leukemia-phase-3-cllm1-trial-treatment-risk/', 'title': 'Lenalidomide Maintenance Therapy Linked With B-Cell Acute Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia', 'source': 'Hematology Advisor', 'date': 'Mar 25, 2021', 'snippet': 'Study of 3 patients from phase 3 CLLM1 trial, researchers showed a link to \nthe development of B-cell ALL with lenalidomide treatment for...', 'thumbnail': 'https://serpapi.com/searches/67241893b5ecbb920ddedc16/images/60e5dd725a8fb92d6a652430f8fb335f8d89b9de81fc607f781ba4d96023cdf7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9085406064987183}",,,,,,,,,,['neutral'],neutral,1
NCT03708328,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-021-00868-x', 'title': 'Emerging new therapeutic antibody derivatives for cancer treatment | Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': '٠٧\u200f/٠٢\u200f/٢٠٢٢', 'snippet': 'In this review, we summarize antibodies of various molecular types, \nantibody applications in cancer therapy, and details of clinical study \nadvances.', 'thumbnail': 'https://serpapi.com/searches/6724189fd997ab53a5e9aa4c/images/1650d23dcc72a9481aba531f07e913b71b51febd30823599b22140bbc751ce53.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8890555500984192}",,,,,,,,,,['neutral'],neutral,1
NCT01194570,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1606468', 'title': 'Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Dec 21, 2016', 'snippet': 'Among patients with primary progressive multiple sclerosis, ocrelizumab was \nassociated with lower rates of clinical and MRI progression than placebo.', 'thumbnail': 'https://serpapi.com/searches/672418a9ba114203b64bb2d6/images/165140e2601530380e5a9c511ba845cf3c4cad697f50ca6b3f396c0f7949fbc0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8376652002334595}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/ocrevus-ocrelizumab-primary-progressive-relapsing-multiple-sclerosis/', 'title': 'Ocrevus (Ocrelizumab) for MS: Uses, Side Effects, and More', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 17, 2022', 'snippet': 'Ocrevus (ocrelizumab) is a disease-modifying therapy for PPMS and relapsing \nMS. Learn more about its uses, indications, and side effects.', 'thumbnail': 'https://serpapi.com/searches/672418a9ba114203b64bb2d6/images/165140e260153038fa519856bd0cf48e02647dceaa06619bbc8b4b360c5168c9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9069978594779968}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2020/04/28/new-6-year-data-for-genentechs-ocrevus-ocrelizumab-show-earlier-treatment-initiation-nearly-halves-risk-of-needing-walking-aid-in-relapsing-multiple-sclerosis/', 'title': 'Ocrevus in MS Trials Seen to Lower Need for Walking Aid Over 6 Years', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 29, 2020', 'snippet': 'Data at 6 years show relapsing MS patients who started on Ocrevus in trials \nless likely to attain a 6.0 EDSS score than those who switched...', 'thumbnail': 'https://serpapi.com/searches/672418a9ba114203b64bb2d6/images/165140e2601530385511df390b34d6400992e50f66285b5feb1789aeae847962.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7668011784553528}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00203112,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/minocycline-for-rrms/', 'title': 'Minocycline in MS | Experimental MS Treatments', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 6, 2022', 'snippet': 'Minocycline is an oral antibiotic being evaluated as a potential treatment \nfor MS. Learn more about its uses, side effects, and clinical...', 'thumbnail': 'https://serpapi.com/searches/672418ab9f8bfc44aaac8a80/images/0473df366c037d9290b78b7c552d5e2e8f6764821787c5ec6884a61f6bb2ffb2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9326553344726562}",,,,,,,,,,['neutral'],neutral,1
NCT02231866,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-024-00833-z', 'title': 'Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials', 'source': 'Nature', 'date': 'Mar 29, 2024', 'snippet': 'Ebola virus disease (EVD) is a filoviral infection caused by virus species \nof the Ebolavirus genus including Zaire ebolavirus (EBOV) and...', 'thumbnail': 'https://serpapi.com/searches/672418bfefad2183fae89c4d/images/fbce37e792eeafb6f8ef932751d86d2fd22a9e74eee07b8765904d9d1e99d5f6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.788805365562439}",,,,,,,,,,['neutral'],neutral,1
NCT03084926,"{'position': 1, 'link': 'https://ascopubs.org/doi/10.1200/JCO.20.00596', 'title': 'First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors', 'source': 'ASCO Publications', 'date': 'Dec 10, 2020', 'snippet': 'PURPOSEA first-in-human study was performed with MP0250, a DARPin drug \ncandidate. MP0250 specifically inhibits both vascular endothelial...', 'thumbnail': 'https://serpapi.com/searches/672418cb48b9f7f46b775d07/images/e6b6f08e5e75547c47b31b52129b1d90f930168e627717a7319230594d9f60d9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9029291272163391}",,,,,,,,,,['neutral'],neutral,1
NCT02857569,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-0994-4', 'title': 'Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives', 'source': 'Nature', 'date': 'Jul 27, 2020', 'snippet': 'The emergence of human intratumoural immunotherapy (HIT-IT) is a major step \nforward in the management of unresectable melanoma.', 'thumbnail': 'https://serpapi.com/searches/672418e20197dd4da32e65aa/images/00e871fe0e17aeaf6e8762ae9ccd4f24ed4f6ecfe1fe6c7ed1ec69808d42a4ab.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8569298386573792}",,,,,,,,,,['neutral'],neutral,1
NCT03517176,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-21858-1', 'title': 'Tumor-penetrating therapy for β5 integrin-rich pancreas cancer', 'source': 'Nature', 'date': 'Mar 9, 2021', 'snippet': 'Pancreatic ductal adenocarcinoma (PDAC) is characterized by marked \ndesmoplasia and drug resistance due, in part, to poor drug delivery to...', 'thumbnail': 'https://serpapi.com/searches/672418fb0197dd4da32e65ad/images/66e5c8d3afc7a68b27379e7afb1ba6a658e86a005b3e9e140045dc7a9c74c932.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6579923033714294}",,,,,,,,,,['negative'],negative,0
NCT01568099,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/experimental-treatments/affitope-pd01a/', 'title': 'ACI-7104 for Parkinson’s disease', 'source': ""Parkinson's News Today"", 'date': 'Jun 14, 2024', 'snippet': 'Last updated June 14, 2024, by Marta Figueiredo, PhD ✓ Fact-checked by Ana \nde Barros, PhD. How ACI-7104 works. Administration. Clinical trials. Side \neffects...', 'thumbnail': 'https://serpapi.com/searches/6724192648c429ecf8b683ef/images/d3faf14b8bd33cabcbb9e0387c3889bccd7304735fb09f37e38a1d6d95955df8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9401443600654602}",,,,,,,,,,['neutral'],neutral,1
NCT02101385,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/news/triple-negative-breast-cancer-ngs-guided-therapy-did-not-improve-outcomes/', 'title': 'NGS-Guided Therapy Did Not Improve Outcomes in Triple-Negative Breast Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Jan 10, 2022', 'snippet': 'Genomically directed therapy did not improve outcomes in patients who had \nresidual triple-negative breast cancer after neoadjuvant...', 'thumbnail': 'https://serpapi.com/searches/6724193b81bab7b8fdf0d64f/images/387a45fe1048c53f4764349a9597a106299a923129e81231bada2f5b1720d939.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8586665391921997}",,,,,,,,,,['negative'],negative,0
NCT05086276,"{'position': 1, 'link': 'https://www.genengnews.com/topics/drug-discovery/stockwatch-regenerons-all-ears-for-hearing-loss-drug-developer/', 'title': 'StockWatch: Regeneron’s All Ears for Hearing Loss Drug Developer', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Aug 11, 2023', 'snippet': 'Decibel Therapeutics finds a buyer as Regeneron Pharmaceuticals agrees to \nbuy the hearing loss drug developer for up to $213 million.', 'thumbnail': 'https://serpapi.com/searches/6724195e2da15795533ddf8e/images/a72b163cfa7d4c008b0f7c4325c8212d34403a554287696a8dfcad7c977cde58.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8836510181427002}","{'position': 2, 'link': 'https://www.genengnews.com/gen-edge/frequency-change-korro-bio-edits-its-message-rewrites-its-future-with-reverse-merger/', 'title': 'Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Aug 7, 2023', 'snippet': 'Korro Bio plans a reverse merger with Frequency Therapeutics to fund \nclinical studies of its lead candidate, designed to treat alpha-1...', 'thumbnail': 'https://serpapi.com/searches/6724195e2da15795533ddf8e/images/a72b163cfa7d4c00157e32282589b1d9d59e16ad55a889ddd8d165ba1756d6a8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8689308762550354}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04577404,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-presents-new-results-of-radicava-edaravone-for-people-living-with-als-at-the-european-network-to-cure-als-encals-meeting-2024-302172441.html', 'title': 'Mitsubishi Tanabe Pharma America Presents New Results of RADICAVA® (edaravone) for People Living with ALS at the European Network to Cure ALS (ENCALS) Meeting 2024', 'source': 'PR Newswire', 'date': 'Jun 17, 2024', 'snippet': 'PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today \nannounced results from two studies of RADICAVA® (edaravone) for...', 'thumbnail': 'https://serpapi.com/searches/67241a17efad2183fae89c9b/images/874490850a28bec464189434bf5108dff595c33b214b4f41d391d8be0bb5e8f2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9170039296150208}",,,,,,,,,,['neutral'],neutral,1
NCT04871711,"{'position': 1, 'link': 'https://nationaleczema.org/blog/leo-12622/', 'title': 'LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 1 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE)', 'source': 'National Eczema Association', 'date': 'Dec 6, 2022', 'snippet': 'The first phase 3 clinical trial (DELTA 1) with delgocitinib cream in \nadults with moderate to severe chronic hand eczema (CHE) met primary...', 'thumbnail': 'https://serpapi.com/searches/67241a3571c62b8d36d253c4/images/fc6366bf096c5a59eb290de56a4e9feda6c15f029a318afb60a6773209cc2250.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5227524638175964}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/delgocitinib-cream-significantly-improves-chronic-hand-eczema-in-trial/', 'title': 'Delgocitinib Cream Significantly Improves Chronic Hand Eczema in Trial', 'source': 'Medical Professionals Reference', 'date': 'Dec 6, 2022', 'snippet': 'Delgocitinib cream significantly improved chronic hand eczema in adult \npatients, according to topline results from the DELTA 1 study.', 'thumbnail': 'https://serpapi.com/searches/67241a3571c62b8d36d253c4/images/fc6366bf096c5a59f568b1998490d90e8fa2447de3e81d1613b900daa18a5127.png', 'sentiment': 'positive', 'sentiment_prob': 0.8139118552207947}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02643862,"{'position': 1, 'link': 'https://www.thelancet.com/journals/langas/article/PIIS2468-1253(17)30392-8/fulltext?elsca1=tlpr', 'title': 'Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial', 'source': 'The Lancet', 'date': 'Dec 11, 2017', 'snippet': 'We did a pilot study testing whether anti-IgE (omalizumab) combined with \nmultifood oral immunotherapy benefited multifood allergic patients.', 'thumbnail': 'https://serpapi.com/searches/67241a3eb691a7ace56a85f8/images/ad9b5c776c1e2b6e1d6d9f8d6e1fea8fd732edf27d70183e593db8539e02cdc3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8796260952949524}",,,,,,,,,,['neutral'],neutral,1
NCT00846040,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/eating-habits-body-fat-related-differences-brain-chemistry', 'title': 'Eating habits, body fat related to differences in brain chemistry', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Sep 9, 2014', 'snippet': 'NIH study ties eating in response to food cues to habit-forming region in \nobese adults.', 'thumbnail': 'https://serpapi.com/searches/67241a48708e2e993b0dde62/images/a8c60ea0a81d2212f8d565e76be060c597a20f4ac8765965ad8c203977d8ca2b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9214413166046143}",,,,,,,,,,['neutral'],neutral,1
NCT04569435,"{'position': 1, 'link': 'https://alsnewstoday.com/news/annexon-anx005-slows-als-progression-phase-2-study/', 'title': ""Annexon's ANX005 Slows ALS Progression in Phase 2a Study"", 'source': 'ALS News Today', 'date': 'Jan 13, 2023', 'snippet': ""ANX005, Annexon Biosciences' lead experimental medication, slowed disease \nprogression in adults with ALS, study results show."", 'thumbnail': 'https://serpapi.com/searches/67241a60e1d1adc069a08148/images/c3997f2c269b61cf8616fa79c7daa82afd2612a80f0749e58ada0ae673317781.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6895772814750671}",,,,,,,,,,['neutral'],neutral,1
NCT04886622,"{'position': 1, 'link': 'https://www.nature.com/articles/s41420-022-01296-8', 'title': 'Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice | Cell Death Discovery', 'source': 'Nature', 'date': 'Jan 2, 2023', 'snippet': 'Small-cell lung cancer (SCLC) is an aggressive malignancy with limited \ntherapeutic options. The dismal prognosis in SCLC is in part...', 'thumbnail': 'https://serpapi.com/searches/67241a62ce1e10a40aec6650/images/e55c15a0e37e8d0703fb2f8aa59fe81e0e55ffa37cbc90ba75e454fa8dee2bf6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6004174947738647}",,,,,,,,,,['neutral'],neutral,1
NCT02795429,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-00264-x', 'title': 'Targeted therapy for hepatocellular carcinoma - Signal Transduction and Targeted Therapy', 'source': 'Nature', 'date': 'Aug 11, 2020', 'snippet': 'The last 3 years have seen the emergence of promising targeted therapies \nfor the treatment of hepatocellular carcinoma (HCC).', 'thumbnail': 'https://serpapi.com/searches/67241a692c83d5b81af4c6c4/images/5a5b8df2aab3ffb3620a95ab8d29bbf41645ccbe523a7397422e3191cb319fe3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6826193332672119}",,,,,,,,,,['neutral'],neutral,1
NCT05136885,"{'position': 1, 'link': 'https://alsnewstoday.com/news/enrollment-complete-als-phase-2-3-trial-sls-005/', 'title': 'Enrollment complete in HEALEY Phase 2/3 trial arm of SLS-005', 'source': 'ALS News Today', 'date': 'Feb 15, 2023', 'snippet': 'Seelos Therapeutics has completed patient enrollment in its Phase 2/3 \nclinical trial evaluating SLS-005 as a treatment for ALS.', 'thumbnail': 'https://serpapi.com/searches/67241a73c117a94b2401b8f6/images/322240eeb7344601b8688c4005e6c7b3e83afab82f8ed9da50414ea50a9dd0cc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8740873336791992}","{'position': 2, 'link': 'https://alsnewstoday.com/news/expanded-access-program-sls-005-trehalose-dosing/', 'title': 'Expanded access program for SLS-005 begins treating first ALS patient', 'source': 'ALS News Today', 'date': 'Apr 11, 2023', 'snippet': 'An expanded access program treating ALS patients ineligible for clinical \ntrials with SLS-005, containing trehalose, has dosed a first...', 'thumbnail': 'https://serpapi.com/searches/67241a73c117a94b2401b8f6/images/322240eeb7344601abfd11dd6dc598cb6392c8f47db1d6e9dcde3c6da546b230.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9012346267700195}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03726515,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.669071/full', 'title': 'Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma', 'source': 'Frontiers', 'date': 'May 6, 2021', 'snippet': 'Autologous chimeric antigen receptor (CAR) T cells targeted to epidermal \ngrowth factor receptor variant III (CAR T-EGFRvIII) have been...', 'thumbnail': 'https://serpapi.com/searches/67241a7d9fd3095e762f9325/images/d1ebc42727554aac59a65dd6a4861b50fdf1f0419858122617b4f84a09cb6a9e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.911949634552002}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-020-16160-5', 'title': 'Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma', 'source': 'Nature', 'date': 'May 8, 2020', 'snippet': 'Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable \nclinical efficacy against B-cell malignancies, yet marked vulnerability...', 'thumbnail': 'https://serpapi.com/searches/67241a7d9fd3095e762f9325/images/d1ebc42727554aace315afe703a3d087bea1a7f89b1819a9ac053e705c50e386.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7855530977249146}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02955355,"{'position': 1, 'link': 'https://www.empr.com/home/news/hyqvia-reduces-relapse-in-chronic-inflammatory-demyelinating-polyradiculoneuropathy-trial/', 'title': 'Hyqvia Reduces Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Trial', 'source': 'Medical Professionals Reference', 'date': 'Jul 21, 2022', 'snippet': 'Topline data were announced from a phase 3 trial evaluating the efficacy \nand safety of Hyqvia® (immune globulin infusion 10% [human] with...', 'thumbnail': 'https://serpapi.com/searches/67241a88f8b05d9ece9f1798/images/902a7492ce0211fa475c739fb30e76e7a94909e81f5a3d4e03b5c087d085d402.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7634502649307251}",,,,,,,,,,['neutral'],neutral,1
NCT01757535,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2004444', 'title': 'Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission', 'source': 'The New England Journal of Medicine', 'date': 'Dec 23, 2020', 'snippet': 'We conducted a phase 3, randomized, double-blind, placebo-controlled trial \nof the oral formulation of azacitidine (CC-486, a hypomethylating...', 'thumbnail': 'https://serpapi.com/searches/67241a895235f60c4e295b9d/images/5ee9c1a6d940b411c194092d81104f9a916423786176bc92cb2504d40d592302.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9053488969802856}","{'position': 2, 'link': 'https://www.cancertherapyadvisor.com/news/leukemia-aml-oral-azacitidine-maintenance-therapy-post-remission-new-standard/', 'title': 'Postremission Oral Azacitidine Maintenance Therapy Proposed As a New Standard of Care in Some Patients With AML', 'source': 'Cancer Therapy Advisor', 'date': 'Dec 12, 2019', 'snippet': 'Eligibility criteria for this study included intermediate- or high-risk \ncytogenetics, and CR or CR with incomplete count recovery following...', 'thumbnail': 'https://serpapi.com/searches/67241a895235f60c4e295b9d/images/5ee9c1a6d940b411118aa402cda231e6c320dfaa446f86257341ed016022bcc8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8953773975372314}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02908685,"{'position': 1, 'link': 'https://smanewstoday.com/news/british-columbia-funds-evrysdi-canadian-province-sma-patients/', 'title': 'Evrysdi for SMA Patients in British Columbia Being Offered at No Cost', 'source': 'SMA News Today', 'date': 'Feb 21, 2022', 'snippet': 'The provincial government of British Columbia will cover the cost of \nEvrysdi (risdiplam), the oral spinal muscular atrophy (SMA) therapy \napproved by Health...', 'thumbnail': 'https://serpapi.com/searches/6724199e23a4b5ab47584d11/images/47b58a4ae3852300ced0592d2a80d43305847ff5d47752da3002b2447911ac3a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9134345054626465}","{'position': 2, 'link': 'https://smanewstoday.com/evrysdi-risdiplam/', 'title': 'Evrysdi (risdiplam) for spinal muscular atrophy', 'source': 'SMA News Today', 'date': 'Aug 8, 2020', 'snippet': 'Evrysdi (risdiplam) is a daily disease-modifying therapy approved for \nchildren and adults with spinal muscular atrophy (SMA).', 'thumbnail': 'https://serpapi.com/searches/6724199e23a4b5ab47584d11/images/47b58a4ae3852300a14bbbdd11d89a2b2ae4f359390c2235861dfed463efed3e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8439708948135376}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03834688,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/twenty-years-of-advancing-discoveries-and-treatment-of-mantle-cell-lymphoma', 'title': 'Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma', 'source': 'Cancer Network', 'date': 'Feb 8, 2024', 'snippet': 'In 2023, the Lymphoma Research Foundation hosted the Mantle Cell Lymphoma \nScientific Consortium and Workshop to discuss treatment...', 'thumbnail': 'https://serpapi.com/searches/6724199f740bdbfb13b90964/images/f7420c77fee35091b8d888e81b8b0d69853000fb8f37343b831294175a84b2eb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8921674489974976}",,,,,,,,,,['neutral'],neutral,1
NCT04013672,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.966696/full', 'title': 'Efficacy and safety of innate and adaptive immunotherapy combined with standard of care in high-grade gliomas: a systematic review and meta-analysis', 'source': 'Frontiers', 'date': 'Feb 6, 2024', 'snippet': 'BackgroundMalignant glioma is the most common intracranial malignant tumor \nwith the highest mortality. In the era of immunotherapy, it is important \nto...', 'thumbnail': 'https://serpapi.com/searches/67241a9a577da558bd156c65/images/c2b309afd07520d97f9e4048cfdbab2187e2635a8bdbbb8f46183270679df7d1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8517996072769165}",,,,,,,,,,['neutral'],neutral,1
NCT02871791,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-45835-6', 'title': 'Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial', 'source': 'Nature', 'date': 'Mar 19, 2024', 'snippet': 'Here we present the final results of a phase Ib/IIa, open-label trial \n(NCT02871791) of exemestane plus everolimus and palbociclib for \nCDK4/6i-resistant...', 'thumbnail': 'https://serpapi.com/searches/67241aa9175de69837edd3ea/images/5a0570c9a46ce9fc347ccef630e50421fe671f926318dd4bb4a3d312c685ac23.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9008781313896179}",,,,,,,,,,['neutral'],neutral,1
NCT00514683,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1103690', 'title': 'Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis', 'source': 'The New England Journal of Medicine', 'date': 'Apr 30, 2018', 'snippet': 'BIBF 1120 is a potent intracellular inhibitor of tyrosine kinases that is \nin clinical development for the treatment of idiopathic pulmonary fibrosis \nand a...', 'thumbnail': 'https://serpapi.com/searches/67241abe49ea5508c8ff20c3/images/eba38665fe5102603944b41a007653b6e1613eb1346ce922e33ee8cb8e0eef35.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8839802145957947}","{'position': 2, 'link': 'https://lungdiseasenews.com/2017/10/24/analysis-shows-ofev-improves-long-term-lung-function-of-pulmonary-fibrosis-patients/', 'title': ""IPF Patients' Long-term Lung Function Improves with Ofev, Study Shows"", 'source': 'Lung Disease News', 'date': 'Oct 24, 2017', 'snippet': ""Read about a Phase 2 trial and extension showing that Ofev improves \npulmonary fibrosis patients' long-term lung function and reduces their..."", 'thumbnail': 'https://serpapi.com/searches/67241abe49ea5508c8ff20c3/images/eba38665fe5102601a90c353032baaf23262f34fd6578c4c3698a4af24a9a0c0.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6028978228569031}","{'position': 3, 'link': 'https://pulmonaryfibrosisnews.com/news/ipf-patients-live-longer-on-nintedanib-pooled-data-from-six-trials-show/', 'title': 'IPF Patients Live Longer on Ofev Compared with Placebo, Analysis Shows', 'source': 'Pulmonary Fibrosis News', 'date': 'Apr 16, 2019', 'snippet': 'Treatment with Ofev (nintedanib) can significantly extend the survival of \npatients with idiopathic pulmonary fibrosis (IPF), an analysis of pooled \ndata from...', 'thumbnail': 'https://serpapi.com/searches/67241abe49ea5508c8ff20c3/images/eba38665fe510260653217e684fdb71399d6facac13dc28bf028bbe41a3fa1c9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.544462263584137}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT02981407,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2307983', 'title': 'Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia', 'source': 'The New England Journal of Medicine', 'date': 'Nov 11, 2023', 'snippet': 'A strategy of administering a transfusion only when the hemoglobin level \nfalls below 7 or 8 g per deciliter has been widely adopted. However, \npatients with...', 'thumbnail': 'https://serpapi.com/searches/67241ac3be1497ff0398f231/images/bea366c3442a5a23cc5a1b7d41a54aa45e53717df7f8dd52b4ceda4ce21bffea.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8786980509757996}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057909', 'title': 'One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial', 'source': 'American Heart Association Journals', 'date': 'Feb 7, 2022', 'snippet': 'Uncertainty exists on the optimal transfusion strategy in patients with \nanemia and acute myocardial infarction (AMI). Observational studies...', 'thumbnail': 'https://serpapi.com/searches/67241ac3be1497ff0398f231/images/bea366c3442a5a236762ca4d77f55896481f12ceb09f6d45a9e9075250331ef9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6346853971481323}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04506463,"{'position': 1, 'link': 'https://www.pharmaceutical-technology.com/news/sun-pharma-moebius-osteoarthritis-treatment/', 'title': 'Sun Pharma and Moebius gain FDA fast track for osteoarthritis drug', 'source': 'Pharmaceutical Technology', 'date': '1 month ago', 'snippet': 'Sun Pharma and Moebius Medical have received fast track designation (FTD) \nfrom the US Food and Drug Administration (FDA) for MM-II.', 'thumbnail': 'https://serpapi.com/searches/67241afe93584c2b3cbbffd0/images/37bacbd5acdc84aa7b416b63538d900ce436885100e31a1908de7c9e1df10d08.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5669798254966736}","{'position': 2, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332223016177', 'title': 'Harnessing the multifunctionality of lipid-based drug delivery systems for the local treatment of osteoarthritis', 'source': 'ScienceDirect.com', 'date': 'Nov 7, 2023', 'snippet': 'This review emphasizes recent advancements in lipid-based drug delivery \nsystems (DDSs) for intra-articular administration of OA therapeutics.', 'thumbnail': 'https://serpapi.com/searches/67241afe93584c2b3cbbffd0/images/37bacbd5acdc84aaeb13b8861ba9783211dbfdc7b9e1d8ee3c5ce40bf13e0b0a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.650626003742218}","{'position': 3, 'link': 'https://www.biospectrumasia.com/news/25/24855/israels-moebius-medical-indias-sun-pharma-receive-fast-track-designation-for-osteoarthritis-knee-pain-medicine.html', 'title': ""Israel's Moebius Medical & India's Sun Pharma receive fast track designation for osteoarthritis knee pain medicine"", 'source': 'BioSpectrum Asia', 'date': '1 month ago', 'snippet': 'The US Food and Drug Administration (FDA) has granted Fast Track \ndesignation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the \ntreatment of...', 'thumbnail': 'https://serpapi.com/searches/67241afe93584c2b3cbbffd0/images/37bacbd5acdc84aa6475b177e784ee961b9b15478c8b3a94559390c6f83d4956.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8736117482185364}","{'position': 4, 'link': 'https://www.expresspharma.in/data-shows-durability-of-pain-relief-for-patients-with-knee-osteoarthritis-oa/', 'title': 'Data shows durability of pain relief for patients with knee osteoarthritis (OA)', 'source': 'Express Pharma', 'date': 'Jun 14, 2024', 'snippet': 'Sun Pharmaceutical Industries, (including its subsidiaries or associate \ncompanies) and Israel-based Moebius Medical presented data...', 'thumbnail': 'https://serpapi.com/searches/67241afe93584c2b3cbbffd0/images/37bacbd5acdc84aad92c73634eef18d90f42e12b551d34a69d34223ec559bc02.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8590989112854004}","{'position': 5, 'link': 'https://www.indianpharmapost.com/drug-approval/sun-pharma-and-moebius-medical-granted-ftd-to-mm-ii-for-treatment-of-osteoarthritis-knee-pain-16140', 'title': 'Sun Pharma and Moebius Medical granted FTD to MM-II for treatment of osteoarthritis knee pain', 'source': 'Indian Pharma Post', 'date': '1 month ago', 'snippet': 'The US Food and Drug Administration (FDA) has granted Fast Track \nDesignation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the \ntreatment of...', 'thumbnail': 'https://serpapi.com/searches/67241afe93584c2b3cbbffd0/images/37bacbd5acdc84aa6c314f2057f7bf39d5ba263c848cf8a9907e69aa944f314a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9046306014060974}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01270074,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/azithromycin-reduces-airway-wall-thickness-infants-study/', 'title': 'Azithromycin reduces airway wall thickness in infants: Study', 'source': 'Cystic Fibrosis News Today', 'date': 'May 3, 2024', 'snippet': 'Azithromycin reduces bronchial wall thickening in CF infants, which may \ntranslate into smoother blood flow to the lungs, per a study.', 'thumbnail': 'https://serpapi.com/searches/67241b2d2da983780b740e3a/images/c6c8f287aa418a1c74eca699b090d511e51d5d07ffb6482ec04e452878a68892.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8316199779510498}",,,,,,,,,,['neutral'],neutral,1
NCT04199169,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-022-00592-9', 'title': 'ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys', 'source': 'Nature', 'date': 'Dec 21, 2022', 'snippet': 'Nipah virus (NiV) is a highly pathogenic and re-emerging virus, which \ncauses sporadic but severe infections in humans.', 'thumbnail': 'https://serpapi.com/searches/67241b2ff60b6f8f33efe72d/images/d2addc037f3d02885e09b14b206917be6b642e3546fad56afa282ddc027c487a.png', 'sentiment': 'negative', 'sentiment_prob': 0.5253660678863525}",,,,,,,,,,['negative'],negative,0
NCT02274766,"{'position': 1, 'link': 'https://www.nature.com/articles/s41531-022-00291-1', 'title': 'Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease', 'source': 'Nature', 'date': 'Mar 18, 2022', 'snippet': 'An amantadine delayed release/extended release (DR/ER) formulation (Gocovri \n® ) indicated for dyskinesia received additional FDA approval as an adjunct \nto...', 'thumbnail': 'https://serpapi.com/searches/67241bba361fd42d611f4c2d/images/4098283d435f6156920733253cfd279809da34f0e7eae2024f4ff285271031a3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6950205564498901}",,,,,,,,,,['neutral'],neutral,1
NCT03461276,"{'position': 1, 'link': 'https://www.neurologylive.com/view/neurovoices-david-greeley-ar1001-oral-pde5-inhibitor-alzheimers', 'title': 'NeuroVoices: David Greeley, MD, on AR1001, an Oral PDE5 Inhibitor for Alzheimer Disease', 'source': 'Neurology live', 'date': 'Nov 1, 2023', 'snippet': 'David Greeley, MD, chief medical officer at AriBio and study author, \nprovided commentary on the mechanism of action of AR1001, its promising...', 'thumbnail': 'https://serpapi.com/searches/67241bcad771bdf678dc5a44/images/8a0c88ac4a8c5b41efa6c12f6edf8b7a137b85a60c9b400c1d2258eaea3119d9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8086296916007996}",,,,,,,,,,['neutral'],neutral,1
NCT02056665,"{'position': 1, 'link': 'https://angelmansyndromenews.com/minocycline/', 'title': 'Angelman Syndrome in Children Improves with Minocycline, Studies Show', 'source': 'Angelman Syndrome News', 'date': 'Nov 19, 2017', 'snippet': 'Read about studies indicating that the antibiotic minocycline can improve \nthe symptoms of children with Angelman syndrome.', 'thumbnail': 'https://serpapi.com/searches/67241bddc5d7698b996f4a6c/images/0420a780ef895e9ec4084cbf654d0f68939a006ed6773d2c29f3539408e93822.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5991294384002686}",,,,,,,,,,['neutral'],neutral,1
NCT02295826,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.119.027569', 'title': 'Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke', 'source': 'American Heart Association Journals', 'date': 'Feb 26, 2020', 'snippet': 'Background and Purpose—Patients with transient ischemic attack (TIA) and \nminor ischemic stroke are at risk for early recurrent cerebral...', 'thumbnail': 'https://serpapi.com/searches/67241be6b57db8f48f367cae/images/ddc89f7f9b9f640636b8dc9bbb3667aee7851e611ad729b820208d89e99e6bb1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6758471727371216}",,,,,,,,,,['neutral'],neutral,1
NCT01958021,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2114663', 'title': 'Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Mar 10, 2022', 'snippet': 'In a previous analysis of this phase 3 trial, first-line ribociclib plus \nletrozole resulted in significantly longer progression-free survival than \nletrozole...', 'thumbnail': 'https://serpapi.com/searches/67241c20f59d00c57d4022eb/images/f8fad5df7edf75345adc4184b478ca9daf625346fc522d9e7ce9641db4b41f7d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6093955039978027}","{'position': 2, 'link': 'https://ascopubs.org/doi/10.1200/JCO.20.02977', 'title': 'Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies', 'source': 'ASCO Publications', 'date': 'Mar 26, 2021', 'snippet': 'PURPOSEThe prognostic and predictive value of intrinsic subtypes in hormone \nreceptor–positive, human epidermal growth factor receptor...', 'thumbnail': 'https://serpapi.com/searches/67241c20f59d00c57d4022eb/images/f8fad5df7edf75349c60c3054c4cf87211a2d092f90f6c750358bd4116828369.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9209080934524536}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/ribociclib-dose-reductions-maintain-comparable-outcomes-in-hr-her2-negative-advanced-breast-cancer', 'title': 'Comparable Outcomes Maintained With Ribociclib Dose Reductions in HR+/HER2-Negative Advanced Breast Cancer', 'source': 'Cancer Network', 'date': 'Jun 7, 2022', 'snippet': 'Dose reductions of ribociclib administered during the phase 2 MONALEESA-2 \ntrial did not have an impact on overall survival for patients with...', 'thumbnail': 'https://serpapi.com/searches/67241c20f59d00c57d4022eb/images/f8fad5df7edf7534d1d08c16ce41540fb27e120d66d9b5b53eb8527e35d08667.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8730349540710449}","{'position': 4, 'link': 'https://breastcancer-news.com/2017/06/05/kisqali-femara-shows-promise-in-hr-positive-her2-negative-advanced-breast-cancer/', 'title': 'In Certain Advanced Breast Cancer, Kisqali, Femara Combo Shows Promise', 'source': 'breastcancer-news.com', 'date': 'Jun 5, 2017', 'snippet': ""The latest results from the Phase 3 MONALEESA-2 study showed that adding \nNovartis' Kisqali (ribociclib) to \u200eFemara (letrozole) for the..."", 'thumbnail': 'https://serpapi.com/searches/67241c20f59d00c57d4022eb/images/f8fad5df7edf753428859ccec79db0181ae1b00793557e89ec8d3dc3548b7fa9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.779985785484314}","{'position': 5, 'link': 'https://dailynews.ascopubs.org/do/making-sense-paloma-2-and-monaleesa-2-data-treatment-hr-positive-her2-negative', 'title': 'Making Sense of PALOMA-2 and MONALEESA-2 Data for the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer', 'source': 'ASCO Daily News', 'date': 'May 3, 2023', 'snippet': 'PALOMA-2 studied palbociclib, MONALEESA-2 studied ribociclib, and MONARCH-3 \nevaluated abemaciclib. The initial results of these pivotal studies—...', 'thumbnail': 'https://serpapi.com/searches/67241c20f59d00c57d4022eb/images/f8fad5df7edf7534dac83d9eef3e39605265b6ef9353b6625e1dd8de3d79b245.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9260327219963074}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01295827,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1501824', 'title': 'Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Feb 6, 2017', 'snippet': 'We assessed the efficacy and safety of programmed cell death 1 (PD-1) \ninhibition with pembrolizumab in patients with advanced non–small-cell lung \ncancer...', 'thumbnail': 'https://serpapi.com/searches/67241c2b81bab7b92fca1c27/images/f5c239c5aa07451a8c98df74a233132937ba5d433f682f181044a0d3f2829af3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8554887771606445}",,,,,,,,,,['neutral'],neutral,1
NCT01286987,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222008472', 'title': 'PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications', 'source': 'ScienceDirect.com', 'date': 'Jul 23, 2022', 'snippet': 'Since the concept, DNA damage repair has been stated as a natural \nbiological event, and research has increasingly revealed its strong \nassociation to tumors,...', 'thumbnail': 'https://serpapi.com/searches/67241c46b6e4db2835632e9d/images/319b84461322d7964e1577c669dea1797d4ae18474b3c9282e7c2d7083cbb90f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7746975421905518}",,,,,,,,,,['neutral'],neutral,1
NCT03469284,"{'position': 1, 'link': 'https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02579-8', 'title': 'Methylene blue for intractable pain from oral mucositis related to cancer treatment: a randomized phase 2 clinical trial', 'source': 'BMC Medicine', 'date': 'Nov 3, 2022', 'snippet': 'Oral mucositis (OM) in patients receiving cancer therapy is thus far not \nwell managed with standard approaches. We aimed to assess the...', 'thumbnail': 'https://serpapi.com/searches/67241d26adc33b14f874ebd6/images/2723452f1475b8a8a2550db7e76d700f69f97aa392c461caf9181ca86d8f40e0.png', 'sentiment': 'negative', 'sentiment_prob': 0.5885791778564453}",,,,,,,,,,['negative'],negative,0
NCT03341689,"{'position': 1, 'link': 'https://psychedelicalpha.com/news/single-dose-of-psilocybin-reduces-migraines-for-at-least-2-weeks', 'title': 'Single Dose of Psilocybin Reduces Migraines for at Least 2 Weeks', 'source': 'Psychedelic Alpha', 'date': 'Nov 14, 2020', 'snippet': 'New research from Yale finds that a single low dose of psilocybin reduces \nthe frequency of migraine headaches for 2 weeks.', 'thumbnail': 'https://serpapi.com/searches/67241d4421e77bd9839caa8f/images/22008069792cb690eb33d18c4cdccf1c071d0e6020e4d62fc3436d47eddd527d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5920467376708984}",,,,,,,,,,['neutral'],neutral,1
NCT04211740,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/10/13/ectrims-2023-och-shows-promise-treating-spms-small-trial/', 'title': 'ECTRIMS 2023: Treating SPMS with OCH shows promise in small study...', 'source': 'Multiple Sclerosis News Today', 'date': 'Oct 13, 2023', 'snippet': 'Five of six people with secondary progressive MS treated with OCH in a \nsmall clinical trial experienced no disease activity over six months.', 'thumbnail': 'https://serpapi.com/searches/67241c568db376552966162c/images/97f795ac1a8587256cf7b701d651f2c7b7bc5aaeb42e0ab030376060996ee9f7.png', 'sentiment': 'positive', 'sentiment_prob': 0.6194054484367371}",,,,,,,,,,['positive'],positive,1
NCT02436096,"{'position': 1, 'link': 'https://fibromyalgianewstoday.com/2020/09/08/enrollment-open-in-second-phase-3-trial-of-higher-tnx-102-sl-dose-for-managing-fm/', 'title': 'Enrollment Open in Second Phase 3 Trial of Higher TNX-102 SL Dose for Managing FM', 'source': 'Fibromyalgia News Today', 'date': 'Sep 8, 2020', 'snippet': ""The second Phase 3 clinical trial examining a higher dose of TNX-102 SL \n(sublingual cyclobenzaprine), Tonix Pharmaceuticals' bedtime..."", 'thumbnail': 'https://serpapi.com/searches/67241c629819f3cca7de750f/images/4059d25dc2ef9ff422556ee8ed3206b0e720314a1ddf4ab1975189273030f1a6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9358941316604614}",,,,,,,,,,['neutral'],neutral,1
NCT02157792,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-021-01405-x', 'title': 'Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours', 'source': 'Nature', 'date': 'May 26, 2021', 'snippet': 'Berzosertib (formerly M6620, VX-970) is a highly potent and selective, \nfirst-in-class inhibitor of ataxia telangiectasia and Rad3-related...', 'thumbnail': 'https://serpapi.com/searches/67241c64cc2987a5b0417be4/images/b6ff5a137e12c94a5eb8be285a97495d522b152b2b33ba7ef0a4e7c9732fcc1f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7692916989326477}","{'position': 2, 'link': 'https://www.targetedonc.com/view/atr-inhibitor-combinations-begin-to-tackle-dna-damage-repair-in-solid-tumors', 'title': 'ATR Inhibitor Combinations Begin to Tackle DNA Damage Repair in Solid Tumors', 'source': 'Targeted Oncology', 'date': 'Dec 17, 2021', 'snippet': ""ATR's integral role in DNA damage repair has made it an appealing target \nfor cancer treatment, and several ATR inhibitors are being..."", 'thumbnail': 'https://serpapi.com/searches/67241c64cc2987a5b0417be4/images/b6ff5a137e12c94af5ce4fd1868e5e6b31d1ef40ee7ba2910a8be9ba2bb41f3e.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5164445042610168}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02347774,"{'position': 1, 'link': 'https://copdnewstoday.com/news/analyses-phase-3-trials-sun-101-eflow-safe-effective-copd/', 'title': 'Analyses of Phase 3 Trials Show SUN-101/eFlow Safe, Effective for COPD', 'source': 'COPD News Today', 'date': 'Nov 2, 2017', 'snippet': 'Pooled data from three Phase 3 clinical trials shows that the investigative \nSUN-101/eFlow product is well-tolerated and improves lung...', 'thumbnail': 'https://serpapi.com/searches/67241c8890b57c015b7287ca/images/f329bc52528cd40285f0c62462992a1356cd6898d146c7513ff9bf14d304c990.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6960063576698303}","{'position': 2, 'link': 'https://copdnewstoday.com/news/new-drug-application-sunovion-copd-therapy-accepted-fda/', 'title': 'New Drug Application for Sunovion’s COPD Therapy Accepted by FDA', 'source': 'COPD News Today', 'date': 'Oct 20, 2016', 'snippet': ""Read about the FDA acceptance of a New Drug Application for Sunovion's COPD \ntreatment SUN-101 delivered with the eFlow nebulizer."", 'thumbnail': 'https://serpapi.com/searches/67241c8890b57c015b7287ca/images/f329bc52528cd402341bdfb8ad0f937b33a2a84be842750c442f6ad450777788.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7361782193183899}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02586038,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-021-00590-5', 'title': 'Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial', 'source': 'Nature', 'date': 'Dec 7, 2021', 'snippet': 'Here we present the results of the UNITO-EMN10 trial assessing four \nixazomib-based induction regimens followed by ixazomib maintenance in \nelderly, transplant-...', 'thumbnail': 'https://serpapi.com/searches/67241c9c910986cafe52bb15/images/8b24439da860dcfa98ba6a6ef616b82d9c5d706325a58117b4501d0f5063d001.png', 'sentiment': 'neutral', 'sentiment_prob': 0.917239248752594}",,,,,,,,,,['neutral'],neutral,1
NCT02417064,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/response-to-esketamine-after-initial-nonresponse/', 'title': 'Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies', 'source': 'Psychiatrist.com', 'date': 'Jul 20, 2021', 'snippet': 'Only some patients with treatment-resistant depression who ultimately \nrespond to esketamine plus an oral antidepressant do so within the...', 'thumbnail': 'https://serpapi.com/searches/67241cabd910393e0892d3ed/images/e10d077c7981ddbb1827cdef3a454e6ce11572a78c57000d4c95e5fdce241cbc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8129125237464905}",,,,,,,,,,['neutral'],neutral,1
NCT04124926,"{'position': 1, 'link': 'https://www.empr.com/home/news/voquezna-approved-for-erosive-esophagitis-and-associated-heartburn/', 'title': 'Voquezna Approved for Erosive Esophagitis and Associated Heartburn', 'source': 'Medical Professionals Reference', 'date': 'Nov 2, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Voquezna (vonoprazan) \nfor healing and maintenance of healing, of all grades of erosive \nesophagitis, and...', 'thumbnail': 'https://serpapi.com/searches/67241cb0fc40bf5b24978216/images/e09cb15706065512bbaf1189d2ffcd8d355bcd4800782ddeeef3270994e40bd2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7418529987335205}",,,,,,,,,,['neutral'],neutral,1
NCT02929329,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2025797', 'title': 'Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure', 'source': 'The New England Journal of Medicine', 'date': 'Nov 13, 2020', 'snippet': 'The selective cardiac myosin activator omecamtiv mecarbil has been shown to \nimprove cardiac function in patients with heart failure with a reduced \nejection...', 'thumbnail': 'https://serpapi.com/searches/67241cd398d8de9a4cffa47b/images/ac6f05d373d86089eb1eaccff2d08bf90c6dea53cc64f77ae8edbe1b3322b4d1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8340839743614197}",,,,,,,,,,['neutral'],neutral,1
NCT00168103,"{'position': 1, 'link': 'https://angioedemanews.com/berinert/', 'title': 'Berinert (human C1 esterase inhibitor) for hereditary angioedema', 'source': 'Angioedema News', 'date': 'Jan 5, 2024', 'snippet': 'Learn more about Berinert, a C1 esterase inhibitor used as an on-demand \ntherapy for swelling attacks in people with hereditary angioedema.', 'thumbnail': 'https://serpapi.com/searches/67241cf49062f85c40db7e88/images/b4c8faca12eabb9fa11da9dc61aa2c81402521170131e83eaac067acde56fc19.png', 'sentiment': 'neutral', 'sentiment_prob': 0.885195255279541}",,,,,,,,,,['neutral'],neutral,1
NCT03093974,"{'position': 1, 'link': 'https://bronchiectasisnewstoday.com/2018/12/13/fda-grants-qidp-fast-track-status-zambon-colistimethate-sodium-solution/', 'title': 'FDA Grants QIDP, Fast Track Status to Zambon’s Colistimethate Sodium', 'source': 'Bronchiectasis News Today', 'date': 'Dec 13, 2018', 'snippet': ""The U.S. Food and Drug Administration (FDA) granted Qualified Infectious \nDiseases Product (QIDP) and Fast Track designations to Zambon's..."", 'thumbnail': 'https://serpapi.com/searches/67241cf59872179945fc3bc8/images/081ad0062e9c555bedfa12816cb4e02b4d7d4610937ed1a05c2c95ecc28669bb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9160192012786865}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/inhaled-therapy-gets-breakthrough-designation-for-non-cystic-fibrosis-bronchiectasis/', 'title': 'Inhaled Therapy Gets Breakthrough Designation for Non-Cystic Fibrosis Bronchiectasis', 'source': 'Medical Professionals Reference', 'date': 'Apr 21, 2022', 'snippet': 'The Food and Drug Administration (FDA) has granted Breakthrough Therapy \ndesignation to colistimethate sodium powder for nebulization solution (CMS \nI–neb)', 'thumbnail': 'https://serpapi.com/searches/67241cf59872179945fc3bc8/images/081ad0062e9c555b7533fdd70e00941c6d0df27d2805940150ec39127c203d77.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6590794920921326}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02729051,"{'position': 1, 'link': 'https://copdnewstoday.com/news/trelegy-ellipta-seeks-expanded-use-europe-patients-moderate-severe-copd/', 'title': 'Trelegy Ellipta Seeks Expanded Use in E.U. for Moderate to Severe COPD', 'source': 'COPD News Today', 'date': 'Feb 16, 2018', 'snippet': ""Trelegy Ellipta significantly slowed COPD progression, and improved \npatients' lung function, breathlessness, and health-related quality of life."", 'thumbnail': 'https://serpapi.com/searches/67241d8271c62b8cf635b289/images/65480870e7bbb48157fcb7ccf0fa60dce0f6277ab28e0bf92d69852f5000258c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5341325402259827}",,,,,,,,,,['neutral'],neutral,1
NCT05027932,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/trial-potential-universal-flu-vaccine-opens-nih-clinical-center', 'title': 'Trial of potential universal flu vaccine opens at NIH Clinical Center', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jun 28, 2022', 'snippet': 'A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating \nhealthy adult volunteers at the National Institutes of Health Clinical \nCenter in...', 'thumbnail': 'https://serpapi.com/searches/67241fb3910986cafe52bc6c/images/30ac80eb2182188796552b86489d32ea69cc60b6f3628a130d340b8807f58d49.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9052539467811584}",,,,,,,,,,['neutral'],neutral,1
NCT04070326,"{'position': 1, 'link': 'https://www.pharmaceutical-technology.com/news/takeda-wins-eu-approval-for-paediatric-use-of-takhzyro-in-hae/', 'title': 'Takeda wins EU approval for paediatric use of Takhzyro in HAE', 'source': 'Pharmaceutical Technology', 'date': 'Nov 20, 2023', 'snippet': 'Takhzyro has been approved for the routine prevention of recurrent \nhereditary angioedema attacks in patients aged two years and older.', 'thumbnail': 'https://serpapi.com/searches/67241fedb4b72d05f51204dc/images/b834e37107cbc28c5d5af6575cc3eb10803b8f335aa528ab52617c730623a01a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.639147162437439}","{'position': 2, 'link': 'https://angioedemanews.com/news/takhzyro-approved-europe-patients-young-2/', 'title': 'Takhzyro approved in Europe for HAE patients as young as 2', 'source': 'Angioedema News', 'date': 'Nov 20, 2023', 'snippet': 'The European Commission has expanded the approval of Takhzyro (lanadelumab) \nto include children with HAE as young as 2 years of age.', 'thumbnail': 'https://serpapi.com/searches/67241fedb4b72d05f51204dc/images/b834e37107cbc28c1b025f3adc087be5b28200fac3a8cc07ffa4d57fb89b7e3b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6072261929512024}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01575834,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1607948', 'title': 'Romosozumab Treatment in Postmenopausal Women with Osteoporosis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 18, 2016', 'snippet': 'Romosozumab, a monoclonal antibody that binds sclerostin, increases bone \nformation and decreases bone resorption.', 'thumbnail': 'https://serpapi.com/searches/67241ff83c9575b4b1b6c54b/images/7976cee1d81bc700341d7d02de98a299213a9e4133810e925d89a99b195222ce.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8609321117401123}","{'position': 2, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/EVENITY-Romosozumab', 'title': 'Romosozumab (EVENITY®)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Osteoporosis, A study to learn how romosozumab worked in women with \nosteoporosis who had gone through menopause, Phase 3, 20070337', 'thumbnail': 'https://serpapi.com/searches/67241ff83c9575b4b1b6c54b/images/7976cee1d81bc7001757c0b2b313e2e9dacd6f21854f241c8116dffb5f76155b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8978717923164368}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01921712,"{'position': 1, 'link': 'https://copdnewstoday.com/news/copd-clinical-trial-shows-pur0200-good-as-spiriva-handihaler/', 'title': 'Phase 1 Trial Shows PUR0200 for COPD as Good as Spiriva HandiHaler', 'source': 'COPD News Today', 'date': 'Jun 19, 2018', 'snippet': 'PUR0200 was shown to promote similar improvements in lung function in \npatients with chronic obstructive pulmonary disease (COPD), but at \nsignificantly lower...', 'thumbnail': 'https://serpapi.com/searches/672420244e9efc855e4bd551/images/d59738989ae703ea27b4e406cdf19b1b2dfd1f703a3c2eb9ece281c72683cb09.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5749086141586304}",,,,,,,,,,['positive'],positive,1
NCT03541174,"{'position': 1, 'link': 'https://www.pharmaceutical-technology.com/news/fda-approves-idorsias-once-daily-antihypertensive-tryvio/', 'title': 'FDA approves Idorsia’s once-daily antihypertensive Tryvio', 'source': 'Pharmaceutical Technology', 'date': 'Mar 20, 2024', 'snippet': 'Switzerland-based Idorsia has received approval from the US Food and Drug \nAdministration (FDA) for the use of Tryvio (aprocitentan) as a combination \ntreatment...', 'thumbnail': 'https://serpapi.com/searches/672420261a5b544a73491ff6/images/af5999a6099b640d742f7d1e1e12c7778021ac3a7ac2f705acdb86daca1363f2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.689048707485199}",,,,,,,,,,['neutral'],neutral,1
NCT05630833,"{'position': 1, 'link': 'https://www.nature.com/articles/s41429-023-00629-8', 'title': 'Antibiotics in the clinical pipeline as of December 2022 - The Journal of Antibiotics', 'source': 'Nature', 'date': 'Jun 8, 2023', 'snippet': 'The need for new antibacterial drugs to treat the increasing global \nprevalence of drug-resistant bacterial infections has clearly attracted...', 'thumbnail': 'https://serpapi.com/searches/67241deb5809e75d7c4f6ff9/images/6ffc981a3a7a243f321156744847b22accbf4af91f76253328f990f4f299438c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8837066888809204}",,,,,,,,,,['neutral'],neutral,1
NCT01603628,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-to-review-botox-for-upper-lower-limb-pediatric-spasticity/', 'title': 'FDA to Review Botox for Upper, Lower Limb Pediatric Spasticity', 'source': 'Medical Professionals Reference', 'date': 'Mar 7, 2019', 'snippet': 'Allergan announced that the Food and Drug Administration (FDA) has accepted \nfor review the supplemental Biologics License Applications...', 'thumbnail': 'https://serpapi.com/searches/67241df6d9c3e68834f9206e/images/b8073c57ff3e622afe7d824d79d2121148c3ac50277ae9c6464188e5f4aa7013.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.91532963514328}",,,,,,,,,,['neutral'],neutral,1
NCT04098406,"{'position': 1, 'link': 'https://alsnewstoday.com/news/long-term-survival-benefit-seen-cnm-au8-healey-als-analyses-trial/', 'title': 'Long-term ALS survival benefit with CNM-Au8 seen in trial analyses...', 'source': 'ALS News Today', 'date': 'Sep 28, 2023', 'snippet': 'New HEALEY ALS trial analyses showed a significant long-term survival \nbenefit for ALS patients treated with CNM-Au8 for up to 2.5 years.', 'thumbnail': 'https://serpapi.com/searches/67241f899fd3095eab7ea103/images/339d934d1f9e216e5be86d517357ebed3ab175d84db8a8840a8b3643eed9ca76.png', 'sentiment': 'positive', 'sentiment_prob': 0.6370849609375}","{'position': 2, 'link': 'https://alsnewstoday.com/news/cnm-au8-seen-to-extend-survival-by-more-than-1-5-years-in-als-trial/', 'title': 'CNM-Au8 seen to extend survival by more than 1.5 years in ALS trial', 'source': 'ALS News Today', 'date': 'Aug 31, 2023', 'snippet': 'CNM-Au8 was associated with prolonged survival and delayed disease \nprogression among ALS patients in the RESCUE-ALS clinical trial.', 'thumbnail': 'https://serpapi.com/searches/67241f899fd3095eab7ea103/images/339d934d1f9e216e60c7e76bcdd2ec355e24519918aba3d70b0939629346c8a7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.815616250038147}","{'position': 3, 'link': 'https://alsnewstoday.com/news/cnm-au8-delayed-clinical-worsening-als-patients-healey-trial/', 'title': 'CNM-Au8 found to delay clinical worsening in ALS HEALEY trial |...', 'source': 'ALS News Today', 'date': 'Mar 10, 2023', 'snippet': ""Treatment with Clene's CNM-Au8 significantly delayed clinical worsening in \nALS patients participating in an arm of the HEALEY platform..."", 'thumbnail': 'https://serpapi.com/searches/67241f899fd3095eab7ea103/images/339d934d1f9e216e83da269e3b09d7f9d06a03ec085b92d475336582338d46d5.png', 'sentiment': 'negative', 'sentiment_prob': 0.5408130288124084}","{'position': 4, 'link': 'https://alsnewstoday.com/news/slower-progression-experimental-als-treatment-cnm-au8/', 'title': 'Slower progression seen with experimental ALS treatment, CNM-Au8 |...', 'source': 'ALS News Today', 'date': 'Mar 7, 2023', 'snippet': 'ALS patients treated earlier with CNM-Au8 in a clinical trial experienced a \nsignificantly slower disease progression than those who started treatment \nnine...', 'thumbnail': 'https://serpapi.com/searches/67241f899fd3095eab7ea103/images/339d934d1f9e216e8b223f833caa9110ae8d9a9e5226ee20c7d019e7f5e17160.png', 'sentiment': 'neutral', 'sentiment_prob': 0.723926842212677}",,,,,,,"['positive', 'neutral', 'negative', 'neutral']",neutral,1
NCT01204684,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-48073-y', 'title': 'TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial', 'source': 'Nature', 'date': 'May 8, 2024', 'snippet': 'In this randomized phase II clinical trial, we evaluated the effectiveness \nof adding the TLR agonists, poly-ICLC or resiquimod, to autologous tumor \nlysate-...', 'thumbnail': 'https://serpapi.com/searches/67241e6d66d995ddc44901c5/images/4ead92de99dde1f4bd0738e187e5bdba6ae8ad10e5edd1fcfd5c08222c6e5b27.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8927802443504333}",,,,,,,,,,['neutral'],neutral,1
NCT03958656,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-43416-7', 'title': 'Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma', 'source': 'Nature', 'date': 'Nov 18, 2023', 'snippet': 'Chimeric Antigen Receptor (CAR) T cells directed to B cell maturation \nantigen (BCMA) mediate profound responses in patients with multiple...', 'thumbnail': 'https://serpapi.com/searches/67241e74d16915235705289a/images/3016fcb47d42eac415947bcc352afe06c0716a482ac6d038c31907b50024a344.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8046839237213135}","{'position': 2, 'link': 'https://www.nature.com/articles/s41408-021-00469-5', 'title': 'CAR T-cell therapy in multiple myeloma: more room for improvement - Blood Cancer Journal', 'source': 'Nature', 'date': 'Apr 29, 2021', 'snippet': 'The emergence of various novel therapies over the last decade has changed \nthe therapeutic landscape for multiple myeloma. While the clinical...', 'thumbnail': 'https://serpapi.com/searches/67241e74d16915235705289a/images/3016fcb47d42eac42246a5154a24d49564fd65634c793ade3e2981714516f5c6.png', 'sentiment': 'positive', 'sentiment_prob': 0.5632189512252808}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT00964340,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-55923-8', 'title': 'Emerging roles of SIRT1 activator, SRT2104, in disease treatment', 'source': 'Nature', 'date': 'Mar 6, 2024', 'snippet': 'Silent information regulator 1 (SIRT1) is a NAD+-dependent class III \ndeacetylase that plays important roles in the pathogenesis of numerous...', 'thumbnail': 'https://serpapi.com/searches/67241e7c1ec32ff94367ba24/images/f24cd9c295d235f25f1c28d2f83fd8ce8f864c382dc32e114790b648e798f4d0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8164551258087158}",,,,,,,,,,['neutral'],neutral,1
NCT02492789,"{'position': 1, 'link': 'https://www.genengnews.com/news/incyte-to-co-develop-hengruis-shr-1210-in-up-to-795m-deal/', 'title': 'Incyte to Co-Develop Hengrui’s SHR-1210 in Up-to-$795M+ Deal', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Sep 2, 2015', 'snippet': 'The anti-PD-1 monoclonal antibody is headed into proof-of-concept studies \non patients with advanced solid tumors.', 'thumbnail': 'https://serpapi.com/searches/67241f2f0053c79278d2522f/images/02ed98908493e002e4b1b4ed39e6121f24ca740f541c1ff70cb085343d1f7fb5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8812228441238403}",,,,,,,,,,['neutral'],neutral,1
NCT01031108,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-55923-8', 'title': 'Emerging roles of SIRT1 activator, SRT2104, in disease treatment', 'source': 'Nature', 'date': 'Mar 6, 2024', 'snippet': 'Silent information regulator 1 (SIRT1) is a NAD+-dependent class III \ndeacetylase that plays important roles in the pathogenesis of numerous...', 'thumbnail': 'https://serpapi.com/searches/67241f36bb64ac868baba5c0/images/051c89500b12d7ae9660cdc73c2b98370c8ea7a64d540e053b9351d214fcb739.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8164551258087158}",,,,,,,,,,['neutral'],neutral,1
NCT02137850,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/fda-approves-esperoct-as-prophylactic-treatment-for-hemophilia-a-novo-nordisk-says/', 'title': 'FDA Approves Esperoct as Prophylactic Treatment for Hemophilia A, Novo Nordisk Says', 'source': 'Hemophilia News Today', 'date': 'Feb 22, 2019', 'snippet': 'The US Food and Drug Administration (FDA) approved N8-GP, or Esperoct, as a \nprophylactic (preventive) therapy to reduce frequency of bleeds.', 'thumbnail': 'https://serpapi.com/searches/67241f5481262ade2810b11d/images/d330047b71544478f1007c022e4d4f5d96bafb7c0b221c777dbaea26ae713822.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7972772121429443}",,,,,,,,,,['neutral'],neutral,1
NCT02807103,"{'position': 1, 'link': 'https://ancavasculitisnews.com/news/guidelines-given-rituximab-maintenance-therapy-3-aav-subtypes/', 'title': 'Guidelines Given for Rituximab as Maintenance Therapy in 3 AAV Subtypes', 'source': 'ANCA Vasculitis News', 'date': 'Jun 11, 2020', 'snippet': 'Guidelines cover adults with granulomatosis with polyangiitis (GPA), \nmicroscopic polyangiitis (MPA) or eosinophilic granulomatosis with...', 'thumbnail': 'https://serpapi.com/searches/67241f63e1c276aef4ff1c3f/images/5149e7c0062a728c4cdf30aa6c9246d098ad15edd007df824d8b3a216122fed1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8778460025787354}",,,,,,,,,,['neutral'],neutral,1
NCT02222545,"{'position': 1, 'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.21.02389', 'title': 'Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy | Journal of Clinical Oncology', 'source': 'ASCO Publications', 'date': 'Apr 19, 2022', 'snippet': 'In this study, narsoplimab treatment was safe, significantly improved \nlaboratory TMA markers, and resulted in clinical response and favorable \noverall survival.', 'thumbnail': 'https://serpapi.com/searches/67241e842da983780b740fb8/images/2df20b4aa1e861e1e69f531b35c85b9111f72d6c09200a634f0fd65c6648997f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7991372346878052}",,,,,,,,,,['neutral'],neutral,1
NCT03954743,"{'position': 1, 'link': 'https://www.empr.com/home/news/new-formulation-of-rotarix-removes-the-need-for-reconstitution/', 'title': 'New Formulation of Rotarix Removes the Need for Reconstitution', 'source': 'Medical Professionals Reference', 'date': 'Nov 9, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved an oral-dosing \napplicator-only presentation (liquid formulation) of Rotarix (rotavirus...', 'thumbnail': 'https://serpapi.com/searches/67241e86e1d1adc069a082ee/images/19489e26246f99ee63c8cdd22f79c43a776ea197f25b04660bf658d3cb2f4dec.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8876544833183289}",,,,,,,,,,['neutral'],neutral,1
NCT00127283,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0707534', 'title': 'Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage', 'source': 'The New England Journal of Medicine', 'date': 'May 15, 2008', 'snippet': 'Intracerebral hemorrhage is the least treatable form of stroke. We \nperformed this phase 3 trial to confirm a previous study in which...', 'thumbnail': 'https://serpapi.com/searches/67241e98cc48795386827a54/images/a5ee9a00e5719fb1aea5e8492785b0bf5fb841edbcb6aab7752c258038bcf7d6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5381135940551758}",,,,,,,,,,['neutral'],neutral,1
NCT01882439,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1615977', 'title': 'Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors', 'source': 'The New England Journal of Medicine', 'date': 'Oct 19, 2017', 'snippet': 'Tofacitinib is an oral Janus kinase inhibitor that is under investigation \nfor the treatment of psoriatic arthritis. We evaluated tofacitinib...', 'thumbnail': 'https://serpapi.com/searches/67241ee9b5ecbb92470e57db/images/14eb356f450e64519ca2aa9c7dbfbc7bca9b6256ca51f898b19b82d8102ea1d8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6472164988517761}","{'position': 2, 'link': 'https://psoriasisnewstoday.com/2016/12/08/pfizer-phase-3-opal-trials-show-xeljanz-benefits-psoriatic-arthritis-patients/', 'title': 'Phase 3 Trials of Xeljanz in Psoriatic Arthritis Show Benefit', 'source': 'Psoriasis News Today', 'date': 'Dec 8, 2016', 'snippet': 'Pfizer presented positive results from its Phase 3 OPAL clinical program \nevaluating the effectiveness and safety of Xeljanz (tofacitinib...', 'thumbnail': 'https://serpapi.com/searches/67241ee9b5ecbb92470e57db/images/14eb356f450e64517c6148dfb15d657db7c1079a757cc6d9fc59797489a1f4cd.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6341595649719238}","{'position': 3, 'link': 'https://psoriasisnewstoday.com/2017/05/04/psoriatic-arthritis-therapy-xeljanz-reviewed-fda-following-approval-pfizer-snda/', 'title': 'FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients', 'source': 'Psoriasis News Today', 'date': 'May 4, 2017', 'snippet': ""The U.S. Food and Drug Administration (FDA) will review Pfizer's medication \nXeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults..."", 'thumbnail': 'https://serpapi.com/searches/67241ee9b5ecbb92470e57db/images/14eb356f450e64517f6e063861b7c66fd120aec5e194ee4745ab5d1251b04b4f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9127993583679199}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT01174004,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/fda-updates-nuplazid-label-clarify-safety-parkinsons-patients/', 'title': ""FDA updates Nuplazid label to clarify its safe use in Parkinson's..."", 'source': ""Parkinson's News Today"", 'date': 'Sep 20, 2023', 'snippet': ""The FDA has updated the prescribing label for Nuplazid for Parkinson's to \nindicate the drug's safety in patients with and without dementia."", 'thumbnail': 'https://serpapi.com/searches/67241ef10f1a3393cf1ef460/images/3afface3ec25c48e5bdf479ee501c5e405cf57f9ff82bc43935fc8f7242a34e0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6673966646194458}",,,,,,,,,,['neutral'],neutral,1
NCT02125357,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-45475-w', 'title': 'Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer', 'source': 'Nature', 'date': 'Feb 28, 2024', 'snippet': 'No consensus strategies exist for prognosticating metastatic \ncastration-resistant prostate cancer (mCRPC). Circulating tumor DNA \nfraction...', 'thumbnail': 'https://serpapi.com/searches/67241ef3f41044183f19b64f/images/ac65785d933bd44097030d360426b3ed8af71b8495094c7f2064727b8e52e49b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5421239137649536}","{'position': 2, 'link': 'https://prostatecancernewstoday.com/2019/01/27/xtandi-should-follow-zytiga-for-castration-resistant-prostate-cancer-phase-2-trial/', 'title': 'CRPC Patients Should Take Xtandi After Zytiga, Phase 2 Trial Shows', 'source': 'prostatecancernewstoday.com', 'date': 'Jan 27, 2019', 'snippet': 'The trial showed that when deciding first- and second-line treatment for \nmen with advanced prostate cancers, Zytiga should be offered first.', 'thumbnail': 'https://serpapi.com/searches/67241ef3f41044183f19b64f/images/ac65785d933bd440ed3abb7d088764ce96877be641e991afee78b32186ed1c96.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8925011157989502}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02991482,"{'position': 1, 'link': 'https://www.asbestos.com/treatment/immunotherapy/keytruda/', 'title': 'Keytruda for Mesothelioma: FDA-Approved Immunotherapy Drug', 'source': 'Mesothelioma Center', 'date': 'Jul 21, 2017', 'snippet': 'Pembrolizumab (Keytruda) is an FDA-approved second-line mesothelioma \ntreatment. Learn about its success rate, side effects and active trials.', 'thumbnail': 'https://serpapi.com/searches/6724203d48c429ecf8b6864e/images/da21aa2a0a5bbd8222a90ca486b08510d72bfb54183e031396553060d014b111.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6644529104232788}",,,,,,,,,,['neutral'],neutral,1
NCT02924766,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Concentration-time-curve-of-1000mg-abiraterone-acetate-taken-fasted-and-500mg-abiraterone_fig2_335775696', 'title': 'Concentration time curve of 1000 mg abiraterone acetate taken fasted...', 'source': 'ResearchGate', 'date': 'Nov 28, 2020', 'snippet': 'A prospective phase I multicentre randomized cross-over pharmacokinetic \nstudy to determine the effect of food on abiraterone pharmacokinetics.', 'thumbnail': 'https://serpapi.com/searches/672420ac7e1d1fae6f2e3b79/images/ead5b8264b2dce65d838bf9d654393f7d46ff9a479565c3cd888ddf330303032.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9221187233924866}",,,,,,,,,,['neutral'],neutral,1
NCT05245838,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/dynavax-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-financial-highlights-and-phase-1-shingles-topline-results-301716193.html', 'title': 'Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results', 'source': 'PR Newswire', 'date': 'Jan 9, 2023', 'snippet': 'PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a \ncommercial-stage biopharmaceutical company focused on developing and...', 'thumbnail': 'https://serpapi.com/searches/672421b824296a89257c166a/images/0263b6ac251b2ac5cd6621b934d74401d046f5645360162acc855e9b9376295d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.861985445022583}",,,,,,,,,,['neutral'],neutral,1
NCT03143985,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-51442-2', 'title': 'The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial', 'source': 'Nature', 'date': 'Aug 27, 2024', 'snippet': 'Functional blockade of the transforming growth factor-beta (TGFβ) \nsignalling pathway improves the efficacy of cytotoxic and immunotherapies.', 'thumbnail': 'https://serpapi.com/searches/672420d87f371950912285e9/images/0ea6d3f453b8b61b8df091d0ad92d01770194f127b2daf7d24ca068cbe7c93f4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7820846438407898}",,,,,,,,,,['neutral'],neutral,1
NCT02207725,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1510991', 'title': 'Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity', 'source': 'The New England Journal of Medicine', 'date': 'Nov 11, 2015', 'snippet': 'Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban \nin older healthy participants within minutes after administration and for \nthe...', 'thumbnail': 'https://serpapi.com/searches/672420d9a88278108589f72e/images/b76e609fcac3a3fcd2ea2548a0109c5b222205c17638fbe073edec363ab9e519.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9071860909461975}",,,,,,,,,,['neutral'],neutral,1
NCT03651102,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-40849-4', 'title': 'Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study', 'source': 'Nature', 'date': 'Aug 21, 2023', 'snippet': 'This study concludes that thalidomide is an effective and well-tolerated \ndrug that can improve Hb levels and reduce transfusion burden in \nhydroxyurea...', 'thumbnail': 'https://serpapi.com/searches/672420df910986cafe52bce2/images/a761e39aaa698bcef7edae33b309a0deda7ec9c4ed0b0b7d0d6d3a0a7694612d.png', 'sentiment': 'positive', 'sentiment_prob': 0.5298553705215454}",,,,,,,,,,['positive'],positive,1
NCT00152464,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Xyzal-levocetirizine', 'title': 'Levocetirizine (Xyzal®)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Allergic Rhinitis, Efficacy and Safety of Levocetirizine 8 Weeks Prior and \nAfter the Onset of the Grass Pollen Season in Subjects With SAR...', 'thumbnail': 'https://serpapi.com/searches/672420eacc2987a57bad0841/images/937637f46ab43c9e13a92c977bdaa390fe7ad48c2f8b896e2769c0e13c47568b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8934985995292664}",,,,,,,,,,['neutral'],neutral,1
NCT02059759,"{'position': 1, 'link': 'https://alsnewstoday.com/news/als-disease-progression-slowed-with-low-dose-aldesleukin-trial/', 'title': 'Low-dose Aldesleukin Slows ALS Progression, Extends Survival: Trial', 'source': 'ALS News Today', 'date': 'Dec 16, 2022', 'snippet': 'A low dose of aldesleukin, an immunotherapy approved for certain cancers, \nslowed disease progression and significantly improved survival in people \nwith...', 'thumbnail': 'https://serpapi.com/searches/672421126aa364780f49d58a/images/871893de37d16d4b99e41177e9aa308ab1c386c9567f7d7058fc8ce85958f040.png', 'sentiment': 'positive', 'sentiment_prob': 0.5697094202041626}",,,,,,,,,,['positive'],positive,1
NCT05018806,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/sanofi-gears-up-for-approval-of-its-btk-inhibitor-meets-phase-iii-endpoint/', 'title': 'Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint', 'source': 'Clinical Trials Arena', 'date': 'Apr 23, 2024', 'snippet': ""Sanofi's rilzabrutinib met the primary endpoint in the Phase III persistent \nor chronic immune thrombocytopenia trial."", 'thumbnail': 'https://serpapi.com/searches/67242143bb64ac868baba67c/images/6401338221eede70e5fbc84c838e372b26de57a848fcd7d327310e3df9b3bbdf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6001195311546326}",,,,,,,,,,['neutral'],neutral,1
NCT02638207,"{'position': 1, 'link': 'https://www.empr.com/home/news/panzyga-immune-globulin-ifas-approved-chronic-inflammatory-demyelinating-polynueuropathy/', 'title': 'Panzyga Approved for Chronic Inflammatory Demyelinating Polyneuropathy', 'source': 'Medical Professionals Reference', 'date': 'Feb 16, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Panzyga (immune \nglobulin intravenous [human] – ifas 10% liquid preparation; Pfizer) for the \ntreatment of...', 'thumbnail': 'https://serpapi.com/searches/6724215014c31ed5c411cfdc/images/215f4f18e4d762dada617a8ef2b54d07af84ead39c8572a643acfe261087bb81.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8948565125465393}",,,,,,,,,,['neutral'],neutral,1
NCT02720263,"{'position': 1, 'link': 'https://www.nature.com/articles/s41386-020-00908-0', 'title': 'Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia | Neuropsychopharmacology', 'source': 'Nature', 'date': 'Nov 17, 2020', 'snippet': 'ASP4345, a novel dopamine D1 receptor positive allosteric modulator, is \nbeing evaluated for the treatment of cognitive impairment associated...', 'thumbnail': 'https://serpapi.com/searches/6724215b7c171214322e9ef7/images/2420c200c8701efb7bf435dda052058a07690bbbdbd7df102803c547592d8604.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9120137095451355}",,,,,,,,,,['neutral'],neutral,1
NCT03805347,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0378874122004743', 'title': 'Effect of the traditional Chinese herb Helminthostachys zeylanica on postsurgical recovery in patients with ankle fracture: A double-blinded randomized controlled clinical trial', 'source': 'ScienceDirect.com', 'date': 'Sep 15, 2022', 'snippet': 'Oral administration of HZ for 42 days can increase serum PINP level and \nreduce the RHT. Therefore, HZ can be used to treat patients with ankle \nfractures...', 'thumbnail': 'https://serpapi.com/searches/67242185f60b6f8ef9bdaaea/images/85284354a2a6eb10f7d2587a4d0309e46dd8f1d96d115c7ace856eb5f4be180d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.738072395324707}",,,,,,,,,,['neutral'],neutral,1
NCT02257567,"{'position': 1, 'link': 'https://lymphomanewstoday.com/2020/01/23/polivy-triple-combo-approved-in-europe-for-select-patients-with-advanced-dlbcl/', 'title': 'Polivy Triple Combo Approved in Europe for Select Patients with Advanced DLBCL', 'source': 'Lymphoma News Today', 'date': 'Jan 23, 2020', 'snippet': ""Conditional approval was given to Roche's Polivy, used with rituximab and \nbendamustine, to treat relapsed or refractory DLBCL patients..."", 'thumbnail': 'https://serpapi.com/searches/672421dcfc183d5decdfb7b2/images/5b64a8c98b1f0f0ace91fb5611be296840f0645aac932957c38cbccd9e74debd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8473636507987976}","{'position': 2, 'link': 'https://lymphomanewstoday.com/2019/11/22/chmp-favors-eu-approval-of-polivy-with-rituxan-and-bendamustine-for-advanced-dlbcl/', 'title': 'EU Advisory Committee Favors Approval of Polivy with MabThera and Bendamustine for Advanced DLBCL', 'source': 'Lymphoma News Today', 'date': 'Nov 22, 2019', 'snippet': ""The European Medicines Agency's advisory committee has recommended the \napproval of Polivy with Rituxan and bendamustine for the treatment of..."", 'thumbnail': 'https://serpapi.com/searches/672421dcfc183d5decdfb7b2/images/5b64a8c98b1f0f0a02a20e7b96be87f9e168c4c29d1ba60cbfbcbaa8f85dfd2f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8113265037536621}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02842827,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01341-7', 'title': 'Targeting epigenetic regulators to overcome drug resistance in cancers', 'source': 'Nature', 'date': 'Feb 17, 2023', 'snippet': 'Drug resistance is mainly responsible for cancer recurrence and poor \nprognosis. Epigenetic regulation is a heritable change in gene...', 'thumbnail': 'https://serpapi.com/searches/672421e10c08f201ce46e13d/images/99c6f8658a40c45eab2e8098aad2ec39b76180049b6290e0ecbce17fdcf3d216.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6539433002471924}",,,,,,,,,,['negative'],negative,0
NCT03625466,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/preschool-aged-childrens-cf-lung-damage-reduced-orkambi/', 'title': ""Preschool-aged children's CF lung damage reduced by Orkambi |..."", 'source': 'Cystic Fibrosis News Today', 'date': 'Apr 3, 2023', 'snippet': 'The main purpose of the small Phase 2 clinical trial was to see how \ntreatment with Orkambi (lumacaftor/ivacaftor) affects MRI global scores.', 'thumbnail': 'https://serpapi.com/searches/67242217cdf155b9fbb89f34/images/eedc34e654abd089446420b4bbba0ae9a38eb4caebcd751d014240e9f4e8d559.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8653139472007751}",,,,,,,,,,['neutral'],neutral,1
NCT05249829,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-30878-4', 'title': 'Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2', 'source': 'Nature', 'date': 'Jun 6, 2022', 'snippet': 'We generate an Omicron-specific lipid nanoparticle (LNP) mRNA vaccine \ncandidate, and test its activity in animals, both alone and as a \nheterologous booster to...', 'thumbnail': 'https://serpapi.com/searches/67242220361fd42d28a88cc5/images/90656de2b01257f244920df5c41a1d01881f7e4f5043053b64f11cb84d7880e1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9088650345802307}",,,,,,,,,,['neutral'],neutral,1
NCT03564821,"{'position': 1, 'link': 'https://www.researchgate.net/figure/History-of-AML-therapies-Timeline-of-approved-clinical-therapies-in-the-United-States_fig1_347673267', 'title': 'Fig. 1 History of AML therapies. Timeline of approved clinical...', 'source': 'ResearchGate', 'date': 'May 8, 2022', 'snippet': 'For many years, treatment options for AML remained stagnant, with the \nstandard 7+3 regimen of cytarabine and daunorubicin and SCT being the only \noption for...', 'thumbnail': 'https://serpapi.com/searches/672422231315022822549dce/images/a86c5d18cecf3575a89e36bbe7e1311ff4dd0bd64a32a0a1fa0579894146caea.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5696207880973816}",,,,,,,,,,['neutral'],neutral,1
NCT01216644,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30531-9/fulltext', 'title': 'Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): res', 'source': 'The Lancet', 'date': 'Oct 21, 2016', 'snippet': 'Prospective, randomized, multicenter, phase III study of fluorouracil, \nleucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine \nin advanced...', 'thumbnail': 'https://serpapi.com/searches/67242252e10f0ad85e5e2f6a/images/ae9045f27fb2eac9a25068cbc0fa16ea3509bed1c6e5ccc0ca6088b0282a5e78.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8513209223747253}",,,,,,,,,,['neutral'],neutral,1
NCT00094718,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMp2301816', 'title': 'Combating West Nile Virus Disease — Time to Revisit Vaccination', 'source': 'The New England Journal of Medicine', 'date': 'Apr 29, 2023', 'snippet': 'WNV remains a public health threat in many areas of the world, and current \napproaches to primary prevention have limitations.', 'thumbnail': 'https://serpapi.com/searches/67242256861b9d63abef912f/images/9eabf85bd9e81ab1a430701fc41cbe59063816cf56c34bd48a6d61fc644dffb9.png', 'sentiment': 'negative', 'sentiment_prob': 0.7227003574371338}",,,,,,,,,,['negative'],negative,0
NCT01491893,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1716435', 'title': 'Recurrent Glioblastoma Treated with Recombinant Poliovirus', 'source': 'The New England Journal of Medicine', 'date': 'Jun 28, 2018', 'snippet': 'The prognosis of patients with recurrent World Health Organization (WHO) \ngrade IV malignant glioma is dismal, and there is currently no...', 'thumbnail': 'https://serpapi.com/searches/6724226008abe42058644933/images/254614f9da9eb8b511e18abf895c1935388e674224b86f3f7b7c1c40cabe8de8.png', 'sentiment': 'negative', 'sentiment_prob': 0.8526854515075684}",,,,,,,,,,['negative'],negative,0
NCT00605514,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-024-00833-z', 'title': 'Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials', 'source': 'Nature', 'date': 'Mar 29, 2024', 'snippet': 'Ebola virus disease (EVD) is a filoviral infection caused by virus species \nof the Ebolavirus genus including Zaire ebolavirus (EBOV) and...', 'thumbnail': 'https://serpapi.com/searches/67242677b6e4db2835633206/images/d87e79f0d7a15079dbf425477eca788d0db7cf0024151723804f25fa23a8859f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.788805365562439}",,,,,,,,,,['neutral'],neutral,1
NCT02626130,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-26415-4', 'title': 'Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma', 'source': 'Nature', 'date': 'Nov 4, 2021', 'snippet': 'Cryoablation in combination with immune checkpoint therapy was previously \nreported to improve anti-tumor immune responses in pre-clinical...', 'thumbnail': 'https://serpapi.com/searches/6724269d360f4e3ba57d84ee/images/49629e27e5e7a65c2620743388b3d2f345b36d4a6be607a74e6f6971d3525a8b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8851354122161865}",,,,,,,,,,['neutral'],neutral,1
NCT03125902,"{'position': 1, 'link': 'https://www.empr.com/home/news/tecentriq-indication-for-triple-negative-breast-cancer-withdrawn/', 'title': 'Tecentriq Indication for Triple-Negative Breast Cancer Withdrawn', 'source': 'Medical Professionals Reference', 'date': 'Aug 30, 2021', 'snippet': 'Roche is voluntarily withdrawing the indication for Tecentriq \n(atezolizumab) in combination with chemotherapy (Abraxane, paclitaxel bound \nto albumin [human];...', 'thumbnail': 'https://serpapi.com/searches/672426a83ad34db6ba165597/images/23ce9b4961d5f5c199039efbab47bad4f47e4967e73af1439b4c129f70166e83.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6629008054733276}",,,,,,,,,,['neutral'],neutral,1
NCT04765449,"{'position': 1, 'link': 'https://www.cgtlive.com/view/second-cohort-dosed-in-covid-19-cell-therapy-trial', 'title': 'COVID-19 Cell Therapy Trial Completes Dosing', 'source': 'CGTLive®', 'date': 'Feb 3, 2022', 'snippet': 'The second, higher-dose cohort has finished dosing in the phase 1 study \n(NCT04765449) of TVGN-489, an investigational allogeneic SARS-CoV-2 \nspecific CD8+ T-...', 'thumbnail': 'https://serpapi.com/searches/672426df9936882cebcb8791/images/1b718d5205588006abe27858d81fbcb8e46a90e9b90051940715f34d05776d4e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9122409224510193}",,,,,,,,,,['neutral'],neutral,1
NCT00997607,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-024-00833-z', 'title': 'Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials', 'source': 'Nature', 'date': 'Mar 29, 2024', 'snippet': 'Ebola virus disease (EVD) is a filoviral infection caused by virus species \nof the Ebolavirus genus including Zaire ebolavirus (EBOV) and...', 'thumbnail': 'https://serpapi.com/searches/672426e07ebde514439a8baf/images/b413708034ffcec82948f3f5f342f7d6f5779a46d53a5f0a618f21aeab463137.png', 'sentiment': 'neutral', 'sentiment_prob': 0.788805365562439}",,,,,,,,,,['neutral'],neutral,1
NCT00605215,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-33269-x', 'title': 'Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning', 'source': 'Nature', 'date': 'Sep 26, 2022', 'snippet': 'We propose to enable short proof-of-concept trials by increasing \nstatistical power using a deep-learning predictive enrichment strategy.', 'thumbnail': 'https://serpapi.com/searches/67242265e50bc005c852de35/images/0c306e9465b4fa19b193a4a9b4c167e98faaaabf67038d4d6d36cccb442e3e57.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8671880960464478}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/laquinimod-nerventra-abr-215062-ppms/', 'title': 'Laquinimod for Multiple Sclerosis', 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 30, 2022', 'snippet': ""Laquinimod (also known as nerventra or ABR-215062) is an investigational \noral therapy that's been tested in clinical trials for treating multiple \nsclerosis (MS..."", 'thumbnail': 'https://serpapi.com/searches/67242265e50bc005c852de35/images/0c306e9465b4fa19a922d73cc1704c49fe19c1097902999119a2f5e46ef474b9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8935969471931458}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01580839,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1813046', 'title': 'Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke', 'source': 'The New England Journal of Medicine', 'date': 'May 8, 2019', 'snippet': 'The time to initiate intravenous thrombolysis for acute ischemic stroke is \ngenerally limited to within 4.5 hours after the onset of symptoms.', 'thumbnail': 'https://serpapi.com/searches/672422a4bb64ac86587e2f6f/images/1e403105a768f939c7e0fadf544b85dfd3e7e93c1ae98f6e9641eb08110474dd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8518437743186951}",,,,,,,,,,['neutral'],neutral,1
NCT02918006,"{'position': 1, 'link': 'https://www.nature.com/articles/s41577-021-00583-2', 'title': 'Mucosal vaccines — fortifying the frontiers', 'source': 'Nature', 'date': 'Jul 26, 2021', 'snippet': 'Mucosal vaccines offer the potential to trigger robust protective immune \nresponses at the predominant sites of pathogen infection.', 'thumbnail': 'https://serpapi.com/searches/672422ccf410441876f5009b/images/7f8fa63a5643297c766ab95c4cb5d21c84fcaefd553523edf9a317d27e496c63.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7149822115898132}",,,,,,,,,,['positive'],positive,1
NCT01377922,"{'position': 1, 'link': 'https://lamberteatonnews.com/news/firdapse-approved-treat-lems-japan/', 'title': 'Firdapse approved to treat LEMS patients in Japan', 'source': 'Lambert-Eaton News', 'date': '1 month ago', 'snippet': 'Oral Firdapse, approved in the US and Europe to treat Lambert-Eaton \nmyasthenic syndrome, now is available to LEMS patients in Japan.', 'thumbnail': 'https://serpapi.com/searches/6724263d13e5d85abd9d822a/images/faf52da1d8df46e9c994d5b989a75b23f870a8acd39168423b47fe16594ba8d8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7561480402946472}",,,,,,,,,,['neutral'],neutral,1
NCT04740827,"{'position': 1, 'link': 'https://www.empr.com/home/news/atogepant-cuts-migraine-days-in-patients-with-prior-treatment-failure/', 'title': 'Atogepant Cuts Migraine Days in Patients With Prior Treatment Failure', 'source': 'Medical Professionals Reference', 'date': 'Apr 21, 2023', 'snippet': 'Atogepant led to a significant reduction in mean monthly migraine days in \npatients with episodic migraine who previously failed 2 to 4...', 'thumbnail': 'https://serpapi.com/searches/672422f3f79a01c19a37ee4f/images/6824cc0e5578ba3f2ac60096447860b3f0665019140df708d27f121e24f8803b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7325939536094666}",,,,,,,,,,['neutral'],neutral,1
NCT02407236,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1900750', 'title': 'Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 25, 2019', 'snippet': 'Ustekinumab was more effective than placebo for inducing and maintaining \nremission in patients with moderate-to-severe ulcerative colitis.', 'thumbnail': 'https://serpapi.com/searches/672425ae167793224537bf48/images/ed5523fd357568d20fae29a92b7e991a6b2cc8f8990cbe406247e5d9cb48c0e7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.4859568178653717}","{'position': 2, 'link': 'https://ibdnewstoday.com/2020/06/01/nice-recommends-stelara-for-moderate-severe-ulcerative-colitis-uk/', 'title': 'Ulcerative Colitis Therapy Stelara Recommended for UK Approval by NICE', 'source': 'IBD News Today', 'date': 'Jun 1, 2020', 'snippet': 'The U.K. National Institute for Health and Care Excellence has recommended \nStelara to treat ulcerative colitis patients who do not respond...', 'thumbnail': 'https://serpapi.com/searches/672425ae167793224537bf48/images/ed5523fd357568d2ab61675bed80dc985750a1f580cb750a9ab118a39f8a133b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8789256811141968}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01540409,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/exondys-51-can-slow-respiratory-decline-in-duchenne-dmd-patients/', 'title': 'Exondys 51 Can Slow Respiratory Decline in DMD Patients, Study Shows', 'source': 'Muscular Dystrophy News', 'date': 'Jan 2, 2018', 'snippet': 'An analysis of clinical trial data shows that Exondys 51 can effectively \nslow respiratory function decline in patients with Duchenne...', 'thumbnail': 'https://serpapi.com/searches/672425cfb2ebaee6e82f44cb/images/65b9cb799c21cc4f95d5937891d73fcb7b44757ba54fda84b3f8c34837d3f72d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8547712564468384}",,,,,,,,,,['neutral'],neutral,1
NCT01002430,"{'position': 1, 'link': 'https://www.nature.com/articles/s41434-021-00295-1', 'title': 'Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-D', 'source': 'Nature', 'date': 'Oct 1, 2021', 'snippet': 'In phase I KAT301 trial, intramyocardial adenovirus-mediated vascular \nendothelial growth factor -DΔNΔC (AdVEGF-D) gene therapy (GT) resulted...', 'thumbnail': 'https://serpapi.com/searches/6724260eea57e9589361bdaa/images/e7a03dde18f269e67d97484f9be15b847137d32474fe25c93a910e970fa3e39b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8766512274742126}",,,,,,,,,,['neutral'],neutral,1
NCT00079066,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa071834', 'title': 'Cetuximab for the Treatment of Colorectal Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Apr 30, 2018', 'snippet': 'Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth \nfactor receptor (EGFR), has activity against colorectal cancers that \nexpress EGFR.', 'thumbnail': 'https://serpapi.com/searches/6724262168831e1c985aee91/images/d6f36a22582cda26819aa2d7b9383d81c4e6fa43f84ca4a88062b903c4f057ba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8861033320426941}",,,,,,,,,,['neutral'],neutral,1
NCT02876328,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2200072', 'title': 'Randomized Trial of Vaccines for Zaire Ebola Virus Disease', 'source': 'The New England Journal of Medicine', 'date': 'Dec 14, 2022', 'snippet': 'We conducted two randomized, placebo-controlled trials — one involving \nadults and one involving children — to evaluate the safety and immune...', 'thumbnail': 'https://serpapi.com/searches/6724262b460b15a5b5a4bdfc/images/e2be59ef65f03f79b5753e0715ea2c68fec3dddded380a0e66db1f70a73c2cea.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8987215161323547}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-024-51453-z', 'title': 'Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases', 'source': 'Nature', 'date': 'Sep 3, 2024', 'snippet': ""Recent Ebola outbreaks underscore the importance of continuous prevention \nand disease control efforts. Authorized vaccines include Merck's..."", 'thumbnail': 'https://serpapi.com/searches/6724262b460b15a5b5a4bdfc/images/e2be59ef65f03f798c0c101dd67bd3c5f3db926f2774f410228d71044bb302e5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8438630700111389}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02939300,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-021-25860-5', 'title': 'Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases', 'source': 'Nature', 'date': 'Oct 12, 2021', 'snippet': 'Our study describes the liquid LMD tumor microenvironment prior to and \nfollowing ICI treatment and demonstrates clinical utility of cell-free and \nsingle-cell...', 'thumbnail': 'https://serpapi.com/searches/672426313d629b3e007c7240/images/c7eef19d30f73a7357a9fbc86ce9bf6082499771e953650d6f673502ece195a8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8978612422943115}",,,,,,,,,,['neutral'],neutral,1
NCT04452214,"{'position': 1, 'link': 'https://www.notimerica.com/comunicados/noticia-comunicado-cantargia-presents-clinical-interim-results-at-asco-2022-highlighting-the-potential-of-nadunolimab-in-combination-with-20220526233306.html', 'title': 'Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with c', 'source': 'Notimérica', 'date': 'May 26, 2022', 'snippet': '(NASDAQ Stockholm: CANTA) today reported new results from the phase Ib \nclinical trial CIRIFOUR in 15 solid...', 'thumbnail': 'https://serpapi.com/searches/67242479a3657a0b1b933a1f/images/5144ab5e066cee9476f457f528933fae19de4c9d0304fa03b3b0f476983ece85.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7152458429336548}",,,,,,,,,,['positive'],positive,1
NCT00535782,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60110-X/fulltext', 'title': 'The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis', 'source': 'The Lancet', 'date': 'Mar 14, 2012', 'snippet': 'IL6R blockade could provide a novel therapeutic approach to prevention of \ncoronary heart disease that warrants testing in suitably powered randomised \ntrials.', 'thumbnail': 'https://serpapi.com/searches/67242490b4fe875869b7a8b2/images/0b5deea919255e4ff2253d0985de3931a4d15372ee22b62d67be2060d22e4b8a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6707221865653992}",,,,,,,,,,['neutral'],neutral,1
NCT03127735,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-020-0996-5', 'title': 'Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results', 'source': 'Nature', 'date': 'Jul 30, 2020', 'snippet': 'The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity \nin preclinical AML models, supporting clinical evaluation.', 'thumbnail': 'https://serpapi.com/searches/672424ce2c566d3926971680/images/71ba8266791f5f8590f4ea5792cbe71ac95d22e904feeae6af02b7fd81420046.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6216301321983337}",,,,,,,,,,['neutral'],neutral,1
NCT04186845,"{'position': 1, 'link': 'https://www.itnonline.com/content/blue-earth-diagnostics-bracco-company-announces-results-evaluating-diagnostic-performance', 'title': 'Blue Earth Diagnostics, a Bracco Company, Announces Results Evaluating Diagnostic Performance of POSLUMA (Flotufolastat F 18) and Clinical Trial Enrollment in African American Men with Prostate Cancer', 'source': 'Imaging Technology News', 'date': 'Jul 30, 2024', 'snippet': 'Post-hoc analysis from Phase 3 SPOTLIGHT trial demonstrated consistent \nperformance between African Americans and other patient groups for \nFDA-approved POSLUMA...', 'thumbnail': 'https://serpapi.com/searches/6724234c72e5c4d06f86cc81/images/5feb0a81aa28e7b5229b0bd452dcf3cccc257b3e35a8e4d488aa396d0c7a24b3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9134331941604614}","{'position': 2, 'link': 'https://jnm.snmjournals.org/content/early/2024/06/13/jnumed.123.267306', 'title': 'Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies', 'source': 'Journal of Nuclear Medicine', 'date': 'Jun 13, 2024', 'snippet': 'Phillip H. Kuo, Giuseppe Esposito, Gary A. Ulaner, Don Yoo, Katherine \nZukotynski, Gregory C. Ravizzini, Ross Penny, Matthew P. Miller,...', 'thumbnail': 'https://serpapi.com/searches/6724234c72e5c4d06f86cc81/images/5feb0a81aa28e7b514aca8a239b09753163b1ac49386913c0b2557bf95df128b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9256315231323242}","{'position': 3, 'link': 'https://www.biospace.com/news/results-of-posluma-flotufolastat-f-18-performance-in-recurrent-prostate-cancer-after-radical-prostatectomy-at-low-prostate-specific-antigen-psa-levels-presented-at-astro', 'title': 'Results of POSLUMA® (Flotufolastat F 18) Performance in Recurrent Prostate Cancer After Radical Prostatectomy at Low Prostate Specific Antigen (PSA) Levels Presented at ASTRO', 'source': 'BioSpace', 'date': '1 month ago', 'snippet': 'Results demonstrated 69% and 67% detection rates for POSLUMA in men with \nPSA < 1 ng/mL (82/119) and < 0.5 ng/mL (57/85), respectively.', 'thumbnail': 'https://serpapi.com/searches/6724234c72e5c4d06f86cc81/images/5feb0a81aa28e7b558b719f09fca1b16b6b1f1c11c06756a7bc3d1d71b001261.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8856648206710815}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02060903,"{'position': 1, 'link': 'https://www.empr.com/home/news/xeglyze-abametapir-head-lice-treatment-approved/', 'title': 'Head Lice Treatment Xeglyze Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Jul 29, 2020', 'snippet': ""The Food and Drug Administration (FDA) has approved Xeglyze™ (abametapir; \nDr. Reddy's Laboratories) for the treatment of head lice..."", 'thumbnail': 'https://serpapi.com/searches/672423566de1e482835aeb3c/images/2abe8cd2370594eaddd8a5347c7cecfc10ab0eee116479e66e1c9db3f73bb550.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7157039046287537}",,,,,,,,,,['neutral'],neutral,1
NCT02218047,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-022-01528-x', 'title': 'Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b', 'source': 'Nature', 'date': 'Feb 24, 2022', 'snippet': 'Interferon alfa not only restores normal blood cell counts in patients with \npolycythemia vera (PV) but can diminish the mutant JAK2V617F...', 'thumbnail': 'https://serpapi.com/searches/6724238e18787da4074e8ce2/images/858147cd50eb8fd15155989795d0867e8d0b3234f7b89d103f93dddf0b0ea977.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7943735122680664}",,,,,,,,,,['neutral'],neutral,1
NCT03138733,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2300220', 'title': 'Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia', 'source': 'The New England Journal of Medicine', 'date': 'Sep 27, 2023', 'snippet': 'Ceftobiprole is a cephalosporin that may be effective for treating \ncomplicated Staphylococcus aureus bacteremia, including \nmethicillin-resistant S. aureus.', 'thumbnail': 'https://serpapi.com/searches/6724246493584c2b3cbc033c/images/9e3e8a44b275ebdf3ed9d50dac6b9eddff1a7bf84cf8b4d71e7d213a0a523fbe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8234276175498962}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/ceftobiprole-antibiotic-fda-review-infections/', 'title': 'IV Antibiotic Ceftobiprole Under Review for Serious Bacterial Infections', 'source': 'Medical Professionals Reference', 'date': 'Oct 2, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted the New Drug \nApplication for ceftobiprole, an investigational, broad spectrum \ncephalosporin antibiotic for...', 'thumbnail': 'https://serpapi.com/searches/6724246493584c2b3cbc033c/images/9e3e8a44b275ebdf10b92fdde5f8e6dcbbd26716135f1cab6c075e4f90ccf6e8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.898817777633667}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02655315,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2209254', 'title': 'Trial of Deferiprone in Parkinson’s Disease', 'source': 'The New England Journal of Medicine', 'date': 'Nov 30, 2022', 'snippet': ""Early research suggests that the iron chelator deferiprone can reduce \nnigrostriatal iron content in persons with Parkinson's disease."", 'thumbnail': 'https://serpapi.com/searches/672423e8d19f1542acb32fa3/images/ebda5a0d4242151194634287fd08c82e6304e13579f3df0df1ad7ce55b668eec.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8972376585006714}",,,,,,,,,,['neutral'],neutral,1
NCT02836873,"{'position': 1, 'link': 'https://www.empr.com/home/news/brenzavvy-approved-for-adults-with-type-2-diabetes/', 'title': 'Brenzavvy Approved for Adults With Type 2 Diabetes', 'source': 'Medical Professionals Reference', 'date': 'Jan 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Brenzavvy™ \n(bexagliflozin) as an adjunct to diet and exercise to improve glycemic...', 'thumbnail': 'https://serpapi.com/searches/672423eab2ebaee6e82f445b/images/cd16a24be4869345bd6945f79ec5e68e924423f4e45a81f6ba042315300b742f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6072625517845154}",,,,,,,,,,['neutral'],neutral,1
NCT05516316,"{'position': 1, 'link': 'https://copdnewstoday.com/news/fda-oks-phase-2-clinical-trial-ep395-copd-patients/', 'title': 'FDA OKs Phase 2 Clinical Trial of EP395 for COPD Patients', 'source': 'COPD News Today', 'date': 'Nov 28, 2022', 'snippet': 'The US Food and Drug Administration (FDA) has authorized EpiEndo \nPharmaceuticals to conduct a Phase 2a clinical trial of its antibiotic \ntreatment EP395 in...', 'thumbnail': 'https://serpapi.com/searches/672423f481bab7b8fdf0d98c/images/2ed3313bc6b677791175a5a59c778955526b2cf19f1b87a791ae5894d02f4a8a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8805156350135803}",,,,,,,,,,['neutral'],neutral,1
NCT01094158,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-022-01119-3', 'title': 'Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)', 'source': 'Nature', 'date': 'Aug 13, 2022', 'snippet': 'In this review, we discussed recent developments in etiology and \nprospective therapeutic targets, as well as pharmacological candidates in \npre/clinical trials...', 'thumbnail': 'https://serpapi.com/searches/67242447be8013c6dfa8c98c/images/c0a3e89f5b7551e592498d6df64b0a082f8abcec40b2e35fed1b19594cb0dd66.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9206169247627258}",,,,,,,,,,['neutral'],neutral,1
NCT04109066,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/reports/neoadjuvant-nivolumab-improves-pcr-in-er-her2-breast-cancer/', 'title': 'Neoadjuvant Nivolumab Improves pCR in ER+/HER2- Breast Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Oct 20, 2023', 'snippet': 'Adding nivolumab to neoadjuvant chemotherapy may provide a benefit in \npatients with high-risk, ER-positive, HER2-negative breast cancer.', 'thumbnail': 'https://serpapi.com/searches/672424544d52b8d3fde5ab46/images/f531e07c07af966fac6ad67e6cbce8e337037f779c7d64c6ba9169dd24bad402.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6388657689094543}",,,,,,,,,,['neutral'],neutral,1
NCT03421743,"{'position': 1, 'link': 'https://bronchiectasisnewstoday.com/2020/03/16/molgradex-stops-bacterial-growth-in-bronchiectasis-patients-with-chronic-lung-infection-phase-2a-trial-shows/', 'title': 'Bronchiectasis Patients with Lung Infections Respond to Molgradex in Trial', 'source': 'Bronchiectasis News Today', 'date': 'Mar 16, 2020', 'snippet': 'Molgradex stopped growth of bacteria in people with bronchiectasis and \nchronic bacterial lung infections, topline data from a Phase 2a...', 'thumbnail': 'https://serpapi.com/searches/672424594d52b8d3fde5ab49/images/d47b2b19ab44156f3fe69fba91b6c88dcca6a62c99316a6f54493c73bae7e4e4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7939971089363098}",,,,,,,,,,['neutral'],neutral,1
NCT03254277,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/genetically-altered-broadly-neutralizing-antibodies-protect-monkeys-hiv-virus', 'title': 'Genetically altered broadly neutralizing antibodies protect monkeys from HIV-like virus', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Apr 16, 2018', 'snippet': 'NIH scientists report single dose elicited long-term protection.', 'thumbnail': 'https://serpapi.com/searches/6724245c2a7727e9d24446e9/images/c2184a39fa69b9aa043b956d68015b5d1ae7c32a81108dcbe1c503bfbc5c04e9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6590275168418884}",,,,,,,,,,['neutral'],neutral,1
NCT01854918,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1500858', 'title': 'Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events', 'source': 'The New England Journal of Medicine', 'date': 'Mar 15, 2015', 'snippet': 'Evolocumab, a monoclonal antibody that inhibits proprotein convertase \nsubtilisin–kexin type 9 (PCSK9), significantly reduced low-density...', 'thumbnail': 'https://serpapi.com/searches/672424e86531cb6eb856026c/images/4bf6f47728040a62e423f3d4b2ef71bd0c197845353446e4bc93503fe0905467.png', 'sentiment': 'neutral', 'sentiment_prob': 0.796350359916687}",,,,,,,,,,['neutral'],neutral,1
NCT00069784,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1203858', 'title': 'Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia', 'source': 'The New England Journal of Medicine', 'date': 'Jun 11, 2012', 'snippet': 'When used to target normal fasting plasma glucose levels for more than 6 \nyears, insulin glargine had a neutral effect on cardiovascular outcomes and \ncancers.', 'thumbnail': 'https://serpapi.com/searches/672424fbb5ecbb920ddedfd1/images/f5779ce914ebdf638f3561b0d7770a72e1819e56f19db4d58200263e4f512070.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.787521243095398}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1203859', 'title': 'n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia', 'source': 'The New England Journal of Medicine', 'date': 'Feb 27, 2017', 'snippet': 'The use of n–3 fatty acids may prevent cardiovascular events in patients \nwith recent myocardial infarction or heart failure. Their effects in \npatients with...', 'thumbnail': 'https://serpapi.com/searches/672424fbb5ecbb920ddedfd1/images/f5779ce914ebdf6399ec4a1f2bf12372d90f5ae06115fd890ea7f004fac0688a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.705805242061615}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03525548,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/benefits-trikafta-cf-sustained-3-5-years-extension-trial/', 'title': 'Benefits of Trikafta for CF sustained 3.5+ years in extension trial', 'source': 'Cystic Fibrosis News Today', 'date': 'Jun 14, 2023', 'snippet': 'Long-term treatment with Trikafta leads to sustained lung function gains, \neasing of respiratory symptoms, and better nutritional status.', 'thumbnail': 'https://serpapi.com/searches/6724252ae9b691746b5d2192/images/504aa91550b00834b6f3a66be4ec3cc175bcc847c113a7f44615ad838a5e69fc.png', 'sentiment': 'positive', 'sentiment_prob': 0.8928873538970947}","{'position': 2, 'link': 'https://cysticfibrosisnewstoday.com/news/northern-ireland-reaches-deal-with-vertex-for-access-to-kaftrio/', 'title': 'CF Drug Kaftrio Will be Available in Northern Ireland After Deal With Vertex', 'source': 'Cystic Fibrosis News Today', 'date': 'Aug 3, 2020', 'snippet': 'Northern Ireland reached a deal with Vertex Pharmaceuticals to make Kaftrio \navailable for treating cystic fibrosis, once the drug gets its...', 'thumbnail': 'https://serpapi.com/searches/6724252ae9b691746b5d2192/images/504aa91550b0083488b06b8262d8c148bdd92a30360dcac3f86529340002900e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7986085414886475}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT00768430,"{'position': 1, 'link': 'https://www.nature.com/articles/npp2014298', 'title': 'Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial', 'source': 'Nature', 'date': 'Nov 6, 2014', 'snippet': 'The glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine \ndisplays rapid antidepressant effects in patients with...', 'thumbnail': 'https://serpapi.com/searches/67242533d9c3e6887205f3a2/images/a1e4831e7bc18d1d71e4aa62082f3d4da6039541e2e74395e71fe9bc653b04d4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8738411664962769}","{'position': 2, 'link': 'https://www.psychiatrictimes.com/view/ketamine-induced-optimism-new-hope-development-rapid-acting-antidepressants', 'title': 'Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants', 'source': 'Psychiatric Times', 'date': 'Jul 13, 2012', 'snippet': 'There is rapidly escalating interest in drugs that target the glutamatergic \nneurotransmitter system, especially NMDA receptor modulators.', 'thumbnail': 'https://serpapi.com/searches/67242533d9c3e6887205f3a2/images/a1e4831e7bc18d1d1e7744b6b1d9b75fb45be6aeeaebb01cffadb9295aa15138.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.798674464225769}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03254485,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036259', 'title': 'Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction', 'source': 'American Heart Association Journals', 'date': 'Mar 11, 2019', 'snippet': 'Mitochondrial abnormalities can significantly contribute to impaired oxygen \nutilization and the resulting exercise intolerance in HFpEF.', 'thumbnail': 'https://serpapi.com/searches/67242786fda26d2d2e7dc6b2/images/3b5aa7a27383abb077d063697eeac72510c2b523cbf17648dbba15cb8db050af.png', 'sentiment': 'negative', 'sentiment_prob': 0.7354979515075684}",,,,,,,,,,['negative'],negative,0
NCT03010176,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.339', 'title': 'Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy - Hao - 2023 - MedComm', 'source': 'Wiley Online Library', 'date': 'Aug 7, 2023', 'snippet': 'In this review, we summarize and discuss the latest developments in \nnanoparticles (NPs) for cancer immuno-oncology therapy with a focus on \nlipid-based NPs (...', 'thumbnail': 'https://serpapi.com/searches/6724279708abe42058644a7b/images/a889c28568966c8cfdbb3f37ca1e25a9b3bf74645879f583d6e2244982defd80.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9235424399375916}",,,,,,,,,,['neutral'],neutral,1
NCT02407990,"{'position': 1, 'link': 'https://immuno-oncologynews.com/2016/07/26/beigene-presents-initial-clinical-data-showing-anti-cancer-activity-in-range-of-solid-tumors/', 'title': ""Immunotherapy Trial's Early Results Show Activity in Solid Tumors"", 'source': 'Immuno-Oncology News', 'date': 'Jul 26, 2016', 'snippet': 'Preliminary study results revealed that BGB-A317 was well-tolerated and \ndisplayed anti-tumor activity in a number of solid tumors.', 'thumbnail': 'https://serpapi.com/searches/672427b7d0253e3d8bb51b56/images/dd2d60e23e04520a92b6535546df3781748fad632f7744a66b83cb39ae1af0a1.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5107393264770508}",,,,,,,,,,['positive'],positive,1
NCT01509677,"{'position': 1, 'link': 'https://copdnewstoday.com/news/daliresp-may-ease-lung-inflammation-in-copd-patients-phase-3-trial-data-suggests/', 'title': 'Daliresp May Ease Lung Inflammation in COPD Patients, Phase 3 Trial Data Suggests', 'source': 'COPD News Today', 'date': 'Sep 28, 2018', 'snippet': 'Read about clinical trial data suggesting Daliresp, approved to treat COPD \nflares, might also work against lung inflammation by its effects...', 'thumbnail': 'https://serpapi.com/searches/672427c4e8735a405074b54a/images/9a50b0cd142cad4a420b6a88439c6eae9b3e599686a3b6a7d29e5745e1be31a4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7673671245574951}",,,,,,,,,,['neutral'],neutral,1
NCT02155660,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1905248', 'title': 'Benralizumab for the Prevention of COPD Exacerbations', 'source': 'The New England Journal of Medicine', 'date': 'May 20, 2019', 'snippet': 'In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a \nratio of approximately 2:1 on the basis of eosinophil count [≥220 per \ncubic...', 'thumbnail': 'https://serpapi.com/searches/672427c64e9efc855e4bd766/images/4d308dc6a6b46bd28cbaee42e4e03d7c6e7fdc4f58f2e30406933a99ef7840f2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8859856724739075}",,,,,,,,,,['neutral'],neutral,1
NCT03345849,"{'position': 1, 'link': 'https://www.empr.com/home/news/rinvoq-approved-for-moderately-to-severely-active-crohn-disease/', 'title': 'Rinvoq Approved for Moderately to Severely Active Crohn Disease', 'source': 'Medical Professionals Reference', 'date': 'May 19, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib) \nfor the treatment of adults with moderately to severely active Crohn \ndisease.', 'thumbnail': 'https://serpapi.com/searches/672427f552a04ebc00472a4a/images/379655d1eb11a3f0b50b681b505aeebae33ed40f33d3fcff69102938b651f1f5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8569288849830627}","{'position': 2, 'link': 'https://www.pharmacypracticenews.com/FDA-News/GI-Disorders/Article/05-23/FDA-Grants-New-Indication-for-Rinvoq%E2%80%94Once-Daily-Pill-for-Crohns-Disease/70347', 'title': 'FDA Grants New Indication for Rinvoq—Once-Daily Pill for Crohn’s Disease', 'source': 'Pharmacy Practice News', 'date': 'May 19, 2023', 'snippet': ""The FDA granted a new indication for Rinvoq to treat adults with moderate \nto severe active Crohn's disease who have not responded adequately..."", 'thumbnail': 'https://serpapi.com/searches/672427f552a04ebc00472a4a/images/379655d1eb11a3f00db937261469e3131a0c96bc0d3855515eb42c07e635416a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8453056812286377}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00581867,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.00830/full', 'title': ""Insulin Resistance in Alzheimer's Disease"", 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': 'Here we review encouraging preclinical and clinical data indicating the \npotential of targeting impaired insulin signaling with antidiabetic drugs \nto treat...', 'thumbnail': 'https://serpapi.com/searches/6724281f213c87df4d44b805/images/a504d30749a4a3f94ab6f14c1af5fcbbcd8f658337fd0abb40f9d7b04351a8ba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9037069082260132}",,,,,,,,,,['neutral'],neutral,1
NCT01728454,"{'position': 1, 'link': 'https://endometriosisnews.com/2017/04/19/endometriosis-uterine-fibrosis-therapy-proellex-wins-us-patent-protection-repros/', 'title': 'Endometriosis, Uterine Fibrosis Therapy Proellex Wins U.S. Patent Protection, Says Repros', 'source': 'Endometriosis News Today', 'date': 'Apr 19, 2017', 'snippet': ""Find more about the new Repros Therapeutics's patent on the therapeutic use \nof Proellex for treatment of endometriosis and uterine fibrosis."", 'thumbnail': 'https://serpapi.com/searches/6724282afcd69e09522383d6/images/6ee8a03066d55702a2e59208b6619a64a8549ee47e55614ef9adea4157a19086.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7862261533737183}",,,,,,,,,,['neutral'],neutral,1
NCT04349241,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-85227-0', 'title': 'RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial', 'source': 'Nature', 'date': 'Mar 31, 2021', 'snippet': 'Favipiravir is considered a potential treatment for COVID-19 due its \nefficacy against different viral infections.', 'thumbnail': 'https://serpapi.com/searches/672428a13c863da09593e423/images/3cb64b2401c4e2a08f1c3822b09c6e4b61dcf96f9fb47488890624ec658793d3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8897945284843445}","{'position': 2, 'link': 'https://retractionwatch.com/2021/09/22/study-comparing-hydroxychloroquine-and-antiviral-drug-for-covid-19-retracted/', 'title': 'Study comparing hydroxychloroquine and antiviral drug for COVID-19 retracted', 'source': 'Retraction Watch', 'date': 'Sep 22, 2021', 'snippet': 'The authors of a study comparing hydroxychloroquine and the antiviral agent \nfavipiravir as treatments for COVID-19 have lost the paper after...', 'thumbnail': 'https://serpapi.com/searches/672428a13c863da09593e423/images/3cb64b2401c4e2a0b9be4d20abb82bb16c4d7a51d4f89b1191b0066e857ca19a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5473102331161499}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT03520946,"{'position': 1, 'link': 'https://www.onclive.com/view/ramucirumab-plus-tas-102-fails-to-improve-os-in-heavily-pretreated-mcrc', 'title': 'Ramucirumab Plus TAS-102 Fails to Improve OS in Heavily Pretreated mCRC', 'source': 'OncLive', 'date': '1 month ago', 'snippet': 'Ramucirumab plus trifluridine/tipiracil failed to improve overall survival \nvs TAS-102 alone in patients with heavily pretreated metastatic...', 'thumbnail': 'https://serpapi.com/searches/672428a9b57db8f4c1c6344d/images/b8bfc8b98fffe774b7387f66286cf016325fa89facaab659a911e159fe186145.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8171577453613281}",,,,,,,,,,['negative'],negative,0
NCT00074971,"{'position': 1, 'link': 'https://fabrydiseasenews.com/fabrazyme-is-first-fabry-disease-therapy/', 'title': 'Fabrazyme (agalsidase beta) for Fabry disease', 'source': 'Fabry Disease News', 'date': 'Mar 4, 2024', 'snippet': 'Fabrazyme is an enzyme replacement therapy and the first treatment that \nscientists developed specifically for Fabry disease.', 'thumbnail': 'https://serpapi.com/searches/672428c47ca6b3ab0d2b4fac/images/3ca6f9c22d71ac237b5c1584ff908002a94999c3801c3419723e6a89e96fbd21.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8877143859863281}",,,,,,,,,,['neutral'],neutral,1
NCT05076149,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/phase-3-trials-new-triple-combo-cftr-modulator-report-results/', 'title': 'Phase 3 trials of new triple-combo CFTR modulator to report results', 'source': 'Cystic Fibrosis News Today', 'date': 'Jan 10, 2024', 'snippet': 'Results of three global clinical trials of a new triple-combination CFTR \nmodulator therapy for cystic fibrosis (CF) — vanzacaftor, tezacaftor...', 'thumbnail': 'https://serpapi.com/searches/672428d0dc969faceef7c9d2/images/b11d97678bfc6e69d7dbb6460aeae1ebe7509692363d30b37f894f0f44276b5d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8913163542747498}",,,,,,,,,,['neutral'],neutral,1
NCT01351415,"{'position': 1, 'link': 'https://theoncologist.onlinelibrary.wiley.com/doi/10.1002/onco.13971', 'title': 'A Long‐Term Extension Study of Bevacizumab in Patients With Solid Tumors - Oza - 2021', 'source': 'The Oncologist', 'date': 'Sep 9, 2021', 'snippet': 'Abstract Background Bevacizumab has been studied in numerous clinical \ntrials in multiple types of cancer; however, patients may receive...', 'thumbnail': 'https://serpapi.com/searches/672428d717b10eb87f4914dc/images/3bb5121066f12fdadfd320e32b1f292cf1d4a3ba8a75cfa7e04cee6fc6bef6a6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9322308897972107}",,,,,,,,,,['neutral'],neutral,1
NCT02716038,"{'position': 1, 'link': 'https://www.onclive.com/view/dr-henick-on-the-use-of-neoadjuvant-atezolizumab-plus-chemotherapy-in-nsclc', 'title': 'Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLC', 'source': 'OncLive', 'date': 'May 16, 2023', 'snippet': 'Brian Henick, MD, associate director, Experimental Therapeutics, director, \nTranslational Research in Aerodigestive Cancers in Medical...', 'thumbnail': 'https://serpapi.com/searches/672428f1e50bc00593807b3f/images/ae9feef2ebe0f946fc3fe9f6e6498a67d1cd976ef2a626a1d6c470e80551c2bf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9444990754127502}",,,,,,,,,,['neutral'],neutral,1
NCT03429933,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/ipf-lung-function-decline-may-slow-with-lpa1-antagonist-bms-986278/', 'title': 'IPF lung function decline may slow with LPA1 antagonist BMS-986278...', 'source': 'Pulmonary Fibrosis News', 'date': 'May 26, 2023', 'snippet': 'BMS-986278 did better than a placebo at slowing lung function decline for \nup to 26 weeks in people with idiopathic pulmonary fibrosis.', 'thumbnail': 'https://serpapi.com/searches/67242a104677bf90f1c1b119/images/979697437c49d28e224de94346a0e979e4ddd3643c172b4e15fdfb5fc22ecc9b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6781575083732605}",,,,,,,,,,['neutral'],neutral,1
NCT04984525,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1267378/full', 'title': 'Systems and synthetic biology-driven engineering of live bacterial therapeutics', 'source': 'Frontiers', 'date': 'Oct 19, 2023', 'snippet': 'In this review, we outline the current progress and latest updates on \nmicrobial therapeutics, with particular emphasis on gut commensal \nengineering driven by...', 'thumbnail': 'https://serpapi.com/searches/67242a7d360f4e3ba57d85e4/images/fc5b9df3324bee92b6f8c21b02e9229e696d36e3aa7e19cc9cb5d92e4eb9f56c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9050130844116211}",,,,,,,,,,['neutral'],neutral,1
NCT03006276,"{'position': 1, 'link': 'https://www.neurologyadvisor.com/news/celecoxib-effective-migraine-pain-relief-symptoms-aura-status-ahs-2022/', 'title': 'Celecoxib Effective for Migraine Pain Relief, Symptoms Regardless of Aura Status', 'source': 'Neurology Advisor', 'date': 'Jun 15, 2022', 'snippet': 'Oral celecoxib is more effective than placebo for the treatment of acute \nmigraine with or without aura, according to a pooled analysis of data from \n2 clinical...', 'thumbnail': 'https://serpapi.com/searches/67242a92a5aae957db437f4c/images/e6ee0ba1d41994e21433fe77e0fe515b1582c14da2e798b45eeab9efb5c88341.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6028152108192444}","{'position': 2, 'link': 'https://www.empr.com/home/news/elyxyb-now-available-for-acute-migraine-treatment/', 'title': 'Elyxyb Now Available for Acute Migraine Treatment', 'source': 'Medical Professionals Reference', 'date': 'Feb 24, 2022', 'snippet': 'Elyxyb (celecoxib oral solution) is now available for the acute treatment \nof migraine with or without aura in adults.', 'thumbnail': 'https://serpapi.com/searches/67242a92a5aae957db437f4c/images/e6ee0ba1d41994e2373ec7a27b4ce8e204338f910a67630fdba6d3aeb62cf21a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.773752748966217}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04622774,"{'position': 1, 'link': 'https://www.immunogen.com/clinical-trials/', 'title': 'CLINICAL TRIALS', 'source': 'ImmunoGen', 'date': '٠٩\u200f/٠٣\u200f/٢٠٢٢', 'snippet': 'We have a variety of ongoing clinical trials in different therapeutic \nareas, which are detailed below.', 'thumbnail': 'https://serpapi.com/searches/67242ab874f0a4921704f810/images/8a1f9ee0e3afbacf8583115df2a614af2d8d4cecbf5c6cd92b75ab04c988f50a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8589240908622742}",,,,,,,,,,['neutral'],neutral,1
NCT04849429,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.992476/full', 'title': 'Exosomes and exosomal miRNAs: A new therapy for intervertebral disc degeneration', 'source': 'Frontiers', 'date': 'Sep 8, 2022', 'snippet': 'The aim of this paper is to identify the latest research results, potential \napplications and challenges of this emerging treatment strategy.', 'thumbnail': 'https://serpapi.com/searches/672429482bab905d51ccb89d/images/495ee0f75d905071504da24545e77d840d2579c421fa5b4f5f0d209b39842d02.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8698508143424988}",,,,,,,,,,['neutral'],neutral,1
NCT02926833,"{'position': 1, 'link': 'https://lymphomahub.com/medical-information/primary-analysis-of-phase-iii-of-the-zuma-6-trial-axicabtagene-ciloleucel-plus-atezolizumab-for-patients-with-refractory-dlbcl', 'title': 'Primary analysis of phase I/II of the ZUMA-6 trial – axicabtagene ciloleucel plus atezolizumab for patients with refractory DLBCL', 'source': 'Lymphoma Hub', 'date': 'Jun 5, 2020', 'snippet': 'The phase I/II of the ZUMA-6 (NCT02926833) study is currently investigating \nthe safety and efficacy of axi-cel in combination with the...', 'thumbnail': 'https://serpapi.com/searches/6724296f7a12fd607b597824/images/3a216ef0ed74a999824e093a850eeaff84fa36330e15c03c00051bf9fdcb3e81.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9170985817909241}",,,,,,,,,,['neutral'],neutral,1
NCT04662281,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/postherpetic-neuralgia-market-to-accelerate-significantly-at-a-cagr-of-14-by-2034--delveinsight-302168037.html', 'title': 'Postherpetic Neuralgia Market to Accelerate Significantly at a CAGR of 14% by 2034 | DelveInsight', 'source': 'PR Newswire', 'date': 'Jun 10, 2024', 'snippet': 'The postherpetic neuralgia market is expected to show positive growth, \nmainly attributed to increased incidence and the anticipated launch of \nnovel therapies.', 'thumbnail': 'https://serpapi.com/searches/6724298d3c9575b4e24eb4d4/images/85429a991056f6b9eb6ee1ffc56963d25130bc9b91151d7a86049653ca21963a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8809778094291687}",,,,,,,,,,['positive'],positive,1
NCT01696396,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222015633', 'title': 'Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies', 'source': 'ScienceDirect.com', 'date': 'Dec 31, 2022', 'snippet': 'Emerging biologics and small molecule drugs are navigating the clinical \nlandscape of inflammatory bowel disease (IBD).', 'thumbnail': 'https://serpapi.com/searches/67242999cb33d04548491b7a/images/08647b64b6a01410dc351b8dbf67b3062e3d75d4848db7631c6af2b4e6639a8c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.830076277256012}",,,,,,,,,,['neutral'],neutral,1
NCT03474198,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2212537', 'title': 'Treatment Strategy for Rifampin-Susceptible Tuberculosis', 'source': 'The New England Journal of Medicine', 'date': 'Feb 20, 2023', 'snippet': 'In this adaptive, open-label, noninferiority trial, we randomly assigned \nparticipants with rifampin-susceptible pulmonary tuberculosis to undergo \neither...', 'thumbnail': 'https://serpapi.com/searches/6724299bce1e10a3d76f1d9e/images/4d05260030c563090bbf6accd9051f624b8487a5929bc414333f0aa071d68e1e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8868440389633179}",,,,,,,,,,['neutral'],neutral,1
NCT04103060,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.986918/full', 'title': 'Advances in vitiligo: Update on therapeutic targets', 'source': 'Frontiers', 'date': 'Aug 30, 2022', 'snippet': 'Vitiligo, whose treatment remains a serious concern and challenge, is an \nautoimmune skin disease characterized by patches of depigmentation.', 'thumbnail': 'https://serpapi.com/searches/672429bc75f97436c9f2c084/images/d761c99f244dc0a7af50ff2ff9d32817264ae05d187549c50801d21da4c4a636.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6913387775421143}",,,,,,,,,,['neutral'],neutral,1
NCT01889186,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00070-6/fulltext', 'title': 'Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial', 'source': 'The Lancet', 'date': 'Mar 8, 2024', 'snippet': 'Most patients with chronic lymphocytic leukaemia progress after treatment \nor retreatment with targeted therapy or chemoimmunotherapy and...', 'thumbnail': 'https://serpapi.com/searches/672429e41fc7c51f052f0fc0/images/39b010b783722fabd86c55d8ce3fad2140ff692a8e974dcf701d4201111eed31.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8870301842689514}","{'position': 2, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30019-5/fulltext', 'title': 'Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study', 'source': 'The Lancet', 'date': 'May 10, 2016', 'snippet': 'Deletion of chromosome 17p (del[17p]) in patients with chronic lymphocytic \nleukaemia confers very poor prognosis when treated with standard...', 'thumbnail': 'https://serpapi.com/searches/672429e41fc7c51f052f0fc0/images/39b010b783722faba67a3b92c070545a43ff6cf67e122747287f181ef9713e4d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6274240016937256}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02260791,"{'position': 1, 'link': 'https://juvenilearthritisnews.com/2020/07/10/hulio-biosimilar-of-humira-wins-fda-approval-jia-but-not-available-until-2023/', 'title': 'Hulio Use for JIA Approved by FDA, Biosimilar of Humira', 'source': 'Juvenile Arthritis News', 'date': 'Jul 10, 2020', 'snippet': 'The US Food and Drug Administration (FDA) has approved Hulio, a biosimilar \nof Humira (adalimumab), for the treatment of juvenile idiopathic arthritis \n(JIA) in...', 'thumbnail': 'https://serpapi.com/searches/67242acd03775653ac4ab52a/images/7a47396e5c40cb87538e0ccb9a8e92b9ffcd8508a6181be382904478c7591089.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.773018479347229}",,,,,,,,,,['neutral'],neutral,1
NCT02041533,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1613493', 'title': 'First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jun 22, 2017', 'snippet': 'Nivolumab has been associated with longer overall survival than docetaxel \namong patients with previously treated non–small-cell lung cancer...', 'thumbnail': 'https://serpapi.com/searches/67242b0e3b3c3238b924e5cb/images/796a6a638c68b4e0a0192e923c958b64f8a5c051aabb7f259cd9ed583742b87e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8376302123069763}",,,,,,,,,,['neutral'],neutral,1
NCT02675790,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2000146', 'title': 'Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa', 'source': 'The New England Journal of Medicine', 'date': 'Jun 24, 2020', 'snippet': 'Hydroxyurea with dose escalation had superior clinical efficacy to that of \nfixed-dose hydroxyurea, with equivalent safety.', 'thumbnail': 'https://serpapi.com/searches/67242b3c8a7c0972a22e3eff/images/1fe0d44d9e7f18856493190f7b379d4c400623f525ebfdaea9fec5633543199b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.4917817711830139}",,,,,,,,,,['neutral'],neutral,1
NCT01691521,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1403290', 'title': 'Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 8, 2014', 'snippet': 'Some patients with severe asthma have frequent exacerbations associated \nwith persistent eosinophilic inflammation despite continuous...', 'thumbnail': 'https://serpapi.com/searches/67242b46360f4e3b5cd9a69e/images/8138e474412c1153a345f0cc365f18d7e3f571602f65648fbbb681b3d1683560.png', 'sentiment': 'negative', 'sentiment_prob': 0.5234540104866028}","{'position': 2, 'link': 'https://www.pulmonologyadvisor.com/news/severe-asthma-benefits-from-mepolizumab-regardless-of-background-therapies/', 'title': 'Mepolizumab Effective in Asthma Regardless of Background Controller Therapies', 'source': 'Pulmonology Advisor', 'date': 'Nov 1, 2019', 'snippet': 'Mepolizumab consistently reduced the annual rate of exacerbations in severe \neosinophilic asthma compared with placebo, according to research.', 'thumbnail': 'https://serpapi.com/searches/67242b46360f4e3b5cd9a69e/images/8138e474412c11536b153c32f6bc02bb25156f56ed8fc6650793afb5b0a60294.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5463080406188965}",,,,,,,,,"['negative', 'positive']",negative,0
NCT00122460,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0802656', 'title': 'Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jan 27, 2017', 'snippet': 'Cetuximab is effective in platinum-resistant recurrent or metastatic \nsquamous-cell carcinoma of the head and neck. We investigated the efficacy \nof cetuximab...', 'thumbnail': 'https://serpapi.com/searches/67242b6788bcde41116354ec/images/cc05c169387494615167777ec17225bcac1c706c1181e5362b7261b084c6e8ab.png', 'sentiment': 'neutral', 'sentiment_prob': 0.752274751663208}",,,,,,,,,,['neutral'],neutral,1
NCT01492686,"{'position': 1, 'link': 'https://alsnewstoday.com/news/radicava-edaravone-slows-decline-als-poorer-lung-function/', 'title': 'Radicava Slows Decline in ALS Patients With Poorer Lung Function |...', 'source': 'ALS News Today', 'date': 'Jul 19, 2022', 'snippet': 'Post-hoc analysis showed slower progression in ALS patients on Radicava \n(edaravone), including those low FVC values; early start supported.', 'thumbnail': 'https://serpapi.com/searches/67242ffd707fd36741531b2d/images/64095e55515b5cff982e58cd07df0dfd3d1378b4623fbf017670fb48700cdad8.png', 'sentiment': 'negative', 'sentiment_prob': 0.537021815776825}","{'position': 2, 'link': 'https://alsnewstoday.com/news/als-early-radicava-lowers-risk-ventilation-hospitalization-mortality/', 'title': 'In ALS, early Radicava lowers risk of ventilation, hospitalization, mortality', 'source': 'ALS News Today', 'date': 'Aug 15, 2023', 'snippet': 'ALS patients in Study 19 on Radicava continuously were 53% less likely to \nhave those events over those who started it six months later.', 'thumbnail': 'https://serpapi.com/searches/67242ffd707fd36741531b2d/images/64095e55515b5cff3419bce7e151e12229f6ad1d12d31c7ed81b43fa983421b9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7491136193275452}","{'position': 3, 'link': 'https://www.empr.com/home/news/oral-suspension-formulation-of-edaravone-approved-for-als/', 'title': 'Oral Suspension Formulation of Edaravone Approved for ALS', 'source': 'Medical Professionals Reference', 'date': 'May 13, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Radicava ORS \n(edaravone) oral suspension for the treatment of adults with amyotrophic \nlateral sclerosis (...', 'thumbnail': 'https://serpapi.com/searches/67242ffd707fd36741531b2d/images/64095e55515b5cffa21a31d9f7bc67545b5a9a7c98f2b4bd27b137760e35c2cf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8913319110870361}","{'position': 4, 'link': 'https://alsnewstoday.com/news/radicava-suggests-more-real-world-data-needed-to-determine-efficacy-of-edaravone-in-als/', 'title': 'Radicava’s Effectiveness for ALS Not Established, Real-life Use Suggests', 'source': 'ALS News Today', 'date': 'Nov 17, 2020', 'snippet': 'A review of Radicava (edaravone), an approved amyotrophic lateral sclerosis \n(ALS) treatment, found the medication generally well tolerated in real-life \nuse by...', 'thumbnail': 'https://serpapi.com/searches/67242ffd707fd36741531b2d/images/64095e55515b5cff583054c5528622e933b5f7f5fb562970ab0b6e912a6f1dbb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6735977530479431}","{'position': 5, 'link': 'https://alsnewstoday.com/news/radicava-prolongs-survival-als-patients-study-japan/', 'title': 'Radicava Prolongs Survival in ALS Patients, Study from Japan Indicates', 'source': 'ALS News Today', 'date': 'Aug 18, 2021', 'snippet': 'Long-term treatment with Radicava (edaravone) is generally safe and nearly \ndoubles survival time in adults with amyotrophic lateral...', 'thumbnail': 'https://serpapi.com/searches/67242ffd707fd36741531b2d/images/64095e55515b5cffc84519553b8b4bc058f6daa649270a010a9b29c89391966d.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5691385865211487}",,,,,,"['negative', 'neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT02804750,"{'position': 1, 'link': 'https://cushingsdiseasenews.com/news/interim-phase-2-trial-data-shows-relacorilant-potential-manage-cortisol-effects-cushings/', 'title': ""In Phase 2 Cushing's Trial, Relacorilant Shows Early Positive Results"", 'source': ""Cushing's Disease News"", 'date': 'May 11, 2018', 'snippet': ""Relacorilant, developed by Corcept Therapeutics, may effectively manage the \neffects of excess cortisol in Cushing's syndrome patients,..."", 'thumbnail': 'https://serpapi.com/searches/6724300e30dfc1771aa82e92/images/0b0ef65c816baacb01d9febbfdcc7eb85fc56a5334d3d61000f9e8a322172e50.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6322821378707886}",,,,,,,,,,['positive'],positive,1
NCT03943264,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/clinical-hold-lifted-phase-2-trial-xpro1595-mild/', 'title': 'Clinical hold lifted for Phase 2 trial of XPro1595 in mild Alzheimer’s', 'source': ""Alzheimer's News Today"", 'date': 'Feb 22, 2024', 'snippet': ""The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on a \nPhase 2 trial testing INmune Bio's investigational treatment..."", 'thumbnail': 'https://serpapi.com/searches/67243011a86921b7552efe19/images/d6308d658c6e933c299a8860c4cdaec5fa58cb26d97091ec1ea5ce7bbe129a31.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9154505133628845}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/07/13/xpro1595-may-promote-myelin-restoration-ms-mouse-study-finds/', 'title': 'XPro1595 may promote myelin restoration, new mouse study finds |...', 'source': 'Multiple Sclerosis News Today', 'date': 'Jul 13, 2023', 'snippet': 'Through the activation of two types of nervous system support cells, \nXPro1595 may promote myelin restoration that could help MS patients.', 'thumbnail': 'https://serpapi.com/searches/67243011a86921b7552efe19/images/d6308d658c6e933c820d92be200663114d471ce3ec969ec84be61167d7a1c7e8.png', 'sentiment': 'positive', 'sentiment_prob': 0.7108244299888611}","{'position': 3, 'link': 'https://alzheimersnewstoday.com/news/alzheimers-phase-2-trial-xpro1595-begins-dosing-patients/', 'title': 'Dosing Begins in Phase 2 Trial of XPro1595, Targeting Inflammation', 'source': ""Alzheimer's News Today"", 'date': 'Apr 20, 2022', 'snippet': ""A first patient has been dosed in a Phase 2 trial of XPro1595, which aims \nto treat mild Alzheimer's patients by lowering neuroinflammation."", 'thumbnail': 'https://serpapi.com/searches/67243011a86921b7552efe19/images/d6308d658c6e933c5b9b469137259278bd5e330e102fffb54f00bfe8cf46982a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.917678952217102}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT02994927,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2023386', 'title': 'Avacopan for the Treatment of ANCA-Associated Vasculitis', 'source': 'The New England Journal of Medicine', 'date': 'Feb 17, 2021', 'snippet': 'In this randomized, controlled trial, we assigned patients with \nANCA-associated vasculitis in a 1:1 ratio to receive oral avacopan at a \ndose...', 'thumbnail': 'https://serpapi.com/searches/6724303454605c243c1bc75f/images/1d66c27d6820914636c00f3c5e526890d71aaa16f1cccc9d16f6f1aa557c92cd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.895490825176239}","{'position': 2, 'link': 'https://ancavasculitisnews.com/news/fda-approves-tavneos-avacopan-add-on-mpa-gpa-therapy/', 'title': 'FDA Approves Tavneos as Add-on Therapy for Severe MPA, GPA', 'source': 'ANCA Vasculitis News', 'date': 'Oct 11, 2021', 'snippet': 'The US Food and Drug Administration (FDA) has approved Tavneos (avacopan) \nas an add-on therapy for people with severe active microscopic polyangiitis \n(MPA) and...', 'thumbnail': 'https://serpapi.com/searches/6724303454605c243c1bc75f/images/1d66c27d682091462d621f862a6eea860448bc8bf032fc01d695733e41208c08.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7773008346557617}","{'position': 3, 'link': 'https://ancavasculitisnews.com/news/tavneos-plus-rituximab-aids-sustained-remission-aav/', 'title': 'Tavneos plus rituximab induction aids sustained remission with AAV', 'source': 'ANCA Vasculitis News', 'date': 'Nov 27, 2023', 'snippet': 'In a Phase 3 ADVOCATE trial, sustained one-year remission rates were higher \nin an AAV patient subgroup on rituximab induction plus Tavneos.', 'thumbnail': 'https://serpapi.com/searches/6724303454605c243c1bc75f/images/1d66c27d6820914629e180e949f0e4ac582a531d9df0fbe4a8ca01d56dd2e1ed.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7185574769973755}","{'position': 4, 'link': 'https://ancavasculitisnews.com/news/chemocentryx-on-track-present-topline-data-advocate-trial-avacopan/', 'title': ""AAV: ADVOCATE Trial's Topline Data Expected to be Presented This Year"", 'source': 'ANCA Vasculitis News', 'date': 'May 14, 2019', 'snippet': 'ChemoCentryx remains on track to report topline results later this year \nfrom its ongoing Phase 3 clinical trial assessing the safety and...', 'thumbnail': 'https://serpapi.com/searches/6724303454605c243c1bc75f/images/1d66c27d682091460753dedd7ecc744881a09168df5afe309ae474cd21b1fceb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8710752725601196}","{'position': 5, 'link': 'https://ancavasculitisnews.com/news/tavneos-better-than-prednisone-treating-aav-ear-nose-throat-symptoms/', 'title': 'Tavneos better than prednisone for treating ear, nose, throat symptoms', 'source': 'ANCA Vasculitis News', 'date': 'Jul 1, 2024', 'snippet': ""Topline data from the Phase 3 ADVOCATE clinical trial supported Tavneos' \napproval as an add-on to standard treatment for GPA, MPA."", 'thumbnail': 'https://serpapi.com/searches/6724303454605c243c1bc75f/images/1d66c27d68209146ffa3c78128649b22b578d3c532496c7c6614556a8cdd1dab.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6747206449508667}","{'position': 6, 'link': 'https://ancavasculitisnews.com/news/anca-associated-vasculitis-remission-rates-high-with-tavenos-study/', 'title': 'ANCA-associated vasculitis remission rates high with Tavneos: Study', 'source': 'ANCA Vasculitis News', 'date': 'Apr 17, 2024', 'snippet': 'Tavneos (avacopan) safely and effectively promotes clinical remission in \npeople with newly diagnosed or relapsing ANCA-associated vasculitis (AAV),', 'thumbnail': 'https://serpapi.com/searches/6724303454605c243c1bc75f/images/1d66c27d682091462f3e4c5ae818f7d4b0d9e468eb8ed777d5515a42890865b0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5173897743225098}","{'position': 7, 'link': 'https://ancavasculitisnews.com/news/abstract-on-how-avacopan-affects-kidney-function-makes-committee-top-10-list/', 'title': 'Abstract on How Avacopan Affects Kidney Function Makes Top 10 List', 'source': 'ANCA Vasculitis News', 'date': 'Jun 16, 2021', 'snippet': 'Avacopan can improve kidney function in AAV patients to a greater extent \nthan steroids, especially among people with advanced kidney disease...', 'thumbnail': 'https://serpapi.com/searches/6724303454605c243c1bc75f/images/1d66c27d68209146a4133deced661712a0d119f0f63a929146a570e4e8d90b39.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7190611958503723}","{'position': 8, 'link': 'https://ancavasculitisnews.com/news/canada-tavneos-approval-add-on-treatment-severe-aav-mpa-gpa-anca-vasculitis/', 'title': 'Canada Approves Tavneos as Add-on Treatment for Severe AAV', 'source': 'ANCA Vasculitis News', 'date': 'Apr 27, 2022', 'snippet': 'Health Canada has approved the oral medicine Tavneos (avacopan) as an \nadd-on therapy to treat adults with severe ANCA-associated vasculitis (AAV).', 'thumbnail': 'https://serpapi.com/searches/6724303454605c243c1bc75f/images/1d66c27d682091463c5996b072bced7c86ba130f9d917a1ba7553f1c7180ecb1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7907763719558716}","{'position': 9, 'link': 'https://ancavasculitisnews.com/news/tavneos-mpa-gpa-approved-japan-marketed-by-kissei/', 'title': 'Tavneos for MPA, GPA Approved in Japan; Will Be Marketed by Kissei', 'source': 'ANCA Vasculitis News', 'date': 'Sep 29, 2021', 'snippet': 'Tavneos has been approved by the Japanese Ministry of Health, Labor, and \nWelfare for the treatment of MPA and GPA patients in Japan.', 'thumbnail': 'https://serpapi.com/searches/6724303454605c243c1bc75f/images/1d66c27d68209146e409b33de9945252fa006361a318ae59b31af1348bbaa67c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8002713918685913}","{'position': 10, 'link': 'https://ancavasculitisnews.com/news/tavneos-approved-european-union-oral-add-on-treatment-mpa-gpa/', 'title': 'Tavneos Approved in EU as Oral Add-on Treatment for MPA, GPA', 'source': 'ANCA Vasculitis News', 'date': 'Jan 24, 2022', 'snippet': 'The European Commission has approved Tavneos (avacopan) as an add-on \ntherapy for adults with severe granulomatosis polyangiitis (GPA) or \nmicroscopic...', 'thumbnail': 'https://serpapi.com/searches/6724303454605c243c1bc75f/images/1d66c27d68209146e8af079f685c5a7494feff2abba2df23ab252ff028cb5847.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7375460267066956}","['neutral', 'neutral', 'neutral', 'neutral', 'positive', 'neutral', 'positive', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04051944,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Rozanolixizumab-UCB7665', 'title': 'Rozanolixizumab (Rystiggo®)', 'source': 'UCB', 'date': 'Aug 30, 2024', 'snippet': 'Autoimmune Encephalitis, A Study to Test the Efficacy, Safety, and \nPharmacokinetics of Rozanolixizumab in Adult Study Participants With...', 'thumbnail': 'https://serpapi.com/searches/6724303d13e5d85abd9d8433/images/434b6925f73b9f81aa2e72c344569a62188a078ece9a3dd4af67dffb9e41b704.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8345304131507874}",,,,,,,,,,['neutral'],neutral,1
NCT04816019,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00349-1/fulltext', 'title': 'Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial', 'source': 'The Lancet', 'date': 'Nov 15, 2023', 'snippet': 'Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a \nmulticentre, randomised, double-blind, placebo-controlled, phase 3 trial', 'thumbnail': 'https://serpapi.com/searches/67242f5fbbc18bf1889e5187/images/8907a9820ff6f5def0f7bc58fb06d903e127d0719bcc9e2264147d19d21d1da5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7518746852874756}","{'position': 2, 'link': 'https://www.nature.com/articles/s44222-022-00012-6', 'title': 'Biomaterials for intranasal and inhaled vaccine delivery', 'source': 'Nature', 'date': 'Jan 24, 2023', 'snippet': 'Delivery of vaccines by nasal sprays may enable more robust, protective \nmucosal immune responses against infectious diseases,...', 'thumbnail': 'https://serpapi.com/searches/67242f5fbbc18bf1889e5187/images/8907a9820ff6f5deefb4c97cb75392585ec043f198044147dd4d33a443174cd1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7103468775749207}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03401229,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/fda-needs-more-data-to-decide-on-benralizumab-for-nasal-polyposis/', 'title': 'FDA Needs More Data to Decide on Benralizumab for Nasal Polyposis', 'source': 'Medical Professionals Reference', 'date': 'Mar 14, 2022', 'snippet': 'AstraZeneca has received a Complete Response Letter (CRL) from the Food and \nDrug Administration (FDA) regarding the supplemental Biologics...', 'thumbnail': 'https://serpapi.com/searches/67242bdce335ec8a13a68b84/images/6b625f1c16be82d740a4ff46feb72dbade90dfd6585a7a4fca7faba79dbfefe6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9298219084739685}",,,,,,,,,,['neutral'],neutral,1
NCT03366480,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-020-02986-w', 'title': 'The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis', 'source': 'Nature', 'date': 'Sep 17, 2020', 'snippet': 'ABTL0812 induced cancer cell death via induction of endoplasmic reticulum \nstress, activation of the unfolded protein response, autophagy and \napoptosis.', 'thumbnail': 'https://serpapi.com/searches/67242bfa48c97dfdbdfd8748/images/3f8d6def91a199eed6ef871cee665b094cc73c1de9a0d63e48d6c3ffae5034fa.png', 'sentiment': 'negative', 'sentiment_prob': 0.8924160003662109}",,,,,,,,,,['negative'],negative,0
NCT03753659,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.783236/full', 'title': 'Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma', 'source': 'Frontiers', 'date': 'Nov 25, 2021', 'snippet': 'This review aims to summarize the currently reported results and ongoing \ntrials of the ICIs-based combination therapies for HCC to explore the \nrational...', 'thumbnail': 'https://serpapi.com/searches/67242c03ea57e9589361befe/images/1ebe7f2a4b99ed4f6c10224994b0fb4d2ebbe316a75d74df11e30095d66d8614.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8643324971199036}",,,,,,,,,,['neutral'],neutral,1
NCT04878354,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/alk-eyes-label-expansion-after-phase-iii-trial-success/', 'title': 'ALK eyes label expansion after Phase III trial success', 'source': 'Clinical Trials Arena', 'date': 'Oct 12, 2023', 'snippet': ""The Phase III trial of ALK's allergy immunotherapy tablet met its primary \nendpoint for the treatment of tree-pollen-induced allergics."", 'thumbnail': 'https://serpapi.com/searches/67242c17c1c8dd2750f4f74c/images/01f92dbbe75aba2812b6534593be8094019722b698bd9064255c75a92672a0a6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5727246999740601}",,,,,,,,,,['positive'],positive,1
NCT05305547,"{'position': 1, 'link': 'https://www.drugdiscoverytrends.com/shionogis-antiviral-ensitrelvir-could-shorten-covid-19-symptoms-by-about-a-day/', 'title': 'Shionogi’s antiviral ensitrelvir could shorten COVID-19 symptoms by about a day', 'source': 'www.drugdiscoverytrends.com', 'date': 'Mar 7, 2023', 'snippet': 'The investigational antiviral ensitrelvir from Shionogi promises to \naccelerate recovery from mild to moderate COVID-19.', 'thumbnail': 'https://serpapi.com/searches/67242c4648c97dfdbdfd875b/images/8459d9033fffa3b7eaf7bc1c61b7a9323c58075733ae375222c3795bfeb60db9.png', 'sentiment': 'positive', 'sentiment_prob': 0.5552641153335571}",,,,,,,,,,['positive'],positive,1
NCT03315130,"{'position': 1, 'link': 'https://myastheniagravisnews.com/news/mda-2024-zilbrysq-benefits-sustained-over-1-year-gmg-study/', 'title': 'MDA 2024: Benefits of Zilbrysq sustained over 1 year in gMG study', 'source': 'Myasthenia Gravis News', 'date': 'Mar 12, 2024', 'snippet': 'Clinical responses to the approved generalized myasthenia gravis (gMG) \ntherapy Zilbrysq (zilucoplan) have now been sustained for more than a...', 'thumbnail': 'https://serpapi.com/searches/67242c5ae1d1adc0a3359f17/images/6e8887d409de1d3d33276d29759e3c4183cc6464a0f9ce09ca8e30ed4065e8c8.png', 'sentiment': 'positive', 'sentiment_prob': 0.6832995414733887}",,,,,,,,,,['positive'],positive,1
NCT03018028,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/jdi.13764', 'title': 'Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials', 'source': 'Wiley Online Library', 'date': 'Feb 3, 2022', 'snippet': 'This subgroup analysis of the PIONEER 9 and PIONEER 10 studies assessed the \nimpact of baseline characteristics on the efficacy and safety of...', 'thumbnail': 'https://serpapi.com/searches/67242d19f6aa534e9217f2f7/images/13638001899ff8707a070d50629fd4a5881768cd4ad99981c15cf3da9c4e30c6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8891476988792419}",,,,,,,,,,['neutral'],neutral,1
NCT01945775,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1802905', 'title': 'Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation', 'source': 'The New England Journal of Medicine', 'date': 'Aug 15, 2018', 'snippet': 'The poly(adenosine diphosphate–ribose) inhibitor talazoparib has shown \nantitumor activity in patients with advanced breast cancer and germline \nmutations in...', 'thumbnail': 'https://serpapi.com/searches/67242d25d16915231ac93d40/images/234de5b851cdaf4aeebb5271d1883aea09c7c36abf07f58d95a5fe3e81bf6e24.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7716460824012756}","{'position': 2, 'link': 'https://www.nature.com/articles/s41598-024-64343-7', 'title': 'Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US', 'source': 'Nature', 'date': 'Jun 17, 2024', 'snippet': 'This study aims to assess the cost-effectiveness of talazoparib for \ntreating advanced breast cancer with germline BRCA1/2 mutations and HER2 \nnegativity.', 'thumbnail': 'https://serpapi.com/searches/67242d25d16915231ac93d40/images/234de5b851cdaf4a6aaf3b095de35fd8713125215d19c7a3d822e7c48d7fb9bd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8253030776977539}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03149003,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2020/11/05/first-patient-dosed-phase-2-study-cancer-vaccine-combination-ovarian-cancer/', 'title': 'First Patient Dosed in Phase 2 Study of Cancer Vaccine Combination in Ovarian Cancer', 'source': 'Ovarian Cancer News Today', 'date': 'Nov 5, 2020', 'snippet': 'A Phase 2 clinical trial investigating the cancer vaccine DSP-7888 in \ncombination with a checkpoint inhibitor has dosed its first ovarian...', 'thumbnail': 'https://serpapi.com/searches/67242d2ace1a752257c185b6/images/4f485a519a5f056734e0bca51062151fd55aa7303c17ae8d13e5853606171095.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8932750821113586}",,,,,,,,,,['neutral'],neutral,1
NCT04795531,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2303208', 'title': 'Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin', 'source': 'The New England Journal of Medicine', 'date': 'Jun 24, 2023', 'snippet': 'We conducted a 78-week randomized, open-label, treat-to-target phase 3a \ntrial (including a 52-week main phase and a 26-week extension phase, plus a \n5-week...', 'thumbnail': 'https://serpapi.com/searches/67242c838f2bc2a6bb868089/images/0c5b4a9b8af58ffd04c4707a5f4c6602d5a9cbba9ea9bd42ce8fe065decf1b1f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9228525757789612}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/news/novo-nordisks-once-weekly-insulin-supersedes-its-once-daily-counterparts/', 'title': 'Novo Nordisk’s once-weekly insulin supersedes its once-daily counterparts', 'source': 'Clinical Trials Arena', 'date': 'Jun 26, 2023', 'snippet': ""Phase IIIa clinical trials reported more patients achieving target HbA1c \nwith Novo Nordisk's insulin compared to its once-daily..."", 'thumbnail': 'https://serpapi.com/searches/67242c838f2bc2a6bb868089/images/0c5b4a9b8af58ffda00746f5c549982a260897fab209ed763f83387d8f717ffe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7205810546875}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03894150,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332223001968', 'title': 'A comprehensive review of key factors affecting the efficacy of antibody drug conjugate', 'source': 'ScienceDirect.com', 'date': 'Feb 25, 2023', 'snippet': 'Antibody Drug Conjugate (ADC) is an emerging technology to overcome the \nlimitations of chemotherapy by selectively targeting the cancer cells.', 'thumbnail': 'https://serpapi.com/searches/67242ca121e77bd9839caecf/images/a0b1586b9d262d317d2b30b9c2254748dc7490aa99ded87f466fc1aa16199ebf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.836857795715332}",,,,,,,,,,['neutral'],neutral,1
NCT04016779,"{'position': 1, 'link': 'https://www.empr.com/home/news/nonstimulant-adhd-treatment-option-approved-for-adults/', 'title': 'Nonstimulant ADHD Treatment Option Approved for Adults', 'source': 'Medical Professionals Reference', 'date': 'May 3, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Qelbree (viloxazine \nextended-release) for the treatment of attention deficit hyperactivity \ndisorder (ADHD)...', 'thumbnail': 'https://serpapi.com/searches/67242cd1a3657a0b1b933c05/images/0e7fc6eab0dc4109798065453edbb707ebb0ead6f614318321a52c21be751a7c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7998640537261963}",,,,,,,,,,['neutral'],neutral,1
NCT01904123,"{'position': 1, 'link': 'https://www.nature.com/articles/nrneurol.2017.64', 'title': 'Vaccine-based immunotherapeutic approaches to gliomas and beyond', 'source': 'Nature', 'date': 'May 12, 2017', 'snippet': 'This Review describes vaccination approaches investigated for the treatment \nof glioma. Several strategies have reached phase III clinical trials.', 'thumbnail': 'https://serpapi.com/searches/67242cf5c821274057f71f2f/images/a630789259183d01853cd4fdc515a143313d5c36f92783a1e4173360c269229f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8667329549789429}",,,,,,,,,,['neutral'],neutral,1
NCT03883113,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.852904/full', 'title': 'Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine', 'source': 'Frontiers', 'date': 'Apr 6, 2022', 'snippet': 'OVX836 is a recombinant protein-based vaccine targeting the highly \nconserved influenza nucleoprotein (NP), which aims to confer a \nbroad-spectrum protection...', 'thumbnail': 'https://serpapi.com/searches/67242ed98d0417f56aa4a66d/images/4d45ab2679df9b0cae0b26a8a670cde71771e13a38a1c52ba176008562013def.png', 'sentiment': 'neutral', 'sentiment_prob': 0.899326741695404}",,,,,,,,,,['neutral'],neutral,1
NCT02745743,"{'position': 1, 'link': 'https://www.nature.com/articles/s41388-022-02347-1', 'title': 'Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer', 'source': 'Nature', 'date': 'May 14, 2022', 'snippet': 'Transcriptional deregulation has emerged as a hallmark of several cancer \ntypes. In metastatic castration-resistant prostate cancer,...', 'thumbnail': 'https://serpapi.com/searches/67242edea5aae957db438062/images/84f97b3f94567a818d815c72fb7f40afd46ffb47e116627e82b59478a9743166.png', 'sentiment': 'neutral', 'sentiment_prob': 0.586356520652771}",,,,,,,,,,['neutral'],neutral,1
NCT00003140,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1604700', 'title': 'Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years', 'source': 'The New England Journal of Medicine', 'date': 'Jun 5, 2016', 'snippet': 'Treatment with an aromatase inhibitor for 5 years as up-front monotherapy \nor after tamoxifen therapy is the treatment of choice for...', 'thumbnail': 'https://serpapi.com/searches/67242eff2fab6292b8d535c9/images/e9360c627ba6c82661d1ccb38b986635f181047418068df2e0e3441626b5e4d8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9065150022506714}",,,,,,,,,,['neutral'],neutral,1
NCT04304482,"{'position': 1, 'link': 'https://rettsyndromenews.com/news/anavex-2-73-shows-promise-rett-children-but-misses-trial-goal/', 'title': 'Anavex 2-73 shows promise for Rett children but misses trial goal', 'source': 'Rett Syndrome News', 'date': 'Jan 2, 2024', 'snippet': 'Treatment with Anavex 2-73 led to improvements in behavior for Rett \nsyndrome children, but a Phase 2/3 clinical trial failed to meet its...', 'thumbnail': 'https://serpapi.com/searches/67242f0f90b57c018e6f43a0/images/f4f2a563a7bf37fc06355efb1fc0140cb2f611745f79544c6bb13fed80b08944.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5686342120170593}","{'position': 2, 'link': 'https://rettsyndromenews.com/news/dosing-complete-anavex-2-73-rett-excellence-safety-trial-girls/', 'title': 'Anavex completes dosing in trial of Anavex 2-73 for Rett |...', 'source': 'Rett Syndrome News', 'date': 'Jun 14, 2023', 'snippet': 'Anavex has completed dosing all 92 girls with Rett syndrome taking part in \na Phase 2/3 clinical trial testing the safety of Anavex 2-73.', 'thumbnail': 'https://serpapi.com/searches/67242f0f90b57c018e6f43a0/images/f4f2a563a7bf37fc2c92c4cd8224612a6ba53ee0d76ea044790f7896d5dea226.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7433744072914124}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04680949,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01499-z', 'title': 'Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial', 'source': 'Nature', 'date': 'Sep 3, 2021', 'snippet': 'The SAVE-MORE double-blind, randomized controlled trial evaluated the \nefficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with \nCOVID-19 at...', 'thumbnail': 'https://serpapi.com/searches/67242f293c863da05c181ec5/images/941be543f5ffc33fc1120fa108b014f47c3763f03206695238be0e67611c9736.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9016565680503845}","{'position': 2, 'link': 'https://www.europeanpharmaceuticalreview.com/news/153048/kineret-improves-clinical-outcomes-in-hospitalised-patients-with-covid-19-pneumonia/', 'title': 'Kineret® improves clinical outcomes in hospitalised patients with COVID-19 pneumonia', 'source': 'European Pharmaceutical Review', 'date': 'May 5, 2021', 'snippet': 'Treating COVID-19 pneumonia patients with poor prognosis with Kineret® \n(anakinra) prevented death and progression to respiratory failure.', 'thumbnail': 'https://serpapi.com/searches/67242f293c863da05c181ec5/images/941be543f5ffc33f9490d9562100c957f70d074816920afd2e7870ee6b6995fd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6885581016540527}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01912456,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1613627', 'title': 'Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor', 'source': 'The New England Journal of Medicine', 'date': 'Mar 23, 2017', 'snippet': 'Hereditary angioedema is a disabling, potentially fatal condition caused by \ndeficiency (type I) or dysfunction (type II) of the C1 inhibitor...', 'thumbnail': 'https://serpapi.com/searches/67242f305c7cb9f0c3203562/images/7bc5c01102b8042a0f7a4a2c94609b3d273b0b494f2d6e8a40142e0e409548ab.png', 'sentiment': 'negative', 'sentiment_prob': 0.6861330270767212}","{'position': 2, 'link': 'https://angioedemanews.com/news/haegarda-safe-effective-older-hae-patients-trial-analysis-shows/', 'title': 'Haegarda Safe, Effective in Older HAE Patients, Trial Analysis Shows', 'source': 'Angioedema News', 'date': 'Jun 26, 2020', 'snippet': 'Preventive Haegarda treatment for people ages 65 and older with hereditary \nHAE was well-tolerated and effective in stopping attacks,...', 'thumbnail': 'https://serpapi.com/searches/67242f305c7cb9f0c3203562/images/7bc5c01102b8042a1d5165e0a74c63d5d465861639494e355a25b6681aad9735.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5605336427688599}","{'position': 3, 'link': 'https://www.pulmonologyadvisor.com/news/subcutaneous-c1-inhibitor-well-tolerated-effective-in-hereditary-angioedema/', 'title': 'Subcutaneous C1-Inhibitor Well-Tolerated, Effective in Hereditary Angioedema', 'source': 'Pulmonology Advisor', 'date': 'Jun 12, 2020', 'snippet': 'Older patients with hereditary angioedema who were treated with a \nsubcutaneous injection of C1-INH had fewer attacks than baseline.', 'thumbnail': 'https://serpapi.com/searches/67242f305c7cb9f0c3203562/images/7bc5c01102b8042a5261d2bc46be42423428ff4f02d6a2d3197028d877d2c860.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7008876204490662}","{'position': 4, 'link': 'https://angioedemanews.com/news/long-term-haegarda-improves-quality-of-life-hae-patients-study-shows/', 'title': 'Long-term Haegarda Found to Improve Quality of Life in HAE Patients', 'source': 'Angioedema News', 'date': 'Mar 5, 2021', 'snippet': 'Long-term treatment with Haegarda leads to improved quality of life in \npeople with type 1 or 2 hereditary angioedema (HAE), new clinical...', 'thumbnail': 'https://serpapi.com/searches/67242f305c7cb9f0c3203562/images/7bc5c01102b8042ac61fe885fc3c1c022238a3baddef6bd32ccd5e677b598354.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8470486998558044}","{'position': 5, 'link': 'https://angioedemanews.com/news/fda-extends-haegarda-routine-preventive-hae-treatment-to-children-6-and-older/', 'title': 'Haegarda to Prevent HAE Attacks Open in Children 6 and Older, FDA Says', 'source': 'Angioedema News', 'date': 'Oct 2, 2020', 'snippet': 'The US Food and Drug Administration (FDA) has extended the use of Haegarda, \na C1-INH replacement medication, as a routine treatment to prevent \nhereditary...', 'thumbnail': 'https://serpapi.com/searches/67242f305c7cb9f0c3203562/images/7bc5c01102b8042a932713eaa885f0f12096c253e366605b05cb244adf7467b6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8517477512359619}",,,,,,"['negative', 'neutral', 'neutral', 'positive', 'neutral']",neutral,1
NCT03809767,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-023-02431-7', 'title': 'A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer', 'source': 'Nature', 'date': 'Sep 20, 2023', 'snippet': 'We assessed nofazinlimab, an anti-PD-1 antibody, in solid tumors and \ncombined with regorafenib in metastatic colorectal cancer (mCRC).', 'thumbnail': 'https://serpapi.com/searches/67242f4ac4bcf5b104d291a1/images/8edd052e7fb8175f79d06d8dd90949db8b27573f537b9cfb17bdd3305ded6fdb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8887736797332764}",,,,,,,,,,['neutral'],neutral,1
NCT02927262,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1902688', 'title': 'Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML', 'source': 'The New England Journal of Medicine', 'date': 'Oct 30, 2019', 'snippet': 'Patients with relapsed or refractory acute myeloid leukemia (AML) with \nmutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently...', 'thumbnail': 'https://serpapi.com/searches/67242f51ea57e958c5952e64/images/393cedd00e1d3ae3824eadee89d0e71c2ce8d8550eedc7de64abfc723bca8fd1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7907082438468933}",,,,,,,,,,['neutral'],neutral,1
NCT02951767,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/news/fda-grants-atezolizumab-accelerated-approval-for-bladder-cancer/', 'title': 'FDA Grants Atezolizumab Accelerated Approval for Bladder Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Apr 18, 2017', 'snippet': 'The US Food and Drug Administration (FDA) has granted the PD-L1-targeting \nmonoclonal antibody atezolizumab (Tecentriq) accelerated approval for \nfirst-line...', 'thumbnail': 'https://serpapi.com/searches/67242d5fdc969fad1f5aec4f/images/de34a12306b6cb7a1b6ac2b107009b38a96c06d3766331a7b0edf8e8fe8546ca.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8297524452209473}",,,,,,,,,,['neutral'],neutral,1
NCT00475865,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/2018/11/20/fda-approves-generic-of-aubagio-tablets-to-treat-relapsing-ms-glenmark-pharma-announces/', 'title': 'FDA Approves Generic Version of Aubagio to Treat Relapsing MS, Glenmark Pharma Says', 'source': 'Multiple Sclerosis News Today', 'date': 'Nov 20, 2018', 'snippet': 'The US Food and Drug Administration (FDA) has approved a generic version of \nAubagio (teriflunomide) tablets at the 7 mg and 14 mg doses marketed by \nSanofi.', 'thumbnail': 'https://serpapi.com/searches/67242d62e92456ab794d48c5/images/af3fdd317d6422d8cd19f3a3f43bf589ba26a8963177abc89df85a00b5f2a55d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7734127044677734}",,,,,,,,,,['neutral'],neutral,1
NCT05502549,"{'position': 1, 'link': 'https://alsnewstoday.com/news/fda-names-cb03-aim-protect-motor-neurons-als-orphan-drug/', 'title': 'FDA names CB03, aiming to protect motor neurons in ALS, orphan drug', 'source': 'ALS News Today', 'date': 'Oct 24, 2023', 'snippet': ""The U.S. Food and Drug Administration (FDA) has given orphan drug \ndesignation to CB03, Zhimeng Biopharma's small molecule treatment..."", 'thumbnail': 'https://serpapi.com/searches/67242d670e6db3745b1e3839/images/ca8479d98ec155a51301d0c3b0aed5c152e822aa1f692f4a74c1a299df9b4335.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7899766564369202}",,,,,,,,,,['neutral'],neutral,1
NCT03559699,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/mitapivat-safely-increases-hemoglobin-levels-in-patients-early-data-phase-1-trial/', 'title': 'SCD Trial Shows Mitapivat Safely Boosts Hemoglobin Levels in Patients', 'source': 'Sickle Cell Disease News', 'date': 'Jun 25, 2020', 'snippet': 'Early Phase 1 trial results show mitapivat safely increases hemoglobin \nlevels and lowers red blood cell damage in adults with sickle cell...', 'thumbnail': 'https://serpapi.com/searches/67242d6d6273fb28dc5d819a/images/d69360a40d24b8f009004ccfa300d230caa5c2826dd26d3e8ed6a5e4fb74eae0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5431870222091675}",,,,,,,,,,['neutral'],neutral,1
NCT05034952,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2209870', 'title': 'Selective Inhibition of NaV1.8 with VX-548 for Acute Pain', 'source': 'The New England Journal of Medicine', 'date': 'Aug 2, 2023', 'snippet': 'The NaV1.8 voltage-gated sodium channel, expressed in peripheral \nnociceptive neurons, plays a role in transmitting nociceptive signals.', 'thumbnail': 'https://serpapi.com/searches/67242d7075f97436c9f2c186/images/0dea481f3471c7bbbddf28030e57c70c09636ad62b9ed7b22b945bb8c6a3884f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8272075057029724}",,,,,,,,,,['neutral'],neutral,1
NCT03301090,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/monoclonal-antibodies-against-mers-coronavirus-show-promise-phase-1-nih-sponsored-trial', 'title': 'Monoclonal antibodies against MERS coronavirus show promise in Phase 1 NIH-sponsored trial', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Feb 23, 2021', 'snippet': 'A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal \nantibodies (mAbs) directed against the coronavirus that causes Middle \nEast...', 'thumbnail': 'https://serpapi.com/searches/67242d866ad3c9c2f7a6a9d4/images/70f42141faa0919b8c2e2a293777893e4aaf7e21d4ceb86e9a564aa42fb39e79.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6738982200622559}",,,,,,,,,,['neutral'],neutral,1
NCT02720744,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-once-nightly-lumryz-for-patients-with-narcolepsy/', 'title': 'FDA Approves Once-Nightly Lumryz for Patients With Narcolepsy', 'source': 'Medical Professionals Reference', 'date': 'May 1, 2023', 'snippet': 'The Food and Drug Administration (FDA) has granted final approval to Lumryz \n(sodium oxybate) for the treatment of cataplexy or excessive daytime \nsleepiness in...', 'thumbnail': 'https://serpapi.com/searches/67242d9eb5ecbb920ddee1ec/images/19a538cc1be6df381d017a6ef4d93202ec0b66963e889e274d9fe864f3509817.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8342679738998413}","{'position': 2, 'link': 'https://www.pharmacytimes.com/view/expert-philosophical-about-pharmacy-services-how-community-health-worker-training-can-bolster-technician-s-role', 'title': 'Expert: ""Philosophical"" About Pharmacy Services, How Community Health Worker Training Can Bolster Technician’s Role', 'source': 'Pharmacy Times', 'date': 'Jul 7, 2023', 'snippet': 'Nancy Lyons, BSPharm, MBA, CDCES, VP, the Chief Pharmacy Officer at Health \nMart, a part of McKesson Corporation, expands on her first...', 'thumbnail': 'https://serpapi.com/searches/67242d9eb5ecbb920ddee1ec/images/19a538cc1be6df3839c9b01bb57d5549f677ede38b95526834f8496c741acb23.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8577273488044739}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02035956,"{'position': 1, 'link': 'https://melanomanewstoday.com/2015/04/30/biontech-collaborative-study-reveals-potential-new-strategy-personalized-melanoma-cancer-immunotherapy/', 'title': 'BioNTech Collaborative Study Reveals a Potential New Strategy for Personalized Cancer Immunotherapy', 'source': 'Melanoma News Today', 'date': 'Apr 30, 2015', 'snippet': 'Biotechnology company BioNTech AG recently announced the publication of a \nstudy entitled “Mutant MHC class II epitopes drive therapeutic...', 'thumbnail': 'https://serpapi.com/searches/67242da1c7d4a1dfe3135487/images/f1b8ed1e6fe49789deee432b2a6f6056d67a3c1cc99b402b0e9f6eeeb73bb740.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7040243744850159}",,,,,,,,,,['neutral'],neutral,1
NCT02124772,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02321-8', 'title': 'Dabrafenib plus trametinib in BRAFV600E -mutated rare cancers: the phase 2 ROAR trial', 'source': 'Nature', 'date': 'Apr 14, 2023', 'snippet': 'Here we present final efficacy and safety results of a phase 2 basket trial \nof dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in \neight...', 'thumbnail': 'https://serpapi.com/searches/67242dad63a844f82690f941/images/ffb37f5d69497925ffaa4d3e337843e407381258cfaed41bf70da1fa7cdc404c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8969771862030029}",,,,,,,,,,['neutral'],neutral,1
NCT01872598,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/fda-approves-phase-3-trial-of-masitinib-alzheimers-disease/', 'title': 'FDA Greenlights Phase 3 Trial of Masitinib for Alzheimer’s Disease', 'source': ""Alzheimer's News Today"", 'date': 'Dec 20, 2022', 'snippet': ""AB Science is initiating a Phase 3 trial to evaluate the safety and \nefficacy of its candidate therapy masitinib in patients with mild to \nmoderate Alzheimer's..."", 'thumbnail': 'https://serpapi.com/searches/67242dbd4300ce9a4f716467/images/eae315ee454853bfbfcbdcefeebb0d6611d1ece919759e6dd7f0ca9cbddf4896.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8828580975532532}",,,,,,,,,,['neutral'],neutral,1
NCT04161495,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/altuviiio-approved-hemophilia-a-japan-taiwan/', 'title': 'Altuviiio approved as hemophilia A treatment in Japan and Taiwan |...', 'source': 'Hemophilia News Today', 'date': 'Sep 27, 2023', 'snippet': 'Regulators in Japan and Taiwan approved Altuviiio (efanesoctocog alfa) to \nprevent and control bleeds in children, adults with hemophilia A.', 'thumbnail': 'https://serpapi.com/searches/67242df7b6e4db286c8d19e1/images/1df8248236a540bba104aa81619706a365c424f9144504992f9f6043d9fbe570.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7902185916900635}","{'position': 2, 'link': 'https://www.empr.com/home/news/altuviiio-approved-as-once-weekly-factor-viii-therapy-for-hemophilia-a/', 'title': 'Altuviiio Approved as Once-Weekly Factor VIII Therapy for Hemophilia A', 'source': 'Medical Professionals Reference', 'date': 'Feb 24, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Altuviiio™ \n(antihemophilic factor [recombinant], Fc-VWF-XTEN fusion protein-ehtl),...', 'thumbnail': 'https://serpapi.com/searches/67242df7b6e4db286c8d19e1/images/1df8248236a540bbfb899ede552930f90de4f6b9667b9d8419cf45978b0cfaec.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.744762659072876}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02480153,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2019/11/21/fda-approves-abrilada-biosimilar-humira-for-adults-with-active-ankylosing-spondylitis/', 'title': 'Adults with Active Ankylosing Spondylitis Have Option of Abrilada, Biosimilar to Humira, FDA Says', 'source': 'Ankylosing Spondylitis News', 'date': 'Nov 21, 2019', 'snippet': 'Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been \napproved by the US Food and Drug Administration (FDA) to treat people with \nseven...', 'thumbnail': 'https://serpapi.com/searches/67242dfe9fd3095eab7ea4cd/images/8c8f4fc5a36b2b6d9cfeb09fe46aefb4b2ba509ae6dcb477a1ff6bb2f7ed5d05.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8899936676025391}",,,,,,,,,,['neutral'],neutral,1
NCT01031901,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0073-2', 'title': 'Cutaneous neurofibromas in the genomics era: current understanding and open questions', 'source': 'Nature', 'date': 'Apr 26, 2018', 'snippet': 'Cutaneous neurofibromas (cNF) are a nearly ubiquitous symptom of \nneurofibromatosis type 1 (NF1), a disorder with a broad phenotypic \nspectrum...', 'thumbnail': 'https://serpapi.com/searches/67242e12b6a79c9a27f66914/images/270af7f168f63a773e807b5b131160c7c76d87e68ae472cc8e93400067d4e838.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8099650740623474}",,,,,,,,,,['neutral'],neutral,1
NCT00111319,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0801479', 'title': 'Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma', 'source': 'The New England Journal of Medicine', 'date': 'Aug 28, 2008', 'snippet': 'The standard treatment for patients with multiple myeloma who are not \ncandidates for high-dose therapy is melphalan and prednisone.', 'thumbnail': 'https://serpapi.com/searches/67242e3b3b3c3238b924e696/images/82aca6061ffd40b35e4bbc4d2b3ff66c7e47dcb727c7bf8d8e7a75a90ce536fd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8991239666938782}",,,,,,,,,,['neutral'],neutral,1
NCT03830203,"{'position': 1, 'link': 'https://www.empr.com/home/news/generics-news/tofidence-tocilizumab-biosimilar-approved/', 'title': 'FDA Approves Tofidence, the First Biosimilar to Tocilizumab', 'source': 'Medical Professionals Reference', 'date': 'Oct 2, 2023', 'snippet': 'The Food and Drug Administration has approved Tofidence (tocilizumab-bavi), \nthe first biosimilar to Actemra (tocilizumab).', 'thumbnail': 'https://serpapi.com/searches/67242e5cc4bcf5b0c882c067/images/0aed7cca41ad63d69c9f227029a79b0acb6329976dd5dd8f108c80b6a3915694.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5141994953155518}","{'position': 2, 'link': 'https://investors.biogen.com/news-releases/news-release-details/biogen-and-bio-thera-solutions-present-positive-phase-3-data', 'title': 'Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)', 'source': 'Biogen', 'date': 'Jun 3, 2022', 'snippet': 'CAMBRIDGE, Mass. and GUANGZHOU, China, June 03, 2022 (GLOBE NEWSWIRE) -- \nBiogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.', 'thumbnail': 'https://serpapi.com/searches/67242e5cc4bcf5b0c882c067/images/0aed7cca41ad63d6bc165bb1e032ad5107eed26374b85b9346a2fb7f88ce8e1f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7950824499130249}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT00700102,"{'position': 1, 'link': 'https://theoncologist.onlinelibrary.wiley.com/doi/10.1002/onco.13971', 'title': 'A Long‐Term Extension Study of Bevacizumab in Patients With Solid Tumors - Oza - 2021', 'source': 'The Oncologist', 'date': 'Sep 9, 2021', 'snippet': 'Abstract Background Bevacizumab has been studied in numerous clinical \ntrials in multiple types of cancer; however, patients may receive...', 'thumbnail': 'https://serpapi.com/searches/67242e7c21b01bfe522bb70d/images/2fb2aa638f90a0f457f6b6d8dc69eb90410bf66a871e710e8a994cc4f2c525d2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9322308897972107}",,,,,,,,,,['neutral'],neutral,1
NCT00193856,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/cohort-study-identified-optimal-minimum-treatment-duration-for-adt-in-high-risk-prostate-cancer', 'title': 'Cohort Study Identified Optimal Minimum Treatment Duration for ADT in High-Risk Prostate Cancer', 'source': 'Cancer Network', 'date': 'Jun 24, 2022', 'snippet': 'A cohort study found that the optimal minimum duration for androgen \ndeprivation therapy (ADT) plus high-dose external beam radiotherapy (EBRT) \nwas more than 18...', 'thumbnail': 'https://serpapi.com/searches/67242e8eee4682bcee5df66d/images/bb69cc8452ec18cdc693ddf5c6dd4b3fb32bb83e74275943cc34114b169a3de0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9076136350631714}",,,,,,,,,,['neutral'],neutral,1
NCT03342053,"{'position': 1, 'link': 'https://huntingtonsdiseasenews.com/ionis-httrx-rg6042/', 'title': 'Tominersen for Huntington’s disease', 'source': ""Huntington's Disease News"", 'date': 'Jun 6, 2024', 'snippet': 'Last updated June 6, 2024, by Marisa Wexler, MS ✓ Fact-checked by Marta \nFigueiredo, PhD. How tominersen works. Administration. Clinical trials. \nSide effects...', 'thumbnail': 'https://serpapi.com/searches/67242e8f7f3719505b76151f/images/f37818a2a2fa9f6fb8702d3cb931032a918637bc0570e89ceca8e7452f583f66.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9408097863197327}","{'position': 2, 'link': 'https://www.nature.com/articles/s41587-021-00955-y', 'title': 'Questions swirl around failures of disease-modifying Huntington’s drugs', 'source': 'Nature', 'date': 'Jun 10, 2021', 'snippet': ""Researchers hope that antisense oligo clinical trial failures in \nHuntington's will shed light on mechanism and drug biodistribution and \ngalvanize ongoing drug..."", 'thumbnail': 'https://serpapi.com/searches/67242e8f7f3719505b76151f/images/f37818a2a2fa9f6f28aff94da1f6f9b8b05cf71ccb55e4d00073b563b1535308.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6443971395492554}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03761537,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/bjd.20832', 'title': 'Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)', 'source': 'Wiley Online Library', 'date': 'Oct 26, 2021', 'snippet': 'Tralokinumab 300 mg plus TCS as needed was effective and well tolerated in \npatients with severe AD whose disease was not adequately controlled with \nCSA.', 'thumbnail': 'https://serpapi.com/searches/67242e92c76a3af3eaa52198/images/7ca7e219b71f5dc9a2d6c816269dd479450f54a5efdc3ccdd33e324064e97376.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7460282444953918}",,,,,,,,,,['neutral'],neutral,1
NCT01522469,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-018-08263-x', 'title': 'Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms', 'source': 'Nature', 'date': 'Jan 16, 2019', 'snippet': 'FLT3 mutations are prevalent in AML patients and confer poor prognosis. \nCrenolanib, a potent type I pan-FLT3 inhibitor, is effective against...', 'thumbnail': 'https://serpapi.com/searches/672430857a12fd607b597a2b/images/9a37cc896f9fa93a456effef02447ff4e6ae4e8d80a2dc001d0521a779c67b0b.png', 'sentiment': 'negative', 'sentiment_prob': 0.5016843676567078}",,,,,,,,,,['negative'],negative,0
NCT04125732,"{'position': 1, 'link': 'https://www.cgtlive.com/view/thomas-povsic-unmet-needs-refractory-angina-xc001', 'title': 'Thomas Povsic, MD, PhD, on Addressing Unmet Needs in Refractory Angina With Gene Therapy', 'source': 'CGTLive®', 'date': 'Aug 25, 2023', 'snippet': '“The phase 1 study results, in general, suggested that there was a dose \nresponse with greater efficacy observed in patients in terms of a...', 'thumbnail': 'https://serpapi.com/searches/672430f7ef60cbc4eeb398df/images/3437428e67e47902481ae31ae22f2d3e26a0a731e0bea6a58c785dba8f96a154.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7850585579872131}",,,,,,,,,,['neutral'],neutral,1
NCT05483998,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/pipeline-moves-aml-trial-fails-endpoints/', 'title': 'Pipeline Moves: Phase III AML trial fails to meet primary endpoint', 'source': 'Clinical Trials Arena', 'date': 'May 28, 2024', 'snippet': 'The Clinical Trials Arena team evaluates assets in oncology and \ngastrointestinal disorders.', 'thumbnail': 'https://serpapi.com/searches/672430f88d0417f531617c04/images/8d82f18c93e809794d413d6a7262e90bdd81d0a67e7ee6d286ee3762af794d8f.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7732141017913818}",,,,,,,,,,['negative'],negative,0
NCT03689712,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/news/fda-denies-approval-of-avasopasem-for-radiotherapy-induced-severe-oral-mucositis/', 'title': 'FDA Denies Approval of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis', 'source': 'Cancer Therapy Advisor', 'date': 'Aug 15, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has issued a complete response \nletter to Galera Therapeutics related to the new drug application for \navasopasem...', 'thumbnail': 'https://serpapi.com/searches/672430fc24296a895db7b630/images/04ad23c771d7f516708cdba2186ad60ce6a7d9994328ff974f9dcd2521445c19.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5011367201805115}",,,,,,,,,,['neutral'],neutral,1
NCT02855944,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2021/01/05/phase-3-trial-confirms-rubraca-clinical-benefit-over-chemotherapy-top-line-data/', 'title': 'Rubraca Shows Clinical Benefit Over Chemo for Advanced Ovarian Cancer', 'source': 'Ovarian Cancer News Today', 'date': 'Jan 5, 2021', 'snippet': 'Rubraca (rucaparib) is superior to chemotherapy at prolonging life without \ndisease worsening in people with advanced ovarian cancer who received at \nleast two...', 'thumbnail': 'https://serpapi.com/searches/67245b6a708e2e98ffa84bd3/images/2bb10887c058c58365d9e01109177908a6636bda0bbdfdc1d150b45c01a86eac.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5081809163093567}",,,,,,,,,,['neutral'],neutral,1
NCT04847557,"{'position': 1, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-successful-phase-3-study-showing-benefit', 'title': ""Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity"", 'source': 'Eli Lilly and Company', 'date': 'Aug 1, 2024', 'snippet': 'Tirzepatide reduced the risk of heart failure outcomes – heart failure \nurgent visit or hospitalization, oral diuretic intensification or...', 'thumbnail': 'https://serpapi.com/searches/67245b7d5a461a844d4dde6e/images/01fb2d22823fccaeb9ae774329fa62d2596b7034ae90ece8aaa0356fda033661.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5786123871803284}","{'position': 2, 'link': 'https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02319-7', 'title': 'Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide', 'source': 'BioMed Central', 'date': 'Jul 10, 2024', 'snippet': 'Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and \ngastric inhibitory polypeptide (GIP) receptors.', 'thumbnail': 'https://serpapi.com/searches/67245b7d5a461a844d4dde6e/images/01fb2d22823fccae96c5ba5b2dacf71e03f900d66d0c39828a5a159bb5329d9d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8541763424873352}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02634346,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/efficacy-and-safety-of-olanzapinesamidorphan/', 'title': 'Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study', 'source': 'Psychiatrist.com', 'date': 'Mar 3, 2020', 'snippet': 'Read a study evaluating the antipsychotic efficacy and safety of OLZ/SAM \ncompared with placebo in patients with an acute exacerbation of...', 'thumbnail': 'https://serpapi.com/searches/67245ba359f911b9ca52eeb9/images/93d240225d45b3213de3ac29f70fe5aead9f43b4594fa74d8a1d5520945d3fe4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8938841223716736}",,,,,,,,,,['neutral'],neutral,1
NCT00136981,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa071359', 'title': 'Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia', 'source': 'The New England Journal of Medicine', 'date': 'Jul 5, 2017', 'snippet': 'Torcetrapib, an inhibitor of cholesteryl ester transfer protein, may reduce \natherosclerotic vascular disease by increasing levels of high-density \nlipoprotein (...', 'thumbnail': 'https://serpapi.com/searches/67245bb89872179945fc4a7f/images/c7a76fdb2ee9c6f2d60de5a5a8215ce71d68f92c07767d16bd8105689f534c93.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8226796984672546}",,,,,,,,,,['neutral'],neutral,1
NCT04015076,"{'position': 1, 'link': 'https://www.nature.com/articles/s12276-024-01261-8', 'title': 'NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders', 'source': 'Nature', 'date': 'Jul 1, 2024', 'snippet': 'Proinflammatory cytokines and chemokines play a crucial role in regulating \nthe inflammatory response, which is essential for the proper...', 'thumbnail': 'https://serpapi.com/searches/67245bbaa8827810858a037d/images/3bcaabc060649962698678a5d02b9da2187a643fec731254a5f8a0b47e25806f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8756292462348938}",,,,,,,,,,['neutral'],neutral,1
NCT02278120,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1903765', 'title': 'Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jun 4, 2019', 'snippet': 'An earlier analysis of this phase 3 trial showed that the addition of a \ncyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy \nprovided a...', 'thumbnail': 'https://serpapi.com/searches/67245c1aba13f269eb52787c/images/9c6c60251a7f595dda91f13533ea7509da9c523e7c87b3b53e7016197b182c54.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8584499359130859}","{'position': 2, 'link': 'https://breastcancer-news.com/2018/07/25/fda-approves-kisqali-for-breast-cancer-in-premenopausal-perimenopausal-women/', 'title': 'FDA Approves Kisqali for Breast Cancer in Pre-, Perimenopausal Women', 'source': 'breastcancer-news.com', 'date': 'Jul 25, 2018', 'snippet': 'Kisqali (ribociclib) now can be used in combination with an aromatase \ninhibitor as first-line therapy for all women with HR-positive, \nHER2-negative advanced or...', 'thumbnail': 'https://serpapi.com/searches/67245c1aba13f269eb52787c/images/9c6c60251a7f595d4309c1f0392778ff2a73746d60ab9065e4e6413ebe28351b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8082779049873352}","{'position': 3, 'link': 'https://breastcancer-news.com/2020/06/04/kisqali-prolongs-overall-survival-of-women-with-advanced-breast-cancer-and-internal-organ-metastases/', 'title': 'Kisqali Prolongs Overall Survival in Advanced Breast Cancer Patients with Internal Organ Metastases', 'source': 'Breast Cancer News', 'date': 'Jun 4, 2020', 'snippet': 'Kisqali and endocrine therapy prolongs the survival of women with \nHR-positive, HER2-negative, advanced or metastatic breast cancer anad...', 'thumbnail': 'https://serpapi.com/searches/67245c1aba13f269eb52787c/images/9c6c60251a7f595d590cbc1c1052121cafe982eab73db192f8b72d1ac4b7790e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5336280465126038}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04176120,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/pipeline-moves-approval-prospects-diabetic-foot-ulcer-biotissue/', 'title': 'Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion', 'source': 'Clinical Trials Arena', 'date': 'Jun 24, 2024', 'snippet': 'The Clinical Trials Arena team evaluates assets in cardiovascular, \ndermatology and oncology.', 'thumbnail': 'https://serpapi.com/searches/67245c22e1d1adc0a335a8ab/images/9796778a68187171f23bab3553e081075876da04186589c6838fe7840f07aed7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7484111785888672}",,,,,,,,,,['neutral'],neutral,1
NCT03037931,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2304968', 'title': 'Ferric Carboxymaltose in Heart Failure with Iron Deficiency', 'source': 'The New England Journal of Medicine', 'date': 'Aug 26, 2023', 'snippet': 'Ferric carboxymaltose therapy reduces symptoms and improves quality of life \nin patients who have heart failure with a reduced ejection fraction and \niron...', 'thumbnail': 'https://serpapi.com/searches/67245c465416d82ede487271/images/8b18486558c2ebdf7ba9d93f27d7a0b9257b57fea94f64d01475326a77ab804d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7124562859535217}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/full/10.1161/CIRCHEARTFAILURE.121.008299', 'title': 'Targeting Iron Deficiency in Heart Failure: Existing Evidence and Future Expectations', 'source': 'American Heart Association Journals', 'date': 'May 18, 2021', 'snippet': 'Iron deficiency (ID) has been recognized as a prevalent comorbidity in HF, \nrelated to exercise intolerance and poor quality of life, independently \npredicting...', 'thumbnail': 'https://serpapi.com/searches/67245c465416d82ede487271/images/8b18486558c2ebdfc3688ee8e58f7082c9b8128b73665bfbbf792613f68cafa7.png', 'sentiment': 'negative', 'sentiment_prob': 0.5712070465087891}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT02325557,"{'position': 1, 'link': 'https://cervicalcancernews.com/2016/11/09/advaxis-begins-phase-3-study-axal-advanced-cervical-cancer/', 'title': 'Advaxis Begins Phase 3 Study of AXAL for Advanced Cervical Cancer', 'source': 'Cervical cancer News', 'date': 'Nov 9, 2016', 'snippet': 'Advaxis has begun its Phase 3 clinical trial evaluating axalimogene \nfilolisbac, or AXAL, in women with high-risk, locally advanced cervical...', 'thumbnail': 'https://serpapi.com/searches/67245c6fa9210b55286be393/images/eab54731a458ff922abe4e11c3d1feeab3afbe841ed2d168f647d2fd763a3b3e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9055874943733215}",,,,,,,,,,['neutral'],neutral,1
NCT00046930,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-022-00736-z', 'title': 'Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999', 'source': 'Nature', 'date': 'Sep 23, 2022', 'snippet': ""Integrative analysis identifies an older female-linked AML patient group \nwith better risk in ECOG-ACRIN Cancer Research Group's clinical trial."", 'thumbnail': 'https://serpapi.com/searches/67245d195bb6a2d5bbfd298c/images/c67c7262165ff163b530dbc9ac86aefe1f8c8c505f990ec24cef4c931e47d225.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9069530367851257}",,,,,,,,,,['neutral'],neutral,1
NCT04534114,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/ionis-announces-positive-topline-results-from-phase-2b-clinical-study-of-fesomersen-a-potential-novel-anti-thrombotic-treatment-301594902.html', 'title': 'Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment', 'source': 'PR Newswire', 'date': 'Jul 28, 2022', 'snippet': 'PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced \npositive topline results of the Phase 2b RE-THINC ESRD study of...', 'thumbnail': 'https://serpapi.com/searches/67245d23fcd69e091e956f91/images/9a7f1543ff516eb286a80389c85b4d90788025fce354451e44f41f523309a78c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6460368037223816}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/ionis-announces-positive-results-from-fesomersen-development-program-301668627.html', 'title': 'Ionis announces positive results from fesomersen development program', 'source': 'PR Newswire', 'date': 'Nov 4, 2022', 'snippet': 'PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced \npositive results from the Phase 2b RE-THINC ESRD study of...', 'thumbnail': 'https://serpapi.com/searches/67245d23fcd69e091e956f91/images/9a7f1543ff516eb27238270b1c7661e0e64b1cb241f9ce04247638f7afdddcc5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6042482256889343}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01412333,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1601277', 'title': 'Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Dec 21, 2016', 'snippet': 'In two identical phase 3 trials, we randomly assigned 821 and 835 patients \nwith relapsing multiple sclerosis to receive intravenous...', 'thumbnail': 'https://serpapi.com/searches/67245c8d17b10eb84e16d054/images/81beefbb6c766536b445c7e64466ebd8f9e628cc6d851e4c57de0bff29b60ad4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9104704856872559}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/03/14/ocrevus-blood-levels-confirmed-disability-progression/', 'title': 'Higher blood levels of Ocrevus lower confirmed disability progression risk', 'source': 'Multiple Sclerosis News Today', 'date': 'Mar 14, 2023', 'snippet': 'Higher blood levels of Ocrevus associate with a significantly lower risk of \nconfirmed disability progression during treatment,...', 'thumbnail': 'https://serpapi.com/searches/67245c8d17b10eb84e16d054/images/81beefbb6c76653633cc098cf93e9ac614e54401d2941b591a2350f31a26fbf2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7976104617118835}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/07/12/nfl-blood-levels-may-help-predict-long-term-ms-progression/', 'title': 'NfL blood levels may help predict long-term progression of MS: Study', 'source': 'Multiple Sclerosis News Today', 'date': 'Jul 12, 2023', 'snippet': 'Elevated blood levels of neurofilament light chain (NfL), a marker of nerve \ndamage, are associated with long-term disability progression in people \nwith...', 'thumbnail': 'https://serpapi.com/searches/67245c8d17b10eb84e16d054/images/81beefbb6c766536605ec9fcdd010f79f992342d9ce8e4cb6889795731557c92.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8781910538673401}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00805194,"{'position': 1, 'link': 'https://www.thelancet.com/article/S1470-2045(13)70586-2/abstract', 'title': 'Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial', 'source': 'The Lancet', 'date': 'Jan 9, 2014', 'snippet': 'The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel \nplus nintedanib as second-line therapy for non-small-cell lung cancer \n(NSCLC).', 'thumbnail': 'https://serpapi.com/searches/67245ca5167793224537cb0a/images/c88b24c9ac7176755479a2dbcbb5d1de256a97c22ed575e2d00042b01e2a0c3b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8813648223876953}",,,,,,,,,,['neutral'],neutral,1
NCT02614742,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-34924-z', 'title': 'Cannabidiol inhibits neuroinflammatory responses and circuit-associated synaptic loss following damage to a songbird vocal pre-motor cortical-like region | Scientific Reports', 'source': 'Nature', 'date': 'May 16, 2023', 'snippet': 'Our findings demonstrate that CBD promotes an array of neuroprotective \nprocesses consistent with modulation of multiple cell signaling systems.', 'thumbnail': 'https://serpapi.com/searches/67245cbfd997ab5360dc83b7/images/d9f8fa51430f401f65a46a7003501a42378dc792f3279b8606b65d8ef88bb5d2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.857406497001648}",,,,,,,,,,['neutral'],neutral,1
NCT04657003,"{'position': 1, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-2-results-published-lancet-show-tirzepatide', 'title': ""Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes"", 'source': 'Eli Lilly and Company', 'date': 'Jun 24, 2023', 'snippet': 'Tirzepatide achieved a mean weight reduction of 15.7% at the highest dose \n(15 mg) in adults with obesity or overweight and type 2 diabetes.', 'thumbnail': 'https://serpapi.com/searches/67245cc15bb6a2d585edb93d/images/c6feaefafa3099ff57bd5f60362d2be3bbf61ee76f1355c73454542059dfd452.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6836703419685364}","{'position': 2, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-achieved-157-weight-loss-adults-obesity-or', 'title': ""Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2"", 'source': 'Eli Lilly and Company', 'date': 'Apr 27, 2023', 'snippet': 'Participants with obesity or overweight and type 2 diabetes taking \ntirzepatide lost up to 34.4 lb. (15.6 kg). Lilly plans to complete...', 'thumbnail': 'https://serpapi.com/searches/67245cc15bb6a2d585edb93d/images/c6feaefafa3099ffaf7776804ca8b42695e640ea0229785aa51224b92c8bad73.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6582523584365845}","{'position': 3, 'link': 'https://www.empr.com/home/news/zepbound-approved-for-chronic-weight-management/', 'title': 'Zepbound Approved for Chronic Weight Management', 'source': 'Medical Professionals Reference', 'date': 'Nov 8, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Zepbound™ (tirzepatide) \nas an adjunct to a reduced-calorie diet and increased physical...', 'thumbnail': 'https://serpapi.com/searches/67245cc15bb6a2d585edb93d/images/c6feaefafa3099ffa24316e1aaf69088d7b556b9733dc746ad14f2680bd7abf8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6654108166694641}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00370331,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/home/topics/anemia/alvaiz-approved-for-itp-thrombocytopenia-with-hep-c-and-severe-aplastic-anemia/', 'title': 'Alvaiz Approved for ITP, Thrombocytopenia With Hep C, and Severe Aplastic Anemia', 'source': 'Hematology Advisor', 'date': 'Dec 5, 2023', 'snippet': 'The Food and Drug Administration has approved Alvaiz (eltrombopag tablets), \na thrombopoietin receptor agonist.', 'thumbnail': 'https://serpapi.com/searches/67245cdafda26d2cf83eaa11/images/1d42372689bd16d93c09a27d0c0b070717bccb6599ae98072de81c043070b382.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7984627485275269}",,,,,,,,,,['neutral'],neutral,1
NCT03333915,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-021-01632-2', 'title': 'Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours', 'source': 'Nature', 'date': 'Nov 18, 2021', 'snippet': 'Pamiparib, a PARP1/2 inhibitor, demonstrated antitumor activity in \npreclinical models. This Phase 1A/1B dose-escalation/dose-expansion study...', 'thumbnail': 'https://serpapi.com/searches/67245cde8db376555d9e6b15/images/51c76aa58053a0c5727c2a92484a19770eda4d0fe1bc65a0f4603d3e0b9adbd6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8837805390357971}",,,,,,,,,,['neutral'],neutral,1
NCT02860780,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-021-03572-4', 'title': 'Pharmacological targeting of the novel β-catenin chromatin-associated kinase p38α in colorectal cancer stem cell tumorspheres and organoids', 'source': 'Nature', 'date': 'Mar 25, 2021', 'snippet': 'The prognosis of locally advanced colorectal cancer (CRC) is currently \nunsatisfactory. This is mainly due to drug resistance, recurrence,...', 'thumbnail': 'https://serpapi.com/searches/67245ce3d364b4f6fa6e080f/images/e0c8de132c7521e2a3d0cc8e8d8eb6619a9b84933093ecf7c5125295f55f05cf.png', 'sentiment': 'negative', 'sentiment_prob': 0.5102999210357666}",,,,,,,,,,['negative'],negative,0
NCT04828005,"{'position': 1, 'link': 'https://www.empr.com/home/news/opvee-nasal-spray-approved-for-treatment-of-opioid-overdose/', 'title': 'Opvee Nasal Spray Approved for Treatment of Opioid Overdose', 'source': 'Medical Professionals Reference', 'date': 'May 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Opvee (nalmefene) nasal \nspray for the emergency treatment of known or suspected overdose induced by \nnatural...', 'thumbnail': 'https://serpapi.com/searches/67245d01642c3189bcbd653f/images/56f8589d225e7517bb76d6f406a03db6dde6821b0992f8b28be781ad86150adc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8920722007751465}",,,,,,,,,,['neutral'],neutral,1
NCT02292654,"{'position': 1, 'link': 'https://www.nature.com/articles/s41436-021-01156-3', 'title': 'One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency', 'source': 'Nature', 'date': 'Apr 19, 2021', 'snippet': 'In this study in children with chronic ASMD, olipudase alfa was generally \nwell-tolerated with significant, comprehensive improvements in disease \npathology.', 'thumbnail': 'https://serpapi.com/searches/67245e0635853912a0cb1c41/images/f78f705708f82a8db7a1568fd0ec8da48920b5b337e497ceae010518c79bceb2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.777836799621582}",,,,,,,,,,['neutral'],neutral,1
NCT00078611,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa054693', 'title': 'Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy', 'source': 'The New England Journal of Medicine', 'date': 'Mar 2, 2006', 'snippet': 'We invited patients who had participated in clinical trials in which they \nreceived recent or long-term treatment with natalizumab for...', 'thumbnail': 'https://serpapi.com/searches/67245f47e1d1adc069a091ae/images/2b52bed45f0316f4f179bf0cd3ac8c0f3c00fd8e0e3edff5516efa4c7a6855c1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9142276048660278}",,,,,,,,,,['neutral'],neutral,1
NCT00203060,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0809335', 'title': ""A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease"", 'source': 'The New England Journal of Medicine', 'date': 'Sep 24, 2009', 'snippet': ""A therapy that slows disease progression is the major unmet need in \nParkinson's disease.In this double-blind trial, we examined the..."", 'thumbnail': 'https://serpapi.com/searches/67245f71910986cafe52cba7/images/1e966702e475297816ada0f3f077175f9b840d9e3de85a9ec4f4f3c86cce3e25.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7325910925865173}",,,,,,,,,,['neutral'],neutral,1
NCT04505722,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2034201', 'title': 'Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine', 'source': 'The New England Journal of Medicine', 'date': 'Jan 13, 2021', 'snippet': 'Efficacious vaccines are urgently needed to contain the ongoing coronavirus \ndisease 2019 (Covid-19) pandemic of infection with severe acute...', 'thumbnail': 'https://serpapi.com/searches/672460a221b01bfe522bc17c/images/54d600bcfd75c362c9cbb0219183a079cf889635fcff8dcde12825f0b727a055.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5869097113609314}","{'position': 2, 'link': 'https://www.nature.com/articles/s41564-022-01262-1', 'title': 'Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial', 'source': 'Nature', 'date': 'Nov 10, 2022', 'snippet': 'Measuring immune correlates of disease acquisition and protection in the \ncontext of a clinical trial is a prerequisite for improved vaccine...', 'thumbnail': 'https://serpapi.com/searches/672460a221b01bfe522bc17c/images/54d600bcfd75c3627c8b9f172cfca69d13565b4d69f96f9865f934348c882b02.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7268779873847961}","{'position': 3, 'link': 'https://www.pulmonologyadvisor.com/news/jansson-covid19-vaccine-granted-emergency-use-authorization-2/', 'title': 'Janssen’s Single-Shot COVID-19 Vaccine Receives Emergency Use Authorization', 'source': 'Pulmonology Advisor', 'date': 'Mar 4, 2021', 'snippet': ""The Food and Drug Administration (FDA) has granted Emergency Use \nAuthorization (EUA) to Janssen's single-dose vaccine for active \nimmunization to prevent..."", 'thumbnail': 'https://serpapi.com/searches/672460a221b01bfe522bc17c/images/54d600bcfd75c3623a30058101ae1cf1a402c1413f42c8847452e9b56f8fd9f5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.909311830997467}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT01986881,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2004967', 'title': 'Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Sep 23, 2020', 'snippet': 'Among patients with type 2 diabetes and atherosclerotic cardiovascular \ndisease, ertugliflozin was noninferior to placebo with respect to major \nadverse...', 'thumbnail': 'https://serpapi.com/searches/67246147a2e99cbceea0bcbc/images/fe5166bd862bf6a1ff383ddb578e94d0a82a8720cfdd7cc221148d862a8587b9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6275863647460938}",,,,,,,,,,['neutral'],neutral,1
NCT03722147,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01600-7', 'title': 'Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma', 'source': 'Nature', 'date': 'Sep 20, 2023', 'snippet': 'Anti-programmed cell death-1 (anti-PD-1) therapies have shown a favorable \nefficacy and good tolerance for relapsed or refractory (r/r) classical \nHodgkin...', 'thumbnail': 'https://serpapi.com/searches/67245df4a2e99cbd222de05b/images/99260a262f535e6cdfa81c635474cbcc698f6acb7ce07ca11153df1dd2b9fa9d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.668369472026825}",,,,,,,,,,['neutral'],neutral,1
NCT01982942,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1803583', 'title': 'Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Aug 29, 2018', 'snippet': 'Ibudilast was associated with slower progression of brain atrophy than \nplacebo but was associated with higher rates of gastrointestinal side \neffects, headache,...', 'thumbnail': 'https://serpapi.com/searches/67245ec848c97dfdbdfd91c7/images/89c0b26675ea13d42c8bca3d9e6db39fb4fe9e0bc7352ecf346428d5953b4cf7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.625451922416687}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2021/08/19/medicinova-planning-phase-3-ibudilast-trial-secondary-progressive-ms/', 'title': 'Phase 3 Trial of Ibudilast in Secondary Progressive MS Being Planned', 'source': 'Multiple Sclerosis News Today', 'date': 'Aug 19, 2021', 'snippet': 'MediciNova is planning to launch a Phase 3 clinical trial that will \nevaluate its investigational oral candidate ibudilast (MN-166) in people \nwith secondary...', 'thumbnail': 'https://serpapi.com/searches/67245ec848c97dfdbdfd91c7/images/89c0b26675ea13d47e59701f31e19d3d5d78d066ab3f56abaacec8298c7f941e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8921599388122559}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/12/18/ibudilast-interferon-beta-european-patent-ms/', 'title': 'Ibudilast plus interferon-beta to get European patent for progressive MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 18, 2023', 'snippet': 'A European patent will cover various uses of ibudilast in combination with \ninterferon-beta medications in treating progressive MS forms.', 'thumbnail': 'https://serpapi.com/searches/67245ec848c97dfdbdfd91c7/images/89c0b26675ea13d4d9b99c07973c8f960957ced1f9c1f5d12de27ea088a7b0a1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7368255853652954}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04535531,"{'position': 1, 'link': 'https://www.contemporarypediatrics.com/view/fda-approves-prescription-berdazimer-gel-10-3-to-treat-molluscum-contagiosum', 'title': 'FDA approves prescription berdazimer gel, 10.3% to treat molluscum contagiosum', 'source': 'Contemporary Pediatrics', 'date': 'Jan 5, 2024', 'snippet': 'Berdazimer gel, 10.3% demonstrated positive, topline data in the phase 3 \nrandomized clinical B-SIMPLE4 trial (NCT04535531) that featured a...', 'thumbnail': 'https://serpapi.com/searches/67245ed3b28e6b6e596def5f/images/4920c5d15701406f790422355e966c75a59c94017698338601251ac511cad129.png', 'sentiment': 'positive', 'sentiment_prob': 0.5087462663650513}","{'position': 2, 'link': 'https://www.empr.com/home/news/topical-antiviral-gel-looks-promising-for-molluscum-contagiosum/', 'title': 'Topical Antiviral Gel Looks Promising for Molluscum Contagiosum', 'source': 'Medical Professionals Reference', 'date': 'Jun 11, 2021', 'snippet': 'Positive topline results were announced from a pivotal phase 3 study \nevaluating SB206, a topical antiviral gel, for the treatment of molluscum \ncontagiosum.', 'thumbnail': 'https://serpapi.com/searches/67245ed3b28e6b6e596def5f/images/4920c5d15701406f8aa3fab66b359c79dc8b66546ad5f33041621aef8438ec62.png', 'sentiment': 'positive', 'sentiment_prob': 0.8182651996612549}",,,,,,,,,"['positive', 'positive']",positive,1
NCT04774237,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20211130005414/en/Visus-Therapeutics-Announces-Positive-Topline-Clinical-Data-from-Phase-2-VIVID-Study-of-BRIMOCHOL-for-the-Treatment-of-Presbyopia', 'title': 'Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia', 'source': 'Business Wire', 'date': 'Nov 30, 2021', 'snippet': 'Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on \ndeveloping innovative ophthalmic therapies to improve vision for...', 'thumbnail': 'https://serpapi.com/searches/67245ed6ce1e10a3d76f2836/images/f5e387c99a08f34e2652be1910c16a4fa7b71b695fb6922c39eddc66735f8a71.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5042712092399597}",,,,,,,,,,['neutral'],neutral,1
NCT05219669,"{'position': 1, 'link': 'https://www.empr.com/home/news/opvee-nasal-spray-approved-for-treatment-of-opioid-overdose/', 'title': 'Opvee Nasal Spray Approved for Treatment of Opioid Overdose', 'source': 'Medical Professionals Reference', 'date': 'May 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Opvee (nalmefene) nasal \nspray for the emergency treatment of known or suspected overdose induced by \nnatural...', 'thumbnail': 'https://serpapi.com/searches/67245f1972f7163d8322042d/images/fee18490e5542a6716cb387e5bb55c571d12f4dd5c13771f3ba46d09a7aafe62.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8920722007751465}",,,,,,,,,,['neutral'],neutral,1
NCT02342379,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-81841-0', 'title': 'Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma', 'source': 'Nature', 'date': 'Jan 27, 2021', 'snippet': 'Evofosfamide (Evo or TH302) is a hypoxia-activated prodrug which is reduced \nleading to the release of alkylating agent...', 'thumbnail': 'https://serpapi.com/searches/67245f285416d82ea72819bf/images/e5f780a66edc0a5254330f8824b839d41367d1a4f238f6ba2721ef993650b68e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8631384968757629}",,,,,,,,,,['neutral'],neutral,1
NCT03777332,"{'position': 1, 'link': 'https://www.nature.com/articles/s41433-021-01766-w', 'title': 'An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma', 'source': 'Nature', 'date': 'Jan 1, 2022', 'snippet': 'In the real-world setting, there is suboptimal compliance with treatments \nthat require frequent administration and assessment visits.', 'thumbnail': 'https://serpapi.com/searches/67245e5974f0a4921705035b/images/7fc408c8d825ff2cf15b5b79662883f2f2da5fc21f3bd04956be9cd334dfc2e1.png', 'sentiment': 'negative', 'sentiment_prob': 0.590781033039093}",,,,,,,,,,['negative'],negative,0
NCT05566639,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-39376-7', 'title': 'Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis', 'source': 'Nature', 'date': 'Jun 19, 2023', 'snippet': 'Despite vaccine availability, influenza remains a substantial global public \nhealth concern. Here, we report interim findings on the primary...', 'thumbnail': 'https://serpapi.com/searches/67245e6df93388521a29bd7b/images/c21acaf6909995964565485dfb6cd3248cbc21b1703be95e3a980fc7ad3ac0af.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8802207112312317}",,,,,,,,,,['neutral'],neutral,1
NCT03536143,"{'position': 1, 'link': 'https://www.cgtlive.com/view/krystal-dystrophic-epidermolysis-bullosa-gene-therapy-b-vec-under-review-eu', 'title': 'Krystal’s Dystrophic Epidermolysis Bullosa Gene Therapy B-VEC Under Review in EU', 'source': 'CGTLive®', 'date': 'Nov 27, 2023', 'snippet': ""An investigational gene therapy intended to treat dystrophic epidermolysis \nbullosa (DEB), has been validated by the European Medicines Agency's (EMA) \nCommittee..."", 'thumbnail': 'https://serpapi.com/searches/67245e72b4e8d64861817c4b/images/5dae00e588cb63fe380fb87cb0e72f56687ad23cf6ffe6708927031f252e3b93.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8852711319923401}","{'position': 2, 'link': 'https://epidermolysisbullosanews.com/news/first-rdeb-adult-patients-fare-well-clinical-trial-gene-therapy-kb103/', 'title': 'First RDEB Adult Patients Fare Well in Clinical Trial With Gene Therapy KB103', 'source': 'Epidermolysis Bullosa News', 'date': 'Oct 17, 2018', 'snippet': 'Read about positive results from the first two adult RDEB patients treated \nwith the topical gene therapy candidate KB103.', 'thumbnail': 'https://serpapi.com/searches/67245e72b4e8d64861817c4b/images/5dae00e588cb63fecc05a0f7cc45de67208e6c5448a81ee9d28dff5d2f0d484f.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6569815874099731}","{'position': 3, 'link': 'https://www.cgtlive.com/view/upcoming-fda-decisions-for-rare-diseases-in-2023', 'title': 'Upcoming FDA Decisions for Rare Diseases in 2023', 'source': 'CGTLive®', 'date': 'Feb 28, 2023', 'snippet': 'CGTLive is taking a look at some of the upcoming FDA decisions on selected \ngene and cell therapies for rare diseases.', 'thumbnail': 'https://serpapi.com/searches/67245e72b4e8d64861817c4b/images/5dae00e588cb63feb246ddc7b3ea8ad71b9678a8853cffe97dc4b501c1cf9a88.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.946054220199585}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT04788511,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2306963', 'title': 'Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity', 'source': 'The New England Journal of Medicine', 'date': 'Aug 25, 2023', 'snippet': 'Heart failure with preserved ejection fraction is increasing in prevalence \nand is associated with a high symptom burden and functional...', 'thumbnail': 'https://serpapi.com/searches/67245e7b1b4e342854b6ebcb/images/a75caf3062c053b0697b927f91cfb07ad0eb0ff09b291c6bf6089738e544b3d1.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5123552680015564}","{'position': 2, 'link': 'https://www.nature.com/articles/s41591-023-02526-x', 'title': 'Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial', 'source': 'Nature', 'date': 'Aug 27, 2023', 'snippet': 'In the STEP-HFpEF trial, semaglutide improved symptoms, physical \nlimitations and exercise function and reduced body weight in patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/67245e7b1b4e342854b6ebcb/images/a75caf3062c053b0e1a26d3036062967a169ba34560932d1c03edc6576562d12.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7419707179069519}","{'position': 3, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067505', 'title': 'Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial | Circulation', 'source': 'American Heart Association Journals', 'date': 'Nov 12, 2023', 'snippet': 'BACKGROUND:Patients with heart failure (HF) with preserved ejection \nfraction (HFpEF) and obesity experience a high burden of symptoms and...', 'thumbnail': 'https://serpapi.com/searches/67245e7b1b4e342854b6ebcb/images/a75caf3062c053b0179db9c1844e52455d98806b3db505c1abc2fb72627aef38.png', 'sentiment': 'neutral', 'sentiment_prob': 0.769500195980072}","{'position': 4, 'link': 'https://finance.yahoo.com/news/novo-nordisk-announces-presentation-data-120000906.html', 'title': 'Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association', 'source': 'Yahoo Finance', 'date': 'Jun 18, 2024', 'snippet': 'FLOW kidney outcomes trial data evaluating efficacy and safety of \nonce-weekly semaglutide 1.0 mg in people with type 2 diabetes1SELECT...', 'thumbnail': 'https://serpapi.com/searches/67245e7b1b4e342854b6ebcb/images/a75caf3062c053b072c1cb1e53657d5eb5dedcd1394841d4f2ce0bc63fb7071c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8996814489364624}",,,,,,,"['negative', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01646021,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-018-0023-2', 'title': 'Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study | Leukemia', 'source': 'Nature', 'date': 'Feb 2, 2018', 'snippet': 'Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a \nreported median overall survival (OS) of 3–5 years [1].', 'thumbnail': 'https://serpapi.com/searches/67245f8418787da3d4090e03/images/aea837cf8bfbefe0d571b2b9409d50d04d23f537eee49136c892cb6ad7d1c922.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8522799611091614}","{'position': 2, 'link': 'https://lymphomahub.com/medical-information/phase-iii-sympatico-study-on-ibrutinib-plus-venetoclax-in-mcl', 'title': 'Phase III SYMPATICO study on ibrutinib plus venetoclax in MCL', 'source': 'Lymphoma Hub', 'date': 'Oct 9, 2020', 'snippet': 'Ibrutinib is an oral inhibitor of Bruton tyrosine kinase (BTK) that \nreceived accelerated approval by the U.S. Food and Drug Administration...', 'thumbnail': 'https://serpapi.com/searches/67245f8418787da3d4090e03/images/aea837cf8bfbefe077c27a911248961b2b054132120307a28a0c1551c734e9a0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8486211895942688}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02218736,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/fast-fail-trial-shows-new-approach-identifying-brain-targets-clinical-treatments', 'title': 'Fast-fail trial shows new approach to identifying brain targets for clinical treatments', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Mar 30, 2020', 'snippet': 'NIH-funded study identifies receptor as possible target for treating \nanhedonia.', 'thumbnail': 'https://serpapi.com/searches/67245f8f98fad6bca0245fd8/images/49efcca3116bd60793c76434750de1e62dff4cae3ce673f886e96ec01e0bbbf5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8001114130020142}",,,,,,,,,,['neutral'],neutral,1
NCT03057977,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2022190', 'title': 'Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure', 'source': 'The New England Journal of Medicine', 'date': 'Aug 28, 2020', 'snippet': 'Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of \nhospitalization for heart failure in patients regardless of the presence or \nabsence of...', 'thumbnail': 'https://serpapi.com/searches/6724603189055ecfb6d62741/images/cf11e2f19678410442050543478a029761d90ee9fb283944d8f824aa065c4bc1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7970401048660278}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.051783', 'title': 'Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction:', 'source': 'American Heart Association Journals', 'date': 'Oct 21, 2020', 'snippet': 'Background:Empagliflozin reduces the risk of cardiovascular death or \nhospitalization for heart failure in patients with heart failure and a...', 'thumbnail': 'https://serpapi.com/searches/6724603189055ecfb6d62741/images/cf11e2f19678410468986eb534673d27a41370fe9c92524bd6427b81ef08d033.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8130537271499634}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01969721,"{'position': 1, 'link': 'https://lungdiseasenews.com/2016/02/10/lung-function-copd-patients-shows-promise-stiolto-respimat-inhalation-spray/', 'title': 'Lung Function in COPD Patients Shows Promise With STIOLTO RESPIMAT Inhalation Spray', 'source': 'Lung Disease News', 'date': 'Feb 10, 2016', 'snippet': ""Read about promising data on Boehringer Ingelheim' STIOLTO RESPIMAT, which \nis able to improve lung function in COPD patients."", 'thumbnail': 'https://serpapi.com/searches/67246046cdf155b9c086ab0d/images/78cb4c252ff74c982384dc30fff6860102e69e611b0153ca8b8095ddaadb475f.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7845652103424072}",,,,,,,,,,['positive'],positive,1
NCT02968433,"{'position': 1, 'link': 'https://www.nature.com/articles/s42003-020-0797-4', 'title': 'Rejuvenating the blood and bone marrow to slow aging-associated cognitive decline and Alzheimer’s disease', 'source': 'Nature', 'date': 'Feb 13, 2020', 'snippet': 'Our Communications Biology study demonstrated that young bone marrow \ntransplantation attenuates cognitive decline in old mice.', 'thumbnail': 'https://serpapi.com/searches/6724609654605c243c1bd104/images/56627d0fad91d7b5b5617f95ea17cc9ef0d8b7a24a41eacbe13cb2748798ead8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8491166234016418}",,,,,,,,,,['neutral'],neutral,1
NCT03946800,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202305769', 'title': 'Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid‐Based Nanoparticles', 'source': 'Wiley Online Library', 'date': 'Dec 6, 2023', 'snippet': 'The implementation of advanced preclinical models such as tumor organoids, \nincorporating immune system cells and tumor extracellular matrix,...', 'thumbnail': 'https://serpapi.com/searches/672460987b05ca37a09e5d55/images/95a48be980f1f54b1f6a60431d2b27ad7cd53e2896738a79510c6a15ccf28fff.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9186938405036926}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/features/pipeline-moves-phase-iii-oncology-trial-failure/', 'title': 'Pipeline Moves: Prospects drop after Phase III ovarian cancer trial failure', 'source': 'Clinical Trials Arena', 'date': 'Nov 13, 2023', 'snippet': 'The Clinical Trials Arena team also review assets in oncology, infectious \ndiseases and cardiology.', 'thumbnail': 'https://serpapi.com/searches/672460987b05ca37a09e5d55/images/95a48be980f1f54b3f71cd5e089410cec5f1e3c7bbb270f467f4ce9ec7a45617.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6975389719009399}","{'position': 3, 'link': 'https://www.cancertherapyadvisor.com/reports/medi1191-durvalumab-advanced-solid-tumors-active-safe/', 'title': 'MEDI1191 Plus Durvalumab Appears Safe, Active in Advanced Solid Tumors', 'source': 'Cancer Therapy Advisor', 'date': 'Apr 24, 2023', 'snippet': 'Combination treatment with MEDI1191 and durvalumab has demonstrated \nactivity in a phase 1 trial of patients with advanced solid tumors.', 'thumbnail': 'https://serpapi.com/searches/672460987b05ca37a09e5d55/images/95a48be980f1f54b0ac1b57a843f6f83eae03198b37dbf3384c9e0b1ebb8e631.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.579197108745575}",,,,,,,,"['neutral', 'negative', 'neutral']",neutral,1
NCT01659255,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-019-0658-7', 'title': 'Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) | Leukemia', 'source': 'Nature', 'date': 'Dec 11, 2019', 'snippet': ""Recent therapeutic advances for mantle cell lymphoma (MCL) include \ninhibitors of Bruton's tyrosine kinase (BTK), a critical component in the..."", 'thumbnail': 'https://serpapi.com/searches/6724609d0f2a2c26f50d788c/images/c93116a7837c4ec6e6371bb1bb5230f94cf425971745ec036ece8928b717aa39.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8483801484107971}",,,,,,,,,,['neutral'],neutral,1
NCT04804111,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.925219/full', 'title': 'Review of Urate-Lowering Therapeutics: From the Past to the Future', 'source': 'Frontiers', 'date': 'Feb 7, 2024', 'snippet': 'We reviewed all currently available ULT, as well as any medications in \ndevelopment using following databases: United States Food and Drug \nAdministration...', 'thumbnail': 'https://serpapi.com/searches/67245fae861b9d63abef9e21/images/d96f1e5cb354a181ee22c14c851687c71c8bf639a2b1c5a64d16e089332ee079.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9270159602165222}",,,,,,,,,,['neutral'],neutral,1
NCT04089566,"{'position': 1, 'link': 'https://investors.biogen.com/news-releases/news-release-details/biogen-announces-positive-topline-results-study-higher-dose', 'title': 'Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA', 'source': 'Biogen', 'date': 'Sep 4, 2024', 'snippet': 'Positive study demonstrates the potential for investigational higher dose \nnusinersen regimen to advance the treatment of SMA; Biogen plans...', 'thumbnail': 'https://serpapi.com/searches/67245fbc81262ade5a9c66f7/images/eb823ce9ac2b8ef23d4493d650baf69b7ce8082993c816e90a97c02f773be0d4.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.8194587826728821}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/features/spinal-muscular-atrophy-trials-to-watch/', 'title': 'Spinal Muscular Atrophy: Four trials to watch over the next 12 months', 'source': 'Clinical Trials Arena', 'date': 'Aug 11, 2023', 'snippet': ""With just five treatments available for spinal muscular atrophy, how are \nclinical trials trying to improve patients' quality of life?"", 'thumbnail': 'https://serpapi.com/searches/67245fbc81262ade5a9c66f7/images/eb823ce9ac2b8ef2c80fda3ac44bbc2171d919a3c40e26bc2010fc41bca7a897.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7752137184143066}","{'position': 3, 'link': 'https://www.cgtlive.com/view/data-roundup-september-2024-features-updates-ophthalmology-gene-therapy-car-t-lymphoma-more', 'title': 'Data Roundup: September 2024 Features Updates in Ophthalmology Gene Therapy, CAR-T for Lymphoma, and More', 'source': 'CGTLive®', 'date': '4 weeks ago', 'snippet': 'Catch up on any of the key data updates you may have missed last month, \nwith coverage highlights from the CGTLive™ team.', 'thumbnail': 'https://serpapi.com/searches/67245fbc81262ade5a9c66f7/images/eb823ce9ac2b8ef2d677064839e55eff686cefdfb1dc6a4a74f8255cfadad38b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8718736171722412}",,,,,,,,"['positive', 'neutral', 'neutral']",neutral,1
NCT03054298,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1204722/full', 'title': 'Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies', 'source': 'Frontiers', 'date': 'Jul 5, 2023', 'snippet': 'The pathetic malignant mesothelioma (MM) is a extremely uncommon and \nconfrontational tumor that evolves in the mesothelium layer of the pleural \ncavities...', 'thumbnail': 'https://serpapi.com/searches/67245fc34d52b8d3fde5b854/images/13203aebdc7d00eae5a74bdcb3b3be9544aa0ba6e97dcf799754c946e5ca86a3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7385631203651428}",,,,,,,,,,['neutral'],neutral,1
NCT04214639,"{'position': 1, 'link': 'https://www.empr.com/home/news/cabtreo-a-triple-combo-topical-gel-for-acne-gets-fda-approval/', 'title': 'Cabtreo, a Triple Combo Topical Gel for Acne, Gets FDA Approval', 'source': 'Medical Professionals Reference', 'date': 'Oct 25, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Cabtreo™ (clindamycin \nphosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1%)...', 'thumbnail': 'https://serpapi.com/searches/67245fd1bd7cf00e347d40b2/images/e009437f79100ef52744d095e5ccaecf287414ad74b28411188f2a7854b43170.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5522952079772949}",,,,,,,,,,['positive'],positive,1
NCT02301481,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.870741/full', 'title': 'Preoperative Concurrent Chemoradiotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Phase II Randomized Study', 'source': 'Frontiers', 'date': 'Apr 29, 2022', 'snippet': '1Department of Radiation Oncology, National Cancer Center/National Clinical \nResearch Center for Cancer/Cancer Hospital, Chinese Academy of...', 'thumbnail': 'https://serpapi.com/searches/67245fe3d0c983711b6fcd01/images/5e21eb0c4ab0d3f121f28df64c0a9ae95b4dd35758b844d4af080212d4842ed6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9293925762176514}",,,,,,,,,,['neutral'],neutral,1
NCT00585195,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1406766', 'title': 'Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Apr 30, 2018', 'snippet': 'In this study, crizotinib showed marked antitumor activity in patients with \nadvanced ROS1-rearranged NSCLC.', 'thumbnail': 'https://serpapi.com/searches/67245fe6c821274057f72961/images/3f3d07e9ef171b70c9b111a6d2201875b04c2a57f4661c98a59cfe5f3f046e08.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8645313382148743}","{'position': 2, 'link': 'https://www.pharmacytimes.com/view/expert-pharmacists-can-find-solutions-for-overspending-driven-by-dose-specific-packaging', 'title': 'Expert: Pharmacists Can Find Solutions for Overspending Driven by Dose-Specific Packaging', 'source': 'Pharmacy Times', 'date': 'Mar 19, 2022', 'snippet': ""In part 2 of a conversation with Emeline Aviki, MD, as part of the Society \nof Gynecologic Oncology 2022 Annual Meeting on Women's Cancer,..."", 'thumbnail': 'https://serpapi.com/searches/67245fe6c821274057f72961/images/3f3d07e9ef171b70874363bec56cfb9e5fa4c0e443bcb0a5e7f4998170879371.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8350730538368225}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03847909,"{'position': 1, 'link': 'https://www.contemporarypediatrics.com/view/nedosiran-injection-fda-approved-for-children-with-primary-hyperoxaluria-type-1', 'title': 'Nedosiran injection FDA-approved for children with primary hyperoxaluria type 1', 'source': 'Contemporary Pediatrics', 'date': 'Oct 5, 2023', 'snippet': 'The approval of the prescription injection for children aged 9 years and up \nis based on data from a phase 2 and an ongoing phase 3 trial...', 'thumbnail': 'https://serpapi.com/searches/67245ff758e433d00fab26ad/images/96110812e33ee22cff2a32c5b7c079a6c9adc35a1751397c691ea4f5968fc5a9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8290620446205139}","{'position': 2, 'link': 'https://www.empr.com/home/news/rivfloza-nedosiran-primary-hyperoxaluria-approved/', 'title': 'Rivfloza Approved for Patients With Primary Hyperoxaluria Type 1', 'source': 'Medical Professionals Reference', 'date': 'Oct 3, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Rivfloza™ (nedosiran) \nto lower urinary oxalate levels in children 9 years of age and...', 'thumbnail': 'https://serpapi.com/searches/67245ff758e433d00fab26ad/images/96110812e33ee22c190e2201b9fa6d0067333ce391355459eacb8371673c1b06.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7843160033226013}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01756118,"{'position': 1, 'link': 'https://www.jci.org/articles/view/78090/figure/2', 'title': 'MicroRNA regulation of lymphocyte tolerance and autoimmunity', 'source': 'JCI - Welcome', 'date': 'Jun 1, 2015', 'snippet': 'PI3K inhibitors are currently in clinical trials for acute and advanced \nleukemia (ClinicalTrials.gov identifiers NCT01756118 and...', 'thumbnail': 'https://serpapi.com/searches/67246006fc40bf5b24979142/images/b6f7c2e55290fdc735c1d778c0fe0d660e7270ed9ca16ebf60c428db2e4a3983.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9191775918006897}",,,,,,,,,,['neutral'],neutral,1
NCT01013415,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-37223-9', 'title': 'Application of ultrasensitive digital ELISA for p24 enables improved evaluation of HIV-1 reservoir diversity and growth kinetics in viral outgrowth assays', 'source': 'Nature', 'date': 'Jul 6, 2023', 'snippet': 'The advent of combined antiretroviral therapy (cART) has been instrumental \nin controlling HIV-1 replication and transmission and decreasing...', 'thumbnail': 'https://serpapi.com/searches/672460b339e2327bb9123c78/images/06a62ea9cd4ea051f22f2e4b7b68160decb4f49f1ece73e086ed5d81bcc10bcc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7045418620109558}",,,,,,,,,,['neutral'],neutral,1
NCT03429543,"{'position': 1, 'link': 'https://investor.lilly.com/news-releases/news-release-details/phase-iii-trial-demonstrated-jardiancer-first-sglt2-inhibitor', 'title': 'Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes', 'source': 'Eli Lilly and Company', 'date': '٠٧\u200f/١٢\u200f/٢٠٢٢', 'snippet': 'Jardiance is the first SGLT2 inhibitor to show statistically significant \nreduction in blood sugar levels in children and adolescents with type 2 \ndiabetes.', 'thumbnail': 'https://serpapi.com/searches/672460b8f60b6f8f33eff744/images/db46303a0a21abb98acc151f4d1a19b315b4b28fbae6f3c720060692d39c1cd8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.683343768119812}","{'position': 2, 'link': 'https://www.drugtopics.com/view/new-study-demonstrates-empagliflozin-effectiveness-in-pediatric-t2d', 'title': 'New Study Demonstrates Empagliflozin Effectiveness in Pediatric T2D', 'source': 'Drug Topics', 'date': '٠٨\u200f/٠٢\u200f/٢٠٢٣', 'snippet': 'Results of the DINAMO clinical trial (NCT03429543) have demonstrated the \neffectiveness of empagliflozin (Jardiance) in children and adolescents with \ntype 2...', 'thumbnail': 'https://serpapi.com/searches/672460b8f60b6f8f33eff744/images/db46303a0a21abb9ee0a7a6bc1081eade6d24018f40ef5b0a5ffadc5aa0e194b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8846713900566101}","{'position': 3, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/empagliflozin-significantly-reduces-hba1c-in-children-with-type-2-diabetes/', 'title': 'Empagliflozin Significantly Reduces HbA1c in Children With Type 2 Diabetes', 'source': 'Medical Professionals Reference', 'date': '٠٧\u200f/١٢\u200f/٢٠٢٢', 'snippet': 'Empagliflozin achieved a significant reduction in hemoglobin A1c (HbA1c) in \npatients 10 to less than 18 years of age with type 2 diabetes.', 'thumbnail': 'https://serpapi.com/searches/672460b8f60b6f8f33eff744/images/db46303a0a21abb912847d2f792f8dda06df7ad112a25d5bee2143026720a2e7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6023697257041931}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03790800,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2314741', 'title': 'Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke', 'source': 'The New England Journal of Medicine', 'date': 'May 16, 2024', 'snippet': 'In this trial, prehospital blood-pressure reduction did not improve \nfunctional outcomes in a cohort of patients with undifferentiated acute \nstroke.', 'thumbnail': 'https://serpapi.com/searches/672460bc81bab7b8fdf0e6e3/images/1648648db8993d40416061147b961995482bcc0b219656e99dd8d6c73f01103c.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5795195698738098}",,,,,,,,,,['negative'],negative,0
NCT05252845,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-024-00920-1', 'title': 'A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults | npj Vaccines', 'source': 'Nature', 'date': 'Jul 6, 2024', 'snippet': 'In preparation for mass vaccinations with R21/Matrix-M™ combined with mass \nadministrations of dihydroartemisinin, piperaquine, and a single...', 'thumbnail': 'https://serpapi.com/searches/672460ccd0d7e31cd144a745/images/dd37c656a828a98f90ba3fef086c0d11eaceb5ea6b75fd1dbb48693a2b66cf58.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9333590269088745}",,,,,,,,,,['neutral'],neutral,1
NCT05193916,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/mash-patients-liver-fat-accumulation-lowered-with-chiglitazar-phase-2-trial/', 'title': ""MASH patients' liver fat accumulation lowered with chiglitazar in Phase 2 trial"", 'source': 'Liver Disease News', 'date': 'Apr 1, 2024', 'snippet': 'Chiglitazar (carfloglitazar), an oral medication approved to treat type 2 \ndiabetes in China, led to significant reductions in liver fat accumulation.', 'thumbnail': 'https://serpapi.com/searches/672460ed1a5b544aac271ad5/images/9157d2d9ee92dc2f0db729bef5f9ff7afd7a1e58b89b08f67f0fd5085ea2b44f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6838760375976562}",,,,,,,,,,['neutral'],neutral,1
NCT03945019,"{'position': 1, 'link': 'https://www.empr.com/home/news/zymfentra-approved-as-the-first-subcutaneous-infliximab-for-inflammatory-bowel-disease/', 'title': 'Zymfentra, a Subcutaneous Formulation of Infliximab, Approved for IBD', 'source': 'Medical Professionals Reference', 'date': 'Oct 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Zymfentra \n(infliximab-dyyb) for the maintenance treatment of adults with moderately \nto severely active...', 'thumbnail': 'https://serpapi.com/searches/672460fa1397ba2adff58fb9/images/c82d318307dd825a3df1af00b5d725b52cc0320196ab4c0b436e1c39d89bb307.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.762981116771698}",,,,,,,,,,['neutral'],neutral,1
NCT00330330,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222010988', 'title': 'Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders', 'source': 'ScienceDirect.com', 'date': 'Sep 20, 2022', 'snippet': 'PTP1B is involved in several pathophysiological mechanisms affecting \nneurons. PTP1B inhibition decreases neuroinflammation, insulin resistance \nand reticulum...', 'thumbnail': 'https://serpapi.com/searches/672460fd69012193a5fee478/images/a27ef4fa8c8181f6022570e949caef60d9ac9a3636139b8c7280182f48bd78c2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7960569262504578}",,,,,,,,,,['neutral'],neutral,1
NCT03635489,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-020-0199-6', 'title': 'Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence', 'source': 'Nature', 'date': 'Jul 29, 2020', 'snippet': 'Advanced and recurrent gynecological cancers are associated with poor \nprognosis and lack of effective treatment. The developments of the...', 'thumbnail': 'https://serpapi.com/searches/6724613aa25104e3b9e6fd7d/images/5ecd2ceae29be190e2839aab120dc61f7bd40633cd51233ad2c3395a9d5a39c4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6648945212364197}",,,,,,,,,,['neutral'],neutral,1
NCT02279745,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/long-term-safety-and-tolerability-of-ralinepag-in-pah/', 'title': 'Long-Term Safety, Tolerability of Ralinepag in Pulmonary Arterial Hypertension', 'source': 'Pulmonology Advisor', 'date': 'May 31, 2022', 'snippet': 'An open-label extension study of the long-term safety of ralinepag for PAH \nfound a positive risk-benefit ratio similar to that of the parent...', 'thumbnail': 'https://serpapi.com/searches/6724613b9872179945fc4be3/images/4e690663fc6e2e98ce455b6eb78242425201e3e25821aa691692ef9bcc83d429.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8393498659133911}",,,,,,,,,,['neutral'],neutral,1
NCT01757808,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/circresaha.115.303827', 'title': 'Current Clinical Management of Pulmonary Arterial Hypertension', 'source': 'American Heart Association Journals', 'date': 'Jun 20, 2014', 'snippet': 'In this article, we discuss the clinical approach and management of PAH \nfrom the perspective of a single US-based academic institution.', 'thumbnail': 'https://serpapi.com/searches/6724618ef410441876f50dd2/images/6f3a88a8a7ca4c209934e36901273202b0682bfe7c004e883cd80a0380012690.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9431232810020447}",,,,,,,,,,['neutral'],neutral,1
NCT00095654,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa065061', 'title': 'Effect of Ramipril on the Incidence of Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'May 1, 2018', 'snippet': 'Previous studies have suggested that blockade of the renin–angiotensin \nsystem may prevent diabetes in people with cardiovascular disease or \nhypertension.', 'thumbnail': 'https://serpapi.com/searches/67246280d11a89e4849146cd/images/e18e3b3c5b0ba93bce1d16cae61a5f85db37b662fb54211ee5e52ad7a92c539e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8563244342803955}",,,,,,,,,,['neutral'],neutral,1
NCT00134563,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1014656', 'title': 'Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis', 'source': 'The New England Journal of Medicine', 'date': 'Oct 6, 2011', 'snippet': 'Teriflunomide is a new oral disease-modifying therapy for relapsing forms \nof multiple sclerosis.We concluded a randomized trial involving...', 'thumbnail': 'https://serpapi.com/searches/672462917b05ca799b944313/images/145c26038612061b9ea5053680672ae280e76a8f393165c5ce3fa67eb99a5e62.png', 'sentiment': 'neutral', 'sentiment_prob': 0.884963870048523}",,,,,,,,,,['neutral'],neutral,1
NCT02434328,"{'position': 1, 'link': 'https://www.nature.com/articles/s41433-022-02077-4', 'title': 'Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis | Eye', 'source': 'Nature', 'date': 'May 6, 2022', 'snippet': 'To assess the therapeutic response to brolucizumab and aflibercept by deep \nlearning/OCT-based analysis of macular fluid volumes in neovascular \nage-related...', 'thumbnail': 'https://serpapi.com/searches/672462a92fab62d9c7da4094/images/e4f88c0e6985293b7d78772d7914ae25e45e57bf78f27e07434f970e8b9dbe45.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.895088255405426}",,,,,,,,,,['neutral'],neutral,1
NCT05032196,"{'position': 1, 'link': 'https://huntingtonsdiseasenews.com/news/wve-003-safely-lowers-mutant-huntingtin-protein-trial/', 'title': 'WVE-003 Safely Lowers Mutant Huntingtin Protein in Phase 1/2 Trial', 'source': ""Huntington's Disease News"", 'date': 'Oct 11, 2022', 'snippet': ""The Wave therapy candidate WVE-003 safely lowered levels of the mutant \nhuntingtin protein in Huntington's disease patients, trial data show."", 'thumbnail': 'https://serpapi.com/searches/6724619a96a329686adfcee3/images/ea510b30aeb26687b0196a0a7a16584b4a12c3619c745704c82bf96236f5df7d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8356421589851379}","{'position': 2, 'link': 'https://www.globenewswire.com/news-release/2022/09/20/2519092/0/en/Wave-Life-Sciences-Announces-Positive-Update-from-Phase-1b-2a-SELECT-HD-Trial-with-Initial-Results-Indicating-Allele-Selective-Target-Engagement-with-WVE-003-in-Huntington-s-Diseas.html', 'title': 'Wave Life Sciences Announces Positive Update from Phase', 'source': 'GlobeNewswire', 'date': 'Sep 20, 2022', 'snippet': 'Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant \nhuntingtin (mHTT) protein was reduced following single doses of...', 'thumbnail': 'https://serpapi.com/searches/6724619a96a329686adfcee3/images/ea510b30aeb2668794891c885e223727bee101252d0df3fbfb28f8538aeaec74.png', 'sentiment': 'positive', 'sentiment_prob': 0.5970595479011536}","{'position': 3, 'link': 'https://huntingtonsdiseasenews.com/news/wave-plans-next-steps-develop-wve-003-after-positive-trial-data/', 'title': 'Wave plans next steps to develop WVE-003 after positive trial data', 'source': ""Huntington's Disease News"", 'date': 'Jul 9, 2024', 'snippet': 'Wave Life Sciences said data from a clinical trial of WVE-003 support a \ncase for accelerated approval, which it will discuss with the FDA.', 'thumbnail': 'https://serpapi.com/searches/6724619a96a329686adfcee3/images/ea510b30aeb266871f4a8175622710f1ee4cf40255a132eaefd3e54b35cc75fc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5348636507987976}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT01414985,"{'position': 1, 'link': 'https://battendiseasenews.com/news/experimental-clinical-trials-often-best-option-batten-patients/', 'title': 'Clinical Trials, Though Experimental, Often Are Best Option for Batten Patients', 'source': 'Batten Disease News', 'date': 'Mar 6, 2018', 'snippet': 'Learn more about how Charlotte and Gwyneth Gray were treated in a clinical \ntrial for their form of Batten disease. Clinical trials often are...', 'thumbnail': 'https://serpapi.com/searches/672461aa98fad6bca024606b/images/b3e48213a4d342c96f242db1a9625d253e0b594b9ee2a6b14d4b902eaef0f378.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8681191802024841}",,,,,,,,,,['neutral'],neutral,1
NCT03430479,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-022-27048-3', 'title': 'Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer | Scientific Reports', 'source': 'Nature', 'date': 'Dec 27, 2022', 'snippet': 'This phase I/II study investigated the efficacy and safety of nivolumab \nplus RT in HER2-negative metastatic breast cancer requiring palliative RT \nfor bone...', 'thumbnail': 'https://serpapi.com/searches/672461fb9f8bfc8b73899d6d/images/eb8ec4690beba31968c9c50448a06a749f67521899561f19f09e9ff2bc7f0db2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.892707109451294}",,,,,,,,,,['neutral'],neutral,1
NCT01896271,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/home/cancer-topics/general-oncology/radio-immunotherapy-combination-may-be-effective-on-specific-tumor-types/', 'title': 'Radio/Immunotherapy Combination May Be Effective on Specific Tumor Types', 'source': 'Cancer Therapy Advisor', 'date': 'Jul 11, 2016', 'snippet': 'A combination of radiotherapy with local and systemic immunotherapy may be \nclinically beneficial for treating some types of tumors.', 'thumbnail': 'https://serpapi.com/searches/6724620429e6fbc169a86d80/images/3c689e2158e8de1bb9db60223d2fc8a1e2eedff337a68333c31b82911f8f81da.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5377838611602783}",,,,,,,,,,['neutral'],neutral,1
NCT04442295,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/stoke-therapeutics-clinical-hold-released/', 'title': 'Stoke Therapeutics eyes Phase III Dravet syndrome trial, as FDA releases hold', 'source': 'Clinical Trials Arena', 'date': 'Aug 8, 2024', 'snippet': 'Stoke Therapeutics has revealed it will move to Phase III trials of its \nDravet syndrome drug zorevunersen after the US Food and Drug Administration \n(FDA)...', 'thumbnail': 'https://serpapi.com/searches/67246209f963e73c2b2ed7c0/images/06039b51a2ca26e8aee3db71f47df1cbb3741c64a636528c246e48947bbeff1b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.917353630065918}","{'position': 2, 'link': 'https://dravetsyndromenews.com/news/stk-001-trials-update-benefits-seizures-cognition-behavior/', 'title': 'STK-001 still showing potential as Dravet syndrome treatment |...', 'source': 'Dravet Syndrome News', 'date': 'Aug 1, 2023', 'snippet': 'STK-001 can reduce seizure frequency and aid cognition and behavior in \nyoung Dravet syndrome, new data from Phase 1/2 clinical trials show.', 'thumbnail': 'https://serpapi.com/searches/67246209f963e73c2b2ed7c0/images/06039b51a2ca26e8f6f4ef56c2e944af5f8d7ea20e78e10bed81fa33d080acff.png', 'sentiment': 'positive', 'sentiment_prob': 0.6383975148200989}","{'position': 3, 'link': 'https://dravetsyndromenews.com/news/stoke-phase-3-trial-stk-001-planned-next-year-phase-1-2a-data/', 'title': ""Stoke's Phase 3 Trial of STK-001 for Dravet Planned for Next Year..."", 'source': 'Dravet Syndrome News', 'date': 'Jan 10, 2023', 'snippet': ""New safety and efficacy data from two Phase 1/2a clinical trials testing \nSTK-001, Stoke Therapeutics' investigational treatment for children and \nadolescents..."", 'thumbnail': 'https://serpapi.com/searches/67246209f963e73c2b2ed7c0/images/06039b51a2ca26e88a6027e9d22c005145c8286bccfc09aabcbf41dc93e67954.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8406557440757751}","{'position': 4, 'link': 'https://dravetsyndromenews.com/news/stk-001-lowers-seizures-aids-cognition-behavior-trials/', 'title': 'STK-001 lowers seizures, aids cognition and behavior in clinical trials', 'source': 'Dravet Syndrome News', 'date': 'Dec 5, 2023', 'snippet': 'An update on open-label studies in young Dravet patients finds STK-001 \nmarkedly reduces seizure frequency, improves cognition and behavior.', 'thumbnail': 'https://serpapi.com/searches/67246209f963e73c2b2ed7c0/images/06039b51a2ca26e8e0721d9912e0d8b6335a3e30bd2f381d213b1e1d27f50aa7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8194456100463867}","{'position': 5, 'link': 'https://dravetsyndromenews.com/news/fda-allows-testing-stk-001-high-dose-monarch-trial/', 'title': 'FDA allows testing of STK-001 at single high dose in MONARCH trial...', 'source': 'Dravet Syndrome News', 'date': 'Mar 21, 2023', 'snippet': 'A 70 mg single dose of STK-001 is being added to the MONARCH trial in \nchildren with Dravet; multiple high dosing is part of ongoing UK...', 'thumbnail': 'https://serpapi.com/searches/67246209f963e73c2b2ed7c0/images/06039b51a2ca26e81d9b3b404ee5cc1c90f968568513082a0d10b87f02886ccf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8700740337371826}","{'position': 6, 'link': 'https://dravetsyndromenews.com/news/stokes-tango-boosts-dravet-protein-in-mice-brains-study-finds/', 'title': 'Stoke’s TANGO Found to Boost Dravet Protein in Mice Brains', 'source': 'Dravet Syndrome News', 'date': 'Jan 26, 2021', 'snippet': ""Stoke Therapeutics' TANGO antisense oligonucleotide-based technology \nboosted NaV1.1 protein – lacking in Dravet patients – in mice brains."", 'thumbnail': 'https://serpapi.com/searches/67246209f963e73c2b2ed7c0/images/06039b51a2ca26e85dd0560f28b45c7b249214c6dfb0c5c2bbcc84584c3bd8e2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8645341992378235}",,,,,"['neutral', 'positive', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03157037,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/hansa-biopharma-imlifidase/', 'title': 'Hansa starts dosing in Phase III trial in anti-GBM disease', 'source': 'Clinical Trials Arena', 'date': 'May 30, 2023', 'snippet': 'The global Phase III trial will evaluate the renal function of patients \nwith a rare autoimmune condition that receive imlifidase and SoC.', 'thumbnail': 'https://serpapi.com/searches/672462291fc7c565347ded9a/images/9a886a47c366b0e0bdf343a49c0af694b80039663dbb4b60701b7556fe6a715b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9224563837051392}",,,,,,,,,,['neutral'],neutral,1
NCT01839487,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2022.1020888/full', 'title': 'Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components', 'source': 'Frontiers', 'date': 'Oct 9, 2022', 'snippet': 'In our review, we shed light on how crosstalk of complex environmental \ncomponents modulates PDAC drug resistance, and we summarize related \nclinical trials.', 'thumbnail': 'https://serpapi.com/searches/6724624c64f11d5673dd9ae1/images/71796ceb37d8c963b7e9b865a81b9f37aaf760350347a60bc592c0b34f295540.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8721804618835449}",,,,,,,,,,['neutral'],neutral,1
NCT03233776,"{'position': 1, 'link': 'https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04847-5', 'title': 'Anakinra: efficacy in the management of fever during neutropenia and mucositis in autologous stem cell transplantation (AFFECT-2)—study protocol for a multicenter randomized double-blind placebo-controlled trial', 'source': 'BioMed Central', 'date': 'Nov 23, 2020', 'snippet': 'The aim of the AFFECT-2 study is to determine the efficacy of anakinra in \npreventing fever during neutropenia (FN) and mucositis in this study \npopulation.', 'thumbnail': 'https://serpapi.com/searches/672462cf20e6eb1dbbbe32c2/images/01a9c861aafb2d7b9ef982e2c5dcbfa90ed3101a01a6ca7f688e78566174cc8a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8506823182106018}",,,,,,,,,,['neutral'],neutral,1
NCT03274804,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-37872-4', 'title': 'CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy', 'source': 'Nature', 'date': 'Apr 20, 2023', 'snippet': 'This biomimetic CAR-neutrophil drug delivery system is a safe, potent and \nversatile platform for treating GBM and possibly other devastating diseases.', 'thumbnail': 'https://serpapi.com/searches/672464fce6862b708a062a86/images/4583a564ccc52542479e3971a729574523e0a1a23fa612dc597d8a21247c51d6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7221992015838623}",,,,,,,,,,['neutral'],neutral,1
NCT05463744,"{'position': 1, 'link': 'https://www.researchgate.net/publication/380177828_Once-weekly_insulins_a_promising_approach_to_reduce_the_treatment_burden_in_people_with_diabetes', 'title': '(PDF) Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes', 'source': 'ResearchGate', 'date': 'Aug 30, 2024', 'snippet': 'PDF | Despite the availability of new classes of glucose-lowering drugs \nthat improve glycaemic levels and minimise long-term complications,...', 'thumbnail': 'https://serpapi.com/searches/6724650aa5e50212a2fc23de/images/39014b7eb8f104f0e0ac2bca5a7a6416b7c76003aaf864aaa40d148ece72b09f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5478062033653259}",,,,,,,,,,['neutral'],neutral,1
NCT05425732,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-21-valent-pneumococcal-conjugate-vaccine-capvaxive/', 'title': 'FDA Approves 21-Valent Pneumococcal Conjugate Vaccine Capvaxive', 'source': 'Medical Professionals Reference', 'date': 'Jun 18, 2024', 'snippet': 'The Food and Drug Administration (FDA) has approved Capvaxive™ (V116; \npneumococcal 21-valent conjugate vaccine) for:.', 'thumbnail': 'https://serpapi.com/searches/67246523e6862b708a062a8c/images/35ad1d847a7378dcb8ad6152c32ad2edb089dba9b9780d2148eb50b15b511ed2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7008212804794312}","{'position': 2, 'link': 'https://www.drugtopics.com/view/fda-roundup-agency-highlights-from-june-2024', 'title': 'FDA Roundup: Agency Highlights From June 2024', 'source': 'Drug Topics', 'date': 'Jun 28, 2024', 'snippet': 'The FDA approved ensifentrine (Ohtuvayre) for the maintenance treatment of \nchronic obstructive pulmonary disease (COPD) in adult patients,...', 'thumbnail': 'https://serpapi.com/searches/67246523e6862b708a062a8c/images/35ad1d847a7378dcd20c972abb5cc86b0bb58521199acf0bc510ff471e691152.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8896152973175049}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02762838,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2018/03/19/infliximab-biosimilar-for-ankylosing-spondylitis-approved-in-russia/', 'title': 'Ankylosing Spondylitis Therapy Infliximab Biosimilar Approved in Russia', 'source': 'Ankylosing Spondylitis News', 'date': 'Mar 19, 2018', 'snippet': ""Russian regulators have approved the Russian company BIOCAD's infliximab \nbiosimilar as a treatment for rheumatoid arthritis and ankylosing \nspondylitis."", 'thumbnail': 'https://serpapi.com/searches/672462dcdc969fec41eb94a6/images/bdfabd9a47208bd937a11c095524ac5b2ad0c625678e3944916c1db453d65f8e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7923818826675415}",,,,,,,,,,['neutral'],neutral,1
NCT03790670,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/long-term-sargramostim-motor-gains-parkinsons-trial/', 'title': ""Long-term sargramostim led to motor gains in Parkinson's trial –..."", 'source': ""Parkinson's News Today"", 'date': 'May 26, 2023', 'snippet': ""Long-term treatment with sargramostim improved motor function for five \nParkinson's patients in a Phase 1 clinical trial."", 'thumbnail': 'https://serpapi.com/searches/672462e2cb33d002fcff386b/images/3bbc45b2a6db13aab763634e075a7742ec9e9abb3a87501679ac583b8033c989.png', 'sentiment': 'positive', 'sentiment_prob': 0.8332988023757935}",,,,,,,,,,['positive'],positive,1
NCT04576689,"{'position': 1, 'link': 'https://www.macula-retina.es/una-revision-exhaustiva-de-87-programas-clinicos-de-tratamientos-para-la-retina/', 'title': 'Una revisión exhaustiva de 87 programas clínicos de tratamientos para la retina', 'source': 'Asociación Mácula Retina', 'date': 'Mar 22, 2023', 'snippet': '2023: El año de la atrofia geográfica. Una revisión exhaustiva de 87 \nprogramas clínicos de tratamientos para la retina.', 'thumbnail': 'https://serpapi.com/searches/672462e614c31e1ae795a990/images/4e702172ba9e1fe03fe37916b94341b256aea10606399ea800d36d9cafe24f0c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9071215987205505}",,,,,,,,,,['neutral'],neutral,1
NCT00421213,"{'position': 1, 'link': 'https://lymphomanewstoday.com/2019/10/22/phase-2-trial-darinaparsin-ptcl-reaches-complete-patient-enrollment/', 'title': 'Phase 2 Trial Testing Darinaparsin Completes Enrollment of Asian Patients with Relapsed or Refractory PTCL', 'source': 'Lymphoma News Today', 'date': 'Oct 22, 2019', 'snippet': ""A Phase 2 clinical trial assessing Solasia Pharma's lead candidate \ndarinaparsin as a treatment for relapsed or refractory peripheral T-cell..."", 'thumbnail': 'https://serpapi.com/searches/672462e9207c88d3232df4e0/images/357729ab5cbfdebd67f50116da322bae417ba35f4f41f15bff6b41eee282a740.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.911586344242096}",,,,,,,,,,['neutral'],neutral,1
NCT02563002,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2017699', 'title': 'Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Dec 2, 2020', 'snippet': 'Programmed death 1 (PD-1) blockade has clinical benefit in \nmicrosatellite-instability–high (MSI-H) or mismatch-repair–deficient \n(dMMR)...', 'thumbnail': 'https://serpapi.com/searches/6724630d671f3fada070da7b/images/64b152b8a21bb40a91ee87f0d77d70307358680decf273fbd67b257a426e52c9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7808395624160767}","{'position': 2, 'link': 'https://dailynews.ascopubs.org/do/assessing-adjuvant-immunotherapy-msi-h-colorectal-cancer', 'title': 'Assessing Adjuvant Immunotherapy for MSI-H Colorectal Cancer', 'source': 'ASCO Daily News', 'date': 'Dec 26, 2018', 'snippet': 'Immune-checkpoint inhibitors demonstrated impressive clinical activity in \npatients with MSI-H and/or dMMR mCRC after progression on standard \nchemotherapy.', 'thumbnail': 'https://serpapi.com/searches/6724630d671f3fada070da7b/images/64b152b8a21bb40a23a1f09fe8e74c328d0bfc76329fe56518ef59392bc0848d.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5896679759025574}","{'position': 3, 'link': 'https://immuno-oncologynews.com/2020/07/01/fda-approves-keytruda-first-line-therapy-certain-advanced-colorectal-cancers/', 'title': 'FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancers', 'source': 'Immuno-Oncology News', 'date': 'Jul 1, 2020', 'snippet': 'The U.S. Food and Drug Administration (FDA) has approved Keytruda \n(pembrolizumab) as a first-line therapy for people with inoperable or...', 'thumbnail': 'https://serpapi.com/searches/6724630d671f3fada070da7b/images/64b152b8a21bb40af7e66a7f34ceb7e49344e2604e41eff523aae16f2fc98d75.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7994595170021057}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT03895203,"{'position': 1, 'link': 'https://www.hcplive.com/view/philip-mease-bimekizumab-efficacy-ustekinumab-risankizumab-psa-axspa', 'title': 'Philip Mease, MD: Bimekizumab’s Efficacy Over Ustekinumab, Risankizumab in Treating PsA, AxSpA', 'source': 'HCPLive', 'date': 'Aug 29, 2024', 'snippet': 'New research has found that bimekizumab seems to be more efficacious than \nboth ustekinumab and risankizumab in treating psoriatic arthritis (PsA) and \naxial...', 'thumbnail': 'https://serpapi.com/searches/672464b793584c8fed18bb4e/images/b26715c43a4e7e2c139e9abb79119617a33a931f0176de619e1f408ba0431f77.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5907276272773743}",,,,,,,,,,['positive'],positive,1
NCT05033080,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/phase-3-trials-new-triple-combo-cftr-modulator-report-results/', 'title': 'Phase 3 trials of new triple-combo CFTR modulator to report results', 'source': 'Cystic Fibrosis News Today', 'date': 'Jan 10, 2024', 'snippet': 'Results of three global clinical trials of a new triple-combination CFTR \nmodulator therapy for cystic fibrosis (CF) — vanzacaftor, tezacaftor...', 'thumbnail': 'https://serpapi.com/searches/672463657ebde5567687a12e/images/81ff9926e46d0b5fc70d00c724875953713a1854e2c5592abb0574c2fde91b23.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8913163542747498}",,,,,,,,,,['neutral'],neutral,1
NCT01818492,"{'position': 1, 'link': 'https://www.biospace.com/fda-approves-gamifant-emapalumab-lzsg-the-first-and-only-treatment-indicated-for-primary-hemophagocytic-lymphohistiocytosis-hlh', 'title': 'FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH)', 'source': 'BioSpace', 'date': 'Nov 20, 2018', 'snippet': 'The US Food and Drug Administration (FDA) has approved Gamifant \n(emapalumab-lzsg), an interferon gamma (IFNγ) blocking antibody for the \ntreatment of pediatric...', 'thumbnail': 'https://serpapi.com/searches/67246373f6aa53974ffe6f1a/images/6ad2e847d5d4b062a20af43f8f4e9b49227260aa17af604aaa58ee9e97b0c8e2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5843455791473389}",,,,,,,,,,['neutral'],neutral,1
NCT01803867,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/rhigm22-multiple-sclerosis/', 'title': 'rHIgM22 for Multiple Sclerosis', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 23, 2019', 'snippet': 'rHIgM22 is an investigational remyelinating antibody being developed by \nAcorda Therapeutics in collaboration with the Mayo Foundation for Medical \nEducation...', 'thumbnail': 'https://serpapi.com/searches/67246396f9f904fdc2c98332/images/893b5138f14f64ec8e28f535672cc46d6a1cb2ecd77c6f508150336410aba653.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9288907647132874}",,,,,,,,,,['neutral'],neutral,1
NCT02008357,"{'position': 1, 'link': 'https://keck.usc.edu/news/data-from-largest-clinical-trial-of-pre-symptomatic-alzheimers-disease-now-widely-available/', 'title': 'Data from largest clinical trial of pre-symptomatic Alzheimer’s disease now widely available', 'source': 'Keck School of Medicine of USC', 'date': 'Jul 23, 2024', 'snippet': 'Researchers from the Keck School of Medicine of USC, who conducted the \nfirst and largest phase 3 clinical trial of pre-symptomatic...', 'thumbnail': 'https://serpapi.com/searches/672463a4d364b43b71ad04c4/images/f9bf738f0644fa6df6837c7aca6f10a20044174a0bc86adc4ff747253577bddc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9137422442436218}","{'position': 2, 'link': 'https://www.nia.nih.gov/news/alzheimers-trial-screening-data-links-high-amyloid-levels-early-stage-disease', 'title': ""Alzheimer's trial screening data links high amyloid levels with early stage disease"", 'source': 'National Institute on Aging (.gov)', 'date': 'Apr 6, 2020', 'snippet': 'The first paper from the NIH-funded A4 study supports the hypothesis that \nhigher levels of amyloid protein in the brain represent an early...', 'thumbnail': 'https://serpapi.com/searches/672463a4d364b43b71ad04c4/images/f9bf738f0644fa6de8a3f3fd5e21911657a7cb36e867084b12d687954fb40bb1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9027205109596252}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02344004,"{'position': 1, 'link': 'https://bronchiectasisnewstoday.com/2020/10/30/arikayce-approved-europe-for-mac-lung-infections-non-cf-adults/', 'title': 'Arikayce Approved in Europe for MAC Lung Infections in Non-CF Adults', 'source': 'Bronchiectasis News Today', 'date': 'Oct 30, 2020', 'snippet': 'The European Commission has approved Arikayce as a treatment for lung \ninfections caused by MAC bacteria in adults without cystic fibrosis.', 'thumbnail': 'https://serpapi.com/searches/672463a50f2a2c7159533100/images/03cedbd90b70e6fd18f63e7ccbe2a6bfeba54dc8d388afa7070fff30d9ba0464.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7679176926612854}",,,,,,,,,,['neutral'],neutral,1
NCT02953665,"{'position': 1, 'link': 'https://www.nature.com/articles/s41380-022-01792-4', 'title': 'Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease', 'source': 'Nature', 'date': 'Oct 18, 2022', 'snippet': 'Incretin mimetics may act through the restoration of insulin signaling \npathways, inducing further neuroprotective effects.', 'thumbnail': 'https://serpapi.com/searches/672463f0861b9da4bf287ae0/images/887bc0432230a41258becd1d7171b581596c815571ab5f4b594dfc99fc75915a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8566185832023621}",,,,,,,,,,['neutral'],neutral,1
NCT00623740,"{'position': 1, 'link': 'https://www.nature.com/articles/s41390-024-03601-w', 'title': 'Bronchopulmonary dysplasia to predict neurodevelopmental impairment in infants born extremely preterm', 'source': 'Nature', 'date': '1 week ago', 'snippet': 'Bronchopulmonary dysplasia (BPD) in extremely low gestational age neonates \n(ELGANs) was associated with neurodevelopmental impairment (NDI).', 'thumbnail': 'https://serpapi.com/searches/67246403361fd472bcccae88/images/6918bf41613f8e03181f1f53d6776b2977d1e06b4b851cfc70ada24c9d0bd6bf.png', 'sentiment': 'negative', 'sentiment_prob': 0.6061035990715027}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/dmcn.15470', 'title': 'Neurocognitive outcomes at age 5 years after prophylactic hydrocortisone in infants born extremely preterm', 'source': 'Wiley Online Library', 'date': 'Nov 23, 2022', 'snippet': 'Hydrocortisone treatment was significantly associated with a greater chance \nto survive at 5 years of age with a full-scale IQ equal to or greater than \n90...', 'thumbnail': 'https://serpapi.com/searches/67246403361fd472bcccae88/images/6918bf41613f8e038d17a96f625367a80f066d157194a1aa85bac4b7d0887f81.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7614339590072632}","{'position': 3, 'link': 'https://www.nature.com/articles/s41390-023-02785-x', 'title': 'The beneficial effect of prophylactic hydrocortisone treatment in extremely preterm infants improves upon adjustment of the baseline characteristics', 'source': 'Nature', 'date': 'Aug 31, 2023', 'snippet': 'Prophylactic low-dose hydrocortisone (HC) was found to improve survival \nwithout bronchopulmonary dysplasia (BPD) in extremely preterm...', 'thumbnail': 'https://serpapi.com/searches/67246403361fd472bcccae88/images/6918bf41613f8e0325e09bc9ef669be6dd4d5ada6ea91bb4aa8e29b383827d70.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6055935621261597}",,,,,,,,"['negative', 'neutral', 'positive']",negative,0
NCT02464033,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.624568/full', 'title': 'Evolving Antibody Therapies for the Treatment of Type 1 Diabetes', 'source': 'Frontiers', 'date': 'Feb 6, 2024', 'snippet': 'Type 1 diabetes (T1D) is widely considered to be a T cell driven autoimmune \ndisease resulting in reduced insulin production due to \ndysfunction/destruction...', 'thumbnail': 'https://serpapi.com/searches/672465cd5ed3ca94b4679a60/images/ae686c97bb4ef7c3d39f57766a9a478bbf7a30b5c784b4b110a82a9104e216a6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5459937453269958}",,,,,,,,,,['neutral'],neutral,1
NCT03041363,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-30578-z', 'title': 'Maximum dose, safety, tolerability and ketonemia after triheptanoin in glucose transporter type 1 deficiency (G1D)', 'source': 'Nature', 'date': 'Mar 1, 2023', 'snippet': 'Augmentation of anaplerosis, or replenishment of carbon lost during \nintermediary metabolic transitions, is desirable in energy metabolism...', 'thumbnail': 'https://serpapi.com/searches/672465e5707fd3a645c49fd5/images/3e2d27effb0a2a9cc3ad30cc920970020000bc5feae2874a02051256cdc00413.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7260956764221191}",,,,,,,,,,['neutral'],neutral,1
NCT04830397,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/oncology-acute-pharyngitis-clinical-trials/', 'title': 'Pipeline Moves: Premature Phase II end of cancer, acute pharyngitis clinical trials leads to advancement shot drop', 'source': 'Clinical Trials Arena', 'date': '17 May 2022', 'snippet': 'The Clinical Trials Arena team also reviews three separate early-phase \ntrial completions in type 2 diabetes, ophthalmic issues, and cancer.', 'thumbnail': 'https://serpapi.com/searches/672465f456f970aa14165782/images/095f860d6b97cde35253c8987d6e073bf2fadf66078e1f00c0871290150f0db6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.826110303401947}",,,,,,,,,,['neutral'],neutral,1
NCT04658186,"{'position': 1, 'link': 'https://www.nature.com/articles/s41531-023-00552-7', 'title': 'In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease', 'source': 'Nature', 'date': 'Jul 17, 2023', 'snippet': ""Direct targeting of alpha-synuclein (ASYN) has emerged as a \ndisease-modifying strategy for Parkinson's disease and other \nsynucleinopathies..."", 'thumbnail': 'https://serpapi.com/searches/672467401a5b548bf79a89cd/images/0faa4602b735309eb68d66963797d9b75153faaf4fbad100b889442df2e0e745.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8450441360473633}","{'position': 2, 'link': 'https://parkinsonsnewstoday.com/news/mice-ucb0599-parkinsons-lowers-inflammation-improves-coordination/', 'title': 'UCB0599 reduces inflammation, improves coordination in mice', 'source': ""Parkinson's News Today"", 'date': 'Aug 4, 2023', 'snippet': 'The experimental oral therapy UCB0599 — now in clinical trials — improves \nmotor coordination and reduces inflammation and levels of the...', 'thumbnail': 'https://serpapi.com/searches/672467401a5b548bf79a89cd/images/0faa4602b735309e047eebb87c1cd90503518e4f09c70665f93f4100b90bbdeb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6931576728820801}","{'position': 3, 'link': 'https://www.apdaparkinson.org/article/american-academy-of-neurology-2021/', 'title': 'Highlights from the 2021 AAN Annual Meeting', 'source': 'American Parkinson Disease Association', 'date': 'Apr 27, 2021', 'snippet': ""Dr. Gilbert reviews the latest updates in Parkinson's research from the \n2021 American Academy of Neurology Annual Meeting."", 'thumbnail': 'https://serpapi.com/searches/672467401a5b548bf79a89cd/images/0faa4602b735309e6be532bc7555ebbe87049ab85f5f5b829bfe196d2e68bdc4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.791485607624054}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02032277,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/os-and-efs-improved-with-neoadjuvant-chemotherapy-carboplatin-for-locally-advanced-tnbc', 'title': 'OS and EFS Improved With Neoadjuvant Chemotherapy/Carboplatin for Locally Advanced TNBC', 'source': 'Cancer Network', 'date': 'Dec 10, 2022', 'snippet': 'Patients with operable, locally advanced triple-negative breast cancer \nexperienced notable improvements in survival following treatment with...', 'thumbnail': 'https://serpapi.com/searches/672466d013e5d89c18174b81/images/80e42b6c623d130eee01b49a940efaf31b2b4829d1c74380be63f8849f902612.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5052809119224548}",,,,,,,,,,['positive'],positive,1
NCT05667779,"{'position': 1, 'link': 'https://alsnewstoday.com/news/first-healthy-volunteers-dosed-mad-study-testing-als-therapy-qrl-101/', 'title': 'First group of healthy volunteers dosed in QRL-101 MAD study', 'source': 'ALS News Today', 'date': '1 month ago', 'snippet': 'The Phase 1 clinical trial is expected to enroll about 60 participants to \ntest how safe and well tolerated multiple doses of QRL-101 are.', 'thumbnail': 'https://serpapi.com/searches/672466f41b4e346ca366c64b/images/bff8c67cbed7b4472c703b9bb95dacbb97ff4082935aafd644cf6f6520a35d01.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7422958612442017}","{'position': 2, 'link': 'https://alsnewstoday.com/news/first-participants-dosed-phase-1-trial-als-therapy-qrl-101/', 'title': 'Dosing Starts in First-in-human Phase 1 Trial of QRL-101 for ALS', 'source': 'ALS News Today', 'date': 'Jan 11, 2023', 'snippet': 'A Phase 1 clinical trial has begun dosing healthy volunteers to investigate \nQRL-101, an oral treatment candidate for ALS.', 'thumbnail': 'https://serpapi.com/searches/672466f41b4e346ca366c64b/images/bff8c67cbed7b44728bc0c09111ffd0b43e9fa1fc3a5a5762e72f5bb54d43069.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9149633049964905}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04777201,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-52942-3', 'title': 'Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis | Scientific Reports', 'source': 'Nature', 'date': 'Jan 30, 2024', 'snippet': 'We conducted a systematic review and meta-analysis to evaluate the visual, \nanatomical, and safety outcomes of the intravitreal faricimab,...', 'thumbnail': 'https://serpapi.com/searches/67246722f7adbf72b3a17a62/images/8dfad76682d55f79d6920b31b2a9f4bd5e2f41e6492d4c49ed648b6922931b32.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8612781763076782}","{'position': 2, 'link': 'https://www.globenewswire.com/news-release/2024/07/30/2920702/0/en/European-Commission-approves-Roche-s-Vabysmo-for-treatment-of-retinal-vein-occlusion-RVO.html', 'title': 'European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)', 'source': 'GlobeNewswire', 'date': 'Jul 30, 2024', 'snippet': 'Approval is based on data from two Phase III studies in branch and central \nretinal vein occlusion (RVO) showing early and sustained vision...', 'thumbnail': 'https://serpapi.com/searches/67246722f7adbf72b3a17a62/images/8dfad76682d55f79737d26c4b4a8092885828c7d7d153759eecbc6e0925e08c5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6009171605110168}","{'position': 3, 'link': 'https://www.stocktitan.net/news/RHHBY/roche-s-vabysmo-improved-vision-in-underrepresented-populations-with-y3hygys486ou.html', 'title': 'Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study', 'source': 'Stock Titan', 'date': '2 weeks ago', 'snippet': 'Roche announced positive one-year results from the ELEVATUM study, \nevaluating Vabysmo® (faricimab) for diabetic macular edema (DME) in...', 'thumbnail': 'https://serpapi.com/searches/67246722f7adbf72b3a17a62/images/8dfad76682d55f7999efbff0664e08bb07ed5af18c5b9eccd76e3218533aa779.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7804692983627319}","{'position': 4, 'link': 'https://www.globenewswire.com/de/news-release/2024/07/17/2914761/0/en/Roche-s-Vabysmo-showed-extended-durability-continued-efficacy-and-a-consistent-safety-profile-in-long-term-diabetic-macular-edema-DME-study.html', 'title': 'Roche’s Vabysmo showed extended durability, continued', 'source': 'GlobeNewswire', 'date': 'Jul 17, 2024', 'snippet': 'More than 90% of patients had absence of DME after four years in a \npre-specified exploratory endpointPeople treated with Vabysmo sustained...', 'thumbnail': 'https://serpapi.com/searches/67246722f7adbf72b3a17a62/images/8dfad76682d55f7974b92db3d4d1a88ea668846e6267fb5d506b0424b956096f.png', 'sentiment': 'positive', 'sentiment_prob': 0.5305542945861816}",,,,,,,"['neutral', 'neutral', 'positive', 'positive']",neutral,1
NCT03249103,"{'position': 1, 'link': 'https://fibromyalgianewstoday.com/2019/10/30/non-opioid-therapy-nyx-2925-shows-potential-treat-fibromyalgia-blocks-pain-processing-biomarkers/', 'title': 'NYX-2925 Non-Opioid Therapy Shows Potential to Treat Fibromyalgia, Study Shows', 'source': 'Fibromyalgia News Today', 'date': 'Oct 30, 2019', 'snippet': 'Treatment with the new, non-opioid therapy NYX-2925 can block \nhypersensitivity to pain in patients with fibromyalgia, results from a...', 'thumbnail': 'https://serpapi.com/searches/67246733c76a222c5beb883c/images/c42bad2f47dd0d78a97d779aac50c3be5876b3c85ca20a9e2490864b9d5724b3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6133267879486084}",,,,,,,,,,['neutral'],neutral,1
NCT03361865,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00423/full', 'title': 'Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers', 'source': 'Frontiers', 'date': 'Oct 3, 2018', 'snippet': 'This minireview will primarily focus on recent clinical research of \nEpacadostat (E) and other IDO1 inhibitors and discuss available data and \nfuture...', 'thumbnail': 'https://serpapi.com/searches/6724663c52a04e033204445c/images/3f8b3ffd347359221de5f73bf33a2ce508c16c515c2b3e28379fa65c622d5783.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9207820296287537}",,,,,,,,,,['neutral'],neutral,1
NCT03533114,"{'position': 1, 'link': 'https://www.psychiatryadvisor.com/news/idiopathic-hypersomnia-treated-with-lxb-weight-loss-equal-to-or-greater-than-5-is-common-in-more-than-25-of-patients/', 'title': 'Weight Changes with Lower-Sodium Oxybate in Idiopathic Hypersomnia', 'source': 'Psychiatry Advisor', 'date': 'Jun 6, 2022', 'snippet': 'Adults with idiopathic hypersomnia treated with LXB, weight loss equal to \nor greater than 5% is common in more than 25% of patients.', 'thumbnail': 'https://serpapi.com/searches/6724663d2fab62d9c7da41a8/images/b364fa305adf50ffb68b4cd1f6a663d8f3a15a9912850d0c21c4a9220b0d56c0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7807514667510986}",,,,,,,,,,['neutral'],neutral,1
NCT02752074,"{'position': 1, 'link': 'https://www.genengnews.com/news/incyte-merck-co-halt-phase-iii-trial-after-epacadostat-keytruda-combination-fails-in-melanoma/', 'title': 'Incyte, Merck & Co. Halt Phase III Trial After Epacadostat/Keytruda Combination Fails in Melanoma', 'source': 'Genetic Engineering and Biotechnology News', 'date': 'Apr 6, 2018', 'snippet': ""A Phase III trial assessing the combination of Incyte's lead cancer \nimmunotherapy candidate epacadostat (INCB024360) and Merck & Co."", 'thumbnail': 'https://serpapi.com/searches/6724665f1f3d4bc2ce222446/images/6dba32f5a7ceeb94687cd054486a659e13f139b204d62c3c9189f924ebc911c0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5240946412086487}",,,,,,,,,,['neutral'],neutral,1
NCT03594110,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2204233', 'title': 'Empagliflozin in Patients with Chronic Kidney Disease', 'source': 'The New England Journal of Medicine', 'date': 'Nov 4, 2022', 'snippet': 'The effects of empagliflozin in patients with chronic kidney disease who \nare at risk for disease progression are not well understood. The \nEMPA-KIDNEY trial...', 'thumbnail': 'https://serpapi.com/searches/6724669b7a12fda58f0b6304/images/d1622d540791aeafe4b05c3a7e87df7ca652e0dd0206d8e61c2697d08206a0c4.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5813755393028259}","{'position': 2, 'link': 'https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00322-4/fulltext', 'title': 'Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial', 'source': 'The Lancet', 'date': 'Dec 4, 2023', 'snippet': 'The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the \nprimary composite outcome of kidney disease progression or cardiovascular \ndeath in...', 'thumbnail': 'https://serpapi.com/searches/6724669b7a12fda58f0b6304/images/d1622d540791aeafbb9a1003d0c72e6c48cb75fbf74ad9dd64d1ea9c0d58defb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8561785817146301}","{'position': 3, 'link': 'https://www.drugtopics.com/view/fda-approves-empagliflozin-for-use-in-ckd', 'title': 'FDA Approves Empagliflozin for Use in CKD', 'source': 'Drug Topics', 'date': 'Sep 22, 2023', 'snippet': 'This is the fourth approval for the drug stemming from the EMPOWER clinical \ntrial program.', 'thumbnail': 'https://serpapi.com/searches/6724669b7a12fda58f0b6304/images/d1622d540791aeaf510b3032fef5a24ca657e90e8476153c14ab6dd5f084a08a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6430405974388123}",,,,,,,,"['negative', 'neutral', 'positive']",negative,0
NCT04033068,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-022-00464-2', 'title': 'Measles-based Zika vaccine induces long-term immunity and requires NS1 antibodies to protect the female reproductive tract', 'source': 'Nature', 'date': 'Apr 19, 2022', 'snippet': 'Zika virus (ZIKV) can cause devastating effects in the unborn fetus of \npregnant women. To develop a candidate vaccine that can protect human...', 'thumbnail': 'https://serpapi.com/searches/672466bf460b15e9a128e9bc/images/29c60fe06dcb5c644eeb2965854f8085b0f81ed431cbd66fc0923abf23b63e01.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6098784804344177}",,,,,,,,,,['negative'],negative,0
NCT03451162,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-44533-z', 'title': 'The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results', 'source': 'Nature', 'date': 'Jan 11, 2024', 'snippet': 'Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer \ninclude trastuzumab emtansine and trastuzumab deruxtecan.', 'thumbnail': 'https://serpapi.com/searches/6724677307c7be524e67fb80/images/85387262b8c404b7cd324828893f77bf52e6e82db06d4bbd812a003bf302babf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8865765333175659}",,,,,,,,,,['neutral'],neutral,1
NCT00195702,"{'position': 1, 'link': 'https://www.rheumatologyadvisor.com/news/number-of-prior-dmards-disease-duration-affect-adalimumab-efficacy-in-ra/', 'title': 'Number of Prior DMARDs, Disease Duration Affect Adalimumab Efficacy in RA', 'source': 'Rheumatology Advisor', 'date': 'Sep 11, 2019', 'snippet': 'Disease duration and the number of prior disease-modifying antirheumatic \ndrugs (DMARDs) limit the potential efficacy of adalimumab therapy.', 'thumbnail': 'https://serpapi.com/searches/6724677d7ca6b3f58b10b70c/images/7429fc039783de09f4facf6d10626fe2cb41854956a3bd19a146bb674acd11d4.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5859185457229614}",,,,,,,,,,['negative'],negative,0
NCT04588298,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-023-00523-4', 'title': 'An emerging generation of endocrine therapies in breast cancer: a clinical perspective | npj Breast Cancer', 'source': 'Nature', 'date': 'Apr 5, 2023', 'snippet': 'Anti-estrogen therapy is a key component of the treatment of both early and \nadvanced-stage hormone receptor (HR)-positive breast cancer.', 'thumbnail': 'https://serpapi.com/searches/6724678d0f2a2c7159533216/images/a7e630067cd4ad30fc5a54ff9a6dce419a8f218937d970e1c5c7ce7f7119e227.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8845224976539612}",,,,,,,,,,['neutral'],neutral,1
NCT03728556,"{'position': 1, 'link': 'https://www.europeanpharmaceuticalreview.com/news/155506/anti-pd-l1-monoclonal-antibody-shows-promise-in-lung-cancer-patient/', 'title': 'Anti-PD-L1 monoclonal antibody shows promise in lung cancer patients', 'source': 'European Pharmaceutical Review', 'date': 'May 28, 2021', 'snippet': 'In a Phase III trial sugemalimab meaningfully improved progression free \nsurvival in patients with stage III non-small cell lung cancer (NSCLC).', 'thumbnail': 'https://serpapi.com/searches/672467c6fc40bf9ccfe06230/images/4ef5d3477a74c6e6f1427abe4315a0048488eb6207c00e7d98e94e82a7ec0d4b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.804133951663971}",,,,,,,,,,['positive'],positive,1
NCT04433585,"{'position': 1, 'link': 'https://lupusnewstoday.com/news/nktr-358-reduces-sle-disease-activity-fails-island-primary-goal/', 'title': 'NKTR-358 reduces SLE disease activity; fails at ISLAND primary goal', 'source': 'Lupus News Today', 'date': 'Mar 2, 2023', 'snippet': 'A middle dose of rezpegaldesleukin, an experimental medicine being \ndeveloped by Nektar Therapeutics, led to clinically meaningful gains in \nmeasures of disease...', 'thumbnail': 'https://serpapi.com/searches/672467c98cf8ae01ba365256/images/a26e19da1269d69ac303edef6caa977d46c5a7a7b202efb98b3e45ad4f98ea93.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7214007377624512}",,,,,,,,,,['neutral'],neutral,1
NCT05842213,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2024/04/24/2868337/0/en/Alvotech-Announces-Topline-Results-from-a-Confirmatory-Clinical-Study-for-AVT05-a-Proposed-Biosimilar-for-Simponi-golimumab.html', 'title': 'Alvotech Announces Topline Results from a Confirmatory', 'source': 'GlobeNewswire', 'date': 'Apr 24, 2024', 'snippet': 'The confirmatory clinical safety and efficacy study for AVT05, biosimilar \ncandidate to Simponi® and Simponi Aria® (golimumab),...', 'thumbnail': 'https://serpapi.com/searches/672467f648c97d44855d28e2/images/4bd51a20672829f14de04bc003265c6c99bc0ad2df7e2f8c192dd31c8d0070da.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7174261212348938}","{'position': 2, 'link': 'https://ankylosingspondylitisnews.com/2023/12/04/in-early-trial-avt05-shows-similar-pharmacological-profile-to-simponi/', 'title': 'In early trial, AVT05 shows similar pharmacological profile to Simponi', 'source': 'Ankylosing Spondylitis News', 'date': 'Dec 4, 2023', 'snippet': ""AVT05, Alvotech's biosimilar candidate to treat ankylosing spondylitis, \nshowed a similar pharmacological profile to Simponi (golimumab)."", 'thumbnail': 'https://serpapi.com/searches/672467f648c97d44855d28e2/images/4bd51a20672829f10d903b8c01a6798434b5dc582331fca0b7f44fbe8f538176.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8694635629653931}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02162303,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.060308', 'title': 'Noninvasive Plaque Imaging to Accelerate Coronary Artery Disease Drug Development | Circulation', 'source': 'American Heart Association Journals', 'date': 'Nov 28, 2022', 'snippet': 'Coronary artery disease (CAD) remains the leading cause of adult mortality \nglobally. Targeting known modifiable risk factors has had...', 'thumbnail': 'https://serpapi.com/searches/672468035f97781090a129f3/images/9d84263085deb8a61a832c9d782c73cac608586bb34a5ce1b3ead134b1197cd4.png', 'sentiment': 'negative', 'sentiment_prob': 0.6367948055267334}",,,,,,,,,,['negative'],negative,0
NCT05160415,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/edg-5506-helping-preserve-muscles-becker-md-phase-1-trial/', 'title': 'EDG-5506 helping to preserve muscles in Becker MD Phase 1 trial |...', 'source': 'Muscular Dystrophy News', 'date': 'Jun 29, 2023', 'snippet': 'Most men with Becker muscular dystrophy in Phase 1 ARCH trial show stable \nor improved motor function after one year of EDG-5506 treatment.', 'thumbnail': 'https://serpapi.com/searches/6724680bd771bd3d1c3e32fa/images/9d12c5ebb893bf4d1af5d81aebfda7f0ea7c2cac8c75462c0112b79c726021ce.png', 'sentiment': 'positive', 'sentiment_prob': 0.6553616523742676}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20230626317214/en/Edgewise-Therapeutics-Announces-Positive-12-Month-Topline-Results-from-the-ARCH-Open-Label-Study-of-EDG-5506-in-Adults-with-Becker-Muscular-Dystrophy-BMD', 'title': 'Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)', 'source': 'Business Wire', 'date': 'Jun 26, 2023', 'snippet': 'Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage \nbiopharmaceutical company focused on developing orally bioavailable, \ntargeted,...', 'thumbnail': 'https://serpapi.com/searches/6724680bd771bd3d1c3e32fa/images/9d12c5ebb893bf4d365db8c63df440c174a357612376b3fe8a14e88484e3e030.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5894675850868225}","{'position': 3, 'link': 'https://musculardystrophynews.com/news/2-year-edg-5506-treatment-helps-preserve-motor-function-bmd/', 'title': '2-year EDG-5506 treatment helps preserve motor function in BMD', 'source': 'Muscular Dystrophy News', 'date': 'Apr 18, 2024', 'snippet': 'Oral treatment with EDG-5506 continued to stabilize muscle function after \ntwo years in men with Becker MD taking part in a Phase 1 trial.', 'thumbnail': 'https://serpapi.com/searches/6724680bd771bd3d1c3e32fa/images/9d12c5ebb893bf4df190dfc3f4c715829ae15cd9566f099dd0af39b4b71795ba.png', 'sentiment': 'neutral', 'sentiment_prob': 0.497831255197525}","{'position': 4, 'link': 'https://musculardystrophynews.com/news/edg-5506-treatment-shows-promise-becker-md-clinical-trial/', 'title': 'EDG-5506 Treatment Shows Promise in Becker MD Clinical Trial |...', 'source': 'Muscular Dystrophy News', 'date': 'Oct 20, 2022', 'snippet': 'Experimental treatment EDG-5506 continues to lower Becker MD-associated \nmuscle damage and improve motor function in a Phase 1 clinical...', 'thumbnail': 'https://serpapi.com/searches/6724680bd771bd3d1c3e32fa/images/9d12c5ebb893bf4d85d826bb4e1b1ff503ab52b3b716644ab25afaca3f7e3b54.png', 'sentiment': 'positive', 'sentiment_prob': 0.6245688796043396}","{'position': 5, 'link': 'https://musculardystrophynews.com/news/top-10-muscular-dystrophy-stories-2023/', 'title': 'Top 10 muscular dystrophy stories of 2023', 'source': 'Muscular Dystrophy News', 'date': 'Jan 2, 2024', 'snippet': 'Throughout 2023, Muscular Dystrophy News Today worked diligently to cover \nnew scientific research, treatment developments, and clinical...', 'thumbnail': 'https://serpapi.com/searches/6724680bd771bd3d1c3e32fa/images/9d12c5ebb893bf4dca87f3007d244d28151aafcb82af9e9e590ab4d6e974bcf1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5096873641014099}",,,,,,"['positive', 'neutral', 'neutral', 'positive', 'neutral']",neutral,1
NCT04129164,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-024-03009-3', 'title': 'CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial', 'source': 'Nature', 'date': 'Jun 5, 2024', 'snippet': ""Sjögren's disease (SjD) is a chronic, systemic autoimmune disease with no \napproved disease-modifying therapies. Dazodalibep (DAZ), a novel..."", 'thumbnail': 'https://serpapi.com/searches/672468495235f64ee067fe04/images/74687fc9f40950cecff16a733a340617eaf4fbb31ce40a44036880d684fde546.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7201964259147644}","{'position': 2, 'link': 'https://sjogrenssyndromenews.com/news/dazodalibep-clinical-trial-sjogrens-syndrome-meets-goal/', 'title': ""Dazodalibep Clinical Trial for Sjogren's Syndrome Meets New Goal |..."", 'source': ""Sjogren's Syndrome News"", 'date': 'Jan 20, 2023', 'snippet': ""Dazodalibep significantly eased symptoms in a second group of patients \nenrolled in a clinical trial for Sjogren's syndrome."", 'thumbnail': 'https://serpapi.com/searches/672468495235f64ee067fe04/images/74687fc9f40950cef1af2cf0033b2733848da9c14b6e20faa1f594193f8b3e57.png', 'sentiment': 'positive', 'sentiment_prob': 0.7016016840934753}","{'position': 3, 'link': 'https://sjogrenssyndromenews.com/news/dazodalibep-eases-sjogrens-syndrome-symptoms-phase-2-trial/', 'title': 'Dazodalibep seen to ease Sjögren’s syndrome symptoms in Phase 2 trial', 'source': ""Sjogren's Syndrome News"", 'date': 'Jun 6, 2023', 'snippet': ""Dazodalibep, Horizon's experimental therapy for Sjögren's syndrome, safely \nand effectively eased symptoms in two groups of patients in..."", 'thumbnail': 'https://serpapi.com/searches/672468495235f64ee067fe04/images/74687fc9f40950cef2bb7c56913028b7433ea93e58dd0e8f1a8c69d9221948ff.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6257803440093994}","{'position': 4, 'link': 'https://sjogrenssyndromenews.com/news/dazodalibep-eases-moderate-high-disease-activity-sjogrens-patients/', 'title': 'Dazodalibep Eases Moderate-to-high Disease Activity in Sjögren’s Patients: Trial Data', 'source': ""Sjogren's Syndrome News"", 'date': 'Sep 13, 2022', 'snippet': ""Dazodalibep markedly eased disease activity in Sjögren's syndrome patients \nwho live with moderate-to-high systemic disease activity."", 'thumbnail': 'https://serpapi.com/searches/672468495235f64ee067fe04/images/74687fc9f40950ce3b4ee0a34fd5d9c690902ea691f4bf09374a95f7258c16f2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7644002437591553}",,,,,,,"['neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT00109681,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S075333222400163X', 'title': 'Comprehensive review of potential drugs with anti-pulmonary fibrosis properties', 'source': 'ScienceDirect.com', 'date': 'Feb 23, 2024', 'snippet': 'This review aims to provide an updated overview of current and future drug \ninterventions for idiopathic pulmonary fibrosis, and to summarize possible \ntargets', 'thumbnail': 'https://serpapi.com/searches/67246859d403e1b040c49182/images/fcde21c8c6292b534e1c4fa16ff916d14c77d90e6a0c68535e3bba4e301270b4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8887006640434265}",,,,,,,,,,['neutral'],neutral,1
NCT04678921,"{'position': 1, 'link': 'https://www.nature.com/articles/s41419-024-06500-4', 'title': 'Blockade of C5aR1 resets M1 via gut microbiota-mediated PFKM stabilization in a TLR5-dependent manner', 'source': 'Nature', 'date': 'Feb 8, 2024', 'snippet': 'Our study suggested that C5aR1 inhibition reduced CRC growth via resetting \nM1 by AKT2 activation-mediated PFKM stabilization in a TLR5-dependent \nmanner.', 'thumbnail': 'https://serpapi.com/searches/67246860f410445e4dd810f8/images/cf354b95c985ecad8ed5b6cad95ae37fa2349b2f2be1ea98e7933ba26b33573c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8999679088592529}",,,,,,,,,,['neutral'],neutral,1
NCT04129294,"{'position': 1, 'link': 'https://musculardystrophynews.com/news/fda-clears-ns-pharma-phase-2-dmd-study-exon-44-skipping-therapy/', 'title': 'FDA clears Phase 2 study of exon skipping therapy for DMD', 'source': 'Muscular Dystrophy News', 'date': 'Apr 18, 2023', 'snippet': 'Having reached an agreement with the U.S. Food and Drug Administration \n(FDA), NS Pharma will be launching a Phase 2 clinical trial to...', 'thumbnail': 'https://serpapi.com/searches/6724689cd0c983b24b1ff907/images/232ba13dac20cf1fac4abec24e9745ed406f14c70a2b9f8c5220eb4ecebc810f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.824338436126709}",,,,,,,,,,['neutral'],neutral,1
NCT01611558,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1292166/full', 'title': 'Limitations and potential of immunotherapy in ovarian cancer', 'source': 'Frontiers', 'date': 'Feb 7, 2024', 'snippet': 'In this perspective, we discuss our view of the current state of some of \nthe combination immunotherapies in the treatment of advanced OC, their \nlimitations,...', 'thumbnail': 'https://serpapi.com/searches/672468a7bb55ffb4294ab331/images/b6f2542301a17495d5fddc8241b94ff488bf52fcbd841f9f9bde1879285e22ee.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8876572847366333}",,,,,,,,,,['neutral'],neutral,1
NCT04064242,"{'position': 1, 'link': 'https://sarcoidosisnews.com/news/phase-2-trial-cmk389-enrolling-adults-with-pulmonary-sarcoidosis/', 'title': 'Pulmonary Sarcoidosis Trial Enrolling to Study Safety, Efficacy of CMK389', 'source': 'Sarcoidosis News', 'date': 'Nov 19, 2021', 'snippet': 'A Phase 2 clinical trial is recruiting adults with chronic pulmonary \nsarcoidosis to investigate the safety and therapeutic potential of CMK389 \nin improving...', 'thumbnail': 'https://serpapi.com/searches/672468a80e6db3be0410f333/images/69c675505942f051bf2934709edc0ddafee9075d1f6debca0cee93b913ff8729.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8593652844429016}",,,,,,,,,,['neutral'],neutral,1
NCT03814720,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01660-8', 'title': 'Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial', 'source': 'Nature', 'date': 'Feb 3, 2022', 'snippet': 'Currently, licensed seasonal influenza vaccines display variable vaccine \neffectiveness, and there remains a need for novel vaccine platforms...', 'thumbnail': 'https://serpapi.com/searches/672468c1a882785909afb369/images/020e6b56bdbd04aab1ea6d448d63d1b326ffb355aa36035146468e15ea6d01fd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8805010914802551}","{'position': 2, 'link': 'https://www.sciencedirect.com/science/article/abs/pii/S014181302400062X', 'title': 'Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice', 'source': 'ScienceDirect.com', 'date': 'Jan 7, 2024', 'snippet': 'Developed an intranasal multiepitope influenza nanovaccine using the \nHelicobacter pylori ferritin nanoplatform. •. The Helicobacter pylori \nferritin is a...', 'thumbnail': 'https://serpapi.com/searches/672468c1a882785909afb369/images/020e6b56bdbd04aa8d4b6c12068571628d73b23730901983441ba6dfa107128d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7409680485725403}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00504595,"{'position': 1, 'link': 'https://www.nature.com/articles/s41368-019-0068-8', 'title': 'Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review', 'source': 'Nature', 'date': 'Jan 2, 2020', 'snippet': 'Interleukin(IL)-1β, a pro-inflammatory cytokine, was elevated and \nparticipates in periodontitis. Not only the link between IL-1β and...', 'thumbnail': 'https://serpapi.com/searches/672468cad169156939375f9a/images/c9cc3a9f476ba08b005b11460621b0d08435cf810e797ed59ece98afc55862d5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8331045508384705}",,,,,,,,,,['neutral'],neutral,1
NCT01473472,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1506273', 'title': 'On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection', 'source': 'The New England Journal of Medicine', 'date': 'Dec 3, 2015', 'snippet': 'We conducted a double-blind, randomized trial of antiretroviral therapy for \npreexposure HIV-1 prophylaxis among men who have unprotected anal sex with \nmen.', 'thumbnail': 'https://serpapi.com/searches/67246927ecf150976cd21ca5/images/a7f855de68ba5598d119d7b02e74f1e413533f3690852649cc62165bc9cf5cc0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7319141626358032}",,,,,,,,,,['neutral'],neutral,1
NCT04460885,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/novo-nordisks-once-weekly-insulin-supersedes-its-once-daily-counterparts/', 'title': 'Novo Nordisk’s once-weekly insulin supersedes its once-daily counterparts', 'source': 'Clinical Trials Arena', 'date': 'Jun 26, 2023', 'snippet': ""Phase IIIa clinical trials reported more patients achieving target HbA1c \nwith Novo Nordisk's insulin compared to its once-daily..."", 'thumbnail': 'https://serpapi.com/searches/6724693790adce1ab35dbc5b/images/1ed3a3ee02abf348dff14cca6c67f98180cc1db91a2e0ba1c8a2aa12ab24bd68.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7205810546875}",,,,,,,,,,['neutral'],neutral,1
NCT02628574,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2018/08/10/collaboration-tests-trx518-bavencio-combo-clinical-trial-solid-tumors/', 'title': 'Collaboration Tests TRX518-Bavencio Combo in Clinical Trial of Solid Tumors', 'source': 'Ovarian Cancer News Today', 'date': '١٠\u200f/٠٨\u200f/٢٠١٨', 'snippet': 'Leap Therapeutics is launching a Phase 1/2 clinical trial to test its \nimmunotherapy TRX518 in combination with Bavencio (avelumab) and \nchemotherapy in advanced...', 'thumbnail': 'https://serpapi.com/searches/67246c4e2da983beb341b46d/images/a553a6d8196c83bf96566712fa13c0594059379abbbaf5d88010912af534d145.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8717562556266785}",,,,,,,,,,['neutral'],neutral,1
NCT00699582,"{'position': 1, 'link': 'https://dravetsyndromenews.com/news/fda-approves-fycompa-focal-seizures-children-ages-4-older/', 'title': 'FDA Approves Fycompa to Treat Focal Seizures in Children 4 and Older', 'source': 'Dravet Syndrome News', 'date': 'Oct 4, 2018', 'snippet': 'The U.S. Food and Drug Administration approved Fycompa (perampanel) – alone \nor as an add-on therapy – for focal seizures in children ages 4...', 'thumbnail': 'https://serpapi.com/searches/67246c65310300dc7f4f051c/images/77ad2ea4e70302b18259487088346bb68228321443c710ddb01ed1a960cc72e3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7756399512290955}","{'position': 2, 'link': 'https://dravetsyndromenews.com/news/fycompa-effectively-reduces-seizure-rate-refractrory-epilepsy-dravet-syndrome/', 'title': 'Add-on Fycompa Effectively Reduces Seizure Rate in Real-world Study', 'source': 'Dravet Syndrome News', 'date': 'Jul 12, 2018', 'snippet': 'Add-on therapy with Fycompa (perampanel) is safe and effective in \npreventing seizures in adolescents with treatment-resistant refractory \nepilepsy.', 'thumbnail': 'https://serpapi.com/searches/67246c65310300dc7f4f051c/images/77ad2ea4e70302b189fabe525e1766c8658688ef01d5f90ee70e336f3a38d6fb.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6034088730812073}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03747497,"{'position': 1, 'link': 'https://www.nature.com/articles/s41429-020-0291-8', 'title': 'Antibiotics in the clinical pipeline in October 2019 - The Journal of Antibiotics', 'source': 'Nature', 'date': 'Mar 10, 2020', 'snippet': 'The development of new and effective antibacterial drugs to treat \nmulti-drug resistant (MDR) bacteria, especially Gram-negative (G−ve)...', 'thumbnail': 'https://serpapi.com/searches/67246c80c76a3a3c4c1e0e14/images/4b4b2f272bae9b786a0476d730ecce883f8425dba837ab5db040dfc1f23f7eca.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7636564373970032}",,,,,,,,,,['neutral'],neutral,1
NCT03122262,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1902824', 'title': 'Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV', 'source': 'The New England Journal of Medicine', 'date': 'Jul 24, 2019', 'snippet': 'Two drugs under consideration for inclusion in antiretroviral therapy (ART) \nregimens for human immunodeficiency virus (HIV) infection are...', 'thumbnail': 'https://serpapi.com/searches/67246c9371c62bd4fa54ddc7/images/9a1c69028d9f49c4c49f84bb39fccf4f722ece00d469421f63286022d08f7274.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8954343199729919}","{'position': 2, 'link': 'https://www.nature.com/articles/s41467-020-19801-x', 'title': 'Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase', 'source': 'Nature', 'date': 'Dec 1, 2020', 'snippet': 'NNRTI resistance prior to treatment is associated with long-term failure of \nintegrase inhibitor-containing first-line regimens, and portends high rates \nof...', 'thumbnail': 'https://serpapi.com/searches/67246c9371c62bd4fa54ddc7/images/9a1c69028d9f49c41faf9ec2c69a2b4474dc5db486c7a69dd48381f9b1870e35.png', 'sentiment': 'negative', 'sentiment_prob': 0.717469334602356}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT03019185,"{'position': 1, 'link': 'https://alportsyndromenews.com/2017/05/12/alport-patients-chronic-kidney-disease-benefit-reata-bardoxolone-methyl-therapy/', 'title': ""Alport Patients with Chronic Kidney Disease May Benefit from Reata's Bardoxolone Methyl Therapy"", 'source': 'Alport Syndrome News', 'date': 'May 12, 2017', 'snippet': ""Read about Reata Pharmaceutical's ongoing CARDINAL trial to assess the \nefficacy of bardoxolone methyl in Alport patients with chronic kidney..."", 'thumbnail': 'https://serpapi.com/searches/67246cad7a12fda58f0b64c2/images/001c123cb1264ec8c8219fe32cc3dbd09bffb288e90d27bd1f16a574c988ac3c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8546569347381592}","{'position': 2, 'link': 'https://alportsyndromenews.com/2017/11/06/alport-syndrome-kidney-function-improved-bardoxolone-methyl-cardinal-study-finds/', 'title': 'Alport Patients See Improved Kidney Function with Bardoxolone Methyl', 'source': 'Alport Syndrome News', 'date': 'Nov 6, 2017', 'snippet': 'Interim results from the Phase 2/3 CARDINAL trial show that using \nbardoxolone methyl can improve kidney function in patients with Alport \nsyndrome.', 'thumbnail': 'https://serpapi.com/searches/67246cad7a12fda58f0b64c2/images/001c123cb1264ec83ae72eb0e28d2bdadffe964faf96f61c5ca1fb9dbf602595.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6310074925422668}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT02390843,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332221006405', 'title': 'The potential use of simvastatin for cancer treatment: A review', 'source': 'ScienceDirect.com', 'date': 'Jul 10, 2021', 'snippet': 'In this review, we present an overview of the most important studies \nconducted from 2015 to date on the use of simvastatin in cancer therapy.', 'thumbnail': 'https://serpapi.com/searches/67246cb2c024d1098b47b46e/images/3ca2c8a5f76f41e977c9ea6ec11f2628d938a19cb0d0737ff97d36e1ee6d63d4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7601056694984436}",,,,,,,,,,['neutral'],neutral,1
NCT03998683,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2023/9967747', 'title': 'A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS)', 'source': 'Wiley Online Library', 'date': 'Nov 1, 2023', 'snippet': 'Introduction. Despite the availability of effective biologic therapies for \npsoriasis, there is no gold-standard treatment for nonpustular...', 'thumbnail': 'https://serpapi.com/searches/67246a382fab62d9fdc4572a/images/e2d1987d1a6d747b524fb13883bf562ba448920ee2bb77ef56c228acd938d34f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7495885491371155}",,,,,,,,,,['neutral'],neutral,1
NCT05093530,"{'position': 1, 'link': 'https://copdnewstoday.com/news/neumifil-nasal-spray-phase-2-trial-new-investments-pneumagen/', 'title': 'Neumifil nasal spray heads to COPD Phase 2 trial with new investments', 'source': 'COPD News Today', 'date': 'Jun 5, 2023', 'snippet': 'Pneumagen has secured £8 million (nearly $10 million) in investments to \nsupport the clinical development of its nasal spray, called Neumifil, for \nthe...', 'thumbnail': 'https://serpapi.com/searches/67246b61d11195d39ee01425/images/8c38a5fbfa3ec22fa285de98de5bc3acbfb945af9004cdd0f03ac3a2b7d77f50.png', 'sentiment': 'neutral', 'sentiment_prob': 0.530219554901123}",,,,,,,,,,['neutral'],neutral,1
NCT02948959,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2106567', 'title': 'Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma', 'source': 'The New England Journal of Medicine', 'date': 'Dec 8, 2021', 'snippet': 'Children with moderate-to-severe asthma continue to have disease \ncomplications despite the receipt of standard-of-care therapy.', 'thumbnail': 'https://serpapi.com/searches/67246b6e8b84c4690f807e39/images/d9c9dede5ef7baefa3b1750f36b71f04f928b9c88f88ee03a67f320c859c0e07.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6032383441925049}","{'position': 2, 'link': 'https://www.dovepress.com/impact-of-exacerbation-history-on-dupilumab-efficacy-in-children-with--peer-reviewed-fulltext-article-JAA', 'title': 'Dupilumab efficacy in children with asthma | JAA', 'source': 'Dove Medical Press', 'date': 'Mar 5, 2024', 'snippet': 'Dupilumab consistently reduced the risk of asthma exacerbations, improved \nlung function, and reduced ACQ-7-IA scores, regardless of exacerbation \nhistory.', 'thumbnail': 'https://serpapi.com/searches/67246b6e8b84c4690f807e39/images/d9c9dede5ef7baeff2aa8550e8e7d73c89d4bf9938126224fbea0d00193e6e7d.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5388872623443604}","{'position': 3, 'link': 'https://www.empr.com/home/news/dupixent-asthma-indication-expanded-to-include-younger-patients/', 'title': 'Dupixent Asthma Indication Expanded to Include Younger Patients', 'source': 'Medical Professionals Reference', 'date': 'Oct 22, 2021', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of \nDupixent (dupilumab) to include add-on maintenance treatment of patients 6 \nto 11 years of...', 'thumbnail': 'https://serpapi.com/searches/67246b6e8b84c4690f807e39/images/d9c9dede5ef7baef11cd4f00df607dbca0299e40728793e1adef2b25ec9133dc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8324267268180847}",,,,,,,,"['negative', 'positive', 'neutral']",negative,0
NCT03525613,"{'position': 1, 'link': 'https://www.ophthalmologytimes.com/view/asrs-live-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-geographic-atrophy', 'title': 'ASRS Live: A novel glyco-mimetic nanoparticle for the treatment of geographic atrophy', 'source': 'Ophthalmology Times', 'date': 'Aug 2, 2023', 'snippet': 'Tarek Hassan, MD, spoke with our team about a novel glyco-mimetic \nnanoparticle for the treatment of geographic atrophy at the 2023 ASRS...', 'thumbnail': 'https://serpapi.com/searches/67246c2c5c7cb933096240ec/images/8d657c2af0246e0d3c776e6556506d696bab39c14b0bea9c65c710bbc5d67bac.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9001842141151428}","{'position': 2, 'link': 'https://www.empr.com/home/news/syfovre-approved-for-geographic-atrophy-secondary-to-amd/', 'title': 'Syfovre Approved for Geographic Atrophy Secondary to AMD', 'source': 'Medical Professionals Reference', 'date': 'Feb 21, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Syfovre™ (pegcetacoplan \ninjection, for intravitreal use) for the treatment of geographic...', 'thumbnail': 'https://serpapi.com/searches/67246c2c5c7cb933096240ec/images/8d657c2af0246e0decb0b52d29883f3ffbf86a20b3e8585a32c2d9193be69b63.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8288508653640747}","{'position': 3, 'link': 'https://www.ophthalmologytimes.com/view/asrs-2023-insights-on-avd-104-a-sialic-acid-coated-nanoparticle-therapeutic-for-geographic-atrophy', 'title': 'ASRS 2023: Insights on AVD-104, a sialic-acid coated nanoparticle therapeutic for geographic atrophy', 'source': 'Ophthalmology Times', 'date': 'Aug 15, 2023', 'snippet': 'Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual \nASRS meeting in Seattle, Washington to share insights from his...', 'thumbnail': 'https://serpapi.com/searches/67246c2c5c7cb933096240ec/images/8d657c2af0246e0ddc52187ac7cfdd23fa7158f7c9ced968187eb5e0e988b2c3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.904371976852417}","{'position': 4, 'link': 'https://www.ophthalmologytimes.com/view/asrs-2023-pegcetacoplan-vs-avacincaptad-pegol-in-patients-with-geographic-atrophy', 'title': 'ASRS 2023: Pegcetacoplan vs avacincaptad pegol in patients with geographic atrophy', 'source': 'Ophthalmology Times', 'date': 'Aug 4, 2023', 'snippet': 'The overall conclusion of our study was that pegcetacoplan monthly appeared \nto show a better efficacy profile than avacincaptad pegol monthly in \nnon-subfoveal...', 'thumbnail': 'https://serpapi.com/searches/67246c2c5c7cb933096240ec/images/8d657c2af0246e0daed7c6d6362b269e43851c1b6f4e1f6666f8bcff9f81a534.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7640917897224426}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02480374,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2017/10/04/ovation-trial-shows-positive-safety-efficacy-profiles-of-gen-1-combo/', 'title': 'Celsion’s GEN-1 Shows Promise in Newly-diagnosed Advanced Ovarian Cancer Patients', 'source': 'Ovarian Cancer News Today', 'date': 'Oct 4, 2017', 'snippet': ""All ovarian cancer patients treated in the Phase 1b OVATION trial benefited \nfrom the combination of Celsion's GEN-1 with standard of care."", 'thumbnail': 'https://serpapi.com/searches/672469776a5dd350c2187378/images/03643af4a11dc075e1fee20727a4183ab7e7b9f916bf7633c37017708fa43314.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7214357256889343}",,,,,,,,,,['positive'],positive,1
NCT05614895,"{'position': 1, 'link': 'https://www.nature.com/articles/s41429-023-00629-8', 'title': 'Antibiotics in the clinical pipeline as of December 2022 - The Journal of Antibiotics', 'source': 'Nature', 'date': 'Jun 8, 2023', 'snippet': 'The need for new antibacterial drugs to treat the increasing global \nprevalence of drug-resistant bacterial infections has clearly attracted...', 'thumbnail': 'https://serpapi.com/searches/6724699b717bff511bd1f846/images/d4c7de2d57e03dcbcfe77bc2255f20759c3a01a97d7c16f5a474cd2de426a857.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8837066888809204}",,,,,,,,,,['neutral'],neutral,1
NCT03104400,"{'position': 1, 'link': 'https://www.empr.com/cch/rinvoq-for-the-treatment-of-psoriatic-arthritis/', 'title': 'Rinvoq for the Treatment of Psoriatic Arthritis', 'source': 'Medical Professionals Reference', 'date': 'May 29, 2024', 'snippet': 'The approval of Rinvoq for psoriatic arthritis was based on the results of \n2 clinical trials — SELECT-PsA 1 (ClinicalTrials.gov Identifier: \nNCT03104400) and...', 'thumbnail': 'https://serpapi.com/searches/6724699f0197dd91dd3b7214/images/bfaf668f263d9b3b1cf6ad8090f57a4d44f11b793a06d75310b7a43b853d1f2a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9160674214363098}","{'position': 2, 'link': 'https://www.europeanpharmaceuticalreview.com/news/167518/nice-recommends-rinvoq-upadacitinib-for-adults-with-active-psoriatic-arthritis/', 'title': 'NICE recommends Rinvoq® for adults with active psoriatic arthritis', 'source': 'European Pharmaceutical Review', 'date': 'Jan 14, 2022', 'snippet': ""AbbVie's Rinvoq (upadacitinib) will be available on the NHS in England and \nWales for adults with active psoriatic arthritis, following NICE approval."", 'thumbnail': 'https://serpapi.com/searches/6724699f0197dd91dd3b7214/images/bfaf668f263d9b3b92f3844caa7854e6af31dfdb55a0af1884076e711ec6f312.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.766755223274231}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00454584,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0810652', 'title': 'Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Jul 10, 2017', 'snippet': 'Biologic agents offer a range of new therapeutic options for patients with \npsoriasis; however, the relative benefit–risk profiles of such therapies \nare not...', 'thumbnail': 'https://serpapi.com/searches/672469b0caddc303e8bfcee3/images/390b63564c45a1da9ce58bcf6a570253d790dc6fee8a40181c7e00c30711d721.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7723560929298401}",,,,,,,,,,['neutral'],neutral,1
NCT01661933,"{'position': 1, 'link': 'https://www.nature.com/articles/srep36797', 'title': 'Changes in duodenal tissue-associated microbiota following hookworm infection and consecutive gluten challenges in humans with coeliac disease', 'source': 'Nature', 'date': 'Nov 9, 2016', 'snippet': 'A reduced diversity of the gastrointestinal commensal microbiota is \nassociated with the development of several inflammatory diseases.', 'thumbnail': 'https://serpapi.com/searches/672469d8a505f7b93bf4278a/images/cb240a03fc8e109bd876c8b5b0e22254ce95194608d404f2b3f2f15f6daa7841.png', 'sentiment': 'negative', 'sentiment_prob': 0.6085220575332642}",,,,,,,,,,['negative'],negative,0
NCT03667690,"{'position': 1, 'link': 'https://www.thelancet.com/article/S1473-3099(23)00551-0/fulltext', 'title': 'Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials', 'source': 'The Lancet', 'date': 'Nov 23, 2023', 'snippet': 'Rezafungin, a new US Food and Drug Administration-approved, long-acting \nechinocandin to treat candidaemia and invasive candidiasis,...', 'thumbnail': 'https://serpapi.com/searches/672469f148c97d44c313ffaa/images/508d6ec347eedcf4f06da20fb6c1ebcb62ea9f4f84d26e4a6eb48edc2c01e54e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9044750332832336}","{'position': 2, 'link': 'https://www.empr.com/home/news/rezzayo-now-available-for-candidemia-invasive-candidiasis-treatment/', 'title': 'Rezzayo Now Available for Candidemia, Invasive Candidiasis Treatment', 'source': 'Medical Professionals Reference', 'date': 'Jul 31, 2023', 'snippet': 'Rezzayo (rezafungin for injection) is now available for the treatment of \ncandidemia and invasive candidiasis in adults with limited or no \nalternative treatment...', 'thumbnail': 'https://serpapi.com/searches/672469f148c97d44c313ffaa/images/508d6ec347eedcf445cfa1a16e7515bd0e5731cbe6071e9fd19a7b5e6e1e12d8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9104976654052734}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02949388,"{'position': 1, 'link': 'https://psoriasisnewstoday.com/2017/05/11/cellceutix-has-70-percent-of-patients-it-wants-for-trial-of-psoriasis-therapy-prurisol/', 'title': 'Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target', 'source': 'Psoriasis News Today', 'date': 'May 11, 2017', 'snippet': 'An already started Phase 2b clinical trial of Prurisol as a treatment for \nmoderate-to-severe chronic plaque psoriasis has recruited more than 70 \npercent of the...', 'thumbnail': 'https://serpapi.com/searches/67246a63caddc303e8bfcf06/images/162bab151b931d422fdbec48da40dc0c25e233114729c170922e7f7f8b471ef9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7885826826095581}",,,,,,,,,,['neutral'],neutral,1
NCT00330681,"{'position': 1, 'link': 'https://alsnewstoday.com/news/radicava-suggests-more-real-world-data-needed-to-determine-efficacy-of-edaravone-in-als/', 'title': 'Radicava’s Effectiveness for ALS Not Established, Real-life Use Suggests', 'source': 'ALS News Today', 'date': 'Nov 17, 2020', 'snippet': 'A review of Radicava (edaravone), an approved amyotrophic lateral sclerosis \n(ALS) treatment, found the medication generally well tolerated in real-life \nuse by...', 'thumbnail': 'https://serpapi.com/searches/67246b1a54163d24d900f7d9/images/82a5acd0119f794bfacd05e17b1223c229cd2aa6b5073a800ca75208207cded0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6735977530479431}",,,,,,,,,,['neutral'],neutral,1
NCT01976364,"{'position': 1, 'link': 'https://psoriasisnewstoday.com/2017/05/04/psoriatic-arthritis-therapy-xeljanz-reviewed-fda-following-approval-pfizer-snda/', 'title': 'FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients', 'source': 'Psoriasis News Today', 'date': 'May 4, 2017', 'snippet': ""The U.S. Food and Drug Administration (FDA) will review Pfizer's medication \nXeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults..."", 'thumbnail': 'https://serpapi.com/searches/67246b2c06f4f2e5cefadf54/images/fa7084f32229f9084ef82d9debd85d79251c20cbbfa706074244a2389916ec99.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9127993583679199}",,,,,,,,,,['neutral'],neutral,1
NCT02648672,"{'position': 1, 'link': 'https://fragilexnewstoday.com/news/fda-grants-bpn14770-orphan-drug-status-fragile-x-syndrome/', 'title': 'Potential Fragile X Therapy BPN14770 Receives FDA Orphan Drug Status', 'source': 'Fragile X News Today', 'date': 'Apr 12, 2018', 'snippet': 'Investigational therapy BPN14770 has been granted orphan drug status by the \nU.S. Food and Drug Administration for the treatment of fragile X...', 'thumbnail': 'https://serpapi.com/searches/67246a898d041735c8b7bbd5/images/e6337856d7682d63b47b300fcbec0eaf7c97c0308441b7e26472d9d4d5b79d87.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8758559226989746}",,,,,,,,,,['neutral'],neutral,1
NCT04383938,"{'position': 1, 'link': 'https://www.nature.com/articles/s41418-023-01122-3', 'title': 'The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells', 'source': 'Nature', 'date': 'Feb 4, 2023', 'snippet': 'Mutant TP53 proteins are thought to drive the development and sustained \nexpansion of cancers at least in part through the loss of the...', 'thumbnail': 'https://serpapi.com/searches/67246a9c400bd547ba52c8cd/images/f8ad49d1aedf68530d869a8c3cc7d983753801eefa6820f4bffe2ab2214d8bfd.png', 'sentiment': 'negative', 'sentiment_prob': 0.6143423318862915}",,,,,,,,,,['negative'],negative,0
NCT01862640,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/rexulti-approved-canada-agitation-dementia/', 'title': 'Rexulti approved in Canada for agitation in Alzheimer’s dementia', 'source': ""Alzheimer's News Today"", 'date': 'Feb 15, 2024', 'snippet': ""Health Canada has approved Rexulti (brexpiprazole) for agitation associated \nwith Alzheimer's disease-related dementia."", 'thumbnail': 'https://serpapi.com/searches/67246ab290adce1ab35dbcca/images/5492b68710f5942b0f451f2e07fe96276ab249862f2e3c536806d697cd0fd21e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7764018774032593}","{'position': 2, 'link': 'https://www.psychiatryadvisor.com/cch/rexulti-for-agitation-associated-with-dementia-due-to-alzheimer-disease/', 'title': 'Rexulti for Agitation Associated With Dementia Due to Alzheimer Disease', 'source': 'Psychiatry Advisor', 'date': 'Jun 11, 2024', 'snippet': 'In May 2023, the US Food and Drug Administration (FDA) approved Rexulti® \n(brexpiprazole; Otsuka Pharmaceutical Co, Ltd), an atypical \nantipsychotic,...', 'thumbnail': 'https://serpapi.com/searches/67246ab290adce1ab35dbcca/images/5492b68710f5942b24aee3ff19238cb1c6df4e91c446e8627e299572b16906dd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8712952733039856}","{'position': 3, 'link': 'https://alzheimersnewstoday.com/news/schizophrenia-medication-brexpiprazole-lowered-agitation-in-alzheimers-patients-in-phase-3-study/', 'title': ""Alzheimer's Agitation Seen to Ease with Schizophrenia Drug, Brexpiprazole, in Clinical Trial"", 'source': ""Alzheimer's News Today"", 'date': 'May 5, 2017', 'snippet': ""Read about how the schizophrenia medication brexpiprazole seemed to reduce \nsymptoms of agitation in Alzheimer's disease patients."", 'thumbnail': 'https://serpapi.com/searches/67246ab290adce1ab35dbcca/images/5492b68710f5942b54f650ddfa773a30a15b2c36159a610a4a14d3cf9d9cdc98.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8714643716812134}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02552953,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-022-01553-w', 'title': 'Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells', 'source': 'Nature', 'date': 'Apr 5, 2022', 'snippet': 'Fadraciclib (CYC065) is a second-generation aminopurine CDK2/9 inhibitor \nwith increased potency and selectivity toward CDK2 and CDK9 compared to \nseliciclib (R-...', 'thumbnail': 'https://serpapi.com/searches/67246ab354605c645e4eee65/images/bff11bf5c3c05b341bcf154c3eba1c52d1239f308adc6a22db347d93c5c3efeb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8343443274497986}",,,,,,,,,,['neutral'],neutral,1
NCT00357825,"{'position': 1, 'link': 'https://fibromyalgianewstoday.com/2020/01/17/axsome-therapeutics-licenses-pfizers-potential-fibromyalgia-treatment-esreboxetine/', 'title': 'Axsome Therapeutics Licenses Pfizer’s Potential Fibromyalgia Treatment Esreboxetine in US', 'source': 'Fibromyalgia News Today', 'date': 'Jan 17, 2020', 'snippet': 'Following an agreement with Pfizer, Axsome Therapeutics now has exclusive \nrights to develop and commercialize AXS-14 (esreboxetine) — a drug...', 'thumbnail': 'https://serpapi.com/searches/67246ac29936886f64d2d7ff/images/b96488e1e7be3ef797474a19629c3b7e0d3d79f255f55f2a36b79bf090046156.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8637092709541321}",,,,,,,,,,['neutral'],neutral,1
NCT04930042,"{'position': 1, 'link': 'https://www.pharmacytimes.com/view/fda-approves-ustekinumab-biosimilar-to-stelara-for-treatment-of-plaque-psoriasis', 'title': 'FDA Approves Ustekinumab Biosimilar to Stelara for Treatment of Plaque Psoriasis', 'source': 'Pharmacy Times', 'date': 'Apr 17, 2024', 'snippet': 'Ustekinumab (Stelara; Janssen Immunology) is a human monoclonal antibody \nthat treats immune-mediated diseases such as psoriasis and...', 'thumbnail': 'https://serpapi.com/searches/67246ac90f2a2c71890fdc6e/images/522889328bd6ff4d62a560a2b330158f3e4307328b542a968dee7d717bacc78f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.846770167350769}",,,,,,,,,,['neutral'],neutral,1
NCT01731951,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1310523', 'title': 'A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 3, 2015', 'snippet': 'Imetelstat was found to be active in patients with myelofibrosis but also \nhad the potential to cause clinically significant myelosuppression.', 'thumbnail': 'https://serpapi.com/searches/67246ad548e6689eaf0f9113/images/c38f69c7a94c0f17b352917630eb7a4130416603a7d3397714fc2eb9da992778.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.85071861743927}",,,,,,,,,,['neutral'],neutral,1
NCT02152228,"{'position': 1, 'link': 'https://hypoparathyroidismnews.com/news/entera-bio-improving-its-eb612-add-on-therapy-for-hypoparathyroidism-publishes-earlier-phase-2a-study/', 'title': 'Entera Bio Improving Its EB612 Add-on Therapy, Publishes Earlier Study', 'source': 'Hypoparathyroidism News', 'date': 'Mar 3, 2021', 'snippet': 'Entera Bio is developing a better formulation of EB612, its add-on therapy \nfor maintaining normal blood calcium levels in people with \nhypoparathyroidism.', 'thumbnail': 'https://serpapi.com/searches/67246ae259f911ff7e29256d/images/31b427d0aeeea271d104c021db370bb861eb8ec30715bc7f727db6aefccfac9d.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7531988620758057}",,,,,,,,,,['positive'],positive,1
NCT00104299,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0909905', 'title': 'Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis', 'source': 'The New England Journal of Medicine', 'date': 'Oct 19, 2017', 'snippet': 'Cyclophosphamide and glucocorticoids have been the cornerstone of \nremission-induction therapy for severe antineutrophil cytoplasmic \nantibody...', 'thumbnail': 'https://serpapi.com/searches/67246ae39e5bd5a90a4a0f90/images/948e0b3f04d4e5da408a7ce8b514f063f078027934cf869a9c2eaafdb0b724b1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.844281792640686}","{'position': 2, 'link': 'https://ancavasculitisnews.com/news/anca-vasculitis-treatment-research-advancing-mayo-researchers-say/', 'title': 'ANCA Vasculitis Treatment Research Advancing, Mayo Researchers Say', 'source': 'ANCA Vasculitis News', 'date': 'Dec 5, 2017', 'snippet': 'Read about how the treatment of ANCA vasculitis is evolving, with clinical \ntrials testing new approaches to keep patients in remission.', 'thumbnail': 'https://serpapi.com/searches/67246ae39e5bd5a90a4a0f90/images/948e0b3f04d4e5da27b357402026393d7986e357053269c8134dc020146ee339.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.880696713924408}","{'position': 3, 'link': 'https://ancavasculitisnews.com/news/blocking-b-and-t-cells-interaction-contributes-to-rituxan-efficacy-in-aav-study-says/', 'title': ""Rituxan's Efficacy Linked to It Blocking How B-cells Interact with Certain T-cells, Study Says"", 'source': 'ANCA Vasculitis News', 'date': 'Nov 20, 2018', 'snippet': 'Blocking the interaction between immune B-cells and CD8-positive T-cells \nmay be what makes Rituxan (rituximab) an effective treatment for \nANCA-associated...', 'thumbnail': 'https://serpapi.com/searches/67246ae39e5bd5a90a4a0f90/images/948e0b3f04d4e5daa1bd99edd0bd63b1dc11e958d5852e2a118b454c98ea37fa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8923890590667725}","{'position': 4, 'link': 'https://ancavasculitisnews.com/news/hematuria-may-predict-renal-relapse-in-anca-patients/', 'title': 'In AAV Patients, Persistent Blood in Urine Seen to Indicate Kidney Relapse in Study', 'source': 'ANCA Vasculitis News', 'date': 'Feb 6, 2018', 'snippet': 'A study, looking at two clinical trials, suggests that urinalysis showing \npersistent blood in the urine (hematuria) can help identify...', 'thumbnail': 'https://serpapi.com/searches/67246ae39e5bd5a90a4a0f90/images/948e0b3f04d4e5dae0e4d2188d1b3af879a40a0595cf797a2fb939c60e970308.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9162073135375977}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT01647516,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1513248', 'title': 'Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis', 'source': 'The New England Journal of Medicine', 'date': 'May 5, 2016', 'snippet': 'In this preliminary trial, ozanimod at a daily dose of 1 mg resulted in a \nslightly higher rate of clinical remission of ulcerative colitis than \nplacebo.', 'thumbnail': 'https://serpapi.com/searches/67246afa483e5b5046d31bc6/images/cf21aa27fe1916f7906021c4551aaf07bc30f3383ba847fe3bef0df4366692df.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8769569396972656}",,,,,,,,,,['neutral'],neutral,1
NCT01336634,"{'position': 1, 'link': 'https://lungcancernewstoday.com/2017/06/26/fda-approves-tafinlar-mekinist-combo-for-braf-v600e-non-small-cell-lung-cancer/', 'title': 'FDA Approves Tafinlar, Mekinist Combo to Treat BRAF V600E NSCLC', 'source': 'Lung Cancer News Today', 'date': 'Jun 26, 2017', 'snippet': 'The US Food and Drug Administration (FDA) announced approval of Tafinlar \n(dabrafenib) and Mekinist (trametinib) to be delivered in combination for \nthe...', 'thumbnail': 'https://serpapi.com/searches/67246b9423793852a78768d0/images/5ff6bdae9d9d9adf9e87358ea6508be5a31700a1efd8b6cb5ad476dd3aa89fe6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8368079662322998}",,,,,,,,,,['neutral'],neutral,1
NCT01093326,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/08/30/long-term-ponvory-treatment-safe-effective-rrms-trial-data/', 'title': 'Long-term Ponvory Treatment Safe, Effective in RRMS, Trial Data Show', 'source': 'Multiple Sclerosis News Today', 'date': 'Aug 30, 2022', 'snippet': 'Long-term treatment with Ponvory was found to reduce the rate of relapses \nand prevent brain volume loss in relapsing-remitting MS patients.', 'thumbnail': 'https://serpapi.com/searches/67246ba9fc40bf9c975998ad/images/732b0cf18803627845db4ffd285abad7bf682c5604561c8e39988a01c2640168.png', 'sentiment': 'positive', 'sentiment_prob': 0.6364147067070007}",,,,,,,,,,['positive'],positive,1
NCT05341609,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2208822', 'title': 'VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Dec 28, 2022', 'snippet': 'VV116 was noninferior to nirmatrelvir–ritonavir with respect to the time to \nsustained clinical recovery, with fewer safety concerns.', 'thumbnail': 'https://serpapi.com/searches/67246bd69109860c774f7e8f/images/3593a2c80b319d13e566a2ebdbd6a216f721b2721c3a0445cb4254b91d792118.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7418916821479797}",,,,,,,,,,['neutral'],neutral,1
NCT01460160,"{'position': 1, 'link': 'https://www.targetedonc.com/view/dasatinib-receives-fda-approval-for-pediatric-ph-all', 'title': 'Dasatinib Receives FDA Approval for Pediatric Ph+ ALL', 'source': 'Targeted Oncology', 'date': 'Jan 2, 2019', 'snippet': 'Dasatinib (Sprycel) tablets has been approved by the FDA to be used in \ncombination with chemotherapy for the treatment of pediatric patients...', 'thumbnail': 'https://serpapi.com/searches/67246cc475f974803561e35f/images/4e8c05bdeae9d2f1e32b9b37a4970f78e98a9c96f21be8dbcd5b3a6df6a11831.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6558439135551453}",,,,,,,,,,['neutral'],neutral,1
NCT04178967,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2206714', 'title': 'Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis', 'source': 'The New England Journal of Medicine', 'date': 'Mar 15, 2023', 'snippet': 'We conducted two identically designed, 52-week, randomized, double-blind, \nplacebo-controlled, phase 3 trials; both trials included a 16-week \ninduction...', 'thumbnail': 'https://serpapi.com/searches/67246cf7310300dcae5bdcdf/images/aa63d52439aa167b49551b778d83c8ea9bd3595393ef2da94b7f7db35dafd65d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8502047657966614}","{'position': 2, 'link': 'https://www.dermatologyadvisor.com/cch/moderate-to-severe-atopic-dermatitis-clinician-insights-2022-american-academy-of-dermatology-annual-meeting/', 'title': 'Moderate to Severe Atopic Dermatitis: Treatment Insights From the 2022 American Academy of Dermatology Annual Meeting', 'source': 'Dermatology Advisor', 'date': 'May 17, 2024', 'snippet': 'Brett King, MD, PhD, FAAD, an associate professor of dermatology at Yale \nSchool of Medicine in New Haven, Connecticut, shares his perspective on \nrecent...', 'thumbnail': 'https://serpapi.com/searches/67246cf7310300dcae5bdcdf/images/aa63d52439aa167b0d8156870b51bd98e2467d8ad47a8823fd299b07a44cf878.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.937115490436554}","{'position': 3, 'link': 'https://www.empr.com/news/ebglyss-approved-for-moderate-to-severe-atopic-dermatitis/', 'title': 'Ebglyss Approved for Moderate to Severe Atopic Dermatitis', 'source': 'Medical Professionals Reference', 'date': '1 month ago', 'snippet': 'The Food and Drug Administration (FDA) has approved Ebglyss™ \n(lebrikizumab-lbkz) for the treatment of adult and pediatric patients aged \n12...', 'thumbnail': 'https://serpapi.com/searches/67246cf7310300dcae5bdcdf/images/aa63d52439aa167b98c62024efab5eda02d478a46439978e1608ff5fa0d9a0cd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8664060831069946}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02715531,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30156-X/fulltext', 'title': 'Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study', 'source': 'The Lancet', 'date': 'Jun 29, 2020', 'snippet': 'Atezolizumab with or without bevacizumab in unresectable hepatocellular \ncarcinoma (GO30140): an open-label, multicentre, phase 1b study', 'thumbnail': 'https://serpapi.com/searches/67246d610377569610780e58/images/5e9b42785d99513ff922d0f33d99fb1a03f8a4f3eb0f238511b455ee51677383.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8255295157432556}","{'position': 2, 'link': 'https://www.targetedonc.com/view/atezolizumab-bevacizumab-shows-survival-and-qol-benefit-in-hcc', 'title': 'Atezolizumab/Bevacizumab Shows Survival and QOL Benefit in HCC', 'source': 'Targeted Oncology', 'date': 'May 1, 2024', 'snippet': 'Stacey Stein, MD, discusses the background and outcomes of the IMbrave150 \ntrial of atezolizumab plus bevacizumab in patients with advanced...', 'thumbnail': 'https://serpapi.com/searches/67246d610377569610780e58/images/5e9b42785d99513f480f6b365cefad3058d1886580b0f2cab145c20d045ec0f8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8851877450942993}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01895309,"{'position': 1, 'link': 'https://juvenilearthritisnews.com/2019/05/07/eticovo-biosimilar-enbrel-fda-approved-juvenile-arthritis-ages-2-older/', 'title': 'Eticovo, a Biosimilar of Enbrel, Approved by FDA for Polyarticular JIA Patients Ages 2 and Older', 'source': 'Juvenile Arthritis News', 'date': 'May 7, 2019', 'snippet': 'Eticovo (etanercept-ykro), a biosimilar of Enbrel (etanercept), has been \napproved by the U.S. Food and Drug Administration (FDA) as a...', 'thumbnail': 'https://serpapi.com/searches/67246d9876079d52a413afe7/images/a0b5126b15126be4e2e4bf318c9bf96cf81cd296dc036dd7b94492c0dd7ef471.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8287097811698914}",,,,,,,,,,['neutral'],neutral,1
NCT03101241,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/jazz-pharmaceuticals-essential-tremor-fails-endpoint/', 'title': 'Jazz Pharmaceuticals’ essential tremor drug falls flat in Phase IIb trial', 'source': 'Clinical Trials Arena', 'date': 'Jun 21, 2024', 'snippet': ""The company will evaluate the data from this trial and another in \nParkinson's disease before deciding on the future of the drug."", 'thumbnail': 'https://serpapi.com/searches/67246db714c31e1ae795ac3b/images/e426b8df7fa5a279f6cc7610c6440f73ee030c6aef1223ce35d287a59e6ea8aa.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.650999903678894}",,,,,,,,,,['negative'],negative,0
NCT04052568,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02455-9', 'title': 'Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study', 'source': 'Nature', 'date': 'Jul 24, 2023', 'snippet': 'Anorexia nervosa (AN) is a deadly illness with no proven treatments to \nreverse core symptoms and no medications approved by the US Food and...', 'thumbnail': 'https://serpapi.com/searches/67246db77ca6b3f5bef7876b/images/515fe6018c2c6c81bd0e60a42c54fba7b3b789d1b7ccd368b72481560be22cdd.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7454364895820618}","{'position': 2, 'link': 'https://pharmaceutical-journal.com/article/feature/untangling-anorexia-psychedelics-offer-hope-for-a-neglected-condition', 'title': 'Untangling anorexia: psychedelics offer hope for a neglected condition', 'source': 'The Pharmaceutical Journal', 'date': 'Mar 2, 2023', 'snippet': 'Anorexia nervosa has the highest mortality rate of any psychiatric disorder \nyet there are no medicines licensed globally to treat it; however, that \nmight be...', 'thumbnail': 'https://serpapi.com/searches/67246db77ca6b3f5bef7876b/images/515fe6018c2c6c81768f36c3b7d53fca700cea2c7f343319ad7a6410fc3ca096.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6351245641708374}",,,,,,,,,"['negative', 'negative']",negative,0
NCT01620255,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-022-22465-w', 'title': 'A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis', 'source': 'Nature', 'date': 'Nov 17, 2022', 'snippet': 'This is the first study using transcriptomic meta-analysis to define a \ntissue gene signature and pathways dysregulated in both PS and UC.', 'thumbnail': 'https://serpapi.com/searches/67246dde35853954fd9f3410/images/94f5aba24e006214ea5ce40d85793b71b575e834943dacbe660bd8e6c70df75f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.810407817363739}",,,,,,,,,,['neutral'],neutral,1
NCT03535740,"{'position': 1, 'link': 'https://www.takeda.com/ja-jp/who-we-are/research/clinical-trial/Brigatinib-2002/', 'title': '進行期非小細胞肺がんに対する第2相試験', 'source': 'Takeda Pharmaceuticals', 'date': 'Oct 4, 2019', 'snippet': '年齢18歳以上、又は地域の成人年齢以上の方（日本国内では20歳以上の方。） \n・組織学的または細胞学的に診断されたステージIIIB（局所的に進行または再発し、根治療法の...', 'thumbnail': 'https://serpapi.com/searches/67246e0154605c64279507fa/images/a88deb56b02c58d1a3c3902fb1c04744b4011e7f0534e1cd3c07399a2028321e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8164567351341248}",,,,,,,,,,['neutral'],neutral,1
NCT00573495,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.828386/full', 'title': 'Breast Cancer Vaccines: Disappointing or Promising?', 'source': 'Frontiers', 'date': 'Feb 7, 2024', 'snippet': '1Department of Breast Surgery, Fudan University Shanghai Cancer Center, \nShanghai, China; 2Shanghai Medical College, Fudan University, Shanghai, \nChina.', 'thumbnail': 'https://serpapi.com/searches/67246e16f7adbf72b3a17c42/images/118b4528939e1fa7592ae3aa86eb26a696b761f09693649f981bf5b37a25e931.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6253421306610107}",,,,,,,,,,['neutral'],neutral,1
NCT00231153,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.1030162/full', 'title': 'Antimicrobial peptides for bone tissue engineering: Diversity, effects and applications', 'source': 'Frontiers', 'date': 'Jun 26, 2024', 'snippet': 'Antimicrobial peptides (AMPs) characterized by cationic, hydrophobic and \namphipathic properties show great promise to be used as next-generation \nantibiotics.', 'thumbnail': 'https://serpapi.com/searches/67246e2717a2e2dbfa5926e4/images/56c6274a0ba35e9ba2b8e04762eccefc33c9952f5060e94ef0240379f06344cc.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.750365674495697}",,,,,,,,,,['positive'],positive,1
NCT03093155,"{'position': 1, 'link': 'https://www.nature.com/articles/s44276-024-00067-5', 'title': 'Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses', 'source': 'Nature', 'date': 'Jun 20, 2024', 'snippet': 'IXA + BEV has activity in heavily pre-treated ovarian cancers and offers \nsignificant improvement in ORR and PFS/OS compared to IXA, despite prior \ntaxane...', 'thumbnail': 'https://serpapi.com/searches/67246e41ef60cb0a53d48499/images/47107da075449fc1019988bf166b4af1ebcfb42fec924bc9b7affa002d67dec5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8542064428329468}","{'position': 2, 'link': 'https://www.nature.com/articles/s41416-022-01717-6', 'title': 'Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer', 'source': 'Nature', 'date': 'Feb 11, 2022', 'snippet': 'IXA + BEV is a well-tolerated, effective combination for \nplatinum/taxane-resistant ovarian cancer that extends PFS and likely OS \nrelative to IXA monotherapy.', 'thumbnail': 'https://serpapi.com/searches/67246e41ef60cb0a53d48499/images/47107da075449fc1680ed8f0bec0ba5bc1e03b408f88fdbe534dc5efb31ea859.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7563627362251282}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05048719,"{'position': 1, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-results-published-new-england-journal-medicine', 'title': ""Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight"", 'source': 'Eli Lilly and Company', 'date': '23 Haz 2023', 'snippet': 'Orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved \nup to 14.7% mean weight reduction at 36 weeks in adults with obesity or \noverweight.', 'thumbnail': 'https://serpapi.com/searches/67246e44f59d0009a46b5bb6/images/1174715e7dc76b87ccfda87f2d4922a829b48e9c5f1b565d99ac7a1770cba737.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8391620516777039}","{'position': 2, 'link': 'https://finance.yahoo.com/news/easd-2024-cardiovascular-inflammatory-markers-155332560.html', 'title': 'EASD 2024: Cardiovascular and inflammatory markers reduce after orforglipron treatment', 'source': 'Yahoo Finance', 'date': '1 ay önce', 'snippet': 'On 10 September 2024 at the European Association for the Study of Diabetes \n(EASD) 60th Annual Meeting, Eli Lilly and Co announced the Phase...', 'thumbnail': 'https://serpapi.com/searches/67246e44f59d0009a46b5bb6/images/1174715e7dc76b87915ff310e6aa22b649ee4bbdc546418ed7210a3fe35ac8d0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8587287664413452}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01897701,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMc1313186', 'title': 'A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine', 'source': 'The New England Journal of Medicine', 'date': 'May 1, 2018', 'snippet': 'Influenza A (H7N9) emerged earlier this year as a health threat in China. \nEfforts to develop a vaccine are under way. This letter presents initial \nphase 1...', 'thumbnail': 'https://serpapi.com/searches/67246e5324296ac82b89b0db/images/100509bb19e552b80e85f2bc2a974879219d0118232c87c77c9cf0556f3cbaf0.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6529706120491028}",,,,,,,,,,['negative'],negative,0
NCT05643794,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/features/pipeline-moves-moderna-pandemic-trial-vaccine-completes/', 'title': 'Pipeline Moves: Moderna’s pandemic influenza vaccine trial completes', 'source': 'Clinical Trials Arena', 'date': '19 Ağu 2024', 'snippet': 'The Clinical Trials Arena team investigates assets in oncology, central \nnervous system and infectious diseases.', 'thumbnail': 'https://serpapi.com/searches/67246e5e48c97d44c3140095/images/bd03762e4d1c3680512db7c2ed210bd87cccb8ac16168dd8120ad87d909cd8af.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8368623852729797}","{'position': 2, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Rozanolixizumab-UCB7665', 'title': 'Rozanolixizumab (Rystiggo®)', 'source': 'UCB', 'date': '30 Ağu 2024', 'snippet': 'Autoimmune Encephalitis, A Study to Test the Efficacy, Safety, and \nPharmacokinetics of Rozanolixizumab in Adult Study Participants With...', 'thumbnail': 'https://serpapi.com/searches/67246e5e48c97d44c3140095/images/bd03762e4d1c3680b0a9fcc32f602cae2fd3993936674e60786310e370b27c4a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8345304131507874}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03829969,"{'position': 1, 'link': 'https://www.onclive.com/view/chmp-recommends-toripalimab-plus-chemo-for-metastatic-nasopharyngeal-carcinoma-and-advanced-escc', 'title': 'CHMP Recommends Toripalimab Plus Chemo for Metastatic Nasopharyngeal Carcinoma and Advanced ESCC', 'source': 'OncLive', 'date': 'Jul 29, 2024', 'snippet': ""The European Medicines Agency's Committee for Medicinal Products for Human \nUse (CHMP) recommended the approval of toripalimab-tpzi..."", 'thumbnail': 'https://serpapi.com/searches/67246e6390b57c461dea52f3/images/b823b7b746f85bec3720921eb086662c2cca1686bb1ff1cad4cf28690f29695b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9107452630996704}",,,,,,,,,,['neutral'],neutral,1
NCT04427501,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2029849', 'title': 'SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Oct 28, 2020', 'snippet': 'Virus-neutralizing monoclonal antibodies are predicted to reduce viral \nload, ameliorate symptoms, and prevent hospitalization.', 'thumbnail': 'https://serpapi.com/searches/67246e84b57db83ec2d863ea/images/e9fe7eb8f10f349ef3cd6fd53a6dbaf431e14172c29d97f4db8efb2f6845dafd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8533226847648621}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2102685', 'title': 'Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Jul 14, 2021', 'snippet': 'Patients with underlying medical conditions are at increased risk for \nsevere coronavirus disease 2019 (Covid-19).', 'thumbnail': 'https://serpapi.com/searches/67246e84b57db83ec2d863ea/images/e9fe7eb8f10f349eaab4b8da877ebb60e96f7dd055b8bcf63b739e13eaf23f78.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5249709486961365}","{'position': 3, 'link': 'https://www.empr.com/home/news/emergency-use-authorization-eua-bamlanivimab-etesevimab-covid-19/', 'title': 'FDA OKs Emergency Use of Bamlanivimab Plus Etesevimab for COVID-19', 'source': 'Medical Professionals Reference', 'date': 'Feb 10, 2021', 'snippet': ""The Food and Drug Administration (FDA) has issued an Emergency Use \nAuthorization (EUA) for Lilly's severe acute respiratory syndrome..."", 'thumbnail': 'https://serpapi.com/searches/67246e84b57db83ec2d863ea/images/e9fe7eb8f10f349ea89df3e4778a6f3bf798794e63f2f0f6f00c420bd578eff6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8884025812149048}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00483782,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1104390', 'title': 'Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Dec 29, 2011', 'snippet': 'Vascular endothelial growth factor is a key promoter of angiogenesis and \ndisease progression in epithelial ovarian cancer.', 'thumbnail': 'https://serpapi.com/searches/67246ea2707fd3a645c4a203/images/eb54450ff1ff92d5e426cff162766fe8588e52fa079534c540b9319a6d97906a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.814798891544342}",,,,,,,,,,['neutral'],neutral,1
NCT05014672,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/pbc-treatment-setanaxib-eases-signs-liver-damage-trial-data/', 'title': 'PBC treatment setanaxib eases signs of liver damage: Trial data', 'source': 'Liver Disease News', 'date': 'Aug 28, 2024', 'snippet': 'PBC treatment setanaxib reduced signs of liver damage in patients with \nhard-to-treat PBC and elevated liver stiffness, trial data showed.', 'thumbnail': 'https://serpapi.com/searches/67246eac8cf8ae01ee852799/images/8a94eae5687d49ab39040fa18b103edf45a10b829edf61bea6c4dc0d5e1790d8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7478822469711304}",,,,,,,,,,['neutral'],neutral,1
NCT01454596,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-021-00233-9', 'title': 'GD2 CAR T cells against human glioblastoma', 'source': 'Nature', 'date': 'Oct 27, 2021', 'snippet': 'Glioblastoma is the most malignant primary brain tumor and is still in need \nof effective medical treatment. We isolated patient-derived...', 'thumbnail': 'https://serpapi.com/searches/67246eb1a505f7b906091d88/images/80311099b3dea6ef127046f084db1978bbccd77917d98c3b27ac27553bebfdec.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7944258451461792}",,,,,,,,,,['negative'],negative,0
NCT00896532,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1305224', 'title': 'Romosozumab in Postmenopausal Women with Low Bone Mineral Density', 'source': 'The New England Journal of Medicine', 'date': 'Jan 1, 2014', 'snippet': 'Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The \nmonoclonal antibody romosozumab binds to sclerostin and increases...', 'thumbnail': 'https://serpapi.com/searches/67246ebbb4e8d68e084e05fd/images/ce000a7aa2438030ea0708716f8950e9c83d64b31d8df46423d16202866afaae.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9022723436355591}",,,,,,,,,,['neutral'],neutral,1
NCT02349841,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMc1513236', 'title': 'β-Lactams against Tuberculosis — New Trick for an Old Dog? | NEJM', 'source': 'The New England Journal of Medicine', 'date': 'Jul 13, 2016', 'snippet': 'Meropenem combined with amoxicillin–clavulanic acid not only resisted \nhydrolysis well but also showed synergistic antituberculosis activity.', 'thumbnail': 'https://serpapi.com/searches/67246ec7ec54104fb652d131/images/f484524852228309906f760f26e2f9f72d25ff70a4dcebd09e2bed96172afca1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8760133981704712}",,,,,,,,,,['neutral'],neutral,1
NCT03497975,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/trevi-therapeutics-reports-positive-results-from-the-ph2b3-prism-trial-of-haduvio-in-the-treatment-of-prurigo-nodularis-301577632.html', 'title': 'Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis', 'source': 'PR Newswire', 'date': 'Jun 29, 2022', 'snippet': 'PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage \nbiopharmaceutical company developing an investigational therapy...', 'thumbnail': 'https://serpapi.com/searches/67246ec854605c645e4eef2c/images/b8876216a87cbf0cb969f3fd60fe3aa76468e4c64c0933f077f9c045f3b4a1d9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.666989803314209}",,,,,,,,,,['neutral'],neutral,1
NCT02307682,"{'position': 1, 'link': 'https://www.nature.com/articles/s41433-022-02077-4', 'title': 'Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis | Eye', 'source': 'Nature', 'date': 'May 6, 2022', 'snippet': 'To assess the therapeutic response to brolucizumab and aflibercept by deep \nlearning/OCT-based analysis of macular fluid volumes in neovascular \nage-related...', 'thumbnail': 'https://serpapi.com/searches/67246ee068831e63a4ce282c/images/8281f9befe6b87c5c3fcbc2a166b985357de4fb0729ce937c6d52616d6cdd07d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.895088255405426}",,,,,,,,,,['neutral'],neutral,1
NCT03204331,"{'position': 1, 'link': 'https://www.empr.com/home/news/myfembree-approved-for-management-of-endometriosis-pain/', 'title': 'Myfembree Approved for Management of Endometriosis Pain', 'source': 'Medical Professionals Reference', 'date': 'Aug 8, 2022', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of \nMyfembree® (relugolix, estradiol, and norethindrone acetate) to include...', 'thumbnail': 'https://serpapi.com/searches/67246eeba32436769945dc38/images/ed479178fb5c9f832525509c50f6dd2f395e8dedc4145e90b95d932cb695abd2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7937327027320862}",,,,,,,,,,['neutral'],neutral,1
NCT02680379,"{'position': 1, 'link': 'https://fragilexnewstoday.com/news/lovastatin-minocycline-combined-helps-fragile-x-behavior-caregivers-report/', 'title': 'Fragile X Behaviors Helped When Loavastatin, Minocycline Are Combined', 'source': 'Fragile X News Today', 'date': 'Apr 11, 2022', 'snippet': 'A clinical trial of 22 adults with Fragile X syndrome showed combining \nlovastatin and minocycline significantly improved several behaviors.', 'thumbnail': 'https://serpapi.com/searches/67246ef14a4a1d3f6d80ff44/images/7e849d0ecc377bde925146a9998ca9bcbc7f78921f598e2114ac2d0d10fed76a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6776238083839417}",,,,,,,,,,['neutral'],neutral,1
NCT03575104,"{'position': 1, 'link': 'https://www.empr.com/home/news/quviviq-approved-for-the-treatment-of-insomnia/', 'title': 'Quviviq Approved for the Treatment of Insomnia', 'source': 'Medical Professionals Reference', 'date': 'Jan 10, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Quviviq™ (daridorexant) \nfor the treatment of adults with insomnia characterized by...', 'thumbnail': 'https://serpapi.com/searches/67246efda5aae9a0ed5c355a/images/764c67043fc8e201093a2346628f55a6653f480e317835d67373e8bb59ab6882.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7724179029464722}",,,,,,,,,,['neutral'],neutral,1
NCT03282760,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/stem-cell-therapy-well-tolerated-secondary-progressive-ms-trial/', 'title': 'Stem cell therapy well tolerated in secondary progressive MS trial', 'source': 'Multiple Sclerosis News Today', 'date': 'Nov 30, 2023', 'snippet': 'A novel therapy in which neural stem cells are injected into the brain was \nwell-tolerated by 15 people with secondary progressive MS.', 'thumbnail': 'https://serpapi.com/searches/67246effa775f2bdb5f75ab8/images/41a0d00fcf5a74b6419903b914829c93e9bf8a6f9b4e540d2a97aaaba515fc5b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5354387760162354}",,,,,,,,,,['neutral'],neutral,1
NCT00846456,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.341', 'title': 'Cancer stem cells in brain tumors: From origin to clinical implications - Lin - 2023 - MedComm', 'source': 'Wiley Online Library', 'date': 'Aug 9, 2023', 'snippet': 'The cancer stem cell (CSC, also named tumor-initiating cell) model states \nthat tumor growth is driven by a subset of CSCs.', 'thumbnail': 'https://serpapi.com/searches/67246f5b1397ba76f05c85d3/images/abb7f9cdeafdae3611ceb5a3ed650589da8448fba8918914f3db7a867dfd4802.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9208656549453735}",,,,,,,,,,['neutral'],neutral,1
NCT01730534,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1812389', 'title': 'Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Nov 10, 2018', 'snippet': 'The cardiovascular safety profile of dapagliflozin, a selective inhibitor \nof sodium–glucose cotransporter 2 that promotes glucosuria in...', 'thumbnail': 'https://serpapi.com/searches/67246f0ca505f7b93bf42878/images/90964dc8e908f0ac87c63016d4e9cb1c36f8c941e0d6bafae56cc8c81682727c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.876888632774353}",,,,,,,,,,['neutral'],neutral,1
NCT02039687,"{'position': 1, 'link': 'https://sarcoidosisnews.com/news/cibinetide-seems-to-regenerate-nerve-fibers-improve-pain-in-sarcoidosis-patients/', 'title': 'Cibinetide Seems to Regenerate Nerve Fibers, Improve Pain in Sarcoidosis Patients', 'source': 'Sarcoidosis News', 'date': 'May 10, 2017', 'snippet': 'Treatment with cibinetide (ARA 290) was shown to promote significant \ncorneal nerve and improve pain and functional capacity in a clinical trial \nwith...', 'thumbnail': 'https://serpapi.com/searches/67246f0e9f8bfc8b7389a0f4/images/b60354c01fb745b08cefe6ab423df4c2c1f58fa85875c5de2b560505e808c815.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6301226019859314}",,,,,,,,,,['positive'],positive,1
NCT05259917,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2314192', 'title': 'Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks', 'source': 'The New England Journal of Medicine', 'date': 'May 31, 2024', 'snippet': 'In this phase 3, double-blind, three-way crossover trial, we randomly \nassigned participants at least 12 years of age with type 1 or type 2...', 'thumbnail': 'https://serpapi.com/searches/67246f1164f11d5673dd9e35/images/0d00320807e3166cbf2fd9cb2da68a41e91c92282ff51e40f301d7b240411188.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9219282865524292}","{'position': 2, 'link': 'https://angioedemanews.com/news/young-children-with-hae-tested-new-clinical-trial-oral-sebetralstat/', 'title': 'Young children with HAE to be tested in new clinical trial of oral sebetralstat', 'source': 'Angioedema News', 'date': 'Jul 8, 2024', 'snippet': 'KalVista Pharmaceuticals has started a clinical trial to test the oral \nmedication sebetralstat as an on-demand treatment for swelling attacks in \nchildren with...', 'thumbnail': 'https://serpapi.com/searches/67246f1164f11d5673dd9e35/images/0d00320807e3166c7fec182e12575e8df11001ca2a43073894132d0e71205db7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9251697063446045}","{'position': 3, 'link': 'https://angioedemanews.com/news/phase-3-trial-sebetralstat-kvd900-fully-enrolled/', 'title': 'Phase 3 trial of sebetralstat (KVD900) in treating attacks fully...', 'source': 'Angioedema News', 'date': 'Jul 10, 2023', 'snippet': 'The Phase 3 clinical trial of oral sebetralstat as an on-demand treatment \nfor swelling attacks in people with hereditary angioedema (HAE) has reached \nits...', 'thumbnail': 'https://serpapi.com/searches/67246f1164f11d5673dd9e35/images/0d00320807e3166cfc62b4722696e646749b48dc16437e02221af7ffdd40368b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8326175808906555}","{'position': 4, 'link': 'https://angioedemanews.com/news/targeted-treated-attack-number-met-phase-3-sebetralstat-trial/', 'title': 'Targeted treated attack number met in Phase 3 sebetralstat trial', 'source': 'Angioedema News', 'date': 'Dec 4, 2023', 'snippet': 'The Phase 3 KONFIDENT trial, testing oral sebetralstat on demand for HAE, \nhas achieved its targeted number of on-treatment attacks.', 'thumbnail': 'https://serpapi.com/searches/67246f1164f11d5673dd9e35/images/0d00320807e3166c2961197a7d8c46dd0e391469fa1c7deeb8e33f38c81fa55e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8411319255828857}","{'position': 5, 'link': 'https://angioedemanews.com/news/on-demand-sebetralstat-quickly-eases-attacks-long-term-hae-trial/', 'title': 'On-demand sebetralstat quickly eases attacks in long-term HAE trial', 'source': 'Angioedema News', 'date': 'Jun 13, 2024', 'snippet': 'Most HAE patients experienced symptom relief within two hours of \nsebetralstat treatment and had complete attack resolution within a day,...', 'thumbnail': 'https://serpapi.com/searches/67246f1164f11d5673dd9e35/images/0d00320807e3166c3acacfaa3cc38c03aabb04b04d4f553dece5f83ed9a41466.png', 'sentiment': 'positive', 'sentiment_prob': 0.6647995114326477}","{'position': 6, 'link': 'https://angioedemanews.com/news/fda-consider-sebetralstat-on-demand-treatment-hae/', 'title': 'FDA to consider sebetralstat as on-demand treatment for HAE', 'source': 'Angioedema News', 'date': 'Sep 5, 2024', 'snippet': ""The US Food and Drug Administration (FDA) has agreed to review Kalvista \nPharmaceuticals' application seeking the approval of sebetralstat as an \non-demand..."", 'thumbnail': 'https://serpapi.com/searches/67246f1164f11d5673dd9e35/images/0d00320807e3166c40ce5182829a36cd774c8911b35e48efecb9dc23167d2a87.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9247790575027466}","{'position': 7, 'link': 'https://angioedemanews.com/news/hae-patients-use-on-demand-care-despite-preventive-treatment/', 'title': 'Despite preventive treatment, HAE patients require on-demand care', 'source': 'Angioedema News', 'date': 'Oct 26, 2023', 'snippet': 'Even with long-term care, many HAE patients still have swelling attacks \nthat require on-demand attention, a KalVista-funded study suggests.', 'thumbnail': 'https://serpapi.com/searches/67246f1164f11d5673dd9e35/images/0d00320807e3166cb92961110cb16b65bc4f8b2cfbcce50a39779d8f5e755c40.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5112860798835754}","{'position': 8, 'link': 'https://angioedemanews.com/news/kalvista-ends-trial-kvd824-hereditary-angioedema/', 'title': 'KalVista Ends Trial of KVD824 for Hereditary Angioedema |...', 'source': 'Angioedema News', 'date': 'Oct 6, 2022', 'snippet': 'The KOMPLETE Phase 2 clinical trial, testing oral KVD824 to prevent attacks \nin people with HAE, has been terminated by KalVista.', 'thumbnail': 'https://serpapi.com/searches/67246f1164f11d5673dd9e35/images/0d00320807e3166c8bb4d4d7251181238b0c174587ea0861f2685fff847b41c9.png', 'sentiment': 'negative', 'sentiment_prob': 0.6245256066322327}",,,"['neutral', 'neutral', 'neutral', 'neutral', 'positive', 'neutral', 'negative', 'negative']",neutral,1
NCT01677780,"{'position': 1, 'link': 'https://pubs.acs.org/doi/10.1021/jm501092z', 'title': 'Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment', 'source': 'ACS Publications', 'date': 'Nov 14, 2014', 'snippet': 'Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 \nprotein–protein interaction has been pursued as a new cancer...', 'thumbnail': 'https://serpapi.com/searches/67246f1cfda26d6e63e8cc9d/images/db4aea6dfe92022d07bf13dff02119924390db1c2161a96338b9560a92312c51.png', 'sentiment': 'neutral', 'sentiment_prob': 0.838661253452301}",,,,,,,,,,['neutral'],neutral,1
NCT02604433,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1910182', 'title': 'A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia', 'source': 'The New England Journal of Medicine', 'date': 'Mar 25, 2020', 'snippet': 'Patients with transfusion-dependent β-thalassemia need regular red-cell \ntransfusions. Luspatercept, a recombinant fusion protein that binds...', 'thumbnail': 'https://serpapi.com/searches/67246f6c51d84d907a8b1fa6/images/4f1171a6e03b208e94608bbdbc1bf4123e0bf73a3a9d98b92387391dfbaffffe.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9287397861480713}",,,,,,,,,,['neutral'],neutral,1
NCT02847598,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2118025', 'title': 'Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus', 'source': 'The New England Journal of Medicine', 'date': 'Sep 7, 2022', 'snippet': 'Antibody-binding of blood dendritic cell antigen 2 (BDCA2), which is \nexpressed exclusively on plasmacytoid dendritic cells, suppresses the...', 'thumbnail': 'https://serpapi.com/searches/67246f742c83d5f870d2c73d/images/0615634bde872c5f14fa110a26009951f28116ee33f62a3af896979cb79679ab.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6943677067756653}",,,,,,,,,,['neutral'],neutral,1
NCT03247309,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-023-00458-w', 'title': 'NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology', 'source': 'Nature', 'date': '26 Eki 2023', 'snippet': 'This manual is intended to be useful for physicians, biologists, and \nbioinformaticians involved in the clinical interpretation of genome-wide \nmolecular...', 'thumbnail': 'https://serpapi.com/searches/67246f7f66d99523296e8cc5/images/fe67a9f4b918b6735aafc99fb2af5a5bd425425086a167efc0278a65c1961cc6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7365184426307678}",,,,,,,,,,['neutral'],neutral,1
NCT05758428,"{'position': 1, 'link': 'https://copdnewstoday.com/news/first-copd-patient-dosed-ensifentrine-enhance-china-trial/', 'title': 'Dosing with ensifentrine begins in ENHANCE China trial | Phase 3...', 'source': 'COPD News Today', 'date': 'Apr 24, 2023', 'snippet': 'Dosing with ensifentrine, a nebulized inhalation therapy, has begun in a \nPhase 3 trial in China in adults with moderate-to-severe COPD.', 'thumbnail': 'https://serpapi.com/searches/67246f85ee46820083b7658f/images/560ca8250411b33c5e92f612ad14bcf460e94ce74291c3ae171d62bfd4d45e1a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9163825511932373}",,,,,,,,,,['neutral'],neutral,1
NCT03370133,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-bimzelx-for-plaque-psoriasis/', 'title': 'FDA Approves Bimzelx for Moderate to Severe Plaque Psoriasis', 'source': 'Medical Professionals Reference', 'date': 'Oct 18, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Bimzelx \n(bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis \nin adults.', 'thumbnail': 'https://serpapi.com/searches/67246fbdf9f904fd8c172d9a/images/5b9ccf304e6aaa35e6c1dd0ce548de73d645b3bbd27eca3f577de518ee8da16a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7481014132499695}",,,,,,,,,,['neutral'],neutral,1
NCT01506882,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Keppra-levetiracetam', 'title': 'Levetiracetam (Keppra®)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Epilepsy, A Study of Levetiracetam as Monotherapy or Adjunctive Treatment \nof Partial Seizures in Pediatric Epileptic Subjects Ranging From 1...', 'thumbnail': 'https://serpapi.com/searches/67246fdd7d533eb4a1b8667e/images/072d66242022c164da6e9d4a31edfde656c8bd2a75f7bd73f648a7d4eab91f78.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9234092831611633}",,,,,,,,,,['neutral'],neutral,1
NCT00412893,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-31788-1', 'title': 'Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies', 'source': 'Nature', 'date': 'Apr 25, 2023', 'snippet': 'Isavuconazole is a triazole with broad-spectrum antifungal activity. In \nthis post-hoc analysis of two prospective clinical trials (VITAL and...', 'thumbnail': 'https://serpapi.com/searches/67246fee6f9f63089737c8bc/images/a9b16e6e11ed2df5d13421c5a55c38a6b202bd4ef2a09fbe5016f669dbf8247a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8639057874679565}",,,,,,,,,,['neutral'],neutral,1
NCT02336230,"{'position': 1, 'link': 'https://www.cgtlive.com/view/mesoblast-third-push-remestemcel-l-approval-gvhd-ryoncil', 'title': ""Mesoblast Gears Up for Third Push for Remestemcel-L's Approval in GvHD"", 'source': 'CGTLive®', 'date': 'Sep 22, 2023', 'snippet': 'Mesoblast is continuing its push to try and get its mesenchymal stromal \ncell therapy remestemcel-L approved to treat pediatric and adult \nsteroid-refractory...', 'thumbnail': 'https://serpapi.com/searches/67246ff848c4292dca67a305/images/03b5b694ce0d1904211e751dbfca65cef8c0be1c630c829fefaeb483ff8d11fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.62732994556427}","{'position': 2, 'link': 'https://epidermolysisbullosanews.com/news/approval-of-off-the-shelf-stem-cell-therapy-to-treat-epidermolysis-bullosa-sought-in-japan-jcr-pharmaceuticals-says/', 'title': 'Off-the-Shelf Stem Cell Therapy for Epidermolysis Bullosa Seeks Approval in Japan', 'source': 'Epidermolysis Bullosa News', 'date': 'Apr 26, 2019', 'snippet': 'JCR Pharmaceuticals is asking regulators in Japan to extend the use of \nTemcell HS Injection, an allogeneic mesenchymal stem cell therapy,...', 'thumbnail': 'https://serpapi.com/searches/67246ff848c4292dca67a305/images/03b5b694ce0d190490ed6f6accce456da473f884cc9dda4aff3e40d2256c3061.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9195193648338318}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03183128,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2106516', 'title': 'SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection', 'source': 'The New England Journal of Medicine', 'date': 'Jan 19, 2022', 'snippet': 'SER-109 is an investigational microbiome therapeutic composed of purified \nFirmicutes spores for the treatment of recurrent C. difficile infection.', 'thumbnail': 'https://serpapi.com/searches/67247030a2e99c0092bb1df0/images/9a18245629394d14261812bce5f20194ee1d80b27fd685c2266107ed00be258f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8969530463218689}","{'position': 2, 'link': 'https://www.empr.com/home/news/vowst-approved-to-prevent-recurrent-c-difficile-infection/', 'title': 'Vowst Approved to Prevent Recurrent C. difficile Infection - MPR', 'source': 'Medical Professionals Reference', 'date': 'Apr 27, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Vowst™ (fecal \nmicrobiota spores, live-brpk) to prevent the recurrence of Clostridioides...', 'thumbnail': 'https://serpapi.com/searches/67247030a2e99c0092bb1df0/images/9a18245629394d14cf12b9a9359f5af6ddbbb064a53c33e637130e0bab84139e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8683273196220398}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03873493,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-021-00443-1', 'title': 'Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia', 'source': 'Nature', 'date': 'Mar 2, 2021', 'snippet': 'We report outcomes of patients with relapsed/refractory T-PLL treated with \nvenetoclax at our institution.', 'thumbnail': 'https://serpapi.com/searches/67247042e8735a843d134255/images/625ff034f165bb24258c17165ae994f6c8e0d40adef1af96dc8c1ab221d9dd41.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8926013708114624}",,,,,,,,,,['neutral'],neutral,1
NCT01360645,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/efficacy-safety-adjunctive-brexpiprazole-mg-major/', 'title': 'Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants', 'source': 'Psychiatrist.com', 'date': '٢٣\u200f/٠٩\u200f/٢٠١٥', 'snippet': 'Adjunctive brexpiprazole therapy demonstrated efficacy and was well \ntolerated in patients with major depressive disorder and inadequate \nresponse to ADTs.', 'thumbnail': 'https://serpapi.com/searches/6724709e175de6d8e6754f61/images/99f41e85ddf8080cd7f97fc6189bd25ee5b9d0211fa57da6047308f547da9f7f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8064937591552734}",,,,,,,,,,['neutral'],neutral,1
NCT01603602,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-to-review-botox-for-upper-lower-limb-pediatric-spasticity/', 'title': 'FDA to Review Botox for Upper, Lower Limb Pediatric Spasticity', 'source': 'Medical Professionals Reference', 'date': 'Mar 7, 2019', 'snippet': 'Allergan announced that the Food and Drug Administration (FDA) has accepted \nfor review the supplemental Biologics License Applications...', 'thumbnail': 'https://serpapi.com/searches/672470d4f59d0009a46b5c39/images/4d7d40063779911bde74da9d9e0d28e34a81bbf7cf872e0c15bb4ed931892a73.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.91532963514328}",,,,,,,,,,['neutral'],neutral,1
NCT02454972,"{'position': 1, 'link': 'https://www.empr.com/home/news/zepzelca-lurbinectedin-sclc-small-cell-lung-cancer-platinum-based-chemotherapy/', 'title': 'Zepzelca Approved for Metastatic Small Cell Lung Cancer', 'source': 'Medical Professionals Reference', 'date': 'Jun 17, 2020', 'snippet': 'The Food and Drug Administration has approved Zepzelca™ (lurbinectedin; \nJazz Pharmaceuticals) for the treatment of adult patients with...', 'thumbnail': 'https://serpapi.com/searches/67247100b6ed334a79d8124b/images/1a3353c223b92744f9c2ee1df3b539e48c94c4c0a174b026789019527b336db1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7931093573570251}",,,,,,,,,,['neutral'],neutral,1
NCT03061201,"{'position': 1, 'link': 'https://hemophilianewstoday.com/news/fda-lifts-hold-phase-3-trial-gene-therapy-sb-525-hemophilia-a/', 'title': 'FDA Lifts Hold on Phase 3 Trial of Gene Therapy SB-525 for Hem A', 'source': 'Hemophilia News Today', 'date': 'May 6, 2022', 'snippet': 'The FDA has lifted a clinical hold on the trial testing the safety and \neffectiveness of SB-525, an experimental gene therapy for hemophilia...', 'thumbnail': 'https://serpapi.com/searches/6724705168831e63a4ce28af/images/6e5cc7317618db1766a1f692c6b18662ee81c0f0dadf5de678f25b097338f702.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8810768127441406}","{'position': 2, 'link': 'https://www.nature.com/articles/s41434-022-00353-2', 'title': 'Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials', 'source': 'Nature', 'date': 'Jul 1, 2022', 'snippet': 'Recombinant adeno-associated virus (AAV) vectors are the leading platform \nfor gene delivery for a variety of clinical applications.', 'thumbnail': 'https://serpapi.com/searches/6724705168831e63a4ce28af/images/6e5cc7317618db174d5094b8747eca1b4ba8cdf59f12facc1401b6bd90f7c7c3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9051162004470825}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05572333,"{'position': 1, 'link': 'https://copdnewstoday.com/news/fda-oks-phase-2-clinical-trial-ep395-copd-patients/', 'title': 'FDA OKs Phase 2 Clinical Trial of EP395 for COPD Patients', 'source': 'COPD News Today', 'date': 'Nov 28, 2022', 'snippet': 'The US Food and Drug Administration (FDA) has authorized EpiEndo \nPharmaceuticals to conduct a Phase 2a clinical trial of its antibiotic \ntreatment EP395 in...', 'thumbnail': 'https://serpapi.com/searches/6724705c98876d3dd867d09d/images/9d73230419f5b7fc22757723008296c9e5a8864d003e9588aefff4ba091baa8c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8805156350135803}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20240410505161/en/EpiEndo-reports-Phase-2A-results-for-lead-asset-EP395-in-COPD', 'title': 'EpiEndo reports Phase 2A results for lead asset, EP395, in COPD', 'source': 'Business Wire', 'date': 'Apr 10, 2024', 'snippet': ""EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage \nbiopharmaceutical company developing a new class of oral,..."", 'thumbnail': 'https://serpapi.com/searches/6724705c98876d3dd867d09d/images/9d73230419f5b7fc9c8d2b4f8d209779c2c687d1434058916c1bd67c8378e9f9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7426509857177734}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03650491,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20210329005145/en/CORRECTING-and-REPLACING-Fortis-Therapeutics-Closes-40-Million-Series-A-Financing-to-Advance-Novel-Anti-CD46-Therapeutic-to-Treat-Late-Stage-Prostate-Cancer-and-Multiple-Myeloma', 'title': 'CORRECTING and REPLACING Fortis Therapeutics Closes $40 Million Series A Financing to Advance Novel Anti-CD46 Therapeutic to Treat Late-Stage Prostate Cancer and Multiple Myeloma', 'source': 'Business Wire', 'date': 'Mar 29, 2021', 'snippet': 'Fortis Therapeutics, Inc., an immuno-oncology biotech developing FOR46, a \nnovel antibody drug conjugate (ADC) against CD46, today announced the close \nof a $40...', 'thumbnail': 'https://serpapi.com/searches/672471085bb6a21d8307913c/images/74ce07c0529c97694ba713943ef3da4f38d78a8ba962bb2fb08d791fbdcefedf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8745080232620239}",,,,,,,,,,['neutral'],neutral,1
NCT02751931,"{'position': 1, 'link': 'https://www.empr.com/home/news/myrbetriq-mirabegron-er-approved-pediatric-neurogenic-detrusor-overactivity/', 'title': 'Myrbetriq Approved for Pediatric Neurogenic Detrusor Overactivity', 'source': 'Medical Professionals Reference', 'date': 'Mar 29, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Myrbetriq (mirabegron \nextended-release tablets) and Myrbetriq Granules (mirabegron for \nextended-release...', 'thumbnail': 'https://serpapi.com/searches/67247120740bdb3eeb124148/images/26b4000c0f8a4884a7a4a1fa952d8925a0db5fe3bbcc933a7533b8179ac2074c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8480504155158997}",,,,,,,,,,['neutral'],neutral,1
NCT02981368,"{'position': 1, 'link': 'https://www.gov.uk/government/news/piflufolastat-approved-as-diagnostic-tool-for-adults-with-prostate-cancer', 'title': 'Piflufolastat approved as diagnostic tool for adults with prostate cancer', 'source': 'GOV.UK', 'date': 'Mar 6, 2024', 'snippet': 'The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 \nMarch 2024) approved the medicine piflufolastat (18F) (Pylclari)...', 'thumbnail': 'https://serpapi.com/searches/6724739d93bb578191022028/images/43c0e1b8de8c87da4b2bdb2ea1ef245b59a8736577e31bafb57e39c6c109f69f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8251745104789734}",,,,,,,,,,['neutral'],neutral,1
NCT01225562,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1500857', 'title': 'Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction', 'source': 'The New England Journal of Medicine', 'date': 'Mar 14, 2015', 'snippet': 'The potential benefit of dual antiplatelet therapy beyond 1 year after a \nmyocardial infarction has not been established.', 'thumbnail': 'https://serpapi.com/searches/67247170d11195d39ee015b1/images/ca46168c397f959d0b37330ec27d26badf7107e29fb2a72b2690bdb194e5525e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8842801451683044}","{'position': 2, 'link': 'https://www.researchgate.net/figure/Risk-factors-of-high-moderate-ischemic-and-high-bleeding-risk-in-patients-with-chronic_tbl1_344651971', 'title': 'Risk factors of high/moderate ischemic and high bleeding risk in...', 'source': 'ResearchGate', 'date': 'Oct 17, 2020', 'snippet': 'The increased risk of non-cardiovascular death in patients receiving \nclopidogrel or prasugrel in comparison with the placebo group in the dual \nantiplatelet...', 'thumbnail': 'https://serpapi.com/searches/67247170d11195d39ee015b1/images/ca46168c397f959d918c5591f00440916fa40d211b91c4f2318dd25fe0443cef.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5228843688964844}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03398655,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2020/06/09/vb-111-ovarian-cancer-chemo-combo-continues-show-promise-new-trial-data-shows/', 'title': 'More Than Half of Patients Respond to VB-111 Chemo Combo, Trial Data Shows', 'source': 'Ovarian Cancer News Today', 'date': 'Jun 9, 2020', 'snippet': 'VB-111 continues to show promise against platinum-resistant ovarian cancer, \nwith more than half of patients responding to the treatment,...', 'thumbnail': 'https://serpapi.com/searches/6724717368831e63a4ce28e8/images/87a9d9ec5d238c3d65c12d8660e13e77e1bd063a51524672f8c11cbdf311ac22.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5964533090591431}",,,,,,,,,,['positive'],positive,1
NCT02600507,"{'position': 1, 'link': 'https://www.empr.com/home/news/caplyta-approved-for-bipolar-depression-in-adults/', 'title': 'Caplyta Approved for Bipolar Depression in Adults', 'source': 'Medical Professionals Reference', 'date': 'Dec 20, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Caplyta (lumateperone) \nfor the treatment of depressive episodes associated with bipolar I or II \ndisorder in...', 'thumbnail': 'https://serpapi.com/searches/672471a28cf8ae01ee852825/images/066534c83425eea27366fe2ce3142956992cde1adb4f4116de8d8cf887869a20.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7934946417808533}",,,,,,,,,,['neutral'],neutral,1
NCT04480840,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/psc-treatment-bexotegrast-safe-eases-liver-scarring-early-trial/', 'title': 'PSC treatment bexotegrast safe, eases liver scarring in early trial', 'source': 'Liver Disease News', 'date': 'Jul 17, 2024', 'snippet': 'A high dose of oral PSC treatment bexotegrast safely reduced markers of \nprimary sclerosing cholangitis progression in a trial.', 'thumbnail': 'https://serpapi.com/searches/67247340e92456efd939a92c/images/a981bf690932686f62f003d6fb4e02ae86310a3ed29e944dd6f6ccd830e01be9.png', 'sentiment': 'positive', 'sentiment_prob': 0.5395350456237793}","{'position': 2, 'link': 'https://liverdiseasenews.com/news/bexotegrast-shows-positive-signs-psc-treatment-phase-2-trial/', 'title': 'Bexotegrast shows positive signs as PSC treatment in Phase 2 trial', 'source': 'Liver Disease News', 'date': 'Feb 21, 2024', 'snippet': 'All doses of bexotegrast tested in primary sclerosing cholangitis patients \nin a clinical trial showed signs of efficacy as a PSC treatment.', 'thumbnail': 'https://serpapi.com/searches/67247340e92456efd939a92c/images/a981bf690932686fcc0e67eb7231d9266acc97002d366caeb284961dafb54bbd.png', 'sentiment': 'positive', 'sentiment_prob': 0.514565646648407}",,,,,,,,,"['positive', 'positive']",positive,1
NCT00122330,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa061648', 'title': 'The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria', 'source': 'The New England Journal of Medicine', 'date': 'Aug 9, 2017', 'snippet': 'Eculizumab stabilized hemoglobin levels and reduced transfusion \nrequirements in 87 transfusion-dependent patients with PNH during 6 months \nof treatment.', 'thumbnail': 'https://serpapi.com/searches/672471edd11a89e484914aea/images/3907183093b86d073fad8b263b1ef67be7319cf37fe4ca96bf70620d61ad64c1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9098618626594543}",,,,,,,,,,['neutral'],neutral,1
NCT03548207,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/carvykti-effective-treating-multiple-myeloma-real-world/', 'title': 'Carvykti found effective at treating multiple myeloma in real world', 'source': 'Myeloma Research News', 'date': '2 weeks ago', 'snippet': 'Carvykti was found to be similarly effective for treating multiple myeloma \npatients in real-world clinical practice as in clinical trials.', 'thumbnail': 'https://serpapi.com/searches/67247208ce1a756514f99615/images/5b2eb8d3504ae411dfde6e6702fb05f624363f04a947bda6a450512e318d89b7.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7464768886566162}","{'position': 2, 'link': 'https://www.cgtlive.com/view/janssen-no-longer-seeking-approval-carvykti-uk', 'title': 'Janssen No Longer Seeking Approval for Carvykti in the UK', 'source': 'CGTLive®', 'date': 'Mar 17, 2023', 'snippet': 'Patients in the UK with r/r multiple myeloma may still be able to access \nthe CAR-T through ongoing clinical trials, which are not impacted...', 'thumbnail': 'https://serpapi.com/searches/67247208ce1a756514f99615/images/5b2eb8d3504ae411103c2f75b211b1cc8617e63694fa12e5dfc99c2ed4f2cfb1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8409854769706726}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/cilta-cel-yields-pfs-durable-responses-in-r-r-multiple-myeloma', 'title': 'Cilta-Cel Yields PFS, Durable Responses in R/R Multiple Myeloma', 'source': 'Cancer Network', 'date': 'Sep 9, 2023', 'snippet': 'Patients with multiple myeloma and enduring MRD-negativity are able to \nachieve the deepest responses with ciltacabtagene autoleucel,...', 'thumbnail': 'https://serpapi.com/searches/67247208ce1a756514f99615/images/5b2eb8d3504ae411861ca2dc79d2430e4744cfb227c00e631da95ed22bab54b7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7981886863708496}","{'position': 4, 'link': 'https://myelomaresearchnews.com/news/europe-committee-medicinal-products-human-use-supports-carvykti-car-t-cell-therapy-approval/', 'title': ""Myeloma Immunotherapy, Carvykti, Is Recommended by Europe's CHMP"", 'source': 'Myeloma Research News', 'date': 'Apr 4, 2022', 'snippet': ""An arm of the European Medicines Agency, CHMP, has recommended Carvykti, a \nT-cell therapy, be OK'd for eligible adults with multiple..."", 'thumbnail': 'https://serpapi.com/searches/67247208ce1a756514f99615/images/5b2eb8d3504ae4117fe7a014e1e9febb662fd0731d8f402c71ecb91cf9d86970.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7035571336746216}",,,,,,,"['positive', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02921789,"{'position': 1, 'link': 'https://www.nature.com/articles/s41581-021-00427-1', 'title': 'Therapeutic trials in adult FSGS: lessons learned and the road forward', 'source': 'Nature', 'date': 'May 20, 2021', 'snippet': 'Focal segmental glomerulosclerosis (FSGS) is not a specific disease entity \nbut a lesion that primarily targets the podocyte.', 'thumbnail': 'https://serpapi.com/searches/672472e4123457faf321159e/images/91c8c349f7d041541f1298b8e1a8e19d546e36946c46f346ea925bbb33c363a5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8861932754516602}",,,,,,,,,,['neutral'],neutral,1
NCT02949128,"{'position': 1, 'link': 'https://ahusnews.com/news/ultomiris-safe-effective-women-postpartum-ahus-311-trial-data/', 'title': 'Ultomiris Safe, Effective for Women with Postpartum aHUS, Data Show', 'source': 'aHUS News', 'date': 'Mar 3, 2021', 'snippet': 'Ultomiris safely and effectively treated women with atypical hemolytic \nuremic syndrome triggered by pregnancy, trial data show.', 'thumbnail': 'https://serpapi.com/searches/672472530e6db3be0410f555/images/b8c30366c524f408d7001c5b2dfc0269840abc9649126a1fd18969ce9617aacc.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7525551319122314}",,,,,,,,,,['positive'],positive,1
NCT04516746,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2105290', 'title': 'Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine', 'source': 'The New England Journal of Medicine', 'date': 'Sep 29, 2021', 'snippet': 'The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a \nlarge, diverse population at increased risk for severe acute...', 'thumbnail': 'https://serpapi.com/searches/67247265ee677f09ee97cf87/images/361e7a77909ea445c5a0be0ebfd88503dbbf121610abbb079f374ba40241b718.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8425669074058533}","{'position': 2, 'link': 'https://www.nih.gov/news-events/news-releases/phase-3-clinical-testing-us-astrazeneca-covid-19-vaccine-candidate-begins', 'title': 'Phase 3 Clinical Testing in the US of AstraZeneca COVID-19 Vaccine Candidate Begins', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Aug 31, 2020', 'snippet': 'The trial will enroll approximately 30000 adult volunteers at 80 sites in \nthe United States to evaluate if the candidate vaccine can prevent...', 'thumbnail': 'https://serpapi.com/searches/67247265ee677f09ee97cf87/images/361e7a77909ea445873694882b1e4e7148e34a5eca162a1c0917d6ca11be697f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9434553980827332}","{'position': 3, 'link': 'https://www.europeanpharmaceuticalreview.com/news/148426/us-finds-covid-19-vaccine-astrazeneca-safe-and-effective/', 'title': 'US finds COVID-19 Vaccine AstraZeneca safe and effective', 'source': 'European Pharmaceutical Review', 'date': 'Mar 23, 2021', 'snippet': ""An analysis of 20000 vaccinnees shows AstraZeneca's vaccine completely \nprevents hospitalisation and severe or critical COVID-19."", 'thumbnail': 'https://serpapi.com/searches/67247265ee677f09ee97cf87/images/361e7a77909ea4458e49872aa21583c3ebfa4446392bec2fb61fb40d4d9f8df0.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6573571562767029}",,,,,,,,"['neutral', 'neutral', 'positive']",neutral,1
NCT02869295,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-019-12901-3', 'title': 'Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist', 'source': 'Nature', 'date': 'Jan 31, 2020', 'snippet': 'Interleukin-2 (IL-2) is a component of most protocols of adoptive cell \ntransfer (ACT) therapy for cancer, but is limited by short exposure...', 'thumbnail': 'https://serpapi.com/searches/6724726756f970aa14165a9a/images/02f643aadb16e517819c92cf21f7d8d5005a0139b05a2e2670c42d5ab5880a9e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8891305327415466}",,,,,,,,,,['neutral'],neutral,1
NCT02651428,"{'position': 1, 'link': 'https://www.renalandurologynews.com/news/adding-taurolidine-to-heparin-cuts-risk-for-catheter-related-bloodstream-infections/', 'title': 'Adding Taurolidine to Heparin Cuts Risk for Catheter-Related Bloodstream Infections', 'source': 'Renal and Urology News', 'date': 'Sep 28, 2023', 'snippet': 'Taurolidine is an antibacterial and antifungal agent with a mechanism of \naction that is less prone to development of antimicrobial...', 'thumbnail': 'https://serpapi.com/searches/6724726cbbc18b33ac2db5df/images/3e369dc7ace1e83448a1b4a7c44a105d5111ffc1652a1366f011634364dae014.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7450513243675232}",,,,,,,,,,['neutral'],neutral,1
NCT03530696,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-021-00311-y', 'title': 'Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer', 'source': 'Nature', 'date': 'Aug 4, 2021', 'snippet': 'Patients with HER2+ metastatic breast cancer are often treated with a \nmultitude of therapies in the metastatic setting, and additional...', 'thumbnail': 'https://serpapi.com/searches/6724727e93bb57815ae7b63c/images/d3ae80a40d3c4f2d0ad55abb519b125815fd1448619caa1207572470a55e3363.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8565197587013245}",,,,,,,,,,['neutral'],neutral,1
NCT00307619,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/double-blind-randomized-placebo-controlled-trial-topiramate/', 'title': 'Double-Blind, Randomized, Placebo-Controlled Trial of Topiramate Plus Cognitive-Behavior Therapy in Binge-Eating Disorder', 'source': 'Psychiatrist.com', 'date': 'Sep 17, 2007', 'snippet': 'Topiramate added to CBT improved the efficacy of the later, increasing \nbinge remission and weight loss in the short run. Topiramate was well \ntolerated.', 'thumbnail': 'https://serpapi.com/searches/6724728654605c64279508f3/images/373ab2e60e2655e9933cdba31751b64ddf800c0ccfec0d81aeaaf93373e0fba1.png', 'sentiment': 'positive', 'sentiment_prob': 0.4973757565021515}",,,,,,,,,,['positive'],positive,1
NCT02688647,"{'position': 1, 'link': 'https://lungdiseasenews.com/2018/02/19/phase-2-trial-shows-kd025-has-potential-treat-ipf-patients/', 'title': ""Kadmon's KD025 Has Potential to Treat IPF Patients, Phase 2 Trial Shows"", 'source': 'Lung Disease News', 'date': 'Feb 19, 2018', 'snippet': ""Find more about Kadmon's investigative drug KD025 and its potential to \nprevent lung function decline in patients with idiopathic pulmonary..."", 'thumbnail': 'https://serpapi.com/searches/6724729576079d5273772bfb/images/4d4fe410612821551f1cbbf159821867908e1604fb53c99e71b1dd4704cabf01.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8374477624893188}",,,,,,,,,,['neutral'],neutral,1
NCT03979313,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-40057-8', 'title': 'Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials', 'source': 'Nature', 'date': 'Jul 19, 2023', 'snippet': 'Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial \nvirus (RSV) fusion protein. During the Phase 2b (NCT02878330)...', 'thumbnail': 'https://serpapi.com/searches/672472a548b9f737d67fdf14/images/23e396bca553a6380aa5c7c54d2d7055cce5d03ffe5cf0257145c388f48b2a2c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9245671629905701}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/nirsevimab-looks-promising-for-protection-against-rsv-for-all-infants/', 'title': 'Nirsevimab Looks Promising for Protection Against RSV for All Infants', 'source': 'Medical Professionals Reference', 'date': 'Mar 4, 2022', 'snippet': 'Positive results were announced from the phase 3 MELODY and phase 2/3 \nMEDLEY trials evaluating nirsevimab for prevention of...', 'thumbnail': 'https://serpapi.com/searches/672472a548b9f737d67fdf14/images/23e396bca553a6386ba6ff0b8bc0251928f1c3d8bd24482b621df3d4e15d238b.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.758328378200531}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT01700751,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-020-0804-2', 'title': 'Treatment and unmet needs in steroid-refractory acute graft-versus-host disease - Leukemia', 'source': 'Nature', 'date': 'Apr 3, 2020', 'snippet': 'This paper reviews current treatment options for patients with \nsteroid-refractory aGVHD and discusses data from recently published \nclinical studies.', 'thumbnail': 'https://serpapi.com/searches/672472ccdda9d9315b739295/images/a11ab98d31caf8b593dddc457ed434eb1d0e11dce88c6bd78c3b36ecb6df1752.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8884297609329224}",,,,,,,,,,['neutral'],neutral,1
NCT03619213,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2206286', 'title': 'Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction', 'source': 'The New England Journal of Medicine', 'date': 'Aug 27, 2022', 'snippet': 'Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of \nhospitalization for heart failure and cardiovascular death among patients \nwith chronic...', 'thumbnail': 'https://serpapi.com/searches/672473dc6f9f6308c942fdc7/images/170307f16bfb6120d6dfb3e5de0901ea81a18743fc7fcef6588f54ead55f7dee.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7346020340919495}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/dapagliflozin-reduces-cv-death-heart-failure-worsening-in-hfpef-patients/', 'title': 'Dapagliflozin Reduces CV Death, Heart Failure Worsening in HFpEF Patients', 'source': 'Medical Professionals Reference', 'date': 'May 5, 2022', 'snippet': 'Dapagliflozin reduced the risk of cardiovascular death or worsening of \nheart failure in heart failure & preserved ejection fraction.', 'thumbnail': 'https://serpapi.com/searches/672473dc6f9f6308c942fdc7/images/170307f16bfb6120c6cc35a98f3d34abcb06224d635293e88ac0b7a0388127cc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7041656374931335}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05233774,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/lomecel-b-fda-rmat-status-mild-alzheimers/', 'title': 'Lomecel-B granted FDA RMAT status for mild Alzheimer’s', 'source': ""Alzheimer's News Today"", 'date': 'Jul 18, 2024', 'snippet': ""The U.S. Food and Drug Administration (FDA) has granted regenerative \nmedicine advanced therapy (RMAT) designation to Longeveron's..."", 'thumbnail': 'https://serpapi.com/searches/67248d46e8735a843d1348d9/images/bf65c036681bc8920bad364b4af858f41ccb0f89dc94d71598e7b3938159036c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8912283182144165}","{'position': 2, 'link': 'https://www.pharmacytimes.com/view/the-clearmind-trial-and-clinical-implications-of-lomecel-b-in-alzheimer-disease', 'title': 'The CLEARMIND Trial and Clinical Implications of Lomecel-B in Alzheimer Disease', 'source': 'Pharmacy Times', 'date': 'Aug 1, 2024', 'snippet': 'The co-founder, chief science officer, and chairman at Longeveron discusses \nthe findings from the phase 2a trial CLEARMIND, as well as next...', 'thumbnail': 'https://serpapi.com/searches/67248d46e8735a843d1348d9/images/bf65c036681bc892c6b9b6c53987960f3421476723b7c1cbffdc0f516a9fc63e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9403055906295776}","{'position': 3, 'link': 'https://www.cgtlive.com/view/hare-promising-data-lomecel-b-alzheimer-disease', 'title': 'Joshua M. Hare, MD, on Promising Data on Lomecel-B for Alzheimer Disease', 'source': 'CGTLive®', 'date': 'Jul 30, 2024', 'snippet': 'The cofounder and chief science officer of Longeveron discussed updated \ndata from the phase 2a CLEAR MIND study.', 'thumbnail': 'https://serpapi.com/searches/67248d46e8735a843d1348d9/images/bf65c036681bc89213e4f5e69f09891d79560931eba8ec13fe7e5230495cc09c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8583436608314514}","{'position': 4, 'link': 'https://www.neurologylive.com/view/understanding-therapeutic-potential-lomecel-b-alzheimer-disease-joshua-hare', 'title': 'Understanding the Therapeutic Potential of Lomecel-B for Alzheimer Disease: Joshua Hare, MD', 'source': 'Neurology live', 'date': 'Jul 30, 2024', 'snippet': 'The co-founder and chief science officer at Longeveron provided commentary \non the therapeutic potential of Lomecel-B, a living cell product...', 'thumbnail': 'https://serpapi.com/searches/67248d46e8735a843d1348d9/images/bf65c036681bc892e4fd7b7011042ac07efdfb72c32c11cdfbda0638b8e542da.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7707139849662781}","{'position': 5, 'link': 'https://alzheimersnewstoday.com/news/lomecel-b-cell-therapy-shows-promising-effects-alzheimers-trial/', 'title': 'Cell therapy Lomecel-B shows promising effects in Phase 2a trial', 'source': ""Alzheimer's News Today"", 'date': 'Dec 22, 2023', 'snippet': ""Treatment with Lomecel-B in early Alzheimer's patients led to improvements \nin cognitive tests relative to a placebo in a clinical trial."", 'thumbnail': 'https://serpapi.com/searches/67248d46e8735a843d1348d9/images/bf65c036681bc8925e011e5af0d31be630b4fd25db87abb10d78bc37b9910f46.png', 'sentiment': 'positive', 'sentiment_prob': 0.8894076943397522}","{'position': 6, 'link': 'https://www.cgtlive.com/view/hare-working-address-unmet-needs-alzheimer-lomecel-b', 'title': 'Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy', 'source': 'CGTLive®', 'date': 'Aug 7, 2024', 'snippet': 'The cofounder and chief science officer of Longeveron discussed working to \nshow potential benefits in a follow-up phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/67248d46e8735a843d1348d9/images/bf65c036681bc8924ebe04fa8c8bab170773e0ef5d7531b68189cc93d3833184.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7776760458946228}","{'position': 7, 'link': 'https://alzheimersnewstoday.com/news/miami-veterans-affairs-clinical-site-joins-phase-2-trial-lomecel-b-mild-alzheimers-disease/', 'title': 'Miami VA Clinical Site Joins Phase 2 Lomecel-B Clinical Trial', 'source': ""Alzheimer's News Today"", 'date': 'May 2, 2022', 'snippet': ""A Miami Veterans Affairs (VA) clinical site is now part of Longeveron's \nPhase 2a clinical trial testing Lomecel-B — an investigational,..."", 'thumbnail': 'https://serpapi.com/searches/67248d46e8735a843d1348d9/images/bf65c036681bc8929d7aec2195e12e3a4347248e44732d43708caa833e353301.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9383242130279541}",,,,"['neutral', 'neutral', 'neutral', 'neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT03006809,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-022-09307-5', 'title': 'Strain-resolved analysis in a randomized trial of antibiotic pretreatment and maintenance dose delivery mode with fecal microbiota transplant for ulcerative colitis', 'source': 'Nature', 'date': 'Apr 1, 2022', 'snippet': 'Fecal microbiota transplant is a promising therapy for ulcerative colitis. \nParameters maximizing effectiveness and tolerability are not yet...', 'thumbnail': 'https://serpapi.com/searches/67248d4ba32436769945e3ff/images/97f1bc0a15d40e940984070258094e3a2cdf058279f85280c4d628d061f4020d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8437386155128479}",,,,,,,,,,['neutral'],neutral,1
NCT00490529,"{'position': 1, 'link': 'https://www.eurekalert.org/news-releases/614464', 'title': 'Early clinical trial supports tumor cell-based vaccine for mantle cell lymphoma', 'source': 'EurekAlert!', 'date': 'Jun 19, 2020', 'snippet': 'image: A schematic of the vaccination schedule used to treat MCL patients \nin the phase I/II trial. ASCT stands for autologous stem cell...', 'thumbnail': 'https://serpapi.com/searches/67248d5fe10f0a1c4155b647/images/f2e5de393f58b2b0822aab313ee4fc98cbf050fa0e9082358a0cc346a8969082.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8884648680686951}",,,,,,,,,,['neutral'],neutral,1
NCT03989544,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-tezspire-for-self-administration-with-new-prefilled-pen/', 'title': 'FDA Approves Tezspire for Self-Administration With New Prefilled Pen', 'source': 'Medical Professionals Reference', 'date': 'Feb 2, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved a new prefilled, \nsingle-use pen for Tezspire™ (tezepelumab-ekko) for the add-on...', 'thumbnail': 'https://serpapi.com/searches/67247423adc33b5331e57a1b/images/29310553485ad69e875bd7985bd91686ba271b631c68ed2342123735a13fb4dc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6245538592338562}",,,,,,,,,,['neutral'],neutral,1
NCT01715298,"{'position': 1, 'link': 'https://copdnewstoday.com/news/new-copd-treament-option-seebri-neohaler-now-available-to-us-patients/', 'title': 'New COPD Treament Option, Seebri Neohaler, Now Available to U.S. Patients', 'source': 'COPD News Today', 'date': 'Oct 23, 2017', 'snippet': 'Seebri Neohaler, a long-term maintenance therapy for airflow obstruction in \npatients with chronic obstructive pulmonary disease (COPD), is now \navailable at US...', 'thumbnail': 'https://serpapi.com/searches/67247437f59d0009dc8dd89f/images/97e7e9d83941026796dcc7a5bcc39ac9ebe8d81550d0bc50503fc5526a5047e0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8668889403343201}",,,,,,,,,,['neutral'],neutral,1
NCT04436276,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2034201', 'title': 'Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine', 'source': 'The New England Journal of Medicine', 'date': 'Jan 13, 2021', 'snippet': 'Efficacious vaccines are urgently needed to contain the ongoing coronavirus \ndisease 2019 (Covid-19) pandemic of infection with severe acute...', 'thumbnail': 'https://serpapi.com/searches/6724749311db45db1fa60efc/images/5098f914b82aa3c6e8c79c9879629a7eaa0828c06862ec87bd504b4b3d8fa2d0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5869097113609314}",,,,,,,,,,['neutral'],neutral,1
NCT04596319,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/results-trial-phage-therapy-ap-pa02-expected-early-2023/', 'title': 'Results from Trial of Phage Therapy AP-PA02 Expected in Early 2023...', 'source': 'Cystic Fibrosis News Today', 'date': 'Dec 23, 2022', 'snippet': 'The Phase 1b/2a clinical trial SWARM–Pa, testing AP-PA02 in cystic fibrosis \npatients, is complete, Armata announced.', 'thumbnail': 'https://serpapi.com/searches/6724749a5416d87c399e230b/images/838ec14f47af341cfd89bf9c40eb1f70506fb0ae1d239b9ab536155b69a9573e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8101717829704285}",,,,,,,,,,['neutral'],neutral,1
NCT00700310,"{'position': 1, 'link': 'https://dravetsyndromenews.com/news/fda-approves-fycompa-focal-seizures-children-ages-4-older/', 'title': 'FDA Approves Fycompa to Treat Focal Seizures in Children 4 and Older', 'source': 'Dravet Syndrome News', 'date': 'Oct 4, 2018', 'snippet': 'The U.S. Food and Drug Administration approved Fycompa (perampanel) – alone \nor as an add-on therapy – for focal seizures in children ages 4...', 'thumbnail': 'https://serpapi.com/searches/67248fa04e9efcc899c8b4dd/images/c053b25d62a77cebd1d4a13117ed66895f5a097cdc240470b1bc879bf0ac384d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7756399512290955}","{'position': 2, 'link': 'https://dravetsyndromenews.com/news/fycompa-effectively-reduces-seizure-rate-refractrory-epilepsy-dravet-syndrome/', 'title': 'Add-on Fycompa Effectively Reduces Seizure Rate in Real-world Study', 'source': 'Dravet Syndrome News', 'date': 'Jul 12, 2018', 'snippet': 'Add-on therapy with Fycompa (perampanel) is safe and effective in \npreventing seizures in adolescents with treatment-resistant refractory \nepilepsy.', 'thumbnail': 'https://serpapi.com/searches/67248fa04e9efcc899c8b4dd/images/c053b25d62a77ceb311b29299cdd6caf2f944fcdf08fe191e34a8d0868a1e3c2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6034088730812073}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT01696474,"{'position': 1, 'link': 'https://coldagglutininnews.com/news/blood-cancer-treatments-may-help-cad-patients-treatment-resistant/', 'title': 'Blood cancer treatments may help people with hard-to-treat CAD |...', 'source': 'Cold Agglutinin Disease News', 'date': 'Jul 21, 2023', 'snippet': 'Two approved blood cancer treatments, daratumumab and bortezomib, were \neffective in people with hard-to-treat cold agglutin disease and...', 'thumbnail': 'https://serpapi.com/searches/67248fbdc76a3a3c16c5df27/images/8d772b33aaa3365191552e7fb1db02af1d2e8abf0de7f24d9b7807d21a864707.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6947653293609619}",,,,,,,,,,['neutral'],neutral,1
NCT01903460,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/livmarli-sustains-benefit-alagille-patients-over-7-years-trial-data/', 'title': 'Livmarli sustains benefit for Alagille patients over 7 years: Trial data', 'source': 'Liver Disease News', 'date': 'Jun 14, 2024', 'snippet': ""Nearly all children with Alagille syndrome who received Mirum \nPharmaceuticals' Livmarli (maralixibat) for seven years as part of clinical \nstudies continued to..."", 'thumbnail': 'https://serpapi.com/searches/67248fcc49ea554d710856db/images/e574c3a772c5bc4e55a56cb242a0e48f64149f871e701f01c5505de531483a8c.png', 'sentiment': 'positive', 'sentiment_prob': 0.49692490696907043}",,,,,,,,,,['positive'],positive,1
NCT00528879,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60407-2/abstract', 'title': 'Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial', 'source': 'The Lancet', 'date': 'Jun 26, 2010', 'snippet': 'Correction of hyperglycaemia and prevention of glucotoxicity are important \nobjectives in the management of type 2 diabetes.', 'thumbnail': 'https://serpapi.com/searches/67248fd1ef60cb0a91edadde/images/b318586d6784805a460a51ace82a8ea1a62f5f076e4da076d01bf6b0056fb6b0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7526994943618774}",,,,,,,,,,['neutral'],neutral,1
NCT04976140,"{'position': 1, 'link': 'https://www.nature.com/articles/s12276-023-01141-7', 'title': 'Mitochondria as secretory organelles and therapeutic cargos | Experimental & Molecular Medicine', 'source': 'Nature', 'date': 'Jan 4, 2024', 'snippet': 'Mitochondria have been primarily considered intracellular organelles that \nare responsible for generating energy for cell survival.', 'thumbnail': 'https://serpapi.com/searches/67248fe5c76a222c5beb920f/images/9d5c61d340ec50dda05e6411024438ff8395d78f080bc5474f76d20b268e6334.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9151709675788879}",,,,,,,,,,['neutral'],neutral,1
NCT03522298,"{'position': 1, 'link': 'https://www.biospace.com/kazia-therapeutics-announces-phase-ii-iii-clinical-trial-results-for-paxalisib-in-glioblastoma', 'title': 'Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma', 'source': 'BioSpace', 'date': 'Jul 10, 2024', 'snippet': 'GBM AGILE trial data shows clinically meaningful improvement in a \nprespecified secondary analysis for overall survival in \npaxalisib-treated,...', 'thumbnail': 'https://serpapi.com/searches/67248ff0fd3b5a2860c67e9a/images/1eb329e5ccc996d54c7f4af1efce020389bf3aa13ea60537f9bab6330b3377bd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.504606306552887}",,,,,,,,,,['neutral'],neutral,1
NCT02065791,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1811744', 'title': 'Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy', 'source': 'The New England Journal of Medicine', 'date': 'Apr 15, 2019', 'snippet': 'Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, \nbut few effective long-term treatments are available. In cardiovascular \ntrials of...', 'thumbnail': 'https://serpapi.com/searches/67248ee776079d52a413b82b/images/469632a80ec17cc4075e120354bd4ecc747c50eea01dd86ed151d6f0ba244d48.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8127669095993042}",,,,,,,,,,['negative'],negative,0
NCT02561988,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01538-9', 'title': 'Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial', 'source': 'Nature', 'date': 'Dec 6, 2021', 'snippet': 'Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm \ndriven by the KIT D816V mutation and associated with poor survival.', 'thumbnail': 'https://serpapi.com/searches/67248f0c310300dcae5be44a/images/93d044a3858aa8674ead6b39a927433181af85a068fc81273e6143b40e92c8fd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.74168461561203}","{'position': 2, 'link': 'https://www.clinicaloncology.com/FDA-Watch/Article/06-21/Ayvakit-Approved-for-Advanced-Systemic-Mastocytosis/63843', 'title': 'Ayvakit Approved for Advanced Systemic Mastocytosis', 'source': 'Clinical Oncology News', 'date': 'Jun 21, 2021', 'snippet': 'The FDA approved avapritinib (Ayvakit, Blueprint Medicines) for adults with \nadvanced systemic mastocytosis, including patients with aggressive \nsystemic...', 'thumbnail': 'https://serpapi.com/searches/67248f0c310300dcae5be44a/images/93d044a3858aa86714bc2eb9d4c12345e2502b8778eb3eecf7acc3a701661d14.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8241908550262451}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04177810,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1258538/full', 'title': 'An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': 'Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest \nmalignancies. It is characterized by a complex and immunosuppressive tumor \nmicroenvironment...', 'thumbnail': 'https://serpapi.com/searches/67248f146273fb68b4d81f0e/images/b24bf0aa039b6f68ae3694446c7e5487ca80cbe1451b1b91866d9e9415df2daf.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6425118446350098}",,,,,,,,,,['negative'],negative,0
NCT04023994,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-41382-0', 'title': 'Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model', 'source': 'Nature', 'date': 'Sep 1, 2023', 'snippet': 'Several anti-tau and anti-alpha synuclein (aSyn) antibodies have failed to \nprovide clinical benefit in clinical trials despite substantial target \nengagement.', 'thumbnail': 'https://serpapi.com/searches/67248f20b691a7ee63b08b79/images/c415f539562dd4353b57f573efb617bb4dca83bb0bde1799bf9b8dd0b703331c.png', 'sentiment': 'negative', 'sentiment_prob': 0.6836323142051697}",,,,,,,,,,['negative'],negative,0
NCT01259817,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-29381-7', 'title': 'Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms', 'source': 'Nature', 'date': 'Apr 1, 2022', 'snippet': 'Interferons (IFNs) are key initiators and effectors of the immune response \nagainst malignant cells and also directly inhibit tumor growth.', 'thumbnail': 'https://serpapi.com/searches/67248f5a4a4a1d3f3ac0ce1f/images/f6e2940ac381203d70aa0aa301e12332172c8cd1a540f69586cbad6d72a98593.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8885598182678223}",,,,,,,,,,['neutral'],neutral,1
NCT02832544,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2209051', 'title': 'Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation', 'source': 'The New England Journal of Medicine', 'date': 'Aug 28, 2022', 'snippet': 'Testing of factor Xa inhibitors for the prevention of cardiovascular events \nin patients with rheumatic heart disease–associated atrial...', 'thumbnail': 'https://serpapi.com/searches/67248f81690121da8493d8d5/images/bf5f337a5db1efea0670fb3269a9e34a66c72f7c4aefbb98bd8d58a9fdb109b0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8898580074310303}",,,,,,,,,,['neutral'],neutral,1
NCT01276639,"{'position': 1, 'link': 'https://psoriasisnewstoday.com/2017/05/09/xeljanz-reduces-nail-psoriasis-phase-3-trials-plaque-disease/', 'title': 'Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease', 'source': 'Psoriasis News Today', 'date': 'May 9, 2017', 'snippet': 'Learn more about how clinical trials demonstrated that the rheumatoid \narthritis drug Xeljanz (tofacitinib) is effective against nail...', 'thumbnail': 'https://serpapi.com/searches/67248d992a77272bc1b69219/images/09d7bf55779390f712fe6be5fb0c10d9b0c0191de2616d51ce4a0f6e0373d357.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6758314371109009}",,,,,,,,,,['neutral'],neutral,1
NCT02796677,"{'position': 1, 'link': 'https://copdnewstoday.com/news/duaklir-available-copd-patients-us/', 'title': 'Duaklir Now Available to COPD Patients in the U.S.', 'source': 'COPD News Today', 'date': 'Oct 29, 2019', 'snippet': 'Duaklir is now available to patients with chronic obstructive pulmonary \ndisease (COPD) living in the U.S., Circassia Pharmaceuticals...', 'thumbnail': 'https://serpapi.com/searches/67248da31315026fdb94b382/images/440ec2d10438778b9f831c5898eb22801c612df08c77113dc2ed9fb472d894c4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7435298562049866}",,,,,,,,,,['neutral'],neutral,1
NCT03838185,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332222000361', 'title': 'The Alzheimer’s disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver', 'source': 'ScienceDirect.com', 'date': 'Jan 18, 2022', 'snippet': 'J147 is a novel drug candidate developed to treat neurological dysfunction. \nNumerous studies have demonstrated the beneficial effects of J147 in \ncellular...', 'thumbnail': 'https://serpapi.com/searches/67248db6fd3b5a2897fa361a/images/4a92904aae6616ba8fda29f426a0e90ae195a2493957ed8c34c9779e7b48febf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7981163263320923}",,,,,,,,,,['neutral'],neutral,1
NCT00130000,"{'position': 1, 'link': 'https://www.researchgate.net/publication/360969794_The_importance_of_terminal_complement_inhibition_in_paroxysmal_nocturnal_hemoglobinuria', 'title': '(PDF) The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria', 'source': 'ResearchGate', 'date': '1 week ago', 'snippet': 'Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic hematologic \ndisorder associated with inappropriate terminal complement activity on \nblood cells.', 'thumbnail': 'https://serpapi.com/searches/67248ed052a04e0332044ec0/images/ecb7938eccb797a6be971881e0180043952b95a12741905cb5c6f3c39cacfd3e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5939037799835205}",,,,,,,,,,['neutral'],neutral,1
NCT00123487,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-018-0122-3', 'title': 'Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib', 'source': 'Nature', 'date': 'Sep 3, 2018', 'snippet': 'Treatment with a frontline BCR-ABL1 tyrosine kinase inhibitor (TKI; e.g., \nimatinib, dasatinib, and nilotinib) allows patients with chronic...', 'thumbnail': 'https://serpapi.com/searches/67248ed3123457fb2a7d8fe9/images/d90b9b948c3fca9e1b94bc24bf4a11c5810aad748d791e62833fd2c4fadedbc0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8288981914520264}",,,,,,,,,,['neutral'],neutral,1
NCT00986154,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1306638', 'title': 'Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism', 'source': 'The New England Journal of Medicine', 'date': 'Sep 1, 2013', 'snippet': 'Edoxaban administered once daily after initial treatment with heparin was \nnoninferior to high-quality standard therapy and caused significantly less \nbleeding.', 'thumbnail': 'https://serpapi.com/searches/67248ed7b4b72d4da19d5f50/images/e6e52c94b3dfa8a522f4d10ae7ecf1a45add9924f6342965ee73a8e8c20a38a7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7694089412689209}",,,,,,,,,,['neutral'],neutral,1
NCT02414854,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1804092', 'title': 'Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma', 'source': 'The New England Journal of Medicine', 'date': 'May 21, 2018', 'snippet': 'In this trial, patients who received dupilumab had significantly lower \nrates of severe asthma exacerbation than those who received placebo, as \nwell as better...', 'thumbnail': 'https://serpapi.com/searches/67248e62f3622ab7bda39fb4/images/e9e94d960b4c271f224c462d634af8b878224d1e8c16c6763f32201108d72854.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6814642548561096}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/cea.14389', 'title': 'Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization', 'source': 'Wiley Online Library', 'date': 'Sep 26, 2023', 'snippet': 'Background Fungal sensitization (FS) exacerbates asthma in patients who \nhave elevated type 2 inflammatory response. Dupilumab, a fully human...', 'thumbnail': 'https://serpapi.com/searches/67248e62f3622ab7bda39fb4/images/e9e94d960b4c271f129ae2f9fab86ef42df481e1c18bf111f84ac33b5f34c725.png', 'sentiment': 'negative', 'sentiment_prob': 0.5187826752662659}","{'position': 3, 'link': 'https://www.pulmonologyadvisor.com/news/dupilumab-improves-chances-of-clinical-remission-in-uncontrolled-asthma/', 'title': 'Dupilumab Improves Chances of Clinical Remission in Uncontrolled Asthma', 'source': 'Pulmonology Advisor', 'date': 'Nov 8, 2021', 'snippet': 'QUEST trial research presented at ACAAI 2021 showed dupilumab led to \nremission in many patients with uncontrolled asthma and reduced...', 'thumbnail': 'https://serpapi.com/searches/67248e62f3622ab7bda39fb4/images/e9e94d960b4c271f9f06c638012f805068f9371d726a0deb84112734587e1854.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6141565442085266}",,,,,,,,"['neutral', 'negative', 'neutral']",neutral,1
NCT00003343,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0278691520302593', 'title': 'In vivo antitumoral effect of 4-nerolidylcatechol (4-NC) in NRAS-mutant human melanoma', 'source': 'ScienceDirect.com', 'date': 'Apr 23, 2020', 'snippet': 'We showed that 4-NC has an antitumor effect in xenograft model of a \nNRAS-mutant melanoma and induces a mild toxicity, indicating this compound \nas a promising...', 'thumbnail': 'https://serpapi.com/searches/67248e72a3657a52007f34ca/images/d30c8dfb93fd78d1262569df80d637ac6f27869a2d91c8a85a083a591844388d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8468425273895264}",,,,,,,,,,['neutral'],neutral,1
NCT03287817,"{'position': 1, 'link': 'https://lymphomahub.com/medical-information/results-from-phase-i-alexander-study-investigating-the-first-car-t-cell-therapy-auto3-plus-pembrolizumab-to-target-both-cd19-and-cd22-in-the-treatment-of-rr-dlbcl', 'title': 'Results from phase I ALEXANDER study investigating the first CAR T-cell therapy, AUTO3, plus pembrolizumab to target both CD19 and CD22 in the treatment of R/R DLBCL', 'source': 'Lymphoma Hub', 'date': 'Jul 31, 2020', 'snippet': 'The Lymphoma & CLL Hub is an independent medical education platform, \nsponsored by Beigene and Roche, and supported through educational...', 'thumbnail': 'https://serpapi.com/searches/67248ea7b9458d2b838d06be/images/75048b6f241156a789eb0de2255133f1dfff4ee1132ee7b352168f3dd362f709.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8411385416984558}",,,,,,,,,,['neutral'],neutral,1
NCT02981602,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01513-4', 'title': 'Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial', 'source': 'Nature', 'date': 'Oct 12, 2021', 'snippet': 'This phase 2 double-blinded, randomized, placebo-controlled trial is the \nfirst evaluation of the safety and activity of an antisense oligonucleotide \ntargeting...', 'thumbnail': 'https://serpapi.com/searches/67249026c76a222c90890b5c/images/56d0226571d02934fa90e3cbba40392ffbc513a00c466e4b8c8ddefca0230c32.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8815107345581055}",,,,,,,,,,['neutral'],neutral,1
NCT01335464,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1402584', 'title': 'Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis', 'source': 'The New England Journal of Medicine', 'date': 'May 18, 2014', 'snippet': 'A phase 2 trial suggested that treatment with 150 mg of nintedanib twice \ndaily reduced lung-function decline and acute exacerbations in patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/672490435a461ac711624b56/images/2318677ccb642e3fcf65a4252d9a12c917477dfd0aa81799893e32948f18e778.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8697701692581177}","{'position': 2, 'link': 'https://lungdiseasenews.com/2017/10/26/ipf-therapy-ofev-shows-long-term-effectiveness-regardless-of-baseline-lung-function-early-analysis/', 'title': 'Early Analysis of Ofev in INPULSIS-ON Trial Shows Long-Term Effectiveness in Treating IPF', 'source': 'Lung Disease News', 'date': 'Oct 26, 2017', 'snippet': 'Read about how Ofev (nintedanib) was shown to slow down IPF progression \nregardless of baseline lung function in the Phase 3 INPULSIS...', 'thumbnail': 'https://serpapi.com/searches/672490435a461ac711624b56/images/2318677ccb642e3f8d2e9b3f0a5c32cb8196884a094e54e516053cee2568fd3c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6172102093696594}","{'position': 3, 'link': 'https://pulmonaryfibrosisnews.com/news/ofev-effective-elderly-patients-comorbidities-ipf-idiopathic-pulmonary-fibrosis/', 'title': 'Ofev Effective in Elderly IPF Patients, Those With Several Comorbidities', 'source': 'Pulmonary Fibrosis News', 'date': 'Apr 30, 2021', 'snippet': 'Study suggests Ofev can preserve lung function in older idiopathic \npulmonary fibrosis patients and those who have several other health...', 'thumbnail': 'https://serpapi.com/searches/672490435a461ac711624b56/images/2318677ccb642e3ffaafbe38aa73cd9f7d306623cb767f34ffeaa383c556b20d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7142563462257385}","{'position': 4, 'link': 'https://pulmonaryfibrosisnews.com/news/ipf-patients-live-longer-on-nintedanib-pooled-data-from-six-trials-show/', 'title': 'IPF Patients Live Longer on Ofev Compared with Placebo, Analysis Shows', 'source': 'Pulmonary Fibrosis News', 'date': 'Apr 16, 2019', 'snippet': 'Treatment with Ofev (nintedanib) can significantly extend the survival of \npatients with idiopathic pulmonary fibrosis (IPF), an analysis of pooled \ndata from...', 'thumbnail': 'https://serpapi.com/searches/672490435a461ac711624b56/images/2318677ccb642e3f1d4ccf80dd9fc5200f209696cce40172fb2fa7ad589dfbd8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.544462263584137}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT00083889,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa065044', 'title': 'Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma', 'source': 'The New England Journal of Medicine', 'date': 'Jan 11, 2007', 'snippet': 'Since sunitinib malate has shown activity in two uncontrolled studies in \npatients with metastatic renal-cell carcinoma, a comparison of the...', 'thumbnail': 'https://serpapi.com/searches/672490649819f30f3cbfcd07/images/509fbb98a677e5cc9f06fc7a873c84d0a989ecf4bde98ebe3b7a4d1e2d6ebef2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9069509506225586}","{'position': 2, 'link': 'https://www.nature.com/articles/bjc2011589', 'title': 'Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma', 'source': 'Nature', 'date': 'Jan 12, 2012', 'snippet': 'In a randomized phase III trial of sunitinib vs interferon-alfa (IFN-α) in \nmetastatic renal cell carcinoma (mRCC), better baseline quality...', 'thumbnail': 'https://serpapi.com/searches/672490649819f30f3cbfcd07/images/509fbb98a677e5cc0b4453826d78ddbd2ebde33b4f48c3b55f1bd806b8a473a9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.739191472530365}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01721161,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2020/10/26/biogen-discontinues-development-opicinumab-data-affinity-trial/', 'title': 'Opicinumab Development for MS Halted by Biogen Based on Trial Data', 'source': 'Multiple Sclerosis News Today', 'date': 'Oct 26, 2020', 'snippet': 'Biogen is discontinuing the clinical development of opicinumab for MS, \nbased on data from the Phase 2 AFFINITY trial.', 'thumbnail': 'https://serpapi.com/searches/67249082c1c8dd6ca987cbf8/images/2364c16bd00f4de8b2f43719c63dbf6f0280754fb808b340a9e47f23c304cff0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.549568772315979}",,,,,,,,,,['neutral'],neutral,1
NCT04602390,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/09/20/patient-enrollment-phase-1-rrms-trial-ank-700-complete/', 'title': 'Patient enrollment is complete in Phase 1 trial of ANK-700 for RRMS', 'source': 'Multiple Sclerosis News Today', 'date': 'Sep 20, 2023', 'snippet': 'Anokion has finished enrolling patients in the second part of its Phase 1 \nclinical trial investigating ANK-700 for relapsing-remitting multiple \nsclerosis (RRMS...', 'thumbnail': 'https://serpapi.com/searches/672490a629e6fbc136ebdc20/images/1a03fbec68633b2ebabcc2b6d8922db52257c3c70db0d9d9f3abd2c6402e8316.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7918606400489807}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/09/14/ms-disease-activity-mice-lowered-with-inverse-vaccine-technique/', 'title': '‘Inverse vaccine’ approach lowers disease in MS mouse model', 'source': 'Multiple Sclerosis News Today', 'date': 'Sep 14, 2023', 'snippet': 'Treatment with an ""inverse vaccine"" effectively reduced disease activity in \nmouse models of multiple sclerosis, a new study reports.', 'thumbnail': 'https://serpapi.com/searches/672490a629e6fbc136ebdc20/images/1a03fbec68633b2e9e8663f0b361aef527e2cc6fa0f2b62bc3111784bef15814.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8017797470092773}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00475852,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1100171', 'title': 'Effect of Nesiritide in Patients with Acute Decompensated Heart Failure', 'source': 'The New England Journal of Medicine', 'date': 'Jul 7, 2011', 'snippet': 'Nesiritide is approved in the United States for early relief of dyspnea in \npatients with acute heart failure. Previous meta-analyses have...', 'thumbnail': 'https://serpapi.com/searches/672490af213c87213e78a155/images/a8a596586ccdf9288b258fc013d60a84453bc12312d519e3b51f27300b6cd05d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6487038731575012}",,,,,,,,,,['neutral'],neutral,1
NCT02770716,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2008290', 'title': 'Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome', 'source': 'The New England Journal of Medicine', 'date': 'Mar 3, 2021', 'snippet': 'The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome \n(HRS-1) in many parts of the world and is part of the clinical...', 'thumbnail': 'https://serpapi.com/searches/672490b2e1c276ffa027f432/images/232e6feb41b9078853710ecb24e6b7906a18ad72ae48b1802d20980671c82e04.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9108983874320984}","{'position': 2, 'link': 'https://www.empr.com/home/news/fda-approves-terlivaz-to-improve-kidney-function-in-hepatorenal-syndrome/', 'title': 'FDA Approves Terlivaz to Improve Kidney Function in Hepatorenal Syndrome', 'source': 'Medical Professionals Reference', 'date': 'Sep 15, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Terlivaz (terlipressin) \ninjection to improve kidney function in adults with hepatorenal syndrome \n(HRS)', 'thumbnail': 'https://serpapi.com/searches/672490b2e1c276ffa027f432/images/232e6feb41b90788aed9076ebd01b8a28dbe73b3781bd3fc99aafd91baa78607.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5924460887908936}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01907087,"{'position': 1, 'link': 'https://battendiseasenews.com/news/fda-approves-brineura-for-batten-disease-type-cln2-for-children/', 'title': 'Batten Disease Type CLN2 Treatment Brineura Approved by FDA for Kids', 'source': 'Batten Disease News', 'date': 'May 1, 2017', 'snippet': ""Patients with a specific type of Batten disease now have an approved \ntreatment, with the U.S. Food and Drug Administration's (FDA) recent..."", 'thumbnail': 'https://serpapi.com/searches/672490f449ea554da5326160/images/04a17366fa013f452bbbc09bac80cb03872c0296f72efce77765e356b3a4be62.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8791516423225403}",,,,,,,,,,['neutral'],neutral,1
NCT02914639,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/drug-delivery/articles/10.3389/fddev.2022.954771/full', 'title': 'Topical ophthalmic administration: Can a drug instilled onto the ocular surface exert an effect at the back of the eye?', 'source': 'Frontiers', 'date': '٠٨\u200f/٠٩\u200f/٢٠٢٢', 'snippet': 'Topical ophthalmic instillation is an appealing strategy to deliver drugs \nto the back of the eye to treat retinal diseases such as...', 'thumbnail': 'https://serpapi.com/searches/672493d1b4fe87984be9a496/images/a573f61bea8da1ec0a23ee0570c4b8df53fb5d3f82cf77406d40325dbdbd9135.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7804790735244751}",,,,,,,,,,['neutral'],neutral,1
NCT04274816,"{'position': 1, 'link': 'https://www.amsterdamumc.org/en/research/institutes/amsterdam-institute-for-immunology-and-infectious-diseases/news/local-injection-of-immunotherapy-for-patients-with-early-stage-melanoma.htm', 'title': 'Local injection of immunotherapy for patients with early-stage melanoma', 'source': 'www.amsterdamumc.org', 'date': 'Aug 1, 2022', 'snippet': 'New discovery: Locally administered cancer immunotherapy may offer a safe \nand effective treatment for early-stage melanoma patients,...', 'thumbnail': 'https://serpapi.com/searches/67249322cc2987ee5a4bd42d/images/a9c79b68e59e5ddbb462fde9a0d6d2b62e9eb195b9d26938ca384789cb2f4144.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6884647607803345}",,,,,,,,,,['neutral'],neutral,1
NCT01063179,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/measuring-blood-vessel-activity-may-predict-multiple-myeloma-prognosis/', 'title': 'Measuring Blood Vessel Activity May Predict Multiple Myeloma Prognosis', 'source': 'Myeloma Research News', 'date': 'Feb 4, 2019', 'snippet': 'A panel of blood markers that identifies tumors with more active blood \nvessels may help stratify multiple myeloma patients according to...', 'thumbnail': 'https://serpapi.com/searches/6724935674f0a4d3e31994fb/images/f529f217648b4dd060f55e4d1bb172107749bf649a1328cea471f72484866924.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9216383099555969}",,,,,,,,,,['neutral'],neutral,1
NCT02763579,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1809064', 'title': 'First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Sep 25, 2018', 'snippet': 'Enhancing tumor-specific T-cell immunity by inhibiting programmed death \nligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown...', 'thumbnail': 'https://serpapi.com/searches/6724911ffab2737a4312ccbe/images/074b4e5126befbb71bb4d45a801811b55dc8c42f2cf137924c402b685937e143.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8680608868598938}","{'position': 2, 'link': 'https://www.expresspharma.in/roche-presents-five-year-survival-outcomes-for-tecentriq-plus-chemotherapy-in-es-sclc/', 'title': 'Roche presents five-year survival outcomes for Tecentriq plus chemotherapy in ES-SCLC', 'source': 'Express Pharma', 'date': 'Sep 11, 2023', 'snippet': ""Results presented from the Phase III IMpower133 study and extension trial \nIMbrella A, show Roche's Tecentriq (atezolizumab), in combination..."", 'thumbnail': 'https://serpapi.com/searches/6724911ffab2737a4312ccbe/images/074b4e5126befbb70b925681a12fe2ae78d61c18d5ecfd19550382519b902b17.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8882242441177368}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03712228,"{'position': 1, 'link': 'https://angioedemanews.com/garadacimab-for-hereditary-angioedema/', 'title': 'Garadacimab for hereditary angioedema', 'source': 'Angioedema News', 'date': 'Apr 3, 2024', 'snippet': 'Last updated April 3, 2024, by Marisa Wexler, MS ✓ Fact-checked by Joana \nCarvalho, PhD. How garadacimab works. Administration. Clinical trials. Side \neffects...', 'thumbnail': 'https://serpapi.com/searches/672491beb4e8d68e084e0e81/images/520083e5f03c7590575016f5566bf224872dc9a42ec94a462dc4361ac3aed332.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9355132579803467}",,,,,,,,,,['neutral'],neutral,1
NCT01619085,"{'position': 1, 'link': 'https://lungdiseasenews.com/2017/10/26/ipf-therapy-ofev-shows-long-term-effectiveness-regardless-of-baseline-lung-function-early-analysis/', 'title': 'Early Analysis of Ofev in INPULSIS-ON Trial Shows Long-Term Effectiveness in Treating IPF', 'source': 'Lung Disease News', 'date': 'Oct 26, 2017', 'snippet': 'Read about how Ofev (nintedanib) was shown to slow down IPF progression \nregardless of baseline lung function in the Phase 3 INPULSIS...', 'thumbnail': 'https://serpapi.com/searches/672491ca2bab90a100096aa2/images/39aff679d8ef7efbd6d415999d67dd0cec95f27fabc88786aed273c5a4457371.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6172102093696594}",,,,,,,,,,['neutral'],neutral,1
NCT04478071,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1328565/full', 'title': 'Hypoxia-adenosine axis as therapeutic targets for acute respiratory distress syndrome', 'source': 'Frontiers', 'date': 'Jan 19, 2024', 'snippet': 'The human respiratory and circulatory systems collaborate intricately to \nensure oxygen delivery to all cells, which is vital for ATP...', 'thumbnail': 'https://serpapi.com/searches/672491d61fc7c565347df93b/images/8a08558864d0dc1f874e991a238b6e1645832601d0433fed2d06f09e52303297.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8608326315879822}","{'position': 2, 'link': 'https://www.nature.com/articles/s41598-021-04444-9', 'title': 'eNAMPT neutralization reduces preclinical ARDS severity via rectified NFkB and Akt/mTORC2 signaling', 'source': 'Nature', 'date': 'Jan 13, 2022', 'snippet': 'Despite encouraging preclinical data, therapies to reduce ARDS mortality \nremains a globally unmet need, including during the COVID-19...', 'thumbnail': 'https://serpapi.com/searches/672491d61fc7c565347df93b/images/8a08558864d0dc1fe41631e5688efef88c4fcc85be81985ae5330875d21cb822.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6769604682922363}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01792310,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-023-02356-1', 'title': 'A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma | British Journal of Cancer', 'source': 'Nature', 'date': 'Jul 24, 2023', 'snippet': 'The first-in-class brain-penetrating synthetic hydroxylated lipid \nidroxioleic acid (2-OHOA; sodium 2-hydroxyoleate), activates \nsphingomyelin...', 'thumbnail': 'https://serpapi.com/searches/672491d817b10ef88bd2cf6c/images/e25c7b90c5d0d97166d33a089c5c0f73c83602274e83e4f71750c0f024f6d0c1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8801302909851074}",,,,,,,,,,['neutral'],neutral,1
NCT03292783,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1035276/full', 'title': 'Current landscape and future directions of bispecific antibodies in cancer immunotherapy', 'source': 'Frontiers', 'date': '٠٧\u200f/٠٢\u200f/٢٠٢٤', 'snippet': 'Bispecific antibody-based tumor immunotherapy has gained broad potential in \npreclinical and clinical investigations in a variety of tumor types.', 'thumbnail': 'https://serpapi.com/searches/672491daf6aa5397882c74fd/images/9aa7a6984cae9d104117be79936fae6ce6f4719290916a556ac19707f89be5c1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6316473484039307}",,,,,,,,,,['neutral'],neutral,1
NCT02611752,"{'position': 1, 'link': 'https://www.nature.com/articles/s41386-023-01793-z', 'title': 'Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder', 'source': 'Nature', 'date': 'Jan 10, 2024', 'snippet': 'Buprenorphine is used to treat opioid use disorder (OUD). Weekly and \nmonthly subcutaneous long-acting buprenorphine injections (CAM2038)...', 'thumbnail': 'https://serpapi.com/searches/67249297667ec51233a77b10/images/42ea64b4d344f213176123ebaba6f717fb1c69456c8742d89ae48348e57025d1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8396375775337219}",,,,,,,,,,['neutral'],neutral,1
NCT05362058,"{'position': 1, 'link': 'https://investor.lilly.com/news-releases/news-release-details/once-weekly-dose-insulin-efsitora-alfa-delivers-a1c-reduction', 'title': 'Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes | Eli Lilly and Company', 'source': 'Eli Lilly and Company', 'date': '1 month ago', 'snippet': 'In QWINT-2, efsitora helped adults naïve to insulin therapy currently using \nand not using GLP-1 receptor agonists achieve an A1C below 7%.', 'thumbnail': 'https://serpapi.com/searches/6724929d54163d250a675ab8/images/b1409e3e3e07fda49a85e20107fc782aa27c29131223fe96469a25f21258a5bc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5163030624389648}","{'position': 2, 'link': 'https://www.pharmacytimes.com/view/once-weekly-efsitora-shows-non-inferiority-in-a1c-reductions-compared-to-daily-basal-insulin', 'title': 'Once Weekly Efsitora Shows Non-Inferiority in A1c Reductions Compared With Daily Basal Insulin', 'source': 'Pharmacy Times', 'date': 'May 31, 2024', 'snippet': 'Topline results of QWINT-2 and QWINT-4 met the primary end point of change \nin hemoglobin A1c compared to degludec and glargine, respectively...', 'thumbnail': 'https://serpapi.com/searches/6724929d54163d250a675ab8/images/b1409e3e3e07fda4b214c6b148d0008ad3812c6e0a6ed111bc3218cb1e7089dd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8300167918205261}","{'position': 3, 'link': 'https://investor.lilly.com/news-releases/news-release-details/once-week-dosing-insulin-efsitora-alfa-delivers-a1c-reduction', 'title': 'With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin', 'source': 'Eli Lilly and Company', 'date': 'May 16, 2024', 'snippet': 'Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with \nonce-a-week dosing regimen for people living with type 2 diabetes.', 'thumbnail': 'https://serpapi.com/searches/6724929d54163d250a675ab8/images/b1409e3e3e07fda46174040eb96b03278b8af6b29b7b286a64df3f32590f510e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5483573079109192}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT00935987,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-018-0067-6', 'title': 'Momelotinib therapy for myelofibrosis: a 7-year follow-up', 'source': 'Nature', 'date': 'Mar 7, 2018', 'snippet': 'One-hundred Mayo Clinic patients with high/intermediate-risk myelofibrosis \n(MF) received momelotinib (MMB; JAK1/2 inhibitor) between 2009...', 'thumbnail': 'https://serpapi.com/searches/672492b754163d250a675ac0/images/9bbde2d4e4063c4f5b111a1dd49920122d91898c59b23198faa99109e4af9f76.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9240283966064453}",,,,,,,,,,['neutral'],neutral,1
NCT05413668,"{'position': 1, 'link': 'https://www.itnonline.com/content/new-gadolinium-free-mri-contrast-agent-advances-safer-patient-care', 'title': 'New Gadolinium-Free MRI Contrast Agent Advances Safer Patient Care', 'source': 'Imaging Technology News', 'date': 'Mar 9, 2023', 'snippet': 'Reveal Pharmaceuticals doses first subjects in Phase 1 Clinical Trial of \nRVP‑001.', 'thumbnail': 'https://serpapi.com/searches/672492c46f9f6308c9430536/images/be7b6cb654a88ece1fd6555c06013d95534a7bff6edd2005d26d7f4fc23a359d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8355599045753479}",,,,,,,,,,['neutral'],neutral,1
NCT03835975,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-20-valent-pneumococcal-conjugate-vaccine-prevnar-20/', 'title': 'FDA Approves 20-Valent Pneumococcal Conjugate Vaccine Prevnar 20', 'source': 'Medical Professionals Reference', 'date': 'Jun 9, 2021', 'snippet': 'The Food and Drug Administration (FDA) has granted accelerated approval to \nPrevnar 20™ (pneumococcal 20-valent conjugate vaccine) for the...', 'thumbnail': 'https://serpapi.com/searches/672491651fc7c5650202e6c3/images/60dd0eec4bdf54faefb324d156c2a92473782451e0ee83e4a6723f1e8440d6e9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7787243127822876}","{'position': 2, 'link': 'https://www.koreabiomed.com/news/articleView.html?idxno=13140', 'title': 'Pfizer scores European approval for 20-valent pneumococcal vaccine', 'source': 'KBR', 'date': 'Feb 16, 2022', 'snippet': 'Pfizer, which dominated the global pneumococcal vaccine market with \n13-valent Prevnar 13, said it won approval for a 20-valent vaccine in \nEurope.', 'thumbnail': 'https://serpapi.com/searches/672491651fc7c5650202e6c3/images/60dd0eec4bdf54fae8a25e56b11593d9ffb618da42f19b94693341190c7ea113.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5019819736480713}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04251182,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/t3d-959-improves-cognitive-function-in-certain-patients-study/', 'title': 'T3D-959 improves cognitive function in certain patients: Study', 'source': ""Alzheimer's News Today"", 'date': 'Nov 10, 2023', 'snippet': ""T3D-959 outperformed a placebo at improving cognitive function in people \nwith mild to moderate Alzheimer's who have a high p-tau217 ratio."", 'thumbnail': 'https://serpapi.com/searches/672491fbe9b691b4208dc24b/images/886ae09a1e02d7b2ea7784d422bd4659f5cb3ee00d8afcecadf5e83cbf87e8c3.png', 'sentiment': 'positive', 'sentiment_prob': 0.7613877058029175}",,,,,,,,,,['positive'],positive,1
NCT02884206,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14097', 'title': 'Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials', 'source': 'Wiley Online Library', 'date': 'Aug 3, 2022', 'snippet': 'The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (S/V) \nhas an important role in the treatment of patients with HFrEF.', 'thumbnail': 'https://serpapi.com/searches/672492299062f89c9a2d4421/images/b02018af1609ca04b2dfdf536d69563426a6d7d9294026ebd3230e53ba6e43bd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7455959320068359}","{'position': 2, 'link': 'https://www.news-medical.net/news/20231218/Common-heart-medication-causes-false-positives-on-Alzheimers-blood-test.aspx', 'title': ""Common heart medication causes false positives on Alzheimer's blood test"", 'source': 'News-Medical', 'date': 'Dec 18, 2023', 'snippet': 'The drug Entresto (sacubitril/valsartan) which is commonly used for the \ntreatment of cardiac failure leads to a marked reduction in plasma Aβ ratio.', 'thumbnail': 'https://serpapi.com/searches/672492299062f89c9a2d4421/images/b02018af1609ca04045e487d11be1bd5e2ed7f9071f4719afb1ac716d9d37605.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.725658118724823}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT01975441,"{'position': 1, 'link': 'https://www.infectiousdiseaseadvisor.com/news/a-single-triple-drug-treatment-for-lymphatic-filariasis/', 'title': 'A Single Triple-Drug Treatment for Lymphatic Filariasis', 'source': 'Infectious Disease Advisor', 'date': 'Dec 14, 2018', 'snippet': 'A single triple-drug treatment for lymphatic filariasis may prove to be \nmore effective and potent than a double-drug regimen.', 'thumbnail': 'https://serpapi.com/searches/67249242e335eccc3e8ab9f7/images/75134174bee4fdc63ab9004b756160a9899c50fefd9dbc6c128a36591545cde3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7072614431381226}",,,,,,,,,,['neutral'],neutral,1
NCT00481247,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1002315', 'title': 'Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia', 'source': 'The New England Journal of Medicine', 'date': 'Jan 26, 2017', 'snippet': 'Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has \nresulted in high rates of complete cytogenetic response and \nprogression-free...', 'thumbnail': 'https://serpapi.com/searches/6724925afc183da7ad7c22ad/images/2dc71f70e95ff3af051c305731e347f177be3ee7f91c682e746c2a7fa918497d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8576435446739197}",,,,,,,,,,['neutral'],neutral,1
NCT00077779,"{'position': 1, 'link': 'https://ibdnewstoday.com/ibd-treatment/humira-adalimumab/', 'title': 'Range of Bowel Diseases Can Be Treated with Humira', 'source': 'ibdnewstoday.com', 'date': 'Aug 31, 2017', 'snippet': 'Humira (adalimumab) is a biological therapy that the US Food and Drug \nAdministration approved for treating inflammatory bowel disease, or IBD.', 'thumbnail': 'https://serpapi.com/searches/672493f8d11a89e4baac2297/images/69f9ad7e42e7ca2c7b7acf059be23084248dc0d70163caf1bc948da0901150da.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9108577370643616}",,,,,,,,,,['neutral'],neutral,1
NCT02159066,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S2211124723005818', 'title': 'Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma', 'source': 'ScienceDirect.com', 'date': 'Jun 27, 2023', 'snippet': 'Here, we show that the magnitude and duration of receptor tyrosine kinase \n(RTK) activation determine ERK reactivation and persister development.', 'thumbnail': 'https://serpapi.com/searches/672495b13c944bd57a5f1de5/images/ad91d973ec55a2b1c573316478f615842be092f7e8ef42fce9e607f5afff16f8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8985692858695984}",,,,,,,,,,['neutral'],neutral,1
NCT03051256,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/time-from-mdd-onset-and-response-to-esmethadone/', 'title': 'Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017)', 'source': 'Psychiatrist.com', 'date': 'May 13, 2024', 'snippet': 'Esmethadone 25 and 50 mg were more effective in reducing depression scale \nscores in patients who had a shorter time since their first major...', 'thumbnail': 'https://serpapi.com/searches/672495ba2c566d84e7d28e54/images/eefff7a583a9547d3d2efeeb197a53d4f6f833ccb337db540e06d3a4e7a38c5f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6382936239242554}",,,,,,,,,,['neutral'],neutral,1
NCT02249338,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2023/2297559', 'title': 'The Molecular Blueprint for Chronic Obstructive Pulmonary Disease (COPD): A New Paradigm for Diagnosis and Therapeutics - Shakeel - 2023 - Oxidative Medicine and Cellular Longevity', 'source': 'Wiley Online Library', 'date': 'Dec 21, 2023', 'snippet': 'This review discusses a narrative opinion and critical review of COPD. We \npresent different aspects of the disease, from cellular and inflammatory \nresponses to...', 'thumbnail': 'https://serpapi.com/searches/672495cff9f904fd8c1736a4/images/22ef429ddf0ab26523683aaea1707f4fcb9e1d6fbc41db6f88a69da681e6c5e6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.930492639541626}",,,,,,,,,,['neutral'],neutral,1
NCT00297388,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/double-blind-study-doses-long-acting-risperidone/', 'title': 'A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder.', 'source': 'Psychiatrist.com', 'date': 'Oct 29, 2023', 'snippet': 'George M. Simpson, MD; Ramy A. Mahmoud, MD; Robert A. Lasser, MD; Mary \nKujawa, MD; Cynthia A. Bossie, PhD; Ibrahim Turkoz, MS; Steven Rodriguez, \nMS;...', 'thumbnail': 'https://serpapi.com/searches/672494f0dda9d931278ca58a/images/02fe05bc2c830983319438bc90028823b4d12d310ff644ef93510bbefacbc5cf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9112716317176819}",,,,,,,,,,['neutral'],neutral,1
NCT03339882,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/abs/pii/S0378874118319159', 'title': 'Effect of cimicifuga racemosa on menopausal syndrome caused by LHRH-a in breast cancer', 'source': 'ScienceDirect.com', 'date': 'Jun 28, 2019', 'snippet': 'Cimicifuga racemose is previously proved effective on nature menopausal \nsyndrome (MPS). However, its clinical value in treating with MPS...', 'thumbnail': 'https://serpapi.com/searches/67249513e10f0a1c4155b849/images/8d71ce17d4a38efa3eeee8007d304b242e0e179d7d75ce2aaa79b0e23cdb6fae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8092305064201355}",,,,,,,,,,['neutral'],neutral,1
NCT01830920,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.864509/full', 'title': 'A Process for the Design and Development of Novel Bone Morphogenetic Protein-7 (BMP-7) Mimetics With an Example: THR-184', 'source': 'Frontiers', 'date': 'Feb 12, 2024', 'snippet': '1Division of Cardiology, Mass General Hospital/Harvard, Boston, MA, United \nStates; 2Harvard Medical School, Boston, MA, United States; 3Therapeutics \nBy...', 'thumbnail': 'https://serpapi.com/searches/67249522c05eb58836389c51/images/6189dfe4b7d087c087c3542e0b29cf18df8904c810e8f02a28a51869f9bb14b9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9013253450393677}",,,,,,,,,,['neutral'],neutral,1
NCT02398461,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/rhigm22-multiple-sclerosis/', 'title': 'rHIgM22 for Multiple Sclerosis', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 23, 2019', 'snippet': 'rHIgM22 is an investigational remyelinating antibody being developed by \nAcorda Therapeutics in collaboration with the Mayo Foundation for Medical \nEducation...', 'thumbnail': 'https://serpapi.com/searches/67249562131502700ed66161/images/7e2038fc35d282ad2915839c0e9cddacb368644b093bb6899186d66cce99c818.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9288907647132874}",,,,,,,,,,['neutral'],neutral,1
NCT02797964,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-023-02279-x', 'title': 'A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer', 'source': 'Nature', 'date': 'Apr 29, 2023', 'snippet': 'This was a first-in-human Phase 1/2 open-label dose-escalation study of the \nnovel checkpoint kinase 1 (Chk1) inhibitor SRA737.', 'thumbnail': 'https://serpapi.com/searches/672495677a12fda5c3c3fd70/images/3802f4fc94fe3d3ca4a6f54fdb21ea2157bd2c8a52765a82426440e6b85eb976.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9178969860076904}",,,,,,,,,,['neutral'],neutral,1
NCT03901144,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/ced.15141', 'title': 'Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis', 'source': 'Wiley Online Library', 'date': 'Feb 15, 2022', 'snippet': 'This study compares the barrier-strengthening properties of a new \nmoisturizer, containing urea and glycerol, to a glycerol-containing...', 'thumbnail': 'https://serpapi.com/searches/672494330197dd91dd3b7bc8/images/db36806806bb8ffd3a2bd787c969b30d886ec4841ac045637141a89bbd1b359d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.870810329914093}",,,,,,,,,,['neutral'],neutral,1
NCT03572933,"{'position': 1, 'link': 'https://www.empr.com/home/news/ztalmy-approved-for-cdkl5-deficiency-disorder/', 'title': 'Ztalmy Approved for CDKL5 Deficiency Disorder', 'source': 'Medical Professionals Reference', 'date': 'Mar 18, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Ztalmy (ganaxolone) for \nthe treatment of seizures associated with cyclin-dependent kinase-like 5 \n(CDKL5)...', 'thumbnail': 'https://serpapi.com/searches/6724946a1f3d4bc2ce222f3d/images/ad85b504780fa9d002850cf3f12f855217c1971d1bc77f0ce7d2e1339d8d3e8c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8341307044029236}",,,,,,,,,,['neutral'],neutral,1
NCT04537793,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/nacfc-2023-long-term-trikafta-maintains-efficacy-cf-children/', 'title': 'NACFC 2023: Long-term Trikafta maintains effectiveness in children', 'source': 'Cystic Fibrosis News Today', 'date': 'Nov 7, 2023', 'snippet': ""Trikafta's developer Vertex Pharmaceuticals presented the findings from two \nopen-label extension studies at the 2023 NACFC in Phoenix."", 'thumbnail': 'https://serpapi.com/searches/672494af58e4331656c95ff4/images/e32d69fb4ffb6a3ce49042095a4c0bd2f7e6d13b20efbc3a69ea1c68bc32b086.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5179463624954224}","{'position': 2, 'link': 'https://www.empr.com/home/news/trikafta-approved-for-children-with-cystic-fibrosis-as-young-as-2-years/', 'title': 'Trikafta Approved for Children With Cystic Fibrosis as Young as 2 Years', 'source': 'Medical Professionals Reference', 'date': 'Apr 26, 2023', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of \nTrikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include \nchildren with cystic...', 'thumbnail': 'https://serpapi.com/searches/672494af58e4331656c95ff4/images/e32d69fb4ffb6a3c532a877f405c094fbca3224dd71053e38fc5b2ad2acc6ca8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8349416851997375}","{'position': 3, 'link': 'https://cysticfibrosisnewstoday.com/news/fda-expands-approval-trikafta-younger-children-ages-2-to-5/', 'title': 'FDA expands its approval of Trikafta to children ages 2 to 5', 'source': 'Cystic Fibrosis News Today', 'date': 'Apr 27, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has approved the expanded use of \nTrikafta (elexacaftor, tezacaftor, and ivacaftor) to children with cystic \nfibrosis (...', 'thumbnail': 'https://serpapi.com/searches/672494af58e4331656c95ff4/images/e32d69fb4ffb6a3ce54ba307495ab85b8f1b02995383535ae24edfbdb7af1c6d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5731809139251709}","{'position': 4, 'link': 'https://cysticfibrosisnewstoday.com/news/vertex-phase-3-trials-vx121-vx561-tezacaftor-triple-combination-cf-therapy/', 'title': 'Vertex Planning Phase 3 Trials in New Triple Combo Therapy for CF', 'source': 'Cystic Fibrosis News Today', 'date': 'Jul 30, 2021', 'snippet': 'Vertex Pharmaceuticals is initiating two Phase 3 clinical trials into the \nsafety and efficacy of a potentially new, next-generation triple \ncombination therapy...', 'thumbnail': 'https://serpapi.com/searches/672494af58e4331656c95ff4/images/e32d69fb4ffb6a3c5918e0c85a5fcb40ea68330f07486365d3c56c4c19209823.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.881530225276947}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04559568,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1002/mco2.481', 'title': 'Drug development advances in human genetics‐based targets - Zhang - 2024 - MedComm', 'source': 'Wiley Online Library', 'date': 'Feb 9, 2024', 'snippet': 'Progress in drug discovery based on targets with favorable LOF variants \nidentified by WES, WGS, and GWAS. Targets primarily include PCSK9,...', 'thumbnail': 'https://serpapi.com/searches/672494afa3243676679b6434/images/1969ffbc4a7246dd8f64a9e26fc7691377ac4df3a787dfc36a3c05a2badf85ed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7308827042579651}",,,,,,,,,,['neutral'],neutral,1
NCT00627588,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/sio-gene-therapies-oxford-biomedica-therapy-candidate-axo-lenti-pd-parkinsons/', 'title': 'Development Halted on Gene Therapy Candidate AXO-Lenti-PD', 'source': ""Parkinson's News Today"", 'date': 'Feb 2, 2022', 'snippet': ""Sio Gene Therapies (Sio) intends to stop its development of AXO-Lenti-PD, \nan investigational gene therapy for Parkinson's disease."", 'thumbnail': 'https://serpapi.com/searches/672494c5d721286a3aac3055/images/dd491db51d5ba58d39e41138476c33e42e6468fc10f94e6695d845d0224d3f91.png', 'sentiment': 'negative', 'sentiment_prob': 0.5223289132118225}",,,,,,,,,,['negative'],negative,0
NCT01908426,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-021-01532-5', 'title': 'Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade', 'source': 'Nature', 'date': 'Oct 7, 2021', 'snippet': 'Albumin-bilirubin (ALBI) grade is an objective measure of liver function \nfor patients with hepatocellular carcinoma (HCC).', 'thumbnail': 'https://serpapi.com/searches/672495df71c62bd52d0da3d9/images/3cbc97b95bc5a25fa506e3a366986b144130edb1961e8a752e584a43aeac96e6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8510801792144775}",,,,,,,,,,['neutral'],neutral,1
NCT02872116,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/updated-checkmate-649-results-show-sustain-benefit-of-nivolumab-plus-chemo-for-gastric-gej-cancer', 'title': 'Updated CheckMate 649 Results Show Sustain Benefit of Nivolumab Plus Chemo for Gastric/GEJ Cancer', 'source': 'Cancer Network', 'date': 'Jan 22, 2022', 'snippet': 'Follow-up data from the CheckMate 649 trial (NCT02872116) that were \npresented at the 2022 Gastrointestinal Cancers Symposium indicated that...', 'thumbnail': 'https://serpapi.com/searches/672495eb9e38e5ac2d35e3fa/images/cb5cdcd3d99d79ae6815551792394362d273b4031744ddd57dacf533753a9e88.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8021529912948608}","{'position': 2, 'link': 'https://psychedelicalpha.com/news/pharmadrug-announces-world-renowned-gastric-cancer-expert-dr-yelena-y-janjigian-joins-sairiyo-therapeutics-scientific-and-clinical-advisory-board', 'title': 'PharmaDrug Announces World-Renowned Gastric Cancer Expert Dr. Yelena Y. Janjigian Joins Sairiyo Therapeutics Scientific and Clinical Advisory Board', 'source': 'Psychedelic Alpha', 'date': 'May 20, 2022', 'snippet': 'Toronto, Ontario–(Newsfile Corp. – March 4, 2021) – PharmaDrug Inc. (CSE: \nBUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”) wholly-owned \nsubsidiary…', 'thumbnail': 'https://serpapi.com/searches/672495eb9e38e5ac2d35e3fa/images/cb5cdcd3d99d79ae36172e4db438d60dea625b7feca2b5ee41b00e0ff37b6c54.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8563597202301025}","{'position': 3, 'link': 'https://immuno-oncologynews.com/2020/10/28/opdivo-combo-extends-survival-advanced-stomach-and-esophageal-cancers-phase-3-trial-shows/', 'title': 'Opdivo Combo Found to Extend Survival in Advanced Stomach, Esophageal Cancers', 'source': 'Immuno-Oncology News', 'date': 'Oct 28, 2020', 'snippet': 'Adding Opdivo (nivolumab) to standard first-line chemotherapy significantly \nextends overall survival and delays disease progression or death in adults.', 'thumbnail': 'https://serpapi.com/searches/672495eb9e38e5ac2d35e3fa/images/cb5cdcd3d99d79aeb71ccacbecc3004c250e0f8b31ebcc91c3e552eb7d74d05e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7953006625175476}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03765073,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2116045', 'title': 'Potential for Maternally Administered Vaccine for Infant Group B Streptococcus', 'source': 'The New England Journal of Medicine', 'date': 'Jul 19, 2023', 'snippet': 'Natural history studies have correlated serotype-specific anti–capsular \npolysaccharide (CPS) IgG in newborns with a reduced risk of group B...', 'thumbnail': 'https://serpapi.com/searches/672498f0707fd3a645c4accf/images/ae473016b78922717e66073e7fbaad9386e2c51dc139e4c0c1e2ec9dcc41bd8a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8743211627006531}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/maternal-vaccine-candidate-for-gbs-prevention-in-infants-gets-breakthrough-tx-status/', 'title': 'Maternal Vaccine Candidate for GBS Prevention in Infants Gets Breakthrough Tx Status', 'source': 'Medical Professionals Reference', 'date': 'Sep 7, 2022', 'snippet': 'The Food and Drug Administration (FDA) has granted Breakthrough Therapy \ndesignation to an investigational Group B Streptococcus (GBS) vaccine \ncandidate.', 'thumbnail': 'https://serpapi.com/searches/672498f0707fd3a645c4accf/images/ae473016b7892271d93cd3cf76382b11736bcaa3388aedcfb227faa3102069a6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6908876299858093}","{'position': 3, 'link': 'https://www.researchgate.net/figure/GBS-vaccine-candidates-in-the-development-pathway_tbl1_368357442', 'title': 'GBS vaccine candidates in the development pathway', 'source': 'ResearchGate', 'date': 'Jul 5, 2023', 'snippet': 'Purpose of review: Intrapartum antibiotic prophylaxis (IAP) is currently \nthe only preventive approach against clinical consequences of maternal \nGroup B...', 'thumbnail': 'https://serpapi.com/searches/672498f0707fd3a645c4accf/images/ae473016b78922718fe6ef4b2d6d0123810927249b8cf3da1797cd27b40eac75.png', 'sentiment': 'neutral', 'sentiment_prob': 0.901256799697876}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03202758,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-023-02497-z', 'title': 'First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial', 'source': 'Nature', 'date': 'Aug 10, 2023', 'snippet': 'The single-arm, phase 1b/2 MEDITREME trial evaluated the safety and \nefficacy of durvalumab plus tremelimumab combined with mFOLFOX6 \nchemotherapy in first line.', 'thumbnail': 'https://serpapi.com/searches/67249942069e5753851d323e/images/147997f720ff5d3c0b01aa31158c41fdd03881f65e9f39b61c62a48875ab60d0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8836589455604553}",,,,,,,,,,['neutral'],neutral,1
NCT00270374,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1100171', 'title': 'Effect of Nesiritide in Patients with Acute Decompensated Heart Failure', 'source': 'The New England Journal of Medicine', 'date': 'Jul 7, 2011', 'snippet': 'Nesiritide is approved in the United States for early relief of dyspnea in \npatients with acute heart failure. Previous meta-analyses have...', 'thumbnail': 'https://serpapi.com/searches/672496317ebde5567687ae56/images/e94bbe97f3a8870b7bccabadb7481bc6e5615f5cf5373931bb9f6ba1db24f5e5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6487038731575012}",,,,,,,,,,['neutral'],neutral,1
NCT05053165,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/lb-p8-probiotic-primary-sclerosing-cholangitis-fda-fast-track/', 'title': 'LB-P8 probiotic on FDA fast track for primary sclerosing cholangitis', 'source': 'Liver Disease News', 'date': 'Apr 3, 2024', 'snippet': 'The FDA has given fast track status to LB-P8, an experimental probiotic \nheading to Phase 2 clinical testing for primary sclerosing...', 'thumbnail': 'https://serpapi.com/searches/67249642cf32e043b585f875/images/33425ed71f2e5c3662df615e19f9fe48b5cdb5acde244f5451250d522a64a3ec.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7736496925354004}","{'position': 2, 'link': 'https://liverdiseasenews.com/news/phase-2-study-lb-pp8-primary-sclerosing-cholangitis-cleared-fda/', 'title': 'Phase 2 study of LB-P8 for primary sclerosing cholangitis cleared by FDA', 'source': 'Liver Disease News', 'date': 'Mar 13, 2024', 'snippet': 'LISCure Biosciences will launch the studyl in the U.S. to evaluate the \nsafety and effectiveness of LB-P8 for primary sclerosing cholangitis.', 'thumbnail': 'https://serpapi.com/searches/67249642cf32e043b585f875/images/33425ed71f2e5c365681ea3a6667f88aaa51e9643dd646090cd49ebff1f969dd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8620840311050415}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02959905,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-39225-7', 'title': 'A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors', 'source': 'Nature', 'date': 'Jun 10, 2023', 'snippet': 'We report a single-arm, open-label and non-randomized phase 1 study \n(NCT02959905) of Neo-T therapy with lymphodepletion at various dose \nintensity in patients...', 'thumbnail': 'https://serpapi.com/searches/672496fb66d995235efc7516/images/63e22014236e26d3578a74f3ff3f980387548ca55d4dada72050270f72198bd4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9180925488471985}",,,,,,,,,,['neutral'],neutral,1
NCT02042391,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-022-01667-1', 'title': 'Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial', 'source': 'Nature', 'date': 'Aug 16, 2022', 'snippet': 'The prospective multicentre Phase II PTLD-2 trial (NCT02042391) tested \nmodified risk-stratification in adult SOT recipients with CD20-positive \nPTLD.', 'thumbnail': 'https://serpapi.com/searches/672496ff81bab7fc548573a3/images/9446ed77e8d5178998857617f70a9e623d08ba6e518b2067dee93fa785b94a3b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8540777564048767}",,,,,,,,,,['neutral'],neutral,1
NCT02673164,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0753332223016682', 'title': 'The recent advances in cell delivery approaches, biochemical and engineering procedures of cell therapy applied to coronary heart disease', 'source': 'ScienceDirect.com', 'date': 'Dec 31, 2023', 'snippet': 'In this review, we give an update on techniques and clinical studies of \ncell treatment as used to cure CHD that are now ongoing or have been \ncompleted in the...', 'thumbnail': 'https://serpapi.com/searches/6724971b5809e7a23c07da82/images/f38ba652e3262f5479456511c083dae1f5d4cf20222f8770f4c823f524b9ee7d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8919031023979187}",,,,,,,,,,['neutral'],neutral,1
NCT05266456,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/pneumococcal-24-valent-conjugate-vaccine-gets-fast-track-designation/', 'title': 'Pneumococcal 24-Valent Conjugate Vaccine Gets Fast Track Designation', 'source': 'Medical Professionals Reference', 'date': 'Aug 4, 2022', 'snippet': 'The Food and Drug Administration (FDA) has granted Fast Track designation \nto VAX-24 for the prevention of invasive pneumococcal disease in adults 18 \nyears of...', 'thumbnail': 'https://serpapi.com/searches/67249654a88278593d01b382/images/36f08890b9abf112497d30191140e1795b58b572cc4fa9db144edf4c8a325abb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9023721218109131}",,,,,,,,,,['neutral'],neutral,1
NCT05816330,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2312775', 'title': 'Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria', 'source': 'The New England Journal of Medicine', 'date': 'Apr 26, 2024', 'snippet': 'Subcutaneous administration of the monoclonal antibody L9LS protected \nadults against controlled Plasmodium falciparum infection in a phase 1...', 'thumbnail': 'https://serpapi.com/searches/672496611fc7c565347dfa3d/images/faeb6f7b0adf344c653f43ea84f3e168ea621d341de121b176aa4472343d6881.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8696849346160889}",,,,,,,,,,['neutral'],neutral,1
NCT00651456,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-019-0379-8', 'title': 'MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial', 'source': 'Nature', 'date': 'Feb 11, 2019', 'snippet': 'The Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS/NCT00651456) \nphase 3 trial demonstrated the superiority of bevacizumab plus...', 'thumbnail': 'https://serpapi.com/searches/6724966e2a77272bc1b6944f/images/25e5637584fe0634772e4725fdda0550aacaf98ee3666d93dbe9cf2661a4570d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5509125590324402}",,,,,,,,,,['neutral'],neutral,1
NCT04889183,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-024-03015-5', 'title': 'Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial', 'source': 'Nature', 'date': 'May 25, 2024', 'snippet': 'The SELECT trial previously reported a 20% reduction in major adverse \ncardiovascular events with semaglutide (n = 8803) versus placebo (n...', 'thumbnail': 'https://serpapi.com/searches/67249692123457faf3211f20/images/27b0cec887f6b4c01616b2b31ae12a4c872e0d88eb9825e3cee8229035295888.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8687243461608887}",,,,,,,,,,['neutral'],neutral,1
NCT00938652,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1011418', 'title': 'Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Jan 5, 2011', 'snippet': 'The addition of iniparib to chemotherapy improved the clinical benefit and \nsurvival of patients with metastatic triple-negative breast cancer \nwithout...', 'thumbnail': 'https://serpapi.com/searches/672496c9861b9da4bf288707/images/f6356496a2138f0ea35606c1d72617db8b1c36321329edc12c4f0808ab394cf6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5897843837738037}",,,,,,,,,,['neutral'],neutral,1
NCT00833781,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S2405844024030020', 'title': 'The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases', 'source': 'ScienceDirect.com', 'date': 'Mar 15, 2024', 'snippet': 'mRNA-based therapeutics have revolutionized medicine and the pharmaceutical \nindustry. The recent progress in the optimization and...', 'thumbnail': 'https://serpapi.com/searches/672496d0dda9d931278ca5e1/images/22e3ee5f21a60caf91746a2e4308712cc287a7059885b8e47423abf95c199940.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6543469429016113}",,,,,,,,,,['positive'],positive,1
NCT03443869,"{'position': 1, 'link': 'https://www.empr.com/home/news/prevymis-approved-for-cmv-disease-prevention-in-kidney-transplant-recipients/', 'title': 'Prevymis Approved for CMV Disease Prevention in Kidney Transplant Recipients', 'source': 'Medical Professionals Reference', 'date': 'Jun 6, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Prevymis (letermovir) \nfor prophylaxis of cytomegalovirus (CMV) disease in adult kidney \ntransplant...', 'thumbnail': 'https://serpapi.com/searches/672496dbb2ebae2669c54936/images/56516c55294ca446d206f59836c8fb01591b859f2a3b0ef1f61f7e737bcdde57.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8343550562858582}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/fda-to-review-letermovir-for-cmv-disease-prevention-in-kidney-transplant-recipients/', 'title': 'FDA to Review Letermovir for CMV Disease Prevention in Kidney Transplant Recipients', 'source': 'Medical Professionals Reference', 'date': 'Feb 17, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted for Priority Review the \nsupplemental New Drug Application (sNDA) for letermovir for...', 'thumbnail': 'https://serpapi.com/searches/672496dbb2ebae2669c54936/images/56516c55294ca44682e1407e2b65036c222006ee2f817b6ca4163f13bb77f5a2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8933071494102478}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01017185,"{'position': 1, 'link': 'https://www.nature.com/articles/s41417-019-0129-3', 'title': 'Oncolytic activity of HF10 in head and neck squamous cell carcinomas', 'source': 'Nature', 'date': 'Sep 3, 2019', 'snippet': 'HF10 killed HNSCC cells and induced antitumoral immunity, thereby \nestablishing it as a promising agent for the treatment of HNSCC patients.', 'thumbnail': 'https://serpapi.com/searches/672496df0d379fad1988fe06/images/9eb24e6b4a56d369212d5e33f7e5229d580091465bace769f3f38192324f9842.png', 'sentiment': 'negative', 'sentiment_prob': 0.5706256031990051}",,,,,,,,,,['negative'],negative,0
NCT03537014,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01336-3', 'title': 'MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study', 'source': 'Nature', 'date': 'May 10, 2021', 'snippet': 'Post-traumatic stress disorder (PTSD) presents a major public health \nproblem for which currently available treatments are modestly effective...', 'thumbnail': 'https://serpapi.com/searches/6724975d59f911ffb566ea06/images/eae96d09009b4b46302042eef67e2469b16845433379074e2ba24818a732ea3c.png', 'sentiment': 'negative', 'sentiment_prob': 0.6106637716293335}",,,,,,,,,,['negative'],negative,0
NCT01621490,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-34877-3', 'title': 'A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma', 'source': 'Nature', 'date': 'Nov 25, 2022', 'snippet': 'Acral melanoma is a dismal subtype of melanoma occurring in glabrous acral \nskin, and has a higher incidence in East Asians.', 'thumbnail': 'https://serpapi.com/searches/6724985c8d147358ee7a5b87/images/5a170dd49d7ff19668ec375dd47cf8f742cc5eb063cc2e793eb7bfd360a11ec6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6061059236526489}",,,,,,,,,,['neutral'],neutral,1
NCT04634409,"{'position': 1, 'link': 'https://investor.lilly.com/news-releases/news-release-details/lillys-bebtelovimab-receives-emergency-use-authorization', 'title': ""Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19"", 'source': 'Eli Lilly and Company', 'date': 'Feb 11, 2022', 'snippet': 'FDA has authorized bebtelovimab for emergency use for certain \nnon-hospitalized patients with mild-to-moderate COVID-19 at high risk of \nprogression to severe...', 'thumbnail': 'https://serpapi.com/searches/67249882483e5b5046d32623/images/bcfd507f2e1a5fa8cbe4eb62dd8327c46f8f5e1088c18aa1d143a5a7b24fc6c0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8874615430831909}",,,,,,,,,,['neutral'],neutral,1
NCT02688608,"{'position': 1, 'link': 'https://www.targetedonc.com/view/immune-checkpoint-inhibitors-show-promising-efficacy-in-anaplastic-thyroid-cancer', 'title': 'Immune Checkpoint Inhibitors Show Promising Efficacy in Anaplastic Thyroid Cancer', 'source': 'Targeted Oncology', 'date': 'Sep 1, 2022', 'snippet': 'Immune checkpoint blockade was well tolerated and had a similar toxicity \nprofile to PD-1/PD-L1-targeting therapies for patients with anaplastic \nthyroid cancer...', 'thumbnail': 'https://serpapi.com/searches/672497e65c7cb9333c7c3152/images/3bb696ef91701a37cf7a8ac83ebffa24bf0f6d5113d48f3ed1b749cf3e6d9dc2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5318613052368164}",,,,,,,,,,['positive'],positive,1
NCT03798106,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-024-44875-2', 'title': 'Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial', 'source': 'Nature', 'date': 'Jan 23, 2024', 'snippet': 'We aimed to determine the activity of the anti-VEGF receptor \ntyrosine-kinase inhibitor, pazopanib, combined with the anti-PD-L1 \ninhibitor,...', 'thumbnail': 'https://serpapi.com/searches/67249836fda26d6e2ce395f1/images/04e4b8bf765ab43e5a88d51c1e5abe7e51a3aaf5e47bb525c206e4e901cf0050.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9073408246040344}",,,,,,,,,,['neutral'],neutral,1
NCT04649151,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2109522', 'title': 'Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents', 'source': 'The New England Journal of Medicine', 'date': 'Aug 11, 2021', 'snippet': 'The incidence of coronavirus disease 2019 (Covid-19) among adolescents \nbetween 12 and 17 years of age was approximately 900 per 100000...', 'thumbnail': 'https://serpapi.com/searches/6724984e39e232bf613925e9/images/a22b2ba20b90523461c45bf31554beb589c7ea27984fecc83bbd664ee3c47ed0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6496191024780273}",,,,,,,,,,['neutral'],neutral,1
NCT00721409,"{'position': 1, 'link': 'https://breastcancer-news.com/2018/11/05/faslodex-ibrance-combo-improves-survival-advanced-breast-cancer-patients/', 'title': 'In Breast Cancer, Ibrance-Faslodex Combo Improves Survival, Phase 3 Data Shows', 'source': 'breastcancer-news.com', 'date': 'Nov 5, 2018', 'snippet': ""Adding Pfizer's Ibrance to standard treatment Faslodex significantly \nextended the survival of advanced breast cancer patients in a Phase 3..."", 'thumbnail': 'https://serpapi.com/searches/6724997869f8ec1211632512/images/4bd8aea591e8934bdb99852deb6b8562f53733f84d40bcf95e880e90ec0ca898.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.631209135055542}",,,,,,,,,,['neutral'],neutral,1
NCT00995137,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.607131/full', 'title': 'Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function', 'source': 'Frontiers', 'date': 'Dec 16, 2020', 'snippet': 'Research and Development, Glycostem Therapeutics, Oss, Netherlands. Natural \nKiller (NK) cells are unique immune cells capable of efficient...', 'thumbnail': 'https://serpapi.com/searches/6724997cf410445e4dd81bea/images/8486bb24d90ce54f131b1300677e69e01e092bdb25d2571c21e30011a498f49c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7305735945701599}",,,,,,,,,,['neutral'],neutral,1
NCT02346201,"{'position': 1, 'link': 'https://www.nia.nih.gov/news/ritalin-reduced-apathy-nia-funded-alzheimers-clinical-trial', 'title': 'Ritalin reduced apathy in NIA-funded Alzheimer’s clinical trial', 'source': 'National Institute on Aging (.gov)', 'date': 'Dec 2, 2021', 'snippet': ""The stimulant drug methylphenidate, commonly known as Ritalin, safely \nreduced measures of apathy among adults with Alzheimer's disease,..."", 'thumbnail': 'https://serpapi.com/searches/6724999c23793852a787739e/images/6b698ca54eb99d9f08038d4f9f017745aae9508cb32db38826d41cce8bcbb456.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7688660621643066}",,,,,,,,,,['neutral'],neutral,1
NCT05400655,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2203067', 'title': 'Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria', 'source': 'The New England Journal of Medicine', 'date': 'Aug 3, 2022', 'snippet': 'In this small trial, L9LS administered intravenously or subcutaneously \nprotected recipients against malaria after controlled infection, without \nevident safety...', 'thumbnail': 'https://serpapi.com/searches/67249e50c76a3a3c4c1e19a5/images/6adfa40f2d3baed1b9767372897c43f0cf0bcbdcb3ee0dcd19cccc6fb0de98de.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7041404843330383}",,,,,,,,,,['neutral'],neutral,1
NCT03401112,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/imara-begins-phase-2-sickle-cell-trial-testing-imr-687/', 'title': 'Imara Begins Phase 2 Sickle Cell Disease Trial Testing IMR-687 in Adults', 'source': 'Sickle Cell Disease News', 'date': 'Feb 15, 2018', 'snippet': 'Imara, a pharmaceutical company developing new therapies for sickle cell \ndisease, has successfully dosed the first patient enrolled in its...', 'thumbnail': 'https://serpapi.com/searches/67249e62d19f158f2a67b89b/images/f1ef6abadf9a8257e6b3ba7ce2b8e368c9178cf30aae0171ea793fd2d8c210bb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.692392110824585}",,,,,,,,,,['neutral'],neutral,1
NCT03243851,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01637-8', 'title': 'From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress', 'source': 'Nature', 'date': 'Oct 20, 2023', 'snippet': 'Glioblastoma, a rare, and highly lethal form of brain cancer, poses \nsignificant challenges in terms of therapeutic resistance, and poor...', 'thumbnail': 'https://serpapi.com/searches/672499ce21b01b4574751d5d/images/9255cf984277a42a16d30ac90112053eb03ca392fbcd48ae7d9d778c3e5bdefc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5414822101593018}",,,,,,,,,,['neutral'],neutral,1
NCT03358875,"{'position': 1, 'link': 'https://www.biopharminternational.com/view/european-commission-approves-tislelizumab-for-non-small-cell-lung-cancer', 'title': 'European Commission Approves Tislelizumab for Non-Small Cell Lung Cancer', 'source': 'BioPharm International', 'date': 'Apr 25, 2024', 'snippet': 'The approval, given across three indications, follows a previous approval \nfor second-line use in esophageal squamous cell carcinoma.', 'thumbnail': 'https://serpapi.com/searches/672499d0f60b6fda68648472/images/4402b2d71cb8c0a922febd88cd962a0a74e2b8c714c10ff535bab0fdb255cbe7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8108032941818237}","{'position': 2, 'link': 'https://immuno-oncologynews.com/2020/12/09/tislelizumab-safely-prolongs-survival-advanced-lung-cancer-patients-interim-data-show/', 'title': 'Tislelizumab Safely Prolongs Survival in Advanced Lung Cancer Patients, Interim Data Show', 'source': 'Immuno-Oncology News', 'date': 'Dec 9, 2020', 'snippet': 'Interim data from a Phase 3 trial showed tislelizumab safely prolonged the \nsurvival of adults with advanced non-small cell lung cancer.', 'thumbnail': 'https://serpapi.com/searches/672499d0f60b6fda68648472/images/4402b2d71cb8c0a969a197c0dd4e6d493c44d9543d41cd23745dfa57d21b37ed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5863035321235657}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04014335,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/ionis-presents-positive-phase-2-data-in-patients-with-iga-nephropathy-at-american-society-of-nephrologys-kidney-week-2022-301669838.html', 'title': ""Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022"", 'source': 'PR Newswire', 'date': 'Nov 7, 2022', 'snippet': 'PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented \npositive results from a Phase 2 clinical study of IONIS-FB-LRx in...', 'thumbnail': 'https://serpapi.com/searches/672499d1b4b72d4dda145d04/images/1da0126ac4ad69135f9885336636cf35a3e1380e46cd4893b32932f0d5e61b41.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5928696990013123}",,,,,,,,,,['neutral'],neutral,1
NCT02305758,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-018-0343-z', 'title': 'A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer', 'source': 'Nature', 'date': 'Dec 11, 2018', 'snippet': 'Metastatic colorectal cancer (mCRC) has low survival rates. We assessed if \naddition of veliparib, concurrent to FOLFIRI, improves survival...', 'thumbnail': 'https://serpapi.com/searches/672499f5fda26d6e63e8d6a7/images/30fc77bc1072572a1529439b9e3588d04f2700ed25edce8ed8a943900fdba428.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7744810581207275}",,,,,,,,,,['neutral'],neutral,1
NCT02343120,"{'position': 1, 'link': 'https://www.onclive.com/view/indirect-comparison-of-efficacy-of-zanubrutinib-versus-acalabrutinib-in-the-treatment-of-patients-with-relapsed-or-refractory-mantle-cell-lymphoma', 'title': 'Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma', 'source': 'OncLive', 'date': 'Jul 5, 2024', 'snippet': 'The study assessed the comparative efficacy of zanubrutinib vs \nacalabrutinib in patients with R/R MCL, in the absence of head-to-head \nclinical trials.', 'thumbnail': 'https://serpapi.com/searches/67249a1b163bdfc2b2af4f9e/images/5d7cf62f5bc82b967eb4a5f5b3e50b0e0fa113407117009cae964805ea289d0d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.884205162525177}",,,,,,,,,,['neutral'],neutral,1
NCT01644890,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-019-0391-z', 'title': 'A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients', 'source': 'Nature', 'date': 'Feb 12, 2019', 'snippet': 'NK105 is a novel nanoparticle drug delivery formulation that encapsulates \npaclitaxel (PTX) in polymeric micelles. We conducted an open-label...', 'thumbnail': 'https://serpapi.com/searches/67249a25e281eed93b036019/images/3733c9f82ee4de973dd95ab1bd152e7a80d8dab9d601247990d4e636a4bb13b9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8983117938041687}",,,,,,,,,,['neutral'],neutral,1
NCT05553366,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2209870', 'title': 'Selective Inhibition of NaV1.8 with VX-548 for Acute Pain', 'source': 'The New England Journal of Medicine', 'date': 'Aug 2, 2023', 'snippet': 'The NaV1.8 voltage-gated sodium channel, expressed in peripheral \nnociceptive neurons, plays a role in transmitting nociceptive signals.', 'thumbnail': 'https://serpapi.com/searches/67249e1517b10ef88bd2d2a2/images/acbb14466dfc0ad8c2a49d072f5341d771c1068f496f15e6ba02141eb4d041e4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8272075057029724}",,,,,,,,,,['neutral'],neutral,1
NCT04123886,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2021.628332/full', 'title': 'The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials', 'source': 'Frontiers', 'date': 'Mar 10, 2021', 'snippet': 'TRAIL (tumor-necrosis factor related apoptosis-inducing ligand, CD253) and \nits death receptors TRAIL-R1 and TRAIL-R2 selectively trigger the...', 'thumbnail': 'https://serpapi.com/searches/67249e1b6273fb68b4d8233e/images/cb6099d4c8c44412db4b14e58308af37a2b1d5b7914815bbee3f4001605660d6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7822306156158447}",,,,,,,,,,['neutral'],neutral,1
NCT01335477,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1402584', 'title': 'Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis', 'source': 'The New England Journal of Medicine', 'date': 'May 18, 2014', 'snippet': 'A phase 2 trial suggested that treatment with 150 mg of nintedanib twice \ndaily reduced lung-function decline and acute exacerbations in patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/67249e2d361fd472bcccbcd0/images/89581440c9f83602b217c95c344c46a41f180c3b7a039388918ded8f3da14987.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8697701692581177}","{'position': 2, 'link': 'https://lungdiseasenews.com/2017/10/26/ipf-therapy-ofev-shows-long-term-effectiveness-regardless-of-baseline-lung-function-early-analysis/', 'title': 'Early Analysis of Ofev in INPULSIS-ON Trial Shows Long-Term Effectiveness in Treating IPF', 'source': 'Lung Disease News', 'date': 'Oct 26, 2017', 'snippet': 'Read about how Ofev (nintedanib) was shown to slow down IPF progression \nregardless of baseline lung function in the Phase 3 INPULSIS...', 'thumbnail': 'https://serpapi.com/searches/67249e2d361fd472bcccbcd0/images/89581440c9f83602eed88dffc2b30f87abbda9c86e097ab0671a32977b535a02.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6172102093696594}","{'position': 3, 'link': 'https://pulmonaryfibrosisnews.com/news/ofev-effective-elderly-patients-comorbidities-ipf-idiopathic-pulmonary-fibrosis/', 'title': 'Ofev Effective in Elderly IPF Patients, Those With Several Comorbidities', 'source': 'Pulmonary Fibrosis News', 'date': 'Apr 30, 2021', 'snippet': 'Study suggests Ofev can preserve lung function in older idiopathic \npulmonary fibrosis patients and those who have several other health...', 'thumbnail': 'https://serpapi.com/searches/67249e2d361fd472bcccbcd0/images/89581440c9f83602db6345265d4a4d0eb42b7dc7720aa8db6dbc4d36a3adca05.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7142563462257385}","{'position': 4, 'link': 'https://pulmonaryfibrosisnews.com/news/ipf-patients-live-longer-on-nintedanib-pooled-data-from-six-trials-show/', 'title': 'IPF Patients Live Longer on Ofev Compared with Placebo, Analysis Shows', 'source': 'Pulmonary Fibrosis News', 'date': 'Apr 16, 2019', 'snippet': 'Treatment with Ofev (nintedanib) can significantly extend the survival of \npatients with idiopathic pulmonary fibrosis (IPF), an analysis of pooled \ndata from...', 'thumbnail': 'https://serpapi.com/searches/67249e2d361fd472bcccbcd0/images/89581440c9f83602d746b3d3e1f920930c4281a6b13e96767c94c1f404e17b31.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.544462263584137}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02983708,"{'position': 1, 'link': 'https://cerebralpalsynewstoday.com/2017/02/17/stimulating-production-certain-white-blood-cells-improve-cp-symptoms-children/', 'title': 'CP Symptoms in Children Improved by Stimulating Production of Certain White Blood Cells', 'source': 'Cerebral Palsy News Today', 'date': 'Feb 17, 2017', 'snippet': 'Read about a study suggesting that stimulating the production of certain \ntypes of white blood cells improves the development of the nervous...', 'thumbnail': 'https://serpapi.com/searches/67249e301397ba76bd3ea55d/images/77e23f186a555f200d3b96abe046b9fb8db85de2fa6b9142309ca4cbf26a4ad4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7238370180130005}",,,,,,,,,,['neutral'],neutral,1
NCT03902691,"{'position': 1, 'link': 'https://www.renalandurologynews.com/news/pegmolesatide-maintains-hemoglobin-in-patients-on-dialysis/', 'title': 'Pegmolesatide Maintains Hemoglobin in Patients on Dialysis', 'source': 'Renal and Urology News', 'date': 'Feb 20, 2024', 'snippet': 'This phase 3 trial is the first to assess the efficacy and safety of a \nnovel EPO-mimetic since the withdrawal of peginesatide from the...', 'thumbnail': 'https://serpapi.com/searches/67249a38544c496fb1cad798/images/901f531be0cec307a943ba41bd9dc5cb9195ccd4087b7505fe65604a6d66f5da.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8224786520004272}",,,,,,,,,,['neutral'],neutral,1
NCT05275400,"{'position': 1, 'link': 'https://www.endocrinologyadvisor.com/news/insulin-efsitora-alfa/', 'title': 'Insulin Efsitora Alfa Demonstrates Non-Inferior Glycemic Control in T2D', 'source': 'Endocrinology Advisor', 'date': '1 month ago', 'snippet': 'Treatment with once-weekly insulin efsitora alfa, compared with daily basal \ninsulins, effects non-inferior glycemic control and a similar safety \nprofile.', 'thumbnail': 'https://serpapi.com/searches/67249a3a360f4e87ed13a2ec/images/779fa01c471bce91d5509c5cd33a50bbd032e214c2ec31fe3292291a1fee7d32.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8644056916236877}",,,,,,,,,,['neutral'],neutral,1
NCT04227470,"{'position': 1, 'link': 'https://myastheniagravisnews.com/news/phase-2-trial-testing-batoclimab-for-mg-begins-dosing/', 'title': 'Phase 2 MG Trial Testing Batoclimab Begins Dosing', 'source': 'Myasthenia Gravis News', 'date': 'Oct 2, 2020', 'snippet': ""A Phase 2 clinical trial of Harbour BioMed's investigational therapy \nbatoclimab, also known as HBM9161, for myasthenia gravis (MG),..."", 'thumbnail': 'https://serpapi.com/searches/67249cde7e1d1ff6c37fd974/images/4912636f97f0d6b1840fa489f0c44af6a0214b47563f8716a946902fee0d8349.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9191279411315918}",,,,,,,,,,['neutral'],neutral,1
NCT04333914,"{'position': 1, 'link': 'https://www.nature.com/articles/s43018-020-00120-5', 'title': 'Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort', 'source': 'Nature', 'date': 'Sep 22, 2020', 'snippet': 'Patients with cancer are presumed to be at increased risk of severe \nCOVID-19 outcomes due to underlying malignancy and treatment-induced \nimmunosuppression.', 'thumbnail': 'https://serpapi.com/searches/67249d91e10f0a1c7374cbdb/images/6eb29f499cbdfbd9259d90b8855ef74a8a029206207c62cdff67199f9c06191d.png', 'sentiment': 'negative', 'sentiment_prob': 0.5159276723861694}",,,,,,,,,,['negative'],negative,0
NCT03525444,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/benefits-trikafta-cf-sustained-3-5-years-extension-trial/', 'title': 'Benefits of Trikafta for CF sustained 3.5+ years in extension trial', 'source': 'Cystic Fibrosis News Today', 'date': 'Jun 14, 2023', 'snippet': 'Long-term treatment with Trikafta leads to sustained lung function gains, \neasing of respiratory symptoms, and better nutritional status.', 'thumbnail': 'https://serpapi.com/searches/67249dc2d0253e868c227f5f/images/95ba711df3d6880394cb3fcb67c678a40ecc49feab6ca31ff9b225629b35c408.png', 'sentiment': 'positive', 'sentiment_prob': 0.8928873538970947}","{'position': 2, 'link': 'https://cysticfibrosisnewstoday.com/news/northern-ireland-reaches-deal-with-vertex-for-access-to-kaftrio/', 'title': 'CF Drug Kaftrio Will be Available in Northern Ireland After Deal With Vertex', 'source': 'Cystic Fibrosis News Today', 'date': 'Aug 3, 2020', 'snippet': 'Northern Ireland reached a deal with Vertex Pharmaceuticals to make Kaftrio \navailable for treating cystic fibrosis, once the drug gets its...', 'thumbnail': 'https://serpapi.com/searches/67249dc2d0253e868c227f5f/images/95ba711df3d68803a692995aef7a8186c53fe0311e73fd810ecdd5cb4266bdc5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7986085414886475}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT00128453,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1208536', 'title': 'A Randomized Trial of Colchicine for Acute Pericarditis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 1, 2013', 'snippet': 'Colchicine is effective for the treatment of recurrent pericarditis. \nHowever, conclusive data are lacking regarding the use of colchicine...', 'thumbnail': 'https://serpapi.com/searches/67249dcad403e1b06e08e8c5/images/458fdfec58e1d25f29b1002fd42201fa5780e57ea84ac4c57bf08bfd74234ce3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8339667320251465}",,,,,,,,,,['neutral'],neutral,1
NCT03823300,"{'position': 1, 'link': 'https://www.globenewswire.com/news-release/2023/04/25/2654401/0/en/New-Vabysmo-data-suggest-greater-retinal-drying-versus-aflibercept-in-nAMD-and-DME.html', 'title': 'New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME', 'source': 'GlobeNewswire', 'date': 'Apr 25, 2023', 'snippet': ""Post-hoc analyses from four phase III studies indicate Vabysmo dried \nretinal fluid faster with fewer injections in neovascular or 'wet'..."", 'thumbnail': 'https://serpapi.com/searches/67249dee17b10ef88bd2d293/images/492be2dc7853d7323deb8cd06087794cff13b4456461d5eb4527fced68299c29.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8941206932067871}",,,,,,,,,,['neutral'],neutral,1
NCT02799602,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/time-to-progression-in-mhspc-cohort-prolonged-with-darolutamide', 'title': 'Time to Progression in mHSPC Cohort Prolonged With Darolutamide', 'source': 'Cancer Network', 'date': 'Jun 3, 2024', 'snippet': 'The rate of subsequent anticancer therapy was reduced with darolutamide vs \nplacebo in patients with mHSPC in the ARASENS trial.', 'thumbnail': 'https://serpapi.com/searches/67249df24a4a1d3f6d810b5d/images/59aeb2ad75caf7e1001c293ba123d736d6fa0c842beb267e96c89dddb665a7bf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.840165913105011}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2119115', 'title': 'Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Feb 17, 2022', 'snippet': 'Darolutamide is a potent androgen-receptor inhibitor that has been \nassociated with increased overall survival among patients with \nnonmetastatic, castration-...', 'thumbnail': 'https://serpapi.com/searches/67249df24a4a1d3f6d810b5d/images/59aeb2ad75caf7e133b9a0107f675eadb331609c220bba681890150f68d1de7f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7056580781936646}","{'position': 3, 'link': 'https://www.urologytimes.com/view/os-benefit-with-darolutamide-maintained-throughout-mhspc-treatment-course', 'title': 'OS benefit with darolutamide maintained throughout mHSPC treatment course', 'source': 'Urology Times', 'date': 'Feb 19, 2024', 'snippet': '""Post-hoc sensitivity analyses from the phase 3 ARASENS trial presented at \nASCO GU were consistent with and supportive of the ARASENS...', 'thumbnail': 'https://serpapi.com/searches/67249df24a4a1d3f6d810b5d/images/59aeb2ad75caf7e124c7fcd9b04c6e44544fb102b2a39ffb3960a0cb311f4bf2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5970762968063354}","{'position': 4, 'link': 'https://www.cancernetwork.com/view/darolutamide-plus-adt-and-docetaxel-improves-quality-of-life-vs-placebo-in-mhspc', 'title': 'Darolutamide Plus ADT and Docetaxel Improves Quality of Life Vs Placebo in mHSPC', 'source': 'Cancer Network', 'date': 'Oct 31, 2022', 'snippet': 'Quality of life data from the phase 3 ARASENS study highlighted how early \ntreatment intensification with darolutamide plus standard androgen...', 'thumbnail': 'https://serpapi.com/searches/67249df24a4a1d3f6d810b5d/images/59aeb2ad75caf7e19338fb8e8c90dafa0f93bea49ef7f5dea7a5c3379e0778a0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5373491644859314}","{'position': 5, 'link': 'https://www.urologytimes.com/view/darolutamide-delays-time-to-progression-from-mhspc-to-mcrpc-vs-placebo', 'title': 'Darolutamide delays time to progression from mHSPC to mCRPC vs placebo', 'source': 'Urology Times', 'date': 'Jun 2, 2024', 'snippet': 'Treatment with darolutamide (Nubeqa) in combination with androgen \ndeprivation therapy (ADT) and docetaxel was found to increase overall \nsurvival and delay time...', 'thumbnail': 'https://serpapi.com/searches/67249df24a4a1d3f6d810b5d/images/59aeb2ad75caf7e1bbc2288fcc20157384dd3031c9f5b9cc169636547dba4078.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.748400866985321}",,,,,,"['neutral', 'neutral', 'positive', 'neutral', 'neutral']",neutral,1
NCT05265325,"{'position': 1, 'link': 'https://www.manilatimes.net/2024/10/29/tmt-newswire/pr-newswire/kind-presents-positive-results-of-and017-to-treat-anemia-associated-with-chronic-kidney-disease-in-two-phase-ii-and-two-phase-i/1992905', 'title': 'KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I', 'source': 'The Manila Times', 'date': '3 days ago', 'snippet': 'Clinical Trials at American Society of Nephrology (ASN) - Kidney Week 2024. \nSAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Kind Pharmaceutical...', 'thumbnail': 'https://serpapi.com/searches/67249a3e3c9575fb6f91065a/images/060aab4c37429123038bbc27d6a4eb05fcb6ca56cbe352f482fda7a6abf923d7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6056104302406311}",,,,,,,,,,['neutral'],neutral,1
NCT05472038,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMc2214916', 'title': 'Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine', 'source': 'The New England Journal of Medicine', 'date': 'Jan 25, 2023', 'snippet': 'Participants who had received three doses of BNT162b2 vaccine received \neither a fourth dose or a bivalent vaccine containing BA.4–BA.5 mRNA;...', 'thumbnail': 'https://serpapi.com/searches/67249bb8f7adbf728190c3a5/images/2c6990faf3ac8d02869f496bfd1a908d367c0fb2046e285c4f560a5a9ca1e129.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9136152863502502}",,,,,,,,,,['neutral'],neutral,1
NCT01611090,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-018-0276-9', 'title': 'Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma', 'source': 'Nature', 'date': 'Oct 12, 2018', 'snippet': 'We report follow-up results from the randomized, placebo-controlled, phase \n3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for...', 'thumbnail': 'https://serpapi.com/searches/67249bcac117a98c398f38c7/images/f5f5c42c5cccef84113a4d070ca0162dc426a03f128b7171b304792af1fd22ee.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9115937948226929}",,,,,,,,,,['neutral'],neutral,1
NCT04839367,"{'position': 1, 'link': 'https://www.prnewswire.com/news-releases/registrational-phase-iii-clarify-trial-in-prostate-cancer-commences-302001515.html', 'title': 'Registrational Phase III CLARIFY trial in prostate cancer commences', 'source': 'PR Newswire', 'date': 'Nov 30, 2023', 'snippet': 'PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) (""Clarity""), a clinical \nstage radiopharmaceutical company with a mission to develop...', 'thumbnail': 'https://serpapi.com/searches/67249bcb5bb6a21d83079b95/images/f1719084756c5ee6f21a5d0f8e5939a8e5aeb73e0a076561b2517850554570e5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8926337957382202}",,,,,,,,,,['neutral'],neutral,1
NCT01682083,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1708539', 'title': 'Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 10, 2017', 'snippet': 'Combination therapy with the BRAF inhibitor dabrafenib plus the MEK \ninhibitor trametinib improved survival in patients with advanced...', 'thumbnail': 'https://serpapi.com/searches/67249bd935853954fd9f3fbd/images/4c260aae3a0668cd9fc23ad78e45469bac8da04c696c562d9d3de17ffb1ac71a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7002543210983276}","{'position': 2, 'link': 'https://www.onclive.com/view/up-to-10-years-of-follow-up-uphold-survival-benefit-with-adjuvant-dabrafenib-trametinib-in-stage-iii-melanoma', 'title': 'Up to 10 Years of Follow-Up Uphold Survival Benefit With Adjuvant Dabrafenib/Trametinib in Stage III Melanoma', 'source': 'OncLive', 'date': 'May 31, 2024', 'snippet': 'The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) \ncontinued to showcase improved survival vs placebo when used as an adjuvant \ntreatment in...', 'thumbnail': 'https://serpapi.com/searches/67249bd935853954fd9f3fbd/images/4c260aae3a0668cd890d670e28d39b899d71cb397a21d6bb77735f6abcb20334.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6742091774940491}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01345019,"{'position': 1, 'link': 'https://myelomaresearchnews.com/xgeva-denosumab/', 'title': 'XGEVA (Denosumab)', 'source': 'Myeloma Research News', 'date': 'Feb 9, 2018', 'snippet': 'Xgeva (denosumab) was approved by the US Food and Drug Administration (FDA) \nto treat bone problems (skeletal-related events) in multiple myeloma (MM) \npatients.', 'thumbnail': 'https://serpapi.com/searches/67249be2e10f0a1c4155b9c2/images/411fce72dfd312d7e879564f2c62edf1d7a587e2d64875b2dc09c19ada39bb9a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7067121267318726}","{'position': 2, 'link': 'https://myelomaresearchnews.com/news/fda-approves-xgeva-to-treat-myeloma-patients-with-bone-lesions/', 'title': 'FDA Extends Xgeva Approval to Include Myeloma Patients with Bone Lesions', 'source': 'Myeloma Research News', 'date': 'Jan 8, 2018', 'snippet': ""The U.S. Food and Drug Administration (FDA) has agreed to extend Xgeva's \n(denosumab) approval to include patients with multiple myeloma who..."", 'thumbnail': 'https://serpapi.com/searches/67249be2e10f0a1c4155b9c2/images/411fce72dfd312d737f0849400b23a054f6239e72ea08e109674c9dadf95a629.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8024888038635254}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00262600,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0905561', 'title': 'Dabigatran versus Warfarin in Patients with Atrial Fibrillation', 'source': 'The New England Journal of Medicine', 'date': 'Aug 30, 2009', 'snippet': 'Dabigatran administered at a dose of 150 mg, as compared with warfarin, was \nassociated with lower rates of stroke and systemic embolism but similar \nrates of...', 'thumbnail': 'https://serpapi.com/searches/67249c9064f11d5673dda938/images/ba016c2223ab9a0aecd0a9e2f7b4c9e3ffd80940b086707ced70218ab5cc8efa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8747334480285645}",,,,,,,,,,['neutral'],neutral,1
NCT02207231,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1501646', 'title': 'A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis', 'source': 'The New England Journal of Medicine', 'date': 'Jul 9, 2015', 'snippet': 'Little is known about the effect of specific anti–interleukin-23 therapy, \nas compared with established anti–tumor necrosis factor therapies,...', 'thumbnail': 'https://serpapi.com/searches/67249c93e10f0a1c7374cb8d/images/0d38a4393f609d871372e816bfcbd2a5d7810dddd43e6611d088960c41a0cc14.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7835938930511475}","{'position': 2, 'link': 'https://psoriasisnewstoday.com/2017/05/25/janssens-phase-3-trials-on-guselkumab-for-plaque-psoriasis-and-psoriatic-arthritis/', 'title': 'Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis', 'source': 'Psoriasis News Today', 'date': 'May 25, 2017', 'snippet': 'Janssen announced two new Phase 3 clinical trials for psoriasis for its \ninvestigational drug guselkumab. The company intends to explore the...', 'thumbnail': 'https://serpapi.com/searches/67249c93e10f0a1c7374cb8d/images/0d38a4393f609d87a16edb53221fbeb7f625e56788d090228cd815c7cf91e15f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9209516644477844}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02519322,"{'position': 1, 'link': 'https://www.nature.com/articles/s41586-022-05368-8', 'title': 'Neoadjuvant relatlimab and nivolumab in resectable melanoma', 'source': 'Nature', 'date': '٢٦\u200f/١٠\u200f/٢٠٢٢', 'snippet': 'Relatlimab and nivolumab combination immunotherapy improves \nprogression-free survival over nivolumab monotherapy in patients with \nunresectable advanced...', 'thumbnail': 'https://serpapi.com/searches/67249c9eee677f09ee97d9c6/images/569fafb0bd32c3795b160742ad0465b5a8132881999a5df04e57ec148fe39e22.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7452478408813477}",,,,,,,,,,['neutral'],neutral,1
NCT01673009,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-020-0903-x', 'title': 'Translating current basic research into future therapies for neurofibromatosis type 1', 'source': 'Nature', 'date': 'May 22, 2020', 'snippet': 'Neurofibromatosis type 1 (NF1) is a hereditary tumour syndrome that \npredisposes to benign and malignant tumours originating from neural...', 'thumbnail': 'https://serpapi.com/searches/67249b4a163bdfc2e8bebf0f/images/ae327f0f085cefa4b548574a3f1c546e5d26ca7cdbd0e54cd77b6fb6744967b5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.803081214427948}",,,,,,,,,,['neutral'],neutral,1
NCT00871910,"{'position': 1, 'link': 'https://www.nature.com/articles/bjc2017288', 'title': 'Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies', 'source': 'Nature', 'date': 'Aug 31, 2017', 'snippet': 'Dinaciclib is a potent inhibitor of cell cycle and transcriptional \ncyclin-dependent kinases. This Phase 1 study evaluated the safety,...', 'thumbnail': 'https://serpapi.com/searches/67249a7698876d3da3da3360/images/ee2816685608698886f5b4e16b90064af11a2c3192a4915d8c119364ac21fe09.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8695429563522339}",,,,,,,,,,['neutral'],neutral,1
NCT00772538,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1208606', 'title': 'Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy', 'source': 'The New England Journal of Medicine', 'date': 'Sep 3, 2012', 'snippet': 'In two replicate, randomized, controlled trials involving 912 patients with \nasthma who were receiving inhaled glucocorticoids and LABAs,...', 'thumbnail': 'https://serpapi.com/searches/67249a7bd9c3e6ccf76a19c9/images/c1de719ce73f96cc17246e8a1aaa4f4a5421e287edd111c643783422334878d1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5179815888404846}",,,,,,,,,,['neutral'],neutral,1
NCT02576509,"{'position': 1, 'link': 'https://www.mayoclinicproceedings.org/article/S0025-6196(18)30002-8/fulltext', 'title': 'Multiple Cranial Neuropathies From Nivolumab in a Patient With Metastatic Hepatocellular Carcinoma', 'source': 'Mayo Clinic Proceedings', 'date': 'Apr 30, 2018', 'snippet': 'Nivolumab is a checkpoint inhibitor immunotherapy with multiple clinical \nindications. Based on encouraging activity from a phase 1/2 single-arm \nstudy,.', 'thumbnail': 'https://serpapi.com/searches/67249aa4ec54104fb652dbfa/images/ec651a09b604949821ebcaca1832a95597b3e2883f284235ba4468c0c36bcb94.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9014251828193665}",,,,,,,,,,['neutral'],neutral,1
NCT04871737,"{'position': 1, 'link': 'https://www.mountsinai.org/about/newsroom/2023/castlevax-inc-receives-barda-project-nextgen-award-valued-at-up-to-three-hundred-thirty-eight-million-to-advance-intranasal-ndvbased-covid-booster-vaccine-into-phase-twob-clinical-efficacy-testing', 'title': 'CastleVax Inc. Receives BARDA Project NextGen Award Valued at up to $338 Million to Advance Intranasal NDV-based COVID-19 Booster Vaccine into Phase 2b Clinical Efficacy Testing', 'source': 'Mount Sinai', 'date': 'Oct 17, 2023', 'snippet': 'CastleVax, a clinical stage vaccine platform company, has received a \nProject NexGen award valued at up to $338 million from the Biomedical...', 'thumbnail': 'https://serpapi.com/searches/67249adfe9b691b4208dc4bd/images/48842c8136046263d54ac00fb74280d547215837c9088244cc1bf206baa007c7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7130514979362488}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20240730713002/en/CastleVax-Inc.-Receives-34-Million-from-BARDA-to-Continue-Advancing-Intranasal-NDV-based-COVID-19-Vaccine-into-Phase-2b-Clinical-Efficacy-Testing', 'title': 'CastleVax Inc. Receives $34 Million from BARDA to Continue Advancing Intranasal NDV-based COVID-19 Vaccine into Phase 2b Clinical Efficacy Testing', 'source': 'Business Wire', 'date': 'Jul 30, 2024', 'snippet': 'CastleVax, a clinical stage mucosal vaccine platform company, has received \nan additional Project NextGen award valued at approximately $34...', 'thumbnail': 'https://serpapi.com/searches/67249adfe9b691b4208dc4bd/images/48842c813604626399fd67a2af9d857d165b68393819c0641cdd1c99ff84d869.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6780118346214294}","{'position': 3, 'link': 'https://www.mountsinai.org/about/newsroom/2022/mount-sinai-announces-the-formation-of-castlevax-inc-a-clinical-stage-infectious-diseases-company-developing-novel-vaccines-and-therapeutics-targeting-pandemic-threats-and-diseases-of-unmet-medical-need', 'title': 'Mount Sinai Announces the Formation of CastleVax Inc., a Clinical-Stage Infectious Diseases Company Developing Novel Vaccines and Therapeutics, Targeting Pandemic Threats and Diseases of Unmet Medical Need', 'source': 'Mount Sinai', 'date': 'Aug 9, 2022', 'snippet': 'The Mount Sinai Health System in New York, NY, has launched CastleVax, Inc. \n(CastleVax), a clinical-stage vaccine research and development company.', 'thumbnail': 'https://serpapi.com/searches/67249adfe9b691b4208dc4bd/images/48842c813604626325529b99be7fb0c8213e2f5120933693c74d3594492f2693.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8842910528182983}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT01296932,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-019-0475-z', 'title': 'Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia', 'source': 'Nature', 'date': 'May 14, 2019', 'snippet': 'Chronic lymphocytic leukemia (CLL) remains incurable for most patients, \nrequiring repeated therapy [1]. The tetraspanin CD37 is...', 'thumbnail': 'https://serpapi.com/searches/67249ae017b10ef85e9c1e3c/images/3769faf858e5b1a376f63fd13f623268f80e5f645df0e8ad562a833a18c8a667.png', 'sentiment': 'negative', 'sentiment_prob': 0.5485190749168396}",,,,,,,,,,['negative'],negative,0
NCT03165617,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2024848', 'title': 'Efficacy of a Cell-Culture–Derived Quadrivalent Influenza Vaccine in Children', 'source': 'The New England Journal of Medicine', 'date': 'Oct 13, 2021', 'snippet': 'Cell-culture–derived influenza vaccines may enable a closer antigenic match \nto circulating strains of influenza virus by avoiding...', 'thumbnail': 'https://serpapi.com/searches/67249ae2b4fe87984be9a68c/images/b48255bb5fd8ca8c42fd9d84fb90b3cb66212463894a4917794c56684eb1fb2c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8928518891334534}",,,,,,,,,,['neutral'],neutral,1
NCT04349072,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062534', 'title': 'Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks | Circulation', 'source': 'American Heart Association Journals', 'date': 'Nov 6, 2022', 'snippet': '32 weeks of mavacamten treatment showed sustained reduction in the \nproportion proceeding to SRT or remaining guideline eligible, with similar \neffects observed...', 'thumbnail': 'https://serpapi.com/searches/67249ae5a47167925e857d6f/images/68e5bf3613a37b4e771987d9a01bf7f155fdb4b8563b57b7924d891472bc462b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8345443606376648}",,,,,,,,,,['neutral'],neutral,1
NCT02277769,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1610020', 'title': 'Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis', 'source': 'The New England Journal of Medicine', 'date': 'Oct 1, 2016', 'snippet': 'In two randomized, placebo-controlled, phase 3 trials of identical design \n(SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe...', 'thumbnail': 'https://serpapi.com/searches/67249c0020e6eb1defbc3545/images/20bd83cfea45195768c31149a6b3613a7f8b0eaac63a09da889bdce3316b92e6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8945711851119995}","{'position': 2, 'link': 'https://www.dermatologytimes.com/view/when-to-progress-to-systemic-therapy', 'title': 'When to Progress to Systemic Therapy', 'source': 'Dermatology Times', 'date': 'Aug 11, 2022', 'snippet': 'This is an exciting time for offering safe and effective novel therapies to \npatients with moderate-to-severe AD who are inadequately controlled with \ntopical...', 'thumbnail': 'https://serpapi.com/searches/67249c0020e6eb1defbc3545/images/20bd83cfea451957eb4af8ae4ea76b542f7adbf08a9186e137cb832e4720ddf5.png', 'sentiment': 'positive', 'sentiment_prob': 0.7247567772865295}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04308681,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/ipf-lung-function-decline-may-slow-with-lpa1-antagonist-bms-986278/', 'title': 'IPF lung function decline may slow with LPA1 antagonist BMS-986278...', 'source': 'Pulmonary Fibrosis News', 'date': 'May 26, 2023', 'snippet': 'BMS-986278 did better than a placebo at slowing lung function decline for \nup to 26 weeks in people with idiopathic pulmonary fibrosis.', 'thumbnail': 'https://serpapi.com/searches/67249c0a9819f30f3cbfcfd4/images/48bc97cdf3cf4ffc08914448ef02f9ed4192cf804e6723d1925601970ebc1736.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6781575083732605}","{'position': 2, 'link': 'https://pulmonaryfibrosisnews.com/news/bms-986278-slows-lung-function-decline-progressive-pf-trial/', 'title': 'Oral BMS-986278 slows lung decline in progressive PF, Phase 2 trial finds', 'source': 'Pulmonary Fibrosis News', 'date': 'Sep 25, 2023', 'snippet': 'The experimental oral therapy BMS-986278, taken at 60 mg twice daily for 26 \nweeks, resulted in a 69% reduction in the rate of lung function decline in \nadults...', 'thumbnail': 'https://serpapi.com/searches/67249c0a9819f30f3cbfcfd4/images/48bc97cdf3cf4ffcf87584e47b16d363c8bf3ab199b81c941dd77311ad7544be.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8356699347496033}","{'position': 3, 'link': 'https://pulmonaryfibrosisnews.com/news/bms-986278-breakthrough-therapy-status-progressive-pf/', 'title': 'BMS-986278 earns breakthrough therapy status for progressive PF', 'source': 'Pulmonary Fibrosis News', 'date': 'Oct 27, 2023', 'snippet': ""The U.S. Food and Drug Administration has granted Bristol Myers Squibb's \ninvestigational therapy BMS-986278 breakthrough therapy status."", 'thumbnail': 'https://serpapi.com/searches/67249c0a9819f30f3cbfcfd4/images/48bc97cdf3cf4ffc24ad930768a120bdd93402ff379a93b5622fb5fbadca2736.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5977893471717834}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04776317,"{'position': 1, 'link': 'https://newsroom.uw.edu/news-releases/second-generation-covid-19-vaccine-clinical-trial-starts', 'title': 'Second-generation COVID-19 vaccine clinical trial starts', 'source': 'UW Medicine | Newsroom', 'date': 'Nov 28, 2023', 'snippet': 'Phase 1 clinical trial at UW Medicine will determine safety, tolerability, \nand immune response to Gritstone experimental vaccine candidate.', 'thumbnail': 'https://serpapi.com/searches/67249c22642c31cda3d5d0dc/images/6bce4b3cf480d129fa94138c543de7378842021a2ddc4e3c476adeb338152f20.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9083326458930969}","{'position': 2, 'link': 'https://www.nature.com/articles/s41591-022-01937-6', 'title': 'Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results', 'source': 'Nature', 'date': 'Aug 15, 2022', 'snippet': 'Checkpoint inhibitor (CPI) therapies provide limited benefit to patients \nwith tumors of low immune reactivity. T cell-inducing vaccines hold...', 'thumbnail': 'https://serpapi.com/searches/67249c22642c31cda3d5d0dc/images/6bce4b3cf480d129679f05a9c9837b1755867037f167f4b9c1ba7053ef95196a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.547188937664032}","{'position': 3, 'link': 'https://newsroom.uw.edu/news-releases/ongoing-booster-vaccine-trial-seeks-vaccinated-volunteers', 'title': 'Ongoing booster vaccine trial seeks vaccinated volunteers', 'source': 'UW Medicine | Newsroom', 'date': 'Nov 28, 2023', 'snippet': 'Researchers are still enrolling study participants who have not already \nreceived a vaccine booster against SARS-CoV-2.', 'thumbnail': 'https://serpapi.com/searches/67249c22642c31cda3d5d0dc/images/6bce4b3cf480d1295a9a91420f6773b553d47611d930d6480af753a3d973ec87.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8936087489128113}","{'position': 4, 'link': 'https://newsroom.uw.edu/news-releases/next-generation-covid-19-vaccine-trial-seeks-volunteers', 'title': '2nd-generation COVID-19 vaccine trial seeks volunteers', 'source': 'UW Medicine | Newsroom', 'date': 'Nov 28, 2023', 'snippet': 'This study is recruiting COVID-19-vaccinated and boosted persons interested \nin receiving additional investigational vaccination against SARS-CoV-2.', 'thumbnail': 'https://serpapi.com/searches/67249c22642c31cda3d5d0dc/images/6bce4b3cf480d129ce4b6cbde380a00c098b4ef1c78eba162eeb68dfe6200bff.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.861581027507782}",,,,,,,"['neutral', 'negative', 'neutral', 'neutral']",neutral,1
NCT01290939,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1707358', 'title': 'Lomustine and Bevacizumab in Progressive Glioblastoma', 'source': 'The New England Journal of Medicine', 'date': 'Nov 16, 2017', 'snippet': 'Treatment with lomustine plus bevacizumab did not confer a survival \nadvantage over treatment with lomustine alone in patients with progressive \nglioblastoma.', 'thumbnail': 'https://serpapi.com/searches/67249c4cd0d7e3608f18697e/images/533484bd3c643681dae573320faa13a2e4fbfd423a8357f6949b48247fff874d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.49823349714279175}",,,,,,,,,,['neutral'],neutral,1
NCT03187678,"{'position': 1, 'link': 'https://www.empr.com/home/news/uptravi-selexipag-injection-approved-for-pulmonary-arterial-hypertension/', 'title': 'FDA Approves IV Formulation of Uptravi for Pulmonary Arterial Hypertension', 'source': 'Medical Professionals Reference', 'date': 'Aug 2, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Uptravi® (selexipag) \ninjection for intravenous (IV) use for the treatment of pulmonary...', 'thumbnail': 'https://serpapi.com/searches/67249c6e7ef9fadce9afafdd/images/4e85d697be074fa08776e56250f8f749b5090abf051d53361fed8e64bc8d1ee0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8002889752388}",,,,,,,,,,['neutral'],neutral,1
NCT01492361,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1812792', 'title': 'Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia', 'source': 'The New England Journal of Medicine', 'date': 'Nov 12, 2018', 'snippet': 'We performed a multicenter, randomized, double-blind, placebo-controlled \ntrial involving patients with established cardiovascular disease or...', 'thumbnail': 'https://serpapi.com/searches/67249c70bcd65263817dbca4/images/b4ceba36cc923b07f58045d231a09c3b664102fc4740fd9b2fc8a1fb0f9d8d3a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8963292837142944}",,,,,,,,,,['neutral'],neutral,1
NCT03356821,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00117-X/abstract', 'title': 'Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study', 'source': 'The Lancet', 'date': 'Oct 3, 2022', 'snippet': 'Perinatal arterial ischaemic stroke (PAIS) is an important cause of \nneurodevelopmental disabilities. In this first-in-human study, we aimed to \nassess the...', 'thumbnail': 'https://serpapi.com/searches/67249c73b6ed334aaa207815/images/b511c27fce54e39b13208be1b6b4bbcd9b1140138a444b172833239a34eb7c5c.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8682438135147095}",,,,,,,,,,['neutral'],neutral,1
NCT03049488,"{'position': 1, 'link': 'https://www.pulmonologyadvisor.com/news/ds-cav1-vaccine-elicits-robust-boost-in-respiratory-syncytial-virus-f-specific-antibodies/', 'title': 'DS-Cav1 Vaccine Elicits Robust Boost in Respiratory Syncytial Virus F-Specific Antibodies', 'source': 'Pulmonology Advisor', 'date': 'May 11, 2021', 'snippet': 'Researchers conducted a phase 1 clinical trial to evaluate the efficacy and \nsafety of the pre-F subunit vaccine DS-Cav1 for respiratory...', 'thumbnail': 'https://serpapi.com/searches/67249ced0197dd9218f2538c/images/a9728498d4e5801300318ea392597ef92497a05fdb5764ba13b5dcc8646d240e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.881048858165741}",,,,,,,,,,['neutral'],neutral,1
NCT04029688,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-023-02057-x', 'title': 'Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia', 'source': 'Nature', 'date': 'Oct 14, 2023', 'snippet': 'T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic \nmalignancy in which activating mutations in the Notch pathway are...', 'thumbnail': 'https://serpapi.com/searches/67249cf9d403e1b040c49dc7/images/0e7f397502ba8c079e1b021e30fa92e864dda37d63a32b260a4f995cb9c7ca23.png', 'sentiment': 'negative', 'sentiment_prob': 0.7140205502510071}",,,,,,,,,,['negative'],negative,0
NCT02978326,"{'position': 1, 'link': 'https://www.empr.com/home/news/fda-approves-zurzuvae-an-oral-treatment-for-postpartum-depression/', 'title': 'FDA Approves Zurzuvae, an Oral Treatment for Postpartum Depression', 'source': 'Medical Professionals Reference', 'date': 'Aug 7, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Zurzuvae™ (zuranolone) \nfor the treatment of postpartum depression (PPD) in adults.', 'thumbnail': 'https://serpapi.com/searches/67249cfab2ebae2669c54b10/images/f1ff91119e50a5d62db8bd57ae8e419a1a9090fc9147b3af08d59c574758e0dd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7844175100326538}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/analyst-comment/zuranolone-postpartum-depression-misses-out-mdd-indication/', 'title': 'Zuranolone approved for postpartum depression but misses out on bigger MDD indication', 'source': 'Clinical Trials Arena', 'date': 'Aug 9, 2023', 'snippet': 'Although the approval for PPD is significant, the FDA rejected Zurzuvae for \nthe treatment of major depressive disorder.', 'thumbnail': 'https://serpapi.com/searches/67249cfab2ebae2669c54b10/images/f1ff91119e50a5d6bcf5674ab44f2b4077290b1672df84a4e361468fa30d46f2.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.511762261390686}","{'position': 3, 'link': 'https://www.empr.com/home/news/oral-postpartum-depression-treatment-zurzuvae-now-available/', 'title': 'Oral Postpartum Depression Treatment Zurzuvae Now Available', 'source': 'Medical Professionals Reference', 'date': 'Dec 14, 2023', 'snippet': 'Zurzuvae (zuranolone) is now available for the treatment of postpartum \ndepression (PPD) in adults. Zuranolone is a neuroactive steroid \ngamma-aminobutyric acid...', 'thumbnail': 'https://serpapi.com/searches/67249cfab2ebae2669c54b10/images/f1ff91119e50a5d681bad23fc47ab52e322009d802c73c2ad95b1673bc934acd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.879035234451294}",,,,,,,,"['neutral', 'negative', 'neutral']",neutral,1
NCT02240407,"{'position': 1, 'link': 'https://pompediseasenews.com/raav9-des-hgaa/', 'title': 'rAAV9-DES-hGAA for Pompe disease', 'source': 'Pompe Disease News', 'date': 'Jun 26, 2023', 'snippet': 'An experimental gene therapy, meaning it replaces a faulty gene with a \nhealthy one, rAAV9-DES-hGAA has been tested in clinical trials as a \ntreatment for Pompe...', 'thumbnail': 'https://serpapi.com/searches/67249d0a2e33c879f5aecdbc/images/5cb6795d72bb3df0b48e2ead3e0c259ce4e24d2512f275b48ff5cde404d879e3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7026476860046387}",,,,,,,,,,['neutral'],neutral,1
NCT03174184,"{'position': 1, 'link': 'https://www.infectiousdiseaseadvisor.com/news/meropenem-plus-clavulanate-and-rifampin-treatment-drug-resistant-tuberculosis-tb/', 'title': 'Meropenem Plus Clavulanate and Rifampin for Treatment of Drug-Resistant TB', 'source': 'Infectious Disease Advisor', 'date': 'Mar 29, 2022', 'snippet': 'A clinical trial found that intravenous meropenem plus \namoxicillin/clavulanate, while effective at certain doses, is poorly \ntolerated by...', 'thumbnail': 'https://serpapi.com/searches/67249d1d8d041735fe1ce5c2/images/169be0b84645f1e9bb85644e029aaf1a500f3f6c07498181d34943d68172dfc1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.563075840473175}",,,,,,,,,,['neutral'],neutral,1
NCT00537147,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMp2301816', 'title': 'Combating West Nile Virus Disease — Time to Revisit Vaccination', 'source': 'The New England Journal of Medicine', 'date': 'Apr 29, 2023', 'snippet': 'WNV remains a public health threat in many areas of the world, and current \napproaches to primary prevention have limitations.', 'thumbnail': 'https://serpapi.com/searches/67249d3771c62bd52d0da5aa/images/91397909a0b339a4e6b463fe6bcefb3c80e675c60ca1590c3aec4965c4329de9.png', 'sentiment': 'negative', 'sentiment_prob': 0.7227003574371338}",,,,,,,,,,['negative'],negative,0
NCT00094302,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.12660', 'title': 'Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes', 'source': 'Wiley Online Library', 'date': 'Mar 11, 2020', 'snippet': 'Aims The aim of this study is to use six previously described heart failure \nwith preserved ejection fraction (HFpEF) phenotypes to describe...', 'thumbnail': 'https://serpapi.com/searches/67249d6a1f3d4bc29b7b350e/images/3b6cdcacf2d9e2237c4d540e36619aa472da15f654f2e8b2f9dd9de7c0e85970.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9017375111579895}",,,,,,,,,,['neutral'],neutral,1
NCT03928704,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2024/09/30/bimekizumab-bimzelx-wins-fda-approval-of-active-as-nr-axspa/', 'title': 'FDA approves bimekizumab, now Bimzelx, for active AS and nr-axSpA', 'source': 'Ankylosing Spondylitis News', 'date': '1 month ago', 'snippet': ""Data from two Phase 3 clinical trials, BE MOBILE 1 and BE MOBILE 2, \nsupported Bimzelx's approvals for active nr-axSpA and AS."", 'thumbnail': 'https://serpapi.com/searches/67249e83cf32e043b585fadc/images/760bd9b439a4c11830f5a026026930f38cfa4a1b22ee4e8bd9024531235a1d17.png', 'sentiment': 'neutral', 'sentiment_prob': 0.694316565990448}",,,,,,,,,,['neutral'],neutral,1
NCT01494506,"{'position': 1, 'link': 'https://www.researchgate.net/figure/NAPOLI-1-and-exploratory-post-hoc-analysis-patient-disposition-flow-diagram_fig1_347280190', 'title': 'NAPOLI-1 and exploratory post hoc analysis: patient disposition flow diagram.', 'source': 'ResearchGate', 'date': 'Mar 5, 2021', 'snippet': 'Background Chemotherapy dose modification to manage adverse events is \ncommonplace in clinical practice. This exploratory analysis evaluates the \nimpact of...', 'thumbnail': 'https://serpapi.com/searches/67249faa2a4882ac457455f0/images/520bc3e7afa7ec9483829c967f3133e9f312c3b21ca032d910443413606ac152.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9004329442977905}",,,,,,,,,,['neutral'],neutral,1
NCT02999178,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1908681', 'title': 'Nintedanib in Progressive Fibrosing Interstitial Lung Diseases', 'source': 'The New England Journal of Medicine', 'date': 'Sep 29, 2019', 'snippet': 'Preclinical data have suggested that nintedanib, an intracellular inhibitor \nof tyrosine kinases, inhibits processes involved in the progression of \nlung...', 'thumbnail': 'https://serpapi.com/searches/67249fc5f79a01079bee74f2/images/c5d2fd340c973e500f5c6c1d244347c287e2abc9eec468f4ccb318880bd95ba9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8144998550415039}","{'position': 2, 'link': 'https://lungdiseasenews.com/2017/03/28/phase-3-study-of-ofev-in-progressive-fibrosing-lung-diseases-enrolling-patients/', 'title': ""Ofev's Efficacy to Be Tested in Progressive Fibrosing Lung Disease Patients in Phase 3 Study"", 'source': 'Lung Disease News', 'date': 'Mar 28, 2017', 'snippet': ""The first patient has been enrolled in Boehringer Ingelheim's Phase 3 \nclinical trial investigating the effectiveness and safety of Ofev..."", 'thumbnail': 'https://serpapi.com/searches/67249fc5f79a01079bee74f2/images/c5d2fd340c973e50aeeeecd0e09331768ddef7e0ee406c2308cdf6f33e3c6ccc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.878416895866394}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03164603,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-019-0664-6', 'title': 'The therapeutic potential of targeting tryptophan catabolism in cancer', 'source': 'Nature', 'date': 'Dec 10, 2019', 'snippet': 'Based on its effects on both tumour cell intrinsic malignant properties as \nwell as anti-tumour immune responses, tryptophan catabolism has...', 'thumbnail': 'https://serpapi.com/searches/67249ed09936886f64d2e40d/images/61aa2d0b192a62bcec626ae557cf0a217d08d05b3e715d702fccea83ff787f56.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7628021240234375}",,,,,,,,,,['neutral'],neutral,1
NCT03093324,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2021/04/13/vumerity-better-quality-of-life-than-tecfidera-for-patients-evolve-ms-2-study/', 'title': 'Vumerity Linked to Better Quality of Life Than Tecfidera in RRMS Trial', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 13, 2021', 'snippet': 'Vumerity (diroximel fumarate) is easier on the gastrointestinal tract than \nTecfidera (dimethyl fumarate), and this translates into better quality of \nlife for...', 'thumbnail': 'https://serpapi.com/searches/67249f39b4fe87984be9a844/images/6a93be02ed229c6e3cf75212311ae406595f87aceb2b4c3c016b07a2b6f26bbb.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6973385810852051}",,,,,,,,,,['positive'],positive,1
NCT04889209,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2116414', 'title': 'Homologous and Heterologous Covid-19 Booster Vaccinations', 'source': 'The New England Journal of Medicine', 'date': 'Jan 26, 2022', 'snippet': 'Although the three vaccines against coronavirus disease 2019 (Covid-19) \nthat have received emergency use authorization in the United States...', 'thumbnail': 'https://serpapi.com/searches/67249f3ca505f7b93bf4348a/images/c610d6262f148407fc6e70c33c76f59f34f6433e9357fd50c6771c68e42f1623.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8153026103973389}",,,,,,,,,,['neutral'],neutral,1
NCT04533022,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/vicore-nippon-reach-285m-deal-ipf-treatment-c21-rights-japan/', 'title': 'Nippon awarded exclusive rights in Japan to IPF treatment C21', 'source': 'Pulmonary Fibrosis News', 'date': 'Feb 23, 2024', 'snippet': 'In a deal that could be worth up to $285 million, Vicore Pharma granted \nNippon Shinyaku exclusive rights in Japan to its IPF treatment C21.', 'thumbnail': 'https://serpapi.com/searches/67249f44bd7cf05235f5ad98/images/6a49a15327b76f9d4462756a430d3eda59ef6ea1bb66bcc72f364b12eddf7400.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8054866194725037}",,,,,,,,,,['neutral'],neutral,1
NCT05924243,"{'position': 1, 'link': 'https://www.apdaparkinson.org/article/new-parkinsons-treatment-in-clinical-trials-2023/', 'title': 'New Parkinson’s Treatments in the Clinical Trial Pipeline for 2024', 'source': 'American Parkinson Disease Association', 'date': 'Sep 26, 2023', 'snippet': ""Extensive research is underway to develop new medications for Parkinson's \ndisease (PD), with several promising candidates at different..."", 'thumbnail': 'https://serpapi.com/searches/67249f4924296ac7f50bb3db/images/1160d4fefd9761b0bbb196420af1fc5ec796ff5a78f6ebbf3cb9e6c73fed6168.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5578852891921997}",,,,,,,,,,['positive'],positive,1
NCT02726581,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/safety-concerns-prompt-fda-to-put-a-hold-on-opdivo-combination-trials-for-myeloma/', 'title': '3 Myeloma Trials of Opdivo Put on Hold Due to Safety Concerns Over Other Therapies', 'source': 'Myeloma Research News', 'date': 'Sep 8, 2017', 'snippet': 'The US Food and Drug Administration has ordered Bristol-Myers Squibb to put \na hold on three clinical trials evaluating Opdivo (nivolumab) in \ncombination with...', 'thumbnail': 'https://serpapi.com/searches/6724a1e7bbc18b33ac2dc1b8/images/d605b0a71ba3e2ace2d67f53236bcc5ba5a400af4d26b88cc41e592734959589.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7855069041252136}",,,,,,,,,,['neutral'],neutral,1
NCT04968574,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20240501177434/en/Endeavor-BioMedicines-to-Present-New-Data-From-Phase-2a-Clinical-Trial-of-ENV-101-at-American-Thoracic-Society-2024-International-Conference', 'title': 'Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference', 'source': 'Business Wire', 'date': 'May 1, 2024', 'snippet': ""Data from a completed Phase 2a clinical trial evaluating the company's lead \ninvestigational candidate ENV-101 in patients with idiopathic pulmonary \nfibrosis (..."", 'thumbnail': 'https://serpapi.com/searches/6724a1eb68831e63a4ce34e2/images/c6f52aa8cd5f79f056adf19dcc17169042894d73892dfb23153e5d3b1ef0481a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.886804461479187}","{'position': 2, 'link': 'https://pulmonaryfibrosisnews.com/news/lung-function-gains-scarring-descreases-seen-study-ipf-therapy-env-101/', 'title': 'Lung function gains, scarring decreases seen in study of IPF therapy ENV-101', 'source': 'Pulmonary Fibrosis News', 'date': 'Jun 7, 2024', 'snippet': 'ENV-101 improved lung function and reversed key signs of lung scarring in \npatients with IPF, according to data from a Phase 2a trial.', 'thumbnail': 'https://serpapi.com/searches/6724a1eb68831e63a4ce34e2/images/c6f52aa8cd5f79f0e82c386fb2b92507df3baa2b2a53eaef59ea3d12e6c90de2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5345757007598877}","{'position': 3, 'link': 'https://pulmonaryfibrosisnews.com/news/endeavor-completes-phase-2a-trial-env-101-ipf/', 'title': 'Endeavor completes its Phase 2a trial of ENV-101 for IPF', 'source': 'Pulmonary Fibrosis News', 'date': 'Feb 9, 2024', 'snippet': 'A Phase 2a clinical trial has finished testing the experimental therapy \nENV-101 (taladegib) in people with idiopathic pulmonary fibrosis (IPF).', 'thumbnail': 'https://serpapi.com/searches/6724a1eb68831e63a4ce34e2/images/c6f52aa8cd5f79f0d009a07acf7ca93673a3efc255d847e7c20c4bfbee4807b4.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8571926355361938}","{'position': 4, 'link': 'https://www.businesswire.com/news/home/20240424918145/en/Endeavor-BioMedicines-Raises-132.5-Million-Oversubscribed-Series-C-Financing-to-Advance-Pipeline-of-Transformational-Medicines', 'title': 'Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines', 'source': 'Business Wire', 'date': 'Apr 24, 2024', 'snippet': 'Endeavor BioMedicines, Inc. (“Endeavor”), a clinical-stage biotechnology \ncompany developing medicines with the potential to deliver...', 'thumbnail': 'https://serpapi.com/searches/6724a1eb68831e63a4ce34e2/images/c6f52aa8cd5f79f03cf0cc13fcc2f55fd4b46bad0d346efc4ba7413fb0e43ce0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5715474486351013}","{'position': 5, 'link': 'https://pulmonaryfibrosisnews.com/news/endeavor-completes-enrollment-in-phase-2-trial-testing-env-101/', 'title': 'Endeavor completes enrollment in Phase 2 trial testing ENV-101 –...', 'source': 'Pulmonary Fibrosis News', 'date': 'Sep 18, 2023', 'snippet': ""A Phase 2a clinical trial to evaluate the safety and efficacy of ENV-101 \n(taladegib), Endeavor's oral IPF treatment, has completed..."", 'thumbnail': 'https://serpapi.com/searches/6724a1eb68831e63a4ce34e2/images/c6f52aa8cd5f79f0fee834bfdf8b7e7654af38afbcd9f9068cfb00d51dfa9222.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7374044060707092}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT05070260,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20240424916910/en/ACTICOR-BIOTECH-Topline-Results-of-ACTISAVE-Phase-23-Study-in-Stroke-Treatment', 'title': 'ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment', 'source': 'Business Wire', 'date': 'Apr 25, 2024', 'snippet': 'Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a \nclinical-stage biotechnology company focused on the development of...', 'thumbnail': 'https://serpapi.com/searches/6724a226667ec51233a77fa5/images/ba376a8476d21c5910d565ca9e34c8b476e044854f98e8d465be94444c45ba9f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8772943615913391}",,,,,,,,,,['neutral'],neutral,1
NCT04327206,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2212616', 'title': 'Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers', 'source': 'The New England Journal of Medicine', 'date': 'Apr 26, 2023', 'snippet': 'In this international, double-blind, placebo-controlled trial, we randomly \nassigned health care workers to receive the BCG-Denmark vaccine or saline \nplacebo...', 'thumbnail': 'https://serpapi.com/searches/6724a4cdd0253e868c22814f/images/b304aa4252857c0388760f4fff3bc8c97ef1f407cae4ba9442e1f21f4a2a6ae9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8976653218269348}",,,,,,,,,,['neutral'],neutral,1
NCT02675465,"{'position': 1, 'link': 'https://fabrydiseasenews.com/news/amicus/', 'title': 'Amicus CEO John Crowley Outlines Progress in Fabry, Pompe, Batten Therapies', 'source': 'Fabry Disease News', 'date': 'Aug 21, 2019', 'snippet': 'Pharmaceutical executives rarely make for a sympathetic Hollywood medical \ndrama. But John Crowley did, and in the nearly 10 years since the...', 'thumbnail': 'https://serpapi.com/searches/6724a4d11fc7c5650202ec2a/images/f334c0a68a7d4b5cc7187cd5c992329dd48c33e72ea8e0df8b4918e115301478.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7708026766777039}",,,,,,,,,,['neutral'],neutral,1
NCT05238675,"{'position': 1, 'link': 'https://www.boehringer-ingelheim.com/human-health/lung-diseases/phase-ii-trials-patients-bronchiectasis', 'title': 'Phase II trials for patients with bronchiectasis', 'source': 'Boehringer Ingelheim', 'date': 'Jun 29, 2023', 'snippet': 'Bronchiectasis is a chronically progressive pulmonary disease. Boehringer \nIngelheim investigates a potential new treatment option in two Phase II \ntrials.', 'thumbnail': 'https://serpapi.com/searches/6724a4ddd771bd3d1c3e418a/images/300f8dc0be018d50bb9f9e50bed054d497961f6007e0fc36307761b25b51283c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9052193760871887}",,,,,,,,,,['neutral'],neutral,1
NCT03677648,"{'position': 1, 'link': 'https://ibdnewstoday.com/2019/06/24/first-uc-and-cd-patients-dosed-in-phase-2-trials-of-shr0302/', 'title': 'First IBD Patients Dosed in 2 Phase 2 Trials of JAK1 inhibitor SHR0302', 'source': 'ibdnewstoday.com', 'date': '٢٤\u200f/٠٦\u200f/٢٠١٩', 'snippet': ""The first patients have been dosed in two Phase 2 trials assessing the \neffects of SHR0302, Reistone's JAK1 inhibitor for inflammatory bowel..."", 'thumbnail': 'https://serpapi.com/searches/6724a0b6ba114246327adc7e/images/94c331ba906c3113d9e9d26e65d6417a01e69fef635881bd08a229fb38b158e5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9314698576927185}",,,,,,,,,,['neutral'],neutral,1
NCT02588677,"{'position': 1, 'link': 'https://alsnewstoday.com/news/als-therapy-masitinib-works-best-add-on-moderate-disease-analysis/', 'title': 'ALS therapy masitinib works best as add-on in moderate disease: Analysis', 'source': 'ALS News Today', 'date': 'May 8, 2023', 'snippet': 'Masitinib, an oral add-on therapy with Rilutek, was most effective in ALS \npatients with mild or moderate disease severity before treatment.', 'thumbnail': 'https://serpapi.com/searches/6724a1653166502b29ad1b49/images/d4b75feb199eb29c6cc78f7e396031dc01b5b2d176404c9c5994d25e6254b654.png', 'sentiment': 'positive', 'sentiment_prob': 0.6862592101097107}","{'position': 2, 'link': 'https://www.als.org/blog/ab-science-publishes-positive-phase-23-clinical-trial-masitinib-als', 'title': 'AB Science Publishes the Positive Phase 2/3 Clinical Trial of Masitinib in ALS', 'source': 'The ALS Association', 'date': 'Aug 14, 2019', 'snippet': 'AB Science has completed a Phase 2/3 human clinical trial of masitinib in \nALS with promising results. The company published the results of...', 'thumbnail': 'https://serpapi.com/searches/6724a1653166502b29ad1b49/images/d4b75feb199eb29c8b0386dbf4a45efd4f6539bea0295d6464bf7cf0d1d70359.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7698723077774048}","{'position': 3, 'link': 'https://alsnewstoday.com/news/als-oral-therapy-masitinib-rejected-health-canada/', 'title': 'ALS oral therapy masitinib rejected by Health Canada', 'source': 'ALS News Today', 'date': 'Feb 27, 2024', 'snippet': 'AB Science has indicated it will ask Health Canada to reconsider its \ndecision not to approve masitinib as an add-on treatment for ALS.', 'thumbnail': 'https://serpapi.com/searches/6724a1653166502b29ad1b49/images/d4b75feb199eb29c878d33055b8e1c8c9f8eca4717692845e03ef952b3e2ee19.png', 'sentiment': 'negative', 'sentiment_prob': 0.5877373814582825}","{'position': 4, 'link': 'https://alsnewstoday.com/news/europe-chmp-recommends-against-masitinib-authorization/', 'title': 'Europe’s CHMP recommends against masitinib authorization', 'source': 'ALS News Today', 'date': 'Jul 2, 2024', 'snippet': 'An advisory committee of the European Medicines Agency (EMA) has \nrecommended against granting conditional marketing authorization to \nmasitinib as an oral add-...', 'thumbnail': 'https://serpapi.com/searches/6724a1653166502b29ad1b49/images/d4b75feb199eb29ccf8d0e61a3fb049a55e18e85547944c0afb036572bc8cb66.png', 'sentiment': 'neutral', 'sentiment_prob': 0.71881103515625}","{'position': 5, 'link': 'https://alsnewstoday.com/news/negative-opinion-masitinib-als-upheld-emas-chmp/', 'title': 'EMA’s CHMP upholds its negative opinion on masitinib for ALS', 'source': 'ALS News Today', 'date': '1 week ago', 'snippet': 'An advisory committee from the European Medicines Agency (EMA) has upheld \nits opinion against granting conditional marketing authorization...', 'thumbnail': 'https://serpapi.com/searches/6724a1653166502b29ad1b49/images/d4b75feb199eb29c80cf4fb009292833f4fbee93d57a58449979ba78f7238b23.png', 'sentiment': 'negative', 'sentiment_prob': 0.49745383858680725}","{'position': 6, 'link': 'https://alsnewstoday.com/news/als-therapy-masitinib-gains-orphan-drug-status-switzerland/', 'title': 'Masitinib Gains Orphan Drug Status for ALS in Switzerland', 'source': 'ALS News Today', 'date': 'Jan 6, 2023', 'snippet': ""Masitinib, an oral medicine that's being developed by AB Science, has \nalready been given orphan drug status in the U.S. and European Union."", 'thumbnail': 'https://serpapi.com/searches/6724a1653166502b29ad1b49/images/d4b75feb199eb29cad5cbda110cca4b4442ea5d6f509d5498e55821f59bf870e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8879489898681641}","{'position': 7, 'link': 'https://alsnewstoday.com/news/early-2024-likely-masitinib-eu-conditional-approval-decision-als/', 'title': 'Early 2024 eyed for approval decision in EU on masitinib for ALS |...', 'source': 'ALS News Today', 'date': 'Sep 22, 2023', 'snippet': 'The European Medicines Agency (EMA) is now expected to issue a decision in \nthe first months of 2024 on the conditional approval of masitinib as an \nadd-on oral...', 'thumbnail': 'https://serpapi.com/searches/6724a1653166502b29ad1b49/images/d4b75feb199eb29c76965e5d7bd936675a6f9090b63465be63eefef5df965d2c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9149961471557617}","{'position': 8, 'link': 'https://alsnewstoday.com/news/ab-science-expects-negative-opinion-application-als-therapy-masitinib/', 'title': 'AB Science expects negative opinion on masitinib application in Europe', 'source': 'ALS News Today', 'date': 'Jun 7, 2024', 'snippet': ""An advisory committee of the European Medicines Agency (EMA) is leaning \nagainst recommending the conditional approval of AB Science's masitinib as \nan oral add-..."", 'thumbnail': 'https://serpapi.com/searches/6724a1653166502b29ad1b49/images/d4b75feb199eb29c4ffe01aea86411de21d1e837f2e5144fe9d451c590715dad.png', 'sentiment': 'negative', 'sentiment_prob': 0.5135619044303894}","{'position': 9, 'link': 'https://alsnewstoday.com/news/chmp-delays-opinion-conditional-eu-approval-masitinib-als/', 'title': 'CHMP delays ruling on conditional EU approval of masitinib for ALS', 'source': 'ALS News Today', 'date': 'Jan 31, 2024', 'snippet': ""The European Medicines Agency committee's request for written answers to \nissues with the add-on ALS therapy could push an opinion to June."", 'thumbnail': 'https://serpapi.com/searches/6724a1653166502b29ad1b49/images/d4b75feb199eb29cc0464117f2c7615f941273a1532fb6803553f6c456062af8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7775599360466003}","{'position': 10, 'link': 'https://alsnewstoday.com/news/ema-given-responses-masitinib-conditional-approval-review/', 'title': 'EMA receives response for ongoing review of masitinib in treating...', 'source': 'ALS News Today', 'date': 'Apr 10, 2023', 'snippet': ""AB Science filed answers for European Union regulators considering \nmasitinab's conditional approval; response to Health Canada to follow."", 'thumbnail': 'https://serpapi.com/searches/6724a1653166502b29ad1b49/images/d4b75feb199eb29cc01776b3df3ab78d4341c99312701275850b750253e17b5a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9234899878501892}","['positive', 'positive', 'negative', 'neutral', 'negative', 'neutral', 'neutral', 'negative', 'neutral', 'neutral']",neutral,1
NCT02845297,"{'position': 1, 'link': 'https://www.jci.org/articles/view/159579/figure/9', 'title': 'Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia', 'source': 'JCI - Welcome', 'date': 'Sep 13, 2022', 'snippet': '( A ) Differentially expressed genes (DEGs) at baseline associated with \ncomplete response (CResp) to AZA+Pembro ( n = 33 patients).', 'thumbnail': 'https://serpapi.com/searches/6724a16b39e232bf613928f9/images/989ab7dd2a9379d919d7d34edb04b3faece7cd45bfd1300fd7c038c34fb248cb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7969392538070679}",,,,,,,,,,['neutral'],neutral,1
NCT02683083,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/62/8/1097', 'title': 'Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients', 'source': 'Journal of Nuclear Medicine', 'date': 'Aug 1, 2021', 'snippet': ""Matthias D'Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, \nJohannes Heemskerk, Francois P. Duhoux, Christel Fontaine,..."", 'thumbnail': 'https://serpapi.com/searches/6724a1757ef9fadd305ba8ab/images/e0299002a00011aad171e65d4ea3b94db4ba18caa7bd0f01da9e846d34cbefac.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7966375946998596}",,,,,,,,,,['neutral'],neutral,1
NCT02465567,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1916046', 'title': 'Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD', 'source': 'The New England Journal of Medicine', 'date': 'Jul 2, 2020', 'snippet': 'Triple therapy with twice-daily budesonide (at either the 160-μg or 320-μg \ndose), glycopyrrolate, and formoterol resulted in a lower rate of moderate \nor severe...', 'thumbnail': 'https://serpapi.com/searches/6724a1930be2f6145cb5d9aa/images/1469b645bcac6859fff50ffe4599027ba377d0a60237feccdc206dc7fcb1e75f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8277775049209595}","{'position': 2, 'link': 'https://copdnewstoday.com/news/copd-trial-breztri-aerosphere-cardiopulmonary-risk-opens/', 'title': 'Phase 3 trial of Breztri in easing cardiopulmonary problems opens', 'source': 'COPD News Today', 'date': 'Mar 18, 2024', 'snippet': 'A Phase 3 clinical trial assessing the potential of triple-combination \nBreztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) to...', 'thumbnail': 'https://serpapi.com/searches/6724a1930be2f6145cb5d9aa/images/1469b645bcac685933ce72a49b80ec4e3253b5e159e9213b45d66fc568a753e6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.820160984992981}","{'position': 3, 'link': 'https://copdnewstoday.com/news/copd-maintenance-treatment-breztri-aerosphere-approved-by-fda/', 'title': 'COPD Maintenance Treatment Breztri Aerosphere Approved by FDA', 'source': 'COPD News Today', 'date': 'Jul 28, 2020', 'snippet': ""AstraZeneca's Breztri Aerosphere has been approved by the U.S. Food and \nDrug Administration as a maintenance treatment for COPD."", 'thumbnail': 'https://serpapi.com/searches/6724a1930be2f6145cb5d9aa/images/1469b645bcac6859a88eeae9aafb6c33689e151d0044b0393d896ef6e607386b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6785445213317871}","{'position': 4, 'link': 'https://copdnewstoday.com/news/fda-warns-astrazeneca-false-misleading-claims-breztri/', 'title': 'FDA warns AstraZeneca about false or misleading claims for Breztri...', 'source': 'COPD News Today', 'date': 'Aug 21, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has issued a warning letter to \nAstraZeneca for making false or misleading claims about Breztri Aerosphere.', 'thumbnail': 'https://serpapi.com/searches/6724a1930be2f6145cb5d9aa/images/1469b645bcac685935c8d42507fa8d278aeb8858bba4539ad8df3c9a5e32cbd3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5239120721817017}","{'position': 5, 'link': 'https://copdnewstoday.com/news/european-chmp-gives-positive-opinion-to-copd-therapy-trixeo-aerosphere/', 'title': 'European CHMP Gives Positive Opinion to COPD Therapy Trixeo Aerosphere', 'source': 'COPD News Today', 'date': 'Oct 20, 2020', 'snippet': 'Trixeo Aerosphere has demonstrated strong clinical benefit when compared \nwith dual-combination therapies and this positive recommendation brings us \ncloser to...', 'thumbnail': 'https://serpapi.com/searches/6724a1930be2f6145cb5d9aa/images/1469b645bcac685912e528634445c07c18982bb3d28ee4ed1835b722122f42ea.png', 'sentiment': 'positive', 'sentiment_prob': 0.8232856392860413}",,,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT02133105,"{'position': 1, 'link': 'https://pulmonaryhypertensionnews.com/news/levosimendan-aids-kidney-function-in-ph-patients-with-heart-disease-and-renal-impairment-phase-3-data-show/', 'title': 'Levosimendan Aids Kidneys in PH Patients with Heart Disease and Renal Impairment, Phase 3 Data Show', 'source': 'Pulmonary Hypertension News', 'date': 'Aug 31, 2018', 'snippet': 'Levosimendan, soon starting a Phase 2 study for PH-HFpEF patients, was seen \nto benefit the kidneys in those with cardiorenal syndrome in a...', 'thumbnail': 'https://serpapi.com/searches/6724a1a7bb55ffb4294ac0d0/images/06aac8cfbfc2426f45b76cbf4b3301add24151216cb79535a938d9a32f11c4fe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8887532949447632}",,,,,,,,,,['neutral'],neutral,1
NCT03657160,"{'position': 1, 'link': 'https://www.nature.com/articles/s41409-021-01356-0', 'title': 'A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease', 'source': 'Nature', 'date': 'Jun 9, 2021', 'snippet': 'Steroid-refractory (SR) acute graft-versus-host disease (aGvHD) remains a \nsignificant complication after allogeneic hematopoietic cell...', 'thumbnail': 'https://serpapi.com/searches/6724a1a90d379fad1989017f/images/3fa017ca5cb088ddf80726e6939c5f001623d02876bac2900ce84d7439fba546.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7030962705612183}",,,,,,,,,,['neutral'],neutral,1
NCT02333370,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/cas.14554', 'title': 'Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer', 'source': 'Wiley Online Library', 'date': 'Jul 3, 2020', 'snippet': 'Results from the ongoing study support the use of ribociclib in combination \nwith letrozole in Asian non-Japanese patients at the same dose (600 mg) as \nWhite...', 'thumbnail': 'https://serpapi.com/searches/67249ff30e6db3bdd1510d8f/images/391dfb7b62e87cee5580b6ed910f0a6b26192c3616834f717c5a4bb19c6def6e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9139898419380188}",,,,,,,,,,['neutral'],neutral,1
NCT00154102,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0805019', 'title': 'Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Apr 30, 2018', 'snippet': 'We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, \nand leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal \ncancer...', 'thumbnail': 'https://serpapi.com/searches/67249ff7460b15e9a128f798/images/2b700889641059bad7bae6cc9e5c50b2a5912f5bb3d1f55f278f9a2fdf76ab05.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8561810255050659}",,,,,,,,,,['neutral'],neutral,1
NCT02616640,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/fda-halts-imfinzi-combination-trials-after-unexplained-keytruda-related-deaths/', 'title': 'FDA Halts Imfinzi Combination Trials After Unexplained Keytruda-related Deaths', 'source': 'Myeloma Research News', 'date': 'Sep 8, 2017', 'snippet': ""The U.S. Food and Drug Administration (FDA) suspended a Phase 1 clinical \ntrial testing a combination of AstraZeneca's Imfinzi (durvalumab)..."", 'thumbnail': 'https://serpapi.com/searches/6724a026a251042cef1b7313/images/058ec633e3e0e3b97b7772dfeca2f1493646703e70271d668fdee79851635660.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5682772994041443}",,,,,,,,,,['negative'],negative,0
NCT00060905,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/placebo-controlled-study-divalproexmania/', 'title': 'A Randomized, Placebo-Controlled, Multicenter Study of Divalproex Sodium Extended Release in the Treatment of Acute Mania', 'source': 'Psychiatrist.com', 'date': 'Oct 20, 2023', 'snippet': 'Charles L. Bowden, MD; Alan C. Swann, MD; Joseph R. Calabrese, MD; Leon M. \nRubenfaer, MD; Patricia J. Wozniak, PhD; Michelle A. Collins, PhD; Walid \nAbi-Saab...', 'thumbnail': 'https://serpapi.com/searches/6724a02a2bab90a0d0acddf3/images/595c77c8d62a0df3e19d645ce257cb7e377328b4b5f087c3ec52982e545639d7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9085224866867065}",,,,,,,,,,['neutral'],neutral,1
NCT01179048,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1603827', 'title': 'Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes', 'source': 'The New England Journal of Medicine', 'date': 'Jun 13, 2016', 'snippet': 'In this double-blind trial, we randomly assigned patients with type 2 \ndiabetes and high cardiovascular risk to receive liraglutide or...', 'thumbnail': 'https://serpapi.com/searches/6724a02f93584c8fed18c9ae/images/4c4778854d24afe10511fb36967796132506dd21d25fb4f91e533f57ac9d3ebe.png', 'sentiment': 'neutral', 'sentiment_prob': 0.886772871017456}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.034516', 'title': 'Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke:', 'source': 'American Heart Association Journals', 'date': 'Oct 2, 2018', 'snippet': 'Background:The glucagon-like peptide-1 analog liraglutide reduced \ncardiovascular events and mortality in patients with type 2 diabetes...', 'thumbnail': 'https://serpapi.com/searches/6724a02f93584c8fed18c9ae/images/4c4778854d24afe1f7ae34d60aa6d81e0b3459d5c5dadbd870761b5b9a186d4c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8767980933189392}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01356849,"{'position': 1, 'link': 'https://www.renalandurologynews.com/reports/atrasentan-reduces-insulin-resistance-in-diabetic-kidney-disease/', 'title': 'Atrasentan Reduces Insulin Resistance in Diabetic Kidney Disease', 'source': 'Renal and Urology News', 'date': 'Nov 2, 2023', 'snippet': 'As insulin resistance increased, so did the risk for adverse cardiorenal \noutcomes, investigators reported. Atrasentan may reduce insulin...', 'thumbnail': 'https://serpapi.com/searches/6724a07515c740400600f8aa/images/ca0f769a0a7773d5f34cf1f3a80bd88ed42bb370383274579dc3ef5fa28e89f9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7896155714988708}",,,,,,,,,,['neutral'],neutral,1
NCT00098878,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2020/08/04/study-tests-used-to-predict-response-to-parp-inhibitors-yield-inconsistent-result/', 'title': 'Study: Tests Used to Predict Response to PARP Inhibitors Yield Inconsistent Result', 'source': 'Ovarian Cancer News Today', 'date': 'Aug 4, 2020', 'snippet': 'Tests used in clinical trials of ovarian cancer to determine if tumors lack \nthe ability to repair their DNA — a status termed “homologous...', 'thumbnail': 'https://serpapi.com/searches/6724a07bd771bd3d1c3e40a6/images/d6647d6bc25cde7c69f0cdca3b0fcf226f681ac0691f73a6d9fb5669df99dbc4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.757084310054779}",,,,,,,,,,['neutral'],neutral,1
NCT02303678,"{'position': 1, 'link': 'https://www.researchgate.net/figure/a-A-brain-histopathologic-picture-shows-that-the-encephalomalacia-ECM-within-the-red_fig2_289367333', 'title': 'a A brain histopathologic picture shows that the encephalomalacia (ECM,...', 'source': 'ResearchGate', 'date': 'Apr 5, 2021', 'snippet': 'Pseudomonas aeruginosa exotoxin A-based immunotoxins (PE-ITs) are fusion \nproteins that harness targeting and toxin moieties. Structural \noptimizations in PE...', 'thumbnail': 'https://serpapi.com/searches/6724a07fd910398432a519bf/images/f8f95769b6e02ede59d1dabda30140550d80be5406fb9a372e3e3d7e4f0c5bd8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8830180764198303}",,,,,,,,,,['neutral'],neutral,1
NCT02927301,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01962-5', 'title': 'Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial', 'source': 'Nature', 'date': 'Sep 12, 2022', 'snippet': 'In an ongoing, open-label, single-arm phase II study ( NCT02927301 ), 181 \npatients with untreated, resectable, stage IB–IIIB non-small cell...', 'thumbnail': 'https://serpapi.com/searches/6724a0bd6de1e4c9f2802c77/images/8190da39c4acc981c9a7586106a82497c08f3689b5db7fca65fc04ce89cb6d78.png', 'sentiment': 'neutral', 'sentiment_prob': 0.835011899471283}",,,,,,,,,,['neutral'],neutral,1
NCT01569451,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/rituximab-for-rrms/', 'title': 'Rituximab in MS | Experimental MS Treatments', 'source': 'Multiple Sclerosis News Today', 'date': 'Apr 12, 2022', 'snippet': 'Rituximab is commonly used off-label in multiple sclerosis patients. Learn \nmore about its uses, side effects, and clinical testing.', 'thumbnail': 'https://serpapi.com/searches/6724a0c98b84c4690f808b48/images/127cda1ee9fef3556f9b9f09347b08da61458b064146dee98c063882642fff36.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9291795492172241}",,,,,,,,,,['neutral'],neutral,1
NCT03472365,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-32570-z', 'title': 'Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment', 'source': 'Nature', 'date': 'Aug 18, 2022', 'snippet': 'A single biomarker is not adequate to identify patients with gastric cancer \n(GC) who have the potential to benefit from anti-PD-1/PD-L1...', 'thumbnail': 'https://serpapi.com/searches/6724a0cb06f4f2e5cefaec56/images/a969764fceaf3f569815ec8661c2db56b50776ce170af8e61a636cf02920636f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6853904724121094}",,,,,,,,,,['neutral'],neutral,1
NCT01171859,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/jnc.15233', 'title': 'Targeting transthyretin - Mechanism-based treatment approaches and future perspectives in hereditary amyloidosis', 'source': 'Wiley Online Library', 'date': 'Nov 6, 2020', 'snippet': 'TTR stabilization and knockdown are approved therapies to mitigate the \notherwise lethal disease course. To date, the variety in phenotypic \npenetrance is not...', 'thumbnail': 'https://serpapi.com/searches/6724a0fde45f3317958e9638/images/a4cf99e81895ba68ff18166e1bb880b6640d966968030f960512dff48b1166b9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.844703197479248}",,,,,,,,,,['neutral'],neutral,1
NCT03524846,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-019-47583-w', 'title': 'A randomized feasibility study of the effect of ascorbic acid on post-angioplasty restenosis of hemodialysis vascular access (NCT03524846)', 'source': 'Nature', 'date': 'Jul 31, 2019', 'snippet': 'Restenosis remains a significant problem after angioplasty of hemodialysis \nvascular access. Both experimental and clinical studies have...', 'thumbnail': 'https://serpapi.com/searches/6724a12b18787de804ad22a8/images/0e391a2f25938d52ef5fb6bba484170fb42e94f0ff356b01243b9c8bea9ec0f5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6441922187805176}",,,,,,,,,,['neutral'],neutral,1
NCT03338972,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-021-00469-5', 'title': 'CAR T-cell therapy in multiple myeloma: more room for improvement - Blood Cancer Journal', 'source': 'Nature', 'date': 'Apr 29, 2021', 'snippet': 'The emergence of various novel therapies over the last decade has changed \nthe therapeutic landscape for multiple myeloma. While the clinical...', 'thumbnail': 'https://serpapi.com/searches/6724a13b72e5c45383f00522/images/0caf7066823ab195367e47d0dce9239c556aa901ac8ed92de3fe6bd9b79c464e.png', 'sentiment': 'positive', 'sentiment_prob': 0.5632189512252808}","{'position': 2, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.01243/full', 'title': 'CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions', 'source': 'Frontiers', 'date': 'Jun 27, 2023', 'snippet': 'CAR T-cell therapy has changed the treatment landscape of B-cell \nmalignancies, providing a potentially curative option for patients who are \nrefractory to...', 'thumbnail': 'https://serpapi.com/searches/6724a13b72e5c45383f00522/images/0caf7066823ab1952641a18674177c6bf3f59e03c1dbb705758d1b5bac1dff8f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5597637295722961}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02456714,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-019-0698-9', 'title': 'Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial', 'source': 'Nature', 'date': 'Jan 10, 2020', 'snippet': 'The objective of this study was to evaluate safety and anti-tumour activity \nof fluorouracil, leucovorin, irinotecan plus oxaliplatin (FOLFIRINOX) as \nsalvage...', 'thumbnail': 'https://serpapi.com/searches/6724a13e90b57c4651791392/images/35970447d75a8ba9166258c92e081a0efbd0e313f5e9bad4a09454623dd96518.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8535820841789246}",,,,,,,,,,['neutral'],neutral,1
NCT02702817,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/naproxen-fails-to-prevent-alzheimers-progression-in-intrepad-trial/', 'title': 'Naproxen Fails to Prevent Alzheimer’s Progression in INTREPAD Trial', 'source': ""Alzheimer's News Today"", 'date': 'Apr 17, 2019', 'snippet': ""Treatment with naproxen, an anti-inflammatory medication, failed to prevent \nthe progression of Alzheimer's in individuals at risk of developing the \ndisease."", 'thumbnail': 'https://serpapi.com/searches/6724a25d15c740400600f950/images/c7c48910858f4cbed1febfecdd93d55560c64046f5575e8cce3e4240e030ccc8.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8102526664733887}",,,,,,,,,,['negative'],negative,0
NCT05719311,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/news/span-phase-2-trial-adrulipase-epi-completes-patient-screening/', 'title': 'SPAN Phase 2 trial of adrulipase for EPI completes CF patient...', 'source': 'Cystic Fibrosis News Today', 'date': 'May 15, 2023', 'snippet': 'First Wave BioPharma has completed patient screening for the Phase 2 SPAN \nclinical trial of a new formulation of adrulipase to treat exocrine \npancreatic...', 'thumbnail': 'https://serpapi.com/searches/6724a3f7be1497433a835140/images/c885c8dc35de7739890fbfc7aef86f6935dfcd333e8c6d68a8ce29f4a3efcd9e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8049291968345642}","{'position': 2, 'link': 'https://cysticfibrosisnewstoday.com/news/trial-adrulipase-exocrine-pancreatic-insufficiency-treatment/', 'title': 'Trial of adrulipase, exocrine pancreatic insufficiency treatment...', 'source': 'Cystic Fibrosis News Today', 'date': 'Mar 10, 2023', 'snippet': 'The first two patients have been dosed in the SPAN clinical trial testing a \nnew formulation of adrulipase, a yeast-derived enzyme, to treat exocrine \npancreatic...', 'thumbnail': 'https://serpapi.com/searches/6724a3f7be1497433a835140/images/c885c8dc35de7739ce47edcc813ac4d3ef34e1c2ba95dd69bb63b0d646d413ef.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8922134637832642}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT00056160,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa070596', 'title': 'Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America', 'source': 'The New England Journal of Medicine', 'date': 'Nov 22, 2007', 'snippet': 'Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide \nbut has a different safety profile, has clinical activity in...', 'thumbnail': 'https://serpapi.com/searches/6724a40fefad21c7f84ec349/images/a4714c5983772b2fb3466602cd5c020a12c349f04dd028a0237de70911a7739b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8970398306846619}",,,,,,,,,,['neutral'],neutral,1
NCT05381948,"{'position': 1, 'link': 'https://www.modernretina.com/view/key-takeaways-from-the-davio-2-study-with-rishi-singh-md', 'title': 'Key takeaways from the DAVIO 2 study with Rishi Singh, MD', 'source': 'Modern Retina', 'date': 'Mar 19, 2024', 'snippet': 'Rishi P. Singh, MD, recently sat down with Modern Retina to share a few of \nthe key takeaways from the phase 2 DAVIO 2 trial (NCT05381948)', 'thumbnail': 'https://serpapi.com/searches/6724a27eefad21c826b08a47/images/8ea6fcbfb058c92c8282e488d853986bba0cc4c50c5c73e25290c456fcf6c36d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.893929660320282}",,,,,,,,,,['neutral'],neutral,1
NCT02770625,"{'position': 1, 'link': 'https://gaucherdiseasenews.com/2017/11/21/abcertin-clinical-data-shows-potential-to-treat-type-1-gaucher-disease/', 'title': 'Potential to Treat Type 1 Gaucher Disease Seen in Abcertin Clinical Data', 'source': 'Gaucher Disease News', 'date': 'Nov 21, 2017', 'snippet': ""Phase 3 trial data demonstrated the safety and effectiveness of ISU Abxis' \nrecombinant GBA formulation Abcertin to treat type 1 Gaucher..."", 'thumbnail': 'https://serpapi.com/searches/6724a28314c31e1ae795b8a9/images/0a966e22b31eeddcaa4470bbf9eb2e7055cfca1239d5281ef7852f41def958cc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6689450144767761}",,,,,,,,,,['neutral'],neutral,1
NCT02669810,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-47079-8', 'title': 'Development of a potency assay for CD34+ cell-based therapy - Scientific Reports', 'source': 'Nature', 'date': 'Nov 11, 2023', 'snippet': 'We have previously shown that intracardiac delivery of autologous CD34+ \ncells after acute myocardial infarction (AMI) is safe and leads to...', 'thumbnail': 'https://serpapi.com/searches/6724a288fbde0d025ef89c19/images/8814ae75b719811c19e556ad3c4acaff17b1844b5a2e5bf620be2ce9dde5a399.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5865443348884583}","{'position': 2, 'link': 'https://www.europeanpharmaceuticalreview.com/article/184185/regenerative-potential-cell%E2%80%91based-therapies-for-heart-failure/', 'title': 'Regenerative potential: cell‑based therapies for heart failure', 'source': 'European Pharmaceutical Review', 'date': 'Jul 27, 2023', 'snippet': 'Dr Ibon Garitaonandia shares how CD34+ cell therapies are demonstrating \npromise in clinical studies as an alternative to heart transplants.', 'thumbnail': 'https://serpapi.com/searches/6724a288fbde0d025ef89c19/images/8814ae75b719811c136239f0471eb491d48075688b07b0a0d735403447b15dbd.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5993127226829529}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT04721223,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01589-z', 'title': 'Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials', 'source': 'Nature', 'date': 'Sep 6, 2023', 'snippet': 'In this review, we focus on the recent development of drug discovery \ntargeting “undruggable” proteins and their application in clinic.', 'thumbnail': 'https://serpapi.com/searches/6724a29c90b57c461dea5f81/images/b72ef227e8eb7d2d1dc06b630fed5cbba905856b0812173b47585572556dfbae.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8479585647583008}",,,,,,,,,,['neutral'],neutral,1
NCT02366949,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-66244-1', 'title': 'A whole-genome CRISPR screen identifies the spindle accessory checkpoint as a locus of nab-paclitaxel resistance in a pancreatic cancer cell line', 'source': 'Nature', 'date': 'Jul 10, 2024', 'snippet': 'A genome-wide CRISPR interference and knockout screen in the PANC-1 cell \nline with the drug nab-paclitaxel has identified a group of spindle \nassembly...', 'thumbnail': 'https://serpapi.com/searches/6724a2acd364b43b71ad147d/images/6e8aebe99596a31c579b8aa8532de1fefbebb7ef5c73c93a958f5cf0b505d28a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.834575355052948}",,,,,,,,,,['neutral'],neutral,1
NCT02883452,"{'position': 1, 'link': 'https://ibdnewstoday.com/2020/03/02/new-remsima-injection-formulation-ct-p13-safe-effective-trial-data-show/', 'title': 'Remsima in New Injection Form Shows Safety and Efficacy in Trial', 'source': 'IBD News Today', 'date': 'Mar 2, 2020', 'snippet': ""Remsima, an approved biosimilar of Remicade for active Crohn's and \nulcerative colitis, was safe and effective given as a potential..."", 'thumbnail': 'https://serpapi.com/searches/6724a2b9cf32e043b585fc4f/images/b00b9e3d42c033a23000a07ebbf7a45a9e0f039340943050b7bc1fa803048ca2.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6795647144317627}",,,,,,,,,,['positive'],positive,1
NCT05017480,"{'position': 1, 'link': 'https://nationaleczema.org/blog/connect-1522/', 'title': 'Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis', 'source': 'National Eczema Association', 'date': 'Feb 10, 2022', 'snippet': 'Connect Biopharma today reported detailed positive data from the global \nPhase 2b clinical trial of CBP-201 administered subcutaneously (SC)...', 'thumbnail': 'https://serpapi.com/searches/6724a2d55ed3ca94eda81396/images/740ccb346a43377caad9b40dba1fdfc72a1bbc13e6f854e0d15fbe3d8e740afd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8072672486305237}",,,,,,,,,,['neutral'],neutral,1
NCT01691508,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1403291', 'title': 'Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma', 'source': 'The New England Journal of Medicine', 'date': 'Sep 8, 2014', 'snippet': 'Many patients with severe asthma require regular treatment with oral \nglucocorticoids despite the use of high-dose inhaled therapy.', 'thumbnail': 'https://serpapi.com/searches/6724a2e1ee677f0a24f8d7f5/images/4ec433a6026130639c99554ee003bfc68a8b894725102e144f8dc64cde7cd67c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7087534666061401}",,,,,,,,,,['neutral'],neutral,1
NCT04453202,"{'position': 1, 'link': 'https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext', 'title': 'Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape', 'source': 'The Lancet', 'date': 'Aug 8, 2022', 'snippet': 'A study to evaluate the safety and efficacy of mRNA-1345 vaccine targeting \nrespiratory syncytial virus (RSV) in adults ≥60 years of age.', 'thumbnail': 'https://serpapi.com/searches/6724a2e91315026fdb94b99b/images/9793bbf8cef5cbc52a3a2877ae525f7ad06c979957534c512ec0d464f9c28f3f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8734835982322693}",,,,,,,,,,['neutral'],neutral,1
NCT04896086,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-54876-2', 'title': 'Mosaic quadrivalent influenza vaccine single nanoparticle characterization | Scientific Reports', 'source': 'Nature', 'date': 'Feb 24, 2024', 'snippet': 'Recent work by our laboratory and others indicates that co-display of \nmultiple antigens on protein-based nanoparticles may be key to induce...', 'thumbnail': 'https://serpapi.com/searches/6724a3037e1d1ff692a5d9db/images/19a75b95b5932c7dacd437fc0624546dc59533c313a32a5c519c1ba612393922.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6587743163108826}",,,,,,,,,,['neutral'],neutral,1
NCT03164772,"{'position': 1, 'link': 'https://www.nature.com/articles/s41587-022-01294-2', 'title': 'The clinical progress of mRNA vaccines and immunotherapies', 'source': 'Nature', 'date': 'May 9, 2022', 'snippet': 'The emergency use authorizations (EUAs) of two mRNA-based severe acute \nrespiratory syndrome coronavirus (SARS-CoV)-2 vaccines approximately...', 'thumbnail': 'https://serpapi.com/searches/6724a34e81bab7fc841fea71/images/e606bc348a595d6e6d800b51235ab52ff81e53f85c6ae64e290252993cb6893d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.921474814414978}",,,,,,,,,,['neutral'],neutral,1
NCT05039190,"{'position': 1, 'link': 'https://myastheniagravisnews.com/news/harbour-biomed-resubmits-batoclimab-application-gmg-china/', 'title': 'Harbour BioMed resubmits request for batoclimab approval in China', 'source': 'Myasthenia Gravis News', 'date': 'Jul 2, 2024', 'snippet': 'Harbour BioMed resubmitted an application to regulators in China, with \nadded long-term safety data, seeking approval of batoclimab for gMG.', 'thumbnail': 'https://serpapi.com/searches/6724a36a1fc7c565347dfd98/images/1a2eb80087f61bdc1b9c65f851c827f3ed62b32e71f8a3243d2f07ded7a9c985.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8841829299926758}","{'position': 2, 'link': 'https://myastheniagravisnews.com/news/mg-therapy-batoclimab-hits-phase-3-trial-main-secondary-goals/', 'title': 'MG therapy batoclimab hits Phase 3 trial main, secondary goals |...', 'source': 'Myasthenia Gravis News', 'date': 'Mar 7, 2023', 'snippet': 'Batoclimab eased the symptoms of generalized myasthenia gravis and their \nimpact on daily function in a Phase 3 clinical trial in China.', 'thumbnail': 'https://serpapi.com/searches/6724a36a1fc7c565347dfd98/images/1a2eb80087f61bdc35a24cc6f3eb7ecb5ff8a74a2ff08eec02f7cbe4370334af.png', 'sentiment': 'positive', 'sentiment_prob': 0.6334934830665588}","{'position': 3, 'link': 'https://myastheniagravisnews.com/news/immunovant-positions-imvt-1402-lead-mg-treatment-candidate/', 'title': 'Immunovant positions IMVT-1402 as lead MG treatment candidate', 'source': 'Myasthenia Gravis News', 'date': 'Jun 4, 2024', 'snippet': 'IImmunovant is prioritizing IMVT-1402 as its lead MG treatment candidate, \nwith registrational clinical trials possible in the next year.', 'thumbnail': 'https://serpapi.com/searches/6724a36a1fc7c565347dfd98/images/1a2eb80087f61bdc5bcfceea6bee7c704af2e3c7b0185e465e70642e23bd2c08.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7960225343704224}","{'position': 4, 'link': 'https://myastheniagravisnews.com/news/gmg-chinese-regulators-agree-consider-approving-batoclimab/', 'title': 'For gMG, Chinese regulators agree to consider approving batoclimab...', 'source': 'Myasthenia Gravis News', 'date': 'Jul 11, 2023', 'snippet': 'Submitted as a biologics license application, the request to review \nbatoclimab is buoyed by positive top-line data from a Phase 3 trial.', 'thumbnail': 'https://serpapi.com/searches/6724a36a1fc7c565347dfd98/images/1a2eb80087f61bdc48f575b466df95965d2d79b2dd2766a69cb6f321b10a6850.png', 'sentiment': 'positive', 'sentiment_prob': 0.6625019907951355}",,,,,,,"['neutral', 'positive', 'neutral', 'positive']",neutral,1
NCT02924883,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30465-4/fulltext', 'title': 'Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial', 'source': 'The Lancet', 'date': 'Sep 29, 2020', 'snippet': 'We aimed to test this combination in HER2-positive advanced breast cancer \nthat had progressed after previous treatment with trastuzumab and a taxane.', 'thumbnail': 'https://serpapi.com/searches/6724a375a5e50212d8cf9665/images/c32914650d5c325e1bb53f37c6d14fd5f2f718d454998fe34eb1cc563b58e84a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8840331435203552}",,,,,,,,,,['neutral'],neutral,1
NCT04353791,"{'position': 1, 'link': 'https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00406-1/fulltext', 'title': 'Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors', 'source': 'The Lancet', 'date': '١٨\u200f/١٠\u200f/٢٠٢٣', 'snippet': 'Deucravacitinib, a first-in-class allosteric TYK2 inhibitor, represents a \nremarkable advancement in the field.', 'thumbnail': 'https://serpapi.com/searches/6724a399b9ab86d08f725134/images/8603d4ccf937229ff37b46e6a173b647ee5ca995b68647a13649023e65946022.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6672559976577759}",,,,,,,,,,['positive'],positive,1
NCT03402503,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/phase-2-trial-montelukast-oral-film-starts-dosing/', 'title': 'Phase 2 trial of montelukast oral film starts dosing', 'source': ""Parkinson's News Today"", 'date': 'Apr 11, 2024', 'snippet': ""The first patients were dosed in the Phase 2 MONTPARK clinical trial of \nMontelukast oral film to treat Parkinson's disease."", 'thumbnail': 'https://serpapi.com/searches/6724a3c3bbc18b33ac2dc20b/images/4843d6156eeaf3377453d60501c88df176d8c3a9cea761a061bfe8818ba74196.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9263402819633484}","{'position': 2, 'link': 'https://alzheimersnewstoday.com/news/montelukast-oral-film-aids-cognition-mild-moderate-alzheimers/', 'title': 'Montelukast oral film may help in mild to moderate Alzheimer’s', 'source': ""Alzheimer's News Today"", 'date': 'Jul 25, 2024', 'snippet': ""The use of Montelukast oral film was shown to improve cognition in patients \nwith mild to moderate Alzheimer's in a Phase 2 clinical trial."", 'thumbnail': 'https://serpapi.com/searches/6724a3c3bbc18b33ac2dc20b/images/4843d6156eeaf337f7b93bd9d42defdb98a9a7c9d210b68c3c874686bb8d623e.png', 'sentiment': 'positive', 'sentiment_prob': 0.6934897899627686}","{'position': 3, 'link': 'https://alzheimersnewstoday.com/news/first-patient-dosed-resumed-trial-montelukast-alzheimers/', 'title': 'First Patient Dosed in Resumed Trial of Montelukast for Alzheimer’s', 'source': ""Alzheimer's News Today"", 'date': 'Jan 27, 2022', 'snippet': ""The first patient has been dosed in the resumed Canadian Phase 2a clinical \ntrial of montelukast for mild to moderate Alzheimer's."", 'thumbnail': 'https://serpapi.com/searches/6724a3c3bbc18b33ac2dc20b/images/4843d6156eeaf33726bb2b5f4d7cc6ca297c3733e7e5c32b4fd307b9221b5766.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9239630699157715}",,,,,,,,"['neutral', 'positive', 'neutral']",neutral,1
NCT05178810,"{'position': 1, 'link': 'https://alsnewstoday.com/news/als-progression-fails-slow-with-edaravone-formulation-fab-122/', 'title': 'ALS progression fails to slow with edaravone formulation FAB122', 'source': 'ALS News Today', 'date': 'Jan 23, 2024', 'snippet': ""The ADORE trial's main goal was to see if adding the oral edaravone \nformulation to standard ALS treatment could slow disease progression."", 'thumbnail': 'https://serpapi.com/searches/6724a42d9936886f64d2e56f/images/6090f3f92972b1cbcfeb6e28567fe6124528db7f1c1f4ae5ccb897d732998357.png', 'sentiment': 'negative', 'sentiment_prob': 0.5879668593406677}","{'position': 2, 'link': 'https://alsnewstoday.com/news/fnp122-oral-formulation-edaravone-enters-phase-3-extension/', 'title': 'FNP122, oral formulation of edaravone, enters Phase 3 extension...', 'source': 'ALS News Today', 'date': 'Jun 28, 2023', 'snippet': ""A Phase 3 clinical trial that's testing FNP122, Ferrer's oral formulation \nof edaravone, in people with amyotrophic lateral sclerosis (ALS)..."", 'thumbnail': 'https://serpapi.com/searches/6724a42d9936886f64d2e56f/images/6090f3f92972b1cba99ead11849ba37606e96c465c9d4feb4b9d99a5c2c472c3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9038548469543457}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT05122650,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/jazz-pharmaceuticals-essential-tremor-fails-endpoint/', 'title': 'Jazz Pharmaceuticals’ essential tremor drug falls flat in Phase IIb trial', 'source': 'Clinical Trials Arena', 'date': 'Jun 21, 2024', 'snippet': ""The company will evaluate the data from this trial and another in \nParkinson's disease before deciding on the future of the drug."", 'thumbnail': 'https://serpapi.com/searches/6724a43f9e38e5ac2d35e811/images/3af66ae5ec8300b33a9cf6471a855256cdd805fed4b32c63f167329124bcad5a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.650999903678894}",,,,,,,,,,['negative'],negative,0
NCT02723773,"{'position': 1, 'link': 'https://www.europeanpharmaceuticalreview.com/news/175431/shingles-vaccine-offers-a-decade-of-protection-in-older-adults/', 'title': 'Shingles vaccine offers a decade of protection in older adults', 'source': 'European Pharmaceutical Review', 'date': 'Oct 21, 2022', 'snippet': 'Shingrix can effectively vaccinate adults over 50 years old against \nshingles for at least 10 years, new data shows.', 'thumbnail': 'https://serpapi.com/searches/6724a44ece1e10df916e1ce9/images/da4d229f429efa468c85ba4d4d09a9f201dbbcebd625a8b929e05deb0861ab50.png', 'sentiment': 'positive', 'sentiment_prob': 0.512775182723999}",,,,,,,,,,['positive'],positive,1
NCT04154072,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20230327005069/en/Neuraly-Announces-Topline-Results-from-Phase-2-Trial-of-NLY01-in-Parkinsons-Disease', 'title': ""Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease"", 'source': 'Business Wire', 'date': 'Mar 27, 2023', 'snippet': 'Neuraly, a clinical-stage biotechnology company pioneering development of \ndisease-modifying agents for neurodegenerative disorders,...', 'thumbnail': 'https://serpapi.com/searches/6724a44eb4fe879881eee5c2/images/cecfd00f0cb0c58b11d88ab1bc3306e8b511aaf94f027264806c05ef6e0876f3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8191664218902588}",,,,,,,,,,['neutral'],neutral,1
NCT01710657,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Vimpat-lacosamide', 'title': 'Lacosamide (Vimpat®)', 'source': 'UCB', 'date': 'Aug 1, 2024', 'snippet': 'Epilepsy, A Study to Evaluate the Efficacy and Safety of Adjunctive Therapy \nWith Lacosamide in Adults With Partial Onset Seizures, Phase 3...', 'thumbnail': 'https://serpapi.com/searches/6724a4659109860c4561e73c/images/d6252d293e29b96d04f7143734efaecd9ab7f5856f70966d9e45410ed069a847.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9128645658493042}",,,,,,,,,,['neutral'],neutral,1
NCT05096403,"{'position': 1, 'link': 'https://coldagglutininnews.com/news/cascade-trial-seeks-enroll-57-patients-us-europe-japan/', 'title': 'CASCADE trial seeks to enroll up to 57 patients in US, Europe, Japan', 'source': 'Cold Agglutinin Disease News', 'date': 'Feb 24, 2023', 'snippet': 'Enrollment is underway in a Phase 3 clinical trial testing the \ninvestigational therapy pegcetacoplan in adults with primary cold \nagglutinin disease (CAD).', 'thumbnail': 'https://serpapi.com/searches/6724a46808abe4630ef2844c/images/706e5fe6e7e1792e139f0bd68309185151ff0ee92efbdb3ec76bf726b24ce79f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8906036019325256}","{'position': 2, 'link': 'https://coldagglutininnews.com/news/experimental-cad-therapy-pegcetacoplan-halted-developers/', 'title': 'Experimental CAD therapy pegcetacoplan halted by developers', 'source': 'Cold Agglutinin Disease News', 'date': 'Mar 7, 2024', 'snippet': 'Apellis Pharmaceuticals and Swedish Orphan Biovitrum (Sobi) have stopped \nthe clinical development of the experimental therapy pegcetacoplan for cold \nagglutinin...', 'thumbnail': 'https://serpapi.com/searches/6724a46808abe4630ef2844c/images/706e5fe6e7e1792e807d5038447010a748ba1636c040f1530ee43acf677da8a5.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5445611476898193}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT02610296,"{'position': 1, 'link': 'https://www.drugdiscoverytrends.com/quark-pharmaceuticals-reports-positive-phase-2-results-to-evaluate-the-efficacy-and-safety-of-qpi-1002/', 'title': 'Quark Pharmaceuticals Reports Positive Phase 2 Results to Evaluate the Efficacy and Safety of QPI-1002', 'source': 'drugdiscoverytrends.com', 'date': 'Jul 28, 2017', 'snippet': 'Quark Pharmaceuticals announced successful completion of a randomized, \ndouble-blinded, placebo-controlled multicenter Phase 2 trial of...', 'thumbnail': 'https://serpapi.com/searches/6724a46f48b9f7380db88e2a/images/4483eff35c01f01c91a9985bd6052c8a1a2e6d5778e36a8c6aea1155223465b1.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6692343354225159}",,,,,,,,,,['positive'],positive,1
NCT02814916,"{'position': 1, 'link': 'https://www.empr.com/home/news/dalvance-approved-for-children-with-acute-bacterial-skin-skin-structure-infections/', 'title': 'Dalvance Approved for Children With Acute Bacterial Skin/Skin Structure Infections', 'source': 'Medical Professionals Reference', 'date': 'Jul 26, 2021', 'snippet': 'The Food and Drug Administration (FDA) has expanded the approval of Dalvance\n® (dalbavancin) to include treatment of acute bacterial skin and...', 'thumbnail': 'https://serpapi.com/searches/6724a49ce335eccc74625d36/images/de32dcfa84cecd2c963b3e65899a4e41b762b22a4679adf81b4a63d1e0c5c024.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8638889789581299}",,,,,,,,,,['neutral'],neutral,1
NCT01866319,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1503093', 'title': 'Pembrolizumab versus Ipilimumab in Advanced Melanoma', 'source': 'The New England Journal of Medicine', 'date': 'Apr 19, 2015', 'snippet': 'The immune checkpoint inhibitor ipilimumab is the standard-of-care \ntreatment for patients with advanced melanoma. Pembrolizumab inhibits the...', 'thumbnail': 'https://serpapi.com/searches/6724a4a468831e63a4ce3576/images/9d54a0755edf960aa81c6378a163934f155595849aedbcf2730d57d6bccf3caf.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8863661289215088}","{'position': 2, 'link': 'https://melanomanewstoday.com/2017/06/08/keytruda-pembrolizumab-trial-data-show-improved-survival-benefit-compared-to-yervoy-in-advanced-melanoma/', 'title': 'Advanced Melanoma Patients Seen to Benefit from Keytruda Over Yervoy in Phase 3 Study', 'source': 'Melanoma News Today', 'date': 'Jun 8, 2017', 'snippet': 'Patients with unresectable or metastatic melanoma who were treated with \nKeytruda (pembrolizumab) in a pivotal clinical trial showed superior and \nsustained time...', 'thumbnail': 'https://serpapi.com/searches/6724a4a468831e63a4ce3576/images/9d54a0755edf960abef855b359194eef6b31cd5a294e0376c87a44ea0677e022.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5045331716537476}","{'position': 3, 'link': 'https://immuno-oncologynews.com/2020/10/23/cancer-vaccine-uv1-keytruda-combo-shows-safety-early-effective-advanced-melanoma-phase-1-trial/', 'title': 'Cancer Vaccine UV1 Plus Keytruda Shows Safety, Early Efficacy in Advanced Melanoma Trial', 'source': 'Immuno-Oncology News', 'date': 'Oct 23, 2020', 'snippet': 'Top-line data from Phase 1 trial in adults with untreated metastatic \nmelanoma found UV1-Keytruda combo safe, and many without disease...', 'thumbnail': 'https://serpapi.com/searches/6724a4a468831e63a4ce3576/images/9d54a0755edf960a6bee3067aaf6bb620d2fe186b917e6a13f6c0ee9732114b6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.625566303730011}","{'position': 4, 'link': 'https://melanomanewstoday.com/2016/10/20/keytruda-pembrolizumab-plus-yervoy-ipilimumab-seen-as-safe-effective-for-advanced-melanoma-in-study/', 'title': 'Advanced Melanomas Seen to Respond to Keytruda-Yervoy Combo in Study', 'source': 'Melanoma News Today', 'date': 'Oct 20, 2016', 'snippet': 'Data from a Phase 1/2 study found a Keytruda-Yervoy combination to have \npotent anti-tumor activity and acceptable toxicity in advanced...', 'thumbnail': 'https://serpapi.com/searches/6724a4a468831e63a4ce3576/images/9d54a0755edf960a3298e556f6448ebf3d191c7e98f468d64913cac7ed4f8b96.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.84476637840271}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT04423718,"{'position': 1, 'link': 'https://www.empr.com/home/news/eylea-hd-approved-for-wet-amd-diabetic-macular-edema-diabetic-retinopathy/', 'title': 'Eylea HD Approved for Wet AMD, Diabetic Macular Edema, Diabetic Retinopathy', 'source': 'Medical Professionals Reference', 'date': 'Aug 21, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Eylea HD (aflibercept) \nfor the treatment of patients with wet age-related macular degeneration \n(wAMD),...', 'thumbnail': 'https://serpapi.com/searches/6724a4ab96a329af7404be4a/images/308073c807342fbebddb2eee48414c2d6dfed3225f0ca1f31c2cb7632d798438.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.869649350643158}",,,,,,,,,,['neutral'],neutral,1
NCT04892446,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1378647/full', 'title': 'Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives', 'source': 'Frontiers', 'date': 'Jul 5, 2024', 'snippet': 'Since its initial report in 2015, CD47 has garnered significant attention \nas an innate immune checkpoint, raising expectations to become the next \n“PD-1.', 'thumbnail': 'https://serpapi.com/searches/6724a4c929e6fbc136ebe166/images/8a89cb6cd9b5d67b6fc9ef4d586ace72a7600395bd6ef4a79dda4476d43f00c6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.739249587059021}",,,,,,,,,,['neutral'],neutral,1
NCT02903771,"{'position': 1, 'link': 'https://ovariancancernewstoday.com/2016/12/12/novogen-enrolls-first-ovarian-cancer-patient-phase-1-trial-cantrixil/', 'title': ""First Ovarian Cancer Patient Enrolled in Novogen's Cantrixil Phase 1 Trial"", 'source': 'Ovarian Cancer News Today', 'date': 'Dec 12, 2016', 'snippet': 'Read about how Novogen enrolled the first ovarian cancer patient into its \nfirst-in-human Phase 1 clinical trial evaluating its lead...', 'thumbnail': 'https://serpapi.com/searches/6724a4e972f71683b34d09fc/images/fbb5f6e7e616875fe275ac2e5af03ad6cb8fd8c4ac3349c480adc63717890055.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.927446722984314}",,,,,,,,,,['neutral'],neutral,1
NCT02897375,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/news/phase-1-trial-of-palbociclib-with-chemotherapy-for-solid-tumors/', 'title': 'Phase 1 Trial of Palbociclib With Chemotherapy for Solid Tumors', 'source': 'Cancer Therapy Advisor', 'date': 'May 1, 2017', 'snippet': 'Safety, tolerability, and efficacy of palbociclib in combination with \ncisplatin or carboplatin among patients with advanced/metastatic solid...', 'thumbnail': 'https://serpapi.com/searches/6724a50ce8735a843d134f17/images/2ff133bb56028d864dea375d8c528e2c60122fa4b95066f6ea18b36b850c9cd0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8757972121238708}",,,,,,,,,,['neutral'],neutral,1
NCT02052778,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2206834', 'title': 'Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma', 'source': 'The New England Journal of Medicine', 'date': 'Jan 18, 2023', 'snippet': 'Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as \npromising drug targets for intrahepatic cholangiocarcinoma,...', 'thumbnail': 'https://serpapi.com/searches/6724a50f5f97781090a138a5/images/b1f2178a4f1a848f402468f95a032284b0961ca6f8b32bd14af2aba5d27020c5.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8662121295928955}","{'position': 2, 'link': 'https://www.oncnursingnews.com/view/futibatinib-approval-ushers-in-targeted-therapy-option-for-patients-with-unresectable-intrahepatic-fgfr2-positive-cholangiocarcinoma', 'title': 'Futibatinib Approval Ushers in Targeted Therapy Option for Patients With Unresectable, Intrahepatic FGFR2-Positive Cholangiocarcinoma', 'source': 'Oncology Nursing News', 'date': 'Dec 6, 2022', 'snippet': 'The approval of futibatinib (Lytgobi) for patients with unresectable, \nlocally advanced or metastatic intrahepatic FGFR2-positive \ncholangiocarcinoma represents...', 'thumbnail': 'https://serpapi.com/searches/6724a50f5f97781090a138a5/images/b1f2178a4f1a848f71e8ac39e9736b1e99f1c6ab64d9739644adcfce293d3e6a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8350123763084412}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03453164,"{'position': 1, 'link': 'https://www.nature.com/articles/s43856-023-00343-4', 'title': 'Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer | Communications Medicine', 'source': 'Nature', 'date': 'Aug 15, 2023', 'snippet': 'Although immune checkpoint inhibitors (ICI) targeting for PD-1 axis is a \npromising approach for advanced gastric cancer (GC) patients,...', 'thumbnail': 'https://serpapi.com/searches/6724a53cc05eb5886b022108/images/14c03ff9a42b078a0df745ce15cec70375c2ef6a9dfa48094f67e702d70cd468.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8860142230987549}",,,,,,,,,,['neutral'],neutral,1
NCT03387670,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2021/12/23/results-trial-simvastatin-spms-expected-2025/', 'title': 'Trial of Potential SPMS Therapy Simvastatin Underway; Results in 2025', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 23, 2021', 'snippet': 'A clinical trial testing whether the cholesterol-lowering medication \nsimvastatin might slow disability progression in secondary progressive \nmultiple sclerosis...', 'thumbnail': 'https://serpapi.com/searches/6724a54c1fc7c5650202ec36/images/ac920c1f102286358ca85bb75f51d0f876182dc5e3669b2f933185dfc1ff225d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9061797857284546}",,,,,,,,,,['neutral'],neutral,1
NCT00499616,"{'position': 1, 'link': 'https://www.uchicagomedicine.org/forefront/cancer-articles/2019/august/improving-standard-therapy-for-intermediate-risk-neuroblastoma', 'title': 'Improving the standard of therapy for patients with intermediate-risk neuroblastoma', 'source': 'UChicago Medicine', 'date': 'Aug 6, 2019', 'snippet': 'Some patients with pediatric cancer neuroblastoma can be treated with less \nchemotherapy and still have excellent survival rates,...', 'thumbnail': 'https://serpapi.com/searches/6724a5544e9efcc8cb2b589a/images/5458d0e8c9dde16158b4f28a1fadb958c21b7aed5f198ab01d164fe454cb45e0.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.49198010563850403}",,,,,,,,,,['neutral'],neutral,1
NCT04555486,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20211019005355/en/Dicerna-Announces-Results-for-PHYOX%E2%84%A24-Single-Dose-Study-of-Nedosiran-in-Primary-Hyperoxaluria-Type-3-PH3', 'title': 'Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)', 'source': 'Business Wire', 'date': 'Oct 19, 2021', 'snippet': 'The PHYOX4 trial (NCT04555486) was a randomized, placebo-controlled, \ndouble-blind, multicenter study evaluating the safety and tolerability of a \nsingle...', 'thumbnail': 'https://serpapi.com/searches/6724a557a5d70219126c41ba/images/d48a288b9e2f9837883fb586430ee8bd1bee9c3f8ee9c0d6e08ce33378fd8b58.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.892909049987793}",,,,,,,,,,['neutral'],neutral,1
NCT03028766,"{'position': 1, 'link': 'https://www.nature.com/articles/s44276-023-00026-6', 'title': 'Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer', 'source': 'Nature', 'date': 'Jan 29, 2024', 'snippet': 'Pre-clinical studies suggest AZD1775, a WEE1 kinase inhibitor, potentiates \nthe activity of various chemotherapeutic agents.', 'thumbnail': 'https://serpapi.com/searches/6724a55717b10ef88bd2d49b/images/c603b595868fe2c02ae058176a8274653012c4021d16aa76ab3f0fb355da3cec.png', 'sentiment': 'neutral', 'sentiment_prob': 0.86203533411026}",,,,,,,,,,['neutral'],neutral,1
NCT02089685,"{'position': 1, 'link': 'https://melanomanewstoday.com/2016/10/20/keytruda-pembrolizumab-plus-yervoy-ipilimumab-seen-as-safe-effective-for-advanced-melanoma-in-study/', 'title': 'Advanced Melanomas Seen to Respond to Keytruda-Yervoy Combo in Study', 'source': 'Melanoma News Today', 'date': 'Oct 20, 2016', 'snippet': 'Data from a Phase 1/2 study found a Keytruda-Yervoy combination to have \npotent anti-tumor activity and acceptable toxicity in advanced...', 'thumbnail': 'https://serpapi.com/searches/6724a56bfd3b5a2897fa3cae/images/772b856df27c90687afe3d632cb1e9609f9e3e14e9271149a1e52b8369c150fe.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.84476637840271}",,,,,,,,,,['neutral'],neutral,1
NCT03359538,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-40734-8', 'title': 'Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis', 'source': 'Nature', 'date': 'Aug 17, 2023', 'snippet': 'In preclinical studies rapamycin was found to target neuroinflammation, by \nexpanding regulatory T cells, and affecting autophagy,...', 'thumbnail': 'https://serpapi.com/searches/6724a5848e13c9b4d3ecae55/images/31fe5454f713a47c173fa70df3475e2239cd64e832ce91cfb9f1db0a3860e2e6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8761885166168213}","{'position': 2, 'link': 'https://alsnewstoday.com/news/rapamycin-fails-raise-regulatory-t-cell-levels-rap-als-trial/', 'title': 'Rapamycin fails to raise regulatory T-cell levels in RAP-ALS trial', 'source': 'ALS News Today', 'date': 'Nov 1, 2023', 'snippet': 'The RAP-ALS trial enrolled 63 participants who were randomly assigned to \nreceive one of two doses of rapamycin or a placebo for 18 weeks.', 'thumbnail': 'https://serpapi.com/searches/6724a5848e13c9b4d3ecae55/images/31fe5454f713a47c32a1c7d30968c177bc49c041dadea51a2975c0f6794dcf2a.png', 'sentiment': 'negative', 'sentiment_prob': 0.5977686047554016}",,,,,,,,,"['neutral', 'negative']",neutral,1
NCT01772472,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/reports/t-dm1-improves-os-vs-trastuzumab-breast-cancer-residual-disease/', 'title': 'T-DM1 Improves OS vs Trastuzumab in Breast Cancer Patients With Residual Disease', 'source': 'Cancer Therapy Advisor', 'date': 'Dec 12, 2023', 'snippet': 'Updated results from the KATHERINE trial suggest that ado-trastuzumab \nemtansine(T-DM1) can improve overall survival (OS) when compared to \ntrastuzumab.', 'thumbnail': 'https://serpapi.com/searches/6724a5bafc40bf9c9759a6ec/images/e761e511104e4df74158146593f3b899e8e8d3832186e76983eaecc60860dd65.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6265843510627747}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1814017', 'title': 'Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer', 'source': 'The New England Journal of Medicine', 'date': 'Dec 5, 2018', 'snippet': 'We conducted a phase 3, open-label trial involving patients with \nHER2-positive early breast cancer who were found to have residual invasive \ndisease.', 'thumbnail': 'https://serpapi.com/searches/6724a5bafc40bf9c9759a6ec/images/e761e511104e4df70f5abcf65f4d4f881f94c8853905256e79713f06000938ce.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8379306793212891}","{'position': 3, 'link': 'https://www.nature.com/articles/s41523-022-00477-z', 'title': 'Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE', 'source': 'Nature', 'date': 'Sep 19, 2022', 'snippet': 'In this descriptive report we provide available outcome information in \nKATHERINE patients with HER2-negative status on re-testing of residual \ndisease after...', 'thumbnail': 'https://serpapi.com/searches/6724a5bafc40bf9c9759a6ec/images/e761e511104e4df7b98ae5373367f3696bc13f7e3144939068311d815f9feee8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8909833431243896}","{'position': 4, 'link': 'https://www.targetedonc.com/view/gupta-discusses-t-dm1-s-role-in-her2-breast-cancer-treatment', 'title': 'Gupta Discusses T-DM1’s Role in HER2+ Breast Cancer Treatment', 'source': 'Targeted Oncology', 'date': '1 week ago', 'snippet': 'Tanya Gupta, MD, medical oncologist in the Stanford University Department \nof Medicine, Division of Medical Oncology, discusses the use of...', 'thumbnail': 'https://serpapi.com/searches/6724a5bafc40bf9c9759a6ec/images/e761e511104e4df76ae09669b6256046d0203994f01b3064df23ea92c7a96530.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9487025141716003}","{'position': 5, 'link': 'https://www.targetedonc.com/view/antibody-drug-conjugates-continue-to-transform-the-oncology-landscape', 'title': 'Antibody-Drug Conjugates Continue to Transform the Oncology Landscape', 'source': 'Targeted Oncology', 'date': 'May 28, 2024', 'snippet': 'Antibody-drug conjugates are revolutionizing oncology, targeting cancer \ncells precisely. Agents like T-DM1, T-DXd, and sacituzumab govitecan \ncontinue to change...', 'thumbnail': 'https://serpapi.com/searches/6724a5bafc40bf9c9759a6ec/images/e761e511104e4df7883cdb638ed7cd8a33a85e3eda7fce3c057de430a930d418.png', 'sentiment': 'positive', 'sentiment_prob': 0.5587568879127502}","{'position': 6, 'link': 'https://www.nature.com/articles/bjc2015426', 'title': 'Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2 -positive breast cancers before and after trastuzumab era: results from a real-life cohort', 'source': 'Nature', 'date': 'Dec 10, 2015', 'snippet': 'Trastuzumab was introduced a decade ago and has improved outcomes for \nHER2-positive breast cancer. We investigated the factors predictive of...', 'thumbnail': 'https://serpapi.com/searches/6724a5bafc40bf9c9759a6ec/images/e761e511104e4df7a22aa4791be0834eb0ebdf477b86ca53817012188c3f39d2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5087625980377197}",,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'positive', 'neutral']",neutral,1
NCT01607957,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1414325', 'title': 'Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer', 'source': 'The New England Journal of Medicine', 'date': 'May 14, 2015', 'snippet': 'Early clinical trials conducted primarily in Japan have shown that TAS-102, \nan oral agent that combines trifluridine and tipiracil...', 'thumbnail': 'https://serpapi.com/searches/6724a5f1b4b72d4da19d6533/images/5dcfa2f3e82f3ed8694026204e23c00ac0abb988db4dd2e1d387b068ae29d4a7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9155271053314209}",,,,,,,,,,['neutral'],neutral,1
NCT04576988,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2213558', 'title': 'Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension', 'source': 'The New England Journal of Medicine', 'date': 'Mar 6, 2023', 'snippet': 'Sotatercept is a fusion protein that traps activins and growth \ndifferentiation factors involved in pulmonary arterial hypertension.', 'thumbnail': 'https://serpapi.com/searches/6724a60008abe4633d04cf57/images/dba6759850d16729b236c32fe5872abac9d648ca37ca4a9361d14c68a0bd610d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9086381196975708}","{'position': 2, 'link': 'https://www.biospace.com/drug-development/winrevair-sotatercept-is-now-authorized-for-use-in-canada-for-adults-with-pulmonary-arterial-hypertension', 'title': 'WINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension', 'source': 'BioSpace', 'date': 'Sep 4, 2024', 'snippet': 'KIRKLAND, QC, Sept. 4, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside \nof the United States and Canada, announced that WINREVAIR®...', 'thumbnail': 'https://serpapi.com/searches/6724a60008abe4633d04cf57/images/dba6759850d16729ace9bc3678a79d598fa2141c07256d3af5172e8ded419153.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7694499492645264}","{'position': 3, 'link': 'https://www.renalandurologynews.com/news/winrevair-approved-for-pulmonary-arterial-hypertension/', 'title': 'Winrevair Approved for Pulmonary Arterial Hypertension', 'source': 'Renal and Urology News', 'date': 'Apr 5, 2024', 'snippet': 'The Food and Drug Administration (FDA) has approved Winrevair™ \n(sotatercept-csrk) for the treatment of adults with pulmonary arterial...', 'thumbnail': 'https://serpapi.com/searches/6724a60008abe4633d04cf57/images/dba6759850d16729527de7f64bd168b7ee4451e92a4249721b9b64677eb3b2f3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8045995235443115}","{'position': 4, 'link': 'https://pulmonaryhypertensionnews.com/news/winrevair-pah-treatment-adults-available-soon-us/', 'title': 'Winrevair, PAH treatment for adults, likely available soon in US', 'source': 'Pulmonary Hypertension News', 'date': 'Apr 10, 2024', 'snippet': 'The PAH injection therapy, recently approved in U.S., is expected to be \navailable via CVS and Accredo pharmacies by late April, Merck says.', 'thumbnail': 'https://serpapi.com/searches/6724a60008abe4633d04cf57/images/dba6759850d167290385e8409c28bc6167c49b13f73eb75d95abf048d7770f94.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7326827645301819}","{'position': 5, 'link': 'https://pulmonaryhypertensionnews.com/news/treatment-safety-efficacy-sotatercept-affected-antibodies/', 'title': 'Treatment safety, efficacy of sotatercept not affected by antibodies', 'source': 'Pulmonary Hypertension News', 'date': 'Dec 20, 2023', 'snippet': ""Antibodies that targeted sotatercept were not found to affect the therapy's \nsafety or effectiveness in an analysis of a clinical trial."", 'thumbnail': 'https://serpapi.com/searches/6724a60008abe4633d04cf57/images/dba6759850d16729a6e271458f00d23b55761d799f5db98cf8ab0e9d159b44c2.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8010830879211426}","{'position': 6, 'link': 'https://pulmonaryhypertensionnews.com/news/model-predicts-sotatercept-therapy-extend-survival-pah-patients/', 'title': 'Model predicts sotatercept will extend survival in PAH patients', 'source': 'Pulmonary Hypertension News', 'date': 'Nov 8, 2023', 'snippet': 'A prediction model estimated that add-on sotatercept will prolong survival \nby threefold for pulmonary arterial hypertension (PAH) patients.', 'thumbnail': 'https://serpapi.com/searches/6724a60008abe4633d04cf57/images/dba6759850d1672963babaa7002f3e353cb4c712fbdc2621ff955570c5741cf8.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5423300266265869}",,,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03672604,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/nly01-fails-slow-motor-symptom-progression-phase-2-trial/', 'title': 'NLY01 fails to slow motor symptom progression in Phase 2 trial |...', 'source': ""Parkinson's News Today"", 'date': 'Mar 28, 2023', 'snippet': ""A Phase 2 clinical trial of Neuraly's NLY01 failed to show the experimental \ntherapy was superior to a placebo at significantly slowing motor..."", 'thumbnail': 'https://serpapi.com/searches/6724a608483e5b507c61e0fc/images/94cc9e97b86907edd3d0c75ca1bc453ac9b31da09264c7e47369ee5eb272ed16.png', 'sentiment': 'negative', 'sentiment_prob': 0.732501208782196}","{'position': 2, 'link': 'https://alzheimersnewstoday.com/news/fda-clears-neuraly-begin-phase-2b-clinical-trial-nly01-alzheimers-patients/', 'title': ""Neuraly Cleared by FDA for Phase 2 Trial of NLY01 in Alzheimer's Patients"", 'source': ""Alzheimer's News Today"", 'date': 'Nov 16, 2020', 'snippet': 'The U.S. Food and Drug Administration has given clearance for a Phase 2B \nclinical trial to evaluate the safety, tolerability, and efficacy...', 'thumbnail': 'https://serpapi.com/searches/6724a608483e5b507c61e0fc/images/94cc9e97b86907ed8889f455dd78ed060c66395f42ef2107da2622d9482fbf00.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8326922059059143}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT02546167,"{'position': 1, 'link': 'https://www.nature.com/articles/s41408-021-00469-5', 'title': 'CAR T-cell therapy in multiple myeloma: more room for improvement - Blood Cancer Journal', 'source': 'Nature', 'date': 'Apr 29, 2021', 'snippet': 'The emergence of various novel therapies over the last decade has changed \nthe therapeutic landscape for multiple myeloma. While the clinical...', 'thumbnail': 'https://serpapi.com/searches/6724a62ea869211c6ffe4ec4/images/5a170cc807c313df5f6638f1f41b6412b0c8b4e5332c22b8f9a0a380180439ae.png', 'sentiment': 'positive', 'sentiment_prob': 0.5632189512252808}",,,,,,,,,,['positive'],positive,1
NCT03792633,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.14132', 'title': 'Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia', 'source': 'Wiley Online Library', 'date': 'Dec 17, 2023', 'snippet': 'European Journal of Haematology is an international haematology journal for \nbasic & clinical research, covering all diseases of the blood,...', 'thumbnail': 'https://serpapi.com/searches/6724a66a0a545a252611fc33/images/9cf10dd09871a36e7444839c16e2c89da917da9e2878e5ebee239dd192cc02d1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9273737072944641}",,,,,,,,,,['neutral'],neutral,1
NCT05607680,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/easd-2024-innovent-shows-off-mazdutides-efficacy-in-diabetes-and-obesity/', 'title': 'EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity', 'source': 'Clinical Trials Arena', 'date': '1 month ago', 'snippet': ""The data from two Phase III trials demonstrated GLP-1/glucagon agonist's \nefficacy in reducing blood glucose and weight."", 'thumbnail': 'https://serpapi.com/searches/6724a68498d8dedb6c797900/images/83be1f6a5c74044a5a138734913c2d7a0f1a369960436eb3fdf78bff17bf4e52.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7004231810569763}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-demonstrates-80-2-reduction-in-liver-fat-content-in-exploratory-analysis-of-phase-3-weight-management-glory-1-study-at-ada-2024--302180984.html', 'title': 'Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024', 'source': 'PR Newswire', 'date': 'Jun 24, 2024', 'snippet': 'The results of the GLORY-1 study further support that mazdutide may promote \nliver fat metabolism through the stimulation of GCGR and significantly \nreduce liver...', 'thumbnail': 'https://serpapi.com/searches/6724a68498d8dedb6c797900/images/83be1f6a5c74044aba4bda7bf8149e3149565084edcd98d7cd53e586386bb613.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5326186418533325}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03006705,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/reports/adjuvant-nivolumab-gastric-gej-cancer-no-benefit/', 'title': 'No Benefit Seen With Adjuvant Nivolumab in Gastric/GEJ Cancer', 'source': 'Cancer Therapy Advisor', 'date': 'Jun 3, 2023', 'snippet': 'Adding nivolumab to adjuvant chemotherapy did not improve relapse-free \nsurvival in a phase 3 trial of patients with gastric/GEJ cancer.', 'thumbnail': 'https://serpapi.com/searches/6724a6a4e1c276ffd62e1bba/images/0263a471c31881a12268b7d4c4a516698a6a4c951ee37061164c658e8d050f82.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7482324838638306}",,,,,,,,,,['negative'],negative,0
NCT04410991,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/09/23/ectrims-2024-tolebrutinib-target-smoldering-inflammation-ms/', 'title': 'ECTRIMS 2024: Tolebrutinib may target smoldering inflammation', 'source': 'Multiple Sclerosis News Today', 'date': '1 month ago', 'snippet': 'The totality of data from Sanofi clinical trials indicates that \nTolebrutinib may target inflammation thought to contribute to MS...', 'thumbnail': 'https://serpapi.com/searches/6724a6ad0a545a252611fc49/images/1f57434d9ddcee8878bf27d925c5b2180b2d9a4741555d047ad611f5d7124b07.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9131849408149719}","{'position': 2, 'link': 'https://www.ajmc.com/view/tolebrutinib-96-week-mri-results-promising-for-the-investigational-btk-inhibitor', 'title': 'Tolebrutinib 96-Week MRI Results Promising for the Investigational BTK Inhibitor', 'source': 'AJMC', 'date': 'Apr 25, 2023', 'snippet': 'Two-year data on MRI, efficacy, and safety findings from the long-term \nsafety extension study of the investigational Bruton tyrosine kinase...', 'thumbnail': 'https://serpapi.com/searches/6724a6ad0a545a252611fc49/images/1f57434d9ddcee883d61400b9848ac46c416c9699168e1dc34f41e113d2e2752.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7719200253486633}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2020/12/14/sanofi-enrolling-for-2-gemini-clinical-trials-testing-experimental-tolebrutinib-vs-aubagio-for-relapsing-ms/', 'title': 'Sanofi Enrolling for 2 GEMINI Trials Testing Tolebrutinib vs. Aubagio for Relapsing MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 14, 2020', 'snippet': ""Sanofi Genzyme's global clinical trials GEMINI 1 and 2, comparing \ntolebrutinib versus Aubagio, are enrolling 1800 relapsing MS patients."", 'thumbnail': 'https://serpapi.com/searches/6724a6ad0a545a252611fc49/images/1f57434d9ddcee88c3a7ae6631b0ea6ecf50ab5d48309c166e7ee1fb317f0e72.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9530969858169556}","{'position': 4, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/10/16/ectrims-2023-tolebrutinib-prevents-relapses-lesions-3-years/', 'title': 'ECTRIMS 2023: Tolebrutinib found to show benefits for up to 3 years', 'source': 'Multiple Sclerosis News Today', 'date': 'Oct 16, 2023', 'snippet': 'Three years of treatment with tolebrutinib was linked to low relapses rates \nand few new brain lesions among relapsing MS patients,...', 'thumbnail': 'https://serpapi.com/searches/6724a6ad0a545a252611fc49/images/1f57434d9ddcee88d39e6c872fcc47bb3388f4fba0432af67710b0fb5e10c6f5.png', 'sentiment': 'positive', 'sentiment_prob': 0.7722958922386169}",,,,,,,"['neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT00473382,"{'position': 1, 'link': 'https://www.nature.com/articles/s41746-019-0172-3', 'title': 'Deep learning algorithm predicts diabetic retinopathy progression in individual patients | npj Digital Medicine', 'source': 'Nature', 'date': 'Sep 20, 2019', 'snippet': 'We describe an algorithm to predict DR progression by means of deep \nlearning (DL), using as input color fundus photographs (CFPs) acquired at a \nsingle visit...', 'thumbnail': 'https://serpapi.com/searches/6724b353f3cbfaa2d1619239/images/1d7a77ff4041f1ce57241338a1c87d3f15f99f5138d99843de7e3bccb2448274.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9201077818870544}",,,,,,,,,,['neutral'],neutral,1
NCT03239340,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-35961-y', 'title': 'Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer', 'source': 'Nature', 'date': 'Feb 27, 2023', 'snippet': 'Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor \n(EGFR-TKI), potently and selectively inhibits...', 'thumbnail': 'https://serpapi.com/searches/6724a6b55ddfbadb2e26240a/images/c64bfdc6b819084b3c4d2b9c4926d3087c6971fca62dfaf9c12a7f5579502d45.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6963797807693481}",,,,,,,,,,['neutral'],neutral,1
NCT03020615,"{'position': 1, 'link': 'https://sicklecellanemianews.com/news/sickle-cell-anemia-toddlers-benefit-from-maximal-hydroxyurea-doses/', 'title': 'Sickle Cell Anemia Toddlers Benefit from Maximal Hydroxyurea Doses, Study Finds', 'source': 'Sickle Cell Disease News', 'date': 'Mar 2, 2017', 'snippet': 'Read about a study that shows how maximizing hydroxyurea treatment in \ntoddlers with sickle cell anemia appears to be safe and beneficial.', 'thumbnail': 'https://serpapi.com/searches/6724a6c64a3fcf4960b581f1/images/b2d56c49f44d80a7b10d05d7104cd161219d3ce53aac339bc68e5950660a874a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7866051197052002}",,,,,,,,,,['positive'],positive,1
NCT04969939,"{'position': 1, 'link': 'https://www.nature.com/articles/s41366-024-01473-y', 'title': 'What is the pipeline for future medications for obesity? - International Journal of Obesity', 'source': 'Nature', 'date': 'Feb 1, 2024', 'snippet': 'In this review, we present the efficacy and safety data for the pipeline of \nobesity pharmacotherapies with a focus on entero-pancreatic hormone-based...', 'thumbnail': 'https://serpapi.com/searches/6724a6d523793852a787772e/images/c479ed4fda3e4771bdbb3e5f6164aba31f93b547dc63df84eef77b2f8a446e0d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9023082256317139}",,,,,,,,,,['neutral'],neutral,1
NCT02615847,"{'position': 1, 'link': 'https://sicklecellanemianews.com/memantine-for-sickle-cell-disease/', 'title': 'Memantine for sickle cell disease', 'source': 'Sickle Cell Disease News', 'date': 'Aug 8, 2024', 'snippet': ""Memantine, a common Alzheimer's therapy, is in clinical testing for \ntreating sickle cell patients by reducing calcium intake by blood cells."", 'thumbnail': 'https://serpapi.com/searches/6724a794f963e73c2b2ee9e2/images/ac7927c42c74ac4f7859ed0ae323e43df714ce2d26792dd25a28d3415df028eb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7642570734024048}","{'position': 2, 'link': 'https://sicklecellanemianews.com/news/sickle-cell-disease-therapy-candidate-memantine-alzheimers-treatment-shows-promise-clinical-trial/', 'title': ""SCD Therapy Candidate Memantine Has Long Been Used for Alzheimer's"", 'source': 'Sickle Cell Disease News', 'date': 'Nov 9, 2017', 'snippet': ""Memantine, a standard treatment for Alzheimer's disease, has shown promise \nin treating sickle cell disease (SCD) in six patients treated for..."", 'thumbnail': 'https://serpapi.com/searches/6724a794f963e73c2b2ee9e2/images/ac7927c42c74ac4ffcd9a3806b7f17657a30e7d82ef7b36e259479bee7a35250.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7553415298461914}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03649477,"{'position': 1, 'link': 'https://praderwillinews.com/news/fda-wants-additional-trial-pws-nasal-spray-lv-101-confirm-efficacy/', 'title': 'FDA Wants Additional Trial of PWS Nasal Spray LV-101 to Confirm Efficacy', 'source': 'Prader-Willi Syndrome News', 'date': 'Jan 20, 2022', 'snippet': 'The US Food and Drug Administration (FDA) has told Levo Therapeutics that \nan additional clinical trial will be necessary to confirm the efficacy of \nLV-101.', 'thumbnail': 'https://serpapi.com/searches/6724a79748e6689eaf0fa090/images/0fe1c06163e76725df27a188a04a7d78187c26f845841ac1a7a3a90a69c3db3e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8743943572044373}","{'position': 2, 'link': 'https://praderwillinews.com/news/acadia-trial-testing-carbetocin-nasal-spray-hyperphagia-pws/', 'title': 'New Acadia trial testing carbetocin nasal spray to treat insatiable hunger in PWS', 'source': 'Prader-Willi Syndrome News', 'date': 'Dec 7, 2023', 'snippet': 'Acadia Pharmaceuticals has launched a Phase 3 clinical trial testing the \nsafety and efficacy of ACP-101, an experimental carbetocin nasal spray, for \nthe...', 'thumbnail': 'https://serpapi.com/searches/6724a79748e6689eaf0fa090/images/0fe1c06163e767253254a127e50bafe711346ffa4f50669a67edd7d96199a53f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8832798004150391}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03422653,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1912770', 'title': 'A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus', 'source': 'The New England Journal of Medicine', 'date': 'Nov 8, 2019', 'snippet': 'Difelikefalin is a peripherally restricted and selective agonist of kappa \nopioid receptors that are considered to be important in modulating pruritus \nin...', 'thumbnail': 'https://serpapi.com/searches/6724b31cadc33b8213216a3e/images/cb28385c312f2e9e39d1471fb82df3f930d25e15c5fcdd68fc07279e5cd2d73c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9009538888931274}","{'position': 2, 'link': 'https://www.empr.com/home/news/korsuva-approved-for-chronic-kidney-disease-associated-pruritus/', 'title': 'Korsuva Approved for Chronic Kidney Disease-Associated Pruritus', 'source': 'Medical Professionals Reference', 'date': 'Aug 24, 2021', 'snippet': 'The Food and Drug Administration has approved Korsuva™ (difelikefalin) \ninjection for the treatment of moderate to severe pruritus associated...', 'thumbnail': 'https://serpapi.com/searches/6724b31cadc33b8213216a3e/images/cb28385c312f2e9e854e1f1b80b190bcad167207dd52a173c9fddf664bb87ef8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.87298184633255}","{'position': 3, 'link': 'https://www.drugtopics.com/view/fda-approves-treatment-for-uremic-pruritis', 'title': 'FDA Approves Treatment for Uremic Pruritis', 'source': 'Drug Topics', 'date': 'Apr 5, 2022', 'snippet': 'The FDA approved difelikefalin (Korsuva) for the treatment of moderate to \nsevere pruritis associated with chronic kidney disease (CKD) in adults \nundergoing...', 'thumbnail': 'https://serpapi.com/searches/6724b31cadc33b8213216a3e/images/cb28385c312f2e9ee57f4c7aadf551cefa7da88c071b789cf55c6d10c57431e6.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8146046996116638}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT04408794,"{'position': 1, 'link': 'https://www.researchgate.net/publication/372852978_Zavegepant_intranasal_spray_for_the_Acute_Treatment_of_Migraine_A_Systematic_Review_and_Meta-Analysis_of_Randomized_Clinical_Trials', 'title': '(PDF) Zavegepant intranasal spray for the Acute Treatment of Migraine : A Systematic Review and Meta-Analysis of Randomized Clinical Trials', 'source': 'ResearchGate', 'date': 'Aug 2, 2023', 'snippet': 'PDF | Migraine is a prevalent and debilitating primary headache disorder \nwith signi cant socioeconomic and personal impacts. This study aims...', 'thumbnail': 'https://serpapi.com/searches/6724b32a81262a4ea1a2e69b/images/8855906a9fd7c1ff16fdf982baef997f673daf3158c6bd0a969cdb16a5454c32.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8745222687721252}",,,,,,,,,,['neutral'],neutral,1
NCT03416179,"{'position': 1, 'link': 'https://www.nature.com/articles/s41375-023-02001-z', 'title': 'Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial', 'source': 'Nature', 'date': 'Aug 21, 2023', 'snippet': 'This is the primary report of the randomized, placebo-controlled phase 3 \nBRIGHT AML 1019 clinical trial of glasdegib in combination with...', 'thumbnail': 'https://serpapi.com/searches/6724b3314300ce12705b01fe/images/7c63d8a0815b3c64d63f64be4d227ed78d13783ee77218de52086584b2dd5f1e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9324925541877747}",,,,,,,,,,['neutral'],neutral,1
NCT03991143,"{'position': 1, 'link': 'https://www.nature.com/articles/s44161-022-00049-1', 'title': 'The why and how of adaptive immune responses in ischemic cardiovascular disease', 'source': 'Nature', 'date': 'Apr 21, 2022', 'snippet': 'Atherosclerotic cardiovascular disease is a major cause of disability and \ndeath worldwide. Most therapeutic approaches target traditional...', 'thumbnail': 'https://serpapi.com/searches/6724b340e1d1ad2e67b3297c/images/1e5819e4d4a8f9493ec29e24157ea237d9b01799cf0197487de56cac46bb6dd4.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6567900776863098}",,,,,,,,,,['negative'],negative,0
NCT02099747,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2109965', 'title': 'Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia', 'source': 'The New England Journal of Medicine', 'date': 'Jan 5, 2022', 'snippet': 'A single-group, phase 1–2 study indicated that eltrombopag improved the \nefficacy of standard immunosuppressive therapy that entailed horse...', 'thumbnail': 'https://serpapi.com/searches/6724a7047ac731fa405270b4/images/7079dc41f363f679ac02e2e3029e49161752fa76d7b278c027a21764258a79b9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7934905290603638}",,,,,,,,,,['neutral'],neutral,1
NCT04134091,"{'position': 1, 'link': 'https://www.biospace.com/lipocine-announces-positive-lpcn-2401-clinical-results-showing-improved-body-composition-in-participants-with-obesity', 'title': 'Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity', 'source': 'BioSpace', 'date': 'Apr 11, 2024', 'snippet': 'Lipocine Inc., a biopharmaceutical company, announced results from a Phase \n2 clinical trial which includes LPCN 2401, an oral proprietary...', 'thumbnail': 'https://serpapi.com/searches/6724a705131502700ed6664a/images/367d5dd8dfba9d83d49890f2cb36dfc25141fc24ed592eff985a34ec051efeb1.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6248332858085632}",,,,,,,,,,['positive'],positive,1
NCT01684241,"{'position': 1, 'link': 'https://www.nature.com/articles/srep22509', 'title': 'Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours', 'source': 'Nature', 'date': 'Mar 2, 2016', 'snippet': 'The lack of appropriate mouse models is likely one of the reasons of a \nlimited translational success rate of therapeutic vaccines against...', 'thumbnail': 'https://serpapi.com/searches/6724a72230dfc1bbc8a085b8/images/8a7ceede7dbe49c6639b40f02f95dfdb666dc1da1957b7900ec2ddf822b33de3.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6804020404815674}",,,,,,,,,,['negative'],negative,0
NCT05514548,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/novo-nordisk-weight-loss-drug-questions-remain/', 'title': 'Questions over Novo Nordisk $1bn weight loss drug after Phase IIa trial', 'source': 'Clinical Trials Arena', 'date': '1 month ago', 'snippet': 'Novo Nordisk acquired monlunabant in a $1bn deal in 2023, but the Phase IIa \ntrial raises questions over the efficacy and safety ratio.', 'thumbnail': 'https://serpapi.com/searches/6724a731310300dc7f4f1315/images/b370adf81c1da88be13ae2e8043587fdfe270dc2c5ce413cf278e791d9692375.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8579468727111816}",,,,,,,,,,['neutral'],neutral,1
NCT03312231,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/h7n9-influenza-vaccine-clinical-trials-begin', 'title': 'H7N9 influenza vaccine clinical trials begin', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Mar 15, 2018', 'snippet': 'Two new clinical trials testing an experimental vaccine to prevent \ninfluenza caused by an H7N9 influenza virus are now enrolling volunteers at \nsites across the...', 'thumbnail': 'https://serpapi.com/searches/6724a73d7a12fda58f0b73b4/images/4688009fe14d154ac045677629e1f97bd3735e34957e9733aeb90e5c1dccc053.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9034222364425659}",,,,,,,,,,['neutral'],neutral,1
NCT04838405,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/roche-targets-obesity-market-with-early-positive-trial-data/', 'title': 'Roche targets obesity market with early positive trial data', 'source': 'Clinical Trials Arena', 'date': 'May 16, 2024', 'snippet': ""Roche's GLP-1/GIP receptor agonist, which it gained in the Carmot \nacquisition, showed 18.8% weight loss in a Phase Ib trial."", 'thumbnail': 'https://serpapi.com/searches/6724a77f7f371998d77793b1/images/975bd46c111f6be39378632cca6cf1b12873ccdcfb198628c96cff9a4b99131c.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6271388530731201}",,,,,,,,,,['positive'],positive,1
NCT05006352,"{'position': 1, 'link': 'https://alsnewstoday.com/news/dnl343-well-tolerated-interim-als-clinical-trial-data/', 'title': 'DNL343 Well-tolerated, Interim ALS Clinical Trial Data Show', 'source': 'ALS News Today', 'date': 'Dec 15, 2022', 'snippet': 'DNL343 can enter the brain and reduce the cellular stress response that \ncontributes to disease progression, ALS clinical trial analysis...', 'thumbnail': 'https://serpapi.com/searches/6724a77fb57db83e86a1eaa6/images/1f7b08faf9ab3c60ddba8719da16b1bd1b12e491114d2c4f30417203f667b699.png', 'sentiment': 'positive', 'sentiment_prob': 0.5634855628013611}",,,,,,,,,,['positive'],positive,1
NCT03673670,"{'position': 1, 'link': 'https://copdnewstoday.com/news/ensifentrine-as-add-on-maintenance-therapy-shows-benefits-in-phase-2-trial/', 'title': 'COPD Patients Benefit Using Ensifentrine as Add-on Therapy in Phase 2 Trial, Verona Pharma Says', 'source': 'COPD News Today', 'date': 'Jan 25, 2019', 'snippet': 'Data from a three-day Phase 2 clinical trial offered positive results for \nnebulized ensifentrine (RPL544) as an add-on treatment for chronic \nobstructive...', 'thumbnail': 'https://serpapi.com/searches/6724a7c948c4292d95eb3e28/images/75be26e02c2b2df4f92abc2b315f7eed20815eec73c8af56d2323917e61d26db.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5392691493034363}","{'position': 2, 'link': 'https://copdnewstoday.com/news/verona-pharma-rpl554-copd-named-ensifentrine/', 'title': 'Verona Pharma’s Candidate RPL554 for COPD Will Be Named Ensifentrine', 'source': 'COPD News Today', 'date': 'Jan 15, 2019', 'snippet': ""The World Health Organization approved the name ensifentrine for Verona \nPharma's investigational bronchodilator and anti-inflammatory agent,..."", 'thumbnail': 'https://serpapi.com/searches/6724a7c948c4292d95eb3e28/images/75be26e02c2b2df42fcb4488aa57399faee668abfa0ed47ea4d37b79272debd2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8575579524040222}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT01346358,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Dose-Cohort-Assignment-QW-weekly-Q2W-every-2weeks_fig1_349542499', 'title': 'Dose Cohort Assignment. QW: weekly; Q2W: every 2 weeks', 'source': 'ResearchGate', 'date': 'Jun 13, 2021', 'snippet': 'This phase 1 study determined the safety, tolerability, \npharmacokinetics-pharmacodynamics, immunogenicity, and efficacy of the \nanti–CSF-1R antibody LY3.', 'thumbnail': 'https://serpapi.com/searches/6724a8033c9575fb6f910a49/images/2af96679d363288d2a311111ecad6fa573fdef6d31222c4715710d9894468454.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8917114734649658}",,,,,,,,,,['neutral'],neutral,1
NCT01447017,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-023-41581-9', 'title': 'Novel cationic cryptides in Penaeus vannamei demonstrate antimicrobial and anti-cancer activities', 'source': 'Nature', 'date': 'Sep 6, 2023', 'snippet': 'In the current study, we employed an in silico approach to identify novel \ncationic cryptides with potential antimicrobial and anti-cancer activities.', 'thumbnail': 'https://serpapi.com/searches/6724a825642c31cda3d5d41d/images/12c422b3616a3d26c3e7dd44cdce7f2c9831b7b1297bab93dc99e58e01af99b4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8964999914169312}",,,,,,,,,,['neutral'],neutral,1
NCT02443961,"{'position': 1, 'link': 'https://www.nature.com/articles/pr2017237', 'title': 'Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: a clinical review', 'source': 'Nature', 'date': 'Oct 25, 2017', 'snippet': 'Advances in neonatal medicine have led to increased survival of infants \nborn at the limits of viability, resulting in an increased incidence...', 'thumbnail': 'https://serpapi.com/searches/6724a8398a7c09b49ca09aab/images/a7621a66e827c31e9a775a661abad0324a21546a1f0fc3aeea01c27038b507de.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8349394202232361}",,,,,,,,,,['neutral'],neutral,1
NCT04973449,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00177-5/fulltext', 'title': 'Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immuno', 'source': 'The Lancet', 'date': 'Sep 29, 2023', 'snippet': 'A multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority \nimmunobridging study in the UK and Poland', 'thumbnail': 'https://serpapi.com/searches/6724a85af79a0107d03b7138/images/806d734610e2f155cc32d722ebc6015b0bfd0efbd4f9e156ff9b37ea21ea1509.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8618715405464172}",,,,,,,,,,['neutral'],neutral,1
NCT04398433,"{'position': 1, 'link': 'https://www.empr.com/home/news/ino-3107-recurrent-respiratory-papillomatosis-breakthrough-status/', 'title': 'DNA Therapy Gets Breakthrough Status for Recurrent Respiratory Papillomatosis', 'source': 'Medical Professionals Reference', 'date': 'Sep 7, 2023', 'snippet': 'The Food and Drug Administration (FDA) has granted Breakthrough Therapy \ndesignation to INO-3107 for the treatment of recurrent respiratory \npapillomatosis.', 'thumbnail': 'https://serpapi.com/searches/6724a8681397ba76bd3ea7f2/images/98e68753d95aba31e9416952885eb47610e5168087e3fe855900d9e28df7b80b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6652581095695496}",,,,,,,,,,['neutral'],neutral,1
NCT04163016,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/Cimzia', 'title': 'Certolizumab Pegol (Cimzia®)', 'source': 'UCB', 'date': 'Oct 12, 2018', 'snippet': 'Axial Spondyloarthritis, Certolizumab Pegol in Subjects With Active Axial \nSpondyloarthritis, Phase 3, AKS001 Completed, NCT01087762 · 2009-011719-19 \n· LINK', 'thumbnail': 'https://serpapi.com/searches/6724a8729936886f9ed7a89c/images/350149cb62698a4ef1f6f8636d3b1645c397203b77250cea659898498b351ea8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9130622744560242}",,,,,,,,,,['neutral'],neutral,1
NCT01433497,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2023/01/03/masitinib-okd-fda-progressive-ms-phase-3-clinical-trial/', 'title': 'FDA OKs Phase 3 Trial of Masitinib for Progressive Forms of MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Jan 3, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has cleared AB Science to \ninitiate a Phase 3 clinical trial of its investigational treatment \nmasitinib in people with...', 'thumbnail': 'https://serpapi.com/searches/6724a8b6400bd547f112ff8e/images/0069713955960144f73afcd25d21a638f1a3098472a98e3ef9ddf2dc859283e0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8227587342262268}",,,,,,,,,,['neutral'],neutral,1
NCT04411641,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/sanofis-eyes-approval-after-ms-therapy-slows-disease-progression-by-31/', 'title': 'Sanofi’s eyes approval after MS therapy slows disease progression by 31%', 'source': 'Clinical Trials Arena', 'date': '1 month ago', 'snippet': 'After missing primary endpoints in relapsing forms of MS, tolebrutinib has \nproved its efficacy in secondary progressive MS patients.', 'thumbnail': 'https://serpapi.com/searches/6724a8c18d147358ee7a5fd5/images/2ffc77b3f9a8ea054bbcd3ac15422ce140b331334c94ad8ebb396f3bb8643afc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.4900601804256439}",,,,,,,,,,['neutral'],neutral,1
NCT01591447,"{'position': 1, 'link': 'https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6206a3.htm', 'title': 'CDC Grand Rounds: The Growing Threat of Multidrug-Resistant Gonorrhea', 'source': 'Centers for Disease Control and Prevention (.gov)', 'date': 'Feb 15, 2013', 'snippet': 'Although gonorrhea has afflicted humans for centuries, and the causative \nbacterium, Neisseria gonorrhoeae, was identified more than a...', 'thumbnail': 'https://serpapi.com/searches/6724a8c2b9458d2b838d0d62/images/dd42b25565316aeacf7f170167b4da2588e7d58d5501442fd644091b59f52856.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6991466879844666}",,,,,,,,,,['neutral'],neutral,1
NCT04410978,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2022/07/01/phase-3-tolebrutinib-trials-pause-us-enrollment-over-safety-concerns/', 'title': 'Phase 3 Tolebrutinib Trials Pause US Enrollment Over Safety Concerns | FDA Clinical Hold', 'source': 'Multiple Sclerosis News Today', 'date': 'Jul 1, 2022', 'snippet': 'The U.S. Food and Drug Administration (FDA) has placed a partial clinical \nhold on Phase 3 trials testing the investigational therapy...', 'thumbnail': 'https://serpapi.com/searches/6724a8ee765857d78c8a9216/images/c90b3faae99c658243650d539bc4053fe30febe3fabf7166d2b7d9d7bb8ccded.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6464643478393555}","{'position': 2, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2024/09/23/ectrims-2024-tolebrutinib-target-smoldering-inflammation-ms/', 'title': 'ECTRIMS 2024: Tolebrutinib may target smoldering inflammation', 'source': 'Multiple Sclerosis News Today', 'date': '1 month ago', 'snippet': 'The totality of data from Sanofi clinical trials indicates that \nTolebrutinib may target inflammation thought to contribute to MS...', 'thumbnail': 'https://serpapi.com/searches/6724a8ee765857d78c8a9216/images/c90b3faae99c658221a57eb8ec4884b1be42c939ccff31e81c39a5f027330b18.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9131849408149719}","{'position': 3, 'link': 'https://multiplesclerosisnewstoday.com/news-posts/2020/12/14/sanofi-enrolling-for-2-gemini-clinical-trials-testing-experimental-tolebrutinib-vs-aubagio-for-relapsing-ms/', 'title': 'Sanofi Enrolling for 2 GEMINI Trials Testing Tolebrutinib vs. Aubagio for Relapsing MS', 'source': 'Multiple Sclerosis News Today', 'date': 'Dec 14, 2020', 'snippet': ""Sanofi Genzyme's global clinical trials GEMINI 1 and 2, comparing \ntolebrutinib versus Aubagio, are enrolling 1800 relapsing MS patients."", 'thumbnail': 'https://serpapi.com/searches/6724a8ee765857d78c8a9216/images/c90b3faae99c65828edcf6f728ee922e59fd9fbe43a677ed8033a75b9efe6ec1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9530969858169556}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02855125,"{'position': 1, 'link': 'https://www.nature.com/articles/s41523-021-00245-5', 'title': 'Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer', 'source': 'Nature', 'date': 'Apr 6, 2021', 'snippet': 'Triple-negative breast cancer (TNBC) remains the most lethal breast cancer \nsubtype with poor response rates to the current chemotherapies...', 'thumbnail': 'https://serpapi.com/searches/6724a8f5eda5f575176c9c4c/images/b910b909371115fa359f7679086cc19a4a3ea8d6f76be6ec131f2e822f141e36.png', 'sentiment': 'neutral', 'sentiment_prob': 0.49946093559265137}",,,,,,,,,,['neutral'],neutral,1
NCT04552418,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.221', 'title': 'Human microbiomes in cancer development and therapy - Xia - 2023 - MedComm', 'source': 'Wiley Online Library', 'date': 'Feb 26, 2023', 'snippet': 'MedComm is a multidisciplinary open access journalpublishing pioneering \nmedical science advances that will improve human health.', 'thumbnail': 'https://serpapi.com/searches/6724a909e30abc589dd7d307/images/a33bb9fafee822c23ca6a0c7776d762ab4f8270dbd9133bff382f195777f9257.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5362311005592346}",,,,,,,,,,['positive'],positive,1
NCT05812781,"{'position': 1, 'link': 'https://www.nature.com/articles/s12276-024-01261-8', 'title': 'NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders', 'source': 'Nature', 'date': 'Jul 1, 2024', 'snippet': 'Proinflammatory cytokines and chemokines play a crucial role in regulating \nthe inflammatory response, which is essential for the proper...', 'thumbnail': 'https://serpapi.com/searches/6724a95293584c8fed18cba6/images/a4913ed42aee8148df453ddf3f87cadd92ca0d2363dc29fe877e1599744a6826.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8756292462348938}",,,,,,,,,,['neutral'],neutral,1
NCT03199872,"{'position': 1, 'link': 'https://prostatecancernewstoday.com/2020/12/08/fda-puts-rv001-on-fast-track-for-treating-prostate-cancer/', 'title': 'FDA Puts RV001 on Fast Track for Treating Prostate Cancer', 'source': 'Prostate Cancer News Today', 'date': 'Dec 8, 2020', 'snippet': ""The U.S. Food and Drug Administration (FDA) has granted fast track status \nto RV001, RhoVac's investigational therapy for prostate cancer,..."", 'thumbnail': 'https://serpapi.com/searches/6724b2cc7ef9fa423a835ff8/images/df4fbdd745114945855641b13293d9c273a019b69a0a5c0138c17fb7971b3a90.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8284792304039001}",,,,,,,,,,['neutral'],neutral,1
NCT01597245,"{'position': 1, 'link': 'https://psoriasisnewstoday.com/2017/02/14/study-shows-retreatment-of-psoriasis-with-taltz-after-interruption-of-therapy-is-effective/', 'title': 'Retreatment of Psoriasis with Taltz after Interruption in Therapy Is Effective, Study Suggests', 'source': 'Psoriasis News Today', 'date': 'Feb 14, 2017', 'snippet': 'Retreatment with Taltz (ixekizumab), after the end of initial treatment led \nto a relapse, restored response in most psoriasis patients, according to a \nstudy.', 'thumbnail': 'https://serpapi.com/searches/6724b2eb7d533ee69a85183b/images/cc4be809724bab1f845e5921630d21bd6af529f47495677af6bacc29b9dd00fb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6104496717453003}",,,,,,,,,,['neutral'],neutral,1
NCT02006472,"{'position': 1, 'link': 'https://huntingtonsdiseasenews.com/news/huntexil-decline-total-functional-capacity-huntingtons-trial-analysis/', 'title': 'Pridopidine Analysis Shows Slowed Decline in Total Functional Capacity', 'source': ""Huntington's Disease News"", 'date': 'Jan 12, 2021', 'snippet': ""Treatment with pridopidine can slow the decline in total functional \ncapacity in people with Huntington's disease, a new analysis of clinical \ntrial data..."", 'thumbnail': 'https://serpapi.com/searches/6724a960e1c276ffa027faa6/images/9d759da34e4d0883c8da2153c1403917e3508319ef73345f7850bcd605f42c50.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7453720569610596}",,,,,,,,,,['neutral'],neutral,1
NCT05425745,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/newamsterdam-cholesterol-busting-drug-success-pivotal/', 'title': 'NewAmsterdam triumphs in first Phase III trial of cholesterol-busting drug', 'source': 'Clinical Trials Arena', 'date': 'Jul 30, 2024', 'snippet': 'NewAmsterdam Pharma announced a win in the first of its four Phase III, \npivotal trials, showing its lead cardio candidate obicetrapib can reduce \ncholesterol...', 'thumbnail': 'https://serpapi.com/searches/6724a984657c661da9d544fb/images/876c5ac92736b4f6c365326917fc04e696638cca8ca05bbc79f418244db734d6.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.9012768268585205}","{'position': 2, 'link': 'https://finance.yahoo.com/news/newamsterdam-pharma-announce-topline-data-200100506.html', 'title': 'NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024', 'source': 'Yahoo Finance', 'date': 'Jul 26, 2024', 'snippet': 'Company to host conference call on Monday, July 29 at 8:30 a.m. ETNAARDEN, \nthe Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE)...', 'thumbnail': 'https://serpapi.com/searches/6724a984657c661da9d544fb/images/876c5ac92736b4f6e74aebe55bbfe97c38c344937f95c23a66b8f5f784c8a45e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9094988703727722}","{'position': 3, 'link': 'https://www.thepharmaletter.com/newamsterdam-phase-3-obicetrapib-trial-meets-endpoint-but-disappoints', 'title': 'NewAmsterdam Phase III obicetrapib trial meets endpoint, but disappoints', 'source': 'The Pharma Letter', 'date': 'Jul 29, 2024', 'snippet': ""Dutch drug developer NewAmsterdam Pharma today announced what it called \npositive top-line data from the company's Phase III BROOKLYN..."", 'thumbnail': 'https://serpapi.com/searches/6724a984657c661da9d544fb/images/876c5ac92736b4f60cb08af1e750cf11501e89edb404856ae2df55dbb777b7ec.png', 'sentiment': 'neutral', 'sentiment_prob': 0.47724267840385437}",,,,,,,,"['positive', 'neutral', 'neutral']",neutral,1
NCT04106557,"{'position': 1, 'link': 'https://angelmansyndromenews.com/news/final-trial-data-support-ovid-decision-stop-ov101-clinical/', 'title': 'Trial data support Ovid’s decision to stop its OV101 program in 2021', 'source': 'angelmansyndromenews.com', 'date': 'Aug 23, 2023', 'snippet': ""Final trial results have now been published that support Ovid Therapeutics' \ndecision to stop clinical testing of OV101 for Angelman..."", 'thumbnail': 'https://serpapi.com/searches/6724a99b358539552e83d3fc/images/e6aa35a846864260b0ebb9f65e58ca30a520452c5470ff2f6fe88eb9b6d1a50a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8800973892211914}",,,,,,,,,,['neutral'],neutral,1
NCT04383574,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Examples-of-marketed-Vero-cell-based-vaccines_tbl1_343465585', 'title': 'Examples of marketed Vero cell-based vaccines.', 'source': 'ResearchGate', 'date': 'Sep 21, 2020', 'snippet': 'The Vero cell line is considered the most used continuous cell line for the \nproduction of viral vectors and vaccines.', 'thumbnail': 'https://serpapi.com/searches/6724b2b7b4fe87c770de3eb3/images/f9e8e5db90b9aa7f58319a25a8472fb007840084f22b9ddbf313c0672405c77f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8455920219421387}",,,,,,,,,,['neutral'],neutral,1
NCT00412984,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1107039', 'title': 'Apixaban versus Warfarin in Patients with Atrial Fibrillation', 'source': 'The New England Journal of Medicine', 'date': 'Aug 30, 2011', 'snippet': 'In patients with atrial fibrillation, apixaban was superior to warfarin in \npreventing stroke or systemic embolism, caused less bleeding, and resulted \nin lower...', 'thumbnail': 'https://serpapi.com/searches/6724a9c5f9f904fdc2c993e6/images/6958fac5453301002bcfcfe4f25f48ba1c4ae714e56d2998536fc42319bb611e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8256852626800537}",,,,,,,,,,['neutral'],neutral,1
NCT03450057,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.27001', 'title': 'Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study', 'source': 'Wiley Online Library', 'date': 'Jun 21, 2023', 'snippet': 'Up to half of multiple myeloma (MM) patients present with renal impairment \n(RI) at the time of diagnosis and 2%–4% require dialysis.', 'thumbnail': 'https://serpapi.com/searches/6724a9d108abe4630ef2856d/images/8410b8d806f6d4a778f4e45d581fbc8c7fdbb545d4483798ab6523417d1bcf67.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8698297142982483}",,,,,,,,,,['neutral'],neutral,1
NCT03175367,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2031049', 'title': 'Evinacumab in Patients with Refractory Hypercholesterolemia', 'source': 'The New England Journal of Medicine', 'date': 'Nov 15, 2020', 'snippet': 'Patients with refractory hypercholesterolemia, who have high low-density \nlipoprotein (LDL) cholesterol levels despite treatment with...', 'thumbnail': 'https://serpapi.com/searches/6724a9d821e77b2811aab280/images/851ab845f76a5096bf2edd357d35debb95c983ff703b2aa0e8c1b33047b15bb5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.706250011920929}",,,,,,,,,,['neutral'],neutral,1
NCT04498832,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S0264410X23002256', 'title': 'Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial', 'source': 'ScienceDirect.com', 'date': 'Mar 10, 2023', 'snippet': 'IIV4-HD provided superior immunogenicity versus IIV4-SD and was well \ntolerated in participants ≥ 60 years of age in Japan.', 'thumbnail': 'https://serpapi.com/searches/6724a9f2be324fe4ff07a783/images/a2dedf5eedc3b9580acecbc936f95822c245a2eda6ca495639551f5e7e766361.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5573321580886841}",,,,,,,,,,['neutral'],neutral,1
NCT03430297,"{'position': 1, 'link': 'https://www.onclive.com/view/toripalimab-snda-under-review-in-china-for-frontline-unresectable-or-metastatic-melanoma', 'title': 'Toripalimab sNDA Under Review in China for Frontline Unresectable or Metastatic Melanoma', 'source': 'OncLive', 'date': 'Aug 13, 2024', 'snippet': 'The National Medical Products Administration has accepted for review a \nsupplemental new drug application (sNDA) seeking the approval of...', 'thumbnail': 'https://serpapi.com/searches/6724a9fbacf7f8f9570db55c/images/182c0e0561f291187e0e719f107c35c7c5737d49085125ae54b8268a5aab7c14.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9305580854415894}",,,,,,,,,,['neutral'],neutral,1
NCT05710783,"{'position': 1, 'link': 'https://www.mountsinai.org/about/newsroom/2023/castlevax-inc-receives-barda-project-nextgen-award-valued-at-up-to-three-hundred-thirty-eight-million-to-advance-intranasal-ndvbased-covid-booster-vaccine-into-phase-twob-clinical-efficacy-testing', 'title': 'CastleVax Inc. Receives BARDA Project NextGen Award Valued at up to $338 Million to Advance Intranasal NDV-based COVID-19 Booster Vaccine into Phase 2b Clinical Efficacy Testing', 'source': 'Mount Sinai', 'date': 'Oct 17, 2023', 'snippet': 'CastleVax, a clinical stage vaccine platform company, has received a \nProject NexGen award valued at up to $338 million from the Biomedical...', 'thumbnail': 'https://serpapi.com/searches/6724a9fd0377569610781db2/images/f361b4d34203c9c2a982dc1b0c3f94cd45491edc311f0da388bdfc82319bdeeb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7130514979362488}","{'position': 2, 'link': 'https://www.businesswire.com/news/home/20240730713002/en/CastleVax-Inc.-Receives-34-Million-from-BARDA-to-Continue-Advancing-Intranasal-NDV-based-COVID-19-Vaccine-into-Phase-2b-Clinical-Efficacy-Testing', 'title': 'CastleVax Inc. Receives $34 Million from BARDA to Continue Advancing Intranasal NDV-based COVID-19 Vaccine into Phase 2b Clinical Efficacy Testing', 'source': 'Business Wire', 'date': 'Jul 30, 2024', 'snippet': 'CastleVax, a clinical stage mucosal vaccine platform company, has received \nan additional Project NextGen award valued at approximately $34...', 'thumbnail': 'https://serpapi.com/searches/6724a9fd0377569610781db2/images/f361b4d34203c9c2d5fd1e9b9ab908af3fe680b2d34c4ea8696096e040f9d2f5.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6780118346214294}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03969212,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/irv.13302', 'title': 'Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial', 'source': 'Wiley Online Library', 'date': 'May 6, 2024', 'snippet': 'Background The transmission of influenza virus in households, especially by \nchildren, is a major route of infection. Prior studies suggest...', 'thumbnail': 'https://serpapi.com/searches/6724aa0e6273fb687d1a9e47/images/a7697010f95a81a80d85eec73399938dd0ecae485d4b1f61e451c5915e533d00.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7998299598693848}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1915341', 'title': 'Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts', 'source': 'The New England Journal of Medicine', 'date': 'Jul 8, 2020', 'snippet': 'Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) \nendonuclease inhibitor with clinical efficacy in the treatment of...', 'thumbnail': 'https://serpapi.com/searches/6724aa0e6273fb687d1a9e47/images/a7697010f95a81a8bf94423b06c3e58120e6ea89fec26225555074433efb3a63.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8460713624954224}","{'position': 3, 'link': 'https://www.koreabiomed.com/news/articleView.html?idxno=20241', 'title': ""Influenza drug 'Xofluza' expands indication to over 1 year old in Europe"", 'source': 'KBR', 'date': 'Jan 13, 2023', 'snippet': ""Roche's influenza treatment Xofluza (baloxavir marboxil) has expanded its \nindication to children aged one or older in Europe."", 'thumbnail': 'https://serpapi.com/searches/6724aa0e6273fb687d1a9e47/images/a7697010f95a81a842cb9868804a3c220d3a5e17a9b68aa266c6eadac295ad32.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8793584108352661}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT03971422,"{'position': 1, 'link': 'https://myastheniagravisnews.com/rozanolixizumab-ucb7665/', 'title': 'Rystiggo (rozanolixizumab-noli) for myasthenia gravis', 'source': 'Myasthenia Gravis News', 'date': 'Jan 25, 2024', 'snippet': 'Rystiggo (rozanolixizumab-noli) is an injection therapy approved for adults \nwith generalized myasthenia gravis (gMG) who have antibodies against the...', 'thumbnail': 'https://serpapi.com/searches/6724aa265ddfbadb2e262508/images/2fec35aa7ef256d3870876259124e76d5a2c19266e8915c332426a1f522bc644.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8568547368049622}","{'position': 2, 'link': 'https://www.prnewswire.com/news-releases/ucb-announces-rozanolixizumab-bla-for-the-treatment-of-generalized-myasthenia-gravis-filed-with-us-fda-and-designated-for-priority-review-301714932.html', 'title': 'UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review', 'source': 'PR Newswire', 'date': 'Jan 6, 2023', 'snippet': 'Biologic License Application (BLA) designated Priority Review by FDA and \nseeks approval for rozanolixizumab for the treatment of adults with...', 'thumbnail': 'https://serpapi.com/searches/6724aa265ddfbadb2e262508/images/2fec35aa7ef256d3c8f594909d6605c5ca774648779da6c9f9ed958135ef3362.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9101318717002869}","{'position': 3, 'link': 'https://www.researchgate.net/figure/Targets-of-novel-therapeutic-agents-in-myasthenia-gravis_fig1_369801660', 'title': 'Figure 1 Targets of novel therapeutic agents in myasthenia gravis.', 'source': 'ResearchGate', 'date': 'Oct 29, 2023', 'snippet': 'Myasthenia gravis (MG), a prototype autoimmune neurological disease, had \nits therapy centred on corticosteroids, non-steroidal broad-spectrum \nimmunotherapy...', 'thumbnail': 'https://serpapi.com/searches/6724aa265ddfbadb2e262508/images/2fec35aa7ef256d3039d9b6ee2ebf78907a386bdcef2d56cd89767312c9de433.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8911361694335938}","{'position': 4, 'link': 'https://myastheniagravisnews.com/news/rystiggo-zilbrysq-ok-generalized-myasthenia-gravis-europe/', 'title': 'Rystiggo, Zilbrysq earn EU approvals for adults with gMG', 'source': 'Myasthenia Gravis News', 'date': 'Jan 11, 2024', 'snippet': 'The European Commission has approved Rystiggo (rozanolixizumab) as an \nadd-on to standard therapy for the treatment of certain adults with \ngeneralized...', 'thumbnail': 'https://serpapi.com/searches/6724aa265ddfbadb2e262508/images/2fec35aa7ef256d3eb97aa9105ffa883d4edbd5ea21556f28eb43f416017c6d1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8328337669372559}",,,,,,,"['neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02849457,"{'position': 1, 'link': 'https://www.uab.edu/news/research/item/13760-preventive-epilepsy-treatment-with-vigabatrin-does-not-improve-neurocognitive-development-in-tsc-infants', 'title': 'Preventive epilepsy treatment with vigabatrin does not improve neurocognitive development in TSC infants', 'source': 'University of Alabama at Birmingham', 'date': 'Sep 7, 2023', 'snippet': 'Infants with tuberous sclerosis complex, a rare genetic disorder, have a \nhigh risk of developing infantile spasms and developmental delay.', 'thumbnail': 'https://serpapi.com/searches/6724b249a8827886cf8fc778/images/3dd5302f436401b029a755ef768e63e2c45faef186c336430684dbff4c241998.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.8327239751815796}","{'position': 2, 'link': 'https://www.neurologylive.com/view/preventing-epilepsy-through-antiseizure-medication-tuberous-sclerosis-complex-gabrielle-rushing', 'title': 'Preventing Epilepsy Through Antiseizure Medication in Tuberous Sclerosis Complex: Gabrielle Rushing, PhD', 'source': 'Neurology live', 'date': 'Jan 3, 2023', 'snippet': 'The director of research at the TSC Alliance spoke with us at the 2022 AES \nConference about future research to be conducted on patients with...', 'thumbnail': 'https://serpapi.com/searches/6724b249a8827886cf8fc778/images/3dd5302f436401b014ca545cace8a7f7fe1d8a051727cbb7c3ad8d8aae19ea67.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8936330676078796}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT04527107,"{'position': 1, 'link': 'https://www.clinicaltrialsarena.com/news/oxurion-to-file-for-bankruptcy-following-trial-failure/', 'title': 'Oxurion to file for bankruptcy following trial failure', 'source': 'Clinical Trials Arena', 'date': 'Nov 20, 2023', 'snippet': ""Oxurion's diabetic macular oedema drug, THR-149, failed to meet its primary \nendpoint in the Phase IIb trial."", 'thumbnail': 'https://serpapi.com/searches/6724b25da5aae9cd06bcdc6f/images/5bdcde47f134616d525e44c974cc71a7469e2698655d3a2f93cc0149f894a086.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7903239727020264}",,,,,,,,,,['negative'],negative,0
NCT03733314,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2022.1022530/full', 'title': 'Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update', 'source': 'Frontiers', 'date': 'Apr 23, 2024', 'snippet': 'Inflammatory bowel diseases (IBD) are chronic disabling conditions with a \ncomplex and multifactorial etiology, which is still not completely \nunderstood.', 'thumbnail': 'https://serpapi.com/searches/6724b26535853982b117860f/images/e0392398319aea251f61e22e40f8c375498c21da2bb40ac83685e448ec5ad938.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6302504539489746}",,,,,,,,,,['neutral'],neutral,1
NCT00910650,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.669474/full', 'title': 'Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy', 'source': 'Frontiers', 'date': 'Feb 5, 2024', 'snippet': '1Clinical Science Division, Moffitt Cancer Center, Tampa, FL, United \nStates; 2Department of Biological Sciences, Kent State University, Kent, \nOH,...', 'thumbnail': 'https://serpapi.com/searches/6724aa2e7ebde5567687b396/images/53918067ed397da8b50fd1c0bc24f1766187f596303b13f44a1c2f0a70c6978c.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9343948364257812}",,,,,,,,,,['neutral'],neutral,1
NCT05076006,"{'position': 1, 'link': 'https://www.dermatologytimes.com/view/brepocitinib-shows-promising-results-for-treatment-of-cicatricial-alopecia', 'title': 'Brepocitinib Shows Promising Results for Treatment of Cicatricial Alopecia', 'source': 'Dermatology Times', 'date': '11 hours ago', 'snippet': ""The phase 2a trial demonstrated the systemic treatment's tolerable safety \nprofile for patients with chronic and progressive hair loss."", 'thumbnail': 'https://serpapi.com/searches/6724aa4b1315026fdb94bb5d/images/edb48d909f1ebcd2514b8a7a428dd109486b279c3899830238366cc9686ede4c.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.722811222076416}",,,,,,,,,,['positive'],positive,1
NCT02954536,"{'position': 1, 'link': 'https://www.onclive.com/view/dr-janjigian-on-pembrolizumab-trastuzumab-chemotherapy-in-her2-gastric-cancer', 'title': 'Dr Janjigian on Pembrolizumab/Trastuzumab/Chemotherapy in HER2+ Gastric Cancer', 'source': 'OncLive', 'date': 'Oct 27, 2023', 'snippet': 'Yelena Y. Janjigian, MD, discusses results from the primary \nprogression-free survival and interim overall survival analyses of the \nphase 3...', 'thumbnail': 'https://serpapi.com/searches/6724aa52d9c3e6cd2651b633/images/72011a88512b16041fcb1fda253a400f55b41c396fb2f9be66e3e81777cdd691.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9270865321159363}",,,,,,,,,,['neutral'],neutral,1
NCT01668784,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1510665', 'title': 'Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma', 'source': 'The New England Journal of Medicine', 'date': 'Nov 6, 2016', 'snippet': 'Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated \nwith encouraging overall survival in uncontrolled studies involving \npreviously...', 'thumbnail': 'https://serpapi.com/searches/6724aa60765857d753f25859/images/6ae9f3b284cb4177db0b65858c94a6352c47383acf4a7138c74a59188b80db03.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8807042241096497}",,,,,,,,,,['neutral'],neutral,1
NCT03525795,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-021-02181-7', 'title': 'EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine', 'source': 'Nature', 'date': 'Nov 23, 2021', 'snippet': 'Small intestinal neuroendocrine tumors (SI-NETs) are slow-growing tumors \nthat seem genetically quite stable without highly recurrent...', 'thumbnail': 'https://serpapi.com/searches/6724aa64a5aae9a0ed5c4428/images/271496383c05987d8b26dfb71ca633d6e2dcde39e53c2d691f8363281d711698.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8022369146347046}",,,,,,,,,,['neutral'],neutral,1
NCT04396756,"{'position': 1, 'link': 'https://pulmonaryfibrosisnews.com/news/high-dose-bexotegrast-continues-safe-effective-integris-ipf/', 'title': 'High-dose bexotegrast continues to be safe, effective for patients...', 'source': 'Pulmonary Fibrosis News', 'date': 'May 2, 2023', 'snippet': 'High-dose bexotegrast continues to be well-tolerated for up to about 10 \nmonths in IPF patients in the INTEGRIS-IPF study.', 'thumbnail': 'https://serpapi.com/searches/6724aa8766d995235efc7a18/images/d3513af2cf2d5d185a5c42fb1b97a2f577943b4e21e923b6d64f467a99c3e5ab.png', 'sentiment': 'positive', 'sentiment_prob': 0.8975121378898621}",,,,,,,,,,['positive'],positive,1
NCT04804605,"{'position': 1, 'link': 'https://www.contemporarypediatrics.com/view/roflumilast-cream-0-05-shows-long-term-efficacy-in-children-with-ad', 'title': 'Roflumilast cream 0.05% shows long-term efficacy in children with AD', 'source': 'Contemporary Pediatrics', 'date': 'Aug 28, 2024', 'snippet': 'Efficacy of roflumilast cream 0.05% improved over time among children aged \n2 to 5 years with mild to moderate atopic dermatitis.', 'thumbnail': 'https://serpapi.com/searches/6724b2333d629bb857628fc6/images/e2aa5204db79405d75d978b0325cec35edf23ec02a558c87e9f908759f6bb541.png', 'sentiment': 'positive', 'sentiment_prob': 0.7503613233566284}",,,,,,,,,,['positive'],positive,1
NCT02420821,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/atezolizumab-bevacizumab-demonstrates-comparable-os-to-sunitinib-for-metastatic-rcc', 'title': 'Atezolizumab/Bevacizumab Demonstrates Comparable OS to Sunitinib for Metastatic RCC', 'source': 'Cancer Network', 'date': 'Feb 22, 2022', 'snippet': 'The final analysis of the phase 3 IMmotion151 trial did not reveal a \nsignificant improvement in overall survival with atezolizumab plus...', 'thumbnail': 'https://serpapi.com/searches/6724aa9a717bff511bd207e7/images/2feb654599fa537412e3c195e08363860639a200905dfcf2803f3ed8deb4e49e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6603785157203674}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/journal-metastatic-renal-cell-carcinoma-with-sarcomatoid-features', 'title': 'Metastatic Renal Cell Carcinoma With Sarcomatoid Features', 'source': 'Cancer Network', 'date': 'Apr 15, 2022', 'snippet': 'In this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and \ncolleagues present a case of an 38-year-old woman who has a...', 'thumbnail': 'https://serpapi.com/searches/6724aa9a717bff511bd207e7/images/2feb654599fa537407fb391c37d45c169fc9fa836b9f9092da5391f54a8d3696.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9248615503311157}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01455701,"{'position': 1, 'link': 'https://juvenilearthritisnews.com/2019/09/10/tocilizumab-is-safe-and-effective-to-treat-sjia-infants-younger-than-2/', 'title': 'Tocilizumab Safe, Effective to Treat Systemic JIA Infants 2 and Younger', 'source': 'Juvenile Arthritis News', 'date': 'Sep 10, 2019', 'snippet': 'Data from a Phase 1 clinical trial demonstrated that treatment with \ntocilizumab is a safe and effective treatment for sJIA in infants...', 'thumbnail': 'https://serpapi.com/searches/6724aab29109860c4561e89b/images/4d45e0b33bec893bd0e96dd5e387327c66888c02664aea9241fa6982c670a140.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5793243646621704}",,,,,,,,,,['positive'],positive,1
NCT00091949,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1506930', 'title': 'Pioglitazone after Ischemic Stroke or Transient Ischemic Attack', 'source': 'The New England Journal of Medicine', 'date': 'Feb 17, 2016', 'snippet': 'Pioglitazone would reduce the rates of stroke and myocardial infarction \nafter ischemic stroke or TIA in patients without diabetes who have insulin \nresistance.', 'thumbnail': 'https://serpapi.com/searches/6724aabdf6aa53974ffe804a/images/3ebbacc17a70874092bce16c4a0f2dc611efd770100858e0ebfc662280dc9864.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7776960730552673}",,,,,,,,,,['neutral'],neutral,1
NCT03877510,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/sustained-parkinsons-symptom-control-seen-with-ipx203-rise-pd-extension/', 'title': ""Sustained Parkinson's symptom control seen with IPX203 in RISE-PD extension"", 'source': ""Parkinson's News Today"", 'date': 'Jan 3, 2024', 'snippet': 'The final published results of the extension study, which included 419 \nparticipants from RISE-PD, indicate IPX203 remained safe and...', 'thumbnail': 'https://serpapi.com/searches/6724aac6ea57e998e6b6d599/images/57a6b14659ef5adb159196a17173aebbbca7f62b9dc09f0229989b19bda9f837.png', 'sentiment': 'neutral', 'sentiment_prob': 0.826775312423706}",,,,,,,,,,['neutral'],neutral,1
NCT03873116,"{'position': 1, 'link': 'https://angioedemanews.com/news/hae-attacks-fall-long-term-orladeyo-use-phase-3-trial-japan/', 'title': 'HAE attacks in adults fall with long-term use of Orladeyo: Phase 3 trial', 'source': 'Angioedema News', 'date': 'Mar 25, 2024', 'snippet': 'Swelling attacks safely declined and life quality rose among adults in \nJapan treated with Orladeyo daily in a roughly 2-year clinical trial.', 'thumbnail': 'https://serpapi.com/searches/6724aac8483e5b507c61e1da/images/d6bc81b41c3a60084cd06bce449d469492dfe6d88fd5db9c76f730256cd5dda4.png', 'sentiment': 'negative', 'sentiment_prob': 0.55438232421875}",,,,,,,,,,['negative'],negative,0
NCT03524508,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/liposomal-irinotecan-plus-5-fu-lv-improves-survival-outcomes-in-biliary-tract-cancer', 'title': 'Liposomal Irinotecan Plus 5-FU/LV Improves Survival Outcomes in Biliary Tract Cancer', 'source': 'Cancer Network', 'date': 'Jun 5, 2021', 'snippet': 'Liposomal irinotecan (Onivyde) plus 5-fluorouracil/leucovorin (5-FU/LV) \nmproved progression-free survival (PFS) and overall survival (OS) in...', 'thumbnail': 'https://serpapi.com/searches/6724aac92c566d84e7d293ad/images/56e6413a31cec2531ec8317930faac2720556e90ce1a77a40b1ce3519dc50dc3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7090133428573608}",,,,,,,,,,['neutral'],neutral,1
NCT04634253,"{'position': 1, 'link': 'https://www.nejm.org/doi/abs/10.1056/NEJMoa2209856', 'title': 'A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis', 'source': 'The New England Journal of Medicine', 'date': 'Apr 12, 2024', 'snippet': 'Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate \nthe endogenous programmed cell death protein 1 (PD-1) inhibitory pathway.', 'thumbnail': 'https://serpapi.com/searches/6724aad0a5aae9a127b6a712/images/bc1d704b3ba3aaa8a0375ad979ae3a6268f5ea335759d50bfed51e240f9bbd8d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8992647528648376}","{'position': 2, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2209856', 'title': 'A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis', 'source': 'The New England Journal of Medicine', 'date': 'May 17, 2023', 'snippet': 'Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate \nthe endogenous programmed cell death protein 1 (PD-1) inhibitory...', 'thumbnail': 'https://serpapi.com/searches/6724aad0a5aae9a127b6a712/images/bc1d704b3ba3aaa812673eb4e1336e505aa8716a1c30f19d29c0204065a34899.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9060916304588318}","{'position': 3, 'link': 'https://www.prnewswire.com/news-releases/lillys-peresolimab-phase-2a-rheumatoid-arthritis-trial-published-in-the-new-england-journal-of-medicine-301827782.html', 'title': ""Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine"", 'source': 'PR Newswire', 'date': 'May 18, 2023', 'snippet': 'Peresolimab met the primary efficacy endpoint in patients with refractory \nrheumatoid arthritis (RA). Study evaluated a novel approach to treating \npatients with...', 'thumbnail': 'https://serpapi.com/searches/6724aad0a5aae9a127b6a712/images/bc1d704b3ba3aaa819490f7de8abb8c2d8ca135a5c7beadcd97f92240dd63cc7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6089026927947998}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02113982,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1815105', 'title': 'Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm', 'source': 'The New England Journal of Medicine', 'date': 'Apr 24, 2019', 'snippet': 'Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive \nhematologic cancer that is caused by transformed plasmacytoid...', 'thumbnail': 'https://serpapi.com/searches/6724aad1e6862b708a063a5c/images/a933e08089b84d3777d8ad79837bfab7aedb6a2c4506d84752d20150bad6cbb5.png', 'sentiment': 'negative', 'sentiment_prob': 0.6274949908256531}","{'position': 2, 'link': 'https://www.empr.com/home/news/elzonris-infusion-approved-for-aggressive-rare-blood-disease/', 'title': 'Elzonris Infusion Approved for Aggressive, Rare Blood Disease', 'source': 'Medical Professionals Reference', 'date': 'Dec 21, 2018', 'snippet': 'The Food and Drug Administration (FDA) has approved Elzonris \n(tagraxofusp-erzs; Stemline Therapeutics) infusion for the treatment of \nblastic plasmacytoid...', 'thumbnail': 'https://serpapi.com/searches/6724aad1e6862b708a063a5c/images/a933e08089b84d3704016c5a0668300589995cd530971f3491a2e1d33901b0b4.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8438403606414795}",,,,,,,,,"['negative', 'neutral']",negative,0
NCT04030143,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/safety-efficacy-aripiprazole-2-month-ready-to-use-960-mg/', 'title': 'Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg', 'source': 'Psychiatrist.com', 'date': 'Sep 4, 2023', 'snippet': 'Ari 2MRTU 960 was well tolerated in clinically stable patients with \nschizophrenia, with efficacy similar to AOM 400.', 'thumbnail': 'https://serpapi.com/searches/6724aae41fc7c5650202ed4f/images/509720ca3449900591984861a32eee5cb6f4d97d11d463a427b96f1497a2cfad.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5956546664237976}",,,,,,,,,,['positive'],positive,1
NCT03085095,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2004325', 'title': 'Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer', 'source': 'The New England Journal of Medicine', 'date': 'May 29, 2020', 'snippet': 'Injectable luteinizing hormone–releasing hormone agonists (e.g., \nleuprolide) are the standard agents for achieving androgen deprivation \nfor...', 'thumbnail': 'https://serpapi.com/searches/6724aba3213c874a9e41e8a8/images/8526a9359f8c95ee9405fcaf5d3332a0b356dd26aa496e7a37da0960387005d7.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7869049310684204}",,,,,,,,,,['neutral'],neutral,1
NCT04440592,"{'position': 1, 'link': 'https://sclerodermanews.com/news/mt-7117-reduces-symptoms-scleroderma-mouse-model/', 'title': 'MT-7117 Reduces Symptoms of Scleroderma in Mouse Model |...', 'source': 'Scleroderma News', 'date': 'Sep 20, 2022', 'snippet': 'Treatment with the experimental therapy reduced lung inflammation, skin \nfibrosis, and blood vessel impairment in a scleroderma mouse model.', 'thumbnail': 'https://serpapi.com/searches/6724b20a360f4ebaf6f9cb71/images/f57b814c2764c74ac20fb1c74464ae3cac893cfb01b671ef4192a6abfc505b68.png', 'sentiment': 'neutral', 'sentiment_prob': 0.652198314666748}",,,,,,,,,,['neutral'],neutral,1
NCT03239392,"{'position': 1, 'link': 'https://www.cancernetwork.com/view/phase-3-trial-of-bnz-1-to-be-initiated-for-treatment-of-relapsed-refractory-ctcl', 'title': 'Phase 3 Trial of BNZ-1 To Be Initiated for Treatment of Relapsed/Refractory CTCL', 'source': 'Cancer Network', 'date': 'Jan 27, 2021', 'snippet': 'Bioniz Therapeutics announced it intends to launch a phase 3 clinical trial \nof the multi-cytokine inhibitor, BNZ-1, for the treatment of patients with \nrelapsed...', 'thumbnail': 'https://serpapi.com/searches/6724aafdcc4879b17e4d2d99/images/952f7f61cf064945e2ff52308212dcb37b8b4e5c198ed6fd4aeac899ed27ef58.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9129712581634521}",,,,,,,,,,['neutral'],neutral,1
NCT02491684,"{'position': 1, 'link': 'https://copdnewstoday.com/news/copd-patients-synairgen-sng001-flu-colds-phase-2-trial/', 'title': 'COPD Patients Get Synairgen’s SNG001 for Flu, Colds in Phase 2 Trial', 'source': 'COPD News Today', 'date': 'Oct 30, 2018', 'snippet': ""With SNG001, researchers hope to boost the body's antiviral system to fight \nrespiratory infections that tend to worsen COPD symptoms."", 'thumbnail': 'https://serpapi.com/searches/6724ab0e861b9da48b37be05/images/c5741db7cddc24c45c216764163116852a3389867f26698cc44d6e78d371552a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8367211222648621}",,,,,,,,,,['neutral'],neutral,1
NCT02612779,"{'position': 1, 'link': 'https://myelomaresearchnews.com/news/safety-concerns-prompt-fda-to-put-a-hold-on-opdivo-combination-trials-for-myeloma/', 'title': '3 Myeloma Trials of Opdivo Put on Hold Due to Safety Concerns Over Other Therapies', 'source': 'Myeloma Research News', 'date': 'Sep 8, 2017', 'snippet': 'The US Food and Drug Administration has ordered Bristol-Myers Squibb to put \na hold on three clinical trials evaluating Opdivo (nivolumab) in \ncombination with...', 'thumbnail': 'https://serpapi.com/searches/6724ab2bbcd6526351ce4fa4/images/6e05f69d544e808abcd7330355fc2db6cb8ffedce668653f47ebc24556187f20.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7855069041252136}",,,,,,,,,,['neutral'],neutral,1
NCT00933530,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-024-55923-8', 'title': 'Emerging roles of SIRT1 activator, SRT2104, in disease treatment', 'source': 'Nature', 'date': 'Mar 6, 2024', 'snippet': 'Silent information regulator 1 (SIRT1) is a NAD+-dependent class III \ndeacetylase that plays important roles in the pathogenesis of numerous...', 'thumbnail': 'https://serpapi.com/searches/6724ab4e17a2e2dbc6752d5a/images/b891353359872dc324d7d1c7bf263594a1d72e0ae0a09ec4ac79bab5967127fb.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8164551258087158}",,,,,,,,,,['neutral'],neutral,1
NCT04551547,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-34280-y', 'title': 'Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents', 'source': 'Nature', 'date': 'Nov 14, 2022', 'snippet': 'Data on safety and immunity elicited by a third booster dose of inactivated \nCOVID-19 vaccine in children and adolescents are scarce.', 'thumbnail': 'https://serpapi.com/searches/6724ab528a7c09b49ca09b46/images/b0def5c06bc1930c46ecb3e7631cf62e0456c2d9f9ef68669f729e4249891914.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8404264450073242}",,,,,,,,,,['neutral'],neutral,1
NCT02066181,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1805052', 'title': 'Sorafenib for Advanced and Refractory Desmoid Tumors', 'source': 'The New England Journal of Medicine', 'date': 'Dec 19, 2018', 'snippet': 'In this double-blind, phase 3 trial, we randomly assigned 87 patients with \nprogressive, symptomatic, or recurrent desmoid tumors to receive...', 'thumbnail': 'https://serpapi.com/searches/6724ab618b84c4694456d640/images/7b8f08099a380dbde87980e2b2570b89c39669afda2bb750291a18fcd12cda7e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9053760766983032}",,,,,,,,,,['neutral'],neutral,1
NCT03112603,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2033122', 'title': 'Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease', 'source': 'The New England Journal of Medicine', 'date': 'Jul 14, 2021', 'snippet': 'Chronic graft-versus-host disease (GVHD), a major complication of \nallogeneic stem-cell transplantation, becomes glucocorticoid-refractory \nor...', 'thumbnail': 'https://serpapi.com/searches/6724ab8bb7d31d18676f5a97/images/b6005957a784c4c6ce469335a0a8ca9619eed8fdce2f01fa41eb1739e9f7c1e8.png', 'sentiment': 'negative', 'sentiment_prob': 0.663324773311615}",,,,,,,,,,['negative'],negative,0
NCT02668653,"{'position': 1, 'link': 'https://ascopost.com/news/july-2023/fda-approves-quizartinib-for-newly-diagnosed-flt3-itd-positive-acute-myeloid-leukemia/', 'title': 'FDA Approves Quizartinib for Newly Diagnosed FLT3 -ITD–Positive Acute Myeloid Leukemia', 'source': 'The ASCO Post', 'date': 'Jul 21, 2023', 'snippet': 'The US Food and Drug Administration (FDA) approved quizartinib (Vanflyta) \nwith standard cytarabine and anthracycline induction and cytarabine \nconsolidation.', 'thumbnail': 'https://serpapi.com/searches/6724abdb3ad34d26809da1f4/images/9c7dae9b57e710e01b55e6d28977c570decadb66deb456a4d06aa8cad03dfa99.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7984702587127686}","{'position': 2, 'link': 'https://www.cancernetwork.com/view/continued-quizartinib-may-show-benefit-in-select-flt3-itd-aml-population', 'title': 'Continued Quizartinib May Show Benefit in Select FLT3-ITD+ AML Population', 'source': 'Cancer Network', 'date': 'Jun 17, 2024', 'snippet': 'Additional analyses of patient-reported outcomes and MRD status in the \nQuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.', 'thumbnail': 'https://serpapi.com/searches/6724abdb3ad34d26809da1f4/images/9c7dae9b57e710e054a226adb793a512242938357db2b13a4cc18eeea49651dc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8261187672615051}","{'position': 3, 'link': 'https://www.cancerhealth.com/blog/fda-approves-vanflyta-newly-diagnosed-acute-myeloid-leukemia', 'title': 'FDA Approves Vanflyta for Newly Diagnosed Acute Myeloid Leukemia', 'source': 'Cancer Health', 'date': 'Jul 21, 2023', 'snippet': 'Trial showed that treatment with quizartinib led to a significant \nimprovement in overall survival.', 'thumbnail': 'https://serpapi.com/searches/6724abdb3ad34d26809da1f4/images/9c7dae9b57e710e069db637f7b3679b86e7c5e8915ac0e483bd5d3991c65e70a.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7023189067840576}",,,,,,,,"['neutral', 'neutral', 'positive']",neutral,1
NCT01721044,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1507247', 'title': 'Baricitinib in Patients with Refractory Rheumatoid Arthritis', 'source': 'The New England Journal of Medicine', 'date': 'Mar 31, 2016', 'snippet': 'In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, \nreduced disease activity in patients with rheumatoid arthritis who...', 'thumbnail': 'https://serpapi.com/searches/6724ac0617b10e2469e2ca1b/images/14fc814316688715dd21f35e8c3b78d6a41aed6451210a737280545cab4eaa7b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8679934144020081}","{'position': 2, 'link': 'https://rheumatoidarthritisnews.com/baricitinib-olumiant-for-rheumatoid-arthritis/', 'title': 'Baricitinib (Olumiant) for Rheumatoid Arthritis', 'source': 'Rheumatoid Arthritis News', 'date': 'Apr 24, 2017', 'snippet': 'Read about Baricitinib (Olumiant), which inhibits the inflammation \nassociated with rheumatoid arthritis, easing the joint pain that stems from \nthe disease.', 'thumbnail': 'https://serpapi.com/searches/6724ac0617b10e2469e2ca1b/images/14fc8143166887159351828a3e7428a298892aac3e66708de9f22e2ac590ea21.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7946578860282898}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03738215,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/vraylar-approved-as-adjunctive-therapy-for-major-depressive-disorder/', 'title': 'Vraylar Approved as Adjunctive Therapy for Major Depressive Disorder', 'source': 'Medical Professionals Reference', 'date': 'Dec 19, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Vraylar (cariprazine) \nas adjunctive therapy to antidepressants for the treatment of major \ndepressive...', 'thumbnail': 'https://serpapi.com/searches/6724ac381f3d4bf4cd7b3fd0/images/6474e965e2256fd70e9c1c4c1418d0c63a0d1abd582b8ef4c30be7634b919004.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8091797828674316}",,,,,,,,,,['neutral'],neutral,1
NCT04292899,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2015301', 'title': 'Remdesivir for 5 or 10 Days in Patients with Severe Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'May 27, 2020', 'snippet': 'In patients with severe Covid-19 not requiring mechanical ventilation, our \ntrial did not show a significant difference between a 5-day course and a \n10-day...', 'thumbnail': 'https://serpapi.com/searches/6724aca58e13c9e2203a3a08/images/fbf0b027415a9e820c563b333377ca3b3209dd468b1929be3d1cbbf70d579ec3.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6665990948677063}",,,,,,,,,,['neutral'],neutral,1
NCT02481674,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-022-01919-8', 'title': 'Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial', 'source': 'Nature', 'date': 'Aug 8, 2022', 'snippet': 'A multicenter, randomized, double-blind, placebo-controlled phase 2 study \n(no. NCT02481674) established to evaluate pepinemab, a semaphorin 4D \n(SEMA4D)-...', 'thumbnail': 'https://serpapi.com/searches/6724afecd9c3e602db8cb197/images/22dae4a967b61f6bd3d33ecf53e93399924635092c78a7f06a0d5a4467ca55b1.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8687688708305359}",,,,,,,,,,['neutral'],neutral,1
NCT00087867,"{'position': 1, 'link': 'https://www.science.org/doi/10.1126/scitranslmed.aaw8412', 'title': 'Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials', 'source': 'Science | AAAS', 'date': 'Sep 11, 2019', 'snippet': 'Ninety-seven percent of drug-indication pairs that are tested in clinical \ntrials in oncology never advance to receive U.S. Food and Drug...', 'thumbnail': 'https://serpapi.com/searches/6724afefbd7cf082585b2d78/images/2d1d4a011b038560b18c3a921927e2991be8e584a2504274893958225b39931a.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7454726099967957}",,,,,,,,,,['negative'],negative,0
NCT00357669,"{'position': 1, 'link': 'https://www.ucb.com/clinical-studies/Clinical-studies-index/brivaracetam', 'title': 'Brivaracetam (Briviact®)', 'source': 'UCB', 'date': 'Aug 30, 2024', 'snippet': 'Epilepsy, A Study to Evaluate the Pharmacokinetics, Safety, and \nTolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16...', 'thumbnail': 'https://serpapi.com/searches/6724b198a47167bf2db0b4de/images/6e84d2c7ba83962f317bc4ffe2e478e4dc63dae8645bf58e5346233b14fd5efb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.901799738407135}",,,,,,,,,,['neutral'],neutral,1
NCT04816669,"{'position': 1, 'link': 'https://www.nature.com/articles/s41587-022-01294-2', 'title': 'The clinical progress of mRNA vaccines and immunotherapies', 'source': 'Nature', 'date': 'May 9, 2022', 'snippet': 'The emergency use authorizations (EUAs) of two mRNA-based severe acute \nrespiratory syndrome coronavirus (SARS-CoV)-2 vaccines approximately...', 'thumbnail': 'https://serpapi.com/searches/6724b19958e433512ffb0ab4/images/74f07323d03d2cb02014ad339235a4ed6ed2a76698108a73e60f7220c9fcfae3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.921474814414978}",,,,,,,,,,['neutral'],neutral,1
NCT00935012,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/circheartfailure.117.004769', 'title': 'TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis', 'source': 'American Heart Association Journals', 'date': 'Apr 3, 2018', 'snippet': 'Background:TTR (transthyretin) cardiac amyloidosis is caused by \ndissociation of TTR into monomers, which misassemble into amyloid fibrils.', 'thumbnail': 'https://serpapi.com/searches/6724b1d80a545a517f22bcf7/images/fe7fdef8957f37b5a200bf734ab088c2dac0f2f37d7c2afbac607cef71c96b48.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8781768679618835}",,,,,,,,,,['neutral'],neutral,1
NCT03131570,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1250504/full', 'title': 'Multi-omics segregate different transcriptomic impacts of anti-IL-17A blockade on type 17 T-cells and regulatory immune cells in psoriasis skin', 'source': 'Frontiers', 'date': 'Sep 11, 2023', 'snippet': 'The purpose of the study was to find translational evidence that systemic \nIL-17A blockade promotes regulatory transcriptome modification in human \npsoriasis...', 'thumbnail': 'https://serpapi.com/searches/6724ad77e95dbf79479328cc/images/e052e3acbb68a4fbd9d4b55a7d1022a4157691e88214f36185060af34ad4a954.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8213093280792236}",,,,,,,,,,['neutral'],neutral,1
NCT02963506,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2017/12/20/bimekizumab-shows-promise-for-ankylosing-spondylitis-patients-in-phase-2b-trial/', 'title': 'Ankylosing Spondylitis Trial of Bimekizumab Shows Promise for Patients', 'source': 'Ankylosing Spondylitis News', 'date': 'Dec 20, 2017', 'snippet': ""UCB's bimekizumab shows significant improvements in symptoms of ankylosing \nspondylitis patients after 12 weeks of treatment in a Phase 2b..."", 'thumbnail': 'https://serpapi.com/searches/6724ad890f2a2c9de44be505/images/5b79d8a52a4e05a23478df9134f75f89d8c58c5e496de9449c60ecc7222d5705.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6875741481781006}",,,,,,,,,,['positive'],positive,1
NCT03254758,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/full/10.1002/cbin.11725', 'title': 'The role of mesenchymal stem cells in liver injury - Sun - 2022 - Cell Biology International', 'source': 'Wiley Online Library', 'date': 'Dec 9, 2021', 'snippet': 'Abstract Recently, mesenchymal stem cell (MSC) therapy has been suggested \nas an effective alternative approach for the treatment of hepatic...', 'thumbnail': 'https://serpapi.com/searches/6724af82e10f0a4d9ab9f8b2/images/9c006c85646bd206a3392369a4141222be083802d596cf51ff5b6565d9a1cd42.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9039925336837769}",,,,,,,,,,['neutral'],neutral,1
NCT00372593,"{'position': 1, 'link': 'https://www.nature.com/articles/s41698-024-00643-5', 'title': 'Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials | npj Precision Oncology', 'source': 'Nature', 'date': 'Aug 1, 2024', 'snippet': 'In this study, we leveraged machine-learning tools by evaluating expression \nof genes of pharmacological relevance to standard-AML...', 'thumbnail': 'https://serpapi.com/searches/6724af83e45f334645884051/images/720a0271d9626f7a3d0301b184f068462b681b843be6734e3e243fc89e16ab15.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.894627571105957}",,,,,,,,,,['neutral'],neutral,1
NCT02224560,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1714631', 'title': 'Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome', 'source': 'The New England Journal of Medicine', 'date': 'May 16, 2018', 'snippet': 'Cannabidiol has been used for treatment-resistant seizures in patients with \nsevere early-onset epilepsy. We investigated the efficacy and...', 'thumbnail': 'https://serpapi.com/searches/6724af8d24296af4b17607a6/images/7b58b2cf148021b01fe8afa29003e3fc1a98d6ed67c2131804a99c3311b79db6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8694579005241394}",,,,,,,,,,['neutral'],neutral,1
NCT01868997,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1614949', 'title': 'Teprotumumab for Thyroid-Associated Ophthalmopathy', 'source': 'The New England Journal of Medicine', 'date': 'May 4, 2017', 'snippet': 'In patients with active ophthalmopathy, teprotumumab was more effective \nthan placebo in reducing proptosis and the Clinical Activity Score.', 'thumbnail': 'https://serpapi.com/searches/6724acb7e10f0a4b53aabe00/images/5031f48ae2b256c8725b5db1a2a6327e5eb880ea2dce8edbb7567b44f5d54b48.png', 'sentiment': 'positive', 'sentiment_prob': 0.5693291425704956}","{'position': 2, 'link': 'https://www.nature.com/articles/s41433-021-01539-5', 'title': 'Teprotumumab for thyroid eye disease: early response is not required for benefit', 'source': 'Nature', 'date': 'Jun 28, 2021', 'snippet': 'In recent trials, 50% of patients treated with teprotumumab for thyroid eye \ndisease had significant improvements in proptosis at 6 weeks.', 'thumbnail': 'https://serpapi.com/searches/6724acb7e10f0a4b53aabe00/images/5031f48ae2b256c8c3200e7e94a8505579c9e212dc926c814ce0662fda45a96d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5698319673538208}",,,,,,,,,"['positive', 'neutral']",positive,1
NCT02960581,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01509-0', 'title': 'Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial', 'source': 'Nature', 'date': 'Oct 7, 2021', 'snippet': 'Human immunodeficiency virus (HIV)-1-specific broadly neutralizing \nmonoclonal antibodies are currently under development to treat and...', 'thumbnail': 'https://serpapi.com/searches/6724acbddc969f174722f880/images/07361dd61bbad045c128a8951d326f1379fbf8ec6f6d11e8ce88beb0f8f45b3a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.846068799495697}",,,,,,,,,,['neutral'],neutral,1
NCT02435992,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2033617', 'title': 'Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis', 'source': 'The New England Journal of Medicine', 'date': 'Sep 29, 2021', 'snippet': 'We conducted a phase 3, multicenter, randomized, double-blind, \nplacebo-controlled trial of ozanimod as induction and maintenance therapy \nin...', 'thumbnail': 'https://serpapi.com/searches/6724acd4aab36d7f847b5045/images/623bbb75e30e9ab41b51015b26ebc5a3ba3bb6bb872ce175b721496d38ece6d6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8953365683555603}","{'position': 2, 'link': 'https://ibdnewstoday.com/2021/01/04/eu-reviewing-zeposia-as-ulcerative-colitis-treatment-for-adults/', 'title': 'Zeposia Under Review in EU to Treat Active Ulcerative Colitis in Adults', 'source': 'ibdnewstoday.com', 'date': 'Jan 4, 2021', 'snippet': 'The anti-inflammatory medication Zeposia (ozanimod) is under review in the \nEuropean Union to treat ulcerative colitis in adults.', 'thumbnail': 'https://serpapi.com/searches/6724acd4aab36d7f847b5045/images/623bbb75e30e9ab4081b75d8cdbfab898b8d27973b2f8e07c31bb955f17426b1.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8333906531333923}","{'position': 3, 'link': 'https://ibdnewstoday.com/2020/10/19/zeposia-effective-in-keeping-ulcerative-colitis-in-remission-phase-3-ibd-study-shows/', 'title': 'Zeposia Effective in Keeping Ulcerative Colitis in Remission, Phase 3 Study Shows', 'source': 'ibdnewstoday.com', 'date': 'Oct 19, 2020', 'snippet': 'Zeposia, an investigational anti-inflammatory medicine, significantly \nincreased clinical remission in ulcerative colitis patients in a...', 'thumbnail': 'https://serpapi.com/searches/6724acd4aab36d7f847b5045/images/623bbb75e30e9ab488bf5763b14adf15259eb2d0c852ff5f538ef01accb16ad8.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5019934177398682}",,,,,,,,"['neutral', 'neutral', 'positive']",neutral,1
NCT02680249,"{'position': 1, 'link': 'https://cysticfibrosisnewstoday.com/ctp-656-cystic-fibrosis/', 'title': 'VX-561 (Formerly CTP-656)', 'source': 'Cystic Fibrosis News Today', 'date': 'Aug 20, 2019', 'snippet': 'CTP-656, now known as VX-561, is the deuterated, or deuterium-modified form \nof Kalydeco (ivacaftor), an FDA-approved treatment for cystic fibrosis (CF).', 'thumbnail': 'https://serpapi.com/searches/6724acda8d04175e361fbe85/images/bb8431c34c87fe548f7b4412b7d465f678f61764f97c15ee23facbfd5ed2200a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.863865852355957}",,,,,,,,,,['neutral'],neutral,1
NCT02904954,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-023-44195-x', 'title': 'Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial', 'source': 'Nature', 'date': 'Dec 19, 2023', 'snippet': 'We previously reported the results of a randomized phase II trial \n(NCT02904954) in patients with early-stage non-small cell lung cancer...', 'thumbnail': 'https://serpapi.com/searches/6724ace668831e95e9de198c/images/0be472c84bf6cee26b915688f3a3df3bc1cb8f06985cfdc71c6a60b2dc834609.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9007678627967834}",,,,,,,,,,['neutral'],neutral,1
NCT04032093,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2106062', 'title': 'Prefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy', 'source': 'The New England Journal of Medicine', 'date': 'Apr 27, 2022', 'snippet': 'Respiratory syncytial virus (RSV), a major cause of illness and death in \ninfants worldwide, could be prevented by vaccination during...', 'thumbnail': 'https://serpapi.com/searches/6724ad3598d8de07c2d59202/images/9b49bf11520e8bcb33c283eab00cac0f83c68f3785f363b5778a0e23076a6d9e.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6773319840431213}",,,,,,,,,,['negative'],negative,0
NCT04523207,"{'position': 1, 'link': 'https://www.targetedonc.com/view/studying-apalutamide-with-adt-in-high-risk-localized-prostate-cancer', 'title': 'Studying Apalutamide With ADT in High-Risk Localized Prostate Cancer', 'source': 'Targeted Oncology', 'date': 'Jun 20, 2024', 'snippet': 'Vitaly Margulis, MD, professor of urology at UT Southwestern Medical \nCenter, discusses the Apa-RP study (NCT04523207) of adjuvant treatment...', 'thumbnail': 'https://serpapi.com/searches/6724ad36b4e8d6b9b2dad243/images/370358015dddc4f6b7d56f26514f4fc872465de18a378a675a64d0b1949675fa.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9437883496284485}","{'position': 2, 'link': 'https://www.urologytimes.com/view/apalutamide-combo-hits-high-2-year-rfs-rate-in-prostate-cancer', 'title': 'Apalutamide combo hits high 2-year RFS rate in prostate cancer', 'source': 'Urology Times', 'date': 'May 3, 2024', 'snippet': 'Treatment with apalutamide and androgen deprivation therapy led to a 2-year \nbiochemical recurrence-free survival rate of 100% in patients...', 'thumbnail': 'https://serpapi.com/searches/6724ad36b4e8d6b9b2dad243/images/370358015dddc4f63ecd22d3cad3c250ff48b27f93c21c94200702e39705d301.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8000161647796631}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT01004991,"{'position': 1, 'link': 'https://www.nature.com/articles/bcj201765', 'title': 'Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells | Blood Cancer Journal', 'source': 'Nature', 'date': 'Jul 21, 2017', 'snippet': 'The Ten Eleven Translocation (TET) enzymes have been found to be mutated in \nboth diffuse large B-cell (DLBCL) and peripheral T-cell (PTCL)...', 'thumbnail': 'https://serpapi.com/searches/6724ad61c117a9b6706ca1b3/images/d8e8624e4f4d3c29b4e6d31b96d8d85949bf2d88b4fae80e42d67f96a96b4f5b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6271765232086182}",,,,,,,,,,['neutral'],neutral,1
NCT01584440,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/avp-786-fails-ease-alzheimers-related-agitation-phase-3-trial/', 'title': 'AVP-786 fails to ease Alzheimer’s-related agitation in Phase 3 trial', 'source': ""Alzheimer's News Today"", 'date': 'Feb 29, 2024', 'snippet': ""A Phase 3 clinical trial of AVP-786 failed to meet its main goal of easing \nagitation in adults with dementia due to Alzheimer's disease."", 'thumbnail': 'https://serpapi.com/searches/6724ae5dd997abefdfc4f9da/images/f4d741efbda300496ab16c908debb685b9b03f8aec7694f6368389a74f3ea36b.png', 'sentiment': 'negative', 'sentiment_prob': 0.8483138084411621}",,,,,,,,,,['negative'],negative,0
NCT03486834,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-024-00860-w', 'title': 'Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine | npj Vaccines', 'source': 'Nature', 'date': 'Apr 1, 2024', 'snippet': 'Human cytomegalovirus (HCMV) is a leading infectious cause of birth defects \nand the most common opportunistic infection that causes...', 'thumbnail': 'https://serpapi.com/searches/6724ae68aab36d81538ed307/images/25ecf20838b00e0ce95ddc63e8c43d2824a4da76288c937e8a5fa65df3fc9260.png', 'sentiment': 'negative', 'sentiment_prob': 0.6538967490196228}",,,,,,,,,,['negative'],negative,0
NCT02633709,"{'position': 1, 'link': 'https://smanewstoday.com/evrysdi-risdiplam/', 'title': 'Evrysdi (risdiplam) for spinal muscular atrophy', 'source': 'SMA News Today', 'date': 'Aug 8, 2020', 'snippet': 'Evrysdi (risdiplam) is a daily disease-modifying therapy approved for \nchildren and adults with spinal muscular atrophy (SMA).', 'thumbnail': 'https://serpapi.com/searches/6724ae77b6e4dba39f39aa9e/images/97de6e361f7a3893cbafa55fa07aec4e0e25faad43a91f3c46c4927964f35e20.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8439708948135376}",,,,,,,,,,['neutral'],neutral,1
NCT01867671,"{'position': 1, 'link': 'https://www.nih.gov/news-events/news-releases/oral-immunotherapy-induces-remission-peanut-allergy-some-young-children', 'title': 'Oral immunotherapy induces remission of peanut allergy in some young children', 'source': 'National Institutes of Health (NIH) (.gov)', 'date': 'Jan 20, 2022', 'snippet': 'A clinical trial funded by the National Institutes of Health has found that \ngiving peanut oral immunotherapy to highly peanut-allergic children ages 1 \nto 3...', 'thumbnail': 'https://serpapi.com/searches/6724ae9eb9458d5afb4cbcee/images/87d837b488d32b1a717a2ccf99e13e8de09c6b89441c3987474f536badf0d774.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7941684722900391}",,,,,,,,,,['neutral'],neutral,1
NCT03739203,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/adjunctive-cariprazine-in-major-depressive-disorder-with-inadequate-response-to-antidepressants-rct/', 'title': 'Adjunctive Cariprazine for MDD With Inadequate Response to Antidepressants', 'source': 'Psychiatrist.com', 'date': 'Aug 16, 2023', 'snippet': 'This study assessed the efficacy of adjunctive use of cariprazine, an \natypical antipsychotic, in MDD patients with inadequate response to...', 'thumbnail': 'https://serpapi.com/searches/6724aea0c1c8dd9a6e6e8e0e/images/370fe7530858e95fe92196f441bd6e58c810422238e464542d3980b321c75a45.png', 'sentiment': 'negative', 'sentiment_prob': 0.6291513442993164}",,,,,,,,,,['negative'],negative,0
NCT03863080,"{'position': 1, 'link': 'https://www.ajmc.com/view/new-data-on-batoclimab-for-mg-indicate-effective-treatment-potential', 'title': 'New Data on Batoclimab for MG Indicate Effective Treatment Potential', 'source': 'AJMC', 'date': 'Dec 15, 2023', 'snippet': 'Two doses of batoclimab were evaluated for their effectiveness in patients \nwith generalized myasthenia gravis (MG) who were seropositive.', 'thumbnail': 'https://serpapi.com/searches/6724adbae10f0a4b22d542d1/images/004f67e3bc43f6a9270ff0d1483681fae805569fcc278ec1364feb4e81c24601.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6212303638458252}",,,,,,,,,,['neutral'],neutral,1
NCT03697252,"{'position': 1, 'link': 'https://www.nature.com/articles/s41537-022-00320-1', 'title': 'Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia', 'source': 'Nature', 'date': 'Dec 3, 2022', 'snippet': 'KarXT combines xanomeline, an M1/M4 preferring muscarinic agonist with no \ndirect D2 receptor antagonism, with the peripherally restricted...', 'thumbnail': 'https://serpapi.com/searches/6724add2b6a79ca77106e0c3/images/6f7922777b6b3b56df5892297e910003ef40c68104bdddbf2c39223501f41dca.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8456377983093262}","{'position': 2, 'link': 'https://www.psychiatrist.com/jcp/antipsychotic-efficacy-of-karxt-xanomeline-trospium/', 'title': 'Antipsychotic Efficacy of KarXT (Xanomeline−Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study', 'source': 'Psychiatrist.com', 'date': 'May 11, 2022', 'snippet': 'KarXT provided clinically meaningful responder rates on PANSS total score \ncompared with placebo at each response threshold, providing further support \nof the...', 'thumbnail': 'https://serpapi.com/searches/6724add2b6a79ca77106e0c3/images/6f7922777b6b3b56eeaeb764a506e27b59e2d3eaffc681e4d519eaaf54fc59ba.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8605852127075195}","{'position': 3, 'link': 'https://www.psychiatrictimes.com/view/post-hoc-analysis-explores-risk-benefit-profile-of-karxt', 'title': 'Post Hoc Analysis Explores Risk-Benefit Profile of KarXT', 'source': 'Psychiatric Times', 'date': 'May 31, 2024', 'snippet': 'A poster presented at the 2024 ASCP Annual Meeting discussed the results of \na study on the efficacy and tolerability of the investigational...', 'thumbnail': 'https://serpapi.com/searches/6724add2b6a79ca77106e0c3/images/6f7922777b6b3b56b1b1df63ed1f187c68d08db11937ccd99f551e24b64b5bd3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8977423906326294}","{'position': 4, 'link': 'https://www.nature.com/articles/s41398-022-02254-9', 'title': 'Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study', 'source': 'Nature', 'date': 'Nov 21, 2022', 'snippet': ""The muscarinic receptor agonist xanomeline improved cognition in phase 2 \ntrials in Alzheimer's disease and schizophrenia."", 'thumbnail': 'https://serpapi.com/searches/6724add2b6a79ca77106e0c3/images/6f7922777b6b3b56554f8a4240b56dd298a89fd1848f5def6e1bf87f10c421d6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8579744100570679}","{'position': 5, 'link': 'https://www.psychiatrictimes.com/view/exploring-the-social-determinants-of-mental-health', 'title': 'Exploring the Social Determinants of Mental Health', 'source': 'Psychiatric Times', 'date': 'May 21, 2022', 'snippet': 'A look at the theme for the 2022 American Psychiatric Association Annual \nMeeting.', 'thumbnail': 'https://serpapi.com/searches/6724add2b6a79ca77106e0c3/images/6f7922777b6b3b56714e0808a977b14a34124a231ccae45ce67eba40b2729c23.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9204825758934021}","{'position': 6, 'link': 'https://www.psychiatrictimes.com/view/addressing-impulsive-side-compulsivie-vice-versa', 'title': 'Addressing the Impulsive Side of Compulsivity (And Vice Versa)', 'source': 'Psychiatric Times', 'date': 'Sep 13, 2020', 'snippet': 'MENTAL HEALTH MINUTE. “Impulsivity” and “compulsivity” are 2 constructs \nthat typify a range of disorder presentation.', 'thumbnail': 'https://serpapi.com/searches/6724add2b6a79ca77106e0c3/images/6f7922777b6b3b564b31225761708684e58d662dd514b77a16c607c6a042eb26.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7359331846237183}","{'position': 7, 'link': 'https://www.psychiatrictimes.com/view/algorithms-for-improved-practice', 'title': 'Algorithms for Improved Practice', 'source': 'Psychiatric Times', 'date': 'Oct 19, 2020', 'snippet': 'Can algorithms improve how you practice? Dr Osser explained more in his \nspeech at the Annual Psychiatric Times® World CME Conference™.', 'thumbnail': 'https://serpapi.com/searches/6724add2b6a79ca77106e0c3/images/6f7922777b6b3b5670b575e50050c1d0ce5dc056152c8dc9c06a32d59b2c1e59.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7513829469680786}",,,,"['neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral', 'neutral']",neutral,1
NCT02558296,"{'position': 1, 'link': 'https://www.empr.com/home/news/brenzavvy-approved-for-adults-with-type-2-diabetes/', 'title': 'Brenzavvy Approved for Adults With Type 2 Diabetes', 'source': 'Medical Professionals Reference', 'date': 'Jan 23, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Brenzavvy™ \n(bexagliflozin) as an adjunct to diet and exercise to improve glycemic...', 'thumbnail': 'https://serpapi.com/searches/6724add9163bdfed2536a343/images/b2d93448a9148f2483b7819f1219861dad64480d6eec097339bd824ef61f3bd7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6072625517845154}",,,,,,,,,,['neutral'],neutral,1
NCT04960202,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2118542', 'title': 'Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19', 'source': 'The New England Journal of Medicine', 'date': 'Feb 16, 2022', 'snippet': 'Nirmatrelvir is an orally administered severe acute respiratory syndrome \ncoronavirus 2 main protease (Mpro) inhibitor with potent...', 'thumbnail': 'https://serpapi.com/searches/6724adfa16779397b676a260/images/b236d6c9824db713f8b2e3f7da75bf4e7c1a47fc16aae4f40928691fac3bf804.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.66453617811203}",,,,,,,,,,['neutral'],neutral,1
NCT00643747,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0802268', 'title': ""Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis"", 'source': 'The New England Journal of Medicine', 'date': 'Apr 30, 2018', 'snippet': 'Early-onset, severe retinal dystrophy caused by mutations in the gene \nencoding retinal pigment epithelium–specific 65-kD protein (RPE65) is \nassociated with...', 'thumbnail': 'https://serpapi.com/searches/6724ae1d54163d5434787430/images/d63b94f27932d7bf31a1aebbcfe4c1a0bd8ae41a78a07f429f7babce83ff7598.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6692816615104675}",,,,,,,,,,['negative'],negative,0
NCT00670254,"{'position': 1, 'link': 'https://www.infectiousdiseaseadvisor.com/news/hydrocortisone-does-not-reduce-risk-of-septic-shock-in-severe-sepsis/', 'title': 'Hydrocortisone Does Not Reduce Risk of Septic Shock in Severe Sepsis', 'source': 'Infectious Disease Advisor', 'date': 'Oct 25, 2016', 'snippet': 'Hydrocortisone appeared to have no significant effect in patients with \nsevere sepsis, according to research published in JAMA.', 'thumbnail': 'https://serpapi.com/searches/6724ae29a8692161abf44d4e/images/d5993d1e9f19b22f6bfd58ddc4d37d62cd6fd71cfda79ac4e5737096f07eb8fe.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.7935938239097595}",,,,,,,,,,['negative'],negative,0
NCT02132026,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/circimaging.116.005131', 'title': 'Optimization and Reproducibility of Aortic Valve 18F-Fluoride Positron Emission Tomography in Patients With Aortic Stenosis | Circulation: Cardiovascular Imaging', 'source': 'American Heart Association Journals', 'date': 'Oct 12, 2016', 'snippet': '18F-Fluoride positron emission tomography (PET) and computed tomography \n(CT) can measure disease activity and progression in aortic stenosis.', 'thumbnail': 'https://serpapi.com/searches/6724af15c82127b2200da88b/images/6bc06ae0f2f29ea26da2506416c09f6892235d1a5890e8f39f87dd68ef46b9eb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9150450825691223}",,,,,,,,,,['neutral'],neutral,1
NCT03131219,"{'position': 1, 'link': 'https://ahusnews.com/news/ultomiris-safe-effective-women-postpartum-ahus-311-trial-data/', 'title': 'Ultomiris Safe, Effective for Women with Postpartum aHUS, Data Show', 'source': 'aHUS News', 'date': 'Mar 3, 2021', 'snippet': 'Ultomiris safely and effectively treated women with atypical hemolytic \nuremic syndrome triggered by pregnancy, trial data show.', 'thumbnail': 'https://serpapi.com/searches/6724af165a461af3ad5fc2ff/images/696f572ab73ca9ea13fede54cb0e227228a59ea3911aee6451b2006016d27706.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7525551319122314}",,,,,,,,,,['positive'],positive,1
NCT03252431,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/ryzneuta-efbemalenograstim-alfa-evive-fda-biologics-license-application-submission/', 'title': 'Novel Biologic for Chemotherapy-Induced Neutropenia Submitted to FDA', 'source': 'Medical Professionals Reference', 'date': 'Mar 31, 2021', 'snippet': 'The Biologics License Application (BLA) for Ryzneuta™ (efbemalenograstim \nalfa; Evive Biotech) has been submitted to the Food and Drug...', 'thumbnail': 'https://serpapi.com/searches/6724af44163bdfef9e7e12c3/images/aa8a8e4deb283665d59da06b294b457386f1ebdbf688d605ff679ae3f74801bc.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9181747436523438}",,,,,,,,,,['neutral'],neutral,1
NCT02999672,"{'position': 1, 'link': 'https://dailynews.ascopubs.org/do/antibody-drug-conjugates-treatment-urothelial-carcinoma', 'title': 'Antibody-Drug Conjugates for Treatment of Urothelial Carcinoma', 'source': 'ASCO Daily News', 'date': 'Dec 3, 2020', 'snippet': 'Antibody-drug conjugates (ADCs) provide a sophisticated pharmacologic \nsystem to deliver cytotoxic drugs to cancer cells.', 'thumbnail': 'https://serpapi.com/searches/6724af57483e5b801804c6c1/images/2b21e775f51733e82acacf62c02d644e9368c90bd329f1f8b51192de9e7d2dfb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7927020192146301}",,,,,,,,,,['neutral'],neutral,1
NCT04421027,"{'position': 1, 'link': 'https://www.idse.net/Covid-19/Article/07-21/FDA-Authorizes-Baricitinib-Alone-as-COVID-19-Treatment/64180', 'title': 'FDA Authorizes Baricitinib Alone as COVID-19 Treatment', 'source': 'Infectious Disease Special Edition', 'date': 'Jul 29, 2021', 'snippet': 'The FDA revised the emergency use authorization (EUA) for baricitinib \n(Olumiant, Lilly) to enable its use alone for the treatment of COVID-19 in \nhospitalized...', 'thumbnail': 'https://serpapi.com/searches/6724b02314c31e490f6d91d8/images/f54837b6b4fd1fa910ad1d564966e7caebce32bba98942518ac9a7e5dad8839a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8929514288902283}","{'position': 2, 'link': 'https://www.genengnews.com/news/eli-lilly-olumiant/', 'title': ""Eli Lilly and Incyte - Olumiant® (baricitinib), with or without Gilead Sciences' Veklury® (remdesivir)"", 'source': 'Genetic Engineering and Biotechnology News', 'date': 'May 18, 2020', 'snippet': 'Candidate: Olumiant ® (baricitinib). Type: Janus kinase (JAK) inhibitor \nindicated for adults with moderately to severely active rheumatoid...', 'thumbnail': 'https://serpapi.com/searches/6724b02314c31e490f6d91d8/images/f54837b6b4fd1fa9bd74f4b2a8c12e2575795d479d13031e43ef5b42f3b30246.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9331957697868347}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03312634,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1002/jbmr.4762', 'title': 'Reduction of New Heterotopic Ossification (HO) in the Open‐Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP) - Pignolo - 2023 - Journal of Bone and Mineral Research', 'source': 'Wiley Online Library', 'date': 'Dec 30, 2022', 'snippet': 'ABSTRACT Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, \nseverely disabling genetic disorder of progressive heterotopic...', 'thumbnail': 'https://serpapi.com/searches/6724b025e924561ed625036a/images/afbbf6170bcb0b6d1be61c00e45d1adcfe8d728c3bd742cc9baa4ecf7c38ab41.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.884096086025238}",,,,,,,,,,['neutral'],neutral,1
NCT00223080,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa0908492', 'title': 'Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand', 'source': 'The New England Journal of Medicine', 'date': 'Oct 20, 2009', 'snippet': 'In a community-based, randomized, multicenter, double-blind, \nplacebo-controlled efficacy trial, we evaluated four priming injections of \na...', 'thumbnail': 'https://serpapi.com/searches/6724b0434a3fcf780dcab777/images/d6e75dac9209a34ef6cbccef597bc232591d5ee80e9c83195a3b1834a643f72e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8920239210128784}",,,,,,,,,,['neutral'],neutral,1
NCT02493868,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/esketamine-nasal-spray-mdd-adverse-events/', 'title': 'Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression', 'source': 'Psychiatrist.com', 'date': 'Sep 19, 2022', 'snippet': 'This study looked at the occurrence and severity of adverse events over \ntime with esketamine nasal spray in MDD patients also receiving an...', 'thumbnail': 'https://serpapi.com/searches/6724b15b0f1a330bb085a637/images/5bceb5a30956150329e34dced2dde76301d44d4be825e4b119aecc2fc47b9f4e.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8946337699890137}",,,,,,,,,,['neutral'],neutral,1
NCT02674880,"{'position': 1, 'link': 'https://copdnewstoday.com/news/inhaled-hyaluronan-treats-acute-copd-exacerbations-clinical-trial/', 'title': 'Inhaled Hyaluronan Found to Ease Acute COPD Exacerbations', 'source': 'COPD News Today', 'date': 'Feb 2, 2021', 'snippet': 'In a pilot Phase 2 study, inhaled hyaluronan — which uses sugar secreted by \nliving tissue that acts as a scaffold for cells — treated people...', 'thumbnail': 'https://serpapi.com/searches/6724b17c8b84c4954dfd8742/images/cbf41826ce71e475ec13fd077e804b1408d6d46659e16c422d8a305742e820be.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7233401536941528}",,,,,,,,,,['neutral'],neutral,1
NCT02436447,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Clinical-trials-related-to-kidney-disease-of-drugs-targeting-mitochondria-according-to_tbl3_361967259', 'title': 'Clinical trials related to kidney disease of drugs targeting...', 'source': 'ResearchGate', 'date': 'Jul 26, 2022', 'snippet': 'Acute kidney injury (AKI) and chronic kidney disease (CKD) are \ninterconnected conditions, and CKD is projected to become the fifth leading \nglobal cause of...', 'thumbnail': 'https://serpapi.com/searches/6724b18935853982821ef16d/images/d5a06079a228492d6f537c89fcc48b48cb513b375742e0b919a560bea22dfa9b.png', 'sentiment': 'negative', 'sentiment_prob': 0.5407861471176147}",,,,,,,,,,['negative'],negative,0
NCT02453711,"{'position': 1, 'link': 'https://www.researchgate.net/figure/Normalisation-of-ALT-at-week-52-among-subjects-with-elevated-baseline-ALT-in-weight_fig4_334078390', 'title': 'Normalisation of ALT at week 52 among subjects with elevated baseline...', 'source': 'ResearchGate', 'date': 'Nov 23, 2021', 'snippet': 'Download scientific diagram | Normalisation of ALT at week 52 among \nsubjects with elevated baseline ALT in weight management trial NCT02453711.', 'thumbnail': 'https://serpapi.com/searches/6724b0dbc117a9b845559882/images/4276db60c8a97043213b9ee41617ae8985dfc75611e03f24f7e240d662fc8d3f.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9222675561904907}",,,,,,,,,,['neutral'],neutral,1
NCT03517085,"{'position': 1, 'link': 'https://www.cgtlive.com/view/gene-therapy-improves-quality-of-life-glycogen-storage-disease-type-1a', 'title': 'Gene Therapy Improves Quality of Life in Patients With Glycogen Storage Disease Type 1a', 'source': 'CGTLive®', 'date': 'May 25, 2023', 'snippet': 'All evaluable patients had significant reductions in daily cornstarch \nintake at 1 year and at last visit during long-term follow-up.', 'thumbnail': 'https://serpapi.com/searches/6724b13b17a2e20afe4de962/images/1642b07a390c6eaf4feec14652f166a8f0df3aa888084d0e264136fe3aca0be5.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.6913791298866272}",,,,,,,,,,['positive'],positive,1
NCT01962363,"{'position': 1, 'link': 'https://friedreichsataxianews.com/friedreichs-ataxia-experimental-treatments/epi-743-vatiquinone/', 'title': ""EPI-743 (Vatiquinone) for Friedreich's Ataxia"", 'source': ""Friedreich's Ataxia News"", 'date': 'Sep 7, 2023', 'snippet': ""EPI-743 (Vatiquinone) is being developed by BioElectron for Friedreich's \nataxia and received FDA orphan drug and fast track designations."", 'thumbnail': 'https://serpapi.com/searches/6724ba739f8bfcc2d8540870/images/6196ef2f3caccd1861c7537f774c59a2af7baace195083076e2e8383b5027f04.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8560620546340942}","{'position': 2, 'link': 'https://friedreichsataxianews.com/news/vatiquinone-slows-fa-progression-after-18-months-trial-data/', 'title': 'Vatiquinone found to slow FA progression by 75% after 1.5 years', 'source': ""Friedreich's Ataxia News"", 'date': 'May 30, 2023', 'snippet': ""The oral therapy vatiquinone was found to slow disease progression in \nFriedreich's ataxia patients by 75% after nearly 18 months in trial."", 'thumbnail': 'https://serpapi.com/searches/6724ba739f8bfcc2d8540870/images/6196ef2f3caccd184a414e462818752012979cb2405143c54c750a49f2dfebcc.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8163461089134216}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03718091,"{'position': 1, 'link': 'https://www.nature.com/articles/s41416-021-01405-x', 'title': 'Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours', 'source': 'Nature', 'date': 'May 26, 2021', 'snippet': 'Berzosertib (formerly M6620, VX-970) is a highly potent and selective, \nfirst-in-class inhibitor of ataxia telangiectasia and Rad3-related...', 'thumbnail': 'https://serpapi.com/searches/6724b84fa5e50241f69a7b57/images/475ad4a1245a809ae6919a93bbc454547b95bb6e5e4bacc5e0e8fa05733f8107.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7692916989326477}",,,,,,,,,,['neutral'],neutral,1
NCT03841630,"{'position': 1, 'link': 'https://www.sciencedirect.com/science/article/pii/S1550413122003126', 'title': 'LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept', 'source': 'ScienceDirect.com', 'date': 'Sep 6, 2022', 'snippet': 'LY3437943 is a novel triple agonist peptide at the glucagon receptor \n(GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and \nglucagon-like...', 'thumbnail': 'https://serpapi.com/searches/6724b84fe335ecf900003b4c/images/284ee880a8ea0413768cdf07fea7d47494144c39fa157379c9b02b5cdb1224c8.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7908094525337219}",,,,,,,,,,['neutral'],neutral,1
NCT01994889,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1805689', 'title': 'Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy', 'source': 'The New England Journal of Medicine', 'date': 'Aug 27, 2018', 'snippet': 'Transthyretin amyloid cardiomyopathy is caused by the deposition of \ntransthyretin amyloid fibrils in the myocardium.', 'thumbnail': 'https://serpapi.com/searches/6724b85b21b01b7b1510972e/images/3252e500f53787e5136f542bd4f8f3b41ea4b02e82490691016546eb611a146e.png', 'sentiment': 'negative', 'sentiment_prob': 0.503507137298584}",,,,,,,,,,['negative'],negative,0
NCT03764293,"{'position': 1, 'link': 'https://www.onclive.com/view/first-line-camrelizumab-plus-rivoceranib-maintains-survival-benefit-in-unresectable-hcc', 'title': 'First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC', 'source': 'OncLive', 'date': 'Jun 2, 2024', 'snippet': 'Frontline treatment with rivoceranib plus camrelizumab maintained a \nclinically meaningful survival improvement compared with sorafenib \n(Nexavar) alone.', 'thumbnail': 'https://serpapi.com/searches/6724b864cb33d030aeaf2574/images/60f2da24c8163e8b33789c19769a25c1611264270b8bbe47ffc2255175c4d671.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.55241459608078}","{'position': 2, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS01406736(23)00961-3/fulltext', 'title': 'Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study', 'source': 'The Lancet', 'date': 'Jul 24, 2023', 'snippet': 'Immunotherapy with immune checkpoint inhibitors combined with an \nanti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve...', 'thumbnail': 'https://serpapi.com/searches/6724b864cb33d030aeaf2574/images/60f2da24c8163e8bc00b57b3c1e90aa45e5eab17331bbc060ad3e98e760eb35a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8328031301498413}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/fda-holds-meeting-for-leronlimab-rationale-dosing-in-ccr5-mss-mcrc', 'title': 'FDA Holds Meeting for Leronlimab Rationale, Dosing in CCR5+ MSS mCRC', 'source': 'Cancer Network', 'date': 'Aug 14, 2024', 'snippet': 'CytoDyn intends to submit its final study protocol to the FDA, engage a \nclinical research organization, and complete preparatory work to...', 'thumbnail': 'https://serpapi.com/searches/6724b864cb33d030aeaf2574/images/60f2da24c8163e8bda743b594d268a23f0ed41e3bb0c00ad63cf6ebce6821d0b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9218313097953796}","{'position': 4, 'link': 'https://www.targetedonc.com/view/unpacking-the-emerald-1-treatment-approach-for-hcc', 'title': 'Unpacking the EMERALD-1 Treatment Approach for HCC', 'source': 'Targeted Oncology', 'date': 'Jan 19, 2024', 'snippet': 'The randomized, double-blind, placebo-controlled, multicenter phase 3 \nEMERALD-1 trial is investigating a combined treatment approach for patients \nwith...', 'thumbnail': 'https://serpapi.com/searches/6724b864cb33d030aeaf2574/images/60f2da24c8163e8ba855e0c3e478b8ad2ceebd1b74c54b795ccfbf7cb8424c79.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9374942183494568}","{'position': 5, 'link': 'https://www.globenewswire.com/news-release/2024/09/12/2945136/0/en/Elevar-Therapeutics-Reports-Advances-in-HCC-and-Other-Oncology-Clinical-Programs-for-Rivoceranib-Plus-Camrelizumab-at-the-European-Society-for-Medical-Oncology-Congress-2024.html', 'title': 'Elevar Therapeutics Reports Advances in HCC and Other', 'source': 'GlobeNewswire', 'date': '1 month ago', 'snippet': 'The results to be presented at ESMO continue to support the safety and \nefficacy of rivoceranib in combination with camrelizumab as a first-line \nsystemic...', 'thumbnail': 'https://serpapi.com/searches/6724b864cb33d030aeaf2574/images/60f2da24c8163e8be23813744c691ac0ab2f89e6d34ca71d9bc4e6a61ce4f684.png', 'sentiment': 'positive', 'sentiment_prob': 0.6583443880081177}","{'position': 6, 'link': 'https://www.onclive.com/view/frontline-camrelizumab-rivoceranib-prolongs-os-vs-sorafenib-in-unresectable-hcc', 'title': 'Frontline Camrelizumab/Rivoceranib Prolongs OS vs Sorafenib in Unresectable HCC', 'source': 'OncLive', 'date': 'Jun 11, 2024', 'snippet': 'Arndt Vogel, MD, discusses the updated OS analysis of CARES-310, as well as \nfuture directions for rivoceranib plus camrelizumab in...', 'thumbnail': 'https://serpapi.com/searches/6724b864cb33d030aeaf2574/images/60f2da24c8163e8bdc5af58bcf7f499a5a4c86839099ef6b7aac0591f29438d7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.937233567237854}","{'position': 7, 'link': 'https://www.cancernetwork.com/view/novel-drug-shows-increased-efficacy-in-small-metastatic-crc-population', 'title': 'Novel Drug Shows Increased Efficacy in Small Metastatic CRC Population', 'source': 'Cancer Network', 'date': 'Feb 6, 2024', 'snippet': 'Results from part 3 of the phase 2a CORIST trial found that combining \nSCO-101 with chemotherapy improved the progression-free survival and...', 'thumbnail': 'https://serpapi.com/searches/6724b864cb33d030aeaf2574/images/60f2da24c8163e8b6ebfba78ac52d3fd8e080abc1dc43f84833f02b7fc9f6ab8.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7051012516021729}","{'position': 8, 'link': 'https://www.onclive.com/view/camrelizumab-plus-rivoceranib-vs-sorafenib-as-first-line-therapy-for-unresectable-hepatocellular-carcinoma-uhcc-final-overall-survival-analysis-of-the-phase-3-cares-310-study', 'title': 'Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 Study', 'source': 'OncLive', 'date': 'Jun 24, 2024', 'snippet': 'This is a final overall survival analysis on the phase 3 CARES-310 study \n(NCT03764293), a randomized, open-label, international phase 3...', 'thumbnail': 'https://serpapi.com/searches/6724b864cb33d030aeaf2574/images/60f2da24c8163e8b46813a9f70b3fc76763bd51e23ead7d02dc460a09d4e1591.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8898683190345764}","{'position': 9, 'link': 'https://www.cancernetwork.com/view/fda-approves-fruquintinib-in-previously-treated-metastatic-crc', 'title': 'FDA Approves Fruquintinib in Previously Treated Metastatic CRC', 'source': 'Cancer Network', 'date': 'Nov 8, 2023', 'snippet': 'Results from the phase 3 FRESCO-2 trial support the approval of \nfruquintinib for patients with previously treated metastatic colorectal...', 'thumbnail': 'https://serpapi.com/searches/6724b864cb33d030aeaf2574/images/60f2da24c8163e8bb07bd3051557ab965176b837db5b67384381fc17c44f3b9b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6722042560577393}","{'position': 10, 'link': 'https://www.cancernetwork.com/view/relativity-123-unlikely-to-reach-primary-endpoints-in-mss-crc-to-be-discontinued', 'title': 'RELATIVITY-123 Unlikely to Reach Primary Endpoints in MSS CRC, To Be Discontinued', 'source': 'Cancer Network', 'date': 'Dec 19, 2023', 'snippet': 'The phase 3 RELATIVITY-123 trial (NCT05328908), which is assessing the \nefficacy of the nivolumab (Opdivo) and relatlimab (Opdualag) combination in \npatients...', 'thumbnail': 'https://serpapi.com/searches/6724b864cb33d030aeaf2574/images/60f2da24c8163e8bb6b14d7491d0b64499621b3a6b9e2384ec709554eae62ac9.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.5725554823875427}","['positive', 'neutral', 'neutral', 'neutral', 'positive', 'neutral', 'positive', 'neutral', 'neutral', 'negative']",neutral,1
NCT03021343,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.122.319808', 'title': 'Targeting Microtubules for the Treatment of Heart Disease', 'source': 'American Heart Association Journals', 'date': 'May 26, 2022', 'snippet': 'In this review, we describe basic roles of microtubules in the \ncardiovascular cells with emphasis on their dysfunction in heart disease.', 'thumbnail': 'https://serpapi.com/searches/6724b86e361fd4acd6684fcd/images/08a02abd31b13f919bd13b6f9c0c7a1040167b6ec894b037ae93dd691a9ef717.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8714327812194824}",,,,,,,,,,['neutral'],neutral,1
NCT04335136,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1084331/full', 'title': 'Engineered soluble ACE2 receptor: Responding to change with change', 'source': 'Frontiers', 'date': 'Feb 6, 2024', 'snippet': 'SARS coronavirus 2 (SARS-CoV-2) invades the human body by binding to major \nreceptors such as ACE2 via its S-spike protein, so the interaction of...', 'thumbnail': 'https://serpapi.com/searches/6724b882cf32e0754532982d/images/0de18fa1f4fe2235b477d3747277b9b874d406e6a7213225ae33a4370ffa6899.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8097319602966309}",,,,,,,,,,['neutral'],neutral,1
NCT02059291,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1706314', 'title': 'Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes', 'source': 'The New England Journal of Medicine', 'date': 'May 16, 2018', 'snippet': 'In this trial, canakinumab was effective in controlling and preventing \nflares in patients with colchicine-resistant familial Mediterranean fever, \nmevalonate...', 'thumbnail': 'https://serpapi.com/searches/6724ba1ba251046300a4f8c3/images/68e8f4e202643827d27adf651510d3892c558bf617526eb16ae14738c70d05d0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7781077027320862}",,,,,,,,,,['neutral'],neutral,1
NCT02546700,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1155/2023/2297559', 'title': 'The Molecular Blueprint for Chronic Obstructive Pulmonary Disease (COPD): A New Paradigm for Diagnosis and Therapeutics - Shakeel - 2023 - Oxidative Medicine and Cellular Longevity', 'source': 'Wiley Online Library', 'date': 'Dec 21, 2023', 'snippet': 'This review discusses a narrative opinion and critical review of COPD. We \npresent different aspects of the disease, from cellular and inflammatory \nresponses to...', 'thumbnail': 'https://serpapi.com/searches/6724ba28ee468238b3e0630e/images/f84737bd0a7df13d7693ed62743f95e1468baf226e26031e7d346fb0bcddd56a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.930492639541626}",,,,,,,,,,['neutral'],neutral,1
NCT02760498,"{'position': 1, 'link': 'https://www.onclive.com/view/cemiplimab-monotherapy-continues-to-generate-responses-in-locally-advanced-or-metastatic-cscc', 'title': 'Cemiplimab Monotherapy Continues to Generate Responses in Locally Advanced or Metastatic CSCC', 'source': 'OncLive', 'date': 'Oct 25, 2022', 'snippet': 'Single-agent cemiplimab demonstrated safety and efficacy in patients with \nlocally advanced or metastatic cutaneous squamous cell carcinoma...', 'thumbnail': 'https://serpapi.com/searches/6724ba317b05cab001f2bbe5/images/cb2a8b7373ed7547b635cb8e7a7bd27ea33517476cc86335fd4e1bd50a350ce3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8140012621879578}",,,,,,,,,,['neutral'],neutral,1
NCT04491604,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2206663', 'title': 'Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa', 'source': 'The New England Journal of Medicine', 'date': 'Dec 14, 2022', 'snippet': 'Beremagene geperpavec (B-VEC) is a topical investigational herpes simplex \nvirus type 1 (HSV-1)–based gene therapy designed to restore C7 protein by \ndelivering...', 'thumbnail': 'https://serpapi.com/searches/6724ba3d66d9955adeca3b25/images/c3be17e54dfe454ebd3f0c324f30fd4e3390acab9ee6dff776200789aa6bb064.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8942225575447083}","{'position': 2, 'link': 'https://www.cgtlive.com/view/krystal-dystrophic-epidermolysis-bullosa-gene-therapy-b-vec-under-review-eu', 'title': 'Krystal’s Dystrophic Epidermolysis Bullosa Gene Therapy B-VEC Under Review in EU', 'source': 'CGTLive®', 'date': 'Nov 27, 2023', 'snippet': ""An investigational gene therapy intended to treat dystrophic epidermolysis \nbullosa (DEB), has been validated by the European Medicines Agency's (EMA) \nCommittee..."", 'thumbnail': 'https://serpapi.com/searches/6724ba3d66d9955adeca3b25/images/c3be17e54dfe454ee277542d42244cad9cba23f2ec4004dff35c85a5a668fa6f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8852711319923401}","{'position': 3, 'link': 'https://epidermolysisbullosanews.com/news/phase-3-deb-trial-testing-topical-gene-therapy-b-vec-now-complete/', 'title': 'Phase 3 DEB Trial Testing Topical Gene Therapy B-VEC Now Complete', 'source': 'Epidermolysis Bullosa News', 'date': 'Nov 5, 2021', 'snippet': 'A Phase 3 clinical trial testing B-VEC (beremagene geperpavec), a topical \ngene therapy for treating skin wounds in patients with dystrophic \nepidermolysis...', 'thumbnail': 'https://serpapi.com/searches/6724ba3d66d9955adeca3b25/images/c3be17e54dfe454e6865c592afd584aa8d25c4fe37d55adeea6b2af55ecde94e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.873982846736908}","{'position': 4, 'link': 'https://epidermolysisbullosanews.com/news/deb-wound-categories-capture-great-complexity-study/', 'title': 'Categories for DEB wounds do not capture their complexity: Study', 'source': 'Epidermolysis Bullosa News', 'date': 'Aug 2, 2024', 'snippet': 'Wounds in dystrophic epidermolysis bullosa are more complex and dynamic \nthan the current categories used to define them, a study says.', 'thumbnail': 'https://serpapi.com/searches/6724ba3d66d9955adeca3b25/images/c3be17e54dfe454e8c2fc4a608579b3cd7bc988e671733063d0669100b85cdc0.png', 'sentiment': 'negative', 'sentiment_prob': 0.6674733757972717}","{'position': 5, 'link': 'https://www.empr.com/home/news/topical-gene-therapy-vyjuvek-approved-dystrophic-epidermolysis-bullosa/', 'title': 'Topical Gene Therapy Vyjuvek Approved for Dystrophic Epidermolysis Bullosa', 'source': 'Medical Professionals Reference', 'date': 'May 19, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Vyjuvek™ (beremagene \ngeperpavec-svdt) for the treatment of wounds in patients 6 months...', 'thumbnail': 'https://serpapi.com/searches/6724ba3d66d9955adeca3b25/images/c3be17e54dfe454e12c09ef0f581ab90112f8a48dd3202127761284abaefbb96.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.566172182559967}","{'position': 6, 'link': 'https://epidermolysisbullosanews.com/news/gene-therapy-eye-drops-improves-vision-deb-boy/', 'title': 'Gene therapy applied as eye drops improves vision for boy with DEB', 'source': 'Epidermolysis Bullosa News', 'date': 'Feb 9, 2024', 'snippet': 'The gene therapy B-VEC, in an eye-drop formulation, was effective for \nimproving vision in a boy with eye scarring related to dystrophic EB.', 'thumbnail': 'https://serpapi.com/searches/6724ba3d66d9955adeca3b25/images/c3be17e54dfe454ea3c8ecab6f587d463615f5efdcbef2bb061456a637abf06e.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5299602746963501}","{'position': 7, 'link': 'https://www.cgtlive.com/view/upcoming-fda-decisions-for-rare-diseases-in-2023', 'title': 'Upcoming FDA Decisions for Rare Diseases in 2023', 'source': 'CGTLive®', 'date': 'Feb 28, 2023', 'snippet': 'CGTLive is taking a look at some of the upcoming FDA decisions on selected \ngene and cell therapies for rare diseases.', 'thumbnail': 'https://serpapi.com/searches/6724ba3d66d9955adeca3b25/images/c3be17e54dfe454e15b1ddb6a210658ecdf3bdda2812954c21cd8a5b650aafea.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.946054220199585}",,,,"['neutral', 'neutral', 'neutral', 'negative', 'neutral', 'neutral', 'neutral']",neutral,1
NCT03934099,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20210701005263/en/LG-Chem-Announces-Topline-Results-of-LC350189-From-the-Phase-2-Study-CLUE-Study-Promising-to-Be-a-New-Treatment-Alternative-With-Improved-Efficacy-and-Safety-Profiles-for-Chronic-Gout-Patients', 'title': 'LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients', 'source': 'Business Wire', 'date': 'Jul 1, 2021', 'snippet': 'LC350189 showed significant serum uric acid (sUA)-lowering effects across \nall dose levels. LC350189 achieved a treatment target of sUA < 5...', 'thumbnail': 'https://serpapi.com/searches/6724ba56a5d702549f3682fe/images/3b379054c007da1a8e704533807c7a05e6de222e7551fa65515dbbecb3a657e4.png', 'sentiment': 'positive', 'sentiment_prob': 0.756885290145874}",,,,,,,,,,['positive'],positive,1
NCT02916537,"{'position': 1, 'link': 'https://www.businesswire.com/news/home/20170412005094/en/Cancer-Targeted-Technology-Announces-Advances-with-its-PSMA-targeted-PET-Imaging-and-Radiotherapeutic-Agents-for-Prostate-Cancer-at-Upcoming-Conferences', 'title': 'Cancer Targeted Technology Announces Advances with its PSMA-targeted PET Imaging and Radiotherapeutic Agents for Prostate Cancer at Upcoming Conferences', 'source': 'Business Wire', 'date': 'Apr 12, 2017', 'snippet': 'Cancer Targeted Technology presents data on its PET imaging agent, CTT1057, \nfrom a prostate cancer clinical trial, and its radiotherapeutic...', 'thumbnail': 'https://serpapi.com/searches/6724ba5ed403e1e5096b5350/images/787bbfbbc4d27dc5717172e09b840fcfe1740276884d1a45fc5b6a0e0d89d22a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9306225180625916}",,,,,,,,,,['neutral'],neutral,1
NCT02447302,"{'position': 1, 'link': 'https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00061-2/fulltext', 'title': 'Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies', 'source': 'The Lancet', 'date': 'Mar 2, 2023', 'snippet': 'Etrasimod as induction and maintenance therapy for ulcerative colitis \n(ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies', 'thumbnail': 'https://serpapi.com/searches/6724b6b1b57db86eab4599b3/images/fcce414e54a5f28bce8de63d5bec4d1679f93ced8889c35211dfded9c5a97dfa.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7826459407806396}",,,,,,,,,,['neutral'],neutral,1
NCT02164461,"{'position': 1, 'link': 'https://cervicalcancernews.com/2017/05/19/one-cervical-cancer-patient-in-clinical-trial-shows-long-lasting-response-to-axal/', 'title': 'Cervical Cancer Patient Achieves Long-lasting Response to AXAL in Clinical Trial', 'source': 'Cervical cancer News', 'date': 'May 19, 2017', 'snippet': 'Read about one of nine cervical cancer patients in a Phase 1 clinical trial \nof AXAL achieving a long-lasting partial response to the...', 'thumbnail': 'https://serpapi.com/searches/6724b6cf6de1e4f859151213/images/046884a4ba931ac90f1c0fd608da047ef14678f933b9e6fbb20803047eb33bcb.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8928074240684509}","{'position': 2, 'link': 'https://cervicalcancernews.com/2017/04/12/cervical-cancer-vaccine-axal-safe-effective-higher-doses-advaxis/', 'title': 'Higher Doses of AXAL Vaccine Are Safe, Effective in Certain Types of Cervical Cancer, Says Advaxis', 'source': 'Cervical cancer News', 'date': 'Apr 12, 2017', 'snippet': 'A recent trial showed the anti-cancer vaccine axalimogene filolisbac, also \nknown as ADXS11-001 or AXAL, to be well tolerated at higher doses.', 'thumbnail': 'https://serpapi.com/searches/6724b6cf6de1e4f859151213/images/046884a4ba931ac9694e91d46bdad399df01c8700d9a73fa1d7ea3b3a5fba157.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.4984729588031769}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT04711005,"{'position': 1, 'link': 'https://www.nimh.nih.gov/news/science-news/2024/new-hope-for-rapid-acting-depression-treatment', 'title': 'New Hope for Rapid-Acting Depression Treatment', 'source': 'National Institute of Mental Health (NIMH) (.gov)', 'date': '1 week ago', 'snippet': 'A new study, funded in part by the National Institute of Mental Health, \nshowed that a new medication derived from ketamine is safe and...', 'thumbnail': 'https://serpapi.com/searches/6724b3fea8827886cf8fc7a8/images/eba1184900aaf080cc150b8f1dc0f28721b61c2a22e6e5b697b730e9367c3f6f.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5346962809562683}",,,,,,,,,,['positive'],positive,1
NCT00294658,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1602489', 'title': 'Randomized Trial of Thymectomy in Myasthenia Gravis', 'source': 'The New England Journal of Medicine', 'date': 'Aug 11, 2016', 'snippet': 'Thymectomy improved clinical outcomes over a 3-year period in patients with \nnonthymomatous myasthenia gravis.', 'thumbnail': 'https://serpapi.com/searches/6724b3ff5c7cb95e509264bc/images/74f19a3dc6a1403d3069496ce13f0468088b3294ae705a57e992e23f7490ccf6.png', 'sentiment': 'positive', 'sentiment_prob': 0.6771420240402222}","{'position': 2, 'link': 'https://myastheniagravisnews.com/news/myasthenia-gravis-patients-robot-assisted-thymectomy-safe-singapore-study-says/', 'title': 'MG Patients Can Safely Have Robot-assisted Thymectomies, Singapore Study Says', 'source': 'Myasthenia Gravis News', 'date': 'Sep 13, 2018', 'snippet': 'Robot-assisted surgery to remove the thymus gland is a safe technique for \nthymectomies in myasthenia gravis patients, a Singapore study...', 'thumbnail': 'https://serpapi.com/searches/6724b3ff5c7cb95e509264bc/images/74f19a3dc6a1403d7d77025f432e8ab880c56e39d2a39e085c31171df321d7a3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6862289309501648}","{'position': 3, 'link': 'https://myastheniagravisnews.com/news/clinical-trial-shows-thymus-surgery-helps-myasthenia-gravis-patients-more-than-medicine/', 'title': 'Myasthenia Gravis Patients Do Better with Thymus Surgery, Trial Reports', 'source': 'Myasthenia Gravis News', 'date': 'Jul 20, 2017', 'snippet': 'Read about a Phase 3 clinical trial showing that thymus surgery plus \nmedicine is better than medicine alone as a treatment for myasthenia...', 'thumbnail': 'https://serpapi.com/searches/6724b3ff5c7cb95e509264bc/images/74f19a3dc6a1403dc00a1cb7b0f2de15d887af1cc93ce077972066089f7de756.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7658814787864685}",,,,,,,,"['positive', 'neutral', 'positive']",positive,1
NCT02167139,"{'position': 1, 'link': 'https://ankylosingspondylitisnews.com/2022/08/18/fda-approves-higher-concentration-hadlima-humira-biosimilar/', 'title': 'FDA Approves Higher Concentration of Hadlima, a Humira Biosimilar...', 'source': 'Ankylosing Spondylitis News', 'date': 'Aug 18, 2022', 'snippet': ""The US Food and Drug Administration (FDA) has approved a new, more highly \nconcentrated formulation of Hadlima (adalimumab-bwwd), a biosimilar to \nAbbVie's..."", 'thumbnail': 'https://serpapi.com/searches/6724b456e30abc8b5967ef2c/images/7d1248b28f50ad1d98cb02bc3cd21b8486e49ef6286c674a5d6b4c5e2ebe7920.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5983152985572815}",,,,,,,,,,['neutral'],neutral,1
NCT04603027,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1292406/full', 'title': 'A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis', 'source': 'Frontiers', 'date': 'May 14, 2024', 'snippet': '1Oregon Medical Research Center, Portland, OR, United States; 2Yale \nUniversity School of Medicine, New Haven, CT, United States...', 'thumbnail': 'https://serpapi.com/searches/6724b45eba13f2dee66bc7db/images/5ebeffc95034be016f182d23354a04d71fef1c8fd91a186a455ba44e997a767a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9029088020324707}",,,,,,,,,,['neutral'],neutral,1
NCT02939391,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/kyowa-kirin-stops-kw-6356-program-despite-promising-phase-2-results/', 'title': 'Kyowa Kirin Stops KW-6356 Program Despite Promising Phase 2 Results', 'source': ""Parkinson's News Today"", 'date': 'Jul 25, 2022', 'snippet': ""Kyowa Kirin is terminating the clinical development program for KW-6356, \nits investigational treatment for Parkinson's disease."", 'thumbnail': 'https://serpapi.com/searches/6724b4665ed3cac2a57040dd/images/2b018a208565e1b92233fb8e850fada23e394cd6c731aa2224e570e1f9141efb.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6626456379890442}",,,,,,,,,,['negative'],negative,0
NCT02970162,"{'position': 1, 'link': 'https://lamberteatonnews.com/news/firdapse-approved-treat-lems-japan/', 'title': 'Firdapse approved to treat LEMS patients in Japan', 'source': 'Lambert-Eaton News', 'date': '1 month ago', 'snippet': 'Oral Firdapse, approved in the US and Europe to treat Lambert-Eaton \nmyasthenic syndrome, now is available to LEMS patients in Japan.', 'thumbnail': 'https://serpapi.com/searches/6724b54d13e5d8cb76227d65/images/06b5e4d853be56bfbfeda0d9a2106776d15917f3ce2bf2bb502e8e85062cd42d.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7561480402946472}",,,,,,,,,,['neutral'],neutral,1
NCT03183206,"{'position': 1, 'link': 'https://www.nature.com/articles/s41423-020-0515-7', 'title': 'Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer', 'source': 'Nature', 'date': 'Sep 16, 2020', 'snippet': 'Vγ9Vδ2 T cells are promising candidates for cellular tumor immunotherapy. \nDue to their HLA-independent mode of action, allogeneic Vγ9Vδ2 T...', 'thumbnail': 'https://serpapi.com/searches/6724b54d8a7c09edb272e583/images/92cf414377f6b226c3841334fd6eac4e5b41301de971af765e881c35dcb280a3.png', 'sentiment': 'positive', 'sentiment_prob': 0.7890372276306152}",,,,,,,,,,['positive'],positive,1
NCT04551534,"{'position': 1, 'link': 'https://parkinsonsnewstoday.com/news/potential-parkinsons-therapy-dnl201-safely-targets-enzyme-studies/', 'title': ""Potential Parkinson's Therapy DNL201 Safely Targets Enzyme: Studies"", 'source': ""Parkinson's News Today"", 'date': 'Jun 23, 2022', 'snippet': ""DNL201, an investigational therapy for Parkinson's, was tolerated in \nhealthy volunteers and patients, and engaged with the LRRK2 protein."", 'thumbnail': 'https://serpapi.com/searches/6724b589db3ac996fe588f02/images/423b82dbf6e548fb92ccd32c474627e3b52eeea06cbc6bb8e15d8f8e292b1693.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5823979377746582}",,,,,,,,,,['neutral'],neutral,1
NCT01202591,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-022-30666-0', 'title': 'Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer', 'source': 'Nature', 'date': 'Jun 10, 2022', 'snippet': 'We conducted a phase IIa, multi-centre, open label, single arm study \n(RADICAL; NCT01791985) of AZD4547 (a potent and selective inhibitor of...', 'thumbnail': 'https://serpapi.com/searches/6724b49848c4295adb38cf44/images/c72f0ea103ced71a4258df91537a39387f329823008a41397ed63d4e509eba03.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8903841972351074}",,,,,,,,,,['neutral'],neutral,1
NCT02065557,"{'position': 1, 'link': 'https://ibdnewstoday.com/ibd-treatment/humira-adalimumab/', 'title': 'Range of Bowel Diseases Can Be Treated with Humira', 'source': 'ibdnewstoday.com', 'date': 'Aug 31, 2017', 'snippet': 'Humira (adalimumab) is a biological therapy that the US Food and Drug \nAdministration approved for treating inflammatory bowel disease, or IBD.', 'thumbnail': 'https://serpapi.com/searches/6724b4aa0c666878cdff8f39/images/3537412aa6578c8ecd3ae42bc8da55b24d73d907198f8017a1119c5a1d9f86ba.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9108577370643616}",,,,,,,,,,['neutral'],neutral,1
NCT01245062,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1203421', 'title': 'Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma', 'source': 'The New England Journal of Medicine', 'date': 'Jun 4, 2012', 'snippet': 'Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are \nfound in 50% of patients with advanced melanoma.', 'thumbnail': 'https://serpapi.com/searches/6724b4b071c62b041b411944/images/5dba743ee5e9443999c0eff79bac64e429faf07688582ae5238306d8ed7a1f72.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8203856945037842}",,,,,,,,,,['neutral'],neutral,1
NCT01913353,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1817307', 'title': 'Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox', 'source': 'The New England Journal of Medicine', 'date': 'Nov 13, 2019', 'snippet': 'Many countries have stockpiled vaccines because of concerns about the \nreemergence of smallpox. Traditional smallpox vaccines are based on...', 'thumbnail': 'https://serpapi.com/searches/6724b4d449ea557bf0b6e171/images/6236677fee46f11fc33be506fc4e57a0aa73f4d907d851dd65805718b54bd697.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8469113111495972}",,,,,,,,,,['neutral'],neutral,1
NCT04666298,"{'position': 1, 'link': 'https://www.nature.com/articles/s41392-023-01690-3', 'title': 'Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside', 'source': 'Nature', 'date': 'Jan 8, 2024', 'snippet': 'Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a \npivotal enzyme in lipid metabolism and a revolutionary therapeutic...', 'thumbnail': 'https://serpapi.com/searches/6724b4d6c4bcf5253169013a/images/9aecfe465cae530ac9b49ebfeabde3f8f91cf157ba07e427710d56373159248b.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6380511522293091}",,,,,,,,,,['neutral'],neutral,1
NCT03296696,"{'position': 1, 'link': 'https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1255611/full', 'title': 'Immunotherapy: a promising approach for glioma treatment', 'source': 'Frontiers', 'date': 'Feb 8, 2024', 'snippet': 'Gliomas are the most prevalent primary malignant brain tumors worldwide, \nwith glioblastoma (GBM) being the most common and aggressive type.', 'thumbnail': 'https://serpapi.com/searches/6724b4e8e45f334645884124/images/90bc9201632a6f983abc895482f0d2c4606864508d8480e0d6b672dd93e4e5b9.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6341026425361633}",,,,,,,,,,['neutral'],neutral,1
NCT03104413,"{'position': 1, 'link': 'https://ibdnewstoday.com/2021/01/18/risankizumab-induces-clinical-endoscopic-remission-after-12-weeks-in-crohns-disease-clinical-trials/', 'title': ""Crohn's Remission Shown After 12 Weeks in Risankizumab Clinical Trial"", 'source': 'ibdnewstoday.com', 'date': 'Jan 18, 2021', 'snippet': ""Treatment with risankizumab for 12 weeks induced both clinical and \nendoscopic remission in people with Crohn's disease, trial data show."", 'thumbnail': 'https://serpapi.com/searches/6724b4ff1ec32f692204234e/images/837f4137dc5422bca6f51401b35fc42756d53df32c41eadd2a3c440bb38b696f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.879081130027771}",,,,,,,,,,['neutral'],neutral,1
NCT05326516,"{'position': 1, 'link': 'https://www.oncozine.com/revumenib-shows-positive-results-in-the-treatment-of-patients-with-acute-leukemias/', 'title': 'Revumenib Shows Positive Results in the Treatment of Patients with Acute Leukemias', 'source': ""Onco'Zine"", 'date': 'Dec 13, 2023', 'snippet': 'The latest study results from multiple trials of revumenib (also known as \nSNDX-5613), a highly selective, oral menin inhibitor being developed by \nSyndax.', 'thumbnail': 'https://serpapi.com/searches/6724b500b9458d5afb4cbe16/images/45bec5f697c3d7dfcac2bfa30a0586938163c71fc314466ca53402ebafe8aaca.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.497280091047287}",,,,,,,,,,['neutral'],neutral,1
NCT00324155,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa1104621', 'title': 'Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma', 'source': 'The New England Journal of Medicine', 'date': 'Jun 6, 2011', 'snippet': 'Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as \ncompared with glycoprotein 100, improved overall survival in a...', 'thumbnail': 'https://serpapi.com/searches/6724b50174f0a404c01d5d01/images/cac35fb6224ab79718c31c611a1272057026e431c6c28750ac16e652169803dd.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6230210065841675}",,,,,,,,,,['neutral'],neutral,1
NCT02508389,"{'position': 1, 'link': 'https://www.cancertherapyadvisor.com/news/fda-denies-approval-of-avasopasem-for-radiotherapy-induced-severe-oral-mucositis/', 'title': 'FDA Denies Approval of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis', 'source': 'Cancer Therapy Advisor', 'date': 'Aug 15, 2023', 'snippet': 'The US Food and Drug Administration (FDA) has issued a complete response \nletter to Galera Therapeutics related to the new drug application for \navasopasem...', 'thumbnail': 'https://serpapi.com/searches/6724b514a8692161d8caa8db/images/0f27a7a4b20db85b9d3b61c092eda32d078f96e0e03416f831a4c1c0833ca3b7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5011367201805115}",,,,,,,,,,['neutral'],neutral,1
NCT02970942,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2028395', 'title': 'A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis', 'source': 'The New England Journal of Medicine', 'date': 'Nov 13, 2020', 'snippet': 'This phase 2 trial involving patients with NASH showed that treatment with \nsemaglutide resulted in a significantly higher percentage of patients with \nNASH...', 'thumbnail': 'https://serpapi.com/searches/6724b525f410448adbbd8375/images/8cb9c7825cd3bf985e23ae30fcb221f61e002b72160d8499a6c68b0743fe9249.png', 'sentiment': 'neutral', 'sentiment_prob': 0.885822057723999}",,,,,,,,,,['neutral'],neutral,1
NCT04754594,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01490-8', 'title': 'Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy', 'source': 'Nature', 'date': 'Sep 7, 2021', 'snippet': 'To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in \npregnant women, we conducted an observational cohort study of...', 'thumbnail': 'https://serpapi.com/searches/6724b59b48e668cbd3106536/images/b064b0ad1d6bb0d43d1985dc6496ff17fbebf7c75baa2c777ea7138644f8bdee.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9023582935333252}",,,,,,,,,,['neutral'],neutral,1
NCT02504216,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2000052', 'title': 'Rivaroxaban in Peripheral Artery Disease after Revascularization', 'source': 'The New England Journal of Medicine', 'date': 'Mar 28, 2020', 'snippet': 'Patients with peripheral artery disease who have undergone lower-extremity \nrevascularization are at high risk for major adverse limb and \ncardiovascular...', 'thumbnail': 'https://serpapi.com/searches/6724b5aac7d4a15132363d25/images/a142e72b22f41a142e544fd10a86a0b0e4a95bb0099f2a191e21c675471edd25.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6069828867912292}",,,,,,,,,,['neutral'],neutral,1
NCT04173494,"{'position': 1, 'link': 'https://www.hematologyadvisor.com/cch/ojjaara-for-intermediate-or-high-risk-myelofibrosis/', 'title': 'Ojjaara for Intermediate or High-Risk Myelofibrosis', 'source': 'Hematology Advisor', 'date': 'Sep 18, 2023', 'snippet': 'In September 2023, the US Food and Drug Administration (FDA) approved \nOjjaara (momelotinib; GlaxoSmithKline), a kinase inhibitor,...', 'thumbnail': 'https://serpapi.com/searches/6724b5b9bcd6529295704a3b/images/544916e16adb36e88cc28312a67fc04ff87f92cbe790dd4a6b649edec8a6399a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8874692916870117}","{'position': 2, 'link': 'https://www.oncnursingnews.com/view/aaron-gerds-on-jak-inhibitor-therapy-for-anemic-patients-with-myelofibrosis', 'title': 'Aaron Gerds on JAK Inhibitor Therapy for Anemic Patients With Myelofibrosis', 'source': 'Oncology Nursing News', 'date': 'Jan 2, 2023', 'snippet': 'Aaron T. Gerds, MD, MS, unpacks data seen with momelotinib for patients \nwith anemic myelofibrosis.', 'thumbnail': 'https://serpapi.com/searches/6724b5b9bcd6529295704a3b/images/544916e16adb36e85a0edfd5856779316e40c2af9df62eb699c5fc6161e1242f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.913780152797699}","{'position': 3, 'link': 'https://www.cancernetwork.com/view/momelotinib-receives-fda-approval-for-myelofibrosis-with-anemia', 'title': 'Momelotinib Receives FDA Approval for Myelofibrosis With Anemia', 'source': 'Cancer Network', 'date': 'Sep 15, 2023', 'snippet': 'The FDA has approved momelotinib (Ojjaara) for the treatment of patients \nwith intermediate- or high-risk myelofibrosis, including primary and \nsecondary...', 'thumbnail': 'https://serpapi.com/searches/6724b5b9bcd6529295704a3b/images/544916e16adb36e82407f91018951f5af9cf6efa1a2b3e4175f56676dfab91e2.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8063039183616638}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT05322473,"{'position': 1, 'link': 'https://www.termedia.pl/Hidradenitis-suppurativa-a-new-therapeutic-approach-for-an-old-disease,7,54608,1,1.html', 'title': 'Hidradenitis suppurativa: a new therapeutic approach for an old disease', 'source': 'Termedia', 'date': 'Aug 12, 2024', 'snippet': 'Hidradenitis suppurativa (HS) is a chronic inflammatory disease \ncharacterised by recurrent painful nodules, abscesses, fistulas and \nscarring...', 'thumbnail': 'https://serpapi.com/searches/6724b5c5d0c983dd0f53c76a/images/f603b6aab4454eda70b2e3fcbac1971207424e277904b25d1d5995df51ccd418.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.6704685091972351}",,,,,,,,,,['negative'],negative,0
NCT04279613,"{'position': 1, 'link': 'https://www.nature.com/articles/s41435-023-00221-y', 'title': 'IL-2 immunotherapy for targeting regulatory T cells in autoimmunity', 'source': 'Nature', 'date': 'Sep 23, 2023', 'snippet': 'A new and promising focus in drug development are IL-2-based approaches for \nin vivo targeted expansion of T reg or for enhancement of their \nsuppressive...', 'thumbnail': 'https://serpapi.com/searches/6724b5d62c83d523bce210e8/images/35f4ea24dffbed6700751784fe8a97c4dc305a52120c340b41592e335cede424.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6119940280914307}",,,,,,,,,,['neutral'],neutral,1
NCT04674761,"{'position': 1, 'link': 'https://www.empr.com/home/news/bylvay-approved-for-cholestatic-pruritus-due-to-alagille-syndrome/', 'title': 'Bylvay Approved for Cholestatic Pruritus Due to Alagille Syndrome', 'source': 'Medical Professionals Reference', 'date': 'Jun 14, 2023', 'snippet': 'The Food and Drug Administration (FDA) has approved Bylvay (odevixibat) for \nthe treatment of cholestatic pruritus in patients 12 months of age and \nolder with...', 'thumbnail': 'https://serpapi.com/searches/6724b5df708e2e0aabc4b0db/images/6484d2857d906b5d6e994432ada786b9687ee017870e2d2fa7afdc0c055f034f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8768388628959656}",,,,,,,,,,['neutral'],neutral,1
NCT00132470,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/full/10.1161/strokeaha.110.579508', 'title': 'AXIS | Stroke', 'source': 'American Heart Association Journals', 'date': 'Oct 14, 2010', 'snippet': 'Background and Purpose—Granulocyte colony-stimulating factor (G-CSF) is a \npromising stroke drug candidate. The present phase IIa study...', 'thumbnail': 'https://serpapi.com/searches/6724b606ba11427ba37ffd12/images/b288402b58b432ecbb7a5bf930ccf25f001dcf8d6efe9569aa2a5cc92e022408.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7770700454711914}",,,,,,,,,,['neutral'],neutral,1
NCT01469377,"{'position': 1, 'link': 'https://www.psychiatrist.com/jcp/efficacy-safety-adjunctive-cariprazine-inadequate/', 'title': 'Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder', 'source': 'Psychiatrist.com', 'date': 'Mar 23, 2016', 'snippet': 'These results show that adjunctive cariprazine 2–4.5 mg/d was effective and \ngenerally well tolerated in adults with MDD who had inadequate responses \nto...', 'thumbnail': 'https://serpapi.com/searches/6724b61a08abe491c5adc7fa/images/b851d9b9df9ee61c5364264c0b9d5ead7f69d1d89d76a014f363d26609570708.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8563286066055298}","{'position': 2, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/vraylar-approved-as-adjunctive-therapy-for-major-depressive-disorder/', 'title': 'Vraylar Approved as Adjunctive Therapy for Major Depressive Disorder', 'source': 'Medical Professionals Reference', 'date': 'Dec 19, 2022', 'snippet': 'The Food and Drug Administration (FDA) has approved Vraylar (cariprazine) \nas adjunctive therapy to antidepressants for the treatment of major \ndepressive...', 'thumbnail': 'https://serpapi.com/searches/6724b61a08abe491c5adc7fa/images/b851d9b9df9ee61cac03788277d5ddc86b56192f557ba468b7d6ac01f595a5e7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8091797828674316}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT03237286,"{'position': 1, 'link': 'https://www.nimh.nih.gov/news/science-news/2023/brief-cognitive-training-may-extend-the-antidepressant-effects-of-ketamine', 'title': 'Brief Cognitive Training May Extend the Antidepressant Effects of Ketamine', 'source': 'National Institute of Mental Health (NIMH) (.gov)', 'date': 'Jan 9, 2023', 'snippet': 'An NIMH-supported study suggests that a brief self-association training \nprogram can extend the effects of a single ketamine infusion by...', 'thumbnail': 'https://serpapi.com/searches/6724b62e069e577fa8409d8a/images/b24ee62a2c9bc8168d033c37a8f42e393217f7297059998b0afcc0c7d5aee534.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9159641861915588}",,,,,,,,,,['neutral'],neutral,1
NCT01358721,"{'position': 1, 'link': 'https://www.nature.com/articles/s41467-019-12361-9', 'title': 'Metabolomic adaptations and correlates of survival to immune checkpoint blockade', 'source': 'Nature', 'date': 'Sep 25, 2019', 'snippet': 'Despite remarkable success of immune checkpoint inhibitors, the majority of \ncancer patients have yet to receive durable benefits.', 'thumbnail': 'https://serpapi.com/searches/6724b6d9a54d7e54a451d884/images/3fbbb4450884e5ed921568912de87d378e2521f5dd2db36759dde6441ec0ede8.png', 'sentiment': 'negative', 'sentiment_prob': 0.5477431416511536}",,,,,,,,,,['negative'],negative,0
NCT02556450,"{'position': 1, 'link': 'https://www.nature.com/articles/s41440-024-01843-z', 'title': 'Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial | Hypertension Research', 'source': 'Nature', 'date': 'Sep 6, 2024', 'snippet': 'None of the spironolactone trials in heart failure (HF) assessed the blood \npressure (BP) responses to exercise, while conflicting results...', 'thumbnail': 'https://serpapi.com/searches/6724b6fb98d8de094eb5b67b/images/41f14e3731a95cb9ecf0df8b2c2329f043b2e54e01ac3fbe5195d978f197d86a.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6945666670799255}","{'position': 2, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.028814', 'title': 'Cardiorenal Syndrome Revisited', 'source': 'American Heart Association Journals', 'date': 'Aug 27, 2018', 'snippet': 'Cardiorenal syndromes have been categorized into 5 clinical subtypes based \non which organ is perceived to be the primary precipitant of the...', 'thumbnail': 'https://serpapi.com/searches/6724b6fb98d8de094eb5b67b/images/41f14e3731a95cb9130a41306586499fecc7f8090fbad9082128d686d313854b.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6989585161209106}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02314819,"{'position': 1, 'link': 'https://www.onclive.com/view/efficacy-and-safety-of-fruquintinib-in-patients-with-metastatic-colorectal-cancer-according-to-prior-treatment-sequence-in-the-refractory-setting-results-from-fresco-and-fresco-2', 'title': 'Efficacy and Safety of Fruquintinib in Patients With Metastatic Colorectal Cancer According to Prior Treatment Sequence in the Refractory Setting: Results From FRESCO and FRESCO-2', 'source': 'OncLive', 'date': 'Jul 5, 2024', 'snippet': 'A phase 3, randomized, double-blind, placebo-controlled study to determine \nif prior TAS-102 and/or regorafenib treatment status and sequence...', 'thumbnail': 'https://serpapi.com/searches/6724b723f3622ae7ee311519/images/4dc5190f0b85642a434d3ecbbb40b854f938728d5bdcc247d769e22e52a4dbed.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9031265377998352}","{'position': 2, 'link': 'https://www.onclive.com/view/fruquintinib-represents-a-novel-therapeutic-approach-in-advanced-mcrc', 'title': 'Fruquintinib Represents a Novel Therapeutic Approach in Advanced mCRC', 'source': 'OncLive', 'date': 'Aug 30, 2024', 'snippet': 'Arvind Dasari, MD, MS, discusses fruquintinib as later-line treatment for \npatients with advanced metastatic colorectal cancer.', 'thumbnail': 'https://serpapi.com/searches/6724b723f3622ae7ee311519/images/4dc5190f0b85642a829d0dd6df67e112acce812842caa238b907032a78e9c9cf.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8593913316726685}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT05507567,"{'position': 1, 'link': 'https://copdnewstoday.com/news/neumifil-nasal-spray-phase-2-trial-new-investments-pneumagen/', 'title': 'Neumifil nasal spray heads to COPD Phase 2 trial with new investments', 'source': 'COPD News Today', 'date': 'Jun 5, 2023', 'snippet': 'Pneumagen has secured £8 million (nearly $10 million) in investments to \nsupport the clinical development of its nasal spray, called Neumifil, for \nthe...', 'thumbnail': 'https://serpapi.com/searches/6724b72c7f3719c897e73854/images/75f842b4ad26910a2ebee055396583e57a1fce5a7f694ba0d4a6ffbb48dab8ff.png', 'sentiment': 'neutral', 'sentiment_prob': 0.530219554901123}",,,,,,,,,,['neutral'],neutral,1
NCT00509145,"{'position': 1, 'link': 'https://multiplesclerosisnewstoday.com/laquinimod-nerventra-abr-215062-ppms/', 'title': 'Laquinimod for Multiple Sclerosis', 'source': 'Multiple Sclerosis News Today', 'date': 'Jun 30, 2022', 'snippet': ""Laquinimod (also known as nerventra or ABR-215062) is an investigational \noral therapy that's been tested in clinical trials for treating multiple \nsclerosis (MS..."", 'thumbnail': 'https://serpapi.com/searches/6724b731a5aae9ccce41fbc5/images/f52d38108fb8ab092833f2ba64dd1c0e8e06bb56adfc3f182235fff10f6f994a.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8935969471931458}",,,,,,,,,,['neutral'],neutral,1
NCT04545580,"{'position': 1, 'link': 'https://medicaldialogues.in/urology/news/eliapixant-might-not-reduce-clinical-outcomes-in-overactive-bladder-ovader-trial-116999', 'title': 'Eliapixant might not reduce clinical outcomes in Overactive Bladder: OVADER Trial', 'source': 'Medical Dialogues', 'date': 'Sep 11, 2023', 'snippet': 'Overactive bladder (OAB) syndrome is a chronic medical condition that \nmajorly influence the patients quality of life in a significant amount...', 'thumbnail': 'https://serpapi.com/searches/6724b781b7d31d48954e28b2/images/e46a0a05f6a585ec841b470787ebacf5a1a306faf5b5604aaa284d588044d88d.jpeg', 'sentiment': 'negative', 'sentiment_prob': 0.571459174156189}",,,,,,,,,,['negative'],negative,0
NCT02628080,"{'position': 1, 'link': 'https://www.nature.com/articles/s41598-022-26199-7', 'title': 'Timing of hypoxia PET/CT imaging after 18F-fluoromisonidazole injection in non-small cell lung cancer patients', 'source': 'Nature', 'date': 'Dec 16, 2022', 'snippet': 'Positron emission tomography (PET)/computed tomography (CT) using the \nradiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to...', 'thumbnail': 'https://serpapi.com/searches/6724b78c98fad632e395d560/images/74a08fa1929dbf5e943406e6e86831608b24f06324bb588f79873c155eaaeded.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8932766914367676}",,,,,,,,,,['neutral'],neutral,1
NCT02446899,"{'position': 1, 'link': 'https://www.empr.com/home/news/saphnelo-approved-for-systemic-lupus-erythematosus/', 'title': 'Saphnelo Approved for Systemic Lupus Erythematosus', 'source': 'Medical Professionals Reference', 'date': 'Aug 2, 2021', 'snippet': 'The Food and Drug Administration (FDA) has approved Saphnelo \n(anifrolumab-fnia) for the treatment of adults with moderate to severe \nsystemic lupus...', 'thumbnail': 'https://serpapi.com/searches/6724b7b6e1d1ad2e67b32a6f/images/66fc5e208b5daa8c6f801ee402a6d857b29bb3902d3b24c104d5c92dc70dc376.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.850493848323822}",,,,,,,,,,['neutral'],neutral,1
NCT04093024,"{'position': 1, 'link': 'https://www.empr.com/home/news/drugs-in-the-pipeline/nintedanib-under-review-for-children-with-fibrosing-interstitial-lung-disease/', 'title': 'Nintedanib Under Review for Children With Fibrosing Interstitial Lung Disease', 'source': 'Medical Professionals Reference', 'date': 'Jul 25, 2023', 'snippet': 'The Food and Drug Administration (FDA) has accepted the supplemental New \nDrug Application (sNDA) for nintedanib for children and adolescents 6 to 17 \nyears of...', 'thumbnail': 'https://serpapi.com/searches/6724b7b76de1e4f859151233/images/0a404746cd98314b98effc3db3b6eb4a349e6f01008a508f0cbc86ddcb5dba10.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9198311567306519}",,,,,,,,,,['neutral'],neutral,1
NCT02036970,"{'position': 1, 'link': 'https://lungdiseasenews.com/2016/10/11/first-patient-enrolled-phase-3-trial-of-bardoxolone-methyl-in-ctd-pah-patients/', 'title': 'First Patient Enrolled in Phase 3 Trial Assessing Bardoxolone Methyl to Treat CTD-PAH', 'source': 'Lung Disease News', 'date': 'Oct 11, 2016', 'snippet': 'Read about Reata Pharmaceuticals recruiting participants for its Phase 3 \nCATALYST trial evaluating bardoxolone methyl in patients with...', 'thumbnail': 'https://serpapi.com/searches/6724b7d4cb33d030aeaf2559/images/270370433d44df9670808514d2d8c3a061b3fbbeede41d89500137a3d162c456.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9395923614501953}","{'position': 2, 'link': 'https://pulmonaryhypertensionnews.com/news/reatas-bardoxolone-methyl-pah-therapy-shows-promise-initial-phase-2-data/', 'title': 'Reata’s Bardoxolone Methyl as PAH Therapy Shows Promise in Initial Phase 2 Data', 'source': 'Pulmonary Hypertension News', 'date': 'Oct 27, 2015', 'snippet': ""Read more about Reata's initial data from LARIAT Phase 2 study of \nBardoxolone Methyl in PAH Patients that shows promising results."", 'thumbnail': 'https://serpapi.com/searches/6724b7d4cb33d030aeaf2559/images/270370433d44df96d1ecf536f658fc32fb9d9438a20ca0b231af080fcabfe4f9.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7200711369514465}",,,,,,,,,"['neutral', 'positive']",neutral,1
NCT03618355,"{'position': 1, 'link': 'https://prostatecancernewstoday.com/2020/02/17/erapa-leads-to-boost-in-immune-cells-in-low-grade-prostate-cancer-patients-phase-1b-data-suggest/', 'title': 'eRapa Leads to Boost in Immune Cells in Low-Grade Prostate Cancer Patients, Phase 1b Data Suggest', 'source': 'Prostate Cancer News Today', 'date': 'Feb 17, 2020', 'snippet': 'Low-dose treatment with eRapa enhanced cancer-fighting immune cells and was \nsafe in low grade prostate cancer patients, a Phase 1B trial...', 'thumbnail': 'https://serpapi.com/searches/6724b8a2b57db8748697d253/images/14e81a4bf7ea149e1153078758ddf2b0c8d51a8e833dace1c38271b542cc8759.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.5228926539421082}",,,,,,,,,,['neutral'],neutral,1
NCT03180840,"{'position': 1, 'link': 'https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-final-results-of-the-bright-phase-iii-clinical-trial-evaluating-prx-102-for-the-treatment-of-fabry-disease-301505728.html', 'title': 'Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease', 'source': 'PR Newswire', 'date': 'Mar 18, 2022', 'snippet': 'PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: \nPLX), a biopharmaceutical company focused on the development,...', 'thumbnail': 'https://serpapi.com/searches/6724b998b6e4dba8f4f5add1/images/b073d0021e949a614185605148a178225825823257a2135ddc95ed2b848d9aad.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9236260056495667}","{'position': 2, 'link': 'https://fabrydiseasenews.com/news/prx-102-shows-safety-efficacy-similar-fabrazyme-top-line-balance-trial/', 'title': 'PRX-102 Shows Safety, Efficacy Similar to Fabrazyme in Phase 3 Trial', 'source': 'Fabry Disease News', 'date': 'Apr 29, 2022', 'snippet': 'Top-line data from Phase 3 BALANCE trial found 2 years of PRX-102 treatment \nsimilar to Fabrazyme in adults with Fabry and kidney disease.', 'thumbnail': 'https://serpapi.com/searches/6724b998b6e4dba8f4f5add1/images/b073d0021e949a6130d35e888b36d7741b372c8908a31dc7fca2c4630da93071.png', 'sentiment': 'neutral', 'sentiment_prob': 0.7387609481811523}","{'position': 3, 'link': 'https://fabrydiseasenews.com/news/protalix-fabry-disease-therapy-pegunigalsidase-alfa-granted-fda-fast-track-designation/', 'title': 'Fabry Disease Therapy Pegunigalsidase Alfa Gets FDA Fast Track Status', 'source': 'Fabry Disease News', 'date': 'Feb 6, 2018', 'snippet': ""The US Food and Drug Administration (FDA) has granted fast track \ndesignation to pegunigalsidase alfa, or PRX-102, Protalix BioTherapeutics' \ntherapy candidate..."", 'thumbnail': 'https://serpapi.com/searches/6724b998b6e4dba8f4f5add1/images/b073d0021e949a612e9ce08436bd3f81e2b6fac2cbda322d9abad92113de4234.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8152209520339966}",,,,,,,,"['neutral', 'neutral', 'neutral']",neutral,1
NCT02365480,"{'position': 1, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/ajco.13941', 'title': 'The therapeutic effects of berberine for gastrointestinal cancers', 'source': 'Wiley Online Library', 'date': 'Mar 13, 2023', 'snippet': 'As previously mentioned, in different experimental and clinical levels, BBR \nplays crucial roles against numerous cancer types.', 'thumbnail': 'https://serpapi.com/searches/6724b9cebb64ac395bd993bd/images/b6901dd9fecb9ce9184a572b104d96c25e686e6aca8f97f4f523de56e987d71d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8705225586891174}",,,,,,,,,,['neutral'],neutral,1
NCT02696967,"{'position': 1, 'link': 'https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.119.313682', 'title': 'Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction:', 'source': 'American Heart Association Journals', 'date': 'May 23, 2019', 'snippet': 'This review explores therapies that have proven successful, those that have \nnot, those that are moving into the clinic but whose utility remains to \nbe...', 'thumbnail': 'https://serpapi.com/searches/6724b9d4f59d003e806ae010/images/1932566fe0d8474081d829c86811172e2b381a269206ea647255891fe971b156.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.7387335896492004}",,,,,,,,,,['neutral'],neutral,1
NCT05686044,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/buntanetap-found-effective-safe-early-alzheimers-trial-data/', 'title': 'Buntanetap found effective, safe in early Alzheimer’s trial: New data', 'source': ""Alzheimer's News Today"", 'date': 'Jun 27, 2024', 'snippet': ""The safety and efficacy of buntanetap therapy are comparable in early \nAlzheimer's patients regardless of APOE4 status, per new trial data."", 'thumbnail': 'https://serpapi.com/searches/6724b9e03c944b0b12b106db/images/76f2c2e6976b8869a4fb3e699ea566ec249c247607a4428472f1f958d42eedd1.png', 'sentiment': 'positive', 'sentiment_prob': 0.7521594166755676}","{'position': 2, 'link': 'https://www.clinicaltrialsarena.com/news/annovis-stock-swells-after-phase-iii-parkinsons-subgroup-success/', 'title': 'Annovis stock swells after Phase III Parkinson’s subgroup success', 'source': 'Clinical Trials Arena', 'date': 'Jul 3, 2024', 'snippet': ""Buntanetap showed a statistical improvement in several disease-related \nscores in certain Parkinson's patients who had been diagnosed for..."", 'thumbnail': 'https://serpapi.com/searches/6724b9e03c944b0b12b106db/images/76f2c2e6976b8869d79d074b5653da6f27499add866ada63a7fa71a8fa6e88c1.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.5898541808128357}","{'position': 3, 'link': 'https://alzheimersnewstoday.com/news/buntanetap-helps-subgroup-mild-alzheimers-patients-data-show/', 'title': 'Buntanetap helps subgroup of mild Alzheimer’s patients, data show', 'source': ""Alzheimer's News Today"", 'date': 'May 30, 2024', 'snippet': ""Buntanetap, a small molecule from Annovis Bio, improved cognitive function \nin people with mild Alzheimer's with certain biomarkers."", 'thumbnail': 'https://serpapi.com/searches/6724b9e03c944b0b12b106db/images/76f2c2e6976b8869bd9bf45dbe50b1b984f51a36cf75339565ea5f224e6aa86a.png', 'sentiment': 'positive', 'sentiment_prob': 0.7748176455497742}","{'position': 4, 'link': 'https://alzheimersnewstoday.com/news/phase-2-3-trial-data-buntanetap-expected-march-2024/', 'title': 'Phase 2/3 trial results for oral buntanetap expected in March 2024', 'source': ""Alzheimer's News Today"", 'date': 'Oct 13, 2023', 'snippet': ""An ongoing Phase 2/3 clinical trial testing Annovis Bio's treatment \ncandidate buntanetap in people with Alzheimer's disease is expected to..."", 'thumbnail': 'https://serpapi.com/searches/6724b9e03c944b0b12b106db/images/76f2c2e6976b8869ac6cf529e43b61136b37609c8e243af0fc2c1e493451b339.png', 'sentiment': 'neutral', 'sentiment_prob': 0.9376084804534912}",,,,,,,"['positive', 'positive', 'positive', 'neutral']",positive,1
NCT01794143,"{'position': 1, 'link': 'https://www.nejm.org/doi/full/10.1056/NEJMoa2200433', 'title': 'Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes', 'source': 'The New England Journal of Medicine', 'date': 'Sep 21, 2022', 'snippet': 'The comparative effectiveness of glucose-lowering medications for use with \nmetformin to maintain target glycated hemoglobin levels in...', 'thumbnail': 'https://serpapi.com/searches/6724b8b12c83d52982fe0b2e/images/f265c1f4bf5fe66e5cb6575940e03338ecb649c73a4fd2144dede2f2b0dcfb4d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8255519270896912}",,,,,,,,,,['neutral'],neutral,1
NCT04388254,"{'position': 1, 'link': 'https://alzheimersnewstoday.com/news/topline-results-phase-3-studies-simufilam-alzheimers-due-this-year/', 'title': 'Topline results from Phase 3 trial of simufilam due this year', 'source': ""Alzheimer's News Today"", 'date': 'Feb 8, 2024', 'snippet': ""Two Phase 3 clinical trials are testing the effectiveness of simufilam, an \nexperimental oral therapy that's designed to improve cognition in people \nwith..."", 'thumbnail': 'https://serpapi.com/searches/6724b8e12fab6209f6ac0197/images/005ae7cd86f2d32749cb1e4c977b8820dc2b04cdc8912ea2c19403e90eeeeded.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5712019801139832}","{'position': 2, 'link': 'https://alzheimersnewstoday.com/news/simufilam-aid-cognition-alzheimers-patients-phase-2-study/', 'title': 'Simufilam aids cognition in 47% of Alzheimer’s patients in Phase 2 study', 'source': ""Alzheimer's News Today"", 'date': 'Mar 14, 2023', 'snippet': ""Cognitive benefits were reported in nearly half of the Alzheimer's disease \npatients given simufilam for one year in a clinical trial."", 'thumbnail': 'https://serpapi.com/searches/6724b8e12fab6209f6ac0197/images/005ae7cd86f2d327a9c3ef692e2fd80cdd345d2bcfdc7c31d47747ee69cc01a9.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5083126425743103}","{'position': 3, 'link': 'https://alzheimersnewstoday.com/news/simufilam-found-safe-review-ongoing-alzheimers-drug-trials/', 'title': 'Simufilam found safe in review of ongoing Alzheimer’s clinical trials', 'source': ""Alzheimer's News Today"", 'date': '1 month ago', 'snippet': 'an independent safety monitoring board has recommended the continuation — \nwithout modifications — of two ongoing Phase 3 clinical trials testing...', 'thumbnail': 'https://serpapi.com/searches/6724b8e12fab6209f6ac0197/images/005ae7cd86f2d32777914aa64dff3ce4a72cf34661989849edb2543c38a61ce6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6725298762321472}","{'position': 4, 'link': 'https://alzheimersnewstoday.com/news/simufilam-improves-cognition-behavior-alzheimers-disease-after-6-months-use-early-clinical-trial-analysis/', 'title': 'Oral Simufilam Found to Improve Cognition, Behavior After 6 Months’ Use', 'source': ""Alzheimer's News Today"", 'date': 'Feb 15, 2021', 'snippet': ""Simufilam improved cognition and behavior in people with Alzheimer's \ndisease after six months of dosing in a clinical trial, data show."", 'thumbnail': 'https://serpapi.com/searches/6724b8e12fab6209f6ac0197/images/005ae7cd86f2d327bcc55b121ab1f9da44f00d1f29155ec3f302eaa223437365.jpeg', 'sentiment': 'positive', 'sentiment_prob': 0.7451538443565369}",,,,,,,"['neutral', 'neutral', 'neutral', 'positive']",neutral,1
NCT02964013,"{'position': 1, 'link': 'https://www.onclive.com/view/vibostolimab-pembrolizumab-combo-elicits-antitumor-activity-in-metastatic-cervical-cancer', 'title': 'Vibostolimab/Pembrolizumab Combo Elicits Antitumor Activity in Metastatic Cervical Cancer', 'source': 'OncLive', 'date': 'May 11, 2022', 'snippet': 'Two investigated doses of vibostolimab in combination with pembrolizumab \nresulted in comparable antitumor activity and safety in patients...', 'thumbnail': 'https://serpapi.com/searches/6724b91cfd3b5a5dbb1cfbc7/images/49c6a43bd1d600afef4d5ddbb37cf2fa4b0840b8711c2f673c6e18edf2b5c590.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8774946331977844}",,,,,,,,,,['neutral'],neutral,1
NCT04812262,"{'position': 1, 'link': 'https://liverdiseasenews.com/news/fatty-liver-disease-treatment-dd01-fda-fast-track-designation/', 'title': 'Fatty liver disease treatment DD01 gets FDA fast track designation', 'source': 'Liver Disease News', 'date': 'Apr 8, 2024', 'snippet': 'The US Food and Drug Administration (FDA) has granted fast track \ndesignation to DD01 as a potential treatment for a severe manifestation of \nfatty liver disease.', 'thumbnail': 'https://serpapi.com/searches/6724b921707fd3db679c1cd3/images/65478170b019d1d4685e9360aed9ecca3af09bacfc82c8276f51bac3bbfaf6c6.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8689566850662231}",,,,,,,,,,['neutral'],neutral,1
NCT01940172,"{'position': 1, 'link': 'https://www.nature.com/articles/s41418-022-01059-z', 'title': 'Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries', 'source': 'Nature', 'date': 'Oct 4, 2022', 'snippet': 'Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) can \ninduce apoptosis in a wide variety of cancer cells, both in vitro...', 'thumbnail': 'https://serpapi.com/searches/6724b94ff3622aede677e9b0/images/3dcb7aca238ef35c16cb8a1ecc24dbab64ff89bf583a0cc6a6f8d2ee3248d52f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6938797235488892}",,,,,,,,,,['neutral'],neutral,1
NCT03536117,"{'position': 1, 'link': 'https://www.nature.com/articles/s41541-020-00262-8', 'title': 'MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies | npj Vaccines', 'source': 'Nature', 'date': 'Jan 4, 2021', 'snippet': 'A single intradermal vaccination with MTBVAC given to adult rhesus macaques \nwas well tolerated and conferred a significant improvement in outcome \nfollowing...', 'thumbnail': 'https://serpapi.com/searches/6724b95cbb55ffe736260dd6/images/80bc6bf3c95731518183484176c5b7c525df79c070b1a6aa77a0c9317c2233ce.png', 'sentiment': 'neutral', 'sentiment_prob': 0.6407263875007629}",,,,,,,,,,['neutral'],neutral,1
NCT03615040,"{'position': 1, 'link': 'https://copdnewstoday.com/news/astegolimab-lifts-quality-of-life-copd-patients-with-frequent-flare-ups/', 'title': 'Astegolimab Lifts Quality of Life For Those With Frequent Flare-ups', 'source': 'COPD News Today', 'date': 'Apr 7, 2022', 'snippet': 'People with moderate-to-very severe chronic obstructive pulmonary disease \nwho were given astegolimab over 48 weeks reported feeling better.', 'thumbnail': 'https://serpapi.com/searches/6724babaa9210bcfa1edaf97/images/5d0483a16deed9b3e0e2eb2e5932411b82960e4bbf46bf10f8331eb05388aee0.png', 'sentiment': 'neutral', 'sentiment_prob': 0.5611549615859985}",,,,,,,,,,['neutral'],neutral,1
NCT03353740,"{'position': 1, 'link': 'https://jnm.snmjournals.org/content/61/12/1793', 'title': 'Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial', 'source': 'Journal of Nuclear Medicine', 'date': 'Dec 1, 2020', 'snippet': 'Wolfgang P. Fendler, Justin Ferdinandus, Johannes Czernin, Matthias Eiber, \nRobert R. Flavell, Spencer C. Behr, I-Wei K. Wu,...', 'thumbnail': 'https://serpapi.com/searches/6724babbc0028e77ec77698b/images/382ad7430b486dfcfbe755c313578a25259fae1f0a7c60a51c08ae1aec3555b7.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9201310873031616}",,,,,,,,,,['neutral'],neutral,1
NCT03137069,"{'position': 1, 'link': 'https://www.nature.com/articles/s41591-021-01537-w', 'title': 'antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial', 'source': 'Nature', 'date': 'Nov 8, 2021', 'snippet': ""Bruton's tyrosine kinase (BTK) is crucial for FcεRI-mediated mast cell \nactivation and essential for autoantibody production by B cells in..."", 'thumbnail': 'https://serpapi.com/searches/6724babe98fad638a9fe4807/images/9442d511923c2ff51815083201459b56abe11b3e70a1e4a4cae359ea691bea81.png', 'sentiment': 'neutral', 'sentiment_prob': 0.8343451619148254}","{'position': 2, 'link': 'https://onlinelibrary.wiley.com/doi/10.1111/all.15261', 'title': ""Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune-mediated dermatological conditions"", 'source': 'Wiley Online Library', 'date': 'Feb 17, 2022', 'snippet': ""Bruton's tyrosine kinase (BTK), a member of the Tec kinase family, is \ncritically involved in a range of immunological pathways. The clinical..."", 'thumbnail': 'https://serpapi.com/searches/6724babe98fad638a9fe4807/images/9442d511923c2ff5afacd700837cf38af10ffb4aa75cf71644e2bc448ce5a4a3.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.9064881801605225}",,,,,,,,,"['neutral', 'neutral']",neutral,1
NCT02741518,"{'position': 1, 'link': 'https://geneticobesitynews.com/2019/05/28/fecal-microbiota-transplant-potential-obesity-more-studies-needed/', 'title': 'Obesity Treatment with Fecal Microbiota Shows Potential, Study Says', 'source': 'Genetic Obesity News', 'date': 'May 28, 2019', 'snippet': 'The first randomized controlled trial exploring the effect of fecal \nmicrobiota transplantation (FMT) as a potential treatment for obese \nindividuals without...', 'thumbnail': 'https://serpapi.com/searches/6724bac8ba13f2e4637a9673/images/8e24bf73e35f6b9ea3c7fb1a7cdb63e9c457bd6cdece46480d013a7876e15b6f.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.8370242118835449}",,,,,,,,,,['neutral'],neutral,1
NCT02166944,"{'position': 1, 'link': 'https://alsnewstoday.com/news/tamoxifen-shows-modest-effects-in-als-patients-phase-1-2-trial-finds/', 'title': 'Tamoxifen Shows Modest Effects in ALS Patients, Phase 1/2 Trial Finds', 'source': 'ALS News Today', 'date': 'Jun 10, 2020', 'snippet': 'Tamoxifen provides only modest and short-lasting benefits to people with \namyotrophic lateral sclerosis (ALS), a small clinical trial shows.', 'thumbnail': 'https://serpapi.com/searches/6724baf8a869216a643dffa2/images/8b1ab657e78d444f44aec1cbc744ee3ac2ab82afa62c00d605a6c244d3d64c6d.jpeg', 'sentiment': 'neutral', 'sentiment_prob': 0.6973245739936829}",,,,,,,,,,['neutral'],neutral,1